Anti	B
-	I
Ro	I
(	I
SSA	I
)	I
autoantibodies	I
are	O
associated	O
with	O
T	O
cell	O
receptor	O
beta	O
genes	O
in	O
systemic	O
lupus	O
erythematosus	O
patients	O
.	O
Several	O
of	O
the	O
heterogeneous	O
clinical	O
manifestations	O
of	O
systemic	O
lupus	O
erythematosus	O
have	O
been	O
associated	O
with	O
specific	O
autoantibodies	B
.	O
Associations	O
between	O
HLA	B
class	I
II	I
antigens	I
and	O
autoantibodies	B
to	O
the	O
ribonucleoproteins	B
Ro	B
(	I
SSA	I
)	I
and	O
La	B
(	I
SSB	I
)	I
have	O
been	O
reported	O
in	O
these	O
patients	O
.	O
Because	O
HLA	B
class	I
II	I
molecules	I
present	O
antigen	O
to	O
T	B
cell	I
receptors	I
(	O
TCRs	B
)	O
,	O
we	O
have	O
searched	O
for	O
a	O
TCR	O
gene	O
associated	O
with	O
the	O
production	O
of	O
anti	B
-	I
Ro	I
(	I
SSA	I
)	I
antibodies	I
.	O
A	O
pair	O
of	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
RFLPs	O
)	O
,	O
one	O
of	O
which	O
hybridizes	O
to	O
the	O
TCR	O
constant	O
region	O
C	O
beta	O
1	O
and	O
the	O
other	O
to	O
the	O
C	O
beta	O
2	O
gene	O
,	O
has	O
been	O
identified	O
,	O
suggesting	O
these	O
may	O
be	O
genotypic	O
markers	O
for	O
an	O
extended	O
region	O
of	O
the	O
TCR	O
beta	O
locus	O
.	O
This	O
RFLP	O
pair	O
occurs	O
in	O
76	O
%	O
of	O
patients	O
with	O
Ro	B
(	I
SSA	I
)	I
precipitins	O
,	O
84	O
%	O
of	O
anti-	O
Ro	B
(	I
SSA	I
)	I
-positive	O
patients	O
lacking	O
La	B
(	I
SSB	I
)	I
precipitins	B
,	O
but	O
only	O
41	O
%	O
of	O
the	O
patients	O
lacking	O
both	O
precipitins	B
(	O
P	O
=	O
0.0004	O
)	O
.	O
This	O
disproportionate	O
occurrence	O
in	O
a	O
subset	O
of	O
lupus	O
patients	O
indicates	O
that	O
these	O
RFLPs	O
are	O
not	O
disease	O
susceptibility	O
markers	O
,	O
but	O
rather	O
are	O
important	O
markers	O
for	O
TCR	O
genes	O
whose	O
products	O
are	O
involved	O
in	O
the	O
production	O
of	O
anti	B
-	I
Ro	I
(	I
SSA	I
)	I
antibodies	I
.	O
The	O
majority	O
of	O
patients	O
who	O
have	O
these	O
RFLPs	O
and	O
HLA	B
class	I
II	I
antigens	I
previously	O
associated	O
with	O
the	O
anti-	O
Ro	B
(	I
SSA	I
)	I
response	O
make	O
this	O
antibody	O
,	O
suggesting	O
that	O
interactions	O
between	O
products	O
of	O
these	O
loci	O
occur	O
in	O
response	O
to	O
Ro	B
(	I
SSA	I
)	I
.	O
Characterization	O
of	O
the	O
human	B
immunodeficiency	I
virus	I
type	I
1	I
enhancer	I
-	I
binding	I
proteins	I
from	O
the	O
human	O
T	O
-	O
cell	O
line	O
Jurkat	O
.	O
The	O
transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
under	O
the	O
control	O
of	O
cellular	B
proteins	I
that	O
bind	O
to	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O
Among	O
the	O
protein	O
-	O
binding	O
regions	O
of	O
the	O
HIV-1	O
LTR	O
is	O
the	O
transcription	O
-	O
enhancer	O
region	O
.	O
We	O
show	O
that	O
at	O
least	O
one	O
inducible	B
,	O
C1	B
,	O
and	O
one	O
constitutive	B
,	I
C2	I
,	I
protein	I
can	O
bind	O
to	O
the	O
HIV	O
enhancer	O
in	O
Jurkat	O
cells	O
.	O
The	O
two	O
proteins	O
differ	O
in	O
their	O
surface	O
charge	O
,	O
since	O
they	O
are	O
separable	O
by	O
anion	O
-	O
exchange	O
chromatography	O
.	O
Bivalent	O
cations	O
such	O
as	O
Mg2	O
+	O
and	O
Zn2	O
+	O
differentially	O
affect	O
their	O
binding	O
to	O
oligonucleotides	O
which	O
contain	O
the	O
HIV	O
-	O
enhancer	O
domain	O
.	O
Both	O
C1	B
and	O
C2	B
proteins	I
also	O
bind	O
to	O
a	O
similar	O
sequence	O
found	O
in	O
the	O
interleukin-2-receptor	O
alpha	O
-	O
subunit	O
enhancer	O
.	O
The	O
inducible	B
C1	I
protein	I
was	O
partially	O
purified	O
by	O
three	O
chromatographic	O
steps	O
and	O
characterized	O
by	O
u.v	O
.	O
cross	O
-	O
linking	O
as	O
a	O
47	B
kDa	I
protein	I
.	O
NF	B
-	I
kappa	I
B	I
as	O
inducible	O
transcriptional	B
activator	I
of	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
gene	O
.	O
The	O
expression	O
of	O
the	O
gene	O
encoding	O
the	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
is	O
induced	O
upon	O
activation	O
of	O
T	O
cells	O
with	O
phytohemagglutinin	B
and	O
active	O
phorbolester	O
and	O
upon	O
expression	O
of	O
tax1	B
,	O
a	O
transactivating	B
protein	I
of	O
the	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
.	O
The	O
same	O
agents	O
induce	O
transcription	O
from	O
the	O
interleukin-2	O
receptor	O
alpha	O
-	O
chain	O
and	O
interleukin-2	O
genes	O
,	O
depending	O
on	O
promoter	O
elements	O
that	O
bind	O
the	O
inducible	B
transcription	I
factor	I
NF	B
-	I
kappa	I
B	I
(	O
or	O
an	O
NF	B
-	I
kappa	I
B	I
-	I
like	I
factor	I
)	O
.	O
We	O
therefore	O
tested	O
the	O
possibility	O
that	O
the	O
GM	O
-	O
CSF	O
gene	O
is	O
also	O
regulated	O
by	O
a	O
cognate	O
motif	O
for	O
the	O
NF	B
-	I
kappa	I
B	I
transcription	I
factor	I
.	O
A	O
recent	O
functional	O
analysis	O
by	O
Miyatake	O
et	O
al.	O
(	O
S.	O
Miyatake	O
,	O
M.	O
Seiki	O
,	O
M.	O
Yoshida	O
,	O
and	O
K.	O
Arai	O
,	O
Mol	O
.	O
Cell	O
.	O
Biol	O
.	O
8	O
:	O
5581	O
-	O
5587	O
,	O
1988	O
)	O
described	O
a	O
short	O
promoter	O
region	O
in	O
the	O
GM	O
-	O
CSF	O
gene	O
that	O
conferred	O
strong	O
inducibility	O
by	O
T	O
-	O
cell	O
-	O
activating	O
signals	O
and	O
tax1	B
,	O
but	O
no	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
motifs	O
were	O
identified	O
.	O
Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
showed	O
binding	O
of	O
purified	O
human	B
NF	I
-	I
kappa	I
B	I
and	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
activated	O
in	O
Jurkat	O
T	O
cells	O
to	O
an	O
oligonucleotide	O
comprising	O
the	O
GM	O
-	O
CSF	O
promoter	O
element	O
responsible	O
for	O
mediating	O
responsiveness	O
to	O
T	O
-	O
cell	O
-	O
activating	O
signals	O
and	O
tax1	B
.	O
As	O
shown	O
by	O
a	O
methylation	O
interference	O
analysis	O
and	O
oligonucleotide	O
competition	O
experiments	O
,	O
purified	O
NF	B
-	I
kappa	I
B	I
binds	O
at	O
positions	O
-82	O
to	O
-91	O
(	O
GGGAACTACC	O
)	O
of	O
the	O
GM	O
-	O
CSF	O
promoter	O
sequence	O
with	O
an	O
affinity	O
similar	O
to	O
that	O
with	O
which	O
it	O
binds	O
to	O
the	O
biologically	O
functional	O
kappa	O
B	O
motif	O
in	O
the	O
beta	O
interferon	O
promoter	O
(	O
GGGAAATTCC	O
)	O
.	O
Two	O
kappa	O
B	O
-	O
like	O
motifs	O
at	O
positions	O
-98	O
to	O
-108	O
of	O
the	O
GM	O
-	O
CSF	O
promoter	O
were	O
also	O
recognized	O
but	O
with	O
much	O
lower	O
affinities	O
.	O
Our	O
data	O
provide	O
strong	O
evidence	O
that	O
the	O
expression	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
following	O
T	O
-	O
cell	O
activation	O
is	O
controlled	O
by	O
binding	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
transcription	I
factor	I
to	O
a	O
high	O
-	O
affinity	O
binding	O
site	O
in	O
the	O
GM	O
-	O
CSF	O
promoter	O
.	O
Octamer	B
transcription	I
factors	I
and	O
the	O
cell	O
type	O
-	O
specificity	O
of	O
immunoglobulin	O
gene	O
expression	O
.	O
Antibodies	B
are	O
produced	O
exclusively	O
in	O
B	O
lymphocytes	O
.	O
The	O
expression	O
of	O
the	O
antibody	O
-	O
encoding	O
genes	O
,	O
the	O
immunoglobulin	O
(	O
Ig	O
)	O
genes	O
,	O
is	O
also	O
restricted	O
to	O
B	O
cells	O
.	O
The	O
octamer	O
sequence	O
ATGCAAAT	O
is	O
present	O
in	O
the	O
promoter	O
and	O
the	O
enhancer	O
of	O
Ig	O
genes	O
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
its	O
tissue	O
-	O
specific	O
expression	O
.	O
This	O
sequence	O
motif	O
is	O
a	O
binding	O
site	O
for	O
nuclear	B
proteins	I
,	O
the	O
so	O
-	O
called	O
octamer	B
transcription	I
factors	I
(	O
Oct	B
or	O
OTF	B
factors	I
)	O
.	O
The	O
Oct-1	B
protein	I
is	O
present	O
in	O
all	O
cell	O
types	O
analyzed	O
so	O
far	O
,	O
whereas	O
Oct-2A	B
and	O
Oct-2B	B
are	O
found	O
mainly	O
in	O
B	O
lymphocytes	O
.	O
All	O
three	O
proteins	O
show	O
the	O
same	O
sequence	O
specificity	O
and	O
binding	O
affinity	O
.	O
It	O
appears	O
that	O
the	O
B	O
cell	O
-	O
specific	O
expression	O
of	O
Ig	O
genes	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
cell	O
type	B
-	I
specific	I
Oct	I
factors	I
,	O
and	O
that	O
there	O
are	O
both	O
quantitative	O
and	O
qualitative	O
differences	O
between	O
Oct-1	B
and	O
Oct-2	B
factors	I
.	O
Recently	O
,	O
a	O
number	O
of	O
other	O
octamer	B
factor	I
variants	I
were	O
identified	O
.	O
Many	O
of	O
these	O
may	O
be	O
created	O
by	O
alternative	O
splicing	O
of	O
a	O
primary	O
transcript	O
of	O
one	O
Oct	O
factor	O
gene	O
and	O
may	O
serve	O
a	O
specific	O
function	O
in	O
the	O
fine	O
tuning	O
of	O
gene	O
expression	O
.	O
Steroid	O
mediated	O
lysis	O
of	O
lymphoblasts	O
requires	O
the	O
DNA	O
binding	O
region	O
of	O
the	O
steroid	O
hormone	O
receptor	O
.	O
Glucocorticoids	O
kill	O
certain	O
types	O
of	O
lymphoblasts	O
,	O
but	O
the	O
mechanisms	O
are	O
unknown	O
.	O
It	O
is	O
clear	O
that	O
sufficient	O
numbers	O
of	O
functional	O
glucocorticoid	B
receptors	I
are	O
required	O
to	O
mediate	O
lysis	O
,	O
but	O
whether	O
they	O
do	O
so	O
through	O
the	O
classical	O
model	O
of	O
steroid	O
hormone	O
activation	O
and	O
modulation	O
of	O
gene	O
expression	O
has	O
not	O
been	O
established	O
.	O
In	O
this	O
report	O
we	O
have	O
asked	O
which	O
region	O
(	O
s	O
)	O
of	O
the	O
steroid	B
receptor	I
are	O
important	O
for	O
mediating	O
lysis	O
in	O
leukemic	O
T	O
lymphoblasts	O
.	O
CEM	O
-	O
ICR	O
27	O
leukemic	O
lymphoblasts	O
,	O
a	O
clone	O
of	O
CEM	O
cells	O
which	O
lack	O
functional	O
glucocorticoid	B
receptors	I
and	O
therefore	O
are	O
neither	O
lysed	O
by	O
dexamethasone	O
nor	O
capable	O
of	O
showing	O
glutamine	B
synthetase	I
induction	O
,	O
were	O
provided	O
with	O
steroid	B
receptors	I
by	O
DNA	O
transfections	O
of	O
various	O
receptor	O
gene	O
constructs	O
.	O
We	O
measured	O
steroid	O
mediated	O
lysis	O
,	O
receptor	O
number	O
and	O
induction	O
of	O
glutamine	B
synthetase	I
in	O
the	O
transfected	O
cells	O
.	O
Our	O
results	O
provide	O
evidence	O
that	O
the	O
lysis	O
mechanism	O
in	O
the	O
ICR27	O
lymphoblasts	O
is	O
restored	O
when	O
functional	O
receptor	O
number	O
is	O
restored	O
.	O
The	O
DNA	B
binding	I
region	I
specifying	O
high	O
affinity	O
for	O
GRE	O
sites	O
is	O
required	O
.	O
Lysis	O
is	O
mediated	O
by	O
any	O
steroid	O
that	O
allows	O
for	O
activation	O
of	O
the	O
receptor	O
containing	O
such	O
a	O
region	O
.	O
Our	O
data	O
support	O
the	O
view	O
that	O
steroid	O
-	O
mediated	O
cell	O
death	O
occurs	O
by	O
a	O
process	O
requiring	O
direct	O
interaction	O
of	O
steroid	B
-	I
receptor	I
complexes	I
with	O
the	O
genome	O
.	O
Tax	B
-independent	O
binding	O
of	O
multiple	O
cellular	B
factors	I
to	O
Tax	O
-	O
response	O
element	O
DNA	O
of	O
HTLV	O
-	O
I	O
.	O
The	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
promoter	O
contains	O
three	O
copies	O
of	O
imperfect	O
repeats	O
of	O
a	O
21-base	O
pair	O
sequence	O
designated	O
here	O
as	O
TRE	O
(	O
Tax	O
-	O
response	O
element	O
)	O
that	O
is	O
responsive	O
to	O
the	O
virally	B
encoded	I
transactivator	I
protein	I
Tax	B
.	O
We	O
have	O
identified	O
and	O
separated	O
four	O
nuclear	B
proteins	I
from	O
C81	O
-	O
66	O
-	O
45	O
cells	O
,	O
an	O
HTLV	O
-	O
I	O
immortalized	O
Tax	O
-	O
expressing	O
human	O
T	O
-	O
lymphocyte	O
line	O
(	O
Salahuddin	O
et	O
al.	O
,	O
1983	O
)	O
,	O
that	O
interact	O
with	O
the	O
TRE	O
-	O
DNA	O
,	O
none	O
of	O
which	O
are	O
identical	O
with	O
the	O
Tax	B
-	I
protein	I
.	O
The	O
proteins	O
identified	O
have	O
molecular	O
weights	O
of	O
about	O
32	O
,	O
36	O
to	O
42	O
,	O
50	O
and	O
110	O
kD	O
.	O
Four	O
different	O
methods	O
were	O
used	O
to	O
identify	O
the	O
proteins	O
.	O
First	O
,	O
from	O
different	O
cell	O
lines	O
three	O
or	O
all	O
four	O
of	O
the	O
nuclear	B
proteins	I
were	O
specifically	O
cross	O
-	O
linked	O
by	O
UV	O
irradiation	O
to	O
the	O
radioactively	O
labeled	O
TRE	O
-	O
DNA	O
fragment	O
.	O
Second	O
,	O
TRE	B
-	I
DNA	I
binding	I
proteins	I
sedimented	O
through	O
a	O
glycerol	O
density	O
gradient	O
at	O
rates	O
corresponding	O
to	O
proteins	O
of	O
native	O
molecular	O
weights	O
of	O
35	O
to	O
50	O
kD	O
and	O
110	O
kD	O
.	O
Third	O
,	O
only	O
the	O
50	B
kD	I
protein	I
was	O
retained	O
on	O
a	O
biotinylated	O
DNA	O
-	O
streptavidin	O
matrix	O
when	O
the	O
DNA	O
fragment	O
contained	O
the	O
TRE	O
-	O
DNA	O
.	O
Fourth	O
,	O
extensive	O
purification	O
by	O
several	O
cycles	O
of	O
TRE	O
-DNA	O
affinity	O
chromatography	O
resulted	O
in	O
the	O
32	B
,	I
36	I
to	I
42	I
and	I
110	I
kD	I
proteins	I
and	O
to	O
less	O
extent	O
the	O
50	B
kD	I
factor	I
.	O
Two	O
abundant	O
proteins	O
of	O
75	O
and	O
80	O
kD	O
were	O
competed	O
out	O
by	O
poly	O
[	O
d	O
(	O
I	O
-	O
C	O
)	O
]	O
in	O
all	O
reactions	O
.	O
The	O
cAMP	O
-	O
response	O
element	O
CRE	O
,	O
TGACGTCA	O
,	O
present	O
in	O
the	O
21	O
base	O
-	O
pair	O
sequence	O
,	O
appears	O
to	O
be	O
essential	O
for	O
specific	O
protein-	O
TRE	O
-DNA	O
interactions	O
because	O
mutation	O
of	O
the	O
two	O
G	O
's	O
destroys	O
this	O
complex	O
.	O
This	O
result	O
suggests	O
that	O
the	O
cAMP	B
response	I
element	I
binding	I
protein	I
,	O
CREB	B
,	O
is	O
involved	O
in	O
the	O
protein	B
-	I
TRE	I
-	I
DNA	I
complex	I
and	O
in	O
mediating	O
the	O
Tax	B
response	O
.	O
Megakaryocytic	O
and	O
erythrocytic	O
lineages	O
share	O
specific	O
transcription	B
factors	I
.	O
Erythroid	O
-	O
specific	O
genes	O
contain	O
binding	O
sites	O
for	O
NF	B
-	I
E1	I
(	O
also	O
called	O
GF-1	B
and	O
Eryf-1	B
;	O
refs	O
1	O
-	O
3	O
respectively	O
)	O
,	O
the	O
principal	O
DNA	B
-	I
binding	I
protein	I
of	O
the	O
erythrocytic	O
lineage	O
.	O
NF	B
-	I
E1	I
expression	O
seems	O
to	O
be	O
restricted	O
to	O
the	O
erythrocytic	O
lineage	O
.	O
A	O
closely	O
related	O
(	O
if	O
not	O
identical	O
)	O
protein	O
is	O
found	O
in	O
both	O
a	O
human	O
megakaryocytic	O
cell	O
line	O
and	O
purified	O
human	O
megakaryocytes	O
;	O
it	O
binds	O
to	O
promoter	O
regions	O
of	O
two	O
megakaryocytic	O
-	O
specific	O
genes	O
.	O
The	O
binding	O
sites	O
and	O
partial	O
proteolysis	O
profile	O
of	O
this	O
protein	O
are	O
indistinguishable	O
from	O
those	O
of	O
the	O
erythroid	B
protein	I
;	O
also	O
,	O
NF	O
-	O
E1	O
messenger	O
RNA	O
is	O
the	O
same	O
size	O
in	O
both	O
the	O
megakaryocytic	O
and	O
erythroid	O
cell	O
lines	O
.	O
Furthermore	O
,	O
point	O
mutations	O
that	O
abolish	O
binding	O
of	O
NF	B
-	I
E1	I
result	O
in	O
a	O
70	O
%	O
decrease	O
in	O
the	O
transcriptional	O
activity	O
of	O
a	O
megakaryocytic	O
-	O
specific	O
promoter	O
.	O
We	O
also	O
find	O
that	O
NF	B
-	I
E2	I
,	O
another	O
trans	B
-	I
acting	I
factor	I
of	O
the	O
erythrocytic	O
lineage	O
,	O
is	O
present	O
in	O
megakaryocytes	O
.	O
Transcriptional	O
effects	O
in	O
both	O
lineages	O
might	O
then	O
be	O
mediated	O
in	O
part	O
by	O
the	O
same	O
specific	O
trans	B
-	I
acting	I
factors	I
.	O
Our	O
data	O
strengthen	O
the	O
idea	O
of	O
a	O
close	O
association	O
between	O
the	O
erythrocytic	O
and	O
the	O
megakaryocytic	O
lineages	O
and	O
could	O
also	O
explain	O
the	O
expression	O
of	O
markers	O
specific	O
to	O
the	O
erythrocytic	O
and	O
megakaryocytic	O
lineages	O
in	O
most	O
erythroblastic	O
and	O
megakaryoblastic	O
permanent	O
cell	O
lines	O
.	O
A	O
new	O
member	O
of	O
the	O
leucine	B
zipper	I
class	I
of	O
proteins	O
that	O
binds	O
to	O
the	O
HLA	O
DR	O
alpha	O
promoter	O
.	O
Several	O
mutants	O
derived	O
from	O
transformed	O
human	O
B	O
cell	O
lines	O
are	O
defective	O
in	O
expressing	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
genes	O
.	O
The	O
failure	O
to	O
express	O
a	O
class	O
II	O
gene	O
in	O
at	O
least	O
one	O
such	O
mutant	O
line	O
has	O
been	O
mapped	O
to	O
the	O
MHC	O
class	O
II	O
X	O
box	O
,	O
a	O
conserved	O
transcriptional	O
element	O
in	O
the	O
promoter	O
region	O
.	O
A	O
complementary	O
DNA	O
encoding	O
a	O
DNA	B
-	I
binding	I
protein	I
(	O
human	B
X	I
box	I
binding	I
protein	I
,	O
hXBP-1	B
)	O
whose	O
target	O
is	O
the	O
human	O
DR	O
alpha	O
X	O
box	O
and	O
the	O
3	O
'	O
flanking	O
region	O
has	O
now	O
been	O
cloned	O
.	O
This	O
complementary	O
DNA	O
encoded	O
a	O
protein	O
with	O
structural	O
similarities	O
to	O
the	O
c	B
-	I
jun	I
proto	I
-	I
oncogene	I
product	I
,	O
and	O
its	O
target	O
sequence	O
was	O
closely	O
related	O
to	O
the	O
palindromic	O
target	O
sequence	O
of	O
c	O
-	O
jun	O
.	O
Mutation	O
of	O
the	O
hXBP-1	O
DNA	O
target	O
sequence	O
decreased	O
DR	O
alpha	O
promoter	O
activity	O
in	O
vivo	O
.	O
These	O
studies	O
suggest	O
that	O
the	O
hXBP-1	B
protein	I
acts	O
as	O
a	O
transcription	B
factor	I
in	O
B	O
cells	O
.	O
Identification	O
of	O
a	O
novel	B
factor	I
that	O
interacts	O
with	O
an	O
immunoglobulin	O
heavy	O
-	O
chain	O
promoter	O
and	O
stimulates	O
transcription	O
in	O
conjunction	O
with	O
the	O
lymphoid	B
cell	I
-	I
specific	I
factor	I
OTF2	B
.	O
The	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
MOPC	O
141	O
immunoglobulin	O
heavy	O
-	O
chain	O
gene	O
was	O
studied	O
by	O
using	O
in	O
vitro	O
transcription	O
.	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
of	O
this	O
gene	O
was	O
dependent	O
on	O
the	O
octamer	O
element	O
5'-ATGCAAAG-3	O
'	O
,	O
located	O
in	O
the	O
upstream	O
region	O
of	O
this	O
promoter	O
and	O
in	O
the	O
promoters	O
of	O
all	O
other	O
immunoglobulin	O
heavy-	O
and	O
light	O
-	O
chain	O
genes	O
.	O
The	O
interaction	O
of	O
purified	O
octamer	B
transcription	I
factors	I
1	O
and	O
2	O
(	O
OTF1	B
and	O
OTF2	B
)	O
with	O
the	O
MOPC	O
141	O
promoter	O
was	O
studied	O
by	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
DNase	B
I	I
footprinting	O
.	O
Purified	O
OTF1	B
from	O
HeLa	O
cells	O
and	O
OTF1	B
and	O
OTF2	B
from	O
B	O
cells	O
bound	O
to	O
identical	O
sequences	O
within	O
the	O
heavy	O
-	O
chain	O
promoter	O
.	O
The	O
OTF	O
interactions	O
we	O
observed	O
extended	O
over	O
the	O
heptamer	O
element	O
5'-CTCAGGA-3	O
'	O
,	O
and	O
it	O
seems	O
likely	O
that	O
the	O
binding	O
of	O
the	O
purified	B
factors	I
involves	O
cooperation	O
between	O
octamer	O
and	O
heptamer	O
sites	O
in	O
this	O
promoter	O
.	O
In	O
addition	O
to	O
these	O
elements	O
,	O
we	O
identified	O
a	O
second	O
regulatory	O
element	O
,	O
the	O
N	O
element	O
with	O
the	O
sequence	O
5'-GGAACCTCCCCC-3	O
'	O
.	O
The	O
N	O
element	O
could	O
independently	O
mediate	O
low	O
levels	O
of	O
transcription	O
in	O
both	O
B	O
-	O
cell	O
and	O
HeLa	O
-	O
cell	O
extracts	O
,	O
and	O
,	O
in	O
conjunction	O
with	O
the	O
octamer	O
element	O
,	O
it	O
can	O
promote	O
high	O
levels	O
of	O
transcription	O
in	O
B	O
-	O
cell	O
extracts	O
.	O
The	O
N	O
element	O
bound	O
a	O
transcription	B
factor	I
,	O
NTF	B
,	O
that	O
is	O
ubiquitous	O
in	O
cell	O
-	O
type	O
distribution	O
,	O
and	O
NTF	B
was	O
distinct	O
from	O
any	O
of	O
the	O
previously	B
described	I
proteins	I
that	O
bind	O
to	O
similar	O
sequences	O
.	O
Based	O
on	O
these	O
results	O
,	O
we	O
propose	O
that	O
NTF	B
and	O
OTF2	B
interactions	O
(	O
both	O
with	O
their	O
cognate	O
DNA	O
elements	O
and	O
possibly	O
at	O
the	O
protein	O
-	O
protein	O
level	O
)	O
may	O
be	O
critical	O
to	O
B	O
-	O
cell	O
-	O
specific	O
expression	O
and	O
that	O
these	O
interactions	O
provide	O
additional	O
pathways	O
for	O
regulating	O
gene	O
expression	O
.	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D2	O
production	O
by	O
T	O
lymphocytes	O
and	O
alveolar	O
macrophages	O
recovered	O
by	O
lavage	O
from	O
normocalcemic	O
patients	O
with	O
tuberculosis	O
.	O
To	O
compare	O
extra	O
-	O
renal	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
in	O
different	O
types	O
of	O
granulomatous	O
disease	O
,	O
and	O
to	O
identify	O
the	O
cell	O
types	O
responsible	O
,	O
we	O
have	O
evaluated	O
the	O
conversion	O
of	O
25	O
(	O
OH	O
)	O
D3	O
in	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
by	O
uncultured	O
cells	O
recovered	O
by	O
bronchoalveolar	O
lavage	O
and	O
blood	O
mononuclear	O
cells	O
from	O
normocalcemic	O
patients	O
with	O
sarcoidosis	O
and	O
tuberculosis	O
.	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
produced	O
both	O
by	O
lavage	O
cells	O
(	O
12	O
/	O
12	O
tuberculosis	O
patients	O
,	O
2	O
/	O
6	O
sarcoidosis	O
patients	O
)	O
and	O
blood	O
mononuclear	O
cells	O
(	O
3	O
/	O
5	O
tuberculosis	O
patients	O
,	O
0	O
/	O
3	O
sarcoidosis	O
patients	O
)	O
from	O
patients	O
but	O
not	O
controls	O
,	O
but	O
significantly	O
greater	O
amounts	O
were	O
produced	O
by	O
lavage	O
cells	O
from	O
tuberculosis	O
patients	O
than	O
those	O
of	O
sarcoidosis	O
patients	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
by	O
lavage	O
cells	O
from	O
tuberculosis	O
patients	O
correlated	O
with	O
the	O
number	O
of	O
CD8	O
+	O
T	O
lymphocytes	O
present	O
but	O
not	O
other	O
cell	O
types	O
.	O
T	O
lymphocytes	O
appeared	O
to	O
be	O
an	O
important	O
source	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
,	O
since	O
purified	O
T	O
lymphocytes	O
from	O
all	O
patients	O
with	O
tuberculosis	O
produced	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
production	O
by	O
these	O
cells	O
correlated	O
closely	O
with	O
that	O
produced	O
by	O
unseparated	O
lavage	O
cells	O
.	O
Because	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
can	O
improve	O
the	O
capacity	O
of	O
macrophages	O
to	O
kill	O
mycobacteria	O
,	O
our	O
results	O
support	O
the	O
conclusion	O
that	O
macrophage	O
-	O
lymphocyte	O
interactions	O
,	O
mediated	O
at	O
least	O
in	O
part	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
may	O
be	O
an	O
important	O
component	O
of	O
a	O
successful	O
antituberculous	O
immune	O
response	O
.	O
Effects	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
on	O
the	O
human	O
chronic	O
myelogenous	O
leukemia	O
cell	O
line	O
RWLeu-4	O
.	O
The	O
effects	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
on	O
proliferation	O
,	O
differentiation	O
,	O
and	O
macromolecular	O
synthesis	O
in	O
the	O
new	O
Philadelphia	O
chromosome	O
-	O
positive	O
chronic	O
myelogenous	O
leukemia	O
cell	O
line	O
,	O
RWLeu-4	O
,	O
were	O
investigated	O
.	O
Binding	O
of	O
[	O
3H	O
]	O
VD3	O
was	O
saturable	O
,	O
with	O
approximately	O
2000	O
-	O
3000	O
sites	O
/	O
cell	O
,	O
and	O
half	O
-	O
maximal	O
binding	O
occurring	O
at	O
0.21	O
-	O
0.33	O
nM	O
.	O
Treatment	O
of	O
RWLeu-4	O
cells	O
with	O
VD3	O
induced	O
24R	B
-	I
hydroxylase	I
activity	O
,	O
a	O
marker	O
of	O
vitamin	O
D3	O
responsiveness	O
in	O
many	O
tissues	O
.	O
Exposure	O
of	O
RWLeu-4	O
cells	O
to	O
VD3	O
also	O
inhibited	O
proliferation	O
and	O
DNA	O
synthesis	O
with	O
a	O
50	O
%	O
effective	O
dose	O
of	O
3.5	O
-	O
10	O
nM	O
within	O
72	O
h	O
;	O
in	O
addition	O
,	O
protein	O
and	O
RNA	O
synthesis	O
were	O
inhibited	O
by	O
VD3	O
treatment	O
.	O
Exposure	O
of	O
RWLeu-4	O
cells	O
to	O
5	O
nM	O
VD3	O
for	O
72	O
h	O
caused	O
50	O
%	O
of	O
the	O
cells	O
to	O
differentiate	O
into	O
macrophage	O
/	O
monocyte	O
type	O
cells	O
as	O
judged	O
by	O
nitroblue	O
tetrazolium	O
staining	O
and	O
adherence	O
to	O
plastic	O
.	O
Progressive	O
expression	O
of	O
cell	B
surface	I
maturation	I
-	I
specific	I
antigens	I
of	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
was	O
induced	O
by	O
treatment	O
of	O
RWLeu-4	O
cells	O
with	O
VD3	O
for	O
24	O
to	O
72	O
h	O
at	O
doses	O
that	O
inhibited	O
cellular	O
proliferation	O
.	O
c	O
-	O
myc	O
RNA	O
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
RWLeu-4	O
cells	O
,	O
increased	O
after	O
0.5	O
h	O
of	O
treatment	O
with	O
50	O
nM	O
VD3	O
and	O
then	O
rapidly	O
decreased	O
to	O
barely	O
detectable	O
levels	O
after	O
4	O
h	O
of	O
treatment	O
.	O
Finally	O
,	O
the	O
in	O
vitro	O
tyrosine	O
kinase	O
activity	O
associated	O
with	O
the	O
p210bcr	B
-	I
abl	I
oncogene	I
product	I
was	O
decreased	O
approximately	O
50	O
%	O
by	O
VD3	O
treatment	O
.	O
Because	O
of	O
the	O
presence	O
of	O
a	O
functional	O
receptor	O
-	O
effector	O
system	O
for	O
VD3	O
and	O
multiple	O
biological	O
responses	O
to	O
the	O
hormone	O
,	O
these	O
cells	O
provide	O
a	O
unique	O
model	O
system	O
with	O
which	O
to	O
probe	O
the	O
specific	O
effects	O
of	O
VD3	O
on	O
cell	O
growth	O
and	O
differentiation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O
Type	B
II	I
estrogen	I
binding	I
sites	I
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
:	O
variations	O
during	O
the	O
menstrual	O
cycle	O
.	O
We	O
have	O
previously	O
reported	O
that	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
contain	O
type	O
II	B
estrogen	I
binding	I
sites	I
(	O
type	B
II	I
EBS	I
)	O
.	O
In	O
this	O
study	O
,	O
the	O
fluctuations	O
of	O
type	B
II	I
EBS	I
during	O
the	O
menstrual	O
cycle	O
were	O
analyzed	O
in	O
6	O
normally	O
menstruating	O
women	O
.	O
Approximately	O
3	O
times	O
higher	O
levels	O
of	O
type	B
II	I
EBS	I
were	O
found	O
in	O
the	O
periovulatory	O
period	O
with	O
respect	O
to	O
both	O
follicular	O
and	O
luteal	O
phases	O
.	O
In	O
postmenopausal	O
women	O
the	O
mean	O
type	B
II	I
EBS	I
levels	O
were	O
similar	O
to	O
those	O
observed	O
in	O
the	O
follicular	O
phase	O
of	O
the	O
cycle	O
.	O
However	O
,	O
in	O
3	O
postmenopausal	O
patients	O
a	O
short	O
course	O
of	O
estrogen	O
or	O
tamoxifen	O
resulted	O
in	O
a	O
marked	O
increase	O
of	O
type	B
II	I
EBS	I
levels	O
.	O
Tamoxifen	O
was	O
also	O
found	O
to	O
compete	O
with	O
17	O
beta	O
-	O
estradiol	O
for	O
type	B
II	I
EBS	I
in	O
PBMC	O
,	O
although	O
to	O
a	O
lesser	O
extent	O
than	O
diethylstilbestrol	O
.	O
Lymphocyte	O
cell	O
lines	O
from	O
vitamin	O
D	O
-	O
dependent	O
rickets	O
type	O
II	O
show	O
functional	O
defects	O
in	O
the	O
1	B
alpha	I
,	I
25-dihydroxyvitamin	I
D3	I
receptor	I
.	O
Lymphocyte	O
cell	O
lines	O
were	O
established	O
from	O
five	O
patients	O
with	O
vitamin	O
D	O
-	O
dependent	O
rickets	O
,	O
type	O
II	O
(	O
VDDR	O
-	O
II	O
)	O
.	O
These	O
lines	O
were	O
established	O
by	O
infection	O
with	O
human	O
T	O
-	O
lymphotrophic	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
.	O
Binding	O
of	O
[	O
3H	O
]	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
to	O
its	O
receptor	O
in	O
these	O
cell	O
lines	O
was	O
compared	O
to	O
binding	O
studies	O
using	O
a	O
T	O
-	O
lymphocyte	O
cell	O
line	O
(	O
S	O
-	O
LB1	O
)	O
from	O
a	O
normal	O
individual	O
.	O
The	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
receptor	O
of	O
S	O
-	O
LB1	O
was	O
comparable	O
to	O
the	O
well	O
-	O
characterized	O
chick	B
intestinal	I
1	I
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptor	I
in	O
terms	O
of	O
its	O
ligand	O
binding	O
affinity	O
and	O
capacity	O
,	O
its	O
mobility	O
on	O
5	O
-	O
20	O
%	O
sucrose	O
gradients	O
,	O
and	O
its	O
adsorption	O
to	O
and	O
elution	O
properties	O
from	O
DNA	O
-	O
cellulose	O
.	O
Three	O
cell	O
lines	O
established	O
from	O
patients	O
with	O
VDDR	O
-	O
II	O
(	O
Rh-	O
VDR	B
,	O
Sh-	O
VDR	B
,	O
and	O
Ab-	O
VDR	B
)	O
showed	O
no	O
specific	O
binding	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
to	O
a	O
receptor	B
and	O
treatment	O
of	O
the	O
cultured	O
cells	O
with	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
did	O
not	O
stimulate	O
production	O
of	O
24	O
,	O
25-dihydroxy	O
-	O
vitamin	O
D3	O
(	O
24	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
,	O
a	O
response	O
which	O
is	O
diagnostic	O
of	O
the	O
presence	O
of	O
a	O
functional	B
1	I
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptor	I
.	O
In	O
a	O
fourth	O
cell	O
line	O
,	O
A1-VDR	O
,	O
the	O
receptor	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
had	O
a	O
low	O
binding	O
capacity	O
and	O
25	B
(	I
OH	I
)	I
D3	I
-	I
24-hydroxylase	I
activity	O
was	O
not	O
detectable	O
.	O
Induction	O
of	O
24	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
synthesis	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
observed	O
in	O
the	O
fifth	O
cell	O
line	O
,	O
designated	O
Ro	O
-	O
VDR	O
,	O
although	O
the	O
sensitivity	O
to	O
hormone	O
treatment	O
was	O
lower	O
than	O
in	O
the	O
control	O
cell	O
line	O
from	O
a	O
normal	O
donor	O
.	O
The	O
capacity	O
of	O
the	O
receptor	B
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
low	O
in	O
Ro	O
-	O
VDR	O
.	O
In	O
all	O
cell	O
lines	O
where	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
binding	O
to	O
a	O
receptor	B
was	O
detectable	O
,	O
the	O
receptor	B
had	O
the	O
typical	O
sedimentation	O
coefficient	O
of	O
3.7	O
S	O
on	O
sucrose	O
density	O
gradient	O
analysis	O
.	O
Binding	O
and	O
elution	O
properties	O
to	O
DNA	O
-	O
cellulose	O
,	O
however	O
,	O
differed	O
from	O
normal	O
in	O
both	O
Ro	O
-	O
VDR	O
and	O
A1-VDR	O
cells	O
where	O
elution	O
from	O
DNA	O
-	O
cellulose	O
occurred	O
at	O
a	O
lower	O
salt	O
concentration	O
than	O
is	O
typical	O
of	O
the	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptor	I
.	O
While	O
Ro	O
-	O
VDR	O
cells	O
showed	O
typical	O
nuclear	O
localization	O
of	O
the	O
unoccupied	B
1	I
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptor	I
,	O
neither	O
the	O
unoccupied	O
nor	O
the	O
occupied	O
receptor	B
from	O
A1-VDR	O
cells	O
was	O
completely	O
localized	O
in	O
the	O
nucleus	O
.	O
In	O
a	O
series	O
of	O
functional	O
studies	O
we	O
found	O
that	O
modulation	O
of	O
the	O
level	O
of	O
the	O
mRNAs	O
coding	O
for	O
both	O
the	O
c	O
-	O
myc	O
oncogene	O
and	O
the	O
growth	O
factor	O
known	O
as	O
granulocyte	O
-	O
monocyte	O
colony	O
stimulating	O
activity	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
correlated	O
with	O
the	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptor	I
status	O
of	O
these	O
cells	O
.	O
Use	O
of	O
these	O
cell	O
lines	O
will	O
facilitate	O
further	O
study	O
of	O
the	O
molecular	O
defect	O
(	O
s	O
)	O
in	O
the	O
receptor	B
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
in	O
vitamin	O
D	O
-	O
dependent	O
rickets	O
type	O
II	O
and	O
will	O
allow	O
a	O
correlation	O
with	O
impairment	O
of	O
cellular	O
functions	O
.	O
Heterogeneity	O
of	O
antigen	B
molecules	I
recognized	O
by	O
anti	B
-	I
tax1	I
monoclonal	I
antibody	I
Lt-4	B
in	O
cell	O
lines	O
bearing	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
and	O
related	O
retroviruses	O
.	O
Using	O
a	O
monoclonal	B
antibody	I
,	O
Lt-4	B
,	O
directed	O
against	O
human	B
T	I
cell	I
leukemia	I
virus	I
type	I
I	I
(	I
HTLV	I
-	I
I	I
)	I
trans	I
-	I
activator	I
(	I
tax1	I
)	I
antigen	I
,	O
we	O
examined	O
the	O
expression	O
of	O
tax1	B
and	O
related	O
antigens	B
in	O
a	O
variety	O
of	O
T	O
cell	O
lines	O
bearing	O
HTLV	O
-	O
I	O
and	O
related	O
retroviruses	O
,	O
simian	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
STLV	O
-	O
I	O
)	O
and	O
HTLV	O
-	O
II	O
,	O
by	O
immunofluorescence	O
and	O
immunoblot	O
assays	O
.	O
Lt-4	B
reacted	O
with	O
all	O
HTLV	O
-	O
I	O
-	O
bearing	O
cell	O
lines	O
tested	O
and	O
five	O
out	O
of	O
eight	O
simian	O
cell	O
lines	O
bearing	O
STLV	O
-	O
I	O
,	O
but	O
not	O
with	O
an	O
HTLV	O
-	O
II	O
-	O
bearing	O
cell	O
line	O
.	O
Lt-4	B
detected	O
40	O
kd	O
tax1	B
antigen	I
molecules	I
in	O
most	O
HTLV	O
-	O
I	O
-	O
bearing	O
cell	O
lines	O
except	O
one	O
cell	O
line	O
that	O
expressed	O
39	B
kd	I
tax1	I
antigen	I
.	O
In	O
the	O
STLV	O
-	O
I	O
-	O
bearing	O
T	O
cell	O
lines	O
,	O
tax1-related	B
antigen	I
molecules	I
detected	O
by	O
Lt-4	B
were	O
heterogeneous	O
,	O
having	O
molecular	O
weights	O
in	O
the	O
range	O
of	O
36	O
-	O
41	O
kd	O
.	O
The	O
expression	O
of	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
,	O
and	O
c	O
-	O
myc	O
genes	O
is	O
regulated	O
by	O
heat	O
shock	O
in	O
human	O
lymphoid	O
cells	O
.	O
The	O
effect	O
of	O
heat	O
shock	O
on	O
the	O
expression	O
of	O
the	O
nuclear	O
protooncogenes	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
,	O
and	O
c	O
-	O
myc	O
was	O
studied	O
in	O
human	O
lymphoid	O
cells	O
.	O
Heat	O
shock	O
caused	O
an	O
increase	O
in	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
levels	O
and	O
a	O
decrease	O
in	O
c	O
-	O
myc	O
mRNA	O
levels	O
in	O
pre	O
-	O
B	O
(	O
Hyon	O
)	O
and	O
T	O
(	O
DND-41	O
)	O
cell	O
lines	O
as	O
well	O
as	O
in	O
freshly	O
isolated	O
normal	O
human	O
thymocytes	O
.	O
The	O
changes	O
in	O
the	O
mRNA	O
levels	O
of	O
these	O
protooncogenes	O
in	O
Hyon	O
cells	O
were	O
most	O
pronounced	O
at	O
42	O
and	O
43	O
degrees	O
C	O
;	O
kinetic	O
analysis	O
demonstrated	O
that	O
the	O
changes	O
could	O
be	O
detected	O
within	O
30	O
min	O
of	O
heat	O
shock	O
.	O
Altered	O
transcription	O
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
myc	O
genes	O
was	O
the	O
primary	O
effect	O
of	O
heat	O
shock	O
.	O
Secondarily	O
,	O
heat	O
shock	O
of	O
Hyon	O
cells	O
stabilized	O
the	O
c	O
-	O
myc	O
mRNA	O
level	O
by	O
increasing	O
its	O
half	O
-	O
life	O
from	O
24	O
to	O
45	O
min	O
.	O
The	O
overall	O
effect	O
of	O
heat	O
shock	O
on	O
c	O
-	O
myc	O
mRNA	O
level	O
,	O
however	O
,	O
was	O
a	O
marked	O
inhibition	O
of	O
its	O
transcription	O
.	O
These	O
results	O
demonstrate	O
that	O
the	O
transcription	O
of	O
nuclear	O
protooncogenes	O
is	O
regulated	O
by	O
heat	O
shock	O
indicating	O
a	O
role	O
for	O
nuclear	O
protooncogenes	O
in	O
the	O
stress	O
response	O
of	O
lymphoid	O
cells	O
.	O
A	O
novel	O
T	B
-	I
cell	I
protein	I
which	O
recognizes	O
a	O
palindromic	O
sequence	O
in	O
the	O
negative	O
regulatory	O
element	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
.	O
Two	O
major	O
protein	O
-	O
binding	O
sites	O
within	O
the	O
negative	O
regulatory	O
element	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
have	O
been	O
identified	O
.	O
One	O
(	O
site	O
B	O
)	O
contained	O
a	O
palindromic	O
sequence	O
with	O
homology	O
to	O
steroid	O
/	O
thyroid	O
hormone	O
response	O
elements	O
but	O
was	O
distinct	O
from	O
previously	O
described	O
binding	O
sites	O
of	O
this	O
class	O
.	O
A	O
novel	O
T	B
-	I
cell	I
protein	I
recognized	O
the	O
palindromic	O
sequence	O
within	O
site	O
B	O
and	O
also	O
bound	O
estrogen-	O
or	O
thyroid	O
hormone	O
-	O
response	O
elements	O
with	O
lower	O
affinity	O
.	O
A	O
7-base	O
-	O
pair	O
mutation	O
in	O
the	O
site	O
B	O
palindrome	O
,	O
which	O
destroyed	O
protein	O
binding	O
,	O
resulted	O
in	O
increased	O
expression	O
from	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
in	O
T	O
cells	O
.	O
Epstein	B
-	I
Barr	I
virus	I
nuclear	I
antigen	I
2	I
transactivates	O
latent	B
membrane	I
protein	I
LMP1	B
.	O
Several	O
lines	O
of	O
evidence	O
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
Epstein	B
-	I
Barr	I
virus	I
(	I
EBV	I
)	I
nuclear	I
antigen	I
2	I
(	O
EBNA-2	B
)	O
or	O
leader	B
protein	I
(	O
EBNA	B
-	I
LP	I
)	O
affects	O
expression	O
of	O
the	O
EBV	B
latent	I
infection	I
membrane	I
protein	I
LMP1	B
.	O
We	O
now	O
demonstrate	O
the	O
following	O
.	O
(	O
i	O
)	O
Acute	O
transfection	O
and	O
expression	O
of	O
EBNA-2	B
under	O
control	O
of	O
simian	O
virus	O
40	O
or	O
Moloney	O
murine	O
leukemia	O
virus	O
promoters	O
resulted	O
in	O
increased	O
LMP1	B
expression	O
in	O
P3HR-1-infected	O
Burkitt	O
's	O
lymphoma	O
cells	O
and	O
the	O
P3HR-1	O
or	O
Daudi	O
cell	O
line	O
.	O
(	O
ii	O
)	O
Transfection	O
and	O
expression	O
of	O
EBNA	B
-	I
LP	I
alone	O
had	O
no	O
effect	O
on	O
LMP1	B
expression	O
and	O
did	O
not	O
act	O
synergistically	O
with	O
EBNA-2	B
to	O
affect	O
LMP1	B
expression	O
.	O
(	O
iii	O
)	O
LMP1	B
expression	O
in	O
Daudi	O
and	O
P3HR-1-infected	O
cells	O
was	O
controlled	O
at	O
the	O
mRNA	O
level	O
,	O
and	O
EBNA-2	B
expression	O
in	O
Daudi	O
cells	O
increased	O
LMP1	O
mRNA	O
.	O
(	O
iv	O
)	O
No	O
other	O
EBV	O
genes	O
were	O
required	O
for	O
EBNA-2	B
transactivation	O
of	O
LMP1	B
since	O
cotransfection	O
of	O
recombinant	O
EBNA-2	O
expression	O
vectors	O
and	O
genomic	O
LMP1	O
DNA	O
fragments	O
enhanced	O
LMP1	B
expression	O
in	O
the	O
EBV	O
-	O
negative	O
B	O
-	O
lymphoma	O
cell	O
lines	O
BJAB	O
,	O
Louckes	O
,	O
and	O
BL30	O
.	O
(	O
v	O
)	O
An	O
EBNA-2-responsive	O
element	O
was	O
found	O
within	O
the	O
-512	O
to	O
+	O
40	O
LMP1	O
DNA	O
since	O
this	O
DNA	O
linked	O
to	O
a	O
chloramphenicol	O
acetyltransferase	O
reporter	O
gene	O
was	O
transactivated	O
by	O
cotransfection	O
with	O
an	O
EBNA-2	O
expression	O
vector	O
.	O
(	O
vi	O
)	O
The	O
EBV	O
type	O
2	O
EBNA-2	B
transactivated	O
LMP1	B
as	O
well	O
as	O
the	O
EBV	B
type	I
1	I
EBNA-2	I
.	O
(	O
vii	O
)	O
Two	O
deletions	O
within	O
the	O
EBNA-2	B
gene	O
which	O
rendered	O
EBV	O
transformation	O
incompetent	O
did	O
not	O
transactivate	O
LMP1	B
,	O
whereas	O
a	O
transformation	O
-	O
competent	O
EBNA-2	O
deletion	O
mutant	O
did	O
transactivate	O
LMP1	B
.	O
LMP1	B
is	O
a	O
potent	O
effector	O
of	O
B	O
-	O
lymphocyte	O
activation	O
and	O
can	O
act	O
synergistically	O
with	O
EBNA-2	B
to	O
induce	O
cellular	O
CD23	O
gene	O
expression	O
.	O
Thus	O
,	O
EBNA-2	B
transactivation	O
of	O
LMP1	B
amplifies	O
the	O
biological	O
impact	O
of	O
EBNA-2	B
and	O
underscores	O
its	O
central	O
role	O
in	O
EBV	O
-	O
induced	O
growth	O
transformation	O
.	O
Protein	O
kinase	O
inhibitor	O
H-7	O
blocks	O
accumulation	O
of	O
unspliced	O
mRNA	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
.	O
Rex	B
,	O
the	O
post	B
-	I
transcriptional	I
regulator	I
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
,	O
is	O
known	O
to	O
induce	O
accumulation	O
of	O
the	O
unspliced	O
viral	O
gag	O
-	O
pol	O
mRNA	O
.	O
Rex	B
is	O
a	O
phosphoprotein	B
found	O
in	O
the	O
cell	O
nucleolus	O
,	O
whose	O
function	O
may	O
be	O
regulated	O
by	O
its	O
localization	O
and	O
phosphorylation	O
.	O
We	O
have	O
examined	O
the	O
role	O
of	O
phosphorylation	O
on	O
Rex	B
function	O
by	O
using	O
a	O
protein	O
kinase	O
inhibitor	O
,	O
H-7	O
[	O
1-	O
(	O
5-isoquinolinyl	O
-	O
sulfonyl	O
)	O
-2-methylpiperazine	O
]	O
.	O
Treatment	O
of	O
an	O
HTLV	O
-	O
I	O
infected	O
human	O
T	O
-	O
cell	O
line	O
with	O
H-7	O
blocked	O
specifically	O
accumulation	O
of	O
the	O
unspliced	O
gag	O
-	O
pol	O
mRNA	O
,	O
resulting	O
in	O
the	O
decreased	O
Gag	B
protein	I
synthesis	O
that	O
corresponds	O
with	O
the	O
decreased	O
in	O
vivo	O
phosphorylation	O
of	O
Rex	B
.	O
In	O
contrast	O
,	O
other	O
viral	O
and	O
cellular	O
products	O
have	O
not	O
been	O
influenced	O
by	O
the	O
level	O
of	O
H-7	O
used	O
.	O
Therefore	O
,	O
the	O
phosphorylation	O
of	O
Rex	B
is	O
required	O
for	O
the	O
viral	O
RNA	O
partition	O
of	O
HTLV	O
-	O
I	O
.	O
Lipopolysaccharide	O
is	O
a	O
potent	O
monocyte	O
/	O
macrophage	O
-	O
specific	O
stimulator	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
.	O
Lipopolysaccharide	O
(	O
LPS	O
)	O
potently	O
stimulates	O
human	O
immunodeficiency	O
virus	O
type	O
1-long	O
terminal	O
repeat	O
(	O
HIV-1-LTR	O
)	O
CAT	O
constructs	O
transfected	O
into	O
monocyte	O
/	O
macrophage	O
-	O
like	O
cell	O
lines	O
but	O
not	O
a	O
T	O
cell	O
line	O
.	O
This	O
effect	O
appears	O
to	O
be	O
mediated	O
through	O
the	O
induction	O
of	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrate	O
that	O
LPS	O
induces	O
a	O
DNA	O
binding	O
activity	O
indistinguishable	O
from	O
NF	B
-	I
kappa	I
B	I
in	O
U937	O
and	O
THP-1	O
cells	O
.	O
LPS	O
is	O
also	O
shown	O
to	O
dramatically	O
increase	O
HIV-1	O
production	O
from	O
a	O
chronically	O
infected	O
monocyte	O
/	O
macrophage	O
-	O
like	O
cloned	O
cell	O
line	O
,	O
U1	O
,	O
which	O
produces	O
very	O
low	O
levels	O
of	O
HIV-1	O
at	O
baseline	O
.	O
The	O
stimulation	O
of	O
viral	O
production	O
from	O
this	O
cell	O
line	O
occurs	O
only	O
if	O
these	O
cells	O
are	O
treated	O
with	O
granulocyte	B
/	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
before	O
treatment	O
with	O
LPS	O
.	O
This	O
stimulation	O
of	O
HIV-1	O
production	O
is	O
correlated	O
with	O
an	O
increase	O
in	O
the	O
level	O
of	O
HIV-1	O
RNA	O
and	O
and	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
LPS	O
is	O
not	O
able	O
to	O
induce	O
HIV-1	O
production	O
in	O
a	O
cloned	O
T	O
cell	O
line	O
.	O
The	O
effect	O
of	O
LPS	O
on	O
HIV-1	O
replication	O
occurs	O
at	O
picogram	O
per	O
milliliter	O
concentrations	O
and	O
may	O
be	O
clinically	O
significant	O
in	O
understanding	O
the	O
variability	O
of	O
the	O
natural	O
history	O
of	O
HIV-1	O
infection	O
.	O
Stimulation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV-2	O
)	O
gene	O
expression	O
by	O
the	O
cytomegalovirus	O
and	O
HIV-2	O
transactivator	O
gene	O
.	O
Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
often	O
causes	O
latent	O
infection	O
.	O
Transactivation	O
by	O
some	O
DNA	O
viruses	O
has	O
been	O
implicated	O
in	O
inducing	O
HIV-1	O
replication	O
and	O
pathogenesis	O
.	O
The	O
transactivator	O
(	O
IE-2	O
)	O
gene	O
of	O
the	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
enhance	O
HIV-2	O
as	O
well	O
as	O
HIV-1	O
gene	O
expression	O
in	O
vitro	O
.	O
This	O
inducer	O
can	O
act	O
in	O
concert	O
with	O
the	O
HIV-2	O
tat	O
gene	O
and	O
T	O
-	O
cell	O
activation	O
in	O
enhancing	O
gene	O
expression	O
in	O
human	O
CD4	O
+	O
lymphocytes	O
.	O
While	O
the	O
HIV-2	O
and	O
HIV-1	O
tat	O
genes	O
and	O
T	B
-	I
cell	I
activators	I
apparently	O
employ	O
independent	O
modes	O
of	O
action	O
,	O
the	O
CMV	O
transactivator	O
in	O
combination	O
with	O
the	O
HIV-2	O
tat	O
or	O
T	B
-	I
cell	I
activators	I
may	O
employ	O
a	O
gene	O
activation	O
pathway	O
with	O
some	O
common	O
and	O
some	O
distinct	O
components	O
.	O
Both	O
HIV-2	O
and	O
CMV	O
transactivators	O
enhance	O
HIV-2	O
gene	O
expression	O
by	O
transcriptional	O
activation	O
involving	O
transcript	O
initiation	O
as	O
well	O
as	O
elongation	O
,	O
with	O
CMV	O
transactivator	O
affecting	O
elongation	O
more	O
than	O
the	O
initiation	O
.	O
A	O
significant	O
proportion	O
of	O
transcripts	O
appear	O
to	O
terminate	O
prematurely	O
in	O
the	O
absence	O
of	O
transactivators	B
.	O
Deletion	O
mutation	O
analysis	O
of	O
the	O
HIV-2	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
suggests	O
that	O
the	O
element	O
that	O
responds	O
to	O
CMV	O
transactivation	O
in	O
human	O
CD4	O
+	O
lymphocytes	O
is	O
either	O
a	O
diffuse	O
one	O
or	O
located	O
downstream	O
of	O
the	O
HIV-2	O
enhancer	O
element	O
.	O
Sequence	O
-	O
specific	O
DNA	O
binding	O
of	O
the	O
proto	B
-	I
oncoprotein	I
ets-1	B
defines	O
a	O
transcriptional	O
activator	O
sequence	O
within	O
the	O
long	O
terminal	O
repeat	O
of	O
the	O
Moloney	O
murine	O
sarcoma	O
virus	O
.	O
The	O
ets	O
proto	O
-	O
oncogene	O
family	O
is	O
a	O
group	O
of	O
sequence	O
-	O
related	O
genes	O
whose	O
normal	O
cellular	O
function	O
is	O
unknown	O
.	O
In	O
a	O
study	O
of	O
cellular	B
proteins	I
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
murine	O
retroviruses	O
in	O
T	O
lymphocytes	O
,	O
we	O
have	O
discovered	O
that	O
a	O
member	O
of	O
the	O
ets	O
gene	O
family	O
encodes	O
a	O
sequence	B
-	I
specific	I
DNA	I
-	I
binding	I
protein	I
.	O
A	O
mouse	O
ets-1	O
cDNA	O
clone	O
was	O
obtained	O
by	O
screening	O
a	O
mouse	O
thymus	O
cDNA	O
expression	O
library	O
with	O
a	O
double	O
-	O
stranded	O
oligonucleotide	O
probe	O
representing	O
20	O
bp	O
of	O
the	O
Moloney	O
murine	O
sarcoma	O
virus	O
(	O
MSV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O
The	O
cDNA	O
sequence	O
has	O
an	O
813-bp	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
whose	O
predicted	O
amino	O
acid	O
sequence	O
is	O
97.6	O
%	O
identical	O
to	O
the	O
272	B
carboxy	I
-	I
terminal	I
amino	I
acids	I
of	O
the	O
human	B
ets-1	I
protein	I
.	O
The	O
ORF	O
was	O
expressed	O
in	O
bacteria	O
,	O
and	O
the	O
30-kD	B
protein	I
product	I
was	O
shown	O
to	O
bind	O
DNA	O
in	O
a	O
sequence	O
-	O
specific	O
manner	O
by	O
mobility	O
-	O
shift	O
assays	O
,	O
Southwestern	O
blot	O
analysis	O
,	O
and	O
methylation	O
interference	O
.	O
A	O
mutant	O
LTR	O
containing	O
four	O
base	O
pair	O
substitutions	O
in	O
the	O
ets-1	O
binding	O
site	O
was	O
constructed	O
and	O
was	O
shown	O
to	O
have	O
reduced	O
binding	O
in	O
vitro	O
.	O
Transcriptional	O
efficiency	O
of	O
the	O
MSV	O
LTR	O
promoter	O
containing	O
this	O
disrupted	O
ets-1	O
binding	O
site	O
was	O
compared	O
to	O
the	O
activity	O
of	O
a	O
wild	O
-	O
type	O
promoter	O
in	O
mouse	O
T	O
lymphocytes	O
in	O
culture	O
,	O
and	O
15-	O
to	O
20-fold	O
reduction	O
in	O
expression	O
of	O
a	O
reporter	O
gene	O
was	O
observed	O
.	O
We	O
propose	O
that	O
ets-1	B
functions	O
as	O
a	O
transcriptional	O
activator	O
of	O
mammalian	O
type	O
-	O
C	O
retroviruses	O
and	O
speculate	O
that	O
ets	O
-	O
related	O
genes	O
constitute	O
a	O
new	O
group	O
of	O
eukaryotic	B
DNA	I
-	I
binding	I
proteins	I
.	O
Cloning	O
of	O
a	O
transcriptionally	B
active	I
human	I
TATA	I
binding	I
factor	I
.	O
Transcription	B
factor	I
IID	I
(	O
TFIID	B
)	O
binds	O
to	O
the	O
TATA	O
box	O
promoter	O
element	O
and	O
regulates	O
the	O
expression	O
of	O
most	O
eukaryotic	O
genes	O
transcribed	O
by	O
RNA	B
polymerase	I
II	I
.	O
Complementary	O
DNA	O
(	O
cDNA	O
)	O
encoding	O
a	O
human	B
TFIID	I
protein	I
has	O
been	O
cloned	O
.	O
The	O
human	B
TFIID	I
polypeptide	I
has	O
339	O
amino	O
acids	O
and	O
a	O
molecular	O
size	O
of	O
37	O
,	O
745	O
daltons	O
.	O
The	O
carboxyl	B
-	I
terminal	I
181	I
amino	I
acids	I
of	O
the	O
human	B
TFIID	I
protein	I
shares	O
80	O
%	O
identity	O
with	O
the	O
TFIID	B
protein	O
from	O
Saccharomyces	O
cerevisiae	O
.	O
The	O
amino	B
terminus	I
contains	O
an	O
unusual	O
repeat	O
of	O
38	O
consecutive	O
glutamine	O
residues	O
and	O
an	O
X	B
-	I
Thr	I
-	I
Pro	I
repeat	I
.	O
Expression	O
of	O
DNA	O
in	O
reticulocyte	O
lysates	O
or	O
in	O
Escherichia	O
coli	O
yielded	O
a	O
protein	O
that	O
was	O
competent	O
for	O
both	O
DNA	O
binding	O
and	O
transcription	O
activation	O
.	O
The	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
BMRF1	O
promoter	O
for	O
early	B
antigen	I
(	O
EA	B
-	I
D	I
)	O
is	O
regulated	O
by	O
the	O
EBV	B
transactivators	I
,	O
BRLF1	B
and	O
BZLF1	B
,	O
in	O
a	O
cell	O
-	O
specific	O
manner	O
.	O
The	O
Epstein	B
-	I
Barr	I
virus	I
early	I
antigen	I
diffuse	I
component	I
(	O
EA	B
-	I
D	I
)	O
is	O
essential	O
for	O
Epstein	O
-	O
Barr	O
virus	O
DNA	O
polymerase	O
activity	O
,	O
and	O
its	O
activity	O
is	O
suppressed	O
during	O
latent	O
infection	O
.	O
We	O
investigated	O
the	O
regulation	O
of	O
the	O
promoter	O
(	O
BMRF1	O
)	O
for	O
this	O
early	O
gene	O
by	O
studying	O
its	O
responsiveness	O
in	O
vitro	O
to	O
two	O
immediate	B
-	I
early	I
viral	I
transactivators	I
,	O
BZLF1	B
(	O
Z	B
)	O
and	O
BRLF1	B
(	O
R	B
)	O
,	O
focusing	O
on	O
the	O
differences	O
in	O
response	O
in	O
lymphoid	O
cells	O
and	O
epithelial	O
cells	O
.	O
In	O
lymphoid	O
cells	O
,	O
Z	B
or	O
R	B
alone	O
produced	O
only	O
small	O
increases	O
in	O
EA	O
-	O
D	O
promoter	O
activity	O
,	O
whereas	O
both	O
transactivators	B
together	O
produced	O
a	O
large	O
stimulatory	O
effect	O
.	O
In	O
epithelial	O
cells	O
,	O
the	O
Z	B
transactivator	I
alone	O
produced	O
maximal	O
stimulation	O
of	O
the	O
EA	O
-	O
D	O
promoter	O
;	O
the	O
effect	O
of	O
R	B
and	O
Z	B
together	O
was	O
no	O
greater	O
than	O
that	O
of	O
Z	B
alone	O
.	O
Deletional	O
analysis	O
and	O
site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
EA	O
-	O
D	O
promoter	O
demonstrated	O
that	O
in	O
epithelial	O
cells	O
the	O
potential	O
AP-1	O
binding	O
site	O
plays	O
an	O
essential	O
role	O
in	O
Z	B
responsiveness	O
,	O
although	O
sequences	O
further	O
upstream	O
are	O
also	O
important	O
.	O
In	O
lymphoid	O
cells	O
,	O
only	O
the	O
upstream	O
sequences	O
are	O
required	O
for	O
transactivation	O
by	O
the	O
Z	B
/	I
R	I
combination	O
,	O
and	O
the	O
AP-1	B
site	I
is	O
dispensable	O
.	O
These	O
data	O
suggest	O
that	O
EA	O
-	O
D	O
(	O
BMRF1	O
)	O
promoter	O
regulation	O
by	O
Z	B
and	O
R	B
is	O
cell	O
type	O
specific	O
and	O
appears	O
to	O
involve	O
different	O
mechanisms	O
in	O
each	O
cell	O
type	O
.	O
Inducible	O
nuclear	B
factor	I
binding	O
to	O
the	O
kappa	O
B	O
elements	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
enhancer	O
in	O
T	O
cells	O
can	O
be	O
blocked	O
by	O
cyclosporin	O
A	O
in	O
a	O
signal	O
-	O
dependent	O
manner	O
.	O
Cyclosporin	O
A	O
(	O
CsA	O
)	O
is	O
thought	O
to	O
exert	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	O
the	O
expression	O
of	O
a	O
distinct	O
set	O
of	O
lymphokine	O
genes	O
which	O
are	O
induced	O
upon	O
T	O
-	O
cell	O
activation	O
,	O
among	O
them	O
the	O
gene	O
coding	O
for	O
interleukin-2	B
.	O
In	O
addition	O
,	O
the	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
partially	O
suppressed	O
.	O
To	O
better	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
suppression	O
by	O
CsA	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
this	O
drug	O
on	O
transcription	B
factors	I
in	O
T	O
cells	O
.	O
Here	O
we	O
report	O
that	O
the	O
formation	O
of	O
two	O
distinct	O
mitogen	B
-	I
inducible	I
DNA	I
-	I
binding	I
complexes	I
,	O
the	O
kappa	B
B	I
complex	I
within	O
the	O
HIV	O
enhancer	O
and	O
the	O
NFAT-1	B
complex	I
within	O
the	O
interleukin-2	O
enhancer	O
,	O
is	O
inhibited	O
in	O
the	O
presence	O
of	O
CsA	O
.	O
The	O
kappa	O
B	O
-	O
binding	O
activity	O
with	O
the	O
HIV	O
enhancer	O
is	O
inhibited	O
only	O
if	O
it	O
is	O
activated	O
via	O
the	O
mitogen	B
phytohemagglutinin	B
whereas	O
phorbol	O
myristate	O
acetate	O
-	O
mediated	O
activation	O
is	O
completely	O
insensitive	O
to	O
the	O
drug	O
.	O
This	O
suggests	O
a	O
model	O
in	O
which	O
functionally	O
indistinguishable	O
kappa	B
B	I
complexes	I
can	O
be	O
activated	O
via	O
two	O
separate	O
pathways	O
of	O
signal	O
transduction	O
distinguishable	O
by	O
CsA	O
.	O
Complementary	O
DNA	O
encoding	O
the	O
human	B
T	I
-	I
cell	I
FK506-binding	I
protein	I
,	O
a	O
peptidylprolyl	B
cis	I
-	I
trans	I
isomerase	I
distinct	O
from	O
cyclophilin	B
.	O
The	O
recently	O
discovered	O
macrolide	O
FK506	O
has	O
been	O
demonstrated	O
to	O
have	O
potent	O
immunosuppressive	O
activity	O
at	O
concentrations	O
100-fold	O
lower	O
than	O
cyclosporin	O
A	O
,	O
a	O
cyclic	O
undecapeptide	O
that	O
is	O
used	O
to	O
prevent	O
rejection	O
after	O
transplantation	O
of	O
bone	O
marrow	O
and	O
organs	O
,	O
such	O
as	O
kidney	O
,	O
heart	O
,	O
and	O
liver	O
.	O
After	O
the	O
recent	O
discovery	O
that	O
the	O
cyclosporin	B
A	I
-	I
binding	I
protein	I
cyclophilin	B
is	O
identical	O
to	O
peptidylprolyl	B
cis	I
-	I
trans	I
isomerase	I
,	O
a	O
cellular	B
binding	I
protein	I
for	O
FK506	O
was	O
found	O
to	O
be	O
distinct	O
from	O
cyclophilin	B
but	O
to	O
have	O
the	O
same	O
enzymatic	O
activity	O
.	O
In	O
this	O
study	O
,	O
we	O
isolated	O
a	O
cDNA	O
coding	O
for	O
FK506-binding	O
protein	O
(	O
FKBP	B
)	O
from	O
human	O
peripheral	O
blood	O
T	O
cells	O
by	O
using	O
mixed	O
20-mer	O
oligonucleotide	O
probes	O
synthesized	O
on	O
the	O
basis	O
of	O
the	O
sequence	O
,	O
Glu	O
-	O
Asp	O
-	O
Gly	O
-	O
Lys	O
-	O
Lys	O
-	O
Phe	O
-	O
Asp	O
,	O
reported	O
for	O
bovine	B
FKBP	I
.	O
The	O
DNA	O
isolated	O
contained	O
an	O
open	O
reading	O
frame	O
encoding	O
108	O
amino	O
acid	O
residues	O
.	O
The	O
first	O
40	O
residues	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
were	O
identical	O
to	O
those	O
of	O
the	O
reported	O
amino	O
-	O
terminal	O
sequence	O
of	O
bovine	O
FKBP	B
,	O
indicating	O
that	O
the	O
DNA	O
sequence	O
isolated	O
represents	O
the	O
gene	O
coding	O
for	O
FKBP	B
.	O
Computer	O
-	O
assisted	O
analysis	O
of	O
the	O
deduced	O
amino	O
acid	O
sequence	O
indicates	O
that	O
FKBP	B
exhibits	O
no	O
internal	O
homology	O
and	O
does	O
not	O
have	O
significant	O
sequence	O
similarity	O
to	O
any	O
other	O
amino	O
acid	O
sequences	O
of	O
known	O
proteins	O
,	O
including	O
cyclophilin	B
.	O
This	O
result	O
suggests	O
that	O
two	O
catalytically	O
similar	O
proteins	O
,	O
cyclophilin	B
and	O
FKBP	B
,	O
evolved	O
independently	O
.	O
In	O
Northern	O
blot	O
analysis	O
,	O
mRNA	O
species	O
of	O
approximately	O
1.8	O
kilobases	O
that	O
hybridized	O
with	O
human	O
FKBP	O
cDNA	O
were	O
detected	O
in	O
poly	O
(	O
A	O
)	O
+	O
RNAs	O
from	O
brain	O
,	O
lung	O
,	O
liver	O
,	O
and	O
placental	O
cells	O
and	O
leukocytes	O
.	O
Induction	O
of	O
Jurkat	O
leukemic	O
T	O
cells	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
ionomycin	O
did	O
not	O
affect	O
the	O
level	O
of	O
FKBP	O
mRNA	O
.	O
Southern	O
blot	O
analysis	O
of	O
human	O
genomic	O
DNA	O
digested	O
with	O
different	O
restriction	B
enzymes	I
suggests	O
the	O
existence	O
of	O
only	O
a	O
few	O
copies	O
of	O
the	O
DNA	O
sequence	O
encoding	O
FKBP	B
.	O
This	O
is	O
in	O
contrast	O
to	O
the	O
result	O
that	O
as	O
many	O
as	O
20	O
copies	O
of	O
the	O
cyclophilin	O
gene	O
and	O
possible	O
pseudogenes	O
may	O
be	O
present	O
in	O
the	O
mammalian	O
genome	O
.	O
The	O
56	B
-	I
59-kilodalton	I
protein	I
identified	O
in	O
untransformed	B
steroid	I
receptor	I
complexes	I
is	O
a	O
unique	B
protein	I
that	O
exists	O
in	O
cytosol	O
in	O
a	O
complex	O
with	O
both	O
the	O
70-	B
and	I
90-kilodalton	I
heat	I
shock	I
proteins	I
.	O
It	O
has	O
previously	O
been	O
shown	O
that	O
9S	B
,	O
untransformed	B
progestin	I
,	I
estrogen	I
,	I
androgen	I
,	I
and	I
glucocorticoid	I
receptor	I
complexes	I
in	O
rabbit	O
uterine	O
and	O
liver	O
cytosols	O
contain	O
a	O
59-kDa	B
protein	I
[	O
Tai	O
,	O
P.K.	O
,	O
Maeda	O
,	O
Y.	O
,	O
Nakao	O
,	O
K.	O
,	O
Wakim	O
,	O
N.G.	O
,	O
Duhring	O
,	O
J.L.	O
,	O
&	O
Faber	O
,	O
L.E.	O
(	O
1986	O
)	O
Biochemistry	O
25	O
,	O
5269	O
-	O
5275	O
]	O
.	O
In	O
this	O
work	O
we	O
show	O
that	O
the	O
monoclonal	B
antibody	I
KN	I
382	I
/	I
EC1	I
raised	O
against	O
the	O
rabbit	B
59-kDa	I
protein	I
reacts	O
with	O
9S	B
,	O
untransformed	B
glucocorticoid	I
receptor	I
complexes	I
in	O
cytosol	O
prepared	O
from	O
human	O
IM-9	O
lymphocytes	O
but	O
not	O
with	O
4S	B
salt	I
-	I
transformed	I
receptors	I
.	O
The	O
human	O
protein	O
recognized	O
by	O
the	O
EC1	B
antibody	I
is	O
a	O
56-kDa	B
protein	I
(	O
p56	B
)	O
of	O
moderate	O
abundance	O
located	O
predominantly	O
in	O
the	O
cytoplasm	O
by	O
indirect	O
immunofluorescence	O
.	O
There	O
are	O
at	O
least	O
six	O
isomorphs	B
of	O
p56	B
by	O
two	O
-	O
dimensional	O
gel	O
analysis	O
.	O
N	O
-	O
Terminal	O
sequencing	O
(	O
20	O
amino	O
acids	O
)	O
shows	O
that	O
p56	B
is	O
a	O
unique	B
human	I
protein	I
.	O
When	O
p56	B
is	O
immunoadsorbed	O
from	O
IM-9	O
cell	O
cytosol	O
,	O
both	O
the	O
70-	B
and	I
90-kDa	I
heat	I
shock	I
proteins	I
are	O
coadsorbed	O
in	O
an	O
immune	O
-	O
specific	O
manner	O
.	O
Neither	O
heat	B
shock	I
protein	I
reacts	O
directly	O
with	O
the	O
EC1	B
antibody	I
.	O
We	O
conclude	O
that	O
p56	B
exists	O
in	O
cytosol	O
in	O
a	O
higher	O
order	O
complex	O
containing	O
hsp70	B
and	O
hsp90	B
,	O
both	O
of	O
which	O
in	O
turn	O
have	O
been	O
found	O
to	O
be	O
associated	O
with	O
untransformed	B
steroid	I
receptors	I
.	O
A	O
novel	O
B	B
-	I
cell	I
lineage	I
-	I
specific	I
transcription	I
factor	I
present	O
at	O
early	O
but	O
not	O
late	O
stages	O
of	O
differentiation	O
.	O
A	O
novel	O
B	B
-	I
cell	I
-	I
specific	I
transcription	I
factor	I
,	O
BSAP	B
,	O
was	O
identified	O
as	O
a	O
mammalian	B
homolog	I
of	O
the	O
sea	B
urchin	I
protein	I
TSAP	B
,	O
which	O
interacts	O
with	O
the	O
promoters	O
of	O
four	O
tissue	O
-	O
specific	O
late	O
histone	O
H2A-2	O
and	O
H2B-2	O
genes	O
.	O
As	O
shown	O
by	O
mobility	O
-	O
shift	O
,	O
methylation	O
interference	O
,	O
and	O
mutational	O
analyses	O
,	O
the	O
mammalian	B
protein	I
BSAP	B
recognizes	O
all	O
four	O
sea	O
urchin	O
binding	O
sites	O
in	O
a	O
manner	O
indistinguishable	O
from	O
TSAP	B
;	O
however	O
,	O
the	O
two	O
proteins	O
differ	O
in	O
molecular	O
weight	O
.	O
BSAP	B
is	O
exclusively	O
restricted	O
to	O
the	O
B	O
-	O
cell	O
lineage	O
of	O
lymphoid	O
differentiation	O
.	O
Its	O
expression	O
appears	O
to	O
be	O
activated	O
during	O
pro	O
-	O
B	O
-	O
cell	O
development	O
,	O
is	O
abundant	O
at	O
the	O
pre	O
-	O
B-	O
and	O
mature	O
B	O
-	O
cell	O
stages	O
,	O
but	O
is	O
absent	O
in	O
terminally	O
differentiated	O
plasma	O
cells	O
.	O
Moreover	O
,	O
BSAP	B
is	O
clearly	O
a	O
B	B
-	I
cell	I
-	I
specific	I
transcription	I
factor	I
,	O
as	O
a	O
wild	O
-	O
type	O
but	O
not	O
a	O
mutant	O
TSAP	O
-	O
binding	O
site	O
of	O
the	O
sea	O
urchin	O
functions	O
only	O
in	O
transfected	O
B	O
cells	O
as	O
an	O
upstream	O
promoter	O
element	O
.	O
Competition	O
experiments	O
did	O
not	O
reveal	O
any	O
high	O
-	O
affinity	O
binding	O
site	O
for	O
BSAP	B
in	O
known	O
regulatory	O
regions	O
of	O
immunoglobulin	O
and	O
class	O
II	O
major	O
histocompatibility	O
(	O
MHC	O
)	O
genes	O
,	O
suggesting	O
that	O
BSAP	B
is	O
a	O
regulator	O
of	O
a	O
different	O
set	O
of	O
B	O
-	O
lymphoid	O
-	O
specific	O
genes	O
.	O
Nuclear	O
3	B
,	I
5	I
,	I
3'-triiodothyronine	I
receptors	I
(	O
T3R	B
)	O
of	O
circulating	O
human	O
lymphocytes	O
in	O
hyper-	O
and	O
hypothyroidism	O
and	O
nonthyroidal	O
diseases	O
.	O
The	O
clinical	O
implications	O
of	O
nuclear	O
T3R	B
alterations	O
of	O
circulating	O
lymphocytes	O
in	O
hyperthyroidism	O
,	O
hypothyroidism	O
and	O
nonthyroidal	O
diseases	O
were	O
investigated	O
.	O
Nuclear	O
T3R	B
in	O
lymphocytes	O
was	O
determined	O
by	O
radio	O
-	O
ligand	O
binding	O
analysis	O
.	O
The	O
results	O
showed	O
that	O
in	O
hyper-	O
and	O
hypothyroid	O
patients	O
the	O
nuclear	O
affinity	O
(	O
Ka	O
)	O
for	O
T3	O
was	O
similar	O
to	O
that	O
of	O
normal	O
subjects	O
.	O
In	O
hyperthyroidism	O
nuclear	O
T3	O
maximal	O
binding	O
capacity	O
(	O
MBC	O
)	O
was	O
unaltered	O
,	O
whereas	O
in	O
hypothyroidism	O
the	O
MBC	O
was	O
significantly	O
increased	O
.	O
In	O
the	O
patients	O
with	O
diabetes	O
mellitus	O
,	O
chronic	O
renal	O
failure	O
and	O
hepatic	O
cirrhosis	O
,	O
the	O
nuclear	B
T3R	I
MBC	O
of	O
lymphocytes	O
was	O
about	O
1.5	O
-	O
1.6	O
times	O
of	O
the	O
normal	O
controls	O
.	O
It	O
was	O
concluded	O
that	O
there	O
existed	O
hormonal	O
regulation	O
of	O
nuclear	B
T3R	I
,	O
and	O
up	O
-	O
regulation	O
was	O
seen	O
in	O
hypothyroidism	O
and	O
low	O
T3	O
syndrome	O
.	O
Cell	O
type	O
specificity	O
and	O
activation	O
requirements	O
for	O
NFAT-1	B
(	O
nuclear	B
factor	I
of	O
activated	O
T	O
-	O
cells	O
)	O
transcriptional	O
activity	O
determined	O
by	O
a	O
new	O
method	O
using	O
transgenic	O
mice	O
to	O
assay	O
transcriptional	O
activity	O
of	O
an	O
individual	O
nuclear	B
factor	I
.	O
Nuclear	B
factor	I
of	O
activated	O
T	O
-	O
cells	O
(	O
NFAT-1	B
)	O
is	O
a	O
transcription	B
factor	I
which	O
is	O
considered	O
to	O
be	O
an	O
important	O
regulator	O
in	O
early	O
T	O
-	O
cell	O
activation	O
.	O
We	O
have	O
developed	O
a	O
system	O
to	O
monitor	O
the	O
transcriptional	O
activity	O
of	O
NFAT-1	B
at	O
the	O
single	O
cell	O
level	O
in	O
whole	O
animals	O
.	O
The	O
system	O
is	O
based	O
on	O
the	O
use	O
of	O
an	O
oligomerized	O
NFAT-1	B
binding	O
motif	O
that	O
directs	O
transcription	B
of	I
SV40	I
T	I
-	I
antigen	I
in	O
transgenic	O
mice	O
.	O
This	O
report	O
represents	O
the	O
first	O
demonstration	O
that	O
a	O
multimerized	O
short	O
binding	O
motif	O
can	O
function	O
appropriately	O
in	O
transgenic	O
mice	O
.	O
NFAT-1	B
activity	O
had	O
previously	O
been	O
thought	O
to	O
be	O
confined	O
to	O
activated	O
T	O
-	O
lymphocytes	O
upon	O
release	O
of	O
intracellular	O
calcium	O
.	O
By	O
targeting	O
NFAT-1	B
-dependent	O
gene	O
expression	O
in	O
transgenic	O
mice	O
we	O
discovered	O
new	O
sites	O
of	O
NFAT-1	B
activity	O
.	O
Besides	O
in	O
T	O
-	O
lymphocytes	O
NFAT-1	B
activity	O
could	O
also	O
be	O
induced	O
in	O
T	O
-	O
lymphocyte	O
-	O
depleted	O
spleen	O
cells	O
and	O
purified	O
B	O
-	O
lymphocytes	O
and	O
requires	O
agents	O
that	O
both	O
release	O
intracellular	O
calcium	O
and	O
activate	O
protein	B
kinase	I
C	I
.	O
A	O
difference	O
in	O
the	O
time	O
course	O
of	O
appearance	O
of	O
NFAT-1	B
activity	O
between	O
T	O
-	O
lymphocytes	O
and	O
non	O
-	O
T	O
-	O
lymphocytes	O
was	O
revealed	O
.	O
Constitutive	O
expression	O
was	O
observed	O
in	O
a	O
small	O
population	O
of	O
cells	O
in	O
the	O
dermis	O
and	O
some	O
mice	O
have	O
developed	O
skin	O
lesions	O
.	O
Interestingly	O
,	O
the	O
tissue	O
pattern	O
of	O
expression	O
of	O
the	O
NFAT-1	B
activity	O
resembles	O
the	O
expression	O
pattern	O
described	O
for	O
HIV	O
-	O
LTR	O
/	O
tat	O
transgenic	O
mice	O
(	O
Vogel	O
,	O
J.	O
,	O
Hinrichs	O
,	O
S.	O
H.	O
,	O
Reynolds	O
,	O
R.	O
K.	O
,	O
Luciw	O
,	O
P.	O
A.	O
,	O
and	O
Jay	O
,	O
G.	O
(	O
1988	O
)	O
Nature	O
335	O
,	O
606	O
-	O
611	O
)	O
.	O
This	O
similarity	O
in	O
expression	O
and	O
the	O
fact	O
that	O
NFAT-1	B
has	O
been	O
shown	O
to	O
bind	O
functional	O
sequences	O
in	O
HIV	O
-	O
LTR	O
suggest	O
a	O
role	O
for	O
NFAT-1	B
in	O
dermal	O
activation	O
of	O
the	O
HIV	O
-	O
LTR	O
.	O
Induction	O
of	O
immediate	O
early	O
response	O
genes	O
by	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
in	O
normal	O
human	O
monocytes	O
.	O
A	O
group	O
of	O
coordinately	O
induced	O
protooncogenes	O
,	O
cytoskeletal	O
,	O
and	O
extracellular	O
matrix	O
genes	O
have	O
been	O
termed	O
immediate	O
early	O
response	O
genes	O
,	O
and	O
their	O
induction	O
has	O
been	O
associated	O
with	O
growth	B
factor	I
-stimulated	O
cell	O
proliferation	O
.	O
We	O
have	O
investigated	O
the	O
induction	O
of	O
these	O
genes	O
by	O
macrophage	B
-	I
CSF	I
(	O
M	B
-	I
CSF	I
)	O
in	O
human	O
monocytes	O
that	O
do	O
not	O
proliferate	O
in	O
response	O
to	O
M	B
-	I
CSF	I
but	O
require	O
the	O
factor	O
for	O
optimal	O
cell	O
differentiation	O
.	O
Normal	O
human	O
monocytes	O
were	O
isolated	O
,	O
carefully	O
washed	O
,	O
and	O
incubated	O
for	O
36	O
to	O
48	O
h	O
in	O
fetal	O
bovine	O
serum	O
-	O
containing	O
medium	O
.	O
At	O
the	O
end	O
of	O
this	O
incubation	O
the	O
resting	O
cells	O
were	O
stimulated	O
with	O
M	B
-	I
CSF	I
,	O
and	O
RNA	O
was	O
isolated	O
for	O
analysis	O
by	O
Northern	O
blotting	O
.	O
RNA	O
from	O
control	O
resting	O
cells	O
contained	O
low	O
to	O
undetectable	O
levels	O
of	O
c	O
-	O
jun	O
,	O
fibronectin	O
receptor	O
,	O
and	O
actin	O
mRNA	O
.	O
Within	O
15	O
to	O
30	O
min	O
of	O
addition	O
of	O
M	B
-	I
CSF	I
,	O
however	O
,	O
there	O
was	O
a	O
dramatic	O
coordinate	O
induction	O
of	O
these	O
genes	O
.	O
The	O
c	O
-	O
jun	O
gene	O
expression	O
was	O
very	O
transient	O
and	O
was	O
not	O
detectable	O
by	O
60	O
min	O
after	O
M	B
-	I
CSF	I
addition	O
.	O
In	O
contrast	O
,	O
the	O
expression	O
of	O
actin	O
and	O
fibronectin	O
receptor	O
mRNA	O
was	O
more	O
sustained	O
,	O
and	O
the	O
expression	O
of	O
these	O
genes	O
remained	O
elevated	O
at	O
24	O
to	O
48	O
h	O
after	O
M	B
-	I
CSF	I
addition	O
.	O
We	O
also	O
observed	O
the	O
induction	O
of	O
the	O
myelomonocytic	O
specific	O
tyrosine	O
kinase	O
hck	O
gene	O
simultaneously	O
with	O
the	O
other	O
immediate	O
early	O
response	O
genes	O
.	O
The	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
did	O
not	O
block	O
the	O
induction	O
of	O
any	O
of	O
these	O
genes	O
,	O
and	O
in	O
fact	O
,	O
super	O
-	O
induced	O
the	O
expression	O
of	O
c	O
-	O
jun	O
and	O
hck	O
.	O
Nuclear	O
run	O
on	O
transcription	O
of	O
the	O
c	O
-	O
jun	O
,	O
hck	O
,	O
and	O
actin	O
genes	O
.	O
Therefore	O
,	O
in	O
normal	O
human	O
monocytes	O
M	B
-	I
CSF	I
induces	O
immediate	O
early	O
response	O
genes	O
without	O
inducing	O
cell	O
proliferation	O
.	O
These	O
genes	O
may	O
then	O
play	O
a	O
role	O
in	O
altering	O
the	O
physiologic	O
status	O
of	O
the	O
cells	O
in	O
response	O
to	O
CSF	B
.	O
Cell	O
-	O
specific	O
differences	O
in	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
regulatory	O
elements	O
of	O
human	O
immunodeficiency	O
virus	O
and	O
beta	O
interferon	O
promoters	O
by	O
tumor	B
necrosis	I
factor	I
.	O
Three	O
aspects	O
of	O
the	O
involvement	O
of	O
tumor	B
necrosis	I
factor	I
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
pathogenesis	O
were	O
examined	O
.	O
Tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
mRNA	O
production	O
was	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
in	O
monocytic	O
U937	O
cells	O
and	O
in	O
a	O
chronically	O
HIV	O
infected	O
U937	O
cell	O
line	O
(	O
U9-IIIB	O
)	O
.	O
TNF	O
-	O
alpha	O
RNA	O
was	O
undetectable	O
in	O
U937	O
cells	O
,	O
whereas	O
a	O
low	O
constitutive	O
level	O
was	O
detected	O
in	O
U9-IIIB	O
cells	O
.	O
Paramyxovirus	O
infection	O
induced	O
a	O
5-	O
to	O
10-fold	O
increase	O
in	O
the	O
steady	O
-	O
state	O
level	O
of	O
TNF	O
-	O
alpha	O
RNA	O
in	O
U9-IIIB	O
cells	O
compared	O
with	O
U937	O
cells	O
,	O
suggesting	O
that	O
HIV	O
-	O
infected	O
monocytic	O
cells	O
produced	O
higher	O
levels	O
of	O
TNF	B
-	I
alpha	I
than	O
did	O
normal	O
cells	O
after	O
a	O
secondary	O
virus	O
infection	O
.	O
The	O
effects	O
of	O
TNF	B
-	I
alpha	I
on	O
gene	O
expression	O
were	O
examined	O
by	O
transient	O
expression	O
assays	O
using	O
reporter	O
chloramphenicol	O
acetyltransferase	O
plasmids	O
linked	O
to	O
regulatory	O
elements	O
from	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
and	O
the	O
beta	O
interferon	O
promoter	O
.	O
In	O
U937	O
and	O
Jurkat	O
T	O
lymphoid	O
cells	O
,	O
the	O
inducibility	O
of	O
the	O
different	O
hybrid	O
promoters	O
by	O
TNF	B
-	I
alpha	I
or	O
phorbol	O
ester	O
varied	O
in	O
a	O
cell	O
type-	O
and	O
promoter	O
context	O
-	O
specific	O
manner	O
;	O
the	O
levels	O
of	O
gene	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
containing	O
plasmids	O
correlated	O
directly	O
with	O
induction	O
of	O
NF	B
-	I
kappa	I
B	I
DNA	O
-	O
binding	O
activity	O
.	O
Although	O
the	O
intact	O
beta	O
interferon	O
promoter	O
was	O
only	O
weakly	O
stimulated	O
by	O
phorbol	O
ester	O
or	O
TNF	B
-	I
alpha	I
,	O
multimers	O
of	O
the	O
PRDII	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
domain	O
were	O
inducible	O
by	O
both	O
agents	O
.	O
TNF	B
-	I
alpha	I
was	O
able	O
to	O
increase	O
expression	O
of	O
the	O
HIV	O
LTR	O
in	O
T	O
cells	O
,	O
but	O
in	O
monocytic	O
cells	O
,	O
TNF	B
-	I
alpha	I
did	O
not	O
induce	O
the	O
HIV	O
LTR	O
above	O
a	O
constitutive	O
level	O
of	O
activity	O
.	O
This	O
level	O
of	O
NF	B
-	I
kappa	I
B	I
-independent	O
activity	O
appears	O
to	O
be	O
sufficient	O
for	O
virus	O
multiplication	O
,	O
since	O
TNF	B
-	I
alpha	I
treatment	O
had	O
no	O
effect	O
on	O
the	O
kinetics	O
of	O
de	O
novo	O
HIV	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
and	O
viral	O
RNA	O
production	O
in	O
U937	O
cells	O
.	O
However	O
,	O
in	O
Jurkat	O
cells	O
,	O
TNF	B
-	I
alpha	I
dramatically	O
enhanced	O
the	O
spread	O
of	O
HIV-1	O
through	O
the	O
cell	O
population	O
and	O
increased	O
viral	O
RNA	O
synthesis	O
,	O
indicating	O
that	O
in	O
T	O
cells	O
HIV-1	O
multiplication	O
was	O
stimulated	O
by	O
TNF	B
-	I
alpha	I
treatment	O
.	O
Retroviral	O
mediated	O
transfer	O
and	O
expression	O
of	O
exogenous	O
genes	O
in	O
primary	O
lymphoid	O
cells	O
:	O
assaying	O
for	O
a	O
viral	O
transactivator	B
activity	O
in	O
normal	O
and	O
malignant	O
cells	O
.	O
In	O
this	O
report	O
we	O
describe	O
the	O
use	O
of	O
recombinant	O
retroviruses	O
to	O
characterize	O
the	O
activity	O
of	O
an	O
exogenous	O
promoter	O
in	O
primary	O
cells	O
obtained	O
from	O
patients	O
with	O
lymphoproliferative	O
disorders	O
.	O
The	O
infection	O
of	O
a	O
variety	O
of	O
cultured	O
and	O
primary	O
lymphoid	O
cells	O
with	O
a	O
recombinant	O
retrovirus	O
containing	O
a	O
histone	O
promoter	O
-	O
driven	O
beta	O
-	O
galactosidase	O
gene	O
is	O
shown	O
to	O
result	O
in	O
the	O
expression	O
of	O
beta	B
-	I
galactosidase	I
in	O
50	O
%	O
to	O
100	O
%	O
of	O
the	O
cells	O
.	O
A	O
similar	O
infection	O
with	O
a	O
recombinant	O
retrovirus	O
containing	O
the	O
beta	O
-	O
galactosidase	O
gene	O
with	O
an	O
adenovirus	O
E2	O
promoter	O
,	O
results	O
in	O
beta	B
-	I
galactosidase	I
activity	O
in	O
a	O
limited	O
number	O
of	O
cultured	O
and	O
primary	O
cells	O
.	O
Since	O
the	O
adenovirus	O
E2	O
promoter	O
has	O
been	O
well	O
characterized	O
and	O
is	O
known	O
to	O
be	O
regulated	O
by	O
transactivators	B
encoded	O
by	O
many	O
viruses	O
,	O
the	O
activity	O
of	O
this	O
promoter	O
in	O
specific	O
cell	O
types	O
is	O
discussed	O
in	O
reference	O
to	O
both	O
the	O
biology	O
of	O
the	O
cell	O
and	O
the	O
possible	O
presence	O
of	O
as	O
yet	O
undetected	O
viral	B
gene	I
products	I
.	O
[	O
The	O
role	O
of	O
glucocorticoid	B
receptors	I
and	O
HLA	B
antigens	I
in	O
the	O
pathogenesis	O
of	O
Cushing	O
's	O
syndrome	O
]	O
Lymphocytic	O
levels	O
of	O
glucocorticoid	B
receptors	I
were	O
evaluated	O
in	O
114	O
patients	O
suffering	O
from	O
Icenko	O
-	O
Cushing	O
's	O
syndrome	O
.	O
Incidence	O
of	O
HLA	B
antigens	I
was	O
determined	O
in	O
94	O
of	O
them	O
.	O
A	O
significant	O
rise	O
of	O
A10	B
and	O
B27	B
antigen	I
incidence	O
compared	O
to	O
that	O
in	O
normal	O
subjects	O
allows	O
these	O
antigens	O
to	O
be	O
considered	O
genetic	O
markers	O
of	O
Icenko	O
-	O
Cushing	O
's	O
syndrome	O
.	O
The	O
levels	O
of	O
glucocorticoid	B
receptors	I
in	O
lymphocytes	O
of	O
the	O
patients	O
are	O
lower	O
than	O
in	O
normal	O
subjects	O
both	O
in	O
the	O
active	O
stage	O
of	O
the	O
disease	O
and	O
following	O
bilateral	O
total	O
adrenalectomy	O
.	O
The	O
patients	O
carrying	O
B27	B
antigen	I
had	O
lymphocytic	O
receptor	O
concentrations	O
under	O
the	O
levels	O
of	O
such	O
in	O
patients	O
free	O
of	O
the	O
antigen	O
carriage	O
.	O
Antigen	B
B27	I
seems	O
to	O
be	O
a	O
cause	O
of	O
lower	O
levels	O
of	O
glucocorticoid	B
receptors	I
in	O
blood	O
lymphocytes	O
.	O
Progesterone	O
suppression	O
of	O
pregnancy	O
lymphocytes	O
is	O
not	O
mediated	O
by	O
glucocorticoid	O
effect	O
.	O
This	O
study	O
investigated	O
whether	O
the	O
suppressive	O
effect	O
of	O
progesterone	O
on	O
pregnancy	O
lymphocytes	O
is	O
mediated	O
by	O
specific	O
progesterone	B
receptors	I
.	O
The	O
effects	O
of	O
a	O
competitive	O
progesterone	O
antagonist	O
(	O
RU486	O
)	O
and	O
a	O
specific	O
glucocorticoid	B
receptor	I
blocker	O
(	O
RU43044	O
)	O
were	O
tested	O
on	O
the	O
release	O
of	O
a	O
blocking	B
factor	I
by	O
progesterone	O
-	O
treated	O
pregnancy	O
lymphocytes	O
.	O
RU	O
486	O
tested	O
at	O
an	O
equal	O
concentration	O
as	O
progesterone	O
significantly	O
inhibited	O
the	O
production	O
of	O
the	O
blocking	B
factor	I
,	O
while	O
RU	O
43044	O
was	O
without	O
effect	O
.	O
These	O
data	O
suggest	O
that	O
in	O
pregnancy	O
,	O
lymphocyte	O
progesterone	O
acts	O
on	O
specific	O
progesterone	B
receptors	I
and	O
glucocorticoid	B
binding	I
sites	I
are	O
not	O
involved	O
.	O
Decreased	O
concentration	O
of	O
1	B
,	I
25-dihydroxyvitamin	I
D3	I
receptors	I
in	O
peripheral	O
mononuclear	O
cells	O
of	O
patients	O
with	O
X	O
-	O
linked	O
hypophosphatemic	O
rickets	O
:	O
effect	O
of	O
phosphate	O
supplementation	O
.	O
Abnormal	O
renal	O
tubular	O
phosphate	O
transport	O
is	O
considered	O
to	O
be	O
the	O
primary	O
defect	O
in	O
X	O
-	O
linked	O
hypophosphatemic	O
rickets	O
(	O
XLH	O
)	O
.	O
However	O
,	O
the	O
resistance	O
to	O
vitamin	O
D	O
treatment	O
in	O
XLH	O
can	O
not	O
be	O
explained	O
by	O
hypophosphatemia	O
alone	O
.	O
Since	O
most	O
of	O
the	O
actions	O
of	O
vitamin	O
D	O
are	O
mediated	O
by	O
its	O
receptors	O
(	O
VDR	B
)	O
,	O
abnormalities	O
of	O
VDR	B
have	O
been	O
postulated	O
in	O
XLH	O
.	O
In	O
order	O
to	O
investigate	O
this	O
possibility	O
,	O
we	O
measured	O
the	O
concentration	O
of	O
VDR	B
in	O
PHA	O
-	O
activated	O
peripheral	O
mononuclear	O
cells	O
from	O
10	O
XLH	O
patients	O
.	O
Patients	O
without	O
phosphate	O
supplementation	O
showed	O
significantly	O
lower	O
concentration	O
(	O
21.7	O
+	O
/-	O
5.1	O
fmol	O
/	O
mg	O
protein	O
,	O
mean	O
+	O
/-	O
SEM	O
)	O
compared	O
to	O
the	O
normal	O
controls	O
(	O
60.7	O
+	O
/-	O
4.0	O
)	O
.	O
On	O
the	O
contrary	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
phosphate	O
-	O
supplemented	O
patients	O
(	O
58.3	O
+	O
/-	O
2.7	O
)	O
and	O
controls	O
.	O
There	O
was	O
a	O
significant	O
positive	O
correlation	O
between	O
VDR	B
concentration	O
and	O
serum	O
phosphate	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O
In	O
two	O
patients	O
,	O
VDR	B
was	O
increased	O
after	O
daily	O
phosphate	O
supplementation	O
was	O
started	O
.	O
These	O
results	O
indicate	O
that	O
a	O
decreased	O
concentration	O
of	O
VDR	B
secondary	O
to	O
persistent	O
hypophosphatemia	O
is	O
one	O
of	O
the	O
causes	O
of	O
vitamin	O
D	O
resistance	O
in	O
XLH	O
.	O
NF	B
-	I
X2	I
that	O
binds	O
to	O
the	O
DRA	O
X2-box	O
is	O
activator	B
protein	I
1	I
.	O
Expression	O
cloning	O
of	O
c	B
-	I
Jun	I
.	O
Human	B
class	I
II	I
MHC	I
Ag	I
are	O
a	O
family	O
of	O
cell	B
surface	I
glycoproteins	I
.	O
Their	O
constitutive	O
expression	O
is	O
limited	O
to	O
B	O
lymphocytes	O
and	O
thymic	O
epithelial	O
cells	O
.	O
In	O
many	O
other	O
cells	O
their	O
expression	O
can	O
be	O
induced	O
by	O
IFN	B
-	I
gamma	I
.	O
Conserved	O
upstream	O
promoter	O
sequences	O
regulate	O
this	O
tissue	O
-	O
specific	O
expression	O
of	O
class	O
II	O
genes	O
.	O
In	O
the	O
DRA	O
promoter	O
,	O
one	O
of	O
these	O
cis	O
-	O
acting	O
regulatory	O
motifs	O
is	O
the	O
X2-box	O
to	O
which	O
nuclear	B
factor	I
X2	I
(	O
NF	B
-	I
X2	I
)	O
binds	O
.	O
Here	O
,	O
we	O
present	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
full	O
-	O
length	O
cDNA	O
clone	O
encoding	O
NF	B
-	I
X2	I
.	O
This	O
cDNA	O
clone	O
was	O
isolated	O
by	O
expression	O
cDNA	O
cloning	O
,	O
and	O
encodes	O
the	O
human	B
c	I
-	I
Jun	I
protein	I
,	O
which	O
together	O
with	O
c	B
-	I
Fos	I
forms	O
the	O
heterodimeric	B
activator	I
protein-1	I
transcription	I
complex	I
.	O
Whereas	O
c	B
-	I
Fos	I
/	I
c	I
-	I
Jun	I
heterodimers	I
do	O
not	O
exist	O
in	O
B	O
cells	O
,	O
they	O
form	O
and	O
bind	O
to	O
the	O
X2-box	O
in	O
class	O
II	O
nonexpressing	O
cells	O
.	O
Thus	O
,	O
c	B
-	I
Fos	I
/	I
c	I
-	I
Jun	I
heterodimers	I
might	O
contribute	O
to	O
the	O
repression	O
of	O
DRA	O
gene	O
expression	O
.	O
Immunohistochemical	O
study	O
of	O
steroid	O
hormones	O
and	O
an	O
estrogen	O
binding	O
assay	O
in	O
malignant	O
soft	O
tissue	O
tumors	O
.	O
Immunohistochemically	O
,	O
the	O
immunoreaction	O
against	O
5	O
steroid	O
hormone	O
anti	O
-	O
sera	O
(	O
estradiol	O
,	O
estriol	O
,	O
cortisol	O
,	O
progesterone	O
and	O
testosterone	O
)	O
was	O
examined	O
in	O
39	O
cases	O
with	O
the	O
malignant	O
soft	O
tissue	O
tumors	O
(	O
fibrosarcoma	O
:	O
8	O
,	O
malignant	O
fibrous	O
histiocytoma	O
:	O
6	O
,	O
rhabdomyosarcoma	O
:	O
10	O
,	O
leiomyosarcoma	O
:	O
10	O
,	O
liposarcoma	O
:	O
5	O
)	O
.	O
Seventeen	O
cases	O
revealed	O
distinct	O
immunostaining	O
against	O
at	O
least	O
1	O
of	O
the	O
5	O
steroid	O
hormones	O
.	O
Immunostained	O
tumor	O
cells	O
were	O
more	O
frequently	O
distributed	O
in	O
the	O
area	O
where	O
tumor	O
cell	O
infiltration	O
was	O
more	O
invasive	O
.	O
The	O
majority	O
of	O
the	O
positive	O
cases	O
occurred	O
in	O
female	O
cases	O
.	O
Furthermore	O
,	O
the	O
existence	O
of	O
estrogen	B
receptor	I
(	O
estrogen	O
binding	O
activity	O
)	O
was	O
examined	O
histochemically	O
in	O
39	O
cases	O
and	O
it	O
was	O
detected	O
in	O
8	O
.	O
We	O
concluded	O
that	O
steroid	O
hormones	O
might	O
be	O
closely	O
related	O
to	O
tumor	O
cell	O
infiltration	O
of	O
some	O
malignant	O
soft	O
tissue	O
tumors	O
.	O
Interferon	B
-	I
gamma	I
and	O
the	O
sexual	O
dimorphism	O
of	O
autoimmunity	O
.	O
The	O
sexual	O
difference	O
in	O
the	O
incidence	O
of	O
autoimmune	O
diseases	O
has	O
remained	O
an	O
enigma	O
for	O
many	O
years	O
.	O
In	O
the	O
examination	O
of	O
the	O
induction	O
of	O
autoimmunity	O
in	O
transgenic	O
mice	O
,	O
evidence	O
has	O
been	O
obtained	O
further	O
implicating	O
the	O
lymphokine	B
interferon	B
-	I
gamma	I
in	O
the	O
etiology	O
of	O
autoimmunity	O
.	O
Sex	O
steroid	O
regulation	O
of	O
the	O
production	O
of	O
this	O
molecule	O
,	O
as	O
well	O
as	O
other	O
cytokines	B
,	O
may	O
help	O
explain	O
the	O
gender	O
-	O
specific	O
differences	O
in	O
the	O
immune	O
system	O
,	O
including	O
autoimmunity	O
.	O
[	O
The	O
effect	O
of	O
24	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
dioxyvit	O
)	O
on	O
Ca	O
metabolism	O
and	O
immune	O
status	O
during	O
chronic	O
kidney	O
failure	O
]	O
Active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
24R	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
(	O
dioxyvit	O
)	O
was	O
used	O
at	O
a	O
daily	O
dose	O
of	O
100	O
micrograms	O
in	O
treatment	O
of	O
children	O
affected	O
with	O
tubulointerstitial	O
disease	O
of	O
kidney	O
and	O
with	O
chronic	O
glomerulonephritis	O
under	O
conditions	O
of	O
kidney	O
insufficiency	O
.	O
The	O
drug	O
exhibited	O
distinct	O
normalizing	O
effect	O
on	O
patterns	O
of	O
calcium	O
metabolism	O
:	O
increase	O
of	O
total	O
and	O
ionized	O
Ca2	O
+	O
and	O
of	O
25-OHD	O
,	O
decrease	O
in	O
concentration	O
of	O
parath	O
hormone	O
and	O
osteocalcine	O
in	O
blood	O
serum	O
as	O
well	O
as	O
on	O
immunological	O
parameters	O
:	O
restoration	O
of	O
decreased	O
content	O
of	O
T-	O
and	O
0-lymphocytes	O
.	O
Concentration	O
of	O
receptors	O
of	O
hormonal	O
form	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
was	O
found	O
to	O
be	O
minimal	O
in	O
lymphocytes	O
under	O
conditions	O
of	O
chronic	O
kidney	O
insufficiency	O
,	O
while	O
their	O
expression	O
,	O
after	O
the	O
dioxyvit	O
action	O
,	O
was	O
detected	O
only	O
in	O
patients	O
with	O
glomerulonephritis	O
.	O
Specific	O
calcitropic	O
effect	O
of	O
dioxyvit	O
with	O
simultaneous	O
correction	O
of	O
vitamin	O
D	O
deficiency	O
were	O
apparently	O
responsible	O
for	O
high	O
efficacy	O
of	O
the	O
drug	O
in	O
treatment	O
of	O
calcium	O
metabolism	O
and	O
immunity	O
impairments	O
in	O
children	O
with	O
renal	O
deteriorations	O
at	O
the	O
step	O
of	O
chronic	O
kidney	O
insufficiency	O
.	O
Extrarenal	O
receptor	O
-	O
effector	O
-	O
mechanisms	O
for	O
aldosterone	O
:	O
the	O
sequence	O
of	O
effects	O
on	O
the	O
cellular	O
electrolyte	O
transport	O
in	O
human	O
lymphocytes	O
and	O
their	O
implications	O
for	O
disorders	O
of	O
the	O
water	O
and	O
electrolyte	O
balances	O
.	O
High	O
affinity	O
aldosterone	O
binding	O
sites	O
have	O
not	O
only	O
been	O
described	O
in	O
the	O
classic	O
target	O
tissues	O
such	O
as	O
the	O
renal	O
tubules	O
,	O
but	O
also	O
in	O
non	O
-	O
classic	O
target	O
tissues	O
such	O
as	O
the	O
hippocampus	O
,	O
mammary	O
gland	O
,	O
endothelial	O
cells	O
and	O
,	O
recently	O
,	O
human	O
mononuclear	O
leukocytes	O
.	O
An	O
in	O
vitro	O
effect	O
of	O
aldosterone	O
on	O
intracellular	O
sodium	O
,	O
potassium	O
and	O
calcium	O
concentrations	O
and	O
cell	O
volume	O
was	O
shown	O
in	O
human	O
mononuclear	O
leukocytes	O
.	O
In	O
the	O
absence	O
of	O
aldosterone	O
,	O
the	O
intracellular	O
Na+	O
,	O
K+	O
and	O
Ca2	O
+	O
concentrations	O
and	O
the	O
cell	O
volume	O
decreased	O
significantly	O
,	O
but	O
remained	O
constant	O
when	O
aldosterone	O
(	O
1.4	O
nmol	O
/	O
l	O
)	O
was	O
added	O
to	O
the	O
incubation	O
medium	O
.	O
These	O
effects	O
of	O
aldosterone	O
were	O
blocked	O
by	O
the	O
aldosterone	O
antagonist	O
canrenone	O
(	O
140	O
nmol	O
/	O
l	O
)	O
.	O
The	O
sodium	B
/	I
proton	I
exchanger	I
of	O
the	O
cell	O
membrane	O
could	O
be	O
identified	O
as	O
the	O
primary	O
target	O
of	O
the	O
aldosterone	O
action	O
,	O
possibly	O
non	O
-	O
genomically	O
mediated	O
through	O
membrane	B
receptors	I
.	O
The	O
clinical	O
significance	O
of	O
this	O
model	O
was	O
underlined	O
by	O
the	O
demonstration	O
of	O
absent	O
or	O
a	O
decreased	O
number	O
of	O
mineralocorticoid	B
receptors	I
and	O
the	O
lack	O
of	O
electrolyte	O
response	O
to	O
aldosterone	O
in	O
human	O
mononuclear	O
leukocytes	O
of	O
patients	O
with	O
pseudohypoaldosteronism	O
and	O
aldosteronism	O
.	O
Additionally	O
,	O
an	O
abnormal	O
effector	O
mechanism	O
could	O
be	O
demonstrated	O
in	O
human	O
mononuclear	O
leukocytes	O
from	O
essential	O
hypertensives	O
.	O
These	O
studies	O
are	O
the	O
first	O
to	O
demonstrate	O
the	O
significance	O
of	O
extrarenal	B
,	I
nonepithelial	I
mineralocorticoid	I
receptors	I
and	O
the	O
related	O
effector	O
mechanism	O
in	O
different	O
disorders	O
of	O
the	O
water	O
and	O
electrolyte	O
balance	O
in	O
man	O
.	O
Two	O
distinct	O
signal	O
transmission	O
pathways	O
in	O
T	O
lymphocytes	O
are	O
inhibited	O
by	O
complexes	O
formed	O
between	O
an	O
immunophilin	B
and	O
either	O
FK506	O
or	O
rapamycin	O
.	O
Proliferation	O
and	O
immunologic	O
function	O
of	O
T	O
lymphocytes	O
are	O
initiated	O
by	O
signals	O
from	O
the	O
antigen	B
receptor	I
that	O
are	O
inhibited	O
by	O
the	O
immunosuppressant	O
FK506	O
but	O
not	O
by	O
its	O
structural	O
analog	O
,	O
rapamycin	O
.	O
On	O
the	O
other	O
hand	O
,	O
interleukin	B
2	I
(	O
IL-2	B
)	O
-induced	O
signals	O
are	O
blocked	O
by	O
rapamycin	O
but	O
not	O
by	O
FK506	O
.	O
Remarkably	O
,	O
these	O
two	O
drugs	O
inhibit	O
each	O
other	O
's	O
actions	O
,	O
raising	O
the	O
possibility	O
that	O
both	O
act	O
by	O
means	O
of	O
a	O
common	O
immunophilin	B
(	O
immunosuppressant	B
binding	I
protein	I
)	O
.	O
We	O
find	O
that	O
the	O
dissociation	O
constant	O
of	O
rapamycin	O
to	O
the	O
FK506	B
binding	I
protein	I
FKBP	B
(	O
Kd	O
=	O
0.2	O
nM	O
)	O
is	O
close	O
to	O
the	O
dissociation	O
constant	O
of	O
FK506	O
to	O
FKBP	B
(	O
Kd	O
=	O
0.4	O
nM	O
)	O
and	O
to	O
their	O
effective	O
biologic	O
inhibitory	O
concentrations	O
.	O
However	O
,	O
an	O
excess	O
of	O
rapamycin	O
is	O
needed	O
to	O
revert	O
FK506-mediated	O
inhibition	O
of	O
IL-2	B
production	O
,	O
apoptosis	O
,	O
and	O
transcriptional	O
activation	O
of	O
NF	B
-	I
AT	I
,	O
a	O
T	B
-	I
cell	I
-	I
specific	I
transcription	I
factor	I
necessary	O
for	O
IL-2	O
gene	O
activation	O
.	O
Similarly	O
,	O
an	O
excess	O
of	O
FK506	O
is	O
needed	O
to	O
revert	O
rapamycin	O
-	O
mediated	O
inhibition	O
of	O
IL-2	B
-induced	O
proliferation	O
.	O
The	O
drug	O
concentrations	O
required	O
for	O
antagonism	O
may	O
be	O
explained	O
by	O
the	O
relative	O
affinity	O
of	O
the	O
drugs	O
to	O
,	O
and	O
by	O
the	O
abundance	O
of	O
,	O
the	O
immunophilin	B
FKBP	B
.	O
FKBP	B
has	O
been	O
shown	O
to	O
catalyze	O
the	O
interconversion	O
of	O
the	O
cis-	O
and	O
trans	O
-	O
rotamers	O
of	O
the	O
peptidyl	B
-	I
prolyl	I
amide	I
bond	I
of	O
peptide	O
substrates	O
;	O
here	O
we	O
show	O
that	O
rapamycin	O
,	O
like	O
FK506	O
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
rotamase	O
activity	O
of	O
FKBP	B
(	O
Ki	O
=	O
0.2	O
nM	O
)	O
.	O
Neither	O
FKBP	B
binding	O
nor	O
inhibition	O
of	O
rotamase	O
activity	O
of	O
FKBP	B
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
biologic	O
actions	O
of	O
these	O
drugs	O
.	O
Rather	O
,	O
these	O
findings	O
suggest	O
that	O
immunophilin	B
bound	O
to	O
FK506	O
interferes	O
with	O
antigen	B
receptor	I
-induced	O
signals	O
,	O
while	O
rapamycin	O
bound	O
to	O
the	O
immunophilin	B
interferes	O
with	O
IL-2	B
-induced	O
signals	O
.	O
Disruption	O
of	O
the	O
human	O
SCL	O
locus	O
by	O
`	O
`	O
illegitimate	O
''	O
V-	O
(	O
D	O
)	O
-J	O
recombinase	O
activity	O
.	O
A	O
fusion	O
complementary	O
DNA	O
in	O
the	O
T	O
cell	O
line	O
HSB-2	O
elucidates	O
a	O
provocative	O
mechanism	O
for	O
the	O
disruption	O
of	O
the	O
putative	O
hematopoietic	B
transcription	I
factor	I
SCL	B
.	O
The	O
fusion	O
cDNA	O
results	O
from	O
an	O
interstitial	O
deletion	O
between	O
a	O
previously	O
unknown	O
locus	O
,	O
SIL	O
(	O
SCL	O
interrupting	O
locus	O
)	O
,	O
and	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
SCL	B
.	O
Similar	O
to	O
1	O
;	O
14	O
translocations	O
,	O
this	O
deletion	O
disrupts	O
the	O
SCL	O
5	O
'	O
regulatory	O
region	O
.	O
This	O
event	O
is	O
probably	O
mediated	O
by	O
V-	O
(	O
D	O
)	O
-J	O
recombinase	O
activity	O
,	O
although	O
neither	O
locus	O
is	O
an	O
immunoglobulin	B
or	O
a	O
T	B
cell	I
receptor	I
.	O
Two	O
other	O
T	O
cell	O
lines	O
,	O
CEM	O
and	O
RPMI	O
8402	O
,	O
have	O
essentially	O
identical	O
deletions	O
.	O
Thus	O
,	O
in	O
lymphocytes	O
,	O
growth	O
-	O
affecting	O
genes	O
other	O
than	O
immune	B
receptors	I
risk	O
rearrangements	O
.	O
Induction	O
of	O
NF	B
-	I
KB	I
during	O
monocyte	O
differentiation	O
by	O
HIV	O
type	O
1	O
infection	O
.	O
The	O
production	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
progeny	O
was	O
followed	O
in	O
the	O
U937	O
promonocytic	O
cell	O
line	O
after	O
stimulation	O
either	O
with	O
retinoic	O
acid	O
or	O
PMA	O
,	O
and	O
in	O
purified	O
human	O
monocytes	O
and	O
macrophages	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
Southwestern	O
blotting	O
experiments	O
were	O
used	O
to	O
detect	O
the	O
binding	O
of	O
cellular	B
transactivation	I
factor	I
NF	B
-	I
KB	I
to	O
the	O
double	O
repeat	O
-	O
KB	O
enhancer	O
sequence	O
located	O
in	O
the	O
long	O
terminal	O
repeat	O
.	O
PMA	O
treatment	O
,	O
and	O
not	O
retinoic	O
acid	O
treatment	O
of	O
the	O
U937	O
cells	O
acts	O
in	O
inducing	O
NF	B
-	I
KB	I
expression	O
in	O
the	O
nuclei	O
.	O
In	O
nuclear	O
extracts	O
from	O
monocytes	O
or	O
macrophages	O
,	O
induction	O
of	O
NF	B
-	I
KB	I
occurred	O
only	O
if	O
the	O
cells	O
were	O
previously	O
infected	O
with	O
HIV-1	O
.	O
When	O
U937	O
cells	O
were	O
infected	O
with	O
HIV-1	O
,	O
no	O
induction	O
of	O
NF	B
-	I
KB	I
factor	I
was	O
detected	O
,	O
whereas	O
high	O
level	O
of	O
progeny	O
virions	O
was	O
produced	O
,	O
suggesting	O
that	O
this	O
factor	O
was	O
not	O
required	O
for	O
viral	O
replication	O
.	O
These	O
results	O
indicate	O
that	O
in	O
monocytic	O
cell	O
lineage	O
,	O
HIV-1	O
could	O
mimic	O
some	O
differentiation	O
/	O
activation	O
stimuli	O
allowing	O
nuclear	O
NF	B
-	I
KB	I
expression	O
.	O
Activation	O
of	O
human	O
CD4	O
T	O
lymphocytes	O
.	O
Interaction	O
of	O
fibronectin	B
with	O
VLA-5	B
receptor	I
on	O
CD4	O
cells	O
induces	O
the	O
AP-1	B
transcription	I
factor	I
.	O
Fibronectin	B
synergized	O
with	O
anti	B
-	I
CD3	I
antibody	I
to	O
promote	O
CD4	B
cell	O
proliferation	O
in	O
a	O
serum	O
-	O
free	O
culture	O
system	O
whereas	O
no	O
proliferation	O
was	O
observed	O
when	O
CD4	O
cells	O
were	O
cultured	O
with	O
anti	B
-	I
CD3	I
alone	O
or	O
fibronectin	B
alone	O
.	O
In	O
addition	O
,	O
anti	B
-	I
CD29	I
(	O
integrin	B
beta	I
1	I
)	O
as	O
well	O
as	O
anti	B
-	I
VLA-5	I
(	O
human	B
fibronectin	I
receptor	I
)	O
antibodies	O
blocked	O
this	O
CD4	O
cell	O
activation	O
in	O
this	O
system	O
.	O
Although	O
anti	B
-	I
CD3	I
alone	O
or	O
fibronectin	B
alone	O
can	O
not	O
induce	O
IL-2	B
message	O
by	O
CD4	O
cells	O
,	O
the	O
combination	O
of	O
anti	B
-	I
CD3	I
plus	O
fibronectin	B
induced	O
IL-2	B
message	O
by	O
CD4	O
cells	O
.	O
In	O
an	O
analysis	O
of	O
the	O
molecular	O
mechanism	O
by	O
which	O
IL-2	B
message	O
was	O
generated	O
,	O
we	O
showed	O
that	O
a	O
fibronectin	B
-VLA-5	O
fibronectin	B
receptor	I
interaction	O
may	O
contribute	O
an	O
independent	O
signal	O
distinct	O
from	O
the	O
CD3	B
pathway	O
of	O
activation	O
by	O
the	O
induction	O
of	O
an	O
AP-1	B
transcriptional	I
factor	I
.	O
Thus	O
the	O
VLA-5	B
fibronectin	I
receptor	I
on	O
CD4	O
cells	O
can	O
play	O
a	O
complementary	O
role	O
in	O
CD3	B
-	O
TCR	B
-mediated	O
signal	O
transduction	O
through	O
its	O
interaction	O
with	O
fibronectin	B
.	O
TAR	O
independent	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
in	O
phorbol	O
ester	O
stimulated	O
T	O
lymphocytes	O
.	O
Multiple	O
regulatory	O
elements	O
in	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
(	O
HIV	O
LTR	O
)	O
are	O
required	O
for	O
activation	O
of	O
HIV	O
gene	O
expression	O
.	O
Previous	O
transfection	O
studies	O
of	O
HIV	O
LTR	O
constructs	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
gene	O
indicated	O
that	O
multiple	O
regulatory	O
regions	O
including	O
the	O
enhancer	O
,	O
SP1	O
,	O
TATA	O
and	O
TAR	O
regions	O
were	O
important	O
for	O
HIV	O
gene	O
expression	O
.	O
To	O
characterize	O
these	O
regulatory	O
elements	O
further	O
,	O
mutations	O
in	O
these	O
regions	O
were	O
inserted	O
into	O
both	O
the	O
5	O
'	O
and	O
3	O
'	O
HIV	O
LTRs	O
and	O
infectious	O
proviral	O
constructs	O
were	O
assembled	O
.	O
These	O
constructs	O
were	O
transfected	O
into	O
either	O
HeLa	O
cells	O
,	O
Jurkat	O
cells	O
or	O
U937	O
cells	O
in	O
both	O
the	O
presence	O
and	O
absence	O
of	O
phorbol	O
esters	O
which	O
have	O
previously	O
been	O
demonstrated	O
to	O
activate	O
HIV	O
gene	O
expression	O
.	O
Viral	O
gene	O
expression	O
was	O
assayed	O
by	O
the	O
level	O
of	O
p24	B
gag	I
protein	I
released	O
from	O
cultures	O
transfected	O
with	O
the	O
proviral	O
constructs	O
.	O
Results	O
in	O
all	O
cell	O
lines	O
indicated	O
that	O
mutations	O
of	O
the	O
SP1	O
,	O
TATA	O
and	O
the	O
TAR	O
loop	O
and	O
stem	O
secondary	O
structure	O
resulted	O
in	O
marked	O
decreases	O
in	O
gene	O
expression	O
while	O
mutations	O
of	O
the	O
enhancer	O
motif	O
or	O
TAR	O
primary	O
sequence	O
resulted	O
in	O
only	O
slight	O
decreases	O
.	O
However	O
,	O
viruses	O
containing	O
mutations	O
in	O
either	O
the	O
TAR	O
loop	O
sequences	O
or	O
stem	O
secondary	O
structure	O
which	O
were	O
very	O
defective	O
for	O
gene	O
expression	O
in	O
untreated	O
Jurkat	O
cells	O
,	O
gave	O
nearly	O
wild	O
-	O
type	O
levels	O
of	O
gene	O
expression	O
in	O
phorbol	O
ester	O
-	O
treated	O
Jurkat	O
cells	O
but	O
not	O
in	O
phorbol	O
ester	O
-	O
treated	O
HeLa	O
or	O
U937	O
cells	O
.	O
High	O
level	O
gene	O
expression	O
of	O
these	O
TAR	O
mutant	O
constructs	O
in	O
phorbol	O
ester	O
-	O
treated	O
Jurkat	O
cells	O
was	O
eliminated	O
by	O
second	O
site	O
mutations	O
in	O
the	O
enhancer	O
region	O
or	O
by	O
disruption	O
of	O
the	O
tat	O
gene	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Positive	O
and	O
negative	O
regulation	O
of	O
immunoglobulin	O
gene	O
expression	O
by	O
a	O
novel	O
B	O
-	O
cell	O
-	O
specific	O
enhancer	O
element	O
.	O
A	O
new	O
B	O
-	O
cell	O
-	O
specific	O
enhancer	O
element	O
has	O
been	O
identified	O
3	O
'	O
of	O
E4	O
and	O
the	O
octamerlike	O
motifs	O
in	O
the	O
human	O
immunoglobulin	O
heavy	O
-	O
chain	O
gene	O
enhancer	O
.	O
Tandem	O
copies	O
of	O
this	O
67-bp	O
MnlI	O
-	O
AluI	O
fragment	O
,	O
when	O
fused	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
gene	O
driven	O
by	O
the	O
conalbumin	O
promoter	O
,	O
stimulated	O
transcription	O
in	O
B	O
cells	O
but	O
not	O
in	O
Jurkat	O
T	O
cells	O
or	O
HeLa	O
cells	O
.	O
Footprinting	O
analysis	O
revealed	O
that	O
the	O
identical	O
sequence	O
CCGAAACTGAAAAGG	O
,	O
designated	O
E6	O
,	O
was	O
protected	O
by	O
nuclear	O
extracts	O
from	O
B	O
cells	O
,	O
T	O
cells	O
,	O
or	O
HeLa	O
cells	O
.	O
Gel	O
mobility	O
shift	O
assays	O
using	O
a	O
synthetic	O
E6	O
motif	O
detected	O
a	O
B	B
-	I
cell	I
-	I
specific	I
complex	I
in	O
addition	O
to	O
a	O
ubiquitous	O
band	O
found	O
also	O
in	O
T	O
cells	O
and	O
HeLa	O
cells	O
.	O
In	O
agreement	O
with	O
the	O
results	O
of	O
gel	O
retardation	O
assays	O
,	O
tandem	O
copies	O
of	O
the	O
E6	O
motif	O
stimulated	O
transcription	O
in	O
ARH77	O
and	O
Raji	O
cells	O
but	O
not	O
in	O
Jurkat	O
or	O
HeLa	O
cells	O
.	O
Furthermore	O
,	O
a	O
mutant	O
E6	O
motif	O
lost	O
both	O
in	O
vitro	O
binding	O
activity	O
and	O
in	O
vivo	O
enhancer	O
activity	O
.	O
In	O
striking	O
contrast	O
to	O
the	O
mouse	O
Ig	O
heavy	O
-	O
chain	O
enhancer	O
,	O
in	O
which	O
the	O
octamer	O
motif	O
acts	O
as	O
a	O
B	O
-	O
cell	O
-	O
specific	O
enhancer	O
element	O
,	O
the	O
human	O
enhancer	O
contains	O
an	O
octamerlike	O
sequence	O
with	O
one	O
base	O
substitution	O
which	O
bound	O
octamer	B
-	I
binding	I
proteins	I
with	O
only	O
very	O
low	O
affinity	O
and	O
showed	O
no	O
enhancer	O
activity	O
of	O
its	O
own	O
.	O
Interestingly	O
,	O
the	O
MnlI	O
-	O
AluI	O
fragment	O
could	O
suppress	O
the	O
basal	O
-	O
level	O
activity	O
of	O
the	O
conalbumin	O
promoter	O
in	O
both	O
Jurkat	O
and	O
HeLa	O
cells	O
.	O
Moreover	O
,	O
simian	O
virus	O
40	O
enhancer	O
activity	O
was	O
blocked	O
by	O
the	O
MnlI	O
-	O
AluI	O
fragment	O
in	O
HeLa	O
cells	O
but	O
not	O
in	O
B	O
cells	O
.	O
Thus	O
,	O
the	O
novel	O
enhancer	O
element	O
identified	O
in	O
this	O
study	O
is	O
probably	O
a	O
target	O
site	O
for	O
both	O
positive	B
and	I
negative	I
factors	I
.	O
[	O
Effect	O
of	O
the	O
regimen	O
of	O
kidney	O
-	O
tonifying	O
and	O
qi	O
-	O
invigorating	O
on	O
aging	O
changes	O
of	O
glucocorticoid	B
receptor	I
]	O
The	O
plasma	O
cortisol	O
concentration	O
and	O
the	O
sites	O
of	O
glucocorticoid	B
receptor	I
(	O
GCR	B
)	O
in	O
the	O
peripheral	O
lymphocytes	O
were	O
measured	O
in	O
32	O
healthy	O
aged	O
persons	O
and	O
13	O
young	O
adults	O
.	O
In	O
animal	O
experiment	O
,	O
GCR	B
of	O
spleen	O
lymphocytic	O
cell	O
was	O
also	O
measured	O
in	O
18	O
aged	O
rats	O
and	O
9	O
young	O
rats	O
.	O
The	O
results	O
showed	O
that	O
GCR	B
was	O
significantly	O
lower	O
in	O
the	O
aged	O
persons	O
or	O
rats	O
than	O
that	O
in	O
the	O
young	O
while	O
the	O
plasma	O
cortisol	O
level	O
did	O
n't	O
change	O
with	O
aging	O
.	O
So	O
we	O
think	O
that	O
GCR	B
is	O
more	O
sensitive	O
than	O
the	O
plasma	O
cortisol	O
level	O
to	O
reflect	O
the	O
aging	O
change	O
of	O
the	O
adrenal	O
cortex	O
function	O
.	O
After	O
the	O
treatment	O
with	O
the	O
regimen	O
of	O
Kidney	O
-	O
tonifying	O
and	O
Qi	O
-	O
invigorating	O
,	O
the	O
GCR	B
of	O
the	O
aged	O
persons	O
and	O
rats	O
was	O
enhanced	O
,	O
and	O
in	O
this	O
way	O
,	O
the	O
function	O
of	O
the	O
aged	O
adrenal	O
cortex	O
was	O
improved	O
.	O
An	O
in	O
vitro	O
globin	O
gene	O
switching	O
model	O
based	O
on	O
differentiated	O
embryonic	O
stem	O
cells	O
.	O
We	O
used	O
mouse	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
to	O
study	O
globin	O
gene	O
expression	O
and	O
switching	O
in	O
vitro	O
.	O
We	O
show	O
that	O
ES	O
-	O
derived	O
embryoid	O
bodies	O
express	O
the	O
full	O
complement	O
of	O
mouse	O
embryonic	O
globin	O
genes	O
in	O
the	O
correct	O
temporal	O
order	O
and	O
that	O
on	O
further	O
differentiation	O
,	O
a	O
switch	O
occurs	O
to	O
the	O
fetal	O
/	O
adult	O
genes	O
.	O
In	O
addition	O
,	O
the	O
erythroid	B
-	I
specific	I
transcription	I
factor	I
NF	B
-	I
E1	I
was	O
shown	O
to	O
be	O
expressed	O
coordinately	O
with	O
that	O
of	O
globin	B
in	O
embryoid	O
bodies	O
.	O
We	O
conclude	O
from	O
these	O
experiments	O
that	O
the	O
ES	O
cell	O
system	O
provides	O
a	O
good	O
model	O
to	O
study	O
hematopoietic	O
development	O
.	O
When	O
the	O
human	O
epsilon-	O
or	O
beta	O
-	O
globin	O
genes	O
driven	O
by	O
the	O
dominant	O
control	O
region	O
(	O
DCR	O
)	O
are	O
introduced	O
into	O
this	O
system	O
,	O
the	O
human	O
epsilon	O
-	O
globin	O
gene	O
,	O
in	O
contrast	O
to	O
the	O
beta	O
-	O
globin	O
gene	O
,	O
is	O
not	O
deregulated	O
by	O
the	O
presence	O
of	O
the	O
DCR	O
and	O
is	O
expressed	O
strictly	O
as	O
an	O
embryonic	O
gene	O
.	O
We	O
conclude	O
from	O
this	O
that	O
the	O
epsilon	O
-	O
globin	O
gene	O
is	O
not	O
regulated	O
by	O
competition	O
with	O
other	O
genes	O
in	O
the	O
human	O
beta	O
-	O
globin	O
locus	O
.	O
The	O
NF	O
kappa	O
B	O
independent	O
cis	O
-	O
acting	O
sequences	O
in	O
HIV-1	O
LTR	O
responsive	O
to	O
T	O
-	O
cell	O
activation	O
.	O
The	O
rate	O
of	O
transcription	O
initiation	O
directed	O
by	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV-1	O
increases	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
of	O
T	O
cells	O
.	O
Here	O
we	O
show	O
that	O
the	O
response	O
of	O
the	O
HIV-1	O
LTR	O
may	O
be	O
governed	O
by	O
two	O
independent	O
sequences	O
located	O
5	O
'	O
to	O
the	O
site	O
of	O
transcription	O
initiation	O
sequences	O
that	O
bind	O
either	O
NFAT-1	B
or	O
NF	B
kappa	I
B	I
.	O
The	O
rate	O
of	O
LTR	O
-directed	O
gene	O
expression	O
increased	O
in	O
response	O
to	O
treatment	O
with	O
either	O
a	O
phorbol	O
ester	O
or	O
tumor	B
necrosis	I
factor	I
alpha	I
if	O
either	O
the	O
NFAT-1	B
or	O
NF	O
kappa	O
B	O
binding	O
sites	O
were	O
deleted	O
,	O
but	O
failed	O
to	O
respond	O
to	O
these	O
mitogenic	O
stimuli	O
if	O
both	O
sequences	O
were	O
absent	O
.	O
The	O
HIV-1	O
mutant	O
virus	O
containing	O
both	O
NF	O
kappa	O
B	O
and	O
NFAT-1	O
deletion	O
was	O
able	O
to	O
replicate	O
although	O
at	O
a	O
much	O
decreased	O
growth	O
rate	O
,	O
while	O
the	O
deletion	O
of	O
NFAT-1	B
alone	O
increased	O
the	O
viral	O
growth	O
rate	O
in	O
Jurkat	O
cells	O
.	O
Neither	O
deletion	O
of	O
NF	B
kappa	I
B	I
nor	O
deletion	O
of	O
NFAT-1	B
decreased	O
activation	O
of	O
viral	O
replication	O
by	O
phorbol	O
ester	O
.	O
Identification	O
and	O
cloning	O
of	O
TCF-1	B
,	O
a	O
T	B
lymphocyte	I
-	I
specific	I
transcription	I
factor	I
containing	O
a	O
sequence	B
-	I
specific	I
HMG	I
box	I
.	O
CD3	B
-epsilon	O
expression	O
is	O
controlled	O
by	O
a	O
downstream	O
T	O
lymphocyte	O
-	O
specific	O
enhancer	O
element	O
.	O
We	O
report	O
the	O
identification	O
of	O
a	O
T	B
cell	I
-	I
specific	I
transcription	I
factor	I
,	O
TCF-1	B
,	O
binding	O
to	O
this	O
element	O
.	O
The	O
multimerized	B
recognition	I
motif	I
of	O
TCF-1	B
constituted	O
a	O
T	O
cell	O
-	O
specific	O
enhancer	O
.	O
Subsequent	O
cloning	O
of	O
TCF-1	B
identified	O
three	O
splice	B
alternatives	I
.	O
TCF-1	B
contained	O
a	O
single	O
DNA	B
-	I
binding	I
HMG	I
box	I
most	O
closely	O
related	O
to	O
similar	O
boxes	O
in	O
the	O
putative	O
mammalian	O
sex	O
-	O
determining	O
gene	O
SRY	O
and	O
in	O
the	O
Schizosaccharomyces	O
pombe	O
Mc	O
mating	O
type	O
gene	O
.	O
TCF-1	O
mRNA	O
was	O
expressed	O
uniquely	O
in	O
T	O
lymphocytes	O
.	O
Upon	O
cotransfection	O
into	O
non	O
-	O
T	O
cells	O
,	O
TCF-1	B
could	O
transactivate	O
through	O
its	O
cognate	O
motif	O
.	O
These	O
results	O
identify	O
TCF-1	B
as	O
a	O
T	B
cell	I
-	I
specific	I
transcription	I
factor	I
,	O
which	O
might	O
play	O
a	O
role	O
in	O
the	O
establishment	O
of	O
the	O
mature	O
T	O
cell	O
phenotype	O
.	O
Expression	O
of	O
c	O
-	O
jun	O
,	O
jun	O
B	O
and	O
jun	O
D	O
proto	O
-	O
oncogenes	O
in	O
human	O
peripheral	O
-	O
blood	O
granulocytes	O
.	O
We	O
have	O
found	O
that	O
purified	O
human	O
peripheral	O
-	O
blood	O
granulocytes	O
express	O
constitutively	O
significant	O
levels	O
of	O
proto	O
-	O
oncogenes	O
c	O
-	O
jun	O
,	O
jun	O
B	O
and	O
jun	O
D	O
mRNA	O
.	O
Upon	O
functional	O
activation	O
of	O
granulocytes	O
by	O
4	O
beta	O
-	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
the	O
levels	O
of	O
c	O
-	O
jun	O
,	O
jun	O
B	O
and	O
jun	O
D	O
transcripts	O
were	O
increased	O
.	O
The	O
three	O
jun	O
genes	O
showed	O
a	O
similar	O
time	O
course	O
in	O
their	O
induction	O
by	O
PMA	O
,	O
maximal	O
mRNA	O
levels	O
being	O
reached	O
after	O
60	O
min	O
of	O
induction	O
.	O
These	O
results	O
suggest	O
that	O
expression	O
of	O
c	O
-	O
jun	O
,	O
jun	O
B	O
and	O
jun	O
D	O
genes	O
might	O
be	O
involved	O
in	O
terminal	O
granulocyte	O
differentiation	O
or	O
in	O
regulating	O
granulocyte	O
functionality	O
.	O
Oestrogen	B
receptor	I
(	O
ER	B
)	O
analysis	O
in	O
B	O
-	O
cell	O
chronic	O
lymphocytic	O
leukemia	O
:	O
correlation	O
of	O
biochemical	O
and	O
immunocytochemical	O
methods	O
.	O
Oestrogen	B
receptors	I
(	O
ER	B
)	O
are	O
present	O
in	O
neoplastic	O
lymphoid	O
cells	O
and	O
have	O
been	O
considered	O
a	O
physiological	O
marker	O
of	O
growth	O
rate	O
or	O
differentiation	O
.	O
Tamoxifen	O
,	O
an	O
oestrogen	O
antagonist	O
,	O
has	O
been	O
given	O
in	O
some	O
patients	O
with	O
CLL	O
and	O
Hodgkin	O
's	O
disease	O
,	O
with	O
dramatic	O
response	O
in	O
single	O
cases	O
.	O
Until	O
now	O
,	O
ER	B
status	O
has	O
been	O
assessed	O
using	O
a	O
steroid	O
binding	O
assay	O
(	O
SBA	O
)	O
which	O
has	O
many	O
inherent	O
problems	O
.	O
Recently	O
,	O
the	O
development	O
of	O
monoclonal	O
antibodies	O
directed	O
against	O
ER	B
has	O
been	O
applied	O
to	O
the	O
study	O
of	O
breast	O
carcinomas	O
and	O
results	O
obtained	O
show	O
good	O
correlation	O
with	O
the	O
quantitative	O
SBA	O
.	O
We	O
studied	O
49	O
cases	O
of	O
B	O
-	O
cell	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
using	O
immunostaining	O
of	O
cytospin	O
preparations	O
.	O
In	O
30	O
of	O
these	O
cases	O
ER	B
enzyme	O
immunoassay	O
(	O
ER	B
-EIA	O
)	O
was	O
also	O
performed	O
.	O
Cultured	O
MCF-7	O
cells	O
,	O
derived	O
from	O
a	O
pleural	O
effusion	O
of	O
a	O
breast	O
cancer	O
patient	O
,	O
known	O
to	O
contain	O
high	O
levels	O
of	O
ER	B
were	O
used	O
as	O
a	O
positive	O
control	O
(	O
40	O
-	O
48	O
%	O
ER	O
positive	O
cells	O
by	O
immunocytochemistry	O
;	O
200	O
fmol	O
/	O
mg	O
protein	O
by	O
EIA	O
)	O
.	O
All	O
of	O
the	O
CLL	O
cases	O
except	O
two	O
(	O
96	O
%	O
)	O
were	O
negative	O
for	O
ER	B
(	O
less	O
than	O
1	O
%	O
staining	O
;	O
less	O
than	O
4	O
fmol	O
/	O
mg	O
protein	O
)	O
.	O
The	O
two	O
positive	O
cases	O
expressed	O
granular	O
ER	B
staining	O
over	O
the	O
nucleus	O
(	O
9.2	O
and	O
12.1	O
%	O
positive	O
cells	O
)	O
and	O
were	O
positive	O
by	O
EIA	O
and	O
SBA	O
.	O
It	O
is	O
concluded	O
that	O
(	O
i	O
)	O
patients	O
with	O
CLL	O
rarely	O
express	O
ER	B
and	O
(	O
ii	O
)	O
immunocytochemical	O
staining	O
of	O
cytospin	O
preparations	O
is	O
a	O
valid	O
technique	O
for	O
the	O
measurement	O
of	O
ER	B
.	O
It	O
is	O
of	O
interest	O
that	O
one	O
of	O
the	O
positive	O
cases	O
was	O
diagnosed	O
as	O
CLL	O
with	O
Richter	O
's	O
transformation	O
confirming	O
earlier	O
findings	O
.	O
Platelet	B
-	I
activating	I
factor	I
induces	O
phospholipid	O
turnover	O
,	O
calcium	O
flux	O
,	O
arachidonic	O
acid	O
liberation	O
,	O
eicosanoid	O
generation	O
,	O
and	O
oncogene	O
expression	O
in	O
a	O
human	O
B	O
cell	O
line	O
.	O
Platelet	B
-	I
activating	I
factor	I
is	O
a	O
potent	O
mediator	O
of	O
the	O
inflammatory	O
response	O
.	O
Studies	O
of	O
the	O
actions	O
of	O
platelet	B
-	I
activating	I
factor	I
have	O
centered	O
mainly	O
around	O
neutrophils	O
,	O
monocytes	O
,	O
and	O
platelets	O
.	O
In	O
this	O
report	O
we	O
begin	O
to	O
uncover	O
the	O
influence	O
of	O
platelet	B
-	I
activating	I
factor	I
on	O
B	O
lymphocytes	O
.	O
Employing	O
the	O
EBV	O
-	O
transformed	O
human	O
B	O
cell	O
line	O
SKW6.4	O
,	O
we	O
demonstrate	O
that	O
platelet	B
-	I
activating	I
factor	I
significantly	O
alters	O
membrane	O
phospholipid	O
metabolism	O
indicated	O
by	O
the	O
incorporation	O
of	O
32P	O
into	O
phosphatidylcholine	O
,	O
phosphatidylinositol	O
,	O
and	O
phosphatidic	O
acid	O
but	O
not	O
significantly	O
into	O
phosphatidylethanolamine	O
at	O
concentrations	O
ranging	O
from	O
10	O
(	O
-9	O
)	O
to	O
10	O
(	O
-6	O
)	O
M	O
.	O
The	O
inactive	O
precursor	O
,	O
lyso	B
-	I
platelet	I
-	I
activating	I
factor	I
,	O
at	O
a	O
concentration	O
as	O
high	O
as	O
10	O
(	O
-7	O
)	O
M	O
had	O
no	O
effect	O
on	O
any	O
of	O
the	O
membrane	O
phospholipids	O
.	O
We	O
also	O
show	O
that	O
platelet	B
-	I
activating	I
factor	I
from	O
10	O
(	O
-12	O
)	O
to	O
10	O
(	O
-6	O
)	O
M	O
induced	O
rapid	O
and	O
significant	O
elevation	O
in	O
intracellular	O
calcium	O
levels	O
,	O
whereas	O
lyso-	O
platelet	B
-	I
activating	I
factor	I
was	O
again	O
ineffective	O
.	O
We	O
further	O
demonstrate	O
the	O
impact	O
of	O
platelet	B
-	I
activating	I
factor	I
binding	O
to	O
B	O
cells	O
by	O
measuring	O
platelet	B
-	I
activating	I
factor	I
induced	O
arachidonic	O
acid	O
release	O
and	O
5-hydroxyeicosatetraenoic	O
acid	O
production	O
.	O
Moreover	O
,	O
platelet	B
-	I
activating	I
factor	I
was	O
capable	O
of	O
inducing	O
transcription	O
of	O
the	O
nuclear	O
proto	O
-	O
oncogenes	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
.	O
Finally	O
we	O
explored	O
the	O
possible	O
role	O
of	O
5-hydroxyeicosatetraenoic	O
acid	O
as	O
a	O
regulator	O
of	O
arachidonic	O
acid	O
liberation	O
demonstrating	O
that	O
endogenous	O
5-lipoxygenase	B
activity	O
modulates	O
platelet	B
-	I
activating	I
factor	I
induced	O
arachidonic	O
acid	O
release	O
perhaps	O
acting	O
at	O
the	O
level	O
of	O
phospholipase	B
A2	I
.	O
In	O
summary	O
,	O
platelet	B
-	I
activating	I
factor	I
is	O
shown	O
here	O
to	O
have	O
a	O
direct	O
and	O
profound	O
effect	O
on	O
a	O
pure	O
B	O
cell	O
line	O
.	O
[	O
Glucocorticoid	B
receptors	I
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
bronchial	O
asthma	O
]	O
Quantitation	O
of	O
glucocorticoid	B
receptors	I
(	O
GCR	B
)	O
and	O
the	O
study	O
of	O
their	O
affinity	O
for	O
glucocorticosteroids	O
(	O
GCS	O
)	O
were	O
made	O
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
bronchial	O
asthma	O
(	O
BA	O
)	O
patients	O
in	O
consideration	O
of	O
GCR	B
treatment	O
and	O
serum	O
levels	O
of	O
endogenous	O
cortisol	O
.	O
It	O
is	O
stated	O
that	O
GCR	B
of	O
healthy	O
controls	O
and	O
GCS	O
-	O
untreated	O
patients	O
outnumbered	O
those	O
of	O
cortisol	O
-	O
dependent	O
BA	O
patients	O
on	O
hormone	O
therapy	O
.	O
Following	O
discontinuation	O
of	O
glucocorticoid	O
drugs	O
GCR	B
count	O
in	O
cortisol	O
-	O
dependent	O
BA	O
tends	O
to	O
rise	O
.	O
Endogenous	O
cortisol	O
has	O
no	O
effect	O
on	O
GCR	B
level	O
estimated	O
by	O
3H	O
-	O
triamcinolone	O
acetonide	O
.	O
1	O
,	O
25-Dihydroxyvitamin	O
D3	O
receptor	O
RNA	O
:	O
expression	O
in	O
hematopoietic	O
cells	O
.	O
1	O
,	O
25-Dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
induces	O
differentiation	O
and	O
inhibits	O
proliferation	O
of	O
myeloid	O
leukemic	O
cells	O
from	O
various	O
lines	O
and	O
patients	O
;	O
these	O
effects	O
are	O
probably	O
mediated	O
through	O
the	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptor	I
.	O
Little	O
is	O
known	O
of	O
expression	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
in	O
hematopoietic	O
cells	O
.	O
We	O
examined	O
the	O
expression	O
and	O
modulation	O
of	O
expression	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
in	O
various	O
proliferating	O
and	O
nonproliferating	O
hematopoietic	O
cells	O
.	O
Constitutive	O
expression	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
was	O
detected	O
in	O
various	O
kinds	O
of	O
hematopoietic	O
cells	O
,	O
including	O
macrophages	O
and	O
activated	O
T	O
lymphocytes	O
,	O
as	O
well	O
as	O
in	O
cell	O
lines	O
KG-1	O
(	O
myeloblasts	O
)	O
,	O
HL-60	O
(	O
promyelocytes	O
)	O
,	O
ML-3	O
(	O
myelomonoblasts	O
)	O
,	O
U937	O
,	O
THP-1	O
(	O
monoblasts	O
)	O
,	O
K562	O
(	O
erythroblasts	O
)	O
,	O
and	O
S	O
-	O
LB1	O
(	O
HTLV-1-transfected	O
T	O
lymphocytes	O
)	O
.	O
Receptor	O
transcripts	O
were	O
4.6	O
kilobases	O
(	O
kb	O
)	O
,	O
and	O
no	O
variant	O
sizes	O
were	O
observed	O
.	O
All	O
cell	O
lines	O
examined	O
in	O
this	O
group	O
also	O
expressed	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptors	I
.	O
Most	O
B	O
lymphocyte	O
lines	O
expressed	O
negligible	O
levels	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
and	O
protein	O
;	O
however	O
;	O
analysis	O
of	O
a	O
lymphoid	O
/	O
myeloid	O
somatic	O
hybrid	O
suggested	O
that	O
suppression	O
of	O
expression	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
in	O
B	O
lymphocytes	O
may	O
be	O
a	O
dominant	O
characteristic	O
.	O
HL-60	O
cells	O
were	O
cultured	O
with	O
10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
for	O
24	O
to	O
72	O
hours	O
,	O
and	O
levels	O
of	O
expression	O
of	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptor	I
and	O
its	O
RNA	O
were	O
examined	O
.	O
Levels	O
of	O
RNA	O
coding	O
for	O
the	O
receptor	B
were	O
not	O
modulated	O
by	O
exposure	O
to	O
high	O
levels	O
of	O
ligand	O
.	O
Levels	O
of	O
occupied	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptor	I
protein	I
increased	O
in	O
these	O
HL-60	O
cells	O
;	O
but	O
the	O
total	O
number	O
of	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptors	I
decreased	O
about	O
50	O
%	O
at	O
24	O
hours	O
and	O
returned	O
toward	O
normal	O
at	O
72	O
hours	O
.	O
Steady	O
-	O
state	O
levels	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
were	O
not	O
affected	O
by	O
terminal	O
differentiation	O
of	O
HL-60	O
toward	O
either	O
granulocytes	O
or	O
macrophages	O
.	O
Nondividing	O
macrophages	O
from	O
normal	O
individuals	O
also	O
expressed	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
.	O
In	O
contrast	O
,	O
nondividing	O
peripheral	O
blood	O
lymphocytes	O
from	O
normal	O
individuals	O
did	O
not	O
express	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
;	O
with	O
stimulation	O
of	O
proliferation	O
of	O
these	O
cells	O
,	O
accumulation	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
increased	O
markedly	O
.	O
Half	O
-	O
life	O
(	O
t1	O
/	O
2	O
)	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
in	O
T	O
lymphocytes	O
was	O
short	O
(	O
1	O
hour	O
)	O
as	O
determined	O
by	O
measuring	O
decay	O
of	O
the	O
message	O
after	O
addition	O
of	O
actinomycin	O
D	O
.	O
Consistent	O
with	O
this	O
short	O
t1	O
/	O
2	O
,	O
accumulation	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
increased	O
in	O
cells	O
as	O
their	O
protein	O
synthesis	O
was	O
inhibited	O
.	O
Further	O
studies	O
are	O
required	O
to	O
understand	O
the	O
physiologic	O
role	O
of	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptors	I
in	O
myeloid	O
cells	O
and	O
proliferating	O
T	O
lymphocytes	O
.	O
Kappa	B
B	I
binding	I
proteins	I
are	O
constitutively	O
expressed	O
in	O
an	O
IL-2	O
autocrine	O
human	O
T	O
cell	O
line	O
.	O
The	O
IL-2	O
and	O
the	O
IL-2-R	O
alpha	O
genes	O
are	O
both	O
expressed	O
transiently	O
in	O
normal	O
T	O
lymphocytes	O
after	O
Ag	O
or	O
mitogen	O
activation	O
.	O
In	O
contrast	O
,	O
the	O
human	O
T	O
cell	O
line	O
,	O
IARC	O
301	O
,	O
expresses	O
these	O
two	O
genes	O
constitutively	O
and	O
we	O
have	O
previously	O
demonstrated	O
that	O
its	O
growth	O
depends	O
on	O
the	O
autocrine	O
production	O
of	O
this	O
T	B
cell	I
growth	I
factor	I
and	O
high	B
affinity	I
IL-2R	I
.	O
To	O
dissect	O
the	O
molecular	O
basis	O
for	O
the	O
unusual	O
persistent	O
expression	O
of	O
the	O
IL-2	O
and	O
IL-2-R	O
alpha	O
genes	O
in	O
these	O
IARC	O
301	O
T	O
cells	O
,	O
we	O
have	O
analyzed	O
the	O
interactions	O
of	O
constitutively	B
expressed	I
nuclear	I
proteins	I
with	O
the	O
5	O
'	O
flanking	O
regions	O
of	O
the	O
IL-2	O
and	O
IL-2-R	O
alpha	O
genes	O
using	O
both	O
DNase	B
I	I
footprinting	O
and	O
gel	O
retardation	O
techniques	O
.	O
We	O
have	O
found	O
that	O
a	O
region	O
in	O
both	O
genes	O
(	O
-276	O
to	O
-250	O
for	O
IL-2-R	O
alpha	O
and	O
-203	O
to	O
-183	O
for	O
IL-2	O
)	O
,	O
which	O
corresponds	O
to	O
a	O
kappa	O
B	O
enhancer	O
element	O
,	O
is	O
specifically	O
protected	O
by	O
nuclear	B
proteins	I
from	O
IARC	O
301	O
.	O
In	O
agreement	O
with	O
this	O
finding	O
,	O
both	O
the	O
IL-2	O
and	O
IL-2-R	O
alpha	O
promoters	O
are	O
active	O
in	O
transient	O
transfection	O
assays	O
in	O
IARC	O
301	O
cells	O
.	O
In	O
contrast	O
,	O
mutation	O
of	O
the	O
kappa	B
B	I
enhancer	I
results	O
in	O
markedly	O
attenuated	O
activities	O
of	O
both	O
promoters	O
.	O
Two	O
proteins	O
binding	O
the	O
kappa	O
B	O
sequence	O
,	O
NF	B
-	I
kappa	I
B	I
and	O
KBF1	B
,	O
are	O
constitutively	O
expressed	O
in	O
IARC	O
301	O
nuclei	O
and	O
induced	O
by	O
PMA	O
and	O
PHA	B
in	O
Jurkat	O
.	O
They	O
bind	O
to	O
the	O
kappa	O
B	O
motifs	O
with	O
different	O
relative	O
affinities	O
that	O
may	O
reflect	O
their	O
different	O
contribution	O
in	O
the	O
expression	O
of	O
various	O
promoters	O
.	O
Isolation	O
of	O
a	O
rel	O
-	O
related	O
human	O
cDNA	O
that	O
potentially	O
encodes	O
the	O
65-kD	B
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
[	O
published	O
erratum	O
appears	O
in	O
Science	O
1991	O
Oct	O
4	O
;	O
254	O
(	O
5028	O
)	O
:	O
11	O
]	O
A	O
DNA	O
probe	O
that	O
spanned	O
a	O
domain	O
conserved	O
among	O
the	O
proto	O
-	O
oncogene	O
c	O
-	O
rel	O
,	O
the	O
Drosophila	B
morphogen	I
dorsal	I
,	O
and	O
the	O
p50	B
DNA	I
binding	I
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
was	O
generated	O
from	O
Jurkat	O
T	O
cell	O
complementary	O
DNA	O
with	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
degenerate	O
oligonucleotides	O
.	O
This	O
probe	O
was	O
used	O
to	O
identify	O
a	O
rel	O
-	O
related	O
complementary	O
DNA	O
that	O
hybridized	O
to	O
a	O
2.6-kilobase	O
messenger	O
RNA	O
present	O
in	O
human	O
T	O
and	O
B	O
lymphocytes	O
.	O
In	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
complementary	O
DNA	O
resulted	O
in	O
the	O
synthesis	O
of	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
size	O
of	O
65	B
kilodaltons	I
(	O
kD	O
)	O
.	O
The	O
translated	O
protein	O
showed	O
weak	O
DNA	O
binding	O
with	O
a	O
specificity	O
for	O
the	O
kappa	O
B	O
binding	O
motif	O
.	O
This	O
protein	B
-	I
DNA	I
complex	I
comigrated	O
with	O
the	O
complex	O
obtained	O
with	O
the	O
purified	B
human	I
p65	I
NF	I
-	I
kappa	I
B	I
subunit	I
and	O
binding	O
was	O
inhibited	O
by	O
I	B
kappa	I
B	I
-	I
alpha	I
and	O
-beta	O
proteins	O
.	O
In	O
addition	O
,	O
the	O
65-kD	B
protein	I
associated	O
with	O
the	O
p50	B
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
and	O
the	O
kappa	O
B	O
probe	O
to	O
form	O
a	O
complex	O
with	O
the	O
same	O
electrophoretic	O
mobility	O
as	O
the	O
NF	B
-	I
kappa	I
B	I
-	I
DNA	I
complex	I
.	O
Therefore	O
the	O
rel	B
-	I
related	I
65-kD	I
protein	I
may	O
represent	O
the	O
p65	B
subunit	I
of	O
the	O
active	B
NF	I
-	I
kappa	I
B	I
transcription	I
factor	I
complex	I
.	O
Transcriptional	O
down	O
-	O
regulation	O
of	O
c	O
-	O
myc	O
expression	O
by	O
protein	O
synthesis	O
-	O
dependent	O
and	O
-independent	O
pathways	O
in	O
a	O
human	O
T	O
lymphoblastic	O
tumor	O
cell	O
line	O
.	O
We	O
show	O
that	O
in	O
the	O
human	O
T	O
lymphoblastic	O
tumor	O
cell	O
line	O
Molt4	O
c	O
-	O
myc	O
mRNA	O
and	O
protein	O
expression	O
is	O
down	O
-	O
regulated	O
after	O
exposure	O
to	O
dimethyl	O
sulfoxide	O
,	O
to	O
phorbol	O
myristate	O
acetate	O
,	O
or	O
to	O
the	O
calcium	O
ionophore	O
A23187	O
,	O
which	O
raises	O
the	O
intracellular	O
calcium	O
concentration	O
.	O
A	O
block	O
to	O
RNA	O
elongation	O
is	O
largely	O
responsible	O
for	O
decreased	O
c	O
-	O
myc	O
transcription	O
.	O
Although	O
negative	O
regulation	O
by	O
dimethyl	O
sulfoxide	O
takes	O
place	O
even	O
when	O
protein	O
synthesis	O
is	O
inhibited	O
by	O
cycloheximide	O
,	O
the	O
phorbol	O
myristate	O
acetate	O
effect	O
is	O
blocked	O
to	O
some	O
extent	O
only	O
by	O
cycloheximide	O
.	O
The	O
calcium	O
ionophore	O
-	O
induced	O
c	O
-	O
myc	O
suppression	O
,	O
however	O
,	O
strictly	O
requires	O
de	O
novo	O
protein	O
synthesis	O
.	O
Therefore	O
,	O
two	O
different	O
negative	O
regulatory	O
pathways	O
are	O
involved	O
in	O
c	O
-	O
myc	O
regulation	O
:	O
one	O
which	O
is	O
independent	O
and	O
one	O
which	O
depends	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O
The	O
latter	O
one	O
appears	O
to	O
be	O
mediated	O
by	O
a	O
rapidly	O
calcium	B
-	I
dependent	I
induced	I
gene	I
product	I
.	O
Human	O
immunodeficiency	O
virus	O
type-2	O
gene	O
expression	O
:	O
two	O
enhancers	O
and	O
their	O
activation	O
by	O
T	O
-	O
cell	O
activators	O
.	O
The	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
may	O
include	O
a	O
spectrum	O
of	O
retroviruses	O
with	O
varying	O
potential	O
to	O
infect	O
their	O
host	O
,	O
undergo	O
long	O
periods	O
of	O
latent	O
infection	O
,	O
and	O
induce	O
pathology	O
.	O
Since	O
expression	O
of	O
the	O
viruses	O
is	O
in	O
large	O
part	O
regulated	O
by	O
the	O
sequence	O
elements	O
in	O
their	O
long	O
terminal	O
repeats	O
(	O
LTRs	O
)	O
,	O
this	O
study	O
was	O
directed	O
to	O
an	O
analysis	O
of	O
the	O
regulatory	O
elements	O
in	O
the	O
HIV-2	O
LTR	O
.	O
The	O
HIV-2	O
LTR	O
was	O
found	O
to	O
contain	O
two	O
enhancers	O
.	O
One	O
of	O
these	O
enhancers	O
is	O
,	O
in	O
part	O
,	O
identical	O
to	O
the	O
HIV-1	O
enhancer	O
.	O
This	O
enhancer	O
in	O
HIV-1	O
is	O
the	O
T	O
-	O
cell	O
activation	O
response	O
element	O
;	O
in	O
HIV-2	O
,	O
however	O
,	O
it	O
is	O
the	O
second	O
enhancer	O
that	O
is	O
mainly	O
responsible	O
for	O
activation	O
in	O
response	O
to	O
T	O
-	O
cell	O
activators	O
.	O
The	O
second	O
enhancer	O
interacts	O
with	O
two	O
nuclear	B
binding	I
proteins	I
(	O
85	O
kD	O
and	O
27	O
kD	O
mobility	O
)	O
that	O
appear	O
to	O
be	O
required	O
for	O
optimal	O
enhancer	O
function	O
and	O
activation	O
.	O
Observations	O
such	O
as	O
these	O
encourage	O
the	O
speculation	O
that	O
there	O
may	O
be	O
subtle	O
differences	O
in	O
the	O
regulation	O
of	O
HIV-1	O
and	O
HIV-2	O
expression	O
that	O
may	O
be	O
relevant	O
to	O
the	O
possible	O
longer	O
latency	O
and	O
reduced	O
pathogenicity	O
of	O
HIV-2	O
.	O
Suppression	O
of	O
signals	O
required	O
for	O
activation	O
of	O
transcription	B
factor	I
NF	I
-	I
kappa	I
B	I
in	O
cells	O
constitutively	O
expressing	O
the	O
HTLV	B
-	I
I	I
Tax	I
protein	I
.	O
Transient	O
short	O
-	O
term	O
expression	O
of	O
the	O
Tax	B
protein	I
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
-	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
leads	O
to	O
activation	O
of	O
the	O
pleiotropic	O
transcription	B
factor	I
NF	I
-	I
kappa	I
B	I
.	O
Consistent	O
with	O
findings	O
obtained	O
with	O
transient	O
expression	O
assays	O
,	O
we	O
observed	O
marked	O
accumulation	O
of	O
the	O
transcription	B
factor	I
NF	I
-	I
kappa	I
B	I
in	O
the	O
nucleus	O
of	O
Namalwa	O
B	O
lymphoid	O
cells	O
,	O
which	O
constitutively	O
express	O
Tax	B
.	O
In	O
contrast	O
,	O
NF	B
-	I
kappa	I
B	I
activity	O
was	O
not	O
detected	O
in	O
the	O
nucleus	O
following	O
long	O
-	O
term	O
expression	O
of	O
Tax	B
in	O
Jurkat	O
T	O
lymphocytes	O
.	O
The	O
ability	O
of	O
both	O
mitogens	O
and	O
cytokines	B
to	O
activate	O
NF	B
-	I
kappa	I
B	I
was	O
also	O
blocked	O
in	O
Jurkat	O
cells	O
constitutively	O
expressing	O
Tax	B
.	O
However	O
,	O
the	O
activation	O
of	O
other	O
mitogen	B
-	I
inducible	I
transcription	I
factors	I
,	O
such	O
as	O
Fos	B
and	O
Jun	B
,	O
was	O
unaffected	O
.	O
Thus	O
,	O
depending	O
on	O
the	O
cellular	O
environment	O
,	O
the	O
short-	O
and	O
long	O
-	O
term	O
effects	O
of	O
Tax	B
expression	O
can	O
be	O
quite	O
different	O
.	O
Consequently	O
,	O
one	O
function	O
of	O
Tax	B
in	O
cells	O
infected	O
with	O
HTLV	O
-	O
I	O
might	O
involve	O
cell	O
-	O
type	O
-	O
specific	O
suppression	O
,	O
as	O
opposed	O
to	O
activation	O
,	O
of	O
distinct	O
signal	O
pathways	O
.	O
The	O
cells	O
lines	O
described	O
here	O
should	O
be	O
useful	O
for	O
the	O
delineation	O
of	O
signaling	O
pathways	O
utilized	O
in	O
the	O
selective	O
regulation	O
of	O
gene	O
expression	O
.	O
A	O
thymus	B
-	I
specific	I
member	I
of	O
the	O
HMG	B
protein	I
family	I
regulates	O
the	O
human	O
T	O
cell	O
receptor	O
C	O
alpha	O
enhancer	O
.	O
The	O
human	B
T	I
cell	I
-	I
specific	I
transcription	I
factor	I
TCF-1	B
alpha	I
plays	O
a	O
key	O
role	O
in	O
the	O
tissue	O
-	O
specific	O
activation	O
of	O
the	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
C	O
alpha	O
enhancer	O
and	O
binds	O
to	O
pyrimidine	O
-	O
rich	O
elements	O
(	O
5'-PyCTTTG-3	O
'	O
)	O
present	O
in	O
a	O
variety	O
of	O
other	O
T	O
cell	O
-	O
specific	O
control	O
regions	O
.	O
Using	O
amino	O
acid	O
sequence	O
information	O
derived	O
from	O
the	O
DNA	B
affinity	I
-	I
purified	I
protein	I
,	O
we	O
have	O
now	O
isolated	O
cDNA	O
clones	O
encoding	O
TCF-1	B
alpha	I
.	O
The	O
TCF-1	O
alpha	O
cDNA	O
contains	O
a	O
single	O
68-amino	B
-	I
acid	I
domain	I
that	O
is	O
homologous	O
to	O
a	O
region	O
conserved	O
among	O
high	B
-	I
mobility	I
group	I
(	O
HMG	B
)	O
and	O
nonhistone	B
chromosomal	I
proteins	I
.	O
Expression	O
of	O
full	O
-	O
length	O
and	O
mutant	O
cDNA	O
clones	O
in	O
bacteria	O
reveal	O
that	O
the	O
single	B
HMG	I
motif	I
,	O
which	O
is	O
predicted	O
to	O
contain	O
two	O
extended	O
alpha	B
-	I
helical	I
segments	I
,	O
is	O
sufficient	O
to	O
direct	O
the	O
sequence	O
-	O
specific	O
binding	O
of	O
TCF-1	B
alpha	I
to	O
DNA	O
.	O
Northern	O
blot	O
experiments	O
demonstrate	O
further	O
that	O
TCF-1	O
alpha	O
mRNA	O
is	O
highly	O
tissue	O
specific	O
,	O
found	O
primarily	O
in	O
the	O
thymus	O
or	O
T	O
cell	O
lines	O
.	O
The	O
immature	O
CEM	O
T	O
cell	O
line	O
expresses	O
relatively	O
low	O
levels	O
of	O
TCF-1	O
alpha	O
mRNA	O
,	O
which	O
are	O
increased	O
upon	O
activation	O
of	O
these	O
cells	O
by	O
phorbol	O
esters	O
.	O
Interestingly	O
,	O
the	O
cloned	O
TCF-1	B
alpha	I
protein	I
is	O
a	O
potent	O
transcriptional	B
activator	I
of	O
the	O
human	O
TCR	O
alpha	O
enhancer	O
in	O
nonlymphoid	O
cell	O
lines	O
,	O
whereas	O
the	O
activity	O
of	O
the	O
endogenous	B
protein	I
in	O
T	O
cell	O
lines	O
is	O
strongly	O
dependent	O
on	O
an	O
additional	O
T	O
cell	O
-	O
specific	O
protein	O
that	O
interacts	O
with	O
the	O
core	O
enhancer	O
.	O
TCF-1	B
alpha	I
is	O
currently	O
unique	O
among	O
the	O
newly	O
emerging	O
family	O
of	O
DNA	B
-	I
binding	I
regulatory	I
proteins	I
that	O
share	O
the	O
HMG	B
motif	I
in	O
that	O
it	O
is	O
a	O
highly	B
tissue	I
-	I
specific	I
RNA	I
polymerase	I
II	I
transcription	B
factor	I
.	O
Immune	O
response	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
to	O
HBx	B
-	I
antigen	I
of	O
hepatitis	O
B	O
virus	O
.	O
The	O
hepatitis	O
B	O
virus	O
genome	O
encodes	O
a	O
transcriptional	B
transactivator	I
protein	I
designated	O
HBxAg	B
.	O
We	O
have	O
investigated	O
whether	O
this	O
antigen	O
is	O
a	O
target	O
structure	O
for	O
human	O
T	O
-	O
lymphocytes	O
.	O
Using	O
recombinant	B
HBxAg	I
protein	I
,	O
we	O
found	O
HBxAg	B
-specific	O
stimulation	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
in	O
patients	O
with	O
acute	O
hepatitis	O
B	O
virus	O
infection	O
(	O
6	O
of	O
6	O
)	O
and	O
chronic	O
hepatitis	O
B	O
virus	O
infection	O
(	O
6	O
of	O
17	O
)	O
but	O
not	O
in	O
healthy	O
individuals	O
.	O
With	O
HBxAg	B
-specific	O
synthetic	O
polypeptides	O
,	O
several	O
T	O
-	O
cell	O
epitopes	O
were	O
identified	O
.	O
Most	O
were	O
located	O
in	O
the	O
carboxyterminal	B
half	I
of	O
the	O
HBxAg	B
protein	I
.	O
Five	O
T	O
-	O
cell	O
clones	O
specific	O
for	O
a	O
T	B
-	I
cell	I
epitope	I
located	O
at	O
the	O
carboxyterminal	B
region	I
of	O
HBxAg	B
were	O
established	O
and	O
found	O
to	O
belong	O
to	O
the	O
CD2	O
/	O
CD4-positive	O
,	O
CD8-negative	O
subtype	O
.	O
These	O
data	O
establish	O
for	O
the	O
first	O
time	O
HBxAg	B
as	O
an	O
antigen	O
in	O
the	O
cellular	O
immune	O
response	O
.	O
A	O
study	O
on	O
the	O
circadian	O
rhythm	O
of	O
glucocorticoid	B
receptor	I
.	O
Circadian	O
rhythm	O
in	O
glucocorticoid	B
receptor	I
(	O
GR	B
)	O
was	O
studied	O
in	O
the	O
rat	O
liver	O
and	O
human	O
peripheral	O
leukocytes	O
.	O
For	O
rats	O
exposed	O
to	O
a	O
natural	O
environmental	O
photic	O
cycle	O
or	O
a	O
12L	O
:	O
12D	O
artificial	O
light	O
regime	O
,	O
peak	O
values	O
of	O
hepatic	B
GR	I
were	O
detected	O
between	O
23	O
:	O
00	O
and	O
02	O
:	O
00	O
h	O
.	O
Except	O
for	O
a	O
4-hour	O
advancement	O
of	O
the	O
peak	O
,	O
a	O
similar	O
circadian	O
rhythm	O
of	O
hepatic	B
GR	I
was	O
detected	O
in	O
rats	O
reared	O
under	O
a	O
reversed	O
lighting	O
regimen	O
(	O
12D	O
:	O
12L	O
;	O
lights	O
on	O
between	O
18	O
:	O
30	O
and	O
06	O
:	O
30	O
h	O
)	O
.	O
In	O
human	O
leukocytes	O
,	O
the	O
peak	O
value	O
of	O
GR	B
was	O
found	O
to	O
parallel	O
that	O
of	O
plasma	O
cortisol	O
with	O
high	O
and	O
low	O
values	O
detected	O
at	O
04	O
:	O
00	O
-	O
08	O
:	O
00	O
h	O
and	O
23	O
:	O
00	O
-	O
24	O
:	O
00	O
h	O
,	O
respectively	O
.	O
In	O
patients	O
suffering	O
from	O
Cushing	O
's	O
syndrome	O
,	O
the	O
circadian	O
rhythm	O
of	O
plasma	O
cortisol	O
either	O
disappeared	O
or	O
was	O
inverted	O
while	O
that	O
of	O
GR	B
did	O
not	O
significantly	O
deviate	O
from	O
the	O
normal	O
subjects	O
.	O
For	O
apoplexic	O
patients	O
with	O
lesions	O
localized	O
to	O
the	O
base	O
of	O
the	O
brain	O
as	O
indicated	O
by	O
computerized	O
tomography	O
,	O
the	O
diurnal	O
variation	O
of	O
GR	B
was	O
abolished	O
.	O
Conversely	O
,	O
diurnal	O
rhythmicity	O
persisted	O
in	O
apoplexy	O
patients	O
whose	O
lesions	O
were	O
in	O
the	O
cerebral	O
cortex	O
.	O
Thus	O
,	O
we	O
postulated	O
that	O
the	O
circadian	O
modification	O
of	O
GR	B
was	O
independent	O
of	O
the	O
diurnal	O
fluctuations	O
in	O
plasma	O
cortisol	O
level	O
or	O
the	O
circadian	O
variations	O
in	O
environmental	O
lighting	O
and	O
that	O
the	O
rhythmicity	O
might	O
be	O
regulated	O
by	O
the	O
'	O
circadian	O
pacemaker	O
'	O
located	O
in	O
the	O
human	O
basal	O
brain	O
.	O
These	O
diurnal	O
variations	O
in	O
GR	B
might	O
serve	O
to	O
coordinate	O
the	O
reactivity	O
of	O
the	O
target	O
cells	O
to	O
cortisol	O
because	O
the	O
diurnal	O
rhythms	O
of	O
a	O
GR	B
-mediated	O
response	O
,	O
the	O
fractional	O
inhibition	O
of	O
chemotactic	O
migration	O
rate	O
of	O
polymorphonuclear	O
leukocytes	O
by	O
cortisol	O
,	O
were	O
found	O
to	O
be	O
synchronous	O
with	O
those	O
of	O
GR	B
.	O
Purification	O
of	O
TCF-1	B
alpha	I
,	O
a	O
T	B
-	I
cell	I
-	I
specific	I
transcription	I
factor	I
that	O
activates	O
the	O
T	O
-	O
cell	O
receptor	O
C	O
alpha	O
gene	O
enhancer	O
in	O
a	O
context	O
-	O
dependent	O
manner	O
.	O
The	O
differentiation	O
of	O
T	O
cells	O
into	O
functionally	O
diverse	O
subpopulations	O
is	O
controlled	O
in	O
part	O
,	O
by	O
transcriptional	O
activation	O
and	O
silencing	O
;	O
however	O
,	O
little	O
is	O
known	O
in	O
detail	O
about	O
the	O
proteins	O
that	O
influence	O
this	O
developmental	O
process	O
.	O
We	O
have	O
purified	O
a	O
new	O
T	B
-	I
cell	I
-	I
specific	I
factor	I
,	O
TCF-1	B
alpha	I
,	O
that	O
is	O
implicated	O
in	O
the	O
activation	O
of	O
genes	O
encoding	O
a	O
major	O
component	O
of	O
the	O
human	B
T	I
-	I
cell	I
receptor	I
(	O
TCR	B
)	O
.	O
TCF-1	B
alpha	I
,	O
originally	O
identified	O
and	O
purified	O
through	O
its	O
binding	O
sites	O
on	O
the	O
HIV-1	O
promoter	O
,	O
was	O
found	O
to	O
bind	O
to	O
the	O
TCR	O
alpha	O
enhancer	O
and	O
to	O
promoters	O
for	O
several	O
genes	O
expressed	O
at	O
significantly	O
earlier	O
stages	O
of	O
T	O
-	O
cell	O
development	O
than	O
the	O
TCR	O
alpha	O
gene	O
(	O
e.g.	O
,	O
p56lck	O
and	O
CD3	O
delta	O
)	O
.	O
Sequences	O
related	O
to	O
the	O
TCF-1	O
alpha	O
binding	O
motif	O
(	O
5'-GGCACCCTTTGA-3	O
'	O
)	O
are	O
also	O
found	O
in	O
the	O
human	O
TCR	O
delta	O
(	O
and	O
possibly	O
TCR	O
beta	O
)	O
enhancers	O
.	O
Southwestern	O
and	O
gel	O
renaturation	O
experiments	O
with	O
the	O
use	O
of	O
purified	O
protein	O
fractions	O
revealed	O
that	O
TCF-1	B
alpha	I
activity	O
is	O
derived	O
from	O
a	O
family	O
of	O
57-	B
to	I
53-kD	I
proteins	I
that	O
are	O
abundantly	O
expressed	O
in	O
mature	O
and	O
immature	O
T	O
-	O
cell	O
lines	O
(	O
Jurkat	O
,	O
CCRF	O
-	O
CEM	O
)	O
and	O
not	O
in	O
mature	O
B	O
cells	O
(	O
JY	O
,	O
Namalwa	O
)	O
or	O
nonlymphoid	O
(	O
HeLa	O
)	O
cell	O
lines	O
.	O
A	O
small	O
95-bp	O
fragment	O
of	O
the	O
TCR	O
alpha	O
control	O
region	O
that	O
contains	O
the	O
TCF-1	O
alpha	O
binding	O
site	O
juxtaposed	O
between	O
a	O
cAMP	O
-	O
response	O
element	O
(	O
the	O
CRE	O
or	O
T	O
alpha	O
1	O
motif	O
)	O
and	O
the	O
binding	O
site	O
for	O
a	O
distinct	O
lymphoid	B
-	I
specific	I
protein	I
(	O
TCF-2	B
alpha	I
)	O
behaved	O
as	O
a	O
potent	O
T	O
-	O
cell	O
-	O
specific	O
enhancer	O
in	O
vivo	O
.	O
Tandem	O
copies	O
of	O
this	O
enhancer	O
functioned	O
synergistically	O
in	O
mature	O
(	O
Jurkat	O
)	O
T	O
-	O
cell	O
lines	O
as	O
well	O
as	O
resting	O
and	O
activated	O
immature	O
(	O
CCRF	O
-	O
CEM	O
)	O
T	O
-	O
cell	O
lines	O
.	O
Mutation	O
of	O
the	O
TCF-1	O
alpha	O
binding	O
site	O
diminished	O
enhancer	O
activity	O
and	O
disrupted	O
the	O
synergism	O
observed	O
in	O
vivo	O
between	O
tandem	O
enhancer	O
repeats	O
.	O
The	O
TCF-1	O
alpha	O
binding	O
site	O
was	O
also	O
required	O
for	O
TCR	B
alpha	O
enhancer	O
activity	O
in	O
transcriptionally	O
active	O
extracts	O
from	O
Jurkat	O
but	O
not	O
HeLa	O
cells	O
,	O
confirming	O
that	O
TCF-1	B
alpha	I
is	O
a	O
T	B
-	I
cell	I
-	I
specific	I
transcription	I
factor	I
.	O
Curiously	O
,	O
the	O
TCF-1	B
alpha	I
binding	O
element	O
was	O
inactive	O
in	O
vivo	O
when	O
removed	O
from	O
its	O
neighboring	O
elements	O
on	O
the	O
TCR	O
alpha	O
enhancer	O
and	O
positioned	O
in	O
one	O
or	O
more	O
copies	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
.	O
Thus	O
,	O
the	O
transcriptional	O
activity	O
of	O
TCF-1	B
alpha	I
appears	O
to	O
depend	O
on	O
the	O
TCF-2	B
alpha	I
and	O
T	B
alpha	I
1	I
(	O
CREB	B
)	O
transcription	B
factors	I
and	O
the	O
context	O
of	O
its	O
binding	O
site	O
within	O
the	O
TCR	O
alpha	O
enhancer	O
.	O
Processing	O
of	O
the	O
precursor	O
of	O
NF	B
-	I
kappa	I
B	I
by	O
the	O
HIV-1	B
protease	I
during	O
acute	O
infection	O
.	O
Transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
genome	O
is	O
regulated	O
in	O
part	O
by	O
cellular	B
factors	I
and	O
is	O
stimulated	O
by	O
activation	O
of	O
latently	O
infected	O
T	O
cells	O
.	O
T	O
-	O
cell	O
activation	O
also	O
correlates	O
with	O
the	O
induction	O
of	O
the	O
factor	O
NF	B
-	I
kappa	I
B	I
which	O
binds	O
to	O
two	O
adjacent	O
sites	O
in	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
.	O
This	O
factor	O
consists	O
of	O
two	O
DNA	B
-	I
binding	I
subunits	I
of	O
relative	O
molecular	O
mass	O
50	O
,	O
000	O
(	O
50	O
K	O
)	O
associated	O
with	O
two	O
65	B
K	I
subunits	I
.	O
It	O
is	O
located	O
in	O
the	O
nucleus	O
in	O
mature	O
B	O
cells	O
,	O
but	O
is	O
present	O
in	O
other	O
cell	O
types	O
as	O
an	O
inactive	B
cytoplasmic	I
complex	I
.	O
External	O
stimuli	O
,	O
including	O
those	O
that	O
activate	O
T	O
cells	O
,	O
result	O
in	O
nuclear	O
translocation	O
of	O
active	O
NF	B
-	I
kappa	I
B	I
.	O
The	O
cloning	O
of	O
the	O
complementary	O
DNA	O
for	O
the	O
50	B
K	I
subunit	I
helped	O
to	O
identify	O
an	O
exclusively	O
cytoplasmic	B
105	I
K	I
precursor	I
(	O
p105	B
)	O
(	O
V.B.	O
,	O
P.K.	O
and	O
A.I.	O
,	O
manuscript	O
submitted	O
)	O
.	O
The	O
expression	O
of	O
active	O
NF	B
-	I
kappa	I
B	I
might	O
therefore	O
also	O
be	O
regulated	O
by	O
the	O
extent	O
of	O
processing	O
of	O
p105	B
.	O
Because	O
HIV-1	O
requires	O
active	O
NF	B
-	I
kappa	I
B	I
for	O
efficient	O
transcription	O
,	O
we	O
tested	O
the	O
effect	O
of	O
HIV-1	O
infection	O
on	O
the	O
processing	O
of	O
the	O
human	B
105	I
K	I
precursor	I
.	O
We	O
show	O
here	O
that	O
the	O
HIV-1	O
protease	O
can	O
process	O
p105	B
and	O
increases	O
levels	O
of	O
active	O
nuclear	B
NF	I
-	I
kappa	I
B	I
complex	I
.	O
Vitamin	B
D	I
receptor	I
expression	O
in	O
human	O
lymphocytes	O
.	O
Signal	O
requirements	O
and	O
characterization	O
by	O
western	O
blots	O
and	O
DNA	O
sequencing	O
.	O
The	O
signals	O
controlling	O
the	O
expression	O
of	O
the	O
receptor	B
protein	I
for	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
in	O
normal	O
human	O
lymphocytes	O
and	O
the	O
relationship	O
of	O
this	O
protein	O
to	O
the	O
classical	B
vitamin	I
D	I
receptor	I
were	O
examined	O
.	O
Lymphocytes	O
activated	O
with	O
the	O
OKT3	B
antibody	I
to	O
the	O
T	B
-	I
cell	I
antigen	I
receptor	I
expressed	O
fewer	O
binding	O
sites	O
as	O
compared	O
to	O
lymphocytes	O
that	O
were	O
activated	O
by	O
the	O
polyclonal	O
activator	O
phytohemagglutinin	B
(	O
PHA	B
)	O
.	O
However	O
,	O
combination	O
of	O
OKT3	B
and	O
phorbol	O
myristate	O
acetate	O
produced	O
a	O
concentration	O
of	O
binding	O
sites	O
similar	O
to	O
the	O
PHA	O
-	O
activated	O
cells	O
.	O
The	O
receptor	O
from	O
OKT3	B
and	O
OKT3	B
+	O
phorbol	O
myristate	O
acetate	O
-activated	O
lymphocytes	O
exhibited	O
decreased	O
binding	O
to	O
DNA	O
-	O
cellulose	O
compared	O
to	O
PHA	O
-	O
activated	O
lymphocytes	O
.	O
In	O
lymphocytes	O
activated	O
either	O
by	O
PHA	B
or	O
OKT3	B
(	O
but	O
not	O
in	O
resting	O
cells	O
)	O
,	O
a	O
50-kDa	B
species	I
cross	O
-	O
reacting	O
with	O
a	O
monoclonal	B
antibody	I
against	O
the	O
intestinal	B
vitamin	I
D	I
receptor	I
was	O
detected	O
.	O
Finally	O
,	O
RNA	O
from	O
activated	O
lymphocytes	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
using	O
oligonucleotide	O
primers	O
flanking	O
the	O
196	O
base	O
pair	O
long	O
region	O
encoding	O
the	O
DNA	B
-	I
binding	I
domain	I
of	O
the	O
human	B
intestinal	I
receptor	I
.	O
The	O
amplified	O
product	O
showed	O
an	O
identical	O
nucleotide	O
sequence	O
to	O
the	O
DNA	B
-	I
binding	I
domain	I
of	O
the	O
human	B
intestinal	I
receptor	I
.	O
These	O
findings	O
suggest	O
that	O
expression	O
of	O
the	O
1	B
,	I
25-	I
(	I
OH	I
)	I
2D3	I
receptor	I
in	O
lymphocytes	O
is	O
triggered	O
by	O
distinct	O
and	O
contingent	O
signals	O
,	O
and	O
that	O
the	O
protein	O
and	O
the	O
mRNA	O
encoding	O
it	O
are	O
identical	O
to	O
the	O
classical	B
vitamin	I
D	I
receptor	I
.	O
Role	O
for	O
the	O
Epstein	B
-	I
Barr	I
virus	I
nuclear	I
antigen	I
2	I
in	O
viral	O
promoter	O
switching	O
during	O
initial	O
stages	O
of	O
infection	O
.	O
During	O
latent	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
of	O
human	O
B	O
lymphocytes	O
,	O
six	B
viral	I
nuclear	I
antigen	I
(	O
EBNAs	B
)	O
are	O
expressed	O
from	O
long	O
primary	O
transcripts	O
by	O
means	O
of	O
alternative	O
splicing	O
and	O
alternative	O
polyadenylylation	O
sites	O
.	O
These	O
transcripts	O
initiate	O
from	O
one	O
of	O
two	O
promoters	O
,	O
Cp	O
or	O
Wp	O
,	O
that	O
function	O
in	O
a	O
mutually	O
exclusive	O
fashion	O
.	O
Wp	O
is	O
exclusively	O
utilized	O
during	O
the	O
initial	O
stages	O
of	O
infection	O
of	O
primary	O
B	O
lymphocytes	O
,	O
followed	O
by	O
a	O
switch	O
to	O
Cp	O
usage	O
.	O
These	O
studies	O
have	O
been	O
extended	O
to	O
show	O
that	O
(	O
i	O
)	O
a	O
mutant	O
EBV	O
strain	O
lacking	O
the	O
gene	O
encoding	O
EBNA	B
2	I
fails	O
to	O
switch	O
from	O
Wp	O
to	O
Cp	O
usage	O
in	O
primary	O
B	O
lymphocytes	O
,	O
although	O
the	O
virus	O
contains	O
a	O
functional	O
Cp	O
;	O
(	O
ii	O
)	O
a	O
region	O
from	O
-429	O
to	O
-245	O
base	O
pairs	O
upstream	O
of	O
Cp	O
is	O
essential	O
for	O
Cp	O
activity	O
in	O
B	O
lymphocytes	O
,	O
but	O
only	O
in	O
the	O
context	O
of	O
upstream	O
and	O
downstream	O
sequences	O
;	O
(	O
iii	O
)	O
this	O
region	O
contains	O
an	O
EBNA	O
2-dependent	O
enhancer	O
;	O
and	O
(	O
iv	O
)	O
DNase	B
I	I
protection	O
employing	O
nuclear	O
extracts	O
from	O
B	O
and	O
T	O
lymphocytes	O
revealed	O
a	O
B	O
-	O
cell	O
-	O
specific	O
footprint	O
in	O
the	O
region	O
of	O
the	O
EBNA	O
2-dependent	O
enhancer	O
.	O
These	O
results	O
support	O
a	O
model	O
for	O
viral	O
promoter	O
switching	O
during	O
the	O
initial	O
stages	O
of	O
infection	O
in	O
which	O
Wp	O
activity	O
leads	O
to	O
the	O
expression	O
of	O
EBNA	B
2	I
,	O
followed	O
by	O
activation	O
of	O
Cp	O
through	O
the	O
EBNA	O
2-dependent	O
enhancer	O
.	O
Glucocorticoid	B
receptor	I
characteristics	O
in	O
monocytes	O
of	O
patients	O
with	O
corticosteroid	O
-	O
resistant	O
bronchial	O
asthma	O
.	O
The	O
mechanism	O
of	O
corticosteroid	O
resistance	O
in	O
bronchial	O
asthma	O
has	O
been	O
studied	O
by	O
determining	O
the	O
rank	O
order	O
of	O
potency	O
for	O
different	O
corticosteroids	O
in	O
inhibiting	O
the	O
generation	O
of	O
a	O
3	O
kD	O
molecule	O
from	O
peripheral	O
blood	O
monocytes	O
isolated	O
from	O
corticosteroid	O
-	O
sensitive	O
(	O
CS	O
)	O
and	O
corticosteroid	O
-	O
resistant	O
(	O
CR	O
)	O
asthmatic	O
subjects	O
,	O
which	O
augments	O
leukotriene	O
B4	O
(	O
LTB4	B
)	O
generation	O
by	O
human	O
neutrophils	O
(	O
PMN	O
)	O
stimulated	O
by	O
calcium	O
ionophore	O
.	O
In	O
addition	O
,	O
binding	O
studies	O
with	O
(	O
3H	O
)	O
dexamethasone	O
have	O
been	O
performed	O
to	O
determine	O
the	O
dissociation	O
constant	O
(	O
Kd	O
)	O
and	O
receptor	O
numbers	O
(	O
Ro	O
)	O
in	O
the	O
monocytes	O
of	O
these	O
two	O
groups	O
of	O
subjects	O
.	O
The	O
concentration	O
of	O
corticosteroid	O
producing	O
50	O
%	O
inhibition	O
(	O
IC50	O
)	O
was	O
600	O
nM	O
,	O
70	O
nM	O
,	O
and	O
0.5	O
nM	O
for	O
hydrocortisone	O
,	O
methylprednisolone	O
,	O
and	O
dexamethasone	O
,	O
respectively	O
,	O
in	O
monocytes	O
from	O
CS	O
individuals	O
.	O
There	O
was	O
only	O
weak	O
inhibition	O
of	O
the	O
generation	O
of	O
enhancing	O
activity	O
by	O
the	O
corticosteroids	O
in	O
the	O
CR	O
asthmatic	O
individuals	O
.	O
The	O
dexamethasone	O
Kd	O
was	O
2.45	O
+	O
/-	O
0.58	O
nM	O
(	O
mean	O
+	O
/-	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CS	O
group	O
and	O
1.6	O
+	O
/-	O
0.35	O
nM	O
(	O
mean	O
+	O
/-	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CR	O
group	O
of	O
patients	O
(	O
p	O
=	O
0.14	O
)	O
.	O
The	O
Ro	O
in	O
the	O
CS	O
group	O
was	O
3	O
,	O
605	O
+	O
/-	O
984	O
binding	O
sites	O
per	O
nucleus	O
(	O
mean	O
+	O
/-	O
SEM	O
,	O
n	O
=	O
6	O
)	O
and	O
4	O
,	O
757	O
+	O
/-	O
692	O
binding	O
sites	O
per	O
nucleus	O
(	O
mean	O
+	O
/-	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CR	O
group	O
(	O
p	O
=	O
0.23	O
)	O
.	O
These	O
findings	O
indicate	O
that	O
corticosteroid	O
resistance	O
in	O
bronchial	O
asthma	O
can	O
not	O
be	O
explained	O
by	O
abnormalities	O
in	O
corticosteroid	O
receptor	O
characteristics	O
.	O
Tissue	O
-	O
specific	O
expression	O
of	O
the	O
platelet	O
GPIIb	O
gene	O
.	O
One	O
of	O
the	O
major	O
objectives	O
in	O
the	O
study	O
of	O
thrombogenesis	O
is	O
to	O
determine	O
the	O
mechanisms	O
by	O
which	O
a	O
hematopoietic	O
progenitor	O
is	O
activated	O
and	O
committed	O
to	O
the	O
megakaryocytic	O
lineage	O
.	O
Recent	O
development	O
of	O
primary	O
cultures	O
of	O
human	O
megakaryocytes	O
and	O
the	O
molecular	O
cloning	O
of	O
genes	O
that	O
are	O
specific	O
to	O
this	O
lineage	O
offer	O
the	O
possibility	O
of	O
getting	O
some	O
insights	O
into	O
the	O
genetic	O
mechanisms	O
that	O
control	O
megakaryocytopoiesis	O
.	O
One	O
gene	O
of	O
interest	O
is	O
the	O
glycoprotein	O
IIb	O
(	O
GPIIb	O
)	O
gene	O
;	O
GPIIb	O
,	O
the	O
alpha	B
subunit	I
of	O
the	O
platelet	B
cytoadhesin	I
GPIIb	I
-	I
IIIa	I
,	O
is	O
produced	O
in	O
megakaryocytes	O
at	O
an	O
early	O
stage	O
of	O
the	O
differentiation	O
,	O
whereas	O
the	O
other	O
subunit	O
of	O
this	O
complex	O
,	O
GPIIIa	B
,	O
is	O
expressed	O
in	O
other	O
cells	O
.	O
For	O
these	O
reasons	O
,	O
the	O
5'-flanking	O
region	O
of	O
the	O
GPIIb	O
gene	O
was	O
used	O
to	O
identify	O
the	O
regions	O
that	O
interact	O
with	O
DNA	B
-	I
binding	I
nuclear	I
factors	I
.	O
A	O
fragment	O
extending	O
from	O
-643	O
to	O
+	O
33	O
is	O
capable	O
of	O
controlling	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
CAT	O
gene	O
in	O
transfection	O
experiments	O
.	O
Within	O
this	O
region	O
,	O
we	O
have	O
identified	O
several	O
sequences	O
that	O
are	O
implicated	O
in	O
DNA	O
protein	O
interactions	O
as	O
shown	O
in	O
DNAse	B
I	I
footprints	O
and	O
gel	O
mobility	O
shift	O
assays	O
.	O
One	O
region	O
,	O
centered	O
at	O
-54	O
,	O
is	O
similar	O
to	O
a	O
nuclear	O
factor	O
E1-binding	O
site	O
,	O
and	O
a	O
region	O
located	O
at	O
position	O
-233	O
contains	O
a	O
CCAAT	O
motif	O
.	O
Two	O
domains	O
centered	O
at	O
positions	O
-345	O
and	O
-540	O
,	O
respectively	O
,	O
bind	O
proteins	O
that	O
are	O
present	O
in	O
megakaryocytic	O
cells	O
and	O
nonrelated	O
cells	O
as	O
well	O
.	O
Finally	O
,	O
two	O
other	O
domains	O
,	O
located	O
at	O
positions	O
-460	O
and	O
-510	O
,	O
interact	O
with	O
proteins	O
that	O
are	O
only	O
present	O
in	O
megakaryocytic	O
cells	O
.	O
In	O
addition	O
,	O
deletion	O
of	O
the	O
region	O
containing	O
these	O
two	O
domains	O
results	O
in	O
a	O
significant	O
decrease	O
of	O
the	O
promoter	O
activity	O
.	O
It	O
is	O
very	O
likely	O
that	O
these	O
domains	O
bind	O
megakaryocyte	B
-	I
specific	I
nuclear	I
proteins	I
acting	O
as	O
positive	B
transcription	I
factors	I
.	O
Demonstration	O
of	O
estrogen	B
and	I
progesterone	I
receptors	I
as	O
well	O
as	O
Ki-67	B
and	I
p-145	I
antigens	I
in	O
single	O
tumor	O
cells	O
from	O
blood	O
and	O
pleural	O
effusions	O
using	O
a	O
slide	O
assay	O
.	O
We	O
describe	O
a	O
slide	O
assay	O
that	O
allows	O
the	O
demonstration	O
of	O
antigens	B
localized	O
in	O
the	O
nucleus	O
from	O
isolated	O
white	O
blood	O
cells	O
as	O
well	O
as	O
from	O
single	O
tumor	O
cells	O
derived	O
from	O
malignant	O
effusions	O
.	O
With	O
the	O
antibodies	O
Ki-67	B
and	O
anti	B
-	I
p-145	I
an	O
increased	O
rate	O
of	O
nuclear	O
and	O
nucleolar	O
staining	O
resulted	O
in	O
cells	O
from	O
highly	O
malignant	O
lymphomas	O
.	O
An	O
almost	O
identical	O
reaction	O
was	O
obtained	O
when	O
tumor	O
cells	O
from	O
malignant	O
effusions	O
were	O
tested	O
.	O
Cells	O
isolated	O
from	O
the	O
blood	O
of	O
patients	O
with	O
leukemic	O
spread	O
of	O
lymphomas	O
of	O
low	O
malignancy	O
yielded	O
a	O
weak	O
staining	O
comparable	O
to	O
that	O
of	O
normal	O
mesothelial	O
cells	O
from	O
non	O
-	O
tumorous	O
cavity	O
fluids	O
.	O
The	O
detection	O
of	O
estrogen	B
and	O
progesterone	B
receptors	I
(	O
ER	B
and	O
PR	B
)	O
localized	O
in	O
the	O
cell	O
nucleus	O
can	O
be	O
achieved	O
by	O
the	O
same	O
assay	O
.	O
The	O
reaction	O
is	O
enhanced	O
by	O
incubation	O
of	O
the	O
tumor	O
cells	O
for	O
30	O
min	O
at	O
37	O
degrees	O
C	O
prior	O
to	O
fixation	O
.	O
Pleural	O
effusions	O
from	O
20	O
patients	O
with	O
breast	O
cancer	O
were	O
tested	O
.	O
ER	B
was	O
positive	O
in	O
13	O
and	O
PR	B
was	O
positive	O
in	O
12	O
of	O
the	O
20	O
samples	O
.	O
In	O
5	O
cases	O
there	O
was	O
a	O
divergent	O
reaction	O
with	O
ER	B
and	O
PR	B
antibody	O
.	O
The	O
hormone	B
receptors	I
of	O
the	O
primary	O
tumor	O
were	O
known	O
in	O
15	O
(	O
ER	B
)	O
and	O
14	O
(	O
PR	B
)	O
patients	O
,	O
respectively	O
.	O
In	O
each	O
cohort	O
there	O
was	O
only	O
one	O
case	O
with	O
a	O
negative	O
reaction	O
of	O
the	O
primary	O
tumor	O
and	O
a	O
positive	O
reaction	O
with	O
the	O
isolated	O
tumor	O
cells	O
from	O
the	O
pleural	O
effusions	O
.	O
These	O
results	O
indicate	O
that	O
the	O
demonstration	O
of	O
hormone	B
receptor	I
proteins	I
in	O
cells	O
from	O
malignant	O
effusions	O
is	O
possible	O
and	O
that	O
there	O
is	O
a	O
correlation	O
with	O
the	O
status	O
of	O
the	O
primary	O
site	O
of	O
cancer	O
.	O
Differentiation	O
-	O
associated	O
expression	O
of	O
the	O
Epstein	B
-	I
Barr	I
virus	I
BZLF1	I
transactivator	I
protein	I
in	O
oral	O
hairy	O
leukoplakia	O
.	O
The	O
BZLF1	B
protein	I
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
a	O
key	O
immediate	B
-	I
early	I
protein	I
which	O
has	O
been	O
shown	O
to	O
disrupt	O
virus	O
latency	O
in	O
EBV	O
-	O
infected	O
B	O
cells	O
.	O
We	O
have	O
generated	O
a	O
monoclonal	B
antibody	I
,	O
BZ1	B
,	O
to	O
BZLF1	B
which	O
reacts	O
in	O
immunohistology	O
,	O
immunoblotting	O
,	O
and	O
immunoprecipitation	O
and	O
which	O
recognizes	O
both	O
the	O
active	B
,	I
dimeric	I
form	I
and	O
the	O
inactive	B
,	I
monomeric	I
form	I
of	O
the	O
protein	O
.	O
Biopsies	O
of	O
oral	O
hairy	O
leukoplakia	O
,	O
an	O
AIDS	O
-	O
associated	O
lesion	O
characterized	O
by	O
high	O
-	O
level	O
EBV	O
replication	O
,	O
were	O
examined	O
by	O
immunohistochemistry	O
using	O
the	O
BZ1	B
monoclonal	B
antibody	I
.	O
A	O
differentiation	O
-	O
associated	O
pattern	O
of	O
BZLF1	B
expression	O
was	O
observed	O
,	O
BZ1	B
reacting	O
with	O
nuclei	O
of	O
the	O
upper	O
spinous	O
layer	O
of	O
the	O
lesion	O
.	O
This	O
finding	O
suggests	O
that	O
the	O
BZLF1	O
promoter	O
may	O
be	O
regulated	O
by	O
the	O
degree	O
of	O
squamous	O
differentiation	O
.	O
A	O
comparison	O
of	O
in	O
situ	O
hybridization	O
to	O
EBV	O
DNA	O
and	O
viral	B
capsid	I
antigen	I
staining	O
with	O
BZ1	B
reactivity	O
suggested	O
that	O
BZLF1	B
expression	O
precedes	O
rampant	O
virus	O
replication	O
.	O
The	O
inability	O
to	O
detect	O
EBV	O
in	O
the	O
lower	O
epithelial	O
layers	O
of	O
oral	O
hairy	O
leukoplakia	O
raises	O
questions	O
concerning	O
the	O
nature	O
of	O
EBV	O
latency	O
and	O
persistence	O
in	O
stratified	O
squamous	O
epithelium	O
.	O
Transactivation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
promoter	O
by	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
strains	O
GS	O
and	O
Z-29	O
in	O
primary	O
human	O
T	O
lymphocytes	O
and	O
identification	O
of	O
transactivating	O
HHV-6	O
(	O
GS	O
)	O
gene	O
fragments	O
.	O
Human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
can	O
activate	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
promoter	O
and	O
accelerate	O
cytopathic	O
effects	O
in	O
HIV	O
-	O
infected	O
human	O
T	O
cells	O
.	O
This	O
study	O
examines	O
the	O
regions	O
of	O
the	O
HIV	O
promoter	O
required	O
for	O
HHV-6	O
transactivation	O
in	O
a	O
heterogeneous	O
population	O
of	O
primary	O
human	O
T	O
lymphocytes	O
with	O
or	O
without	O
antigenic	O
stimulation	O
.	O
Two	O
different	O
strains	O
of	O
HHV-6	O
,	O
GS	O
and	O
Z29	O
,	O
transactivated	O
the	O
HIV	O
promoter	O
.	O
The	O
GS	O
strain	O
transactivated	O
the	O
promoter	O
in	O
both	O
stimulated	O
and	O
resting	O
T	O
cells	O
,	O
while	O
the	O
Z29	O
strain	O
increased	O
HIV	O
promoter	O
activity	O
only	O
in	O
stimulated	O
T	O
cells	O
.	O
Three	O
DNA	O
clones	O
containing	O
HHV-6	O
(	O
GS	O
)	O
genomic	O
fragments	O
transactivated	O
the	O
HIV	O
promoter	O
in	O
cotransfected	O
T	O
cells	O
.	O
A	O
21.4-kb	O
DNA	O
clone	O
,	O
pZVB70	O
,	O
showed	O
the	O
highest	O
transactivating	O
ability	O
,	O
while	O
two	O
other	O
DNA	O
fragments	O
,	O
pZVB10	O
(	O
6.2	O
kb	O
)	O
and	O
pZVH14	O
(	O
8.7	O
kb	O
)	O
,	O
showed	O
lower	O
activity	O
.	O
One	O
of	O
these	O
clones	O
,	O
pZVH14	O
,	O
activated	O
the	O
HIV	O
promoter	O
construct	O
containing	O
a	O
mutation	O
in	O
the	O
NF	O
kappa	O
B	O
site	O
.	O
However	O
,	O
this	O
mutated	O
NF	O
kappa	O
B	O
promoter	O
was	O
not	O
transactivated	O
during	O
HHV-6	O
(	O
GS	O
)	O
infection	O
or	O
after	O
cotransfection	O
with	O
pZVB70	O
or	O
pZVB10	O
.	O
These	O
data	O
indicate	O
that	O
the	O
NF	O
kappa	O
B	O
sites	O
of	O
the	O
HIV	O
promoter	O
are	O
essential	O
for	O
its	O
transactivation	O
during	O
HHV-6	O
(	O
GS	O
)	O
infection	O
.	O
By	O
increasing	O
HIV	O
promoter	O
activity	O
in	O
primary	O
T	O
lymphocytes	O
,	O
HHV-6	O
may	O
consequently	O
increase	O
HIV	O
replication	O
,	O
leading	O
to	O
an	O
increase	O
in	O
the	O
cytopathic	O
effect	O
on	O
coinfected	O
human	O
T	O
cells	O
.	O
The	O
rhombotin	O
family	O
of	O
cysteine	O
-	O
rich	O
LIM	O
-	O
domain	O
oncogenes	O
:	O
distinct	O
members	O
are	O
involved	O
in	O
T	O
-	O
cell	O
translocations	O
to	O
human	O
chromosomes	O
11p15	O
and	O
11p13	O
.	O
A	O
chromosomal	O
translocation	O
in	O
a	O
T	O
-	O
cell	O
leukemia	O
involving	O
the	O
short	O
arm	O
of	O
human	O
chromosome	O
11	O
at	O
band	O
11p15	O
disrupts	O
the	O
rhombotin	O
gene	O
.	O
This	O
gene	O
encodes	O
a	O
protein	O
with	O
duplicated	O
cysteine	B
-	I
rich	I
regions	I
called	O
LIM	B
domains	I
,	O
which	O
show	O
homology	O
to	O
zinc	B
-	I
binding	I
proteins	I
and	O
to	O
iron	B
-	I
sulfur	I
centers	I
of	O
ferredoxins	B
.	O
Two	O
homologues	O
of	O
the	O
rhombotin	O
gene	O
have	O
now	O
been	O
isolated	O
.	O
One	O
of	O
these	O
,	O
designated	O
Rhom-2	O
,	O
is	O
located	O
on	O
human	O
chromosome	O
11	O
at	O
band	O
11p13	O
,	O
where	O
a	O
cluster	O
of	O
T	O
-	O
cell	O
leukemia	O
-	O
specific	O
translocations	O
occur	O
;	O
all	O
translocation	O
breakpoints	O
at	O
11p13	O
are	O
upstream	O
of	O
the	O
Rhom-2	O
gene	O
.	O
Human	O
and	O
mouse	O
Rhom-2	O
are	O
highly	O
conserved	O
and	O
,	O
like	O
rhombotin	O
,	O
encode	O
two	O
tandem	O
cysteine	O
-	O
rich	O
LIM	O
domains	O
.	O
Rhom-2	O
mRNA	O
is	O
expressed	O
in	O
early	O
mouse	O
development	O
in	O
central	O
nervous	O
system	O
,	O
lung	O
,	O
kidney	O
,	O
liver	O
,	O
and	O
spleen	O
but	O
only	O
very	O
low	O
levels	O
occur	O
in	O
thymus	O
.	O
The	O
other	O
gene	O
,	O
designated	O
Rhom-3	O
,	O
is	O
not	O
on	O
chromosome	O
11	O
but	O
also	O
retains	O
homology	O
to	O
the	O
LIM	O
domain	O
of	O
rhombotin	O
.	O
Since	O
the	O
Rhom-2	O
gene	O
is	O
such	O
a	O
common	O
site	O
of	O
chromosomal	O
damage	O
in	O
T	O
-	O
cell	O
tumors	O
,	O
the	O
consistency	O
of	O
translocations	O
near	O
the	O
rhombotin	O
gene	O
was	O
further	O
examined	O
.	O
A	O
second	O
translocation	O
adjacent	O
to	O
rhombotin	O
was	O
found	O
and	O
at	O
the	O
same	O
position	O
as	O
in	O
the	O
previous	O
example	O
.	O
Therefore	O
,	O
chromosome	O
bands	O
11p15	O
(	O
rhombotin	O
)	O
and	O
11p13	O
(	O
Rhom-2	O
)	O
are	O
consistent	O
sites	O
of	O
chromosome	O
translocation	O
in	O
T	O
-	O
cell	O
leukemia	O
,	O
with	O
the	O
11p15	O
target	O
more	O
rarely	O
involved	O
.	O
The	O
results	O
define	O
the	O
rhombotin	O
gene	O
family	O
as	O
a	O
class	O
of	O
T	O
-	O
cell	O
oncogenes	O
with	O
duplicated	O
cysteine	O
-	O
rich	O
LIM	O
domains	O
.	O
The	O
human	O
myelomonocytic	O
cell	O
line	O
U-937	O
as	O
a	O
model	O
for	O
studying	O
alterations	O
in	O
steroid	O
-	O
induced	O
monokine	O
gene	O
expression	O
:	O
marked	O
enhancement	O
of	O
lipopolysaccharide	O
-	O
stimulated	O
interleukin-1	O
beta	O
messenger	O
RNA	O
levels	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
.	O
The	O
active	O
metabolite	O
of	O
vitamin	O
D	O
,	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
is	O
a	O
potent	O
regulator	O
of	O
human	O
monocyte	O
/	O
macrophage	O
function	O
in	O
vitro	O
.	O
To	O
establish	O
a	O
model	O
for	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
regulation	O
of	O
human	O
monocyte	O
monokine	O
synthesis	O
,	O
three	O
human	O
cell	O
lines	O
(	O
U-937	O
,	O
THP-1	O
,	O
and	O
HL-60	O
)	O
were	O
examined	O
for	O
:	O
1	O
)	O
the	O
presence	O
of	O
functional	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
receptors	O
;	O
2	O
)	O
the	O
accumulation	O
of	O
interleukin-1	O
beta	O
(	O
IL-1	O
beta	O
)	O
mRNA	O
and	O
IL-1	B
beta	I
protein	I
in	O
response	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
;	O
and	O
3	O
)	O
the	O
regulation	O
of	O
this	O
response	O
by	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O
All	O
three	O
cell	O
lines	O
expressed	O
vitamin	O
D	O
receptor	O
and	O
had	O
increased	O
levels	O
of	O
IL-1	O
beta	O
mRNA	O
in	O
response	O
to	O
LPS	O
.	O
Preincubation	O
of	O
cells	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
augmented	O
IL-1	O
beta	O
mRNA	O
levels	O
only	O
in	O
U-937	O
and	O
HL-60	O
cells	O
.	O
From	O
these	O
data	O
,	O
and	O
taking	O
into	O
consideration	O
their	O
state	O
of	O
differentiation	O
and	O
relative	O
ease	O
of	O
culture	O
,	O
U-937	O
was	O
chosen	O
over	O
HL-60	O
and	O
THP-1	O
as	O
the	O
cell	O
line	O
we	O
further	O
characterized	O
.	O
In	O
U-937	O
cells	O
,	O
optimum	O
time	O
and	O
dose	O
of	O
pretreatment	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
were	O
determined	O
to	O
be	O
12	O
-	O
24	O
h	O
at	O
a	O
receptor	O
saturating	O
concentration	O
of	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
(	O
10	O
nM	O
)	O
.	O
Preincubation	O
of	O
cells	O
with	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
had	O
no	O
effect	O
on	O
the	O
time	O
course	O
of	O
IL-1	O
beta	O
mRNA	O
appearance	O
in	O
response	O
to	O
LPS	O
.	O
However	O
,	O
exposure	O
of	O
U-937	O
cells	O
to	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
increased	O
by	O
200	O
%	O
the	O
level	O
of	O
IL-1	O
beta	O
mRNA	O
detected	O
and	O
decreased	O
by	O
three	O
orders	O
of	O
magnitude	O
the	O
concentration	O
of	O
LPS	O
required	O
to	O
achieve	O
steady	O
state	O
mRNA	O
levels	O
equivalent	O
to	O
those	O
observed	O
in	O
U-937	O
cells	O
not	O
preincubated	O
with	O
the	O
hormone.2+o	O
A	O
case	O
of	O
hypersensitivity	O
to	O
thyroid	O
hormones	O
with	O
normally	O
functioning	O
thyroid	O
gland	O
and	O
increased	O
nuclear	O
triiodothyronine	B
receptors	I
.	O
A	O
52-year	O
-	O
old	O
male	O
presented	O
himself	O
with	O
tachycardia	O
crises	O
which	O
appeared	O
first	O
during	O
childhood	O
,	O
increased	O
in	O
frequency	O
without	O
goiter	O
or	O
exophthalmos	O
.	O
Cardiac	O
and	O
adrenergic	O
diseases	O
were	O
excluded	O
.	O
The	O
thyroid	O
function	O
was	O
normal	O
regarding	O
T4	O
,	O
free	O
T4	O
and	O
T3	O
,	O
TBG	O
,	O
radioiodine	O
uptake	O
,	O
TSH	O
and	O
T3	O
suppressibility	O
;	O
however	O
the	O
TSH	O
response	O
to	O
TRH	O
was	O
decreased	O
.	O
The	O
lymphocyte	B
nuclear	I
T3	I
receptor	I
was	O
found	O
with	O
an	O
affinity	O
close	O
to	O
that	O
of	O
normal	O
volunteers	O
(	O
Ka	O
:	O
1.42	O
x	O
10	O
(	O
10	O
)	O
M-1	O
vs	O
1.95	O
+	O
/-	O
0.35	O
x	O
10	O
(	O
10	O
)	O
M-1	O
)	O
and	O
a	O
binding	O
capacity	O
markedly	O
increased	O
(	O
9.9	O
vs	O
3.7	O
+	O
/-	O
0.4	O
fmol	O
T3	O
/	O
100	O
micrograms	O
DNA	O
)	O
.	O
Pindolol	O
was	O
inefficient	O
on	O
the	O
dysrhythmia	O
which	O
disappeared	O
with	O
carbimazole	O
and	O
relapsed	O
after	O
withdrawal	O
of	O
the	O
antithyroid	O
drug	O
.	O
Under	O
carbimazole	O
,	O
the	O
plasma	O
T4	O
markedly	O
decreased	O
(	O
27.7	O
+	O
/-	O
3.6	O
nmol	O
/	O
l	O
)	O
but	O
the	O
patient	O
remained	O
euthyroid	O
.	O
The	O
clinical	O
course	O
and	O
the	O
laboratory	O
data	O
suggest	O
that	O
the	O
tachycardia	O
crises	O
are	O
the	O
consequence	O
of	O
a	O
hypersensitivity	O
of	O
the	O
heart	O
to	O
thyroid	O
hormones	O
,	O
associated	O
with	O
an	O
increased	O
number	O
of	O
T3	B
nuclear	I
receptor	I
sites	O
in	O
lymphocytes	O
.	O
Expression	O
of	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptors	I
on	O
alveolar	O
lymphocytes	O
from	O
patients	O
with	O
pulmonary	O
granulomatous	O
diseases	O
.	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
known	O
to	O
be	O
produced	O
at	O
sites	O
of	O
granulomatous	O
reactions	O
.	O
In	O
order	O
to	O
characterize	O
the	O
cell	O
types	O
that	O
are	O
targets	O
for	O
this	O
immunoregulatory	O
hormone	O
,	O
we	O
have	O
evaluated	O
the	O
expression	O
of	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptors	I
on	O
peripheral	O
blood	O
T	O
-	O
lymphocytes	O
and	O
those	O
recovered	O
from	O
the	O
lung	O
by	O
bronchoalveolar	O
lavage	O
from	O
patients	O
with	O
pulmonary	O
granulomatous	O
diseases	O
(	O
tuberculosis	O
and	O
sarcoidosis	O
)	O
and	O
from	O
normal	O
control	O
subjects	O
using	O
combined	O
autoradiographic	O
and	O
immunohistochemical	O
techniques	O
.	O
Lavage	O
T	O
-	O
lymphocytes	O
from	O
patients	O
with	O
tuberculosis	O
or	O
with	O
sarcoidosis	O
,	O
but	O
not	O
those	O
from	O
normal	O
control	O
subjects	O
,	O
expressed	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptors	I
as	O
demonstrated	O
by	O
binding	O
of	O
[	O
3H	O
]	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
which	O
was	O
inhibited	O
by	O
the	O
presence	O
of	O
excess	O
unlabeled	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
but	O
not	O
by	O
the	O
presence	O
of	O
unlabeled	O
25	O
(	O
OH	O
)	O
D3	O
(	O
receptor	O
-	O
positive	O
lymphocytes	O
:	O
sarcoidosis	O
,	O
20	O
+	O
/-	O
12	O
%	O
;	O
tuberculosis	O
,	O
31	O
+	O
/-	O
17	O
%	O
)	O
.	O
In	O
contrast	O
,	O
blood	O
lymphocytes	O
from	O
patients	O
with	O
granulomatous	O
diseases	O
did	O
not	O
express	O
detectable	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptors	I
.	O
The	O
percentage	O
of	O
lavage	O
T	O
-	O
lymphocytes	O
expressing	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptors	I
was	O
significantly	O
greater	O
for	O
patients	O
with	O
tuberculosis	O
presenting	O
with	O
isolated	O
hilar	O
adenopathy	O
than	O
for	O
patients	O
with	O
pulmonary	O
infiltrates	O
and/or	O
cavities	O
.	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptors	I
were	O
expressed	O
to	O
a	O
greater	O
extent	O
on	O
CD8	O
+	O
T	O
-	O
lymphocytes	O
than	O
on	O
CD4	O
+	O
T	O
-	O
lymphocytes	O
in	O
sarcoidosis	O
,	O
whereas	O
a	O
greater	O
proportion	O
of	O
CD4	O
+	O
than	O
of	O
CD8	O
+	O
T	O
-	O
lymphocytes	O
from	O
patients	O
with	O
tuberculosis	O
were	O
receptor	O
-	O
positive	O
.	O
These	O
findings	O
support	O
the	O
conclusion	O
that	O
the	O
interaction	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
with	O
its	O
receptor	O
on	O
T	O
-	O
lymphocytes	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
granulomatous	O
reactions	O
,	O
but	O
because	O
these	O
receptors	O
are	O
expressed	O
on	O
different	O
lymphocyte	O
populations	O
,	O
the	O
net	O
effect	O
of	O
this	O
potent	O
immunoregulatory	B
molecule	I
is	O
likely	O
different	O
in	O
sarcoidosis	O
and	O
tuberculosis	O
.	O
Inhibition	O
of	O
transcription	B
factors	I
belonging	O
to	O
the	O
rel	B
/	I
NF	I
-	I
kappa	I
B	I
family	I
by	O
a	O
transdominant	B
negative	I
mutant	I
.	O
The	O
KBF1	B
factor	I
,	O
which	O
binds	O
to	O
the	O
enhancer	O
A	O
located	O
in	O
the	O
promoter	O
of	O
the	O
mouse	O
MHC	O
class	O
I	O
gene	O
H-2Kb	O
,	O
is	O
indistinguishable	O
from	O
the	O
p50	B
DNA	I
binding	I
subunit	I
of	O
the	O
transcription	B
factor	I
NF	I
-	I
kappa	I
B	I
,	O
which	O
regulates	O
a	O
series	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O
The	O
KBF1	B
/	I
p50	I
factor	I
binds	O
as	O
a	O
homodimer	B
but	O
can	O
also	O
form	O
heterodimers	B
with	O
the	O
products	O
of	O
other	O
members	O
of	O
the	O
same	O
family	O
,	O
like	O
the	O
c	O
-	O
rel	O
and	O
v	O
-	O
rel	O
(	O
proto	O
)	O
oncogenes	O
.	O
The	O
dimerization	B
domain	I
of	O
KBF1	B
/	I
p50	I
is	O
contained	O
between	B
amino	I
acids	I
201	I
and	I
367	I
.	O
A	O
mutant	O
of	O
KBF1	B
/	I
p50	I
(	O
delta	B
SP	I
)	O
,	O
unable	O
to	O
bind	O
to	O
DNA	O
but	O
able	O
to	O
form	O
homo-	O
or	O
heterodimers	B
,	O
has	O
been	O
constructed	O
.	O
This	O
protein	O
reduces	O
or	O
abolishes	O
in	O
vitro	O
the	O
DNA	O
binding	O
activity	O
of	O
wild	B
-	I
type	I
proteins	I
of	O
the	O
same	O
family	O
(	O
KBF1	B
/	I
p50	I
,	O
c-	B
and	I
v	I
-	I
rel	I
)	O
.	O
This	O
mutant	O
also	O
functions	O
in	O
vivo	O
as	O
a	O
trans	B
-	I
acting	I
dominant	I
negative	I
regulator	I
:	O
the	O
transcriptional	O
inducibility	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
which	O
contains	O
two	O
potential	O
NF	B
-	I
kappa	I
B	I
binding	O
sites	O
)	O
by	O
phorbol	O
ester	O
(	O
PMA	O
)	O
is	O
inhibited	O
when	O
it	O
is	O
co	O
-	O
transfected	O
into	O
CD4	O
+	O
T	O
cells	O
with	O
the	O
delta	B
SP	I
mutant	O
.	O
Similarly	O
the	O
basal	O
as	O
well	O
as	O
TNF	B
or	O
IL1-induced	O
activity	O
of	O
the	O
MHC	O
class	O
I	O
H-2Kb	O
promoter	O
can	O
be	O
inhibited	O
by	O
this	O
mutant	O
in	O
two	O
different	O
cell	O
lines	O
.	O
These	O
results	O
constitute	O
the	O
first	O
formal	O
demonstration	O
that	O
these	O
genes	O
are	O
regulated	O
by	O
members	O
of	O
the	O
rel	B
/	I
NF	I
-	I
kappa	I
B	I
family	I
.	O
Human	B
erythroid	I
5-aminolevulinate	I
synthase	I
:	O
promoter	O
analysis	O
and	O
identification	O
of	O
an	O
iron	O
-	O
responsive	O
element	O
in	O
the	O
mRNA	O
.	O
5-Aminolevulinate	B
synthase	I
(	O
ALAS	B
)	O
catalyzes	O
the	O
first	O
step	O
of	O
the	O
heme	B
biosynthetic	O
pathway	O
.	O
cDNA	O
clones	O
for	O
the	O
human	B
erythroid	I
ALAS	I
isozyme	I
were	O
isolated	O
from	O
a	O
fetal	O
liver	O
library	O
.	O
It	O
can	O
be	O
deduced	O
that	O
the	O
erythroid	B
ALAS	I
precursor	I
protein	I
has	O
a	O
molecular	O
weight	O
of	O
64.6	O
kd	O
,	O
and	O
is	O
similar	O
in	O
size	O
to	O
the	O
previously	O
isolated	O
human	B
housekeeping	I
ALAS	I
precursor	I
of	O
molecular	O
weight	O
70.6	O
kd	O
.	O
The	O
mature	O
mitochondrial	O
forms	O
of	O
the	O
erythroid	O
and	O
housekeeping	B
ALAS	I
isozymes	I
are	O
predicted	O
to	O
have	O
molecular	O
weights	O
of	O
59.5	O
kd	O
and	O
64.6	O
kd	O
,	O
respectively	O
.	O
The	O
two	O
isozymes	B
show	O
little	O
amino	O
acid	O
identity	O
in	O
their	O
N	B
-	I
terminal	I
signal	I
sequences	I
but	O
have	O
considerable	O
sequence	O
identity	O
in	O
the	O
C	B
-	I
terminal	I
two	I
-	I
thirds	I
of	O
their	O
proteins	O
.	O
An	O
analysis	O
of	O
the	O
immediate	O
promoter	O
of	O
the	O
human	O
erythroid	O
ALAS	O
gene	O
revealed	O
several	O
putative	O
erythroid	O
-	O
specific	O
cis	O
-	O
acting	O
elements	O
including	O
both	O
a	O
GATA-1	O
and	O
an	O
NF	O
-	O
E2	O
binding	O
site	O
.	O
An	O
iron	O
-	O
responsive	O
element	O
(	O
IRE	O
)	O
motif	O
has	O
been	O
identified	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
human	O
erythroid	O
ALAS	O
mRNA	O
,	O
but	O
is	O
not	O
present	O
in	O
the	O
housekeeping	O
ALAS	O
mRNA	O
.	O
Gel	O
retardation	O
experiments	O
established	O
that	O
this	O
IRE	O
motif	O
formed	O
a	O
protein	B
-	I
RNA	I
complex	I
with	O
cytosolic	O
extracts	O
from	O
human	O
K562	O
cells	O
and	O
this	O
binding	O
was	O
strongly	O
competed	O
with	O
IRE	O
transcripts	O
from	O
ferritin	O
or	O
transferrin	O
receptor	O
mRNAs	O
.	O
A	O
transcript	O
of	O
the	O
ALAS	O
IRE	O
,	O
mutated	O
in	O
the	O
conserved	O
loop	O
of	O
the	O
IRE	O
,	O
did	O
not	O
readily	O
form	O
this	O
protein	B
-	I
RNA	I
complex	I
.	O
These	O
results	O
suggest	O
that	O
the	O
IRE	O
motif	O
in	O
the	O
ALAS	O
mRNA	O
is	O
functional	O
and	O
imply	O
that	O
translation	O
of	O
the	O
mRNA	O
is	O
controlled	O
by	O
cellular	O
iron	O
availability	O
during	O
erythropoiesis	O
.	O
Human	O
tumor	B
necrosis	I
factor	I
alpha	I
gene	O
regulation	O
in	O
phorbol	O
ester	O
stimulated	O
T	O
and	O
B	O
cell	O
lines	O
.	O
The	O
minimal	O
region	O
of	O
the	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
gene	O
promoter	O
necessary	O
for	O
its	O
transcriptional	O
induction	O
by	O
phorbol	O
esters	O
(	O
PMA	O
)	O
in	O
human	O
T	O
and	O
B	O
lymphocyte	O
cell	O
lines	O
has	O
been	O
localized	O
between	O
-52	O
and	O
+	O
89	O
nucleotides	O
(	O
nt	O
)	O
relative	O
to	O
the	O
gene	O
's	O
transcriptional	O
start	O
site	O
.	O
Comparison	O
of	O
these	O
sequences	O
to	O
those	O
required	O
to	O
mediate	O
virus	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
the	O
gene	O
reveal	O
significant	O
differences	O
,	O
and	O
thus	O
,	O
the	O
sequence	O
requirements	O
for	O
PMA	O
induction	O
are	O
distinct	O
from	O
those	O
that	O
mediate	O
induction	O
by	O
virus	O
or	O
LPS	O
.	O
Although	O
three	O
sites	O
in	O
the	O
TNF	O
-	O
alpha	O
promoter	O
(	O
kappa	O
1	O
,	O
kappa	O
2	O
,	O
and	O
kappa	O
3	O
)	O
specifically	O
bind	O
the	O
transcription	B
factor	I
NF	B
-	I
kappa	I
B	I
in	O
lymphoid	O
nuclear	O
extracts	O
,	O
TNF	O
-	O
alpha	O
mRNA	O
induction	O
by	O
PMA	O
does	O
not	O
correlate	O
with	O
NF	B
-	I
kappa	I
B	I
binding	O
activities	O
displayed	O
by	O
different	O
T	O
and	O
B	O
cell	O
lines	O
.	O
Moreover	O
,	O
kappa	O
1-kappa	O
3	O
can	O
each	O
be	O
deleted	O
from	O
the	O
TNF	O
-	O
alpha	O
promoter	O
with	O
little	O
effect	O
on	O
the	O
gene	O
's	O
inducibility	O
by	O
PMA	O
.	O
Therefore	O
,	O
TNF	O
-	O
alpha	O
mRNA	O
induction	O
by	O
PMA	O
,	O
like	O
its	O
induction	O
by	O
virus	O
and	O
LPS	O
,	O
is	O
not	O
primarily	O
mediated	O
by	O
NF	B
-	I
kappa	I
B	I
,	O
but	O
rather	O
is	O
mediated	O
through	O
other	O
sequences	O
and	O
protein	B
factors	I
.	O
Surprisingly	O
,	O
multimers	O
of	O
kappa	O
1-kappa	O
3	O
can	O
confer	O
PMA	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
in	O
a	O
B	O
(	O
Raji	O
)	O
,	O
but	O
not	O
a	O
T	O
(	O
HUT78	O
)	O
cell	O
line	O
.	O
However	O
they	O
are	O
not	O
functional	O
on	O
a	O
truncated	O
TNF	O
-	O
alpha	O
promoter	O
,	O
indicating	O
that	O
promoter	O
context	O
and	O
cell	O
type	O
specificity	O
influence	O
the	O
PMA	O
inducible	O
function	O
of	O
these	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
.	O
Cloning	O
of	O
a	O
human	O
homeobox	O
gene	O
that	O
resembles	O
a	O
diverged	O
Drosophila	O
homeobox	O
gene	O
and	O
is	O
expressed	O
in	O
activated	O
lymphocytes	O
.	O
A	O
new	O
homeobox	O
gene	O
,	O
HB24	O
,	O
has	O
been	O
isolated	O
from	O
a	O
human	O
B	O
-	O
lymphocyte	O
cDNA	O
library	O
.	O
Northern	O
blot	O
analysis	O
of	O
polyadenylated	O
RNA	O
purified	O
from	O
activated	O
human	O
B	O
cells	O
revealed	O
a	O
single	O
mRNA	O
transcript	O
of	O
approximately	O
2.3	O
kb	O
.	O
Two	O
cDNA	O
clones	O
were	O
sequenced	O
and	O
provided	O
2	O
,	O
250	O
nucleotides	O
(	O
nt	O
)	O
of	O
DNA	O
sequence	O
information	O
.	O
There	O
is	O
a	O
single	O
methionine	O
codon	O
-	O
initiated	O
open	O
reading	O
frame	O
of	O
1	O
,	O
458	O
nt	O
in	O
frame	O
with	O
a	O
homeobox	O
and	O
a	O
CAX	O
repeat	O
,	O
and	O
the	O
open	O
reading	O
frame	O
is	O
predicted	O
to	O
encode	O
a	O
protein	O
of	O
51	O
,	O
659	O
daltons	O
.	O
When	O
the	O
homeodomain	O
from	O
HB24	O
was	O
compared	O
to	O
known	O
mammalian	O
and	O
Drosophila	O
homeodomains	O
it	O
was	O
found	O
to	O
be	O
only	O
moderately	O
conserved	O
,	O
but	O
when	O
it	O
was	O
compared	O
to	O
a	O
highly	O
diverged	O
Drosophila	O
homeodomain	O
,	O
H2.0	O
,	O
it	O
was	O
found	O
to	O
be	O
80	O
%	O
identical	O
.	O
The	O
HB24	O
mRNA	O
was	O
absent	O
or	O
present	O
at	O
low	O
levels	O
in	O
normal	O
B	O
and	O
T	O
lymphocytes	O
;	O
however	O
,	O
with	O
the	O
appropriate	O
activation	O
signal	O
HB24	O
mRNA	O
was	O
induced	O
within	O
several	O
hours	O
even	O
in	O
the	O
presence	O
of	O
cycloheximide	O
.	O
Characterization	O
of	O
HB24	O
expression	O
in	O
lymphoid	O
and	O
select	O
developing	O
tissues	O
was	O
performed	O
by	O
in	O
situ	O
hybridization	O
.	O
Positive	O
hybridization	O
was	O
found	O
in	O
thymus	O
,	O
tonsil	O
,	O
bone	O
marrow	O
,	O
developing	O
vessels	O
,	O
and	O
in	O
fetal	O
brain	O
.	O
HB24	O
is	O
likely	O
to	O
have	O
an	O
important	O
role	O
in	O
lymphocytes	O
as	O
well	O
as	O
in	O
certain	O
developing	O
tissues	O
.	O
Severe	O
5-fluorouracil	O
toxicity	O
secondary	O
to	O
dihydropyrimidine	B
dehydrogenase	I
deficiency	O
.	O
A	O
potentially	O
more	O
common	O
pharmacogenetic	O
syndrome	O
.	O
This	O
study	O
describes	O
the	O
inheritance	O
of	O
a	O
defect	O
in	O
pyrimidine	O
catabolism	O
and	O
its	O
association	O
with	O
drug	O
-	O
induced	O
toxicity	O
in	O
a	O
patient	O
receiving	O
5-fluorouracil	O
(	O
FUra	O
)	O
as	O
adjuvant	O
chemotherapy	O
for	O
breast	O
carcinoma	O
.	O
The	O
study	O
population	O
included	O
the	O
affected	O
patient	O
(	O
proband	O
)	O
,	O
nine	O
of	O
her	O
blood	O
relatives	O
,	O
and	O
seven	O
healthy	O
volunteers	O
.	O
The	O
activity	O
of	O
dihydropyrimidine	B
dehydrogenase	I
(	O
DPD	B
)	O
,	O
the	O
initial	O
enzyme	B
of	O
pyrimidine	O
(	O
and	O
FUra	O
)	O
catabolism	O
,	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
was	O
measured	O
in	O
each	O
subject	O
by	O
a	O
specific	O
radiometric	O
assay	O
using	O
FUra	O
as	O
the	O
substrate	O
.	O
The	O
proband	O
had	O
no	O
detectable	O
DPD	B
activity	O
.	O
When	O
enzyme	O
levels	O
in	O
the	O
proband	O
and	O
relatives	O
were	O
compared	O
with	O
that	O
in	O
controls	O
,	O
an	O
autosomal	O
recessive	O
pattern	O
of	O
inheritance	O
was	O
demonstrated	O
.	O
This	O
is	O
the	O
third	O
patient	O
with	O
severe	O
FUra	O
toxicity	O
secondary	O
to	O
an	O
alteration	O
in	O
pyrimidine	O
catabolism	O
and	O
the	O
second	O
from	O
our	O
clinic	O
population	O
suggesting	O
that	O
the	O
frequency	O
of	O
this	O
genetic	O
defect	O
may	O
be	O
greater	O
than	O
previously	O
thought	O
.	O
Monitoring	O
DPD	B
activity	O
may	O
be	O
important	O
in	O
the	O
management	O
of	O
patients	O
experiencing	O
severe	O
toxicity	O
secondary	O
to	O
FUra	O
chemotherapy	O
.	O
Characterization	O
of	O
an	O
immediate	O
-	O
early	O
gene	O
induced	O
in	O
adherent	O
monocytes	O
that	O
encodes	O
I	B
kappa	I
B	I
-like	O
activity	O
.	O
We	O
have	O
cloned	O
a	O
group	O
of	O
cDNAs	O
representing	O
mRNAs	O
that	O
are	O
rapidly	O
induced	O
following	O
adherence	O
of	O
human	O
monocytes	O
.	O
One	O
of	O
the	O
induced	O
transcripts	O
(	O
MAD-3	O
)	O
encodes	O
a	O
protein	O
of	O
317	O
amino	O
acids	O
with	O
one	O
domain	O
containing	O
five	B
tandem	I
repeats	I
of	O
the	O
cdc10	B
/	I
ankyrin	I
motif	I
,	O
which	O
is	O
60	O
%	O
similar	O
(	O
46	O
%	O
identical	O
)	O
to	O
the	O
ankyrin	B
repeat	I
region	I
of	O
the	O
precursor	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
KBF1	I
p50	I
.	O
The	O
C	B
-	I
terminus	I
has	O
a	O
putative	O
protein	B
kinase	I
C	I
phosphorylation	I
site	I
.	O
In	O
vitro	O
translated	O
MAD-3	B
protein	I
was	O
found	O
to	O
specifically	O
inhibit	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
the	O
p50	B
/	I
p65	I
NF	I
-	I
kappa	I
B	I
complex	I
but	O
not	O
that	O
of	O
the	O
p50	B
/	I
p50	I
KBF1	I
factor	I
or	O
of	O
other	O
DNA	B
-	I
binding	I
proteins	I
.	O
The	O
MAD-3	O
cDNA	O
encodes	O
an	O
I	B
kappa	I
B	I
-	I
like	I
protein	I
that	O
is	O
likely	O
to	O
be	O
involved	O
in	O
regulation	O
of	O
transcriptional	O
responses	O
to	O
NF	B
-	I
kappa	I
B	I
,	O
including	O
adhesion	O
-	O
dependent	O
pathways	O
of	O
monocyte	O
activation	O
.	O
Reactive	O
oxygen	O
intermediates	O
as	O
apparently	O
widely	O
used	O
messengers	O
in	O
the	O
activation	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
transcription	I
factor	I
and	O
HIV-1	O
.	O
Hydrogen	O
peroxide	O
and	O
oxygen	O
radicals	O
are	O
agents	O
commonly	O
produced	O
during	O
inflammatory	O
processes	O
.	O
In	O
this	O
study	O
,	O
we	O
show	O
that	O
micromolar	O
concentrations	O
of	O
H2O2	O
can	O
induce	O
the	O
expression	O
and	O
replication	O
of	O
HIV-1	O
in	O
a	O
human	O
T	O
cell	O
line	O
.	O
The	O
effect	O
is	O
mediated	O
by	O
the	O
NF	B
-	I
kappa	I
B	I
transcription	B
factor	I
which	O
is	O
potently	O
and	O
rapidly	O
activated	O
by	O
an	O
H2O2	O
treatment	O
of	O
cells	O
from	O
its	O
inactive	B
cytoplasmic	I
form	I
.	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
,	O
a	O
well	O
characterized	O
antioxidant	O
which	O
counteracts	O
the	O
effects	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
in	O
living	O
cells	O
,	O
prevented	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
by	O
H2O2	O
.	O
NAC	O
and	O
other	O
thiol	O
compounds	O
also	O
blocked	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
by	O
cycloheximide	O
,	O
double	O
-	O
stranded	O
RNA	O
,	O
calcium	O
ionophore	O
,	O
TNF	B
-	I
alpha	I
,	O
active	O
phorbol	O
ester	O
,	O
interleukin-1	B
,	O
lipopolysaccharide	O
and	O
lectin	B
.	O
This	O
suggests	O
that	O
diverse	O
agents	O
thought	O
to	O
activate	O
NF	B
-	I
kappa	I
B	I
by	O
distinct	O
intracellular	O
pathways	O
might	O
all	O
act	O
through	O
a	O
common	O
mechanism	O
involving	O
the	O
synthesis	O
of	O
ROI	O
.	O
ROI	O
appear	O
to	O
serve	O
as	O
messengers	O
mediating	O
directly	O
or	O
indirectly	O
the	O
release	O
of	O
the	O
inhibitory	B
subunit	I
I	B
kappa	I
B	I
from	O
NF	B
-	I
kappa	I
B	I
.	O
[	O
Differential	O
diagnostic	O
value	O
of	O
receptors	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
calcitriol	O
)	O
determination	O
in	O
lymphocytes	O
of	O
children	O
with	O
rickets	O
and	O
rickets	O
-	O
like	O
diseases	O
]	O
The	O
authors	O
provide	O
the	O
results	O
of	O
studying	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
calcitriol	O
)	O
in	O
lymphocytes	O
of	O
children	O
with	O
rickets	O
and	O
rickets	O
-	O
like	O
diseases	O
.	O
It	O
is	O
proposed	O
that	O
the	O
character	O
of	O
their	O
expression	O
under	O
the	O
influence	O
of	O
vitamin	O
D	O
may	O
be	O
used	O
with	O
differential	O
diagnostic	O
purposes	O
in	O
view	O
.	O
Enhancement	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
replication	O
in	O
monocytes	O
by	O
1	O
,	O
25-dihydroxycholecalciferol	O
.	O
Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
expression	O
and	O
replication	O
are	O
under	O
tight	O
regulatory	O
control	O
.	O
We	O
demonstrate	O
that	O
1	O
,	O
25-dihydroxycholecalciferol	O
[	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
]	O
enhances	O
the	O
replication	O
of	O
monocyte-	O
and	O
lymphocyte	O
-	O
tropic	O
strains	O
of	O
HIV-1	O
up	O
to	O
10	O
,	O
000-fold	O
in	O
monocyte	O
cell	O
lines	O
,	O
peripheral	O
blood	O
monocytes	O
,	O
and	O
unfractionated	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
therefore	O
one	O
of	O
the	O
most	O
potent	O
regulators	O
of	O
HIV-1	O
replication	O
described	O
to	O
date	O
.	O
Precursors	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
enhance	O
HIV-1	O
replication	O
in	O
proportion	O
to	O
their	O
affinity	O
for	O
the	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
intracellular	I
receptor	I
,	O
suggesting	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
influences	O
HIV-1	O
replication	O
by	O
mechanisms	O
involving	O
this	O
receptor	O
.	O
These	O
studies	O
may	O
have	O
important	O
implications	O
for	O
the	O
design	O
of	O
effective	O
therapy	O
of	O
HIV-1	O
infection	O
.	O
Inhibition	O
of	O
HIV-1	O
replication	O
and	O
NF	B
-	I
kappa	I
B	I
activity	O
by	O
cysteine	O
and	O
cysteine	O
derivatives	O
.	O
HIV-1	O
proviral	O
DNA	O
contains	O
two	O
binding	O
sites	O
for	O
the	O
transcription	B
factor	I
NF	B
-	I
kappa	I
B	I
.	O
HIV-1-infected	O
individuals	O
have	O
,	O
on	O
average	O
,	O
abnormally	O
high	O
levels	O
of	O
tumour	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
alpha	I
)	O
and	O
abnormally	O
low	O
plasma	O
cysteine	O
levels	O
.	O
We	O
therefore	O
investigated	O
the	O
effects	O
of	O
cysteine	O
and	O
related	O
thiols	O
on	O
HIV-1	O
replication	O
and	O
NF	B
-	I
kappa	I
B	I
expression	O
.	O
The	O
experiments	O
in	O
this	O
report	O
show	O
that	O
cysteine	O
or	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
)	O
raise	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
level	O
and	O
inhibit	O
HIV-1	O
replication	O
in	O
persistently	O
infected	O
Molt-4	O
and	O
U937	O
cells	O
.	O
However	O
,	O
inhibition	O
of	O
HIV-1	O
replication	O
appears	O
not	O
to	O
be	O
directly	O
correlated	O
with	O
GSH	O
levels	O
.	O
Cysteine	O
and	O
NAC	O
also	O
inhibit	O
NF	B
-	I
kappa	I
B	I
activity	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
chloramphenicol	B
acetyl	I
-	I
transferase	I
(	O
CAT	B
)	O
gene	O
expression	O
under	O
control	O
of	O
NF	B
-	I
kappa	I
B	I
binding	O
sites	O
in	O
uninfected	O
cells	O
.	O
This	O
suggests	O
that	O
the	O
cysteine	O
deficiency	O
in	O
HIV-1-infected	O
individuals	O
may	O
cause	O
an	O
over	O
-	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
genes	O
and	O
enhance	O
HIV-1	O
replication	O
.	O
NAC	O
may	O
be	O
considered	O
for	O
the	O
treatment	O
of	O
HIV-1-infected	O
individuals	O
.	O
Glucocorticoid	B
receptors	I
in	O
systemic	O
lupus	O
erythematosus	O
.	O
Glucocorticosteroids	O
remain	O
the	O
major	O
treatment	O
modality	O
for	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
but	O
their	O
mechanism	O
of	O
action	O
is	O
unclear	O
.	O
Over	O
the	O
past	O
decade	O
it	O
has	O
become	O
clear	O
that	O
glucocorticosteroid	B
receptors	I
play	O
a	O
significant	O
role	O
in	O
the	O
mechanism	O
of	O
glucocorticosteroid	O
action	O
.	O
We	O
studied	O
glucocorticosteroid	B
receptor	I
density	O
and	O
affinity	O
on	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
the	O
glucocorticosteroid	O
binding	O
assay	O
in	O
33	O
patients	O
with	O
SLE	O
who	O
had	O
taken	O
no	O
glucocorticosteroid	O
for	O
the	O
previous	O
6	O
months	O
and	O
in	O
32	O
healthy	O
controls	O
.	O
Patients	O
'	O
disease	O
activity	O
was	O
measured	O
by	O
the	O
SLE	O
Disease	O
Activity	O
Index	O
(	O
SLEDAI	O
)	O
.	O
Glucocorticosteroid	B
receptors	I
on	O
leukocytes	O
of	O
patients	O
with	O
SLE	O
were	O
significantly	O
higher	O
than	O
in	O
healthy	O
controls	O
(	O
4419	O
+	O
/-	O
306	O
vs	O
3369	O
+	O
/-	O
196	O
,	O
p	O
less	O
than	O
0.005	O
)	O
.	O
The	O
binding	O
affinity	O
was	O
not	O
different	O
between	O
patients	O
and	O
controls	O
.	O
There	O
was	O
no	O
correlation	O
between	O
glucocorticosteroid	B
receptor	I
number	O
and	O
SLE	O
disease	O
activity	O
.	O
[	O
Changes	O
in	O
levels	O
of	O
leucocytic	B
estrogen	I
receptor	I
in	O
patients	O
with	O
menopausal	O
type	O
II	O
diabetes	O
and	O
its	O
significance	O
]	O
The	O
number	O
of	O
estrogen	B
receptors	I
(	O
ER	B
)	O
in	O
human	O
peripheral	O
leucocytes	O
in	O
12	O
women	O
with	O
menopausal	O
type	O
II	O
diabetes	O
was	O
measured	O
with	O
radio	O
-	O
ligand	O
binding	O
method	O
.	O
The	O
results	O
were	O
compared	O
with	O
those	O
of	O
12	O
menopausal	O
women	O
without	O
diabetes	O
and	O
12	O
normal	O
women	O
of	O
childbearing	O
age	O
.	O
It	O
was	O
found	O
that	O
the	O
number	O
of	O
ER	B
in	O
the	O
patients	O
was	O
significantly	O
decreased	O
.	O
Our	O
data	O
indicate	O
that	O
decrease	O
of	O
ER	B
level	O
in	O
leukocytes	O
may	O
be	O
related	O
to	O
the	O
pathogenesis	O
of	O
type	O
II	O
diabetes	O
in	O
menopausal	O
period	O
.	O
Nuclear	O
association	O
of	O
a	O
T	B
-	I
cell	I
transcription	I
factor	I
blocked	O
by	O
FK-506	O
and	O
cyclosporin	O
A	O
[	O
see	O
comments	O
]	O
Cyclosporin	O
A	O
and	O
FK506	O
inhibit	O
T-	O
and	O
B	O
-	O
cell	O
activation	O
and	O
other	O
processes	O
essential	O
to	O
an	O
effective	O
immune	O
response	O
.	O
In	O
T	O
lymphocytes	O
these	O
drugs	O
disrupt	O
an	O
unknown	O
step	O
in	O
the	O
transmission	O
of	O
signals	O
from	O
the	O
T	B
-	I
cell	I
antigen	I
receptor	I
to	O
cytokine	O
genes	O
that	O
coordinate	O
the	O
immune	O
response	O
.	O
The	O
putative	B
intracellular	I
receptors	I
for	O
FK506	O
and	O
cyclosporin	O
are	O
cis	O
-	O
trans	O
prolyl	O
isomerases	O
.	O
Binding	O
of	O
the	O
drug	O
inhibits	O
isomerase	B
activity	O
,	O
but	O
studies	O
with	O
other	O
prolyl	O
isomerase	B
inhibitors	O
and	O
analysis	O
of	O
cyclosporin	O
-	O
resistant	O
mutants	O
in	O
yeast	O
suggest	O
that	O
the	O
effects	O
of	O
the	O
drug	O
result	O
from	O
the	O
formation	O
of	O
an	O
inhibitory	B
complex	I
between	O
the	O
drug	O
and	O
isomerase	B
,	O
and	O
not	O
from	O
inhibition	O
of	O
isomerase	B
activity	O
.	O
A	O
transcription	B
factor	I
,	O
NF	B
-	I
AT	I
,	O
which	O
is	O
essential	O
for	O
early	O
T	O
-	O
cell	O
gene	O
activation	O
,	O
seems	O
to	O
be	O
a	O
specific	O
target	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
action	O
because	O
transcription	O
directed	O
by	O
this	O
protein	O
is	O
blocked	O
in	O
T	O
cells	O
treated	O
with	O
these	O
drugs	O
,	O
with	O
little	O
or	O
no	O
effect	O
on	O
other	O
transcription	B
factors	I
such	O
as	O
AP-1	B
and	O
NF	B
-	I
kappa	I
B	I
.	O
Here	O
we	O
demonstrate	O
that	O
NF	B
-	I
AT	I
is	O
formed	O
when	O
a	O
signal	O
from	O
the	O
antigen	B
receptor	I
induces	O
a	O
pre	O
-	O
existing	O
cytoplasmic	O
subunit	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
combine	O
with	O
a	O
newly	O
synthesized	O
nuclear	O
subunit	O
of	O
NF	B
-	I
AT	I
.	O
FK506	O
and	O
cyclosporin	O
A	O
block	O
translocation	O
of	O
the	O
cytoplasmic	B
component	I
without	O
affecting	O
synthesis	O
of	O
the	O
nuclear	B
subunit	I
.	O
NF	B
-	I
kappa	I
B	I
activation	O
by	O
tumor	B
necrosis	I
factor	I
alpha	I
in	O
the	O
Jurkat	O
T	O
cell	O
line	O
is	O
independent	O
of	O
protein	B
kinase	I
A	I
,	O
protein	B
kinase	I
C	I
,	O
and	O
Ca	B
(	I
2	I
+	I
)	I
-regulated	I
kinases	I
.	O
NF	B
-	I
kappa	I
B	I
is	O
a	O
DNA	B
-	I
binding	I
regulatory	I
factor	I
able	O
to	O
control	O
transcription	O
of	O
a	O
number	O
of	O
genes	O
,	O
including	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
genes	O
.	O
In	O
T	O
cells	O
,	O
NF	B
-	I
kappa	I
B	I
is	O
activated	O
upon	O
cellular	O
treatment	O
by	O
phorbol	O
esters	O
and	O
the	O
cytokine	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
alpha	I
)	O
.	O
In	O
the	O
present	O
work	O
,	O
we	O
investigated	O
the	O
molecular	O
events	O
leading	O
to	O
NF	B
-	I
kappa	I
B	I
activation	O
by	O
TNF	B
alpha	I
in	O
a	O
human	O
T	O
cell	O
line	O
(	O
Jurkat	O
)	O
and	O
its	O
subclone	O
JCT6	O
,	O
which	O
presents	O
a	O
deficiency	O
in	O
the	O
PKA	B
transduction	O
pathway	O
.	O
We	O
found	O
that	O
in	O
both	O
cell	O
lines	O
,	O
both	O
phorbol	O
ester	O
and	O
TNF	B
alpha	I
were	O
able	O
to	O
activate	O
NF	B
-	I
kappa	I
B	I
.	O
Phorbol	O
activation	O
was	O
positively	O
modulated	O
by	O
Ca2	O
+	O
influx	O
while	O
TNF	B
alpha	I
activation	O
was	O
not	O
.	O
Furthermore	O
,	O
while	O
PMA	O
activation	O
was	O
inhibited	O
by	O
the	O
PKC	B
inhibitor	O
staurosporin	O
,	O
the	O
TNF	B
alpha	I
effect	O
was	O
unchanged	O
.	O
TNF	B
alpha	I
did	O
not	O
activate	O
cAMP	O
production	O
and	O
its	O
signal	O
was	O
not	O
modulated	O
by	O
cAMP	O
activators	O
.	O
Moreover	O
,	O
cAMP	O
activators	O
did	O
not	O
activate	O
NF	B
-	I
kappa	I
B	I
in	O
Jurkat	O
cells	O
.	O
Thus	O
,	O
TNF	B
alpha	I
-induced	O
NF	B
-	I
kappa	I
B	I
activation	O
was	O
found	O
to	O
be	O
mediated	O
by	O
none	O
of	O
the	O
major	O
signal	B
-	I
mediating	I
kinases	I
such	O
as	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
,	O
protein	B
kinase	I
A	I
,	O
or	O
Ca	B
(	I
2	I
+	I
)	I
-regulated	I
kinases	I
.	O
Furthermore	O
,	O
we	O
found	O
that	O
cytoplasmic	O
acidification	O
facilitated	O
NF	B
-	I
kappa	I
B	I
activation	O
by	O
both	O
TNF	B
alpha	I
and	O
PKC	B
,	O
by	O
a	O
mechanism	O
that	O
increases	O
NF	B
-	I
kappa	I
B	I
/I	B
kappa	I
B	I
dissociation	O
without	O
affecting	O
the	O
NF	B
-	I
kappa	I
B	I
translocation	O
step	O
.	O
NF	B
-	I
kappa	I
B	I
activity	O
in	O
T	O
cells	O
stably	O
expressing	O
the	O
Tax	B
protein	I
of	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
.	O
The	O
effect	O
of	O
constitutive	O
Tax	B
expression	O
on	O
the	O
interaction	O
of	O
NF	B
-	I
kappa	I
B	I
with	O
its	O
recognition	O
sequence	O
and	O
on	O
NF	B
-	I
kappa	I
B	I
-dependent	O
gene	O
expression	O
was	O
examined	O
in	O
T	O
lymphoid	O
Jurkat	O
cell	O
lines	O
(	O
19D	O
and	O
9J	O
)	O
stably	O
transformed	O
with	O
a	O
Tax	O
expression	O
vector	O
.	O
Tax	O
expressing	O
T	O
cell	O
lines	O
contained	O
a	O
constitutive	O
level	O
of	O
NF	B
-	I
kappa	I
B	I
binding	O
activity	O
,	O
detectable	O
by	O
mobility	O
shift	O
assay	O
and	O
uv	O
cross	O
-	O
linking	O
using	O
a	O
palindromic	O
NF	O
-	O
kappa	O
B	O
probe	O
homologous	O
to	O
the	O
interferon	O
beta	O
PRDII	O
site	O
.	O
In	O
Jurkat	O
and	O
NC2.10	O
induction	O
with	O
phorbol	O
esters	O
resulted	O
in	O
the	O
appearance	O
of	O
new	O
DNA	B
binding	I
proteins	I
of	O
85	B
,	I
75	I
,	I
and	I
54	I
kDa	I
,	O
whereas	O
in	O
Tax	O
expressing	O
cells	O
the	O
85-kDa	B
protein	I
and	O
a	O
92-kDa	B
DNA	I
binding	I
protein	I
were	O
constitutively	O
induced	O
.	O
Expression	O
of	O
Tax	B
protein	I
in	O
19D	O
and	O
9J	O
resulted	O
in	O
transcription	O
of	O
the	O
endogenous	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
granulocyte	O
-	O
macrophage	O
colony	O
stimulating	O
factor	O
gene	O
and	O
increased	O
basal	O
level	O
expression	O
of	O
transfected	O
NF	O
-	O
kappa	O
B	O
-	O
regulated	O
promoters	O
.	O
Nonetheless	O
transcription	O
of	O
both	O
the	O
endogenous	O
and	O
the	O
transfected	O
gene	O
was	O
inducible	O
by	O
PMA	O
treatment	O
.	O
Tax	B
expression	O
in	O
Jurkat	O
T	O
cells	O
may	O
alter	O
the	O
stoichiometry	O
of	O
NF	B
-	I
kappa	I
B	I
DNA	B
binding	I
proteins	I
and	O
thus	O
change	O
the	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
regulated	O
promoters	O
.	O
Glucocorticoid	B
receptors	I
in	O
lymphocytes	O
in	O
anorexia	O
nervosa	O
.	O
OBJECTIVE	O
:	O
The	O
aim	O
was	O
to	O
explore	O
the	O
down	O
-	O
regulation	O
of	O
the	O
glucocorticoid	B
receptors	I
during	O
hypercortisolaemia	O
in	O
anorexia	O
nervosa	O
.	O
DESIGN	O
:	O
Urine	O
and	O
plasma	O
samples	O
were	O
obtained	O
for	O
cortisol	O
determination	O
and	O
blood	O
lymphocytes	O
were	O
isolated	O
for	O
receptor	O
binding	O
studies	O
.	O
PATIENTS	O
:	O
Sixteen	O
anorexic	O
patients	O
,	O
aged	O
16	O
-	O
27	O
years	O
,	O
with	O
a	O
mean	O
+	O
/-	O
SEM	O
body	O
mass	O
index	O
of	O
14.2	O
+	O
/-	O
2.0	O
(	O
ranging	O
from	O
11.1	O
to	O
17.4	O
)	O
,	O
and	O
15	O
normal	O
women	O
were	O
studied	O
.	O
Six	O
patients	O
were	O
reinvestigated	O
after	O
a	O
significant	O
weight	O
gain	O
.	O
MEASUREMENTS	O
:	O
The	O
binding	O
capacity	O
and	O
affinity	O
of	O
the	O
glucocorticoid	B
receptors	I
were	O
measured	O
with	O
dexamethasone	O
as	O
ligand	O
on	O
lymphocytes	O
.	O
RESULTS	O
:	O
In	O
patients	O
,	O
both	O
total	O
and	O
free	O
plasma	O
cortisol	O
concentrations	O
were	O
higher	O
than	O
in	O
the	O
normal	O
women	O
,	O
as	O
was	O
their	O
urinary	O
free	O
cortisol	O
;	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
per	O
cell	O
(	O
Ro	O
)	O
and	O
the	O
binding	O
affinity	O
(	O
Kd	O
)	O
for	O
dexamethasone	O
were	O
,	O
however	O
,	O
not	O
significantly	O
different	O
(	O
Ro	O
:	O
7687	O
+	O
/-	O
1750	O
vs	O
7347	O
+	O
/-	O
1285	O
sites	O
/	O
cell	O
;	O
Kd	O
:	O
7.7	O
+	O
/-	O
2.4	O
vs	O
7.4	O
+	O
/-	O
1.7	O
nM	O
at	O
24	O
degrees	O
C	O
)	O
.	O
After	O
weight	O
gain	O
(	O
14	O
+	O
/-	O
2	O
to	O
16	O
+	O
/-	O
2	O
kg	O
/	O
m2	O
)	O
,	O
receptor	O
numbers	O
were	O
8421	O
+	O
/-	O
2126	O
(	O
pre	O
)	O
and	O
9011	O
+	O
/-	O
500	O
(	O
post	O
)	O
sites	O
/	O
cell	O
,	O
which	O
are	O
not	O
significantly	O
different	O
(	O
P	O
greater	O
than	O
0.2	O
)	O
;	O
the	O
Kd	O
was	O
unchanged	O
(	O
9.3	O
+	O
/-	O
2.6	O
vs	O
9.2	O
+	O
/-	O
2.4	O
nM	O
)	O
.	O
CONCLUSIONS	O
Hypercortisolaemia	O
does	O
not	O
down	O
-	O
regulate	O
the	O
lymphocyte	O
glucocorticoid	B
receptors	I
in	O
anorexia	O
nervosa	O
and	O
a	O
post	O
-	O
receptor	O
defect	O
might	O
be	O
involved	O
in	O
peripheral	O
tissue	O
resistance	O
to	O
the	O
effects	O
of	O
glucocorticoid	O
hormones	O
in	O
undernutrition	O
.	O
Tumor	O
necrosis	O
factor	O
-	O
alpha	O
mRNA	O
accumulation	O
in	O
human	O
myelomonocytic	O
cell	O
lines	O
.	O
Role	O
of	O
transcriptional	O
regulation	O
by	O
DNA	O
sequence	O
motifs	O
and	O
mRNA	O
stabilization	O
.	O
The	O
cytokine	B
TNF	B
mediates	O
many	O
of	O
the	O
pathologic	O
signs	O
of	O
cachexia	O
,	O
inflammation	O
,	O
and	O
sepsis	O
.	O
The	O
current	O
work	O
describes	O
the	O
regulation	O
of	O
TNF	B
in	O
human	O
myelomonocytic	O
cell	O
lines	O
after	O
PMA	O
stimulation	O
.	O
The	O
cell	O
lines	O
exhibit	O
a	O
low	O
level	O
of	O
constitutive	O
TNF	O
mRNA	O
expression	O
.	O
Within	O
2	O
to	O
4	O
h	O
of	O
PMA	O
exposure	O
,	O
steady	O
state	O
levels	O
of	O
TNF	O
mRNA	O
are	O
markedly	O
elevated	O
in	O
all	O
myelomonocytic	O
cell	O
lines	O
studied	O
.	O
This	O
rise	O
is	O
due	O
to	O
increased	O
mRNA	O
stability	O
,	O
which	O
increased	O
by	O
almost	O
twofold	O
,	O
and	O
to	O
an	O
overall	O
increase	O
in	O
transcription	O
,	O
which	O
rises	O
by	O
more	O
than	O
sixfold	O
.	O
At	O
the	O
level	O
of	O
the	O
genomic	O
TNF	O
gene	O
,	O
a	O
DNase	O
I	O
hypersensitive	O
site	O
is	O
detected	O
within	O
the	O
TNF	O
promoter	O
between	O
-200	O
to	O
-100	O
bp	O
relative	O
to	O
the	O
transcription	O
initiation	O
site	O
.	O
Although	O
absent	O
in	O
nonexpressing	O
erythroleukemia	O
cell	O
lines	O
,	O
the	O
DNase	O
I	O
site	O
is	O
present	O
in	O
uninduced	O
myelomonocytic	O
cell	O
lines	O
and	O
is	O
not	O
changed	O
after	O
PMA	O
induction	O
.	O
The	O
PMA	O
induction	O
of	O
c	O
-	O
fos	O
mRNA	O
correlated	O
well	O
with	O
TNF	B
gene	O
induction	O
;	O
expression	O
of	O
genes	O
encoding	O
other	O
proteins	O
in	O
the	O
AP-1	B
complex	I
(	O
junB	B
and	O
junD	B
)	O
were	O
also	O
induced	O
by	O
PMA	O
.	O
The	O
nuclear	O
extracts	O
from	O
resting	O
and	O
induced	O
ML-1	O
cells	O
contain	O
proteins	O
binding	O
specifically	O
to	O
the	O
AP-1	O
,	O
AP-2	O
,	O
and	O
NF	O
kappa	O
B	O
sequence	O
located	O
within	O
the	O
TNF	O
promoter	O
.	O
PMA	O
induction	O
increases	O
the	O
level	O
of	O
a	O
number	O
of	O
specific	B
binding	I
complexes	I
relative	O
to	O
the	O
resting	O
cells	O
.	O
The	O
regulatory	O
mechanisms	O
of	O
the	O
human	O
and	O
murine	O
TNF	O
genes	O
are	O
discussed	O
.	O
The	O
effect	O
of	O
toremifene	O
therapy	O
on	O
serum	B
immunoglobulin	I
levels	O
in	O
breast	O
cancer	O
.	O
Estrogens	O
and	O
anti	O
-	O
estrogens	O
enhance	O
the	O
number	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
-secreting	O
cells	O
in	O
pokeweed	O
mitogen	O
(	O
PWM	O
)	O
-stimulated	O
lymphocyte	O
cultures	O
.	O
Lymphocytes	O
from	O
patients	O
who	O
have	O
received	O
anti	O
-	O
estrogen	O
therapy	O
show	O
similar	O
enhancement	O
of	O
Ig	O
-	O
secreting	O
cells	O
after	O
PWM	B
stimulation	O
.	O
In	O
this	O
study	O
the	O
effect	O
of	O
anti	O
-	O
estrogen	O
(	O
toremifene	O
)	O
therapy	O
on	O
serum	B
immunoglobulin	I
(	O
IgA	B
,	O
IgM	B
,	O
IgG	B
)	O
levels	O
in	O
breast	O
cancer	O
patients	O
was	O
investigated	O
.	O
Serum	O
Ig	O
levels	O
were	O
followed	O
up	O
to	O
two	O
years	O
after	O
or	O
during	O
the	O
therapy	O
.	O
An	O
unexpected	O
finding	O
was	O
that	O
the	O
Ig	O
levels	O
decreased	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O
This	O
decrease	O
was	O
seen	O
in	O
patients	O
who	O
responded	O
to	O
the	O
therapy	O
as	O
well	O
as	O
in	O
those	O
who	O
did	O
not	O
.	O
HIV1	O
infection	O
of	O
human	O
monocytes	O
and	O
macrophages	O
promotes	O
induction	O
or	O
translocation	O
of	O
NF	B
-	I
KB	I
-	I
related	I
factors	I
.	O
In	O
1991	O
,	O
we	O
demonstrated	O
,	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
that	O
3	O
different	O
factors	O
(	O
termed	O
B1	B
,	O
B2	B
and	O
B3	B
)	O
with	O
affinity	O
for	O
the	O
KB	O
-	O
enhancer	O
target	O
sequence	O
were	O
specifically	O
detected	O
in	O
nuclear	O
extracts	O
from	O
HIV1-infected	O
monocytes	O
and	O
macrophages	O
.	O
The	O
B2	B
factor	I
was	O
induced	O
in	O
the	O
nuclei	O
of	O
these	O
cells	O
only	O
upon	O
HIV1	O
infection	O
.	O
The	O
B3	B
factor	I
was	O
only	O
slightly	O
evident	O
in	O
nuclei	O
of	O
uninfected	O
cells	O
but	O
was	O
readily	O
detectable	O
in	O
nuclei	O
of	O
infected	O
monocytes	O
.	O
Its	O
expression	O
remained	O
very	O
low	O
in	O
nuclei	O
of	O
HIV1-infected	O
macrophages	O
.	O
In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
B2	B
factor	I
is	O
expressed	O
in	O
the	O
cytosol	O
of	O
monocytes	O
and	O
macrophages	O
as	O
a	O
DNA	B
-	I
binding	I
protein	I
,	O
indicating	O
that	O
it	O
is	O
not	O
associated	O
with	O
an	O
inhibitor	O
(	O
IKB	O
)	O
.	O
This	O
factor	O
remained	O
clustered	O
in	O
the	O
cytosol	O
and	O
was	O
translocated	O
to	O
the	O
nuclei	O
only	O
after	O
HIV1	O
infection	O
.	O
The	O
B3	B
factor	I
is	O
detected	O
in	O
the	O
cytosol	O
only	O
when	O
cells	O
are	O
HIV1-infected	O
.	O
The	O
role	O
of	O
HIV1	O
infection	O
in	O
the	O
expression	O
and	O
the	O
translocation	O
of	O
these	O
factors	O
is	O
discussed	O
.	O
A	O
nuclear	B
factor	I
NF	B
-	I
GM2	I
that	O
interacts	O
with	O
a	O
regulatory	O
region	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
essential	O
for	O
its	O
induction	O
in	O
responses	O
to	O
T	O
-	O
cell	O
activation	O
:	O
purification	O
from	O
human	O
T	O
-	O
cell	O
leukemia	O
line	O
Jurkat	O
cells	O
and	O
similarity	O
to	O
NF	B
-	I
kappa	I
B	I
.	O
Activation	O
of	O
T	O
cells	O
by	O
antigen	O
,	O
lectin	B
,	O
or	O
a	O
combination	O
of	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
leads	O
to	O
the	O
induction	O
of	O
genes	O
for	O
a	O
set	O
of	O
lymphokines	B
,	O
including	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
.	O
We	O
demonstrated	O
in	O
earlier	O
studies	O
that	O
the	O
upstream	O
region	O
of	O
the	O
mouse	O
GM	O
-	O
CSF	O
promoter	O
at	O
positions	O
between	O
-95	O
and	O
-73	O
is	O
essential	O
for	O
transcriptional	O
activation	O
in	O
response	O
to	O
PMA	O
/	O
A23187	O
.	O
This	O
region	O
contains	O
two	O
DNA	O
-	O
binding	O
motifs	O
,	O
GM2	O
and	O
GC	O
-	O
box	O
.	O
The	O
GM2	O
sequence	O
(	O
GGTAGTTCCC	O
)	O
is	O
recognized	O
by	O
an	O
inducible	B
factor	I
NF	I
-	I
GM2	I
;	O
the	O
other	O
(	O
CCGCCC	O
)	O
by	O
constitutive	B
factors	I
A1	B
,	O
A2	B
,	O
and	O
B	B
.	O
To	O
elucidate	O
the	O
mechanism	O
of	O
GM	B
-	I
CSF	I
gene	O
activation	O
,	O
we	O
have	O
purified	O
the	O
inducible	B
factor	I
NF	I
-	I
GM2	I
from	O
the	O
nuclear	O
extract	O
of	O
stimulated	O
Jurkat	O
cells	O
on	O
the	O
basis	O
of	O
specific	O
DNA	O
-	O
binding	O
activity	O
.	O
The	O
purified	O
NF	B
-	I
GM2	I
consists	O
of	O
50	O
(	O
p50	B
)	O
and	O
65	O
kDa	O
(	O
p65	B
)	O
polypeptides	O
and	O
has	O
a	O
binding	O
activity	O
specific	O
for	O
both	O
the	O
GM	B
-	I
CSF	I
and	O
immunoglobulin	O
kappa	O
(	O
GGAAAGTCCC	O
)	O
enhancers	O
.	O
Electrophoretically	O
purified	O
p50	B
alone	O
can	O
form	O
a	O
protein	B
-	I
DNA	I
complex	I
,	O
but	O
in	O
the	O
mixture	O
,	O
p50	B
associates	O
preferentially	O
with	O
p65	B
to	O
form	O
the	O
NF	B
-	I
GM2	I
complex	I
.	O
In	O
addition	O
,	O
p65	B
gave	O
per	O
se	O
,	O
with	O
low	O
affinity	O
,	O
a	O
protein	B
-	I
DNA	I
complex	I
that	O
migrated	O
more	O
slowly	O
than	O
native	O
NF	B
-	I
GM2	I
complex	I
.	O
Furthermore	O
,	O
an	O
antiserum	O
against	O
KBF1	B
(	O
identical	O
to	O
50	B
kDa	I
NF	I
-	I
kappa	I
B	I
protein	I
)	O
reacted	O
with	O
the	O
p50	B
of	O
NF	B
-	I
GM2	I
,	O
indicating	O
that	O
the	O
NF	B
-	I
GM2	I
polypeptide	I
can	O
not	O
be	O
immunologically	O
differentiated	O
from	O
the	O
50	B
kDa	I
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
.	O
The	O
purified	O
NF	B
-	I
GM2	I
activated	O
in	O
vitro	O
transcription	O
from	O
the	O
kappa	O
B	O
enhancer	O
,	O
while	O
it	O
failed	O
to	O
stimulate	O
transcription	O
from	O
the	O
GM	O
-	O
CSF	O
promoter	O
harboring	O
the	O
GM2	O
sequence	O
.	O
This	O
suggests	O
that	O
the	O
activation	O
mechanism	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
through	O
the	O
GM2	O
/	O
GC	O
-	O
box	O
sequence	O
is	O
different	O
from	O
that	O
of	O
genes	O
carrying	O
the	O
kappa	O
B	O
enhancer	O
alone	O
.	O
To	O
be	O
or	O
not	O
to	O
be	O
a	O
responder	O
in	O
T	O
-	O
cell	O
responses	O
:	O
ubiquitous	O
oligopeptides	O
in	O
all	O
proteins	O
.	O
Amino	O
acid	O
sequences	O
of	O
all	O
proteins	O
are	O
essays	O
written	O
in	O
the	O
same	O
language	O
.	O
Accordingly	O
,	O
the	O
same	O
set	O
of	O
words	O
and	O
phrases	O
(	O
oligopeptides	O
)	O
appear	O
in	O
totally	O
unrelated	O
proteins	O
.	O
The	O
reason	O
that	O
only	O
certain	O
individuals	O
of	O
particular	O
major	B
histocompatibility	I
complex	I
(	I
MHC	I
)	I
haplotypes	I
can	O
mount	O
T	O
-	O
cell	O
responses	O
against	O
a	O
given	O
antigen	O
of	O
pathogens	O
is	O
found	O
in	O
the	O
fact	O
that	O
T	B
-	I
cell	I
receptors	I
are	O
designed	O
to	O
recognize	O
18	O
-	O
20	O
residue	O
-	O
long	O
peptide	O
fragments	O
sandwiched	O
between	O
two	O
alpha	B
-	I
helices	I
of	O
class	B
I	I
or	O
class	O
II	O
MHC	O
molecules	O
.	O
At	O
this	O
range	O
of	O
peptide	O
lengths	O
,	O
most	O
would	O
appear	O
as	O
self	O
,	O
while	O
nonselfness	O
of	O
the	O
remainders	O
are	O
destined	O
to	O
be	O
quite	O
ambiguous	O
,	O
hence	O
creating	O
responders	O
and	O
nonresponders	O
.	O
Anti	B
-	I
CD2	I
receptor	I
antibodies	I
activate	O
the	O
HIV	O
long	O
terminal	O
repeat	O
in	O
T	O
lymphocytes	O
.	O
The	O
CD2	B
T	I
lymphocyte	I
glycoprotein	I
surface	I
molecule	I
mediates	O
both	O
cell	O
to	O
cell	O
adhesion	O
and	O
T	O
cell	O
activation	O
,	O
two	O
processes	O
that	O
are	O
involved	O
in	O
the	O
spread	O
of	O
HIV	O
infection	O
.	O
Treatment	O
of	O
chronically	O
HIV	O
-	O
infected	O
PBMC	O
with	O
anti	B
-	I
CD2	I
mAb	I
has	O
been	O
shown	O
to	O
induce	O
the	O
expression	O
of	O
infectious	O
virus	O
from	O
these	O
cultures	O
.	O
In	O
this	O
study	O
we	O
investigated	O
the	O
mechanisms	O
whereby	O
anti	B
-	I
CD2	I
antibodies	I
stimulate	O
viral	O
production	O
.	O
We	O
demonstrate	O
that	O
treatment	O
of	O
transiently	O
transfected	O
T	O
lymphocytes	O
with	O
anti	B
-	I
CD2	I
antibodies	I
results	O
in	O
activation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O
Furthermore	O
,	O
CAT	B
assays	O
using	O
mutated	O
HIV	O
long	O
terminal	O
repeat	O
-	O
CAT	O
constructs	O
and	O
gel	O
shift	O
assays	O
demonstrate	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
NF	O
-	O
kappa	O
B	O
enhancer	O
.	O
These	O
studies	O
suggest	O
that	O
interaction	O
of	O
CD2	B
with	O
its	O
natural	O
ligand	O
,	O
LFA-3	B
,	O
may	O
play	O
a	O
role	O
in	O
regulation	O
of	O
HIV	O
expression	O
.	O
Nuclear	B
transcription	I
factors	I
that	O
bind	O
to	O
elements	O
of	O
the	O
IL-2	O
promoter	O
.	O
Induction	O
requirements	O
in	O
primary	O
human	O
T	O
cells	O
.	O
Prior	O
studies	O
have	O
identified	O
several	O
elements	O
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL-2	O
promoter	O
in	O
the	O
stimulated	O
T	O
cell	O
line	O
,	O
Jurkat	O
.	O
The	O
sites	O
and	O
their	O
corresponding	O
nuclear	O
binding	O
factors	O
include	O
:	O
NF	B
-	I
kappa	I
B	I
,	O
AP-1	B
,	O
AP-3	B
,	O
OCT-1	B
,	O
and	O
NF	B
-	I
AT	I
.	O
The	O
latter	O
`	O
`	O
nuclear	B
factor	I
for	I
activated	I
T	I
cells	I
`	O
`	O
likely	O
contributes	O
to	O
the	O
tissue	O
specificity	O
of	O
IL-2	O
gene	O
expression	O
.	O
Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
have	O
studied	O
these	O
transcription	B
factors	I
in	O
primary	O
T	O
cells	O
from	O
human	O
blood	O
to	O
verify	O
their	O
presence	O
in	O
a	O
physiologic	O
setting	O
and	O
to	O
identify	O
the	O
signals	O
that	O
stimulate	O
factor	O
activity	O
.	O
All	O
factors	O
are	O
induced	O
in	O
the	O
nuclei	O
of	O
T	O
cells	O
upon	O
activation	O
with	O
mitogens	B
but	O
not	O
with	O
exogenous	B
IL-2	I
growth	I
factor	I
.	O
However	O
,	O
the	O
signaling	O
requirements	O
and	O
sensitivity	O
to	O
protein	O
synthesis	O
inhibitors	O
differ	O
considerably	O
.	O
Only	O
the	O
activities	O
for	O
NF	O
-	O
AT	O
and	O
AP-1	O
sites	O
require	O
two	O
signals	O
for	O
optimal	O
induction	O
,	O
i.e.	O
,	O
PMA	O
plus	O
either	O
lectin	B
or	O
antibody	B
to	O
the	O
CD3	B
or	O
CD28	B
surface	I
molecules	I
.	O
Other	O
factors	O
are	O
induced	O
by	O
lectin	B
,	O
antibody	B
,	O
and/or	O
PMA	O
alone	O
.	O
After	O
appropriate	O
stimulation	O
,	O
both	O
NF	B
-	I
AT	I
and	O
AP-1	B
are	O
peculiarly	O
sensitive	O
to	O
the	O
protein	O
synthesis	O
inhibitor	O
anisomycin	O
.	O
Our	O
data	O
correlate	O
the	O
activity	O
of	O
NF	B
-	I
AT	I
and	O
AP-1	B
in	O
gel	O
shift	O
assays	O
with	O
the	O
two	O
signals	O
requirements	O
for	O
IL-2	O
gene	O
expression	O
.	O
An	O
erythroid	O
specific	O
enhancer	O
upstream	O
to	O
the	O
gene	O
encoding	O
the	O
cell	B
-	I
type	I
specific	I
transcription	I
factor	I
GATA-1	B
.	O
The	O
transcription	B
factor	I
GATA-1	B
is	O
expressed	O
in	O
a	O
subset	O
of	O
hemopoietic	O
cells	O
,	O
where	O
it	O
mediates	O
the	O
cell	O
-	O
type	O
specific	O
expression	O
of	O
several	O
genes	O
.	O
We	O
have	O
cloned	O
the	O
mouse	O
and	O
human	O
GATA-1	O
genes	O
.	O
A	O
region	O
upstream	O
to	O
the	O
first	O
exon	O
,	O
and	O
highly	O
conserved	O
between	O
mouse	O
and	O
man	O
,	O
acts	O
as	O
an	O
erythroid	O
specific	O
enhancer	O
in	O
transient	O
assays	O
,	O
if	O
linked	O
to	O
the	O
GATA-1	B
or	O
to	O
the	O
SV40	O
promoter	O
.	O
The	O
activity	O
of	O
the	O
enhancer	O
is	O
almost	O
completely	O
dependent	O
on	O
the	O
integrity	O
of	O
a	O
dimeric	O
GATA-1	O
binding	O
site	O
.	O
Demonstration	O
of	O
a	O
1	B
,	I
25-dihydroxyvitamin	I
D3-responsive	I
protein	I
in	O
human	O
lymphocytes	O
:	O
immunologic	O
crossreactivity	O
and	O
inverse	O
regulation	O
with	O
the	O
vitamin	B
D	I
receptor	I
.	O
Using	O
Western	O
blot	O
analysis	O
with	O
a	O
monoclonal	B
antibody	I
recognizing	O
a	O
17-amino	B
acid	I
epitope	I
of	O
the	O
1	B
,	I
25-dihydroxyvitamin	I
D3	I
[	I
1	I
,	I
25	I
(	I
OH	I
)	I
2D3	I
]	I
receptor	I
,	O
we	O
have	O
detected	O
two	O
crossreacting	B
proteins	I
in	O
activated	O
normal	O
human	O
lymphocytes	O
.	O
The	O
smaller	O
of	O
the	O
two	O
proteins	O
(	O
50	B
kDa	I
)	O
was	O
indistinguishable	O
from	O
the	O
classical	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptor	I
and	O
,	O
similar	O
to	O
the	O
classical	O
1	B
,	I
25	I
(	I
OH	I
)	I
2D3	I
receptor	I
,	O
was	O
upregulated	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O
The	O
larger	O
crossreacting	O
protein	O
exhibited	O
an	O
electrophoretic	O
mobility	O
of	O
80	O
kDa	O
,	O
was	O
localized	O
in	O
the	O
cell	O
cytosol	O
,	O
and	O
appeared	O
to	O
be	O
specific	O
for	O
activated	O
lymphocytes	O
since	O
it	O
was	O
not	O
detected	O
in	O
several	O
other	O
human	O
cells	O
including	O
monocytes	O
.	O
More	O
strikingly	O
,	O
the	O
80-kDa	B
protein	I
was	O
downregulated	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
;	O
this	O
effect	O
was	O
independent	O
of	O
the	O
mode	O
of	O
lymphocyte	O
activation	O
and	O
specific	O
for	O
the	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
metabolite	O
of	O
vitamin	O
D3	O
.	O
However	O
,	O
two	O
potent	O
immunosuppressive	O
agents	O
,	O
glucocorticoids	O
and	O
cyclosporin	O
A	O
,	O
also	O
inhibited	O
the	O
80-kDa	B
protein	I
.	O
T	B
-	I
helper	I
-	I
cell	I
determinants	I
in	O
protein	B
antigens	I
are	O
preferentially	O
located	O
in	O
cysteine	B
-	I
rich	I
antigen	I
segments	I
resistant	O
to	O
proteolytic	O
cleavage	O
by	O
cathepsin	B
B	I
,	I
L	I
,	I
and	I
D	I
.	O
We	O
report	O
on	O
a	O
computer	O
algorithm	O
capable	O
of	O
predicting	O
the	O
location	O
of	O
T	B
-	I
helper	I
-	I
cell	I
epitopes	I
in	O
protein	B
antigen	I
(	O
Ag	B
)	O
by	O
analysing	O
the	O
Ag	B
amino	B
acid	I
sequence	I
.	O
The	O
algorithm	O
was	O
constructed	O
with	O
the	O
aim	O
of	O
identifying	O
segments	O
in	O
Ag	B
which	O
are	O
resistant	O
to	O
proteolytic	O
degradation	O
by	O
the	O
enzymes	O
cathepsin	B
B	I
,	I
L	I
,	I
and	I
D	I
.	O
These	O
are	O
prominent	O
enzymes	B
in	O
the	O
endocytic	O
pathway	O
through	O
which	O
soluble	B
protein	I
Ag	I
enter	O
APC	B
,	O
and	O
resistant	B
segments	I
in	O
Ag	B
may	O
,	O
therefore	O
,	O
be	O
expected	O
to	O
contain	O
more	O
T	B
-	I
cell	I
determinants	I
than	O
susceptible	B
segments	I
.	O
From	O
information	O
available	O
in	O
the	O
literature	O
on	O
the	O
substrate	O
specificity	O
of	O
the	O
three	O
enzymes	B
,	O
it	O
is	O
clear	O
that	O
a	O
cysteine	O
is	O
not	O
accepted	O
in	O
any	O
of	O
the	O
S2	B
,	I
S1	I
,	I
S1	I
'	I
,	I
and	I
S2	I
'	I
subsites	I
of	O
cathepsin	B
B	I
and	I
L	I
,	O
and	O
not	O
in	O
the	O
S1	B
and	O
S1	B
'	I
subsites	O
of	O
cathepsin	B
D	I
.	O
Moreover	O
,	O
we	O
have	O
noticed	O
that	O
cysteine	B
-	I
containing	I
T	I
-	I
cell	I
determinants	I
in	O
a	O
number	O
of	O
protein	B
Ag	I
are	O
particularly	O
rich	O
in	O
the	O
amino	O
acids	O
alanine	O
,	O
glycine	O
,	O
lysine	O
,	O
leucine	O
,	O
serine	O
,	O
threonine	O
,	O
and	O
valine	O
.	O
By	O
searching	O
protein	O
Ag	B
for	O
clusters	O
of	O
amino	O
acids	O
containing	O
cysteine	O
and	O
two	O
of	O
the	O
other	O
amino	O
acids	O
we	O
were	O
able	O
to	O
predict	O
17	O
out	O
of	O
23	O
empirically	O
known	O
T	B
-	I
cell	I
determinants	I
in	O
the	O
Ag	B
with	O
a	O
relatively	O
low	O
number	O
of	O
false	O
(	O
positive	O
)	O
predictions	O
.	O
Furthermore	O
,	O
we	O
present	O
a	O
new	O
principle	O
for	O
searching	O
Ag	B
for	O
potential	O
amphipatic	B
alpha	I
-	I
helical	I
protein	I
segments	I
.	O
Such	O
segments	O
accord	O
well	O
with	O
empirically	O
known	O
T	B
-	I
cell	I
determinants	I
and	O
our	O
algorithm	O
produces	O
a	O
lower	O
number	O
of	O
false	O
positive	O
predictions	O
than	O
the	O
principle	O
based	O
on	O
discrete	O
Fourier	O
transformations	O
previously	O
described	O
.	O
v	B
-	I
erbA	I
overexpression	O
is	O
required	O
to	O
extinguish	O
c	B
-	I
erbA	I
function	O
in	O
erythroid	O
cell	O
differentiation	O
and	O
regulation	O
of	O
the	O
erbA	O
target	O
gene	O
CAII	O
.	O
The	O
v	B
-	I
erbA	I
oncoprotein	I
represents	O
a	O
retrovirus	O
-	O
transduced	O
oncogenic	O
version	O
of	O
the	O
thyroid	B
hormone	I
(	I
T3	I
/	I
T4	I
)	I
receptor	I
c	B
-	I
erbA	I
(	I
type	I
alpha	I
)	I
.	O
It	O
contributes	O
to	O
virus	O
-	O
induced	O
erythroleukemia	O
by	O
efficiently	O
arresting	O
differentiation	O
of	O
red	O
cell	O
progenitors	O
and	O
by	O
suppressing	O
transcription	O
of	O
erythrocyte	O
-	O
specific	O
genes	O
.	O
Here	O
,	O
we	O
show	O
that	O
v	B
-	I
erbA	I
and	O
c	B
-	I
erbA	I
bind	O
directly	O
to	O
sequences	O
within	O
the	O
promoter	O
of	O
the	O
erythrocyte	B
-	I
specific	I
carbonic	I
anhydrase	I
II	I
(	O
CAII	O
)	O
,	O
a	O
gene	O
whose	O
transcription	O
is	O
efficiently	O
suppressed	O
by	O
v	B
-	I
erbA	I
.	O
This	O
erbA	O
-	O
binding	O
site	O
confers	O
thyroid	O
hormone	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
in	O
transient	O
expression	O
experiments	O
and	O
is	O
a	O
target	O
for	O
efficient	O
down	O
-	O
regulation	O
of	O
CAII	O
transcription	O
by	O
the	O
v	B
-	I
erbA	I
oncoprotein	I
.	O
In	O
stably	O
transformed	O
erythroblasts	O
coexpressing	O
the	O
v	B
-	I
erbA	I
oncoprotein	I
and	O
the	O
c	B
-	I
erbA	I
/	I
T3	I
receptor	I
at	O
an	O
approximately	O
equimolar	O
ratio	O
,	O
c	B
-	I
erbA	I
activity	O
is	O
dominant	O
over	O
v	B
-	I
erbA	I
.	O
T3	O
efficiently	O
induced	O
erythroid	O
differentiation	O
in	O
these	O
cells	O
,	O
thus	O
overcoming	O
the	O
v	B
-	I
erbA	I
-mediated	O
differentiation	O
arrest	O
.	O
Likewise	O
,	O
T3	O
activated	O
CAII	O
transcription	O
as	O
well	O
as	O
transient	O
expression	O
of	O
a	O
T3-responsive	O
reporter	O
gene	O
containing	O
the	O
CAII	O
-	O
specific	O
erbA	O
-	O
binding	O
site	O
.	O
The	O
c	B
-	I
erbA	I
-dependent	O
activation	O
of	O
this	O
CAII	O
reporter	O
construct	O
could	O
only	O
be	O
suppressed	O
by	O
very	O
high	O
amounts	O
of	O
v	B
-	I
erbA	I
.	O
Our	O
results	O
suggest	O
that	O
overexpression	O
of	O
v	B
-	I
erbA	I
is	O
required	O
for	O
its	O
function	O
as	O
an	O
oncoprotein	B
.	O
Charybdotoxin	O
-	O
sensitive	O
,	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
membrane	O
potential	O
changes	O
are	O
not	O
involved	O
in	O
human	O
T	O
or	O
B	O
cell	O
activation	O
and	O
proliferation	O
.	O
The	O
involvement	O
of	O
ion	O
channels	O
in	O
B	O
and	O
T	O
lymphocyte	O
activation	O
is	O
supported	O
by	O
many	O
reports	O
of	O
changes	O
in	O
ion	O
fluxes	O
and	O
membrane	O
potential	O
after	O
mitogen	B
binding	O
.	O
Human	O
T	O
and	O
B	O
lymphocytes	O
demonstrate	O
an	O
early	O
and	O
transient	O
hyperpolarization	O
after	O
ligand	O
binding	O
.	O
Inasmuch	O
as	O
the	O
change	O
in	O
membrane	O
potential	O
is	O
dependent	O
on	O
elevation	O
of	O
free	O
cytosolic	O
calcium	O
,	O
the	O
hyperpolarization	O
is	O
presumably	O
through	O
opening	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-stimulated	O
K+	O
channels	O
.	O
We	O
have	O
used	O
charybdotoxin	O
,	O
a	O
known	O
inhibitor	O
of	O
Ca	B
(	I
2	I
+	I
)	I
-dependent	I
K+	I
channels	I
,	O
to	O
study	O
the	O
role	O
of	O
these	O
channels	O
in	O
lymphocyte	O
activation	O
and	O
mitogenesis	O
.	O
We	O
demonstrate	O
that	O
charybdotoxin	O
inhibits	O
the	O
ligand	O
-	O
induced	O
transient	O
membrane	O
hyperpolarization	O
in	O
B	O
and	O
T	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
,	O
without	O
affecting	O
changes	O
in	O
cytosolic	O
Ca2	O
+	O
.	O
However	O
,	O
blockade	O
of	O
the	O
Ca	B
(	I
2	I
+	I
)	I
-activated	I
K+	I
channel	I
is	O
not	O
associated	O
with	O
changes	O
in	O
cell	O
-	O
cycle	O
gene	O
activation	O
,	O
IL-2	B
production	O
,	O
IL-2R	B
expression	O
or	O
B	O
and	O
T	O
cell	O
mitogenesis	O
.	O
These	O
results	O
imply	O
that	O
membrane	O
potential	O
changes	O
secondary	O
to	O
the	O
ligand	O
-	O
dependent	O
opening	O
of	O
Ca	B
(	I
2	I
+	I
)	I
-activated	I
K+	I
channels	I
are	O
not	O
involved	O
in	O
B	O
and	O
T	O
lymphocyte	O
activation	O
and	O
mitogenesis	O
.	O
Evaluation	O
of	O
the	O
role	O
of	O
ligand	O
and	O
thermal	O
activation	O
of	O
specific	O
DNA	O
binding	O
by	O
in	B
vitro	I
synthesized	I
human	I
glucocorticoid	I
receptor	I
.	O
We	O
have	O
used	O
a	O
DNA	O
-	O
binding	O
/	O
immunoprecipitation	O
assay	O
to	O
analyze	O
the	O
capacity	O
of	O
human	B
glucocorticoid	I
receptor	I
(	O
hGR	B
)	O
,	O
generated	O
in	O
rabbit	O
reticulocyte	O
lysates	O
,	O
to	O
bind	O
DNA	O
.	O
In	B
vitro	I
translated	I
hGR	I
was	O
indistinguishable	O
from	O
native	B
hGR	I
,	O
as	O
determined	O
by	O
migration	O
on	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gels	O
,	O
sedimentation	O
on	O
sucrose	O
density	O
gradients	O
,	O
and	O
reactivity	O
with	O
antipeptide	B
antibodies	I
generated	O
against	O
hGR	B
.	O
In	O
addition	O
,	O
cell	B
-	I
free	I
synthesized	I
hGR	I
was	O
capable	O
of	O
specific	O
binding	O
to	O
glucocorticoid	O
response	O
element	O
(	O
GRE	O
)	O
-containing	O
DNA	O
fragments	O
.	O
Using	O
this	O
assay	O
system	O
,	O
we	O
have	O
evaluated	O
the	O
contributions	O
of	O
ligand	O
binding	O
and	O
heat	O
activation	O
to	O
DNA	O
binding	O
by	O
these	O
glucocorticoid	B
receptors	I
.	O
In	B
vitro	I
translated	I
hGR	I
was	O
capable	O
of	O
selective	O
DNA	O
binding	O
even	O
in	O
the	O
absence	O
of	O
glucocorticoid	O
.	O
Treatment	O
with	O
dexamethasone	O
or	O
the	O
antiglucocorticoid	O
RU486	O
had	O
no	O
additional	O
effect	O
on	O
the	O
DNA	O
-	O
binding	O
capacity	O
when	O
receptor	O
preparations	O
were	O
maintained	O
at	O
0	O
C	O
(	O
no	O
activation	O
)	O
.	O
In	O
contrast	O
,	O
addition	O
of	O
either	O
ligand	O
or	O
antagonist	O
in	O
combination	O
with	O
a	O
heat	O
activation	O
step	O
promoted	O
DNA	O
binding	O
by	O
approximately	O
3-fold	O
over	O
that	O
of	O
heat	O
-	O
activated	O
unliganded	B
receptors	I
.	O
Agonist	O
(	O
dexamethasone	O
)	O
was	O
slightly	O
more	O
effective	O
in	O
supporting	O
specific	O
DNA	O
binding	O
than	O
antagonist	O
(	O
RU486	O
)	O
.	O
DNA	O
binding	O
by	O
in	B
vitro	I
synthesized	I
GR	I
was	O
blocked	O
by	O
the	O
addition	O
of	O
sodium	O
molybdate	O
to	O
the	O
receptor	O
preparations	O
before	O
steroid	O
addition	O
and	O
thermal	O
activation	O
.	O
Addition	O
of	O
KCl	O
resulted	O
in	O
less	O
DNA	O
binding	O
either	O
due	O
to	O
blockage	O
of	O
DNA-	O
receptor	B
complex	I
formation	O
or	O
disruption	O
of	O
the	O
complexes	O
.	O
The	O
specificity	O
of	O
DNA	O
binding	O
by	O
cell	B
-	I
free	I
synthesized	I
hGR	I
was	O
analyzed	O
further	O
by	O
examining	O
the	O
abilities	O
of	O
various	O
DNAs	O
to	O
compete	O
for	O
binding	O
to	O
a	O
naturally	O
occurring	O
GRE	O
found	O
in	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
-	O
long	O
terminal	O
repeat	O
.	O
Oligonucleotides	O
containing	O
the	O
consensus	O
GRE	O
were	O
the	O
most	O
efficient	O
competitors	O
,	O
and	O
fragments	O
containing	O
regulatory	O
sequences	O
from	O
glucocorticoid	O
-	O
repressible	O
genes	O
were	O
somewhat	O
competitive	O
,	O
whereas	O
single	O
stranded	O
oligonucleotides	O
were	O
unable	O
to	O
compete	O
for	O
mouse	O
mammary	O
tumor	O
virus	O
-	O
long	O
terminal	O
repeat	O
DNA	O
binding	O
,	O
except	O
when	O
competitor	O
was	O
present	O
at	O
extremely	O
high	O
concentrations	O
.	O
Together	O
these	O
studies	O
indicate	O
that	O
hGR	B
synthesized	O
in	O
rabbit	O
reticulocyte	O
lysates	O
displays	O
many	O
of	O
the	O
same	O
properties	O
,	O
including	O
GRE	O
-specific	O
DNA	O
binding	O
,	O
observed	O
for	O
glucocorticoid	B
receptor	I
present	O
in	O
cytosolic	O
extracts	O
of	O
mammalian	O
cells	O
and	O
tissues	O
.	O
Similarities	O
between	O
the	O
effects	O
of	O
dexamethasone	O
and	O
RU486	O
suggest	O
that	O
the	O
antiglucocorticoid	O
properties	O
of	O
RU486	O
do	O
not	O
occur	O
at	O
the	O
level	O
of	O
specific	O
DNA	O
binding	O
.	O
One	O
base	O
pair	O
change	O
abolishes	O
the	O
T	O
cell	O
-	O
restricted	O
activity	O
of	O
a	O
kB	O
-	O
like	O
proto	O
-	O
enhancer	O
element	O
from	O
the	O
interleukin	O
2	O
promoter	O
.	O
The	O
inducible	O
,	O
T	O
cell	O
-	O
specific	O
enhancers	O
of	O
murine	O
and	O
human	O
Interleukin	O
2	O
(	O
Il-2	O
)	O
genes	O
contain	O
the	O
kB	O
-	O
like	O
sequence	O
GGGATTTCACC	O
as	O
an	O
essential	O
cis	O
-	O
acting	O
enhancer	O
motif	O
.	O
When	O
cloned	O
in	O
multiple	O
copies	O
this	O
so	O
-	O
called	O
TCEd	O
(	O
distal	O
T	O
cell	O
element	O
)	O
acts	O
as	O
an	O
inducible	O
proto	O
-	O
enhancer	O
element	O
in	O
E14	O
T	O
lymphoma	O
cells	O
,	O
but	O
not	O
in	O
HeLa	O
cells	O
.	O
In	O
extracts	O
of	O
induced	O
,	O
Il-2	O
secreting	O
El4	O
cells	O
three	O
individual	O
protein	B
factors	I
bind	O
to	O
TCEd	O
DNA	O
.	O
The	O
binding	O
of	O
the	O
most	O
prominent	O
factor	O
,	O
named	O
TCF-1	B
(	O
T	B
cell	I
factor	I
1	I
)	O
,	O
is	O
correlated	O
with	O
the	O
proto	O
-	O
enhancer	O
activity	O
of	O
TCEd	O
.	O
TCF-1	B
consists	O
of	O
two	O
polypeptides	O
of	O
about	O
50	O
kD	O
and	O
105	O
kD	O
;	O
the	O
former	O
seems	O
to	O
be	O
related	O
to	O
the	O
50	B
kD	I
polypeptide	I
of	O
NF	B
-	I
kB	I
.	O
Purified	B
NF	I
-	I
kB	I
is	O
also	O
able	O
to	O
bind	O
to	O
the	O
TCEd	O
,	O
but	O
TCF-1	B
binds	O
stronger	O
than	O
NF	B
-	I
kB	I
to	O
TCEd	O
DNA	O
.	O
The	O
conversion	O
of	O
the	O
TCEd	O
to	O
a	O
'	O
perfect	O
'	O
NF	O
-	O
kB	O
binding	O
site	O
leads	O
to	O
a	O
tighter	O
binding	O
of	O
NF	B
-	I
kB	I
to	O
TCEd	O
DNA	O
and	O
,	O
as	O
a	O
functional	O
consequence	O
,	O
to	O
the	O
activity	O
of	O
the	O
'	O
converted	O
'	O
TCEd	O
motifs	O
in	O
HeLa	O
cells	O
.	O
Thus	O
,	O
the	O
substitution	O
of	O
the	O
underlined	O
A	O
residue	O
to	O
a	O
C	O
within	O
the	O
GGGATTTCACC	O
motif	O
abolishes	O
its	O
T	O
cell	O
-	O
restricted	O
activity	O
and	O
leads	O
to	O
its	O
functioning	O
in	O
both	O
El4	O
cells	O
and	O
HeLa	O
cells	O
.	O
These	O
results	O
indicate	O
that	O
lymphocyte	O
-	O
specific	O
factors	O
binding	O
to	O
the	O
TCEd	O
are	O
involved	O
in	O
the	O
control	O
of	O
T	O
cell	O
specific	O
-	O
transcription	O
of	O
the	O
Il-2	O
gene	O
.	O
Negative	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
in	O
monocytes	O
:	O
role	O
of	O
the	O
65-kDa	B
plus	O
50-kDa	B
NF	I
-	I
kappa	I
B	I
dimer	I
.	O
Although	O
monocytic	O
cells	O
can	O
provide	O
a	O
reservoir	O
for	O
viral	O
production	O
in	O
vivo	O
,	O
their	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
transcription	O
can	O
be	O
either	O
latent	O
,	O
restricted	O
,	O
or	O
productive	O
.	O
These	O
differences	O
in	O
gene	O
expression	O
have	O
not	O
been	O
molecularly	O
defined	O
.	O
In	O
THP-1	O
cells	O
with	O
restricted	O
HIV	O
expression	O
,	O
there	O
is	O
an	O
absence	O
of	O
DNA	B
-	I
protein	I
binding	I
complex	I
formation	O
with	O
the	O
HIV-1	O
promoter	O
-	O
enhancer	O
associated	O
with	O
markedly	O
less	O
viral	O
RNA	O
production	O
.	O
This	O
absence	O
of	O
binding	O
was	O
localized	O
to	O
the	O
NF	O
-	O
kappa	O
B	O
region	O
of	O
the	O
HIV-1	O
enhancer	O
;	O
the	O
65-kDa	B
plus	I
50-kDa	I
NF	I
-	I
kappa	I
B	I
heterodimer	I
was	O
preferentially	O
lost	O
.	O
Adding	O
purified	O
NF	B
-	I
kappa	I
B	I
protein	I
to	O
nuclear	O
extracts	O
from	O
cells	O
with	O
restricted	O
expression	O
overcomes	O
this	O
lack	O
of	O
binding	O
.	O
In	O
addition	O
,	O
treatment	O
of	O
these	O
nuclear	O
extracts	O
with	O
sodium	O
deoxycholate	O
restored	O
their	O
ability	O
to	O
form	O
the	O
heterodimer	B
,	O
suggesting	O
the	O
presence	O
of	O
an	O
inhibitor	O
of	O
NF	B
-	I
kappa	I
B	I
activity	O
.	O
Furthermore	O
,	O
treatment	O
of	O
nuclear	O
extracts	O
from	O
these	O
cells	O
that	O
had	O
restricted	O
expression	O
with	O
lipopolysaccharide	O
increased	O
viral	O
production	O
and	O
NF	B
-	I
kappa	I
B	I
activity	O
.	O
Antiserum	O
specific	O
for	O
NF	B
-	I
kappa	I
B	I
binding	I
proteins	I
,	O
but	O
not	O
c	O
-	O
rel	O
-	O
specific	O
antiserum	O
,	O
disrupted	O
heterodimer	B
complex	I
formation	O
.	O
Thus	O
,	O
both	O
NF	B
-	I
kappa	I
B	I
-	I
binding	I
complexes	I
are	O
needed	O
for	O
optimal	O
viral	O
transcription	O
.	O
Binding	O
of	O
the	O
65-kDa	B
plus	O
50-kDa	B
heterodimer	I
to	O
the	O
HIV-1	O
enhancer	O
can	O
be	O
negatively	O
regulated	O
in	O
monocytes	O
,	O
providing	O
one	O
mechanism	O
restricting	O
HIV-1	O
gene	O
expression	O
.	O
Isolation	O
of	O
a	O
candidate	O
repressor	O
/	O
activator	O
,	O
NF	B
-	I
E1	I
(	O
YY-1	B
,	O
delta	B
)	O
,	O
that	O
binds	O
to	O
the	O
immunoglobulin	O
kappa	O
3	O
'	O
enhancer	O
and	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
mu	O
E1	O
site	O
.	O
We	O
have	O
determined	O
that	O
the	O
developmental	O
control	O
of	O
immunoglobulin	O
kappa	O
3	O
'	O
enhancer	O
(	O
kappa	O
E3	O
'	O
)	O
activity	O
is	O
the	O
result	O
of	O
the	O
combined	O
influence	O
of	O
positive-	O
and	O
negative	O
-	O
acting	O
elements	O
.	O
We	O
show	O
that	O
a	O
central	O
core	O
in	O
the	O
kappa	O
E3	O
'	O
enhancer	O
is	O
active	O
at	O
the	O
pre	O
-	O
B	O
-	O
cell	O
stage	O
but	O
is	O
repressed	O
by	O
flanking	O
negative	O
-	O
acting	O
elements	O
.	O
The	O
negative	O
-	O
acting	O
sequences	O
repress	O
enhancer	O
activity	O
in	O
a	O
position-	O
and	O
orientation	O
-	O
independent	O
manner	O
at	O
the	O
pre	O
-	O
B	O
-	O
cell	O
stage	O
.	O
We	O
have	O
isolated	O
a	O
human	O
cDNA	O
clone	O
encoding	O
a	O
zinc	B
finger	I
protein	I
(	O
NF	B
-	I
E1	I
)	O
that	O
binds	O
to	O
the	O
negative	O
-	O
acting	O
segment	O
of	O
the	O
kappa	O
E3	O
'	O
enhancer	O
.	O
This	O
protein	O
also	O
binds	O
to	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
enhancer	O
mu	O
E1	O
site	O
.	O
NF	B
-	I
E1	I
is	O
encoded	O
by	O
the	O
same	O
gene	O
as	O
the	O
YY-1	B
protein	I
,	O
which	O
binds	O
to	O
the	O
adeno	O
-	O
associated	O
virus	O
P5	O
promoter	O
.	O
NF	B
-	I
E1	I
is	O
also	O
the	O
human	B
homologue	I
of	O
the	O
mouse	O
delta	O
protein	O
,	O
which	O
binds	O
to	O
ribosomal	O
protein	O
gene	O
promoters	O
.	O
The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
this	O
protein	O
contains	O
features	O
characteristic	O
of	O
transcriptional	B
activators	I
as	O
well	O
as	O
transcriptional	B
repressors	I
.	O
Cotransfection	O
studies	O
with	O
this	O
cDNA	O
indicate	O
that	O
it	O
can	O
repress	O
basal	O
promoter	O
activity	O
.	O
The	O
apparent	O
dual	O
function	O
of	O
this	O
protein	O
is	O
discussed	O
.	O
cAMP	O
-	O
dependent	O
regulation	O
of	O
proenkephalin	O
by	O
JunD	B
and	O
JunB	B
:	O
positive	O
and	O
negative	O
effects	O
of	O
AP-1	B
proteins	I
.	O
We	O
demonstrate	O
that	O
JunD	B
,	O
a	O
component	O
of	O
the	O
AP-1	B
transcription	I
factor	I
complex	I
,	O
activates	O
transcription	O
of	O
the	O
human	O
proenkephalin	O
gene	O
in	O
a	O
fashion	O
that	O
is	O
completely	O
dependent	O
upon	O
the	O
cAMP	B
-	I
dependent	I
protein	I
kinase	I
,	O
protein	B
kinase	I
A	I
.	O
Activation	O
of	O
proenkephalin	O
transcription	O
by	O
JunD	B
is	O
dependent	O
upon	O
a	O
previously	O
characterized	O
cAMP-	O
,	O
phorbol	O
ester-	O
,	O
and	O
Ca	O
(	O
2	O
+	O
)	O
-inducible	O
enhancer	O
,	O
and	O
JunD	B
is	O
shown	O
to	O
bind	O
the	O
enhancer	O
as	O
a	O
homodimer	B
.	O
Another	O
component	O
of	O
the	O
AP-1	B
transcription	I
complex	I
,	O
JunB	B
,	O
is	O
shown	O
to	O
inhibit	O
activation	O
mediated	O
by	O
JunD	B
.	O
As	O
a	O
homodimer	O
JunB	B
is	O
unable	O
to	O
bind	O
the	O
enhancer	O
;	O
however	O
in	O
the	O
presence	O
of	O
c	B
-	I
Fos	I
,	O
high	O
-	O
affinity	O
binding	O
is	O
observed	O
.	O
Furthermore	O
,	O
JunD	B
is	O
shown	O
to	O
activate	O
transcription	O
of	O
genes	O
linked	O
to	O
both	O
cAMP	O
and	O
phorbol	O
ester	O
response	O
elements	O
in	O
a	O
protein	B
kinase	I
A	I
-dependent	O
fashion	O
,	O
further	O
blurring	O
the	O
distinction	O
between	O
these	O
response	O
elements	O
.	O
These	O
results	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
an	O
AP-1-related	B
protein	I
is	O
regulated	O
by	O
the	O
cAMP	O
-	O
dependent	O
second	O
-	O
messenger	O
pathway	O
and	O
suggest	O
that	O
JunD	B
and	O
other	O
AP-1-related	B
proteins	I
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
by	O
cAMP	O
-	O
dependent	O
intracellular	O
signaling	O
pathways	O
.	O
Glucocorticoid	O
resistance	O
in	O
chronic	O
asthma	O
.	O
Glucocorticoid	O
pharmacokinetics	O
,	O
glucocorticoid	B
receptor	I
characteristics	O
,	O
and	O
inhibition	O
of	O
peripheral	O
blood	O
T	O
cell	O
proliferation	O
by	O
glucocorticoids	O
in	O
vitro	O
.	O
A	O
total	O
of	O
37	O
chronic	O
,	O
severe	O
,	O
nonsmoking	O
asthmatic	O
patients	O
with	O
documented	O
reversible	O
airways	O
obstruction	O
were	O
classified	O
as	O
glucocorticoid	O
-	O
sensitive	O
or	O
-resistant	O
on	O
the	O
basis	O
of	O
changes	O
in	O
FEV1	O
,	O
FVC	O
,	O
and	O
peak	O
expiratory	O
flow	O
(	O
PEF	O
)	O
after	O
oral	O
prednisolone	O
.	O
The	O
resistant	O
patients	O
showed	O
no	O
significant	O
improvements	O
in	O
airflow	O
limitation	O
.	O
Phytohemagglutinin	B
(	O
PHA	B
)	O
-induced	O
proliferation	O
of	O
peripheral	O
blood	O
T	O
lymphocytes	O
from	O
the	O
sensitive	O
but	O
not	O
the	O
resistant	O
asthmatic	O
patients	O
was	O
significantly	O
(	O
p	O
less	O
than	O
0.01	O
)	O
inhibited	O
by	O
dexamethasone	O
(	O
10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
)	O
,	O
reflecting	O
a	O
shift	O
of	O
the	O
dose	O
-	O
response	O
curve	O
.	O
When	O
all	O
the	O
asthmatic	O
patients	O
were	O
analyzed	O
together	O
,	O
there	O
was	O
a	O
significant	O
correlation	O
between	O
the	O
degree	O
of	O
sensitivity	O
of	O
T	O
cells	O
to	O
dexamethasone	O
and	O
the	O
clinical	O
responsiveness	O
to	O
prednisolone	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O
No	O
differences	O
were	O
observed	O
between	O
six	O
of	O
the	O
sensitive	O
and	O
resistant	O
patients	O
in	O
the	O
clearance	O
of	O
plasma	O
prednisolone	O
derived	O
from	O
orally	O
administered	O
prednisone	O
.	O
Peripheral	B
blood	I
mononuclear	I
cell	I
glucocorticoid	I
receptors	I
were	O
also	O
characterized	O
in	O
five	O
sensitive	O
and	O
seven	O
resistant	O
patients	O
.	O
The	O
numbers	O
and	O
binding	O
affinities	O
of	O
these	O
receptors	B
could	O
not	O
account	O
for	O
the	O
observed	O
difference	O
in	O
the	O
susceptibility	O
of	O
these	O
cells	O
to	O
functional	O
inhibition	O
by	O
dexamethasone	O
in	O
vitro	O
.	O
These	O
results	O
suggest	O
that	O
clinical	O
glucocorticoid	O
resistance	O
in	O
chronic	O
asthma	O
does	O
not	O
reflect	O
abnormal	O
glucocorticoid	O
clearance	O
but	O
may	O
be	O
due	O
at	O
least	O
partly	O
to	O
a	O
relative	O
insensitivity	O
of	O
T	O
lymphocytes	O
to	O
glucocorticoids	O
.	O
This	O
lack	O
of	O
sensitivity	O
is	O
unexplained	O
but	O
is	O
not	O
attributable	O
to	O
abnormalities	O
of	O
cellular	B
glucocorticoid	I
receptors	I
.	O
Identification	O
of	O
transcriptional	B
suppressor	I
proteins	I
that	O
bind	O
to	O
the	O
negative	O
regulatory	O
element	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O
Two	O
different	O
proteins	O
which	O
independently	O
bound	O
to	O
neighboring	O
sequences	O
within	O
the	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
were	O
detected	O
in	O
the	O
nuclear	O
extract	O
of	O
a	O
virus	O
-	O
infected	O
human	O
T	O
cell	O
line	O
.	O
One	O
of	O
the	O
factors	O
bound	O
to	O
a	O
novel	O
dyad	O
symmetrical	O
sequence	O
.	O
This	O
sequence	O
is	O
well	O
conserved	O
in	O
various	O
HIV-1	O
isolates	O
and	O
partial	O
homology	O
was	O
found	O
with	O
the	O
promoter	O
region	O
of	O
the	O
human	O
retinoblastoma	O
gene	O
.	O
Similar	O
DNA	O
binding	O
activity	O
was	O
detected	O
in	O
a	O
variety	O
of	O
virus	O
-	O
uninfected	O
human	O
T	O
cell	O
lines	O
and	O
HeLa	O
cells	O
by	O
means	O
of	O
a	O
gel	O
mobility	O
shift	O
assay	O
.	O
The	O
other	O
factor	O
bound	O
to	O
a	O
putative	O
AP-1	O
recognition	O
sequence	O
predicted	O
for	O
the	O
HIV-1	O
NRE	O
.	O
However	O
,	O
this	O
factor	O
did	O
not	O
bind	O
to	O
a	O
typical	O
AP-1	O
site	O
.	O
The	O
insertion	O
of	O
multiple	O
copies	O
of	O
the	O
binding	O
site	O
for	O
the	O
former	O
or	O
latter	O
factor	O
into	O
a	O
heterologous	O
promoter	O
reduced	O
the	O
promoter	O
activity	O
to	O
one	O
-	O
tenth	O
or	O
one	O
-	O
third	O
,	O
respectively	O
.	O
Thus	O
,	O
each	O
factor	O
may	O
function	O
as	O
a	O
novel	B
negative	I
regulator	I
of	O
transcription	O
.	O
Constitutive	O
activation	O
of	O
NF	B
-	I
kB	I
in	O
human	O
thymocytes	O
.	O
NF	B
-	I
kB	I
is	O
a	O
eukaryotic	B
transcription	I
regulatory	I
factor	I
.	O
In	O
T	O
cells	O
and	O
T	O
cell	O
lines	O
,	O
NF	B
-	I
kB	I
is	O
bound	O
to	O
a	O
cytoplasmic	B
proteic	I
inhibitor	I
,	O
the	O
IkB	B
.	O
Treatment	O
of	O
T	O
cells	O
with	O
mitogens	O
(	O
phorbol	O
esters	O
)	O
or	O
cytokines	B
(	O
TNF	B
alpha	I
)	O
induces	O
NF	B
-	I
kB	I
nuclear	O
translocation	O
and	O
the	O
subsequent	O
expression	O
of	O
NF	O
-	O
kB	O
dependent	O
T	O
cell	O
genes	O
.	O
Here	O
we	O
examined	O
the	O
activation	O
of	O
NF	B
-	I
kB	I
in	O
human	O
T	O
cell	O
thymic	O
progenitors	O
.	O
We	O
report	O
differences	O
in	O
(	O
Ca2	O
+	O
)	O
i	O
requirement	O
for	O
NF	B
-	I
kB	I
activation	O
in	O
thymocytes	O
as	O
compared	O
to	O
mature	O
T	O
cells	O
.	O
Furthermore	O
,	O
our	O
results	O
indicated	O
that	O
thymocytes	O
have	O
a	O
constitutively	B
active	I
form	I
of	O
NF	B
-	I
kB	I
,	O
suggesting	O
that	O
they	O
are	O
activated	O
in	O
vivo	O
.	O
TCF-1	B
,	O
a	O
T	B
cell	I
-	I
specific	I
transcription	I
factor	I
of	O
the	O
HMG	B
box	I
family	I
,	O
interacts	O
with	O
sequence	O
motifs	O
in	O
the	O
TCR	O
beta	O
and	O
TCR	O
delta	O
enhancers	O
.	O
We	O
have	O
recently	O
identified	O
and	O
cloned	O
TCF-1	B
,	O
a	O
T	B
cell	I
-	I
specific	I
transcription	I
factor	I
with	O
specificity	O
for	O
the	O
AACAAAG	O
motif	O
in	O
the	O
CD3	O
epsilon	O
enhancer	O
and	O
for	O
the	O
TTCAAAG	O
motif	O
in	O
the	O
TCR	O
alpha	O
enhancer	O
.	O
TCF-1	B
belongs	O
to	O
the	O
family	O
of	O
transcription	B
-	I
regulating	I
proteins	I
which	O
share	O
a	O
region	O
of	O
homology	O
termed	O
the	O
HMG	B
-	I
box	I
.	O
Here	O
,	O
we	O
show	O
by	O
gel	O
retardation	O
analysis	O
that	O
TCF-1	B
specifically	O
recognizes	O
the	O
T	O
beta	O
5	O
element	O
of	O
the	O
TCR	O
beta	O
enhancer	O
and	O
the	O
T	O
delta	O
7	O
element	O
of	O
the	O
TCR	O
delta	O
enhancer	O
.	O
Comparison	O
of	O
the	O
sequences	O
of	O
all	O
elements	O
recognized	O
by	O
TCF-1	B
defines	O
a	O
consensus	O
motif	O
A	O
/	O
T	O
A	O
/	O
T	O
C	O
A	O
A	O
/	O
G	O
A	O
G	O
.	O
These	O
observations	O
imply	O
that	O
TCF-1	B
is	O
involved	O
in	O
the	O
control	O
of	O
several	O
T	O
cell	O
-	O
specific	O
genes	O
and	O
might	O
thus	O
play	O
an	O
important	O
role	O
in	O
the	O
establishment	O
and	O
maintenance	O
of	O
the	O
mature	O
T	O
cell	O
phenotype	O
.	O
The	O
cellular	O
oncogene	O
c	O
-	O
myb	O
can	O
interact	O
synergistically	O
with	O
the	O
Epstein	B
-	I
Barr	I
virus	I
BZLF1	I
transactivator	I
in	O
lymphoid	O
cells	O
.	O
Regulation	O
of	O
replicative	O
functions	O
in	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
genome	O
is	O
mediated	O
through	O
activation	O
of	O
a	O
virally	B
encoded	I
transcription	I
factor	I
,	O
Z	B
(	O
BZLF1	B
)	O
.	O
We	O
have	O
shown	O
that	O
the	O
Z	B
gene	I
product	I
,	O
which	O
binds	O
to	O
AP-1	O
sites	O
as	O
a	O
homodimer	O
and	O
has	O
sequence	O
similarity	O
to	O
c	O
-	O
Fos	O
,	O
can	O
efficiently	O
activate	O
the	O
EBV	O
early	O
promoter	O
,	O
BMRF1	O
,	O
in	O
certain	O
cell	O
types	O
(	O
i.e.	O
,	O
HeLa	O
cells	O
)	O
but	O
not	O
others	O
(	O
i.e.	O
,	O
Jurkat	O
cells	O
)	O
.	O
Here	O
we	O
demonstrate	O
that	O
the	O
c	B
-	I
myb	I
proto	I
-	I
oncogene	I
product	I
,	O
which	O
is	O
itself	O
a	O
DNA	B
-	I
binding	I
protein	I
and	O
transcriptional	B
transactivator	I
,	O
can	O
interact	O
synergistically	O
with	O
Z	B
in	O
activating	O
the	O
BMRF1	O
promoter	O
in	O
Jurkat	O
cells	O
(	O
a	O
T	O
-	O
cell	O
line	O
)	O
or	O
Raji	O
cells	O
(	O
an	O
EBV	O
-	O
positive	O
B	O
-	O
cell	O
)	O
,	O
whereas	O
the	O
c	B
-	I
myb	I
gene	I
product	I
by	O
itself	O
has	O
little	O
effect	O
.	O
The	O
simian	O
virus	O
40	O
early	O
promoter	O
is	O
also	O
synergistically	O
activated	O
by	O
the	O
Z	B
/	I
c	I
-	I
myb	I
combination	I
.	O
Synergistic	O
transactivation	O
of	O
the	O
BMRF1	O
promoter	O
by	O
the	O
Z	B
/	I
c	I
-	I
myb	I
combination	I
appears	O
to	O
involve	O
direct	O
binding	O
by	O
the	O
Z	B
protein	I
but	O
not	O
the	O
c	B
-	I
myb	I
protein	I
.	O
A	O
30-bp	O
sequence	O
in	O
the	O
BMRF1	O
promoter	O
which	O
contains	O
a	O
Z	O
binding	O
site	O
(	O
a	O
consensus	O
AP-1	O
site	O
)	O
is	O
sufficient	O
to	O
transfer	O
high	O
-	O
level	O
lymphoid	O
-	O
specific	O
responsiveness	O
to	O
the	O
Z	B
/	I
c	I
-	I
myb	I
combination	I
to	O
a	O
heterologous	O
promoter	O
.	O
That	O
the	O
c	B
-	I
myb	I
oncogene	I
product	I
can	O
interact	O
synergistically	O
with	O
an	O
EBV	B
-	I
encoded	I
member	I
of	O
the	O
leucine	B
zipper	I
protein	I
family	I
suggests	O
c	O
-	O
myb	O
is	O
likely	O
to	O
engage	O
in	O
similar	O
interactions	O
with	O
cellularly	B
encoded	I
transcription	I
factors	I
.	O
[	O
Endocrine	O
status	O
changes	O
in	O
children	O
with	O
bronchial	O
asthma	O
]	O
A	O
study	O
was	O
made	O
of	O
adrenocortical	O
function	O
by	O
measuring	O
blood	O
plasma	O
cortisol	O
concentration	O
and	O
amount	O
of	O
glucocorticoid	B
receptors	I
in	O
lymphocytes	O
as	O
well	O
as	O
thyroid	O
function	O
by	O
measuring	O
blood	O
plasma	O
triidothyronine	O
and	O
thyroxine	O
concentration	O
in	O
58	O
bronchial	O
asthma	O
children	O
aged	O
1	O
to	O
14	O
years	O
.	O
The	O
authors	O
revealed	O
alterations	O
in	O
the	O
functional	O
activity	O
of	O
the	O
indicated	O
endocrine	O
glands	O
depending	O
on	O
the	O
intensity	O
of	O
bronchial	O
patency	O
disorders	O
and	O
the	O
nature	O
of	O
the	O
therapeutic	O
measures	O
carried	O
out	O
.	O
High	O
affinity	O
aldosterone	O
binding	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
from	O
mononuclear	O
leukocytes	O
:	O
is	O
there	O
a	O
membrane	B
receptor	I
for	O
mineralocorticoids	O
?	O
In	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
the	O
intracellular	O
concentrations	O
of	O
sodium	O
,	O
potassium	O
and	O
calcium	O
,	O
cell	O
volume	O
and	O
the	O
sodium	B
-	I
proton	I
-	I
antiport	I
have	O
been	O
described	O
in	O
intact	O
human	O
mononuclear	O
leukocytes	O
(	O
HML	O
)	O
.	O
In	O
the	O
present	O
paper	O
,	O
the	O
binding	O
of	O
a	O
[	O
125I	O
]	O
-labeled	O
aldosterone	O
derivative	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
of	O
HML	O
was	O
studied	O
.	O
High	O
affinity	O
binding	O
of	O
the	O
radioligand	O
with	O
an	O
apparent	O
Kd	O
of	O
approximately	O
0.1	O
nM	O
was	O
found	O
.	O
Aldosterone	O
displaced	O
the	O
tracer	O
at	O
a	O
similar	O
Kd	O
.	O
Both	O
canrenone	O
and	O
cortisol	O
were	O
inactive	O
as	O
ligands	O
up	O
to	O
concentrations	O
of	O
0.1	O
microM	O
.	O
The	O
findings	O
are	O
the	O
first	O
to	O
demonstrate	O
membrane	O
binding	O
sites	O
with	O
a	O
high	O
affinity	O
for	O
aldosterone	O
,	O
but	O
not	O
for	O
cortisol	O
.	O
These	O
data	O
are	O
perfectly	O
compatible	O
with	O
major	O
properties	O
of	O
steroidal	O
effects	O
on	O
the	O
sodium	B
-	I
proton	I
-	I
antiport	I
in	O
HML	O
and	O
thus	O
very	O
likely	O
represent	O
membrane	B
receptors	I
for	O
aldosterone	O
.	O
Transcription	B
factor	I
requirements	O
for	O
U2	O
snRNA	O
-encoding	O
gene	O
activation	O
in	O
B	O
lymphoid	O
cells	O
.	O
Transcription	O
of	O
a	O
human	O
U2	O
small	O
nuclear	O
RNA	O
(	O
snRNA	O
)	O
-encoding	O
gene	O
in	O
HeLa	O
cells	O
requires	O
a	O
distal	O
enhancer	O
element	O
,	O
which	O
is	O
composed	O
of	O
one	O
octamer	O
motif	O
(	O
Oct	O
)	O
and	O
three	O
Sp	O
1-binding	O
sites	O
.	O
To	O
study	O
the	O
transcription	B
factor	I
requirement	O
in	O
B	O
-	O
cells	O
,	O
different	O
U2	O
enhancer	O
constructions	O
were	O
transfected	O
into	O
the	O
lymphoid	O
cell	O
line	O
,	O
BJA	O
-	O
B	O
.	O
The	O
results	O
showed	O
that	O
the	O
activation	O
of	O
U2	O
snRNA	O
transcription	O
in	O
B	O
-	O
cells	O
also	O
requires	O
an	O
enhancer	O
comprising	O
both	O
the	O
Oct	O
and	O
at	O
least	O
one	O
Sp	O
1-binding	O
site	O
.	O
Deletion	O
of	O
all	O
the	O
Sp	O
1-binding	O
sites	O
from	O
the	O
enhancer	O
reduces	O
transcription	O
by	O
80	O
-	O
90	O
%	O
in	O
HeLa	O
,	O
as	O
well	O
as	O
in	O
BJA	O
-	O
B	O
cells	O
,	O
whereas	O
the	O
removal	O
of	O
the	O
octamer	O
-	O
binding	O
site	O
reduces	O
transcription	O
to	O
levels	O
below	O
detection	O
in	O
both	O
cell	O
types	O
.	O
Enhancers	O
containing	O
a	O
single	O
Oct	O
have	O
,	O
nevertheless	O
,	O
the	O
capacity	O
to	O
partially	O
activate	O
U2	O
snRNA	O
transcription	O
in	O
both	O
HeLa	O
cells	O
,	O
in	O
which	O
only	O
OTF-1	O
is	O
expressed	O
,	O
and	O
in	O
BJA	O
-	O
B	O
cells	O
in	O
which	O
OTF-2	B
is	O
the	O
predominantly	O
expressed	O
octamer	B
-	I
binding	I
factor	I
.	O
The	O
most	O
likely	O
interpretation	O
of	O
our	O
results	O
is	O
that	O
both	O
the	O
ubiquitous	O
transcription	B
factor	I
,	O
OTF-1	B
,	O
and	O
the	O
B	B
-	I
cell	I
-	I
specific	I
transcription	I
factor	I
,	O
OTF-2	B
,	O
can	O
activate	O
U2	O
snRNA	O
transcription	O
.	O
The	O
results	O
also	O
revealed	O
a	O
similar	O
functional	O
cooperation	O
between	O
the	O
transcription	O
factors	O
which	O
bind	O
to	O
the	O
Oct	O
and	O
the	O
adjacent	O
Sp	O
1-binding	O
site	O
in	O
BJA	O
-	O
B	O
cells	O
,	O
as	O
has	O
been	O
observed	O
in	O
HeLa	O
cells	O
,	O
since	O
a	O
template	O
which	O
contains	O
a	O
weak	O
binding	O
site	O
for	O
OTFs	O
expresses	O
wild	O
-	O
type	O
levels	O
of	O
U2	O
snRNA	O
in	O
both	O
cell	O
types	O
when	O
the	O
weak	O
octamer	O
-	O
binding	O
site	O
is	O
combined	O
with	O
a	O
Sp	O
1-binding	O
site	O
.	O
Kappa	B
B	I
-	I
specific	I
DNA	I
binding	I
proteins	I
are	O
differentially	O
inhibited	O
by	O
enhancer	O
mutations	O
and	O
biological	O
oxidation	O
.	O
Kappa	B
B	I
(	I
kappa	I
B	I
)	I
enhancer	I
binding	I
proteins	I
isolated	O
from	O
the	O
nuclei	O
of	O
activated	O
human	O
T	O
cells	O
produce	O
two	O
distinct	O
nucleoprotein	B
complexes	I
when	O
incubated	O
with	O
the	O
kappa	O
B	O
element	O
from	O
the	O
interleukin-2	O
receptor	O
-	O
alpha	O
(	O
IL-2R	O
alpha	O
)	O
gene	O
.	O
These	O
two	O
DNA	B
-	I
protein	I
complexes	I
are	O
composed	O
of	O
at	O
least	O
four	O
host	O
proteins	O
(	O
p50	B
,	O
p55	B
,	O
p75	B
,	O
p85	B
)	O
,	O
each	O
of	O
which	O
shares	O
structural	O
similarity	O
with	O
the	O
v	B
-	I
rel	I
oncogene	I
product	I
.	O
Nuclear	O
expression	O
of	O
these	O
proteins	O
is	O
induced	O
with	O
distinctly	O
biphasic	O
kinetics	O
following	O
phorbol	O
ester	O
activation	O
of	O
T	O
cells	O
(	O
p55	B
/	I
p75	I
early	I
and	O
p50	B
/	I
p85	I
late	I
)	O
.	O
DNA	O
-	O
protein	O
crosslinking	O
studies	O
have	O
revealed	O
that	O
the	O
more	O
rapidly	O
migrating	O
B2	B
complex	I
contains	O
both	O
p50	B
and	O
p55	B
while	O
the	O
more	O
slowly	O
migrating	O
B1	B
complex	I
is	O
composed	O
of	O
p50	B
,	O
p55	B
,	O
p75	B
,	O
and	O
p85	B
.	O
Site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
wild	O
-	O
type	O
IL-2R	O
alpha	O
kappa	O
B	O
enhancer	O
(	O
GGGGAATCTCCC	O
)	O
has	O
revealed	O
that	O
the	O
binding	O
of	O
p50	O
and	O
p55	B
(	O
B2	B
complex	I
)	O
is	O
particularly	O
sensitive	O
to	O
alteration	O
of	O
the	O
5	O
'	O
triplet	O
of	O
deoxyguanosine	O
residues	O
.	O
In	O
contrast	O
,	O
formation	O
of	O
the	O
B1	B
complex	I
,	O
reflecting	O
the	O
binding	O
of	O
p75	B
and	O
p85	B
,	O
critically	O
depends	O
upon	O
the	O
more	O
3	O
'	O
sequences	O
of	O
this	O
enhancer	O
element	O
.	O
DNA	O
binding	O
by	O
all	O
four	O
of	O
these	O
Rel	B
-	I
related	I
factors	I
is	O
blocked	O
by	O
selective	O
chemical	O
modification	O
of	O
lysine	O
and	O
arginine	O
residues	O
,	O
suggesting	O
that	O
both	O
of	O
these	O
basic	O
amino	O
acids	O
are	O
required	O
for	O
binding	O
to	O
the	O
kappa	O
B	O
element	O
.	O
Similarly	O
,	O
covalent	O
modification	O
of	O
free	O
sulfhydryl	O
groups	O
with	O
diamide	O
(	O
reversible	O
)	O
or	O
N	O
-	O
ethylmaleimide	O
(	O
irreversible	O
)	O
results	O
in	O
a	O
complete	O
loss	O
of	O
DNA	O
binding	O
activity	O
.	O
In	O
contrast	O
,	O
mild	O
oxidation	O
with	O
glucose	B
oxidase	I
selectively	O
inhibits	O
p75	B
and	O
p85	B
binding	O
while	O
not	O
blocking	O
p50	B
and	O
p55	B
interactions	O
.	O
These	O
findings	O
suggest	O
that	O
reduced	O
cysteine	O
thiols	O
play	O
an	O
important	O
role	O
in	O
the	O
DNA	O
binding	O
activity	O
of	O
this	O
family	O
of	O
Rel	B
-	I
related	I
transcription	I
factors	I
.	O
A	O
novel	O
mitogen	B
-	I
inducible	I
gene	I
product	I
related	O
to	O
p50	B
/	I
p105-NF	I
-	I
kappa	I
B	I
participates	O
in	O
transactivation	O
through	O
a	O
kappa	O
B	O
site	O
.	O
A	O
Rel	B
-	I
related	I
,	I
mitogen	I
-	I
inducible	I
,	I
kappa	I
B	I
-	I
binding	I
protein	I
has	O
been	O
cloned	O
as	O
an	O
immediate	O
-	O
early	O
activation	O
gene	O
of	O
human	O
peripheral	O
blood	O
T	O
cells	O
.	O
The	O
cDNA	O
has	O
an	O
open	O
reading	O
frame	O
of	O
900	O
amino	O
acids	O
capable	O
of	O
encoding	O
a	O
97-kDa	B
protein	I
.	O
This	O
protein	O
is	O
most	O
similar	O
to	O
the	O
105-kDa	O
precursor	O
polypeptide	O
of	O
p50-NF	B
-	I
kappa	I
B	I
.	O
Like	O
the	O
105-kDa	O
precursor	O
,	O
it	O
contains	O
an	O
amino	B
-	I
terminal	I
Rel	I
-	I
related	I
domain	I
of	O
about	O
300	O
amino	O
acids	O
and	O
a	O
carboxy	B
-	I
terminal	I
domain	I
containing	O
six	O
full	B
cell	I
cycle	I
or	O
ankyrin	B
repeats	I
.	O
In	O
vitro	B
-	I
translated	I
proteins	I
,	O
truncated	O
downstream	O
of	O
the	O
Rel	O
domain	O
and	O
excluding	O
the	O
repeats	O
,	O
bind	O
kappa	O
B	O
sites	O
.	O
We	O
refer	O
to	O
the	O
kappa	B
B	I
-	I
binding	I
,	I
truncated	I
protein	I
as	O
p50B	B
by	O
analogy	O
with	O
p50-NF	B
-	I
kappa	I
B	I
and	O
to	O
the	O
full	O
-	O
length	O
protein	O
as	O
p97	B
.	O
p50B	B
is	O
able	O
to	O
form	O
heteromeric	B
kappa	I
B	I
-	I
binding	I
complexes	I
with	O
RelB	B
,	O
as	O
well	O
as	O
with	O
p65	B
and	O
p50	B
,	O
the	O
two	O
subunits	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
Transient	O
-	O
transfection	O
experiments	O
in	O
embryonal	O
carcinoma	O
cells	O
demonstrate	O
a	O
functional	O
cooperation	O
between	O
p50B	B
and	O
RelB	B
or	O
p65	B
in	O
transactivation	O
of	O
a	O
reporter	O
plasmid	O
dependent	O
on	O
a	O
kappa	O
B	O
site	O
.	O
The	O
data	O
imply	O
the	O
existence	O
of	O
a	O
complex	O
family	O
of	O
NF	B
-	I
kappa	I
B	I
-	I
like	I
transcription	I
factors	I
.	O
[	O
Changes	O
in	O
leucocytic	O
estrogen	B
receptor	I
levels	O
in	O
patients	O
with	O
climacteric	O
syndrome	O
and	O
therapeutic	O
effect	O
of	O
liuwei	O
dihuang	O
pills	O
]	O
The	O
numbers	O
of	O
estrogen	B
receptor	I
(	O
ER	B
)	O
in	O
human	O
peripheral	O
leucocytes	O
in	O
22	O
women	O
with	O
climacteric	O
syndrome	O
were	O
measured	O
by	O
radioligand	O
method	O
.	O
The	O
results	O
were	O
compared	O
with	O
those	O
of	O
12	O
normal	O
child	O
-	O
bearing	O
-	O
age	O
women	O
.	O
It	O
wat	O
found	O
that	O
the	O
contents	O
of	O
leucocytic	B
ER	I
in	O
climacteric	O
syndrome	O
patients	O
were	O
significantly	O
lower	O
than	O
normal	O
child	O
-	O
bearing	O
-	O
age	O
women	O
.	O
The	O
authors	O
used	O
a	O
Chinese	O
prescription	O
--	O
Liuwei	O
Dihuang	O
Pills	O
(	O
LDP	O
)	O
to	O
treat	O
the	O
patients	O
for	O
2	O
months	O
.	O
The	O
numbers	O
of	O
leucocytic	B
ER	I
were	O
significantly	O
increased	O
after	O
treatment	O
.	O
The	O
data	O
indicate	O
that	O
decrease	O
of	O
ER	B
levels	O
in	O
cell	O
may	O
involve	O
in	O
the	O
pathogenesis	O
of	O
climacteric	O
syndrome	O
.	O
LDP	O
not	O
only	O
increases	O
plasma	O
estradiol	O
levels	O
,	O
but	O
also	O
increases	O
the	O
leucocytic	O
ER	B
levels	O
.	O
This	O
may	O
be	O
the	O
basis	O
of	O
the	O
therapeutic	O
effect	O
on	O
the	O
disease	O
.	O
A	O
novel	O
primer	O
extension	O
method	O
to	O
detect	O
the	O
number	O
of	O
CAG	O
repeats	O
in	O
the	O
androgen	O
receptor	O
gene	O
in	O
families	O
with	O
X	O
-	O
linked	O
spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
.	O
X	O
-	O
linked	O
spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
(	O
SBMA	O
)	O
,	O
an	O
adult	O
-	O
onset	O
form	O
of	O
motor	O
neuron	O
disease	O
,	O
was	O
recently	O
reported	O
to	O
be	O
caused	O
by	O
amplification	O
of	O
the	O
CAG	O
repeats	O
in	O
the	O
androgen	O
receptor	O
gene	O
.	O
We	O
report	O
here	O
a	O
simple	O
and	O
rapid	O
strategy	O
to	O
detect	O
the	O
precise	O
number	O
of	O
the	O
CAGs	O
.	O
After	O
the	O
DNA	O
fragment	O
containing	O
the	O
CAG	O
repeats	O
is	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
,	O
a	O
primer	O
extension	O
is	O
carried	O
out	O
;	O
the	O
extension	O
of	O
the	O
end	O
-	O
labelled	O
reverse	O
primer	O
adjacent	O
to	O
3	O
'	O
end	O
of	O
CAG	O
repeats	O
stops	O
at	O
the	O
first	O
T	O
after	O
CAG	O
repeats	O
with	O
the	O
incorporation	O
of	O
dideoxy	O
ATP	O
in	O
the	O
reaction	O
mixture	O
.	O
The	O
resultant	O
primer	O
products	O
are	O
analysed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
autoradiography	O
.	O
This	O
method	O
could	O
be	O
quite	O
useful	O
to	O
detect	O
not	O
only	O
CAG	O
repeats	O
in	O
SBMA	O
but	O
also	O
other	O
polymorphic	O
dinucleotide	O
and	O
trinucleotide	O
repeats	O
.	O
Structure	O
function	O
analysis	O
of	O
vitamin	O
D	O
analogs	O
with	O
C	O
-	O
ring	O
modifications	O
.	O
Analogs	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
)	O
with	O
substitutions	O
on	O
C-11	O
were	O
synthesized	O
.	O
Small	O
apolar	O
substitutions	O
(	O
11	O
alpha	O
-	O
methyl	O
,	O
11	O
alpha	O
-	O
fluoromethyl	O
)	O
did	O
not	O
markedly	O
decrease	O
the	O
affinity	O
for	O
the	O
vitamin	B
D	I
receptor	I
,	O
but	O
larger	O
(	O
11	O
alpha	O
-	O
chloromethyl	O
or	O
11	O
alpha-	O
or	O
11	O
beta	O
-	O
phenyl	O
)	O
or	O
more	O
polar	O
substitutions	O
(	O
11	O
alpha	O
-	O
hydroxymethyl	O
,	O
11	O
alpha-	O
(	O
2-hydroxyethyl	O
]	O
decreased	O
the	O
affinity	O
to	O
less	O
than	O
5	O
%	O
of	O
that	O
of	O
1	O
alpha	O
,	O
25-OH	O
)	O
2D3	O
.	O
Their	O
affinity	O
for	O
the	O
vitamin	B
D	I
-	I
binding	I
protein	I
,	O
however	O
,	O
increased	O
up	O
to	O
4-fold	O
.	O
The	O
biological	O
activity	O
of	O
11	O
alpha	O
-	O
methyl-1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
closely	O
resembled	O
that	O
of	O
the	O
natural	O
hormone	O
on	O
normal	O
and	O
leukemic	O
cell	O
proliferation	O
and	O
bone	O
resorption	O
,	O
whereas	O
its	O
in	O
vivo	O
effect	O
on	O
calcium	O
metabolism	O
of	O
the	O
rachitic	O
chick	O
was	O
about	O
50	O
%	O
of	O
that	O
of	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O
The	O
11	O
beta	O
-	O
methyl	O
analog	O
had	O
a	O
greater	O
than	O
10-fold	O
lower	O
activity	O
.	O
The	O
differentiating	O
effects	O
of	O
the	O
other	O
C-11	O
analogs	O
on	O
human	O
promyeloid	O
leukemia	O
cells	O
(	O
HL-60	O
)	O
agreed	O
well	O
with	O
their	O
bone	O
-	O
resorbing	O
activity	O
and	O
receptor	O
affinity	O
,	O
but	O
they	O
demonstrated	O
lower	O
calcemic	O
effects	O
in	O
vivo	O
.	O
Large	O
or	O
polar	O
substitutions	O
on	O
C-11	O
of	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
thus	O
impair	O
the	O
binding	O
of	O
the	O
vitamin	B
D	I
receptor	I
but	O
increase	O
the	O
affinity	O
to	O
vitamin	B
D	I
-	I
binding	I
protein	I
.	O
The	O
effects	O
of	O
many	O
C-11-substituted	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
analogs	O
on	O
HL-60	O
cell	O
differentiation	O
exceeded	O
their	O
activity	O
on	O
calcium	O
metabolism	O
.	O
The	O
AP-1	O
site	O
at	O
-150	O
bp	O
,	O
but	O
not	O
the	O
NF	O
-	O
kappa	O
B	O
site	O
,	O
is	O
likely	O
to	O
represent	O
the	O
major	O
target	O
of	O
protein	B
kinase	I
C	I
in	O
the	O
interleukin	O
2	O
promoter	O
.	O
Stimulation	O
of	O
T	O
cells	O
with	O
antigen	O
results	O
in	O
activation	O
of	O
several	O
kinases	B
,	O
including	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
,	O
that	O
may	O
mediate	O
the	O
later	O
induction	O
of	O
activation	O
-	O
related	O
genes	O
.	O
We	O
have	O
examined	O
the	O
potential	O
role	O
of	O
PKC	B
in	O
induction	O
of	O
the	O
interleukin	O
2	O
(	O
IL-2	O
)	O
gene	O
in	O
T	O
cells	O
stimulated	O
through	O
the	O
T	B
cell	I
receptor	I
/	I
CD3	I
complex	I
.	O
We	O
have	O
previously	O
shown	O
that	O
prolonged	O
treatment	O
of	O
the	O
untransformed	O
T	O
cell	O
clone	O
Ar-5	O
with	O
phorbol	O
esters	O
results	O
in	O
downmodulation	O
of	O
the	O
alpha	B
and	I
beta	I
isozymes	I
of	O
PKC	B
,	O
and	O
abrogates	O
induction	O
of	O
IL-2	O
mRNA	O
and	O
protein	B
.	O
Here	O
we	O
show	O
that	O
phorbol	O
ester	O
treatment	O
also	O
abolishes	O
induction	O
of	O
chloramphenicol	B
acetyltransferase	I
activity	O
in	O
Ar-5	O
cells	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
IL-2	O
promoter	O
linked	O
to	O
this	O
reporter	O
gene	O
.	O
The	O
IL-2	O
promoter	O
contains	O
binding	O
sites	O
for	O
nuclear	B
factors	I
including	O
NFAT-1	B
,	O
Oct	B
,	O
NF	B
-	I
kappa	I
B	I
,	O
and	O
AP-1	B
,	O
which	O
are	O
all	O
potentially	O
sensitive	O
to	O
activation	O
of	O
PKC	B
.	O
We	O
show	O
that	O
induction	O
of	O
a	O
trimer	O
of	O
the	O
NFAT	O
and	O
Oct	O
sites	O
is	O
not	O
sensitive	O
to	O
phorbol	O
ester	O
treatment	O
,	O
and	O
that	O
mutations	O
in	O
the	O
NF	O
-	O
kappa	O
B	O
site	O
have	O
no	O
effect	O
on	O
inducibility	O
of	O
the	O
IL-2	O
promoter	O
.	O
In	O
contrast	O
,	O
mutations	O
in	O
the	O
AP-1	O
site	O
located	O
at	O
-150	O
bp	O
almost	O
completely	O
abrogate	O
induction	O
of	O
the	O
IL-2	O
promoter	O
,	O
and	O
appearance	O
of	O
an	O
inducible	B
nuclear	I
factor	I
binding	O
to	O
this	O
site	O
is	O
sensitive	O
to	O
PKC	B
depletion	O
.	O
Moreover	O
,	O
cotransfections	O
with	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
expression	O
plasmids	O
markedly	O
enhance	O
induction	O
of	O
the	O
IL-2	O
promoter	O
in	O
minimally	O
stimulated	O
T	O
cells	O
.	O
Our	O
results	O
indicate	O
that	O
the	O
AP-1	O
site	O
at	O
-150	O
bp	O
represents	O
a	O
major	O
,	O
if	O
not	O
the	O
only	O
,	O
site	O
of	O
PKC	B
responsiveness	O
in	O
the	O
IL-2	O
promoter	O
.	O
Interleukin	O
6-induced	O
differentiation	O
of	O
a	O
human	O
B	O
cell	O
line	O
into	O
IgM	O
-	O
secreting	O
plasma	O
cells	O
is	O
mediated	O
by	O
c	O
-	O
fos	O
.	O
The	O
role	O
of	O
the	O
protooncogene	O
c	O
-	O
fos	O
in	O
interleukin	B
(	I
IL	I
)	I
6	I
-induced	O
B	O
cell	O
differentiation	O
was	O
assessed	O
.	O
Treatment	O
of	O
SKW	O
6.4	O
cells	O
with	O
IL	B
6	I
induced	O
a	O
transient	O
and	O
early	O
stimulation	O
of	O
c	O
-	O
fos	O
sense	O
mRNA	O
expression	O
.	O
The	O
effect	O
appeared	O
within	O
30	O
min	O
and	O
returned	O
to	O
basal	O
levels	O
after	O
2	O
h	O
.	O
The	O
addition	O
of	O
antisense	O
oligonucleotides	O
to	O
c	O
-	O
fos	O
significantly	O
inhibited	O
IL	B
6	I
-induced	O
IgM	B
production	O
by	O
SKW	O
6.4	O
cells	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
whereas	O
control	O
oligonucleotides	O
had	O
no	O
inhibitory	O
effect	O
.	O
These	O
results	O
indicate	O
that	O
activation	O
of	O
c	O
-	O
fos	O
is	O
involved	O
in	O
IL	B
6	I
-induced	O
differentiation	O
of	O
SKW	O
6.4	O
cells	O
into	O
IgM	O
-	O
secreting	O
cells	O
.	O
Gangliosides	O
suppress	O
tumor	B
necrosis	I
factor	I
production	O
in	O
human	O
monocytes	O
.	O
Both	O
normal	O
and	O
malignant	O
cells	O
contain	O
gangliosides	O
as	O
important	O
cell	O
membrane	O
constituents	O
that	O
,	O
after	O
being	O
shed	O
,	O
may	O
influence	O
cells	O
of	O
the	O
immune	O
system	O
.	O
We	O
have	O
studied	O
the	O
impact	O
of	O
gangliosides	O
on	O
the	O
expression	O
of	O
TNF	B
in	O
blood	O
monocytes	O
and	O
in	O
the	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
.	O
Although	O
under	O
standard	O
culture	O
conditions	O
,	O
bovine	O
brain	O
gangliosides	O
(	O
100	O
micrograms	O
/	O
ml	O
)	O
suppressed	O
LPS	O
-	O
stimulated	O
TNF	B
production	O
5-fold	O
in	O
PBMC	O
and	O
10-fold	O
in	O
Mono	O
Mac	O
6	O
cells	O
,	O
suppression	O
was	O
more	O
efficient	O
under	O
serum	O
-	O
free	O
conditions	O
.	O
Looking	O
at	O
highly	O
purified	O
gangliosides	O
,	O
GD3	O
,	O
GD1a	O
,	O
GM3	O
,	O
GM2	O
,	O
and	O
GM1	O
were	O
all	O
effective	O
in	O
reducing	O
TNF	B
production	O
in	O
PBMC	O
,	O
and	O
in	O
Mono	O
Mac	O
6	O
by	O
factor	O
10	O
to	O
50	O
.	O
The	O
suppressive	O
activity	O
was	O
lost	O
in	O
molecules	O
,	O
lacking	O
the	O
sugar	O
moiety	O
or	O
the	O
lipid	O
moiety	O
.	O
Gangliosides	O
appear	O
to	O
act	O
at	O
an	O
early	O
step	O
of	O
activation	O
in	O
that	O
TNF	O
transcripts	O
were	O
reduced	O
and	O
the	O
mobilization	O
of	O
the	O
nuclear	B
factor	I
kappa	I
B	I
was	O
blocked	O
.	O
Furthermore	O
,	O
in	O
time	O
kinetics	O
,	O
gangliosides	O
were	O
effective	O
for	O
up	O
to	O
30	O
min	O
after	O
addition	O
of	O
LPS	O
,	O
but	O
not	O
thereafter	O
.	O
However	O
,	O
the	O
expression	O
of	O
the	O
CD14	B
Ag	I
,	O
a	O
receptor	B
molecule	I
for	O
LPS	B
-	I
LPS	I
binding	I
protein	I
complexes	I
,	O
was	O
unaffected	O
by	O
gangliosides	O
.	O
Finally	O
,	O
when	O
using	O
Staphylococcus	O
aureus	O
or	O
platelet	B
activating	I
factor	I
as	O
a	O
stimulus	O
,	O
gangliosides	O
were	O
able	O
to	O
suppress	O
TNF	B
production	O
in	O
Mono	O
Mac	O
6	O
cells	O
by	O
factor	O
5	O
to	O
10	O
,	O
as	O
well	O
.	O
On	O
the	O
other	O
hand	O
,	O
phorbol	O
ester	O
-	O
induced	O
production	O
of	O
O2-	O
was	O
similar	O
in	O
cells	O
treated	O
with	O
and	O
without	O
gangliosides	O
.	O
Taken	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
TNF	B
gene	O
expression	O
in	O
monocytes	O
induced	O
by	O
different	O
types	O
of	O
stimuli	O
can	O
be	O
blocked	O
by	O
gangliosides	O
at	O
an	O
early	O
step	O
of	O
signal	O
transduction	O
.	O
T	O
cell	O
-	O
specific	O
negative	O
regulation	O
of	O
transcription	O
of	O
the	O
human	B
cytokine	I
IL-4	I
.	O
IL-4	B
secreted	O
by	O
activated	O
T	O
cells	O
is	O
a	O
pleiotropic	B
cytokine	I
affecting	O
growth	O
and	O
differentiation	O
of	O
diverse	O
cell	O
types	O
such	O
as	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
mast	O
cells	O
.	O
We	O
investigated	O
the	O
upstream	O
regulatory	O
elements	O
of	O
the	O
human	O
IL-4	O
promoter	O
.	O
A	O
novel	O
T	O
cell	O
-	O
specific	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
composed	O
of	O
two	O
protein	O
-	O
binding	O
sites	O
were	O
mapped	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
IL-4	O
gene	O
:	O
-311CTCCCTTCT-303	O
(	O
NRE	O
-	O
I	O
)	O
and	O
-288CTTTTTGCTT	O
-	O
TGC-300	O
(	O
NRE	O
-	O
II	O
)	O
.	O
A	O
T	B
cell	I
-	I
specific	I
protein	I
Neg-1	B
and	O
a	O
ubiquitous	B
protein	I
Neg-2	B
binding	O
to	O
NRE	O
-	O
I	O
and	O
NRE	O
-	O
II	O
,	O
respectively	O
,	O
were	O
identified	O
.	O
Furthermore	O
,	O
a	O
positive	O
regulatory	O
element	O
was	O
found	O
45	O
bp	O
downstream	O
of	O
the	O
NRE	O
.	O
The	O
enhancer	O
activity	O
of	O
the	O
PRE	O
was	O
completely	O
suppressed	O
when	O
the	O
NRE	O
was	O
present	O
.	O
These	O
data	O
suggest	O
that	O
IL-4	O
promoter	O
activity	O
is	O
normally	O
down	O
-	O
regulated	O
by	O
an	O
NRE	O
via	O
repression	O
of	O
the	O
enhancer	O
positive	O
regulatory	O
element	O
.	O
These	O
data	O
may	O
have	O
implications	O
for	O
the	O
stringent	O
control	O
of	O
IL-4	B
expression	O
in	O
T	O
cells	O
.	O
[	O
Regulatory	O
effect	O
of	O
insulin	B
on	O
glucocorticoid	B
receptor	I
in	O
human	O
peripheral	O
leukocytes	O
]	O
The	O
regulatory	O
effect	O
of	O
insulin	B
on	O
the	O
specific	O
binding	O
power	O
of	O
glucocorticoid	B
receptor	I
(	O
GR	B
)	O
of	O
human	O
leukocytes	O
was	O
assessed	O
by	O
the	O
unoccupied	B
receptor	I
sites	I
capable	O
of	O
combining	O
with	O
[	O
3H	O
]	O
labelled	O
dexamethasone	O
measured	O
at	O
3	O
and	O
24	O
h	O
after	O
incubation	O
with	O
various	O
concentrations	O
of	O
insulin	B
added	O
to	O
the	O
medium	O
.	O
After	O
3	O
h	O
incubation	O
the	O
specific	O
binding	O
power	O
with	O
[	O
3H	O
]	O
Dex	O
was	O
decreased	O
by	O
23.3	O
+	O
/-	O
10.0	O
,	O
32.2	O
+	O
/-	O
13.2	O
and	O
54.3	O
+	O
/-	O
9.2	O
%	O
(	O
P	O
greater	O
than	O
0.05	O
,	O
P	O
greater	O
than	O
0.05	O
and	O
P	O
less	O
than	O
0.01	O
as	O
compared	O
with	O
the	O
control	O
value	O
of	O
100	O
in	O
the	O
absence	O
of	O
insulin	B
)	O
respectively	O
in	O
the	O
presence	O
of	O
20	O
mU	O
/	O
L	O
(	O
physiological	O
testing	O
concentration	O
)	O
,	O
200	O
mU	O
/	O
L	O
(	O
physiological	O
upper	O
limit	O
)	O
and	O
2	O
,	O
000	O
mU	O
/	O
L	O
(	O
pharmacological	O
concentration	O
)	O
insulin	B
in	O
the	O
incubation	O
medium	O
.	O
After	O
24	O
h	O
incubation	O
the	O
decrease	O
of	O
these	O
values	O
increased	O
respectively	O
to	O
43.5	O
+	O
/-	O
19.0	O
,	O
56.1	O
+	O
/-	O
20.7	O
and	O
80.2	O
+	O
/-	O
15.5	O
(	O
P	O
less	O
than	O
0.05	O
,	O
P	O
less	O
than	O
0.01	O
and	O
P	O
less	O
than	O
0.01	O
compared	O
with	O
control	O
)	O
.	O
Thus	O
the	O
inhibitory	O
effect	O
of	O
insulin	B
on	O
the	O
GR	B
binding	O
power	O
is	O
both	O
dose-	O
and	O
time	O
-	O
dependent	O
,	O
which	O
strongly	O
suggests	O
that	O
GR	B
is	O
tonically	O
controlled	O
by	O
insulin	B
concentration	O
change	O
under	O
physiological	O
conditions	O
.	O
Human	O
T	O
cell	O
activation	O
through	O
the	O
activation	B
-	I
inducer	I
molecule	I
/	I
CD69	I
enhances	O
the	O
activity	O
of	O
transcription	B
factor	I
AP-1	I
.	O
The	O
induction	O
of	O
the	O
AP-1	B
transcription	I
factor	I
has	O
been	O
ascribed	O
to	O
the	O
early	O
events	O
leading	O
to	O
T	O
cell	O
differentiation	O
and	O
activation	O
.	O
We	O
have	O
studied	O
the	O
regulation	O
of	O
AP-1	B
activity	O
in	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
stimulated	O
through	O
the	O
activation	O
inducer	O
molecule	O
(	O
AIM	O
)	O
/	O
CD69	B
activation	O
pathway	O
.	O
Phorbol	O
esters	O
are	O
required	O
to	O
induce	O
AIM	B
/	I
CD69	I
cell	O
-	O
surface	O
expression	O
as	O
well	O
as	O
for	O
triggering	O
the	O
proliferation	O
of	O
T	O
cells	O
in	O
conjunction	O
with	O
anti	B
-	I
AIM	I
mAb	I
.	O
Mobility	O
shift	O
assays	O
showed	O
that	O
addition	O
of	O
anti	B
-	I
AIM	I
mAb	I
to	O
PMA	O
-	O
treated	O
T	O
lymphocytes	O
markedly	O
enhanced	O
the	O
binding	O
activity	O
of	O
AP-1	B
to	O
its	O
cognate	O
sequence	O
,	O
the	O
phorbol	O
ester	O
response	O
element	O
.	O
In	O
contrast	O
,	O
anti	B
-	I
AIM	I
mAb	I
did	O
not	O
induce	O
any	O
change	O
in	O
the	O
binding	O
activity	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
a	O
transcription	B
factor	I
whose	O
activity	O
is	O
also	O
regulated	O
by	O
protein	B
kinase	I
C	I
.	O
The	O
increase	O
in	O
AP-1	B
-binding	O
activity	O
was	O
accompanied	O
by	O
the	O
marked	O
stimulation	O
of	O
the	O
transcription	O
of	O
c	B
-	I
fos	I
but	O
not	O
that	O
of	O
c	B
-	I
jun	I
.	O
Blockade	O
of	O
the	O
DNA	B
-	I
binding	I
complexes	I
with	O
an	O
anti	B
-	I
Fos	I
mAb	I
demonstrated	O
a	O
direct	O
participation	O
of	O
c	B
-	I
Fos	I
in	O
the	O
AP-1	B
complexes	I
induced	O
by	O
anti	B
-	I
AIM	I
mAb	I
.	O
Most	O
of	O
the	O
AP-1	B
activity	O
could	O
be	O
eliminated	O
when	O
the	O
anti	B
-	I
AIM	I
mAb	I
was	O
added	O
to	O
the	O
culture	O
medium	O
in	O
the	O
presence	O
of	O
cycloheximide	O
,	O
suggesting	O
that	O
de	O
novo	O
protein	O
synthesis	O
is	O
crucial	O
for	O
the	O
induction	O
of	O
AP-1	B
-binding	O
activity	O
.	O
These	O
data	O
provide	O
the	O
evidence	O
that	O
activation	O
of	O
human	O
peripheral	O
blood	O
T	O
cells	O
through	O
the	O
AIM	O
activation	O
pathway	O
regulate	O
the	O
activity	O
of	O
AP-1	B
.	O
Therefore	O
,	O
this	O
pathway	O
appears	O
as	O
a	O
crucial	O
step	O
in	O
the	O
initiation	O
of	O
early	O
T	O
cell	O
activation	O
events	O
.	O
cis	O
-	O
acting	O
sequences	O
required	O
for	O
inducible	O
interleukin-2	O
enhancer	O
function	O
bind	O
a	O
novel	O
Ets	B
-	I
related	I
protein	I
,	O
Elf-1	B
.	O
The	O
recent	O
definition	O
of	O
a	O
consensus	O
DNA	O
binding	O
sequence	O
for	O
the	O
Ets	B
family	I
of	O
transcription	B
factors	I
has	O
allowed	O
the	O
identification	O
of	O
potential	O
Ets	O
binding	O
sites	O
in	O
the	O
promoters	O
and	O
enhancers	O
of	O
many	O
inducible	O
T	O
-	O
cell	O
genes	O
.	O
In	O
the	O
studies	O
described	O
in	O
this	O
report	O
,	O
we	O
have	O
identified	O
two	O
potential	O
Ets	O
binding	O
sites	O
,	O
EBS1	O
and	O
EBS2	O
,	O
which	O
are	O
conserved	O
in	O
both	O
the	O
human	O
and	O
murine	O
interleukin-2	O
enhancers	O
.	O
Within	O
the	O
human	O
enhancer	O
,	O
these	O
two	O
sites	O
are	O
located	O
within	O
the	O
previously	O
defined	O
DNase	B
I	I
footprints	O
,	O
NFAT-1	O
and	O
NFIL-2B	O
,	O
respectively	O
.	O
Electrophoretic	O
mobility	O
shift	O
and	O
methylation	O
interference	O
analyses	O
demonstrated	O
that	O
EBS1	O
and	O
EBS2	O
are	O
essential	O
for	O
the	O
formation	O
of	O
the	O
NFAT-1	B
and	I
NFIL-2B	I
nuclear	I
protein	I
complexes	I
.	O
Furthermore	O
,	O
in	O
vitro	O
mutagenesis	O
experiments	O
demonstrated	O
that	O
inducible	O
interleukin-2	O
enhancer	O
function	O
requires	O
the	O
presence	O
of	O
either	O
EBS1	O
or	O
EBS2	O
.	O
Two	O
well	O
-	O
characterized	O
Ets	B
family	I
members	I
,	O
Ets-1	B
and	O
Ets-2	B
,	O
are	O
reciprocally	O
expressed	O
during	O
T	O
-	O
cell	O
activation	O
.	O
Surprisingly	O
,	O
however	O
,	O
neither	O
of	O
these	O
proteins	O
bound	O
in	O
vitro	O
to	O
EBS1	O
or	O
EBS2	O
.	O
We	O
therefore	O
screened	O
a	O
T	O
-	O
cell	O
cDNA	O
library	O
under	O
low	O
-	O
stringency	O
conditions	O
with	O
a	O
probe	O
from	O
the	O
DNA	B
binding	I
domain	I
of	O
Ets-1	B
and	O
isolated	O
a	O
novel	B
Ets	I
family	I
member	I
,	O
Elf-1	B
.	O
Elf-1	B
contains	O
a	O
DNA	B
binding	I
domain	I
that	O
is	O
nearly	O
identical	O
to	O
that	O
of	O
E74	B
,	O
the	O
ecdysone	B
-	I
inducible	I
Drosophila	I
transcription	I
factor	I
required	O
for	O
metamorphosis	O
(	O
hence	O
the	O
name	O
Elf-1	B
,	O
for	O
E74-like	B
factor	I
1	I
)	O
.	O
Elf-1	B
bound	O
specifically	O
to	O
both	O
EBS1	O
and	O
EBS2	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
It	O
also	O
bound	O
to	O
the	O
purine	O
-	O
rich	O
CD3R	O
element	O
from	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
long	O
terminal	O
repeat	O
,	O
which	O
is	O
required	O
for	O
inducible	O
virus	O
expression	O
in	O
response	O
to	O
signalling	O
through	O
the	O
T	B
-	I
cell	I
receptor	I
.	O
Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
multiple	B
Ets	I
family	I
members	I
with	O
apparently	O
distinct	O
DNA	O
binding	O
specificities	O
regulate	O
differential	O
gene	O
expression	O
in	O
resting	O
and	O
activated	O
T	O
cells	O
.	O
Mineralocorticoids	O
and	O
mineralocorticoid	B
receptors	I
in	O
mononuclear	O
leukocytes	O
in	O
patients	O
with	O
pregnancy	O
-	O
induced	O
hypertension	O
.	O
To	O
examine	O
the	O
role	O
of	O
mineralocorticoids	O
in	O
the	O
pathophysiology	O
of	O
pregnancy	O
-	O
induced	O
hypertension	O
(	O
PIH	O
)	O
,	O
we	O
studied	O
plasma	O
aldosterone	O
and	O
18-hydroxycorticosterone	O
levels	O
in	O
25	O
women	O
with	O
PIH	O
and	O
25	O
normal	O
pregnant	O
women	O
,	O
as	O
controls	O
.	O
Furthermore	O
,	O
we	O
evaluated	O
the	O
mineralocorticoid	B
receptor	I
(	O
MR	B
)	O
status	O
in	O
mononuclear	O
leukocytes	O
in	O
the	O
2	O
groups	O
.	O
MR	B
count	O
was	O
significantly	O
(	O
P	O
less	O
than	O
0.0005	O
)	O
decreased	O
in	O
the	O
PIH	O
group	O
(	O
148	O
+	O
/-	O
9	O
binding	O
sites	O
/	O
cell	O
)	O
compared	O
with	O
the	O
control	O
group	O
(	O
300	O
+	O
/-	O
17	O
binding	O
sites	O
/	O
cell	O
;	O
mean	O
+	O
/-	O
SEM	O
)	O
.	O
Plasma	O
aldosterone	O
in	O
women	O
with	O
PIH	O
was	O
281	O
+	O
/-	O
61	O
pmol	O
/	O
L	O
;	O
in	O
normal	O
pregnant	O
women	O
it	O
was	O
697	O
+	O
/-	O
172	O
pmol	O
/	O
L	O
(	O
P	O
less	O
than	O
0.025	O
)	O
.	O
Plasma	O
18-hydroxycorticosterone	O
was	O
also	O
significantly	O
(	O
P	O
less	O
than	O
0.025	O
)	O
lower	O
(	O
PIH	O
,	O
1071	O
+	O
/-	O
149	O
pmol	O
/	O
L	O
;	O
controls	O
,	O
1907	O
+	O
/-	O
318	O
pmol	O
/	O
L	O
)	O
.	O
These	O
values	O
were	O
determined	O
at	O
the	O
onset	O
of	O
clinical	O
symptoms	O
of	O
PIH	O
.	O
These	O
results	O
can	O
not	O
be	O
explained	O
by	O
receptor	O
down	O
-	O
regulation	O
due	O
to	O
higher	O
levels	O
of	O
mineralocorticoids	O
in	O
PIH	O
;	O
a	O
hitherto	O
unknown	O
mineralocorticoid	O
may	O
,	O
thus	O
,	O
be	O
responsible	O
for	O
the	O
hypertension	O
and	O
altered	O
MR	B
status	O
.	O
A	O
lymphoid	B
cell	I
-	I
specific	I
nuclear	I
factor	I
containing	O
c	B
-	I
Rel	I
-	I
like	I
proteins	I
preferentially	O
interacts	O
with	O
interleukin-6	O
kappa	O
B	O
-	O
related	O
motifs	O
whose	O
activities	O
are	O
repressed	O
in	O
lymphoid	O
cells	O
.	O
The	O
proto	B
-	I
oncoprotein	I
c	I
-	I
Rel	I
is	O
a	O
member	O
of	O
the	O
nuclear	B
factor	I
kappa	I
B	I
transcription	I
factor	I
family	I
,	O
which	O
includes	O
the	O
p50	B
and	O
p65	B
subunits	I
of	O
nuclear	B
factor	I
kappa	I
B	I
.	O
We	O
show	O
here	O
that	O
c	B
-	I
Rel	I
binds	O
to	O
kappa	O
B	O
sites	O
as	O
homodimers	B
as	O
well	O
as	O
heterodimers	B
with	O
p50	B
.	O
These	O
homodimers	B
and	O
heterodimers	B
show	O
distinct	O
DNA	O
-	O
binding	O
specificities	O
and	O
affinities	O
for	O
various	O
kappa	O
B	O
motifs	O
.	O
In	O
particular	O
,	O
the	O
c	B
-	I
Rel	I
homodimer	I
has	O
a	O
high	O
affinity	O
for	O
interleukin-6	B
(	O
IL-6	B
)	O
and	O
beta	O
interferon	O
kappa	O
B	O
sites	O
.	O
In	O
spite	O
of	O
its	O
association	O
with	O
p50	B
in	O
vitro	O
,	O
however	O
,	O
we	O
found	O
a	O
lymphoid	B
cell	I
-	I
specific	I
nuclear	I
factor	I
in	O
vivo	O
that	O
contains	O
c	B
-	I
Rel	I
but	O
not	O
p50	B
epitopes	I
;	O
this	O
factor	O
,	O
termed	O
IL-6	B
kappa	I
B	I
binding	I
factor	I
II	I
,	O
appears	O
to	O
contain	O
the	O
c	B
-	I
Rel	I
homodimer	I
and	O
preferentially	O
recognizes	O
several	O
IL-6	O
kappa	O
B	O
-	O
related	O
kappa	O
B	O
motifs	O
.	O
Although	O
it	O
has	O
been	O
previously	O
shown	O
that	O
the	O
IL-6	O
kappa	O
B	O
motif	O
functions	O
as	O
a	O
potent	O
IL-1	O
/	O
tumor	O
necrosis	O
factor	O
-	O
responsive	O
element	O
in	O
nonlymphoid	O
cells	O
,	O
its	O
activity	O
was	O
found	O
to	O
be	O
repressed	O
in	O
lymphoid	O
cells	O
such	O
as	O
a	O
Jurkat	O
T	O
-	O
cell	O
line	O
.	O
We	O
also	O
present	O
evidence	O
that	O
IL-6	B
kappa	I
B	I
binding	I
factor	I
II	I
functions	O
as	O
a	O
repressor	O
specific	O
for	O
IL-6	O
kappa	O
B	O
-	O
related	O
kappa	O
B	O
motifs	O
in	O
lymphoid	O
cells	O
.	O
Modulation	O
of	O
normal	O
erythroid	O
differentiation	O
by	O
the	O
endogenous	O
thyroid	O
hormone	O
and	O
retinoic	B
acid	I
receptors	I
:	O
a	O
possible	O
target	O
for	O
v	O
-	O
erbA	O
oncogene	O
action	O
.	O
The	O
v	O
-	O
erbA	O
oncogene	O
,	O
a	O
mutated	O
version	O
of	O
the	O
thyroid	B
hormone	I
receptor	I
alpha	I
(	O
c	B
-	I
erbA	I
/	I
TR	I
-	I
alpha	I
)	O
,	O
inhibits	O
erythroid	O
differentiation	O
and	O
constitutively	O
represses	O
transcription	O
of	O
certain	O
erythrocyte	O
genes	O
,	O
suggesting	O
a	O
normal	O
function	O
of	O
the	O
proto	O
-	O
oncogene	O
c	O
-	O
erbA	O
in	O
erythropoiesis	O
.	O
Here	O
we	O
demonstrate	O
that	O
the	O
endogenous	O
thyroid	B
hormone	I
receptor	I
alpha	I
(	O
c	B
-	I
erbA	I
/	I
TR	I
-	I
alpha	I
)	O
and	O
the	O
closely	O
related	O
retinoic	B
acid	I
receptor	I
alpha	I
(	O
RAR	B
-	I
alpha	I
)	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
normal	O
erythroid	O
differentiation	O
.	O
Retinoic	O
acid	O
(	O
RA	O
)	O
distinctly	O
modulated	O
the	O
erythroid	O
differentiation	O
program	O
of	O
normal	O
erythroid	O
progenitors	O
and	O
erythroblasts	O
reversibly	O
transformed	O
by	O
a	O
conditional	O
tyrosine	O
kinase	O
oncogene	O
.	O
When	O
added	O
pulsewise	O
to	O
immature	O
cells	O
,	O
differentiation	O
was	O
accelerated	O
while	O
more	O
mature	O
cells	O
underwent	O
premature	O
cell	O
death	O
.	O
Thyroid	O
hormone	O
(	O
T3	O
)	O
alone	O
caused	O
similar	O
but	O
weaker	O
effects	O
.	O
Interestingly	O
,	O
T3	O
strongly	O
enhanced	O
the	O
action	O
of	O
RA	O
,	O
suggesting	O
cooperative	O
action	O
of	O
the	O
two	O
receptors	O
in	O
modulating	O
erythroid	O
differentiation	O
.	O
Expression	O
of	O
the	O
human	B
RAR	I
-	I
alpha	I
in	O
receptor	O
-	O
negative	O
erythroblasts	O
conferred	O
RA	O
-	O
induced	O
regulation	O
of	O
differentiation	O
to	O
the	O
otherwise	O
unresponsive	O
cells	O
,	O
thus	O
showing	O
that	O
the	O
RAR	B
-	I
alpha	I
is	O
essential	O
for	O
the	O
RA	O
effect	O
.	O
Likewise	O
,	O
enhanced	O
expression	O
of	O
exogenous	B
c	I
-	I
erbA	I
/	I
TR	I
-	I
alpha	I
in	O
erythroblasts	O
rendered	O
them	O
susceptible	O
to	O
modulation	O
of	O
differentiation	O
by	O
T3	O
,	O
suggesting	O
a	O
similar	O
function	O
of	O
both	O
receptors	O
.	O
Glucocorticoid	B
receptor	I
binding	O
in	O
three	O
different	O
cell	O
types	O
in	O
major	O
depressive	O
disorder	O
:	O
lack	O
of	O
evidence	O
of	O
receptor	O
binding	O
defect	O
.	O
1	O
.	O
In	O
order	O
to	O
further	O
understand	O
the	O
apparent	O
glucocorticoid	O
resistance	O
in	O
major	O
depressive	O
disorder	O
,	O
circadian	O
variation	O
in	O
cortisol	O
concentration	O
,	O
dexamethasone	O
suppression	O
and	O
glucocorticoid	O
receptor	O
binding	O
in	O
mononuclear	O
leukocytes	O
,	O
polymorphonuclear	O
leukocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
were	O
measured	O
in	O
rigidly	O
defined	O
major	O
depressive	O
disorder	O
patients	O
and	O
non	O
-	O
depressed	O
psychiatric	O
controls	O
.	O
2	O
.	O
Mononuclear	O
leukocytes	O
binding	O
to	O
glucocorticoid	O
correlated	O
significantly	O
with	O
polymorphonuclear	O
leukocytes	O
binding	O
to	O
glucocorticoid	O
,	O
but	O
both	O
determinations	O
failed	O
to	O
differentiate	O
major	O
depressive	O
disorder	O
and	O
control	O
subjects	O
.	O
3	O
.	O
Initial	O
and	O
post	O
-	O
dexamethasone	O
in	O
vitro	O
fibroblast	O
binding	O
to	O
glucocorticoid	O
was	O
not	O
different	O
between	O
major	O
depressive	O
disorder	O
and	O
non	O
-	O
depressed	O
control	O
subjects	O
.	O
4	O
.	O
The	O
phenomenon	O
of	O
glucocorticoid	O
resistance	O
in	O
major	O
depressive	O
disorder	O
remains	O
unexplained	O
.	O
The	O
B	B
cell	I
-	I
specific	I
nuclear	I
factor	I
OTF-2	B
positively	O
regulates	O
transcription	O
of	O
the	O
human	O
class	O
II	O
transplantation	O
gene	O
,	O
DRA	O
.	O
The	O
promoter	O
of	O
the	O
major	O
histocompatibility	O
class	O
II	O
gene	O
DRA	O
contains	O
an	O
octamer	O
element	O
(	O
ATTTGCAT	O
)	O
that	O
is	O
required	O
for	O
efficient	O
DRA	O
expression	O
in	O
B	O
cells	O
.	O
Several	O
DNA	B
-	I
binding	I
proteins	I
are	O
known	O
to	O
bind	O
this	O
sequence	O
.	O
The	O
best	O
characterized	O
are	O
the	O
B	B
cell	I
-	I
specific	I
OTF-2	I
and	O
the	O
ubiquitous	O
OTF-1	B
.	O
This	O
report	O
directly	O
demonstrates	O
that	O
OTF-2	B
but	O
not	O
OTF-1	B
regulates	O
the	O
DRA	O
gene	O
.	O
In	O
vitro	O
transcription	O
analysis	O
using	O
protein	O
fractions	O
enriched	O
for	O
the	O
octamer	O
-	O
binding	O
protein	O
OTF-2	B
demonstrate	O
a	O
positive	O
functional	O
role	O
for	O
OTF-2	B
in	O
DRA	O
gene	O
transcription	O
.	O
In	O
contrast	O
,	O
OTF-1	B
-enriched	O
protein	O
fractions	O
did	O
not	O
affect	O
DRA	O
gene	O
transcription	O
although	O
it	O
functionally	O
enhanced	O
the	O
transcription	O
of	O
another	O
gene	O
.	O
Recombinant	B
OTF-2	I
protein	I
produced	O
by	O
in	O
vitro	O
transcription	O
/	O
translation	O
could	O
also	O
enhance	O
DRA	O
gene	O
transcription	O
in	O
vitro	O
.	O
In	O
vivo	O
transient	O
transfection	O
studies	O
utilizing	O
an	O
OTF-2	O
expression	O
vector	O
resulted	O
in	O
similar	O
findings	O
:	O
that	O
OTF-2	B
protein	I
enhanced	O
DRA	O
gene	O
transcription	O
,	O
and	O
that	O
this	O
effect	O
requires	O
an	O
intact	O
octamer	O
element	O
.	O
Together	O
these	O
results	O
constitute	O
the	O
first	O
direct	O
evidence	O
of	O
a	O
positive	O
role	O
for	O
the	O
lymphoid	B
-	I
specific	I
octamer	I
-	I
binding	I
factor	I
in	O
DRA	O
gene	O
transcription	O
.	O
[	O
Regulation	O
of	O
intracellular	O
cholesterol	O
synthesis	O
in	O
hypercholesterolemia	O
by	O
glucocorticoids	O
]	O
The	O
rate	O
of	O
endogenous	O
cholesterol	O
synthesis	O
in	O
blood	O
lymphocytes	O
and	O
skin	O
fibroblasts	O
from	O
patients	O
with	O
type	O
IIa	O
hyperlipidemia	O
was	O
found	O
to	O
be	O
increased	O
in	O
comparison	O
with	O
healthy	O
donors	O
.	O
The	O
cells	O
of	O
hyperlipidemic	O
patients	O
had	O
lowered	O
levels	O
of	O
glucocorticoid	B
receptors	I
concomitantly	O
with	O
a	O
partial	O
loss	O
of	O
their	O
sensitivity	O
to	O
glucocorticoids	O
.	O
In	O
fibroblasts	O
from	O
patients	O
with	O
hereditary	O
hypercholesteremia	O
of	O
homozygous	O
type	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
did	O
not	O
exceed	O
10	O
%	O
of	O
their	O
content	O
in	O
normal	O
cells	O
.	O
The	O
decrease	O
of	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
in	O
patients	O
with	O
type	O
IIa	O
hyperlipidemia	O
seems	O
to	O
be	O
a	O
compensatory	O
response	O
of	O
cells	O
culminating	O
in	O
activation	O
of	O
endogenous	O
cholesterol	O
synthesis	O
.	O
Transcription	B
factor	I
activation	O
and	O
functional	O
stimulation	O
of	O
human	O
monocytes	O
.	O
Activation	O
of	O
expression	O
of	O
genes	O
encoding	O
transcription	B
factors	I
:	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
and	O
formation	O
of	O
AP1	B
transcriptional	I
complex	I
in	O
human	O
monocytes	O
was	O
investigated	O
.	O
It	O
was	O
found	O
that	O
lipopolysaccharide	O
induced	O
strongly	O
both	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
expression	O
as	O
well	O
as	O
AP1	B
formation	O
.	O
Interferon	B
gamma	I
activated	O
strongly	O
c	O
-	O
fos	O
and	O
weakly	O
c	O
-	O
jun	O
and	O
AP1	B
.	O
Tumor	B
necrosis	I
factor	I
induced	O
slightly	O
c	O
-	O
fos	O
and	O
had	O
almost	O
no	O
effect	O
on	O
c	O
-	O
jun	O
and	O
AP1	B
.	O
The	O
data	O
suggest	O
that	O
differences	O
in	O
functional	O
responses	O
elicited	O
in	O
monocytes	O
by	O
all	O
three	O
factors	B
may	O
be	O
dependent	O
on	O
different	O
routes	O
on	O
nuclear	O
signalling	O
employed	O
by	O
the	O
factors	B
.	O
Corticosteroid	B
receptors	I
and	O
lymphocyte	O
subsets	O
in	O
mononuclear	O
leukocytes	O
in	O
aging	O
.	O
Plasma	O
cortisol	O
and	O
aldosterone	O
levels	O
and	O
number	O
of	O
related	O
receptors	O
in	O
mononuclear	O
leukocytes	O
were	O
measured	O
in	O
49	O
healthy	O
aged	O
subjects	O
(	O
62	O
-	O
97	O
yr	O
)	O
and	O
in	O
21	O
adult	O
controls	O
(	O
21	O
-	O
50	O
yr	O
)	O
.	O
In	O
all	O
subjects	O
,	O
in	O
addition	O
,	O
lymphocyte	O
subsets	O
were	O
determined	O
as	O
an	O
index	O
of	O
corticosteroid	O
action	O
.	O
The	O
mean	O
number	O
of	O
type	B
I	I
and	I
type	I
II	I
receptors	I
was	O
significantly	O
lower	O
in	O
aged	O
subjects	O
than	O
in	O
controls	O
(	O
respectively	O
,	O
198	O
+	O
/-	O
96	O
and	O
272	O
+	O
/-	O
97	O
receptors	B
/cell	O
for	O
type	B
I	I
,	O
and	O
1	O
,	O
794	O
+	O
/-	O
803	O
and	O
3	O
,	O
339	O
+	O
/-	O
918	O
for	O
type	O
II	B
receptors	I
)	O
.	O
Plasma	O
aldosterone	O
and	O
cortisol	O
and	O
lymphocyte	O
subsets	O
were	O
not	O
different	O
in	O
the	O
two	O
groups	O
.	O
All	O
of	O
the	O
parameters	O
were	O
also	O
tested	O
for	O
correlation	O
,	O
and	O
a	O
significant	O
inverse	O
correlation	O
was	O
found	O
between	O
age	O
and	O
type	B
I	I
and	O
type	B
II	I
receptors	I
when	O
all	O
subjects	O
were	O
plotted	O
and	O
between	O
aged	O
and	O
CD4	O
and	O
age	O
and	O
CD4	O
/	O
CD8	O
in	O
the	O
aged	O
group	O
.	O
These	O
data	O
show	O
that	O
aged	O
subjects	O
have	O
reductions	O
of	O
corticosteroid	B
receptors	I
that	O
are	O
not	O
associated	O
with	O
increase	O
of	O
related	O
steroids	O
and	O
that	O
this	O
situation	O
probably	O
represents	O
a	O
concomitant	O
of	O
the	O
normal	O
aging	O
process	O
.	O
Stable	O
expression	O
of	O
HB24	O
,	O
a	O
diverged	O
human	O
homeobox	O
gene	O
,	O
in	O
T	O
lymphocytes	O
induces	O
genes	O
involved	O
in	O
T	O
cell	O
activation	O
and	O
growth	O
.	O
A	O
diverged	O
homeobox	O
gene	O
,	O
HB24	O
,	O
which	O
is	O
known	O
to	O
be	O
induced	O
following	O
lymphocyte	O
activation	O
,	O
was	O
introduced	O
into	O
Jurkat	O
T	O
cells	O
under	O
the	O
control	O
of	O
a	O
constitutive	O
promoter	O
.	O
Stable	O
transfectants	O
of	O
HB24	O
were	O
established	O
that	O
expressed	O
high	O
levels	O
of	O
HB24	O
mRNA	O
and	O
possessed	O
an	O
altered	O
phenotype	O
suggestive	O
of	O
activated	O
T	O
cells	O
.	O
A	O
number	O
of	O
genes	O
known	O
to	O
be	O
induced	O
following	O
T	O
cell	O
activation	O
and	O
associated	O
with	O
cell	O
growth	O
were	O
increased	O
in	O
the	O
transfectants	O
,	O
including	O
c	O
-	O
fos	O
,	O
c	O
-	O
myc	O
,	O
c	O
-	O
myb	O
,	O
HLA	O
-	O
DR	O
,	O
lck	O
,	O
NF	B
-	I
kappa	I
B	I
,	O
interleukin-2	O
and	O
interleukin-2	O
receptor	O
alpha	O
(	O
IL-2R	O
alpha	O
)	O
.	O
Analysis	O
of	O
IL-2R	B
alpha	I
expression	O
by	O
transient	O
transfection	O
of	O
IL-2R	O
alpha	O
promoter	O
constructs	O
into	O
the	O
HB24	O
transfectants	O
revealed	O
constitutive	O
expression	O
(	O
about	O
60	O
%	O
of	O
phytohemagglutinin-	O
and	O
phorbol	O
ester	O
-	O
activated	O
Jurkat	O
cells	O
)	O
that	O
was	O
dependent	O
on	O
the	O
kappa	O
B	O
site	O
in	O
the	O
IL-2R	O
alpha	O
promoter	O
.	O
Furthermore	O
,	O
as	O
a	O
consequence	O
of	O
the	O
increased	O
HB24	O
mRNA	O
levels	O
,	O
the	O
Jurkat	O
HB24	O
transfectants	O
proliferated	O
more	O
rapidly	O
than	O
control	O
cell	O
lines	O
.	O
Thus	O
,	O
stable	O
expression	O
of	O
HB24	O
confers	O
an	O
activation	O
phenotype	O
on	O
a	O
human	O
T	O
cell	O
line	O
,	O
implicating	O
this	O
gene	O
as	O
an	O
important	O
transcriptional	B
factor	I
during	O
T	O
cell	O
activation	O
and	O
growth	O
.	O
Interferon	B
-	I
gamma	I
potentiates	O
the	O
antiviral	O
activity	O
and	O
the	O
expression	O
of	O
interferon	O
-	O
stimulated	O
genes	O
induced	O
by	O
interferon	O
-	O
alpha	O
in	O
U937	O
cells	O
.	O
Binding	O
of	O
type	B
I	I
interferon	I
(	I
IFN	I
-	I
alpha	I
/	I
beta	I
)	I
to	I
specific	I
receptors	I
results	O
in	O
the	O
rapid	O
transcriptional	O
activation	O
,	O
independent	O
of	O
protein	O
synthesis	O
,	O
of	O
IFN	O
-	O
alpha	O
-	O
stimulated	O
genes	O
(	O
ISGs	O
)	O
in	O
human	O
fibroblasts	O
and	O
HeLa	O
and	O
Daudi	O
cell	O
lines	O
.	O
The	O
binding	O
of	O
ISGF3	B
(	O
IFN	B
-	I
stimulated	I
gene	I
factor	I
3	I
)	O
to	O
the	O
conserved	O
IFN	O
-	O
stimulated	O
response	O
element	O
(	O
ISRE	O
)	O
results	O
in	O
transcriptional	O
activation	O
.	O
This	O
factor	O
is	O
composed	O
of	O
a	O
DNA	B
-	I
binding	I
protein	I
(	O
ISGF3	B
gamma	I
)	O
,	O
which	O
normally	O
is	O
present	O
in	O
the	O
cytoplasm	O
,	O
and	O
other	O
IFN	B
-	I
alpha	I
-	I
activated	I
proteins	I
which	O
preexist	O
as	O
latent	B
cytoplasmic	I
precursors	I
(	O
ISGF3	B
alpha	I
)	O
.	O
We	O
have	O
found	O
that	O
ISG	O
expression	O
in	O
the	O
monocytic	O
U937	O
cell	O
line	O
differs	O
from	O
most	O
cell	O
lines	O
previously	O
examined	O
.	O
U937	O
cells	O
express	O
both	O
type	B
I	I
and	I
type	I
II	I
IFN	I
receptors	I
,	O
but	O
only	O
IFN	B
-	I
alpha	I
is	O
capable	O
of	O
inducing	O
antiviral	O
protection	O
in	O
these	O
cells	O
.	O
Pretreatment	O
with	O
IFN	B
-	I
gamma	I
potentiates	O
the	O
IFN	B
-	I
alpha	I
-induced	O
protection	O
,	O
but	O
IFN	B
-	I
gamma	I
alone	O
does	O
not	O
have	O
any	O
antiviral	O
activity	O
.	O
ISG15	O
mRNA	O
accumulation	O
in	O
U937	O
cells	O
is	O
not	O
detectable	O
before	O
6	O
h	O
of	O
IFN	B
-	I
alpha	I
treatment	O
,	O
peaks	O
at	O
24	O
h	O
,	O
and	O
requires	O
protein	O
synthesis	O
.	O
Although	O
IFN	B
-	I
gamma	I
alone	O
does	O
not	O
induce	O
ISG	O
expression	O
,	O
IFN	B
-	I
gamma	I
pretreatment	O
markedly	O
increases	O
and	O
hastens	O
ISG	O
expression	O
and	O
transcriptional	O
induction	O
.	O
Nuclear	O
extracts	O
assayed	O
for	O
the	O
presence	O
of	O
ISRE	B
binding	I
factors	I
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
show	O
that	O
ISGF3	B
is	O
induced	O
by	O
IFN	B
-	I
alpha	I
within	O
6	O
h	O
from	O
undetectable	O
basal	O
levels	O
in	O
untreated	O
U937	O
cells	O
.	O
Activation	O
of	O
ISGF3	B
alpha	I
,	O
the	O
latent	O
component	O
of	O
ISGF3	B
,	O
occurs	O
rapidly	O
.	O
However	O
,	O
the	O
increase	O
in	O
ISGF3	B
activity	O
ultimately	O
correlates	O
with	O
the	O
accumulation	O
of	O
ISGF3	B
gamma	I
induced	O
by	O
IFN	B
-	I
alpha	I
or	O
IFN	B
-	I
gamma	I
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
[	O
Plasma	O
cortisol	O
concentration	O
and	O
blood	O
leukocyte	O
content	O
of	O
glucocorticoid	B
receptors	I
in	O
patients	O
with	O
deficiency	O
-	O
cold	O
vs	O
deficiency	O
-	O
heat	O
syndromes	O
]	O
Plasma	O
cortisol	O
concentration	O
and	O
blood	O
leukocyte	O
content	O
of	O
glucocorticoid	B
receptors	I
(	O
GCR	B
)	O
were	O
assayed	O
in	O
20	O
patients	O
with	O
deficiency	O
syndromes	O
,	O
10	O
cold	O
in	O
property	O
(	O
deficiency	O
-	O
cold	O
)	O
,	O
the	O
other	O
10	O
hot	O
in	O
property	O
(	O
deficiency	O
-	O
heat	O
)	O
,	O
and	O
also	O
in	O
10	O
healthy	O
individuals	O
as	O
normal	O
control	O
for	O
the	O
purpose	O
of	O
investigating	O
the	O
nature	O
of	O
cold	O
and	O
heat	O
syndromes	O
.	O
As	O
a	O
result	O
,	O
the	O
cases	O
of	O
deficiency	O
-	O
cold	O
syndrome	O
(	O
DCS	O
)	O
had	O
a	O
normal	O
concentration	O
of	O
plasma	O
cortisol	O
but	O
a	O
lowered	O
content	O
of	O
GCR	B
in	O
leukocytes	O
when	O
compared	O
with	O
the	O
normal	O
control	O
(	O
P	O
less	O
than	O
0.05	O
)	O
;	O
the	O
cases	O
of	O
deficiency	O
-	O
heat	O
syndrome	O
(	O
DHS	O
)	O
had	O
a	O
higher	O
concentration	O
of	O
plasma	O
cortisol	O
than	O
the	O
normal	O
control	O
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
a	O
slightly	O
higher	O
content	O
of	O
GCR	B
in	O
leukocytes	O
.	O
It	O
was	O
concluded	O
that	O
the	O
DCS	O
is	O
characterized	O
by	O
diminished	O
biological	O
effects	O
of	O
adrenocortical	O
activity	O
,	O
while	O
the	O
DHS	O
,	O
by	O
augmented	O
biological	O
effects	O
of	O
adrenocortical	O
activity	O
.	O
Protein	B
kinase	I
C	I
activation	O
and	O
protooncogene	O
expression	O
in	O
differentiation	O
/	O
retrodifferentiation	O
of	O
human	O
U-937	O
leukemia	O
cells	O
.	O
Human	O
U-937	O
leukemia	O
cells	O
differentiate	O
along	O
the	O
monocytic	O
lineage	O
following	O
3-day	O
exposures	O
to	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O
This	O
induction	O
of	O
differentiation	O
is	O
accompanied	O
by	O
adherence	O
and	O
loss	O
of	O
proliferation	O
,	O
as	O
well	O
as	O
expression	O
/	O
repression	O
of	O
differentiation	O
-	O
associated	O
genes	O
.	O
Long	O
term	O
culture	O
of	O
TPA	O
-	O
differentiated	O
U-937	O
cells	O
in	O
the	O
absence	O
of	O
phorbol	O
ester	O
for	O
32	O
-	O
36	O
days	O
resulted	O
in	O
a	O
process	O
of	O
retrodifferentiation	O
.	O
The	O
retrodifferentiated	O
cells	O
detached	O
from	O
the	O
substrate	O
and	O
reinitiated	O
proliferation	O
.	O
Other	O
cellular	O
parameters	O
,	O
such	O
as	O
glycosidase	O
activities	O
,	O
cytokine	B
release	O
,	O
and	O
filament	O
expression	O
,	O
returned	O
to	O
levels	O
similar	O
to	O
that	O
observed	O
in	O
uninduced	O
cells	O
.	O
Treatment	O
of	O
U-937	O
cells	O
with	O
TPA	O
resulted	O
in	O
a	O
rapid	O
translocation	O
of	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
from	O
the	O
cytosol	O
to	O
cell	O
membrane	O
fractions	O
within	O
2	O
-	O
8	O
min	O
.	O
Increased	O
levels	O
of	O
membrane	O
-	O
associated	O
PKC	B
activity	O
persisted	O
until	O
17	O
-	O
29	O
days	O
.	O
However	O
,	O
longer	O
periods	O
of	O
incubation	O
were	O
associated	O
with	O
a	O
return	O
to	O
the	O
distribution	O
of	O
PKC	B
in	O
control	O
cells	O
.	O
Activation	O
of	O
PKC	B
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
certain	O
immediate	O
early	O
response	O
genes	O
,	O
and	O
in	O
the	O
present	O
studies	O
,	O
TPA	O
rapidly	O
induced	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
gene	O
expression	O
.	O
Levels	O
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
transcripts	O
remained	O
elevated	O
during	O
periods	O
of	O
PKC	B
activation	O
and	O
also	O
returned	O
to	O
levels	O
observed	O
in	O
control	O
cells	O
by	O
30	O
-	O
36	O
days	O
,	O
when	O
the	O
cells	O
entered	O
retrodifferentiation	O
.	O
Staurosporine	O
,	O
a	O
nonspecific	O
inhibitor	O
of	O
PKC	B
,	O
partially	O
blocked	O
TPA	O
-	O
induced	O
adherence	O
and	O
growth	O
inhibition	O
and	O
concomitantly	O
prevented	O
TPA	O
-	O
induced	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
gene	O
expression	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
The	O
promoter	O
of	O
the	O
CD19	O
gene	O
is	O
a	O
target	O
for	O
the	O
B	B
-	I
cell	I
-	I
specific	I
transcription	I
factor	I
BSAP	B
.	O
The	O
CD19	B
protein	I
is	O
expressed	O
on	O
the	O
surface	O
of	O
all	O
B	O
-	O
lymphoid	O
cells	O
with	O
the	O
exception	O
of	O
terminally	O
differentiated	O
plasma	O
cells	O
and	O
has	O
been	O
implicated	O
as	O
a	O
signal	O
-	O
transducing	O
receptor	O
in	O
the	O
control	O
of	O
proliferation	O
and	O
differentiation	O
.	O
Here	O
we	O
demonstrate	O
complete	O
correlation	O
between	O
the	O
expression	O
pattern	O
of	O
the	O
CD19	O
gene	O
and	O
the	O
B	B
-	I
cell	I
-	I
specific	I
transcription	I
factor	I
BSAP	B
in	O
a	O
large	O
panel	O
of	O
B	O
-	O
lymphoid	O
cell	O
lines	O
.	O
The	O
human	O
CD19	O
gene	O
has	O
been	O
cloned	O
,	O
and	O
several	O
BSAP	O
-	O
binding	O
sites	O
have	O
been	O
mapped	O
by	O
in	O
vitro	O
protein	O
-	O
DNA	O
binding	O
studies	O
.	O
In	O
particular	O
,	O
a	O
high	O
-	O
affinity	O
BSAP	O
-	O
binding	O
site	O
instead	O
of	O
a	O
TATA	O
sequence	O
is	O
located	O
in	O
the	O
-30	O
promoter	O
region	O
upstream	O
of	O
a	O
cluster	O
of	O
heterogeneous	O
transcription	O
start	O
sites	O
.	O
Moreover	O
,	O
this	O
site	O
is	O
occupied	O
by	O
BSAP	B
in	O
vivo	O
in	O
a	O
CD19-expressing	O
B	O
-	O
cell	O
line	O
but	O
not	O
in	O
plasma	O
or	O
HeLa	O
cells	O
.	O
This	O
high	O
-	O
affinity	O
site	O
has	O
been	O
conserved	O
in	O
the	O
promoters	O
of	O
both	O
human	O
and	O
mouse	O
CD19	O
genes	O
and	O
was	O
furthermore	O
shown	O
to	O
confer	O
B	O
-	O
cell	O
specificity	O
to	O
a	O
beta	O
-	O
globin	O
reporter	O
gene	O
in	O
transient	O
transfection	O
experiments	O
.	O
In	O
addition	O
,	O
BSAP	B
was	O
found	O
to	O
be	O
the	O
only	O
abundant	O
DNA	O
-	O
binding	O
activity	O
of	O
B	O
-	O
cell	O
nuclear	O
extracts	O
that	O
interacts	O
with	O
the	O
CD19	O
promoter	O
.	O
Together	O
,	O
this	O
evidence	O
strongly	O
implicates	O
BSAP	B
in	O
the	O
regulation	O
of	O
the	O
CD19	O
gene	O
.	O
Eicosanoids	O
in	O
breast	O
cancer	O
patients	O
before	O
and	O
after	O
mastectomy	O
.	O
In	O
19	O
patients	O
with	O
a	O
malignant	O
breast	O
tumor	O
,	O
tumor	O
tissue	O
and	O
blood	O
were	O
taken	O
to	O
determine	O
the	O
eicosanoid	O
profile	O
and	O
platelet	O
aggregation	O
.	O
Values	O
were	O
compared	O
with	O
those	O
of	O
patients	O
with	O
benign	O
tumors	O
(	O
n	O
=	O
4	O
)	O
,	O
or	O
undergoing	O
a	O
mammary	O
reduction	O
(	O
n	O
=	O
7	O
)	O
.	O
Postoperatively	O
,	O
blood	O
was	O
taken	O
as	O
well	O
in	O
order	O
to	O
compare	O
pre-	O
and	O
postoperative	O
values	O
.	O
Eicosanoids	O
were	O
measured	O
in	O
peripheral	O
blood	O
monocytes	O
and	O
mammary	O
tissue	O
by	O
means	O
of	O
HPLC	O
;	O
furthermore	O
,	O
TXA2	O
,	O
6-keto	O
-	O
PGF1	O
alpha	O
,	O
and	O
PGE2	O
were	O
determined	O
by	O
RIA	O
.	O
Differences	O
in	O
pre-	O
and	O
postoperative	O
values	O
of	O
cancer	O
patients	O
were	O
seen	O
in	O
plasma	O
RIA	O
values	O
:	O
PGE2	O
and	O
6-k	O
-	O
PGF1	O
alpha	O
were	O
significantly	O
higher	O
preoperatively	O
when	O
compared	O
with	O
postoperatively	O
,	O
however	O
,	O
such	O
differences	O
were	O
seen	O
in	O
the	O
control	O
groups	O
as	O
well	O
.	O
Compared	O
to	O
benign	O
tumor	O
or	O
mammary	O
reduction	O
test	O
material	O
the	O
eicosanoid	O
profile	O
of	O
tissue	O
obtained	O
from	O
malignant	O
mammary	O
tumors	O
showed	O
important	O
differences	O
.	O
Except	O
for	O
PGF2	O
alpha	O
,	O
HHT	O
and	O
15-HETE	O
no	O
detectable	O
quantities	O
of	O
eicosanoids	O
were	O
found	O
in	O
the	O
non	O
-	O
tumor	O
material	O
,	O
whereas	O
in	O
the	O
malignant	O
tumor	O
material	O
substantial	O
quantities	O
of	O
a	O
number	O
of	O
eicosanoid	O
metabolites	O
were	O
present	O
.	O
Statistically	O
significant	O
correlations	O
could	O
be	O
established	O
between	O
patient	O
/	O
histopathology	O
data	O
and	O
the	O
results	O
of	O
the	O
platelet	O
aggregation	O
assays	O
,	O
e.g.	O
between	O
menopausal	O
status	O
and	O
ADP	O
aggregation	O
;	O
oestrogen	B
receptor	I
(	O
+	O
/-	O
)	O
and	O
collagen	B
and	O
arachidonic	O
acid	O
aggregation	O
,	O
inflammatory	O
cell	O
infiltration	O
score	O
and	O
arachidonic	O
acid	O
aggregation	O
and	O
fibrosis	O
score	O
and	O
ADP	O
aggregation	O
.	O
The	O
results	O
show	O
that	O
eicosanoid	O
synthesis	O
in	O
material	O
from	O
mammary	O
cancer	O
patients	O
is	O
different	O
from	O
that	O
in	O
benign	O
mammary	O
tissue	O
.	O
The	O
implications	O
,	O
in	O
particular	O
,	O
in	O
relation	O
to	O
future	O
prognosis	O
of	O
the	O
patient	O
,	O
remain	O
obscure	O
.	O
c	O
-	O
myc	O
mRNA	O
expression	O
in	O
minor	O
salivary	O
glands	O
of	O
patients	O
with	O
Sjogren	O
's	O
syndrome	O
.	O
c	O
-	O
myc	O
protooncogene	O
is	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
B	O
cell	O
lymphoid	O
malignancies	O
and	O
high	O
levels	O
of	O
c	O
-	O
myc	O
mRNA	O
expression	O
are	O
observed	O
in	O
activated	O
blood	O
mononuclear	O
cells	O
.	O
Sjogren	O
's	O
syndrome	O
(	O
SS	O
)	O
is	O
characterized	O
by	O
lymphocytic	O
infiltrates	O
of	O
exocrine	O
glands	O
,	O
remarkable	O
B	O
cell	O
hyperreactivity	O
and	O
a	O
strong	O
predisposition	O
to	O
B	O
cell	O
neoplasia	O
.	O
In	O
this	O
study	O
,	O
c	O
-	O
myc	O
protooncogene	O
mRNA	O
expression	O
in	O
29	O
labial	O
minor	O
salivary	O
gland	O
biopsies	O
from	O
patients	O
with	O
primary	O
SS	O
and	O
15	O
controls	O
was	O
examined	O
using	O
in	O
situ	O
hybridization	O
histochemistry	O
.	O
Two	O
40mer	O
oligonucleotides	O
from	O
the	O
1st	O
and	O
the	O
2nd	O
exon	O
of	O
the	O
c	O
-	O
myc	O
gene	O
,	O
labeled	O
with	O
35S	O
,	O
were	O
used	O
as	O
probes	O
.	O
To	O
detect	O
the	O
origin	O
of	O
the	O
cell	O
hybridized	O
with	O
a	O
c	O
-	O
myc	O
probe	O
,	O
a	O
combined	O
immunochemistry	O
in	O
situ	O
hybridization	O
histochemistry	O
technique	O
was	O
used	O
.	O
High	O
c	O
-	O
myc	O
mRNA	O
expression	O
was	O
detected	O
on	O
acinar	O
epithelial	O
cells	O
.	O
c	B
-	I
myc	I
did	O
not	O
correlate	O
with	O
c	B
-	I
fos	I
and	O
c	B
-	I
jun	I
protein	O
expression	O
.	O
Stronger	O
c	O
-	O
myc	O
mRNA	O
expression	O
was	O
detected	O
in	O
labial	O
salivary	O
glands	O
of	O
patients	O
with	O
longer	O
disease	O
duration	O
(	O
p	O
less	O
than	O
or	O
equal	O
to	O
0.002	O
)	O
and	O
more	O
intense	O
T	O
lymphocyte	O
infiltrates	O
(	O
p	O
less	O
than	O
0.05	O
)	O
although	O
these	O
patients	O
revealed	O
no	O
hypergammaglobulinemia	O
.	O
No	O
correlation	O
was	O
observed	O
between	O
c	O
-	O
myc	O
mRNA	O
and	O
B	O
lymphocyte	O
monoclonicity	O
or	O
lymphoma	O
.	O
In	O
conclusion	O
,	O
strong	O
c	O
-	O
myc	O
mRNA	O
expression	O
was	O
observed	O
on	O
epithelial	O
cells	O
of	O
labial	O
salivary	O
glands	O
from	O
patients	O
with	O
primary	O
SS	O
.	O
Our	O
findings	O
may	O
indicate	O
the	O
presence	O
of	O
a	O
reactivated	O
virus	O
hosted	O
in	O
these	O
cells	O
.	O
Cytoplasmic	O
domain	O
heterogeneity	O
and	O
functions	O
of	O
IgG	B
Fc	I
receptors	I
in	O
B	O
lymphocytes	O
.	O
B	O
lymphocytes	O
and	O
macrophages	O
express	O
closely	O
related	O
immunoglobulin	B
G	I
(	I
IgG	I
)	I
Fc	I
receptors	I
(	O
Fc	B
gamma	I
RII	I
)	O
that	O
differ	O
only	O
in	O
the	O
structures	O
of	O
their	O
cytoplasmic	B
domains	I
.	O
Because	O
of	O
cell	O
type	O
-	O
specific	O
alternative	O
messenger	O
RNA	O
splicing	O
,	O
B	B
-	I
cell	I
Fc	I
gamma	I
RII	I
contains	O
an	O
insertion	O
of	O
47	O
amino	O
acids	O
that	O
participates	O
in	O
determining	O
receptor	O
function	O
in	O
these	O
cells	O
.	O
Transfection	O
of	O
an	O
Fc	O
gamma	O
RII	O
-	O
negative	O
B	O
-	O
cell	O
line	O
with	O
complementary	O
DNA	O
's	O
encoding	O
the	O
two	O
splice	O
products	O
and	O
various	O
receptor	O
mutants	O
indicated	O
that	O
the	O
insertion	O
was	O
responsible	O
for	O
preventing	O
both	O
Fc	B
gamma	I
RII	I
-mediated	O
endocytosis	O
and	O
Fc	B
gamma	I
RII	I
-mediated	O
antigen	O
presentation	O
.	O
The	O
insertion	O
was	O
not	O
required	O
for	O
Fc	B
gamma	I
RII	I
to	O
modulate	O
surface	B
immunoglobulin	I
-triggered	O
B	O
-	O
cell	O
activation	O
.	O
Instead	O
,	O
regulation	O
of	O
activation	O
involved	O
a	O
region	O
of	O
the	O
cytoplasmic	B
domain	I
common	O
to	O
both	O
the	O
lymphocyte	B
and	I
macrophage	I
receptor	I
isoforms	I
.	O
In	O
contrast	O
,	O
the	O
insertion	O
did	O
contribute	O
to	O
the	O
formation	O
of	O
caps	O
in	O
response	O
to	O
receptor	O
cross	O
-	O
linking	O
,	O
consistent	O
with	O
suggestions	O
that	O
the	O
lymphocyte	O
but	O
not	O
macrophage	O
form	O
of	O
the	O
receptor	O
can	O
associate	O
with	O
the	O
detergent	O
-	O
insoluble	O
cytoskeleton	O
.	O
Heterodimerization	O
and	O
transcriptional	O
activation	O
in	O
vitro	O
by	O
NF	B
-	I
kappa	I
B	I
proteins	I
.	O
The	O
NF	B
-	I
kappa	I
B	I
family	I
of	O
transcription	B
proteins	I
represents	O
multiple	O
DNA	O
binding	O
,	O
rel	B
related	I
polypeptides	I
that	O
contribute	O
to	O
regulation	O
of	O
genes	O
involved	O
in	O
immune	O
responsiveness	O
and	O
inflammation	O
,	O
as	O
well	O
as	O
activation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O
In	O
this	O
study	O
multiple	O
NF	B
-	I
kappa	I
B	I
related	I
polypeptides	I
ranging	O
from	O
85	O
to	O
45	O
kDa	O
were	O
examined	O
for	O
their	O
capacity	O
to	O
interact	O
with	O
the	O
PRDII	O
regulatory	O
element	O
of	O
interferon	O
beta	O
and	O
were	O
shown	O
to	O
possess	O
distinct	O
intrinsic	O
DNA	O
binding	O
affinities	O
for	O
this	O
NF	O
-	O
kappa	O
B	O
site	O
and	O
form	O
multiple	B
DNA	I
binding	I
homo-	I
and	I
heterodimer	I
complexes	I
in	O
co	O
-	O
renaturation	O
experiments	O
.	O
Furthermore	O
,	O
using	O
DNA	O
templates	O
containing	O
two	O
copies	O
of	O
the	O
PRDII	O
domain	O
linked	O
to	O
the	O
rabbit	O
beta	O
globin	O
gene	O
,	O
the	O
purified	O
polypeptides	O
specifically	O
stimulated	O
NF	B
-	I
kappa	I
B	I
dependent	O
transcription	O
in	O
an	O
in	O
vitro	O
reconstitution	O
assay	O
as	O
heterodimers	O
but	O
not	O
as	O
p50	B
homodimers	I
.	O
These	O
experiments	O
emphasize	O
the	O
role	O
of	O
NF	B
-	I
kappa	I
B	I
dimerization	O
as	O
a	O
distinct	O
level	O
of	O
transcriptional	O
control	O
that	O
may	O
permit	O
functional	O
diversification	O
of	O
a	O
limited	O
number	O
of	O
regulatory	B
proteins	I
.	O
Induction	O
of	O
the	O
POU	B
domain	I
transcription	I
factor	I
Oct-2	B
during	O
T	O
-	O
cell	O
activation	O
by	O
cognate	O
antigen	O
.	O
Oct-2	B
is	O
a	O
transcription	B
factor	I
that	O
binds	O
specifically	O
to	O
octamer	O
DNA	O
motifs	O
in	O
the	O
promoters	O
of	O
immunoglobulin	O
and	O
interleukin-2	O
genes	O
.	O
All	O
tumor	O
cell	O
lines	O
from	O
the	O
B	O
-	O
cell	O
lineage	O
and	O
a	O
few	O
from	O
the	O
T	O
-	O
cell	O
lineage	O
express	O
Oct-2	B
.	O
To	O
address	O
the	O
role	O
of	O
Oct-2	B
in	O
the	O
T	O
-	O
cell	O
lineage	O
,	O
we	O
studied	O
the	O
expression	O
of	O
Oct-2	O
mRNA	O
and	O
protein	O
in	O
nontransformed	O
human	O
and	O
mouse	O
T	O
cells	O
.	O
Oct-2	B
was	O
found	O
in	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
prepared	O
from	O
human	O
peripheral	O
blood	O
and	O
in	O
mouse	O
lymph	O
node	O
T	O
cells	O
.	O
In	O
a	O
T	O
-	O
cell	O
clone	O
specific	O
for	O
pigeon	B
cytochrome	I
c	I
in	O
the	O
context	O
of	O
I	B
-	I
Ek	I
,	O
Oct-2	B
was	O
induced	O
by	O
antigen	O
stimulation	O
,	O
with	O
the	O
increase	O
in	O
Oct-2	B
protein	I
seen	O
first	O
at	O
3	O
h	O
after	O
activation	O
and	O
continuing	O
for	O
at	O
least	O
24	O
h	O
.	O
Oct-2	O
mRNA	O
induction	O
during	O
antigen	O
-	O
driven	O
T	O
-	O
cell	O
activation	O
was	O
blocked	O
by	O
cyclosporin	O
A	O
,	O
as	O
well	O
as	O
by	O
protein	O
synthesis	O
inhibitors	O
.	O
These	O
results	O
suggest	O
that	O
Oct-2	B
participates	O
in	O
transcriptional	O
regulation	O
during	O
T	O
-	O
cell	O
activation	O
.	O
The	O
relatively	O
delayed	O
kinetics	O
of	O
Oct-2	B
induction	O
suggests	O
that	O
Oct-2	B
mediates	O
the	O
changes	O
in	O
gene	O
expression	O
which	O
occur	O
many	O
hours	O
or	O
days	O
following	O
antigen	O
stimulation	O
of	O
T	O
lymphocytes	O
.	O
[	O
Changes	O
in	O
plasma	B
interleukin-1	I
and	O
their	O
possible	O
relationship	O
with	O
the	O
changes	O
in	O
glucocorticoid	B
receptor	I
in	O
aged	O
long	O
-	O
distance	O
runner	O
]	O
For	O
the	O
study	O
of	O
the	O
changes	O
in	O
plasma	B
interleukin-1	I
(	O
IL-1	B
)	O
and	O
their	O
possible	O
relationship	O
with	O
the	O
changes	O
in	O
glucocorticoid	B
receptor	I
(	O
GR	B
)	O
,	O
plasma	B
IL-1	I
and	O
GR	B
in	O
peripheral	O
blood	O
leukocytes	O
in	O
aged	O
long	O
-	O
distance	O
runner	O
were	O
measured	O
simultaneously	O
.	O
The	O
activity	O
of	O
IL-1	B
was	O
expressed	O
as	O
its	O
ability	O
to	O
stimulate	O
3H	B
-	I
TdR	I
incorporation	O
in	O
the	O
thymocytes	O
of	O
C57	O
mice	O
.	O
GR	B
was	O
determined	O
by	O
whole	O
cell	O
assay	O
with	O
3H	O
-	O
Dex	O
.	O
The	O
results	O
showed	O
that	O
the	O
activity	O
of	O
plasma	O
IL-1	B
in	O
aged	O
long	O
-	O
distance	O
runner	O
was	O
209	O
%	O
,	O
223	O
%	O
and	O
145	O
%	O
of	O
the	O
control	O
at	O
14.7	O
-	O
18.7	O
,	O
3.8	O
-	O
7.0	O
and	O
1.5	O
-	O
2.6	O
KD	O
fractions	O
.	O
The	O
GR	B
in	O
peripheral	O
blood	O
leukocytes	O
in	O
aged	O
runner	O
was	O
65	O
%	O
of	O
the	O
control	O
.	O
Possible	O
relationship	O
between	O
the	O
changes	O
in	O
IL-1	B
and	O
GR	B
in	O
aged	O
long	O
-	O
distance	O
runner	O
and	O
its	O
physiological	O
significance	O
are	O
discussed	O
.	O
Transcription	B
factor	I
AP-2	I
activates	O
gene	O
expression	O
of	O
HTLV	O
-	O
I	O
.	O
The	O
HTLV	O
-	O
I	O
LTR	O
contains	O
three	O
conserved	O
regulatory	O
elements	O
known	O
as	O
21	O
base	O
pair	O
repeats	O
which	O
are	O
required	O
for	O
stimulation	O
of	O
gene	O
expression	O
by	O
the	O
transactivator	B
protein	I
tax	B
.	O
Mutagenesis	O
indicates	O
that	O
the	O
21	O
bp	O
repeats	O
can	O
be	O
subdivided	O
into	O
three	O
motifs	O
,	O
A	O
,	O
B	O
and	O
C	O
,	O
each	O
of	O
which	O
influences	O
the	O
level	O
of	O
tax	B
activation	O
.	O
The	O
A	O
site	O
in	O
the	O
21	O
bp	O
repeat	O
has	O
strong	O
homology	O
with	O
previously	O
described	O
binding	O
sites	O
for	O
the	O
transcription	B
factor	I
AP-2	I
.	O
We	O
demonstrated	O
that	O
AP-2	O
mRNA	O
was	O
present	O
in	O
T	O
-	O
lymphocytes	O
and	O
that	O
cellular	O
factors	O
from	O
both	O
non	O
-	O
transformed	O
and	O
transformed	O
T	O
-	O
lymphocytes	O
specifically	O
bound	O
to	O
the	O
consensus	O
motif	O
for	O
AP-2	B
in	O
each	O
21	O
bp	O
.	O
To	O
determine	O
the	O
role	O
of	O
AP-2	B
in	O
the	O
regulation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
gene	O
expression	O
,	O
we	O
used	O
an	O
AP-2	O
cDNA	O
in	O
DNA	O
binding	O
and	O
transient	O
expression	O
assays	O
.	O
Gel	O
retardation	O
and	O
methylation	O
interference	O
studies	O
revealed	O
that	O
bacterially	B
produced	I
AP-2	I
bound	O
specifically	O
and	O
with	O
high	O
affinity	O
to	O
all	O
three	O
21	O
bp	O
repeats	O
,	O
and	O
that	O
it	O
required	O
the	O
core	O
sequence	O
AGGC	O
for	O
specific	O
binding	O
.	O
Binding	O
of	O
AP-2	B
prevented	O
the	O
subsequent	O
binding	O
of	O
members	O
of	O
the	O
CREB	B
/	I
ATF	I
family	I
to	O
an	O
adjacent	O
regulatory	O
motif	O
in	O
the	O
21	O
bp	O
repeat	O
.	O
Transfection	O
of	O
an	O
AP-2	O
expression	O
construct	O
into	O
T	O
-	O
lymphocytes	O
activated	O
gene	O
expression	O
from	O
the	O
HTLV	O
-	O
I	O
LTR	O
.	O
At	O
least	O
two	O
21	O
bp	O
repeats	O
were	O
required	O
for	O
high	O
levels	O
of	O
AP-2	B
activation	O
and	O
mutagenesis	O
of	O
the	O
AP-2	O
consensus	O
binding	O
sequences	O
in	O
the	O
21	O
bp	O
repeats	O
eliminate	O
this	O
activation	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
In	O
vivo	O
footprint	O
analysis	O
of	O
the	O
HLA	O
-	O
DRA	O
gene	O
promoter	O
:	O
cell	O
-	O
specific	O
interaction	O
at	O
the	O
octamer	O
site	O
and	O
up	O
-	O
regulation	O
of	O
X	O
box	O
binding	O
by	O
interferon	B
gamma	I
.	O
Analysis	O
of	O
the	O
major	O
histocompatibility	O
complex	O
class	O
II	O
gene	O
promoter	O
DRA	O
has	O
previously	O
identified	O
at	O
least	O
five	O
cis	O
-	O
acting	O
regions	O
required	O
for	O
maximal	O
expression	O
.	O
We	O
have	O
examined	O
the	O
DRA	O
promoter	O
for	O
protein	O
-	O
DNA	O
interactions	O
in	O
the	O
intact	O
cell	O
,	O
which	O
may	O
mediate	O
transcriptional	O
activation	O
.	O
Using	O
in	O
vivo	O
genomic	O
footprinting	O
we	O
identified	O
interactions	O
in	O
B	O
-	O
cell	O
lines	O
at	O
the	O
octamer	O
site	O
and	O
the	O
Y	O
,	O
X1	O
,	O
and	O
X2	O
boxes	O
.	O
Class	O
II	O
antigen	O
expressing	O
T	O
-	O
cell	O
lines	O
maintained	O
contacts	O
identical	O
to	O
B	O
-	O
cell	O
lines	O
,	O
while	O
class	O
II	O
-	O
negative	O
T	O
-	O
cell	O
lines	O
exhibited	O
no	O
interactions	O
.	O
In	O
lymphoid	O
cell	O
lines	O
,	O
the	O
octamer	O
site	O
is	O
occupied	O
and	O
required	O
for	O
maximal	O
expression	O
.	O
This	O
is	O
most	O
likely	O
due	O
to	O
the	O
presence	O
of	O
the	O
lymphoid	B
-	I
specific	I
OTF-2	I
factor	I
.	O
In	O
contrast	O
,	O
the	O
class	O
II	O
-	O
positive	O
nonlymphoid	O
glioblastoma	O
cell	O
line	O
does	O
not	O
exhibit	O
interactions	O
at	O
the	O
octamer	O
site	O
despite	O
the	O
presence	O
of	O
the	O
ubiquitous	B
OTF-1	I
factor	I
and	O
an	O
open	O
binding	O
site	O
.	O
Thus	O
,	O
the	O
DRA	O
promoter	O
discriminates	O
against	O
OTF-1	B
activation	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
in	O
the	O
glioblastoma	O
line	O
.	O
Interferon	B
gamma	I
induces	O
class	O
II	O
expression	O
in	O
this	O
glioblastoma	O
cell	O
line	O
and	O
,	O
in	O
parallel	O
,	O
up	O
-	O
regulates	O
X1	O
and	O
X2	O
box	O
protein	O
-	O
DNA	O
interactions	O
,	O
while	O
all	O
other	O
interactions	O
remain	O
unchanged	O
.	O
These	O
results	O
suggest	O
that	O
interferon	B
gamma	I
functions	O
on	O
a	O
poised	O
promoter	O
by	O
altering	O
weak	O
,	O
nonproductive	O
interactions	O
at	O
the	O
X	O
boxes	O
to	O
strong	O
interactions	O
.	O
These	O
findings	O
provide	O
direct	O
in	O
vivo	O
evidence	O
to	O
strongly	O
suggest	O
that	O
the	O
modulation	O
of	O
X1	O
and	O
X2	O
interactions	O
is	O
an	O
important	O
constituent	O
of	O
the	O
interferon	B
gamma	I
induction	O
pathway	O
.	O
Simple	O
derivation	O
of	O
TFIID	O
-	O
dependent	O
RNA	B
polymerase	I
II	I
transcription	O
systems	O
from	O
Schizosaccharomyces	O
pombe	O
and	O
other	O
organisms	O
,	O
and	O
factors	O
required	O
for	O
transcriptional	O
activation	O
.	O
Resolution	O
of	O
whole	O
cell	O
extract	O
through	O
two	O
chromatographic	O
steps	O
yields	O
a	O
single	O
protein	O
fraction	O
requiring	O
only	O
the	O
addition	O
of	O
TFIID	B
for	O
the	O
initiation	O
of	O
transcription	O
at	O
RNA	O
polymerase	O
II	O
promoters	O
.	O
This	O
approach	O
allows	O
the	O
convenient	O
generation	O
of	O
RNA	B
polymerase	I
II	I
transcription	O
systems	O
from	O
Saccharomyces	O
cerevisiae	O
,	O
human	O
lymphocytes	O
,	O
and	O
Schizosaccharomyces	O
pombe	O
.	O
TFIIDs	B
from	O
all	O
three	O
organisms	O
are	O
interchangeable	O
among	O
all	O
three	O
systems	O
.	O
The	O
S.	O
cerevisiae	O
and	O
Sch	O
.	O
pombe	O
systems	O
support	O
effects	O
of	O
acidic	B
activator	I
proteins	I
,	O
provided	O
a	O
further	O
protein	O
fraction	O
from	O
S.	O
cerevisiae	O
is	O
supplied	O
.	O
This	O
further	O
fraction	O
is	O
distinct	O
from	O
the	O
mediator	O
of	O
transcriptional	O
activation	O
described	O
previously	O
and	O
represents	O
a	O
second	O
component	O
in	O
addition	O
to	O
general	B
initiation	I
factors	I
that	O
may	O
facilitate	O
a	O
response	O
to	O
acidic	B
activators	I
.	O
The	O
development	O
of	O
functionally	O
responsive	O
T	O
cells	O
.	O
The	O
work	O
reviewed	O
in	O
this	O
article	O
separates	O
T	O
cell	O
development	O
into	O
four	O
phases	O
.	O
First	O
is	O
an	O
expansion	O
phase	O
prior	O
to	O
TCR	B
rearrangement	O
,	O
which	O
appears	O
to	O
be	O
correlated	O
with	O
programming	O
of	O
at	O
least	O
some	O
response	O
genes	O
for	O
inducibility	O
.	O
This	O
phase	O
can	O
occur	O
to	O
some	O
extent	O
outside	O
of	O
the	O
thymus	O
.	O
However	O
,	O
the	O
profound	O
T	O
cell	O
deficit	O
of	O
nude	O
mice	O
indicates	O
that	O
the	O
thymus	O
is	O
by	O
far	O
the	O
most	O
potent	O
site	O
for	O
inducing	O
the	O
expansion	O
per	O
se	O
,	O
even	O
if	O
other	O
sites	O
can	O
induce	O
some	O
response	O
acquisition	O
.	O
Second	O
is	O
a	O
controlled	O
phase	O
of	O
TCR	O
gene	O
rearrangement	O
.	O
The	O
details	O
of	O
the	O
regulatory	O
mechanism	O
that	O
selects	O
particular	O
loci	O
for	O
rearrangement	O
are	O
still	O
not	O
known	O
.	O
It	O
seems	O
that	O
the	O
rearrangement	O
of	O
the	O
TCR	O
gamma	O
loci	O
in	O
the	O
gamma	O
delta	O
lineage	O
may	O
not	O
always	O
take	O
place	O
at	O
a	O
developmental	O
stage	O
strictly	O
equivalent	O
to	O
the	O
rearrangement	O
of	O
TCR	O
beta	O
in	O
the	O
alpha	O
beta	O
lineage	O
,	O
and	O
it	O
is	O
not	O
clear	O
just	O
how	O
early	O
the	O
two	O
lineages	O
diverge	O
.	O
In	O
the	O
TCR	O
alpha	O
beta	O
lineage	O
,	O
however	O
,	O
the	O
final	O
gene	O
rearrangement	O
events	O
are	O
accompanied	O
by	O
rapid	O
proliferation	O
and	O
an	O
interruption	O
in	O
cellular	O
response	O
gene	O
inducibility	O
.	O
The	O
loss	O
of	O
conventional	O
responsiveness	O
is	O
probably	O
caused	O
by	O
alterations	O
at	O
the	O
level	O
of	O
signaling	O
,	O
and	O
may	O
be	O
a	O
manifestation	O
of	O
the	O
physiological	O
state	O
that	O
is	O
a	O
precondition	O
for	O
selection	O
.	O
Third	O
is	O
the	O
complex	O
process	O
of	O
selection	O
.	O
Whereas	O
peripheral	O
T	O
cells	O
can	O
undergo	O
forms	O
of	O
positive	O
selection	O
(	O
by	O
antigen	O
-	O
driven	O
clonal	O
expansion	O
)	O
and	O
negative	O
selection	O
(	O
by	O
abortive	O
stimulation	O
leading	O
to	O
anergy	O
or	O
death	O
)	O
,	O
neither	O
is	O
exactly	O
the	O
same	O
phenomenon	O
that	O
occurs	O
in	O
the	O
thymic	O
cortex	O
.	O
Negative	O
selection	O
in	O
the	O
cortex	O
appears	O
to	O
be	O
a	O
suicidal	O
inversion	O
of	O
antigen	O
responsiveness	O
:	O
instead	O
of	O
turning	O
on	O
IL-2	B
expression	O
,	O
the	O
activated	O
cell	O
destroys	O
its	O
own	O
chromatin	O
.	O
The	O
genes	O
that	O
need	O
to	O
be	O
induced	O
for	O
this	O
response	O
are	O
not	O
yet	O
identified	O
,	O
but	O
it	O
is	O
unquestionably	O
a	O
form	O
of	O
activation	O
.	O
It	O
is	O
interesting	O
that	O
in	O
humans	O
and	O
rats	O
,	O
cortical	O
thymocytes	O
undergoing	O
negative	O
selection	O
can	O
still	O
induce	O
IL-2R	B
alpha	I
expression	O
and	O
even	O
be	O
rescued	O
in	O
vitro	O
,	O
if	O
exogenous	B
IL-2	I
is	O
provided	O
.	O
Perhaps	O
murine	O
thymocytes	O
are	O
denied	O
this	O
form	O
of	O
rescue	O
because	O
they	O
shut	O
off	O
IL-2R	B
beta	I
chain	I
expression	O
at	O
an	O
earlier	O
stage	O
or	O
because	O
they	O
may	O
be	O
uncommonly	O
Bcl-2	B
deficient	O
(	O
cf	O
.	O
Sentman	O
et	O
al.	O
,	O
1991	O
;	O
Strasser	O
et	O
al.	O
,	O
1991	O
)	O
.	O
Even	O
so	O
,	O
medullary	O
thymocytes	O
remain	O
at	O
least	O
partially	O
susceptible	O
to	O
negative	O
selection	O
even	O
as	O
they	O
continue	O
to	O
mature	O
.	O
SRC	O
-	O
related	O
proto	O
-	O
oncogenes	O
and	O
transcription	B
factors	I
in	O
primary	O
human	O
T	O
cells	O
:	O
modulation	O
by	O
cyclosporin	O
A	O
and	O
FK506	O
.	O
Activation	O
of	O
T	O
lymphocytes	O
induces	O
transcription	O
of	O
genes	O
encoding	O
for	O
lymphokines	B
.	O
Interleukin-2	O
(	O
IL-2	O
)	O
gene	O
expression	O
is	O
controlled	O
transcriptionally	O
by	O
the	O
cooperative	O
activity	O
of	O
specific	O
trans	B
-	I
activating	I
factors	I
that	O
bind	O
to	O
the	O
IL-2	O
enhancer	O
.	O
Cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
inhibit	O
the	O
production	O
of	O
IL-2	B
in	O
T	O
lymphocytes	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O
A	O
member	O
of	O
the	O
src	O
gene	O
family	O
,	O
the	O
lymphocyte	B
-	I
specific	I
protein	I
tyrosine	I
kinase	I
,	O
p56lck	B
,	O
has	O
been	O
implicated	O
in	O
IL-2	B
production	O
.	O
CsA	O
was	O
found	O
not	O
to	O
inhibit	O
lck	B
gene	O
expression	O
,	O
nor	O
the	O
activity	O
of	O
the	O
lck	O
gene	O
product	O
.	O
However	O
,	O
CsA	O
and	O
FK506	O
inhibit	O
the	O
appearance	O
of	O
DNA	O
binding	O
activity	O
of	O
factors	O
that	O
bind	O
to	O
the	O
NF	O
-	O
AT	O
and	O
AP-1	O
sites	O
in	O
the	O
IL-2	O
enhancer	O
.	O
Since	O
the	O
induction	O
of	O
NF	B
-	I
AT	I
and	O
AP-1	B
is	O
induced	O
by	O
the	O
same	O
stimuli	O
that	O
stimulate	O
IL-2	B
production	O
,	O
these	O
results	O
indicate	O
that	O
the	O
immunosuppressant	O
action	O
of	O
CsA	O
and	O
FK506	O
is	O
exerted	O
at	O
the	O
level	O
of	O
these	O
trans	B
-	I
activating	I
factors	I
.	O
Bcl-2	B
:	O
a	O
repressor	O
of	O
lymphocyte	O
death	O
.	O
The	O
genes	O
and	O
mechanisms	O
that	O
control	O
programmed	O
cell	O
death	O
are	O
currently	O
the	O
subject	O
of	O
intense	O
study	O
.	O
The	O
bcl-2	O
gene	O
,	O
a	O
repressor	O
of	O
lymphocyte	O
death	O
,	O
is	O
perhaps	O
the	O
best	O
understood	O
of	O
the	O
programmed	O
cell	O
death	O
associated	O
genes	O
.	O
Here	O
,	O
Stanley	O
Korsmeyer	O
provides	O
a	O
brief	O
overview	O
of	O
bcl-2	B
,	O
concentrating	O
on	O
its	O
roles	O
in	O
B-	O
and	O
T	O
-	O
cell	O
development	O
and	O
in	O
oncogenesis	O
.	O
Mitogen	O
stimulation	O
of	O
T	O
-	O
cells	O
increases	O
c	B
-	I
Fos	I
and	O
c	B
-	I
Jun	I
protein	O
levels	O
,	O
AP-1	O
binding	O
and	O
AP-1	O
transcriptional	O
activity	O
.	O
We	O
have	O
analysed	O
the	O
effect	O
of	O
mitogenic	O
lectins	O
on	O
c	B
-	I
Fos	I
and	O
c	B
-	I
Jun	I
protein	O
levels	O
as	O
well	O
as	O
on	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
binding	O
and	O
enhancer	O
activity	O
in	O
Jurkat	O
T	O
-	O
cells	O
.	O
Both	O
c	B
-	I
Fos	I
and	O
c	B
-	I
Jun	I
protein	O
levels	O
were	O
increased	O
after	O
Con	O
A	O
and	O
PHA	O
stimulation	O
.	O
Since	O
T	O
-	O
cell	O
stimulation	O
increases	O
both	O
intracellular	O
Ca2	O
+	O
and	O
cAMP	O
levels	O
and	O
activates	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
the	O
possible	O
involvement	O
of	O
these	O
intracellular	O
messengers	O
in	O
c	B
-	I
Fos	I
and	O
c	B
-	I
Jun	I
induction	O
was	O
tested	O
.	O
PMA	O
,	O
which	O
directly	O
activates	O
PKC	O
,	O
mimicked	O
the	O
effect	O
of	O
the	O
lectins	O
on	O
c	O
-	O
Fos	O
and	O
c	B
-	I
Jun	I
,	O
but	O
elevation	O
of	O
either	O
intracellular	O
Ca2	O
+	O
or	O
cAMP	O
levels	O
had	O
little	O
or	O
no	O
effect	O
.	O
The	O
mitogen	O
-	O
induced	O
increase	O
of	O
c	B
-	I
Fos	I
and	O
c	B
-	I
Jun	I
immunoreactivity	O
was	O
inhibited	O
by	O
H-7	O
,	O
a	O
kinase	O
inhibitor	O
with	O
relatively	O
high	O
specificity	O
for	O
PKC	O
,	O
and	O
less	O
efficiently	O
by	O
H-8	O
,	O
a	O
structurally	O
related	O
kinase	O
inhibitor	O
less	O
active	O
on	O
PKC	O
,	O
but	O
more	O
active	O
on	O
cyclic	O
nucleotide	O
-	O
dependent	O
kinases	O
.	O
Con	O
A	O
stimulation	O
was	O
found	O
to	O
increase	O
both	O
binding	O
of	O
AP-1	O
to	O
the	O
AP-1	O
consensus	O
sequence	O
,	O
TRE	O
,	O
and	O
AP-1	O
enhancer	O
activity	O
,	O
in	O
Jurkat	O
cells	O
.	O
PMA	O
was	O
also	O
found	O
to	O
increase	O
the	O
AP-1	O
enhancer	O
activity	O
,	O
whereas	O
elevation	O
of	O
Ca2	O
+	O
or	O
cAMP	O
had	O
only	O
minor	O
effects	O
.	O
We	O
conclude	O
that	O
stimulation	O
with	O
mitogenic	O
lectins	O
is	O
sufficient	O
to	O
increase	O
both	O
c	B
-	I
Fos	I
and	O
c	B
-	I
Jun	I
protein	O
levels	O
,	O
AP-1	O
binding	O
and	O
AP-1	O
enhancer	O
activity	O
in	O
Jurkat	O
cells	O
and	O
that	O
they	O
act	O
via	O
mechanisms	O
that	O
could	O
involve	O
the	O
activation	O
of	O
PKC	O
.	O
Functional	O
interaction	O
between	O
the	O
two	O
zinc	B
finger	I
domains	I
of	O
the	O
v	B
-	I
erb	I
A	I
oncoprotein	I
.	O
The	O
v	O
-	O
erb	O
A	O
oncogene	O
of	O
avian	O
erythroblastosis	O
virus	O
is	O
a	O
mutated	O
and	O
virally	O
transduced	O
copy	O
of	O
a	O
host	O
cell	O
gene	O
encoding	O
a	O
thyroid	B
hormone	I
receptor	I
.	O
The	O
protein	O
expressed	O
by	O
the	O
v	O
-	O
erb	O
A	O
oncogene	O
binds	O
to	O
DNA	O
and	O
acts	O
as	O
a	O
dominant	O
negative	O
inhibitor	O
of	O
both	O
the	O
thyroid	B
hormone	I
receptor	I
and	O
the	O
closely	O
related	O
retinoic	B
acid	I
receptor	I
.	O
The	O
v	B
-	I
erb	I
A	I
protein	I
has	O
sustained	O
two	O
amino	O
acid	O
alterations	O
within	O
its	O
DNA	B
-	I
binding	I
domain	I
relative	O
to	O
that	O
of	O
c	B
-	I
erb	I
A	I
,	O
one	O
of	O
which	O
,	O
at	O
serine	O
61	O
,	O
is	O
known	O
to	O
be	O
important	O
for	O
v	B
-	I
erb	I
A	I
function	O
in	O
the	O
neoplastic	O
cell	O
.	O
We	O
report	O
here	O
that	O
the	O
second	O
alteration	O
,	O
at	O
threonine	O
78	O
,	O
also	O
plays	O
an	O
important	O
,	O
although	O
more	O
indirect	O
,	O
role	O
:	O
alteration	O
of	O
the	O
sequence	O
at	O
threonine	O
78	O
such	O
that	O
it	O
resembles	O
that	O
of	O
c	B
-	I
erb	I
A	I
can	O
act	O
as	O
an	O
intragenic	O
suppressor	O
and	O
can	O
partially	O
restore	O
function	O
to	O
a	O
v	B
-	I
erb	I
A	I
protein	I
rendered	O
defective	O
due	O
to	O
a	O
mutation	O
at	O
position	B
61	I
.	O
Threonine	O
78	O
lies	O
within	O
the	O
D	B
-	I
box	I
of	O
the	O
v	B
-	I
erb	I
A	I
protein	I
,	O
a	O
region	O
thought	O
to	O
mediate	O
receptor	O
-	O
receptor	O
dimerizations	O
,	O
and	O
is	O
not	O
in	O
physical	O
proximity	O
to	O
the	O
serine	O
at	O
position	B
61	I
.	O
It	O
therefore	O
appears	O
that	O
an	O
indirect	O
interaction	O
occurs	O
between	O
these	O
two	O
sites	O
and	O
that	O
this	O
interaction	O
is	O
crucial	O
for	O
v	B
-	I
erb	I
A	I
function	O
.	O
Pax-5	O
encodes	O
the	O
transcription	B
factor	I
BSAP	B
and	O
is	O
expressed	O
in	O
B	O
lymphocytes	O
,	O
the	O
developing	O
CNS	O
,	O
and	O
adult	O
testis	O
.	O
BSAP	B
has	O
been	O
identified	O
previously	O
as	O
a	O
transcription	B
factor	I
that	O
is	O
expressed	O
at	O
early	O
,	O
but	O
not	O
late	O
,	O
stages	O
of	O
B	O
-	O
cell	O
differentiation	O
.	O
Biochemical	O
purification	O
and	O
cDNA	O
cloning	O
has	O
now	O
revealed	O
that	O
BSAP	B
belongs	O
to	O
the	O
family	O
of	O
paired	B
domain	I
proteins	I
.	O
BSAP	B
is	O
encoded	O
by	O
the	O
Pax-5	O
gene	O
and	O
has	O
been	O
highly	O
conserved	O
between	O
human	O
and	O
mouse	O
.	O
An	O
intact	O
paired	O
domain	O
was	O
shown	O
to	O
be	O
both	O
necessary	O
and	O
sufficient	O
for	O
DNA	O
binding	O
of	O
BSAP	B
.	O
Binding	O
studies	O
with	O
several	O
BSAP	O
recognition	O
sequences	O
demonstrated	O
that	O
the	O
sequence	O
specificity	O
of	O
BSAP	B
differs	O
from	O
that	O
of	O
the	O
distantly	O
related	O
paired	B
domain	I
protein	I
Pax-1	I
.	O
During	O
embryogenesis	O
,	O
the	O
BSAP	O
gene	O
is	O
transiently	O
expressed	O
in	O
the	O
mesencephalon	O
and	O
spinal	O
cord	O
with	O
a	O
spatial	O
and	O
temporal	O
expression	O
pattern	O
that	O
is	O
distinct	O
from	O
that	O
of	O
other	O
Pax	O
genes	O
in	O
the	O
developing	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O
Later	O
,	O
the	O
expression	O
of	O
the	O
BSAP	O
gene	O
shifts	O
to	O
the	O
fetal	O
liver	O
where	O
it	O
correlates	O
with	O
the	O
onset	O
of	O
B	O
lymphopoiesis	O
.	O
BSAP	B
expression	O
persists	O
in	O
B	O
lymphocytes	O
and	O
is	O
also	O
seen	O
in	O
the	O
testis	O
of	O
the	O
adult	O
mouse	O
.	O
All	O
of	O
this	O
evidence	O
indicates	O
that	O
the	O
transcription	B
factor	I
BSAP	B
may	O
not	O
only	O
play	O
an	O
important	O
role	O
in	O
B	O
-	O
cell	O
differentiation	O
but	O
also	O
in	O
neural	O
development	O
and	O
spermatogenesis	O
.	O
A	O
novel	O
Ets	B
-	I
related	I
transcription	I
factor	I
,	O
Elf-1	B
,	O
binds	O
to	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
regulatory	O
elements	O
that	O
are	O
required	O
for	O
inducible	O
trans	O
activation	O
in	O
T	O
cells	O
.	O
Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
and	O
HIV-2	O
are	O
structurally	O
related	O
retroviruses	O
which	O
both	O
cause	O
AIDS	O
in	O
humans	O
.	O
Although	O
both	O
viruses	O
establish	O
latency	O
in	O
quiescent	O
human	O
-	O
peripheral	O
-	O
blood	O
T	O
cells	O
,	O
the	O
asymptomatic	O
phase	O
of	O
HIV-2	O
infection	O
may	O
be	O
more	O
prolonged	O
than	O
that	O
of	O
HIV-1	O
.	O
The	O
latent	O
phases	O
of	O
both	O
HIV-1	O
and	O
HIV-2	O
infection	O
have	O
been	O
shown	O
to	O
be	O
disrupted	O
by	O
T	O
-	O
cell	O
activation	O
,	O
a	O
process	O
that	O
requires	O
host	O
cell	O
transcription	O
factors	O
.	O
In	O
the	O
case	O
of	O
HIV-1	O
,	O
the	O
transcription	O
factor	O
NF	B
-	I
kappa	I
B	I
is	O
sufficient	O
for	O
inducible	O
transcriptional	O
activation	O
.	O
In	O
contrast	O
,	O
factors	O
in	O
addition	O
to	O
NF	B
-	I
kappa	I
B	I
are	O
required	O
to	O
activate	O
HIV-2	O
transcription	O
in	O
infected	O
T	O
cells	O
.	O
In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
a	O
novel	O
Ets	B
-	I
related	I
transcription	I
factor	I
,	O
Elf-1	B
,	O
binds	O
specifically	O
to	O
two	O
purine	O
-	O
rich	O
motifs	O
in	O
the	O
HIV-2	O
enhancer	O
.	O
Mutagenesis	O
experiments	O
demonstrated	O
that	O
these	O
Elf-1	O
binding	O
sites	O
are	O
required	O
for	O
induction	O
of	O
HIV-2	O
transcription	O
following	O
T	O
-	O
cell	O
-	O
receptor	O
-	O
mediated	O
T	O
-	O
cell	O
activation	O
.	O
Moreover	O
,	O
Elf-1	B
is	O
the	O
only	O
factor	O
present	O
in	O
activated	O
T	O
-	O
cell	O
nuclear	O
extracts	O
that	O
binds	O
to	O
these	O
sites	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
Thus	O
,	O
Elf-1	B
is	O
a	O
novel	B
transcription	I
factor	I
that	O
appears	O
to	O
be	O
required	O
for	O
the	O
T	O
-	O
cell	O
-	O
receptor	O
-	O
mediated	O
trans	O
activation	O
of	O
HIV-2	O
gene	O
expression	O
.	O
These	O
results	O
may	O
explain	O
differences	O
in	O
the	O
clinical	O
spectra	O
of	O
diseases	O
caused	O
by	O
HIV-1	O
and	O
HIV-2	O
and	O
may	O
also	O
have	O
implications	O
for	O
the	O
design	O
of	O
therapeutic	O
approaches	O
to	O
HIV-2	O
infection	O
.	O
Human	B
immunodeficiency	I
virus	I
type	I
1	I
Nef	I
protein	I
inhibits	O
NF	B
-	I
kappa	I
B	I
induction	O
in	O
human	O
T	O
cells	O
.	O
Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
can	O
establish	O
a	O
persistent	O
and	O
latent	O
infection	O
in	O
CD4	O
+	O
T	O
lymphocytes	O
(	O
W.C.Greene	O
,	O
N.Engl	O
.	O
J.	O
Med.324	O
:	O
308	O
-	O
317	O
,	O
1991	O
;	O
S.M.Schnittman	O
,	O
M.C.Psallidopoulos	O
,	O
H.C.	O
Lane	O
,	O
L.Thompson	O
,	O
M.Baseler	O
,	O
F.Massari	O
,	O
C.H.Fox	O
,	O
N.P.Salzman	O
,	O
and	O
A.S.Fauci	O
,	O
Science	O
245	O
:	O
305	O
-	O
308	O
,	O
1989	O
)	O
.	O
Production	O
of	O
HIV-1	O
from	O
latently	O
infected	O
cells	O
requires	O
host	O
cell	O
activation	O
by	O
T	B
-	I
cell	I
mitogens	I
(	O
T.Folks	O
,	O
D.M.Powell	O
,	O
M.M.Lightfoote	O
,	O
S.Benn	O
,	O
M.A.	O
Martin	O
,	O
and	O
A.S.Fauci	O
,	O
Science	O
231	O
:	O
600	O
-	O
602	O
,	O
1986	O
;	O
D.Zagury	O
,	O
J.	O
Bernard	O
,	O
R.Leonard	O
,	O
R.Cheynier	O
,	O
M.Feldman	O
,	O
P.S.Sarin	O
,	O
and	O
R.C.	O
Gallo	O
,	O
Science	O
231	O
:	O
850	O
-	O
853	O
,	O
1986	O
)	O
.	O
This	O
activation	O
is	O
mediated	O
by	O
the	O
host	B
transcription	I
factor	I
NF	B
-	I
kappa	I
B	I
[	O
G.Nabel	O
and	O
D.Baltimore	O
,	O
Nature	O
(	O
London	O
)	O
326	O
:	O
711	O
-	O
717	O
,	O
1987	O
]	O
.	O
We	O
report	O
here	O
that	O
the	O
HIV-1-encoded	B
Nef	I
protein	I
inhibits	O
the	O
induction	O
of	O
NF	B
-	I
kappa	I
B	I
DNA	O
-	O
binding	O
activity	O
by	O
T-	B
cell	I
mitogens	I
.	O
However	O
,	O
Nef	B
does	O
not	O
affect	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
other	O
transcription	B
factors	I
implicated	O
in	O
HIV-1	O
regulation	O
,	O
including	O
SP-1	B
,	O
USF	B
,	O
URS	B
,	O
and	O
NF	B
-	I
AT	I
.	O
Additionally	O
,	O
Nef	B
inhibits	O
the	O
induction	O
of	O
HIV-1-	O
and	O
interleukin	O
2-directed	O
gene	O
expression	O
,	O
and	O
the	O
effect	O
on	O
HIV-1	O
transcription	O
depends	O
on	O
an	O
intact	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
site	O
.	O
These	O
results	O
indicate	O
that	O
defective	O
recruitment	O
of	O
NF	B
-	I
kappa	I
B	I
may	O
underlie	O
Nef	B
's	O
negative	O
transcriptional	O
effects	O
on	O
the	O
HIV-1	O
and	O
interleukin	O
2	O
promoters	O
.	O
Further	O
evidence	O
suggests	O
that	O
Nef	B
inhibits	O
NF	B
-	I
kappa	I
B	I
induction	O
by	O
interfering	O
with	O
a	O
signal	O
derived	O
from	O
the	O
T	B
-	I
cell	I
receptor	I
complex	I
.	O
[	O
Effect	O
of	O
antihypertensive	O
therapy	O
with	O
captopril	O
on	O
gluco-	B
and	I
mineralocorticoid	I
receptors	I
of	O
peripheral	O
blood	O
lymphocytes	O
in	O
hypertensive	O
patients	O
of	O
various	O
age	O
]	O
Binding	O
of	O
3H	O
-	O
dexamethasone	O
and	O
3H	O
-	O
aldosterone	O
by	O
peripheral	B
lymphocyte	I
receptors	I
was	O
investigated	O
in	O
healthy	O
persons	O
and	O
hypertensive	O
patients	O
before	O
and	O
after	O
2-week	O
captopril	O
treatment	O
.	O
The	O
number	O
of	O
glucocorticoid	B
and	I
mineralocorticoid	I
binding	I
sites	I
was	O
increased	O
in	O
hypertensives	O
vs	O
normotensives	O
.	O
The	O
treatment	O
with	O
the	O
ACE	O
inhibitor	O
captopril	O
led	O
to	O
activation	O
of	O
hormone	O
-	O
receptor	O
interactions	O
.	O
There	O
was	O
a	O
more	O
marked	O
rise	O
of	O
the	O
number	O
of	O
receptors	B
in	O
middle	O
-	O
aged	O
(	O
44	O
-	O
55	O
years	O
)	O
hypertensives	O
vs	O
elderly	O
(	O
61	O
-	O
80	O
years	O
)	O
subjects	O
after	O
captopril	O
treatment	O
.	O
Leukotriene	O
B4	O
transcriptionally	O
activates	O
interleukin-6	B
expression	O
involving	O
NK	B
-	I
chi	I
B	I
and	O
NF	B
-	I
IL6	I
.	O
Leukotriene	O
B4	O
(	O
LTB4	O
)	O
is	O
a	O
notable	O
participant	O
in	O
inflammation	O
and	O
chemotaxis	O
.	O
It	O
is	O
,	O
however	O
,	O
still	O
unclear	O
whether	O
LTB4	O
acts	O
in	O
this	O
regard	O
directly	O
or	O
indirectly	O
by	O
stimulating	O
the	O
release	O
of	O
chemotactic	O
and	O
inflammatory	B
cytokines	I
.	O
Here	O
we	O
report	O
that	O
LTB4	O
induces	O
synthesis	O
of	O
interleukin	B
(	I
IL	I
)	I
-6	I
by	O
human	O
blood	O
monocytes	O
through	O
transcriptional	O
activation	O
of	O
the	O
IL-6	O
gene	O
.	O
We	O
furthermore	O
demonstrate	O
that	O
this	O
process	O
involves	O
activation	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
chi	I
B	I
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
of	O
NF	B
-	I
IL6	I
,	O
while	O
the	O
activity	O
of	O
the	O
transcription	B
factor	I
AP-1	B
,	O
shown	O
to	O
otherwise	O
confer	O
IL-6	B
inducibility	O
,	O
appeared	O
to	O
be	O
unaffected	O
by	O
LTB4	O
.	O
Involvement	O
of	O
NF	B
-	I
chi	I
B	I
and	O
NF	B
-	I
IL6	I
in	O
induction	O
of	O
IL-6	B
transcription	O
by	O
monocytes	O
was	O
demonstrated	O
using	O
deleted	O
forms	O
of	O
the	O
IL-6	O
promoter	O
.	O
Activation	O
of	O
the	O
IL-6	O
promoter	O
by	O
LTB4	O
was	O
not	O
only	O
associated	O
with	O
accumulation	O
of	O
the	O
respective	O
transcripts	O
but	O
resulted	O
in	O
synthesis	O
of	O
functional	O
IL-6	B
protein	I
as	O
well	O
.	O
In	O
addition	O
,	O
LTB4	O
mediated	O
transactivation	O
of	O
a	O
heterologous	O
promoter	O
construct	O
containing	O
the	O
NF	O
-	O
chi	O
B	O
or	O
the	O
NF	O
-	O
IL6	O
enhancer	O
,	O
but	O
not	O
the	O
AP-1	O
enhancer	O
.	O
The	O
signaling	O
events	O
mediating	O
this	O
effect	O
appeared	O
to	O
involve	O
the	O
release	O
of	O
H2O2	O
,	O
since	O
LTB4	O
failed	O
to	O
induce	O
NF	B
-	I
chi	I
B	I
or	O
NF	B
-	I
IL6	I
in	O
the	O
presence	O
of	O
the	O
scavenger	O
of	O
H2O2	O
,	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
.	O
Estrogen	O
binding	O
sites	O
in	O
peripheral	O
blood	O
monocytes	O
and	O
effects	O
of	O
danazol	O
on	O
their	O
sites	O
in	O
vitro	O
.	O
1	O
.	O
This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
presence	O
of	O
estrogen	O
type	O
I	O
(	O
high	O
affinity	O
,	O
low	O
capacity	O
)	O
and	O
type	O
II	O
(	O
low	O
affinity	O
,	O
high	O
capacity	O
)	O
binding	O
sites	O
in	O
human	O
peripheral	O
blood	O
monocytes	O
and	O
the	O
effects	O
of	O
danazol	O
on	O
these	O
sites	O
.	O
2	O
.	O
These	O
two	O
types	O
of	O
estrogen	O
binding	O
sites	O
existed	O
in	O
human	O
peripheral	O
blood	O
monocytes	O
.	O
3	O
.	O
Danazol	O
bound	O
to	O
these	O
sites	O
in	O
high	O
concentration	O
(	O
10	O
(	O
-6	O
)	O
M	O
,	O
clinical	O
serum	O
concentration	O
during	O
danazol	O
therapy	O
)	O
and	O
decreased	O
the	O
number	O
of	O
both	O
sites	O
.	O
4	O
.	O
It	O
is	O
suggested	O
that	O
danazol	O
has	O
an	O
anti	O
-	O
estrogenic	O
action	O
to	O
the	O
monocytes	O
through	O
the	O
competition	O
and	O
suppression	O
of	O
estrogen	O
binding	O
sites	O
as	O
seen	O
in	O
the	O
estrogen	O
target	O
organ	O
.	O
[	O
Mechanism	O
of	O
action	O
of	O
steroid	O
hormones	O
.	O
I.	O
Estrogens	O
]	O
The	O
steroid	O
hormone	O
are	O
very	O
versatile	O
molecules	O
:	O
although	O
they	O
are	O
related	O
among	O
them	O
by	O
their	O
chemical	O
structure	O
,	O
they	O
have	O
very	O
diverse	O
functions	O
and	O
including	O
antagonic	O
.	O
Their	O
action	O
mechanism	O
is	O
not	O
completely	O
cleared	O
.	O
The	O
estrogens	O
participate	O
in	O
the	O
regulation	O
of	O
practically	O
all	O
the	O
reproductive	O
and	O
sexual	O
events	O
of	O
the	O
female	O
,	O
although	O
the	O
intracellular	O
actions	O
by	O
which	O
they	O
take	O
place	O
are	O
not	O
well	O
known	O
and	O
the	O
proposed	O
models	O
do	O
not	O
adequately	O
satisfy	O
the	O
questions	O
.	O
Currently	O
it	O
is	O
accepted	O
the	O
existence	O
of	O
a	O
cytoplasmic	B
and/or	I
nuclear	I
receptor	I
,	O
without	O
explaining	O
satisfactorily	O
how	O
the	O
hormones	O
come	O
to	O
the	O
nucleus	O
.	O
The	O
endocrine	O
events	O
that	O
are	O
rapidly	O
expressed	O
(	O
seconds	O
)	O
are	O
due	O
to	O
a	O
possible	O
interaction	O
with	O
cellular	O
membrane	O
.	O
The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
analyze	O
and	O
concilliate	O
the	O
reported	O
data	O
on	O
the	O
mechanism	O
of	O
action	O
of	O
estrogens	O
.	O
Stable	O
expression	O
of	O
transdominant	B
Rev	I
protein	I
in	O
human	O
T	O
cells	O
inhibits	O
human	O
immunodeficiency	O
virus	O
replication	O
.	O
The	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
Rev	B
protein	I
is	O
essential	O
for	O
viral	O
structural	O
protein	O
expression	O
(	O
Gag	B
,	O
Pol	B
,	O
and	O
Env	B
)	O
and	O
,	O
hence	O
,	O
for	O
viral	O
replication	O
.	O
In	O
transient	O
transfection	O
assays	O
,	O
mutant	O
forms	O
of	O
Rev	B
have	O
been	O
identified	O
that	O
inhibit	O
wild	O
-	O
type	O
Rev	B
activity	O
and	O
therefore	O
suppress	O
viral	O
replication	O
.	O
To	O
determine	O
whether	O
such	O
transdominant	B
Rev	I
proteins	I
could	O
provide	O
long	O
-	O
term	O
protection	O
against	O
HIV	O
infection	O
without	O
affecting	O
T	O
cell	O
function	O
,	O
T	O
leukemia	O
cell	O
lines	O
were	O
stably	O
transduced	O
with	O
a	O
retroviral	O
vector	O
encoding	O
a	O
transdominant	O
mutant	O
of	O
the	O
Rev	B
protein	I
,	O
M10	B
.	O
While	O
all	O
the	O
M10-expressing	O
cell	O
lines	O
remained	O
infectable	O
by	O
HIV-1	O
,	O
these	O
same	O
cells	O
failed	O
to	O
support	O
a	O
productive	O
replication	O
cycle	O
when	O
infected	O
with	O
a	O
cloned	O
isolate	O
of	O
HIV-1	O
.	O
In	O
addition	O
,	O
two	O
out	O
of	O
three	O
M10-expressing	O
CEM	O
clones	O
were	O
also	O
resistant	O
to	O
highly	O
productive	O
infection	O
by	O
a	O
heterogeneous	O
HIV-1	O
pool	O
.	O
Expression	O
of	O
M10	B
did	O
not	O
affect	O
induction	O
of	O
HIV	O
transcription	O
mediated	O
by	O
the	O
kappa	O
B	O
regulatory	O
element	O
or	O
Tat	B
.	O
Importantly	O
,	O
constitutive	O
expression	O
of	O
Rev	B
M10	I
did	O
not	O
alter	O
the	O
secretion	O
of	O
interleukin	B
2	I
in	O
response	O
to	O
mitogen	O
stimulation	O
of	O
EL-4	O
and	O
Jurkat	O
cells	O
.	O
The	O
inhibition	O
of	O
HIV	O
infection	O
in	O
cells	O
stably	O
expressing	O
a	O
transdominant	B
Rev	I
protein	I
,	O
in	O
the	O
absence	O
of	O
any	O
deleterious	O
effect	O
on	O
T	O
cell	O
function	O
,	O
suggests	O
that	O
such	O
a	O
strategy	O
could	O
provide	O
a	O
therapeutic	O
effect	O
in	O
the	O
T	O
lymphocytes	O
of	O
acquired	O
immunodeficiency	O
syndrome	O
patients	O
.	O
Glucocorticoid	B
receptor	I
in	O
patients	O
with	O
lupus	O
nephritis	O
:	O
relationship	O
between	O
receptor	O
levels	O
in	O
mononuclear	O
leukocytes	O
and	O
effect	O
of	O
glucocorticoid	O
therapy	O
.	O
We	O
investigated	O
the	O
clinical	O
significance	O
of	O
glucocorticoid	B
receptor	I
determination	O
in	O
20	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
who	O
afterwards	O
developed	O
nephrotic	O
syndrome	O
.	O
Glucocorticoid	B
receptor	I
concentrations	O
in	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
in	O
these	O
patients	O
were	O
comparable	O
with	O
those	O
in	O
both	O
other	O
patients	O
with	O
SLE	O
and	O
healthy	O
persons	O
.	O
Improvement	O
in	O
urinary	O
protein	O
excretion	O
and	O
in	O
disease	O
activity	O
,	O
which	O
was	O
scored	O
according	O
to	O
the	O
SLE	O
Disease	O
Activity	O
Index	O
system	O
of	O
the	O
University	O
of	O
Toronto	O
,	O
closely	O
related	O
to	O
the	O
glucocorticoid	B
receptor	I
concentrations	O
in	O
MNL	O
isolated	O
from	O
the	O
corresponding	O
patients	O
.	O
In	O
summary	O
,	O
glucocorticoid	B
receptor	I
determination	O
in	O
patients	O
with	O
lupus	O
nephritis	O
may	O
be	O
a	O
predictive	O
clue	O
for	O
assessing	O
responsiveness	O
to	O
glucocorticoid	O
therapy	O
.	O
Selection	O
of	O
optimal	O
kappa	O
B	O
/	O
Rel	O
DNA	O
-	O
binding	O
motifs	O
:	O
interaction	O
of	O
both	O
subunits	O
of	O
NF	B
-	I
kappa	I
B	I
with	O
DNA	O
is	O
required	O
for	O
transcriptional	O
activation	O
.	O
Analysis	O
of	O
the	O
p50	B
and	O
p65	B
subunits	I
of	O
the	O
NF	B
-	I
kappa	I
B	I
transcription	I
factor	I
complex	I
has	O
revealed	O
that	O
both	O
proteins	O
can	O
interact	O
with	O
related	O
DNA	O
sequences	O
through	O
either	O
homo-	O
or	O
heterodimer	O
formation	O
.	O
In	O
addition	O
,	O
the	O
product	O
of	O
the	O
proto	O
-	O
oncogene	O
c	O
-	O
rel	O
can	O
bind	O
to	O
similar	O
DNA	O
motifs	O
by	O
itself	O
or	O
as	O
a	O
heterodimer	O
with	O
p50	B
or	O
p65	B
.	O
However	O
,	O
these	O
studies	O
have	O
used	O
a	O
limited	O
number	O
of	O
known	O
kappa	O
B	O
DNA	O
motifs	O
,	O
and	O
the	O
question	O
of	O
the	O
optimal	O
DNA	O
sequences	O
preferred	O
by	O
each	O
homodimer	O
has	O
not	O
been	O
addressed	O
.	O
Using	O
purified	O
recombinant	O
p50	B
,	O
p65	B
,	O
and	O
c	B
-	I
Rel	I
proteins	I
,	O
optimal	O
DNA	O
-	O
binding	O
motifs	O
were	O
selected	O
from	O
a	O
pool	O
of	O
random	O
oligonucleotides	O
.	O
Alignment	O
of	O
the	O
selected	O
sequences	O
allowed	O
us	O
to	O
predict	O
a	O
consensus	O
sequence	O
for	O
binding	O
of	O
the	O
individual	O
homodimeric	B
Rel	I
-	I
related	I
proteins	I
,	O
and	O
DNA	O
-	O
protein	O
binding	O
analysis	O
of	O
the	O
selected	O
DNA	O
sequences	O
revealed	O
sequence	O
specificity	O
of	O
the	O
proteins	O
.	O
Contrary	O
to	O
previous	O
assumptions	O
,	O
we	O
observed	O
that	O
p65	B
homodimers	O
can	O
interact	O
with	O
a	O
subset	O
of	O
DNA	O
sequences	O
not	O
recognized	O
by	O
p50	B
homodimers	I
.	O
Differential	O
binding	O
affinities	O
were	O
also	O
obtained	O
with	O
p50-	O
and	O
c	O
-	O
Rel	O
-	O
selected	O
sequences	O
.	O
Using	O
either	O
a	O
p50-	O
or	O
p65-	O
selected	O
kappa	O
B	O
motif	O
,	O
which	O
displayed	O
differential	O
binding	O
with	O
respect	O
to	O
the	O
other	O
protein	O
,	O
little	O
to	O
no	O
binding	O
was	O
observed	O
with	O
the	O
heterodimeric	B
NF	I
-	I
kappa	I
B	I
complex	I
.	O
Similarly	O
,	O
in	O
transfection	O
experiments	O
in	O
which	O
the	O
selective	O
kappa	O
B	O
binding	O
sites	O
were	O
used	O
to	O
drive	O
the	O
expression	O
of	O
a	O
chloramphenicol	O
acetyltransferase	O
reporter	O
construct	O
,	O
the	O
p65	O
-and	O
p50-selected	O
motifs	O
were	O
activated	O
only	O
in	O
the	O
presence	O
of	O
p65	B
and	O
p50	B
/	I
65	I
(	O
a	O
chimeric	B
protein	I
with	O
the	O
p50	B
DNA	I
binding	I
domain	I
and	O
p65	B
activation	I
domain	I
)	O
expression	O
vectors	O
,	O
respectively	O
,	O
and	O
neither	O
demonstrated	O
a	O
significant	O
response	O
to	O
stimuli	O
that	O
induce	O
NF	B
-	I
kappa	I
B	I
activity	O
.	O
These	O
findings	O
demonstrate	O
that	O
interaction	O
of	O
both	O
subunits	O
of	O
the	O
heterodimeric	B
NF	I
-	I
kappa	I
B	I
complex	I
with	O
DNA	O
is	O
required	O
for	O
DNA	O
binding	O
and	O
transcriptional	O
activation	O
and	O
suggest	O
that	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
individual	O
rel	B
-	I
related	I
proteins	I
will	O
differ	O
dramatically	O
,	O
depending	O
on	O
the	O
specific	O
kappa	O
B	O
motifs	O
present	O
.	O
The	O
candidate	B
oncoprotein	I
Bcl-3	I
is	O
an	O
antagonist	O
of	O
p50	B
/	I
NF	I
-	I
kappa	I
B	I
-mediated	O
inhibition	O
.	O
The	O
candidate	O
oncogene	O
bcl-3	O
was	O
discovered	O
as	O
a	O
translocation	O
into	O
the	O
immunoglobulin	O
alpha	O
-	O
locus	O
in	O
some	O
cases	O
of	O
B	O
-	O
cell	O
chronic	O
lymphocytic	O
leukaemias	O
.	O
The	O
protein	B
Bcl-3	I
contains	O
seven	O
so	O
-	O
called	O
ankyrin	B
repeats	I
.	O
Similar	O
repeat	B
motifs	I
are	O
found	O
in	O
a	O
number	O
of	O
diverse	B
regulatory	I
proteins	I
but	O
the	O
motifs	O
of	O
Bcl-3	B
are	O
most	O
closely	O
related	O
to	O
those	O
found	O
in	O
I	B
kappa	I
B	I
proteins	I
in	O
which	O
the	O
ankyrin	B
repeat	I
domain	O
is	O
thought	O
to	O
be	O
directly	O
involved	O
in	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activity	O
.	O
No	O
biological	O
function	O
has	O
yet	O
been	O
described	O
for	O
Bcl-3	B
,	O
but	O
it	O
was	O
noted	O
recently	O
that	O
Bcl-3	B
interferes	O
with	O
DNA	O
-	O
binding	O
of	O
the	O
p50	B
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
in	O
vitro	O
.	O
Here	O
we	O
demonstrate	O
that	O
Bcl-3	B
can	O
aid	O
kappa	O
B	O
site	O
-dependent	O
transcription	O
in	O
vivo	O
by	O
counteracting	O
the	O
inhibitory	O
effects	O
of	O
p50	B
/	I
NF	I
-	I
kappa	I
B	I
homodimers	I
.	O
Bcl-3	B
may	O
therefore	O
aid	O
activation	O
of	O
select	O
NF	O
-	O
kappa	O
B	O
-	O
regulated	O
genes	O
,	O
including	O
those	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
.	O
A	O
microtitre	O
assay	O
system	O
for	O
glucocorticoid	B
receptors	I
:	O
decreased	O
receptor	O
concentration	O
in	O
myocardial	O
infarction	O
.	O
A	O
major	O
difficulty	O
in	O
determination	O
of	O
glucocorticoid	O
receptor	O
sites	O
is	O
the	O
very	O
complicated	O
assay	O
procedure	O
.	O
Therefore	O
,	O
we	O
describe	O
a	O
microtitre	O
assay	O
system	O
for	O
glucocorticoid	B
receptors	I
which	O
is	O
a	O
whole	O
-	O
cell	O
competitive	O
binding	O
radioassay	O
using	O
[	O
3H	O
]	O
-dexamethasone	O
as	O
radioligand	O
.	O
This	O
modification	O
of	O
a	O
previously	O
described	O
protocol	O
simplifies	O
and	O
reduces	O
laboratory	O
work	O
and	O
allows	O
assay	O
reproducibility	O
to	O
be	O
controlled	O
more	O
reliably	O
.	O
Thus	O
enabled	O
to	O
perform	O
the	O
test	O
on	O
multiple	O
blood	O
samples	O
in	O
parallel	O
,	O
we	O
investigated	O
cardiac	O
infarction	O
patients	O
over	O
a	O
12-day	O
period	O
to	O
test	O
if	O
glucocorticoid	B
receptor	I
binding	O
is	O
altered	O
in	O
this	O
'	O
stressful	O
'	O
disease	O
.	O
On	O
the	O
first	O
day	O
of	O
the	O
disease	O
,	O
glucocorticoid	B
receptor	I
capacity	O
was	O
significantly	O
decreased	O
without	O
alteration	O
of	O
the	O
receptor	O
-	O
ligand	O
affinity	O
,	O
whereas	O
on	O
days	O
4	O
and	O
12	O
the	O
number	O
of	O
receptor	O
sites	O
was	O
normal	O
again	O
.	O
This	O
result	O
fits	O
well	O
into	O
the	O
general	O
observation	O
of	O
stress	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
immune	O
responses	O
.	O
Regulation	O
of	O
c	O
-	O
jun	O
expression	O
during	O
induction	O
of	O
monocytic	O
differentiation	O
by	O
okadaic	O
acid	O
.	O
The	O
present	O
work	O
has	O
examined	O
the	O
effects	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
type	B
1	I
and	I
2A	I
protein	I
phosphatases	I
,	O
on	O
the	O
regulation	O
of	O
c	O
-	O
jun	O
expression	O
during	O
monocytic	O
differentiation	O
of	O
U-937	O
leukemia	O
cells	O
.	O
The	O
results	O
demonstrate	O
that	O
okadaic	O
acid	O
treatment	O
is	O
associated	O
with	O
induction	O
of	O
a	O
differentiated	O
monocyte	O
phenotype	O
characterized	O
by	O
:	O
(	O
a	O
)	O
growth	O
arrest	O
;	O
(	O
b	O
)	O
increases	O
in	O
Mac-1	B
cell	I
surface	I
antigen	I
expression	O
;	O
(	O
c	O
)	O
down	O
-	O
regulation	O
of	O
c	B
-	I
myc	I
transcripts	I
;	O
and	O
(	O
d	O
)	O
induction	O
of	O
tumor	O
necrosis	O
factor	O
gene	O
expression	O
.	O
This	O
induction	O
of	O
monocytic	O
differentiation	O
was	O
associated	O
with	O
transient	O
increases	O
in	O
c	O
-	O
jun	O
mRNA	O
levels	O
,	O
which	O
were	O
maximal	O
at	O
6	O
h	O
.	O
Similar	O
effects	O
were	O
obtained	O
for	O
the	O
c	O
-	O
fos	O
gene	O
.	O
Run	O
-	O
on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c	O
-	O
jun	O
transcription	O
in	O
U-937	O
cells	O
and	O
that	O
this	O
rate	O
is	O
increased	O
approximately	O
40-fold	O
following	O
okadaic	O
acid	O
exposure	O
.	O
c	O
-	O
jun	O
mRNA	O
levels	O
were	O
superinduced	O
in	O
cells	O
treated	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
,	O
whereas	O
inhibition	O
of	O
protein	O
synthesis	O
had	O
little	O
,	O
if	O
any	O
,	O
effect	O
on	O
okadaic	O
acid	O
-	O
induced	O
c	O
-	O
jun	O
transcription	O
.	O
The	O
half	O
-	O
life	O
of	O
c	O
-	O
jun	O
mRNA	O
was	O
similar	O
(	O
45	O
-	O
50	O
min	O
)	O
in	O
both	O
untreated	O
and	O
okadaic	O
acid	O
-	O
induced	O
cells	O
.	O
In	O
contrast	O
,	O
treatment	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
was	O
associated	O
with	O
stabilization	O
(	O
t	O
1	O
/	O
2	O
=	O
90	O
min	O
)	O
of	O
c	B
-	I
jun	I
transcripts	I
.	O
Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
induction	O
of	O
c	O
-	O
jun	O
transcription	O
by	O
okadaic	O
acid	O
is	O
controlled	O
primarily	O
by	O
a	O
transcriptional	O
mechanism	O
.	O
Since	O
previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
c	O
-	O
jun	O
gene	O
is	O
autoinduced	O
by	O
Jun	B
/	I
AP-1	I
,	O
we	O
also	O
studied	O
transcription	O
of	O
c	O
-	O
jun	O
promoter	O
(	O
positions	O
-132	O
/	O
+170	O
)	O
-reporter	O
gene	O
constructs	O
with	O
and	O
without	O
a	O
mutated	O
AP-1	O
element	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Activation	O
of	O
NF	B
-	I
kappa	I
B	I
by	O
interleukin	B
2	I
in	O
human	O
blood	O
monocytes	O
.	O
We	O
report	O
here	O
that	O
interleukin	B
2	I
(	O
IL-2	B
)	O
acts	O
on	O
human	O
blood	O
monocytes	O
by	O
enhancing	O
binding	O
activity	O
of	O
the	O
transcription	B
factor	I
NF	I
-	I
kappa	I
B	I
to	O
its	O
consensus	O
sequence	O
in	O
the	O
5	O
'	O
regulatory	O
enhancer	O
region	O
of	O
the	O
IL-2	O
receptor	O
alpha	O
chain	O
(	O
p55	B
)	O
.	O
Similarly	O
,	O
IL-2	B
activates	O
NF	B
-	I
kappa	I
B	I
in	O
the	O
human	O
monocytic	O
cell	O
line	O
U	O
937	O
,	O
but	O
not	O
in	O
resting	O
human	O
T	O
-	O
cells	O
.	O
This	O
effect	O
is	O
detectable	O
within	O
15	O
min	O
and	O
peaks	O
1	O
h	O
after	O
exposure	O
to	O
IL-2	B
.	O
Enhanced	O
NF	B
-	I
kappa	I
B	I
binding	O
activity	O
is	O
followed	O
by	O
functional	O
activation	O
in	O
that	O
inducibility	O
of	O
the	O
IL-2	B
receptor	I
alpha	I
chain	I
is	O
mediated	O
by	O
enhanced	O
NF	B
-	I
kappa	I
B	I
binding	O
and	O
that	O
a	O
heterologous	O
promoter	O
containing	O
the	O
NF	O
-	O
kappa	O
B	O
consensus	O
sequence	O
(	O
-291	O
to	O
-245	O
)	O
of	O
the	O
IL-2	O
receptor	O
alpha	O
chain	O
gene	O
is	O
activated	O
.	O
In	O
addition	O
,	O
IL-2	B
is	O
capable	O
of	O
increasing	O
transcript	O
levels	O
of	O
the	O
p50	B
gene	O
coding	O
for	O
the	O
p50	B
subunit	I
of	O
the	O
NF	B
-	I
kappa	I
B	I
transcription	O
factor	O
,	O
whereas	O
mRNA	O
levels	O
of	O
the	O
p65	B
NF	O
-	O
kappa	O
B	O
gene	O
remained	O
unchanged	O
.	O
Single	O
point	O
estimation	O
of	O
glucocorticoid	B
receptors	I
in	O
lymphocytes	O
of	O
normal	O
subjects	O
and	O
of	O
children	O
under	O
long	O
term	O
glucocorticoid	O
treatment	O
.	O
A	O
single	O
point	O
assay	O
of	O
glucocorticoid	B
receptors	I
(	O
GR	B
)	O
in	O
human	O
lymphocytes	O
based	O
on	O
the	O
measurement	O
of	O
specific	O
dexamethasone	O
binding	O
has	O
been	O
developed	O
and	O
compared	O
with	O
a	O
common	O
multi	O
-	O
point	O
Scatchard	O
analysis	O
.	O
The	O
assay	O
conditions	O
-	O
concentration	O
of	O
the	O
ligand	O
20	O
nmol	O
/	O
l	O
,	O
incubation	O
time	O
2	O
h	O
and	O
the	O
cell	O
count	O
2	O
-	O
6	O
mil	O
.	O
cells	O
/	O
tube	O
in	O
the	O
assay	O
volume	O
0.25	O
ml	O
were	O
found	O
to	O
be	O
optimal	O
.	O
An	O
attempt	O
was	O
also	O
undertaken	O
to	O
use	O
a	O
cell	O
harvester	O
for	O
the	O
separation	O
of	O
cells	O
from	O
unbound	O
ligand	O
.	O
Though	O
specifically	O
bound	O
dexamethasone	O
measured	O
by	O
whole	O
-	O
cell	O
assay	O
and	O
that	O
using	O
cell	O
harvester	O
correlated	O
well	O
,	O
almost	O
by	O
one	O
order	O
lower	O
values	O
obtained	O
with	O
the	O
latter	O
method	O
render	O
it	O
non	O
-	O
applicable	O
for	O
receptor	O
quantitation	O
.	O
The	O
results	O
from	O
9	O
healthy	O
volunteers	O
(	O
average	O
GR	B
concentration	O
7131	O
+	O
/-	O
1256	O
sites	O
/	O
cell	O
)	O
correlated	O
excellently	O
with	O
those	O
obtained	O
by	O
the	O
Scatchard	O
analysis	O
.	O
The	O
single	O
point	O
assay	O
has	O
been	O
also	O
applied	O
for	O
determination	O
of	O
GH	O
in	O
10	O
children	O
treated	O
with	O
large	O
doses	O
of	O
prednisone	O
.	O
The	O
average	O
values	O
from	O
healthy	O
volunteers	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
found	O
in	O
these	O
children	O
,	O
though	O
much	O
broader	O
range	O
was	O
found	O
in	O
patients	O
.	O
The	O
regulation	O
of	O
the	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
promoter	O
region	O
in	O
macrophage	O
,	O
T	O
cell	O
,	O
and	O
B	O
cell	O
lines	O
.	O
The	O
1311-base	O
pair	O
human	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
alpha	O
promoter	O
region	O
was	O
fused	O
to	O
the	O
luciferase	O
(	O
Luc	O
)	O
reporter	O
gene	O
and	O
studied	O
in	O
a	O
transient	O
transfection	O
system	O
in	O
three	O
TNF	O
producing	O
cell	O
lines	O
,	O
the	O
U937	O
macrophage	O
cell	O
line	O
,	O
the	O
MLA	O
144	O
T	O
cell	O
line	O
,	O
and	O
the	O
729	O
-	O
6	O
B	O
cell	O
line	O
.	O
This	O
full	O
length	O
promoter	O
construct	O
can	O
be	O
induced	O
by	O
phorbol	O
13-myristate	O
acetate	O
(	O
PMA	O
)	O
in	O
each	O
of	O
these	O
cell	O
types	O
.	O
Analysis	O
of	O
a	O
series	O
of	O
5'-truncations	O
showed	O
several	O
peaks	O
of	O
basal	O
and	O
PMA	O
induced	O
activity	O
suggesting	O
the	O
presence	O
of	O
several	O
positive	O
and	O
negative	O
regulatory	O
elements	O
.	O
A	O
PMA	O
responsive	O
element	O
was	O
localized	O
to	O
a	O
region	O
between	O
-95	O
and	O
-36	O
bp	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
.	O
Within	O
this	O
region	O
,	O
single	O
AP-2-	O
and	O
AP-1-	O
like	O
consensus	O
sequences	O
were	O
noted	O
.	O
These	O
AP-2	O
and	O
AP-1	O
sites	O
were	O
each	O
modified	O
with	O
a	O
double	O
point	O
mutation	O
.	O
A	O
modest	O
(	O
20	O
-	O
50	O
%	O
)	O
reduction	O
in	O
TNF	O
promoter	O
activity	O
was	O
observed	O
with	O
the	O
AP-2	O
site	O
mutation	O
.	O
However	O
,	O
mutation	O
of	O
the	O
AP-1	O
site	O
markedly	O
diminished	O
both	O
the	O
basal	O
and	O
PMA	O
-	O
activated	O
promoter	O
activity	O
.	O
Also	O
co	O
-	O
transfections	O
of	O
the	O
wild	O
-	O
type	O
promoter	O
construct	O
with	O
an	O
AP-1	O
/	O
c	O
-	O
jun	O
expression	O
vector	O
resulted	O
in	O
augmented	O
basal	O
and	O
PMA	O
-	O
induced	O
promoter	O
activity	O
.	O
Redox	O
status	O
of	O
cells	O
influences	O
constitutive	O
or	O
induced	O
NF	B
-	I
kappa	I
B	I
translocation	O
and	O
HIV	O
long	O
terminal	O
repeat	O
activity	O
in	O
human	O
T	O
and	O
monocytic	O
cell	O
lines	O
.	O
We	O
have	O
tested	O
the	O
hypothesis	O
that	O
cellular	O
activation	O
events	O
occurring	O
in	O
T	O
lymphocytes	O
and	O
monocytes	O
and	O
mediated	O
through	O
translocation	O
of	O
the	O
transcription	B
factor	I
NF	I
-	I
kappa	I
B	I
are	O
dependent	O
upon	O
the	O
constitutive	O
redox	O
status	O
of	O
these	O
cells	O
.	O
We	O
used	O
phenolic	O
,	O
lipid	O
-	O
soluble	O
,	O
chain	O
-	O
breaking	O
antioxidants	O
(	O
butylated	O
hydroxyanisole	O
(	O
BHA	O
)	O
,	O
nordihydroquairetic	O
acid	O
,	O
or	O
alpha	O
-	O
tocopherol	O
(	O
vitamin	O
E	O
)	O
to	O
show	O
that	O
peroxyl	O
radical	O
scavenging	O
in	O
unstimulated	O
and	O
PMA-	O
or	O
TNF	O
-	O
stimulated	O
cells	O
blocks	O
the	O
functions	O
depending	O
on	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
BHA	O
was	O
found	O
to	O
suppress	O
not	O
only	O
PMA-	O
or	O
TNF	O
-	O
induced	O
,	O
but	O
also	O
constitutive	O
,	O
HIV	O
-	O
enhancer	O
activity	O
concomitant	O
to	O
an	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
binding	O
activity	O
in	O
both	O
lymphoblastoid	O
T	O
(	O
J.Jhan	O
)	O
and	O
monocytic	O
(	O
U937	O
)	O
cell	O
lines	O
.	O
This	O
was	O
also	O
true	O
for	O
KBF	O
(	O
p50	O
homodimer	O
)	O
binding	O
activity	O
in	O
U937	O
cells	O
.	O
Secretion	O
of	O
TNF	B
,	O
the	O
product	O
of	O
another	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
gene	O
,	O
was	O
abolished	O
by	O
BHA	O
in	O
PMA	O
-	O
stimulated	O
U937	O
cells	O
.	O
The	O
anti	O
-	O
oxidative	O
effect	O
of	O
BHA	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
thiol	O
,	O
but	O
not	O
glutathione	O
,	O
content	O
in	O
stimulated	O
and	O
unstimulated	O
T	O
cell	O
,	O
whereas	O
TNF	B
stimulation	O
itself	O
barely	O
modified	O
the	O
cellular	O
thiol	O
level	O
.	O
Oxidative	O
stress	O
obtained	O
by	O
the	O
addition	O
of	O
H2O2	O
to	O
the	O
culture	O
medium	O
of	O
J.Jhan	O
or	O
U937	O
cells	O
could	O
not	O
by	O
itself	O
induce	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
These	O
observations	O
suggest	O
that	O
TNF	B
and	O
PMA	B
do	O
not	O
lead	O
to	O
NF	B
-	I
kappa	I
B	I
activation	O
through	O
induction	O
of	O
changes	O
in	O
the	O
cell	O
redox	O
status	O
.	O
Rather	O
,	O
TNF	B
and	O
PMA	B
can	O
exert	O
their	O
effect	O
only	O
if	O
cells	O
are	O
in	O
an	O
appropriate	O
redox	O
status	O
,	O
because	O
prior	O
modification	O
toward	O
reduction	O
with	O
BHA	O
treatment	O
prevents	O
this	O
activation	O
.	O
It	O
appears	O
that	O
a	O
basal	O
redox	O
equilibrium	O
tending	O
toward	O
oxidation	O
is	O
a	O
prerequisite	O
for	O
full	O
activation	O
of	O
transduction	O
pathways	O
regulating	O
the	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
genes	O
.	O
Expression	O
of	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
and	O
jun	O
B	O
in	O
peripheral	O
blood	O
lymphocytes	O
from	O
young	O
and	O
elderly	O
adults	O
.	O
The	O
expression	O
of	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
and	O
jun	O
B	O
proto	O
-	O
oncogenes	O
was	O
studied	O
in	O
phytohemagglutinin	O
(	O
PHA	O
)	O
activated	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
from	O
young	O
and	O
aged	O
humans	O
.	O
Specific	O
mRNAs	O
for	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
were	O
detectable	O
within	O
30	O
min	O
after	O
cell	O
activation	O
and	O
reached	O
maximal	O
levels	O
within	O
2	O
h	O
.	O
Both	O
c	O
-	O
fos	O
and	O
jun	O
B	O
mRNAs	O
decreased	O
to	O
pre	O
-	O
activation	O
levels	O
within	O
6	O
h	O
,	O
while	O
c	O
-	O
jun	O
mRNA	O
remained	O
elevated	O
.	O
In	O
PHA	O
-	O
activated	O
PBL	O
,	O
no	O
age	O
-	O
related	O
differences	O
were	O
observed	O
in	O
c	O
-	O
fos	O
or	O
jun	O
B	O
mRNA	O
expression	O
.	O
However	O
,	O
c	O
-	O
jun	O
mRNA	O
levels	O
decreased	O
significantly	O
(	O
1.73	O
+	O
/-	O
0.08	O
vs.	O
1.16	O
+	O
/-	O
0.09	O
arbitrary	O
units	O
,	O
P	O
<	O
0.01	O
,	O
young	O
vs.	O
old	O
)	O
in	O
PBL	O
from	O
elderly	O
individuals	O
activated	O
with	O
PHA	B
.	O
Because	O
previous	O
work	O
has	O
demonstrated	O
that	O
T	O
cells	O
from	O
elderly	O
individuals	O
may	O
display	O
normal	O
proliferative	O
responses	O
when	O
activated	O
via	O
the	O
anti	B
-	I
CD2	I
pathway	O
,	O
c	O
-	O
jun	O
and	O
jun	O
B	O
mRNA	O
expression	O
was	O
also	O
studied	O
in	O
anti	O
-	O
CD2-activated	O
purified	O
T	O
cells	O
.	O
No	O
age	O
-	O
related	O
differences	O
were	O
found	O
in	O
the	O
expression	O
of	O
either	O
of	O
these	O
two	O
proto	O
-	O
oncogenes	O
by	O
anti	O
-	O
CD2	O
activated	O
T	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
the	O
decreased	O
IL-2	B
production	O
and	O
proliferative	O
response	O
displayed	O
by	O
PHA	O
-	O
activated	O
PBL	O
from	O
elderly	O
adults	O
may	O
be	O
related	O
to	O
age	O
-	O
related	O
changes	O
in	O
c	O
-	O
jun	O
mRNA	O
expression	O
and	O
in	O
the	O
ratio	O
of	O
c	O
-	O
fos	O
to	O
c	O
-	O
jun	O
mRNA	O
.	O
Characterization	O
of	O
a	O
novel	B
T	I
lymphocyte	I
protein	I
which	O
binds	O
to	O
a	O
site	O
related	O
to	O
steroid	O
/	O
thyroid	O
hormone	O
receptor	O
response	O
elements	O
in	O
the	O
negative	O
regulatory	O
sequence	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
.	O
We	O
have	O
previously	O
identified	O
a	O
T	B
lymphocyte	I
protein	I
which	O
binds	O
to	O
a	O
site	O
within	O
the	O
LTR	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
and	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
virus	O
gene	O
expression	O
.	O
The	O
palindromic	O
site	O
(	O
site	O
B	O
)	O
recognized	O
by	O
this	O
protein	O
is	O
related	O
to	O
the	O
palindromic	O
binding	O
sites	O
of	O
members	O
of	O
the	O
steroid	B
/	I
thyroid	I
hormone	I
receptor	I
family	I
.	O
Here	O
we	O
characterize	O
the	O
T	B
cell	I
protein	I
binding	O
to	O
this	O
site	O
as	O
a	O
100	O
kD	O
protein	O
which	O
is	O
most	O
abundant	O
in	O
T	O
cells	O
and	O
which	O
binds	O
to	O
site	O
B	O
as	O
a	O
200	B
kD	I
complex	I
.	O
This	O
protein	O
is	O
distinct	O
from	O
other	O
members	O
of	O
the	O
steroid	B
/	I
thyroid	I
hormone	I
receptor	I
family	I
including	O
the	O
COUP	B
protein	I
which	O
has	O
a	O
closely	O
related	O
DNA	O
binding	O
specificity	O
.	O
Reticuloendotheliosis	O
virus	O
long	O
terminal	O
repeat	O
elements	O
are	O
efficient	O
promoters	O
in	O
cells	O
of	O
various	O
species	O
and	O
tissue	O
origin	O
,	O
including	O
human	O
lymphoid	O
cells	O
.	O
Promiscuous	O
transcriptional	O
activity	O
of	O
the	O
reticuloendotheliosis	O
virus	O
(	O
REV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
was	O
detected	O
in	O
transient	O
expression	O
assays	O
using	O
LTR	O
-	O
chloramphenicol	O
acetyltransferase	O
-	O
encoding	O
gene	O
chimeras	O
,	O
and	O
cells	O
of	O
diverse	O
species	O
and	O
tissue	O
type	O
;	O
levels	O
of	O
expression	O
from	O
two	O
different	O
REV	O
LTRs	O
correlate	O
with	O
reports	O
of	O
pathogenicity	O
of	O
the	O
respective	O
viruses	O
in	O
vivo	O
.	O
REVs	O
do	O
not	O
encode	O
a	O
transactivator	O
targeted	O
to	O
the	O
viral	O
LTR	O
,	O
and	O
cells	O
infected	O
with	O
Marek	O
's	O
disease	O
virus	O
,	O
a	O
herpesvirus	O
with	O
an	O
overlapping	O
host	O
range	O
,	O
do	O
not	O
express	O
factors	O
that	O
preferentially	O
enhance	O
expression	O
from	O
REV	O
or	O
avian	O
sarcoma	O
/	O
leukemia	O
virus	O
LTRs	O
.	O
REV	O
LTRs	O
work	O
efficiently	O
in	O
human	O
lymphoid	O
cells	O
,	O
and	O
are	O
viable	O
alternatives	O
to	O
promoters	O
commonly	O
used	O
for	O
expression	O
of	O
cloned	O
genes	O
.	O
They	O
may	O
also	O
prove	O
useful	O
in	O
the	O
identification	O
of	O
new	O
,	O
ubiquitous	B
cellular	I
transcription	I
factors	I
.	O
SCL	B
and	O
related	O
hemopoietic	B
helix	I
-	I
loop	I
-	I
helix	I
transcription	I
factors	I
.	O
The	O
helix	B
-	I
loop	I
-	I
helix	I
(	I
HLH	I
)	I
proteins	I
are	O
a	O
family	O
of	O
transcription	B
factors	I
that	O
include	O
proteins	O
critical	O
to	O
differentiation	O
and	O
development	O
in	O
species	O
ranging	O
from	O
plants	O
to	O
mammals	O
.	O
Five	O
members	O
of	O
this	O
family	O
(	O
MYC	B
,	O
SCL	B
,	O
TAL-2	B
,	O
LYL-1	B
and	O
E2A	B
)	O
are	O
implicated	O
in	O
oncogenic	O
events	O
in	O
human	O
lymphoid	O
tumors	O
because	O
of	O
their	O
consistent	O
involvement	O
in	O
chromosomal	O
translocations	O
.	O
Although	O
activated	O
in	O
T	O
cell	O
leukemias	O
,	O
expression	O
of	O
SCL	B
and	O
LYL-1	B
is	O
low	O
or	O
undetectable	O
in	O
normal	O
T	O
cell	O
populations	O
.	O
SCL	B
is	O
expressed	O
in	O
erythroid	O
,	O
megakaryocyte	O
and	O
mast	O
cell	O
populations	O
(	O
the	O
same	O
cell	O
lineages	O
as	O
GATA-1	B
,	O
a	O
zinc	B
-	I
finger	I
transcription	I
factor	I
)	O
.	O
In	O
addition	O
,	O
both	O
SCL	B
and	O
GATA-1	B
undergo	O
coordinate	O
modulation	O
during	O
chemically	O
induced	O
erythroid	O
differentiation	O
of	O
mouse	O
erythroleukemia	O
cells	O
and	O
are	O
down	O
-	O
modulated	O
during	O
myeloid	O
differentiation	O
of	O
human	O
K562	O
cells	O
,	O
thus	O
implying	O
a	O
role	O
for	O
SCL	B
in	O
erythroid	O
differentiation	O
events	O
.	O
However	O
,	O
in	O
contrast	O
to	O
GATA-1	B
,	O
SCL	B
is	O
expressed	O
in	O
the	O
developing	O
brain	O
.	O
Studies	O
of	O
the	O
function	O
of	O
SCL	B
suggest	O
it	O
is	O
also	O
important	O
in	O
proliferation	O
and	O
self	O
-	O
renewal	O
events	O
in	O
erythroid	O
cells	O
.	O
Phorbol	O
ester	O
reduces	O
constitutive	B
nuclear	I
NF	I
kappa	I
B	I
and	O
inhibits	O
HIV-1	O
production	O
in	O
mature	O
human	O
monocytic	O
cells	O
.	O
NF	B
kappa	I
B	I
is	O
a	O
potent	O
mediator	O
of	O
specific	O
gene	O
expression	O
in	O
human	O
monocytes	O
and	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
transcription	O
of	O
the	O
HIV-1	O
genome	O
in	O
promonocytic	O
leukemias	O
.	O
There	O
is	O
little	O
information	O
available	O
on	O
the	O
response	O
of	O
NF	B
kappa	I
B	I
to	O
cytokines	B
in	O
normal	O
human	O
monocytes	O
.	O
We	O
have	O
used	O
a	O
32P	O
-	O
labeled	O
oligonucleotide	O
derived	O
from	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
long	O
terminal	O
repeat	O
,	O
which	O
contains	O
a	O
tandem	O
repeat	O
of	O
the	O
NF	O
kappa	O
B	O
binding	O
sequence	O
,	O
as	O
a	O
probe	O
in	O
a	O
gel	O
retardation	O
assay	O
to	O
study	O
this	O
transcription	B
factor	I
.	O
Using	O
this	O
assay	O
,	O
we	O
have	O
detected	O
NF	B
kappa	I
B	I
in	O
extracts	O
of	O
nuclei	O
from	O
normal	O
human	O
monocytes	O
.	O
Treatment	O
of	O
normal	O
monocytes	O
with	O
12	O
-	O
0-tetradecanoyl	O
phorbol-13-acetate	O
(	O
TPA	O
)	O
for	O
4	O
-	O
24	O
h	O
caused	O
the	O
complete	O
disappearance	O
of	O
NF	B
kappa	I
B	I
from	O
nuclear	O
extracts	O
of	O
monocytes	O
.	O
A	O
similar	O
result	O
was	O
obtained	O
with	O
the	O
mature	O
monocytic	O
leukemia	O
cell	O
line	O
THP-1	O
.	O
The	O
constitutive	B
transcription	I
factor	I
SP1	B
was	O
unaffected	O
by	O
addition	O
of	O
TPA	O
.	O
The	O
disappearance	O
of	O
NF	B
kappa	I
B	I
from	O
the	O
nucleus	O
was	O
concentration	O
dependent	O
between	O
10	O
and	O
50	O
ng	O
/	O
ml	O
of	O
phorbol	O
ester	O
.	O
In	O
THP-1	O
cells	O
,	O
TPA	O
also	O
induced	O
a	O
new	O
,	O
faster	B
-	I
migrating	I
NF	I
kappa	I
B	I
species	I
not	O
induced	O
in	O
monocytes	O
.	O
Protein	O
kinase	O
C	O
inhibitor	O
staurosporine	O
,	O
but	O
not	O
cyclic	O
nucleotide	O
-	O
dependent	O
protein	O
kinase	O
inhibitor	O
HA-1004	O
,	O
also	O
dramatically	O
reduced	O
constitutive	O
levels	O
of	O
nuclear	B
NF	I
kappa	I
B	I
.	O
Finally	O
,	O
TPA	O
addition	O
to	O
monocytes	O
infected	O
with	O
HIV-1	O
inhibited	O
HIV-1	O
replication	O
,	O
as	O
determined	O
by	O
reverse	B
transcriptase	I
assays	O
,	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O
These	O
results	O
are	O
in	O
striking	O
contrast	O
to	O
the	O
increase	O
in	O
nuclear	O
NF	B
kappa	I
B	I
and	O
HIV-1	O
replication	O
induced	O
by	O
phorbol	O
esters	O
in	O
promonocytic	O
leukemia	O
cells	O
U937	O
and	O
HL-60	O
,	O
and	O
emphasize	O
the	O
importance	O
of	O
studying	O
cytokine	B
regulation	O
of	O
HIV-1	O
in	O
normal	O
monocytes	O
.	O
Inhibition	O
of	O
anti	B
-	I
CD3	I
monoclonal	I
antibody	I
-induced	O
T	O
-	O
cell	O
proliferation	O
by	O
dexamethasone	O
,	O
isoproterenol	O
,	O
or	O
prostaglandin	O
E2	O
either	O
alone	O
or	O
in	O
combination	O
.	O
1	O
.	O
The	O
purpose	O
of	O
these	O
studies	O
was	O
to	O
investigate	O
the	O
modulation	O
of	O
the	O
proliferation	O
of	O
human	O
T	O
cells	O
obtained	O
from	O
peripheral	O
blood	O
by	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
isoproterenol	O
(	O
ISO	O
)	O
,	O
and	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
.	O
The	O
former	O
two	O
substances	O
interact	O
with	O
T	O
cells	O
via	O
the	O
glucocorticoid	B
and	I
beta	I
-	I
adrenergic	I
receptors	I
respectively	O
.	O
When	O
occupied	O
by	O
their	O
natural	O
ligands	O
,	O
glucocorticosteroids	O
and	O
catecholamines	O
,	O
these	O
receptors	O
have	O
a	O
role	O
in	O
modulating	O
T	O
-	O
cell	O
function	O
during	O
stress	O
.	O
During	O
the	O
inflammatory	O
response	O
increased	O
levels	O
of	O
PGE2	O
bind	O
to	O
their	O
receptors	O
on	O
T	O
cells	O
and	O
thus	O
alter	O
responsiveness	O
.	O
Proliferation	O
of	O
T	O
cells	O
was	O
induced	O
by	O
immobilized	O
anti	B
-	I
CD3	I
monoclonal	I
antibody	I
(	O
mAb	B
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
an	O
additional	O
costimulatory	O
signal	O
delivered	O
by	O
anti	B
-	I
CD28	I
mAb	I
.	O
2	O
.	O
Various	O
physiologic	O
concentrations	O
of	O
DEX	O
,	O
ISO	O
,	O
or	O
PGE2	O
were	O
added	O
at	O
the	O
time	O
of	O
initiation	O
of	O
the	O
cultures	O
and	O
subsequent	O
proliferation	O
of	O
the	O
unstimulated	O
T	O
cells	O
was	O
determined	O
.	O
The	O
results	O
demonstrate	O
that	O
physiologic	O
concentrations	O
of	O
all	O
three	O
of	O
these	O
agents	O
inhibit	O
the	O
anti	B
-	I
CD3	I
mAb	I
-induced	O
proliferation	O
of	O
T	O
cells	O
.	O
3	O
.	O
Although	O
DEX	O
and	O
PGE2	O
were	O
equipotent	O
in	O
suppressing	O
T	O
-	O
cell	O
proliferation	O
,	O
ISO	O
was	O
much	O
less	O
effective	O
.	O
4	O
.	O
Because	O
concomitant	O
elevations	O
in	O
the	O
peripheral	O
levels	O
of	O
these	O
substances	O
may	O
occur	O
,	O
experiments	O
were	O
performed	O
to	O
determine	O
the	O
T	O
-	O
cell	O
inhibitory	O
effects	O
of	O
DEX	O
together	O
with	O
either	O
PGE2	O
or	O
ISO	O
.	O
Synergistic	O
suppression	O
of	O
T	O
-	O
cell	O
proliferation	O
was	O
observed	O
when	O
various	O
concentrations	O
of	O
DEX	O
and	O
PGE2	O
,	O
but	O
not	O
DEX	O
and	O
ISO	O
,	O
were	O
added	O
to	O
cultures	O
.	O
This	O
synergistic	O
suppression	O
could	O
not	O
be	O
explained	O
by	O
an	O
increase	O
in	O
cAMP	O
accumulation	O
in	O
T	O
cells	O
stimulated	O
with	O
DEX	O
and	O
PGE2	O
.	O
5	O
.	O
Finally	O
,	O
the	O
addition	O
of	O
anti	B
-	I
CD28	I
mAb	I
to	O
anti	O
-	O
CD3	O
mAb	O
-	O
stimulated	O
T	O
cells	O
overcame	O
much	O
of	O
the	O
suppression	O
of	O
proliferation	O
induced	O
by	O
PGE2	O
or	O
ISO	O
but	O
less	O
so	O
than	O
that	O
induced	O
by	O
DEX	O
.	O
Involvement	O
of	O
Alu	O
sequences	O
in	O
the	O
cell	O
-	O
specific	O
regulation	O
of	O
transcription	O
of	O
the	O
gamma	B
chain	I
of	O
Fc	B
and	O
T	B
cell	I
receptors	I
.	O
The	O
Fc	B
epsilon	I
RI	I
-	I
gamma	I
chains	I
are	O
expressed	O
in	O
a	O
variety	O
of	O
hematopoietic	O
cells	O
where	O
they	O
play	O
a	O
critical	O
role	O
in	O
signal	O
transduction	O
.	O
They	O
are	O
part	O
of	O
the	O
high	B
affinity	I
IgE	I
receptor	I
in	O
mast	O
cells	O
,	O
basophils	O
,	O
Langerhans	O
cells	O
,	O
and	O
possibly	O
other	O
cells	O
;	O
a	O
component	O
of	O
the	O
low	O
affinity	O
receptor	O
for	O
IgG	B
(	O
Fc	B
gamma	I
RIIIA	I
or	O
CD16	B
)	O
in	O
natural	O
killer	O
cells	O
and	O
macrophages	O
;	O
and	O
part	O
of	O
the	O
T	B
cell	I
antigen	I
receptor	I
in	O
subsets	O
of	O
T	O
cells	O
.	O
Here	O
we	O
have	O
investigated	O
the	O
transcriptional	O
regulation	O
of	O
the	O
gamma	B
chain	I
gene	O
by	O
analyzing	O
the	O
2.5-kilobase	O
sequence	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O
This	O
sequence	O
contains	O
a	O
promoter	O
specific	O
to	O
cells	O
of	O
hematopoietic	O
lineage	O
.	O
However	O
,	O
the	O
tissue	O
specificity	O
of	O
this	O
promoter	O
is	O
only	O
partial	O
because	O
it	O
is	O
active	O
in	O
all	O
of	O
the	O
hematopoietic	O
cells	O
tested	O
here	O
,	O
regardless	O
of	O
whether	O
they	O
constitutively	O
express	O
Fc	O
epsilon	O
RI-	O
gamma	B
chain	I
transcripts	O
.	O
We	O
have	O
identified	O
two	O
adjacent	O
cis	O
-	O
acting	O
regulatory	O
elements	O
,	O
both	O
of	O
which	O
are	O
part	O
of	O
an	O
Alu	O
repeat	O
.	O
The	O
first	O
(	O
-445	O
/	O
-366	O
)	O
is	O
a	O
positive	O
element	O
active	O
in	O
both	O
basophils	O
and	O
T	O
cells	O
.	O
The	O
second	O
(	O
-365	O
/	O
-264	O
)	O
binds	O
to	O
nuclear	B
factors	I
,	O
which	O
appear	O
to	O
be	O
different	O
in	O
basophils	O
and	O
T	O
cells	O
,	O
and	O
acts	O
as	O
a	O
negative	O
element	O
in	O
basophils	O
and	O
as	O
a	O
positive	O
one	O
in	O
T	O
cells	O
.	O
Thus	O
,	O
this	O
Alu	O
repeat	O
(	O
90	O
%	O
identical	O
to	O
Alu	O
consensus	O
sequences	O
)	O
has	O
evolved	O
to	O
become	O
both	O
a	O
positive	O
and	O
negative	O
regulator	O
.	O
Human	O
immunodeficiency	O
viruses	O
containing	O
heterologous	O
enhancer	O
/	O
promoters	O
are	O
replication	O
competent	O
and	O
exhibit	O
different	O
lymphocyte	O
tropisms	O
.	O
The	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
type	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
contains	O
binding	O
sites	O
for	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
and	O
the	O
constitutively	O
expressed	O
transcription	B
factor	I
Sp1	I
,	O
both	O
of	O
which	O
are	O
highly	O
conserved	O
in	O
HIV	O
and	O
simian	O
immunodeficiency	O
virus	O
isolates	O
.	O
To	O
delineate	O
the	O
effects	O
of	O
these	O
motifs	O
on	O
the	O
replicative	O
capacity	O
of	O
HIV	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
extending	O
the	O
virus	O
host	O
range	O
,	O
known	O
heterologous	O
enhancer	O
/	O
promoters	O
were	O
inserted	O
into	O
the	O
HIV-1	O
LTR	O
in	O
place	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
and	O
Sp1	O
binding	O
sites	O
.	O
The	O
effects	O
of	O
these	O
substitutions	O
on	O
viral	O
replication	O
in	O
transfected	O
HeLa	O
cells	O
and	O
on	O
HIV	O
infection	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
or	O
continuous	O
T	O
-	O
leukemia	O
cell	O
lines	O
were	O
evaluated	O
.	O
HIVs	O
in	O
which	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Sp1	O
enhancer	O
plus	O
the	O
downstream	O
TATA	O
element	O
were	O
replaced	O
with	O
heterologous	O
enhancer	O
/	O
promoters	O
were	O
also	O
constructed	O
.	O
Viruses	O
containing	O
the	O
human	O
cytomegalovirus	O
immediate	O
-	O
early	O
enhancer	O
exhibited	O
infectious	O
kinetics	O
similar	O
to	O
that	O
of	O
wild	O
-	O
type	O
HIV	O
in	O
activated	O
human	O
peripheral	O
blood	O
lymphocytes	O
and	O
AA2	O
cells	O
but	O
replicated	O
less	O
efficiently	O
in	O
H9	O
and	O
CEM	O
cells	O
.	O
These	O
studies	O
indicate	O
that	O
heterologous	O
enhancer	O
elements	O
are	O
capable	O
of	O
restoring	O
Tat	B
responsiveness	O
to	O
the	O
HIV	O
LTR	O
in	O
the	O
context	O
of	O
directing	O
reporter	O
gene	O
expression	O
as	O
well	O
as	O
in	O
the	O
production	O
of	O
infectious	O
progeny	O
virions	O
.	O
Photoaffinity	O
labeling	O
of	O
plasma	B
membrane	I
receptors	I
for	O
aldosterone	O
from	O
human	O
mononuclear	O
leukocytes	O
.	O
Non	O
-	O
genomic	O
effects	O
of	O
aldosterone	O
on	O
the	O
sodium	B
-	I
proton	I
-	I
antiport	I
have	O
been	O
shown	O
in	O
human	O
mononuclear	O
leukocytes	O
which	O
could	O
be	O
related	O
to	O
a	O
new	O
aldosterone	B
membrane	I
receptor	I
.	O
In	O
the	O
present	O
paper	O
plasma	O
membranes	O
from	O
human	O
mononuclear	O
leukocytes	O
were	O
covalently	O
photolabeled	O
with	O
a	O
[	O
125I	O
]	O
-aldosterone	O
derivative	O
.	O
Sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
showed	O
significant	O
aldosterone	O
binding	O
at	O
a	O
molecular	O
weight	O
of	O
approximately	O
50000	O
Dalton	O
which	O
was	O
absent	O
with	O
1	O
microM	O
cold	O
aldosterone	O
,	O
but	O
not	O
cortisol	O
in	O
the	O
binding	O
media	O
.	O
The	O
presence	O
of	O
the	O
sulfhydryl	O
agent	O
dithiothreitol	O
did	O
not	O
affect	O
results	O
suggesting	O
the	O
absence	O
of	O
disulfide	B
bridges	I
in	O
the	O
steroid	B
binding	I
domain	I
of	O
the	O
receptor	O
.	O
These	O
data	O
are	O
the	O
first	O
to	O
define	O
the	O
molecular	O
weight	O
of	O
the	O
membrane	B
receptor	I
for	O
aldosterone	O
.	O
Alpha	O
-	O
lipoic	O
acid	O
is	O
a	O
potent	O
inhibitor	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
human	O
T	O
cells	O
.	O
Acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
results	O
from	O
infection	O
with	O
a	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O
The	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
region	O
of	O
HIV	O
proviral	O
DNA	O
contains	O
binding	O
sites	O
for	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
,	O
and	O
this	O
transcriptional	B
activator	I
appears	O
to	O
regulate	O
HIV	O
activation	O
.	O
Recent	O
findings	O
suggest	O
an	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
signal	O
transduction	O
pathways	O
leading	O
to	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
The	O
present	O
study	O
was	O
based	O
on	O
reports	O
that	O
antioxidants	O
which	O
eliminate	O
ROS	O
should	O
block	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
subsequently	O
HIV	O
transcription	O
,	O
and	O
thus	O
antioxidants	O
can	O
be	O
used	O
as	O
therapeutic	O
agents	O
for	O
AIDS	O
.	O
Incubation	O
of	O
Jurkat	O
T	O
cells	O
(	O
1	O
x	O
10	O
(	O
6	O
)	O
cells	O
/	O
ml	O
)	O
with	O
a	O
natural	O
thiol	O
antioxidant	O
,	O
alpha	O
-	O
lipoic	O
acid	O
,	O
prior	O
to	O
the	O
stimulation	O
of	O
cells	O
was	O
found	O
to	O
inhibit	O
NF	B
-	I
kappa	I
B	I
activation	O
induced	O
by	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
25	O
ng	O
/	O
ml	O
)	O
or	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
50	O
ng	O
/	O
ml	O
)	O
.	O
The	O
inhibitory	O
action	O
of	O
alpha	O
-	O
lipoic	O
acid	O
was	O
found	O
to	O
be	O
very	O
potent	O
as	O
only	O
4	O
mM	O
was	O
needed	O
for	O
a	O
complete	O
inhibition	O
,	O
whereas	O
20	O
mM	O
was	O
required	O
for	O
N	O
-	O
acetylcysteine	O
.	O
These	O
results	O
indicate	O
that	O
alpha	O
-	O
lipoic	O
acid	O
may	O
be	O
effective	O
in	O
AIDS	O
therapeutics	O
.	O
A	O
human	O
putative	O
lymphocyte	O
G0	O
/	O
G1	O
switch	O
gene	O
homologous	O
to	O
a	O
rodent	O
gene	O
encoding	O
a	O
zinc	B
-	I
binding	I
potential	I
transcription	I
factor	I
.	O
G0S24	O
is	O
a	O
member	O
of	O
a	O
set	O
of	O
genes	O
(	O
putative	O
G0	O
/	O
G1	O
switch	O
regulatory	O
genes	O
)	O
that	O
are	O
expressed	O
transiently	O
within	O
1	O
-	O
2	O
hr	O
of	O
the	O
addition	O
of	O
lectin	B
or	O
cycloheximide	O
to	O
human	O
blood	O
mononuclear	O
cells	O
.	O
Comparison	O
of	O
a	O
full	O
-	O
length	O
cDNA	O
sequence	O
with	O
the	O
corresponding	O
genomic	O
sequence	O
reveals	O
an	O
open	O
reading	O
frame	O
of	O
326	O
amino	O
acids	O
,	O
distributed	O
across	O
two	O
exons	O
.	O
Potential	O
phosphorylation	B
sites	I
include	O
the	O
sequence	O
PSPTSPT	B
,	O
which	O
resembles	O
an	O
RNA	B
polymerase	I
II	I
repeat	I
reported	O
to	O
be	O
a	O
target	O
of	O
the	O
cell	B
cycle	I
control	I
kinase	I
cdc2	I
.	O
Comparison	O
of	O
the	O
derived	O
protein	O
sequence	O
with	O
those	O
of	O
rodent	O
homologs	O
allows	O
classification	O
into	O
three	O
groups	O
.	O
Group	O
1	O
contains	O
G0S24	O
and	O
the	O
rat	O
and	O
mouse	O
TIS11	O
genes	O
(	O
also	O
known	O
as	O
TTP	O
,	O
Nup475	O
,	O
and	O
Zfp36	O
)	O
.	O
Members	O
of	O
this	O
group	O
have	O
three	B
tetraproline	I
repeats	I
.	O
Groups	O
1	O
and	O
2	O
have	O
a	O
serine	B
-	I
rich	I
region	I
and	O
an	O
`	O
`	O
arginine	B
element	I
`	O
`	O
(	O
RRLPIF	B
)	O
at	O
the	O
carboxyl	B
terminus	I
.	O
All	O
groups	O
contain	O
cysteine-	B
and	I
histidine	I
-	I
rich	I
putative	I
zinc	I
finger	I
domains	I
and	O
a	O
serine	B
-	I
phenylalanine	I
`	I
`	I
SFS	I
''	I
domain	I
similar	O
to	O
part	O
of	O
the	O
large	O
subunit	O
of	O
eukaryotic	B
RNA	I
polymerase	I
II	I
.	O
Comparison	O
of	O
group	O
1	O
human	O
and	O
mouse	O
genomic	O
sequences	O
shows	O
high	O
conservation	O
in	O
the	O
5	O
'	O
flank	O
and	O
exons	O
.	O
A	O
CpG	O
island	O
suggests	O
expression	O
in	O
the	O
germ	O
line	O
.	O
G0S24	O
has	O
potential	O
sites	O
for	O
transcription	B
factors	I
in	O
the	O
5	O
'	O
flank	O
and	O
intron	O
;	O
these	O
include	O
a	O
serum	O
response	O
element	O
.	O
Protein	O
and	O
genomic	O
sequences	O
show	O
similarities	O
with	O
those	O
of	O
a	O
variety	O
of	O
proteins	O
involved	O
in	O
transcription	O
,	O
suggesting	O
that	O
the	O
G0S24	B
product	I
has	O
a	O
similar	O
role	O
.	O
Interleukin-4	B
inhibits	O
the	O
lipopolysaccharide	O
-	O
induced	O
expression	O
of	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
messenger	O
RNA	O
and	O
activator	B
protein-1	I
binding	O
activity	O
in	O
human	O
monocytes	O
.	O
We	O
studied	O
the	O
effect	O
of	O
interleukin-4	B
(	O
IL-4	B
)	O
on	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
two	O
immediate	O
early	O
genes	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
.	O
These	O
genes	O
encode	O
proteins	O
that	O
form	O
the	O
dimeric	B
complex	I
activator	B
protein-1	I
(	O
AP-1	B
)	O
,	O
which	O
is	O
active	O
as	O
a	O
transcriptional	B
factor	I
.	O
Maximal	O
accumulation	O
of	O
either	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
occurred	O
30	O
minutes	O
after	O
LPS	O
addition	O
.	O
When	O
cells	O
were	O
treated	O
with	O
IL-4	B
for	O
5	O
hours	O
before	O
LPS	O
activation	O
,	O
both	O
the	O
c	O
-	O
fos	O
and	O
the	O
c	O
-	O
jun	O
mRNA	O
expression	O
was	O
decreased	O
.	O
The	O
inhibition	O
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
expression	O
by	O
IL-4	B
in	O
LPS	O
-	O
treated	O
cells	O
was	O
shown	O
to	O
be	O
due	O
to	O
a	O
lower	O
transcription	O
rate	O
of	O
the	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
genes	O
.	O
IL-4	B
did	O
not	O
affect	O
the	O
stability	O
of	O
the	O
c	B
-	I
fos	I
and	O
c	B
-	I
jun	I
transcripts	I
.	O
Finally	O
,	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
evidence	O
was	O
obtained	O
that	O
IL-4	B
inhibits	O
LPS	O
-	O
induced	O
expression	O
of	O
AP-1	B
protein	O
.	O
These	O
data	O
indicate	O
that	O
IL-4	B
suppresses	O
the	O
induction	O
of	O
transcription	B
factors	I
in	O
human	O
activated	O
monocytes	O
.	O
Ras	O
oncogene	O
transformation	O
of	O
human	O
B	O
lymphoblasts	O
is	O
associated	O
with	O
lymphocyte	O
activation	O
and	O
with	O
a	O
block	O
of	O
differentiation	O
.	O
The	O
p21ras	B
small	I
GTP	I
binding	I
proteins	I
participate	O
in	O
signal	O
transduction	O
from	O
cell	O
surface	O
receptors	O
and	O
affect	O
neoplastic	O
transformation	O
and	O
development	O
in	O
many	O
different	O
cell	O
types	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
relationship	O
between	O
ras	O
transformation	O
and	O
differentiation	O
of	O
human	O
B	O
lymphocytes	O
.	O
We	O
show	O
that	O
the	O
constitutive	O
expression	O
of	O
the	O
T24	O
Ha	O
-	O
ras	O
oncogene	O
in	O
EBV	O
-	O
immortalized	O
B	O
lymphoblasts	O
was	O
associated	O
with	O
the	O
induction	O
of	O
the	O
interleukin	B
2	I
receptor	I
alpha	I
subunit	I
,	O
with	O
an	O
impaired	O
immunoglobulin	O
gene	O
expression	O
,	O
altered	O
adhesion	O
properties	O
and	O
increased	O
survival	O
in	O
serum	O
-	O
free	O
medium	O
.	O
Since	O
induction	O
of	O
the	O
IL-2	B
receptor	I
alpha	I
subunit	I
is	O
a	O
hallmark	O
of	O
lymphocyte	O
activation	O
,	O
we	O
suggest	O
that	O
p21ras	B
naturally	O
triggers	O
B	O
cell	O
activation	O
.	O
The	O
ras	O
-	O
transformed	O
lymphocytes	O
displayed	O
a	O
fully	O
functional	O
IL-2r	B
,	O
as	O
assessed	O
by	O
c	O
-	O
fos	O
induction	O
following	O
treatment	O
with	O
IL-2	B
;	O
nevertheless	O
,	O
they	O
were	O
not	O
growth	O
stimulated	O
by	O
this	O
lymphokine	B
.	O
The	O
decreased	O
expression	O
of	O
immunoglobulin	O
genes	O
indicates	O
that	O
the	O
ras	O
oncogene	O
blocks	O
terminal	O
differentiation	O
to	O
plasma	O
cells	O
,	O
possibly	O
by	O
inhibiting	O
the	O
activity	O
of	O
lymphocyte	B
-	I
specific	I
transcription	I
factors	I
.	O
Somewhat	O
unexpectedly	O
,	O
the	O
constitutive	O
p21ras	B
activity	O
did	O
not	O
cause	O
an	O
increased	O
DNA	O
binding	O
of	O
transcription	B
factors	I
PEA1	B
(	O
AP1	B
)	O
,	O
PEA3	B
,	O
Oct-2	B
or	O
NF	B
-	I
kB	I
Transcription	B
factor	I
GATA-1	B
and	O
erythroid	O
development	O
.	O
In	O
summary	O
,	O
we	O
derived	O
an	O
experimental	O
system	O
that	O
allows	O
us	O
to	O
dissect	O
the	O
function	O
of	O
GATA-1	B
in	O
red	O
cell	O
development	O
at	O
a	O
genetic	O
level	O
.	O
We	O
have	O
established	O
the	O
essential	O
nature	O
of	O
GATA-1	B
during	O
both	O
primitive	O
and	O
definitive	O
erythropoiesis	O
.	O
By	O
ablating	O
the	O
expression	O
of	O
the	O
endogenous	O
GATA-1	O
gene	O
,	O
we	O
are	O
in	O
a	O
position	O
to	O
introduce	O
a	O
variety	O
of	O
constructs	O
that	O
harbor	O
subtle	O
modifications	O
in	O
flanking	O
or	O
protein	O
-	O
coding	O
sequences	O
.	O
We	O
can	O
now	O
study	O
regulatory	O
regions	O
and	O
functional	O
domains	O
of	O
the	O
protein	O
in	O
the	O
context	O
of	O
a	O
true	O
erythroid	O
environment	O
,	O
experiments	O
that	O
have	O
not	O
been	O
possible	O
heretofore	O
.	O
Although	O
the	O
assay	O
involves	O
the	O
dramatic	O
loss	O
of	O
red	O
cell	O
production	O
,	O
it	O
should	O
be	O
possible	O
to	O
define	O
important	O
regulatory	O
domains	O
that	O
can	O
then	O
be	O
assayed	O
using	O
less	O
stringent	O
systems	O
,	O
such	O
as	O
cell	O
-	O
free	O
extracts	O
for	O
in	O
vitro	O
transcription	O
.	O
The	O
ideal	O
situation	O
would	O
be	O
analyses	O
conducted	O
in	O
GATA-1	O
-erythroid	O
cells	O
.	O
However	O
,	O
these	O
cells	O
have	O
been	O
impossible	O
to	O
generate	O
given	O
the	O
requirement	O
of	O
GATA-1	B
for	O
Epo	B
receptor	I
expression	O
and	O
red	O
cell	O
viability	O
(	O
C.	O
Simon	O
and	O
S.	O
Orkin	O
,	O
unpublished	O
observations	O
)	O
.	O
It	O
may	O
be	O
possible	O
to	O
produce	O
such	O
cells	O
by	O
first	O
expressing	O
the	O
Epo	B
receptor	I
under	O
the	O
influence	O
of	O
a	O
constitutive	O
promoter	O
and	O
then	O
targeting	O
the	O
GATA-1	O
gene	O
.	O
If	O
GATA-1	O
-red	O
cells	O
were	O
available	O
,	O
the	O
analyses	O
would	O
involve	O
the	O
actual	O
transcription	O
of	O
or	O
chromatin	O
structure	O
surrounding	O
the	O
globin	O
genes	O
.	O
Structure	O
-	O
function	O
studies	O
of	O
the	O
GATA-1	B
protein	O
could	O
be	O
greatly	O
simplified	O
and	O
a	O
larger	O
number	O
of	O
mutants	O
studied	O
.	O
However	O
,	O
the	O
ES	O
cell	O
system	O
can	O
be	O
used	O
as	O
an	O
alternative	O
until	O
targeted	O
erythroleukemia	O
cells	O
become	O
available	O
.	O
Other	O
applications	O
involve	O
the	O
introduction	O
of	O
other	O
GATA	B
-	I
binding	I
protein	I
family	I
members	I
to	O
determine	O
whether	O
they	O
rescue	O
the	O
mutation	O
.	O
If	O
they	O
can	O
not	O
,	O
chimeric	B
proteins	I
can	O
be	O
tested	O
to	O
identify	O
which	O
amino	O
acids	O
distinguish	O
the	O
different	O
family	O
members	O
.	O
We	O
feel	O
that	O
these	O
experiments	O
are	O
vital	O
to	O
understanding	O
the	O
function	O
of	O
GATA-1	B
during	O
erythroid	O
ontogeny	O
.	O
How	O
does	O
GATA-1	B
regulate	O
red	O
cell	O
genes	O
like	O
globin	O
or	O
the	O
Epo	B
receptor	I
?	O
Once	O
we	O
identify	O
the	O
functional	O
domains	O
of	O
the	O
GATA	B
-	I
binding	I
proteins	I
,	O
we	O
hope	O
to	O
learn	O
what	O
proteins	O
GATA-1	B
binds	O
to	O
in	O
the	O
basic	O
transcription	O
machinery	O
or	O
in	O
chromatin	O
.	O
Is	O
GATA-1	B
necessary	O
for	O
globin	O
gene	O
switching	O
?	O
GATA-1	B
may	O
be	O
modified	O
differently	O
during	O
development	O
so	O
that	O
the	O
locus	O
control	O
region	O
can	O
interact	O
with	O
different	O
globin	O
promoters	O
.	O
We	O
may	O
find	O
that	O
one	O
region	O
of	O
the	O
protein	O
is	O
required	O
for	O
embryonic	O
expression	O
and	O
another	O
for	O
adult	O
globin	O
gene	O
expression	O
.	O
Activation	O
of	O
lymphokine	O
genes	O
in	O
T	O
cells	O
:	O
role	O
of	O
cis	O
-	O
acting	O
DNA	O
elements	O
that	O
respond	O
to	O
T	O
cell	O
activation	O
signals	O
.	O
Activation	O
of	O
T	O
cells	O
is	O
initiated	O
by	O
the	O
recognition	O
of	O
antigen	O
on	O
antigen	O
presenting	O
cells	O
to	O
exert	O
the	O
effector	O
functions	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O
Two	O
types	O
of	O
helper	O
T	O
cell	O
(	O
Th	O
)	O
clones	O
(	O
Th1	O
and	O
Th2	O
)	O
are	O
defined	O
on	O
the	O
basis	O
of	O
different	O
patterns	O
of	O
cytokine	B
(	O
lymphokine	B
)	O
secretion	O
.	O
They	O
determine	O
the	O
outcome	O
of	O
an	O
antigenic	O
response	O
toward	O
humoral	O
or	O
cell	O
-	O
mediated	O
immunity	O
.	O
Although	O
lymphokine	O
genes	O
are	O
coordinately	O
regulated	O
upon	O
antigen	O
stimulation	O
,	O
they	O
are	O
regulated	O
by	O
the	O
mechanisms	O
common	O
to	O
all	O
as	O
well	O
as	O
those	O
which	O
are	O
unique	O
to	O
each	O
gene	O
.	O
For	O
most	O
lymphokine	O
genes	O
,	O
a	O
combination	O
of	O
phorbol	O
esters	O
(	O
phorbol	O
12-myristate	O
13	O
acetate	O
,	O
PMA	O
)	O
and	O
calcium	O
ionophores	O
(	O
A23187	O
)	O
is	O
required	O
for	O
their	O
maximal	O
induction	O
.	O
Yet	O
phorbol	O
ester	O
alone	O
or	O
calcium	O
ionophore	O
alone	O
produce	O
several	O
lymphokines	B
.	O
The	O
production	O
of	O
the	O
granulocyte	B
-	I
macrophage	I
colony	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
is	O
completely	O
dependent	O
on	O
the	O
two	O
signals	O
.	O
We	O
have	O
previously	O
found	O
a	O
cis	O
-	O
acting	O
region	O
spanning	O
the	O
GM	O
-	O
CSF	O
promoter	O
region	O
(	O
positions	O
-95	O
to	O
+	O
27	O
)	O
that	O
confers	O
inducibility	O
to	O
reporter	O
genes	O
in	O
transient	O
transfection	O
assays	O
.	O
Further	O
analysis	O
identified	O
three	O
elements	O
required	O
for	O
efficient	O
induction	O
,	O
referred	O
to	O
as	O
GM2	O
,	O
GC	O
-	O
box	O
and	O
conserved	O
lymphokine	O
element	O
(	O
CLE0	O
)	O
.	O
GM2	O
defines	O
a	O
binding	O
site	O
for	O
protein	O
(	O
s	O
)	O
whose	O
binding	O
is	O
inducible	O
by	O
PMA	O
.	O
One	O
protein	O
,	O
NF	B
-	I
GM2	I
is	O
similar	O
to	O
the	O
transcription	B
factor	I
NF	B
-	I
kB	I
.	O
GC	O
-	O
box	O
is	O
a	O
binding	O
site	O
for	O
constitutively	B
bound	I
proteins	I
.	O
CLEO	O
defines	O
a	O
binding	O
site	O
for	O
protein	O
(	O
s	O
)	O
whose	O
optimum	O
binding	O
is	O
stimulated	O
by	O
PMA	O
and	O
A23187	O
.	O
Viral	B
trans	I
-	I
activators	I
such	O
as	O
Tax	B
(	O
human	O
T	O
cell	O
leukemia	O
virus-1	O
,	O
HTLV-1	O
)	O
and	O
E2	B
(	O
bovine	O
papilloma	O
virus	O
,	O
BPV	O
)	O
proteins	O
are	O
other	O
agents	O
which	O
activate	O
lymphokine	O
gene	O
expression	O
by	O
bypassing	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
mediated	O
signaling	O
.	O
The	O
trans	O
-	O
activation	O
domain	O
of	O
E2	B
and	O
Tax	B
is	O
interchangeable	O
although	O
they	O
have	O
no	O
obvious	O
sequence	O
homology	O
between	O
them	O
.	O
The	O
viral	B
trans	I
-	I
activators	I
appear	O
to	O
target	O
specific	O
DNA	B
binding	I
protein	I
such	O
as	O
NF	B
-	I
kB	I
and	O
Sp1	B
to	O
cis	O
-	O
acting	O
DNA	O
site	O
and	O
promote	O
lymphokine	O
gene	O
expression	O
without	O
TCR	B
-mediated	O
stimulation	O
.	O
Cell	O
-	O
type	O
-	O
specific	O
transactivation	O
of	O
the	O
parathyroid	O
hormone	O
-	O
related	O
protein	O
gene	O
promoter	O
by	O
the	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
I	I
(	I
HTLV	I
-	I
I	I
)	I
tax	I
and	O
HTLV	B
-	I
II	I
tax	I
proteins	I
.	O
The	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
I	I
(	I
HTLV	I
-	I
I	I
)	I
and	I
HTLV	I
-	I
II	I
Tax	I
proteins	I
are	O
potent	O
transactivators	B
of	O
viral	O
and	O
cellular	O
gene	O
expression	O
.	O
Using	O
deletion	O
mutants	O
,	O
the	O
downstream	O
parathyroid	O
hormone	O
-	O
related	O
protein	O
(	O
PTHrP	O
)	O
promoter	O
is	O
shown	O
to	O
be	O
responsive	O
to	O
both	O
HTLV	B
-	I
I	I
and	I
HTLV	I
-	I
II	I
Tax	I
as	O
well	O
as	O
the	O
AP1	O
/	O
c	O
-	O
jun	O
proto	O
-	O
oncogene	O
.	O
Transactivation	O
of	O
PTHrP	B
by	O
Tax	B
was	O
seen	O
in	O
T	O
cells	O
but	O
not	O
in	O
B	O
-	O
cell	O
lines	O
or	O
fibroblasts	O
.	O
A	O
carboxy	O
terminal	O
Tax	O
deletion	O
mutant	O
was	O
deficient	O
in	O
transactivation	O
of	O
both	O
the	O
PTHrP	O
and	O
IL2R	O
alpha	O
promoters	O
but	O
not	O
the	O
HTLV	O
-	O
I	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O
Exogenous	O
provision	O
of	O
NFkB	B
rescued	O
IL2R	B
alpha	O
expression	O
but	O
not	O
the	O
PTHrP	O
promoter	O
.	O
Thus	O
,	O
HTLV	B
-	I
I	I
Tax	I
,	O
HTLV	B
-	I
II	I
Tax	I
,	O
and	O
c	B
-	I
jun	I
transactivate	O
PTHrP	B
and	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
hypercalcemia	O
in	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O
I	B
kappa	I
B	I
/	I
MAD-3	I
masks	O
the	O
nuclear	O
localization	O
signal	O
of	O
NF	B
-	I
kappa	I
B	I
p65	I
and	O
requires	O
the	O
transactivation	B
domain	I
to	O
inhibit	O
NF	B
-	I
kappa	I
B	I
p65	I
DNA	O
binding	O
.	O
The	O
active	O
nuclear	O
form	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
transcription	I
factor	I
complex	I
is	O
composed	O
of	O
two	O
DNA	B
binding	I
subunits	I
,	O
NF	B
-	I
kappa	I
B	I
p65	I
and	O
NF	B
-	I
kappa	I
B	I
p50	I
,	O
both	O
of	O
which	O
share	O
extensive	O
N	O
-	O
terminal	O
sequence	O
homology	O
with	O
the	O
v	B
-	I
rel	I
oncogene	I
product	I
.	O
The	O
NF	B
-	I
kappa	I
B	I
p65	I
subunit	I
provides	O
the	O
transactivation	O
activity	O
in	O
this	O
complex	O
and	O
serves	O
as	O
an	O
intracellular	O
receptor	O
for	O
a	O
cytoplasmic	O
inhibitor	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
termed	O
I	O
kappa	O
B	O
.	O
In	O
contrast	O
,	O
NF	B
-	I
kappa	I
B	I
p50	I
alone	O
fails	O
to	O
stimulate	O
kappa	O
B	O
-	O
directed	O
transcription	O
,	O
and	O
based	O
on	O
prior	O
in	O
vitro	O
studies	O
,	O
is	O
not	O
directly	O
regulated	O
by	O
I	B
kappa	I
B	I
.	O
To	O
investigate	O
the	O
molecular	O
basis	O
for	O
the	O
critical	O
regulatory	O
interaction	O
between	O
NF	B
-	I
kappa	I
B	I
and	O
I	B
kappa	I
B	I
/	I
MAD-3	I
,	O
a	O
series	O
of	O
human	B
NF	I
-	I
kappa	I
B	I
p65	I
mutants	I
was	O
identified	O
that	O
functionally	O
segregated	O
DNA	O
binding	O
,	O
I	B
kappa	I
B	I
-mediated	O
inhibition	O
,	O
and	O
I	B
kappa	I
B	I
-induced	O
nuclear	O
exclusion	O
of	O
this	O
transcription	B
factor	I
.	O
Results	O
from	O
in	O
vivo	O
expression	O
studies	O
performed	O
with	O
these	O
NF	B
-	I
kappa	I
B	I
p65	I
mutants	I
revealed	O
the	O
following	O
:	O
1	O
)	O
I	B
kappa	I
B	I
/	I
MAD-3	I
completely	O
inhibits	O
NF	B
-	I
kappa	I
B	I
p65	I
-dependent	O
transcriptional	O
activation	O
mediated	O
through	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
kappa	O
B	O
enhancer	O
in	O
human	O
T	O
lymphocytes	O
,	O
2	O
)	O
the	O
binding	O
of	O
I	B
kappa	I
B	I
/	I
MAD-3	I
to	O
NF	B
-	I
kappa	I
B	I
p65	I
is	O
sufficient	O
to	O
retarget	O
NF	B
-	I
kappa	I
B	I
p65	I
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
,	O
3	O
)	O
selective	O
deletion	O
of	O
the	O
functional	O
nuclear	O
localization	O
signal	O
present	O
in	O
the	O
Rel	B
homology	I
domain	I
of	O
NF	B
-	I
kappa	I
B	I
p65	I
disrupts	O
its	O
ability	O
to	O
engage	O
I	B
kappa	I
B	I
/	I
MAD-3	I
,	O
and	O
4	O
)	O
the	O
unique	O
C	B
-	I
terminus	I
of	O
NF	B
-	I
kappa	I
B	I
p65	I
attenuates	O
its	O
own	O
nuclear	O
localization	O
and	O
contains	O
sequences	O
that	O
are	O
required	O
for	O
I	B
kappa	I
B	I
-mediated	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
p65	I
DNA	O
binding	O
activity	O
.	O
Together	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
nuclear	O
localization	O
signal	O
and	O
transactivation	B
domain	I
of	O
NF	B
-	I
kappa	I
B	I
p65	I
constitute	O
a	O
bipartite	O
system	O
that	O
is	O
critically	O
involved	O
in	O
the	O
inhibitory	O
function	O
of	O
I	B
kappa	I
B	I
/	I
MAD-3	I
.	O
Unexpectedly	O
,	O
our	O
in	O
vivo	O
studies	O
also	O
demonstrate	O
that	O
I	B
kappa	I
B	I
/	I
MAD-3	I
binds	O
directly	O
to	O
NF	B
-	I
kappa	I
B	I
p50	I
.	O
This	O
interaction	O
is	O
functional	O
as	O
it	O
leads	O
to	O
retargeting	O
of	O
NF	B
-	I
kappa	I
B	I
p50	I
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O
However	O
,	O
no	O
loss	O
of	O
DNA	O
binding	O
activity	O
is	O
observed	O
,	O
presumably	O
reflecting	O
the	O
unique	O
C	B
-	I
terminal	I
domain	I
that	O
is	O
distinct	O
from	O
that	O
present	O
in	O
NF	B
-	I
kappa	I
B	I
p65	I
.	O
Surrogate	O
thyroglobulin	B
receptors	I
and	O
T	O
cell	O
proliferation	O
in	O
Hashimoto	O
's	O
thyroiditis	O
.	O
Immunoglobulin	B
molecules	I
on	O
the	O
surface	O
of	O
a	O
B	O
lymphocyte	O
are	O
the	O
endogenous	O
`	O
`	O
receptors	O
''	O
to	O
which	O
specific	O
antigens	O
bind	O
.	O
Studies	O
in	O
mice	O
have	O
shown	O
that	O
a	O
monoclonal	B
antibody	I
,	O
conjugated	O
with	O
palmitate	O
to	O
provide	O
a	O
lipid	O
tail	O
,	O
can	O
be	O
inserted	O
into	O
the	O
cell	O
membrane	O
to	O
provide	O
a	O
`	O
`	O
surrogate	O
''	O
antigen	O
receptor	O
.	O
We	O
have	O
investigated	O
whether	O
a	O
palmitate	B
conjugate	I
of	O
a	O
human	B
monoclonal	I
antibody	I
specific	O
for	O
thyroglobulin	B
(	O
TG	B
)	O
could	O
function	O
as	O
a	O
surrogate	B
TG	I
receptor	I
on	O
blood	O
mononuclear	O
cells	O
separated	O
into	O
fractions	O
enriched	O
for	O
T	O
cells	O
or	O
depleted	O
of	O
T	O
cells	O
(	O
non	O
-	O
T	O
cells	O
)	O
.	O
Using	O
flow	O
cytometry	O
,	O
we	O
detected	O
surrogate	B
TG	I
receptors	I
on	O
non	O
-	O
T	O
(	O
but	O
not	O
on	O
T	O
)	O
cells	O
from	O
11	O
of	O
11	O
individuals	O
studied	O
(	O
5	O
Hashimoto	O
patients	O
and	O
6	O
control	O
donors	O
)	O
.	O
In	O
contrast	O
,	O
endogenous	B
TG	I
receptors	I
could	O
only	O
be	O
detected	O
on	O
non	O
-	O
T	O
cells	O
from	O
1	O
of	O
3	O
Hashimoto	O
patients	O
and	O
from	O
0	O
of	O
4	O
control	O
donors	O
.	O
Because	O
of	O
the	O
efficient	O
binding	O
of	O
TG	B
by	O
surrogate	B
receptors	I
on	O
non	O
-	O
T	O
cells	O
,	O
we	O
assessed	O
the	O
ability	O
of	O
such	O
cells	O
to	O
present	O
TG	B
to	O
T	O
cells	O
.	O
Proliferation	O
in	O
response	O
to	O
TG	B
was	O
observed	O
in	O
T	O
cells	O
from	O
only	O
1	O
of	O
5	O
Hashimoto	O
patients	O
.	O
This	O
low	O
frequency	O
of	O
response	O
was	O
no	O
different	O
from	O
that	O
previously	O
detected	O
using	O
cultures	O
of	O
T	O
cells	O
and	O
autologous	O
dendritic	O
cells	O
.	O
Therefore	O
,	O
the	O
successful	O
generation	O
of	O
surrogate	B
receptors	I
on	O
non	O
-	O
T	O
cells	O
is	O
not	O
associated	O
with	O
more	O
efficient	O
TG	B
presentation	O
of	O
T	O
cells	O
.	O
Furthermore	O
,	O
the	O
significance	O
of	O
the	O
present	O
study	O
is	O
that	O
the	O
T	O
cells	O
,	O
not	O
the	O
antigen	O
-	O
presenting	O
cells	O
,	O
are	O
likely	O
to	O
be	O
the	O
limiting	O
element	O
in	O
the	O
T	O
cell	O
proliferative	O
response	O
to	O
TG	B
and	O
other	O
thyroid	B
autoantigens	I
.	O
The	O
Epstein	B
-	I
Barr	I
virus	I
nuclear	I
antigen	I
2	I
interacts	O
with	O
an	O
EBNA2	O
responsive	O
cis	O
-	O
element	O
of	O
the	O
terminal	O
protein	O
1	O
gene	O
promoter	O
.	O
The	O
Epstein	B
-	I
Barr	I
virus	I
protein	I
EBNA2	I
acts	O
as	O
a	O
transcriptional	B
activator	I
of	O
cellular	O
and	O
viral	O
genes	O
and	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
immortalization	O
of	O
human	O
primary	O
B	O
-	O
cells	O
by	O
EBV	O
.	O
We	O
have	O
shown	O
previously	O
that	O
EBNA2	B
transactivates	O
the	O
promoters	O
of	O
the	O
latent	B
membrane	I
antigens	I
LMP	B
,	O
TP1	B
and	O
TP2	B
.	O
The	O
promoter	O
of	O
the	O
TP1	O
gene	O
was	O
chosen	O
as	O
a	O
model	O
system	O
to	O
study	O
the	O
molecular	O
mechanism	O
of	O
EBNA2	B
mediated	O
transactivation	O
.	O
To	O
identify	O
an	O
EBNA2	O
dependent	O
cis	O
-	O
acting	O
element	O
,	O
various	O
TP1	O
promoter	O
-	O
reporter	O
gene	O
constructs	O
were	O
transfected	O
in	O
the	O
absence	O
and	O
presence	O
of	O
an	O
EBNA2	O
expression	O
vector	O
into	O
the	O
established	O
B	O
-	O
cell	O
line	O
BL41-P3HR1	O
.	O
We	O
were	O
able	O
to	O
delineate	O
an	O
81	O
bp	O
EBNA2	O
responsive	O
region	O
between	O
-258	O
and	O
-177	O
relative	O
to	O
the	O
TP1	O
RNA	O
start	O
site	O
.	O
The	O
element	O
worked	O
in	O
either	O
orientation	O
and	O
could	O
mediate	O
EBNA2	B
dependent	O
transactivation	O
on	O
a	O
heterologous	O
promoter	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
revealed	O
three	O
specific	O
protein	B
-	I
DNA	I
complexes	I
formed	O
with	O
sequences	O
of	O
the	O
EBNA2	O
responsive	O
element	O
.	O
Two	O
of	O
these	O
were	O
not	O
cell	O
type	O
specific	O
,	O
but	O
the	O
third	O
was	O
detected	O
only	O
in	O
EBNA2	B
positive	O
cell	O
extracts	O
.	O
Gel	O
-	O
shift	O
analysis	O
in	O
the	O
presence	O
of	O
EBNA2	B
specific	O
monoclonal	O
antibodies	O
revealed	O
that	O
EBNA2	B
is	O
a	O
component	O
of	O
the	O
third	O
complex	O
.	O
Thus	O
,	O
these	O
experiments	O
demonstrate	O
that	O
EBNA2	B
interacts	O
with	O
an	O
EBNA2	O
responsive	O
cis	O
-	O
element	O
of	O
the	O
TP1	O
promoter	O
The	O
c	B
-	I
rel	I
protooncogene	I
product	I
represses	O
NF	B
-	I
kappa	I
B	I
p65	B
-mediated	O
transcriptional	O
activation	O
of	O
the	O
long	O
terminal	O
repeat	O
of	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
.	O
The	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
the	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
and	O
the	O
5	O
'	O
regulatory	O
region	O
of	O
the	O
gene	O
encoding	O
the	O
interleukin	B
2	I
receptor	I
alpha	I
subunit	I
(	O
IL-2R	B
alpha	I
)	O
share	O
functional	O
kappa	O
B	O
enhancer	O
elements	O
involved	O
in	O
the	O
regulation	O
of	O
these	O
inducible	O
transcription	O
units	O
during	O
T	O
-	O
cell	O
activation	O
.	O
These	O
kappa	O
B	O
enhancer	O
elements	O
are	O
recognized	O
by	O
a	O
structurally	O
related	O
family	O
of	O
interactive	O
proteins	O
that	O
includes	O
p50	B
,	O
p65	B
,	O
and	O
the	O
product	O
of	O
the	O
c	O
-	O
rel	O
protooncogene	O
(	O
c	B
-	I
Rel	I
)	O
.	O
Recent	O
biochemical	O
studies	O
have	O
shown	O
that	O
p65	B
and	O
p50	B
form	O
the	O
prototypical	O
NF	B
-	I
kappa	I
B	I
complex	I
,	O
which	O
is	O
rapidly	O
translocated	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
during	O
T	O
-	O
cell	O
activation	O
.	O
This	O
intracellular	O
signaling	O
complex	O
potently	O
stimulates	O
kappa	O
B	O
-	O
directed	O
transcription	O
from	O
either	O
the	O
HIV-1	O
LTR	O
or	O
the	O
IL-2R	O
alpha	O
promoter	O
via	O
the	O
strong	O
transactivation	O
domain	O
present	O
in	O
p65	B
.	O
We	O
now	O
demonstrate	O
that	O
nuclear	O
expression	O
of	O
human	O
c	B
-	I
Rel	I
,	O
which	O
is	O
induced	O
by	O
either	O
phorbol	O
ester	O
or	O
tumor	B
necrosis	I
factor	I
alpha	I
with	O
delayed	O
kinetics	O
relative	O
to	O
p65	B
,	O
markedly	O
represses	O
p65	B
-mediated	O
activation	O
of	O
these	O
transcription	O
units	O
.	O
These	O
inhibitory	O
effects	O
of	O
c	B
-	I
Rel	I
correlate	O
with	O
its	O
DNA	O
-	O
binding	O
activity	O
but	O
not	O
with	O
its	O
ability	O
to	O
heterodimerize	O
with	O
p50	B
,	O
suggesting	O
that	O
c	B
-	I
Rel	I
inhibition	O
involves	O
competition	O
with	O
p50	B
/	I
p65	I
for	O
occupancy	O
of	O
the	O
kappa	O
B	O
enhancer	O
element	O
.	O
Together	O
,	O
these	O
findings	O
suggest	O
that	O
one	O
function	O
of	O
c	B
-	I
Rel	I
is	O
as	O
a	O
physiologic	O
repressor	O
of	O
the	O
HIV-1	O
LTR	O
and	O
IL-2R	B
alpha	I
promoters	O
,	O
serving	O
to	O
efficiently	O
counter	O
the	O
strong	O
transcriptional	O
activating	O
effects	O
of	O
p65	B
.	O
Protease	O
treatment	O
of	O
nuclear	O
extracts	O
distinguishes	O
between	O
class	B
II	I
MHC	I
X1	I
box	I
DNA	I
-	I
binding	I
proteins	I
in	O
wild	O
-	O
type	O
and	O
class	O
II	O
-	O
deficient	O
B	O
cells	O
.	O
The	O
X	O
box	O
region	O
is	O
critical	O
for	O
directing	O
the	O
expression	O
of	O
class	O
II	O
major	O
histocompatibility	O
complex	O
genes	O
in	O
B	O
lymphocytes	O
.	O
Although	O
several	O
class	B
II	I
promoter	I
-	I
specific	I
DNA	I
binding	I
factors	I
have	O
been	O
described	O
,	O
only	O
the	O
X	O
box	O
region	O
factor	O
,	O
RFX	B
,	O
shows	O
a	O
genetic	O
correlation	O
with	O
class	O
II	O
expression	O
,	O
being	O
deficient	O
in	O
some	O
B	O
cell	O
lines	O
derived	O
from	O
patients	O
with	O
class	O
II	O
-	O
deficient	O
congenital	O
immunodeficiency	O
.	O
To	O
further	O
evaluate	O
the	O
role	O
of	O
X	B
box	I
DNA	I
-	I
binding	I
proteins	I
in	O
class	O
II	O
gene	O
expression	O
,	O
the	O
role	O
of	O
the	O
X	O
box	O
region	O
was	O
examined	O
in	O
both	O
class	O
II	O
-	O
positive	O
and	O
-negative	O
lymphoid	O
cells	O
.	O
In	O
addition	O
to	O
the	O
wild	O
-	O
type	O
B	O
cell	O
line	O
Raji	O
,	O
two	O
class	O
II	O
transcriptional	O
mutant	O
cell	O
lines	O
,	O
SJO	O
and	O
RJ2.2.5	O
,	O
and	O
Jurkat	O
,	O
a	O
class	O
II	O
negative	O
T	O
cell	O
line	O
,	O
were	O
examined	O
.	O
In	O
contrast	O
to	O
wild	O
-	O
type	O
B	O
cells	O
,	O
neither	O
of	O
the	O
class	O
II	O
mutant	O
cell	O
lines	O
could	O
use	O
the	O
X	O
box	O
region	O
to	O
direct	O
the	O
expression	O
of	O
a	O
transiently	O
transfected	O
reporter	O
gene	O
,	O
indicating	O
that	O
the	O
X	O
box	O
-	O
dependent	O
transcriptional	O
pathway	O
is	O
defective	O
in	O
these	O
cells	O
.	O
The	O
binding	O
activity	O
of	O
the	O
X1	B
box	I
DNA	I
-	I
binding	I
protein	I
RFX	B
was	O
examined	O
and	O
found	O
to	O
be	O
present	O
in	O
wild	O
-	O
type	O
B	O
cells	O
and	O
the	O
mutant	O
RJ2.2.5	O
but	O
was	O
absent	O
in	O
SJO	O
and	O
Jurkat	O
.	O
However	O
,	O
other	O
X1	O
box	O
-	O
specific	O
activities	O
were	O
detected	O
in	O
all	O
these	O
cell	O
lines	O
.	O
To	O
determine	O
whether	O
these	O
different	O
X1	O
box	O
activities	O
represented	O
distinct	O
DNA	B
binding	I
proteins	I
or	O
multimeric	O
forms	O
of	O
the	O
same	O
factor	O
(	O
s	O
)	O
,	O
protease	B
treatment	O
of	O
the	O
crude	O
nuclear	O
extracts	O
followed	O
by	O
DNA	O
-	O
binding	O
assays	O
were	O
carried	O
out	O
and	O
demonstrated	O
that	O
B	O
cell	O
extracts	O
contain	O
at	O
least	O
two	O
X1-specific	B
factors	I
.	O
One	O
of	O
these	O
cleaved	O
products	O
(	O
band	O
1	O
pk	O
)	O
correlates	O
with	O
RFX	B
activity	O
.	O
A	O
similar	O
comparison	O
with	O
protease	O
-	O
treated	O
extracts	O
prepared	O
from	O
Jurkat	O
cells	O
demonstrated	O
the	O
presence	O
of	O
the	O
band	O
1pk	O
activity	O
despite	O
an	O
absence	O
of	O
the	O
native	O
RFX	B
activity	O
.	O
In	O
contrast	O
,	O
protease	O
treatment	O
and	O
analysis	O
of	O
SJO	O
extracts	O
showed	O
no	O
detectable	O
levels	O
of	O
the	O
band	O
1pk	O
activity	O
.	O
These	O
results	O
demonstrate	O
that	O
multiple	O
X1	O
box	O
-	O
specific	O
DNA	O
-	O
binding	O
activities	O
exist	O
in	O
all	O
lymphoid	O
cells	O
,	O
but	O
the	O
presence	O
of	O
an	O
actively	O
binding	O
RFX	B
species	O
correlates	O
with	O
class	O
II	O
transcription	O
.	O
Dimerization	O
of	O
NF	B
-	I
KB2	I
with	O
RelA	B
(	I
p65	I
)	I
regulates	O
DNA	O
binding	O
,	O
transcriptional	O
activation	O
,	O
and	O
inhibition	O
by	O
an	O
I	B
kappa	I
B	I
-	I
alpha	I
(	O
MAD-3	B
)	O
.	O
Inducible	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
regulated	O
by	O
a	O
cellular	O
transcription	B
factor	I
,	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
.	O
NF	B
-	I
kappa	I
B	I
is	O
composed	O
of	O
distinct	O
subunits	O
;	O
five	O
independent	O
genes	O
,	O
NFKB1	O
(	O
p105	B
)	O
,	O
NFKB2	O
(	O
p100	B
)	O
,	O
RelA	B
(	I
p65	I
)	I
,	O
c	O
-	O
rel	O
and	O
relB	O
,	O
that	O
encode	O
related	O
proteins	O
that	O
bind	O
to	O
kappa	O
B	O
DNA	O
elements	O
have	O
been	O
isolated	O
.	O
We	O
have	O
previously	O
found	O
that	O
NFKB2	B
(	I
p49	I
/	I
p52	I
)	I
acts	O
in	O
concert	O
with	O
RelA	B
(	I
p65	I
)	I
to	O
stimulate	O
the	O
HIV	O
enhancer	O
in	O
Jurkat	O
T	O
-	O
leukemia	O
cells	O
.	O
Here	O
we	O
examine	O
the	O
biochemical	O
basis	O
for	O
the	O
transcriptional	O
regulation	O
of	O
HIV	O
by	O
NFKB2	B
.	O
Using	O
Scatchard	O
analysis	O
,	O
we	O
have	O
determined	O
the	O
dissociation	O
constants	O
of	O
homodimeric	B
p49	I
and	O
heterodimeric	B
p49	I
/	I
p65	I
for	O
binding	O
to	O
the	O
HIV	O
kappa	O
B	O
site	O
.	O
p49	B
has	O
a	O
approximately	O
18-fold	O
-	O
lower	O
affinity	O
for	O
the	O
HIV	O
kappa	O
B	O
site	O
(	O
KD	O
=	O
69.1	O
pM	O
)	O
than	O
does	O
the	O
approximately	O
50-kDa	O
protein	O
NFKB1	B
(	I
p50	I
)	I
derived	O
from	O
p105	B
(	O
KD	O
=	O
3.9	O
pM	O
)	O
.	O
In	O
contrast	O
,	O
the	O
affinity	O
of	O
heterodimeric	B
NFKB2	I
(	I
p49	I
)	I
/RelA	I
(	I
p65	I
)	I
for	O
this	O
site	O
is	O
approximately	O
6-fold	O
higher	O
(	O
KD	O
=	O
11.8	O
pM	O
)	O
than	O
that	O
of	O
p49	B
alone	O
.	O
Consistent	O
with	O
these	O
findings	O
,	O
in	O
vitro	O
transcription	O
was	O
stimulated	O
18-fold	O
by	O
the	O
addition	O
of	O
preformed	O
,	O
heterodimeric	B
NFKB2	I
(	I
p49	I
)	I
/RelA	I
(	I
p65	I
)	I
protein	I
.	O
Transcriptional	O
activation	O
of	O
the	O
HIV	O
enhancer	O
was	O
also	O
subject	O
to	O
regulation	O
by	O
recently	O
cloned	O
I	B
kappa	I
B	I
-	I
alpha	I
(	O
MAD-3	B
)	O
.	O
Recombinant	O
I	O
kappa	O
B	O
-	O
alpha	O
(	O
MAD-3	B
)	O
inhibited	O
the	O
DNA	O
binding	O
activity	O
of	O
p65	B
,	O
p49	B
/	I
p65	I
,	O
and	O
p50	B
/	I
p65	I
but	O
stimulated	O
the	O
binding	O
of	O
NFKB2	B
(	O
p49	B
)	O
or	O
NFKB1	O
(	O
p50	O
)	O
.	O
Functional	O
activation	O
of	O
an	O
HIV	O
reporter	O
plasmid	O
by	O
p49	B
/	I
p65	I
in	O
transiently	O
transfected	O
Jurkat	O
T	O
-	O
leukemia	O
cells	O
was	O
also	O
inhibited	O
by	O
coexpression	O
of	O
MAD-3	B
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
The	O
human	O
prointerleukin	O
1	O
beta	O
gene	O
requires	O
DNA	O
sequences	O
both	O
proximal	O
and	O
distal	O
to	O
the	O
transcription	O
start	O
site	O
for	O
tissue	O
-	O
specific	O
induction	O
.	O
In	O
these	O
studies	O
,	O
we	O
have	O
identified	O
DNA	O
sequences	O
and	O
specific	O
protein	O
interactions	O
necessary	O
for	O
transcriptional	O
regulation	O
of	O
the	O
human	O
prointerleukin	O
1	O
beta	O
(	O
proIL-1	O
beta	O
)	O
gene	O
.	O
A	O
cell	O
-	O
type	O
-	O
independent	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-responsive	O
enhancer	O
element	O
located	O
between	O
-3757	O
and	O
-2729	O
bp	O
upstream	O
from	O
the	O
transcription	O
start	O
site	O
(	O
cap	O
site	O
)	O
consisted	O
of	O
at	O
least	O
six	O
discrete	O
subregions	O
which	O
were	O
essential	O
to	O
the	O
maximal	O
induction	O
by	O
LPS	O
in	O
transfected	O
monocytes	O
.	O
The	O
enhancer	O
also	O
appeared	O
to	O
mediate	O
phorbol	O
myristate	O
acetate	O
induction	O
in	O
monocytes	O
and	O
IL-1	B
responsiveness	O
in	O
fibroblasts	O
.	O
Deletion	O
and	O
base	O
substitution	O
mutations	O
along	O
with	O
DNA	O
binding	O
studies	O
demonstrated	O
that	O
the	O
enhancer	O
contained	O
a	O
minimum	O
of	O
three	O
functional	O
protein	O
binding	O
sequences	O
,	O
two	O
of	O
which	O
appeared	O
to	O
be	O
important	O
for	O
gene	O
induction	O
.	O
One	O
of	O
the	O
essential	O
proteins	O
which	O
bound	O
to	O
the	O
enhancer	O
was	O
similar	O
or	O
identical	O
to	O
members	O
of	O
the	O
C	B
/	I
EBP	I
family	I
of	O
transcription	B
factors	I
required	O
for	O
both	O
IL-1	B
-and	O
LPS	O
-	O
specific	O
induction	O
of	O
the	O
IL-6	O
gene	O
(	O
i.e.	O
,	O
the	O
NF	O
-	O
IL6	O
proteins	O
)	O
.	O
When	O
ligated	O
to	O
the	O
proIL-1	O
beta	O
cap	O
site	O
-proximal	O
region	O
(	O
located	O
between	O
-131	O
to	O
+	O
12	O
)	O
,	O
both	O
the	O
proIL-1	O
beta	O
and	O
the	O
simian	O
virus	O
40	O
enhancer	O
elements	O
functioned	O
more	O
efficiently	O
in	O
monocytes	O
than	O
in	O
HeLa	O
cells	O
,	O
which	O
are	O
not	O
normally	O
competent	O
for	O
IL-1	B
beta	I
expression	O
.	O
When	O
ligated	O
to	O
the	O
murine	O
c	O
-	O
fos	O
promoter	O
,	O
however	O
,	O
the	O
proIL-1	O
beta	O
enhancer	O
was	O
inducible	O
in	O
phorbol	O
myristate	O
acetate	O
-	O
stimulated	O
HeLa	O
cells	O
,	O
suggesting	O
the	O
existence	O
of	O
a	O
proIL-1	B
beta	I
promoter	O
-	O
proximal	O
requirement	O
for	O
tissue	O
specificity	O
.	O
Expression	O
of	O
PILOT	B
,	O
a	O
putative	O
transcription	B
factor	I
,	O
requires	O
two	O
signals	O
and	O
is	O
cyclosporin	O
A	O
sensitive	O
in	O
T	O
cells	O
.	O
Few	O
known	O
genes	O
(	O
IL-2	B
,	O
members	O
of	O
the	O
IL-8	O
family	O
,	O
interferon	O
-	O
gamma	O
)	O
are	O
induced	O
in	O
T	O
cells	O
only	O
through	O
the	O
combined	O
effect	O
of	O
phorbol	O
myristic	O
acetate	O
(	O
PMA	O
)	O
and	O
a	O
Ca	O
(	O
2	O
+	O
)	O
-ionophore	O
,	O
and	O
expression	O
of	O
only	O
these	O
genes	O
can	O
be	O
fully	O
suppressed	O
by	O
Cyclosporin	O
A	O
(	O
CyA	O
)	O
.	O
We	O
have	O
identified	O
a	O
putative	O
transcription	B
factor	I
,	O
designated	O
PILOT	B
,	O
with	O
an	O
identical	O
dual	O
signal	O
requirement	O
for	O
expression	O
.	O
Induction	O
of	O
the	O
PILOT	B
gene	O
is	O
detectable	O
in	O
human	O
T	O
cells	O
20	O
min	O
following	O
activation	O
in	O
the	O
presence	O
of	O
cycloheximide	O
and	O
is	O
fully	O
suppressed	O
by	O
CyA	O
.	O
The	O
PILOT	B
protein	O
has	O
a	O
calculated	O
M	O
(	O
r	O
)	O
of	O
42.6	O
kDa	O
and	O
contains	O
three	O
zinc	B
fingers	I
of	O
the	O
C2H2-type	B
at	O
the	O
carboxyl	B
-	I
terminus	I
which	O
are	O
highly	O
homologous	O
to	O
the	O
zinc	B
finger	I
regions	I
of	O
the	O
transcription	B
factors	I
EGR1	B
,	O
EGR2	B
,	O
and	O
pAT	B
133	I
.	O
In	O
contrast	O
to	O
T	O
cells	O
,	O
in	O
fibroblasts	O
PILOT	B
gene	O
expression	O
requires	O
only	O
one	O
signal	O
(	O
PMA	O
)	O
and	O
is	O
not	O
affected	O
by	O
CyA	O
.	O
This	O
observation	O
directly	O
demonstrates	O
the	O
existence	O
of	O
a	O
Ca2	B
+	I
signal	I
-	I
dependent	I
regulatory	I
element	I
obligatory	O
for	O
expression	O
of	O
some	O
genes	O
in	O
T	O
cells	O
but	O
not	O
in	O
fibroblasts	O
.	O
This	O
differential	O
expression	O
model	O
will	O
be	O
valuable	O
in	O
the	O
dissection	O
of	O
the	O
dual	O
signal	O
pathway	O
in	O
T	O
cells	O
and	O
the	O
effects	O
of	O
CyA	O
upon	O
it	O
.	O
A	O
serum	O
response	O
element	O
and	O
a	O
binding	O
site	O
for	O
NF	O
-	O
Y	O
mediate	O
the	O
serum	O
response	O
of	O
the	O
human	O
thrombospondin	O
1	O
gene	O
.	O
The	O
expression	O
of	O
thrombospondin	B
1	I
(	O
TSP	B
1	I
)	O
,	O
a	O
member	O
of	O
the	O
TSP	O
gene	O
family	O
,	O
is	O
rapidly	O
induced	O
by	O
growth	O
factors	O
.	O
We	O
tested	O
the	O
ability	O
of	O
human	O
TSP	O
1-chloramphenicol	O
acetyltransferase	O
constructs	O
to	O
respond	O
to	O
serum	O
in	O
stably	O
transfected	O
NIH-3T3	O
cells	O
.	O
Two	O
transcriptional	O
elements	O
in	O
the	O
TSP	B
1	I
promoter	O
,	O
a	O
distal	O
element	O
at	O
-1280	O
and	O
a	O
proximal	O
element	O
at	O
-65	O
,	O
were	O
required	O
for	O
the	O
response	O
of	O
the	O
human	O
TSP	O
1	O
gene	O
to	O
serum	O
.	O
The	O
distal	O
element	O
contains	O
the	O
5'-CC	O
(	O
A	O
+	O
T	O
)	O
6GG-3	O
'	O
consensus	O
sequence	O
characteristic	O
of	O
a	O
serum	O
-	O
response	O
element	O
(	O
SRE	O
)	O
.	O
Deletions	O
or	O
mutations	O
in	O
this	O
element	O
reduced	O
the	O
serum	O
response	O
of	O
the	O
TSP	O
1	O
gene	O
by	O
80	O
-	O
90	O
%	O
.	O
In	O
gel	O
-	O
shift	O
assays	O
,	O
the	O
-1280	O
element	O
and	O
the	O
c	O
-	O
fos	O
SRE	O
cross	O
-competed	O
,	O
whereas	O
their	O
functional	O
and	O
binding	O
mutants	O
did	O
not	O
.	O
The	O
proximal	O
element	O
contains	O
the	O
sequence	O
5'-GGCCAATGGG-3	O
'	O
,	O
which	O
closely	O
resembles	O
the	O
consensus	O
binding	O
motif	O
for	O
the	O
CCAAT	O
-	O
binding	O
factor	O
NF	B
-	I
Y	I
(	O
CBF	B
,	O
CP1	B
,	O
alpha	B
CP1	I
)	O
.	O
Deletions	O
or	O
mutations	O
in	O
this	O
element	O
also	O
reduced	O
the	O
serum	O
response	O
by	O
80	O
-	O
90	O
%	O
.	O
Methylation	O
interference	O
analysis	O
of	O
the	O
-65	O
region	O
identified	O
a	O
pattern	O
of	O
contacts	O
with	O
nuclear	B
factors	I
resembling	O
that	O
for	O
NF	B
-	I
Y	I
,	O
and	O
an	O
NF	O
-	O
Y	O
-	O
binding	O
site	O
and	O
the	O
proximal	O
TSP	O
1	O
element	O
cross	O
-	O
competed	O
in	O
gel	O
-	O
shift	O
assays	O
,	O
whereas	O
their	O
binding	O
mutants	O
did	O
not	O
.	O
Finally	O
,	O
an	O
abbreviated	O
TSP	O
1	O
promoter	O
/	O
5'-flank	O
,	O
containing	O
the	O
SRE-	O
and	O
NF	O
-	O
Y	O
-	O
binding	O
sites	O
,	O
mediated	O
a	O
serum	O
response	O
that	O
was	O
close	O
in	O
magnitude	O
to	O
that	O
of	O
the	O
parent	O
promoter	O
.	O
We	O
conclude	O
that	O
the	O
serum	O
response	O
of	O
the	O
human	O
TSP	O
1	O
gene	O
requires	O
the	O
coordinated	O
function	O
of	O
an	O
SRE-	O
and	O
NF	O
-	O
Y	O
-	O
binding	O
site	O
.	O
Suppression	O
of	O
a	O
cellular	O
differentiation	O
program	O
by	O
phorbol	O
esters	O
coincides	O
with	O
inhibition	O
of	O
binding	O
of	O
a	O
cell	B
-	I
specific	I
transcription	I
factor	I
(	O
NF	B
-	I
E2	I
)	O
to	O
an	O
enhancer	O
element	O
required	O
for	O
expression	O
of	O
an	O
erythroid	O
-	O
specific	O
gene	O
.	O
Induction	O
by	O
hemin	O
increases	O
,	O
while	O
induction	O
with	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
represses	O
,	O
erythroid	O
-	O
specific	O
gene	O
expression	O
in	O
the	O
human	O
cell	O
line	O
K562	O
.	O
We	O
analyzed	O
the	O
effects	O
of	O
hemin	O
or	O
TPA	O
induction	O
on	O
the	O
binding	O
and	O
activity	O
of	O
transcription	B
factors	I
at	O
a	O
regulatory	O
element	O
found	O
within	O
the	O
transcriptional	O
regulatory	O
sequences	O
of	O
many	O
erythroid	O
-	O
specific	O
genes	O
.	O
TPA	O
induction	O
increases	O
the	O
binding	O
of	O
ubiquitous	B
AP-1	I
factors	I
to	O
this	O
element	O
.	O
TPA	O
induction	O
inhibits	O
the	O
binding	O
of	O
the	O
lineage	B
limited	I
transcription	I
factor	I
NF	B
-	I
E2	I
to	O
this	O
transcriptional	O
control	O
element	O
.	O
Hemin	O
induction	O
of	O
K562	O
cells	O
does	O
not	O
facilitate	O
the	O
binding	O
of	O
NF	B
-	I
E2	I
to	O
its	O
recognition	O
site	O
.	O
Hemin	O
induction	O
appears	O
to	O
nonspecifically	O
increase	O
the	O
expression	O
of	O
transiently	O
transfected	O
genes	O
in	O
K562	O
cells	O
.	O
Beyond	O
this	O
nonspecific	O
increase	O
in	O
gene	O
expression	O
,	O
hemin	B
induction	O
acts	O
to	O
increase	O
the	O
activity	O
of	O
the	O
lineage	B
limited	I
transcription	I
factor	I
NF	O
-	O
E2	O
.	O
The	O
divergent	O
effects	O
of	O
hemin	O
and	O
TPA	O
on	O
gene	O
expression	O
in	O
K562	O
cells	O
are	O
mediated	O
,	O
in	O
part	O
,	O
by	O
their	O
contrasting	O
effects	O
on	O
the	O
transcription	B
factor	I
NF	B
-	I
E2	I
.	O
The	O
interleukin	B
2	I
CD28-responsive	I
complex	I
contains	O
at	O
least	O
three	O
members	O
of	O
the	O
NF	B
kappa	I
B	I
family	I
:	O
c	B
-	I
Rel	I
,	O
p50	B
,	O
and	O
p65	B
.	O
Optimal	O
activation	O
of	O
T	O
cells	O
requires	O
at	O
least	O
two	O
signals	O
.	O
One	O
signal	O
can	O
be	O
delivered	O
by	O
the	O
antigen	B
-	I
specific	I
T	I
-	I
cell	I
receptor	I
,	O
and	O
the	O
second	O
signal	O
is	O
provided	O
by	O
the	O
costimulatory	O
molecule	O
(	O
s	O
)	O
delivered	O
by	O
the	O
antigen	O
-	O
presenting	O
cell	O
.	O
CD28	B
is	O
a	O
T	B
-	I
cell	I
surface	I
molecule	I
and	O
stimulation	O
through	O
this	O
protein	O
plays	O
an	O
important	O
role	O
in	O
delivering	O
the	O
second	O
activation	O
signal	O
.	O
In	O
this	O
report	O
,	O
we	O
show	O
that	O
in	O
human	O
peripheral	O
blood	O
T	O
cells	O
,	O
CD28	B
-mediated	O
signal	O
transduction	O
involves	O
the	O
rel	B
family	I
proteins	I
--	O
c	B
-	I
Rel	I
,	O
p50	B
,	O
and	O
p65	B
.	O
Treatment	O
of	O
peripheral	O
blood	O
T	O
cells	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
anti	B
-	I
CD28	I
monoclonal	I
antibody	I
(	O
mAb	B
)	O
results	O
in	O
augmentation	O
of	O
nuclear	B
c	I
-	I
Rel	I
,	O
p50	B
,	O
and	O
p65	B
,	O
and	O
this	O
augmentation	O
can	O
occur	O
in	O
the	O
presence	O
of	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
.	O
It	O
is	O
also	O
shown	O
in	O
this	O
report	O
that	O
,	O
in	O
response	O
to	O
PMA	B
/	I
anti	I
-	I
CD28	I
mAb	I
or	O
anti	B
-	I
CD3	I
/	I
anti	I
-	I
CD28	I
mAb	I
,	O
c	B
-	I
Rel	I
,	O
p50	B
,	O
and	O
p65	B
are	O
associated	O
with	O
CD28-responsive	O
element	O
present	O
in	O
the	O
promoter	O
of	O
the	O
human	O
interleukin	O
2	O
gene	O
.	O
The	O
functional	O
significance	O
of	O
c	B
-	I
Rel	I
involvement	O
in	O
the	O
CD28-responsive	B
complex	I
is	O
demonstrated	O
by	O
transient	O
transfection	O
analysis	O
,	O
where	O
cotransfection	O
of	O
c	B
-	I
Rel	I
augments	O
the	O
level	O
of	O
expression	O
of	O
a	O
chloramphenicol	O
acetyltransferase	O
reporter	O
gene	O
linked	O
to	O
the	O
CD28-responsive	O
element	O
.	O
Transcriptional	O
regulation	O
of	O
interleukin	B
3	I
(	O
IL3	B
)	O
in	O
primary	O
human	O
T	O
lymphocytes	O
.	O
Role	O
of	O
AP-1-	B
and	I
octamer	I
-	I
binding	I
proteins	I
in	O
control	O
of	O
IL3	B
gene	O
expression	O
.	O
We	O
have	O
investigated	O
the	O
molecular	O
and	O
biochemical	O
basis	O
for	O
activation	O
of	O
interleukin	B
3	I
(	O
IL3	B
)	O
gene	O
expression	O
in	O
primary	O
human	O
T	O
lymphocytes	O
following	O
CD3	O
and	O
CD2	O
receptor	O
stimulation	O
or	O
activation	O
by	O
phytohemagglutinin	B
plus	O
phorbol	O
12-myristate	O
13-acetate	O
.	O
Using	O
transfection	O
and	O
reporter	O
gene	O
assays	O
specifically	O
designed	O
for	O
primary	O
T	O
lymphocytes	O
in	O
conjunction	O
with	O
gel	O
retardation	O
assays	O
,	O
Western	O
blot	O
analyses	O
and	O
UV	O
cross	O
-	O
linking	O
studies	O
,	O
we	O
found	O
that	O
c	B
-	I
Jun	I
,	O
c	B
-	I
Fos	I
,	O
and	O
octamer	B
-	I
binding	I
proteins	I
play	O
a	O
major	O
role	O
in	O
transcriptional	O
activation	O
of	O
the	O
IL3	O
gene	O
via	O
their	O
interaction	O
with	O
two	O
specific	O
regions	O
contained	O
within	O
the	O
IL3	O
5'-flanking	O
sequence	O
.	O
Additionally	O
,	O
the	O
region	O
between	O
bases	O
-107	O
and	O
-59	O
of	O
the	O
IL3	O
promoter	O
containing	O
putative	O
AP-2	O
and	O
Sp1	O
binding	O
motifs	O
appears	O
necessary	O
for	O
basal	O
level	O
expression	O
of	O
the	O
IL3	B
gene	O
.	O
The	O
data	O
also	O
indicate	O
that	O
CD2	B
receptor	O
activation	O
and	O
phytohemagglutinin	B
plus	O
phorbol	O
12-myristate	O
13-acetate	O
stimulation	O
augment	O
T	O
cell	O
IL3	B
gene	O
expression	O
through	O
the	O
same	O
cis-	O
and	O
trans	O
-	O
activating	O
signals	O
.	O
These	O
results	O
should	O
contribute	O
to	O
a	O
better	O
understanding	O
of	O
the	O
regulation	O
of	O
IL3	B
gene	O
expression	O
in	O
human	O
T	O
lymphocytes	O
.	O
Transcriptional	O
activation	O
of	O
human	O
zeta	O
2	O
globin	O
promoter	O
by	O
the	O
alpha	O
globin	O
regulatory	O
element	O
(	O
HS-40	O
)	O
:	O
functional	O
role	O
of	O
specific	O
nuclear	B
factor	I
-	I
DNA	I
complexes	I
.	O
We	O
studied	O
the	O
functional	O
interaction	O
between	O
human	O
embryonic	O
zeta	O
2	O
globin	O
promoter	O
and	O
the	O
alpha	O
globin	O
regulatory	O
element	O
(	O
HS-40	O
)	O
located	O
40	O
kb	O
upstream	O
of	O
the	O
zeta	O
2	O
globin	O
gene	O
.	O
It	O
was	O
shown	O
by	O
transient	O
expression	O
assay	O
that	O
HS-40	O
behaved	O
as	O
an	O
authentic	O
enhancer	O
for	O
high	O
-	O
level	O
zeta	O
2	O
globin	O
promoter	O
activity	O
in	O
K562	O
cells	O
,	O
an	O
erythroid	O
cell	O
line	O
of	O
embryonic	O
and/or	O
fetal	O
origin	O
.	O
Although	O
sequences	O
located	O
between	O
-559	O
and	O
-88	O
of	O
the	O
zeta	O
2	O
globin	O
gene	O
were	O
dispensable	O
for	O
its	O
expression	O
on	O
enhancerless	O
plasmids	O
,	O
they	O
were	O
required	O
for	O
the	O
HS-40	O
enhancer	O
-mediated	O
activity	O
of	O
the	O
zeta	O
2	O
globin	O
promoter	O
.	O
Site	O
-	O
directed	O
mutagenesis	O
demonstrated	O
that	O
this	O
HS-40	O
enhancer-	O
zeta	O
2	O
globin	O
promoter	O
interaction	O
is	O
mediated	O
by	O
the	O
two	O
GATA-1	O
factor	O
binding	O
motifs	O
located	O
at	O
-230	O
and	O
-104	O
,	O
respectively	O
.	O
The	O
functional	O
domains	O
of	O
HS-40	O
were	O
also	O
mapped	O
.	O
Bal	O
31	O
deletion	O
mapping	O
data	O
suggested	O
that	O
one	O
GATA-1	O
motif	O
,	O
one	O
GT	O
motif	O
,	O
and	O
two	O
NF	O
-	O
E2	O
/	O
AP1	O
motifs	O
together	O
formed	O
the	O
functional	O
core	O
of	O
HS-40	O
in	O
the	O
erythroid	O
-	O
specific	O
activation	O
of	O
the	O
zeta	O
2	O
globin	O
promoter	O
.	O
Site	O
-	O
directed	O
mutagenesis	O
further	O
demonstrated	O
that	O
the	O
enhancer	O
function	O
of	O
one	O
of	O
the	O
two	O
NF	O
-	O
E2	O
/	O
AP1	O
motifs	O
of	O
HS-40	O
is	O
mediated	O
through	O
its	O
binding	O
to	O
NF	B
-	I
E2	I
but	O
not	O
AP1	B
transcription	I
factor	I
.	O
Finally	O
,	O
we	O
did	O
genomic	O
footprinting	O
of	O
the	O
HS-40	O
enhancer	O
region	O
in	O
K562	O
cells	O
,	O
adult	O
nucleated	O
erythroblasts	O
,	O
and	O
different	O
nonerythroid	O
cells	O
.	O
All	O
sequence	O
motifs	O
within	O
the	O
functional	O
core	O
of	O
HS-40	O
,	O
as	O
mapped	O
by	O
transient	O
expression	O
analysis	O
,	O
appeared	O
to	O
bind	O
a	O
nuclear	B
factor	I
(	O
s	O
)	O
in	O
living	O
K562	O
cells	O
but	O
not	O
in	O
nonerythroid	O
cells	O
.	O
On	O
the	O
other	O
hand	O
,	O
only	O
one	O
of	O
the	O
apparently	O
nonfunctional	O
sequence	O
motifs	O
was	O
bound	O
with	O
factors	O
in	O
vivo	O
.	O
In	O
comparison	O
to	O
K562	O
,	O
nucleated	O
erythroblasts	O
from	O
adult	O
human	O
bone	O
marrow	O
exhibited	O
a	O
similar	O
but	O
nonidentical	O
pattern	O
of	O
nuclear	B
factor	I
binding	O
in	O
vivo	O
at	O
the	O
HS-40	O
region	O
.	O
These	O
data	O
suggest	O
that	O
transcriptional	O
activation	O
of	O
human	O
embryonic	O
zeta	O
2	O
globin	O
gene	O
and	O
the	O
fetal	O
/	O
adult	O
alpha	O
globin	O
genes	O
is	O
mediated	O
by	O
erythroid	O
cell	O
-	O
specific	O
and	O
developmental	B
stage	I
-	I
specific	I
nuclear	I
factor	I
-	I
DNA	I
complexes	I
which	O
form	O
at	O
the	O
enhancer	O
(	O
HS-40	O
)	O
and	O
the	O
globin	O
promoters	O
.	O
Interaction	O
between	O
NF	B
-	I
kappa	I
B	I
-and	O
serum	B
response	I
factor	I
-binding	O
elements	O
activates	O
an	O
interleukin-2	O
receptor	O
alpha	O
-	O
chain	O
enhancer	O
specifically	O
in	O
T	O
lymphocytes	O
.	O
We	O
find	O
that	O
a	O
short	O
enhancer	O
element	O
containing	O
the	O
NF	O
-	O
kappa	O
B	O
binding	O
site	O
from	O
the	O
interleukin-2	O
receptor	O
alpha	O
-	O
chain	O
gene	O
(	O
IL-2R	B
alpha	I
)	O
is	O
preferentially	O
activated	O
in	O
T	O
cells	O
.	O
The	O
IL-2R	B
alpha	I
enhancer	O
binds	O
NF	B
-	I
kappa	I
B	I
poorly	O
and	O
is	O
only	O
weakly	O
activated	O
by	O
the	O
NF	O
-	O
kappa	O
B	O
site	O
alone	O
.	O
Serum	B
response	I
factor	I
(	O
SRF	B
)	O
binds	O
to	O
a	O
site	O
adjacent	O
to	O
the	O
NF	O
-	O
kappa	O
B	O
site	O
in	O
the	O
IL-2R	O
enhancer	O
,	O
and	O
both	O
sites	O
together	O
have	O
strong	O
transcriptional	O
activity	O
specifically	O
in	O
T	O
cells	O
.	O
Surprisingly	O
,	O
the	O
levels	O
of	O
SRF	B
constitutively	O
expressed	O
in	O
T	O
cells	O
are	O
consistently	O
higher	O
than	O
in	O
other	O
cell	O
types	O
.	O
Overexpression	O
of	O
SRF	B
in	O
B	O
cells	O
causes	O
the	O
IL-2R	O
enhancer	O
to	O
function	O
as	O
well	O
as	O
it	O
does	O
in	O
T	O
cells	O
,	O
suggesting	O
that	O
the	O
high	O
level	O
of	O
SRF	B
binding	O
in	O
T	O
cells	O
is	O
functionally	O
important	O
.	O
The	O
transcriptionally	B
active	I
factors	I
mediating	O
the	O
effect	O
of	O
the	O
HTLV	B
-	I
I	I
Tax	I
transactivator	I
on	O
the	O
IL-2R	O
alpha	O
kappa	O
B	O
enhancer	O
include	O
the	O
product	O
of	O
the	O
c	O
-	O
rel	O
proto	O
-	O
oncogene	O
.	O
The	O
transactivator	O
HTLV	B
-	I
I	I
Tax	I
activates	O
the	O
promoter	O
of	O
the	O
gene	O
coding	O
for	O
the	O
interleukin	B
2	I
alpha	I
-	I
chain	I
receptor	I
(	O
IL-2R	B
alpha	I
)	O
via	O
a	O
kappa	O
B	O
site	O
that	O
can	O
bind	O
several	O
protein	O
species	O
of	O
the	O
rel	B
family	I
.	O
Tax1	B
strongly	O
activates	O
the	O
enhancer	O
activity	O
of	O
this	O
motif	O
,	O
in	O
both	O
epithelial	O
HeLa	O
and	O
lymphoid	O
Jurkat	O
cells	O
.	O
This	O
activation	O
was	O
not	O
observed	O
in	O
undifferentiated	O
embryocarcinoma	O
F9	O
cells	O
.	O
Overexpression	O
of	O
the	O
p50	B
,	O
p65	B
and	O
Rel	B
proteins	I
in	O
these	O
cells	O
showed	O
that	O
significant	O
activation	O
of	O
the	O
IL-2R	B
alpha	I
kappa	O
B	O
site	O
was	O
observed	O
only	O
with	O
Rel	B
and	O
Rel	B
plus	O
p65	B
.	O
Moreover	O
,	O
whereas	O
both	O
Tax	B
and	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
are	O
able	O
to	O
efficiently	O
induce	O
the	O
binding	O
of	O
NF	B
-	I
kappa	I
B	I
to	O
the	O
IL-2R	O
alpha	O
kappa	O
B	O
site	O
,	O
PMA	O
is	O
functionally	O
inactive	O
.	O
Using	O
the	O
DNA	O
affinity	O
precipitation	O
assay	O
,	O
we	O
observed	O
that	O
Tax1	B
is	O
able	O
to	O
efficiently	O
induce	O
the	O
binding	O
of	O
Rel	O
,	O
whereas	O
PMA	O
is	O
not	O
.	O
This	O
established	O
a	O
clear	O
difference	O
between	O
both	O
stimuli	O
,	O
indicating	O
that	O
Rel	B
is	O
the	O
functionally	B
active	I
factor	I
.	O
We	O
conclude	O
from	O
these	O
results	O
that	O
the	O
functional	O
activity	O
of	O
members	O
of	O
the	O
rel	B
family	I
is	O
regulated	O
by	O
their	O
interaction	O
with	O
DNA	O
and	O
that	O
Rel	B
can	O
be	O
a	O
potent	O
transcriptional	O
activator	O
on	O
specific	O
kappa	O
B	O
sites	O
.	O
p105	B
and	O
p98	B
precursor	B
proteins	I
play	O
an	O
active	O
role	O
in	O
NF	B
-	I
kappa	I
B	I
-mediated	O
signal	O
transduction	O
.	O
The	O
Rel	B
/	I
NF	I
-	I
kappa	I
B	I
family	I
of	O
transcription	B
factors	I
is	O
composed	O
of	O
two	O
distinct	O
subgroups	O
,	O
proteins	O
that	O
undergo	O
proteolytic	O
processing	O
and	O
contain	O
SWI6	B
/	I
ankyrin	I
repeats	I
in	O
their	O
carboxyl	B
termini	I
(	O
p105	B
,	O
p98	B
)	O
,	O
and	O
those	O
without	O
such	O
repeats	O
that	O
do	O
not	O
require	O
processing	O
(	O
p65	B
,	O
c	B
-	I
Rel	I
,	O
RelB	B
,	O
and	O
Dorsal	B
)	O
.	O
We	O
demonstrate	O
that	O
the	O
p105	B
and	O
p98	B
precursors	O
share	O
functional	O
properties	O
with	O
the	O
I	B
kappa	I
B	I
proteins	I
,	O
which	O
also	O
contain	O
SWI6	B
/	I
ankyrin	I
repeats	I
.	O
Both	O
p105	B
and	O
p98	B
were	O
found	O
to	O
form	O
stable	O
complexes	O
with	O
other	O
Rel	B
/	I
NF	I
-	I
kappa	I
B	I
family	I
members	I
,	O
including	O
p65	B
and	O
c	B
-	I
Rel	I
.	O
Association	O
with	O
the	O
precursors	O
is	O
sufficient	O
for	O
cytoplasmic	O
retention	O
of	O
either	O
p65	B
or	O
c	B
-	I
Rel	I
,	O
both	O
of	O
which	O
are	O
otherwise	O
nuclear	O
.	O
These	O
complexes	O
undergo	O
stimulus	O
-	O
responsive	O
processing	O
to	O
produce	O
active	O
p50	B
/	I
c	I
-	I
Rel	I
and	O
p55	B
/	I
c	I
-	I
Rel	I
complexes	O
.	O
These	O
observations	O
suggest	O
a	O
second	O
pathway	O
leading	O
to	O
NF	B
-	I
kappa	I
B	I
induction	O
,	O
in	O
which	O
processing	O
of	O
the	O
precursors	O
rather	O
than	O
phosphorylation	O
of	O
I	B
kappa	I
B	I
plays	O
a	O
major	O
role	O
.	O
Mutual	O
regulation	O
of	O
the	O
transcriptional	B
activator	I
NF	B
-	I
kappa	I
B	I
and	O
its	O
inhibitor	O
,	O
I	B
kappa	I
B	I
-	I
alpha	I
.	O
The	O
NK	B
-	I
kappa	I
B	I
transcription	I
factor	I
complex	I
is	O
sequestered	O
in	O
the	O
cytoplasm	O
by	O
the	O
inhibitory	O
protein	O
I	B
kappa	I
B	I
-	I
alpha	I
(	O
MAD-3	B
)	O
.	O
Various	O
cellular	O
stimuli	O
relieve	O
this	O
inhibition	O
by	O
mechanisms	O
largely	O
unknown	O
,	O
leading	O
to	O
NF	B
-	I
kappa	I
B	I
nuclear	O
localization	O
and	O
transactivation	O
of	O
its	O
target	O
genes	O
.	O
It	O
is	O
demonstrated	O
here	O
with	O
human	O
T	O
lymphocytes	O
and	O
monocytes	O
that	O
different	O
stimuli	O
,	O
including	O
tumor	B
necrosis	I
factor	I
alpha	I
and	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
cause	O
rapid	O
degradation	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
,	O
with	O
concomitant	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
followed	O
by	O
a	O
dramatic	O
increase	O
in	O
I	O
kappa	O
B	O
-	O
alpha	O
mRNA	O
and	O
protein	O
synthesis	O
.	O
Transfection	O
studies	O
reveal	O
that	O
the	O
I	O
kappa	O
B	O
-	O
alpha	O
mRNA	O
and	O
the	O
encoded	O
protein	O
are	O
potently	O
induced	O
by	O
NF	B
-	I
kappa	I
B	I
and	O
by	O
homodimers	O
of	O
p65	B
and	O
of	O
c	B
-	I
Rel	I
.	O
We	O
propose	O
a	O
model	O
in	O
which	O
NF	B
-	I
kappa	I
B	I
and	O
I	B
kappa	I
B	I
-	I
alpha	I
mutually	O
regulate	O
each	O
other	O
in	O
a	O
cycle	O
:	O
saturating	O
amounts	O
of	O
the	O
inhibitory	O
I	B
kappa	I
B	I
-	I
alpha	I
protein	O
are	O
destroyed	O
upon	O
stimulation	O
,	O
allowing	O
rapid	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
Subsequently	O
,	O
I	O
kappa	O
B	O
-	O
alpha	O
mRNA	O
and	O
protein	O
levels	O
are	O
quickly	O
induced	O
by	O
the	O
activated	O
NF	B
-	I
kappa	I
B	I
.	O
This	O
resurgence	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
protein	O
acts	O
to	O
restore	O
an	O
equilibrium	O
in	O
which	O
NF	B
-	I
kappa	I
B	I
is	O
again	O
inhibited	O
.	O
The	O
Sp1	B
transcription	I
factor	I
binds	O
the	O
CD11b	O
promoter	O
specifically	O
in	O
myeloid	O
cells	O
in	O
vivo	O
and	O
is	O
essential	O
for	O
myeloid	O
-	O
specific	O
promoter	O
activity	O
.	O
The	O
myeloid	B
integrin	I
CD11b	I
is	O
expressed	O
selectively	O
on	O
the	O
surface	O
of	O
mature	O
macrophages	O
,	O
monocytes	O
,	O
neutrophils	O
,	O
and	O
natural	O
killer	O
cells	O
.	O
Lineage	O
-	O
specific	O
expression	O
is	O
controlled	O
at	O
the	O
level	O
of	O
mRNA	O
transcription	O
.	O
Recent	O
isolation	O
of	O
the	O
CD11b	O
promoter	O
shows	O
that	O
92	O
base	O
pairs	O
(	O
bp	O
)	O
of	O
5'-flanking	O
DNA	O
are	O
sufficient	O
to	O
direct	O
myeloid	O
-	O
specific	O
expression	O
of	O
a	O
reporter	O
gene	O
.	O
To	O
characterize	O
regulatory	O
sequences	O
important	O
for	O
promoter	O
activity	O
,	O
we	O
performed	O
linker	O
scanning	O
analysis	O
of	O
the	O
92-bp	O
CD11b	O
promoter	O
and	O
demonstrate	O
that	O
a	O
sequence	O
at	O
bp	O
-60	O
is	O
essential	O
for	O
CD11b	O
promoter	O
activity	O
.	O
We	O
show	O
that	O
this	O
sequence	O
binds	O
the	O
transcription	B
factor	I
Sp1	B
in	O
vitro	O
and	O
in	O
vivo	O
.	O
In	O
vivo	O
the	O
Sp1	O
site	O
is	O
bound	O
only	O
in	O
myeloid	O
(	O
U937	O
)	O
cells	O
,	O
not	O
in	O
cervical	O
carcinoma	O
(	O
HeLa	O
)	O
cells	O
.	O
In	O
addition	O
,	O
the	O
macrophage	O
transcription	B
factor	I
PU.1	O
binds	O
the	O
CD11b	O
promoter	O
in	O
vitro	O
and	O
in	O
vivo	O
close	O
to	O
the	O
Sp1	O
site	O
.	O
We	O
propose	O
a	O
model	O
in	O
which	O
binding	O
of	O
a	O
myeloid	B
-	I
specific	I
factor	I
(	O
PU.1	B
)	O
allows	O
a	O
general	O
factor	O
(	O
Sp1	B
)	O
to	O
bind	O
in	O
a	O
tissue	O
-	O
specific	O
fashion	O
thereby	O
contributing	O
to	O
the	O
myeloid	O
-	O
specific	O
expression	O
of	O
CD11b	O
.	O
Costimulation	O
of	O
peripheral	O
blood	O
T	O
cell	O
activation	O
by	O
human	O
endothelial	O
cells	O
.	O
Enhanced	O
IL-2	B
transcription	O
correlates	O
with	O
increased	O
c	B
-	I
fos	I
synthesis	O
and	O
increased	O
Fos	B
content	O
of	O
AP-1	B
.	O
Endothelial	O
cells	O
(	O
EC	O
)	O
act	O
as	O
APC	O
for	O
resting	O
PBL	O
in	O
vitro	O
,	O
and	O
may	O
have	O
important	O
roles	O
in	O
vivo	O
in	O
the	O
pathogenesis	O
of	O
allograft	O
rejection	O
and	O
delayed	O
hypersensitivity	O
.	O
We	O
previously	O
reported	O
that	O
human	O
umbilical	O
vein	O
EC	O
provide	O
costimulatory	O
signals	O
to	O
PHA	O
-	O
stimulated	O
PBL	O
via	O
CD2	B
:	I
lymphocyte	I
function	I
-	I
associated	I
Ag-3	I
and	O
an	O
unidentified	O
ligand	O
pair	O
,	O
resulting	O
in	O
a	O
three-	O
to	O
eight	O
-	O
fold	O
enhancement	O
of	O
IL-2	B
production	O
.	O
The	O
physiologic	O
relevance	O
of	O
this	O
increase	O
was	O
demonstrated	O
by	O
the	O
proliferative	O
advantage	O
provided	O
by	O
EC	O
to	O
PBL	O
suboptimally	O
stimulated	O
with	O
mAb	B
OKT3	I
.	O
We	O
now	O
report	O
that	O
EC	O
costimulation	O
causes	O
increased	O
levels	O
of	O
IL-2	O
mRNA	O
as	O
a	O
result	O
of	O
increased	O
IL-2	B
transcription	O
in	O
PBL	O
.	O
We	O
therefore	O
examined	O
the	O
effects	O
of	O
EC	O
on	O
T	B
cell	I
nuclear	I
factors	I
known	O
to	O
regulate	O
IL-2	B
transcription	O
,	O
including	O
c	B
-	I
jun	I
and	O
c	B
-	I
fos	I
-	I
two	I
components	I
of	O
the	O
transcription	B
factor	I
AP-1	B
,	O
NFAT	B
,	O
and	O
others	O
.	O
PBL	O
constitutively	O
express	O
c	B
-	I
jun	I
transcripts	I
,	O
and	O
the	O
level	O
of	O
c	O
-	O
jun	O
mRNA	O
is	O
not	O
altered	O
by	O
PHA	B
activation	O
in	O
the	O
absence	O
or	O
presence	O
of	O
EC	O
.	O
In	O
contrast	O
,	O
c	O
-	O
fos	O
mRNA	O
is	O
absent	O
from	O
resting	O
T	O
cells	O
and	O
is	O
induced	O
on	O
PHA	B
activation	O
.	O
EC	O
alone	O
do	O
not	O
induce	O
c	O
-	O
fos	O
mRNA	O
but	O
augment	O
the	O
level	O
of	O
c	O
-	O
fos	O
mRNA	O
in	O
PHA	O
-	O
activated	O
T	O
cells	O
by	O
3-	O
to	O
10-fold	O
.	O
This	O
effect	O
is	O
largely	O
independent	O
of	O
the	O
CD2	O
:	O
lymphocyte	O
function	O
-	O
associated	O
Ag-3	O
pathway	O
.	O
Gel	O
-	O
shift	O
analysis	O
reveals	O
the	O
constitutive	O
presence	O
of	O
nuclear	O
factors	O
in	O
resting	O
PBL	O
that	O
bind	O
to	O
the	O
proximal	O
AP-1	O
site	O
of	O
the	O
IL-2	O
promoter	O
and	O
that	O
contain	O
immunoreactive	O
c	B
-	I
Jun	I
but	O
not	O
c	B
-	I
Fos	I
protein	O
.	O
In	O
contrast	O
,	O
AP-1	B
from	O
PHA	O
-	O
activated	O
cells	O
contains	O
c	B
-	I
Jun	I
and	O
low	O
levels	O
of	O
c	B
-	I
Fos	I
.	O
Strikingly	O
,	O
costimulation	O
with	O
EC	O
results	O
in	O
a	O
dramatic	O
increase	O
(	O
up	O
to	O
15-fold	O
)	O
in	O
the	O
c	B
-	I
Fos	I
content	O
of	O
AP-1	B
.	O
Levels	O
of	O
other	O
nuclear	B
factors	I
involved	O
in	O
IL-2	B
regulation	O
were	O
not	O
altered	O
by	O
EC	O
,	O
although	O
NFAT	B
-	I
DNA	I
complexes	I
migrated	O
at	O
a	O
slightly	O
different	O
mobility	O
.	O
In	O
summary	O
,	O
our	O
data	O
suggest	O
that	O
changes	O
in	O
the	O
composition	O
of	O
transcription	B
factor	I
AP-1	B
is	O
a	O
key	O
molecular	O
mechanism	O
for	O
increasing	O
IL-2	B
transcription	O
and	O
may	O
underlie	O
the	O
phenomenon	O
of	O
costimulation	O
by	O
EC	O
.	O
Functional	O
antagonism	O
between	O
vitamin	O
D3	O
and	O
retinoic	O
acid	O
in	O
the	O
regulation	O
of	O
CD14	O
and	O
CD23	O
expression	O
during	O
monocytic	O
differentiation	O
of	O
U-937	O
cells	O
.	O
1	O
,	O
25	O
alpha	O
-	O
Dihydroxicholecalciferol	O
(	O
VitD3	O
)	O
and	O
retinoic	O
acid	O
(	O
RA	O
)	O
are	O
important	O
regulators	O
of	O
the	O
proliferation	O
and	O
differentiation	O
of	O
several	O
cell	O
types	O
.	O
This	O
paper	O
describes	O
how	O
the	O
expression	O
of	O
the	O
monocyte	B
-	I
macrophage	I
Ag	I
,	O
CD14	B
,	O
and	O
the	O
low	O
affinity	B
Fc	I
receptor	I
for	O
IgE	B
,	O
CD23	B
,	O
were	O
inversely	O
regulated	O
during	O
VitD3	O
-and	O
RA	O
-	O
induced	O
monocytic	O
differentiation	O
of	O
human	O
U-937	O
monoblasts	O
.	O
PMA	O
induced	O
the	O
expression	O
of	O
both	O
CD14	B
and	O
CD23	O
mRNA	O
and	O
protein	O
.	O
Exposure	O
to	O
VitD3	O
rapidly	O
induced	O
the	O
de	O
novo	O
expression	O
of	O
CD14	O
mRNA	O
and	O
protein	O
.	O
The	O
addition	O
of	O
cycloheximide	O
completely	O
blocked	O
the	O
VitD3	O
induction	O
of	O
CD14	O
mRNA	O
expression	O
,	O
indicating	O
that	O
the	O
induction	O
was	O
dependent	O
on	O
ongoing	O
protein	O
synthesis	O
.	O
While	O
inducing	O
CD14	B
expression	O
,	O
VitD3	O
concomitantly	O
suppressed	O
the	O
basal	O
,	O
PMA-	O
,	O
and	O
RA	O
-	O
inducible	O
CD23	B
expression	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
In	O
contrast	O
,	O
U-937	O
cells	O
induced	O
by	O
RA	O
strongly	O
increased	O
their	O
expression	O
of	O
CD23	O
mRNA	O
and	O
protein	O
,	O
whereas	O
they	O
completely	O
lacked	O
detectable	O
CD14	O
cell	O
surface	O
or	O
mRNA	O
expression	O
.	O
Furthermore	O
,	O
the	O
VitD3	O
-and	O
the	O
PMA	O
-	O
induced	O
CD14	B
expression	O
was	O
inhibited	O
as	O
a	O
temporal	O
consequence	O
of	O
the	O
RA	O
-	O
induced	O
differentiation	O
.	O
The	O
results	O
suggest	O
that	O
there	O
exists	O
a	O
functional	O
antagonism	O
between	O
VitD3	O
and	O
RA	O
that	O
may	O
have	O
important	O
implications	O
for	O
the	O
regulation	O
of	O
certain	O
immune	O
and	O
inflammatory	O
responses	O
through	O
their	O
inverse	O
effects	O
on	O
CD14	O
and	O
CD23	O
gene	O
expression	O
.	O
Negative	O
transcriptional	O
regulation	O
of	O
human	O
interleukin	O
2	O
(	O
IL-2	O
)	O
gene	O
by	O
glucocorticoids	O
through	O
interference	O
with	O
nuclear	B
transcription	I
factors	I
AP-1	B
and	O
NF	B
-	I
AT	I
.	O
IL-2	O
gene	O
transcription	O
is	O
affected	O
by	O
several	O
nuclear	B
proteins	I
.	O
We	O
asked	O
whether	O
dexamethasone	O
(	O
Dex	O
)	O
and	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
inhibit	O
IL-2	O
gene	O
transcription	O
by	O
interfering	O
with	O
the	O
activity	O
of	O
nuclear	B
proteins	I
that	O
bind	O
to	O
the	O
IL-2	O
promoter	O
.	O
Nuclear	O
extracts	O
from	O
primary	O
human	O
T	O
lymphocytes	O
were	O
analyzed	O
by	O
electrophoretic	O
DNA	O
mobility	O
shift	O
assays	O
.	O
Both	O
Dex	O
and	O
CsA	O
inhibited	O
the	O
binding	O
of	O
transcription	O
factors	O
AP-1	B
and	O
NF	B
-	I
AT	I
,	O
but	O
not	O
of	O
NF	B
-	I
kB	I
and	O
OCT-1	B
/	I
OAF	I
,	O
to	O
their	O
corresponding	O
sites	O
on	O
the	O
IL-2	O
gene	O
promoter	O
.	O
To	O
correlate	O
changes	O
in	O
nuclear	O
factor	O
binding	O
in	O
vitro	O
with	O
transcriptional	O
activity	O
in	O
vivo	O
and	O
define	O
the	O
structural	O
requirements	O
for	O
IL-2	O
promoter	O
repression	O
,	O
we	O
used	O
transient	O
DNA	O
transfections	O
.	O
Jurkat	O
cells	O
were	O
transfected	O
with	O
plasmids	O
containing	O
either	O
the	O
intact	O
IL-2	O
promoter	O
or	O
its	O
AP-1	O
,	O
NF	O
-	O
AT	O
,	O
and	O
NF	O
-	O
kB	O
motifs	O
.	O
Dex	O
inhibited	O
the	O
IL-2	O
promoter	O
and	O
the	O
AP-1	O
,	O
but	O
not	O
the	O
NF	O
-	O
AT	O
and	O
NF	O
-	O
kB	O
plasmids	O
.	O
In	O
contrast	O
,	O
CsA	O
inhibited	O
the	O
IL-2	O
promoter	O
and	O
the	O
NF	O
-	O
AT	O
,	O
but	O
not	O
the	O
AP-1	O
and	O
NF	O
-	O
kB	O
plasmids	O
.	O
These	O
results	O
suggest	O
that	O
in	O
human	O
T	O
lymphocytes	O
both	O
Dex	O
and	O
CsA	O
inhibited	O
IL-2	O
gene	O
transcription	O
through	O
interference	O
with	O
transcription	B
factors	I
AP-1	B
and	O
NF	B
-	I
AT	I
.	O
We	O
propose	O
that	O
,	O
while	O
maximum	O
inhibition	O
may	O
involve	O
interaction	O
with	O
both	O
transcription	B
factors	I
,	O
AP-1	B
is	O
the	O
primary	O
target	O
of	O
Dex	O
.	O
Lymphocytes	O
from	O
the	O
site	O
of	O
disease	O
suggest	O
adenovirus	O
is	O
one	O
cause	O
of	O
persistent	O
or	O
recurrent	O
inflammatory	O
arthritis	O
.	O
The	O
assessment	O
of	O
synovial	O
lymphocyte	O
reactivity	O
to	O
adenovirus	O
antigen	O
stimulation	O
was	O
undertaken	O
in	O
patients	O
with	O
persistent	O
or	O
recurrent	O
inflammatory	O
arthritis	O
.	O
The	O
3H	O
-	O
thymidine	O
uptake	O
procedure	O
was	O
employed	O
,	O
incorporating	O
multiple	O
microbiological	B
antigens	I
.	O
Five	O
patients	O
were	O
found	O
with	O
repeated	O
maximal	O
responses	O
to	O
adenovirus	B
antigen	I
;	O
in	O
one	O
of	O
these	O
adenovirus	O
nucleotide	O
sequences	O
were	O
present	O
in	O
a	O
synovial	O
biopsy	O
specimen	O
.	O
It	O
is	O
concluded	O
that	O
adenovirus	O
may	O
be	O
one	O
cause	O
of	O
persistent	O
or	O
recurrent	O
inflammatory	O
arthritis	O
.	O
Cell	O
-	O
specific	O
expression	O
of	O
helix	B
-	I
loop	I
-	I
helix	I
transcription	I
factors	I
encoded	O
by	O
the	O
E2A	O
gene	O
.	O
The	O
E2A	O
gene	O
encodes	O
transcription	B
factors	I
of	O
the	O
helix	B
-	I
loop	I
-	I
helix	I
family	I
that	O
are	O
implicated	O
in	O
cell	O
-	O
specific	O
gene	O
expression	O
as	O
part	O
of	O
dimeric	B
complexes	I
that	O
interact	O
with	O
E	O
box	O
enhancer	O
elements	O
.	O
It	O
has	O
previously	O
been	O
shown	O
that	O
transcripts	O
of	O
the	O
E2A	O
gene	O
can	O
be	O
detected	O
in	O
a	O
wide	O
range	O
of	O
cell	O
types	O
.	O
We	O
have	O
now	O
examined	O
expression	O
of	O
the	O
mouse	O
E2A	O
gene	O
at	O
the	O
protein	O
level	O
using	O
polyclonal	O
antisera	O
directed	O
against	O
distinct	O
portions	O
of	O
the	O
E2A	B
protein	I
to	O
probe	O
blots	O
of	O
cellular	O
extracts	O
.	O
A	O
73	B
kDa	I
protein	I
was	O
identified	O
by	O
this	O
analysis	O
:	O
this	O
protein	O
is	O
highly	O
enriched	O
in	O
cell	O
lines	O
of	O
B	O
lymphoid	O
origin	O
as	O
compared	O
to	O
pancreatic	O
beta	O
-	O
cells	O
and	O
fibroblast	O
cells	O
.	O
The	O
detection	O
of	O
this	O
protein	O
selectively	O
in	O
extracts	O
of	O
lymphoid	O
cells	O
correlates	O
with	O
the	O
presence	O
of	O
the	O
E	O
box	O
-binding	O
activity	O
LEF1	B
/	I
BCF1	I
in	O
these	O
cells	O
;	O
this	O
binding	O
activity	O
was	O
previously	O
shown	O
to	O
be	O
efficiently	O
recognized	O
by	O
antiserum	O
directed	O
against	O
E2A	B
gene	I
products	I
.	O
Transfection	O
of	O
cells	O
with	O
full	O
length	O
E2A	O
cDNA	O
leads	O
to	O
appearance	O
of	O
protein	O
co	O
-	O
migrating	O
with	O
the	O
73	B
kDa	I
protein	I
on	O
SDS	O
gel	O
electrophoresis	O
and	O
co	O
-	O
migrating	O
with	O
LEF1	B
/	I
BCF1	I
on	O
mobility	O
shift	O
analysis	O
.	O
Our	O
results	O
are	O
consistent	O
with	O
the	O
view	O
that	O
the	O
DNA	O
-	O
binding	O
activity	O
LEF1	B
/	I
BCF1	I
is	O
a	O
homodimer	B
of	I
E2A	I
proteins	I
;	O
the	O
selective	O
appearance	O
of	O
this	O
putative	O
cell	O
-	O
specific	O
transcription	O
factor	O
in	O
B	O
lymphoid	O
cells	O
seems	O
to	O
be	O
attributable	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
elevated	O
E2A	B
protein	I
concentrations	O
in	O
these	O
cells	O
.	O
HIV-1	B
Nef	I
protein	I
inhibits	O
the	O
recruitment	O
of	O
AP-1	B
DNA	O
-	O
binding	O
activity	O
in	O
human	O
T	O
-	O
cells	O
.	O
The	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
,	O
HIV-1-LTR	O
,	O
contains	O
binding	O
sites	O
for	O
several	O
cellular	O
transcription	O
factors	O
which	O
contribute	O
to	O
HIV-1	O
gene	O
expression	O
.	O
Our	O
previous	O
studies	O
on	O
the	O
function	O
of	O
the	O
HIV-1-encoded	B
Nef	I
protein	I
suggested	O
that	O
Nef	B
may	O
be	O
an	O
inhibitor	O
HIV-1	O
transcription	O
.	O
To	O
determine	O
whether	O
Nef	B
affects	O
the	O
binding	O
of	O
cellular	B
factors	I
implicated	O
in	O
HIV-1	O
regulation	O
,	O
32P	O
-	O
labeled	O
oligonucleotides	O
corresponding	O
to	O
the	O
binding	O
sites	O
were	O
incubated	O
with	O
nuclear	O
extracts	O
prepared	O
from	O
Nef	O
-	O
expressing	O
T	O
-	O
cell	O
lines	O
that	O
were	O
not	O
stimulated	O
or	O
were	O
stimulated	O
with	O
T	B
-	I
cell	I
mitogens	I
.	O
We	O
found	O
that	O
Nef	B
inhibited	O
the	O
recruitment	O
of	O
AP-1	B
DNA	O
-	O
binding	O
activity	O
in	O
mitogen	O
-	O
stimulated	O
human	O
T	O
-	O
cells	O
.	O
Additionally	O
,	O
Nef	O
expressing	O
cells	O
were	O
transiently	O
transfected	O
with	O
a	O
plasmid	O
in	O
which	O
HIV-1	O
AP-1	O
DNA	O
recognition	O
sequences	O
were	O
cloned	O
downstream	O
of	O
the	O
chloramphenicol	B
acetyltransferase	I
(	O
CAT	B
)	O
gene	O
.	O
Mitogen	O
-	O
mediated	O
transcriptional	O
activation	O
of	O
the	O
CAT	O
gene	O
in	O
this	O
construct	O
was	O
inhibited	O
in	O
Nef	O
-	O
expressing	O
cells	O
but	O
not	O
in	O
control	O
cells	O
.	O
These	O
studies	O
suggest	O
that	O
,	O
by	O
inhibiting	O
AP-1	B
activation	O
,	O
Nef	B
may	O
play	O
a	O
role	O
in	O
regulating	O
HIV-1	O
gene	O
expression	O
in	O
infected	O
T	O
-	O
cells	O
.	O
Adenovirus	O
E1A	O
inhibits	O
IFN	B
-induced	O
resistance	O
to	O
cytolysis	O
by	O
natural	O
killer	O
cells	O
.	O
Infection	O
of	O
target	O
cells	O
with	O
cytopathic	O
viruses	O
inhibits	O
IFN	B
induction	O
of	O
cytolytic	O
resistance	O
to	O
NK	O
cell	O
-	O
mediated	O
cytolysis	O
[	O
IFN	B
-mediated	O
cytoprotection	O
(	O
IFN	B
-MCP	O
)	O
]	O
.	O
It	O
has	O
been	O
thought	O
that	O
the	O
virally	O
induced	O
inhibition	O
of	O
IFN	B
-MCP	O
is	O
secondary	O
to	O
the	O
shutdown	O
of	O
cellular	O
macromolecular	O
synthesis	O
that	O
accompanies	O
cytopathic	O
virus	O
infections	O
.	O
Group	O
C	O
,	O
adenovirus	O
serotype	O
5	O
(	O
Ad5	O
)	O
infection	O
inhibits	O
both	O
IFN	B
-MCP	O
and	O
cellular	B
protein	I
synthesis	O
.	O
This	O
study	O
determined	O
if	O
the	O
Ad5-induced	O
inhibition	O
of	O
IFN	B
-MCP	O
was	O
independent	O
of	O
adenovirus	O
(	O
Ad	O
)	O
infection	O
and	O
secondary	O
only	O
to	O
the	O
expression	O
of	O
the	O
Ad	O
early	O
region	O
1A	O
gene	O
(	O
E1A	O
)	O
.	O
To	O
test	O
this	O
hypothesis	O
,	O
4-h	O
NK	O
cytolysis	O
assays	O
were	O
performed	O
on	O
IFN	O
-	O
gamma	O
-	O
treated	O
human	O
cells	O
infected	O
with	O
an	O
Ad5	O
E1A	O
deletion	O
mutant	O
,	O
dl343	O
,	O
or	O
transfected	O
with	O
the	O
Ad5	O
E1A	O
gene	O
.	O
IFN	B
-MCP	O
was	O
not	O
inhibited	O
by	O
infection	O
with	O
dl343	O
,	O
despite	O
the	O
production	O
of	O
large	O
amounts	O
of	O
both	O
early	O
(	O
E1B	B
,	O
p55	B
)	O
and	O
late	O
(	O
hexon	B
)	O
Ad	B
proteins	I
.	O
In	O
contrast	O
to	O
E1A	O
-	O
negative	O
,	O
parental	O
cell	O
lines	O
,	O
IFN	B
-MCP	O
was	O
blocked	O
in	O
Ad5	O
E1A	O
-	O
transfected	O
epithelial	O
and	O
fibroblastic	O
cell	O
lines	O
.	O
Genetic	O
mapping	O
studies	O
within	O
the	O
E1A	O
gene	O
demonstrated	O
that	O
expression	O
of	O
only	O
the	O
first	O
exon	O
of	O
E1A	O
was	O
sufficient	O
to	O
inhibit	O
IFN	B
-MCP	O
.	O
DNA	O
sequence	O
homology	O
of	O
E1A	O
genes	O
between	O
different	O
Ad	O
groups	O
(	O
group	O
A	O
,	O
Ad12	O
;	O
group	O
C	O
,	O
Ad5	O
)	O
is	O
limited	O
almost	O
entirely	O
to	O
three	O
conserved	O
regions	O
located	O
within	O
the	O
first	O
exon	O
of	O
E1A	O
.	O
Because	O
IFN	B
-MCP	O
was	O
also	O
blocked	O
in	O
Ad12	O
E1A	O
-	O
transfected	O
cell	O
lines	O
,	O
expression	O
of	O
one	O
or	O
more	O
of	O
the	O
E1A	O
-	O
conserved	O
regions	O
may	O
be	O
necessary	O
to	O
inhibit	O
IFN	B
-MCP	O
.	O
In	O
summary	O
,	O
the	O
expression	O
of	O
E1A	B
gene	I
products	I
inhibited	O
IFN	B
-MCP	O
independently	O
of	O
virus	O
infection	O
.	O
E1A	O
's	O
inhibition	O
of	O
IFN	B
-MCP	O
has	O
the	O
net	O
effect	O
of	O
promoting	O
the	O
selective	O
NK	O
cell	O
-	O
mediated	O
clearance	O
of	O
Ad	O
-	O
infected	O
or	O
Ad	O
-	O
transformed	O
human	O
cells	O
.	O
A	O
chimeric	B
type	I
II	I
/	I
type	I
I	I
interleukin-1	I
receptor	I
can	O
mediate	O
interleukin-1	B
induction	O
of	O
gene	O
expression	O
in	O
T	O
cells	O
.	O
The	O
type	B
I	I
interleukin-1	I
receptor	I
(	O
IL-1R	B
)	O
is	O
capable	O
of	O
transducing	O
a	O
signal	O
resulting	O
in	O
promoter	O
activation	O
in	O
T	O
cells	O
.	O
This	O
signal	O
transduction	O
is	O
dependent	O
on	O
the	O
cytoplasmic	B
domain	I
,	O
which	O
consists	O
of	O
213	O
amino	O
acids	O
.	O
In	O
contrast	O
to	O
the	O
type	B
I	I
receptor	I
,	O
the	O
type	B
II	I
IL-1R	I
has	O
a	O
small	O
cytoplasmic	B
tail	I
,	O
and	O
it	O
is	O
not	O
clear	O
whether	O
this	O
receptor	O
is	O
a	O
signal	B
-	I
transducing	I
or	O
a	O
regulatory	B
molecule	I
.	O
Here	O
we	O
report	O
that	O
the	O
type	B
II	I
IL-1R	I
does	O
not	O
mediate	O
gene	O
activation	O
in	O
Jurkat	O
cells	O
.	O
However	O
,	O
a	O
hybrid	O
receptor	O
composed	O
of	O
the	O
extracellular	B
and	I
transmembrane	I
regions	I
of	O
the	O
human	B
type	I
II	I
interleukin-1	I
fused	O
to	O
the	O
cytoplasmic	B
domain	I
of	O
the	O
human	B
type	I
I	I
IL-1R	I
was	O
capable	O
of	O
transducing	O
a	O
signal	O
across	O
the	O
membrane	O
resulting	O
in	O
a	O
pattern	O
of	O
gene	O
activation	O
identical	O
to	O
that	O
mediated	O
by	O
the	O
type	B
I	I
IL-1R	I
.	O
Our	O
results	O
indicated	O
that	O
the	O
extracellular	B
domain	I
of	O
the	O
type	B
II	I
IL-1R	I
was	O
capable	O
of	O
functionally	O
interacting	O
with	O
interleukin-1	B
and	O
transmitting	O
the	O
resulting	O
signal	O
to	O
a	O
heterologous	B
cytoplasmic	I
domain	I
.	O
A	O
mutation	O
of	O
the	O
glucocorticoid	B
receptor	I
in	O
primary	O
cortisol	O
resistance	O
.	O
The	O
precise	O
molecular	O
abnormalities	O
that	O
cause	O
primary	O
cortisol	O
resistance	O
have	O
not	O
been	O
completely	O
described	O
.	O
In	O
a	O
subject	O
with	O
primary	O
cortisol	O
resistance	O
we	O
have	O
observed	O
glucocorticoid	B
receptors	I
(	O
hGR	B
)	O
with	O
a	O
decreased	O
affinity	O
for	O
dexamethasone	O
.	O
We	O
hypothesize	O
that	O
a	O
mutation	O
of	O
the	O
hGR	B
glucocorticoid	I
-	I
binding	I
domain	I
is	O
the	O
cause	O
of	O
cortisol	O
resistance	O
.	O
Total	O
RNA	O
isolated	O
from	O
the	O
index	O
subject	O
's	O
mononuclear	O
leukocytes	O
was	O
used	O
to	O
produce	O
first	O
strand	O
hGR	O
cDNAs	O
,	O
and	O
the	O
entire	O
hGR	O
cDNA	O
was	O
amplified	O
in	O
segments	O
and	O
sequenced	O
.	O
At	O
nucleotide	O
2	O
,	O
317	O
we	O
identified	O
a	O
homozygous	O
A	O
for	O
G	O
point	O
mutation	O
that	O
predicts	O
an	O
isoleucine	O
(	O
ATT	O
)	O
for	O
valine	O
(	O
GTT	O
)	O
substitution	O
at	O
amino	O
acid	O
729	O
.	O
When	O
the	O
wild	B
-	I
type	I
hGR	I
and	O
hGR	B
-	I
Ile	I
729	I
were	O
expressed	O
in	O
COS-1	O
cells	O
and	O
assayed	O
for	O
[	O
3H	O
]	O
-Dexamethasone	O
binding	O
,	O
the	O
dissociation	O
constants	O
were	O
0.799	O
+	O
/-	O
0.068	O
and	O
1.54	O
+	O
/-	O
0.06	O
nM	O
(	O
mean	O
+	O
/-	O
SEM	O
)	O
(	O
P	O
<	O
0.01	O
)	O
,	O
respectively	O
.	O
When	O
the	O
wild	B
-	I
type	I
hGR	I
and	O
hGR	B
-	I
Ile	I
729	I
were	O
expressed	O
in	O
CV-1	O
cells	O
that	O
were	O
cotransfected	O
with	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
long	O
terminal	O
repeat	O
fused	O
to	O
the	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
gene	O
,	O
the	O
hGR	B
-	I
Ile	I
729	I
conferred	O
a	O
fourfold	O
decrease	O
in	O
apparent	O
potency	O
on	O
dexamethasone	O
stimulation	O
of	O
CAT	B
activity	O
.	O
The	O
isoleucine	O
for	O
valine	O
substitution	O
at	O
amino	O
acid	O
729	O
impairs	O
the	O
function	O
of	O
the	O
hGR	B
and	O
is	O
the	O
likely	O
cause	O
of	O
primary	O
cortisol	O
resistance	O
in	O
this	O
subject	O
.	O
Mice	O
deficient	O
for	O
the	O
55	B
kd	I
tumor	I
necrosis	I
factor	I
receptor	I
are	O
resistant	O
to	O
endotoxic	O
shock	O
,	O
yet	O
succumb	O
to	O
L.	O
monocytogenes	O
infection	O
.	O
The	O
multiple	O
biological	O
activities	O
of	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
are	O
mediated	O
by	O
two	O
distinct	O
cell	B
surface	I
receptors	I
of	O
55	B
kd	I
(	O
TNFRp55	B
)	O
and	O
75	B
kd	I
(	O
TNFRp75	B
)	O
.	O
Using	O
gene	O
targeting	O
,	O
we	O
generated	O
a	O
TNFRp55	B
-deficient	O
mouse	O
strain	O
.	O
Cells	O
from	O
TNFRp55-	O
/	O
-mutant	O
mice	O
lack	O
expression	O
of	O
TNFRp55	B
but	O
display	O
normal	O
numbers	O
of	O
high	B
affinity	I
TNFRp75	I
molecules	I
.	O
Thymocyte	O
development	O
and	O
lymphocyte	O
populations	O
are	O
unaltered	O
,	O
and	O
clonal	O
deletion	O
of	O
potentially	O
self	O
-	O
reactive	O
T	O
cells	O
is	O
not	O
impaired	O
.	O
However	O
,	O
TNF	B
signaling	O
is	O
largely	O
abolished	O
,	O
as	O
judged	O
by	O
the	O
failure	O
of	O
TNF	B
to	O
induce	O
NF	B
-	I
kappa	I
B	I
in	O
T	O
lymphocytes	O
from	O
TNFRp55	B
-deficient	O
mice	O
.	O
The	O
loss	O
of	O
TNFRp55	B
function	O
renders	O
mice	O
resistant	O
to	O
lethal	O
dosages	O
of	O
either	O
lipopolysaccharides	O
or	O
S.	B
aureus	I
enterotoxin	I
B	I
.	O
In	O
contrast	O
,	O
TNFRp55-deficient	O
mice	O
are	O
severely	O
impaired	O
to	O
clear	O
L.	O
monocytogenes	O
and	O
readily	O
succumb	O
to	O
infection	O
.	O
Thus	O
,	O
the	O
55	B
kd	I
TNFR	I
plays	O
a	O
decisive	O
role	O
in	O
the	O
host	O
's	O
defense	O
against	O
microorganisms	O
and	O
their	O
pathogenic	O
factors	O
.	O
Cloning	O
and	O
functional	O
characterization	O
of	O
early	B
B	I
-	I
cell	I
factor	I
,	O
a	O
regulator	O
of	O
lymphocyte	O
-	O
specific	O
gene	O
expression	O
.	O
Early	B
B	I
-	I
cell	I
factor	I
(	O
EBF	B
)	O
was	O
identified	O
previously	O
as	O
a	O
tissue	O
-	O
specific	O
and	O
differentiation	O
stage	O
-	O
specific	O
DNA	B
-	I
binding	I
protein	I
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
pre	O
-	O
B	O
and	O
B	O
lymphocyte	O
-	O
specific	O
mb-1	O
gene	O
.	O
Partial	O
amino	O
acid	O
sequences	O
obtained	O
from	O
purified	O
EBF	B
were	O
used	O
to	O
isolate	O
cDNA	O
clones	O
,	O
which	O
by	O
multiple	O
criteria	O
encode	O
EBF	B
.	O
The	O
recombinant	B
polypeptide	I
formed	O
sequence	O
-	O
specific	O
complexes	O
with	O
the	O
EBF	O
-	O
binding	O
site	O
in	O
the	O
mb-1	O
promoter	O
.	O
The	O
cDNA	O
hybridized	O
to	O
multiple	O
transcripts	O
in	O
pre	O
-	O
B	O
and	O
B	O
-	O
cell	O
lines	O
,	O
but	O
transcripts	O
were	O
not	O
detected	O
at	O
significant	O
levels	O
in	O
plasmacytoma	O
,	O
T	O
-	O
cell	O
,	O
and	O
nonlymphoid	O
cell	O
lines	O
.	O
Expression	O
of	O
recombinant	O
EBF	B
in	O
transfected	O
nonlymphoid	O
cells	O
strongly	O
activated	O
transcription	O
from	O
reporter	O
plasmids	O
containing	O
functional	O
EBF	O
-	O
binding	O
sites	O
.	O
Analysis	O
of	O
DNA	O
binding	O
by	O
deletion	O
mutants	O
of	O
EBF	B
identified	O
an	O
amino	B
-	I
terminal	I
cysteine	I
-	I
rich	I
DNA	I
-	I
binding	I
domain	I
lacking	O
obvious	O
sequence	O
similarity	O
to	O
known	O
transcription	B
factors	I
.	O
DNA	O
-	O
binding	O
assays	O
with	O
cotranslated	O
wild	O
-	O
type	O
and	O
truncated	O
forms	O
of	O
EBF	B
indicated	O
that	O
the	O
protein	O
interacts	O
with	O
its	O
site	O
as	O
a	O
homodimer	B
.	O
Deletions	O
delineated	O
a	O
carboxy	B
-	I
terminal	I
dimerization	I
region	I
containing	O
two	O
repeats	O
of	O
15	O
amino	O
acids	O
that	O
show	O
similarity	O
with	O
the	O
dimerization	B
domains	I
of	O
basic	B
-	I
helix	I
-	I
loop	I
-	I
helix	I
proteins	I
.	O
Together	O
,	O
these	O
data	O
suggest	O
that	O
EBF	B
represents	O
a	O
novel	O
regulator	O
of	O
B	O
lymphocyte	O
-	O
specific	O
gene	O
expression	O
.	O
Regulation	O
of	O
the	O
Ets	B
-	I
related	I
transcription	I
factor	I
Elf-1	B
by	O
binding	O
to	O
the	O
retinoblastoma	B
protein	I
.	O
The	O
retinoblastoma	B
gene	I
product	I
(	O
Rb	B
)	O
is	O
a	O
nuclear	B
phosphoprotein	I
that	O
regulates	O
cell	O
cycle	O
progression	O
.	O
Elf-1	B
is	O
a	O
lymphoid	B
-	I
specific	I
Ets	I
transcription	I
factor	I
that	O
regulates	O
inducible	O
gene	O
expression	O
during	O
T	O
cell	O
activation	O
.	O
In	O
this	O
report	O
,	O
it	O
is	O
demonstrated	O
that	O
Elf-1	B
contains	O
a	O
sequence	O
motif	O
that	O
is	O
highly	O
related	O
to	O
the	O
Rb	B
binding	I
sites	I
of	O
several	O
viral	O
oncoproteins	B
and	O
binds	O
to	O
the	O
pocket	O
region	O
of	O
Rb	B
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Elf-1	B
binds	O
exclusively	O
to	O
the	O
underphosphorylated	O
form	O
of	O
Rb	B
and	O
fails	O
to	O
bind	O
to	O
Rb	B
mutants	I
derived	O
from	O
patients	O
with	O
retinoblastoma	O
.	O
Co	O
-	O
immunoprecipitation	O
experiments	O
demonstrated	O
an	O
association	O
between	O
Elf-1	B
and	O
Rb	B
in	O
resting	O
normal	O
human	O
T	O
cells	O
.	O
After	O
T	O
cell	O
activation	O
,	O
the	O
phosphorylation	O
of	O
Rb	B
results	O
in	O
the	O
release	O
of	O
Elf-1	B
,	O
which	O
is	O
correlated	O
temporally	O
with	O
the	O
activation	O
of	O
Elf-1	B
-mediated	O
transcription	O
.	O
Overexpression	O
of	O
a	O
phosphorylation	O
-	O
defective	O
form	O
of	O
Rb	B
inhibited	O
Elf-1	B
-dependent	O
transcription	O
during	O
T	O
cell	O
activation	O
.	O
These	O
results	O
demonstrate	O
that	O
Rb	B
interacts	O
specifically	O
with	O
a	O
lineage	B
-	I
restricted	I
Ets	I
transcription	I
factor	I
.	O
This	O
regulated	O
interaction	O
may	O
be	O
important	O
for	O
the	O
coordination	O
of	O
lineage	O
-	O
specific	O
effector	O
functions	O
such	O
as	O
lymphokine	B
production	O
with	O
cell	O
cycle	O
progression	O
in	O
activated	O
T	O
cells	O
.	O
Expression	O
levels	O
of	O
the	O
thyrotropin	O
receptor	O
gene	O
in	O
autoimmune	O
thyroid	O
disease	O
:	O
coregulation	O
with	O
parameters	O
of	O
thyroid	O
function	O
and	O
inverse	O
relation	O
to	O
major	B
histocompatibility	I
complex	I
classes	I
I	I
and	I
II	I
.	O
Using	O
a	O
human	O
TSH	O
receptor	O
(	O
TSH	O
-	O
R	O
)	O
cDNA	O
probe	O
,	O
we	O
investigated	O
TSH	B
-	I
R	I
transcript	O
levels	O
in	O
13	O
human	O
thyroid	O
fragments	O
by	O
Northern	O
blot	O
analysis	O
;	O
7	O
Graves	O
'	O
disease	O
,	O
2	O
Hashimoto	O
's	O
disease	O
,	O
3	O
endemic	O
goiter	O
,	O
and	O
1	O
healthy	O
thyroid	O
gland	O
were	O
studied	O
.	O
TSH	B
-	I
R	I
expression	O
levels	O
were	O
variable	O
,	O
but	O
displayed	O
a	O
close	O
correlation	O
to	O
the	O
expression	O
of	O
thyroid	B
peroxidase	I
(	O
r	O
=	O
0.703	O
;	O
P	O
<	O
0.05	O
)	O
,	O
thyroglobulin	B
(	O
r	O
=	O
0.817	O
;	O
P	O
<	O
0.01	O
)	O
,	O
and	O
the	O
nuclear	O
oncogene	O
c	O
-	O
fos	O
(	O
r	O
=	O
0.935	O
;	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
c	B
-	I
myc	I
.	O
Overall	O
,	O
TSH	B
-	I
R	I
transcript	O
levels	O
were	O
low	O
or	O
absent	O
in	O
those	O
thyroids	O
in	O
which	O
expression	O
of	O
the	O
major	B
histocompatibility	I
complex	I
class	I
I	I
or	I
II	I
(	O
MHC	B
I	I
or	I
II	I
)	O
was	O
high	O
,	O
thus	O
establishing	O
an	O
inverse	O
relation	O
(	O
MHC	B
I	I
,	O
r	O
=	O
-0.791	O
;	O
P	O
<	O
0.01	O
;	O
MHC	B
II	I
,	O
r	O
=	O
-0.784	O
;	O
P	O
<	O
0.01	O
)	O
.	O
In	O
situ	O
hybridization	O
showed	O
that	O
apart	O
from	O
lymphocytes	O
,	O
thyroid	O
cells	O
themselves	O
were	O
the	O
source	O
of	O
MHC	B
II	I
transcripts	I
.	O
gamma	B
-	I
Interferon	I
expression	O
was	O
only	O
detectable	O
in	O
1	O
Hashimoto	O
's	O
goiter	O
.	O
Our	O
findings	O
suggest	O
that	O
next	O
to	O
lymphocyte	O
infiltration	O
,	O
active	O
regulatory	O
events	O
in	O
the	O
thyrocyte	O
are	O
responsible	O
for	O
the	O
inverse	O
relation	O
between	O
functional	O
parameters	O
(	O
TSH	B
-	I
R	I
,	O
thyroid	B
peroxidase	I
,	O
thyroglobulin	B
,	O
and	O
c	O
-	O
fos	O
)	O
and	O
immunological	O
markers	O
(	O
MHC	B
I	I
and	I
II	I
)	O
.	O
Regulation	O
of	O
the	O
interleukin-1	O
beta	O
(	O
IL-1	O
beta	O
)	O
gene	O
by	O
mycobacterial	B
components	I
and	O
lipopolysaccharide	O
is	O
mediated	O
by	O
two	O
nuclear	O
factor	O
-	O
IL6	O
motifs	O
.	O
The	O
cytokines	O
interleukin-1	O
beta	O
(	O
IL-1	B
beta	I
)	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	B
-	I
alpha	I
)	O
are	O
released	O
by	O
mononuclear	O
phagocytes	O
in	O
vitro	O
after	O
stimulation	O
with	O
mycobacteria	O
and	O
are	O
considered	O
to	O
mediate	O
pathophysiologic	O
events	O
,	O
including	O
granuloma	O
formation	O
and	O
systemic	O
symptoms	O
.	O
We	O
demonstrated	O
that	O
the	O
Mycobacterium	O
tuberculosis	O
cell	O
wall	O
component	O
lipoarabinomannan	O
(	O
LAM	O
)	O
is	O
a	O
very	O
potent	O
inducer	O
of	O
IL-1	O
beta	O
gene	O
expression	O
in	O
human	O
monocytes	O
and	O
investigated	O
the	O
mechanism	O
of	O
this	O
effect	O
.	O
We	O
localized	O
the	O
LAM-	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
,	O
and	O
TNF	B
-	I
alpha	I
-inducible	O
promoter	O
activity	O
to	O
a	O
-131	O
/	O
+15	O
(	O
positions	O
-131	O
to	O
+	O
15	O
)	O
DNA	O
fragment	O
of	O
the	O
IL-1	O
beta	O
gene	O
by	O
deletion	O
analysis	O
and	O
chloramphenicol	B
acetyltransferase	I
assay	O
.	O
Within	O
this	O
DNA	O
fragment	O
,	O
there	O
were	O
two	O
novel	O
9-bp	O
motifs	O
(	O
-90	O
/	O
-82	O
and	O
-40	O
/	O
-32	O
)	O
with	O
high	O
homology	O
to	O
the	O
nuclear	O
factor	O
-	O
IL6	O
(	O
NF	O
-	O
IL6	O
)	O
binding	O
site	O
.	O
Site	O
-	O
directed	O
mutagenesis	O
demonstrated	O
that	O
the	O
two	O
NF	O
-	O
IL-6	O
motifs	O
could	O
be	O
independently	O
activated	O
by	O
LAM	O
,	O
LPS	O
,	O
or	O
TNF	B
-	I
alpha	I
and	O
that	O
they	O
acted	O
in	O
an	O
orientation	O
-	O
independent	O
manner	O
.	O
DNA	O
mobility	O
shift	O
assay	O
revealed	O
specific	O
binding	O
of	O
nuclear	B
protein	I
(	O
s	O
)	O
from	O
LAM-	O
,	O
LPS-	O
,	O
or	O
TNF	O
-	O
alpha-	O
stimulated	O
THP-1	O
cells	O
to	O
the	O
NF	O
-	O
IL6	O
motifs	O
.	O
We	O
conclude	O
that	O
the	O
two	O
NF	O
-	O
IL6	O
sites	O
mediate	O
induction	O
of	O
IL-1	B
beta	I
in	O
response	O
to	O
the	O
stimuli	O
LAM	O
,	O
LPS	O
,	O
and	O
TNF	B
-	I
alpha	I
.	O
Calcium	O
dependent	O
activation	O
of	O
the	O
NF	B
-	I
AT	I
transcription	I
factor	I
by	O
p59fyn	B
.	O
A	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
a	O
T	O
-	O
cell	O
antigen	O
receptor	O
element	O
was	O
activated	O
in	O
Jurkat	O
cells	O
by	O
antigen	O
receptor	O
triggering	O
or	O
by	O
a	O
combination	O
of	O
phorbol	O
myristate	O
acetate	O
,	O
which	O
activates	O
protein	B
kinase	I
C	I
,	O
and	O
a	O
calcium	O
ionophore	O
.	O
Both	O
these	O
signals	O
were	O
necessary	O
for	O
expression	O
of	O
the	O
reporter	O
gene	O
.	O
When	O
co	O
-	O
transfected	O
with	O
a	O
construct	O
capable	O
of	O
overexpressing	O
the	O
tyrosine	B
kinase	I
p59fyn	B
,	O
the	O
reporter	O
gene	O
was	O
activated	O
by	O
PMA	B
alone	O
.	O
Thus	O
p59fyn	B
could	O
replace	O
the	O
calcium	O
ionophore	O
but	O
not	O
activation	O
of	O
protein	B
kinase	I
C	I
.	O
The	O
activation	O
by	O
p59fyn	B
plus	O
PMA	B
was	O
blocked	O
by	O
EGTA	O
and	O
by	O
the	O
immunosuppressant	O
drug	O
cyclosporin	O
A	O
.	O
Cell	O
-	O
specific	O
bifunctional	O
role	O
of	O
Jun	O
oncogene	O
family	O
members	O
on	O
glucocorticoid	B
receptor	I
-dependent	O
transcription	O
.	O
Interaction	O
between	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
-	O
and	O
glucocorticoid	B
receptor	I
(	O
GR	B
)	O
-mediated	O
signaling	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
the	O
PKC	B
activating	O
phorbol	O
ester	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
to	O
inhibit	O
GR	B
-dependent	O
transcription	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O
Here	O
we	O
report	O
that	O
this	O
interference	O
is	O
cell	O
specific	O
,	O
as	O
TPA	O
augmented	O
dexamethasone	O
-	O
induced	O
transcriptional	O
activation	O
of	O
the	O
MMTV	O
LTR	O
in	O
several	O
T	O
cell	O
lines	O
but	O
was	O
inhibitory	O
in	O
NIH-3T3	O
fibroblasts	O
.	O
TPA	O
-	O
GR	O
synergism	O
was	O
determined	O
to	O
have	O
occurred	O
at	O
the	O
GR	O
-	O
responsive	O
element	O
(	O
GRE	O
)	O
level	O
by	O
functional	O
analysis	O
of	O
deletion	O
mutants	O
or	O
synthetic	O
GRE	O
oligonucleotides	O
driving	O
chloramphenicol	B
acetyl	I
-	I
transferase	I
expression	O
.	O
Synergism	O
required	O
an	O
intact	O
GR	B
DNA	I
-	I
binding	I
domain	I
,	O
whereas	O
amino-	B
or	I
carboxyl	I
-	I
terminal	I
domains	I
were	O
dispensable	O
.	O
The	O
effect	O
was	O
abrogated	O
by	O
the	O
PKC	B
inhibitor	O
staurosporine	O
,	O
suggesting	O
a	O
role	O
for	O
PKC	B
.	O
Increased	O
c	B
-	I
jun	I
,	O
jun	B
-	I
B	I
,	O
and	O
jun	B
-	I
D	I
expression	O
above	O
basal	O
levels	O
and	O
increased	O
transcriptional	O
activity	O
of	O
AP-1	O
/	O
TPA	O
responsive	O
elements	O
fused	O
to	O
chloramphenicol	O
acetyl	O
-	O
transferase	O
vectors	O
were	O
observed	O
in	O
T	O
cells	O
treated	O
with	O
TPA	O
alone	O
or	O
in	O
combination	O
with	O
dexamethasone	O
.	O
The	O
ability	O
of	O
Jun	B
proteins	I
to	O
cooperate	O
with	O
GR	B
in	O
T	O
cells	O
has	O
been	O
investigated	O
after	O
transfection	O
of	O
c	O
-	O
jun	O
,	O
jun	O
-	O
B	O
,	O
or	O
jun	O
-	O
D	O
expression	O
vectors	O
,	O
which	O
augmented	O
GR	B
-dependent	O
transcription	O
from	O
either	O
MMTV	O
LTR	O
or	O
GRE	O
.	O
Conversely	O
,	O
c	B
-	I
jun	I
and	O
jun	B
-	I
B	I
transfection	O
blunted	O
GR	B
-dependent	O
transcription	O
in	O
HeLa	O
cells	O
.	O
The	O
presence	O
of	O
c	B
-	I
fos	I
had	O
a	O
negative	O
influence	O
on	O
GR	B
function	O
and	O
correlated	O
with	O
the	O
cell	O
-	O
specific	O
synergistic	O
or	O
antagonistic	O
activity	O
of	O
Jun	B
with	O
respect	O
to	O
GR	B
;	O
high	O
basal	O
expression	O
of	O
c	B
-	I
fos	I
as	O
well	O
as	O
AP-1	B
DNA	O
binding	O
and	O
transcriptional	O
activity	O
were	O
observed	O
in	O
HeLa	O
cells	O
,	O
but	O
not	O
in	O
T	O
cells	O
.	O
Furthermore	O
overexpression	O
of	O
exogenous	B
c	I
-	I
fos	I
has	O
an	O
inhibitory	O
effect	O
on	O
GR	B
-dependent	O
transcription	O
from	O
GRE	O
in	O
T	O
cells	O
.	O
We	O
propose	O
that	O
Jun	B
plays	O
a	O
bifunctional	O
role	O
on	O
GR	B
-dependent	O
transcriptional	O
activation	O
of	O
GRE	O
,	O
selecting	O
either	O
synergistic	O
or	O
antagonistic	O
activity	O
depending	O
on	O
the	O
cell	O
-	O
specific	O
microenvironment	O
.	O
In	O
this	O
regard	O
,	O
intracellular	O
levels	O
of	O
c	B
-	I
fos	I
appear	O
to	O
be	O
influential	O
.	O
Regulation	O
of	O
the	O
beta	O
-	O
globin	O
locus	O
.	O
Transcription	O
of	O
the	O
human	O
beta	O
-	O
globin	O
gene	O
cluster	O
depends	O
upon	O
upstream	O
regulatory	O
sequences	O
,	O
which	O
are	O
collectively	O
termed	O
the	O
locus	O
control	O
region	O
.	O
Recent	O
studies	O
have	O
provided	O
new	O
insights	O
into	O
how	O
the	O
individual	O
genes	O
of	O
the	O
cluster	O
are	O
regulated	O
through	O
development	O
.	O
The	O
crux	O
of	O
transcriptional	O
activation	O
is	O
how	O
the	O
locus	O
control	O
region	O
communicates	O
with	O
the	O
gene	O
-	O
proximal	O
regulatory	O
elements	O
.	O
Ectopic	O
expression	O
of	O
a	O
conditional	O
GATA-2	B
/	I
estrogen	I
receptor	I
chimera	I
arrests	O
erythroid	O
differentiation	O
in	O
a	O
hormone	O
-	O
dependent	O
manner	O
.	O
The	O
GATA	B
factors	I
are	O
a	O
family	O
of	O
transcriptional	B
regulatory	I
proteins	I
in	O
eukaryotes	O
that	O
share	O
extensive	O
homology	O
in	O
their	O
DNA	B
-	I
binding	I
domains	I
.	O
One	O
enigmatic	O
aspect	O
of	O
GATA	B
factor	I
expression	O
is	O
that	O
several	O
GATA	B
proteins	I
,	O
which	O
ostensibly	O
share	O
the	O
same	O
DNA	B
-	I
binding	I
site	I
specificity	O
,	O
are	O
coexpressed	O
in	O
erythroid	O
cells	O
.	O
To	O
elucidate	O
the	O
roles	O
of	O
individual	O
GATA	B
factors	I
in	O
erythropoiesis	O
,	O
conditional	O
alleles	O
of	O
GATA-1	B
,	O
GATA-2	B
,	O
and	O
GATA-3	B
were	O
prepared	O
by	O
fusing	O
each	O
of	O
the	O
factors	O
to	O
the	O
hormone	B
-	I
binding	I
domain	I
of	O
the	O
human	B
estrogen	I
receptor	I
(	O
ER	B
)	O
.	O
These	O
GATA	B
/	I
ER	I
chimeric	I
factors	I
were	O
shown	O
to	O
be	O
hormone	B
-	I
inducible	I
trans	I
-	I
activating	I
proteins	I
in	O
transient	O
transfection	O
assays	O
.	O
When	O
stably	O
introduced	O
into	O
primary	O
erythroblasts	O
or	O
conditionally	O
transformed	O
erythroid	O
progenitors	O
cells	O
,	O
exogenous	O
GATA-2	B
/	I
ER	I
promoted	O
proliferation	O
and	O
inhibited	O
terminal	O
differentiation	O
in	O
an	O
estrogen	O
-	O
dependent	O
manner	O
.	O
These	O
phenotypic	O
effects	O
are	O
specifically	O
attributable	O
to	O
the	O
action	O
of	O
ectopically	O
expressed	O
GATA-2	B
/	I
ER	I
because	O
erythroblasts	O
expressing	O
exogenous	O
GATA-2	B
are	O
constitutively	O
arrested	O
in	O
differentiation	O
and	O
because	O
erythroid	O
progenitors	O
expressing	O
either	O
Gal	B
/	I
ER	I
or	O
GATA-3	B
/	I
ER	I
do	O
not	O
display	O
a	O
hormone	O
-	O
responsive	O
block	O
in	O
differentiation	O
.	O
Thus	O
,	O
the	O
GATA-2	B
transcription	I
factor	I
appears	O
to	O
play	O
a	O
role	O
in	O
regulating	O
the	O
self	O
-	O
renewal	O
capacity	O
of	O
early	O
erythroid	O
progenitor	O
cells	O
.	O
Proliferation	O
index	O
as	O
a	O
prognostic	O
marker	O
in	O
breast	O
cancer	O
.	O
BACKGROUND	O
.	O
The	O
proliferative	O
activity	O
of	O
tumors	O
has	O
been	O
extensively	O
investigated	O
with	O
different	O
approaches	O
,	O
among	O
which	O
the	O
use	O
of	O
the	O
monoclonal	B
antibody	I
Ki-67	I
represents	O
an	O
easy	O
and	O
reliable	O
means	O
of	O
assessing	O
cell	O
proliferation	O
.	O
In	O
this	O
study	O
,	O
the	O
proliferative	O
activity	O
of	O
129	O
primary	O
breast	O
cancers	O
was	O
investigated	O
,	O
and	O
the	O
results	O
were	O
related	O
to	O
prognosis	O
.	O
METHODS	O
.	O
Tumor	O
samples	O
,	O
obtained	O
from	O
129	O
patients	O
who	O
underwent	O
surgery	O
between	O
January	O
1987	O
and	O
December	O
1988	O
,	O
were	O
processed	O
for	O
staining	O
by	O
an	O
immunohistochemical	O
procedure	O
(	O
avidin	B
-	I
biotin	I
complex	I
)	O
.	O
The	O
median	O
time	O
of	O
observation	O
was	O
42	O
months	O
(	O
range	O
,	O
31	O
-	O
55	O
months	O
)	O
.	O
Life	O
-	O
table	O
analysis	O
(	O
Mantel	O
-	O
Cox	O
)	O
was	O
used	O
to	O
assess	O
the	O
probability	O
of	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
RESULTS	O
.	O
Tumors	O
with	O
high	O
Ki-67	B
proliferation	O
indices	O
(	O
>	O
20	O
%	O
)	O
were	O
associated	O
with	O
a	O
higher	O
4-year	O
probability	O
of	O
relapse	O
of	O
disease	O
(	O
55.3	O
%	O
versus	O
79.1	O
%	O
;	O
P	O
=	O
0.003	O
)	O
and	O
death	O
(	O
71	O
%	O
versus	O
95.6	O
%	O
;	O
P	O
=	O
0.00005	O
)	O
when	O
compared	O
with	O
tumors	O
with	O
low	O
Ki-67	B
values	O
.	O
In	O
addition	O
,	O
this	O
proliferative	O
parameter	O
maintained	O
its	O
prognostic	O
significance	O
when	O
the	O
patients	O
were	O
stratified	O
according	O
to	O
lymph	O
node	O
involvement	O
,	O
menopausal	O
status	O
,	O
and	O
nuclear	B
estrogen	I
receptor	I
content	O
.	O
CONCLUSIONS	O
.	O
Tumor	O
proliferative	O
activity	O
as	O
evaluated	O
by	O
the	O
monoclonal	B
antibody	I
Ki-67	I
seems	O
to	O
be	O
an	O
effective	O
indicator	O
of	O
prognosis	O
in	O
breast	O
cancer	O
for	O
DFS	O
and	O
OS	O
.	O
Glucocorticoid	B
receptors	I
in	O
mononuclear	O
cells	O
of	O
patients	O
with	O
sepsis	O
.	O
Glucocorticoid	B
receptor	I
(	O
GR	B
)	O
hormone	O
-	O
binding	O
activity	O
was	O
studied	O
by	O
a	O
whole	O
-	O
cell	O
method	O
in	O
mononuclear	O
cells	O
(	O
MNC	O
)	O
from	O
peripheral	O
blood	O
of	O
7	O
patients	O
during	O
the	O
hemodynamic	O
compensatory	O
phase	O
of	O
sepsis	O
.	O
4	O
patients	O
were	O
receiving	O
dopamine	O
,	O
which	O
did	O
not	O
affect	O
the	O
GR	B
count	O
.	O
The	O
patients	O
'	O
plasma	O
cortisol	O
concentrations	O
were	O
normal	O
or	O
slightly	O
elevated	O
.	O
Despite	O
a	O
wide	O
range	O
,	O
the	O
mean	O
GR	B
count	O
and	O
affinity	O
in	O
MNC	O
from	O
septic	O
patients	O
did	O
not	O
differ	O
from	O
those	O
in	O
normal	O
controls	O
,	O
suggesting	O
that	O
glucocorticoids	O
could	O
still	O
be	O
effective	O
in	O
the	O
hemodynamic	O
compensatory	O
phase	O
of	O
sepsis	O
.	O
Dependence	O
for	O
the	O
proliferative	O
response	O
to	O
erythropoietin	B
on	O
an	O
established	O
erythroid	O
differentiation	O
program	O
in	O
a	O
human	O
hematopoietic	O
cell	O
line	O
,	O
UT-7	O
.	O
Erythroid	O
differentiation	O
involves	O
the	O
activation	O
of	O
a	O
number	O
of	O
erythroid	O
-	O
specific	O
genes	O
,	O
most	O
of	O
which	O
,	O
including	O
the	O
globin	O
genes	O
and	O
the	O
erythropoietin	O
receptor	O
(	O
Epo	O
-	O
R	O
)	O
gene	O
,	O
are	O
,	O
at	O
least	O
in	O
part	O
,	O
regulated	O
by	O
the	O
transcription	B
factor	I
GATA-1	B
.	O
In	O
order	O
to	O
understand	O
the	O
relationship	O
,	O
if	O
any	O
,	O
between	O
expression	O
of	O
GATA-1	B
,	O
response	O
to	O
Epo	O
and	O
erythroid	O
differentiation	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
GATA-1	B
,	O
Epo	B
-	I
R	I
and	O
globin	O
genes	O
in	O
an	O
Epo	O
-	O
dependent	O
human	O
cell	O
line	O
,	O
UT-7	O
Epo	O
.	O
The	O
results	O
were	O
compared	O
to	O
those	O
obtained	O
with	O
the	O
parental	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
-dependent	O
cell	O
line	O
,	O
UT-7	O
,	O
which	O
has	O
a	O
predominantly	O
megakaryoblastic	O
phenotype	O
and	O
is	O
unable	O
to	O
proliferate	O
continuously	O
in	O
the	O
presence	O
of	O
Epo	B
.	O
UT-7	B
Epo	I
and	O
UT-7	O
expressed	O
similar	O
levels	O
of	O
GATA-1	O
mRNA	O
and	O
binding	O
activity	O
.	O
The	O
two	O
lines	O
also	O
expressed	O
comparable	O
levels	O
of	O
Epo	O
-	O
R	O
mRNA	O
while	O
the	O
number	O
of	O
Epo	B
-binding	O
sites	O
on	O
UT-7	O
Epo	O
cells	O
was	O
one	O
-	O
sixth	O
the	O
number	O
of	O
UT-7	O
cells	O
(	O
2400	O
+	O
/-	O
3	O
vs.	O
13	O
,	O
800	O
+	O
/-	O
300	O
)	O
.	O
This	O
difference	O
in	O
the	O
number	O
of	O
binding	O
sites	O
could	O
be	O
due	O
to	O
differences	O
in	O
cell	O
surface	O
(	O
UT-7	O
cells	O
are	O
20	O
%	O
smaller	O
than	O
the	O
parental	O
UT-7	O
cells	O
)	O
or	O
in	O
receptor	O
turnover	O
.	O
By	O
Northern	O
analysis	O
,	O
UT-7	O
cells	O
expressed	O
detectable	O
levels	O
of	O
beta-	B
and	I
gamma	I
-	I
globin	I
but	O
not	O
alpha	B
-	I
globin	I
.	O
In	O
comparison	O
,	O
UT-7	O
Epo	O
cells	O
expressed	O
alpha	O
-	O
globin	O
and	O
higher	O
levels	O
of	O
gamma	B
-	I
globin	I
(	O
5-fold	O
)	O
and	O
beta	B
-	I
globin	I
(	O
from	O
barely	O
to	O
clearly	O
detectable	O
)	O
.	O
Globin	B
chains	I
(	O
alpha	B
,	O
beta	B
and	O
gamma	B
)	O
were	O
clearly	O
detectable	O
by	O
affinity	O
chromatography	O
in	O
UT-7	B
Epo	I
but	O
not	O
in	O
UT-7	O
cells	O
.	O
The	O
frequency	O
of	O
the	O
cells	O
which	O
expressed	O
beta-	O
and	O
gamma-	O
globin	O
genes	O
in	O
the	O
two	O
cell	O
populations	O
was	O
measured	O
by	O
immunofluorescence	O
with	O
beta-	B
and	I
gamma	I
-	I
specific	I
antibodies	I
.	O
The	O
number	O
of	O
gamma	O
-	O
positive	O
cells	O
and	O
their	O
fluorescence	O
intensity	O
were	O
higher	O
in	O
UT-7	B
Epo	I
than	O
in	O
UT-7	O
cells	O
(	O
0	O
to	O
17	O
%	O
barely	O
positive	O
cells	O
and	O
23	O
to	O
40	O
%	O
clearly	O
positive	O
cells	O
,	O
respectively	O
)	O
,	O
indicating	O
that	O
the	O
increase	O
in	O
globin	O
mRNA	O
observed	O
in	O
UT-7	B
Epo	I
is	O
due	O
to	O
both	O
an	O
increase	O
of	O
gene	O
expression	O
per	O
cell	O
and	O
an	O
increase	O
in	O
numbers	O
of	O
cells	O
containing	O
gamma	B
-	I
globin	I
.	O
The	O
levels	O
of	O
GATA-1	B
,	O
Epo	B
-	I
R	I
and	O
globin	O
mRNA	O
expressed	O
were	O
not	O
affected	O
by	O
a	O
24-hour	O
incubation	O
of	O
either	O
cell	O
line	O
with	O
Epo	B
,	O
GM	B
-	I
CSF	I
or	O
interleukin-3	B
(	O
IL-3	B
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
Comparative	O
analysis	O
of	O
NFAT	B
(	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
)	O
complex	O
in	O
human	O
T	O
and	O
B	O
lymphocytes	O
.	O
Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	B
)	O
is	O
a	O
transcriptional	B
activator	I
that	O
binds	O
to	O
sequences	O
in	O
the	O
interleukin-2	O
(	O
IL-2	O
)	O
promoter	O
and	O
is	O
thought	O
to	O
be	O
largely	O
responsible	O
for	O
the	O
T	O
cell	O
-	O
specific	O
inducibility	O
of	O
IL-2	B
expression	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
showed	O
that	O
specific	O
NFAT	B
binding	O
activity	O
could	O
also	O
be	O
induced	O
in	O
human	O
B	O
cells	O
.	O
The	O
B	B
cell	I
NFAT	I
complex	I
,	O
however	O
,	O
was	O
not	O
functional	O
,	O
since	O
it	O
failed	O
to	O
activate	O
transcription	O
from	O
an	O
NFAT	O
-	O
driven	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
construct	O
.	O
Competition	O
with	O
an	O
AP-1	O
motif	O
or	O
with	O
anti	B
-	I
Jun	I
and	O
anti	B
-	I
Fos	I
antibodies	I
abolished	O
binding	O
to	O
the	O
NFAT	O
motif	O
in	O
both	O
T	O
and	O
B	O
cells	O
,	O
indicating	O
that	O
Jun	O
and	O
Fos	O
are	O
critical	O
for	O
NFAT	B
complex	I
formation	O
in	O
both	O
cell	O
types	O
.	O
Purified	O
recombinant	O
Jun	B
and	I
Fos	I
proteins	I
failed	O
to	O
bind	O
directly	O
to	O
the	O
NFAT	O
motif	O
.	O
However	O
,	O
when	O
combined	O
with	O
unstimulated	O
B	O
or	O
T	O
cell	O
extracts	O
,	O
full	O
-	O
length	O
,	O
but	O
not	O
truncated	O
,	O
Jun	O
/	O
Fos	O
heterodimers	O
were	O
able	O
to	O
form	O
an	O
NFAT	B
complex	I
,	O
indicating	O
the	O
presence	O
of	O
a	O
constitutively	B
expressed	I
nuclear	I
factor	I
(	O
s	O
)	O
in	O
B	O
and	O
T	O
cells	O
necessary	O
for	O
the	O
formation	O
of	O
the	O
NFAT	B
complex	I
in	O
both	O
cell	O
types	O
.	O
An	O
NFAT	B
oligonucleotide	O
carrying	O
mutations	O
in	O
the	O
5	O
'	O
purine	O
-	O
rich	O
part	O
of	O
the	O
NFAT	O
sequence	O
failed	O
to	O
form	O
a	O
complex	O
and	O
to	O
compete	O
with	O
the	O
wild	O
type	O
motif	O
for	O
NFAT	B
complex	I
formation	O
in	O
both	O
T	O
and	O
B	O
cells	O
.	O
We	O
therefore	O
propose	O
a	O
model	O
whereby	O
a	O
core	O
NFAT	B
complex	I
consisting	O
of	O
Jun	B
,	O
Fos	B
,	O
and	O
a	O
constitutive	B
nuclear	I
factor	I
is	O
formed	O
in	O
both	O
T	O
and	O
B	O
cells	O
,	O
but	O
an	O
additional	O
factor	O
and/or	O
post	O
-	O
translational	O
modification	O
of	O
a	O
factor	O
,	O
missing	O
in	O
B	O
cells	O
,	O
might	O
be	O
required	O
for	O
transactivation	O
by	O
NFAT	B
.	O
1	O
,	O
25-Dihydroxy	O
vitamin	O
D3	O
and	O
12-O	O
-	O
tetradecanoyl	O
phorbol-13-acetate	O
synergistically	O
induce	O
monocytic	O
cell	O
differentiation	O
:	O
FOS	B
and	O
RB	B
expression	O
.	O
1	O
,	O
25-dihydroxy	O
vitamin	O
D3	O
and	O
12-O	O
-	O
tetradecanoyl	O
phorbol-13-acetate	O
(	O
TPA	O
)	O
interact	O
synergistically	O
to	O
induce	O
monocytic	O
differentiation	O
of	O
U937	O
histiocytic	O
lymphoma	O
cells	O
.	O
Addition	O
of	O
TPA	O
causes	O
an	O
otherwise	O
ineffective	O
dose	O
of	O
1	O
,	O
25-dihydroxy	O
vitamin	O
D3	O
to	O
induce	O
differentiation	O
.	O
The	O
induced	O
differentiation	O
depends	O
on	O
the	O
simultaneous	O
(	O
vs.	O
sequential	O
)	O
presence	O
of	O
both	O
agents	O
.	O
The	O
kinetics	O
of	O
induced	O
differentiation	O
are	O
consistent	O
with	O
a	O
G1	O
specific	O
cellular	O
response	O
to	O
initiate	O
the	O
metabolic	O
cascade	O
culminating	O
in	O
cell	O
differentiation	O
.	O
The	O
induced	O
differentiation	O
occurs	O
with	O
down	O
-	O
regulation	O
of	O
c	B
-	I
fos	I
protein	I
and	O
an	O
accompanying	O
up	O
-	O
regulation	O
of	O
RB	B
protein	I
expression	O
,	O
consistent	O
with	O
a	O
possible	O
need	O
for	O
up	O
-	O
regulated	O
RB	B
expression	O
to	O
maintain	O
a	O
given	O
differentiated	O
phenotype	O
and	O
suppress	O
transcriptional	B
activators	I
that	O
might	O
typically	O
be	O
associated	O
with	O
proliferation	O
.	O
Differential	O
autoregulation	O
of	O
glucocorticoid	B
receptor	I
expression	O
in	O
human	O
T-	O
and	O
B	O
-	O
cell	O
lines	O
.	O
Regulation	O
of	O
glucocorticoid	B
receptor	I
(	O
GR	O
)	O
expression	O
by	O
its	O
cognate	O
ligand	O
was	O
examined	O
in	O
the	O
glucocorticoid	O
-	O
sensitive	O
human	O
leukemic	O
T	O
-	O
cell	O
line	O
6TG1.1	O
and	O
in	O
the	O
human	O
B	O
-	O
cell	O
line	O
IM-9	O
.	O
In	O
contrast	O
to	O
the	O
decrease	O
in	O
GR	O
mRNA	O
seen	O
in	O
IM-9	O
cells	O
after	O
treatment	O
with	O
1	O
microM	O
dexamethasone	O
for	O
16	O
-	O
18	O
h	O
,	O
treatment	O
of	O
6TG1.1	O
cells	O
resulted	O
in	O
an	O
8-fold	O
increase	O
in	O
GR	O
mRNA	O
,	O
as	O
determined	O
by	O
Northern	O
blot	O
and	O
RNase	B
protection	O
analysis	O
,	O
with	O
a	O
corresponding	O
3-	O
to	O
4-fold	O
increase	O
in	O
GR	B
protein	I
.	O
Half	O
-	O
maximal	O
induction	O
of	O
GR	O
mRNA	O
and	O
protein	O
in	O
6TG1.1	O
cells	O
was	O
observed	O
between	O
10	O
-	O
100	O
nM	O
dexamethasone	O
,	O
and	O
inclusion	O
of	O
1	O
microM	O
RU	O
38486	O
completely	O
blocked	O
the	O
effects	O
of	O
100	O
nM	O
dexamethasone	O
,	O
demonstrating	O
that	O
positive	O
autoregulation	O
of	O
GR	B
expression	O
in	O
6TG1.1	O
cells	O
is	O
a	O
receptor	O
-	O
mediated	O
response	O
.	O
Positive	O
autoregulation	O
of	O
GR	B
expression	O
was	O
also	O
observed	O
in	O
glucocorticoid	O
-	O
resistant	O
CEM	O
-	O
C1	O
cells	O
,	O
which	O
contain	O
functional	O
GR	B
,	O
but	O
whose	O
growth	O
is	O
unaffected	O
by	O
glucocorticoids	O
.	O
Thus	O
,	O
positive	O
autoregulation	O
is	O
neither	O
a	O
consequence	O
nor	O
the	O
sole	O
cause	O
of	O
growth	O
arrest	O
.	O
The	O
degree	O
of	O
negative	O
autoregulation	O
in	O
IM-9	O
cells	O
and	O
positive	O
autoregulation	O
in	O
6TG1.1	O
cells	O
was	O
unaffected	O
by	O
inhibition	O
of	O
protein	O
synthesis	O
with	O
cycloheximide	O
.	O
Measurement	O
of	O
GR	O
mRNA	O
turnover	O
in	O
6TG1.1	O
cells	O
treated	O
with	O
actinomycin	O
-	O
D	O
revealed	O
a	O
half	O
-	O
life	O
of	O
2.5	O
h	O
,	O
which	O
was	O
unaffected	O
by	O
dexamethasone	O
treatment	O
.	O
A	O
similar	O
half	O
-	O
life	O
was	O
determined	O
in	O
IM-9	O
cells	O
and	O
was	O
also	O
unaffected	O
by	O
steroid	O
treatment	O
.	O
These	O
results	O
are	O
consistent	O
with	O
the	O
interpretation	O
that	O
glucocorticoid	O
-	O
mediated	O
autoregulation	O
of	O
GR	O
expression	O
is	O
a	O
tissue	O
-	O
specific	O
primary	O
transcriptional	O
response	O
.	O
The	O
p65	B
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
regulates	O
I	B
kappa	I
B	I
by	O
two	O
distinct	O
mechanisms	O
.	O
Transcription	O
factor	O
NF	B
-	I
kappa	I
B	I
(	O
p50	B
/	I
p65	I
)	O
is	O
generally	O
localized	O
to	O
the	O
cytoplasm	O
by	O
its	O
inhibitor	O
I	B
kappa	I
B	I
.	O
Overproduced	O
I	B
kappa	I
B	I
,	O
free	O
from	O
NF	B
-	I
kappa	I
B	I
,	O
is	O
rapidly	O
degraded	O
.	O
Overexpression	O
of	O
p65	B
increases	O
endogenous	O
I	B
kappa	I
B	I
protein	O
in	O
both	O
carcinoma	O
and	O
lymphoid	O
cells	O
by	O
two	O
mechanisms	O
:	O
protein	O
stabilization	O
and	O
increased	O
transcription	O
of	O
I	O
kappa	O
B	O
mRNA	O
.	O
In	O
contrast	O
,	O
p65	B
delta	I
,	O
a	O
naturally	O
occurring	O
splice	O
variant	O
,	O
fails	O
to	O
markedly	O
augment	O
I	B
kappa	I
B	I
protein	O
levels	O
.	O
Both	O
overexpressed	O
p65	B
and	O
coexpressed	O
p50	B
are	O
cytoplasmic	O
,	O
whereas	O
p65	B
delta	I
is	O
partly	O
nuclear	O
,	O
indicating	O
that	O
the	O
I	B
kappa	I
B	I
induced	O
by	O
p65	B
can	O
maintain	O
NF	B
-	I
kappa	I
B	I
in	O
the	O
cytoplasm	O
.	O
Thus	O
,	O
p65	B
and	O
I	B
kappa	I
B	I
are	O
linked	O
in	O
an	O
autoregulatory	O
loop	O
,	O
ensuring	O
that	O
NF	B
-	I
kappa	I
B	I
is	O
held	O
in	O
the	O
cytoplasm	O
until	O
cells	O
are	O
specifically	O
induced	O
to	O
translocate	O
it	O
to	O
the	O
nucleus	O
.	O
Occurrence	O
of	O
a	O
silencer	O
of	O
the	O
interleukin-2	O
gene	O
in	O
naive	O
but	O
not	O
in	O
memory	O
resting	O
T	O
helper	O
lymphocytes	O
.	O
In	O
the	O
immune	O
system	O
the	O
first	O
activation	O
of	O
a	O
naive	O
T	O
cell	O
by	O
antigen	O
is	O
a	O
key	O
step	O
in	O
the	O
shaping	O
of	O
the	O
peripheral	O
T	O
cell	O
specificity	O
repertoire	O
and	O
maintenance	O
of	O
self	O
-	O
tolerance	O
.	O
In	O
the	O
present	O
study	O
,	O
analysis	O
of	O
the	O
interleukin-2	O
(	O
IL-2	O
)	O
gene	O
activation	O
shows	O
that	O
naive	O
human	O
helper	O
T	O
cells	O
(	O
cord	O
blood	O
CD4	O
+	O
T	O
cells	O
,	O
adult	O
CD4+CD45RO-	O
T	O
cells	O
)	O
regulate	O
IL-2	B
transcription	O
by	O
a	O
mechanism	O
involving	O
both	O
a	O
silencer	O
and	O
an	O
activator	O
acting	O
on	O
the	O
purine	O
-	O
rich	O
IL-2	O
promoter	O
elements	O
(	O
NF	O
-	O
AT	O
binding	O
sites	O
)	O
.	O
By	O
contrast	O
,	O
memory	O
cells	O
,	O
either	O
in	O
vitro	O
activated	O
helper	O
T	O
cells	O
reverting	O
to	O
a	O
resting	O
state	O
,	O
or	O
CD4	O
+	O
T	O
(	O
memory	O
)	O
clones	O
,	O
or	O
CD4+CD45RO+	O
T	O
cells	O
isolated	O
ex	O
vivo	O
,	O
no	O
longer	O
have	O
a	O
silencer	O
.	O
Their	O
IL-2	B
transcription	O
seems	O
to	O
be	O
controlled	O
solely	O
by	O
the	O
transition	O
from	O
inactive	O
to	O
active	O
functional	O
state	O
of	O
a	O
positive	B
transcription	I
factor	I
binding	O
to	O
these	O
promoter	O
elements	O
as	O
well	O
as	O
its	O
cytoplasmic	O
or	O
nuclear	O
location	O
:	O
in	O
resting	O
memory	O
T	O
cells	O
the	O
activator	O
is	O
located	O
in	O
the	O
cytoplasm	O
and	O
is	O
inactive	O
,	O
whereas	O
in	O
stimulated	O
cells	O
it	O
is	O
functional	O
in	O
promoting	O
transcription	O
and	O
now	O
resides	O
in	O
the	O
nucleus	O
.	O
Thus	O
,	O
the	O
regulation	O
of	O
the	O
gene	O
coding	O
for	O
the	O
main	O
T	B
cell	I
growth	I
factor	I
changes	O
irreversibly	O
after	O
the	O
first	O
encounter	O
of	O
T	O
cells	O
with	O
antigen	O
.	O
It	O
is	O
most	O
likely	O
that	O
the	O
presence	O
of	O
a	O
silencer	O
contributes	O
to	O
the	O
more	O
stringent	O
activation	O
requirements	O
of	O
naive	O
CD4	O
+	O
T	O
cells	O
.	O
Single	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
androgen	O
receptor	O
gene	O
mutations	O
in	O
patients	O
with	O
androgen	O
insensitivity	O
syndromes	O
:	O
application	O
for	O
diagnosis	O
,	O
genetic	O
counseling	O
,	O
and	O
therapy	O
.	O
Recent	O
studies	O
indicate	O
that	O
mutations	O
in	O
the	O
androgen	O
receptor	O
gene	O
are	O
associated	O
with	O
androgen	O
insensitivity	O
syndromes	O
,	O
a	O
heterogeneous	O
group	O
of	O
related	O
disorders	O
involving	O
defective	O
sexual	O
differentiation	O
in	O
karyotypic	O
males	O
.	O
In	O
this	O
report	O
,	O
we	O
address	O
the	O
possibility	O
of	O
rapid	O
mutational	O
analysis	O
of	O
the	O
androgen	O
receptor	O
gene	O
for	O
initial	O
diagnosis	O
,	O
genetic	O
counseling	O
,	O
and	O
molecular	O
subclassification	O
of	O
affected	O
patients	O
and	O
their	O
families	O
.	O
DNA	O
from	O
peripheral	O
blood	O
leukocytes	O
of	O
six	O
patients	O
from	O
five	O
families	O
with	O
various	O
degrees	O
of	O
androgen	O
insensitivity	O
was	O
studied	O
.	O
Exons	O
2	O
to	O
8	O
of	O
the	O
androgen	O
receptor	O
gene	O
were	O
analyzed	O
using	O
a	O
combination	O
of	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
DNA	O
sequencing	O
.	O
Female	O
family	O
members	O
were	O
also	O
studied	O
to	O
identify	O
heterozygote	O
carriers	O
.	O
Point	O
mutations	O
in	O
the	O
AR	O
gene	O
were	O
identified	O
in	O
all	O
six	O
patients	O
,	O
and	O
all	O
mutations	O
caused	O
amino	O
acid	O
substitutions	O
.	O
One	O
patient	O
with	O
incomplete	O
androgen	O
insensitivity	O
was	O
a	O
mosaic	O
for	O
the	O
mutation	O
.	O
Four	O
of	O
the	O
five	O
mothers	O
,	O
as	O
well	O
as	O
a	O
young	O
sister	O
of	O
one	O
patient	O
,	O
were	O
carriers	O
of	O
the	O
mutation	O
present	O
in	O
the	O
affected	O
child	O
.	O
Our	O
data	O
show	O
that	O
new	O
mutations	O
may	O
occur	O
in	O
the	O
androgen	O
receptor	O
gene	O
leading	O
to	O
sporadic	O
androgen	O
insensitivity	O
syndrome	O
.	O
Molecular	O
genetic	O
characterization	O
of	O
the	O
variant	O
allele	O
can	O
serve	O
as	O
a	O
primary	O
tool	O
for	O
diagnosis	O
and	O
subsequent	O
therapy	O
,	O
and	O
can	O
provide	O
a	O
basis	O
for	O
distinguishing	O
heterozygous	O
carriers	O
in	O
familial	O
androgen	O
resistance	O
.	O
The	O
identification	O
of	O
carriers	O
is	O
of	O
substantial	O
clinical	O
importance	O
for	O
genetic	O
counseling	O
.	O
Minimally	O
modified	O
low	O
density	O
lipoprotein	B
-induced	O
inflammatory	O
responses	O
in	O
endothelial	O
cells	O
are	O
mediated	O
by	O
cyclic	O
adenosine	O
monophosphate	O
.	O
We	O
have	O
previously	O
shown	O
that	O
minimally	O
oxidized	O
LDL	O
(	O
MM	O
-	O
LDL	O
)	O
activated	O
endothelial	O
cells	O
to	O
increase	O
their	O
interaction	O
with	O
monocytes	O
but	O
not	O
neutrophils	O
,	O
inducing	O
monocyte	O
but	O
not	O
neutrophil	O
binding	O
and	O
synthesis	O
of	O
monocyte	B
chemotactic	I
protein-1	I
and	O
monocyte	B
colony	I
-	I
stimulating	I
factor	I
(	O
M	B
-	I
CSF	I
)	O
.	O
In	O
the	O
present	O
studies	O
we	O
have	O
examined	O
the	O
signaling	O
pathways	O
by	O
which	O
this	O
monocyte	O
-	O
specific	O
response	O
is	O
induced	O
.	O
Both	O
induction	O
of	O
monocyte	O
binding	O
and	O
mRNA	O
levels	O
for	O
M	B
-	I
CSF	I
by	O
MM	B
-	I
LDL	I
were	O
not	O
inhibited	O
in	O
protein	O
kinase	O
C	O
-	O
depleted	O
endothelial	O
cells	O
.	O
A	O
number	O
of	O
our	O
studies	O
indicate	O
that	O
cAMP	O
is	O
the	O
second	O
messenger	O
for	O
the	O
effects	O
of	O
MM	B
-	I
LDL	I
cited	O
above	O
.	O
Incubation	O
of	O
endothelial	O
cells	O
with	O
MM	B
-	I
LDL	I
caused	O
a	O
173	O
%	O
increase	O
in	O
intracellular	O
cAMP	O
levels	O
.	O
Agents	O
which	O
increased	O
cAMP	O
levels	O
,	O
including	O
cholera	O
toxin	O
,	O
pertussis	O
toxin	O
,	O
dibutyryl	O
cAMP	O
,	O
and	O
isoproterenol	O
mimicked	O
the	O
actions	O
of	O
MM	B
-	I
LDL	I
.	O
Agents	O
which	O
elevated	O
cAMP	O
were	O
also	O
shown	O
to	O
activate	O
NF	B
kappa	I
B	I
,	O
suggesting	O
a	O
role	O
for	O
this	O
transcription	O
factor	O
in	O
activation	O
of	O
monocyte	O
-	O
endothelial	O
interactions	O
.	O
Although	O
endothelial	O
leukocyte	O
adhesion	O
molecule	O
(	O
ELAM	O
)	O
mRNA	O
synthesis	O
can	O
be	O
regulated	O
by	O
NF	B
kappa	I
B	I
,	O
ELAM	B
was	O
not	O
expressed	O
and	O
ELAM	O
mRNA	O
was	O
only	O
slightly	O
elevated	O
in	O
response	O
to	O
MM	B
-	I
LDL	I
.	O
We	O
present	O
evidence	O
that	O
induction	O
of	O
neutrophil	O
binding	O
by	O
LPS	O
is	O
actually	O
suppressed	O
by	O
agents	O
that	O
elevated	O
cAMP	O
levels	O
.	O
Costimulation	O
of	O
cAMP	O
and	O
protein	B
kinase	I
C	I
pathways	O
inhibits	O
the	O
CD3	B
-dependent	O
T	O
cell	O
activation	O
and	O
leads	O
to	O
a	O
persistent	O
expression	O
of	O
the	O
AP-1	B
transcription	I
factor	I
.	O
The	O
effects	O
mediated	O
by	O
a	O
combined	O
stimulation	O
of	O
cAMP	O
-and	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
-dependent	O
pathways	O
have	O
been	O
investigated	O
in	O
different	O
cellular	O
systems	O
,	O
and	O
it	O
has	O
been	O
shown	O
that	O
they	O
may	O
complement	O
each	O
other	O
in	O
activating	O
cell	O
proliferation	O
and	O
differentiation	O
.	O
In	O
this	O
report	O
,	O
we	O
show	O
that	O
upon	O
the	O
stimulation	O
of	O
both	O
pathways	O
T	O
lymphocytes	O
became	O
refractory	O
to	O
activation	O
via	O
the	O
CD3	B
/	I
T	I
cell	I
receptor	I
(	O
TcR	B
)	O
complex	O
.	O
T	O
cells	O
preincubated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
dibutyryl	O
cAMP	O
(	O
Bt2cAMP	O
)	O
displayed	O
a	O
deficient	O
proliferative	O
ability	O
in	O
response	O
to	O
anti	B
-	I
CD3	I
mAb	I
stimulation	O
,	O
whereas	O
lymphocytes	O
treated	O
individually	O
with	O
either	O
Bt2cAMP	O
or	O
PMA	O
responded	O
comparably	O
to	O
untreated	O
samples	O
.	O
We	O
detected	O
an	O
association	O
between	O
the	O
reduced	O
mitogenic	O
response	O
and	O
low	O
expression	O
of	O
both	O
interleukin-2	B
(	O
IL-2	B
)	O
and	O
the	O
alpha	B
chain	I
(	O
CD25	B
)	O
of	O
the	O
IL-2	B
receptor	I
(	O
IL-2R	B
)	O
.	O
Analysis	O
of	O
intracellular	O
Ca2	O
+	O
mobilization	O
suggested	O
that	O
the	O
CD3	B
/	O
TcR	B
-dependent	O
signal	O
transduction	O
was	O
impaired	O
in	O
PMA	O
/	O
Bt2cAMP	O
-	O
treated	O
cells	O
.	O
Remarkably	O
,	O
we	O
observed	O
that	O
these	O
samples	O
displayed	O
a	O
persistent	O
expression	O
of	O
the	O
c	O
-	O
fos	O
protooncogene	O
,	O
associated	O
to	O
an	O
increased	O
AP-1	B
DNA	O
-	O
binding	O
activity	O
,	O
whereas	O
no	O
variations	O
of	O
CREB	B
or	O
NF	B
-	I
kB	I
were	O
detected	O
.	O
Neither	O
Bt2cAMP	O
nor	O
PMA	O
individually	O
mediated	O
these	O
sustained	O
effects	O
,	O
which	O
therefore	O
appear	O
as	O
a	O
consequence	O
of	O
the	O
interplay	O
between	O
both	O
metabolic	O
stimuli	O
.	O
Altogether	O
,	O
the	O
data	O
provide	O
the	O
evidence	O
that	O
both	O
pathways	O
complement	O
each	O
other	O
in	O
regulating	O
gene	O
expression	O
and	O
,	O
conversely	O
,	O
downregulate	O
the	O
TcR	B
transduction	O
mechanisms	O
.	O
Human	B
T	I
cell	I
transcription	I
factor	I
GATA-3	B
stimulates	O
HIV-1	O
expression	O
.	O
A	O
family	O
of	O
transcriptional	O
activating	O
proteins	O
,	O
the	O
GATA	B
factors	I
,	O
has	O
been	O
shown	O
to	O
bind	O
to	O
a	O
consensus	O
motif	O
through	O
a	O
highly	B
conserved	I
C4	I
zinc	I
finger	I
DNA	I
binding	I
domain	I
.	O
One	O
member	O
of	O
this	O
multigene	O
family	O
,	O
GATA-3	B
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
T	O
lymphocytes	O
,	O
a	O
cellular	O
target	O
for	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
and	O
replication	O
.	O
In	O
vitro	O
DNase	B
I	I
footprinting	O
analysis	O
revealed	O
six	O
hGATA-3	O
binding	O
sites	O
in	O
the	O
U3	O
region	O
(	O
the	O
transcriptional	O
regulatory	O
domain	O
)	O
of	O
the	O
HIV-1	O
LTR	O
.	O
Cotransfection	O
of	O
an	O
hGATA-3	O
expression	O
plasmid	O
with	O
a	O
reporter	O
plasmid	O
whose	O
transcription	O
is	O
directed	O
by	O
the	O
HIV-1	O
LTR	O
resulted	O
in	O
6-	O
to	O
10-fold	O
stimulation	O
of	O
LTR	O
-mediated	O
transcription	O
,	O
whereas	O
site	O
specific	O
mutation	O
of	O
these	O
GATA	O
sites	O
resulted	O
in	O
virtual	O
abrogation	O
of	O
the	O
activation	O
by	O
hGATA-3	B
.	O
Further	O
,	O
deletion	O
of	O
the	O
hGATA-3	O
transcriptional	O
activation	O
domain	O
abolished	O
GATA	O
-	O
dependent	O
HIV-1	O
trans	O
-	O
activation	O
,	O
showing	O
that	O
the	O
stimulation	O
of	O
viral	O
transcription	O
observed	O
is	O
a	O
direct	O
effect	O
of	O
cotransfected	B
hGATA-3	I
.	O
Introduction	O
of	O
the	O
HIV-1	O
plasmids	O
in	O
which	O
the	O
GATA	O
sites	O
have	O
been	O
mutated	O
into	O
human	O
T	O
lymphocytes	O
also	O
caused	O
a	O
significant	O
reduction	O
in	O
LTR	O
-mediated	O
transcription	O
at	O
both	O
the	O
basal	O
level	O
and	O
in	O
(	O
PHA-	O
plus	O
PMA-	O
)	O
stimulated	O
T	O
cells	O
.	O
These	O
observations	O
suggest	O
that	O
in	O
addition	O
to	O
its	O
normal	O
role	O
in	O
T	O
lymphocyte	O
gene	O
regulation	O
,	O
hGATA-3	B
may	O
also	O
play	O
a	O
significant	O
role	O
in	O
HIV-1	O
transcriptional	O
activation	O
.	O
Enhancing	O
effect	O
of	O
17	O
beta	O
-	O
estradiol	O
on	O
human	O
NK	O
cell	O
activity	O
.	O
The	O
in	O
vitro	O
effect	O
of	O
17	O
beta	O
-	O
estradiol	O
on	O
NK	O
activity	O
was	O
studied	O
.	O
The	O
proliferation	O
and	O
NK	O
activity	O
of	O
YT	O
-	O
N17	O
(	O
a	O
human	O
NK	O
-	O
like	O
cell	O
line	O
)	O
were	O
enhanced	O
by	O
17	O
beta	O
-	O
estradiol	O
(	O
E2	O
)	O
,	O
and	O
the	O
enhancement	O
was	O
blocked	O
by	O
tamoxifen	O
(	O
Tx	O
)	O
,	O
an	O
antagonist	O
of	O
E2	O
.	O
On	O
the	O
contrary	O
,	O
other	O
steroid	O
hormones	O
such	O
as	O
Tx	O
,	O
progesterone	O
,	O
and	O
testosterone	O
had	O
no	O
effect	O
.	O
YT	O
-	O
N17	O
contained	O
11.8	O
fmol	O
/	O
mg	O
protein	O
of	O
estrogen	B
receptor	I
(	O
mean	O
of	O
two	O
independent	O
assays	O
)	O
,	O
a	O
value	O
which	O
was	O
5	O
-	O
10-fold	O
higher	O
than	O
that	O
of	O
other	O
hematopoietic	O
cell	O
lines	O
.	O
An	O
enhancement	O
of	O
NK	O
activity	O
by	O
E2	O
was	O
also	O
seen	O
in	O
large	O
granular	O
lymphocytes	O
obtained	O
from	O
normal	O
subjects	O
,	O
and	O
it	O
was	O
again	O
suppressed	O
by	O
Tx	O
.	O
These	O
data	O
suggest	O
that	O
E2	O
is	O
one	O
of	O
the	O
activating	O
factors	O
for	O
NK	O
/	O
LGL	O
cells	O
.	O
Cytokine	O
modulation	O
of	O
HIV	O
expression	O
.	O
Cytokines	B
,	O
the	O
peptide	B
hormones	I
which	O
control	O
the	O
homeostasis	O
of	O
the	O
immune	O
system	O
and	O
also	O
play	O
a	O
fundamental	O
role	O
in	O
inflammatory	O
and	O
immune	O
mediated	O
reactions	O
,	O
have	O
been	O
involved	O
at	O
multiple	O
levels	O
in	O
the	O
pathogenesis	O
of	O
the	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
.	O
Infection	O
with	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
has	O
been	O
shown	O
to	O
induce	O
production	O
of	O
several	O
cytokines	B
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Conversely	O
,	O
several	O
cytokines	B
modulate	O
the	O
levels	O
of	O
HIV	O
expression	O
in	O
infected	O
cells	O
of	O
both	O
T	O
lymphocytic	O
and	O
mononuclear	O
phagocytic	O
lineage	O
.	O
Activated	O
mononuclear	O
cells	O
,	O
particularly	O
B	O
cells	O
which	O
are	O
in	O
a	O
state	O
of	O
chronic	O
activation	O
in	O
HIV	O
infected	O
individuals	O
,	O
release	O
HIV	B
-	I
inductive	I
cytokines	I
and	O
thus	O
play	O
a	O
potentially	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
HIV	O
infection	O
.	O
Tumor	B
necrosis	I
factor	I
receptor	I
expression	O
and	O
signal	O
transduction	O
in	O
HIV-1-infected	O
cells	O
.	O
OBJECTIVE	O
:	O
To	O
examine	O
the	O
inter	O
-	O
relationship	O
between	O
HIV-1	O
infection	O
and	O
the	O
cell	O
surface	O
receptors	O
for	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
-alpha	I
,	O
an	O
immunoregulatory	O
cytokine	O
that	O
can	O
enhance	O
HIV-1	O
replication	O
.	O
DESIGN	O
:	O
Infected	O
promyelocytic	O
and	O
promonocytic	O
cells	O
were	O
examined	O
because	O
they	O
normally	O
express	O
both	O
types	O
of	O
TNF	B
receptors	I
.	O
METHODS	O
:	O
TNF	B
receptor	O
surface	O
expression	O
was	O
determined	O
by	O
specific	O
monoclonal	B
antibody	I
recognition	O
and	O
flow	O
cytometry	O
,	O
and	O
signal	O
transduction	O
was	O
detected	O
by	O
gel	O
shift	O
analysis	O
.	O
HIV-1	O
activation	O
and	O
expression	O
was	O
quantitated	O
by	O
reverse	B
transcriptase	I
assay	O
.	O
RESULTS	O
:	O
In	O
the	O
OM-10.1	O
promyelocytic	O
model	O
of	O
chronic	O
infection	O
,	O
TNF	O
-	O
alpha	O
-	O
induced	O
HIV-1	O
expression	O
also	O
resulted	O
in	O
a	O
substantial	O
increase	O
in	O
75	B
kd	I
TNF	I
receptor	I
(	O
TR75	B
)	O
expression	O
although	O
55	B
kD	I
TNF	I
receptor	I
(	O
TR55	B
)	O
levels	O
were	O
not	O
dramatically	O
altered	O
.	O
A	O
series	O
of	O
uninfected	O
parental	O
HL-60	O
subclones	O
all	O
reduced	O
TR75	B
surface	O
expression	O
in	O
response	O
to	O
TNF	B
-	I
alpha	I
treatment	O
.	O
Enhanced	O
TR75	B
expression	O
on	O
OM-10.1	O
cells	O
followed	O
the	O
same	O
TNF	B
-	I
alpha	I
-dose	O
dependency	O
as	O
that	O
observed	O
for	O
HIV-1	O
production	O
.	O
An	O
increase	O
in	O
TR75	B
expression	O
was	O
also	O
evident	O
during	O
the	O
peak	O
of	O
an	O
acute	O
HIV-1	O
infection	O
of	O
HL-60	O
promyelocytes	O
.	O
Although	O
TR55	B
expression	O
was	O
unaltered	O
during	O
TNF	B
-	I
alpha	I
-induced	O
HIV	O
activation	O
,	O
this	O
receptor	O
was	O
still	O
involved	O
in	O
the	O
viral	O
activation	O
process	O
.	O
Antibody	O
cross	O
-	O
linking	O
of	O
TR55	B
,	O
in	O
the	O
absence	O
of	O
exogenous	B
TNF	I
-	I
alpha	I
,	O
induced	O
maximal	O
HIV-1	O
expression	O
,	O
an	O
up	O
-	O
modulation	O
of	O
surface	O
TR75	B
,	O
and	O
nuclear	O
NF	B
-	I
kappa	I
B	I
activity	O
in	O
OM-10.1	O
cultures	O
.	O
Surprisingly	O
,	O
this	O
was	O
the	O
case	O
even	O
when	O
an	O
antagonistic	B
anti	I
-	I
TR55	I
antibody	I
was	O
used	O
.	O
Anti	B
-	I
TR55	I
antibody	I
cross	O
-	O
linking	O
in	O
chronically	O
infected	O
U1	O
promonocytic	O
cultures	O
could	O
only	O
partially	O
substitute	O
for	O
TNF	O
-	O
alpha	O
-	O
induced	O
HIV-1	O
expression	O
.	O
CONCLUSIONS	O
:	O
Our	O
results	O
demonstrated	O
that	O
HIV-1	O
infection	O
can	O
selectively	O
influence	O
the	O
surface	O
expression	O
of	O
TNF	B
receptors	I
,	O
potentially	O
influencing	O
its	O
own	O
expression	O
and	O
altering	O
normal	O
immunoregulatory	B
signal	O
transduction	O
.	O
Inhibition	O
of	O
HIV-1	O
latency	O
reactivation	O
by	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
and	O
an	O
analog	O
of	O
DHEA	O
.	O
The	O
initial	O
infection	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
in	O
most	O
individuals	O
usually	O
results	O
in	O
the	O
establishment	O
of	O
a	O
latent	O
or	O
chronic	O
infection	O
before	O
eventual	O
progression	O
toward	O
acquired	O
immunodeficiency	O
syndrome	O
.	O
HIV-1	O
can	O
also	O
establish	O
a	O
latent	O
or	O
persistent	O
infection	O
in	O
some	O
T	O
cell	O
lines	O
that	O
show	O
minimal	O
constitutive	O
virus	O
expression	O
.	O
However	O
,	O
activation	O
of	O
the	O
T	O
cell	O
lines	O
leading	O
to	O
enhanced	O
HIV-1	O
replication	O
can	O
be	O
induced	O
by	O
antigens	B
,	O
mitogens	O
,	O
and	O
cytokines	B
(	O
tumor	B
necrosis	I
factor	I
alpha	I
[	O
TNF	B
-	I
alpha	I
]	O
,	O
interleukin	B
1	I
,	O
and	O
interleukin-2	B
)	O
.	O
Various	O
gene	O
products	O
from	O
other	O
viruses	O
(	O
HTLV-1	O
,	O
HSV	O
,	O
EBV	O
,	O
CMV	O
,	O
HBV	O
,	O
and	O
HHV-6	O
)	O
can	O
also	O
enhance	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-driven	O
reporter	O
gene	O
activity	O
.	O
On	O
the	O
basis	O
of	O
these	O
observations	O
,	O
it	O
has	O
been	O
proposed	O
that	O
reactivation	O
of	O
latent	O
HIV-1	O
harbored	O
in	O
chronically	O
infected	O
T	O
lymphocytes	O
,	O
monocytes	O
,	O
or	O
macrophages	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
.	O
So	O
far	O
,	O
there	O
are	O
no	O
drugs	O
or	O
therapy	O
available	O
that	O
can	O
provide	O
protection	O
against	O
HIV-1	O
latency	O
reactivation	O
.	O
ACH-2	O
,	O
derived	O
from	O
a	O
human	O
T	O
cell	O
line	O
(	O
CEM	O
)	O
,	O
is	O
chronically	O
infected	O
with	O
HIV-1	O
,	O
with	O
low	O
levels	O
of	O
constitutive	O
virus	O
expression	O
.	O
ACH-2	O
can	O
be	O
converted	O
to	O
productive	O
infection	O
by	O
stimulation	O
of	O
the	O
cells	O
with	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
,	O
mitogen	O
or	O
cytokines	B
(	O
TNF	B
-	I
alpha	I
)	O
,	O
or	O
infection	O
with	O
HSV	O
.	O
Therefore	O
the	O
ACH-2	O
cell	O
line	O
is	O
a	O
good	O
candidate	O
for	O
studying	O
the	O
effects	O
of	O
drugs	O
on	O
HIV-1	O
activation	O
.	O
Previously	O
,	O
we	O
have	O
reported	O
that	O
DHEA	O
and	O
synthetic	O
analogs	O
of	O
DHEA	O
can	O
be	O
modest	O
inhibitors	O
of	O
HIV-1	O
IIIB	O
replication	O
in	O
phytohemagglutinin	O
-	O
stimulated	O
peripheral	O
blood	O
lymphocyte	O
cultures	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Visualization	O
of	O
the	O
endogenous	B
NF	I
-	I
kappa	I
B	I
p50	I
subunit	I
in	O
the	O
nucleus	O
of	O
follicular	O
dendritic	O
cells	O
in	O
germinal	O
centers	O
.	O
NF	B
-	I
kappa	I
B	I
,	O
a	O
50	B
kDa	I
/	I
65	I
kDa	I
(	I
p50	I
/	I
p65	I
)	I
heterodimer	I
,	O
is	O
a	O
ubiquitous	B
transcription	I
factor	I
involved	O
in	O
the	O
positive	O
regulation	O
of	O
various	O
immune	O
genes	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
NF	B
-	I
kappa	I
B	I
is	O
related	O
to	O
a	O
particular	O
cell	O
type	O
and/or	O
differentiation	O
step	O
during	O
immunopoiesis	O
.	O
Using	O
in	O
situ	O
hybridization	O
on	O
sections	O
from	O
non	O
HIV	O
hyperplastic	O
lymph	O
nodes	O
,	O
we	O
found	O
that	O
the	O
gene	O
of	O
the	O
105	B
kDa	I
precursor	I
of	O
p50	B
was	O
overexpressed	O
in	O
the	O
light	O
zone	O
of	O
germinal	O
centers	O
,	O
with	O
a	O
network	O
aspect	O
,	O
which	O
suggested	O
the	O
involvement	O
of	O
follicular	O
dendritic	O
cells	O
(	O
FDC	O
)	O
.	O
By	O
immunohistochemistry	O
,	O
p50	B
protein	O
was	O
detected	O
in	O
the	O
cytoplasm	O
and	O
nucleus	O
of	O
FDC	O
,	O
confirming	O
the	O
involvement	O
of	O
FDC	O
.	O
Furthermore	O
,	O
p50	B
protein	O
was	O
detected	O
in	O
the	O
cytoplasm	O
of	O
all	O
lymphocytes	O
.	O
Thus	O
,	O
we	O
focused	O
our	O
study	O
on	O
isolated	O
FDC	O
clusters	O
from	O
normal	O
tonsils	O
.	O
As	O
showed	O
on	O
tissue	O
sections	O
,	O
we	O
detected	O
the	O
p50	B
in	O
both	O
cytoplasm	O
and	O
nucleus	O
of	O
FDC	O
.	O
Nuclei	O
of	O
lymphocytes	O
from	O
FDC	O
clusters	O
were	O
negative	O
.	O
We	O
next	O
studied	O
p65	O
and	O
c	O
-	O
Rel	O
protein	O
expression	O
in	O
FDC	O
clusters	O
.	O
p65	B
was	O
detected	O
in	O
the	O
cytoplasm	O
of	O
FDC	O
,	O
whereas	O
nuclei	O
were	O
negative	O
.	O
Furthermore	O
,	O
p65	B
was	O
detected	O
in	O
the	O
nuclei	O
of	O
some	O
lymphocytes	O
.	O
c	B
-	I
Rel	I
protein	I
was	O
detected	O
only	O
in	O
the	O
cytoplasm	O
of	O
lymphocytes	O
and	O
not	O
in	O
the	O
nucleus	O
and	O
cytoplasm	O
of	O
FDC	O
.	O
Our	O
results	O
indicated	O
that	O
,	O
in	O
the	O
context	O
of	O
T	O
cell	O
-	O
dependent	O
B	O
cell	O
immunopoiesis	O
occurring	O
in	O
FDC	O
clusters	O
,	O
p50	B
is	O
mainly	O
related	O
to	O
FDC	O
with	O
a	O
massive	O
overexpression	O
in	O
the	O
nuclei	O
,	O
whereas	O
p65	B
is	O
expressed	O
in	O
a	O
scattered	O
manner	O
in	O
the	O
nuclei	O
of	O
lymphocytes	O
and	O
c	O
-	O
Rel	O
protein	O
exclusively	O
in	O
the	O
cytoplasm	O
of	O
lymphocytes	O
from	O
FDC	O
clusters	O
.	O
These	O
results	O
suggested	O
that	O
the	O
two	O
subunits	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
the	O
c	B
-	I
Rel	I
protein	I
have	O
different	O
roles	O
in	O
different	O
cell	O
types	O
during	O
B	O
cell	O
immunopoiesis	O
.	O
Involvement	O
of	O
transcription	B
factor	I
YB-1	B
in	O
human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
basal	O
gene	O
expression	O
.	O
Sequences	O
which	O
control	O
basal	O
human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
transcription	O
likely	O
play	O
an	O
important	O
role	O
in	O
initiation	O
and	O
maintenance	O
of	O
virus	O
replication	O
.	O
We	O
previously	O
identified	O
and	O
analyzed	O
a	O
45-nucleotide	O
sequence	O
(	O
downstream	O
regulatory	O
element	O
1	O
[	O
DRE	O
1	O
]	O
)	O
,	O
+	O
195	O
to	O
+	O
240	O
,	O
at	O
the	O
boundary	O
of	O
the	O
R	O
/	O
U5	O
region	O
of	O
the	O
long	O
terminal	O
repeat	O
which	O
is	O
required	O
for	O
HTLV	O
-	O
I	O
basal	O
transcription	O
.	O
We	O
identified	O
a	O
protein	O
,	O
p37	O
,	O
which	O
specifically	O
bound	O
to	O
DRE	O
1	O
.	O
An	O
affinity	O
column	O
fraction	O
,	O
containing	O
p37	B
,	O
stimulated	O
HTLV	O
-	O
I	O
transcription	O
approximately	O
12-fold	O
in	O
vitro	O
.	O
We	O
now	O
report	O
the	O
identification	O
of	O
a	O
cDNA	O
clone	O
(	O
15B-7	O
)	O
,	O
from	O
a	O
Jurkat	O
expression	O
library	O
,	O
that	O
binds	O
specifically	O
to	O
the	O
DRE	O
1	O
regulatory	O
sequence	O
.	O
Binding	O
of	O
the	O
cDNA	B
fusion	I
protein	I
,	O
similarly	O
to	O
the	O
results	O
obtained	O
with	O
purified	O
Jurkat	O
protein	O
,	O
was	O
decreased	O
by	O
introduction	O
of	O
site	O
-	O
specific	O
mutations	O
in	O
the	O
DRE	O
1	O
regulatory	O
sequence	O
.	O
In	O
vitro	O
transcription	O
and	O
translation	O
of	O
15B-7	O
cDNA	O
produced	O
a	O
fusion	B
protein	I
which	O
bound	O
specifically	O
to	O
the	O
HTLV	O
-	O
I	O
+	O
195	O
to	O
+	O
240	O
oligonucleotide	O
.	O
The	O
partial	O
cDNA	O
encodes	O
a	O
protein	O
which	O
is	O
homologous	O
to	O
the	O
C	B
-	I
terminal	I
196	I
amino	I
acids	I
of	O
the	O
36-kDa	B
transcription	I
factor	I
,	O
YB-1	B
.	O
Cotransfection	O
of	O
a	O
YB-1	O
expression	O
plasmid	O
increases	O
HTLV	O
-	O
I	O
basal	O
transcription	O
approximately	O
14-fold	O
in	O
Jurkat	O
T	O
lymphocytes	O
.	O
On	O
the	O
basis	O
of	O
the	O
molecular	O
weight	O
,	O
DNA	O
-	O
binding	O
characteristics	O
,	O
and	O
in	O
vivo	O
transactivation	O
activity	O
,	O
we	O
suggest	O
that	O
the	O
previously	O
identified	O
DRE	O
1	O
-binding	O
protein	O
,	O
p37	B
,	O
is	O
YB-1	B
.	O
Chlorinated	O
dibenzo	O
-	O
p	O
-	O
dioxins	O
and	O
dibenzofurans	O
and	O
the	O
human	O
immune	O
system	O
.	O
1	O
.	O
Blood	B
cell	I
receptors	I
in	O
volunteers	O
with	O
moderately	O
increased	O
body	O
burdens	O
.	O
Using	O
monoclonal	B
antibodies	I
(	O
mAbs	B
)	O
and	O
flow	O
cytometry	O
,	O
we	O
studied	O
a	O
variety	O
of	O
surface	B
receptors	I
on	O
lymphocyte	O
subpopulations	O
of	O
workers	O
with	O
moderately	O
increased	O
body	O
burdens	O
of	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
(	O
TCDD	O
)	O
and	O
of	O
other	O
polychlorinated	O
dibenzo	O
-	O
p	O
-	O
dioxins	O
and	O
dibenzofurans	O
(	O
PCDD	O
/	O
PCDF	O
)	O
,	O
expressed	O
here	O
as	O
International	O
-	O
Toxicity	O
Equivalencies	O
(	O
I	O
-	O
TE	O
)	O
.	O
The	O
hypothesis	O
to	O
be	O
tested	O
was	O
whether	O
or	O
not	O
humans	O
exhibit	O
a	O
similar	O
susceptibility	O
to	O
PCDDs	O
/	O
PCDFs	O
with	O
respect	O
to	O
the	O
surface	B
receptors	I
found	O
previously	O
to	O
respond	O
to	O
small	O
doses	O
of	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
(	O
TCDD	O
)	O
in	O
Callithrix	O
jacchus	O
.	O
These	O
are	O
:	O
helper	O
-	O
inducer	O
(	O
memory	O
)	O
T	O
cells	O
(	O
CD4+CD45R0+CD45RA	O
-	O
CD29highCD11a+	O
)	O
,	O
CD20	O
+	O
B	O
cells	O
,	O
and	O
cytotoxic	O
T	O
cells	O
(	O
CD8+CD56+	O
/	O
CD57	O
+	O
)	O
.	O
Furthermore	O
,	O
68	O
triple	O
-	O
labellings	O
with	O
mAbs	B
were	O
performed	O
on	O
the	O
cells	O
of	O
each	O
volunteer	O
to	O
possibly	O
generate	O
further	O
hypotheses	O
.	O
It	O
was	O
evaluated	O
whether	O
any	O
of	O
the	O
variables	O
might	O
be	O
used	O
as	O
a	O
biomarker	O
of	O
effects	O
for	O
this	O
class	O
of	O
compounds	O
.	O
There	O
were	O
two	O
main	O
goals	O
:	O
(	O
1	O
)	O
to	O
evaluate	O
whether	O
workers	O
with	O
a	O
moderately	O
increased	O
PCDD	O
/	O
PCDF	O
-	O
body	O
burden	O
[	O
25	O
-	O
140	O
ppt	O
TCDD	O
or	O
104	O
-	O
522	O
ppt	O
I	O
-	O
TE	O
in	O
blood	O
fat	O
]	O
exhibit	O
changes	O
in	O
the	O
surface	B
receptors	I
of	O
white	O
blood	O
cells	O
,	O
as	O
observed	O
in	O
previous	O
studies	O
in	O
non	O
-	O
human	O
primates	O
,	O
and	O
(	O
2	O
)	O
to	O
clarify	O
whether	O
persons	O
at	O
the	O
upper	O
range	O
[	O
10	O
-	O
23	O
ppt	O
TCDD	O
or	O
30	O
-	O
90	O
ppt	O
I	O
-	O
TE	O
in	O
blood	O
fat	O
]	O
of	O
the	O
body	O
burden	O
reference	O
values	O
of	O
a	O
not	O
particularly	O
exposed	O
population	O
show	O
detectable	O
deviations	O
in	O
these	O
immunological	O
variables	O
,	O
when	O
compared	O
with	O
persons	O
at	O
the	O
lower	O
and	O
medium	O
range	O
[	O
1	O
-	O
3	O
ppt	O
TCDD	O
or	O
9	O
-	O
29	O
ppt	O
I	O
-	O
TE	O
]	O
of	O
these	O
body	O
burden	O
reference	O
values	O
.	O
Regression	O
analysis	O
of	O
our	O
data	O
revealed	O
slight	O
trends	O
for	O
some	O
of	O
the	O
biomarkers	O
(	O
e.g.	O
CD45R0	O
+	O
)	O
.	O
With	O
one	O
exception	O
,	O
these	O
were	O
all	O
increases	O
.	O
None	O
of	O
the	O
alterations	O
observed	O
are	O
of	O
medical	O
relevance	O
.	O
The	O
slight	O
increase	O
in	O
the	O
percentage	O
of	O
CD4+CD45R0	O
+	O
cells	O
remained	O
significant	O
even	O
after	O
covariant	O
analysis	O
taking	O
age	O
-	O
related	O
changes	O
into	O
account	O
.	O
Altogether	O
,	O
the	O
data	O
do	O
not	O
provide	O
any	O
evidence	O
to	O
support	O
an	O
assumption	O
that	O
moderately	O
increased	O
body	O
burdens	O
of	O
PCDDs	O
/	O
PCDFs	O
in	O
adults	O
induce	O
decreases	O
in	O
the	O
cellular	O
components	O
of	O
the	O
human	O
immune	O
system	O
.	O
Adult	O
humans	O
certainly	O
are	O
less	O
susceptible	O
to	O
this	O
action	O
of	O
PCDDs	O
/	O
PCDFs	O
than	O
adolescent	O
Callithrix	O
jacchus	O
The	O
macrophage	B
transcription	I
factor	I
PU.1	B
directs	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
receptor	I
.	O
The	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
(	I
M	I
-	I
CSF	I
)	I
receptor	I
is	O
expressed	O
in	O
a	O
tissue	O
-	O
specific	O
fashion	O
from	O
two	O
distinct	O
promoters	O
in	O
monocytes	O
/	O
macrophages	O
and	O
the	O
placenta	O
.	O
In	O
order	O
to	O
further	O
understand	O
the	O
transcription	O
factors	O
which	O
play	O
a	O
role	O
in	O
the	O
commitment	O
of	O
multipotential	O
progenitors	O
to	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
,	O
we	O
have	O
initiated	O
an	O
investigation	O
of	O
the	O
factors	O
which	O
activate	O
the	O
M	B
-	I
CSF	I
receptor	I
very	O
early	O
during	O
the	O
monocyte	O
differentiation	O
process	O
.	O
Here	O
we	O
demonstrate	O
that	O
the	O
human	O
monocytic	O
M	O
-	O
CSF	O
receptor	O
promoter	O
directs	O
reporter	O
gene	O
activity	O
in	O
a	O
tissue	O
-	O
specific	O
fashion	O
.	O
Since	O
one	O
of	O
the	O
few	O
transcription	B
factors	I
which	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
monocyte	O
genes	O
is	O
the	O
macrophage-	B
and	I
B	I
-	I
cell	I
-	I
specific	I
PU.1	I
transcription	B
factor	I
,	O
we	O
investigated	O
whether	O
PU.1	B
binds	O
and	O
activates	O
the	O
M	O
-	O
CSF	O
receptor	O
promoter	O
.	O
Here	O
we	O
demonstrate	O
that	O
both	O
in	O
vitro	B
-	I
translated	I
PU.1	I
and	O
PU.1	B
from	O
nuclear	O
extracts	O
bind	O
to	O
a	O
specific	O
site	O
in	O
the	O
M	O
-	O
CSF	O
receptor	O
promoter	O
just	O
upstream	O
from	O
the	O
major	O
transcription	O
initiation	O
site	O
.	O
Mutations	O
in	O
this	O
site	O
which	O
eliminate	O
PU.1	B
binding	O
decrease	O
M	B
-	I
CSF	I
receptor	I
promoter	O
activity	O
significantly	O
in	O
macrophage	O
cell	O
lines	O
only	O
.	O
Furthermore	O
,	O
PU.1	B
transactivates	O
the	O
M	O
-	O
CSF	O
receptor	O
promoter	O
in	O
nonmacrophage	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
PU.1	B
plays	O
a	O
major	O
role	O
in	O
macrophage	O
gene	O
regulation	O
and	O
development	O
by	O
directing	O
the	O
expression	O
of	O
a	O
receptor	O
for	O
a	O
key	B
macrophage	I
growth	I
factor	I
.	O
Increased	O
natural	O
killer	O
cell	O
activity	O
correlates	O
with	O
low	O
or	O
negative	O
expression	O
of	O
the	O
HER-2	O
/	O
neu	O
oncogene	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O
BACKGROUND	O
.	O
Increased	O
expression	O
of	O
the	O
HER-2	O
/	O
neu	O
oncogene	O
in	O
breast	O
cancer	O
correlates	O
with	O
decreased	O
estrogen	B
receptor	I
concentration	O
and	O
seems	O
to	O
be	O
an	O
important	O
prognostic	O
factor	O
.	O
The	O
authors	O
investigated	O
whether	O
there	O
is	O
a	O
correlation	O
between	O
HER-2	B
/	I
neu	I
expression	O
and	O
immunologic	O
parameters	O
representing	O
tumor	O
defense	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O
METHOD	O
.	O
A	O
Western	O
blot	O
analysis	O
was	O
used	O
to	O
investigate	O
HER-2	B
/	I
neu	I
expression	O
,	O
whereas	O
a	O
chromium	O
-	O
release	O
assay	O
using	O
the	O
K562	O
cell	O
line	O
as	O
target	O
was	O
used	O
to	O
measure	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
activity	O
.	O
RESULTS	O
.	O
In	O
patients	O
with	O
breast	O
cancer	O
,	O
NK	O
cell	O
activity	O
was	O
significantly	O
higher	O
compared	O
with	O
patients	O
with	O
benign	O
tumors	O
(	O
P	O
=	O
0.006	O
)	O
or	O
healthy	O
control	O
subjects	O
(	O
P	O
=	O
0.002	O
)	O
.	O
Moreover	O
,	O
23.3	O
%	O
of	O
patients	O
with	O
breast	O
cancer	O
showed	O
an	O
overexpression	O
of	O
HER-2	B
/	I
neu	I
protein	I
.	O
Within	O
this	O
group	O
of	O
patients	O
,	O
NK	O
cell	O
activity	O
was	O
significantly	O
lower	O
(	O
45.6	O
+	O
/-	O
16.1	O
%	O
)	O
compared	O
with	O
the	O
group	O
with	O
no	O
HER-2	B
/	I
neu	I
overexpression	O
(	O
57.3	O
+	O
/-	O
11.0	O
%	O
)	O
.	O
NK	O
cell	O
activity	O
did	O
not	O
increase	O
in	O
patients	O
with	O
HER-2	B
/	I
neu	I
overexpression	O
.	O
Thus	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
correlation	O
of	O
cytolytic	O
effector	O
cell	O
function	O
with	O
HER-2	B
/	I
neu	I
expression	O
of	O
the	O
tumor	O
(	O
P	O
=	O
0.003	O
)	O
,	O
and	O
HER-2	B
/	I
neu	I
overexpression	O
correlated	O
with	O
a	O
negative	O
estrogen	B
receptor	I
status	O
(	O
P	O
=	O
0.005	O
)	O
.	O
CONCLUSION	O
.	O
These	O
data	O
add	O
further	O
evidence	O
to	O
previous	O
observations	O
from	O
the	O
authors	O
'	O
laboratory	O
that	O
certain	O
tumor	O
characteristics	O
may	O
be	O
associated	O
with	O
reactions	O
of	O
the	O
host	O
with	O
breast	O
cancer	O
.	O
Induction	O
of	O
tyrosine	O
phosphorylation	O
and	O
T	O
-	O
cell	O
activation	O
by	O
vanadate	O
peroxide	O
,	O
an	O
inhibitor	O
of	O
protein	B
tyrosine	I
phosphatases	I
.	O
Rapid	O
tyrosine	O
phosphorylation	O
of	O
key	O
cellular	O
proteins	O
is	O
a	O
crucial	O
event	O
in	O
the	O
transduction	O
of	O
activation	O
signals	O
to	O
T	O
-	O
lymphocytes	O
.	O
The	O
regulatory	O
role	O
of	O
protein	B
tyrosine	I
phosphatases	I
(	O
PTPases	B
)	O
in	O
this	O
process	O
was	O
explored	O
by	O
studying	O
the	O
effects	O
of	O
a	O
powerful	O
PTPase	B
inhibitor	O
,	O
vanadate	O
peroxide	O
(	O
pervanadate	O
)	O
,	O
on	O
the	O
activation	O
cascade	O
of	O
Jurkat	O
human	O
leukaemic	O
T	O
-	O
cells	O
.	O
Pervanadate	O
induced	O
activation	O
of	O
the	O
tyrosine	B
kinases	I
lck	B
and	O
fyn	B
(	O
4-	O
and	O
3-fold	O
respectively	O
)	O
and	O
a	O
dramatic	O
increase	O
in	O
tyrosine	O
phosphorylation	O
of	O
cellular	B
proteins	I
,	O
notably	O
phospholipase	B
C	I
gamma	I
1	I
.	O
After	O
this	O
event	O
,	O
we	O
observed	O
a	O
rise	O
in	O
intracellular	O
Ca2	O
+	O
concentration	O
,	O
corresponding	O
to	O
an	O
influx	O
.	O
This	O
effect	O
required	O
surface	O
expression	O
of	O
the	O
CD45	B
PTPase	I
and	O
was	O
not	O
observed	O
in	O
CD45-deficient	O
variants	O
of	O
Jurkat	O
cells	O
.	O
In	O
the	O
CD45-negative	O
variant	O
,	O
the	O
effect	O
of	O
pervanadate	O
on	O
tyrosine	O
phosphorylation	O
was	O
globally	O
decreased	O
and	O
some	O
phosphorylated	O
substrates	O
were	O
specifically	O
missing	O
.	O
Pervanadate	O
also	O
stimulated	O
transcription	O
of	O
the	O
c	O
-	O
fos	O
gene	O
and	O
accumulation	O
of	O
its	O
mRNA	O
as	O
well	O
as	O
several	O
other	O
hallmarks	O
of	O
T	O
-	O
lymphocyte	O
activation	O
such	O
as	O
surface	O
expression	O
of	O
the	O
CD69	O
antigen	O
and	O
the	O
interleukin	O
2	O
receptor	O
alpha	O
-	O
chain	O
(	O
CD25	O
)	O
.	O
Pervanadate	O
synergized	O
with	O
signals	O
delivered	O
by	O
T	O
-	O
cell	O
antigen	B
receptor	I
engagement	O
or	O
by	O
a	O
phorbol	O
ester	O
to	O
induce	O
interleukin	O
2	O
production	O
.	O
Pervanadate	B
activated	I
NF	I
-	I
kappa	I
B	I
,	O
as	O
shown	O
by	O
an	O
increase	O
in	O
DNA	O
-	O
binding	O
activity	O
of	O
this	O
transcription	B
factor	I
.	O
We	O
thus	O
conclude	O
that	O
PTPases	B
play	O
a	O
crucial	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
signal	O
transduction	O
culminating	O
in	O
T	O
-	O
lymphocyte	O
activation	O
.	O
Moreover	O
,	O
induction	O
of	O
tyrosine	O
phosphorylation	O
appears	O
sufficient	O
per	O
se	O
to	O
initiate	O
a	O
complete	O
activation	O
programme	O
.	O
Steroid	O
-	O
resistant	O
asthma	O
.	O
Cellular	O
mechanisms	O
contributing	O
to	O
inadequate	O
response	O
to	O
glucocorticoid	O
therapy	O
.	O
The	O
current	O
study	O
examined	O
whether	O
alterations	O
in	O
glucocorticoid	B
receptor	I
(	O
GR	B
)	O
binding	O
contribute	O
to	O
poor	O
response	O
to	O
glucocorticoid	O
therapy	O
in	O
asthma	O
.	O
29	O
asthma	O
patients	O
with	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
(	O
FEV1	O
)	O
<	O
70	O
%	O
predicted	O
were	O
studied	O
.	O
Patients	O
were	O
classified	O
as	O
steroid	O
sensitive	O
(	O
SS	O
)	O
if	O
their	O
morning	O
FEV1	O
increased	O
>	O
30	O
%	O
after	O
a	O
1-wk	O
course	O
of	O
oral	O
prednisone	O
20	O
mg	O
twice	O
daily	O
and	O
steroid	O
resistant	O
(	O
SR	O
)	O
if	O
they	O
failed	O
to	O
increase	O
>	O
15	O
%	O
.	O
PBMC	O
obtained	O
from	O
these	O
two	O
groups	O
,	O
17	O
SR	O
and	O
12	O
SS	O
,	O
as	O
well	O
as	O
12	O
normal	O
controls	O
were	O
analyzed	O
.	O
SR	O
patients	O
had	O
two	O
distinguishable	O
GR	B
binding	O
abnormalities	O
:	O
15	O
of	O
the	O
17	O
SR	O
patients	O
demonstrated	O
a	O
significantly	O
reduced	O
GR	B
binding	O
affinity	O
,	O
as	O
compared	O
with	O
SS	O
patients	O
(	O
P	O
=	O
0.0001	O
)	O
and	O
normal	O
controls	O
(	O
P	O
=	O
0.0001	O
)	O
.	O
This	O
defect	O
was	O
localized	O
to	O
T	O
cells	O
and	O
reverted	O
to	O
normal	O
after	O
48	O
h	O
in	O
culture	O
media	O
.	O
However	O
,	O
incubation	O
with	O
a	O
combination	O
of	O
IL-2	B
and	O
IL-4	B
sustained	O
this	O
abnormality	O
.	O
The	O
other	O
two	O
SR	O
patients	O
had	O
an	O
abnormally	O
low	O
GR	B
number	O
with	O
normal	O
binding	O
affinity	O
that	O
was	O
not	O
limited	O
to	O
T	O
cells	O
.	O
Furthermore	O
,	O
GR	B
number	O
failed	O
to	O
normalize	O
after	O
incubation	O
in	O
media	O
alone	O
or	O
IL-2	B
and	O
IL-4	B
.	O
Therefore	O
,	O
SR	O
asthma	O
may	O
be	O
due	O
to	O
more	O
than	O
one	O
abnormality	O
,	O
the	O
majority	O
related	O
to	O
a	O
reversible	O
cytokine	B
-induced	O
reduction	O
in	O
GR	B
binding	O
affinity	O
and	O
the	O
second	O
related	O
to	O
an	O
irreversible	O
reduction	O
in	O
GR	B
number	O
.	O
These	O
findings	O
may	O
have	O
important	O
implications	O
for	O
the	O
design	O
of	O
alternative	O
treatment	O
approaches	O
for	O
recalcitrant	O
asthma	O
.	O
Increased	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
gene	O
expression	O
after	O
stimulation	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
through	O
a	O
surface	O
ganglioside	O
(	O
GD3	O
)	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Immunol	O
1994	O
Jul	O
15	O
;	O
153	O
(	O
2	O
)	O
:	O
910	O
]	O
Previous	O
studies	O
have	O
suggested	O
that	O
gangliosides	O
have	O
an	O
important	O
role	O
in	O
cell	O
signaling	O
and	O
recognition	O
.	O
However	O
,	O
their	O
specific	O
function	O
in	O
these	O
processes	O
has	O
not	O
been	O
clearly	O
defined	O
.	O
A	O
mAb	B
,	O
R24	B
,	O
that	O
reacts	O
specifically	O
with	O
a	O
cell	O
surface	O
ganglioside	O
(	O
GD3	O
)	O
has	O
been	O
demonstrated	O
to	O
stimulate	O
proliferation	O
of	O
T	O
cells	O
derived	O
from	O
human	O
peripheral	O
blood	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
mechanisms	O
by	O
which	O
the	O
R24	B
mAb	I
affects	O
T	O
cell	O
functions	O
.	O
We	O
have	O
observed	O
that	O
the	O
R24	B
mAb	I
stimulates	O
GD3	O
+	O
T	O
cell	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
surface	O
marker	O
expression	O
of	O
IL-2R	B
alpha	I
-	I
chain	I
,	O
IL-2R	B
beta	I
-	I
chain	I
,	O
HLA	B
-	I
DR	I
,	O
CD11a	B
,	O
and	O
CD11c	B
.	O
Additionally	O
,	O
IFN	B
-	I
gamma	I
activity	O
but	O
not	O
IL-1	O
,	O
IL-2	O
,	O
or	O
IL-4	O
activity	O
was	O
present	O
in	O
culture	O
supernatants	O
72	O
h	O
after	O
R24	B
stimulation	O
.	O
In	O
some	O
donors	O
,	O
increased	O
IL-6	B
and	O
TNF	B
-	I
alpha	I
activity	O
also	O
was	O
detected	O
after	O
R24	B
treatment	O
.	O
Furthermore	O
,	O
R24	B
treatment	O
resulted	O
in	O
translocation	O
of	O
c	B
-	I
rel	I
,	O
but	O
little	O
or	O
no	O
NF	B
kappa	I
B	I
p50	I
or	O
p65	B
,	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
and	O
an	O
increase	O
of	O
NF	B
kappa	I
B	I
binding	I
complexes	I
containing	O
c	B
-	I
rel	I
and	O
p50	B
.	O
This	O
treatment	O
also	O
caused	O
increased	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	O
substrates	O
.	O
R24	B
-stimulated	O
increases	O
in	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
cell	O
surface	O
protein	O
expression	O
could	O
be	O
blocked	O
by	O
cyclosporin	O
and	O
staurosporin	O
,	O
indicating	O
that	O
cyclophilin	B
/	I
calcineurin	I
and	O
protein	B
kinase	I
C	I
may	O
be	O
involved	O
in	O
the	O
R24	B
signaling	O
pathway	O
.	O
Additionally	O
,	O
herbimycin	O
A	O
,	O
a	O
tyrosine	B
kinase	I
inhibitor	O
,	O
blocked	O
the	O
R24	B
-stimulated	O
increase	O
in	O
proliferation	O
but	O
not	O
cytotoxicity	O
at	O
concentrations	O
consistent	O
with	O
specificity	O
for	O
tyrosine	B
kinases	I
.	O
These	O
results	O
suggest	O
that	O
multiple	O
biochemical	O
pathways	O
are	O
involved	O
in	O
the	O
activation	O
of	O
human	O
T	O
cells	O
by	O
R24	B
.	O
Regulation	O
of	O
the	O
BZLF1	O
promoter	O
of	O
Epstein	O
-	O
Barr	O
virus	O
by	O
second	O
messengers	O
in	O
anti	O
-	O
immunoglobulin	O
-	O
treated	O
B	O
cells	O
.	O
Initiation	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
lytic	O
cycle	O
is	O
dependent	O
on	O
the	O
transcription	O
of	O
the	O
BZLF1	O
gene	O
.	O
The	O
BZLF1	O
gene	O
promoter	O
(	O
Zp	O
)	O
was	O
activated	O
by	O
crosslinking	O
of	O
cell	B
surface	I
immunoglobulin	I
(	O
Ig	B
)	O
with	O
anti	B
-	I
Ig	I
antibody	I
in	O
B	O
cells	O
,	O
even	O
in	O
the	O
absence	O
of	O
other	O
viral	O
genes	O
.	O
We	O
identified	O
several	O
anti	O
-	O
Ig	O
response	O
elements	O
within	O
Zp	O
,	O
which	O
were	O
originally	O
defined	O
as	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
response	O
elements	O
(	O
ZI	O
repeats	O
and	O
ZII	O
,	O
an	O
AP-1-like	O
domain	O
)	O
.	O
Since	O
anti	O
-	O
Ig	O
crosslinking	O
leads	O
to	O
activation	O
of	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
and	O
an	O
increase	O
in	O
intracellular	O
calcium	O
level	O
,	O
Zp	O
was	O
tested	O
for	O
the	O
response	O
to	O
these	O
cellular	B
factors	I
.	O
Treatment	O
with	O
calcium	O
ionophore	O
A23187	O
increased	O
Zp	O
activity	O
.	O
When	O
the	O
calcium	O
ionophore	O
was	O
used	O
in	O
conjunction	O
with	O
TPA	O
,	O
a	O
PKC	B
activator	O
,	O
the	O
Zp	O
induction	O
was	O
synergistically	O
enhanced	O
.	O
1-	O
(	O
5-Isoquinolinyl	O
sulfonyl	O
)	O
-2-methylpiperazine	O
,	O
an	O
inhibitor	O
of	O
PKC	B
,	O
inhibited	O
the	O
anti	B
-	I
Ig	I
inducibility	O
of	O
Zp	O
.	O
Calmodulin	O
antagonists	O
,	O
compound	O
R24571	O
and	O
trifluoperazine	O
,	O
blocked	O
the	O
Zp	O
activation	O
with	O
anti	B
-	I
Ig	I
.	O
These	O
findings	O
suggest	O
that	O
Zp	O
responds	O
directly	O
to	O
changes	O
in	O
the	O
activity	O
of	O
both	O
PKC	B
and	O
calcium	B
/	I
calmodulin	I
-	I
dependent	I
protein	I
kinase	I
.	O
Requirement	O
of	O
tyrosine	B
kinase	I
activation	O
for	O
the	O
anti	B
-	I
Ig	I
-mediated	O
Zp	O
activation	O
was	O
also	O
demonstrated	O
through	O
the	O
use	O
of	O
the	O
tyrosine	O
kinase	O
inhibitor	O
herbimycin	O
.	O
These	O
cellular	B
gene	I
regulatory	I
molecules	I
induced	O
with	O
anti	O
-	O
Ig	O
may	O
cooperatively	O
play	O
an	O
important	O
part	O
in	O
achieving	O
efficient	O
EBV	O
activation	O
as	O
seen	O
with	O
anti	B
-	I
Ig	I
treatment	O
in	O
B	O
cells	O
.	O
Retinoic	O
acid	O
downmodulates	O
erythroid	O
differentiation	O
and	O
GATA1	B
expression	O
in	O
purified	O
adult	O
-	O
progenitor	O
culture	O
.	O
All	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
is	O
an	O
important	O
morphogen	O
in	O
vertebrate	O
development	O
,	O
a	O
normal	O
constituent	O
in	O
human	O
adult	O
blood	O
and	O
is	O
also	O
involved	O
in	O
the	O
control	O
of	O
cell	O
growth	O
and	O
differentiation	O
in	O
acute	O
promyelocytic	O
leukemia	O
.	O
We	O
have	O
examined	O
the	O
effects	O
of	O
RA	O
on	O
normal	O
hematopoiesis	O
by	O
using	O
early	O
hematopoietic	O
progenitor	O
cells	O
(	O
HPC	O
)	O
stringently	O
purified	O
from	O
adult	O
peripheral	O
blood	O
.	O
In	O
clonogenetic	O
fetal	O
calf	O
serum	O
-	O
supplemented	O
(	O
FCS+	O
)	O
or	O
-nonsupplemented	O
(	O
FCS-	O
)	O
culture	O
treated	O
with	O
saturating	O
levels	O
of	O
interleukin-3	B
(	O
IL-3	B
)	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
and	O
erythropoietin	B
(	O
Ep	B
)	O
(	O
combined	O
with	O
c	B
-	I
kit	I
ligand	O
in	O
FCS	O
(	O
-	O
)	O
-culture	O
conditions	O
)	O
,	O
RA	O
induces	O
a	O
dramatic	O
dose	O
-	O
dependent	O
shift	O
from	O
erythroid	O
to	O
granulomonocytic	O
colony	O
formation	O
,	O
the	O
latter	O
colonies	O
being	O
essentially	O
represented	O
by	O
granulocytic	O
clones	O
.	O
This	O
shift	O
is	O
apparently	O
not	O
caused	O
by	O
a	O
recruitment	O
phenomenon	O
,	O
because	O
in	O
FCS+	O
culture	O
,	O
the	O
total	O
number	O
of	O
colonies	O
is	O
not	O
significantly	O
modified	O
by	O
RA	O
addition	O
.	O
In	O
FCS-	O
liquid	O
-	O
suspension	O
culture	O
supplemented	O
with	O
saturating	O
Ep	B
level	O
and	O
low	B
-	I
dose	I
IL-3	I
/	I
GM	I
-	I
CSF	I
,	O
adult	O
HPC	O
undergo	O
unilineage	O
erythropoietic	O
differentiation	O
:	O
Here	O
again	O
,	O
treatment	O
with	O
high	O
-	O
dose	O
RA	O
induces	O
a	O
shift	O
from	O
the	O
erythroid	O
to	O
granulocytic	O
differentiation	O
pathway	O
.	O
Studies	O
on	O
RA	O
time	O
-	O
response	O
or	O
pulse	O
treatment	O
in	O
semisolid	O
or	O
liquid	O
culture	O
show	O
that	O
early	O
RA	O
addition	O
is	O
most	O
effective	O
,	O
thus	O
indicating	O
that	O
early	O
but	O
not	O
late	O
HPC	O
are	O
sensitive	O
to	O
its	O
action	O
.	O
We	O
then	O
analyzed	O
the	O
expression	O
of	O
the	O
master	O
GATA1	O
gene	O
,	O
which	O
encodes	O
a	O
finger	B
transcription	I
factor	I
required	O
for	O
normal	O
erythroid	O
development	O
;	O
addition	O
of	O
RA	O
to	O
HPC	O
stimulated	O
into	O
unilineage	O
erythropoietic	O
differentiation	O
in	O
liquid	O
culture	O
caused	O
a	O
virtually	O
complete	O
inhibition	O
of	O
GATA1	O
mRNA	O
induction	O
.	O
These	O
results	O
indicate	O
that	O
RA	O
directly	O
inhibits	O
the	O
erythroid	O
differentiation	O
program	O
at	O
the	O
level	O
of	O
early	O
adult	O
HPC	O
,	O
and	O
may	O
lead	O
to	O
a	O
shift	O
from	O
the	O
erythroid	O
to	O
granulocytic	O
differentiation	O
pathway	O
.	O
This	O
phenomenon	O
is	O
correlated	O
with	O
inhibition	O
of	O
GATA1	B
induction	O
in	O
the	O
early	O
stages	O
of	O
erythropoietic	O
differentiation	O
.	O
Human	O
interferon	O
regulatory	O
factor	O
2	O
gene	O
.	O
Intron	O
-	O
exon	O
organization	O
and	O
functional	O
analysis	O
of	O
5'-flanking	O
region	O
.	O
Interferon	B
regulatory	I
factor	I
2	I
(	O
IRF-2	B
)	O
is	O
a	O
transcriptional	B
regulatory	I
protein	I
that	O
terminates	O
interferon	B
beta	I
expression	O
initiated	O
by	O
interferon	B
regulatory	I
factor	I
1	I
.	O
In	O
this	O
study	O
,	O
we	O
isolated	O
the	O
genomic	O
DNA	O
for	O
human	O
IRF-2	O
gene	O
,	O
determined	O
the	O
intron	O
-	O
exon	O
structure	O
of	O
the	O
human	O
IRF-2	O
gene	O
,	O
mapped	O
the	O
major	O
transcription	O
initiation	O
site	O
,	O
identified	O
a	O
number	O
of	O
potential	O
regulatory	O
elements	O
in	O
the	O
5'-flanking	O
region	O
,	O
and	O
localized	O
the	O
IRF-2	O
gene	O
on	O
human	O
chromosome	O
4	O
.	O
The	O
IRF-2	B
promoter	O
region	O
contains	O
a	O
CpG	O
island	O
,	O
with	O
several	O
GC	O
boxes	O
,	O
a	O
putative	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
site	O
,	O
and	O
a	O
CAAT	O
box	O
,	O
but	O
no	O
TATA	O
box	O
.	O
When	O
the	O
promoter	O
region	O
was	O
linked	O
with	O
a	O
heterologous	O
reporter	O
gene	O
,	O
we	O
found	O
that	O
the	O
promoter	O
region	O
is	O
inducible	O
by	O
both	O
interferons	B
(	O
interferon	B
-	I
alpha	I
and	I
-gamma	I
)	O
and	O
interferon	B
regulatory	I
factor	I
1	I
.	O
The	O
region	O
which	O
induced	O
these	O
inductions	O
was	O
identified	O
as	O
being	O
confined	O
to	O
40	O
nucleotides	O
5	O
'	O
to	O
the	O
major	O
transcriptional	O
initiation	O
site	O
by	O
testing	O
a	O
series	O
of	O
clones	O
with	O
truncated	O
promoter	O
of	O
IRF-2	B
.	O
This	O
region	O
contains	O
elements	O
which	O
are	O
shared	O
with	O
the	O
transcriptional	O
enhancers	O
of	O
other	O
genes	O
including	O
interferon	B
regulatory	I
factor	I
1	I
,	O
interferon	B
beta	I
,	O
and	O
interferon	O
-	O
inducible	O
genes	O
.	O
These	O
data	O
suggest	O
that	O
interferon	B
regulatory	I
factor	I
1	I
not	O
only	O
triggers	O
the	O
activation	O
of	O
the	O
interferon	B
signal	O
transduction	O
pathway	O
,	O
but	O
also	O
may	O
play	O
a	O
role	O
in	O
limiting	O
the	O
duration	O
of	O
this	O
response	O
by	O
activating	O
the	O
transcription	O
of	O
IRF-2	B
.	O
rel	B
Is	O
rapidly	O
tyrosine	O
-	O
phosphorylated	O
following	O
granulocyte	B
-	I
colony	I
stimulating	I
factor	I
treatment	O
of	O
human	O
neutrophils	O
.	O
Stimulation	O
of	O
neutrophils	O
with	O
granulocyte	B
-	I
colony	I
stimulating	I
factor	I
(	O
G	B
-	I
CSF	I
)	O
results	O
in	O
an	O
enhanced	O
respiratory	O
burst	O
,	O
prolonged	O
survival	O
,	O
and	O
increased	O
tumor	O
cell	O
killing	O
.	O
The	O
effects	O
of	O
G	B
-	I
CSF	I
are	O
mediated	O
by	O
binding	O
to	O
specific	O
,	O
high	O
affinity	B
receptors	I
.	O
G	B
-	I
CSF	I
receptors	I
lack	O
intrinsic	O
tyrosine	B
kinase	I
activity	O
,	O
but	O
activation	O
of	O
the	O
receptor	O
results	O
in	O
the	O
rapid	O
induction	O
of	O
tyrosine	O
kinase	O
activity	O
.	O
Antiphosphotyrosine	O
immunoblots	O
of	O
whole	O
cell	O
lysates	O
prepared	O
from	O
neutrophils	O
show	O
that	O
the	O
G	B
-	I
CSF	I
rapidly	O
induces	O
prominent	O
tyrosine	O
phosphorylation	O
of	O
a	O
protein	O
of	O
a	O
relative	O
molecular	O
mass	O
of	O
80	O
kDa	O
.	O
Using	O
monospecific	B
antibodies	I
,	O
the	O
80-kDa	O
tyrosine	B
-	I
phosphorylated	I
protein	I
has	O
been	O
shown	O
to	O
be	O
p80c	B
-	I
rel	I
,	O
a	O
proto	O
-	O
oncogene	O
belonging	O
to	O
a	O
family	O
of	O
transcriptional	B
regulators	I
which	O
include	O
NF	B
-	I
kB	I
.	O
The	O
induction	O
of	O
tyrosine	O
phosphorylation	O
of	O
p80c	B
-	I
rel	I
was	O
unique	O
to	O
G	B
-	I
CSF	I
in	O
that	O
granulocyte	B
-	I
macrophage	I
colony	I
stimulating	I
factor	I
which	O
also	O
stimulates	O
neutrophils	O
and	O
induces	O
tyrosine	O
phosphorylation	O
does	O
not	O
result	O
in	O
tyrosine	O
phosphorylation	O
of	O
p80c	B
-	I
rel	I
.	O
The	O
consequences	O
of	O
p80c	B
-	I
rel	I
tyrosine	O
phosphorylation	O
are	O
not	O
yet	O
known	O
;	O
however	O
,	O
tyrosine	O
-	O
phosphorylated	O
p80c	B
-	I
rel	I
is	O
capable	O
of	O
binding	O
to	O
DNA	O
,	O
and	O
G	B
-	I
CSF	I
stimulation	O
results	O
in	O
an	O
increase	O
in	O
the	O
amount	O
of	O
p80c	B
-	I
rel	I
which	O
binds	O
to	O
DNA	O
.	O
These	O
results	O
demonstrate	O
that	O
one	O
of	O
the	O
first	O
biochemical	O
events	O
which	O
occurs	O
in	O
neutrophils	O
following	O
G	B
-	I
CSF	I
stimulation	O
,	O
activation	O
of	O
a	O
tyrosine	B
kinase	I
,	O
leads	O
directly	O
to	O
the	O
tyrosine	O
phosphorylation	O
of	O
p80c	B
-	I
rel	I
.	O
Thus	O
,	O
the	O
tyrosine	B
kinase	I
activated	O
by	O
G	B
-	I
CSF	I
appears	O
to	O
directly	O
transduce	O
a	O
signal	O
to	O
a	O
protein	O
which	O
functions	O
as	O
a	O
transcriptional	B
regulator	I
.	O
Overproduction	O
of	O
NFKB2	B
(	O
lyt-10	B
)	O
and	O
c	B
-	I
Rel	I
:	O
a	O
mechanism	O
for	O
HTLV	B
-	I
I	I
Tax	I
-mediated	O
trans	O
-	O
activation	O
via	O
the	O
NF	B
-	I
kappa	I
B	I
signalling	O
pathway	O
.	O
Molecular	O
,	O
biochemical	O
and	O
epidemiological	O
evidence	O
implicate	O
HTLV	O
-	O
I	O
as	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O
The	O
Tax	B
protein	I
of	O
HTLV	O
-	O
I	O
,	O
a	O
positive	B
transcriptional	I
activator	I
of	O
HTLV	O
-	O
I	O
gene	O
expression	O
,	O
is	O
a	O
viral	O
oncogene	O
that	O
also	O
increases	O
transcription	O
of	O
cellular	O
genes	O
including	O
GM	B
-	I
CSF	I
,	O
IL-2R	B
alpha	I
and	O
IL-2	B
.	O
One	O
of	O
the	O
cellular	O
targets	O
of	O
the	O
trans	O
-	O
activating	O
effects	O
of	O
Tax	O
is	O
the	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
family	I
of	O
transcription	B
factors	I
,	O
pleiotropic	B
regulators	I
of	O
immunoregulatory	O
,	O
cytokine	O
and	O
viral	O
gene	O
expression	O
.	O
In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
NFKB2	B
(	O
lyt-10	B
)	O
and	O
c	B
-	I
Rel	I
are	O
overexpressed	O
in	O
HTLV	O
-	O
I	O
infected	O
and	O
Tax	O
-	O
expressing	O
cells	O
and	O
,	O
together	O
,	O
account	O
for	O
the	O
majority	O
of	O
the	O
constitutive	O
NF	B
-	I
kappa	I
B	I
binding	O
activity	O
in	O
these	O
cells	O
before	O
and	O
after	O
PMA	O
stimulation	O
.	O
Most	O
importantly	O
,	O
we	O
show	O
a	O
Tax	B
-dependent	O
correlation	O
between	O
expression	O
of	O
NFKB2	B
(	O
p100	B
)	O
and	O
processing	O
to	O
the	O
DNA	O
binding	O
NFKB2	B
(	O
p52	B
)	O
form	O
,	O
induction	O
of	O
c	B
-	I
Rel	I
,	O
and	O
trans	O
-	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
-mediated	O
gene	O
expression	O
.	O
Furthermore	O
,	O
the	O
NFKB2	B
precursor	O
is	O
physically	O
associated	O
with	O
c	B
-	I
Rel	I
and	O
with	O
Tax	B
in	O
HTLV	O
-	O
I	O
infected	O
cells	O
.	O
We	O
propose	O
that	O
NFKB2	B
synthesis	O
and	O
processing	O
allows	O
continuous	O
nuclear	O
expression	O
of	O
an	O
otherwise	O
cytoplasmic	B
protein	I
and	O
,	O
in	O
conjunction	O
with	O
overexpression	O
of	O
c	B
-	I
Rel	I
,	O
NFKB2	B
alters	O
the	O
NF	B
-	I
kappa	I
B	I
signalling	O
pathway	O
and	O
contributes	O
to	O
leukemic	O
transformation	O
of	O
T	O
cells	O
by	O
HTLV	O
-	O
I	O
.	O
Autoregulation	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
transactivator	I
RelA	B
(	O
p65	B
)	O
by	O
multiple	O
cytoplasmic	B
inhibitors	I
containing	O
ankyrin	B
motifs	I
.	O
RelA	B
(	O
p65	B
)	O
functions	O
as	O
the	O
critical	O
transactivating	O
component	O
of	O
the	O
heterodimeric	B
p50-p65	I
NF	I
-	I
kappa	I
B	I
complex	I
and	O
contains	O
a	O
high	B
-	I
affinity	I
binding	I
site	I
for	O
its	O
cytoplasmic	B
inhibitor	I
,	O
I	B
kappa	I
B	I
alpha	I
.	O
After	O
cellular	O
activation	O
,	O
I	B
kappa	I
B	I
alpha	I
is	O
rapidly	O
degraded	O
in	O
concert	O
with	O
the	O
induced	O
nuclear	O
translocation	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
The	O
present	O
study	O
demonstrates	O
that	O
tumor	B
necrosis	I
factor	I
alpha	I
-induced	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
in	O
human	O
T	O
cells	O
is	O
preceded	O
by	O
its	O
rapid	O
phosphorylation	O
in	O
vivo	O
.	O
However	O
,	O
these	O
effects	O
on	O
I	B
kappa	I
B	I
alpha	I
result	O
in	O
nuclear	O
mobilization	O
of	O
only	O
a	O
fraction	O
of	O
the	O
entire	O
cytoplasmic	O
pool	O
of	O
RelA	B
.	O
Subsequent	O
studies	O
have	O
revealed	O
that	O
(	O
i	O
)	O
cytoplasmic	B
RelA	I
is	O
stably	O
associated	O
not	O
only	O
with	O
I	B
kappa	I
B	I
alpha	I
but	O
also	O
with	O
other	O
ankyrin	B
motif	I
-	I
rich	I
proteins	I
including	O
the	O
products	O
of	O
the	O
NF	O
-	O
kappa	O
B2	O
(	O
p100	O
)	O
and	O
NF	O
-	O
kappa	O
B1	O
(	O
p105	O
)	O
genes	O
;	O
(	O
ii	O
)	O
in	O
contrast	O
to	O
RelA	B
-I	B
kappa	I
B	I
alpha	I
,	O
RelA	B
-	I
p100	I
cytoplasmic	I
complexes	I
are	O
not	O
dissociated	O
following	O
tumor	B
necrosis	I
factor	I
alpha	I
activation	O
;	O
(	O
iii	O
)	O
p100	B
functions	O
as	O
a	O
potent	O
inhibitor	O
of	O
RelA	B
-mediated	O
transcription	O
in	O
vivo	O
;	O
(	O
iv	O
)	O
the	O
interaction	O
of	O
RelA	B
and	O
p100	B
involves	O
the	O
conserved	B
Rel	I
homology	I
domain	I
of	O
both	O
proteins	O
but	O
not	O
the	O
nuclear	B
localization	I
signal	I
of	O
RelA	B
,	O
which	O
is	O
required	O
for	O
I	B
kappa	I
B	I
alpha	I
binding	O
;	O
(	O
v	O
)	O
p100	B
inhibition	O
of	O
RelA	B
function	O
requires	O
the	O
C	B
-	I
terminal	I
ankyrin	I
motif	I
domain	I
,	O
which	O
mediates	O
cytoplasmic	O
retention	O
of	O
RelA	B
;	O
and	O
(	O
vi	O
)	O
as	O
observed	O
with	O
I	B
kappa	I
B	I
alpha	I
,	O
nuclear	O
RelA	B
stimulates	O
p100	O
mRNA	O
and	O
protein	O
expression	O
.	O
These	O
findings	O
thus	O
reveal	O
the	O
presence	O
of	O
a	O
second	O
inducible	O
autoregulated	O
inhibitory	O
pathway	O
that	O
helps	O
ensure	O
the	O
rapid	O
but	O
transient	O
action	O
of	O
nuclear	B
NF	I
-	I
kappa	I
B	I
.	O
Calcineurin	B
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
inactivate	O
I	B
kappa	I
B	I
/	I
MAD3	I
,	O
an	O
inhibitor	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
The	O
interleukin-2	O
(	O
IL-2	O
)	O
promoter	O
consists	O
of	O
several	O
independent	O
T	O
cell	O
receptor	O
(	O
TcR	O
)	O
responsive	O
elements	O
.	O
The	O
induction	O
of	O
promoters	O
dependent	O
on	O
these	O
elements	O
is	O
inhibitable	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
tacrolimus	O
(	O
FK-506	O
)	O
.	O
Calcineurin	B
,	O
a	O
Ca2+	B
/	I
calmodulin	I
-	I
dependent	I
protein	I
phosphatase	I
,	O
is	O
the	O
FK-506	O
-and	O
CsA	O
-	O
sensitive	O
enzyme	O
required	O
for	O
TcR	O
mediated	O
activation	O
of	O
the	O
IL-2	O
promoter	O
.	O
We	O
report	O
that	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	B
partially	O
substitutes	O
for	O
the	O
Ca2	O
+	O
co	O
-	O
stimulus	O
required	O
to	O
activate	O
the	O
IL-2	O
promoter	O
elements	O
IL-2A	O
(	O
which	O
binds	O
the	O
factors	O
OAP	B
and	O
Oct-1	B
)	O
and	O
IL-2E	O
(	O
which	O
binds	O
NF	B
-	I
AT	I
)	O
,	O
and	O
completely	O
substitutes	O
for	O
the	O
Ca2	O
+	O
co	O
-	O
stimulus	O
required	O
to	O
stimulate	O
an	O
NF	B
-	I
kappa	I
B	I
-dependent	O
element	O
.	O
Calcineurin	B
stimulates	O
the	O
NF	O
-	O
kappa	O
B	O
element	O
by	O
enhancing	O
inactivation	O
of	O
I	B
kappa	I
B	I
/	I
MAD3	I
,	O
an	O
inhibitor	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
thereby	O
increasing	O
the	O
amount	O
of	O
nuclear	O
NF	B
-	I
kappa	I
B	I
DNA	O
binding	O
activity	O
.	O
These	O
data	O
provide	O
the	O
first	O
demonstration	O
in	O
vivo	O
that	O
activation	O
of	O
a	O
protein	B
phosphatase	I
can	O
inactivate	O
I	B
kappa	I
B	I
,	O
and	O
suggest	O
one	O
possible	O
explanation	O
for	O
mechanism	O
-	O
based	O
toxicities	O
associated	O
with	O
FK-506	O
and	O
CsA	O
by	O
demonstrating	O
that	O
these	O
drugs	O
can	O
inhibit	O
the	O
calcineurin	B
-dependent	O
activation	O
of	O
a	O
virtually	O
ubiquitous	B
transcription	I
factor	I
.	O
Direct	O
exposure	O
to	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
(	O
TCDD	O
)	O
increases	O
infectivity	O
of	O
human	O
erythrocytes	O
to	O
a	O
malarial	O
parasite	O
.	O
Direct	O
exposure	O
to	O
10	O
nM	O
2	O
,	O
3	O
,	O
7	O
,	O
8-TCDD	O
caused	O
a	O
75	O
%	O
increase	O
and	O
a	O
2-fold	O
increase	O
in	O
the	O
infectivity	O
of	O
isolated	O
human	O
erythrocytes	O
to	O
P.	O
falciparum	O
after	O
48	O
hours	O
when	O
the	O
parasites	O
were	O
in	O
an	O
unsynchronized	O
or	O
synchronized	O
state	O
of	O
growth	O
,	O
respectively	O
.	O
Treatment	O
of	O
human	O
erythrocytes	O
with	O
10	O
microM	O
sodium	O
orthovanadate	O
(	O
NaOV	O
)	O
,	O
an	O
inhibitor	O
of	O
plasma	B
membrane	I
Ca	I
-	I
ATPase	I
and	O
phosphotyrosine	B
phosphatase	I
,	O
decreased	O
parasitemia	O
by	O
30	O
%	O
.	O
Co	O
-	O
treatment	O
of	O
RBCs	O
with	O
TCDD	O
and	O
NaOV	O
completely	O
blocked	O
the	O
TCDD	O
-	O
induced	O
increase	O
in	O
parasitemia	O
.	O
Because	O
erythrocytes	O
are	O
anucleated	O
,	O
these	O
results	O
are	O
discussed	O
as	O
evidence	O
for	O
biochemical	O
changes	O
by	O
TCDD	O
without	O
requiring	O
the	O
activation	O
of	O
gene	B
products	I
.	O
trans	O
-	O
activation	O
of	O
the	O
HIV	O
promoter	O
by	O
a	O
cDNA	O
and	O
its	O
genomic	O
clones	O
of	O
human	O
herpesvirus-6	O
.	O
Human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
is	O
a	O
lymphotropic	O
herpesvirus	O
,	O
and	O
in	O
vitro	O
,	O
it	O
can	O
productively	O
infect	O
human	O
CD4	O
+	O
T	O
cells	O
as	O
HIV-1	O
.	O
Co	O
-	O
infection	O
of	O
T	O
cells	O
by	O
HIV-1	O
and	O
HHV-6	O
can	O
lead	O
to	O
both	O
activation	O
of	O
the	O
HIV-1	O
promoter	O
and	O
acceleration	O
of	O
the	O
cytopathic	O
effects	O
.	O
An	O
HHV-6	O
(	O
GS	O
)	O
cDNA	O
clone	O
,	O
pCD41	O
,	O
encoding	O
for	O
a	O
41-kDa	B
nuclear	I
protein	I
was	O
identified	O
and	O
characterized	O
previously	O
(	O
Chang	O
and	O
Balachandran	O
,	O
J.	O
Virol	O
.	O
65	O
,	O
2884	O
-	O
2894	O
and	O
7085	O
,	O
1991	O
)	O
.	O
Sequence	O
analyses	O
show	O
that	O
this	O
protein	O
has	O
significant	O
homology	O
with	O
the	O
human	O
cytomegalovirus	O
UL44	O
gene	O
coding	O
for	O
the	O
ICP36	B
family	I
of	O
early	B
-	I
late	I
-	I
class	I
phosphoprotein	I
.	O
Using	O
this	O
cDNA	O
as	O
the	O
probe	O
,	O
a	O
3.8-kb	O
EcoRI	O
genomic	O
fragment	O
encoding	O
the	O
HHV-6	B
(	I
GS	I
)	I
P41	I
was	O
cloned	O
and	O
designated	O
as	O
pGD41	O
.	O
When	O
cotransfected	O
with	O
the	O
HIV	O
LTR	O
CAT	O
into	O
CV-1	O
cells	O
,	O
both	O
the	O
pCD41	O
and	O
pGD41	O
clones	O
trans	O
-	O
activated	O
the	O
HIV	O
LTR	O
.	O
Sequence	O
analyses	O
of	O
pCD41	O
indicate	O
that	O
there	O
are	O
two	O
potential	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
,	O
A	O
and	O
B	O
,	O
which	O
are	O
homologous	O
to	O
the	O
ORFs	O
found	O
in	O
the	O
genomic	O
clone	O
pGD41	O
.	O
Deletion	O
constructs	O
of	O
the	O
pCD41	O
clone	O
demonstrated	O
that	O
ORF	B
-	I
A	I
was	O
critical	O
for	O
the	O
HIV	O
LTR	O
activation	O
.	O
Deletion	O
analyses	O
of	O
the	O
pCD41	O
ORF	B
-	I
A	I
and	O
the	O
use	O
of	O
promoter	O
constructs	O
further	O
mapped	O
an	O
internal	O
functional	O
promoter	O
within	O
the	O
pCD41	O
sequence	O
that	O
can	O
direct	O
the	O
synthesis	O
of	O
the	O
trans	B
-	I
activating	I
protein	I
.	O
By	O
using	O
HIV	O
LTR	O
deletion	O
mutants	O
,	O
the	O
NF	B
-	I
kappa	I
B	I
binding	O
sites	O
were	O
found	O
to	O
be	O
critical	O
for	O
response	O
to	O
the	O
pCD41	O
trans	O
-	O
activation	O
.	O
Isolation	O
and	O
characterization	O
of	O
gelatinase	O
granules	O
from	O
human	O
neutrophils	O
.	O
We	O
recently	O
confirmed	O
the	O
existence	O
of	O
gelatinase	O
granules	O
as	O
a	O
subpopulation	O
of	O
peroxidase	O
-	O
negative	O
granules	O
by	O
double	O
-	O
labeling	O
immunogold	O
electron	O
microscopy	O
on	O
intact	O
cells	O
and	O
by	O
subcellular	O
fractionation	O
.	O
Further	O
characterization	O
of	O
gelatinase	O
granules	O
has	O
been	O
hampered	O
by	O
poor	O
separation	O
of	O
specific	O
and	O
gelatinase	O
granules	O
on	O
both	O
two	O
-	O
layer	O
Percoll	O
gradients	O
and	O
sucrose	O
gradients	O
.	O
We	O
have	O
developed	O
a	O
three	O
-	O
layer	O
Percoll	O
density	O
gradient	O
that	O
allows	O
separation	O
of	O
the	O
different	O
granules	O
and	O
vesicles	O
from	O
human	O
neutrophils	O
;	O
in	O
particular	O
,	O
it	O
allows	O
separation	O
of	O
specific	O
and	O
gelatinase	O
granules	O
.	O
This	O
allows	O
us	O
to	O
characterize	O
these	O
two	O
granule	O
populations	O
with	O
regard	O
to	O
their	O
content	O
of	O
membrane	B
proteins	I
,	O
which	O
become	O
incorporated	O
into	O
the	O
plasma	O
membrane	O
during	O
exocytosis	O
.	O
We	O
found	O
that	O
gelatinase	O
granules	O
,	O
defined	O
as	O
peroxidase	O
-	O
negative	O
granules	O
containing	O
gelatinase	B
but	O
lacking	O
lactoferrin	B
,	O
contain	O
50	O
%	O
of	O
total	O
cell	O
gelatinase	B
,	O
with	O
the	O
remaining	O
residing	O
in	O
specific	O
granules	O
.	O
Furthermore	O
,	O
we	O
found	O
that	O
20	O
%	O
to	O
25	O
%	O
of	O
both	O
the	O
adhesion	B
protein	I
Mac-1	I
and	O
the	O
NADPH	B
-	I
oxidase	I
component	I
cytochrome	I
b558	B
is	O
localized	O
in	O
gelatinase	B
granules	O
.	O
Although	O
no	O
qualitative	O
difference	O
was	O
observed	O
between	O
specific	O
granules	O
and	O
gelatinase	B
granules	O
with	O
respect	O
to	O
cytochrome	B
b558	I
and	O
Mac-1	B
,	O
stimulation	O
of	O
the	O
neutrophil	O
with	O
FMLP	B
resulted	O
in	O
a	O
selective	O
mobilization	O
of	O
the	O
least	O
dense	O
peroxidase	O
-	O
negative	O
granules	O
,	O
ie	O
,	O
gelatinase	B
granules	O
,	O
which	O
,	O
in	O
concert	O
with	O
secretory	O
vesicles	O
,	O
furnish	O
the	O
plasma	O
membrane	O
with	O
Mac-1	B
and	O
cytochrome	B
b558	I
.	O
This	O
shows	O
that	O
gelatinase	B
granules	O
are	O
functionally	O
important	O
relative	O
to	O
specific	O
granules	O
in	O
mediating	O
early	O
inflammatory	O
responses	O
.	O
Thrombin	B
and	O
thrombin	B
receptor	I
agonist	O
peptide	O
induce	O
early	O
events	O
of	O
T	O
cell	O
activation	O
and	O
synergize	O
with	O
TCR	B
cross	O
-	O
linking	O
for	O
CD69	B
expression	O
and	O
interleukin	O
2	O
production	O
.	O
Thrombin	B
stimulation	O
of	O
the	O
T	O
leukemic	O
cell	O
line	O
Jurkat	O
induced	O
a	O
transient	O
increase	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
.	O
Proteolytic	O
activity	O
of	O
the	O
enzyme	B
was	O
required	O
for	O
this	O
effect	O
since	O
diisopropyl	B
fluorophosphate	I
-	I
thrombin	I
failed	O
to	O
increase	O
[	O
Ca2	O
+	O
]	O
i	O
.	O
Furthermore	O
,	O
hirudin	O
and	O
anti	B
-	I
thrombin	I
III	I
inhibited	O
the	O
thrombin	O
-	O
induced	O
[	O
Ca2	O
+	O
]	O
i	O
rise	O
in	O
Jurkat	O
T	O
cells	O
.	O
A	O
synthetic	O
thrombin	B
receptor	I
agonist	O
peptide	O
(	O
TRP	O
)	O
of	O
7	O
residues	O
(	O
SFLLRNP	O
)	O
was	O
found	O
to	O
be	O
as	O
effective	O
as	O
thrombin	B
for	O
[	O
Ca2	O
+	O
]	O
i	O
mobilization	O
,	O
and	O
both	O
agonists	O
induced	O
Ca2	O
+	O
release	O
exclusively	O
from	O
internal	O
stores	O
.	O
Thrombin	B
stimulated	O
tyrosine	O
phosphorylation	O
of	O
several	O
proteins	O
of	O
molecular	B
mass	I
40	I
,	I
42	I
,	I
70	I
,	I
120	I
,	I
and	I
130	I
kDa	I
.	O
There	O
was	O
a	O
good	O
correlation	O
between	O
thrombin	B
-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
latter	O
three	O
proteins	O
and	O
Ca2	O
+	O
mobilization	O
.	O
Thrombin	B
and	O
TRP	O
also	O
caused	O
translocation	O
of	O
protein	B
kinase	I
C	I
from	O
the	O
cytosol	O
to	O
the	O
plasma	O
membrane	O
.	O
As	O
a	O
likely	O
consequence	O
of	O
these	O
events	O
,	O
thrombin	B
activated	O
the	O
nuclear	B
factor	I
NF	I
-	I
kB	I
.	O
Several	O
cell	O
lines	O
of	O
hematopoietic	O
origin	O
including	O
the	O
leukemic	O
T	O
cell	O
line	O
HPB.ALL	O
and	O
the	O
erythroleukemic	O
cell	O
line	O
K562	O
were	O
responsive	O
to	O
thrombin	B
,	O
whereas	O
others	O
such	O
as	O
THP1	O
,	O
a	O
myelomonocytic	O
cell	O
line	O
,	O
and	O
BL2	O
,	O
a	O
Burkitt	O
lymphoma	O
were	O
refractory	O
to	O
thrombin	B
or	O
TRP	O
stimulation	O
.	O
The	O
magnitude	O
of	O
the	O
thrombin	B
response	O
in	O
the	O
different	O
cell	O
types	O
paralleled	O
the	O
expression	O
of	O
the	O
thrombin	O
receptor	O
mRNA	O
.	O
We	O
found	O
that	O
activation	O
of	O
Jurkat	O
T	O
cells	O
by	O
a	O
combination	O
of	O
phytohemagglutinin	B
and	O
phorbol	O
12-myristate	O
13-acetate	O
led	O
to	O
a	O
dramatic	O
inhibition	O
of	O
thrombin	O
receptor	O
mRNA	O
expression	O
and	O
to	O
a	O
concomitant	O
loss	O
of	O
the	O
thrombin	B
response	O
.	O
Finally	O
,	O
we	O
demonstrate	O
that	O
thrombin	B
and	O
TRP	O
enhanced	O
CD69	B
expression	O
and	O
interleukin	B
2	I
production	O
induced	O
by	O
T	B
cell	I
receptor	I
cross	O
-	O
linking	O
in	O
both	O
Jurkat	O
T	O
cells	O
and	O
peripheral	O
blood	O
lymphocytes	O
.	O
These	O
findings	O
highlight	O
the	O
role	O
of	O
thrombin	B
as	O
a	O
potential	O
regulator	O
of	O
T	O
lymphocyte	O
activation	O
.	O
Activation	O
of	O
the	O
interleukin	O
6	O
gene	O
by	O
Mycobacterium	O
tuberculosis	O
or	O
lipopolysaccharide	O
is	O
mediated	O
by	O
nuclear	B
factors	I
NF	I
-	I
IL6	I
and	O
NF	B
-	I
kappa	I
B	I
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1995	O
Apr	O
11	O
;	O
92	O
(	O
8	O
)	O
:	O
3632	O
]	O
The	O
host	O
response	O
to	O
Mycobacterium	O
tuberculosis	O
includes	O
granuloma	O
formation	O
at	O
sites	O
of	O
infection	O
and	O
systemic	O
symptoms	O
.	O
Cytokines	B
have	O
been	O
identified	O
by	O
immunohistochemistry	O
in	O
granulomas	O
in	O
animal	O
models	O
of	O
bacillus	O
Calmette	O
-	O
Guerin	O
(	O
BCG	O
)	O
infection	O
and	O
are	O
released	O
by	O
mononuclear	O
phagocytes	O
upon	O
stimulation	O
by	O
mycobacterial	O
proteins	O
.	O
In	O
this	O
regard	O
,	O
the	O
cytokine	B
interleukin	B
6	I
(	O
IL-6	B
)	O
may	O
play	O
a	O
role	O
in	O
the	O
clinical	O
manifestations	O
and	O
pathological	O
events	O
of	O
tuberculosis	O
infection	O
.	O
We	O
have	O
demonstrated	O
that	O
lipoarabinomannan	B
(	O
LAM	B
)	O
from	O
the	O
mycobacterial	O
cell	O
wall	O
,	O
which	O
was	O
virtually	O
devoid	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
stimulated	O
mononuclear	O
phagocytes	O
to	O
release	O
IL-6	B
in	O
a	O
dose	O
-	O
response	O
manner	O
.	O
LAM	B
and	O
LPS	O
were	O
potent	O
inducers	O
of	O
IL-6	O
gene	O
expression	O
in	O
peripheral	O
blood	O
monocytes	O
.	O
Both	O
LAM	B
-and	O
LPS	O
-	O
inducible	O
IL-6	O
promoter	O
activity	O
was	O
localized	O
to	O
a	O
DNA	O
fragment	O
,	O
positions	O
-158	O
to	O
-49	O
,	O
by	O
deletion	O
analysis	O
and	O
chloramphenicol	B
acetyltransferase	I
assay	O
.	O
Two	O
nuclear	B
factor	I
NF	I
-	I
IL6	I
(	O
positions	O
-153	O
to	O
-145	O
and	O
-83	O
to	O
-75	O
)	O
and	O
one	O
nuclear	O
factor	O
NF	O
-	O
kappa	O
B	O
(	O
positions	O
-72	O
to	O
-63	O
)	O
motifs	O
are	O
present	O
within	O
this	O
fragment	O
.	O
Site	O
-	O
directed	O
mutagenesis	O
of	O
one	O
or	O
more	O
of	O
these	O
motifs	O
within	O
the	O
IL-6	B
promoter	O
demonstrated	O
that	O
each	O
has	O
positive	O
regulatory	O
activity	O
and	O
that	O
they	O
could	O
act	O
in	O
a	O
function-	O
and	O
orientation	O
-	O
independent	O
manner	O
.	O
Deletion	O
of	O
all	O
three	O
elements	O
abolished	O
inducibility	O
of	O
IL-6	O
promoter	O
activity	O
by	O
both	O
LAM	B
and	O
LPS	O
.	O
We	O
conclude	O
that	O
the	O
NF	O
-	O
IL6	O
and	O
NF	O
-	O
kappa	O
B	O
sites	O
mediate	O
IL-6	B
induction	O
in	O
response	O
to	O
both	O
LPS	O
and	O
LAM	B
,	O
acting	O
as	O
bacterial	O
or	O
mycobacterial	O
response	O
elements	O
.	O
Calcineurin	B
activates	O
transcription	O
from	O
the	O
GM	O
-	O
CSF	O
promoter	O
in	O
synergy	O
with	O
either	O
protein	B
kinase	I
C	I
or	O
NF	B
-	I
kappa	I
B	I
/AP-1	B
in	O
T	O
cells	O
.	O
Two	O
cis	O
-	O
acting	O
elements	O
GM	O
-	O
kappa	O
B	O
/	O
GC	O
-	O
box	O
and	O
CLE0	O
,	O
of	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
gene	O
are	O
required	O
for	O
maximal	O
induction	O
in	O
Jurkat	O
T	O
cells	O
by	O
costimulation	O
with	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
Ca2	O
+	O
ionophore	O
(	O
A23187	O
)	O
.	O
The	O
GM	O
-	O
kappa	O
B	O
sequence	O
is	O
recognized	O
by	O
NF	B
-	I
kappa	I
B	I
,	O
which	O
is	O
mainly	O
induced	O
by	O
PMA	O
.	O
The	O
CLE0	O
sequence	O
interacts	O
with	O
factors	O
,	O
related	O
to	O
a	O
PMA	B
-	I
induced	I
AP-1	I
and	O
a	O
PMA	B
/	I
A23187-induced	I
NF	I
-	I
AT	I
.	O
We	O
examined	O
whether	O
signal	O
transducing	O
components	O
in	O
T	O
cells	O
can	O
activate	O
transcription	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
.	O
Cotransfection	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
p50	O
/	O
p65	O
)	O
-	O
or	O
AP-1	O
(	O
c	O
-	O
Jun	O
/	O
c	O
-	O
Fos	O
)	O
-	O
expression	O
vectors	O
into	O
Jurkat	O
cells	O
with	O
a	O
luciferase	O
reporter	O
containing	O
the	O
GM	O
-	O
CSF	O
promoter	O
did	O
not	O
stimulate	O
transcription	O
from	O
the	O
GM	O
-	O
CSF	O
promoter	O
.	O
In	O
contrast	O
,	O
cotransfection	O
with	O
a	O
combination	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
AP-1	B
significantly	O
augmented	O
transcription	O
from	O
the	O
GM	O
-	O
CSF	O
promoter	O
containing	O
the	O
GM	O
-	O
kappa	O
B	O
/	O
GC	O
-	O
box	O
and	O
the	O
CLE0	O
(	O
AP-1	B
/	I
NF	I
-	I
AT	I
)	O
.	O
Expression	O
of	O
a	O
constitutively	O
active	O
calcineurin	B
(	O
CN	B
)	O
,	O
a	O
Ca2+	B
/	I
calmodulin	I
-	I
dependent	I
protein	I
phosphatase	I
,	O
potentiated	O
by	O
two	O
fold	O
the	O
transcriptional	O
activation	O
by	O
NF	B
-	I
kappa	I
B	I
/AP-1	B
.	O
Both	O
constitutively	O
active	O
forms	O
of	O
CN	B
and	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
synergistically	O
activated	O
transcription	O
from	O
the	O
GM	O
-	O
CSF	O
promoter	O
.	O
These	O
results	O
suggest	O
that	O
cooperation	O
among	O
NF	O
-	O
kappa	O
B-	O
,	O
AP-1-	O
and	O
NF	O
-	O
AT	O
-	O
binding	O
sequences	O
is	O
required	O
for	O
induction	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
through	O
PKC-	O
and	O
Ca2	O
+	O
-	O
signaling	O
pathways	O
downstream	O
of	O
T	O
cell	O
activation	O
.	O
Retinoic	O
acid	O
-	O
induced	O
expression	O
of	O
CD38	B
antigen	I
in	O
myeloid	O
cells	O
is	O
mediated	O
through	O
retinoic	B
acid	I
receptor	I
-	I
alpha	I
.	O
CD38	B
is	O
a	O
leukocyte	B
differentiation	I
antigen	I
that	O
has	O
been	O
thought	O
to	O
be	O
a	O
phenotypic	O
marker	O
of	O
different	O
subpopulations	O
of	O
T-	O
and	O
B-	O
lymphocytes	O
.	O
In	O
myeloid	O
cells	O
,	O
CD38	B
is	O
expressed	O
during	O
early	O
stages	O
of	O
differentiation	O
.	O
Virtually	O
no	O
information	O
is	O
available	O
on	O
regulation	O
and	O
functions	O
of	O
CD38	B
.	O
Recently	O
we	O
reported	O
that	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
a	O
potent	O
and	O
highly	O
specific	O
inducer	O
of	O
CD38	B
expression	O
in	O
human	O
promyelocytic	O
leukemia	O
cells	O
.	O
Here	O
we	O
report	O
that	O
ATRA	O
-	O
induced	O
expression	O
of	O
CD38	B
antigen	I
in	O
myeloid	O
cells	O
is	O
mediated	O
through	O
retinoic	B
acid	I
-	I
alpha	I
receptor	I
(	O
RAR	B
alpha	I
)	O
.	O
ATRA	O
failed	O
to	O
induce	O
CD38	B
expression	O
in	O
a	O
mutant	O
subclone	O
of	O
the	O
HL-60	O
myeloid	O
leukemia	O
cell	O
line	O
(	O
designated	O
HL-60R	O
)	O
that	O
is	O
relatively	O
resistant	O
to	O
ATRA	O
-	O
induced	O
granulocytic	O
differentiation	O
.	O
Retroviral	O
vector	O
-	O
mediated	O
transduction	O
of	O
RA	B
receptor	I
(	O
RAR	B
alpha	I
)	O
into	O
this	O
HL-60R	O
subclone	O
completely	O
restored	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
ATRA	O
in	O
terms	O
of	O
their	O
ability	O
to	O
express	O
CD38	B
.	O
In	O
contrast	O
,	O
CD38	B
expression	O
was	O
not	O
inducible	O
by	O
ATRA	O
in	O
HL-60R	O
cells	O
,	O
transfected	O
with	O
a	O
functional	O
RAR	B
beta	I
,	O
RAR	B
gamma	I
,	O
or	O
RXR	B
alpha	I
receptor	I
.	O
Induction	O
of	O
CD38	B
in	O
acute	O
promyelocytic	O
and	O
acute	O
myeloblastic	O
leukemia	O
cells	O
was	O
independent	O
of	O
ATRA	O
-	O
induced	O
cytodifferentiation	O
.	O
Following	O
culture	O
with	O
ATRA	O
,	O
increased	O
CD38	B
protein	O
levels	O
were	O
also	O
observed	O
in	O
normal	O
CD34	O
+	O
bone	O
marrow	O
cells	O
,	O
but	O
not	O
on	O
normal	O
circulating	O
granulocytes	O
.	O
From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
CD38	B
is	O
ATRA	O
inducible	O
in	O
myeloid	O
leukemia	O
cells	O
and	O
normal	O
CD34	O
+	O
bone	O
marrow	O
cells	O
.	O
This	O
effect	O
is	O
independent	O
of	O
differentiation	O
and	O
is	O
mediated	O
by	O
RAR	B
alpha	I
in	O
HL-60	O
cells	O
,	O
suggesting	O
a	O
similar	O
role	O
for	O
RAR	B
alpha	I
in	O
CD38	B
expression	O
in	O
other	O
hematopoietic	O
cells	O
.	O
A	O
transcriptional	O
regulatory	O
element	O
is	O
associated	O
with	O
a	O
nuclease	O
-	O
hypersensitive	O
site	O
in	O
the	O
pol	O
gene	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O
Analysis	O
of	O
the	O
chromatin	O
organization	O
of	O
the	O
integrated	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
genome	O
has	O
previously	O
revealed	O
a	O
major	O
constitutive	O
DNase	O
I	O
-	O
hypersensitive	O
site	O
associated	O
with	O
the	O
pol	O
gene	O
(	O
E.	O
Verdin	O
,	O
J.	O
Virol	O
.	O
65	O
:	O
6790	O
-	O
6799	O
,	O
1991	O
)	O
.	O
In	O
the	O
present	O
report	O
,	O
high	O
-	O
resolution	O
mapping	O
of	O
this	O
site	O
with	O
DNase	B
I	I
and	O
micrococcal	B
nuclease	I
identified	O
a	O
nucleosome	O
-	O
free	O
region	O
centered	O
around	O
nucleotides	O
(	O
nt	O
)	O
4490	O
to	O
4766	O
.	O
A	O
500-bp	O
fragment	O
encompassing	O
this	O
hypersensitive	O
site	O
(	O
nt	O
4481	O
to	O
4982	O
)	O
exhibited	O
transcription	O
-	O
enhancing	O
activity	O
(	O
two-	O
to	O
threefold	O
)	O
when	O
it	O
was	O
cloned	O
in	O
its	O
natural	O
position	O
with	O
respect	O
to	O
the	O
HIV-1	O
promoter	O
after	O
transient	O
transfection	O
in	O
U937	O
and	O
CEM	O
cells	O
.	O
Using	O
in	O
vitro	O
footprinting	O
and	O
gel	O
shift	O
assays	O
,	O
we	O
have	O
identified	O
four	O
distinct	O
binding	O
sites	O
for	O
nuclear	B
proteins	I
within	O
this	O
positive	O
regulatory	O
element	O
.	O
Site	O
B	O
(	O
nt	O
4519	O
to	O
4545	O
)	O
specifically	O
bound	O
four	O
distinct	O
nuclear	B
protein	I
complexes	I
:	O
a	O
ubiquitous	B
factor	I
,	O
a	O
T	B
-	I
cell	I
-	I
specific	I
factor	I
,	O
a	O
B	B
-	I
cell	I
-	I
specific	I
factor	I
,	O
and	O
the	O
monocyte	B
/	I
macrophage-	I
and	I
B	I
-	I
cell	I
-	I
specific	I
transcription	I
factor	I
PU.1	B
/	I
Spi-1	I
.	O
In	O
most	O
HIV-1	O
isolates	O
in	O
which	O
this	O
PU	O
box	O
was	O
not	O
conserved	O
,	O
it	O
was	O
replaced	O
by	O
a	O
binding	O
site	O
for	O
the	O
related	O
factor	O
Ets1	B
.	O
Factors	O
binding	O
to	O
site	O
C	O
(	O
nt	O
4681	O
to	O
4701	O
)	O
had	O
a	O
DNA	O
-	O
binding	O
specificity	O
similar	O
to	O
that	O
of	O
factors	O
binding	O
to	O
site	O
B	O
,	O
except	O
for	O
PU.1	B
/	I
Spi-1	I
.	O
A	O
GC	O
box	O
containing	O
a	O
binding	O
site	O
for	O
Sp1	B
was	O
identified	O
(	O
nt	O
4623	O
to	O
4631	O
)	O
.	O
Site	O
D	O
(	O
nt	O
4816	O
to	O
4851	O
)	O
specifically	O
bound	O
a	O
ubiquitously	B
expressed	I
factor	I
.	O
These	O
results	O
identify	O
a	O
transcriptional	O
regulatory	O
element	O
associated	O
with	O
a	O
nuclease	O
-	O
hypersensitive	O
site	O
in	O
the	O
pol	O
gene	O
of	O
HIV-1	O
and	O
suggest	O
that	O
its	O
activity	O
may	O
be	O
controlled	O
by	O
a	O
complex	O
interplay	O
of	O
cis-	O
regulatory	O
elements	O
.	O
Detection	O
of	O
minimal	O
residual	O
disease	O
in	O
a	O
patient	O
with	O
acute	O
promyelocytic	O
leukemia	O
by	O
RT	O
-	O
PCR	O
:	O
necessity	O
of	O
chemotherapy	O
following	O
ATRA	O
therapy	O
.	O
The	O
PML	O
/	O
RAR	O
alpha	O
fusion	O
gene	O
resulting	O
from	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
translocation	O
is	O
a	O
specific	O
marker	O
for	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O
We	O
examined	O
bone	O
marrow	O
cells	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
to	O
detect	O
residual	O
PML	O
/	O
RAR	O
alpha	O
mRNA	O
-	O
containing	O
cells	O
following	O
treatment	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
cytotoxic	O
chemotherapy	O
in	O
a	O
patient	O
with	O
APL	O
.	O
This	O
RT	O
-	O
PCR	O
assay	O
can	O
detect	O
one	O
leukemic	O
cell	O
in	O
10	O
(	O
2	O
)	O
normal	O
cells	O
in	O
vitro	O
.	O
We	O
show	O
that	O
PML	O
/	O
RAR	O
alpha	O
mRNA	O
was	O
still	O
detectable	O
despite	O
clinical	O
remission	O
following	O
ATRA	O
treatment	O
,	O
but	O
undetectable	O
following	O
consolidation	O
with	O
chemotherapy	O
.	O
These	O
data	O
show	O
that	O
this	O
technique	O
is	O
useful	O
for	O
the	O
identification	O
of	O
minimal	O
residual	O
disease	O
in	O
patients	O
with	O
APL	O
and	O
that	O
cytotoxic	O
chemotherapy	O
following	O
ATRA	O
therapy	O
is	O
required	O
for	O
the	O
elimination	O
of	O
APL	O
cells	O
.	O
Expression	O
of	O
v	O
-	O
src	O
in	O
T	O
cells	O
correlates	O
with	O
nuclear	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
NF	B
-	I
kappa	I
B	I
is	O
a	O
rapidly	O
inducible	O
transcriptional	O
activator	O
that	O
responds	O
to	O
a	O
variety	O
of	O
signals	O
and	O
influences	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
the	O
immune	O
response	O
.	O
Protein	O
tyrosine	B
kinases	I
transmit	O
signals	O
from	O
cytokine	B
and	I
immune	I
receptors	I
.	O
Very	O
little	O
information	O
exists	O
linking	O
these	O
two	O
important	O
classes	O
of	O
signaling	B
molecules	I
.	O
We	O
now	O
demonstrate	O
that	O
v	O
-	O
src	O
expression	O
correlates	O
with	O
nuclear	O
expression	O
of	O
a	O
kappa	B
B	I
binding	I
complex	I
similar	O
to	O
that	O
induced	O
by	O
phorbol	O
ester	O
and	O
ionomycin	O
,	O
as	O
detected	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
variety	O
of	O
kappa	O
B	O
sites	O
.	O
This	O
complex	O
was	O
blocked	O
by	O
the	O
tyrosine	B
kinase	I
inhibitor	O
,	O
herbimycin	O
A	O
.	O
The	O
v	B
-	I
src	I
-	I
induced	I
complex	I
comprised	O
the	O
p50	B
and	O
p65	B
components	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
as	O
determined	O
by	O
supershift	O
and	O
immunoblot	O
analysis	O
.	O
As	O
a	O
functional	O
correlate	O
of	O
this	O
finding	O
,	O
transient	O
co	O
-	O
transfection	O
of	O
HIV-1	O
LTR	O
reporter	O
constructs	O
in	O
a	O
different	O
T	O
cell	O
line	O
demonstrated	O
that	O
v	O
-	O
src	O
activated	O
this	O
promoter	B
in	O
a	O
kappa	O
B	O
-	O
dependent	O
manner	O
.	O
We	O
found	O
that	O
transactivation	O
of	O
the	O
HIV-1	O
LTR	O
by	O
v	O
-	O
src	O
was	O
more	O
sensitive	O
to	O
mutations	O
of	O
the	O
proximal	O
,	O
rather	O
than	O
the	O
distal	O
,	O
kappa	O
B	O
element	O
.	O
The	O
implications	O
for	O
T	B
cell	I
receptor	I
signaling	O
and	O
HIV-1	O
gene	O
expression	O
are	O
considered	O
.	O
Comparison	O
of	O
retinoic	O
acid	O
and	O
phorbol	O
myristate	O
acetate	O
as	O
inducers	O
of	O
monocytic	O
differentiation	O
.	O
Several	O
human	O
myeloid	O
leukemia	O
cell	O
lines	O
growing	O
in	O
vitro	O
can	O
be	O
induced	O
to	O
differentiate	O
to	O
more	O
mature	O
monocyte	O
/	O
macrophage	O
-	O
like	O
cells	O
by	O
treatment	O
with	O
protein	B
kinase	I
C	I
-activating	O
phorbol	O
esters	O
,	O
such	O
as	O
PMA	O
.	O
In	O
addition	O
to	O
PMA	O
,	O
cells	O
of	O
the	O
THP-1	O
myeloid	O
leukemia	O
cell	O
line	O
acquire	O
macrophage	O
-	O
like	O
characteristics	O
after	O
treatment	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
.	O
To	O
analyze	O
the	O
signal	O
transduction	O
mechanisms	O
induced	O
by	O
RA	O
,	O
we	O
first	O
compared	O
the	O
effects	O
of	O
PMA	O
and	O
RA	O
on	O
the	O
expression	O
of	O
genes	O
which	O
are	O
known	O
to	O
be	O
regulated	O
during	O
monocytic	O
differentiation	O
.	O
Both	O
RA	O
and	O
PMA	O
effectively	O
down	O
-	O
regulated	O
c	O
-	O
myc	O
expression	O
,	O
while	O
c	O
-	O
myb	O
expression	O
decreased	O
only	O
after	O
PMA	O
treatment	O
.	O
Expression	O
of	O
the	O
beta	O
2-integrin	O
genes	O
,	O
CD11a	O
and	O
CD11b	O
,	O
was	O
clearly	O
increased	O
after	O
both	O
of	O
these	O
treatments	O
.	O
Their	O
effects	O
on	O
the	O
src	O
-	O
family	O
tyrosine	O
kinase	O
genes	O
were	O
different	O
:	O
hck	O
expression	O
was	O
similarly	O
induced	O
by	O
these	O
agents	O
but	O
lyn	O
expression	O
was	O
stronger	O
and	O
more	O
rapid	O
after	O
RA	O
treatment	O
.	O
RA	O
also	O
enhanced	O
lyn	O
mRNA	O
production	O
rapidly	O
in	O
HL-60	O
,	O
indicating	O
that	O
the	O
activation	O
of	O
lyn	O
gene	O
expression	O
is	O
common	O
in	O
monocytic	O
and	O
granulocytic	O
maturation	O
of	O
myeloid	O
leukemia	O
cells	O
.	O
To	O
examine	O
whether	O
the	O
AP-1	O
enhancer	O
activity	O
is	O
involved	O
in	O
RA	O
-	O
induced	O
monocytic	O
differentiation	O
,	O
THP-1	O
cells	O
were	O
transiently	O
transfected	O
with	O
a	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
-reporter	O
gene	O
containing	O
5	O
copies	O
of	O
the	O
AP-1	O
binding	O
sites	O
.	O
In	O
contrast	O
to	O
PMA	O
,	O
RA	O
did	O
not	O
induce	O
any	O
CAT	B
activity	O
in	O
these	O
cells	O
,	O
thus	O
suggesting	O
that	O
the	O
RA	O
-	O
induced	O
changes	O
in	O
the	O
expression	O
of	O
those	O
genes	O
described	O
above	O
were	O
not	O
dependent	O
on	O
the	O
AP-1	O
enhancer	O
activity	O
.	O
Antigenic	O
specificities	O
of	O
human	O
CD4	O
+	O
T	O
-	O
cell	O
clones	O
recovered	O
from	O
recurrent	O
genital	O
herpes	O
simplex	O
virus	O
type	O
2	O
lesions	O
.	O
Lesions	O
resulting	O
from	O
recurrent	O
genital	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
infection	O
are	O
characterized	O
by	O
infiltration	O
of	O
CD4	O
+	O
lymphocytes	O
.	O
We	O
have	O
investigated	O
the	O
antigenic	O
specificity	O
of	O
47	O
HSV	O
-	O
specific	O
CD4	O
+	O
T	O
-	O
cell	O
clones	O
recovered	O
from	O
the	O
HSV-2	O
buttock	O
and	O
thigh	O
lesions	O
of	O
five	O
patients	O
.	O
Clones	O
with	O
proliferative	O
responses	O
to	O
recombinant	B
truncated	I
glycoprotein	I
B	I
(	O
gB	B
)	O
or	O
gD	B
of	O
HSV-2	O
or	O
purified	O
natural	O
gC	O
of	O
HSV-2	O
comprised	O
a	O
minority	O
of	O
the	O
total	O
number	O
of	O
HSV	O
-	O
specific	O
clones	O
isolated	O
from	O
lesions	O
.	O
The	O
gC2-	O
and	O
gD2-specific	O
CD4	O
+	O
clones	O
had	O
cytotoxic	O
activity	O
.	O
The	O
approximate	O
locations	O
of	O
the	O
HSV-2	O
genes	O
encoding	O
HSV-2	O
type	O
-	O
specific	O
CD4	B
+	I
antigens	I
have	O
been	O
determined	O
by	O
using	O
HSV-1	O
x	O
HSV-2	O
intertypic	O
recombinant	O
virus	O
and	O
include	O
the	O
approximate	O
map	O
regions	O
0.30	O
to	O
0.46	O
,	O
0.59	O
to	O
0.67	O
,	O
0.67	O
to	O
0.73	O
,	O
and	O
0.82	O
to	O
1.0	O
units	O
.	O
The	O
antigenic	O
specificity	O
of	O
an	O
HLA	O
DQ2-restricted	O
,	O
HSV-2	O
type	O
-	O
specific	O
T	O
-	O
cell	O
clone	O
was	O
mapped	O
to	O
amino	B
acids	I
425	I
to	I
444	I
of	O
VP16	B
of	O
HSV-2	O
by	O
sequential	O
use	O
of	O
an	O
intertypic	O
recombinant	O
virus	O
containing	O
VP16	B
of	O
HSV-2	O
in	O
an	O
HSV-1	O
background	O
,	O
recombinant	B
VP16	I
fusion	I
proteins	I
,	O
and	O
synthetic	O
peptides	O
.	O
Each	O
of	O
the	O
remaining	O
four	O
patients	O
also	O
yielded	O
at	O
least	O
one	O
type	O
-	O
specific	O
T	O
-	O
cell	O
clone	O
reactive	O
with	O
an	O
HSV-2	O
epitope	O
mapping	O
to	O
approximately	O
0.67	O
to	O
0.73	O
map	O
units	O
.	O
The	O
antigenic	O
specificities	O
of	O
lesion	O
-	O
derived	O
CD4	O
+	O
T	O
-	O
cell	O
clones	O
are	O
quite	O
diverse	O
and	O
include	O
at	O
least	O
10	O
epitopes	O
.	O
Human	O
T	O
-	O
cell	O
clones	O
reactive	O
with	O
gC	B
and	O
VP16	B
are	O
reported	O
here	O
for	O
the	O
first	O
time	O
.	O
Encephalomyocarditis	O
virus	O
internal	O
ribosomal	O
entry	O
site	O
RNA	O
-	O
protein	O
interactions	O
.	O
Translational	O
initiation	O
of	O
encephalomyocarditis	O
virus	O
(	O
EMCV	O
)	O
mRNA	O
occurs	O
by	O
ribosomal	O
entry	O
into	O
the	O
5	O
'	O
nontranslated	O
region	O
of	O
the	O
EMCV	O
mRNA	O
,	O
rather	O
than	O
by	O
ribosomal	O
scanning	O
.	O
Internal	O
ribosomal	O
binding	O
requires	O
a	O
cis	O
-	O
acting	O
element	O
termed	O
the	O
internal	O
ribosomal	O
entry	O
site	O
(	O
IRES	O
)	O
.	O
IRES	O
elements	O
have	O
been	O
proposed	O
to	O
be	O
involved	O
in	O
the	O
translation	O
of	O
picornavirus	O
mRNAs	O
and	O
some	O
cellular	O
mRNAs	O
.	O
Internal	O
ribosome	O
binding	O
likely	O
requires	O
the	O
interaction	O
of	O
trans	B
-	I
acting	I
factors	I
that	O
recognize	O
both	O
the	O
mRNA	O
and	O
the	O
ribosomal	B
complex	I
.	O
Five	O
cellular	B
proteins	I
(	O
p52	B
,	O
p57	B
,	O
p70	B
,	O
p72	B
,	O
and	O
p100	B
)	O
cross	O
-	O
link	O
the	O
EMCV	O
IRES	O
or	O
fragments	O
of	O
the	O
IRES	O
.	O
For	O
one	O
of	O
these	O
proteins	O
,	O
p57	B
,	O
binding	O
to	O
the	O
IRES	O
correlates	O
with	O
translation	O
.	O
Recently	O
,	O
p57	B
was	O
identified	O
to	O
be	O
very	O
similar	O
,	O
if	O
not	O
identical	O
,	O
to	O
polypyrimidine	B
tract	I
-	I
binding	I
protein	I
.	O
On	O
the	O
basis	O
of	O
cross	O
-	O
linking	O
results	O
with	O
21	O
different	O
EMCV	O
IRES	O
fragments	O
and	O
cytoplasmic	O
HeLa	O
extract	O
or	O
rabbit	O
reticulocyte	O
lysate	O
as	O
the	O
source	O
of	O
polypeptides	O
,	O
consensus	O
binding	O
sites	O
for	O
p52	B
,	O
p57	B
,	O
p70	B
,	O
and	O
p100	B
are	O
proposed	O
.	O
It	O
is	O
suggested	O
that	O
each	O
of	O
these	O
proteins	O
recognizes	O
primarily	O
a	O
structural	O
feature	O
of	O
the	O
RNA	O
rather	O
than	O
a	O
specific	O
sequence	O
.	O
Human	O
immunodeficiency	O
virus	O
type	O
1	O
Nef	O
protein	O
down	O
-	O
regulates	O
transcription	B
factors	I
NF	B
-	I
kappa	I
B	I
and	O
AP-1	B
in	O
human	O
T	O
cells	O
in	O
vitro	O
after	O
T	O
-	O
cell	O
receptor	O
stimulation	O
.	O
Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
negative	B
factor	I
(	O
Nef	B
)	O
has	O
been	O
shown	O
to	O
down	O
-	O
regulate	O
the	O
transcription	B
factors	I
NF	B
-	I
kappa	I
B	I
and	O
AP-1	B
in	O
vitro	O
.	O
To	O
define	O
the	O
mechanism	O
of	O
action	O
of	O
the	O
Nef	B
protein	O
,	O
the	O
signal	O
transduction	O
pathways	O
which	O
may	O
be	O
affected	O
in	O
T	O
cells	O
by	O
constitutive	O
expression	O
of	O
the	O
nef	O
gene	O
were	O
examined	O
.	O
Stimulation	O
of	O
T	O
cells	O
with	O
tumor	O
necrosis	O
factor	O
,	O
interleukin-1	O
,	O
or	O
lipopolysaccharide	O
resulted	O
in	O
the	O
recruitment	O
of	O
transcriptional	O
factors	O
to	O
a	O
similar	O
level	O
whether	O
or	O
not	O
the	O
cells	O
expressed	O
the	O
nef	O
gene	O
.	O
On	O
the	O
other	O
hand	O
,	O
stimulation	O
of	O
T	O
cells	O
by	O
mitogens	O
or	O
antibodies	O
to	O
the	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
-	O
CD3	B
complex	O
resulted	O
in	O
the	O
down	O
-	O
regulation	O
of	O
transcriptional	O
factors	O
NF	B
-	I
kappa	I
B	I
and	O
AP-1	B
in	O
cells	O
expressing	O
the	O
nef	O
gene	O
compared	O
with	O
cells	O
not	O
expressing	O
the	O
nef	O
gene	O
.	O
Because	O
the	O
Nef	B
protein	O
does	O
not	O
affect	O
the	O
surface	O
expression	O
of	O
the	O
CD3	B
-TCR	O
complex	O
,	O
we	O
conclude	O
that	O
the	O
Nef	B
protein	O
down	O
-	O
regulates	O
the	O
transcriptional	O
factors	O
NF	B
-	I
kappa	I
B	I
and	O
AP-1	B
in	O
T	O
cells	O
in	O
vitro	O
through	O
an	O
effect	O
on	O
the	O
TCR	O
-	O
dependent	O
signal	O
transduction	O
pathway	O
.	O
Characterization	O
of	O
the	O
human	O
gene	O
encoding	O
LBR	B
,	O
an	O
integral	B
protein	I
of	O
the	O
nuclear	O
envelope	O
inner	O
membrane	O
.	O
We	O
have	O
characterized	O
the	O
human	O
gene	O
encoding	O
LBR	B
,	O
an	O
integral	B
protein	I
of	O
the	O
nuclear	O
envelope	O
inner	O
membrane	O
.	O
Restriction	O
mapping	O
shows	O
that	O
the	O
transcription	O
unit	O
spans	O
approximately	O
35	O
kilobases	O
.	O
A	O
transcription	O
start	O
site	O
is	O
located	O
approximately	O
4	O
kilobases	O
5	O
'	O
to	O
the	O
translation	O
initiation	O
codon	O
,	O
and	O
an	O
RNA	O
splice	O
of	O
3863	O
bases	O
occurs	O
in	O
the	O
5'-untranslated	O
region	O
to	O
generate	O
mature	O
HeLa	O
cell	O
mRNA	O
.	O
5	O
'	O
to	O
the	O
identified	O
transcription	O
start	O
site	O
are	O
two	O
CCAAT	O
sequences	O
and	O
potential	O
recognition	O
sites	O
for	O
several	O
transcription	B
factors	I
including	O
Sp1	B
,	O
AP-1	B
,	O
AP-2	B
,	O
and	O
NF	B
-	I
kB	I
.	O
There	O
are	O
13	O
protein	O
coding	O
exons	O
in	O
the	O
LBR	O
gene	O
.	O
LBR	B
's	O
nucleoplasmic	B
domain	I
is	O
encoded	O
by	O
exons	O
1	O
-	O
4	O
,	O
and	O
its	O
hydrophobic	B
domain	I
,	O
with	O
eight	O
putative	O
transmembrane	B
segments	I
,	O
is	O
encoded	O
by	O
exons	O
5	O
-	O
13	O
.	O
The	O
hydrophobic	B
domain	I
is	O
homologous	O
to	O
three	O
yeast	O
polypeptides	O
,	O
suggesting	O
that	O
this	O
higher	O
eukaryotic	O
gene	O
could	O
have	O
evolved	O
from	O
recombination	O
between	O
a	O
gene	O
that	O
encoded	O
a	O
soluble	B
nuclear	I
protein	I
and	O
a	O
membrane	O
protein	O
gene	O
similar	O
to	O
those	O
in	O
yeast	O
.	O
These	O
results	O
are	O
the	O
first	O
to	O
demonstrate	O
the	O
structural	O
organization	O
of	O
a	O
vertebrate	O
gene	O
encoding	O
an	O
integral	B
membrane	I
protein	I
of	O
the	O
nuclear	O
envelope	O
that	O
may	O
be	O
a	O
member	O
of	O
a	O
family	O
of	O
polypeptides	O
conserved	O
in	O
evolution	O
.	O
Sp1	B
is	O
a	O
critical	O
factor	O
for	O
the	O
monocytic	O
specific	O
expression	O
of	O
human	B
CD14	I
.	O
CD14	B
is	O
a	O
membrane	B
glycoprotein	I
expressed	O
specifically	O
on	O
monocytes	O
and	O
macrophages	O
,	O
and	O
its	O
expression	O
is	O
markedly	O
increased	O
during	O
the	O
process	O
of	O
monocyte	O
differentiation	O
.	O
In	O
order	O
to	O
study	O
CD14	O
gene	O
regulation	O
,	O
the	O
human	O
CD14	O
gene	O
was	O
cloned	O
from	O
a	O
partial	O
EcoRI	O
digested	O
chromosome	O
5	O
library	O
.	O
A	O
5.5-kilobase	O
genomic	O
clone	O
contained	O
the	O
full	O
-	O
length	O
CD14	O
coding	O
sequence	O
and	O
4.2	O
kilobases	O
of	O
5'-upstream	O
sequence	O
.	O
One	O
major	O
and	O
one	O
minor	O
transcription	O
start	O
site	O
were	O
identified	O
101	O
and	O
130	O
base	O
pairs	O
(	O
bp	O
)	O
upstream	O
,	O
respectively	O
,	O
from	O
the	O
protein	O
translation	O
start	O
ATG	O
.	O
A	O
DNA	O
fragment	O
containing	O
128	O
bp	O
of	O
upstream	O
sequence	O
had	O
strong	O
,	O
monocyte	O
-	O
specific	O
promoter	O
activity	O
in	O
the	O
CD14	O
positive	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
as	O
compared	O
to	O
the	O
nonmonocytic	O
cell	O
lines	O
HeLa	O
and	O
REX	O
.	O
Four	O
regions	O
in	O
this	O
DNA	O
fragment	O
interact	O
with	O
nuclear	B
proteins	I
isolated	O
from	O
monocytic	O
cells	O
.	O
The	O
Sp1	B
transcription	B
factor	I
bound	O
to	O
three	O
different	O
regions	O
in	O
the	O
CD14	O
promoter	O
.	O
Mutation	O
of	O
the	O
major	O
Sp1	O
binding	O
site	O
(	O
-110	O
bp	O
)	O
decreased	O
tissue	O
-	O
specific	O
promoter	O
activity	O
,	O
and	O
these	O
results	O
,	O
together	O
with	O
transactivation	O
experiments	O
,	O
demonstrate	O
that	O
Sp1	B
plays	O
a	O
critical	O
role	O
in	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
CD14	B
in	O
monocytic	O
cells	O
.	O
CD14	B
Sp1	B
site	O
oligonucleotides	O
bound	O
preferentially	O
to	O
a	O
105-kDa	B
Sp1	I
species	I
,	O
which	O
is	O
present	O
in	O
higher	O
relative	O
levels	O
in	O
monocytic	O
than	O
non	O
-	O
monocytic	O
cells	O
,	O
suggesting	O
that	O
modification	O
of	O
Sp1	B
,	O
such	O
as	O
phosphorylation	O
,	O
may	O
explain	O
how	O
the	O
Sp1	B
site	O
mediates	O
monocytic	O
specific	O
promoter	O
activity	O
.	O
Genes	O
encoding	O
general	B
initiation	I
factors	I
for	O
RNA	B
polymerase	I
II	I
transcription	O
are	O
dispersed	O
in	O
the	O
human	O
genome	O
.	O
General	B
transcription	I
factors	I
are	O
required	O
for	O
accurate	O
initiation	O
of	O
transcription	O
by	O
RNA	B
polymerase	I
II	I
.	O
Human	O
cDNAs	O
encoding	O
subunits	O
of	O
these	O
factors	O
have	O
been	O
cloned	O
and	O
sequenced	O
.	O
Using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
,	O
we	O
show	O
here	O
that	O
the	O
genes	O
encoding	O
the	O
TATA	B
-	I
box	I
binding	I
protein	I
(	O
TBP	B
)	O
,	O
TFIIB	B
,	O
TFIIE	B
alpha	I
,	O
TFIIE	B
beta	I
,	O
RAP30	B
,	O
RAP74	B
and	O
the	O
62	B
kDa	I
subunit	I
,	O
of	O
TFIIH	B
are	O
located	O
at	O
the	O
human	O
chromosomal	O
bands	O
6q26	O
-	O
27	O
,	O
1p21	O
-	O
22	O
,	O
3q21	O
-	O
24	O
,	O
8p12	O
,	O
13q14	O
,	O
19p13.3	O
and	O
11p14	O
-	O
15.1	O
,	O
respectively	O
.	O
This	O
dispersed	O
localization	O
of	O
a	O
group	O
of	O
functionally	O
related	O
gene	O
provides	O
insights	O
into	O
the	O
molecular	O
mechanism	O
of	O
human	O
genome	O
evolution	O
and	O
their	O
possible	O
involvement	O
in	O
human	O
diseases	O
.	O
ERP	B
,	O
a	O
new	O
member	O
of	O
the	O
ets	B
transcription	I
factor	I
/	I
oncoprotein	I
family	I
:	O
cloning	O
,	O
characterization	O
,	O
and	O
differential	O
expression	O
during	O
B	O
-	O
lymphocyte	O
development	O
.	O
The	O
ets	O
gene	O
family	O
encodes	O
a	O
group	O
of	O
proteins	O
which	O
function	O
as	O
transcription	B
factors	I
under	O
physiological	O
conditions	O
and	O
,	O
if	O
aberrantly	O
expressed	O
,	O
can	O
cause	O
cellular	O
transformation	O
.	O
We	O
have	O
recently	O
identified	O
two	O
regulatory	O
elements	O
in	O
the	O
murine	O
immunoglobulin	O
heavy	O
-	O
chain	O
(	O
IgH	O
)	O
enhancer	O
,	O
pi	O
and	O
microB	O
,	O
which	O
exhibit	O
striking	O
similarity	O
to	O
binding	O
sites	O
for	O
ets	O
-	O
related	O
proteins	O
.	O
To	O
identify	O
ets	B
-	I
related	I
transcriptional	I
regulators	I
expressed	O
in	O
pre	O
-	O
B	O
lymphocytes	O
that	O
may	O
interact	O
with	O
either	O
the	O
pi	O
or	O
the	O
microB	O
site	O
,	O
we	O
have	O
used	O
a	O
PCR	O
approach	O
with	O
degenerate	O
oligonucleotides	O
encoding	O
conserved	O
sequences	O
in	O
all	O
members	O
of	O
the	O
ets	O
family	O
.	O
We	O
have	O
cloned	O
the	O
gene	O
for	O
a	O
new	O
ets	B
-	I
related	I
transcription	I
factor	I
,	O
ERP	B
(	O
ets	B
-	I
related	I
protein	I
)	O
,	O
from	O
the	O
murine	O
pre	O
-	O
B	O
cell	O
line	O
BASC	O
6C2	O
and	O
from	O
mouse	O
lung	O
tissue	O
.	O
The	O
ERP	B
protein	O
contains	O
a	O
region	O
of	O
high	O
homology	O
with	O
the	O
ETS	O
DNA	O
-	O
binding	O
domain	O
common	O
to	O
all	O
members	O
of	O
the	O
ets	B
transcription	I
factor	I
/	I
oncoprotein	I
family	I
.	O
Three	O
additional	O
smaller	O
regions	O
show	O
homology	O
to	O
the	O
ELK-1	O
and	O
SAP-1	B
genes	O
,	O
a	O
subgroup	O
of	O
the	O
ets	O
gene	O
family	O
that	O
interacts	O
with	O
the	O
serum	B
response	I
factor	I
.	O
Full	O
-	O
length	O
ERP	B
expresses	O
only	O
negligible	O
DNA	O
-	O
binding	O
activity	O
by	O
itself	O
.	O
Removal	O
of	O
the	O
carboxy	B
terminus	I
enables	O
ERP	B
to	O
interact	O
with	O
a	O
variety	O
of	O
ets	O
-	O
binding	O
sites	O
including	O
the	O
E74	O
site	O
,	O
the	O
IgH	O
enhancer	O
pi	O
site	O
,	O
and	O
the	O
lck	O
promoter	O
ets	O
site	O
,	O
suggesting	O
a	O
carboxy	B
-	I
terminal	I
negative	I
regulatory	I
domain	I
.	O
At	O
least	O
three	O
ERP	B
-	I
related	I
transcripts	I
are	O
expressed	O
in	O
a	O
variety	O
of	O
tissues	O
.	O
However	O
,	O
within	O
the	O
B	O
-	O
cell	O
lineage	O
,	O
ERP	B
is	O
highly	O
expressed	O
primarily	O
at	O
early	O
stages	O
of	O
B	O
-	O
lymphocyte	O
development	O
,	O
and	O
expression	O
declines	O
drastically	O
upon	O
B	O
-	O
cell	O
maturation	O
,	O
correlating	O
with	O
the	O
enhancer	O
activity	O
of	O
the	O
IgH	O
pi	O
site	O
.	O
These	O
data	O
suggest	O
that	O
ERP	B
might	O
play	O
a	O
role	O
in	O
B	O
-	O
cell	O
development	O
and	O
in	O
IgH	O
gene	O
regulation	O
.	O
Functional	O
block	O
for	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3-mediated	O
gene	O
regulation	O
in	O
human	O
B	O
lymphocytes	O
.	O
Elements	O
necessary	O
for	O
the	O
steroid	O
hormone	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
)	O
to	O
induce	O
a	O
biological	O
response	O
include	O
the	O
presence	O
of	O
specific	O
intracellular	B
receptors	I
(	O
vitamin	B
D3	I
receptors	I
(	O
VDR	B
)	O
)	O
and	O
modulation	O
of	O
gene	O
expression	O
via	O
hormone	O
-	O
activated	O
receptor	O
binding	O
to	O
regulatory	B
regions	I
of	O
target	O
genes	O
.	O
These	O
parameters	O
were	O
examined	O
in	O
normal	O
and	O
Epstein	O
-	O
Barr	O
virus	O
-	O
immortalized	O
human	O
B	O
cells	O
and	O
compared	O
with	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3-responsive	O
cells	O
of	O
the	O
T	O
and	O
monocytic	O
lineages	O
.	O
Although	O
resting	O
tonsillar	O
B	O
cells	O
did	O
not	O
express	O
VDR	O
mRNA	O
,	O
activation	O
of	O
these	O
cells	O
with	O
interleukin-4	B
induced	O
VDR	B
in	O
the	O
absence	O
of	O
exogenously	O
supplemented	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O
As	O
indicators	O
of	O
hormone	O
-	O
mediated	O
gene	O
regulation	O
we	O
analyzed	O
modulation	O
of	O
CD23	B
,	O
a	O
common	B
B	I
cell	I
/	I
monocyte	I
surface	I
antigen	I
,	O
and	O
24-hydroxylase	B
.	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
inhibited	O
CD23	B
expression	O
in	O
U937	O
cells	O
,	O
yet	O
failed	O
to	O
modulate	O
CD23	B
expression	O
in	O
B	O
cells	O
.	O
Furthermore	O
,	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
induced	O
24-hydroxylase	B
mRNA	O
expression	O
and	O
metabolic	O
activity	O
in	O
both	O
U937	O
cells	O
and	O
lectin	O
-	O
activated	O
T	O
cells	O
,	O
yet	O
failed	O
to	O
induce	O
24-hydroxylase	O
mRNA	O
or	O
its	O
metabolic	O
activity	O
in	O
B	O
cells	O
.	O
These	O
findings	O
suggest	O
that	O
although	O
human	O
B	O
lymphocytes	O
can	O
express	O
VDR	O
mRNA	O
and	O
protein	B
,	O
they	O
exhibit	O
a	O
functional	O
block	O
for	O
vitamin	O
D	O
-	O
dependent	O
gene	O
regulation	O
.	O
Interferon	B
alpha	I
selectively	O
affects	O
expression	O
of	O
the	O
human	B
myeloid	I
cell	I
nuclear	I
differentiation	I
antigen	I
in	O
late	O
stage	O
cells	O
in	O
the	O
monocytic	O
but	O
not	O
the	O
granulocytic	O
lineage	O
.	O
The	O
human	B
myeloid	I
cell	I
nuclear	I
differentiation	I
antigen	I
(	O
MNDA	B
)	O
is	O
expressed	O
constitutively	O
in	O
cells	O
of	O
the	O
myeloid	O
lineage	O
,	O
appearing	O
in	O
myeloblast	O
cells	O
in	O
some	O
cases	O
of	O
acute	O
myeloid	O
leukemia	O
and	O
consistently	O
being	O
detected	O
in	O
promyelocyte	O
stage	O
cells	O
as	O
well	O
as	O
in	O
all	O
later	O
stage	O
cells	O
including	O
peripheral	O
blood	O
monocytes	O
and	O
granulocytes	O
.	O
The	O
human	O
myeloid	O
leukemia	O
cell	O
lines	O
,	O
HL-60	O
,	O
U937	O
,	O
and	O
THP-1	O
,	O
express	O
similar	O
levels	O
of	O
immunochemically	O
detectable	O
MNDA	B
.	O
Although	O
,	O
the	O
level	O
of	O
MNDA	O
mRNA	O
in	O
primary	O
monocytes	O
is	O
very	O
low	O
it	O
was	O
up	O
-	O
regulated	O
at	O
6	O
h	O
following	O
the	O
addition	O
of	O
interferon	B
alpha	I
.	O
The	O
effect	O
of	O
interferon	B
alpha	I
on	O
the	O
MNDA	O
mRNA	O
is	O
also	O
observed	O
in	O
the	O
cell	O
lines	O
HL-60	O
,	O
U937	O
,	O
and	O
THP-1	O
.	O
The	O
MNDA	O
mRNA	O
level	O
in	O
primary	O
granulocytes	O
was	O
unaffected	O
by	O
addition	O
of	O
interferon	B
alpha	I
and	O
other	O
agents	O
including	O
interferon	B
gamma	I
,	O
endotoxin	B
,	O
poly	B
(	I
I	I
)	I
.poly	I
(	I
C	I
)	I
,	O
and	O
FMLP	B
.	O
The	O
MNDA	O
mRNA	O
level	O
in	O
the	O
myeloid	O
cell	O
lines	O
was	O
also	O
unaffected	O
by	O
the	O
latter	O
four	O
agents	O
.	O
Induction	O
of	O
differentiation	O
in	O
the	O
myeloid	O
cell	O
lines	O
with	O
phorbol	O
ester	O
induces	O
monocyte	O
differentiation	O
which	O
was	O
accompanied	O
by	O
a	O
decrease	O
in	O
MNDA	O
mRNA	O
level	O
.	O
This	O
reduced	O
level	O
of	O
mRNA	O
could	O
then	O
be	O
elevated	O
with	O
subsequent	O
interferon	B
alpha	I
treatment	O
.	O
The	O
effects	O
of	O
phorbol	O
ester	O
on	O
MNDA	O
mRNA	O
appeared	O
to	O
be	O
associated	O
with	O
induced	O
differentiation	O
since	O
inhibiting	O
cell	O
proliferation	O
did	O
not	O
alter	O
the	O
level	O
of	O
MNDA	O
mRNA	O
and	O
cell	O
cycle	O
variation	O
in	O
MNDA	O
mRNA	O
levels	O
were	O
not	O
observed	O
.	O
The	O
ability	O
of	O
interferon	B
alpha	I
to	O
up	O
-	O
regulate	O
MNDA	O
mRNA	O
in	O
phorbol	O
ester	O
treated	O
myeloid	O
cell	O
lines	O
is	O
consistent	O
with	O
the	O
observations	O
made	O
in	O
primary	O
monocytes	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Induction	O
of	O
proto	O
-	O
oncogene	O
and	O
cytokine	B
expression	O
in	O
human	O
peripheral	O
blood	O
monocytes	O
and	O
the	O
monocytic	O
cell	O
line	O
THP-1	O
after	O
stimulation	O
with	O
mycoplasma	O
-	O
derived	O
material	O
MDHM	O
.	O
Mycoplasma	O
fermentans	O
-	O
derived	O
high	O
-	O
molecular	O
-	O
weight	O
material	O
(	O
MDHM	O
)	O
was	O
originally	O
described	O
to	O
induce	O
differentiation	O
of	O
murine	O
thymocytes	O
to	O
cytolytic	O
effector	O
T	O
-	O
cells	O
by	O
stimulating	O
IL-6	B
release	O
from	O
adherent	O
cells	O
.	O
This	O
study	O
shows	O
that	O
human	O
peripheral	O
blood	O
monocytes	O
(	O
PBMo	O
)	O
also	O
respond	O
to	O
MDHM	O
with	O
increases	O
in	O
IL-1	B
beta	I
,	O
IL-6	B
and	O
TNF	B
alpha	I
expression	O
,	O
both	O
at	O
the	O
mRNA	O
and	O
protein	O
level	O
.	O
The	O
induced	O
expression	O
of	O
IL-1	O
beta	O
and	O
TNF	O
alpha	O
mRNA	O
in	O
the	O
monocytic	O
THP-1	O
cell	O
line	O
increased	O
as	O
quickly	O
as	O
in	O
primary	O
cells	O
.	O
In	O
contrast	O
to	O
PBMo	O
,	O
THP-1	O
and	O
14	O
other	O
monocytic	O
/	O
myeloid	O
leukemia	O
-	O
derived	O
cell	O
lines	O
did	O
not	O
secrete	O
measurable	O
amounts	O
of	O
the	O
cytokines	B
upon	O
treatment	O
with	O
MDHM	O
.	O
IL-1	O
beta	O
and	O
IL-6	O
genes	O
contain	O
AP-1	O
binding	O
sites	O
as	O
regulatory	O
elements	O
,	O
the	O
AP-1	B
protein	O
being	O
composed	O
of	O
c	B
-	I
jun	I
and	I
c	I
-	I
fos	I
gene	I
products	I
.	O
In	O
THP-1	O
cells	O
c	O
-	O
jun	O
mRNA	O
expression	O
increased	O
after	O
incubation	O
with	O
MDHM	O
while	O
positive	O
c	O
-	O
fos	O
expression	O
remained	O
unaffected	O
.	O
Although	O
these	O
data	O
suggest	O
AP-1	B
regulated	O
cytokine	B
mRNA	O
expression	O
,	O
results	O
from	O
PBMo	O
are	O
not	O
in	O
accordance	O
with	O
this	O
notion	O
.	O
In	O
the	O
primary	O
cells	O
MDHM	O
-	O
induced	O
elevation	O
of	O
cytokine	O
mRNA	O
levels	O
was	O
preceded	O
by	O
a	O
downregulation	O
of	O
c	O
-	O
fos	O
expression	O
while	O
positive	O
c	O
-	O
jun	O
expression	O
was	O
not	O
modulated	O
.	O
c	O
-	O
myc	O
mRNA	O
expression	O
,	O
constitutively	O
high	O
in	O
THP-1	O
cells	O
,	O
was	O
induced	O
in	O
MDHM	O
-	O
stimulated	O
PBMo	O
.	O
In	O
conclusion	O
,	O
MDHM	O
-	O
stimulated	O
induction	O
of	O
cytokine	O
mRNA	O
expression	O
was	O
accompanied	O
by	O
different	O
proto	O
-	O
oncogene	O
responses	O
in	O
PBMo	O
and	O
THP-1	O
cells	O
.	O
These	O
differences	O
may	O
represent	O
different	O
regulatory	O
pathways	O
of	O
the	O
two	O
cell	O
systems	O
.	O
Alternatively	O
,	O
these	O
data	O
support	O
the	O
notion	O
that	O
neither	O
AP-1	B
nor	O
the	O
c	B
-	I
myc	I
protein	I
are	O
involved	O
in	O
the	O
MDHM	O
-	O
induced	O
increase	O
in	O
IL-1	O
beta	O
,	O
IL-6	O
or	O
TNF	O
alpha	O
mRNA	O
levels	O
.	O
Furthermore	O
,	O
the	O
present	O
results	O
demonstrate	O
clearly	O
that	O
mycoplasma	B
products	I
can	O
have	O
a	O
profound	O
impact	O
on	O
the	O
activation	O
status	O
of	O
eukaryotic	O
cells	O
.	O
All	O
-	O
trans	O
retinoic	O
acid	O
and	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
co	O
-	O
operate	O
to	O
promote	O
differentiation	O
of	O
the	O
human	O
promyeloid	O
leukemia	O
cell	O
line	O
HL60	O
to	O
monocytes	O
.	O
A	O
basis	O
for	O
differentiation	O
therapy	O
of	O
leukemias	O
is	O
provided	O
by	O
knowledge	O
of	O
agents	O
which	O
induce	O
specific	O
lineage	O
maturation	O
.	O
All	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
induces	O
differentiation	O
of	O
HL60	O
cells	O
to	O
neutrophils	O
and	O
is	O
used	O
to	O
treat	O
acute	O
promyelocytic	O
leukemia	O
.	O
We	O
observed	O
that	O
RA	O
did	O
not	O
induced	O
neutrophil	O
differentiation	O
in	O
serum	O
-	O
free	O
grown	O
HL60	O
cells	O
whereas	O
50	O
nM	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
D3	O
)	O
induced	O
maximal	O
monocyte	O
differentiation	O
.	O
Increasing	O
RA	O
concentrations	O
reduced	O
the	O
D3	O
concentration	O
required	O
for	O
monocyte	O
differentiation	O
.	O
Cells	O
treated	O
with	O
5	O
nM	O
D3	O
showed	O
little	O
response	O
,	O
but	O
differentiated	O
maximally	O
with	O
5	O
nM	O
D3	O
and	O
10	O
nM	O
RA	O
.	O
The	O
D3	O
analogs	O
MC903	O
,	O
EB1089	O
and	O
KH1060	O
were	O
more	O
potent	O
inducers	O
of	O
monocyte	O
differentiation	O
.	O
The	O
extent	O
to	O
which	O
analog	O
activity	O
was	O
increased	O
after	O
cotreatment	O
with	O
RA	O
was	O
inversely	O
related	O
to	O
potency	O
.	O
Twenty	O
-	O
four	O
hour	O
treatment	O
with	O
10	O
nM	O
RA	O
primed	O
cells	O
for	O
response	O
to	O
5	O
nM	O
D3	O
;	O
the	O
reverse	O
sequence	O
being	O
ineffective	O
.	O
Priming	O
with	O
10	O
nM	O
RA	O
,	O
or	O
subsequent	O
treatment	O
with	O
D3	O
(	O
5	O
nM	O
)	O
,	O
did	O
not	O
alter	O
expression	O
of	O
mRNAs	O
encoding	O
receptors	B
for	O
D3	O
(	O
VDR	B
)	O
,	O
RA	O
(	O
RAR	B
alpha	I
)	O
or	O
9-CIS	O
RA	O
(	O
RXR	B
alpha	I
,	I
beta	I
,	I
gamma	I
)	O
.	O
That	O
RA	O
promotes	O
both	O
neutrophil	O
and	O
monocyte	O
differentiation	O
has	O
implications	O
for	O
the	O
use	O
of	O
RA	O
and	O
D3	O
in	O
treatment	O
of	O
leukemias	O
and	O
provides	O
insight	O
into	O
mechanisms	O
whereby	O
RAR	O
,	O
VDR	B
and	O
RXR	B
facilitate	O
monocyte	O
differentiation	O
.	O
Alternative	O
splicing	O
of	O
RNA	O
transcripts	O
encoded	O
by	O
the	O
murine	O
p105	O
NF	O
-	O
kappa	O
B	O
gene	O
generates	O
I	B
kappa	I
B	I
gamma	I
isoforms	I
with	O
different	O
inhibitory	O
activities	O
.	O
The	O
gene	O
encoding	O
the	O
105-kDa	B
protein	I
(	I
p105	I
)	I
precursor	I
of	O
the	O
p50	B
subunit	O
of	O
transcription	O
factor	O
NF	B
-	I
kappa	I
B	I
also	O
encodes	O
a	O
p70	B
I	I
kappa	I
B	I
protein	I
,	O
I	B
kappa	I
B	I
gamma	I
,	O
which	O
is	O
identical	O
to	O
the	O
C	B
-	I
terminal	I
607	I
amino	I
acids	I
of	O
p105	B
.	O
Here	O
we	O
show	O
that	O
alternative	O
RNA	O
splicing	O
generates	O
I	B
kappa	I
B	I
gamma	I
isoforms	I
with	O
properties	O
different	O
from	O
those	O
of	O
p70	B
.	O
One	O
63-kDa	B
isoform	I
,	O
termed	O
I	B
kappa	I
B	I
gamma-1	I
,	O
which	O
lacks	O
59	O
amino	O
acids	O
C	O
-	O
terminal	O
to	O
ankyrin	B
repeat	I
7	I
,	O
has	O
a	O
novel	O
35-amino	B
acid	I
C	I
terminus	I
encoded	O
by	O
an	O
alternative	O
reading	O
frame	O
of	O
the	O
p105	O
gene	O
.	O
A	O
55-kDa	B
isoform	I
,	O
I	B
kappa	I
B	I
gamma-2	I
,	O
lacks	O
the	O
190	B
C	I
-	I
terminal	I
amino	I
acids	I
of	O
p70	B
I	B
kappa	I
B	I
gamma	I
.	O
In	O
contrast	O
to	O
p70	B
I	B
kappa	I
B	I
gamma	I
,	O
which	O
is	O
a	O
cytoplasmic	B
protein	I
,	O
I	B
kappa	I
B	I
gamma-1	I
is	O
found	O
in	O
both	O
the	O
cytoplasm	O
and	O
nucleus	O
,	O
whereas	O
I	B
kappa	I
B	I
gamma-2	I
is	O
predominantly	O
nuclear	O
.	O
The	O
I	B
kappa	I
B	I
gamma	I
isoforms	I
also	O
display	O
differences	O
in	O
specificity	O
and	O
affinity	O
for	O
Rel	B
/	I
NF	I
-	I
kappa	I
B	I
proteins	I
.	O
While	O
p70	B
I	B
kappa	I
B	I
gamma	I
inhibits	O
p50-	O
,	O
p65-	O
,	O
and	O
c	O
-	O
Rel	O
-	O
mediated	O
transactivation	O
and/or	O
DNA	O
binding	O
,	O
both	O
I	B
kappa	I
B	I
gamma-1	I
and	O
I	B
kappa	I
B	I
gamma-2	I
are	O
specific	O
for	O
p50	B
and	O
have	O
different	O
affinities	O
for	O
this	O
subunit	O
.	O
The	O
absence	O
in	O
I	B
kappa	I
B	I
gamma-1	I
and	O
I	B
kappa	I
B	I
gamma-2	I
of	O
a	O
protein	O
kinase	O
A	O
site	O
whose	O
phosphorylation	O
modulates	O
p70	B
I	B
kappa	I
B	I
gamma	I
inhibitory	O
activity	O
suggests	O
that	O
alternative	O
RNA	O
splicing	O
may	O
be	O
used	O
to	O
generate	O
I	B
kappa	I
B	I
gamma	I
isoforms	I
that	O
respond	O
differently	O
to	O
intracellular	O
signals	O
.	O
Some	O
antioxidants	O
inhibit	O
,	O
in	O
a	O
co	O
-	O
ordinate	O
fashion	O
,	O
the	O
production	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
,	O
IL	B
-	I
beta	I
,	O
and	O
IL-6	B
by	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
Some	O
antioxidants	O
,	O
including	O
butylated	O
hydroxyanisole	O
(	O
BHA	O
)	O
,	O
tetrahydropapaveroline	O
(	O
THP	O
)	O
,	O
nordihydroguiauretic	O
acid	O
,	O
and	O
10	O
,	O
11-dihydroxyaporphine	O
(	O
DHA	O
)	O
,	O
were	O
found	O
to	O
be	O
potent	O
inhibitors	O
of	O
the	O
production	O
of	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
-alpha	I
,	O
IL-1	B
beta	I
,	O
and	O
IL-6	B
by	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
stimulated	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
(	O
IC50s	O
in	O
the	O
low	O
micromolar	O
range	O
)	O
.	O
Inhibition	O
of	O
cytokine	B
production	O
was	O
gene	O
selective	O
and	O
not	O
due	O
to	O
general	O
effects	O
on	O
protein	O
synthesis	O
.	O
Inhibition	O
of	O
cytokine	B
production	O
by	O
PBMC	O
was	O
observed	O
also	O
when	O
other	O
inducers	O
were	O
used	O
(	O
staphylococci	O
,	O
silica	O
,	O
zymosan	O
)	O
.	O
Much	O
higher	O
concentrations	O
of	O
other	O
antioxidants	O
--	O
including	O
ascorbic	O
acid	O
,	O
trolox	O
,	O
alpha	O
-	O
tocopherol	O
,	O
butylated	O
hydroxytoluene	O
,	O
and	O
the	O
5-lipoxygenase	O
inhibitor	O
zileuton	O
--	O
did	O
not	O
affect	O
the	O
production	O
of	O
these	O
cytokines	B
.	O
The	O
active	O
compounds	O
did	O
not	O
inhibit	O
IL-1	B
-induced	O
production	O
of	O
IL-6	B
in	O
fibroblasts	O
,	O
showing	O
the	O
cell	O
selectivity	O
of	O
the	O
effect	O
.	O
Antioxidant	O
-	O
mediated	O
inhibition	O
of	O
cytokine	B
production	O
was	O
correlated	O
with	O
low	O
levels	O
of	O
the	O
corresponding	O
messenger	O
RNAs	O
.	O
Nuclear	O
run	O
-	O
on	O
experiments	O
showed	O
that	O
THP	O
inhibited	O
transcription	O
of	O
the	O
IL-1	O
beta	O
gene	O
.	O
THP	O
decreased	O
the	O
concentration	O
of	O
the	O
transcription	B
factors	I
NF	B
-	I
kappa	I
B	I
and	O
AP-1	B
detected	O
in	O
nuclear	O
extracts	O
of	O
PBMC	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
LPS	O
.	O
THP	O
and	O
DHA	O
markedly	O
decreased	O
the	O
levels	O
of	O
TNF	B
-	I
alpha	I
and	O
IL-1	B
beta	I
in	O
the	O
circulation	O
of	O
mice	O
following	O
LPS	O
injection	O
.	O
Thus	O
antioxidants	O
vary	O
widely	O
in	O
potency	O
as	O
inhibitors	O
of	O
the	O
activation	O
of	O
transcription	B
factors	I
and	O
of	O
the	O
transcription	O
of	O
genes	O
for	O
pro	B
-	I
inflammatory	I
cytokines	I
.	O
Coordinate	O
inhibition	O
of	O
the	O
transcription	O
of	O
genes	O
for	O
inflammatory	O
cytokines	B
could	O
provide	O
a	O
strategy	O
for	O
therapy	O
of	O
diseases	O
with	O
inflammatory	O
pathogenesis	O
and	O
for	O
septic	O
shock	O
.	O
An	O
intricate	O
arrangement	O
of	O
binding	O
sites	O
for	O
the	O
Ets	B
family	I
of	O
transcription	B
factors	I
regulates	O
activity	O
of	O
the	O
alpha	O
4	O
integrin	O
gene	O
promoter	O
.	O
alpha	B
4	I
integrins	I
mediate	O
cell	O
-	O
cell	O
and	O
cell	O
-	O
extracellular	O
matrix	O
interactions	O
that	O
are	O
critical	O
for	O
maturation	O
and	O
function	O
of	O
the	O
immune	O
system	O
as	O
well	O
as	O
differentiation	O
of	O
skeletal	O
muscle	O
.	O
Here	O
we	O
examine	O
molecular	O
mechanisms	O
controlling	O
the	O
pattern	O
of	O
alpha	B
4	I
expression	O
.	O
The	O
activity	O
of	O
constructs	O
containing	O
5	O
'	O
deletion	O
mutants	O
of	O
the	O
alpha	O
4	O
gene	O
promoter	O
was	O
compared	O
in	O
transfection	O
assays	O
into	O
cell	O
lines	O
that	O
express	O
alpha	B
4	I
and	O
cell	O
lines	O
that	O
do	O
not	O
.	O
The	O
sequence	O
between	O
position	O
-42	O
and	O
-76	O
base	O
pairs	O
(	O
bp	O
)	O
was	O
required	O
for	O
efficient	O
transcription	O
in	O
cells	O
that	O
express	O
alpha	B
4	I
,	O
but	O
it	O
showed	O
no	O
activity	O
in	O
HeLa	O
cells	O
,	O
which	O
do	O
not	O
express	O
alpha	B
4	I
.	O
Three	O
binding	O
sites	O
for	O
the	O
Ets	B
family	I
of	O
transcription	B
factors	I
are	O
found	O
in	O
this	O
region	O
:	O
two	O
adjacent	O
sites	O
at	O
positions	O
-50	O
and	O
-54	O
bp	O
and	O
a	O
more	O
5	O
'	O
site	O
at	O
position	O
-67	O
bp	O
.	O
Using	O
a	O
series	O
of	O
constructs	O
containing	O
deletions	O
and	O
mutations	O
in	O
this	O
region	O
,	O
we	O
found	O
that	O
the	O
3'-most	O
site	O
alone	O
was	O
sufficient	O
for	O
binding	O
GA	B
-	I
binding	I
protein	I
alpha	I
(	O
GABP	B
alpha	I
)	I
/GABP	I
beta	I
and	O
for	O
a	O
low	O
level	O
of	O
transcriptional	O
activation	O
.	O
When	O
all	O
three	O
sites	O
were	O
present	O
,	O
a	O
second	O
complex	O
`	O
`	O
a	O
''	O
was	O
detected	O
,	O
which	O
contains	O
an	O
unknown	O
member	O
of	O
the	O
Ets	B
family	I
.	O
Formation	O
of	O
complex	O
a	O
was	O
cell	O
-	O
type	O
specific	O
and	O
correlated	O
with	O
a	O
high	O
level	O
of	O
transcription	O
.	O
Deletion	O
of	O
the	O
5'-most	O
Ets	O
site	O
had	O
no	O
effect	O
on	O
binding	O
to	O
GABP	B
alpha	I
/	I
GABP	I
beta	I
,	O
but	O
it	O
eliminated	O
a	O
.	O
Concomitant	O
with	O
this	O
loss	O
of	O
a	O
,	O
a	O
new	B
Ets-1-containing	I
complex	I
`	O
`	O
c	B
`	O
`	O
appeared	O
.	O
Complex	O
c	O
substituted	O
efficiently	O
for	O
complex	O
a	O
in	O
transcriptional	O
activation	O
.	O
We	O
conclude	O
that	O
although	O
neither	O
of	O
the	O
two	O
5'-most	O
Ets	O
sites	O
alone	O
binds	O
nuclear	B
protein	I
,	O
they	O
appear	O
to	O
act	O
as	O
modulators	O
which	O
control	O
the	O
pattern	O
of	O
Ets	B
proteins	I
that	O
bind	O
the	O
alpha	O
4	O
gene	O
promoter	O
.	O
This	O
arrangement	O
of	O
Ets	O
sites	O
,	O
coupled	O
with	O
the	O
tissue-	O
and	O
developmental	O
-	O
specific	O
expression	O
of	O
Ets	B
members	I
,	O
likely	O
play	O
a	O
key	O
role	O
in	O
defining	O
the	O
pattern	O
of	O
alpha	B
4	I
integrin	I
.	O
Lipopolysaccharide	O
induction	O
of	O
tissue	O
factor	O
gene	O
expression	O
in	O
monocytic	O
cells	O
is	O
mediated	O
by	O
binding	O
of	O
c	B
-	I
Rel	I
/	I
p65	I
heterodimers	I
to	O
a	O
kappa	O
B	O
-	O
like	O
site	O
.	O
Exposure	O
of	O
monocytic	O
cells	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
activates	O
the	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
family	I
of	O
proteins	O
and	O
leads	O
to	O
the	O
rapid	O
induction	O
of	O
inflammatory	B
gene	I
products	I
,	O
including	O
tissue	B
factor	I
(	O
TF	B
)	O
.	O
TF	B
is	O
the	O
primary	O
cellular	O
initiator	O
of	O
the	O
coagulation	B
protease	I
cascades	O
.	O
Here	O
we	O
report	O
the	O
characterization	O
of	O
a	O
nuclear	B
complex	I
from	O
human	O
monocytic	O
cells	O
that	O
bound	O
to	O
a	O
kappa	O
B	O
-	O
like	O
site	O
,	O
5'-CGGAGTTTCC-3	O
'	O
,	O
in	O
the	O
5'-flanking	O
region	O
of	O
the	O
human	O
TF	O
gene	O
.	O
This	O
nuclear	B
complex	I
was	O
activated	O
by	O
LPS	O
with	O
kinetics	O
that	O
preceded	O
induction	O
of	O
the	O
TF	O
gene	O
.	O
In	O
vitro	O
binding	O
studies	O
demonstrated	O
that	O
the	O
TF	O
site	O
bound	O
translated	O
c	B
-	I
Rel	I
and	I
p65	I
homodimers	I
but	O
not	O
p50	B
/	I
p65	I
heterodimers	I
or	O
p50	B
homodimers	I
.	O
Base	O
-	O
pair	O
substitutions	O
in	O
the	O
TF	O
site	O
indicated	O
that	O
the	O
presence	O
of	O
a	O
cytosine	O
at	O
position	B
1	I
precluded	O
binding	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
In	O
fact	O
,	O
under	O
low	O
-	O
ionic	O
-	O
strength	O
conditions	O
,	O
the	O
TF	B
complex	I
did	O
not	O
migrate	O
with	O
translated	O
p50	B
/	I
p65	I
dimers	I
but	O
instead	O
comigrated	O
with	O
c	B
-	I
Rel	I
/	I
p65	I
dimers	I
.	O
Antibodies	O
against	O
the	O
NF	B
-	I
kappa	I
B	I
and	O
Rel	O
proteins	O
and	O
UV	O
cross	O
-	O
linking	O
studies	O
revealed	O
the	O
presence	O
of	O
c	B
-	I
Rel	I
and	O
p65	O
and	O
the	O
absence	O
of	O
p50	B
in	O
the	O
TF	B
complex	I
and	O
further	O
showed	O
that	O
c	B
-	I
Rel	I
/	I
p65	I
heterodimers	I
selectively	O
bound	O
to	O
the	O
TF	O
kappa	O
B	O
-	O
like	O
site	O
.	O
Functional	O
studies	O
indicated	O
that	O
the	O
TF	O
site	O
conferred	O
LPS	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
and	O
was	O
transactivated	O
by	O
c	B
-	I
Rel	I
or	O
p65	O
.	O
Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
binding	O
of	O
c	B
-	I
Rel	I
/	I
p65	I
heterodimers	I
to	O
a	O
novel	O
kappa	O
B	O
-	O
like	O
site	O
mediated	O
LPS	O
induction	O
of	O
TF	B
gene	O
expression	O
in	O
monocytic	O
cells	O
.	O
Prenatal	O
immune	O
challenge	O
alters	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenocortical	O
axis	O
in	O
adult	O
rats	O
.	O
We	O
investigated	O
whether	O
non	O
-	O
abortive	O
maternal	O
infections	O
would	O
compromise	O
fetal	O
brain	O
development	O
and	O
alter	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenocortical	O
(	O
HPA	O
)	O
axis	O
functioning	O
when	O
adult	O
.	O
To	O
study	O
putative	O
teratogenic	O
effects	O
of	O
a	O
T	O
cell	O
-	O
mediated	O
immune	O
response	O
versus	O
an	O
endotoxic	O
challenge	O
,	O
10-d	O
-	O
pregnant	O
rats	O
received	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
5	O
x	O
10	O
(	O
8	O
)	O
human	O
red	O
blood	O
cells	O
(	O
HRBC	O
)	O
or	O
gram	O
-	O
negative	O
bacterial	O
endotoxin	O
(	O
Escherichia	O
coli	O
LPS	O
:	O
30	O
micrograms	O
/	O
kg	O
)	O
.	O
The	O
adult	O
male	O
progeny	O
(	O
3	O
mo	O
old	O
)	O
of	O
both	O
experimental	O
groups	O
showed	O
increased	O
basal	O
plasma	O
corticosterone	O
levels	O
.	O
In	O
addition	O
,	O
after	O
novelty	O
stress	O
the	O
HRBC	O
group	O
,	O
but	O
not	O
the	O
LPS	O
group	O
,	O
showed	O
increased	O
ACTH	O
and	O
corticosterone	O
levels	O
.	O
Both	O
groups	O
showed	O
substantial	O
decreases	O
in	O
mineralocorticoid	O
(	O
MR	O
)	O
and	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
levels	O
in	O
the	O
hippocampus	O
,	O
a	O
limbic	O
brain	O
structure	O
critical	O
for	O
HPA	O
axis	O
regulation	O
,	O
whereas	O
GR	B
concentrations	O
in	O
the	O
hypothalamus	O
were	O
unchanged	O
and	O
in	O
anterior	O
pituitary	O
were	O
slightly	O
increased	O
.	O
HRBC	O
and	O
LPS	O
indeed	O
stimulated	O
the	O
maternal	O
immune	O
system	O
as	O
revealed	O
by	O
specific	O
anti	B
-	I
HRBC	I
antibody	I
production	O
and	O
enhanced	O
IL-1	O
beta	O
mRNA	O
expression	O
in	O
splenocytes	O
,	O
respectively	O
.	O
This	O
study	O
demonstrates	O
that	O
a	O
T	O
cell	O
-	O
mediated	O
immune	O
response	O
as	O
well	O
as	O
an	O
endotoxic	O
challenge	O
during	O
pregnancy	O
can	O
induce	O
anomalies	O
in	O
HPA	O
axis	O
function	O
in	O
adulthood	O
.	O
Clinically	O
,	O
it	O
may	O
be	O
postulated	O
that	O
disturbed	O
fetal	O
brain	O
development	O
due	O
to	O
prenatal	O
immune	O
challenge	O
increases	O
the	O
vulnerability	O
to	O
develop	O
mental	O
illness	O
involving	O
inadequate	O
responses	O
to	O
stress	O
.	O
Tolerance	O
to	O
lipopolysaccharide	O
involves	O
mobilization	O
of	O
nuclear	B
factor	I
kappa	I
B	I
with	O
predominance	O
of	O
p50	B
homodimers	O
.	O
Stimulation	O
of	O
the	O
human	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
leads	O
to	O
rapid	O
and	O
transient	O
expression	O
of	O
cytokines	B
like	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
.	O
When	O
such	O
cells	O
are	O
precultured	O
for	O
2	O
days	O
with	O
a	O
low	O
dose	O
of	O
LPS	O
(	O
20	O
ng	O
/	O
ml	O
)	O
followed	O
by	O
stimulation	O
with	O
a	O
high	O
dose	O
of	O
LPS	O
(	O
1	O
microgram	O
/	O
ml	O
)	O
,	O
expression	O
of	O
the	O
TNF	O
gene	O
is	O
minimal	O
,	O
i.e.	O
the	O
cells	O
are	O
tolerant	O
.	O
In	O
nuclear	O
run	O
-	O
on	O
analysis	O
,	O
such	O
tolerant	O
cells	O
show	O
only	O
a	O
low	O
degree	O
of	O
transcription	O
,	O
indicating	O
that	O
tolerance	O
operates	O
at	O
or	O
upstream	O
of	O
the	O
transcription	O
level	O
.	O
The	O
CD14	B
LPS	O
receptor	O
is	O
,	O
however	O
,	O
up	O
-	O
regulated	O
(	O
not	O
down	O
-	O
regulated	O
)	O
in	O
tolerant	O
cells	O
,	O
and	O
LPS	O
can	O
,	O
in	O
fact	O
,	O
still	O
lead	O
to	O
activation	O
of	O
tolerant	O
cells	O
as	O
evidenced	O
by	O
mobilization	O
of	O
the	O
transcription	B
factor	I
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
.	O
Resolution	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
complex	I
in	O
gel	O
shift	O
analysis	O
shows	O
that	O
the	O
binding	B
protein	I
,	O
mobilized	O
in	O
naive	O
Mono	O
Mac	O
6	O
cells	O
,	O
consists	O
mainly	O
of	O
p50-p65	B
heterodimers	I
,	O
while	O
in	O
tolerant	O
cells	O
,	O
the	O
p50	B
homodimer	I
is	O
predominant	O
.	O
This	O
increase	O
in	O
p50	B
homodimers	I
coincides	O
with	O
an	O
increase	O
in	O
p105	O
mRNA	O
,	O
suggestive	O
of	O
a	O
transcriptional	O
up	O
-	O
regulation	O
of	O
p50	B
.	O
Reporter	O
gene	O
analysis	O
reveals	O
that	O
the	O
NF	B
-	I
kappa	I
B	I
complex	I
mobilized	O
in	O
tolerant	O
cells	O
is	O
functionally	O
inactive	O
in	O
that	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
luciferase	O
constructs	O
containing	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
or	O
the	O
TNF	O
5'-region	O
show	O
only	O
minimal	O
transactivation	O
after	O
LPS	O
stimulation	O
.	O
Similar	O
to	O
Mono	O
Mac	O
6	O
cells	O
,	O
primary	O
blood	O
monocytes	O
,	O
when	O
precultured	O
with	O
a	O
low	O
dose	O
of	O
LPS	O
,	O
also	O
become	O
tolerant	O
and	O
produce	O
little	O
TNF	B
after	O
LPS	O
stimulation	O
.	O
The	O
tolerant	O
blood	O
monocytes	O
also	O
up	O
-	O
regulate	O
CD14	B
,	O
and	O
they	O
mobilize	O
NF	B
-	I
kappa	I
B	I
with	O
a	O
predominance	O
of	O
p50	B
homodimers	I
.	O
Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
tolerance	O
to	O
LPS	O
is	O
determined	O
by	O
post	O
-	O
receptor	O
mechanisms	O
that	O
involve	O
an	O
altered	O
composition	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
complex	I
.	O
Analysis	O
of	O
Oct2-isoform	B
expression	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
B	O
lymphocytes	O
.	O
Oct2-isoform	B
expression	O
in	O
splenic	O
B	O
cells	O
stimulated	O
with	O
lipopolysaccharide	O
or	O
lipopolysaccharide	O
plus	O
phorbol	O
-	O
di	O
-	O
butyrate	O
was	O
analysed	O
by	O
cDNA	O
cloning	O
.	O
The	O
frequency	O
of	O
Oct2-positive	O
clones	O
was	O
1	O
/	O
15	O
,	O
000	O
in	O
both	O
libraries	O
.	O
Two	O
new	O
isoforms	O
were	O
found	O
that	O
generate	O
novel	O
amino-	B
or	I
carboxy	I
-	I
terminal	I
sequences	I
.	O
An	O
isoform	O
lacking	O
exon	O
11	O
destroyed	O
the	O
carboxy	B
-	I
terminal	I
leucin	I
-	I
zipper	I
region	I
and	O
introduced	O
a	O
frame	O
shift	O
creating	O
a	O
novel	O
,	O
proline	B
-	I
rich	I
carboxy	I
terminus	I
.	O
A	O
new	O
exon	O
containing	O
a	O
highly	O
basic	O
region	O
(	O
4c	O
)	O
was	O
characterized	O
,	O
between	O
exons	O
4	O
and	O
5	O
.	O
This	O
exon	O
was	O
inserted	O
between	O
glutamine	O
-	O
rich	O
regions	O
2	O
and	O
3	O
,	O
carboxy	B
terminal	I
of	O
a	O
tentative	O
leucine	B
-	I
zipper	I
structure	I
.	O
In	O
addition	O
,	O
a	O
new	O
combination	O
isoform	O
containing	O
Oct2a	B
's	I
amino	I
terminal	I
insert	I
(	O
exon	O
7a	O
)	O
and	O
Oct2b	B
's	I
carboxy	I
terminal	I
insert	I
(	O
exon	O
13	O
)	O
was	O
found	O
that	O
created	O
a	O
novel	O
large	O
isoform	O
,	O
Oct2ab	B
.	O
More	O
frequent	O
use	O
of	O
the	O
classical	O
Oct2a	B
and	O
Oct2b	B
isoforms	O
was	O
observed	O
in	O
the	O
lipopolysaccharide	O
-	O
stimulated	O
B	O
cells	O
,	O
while	O
a	O
preference	O
for	O
the	O
Oct2ab	B
and	O
Oct2ba	B
isoforms	O
was	O
observed	O
in	O
lipopolysaccharide	O
plus	O
phorbol	O
-	O
di	O
-	O
butyrate	O
-	O
treated	O
cells	O
.	O
Function	O
and	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
the	O
immune	O
system	O
.	O
NF	B
-	I
kappa	I
B	I
is	O
a	O
ubiquitous	B
transcription	I
factor	I
.	O
Nevertheless	O
,	O
its	O
properties	O
seem	O
to	O
be	O
most	O
extensively	O
exploited	O
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O
Among	O
these	O
properties	O
are	O
NF	B
-	I
kappa	I
B	I
's	O
rapid	O
posttranslational	O
activation	O
in	O
response	O
to	O
many	O
pathogenic	O
signals	O
,	O
its	O
direct	O
participation	O
in	O
cytoplasmic	O
/	O
nuclear	O
signaling	O
,	O
and	O
its	O
potency	O
to	O
activate	O
transcription	O
of	O
a	O
great	O
variety	O
of	O
genes	O
encoding	O
immunologically	B
relevant	I
proteins	I
.	O
In	O
vertebrates	O
,	O
five	O
distinct	O
DNA	B
binding	I
subunits	I
are	O
currently	O
known	O
which	O
might	O
extensively	O
heterodimerize	O
,	O
thereby	O
forming	O
complexes	O
with	O
distinct	O
transcriptional	O
activity	O
,	O
DNA	O
sequence	O
specificity	O
,	O
and	O
cell	O
type-	O
and	O
cell	O
stage	O
-	O
specific	O
distribution	O
.	O
The	O
activity	O
of	O
DNA	B
binding	I
NF	I
-	I
kappa	I
B	I
dimers	I
is	O
tightly	O
controlled	O
by	O
accessory	B
proteins	I
called	O
I	B
kappa	I
B	I
subunits	I
of	O
which	O
there	O
are	O
also	O
five	O
different	O
species	O
currently	O
known	O
in	O
vertebrates	O
.	O
I	B
kappa	I
B	I
proteins	I
inhibit	O
DNA	O
binding	O
and	O
prevent	O
nuclear	O
uptake	O
of	O
NF	B
-	I
kappa	I
B	I
complexes	I
.	O
An	O
exception	O
is	O
the	O
Bcl-3	B
protein	I
which	O
in	O
addition	O
can	O
function	O
as	O
a	O
transcription	B
activating	I
subunit	I
in	O
th	O
nucleus	O
.	O
Other	O
I	B
kappa	I
B	I
proteins	I
are	O
rather	O
involved	O
in	O
terminating	O
NF	B
-	I
kappa	I
B	I
's	O
activity	O
in	O
the	O
nucleus	O
.	O
The	O
intracellular	O
events	O
that	O
lead	O
to	O
the	O
inactivation	O
of	O
I	B
kappa	I
B	I
,	O
i.e.	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
are	O
complex	O
.	O
They	O
involve	O
phosphorylation	O
and	O
proteolytic	O
reactions	O
and	O
seem	O
to	O
be	O
controlled	O
by	O
the	O
cells	O
'	O
redox	O
status	O
.	O
Interference	O
with	O
the	O
activation	O
or	O
activity	O
of	O
NF	B
-	I
kappa	I
B	I
may	O
be	O
beneficial	O
in	O
suppressing	O
toxic	O
/	O
septic	O
shock	O
,	O
graft	O
-	O
vs	O
-	O
host	O
reactions	O
,	O
acute	O
inflammatory	O
reactions	O
,	O
acute	O
phase	O
response	O
,	O
and	O
radiation	O
damage	O
.	O
The	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
by	O
antioxidants	O
and	O
specific	O
protease	O
inhibitors	O
may	O
provide	O
a	O
pharmacological	O
basis	O
for	O
interfering	O
with	O
these	O
acute	O
processes	O
.	O
Pentoxifylline	O
for	O
the	O
treatment	O
of	O
infection	O
with	O
human	O
immunodeficiency	O
virus	O
.	O
Cytokine	O
dysregulation	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
has	O
been	O
documented	O
in	O
numerous	O
studies	O
and	O
has	O
been	O
cited	O
as	O
an	O
important	O
component	O
in	O
the	O
pathogenesis	O
of	O
this	O
retroviral	O
infection	O
.	O
Pharmacological	O
modification	O
of	O
cytokine	B
dysregulation	O
,	O
therefore	O
,	O
has	O
been	O
suggested	O
as	O
a	O
therapeutic	O
modality	O
for	O
HIV-1	O
infection	O
.	O
Dr.	O
Dezube	O
of	O
Beth	O
Israel	O
Hospital	O
(	O
Boston	O
)	O
concisely	O
reviews	O
the	O
state	O
of	O
our	O
knowledge	O
regarding	O
the	O
effects	O
of	O
pentoxifylline	O
on	O
expression	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
,	O
a	O
cytokine	B
known	O
to	O
influence	O
HIV-1	O
replication	O
and	O
to	O
play	O
a	O
possible	O
role	O
in	O
the	O
clinical	O
manifestations	O
of	O
advanced	O
infection	O
with	O
this	O
virus	O
.	O
Pentoxifylline	O
,	O
a	O
trisubstituted	O
xanthine	O
derivative	O
,	O
has	O
been	O
used	O
to	O
decrease	O
blood	O
viscosity	O
and	O
is	O
reasonably	O
well	O
tolerated	O
by	O
most	O
recipients	O
of	O
the	O
drug	O
.	O
Results	O
of	O
preliminary	O
studies	O
,	O
many	O
of	O
which	O
were	O
conducted	O
by	O
Dr.	O
Dezube	O
,	O
suggest	O
that	O
use	O
of	O
this	O
agent	O
in	O
combination	O
with	O
antiretroviral	O
compounds	O
may	O
prove	O
useful	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
HIV-1	O
infection	O
.	O
Increased	O
interleukin	B
2	I
transcription	O
in	O
murine	O
lymphocytes	O
by	O
ciprofloxacin	O
.	O
The	O
fluoroquinolone	O
antibiotic	O
,	O
ciprofloxacin	O
(	O
cipro	O
)	O
,	O
induces	O
hyperproduction	O
of	O
interleukin	B
2	I
(	O
IL-2	B
)	O
and	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
in	O
stimulated	O
human	O
peripheral	O
blood	O
lymphocytes	O
.	O
In	O
this	O
investigation	O
an	O
enhanced	O
and	O
prolonged	O
IL-2	B
and	O
IL-2	O
mRNA	O
response	O
was	O
also	O
detected	O
in	O
both	O
stimulated	O
(	O
T	B
cell	I
mitogens	I
or	O
alloantigens	B
)	O
murine	O
splenocytes	O
and	O
in	O
the	O
stimulated	O
murine	O
T	O
cell	O
line	O
EL-4	O
in	O
the	O
presence	O
of	O
ciprofloxacin	O
(	O
5	O
-	O
80	O
micrograms	O
/	O
ml	O
)	O
as	O
compared	O
to	O
control	O
cells	O
without	O
antibiotics	O
.	O
However	O
,	O
in	O
contrast	O
to	O
human	O
lymphocytes	O
,	O
IFN	B
-	I
gamma	I
production	O
was	O
inhibited	O
and	O
IFN	O
-	O
gamma	O
mRNA	O
levels	O
were	O
unaffected	O
at	O
24	O
h	O
and	O
only	O
slightly	O
upregulated	O
at	O
48	O
and	O
72	O
h	O
of	O
culture	O
in	O
murine	O
splenocytes	O
incubated	O
with	O
cipro	O
(	O
20	O
micrograms	O
/	O
ml	O
)	O
.	O
EL-4	O
cells	O
were	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
IL-2	O
promoter	O
and	O
enhancer	O
region	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
.	O
Analysis	O
of	O
CAT	B
activity	O
revealed	O
that	O
cipro	O
enhanced	O
IL-2	O
gene	O
induction	O
.	O
In	O
addition	O
,	O
EL-4	O
cells	O
incubated	O
with	O
ciprofloxacin	O
showed	O
an	O
early	O
peak	O
and	O
more	O
activated	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT-1	B
)	O
as	O
compared	O
to	O
control	O
cells	O
without	O
antibiotics	O
.	O
Cipro	O
did	O
not	O
affect	O
the	O
nuclear	B
transcription	I
factors	I
AP-1	B
or	O
NFIL-2A	B
.	O
Taken	O
together	O
,	O
cipro	O
inhibited	O
IFN	B
-	I
gamma	I
synthesis	O
,	O
but	O
enhanced	O
IL-2	B
production	O
in	O
murine	O
lymphocytes	O
by	O
means	O
of	O
influencing	O
NFAT-1	B
and	O
causing	O
an	O
increased	O
IL-2	B
transcription	O
.	O
Nonpituitary	O
human	O
prolactin	O
gene	O
transcription	O
is	O
independent	O
of	O
Pit-1	B
and	O
differentially	O
controlled	O
in	O
lymphocytes	O
and	O
in	O
endometrial	O
stroma	O
.	O
Expression	O
of	O
the	O
human	O
PRL	O
(	O
hPRL	O
)	O
gene	O
in	O
extrapituitary	O
sites	O
such	O
as	O
the	O
uterus	O
(	O
decidualized	O
endometrial	O
stroma	O
and	O
myometrium	O
)	O
and	O
cells	O
of	O
the	O
hematopoietic	O
lineage	O
is	O
directed	O
by	O
an	O
alternative	O
promoter	O
which	O
is	O
located	O
approximately	O
6	O
kilobases	O
(	O
kb	O
)	O
upstream	O
of	O
the	O
pituitary	O
-	O
specific	O
start	O
site	O
.	O
In	O
order	O
to	O
delineate	O
the	O
tissue	O
-	O
specific	O
mechanisms	O
governing	O
the	O
control	O
of	O
nonpituitary	O
PRL	O
gene	O
expression	O
,	O
we	O
have	O
cloned	O
and	O
sequenced	O
3	O
kb	O
5'-flanking	O
DNA	O
of	O
the	O
upstream	O
decidual	O
/	O
lymphoid	O
(	O
dPRL	O
)	O
promoter	O
.	O
Based	O
on	O
sequence	O
homology	O
we	O
identified	O
two	O
binding	O
motifs	O
for	O
Pit-1	B
and	O
seven	O
half	O
-	O
sites	O
for	O
glucocorticoid	B
receptor	I
/	I
progesterone	I
receptor	I
(	O
PR	B
)	O
binding	O
.	O
We	O
focused	O
our	O
studies	O
on	O
the	O
role	O
of	O
Pit-1	B
and	O
of	O
PR	B
as	O
potential	O
transcriptional	B
regulators	I
,	O
since	O
the	O
POU	B
domain	I
protein	I
Pit-1	B
is	O
essential	O
in	O
the	O
control	O
of	O
pituitary	O
PRL	B
expression	O
,	O
and	O
progesterone	O
induces	O
decidual	O
transformation	O
of	O
the	O
endometrial	O
stroma	O
,	O
a	O
differentiation	O
process	O
during	O
which	O
the	O
decidual	O
PRL	O
gene	O
is	O
activated	O
.	O
We	O
demonstrate	O
in	O
a	O
variety	O
of	O
cell	O
types	O
,	O
including	O
lymphocytes	O
and	O
endometrial	O
stroma	O
,	O
that	O
Pit-1	B
is	O
not	O
involved	O
in	O
the	O
regulation	O
of	O
dPRL	O
promoter	O
/	O
reporter	O
gene	O
constructs	O
carrying	O
3	O
kb	O
5'-flanking	O
DNA	O
.	O
Our	O
experiments	O
also	O
show	O
that	O
activated	O
PR	B
does	O
not	O
confer	O
direct	O
transcriptional	O
control	O
on	O
the	O
dPRL	O
promoter	O
.	O
When	O
we	O
compared	O
the	O
activity	O
of	O
the	O
transfected	O
dPRL	O
promoter	O
in	O
PRL	O
-	O
secreting	O
and	O
nonsecreting	O
lymphoid	O
cells	O
,	O
we	O
found	O
that	O
the	O
3	O
kb	O
5'-flanking	O
region	O
of	O
the	O
dPRL	O
promoter	O
did	O
not	O
contain	O
elements	O
restricting	O
expression	O
to	O
only	O
those	O
lymphocytes	O
that	O
produce	O
PRL	O
but	O
allowed	O
expression	O
of	O
fusion	O
reporter	O
genes	O
irrespective	O
of	O
the	O
status	O
of	O
the	O
endogenous	O
PRL	O
gene	O
.	O
This	O
was	O
in	O
sharp	O
contrast	O
to	O
endometrial	O
cells	O
where	O
3	O
kb	O
5'-flanking	O
DNA	O
conferred	O
strong	O
transcriptional	O
activation	O
on	O
the	O
dPRL	O
promoter	O
in	O
decidualized	O
endometrial	O
stromal	O
cells	O
actively	O
secreting	O
PRL	B
,	O
but	O
did	O
not	O
allow	O
transcription	O
in	O
undifferentiated	O
non	O
-	O
PRL	O
-	O
secreting	O
endometrial	O
stromal	O
cells	O
.	O
Activation	O
of	O
the	O
dPRL	O
promoter	O
construct	O
in	O
these	O
undifferentiated	O
cells	O
could	O
however	O
be	O
induced	O
by	O
the	O
addition	O
of	O
cAMP	O
,	O
in	O
the	O
absence	O
of	O
progesterone	O
,	O
suggesting	O
that	O
a	O
signal	O
transduced	O
through	O
the	O
cAMP	O
signaling	O
pathway	O
is	O
a	O
primary	O
inducer	O
of	O
decidual	O
PRL	O
gene	O
expression	O
.	O
Activation	O
of	O
early	O
growth	O
response	O
1	O
gene	O
transcription	O
and	O
pp90rsk	B
during	O
induction	O
of	O
monocytic	O
differentiation	O
.	O
The	O
present	O
work	O
has	O
studied	O
mechanisms	O
responsible	O
for	O
induction	O
of	O
early	O
growth	O
response	O
1	O
(	O
EGR-1	O
)	O
gene	O
expression	O
during	O
monocytic	O
differentiation	O
of	O
U-937	O
myeloid	O
leukemia	O
cells	O
.	O
Differentiation	O
of	O
U-937	O
cells	O
with	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
,	O
an	O
activator	O
of	O
the	O
serine	B
/	I
threonine	I
protein	I
kinase	I
C	I
,	O
was	O
associated	O
with	O
transcriptional	O
activation	O
of	O
EGR-1	O
promoter	O
-	O
reporter	O
constructs	O
.	O
The	O
EGR-1	O
promoter	O
contains	O
six	O
CC	O
(	O
A	O
/	O
T	O
)	O
6GG	O
(	O
CArG	O
)	O
motifs	O
.	O
The	O
two	O
5'-most	O
distal	O
CArG	O
sequences	O
conferred	O
TPA	O
inducibility	O
.	O
In	O
contrast	O
,	O
there	O
was	O
little	O
effect	O
of	O
TPA	O
on	O
EGR-1	O
transcription	O
in	O
a	O
TPA	O
-	O
resistant	O
U-937	O
cell	O
variant	O
,	O
designated	O
TUR	O
.	O
Treatment	O
of	O
both	O
U-937	O
and	O
TUR	O
cells	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
serine	B
/	I
threonine	I
protein	I
phosphatases	I
1	I
and	I
2A	I
,	O
was	O
associated	O
with	O
induction	O
of	O
monocytic	O
differentiation	O
and	O
EGR-1	O
transcription	O
through	O
the	O
5'-most	O
CArG	O
element	O
.	O
Since	O
these	O
findings	O
supported	O
the	O
involvement	O
of	O
serine	O
/	O
threonine	O
protein	O
phosphorylation	O
in	O
the	O
regulation	O
of	O
EGR-1	O
expression	O
,	O
we	O
studied	O
activation	O
of	O
the	O
40S	B
ribosomal	I
protein	I
S6	I
serine	I
/	I
threonine	I
kinases	I
,	O
pp70S6	B
K	I
and	O
pp90rsk	B
.	O
Although	O
both	O
kinases	O
participate	O
in	O
regulating	O
cell	O
growth	O
,	O
there	O
was	O
no	O
detectable	O
activation	O
of	O
pp70S6	B
K	I
during	O
TPA-	O
or	O
okadaic	O
acid	O
-	O
induced	O
monocytic	O
differentiation	O
.	O
Moreover	O
,	O
rapamycin	O
,	O
an	O
inhibitor	O
of	O
pp70S6	B
K	I
activation	O
,	O
had	O
no	O
effect	O
on	O
induction	O
of	O
EGR-1	O
expression	O
.	O
In	O
contrast	O
,	O
analysis	O
of	O
pp90rsk	B
activity	O
by	O
phosphorylation	O
of	O
a	O
peptide	O
derived	O
from	O
S6	B
protein	I
demonstrated	O
stimulation	O
of	O
this	O
kinase	B
in	O
TPA	O
-	O
treated	O
U-937	O
,	O
and	O
not	O
TUR	O
,	O
cells	O
.	O
Okadaic	O
acid	O
treatment	O
of	O
both	O
cell	O
types	O
was	O
associated	O
with	O
activation	O
of	O
pp90rsk	B
.	O
Description	O
and	O
functional	O
implications	O
of	O
a	O
novel	O
mutation	O
in	O
the	O
sex	O
-	O
determining	O
gene	O
SRY	O
.	O
The	O
sex	O
-	O
determining	O
gene	O
SRY	O
was	O
screened	O
for	O
molecular	O
alteration	O
in	O
an	O
XY	O
sex	O
-	O
reversed	O
female	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
technique	O
.	O
An	O
A	O
-	O
to	O
-	O
G	O
transition	O
was	O
detected	O
which	O
leads	O
to	O
an	O
exchange	O
of	O
a	O
tyrosine	O
by	O
a	O
cysteine	O
in	O
the	O
SRY	B
protein	I
.	O
The	O
affected	O
tyrosine	O
residue	O
located	O
at	O
the	O
C	B
terminus	I
of	O
the	O
DNA	B
binding	I
protein	I
is	O
evolutionarily	O
strongly	O
conserved	O
among	O
the	O
members	O
of	O
the	O
HMG	B
box	I
containing	I
proteins	I
.	O
Using	O
gel	O
shift	O
assay	O
and	O
peptide	O
synthesis	O
such	O
a	O
mutation	O
is	O
shown	O
to	O
abolish	O
the	O
SRY	O
protein	O
DNA	O
binding	O
ability	O
.	O
The	O
involvement	O
of	O
this	O
particular	O
amino	O
acid	O
in	O
the	O
binding	O
specificity	O
is	O
also	O
discussed	O
.	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
and	O
-independent	O
pathways	O
of	O
HIV	O
activation	O
in	O
a	O
chronically	O
infected	O
T	O
cell	O
line	O
.	O
J	O
delta	O
K	O
cells	O
were	O
isolated	O
as	O
a	O
chronically	O
infected	O
survivor	O
cell	O
line	O
,	O
following	O
infection	O
of	O
Jurkat	O
CD4	O
+	O
T	O
cells	O
with	O
dl	O
-	O
NF	O
,	O
a	O
mutated	O
strain	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
containing	O
a	O
deletion	O
of	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
NF	B
-	I
kappa	I
B	I
sites	O
.	O
J	O
delta	O
K	O
cells	O
exhibited	O
very	O
low	O
levels	O
of	O
constitutive	O
HIV	O
production	O
.	O
HIV-1	O
expression	O
was	O
activated	O
from	O
J	O
delta	O
K	O
cells	O
by	O
treatment	O
with	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
sodium	O
butyrate	O
(	O
NaB	O
)	O
,	O
or	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
,	O
but	O
not	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
,	O
confirming	O
the	O
role	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
mediating	O
TNF	B
-	I
alpha	I
induction	O
of	O
HIV	O
transcription	O
.	O
The	O
strong	O
induction	O
of	O
HIV	O
expression	O
by	O
NaB	O
or	O
HMBA	O
in	O
J	O
delta	O
K	O
cells	O
clearly	O
demonstrates	O
the	O
existence	O
of	O
NF	B
-	I
kappa	I
B	I
-independent	O
mechanisms	O
of	O
HIV	O
activation	O
in	O
chronically	O
infected	O
cells	O
.	O
J	O
delta	O
K	O
cells	O
may	O
provide	O
a	O
useful	O
model	O
for	O
characterizing	O
NF	B
-	I
kappa	I
B	I
-independent	O
transcriptional	O
activation	O
of	O
the	O
HIV	O
LTR	O
.	O
IL-4	B
down	O
-	O
regulates	O
IL-2	B
-	O
,	O
IL-3	B
-	O
,	O
and	O
GM	B
-	I
CSF	I
-induced	O
cytokine	O
gene	O
expression	O
in	O
peripheral	O
blood	O
monocytes	O
.	O
IL-4	B
,	O
a	O
product	O
of	O
the	O
T	O
-	O
helper	O
0	O
(	O
Th0	O
)	O
and	O
2	O
(	O
Th2	O
)	O
subset	O
,	O
was	O
originally	O
described	O
as	O
a	O
B	B
-	I
cell	I
stimulatory	I
factor	I
and	O
has	O
subsequently	O
been	O
found	O
to	O
suppress	O
IL-1	O
alpha	O
,	O
IL-1	O
beta	O
,	O
IL-6	O
,	O
IL-8	O
,	O
and	O
TNF	O
-	O
alpha	O
gene	O
expression	O
in	O
monocytes	O
stimulated	O
with	O
LPS	O
,	O
and	O
to	O
upregulate	O
IL-1	O
receptor	O
antagonist	O
(	O
IL1-RA	O
)	O
gene	O
expression	O
.	O
In	O
this	O
study	O
we	O
investigated	O
the	O
effect	O
of	O
IL-4	B
on	O
the	O
expression	O
of	O
cytokine	O
genes	O
in	O
monocytes	O
evoked	O
by	O
other	O
T	B
-	I
helper	I
cell	I
cytokines	I
:	O
IL-2	B
,	O
IL-3	B
,	O
and	O
GM	B
-	I
CSF	I
.	O
IL-4	B
down	O
-	O
regulated	O
mRNA	O
accumulation	O
of	O
the	O
proinflammatory	B
cytokines	I
IL-1	B
beta	I
,	O
IL-8	B
,	O
and	O
TNF	B
-	I
alpha	I
in	O
monocytes	O
stimulated	O
with	O
IL-2	B
,	O
IL-3	B
,	O
and	O
GM	B
-	I
CSF	I
.	O
IL-4	B
also	O
suppressed	O
the	O
IL-2	B
-induced	O
IL-6	B
mRNA	O
expression	O
.	O
Temporal	O
analysis	O
of	O
the	O
IL-4	B
down	O
-	O
regulatory	O
effect	O
on	O
the	O
IL-2-	O
,	O
IL-3-	O
,	O
or	O
GM	O
-	O
CSF	O
-	O
induced	O
proinflammatory	O
cytokine	O
gene	O
expression	O
in	O
monocytes	O
provided	O
evidence	O
that	O
IL-4	B
acts	O
predominantly	O
on	O
the	O
post	O
-	O
transcriptional	O
level	O
.	O
This	O
was	O
supported	O
by	O
the	O
observation	O
that	O
the	O
down	O
-	O
regulatory	O
capacity	O
of	O
IL-4	B
appeared	O
to	O
be	O
dependent	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O
IL-4	B
did	O
not	O
exert	O
significant	O
influence	O
on	O
the	O
induction	O
of	O
expression	O
of	O
IL-1-RA	B
or	O
various	O
CSFs	B
by	O
IL-2	B
,	O
IL-3	B
,	O
and	O
GM	B
-	I
CSF	I
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Long	O
-	O
term	O
inositol	O
phosphate	O
release	O
,	O
but	O
not	O
tyrosine	B
kinase	I
activity	O
,	O
correlates	O
with	O
IL-2	B
secretion	O
and	O
NF	B
-	I
AT	I
induction	O
in	O
anti	O
-	O
CD3-activated	O
peripheral	O
human	O
T	O
lymphocytes	O
.	O
The	O
cascade	O
of	O
events	O
within	O
the	O
first	O
few	O
minutes	O
of	O
T	O
cell	O
stimulation	O
has	O
been	O
well	O
characterized	O
.	O
Although	O
many	O
second	O
messengers	O
have	O
been	O
shown	O
to	O
be	O
necessary	O
and	O
sufficient	O
for	O
T	O
cell	O
activation	O
in	O
a	O
number	O
of	O
model	O
systems	O
,	O
the	O
rate	O
-	O
limiting	O
step	O
in	O
peripheral	O
T	O
cells	O
has	O
not	O
been	O
demonstrated	O
.	O
To	O
model	O
effective	O
versus	O
ineffective	O
CD3	B
-mediated	O
stimulation	O
in	O
peripheral	O
T	O
cells	O
,	O
we	O
used	O
two	O
anti	B
-	I
CD3	I
mAbs	I
that	O
differ	O
in	O
their	O
ability	O
to	O
stimulate	O
purified	O
T	O
cells	O
:	O
OKT3	B
,	O
which	O
causes	O
early	O
second	O
messenger	O
generation	O
but	O
is	O
unable	O
to	O
activate	O
T	O
cells	O
without	O
a	O
second	O
signal	O
,	O
and	O
64.1	B
,	O
which	O
stimulates	O
T	O
cell	O
proliferation	O
on	O
its	O
own	O
.	O
We	O
found	O
that	O
tyrosine	B
kinase	I
activity	O
was	O
similar	O
for	O
both	O
mAbs	B
over	O
a	O
period	O
of	O
hours	O
.	O
However	O
,	O
the	O
inositol	O
phosphate	O
response	O
was	O
stronger	O
for	O
64.1	B
than	O
for	O
OKT3	B
.	O
To	O
tie	O
these	O
events	O
to	O
gene	O
activation	O
,	O
we	O
measured	O
NF	B
-	I
kappa	I
B	I
and	O
NF	B
-	I
AT	I
activity	O
in	O
the	O
nucleus	O
after	O
anti	B
-	I
CD3	I
stimulation	O
.	O
Both	O
stimuli	O
induced	O
the	O
appearance	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
components	I
(	O
c	B
-	I
Rel	I
,	O
p65	B
(	O
RelA	B
)	O
,	O
and	O
p50	B
(	O
NF	B
-	I
kappa	I
B1	I
)	O
)	O
and	O
NF	B
-	I
kappa	I
B	I
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O
However	O
,	O
only	O
64.1	B
induced	O
NF	B
-	I
AT	I
in	O
the	O
nucleus	O
,	O
correlating	O
with	O
its	O
ability	O
to	O
activate	O
T	O
cells	O
.	O
Thus	O
,	O
NF	B
-	I
AT	I
induction	O
and	O
IL-2	B
secretion	O
were	O
correlated	O
with	O
the	O
levels	O
of	O
inositol	O
phosphate	O
release	O
but	O
not	O
with	O
gross	O
levels	O
of	O
tyrosine	B
kinase	I
activity	O
induced	O
late	O
following	O
the	O
response	O
.	O
On	O
the	O
other	O
hand	O
,	O
NF	B
-	I
kappa	I
B	I
induction	O
and	O
IL-2	B
receptor	O
expression	O
occurred	O
even	O
with	O
the	O
smaller	O
second	O
messenger	O
response	O
generated	O
by	O
OKT3	B
.	O
Evidence	O
for	O
a	O
trans	B
-	I
acting	I
activator	I
function	O
regulating	O
the	O
expression	O
of	O
the	O
human	B
CD5	I
antigen	I
.	O
Interspecies	O
somatic	O
cell	O
hybrids	O
were	O
generated	O
by	O
fusing	O
the	O
mouse	O
T	O
-	O
lymphoma	O
cell	O
line	O
,	O
BW5147	O
,	O
with	O
normal	O
human	O
T	O
lymphocytes	O
at	O
different	O
stages	O
of	O
differentiation	O
.	O
Thymocytes	O
,	O
activated	O
peripheral	O
T	O
lymphocytes	O
,	O
or	O
an	O
activated	O
T	O
-	O
cell	O
clone	O
were	O
used	O
as	O
human	O
partners	O
,	O
respectively	O
,	O
in	O
three	O
independent	O
fusions	O
.	O
Irrespective	O
of	O
the	O
human	O
cell	O
partner	O
used	O
for	O
fusion	O
,	O
a	O
certain	O
number	O
of	O
hybrids	O
lost	O
CD5	B
surface	O
expression	O
over	O
a	O
period	O
of	O
time	O
in	O
culture	O
.	O
Analysis	O
at	O
the	O
phenotype	O
and	O
genetic	O
level	O
showed	O
that	O
lack	O
of	O
CD5	B
expression	O
was	O
due	O
neither	O
to	O
segregation	O
of	O
human	O
autosome	O
11	O
,	O
on	O
which	O
the	O
CD5	O
gene	O
has	O
been	O
mapped	O
,	O
nor	O
to	O
deletion	O
of	O
the	O
CD5	O
structural	O
gene	O
.	O
Furthermore	O
,	O
loss	O
of	O
CD5	B
surface	O
expression	O
correlated	O
with	O
the	O
absence	O
of	O
specific	O
mRNA	O
.	O
Since	O
these	O
hybrids	O
preferentially	O
segregate	O
human	O
chromosomes	O
,	O
these	O
results	O
indicate	O
the	O
existence	O
of	O
a	O
non	O
-	O
syntenic	O
trans	O
-	O
active	O
locus	O
,	O
or	O
loci	O
,	O
positively	O
controlling	O
the	O
expression	O
of	O
the	O
human	O
CD5	O
gene	O
.	O
Alpha	O
-	O
tocopherol	O
inhibits	O
agonist	O
-	O
induced	O
monocytic	O
cell	O
adhesion	O
to	O
cultured	O
human	O
endothelial	O
cells	O
.	O
Antioxidants	O
have	O
been	O
proposed	O
to	O
be	O
anti	O
-	O
atherosclerotic	O
agents	O
;	O
however	O
,	O
the	O
mechanisms	O
underlying	O
their	O
beneficial	O
effects	O
are	O
poorly	O
understood	O
.	O
We	O
have	O
examined	O
the	O
effect	O
of	O
alpha	O
-	O
tocopherol	O
(	O
alpha	O
-	O
tcp	O
)	O
on	O
one	O
cellular	O
event	O
in	O
atherosclerotic	O
plaque	O
development	O
,	O
monocyte	O
adhesion	O
to	O
stimulated	O
endothelial	O
cells	O
(	O
ECs	O
)	O
.	O
Human	O
umbilical	O
vein	O
ECs	O
were	O
pretreated	O
with	O
alpha	O
-	O
tcp	O
before	O
stimulation	O
with	O
known	O
agonists	O
of	O
monocyte	O
adhesion	O
:	O
IL-1	B
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
LPS	O
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
thrombin	B
(	O
30	O
U	O
/	O
ml	O
)	O
,	O
or	O
PMA	O
(	O
10	O
nM	O
)	O
.	O
Agonist	O
-	O
induced	O
monocytic	O
cell	O
adhesion	O
,	O
but	O
not	O
basal	O
adhesion	O
,	O
was	O
inhibited	O
in	O
a	O
time-	O
and	O
concentration	O
-	O
dependent	O
manner	O
by	O
alpha	O
-	O
tcp	O
.	O
The	O
IC50	O
of	O
alpha	O
-	O
tcp	O
on	O
an	O
IL-1	B
-induced	O
response	O
was	O
45	O
microM	O
.	O
The	O
inhibition	O
correlated	O
with	O
a	O
decrease	O
in	O
steady	O
state	O
levels	O
of	O
E	O
-	O
selectin	O
mRNA	O
and	O
cell	O
surface	O
expression	O
of	O
E	B
-	I
selectin	I
which	O
is	O
consistent	O
with	O
the	O
ability	O
of	O
a	O
monoclonal	B
antibody	I
to	O
E	B
-	I
selectin	I
to	O
inhibit	O
monocytic	O
cell	O
adhesion	O
in	O
this	O
system	O
.	O
Probucol	O
(	O
50	O
microM	O
)	O
and	O
N	O
-	O
acetylcysteine	O
(	O
20	O
mM	O
)	O
also	O
inhibited	O
agonist	O
-	O
induced	O
monocytic	O
cell	O
adhesion	O
;	O
whereas	O
,	O
several	O
other	O
antioxidants	O
had	O
no	O
significant	O
effect	O
.	O
Protein	B
kinase	I
C	I
(	O
PKC	B
)	O
does	O
not	O
appear	O
to	O
play	O
a	O
role	O
in	O
the	O
alpha	O
-	O
tcp	O
effect	O
since	O
no	O
suppression	O
of	O
phosphorylation	O
of	O
PKC	B
substrates	O
was	O
observed	O
.	O
Activation	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappa	I
B	I
is	O
reported	O
to	O
be	O
necessary	O
but	O
not	O
sufficient	O
for	O
E	B
-	I
selectin	I
expression	O
in	O
EC	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
failed	O
to	O
show	O
an	O
alpha	O
-	O
tcp	O
-	O
induced	O
decrease	O
in	O
activation	O
of	O
this	O
transcription	B
factor	I
after	O
cytokine	B
stimulation	O
.	O
It	O
has	O
been	O
hypothesized	O
that	O
alpha	O
-	O
tcp	O
acts	O
as	O
an	O
anti	O
-	O
atherosclerotic	O
molecule	O
by	O
inhibiting	O
generation	O
of	O
oxidized	O
LDL	O
--	O
a	O
putative	O
triggering	O
molecule	O
in	O
the	O
atherosclerotic	O
process	O
.	O
Our	O
results	O
point	O
to	O
a	O
novel	O
alternative	O
mechanism	O
of	O
action	O
of	O
alpha	O
-	O
tcp	O
.	O
Corticosteroid	B
receptors	I
in	O
lymphocytes	O
:	O
a	O
possible	O
marker	O
of	O
brain	O
involution	O
?	O
A	O
similarity	O
has	O
recently	O
been	O
found	O
between	O
the	O
regulation	O
of	O
corticosteroid	B
receptors	I
in	O
brain	O
and	O
in	O
lymphoid	O
tissue	O
.	O
We	O
have	O
studied	O
the	O
regulation	O
of	O
corticosteroid	B
receptors	I
in	O
human	O
mononuclear	O
leukocytes	O
as	O
a	O
possible	O
marker	O
of	O
brain	O
involution	O
.	O
Type	B
I	I
corticosteroid	I
receptors	I
are	O
down	O
regulated	O
by	O
excess	O
of	O
mineralocorticoids	O
(	O
primary	O
and	O
secondary	O
hyperaldosteronism	O
,	O
pseudohyperaldosteronism	O
)	O
and	O
of	O
glucocorticoids	O
(	O
Cushing	O
's	O
syndrome	O
)	O
.	O
Type	B
II	I
corticosteroid	I
receptors	I
are	O
not	O
reduced	O
by	O
excess	O
of	O
endogenous	O
corticosteroids	O
(	O
Cushing	O
's	O
syndrome	O
)	O
.	O
In	O
normal	O
adults	O
there	O
is	O
a	O
direct	O
significant	O
correlation	O
between	O
plasma	O
cortisol	O
and	O
Type	B
I	I
and	O
between	O
plasma	O
cortisol	O
and	O
Type	B
II	I
receptors	I
in	O
mononuclear	O
leukocytes	O
,	O
while	O
in	O
Cushing	O
's	O
syndrome	O
the	O
correlation	O
is	O
inverse	O
between	O
plasma	O
cortisol	O
at	O
8	O
a.m.	O
and	O
Type	B
II	I
receptors	I
.	O
In	O
an	O
aged	O
population	O
the	O
mean	O
numbers	O
of	O
Type	B
I	I
and	O
of	O
Type	B
II	I
receptors	I
are	O
lower	O
and	O
plasma	O
cortisol	O
is	O
higher	O
than	O
in	O
adult	O
controls	O
,	O
but	O
the	O
increase	O
of	O
plasma	O
cortisol	O
is	O
not	O
followed	O
by	O
a	O
clinical	O
picture	O
of	O
hypercorticism	O
.	O
Corticosteroid	B
Type	I
I	I
and	I
Type	I
II	I
receptors	I
are	O
inversely	O
correlated	O
with	O
age	O
.	O
After	O
dexamethasone	O
suppression	O
(	O
1	O
mg	O
at	O
11	O
p.m.	O
)	O
Type	B
I	I
receptors	I
always	O
decrease	O
in	O
controls	O
while	O
the	O
response	O
of	O
Type	B
II	I
is	O
not	O
homogeneous	O
.	O
In	O
an	O
aged	O
group	O
of	O
patients	O
,	O
both	O
receptors	O
are	O
reduced	O
by	O
dexamethasone	O
.	O
We	O
conclude	O
that	O
the	O
decrease	O
with	O
age	O
of	O
corticosteroid	B
receptors	I
is	O
possibly	O
related	O
to	O
a	O
physiological	O
involution	O
of	O
corticosteroid	B
receptors	I
and	O
that	O
this	O
reduction	O
does	O
increase	O
plasma	O
cortisol	O
concentration	O
,	O
without	O
affecting	O
the	O
glucocorticoid	O
effector	O
mechanism	O
.	O
Mitogen	O
activation	O
of	O
human	O
peripheral	O
T	O
lymphocytes	O
induces	O
the	O
formation	O
of	O
new	O
cyclic	B
AMP	I
response	I
element	I
-	I
binding	I
protein	I
nuclear	I
complexes	I
.	O
A	O
large	O
body	O
of	O
evidence	O
indicates	O
that	O
experimental	O
agents	O
which	O
raise	O
cellular	O
cAMP	O
levels	O
inhibit	O
T	O
cell	O
growth	O
and	O
division	O
.	O
By	O
contrast	O
,	O
many	O
studies	O
have	O
reported	O
that	O
mitogen	B
activation	O
of	O
T	O
cells	O
increases	O
cAMP	O
levels	O
,	O
implying	O
a	O
positive	O
physiological	O
role	O
for	O
cAMP	O
in	O
the	O
activation	O
process	O
.	O
In	O
the	O
present	O
study	O
we	O
demonstrate	O
that	O
mitogen	B
activation	O
of	O
human	O
peripheral	O
T	O
lymphocytes	O
induces	O
nuclear	O
factors	O
that	O
form	O
complexes	O
with	O
cyclic	B
AMP	I
response	I
element	I
-	I
binding	I
protein	I
(	O
CREB	B
)	O
.	O
Four	O
complexes	O
are	O
identified	O
by	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
two	O
of	O
which	O
are	O
induced	O
by	O
mitogen	B
activation	O
.	O
All	O
four	O
complexes	O
contain	O
CREB	B
and	O
are	O
bound	O
to	O
the	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
core	O
sequence	O
(	O
TGACGTCA	O
)	O
,	O
as	O
indicated	O
by	O
antibody	O
and	O
oligonucleotide	O
competition	O
experiments	O
.	O
Binding	O
of	O
the	O
four	O
complexes	O
to	O
CRE	O
is	O
prevented	O
by	O
dephosphorylation	O
of	O
nuclear	O
extracts	O
and	O
is	O
restored	O
by	O
rephosphorylation	O
with	O
cAMP	B
-	I
dependent	I
protein	I
kinase	I
or	O
endogenous	B
kinases	I
.	O
Similar	O
complexes	O
are	O
detected	O
in	O
nuclear	O
extracts	O
of	O
Jurkat	O
cells	O
.	O
Mitogen	O
induction	O
of	O
the	O
electrophoretic	B
mobility	I
shift	I
assay	I
complexes	I
is	O
not	O
accounted	O
for	O
by	O
protein	O
phosphorylation	O
or	O
by	O
induction	O
of	O
CREB	B
.	O
Rather	O
,	O
the	O
data	O
indicate	O
that	O
mitogen	O
increases	O
the	O
levels	O
of	O
a	O
nuclear	O
factor	O
(	O
s	O
)	O
that	O
dimerizes	O
with	O
CREB	B
.	O
Induction	O
of	O
new	O
CREB	B
complexes	I
implies	O
a	O
physiological	O
role	O
for	O
cAMP	O
in	O
mitogen	B
activation	O
of	O
T	O
lymphocytes	O
.	O
A	O
novel	O
human	O
homeobox	O
gene	O
distantly	O
related	O
to	O
proboscipedia	O
is	O
expressed	O
in	O
lymphoid	O
and	O
pancreatic	O
tissues	O
.	O
A	O
novel	O
human	O
homeobox	O
gene	O
,	O
HB9	O
,	O
was	O
isolated	O
from	O
a	O
cDNA	O
library	O
prepared	O
from	O
in	O
vitro	O
stimulated	O
human	O
tonsil	O
B	O
lymphocytes	O
and	O
from	O
a	O
human	O
genomic	O
library	O
.	O
The	O
HB9	O
gene	O
is	O
composed	O
of	O
3	O
exons	O
spread	O
over	O
6	O
kilobases	O
of	O
DNA	O
.	O
An	O
open	O
reading	O
frame	O
of	O
1206	O
nucleotides	O
is	O
in	O
frame	O
with	O
a	O
diverged	O
homeodomain	O
.	O
The	O
predicted	O
HB9	B
protein	I
has	O
a	O
molecular	O
mass	O
of	O
41	O
kilodaltons	O
and	O
is	O
enriched	O
for	O
alanine	O
,	O
glycine	O
,	O
and	O
leucine	O
.	O
The	O
HB9	O
homeodomain	O
is	O
most	O
similar	O
to	O
that	O
of	O
the	O
Drosophila	O
melanogaster	O
homeobox	O
gene	O
proboscipedia	O
.	O
Northern	O
blot	O
analysis	O
of	O
poly	O
(	O
A	O
)	O
RNA	O
purified	O
from	O
the	O
human	O
B	O
cell	O
line	O
RPMI	O
8226	O
and	O
from	O
activated	O
T	O
cells	O
revealed	O
a	O
major	O
mRNA	O
transcript	O
of	O
2.2	O
kilobases	O
.	O
Similar	O
analysis	O
of	O
poly	O
(	O
A	O
)	O
RNA	O
from	O
a	O
variety	O
of	O
adult	O
tissues	O
demonstrated	O
HB9	O
transcripts	O
in	O
pancreas	O
,	O
small	O
intestine	O
,	O
and	O
colon	O
.	O
Reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
examine	O
HB9	O
RNA	O
transcripts	O
in	O
hematopoietic	O
cell	O
lines	O
.	O
HB9	O
RNA	O
transcripts	O
were	O
most	O
prevalent	O
in	O
several	O
human	O
B	O
cell	O
lines	O
and	O
K562	O
cells	O
.	O
In	O
addition	O
,	O
transcripts	O
were	O
detected	O
in	O
RNA	O
prepared	O
from	O
tonsil	O
B	O
cells	O
and	O
in	O
situ	O
hybridization	O
studies	O
localized	O
them	O
in	O
the	O
germinal	O
center	O
region	O
of	O
adult	O
tonsil	O
.	O
These	O
findings	O
suggest	O
the	O
involvement	O
of	O
HB9	O
in	O
regulating	O
gene	O
transcription	O
in	O
lymphoid	O
and	O
pancreatic	O
tissues	O
.	O
ZAP-70	B
tyrosine	I
kinase	I
,	O
CD45	B
,	O
and	O
T	B
cell	I
receptor	I
involvement	O
in	O
UV-	O
and	O
H2O2-induced	O
T	O
cell	O
signal	O
transduction	O
.	O
Several	O
mammalian	O
responses	O
to	O
UV	O
irradiation	O
,	O
including	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
are	O
believed	O
to	O
involve	O
tyrosine	O
phosphorylation	O
.	O
UV	O
irradiation	O
and	O
H2O2	O
treatment	O
of	O
T	O
lymphocytes	O
induce	O
protein	O
tyrosine	O
phosphorylation	O
and	O
Ca2	O
+	O
signals	O
similar	O
to	O
those	O
observed	O
following	O
biological	O
stimulation	O
.	O
We	O
have	O
examined	O
the	O
role	O
of	O
cell	O
surface	O
molecules	O
in	O
these	O
responses	O
.	O
Normal	O
T	O
lymphocytes	O
whose	O
surface	O
expression	O
of	O
CD3	B
was	O
depleted	O
showed	O
impaired	O
UV	O
-	O
induced	O
tyrosine	O
phosphorylation	O
and	O
Ca2	O
+	O
signals	O
.	O
Similarly	O
,	O
Jurkat	O
T	O
cell	O
lines	O
deficient	O
in	O
CD3	O
or	O
CD45	O
expression	O
also	O
gave	O
impaired	O
UV	O
responses	O
.	O
However	O
,	O
all	O
these	O
cell	O
types	O
still	O
gave	O
strong	O
Ca2	O
+	O
and	O
tyrosine	O
phosphorylation	O
responses	O
to	O
H2O2	O
.	O
The	O
T	O
cell	O
tyrosine	O
kinase	B
ZAP-70	I
was	O
found	O
to	O
be	O
highly	O
responsive	O
to	O
UV	O
and	O
H2O2	O
treatment	O
.	O
ZAP-70	B
responsiveness	O
to	O
UV	O
required	O
expression	O
of	O
both	O
CD3	B
and	O
CD45	B
,	O
whereas	O
only	O
CD3	B
was	O
required	O
for	O
the	O
response	O
to	O
H2O2	O
.	O
UV	O
-	O
induced	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
was	O
blocked	O
by	O
CD3	B
depletion	O
,	O
indicating	O
the	O
importance	O
of	O
such	O
cell	B
surface	I
molecules	I
in	O
biological	O
responses	O
to	O
UV	O
.	O
In	O
nonlymphoid	O
cells	O
,	O
the	O
epidermal	B
growth	I
factor	I
receptor	I
displayed	O
increased	O
tyrosine	O
phosphorylation	O
within	O
seconds	O
of	O
UV	O
irradiation	O
.	O
These	O
results	O
suggest	O
that	O
UV	O
-	O
induced	O
signal	O
transduction	O
is	O
mediated	O
via	O
cell	B
surface	I
receptors	I
that	O
normally	O
respond	O
to	O
biological	O
stimulation	O
,	O
whereas	O
H2O2	O
is	O
able	O
to	O
partially	O
bypass	O
this	O
requirement	O
.	O
Inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
by	O
sodium	O
salicylate	O
and	O
aspirin	O
[	O
see	O
comments	O
]	O
The	O
transcription	B
factor	I
nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
is	O
critical	O
for	O
the	O
inducible	O
expression	O
of	O
multiple	O
cellular	O
and	O
viral	O
genes	O
involved	O
in	O
inflammation	O
and	O
infection	O
including	O
interleukin-1	B
(	O
IL-1	B
)	O
,	O
IL-6	B
,	O
and	O
adhesion	B
molecules	I
.	O
The	O
anti	O
-	O
inflammatory	O
drugs	O
sodium	O
salicylate	O
and	O
aspirin	O
inhibited	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
which	O
further	O
explains	O
the	O
mechanism	O
of	O
action	O
of	O
these	O
drugs	O
.	O
This	O
inhibition	O
prevented	O
the	O
degradation	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
inhibitor	I
,	O
I	B
kappa	I
B	I
,	O
and	O
therefore	O
NF	B
-	I
kappa	I
B	I
was	O
retained	O
in	O
the	O
cytosol	O
.	O
Sodium	O
salicylate	O
and	O
aspirin	O
also	O
inhibited	O
NF	B
-	I
kappa	I
B	I
-dependent	O
transcription	O
from	O
the	O
Ig	O
kappa	O
enhancer	O
and	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
in	O
transfected	O
T	O
cells	O
.	O
Inhibition	O
of	O
the	O
differentiation	O
of	O
human	O
myeloid	O
cell	O
lines	O
by	O
redox	O
changes	O
induced	O
through	O
glutathione	O
depletion	O
.	O
We	O
have	O
investigated	O
the	O
effect	O
of	O
redox	O
changes	O
in	O
vivo	O
on	O
the	O
differentiation	O
of	O
two	O
human	O
myeloid	O
cell	O
lines	O
,	O
HL-60	O
and	O
KG-1	O
.	O
The	O
glutathione	O
-	O
depleting	O
agent	O
diethyl	O
maleate	O
(	O
DEM	O
)	O
prevented	O
the	O
development	O
of	O
differentiated	O
features	O
in	O
response	O
to	O
phorbol	O
esters	O
,	O
including	O
adherence	O
of	O
the	O
cells	O
to	O
plastic	O
surfaces	O
and	O
repression	O
of	O
the	O
myeloperoxidase	O
and	O
CD34	O
genes	O
.	O
Moreover	O
,	O
DEM	O
abolished	O
phorbol	O
12-myristate	O
13-acetate	O
-	O
induced	O
activation	O
of	O
the	O
transcription	B
factors	I
AP-1	B
and	O
Egr-1	B
,	O
suggesting	O
that	O
inhibition	O
of	O
differentiation	O
may	O
be	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
redox	O
modifications	O
of	O
these	O
proteins	B
.	O
Effects	O
of	O
glucocorticoids	O
in	O
rheumatoid	O
arthritis	O
.	O
Diminished	O
glucocorticoid	B
receptors	I
do	O
not	O
result	O
in	O
glucocorticoid	O
resistance	O
.	O
OBJECTIVE	O
.	O
Lymphocytes	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
have	O
diminished	O
receptor	O
density	O
;	O
thus	O
,	O
patients	O
with	O
RA	O
should	O
show	O
partial	O
resistance	O
to	O
glucocorticoids	O
.	O
We	O
investigated	O
the	O
glucocorticoid	O
sensitivity	O
of	O
lymphocytes	O
in	O
RA	O
patients	O
compared	O
with	O
healthy	O
subjects	O
.	O
METHODS	O
.	O
We	O
determined	O
the	O
effects	O
of	O
glucocorticoids	O
on	O
lymphocyte	O
proliferation	O
and	O
cytokine	B
release	O
.	O
RESULTS	O
.	O
Proliferation	O
and	O
cytokine	B
release	O
were	O
inhibited	O
in	O
RA	O
patients	O
to	O
the	O
same	O
extent	O
as	O
in	O
healthy	O
controls	O
.	O
CONCLUSION	O
.	O
Diminished	O
receptor	O
density	O
in	O
RA	O
patients	O
does	O
not	O
result	O
in	O
glucocorticoid	O
resistance	O
.	O
Solution	O
structure	O
of	O
a	O
POU	B
-	I
specific	I
homeodomain	I
:	O
3D	O
-	O
NMR	O
studies	O
of	O
human	O
B	B
-	I
cell	I
transcription	I
factor	I
Oct-2	B
.	O
The	O
POU	B
DNA	I
-	I
binding	I
motif	I
defines	O
a	O
conserved	O
family	O
of	O
eukaryotic	B
transcription	I
factors	I
involved	O
in	O
regulation	O
of	O
gene	O
expression	O
.	O
This	O
bipartite	B
motif	I
consists	O
of	O
an	O
N	B
-	I
terminal	I
POU	I
-	I
specific	I
domain	I
(	O
POUs	B
)	O
,	O
a	O
flexible	B
linker	I
,	O
and	O
a	O
C	B
-	I
terminal	I
POU	I
-	I
specific	I
homeodomain	I
(	O
POUHD	B
)	O
.	O
Here	O
we	O
describe	O
the	O
solution	O
structure	O
of	O
a	O
POU	B
-	I
specific	I
homeodomain	I
.	O
An	O
NMR	O
model	O
is	O
obtained	O
from	O
Oct-2	B
,	O
a	O
human	B
B	I
-	I
cell	I
specific	I
transcription	I
factor	I
which	O
participates	O
in	O
the	O
regulation	O
of	O
immunoglobulin	O
genes	O
.	O
A	O
fragment	O
of	O
Oct-2	B
containing	O
POUHD	B
and	O
an	O
adjoining	O
linker	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
characterized	O
by	O
three	O
-	O
dimensional	O
nuclear	O
magnetic	O
resonance	O
(	O
3D	O
-	O
NMR	O
)	O
spectroscopy	O
.	O
Complete	O
1H	O
and	O
15N	O
resonance	O
assignment	O
of	O
the	O
POUHD	B
moiety	I
is	O
presented	O
.	O
The	O
POUHD	B
solution	O
structure	O
,	O
as	O
calculated	O
by	O
distance	O
geometry	O
and	O
simulated	O
annealing	O
(	O
DG	O
/	O
SA	O
)	O
,	O
is	O
similar	O
to	O
that	O
of	O
canonical	B
homeodomains	I
.	O
A	O
salient	O
difference	O
between	O
solution	O
and	O
crystal	O
structures	O
is	O
observed	O
in	O
the	O
C	B
-	I
terminal	I
segment	I
of	O
alpha	B
-	I
helix	I
3	I
(	O
the	O
HTH	B
recognition	I
helix	I
)	O
,	O
which	O
is	O
not	O
well	O
ordered	O
in	O
solution	O
.	O
Because	O
this	O
segment	O
presumably	O
folds	O
upon	O
specific	O
DNA	O
binding	O
,	O
its	O
flexibility	O
in	O
solution	O
may	O
reduce	O
the	O
intrinsic	O
DNA	O
affinity	O
of	O
POUHD	B
in	O
the	O
absence	O
of	O
POUs	B
.	O
Superantigens	B
activate	O
HIV-1	O
gene	O
expression	O
in	O
monocytic	O
cells	O
.	O
Binding	O
of	O
superantigens	O
to	O
MHC	B
class	I
II	I
molecules	I
results	O
in	O
transduction	O
of	O
biochemical	O
signals	O
leading	O
to	O
cellular	O
activation	O
and	O
gene	O
expression	O
.	O
We	O
demonstrate	O
that	O
the	O
staphylococcal	B
superantigens	I
toxic	B
shock	I
syndrome	I
toxin-1	I
(	O
TSST-1	B
)	O
and	O
staphylococcal	B
enterotoxin	I
A	I
(	O
SEA	B
)	O
activate	O
HIV-1-LTR	O
-driven	O
transcription	O
of	O
chloramphenicol	B
acetyl	I
transferase	I
in	O
the	O
human	O
monocytic	O
cell	O
line	O
THP-1	O
.	O
Induction	O
of	O
HIV-1-	O
LTR	O
-driven	O
transcription	O
in	O
THP-1	O
cells	O
by	O
superantigens	B
was	O
associated	O
with	O
the	O
induction	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
DNA	O
-	O
binding	O
activity	O
.	O
Superantigens	B
also	O
increased	O
viral	O
protein	O
secretion	O
from	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
-	O
pretreated	O
chronically	O
infected	O
human	O
monocytic	O
cell	O
line	O
U1	O
.	O
Induction	O
of	O
HIV-1	O
gene	O
expression	O
in	O
monocytic	O
cells	O
by	O
superantigens	B
occurred	O
via	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
-	O
dependent	O
and	O
-independent	O
mechanisms	O
.	O
Our	O
results	O
suggest	O
that	O
superantigens	B
and	O
other	O
MHC	B
class	I
II	I
ligands	I
may	O
activate	O
HIV-1	O
gene	O
expression	O
in	O
monocytes	O
/	O
macrophages	O
.	O
Leiomyosarcoma	O
of	O
the	O
vulva	O
:	O
report	O
of	O
a	O
case	O
.	O
A	O
52-year	O
-	O
old	O
female	O
presented	O
with	O
a	O
progressively	O
enlarging	O
vulvar	O
mass	O
.	O
Pathological	O
evaluation	O
revealed	O
a	O
high	O
-	O
grade	O
vulvar	O
leiomyosarcoma	O
.	O
Immunohistochemical	O
and	O
ultrastructural	O
studies	O
were	O
performed	O
to	O
support	O
the	O
diagnosis	O
.	O
In	O
an	O
effort	O
to	O
better	O
understand	O
the	O
biology	O
of	O
this	O
tumor	O
additional	O
immunohistochemical	O
studies	O
for	O
the	O
protein	B
product	I
of	O
p53	O
tumor	O
suppressor	O
gene	O
and	O
estrogen	B
receptor	I
expression	O
by	O
tumor	O
cells	O
,	O
as	O
well	O
as	O
the	O
type	O
of	O
immune	O
cells	O
infiltrating	O
the	O
tumor	O
were	O
performed	O
.	O
Tumor	O
cells	O
showed	O
an	O
overexpression	O
of	O
p53	B
protein	I
and	O
were	O
estrogen	B
receptor	I
-positive	O
.	O
Macrophages	O
and	O
T	O
and	O
B	O
lymphocytes	O
infiltrated	O
the	O
tumor	O
in	O
moderate	O
numbers	O
with	O
occasional	O
lymphoid	O
aggregate	O
formation	O
.	O
This	O
study	O
is	O
the	O
first	O
attempt	O
to	O
better	O
understand	O
the	O
biology	O
of	O
these	O
tumors	O
.	O
DNA	O
-	O
binding	O
and	O
transcriptional	O
regulatory	O
properties	O
of	O
hepatic	B
leukemia	I
factor	I
(	O
HLF	B
)	O
and	O
the	O
t	O
(	O
17	O
;	O
19	O
)	O
acute	B
lymphoblastic	I
leukemia	I
chimera	I
E2A	I
-	I
HLF	I
.	O
The	O
t	O
(	O
17	O
;	O
19	O
)	O
translocation	O
in	O
acute	O
lymphoblastic	O
leukemias	O
results	O
in	O
creation	O
of	O
E2A	B
-	I
hepatic	I
leukemia	I
factor	I
(	O
HLF	B
)	O
chimeric	B
proteins	I
that	O
contain	O
the	O
DNA	B
-	I
binding	I
and	I
protein	I
dimerization	I
domains	I
of	O
the	O
basic	B
leucine	I
zipper	I
(	I
bZIP	I
)	I
protein	I
HLF	B
fused	O
to	O
a	O
portion	O
of	O
E2A	B
proteins	I
with	O
transcriptional	O
activation	O
properties	O
.	O
An	O
in	O
vitro	O
binding	O
site	O
selection	O
procedure	O
was	O
used	O
to	O
determine	O
DNA	O
sequences	O
preferentially	O
bound	O
by	O
wild	B
-	I
type	I
HLF	I
and	O
chimeric	B
E2A	I
-	I
HLF	I
proteins	O
isolated	O
from	O
various	O
t	O
(	O
17	O
;	O
19	O
)	O
-bearing	O
leukemias	O
.	O
All	O
were	O
found	O
to	O
selectively	O
bind	O
the	O
consensus	O
sequence	O
5'-GTTACGTAAT-3	O
'	O
with	O
high	O
affinity	O
.	O
Wild	O
-	O
type	O
and	O
chimeric	B
HLF	I
proteins	I
also	O
bound	O
closely	O
related	O
sites	O
identified	O
previously	O
for	O
bZIP	B
proteins	I
of	O
both	O
the	O
proline	B
-and	O
acidic	O
amino	O
acid	O
-	O
rich	O
(	O
PAR	B
)	O
and	O
C	B
/	I
EBP	I
subfamilies	I
;	O
however	O
,	O
E2A	B
-	I
HLF	I
proteins	O
were	O
significantly	O
less	O
tolerant	O
of	O
certain	O
deviations	O
from	O
the	O
HLF	O
consensus	O
binding	O
site	O
.	O
These	O
differences	O
were	O
directly	O
attributable	O
to	O
loss	O
of	O
an	O
HLF	O
ancillary	O
DNA	O
-	O
binding	O
domain	O
in	O
all	O
E2A	B
-	I
HLF	I
chimeras	I
and	O
were	O
further	O
exacerbated	O
by	O
a	O
zipper	O
mutation	O
in	O
one	O
isolate	O
.	O
Both	O
wild	B
-	I
type	I
and	O
chimeric	B
HLF	I
proteins	I
displayed	O
transcriptional	B
activator	I
properties	O
in	O
lymphoid	O
and	O
nonlymphoid	O
cells	O
on	O
reporter	O
genes	O
containing	O
HLF	O
or	O
C	O
/	O
EBP	O
consensus	O
binding	O
sites	O
.	O
But	O
on	O
reporter	O
genes	O
with	O
nonoptimal	O
binding	O
sites	O
,	O
their	O
transcriptional	O
properties	O
diverged	O
and	O
E2A	B
-	I
HLF	I
competitively	O
inhibited	O
activation	O
by	O
wild	B
-	I
type	I
PAR	I
proteins	I
.	O
These	O
findings	O
establish	O
a	O
spectrum	O
of	O
binding	O
site	O
-	O
specific	O
transcriptional	O
properties	O
for	O
E2A	B
-	I
HLF	I
which	O
may	O
preferentially	O
activate	O
expression	O
of	O
select	O
subordinate	O
genes	O
as	O
a	O
homodimer	O
and	O
potentially	O
antagonize	O
expression	O
of	O
others	O
through	O
heteromeric	O
interactions	O
.	O
Inhibition	O
of	O
activation	O
of	O
transcription	B
factor	I
AP-1	I
by	O
CD28	B
signalling	O
in	O
human	O
T	O
-	O
cells	O
.	O
Co	O
-	O
stimulation	O
of	O
T	O
-	O
lymphocytes	O
by	O
T	B
-	I
cell	I
receptor	I
(	O
TcR	B
)	O
occupancy	O
and	O
activation	O
of	O
the	O
CD28	B
surface	I
molecule	I
results	O
in	O
enhanced	O
proliferation	O
and	O
interleukin	B
2	I
(	O
IL-2	B
)	O
production	O
.	O
The	O
increase	O
in	O
IL-2	B
gene	O
expression	O
triggered	O
by	O
CD28	B
involves	O
a	O
kappa	O
B	O
-	O
like	O
sequence	O
in	O
the	O
5'-regulatory	O
region	O
of	O
the	O
IL-2	O
promoter	O
,	O
called	O
CD28-responsive	O
element	O
.	O
Stimulation	O
of	O
T	O
-	O
cells	O
by	O
agonistic	O
anti	B
-	I
CD28	I
antibodies	I
in	O
conjunction	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-	O
or	O
TcR	B
-derived	O
signals	O
induces	O
the	O
enhanced	O
activation	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappa	I
B	I
.	O
Here	O
we	O
report	O
that	O
CD28	B
engagement	O
,	O
however	O
,	O
exerts	O
opposite	O
effects	O
on	O
the	O
transcription	B
factor	I
AP-1	I
.	O
Whereas	O
anti	B
-	I
CD28	I
together	O
with	O
PMA	O
increased	O
the	O
DNA	O
binding	O
and	O
trans	O
-	O
activation	O
activity	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
PMA	O
-	O
induced	O
activation	O
of	O
AP-1	B
was	O
significantly	O
suppressed	O
.	O
The	O
inhibitory	O
effect	O
exerted	O
by	O
anti	B
-	I
CD28	I
was	O
observed	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
as	O
well	O
as	O
in	O
functional	O
reporter	O
-	O
gene	O
assays	O
.	O
These	O
results	O
suggest	O
that	O
the	O
two	O
transcription	B
factors	I
are	O
independently	O
regulated	O
and	O
may	O
perform	O
different	O
functions	O
during	O
T	O
-	O
cell	O
activation	O
.	O
CD14	B
-mediated	O
translocation	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
induced	O
by	O
lipopolysaccharide	O
does	O
not	O
require	O
tyrosine	B
kinase	I
activity	O
.	O
During	O
the	O
course	O
of	O
serious	O
bacterial	O
infections	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
believed	O
to	O
interact	O
with	O
macrophage	B
receptors	I
,	O
resulting	O
in	O
the	O
generation	O
of	O
inflammatory	O
mediators	O
and	O
systemic	O
symptoms	O
including	O
hemodynamic	O
instability	O
and	O
shock	O
.	O
CD14	B
,	O
a	O
glycosylphosphatidylinositol	B
-	I
linked	I
antigen	I
,	O
functions	O
as	O
an	O
LPS	B
signaling	I
receptor	I
.	O
A	O
critical	O
issue	O
concerns	O
the	O
mechanism	O
by	O
which	O
CD14	B
,	O
which	O
has	O
no	O
transmembrane	B
domain	I
,	O
transduces	O
its	O
signal	O
following	O
LPS	O
binding	O
.	O
Recently	O
,	O
investigators	O
have	O
hypothesized	O
that	O
CD14	B
-mediated	O
signaling	O
is	O
effected	O
through	O
a	O
receptor	O
-	O
associated	O
tyrosine	B
kinase	I
(	O
TK	O
)	O
,	O
suggesting	O
a	O
multicomponent	O
receptor	O
model	O
of	O
LPS	O
signaling	O
.	O
Wild	O
-	O
type	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
-K1	O
cells	O
can	O
be	O
activated	O
by	O
endotoxin	O
to	O
release	O
arachidonate	O
following	O
transfection	O
with	O
human	O
CD14	B
(	O
CHO	B
/	I
CD14	I
)	O
.	O
Nuclear	O
translocation	O
of	O
cytosolic	O
NF	O
-	O
kappa	O
B	O
is	O
correlated	O
with	O
a	O
number	O
of	O
LPS	O
-	O
inducible	O
responses	O
.	O
We	O
sought	O
to	O
determine	O
if	O
this	O
pathway	O
were	O
present	O
in	O
CHO	O
/	O
CD14	O
cells	O
and	O
to	O
elucidate	O
the	O
relationship	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
to	O
the	O
CD14	B
receptor	O
system	O
.	O
LPS	O
-	O
stimulated	O
translocation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
CHO	O
/	O
CD14	O
cells	O
resembled	O
the	O
same	O
response	O
in	O
the	O
murine	O
macrophage	O
-	O
like	O
cell	O
line	O
RAW	O
264.7	O
.	O
Protein	O
synthesis	O
inhibitors	O
and	O
corticosteroids	O
,	O
which	O
suppress	O
arachidonate	O
release	O
and	O
the	O
synthesis	O
of	O
proinflammatory	B
cytokines	I
,	O
had	O
no	O
effect	O
on	O
translocation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
CHO	O
/	O
CD14	B
or	O
RAW	O
264.7	O
cells	O
,	O
demonstrating	O
that	O
NF	B
-	I
kappa	I
B	I
translocation	O
is	O
an	O
early	O
event	O
.	O
Although	O
TK	O
activity	O
was	O
consistently	O
observed	O
by	O
immunoblotting	O
extracts	O
from	O
activated	O
RAW	O
264.7	O
cells	O
,	O
LPS	O
-	O
induced	O
phosphotyrosine	O
residues	O
were	O
not	O
observed	O
from	O
similarly	O
treated	O
CHO	O
/	O
CD14	O
cells	O
.	O
Furthermore	O
,	O
the	O
TK	O
inhibitors	O
herbimycin	O
A	O
and	O
genistein	O
failed	O
to	O
inhibit	O
translocation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
CHO	O
/	O
CD14	O
or	O
RAW	O
264.7	O
cells	O
,	O
although	O
both	O
of	O
these	O
agents	O
inhibited	O
LPS	O
-	O
induced	O
TK	O
activity	O
in	O
RAW	O
264.7	O
cells	O
.	O
These	O
results	O
imply	O
that	O
TK	O
activity	O
is	O
not	O
obligatory	O
for	O
CD14	B
-mediated	O
signal	O
transduction	O
to	O
occur	O
in	O
response	O
to	O
LPS	O
.	O
Signals	O
transduced	O
through	O
the	O
CD4	B
molecule	I
on	O
T	O
lymphocytes	O
activate	O
NF	B
-	I
kappa	I
B	I
.	O
We	O
have	O
demonstrated	O
that	O
native	B
envelope	I
glycoproteins	I
of	O
HIV-1	O
,	O
gp160	O
can	O
induce	O
activation	O
of	O
the	O
transcription	B
factor	I
,	O
NF	B
-	I
kappa	I
B	I
.	O
The	O
stimulatory	O
effects	O
of	O
gp160	O
are	O
mediated	O
through	O
the	O
CD4	B
molecule	I
,	O
since	O
pretreatment	O
with	O
soluble	O
CD4	B
abrogates	O
its	O
activity	O
.	O
The	O
gp160-induced	B
NF	I
-	I
kappa	I
B	I
complex	I
consists	O
of	O
p65	B
,	O
p50	B
and	O
c	B
-	I
rel	I
proteins	I
.	O
The	O
stimulatory	O
effect	O
of	O
gp160	O
on	O
NF	B
-	I
kappa	I
B	I
activation	O
is	O
protein	O
synthesis	O
independent	O
,	O
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
,	O
and	O
abrogated	O
by	O
inhibitors	O
of	O
protein	B
kinase	I
C	I
.	O
The	O
gp160-mediated	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
CD4	O
positive	O
T	O
cells	O
may	O
be	O
involved	O
in	O
biological	O
effects	O
,	O
e.g.	O
,	O
enhanced	O
HIV	O
replication	O
,	O
hypergammaglobulinemia	O
,	O
increased	O
cytokine	B
secretion	O
,	O
hypercellularity	O
in	O
bone	O
marrow	O
and	O
apoptosis	O
.	O
Involvement	O
of	O
phospholipase	B
D	I
in	O
the	O
activation	O
of	O
transcription	B
factor	I
AP-1	I
in	O
human	O
T	O
lymphoid	O
Jurkat	O
cells	O
.	O
The	O
induction	O
of	O
the	O
AP-1	B
transcription	B
factor	I
has	O
been	O
ascribed	O
to	O
the	O
early	O
events	O
leading	O
to	O
T	O
lymphocyte	O
activation	O
.	O
We	O
have	O
examined	O
the	O
possibility	O
that	O
stimulation	O
of	O
phospholipase	B
D	I
(	O
PLD	B
)	O
may	O
regulate	O
activation	O
of	O
transcription	B
factor	I
AP-1	I
in	O
human	O
T	O
cells	O
by	O
transfecting	O
human	O
T	O
lymphocyte	O
Jurkat	O
cells	O
with	O
a	O
plasmid	O
containing	O
an	O
AP-1	O
enhancer	O
element	O
and	O
a	O
chloramphenicol	O
acetyltransferase	O
reporter	O
gene	O
.	O
We	O
have	O
detected	O
activatable	O
PLD	B
in	O
Jurkat	O
cells	O
,	O
and	O
we	O
have	O
found	O
that	O
addition	O
of	O
phosphatidic	O
acid	O
(	O
PA	O
)	O
,	O
the	O
physiologic	O
product	O
of	O
PLD	B
action	O
on	O
phospholipids	O
,	O
is	O
rapidly	O
incorporated	O
into	O
Jurkat	O
cells	O
and	O
leads	O
to	O
activation	O
of	O
transcription	B
factor	I
AP-1	I
.	O
Treatment	O
of	O
Jurkat	O
cells	O
with	O
anti	B
-	I
CD3	I
mAb	I
activated	O
both	O
PLD	B
and	O
transcription	B
factor	I
AP-1	I
.	O
Wortmannin	O
,	O
an	O
inhibitor	O
of	O
receptor	O
-	O
coupled	O
PLD	B
activation	O
,	O
blocked	O
the	O
anti	B
-	I
CD3	I
-induced	O
increases	O
in	O
both	O
PLD	B
activity	O
and	O
AP-1	O
enhancer	O
activity	O
.	O
We	O
found	O
a	O
good	O
correlation	O
in	O
the	O
transfected	O
cells	O
between	O
PLD	B
activation	O
and	O
induction	O
of	O
AP-1	O
enhancer	O
activity	O
under	O
different	O
experimental	O
conditions	O
.	O
Furthermore	O
,	O
ethanol	O
,	O
an	O
inhibitor	O
of	O
the	O
PLD	B
pathway	O
,	O
blocked	O
the	O
anti	O
-	O
CD3-stimulated	O
AP-1	O
enhancer	O
activity	O
.	O
However	O
,	O
this	O
anti	B
-	I
CD3	I
-mediated	O
response	O
was	O
not	O
inhibited	O
by	O
neomycin	O
,	O
an	O
inhibitor	O
of	O
phosphoinositide	O
hydrolysis	O
.	O
The	O
increases	O
in	O
AP-1	O
enhancer	O
activity	O
induced	O
by	O
PA	O
or	O
anti	B
-	I
CD3	I
mAb	I
were	O
efficiently	O
abrogated	O
by	O
the	O
presence	O
of	O
propranolol	O
,	O
an	O
inhibitor	O
of	O
PA	O
phosphohydrolase	B
and	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
.	O
Furthermore	O
,	O
the	O
PA	O
-and	O
the	O
anti	B
-	I
CD3	I
-induced	O
increases	O
in	O
AP-1	O
enhancer	O
activity	O
were	O
blocked	O
by	O
the	O
presence	O
of	O
PKC	B
inhibitors	O
or	O
by	O
PKC	B
down	O
-	O
regulation	O
.	O
These	O
data	O
indicate	O
that	O
PLD	B
stimulation	O
can	O
activate	O
the	O
transcription	B
factor	I
AP-1	I
in	O
T	O
lymphocytes	O
,	O
and	O
suggest	O
that	O
the	O
induction	O
of	O
AP-1	O
enhancer	O
factor	O
activity	O
by	O
PA	O
is	O
mediated	O
via	O
PKC	B
stimulation	O
,	O
either	O
through	O
a	O
direct	O
activating	O
effect	O
of	O
PA	O
or	O
through	O
PA	O
-	O
derived	O
diacylglycerol	O
formation	O
.	O
These	O
data	O
also	O
provide	O
evidence	O
for	O
a	O
role	O
of	O
PLD	B
-derived	O
lipids	O
in	O
the	O
induction	O
of	O
AP-1	O
enhancer	O
activity	O
resulting	O
from	O
stimulation	O
of	O
the	O
TCR	B
/	I
CD3	I
complex	I
,	O
suggesting	O
that	O
increased	O
PLD	B
activity	O
can	O
play	O
an	O
important	O
role	O
in	O
T	O
lymphocyte	O
activation	O
.	O
Induction	O
of	O
IL-8	B
expression	O
in	O
T	O
cells	O
uses	O
the	O
CD28	B
costimulatory	O
pathway	O
.	O
IL-8	B
,	O
a	O
potent	O
chemotactic	B
factor	I
for	O
neutrophil	O
granulocytes	O
and	O
lymphocytes	O
,	O
is	O
a	O
proinflammatory	O
cytokine	O
secreted	O
by	O
a	O
variety	O
of	O
cell	O
types	O
,	O
including	O
T	O
cells	O
.	O
Stimulation	O
of	O
the	O
CD28	B
cell	I
surface	I
molecule	I
delivers	O
costimulatory	O
signals	O
essential	O
for	O
lymphokine	B
production	O
in	O
activated	O
T	O
cells	O
via	O
a	O
conserved	O
sequence	O
element	O
found	O
in	O
the	O
promoter	O
of	O
several	O
lymphokine	O
genes	O
.	O
Anti	O
-	O
CD28-stimulated	O
T	O
cells	O
produced	O
significant	O
amounts	O
of	O
IL-8	B
;	O
additionally	O
,	O
costimulation	O
with	O
anti	B
-	I
CD3	I
and	O
anti	B
-	I
CD28	I
Abs	I
resulted	O
in	O
a	O
synergistic	O
induction	O
of	O
IL-8	B
secretion	O
.	O
Sequence	O
homology	O
,	O
single	O
nucleotide	O
mutations	O
,	O
and	O
anti	B
-	I
CD28	I
Ab	I
stimulation	O
studies	O
established	O
that	O
the	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
sequence	O
in	O
the	O
promoter	O
of	O
the	O
IL-8	O
gene	O
functioned	O
as	O
a	O
CD28	O
response	O
element	O
.	O
Furthermore	O
,	O
cyclosporin	O
A	O
,	O
but	O
not	O
rapamycin	O
,	O
blocked	O
the	O
synergistic	O
induction	O
of	O
IL-8	B
expression	O
achieved	O
with	O
anti	B
-	I
CD3	I
and	O
anti-	O
CD28	B
costimulation	O
.	O
The	O
involvement	O
of	O
a	O
CD28	O
response	O
element	O
in	O
the	O
induction	O
of	O
IL-8	B
expression	O
in	O
activated	O
T	O
cells	O
may	O
provide	O
new	O
insights	O
into	O
the	O
pathogenesis	O
and	O
persistence	O
of	O
immune	O
disorders	O
characterized	O
by	O
increased	O
levels	O
of	O
IL-8	B
,	O
such	O
as	O
psoriasis	O
and	O
rheumatoid	O
arthritis	O
.	O
Signals	O
and	O
nuclear	B
factors	I
that	O
regulate	O
the	O
expression	O
of	O
interleukin-4	O
and	O
interleukin-5	O
genes	O
in	O
helper	O
T	O
cells	O
.	O
Mouse	O
thymoma	O
line	O
EL-4	O
cells	O
produce	O
cytokines	B
such	O
as	O
interleukin	B
(	I
IL	I
)	I
-2	I
,	O
IL-3	B
,	O
IL-4	B
,	O
IL-10	B
,	O
and	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
in	O
response	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O
EL-4	O
cells	O
also	O
produce	O
low	O
levels	O
of	O
IL-5	B
when	O
stimulated	O
by	O
PMA	O
alone	O
;	O
however	O
,	O
cAMP	O
greatly	O
augments	O
PMA	O
-	O
dependent	O
IL-5	B
production	O
.	O
A	O
transient	O
transfection	O
assay	O
revealed	O
that	O
two	O
signals	O
,	O
PMA	O
and	O
cAMP	O
,	O
are	O
required	O
for	O
optimal	O
activation	O
of	O
the	O
IL-5	O
promoter	O
.	O
In	O
contrast	O
,	O
cAMP	O
almost	O
completely	O
inhibited	O
the	O
PMA	O
-	O
dependent	O
activation	O
of	O
the	O
endogenous	O
IL-2	O
gene	O
,	O
as	O
well	O
as	O
the	O
transfected	O
IL-2	O
promoter	O
.	O
These	O
results	O
indicate	O
that	O
the	O
IL-5	O
gene	O
is	O
positively	O
regulated	O
by	O
cAMP	O
in	O
a	O
manner	O
opposite	O
to	O
that	O
for	O
the	O
IL-2	O
gene	O
.	O
One	O
of	O
the	O
nuclear	B
factors	I
(	O
NFs	B
)	O
that	O
regulates	O
the	O
response	O
of	O
the	O
IL-5	O
promoter	O
to	O
cAMP	O
and	O
PMA	O
has	O
properties	O
similar	O
to	O
NF	B
for	O
activated	O
t	O
cell	O
.	O
The	O
P	O
sequence	O
of	O
the	O
IL-4	O
gene	O
,	O
defined	O
as	O
a	O
responsive	O
element	O
for	O
PMA	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
,	O
shares	O
sequence	O
similarity	O
with	O
the	O
NF	O
kappa	O
B	O
and	O
the	O
NF	O
-	O
activated	O
T	O
cell	O
binding	O
sites	O
.	O
We	O
attempted	O
to	O
determine	O
whether	O
NF	B
(	I
P	I
)	I
,	O
a	O
nuclear	O
factor	O
specific	O
for	O
the	O
P	O
sequence	O
,	O
is	O
related	O
to	O
NF	B
-	I
kappa	I
B	I
and	O
nuclear	B
factor	I
for	I
activated	I
T	I
cell	I
(	O
NF	B
-	I
AT	I
)	O
.	O
In	O
electromobility	O
shift	O
assays	O
both	O
NF	B
-	I
kappa	I
B	I
(	O
P65	B
or	O
P65	B
/	I
P50	I
heterodimer	I
)	O
and	O
NF	B
-	I
AT	I
bound	O
to	O
the	O
P	O
sequence	O
.	O
However	O
,	O
sequence	O
specificity	O
of	O
NF	B
-	I
AT	I
was	O
more	O
similar	O
to	O
that	O
of	O
NF	B
(	I
P	I
)	I
,	O
and	O
only	O
a	O
small	O
amount	O
of	O
P65	B
was	O
detected	O
in	O
NF	B
(	I
P	I
)	I
.	O
These	O
results	O
indicate	O
that	O
a	O
component	O
or	O
components	O
of	O
NF	B
-	I
AT	I
have	O
the	O
potential	O
to	O
reconstitute	O
NF	B
(	I
P	I
)	I
,	O
whereas	O
NF	B
-	I
kappa	I
B	I
alone	O
does	O
not	O
account	O
for	O
NF	B
(	I
P	I
)	I
in	O
Jurkat	O
crude	O
extract	O
.	O
Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
NF	B
-	I
AT	I
-	I
like	I
factors	I
are	O
involved	O
in	O
the	O
regulation	O
of	O
IL-4	O
and	O
IL-5	O
genes	O
.	O
Mechanisms	O
involved	O
in	O
the	O
inhibition	O
of	O
growth	O
of	O
a	O
human	O
B	O
lymphoma	O
cell	O
line	O
,	O
B104	O
,	O
by	O
anti	B
-	I
MHC	I
class	I
II	I
antibodies	I
.	O
The	O
mechanisms	O
involved	O
in	O
the	O
inhibition	O
of	O
growth	O
of	O
a	O
human	O
B	O
lymphoma	O
cell	O
line	O
,	O
B104	O
,	O
by	O
anti	B
-	I
MHC	I
class	I
II	I
antibodies	I
(	O
Ab	B
)	O
were	O
compared	O
with	O
those	O
in	O
anti	B
-	I
IgM	I
Ab	I
-induced	O
B104	O
growth	O
inhibition	O
.	O
Two	O
anti	B
-	I
MHC	I
class	I
II	I
Ab	I
,	O
L227	B
and	O
2.06	B
,	O
inhibited	O
the	O
growth	O
of	O
B104	O
cells	O
,	O
although	O
2.06	B
,	O
but	O
not	O
L227	B
,	O
needed	O
to	O
be	O
further	O
cross	O
-	O
linked	O
with	O
a	O
goat	B
anti	I
-	I
mouse	I
IgG	I
Ab	I
(	O
GAM	B
)	O
to	O
show	O
the	O
effect	O
.	O
L227	B
induced	O
an	O
increase	O
in	O
intracellular	O
free	O
Ca2	O
+	O
concentration	O
(	O
[	O
Ca2	O
+	O
]	O
i	O
)	O
from	O
the	O
intracellular	O
pool	O
and	O
little	O
or	O
no	O
protein	O
tyrosine	O
phosphorylation	O
,	O
phosphatidyl	O
inositol	O
turnover	O
,	O
or	O
expression	O
of	O
Egr-1	O
mRNA	O
,	O
whereas	O
2.06	B
plus	O
GAM	B
induced	O
an	O
increase	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
from	O
both	O
the	O
intracellular	O
and	O
,	O
in	O
particular	O
,	O
the	O
extracellular	O
pools	O
.	O
The	O
inhibition	O
of	O
B104	O
cell	O
growth	O
induced	O
by	O
anti	B
-	I
MHC	I
class	I
II	I
Ab	I
was	O
Ca	O
(	O
2	O
+	O
)	O
-independent	O
and	O
not	O
inhibited	O
by	O
actinomycin	O
D	O
or	O
cyclosporin	O
A	O
,	O
and	O
cell	O
cycle	O
arrest	O
at	O
the	O
G2	O
/	O
M	O
interphase	O
was	O
not	O
observed	O
.	O
These	O
features	O
are	O
very	O
different	O
from	O
those	O
observed	O
in	O
B104	O
cell	O
death	O
induced	O
by	O
anti	B
-	I
IgM	I
Ab	I
.	O
Neither	O
DNA	O
fragmentation	O
nor	O
the	O
morphology	O
of	O
apoptosis	O
was	O
observed	O
.	O
These	O
findings	O
demonstrate	O
that	O
cross	O
-	O
linking	O
of	O
MHC	B
class	I
II	I
molecules	I
transduced	O
the	O
negative	O
signals	O
through	O
intracellular	O
mechanisms	O
different	O
from	O
those	O
present	O
in	O
the	O
cross	O
-	O
linking	O
of	O
surface	O
IgM	B
.	O
Regulation	O
of	O
CD14	B
expression	O
during	O
monocytic	O
differentiation	O
induced	O
with	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
.	O
CD14	B
,	O
a	O
monocyte	B
/	I
macrophage	I
receptor	I
for	O
the	O
complex	O
of	O
LPS	O
and	O
LPS	B
binding	I
protein	I
,	O
is	O
a	O
differentiation	O
marker	O
for	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
.	O
We	O
have	O
analyzed	O
the	O
regulation	O
of	O
CD14	B
expression	O
during	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VitD3	O
)	O
-induced	O
monocytic	O
differentiation	O
.	O
Using	O
FACS	O
,	O
Northern	O
blotting	O
,	O
and	O
nuclear	O
run	O
-	O
on	O
analyses	O
,	O
we	O
demonstrate	O
that	O
the	O
up	O
-	O
regulation	O
of	O
CD14	B
expression	O
during	O
monocytic	O
cell	O
maturation	O
is	O
regulated	O
mainly	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
,	O
and	O
that	O
new	O
protein	O
synthesis	O
is	O
required	O
for	O
CD14	B
induction	O
.	O
We	O
have	O
recently	O
cloned	O
the	O
CD14	O
5	O
'	O
upstream	O
sequence	O
and	O
demonstrated	O
its	O
tissue	O
-	O
specific	O
promoter	O
activity	O
.	O
Using	O
stable	O
transfection	O
of	O
the	O
monocytoid	O
U937	O
cell	O
line	O
with	O
a	O
series	O
of	O
deletion	O
mutants	O
of	O
the	O
CD14	O
5	O
'	O
upstream	O
sequence	O
coupled	O
to	O
a	O
reporter	O
gene	O
construct	O
,	O
we	O
show	O
that	O
bp	O
-128	O
to	O
-70	O
is	O
the	O
critical	O
region	O
for	O
the	O
induction	O
of	O
CD14	B
expression	O
.	O
This	O
region	O
contains	O
two	O
binding	O
sites	O
for	O
the	O
Sp1	B
transcription	I
factor	I
.	O
A	O
3-bp	O
mutation	O
at	O
the	O
distal	O
Sp1-binding	O
site	O
not	O
only	O
eliminates	O
Sp1	B
interaction	O
,	O
but	O
also	O
abolishes	O
most	O
of	O
the	O
VitD3	O
induction	O
of	O
CD14	B
expression	O
.	O
Electrophoretic	O
mobility	O
shift	O
analysis	O
does	O
not	O
detect	O
a	O
direct	O
interaction	O
of	O
the	O
CD14	B
distal	O
Sp1-binding	O
site	O
with	O
the	O
vitamin	B
D3	I
receptor	I
and	O
its	O
partner	O
,	O
the	O
retinoid	B
X	I
receptor	I
.	O
These	O
data	O
demonstrate	O
that	O
VitD3	O
induces	O
CD14	B
indirectly	O
through	O
some	O
intermediary	B
factor	I
,	O
and	O
suggest	O
a	O
critical	O
role	O
for	O
Sp1	B
in	O
this	O
process	O
.	O
Calcium	O
signalling	O
in	O
T	O
cells	O
stimulated	O
by	O
a	O
cyclophilin	B
B	I
-	I
binding	I
protein	I
.	O
The	O
immunosuppressant	O
drug	O
cyclosporin	O
A	O
blocks	O
a	O
calcium	O
-	O
dependent	O
signal	O
from	O
the	O
T	B
-	I
cell	I
receptor	I
(	O
TCR	B
)	O
that	O
normally	O
leads	O
to	O
T	O
-	O
cell	O
activation	O
.	O
When	O
bound	O
to	O
cyclophilin	B
,	O
cyclosporin	O
A	O
binds	O
and	O
inactivates	O
the	O
key	O
signalling	O
intermediate	O
calcineurin	B
.	O
To	O
identify	O
potential	O
cellular	O
homologues	O
of	O
cyclosporin	O
A	O
that	O
might	O
regulate	O
calcium	O
signalling	O
,	O
we	O
have	O
cloned	O
human	O
genes	O
encoding	O
cyclophilin	B
B	I
-	I
binding	I
-	I
proteins	I
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
.	O
One	O
gene	O
product	O
,	O
when	O
overexpressed	O
in	O
Jurkat	O
T	O
cells	O
,	O
specifically	O
induced	O
transcription	O
from	O
the	O
interleukin-2	O
enhancer	O
,	O
by	O
activating	O
the	O
T	B
-	I
cell	I
-	I
specific	I
transcription	I
factors	I
NF	B
-	I
AT	I
and	O
NF	B
-	I
IL2A	I
.	O
This	O
protein	O
,	O
termed	O
calcium	B
-	I
signal	I
modulating	I
cyclophilin	I
ligand	I
(	O
CAML	B
)	O
,	O
acts	O
downstream	O
of	O
the	O
TCR	B
and	O
upstream	O
of	O
calcineurin	B
by	O
causing	O
an	O
influx	O
of	O
calcium	O
.	O
CAML	B
appears	O
to	O
be	O
a	O
new	O
participant	O
in	O
the	O
calcium	O
-	O
signal	O
transduction	O
pathway	O
,	O
implicating	O
cyclophilin	B
B	I
in	O
calcium	O
signalling	O
,	O
even	O
in	O
the	O
absence	O
of	O
cyclosporin	O
.	O
Role	O
of	O
HIV-1	B
Nef	I
expression	O
in	O
activation	O
pathways	O
in	O
CD4	B
+	O
T	O
cells	O
.	O
The	O
role	O
of	O
the	O
human	B
immunodeficiency	I
virus	I
(	I
HIV-1	I
)	I
Nef	I
protein	I
in	O
T	O
cell	O
activation	O
pathways	O
was	O
investigated	O
using	O
a	O
Jurkat	O
CD4	O
+	O
cell	O
line	O
stably	O
transfected	O
with	O
a	O
Nef	O
expression	O
vector	O
.	O
Secretion	O
of	O
IL-2	B
and	O
TNF	B
-	I
alpha	I
,	O
surface	O
expression	O
of	O
IL-2R	B
,	O
and	O
DNA	O
-	O
binding	O
activity	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
AP-1	B
(	I
Fos	I
/	I
Jun	I
)	I
complex	I
in	O
response	O
to	O
phorbol	O
myristate	O
acetate	O
,	O
TNF	B
-	I
alpha	I
,	O
or	O
immobilized	O
antibodies	O
to	O
CD3	B
were	O
monitored	O
.	O
These	O
parameters	O
were	O
not	O
modified	O
by	O
Nef	B
expression	O
in	O
Jurkat	O
cells	O
,	O
whereas	O
stimulation	O
with	O
the	O
same	O
stimuli	O
resulted	O
in	O
partial	O
inhibition	O
of	O
LTR	O
activation	O
in	O
Nef+	O
Jurkat	O
cells	O
.	O
This	O
inhibition	O
was	O
not	O
mediated	O
through	O
Nef	B
phosphorylation	O
on	O
Thr-15	O
or	O
GTP	O
-	O
binding	O
activity	O
because	O
mutations	O
in	O
critical	O
sites	O
did	O
not	O
alter	O
this	O
inhibition	O
.	O
Analysis	O
of	O
truncated	O
LTRs	O
confirmed	O
that	O
inhibition	O
of	O
LTR	O
activation	O
was	O
not	O
mediated	O
through	O
NF	B
-	I
kappa	I
B	I
-binding	O
activity	O
but	O
through	O
the	O
region	O
containing	O
the	O
negative	O
responding	O
elements	O
(	O
NREs	O
)	O
.	O
These	O
results	O
suggest	O
that	O
Nef	B
downmodulates	O
LTR	O
activation	O
without	O
significantly	O
inhibiting	O
the	O
capacity	O
of	O
T	O
cells	O
to	O
respond	O
to	O
immunological	O
activations	O
.	O
Marked	O
basophilia	O
in	O
acute	O
promyelocytic	O
leukaemia	O
treated	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
:	O
molecular	O
analysis	O
of	O
the	O
cell	O
origin	O
of	O
the	O
basophils	O
.	O
We	O
report	O
a	O
patient	O
with	O
acute	O
promyelocytic	O
leukaemia	O
who	O
developed	O
marked	O
basophilia	O
during	O
all	O
-	O
trans	O
retinoic	O
acid	O
treatment	O
.	O
We	O
studied	O
genomic	O
DNA	O
and	O
RNA	O
extracted	O
from	O
the	O
patient	O
's	O
peripheral	O
leucocytes	O
in	O
order	O
to	O
determine	O
the	O
origin	O
of	O
the	O
basophils	O
.	O
The	O
RAR	B
alpha	I
rearranged	O
band	O
in	O
the	O
Southern	O
blot	O
analysis	O
and	O
a	O
chimaeric	B
product	I
of	O
PML	B
-	I
RAR	I
alpha	I
by	O
polymerase	O
chain	O
reaction	O
were	O
strongly	O
visible	O
before	O
ATRA	O
treatment	O
,	O
but	O
at	O
the	O
time	O
of	O
maximal	O
basophilia	O
both	O
of	O
them	O
were	O
markedly	O
diminished	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
basophils	O
which	O
appeared	O
during	O
the	O
ATRA	O
treatment	O
are	O
reactive	O
in	O
nature	O
rather	O
than	O
a	O
leukaemic	O
clone	O
.	O
Antioxidants	O
inhibit	O
monocyte	O
adhesion	O
by	O
suppressing	O
nuclear	B
factor	I
-	I
kappa	I
B	I
mobilization	O
and	O
induction	O
of	O
vascular	B
cell	I
adhesion	I
molecule-1	I
in	O
endothelial	O
cells	O
stimulated	O
to	O
generate	O
radicals	O
.	O
Cell	O
adhesion	O
to	O
endothelial	O
cells	O
stimulated	B
by	I
tumor	I
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
)	O
is	O
due	O
to	O
induction	O
of	O
surface	B
receptors	I
,	O
such	O
as	O
vascular	B
cell	I
adhesion	I
molecule-1	I
(	O
VCAM-1	B
)	O
.	O
The	O
antioxidant	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
specifically	O
inhibits	O
activation	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
.	O
Since	O
kappa	O
B	O
motifs	O
are	O
present	O
in	O
VCAM-1	O
and	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
)	O
promoters	O
,	O
we	O
used	O
PDTC	O
to	O
study	O
the	O
regulatory	O
mechanisms	O
of	O
VCAM-1	B
and	O
ICAM-1	B
induction	O
and	O
subsequent	O
monocyte	O
adhesion	O
in	O
TNF	O
-	O
treated	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O
PDTC	O
or	O
N	O
-	O
acetylcysteine	O
dose	O
dependently	O
reduced	O
TNF	B
-	I
induced	I
VCAM-1	I
but	O
not	O
ICAM-1	B
surface	I
protein	I
(	O
also	O
in	O
human	O
umbilical	O
arterial	O
endothelial	O
cells	O
)	O
and	O
mRNA	O
expression	O
(	O
by	O
70	O
%	O
at	O
100	O
mumol	O
/	O
L	O
PDTC	O
)	O
in	O
HUVECs	O
as	O
assessed	O
by	O
flow	O
cytometry	O
and	O
polymerase	O
chain	O
reaction	O
.	O
Gel	O
-	O
shift	O
analysis	O
in	O
HUVECs	O
demonstrated	O
that	O
PDTC	O
prevented	O
NF	B
-	I
kappa	I
B	I
mobilization	O
by	O
TNF	B
,	O
suggesting	O
that	O
only	O
VCAM-1	B
induction	O
was	O
controlled	O
by	O
NF	B
-	I
kappa	I
B	I
.	O
Since	O
HUVECs	O
released	O
superoxide	O
anions	O
in	O
response	O
to	O
TNF	O
,	O
and	O
H2O2	O
induces	O
VCAM-1	B
,	O
PDTC	O
may	O
act	O
as	O
a	O
radical	O
scavenger	O
.	O
Although	O
ICAM-1	B
induction	O
was	O
unaffected	O
,	O
inhibitors	O
of	O
NADPH	B
oxidase	I
(	O
apocynin	O
)	O
or	O
cytochrome	B
P-450	I
(	O
SKF525a	O
)	O
suppressed	O
VCAM-1	B
induction	O
by	O
TNF	O
,	O
revealing	O
that	O
several	O
radical	O
-	O
generating	O
systems	O
are	O
involved	O
in	O
its	O
regulation	O
.	O
PDTC	O
,	O
apocynin	O
,	O
or	O
SKF525a	O
decreased	O
adhesion	O
of	O
monocytic	O
U937	O
cells	O
to	O
TNF	O
-	O
treated	O
HUVECs	O
(	O
by	O
75	O
%	O
at	O
100	O
mumol	O
/	O
L	O
PDTC	O
)	O
.	O
Inhibition	O
by	O
anti	B
-	I
VCAM-1	I
monoclonal	I
antibody	I
1G11	B
indicated	O
that	O
U937	O
adhesion	O
was	O
VCAM-1	B
dependent	O
and	O
suppression	O
by	O
antioxidants	O
was	O
due	O
to	O
reduced	O
VCAM-1	B
induction	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Novel	B
membrane	I
receptors	I
for	O
aldosterone	O
in	O
human	O
lymphocytes	O
:	O
a	O
50	B
kDa	I
protein	I
on	O
SDS	O
-	O
PAGE	O
.	O
Fast	O
in	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
the	O
Na+	B
/	I
H	I
(	I
+	I
)	I
-exchanger	I
,	O
inositoltrisphosphate	O
generation	O
and	O
corresponding	O
specific	O
binding	O
to	O
plasma	O
membranes	O
at	O
Kd	O
-	O
values	O
of	O
approximately	O
0.1	O
nM	O
have	O
been	O
found	O
in	O
human	O
mononuclear	O
leukocytes	O
and	O
vascular	O
smooth	O
muscle	O
cells	O
.	O
The	O
novel	O
aldosterone	O
membrane	O
receptor	O
was	O
analyzed	O
on	O
SDS	O
-	O
PAGE	O
after	O
labeling	O
of	O
microsomal	O
membranes	O
from	O
human	O
mononuclear	O
leukocytes	O
with	O
a	O
[	O
125I	O
]	O
-aldosterone	O
-	O
derivative	O
by	O
use	O
of	O
BASED	O
as	O
a	O
photoactivatable	O
crosslinker	O
.	O
Binding	O
of	O
1	O
nM	O
[	O
125I	O
]	O
-aldosterone	O
was	O
found	O
at	O
a	O
molecular	O
weight	O
of	O
approximately	O
50	O
kDa	O
which	O
was	O
absent	O
with	O
1	O
microM	O
cold	O
aldosterone	O
,	O
but	O
not	O
cortisol	O
in	O
the	O
binding	O
media	O
.	O
This	O
aldosterone	O
-	O
selectivity	O
is	O
typical	O
and	O
discriminatory	O
for	O
the	O
new	O
aldosterone	B
membrane	I
receptor	I
.	O
Solubilization	O
of	O
the	O
receptor	B
protein	I
from	O
membranes	O
by	O
high	O
salt	O
concentrations	O
(	O
1	O
M	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
)	O
was	O
not	O
achieved	O
.	O
It	O
,	O
thus	O
,	O
appears	O
as	O
an	O
integral	B
membrane	I
protein	I
.	O
Dithiothreitol	O
,	O
a	O
sulfhydryl	O
agent	O
,	O
does	O
not	O
reduce	O
specific	O
aldosterone	O
binding	O
indicating	O
the	O
absence	O
of	O
SH	B
-	I
groups	I
in	O
the	O
binding	B
domain	I
or	O
sensitive	O
structures	O
of	O
the	O
receptors	O
.	O
The	O
results	O
are	O
the	O
first	O
to	O
characterize	O
the	O
novel	B
membrane	I
receptor	I
for	O
aldosterone	O
with	O
regard	O
to	O
molecular	O
weight	O
and	O
basic	O
properties	O
.	O
These	O
findings	O
and	O
other	O
related	O
results	O
are	O
reviewed	O
here	O
.	O
Activation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
vivo	O
is	O
regulated	O
by	O
multiple	O
phosphorylations	O
.	O
The	O
activation	O
of	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
in	O
intact	O
cells	O
is	O
mechanistically	O
not	O
well	O
understood	O
.	O
Therefore	O
we	O
investigated	O
the	O
modifications	O
imposed	O
on	O
NF	B
-	I
kappa	I
B	I
/	I
I	I
kappa	I
B	I
components	I
following	O
stimulation	O
and	O
show	O
that	O
the	O
final	O
step	O
of	O
NF	B
-	I
kappa	I
B	I
induction	O
in	O
vivo	O
involves	O
phosphorylation	O
of	O
several	O
members	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
/	I
I	I
kappa	I
B	I
protein	I
families	I
.	O
In	O
HeLa	O
cells	O
as	O
well	O
as	O
in	O
B	O
cells	O
,	O
TNF	O
-	O
alpha	O
rapidly	O
induced	O
nuclear	O
translocation	O
primarily	O
of	O
p50-p65	B
,	O
but	O
not	O
of	O
c	B
-	I
rel	I
.	O
Both	O
NF	B
-	I
kappa	I
B	I
precursors	O
and	O
I	B
kappa	I
B	I
alpha	I
became	O
strongly	O
phosphorylated	O
with	O
the	O
same	O
kinetics	O
.	O
In	O
addition	O
to	O
the	O
inducible	O
phosphorylation	O
after	O
stimulation	O
,	O
B	O
lymphocytes	O
containing	O
constitutive	O
nuclear	O
NF	B
-	I
kappa	I
B	I
revealed	O
constitutively	O
phosphorylated	O
p65	B
and	O
I	B
kappa	I
B	I
alpha	I
.	O
Phosphorylation	O
was	O
accompanied	O
by	O
induced	O
processing	O
of	O
the	O
precursors	O
p100	B
and	O
p105	B
and	O
by	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
.	O
As	O
an	O
in	O
vitro	O
model	O
we	O
show	O
that	O
phosphorylation	O
of	O
p105	B
impedes	O
its	O
ability	O
to	O
interact	O
with	O
NF	B
-	I
kappa	I
B	I
,	O
as	O
has	O
been	O
shown	O
before	O
for	O
I	B
kappa	I
B	I
alpha	I
.	O
Surprisingly	O
,	O
even	O
p65	B
,	O
but	O
not	O
c	B
-	I
rel	I
,	O
was	O
phosphorylated	O
after	O
induction	O
in	O
vivo	O
,	O
suggesting	O
that	O
TNF	B
-	I
alpha	I
selectively	O
activates	O
only	O
specific	O
NF	B
-	I
kappa	I
B	I
heteromers	O
and	O
that	O
modifications	O
regulate	O
not	O
only	O
I	B
kappa	I
B	I
molecules	I
but	O
also	O
NF	B
-	I
kappa	I
B	I
molecules	O
.	O
In	O
fact	O
,	O
cellular	O
NF	B
-	I
kappa	I
B	I
activity	O
was	O
phosphorylation	O
-	O
dependent	O
and	O
the	O
DNA	O
binding	O
activity	O
of	O
p65-containing	B
NF	I
-	I
kappa	I
B	I
was	O
enhanced	O
by	O
phosphorylation	O
in	O
vitro	O
.	O
Furthermore	O
,	O
we	O
found	O
that	O
the	O
induction	O
by	O
hydrogen	O
peroxide	O
of	O
NF	B
-	I
kappa	I
B	I
translocation	O
to	O
the	O
nucleus	O
,	O
which	O
is	O
assumed	O
to	O
be	O
triggered	O
by	O
reactive	O
oxygen	O
intermediates	O
,	O
also	O
coincided	O
with	O
incorporation	O
of	O
phosphate	O
into	O
the	O
same	O
subunits	O
that	O
were	O
modified	O
after	O
stimulation	O
by	O
TNF	B
-	I
alpha	I
.	O
Thus	O
,	O
phosphorylation	O
appears	O
to	O
be	O
a	O
general	O
mechanism	O
for	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
vivo	O
.	O
An	O
active	O
v	B
-	I
abl	I
protein	I
tyrosine	I
kinase	I
blocks	O
immunoglobulin	O
light	O
-	O
chain	O
gene	O
rearrangement	O
.	O
Lymphoid	O
cells	O
transformed	O
by	O
Abelson	O
murine	O
leukemia	O
virus	O
have	O
provided	O
one	O
of	O
the	O
classic	O
models	O
for	O
study	O
of	O
early	O
B	O
-	O
cell	O
development	O
and	O
immunoglobulin	B
rearrangement	O
.	O
Most	O
of	O
these	O
cells	O
have	O
rearranged	O
their	O
heavy	O
-	O
chain	O
locus	O
but	O
not	O
their	O
light	O
chain	O
genes	O
,	O
suggesting	O
that	O
an	O
active	O
v	B
-	I
abl	I
protein	I
interferes	O
with	O
this	O
differentiation	O
step	O
.	O
To	O
test	O
this	O
hypothesis	O
,	O
light	O
-	O
chain	O
gene	O
structure	O
was	O
examined	O
in	O
pre	O
-	O
B	O
cells	O
transformed	O
by	O
temperature	O
-	O
sensitive	O
mutants	O
of	O
the	O
Abelson	O
virus	O
and	O
in	O
derivatives	O
that	O
survive	O
at	O
the	O
nonpermissive	O
temperature	O
because	O
they	O
express	O
a	O
human	O
BCL-2	O
gene	O
.	O
Our	O
studies	O
reveal	O
that	O
inactivation	O
of	O
the	O
v	B
-	I
abl	I
protein	I
tyrosine	I
kinase	I
triggers	O
high	O
-	O
frequency	O
rearrangement	O
of	O
kappa	O
and	O
lambda	O
light	O
-	O
chain	O
genes	O
.	O
These	O
events	O
are	O
accompanied	O
by	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
RAG-1	O
and	O
RAG-2	O
RNAs	O
.	O
These	O
increases	O
occur	O
in	O
the	O
absence	O
of	O
protein	O
synthesis	O
but	O
are	O
dependent	O
on	O
inactivation	O
of	O
the	O
v	B
-	I
abl	I
protein	I
tyrosine	I
kinase	I
.	O
As	O
documented	O
in	O
the	O
accompanying	O
paper	O
(	O
Klug	O
et	O
al.	O
,	O
this	O
issue	O
)	O
,	O
an	O
active	O
v	B
-	I
abl	I
protein	I
also	O
suppresses	O
the	O
activity	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
rel	I
and	O
expression	O
controlled	O
by	O
the	O
kappa	O
intron	O
enhancer	O
.	O
Together	O
these	O
data	O
demonstrate	O
that	O
the	O
v	B
-	I
abl	I
protein	I
specifically	O
interferes	O
with	O
light	O
-	O
chain	O
gene	O
rearrangement	O
by	O
suppressing	O
at	O
least	O
two	O
pathways	O
essential	O
for	O
this	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
and	O
suggest	O
that	O
tyrosine	O
phosphorylation	O
is	O
important	O
in	O
regulating	O
RAG	O
gene	O
expression	O
.	O
Regulation	O
of	O
interleukin-2	B
receptor	I
alpha	I
chain	I
expression	O
and	O
nuclear	B
factor.kappa	I
B	I
activation	O
by	O
protein	B
kinase	I
C	I
in	O
T	O
lymphocytes	O
.	O
Autocrine	O
role	O
of	O
tumor	B
necrosis	I
factor	I
alpha	I
.	O
The	O
regulation	O
of	O
interleukin-2	B
receptor	I
alpha	I
chain	I
(	O
IL-2R	B
alpha	I
)	O
expression	O
and	O
nuclear	B
factor	I
(	O
NF	O
)	O
activation	O
by	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
in	O
resting	O
T	O
cells	O
,	O
has	O
been	O
studied	O
.	O
Treatment	O
of	O
human	O
resting	O
T	O
cells	O
with	O
phorbol	O
esters	O
strongly	O
induced	O
the	O
expression	O
of	O
IL-2R	B
alpha	I
and	O
the	O
activation	O
of	O
NF.kappa	B
B	I
.	O
This	O
activation	O
was	O
due	O
to	O
the	O
translocation	O
of	O
p65	B
and	O
c	B
-	I
Rel	I
NF.kappa	B
B	I
proteins	O
from	O
cytoplasmic	O
stores	O
to	O
the	O
nucleus	O
,	O
where	O
they	O
bound	O
the	O
kappa	O
B	O
sequence	O
of	O
the	O
IL-2R	O
alpha	O
promoter	O
either	O
as	O
p50.p65	B
or	O
as	O
p50.c	B
-	I
Rel	I
heterodimers	O
.	O
Interestingly	O
,	O
all	O
of	O
those	O
events	O
were	O
largely	O
indirect	O
and	O
mediated	O
by	O
endogenously	O
secreted	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
alpha	I
)	O
,	O
as	O
they	O
were	O
strongly	O
inhibited	O
by	O
a	O
neutralizing	B
anti	I
-	I
TNF	I
alpha	I
monoclonal	I
antibody	I
.	O
Furthermore	O
,	O
cyclosporin	O
A	O
,	O
which	O
blocked	O
TNF	B
alpha	I
production	O
induced	O
by	O
PKC	B
,	O
strongly	O
inhibited	O
IL-2R	B
alpha	I
and	O
NF.kappa	B
B	I
activation	O
.	O
The	O
addition	O
of	O
either	O
TNF	B
alpha	I
or	O
IL-2	B
partially	O
recovered	O
cyclosporin	O
A	O
-	O
induced	O
IL-2R	B
alpha	I
inhibition	O
,	O
but	O
only	O
TNF	B
alpha	I
completely	O
recovered	O
NF.kappa	B
B	I
activation	O
.	O
Those	O
results	O
indicate	O
that	O
,	O
in	O
resting	O
T	O
cells	O
,	O
PKC	B
activation	O
has	O
only	O
a	O
triggering	O
role	O
,	O
whereas	O
the	O
endogenously	O
secreted	O
TNF	B
alpha	I
plays	O
an	O
essential	O
role	O
in	O
the	O
quantitative	O
control	O
of	O
the	O
expression	O
of	O
IL-2R	B
alpha	I
chain	O
or	O
NF.kappa	B
B	I
activation	O
.	O
The	O
role	O
of	O
cellular	B
transcription	I
factor	I
E2F	I
in	O
the	O
regulation	O
of	O
cdc2	O
mRNA	O
expression	O
and	O
cell	O
cycle	O
control	O
of	O
human	O
hematopoietic	O
cells	O
.	O
cdc2	O
mRNA	O
transcripts	O
were	O
detected	O
in	O
immature	O
bone	O
marrow	O
cells	O
and	O
became	O
undetectable	O
along	O
with	O
differentiation	O
.	O
Peripheral	O
blood	O
resting	O
cells	O
did	O
not	O
express	O
cdc2	O
mRNA	O
,	O
but	O
it	O
was	O
induced	O
in	O
T	O
-	O
lymphocytes	O
when	O
the	O
cells	O
reentered	O
the	O
cell	O
cycle	O
in	O
response	O
to	O
specific	O
mitogens	O
.	O
In	O
contrast	O
,	O
cdc2	O
mRNA	O
could	O
not	O
be	O
induced	O
in	O
granulocytes	O
and	O
monocytes	O
even	O
after	O
the	O
culture	O
with	O
the	O
appropriate	O
stimulants	O
.	O
In	O
order	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
regulation	O
of	O
cdc2	O
mRNA	O
expression	O
in	O
hematopoietic	O
cells	O
,	O
we	O
isolated	O
the	O
5'-flanking	O
sequence	O
of	O
the	O
cdc2	O
gene	O
and	O
found	O
the	O
putative	O
E2F	O
binding	O
site	O
at	O
the	O
position	O
of	O
nucleotides	O
-124	O
to	O
-117	O
.	O
The	O
binding	O
of	O
E2F	B
at	O
this	O
region	O
was	O
detected	O
by	O
a	O
gel	O
-	O
retardation	O
assay	O
and	O
DNaseI	B
footprinting	O
in	O
phytohemagglutinin	O
-	O
stimulated	O
T	O
-	O
lymphocytes	O
,	O
which	O
was	O
coincident	O
with	O
the	O
expression	O
of	O
cdc2	O
mRNA	O
.	O
E2F	B
binding	O
was	O
not	O
observed	O
in	O
both	O
granulocytes	O
and	O
monocytes	O
.	O
Transient	O
chloramphenicol	B
acetyltransferase	I
assay	O
revealed	O
that	O
the	O
region	O
containing	O
E2F	O
binding	O
site	O
had	O
a	O
strong	O
promoter	O
activity	O
,	O
and	O
introduction	O
of	O
the	O
mutation	O
at	O
the	O
E2F	O
binding	O
site	O
resulted	O
in	O
a	O
significant	O
loss	O
of	O
the	O
activity	O
.	O
E2F-1	O
and	O
DP-1	O
mRNAs	O
were	O
not	O
detectable	O
in	O
granulocytes	O
,	O
monocytes	O
and	O
resting	O
T	O
-	O
lymphocytes	O
but	O
were	O
induced	O
after	O
the	O
mitogenic	O
stimulation	O
of	O
T	O
-	O
lymphocytes	O
.	O
The	O
induction	O
of	O
E2F	B
activity	O
preceded	O
the	O
appearance	O
of	O
cdc2	O
mRNA	O
,	O
which	O
is	O
consistent	O
with	O
the	O
role	O
of	O
E2F	B
in	O
the	O
regulation	O
of	O
cdc2	O
mRNA	O
expression	O
.	O
These	O
results	O
suggest	O
that	O
cdc2	O
mRNA	O
expression	O
is	O
related	O
to	O
the	O
cell	O
cycling	O
of	O
normal	O
human	O
hematopoietic	O
cells	O
and	O
that	O
E2F	B
plays	O
some	O
roles	O
in	O
the	O
regulation	O
of	O
its	O
expression	O
.	O
Inducible	O
binding	O
to	O
the	O
c	O
-	O
fos	O
serum	O
response	O
element	O
during	O
T	O
cell	O
activation	O
is	O
regulated	O
by	O
a	O
phosphotyrosine	B
-	I
containing	I
protein	I
.	O
The	O
proto	O
-	O
oncogene	O
c	O
-	O
fos	O
is	O
an	O
immediate	O
-	O
early	O
gene	O
,	O
and	O
one	O
of	O
the	O
first	O
genes	O
transcribed	O
after	O
stimulation	O
of	O
most	O
cells	O
with	O
a	O
variety	O
of	O
ligands	O
.	O
Fos	O
expression	O
may	O
be	O
a	O
pivotal	O
event	O
in	O
converting	O
ligand	O
-	O
receptor	O
interactions	O
at	O
the	O
membrane	O
into	O
functional	O
modulation	O
of	O
cell	O
phenotype	O
.	O
The	O
serum	O
response	O
element	O
(	O
SRE	O
)	O
in	O
the	O
c	O
-	O
fos	O
regulatory	O
region	O
participates	O
in	O
induction	O
of	O
transcription	O
by	O
various	O
growth	B
factors	I
and	O
by	O
phorbol	O
esters	O
and	O
subsequent	O
squelching	O
of	O
transcription	O
.	O
We	O
show	O
that	O
an	O
inducible	O
protein	B
complex	I
(	O
Band	B
A	I
)	O
binds	O
to	O
SRE	O
DNA	O
within	O
10	O
min	O
after	O
mitogenic	O
stimulation	O
of	O
human	O
PBL	O
-	O
T	O
,	O
and	O
becomes	O
nondetectable	O
by	O
60	O
min	O
.	O
Band	B
A	I
contains	O
the	O
serum	B
response	I
factor	I
plus	O
additional	O
factor	O
(	O
s	O
)	O
.	O
A	O
protein	O
that	O
is	O
phosphorylated	O
on	O
a	O
tyrosine	O
residue	O
in	O
resting	O
PBL	O
-	O
T	O
suppresses	O
binding	O
of	O
a	O
component	O
of	O
Band	B
A	I
to	O
the	O
SRE	O
motif	O
.	O
Upon	O
stimulation	O
of	O
the	O
cells	O
,	O
this	O
protein	O
no	O
longer	O
prevents	O
binding	O
of	O
DNA	O
by	O
Band	B
A	I
,	O
and	O
suppression	O
of	O
binding	O
is	O
restored	O
within	O
30	O
min	O
.	O
The	O
phosphorylated	O
tyrosine	O
residue	O
itself	O
is	O
important	O
for	O
the	O
protein	O
-	O
protein	O
interaction	O
.	O
A	O
family	O
of	O
serine	B
proteases	I
expressed	O
exclusively	O
in	O
myelo-	O
monocytic	O
cells	O
specifically	O
processes	O
the	O
nuclear	B
factor	I
-	I
kappa	I
B	I
subunit	I
p65	I
in	O
vitro	O
and	O
may	O
impair	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
these	O
cells	O
.	O
Two	O
groups	O
of	O
U937	O
promonocytic	O
cells	O
were	O
obtained	O
by	O
limiting	O
dilution	O
cloning	O
which	O
differed	O
strikingly	O
in	O
their	O
ability	O
to	O
support	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
replication	O
.	O
`	O
`	O
Plus	O
''	O
clones	O
replicated	O
the	O
virus	O
efficiently	O
,	O
whereas	O
`	O
`	O
minus	O
''	O
clones	O
did	O
not	O
.	O
We	O
examined	O
these	O
clones	O
for	O
differences	O
in	O
nuclear	B
factor	I
(	I
NF	I
)	I
-kappa	I
B	I
activity	O
which	O
might	O
account	O
for	O
the	O
observed	O
phenomenon	O
.	O
Stimulation	O
of	O
plus	O
clones	O
liberated	O
the	O
classical	O
p50-p65	B
complex	I
from	O
cytoplasmic	O
pools	O
,	O
whereas	O
minus	O
clones	O
produced	O
an	O
apparently	O
novel	O
,	O
faster	B
-	I
migrating	I
complex	I
,	O
as	O
judged	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
It	O
is	O
surprising	O
that	O
the	O
faster	B
-	I
migrating	I
complex	I
was	O
composed	O
also	O
of	O
p50	B
and	O
p65	B
.	O
However	O
,	O
the	O
p65	B
subunit	I
was	O
COOH	O
-	O
terminally	O
truncated	O
,	O
as	O
shown	O
by	O
immunoprecipitation	O
.	O
The	O
truncation	O
resulted	O
from	O
limited	O
proteolysis	O
of	O
p65	B
during	O
cellular	O
extraction	O
which	O
released	O
particular	O
lysosomal	B
serine	I
proteases	I
,	O
such	O
as	O
elastase	B
,	O
cathepsin	B
G	I
,	O
and	O
proteinase	B
3	I
.	O
These	O
specific	O
proteases	O
are	O
coordinately	O
expressed	O
and	O
were	O
present	O
exclusively	O
in	O
the	O
minus	O
U937	O
clones	O
,	O
but	O
not	O
in	O
the	O
plus	O
clones	O
,	O
as	O
demonstrated	O
in	O
the	O
case	O
of	O
cathepsin	B
G	I
.	O
In	O
addition	O
,	O
these	O
proteases	O
were	O
detected	O
in	O
certain	O
subclones	O
of	O
THP-1	O
and	O
HL-60	O
cells	O
and	O
in	O
primary	O
monocytes	O
,	O
in	O
each	O
case	O
correlating	O
with	O
the	O
truncated	O
from	O
of	O
p65	B
.	O
We	O
demonstrate	O
in	O
vitro	O
cleavage	O
of	O
p65	B
by	O
purified	O
elastase	B
and	O
cathepsin	B
G	I
.	O
It	O
is	O
possible	O
that	O
particular	O
serine	B
proteases	I
may	O
have	O
inhibiting	O
effects	O
on	O
the	O
replication	O
of	O
HIV-1	O
in	O
myelo	O
-	O
monocytic	O
cells	O
.	O
The	O
data	O
also	O
demonstrate	O
that	O
special	O
precautions	O
must	O
be	O
taken	O
when	O
making	O
extracts	O
from	O
myelo	O
-	O
monocytic	O
cells	O
.	O
Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
Tax	B
activation	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
involves	O
phosphorylation	O
and	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
and	O
RelA	B
(	O
p65	B
)	O
-mediated	O
induction	O
of	O
the	O
c	O
-	O
rel	O
gene	O
.	O
The	O
tax	O
gene	O
product	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
a	O
potent	O
transcriptional	B
activator	I
that	O
both	O
stimulates	O
viral	O
gene	O
expression	O
and	O
activates	O
an	O
array	O
of	O
cellular	O
genes	O
involved	O
in	O
T	O
-	O
cell	O
growth	O
.	O
Tax	O
acts	O
indirectly	O
by	O
inducing	O
or	O
modifying	O
the	O
action	O
of	O
various	O
host	O
transcription	B
factors	I
,	O
including	O
members	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
family	I
of	O
enhancer	B
-	I
binding	I
proteins	I
.	O
In	O
resting	O
T	O
cells	O
,	O
many	O
of	O
these	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
factors	I
are	O
sequestered	O
in	O
the	O
cytoplasm	O
by	O
various	O
ankyrin	B
-	I
rich	I
inhibitory	I
proteins	I
,	O
including	O
I	B
kappa	I
B	I
alpha	I
.	O
HTLV	B
-	I
I	I
Tax	I
expression	O
leads	O
to	O
the	O
constitutive	O
nuclear	O
expression	O
of	O
biologically	O
active	O
NF	B
-	I
kappa	I
B	I
and	O
c	B
-	I
Rel	I
complexes	I
;	O
however	O
,	O
the	O
biochemical	O
mechanism	O
(	O
s	O
)	O
underlying	O
this	O
response	O
remains	O
poorly	O
understood	O
.	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
Tax	B
-stimulated	O
nuclear	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
both	O
HTLV	O
-	O
I	O
-	O
infected	O
and	O
Tax	O
-	O
transfected	O
human	O
T	O
cells	O
is	O
associated	O
with	O
the	O
phosphorylation	O
and	O
rapid	O
proteolytic	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
.	O
In	O
contrast	O
to	O
prior	O
in	O
vitro	O
studies	O
,	O
at	O
least	O
a	O
fraction	O
of	O
the	O
phosphorylated	O
form	O
of	O
I	B
kappa	I
B	I
alpha	I
remains	O
physically	O
associated	O
with	O
the	O
NF	B
-	I
kappa	I
B	I
complex	I
in	O
vivo	O
but	O
is	O
subject	O
to	O
rapid	O
degradation	O
,	O
thereby	O
promoting	O
the	O
nuclear	O
translocation	O
of	O
the	O
active	O
NF	B
-	I
kappa	I
B	I
complex	I
.	O
We	O
further	O
demonstrate	O
that	O
Tax	B
induction	O
of	O
nuclear	O
c	B
-	I
Rel	I
expression	O
is	O
activated	O
by	O
the	O
RelA	B
(	O
p65	B
)	O
subunit	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
which	O
activates	O
transcription	O
of	O
the	O
c	O
-	O
rel	O
gene	O
through	O
an	O
intrinsic	O
kappa	O
B	O
enhancer	O
element	O
.	O
In	O
normal	O
cells	O
,	O
the	O
subsequent	O
accumulation	O
of	O
nuclear	B
c	I
-	I
Rel	I
acts	O
to	O
inhibit	O
its	O
own	O
continued	O
production	O
,	O
indicating	O
the	O
presence	O
of	O
an	O
autoregulatory	O
loop	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Arrested	O
development	O
:	O
understanding	O
v	O
-	O
abl	O
.	O
The	O
protein	B
tyrosine	I
kinase	I
activity	O
of	O
the	O
v	O
-	O
abl	O
oncogene	O
has	O
been	O
demonstrated	O
to	O
subvert	O
the	O
normal	O
second	O
messenger	O
systems	O
used	O
by	O
lymphoid	O
cells	O
for	O
growth	O
and	O
differentiation	O
.	O
Transformation	O
of	O
bone	O
marrow	O
with	O
the	O
Abelson	O
murine	O
leukemia	O
virus	O
results	O
in	O
the	O
appearance	O
of	O
B	O
cell	O
lineage	O
cells	O
arrested	O
at	O
the	O
pre	O
-	O
B	O
cell	O
stage	O
.	O
Recent	O
reports	O
have	O
characterized	O
these	O
cells	O
expressing	O
high	O
v	O
-	O
abl	O
kinase	O
activity	O
as	O
deficient	O
in	O
detectable	O
NF	B
-	I
kappaB	I
DNA	O
binding	O
activity	O
and	O
low	O
level	O
RAG	O
gene	O
expression	O
.	O
These	O
observations	O
suggest	O
that	O
v	O
-	O
abl	O
may	O
be	O
inhibiting	O
the	O
differentiation	O
of	O
B	O
cells	O
by	O
blocking	O
these	O
two	O
crucial	O
elements	O
in	O
the	O
maturation	O
pathway	O
.	O
MHC	B
class	I
II	I
signaling	O
in	O
B	O
-	O
cell	O
activation	O
[	O
see	O
comments	O
]	O
The	O
cognate	O
interaction	O
between	O
T	O
cells	O
and	O
antigen	O
-	O
presenting	O
cells	O
(	O
APCs	O
)	O
,	O
mediated	O
by	O
major	B
histocompatibility	I
complex	I
(	I
MHC	I
)	I
class	I
II	I
molecules	I
,	O
results	O
in	O
the	O
delivery	O
of	O
activation	O
signals	O
to	O
the	O
APC	O
.	O
These	O
signals	O
contribute	O
to	O
the	O
expression	O
of	O
co	O
-	O
stimulatory	O
activity	O
by	O
APCs	O
and	O
have	O
important	O
consequences	O
for	O
cell	O
effector	O
function	O
.	O
MHC	B
class	I
II	I
molecules	O
also	O
serve	O
as	O
receptors	O
for	O
B	O
-	O
cell	O
stimulation	O
by	O
microbial	B
superantigens	I
.	O
In	O
this	O
review	O
,	O
Paul	O
Scholl	O
and	O
Raif	O
Geha	O
discuss	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
mechanisms	O
of	O
MHC	B
class	I
II	I
signaling	O
and	O
analyse	O
their	O
role	O
in	O
human	O
B	O
-	O
cell	O
activation	O
.	O
Distinct	O
DNase	O
-	O
I	O
hypersensitive	O
sites	O
are	O
associated	O
with	O
TAL-1	B
transcription	O
in	O
erythroid	O
and	O
T	O
-	O
cell	O
lines	O
.	O
The	O
tal-1	O
gene	O
,	O
frequently	O
activated	O
in	O
human	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
,	O
is	O
expressed	O
in	O
the	O
erythroid	O
,	O
megakaryocytic	O
,	O
and	O
mast	O
cell	O
lineages	O
during	O
normal	O
hematopoiesis	O
.	O
To	O
gain	O
further	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
that	O
control	O
tal-1	O
expression	O
,	O
we	O
investigated	O
tal-1	O
chromatin	O
structure	O
in	O
erythroid	O
/	O
megakaryocytic	O
cell	O
lines	O
and	O
in	O
T	O
-	O
cell	O
lines	O
either	O
with	O
or	O
without	O
tal-1	O
rearrangements	O
.	O
Tal-1	O
transcription	O
was	O
shown	O
to	O
be	O
monoallelic	O
in	O
Jurkat	O
,	O
a	O
T	O
-	O
cell	O
line	O
that	O
expresses	O
tal-1	O
in	O
the	O
absence	O
of	O
apparent	O
genomic	O
alteration	O
of	O
the	O
locus	O
.	O
Methylation	O
studies	O
indicated	O
that	O
the	O
tal-15	O
'	O
GC	O
-	O
rich	O
region	O
behaves	O
like	O
a	O
CpG	O
island	O
,	O
hypomethylated	O
in	O
normal	O
cells	O
,	O
and	O
methylated	O
de	O
novo	O
on	O
transcriptionally	O
inactive	O
alleles	O
in	O
established	O
cell	O
lines	O
.	O
Five	O
major	O
DNase	O
-	O
I	O
hypersensitive	O
sites	O
(	O
HS	O
)	O
were	O
mapped	O
in	O
the	O
tal-1	O
locus	O
.	O
HS	O
I	O
,	O
IV	O
,	O
and	O
V	O
were	O
exclusively	O
observed	O
in	O
the	O
erythroid	O
/	O
megakaryocytic	O
cell	O
lines	O
that	O
express	O
tal-1	O
from	O
the	O
promoters	O
1a	O
and	O
1b	O
.	O
HS	O
II	O
was	O
weak	O
in	O
hematopoietic	O
cell	O
lines	O
,	O
absent	O
in	O
Hela	O
,	O
and	O
greatly	O
enhanced	O
in	O
Jurkat	O
,	O
suggesting	O
that	O
this	O
region	O
might	O
be	O
implicated	O
in	O
the	O
cis	O
-	O
activation	O
of	O
tal-1	O
promoter	O
1b	O
in	O
this	O
cell	O
line	O
.	O
HS	O
III	O
was	O
weak	O
in	O
HEL	O
and	O
Jurkat	O
,	O
and	O
greatly	O
enhanced	O
in	O
DU528	O
,	O
a	O
T	O
-	O
cell	O
line	O
that	O
bears	O
a	O
t	O
(	O
1	O
;	O
14	O
)	O
and	O
initiates	O
tal-1	O
transcription	O
within	O
exon	O
4	O
.	O
These	O
results	O
suggest	O
that	O
distinct	O
regulatory	O
elements	O
are	O
associated	O
with	O
the	O
use	O
of	O
the	O
different	O
tal-1	O
promoters	O
.	O
Erythropoietin	B
-dependent	O
induction	O
of	O
hemoglobin	B
synthesis	O
in	O
a	O
cytokine	O
-	O
dependent	O
cell	O
line	O
M	O
-	O
TAT	O
.	O
M	O
-	O
TAT	O
is	O
a	O
cytokine	O
-	O
dependent	O
cell	O
line	O
with	O
the	O
potential	O
to	O
differentiate	O
along	O
the	O
erythroid	O
and	O
megakaryocytic	O
lineages	O
.	O
We	O
cultured	O
M	O
-	O
TAT	O
cells	O
long	O
term	O
(	O
>	O
1	O
year	O
)	O
in	O
the	O
continuous	O
presence	O
of	O
erythropoietin	B
(	O
EPO	B
)	O
,	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
,	O
or	O
stem	B
cell	I
factor	I
(	O
SCF	B
)	O
.	O
These	O
long	O
term	O
cultures	O
are	O
referred	O
to	O
as	O
M	O
-	O
TAT	O
/	O
EPO	O
,	O
M	O
-	O
TAT	O
/	O
GM	O
-	O
CSF	O
,	O
and	O
M	O
-	O
TAT	O
/	O
SCF	O
cells	O
,	O
respectively	O
.	O
Hemoglobin	B
concentration	O
and	O
gamma	B
-	I
globin	I
and	O
erythroid	O
delta	O
-	O
aminolevulinate	O
synthase	O
mRNA	O
levels	O
were	O
significantly	O
higher	O
in	O
M	O
-	O
TAT	O
/	O
EPO	O
cells	O
than	O
in	O
M	O
-	O
TAT	O
/	O
GM	O
-	O
CSF	O
cells	O
.	O
When	O
the	O
supplemented	O
cytokine	B
was	O
switched	O
from	O
GM	B
-	I
CSF	I
to	O
EPO	B
,	O
hemoglobin	B
synthesis	O
in	O
M	O
-	O
TAT	O
/	O
GM	O
-	O
CSF	O
cells	O
increased	O
rapidly	O
(	O
within	O
5	O
h	O
)	O
,	O
and	O
the	O
level	O
of	O
GATA-1	O
mRNA	O
increased	O
.	O
In	O
contrast	O
,	O
the	O
addition	O
of	O
GM	B
-	I
CSF	I
to	O
the	O
M	O
-	O
TAT	O
/	O
EPO	O
cell	O
culture	O
decreased	O
the	O
amount	O
of	O
hemoglobin	O
,	O
even	O
in	O
the	O
presence	O
of	O
EPO	B
,	O
indicating	O
that	O
the	O
EPO	B
signal	O
for	O
erythroid	O
differentiation	O
is	O
suppressed	O
by	O
GM	B
-	I
CSF	I
.	O
Thus	O
,	O
erythroid	O
development	O
of	O
M	O
-	O
TAT	O
cells	O
is	O
promoted	O
by	O
EPO	B
and	O
suppressed	O
by	O
GM	B
-	I
CSF	I
.	O
These	O
results	O
support	O
the	O
hypothesis	O
that	O
EPO	B
actively	O
influences	O
the	O
programming	O
of	O
gene	O
expression	O
required	O
for	O
erythroid	O
progenitor	O
cell	O
differentiation	O
.	O
Functional	O
Myc	B
-	I
Max	I
heterodimer	I
is	O
required	O
for	O
activation	O
-	O
induced	O
apoptosis	O
in	O
T	O
cell	O
hybridomas	O
.	O
T	O
cell	O
hybridomas	O
respond	O
to	O
activation	O
signals	O
by	O
undergoing	O
apoptotic	O
cell	O
death	O
,	O
and	O
this	O
is	O
likely	O
to	O
represent	O
comparable	O
events	O
related	O
to	O
tolerance	O
induction	O
in	O
immature	O
and	O
mature	O
T	O
cells	O
in	O
vivo	O
.	O
Previous	O
studies	O
using	O
antisense	O
oligonucleotides	O
implicated	O
the	O
c	B
-	I
Myc	I
protein	I
in	O
the	O
phenomenon	O
of	O
activation	O
-	O
induced	O
apoptosis	O
.	O
This	O
role	O
for	O
c	B
-	I
Myc	I
in	O
apoptosis	O
is	O
now	O
confirmed	O
in	O
studies	O
using	O
a	O
dominant	O
negative	O
form	O
of	O
its	O
heterodimeric	O
binding	O
partner	O
,	O
Max	B
,	O
which	O
we	O
show	O
here	O
inhibits	O
activation	O
-	O
induced	O
apoptosis	O
.	O
Further	O
,	O
coexpression	O
of	O
a	O
reciprocally	B
mutant	I
Myc	I
protein	I
capable	O
of	O
forming	O
functional	O
heterodimers	B
with	O
the	O
mutant	O
Max	B
can	O
compensate	O
for	O
the	O
dominant	O
negative	O
activity	O
and	O
restore	O
activation	O
-	O
induced	O
apoptosis	O
.	O
These	O
results	O
imply	O
that	O
Myc	B
promotes	O
activation	O
-	O
induced	O
apoptosis	O
by	O
obligatory	O
heterodimerization	O
with	O
Max	B
,	O
and	O
therefore	O
,	O
by	O
regulating	O
gene	O
transcription	O
.	O
Enhanced	O
responsiveness	O
to	O
nuclear	B
factor	I
kappa	I
B	I
contributes	O
to	O
the	O
unique	O
phenotype	O
of	O
simian	O
immunodeficiency	O
virus	O
variant	O
SIVsmmPBj14	O
.	O
Infection	O
with	O
a	O
variant	O
of	O
simian	O
immunodeficiency	O
virus	O
,	O
SIVsmmPBj14	O
,	O
leads	O
to	O
severe	O
acute	O
disease	O
in	O
macaques	O
.	O
This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
functional	O
significance	O
of	O
previously	O
described	O
mutations	O
in	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
and	O
to	O
elucidate	O
their	O
contribution	O
to	O
the	O
unique	O
phenotype	O
of	O
SIVsmmPBj14	O
.	O
LTR	O
-directed	O
transcription	O
was	O
measured	O
by	O
using	O
luciferase	O
reporter	O
constructs	O
that	O
were	O
transiently	O
transfected	O
into	O
cultured	O
cells	O
.	O
In	O
a	O
wide	O
range	O
of	O
cell	O
types	O
,	O
the	O
basal	O
transcriptional	O
activity	O
of	O
the	O
LTR	O
from	O
SIVsmmPBj14	O
was	O
found	O
to	O
be	O
2-	O
to	O
4.5-fold	O
higher	O
than	O
that	O
of	O
an	O
LTR	O
from	O
a	O
non	O
-	O
acutely	O
pathogenic	O
strain	O
.	O
These	O
LTRs	O
differ	O
by	O
five	O
point	O
mutations	O
and	O
a	O
22-bp	O
duplication	O
in	O
SIVsmmPBj14	O
,	O
which	O
includes	O
a	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
site	O
.	O
Transcriptional	O
differences	O
between	O
these	O
LTRs	O
were	O
further	O
enhanced	O
by	O
two-	O
to	O
threefold	O
upon	O
treatment	O
of	O
cells	O
with	O
phorbol	O
ester	O
or	O
tumor	B
necrosis	I
factor	I
alpha	I
or	O
by	O
cotransfection	O
with	O
plasmids	O
expressing	O
NF	B
kappa	I
B	I
subunits	O
.	O
Mutagenesis	O
studies	O
,	O
and	O
the	O
use	O
of	O
a	O
reporter	O
construct	O
containing	O
an	O
enhancerless	O
promoter	O
,	O
indicate	O
that	O
these	O
transcriptional	O
effects	O
are	O
due	O
principally	O
to	O
the	O
22-bp	O
sequence	O
duplication	O
and	O
the	O
NF	O
kappa	O
B	O
site	O
contained	O
within	O
it	O
.	O
Finally	O
,	O
infectious	O
virus	O
stocks	O
that	O
were	O
isogenic	O
except	O
for	O
the	O
LTR	O
were	O
generated	O
.	O
The	O
LTR	O
from	O
SIVsmmPBj14	O
was	O
found	O
to	O
confer	O
an	O
increase	O
in	O
the	O
kinetics	O
of	O
virus	O
replication	O
in	O
cultured	O
cells	O
.	O
Inclusion	O
of	O
this	O
LTR	O
in	O
recombinant	O
SIVs	O
also	O
resulted	O
in	O
a	O
two-	O
to	O
threefold	O
rise	O
in	O
the	O
extent	O
of	O
cellular	O
proliferation	O
that	O
was	O
induced	O
in	O
quiescent	O
simian	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
These	O
studies	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
LTR	O
mutations	O
assist	O
SIVsmmPBj14	O
in	O
responding	O
efficiently	O
to	O
cellular	O
stimulation	O
and	O
allow	O
it	O
to	O
replicate	O
to	O
high	O
titers	O
during	O
the	O
acute	O
phase	O
of	O
viral	O
infection	O
.	O
Identification	O
of	O
a	O
region	O
which	O
directs	O
the	O
monocytic	O
activity	O
of	O
the	O
colony	O
-	O
stimulating	O
factor	O
1	O
(	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
)	O
receptor	O
promoter	O
and	O
binds	O
PEBP2	B
/	I
CBF	I
(	O
AML1	B
)	O
.	O
The	O
receptor	O
for	O
the	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
(	O
or	O
colony	B
-	I
stimulating	I
factor	I
1	I
[	O
CSF-1	B
]	O
)	O
is	O
expressed	O
from	O
different	O
promoters	O
in	O
monocytic	O
cells	O
and	O
placental	O
trophoblasts	O
.	O
We	O
have	O
demonstrated	O
that	O
the	O
monocyte	O
-	O
specific	O
expression	O
of	O
the	O
CSF-1	B
receptor	I
is	O
regulated	O
at	O
the	O
level	O
of	O
transcription	O
by	O
a	O
tissue	O
-	O
specific	O
promoter	O
whose	O
activity	O
is	O
stimulated	O
by	O
the	O
monocyte	B
/	I
B	I
-	I
cell	I
-	I
specific	I
transcription	I
factor	I
PU.1	B
(	O
D	O
.-	O
E.Zhang	O
,	O
C.J.Hetherington	O
,	O
H	O
.-	O
M.Chen	O
,	O
and	O
D.G.Tenen	O
,	O
Mol	O
.	O
Cell	O
.	O
Biol.14	O
:	O
373	O
-	O
381	O
,	O
1994	O
)	O
.	O
Here	O
we	O
report	O
that	O
the	O
tissue	O
specificity	O
of	O
this	O
promoter	O
is	O
also	O
mediated	O
by	O
sequences	O
in	O
a	O
region	O
II	O
(	O
bp	O
-88	O
to	O
-	O
59	O
)	O
,	O
which	O
lies	O
10	O
bp	O
upstream	O
from	O
the	O
PU.1-binding	O
site	O
.	O
When	O
analyzed	O
by	O
DNase	B
footprinting	O
,	O
region	O
II	O
was	O
protected	O
preferentially	O
in	O
monocytic	O
cells	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
confirmed	O
that	O
region	O
II	O
interacts	O
specifically	O
with	O
nuclear	B
proteins	I
from	O
monocytic	O
cells	O
.	O
Two	O
gel	B
shift	I
complexes	I
(	O
Mono	B
A	I
and	O
Mono	B
B	I
)	O
were	O
formed	O
with	O
separate	O
sequence	O
elements	O
within	O
this	O
region	O
.	O
Competition	O
and	O
supershift	O
experiments	O
indicate	O
that	O
Mono	B
B	I
contains	O
a	O
member	O
of	O
the	O
polyomavirus	B
enhancer	I
-	I
binding	I
protein	I
2	I
/	I
core	I
-	I
binding	I
factor	I
(	I
PEBP2	I
/	I
CBF	I
)	I
family	I
,	I
which	O
includes	O
the	O
AML1	O
gene	O
product	O
,	O
while	O
Mono	B
A	I
is	O
a	O
distinct	O
complex	O
preferentially	O
expressed	O
in	O
monocytic	O
cells	O
.	O
Promoter	O
constructs	O
with	O
mutations	O
in	O
these	O
sequence	O
elements	O
were	O
no	O
longer	O
expressed	O
specifically	O
in	O
monocytes	O
.	O
Furthermore	O
,	O
multimerized	O
region	O
II	O
sequence	O
elements	O
enhanced	O
the	O
activity	O
of	O
a	O
heterologous	O
thymidine	O
kinase	O
promoter	O
in	O
monocytic	O
cells	O
but	O
not	O
other	O
cell	O
types	O
tested	O
.	O
These	O
results	O
indicate	O
that	O
the	O
monocyte	B
/	I
B	I
-	I
cell	I
-	I
specific	I
transcription	I
factor	I
PU.1	B
and	O
the	O
Mono	B
A	I
and	I
Mono	I
B	I
protein	I
complexes	I
act	O
in	O
concert	O
to	O
regulate	O
monocyte	O
-	O
specific	O
transcription	O
of	O
the	O
CSF-1	B
receptor	I
.	O
A	O
factor	O
that	O
regulates	O
the	O
class	O
II	O
major	O
histocompatibility	O
complex	O
gene	O
DPA	O
is	O
a	O
member	O
of	O
a	O
subfamily	O
of	O
zinc	B
finger	I
proteins	I
that	O
includes	O
a	O
Drosophila	B
developmental	I
control	I
protein	I
.	O
A	O
novel	O
DNA	O
sequence	O
element	O
termed	O
the	O
J	O
element	O
involved	O
in	O
the	O
regulated	O
expression	O
of	O
class	O
II	O
major	O
histocompatibility	O
complex	O
genes	O
was	O
recently	O
described	O
.	O
To	O
study	O
this	O
element	O
and	O
its	O
role	O
in	O
class	O
II	O
gene	O
regulation	O
further	O
,	O
a	O
cDNA	O
library	O
was	O
screened	O
with	O
oligonucleotide	O
probes	O
containing	O
both	O
the	O
S	O
element	O
and	O
the	O
nearby	O
J	O
element	O
of	O
the	O
human	O
DPA	O
gene	O
.	O
Several	O
DNA	O
clones	O
were	O
obtained	O
by	O
this	O
procedure	O
,	O
one	O
of	O
which	O
,	O
clone	O
18	O
,	O
is	O
reported	O
and	O
characterized	O
here	O
.	O
It	O
encodes	O
a	O
protein	O
predicted	O
to	O
contain	O
688	O
amino	O
acid	O
residues	O
,	O
including	O
11	O
zinc	B
finger	I
motifs	I
of	O
the	O
C2H2	B
type	I
in	O
the	O
C	B
-	I
terminal	I
region	I
,	O
that	O
are	O
Kruppel	O
-	O
like	O
in	O
the	O
conservation	O
of	O
the	O
H	B
/	I
C	I
link	I
sequence	I
connecting	O
them	O
.	O
The	O
160	B
N	I
-	I
terminal	I
amino	I
acids	I
in	O
the	O
nonfinger	B
region	I
of	O
clone	B
18	I
are	O
highly	O
homologous	O
with	O
similar	O
regions	O
of	O
several	O
other	O
human	O
,	O
mouse	O
,	O
and	O
Drosophila	O
sequences	O
,	O
defining	O
a	O
subfamily	O
of	O
Kruppel	O
-	O
like	O
zinc	B
finger	I
proteins	I
termed	O
TAB	B
(	O
tramtrack	B
[	I
ttk	I
]	I
-associated	I
box	I
)	O
here	O
.	O
One	O
of	O
the	O
Drosophila	O
sequences	O
,	O
ttk	O
,	O
is	O
a	O
developmental	O
control	O
gene	O
,	O
while	O
a	O
second	O
does	O
not	O
contain	O
a	O
zinc	B
finger	I
region	I
but	O
encodes	O
a	O
structure	O
important	O
in	O
oocyte	O
development	O
.	O
An	O
acidic	B
activation	I
domain	I
is	O
located	O
between	O
the	O
N	B
-	I
terminal	I
conserved	I
region	I
of	O
clone	B
18	I
and	O
its	O
zinc	B
fingers	I
.	O
This	O
protein	O
appears	O
to	O
require	O
both	O
the	O
S	O
and	O
J	O
elements	O
,	O
which	O
are	O
separated	O
by	O
10	O
bp	O
for	O
optimal	O
binding	O
.	O
Antisense	O
cDNA	O
to	O
clone	B
18	I
inhibited	O
the	O
expression	O
of	O
a	O
reporter	O
construct	O
containing	O
the	O
DPA	O
promoter	O
,	O
indicating	O
its	O
functional	O
importance	O
in	O
the	O
expression	O
of	O
this	O
class	O
II	O
gene	O
.	O
Epstein	B
-	I
Barr	I
virus	I
SM	I
protein	I
.	O
The	O
protein	O
products	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
BMLF1	O
open	O
reading	O
frame	O
have	O
been	O
characterized	O
in	O
the	O
early	O
productive	O
cycle	O
in	O
B95	O
-	O
8	O
and	O
Akata	O
cells	O
.	O
The	O
SM	B
protein	I
derived	O
from	O
the	O
spliced	O
RNA	O
joining	O
BSLF2	B
to	O
BMLF1	B
is	O
much	O
the	O
most	O
abundant	O
protein	O
.	O
SM	B
is	O
a	O
phosphoprotein	B
in	O
EBV	O
-infected	O
cells	O
and	O
can	O
be	O
phosphorylated	O
in	O
vitro	O
with	O
casein	B
kinase	I
II	I
(	O
CKII	B
)	O
.	O
Computer	O
analysis	O
of	O
the	O
SM	B
protein	I
sequence	O
showed	O
a	O
C	B
terminal	I
section	I
of	O
SM	B
to	O
be	O
related	O
to	O
genome	B
positional	I
homologues	I
of	O
four	O
other	O
herpesviruses	O
and	O
revealed	O
consensus	B
CKII	I
sites	I
near	O
the	O
N	B
termini	I
of	O
the	O
EBV	B
SM	I
protein	I
,	O
the	O
herpes	B
simplex	I
virus	I
(	I
HSV	I
)	I
ICP27	I
protein	I
and	O
the	O
herpesvirus	B
saimiri	I
(	I
HVS	I
)	I
open	I
reading	I
frame	I
57	I
protein	I
.	O
Site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
consensus	O
CKII	O
site	O
in	O
EBV	O
SM	O
greatly	O
reduced	O
the	O
in	O
vitro	O
phosphorylation	O
of	O
SM	B
by	O
CKII	B
.	O
The	O
mechanism	O
of	O
transactivation	O
by	O
BMLF1	B
proteins	I
has	O
been	O
controversial	O
but	O
SM	B
was	O
shown	O
to	O
transactivate	O
gene	O
expression	O
from	O
a	O
CAT	O
reporter	O
construct	O
by	O
increasing	O
the	O
amount	O
of	O
cytoplasmic	O
CAT	O
mRNA	O
.	O
Mutagenesis	O
of	O
the	O
CKII	B
site	O
in	O
SM	B
made	O
no	O
difference	O
to	O
the	O
transactivation	O
in	O
this	O
transient	O
transfection	O
assay	O
.	O
The	O
role	O
of	O
NFATp	B
in	O
cyclosporin	O
A	O
-	O
sensitive	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
gene	O
transcription	O
.	O
The	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
alpha	O
)	O
gene	O
is	O
an	O
immediate	O
early	O
gene	O
in	O
activated	O
T	O
cells	O
,	O
in	O
that	O
it	O
is	O
rapidly	O
induced	O
without	O
a	O
requirement	O
for	O
protein	O
synthesis	O
.	O
Maximal	O
induction	O
of	O
TNF	O
alpha	O
mRNA	O
can	O
be	O
induced	O
by	O
treatment	O
of	O
T	O
cells	O
with	O
calcium	O
ionophores	O
alone	O
,	O
via	O
a	O
calcineurin	B
-dependent	O
process	O
that	O
is	O
blocked	O
by	O
cyclosporin	O
A	O
.	O
We	O
have	O
previously	O
identified	O
a	O
promoter	O
element	O
,	O
kappa	O
3	O
,	O
that	O
is	O
required	O
for	O
calcium	O
-	O
stimulated	O
,	O
cyclosporin	O
A	O
-	O
sensitive	O
induction	O
of	O
the	O
TNF	O
alpha	O
gene	O
in	O
activated	O
T	O
cells	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
the	O
kappa	B
3	I
binding	I
factor	I
contains	O
NFATp	B
,	O
a	O
cyclosporin	B
-	I
sensitive	I
DNA	I
-	I
binding	I
protein	I
required	O
for	O
interleukin-2	O
gene	O
transcription	O
.	O
NFATp	B
binds	O
to	O
two	O
sites	O
within	O
the	O
kappa	O
3	O
element	O
,	O
and	O
occupancy	O
of	O
both	O
sites	O
is	O
required	O
for	O
TNF	B
alpha	O
gene	O
induction	O
.	O
Thus	O
,	O
although	O
the	O
kappa	O
3	O
element	O
has	O
little	O
sequence	O
similarity	O
to	O
other	O
NFATp	O
-	O
binding	O
sites	O
,	O
it	O
appears	O
to	O
function	O
as	O
a	O
cyclosporin	O
-	O
sensitive	O
promoter	O
element	O
in	O
T	O
cells	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
bind	O
NFATp	B
.	O
The	O
involvement	O
of	O
NFATp	B
in	O
transcriptional	O
activation	O
of	O
both	O
the	O
interleukin-2	B
and	O
TNF	O
alpha	O
genes	O
suggests	O
that	O
this	O
factor	O
plays	O
an	O
important	O
role	O
in	O
the	O
coordinate	O
induction	O
of	O
multiple	O
cytokine	O
genes	O
,	O
starting	O
at	O
the	O
earliest	O
stages	O
of	O
T	O
cell	O
activation	O
.	O
Epstein	B
-	I
Barr	I
virus	I
nuclear	I
protein	I
2	I
transactivation	O
of	O
the	O
latent	O
membrane	O
protein	O
1	O
promoter	O
is	O
mediated	O
by	O
J	B
kappa	I
and	O
PU.1	B
.	O
Expression	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
latent	O
membrane	O
protein	O
1	O
(	O
LMP-1	O
)	O
oncogene	O
is	O
regulated	O
by	O
the	O
EBV	B
nuclear	I
protein	I
2	I
(	I
EBNA-2	I
)	I
transactivator	I
.	O
EBNA-2	B
is	O
known	O
to	O
interact	O
with	O
the	O
cellular	B
DNA	I
-	I
binding	I
protein	I
J	B
kappa	I
and	O
is	O
recruited	O
to	O
promoters	O
containing	O
the	O
GTGGGAA	O
J	O
kappa	O
recognition	O
sequence	O
.	O
The	O
minimal	O
EBNA-2-responsive	O
LMP-1	O
promoter	O
includes	O
one	O
J	O
kappa	O
-	O
binding	O
site	O
,	O
and	O
we	O
now	O
show	O
that	O
mutation	O
of	O
that	O
site	O
,	O
such	O
that	O
J	B
kappa	I
can	O
not	O
bind	O
,	O
reduces	O
EBNA-2	B
responsiveness	O
by	O
60	O
%	O
.	O
To	O
identify	O
other	O
factors	O
which	O
interact	O
with	O
the	O
LMP-1	O
EBNA-2	O
response	O
element	O
(	O
E2RE	O
)	O
,	O
a	O
-236	O
/	O
-145	O
minimal	O
E2RE	O
was	O
used	O
as	O
a	O
probe	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
The	O
previously	O
characterized	O
factors	O
J	B
kappa	I
,	O
PU.1	B
,	O
and	O
AML1	B
bind	O
to	O
the	O
LMP-1	O
E2RE	O
,	O
along	O
with	O
six	O
other	O
unidentified	O
factors	O
(	O
LBF2	B
to	O
LBF7	B
)	O
.	O
Binding	O
sites	O
were	O
mapped	O
for	O
each	O
factor	O
.	O
LBF4	B
is	O
B-	O
and	O
T	O
-	O
cell	O
specific	O
and	O
recognizes	O
the	O
PU.1	O
GGAA	O
core	O
sequence	O
as	O
shown	O
by	O
methylation	O
interference	O
.	O
LBF4	B
has	O
a	O
molecular	O
mass	O
of	O
105	O
kDa	O
and	O
is	O
probably	O
unrelated	O
to	O
PU.1	B
.	O
LBF2	B
was	O
found	O
only	O
in	O
epithelial	O
cell	O
lines	O
,	O
whereas	O
LBF3	B
,	O
LBF5	B
,	O
LBF6	B
,	O
and	O
LBF7	B
were	O
not	O
cell	O
type	O
specific	O
.	O
Mutations	O
of	O
the	O
AML1-	O
or	O
LBF4-binding	O
sites	O
had	O
no	O
effect	O
on	O
EBNA-2	B
transactivation	O
,	O
whereas	O
mutation	O
of	O
the	O
PU.1-binding	O
site	O
completely	O
eliminated	O
EBNA-2	B
responses	O
.	O
A	O
gst	B
-	I
EBNA-2	I
fusion	I
protein	I
specifically	O
depleted	O
PU.1	B
from	O
nuclear	O
extracts	O
and	O
bound	O
in	O
vitro	O
translated	O
PU.1	B
,	O
providing	O
biochemical	O
evidence	O
for	O
a	O
direct	O
EBNA-2	B
-PU.1	B
interaction	O
.	O
Thus	O
,	O
EBNA-2	B
transactivation	O
of	O
the	O
LMP-1	O
promoter	O
is	O
dependent	O
on	O
interaction	O
with	O
at	O
least	O
two	O
distinct	O
sequence	O
-	O
specific	O
DNA	B
-	I
binding	I
proteins	I
,	O
J	B
kappa	I
and	O
PU.1	B
.	O
LBF3	B
,	O
LBF5	B
,	O
LBF6	B
,	O
or	O
LBF7	B
may	O
also	O
be	O
involved	O
,	O
since	O
their	O
binding	O
sites	O
also	O
contribute	O
to	O
EBNA-2	B
responsiveness	O
.	O
Pyrrolidine	O
dithiocarbamate	O
,	O
a	O
potent	O
inhibitor	O
of	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
activation	O
,	O
prevents	O
apoptosis	O
in	O
human	O
promyelocytic	O
leukemia	O
HL-60	O
cells	O
and	O
thymocytes	O
.	O
We	O
examined	O
the	O
effect	O
of	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
which	O
potently	O
blocks	O
the	O
activation	O
of	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
,	O
on	O
the	O
induction	O
of	O
apoptosis	O
by	O
a	O
variety	O
of	O
agents	O
.	O
Treatment	O
of	O
a	O
human	O
promyelocytic	O
leukemia	O
cell	O
line	O
,	O
HL-60	O
,	O
with	O
10	O
micrograms	O
/	O
mL	O
etoposide	O
or	O
2	O
microM	O
1-beta	O
-	O
D	O
-	O
arabinofuranosylcytosine	O
induced	O
NF	B
-	I
kappa	I
B	I
activation	O
within	O
1	O
hr	O
and	O
subsequently	O
caused	O
apoptosis	O
within	O
3	O
-	O
4	O
hr	O
.	O
The	O
simultaneous	O
addition	O
of	O
50	O
-	O
500	O
microM	O
PDTC	O
with	O
these	O
agents	O
blocked	O
NF	B
-	I
kappa	I
B	I
activation	O
and	O
completely	O
abrogated	O
both	O
morphologically	O
apoptotic	O
changes	O
and	O
internucleosomal	O
DNA	O
fragmentation	O
for	O
up	O
to	O
6	O
hr	O
.	O
However	O
,	O
PDTC	O
failed	O
to	O
inhibit	O
the	O
endonuclease	B
activity	O
contained	O
in	O
the	O
whole	O
cell	O
lysates	O
.	O
The	O
inhibitory	O
effect	O
of	O
PDTC	O
was	O
also	O
observed	O
in	O
etoposide	O
-and	O
dexamethasone	O
-	O
induced	O
apoptosis	O
in	O
human	O
thymocytes	O
at	O
a	O
concentration	O
of	O
1	O
-	O
10	O
microM	O
.	O
Since	O
PDTC	O
has	O
both	O
antioxidant	O
and	O
metal	O
-	O
ion	O
chelating	O
activities	O
,	O
we	O
tested	O
the	O
effects	O
of	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
(	O
antioxidant	O
)	O
or	O
o	O
-	O
phenanthroline	O
(	O
OP	O
)	O
(	O
metal	O
-	O
ion	O
chelator	O
)	O
on	O
the	O
induction	O
of	O
apoptosis	O
.	O
Pretreatment	O
of	O
HL-60	O
cells	O
or	O
thymocytes	O
with	O
100	O
-	O
500	O
microM	O
OP	O
for	O
2	O
hr	O
,	O
but	O
not	O
10	O
-	O
60	O
mM	O
NAC	O
,	O
suppressed	O
subsequent	O
occurrence	O
of	O
apoptosis	O
induced	O
by	O
etoposide	O
.	O
These	O
results	O
suggest	O
that	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
plays	O
an	O
important	O
role	O
in	O
the	O
apoptotic	O
process	O
of	O
human	O
hematopoietic	O
cells	O
.	O
Differential	O
regulation	O
of	O
proto	O
-	O
oncogenes	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
in	O
T	O
lymphocytes	O
activated	O
through	O
CD28	B
.	O
The	O
T	B
cell	I
surface	I
molecule	I
CD28	B
binds	O
to	O
ligands	O
on	O
accessory	O
cells	O
and	O
APCs	O
,	O
playing	O
an	O
important	O
costimulatory	O
role	O
in	O
the	O
response	O
of	O
T	O
cells	O
to	O
Ags	B
.	O
Our	O
knowledge	O
of	O
the	O
intracellular	O
signaling	O
pathways	O
coupled	O
to	O
this	O
receptor	O
is	O
incomplete	O
.	O
In	O
addition	O
to	O
activation	O
of	O
phospholipase	B
C	I
gamma	I
1	I
,	O
ligation	O
of	O
this	O
receptor	O
also	O
seems	O
to	O
activate	O
a	O
calcium	O
-	O
independent	O
,	O
CD28	B
-specific	O
pathway	O
.	O
In	O
this	O
paper	O
,	O
we	O
report	O
that	O
cross	O
-	O
linking	O
of	O
CD28	B
(	O
but	O
not	O
CD2	B
,	O
CD5	B
,	O
LFA-1	B
,	O
or	O
CD7	B
)	O
leads	O
to	O
an	O
elevation	O
of	O
c	O
-	O
jun	O
mRNA	O
,	O
with	O
only	O
minimal	O
activation	O
of	O
c	O
-	O
fos	O
expression	O
.	O
CD28	B
-dependent	O
induction	O
of	O
c	O
-	O
jun	O
expression	O
requires	O
protein	B
tyrosine	I
kinase	I
activity	O
,	O
but	O
does	O
not	O
depend	O
on	O
activation	O
of	O
a	O
phorbol	B
ester	I
-	I
responsive	I
protein	I
kinase	I
C	I
or	O
elevation	O
of	O
cytosolic	O
calcium	O
.	O
Furthermore	O
,	O
CD28	B
-dependent	O
elevation	O
of	O
c	O
-	O
jun	O
mRNA	O
does	O
not	O
appear	O
to	O
be	O
mediated	O
at	O
the	O
level	O
of	O
mRNA	O
stability	O
.	O
A	O
mechanism	O
is	O
suggested	O
whereby	O
expression	O
of	O
c	O
-	O
jun	O
and	O
junB	O
,	O
in	O
the	O
absence	O
of	O
members	O
of	O
the	O
fos	O
family	O
,	O
can	O
prevent	O
inappropriate	O
activation	O
of	O
T	O
cells	O
caused	O
by	O
ligation	O
of	O
CD28	B
in	O
the	O
absence	O
of	O
a	O
specific	O
antigenic	O
stimulus	O
.	O
Constitutive	O
nuclear	B
NF	I
-	I
kappa	I
B	I
in	O
cells	O
of	O
the	O
monocyte	O
lineage	O
.	O
In	O
monocytes	O
,	O
the	O
nuclear	B
factor	I
NF	I
-	I
kappa	I
B	I
has	O
been	O
invoked	O
as	O
an	O
important	O
transcription	B
factor	I
in	O
the	O
expression	O
of	O
cytokine	O
genes	O
,	O
of	O
cell	B
-	I
surface	I
receptors	I
and	O
in	O
the	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
.	O
In	O
such	O
cells	O
,	O
DNA	O
binding	O
activity	O
of	O
NF	B
-	I
kappa	I
B	I
can	O
be	O
detected	O
without	O
intentional	O
stimulation	O
.	O
In	O
our	O
studies	O
,	O
cells	O
of	O
the	O
human	O
monocytic	O
line	O
Mono	O
Mac	O
6	O
,	O
cultured	O
in	O
medium	O
containing	O
fetal	O
-	O
calf	O
serum	O
and	O
low	O
levels	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
also	O
exhibit	O
such	O
'	O
constitutive	O
'	O
NF	B
-	I
kappa	I
B	I
,	O
as	O
demonstrated	O
by	O
mobility	O
-	O
shift	O
analysis	O
of	O
nuclear	O
extracts	O
.	O
This	O
nuclear	B
NF	I
-	I
kappa	I
B	I
was	O
still	O
present	O
when	O
contaminant	O
LPS	O
was	O
removed	O
by	O
ultrafiltration	O
and	O
when	O
serum	O
was	O
omitted	O
.	O
Protein	O
-	O
DNA	O
complexes	O
of	O
constitutive	O
NF	B
-	I
kappa	I
B	I
are	O
similar	O
in	O
mobility	O
to	O
the	O
LPS	B
-	I
induced	I
NF	I
-	I
kappa	I
B	I
and	O
both	O
are	O
recognized	O
by	O
an	O
antibody	O
specific	O
to	O
the	O
p50	B
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
.	O
By	O
contrast	O
,	O
treatment	O
of	O
cells	O
with	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
will	O
only	O
block	O
LPS	B
-	I
induced	I
NF	I
-	I
kappa	I
B	I
,	O
but	O
not	O
the	O
constitutive	B
binding	I
protein	I
.	O
Using	O
LPS	O
-	O
free	O
and	O
serum	O
-	O
free	O
conditions	O
,	O
constitutive	O
NF	B
-	I
kappa	I
B	I
can	O
be	O
detected	O
in	O
different	O
cell	O
lines	O
of	O
the	O
monocytic	O
lineage	O
(	O
HL60	O
,	O
U937	O
,	O
THP-1	O
,	O
Mono	O
Mac	O
1	O
and	O
Mono	O
Mac	O
6	O
)	O
,	O
but	O
not	O
in	O
Molt	O
4	O
T	O
cells	O
or	O
K562	O
stem	O
cells	O
.	O
When	O
ordered	O
according	O
to	O
stage	O
of	O
maturation	O
,	O
the	O
amount	O
of	O
constitutive	O
NF	B
-	I
kappa	I
B	I
was	O
not	O
increased	O
in	O
more	O
mature	O
cell	O
lines	O
.	O
Furthermore	O
,	O
when	O
inducing	O
differentiation	O
in	O
Mono	O
Mac	O
6	O
cells	O
,	O
with	O
vitamin	O
D3	O
,	O
no	O
change	O
in	O
constitutive	O
or	O
inducible	O
NF	B
-	I
kappa	I
B	I
can	O
be	O
detected	O
.	O
Analysis	O
of	O
primary	O
cells	O
revealed	O
substantial	O
constitutive	O
NF	B
-	I
kappa	I
B	I
-binding	O
activity	O
in	O
blood	O
monocytes	O
,	O
pleural	O
macrophages	O
and	O
alveolar	O
macrophages	O
.	O
The	O
constitutive	O
NF	B
-	I
kappa	I
B	I
appears	O
to	O
be	O
functionally	O
active	O
,	O
since	O
a	O
low	O
level	O
of	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)	O
transcript	O
is	O
detectable	O
in	O
monocytes	O
,	O
and	O
this	O
level	O
can	O
be	O
increased	O
by	O
blocking	O
transcript	O
degradation	O
using	O
cycloheximide	O
.	O
The	O
level	O
of	O
constitutive	O
NF	B
-	I
kappa	I
B	I
in	O
these	O
cells	O
is	O
variable	O
and	O
is	O
frequently	O
found	O
to	O
be	O
lower	O
in	O
the	O
more	O
mature	O
macrophages	O
.	O
Constitutive	O
NF	B
-	I
kappa	I
B	I
was	O
not	O
maintained	O
by	O
autocrine	O
action	O
of	O
cytokines	B
TNF	B
,	O
interleukin	B
6	I
,	O
interleukin	B
10	O
,	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
or	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
,	O
since	O
neutralizing	O
antibodies	O
did	O
not	O
reduce	O
constitutive	O
DNA	O
-	O
binding	O
activity	O
.	O
Furthermore	O
,	O
blockade	O
of	O
prostaglandin	O
or	O
leukotriene	O
biosynthesis	O
did	O
not	O
affect	O
constitutive	O
NF	B
-	I
kappa	I
B	I
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
Platelet	B
-	I
activating	I
factor	I
(	O
PAF	B
)	O
positively	O
auto	O
-	O
regulates	O
the	O
expression	O
of	O
human	B
PAF	I
receptor	I
transcript	I
1	I
(	O
leukocyte	O
-	O
type	O
)	O
through	O
NF	B
-	I
kappa	I
B	I
.	O
The	O
human	O
platelet	O
-	O
activating	O
factor	O
receptor	O
(	O
PAFR	O
)	O
gene	O
is	O
transcribed	O
by	O
two	O
distinct	O
promoters	O
(	O
promoter	O
1	O
and	O
promoter	O
2	O
)	O
to	O
generate	O
two	O
transcripts	O
(	O
designated	O
as	O
PAFR	O
transcript	O
1	O
and	O
PAFR	O
transcript	O
2	O
)	O
,	O
though	O
their	O
open	O
reading	O
frames	O
are	O
identical	O
.	O
By	O
primer	O
extension	O
analysis	O
to	O
discriminate	O
two	O
transcripts	O
,	O
we	O
found	O
that	O
the	O
levels	O
of	O
PAFR	O
transcript	O
1	O
(	O
leukocyte	O
-	O
type	O
)	O
,	O
but	O
not	O
PAFR	O
transcript	O
2	O
(	O
tissue	O
-	O
type	O
)	O
,	O
are	O
upregulated	O
by	O
PAF	B
as	O
well	O
as	O
by	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
in	O
the	O
human	O
stomach	O
cancer	O
cell	O
line	O
(	O
JR	O
-	O
St	O
cells	O
)	O
which	O
expresses	O
both	O
functional	O
PAFR	O
transcript	O
1	O
and	O
PAFR	O
transcript	O
2	O
endogenously	O
.	O
Functional	O
analysis	O
of	O
the	O
promoter	O
1	O
with	O
a	O
transient	O
expression	O
assay	O
using	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
gene	O
as	O
a	O
reporter	O
showed	O
that	O
both	O
PAF	B
and	O
TPA	O
activated	O
the	O
promoter	O
1	O
but	O
not	O
the	O
deleted	O
promoter	O
lacking	O
the	O
three	O
consensus	O
binding	O
sites	O
for	O
NF	B
-	I
kappa	I
B	I
located	O
from	O
-571	O
bp	O
to	O
-459	O
bp	O
.	O
These	O
findings	O
suggest	O
a	O
molecular	O
mechanism	O
of	O
positive	O
regulation	O
of	O
PAFR	B
gene	O
expression	O
by	O
PAF	B
through	O
NF	B
-	I
kappa	I
B	I
,	O
possibly	O
by	O
a	O
phosphorylation	O
reaction	O
involving	O
protein	B
kinase	I
C	I
by	O
PAF	B
.	O
Interleukin-2	B
induces	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
stat3	B
in	O
human	O
T	O
lymphocytes	O
.	O
An	O
early	O
biochemical	O
event	O
associated	O
with	O
T	O
cell	O
activation	O
through	O
the	O
interleukin-2	B
receptor	I
(	O
IL-2R	B
)	O
is	O
tyrosine	O
phosphorylation	O
of	O
several	O
intracellular	O
substrates	O
.	O
The	O
exact	O
mechanism	O
by	O
which	O
IL-2	B
regulates	O
transcription	O
of	O
different	O
genes	O
is	O
presently	O
unknown	O
.	O
Here	O
,	O
we	O
report	O
that	O
stimulation	O
through	O
the	O
IL-2R	B
induced	O
tyrosine	O
phosphorylation	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
stat3	B
,	O
a	O
newly	O
identified	O
member	O
of	O
the	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	I
STAT	I
)	I
family	I
of	O
proteins	O
.	O
In	O
contrast	O
,	O
stat1	O
proteins	O
were	O
not	O
tyrosine	O
phosphorylated	O
after	O
IL-2	B
ligation	O
,	O
whereas	O
tyrosine	B
-	I
phosphorylated	I
stat1	I
proteins	I
(	O
91	B
and	I
84	I
kDa	I
proteins	I
)	O
were	O
translocated	O
to	O
the	O
nucleus	O
following	O
interferon	B
-	I
gamma	I
treatment	O
of	O
HeLa	O
cells	O
.	O
Apart	O
from	O
stat3	B
,	O
another	O
cytoplasmic	B
protein	I
was	O
tyrosine	O
phosphorylated	O
and	O
subsequently	O
translocated	O
to	O
the	O
nucleus	O
in	O
response	O
to	O
IL-2	B
.	O
This	O
protein	O
had	O
an	O
apparent	O
molecular	O
mass	O
of	O
84	O
kDa	O
and	O
was	O
not	O
recognized	O
by	O
stat3	B
or	O
stat1	B
mAb	I
or	O
antisera	O
.	O
Since	O
IL-2	B
induced	O
nuclear	O
translocation	O
of	O
the	O
84	B
kDa	I
protein	I
and	O
stat3	B
followed	O
identical	O
kinetics	O
,	O
p84	B
is	O
a	O
candidate	O
for	O
a	O
new	O
,	O
yet	O
undefined	O
,	O
member	O
of	O
the	O
STAT	O
family	O
.	O
Taken	O
together	O
,	O
we	O
report	O
that	O
IL-2	B
induces	O
tyrosine	O
phosphorylation	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
stat3	B
and	O
an	O
as	O
yet	O
undefined	O
84-kDa	B
protein	I
in	O
antigen	O
-	O
specific	O
human	O
T	O
cell	O
lines	O
.	O
Identification	O
of	O
the	O
TCL1	O
gene	O
involved	O
in	O
T	O
-	O
cell	O
malignancies	O
.	O
The	O
TCL1	O
locus	O
on	O
chromosome	O
14q32.1	O
is	O
frequently	O
involved	O
in	O
chromosomal	O
translocations	O
and	O
inversions	O
with	O
one	O
of	O
the	O
T	O
-	O
cell	O
receptor	O
loci	O
in	O
human	O
T	O
-	O
cell	O
leukemias	O
and	O
lymphomas	O
.	O
The	O
chromosome	O
14	O
region	O
translocated	O
or	O
rearranged	O
involves	O
approximately	O
350	O
kb	O
of	O
DNA	O
at	O
chromosome	O
band	O
14q32.1	O
.	O
Within	O
this	O
region	O
we	O
have	O
identified	O
a	O
gene	O
coding	O
for	O
a	O
1.3-kb	O
transcript	O
,	O
expressed	O
only	O
in	O
restricted	O
subsets	O
of	O
cells	O
within	O
the	O
lymphoid	O
lineage	O
and	O
expressed	O
at	O
high	O
levels	O
in	O
leukemic	O
cells	O
carrying	O
a	O
t	O
(	O
14	O
;	O
14	O
)	O
(	O
q11	O
;	O
q32	O
)	O
chromosome	O
translocation	O
or	O
a	O
inv	O
(	O
14	O
)	O
(	O
q11	O
;	O
q32	O
)	O
chromosome	O
inversion	O
.	O
The	O
cognate	O
cDNA	O
sequence	O
reveals	O
an	O
open	O
reading	O
frame	O
of	O
342	O
nt	O
encoding	O
a	O
protein	B
of	I
14	I
kDa	I
.	O
The	O
TCL1	O
gene	O
sequence	O
,	O
which	O
,	O
to	O
our	O
knowledge	O
,	O
shows	O
no	O
sequence	O
homology	O
with	O
other	O
human	O
genes	O
,	O
is	O
preferentially	O
expressed	O
early	O
in	O
T-	O
and	O
B	O
-	O
lymphocyte	O
differentiation	O
.	O
The	O
transcription	B
factor	I
Sp1	I
is	O
required	O
for	O
induction	O
of	O
the	O
murine	O
GM	O
-	O
CSF	O
promoter	O
in	O
T	O
cells	O
.	O
The	O
cis	O
-	O
acting	O
region	O
,	O
GM	O
-	O
kappa	O
B	O
/	O
GC	O
-	O
box	O
(	O
positions	O
-95	O
and	O
-73	O
)	O
,	O
within	O
the	O
murine	O
GM	O
-	O
CSF	O
gene	O
promoter	O
is	O
required	O
for	O
maximal	O
induction	O
by	O
stimulation	O
with	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
T	O
cells	O
.	O
GM	B
-	I
kappa	I
B	I
defines	O
a	O
binding	O
site	O
for	O
NF	B
-	I
kappa	I
B	I
,	O
and	O
GC	O
-	O
box	O
defines	O
a	O
binding	O
site	O
for	O
three	O
(	O
A1	B
,	O
A2	B
,	O
B	B
)	O
constitutive	B
proteins	I
.	O
We	O
report	O
here	O
that	O
three	O
copies	O
of	O
the	O
GC	O
-	O
box	O
can	O
functionally	O
compensate	O
for	O
the	O
GM	O
-	O
kappa	O
B	O
/	O
GC	O
-	O
box	O
region	O
,	O
suggesting	O
that	O
the	O
GC	O
-	O
motif	O
can	O
function	O
independently	O
of	O
the	O
GM	O
-	O
kappa	O
B	O
motif	O
.	O
The	O
major	O
GC	O
-	O
box	O
binding	O
activity	O
A1	B
was	O
purified	O
and	O
identified	O
as	O
the	O
transcription	B
factor	I
Sp1	I
.	O
We	O
show	O
that	O
depletion	O
of	O
Sp1	B
(	O
A1	B
)	O
from	O
nuclear	O
extracts	O
specifically	O
decreases	O
in	O
vitro	O
transcription	O
activity	O
on	O
GM	B
-	I
CSF	I
templates	O
.	O
Since	O
the	O
human	O
GM	O
-	O
CSF	O
promoter	O
has	O
a	O
base	O
difference	O
within	O
the	O
GC	O
-	O
box	O
,	O
we	O
speculate	O
that	O
this	O
may	O
explain	O
why	O
the	O
human	O
promoter	O
is	O
weak	O
and	O
that	O
an	O
upstream	O
enhancer	O
is	O
required	O
for	O
the	O
induction	O
of	O
the	O
human	O
GM	O
-	O
CSF	O
gene	O
.	O
The	O
C	B
-	I
terminus	I
of	O
the	O
B	B
cell	I
activator	I
Oct-2	B
functions	O
as	O
an	O
activation	B
domain	I
in	O
yeast	O
.	O
Oct-1	B
and	O
Oct-2	B
are	O
human	O
transcriptional	B
activators	I
that	O
bind	O
to	O
the	O
same	O
DNA	O
element	O
but	O
activate	O
distinct	O
sets	O
of	O
genes	O
.	O
We	O
expressed	O
these	O
factors	O
in	O
S.	O
cerevisiae	O
and	O
observed	O
greater	O
than	O
5-fold	O
stimulation	O
of	O
a	O
lacZ	O
reporter	O
gene	O
only	O
with	O
Oct-2	B
.	O
Transfer	O
of	O
the	O
Oct-2	B
C	I
-	I
terminal	I
domain	I
onto	O
either	O
Oct-1	B
(	O
Oct1.2	B
)	O
or	O
a	O
nonactivating	B
DNA	I
-	I
binding	I
domain	I
from	O
GAL4	B
created	O
activators	O
capable	O
of	O
greater	O
than	O
15	O
and	O
10-fold	O
stimulation	O
of	O
activity	O
,	O
respectively	O
.	O
Thus	O
,	O
the	O
C	B
-	I
terminus	I
of	O
Oct-2	B
is	O
sufficient	O
to	O
confer	O
activation	O
potential	O
to	O
nonactive	O
DNA	O
-	O
binding	O
fragments	O
in	O
yeast	O
.	O
An	O
AP1	O
binding	O
site	O
upstream	O
of	O
the	O
kappa	O
immunoglobulin	O
intron	O
enhancer	O
binds	O
inducible	B
factors	I
and	O
contributes	O
to	O
expression	O
.	O
Expression	O
of	O
the	O
kappa	O
immunoglobulin	O
light	O
chain	O
gene	O
requires	O
developmental-	O
and	O
tissue	O
-	O
specific	O
regulation	O
by	O
trans	B
-	I
acting	I
factors	I
which	O
interact	O
with	O
two	O
distinct	O
enhancer	O
elements	O
.	O
A	O
new	O
protein	O
-	O
DNA	O
interaction	O
has	O
been	O
identified	O
upstream	O
of	O
the	O
intron	O
enhancer	O
,	O
within	O
the	O
matrix	O
-	O
associated	O
region	O
of	O
the	O
J	O
-	O
C	O
intron	O
.	O
The	O
binding	O
activity	O
is	O
greatly	O
inducible	O
in	O
pre	O
-	O
B	O
cells	O
by	O
bacterial	O
lipopolysaccharide	O
and	O
interleukin-1	B
but	O
specific	O
complexes	O
are	O
found	O
at	O
all	O
stages	O
of	O
B	O
cell	O
development	O
tested	O
.	O
The	O
footprinted	O
binding	O
site	O
is	O
homologous	O
to	O
the	O
consensus	O
AP1	O
motif	O
.	O
The	O
protein	O
components	O
of	O
this	O
complex	O
are	O
specifically	O
competed	O
by	O
an	O
AP1	O
consensus	O
motif	O
and	O
were	O
shown	O
by	O
supershift	O
to	O
include	O
c	B
-	I
Jun	I
and	O
c	B
-	I
Fos	I
,	O
suggesting	O
that	O
this	O
binding	O
site	O
is	O
an	O
AP1	O
motif	O
and	O
that	O
the	O
Jun	B
and	I
Fos	I
families	I
of	O
transcription	B
factors	I
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
the	O
kappa	O
light	O
chain	O
gene	O
.	O
Mutation	O
of	O
the	O
AP1	O
motif	O
in	O
the	O
context	O
of	O
the	O
intron	O
enhancer	O
was	O
shown	O
to	O
decrease	O
enhancer	O
-	O
mediated	O
activation	O
of	O
the	O
promoter	O
in	O
both	O
pre	O
-	O
B	O
cells	O
induced	O
with	O
LPS	O
and	O
constitutive	O
expression	O
in	O
mature	O
B	O
cells	O
.	O
Distinct	O
roles	O
of	O
the	O
molecular	O
chaperone	B
hsp90	I
in	O
modulating	O
dioxin	O
receptor	O
function	O
via	O
the	O
basic	O
helix	B
-	I
loop	I
-	I
helix	I
and	O
PAS	B
domains	I
.	O
The	O
intracellular	B
dioxin	I
receptor	I
mediates	O
signal	O
transduction	O
by	O
dioxin	O
and	O
functions	O
as	O
a	O
ligand	B
-	I
activated	I
transcription	I
factor	I
.	O
It	O
contains	O
a	O
basic	B
helix	I
-	I
loop	I
-	I
helix	I
(	I
bHLH	I
)	I
motif	I
contiguous	O
with	O
a	O
Per	B
-	I
Arnt	I
-	I
Sim	I
(	I
PAS	I
)	I
homology	I
region	I
.	O
In	O
extracts	O
from	O
nonstimulated	O
cells	O
the	O
receptor	O
is	O
recovered	O
in	O
an	O
inducible	O
cytoplasmic	O
form	O
associated	O
with	O
the	O
90-kDa	B
heat	I
shock	I
protein	I
(	O
hsp90	B
)	O
,	O
a	O
molecular	B
chaperone	I
.	O
We	O
have	O
reconstituted	O
ligand	O
-	O
dependent	O
activation	O
of	O
the	O
receptor	O
to	O
a	O
DNA	B
-	I
binding	I
form	I
by	O
using	O
the	O
dioxin	B
receptor	I
and	O
its	O
bHLH	B
-	I
PAS	I
partner	I
factor	I
Arnt	B
expressed	O
by	O
in	O
vitro	O
translation	O
in	O
reticulocyte	O
lysate	O
.	O
Deletion	O
of	O
the	O
PAS	B
domain	I
of	O
the	O
receptor	O
resulted	O
in	O
constitutive	O
dimerization	O
with	O
Arnt	B
.	O
In	O
contrast	O
,	O
this	O
receptor	O
mutant	O
showed	O
low	O
levels	O
of	O
xenobiotic	O
response	O
element	O
-	O
binding	O
activity	O
,	O
indicating	O
that	O
the	O
PAS	B
domain	I
may	O
be	O
important	O
for	O
DNA	O
-	O
binding	O
affinity	O
and/or	O
specificity	O
of	O
the	O
receptor	O
.	O
It	O
was	O
not	O
possible	O
to	O
reconstitute	O
dioxin	B
receptor	I
function	O
with	O
proteins	O
expressed	O
in	O
wheat	O
germ	O
lysate	O
.	O
In	O
line	O
with	O
these	O
observations	O
,	O
reticulocyte	O
lysate	O
but	O
not	O
wheat	O
germ	O
lysate	O
promoted	O
the	O
association	O
of	O
de	O
novo	O
synthesized	O
dioxin	B
receptor	I
with	O
hsp90	B
.	O
At	O
least	O
two	O
distinct	O
domains	O
of	O
the	O
receptor	O
mediated	O
interaction	O
with	O
hsp90	B
:	O
the	O
ligand	B
-	I
binding	I
domain	I
located	O
within	O
the	O
PAS	B
region	I
and	O
,	O
surprisingly	O
,	O
the	O
bHLH	B
domain	I
.	O
Whereas	O
ligand	O
-	O
binding	O
activity	O
correlated	O
with	O
association	O
with	O
hsp90	B
,	O
bHLH-	O
hsp90	B
interaction	O
appeared	O
to	O
be	O
important	O
for	O
DNA	O
-	O
binding	O
activity	O
but	O
not	O
for	O
dimerization	O
of	O
the	O
receptor	O
.	O
Several	O
distinct	O
roles	O
for	O
hsp90	B
in	O
modulating	O
dioxin	B
receptor	I
function	O
are	O
therefore	O
likely	O
:	O
correct	O
folding	O
of	O
the	O
ligand	O
-	O
binding	O
domain	O
,	O
interference	O
with	O
Arnt	B
heterodimerization	O
,	O
and	O
folding	O
of	O
a	O
DNA	O
-	O
binding	O
conformation	O
of	O
the	O
bHLH	B
domain	I
.	O
Thus	O
,	O
the	O
dioxin	B
receptor	I
system	O
provides	O
a	O
complex	O
and	O
interesting	O
model	O
of	O
the	O
regulation	O
of	O
transcription	B
factors	I
by	O
hsp90	B
.	O
B	O
-	O
cell	O
proliferation	O
and	O
induction	O
of	O
early	O
G1-regulating	B
proteins	I
by	O
Epstein	O
-	O
Barr	O
virus	O
mutants	O
conditional	O
for	O
EBNA2	B
.	O
Infection	O
of	O
primary	O
B	O
-	O
lymphocytes	O
by	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
leads	O
to	O
growth	O
transformation	O
of	O
these	O
B	O
-	O
cells	O
in	O
vitro	O
.	O
EBV	O
nuclear	O
antigen	O
2	O
(	O
EBNA2	B
)	O
,	O
one	O
of	O
the	O
first	O
genes	O
expressed	O
after	O
EBV	O
infection	O
of	O
B	O
-	O
cells	O
,	O
is	O
a	O
transcriptional	O
activator	O
of	O
viral	O
and	O
cellular	O
genes	O
and	O
is	O
essential	O
for	O
the	O
transforming	O
potential	O
of	O
the	O
virus	O
.	O
We	O
generated	O
conditional	O
EBV	O
mutants	O
by	O
expressing	O
EBNA2	B
as	O
chimeric	B
fusion	I
protein	I
with	O
the	O
hormone	O
binding	O
domain	O
of	O
the	O
estrogen	B
receptor	I
on	O
the	O
genetic	O
background	O
of	O
the	O
virus	O
.	O
Growth	O
transformation	O
of	O
primary	O
normal	O
B	O
-	O
cells	O
by	O
mutant	O
virus	O
resulted	O
in	O
estrogen	O
-	O
dependent	O
lymphoblastoid	O
cell	O
lines	O
expressing	O
the	O
chimeric	O
EBNA2	B
protein	I
.	O
In	O
the	O
absence	O
of	O
estrogen	O
about	O
half	O
of	O
the	O
cells	O
enter	O
a	O
quiescent	O
non	O
-	O
proliferative	O
state	O
whereas	O
the	O
others	O
die	O
by	O
apoptosis	O
.	O
EBNA2	B
is	O
thus	O
required	O
not	O
only	O
for	O
initiation	O
but	O
also	O
for	O
maintenance	O
of	O
transformation	O
.	O
Growth	O
arrest	O
occurred	O
at	O
G1	O
and	O
G2	O
stages	O
of	O
the	O
cell	O
cycle	O
,	O
indicating	O
that	O
functional	O
EBNA2	B
is	O
required	O
at	O
different	O
restriction	O
points	O
of	O
the	O
cell	O
cycle	O
.	O
Growth	O
arrest	O
is	O
reversible	O
for	O
G1	O
/	O
G0	O
cells	O
as	O
indicated	O
by	O
the	O
sequential	O
accumulation	O
and	O
modification	O
of	O
cell	B
cycle	I
regulating	I
proteins	I
.	O
EBV	O
induces	O
the	O
same	O
cell	O
cycle	O
regulating	O
proteins	O
as	O
polyclonal	O
stimuli	O
in	O
primary	O
B	O
-	O
cells	O
.	O
These	O
data	O
suggest	O
that	O
EBV	O
is	O
using	O
a	O
common	O
pathway	O
for	O
B	O
-	O
cell	O
activation	O
bypassing	O
the	O
requirement	O
for	O
antigen	O
,	O
T	O
-	O
cell	O
signals	O
and	O
growth	B
factors	I
.	O
Induction	O
of	O
ICAM-1	B
and	O
LFA-3	B
by	O
Tax1	B
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
and	O
mechanism	O
of	O
down	O
-	O
regulation	O
of	O
ICAM-1	B
or	O
LFA-1	B
in	O
adult	O
-	O
T	O
-	O
cell	O
-	O
leukemia	O
cell	O
lines	O
.	O
The	O
present	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
role	O
of	O
HTLV	B
-	I
I	I
TaxI	I
in	O
the	O
up	O
-	O
regulation	O
of	O
ICAM	B
-	I
I	I
and	O
LFA-3	B
in	O
human	O
T	O
cells	O
transformed	O
with	O
HTLV	O
-	O
I	O
and	O
the	O
mechanism	O
of	O
down	O
-	O
regulation	O
of	O
ICAM	B
-	I
I	I
and	O
LFA	B
-	I
I	I
in	O
ATL	O
-	O
derived	O
cell	O
lines	O
.	O
Induction	O
of	O
TaxI	B
in	O
a	O
human	O
T	O
-	O
cell	O
line	O
Jurkat	O
carrying	O
the	O
TaxI	O
gene	O
under	O
the	O
metallothionein	O
promoter	O
led	O
to	O
increases	O
in	O
mRNA	O
and	O
surface	O
expression	O
of	O
ICAM	B
-	I
I	I
.	O
The	O
response	O
of	O
LFA-3	B
to	O
TaxI	B
induction	O
was	O
,	O
on	O
the	O
other	O
hand	O
,	O
relatively	O
slow	O
and	O
weak	O
,	O
and	O
might	O
be	O
indirect	O
.	O
Transactivation	O
of	O
the	O
ICAM	O
-	O
I	O
promoter	O
by	O
TaxI	B
was	O
further	O
shown	O
by	O
co	O
-	O
transfection	O
of	O
a	O
CAT	O
reporter	O
construct	O
with	O
the	O
ICAM	O
-	O
I	O
promoter	O
and	O
a	O
plasmid	O
expressing	O
TaxI	B
.	O
The	O
mechanism	O
of	O
down	O
-	O
regulation	O
of	O
ICAM	B
-	I
I	I
or	O
LFA	B
-	I
I	I
in	O
4	O
ATL	O
cell	O
lines	O
was	O
next	O
examined	O
.	O
ICAM	O
-	O
I	O
mRNA	O
was	O
quite	O
low	O
in	O
MT	O
-	O
I	O
,	O
but	O
no	O
genomic	O
changes	O
were	O
found	O
.	O
The	O
CAT	O
reporter	O
with	O
the	O
ICAM	O
-	O
I	O
promoter	O
was	O
inactive	O
in	O
MT	O
-	O
I	O
.	O
Finally	O
,	O
combined	O
treatment	O
of	O
MT	O
-	O
I	O
with	O
5-azacytidine	O
and	O
IFN	B
-	I
gamma	I
induced	O
re	O
-	O
expression	O
of	O
ICAM	B
-	I
I	I
.	O
Collectively	O
,	O
(	O
a	O
)	O
transcriptional	B
factor	I
(	O
s	O
)	O
necessary	O
for	O
expression	O
of	O
ICAM	O
-	O
I	O
gene	O
may	O
be	O
repressed	O
in	O
MT	O
-	O
I	O
through	O
DNA	O
methylation	O
.	O
Three	O
other	O
ATL	O
cell	O
lines	O
(	O
TL	O
-	O
OmI	O
,	O
H582	O
,	O
HuT102	O
)	O
were	O
found	O
to	O
have	O
little	O
mRNA	O
for	O
the	O
LFA	B
-	I
I	I
beta	I
chain	I
(	O
CD18	B
)	O
.	O
H582	O
and	O
HuT102	O
were	O
also	O
negative	O
for	O
the	O
LFA	O
-	O
I	O
alpha	O
chain	O
(	O
CDIIa	O
)	O
mRNA	O
.	O
No	O
genomic	O
changes	O
were	O
found	O
,	O
and	O
a	O
CAT	O
reporter	O
gene	O
with	O
the	O
CD18	O
promoter	O
was	O
inactive	O
in	O
the	O
3	O
of	O
them	O
,	O
again	O
suggesting	O
lack	O
of	O
(	O
a	O
)	O
transcriptional	B
factor	I
(	O
s	O
)	O
necessary	O
for	O
CD18	B
expression	O
.	O
Evaluation	O
of	O
the	O
respiratory	O
epithelium	O
of	O
normals	O
and	O
individuals	O
with	O
cystic	O
fibrosis	O
for	O
the	O
presence	O
of	O
adenovirus	O
E1a	O
sequences	O
relevant	O
to	O
the	O
use	O
of	O
E1a-	O
adenovirus	O
vectors	O
for	O
gene	O
therapy	O
for	O
the	O
respiratory	O
manifestations	O
of	O
cystic	O
fibrosis	O
.	O
Lung	O
disease	O
associated	O
with	O
disorders	O
such	O
as	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
may	O
be	O
amenable	O
to	O
somatic	O
gene	O
therapy	O
in	O
which	O
there	O
is	O
delivery	O
of	O
the	O
normal	O
gene	O
directly	O
to	O
the	O
respiratory	O
epithelium	O
using	O
E1a-	O
adenovirus	O
(	O
Ad	O
)	O
type	O
2-	O
or	O
5-based	O
vectors	O
.	O
For	O
safety	O
reasons	O
,	O
the	O
Ad	O
vectors	O
are	O
rendered	O
replication	O
deficient	O
by	O
deletion	O
of	O
the	O
E1a	O
region	O
.	O
Because	O
there	O
is	O
the	O
theoretical	O
possibility	O
of	O
an	O
E1a-	O
replication	O
-	O
deficient	O
vector	O
replicating	O
as	O
a	O
result	O
of	O
recombination	O
or	O
complementation	O
with	O
Ad	O
2	O
/	O
5	O
E1a	O
sequences	O
present	O
in	O
the	O
target	O
cell	O
,	O
this	O
study	O
is	O
directed	O
toward	O
evaluating	O
respiratory	O
epithelium	O
of	O
normals	O
and	O
individuals	O
with	O
CF	O
for	O
the	O
presence	O
of	O
E1a	O
sequences	O
.	O
Using	O
Ad	O
2	O
/	O
5	O
E1a	O
-	O
specific	O
primers	O
and	O
the	O
polymerase	O
chain	O
reaction	O
to	O
evaluate	O
DNA	O
recovered	O
from	O
freshly	O
isolated	O
nasal	O
and	O
bronchial	O
epithelium	O
recovered	O
by	O
brushing	O
,	O
E1a	O
sequences	O
were	O
detected	O
in	O
respiratory	O
epithelium	O
of	O
19	O
of	O
91	O
normals	O
(	O
21	O
%	O
)	O
.	O
In	O
the	O
E1a	O
-	O
positive	O
samples	O
,	O
the	O
average	O
of	O
E1a	O
copy	O
number	O
was	O
55	O
+	O
/-	O
18	O
/	O
10	O
(	O
3	O
)	O
recovered	O
cells	O
.	O
In	O
CF	O
individuals	O
,	O
7	O
of	O
52	O
(	O
13	O
%	O
)	O
had	O
detectable	O
E1a	O
sequences	O
in	O
the	O
respiratory	O
epithelium	O
,	O
with	O
E1a	O
copy	O
number	O
in	O
the	O
positive	O
samples	O
of	O
80	O
+	O
/-	O
21	O
/	O
10	O
(	O
3	O
)	O
recovered	O
cells	O
.	O
These	O
results	O
demonstrate	O
that	O
there	O
are	O
detectable	O
Ad	O
2	O
/	O
5	O
E1a	O
sequences	O
in	O
the	O
respiratory	O
epithelium	O
of	O
a	O
small	O
percentage	O
of	O
normals	O
and	O
individuals	O
with	O
CF	O
.	O
Because	O
of	O
the	O
theoretical	O
potential	O
of	O
such	O
sequences	O
supporting	O
replication	O
of	O
E1a-	O
Ad	O
vectors	O
,	O
human	O
gene	O
therapy	O
protocols	O
for	O
CF	O
utilizing	O
such	O
vectors	O
should	O
consider	O
evaluating	O
study	O
individuals	O
for	O
the	O
presence	O
of	O
Ad	O
2	O
/	O
5	O
E1a	O
sequences	O
in	O
the	O
respiratory	O
epithelium	O
.	O
Biphasic	O
control	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
activation	O
by	O
the	O
T	B
cell	I
receptor	I
complex	I
:	O
role	O
of	O
tumor	B
necrosis	I
factor	I
alpha	I
.	O
The	O
regulation	O
of	O
nuclear	B
factor	I
(	I
NF	I
)	I
-kappa	I
B	I
activation	O
by	O
the	O
T	B
cell	I
receptor	I
(	I
TcR	I
)	I
/CD3	I
complex	I
in	O
primary	O
human	O
T	O
cells	O
has	O
been	O
studied	O
at	O
various	O
times	O
after	O
activation	O
.	O
Only	O
p50	B
NF	I
-	I
kappa	I
B	I
protein	I
bound	O
the	O
kappa	O
B	O
element	O
of	O
interleukin-2	O
receptor	O
(	O
IL-2R	O
)	O
alpha	O
chain	O
promoter	O
on	O
resting	O
T	O
cells	O
.	O
However	O
,	O
immediately	O
after	O
TcR	B
/	I
CD3	I
cross	O
-	O
linking	O
(	O
after	O
approximately	O
1	O
h	O
;	O
immediate	O
)	O
binding	O
of	O
p50.p65	B
heterodimers	I
was	O
observed	O
.	O
p50.c	B
-	I
rel	I
heterodimers	I
were	O
also	O
detected	O
bound	O
to	O
this	O
sequence	O
at	O
early	O
time	O
points	O
(	O
7	O
-	O
16	O
h	O
;	O
early	O
)	O
,	O
and	O
both	O
remained	O
active	O
at	O
later	O
time	O
points	O
(	O
40	O
h	O
;	O
late	O
)	O
after	O
activation	O
.	O
This	O
regulation	O
takes	O
place	O
mainly	O
at	O
the	O
level	O
of	O
nuclear	O
translocation	O
of	O
p65	B
and	O
c	B
-	I
rel	I
,	O
at	O
immediate	O
and	O
early	O
time	O
points	O
.	O
Activation	O
also	O
induced	O
c	O
-	O
rel	O
and	O
p105	O
/	O
p50	O
mRNA	O
synthesis	O
,	O
but	O
not	O
p65	O
mRNA	O
whose	O
expression	O
was	O
constitutive	O
.	O
Interestingly	O
,	O
all	O
those	O
early	O
and	O
late	O
events	O
,	O
but	O
not	O
the	O
immediate	O
ones	O
,	O
were	O
inhibited	O
by	O
a	O
neutralizing	O
anti	B
-	I
tumor	I
necrosis	I
factor	I
alpha	I
(	I
TNF	I
-	I
alpha	I
)	I
monoclonal	I
antibody	I
.	O
Similarly	O
,	O
cycloheximide	O
prevented	O
the	O
p65	B
and	O
c	B
-	I
rel	I
translocation	O
and	O
consequent	O
formation	O
of	O
active	O
binding	O
heterodimers	O
,	O
at	O
early	O
and	O
late	O
times	O
.	O
Cyclosporin	O
A	O
impaired	O
not	O
only	O
early	O
and	O
late	O
,	O
but	O
also	O
immediate	O
events	O
;	O
however	O
,	O
addition	O
of	O
TNF	B
-	I
alpha	I
prevented	O
all	O
inhibition	O
.	O
These	O
results	O
indicate	O
that	O
the	O
regulation	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
during	O
T	O
cell	O
activation	O
by	O
TcR	B
/	I
CD3	I
signals	O
is	O
biphasic	O
:	O
TcR	B
/	I
CD3	I
triggers	O
its	O
immediate	O
translocation	O
,	O
which	O
is	O
transient	O
if	O
no	O
TNF	B
-	I
alpha	I
is	O
present	O
.	O
TNF	B
-	I
alpha	I
,	O
therefore	O
,	O
emerges	O
as	O
the	O
main	O
factor	O
responsible	O
for	O
a	O
second	O
phase	O
of	O
NF	B
-	I
kappa	I
B	I
regulation	O
,	O
controlling	O
both	O
translocation	O
of	O
p65	B
and	O
c	B
-	I
rel	I
,	O
and	O
new	O
mRNA	O
synthesis	O
for	O
c	B
-	I
rel	I
and	O
p105	B
/	I
p50	I
.	O
Overexpression	O
of	O
protein	B
kinase	I
C	I
-	I
zeta	I
stimulates	O
leukemic	O
cell	O
differentiation	O
.	O
A	O
function	O
for	O
protein	B
kinase	I
C	I
-	I
zeta	I
(	O
PKC	B
-	I
zeta	I
)	O
,	O
a	O
member	O
of	O
the	O
phorbol	O
ester	O
nonresponsive	O
atypical	O
protein	B
kinase	I
C	I
subfamily	I
,	O
in	O
modulating	O
differentiation	O
was	O
examined	O
in	O
the	O
leukemic	O
U937	O
cell	O
.	O
Transfected	O
U937	O
cells	O
stably	O
overexpressing	O
PKC	B
-	I
zeta	I
displayed	O
a	O
longer	O
doubling	O
time	O
,	O
lower	O
saturation	O
density	O
at	O
confluency	O
,	O
and	O
an	O
increase	O
in	O
adherence	O
to	O
plastic	O
as	O
compared	O
to	O
control	O
cells	O
.	O
PKC	O
-	O
zeta	O
cells	O
expressed	O
a	O
more	O
differentiated	O
phenotype	O
as	O
assessed	O
by	O
changes	O
in	O
morphology	O
,	O
surface	O
antigen	O
expression	O
,	O
and	O
lysosomal	B
enzyme	I
activities	O
and	O
were	O
distinct	O
from	O
parental	O
U937	O
cells	O
stimulated	O
to	O
differentiate	O
by	O
exposure	O
to	O
phorbol	O
esters	O
.	O
In	O
contrast	O
to	O
parental	O
U937	O
cells	O
,	O
PKC	O
-	O
zeta	O
cells	O
constitutively	O
expressed	O
mRNA	O
transcripts	O
for	O
c	O
-	O
jun	O
and	O
a	O
low	O
mobility	O
AP-1	B
binding	O
activity	O
.	O
Thus	O
,	O
PKC	B
-	I
zeta	I
overexpression	O
stimulates	O
a	O
type	O
of	O
phenotypic	O
differentiation	O
that	O
differs	O
significantly	O
from	O
maturation	O
occurring	O
upon	O
activation	O
of	O
other	O
PKC	B
subfamilies	I
induced	O
by	O
phorbol	O
ester	O
treatment	O
.	O
Increased	O
expression	O
of	O
the	O
c	O
-	O
jun	O
protooncogene	O
and	O
an	O
increase	O
in	O
AP-1	B
binding	O
activity	O
in	O
PKC	O
-	O
zeta	O
cells	O
provides	O
a	O
potential	O
mechanism	O
for	O
explaining	O
the	O
altered	O
differentiation	O
status	O
of	O
this	O
cell	O
.	O
Posttranscriptional	O
regulation	O
of	O
macrophage	O
tissue	B
factor	I
expression	O
by	O
antioxidants	O
.	O
Tissue	B
factor	I
(	O
TF	B
)	O
expression	O
by	O
cells	O
of	O
monocyte	O
/	O
macrophage	O
lineage	O
represents	O
an	O
important	O
mechanism	O
underlying	O
the	O
initiation	O
of	O
fibrin	B
deposition	O
at	O
sites	O
of	O
extravascular	O
inflammation	O
.	O
Recent	O
evidence	O
suggests	O
a	O
role	O
for	O
oxidant	O
stress	O
in	O
the	O
signalling	O
pathway	O
of	O
various	O
cell	O
types	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
induce	O
DNA	O
binding	O
of	O
various	O
transcription	B
factors	I
,	O
including	O
nuclear	B
factor	I
kappa	I
B	I
and	O
AP-1	B
.	O
The	O
effect	O
of	O
antioxidant	O
treatment	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
TF	B
expression	O
was	O
examined	O
in	O
murine	O
peritoneal	O
macrophages	O
and	O
human	O
monocytes	O
.	O
Both	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxidant	O
scavenger	O
,	O
and	O
N	O
-	O
acetyl	O
-	O
cysteine	O
,	O
a	O
precursor	O
of	O
the	O
endogenous	O
antioxidant	O
glutathione	O
,	O
inhibited	O
stimulation	O
of	O
macrophage	O
procoagulant	O
activity	O
by	O
LPS	O
.	O
Northern	O
blot	O
analysis	O
showed	O
that	O
neither	O
of	O
these	O
agents	O
reduced	O
LPS	O
-	O
stimulated	O
TF	B
mRNA	O
accumulation	O
,	O
thereby	O
suggesting	O
a	O
posttranscriptional	O
mechanism	O
for	O
the	O
effect	O
.	O
Immunofluorescence	O
studies	O
of	O
human	O
monocytes	O
using	O
polyclonal	O
anti	B
-	I
TF	I
antibody	I
showed	O
that	O
N	O
-	O
acetyl	O
-	O
cysteine	O
treatment	O
prevented	O
the	O
characteristic	O
plasmalemmal	O
localization	O
of	O
TF	B
antigen	I
that	O
occurs	O
in	O
response	O
to	O
LPS	O
.	O
Western	O
blot	O
analysis	O
showed	O
that	O
N	O
-	O
acetyl	O
-	O
cysteine	O
reduced	O
the	O
accumulation	O
of	O
the	O
47-kD	B
mature	I
glycoprotein	I
in	O
LPS	O
-	O
treated	O
cells	O
,	O
a	O
finding	O
consistent	O
with	O
the	O
results	O
of	O
the	O
immunofluorescence	O
studies	O
.	O
Furthermore	O
,	O
these	O
conditions	O
did	O
not	O
result	O
in	O
an	O
accumulation	O
of	O
the	O
less	O
mature	O
forms	O
of	O
TF	B
.	O
When	O
considered	O
together	O
,	O
these	O
data	O
suggest	O
that	O
antioxidants	O
exert	O
their	O
effects	O
by	O
impairing	O
translation	O
and/or	O
by	O
causing	O
degradation	O
of	O
newly	O
translated	B
protein	I
.	O
The	O
effect	O
of	O
antioxidants	O
on	O
tumor	B
necrosis	I
factor	I
appeared	O
to	O
be	O
species	O
specific	O
,	O
with	O
no	O
effect	O
on	O
LPS	O
-	O
induced	O
tumor	O
necrosis	O
factor	O
in	O
murine	O
cells	O
,	O
but	O
with	O
inhibition	O
in	O
human	O
monocytes	O
.	O
The	O
posttranscriptional	O
effect	O
of	O
antioxidants	O
on	O
TF	B
expression	O
data	O
suggests	O
a	O
novel	O
mechanism	O
whereby	O
these	O
agents	O
might	O
modulate	O
monocyte	O
/macrophage	O
activation	O
.	O
1	B
,	I
25-Dihydroxyvitamin	I
D3	I
receptors	I
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
patients	O
with	O
primary	O
and	O
secondary	O
hyperparathyroidism	O
.	O
A	O
decreased	O
number	O
of	O
calcitriol	B
(	I
1	I
,	I
25	I
(	I
OH	I
)	I
2D3	I
)	I
receptors	I
has	O
been	O
observed	O
in	O
parathyroid	O
glands	O
of	O
uremic	O
animals	O
.	O
In	O
humans	O
,	O
studies	O
carried	O
out	O
in	O
surgically	O
removed	O
parathyroid	O
glands	O
have	O
shown	O
that	O
calcitriol	O
binding	O
is	O
higher	O
in	O
primary	O
than	O
in	O
secondary	O
hyperparathyroidism	O
.	O
Since	O
specific	O
receptors	O
for	O
calcitriol	O
have	O
been	O
described	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
,	O
we	O
have	O
investigated	O
the	O
specific	O
uptake	O
of	O
3H	O
-	O
labelled	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
in	O
PBMC	O
of	O
12	O
women	O
with	O
primary	O
hyperparathyroidism	O
(	O
PHP	O
)	O
,	O
8	O
women	O
with	O
hyperparathyroidism	O
secondary	O
to	O
chronic	O
renal	O
failure	O
(	O
SH	O
)	O
,	O
9	O
women	O
with	O
renal	O
transplant	O
(	O
RT	O
)	O
,	O
and	O
23	O
healthy	O
women	O
.	O
The	O
median	O
dissociation	O
constant	O
(	O
Kd	O
)	O
was	O
similar	O
in	O
all	O
three	O
groups	O
of	O
patients	O
and	O
in	O
healthy	O
women	O
(	O
mean	O
+	O
/-	O
S.D.	O
(	O
range	O
)	O
:	O
PHP	O
,	O
1.2	O
+	O
/-	O
1.0	O
(	O
0.2	O
-	O
4	O
)	O
x	O
10	O
(	O
-10	O
)	O
M	O
;	O
SH	O
,	O
0.6	O
+	O
/-	O
0.4	O
(	O
0.2	O
-	O
1.2	O
)	O
x	O
10	O
(	O
-10	O
)	O
M	O
;	O
RT	O
,	O
1.1	O
+	O
/-	O
0.5	O
(	O
0.4	O
-	O
1.9	O
)	O
x	O
10	O
(	O
-10	O
)	O
M	O
;	O
controls	O
,	O
1.0	O
+	O
/-	O
0.6	O
(	O
0.3	O
-	O
2.6	O
)	O
x	O
10	O
(	O
-10	O
)	O
M	O
)	O
.	O
However	O
,	O
the	O
maximal	O
binding	O
capacity	O
(	O
Nmax	O
)	O
was	O
significantly	O
enhanced	O
in	O
PHP	O
(	O
3.9	O
+	O
/-	O
1.9	O
(	O
1.3	O
-	O
7.6	O
)	O
fmol	O
/	O
10	O
(	O
7	O
)	O
cells	O
vs.	O
2.3	O
+	O
/-	O
0.9	O
(	O
1.1	O
-	O
4.4	O
)	O
fmol	O
/	O
10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
;	O
P	O
=	O
0.0006	O
)	O
and	O
decreased	O
in	O
SH	O
(	O
0.8	O
+	O
/-	O
0.5	O
(	O
0.2	O
-	O
1.6	O
)	O
fmol	O
/	O
10	O
(	O
7	O
)	O
cells	O
vs.	O
2.3	O
+	O
/-	O
0.9	O
(	O
1.1	O
-	O
4.4	O
)	O
fmol	O
/	O
10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
;	O
P	O
=	O
0.0001	O
)	O
,	O
whereas	O
no	O
changes	O
were	O
seen	O
in	O
RT	O
(	O
2.3	O
+	O
/-	O
0.7	O
(	O
1.2	O
-	O
3.3	O
)	O
fmol	O
/	O
10	O
(	O
7	O
)	O
cells	O
vs.	O
2.3	O
+	O
/-	O
0.9	O
(	O
1.1	O
-	O
4.4	O
)	O
fmol	O
/	O
10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
)	O
.	O
In	O
three	O
patients	O
with	O
PHP	O
who	O
were	O
subjected	O
to	O
parathyroidectomy	O
,	O
the	O
calcitriol	O
number	O
came	O
down	O
to	O
normal	O
.	O
Changes	O
of	O
calcitriol	B
receptors	I
in	O
primary	O
and	O
secondary	O
hyperparathyroidism	O
could	O
magnify	O
the	O
consequences	O
of	O
disturbances	O
in	O
serum	O
concentration	O
of	O
calcitriol	O
itself	O
and	O
might	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
secondary	O
hyperparathyroidism	O
in	O
uremia	O
.	O
Effects	O
of	O
the	O
antisense	O
myb	O
expression	O
on	O
hemin-	O
and	O
erythropoietin-	O
induced	O
erythroid	O
differentiation	O
of	O
K562	O
cells	O
.	O
In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
c	O
-	O
myb	O
gene	O
in	O
erythroid	O
differentiation	O
of	O
K562	O
cell	O
induced	O
by	O
hemin	B
(	O
Hm	B
)	O
and	O
erythropoietin	B
(	O
Epo	B
)	O
,	O
we	O
constructed	O
recombinant	O
plasmid	O
that	O
could	O
produce	O
antisense	O
myb	O
RNA	O
after	O
induction	O
with	O
dexamethasone	O
.	O
During	O
treatment	O
with	O
Hm	B
,	O
K562	O
cells	O
constitutively	O
expressed	O
c	O
-	O
myb	O
mRNA	O
,	O
and	O
50	O
%	O
of	O
them	O
began	O
to	O
synthesize	O
hemoglobin	B
(	O
Hb	B
)	O
.	O
Expression	O
of	O
antisense	O
myb	O
RNA	O
reduced	O
the	O
amount	O
of	O
c	O
-	O
myb	O
mRNA	O
,	O
and	O
the	O
percentage	O
of	O
Hb	O
-	O
synthesizing	O
cells	O
was	O
decreased	O
to	O
20	O
%	O
.	O
In	O
the	O
presence	O
of	O
Epo	B
,	O
c	O
-	O
myb	O
mRNA	O
declined	O
and	O
20	O
%	O
of	O
K562	O
cells	O
synthesized	O
Hb	B
regardless	O
of	O
antisense	O
myb	O
RNA	O
expression	O
.	O
It	O
is	O
suggested	O
that	O
constitutive	O
expression	O
of	O
c	O
-	O
myb	O
mRNA	O
is	O
necessary	O
for	O
Hm	B
-induced	O
differentiation	O
,	O
and	O
that	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
c	O
-	O
myb	O
mRNA	O
induced	O
by	O
antisense	O
myb	O
RNA	O
expression	O
suppresses	O
Hm	B
-induced	O
differentiation	O
.	O
The	O
amount	O
of	O
c	O
-	O
myb	O
mRNA	O
in	O
K562	O
cells	O
was	O
reduced	O
during	O
the	O
differentiation	O
induced	O
by	O
Epo	B
.	O
Expression	O
of	O
GATA-1	O
mRNA	O
was	O
almost	O
constant	O
during	O
Hm	B
-induced	O
differentiation	O
,	O
but	O
increased	O
during	O
Epo	B
treatment	O
.	O
It	O
is	O
supposed	O
that	O
the	O
mechanism	O
of	O
Hm	B
-induced	O
differentiation	O
is	O
distinguished	O
from	O
that	O
of	O
Epo	B
-induced	O
differentiation	O
in	O
K562	O
cells	O
.	O
Regulation	O
of	O
I	B
kappa	I
B	I
alpha	I
and	O
p105	B
in	O
monocytes	O
and	O
macrophages	O
persistently	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
.	O
The	O
mechanisms	O
regulating	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
persistence	O
in	O
human	O
monocytes	O
/macrophages	O
are	O
partially	O
understood	O
.	O
Persistent	O
HIV	O
infection	O
of	O
U937	O
monocytic	O
cells	O
results	O
in	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
Whether	O
virus	O
-	O
induced	O
NF	B
-	I
kappa	I
B	I
activation	O
is	O
a	O
mechanism	O
that	O
favors	O
continuous	O
viral	O
replication	O
in	O
macrophages	O
remains	O
unknown	O
.	O
To	O
further	O
delineate	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
HIV	O
-	O
infected	O
monocytes	O
and	O
macrophages	O
,	O
we	O
have	O
focused	O
on	O
the	O
regulation	O
of	O
the	O
I	O
kappa	O
B	O
molecules	O
.	O
First	O
,	O
we	O
show	O
that	O
persistent	O
HIV	O
infection	O
results	O
in	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
not	O
only	O
in	O
monocytic	O
cells	O
but	O
also	O
in	O
macrophages	O
.	O
In	O
HIV	O
-	O
infected	O
cells	O
,	O
I	B
kappa	I
B	I
alpha	I
protein	O
levels	O
are	O
decreased	O
secondary	O
to	O
enhanced	O
protein	O
degradation	O
.	O
This	O
parallels	O
the	O
increased	O
I	B
kappa	I
B	I
alpha	I
synthesis	O
secondary	O
to	O
increased	O
I	B
kappa	I
B	I
alpha	I
gene	O
transcription	O
,	O
i.e.	O
,	O
increased	O
RNA	O
and	O
transcriptional	O
activity	O
of	O
its	O
promoter	O
-	O
enhancer	O
.	O
Another	O
protein	O
with	O
I	O
kappa	O
B	O
function	O
,	O
p105	B
,	O
is	O
also	O
modified	O
in	O
HIV	O
-	O
infected	O
cells	O
:	O
p105	B
and	O
p50	B
steady	O
-	O
state	O
protein	O
levels	O
are	O
increased	O
as	O
a	O
result	O
of	O
increased	O
synthesis	O
and	O
proteolytic	O
processing	O
of	O
p105	B
.	O
Transcriptional	O
activity	O
of	O
p105	B
is	O
also	O
increased	O
in	O
infected	O
cells	O
and	O
is	O
also	O
mediated	O
by	O
NF	B
-	I
kappa	I
B	I
through	O
a	O
specific	O
kappa	O
B	O
motif	O
.	O
These	O
results	O
demonstrate	O
the	O
existence	O
of	O
a	O
triple	O
autoregulatory	O
loop	O
in	O
monocytes	O
and	O
macrophages	O
involving	O
HIV	O
,	O
p105	B
and	O
p50	B
,	O
and	O
MAD3	B
,	O
with	O
the	O
end	O
result	O
of	O
persistent	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
viral	O
persistence	O
.	O
Furthermore	O
,	O
persistent	O
HIV	O
infection	O
of	O
monocytes	O
and	O
macrophages	O
provides	O
a	O
useful	O
model	O
with	O
which	O
to	O
study	O
concomitant	O
modifications	O
of	O
different	O
I	B
kappa	I
B	I
molecules	I
.	O
OBF-1	B
,	O
a	O
novel	B
B	I
cell	I
-	I
specific	I
coactivator	I
that	O
stimulates	O
immunoglobulin	O
promoter	O
activity	O
through	O
association	O
with	O
octamer	B
-	I
binding	I
proteins	I
.	O
Recent	O
biochemical	O
and	O
genetic	O
studies	O
indicate	O
that	O
in	O
addition	O
to	O
the	O
octamer	B
-	I
binding	I
proteins	I
Oct-1	B
and	O
Oct-2	B
,	O
other	O
B	B
cell	I
components	I
are	O
required	O
for	O
lymphoid	O
-	O
restricted	O
,	O
octamer	O
site	O
-	O
mediated	O
immunoglobulin	O
gene	O
promoter	O
activity	O
.	O
Using	O
a	O
genetic	O
screen	O
in	O
yeast	O
,	O
we	O
have	O
isolated	O
B	O
cell	O
-	O
derived	O
cDNAs	O
encoding	O
Oct	B
-	I
binding	I
factor	I
1	I
(	O
OBF-1	B
)	O
,	O
a	O
novel	O
protein	O
that	O
specifically	O
associates	O
with	O
Oct-1	B
and	O
Oct-2	B
.	O
Biochemical	O
studies	O
demonstrate	O
that	O
OBF-1	B
has	O
no	O
intrinsic	O
DNA	O
-	O
binding	O
activity	O
and	O
recognizes	O
the	O
POU	B
domains	I
of	O
Oct-1	B
and	O
Oct-2	B
,	O
but	O
not	O
those	O
of	O
Oct-4	B
and	O
Oct-6	B
.	O
The	O
OBF-1	O
mRNA	O
is	O
expressed	O
in	O
a	O
highly	O
cell	O
-	O
specific	O
manner	O
,	O
being	O
most	O
abundant	O
in	O
B	O
cells	O
and	O
essentially	O
absent	O
in	O
most	O
of	O
the	O
other	O
cells	O
or	O
tissues	O
tested	O
.	O
Furthermore	O
,	O
expression	O
of	O
OBF-1	B
in	O
HeLa	O
cells	O
selectively	O
stimulates	O
the	O
activity	O
of	O
a	O
natural	O
immunoglobulin	O
promoter	O
in	O
an	O
octamer	O
site	O
-dependent	O
manner	O
.	O
Thus	O
,	O
OBF-1	B
has	O
all	O
the	O
properties	O
expected	O
for	O
a	O
B	B
cell	I
-	I
specific	I
transcriptional	I
coactivator	I
protein	I
.	O
Transcription	O
-	O
independent	O
turnover	O
of	O
I	B
kappa	I
B	I
alpha	I
during	O
monocyte	O
adherence	O
:	O
implications	O
for	O
a	O
translational	O
component	O
regulating	O
I	O
kappa	O
B	O
alpha	O
/	O
MAD-3	O
mRNA	O
levels	O
.	O
We	O
identified	O
I	B
kappa	I
B	I
alpha	I
/	I
MAD-3	I
as	O
an	O
immediate	O
-	O
early	O
gene	O
in	O
human	O
monocytes	O
that	O
is	O
expressed	O
in	O
response	O
to	O
a	O
variety	O
of	O
signals	O
,	O
including	O
adhesion	O
,	O
lipopolysaccharide	O
,	O
and	O
phorbol	O
myristate	O
acetate	O
.	O
Within	O
5	O
min	O
of	O
monocyte	O
adhesion	O
,	O
the	O
level	O
of	O
the	O
I	B
kappa	I
B	I
alpha	I
protein	I
is	O
markedly	O
diminished	O
but	O
is	O
rapidly	O
replaced	O
in	O
a	O
cycloheximide	O
-	O
sensitive	O
manner	O
within	O
20	O
min	O
.	O
Accompanying	O
the	O
rapid	O
turnover	O
of	O
the	O
I	B
kappa	I
B	I
alpha	I
protein	I
is	O
simultaneous	O
translocation	O
of	O
NF	B
-	I
kappa	I
B	I
-	I
related	I
transcription	I
factors	I
to	O
nuclei	O
of	O
adhered	O
monocytes	O
.	O
The	O
demonstration	O
that	O
NF	B
-	I
kappa	I
B	I
can	O
regulate	O
I	O
kappa	O
B	O
alpha	O
/	O
MAD-3	O
gene	O
transcription	O
in	O
other	O
cell	O
types	O
suggested	O
that	O
the	O
rapid	O
increase	O
in	O
steady	O
-	O
state	O
I	O
kappa	O
B	O
alpha	O
/	O
MAD-3	O
mRNA	O
levels	O
we	O
observed	O
within	O
30	O
min	O
of	O
monocyte	O
adherence	O
would	O
result	O
from	O
NF	B
-	I
kappa	I
B	I
-dependent	O
transcriptional	O
stimulation	O
of	O
the	O
I	O
kappa	O
B	O
alpha	O
/	O
MAD-3	O
gene	O
.	O
Nuclear	O
run	O
-	O
on	O
analyses	O
indicated	O
that	O
,	O
instead	O
,	O
while	O
several	O
immediate	O
-	O
early	O
cytokine	O
genes	O
,	O
such	O
as	O
the	O
interleukin	O
1	O
beta	O
(	O
IL-1	O
beta	O
)	O
gene	O
,	O
were	O
transcriptionally	O
activated	O
during	O
monocyte	O
adhesion	O
,	O
the	O
rate	O
of	O
I	O
kappa	O
B	O
alpha	O
/	O
MAD-3	O
gene	O
transcription	O
remained	O
constant	O
.	O
The	O
adherence	O
-	O
dependent	O
increase	O
in	O
I	O
kappa	O
B	O
alpha	O
/	O
MAD-3	O
mRNA	O
levels	O
was	O
also	O
not	O
a	O
consequence	O
of	O
mRNA	O
stabilization	O
events	O
.	O
Interestingly	O
,	O
while	O
increases	O
in	O
both	O
IL-1	O
beta	O
and	O
I	O
kappa	O
B	O
alpha	O
/	O
MAD-3	O
mRNA	O
levels	O
were	O
detected	O
in	O
nuclei	O
of	O
adherent	O
monocytes	O
,	O
cytoplasmic	O
levels	O
of	O
IL-1	O
beta	O
mRNA	O
increased	O
during	O
adherence	O
whereas	O
those	O
of	O
I	O
kappa	O
B	O
alpha	O
/	O
MAD-3	O
mRNA	O
did	O
not	O
.	O
Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
two	O
interactive	O
mechanisms	O
regulate	O
monocytic	O
I	O
kappa	O
B	O
alpha	O
/	O
MAD-3	O
mRNA	O
levels	O
.	O
We	O
propose	O
that	O
adherent	O
monocytes	O
regulate	O
nuclear	O
processing	O
(	O
or	O
decay	O
)	O
of	O
I	O
kappa	O
B	O
alpha	O
/	O
MAD-3	O
mRNA	O
,	O
thereby	O
increasing	O
mRNA	O
levels	O
without	O
stimulating	O
I	O
kappa	O
B	O
alpha	O
/	O
MAD-3	O
gene	O
transcription	O
.	O
Moreover	O
,	O
since	O
inhibition	O
of	O
protein	O
synthesis	O
leads	O
to	O
accumulation	O
of	O
I	O
kappa	O
B	O
alpha	O
/	O
MAD-3	O
mRNA	O
without	O
stimulating	O
I	O
kappa	O
B	O
alpha	O
/	O
MAD-3	O
gene	O
transcription	O
,	O
we	O
suggest	O
that	O
low	O
cytoplasmic	O
levels	O
of	O
I	O
kappa	O
B	O
alpha	O
/	O
MAD-3	O
mRNA	O
are	O
maintained	O
by	O
a	O
translation	O
-	O
dependent	O
degradation	O
mechanism	O
.	O
Regulation	O
of	O
cell	O
-	O
type	O
-	O
specific	O
interleukin-2	B
receptor	I
alpha	I
-	I
chain	I
gene	O
expression	O
:	O
potential	O
role	O
of	O
physical	O
interactions	O
between	O
Elf-1	B
,	O
HMG	B
-	I
I	I
(	I
Y	I
)	I
,	O
and	O
NF	B
-	I
kappa	I
B	I
family	I
proteins	I
.	O
The	O
interleukin	O
2	O
receptor	O
alpha	O
-	O
chain	O
(	O
IL-2R	O
alpha	O
)	O
gene	O
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	O
cells	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O
Previously	O
,	O
an	O
inducible	O
enhancer	O
between	O
nucleotides	O
-299	O
and	O
-228	O
that	O
contains	O
NF	O
-	O
kappa	O
B	O
and	O
CArG	O
motifs	O
was	O
identified	O
.	O
We	O
now	O
report	O
the	O
characterization	O
of	O
a	O
second	O
essential	O
positive	O
regulatory	O
element	O
located	O
between	O
nucleotides	O
-137	O
and	O
-64	O
that	O
binds	O
Elf-1	B
and	O
HMG	B
-	I
I	I
(	I
Y	I
)	I
.	O
This	O
element	O
had	O
maximal	O
activity	O
in	O
lymphoid	O
cells	O
,	O
paralleling	O
the	O
cell	O
type	O
specificity	O
of	O
Elf-1	B
expression	O
.	O
Transcription	O
from	O
the	O
IL-2R	O
alpha	O
promoter	O
was	O
inhibited	O
when	O
either	O
the	O
Elf-1	O
or	O
the	O
HMG	O
-	O
I	O
(	O
Y	O
)	O
binding	O
site	O
was	O
mutated	O
.	O
Coexpression	O
of	O
both	O
proteins	O
activated	O
transcription	O
of	O
the	O
-137	O
to	O
-64	O
element	O
in	O
COS-7	O
cells	O
.	O
Elf-1	B
physically	O
associated	O
with	O
HMG	B
-	I
I	I
and	O
with	O
NF	B
-	I
kappa	I
B	I
p50	B
and	O
c	B
-	I
Rel	I
in	O
vitro	O
,	O
suggesting	O
that	O
protein	O
-	O
protein	O
interactions	O
might	O
functionally	O
coordinate	O
the	O
actions	O
of	O
the	O
upstream	O
and	O
downstream	O
positive	O
regulatory	O
elements	O
.	O
This	O
is	O
the	O
first	O
report	O
of	O
a	O
physical	O
interaction	O
between	O
an	O
Ets	O
family	O
member	O
and	O
NF	B
-	I
kappa	I
B	I
family	I
proteins	I
.	O
These	O
findings	O
provide	O
significant	O
new	O
insights	O
into	O
the	O
protein	O
-	O
protein	O
and	O
protein	O
-	O
DNA	O
interactions	O
that	O
regulate	O
cell	O
-	O
type	O
-	O
specific	O
and	O
inducible	O
IL-2R	B
alpha	I
gene	O
expression	O
and	O
also	O
have	O
implications	O
for	O
other	O
genes	O
regulated	O
by	O
Elf-1	B
and	O
NF	B
-	I
kappa	I
B	I
family	I
proteins	I
.	O
Isolation	O
of	O
cDNA	O
clones	O
for	O
42	O
different	O
Kruppel	B
-	I
related	I
zinc	I
finger	I
proteins	I
expressed	O
in	O
the	O
human	O
monoblast	O
cell	O
line	O
U-937	O
.	O
To	O
study	O
the	O
complexity	O
and	O
structural	O
characteristics	O
of	O
zinc	B
finger	I
proteins	I
expressed	O
during	O
human	O
hematopoiesis	O
and	O
to	O
isolate	O
novel	O
regulators	O
of	O
blood	O
cell	O
development	O
,	O
a	O
degenerate	O
oligonucleotide	O
probe	O
specific	O
for	O
a	O
consensus	B
zinc	I
finger	I
peptide	I
domain	I
was	O
used	O
to	O
isolate	O
63	O
cDNA	O
clones	O
for	O
Kruppel	O
-	O
related	O
zinc	O
finger	O
genes	O
from	O
the	O
human	O
monoblast	O
cell	O
line	O
U-937	O
.	O
By	O
extensive	O
nucleotide	O
sequence	O
and	O
Northern	O
blot	O
analysis	O
,	O
these	O
cDNA	O
clones	O
were	O
found	O
to	O
originate	O
from	O
approximately	O
42	O
different	O
genes	O
(	O
HZF	O
1	O
-	O
42	O
)	O
of	O
which	O
only	O
8	O
have	O
previously	O
been	O
described	O
.	O
Northern	O
blot	O
analysis	O
showed	O
that	O
a	O
majority	O
of	O
these	O
genes	O
were	O
expressed	O
at	O
comparable	O
levels	O
in	O
U-937	O
and	O
HeLa	O
cells	O
.	O
The	O
large	O
number	O
of	O
individual	O
genes	O
represented	O
among	O
the	O
63	O
clones	O
and	O
their	O
apparent	O
non	O
-	O
cell	O
-	O
type	O
-	O
specific	O
expression	O
suggest	O
that	O
the	O
majority	O
of	O
the	O
Kruppel	O
-	O
related	O
zinc	O
finger	O
genes	O
are	O
likely	O
to	O
be	O
expressed	O
in	O
most	O
human	O
tissues	O
.	O
In	O
contrast	O
,	O
some	O
of	O
the	O
genes	O
displayed	O
a	O
restricted	O
expression	O
pattern	O
,	O
indicating	O
that	O
they	O
represent	O
potential	O
regulators	O
of	O
monocyte	O
differentiation	O
or	O
proliferation	O
.	O
Detailed	O
structural	O
analysis	O
of	O
the	O
first	O
12	O
cDNAs	O
(	O
HZF	O
1	O
-	O
10	O
)	O
and	O
a	O
partial	O
characterization	O
of	O
HZF	O
11	O
-	O
42	O
revealed	O
that	O
a	O
common	O
feature	O
of	O
human	B
Kruppel	I
-	I
related	I
zinc	I
finger	I
proteins	I
is	O
the	O
presence	O
of	O
tandem	O
arrays	O
of	O
zinc	B
fingers	I
ranging	O
in	O
number	O
from	O
3	O
to	O
over	O
20	O
that	O
are	O
preferentially	O
located	O
in	O
the	O
carboxy	B
-	I
terminal	I
regions	I
of	O
the	O
proteins	O
.	O
In	O
addition	O
,	O
several	O
novel	O
KRAB	O
-	O
containing	O
zinc	O
finger	O
genes	O
and	O
a	O
novel	O
conserved	O
sequence	O
element	O
were	O
identified	O
.	O
Calcium	B
/	I
calmodulin	I
-	I
dependent	I
protein	I
kinase	I
II	I
downregulates	O
both	O
calcineurin	O
and	O
protein	O
kinase	O
C	O
-	O
mediated	O
pathways	O
for	O
cytokine	O
gene	O
transcription	O
in	O
human	O
T	O
cells	O
.	O
Engagement	O
of	O
the	O
T	B
cell	I
receptor	I
for	O
antigen	O
activates	O
phospholipase	B
C	I
resulting	O
in	O
an	O
increase	O
in	O
intracellular	O
free	O
calcium	O
concentration	O
(	O
[	O
Ca2	O
+	O
]	O
i	O
)	O
and	O
activation	O
of	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
.	O
Increased	O
[	O
Ca2	O
+	O
]	O
i	O
activates	O
Ca2+	B
/	I
calmodulin	I
-	I
dependent	I
kinases	I
including	O
the	O
multifunctional	O
Ca2+	B
/	I
calmodulin	I
-	I
dependent	I
protein	I
kinase	I
II	I
(	O
CaM	B
-	I
K	I
II	I
)	O
,	O
as	O
well	O
as	O
calcineurin	B
,	O
a	O
type	B
2B	I
protein	I
phosphatase	I
.	O
Recent	O
studies	O
have	O
identified	O
calcineurin	B
as	O
a	O
key	O
enzyme	O
for	O
interleukin	O
(	O
IL	O
)	O
-2	O
and	O
IL-4	O
promoter	O
activation	O
.	O
However	O
,	O
the	O
role	O
of	O
CaM	B
-	I
K	I
II	I
remains	O
unknown	O
.	O
We	O
have	O
used	O
mutants	O
of	O
these	O
kinases	B
and	O
phosphatases	B
(	O
gamma	B
B*CaM	I
-	I
K	I
and	O
delta	B
CaM	I
-	I
AI	I
,	O
respectively	O
)	O
to	O
explore	O
their	O
relative	O
role	O
in	O
cytokine	O
gene	O
transcription	O
and	O
their	O
interactions	O
with	O
PKC	B
-dependent	O
signaling	O
systems	O
.	O
gamma	B
B*CaM	I
-	I
K	I
and	O
delta	B
CaM	I
-	I
AI	I
,	O
known	O
to	O
exhibit	O
constitutive	O
Ca	O
(	O
2	O
+	O
)	O
-independent	O
activity	O
,	O
were	O
cotransfected	O
(	O
alone	O
or	O
in	O
combination	O
)	O
in	O
Jurkat	O
T	O
cells	O
with	O
a	O
plasmid	O
containing	O
the	O
intact	O
IL-2	O
promoter	O
driving	O
the	O
expression	O
of	O
the	O
chloramphenicol	O
acetyltransferase	O
reporter	O
gene	O
.	O
Cotransfection	O
of	O
gamma	B
B*CaM	I
-	I
K	I
with	O
the	O
IL-2	O
promoter	O
construct	O
downregulated	O
its	O
transcription	O
in	O
response	O
to	O
stimulation	O
with	O
ionomycin	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O
The	O
inhibitory	O
effect	O
of	O
CaM	B
-	I
K	I
II	I
on	O
IL-2	O
promoter	O
was	O
associated	O
with	O
decreased	O
transcription	O
of	O
its	O
AP-1	O
and	O
NF	O
-	O
AT	O
transactivating	O
pathways	O
.	O
Under	O
the	O
same	O
conditions	O
,	O
delta	B
CaM	I
-	I
AI	I
superinduced	O
IL-2	O
promoter	O
activity	O
(	O
approximately	O
twofold	O
increase	O
)	O
.	O
When	O
both	O
mutants	O
were	O
used	O
in	O
combination	O
,	O
gamma	B
B*CaM	I
-	I
K	I
inhibited	O
the	O
induction	O
of	O
the	O
IL-2	O
promoter	O
by	O
delta	B
CaM	I
-	I
AI	I
.	O
Similar	O
results	O
were	O
obtained	O
when	O
a	O
construct	O
containing	O
the	O
IL-4	O
promoter	O
also	O
was	O
used	O
.	O
gamma	B
B*CaM	I
-	I
K	I
also	O
downregulated	O
the	O
activation	O
of	O
AP-1	B
in	O
response	O
to	O
transfection	O
with	O
a	O
constitutively	O
active	O
mutant	O
of	O
PKC	B
or	O
stimulation	O
with	O
PMA	O
.	O
These	O
results	O
suggest	O
that	O
CaM	B
-	I
K	I
II	I
may	O
exert	O
negative	O
influences	O
on	O
cytokine	O
gene	O
transcription	O
in	O
human	O
T	O
cells	O
,	O
and	O
provide	O
preliminary	O
evidence	O
for	O
negative	O
cross	O
-	O
talk	O
with	O
the	O
calcineurin-	O
and	O
PKC-	O
dependent	O
signaling	O
systems	O
.	O
Deleted	O
chromosome	O
20	O
from	O
a	O
patient	O
with	O
Alagille	O
syndrome	O
isolated	O
in	O
a	O
cell	O
hybrid	O
through	O
leucine	O
transport	O
selection	O
:	O
study	O
of	O
three	O
candidate	O
genes	O
.	O
Alagille	O
syndrome	O
(	O
AGS	O
)	O
is	O
a	O
well	O
-	O
defined	O
genetic	O
entity	O
assigned	O
to	O
the	O
short	O
arm	O
of	O
Chromosome	O
(	O
Chr	O
)	O
20	O
by	O
a	O
series	O
of	O
observations	O
of	O
AGS	O
patients	O
associated	O
with	O
microdeletions	O
in	O
this	O
region	O
.	O
By	O
fusing	O
lymphoblastoid	O
cells	O
of	O
an	O
AGS	O
patient	O
that	O
exhibited	O
a	O
microdeletion	O
in	O
the	O
short	O
arm	O
of	O
Chr	O
20	O
encompassing	O
bands	O
p11.23	O
to	O
p12.3	O
with	O
rodent	O
thermosensitive	O
mutant	O
cells	O
(	O
CHOtsH1	O
-	O
1	O
)	O
deficient	O
in	B
-	I
leucyl	I
-	I
tRNA	I
synthetase	I
,	O
we	O
isolated	O
a	O
somatic	O
cell	O
hybrid	O
segregating	O
the	O
deleted	O
human	O
Chr	O
20	O
.	O
This	O
hybrid	O
clone	O
,	O
designated	O
NR2	O
,	O
was	O
characterized	O
by	O
several	O
methods	O
,	O
including	O
PCR	O
,	O
with	O
eight	O
pairs	O
of	O
oligonucleotides	O
mapped	O
to	O
Chr	O
20	O
:	O
D20S5	O
,	O
D20S41	O
,	O
D20S42	O
,	O
D20S56	O
,	O
D20S57	O
,	O
D20S58	O
,	O
adenosine	O
deaminase	O
(	O
ADA	B
)	O
,	O
and	O
Prion	O
protein	O
(	O
PRIP	B
)	O
;	O
Restriction	O
Fragment	O
Length	O
Polymorphism	O
(	O
RFLP	O
)	O
analyses	O
with	O
four	O
genomic	O
anonymous	O
probes	O
(	O
D20S5	O
,	O
cD3H12	O
,	O
D20S17	O
,	O
D20S18	O
)	O
;	O
and	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
with	O
total	O
human	O
DNA	O
and	O
D20Z1	O
,	O
a	O
sequence	O
specific	O
to	O
the	O
human	O
Chr	O
20	O
centromere	O
,	O
as	O
probes	O
.	O
The	O
NR2	O
hybrid	O
allowed	O
us	O
to	O
exclude	O
three	O
candidate	O
genes	O
for	O
AGS	O
:	O
hepatic	O
nuclear	O
factor	O
3	O
beta	O
(	O
HNF3	O
beta	O
)	O
,	O
paired	O
box	O
1	O
(	O
PAX1	O
)	O
,	O
and	O
cystatin	O
C	O
(	O
CST3	O
)	O
as	O
shown	O
by	O
their	O
localization	O
outside	O
of	O
the	O
deletion	O
.	O
The	O
NR2	O
hybrid	O
is	O
a	O
powerful	O
tool	O
for	O
the	O
mapping	O
of	O
new	O
probes	O
of	O
this	O
region	O
,	O
as	O
well	O
as	O
for	O
obtaining	O
new	O
informative	O
probes	O
specific	O
for	O
the	O
deletion	O
by	O
subtractive	O
cloning	O
of	O
the	O
region	O
.	O
Such	O
markers	O
will	O
be	O
useful	O
for	O
linkage	O
analysis	O
and	O
screening	O
of	O
cDNA	O
libraries	O
.	O
Missense	O
mutation	O
in	O
exon	O
7	O
of	O
the	O
common	O
gamma	O
chain	O
gene	O
causes	O
a	O
moderate	O
form	O
of	O
X	O
-	O
linked	O
combined	O
immunodeficiency	O
.	O
Clinical	O
and	O
immunologic	O
features	O
of	O
a	O
recently	O
recognized	O
X	O
-	O
linked	O
combined	O
immunodeficiency	O
disease	O
(	O
XCID	O
)	O
suggested	O
that	O
XCID	O
and	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
(	O
XSCID	O
)	O
might	O
arise	O
from	O
different	O
genetic	O
defects	O
.	O
The	O
recent	O
discovery	O
of	O
mutations	O
in	O
the	O
common	O
gamma	O
chain	O
(	O
gamma	O
c	O
)	O
gene	O
,	O
a	O
constituent	O
of	O
several	O
cytokine	B
receptors	I
,	O
in	O
XSCID	O
provided	O
an	O
opportunity	O
to	O
test	O
directly	O
whether	O
a	O
previously	O
unrecognized	O
mutation	O
in	O
this	O
same	O
gene	O
was	O
responsible	O
for	O
XCID	O
.	O
The	O
status	O
of	O
X	O
chromosome	O
inactivation	O
in	O
blood	O
leukocytes	O
from	O
obligate	O
carriers	O
of	O
XCID	O
was	O
determined	O
from	O
the	O
polymorphic	O
,	O
short	O
tandem	O
repeats	O
(	O
CAG	O
)	O
,	O
in	O
the	O
androgen	O
receptor	O
gene	O
,	O
which	O
also	O
contains	O
a	O
methylation	O
-	O
sensitive	O
HpaII	O
site	O
.	O
As	O
in	O
XSCID	O
,	O
X	O
-	O
chromosome	O
inactivation	O
in	O
obligate	O
carriers	O
of	O
XCID	O
was	O
nonrandom	O
in	O
T	O
and	O
B	O
lymphocytes	O
.	O
In	O
addition	O
,	O
X	O
chromosome	O
inactivation	O
in	O
PMNs	O
was	O
variable	O
.	O
Findings	O
from	O
this	O
analysis	O
prompted	O
sequencing	O
of	O
the	O
gamma	O
c	O
gene	O
in	O
this	O
pedigree	O
.	O
A	O
missense	O
mutation	O
in	O
the	O
region	O
coding	O
for	O
the	O
cytoplasmic	O
portion	O
of	O
the	O
gamma	O
c	O
gene	O
was	O
found	O
in	O
three	O
affected	O
males	O
but	O
not	O
in	O
a	O
normal	O
brother	O
.	O
Therefore	O
,	O
this	O
point	O
mutation	O
in	O
the	O
gamma	O
c	O
gene	O
leads	O
to	O
a	O
less	O
severe	O
degree	O
of	O
deficiency	O
in	O
cellular	O
and	O
humoral	O
immunity	O
than	O
that	O
seen	O
in	O
XSCID	O
.	O
LMP-1	B
activates	O
NF	B
-	I
kappa	I
B	I
by	O
targeting	O
the	O
inhibitory	B
molecule	I
I	I
kappa	I
B	I
alpha	I
.	O
LMP-1	B
,	O
an	O
Epstein	B
-	I
Barr	I
virus	I
membrane	I
protein	I
expressed	O
during	O
latent	O
infection	O
,	O
has	O
oncogenic	O
properties	O
,	O
as	O
judged	O
from	O
its	O
ability	O
to	O
transform	O
B	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O
LMP-1	B
induces	O
the	O
expression	O
of	O
bcl2	O
,	O
an	O
oncogene	O
which	O
protects	O
cells	O
from	O
apoptosis	O
,	O
as	O
well	O
as	O
of	O
genes	O
encoding	O
other	O
proteins	O
involved	O
in	O
cell	O
regulation	O
and	O
growth	O
control	O
.	O
The	O
mechanisms	O
by	O
which	O
LMP-1	B
upregulates	O
these	O
proteins	O
is	O
unknown	O
,	O
but	O
it	O
is	O
plausible	O
that	O
LMP-1	B
modifies	O
signal	O
transduction	O
pathways	O
that	O
result	O
in	O
the	O
activation	O
of	O
one	O
or	O
more	O
transcription	B
factors	I
that	O
ultimately	O
regulate	O
transcription	O
of	O
oncogenic	O
genes	O
.	O
NF	B
-	I
kappa	I
B	I
,	O
a	O
transcription	B
factor	I
controlling	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
cell	O
activation	O
and	O
growth	O
control	O
,	O
has	O
been	O
shown	O
to	O
be	O
activated	O
by	O
LMP-1	B
.	O
The	O
mechanism	O
(	O
s	O
)	O
regulating	O
this	O
activation	O
remains	O
unknown	O
.	O
Our	O
data	O
indicate	O
that	O
increased	O
NF	B
-	I
kappa	I
B	I
DNA	O
binding	O
and	O
functional	O
activity	O
are	O
present	O
in	O
B	O
-	O
lymphoid	O
cells	O
stably	O
or	O
transiently	O
expressing	O
LMP-1	B
.	O
I	B
kappa	I
B	I
alpha	I
is	O
selectively	O
modified	O
in	O
LMP-1-expressing	O
B	O
cells	O
.	O
A	O
phosphorylated	O
form	O
of	O
I	B
kappa	I
B	I
alpha	I
and	O
increased	O
protein	O
turnover	O
-	O
degradation	O
correlate	O
with	O
increased	O
NF	B
-	I
kappa	I
B	I
nuclear	O
translocation	O
.	O
This	O
results	O
in	O
increased	O
transcription	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
dependent	O
-	O
genes	O
,	O
including	O
those	O
encoding	O
p105	B
and	O
I	B
kappa	I
B	I
alpha	I
(	O
MAD3	O
)	O
.	O
These	O
results	O
indicate	O
that	O
LMP-1	B
activates	O
NF	B
-	I
kappa	I
B	I
in	O
B	O
-	O
cell	O
lines	O
by	O
targeting	O
I	B
kappa	I
B	I
alpha	I
.	O
Identification	O
of	O
the	O
pathways	O
activated	O
by	O
LMP-1	B
to	O
result	O
in	O
posttranslational	O
modifications	O
of	O
I	B
kappa	I
B	I
alpha	I
will	O
aid	O
in	O
determining	O
the	O
role	O
of	O
this	O
virus	O
-	O
host	O
cell	O
protein	O
interaction	O
in	O
Epstein	O
-	O
Barr	O
virus	O
-	O
mediated	O
oncogenesis	O
.	O
Treatment	O
of	O
HL60	O
cells	O
with	O
various	O
combinations	O
of	O
retinoids	O
and	O
1	O
alpha	O
,	O
25	O
dihydroxyvitamin	O
D3	O
results	O
in	O
differentiation	O
towards	O
neutrophils	O
or	O
monocytes	O
or	O
a	O
failure	O
to	O
differentiate	O
and	O
apoptosis	O
.	O
It	O
is	O
well	O
documented	O
that	O
treatment	O
of	O
serum	O
-	O
grown	O
HL60	O
cells	O
with	O
10	O
(	O
-7	O
)	O
M	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
all	O
-	O
trans	O
RA	O
)	O
induces	O
neutrophil	O
differentiation	O
,	O
whereas	O
treatment	O
with	O
10	O
(	O
-7	O
)	O
M	O
1	O
alpha	O
,	O
25	O
dihydroxyvitamin	O
D3	O
(	O
D3	O
)	O
induces	O
differentiation	O
towards	O
monocytes	O
.	O
In	O
recent	O
investigations	O
,	O
using	O
serum	O
-	O
free	O
grown	O
HL60	O
cells	O
,	O
we	O
observed	O
that	O
all	O
-	O
trans	O
RA	O
,	O
at	O
10	O
(	O
-7	O
)	O
M	O
,	O
did	O
not	O
induce	O
neutrophil	O
differentiation	O
and	O
that	O
all	O
-	O
trans	O
RA	O
,	O
at	O
10	O
(	O
-8	O
)	O
M	O
,	O
reduced	O
the	O
D3	O
concentration	O
required	O
for	O
monocyte	O
differentiation	O
to	O
5	O
x	O
10	O
(	O
-9	O
)	O
M	O
.	O
In	O
this	O
study	O
,	O
co	O
-	O
operative	O
interactions	O
between	O
all	O
-	O
trans	O
and	O
9-cis	O
RA	O
and	O
D3	O
which	O
promote	O
neutrophil	O
and	O
monocyte	O
differentiation	O
of	O
HL60	O
cells	O
have	O
been	O
analysed	O
in	O
detail	O
.	O
Treatment	O
of	O
serum	O
-	O
free	O
grown	O
HL60	O
cells	O
with	O
5	O
x	O
10	O
(	O
-7	O
)	O
M	O
all	O
-	O
trans	O
RA	O
or	O
9-cis	O
RA	O
resulted	O
in	O
sub	O
-	O
optimal	O
neutrophil	O
differentiation	O
(	O
up	O
to	O
25	O
%	O
mature	O
cells	O
)	O
.	O
As	O
shown	O
for	O
all	O
-	O
trans	O
RA	O
,	O
9-cis	O
RA	O
cooperated	O
with	O
D3	O
to	O
promote	O
monocyte	O
differentiation	O
.	O
Culture	O
of	O
HL60	O
cells	O
in	O
5	O
x	O
10	O
(	O
-7	O
)	O
M	O
9-cis	O
RA	O
together	O
with	O
a	O
wide	O
range	O
of	O
concentrations	O
of	O
D3	O
resulted	O
in	O
promotion	O
of	O
neutrophil	O
differentiation	O
at	O
10	O
(	O
-15	O
)	O
-10	O
(	O
-12	O
)	O
D3	O
,	O
a	O
failure	O
to	O
differentiate	O
and	O
apoptosis	O
at	O
10	O
(	O
-11	O
)	O
-10	O
(	O
-10	O
)	O
M	O
D3	O
,	O
followed	O
by	O
co	O
-	O
operativity	O
between	O
9-cis	O
RA	O
and	O
5	O
x	O
10	O
(	O
-9	O
)	O
M	O
D3	O
in	O
inducing	O
monocyte	O
differentiation	O
in	O
the	O
absence	O
of	O
neutrophil	O
differentiation	O
.	O
Similar	O
results	O
were	O
obtained	O
when	O
HL60	O
cells	O
were	O
treated	O
with	O
5	O
x	O
10	O
(	O
-7	O
)	O
all	O
-	O
trans	O
RA	O
together	O
with	O
a	O
wide	O
range	O
of	O
concentrations	O
of	O
D3	O
.	O
Cross	O
titration	O
analyses	O
of	O
the	O
effects	O
of	O
9-cis	O
RA	O
and	O
D3	O
on	O
HL60	O
cell	O
differentiation	O
were	O
undertaken	O
to	O
determine	O
the	O
boundaries	O
of	O
the	O
concentrations	O
of	O
each	O
agent	O
,	O
alone	O
and	O
in	O
combination	O
,	O
that	O
give	O
rise	O
to	O
optimal	O
neutrophil	O
and	O
monocyte	O
differentiation	O
of	O
HL60	O
cells	O
.	O
The	O
observed	O
cooperativities	O
between	O
either	O
9-cis	O
RA	O
or	O
all	O
-	O
trans	O
RA	O
and	O
D3	O
have	O
important	O
implications	O
for	O
the	O
use	O
of	O
combinations	O
of	O
these	O
agents	O
in	O
differentiation	O
therapy	O
.	O
Cloning	O
and	O
characterization	O
of	O
NF	B
-	I
ATc	I
and	O
NF	B
-	I
ATp	I
:	O
the	O
cytoplasmic	O
components	O
of	O
NF	B
-	I
AT	I
.	O
Present	O
evidence	O
indicates	O
a	O
pathway	O
of	O
signal	O
transmission	O
in	O
T	O
cells	O
that	O
is	O
outlined	O
in	O
figure	O
1	O
.	O
The	O
elevation	O
in	O
intracellular	O
calcium	O
that	O
is	O
induced	O
by	O
interactions	O
at	O
the	O
antigen	B
receptor	I
leads	O
to	O
the	O
activation	O
of	O
the	O
calcium	B
-	I
dependent	I
phosphatase	I
calcineurin	B
.	O
This	O
in	O
turn	O
leads	O
to	O
the	O
nuclear	O
association	O
of	O
the	O
cytosolic	B
component	I
of	O
NF	B
-	I
ATc	I
.	O
The	O
activation	O
of	O
calcineurin	B
and	O
the	O
nuclear	O
import	O
of	O
NF	B
-	I
ATc	I
can	O
both	O
be	O
blocked	O
by	O
cyclosporin	O
A	O
or	O
FK506	O
in	O
complex	O
with	O
their	O
respective	O
immunophilins	B
.	O
Once	O
in	O
the	O
nucleus	O
,	O
NF	B
-	I
ATc	I
interacts	O
with	O
NF	B
-	I
ATn	I
to	O
form	O
an	O
active	B
transcriptional	I
complex	I
.	O
NF	B
-	I
ATn	I
is	O
a	O
ubiquitous	O
protein	O
,	O
can	O
be	O
synthesized	O
in	O
response	O
to	O
PMA	O
,	O
and	O
has	O
many	O
similarities	O
to	O
AP-1	B
.	O
The	O
mechanism	O
by	O
which	O
NF	B
-	I
ATc	I
enters	O
the	O
nucleus	O
is	O
unknown	O
,	O
and	O
although	O
it	O
appears	O
to	O
require	O
calcineurin	B
,	O
NF	B
-	I
ATc	I
has	O
not	O
yet	O
been	O
shown	O
to	O
be	O
an	O
in	O
vivo	O
substrate	O
of	O
calcineurin	B
.	O
Alternative	O
mechanisms	O
include	O
the	O
possibility	O
that	O
NF	B
-	I
ATc	I
operates	O
on	O
some	O
cytoplasmic	B
anchor	I
or	O
that	O
other	O
proteins	O
that	O
are	O
controlled	O
by	O
calcineurin	B
carry	O
out	O
the	O
nuclear	O
import	O
of	O
NF	B
-	I
ATc	I
.	O
Although	O
NF	B
-	I
ATp	I
copurifies	O
with	O
NF	B
-	I
ATc	I
,	O
there	O
is	O
as	O
yet	O
no	O
understanding	O
of	O
how	O
NF	B
-	I
ATp	I
is	O
functioning	O
in	O
vivo	O
.	O
Now	O
that	O
these	O
proteins	O
are	O
purified	O
and	O
cloned	O
,	O
the	O
major	O
goals	O
will	O
be	O
to	O
understand	O
their	O
role	O
and	O
the	O
roles	O
of	O
other	O
family	O
members	O
in	O
thymic	O
development	O
.	O
Interleukin-5	B
signaling	O
in	O
human	O
eosinophils	O
involves	O
JAK2	B
tyrosine	I
kinase	I
and	O
Stat1	B
alpha	I
.	O
Signaling	O
by	O
a	O
wide	O
variety	O
of	O
cytokines	B
,	O
including	O
interferons	B
,	O
interleukins	B
,	O
and	O
growth	B
factors	I
,	O
involves	O
activation	O
of	O
JAK	B
kinases	I
and	O
Stat	B
(	I
Signal	I
transducers	I
and	I
activators	I
of	I
transcription	I
)	I
proteins	I
.	O
At	O
present	O
,	O
not	O
much	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
by	O
which	O
interleukin-5	B
(	O
IL-5	B
)	O
exerts	O
its	O
diverse	O
biologic	O
effects	O
.	O
Human	O
eosinophils	O
are	O
one	O
of	O
the	O
most	O
important	O
target	O
cells	O
for	O
IL-5	B
and	O
were	O
used	O
here	O
to	O
study	O
IL-5	B
signaling	O
in	O
a	O
primary	O
human	O
cell	O
.	O
IL-5	B
induced	O
rapid	O
and	O
transient	O
tyrosine	O
phosphorylation	O
of	O
JAK2	B
.	O
Moreover	O
,	O
IL-5	B
induced	O
at	O
least	O
two	O
DNA	B
-	I
binding	I
complexes	I
,	O
using	O
nuclear	O
extracts	O
from	O
normal	O
human	O
eosinophils	O
and	O
the	O
IL-6	O
/	O
interferon	O
-	O
gamma	O
response	O
element	O
of	O
the	O
ICAM-1	O
promoter	O
(	O
ICAM-1	O
pIRE	O
)	O
in	O
an	O
electromobility	O
shift	O
assay	O
.	O
From	O
supershift	O
experiments	O
it	O
was	O
concluded	O
that	O
one	O
DNA	B
-	I
binding	I
complex	I
contained	O
Stat1	B
alpha	I
,	O
probably	O
as	O
a	O
homodimer	O
.	O
Both	O
DNA	B
-	I
binding	I
complexes	I
were	O
inhibited	O
by	O
a	O
phosphotyrosine	B
antibody	I
(	O
4G10	B
)	O
,	O
suggesting	O
that	O
tyrosine	O
phosphorylation	O
is	O
required	O
for	O
complex	O
formation	O
.	O
IL-3	B
and	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
induced	O
,	O
similar	O
to	O
IL-5	B
,	O
two	O
DNA	B
-	I
binding	I
complexes	I
in	O
human	O
eosinophils	O
,	O
including	O
Stat1	B
alpha	I
.	O
These	O
data	O
show	O
for	O
the	O
first	O
time	O
that	O
molecular	O
mechanisms	O
of	O
IL-5	B
signaling	O
in	O
human	O
eosinophils	O
involve	O
members	O
of	O
the	O
JAK	B
kinase	I
family	I
as	O
well	O
as	O
members	O
of	O
the	O
Stat	B
family	I
.	O
E2F-1	B
and	O
a	O
cyclin	B
-	I
like	I
DNA	I
repair	I
enzyme	I
,	O
uracil	B
-	I
DNA	I
glycosylase	I
,	O
provide	O
evidence	O
for	O
an	O
autoregulatory	O
mechanism	O
for	O
transcription	O
.	O
The	O
cell	B
cycle	I
-	I
dependent	I
transcription	I
factor	I
,	O
E2F-1	B
,	O
regulates	O
the	O
cyclin	B
-like	O
species	O
of	O
the	O
DNA	B
repair	I
enzyme	I
uracil	O
-	O
DNA	O
glycosylase	O
(	O
UDG	O
)	O
gene	O
in	O
human	O
osteosarcoma	O
(	O
Saos-2	O
)	O
cells	O
.	O
We	O
demonstrate	O
,	O
through	O
the	O
deletion	O
of	O
the	O
human	O
UDG	O
promoter	O
sequences	O
,	O
that	O
expression	O
of	O
E2F-1	B
activates	O
the	O
UDG	O
promoter	O
through	O
several	O
E2F	O
sites	O
.	O
The	O
major	O
putative	O
downstream	O
site	O
for	O
E2F	B
,	O
located	O
in	O
the	O
first	O
exon	O
,	O
serves	O
as	O
a	O
target	O
for	O
E2F-1	B
/	I
DP1	I
complex	I
binding	O
in	O
vitro	O
.	O
We	O
also	O
provide	O
evidence	O
for	O
the	O
functional	O
relationship	O
between	O
the	O
cyclin	B
-	I
like	I
UDG	I
gene	I
product	I
and	O
E2F	B
.	O
High	O
levels	O
of	O
UDG	B
expression	O
in	O
a	O
transient	O
transfection	O
assay	O
result	O
in	O
the	O
down	O
-	O
regulation	O
of	O
transcriptional	O
activity	O
through	O
elements	O
specific	O
for	O
E2F	B
-mediated	O
transcription	O
.	O
Overexpression	O
of	O
UDG	B
in	O
Saos	O
2	O
cells	O
was	O
observed	O
to	O
delay	O
growth	O
late	O
in	O
G1	O
phase	O
and	O
transiently	O
arrest	O
these	O
cells	O
from	O
progressing	O
into	O
the	O
S	O
phase	O
.	O
This	O
hypothetical	O
model	O
integrates	O
one	O
mechanism	O
of	O
DNA	O
repair	O
with	O
the	O
cell	O
cycle	O
control	O
of	O
gene	O
transcription	O
,	O
likely	O
through	O
E2F	B
.	O
This	O
implicates	O
E2F	B
as	O
a	O
multifunctional	O
target	O
for	O
proteins	O
and	O
enzymes	O
,	O
possibly	O
,	O
responsive	O
to	O
DNA	O
damage	O
through	O
the	O
negative	O
effect	O
of	O
UDG	B
on	O
E2F	B
-mediated	O
transcriptional	O
activity	O
.	O
Mapping	O
of	O
the	O
interaction	B
site	I
of	O
the	O
defective	B
transcription	I
factor	I
in	O
the	O
class	O
II	O
major	O
histocompatibility	O
complex	O
mutant	O
cell	O
line	O
clone-13	O
to	O
the	O
divergent	O
X2-box	O
.	O
We	O
have	O
previously	O
described	O
a	O
mutant	O
B	O
lymphoblastoid	O
cell	O
line	O
,	O
Clone-13	O
,	O
that	O
expresses	O
HLA	B
-	I
DQ	I
in	O
the	O
absence	O
of	O
HLA	B
-	I
DR	I
and	I
-DP	I
.	O
Several	O
criteria	O
indicated	O
that	O
the	O
defect	O
in	O
this	O
cell	O
line	O
influences	O
the	O
activity	O
of	O
an	O
isotype	B
-	I
specific	I
transcription	I
factor	I
.	O
Indeed	O
,	O
transient	O
transfection	O
of	O
HLA	O
-	O
DRA	O
and	O
DQB	O
reporter	O
constructs	O
indicated	O
that	O
the	O
affected	O
factor	O
operates	O
via	O
cis	O
-	O
elements	O
located	O
between	O
-141	O
base	O
pairs	O
and	O
the	O
transcription	O
initiation	O
site	O
.	O
A	O
series	O
of	O
hybrid	O
DRA	O
/	O
DQB	O
reporter	O
constructs	O
was	O
generated	O
to	O
further	O
map	O
the	O
relevant	O
cis	O
-	O
elements	O
in	O
this	O
system	O
.	O
Insertion	O
of	O
oligonucleotides	O
spanning	O
the	O
DQB	O
X	O
-	O
box	O
(	O
but	O
not	O
the	O
DQB	O
-	O
W	O
region	O
or	O
the	O
DQB	O
Y	O
-	O
box	O
)	O
upstream	O
of	O
-141	O
in	O
a	O
DRA	O
reporter	O
plasmid	O
rescued	O
expression	O
to	O
nearly	O
wild	O
-	O
type	O
levels	O
.	O
Substitution	O
promoters	O
were	O
then	O
generated	O
where	O
the	O
entire	O
X	O
-	O
box	O
,	O
or	O
only	O
the	O
X1-	O
or	O
X2-boxes	O
of	O
HLA	O
-	O
DRA	O
were	O
replaced	O
with	O
the	O
analogous	O
regions	O
of	O
HLA	O
-	O
DQB	O
.	O
The	O
DQB	O
X2-box	O
was	O
able	O
to	O
restore	O
expression	O
to	O
the	O
silent	O
DRA	O
reporter	O
construct	O
.	O
Moreover	O
,	O
replacement	O
of	O
the	O
DQB	O
X2-box	O
with	O
the	O
DRA	O
X2-box	O
markedly	O
diminished	O
the	O
activity	O
of	O
the	O
DQB	O
promoter	O
in	O
the	O
mutant	O
cell	O
.	O
None	O
of	O
the	O
hybrid	O
reporter	O
constructs	O
were	O
defective	O
when	O
transfected	O
into	O
the	O
wild	B
-	I
type	I
,	O
HLA	O
-	O
DR	O
/	O
-DQ	O
positive	O
parental	O
cell	O
line	O
,	O
Jijoye	O
.	O
These	O
studies	O
suggest	O
that	O
the	O
divergent	O
X2-box	O
of	O
the	O
class	O
II	O
major	O
histocompatibility	O
complex	O
promoters	O
plays	O
an	O
important	O
role	O
in	O
influencing	O
differential	O
expression	O
of	O
the	O
human	O
class	O
II	O
isotypes	O
.	O
Regulation	O
and	O
specificity	O
of	O
MNDA	B
expression	O
in	O
monocytes	O
,	O
macrophages	O
,	O
and	O
leukemia	O
/	O
B	O
lymphoma	O
cell	O
lines	O
.	O
The	O
expression	O
of	O
the	O
human	B
myeloid	I
cell	I
nuclear	I
differentiation	I
antigen	I
(	O
MNDA	B
)	O
was	O
observed	O
specifically	O
in	O
cells	O
of	O
the	O
granulocyte	O
-	O
macrophage	O
lineage	O
in	O
our	O
earlier	O
reports	O
.	O
The	O
specificity	O
of	O
MNDA	B
expression	O
for	O
cells	O
in	O
the	O
granulocyte	O
-	O
macrophage	O
lineage	O
was	O
reexamined	O
in	O
cell	O
lines	O
established	O
from	O
patients	O
with	O
Philadelphia	O
chromosome	O
-	O
positive	O
chronic	O
myeloid	O
leukemia	O
.	O
Cell	O
lines	O
that	O
expressed	O
MNDA	B
exhibited	O
myeloid	O
cell	O
features	O
and	O
granulocyte	O
or	O
monocyte	O
differentiation	O
could	O
be	O
induced	O
in	O
vitro	O
,	O
while	O
cell	O
lines	O
exhibiting	O
properties	O
of	O
very	O
early	O
stage	O
cells	O
or	O
multipotential	O
cells	O
did	O
not	O
express	O
MNDA	B
.	O
Cells	O
originating	O
from	O
cases	O
of	O
Burkitt	O
's	O
lymphoma	O
were	O
negative	O
.	O
By	O
contrast	O
,	O
three	O
lymphoblastoid	O
cell	O
lines	O
(	O
immortalized	O
in	O
vitro	O
with	O
Epstein	O
-	O
Barr	O
virus	O
)	O
were	O
weakly	O
positive	O
and	O
MNDA	B
was	O
up	O
-	O
regulated	O
by	O
interferon	B
-	I
alpha	I
(	O
IFN	B
-	I
alpha	I
)	O
treatment	O
.	O
As	O
we	O
reported	O
previously	O
,	O
MNDA	O
mRNA	O
level	O
in	O
adherent	O
monocytes	O
is	O
elevated	O
by	O
IFN	B
-	I
alpha	I
;	O
in	O
this	O
study	O
,	O
we	O
further	O
assessed	O
MNDA	B
expression	O
in	O
in	O
vitro	O
monocyte	O
-	O
derived	O
macrophages	O
.	O
Three	O
additional	O
agents	O
(	O
endotoxin	O
,	O
phytohemagglutinin	B
,	O
and	O
phorbol	O
ester	O
)	O
and	O
other	O
conditions	O
that	O
affect	O
function	O
,	O
cytokine	B
production	O
,	O
differentiation	O
,	O
and/or	O
growth	O
of	O
monocytes	O
were	O
examined	O
for	O
their	O
ability	O
to	O
alter	O
MNDA	B
expression	O
.	O
The	O
results	O
varied	O
with	O
the	O
agent	O
,	O
cell	O
type	O
,	O
and	O
stage	O
of	O
differentiation	O
.	O
Changes	O
in	O
MNDA	B
expression	O
occurred	O
slowly	O
(	O
hours	O
to	O
days	O
)	O
,	O
suggesting	O
that	O
MNDA	B
could	O
mediate	O
changes	O
realized	O
over	O
a	O
long	O
period	O
.	O
The	O
results	O
also	O
reveal	O
a	O
discordance	O
in	O
certain	O
MNDA	O
positive	O
cells	O
between	O
steady	O
-	O
state	O
levels	O
or	O
changes	O
in	O
levels	O
of	O
protein	O
and	O
mRNA	O
indicating	O
that	O
the	O
regulation	O
of	O
MNDA	B
expression	O
occurs	O
at	O
more	O
than	O
one	O
point	O
.	O
Changes	O
in	O
MNDA	B
expression	O
are	O
consistent	O
with	O
a	O
role	O
in	O
opposing	O
macrophage	O
differentiation	O
and	O
activation	O
of	O
monocytes	O
/macrophages	O
.	O
Aspirin	O
inhibits	O
nuclear	B
factor	I
-	I
kappa	I
B	I
mobilization	O
and	O
monocyte	O
adhesion	O
in	O
stimulated	O
human	O
endothelial	O
cells	O
.	O
BACKGROUND	O
:	O
The	O
induction	O
of	O
vascular	B
cell	I
adhesion	I
molecule-1	I
(	O
VCAM-1	B
)	O
and	O
E	B
-	I
selectin	I
by	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
)	O
is	O
mediated	O
by	O
mobilization	O
of	O
the	O
transcription	B
factor	I
nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
.	O
Since	O
salicylates	O
have	O
been	O
reported	O
to	O
inhibit	O
NF	B
-	I
kappa	I
B	I
activation	O
by	O
preventing	O
the	O
degradation	O
of	O
its	O
inhibitor	O
I	B
kappa	I
B	I
,	O
we	O
studied	O
a	O
potential	O
inhibition	O
of	O
this	O
pathway	O
by	O
acetylsalicylate	O
(	O
aspirin	O
)	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
Gel	O
-	O
shift	O
analyses	O
demonstrated	O
dose	O
-	O
dependent	O
inhibition	O
of	O
TNF	B
-induced	O
NF	B
-	I
kappa	I
B	I
mobilization	O
by	O
aspirin	O
at	O
concentrations	O
ranging	O
from	O
1	O
to	O
10	O
mmol	O
/	O
L	O
.	O
Induction	O
of	O
VCAM-1	B
and	O
E	B
-	I
selectin	I
surface	O
expression	O
by	O
TNF	B
was	O
dose	O
-	O
dependently	O
reduced	O
by	O
aspirin	O
over	O
the	O
same	O
range	O
,	O
while	O
induction	O
of	O
intercellular	B
adhesion	I
molecule-1	I
(	O
ICAM-1	B
)	O
was	O
hardly	O
affected	O
.	O
Aspirin	O
appeared	O
to	O
prevent	O
VCAM-1	B
transcription	O
,	O
since	O
it	O
dose	O
-	O
dependently	O
inhibited	O
induction	O
of	O
VCAM-1	O
mRNA	O
by	O
TNF	B
.	O
As	O
a	O
functional	O
consequence	O
,	O
adhesion	O
of	O
U937	O
monocytes	O
to	O
TNF	O
-	O
stimulated	O
HUVECs	O
was	O
markedly	O
reduced	O
by	O
aspirin	O
due	O
to	O
suppression	O
of	O
VCAM-1	B
and	O
E	B
-	I
selectin	I
upregulation	O
.	O
These	O
effects	O
of	O
aspirin	O
were	O
not	O
related	O
to	O
the	O
inhibition	O
of	O
cyclooxygenase	B
activity	O
,	O
since	O
indomethacin	O
was	O
ineffective	O
.	O
CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
aspirin	O
inhibits	O
NF	B
-	I
kappa	I
B	I
mobilization	O
,	O
induction	O
of	O
VCAM-1	B
and	O
E	B
-	I
selectin	I
,	O
and	O
subsequent	O
monocyte	O
adhesion	O
in	O
endothelial	O
cells	O
stimulated	O
by	O
TNF	B
,	O
thereby	O
providing	O
an	O
additional	O
mechanism	O
for	O
therapeutic	O
effects	O
of	O
aspirin	O
.	O
Differences	O
in	O
binding	O
of	O
glucocorticoid	B
receptor	I
to	O
DNA	O
in	O
steroid	O
-	O
resistant	O
asthma	O
.	O
Although	O
glucocorticosteroids	O
are	O
a	O
very	O
effective	O
treatment	O
for	O
asthma	O
and	O
other	O
chronic	O
inflammatory	O
diseases	O
,	O
a	O
small	O
proportion	O
of	O
patients	O
are	O
resistant	O
to	O
their	O
therapeutic	O
effects	O
.	O
The	O
molecular	O
mechanism	O
for	O
this	O
steroid	O
resistance	O
is	O
unclear	O
.	O
Steroid	O
resistance	O
can	O
not	O
be	O
explained	O
by	O
pharmacokinetic	O
mechanisms	O
,	O
by	O
a	O
defect	O
in	O
the	O
binding	O
of	O
steroids	O
to	O
glucocorticoid	B
receptors	I
,	O
nor	O
by	O
defective	O
nuclear	O
translocation	O
of	O
this	O
receptor	O
,	O
thereby	O
suggesting	O
that	O
the	O
molecular	O
abnormality	O
lies	O
distal	O
to	O
nuclear	O
translocation	O
.	O
We	O
examined	O
the	O
ability	O
of	O
nuclear	O
translocated	O
glucocorticoid	B
receptors	I
to	O
bind	O
to	O
their	O
DNA	O
binding	O
sites	O
(	O
GRE	O
)	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
in	O
PBMC	O
from	O
patients	O
with	O
steroid	O
-	O
sensitive	O
and	O
steroid	O
-	O
resistant	O
asthma	O
.	O
The	O
binding	O
of	O
the	O
glucocorticoid	B
receptor	I
to	O
DNA	O
in	O
these	O
patients	O
was	O
also	O
studied	O
using	O
Scatchard	O
analysis	O
.	O
Dexamethasone	O
induced	O
a	O
significant	O
rapid	O
and	O
sustained	O
twofold	O
increase	O
in	O
GRE	O
binding	O
in	O
PBMCs	O
from	O
steroid	O
-	O
sensitive	O
asthmatic	O
patients	O
and	O
nonasthmatic	O
individuals	O
,	O
but	O
this	O
was	O
markedly	O
reduced	O
in	O
steroid	O
-	O
resistant	O
asthmatic	O
patients	O
.	O
Scatchard	O
analysis	O
of	O
glucocorticoid	B
receptor	I
-	O
GRE	O
binding	O
showed	O
no	O
change	O
in	O
binding	O
affinity	O
but	O
did	O
show	O
a	O
reduced	O
number	O
of	O
receptors	B
available	O
for	O
DNA	O
binding	O
in	O
the	O
steroid	O
-	O
resistant	O
patients	O
.	O
These	O
results	O
suggest	O
that	O
the	O
ability	O
of	O
the	O
glucocorticoid	B
receptor	I
to	O
bind	O
to	O
GRE	O
is	O
impaired	O
in	O
steroid	O
-	O
resistant	O
patients	O
because	O
of	O
a	O
reduced	O
number	O
of	O
receptors	B
available	O
for	O
binding	O
to	O
DNA	O
.	O
Transcriptional	O
regulation	O
of	O
the	O
vacuolar	O
H	O
(	O
+	O
)	O
-ATPase	O
B2	O
subunit	O
gene	O
in	O
differentiating	O
THP-1	O
cells	O
.	O
Monocyte	O
-	O
macrophage	O
differentiation	O
was	O
used	O
as	O
a	O
model	O
system	O
for	O
studying	O
gene	O
regulation	O
of	O
the	O
human	B
vacuolar	I
H	I
(	I
+	I
)	I
-ATPase	I
(	O
V	B
-	I
ATPase	I
)	O
.	O
We	O
examined	O
mRNA	O
levels	O
of	O
various	O
V	B
-	I
ATPase	I
subunits	O
during	O
differentiation	O
of	O
both	O
native	O
monocytes	O
and	O
the	O
cell	O
line	O
THP-1	O
,	O
and	O
found	O
that	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
mechanisms	O
could	O
account	O
for	O
increases	O
in	O
cell	O
V	B
-	I
ATPase	I
content	O
.	O
From	O
nuclear	O
runoff	O
experiments	O
,	O
we	O
found	O
that	O
one	O
subunit	O
in	O
particular	O
,	O
the	O
B2	B
isoform	I
(	O
Mr	O
=	O
56	O
,	O
000	O
)	O
,	O
was	O
amplified	O
primarily	O
by	O
transcriptional	O
means	O
.	O
We	O
have	O
begun	O
to	O
examine	O
the	O
structure	O
of	O
the	O
B2	O
subunit	O
promoter	O
region	O
.	O
Isolation	O
and	O
sequencing	O
of	O
the	O
first	O
exon	O
and	O
5'-flanking	O
region	O
of	O
this	O
gene	O
reveal	O
a	O
TATA	O
-	O
less	O
promoter	O
with	O
a	O
high	O
G	O
+	O
C	O
content	O
.	O
Primer	O
extension	O
and	O
ribonuclease	B
protection	O
analyses	O
indicate	O
a	O
single	O
major	O
transcriptional	O
start	O
site	O
.	O
We	O
transfected	O
promoter	O
-	O
luciferase	O
reporter	O
plasmids	O
into	O
THP-1	O
cells	O
to	O
define	O
sequences	O
that	O
mediate	O
transcriptional	O
control	O
during	O
monocyte	O
differentiation	O
.	O
We	O
found	O
that	O
sequences	O
downstream	O
from	O
the	O
transcriptional	O
start	O
site	O
were	O
sufficient	O
to	O
confer	O
increased	O
expression	O
during	O
THP-1	O
differentiation	O
.	O
DNase	B
I	I
footprinting	O
and	O
sequence	O
analysis	O
revealed	O
the	O
existence	O
of	O
multiple	O
AP2	O
and	O
Sp1	O
binding	O
sites	O
in	O
the	O
5'-untranslated	O
and	O
proximal	O
coding	O
regions	O
.	O
Effects	O
of	O
intranasal	O
glucocorticoids	O
on	O
endogenous	O
glucocorticoid	O
peripheral	O
and	O
central	O
function	O
.	O
Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
antiinflammatory	O
agents	O
that	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
rhinitis	O
.	O
Their	O
mechanisms	O
of	O
action	O
are	O
multiple	O
and	O
complex	O
and	O
a	O
number	O
of	O
reports	O
describe	O
significant	O
systemic	O
effects	O
of	O
locally	O
administered	O
glucocorticoids	O
.	O
In	O
order	O
to	O
evaluate	O
the	O
short	O
-	O
term	O
systemic	O
effects	O
of	O
intranasally	O
administered	O
glucocorticoids	O
,	O
14	O
normal	O
healthy	O
subjects	O
were	O
treated	O
with	O
two	O
doses	O
of	O
either	O
budesonide	O
(	O
BUD	O
)	O
or	O
fluticasone	O
propionate	O
(	O
FP	O
)	O
for	O
2	O
weeks	O
.	O
Before	O
treatment	O
,	O
at	O
regular	O
intervals	O
during	O
the	O
treatment	O
,	O
1	O
week	O
and	O
finally	O
6	O
weeks	O
after	O
termination	O
of	O
treatment	O
,	O
the	O
effects	O
on	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
and	O
methallothionein	O
(	O
MTIIa	O
)	O
mRNA	O
expression	O
levels	O
were	O
examined	O
in	O
peripheral	O
lymphocytes	O
using	O
a	O
solution	O
hybridization	O
assay	O
.	O
Serum	O
cortisol	O
,	O
osteocalcin	O
and	O
urinary	O
cortisol	O
levels	O
were	O
also	O
determined	O
.	O
An	O
insulin	O
tolerance	O
test	O
(	O
ITT	O
)	O
was	O
performed	O
at	O
the	O
end	O
of	O
the	O
second	O
week	O
of	O
treatment	O
and	O
at	O
the	O
end	O
of	O
the	O
6-week	O
washout	O
period	O
with	O
no	O
statistically	O
significant	O
change	O
in	O
cortisol	O
response	O
.	O
In	O
peripheral	O
lymphocytes	O
,	O
GR	O
mRNA	O
levels	O
were	O
significantly	O
down	O
-	O
regulated	O
.	O
MTIIa	O
mRNA	O
levels	O
increased	O
significantly	O
.	O
Serum	O
osteocalcin	B
decreased	O
significantly	O
during	O
treatment	O
with	O
both	O
BUD	O
and	O
FP	O
.	O
Serum	O
cortisol	O
decreased	O
after	O
1	O
week	O
of	O
treatment	O
whereas	O
urinary	O
cortisol	O
was	O
not	O
affected	O
until	O
the	O
second	O
week	O
of	O
treatment	O
.	O
In	O
conclusion	O
,	O
intranasal	O
glucocorticoids	O
at	O
clinically	O
recommended	O
doses	O
have	O
not	O
only	O
significant	O
systemic	O
effects	O
on	O
adrenal	O
function	O
,	O
but	O
also	O
have	O
an	O
effect	O
on	O
specific	O
gene	O
expression	O
in	O
peripheral	O
lymphocytes	O
.	O
These	O
effects	O
are	O
receptor	O
-	O
dependent	O
,	O
reversible	O
,	O
and	O
according	O
to	O
serum	O
and	O
urinary	O
cortisol	O
levels	O
and	O
ITT	O
,	O
leave	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
function	O
intact	O
.	O
Finally	O
,	O
these	O
short	O
-	O
term	O
systemic	O
effects	O
were	O
not	O
associated	O
with	O
any	O
of	O
the	O
noticeable	O
side	O
-	O
effects	O
usually	O
observed	O
during	O
long	O
-	O
term	O
treatment	O
with	O
glucocorticoids	O
.	O
Transcriptional	O
activity	O
of	O
core	B
binding	I
factor	I
-	I
alpha	I
(	I
AML1	I
)	I
and	I
beta	I
subunits	O
on	O
murine	O
leukemia	O
virus	O
enhancer	O
cores	O
.	O
Core	B
binding	I
factor	I
(	O
CBF	B
)	O
,	O
also	O
known	O
as	O
polyomavirus	B
enhancer	I
-	I
binding	I
protein	I
2	I
and	O
SL3	B
enhancer	I
factor	I
1	I
,	O
is	O
a	O
mammalian	B
transcription	I
factor	I
that	O
binds	O
to	O
an	O
element	O
termed	O
the	O
core	O
within	O
the	O
enhancers	O
of	O
the	O
murine	O
leukemia	O
virus	O
family	O
of	O
retroviruses	O
.	O
The	O
core	O
elements	O
of	O
the	O
SL3	O
virus	O
are	O
important	O
genetic	O
determinants	O
of	O
the	O
ability	O
of	O
this	O
virus	O
to	O
induce	O
T	O
-	O
cell	O
lymphomas	O
and	O
the	O
transcriptional	O
activity	O
of	O
the	O
viral	O
long	O
terminal	O
repeat	O
in	O
T	O
lymphocytes	O
.	O
CBF	B
consists	O
of	O
two	O
subunits	O
,	O
a	O
DNA	B
binding	I
subunit	I
,	O
CBF	B
alpha	I
,	O
and	O
a	O
second	O
subunit	O
,	O
CBF	B
beta	I
,	O
that	O
stimulates	O
the	O
DNA	O
binding	O
activity	O
of	O
CBF	B
alpha	I
.	O
One	O
of	O
the	O
genes	O
that	O
encodes	O
a	O
CBF	B
alpha	I
subunit	I
is	O
AML1	B
,	O
also	O
called	O
Cbf	B
alpha	I
2	I
.	O
This	O
locus	O
is	O
rearranged	O
by	O
chromosomal	O
translocations	O
in	O
human	O
myeloproliferative	O
disorders	O
and	O
leukemias	O
.	O
An	O
exogenously	O
expressed	O
Cbf	B
alpha	I
2-encoded	I
subunit	I
(	O
CBF	B
alpha	I
2	I
-	I
451	I
)	O
stimulated	O
transcription	O
from	O
the	O
SL3	O
enhancer	O
in	O
P19	B
and	O
HeLa	O
cells	O
.	O
Activity	O
was	O
mediated	O
through	O
the	O
core	O
elements	O
.	O
Three	O
different	O
isoforms	O
of	O
CBF	B
beta	I
were	O
also	O
tested	O
for	O
transcriptional	O
activity	O
on	O
the	O
SL3	O
enhancer	O
.	O
The	O
longest	O
form	O
,	O
CBF	B
beta-187	I
,	O
increased	O
the	O
transcriptional	O
stimulation	O
by	O
CBF	B
alpha	I
2	I
-	I
451	I
twofold	O
in	O
HeLa	O
cells	O
,	O
although	O
it	O
had	O
no	O
effect	O
in	O
P19	O
cells	O
.	O
Transcriptional	O
activation	O
by	O
CBF	B
beta	I
required	O
binding	O
to	O
the	O
CBF	B
alpha	I
subunit	I
,	O
as	O
a	O
form	O
of	O
CBF	B
beta	I
that	O
lacked	O
binding	O
ability	O
,	O
CBF	B
beta-148	I
,	O
failed	O
to	O
increase	O
activity	O
.	O
These	O
results	O
indicated	O
that	O
at	O
least	O
in	O
certain	O
cell	O
types	O
,	O
the	O
maximum	O
activity	O
of	O
CBF	B
required	O
both	O
subunits	O
.	O
They	O
also	O
provided	O
support	O
for	O
the	O
hypothesis	O
that	O
CBF	B
is	O
a	O
factor	O
in	O
T	O
lymphocytes	O
that	O
is	O
responsible	O
for	O
recognition	O
of	O
the	O
SL3	O
cores	O
.	O
We	O
also	O
examined	O
whether	O
CBF	B
could	O
distinguish	O
a	O
1-bp	O
difference	O
between	O
the	O
enhancer	O
core	O
of	O
SL3	O
and	O
the	O
core	O
of	O
the	O
nonleukemogenic	O
virus	O
,	O
Akv	O
.	O
This	O
difference	O
strongly	O
affects	O
transcription	O
in	O
T	O
cells	O
and	O
leukemogenicity	O
of	O
SL3	O
.	O
However	O
,	O
no	O
combination	O
of	O
CBF	B
alpha	I
and	O
CBF	B
beta	I
subunits	O
that	O
we	O
tested	O
was	O
able	O
to	O
distinguish	O
the	O
1-bp	O
difference	O
in	O
transcription	O
assays	O
.	O
Thus	O
,	O
a	O
complete	O
understanding	O
of	O
how	O
T	O
cells	O
recognize	O
the	O
SL3	O
core	O
remains	O
to	O
be	O
elucidated	O
.	O
A	O
newly	O
established	O
megakaryoblastic	O
/	O
erythroid	O
cell	O
line	O
that	O
differentiates	O
to	O
red	O
cells	O
in	O
the	O
presence	O
of	O
erythropoietin	B
and	O
produces	O
platelet	O
-	O
like	O
particles	O
.	O
In	O
August	O
,	O
1992	O
,	O
we	O
established	O
a	O
leukemic	O
cell	O
line	O
(	O
NS	O
-	O
Meg	O
)	O
from	O
a	O
patient	O
in	O
megakaryoblastic	O
transformation	O
of	O
Philadelphia	O
chromosome	O
-	O
positive	O
chronic	O
myeloid	O
leukemia	O
.	O
The	O
NS	O
-	O
Meg	O
cells	O
were	O
positive	O
for	O
alpha	B
-	I
naphthyl	I
acetate	I
esterase	I
and	O
periodic	O
acid	O
-	O
Schiff	O
(	O
PAS	O
)	O
staining	O
and	O
for	O
surface	O
CD4	B
,	O
CD7	B
,	O
CD13	B
,	O
CD34	B
,	O
CD41a	B
,	O
and	O
glycophorin	B
A	I
antigens	I
.	O
Ultrastructurally	O
,	O
the	O
cells	O
had	O
alpha	O
-	O
granules	O
,	O
demarcation	O
membranes	O
,	O
and	O
platelet	B
peroxidase	I
activity	O
.	O
The	O
NS	O
-	O
Meg	O
cells	O
spontaneously	O
produced	O
platelet	O
-	O
like	O
particles	O
which	O
contained	O
alpha	O
-	O
granules	O
,	O
mitochondria	O
and	O
dense	O
bodies	O
,	O
strongly	O
suggesting	O
platelet	O
production	O
.	O
Erythropoietin	B
(	O
Epo	B
)	O
,	O
granulocyte	B
/	I
macrophage	I
colony	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
,	O
and	O
interleukin	B
3	I
(	O
IL-3	B
)	O
promoted	O
the	O
growth	O
of	O
NS	O
-	O
Meg	O
cells	O
.	O
Phorbol-12-myristate-13-acetate	O
increased	O
the	O
expression	O
of	O
both	O
CD41a	B
and	O
CD61	O
antigens	O
.	O
Ten	O
-	O
day	O
exposure	O
to	O
Epo	B
induced	O
mature	O
erythroblasts	O
and	O
red	O
cells	O
.	O
These	O
benzidine	O
-	O
positive	O
cells	O
were	O
positive	O
for	O
hemoglobin	B
F	O
staining	O
.	O
Untreated	O
NS	O
-	O
Meg	O
cells	O
expressed	O
mRNA	O
for	O
the	O
Epo	B
receptor	I
(	O
EpoR	B
)	O
,	O
for	O
GATA-1	B
,	O
and	O
for	O
alpha	O
1	O
,	O
alpha	O
2	O
and	O
gamma	O
globin	O
genes	O
.	O
These	O
results	O
indicate	O
that	O
NS	O
-	O
Meg	O
cells	O
undergo	O
terminal	O
differentiation	O
of	O
both	O
megakaryocytic	O
and	O
erythroid	O
lineages	O
.	O
This	O
cell	O
line	O
should	O
be	O
a	O
very	O
useful	O
tool	O
for	O
the	O
investigation	O
of	O
both	O
megakaryocytic	O
and	O
erythroid	O
maturation	O
.	O
The	O
role	O
of	O
shared	B
receptor	I
motifs	I
and	O
common	B
Stat	I
proteins	I
in	O
the	O
generation	O
of	O
cytokine	B
pleiotropy	O
and	O
redundancy	O
by	O
IL-2	B
,	O
IL-4	B
,	O
IL-7	B
,	O
IL-13	B
,	O
and	O
IL-15	B
.	O
To	O
understand	O
the	O
molecular	O
bases	O
for	O
cytokine	O
redundancy	O
and	O
pleiotropy	O
,	O
we	O
have	O
compared	O
the	O
Stat	B
proteins	I
activated	O
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBLs	O
)	O
by	O
cytokines	B
with	O
shared	O
and	O
distinct	O
actions	O
.	O
Interleukin-2	B
(	O
IL-2	B
)	O
rapidly	O
activated	O
Stat5	B
in	O
fresh	O
PBL	O
,	O
and	O
Stat3	B
and	O
Stat5	B
in	O
preactivated	O
PBL	O
.	O
IL-7	B
and	O
IL-15	B
induced	O
the	O
same	O
complexes	O
as	O
IL-2	B
,	O
a	O
feature	O
explained	O
by	O
the	O
existence	O
of	O
similar	O
tyrosine	B
-	I
phosphorylated	I
motifs	I
in	O
the	O
cytoplasmic	B
domains	I
of	O
IL-2R	B
beta	I
and	O
IL-7R	B
that	O
can	O
serve	O
as	O
docking	O
sites	O
for	O
Stat	B
proteins	I
.	O
IL-13	B
Induced	O
the	O
same	O
complexes	O
as	O
IL-4	B
,	O
a	O
finding	O
explained	O
by	O
our	O
studies	O
implicating	O
IL-4R	B
as	O
a	O
shared	O
component	O
of	O
the	O
receptors	B
.	O
These	O
studies	O
demonstrate	O
that	O
a	O
single	O
cytokine	B
can	O
activate	O
different	O
combinations	O
of	O
Stat	B
proteins	I
under	O
different	O
physiological	O
conditions	O
,	O
and	O
also	O
indicate	O
two	O
mechanisms	O
by	O
which	O
distinct	O
cytokines	B
can	O
activate	O
the	O
same	O
Stat	B
protein	I
.	O
Induction	O
of	O
transcription	B
factors	I
in	O
human	O
T	O
lymphocytes	O
by	O
aspirin	O
-	O
like	O
drugs	O
.	O
Aspirin	O
-	O
like	O
drugs	O
(	O
ALD	O
)	O
induce	O
calcium	O
mobilization	O
,	O
an	O
essential	O
component	O
of	O
T	O
cell	O
activation	O
,	O
but	O
do	O
not	O
induce	O
the	O
biosynthesis	O
of	O
IL-2	B
.	O
To	O
understand	O
the	O
extent	O
to	O
which	O
ALD	O
may	O
mimic	O
mitogenic	O
stimulation	O
,	O
we	O
studied	O
cytoplasmic	O
and	O
nuclear	O
signaling	O
steps	O
in	O
ALD	O
-	O
treated	O
T	O
cells	O
.	O
We	O
found	O
that	O
ALD	O
induce	O
a	O
transient	O
activation	O
of	O
protein	B
kinase	I
(	O
PKC	B
)	O
but	O
have	O
no	O
effect	O
(	O
in	O
comparison	O
to	O
anti	B
-	I
CD3	I
antibodies	I
)	O
on	O
protein	O
tyrosine	O
phosphorylation	O
nor	O
on	O
PCL	O
gamma	O
1	O
tyrosine	O
phosphorylation	O
.	O
ALD	O
-	O
induced	O
calcium	O
mobilization	O
and	O
PKC	B
activation	O
are	O
independent	O
of	O
tyrosine	B
protein	I
kinase	I
activity	O
as	O
shown	O
by	O
the	O
lack	O
of	O
effect	O
of	O
herbimycin	O
,	O
a	O
tyrosine	B
-	I
protein	I
kinase	I
-specific	O
inhibitor	O
.	O
Although	O
we	O
detected	O
no	O
IL-2	O
mRNA	O
in	O
ALD	O
-	O
treated	O
cells	O
,	O
the	O
nuclei	O
of	O
these	O
cells	O
contain	O
proteins	O
capable	O
of	O
binding	O
to	O
three	O
regulatory	O
sequences	O
in	O
the	O
IL-2	O
promoter	O
region	O
:	O
NFAT	B
,	O
NF	B
kappa	I
B	I
,	O
and	O
AP-1	B
.	O
These	O
binding	O
activities	O
are	O
expressed	O
only	O
in	O
activated	O
T	O
cells	O
.	O
The	O
expression	O
of	O
AP-1	B
depended	O
on	O
calcium	O
mobilization	O
and	O
PKC	B
activation	O
.	O
These	O
data	O
suggest	O
that	O
ALD	O
cause	O
transient	O
but	O
significant	O
changes	O
in	O
T	O
cell	O
transmembrane	O
signaling	O
,	O
although	O
some	O
events	O
induced	O
by	O
stimulation	O
with	O
anti	B
-	I
CD3	I
antibodies	I
are	O
not	O
induced	O
by	O
ALD	O
.	O
The	O
signal	O
is	O
transmitted	O
to	O
the	O
nucleus	O
and	O
induces	O
DNA	O
-	O
binding	O
activity	O
by	O
several	O
transcription	B
factors	I
.	O
However	O
,	O
the	O
ALD	O
stimulus	O
is	O
not	O
capable	O
of	O
causing	O
complete	O
T	O
cell	O
activation	O
.	O
Functional	O
roles	O
of	O
in	O
vivo	O
footprinted	O
DNA	O
motifs	O
within	O
an	O
alpha	O
-	O
globin	O
enhancer	O
.	O
Erythroid	O
lineage	O
and	O
developmental	O
stage	O
specificities	O
.	O
Transcriptional	O
regulation	O
of	O
the	O
human	O
alpha	O
-	O
like	O
globin	O
genes	O
,	O
embryonic	O
zeta	O
2	O
and	O
adult	O
alpha	O
,	O
during	O
erythroid	O
development	O
is	O
mediated	O
by	O
a	O
distal	O
enhancer	O
,	O
HS-40	O
.	O
Previous	O
protein	O
-	O
DNA	O
binding	O
studies	O
have	O
shown	O
that	O
HS-40	O
consists	O
of	O
multiple	O
nuclear	O
factor	O
binding	O
motifs	O
that	O
are	O
occupied	O
in	O
vivo	O
in	O
an	O
erythroid	O
lineage-	O
and	O
developmental	O
stage	O
-	O
specific	O
manner	O
.	O
We	O
have	O
systematically	O
analyzed	O
the	O
functional	O
roles	O
of	O
these	O
factor	O
binding	O
motifs	O
of	O
HS-40	O
by	O
site	O
-	O
directed	O
mutagenesis	O
and	O
transient	O
expression	O
assay	O
in	O
erythroid	O
cell	O
cultures	O
.	O
Three	O
of	O
these	O
HS-40	O
enhancer	O
motifs	O
,	O
5'NF	O
-	O
E2	O
/	O
AP1	O
,	O
GT	O
II	O
,	O
and	O
GATA-1	O
(	O
c	O
)	O
,	O
positively	O
regulate	O
the	O
zeta	O
2-globin	O
promoter	O
activity	O
in	O
embryonic	O
/	O
fetal	O
erythroid	O
K562	O
cells	O
and	O
the	O
adult	O
alpha	O
-	O
globin	O
promoter	O
activity	O
in	O
adult	O
erythroid	O
MEL	O
cells	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
3'NF	O
-	O
E2	O
/	O
AP1	O
motif	O
is	O
able	O
to	O
exert	O
both	O
positive	O
and	O
negative	O
regulatory	O
effects	O
on	O
the	O
zeta	O
2-globin	O
promoter	O
activity	O
in	O
K562	O
cells	O
,	O
and	O
this	O
dual	O
function	O
appears	O
to	O
be	O
modulated	O
through	O
differential	O
binding	O
of	O
the	O
ubiquitous	B
AP1	I
factors	I
and	O
the	O
erythroid	B
-	I
enriched	I
NF	I
-	I
E2	I
factor	I
.	O
Mutation	O
in	O
the	O
GATA-1	O
(	O
d	O
)	O
motif	O
,	O
which	O
exhibits	O
an	O
adult	O
erythroid	O
-	O
specific	O
genomic	O
footprint	O
,	O
decreases	O
the	O
HS-40	O
enhancer	O
function	O
in	O
dimethyl	O
sulfoxide	O
-	O
induced	O
MEL	O
cells	O
but	O
not	O
in	O
K562	O
cells	O
.	O
These	O
studies	O
have	O
defined	O
the	O
regulatory	O
roles	O
of	O
the	O
different	O
HS-40	O
motifs	O
.	O
The	O
remarkable	O
correlation	O
between	O
genomic	O
footprinting	O
data	O
and	O
the	O
mutagenesis	O
results	O
also	O
suggests	O
that	O
the	O
erythroid	O
lineage-	O
and	O
developmental	O
stage	O
-	O
specific	O
regulation	O
of	O
human	O
alpha	O
-	O
like	O
globin	O
promoters	O
is	O
indeed	O
modulated	O
by	O
stable	O
binding	O
of	O
specific	B
nuclear	I
factors	I
in	O
vivo	O
.	O
Interleukin	B
(	I
IL	I
)	I
-10	I
inhibits	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
kappa	I
B	I
)	O
activation	O
in	O
human	O
monocytes	O
.	O
IL-10	B
and	O
IL-4	B
suppress	O
cytokine	B
synthesis	O
by	O
different	O
mechanisms	O
.	O
Our	O
previous	O
studies	O
in	O
human	O
monocytes	O
have	O
demonstrated	O
that	O
interleukin	B
(	I
IL	I
)	I
-10	I
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-stimulated	O
production	O
of	O
inflammatory	B
cytokines	I
,	O
IL-1	B
beta	I
,	O
IL-6	B
,	O
IL-8	B
,	O
and	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
-alpha	I
by	O
blocking	O
gene	O
transcription	O
.	O
Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
,	O
we	O
now	O
show	O
that	O
,	O
in	O
monocytes	O
stimulated	O
with	O
LPS	O
or	O
TNF	B
alpha	I
,	O
IL-10	B
inhibits	O
nuclear	O
stimulation	O
of	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
kappa	I
B	I
)	O
,	O
a	O
transcription	B
factor	I
involved	O
in	O
the	O
expression	O
of	O
inflammatory	O
cytokine	O
genes	O
.	O
Several	O
other	O
transcription	B
factors	I
including	O
NF-	O
IL-6	B
,	O
AP-1	B
,	O
AP-2	B
,	O
GR	B
,	O
CREB	B
,	O
Oct-1	B
,	O
and	O
Sp-1	B
are	O
not	O
affected	O
by	O
IL-10	B
.	O
This	O
selective	O
inhibition	O
by	O
IL-10	B
of	O
NF	B
kappa	I
B	I
activation	O
occurs	O
rapidly	O
and	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
correlates	O
well	O
with	O
IL-10	B
's	O
cytokine	B
synthesis	O
inhibitory	O
activity	O
in	O
terms	O
of	O
both	O
kinetics	O
and	O
dose	O
responsiveness	O
.	O
Furthermore	O
,	O
compounds	O
such	O
as	O
tosylphenylalanyl	O
chloromethyl	O
ketone	O
and	O
pyrrolidinedithiocarbamate	O
that	O
are	O
known	O
to	O
selectively	O
inhibit	O
NF	B
kappa	I
B	I
activation	O
block	O
cytokine	O
gene	O
transcription	O
in	O
LPS	O
-	O
stimulated	O
monocytes	O
.	O
Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
inhibition	O
of	O
NF	B
kappa	I
B	I
activation	O
may	O
be	O
an	O
important	O
mechanism	O
for	O
IL-10	B
suppression	O
of	O
cytokine	O
gene	O
transcription	O
in	O
human	O
monocytes	O
.	O
IL-4	B
,	O
another	O
cytokine	B
that	O
inhibits	O
cytokine	O
mRNA	O
accumulation	O
in	O
monocytes	O
,	O
shows	O
little	O
inhibitory	O
effect	O
on	O
LPS	O
-	O
induced	O
NF	B
kappa	I
B	I
activation	O
.	O
Further	O
examination	O
reveals	O
that	O
,	O
unlike	O
IL-10	B
,	O
IL-4	B
enhances	O
mRNA	O
degradation	O
and	O
does	O
not	O
suppress	O
cytokine	O
gene	O
transcription	O
.	O
These	O
data	O
indicate	O
that	O
IL-10	B
and	O
IL-4	B
inhibit	O
cytokine	B
production	O
by	O
different	O
mechanisms	O
.	O
Identification	O
of	O
a	O
major	O
positive	O
regulatory	O
element	O
located	O
5	O
'	O
to	O
the	O
human	O
zeta	O
-	O
globin	O
gene	O
.	O
The	O
function	O
of	O
the	O
zeta	O
-	O
globin	O
promoter	O
was	O
studied	O
using	O
a	O
series	O
of	O
zeta	O
-	O
globin	O
promoter	O
deletion	O
constructs	O
to	O
drive	O
luciferase	B
expression	O
in	O
transiently	O
transfected	O
human	O
erythroleukemia	O
cells	O
.	O
The	O
promoters	O
were	O
used	O
without	O
enhancers	O
,	O
or	O
with	O
enhancers	O
derived	O
from	O
the	O
beta	O
-	O
globin	O
locus	O
control	O
region	O
and	O
the	O
alpha	O
-	O
globin	O
HS-40	O
enhancer	O
.	O
When	O
transfected	O
into	O
K562	O
cells	O
,	O
which	O
express	O
zeta	B
-	I
globin	I
,	O
comparable	O
amounts	O
of	O
activity	O
were	O
obtained	O
from	O
the	O
-557	O
and	O
-417	O
zeta	O
-	O
luciferase	O
constructs	O
and	O
the	O
alpha	O
-	O
luciferase	O
constructs	O
when	O
no	O
enhancers	O
or	O
the	O
alpha	O
-	O
globin	O
locus	O
enhancers	O
were	O
used	O
.	O
When	O
the	O
constructs	O
were	O
transfected	O
into	O
OCIM1	O
cells	O
,	O
which	O
do	O
not	O
express	O
zeta	B
-	I
globin	I
,	O
the	O
zeta	O
-	O
globin	O
promoters	O
were	O
at	O
best	O
20	O
%	O
as	O
active	O
as	O
the	O
alpha	O
-	O
globin	O
promoters	O
.	O
When	O
sequences	O
from	O
-417	O
to	O
-207	O
5	O
'	O
to	O
the	O
zeta	O
-	O
globin	O
mRNA	O
cap	O
site	O
were	O
deleted	O
,	O
up	O
to	O
95	O
%	O
of	O
the	O
zeta	O
-	O
globin	O
promoter	O
activity	O
was	O
lost	O
in	O
K562	O
cells	O
.	O
Reinsertion	O
of	O
these	O
sequences	O
into	O
zeta	O
-	O
luciferase	O
constructs	O
missing	O
the	O
-417	O
to	O
-207	O
region	O
showed	O
that	O
the	O
sequences	O
lack	O
classical	O
enhancer	O
activity	O
.	O
Point	O
mutation	O
of	O
a	O
GATA-1	O
site	O
at	O
-230	O
reduced	O
promoter	O
activity	O
by	O
37	O
%	O
.	O
Point	O
mutation	O
of	O
a	O
CCACC	O
site	O
at	O
-240	O
had	O
no	O
effect	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
that	O
the	O
-230	O
GATA-1	O
site	O
has	O
a	O
relatively	O
low	O
affinity	O
for	O
GATA-1	B
.	O
These	O
experiments	O
show	O
the	O
presence	O
of	O
a	O
strong	O
positive	O
-	O
acting	O
element	O
,	O
located	O
between	O
-417	O
and	O
-207	O
bp	O
5	O
'	O
to	O
the	O
zeta	O
-	O
globin	O
mRNA	O
cap	O
site	O
,	O
is	O
necessary	O
for	O
high	O
-	O
level	O
promoter	O
activity	O
in	O
K562	O
cells	O
.	O
This	O
element	O
requires	O
GATA-1	B
and	O
additional	B
unknown	I
factors	I
for	O
maximal	O
activity	O
.	O
Activation	O
of	O
transcription	O
by	O
binding	O
of	O
NF	B
-	I
E1	I
(	O
YY1	B
)	O
to	O
a	O
newly	O
identified	O
element	O
in	O
the	O
first	O
exon	O
of	O
the	O
human	O
DR	O
alpha	O
gene	O
.	O
A	O
previously	O
unrecognized	O
element	O
,	O
located	O
downstream	O
of	O
the	O
start	O
site	O
of	O
transcription	O
in	O
the	O
first	O
exon	O
of	O
the	O
DR	O
alpha	O
gene	O
,	O
has	O
been	O
defined	O
that	O
enhances	O
promoter	O
activity	O
up	O
to	O
eightfold	O
in	O
a	O
position	O
-	O
dependent	O
manner	O
.	O
Mutations	O
in	O
this	O
DNA	O
-	O
binding	O
site	O
abolished	O
binding	O
of	O
a	O
nuclear	B
factor	I
in	O
human	O
B	O
cell	O
nuclear	O
extract	O
and	O
decreased	O
the	O
activity	O
of	O
the	O
DR	O
alpha	O
promoter	O
to	O
a	O
basal	O
level	O
.	O
Significant	O
sequence	O
homology	O
of	O
this	O
element	O
was	O
found	O
in	O
the	O
DNA	O
of	O
the	O
DR	O
beta	O
,	O
DP	O
alpha	O
and	O
-beta	O
,	O
and	O
DQ	O
alpha	O
genes	O
,	O
always	O
located	O
downstream	O
of	O
the	O
transcriptional	O
start	O
site	O
.	O
The	O
nuclear	O
factor	O
binds	O
to	O
the	O
DR	O
alpha	O
and	O
DP	O
alpha	O
element	O
but	O
not	O
to	O
the	O
element	O
in	O
the	O
DQ	O
alpha	O
gene	O
.	O
It	O
was	O
identified	O
as	O
NF	B
-	I
E1	I
(	O
YY1	B
)	O
.	O
This	O
protein	O
,	O
previously	O
identified	O
by	O
its	O
binding	O
to	O
the	O
Ig	O
kappa	O
3	O
'	O
enhancer	O
and	O
the	O
Ig	O
heavy	O
chain	O
mu	O
E1	O
site	O
,	O
thus	O
also	O
appears	O
to	O
be	O
quite	O
important	O
in	O
the	O
regulation	O
of	O
MHC	O
class	O
II	O
gene	O
expression	O
.	O
Monocyte	O
tethering	O
by	O
P	B
-	I
selectin	I
regulates	O
monocyte	B
chemotactic	I
protein-1	I
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
secretion	O
.	O
Signal	O
integration	O
and	O
NF	B
-	I
kappa	I
B	I
translocation	O
[	O
see	O
comments	O
]	O
Adhesion	B
molecules	I
that	O
tether	O
circulating	O
leukocytes	O
to	O
endothelial	O
cells	O
may	O
also	O
transduce	O
or	O
modulate	O
outside	O
-	O
in	O
signals	O
for	O
cellular	O
activation	O
,	O
providing	O
an	O
initial	O
regulatory	O
point	O
in	O
the	O
inflammatory	O
response	O
.	O
Adhesion	O
of	O
human	O
monocytes	O
to	O
P	B
-	I
selectin	I
,	O
the	O
most	O
rapidly	O
expressed	O
endothelial	B
tethering	I
factor	I
,	O
increased	O
the	O
secretion	O
of	O
monocyte	B
chemotactic	I
protein-1	I
(	O
MCP-1	B
)	O
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
by	O
the	O
leukocytes	O
when	O
they	O
were	O
stimulated	O
with	O
platelet	B
-	I
activating	I
factor	I
.	O
Increased	O
cytokine	O
secretion	O
was	O
specifically	O
inhibited	O
by	O
G1	B
,	O
an	O
anti	B
-	I
P	I
-	I
selectin	I
mAb	I
that	O
prevents	O
P	B
-	I
selectin	I
from	O
binding	O
to	O
its	O
ligand	O
(	O
P	B
-	I
selectin	I
glycoprotein	I
ligand-1	I
)	O
on	O
myeloid	O
cells	O
.	O
Moreover	O
,	O
tethering	O
by	O
P	B
-	I
selectin	I
specifically	O
enhanced	O
nuclear	O
translocation	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
,	O
a	O
transcription	B
factor	I
required	O
for	O
expression	O
of	O
MCP-1	B
,	O
TNF	B
-	I
alpha	I
,	O
and	O
other	O
immediate	O
-	O
early	O
genes	O
.	O
These	O
results	O
demonstrate	O
that	O
P	B
-	I
selectin	I
,	O
through	O
its	O
ligands	O
on	O
monocytes	O
,	O
may	O
locally	O
regulate	O
cytokine	B
secretion	O
in	O
inflamed	O
tissues	O
.	O
Coupling	O
of	O
a	O
signal	B
response	I
domain	I
in	O
I	B
kappa	I
B	I
alpha	I
to	O
multiple	O
pathways	O
for	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
The	O
eukaryotic	B
transcription	I
factor	I
NF	B
-	I
kappa	I
B	I
plays	O
a	O
central	O
role	O
in	O
the	O
induced	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
in	O
many	O
aspects	O
of	O
the	O
genetic	O
program	O
mediating	O
normal	O
T	O
-	O
cell	O
activation	O
and	O
growth	O
.	O
The	O
nuclear	O
activity	O
of	O
NF	B
-	I
kappa	I
B	I
is	O
tightly	O
regulated	O
from	O
the	O
cytoplasmic	O
compartment	O
by	O
an	O
inhibitory	B
subunit	I
called	O
I	B
kappa	I
B	I
alpha	I
.	O
This	O
cytoplasmic	O
inhibitor	O
is	O
rapidly	O
phosphorylated	O
and	O
degraded	O
in	O
response	O
to	O
a	O
diverse	O
set	O
of	O
NF	B
-	I
kappa	I
B	I
-	I
inducing	I
agents	I
,	O
including	O
T	B
-	I
cell	I
mitogens	I
,	I
proinflammatory	B
cytokines	I
,	O
and	O
viral	B
transactivators	I
such	O
as	O
the	O
Tax	B
protein	I
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
.	O
To	O
explore	O
these	O
I	B
kappa	I
B	I
alpha	I
-dependent	O
mechanisms	O
for	O
NF	B
-	I
kappa	I
B	I
induction	O
,	O
we	O
identified	O
novel	O
mutants	O
of	O
I	B
kappa	I
B	I
alpha	I
that	O
uncouple	O
its	O
inhibitory	O
and	O
signal	O
-	O
transducing	O
functions	O
in	O
human	O
T	O
lymphocytes	O
.	O
Specifically	O
,	O
removal	O
of	O
the	O
N	B
-	I
terminal	I
36	I
amino	I
acids	I
of	O
I	B
kappa	I
B	I
alpha	I
failed	O
to	O
disrupt	O
its	O
ability	O
to	O
form	O
latent	O
complexes	O
with	O
NF	B
-	I
kappa	I
B	I
in	O
the	O
cytoplasm	O
.	O
However	O
,	O
this	O
deletion	O
mutation	O
prevented	O
the	O
induced	O
phosphorylation	O
,	O
degradative	O
loss	O
,	O
and	O
functional	O
release	O
of	O
I	B
kappa	I
B	I
alpha	I
from	O
NF	B
-	I
kappa	I
B	I
in	O
Tax	O
-	O
expressing	O
cells	O
.	O
Alanine	O
substitutions	O
introduced	O
at	O
two	O
serine	O
residues	O
positioned	O
within	O
this	O
N	B
-	I
terminal	I
regulatory	I
region	I
of	O
I	B
kappa	I
B	I
alpha	I
also	O
yielded	O
constitutive	O
repressors	O
that	O
escaped	O
from	O
Tax	B
-induced	O
turnover	O
and	O
that	O
potently	O
inhibited	O
immune	O
activation	O
pathways	O
for	O
NF	B
-	I
kappa	I
B	I
induction	O
,	O
including	O
those	O
initiated	O
from	O
antigen	B
and	I
cytokine	I
receptors	I
.	O
In	O
contrast	O
,	O
introduction	O
of	O
a	O
phosphoserine	O
mimetic	O
at	O
these	O
sites	O
rectified	O
this	O
functional	O
defect	O
,	O
a	O
finding	O
consistent	O
with	O
a	O
causal	O
linkage	O
between	O
the	O
phosphorylation	O
status	O
and	O
proteolytic	O
stability	O
of	O
this	O
cytoplasmic	B
inhibitor	I
.	O
Together	O
,	O
these	O
in	O
vivo	O
studies	O
define	O
a	O
critical	O
signal	O
response	O
domain	O
in	O
I	B
kappa	I
B	I
alpha	I
that	O
coordinately	O
controls	O
the	O
biologic	O
activities	O
of	O
I	B
kappa	I
B	I
alpha	I
and	O
NF	B
-	I
kappa	I
B	I
in	O
response	O
to	O
viral	O
and	O
immune	O
stimuli	O
.	O
HIV	O
type	O
1	O
protease	B
activation	O
of	O
NF	B
-	I
kappa	I
B	I
within	O
T	O
lymphoid	O
cells	O
.	O
NF	B
-	I
kappa	I
B	I
is	O
a	O
nuclear	B
protein	I
of	O
the	O
rel	B
oncogene	I
family	I
capable	O
of	O
enhancing	O
transcription	O
of	O
several	O
cellular	O
genes	O
,	O
including	O
IL-2	B
and	O
the	O
IL-2	B
receptor	I
,	O
and	O
viral	O
genes	O
transcribed	O
from	O
the	O
HIV-1	O
LTR	O
.	O
It	O
has	O
been	O
reported	O
that	O
HIV-1	B
protease	I
may	O
cleave	O
the	O
NF	B
-	I
kappa	I
B	I
precursor	O
to	O
its	O
active	O
form	O
in	O
vitro	O
.	O
In	O
this	O
study	O
the	O
effects	O
of	O
HIV	O
protease	O
on	O
NF	B
-	I
kappa	I
B	I
precursor	O
activation	O
were	O
examined	O
in	O
Jurkat	O
T	O
cells	O
by	O
introducing	O
a	O
protease	O
expression	O
vector	O
into	O
the	O
cells	O
.	O
Increased	O
NF	B
-	I
kappa	I
B	I
activity	O
was	O
observed	O
and	O
this	O
increased	O
activity	O
was	O
blocked	O
by	O
a	O
specific	O
inhibitor	O
of	O
the	O
viral	B
protease	I
.	O
Viral	O
transcription	O
,	O
as	O
measured	O
using	O
LTR	O
-CAT	B
assays	O
,	O
was	O
only	O
slightly	O
enhanced	O
in	O
the	O
HIV	O
-	O
protease	O
expressing	O
cells	O
,	O
while	O
secretion	O
of	O
IL-2	B
and	O
expression	O
of	O
the	O
IL-2	B
receptor	O
were	O
not	O
affected	O
.	O
The	O
limited	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
by	O
HIV	B
protease	I
appears	O
unlikely	O
to	O
have	O
a	O
significant	O
effect	O
on	O
virus	O
expression	O
or	O
T	O
cell	O
function	O
.	O
The	O
use	O
of	O
glucocorticoids	O
in	O
acute	O
lymphoblastic	O
leukemia	O
of	O
childhood	O
.	O
Molecular	O
,	O
cellular	O
,	O
and	O
clinical	O
considerations	O
.	O
Glucocorticoids	O
have	O
been	O
included	O
in	O
almost	O
all	O
treatment	O
regimens	O
for	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
for	O
decades	O
.	O
However	O
,	O
optimal	O
agents	O
,	O
doses	O
,	O
and/or	O
schedules	O
have	O
yet	O
to	O
be	O
defined	O
despite	O
extensive	O
clinical	O
application	O
.	O
New	O
data	O
on	O
the	O
pharmacokinetics	O
,	O
pharmacodynamics	O
,	O
and	O
molecular	O
mechanisms	O
of	O
action	O
of	O
glucocorticoids	O
have	O
suggested	O
alternative	O
approaches	O
in	O
ALL	O
.	O
These	O
suggest	O
that	O
prolonged	O
,	O
i.e.	O
28	O
day	O
,	O
glucocorticoid	O
therapy	O
may	O
be	O
unnecessary	O
as	O
exposure	O
to	O
glucocorticoid	O
induces	O
down	O
-	O
regulation	O
of	O
glucocorticoid	B
receptors	I
.	O
Dexamethasone	O
may	O
be	O
superior	O
to	O
prednisone	O
in	O
conventional	O
equi	O
-	O
effective	O
doses	O
.	O
Blast	O
sensitivity	O
to	O
glucocorticoids	O
correlates	O
closely	O
with	O
sensitivity	O
to	O
other	O
,	O
putatively	O
non	O
-	O
cross	O
-	O
resisting	O
agents	O
and	O
with	O
outcome	O
after	O
multi	O
-	O
agent	O
therapy	O
,	O
suggesting	O
overlapping	O
mechanisms	O
of	O
action	O
,	O
and	O
focusing	O
attention	O
on	O
the	O
determinants	O
of	O
the	O
threshold	O
for	O
apoptosis	O
.	O
Increasing	O
success	O
in	O
the	O
treatment	O
of	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
has	O
led	O
to	O
increasing	O
awareness	O
of	O
avascular	O
necrosis	O
of	O
bone	O
as	O
a	O
potentially	O
disabling	O
sequela	O
of	O
glucocorticoid	O
therapy	O
,	O
especially	O
in	O
adolescent	O
and	O
young	O
adult	O
patients	O
.	O
Human	O
MHC	O
class	O
II	O
gene	O
transcription	O
directed	O
by	O
the	O
carboxyl	B
terminus	I
of	O
CIITA	O
,	O
one	O
of	O
the	O
defective	O
genes	O
in	O
type	O
II	O
MHC	B
combined	O
immune	O
deficiency	O
.	O
Type	B
II	I
major	I
histocompatibility	I
complex	I
combined	O
immune	O
deficiency	O
(	O
type	O
II	O
MHC	B
CID	O
or	O
bare	O
lymphocyte	O
syndrome	O
)	O
is	O
a	O
congenital	O
immunodeficiency	O
disease	O
characterized	O
by	O
absent	O
MHC	B
class	I
II	I
expression	O
.	O
Four	O
distinct	O
complementation	O
groups	O
have	O
been	O
identified	O
.	O
Recently	O
,	O
the	O
defective	O
gene	O
in	O
group	O
II	O
type	O
II	O
MHC	B
CID	O
has	O
been	O
isolated	O
and	O
termed	O
CIITA	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
CIITA	O
is	O
an	O
MHC	O
class	O
II	O
gene	O
-	O
specific	O
transcription	O
activator	O
.	O
The	O
transcription	O
activation	O
function	O
is	O
provided	O
by	O
the	O
N	B
-	I
terminal	I
acidic	I
domain	I
(	O
amino	B
acids	I
26	I
-	I
137	I
)	O
,	O
which	O
is	O
experimentally	O
exchangeable	O
with	O
a	O
heterologous	B
viral	I
transcription	I
-	I
activating	I
domain	I
.	O
The	O
specificity	O
of	O
CIITA	B
for	O
three	O
major	O
MHC	O
class	O
II	O
genes	O
,	O
DR	O
,	O
DQ	O
and	O
DP	O
,	O
is	O
mediated	O
by	O
its	O
remaining	O
C	B
-	I
terminal	I
residues	I
(	O
amino	B
acids	I
317	I
-	I
1130	I
)	O
.	O
The	O
transactivation	O
of	O
multiple	O
cis	O
elements	O
,	O
especially	O
S	O
and	O
X2	O
,	O
of	O
the	O
DR	O
alpha	O
proximal	O
promoter	O
in	O
group	O
II	O
CID	O
cells	O
is	O
CIITA	B
dependent	O
.	O
Since	O
CIITA	B
overexpression	O
in	O
normal	O
cells	O
did	O
not	O
increase	O
class	O
II	O
expression	O
,	O
we	O
propose	O
that	O
initiation	O
of	O
CIITA	B
expression	O
serves	O
as	O
the	O
on	O
-	O
off	O
switch	O
,	O
while	O
availability	O
of	O
downstream	O
interactor	O
(	O
s	O
)	O
limits	O
transcription	O
.	O
CAG	O
repeat	O
length	O
variation	O
in	O
sperm	O
from	O
a	O
patient	O
with	O
Kennedy	O
's	O
disease	O
.	O
Using	O
a	O
modified	O
sperm	O
typing	O
protocol	O
,	O
the	O
mutation	O
frequency	O
of	O
the	O
CAG	O
repeat	O
region	O
at	O
the	O
androgen	O
receptor	O
locus	O
has	O
been	O
measured	O
using	O
a	O
rare	O
semen	O
sample	O
from	O
an	O
individual	O
with	O
spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
(	O
SBMA	O
)	O
.	O
Among	O
258	O
X	O
chromosome	O
-	O
containing	O
sperm	O
,	O
19	O
%	O
had	O
a	O
repeat	O
number	O
equal	O
to	O
the	O
donor	O
's	O
somatic	O
DNA	O
(	O
47	O
repeats	O
)	O
,	O
66	O
%	O
were	O
expansions	O
and	O
15	O
%	O
were	O
contractions	O
.	O
The	O
average	O
expansion	O
was	O
2.7	O
repeats	O
.	O
More	O
than	O
half	O
of	O
the	O
expansions	O
involved	O
one	O
or	O
two	O
repeats	O
;	O
the	O
largest	O
was	O
11	O
repeats	O
.	O
68	O
%	O
of	O
the	O
contractions	O
were	O
also	O
one	O
or	O
two	O
repeats	O
but	O
six	O
(	O
16	O
%	O
)	O
were	O
very	O
large	O
(	O
12	O
-	O
25	O
repeats	O
)	O
.	O
One	O
contraction	O
generated	O
an	O
allele	O
in	O
an	O
intermediate	O
size	O
range	O
(	O
33	O
-	O
39	O
repeats	O
)	O
.	O
Such	O
alleles	O
have	O
not	O
been	O
observed	O
among	O
more	O
than	O
900	O
normal	O
and	O
SBMA	O
X	O
-	O
chromosomes	O
that	O
have	O
been	O
examined	O
.	O
Comparison	O
of	O
the	O
SBMA	O
sperm	O
typing	O
results	O
with	O
mutation	O
frequency	O
data	O
on	O
normal	O
alleles	O
supports	O
the	O
hypothesis	O
that	O
trinucleotide	O
repeat	O
expansions	O
may	O
have	O
a	O
different	O
molecular	O
origin	O
than	O
contractions	O
.	O
Isolation	O
of	O
differentially	O
expressed	O
sequence	O
tags	O
from	O
steroid	O
-	O
responsive	O
cells	O
using	O
mRNA	O
differential	O
display	O
.	O
Transcriptional	O
control	O
of	O
steroid	O
-	O
regulated	O
gene	O
networks	O
by	O
nuclear	B
receptor	I
proteins	I
results	O
in	O
the	O
coordinate	O
expression	O
of	O
a	O
limited	O
number	O
of	O
target	O
genes	O
.	O
Although	O
much	O
is	O
known	O
about	O
the	O
structure	O
and	O
function	O
of	O
steroid	O
receptors	O
,	O
relatively	O
few	O
cell	O
-	O
specific	O
steroid	O
-	O
regulated	O
genes	O
have	O
been	O
isolated	O
and	O
characterized	O
.	O
In	O
this	O
paper	O
we	O
describe	O
results	O
using	O
mRNA	O
differential	O
display	O
reverse	B
transcriptase	I
PCR	O
(	O
DDPCR	O
)	O
to	O
identify	O
and	O
isolate	O
short	O
cDNA	O
sequence	O
tags	O
from	O
thymocyte	O
and	O
prostate	O
cells	O
under	O
various	O
hormone	O
conditions	O
.	O
Using	O
this	O
technique	O
we	O
have	O
isolated	O
several	O
differentially	O
expressed	O
sequence	O
tags	O
(	O
DESTs	O
)	O
from	O
the	O
mouse	O
thymocyte	O
cell	O
line	O
WEHI	O
7.2	O
.	O
Two	O
of	O
these	O
DESTs	O
,	O
GIG10	O
and	O
GIG18	O
,	O
are	O
rapidly	O
induced	O
by	O
dexamethasone	O
within	O
2	O
h	O
of	O
treatment	O
.	O
GIG10	O
is	O
a	O
novel	O
sequence	O
and	O
GIG18	O
is	O
the	O
mouse	O
homologue	O
of	O
a	O
human	O
expressed	O
sequence	O
tag	O
isolated	O
from	O
activated	O
B	O
lymphocytes	O
.	O
We	O
also	O
used	O
DDPCR	O
to	O
isolate	O
DESTs	O
from	O
androgen	O
-	O
modulated	O
rat	O
ventral	O
prostate	O
tissue	O
,	O
one	O
of	O
which	O
we	O
characterized	O
and	O
found	O
to	O
correspond	O
to	O
the	O
3	O
'	O
end	O
of	O
prostatic	O
spermine	O
binding	O
protein	O
mRNA	O
,	O
a	O
known	O
androgen	O
-	O
regulated	O
gene	O
.	O
Modifications	O
of	O
the	O
original	O
DDPCR	O
protocol	O
,	O
which	O
we	O
found	O
can	O
potentially	O
decrease	O
the	O
frequency	O
of	O
isolating	O
false	O
-	O
positive	O
DESTs	O
,	O
are	O
described	O
and	O
the	O
merits	O
of	O
DDPCR	O
,	O
relative	O
to	O
other	O
differential	O
cDNA	O
cloning	O
strategies	O
,	O
are	O
discussed	O
.	O
Abnormal	O
regulation	O
of	O
the	O
IL-2	O
promoter	O
in	O
lpr	O
CD4-CD8-	O
T	O
lymphocytes	O
results	O
in	O
constitutive	O
expression	O
of	O
a	O
novel	B
nuclear	I
factor	I
of	I
activated	I
T	I
cells	I
-	I
binding	I
factor	I
.	O
The	O
inert	O
quality	O
of	O
MRL	O
-	O
Ipr	O
/	O
Ipr	O
(	O
Ipr	O
)	O
peripheral	O
CD4-CD8-	O
(	O
CD4	O
-	O
8-	O
)	O
T	O
cells	O
manifests	O
primarily	O
as	O
an	O
inability	O
to	O
proliferate	O
or	O
produce	O
IL-2	B
in	O
response	O
to	O
TCR	B
or	O
mitogenic	O
stimulation	O
.	O
Yet	O
these	O
same	O
cells	O
do	O
initiate	O
early	O
TCR	B
-mediated	O
signaling	O
events	O
,	O
such	O
as	O
generation	O
of	O
inositol	O
phosphates	O
and	O
increased	O
intracellular	O
calcium	O
.	O
They	O
also	O
display	O
constitutively	O
high	O
levels	O
of	O
p59fyn	B
and	O
CD3	B
zeta	I
tyrosine	O
phosphorylation	O
.	O
The	O
generation	O
of	O
second	O
messengers	O
in	O
T	O
cells	O
normally	O
leads	O
to	O
downstream	O
signaling	O
that	O
results	O
in	O
transcriptional	O
activation	O
of	O
the	O
IL-2	O
gene	O
.	O
We	O
,	O
therefore	O
,	O
compared	O
the	O
activation	O
state	O
of	O
the	O
IL-2	O
gene	O
promoter	O
region	O
in	O
freshly	O
isolated	O
and	O
stimulated	O
Ipr	O
CD4	O
-	O
8-	O
T	O
cells	O
with	O
that	O
of	O
normal	O
T	O
lymphocytes	O
.	O
Levels	O
of	O
the	O
octamer	O
,	O
NF	B
-	I
kappa	I
B	I
(	O
p50-p65	B
heterodimer	I
)	O
,	O
and	O
AP-1	B
transcriptional	I
factors	I
are	O
constitutively	O
elevated	O
in	O
freshly	O
isolated	O
Ipr	O
CD4	O
-	O
8-	O
T	O
cells	O
,	O
consistent	O
with	O
the	O
activated	O
phenotype	O
of	O
these	O
cells	O
.	O
Upon	O
stimulation	O
with	O
mitogens	O
,	O
formation	O
of	O
the	O
transactivating	O
complex	O
,	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
,	O
occurs	O
with	O
normal	O
kinetics	O
in	O
Ipr	O
CD4	O
-	O
8-	O
T	O
cells	O
.	O
Yet	O
,	O
the	O
levels	O
of	O
the	O
activating	O
NF	B
-	I
AT	I
complex	I
never	O
reach	O
those	O
observed	O
in	O
similarly	O
stimulated	O
normal	O
T	O
cells	O
.	O
Furthermore	O
,	O
nuclear	O
extracts	O
from	O
Ipr	O
CD4	O
-	O
8-	O
T	O
cells	O
display	O
high	O
levels	O
of	O
a	O
novel	O
specific	O
binding	O
activity	O
at	O
the	O
NF	O
-	O
AT	O
site	O
,	O
which	O
is	O
present	O
at	O
much	O
lower	O
levels	O
in	O
freshly	O
isolated	O
normal	O
T	O
lymphocytes	O
.	O
Upon	O
mitogenic	O
stimulation	O
,	O
the	O
binding	O
activity	O
of	O
the	O
novel	O
NF	B
-	I
AT	I
-	I
binding	I
factor	I
is	O
rapidly	O
down	O
-	O
regulated	O
in	O
normal	O
T	O
cells	O
,	O
but	O
persists	O
at	O
high	O
levels	O
in	O
Ipr	O
CD4	O
-	O
8-	O
T	O
cells	O
.	O
These	O
two	O
abnormalities	O
at	O
the	O
NF	O
-	O
AT	O
site	O
provide	O
a	O
potential	O
mechanism	O
to	O
account	O
for	O
the	O
defect	O
in	O
IL-2	B
production	O
from	O
Ipr	O
CD4	O
-	O
8-	O
T	O
cells	O
.	O
Ligand	O
-	O
dependent	O
repression	O
of	O
the	O
erythroid	B
transcription	I
factor	I
GATA-1	B
by	O
the	O
estrogen	B
receptor	I
.	O
High	O
-	O
dose	O
estrogen	O
administration	O
induces	O
anemia	O
in	O
mammals	O
.	O
In	O
chickens	O
,	O
estrogens	O
stimulate	O
outgrowth	O
of	O
bone	O
marrow	O
-	O
derived	O
erythroid	O
progenitor	O
cells	O
and	O
delay	O
their	O
maturation	O
.	O
This	O
delay	O
is	O
associated	O
with	O
down	O
-	O
regulation	O
of	O
many	O
erythroid	O
cell	O
-	O
specific	O
genes	O
,	O
including	O
alpha-	O
and	O
beta	O
-	O
globin	O
,	O
band	O
3	O
,	O
band	O
4.1	O
,	O
and	O
the	O
erythroid	B
cell	I
-	I
specific	I
histone	I
H5	B
.	O
We	O
show	O
here	O
that	O
estrogens	O
also	O
reduce	O
the	O
number	O
of	O
erythroid	O
progenitor	O
cells	O
in	O
primary	O
human	O
bone	O
marrow	O
cultures	O
.	O
To	O
address	O
potential	O
mechanisms	O
by	O
which	O
estrogens	O
suppress	O
erythropoiesis	O
,	O
we	O
have	O
examined	O
their	O
effects	O
on	O
GATA-1	B
,	O
an	O
erythroid	B
transcription	I
factor	I
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
majority	O
of	O
erythroid	O
cell	O
-	O
specific	O
genes	O
and	O
is	O
necessary	O
for	O
full	O
maturation	O
of	O
erythrocytes	O
.	O
We	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
GATA-1	B
is	O
strongly	O
repressed	O
by	O
the	O
estrogen	B
receptor	I
(	O
ER	B
)	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
and	O
that	O
this	O
repression	O
is	O
reversible	O
in	O
the	O
presence	O
of	O
4-hydroxytamoxifen	O
.	O
ER	B
-mediated	O
repression	O
of	O
GATA-1	B
activity	O
occurs	O
on	O
an	O
artificial	O
promoter	O
containing	O
a	O
single	O
GATA	O
-	O
binding	O
site	O
,	O
as	O
well	O
as	O
in	O
the	O
context	O
of	O
an	O
intact	O
promoter	O
which	O
is	O
normally	O
regulated	O
by	O
GATA-1	B
.	O
GATA-1	B
and	O
ER	B
bind	O
to	O
each	O
other	O
in	O
vitro	O
in	O
the	O
absence	O
of	O
DNA	O
.	O
In	O
coimmunoprecipitation	O
experiments	O
using	O
transfected	O
COS	O
cells	O
,	O
GATA-1	B
and	O
ER	B
associate	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
.	O
Mapping	O
experiments	O
indicate	O
that	O
GATA-1	B
and	O
the	O
ER	B
form	O
at	O
least	O
two	O
contacts	O
,	O
which	O
involve	O
the	O
finger	O
region	O
and	O
the	O
N	B
-	I
terminal	I
activation	I
domain	I
of	O
GATA-1	B
.	O
We	O
speculate	O
that	O
estrogens	O
exert	O
effects	O
on	O
erythropoiesis	O
by	O
modulating	O
GATA-1	B
activity	O
through	O
protein	O
-	O
protein	O
interaction	O
with	O
the	O
ER	B
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Activation	O
of	O
pp90rsk	B
and	O
early	O
growth	O
response-1	O
gene	O
expression	O
by	O
pokeweed	B
mitogen	I
in	O
human	O
B	O
cells	O
.	O
The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
pokeweed	B
mitogen	I
(	O
PWM	B
)	O
on	O
the	O
induction	O
of	O
early	O
growth	O
response-1	O
gene	O
(	O
EGR-1	O
)	O
in	O
normal	O
human	O
B	O
cells	O
.	O
PWM	B
regulates	O
EGR-1	O
gene	O
expression	O
by	O
both	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
mechanisms	O
.	O
Transient	O
transfection	O
assays	O
with	O
EGR-1	O
promoter	O
fragments	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
gene	O
demonstrated	O
that	O
PWM	B
induced	O
EGR-1	O
transcription	O
is	O
conferred	O
by	O
the	O
CArG	O
motif	O
(	O
C	O
C	O
[	O
AT	O
]	O
6GG	O
)	O
in	O
the	O
EGR-1	O
promoter	O
.	O
The	O
results	O
further	O
demonstrated	O
the	O
activation	O
of	O
S6	B
kinase	I
(	O
pp90rsk	B
)	O
,	O
evidenced	O
by	O
phosphorylation	O
of	O
S6	B
and	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
peptides	O
,	O
in	O
PWM	O
treated	O
B	O
cells	O
.	O
Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
PWM	B
is	O
able	O
to	O
initiate	O
an	O
intracytoplasmic	O
signalling	O
cascade	O
and	O
EGR-1	O
induction	O
in	O
normal	O
human	O
B	O
cells	O
.	O
Infection	O
with	O
Theileria	O
annulata	O
induces	O
expression	O
of	O
matrix	B
metalloproteinase	I
9	I
and	O
transcription	B
factor	I
AP-1	B
in	O
bovine	O
leucocytes	O
.	O
Theileria	O
annulata	O
infects	O
bovine	O
leucocytes	O
and	O
results	O
in	O
their	O
reversible	O
transformation	O
such	O
that	O
they	O
become	O
immortalised	O
and	O
metastatic	O
.	O
The	O
present	O
study	O
describes	O
parasite	O
-	O
induced	O
changes	O
in	O
host	O
cell	O
gene	O
expression	O
which	O
have	O
a	O
direct	O
bearing	O
on	O
this	O
transformation	O
process	O
.	O
T.	O
annulata	O
-	O
infected	O
leucocytes	O
produce	O
a	O
number	O
of	O
novel	O
metalloproteinase	B
activities	O
.	O
One	O
of	O
these	O
,	O
previously	O
called	O
B1	B
,	O
is	O
a	O
97-kDa	B
protein	I
which	O
is	O
secreted	O
in	O
large	O
amounts	O
and	O
has	O
been	O
purified	O
from	O
protein	O
-	O
free	O
,	O
conditioned	O
medium	O
.	O
An	O
antiserum	O
to	O
this	O
enzyme	O
was	O
used	O
to	O
isolate	O
a	O
cDNA	O
clone	O
.	O
The	O
predicted	O
protein	O
sequence	O
of	O
B1	B
is	O
81	O
%	O
identical	O
to	O
human	O
matrix	B
metalloproteinase	I
9	I
(	O
MMP9	B
)	O
,	O
demonstrating	O
that	O
it	O
is	O
the	O
bovine	O
homologue	O
of	O
this	O
enzyme	O
.	O
RNAase	B
protection	O
assays	O
demonstrated	O
that	O
the	O
MMP9	B
activity	O
,	O
unique	O
to	O
infected	O
cells	O
,	O
is	O
due	O
to	O
increased	O
MMP9	B
mRNA	O
levels	O
.	O
We	O
also	O
assayed	O
the	O
levels	O
of	O
transcription	B
factor	I
AP-1	B
and	O
demonstrated	O
that	O
it	O
was	O
constitutively	O
present	O
in	O
increased	O
amounts	O
in	O
Theileria	O
-	O
infected	O
cells	O
.	O
In	O
addition	O
we	O
assayed	O
the	O
level	O
of	O
mRNA	O
encoding	O
c	B
-	I
Fos	I
,	O
a	O
common	O
component	O
of	O
AP-1	B
and	O
observed	O
that	O
it	O
was	O
indeed	O
up	O
-	O
regulated	O
in	O
infected	O
cells	O
.	O
Since	O
AP-1	B
is	O
implicated	O
in	O
the	O
control	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
MMP9	B
can	O
confer	O
metastatic	O
properties	O
,	O
these	O
results	O
are	O
of	O
considerable	O
significance	O
with	O
respect	O
to	O
the	O
transformed	O
phenotype	O
induced	O
by	O
Theileria	O
infection	O
.	O
Reduced	O
mitogenic	O
stimulation	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
as	O
a	O
prognostic	O
parameter	O
for	O
the	O
course	O
of	O
breast	O
cancer	O
:	O
a	O
prospective	O
longitudinal	O
study	O
.	O
Immunosuppression	O
has	O
been	O
often	O
associated	O
with	O
the	O
course	O
of	O
malignant	O
diseases	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
proliferation	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
in	O
response	O
to	O
mitogenic	O
stimulation	O
with	O
phytohaemagglutinin	B
(	O
PHA	B
)	O
was	O
assessed	O
prospectively	O
in	O
90	O
patients	O
with	O
stage	O
I	O
-	O
III	O
breast	O
cancer	O
.	O
Whereas	O
PHA	B
-induced	O
proliferation	O
of	O
PBMCs	O
derived	O
from	O
patients	O
with	O
breast	O
cancer	O
preoperatively	O
was	O
significantly	O
decreased	O
when	O
compared	O
with	O
data	O
obtained	O
in	O
healthy	O
control	O
individuals	O
(	O
P	O
<	O
0.001	O
)	O
,	O
the	O
degree	O
of	O
the	O
defect	O
in	O
PHA	B
-induced	O
proliferation	O
of	O
PBMCs	O
depended	O
upon	O
the	O
tumour	O
burden	O
as	O
manifested	O
by	O
tumour	O
size	O
and	O
axillary	O
lymph	O
node	O
involvement	O
(	O
P	O
<	O
0.003	O
in	O
each	O
case	O
)	O
.	O
PHA	B
-induced	O
proliferation	O
of	O
PBMCs	O
dropped	O
significantly	O
in	O
patients	O
who	O
received	O
adjuvant	O
chemotherapy	O
consisting	O
of	O
cyclophosphamide	O
,	O
methotrexate	O
and	O
fluorouracil	O
(	O
CMF	O
)	O
after	O
an	O
observation	O
period	O
of	O
6	O
months	O
(	O
P	O
<	O
0.01	O
)	O
,	O
but	O
not	O
in	O
patients	O
under	O
adjuvant	O
treatment	O
with	O
tamoxifen	O
only	O
.	O
After	O
an	O
additional	O
6	O
months	O
(	O
i.e.	O
12	O
months	O
after	O
surgery	O
)	O
,	O
PHA	B
-induced	O
proliferation	O
of	O
PBMCs	O
was	O
similar	O
in	O
patients	O
after	O
adjuvant	O
chemotherapy	O
with	O
CMF	O
and	O
in	O
those	O
receiving	O
continued	O
adjuvant	O
tamoxifen	O
treatment	O
(	O
P	O
>	O
0.1	O
)	O
,	O
but	O
in	O
all	O
patients	O
still	O
significantly	O
decreased	O
as	O
compared	O
with	O
healthy	O
controls	O
(	O
P	O
<	O
0.001	O
)	O
.	O
When	O
data	O
obtained	O
preoperatively	O
and	O
after	O
12	O
months	O
were	O
compared	O
,	O
it	O
was	O
found	O
that	O
out	O
of	O
23	O
patients	O
whose	O
PBMCs	O
had	O
experienced	O
a	O
drop	O
in	O
their	O
PHA	B
-induced	O
proliferation	O
,	O
14	O
(	O
61	O
%	O
)	O
had	O
developed	O
metastatic	O
disease	O
within	O
the	O
subsequent	O
24	O
months	O
(	O
i.e.	O
36	O
months	O
after	O
surgery	O
)	O
.	O
In	O
contrast	O
,	O
out	O
of	O
59	O
patients	O
whose	O
PBMCs	O
showed	O
an	O
increase	O
in	O
their	O
PHA	B
-induced	O
proliferation	O
within	O
the	O
first	O
12	O
months	O
after	O
surgery	O
,	O
only	O
one	O
(	O
2	O
%	O
)	O
presented	O
with	O
disease	O
progression	O
.	O
We	O
thus	O
conclude	O
that	O
PHA	B
-induced	O
proliferation	O
of	O
PBMCs	O
derived	O
from	O
patients	O
with	O
breast	O
cancer	O
depends	O
upon	O
the	O
tumour	O
load	O
and	O
is	O
a	O
good	O
clinical	O
predictor	O
for	O
the	O
further	O
course	O
of	O
the	O
disease	O
.	O
Expression	O
of	O
Ah	B
receptor	I
(	O
TCDD	B
receptor	I
)	O
during	O
human	O
monocytic	O
differentiation	O
.	O
We	O
have	O
previously	O
found	O
a	O
high	O
expression	O
of	O
human	O
Ah	O
receptor	O
(	O
TCDD	O
receptor	O
)	O
mRNA	O
in	O
peripheral	O
blood	O
cells	O
of	O
individuals	O
.	O
In	O
this	O
paper	O
,	O
the	O
expression	O
of	O
this	O
gene	O
in	O
blood	O
cells	O
was	O
first	O
investigated	O
in	O
fractions	O
of	O
nucleated	O
cells	O
,	O
revealing	O
predominant	O
expression	O
of	O
the	O
Ah	O
receptor	O
gene	O
in	O
the	O
monocyte	O
fraction	O
.	O
Then	O
the	O
expression	O
levels	O
of	O
AhR	O
mRNA	O
in	O
various	O
hematopoietic	O
cell	O
lines	O
were	O
examined	O
together	O
with	O
those	O
of	O
Arnt	B
and	O
P450IA1	B
.	O
AhR	B
was	O
expressed	O
at	O
high	O
levels	O
in	O
monocytoid	O
U937	O
,	O
THP1	O
,	O
and	O
HEL	O
/	O
S	O
cells	O
,	O
and	O
at	O
moderate	O
levels	O
in	O
promyelocytic	O
HL60	O
cells	O
and	O
erythroblastic	O
HEL	O
cells	O
.	O
However	O
,	O
it	O
was	O
not	O
detected	O
in	O
lymphoid	O
cells	O
MOLT4	O
(	O
T	O
cell	O
)	O
and	O
BALL1	O
(	O
B	O
cell	O
)	O
,	O
nor	O
in	O
K562	O
erythroblasts	O
.	O
Furthermore	O
,	O
a	O
specific	O
induction	O
of	O
AhR	B
during	O
monocytic	O
differentiation	O
was	O
investigated	O
in	O
HL60	O
and	O
HEL	O
cells	O
.	O
HL60	O
cells	O
were	O
induced	O
to	O
differentiate	O
toward	O
monocytes	O
-	O
macrophages	O
by	O
incubation	O
with	O
phorbol	O
ester	O
,	O
showing	O
a	O
5-	O
to	O
2-fold	O
increase	O
of	O
AhR	O
mRNA	O
.	O
The	O
incubation	O
with	O
transforming	B
growth	I
factor	I
beta	I
1	I
and	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
resulted	O
in	O
a	O
5-	O
to	O
7-fold	O
increase	O
of	O
AhR	O
mRNA	O
.	O
The	O
HEL	O
cells	O
also	O
exhibited	O
a	O
similar	O
elevation	O
of	O
AhR	O
mRNA	O
level	O
,	O
when	O
they	O
had	O
differentiated	O
toward	O
monocyte	O
-	O
macrophage	O
cells	O
by	O
these	O
combined	O
inducers	O
,	O
but	O
little	O
change	O
in	O
the	O
mRNA	O
level	O
was	O
observed	O
when	O
the	O
cells	O
were	O
induced	O
to	O
differentiate	O
into	O
other	O
cell	O
types	O
.	O
Treatment	O
of	O
the	O
differentiated	O
HL60	O
cells	O
with	O
3-methylcholanthrene	O
,	O
a	O
ligand	O
of	O
AhR	B
,	O
induced	O
the	O
expression	O
of	O
the	O
P450IA1	B
gene	O
.	O
These	O
results	O
indicated	O
that	O
expression	O
of	O
AhR	O
mRNA	O
was	O
significantly	O
induced	O
during	O
monocytic	O
differentiation	O
and	O
that	O
the	O
differentiated	O
cells	O
were	O
responsive	O
to	O
xenobiotics	O
.	O
Our	O
results	O
suggest	O
that	O
AhR	B
may	O
play	O
an	O
important	O
role	O
in	O
the	O
function	O
of	O
monocytes	O
and	O
also	O
in	O
the	O
eventual	O
activation	O
of	O
environmental	O
carcinogens	O
.	O
Danazol	O
decreases	O
transcription	O
of	O
estrogen	O
receptor	O
gene	O
in	O
human	O
monocytes	O
.	O
1	O
.	O
Administration	O
of	O
danazol	O
for	O
over	O
one	O
month	O
reduced	O
the	O
levels	O
of	O
estrogen	B
receptor	I
(	O
ER	B
)	O
and	O
its	O
mRNA	O
to	O
approximately	O
50	O
and	O
20	O
%	O
,	O
respectively	O
in	O
monocytes	O
.	O
2	O
.	O
Danazol	O
did	O
not	O
alter	O
the	O
degradation	O
rate	O
of	O
ER	O
mRNA	O
in	O
monocytes	O
.	O
3	O
.	O
Danazol	O
decreased	O
the	O
transcription	O
rate	O
of	O
ER	O
gene	O
to	O
approximately	O
50	O
%	O
in	O
monocytes	O
in	O
a	O
run	O
-	O
on	O
assay	O
.	O
4	O
.	O
Danazol	O
may	O
release	O
estrogen	O
predominance	O
via	O
the	O
reduction	O
of	O
transcription	O
for	O
ER	O
gene	O
,	O
which	O
leads	O
to	O
the	O
reduction	O
of	O
ER	O
mRNA	O
and	O
ER	B
expressions	O
in	O
monocytes	O
.	O
Physiological	O
concentration	O
of	O
estradiol	O
inhibits	O
polymorphonuclear	O
leukocyte	O
chemotaxis	O
via	O
a	O
receptor	O
mediated	O
system	O
.	O
Estrogen	O
exhibits	O
a	O
variety	O
of	O
actions	O
,	O
including	O
immuno	O
-	O
modulatory	O
effects	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
The	O
mechanism	O
by	O
which	O
estrogen	O
exerts	O
its	O
anti	O
-	O
inflammatory	O
effect	O
is	O
not	O
yet	O
understood	O
.	O
We	O
investigated	O
the	O
possible	O
mechanisms	O
of	O
estradiol	O
acting	O
via	O
the	O
polymorphonuclear	O
leukocytes	O
(	O
PMNs	O
)	O
,	O
which	O
are	O
important	O
in	O
the	O
immune	O
response	O
.	O
The	O
agent	O
,	O
17	O
beta	O
-	O
estradiol	O
,	O
but	O
not	O
17	O
alpha	O
-	O
estradiol	O
,	O
significantly	O
reduced	O
PMNs	O
chemotaxis	O
to	O
FMLP	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
control	O
vs	O
estrogen	O
10	O
(	O
-10	O
)	O
-	O
(	O
-6	O
)	O
M	O
,	O
P	O
<	O
0.05	O
)	O
.	O
Physiological	O
concentrations	O
of	O
estradiol	O
significantly	O
reduced	O
the	O
chemotaxis	O
of	O
PMNs	O
(	O
10	O
(	O
-10	O
)	O
mol	O
)	O
.	O
Pre	O
-	O
incubation	O
with	O
clomiphene	O
or	O
tamoxifen	O
which	O
are	O
estrogen	O
receptor	O
antagonists	O
,	O
eliminated	O
the	O
inhibitory	O
effect	O
of	O
17	O
beta	O
-	O
estradiol	O
on	O
the	O
chemotaxis	O
of	O
PMNs	O
,	O
restoring	O
it	O
to	O
the	O
control	O
level	O
.	O
These	O
observations	O
suggest	O
that	O
17	O
beta	O
-	O
estradiol	O
suppressed	O
the	O
chemotaxis	O
of	O
PMNs	O
by	O
a	O
receptor	O
-	O
dependent	O
mechanism	O
.	O
In	O
addition	O
,	O
the	O
level	O
of	O
estradiol	O
in	O
human	O
plasma	O
,	O
which	O
PMNs	O
were	O
drawn	O
,	O
showed	O
a	O
close	O
,	O
inverse	O
correlation	O
with	O
the	O
PMNs	O
chemotaxis	O
to	O
FMLP	O
(	O
r	O
=	O
-0.821	O
p	O
<	O
0.001	O
)	O
.	O
Estrogen	O
may	O
modify	O
the	O
activity	O
of	O
neutrophils	O
during	O
the	O
normal	O
menstrual	O
cycle	O
,	O
not	O
only	O
during	O
pregnancy	O
,	O
and	O
influence	O
inflammation	O
.	O
Cross	O
-	O
linking	O
of	O
CD30	B
induces	O
HIV	O
expression	O
in	O
chronically	O
infected	O
T	O
cells	O
.	O
CD30	B
,	O
a	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
family	O
,	O
is	O
expressed	O
constitutively	O
on	O
the	O
surface	O
of	O
the	O
human	O
T	O
cell	O
line	O
ACH-2	O
,	O
which	O
is	O
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV	O
)	O
-1	O
.	O
We	O
demonstrate	O
that	O
cross	O
-	O
linking	O
CD30	B
with	O
an	O
anti-	O
CD30	B
-specific	O
monoclonal	O
antibody	O
,	O
which	O
mimics	O
the	O
described	O
biological	O
activities	O
of	O
the	O
CD30	B
ligand	I
(	O
CD30L	B
)	O
,	O
results	O
in	O
HIV	O
expression	O
.	O
CD30	B
cross	O
-	O
linking	O
does	O
not	O
alter	O
proliferation	O
of	O
ACH-2	O
cells	O
and	O
the	O
induction	O
of	O
HIV	O
expression	O
is	O
not	O
mediated	O
by	O
endogenous	O
TNF	B
alpha	I
/	I
beta	I
.	O
Furthermore	O
,	O
cross	O
-	O
linking	O
of	O
CD30	B
leads	O
to	O
NF	B
-	I
kappa	I
B	I
activation	O
and	O
enhanced	O
HIV	O
transcription	O
.	O
Thus	O
,	O
CD30	B
-CD30L	B
interactions	O
mediate	O
the	O
induction	O
of	O
HIV	O
expression	O
by	O
a	O
kappa	O
B	O
-	O
dependent	O
pathway	O
that	O
is	O
independent	O
of	O
TNF	B
.	O
This	O
mechanism	O
may	O
be	O
important	O
in	O
the	O
activation	O
of	O
HIV	O
expression	O
from	O
latently	O
infected	O
CD4	O
+	O
T	O
cells	O
,	O
especially	O
in	O
lymphoid	O
organs	O
where	O
cell	O
to	O
cell	O
contact	O
is	O
conducive	O
to	O
receptor	O
-	O
ligand	O
interactions	O
.	O
The	O
activation	O
of	O
the	O
Jak	B
-STAT	B
1	I
signaling	O
pathway	O
by	O
IL-5	B
in	O
eosinophils	O
.	O
The	O
intracellular	O
signal	O
transduction	O
of	O
IL-5	B
in	O
eosinophils	O
is	O
unknown	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
involvement	O
of	O
the	O
newly	O
discovered	O
Jak	B
-STAT	B
pathway	O
in	O
the	O
IL-5	B
signal	O
transduction	O
mechanism	O
.	O
Eosinophils	O
were	O
purified	O
from	O
peripheral	O
blood	O
by	O
discontinuous	O
Percoll	O
gradients	O
and	O
stimulated	O
with	O
IL-5	B
.	O
The	O
involvement	O
of	O
Jak	B
2	I
was	O
investigated	O
by	O
immunoprecipitation	O
followed	O
by	O
immunoblotting	O
for	O
tyrosine	O
phosphorylation	O
.	O
The	O
activation	O
of	O
Jak	B
2	I
was	O
studied	O
by	O
autophosphorylation	O
of	O
the	O
immunoprecipitated	B
kinase	I
.	O
Jak	B
2	I
was	O
tyrosine	O
phosphorylated	O
within	O
1	O
to	O
3	O
min	O
after	O
stimulation	O
of	O
eosinophils	O
with	O
IL-5	B
.	O
Further	O
,	O
the	O
immunoprecipitated	B
Jak	I
2	I
obtained	O
from	O
IL-5-stimulated	O
cells	O
underwent	O
autophosphorylation	O
.	O
Jak	B
2	I
coprecipitated	O
with	O
the	O
beta	O
-	O
subunit	O
of	O
the	O
IL-5	B
receptor	I
,	O
suggesting	O
a	O
physical	O
association	O
of	O
the	O
kinase	B
with	O
the	O
receptor	O
.	O
The	O
nuclear	B
factor	I
STAT-1	I
(	O
p91	B
)	O
was	O
investigated	O
by	O
immunoprecipitation	O
followed	O
by	O
immunoblotting	O
for	O
tyrosine	O
phosphorylation	O
.	O
STAT-1	B
was	O
tyrosine	O
phosphorylated	O
within	O
15	O
min	O
of	O
IL-5	B
stimulation	O
.	O
The	O
presence	O
of	O
STAT-1	B
in	O
the	O
nuclear	O
extract	O
was	O
studied	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
IL-5	B
induced	O
two	O
proteins	O
that	O
bound	O
to	O
the	O
gamma	O
-	O
activating	O
sequence	O
.	O
In	O
the	O
presence	O
of	O
an	O
anti	B
-	I
STAT-1	I
Ab	I
,	O
the	O
band	O
was	O
supershifted	O
.	O
Thus	O
,	O
we	O
demonstrated	O
that	O
IL-5	B
activated	O
the	O
Jak	B
2	I
-STAT	B
1	I
signaling	O
pathway	O
in	O
eosinophils	O
.	O
We	O
speculate	O
that	O
the	O
Jak	B
2	I
-STAT	B
1	I
pathway	O
may	O
be	O
involved	O
in	O
the	O
activation	O
of	O
IL-5-inducible	O
genes	O
in	O
eosinophils	O
.	O
Constitutively	O
activated	O
Jak	B
-STAT	B
pathway	O
in	O
T	O
cells	O
transformed	O
with	O
HTLV	O
-	O
I	O
.	O
Human	O
T	O
cell	O
lymphotropic	O
virus	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
the	O
etiological	O
agent	O
for	O
adult	O
T	O
cell	O
leukemia	O
and	O
tropical	O
spastic	O
paraparesis	O
(	O
also	O
termed	O
HTLV	O
-	O
I	O
-	O
associated	O
myelopathy	O
)	O
.	O
HTLV	O
-	O
I	O
-	O
infected	O
peripheral	O
blood	O
T	O
cells	O
exhibit	O
an	O
initial	O
phase	O
of	O
interleukin-2	B
(	O
IL-2	B
)	O
-dependent	O
growth	O
;	O
over	O
time	O
,	O
by	O
an	O
unknown	O
mechanism	O
,	O
the	O
cells	O
become	O
IL-2	B
-independent	O
.	O
Whereas	O
the	O
Jak	B
kinases	I
Jak1	B
and	O
Jak3	B
and	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B
proteins	I
Stat3	B
and	O
Stat5	B
are	O
activated	O
in	O
normal	O
T	O
cells	O
in	O
response	O
to	O
IL-2	B
,	O
this	O
signaling	O
pathway	O
was	O
constitutively	O
activated	O
in	O
HTLV	O
-	O
I	O
-	O
transformed	O
cells	O
.	O
In	O
HTLV	O
-	O
I	O
-	O
infected	O
cord	O
blood	O
lymphocytes	O
,	O
the	O
transition	O
from	O
IL-2	B
-dependent	O
to	O
IL-2	B
-independent	O
growth	O
correlated	O
with	O
the	O
acquisition	O
of	O
a	O
constitutively	O
activated	O
Jak	B
-STAT	B
pathway	O
,	O
which	O
suggests	O
that	O
this	O
pathway	O
participates	O
in	O
HTLV	O
-	O
I	O
-	O
mediated	O
T	O
cell	O
transformation	O
.	O
Positive	O
and	O
negative	O
regulation	O
of	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
promoter	O
activity	O
by	O
AML1-related	B
transcription	I
factor	I
,	O
PEBP2	B
.	O
The	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
gene	O
promoter	O
contains	O
a	O
consensus	O
sequence	O
for	O
the	O
polyomavirus	B
enhancer	I
binding	I
-	I
protein	I
2	I
(	I
PEBP2	I
)	I
transcription	I
factor	I
,	O
which	O
consists	O
of	O
alpha	B
and	I
beta	I
subunits	I
.	O
There	O
are	O
at	O
least	O
two	O
genes	O
,	O
alpha	O
A	O
and	O
alpha	O
B	O
,	O
encoding	O
the	O
alpha	B
subunit	I
.	O
alpha	O
B	O
is	O
the	O
mouse	O
homologue	O
of	O
human	O
AML1	O
gene	O
detected	O
at	O
the	O
breakpoints	O
of	O
t	O
(	O
8	O
;	O
21	O
)	O
and	O
t	O
(	O
3	O
;	O
21	O
)	O
myeloid	O
leukemias	O
.	O
We	O
examined	O
alpha	B
A1	I
(	O
an	O
alpha	B
A	I
-	I
gene	I
product	I
)	O
and	O
alpha	B
B1	I
and	O
alpha	B
B2	I
(	O
two	O
alpha	B
B	I
-	I
encoded	I
isomers	I
)	O
for	O
their	O
effects	O
on	O
the	O
GM	O
-	O
CSF	O
promoter	O
.	O
PEBP2	B
alpha	I
A1	I
,	O
alpha	B
B1	I
,	O
and	O
alpha	B
B2	I
proteins	I
bound	O
the	O
PEBP2	O
site	O
within	O
the	O
mouse	O
GM	O
-	O
CSF	O
promoter	O
.	O
PEBP2	B
alpha	I
A1	I
and	O
alpha	B
B1	I
enhanced	O
the	O
expression	O
of	O
the	O
GM	O
-	O
CSF	O
promoter	O
-	O
driven	O
reporter	O
plasmid	O
in	O
unstimulated	O
and	O
12-O	O
-	O
tetradecanoylphorbol	O
13-acetate	O
/	O
phytohemagglutinin	O
-	O
stimulated	O
human	O
Jurkat	O
T	O
cells	O
.	O
In	O
contrast	O
,	O
the	O
promoter	O
activity	O
was	O
suppressed	O
by	O
alpha	B
B2	I
.	O
Coexpression	O
of	O
alpha	B
B1	I
and	O
alpha	B
B2	I
showed	O
that	O
the	O
promoter	O
activity	O
could	O
be	O
determined	O
by	O
the	O
alpha	B
B1	I
/alpha	B
B2	I
ratio	O
.	O
Jurkat	O
cell	O
extract	O
contained	O
PEBP2	B
site	I
-	I
binding	I
protein	I
(	O
s	O
)	O
that	O
cross	O
-	O
reacted	O
with	O
antimouse	B
alpha	I
A1	I
antibodies	I
.	O
Northern	O
blot	O
analysis	O
indicated	O
the	O
expression	O
of	O
human	O
PEBP2	B
alpha	I
A	I
,	O
alpha	O
B	O
(	O
AML1	O
)	O
,	O
and	O
beta	O
genes	O
in	O
Jurkat	O
cells	O
.	O
Although	O
further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
precise	O
role	O
of	O
PEBP2	B
in	O
the	O
GM	B
-	I
CSF	I
promoter	O
activity	O
,	O
the	O
present	O
findings	O
suggested	O
the	O
importance	O
of	O
the	O
relative	O
ratio	O
of	O
different	O
PEBP2	B
isoforms	I
in	O
regulating	O
the	O
levels	O
of	O
the	O
promoter	O
activity	O
.	O
Heterogeneous	O
expression	O
of	O
Epstein	B
-	I
Barr	I
virus	I
latent	I
proteins	I
in	O
endemic	O
Burkitt	O
's	O
lymphoma	O
.	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-infected	O
cells	O
may	O
sustain	O
three	O
distinct	O
forms	O
of	O
virus	O
latency	O
.	O
In	O
lymphoblastoid	O
cell	O
lines	O
,	O
six	O
EBV	B
-	I
encoded	I
nuclear	I
antigens	I
(	O
EBNA1	B
,	I
2	I
,	I
3A	I
,	I
3B	I
,	I
3C	I
,	I
-LP	I
)	O
,	O
three	O
latent	B
membrane	I
proteins	I
(	O
LMP1	B
,	O
2A	B
,	O
2B	B
)	O
,	O
and	O
two	O
nuclear	O
RNAs	O
(	O
EBERs	O
)	O
are	O
expressed	O
.	O
This	O
form	O
of	O
latency	O
,	O
termed	O
latency	O
III	O
,	O
is	O
also	O
encountered	O
in	O
some	O
posttransplant	O
lymphoproliferative	O
disorders	O
.	O
In	O
EBV	O
-	O
positive	O
cases	O
of	O
Hodgkin	O
's	O
disease	O
,	O
the	O
EBERs	O
,	O
EBNA1	B
,	O
and	O
the	O
LMPs	B
are	O
expressed	O
(	O
latency	O
II	O
)	O
,	O
whereas	O
in	O
Burkitt	O
's	O
lymphoma	O
(	O
BL	O
)	O
only	O
the	O
EBERs	O
and	O
EBNA1	B
have	O
been	O
detected	O
(	O
latency	O
I	O
)	O
.	O
We	O
have	O
studied	O
the	O
expression	O
of	O
EBV	B
proteins	I
in	O
17	O
cases	O
of	O
EBV	O
-	O
positive	O
endemic	O
BL	O
by	O
immunohistology	O
.	O
Expression	O
of	O
LMP1	B
was	O
seen	O
in	O
variable	O
proportions	O
of	O
tumor	O
cells	O
in	O
two	O
cases	O
and	O
EBNA2	B
was	O
detected	O
in	O
some	O
tumor	O
cells	O
in	O
three	O
other	O
cases	O
.	O
Also	O
,	O
the	O
BZLF1	B
trans	I
-	I
activator	I
protein	I
was	O
expressed	O
in	O
a	O
few	O
tumor	O
cells	O
in	O
6	O
cases	O
,	O
indicating	O
entry	O
into	O
the	O
lytic	O
cycle	O
.	O
A	O
phenotypic	O
drift	O
from	O
latency	O
I	O
to	O
latency	O
III	O
has	O
been	O
observed	O
previously	O
in	O
some	O
BL	O
cell	O
lines	O
.	O
Our	O
results	O
suggest	O
that	O
a	O
similar	O
phenomenon	O
may	O
occur	O
in	O
BL	O
in	O
vivo	O
and	O
indicate	O
that	O
the	O
operational	O
definition	O
of	O
EBV	O
latencies	O
is	O
not	O
easily	O
applied	O
to	O
human	O
tumors	O
.	O
Integrin	O
-	O
mediated	O
tyrosine	O
phosphorylation	O
and	O
cytokine	B
message	O
induction	O
in	O
monocytic	O
cells	O
.	O
A	O
possible	O
signaling	O
role	O
for	O
the	O
Syk	B
tyrosine	I
kinase	I
.	O
Activation	O
of	O
cytoplasmic	B
tyrosine	I
kinases	I
is	O
an	O
important	O
aspect	O
of	O
signal	O
transduction	O
mediated	O
by	O
integrins	B
.	O
In	O
the	O
human	O
monocytic	O
cell	O
line	O
THP-1	O
,	O
either	O
integrin	B
-dependent	O
cell	O
adhesion	O
to	O
fibronectin	B
or	O
ligation	O
of	O
beta	O
1	O
integrins	O
with	O
antibodies	B
causes	O
a	O
rapid	O
and	O
intense	O
tyrosine	O
phosphorylation	O
of	O
two	O
sets	O
of	O
proteins	O
of	O
about	O
65	B
-	I
75	I
and	I
120	I
-	I
125	I
kDa	I
.	O
In	O
addition	O
,	O
integrin	B
ligation	O
leads	O
to	O
nuclear	O
translocation	O
of	O
the	O
p50	B
and	O
p65	B
subunits	I
of	O
the	O
NF	B
-	I
kappa	I
B	I
transcription	I
factor	I
,	O
to	O
activation	O
of	O
a	O
reporter	O
gene	O
driven	O
by	O
a	O
promoter	O
containing	O
NF	O
-	O
kappa	O
B	O
sites	O
,	O
and	O
to	O
increased	O
levels	O
of	O
mRNAs	O
for	O
immediate	O
-	O
early	O
genes	O
,	O
including	O
the	O
cytokine	B
interleukin	I
(	I
IL	I
)	I
-1	I
beta	I
.	O
The	O
tyrosine	O
kinase	O
inhibitors	O
genistein	O
and	O
herbimycin	O
A	O
block	O
both	O
integrin	B
-mediated	O
tyrosine	O
phosphorylation	O
and	O
increases	O
in	O
IL-1	B
beta	I
message	O
levels	O
,	O
indicating	O
a	O
causal	O
relationship	O
between	O
the	O
two	O
events	O
.	O
The	O
components	O
tyrosine	O
phosphorylated	O
subsequent	O
to	O
cell	O
adhesion	O
include	O
paxillin	B
,	O
pp125FAK	B
,	O
and	O
the	O
SH2	B
domain	I
containing	I
tyrosine	I
kinase	I
Syk	I
.	O
In	O
contrast	O
,	O
integrin	B
ligation	O
with	O
antibodies	B
induces	O
tyrosine	O
phosphorylation	O
of	O
Syk	B
but	O
not	O
of	O
FAK	B
or	O
paxillin	B
.	O
In	O
adhering	O
cells	O
,	O
pre	O
-	O
treatment	O
with	O
cytochalasin	O
D	O
suppresses	O
tyrosine	O
phosphorylation	O
of	O
FAK	B
and	O
paxillin	B
but	O
not	O
of	O
Syk	B
,	O
while	O
IL-1	B
beta	I
message	O
induction	O
is	O
unaffected	O
.	O
These	O
observations	O
indicate	O
that	O
the	O
Syk	B
tyrosine	O
kinase	O
may	O
be	O
an	O
important	O
component	O
of	O
an	O
integrin	B
signaling	O
pathway	O
in	O
monocytic	O
cells	O
,	O
leading	O
to	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
to	O
increased	O
levels	O
of	O
cytokine	B
messages	O
.	O
The	O
peri	O
-	O
kappa	O
B	O
site	O
mediates	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
enhancer	O
activation	O
in	O
monocytes	O
but	O
not	O
in	O
T	O
cells	O
.	O
Human	O
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV-2	O
)	O
,	O
like	O
HIV-1	O
,	O
causes	O
AIDS	O
and	O
is	O
associated	O
with	O
AIDS	O
cases	O
primarily	O
in	O
West	O
Africa	O
.	O
HIV-1	O
and	O
HIV-2	O
display	O
significant	O
differences	O
in	O
nucleic	O
acid	O
sequence	O
and	O
in	O
the	O
natural	O
history	O
of	O
clinical	O
disease	O
.	O
Consistent	O
with	O
these	O
differences	O
,	O
we	O
have	O
previously	O
demonstrated	O
that	O
the	O
enhancer	O
/	O
promoter	O
region	O
of	O
HIV-2	O
functions	O
quite	O
differently	O
from	O
that	O
of	O
HIV-1	O
.	O
Whereas	O
activation	O
of	O
the	O
HIV-1	O
enhancer	O
following	O
T	O
-	O
cell	O
stimulation	O
is	O
mediated	O
largely	O
through	O
binding	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappa	I
B	I
to	O
two	O
adjacent	O
kappa	O
B	O
sites	O
in	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
,	O
activation	O
of	O
the	O
HIV-2	O
enhancer	O
in	O
monocytes	O
and	O
T	O
cells	O
is	O
dependent	O
on	O
four	O
cis	O
-	O
acting	O
elements	O
:	O
a	O
single	O
kappa	O
B	O
site	O
,	O
two	O
purine	O
-	O
rich	O
binding	O
sites	O
,	O
PuB1	O
and	O
PuB2	O
,	O
and	O
a	O
pets	O
site	O
.	O
We	O
have	O
now	O
identified	O
a	O
novel	O
cis	O
-	O
acting	O
element	O
within	O
the	O
HIV-2	O
enhancer	O
,	O
immediately	O
upstream	O
of	O
the	O
kappa	O
B	O
site	O
,	O
designated	O
peri	O
-	O
kappa	O
B	O
.	O
This	O
site	O
is	O
conserved	O
among	O
isolates	O
of	O
HIV-2	O
and	O
the	O
closely	O
related	O
simian	O
immunodeficiency	O
virus	O
,	O
and	O
transfection	O
assays	O
show	O
this	O
site	O
to	O
mediate	O
HIV-2	O
enhancer	O
activation	O
following	O
stimulation	O
of	O
monocytic	O
but	O
not	O
T	O
-	O
cell	O
lines	O
.	O
This	O
is	O
the	O
first	O
description	O
of	O
an	O
HIV-2	O
enhancer	O
element	O
which	O
displays	O
such	O
monocyte	O
specificity	O
,	O
and	O
no	O
comparable	O
enhancer	O
element	O
has	O
been	O
clearly	O
defined	O
for	O
HIV-1	O
.	O
While	O
a	O
nuclear	B
factor	I
(	O
s	O
)	O
from	O
both	O
peripheral	O
blood	O
monocytes	O
and	O
T	O
cells	O
binds	O
the	O
peri	O
-	O
kappa	O
B	O
site	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
either	O
a	O
different	O
protein	O
binds	O
to	O
this	O
site	O
in	O
monocytes	O
versus	O
T	O
cells	O
or	O
that	O
the	O
protein	O
recognizing	O
this	O
enhancer	O
element	O
undergoes	O
differential	O
modification	O
in	O
monocytes	O
and	O
T	O
cells	O
,	O
thus	O
supporting	O
the	O
transfection	O
data	O
.	O
Further	O
,	O
while	O
specific	O
constitutive	O
binding	O
to	O
the	O
peri	O
-	O
kappa	O
B	O
site	O
is	O
seen	O
in	O
monocytes	O
,	O
stimulation	O
with	O
phorbol	O
esters	O
induces	O
additional	O
,	O
specific	O
binding	O
.	O
Understanding	O
the	O
monocyte	O
-	O
specific	O
function	O
of	O
the	O
peri	B
-	I
kappa	I
B	I
factor	I
may	O
ultimately	O
provide	O
insight	O
into	O
the	O
different	O
role	O
monocytes	O
and	O
T	O
cells	O
play	O
in	O
HIV	O
pathogenesis	O
.	O
The	O
Ah	B
receptor	I
recognizes	O
DNA	O
binding	O
sites	O
for	O
the	O
B	B
cell	I
transcription	I
factor	I
,	O
BSAP	B
:	O
a	O
possible	O
mechanism	O
for	O
dioxin	O
-	O
mediated	O
alteration	O
of	O
CD19	O
gene	O
expression	O
in	O
human	O
B	O
lymphocytes	O
.	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
(	O
TCDD	O
)	O
inhibits	O
murine	O
and	O
human	O
B	O
lymphocyte	O
immunoglobulin	O
production	O
through	O
an	O
unknown	O
mechanism	O
.	O
This	O
study	O
investigated	O
the	O
effect	O
of	O
TCDD	O
on	O
expression	O
of	O
the	O
CD19	O
gene	O
in	O
a	O
human	O
B	O
lymphocyte	O
cell	O
line	O
.	O
Northern	O
blot	O
analysis	O
showed	O
that	O
TCDD	O
treatment	O
decreased	O
steady	O
state	O
levels	O
of	O
CD19	O
mRNA	O
by	O
67	O
%	O
in	O
the	O
IM-9	O
cell	O
line	O
.	O
Using	O
a	O
gel	O
mobility	O
shift	O
assay	O
,	O
we	O
identified	O
a	O
DNA	B
-	I
binding	I
complex	I
in	O
IM-9	O
nuclear	O
extracts	O
that	O
by	O
several	O
criteria	O
appears	O
to	O
be	O
the	O
Ah	B
receptor	I
.	O
In	O
addition	O
,	O
the	O
Ah	B
receptor	I
complex	I
recognized	O
a	O
DNA	O
binding	O
site	O
for	O
B	B
cell	I
lineage	I
-	I
specific	I
activator	I
protein	I
(	O
BSAP	B
)	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	O
CD19	O
gene	O
which	O
is	O
similar	O
to	O
the	O
consensus	O
Ah	O
receptor	O
DNA	O
binding	O
site	O
.	O
These	O
results	O
suggest	O
that	O
the	O
AhR	B
could	O
interfere	O
with	O
BSAP	B
-stimulated	O
CD19	O
gene	O
transcription	O
by	O
competition	O
for	O
a	O
common	O
DNA	O
binding	O
site	O
.	O
Inhibitory	O
action	O
of	O
nm23	B
proteins	I
on	O
induction	O
of	O
erythroid	O
differentiation	O
of	O
human	O
leukemia	O
cells	O
.	O
We	O
recently	O
identified	O
a	O
differentiation	B
inhibitory	I
factor	I
(	O
I	B
-	I
factor	I
)	O
in	O
mouse	O
myeloid	O
leukemia	O
M1	O
cells	O
as	O
a	O
murine	B
homolog	I
of	O
the	O
human	B
nm23-H2	I
gene	I
product	I
.	O
nm23	O
genes	O
encode	O
proteins	O
that	O
participate	O
in	O
tumor	O
metastasis	O
regulation	O
and	O
in	O
various	O
fundamental	O
cellular	O
processes	O
,	O
although	O
their	O
mechanisms	O
of	O
action	O
are	O
still	O
unknown	O
.	O
Although	O
all	O
nm23	B
proteins	I
contain	O
nucleoside	B
diphosphate	I
(	I
NDP	I
)	I
kinase	I
activity	O
,	O
it	O
has	O
not	O
been	O
established	O
that	O
the	O
enzyme	O
activity	O
mediated	O
the	O
various	O
functions	O
of	O
nm23	B
proteins	I
.	O
In	O
the	O
present	O
experiment	O
,	O
we	O
examined	O
the	O
effect	O
of	O
nm23	B
proteins	I
on	O
various	O
differentiation	O
induction	O
systems	O
of	O
human	O
leukemic	O
cells	O
including	O
HL-60	O
,	O
U937	O
,	O
HEL	O
/	O
S	O
,	O
KU812F	O
,	O
K562	O
,	O
and	O
HEL	O
cells	O
.	O
Native	B
human	I
erythrocyte	I
NDP	I
kinase	I
protein	I
inhibited	O
the	O
induction	O
of	O
erythroid	O
differentiation	O
of	O
HEL	O
,	O
KU812	O
and	O
K562	O
cells	O
,	O
but	O
not	O
the	O
induction	O
of	O
monocytic	O
or	O
granulocytic	O
differentiation	O
of	O
HL-60	O
,	O
U937	O
and	O
HEL	O
/	O
S	O
cells	O
.	O
The	O
erythroid	O
differentiation	O
of	O
HEL	O
cells	O
was	O
inhibited	O
by	O
recombinant	B
human	I
nm23-H1	I
,	I
-H2	I
,	I
mouse	I
nm23-M1	I
,	I
and	I
-M2	I
proteins	I
.	O
Moreover	O
,	O
both	O
the	O
mutant	B
nm23-H2His	I
protein	I
and	O
truncated	B
nm23-H2	I
protein	I
containing	O
N	B
-	I
terminal	I
(	I
1	I
-	I
60	I
)	I
peptide	I
,	O
which	O
do	O
not	O
have	O
NDP	B
kinase	I
activity	O
,	O
also	O
inhibited	O
erythroid	O
differentiation	O
of	O
HEL	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
(	O
1	O
)	O
the	O
differentiation	O
inhibitory	O
activity	O
of	O
I	B
-	I
factor	I
/	I
nm23	I
protein	I
is	O
not	O
restricted	O
to	O
monocytic	O
differentiation	O
of	O
M1	O
cells	O
,	O
(	O
2	O
)	O
the	O
inhibitory	O
activity	O
is	O
exhibited	O
without	O
species	O
specificity	O
,	O
and	O
(	O
3	O
)	O
the	O
differentiation	O
inhibitory	O
activity	O
of	O
the	O
nm23	B
/	I
NDP	I
kinase	I
protein	I
is	O
independent	O
of	O
its	O
enzyme	O
activity	O
and	O
requires	O
the	O
presence	O
of	O
N	O
-	O
terminal	O
peptides	O
.	O
A	O
conserved	O
motif	O
in	O
the	O
promoters	O
of	O
several	O
cytokines	B
expressed	O
by	O
human	O
Th2-type	O
lymphocytes	O
.	O
We	O
have	O
recently	O
found	O
a	O
novel	O
conserved	O
motif	O
in	O
the	O
promoters	O
of	O
several	O
T	B
-	I
cell	I
-	I
expressed	I
cytokines	I
[	O
human	B
interleukin-2	I
,	I
-4	I
,	I
-5	I
and	I
-13	I
and	O
human	B
and	I
mouse	I
granulocyte	I
/	I
macrophage	I
-	I
colony	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
]	O
.	O
It	O
contains	O
a	O
core	O
sequence	O
CTTGG	O
...	O
CCAAG	O
which	O
is	O
present	O
as	O
part	O
of	O
larger	O
palindromic	O
sequences	O
in	O
each	O
gene	O
.	O
This	O
suggest	O
that	O
they	O
may	O
interact	O
with	O
a	O
new	O
family	O
of	O
trans	B
-	I
acting	I
factors	I
.	O
In	O
transfection	O
assays	O
,	O
the	O
human	O
GM	O
-	O
CSF	O
element	O
has	O
a	O
strong	O
positive	O
effect	O
on	O
the	O
expression	O
of	O
a	O
reporter	O
gene	O
by	O
the	O
human	O
T	O
cell	O
line	O
Jurkat	O
J6	O
upon	O
stimulation	O
.	O
In	O
DNA	O
mobility	O
shift	O
assays	O
,	O
this	O
sequence	O
can	O
give	O
either	O
six	O
different	O
specific	O
bands	O
which	O
are	O
competed	O
out	O
by	O
different	O
parts	O
of	O
the	O
sequence	O
or	O
one	O
specific	O
band	O
which	O
is	O
competed	O
out	O
by	O
each	O
of	O
the	O
inverted	O
repeats	O
,	O
depending	O
on	O
the	O
reconstitution	O
conditions	O
.	O
In	O
different	O
genes	O
,	O
the	O
core	O
sequences	O
are	O
separated	O
by	O
integer	O
numbers	O
of	O
helical	O
turns	O
.	O
Considering	O
the	O
strong	O
positive	O
regulatory	O
effect	O
of	O
this	O
element	O
and	O
its	O
presence	O
in	O
several	O
T	O
-	O
cell	O
-	O
expressed	O
cytokine	O
genes	O
,	O
it	O
may	O
be	O
crucial	O
to	O
the	O
coordinated	O
expression	O
of	O
these	O
cytokines	B
in	O
T	O
helper	O
cells	O
.	O
The	O
interleukin-5	B
/receptor	O
interaction	O
activates	O
Lyn	B
and	I
Jak2	I
tyrosine	I
kinases	I
and	O
propagates	O
signals	O
via	O
the	O
Ras	B
-	I
Raf-1-MAP	I
kinase	I
and	O
the	O
Jak	B
-STAT	B
pathways	O
in	O
eosinophils	O
.	O
We	O
have	O
shown	O
that	O
the	O
interaction	O
of	O
interleukin	B
(	I
IL	I
)	I
-5	I
with	O
the	O
receptor	O
activates	O
Lyn	B
tyrosine	I
kinase	I
within	O
1	O
min	O
and	O
Jak2	B
tyrosine	I
kinase	I
within	O
1	O
-	O
3	O
min	O
.	O
IL-5	B
also	O
stimulates	O
GTP	O
binding	O
to	O
p21ras	B
.	O
The	O
signal	O
is	O
subsequently	O
propagated	O
through	O
the	O
activation	O
of	O
Raf-1	B
,	O
MEK	B
,	O
and	O
MAP	B
kinases	I
as	O
shown	O
by	O
their	O
increased	O
autophosphorylation	O
in	O
vitro	O
and	O
phosphorylation	O
in	O
situ	O
.	O
Jak2	B
kinase	I
has	O
been	O
shown	O
to	O
phosphorylate	O
STAT	B
nuclear	I
proteins	I
.	O
The	O
activation	O
of	O
STAT	B
nuclear	I
factors	I
was	O
studied	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
gamma	O
activation	O
site	O
(	O
GAS	O
)	O
probe	O
.	O
We	O
found	O
that	O
IL-5	B
induces	O
two	O
GAS	B
-	I
binding	I
proteins	I
in	O
eosinophils	O
,	O
one	O
of	O
which	O
is	O
STAT1	B
.	O
We	O
conclude	O
that	O
IL-5	B
induced	O
signals	O
are	O
propagated	O
through	O
two	O
distinct	O
pathways	O
:	O
(	O
1	O
)	O
Lyn	B
--	O
>	O
Ras	B
--	O
>	O
Raf-1	B
--	O
>	O
MEK	B
--	O
>	O
MAP	B
kinase	I
and	O
(	O
2	O
)	O
Jak2	B
--	O
>	O
STAT1	B
.	O
Nitric	O
oxide	O
decreases	O
cytokine	B
-induced	O
endothelial	O
activation	O
.	O
Nitric	O
oxide	O
selectively	O
reduces	O
endothelial	O
expression	O
of	O
adhesion	B
molecules	I
and	O
proinflammatory	B
cytokines	I
.	O
To	O
test	O
the	O
hypothesis	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
limits	O
endothelial	O
activation	O
,	O
we	O
treated	O
cytokine	O
-	O
stimulated	O
human	O
saphenous	O
vein	O
endothelial	O
cells	O
with	O
several	O
NO	O
donors	O
and	O
assessed	O
their	O
effects	O
on	O
the	O
inducible	O
expression	O
of	O
vascular	B
cell	I
adhesion	I
molecule-1	I
(	O
VCAM-1	B
)	O
.	O
In	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
NO	O
inhibited	O
interleukin	B
(	I
IL	I
)	I
-1	I
alpha	O
-	O
stimulated	O
VCAM-1	B
expression	O
by	O
35	O
-	O
55	O
%	O
as	O
determined	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
and	O
flow	O
cytometry	O
.	O
This	O
inhibition	O
was	O
paralleled	O
by	O
reduced	O
monocyte	O
adhesion	O
to	O
endothelial	O
monolayers	O
in	O
nonstatic	O
assays	O
,	O
was	O
unaffected	O
by	O
cGMP	O
analogues	O
,	O
and	O
was	O
quantitatively	O
similar	O
after	O
stimulation	O
by	O
either	O
IL-1	B
alpha	I
,	O
IL-1	B
beta	I
,	O
IL-4	B
,	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
alpha	I
)	O
,	O
or	O
bacterial	O
lipopolysaccharide	O
.	O
NO	O
also	O
decreased	O
the	O
endothelial	O
expression	O
of	O
other	O
leukocyte	B
adhesion	I
molecules	I
(	O
E	B
-	I
selectin	I
and	O
to	O
a	O
lesser	O
extent	O
,	O
intercellular	B
adhesion	I
molecule-1	I
)	O
and	O
secretable	O
cytokines	B
(	O
IL-6	B
and	O
IL-8	B
)	O
.	O
Inhibition	O
of	O
endogenous	O
NO	O
production	O
by	O
L	O
-	O
N	O
-	O
monomethyl	O
-	O
arginine	O
also	O
induced	O
the	O
expression	O
of	O
VCAM-1	B
,	O
but	O
did	O
not	O
augment	O
cytokine	O
-	O
induced	O
VCAM-1	B
expression	O
.	O
Nuclear	O
run	O
-	O
on	O
assays	O
,	O
transfection	O
studies	O
using	O
various	O
VCAM-1	O
promoter	O
reporter	O
gene	O
constructs	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
that	O
NO	O
represses	O
VCAM-1	B
gene	O
transcription	O
,	O
in	O
part	O
,	O
by	O
inhibiting	O
NF	B
-	I
kappa	I
B	I
.	O
We	O
propose	O
that	O
NO	O
's	O
ability	O
to	O
limit	O
endothelial	O
activation	O
and	O
inhibit	O
monocyte	O
adhesion	O
may	O
contribute	O
to	O
some	O
of	O
its	O
antiatherogenic	O
and	O
antiinflammatory	O
properties	O
within	O
the	O
vessel	O
wall	O
.	O
Does	O
thyroidectomy	O
,	O
radioactive	O
iodine	O
therapy	O
,	O
or	O
antithyroid	O
drug	O
treatment	O
alter	O
reactivity	O
of	O
patients	O
'	O
T	O
cells	O
to	O
epitopes	O
of	O
thyrotropin	B
receptor	I
in	O
autoimmune	O
thyroid	O
diseases	O
?	O
The	O
effect	O
of	O
treatment	O
on	O
thyroid	O
antibody	O
production	O
and	O
T	O
cell	O
reactivity	O
to	O
thyroid	O
antigens	O
was	O
studied	O
in	O
15	O
patients	O
with	O
Graves	O
'	O
disease	O
(	O
GD	O
)	O
before	O
and	O
after	O
thyroidectomy	O
,	O
19	O
patients	O
with	O
GD	O
before	O
and	O
after	O
radioactive	O
iodine	O
(	O
RAI	O
)	O
therapy	O
,	O
and	O
9	O
patients	O
maintained	O
euthyroid	O
on	O
antithyroid	O
drugs	O
(	O
ATD	O
)	O
.	O
Twenty	O
subjects	O
matched	O
for	O
age	O
and	O
sex	O
without	O
known	O
thyroid	O
disease	O
served	O
as	O
controls	O
.	O
In	O
GD	O
patients	O
,	O
the	O
responses	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
TSH	O
receptor	O
(	O
TSHR	O
)	O
-specific	O
T	O
cell	O
lines	O
to	O
recombinant	B
human	I
TSHR	I
extracellular	I
domain	I
,	O
thyroglobulin	B
,	O
and	O
TSHR	B
peptides	O
were	O
examined	O
on	O
the	O
day	O
of	O
surgery	O
or	O
RAI	O
therapy	O
(	O
day	O
0	O
)	O
and	O
also	O
6	O
-	O
8	O
weeks	O
and	O
3	O
-	O
6	O
months	O
thereafter	O
.	O
Reactivity	O
to	O
TSHR	B
peptides	O
before	O
surgery	O
was	O
heterogeneous	O
and	O
spanned	O
the	O
entire	O
extracellular	B
domain	I
.	O
Six	O
to	O
8	O
weeks	O
after	O
subtotal	O
thyroidectomy	O
,	O
the	O
number	O
of	O
patients	O
'	O
PBMC	O
responding	O
to	O
any	O
peptide	O
and	O
the	O
average	O
number	O
of	O
recognized	O
peptides	O
decreased	O
.	O
A	O
further	O
decrease	O
in	O
the	O
T	O
cell	O
reactivity	O
to	O
TSHR	B
peptides	O
was	O
observed	O
3	O
-	O
6	O
months	O
after	O
surgery	O
.	O
The	O
responses	O
of	O
PBMC	O
from	O
Graves	O
'	O
patients	O
before	O
RAI	O
therapy	O
were	O
less	O
than	O
those	O
in	O
the	O
presurgical	O
group	O
.	O
Six	O
to	O
8	O
weeks	O
after	O
RAI	O
therapy	O
,	O
the	O
number	O
of	O
patients	O
responding	O
to	O
any	O
peptide	O
and	O
the	O
average	O
number	O
of	O
recognized	O
peptides	O
increased	O
.	O
Three	O
to	O
6	O
months	O
after	O
RAI	O
,	O
T	O
cell	O
responses	O
to	O
TSHR	B
peptides	O
were	O
less	O
than	O
those	O
6	O
-	O
8	O
weeks	O
after	O
RAI	O
therapy	O
,	O
but	O
still	O
higher	O
than	O
the	O
values	O
on	O
day	O
0	O
.	O
Responses	O
of	O
PBMC	O
from	O
patients	O
with	O
GD	O
,	O
maintained	O
euthyroid	O
on	O
ATD	O
,	O
were	O
lower	O
than	O
those	O
before	O
surgery	O
or	O
RAI	O
therapy	O
.	O
The	O
reactivity	O
of	O
T	O
cell	O
lines	O
in	O
different	O
groups	O
reflected	O
a	O
pattern	O
similar	O
to	O
PBMC	O
after	O
treatment	O
.	O
TSHR	B
antibody	I
and	O
microsomal	B
antibody	I
levels	O
decreased	O
after	O
surgery	O
,	O
but	O
increased	O
after	O
RAI	O
therapy	O
.	O
The	O
difference	O
in	O
the	O
number	O
of	O
recognized	O
peptides	O
by	O
patients	O
'	O
PBMC	O
before	O
RAI	O
and	O
surgery	O
may	O
reflect	O
the	O
effect	O
of	O
long	O
term	O
therapy	O
with	O
ATD	O
in	O
the	O
patients	O
before	O
RAI	O
vs.	O
the	O
shorter	O
period	O
in	O
patients	O
before	O
surgery	O
.	O
The	O
decreased	O
T	O
cell	O
reactivity	O
to	O
thyroid	B
antigens	I
after	O
thyroidectomy	O
could	O
be	O
the	O
result	O
of	O
removal	O
of	O
a	O
major	O
part	O
of	O
the	O
thyroid	O
gland	O
or	O
redistribution	O
of	O
suppressor	O
-	O
inducer	O
T	O
cells	O
.	O
The	O
increased	O
T	O
cell	O
response	O
after	O
RAI	O
therapy	O
is	O
probably	O
epitope	O
specific	O
,	O
rather	O
than	O
a	O
response	O
to	O
the	O
whole	O
TSHR	B
molecule	O
.	O
Synchronous	O
recognition	O
of	O
peptides	O
158	O
-	O
176	O
and	O
248	O
-	O
263	O
is	O
important	O
for	O
the	O
development	O
of	O
GD	O
,	O
and	O
the	O
loss	O
of	O
recognition	O
of	O
one	O
of	O
these	O
epitopes	B
may	O
be	O
an	O
early	O
sign	O
of	O
immune	O
remission	O
and	O
a	O
predictor	O
of	O
euthyroidism	O
.	O
Functional	O
roles	O
of	O
the	O
transcription	B
factor	I
Oct-2A	I
and	O
the	O
high	B
mobility	I
group	I
protein	I
I	B
/	I
Y	I
in	O
HLA	O
-	O
DRA	O
gene	O
expression	O
.	O
The	O
class	O
II	O
major	O
histocompatibility	O
complex	O
gene	O
HLA	O
-	O
DRA	O
is	O
expressed	O
in	O
B	O
cells	O
,	O
activated	O
T	O
lymphocytes	O
,	O
and	O
in	O
antigen	O
-	O
presenting	O
cells	O
.	O
In	O
addition	O
,	O
HLA	O
-	O
DRA	O
gene	O
expression	O
is	O
inducible	O
in	O
a	O
variety	O
of	O
cell	O
types	O
by	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
.	O
Here	O
we	O
show	O
that	O
the	O
lymphoid	B
-	I
specific	I
transcription	I
factor	I
Oct-2A	I
plays	O
a	O
critical	O
role	O
in	O
HLA	O
-	O
DRA	O
gene	O
expression	O
in	O
class	O
II	O
-	O
positive	O
B	O
cell	O
lines	O
,	O
and	O
that	O
the	O
high	B
mobility	I
group	I
protein	I
(	O
HMG	B
)	O
I	B
/	I
Y	I
binds	O
to	O
multiple	O
sites	O
within	O
the	O
DRA	O
promoter	O
,	O
including	O
the	O
Oct-2A	O
binding	O
site	O
.	O
Coexpression	O
of	O
HMG	B
I	I
/	I
Y	I
and	O
Oct-2	B
in	O
cell	O
lines	O
lacking	O
Oct-2	B
results	O
in	O
high	O
levels	O
of	O
HLA	O
-	O
DRA	O
gene	O
expression	O
,	O
and	O
in	O
vitro	O
DNA	O
-	O
binding	O
studies	O
reveal	O
that	O
HMG	O
I	B
/	I
Y	I
stimulates	O
Oct-2A	B
binding	O
to	O
the	O
HLA	O
-	O
DRA	O
promoter	O
.	O
Thus	O
,	O
Oct-2A	B
and	O
HMG	B
I	I
/	I
Y	I
may	O
synergize	O
to	O
activate	O
HLA	O
-	O
DRA	O
expression	O
in	O
B	O
cells	O
.	O
By	O
contrast	O
,	O
Oct-2A	B
is	O
not	O
involved	O
in	O
the	O
IFN	B
-	I
gamma	I
induction	O
of	O
the	O
HLA	O
-	O
DRA	O
gene	O
in	O
HeLa	O
cells	O
,	O
but	O
antisense	O
HMG	O
I	O
/	O
Y	O
dramatically	O
decreases	O
the	O
level	O
of	O
induction	O
.	O
We	O
conclude	O
that	O
distinct	O
sets	O
of	O
transcription	B
factors	I
are	O
involved	O
in	O
the	O
two	O
modes	O
of	O
HLA	O
-	O
DRA	O
expression	O
,	O
and	O
that	O
HMG	B
I	I
/	I
Y	I
may	O
be	O
important	O
for	O
B	O
cell	O
-	O
specific	O
expression	O
,	O
and	O
is	O
essential	O
for	O
IFN	B
-	I
gamma	I
induction	O
.	O
RB	B
and	O
a	O
novel	O
E2F-1	B
binding	I
protein	I
in	O
MHC	O
class	O
II	O
deficient	O
B	O
-	O
cell	O
lines	O
and	O
normal	O
IFN	B
-	I
gamma	I
induction	O
of	O
the	O
class	O
IL	O
transactivator	O
CIITA	O
in	O
class	O
II	O
non	O
-	O
inducible	O
RB	O
-	O
defective	O
tumor	O
lines	O
.	O
The	O
major	O
histocompatibility	O
(	O
MHC	O
)	O
class	O
II	O
genes	O
encode	O
cell	B
surface	I
proteins	I
that	O
bind	O
antigenic	O
peptide	O
for	O
presentation	O
to	O
T	O
-	O
cells	O
.	O
The	O
class	B
II	I
proteins	I
are	O
expressed	O
constitutively	O
on	O
B	O
-	O
cells	O
and	O
EBV	O
-	O
transformed	O
B	O
-	O
cells	O
,	O
and	O
are	O
inducible	O
by	O
IFN	B
-	I
gamma	I
on	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
.	O
Retinoblastoma	B
protein	I
(	O
RB	B
)	O
is	O
a	O
tumor	O
suppressor	O
and	O
functions	O
as	O
a	O
transcriptional	B
repressor	I
by	O
binding	O
and	O
inactivating	O
the	O
transactivator	O
E2F	O
-	O
I	O
.	O
RB	O
-	O
defective	O
tumor	O
lines	O
are	O
non	O
-	O
inducible	O
for	O
MHC	B
class	I
II	I
by	O
IFN	B
-	I
gamma	I
,	O
or	O
very	O
weakly	O
inducible	O
,	O
but	O
transfection	O
of	O
2	O
different	O
lines	O
with	O
RB	O
expression	O
vectors	O
re	O
-	O
establishes	O
or	O
substantially	O
enhances	O
class	O
II	O
inducibility	O
.	O
Therefore	O
,	O
we	O
examined	O
the	O
RB	B
status	O
of	O
a	O
series	O
of	O
B	O
-	O
cell	O
mutants	O
that	O
are	O
defective	O
in	O
class	O
II	O
expression	O
,	O
generated	O
either	O
in	O
vitro	O
or	O
derived	O
from	O
Bare	O
Lymphocyte	O
Syndrome	O
(	O
BLS	O
)	O
patients	O
.	O
Nuclear	O
matrix	O
-	O
bound	O
RB	B
was	O
detectable	O
in	O
all	O
cases	O
,	O
indicating	O
that	O
loss	O
of	O
RB	B
is	O
not	O
responsible	O
for	O
decreased	O
class	O
II	O
expression	O
in	O
these	O
lines	O
.	O
A	O
second	O
E2F	O
-	O
I	O
binding	O
protein	O
,	O
most	O
likely	O
DP	O
-	O
I	O
,	O
was	O
also	O
apparently	O
normal	O
in	O
both	O
class	O
II	O
-	O
positive	O
and	O
-negative	O
B	O
-	O
cell	O
lines	O
.	O
We	O
also	O
examined	O
the	O
IFN	B
-	I
gamma	I
induction	O
of	O
CIITA	O
in	O
RB	B
-defective	O
lines	O
.	O
CIITA	O
is	O
a	O
class	O
II	O
gene	O
transactivator	O
known	O
to	O
be	O
defective	O
in	O
one	O
form	O
of	O
BLS	O
and	O
to	O
be	O
required	O
for	O
the	O
induction	O
of	O
MHC	B
class	I
II	I
by	O
IFN	B
-	I
gamma	I
.	O
CIITA	O
mRNA	O
is	O
normally	O
inducible	O
by	O
IFN	B
-	I
gamma	I
in	O
class	O
II	O
non	O
-	O
inducible	O
,	O
RB	O
-	O
defective	O
lines	O
,	O
and	O
in	O
one	O
line	O
,	O
re	O
-	O
expression	O
of	O
RB	B
has	O
no	O
effect	O
on	O
CIITA	O
mRNA	O
induction	O
levels	O
.	O
Thus	O
,	O
the	O
block	O
in	O
MHC	O
class	O
II	O
inducibility	O
in	O
RB	O
-	O
defective	O
cells	O
is	O
not	O
due	O
to	O
a	O
block	O
in	O
CIITA	O
inducibility	O
.	O
Latent	B
membrane	I
protein-1	I
induces	O
cyclin	B
D2	I
expression	O
,	O
pRb	B
hyperphosphorylation	O
,	O
and	O
loss	O
of	O
TGF	B
-	I
beta	I
1	I
-mediated	O
growth	O
inhibition	O
in	O
EBV	O
-	O
positive	O
B	O
cells	O
.	O
The	O
normal	O
cell	O
cycle	O
is	O
regulated	O
by	O
several	O
molecules	O
,	O
such	O
as	O
the	O
tumor	B
-	I
suppressor	I
protein	I
pRb	I
,	O
the	O
G1	B
cyclins	I
,	O
the	O
cyclin	B
-	I
dependent	I
kinases	I
,	O
and	O
their	O
inhibitors	O
.	O
These	O
regulators	O
are	O
targeted	O
by	O
negative	O
growth	O
regulatory	O
signals	O
,	O
such	O
as	O
that	O
provided	O
by	O
TGF	B
-	I
beta	I
.	O
Here	O
,	O
we	O
show	O
that	O
the	O
presence	O
of	O
either	O
wild	O
-	O
type	O
EBV	O
or	O
its	O
transforming	B
latent	I
membrane	I
protein-1	I
(	O
LMP-1	B
)	O
results	O
in	O
the	O
loss	O
of	O
TGF	B
-	I
beta	I
1	I
-mediated	O
growth	O
inhibition	O
in	O
human	O
B	O
cells	O
.	O
Chemical	O
cross	O
-	O
linking	O
with	O
125I	B
-	I
labeled	I
TGF	I
-	I
beta	I
1	I
showed	O
an	O
essentially	O
normal	O
TGF	B
-	I
beta	I
receptor	I
profile	O
in	O
EBV	O
-	O
positive	O
and	O
EBV	O
-	O
negative	O
Burkitt	O
's	O
lymphoma	O
cell	O
lines	O
,	O
and	O
these	O
receptors	O
were	O
shown	O
to	O
be	O
functional	O
in	O
transducing	O
signals	O
,	O
as	O
evidenced	O
by	O
the	O
TGF	B
-	I
beta	I
1	I
-mediated	O
modulation	O
of	O
junB	O
gene	O
expression	O
.	O
However	O
,	O
TGF	B
-	I
beta	I
1	I
did	O
not	O
induce	O
dephosphorylation	O
of	O
pRb	B
in	O
EBV	O
(	O
or	O
LMP-1	O
)	O
-positive	O
cells	O
as	O
opposed	O
to	O
EBV	O
-	O
negative	O
cells	O
,	O
suggesting	O
a	O
dichotomy	O
in	O
the	O
TGF	B
-	I
beta	I
1	I
signaling	O
pathway	O
leading	O
to	O
separable	O
gene	O
regulatory	O
and	O
growth	O
inhibitory	O
responses	O
.	O
Furthermore	O
,	O
LMP-1	B
was	O
found	O
to	O
induce	O
the	O
expression	O
of	O
cyclin	B
D2	I
;	O
normal	O
B	O
cells	O
or	O
EBV	O
-	O
negative	O
Burkitt	O
's	O
lymphoma	O
cells	O
do	O
not	O
express	O
D	B
-	I
type	I
cyclins	I
.	O
Taken	O
together	O
,	O
these	O
data	O
point	O
to	O
a	O
potential	O
mechanism	O
underlying	O
EBV	O
-	O
mediated	O
B	O
cell	O
transformation	O
whereby	O
constitutive	O
induction	O
of	O
key	B
cell	I
cycle	I
regulators	I
by	O
LMP-1	B
can	O
lead	O
to	O
pRb	B
hyperphosphorylation	O
and	O
uncontrolled	O
cell	O
proliferation	O
.	O
Costimulation	O
of	O
human	O
CD4	O
+	O
T	O
cells	O
with	O
LFA-3	B
and	O
B7	B
induce	O
distinct	O
effects	O
on	O
AP-1	O
and	O
NF	B
-	I
kappa	I
B	I
transcription	B
factors	I
.	O
We	O
have	O
earlier	O
shown	O
that	O
stimulation	O
of	O
human	O
CD4	O
+	O
T	O
cells	O
with	O
SEA	O
presented	O
on	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
-DR	O
transfectants	O
coexpressing	O
either	O
B7	B
or	O
LFA-3	B
resulted	O
in	O
distinct	O
cytokine	B
profiles	O
.	O
We	O
now	O
demonstrate	O
that	O
B7	B
,	O
but	O
not	O
LFA-3	B
,	O
strongly	O
costimulated	O
IL-2	B
transcription	O
and	O
mRNA	O
expression	O
in	O
CD4	O
+	O
T	O
cells	O
.	O
Maximal	O
increase	O
in	O
IL-2	B
transcription	O
was	O
recorded	O
with	O
CHO	B
-	I
DR	I
/	I
B7	I
/	I
LFA-3	I
,	O
suggesting	O
a	O
cooperative	O
effect	O
of	O
B7	B
and	O
LFA-3	B
at	O
the	O
transcriptional	O
level	O
.	O
Gel	O
-	O
shift	O
analysis	O
demonstrated	O
that	O
stimulation	O
of	O
CD4	O
+	O
T	O
cells	O
with	O
CHO	B
-	I
DR	I
and	O
staphylococcal	O
enterotoxin	O
A	O
was	O
sufficient	O
to	O
induce	O
significant	O
amounts	O
of	O
NF	B
-	I
kappa	I
B	I
binding	O
proteins	O
,	O
whereas	O
induction	O
of	O
AP-1	B
binding	I
proteins	I
required	O
costimulation	O
.	O
LFA-3	B
induced	O
moderate	O
levels	O
of	O
AP-1	B
,	O
but	O
did	O
not	O
influence	O
the	O
levels	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
while	O
B7	B
costimulation	O
strongly	O
induced	O
both	O
AP-1	B
and	O
substantially	O
enhanced	O
NF	B
-	I
kappa	I
B	I
binding	I
proteins	I
.	O
The	O
CHO	O
-	O
DR	O
/	O
B7	O
/	O
LFA-3	O
triple	O
transfectant	O
induced	O
a	O
further	O
increase	O
in	O
AP-1	B
and	O
NF	B
-	I
kappa	I
B	I
binding	B
proteins	I
compared	O
with	O
the	O
double	O
transfectants	O
.	O
The	O
level	O
of	O
Oct-1	B
binding	I
proteins	I
remained	O
similar	O
in	O
all	O
samples	O
.	O
Super	O
-	O
shift	O
analysis	O
revealed	O
that	O
the	O
NF	B
-	I
kappa	I
B	I
complex	I
of	O
costimulated	O
CD4	O
+	O
T	O
cells	O
contained	O
large	O
amounts	O
of	O
p50	B
,	O
substantial	O
amounts	O
of	O
p65	B
,	O
and	O
marginal	O
levels	O
of	O
c	B
-	I
Rel	I
proteins	I
.	O
The	O
AP-1	B
binding	I
proteins	I
contained	O
c	B
-	I
Jun	I
,	O
Jun	B
-	I
D	I
,	O
and	O
Fra-1	B
,	O
but	O
marginal	O
amounts	O
of	O
Jun	B
-	I
B	I
and	O
c	B
-	I
Fos	I
.	O
Our	O
results	O
indicate	O
distinct	O
effects	O
of	O
B7	B
and	O
LFA-3	B
costimulation	O
on	O
the	O
activity	O
of	O
AP-1	B
and	O
NF	B
-	I
kappa	I
B	I
.	O
These	O
may	O
partly	O
account	O
for	O
the	O
differential	O
effects	O
of	O
B7	B
and	O
LFA-3	B
costimulation	O
on	O
IL-2	B
expression	O
.	O
Multiple	O
signals	O
are	O
required	O
for	O
function	O
of	O
the	O
human	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
gene	O
promoter	O
in	O
T	O
cells	O
.	O
The	O
human	O
granulocyte	O
-	O
macrophage	O
CSF	O
(	O
GM	O
-	O
CSF	O
)	O
gene	O
is	O
expressed	O
in	O
T	O
cells	O
in	O
response	O
to	O
TCR	B
activation	O
that	O
can	O
be	O
mimicked	O
by	O
treatment	O
of	O
the	O
cells	O
with	O
PMA	O
and	O
Ca2	O
+	O
ionophore	O
.	O
The	O
gene	O
contains	O
a	O
proximal	O
functional	O
promoter	O
region	O
(	O
-620	O
to	O
+	O
34	O
)	O
,	O
as	O
well	O
as	O
a	O
powerful	O
enhancer	O
located	O
3	O
kb	O
upstream	O
,	O
both	O
of	O
which	O
are	O
involved	O
in	O
the	O
response	O
of	O
the	O
gene	O
to	O
TCR	B
activation	O
.	O
The	O
proximal	O
promoter	O
contains	O
a	O
region	O
termed	O
CLEO	O
(	O
-54	O
to	O
-31	O
)	O
that	O
consists	O
of	O
a	O
purine	O
-	O
rich	O
element	O
abutting	O
an	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
-like	O
site	O
,	O
as	O
well	O
as	O
an	O
upstream	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
site	O
(	O
-85	O
to	O
-76	O
)	O
and	O
a	O
CK-1	O
element	O
(	O
-101	O
to	O
-92	O
)	O
.	O
We	O
show	O
in	O
this	O
work	O
that	O
mutations	O
in	O
either	O
the	O
purine	O
-	O
rich	O
region	O
of	O
the	O
CLEO	O
element	O
or	O
the	O
NF	O
-	O
kappa	O
B	O
site	O
result	O
in	O
reduced	O
PMA	O
/	O
Ca2	O
+	O
activation	O
of	O
a	O
620-bp	O
human	O
GM	O
-	O
CSF	O
promoter	O
-	O
luciferase	O
reporter	O
construct	O
in	O
Jurkat	O
T	O
cells	O
by	O
65	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O
The	O
major	O
inducible	B
protein	I
complex	I
that	O
binds	O
to	O
the	O
human	O
CLEO	O
(	O
hCLEO	O
)	O
element	O
is	O
an	O
AP-1-like	B
complex	I
that	O
is	O
inducible	O
by	O
PMA	O
alone	O
,	O
but	O
shows	O
increased	O
binding	O
in	O
response	O
to	O
PMA	O
together	O
with	O
Ca2	O
+	O
ionophore	O
.	O
Although	O
the	O
binding	O
of	O
this	O
complex	O
is	O
not	O
cyclosporin	O
-	O
sensitive	O
,	O
promoter	O
induction	O
is	O
inhibited	O
by	O
cyclosporin	O
treatment	O
.	O
A	O
second	O
weak	O
inducible	O
complex	O
resembling	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
was	O
also	O
observed	O
binding	O
to	O
the	O
hCLEO	O
region	O
.	O
By	O
using	O
recombinant	B
proteins	I
,	O
we	O
confirmed	O
that	O
AP-1	B
,	O
NF	B
-	I
ATp	I
,	O
and	O
a	O
higher	O
order	O
NF	B
-	I
ATp	I
/	I
AP-1	I
complex	I
could	O
all	O
form	O
with	O
the	O
hCLEO	O
element	O
,	O
and	O
we	O
have	O
also	O
defined	O
the	O
sequence	O
requirements	O
for	O
binding	O
of	O
each	O
of	O
these	O
complexes	O
.	O
We	O
found	O
that	O
expression	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	B
could	O
substitute	O
for	O
Ca2	O
+	O
ionophore	O
and	O
synergize	O
with	O
PMA	O
to	O
activate	O
the	O
GM	O
-	O
CSF	O
promoter	O
,	O
and	O
conversely	O
that	O
mutant	B
-	I
activated	I
Ras	I
could	O
substitute	O
for	O
PMA	O
and	O
cooperate	O
with	O
Ca2	O
+	O
ionophore	O
.	O
Co	O
-	O
expression	O
of	O
Ras	B
and	O
calcineurin	B
,	O
however	O
,	O
did	O
not	O
activate	O
the	O
GM	O
-	O
CSF	O
promoter	O
,	O
but	O
required	O
the	O
additional	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
p65	I
.	O
These	O
results	O
imply	O
that	O
at	O
least	O
three	O
signals	O
are	O
required	O
to	O
activate	O
the	O
GM	O
-	O
CSF	O
proximal	O
promoter	O
,	O
and	O
that	O
the	O
signals	O
impinge	O
on	O
distinct	O
transcription	B
factors	I
that	O
bind	O
to	O
the	O
hCLEO	O
and	O
NF	O
-	O
kappa	O
B	O
regions	O
of	O
the	O
promoter	O
.	O
C	B
/	I
EBP	I
proteins	I
activate	O
transcription	O
from	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
in	O
macrophages	O
/	O
monocytes	O
.	O
Three	O
binding	O
sites	O
for	O
C	B
/	I
EBP	I
proteins	I
are	O
found	O
in	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
(	O
V.M.	O
Tesmer	O
,	O
A.Rajadhyaksha	O
,	O
J.Babin	O
,	O
and	O
M.Bina	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
90	O
:	O
7298	O
-	O
7302	O
,	O
1993	O
)	O
.	O
We	O
have	O
determined	O
the	O
functional	O
role	O
of	O
C	B
/	I
EBP	I
proteins	I
and	O
C	O
/	O
EBP	O
sites	O
in	O
regulating	O
transcription	O
from	O
the	O
HIV-	O
1	O
LTR	O
in	O
monocytes	O
/	O
macrophages	O
.	O
Inhibition	O
of	O
endogenous	B
C	I
/	I
EBP	I
proteins	I
,	O
using	O
either	O
an	O
excess	O
of	O
C	O
/	O
EBP	O
binding	O
sites	O
or	O
a	O
trans-	O
dominant	O
negative	O
inhibitor	O
,	O
demonstrated	O
that	O
C	B
/	I
EBP	I
proteins	I
are	O
required	O
for	O
basal	O
and	O
activated	O
levels	O
of	O
HIV-1	O
LTR	O
transcription	O
in	O
the	O
promonocytic	O
cell	O
line	O
U937	O
.	O
Northern	O
(	O
RNA	O
)	O
blots	O
and	O
binding	O
assays	O
showed	O
that	O
NF	B
-	I
IL6	I
is	O
the	O
only	O
known	O
C	B
/	I
EBP	I
family	I
member	I
which	O
is	O
increased	O
when	O
U937	O
cells	O
are	O
activated	O
.	O
Mutational	O
analyses	O
of	O
the	O
HIV-1	O
LTR	O
showed	O
that	O
one	O
C	O
/	O
EBP	O
site	O
is	O
required	O
for	O
normal	O
LTR	O
transcription	O
both	O
before	O
and	O
after	O
cellular	O
activation	O
and	O
that	O
the	O
two	O
3	O
'	O
C	O
/	O
EBP	O
sites	O
are	O
functionally	O
equivalent	O
.	O
However	O
,	O
transcription	O
from	O
crippled	O
HIV-1	O
LTRs	O
lacking	O
C	O
/	O
EBP	O
sites	O
can	O
still	O
be	O
induced	O
following	O
activation	O
of	O
U937	O
cells	O
.	O
Several	O
models	O
are	O
suggested	O
for	O
how	O
elevated	O
NF	B
-	I
IL6	I
may	O
participate	O
in	O
an	O
autostimulatory	O
loop	O
involving	O
HIV	O
infection	O
,	O
macrophage	O
activation	O
,	O
cytokine	B
expression	O
,	O
and	O
HIV	O
replication	O
.	O
An	O
IRF-1	B
-dependent	O
pathway	O
of	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
in	O
mitogen	O
-	O
activated	O
T	O
lymphocytes	O
.	O
Lymphocytes	O
are	O
particularly	O
susceptible	O
to	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
,	O
a	O
response	O
which	O
may	O
serve	O
as	O
a	O
form	O
of	O
'	O
altruistic	O
suicide	O
'	O
to	O
counter	O
their	O
intrinsic	O
high	O
potential	O
for	O
mutation	O
and	O
clonal	O
expansion	O
.	O
The	O
tumour	B
suppressor	I
p53	I
has	O
been	O
shown	O
to	O
regulate	O
this	O
type	O
of	O
apoptosis	O
in	O
thymocytes	O
,	O
but	O
an	O
as	O
yet	O
unknown	O
,	O
p53	B
-independent	O
pathway	O
(	O
s	O
)	O
appears	O
to	O
mediate	O
the	O
same	O
event	O
in	O
mitogen	O
-	O
activated	O
mature	O
T	O
lymphocytes	O
.	O
Here	O
we	O
show	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
in	O
these	O
T	O
lymphocytes	O
is	O
dependent	O
on	O
the	O
antioncogenic	B
transcription	I
factor	I
interferon	I
regulatory	I
factor	I
(	B
IRF	I
)	I
-1	I
.	O
Thus	O
two	O
different	O
anti	B
-	I
onco	I
-	I
genic	I
transcription	I
factors	I
,	O
p53	B
and	O
IRF-1	B
,	O
are	O
required	O
for	O
distinct	O
apoptotic	O
pathways	O
in	O
T	O
lymphocytes	O
.	O
We	O
also	O
show	O
that	O
mitogen	O
induction	O
of	O
the	O
interleukin-1	O
beta	O
converting	O
enzyme	O
(	O
ICE	O
)	O
gene	O
,	O
a	O
mammalian	B
homologue	I
of	O
the	O
Caenorhabditis	O
elegans	O
cell	O
death	O
gene	O
ced-3	O
,	O
is	O
IRF-1	B
-dependent	O
.	O
Ectopic	O
overexpression	O
of	O
IRF-1	B
results	O
in	O
the	O
activation	O
of	O
the	O
endogenous	O
gene	O
for	O
ICE	B
and	O
enhances	O
the	O
sensitivity	O
of	O
cells	O
to	O
radiation	O
-	O
induced	O
apoptosis	O
.	O
Sp1	B
functions	O
in	O
a	O
chromatin	O
-dependent	O
manner	O
to	O
augment	O
human	O
alpha	O
-	O
globin	O
promoter	O
activity	O
.	O
The	O
5	O
'	O
flanking	O
region	O
of	O
the	O
human	O
alpha	O
-	O
globin	O
gene	O
is	O
highly	O
G	O
+	O
C	O
rich	O
and	O
contains	O
multiple	O
copies	O
of	O
the	O
consensus	O
sequence	O
for	O
the	O
Sp1	O
binding	O
site	O
.	O
We	O
investigated	O
the	O
role	O
of	O
this	O
G	O
+	O
C	O
-	O
rich	O
region	O
in	O
augmenting	O
alpha	O
-	O
globin	O
promoter	O
activity	O
in	O
the	O
presence	O
of	O
the	O
far	O
-	O
upstream	O
alpha	O
-	O
globin	O
enhancer	O
,	O
HS-40	O
.	O
We	O
show	O
that	O
in	O
transiently	O
transfected	O
erythroid	O
cells	O
,	O
deletion	O
of	O
the	O
alpha	O
-	O
globin	O
G	O
+	O
C	O
-	O
rich	O
5	O
'	O
flanking	O
region	O
has	O
no	O
effect	O
on	O
alpha	O
-	O
globin	O
promoter	O
activity	O
.	O
However	O
,	O
upon	O
stable	O
integration	O
into	O
chromatin	O
,	O
deletion	O
of	O
this	O
region	O
causes	O
a	O
nearly	O
90	O
%	O
decrease	O
in	O
promoter	O
activity	O
compared	O
with	O
expression	O
from	O
an	O
alpha	O
-	O
globin	O
promoter	O
retaining	O
this	O
region	O
.	O
These	O
results	O
suggest	O
that	O
the	O
alpha	O
-	O
globin	O
G	O
+	O
C	O
-	O
rich	O
5	O
'	O
flanking	O
region	O
augments	O
alpha	O
-	O
globin	O
promoter	O
activity	O
in	O
a	O
chromatin	O
-dependent	O
manner	O
.	O
We	O
further	O
show	O
that	O
this	O
G	O
+	O
C	O
-	O
rich	O
region	O
is	O
required	O
for	O
the	O
activation	O
of	O
alpha	O
-	O
globin	O
gene	O
expression	O
during	O
erythroid	O
differentiation	O
.	O
Finally	O
,	O
we	O
show	O
by	O
both	O
footprint	O
analysis	O
and	O
functional	O
assays	O
that	O
the	O
ability	O
of	O
the	O
G	O
+	O
C	O
-	O
rich	O
region	O
to	O
increase	O
alpha	O
-	O
globin	O
promoter	O
activity	O
from	O
a	O
stably	O
integrated	O
alpha	O
-	O
globin	O
gene	O
is	O
mediated	O
by	O
its	O
multiple	O
binding	O
sites	O
for	O
the	O
transcription	B
factor	I
Sp1	B
.	O
Regulation	O
of	O
c	O
-	O
jun	O
mRNA	O
expression	O
by	O
hydroxyurea	O
in	O
human	O
K562	O
cells	O
during	O
erythroid	O
differentiation	O
[	O
published	O
erratum	O
appears	O
in	O
Biochim	O
Biophys	O
Acta	O
1995	O
Dec	O
27	O
;	O
1264	O
(	O
3	O
)	O
:	O
409	O
]	O
Hydroxyurea	O
(	O
HU	O
)	O
is	O
an	O
antitumor	O
agent	O
which	O
also	O
induces	O
hemoglobinization	O
during	O
erythroid	O
differentiation	O
.	O
In	O
addition	O
,	O
HU	O
stimulates	O
the	O
synthesis	O
of	O
fetal	B
hemoglobin	I
in	O
sickle	O
cell	O
anemia	O
patients	O
.	O
To	O
further	O
understand	O
its	O
mechanism	O
of	O
action	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
HU	O
on	O
regulation	O
of	O
c	O
-	O
jun	O
expression	O
prior	O
to	O
the	O
onset	O
of	O
erythroid	O
differentiation	O
of	O
K562	O
cells	O
.	O
HU	O
induced	O
a	O
dose	O
-	O
dependent	O
stimulation	O
of	O
c	O
-	O
jun	O
synthesis	O
.	O
The	O
levels	O
of	O
c	O
-	O
jun	O
mRNA	O
was	O
elevated	O
4	O
to	O
7.5-fold	O
by	O
HU	O
within	O
2	O
h	O
.	O
This	O
was	O
followed	O
by	O
a	O
gradual	O
decline	O
to	O
the	O
basal	O
level	O
by	O
24	O
h	O
.	O
Both	O
nuclear	O
run	O
-	O
on	O
and	O
actinomycin	O
D	O
pulse	O
experiments	O
strongly	O
indicate	O
that	O
HU	O
regulates	O
c	O
-	O
jun	O
mRNA	O
expression	O
by	O
increasing	O
the	O
rate	O
of	O
synthesis	O
as	O
well	O
as	O
stabilizing	O
the	O
c	O
-	O
jun	O
mRNA	O
.	O
In	O
addition	O
,	O
the	O
level	O
of	O
jun	B
protein	I
was	O
elevated	O
by	O
2	O
to	O
5-fold	O
within	O
4	O
h	O
in	O
HU	O
treated	O
cells	O
.	O
Furthermore	O
,	O
concentrations	O
of	O
HU	O
below	O
250	O
microM	O
slightly	O
increased	O
the	O
5X	O
AP-1	B
/CAT	B
activity	O
.	O
These	O
results	O
strongly	O
suggest	O
that	O
HU	O
induces	O
both	O
transcriptional	O
and	O
post	O
-	O
transcription	O
regulation	O
of	O
c	O
-	O
jun	O
during	O
erythroid	O
differentiation	O
.	O
IL-2	O
gene	O
expression	O
and	O
NF	B
-	I
kappa	I
B	I
activation	O
through	O
CD28	B
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	B
.	O
Activation	O
of	O
the	O
CD28	B
surface	I
receptor	I
provides	O
a	O
major	O
costimulatory	O
signal	O
for	O
T	O
cell	O
activation	O
resulting	O
in	O
enhanced	O
production	O
of	O
interleukin-2	B
(	O
IL-2	B
)	O
and	O
cell	O
proliferation	O
.	O
In	O
primary	O
T	O
lymphocytes	O
we	O
show	O
that	O
CD28	B
ligation	O
leads	O
to	O
the	O
rapid	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
which	O
are	O
required	O
for	O
CD28	B
-mediated	O
activation	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
/	O
CD28-responsive	B
complex	I
and	O
IL-2	B
expression	O
.	O
Delineation	O
of	O
the	O
CD28	B
signaling	O
cascade	O
was	O
found	O
to	O
involve	O
protein	B
tyrosine	I
kinase	I
activity	O
,	O
followed	O
by	O
the	O
activation	O
of	O
phospholipase	B
A2	I
and	O
5-lipoxygenase	B
.	O
Our	O
data	O
suggest	O
that	O
lipoxygenase	B
metabolites	I
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	B
expression	O
via	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
These	O
findings	O
should	O
be	O
useful	O
for	O
therapeutic	O
strategies	O
and	O
the	O
development	O
of	O
immunosuppressants	O
targeting	O
the	O
CD28	B
costimulatory	O
pathway	O
.	O
Flutamide	O
in	O
the	O
treatment	O
of	O
hirsutism	O
:	O
long	O
-	O
term	O
clinical	O
effects	O
,	O
endocrine	O
changes	O
,	O
and	O
androgen	B
receptor	I
behavior	O
.	O
OBJECTIVE	O
:	O
To	O
investigate	O
the	O
long	O
-	O
term	O
effects	O
of	O
treatment	O
with	O
low	O
doses	O
of	O
flutamide	O
on	O
clinical	O
and	O
hormonal	O
parameters	O
,	O
as	O
well	O
as	O
on	O
the	O
androgen	B
receptor	I
status	O
,	O
in	O
hirsute	O
women	O
.	O
DESIGN	O
:	O
Eighteen	O
hirsute	O
patients	O
with	O
regular	O
menses	O
were	O
studied	O
basally	O
and	O
during	O
treatment	O
with	O
125	O
mg	O
flutamide	O
,	O
three	O
times	O
per	O
day	O
for	O
12	O
months	O
.	O
Barrier	O
or	O
intrauterine	O
contraception	O
was	O
used	O
during	O
the	O
study	O
in	O
sexually	O
active	O
women	O
.	O
Safety	O
parameters	O
were	O
assessed	O
throughout	O
the	O
study	O
.	O
Hirsutism	O
,	O
graded	O
by	O
the	O
modified	O
Ferriman	O
-	O
Gallwey	O
score	O
,	O
and	O
hormonal	O
parameters	O
were	O
evaluated	O
basally	O
and	O
at	O
4-month	O
intervals	O
during	O
treatment	O
.	O
Gonadotropin	O
-	O
releasing	O
hormone	O
and	O
ACTH	O
stimulation	O
tests	O
were	O
performed	O
before	O
and	O
after	O
3	O
to	O
4	O
months	O
of	O
therapy	O
.	O
In	O
addition	O
,	O
the	O
concentration	O
of	O
androgen	B
receptors	I
in	O
mononuclear	O
leukocytes	O
was	O
measured	O
,	O
in	O
both	O
the	O
follicular	O
and	O
luteal	O
phases	O
of	O
the	O
menstrual	O
cycle	O
,	O
basally	O
and	O
after	O
4	O
months	O
of	O
flutamide	O
treatment	O
.	O
RESULTS	O
:	O
Flutamide	O
was	O
well	O
tolerated	O
in	O
all	O
women	O
,	O
with	O
the	O
noticeable	O
exception	O
of	O
one	O
patient	O
who	O
presented	O
increased	O
serum	B
transaminase	I
after	O
8	O
months	O
of	O
therapy	O
.	O
Hirsutism	O
markedly	O
improved	O
in	O
all	O
women	O
during	O
the	O
treatment	O
(	O
Ferriman	O
-	O
Gallwey	O
score	O
after	O
1	O
year	O
:	O
4.1	O
+	O
/-	O
0.5	O
versus	O
14.1	O
+	O
/-	O
0.9	O
)	O
.	O
A	O
reduction	O
of	O
serum	O
androgens	O
was	O
found	O
,	O
whereas	O
no	O
change	O
was	O
observed	O
in	O
either	O
basal	O
or	O
GnRH	O
-	O
stimulated	O
gonadotropins	O
or	O
in	O
the	O
cortisol	O
and	O
17	O
alpha	O
-	O
hydroxyprogesterone	O
response	O
to	O
ACTH	O
.	O
Cycles	O
remained	O
ovulatory	O
.	O
Before	O
treatment	O
,	O
the	O
number	O
of	O
androgen	B
receptors	I
was	O
higher	O
in	O
the	O
luteal	O
than	O
in	O
the	O
follicular	O
phase	O
.	O
This	O
rhythmic	O
differentiation	O
disappeared	O
after	O
the	O
patients	O
had	O
been	O
given	O
the	O
antiandrogen	O
drug	O
.	O
CONCLUSIONS	O
:	O
Flutamide	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
hirsutism	O
but	O
requires	O
constant	O
surveillance	O
of	O
liver	O
function	O
.	O
Androgen	O
receptor	O
blockade	O
might	O
be	O
potentiated	O
by	O
a	O
reduction	O
of	O
serum	O
androgens	O
.	O
Flutamide	O
affects	O
androgen	B
receptor	I
behavior	O
during	O
the	O
menstrual	O
cycle	O
.	O
The	O
meaning	O
of	O
this	O
finding	O
remains	O
to	O
be	O
elucidated	O
.	O
Interleukin	O
2	O
signaling	O
involves	O
the	O
phosphorylation	O
of	O
Stat	B
proteins	I
.	O
One	O
of	O
the	O
most	O
important	O
cytokines	B
involved	O
in	O
immune	O
response	O
regulation	O
is	O
interleukin	O
2	O
(	O
IL-2	O
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
proliferation	O
and	O
function	O
of	O
T	O
lymphocytes	O
and	O
natural	O
killer	O
cells	O
.	O
The	O
mechanisms	O
by	O
which	O
the	O
effects	O
of	O
IL-2	B
are	O
propagated	O
within	O
cells	O
are	O
not	O
understood	O
.	O
While	O
the	O
binding	O
of	O
IL-2	B
to	O
its	O
receptor	O
was	O
recently	O
shown	O
to	O
lead	O
to	O
the	O
activation	O
of	O
two	O
kinases	B
,	O
Jak-1	B
and	O
Jak-3	B
,	O
subsequent	O
steps	O
in	O
the	O
signaling	O
pathway	O
to	O
the	O
nucleus	O
that	O
lead	O
to	O
the	O
activation	O
of	O
specific	O
genes	O
had	O
not	O
been	O
characterized	O
.	O
Since	O
many	O
cytokines	B
that	O
activate	O
Jak	B
kinases	I
also	O
lead	O
to	O
the	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
members	O
of	O
the	O
Stat	B
family	I
of	O
transcription	B
factors	I
,	O
the	O
ability	O
of	O
IL-2	B
to	O
trigger	O
Stat	O
phosphorylation	O
was	O
examined	O
.	O
Exposure	O
of	O
activated	O
human	O
T	O
lymphocytes	O
or	O
of	O
a	O
natural	O
killer	O
cell	O
line	O
(	O
NKL	O
)	O
to	O
IL-2	B
leads	O
to	O
the	O
phosphorylation	O
of	O
Stat1	B
alpha	I
,	O
Stat1	O
beta	O
,	O
and	O
Stat3	B
,	O
as	O
well	O
as	O
of	O
two	O
Stat	B
-	I
related	I
proteins	I
,	O
p94	B
and	O
p95	B
.	O
p94	B
and	O
p95	B
share	O
homology	O
with	O
Stat1	B
at	O
the	O
phosphorylation	B
site	I
and	O
in	O
the	O
Src	B
homology	I
2	I
(	I
SH2	I
)	I
domain	I
,	O
but	O
otherwise	O
are	O
immunologically	O
distinct	O
from	O
Stat1	B
.	O
These	O
Stat	B
proteins	I
were	O
found	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
to	O
bind	O
to	O
a	O
specific	O
DNA	O
sequence	O
.	O
These	O
findings	O
suggest	O
a	O
mechanism	O
by	O
which	O
IL-2	B
binding	O
to	O
its	O
receptor	O
may	O
activate	O
specific	O
genes	O
involved	O
in	O
immune	O
cell	O
function	O
.	O
Activation	O
of	O
the	O
HIV-1	O
enhancer	O
by	O
the	O
LEF-1	B
HMG	I
protein	I
on	O
nucleosome	O
-	O
assembled	O
DNA	O
in	O
vitro	O
.	O
Lymphoid	B
enhancer	I
-	I
binding	I
factor	I
1	I
(	O
LEF-1	B
)	O
is	O
a	O
regulatory	B
high	I
mobility	I
group	I
(	I
HMG	I
)	I
protein	I
that	O
activates	O
the	O
T	O
cell	O
receptor	O
alpha	O
(	O
TCR	O
alpha	O
)	O
enhancer	O
in	O
a	O
context	O
-	O
restricted	O
manner	O
in	O
T	O
cells	O
.	O
In	O
this	O
paper	O
we	O
demonstrate	O
that	O
the	O
distal	O
region	O
of	O
the	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
enhancer	O
,	O
which	O
contains	O
DNA	O
-	O
binding	O
sites	O
for	O
LEF-1	B
and	O
Ets-1	O
,	O
also	O
provides	O
a	O
functional	O
context	O
for	O
activation	O
by	O
LEF-1	B
.	O
First	O
,	O
we	O
show	O
that	O
mutations	O
in	O
the	O
LEF-1-binding	O
site	O
inhibit	O
the	O
activity	O
of	O
multimerized	O
copies	O
of	O
the	O
HIV-1	O
enhancer	O
in	O
Jurkat	O
T	O
cells	O
,	O
and	O
that	O
LEF-1	B
/	I
GAL4	I
can	O
activate	O
a	O
GAL4-substituted	O
HIV-1	O
enhancer	O
80-	O
to	O
100-fold	O
in	O
vivo	O
.	O
Second	O
,	O
recombinant	B
LEF-1	I
is	O
shown	O
to	O
activate	O
HIV-1	O
transcription	O
on	O
chromatin	O
-	O
assembled	O
DNA	O
in	O
vitro	O
.	O
By	O
using	O
a	O
nucleosome	B
-assembly	O
system	O
derived	O
from	O
Drosophila	O
embryos	O
,	O
we	O
find	O
that	O
the	O
packaging	O
of	O
DNA	O
into	O
chromatin	O
in	O
vitro	O
strongly	O
represses	O
HIV-1	O
transcription	O
and	O
that	O
repression	O
can	O
be	O
counteracted	O
efficiently	O
by	O
preincubation	O
of	O
the	O
DNA	O
with	O
LEF-1	B
(	O
or	O
LEF-1	B
and	O
Ets-1	B
)	O
supplemented	O
with	O
fractions	O
containing	O
the	O
promoter	B
-	I
binding	I
protein	I
,	O
Sp1	B
.	O
Addition	O
of	O
TFE-3	B
,	O
which	O
binds	O
to	O
an	O
E	O
-	O
box	O
motif	O
upstream	O
of	O
the	O
LEF-1	O
and	O
Ets-1	O
sites	O
,	O
further	O
augments	O
transcription	O
in	O
this	O
system	O
.	O
Individually	O
or	O
collectively	O
,	O
none	O
of	O
the	O
three	O
enhancer	B
-	I
binding	I
proteins	I
(	O
LEF-1	B
,	O
Ets-1	B
,	O
and	O
TFE-3	B
)	O
could	O
activate	O
transcription	O
in	O
the	O
absence	O
of	O
Sp1	B
.	O
A	O
truncation	B
mutant	I
of	O
LEF-1	B
(	O
HMG-88	B
)	O
,	O
which	O
contains	O
the	O
HMG	B
box	I
but	O
lacks	O
the	O
trans	B
-	I
activation	I
domain	I
,	O
did	O
not	O
activate	O
transcription	O
from	O
nucleosomal	O
DNA	O
,	O
indicating	O
that	O
bending	O
of	O
DNA	O
by	O
the	O
HMG	B
domain	I
is	O
not	O
sufficient	O
to	O
activate	O
transcription	O
in	O
vitro	O
.	O
We	O
conclude	O
that	O
transcription	O
activation	O
by	O
LEF-1	B
in	O
vitro	O
is	O
a	O
chromatin	O
-dependent	O
process	O
that	O
requires	O
a	O
functional	O
trans	B
-	I
activation	I
domain	I
in	O
addition	O
to	O
the	O
HMG	B
domain	I
.	O
Phosphorylation	O
of	O
the	O
transcription	B
factor	I
NFATp	B
inhibits	O
its	O
DNA	O
binding	O
activity	O
in	O
cyclosporin	O
A	O
-	O
treated	O
human	O
B	O
and	O
T	O
cells	O
.	O
Cyclosporin	O
A	O
(	O
CsA	O
)	O
exerts	O
its	O
immunosuppressive	O
effect	O
by	O
inhibiting	O
the	O
activity	O
of	O
nuclear	B
factor	I
of	O
activated	O
T	O
cells	O
(	O
NFAT	B
)	O
,	O
thus	O
preventing	O
transcriptional	O
induction	O
of	O
several	O
cytokine	O
genes	O
.	O
This	O
effect	O
is	O
thought	O
to	O
be	O
largely	O
mediated	O
through	O
inactivation	O
of	O
the	O
phosphatase	O
calcineurin	B
,	O
which	O
in	O
turn	O
inhibits	O
translocation	O
of	O
an	O
NFAT	B
component	O
to	O
the	O
nucleus	O
.	O
Here	O
we	O
report	O
that	O
CsA	O
treatment	O
of	O
Raji	O
B	O
and	O
Jurkat	O
T	O
cell	O
lines	O
yields	O
a	O
phosphorylated	O
form	O
of	O
NFATp	B
that	O
is	O
inhibited	O
in	O
DNA	O
-	O
binding	O
and	O
in	O
its	O
ability	O
to	O
form	O
an	O
NFAT	B
complex	I
with	O
Fos	B
and	O
Jun	B
.	O
Immunoblot	O
analyses	O
and	O
metabolic	O
labeling	O
with	O
[	O
32P	O
]	O
orthophosphate	O
show	O
that	O
CsA	O
alters	O
NFATp	B
migration	O
on	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
by	O
increasing	O
its	O
phosphorylation	O
level	O
without	O
affecting	O
subcellular	O
distribution	O
.	O
Dephosphorylation	O
by	O
in	O
vitro	O
treatment	O
with	O
calcineurin	B
or	O
alkaline	B
phosphatase	I
restores	O
NFATp	B
DNA	O
binding	O
activity	O
and	O
its	O
ability	O
to	O
reconstitute	O
an	O
NFAT	B
complex	I
with	O
Fos	B
and	O
Jun	B
proteins	O
.	O
These	O
data	O
point	O
to	O
a	O
new	O
mechanism	O
for	O
CsA	O
-	O
sensitive	O
regulation	O
of	O
NFATp	B
in	O
which	O
dephosphorylation	O
is	O
critical	O
for	O
DNA	O
binding	O
.	O
Regulation	O
of	O
transcription	O
of	O
the	O
human	O
erythropoietin	O
receptor	O
gene	O
by	O
proteins	O
binding	O
to	O
GATA-1	O
and	O
Sp1	O
motifs	O
.	O
Erythropoietin	B
(	O
Epo	B
)	O
,	O
the	O
primary	O
regulator	O
of	O
the	O
production	O
of	O
erythroid	O
cells	O
,	O
acts	O
by	O
binding	O
to	O
a	O
cell	B
surface	I
receptor	I
(	O
EpoR	B
)	O
on	O
erythroid	O
progenitors	O
.	O
We	O
used	O
deletion	O
analysis	O
and	O
transfection	O
assays	O
with	O
reporter	O
gene	O
constructs	O
to	O
examine	O
the	O
transcription	O
control	O
elements	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
human	O
EpoR	O
gene	O
.	O
In	O
erythroid	O
cells	O
most	O
of	O
the	O
transcription	O
activity	O
was	O
contained	O
in	O
a	O
150	O
bp	O
promoter	O
fragment	O
with	O
binding	O
sites	O
for	O
transcription	B
factors	I
AP2	B
,	O
Sp1	B
and	O
the	O
erythroid	B
-	I
specific	I
GATA-1	I
.	O
The	O
150	O
bp	O
hEpoR	O
promoter	O
exhibited	O
high	O
and	O
low	O
activity	O
in	O
erythroid	O
OCIM1	O
and	O
K562	O
cells	O
,	O
respectively	O
,	O
reflecting	O
the	O
high	O
and	O
low	O
levels	O
of	O
constitutive	O
hEpoR	B
expression	O
.	O
The	O
GATA-1	O
and	O
Sp1	O
binding	O
sites	O
in	O
this	O
promoter	O
lacking	O
a	O
TATA	O
sequence	O
were	O
necessary	O
for	O
a	O
high	O
level	O
of	O
transcription	O
activation	O
.	O
Protein	O
-	O
DNA	O
binding	O
studies	O
suggested	O
that	O
Sp1	B
and	O
two	O
other	O
CCGCCC	B
binding	I
proteins	I
from	O
erythroid	O
and	O
non	O
-	O
erythroid	O
cells	O
could	O
bind	O
to	O
the	O
Sp1	O
binding	O
motif	O
.	O
By	O
increasing	O
GATA-1	B
levels	O
via	O
co	O
-	O
transfection	O
,	O
we	O
were	O
able	O
to	O
transactivate	O
the	O
hEpoR	O
promoter	O
in	O
K562	O
cells	O
and	O
non	O
-	O
erythroid	O
cells	O
,	O
but	O
not	O
in	O
the	O
highly	O
active	O
OCIM1	O
cells	O
,	O
although	O
GATA-1	O
mRNA	O
levels	O
were	O
comparable	O
in	O
OCIM1	O
and	O
K562	O
.	O
Interestingly	O
,	O
when	O
we	O
mutated	O
the	O
Sp1	O
site	O
,	O
resulting	O
in	O
a	O
marked	O
decrease	O
in	O
hEpoR	O
promoter	O
activity	O
,	O
we	O
could	O
restore	O
transactivation	O
by	O
increasing	O
GATA-1	B
levels	O
in	O
OCIM1	O
cells	O
.	O
These	O
data	O
suggest	O
that	O
while	O
GATA-1	B
can	O
transactivate	O
the	O
EpoR	O
promoter	O
,	O
the	O
level	O
of	O
hEpoR	O
gene	O
expression	O
does	O
not	O
depend	O
on	O
GATA-1	B
alone	O
.	O
Rather	O
,	O
hEpoR	B
transcription	O
activity	O
depends	O
on	O
coordination	O
between	O
Sp1	B
and	O
GATA-1	B
with	O
other	O
cell	B
-	I
specific	I
factors	I
,	O
including	O
possibly	O
other	O
Sp1-like	B
binding	I
proteins	I
,	O
to	O
provide	O
high	O
level	O
,	O
tissue	O
-	O
specific	O
expression	O
.	O
TCL1	O
oncogene	O
activation	O
in	O
preleukemic	O
T	O
cells	O
from	O
a	O
case	O
of	O
ataxia	O
-	O
telangiectasia	O
.	O
The	O
TCL1	O
oncogene	O
on	O
human	O
chromosome	O
14q32.1	O
is	O
involved	O
in	O
chromosome	O
translocations	O
[	O
t	O
(	O
14	O
;	O
14	O
)	O
(	O
q11	O
;	O
q32.1	O
)	O
and	O
t	O
(	O
7	O
;	O
14	O
)	O
(	O
q35	O
;	O
q32.1	O
)	O
]	O
and	O
inversions	O
[	O
inv14	O
(	O
q11	O
;	O
q32.1	O
)	O
]	O
with	O
TCR	O
alpha	O
/	O
beta	O
loci	O
in	O
T	O
-	O
cell	O
leukemias	O
,	O
such	O
as	O
T	O
-	O
prolymphocytic	O
(	O
T	O
-	O
PLL	O
)	O
.	O
It	O
is	O
also	O
involved	O
in	O
T-	O
acute	O
and-	O
chronic	O
leukemias	O
arising	O
in	O
cases	O
of	O
ataxia	O
-	O
telangiectasia	O
(	O
AT	O
)	O
,	O
an	O
immunodeficiency	O
syndrome	O
.	O
Similar	O
chromosomal	O
rearrangements	O
occur	O
also	O
in	O
the	O
clonally	O
expanded	O
T	O
cells	O
in	O
AT	O
patients	O
before	O
the	O
appearance	O
of	O
the	O
overt	O
leukemia	O
.	O
We	O
have	O
analyzed	O
the	O
expression	O
of	O
TCL1	O
mRNA	O
and	O
protein	B
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBLs	O
)	O
from	O
four	O
AT	O
cases	O
and	O
from	O
healthy	O
controls	O
.	O
We	O
found	O
that	O
the	O
TCL1	O
gene	O
was	O
overexpressed	O
in	O
the	O
PBLs	O
of	O
an	O
AT	O
patient	O
with	O
a	O
large	O
clonal	O
T	O
-	O
cell	O
population	O
exhibiting	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
but	O
not	O
in	O
the	O
lymphocytes	O
of	O
the	O
other	O
cases	O
.	O
Fluorescence	O
in	O
situ	O
hybridization	O
of	O
the	O
TCL1	O
genomic	O
locus	O
to	O
lymphocyte	O
metaphases	O
from	O
the	O
AT	O
patient	O
with	O
the	O
T	O
-	O
cell	O
clonal	O
expansion	O
showed	O
that	O
the	O
breakpoint	O
of	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
lies	O
within	O
the	O
TCL1	O
locus	O
and	O
is	O
accompanied	O
by	O
an	O
inverted	O
duplication	O
of	O
the	O
distal	O
part	O
of	O
chromosome	O
14	O
.	O
These	O
data	O
indicate	O
that	O
TCL1	O
is	O
activated	O
in	O
preleukemic	O
clonal	O
cells	O
as	O
a	O
consequence	O
of	O
chromosome	O
translocation	O
involving	O
sequences	O
from	O
the	O
TCR	O
locus	O
at	O
14q11	O
.	O
Deregulation	O
of	O
TCL1	O
is	O
the	O
first	O
event	O
in	O
the	O
initiation	O
of	O
malignancy	O
in	O
these	O
types	O
of	O
leukemias	O
and	O
represents	O
a	O
potential	O
tool	O
for	O
clinical	O
evaluation	O
.	O
Transcriptional	O
regulation	O
of	O
the	O
gene	O
encoding	O
the	O
human	B
C	I
-	I
type	I
lectin	I
leukocyte	I
receptor	I
AIM	B
/	I
CD69	I
and	O
functional	O
characterization	O
of	O
its	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
-	O
responsive	O
elements	O
.	O
The	O
human	B
activation	I
antigen	I
CD69	B
is	O
a	O
member	O
of	O
the	O
C	B
-	I
type	I
animal	I
lectin	I
superfamily	I
that	O
functions	O
as	O
a	O
signal	B
-	I
transmitting	I
receptor	I
.	O
Although	O
the	O
expression	O
of	O
CD69	B
can	O
be	O
induced	O
in	O
vitro	O
on	O
cells	O
of	O
most	O
hematopoietic	O
lineages	O
with	O
a	O
wide	O
variety	O
of	O
stimuli	O
,	O
in	O
vivo	O
it	O
is	O
mainly	O
expressed	O
by	O
T	O
-	O
lymphocytes	O
located	O
in	O
the	O
inflammatory	O
infiltrates	O
of	O
several	O
human	O
diseases	O
.	O
To	O
elucidate	O
the	O
mechanisms	O
that	O
regulate	O
the	O
constitutive	O
and	O
inducible	O
expression	O
of	O
CD69	B
by	O
leukocytes	O
,	O
we	O
isolated	O
the	O
promoter	O
region	O
of	O
the	O
CD69	B
gene	O
and	O
carried	O
out	O
its	O
functional	O
characterization	O
.	O
Sequence	O
analysis	O
of	O
the	O
5'-flanking	O
region	O
of	O
the	O
CD69	O
gene	O
revealed	O
the	O
presence	O
of	O
a	O
potential	O
TATA	O
element	O
30	O
base	O
pairs	O
upstream	O
of	O
the	O
major	O
transcription	O
initiation	O
site	O
and	O
several	O
putative	O
binding	O
sequences	O
for	O
inducible	O
transcription	B
factors	I
(	O
NF	B
-	I
kappa	I
B	I
,	O
Egr-1	B
,	O
AP-1	B
)	O
,	O
which	O
might	O
mediate	O
the	O
inducible	O
expression	O
of	O
this	O
gene	O
.	O
Transient	O
expression	O
of	O
CD69	O
promoter	O
-	O
based	O
reporter	O
gene	O
constructs	O
in	O
K562	O
cells	O
indicated	O
that	O
the	O
proximal	O
promoter	O
region	O
spanning	O
positions	O
-78	O
to	O
+	O
16	O
contained	O
the	O
cis	O
-	O
acting	O
sequences	O
necessary	O
for	O
basal	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
-	O
inducible	O
transcription	O
of	O
the	O
CD69	O
gene	O
.	O
Removal	O
of	O
the	O
upstream	O
sequences	O
located	O
between	O
positions	O
-78	O
and	O
-38	O
resulted	O
in	O
decreased	O
promoter	O
strength	O
and	O
abolished	O
the	O
response	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
.	O
We	O
also	O
found	O
that	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
is	O
capable	O
of	O
inducing	O
the	O
surface	O
expression	O
of	O
the	O
CD69	B
molecule	O
as	O
well	O
as	O
the	O
promoter	O
activity	O
of	O
fusion	O
plasmids	O
that	O
contain	O
5'-flanking	O
sequences	O
of	O
the	O
CD69	B
gene	O
,	O
suggesting	O
that	O
this	O
cytokine	O
may	O
regulate	O
in	O
vivo	O
the	O
expression	O
of	O
CD69	B
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Ubiquitin	O
-	O
mediated	O
processing	O
of	O
NF	B
-	I
kappa	I
B	I
transcriptional	B
activator	I
precursor	I
p105	B
.	O
Reconstitution	O
of	O
a	O
cell	O
-	O
free	O
system	O
and	O
identification	O
of	O
the	O
ubiquitin	B
-	I
carrier	I
protein	I
,	O
E2	B
,	O
and	O
a	O
novel	O
ubiquitin	B
-	I
protein	I
ligase	I
,	O
E3	B
,	O
involved	O
in	O
conjugation	O
.	O
In	O
most	O
cases	O
,	O
the	O
transcriptional	B
factor	I
NF	B
-	I
kappa	I
B	I
is	O
a	O
heterodimer	B
consisting	O
of	O
two	O
subunits	O
,	O
p50	B
and	O
p65	B
,	O
which	O
are	O
encoded	O
by	O
two	O
distinct	O
genes	O
of	O
the	O
Rel	O
family	O
.	O
p50	B
is	O
translated	O
as	O
a	O
precursor	O
of	O
105	B
kDa	I
.	O
The	O
C	B
-	I
terminal	I
domain	I
of	O
the	O
precursor	O
is	O
rapidly	O
degraded	O
,	O
forming	O
the	O
mature	B
p50	I
subunit	I
consisted	O
of	O
the	O
N	B
-	I
terminal	I
region	I
of	O
the	O
molecule	O
.	O
The	O
mechanism	O
of	O
generation	O
of	O
p50	B
is	O
not	O
known	O
.	O
It	O
has	O
been	O
suggested	O
that	O
the	O
ubiquitin	B
-proteasome	B
system	O
is	O
involved	O
in	O
the	O
process	O
;	O
however	O
,	O
the	O
specific	O
enzymes	B
involved	O
and	O
the	O
mechanism	O
of	O
limited	O
proteolysis	O
,	O
in	O
which	O
half	O
of	O
the	O
molecule	O
is	O
spared	O
,	O
have	O
been	O
obscure	O
.	O
Palombella	O
and	O
colleagues	O
(	O
Palombella	O
,	O
V.J.	O
,	O
Rando	O
,	O
O.J.	O
,	O
Goldberg	O
,	O
A.L.	O
,	O
and	O
Maniatis	O
,	O
T.	O
(	O
1994	O
)	O
Cell	O
78	O
,	O
773	O
-	O
785	O
)	O
have	O
shown	O
that	O
ubiquitin	B
is	O
required	O
for	O
the	O
processing	O
in	O
a	O
cell	O
-	O
free	O
system	O
of	O
a	O
truncated	O
,	O
artificially	O
constructed	O
,	O
60-kDa	B
precursor	I
.	O
They	O
have	O
also	O
shown	O
that	O
proteasome	B
inhibitors	O
block	O
the	O
processing	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
reconstitution	O
of	O
a	O
cell	O
-	O
free	O
processing	O
system	O
and	O
demonstrate	O
directly	O
that	O
:	O
(	O
a	O
)	O
the	O
ubiquitin	B
-proteasome	B
system	O
is	O
involved	O
in	O
processing	O
of	O
the	O
intact	O
p105	B
precursor	O
,	O
(	O
b	O
)	O
conjugation	O
of	O
ubiquitin	B
to	O
the	O
precursor	O
is	O
an	O
essential	O
intermediate	O
step	O
in	O
the	O
processing	O
,	O
(	O
c	O
)	O
the	O
recently	O
discovered	O
novel	O
species	O
of	O
the	O
ubiquitin	B
-	I
carrier	I
protein	I
,	O
E2-F1	B
,	O
that	O
is	O
involved	O
in	O
the	O
conjugation	O
and	O
degradation	O
of	O
p53	B
,	O
is	O
also	O
required	O
for	O
the	O
limited	O
processing	O
of	O
the	O
p105	B
precursor	I
,	O
and	O
(	O
d	O
)	O
a	O
novel	O
,	O
approximately	O
320-kDa	B
species	I
of	O
ubiquitin	B
-	I
protein	I
ligase	I
,	O
is	O
involved	O
in	O
the	O
process	O
.	O
This	O
novel	O
enzyme	O
is	O
distinct	O
from	O
E6-AP	B
,	O
the	O
p53-conjugating	B
ligase	I
,	O
and	O
from	O
E3	B
alpha	I
,	O
the	O
`	B
`	I
N	I
-	I
end	I
rule	I
''	I
ligase	I
.	O
Regulation	O
of	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
and	O
E	B
-	I
selectin	I
expression	O
in	O
endothelial	O
cells	O
by	O
cyclosporin	O
A	O
and	O
the	O
T	B
-	I
cell	I
transcription	I
factor	I
NFAT	B
.	O
Nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT	B
)	O
was	O
originally	O
described	O
as	O
a	O
T	B
-	I
cell	I
-	I
specific	I
transcription	I
factor	I
athat	O
supported	O
the	O
activation	O
of	O
cytokine	B
gene	O
expression	O
and	O
mediated	O
the	O
immunoregulatory	B
effects	O
of	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O
As	O
we	O
observed	O
that	O
activated	O
endothelial	O
cells	O
also	O
expressed	O
NFAT	B
,	O
we	O
tested	O
the	O
antiinflammatory	O
properties	O
of	O
CsA	O
in	O
endothelial	O
cells	O
.	O
Significantly	O
,	O
CsA	O
completely	O
suppressed	O
the	O
induction	O
of	O
NFAT	B
in	O
endothelial	O
cells	O
and	O
inhibited	O
the	O
activity	O
of	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
gene	O
regulatory	O
elements	O
that	O
use	O
NFAT	B
by	O
60	O
%	O
.	O
CsA	O
similarly	O
mediated	O
a	O
reduction	O
of	O
up	O
to	O
65	O
%	O
in	O
GM	O
-	O
CSF	O
mRNA	O
and	O
protein	O
expression	O
in	O
activated	O
endothelial	O
cells	O
.	O
CsA	O
also	O
suppressed	O
E	B
-	I
selectin	I
,	O
but	O
not	O
vascular	B
cell	I
adhesion	I
molecule-1	I
(	O
VCAM-1	B
)	O
expression	O
in	O
endothelial	O
cells	O
,	O
even	O
though	O
the	O
E	O
-	O
selectin	O
promoter	O
is	O
activated	O
by	O
NF	B
-	I
kappa	I
B	I
rather	O
than	O
NFAT	B
.	O
Hence	O
,	O
induction	O
of	O
cell	O
surface	O
expression	O
of	O
this	O
leukocyte	B
adhesion	I
molecule	I
by	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
-alpha	I
was	O
reduced	O
by	O
40	O
%	O
in	O
the	O
presence	O
of	O
CsA	O
,	O
and	O
this	O
was	O
reflected	O
by	O
a	O
29	O
%	O
decrease	O
in	O
neutrophil	O
adhesion	O
.	O
The	O
effects	O
of	O
CsA	O
on	O
endothelial	O
cells	O
were	O
also	O
detected	O
at	O
the	O
chromatin	O
structure	O
level	O
,	O
as	O
DNasel	O
hypersensitive	O
sites	O
within	O
both	O
the	O
GM	B
-	I
CSF	I
enhancer	O
and	O
the	O
E	O
-	O
selectin	O
promoter	O
were	O
suppressed	O
by	O
CsA	O
.	O
This	O
represents	O
the	O
first	O
report	O
of	O
NFAT	B
in	O
endothelial	O
cells	O
and	O
suggests	O
mechanisms	O
by	O
which	O
CsA	O
could	O
function	O
as	O
an	O
antiinflammatory	O
agent	O
.	O
The	O
hematopoietic	B
transcription	I
factor	I
PU.1	B
is	O
downregulated	O
in	O
human	O
multiple	O
myeloma	O
cell	O
lines	O
.	O
PU.1	B
is	O
a	O
hematopoietic	B
transcription	I
factor	I
belonging	O
to	O
the	O
Ets	B
-	I
family	I
.	O
It	O
is	O
identical	O
to	O
the	O
Spi-1	O
oncogene	O
,	O
which	O
is	O
implicated	O
in	O
spleen	O
focus	O
-	O
forming	O
virus	O
-	O
induced	O
murine	O
erythroleukemias	O
.	O
PU.1	B
seems	O
to	O
be	O
required	O
for	O
early	O
development	O
of	O
multiple	O
hematopoietic	O
lineages	O
,	O
but	O
its	O
expression	O
in	O
mature	O
cells	O
is	O
preferentially	O
observed	O
in	O
cells	O
of	O
the	O
B	O
-	O
cell	O
-	O
and	O
monocyte	O
/	O
macrophage	O
-	O
differentiation	O
lineage	O
.	O
It	O
binds	O
the	O
so	O
-	O
called	O
Pu	O
box	O
,	O
an	O
important	O
tissue	O
-	O
specific	O
regulatory	O
DNA	O
element	O
present	O
in	O
a	O
number	O
of	O
genes	O
expressed	O
in	O
these	O
cell	O
lineages	O
.	O
We	O
have	O
analyzed	O
the	O
expression	O
and	O
activity	O
of	O
PU.1	B
during	O
human	O
B	O
-	O
cell	O
development	O
using	O
a	O
panel	O
of	O
B	O
-	O
cell	O
lines	O
representing	O
different	O
stages	O
of	O
maturation	O
,	O
from	O
early	O
precursors	O
to	O
differentiated	O
plasma	O
cells	O
.	O
PU.1	O
mRNA	O
expression	O
and	O
PU.1	B
DNA	O
binding	O
activity	O
,	O
as	O
measured	O
by	O
Northern	O
blot	O
analysis	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
were	O
evident	O
in	O
cell	O
lines	O
representing	O
pro	O
-	O
B	O
,	O
pre	O
-	O
B	O
,	O
and	O
mature	O
B	O
cells	O
.	O
We	O
could	O
also	O
show	O
Pu	O
box	O
-dependent	O
transactivation	O
of	O
a	O
reporter	O
gene	O
in	O
transient	O
transfections	O
in	O
these	O
cell	O
lines	O
.	O
In	O
contrast	O
,	O
in	O
a	O
number	O
of	O
multiple	O
myeloma	O
cell	O
lines	O
,	O
representing	O
differentiated	O
,	O
plasma	O
cell	O
-	O
like	O
B	O
cells	O
,	O
PU.1	B
DNA	O
binding	O
activity	O
,	O
mRNA	O
expression	O
,	O
and	O
Pu	O
box	O
-dependent	O
transactivation	O
were	O
absent	O
or	O
detectable	O
at	O
a	O
very	O
low	O
level	O
.	O
In	O
lymphoblastoid	O
cell	O
lines	O
,	O
which	O
exemplify	O
an	O
intermediate	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
,	O
a	O
reduced	O
expression	O
and	O
activity	O
were	O
observed	O
.	O
The	O
findings	O
in	O
the	O
human	O
multiple	O
myeloma	O
cell	O
lines	O
represent	O
the	O
first	O
examples	O
of	O
B	O
cells	O
with	O
downregulated	O
PU.1	B
expression	O
and	O
apparently	O
contradict	O
observations	O
in	O
the	O
murine	O
system	O
in	O
which	O
PU.1	B
is	O
expressed	O
and	O
active	O
in	O
plasmacytoma	O
cell	O
lines	O
.	O
At	O
present	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
lack	O
of	O
PU.1	B
expression	O
and	O
activity	O
in	O
human	O
multiple	O
myeloma	O
cell	O
lines	O
represents	O
a	O
malignancy	O
-	O
associated	O
defect	O
in	O
these	O
cells	O
or	O
exemplifies	O
a	O
normal	O
developmental	O
regulation	O
in	O
terminally	O
differentiated	O
B	O
cells	O
.	O
Microtubules	B
mediate	O
cellular	O
25-hydroxyvitamin	O
D3	O
trafficking	O
and	O
the	O
genomic	O
response	O
to	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
in	O
normal	O
human	O
monocytes	O
.	O
The	O
genomic	O
actions	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
are	O
mediated	O
by	O
the	O
intracellular	O
vitamin	B
D	I
receptor	I
(	O
VDR	B
)	O
.	O
Although	O
immunocytochemistry	O
has	O
shown	O
that	O
disruption	O
of	O
microtubular	O
assembly	O
prevents	O
nuclear	O
access	O
of	O
the	O
sterol	B
-	I
VDR	I
complex	I
,	O
the	O
role	O
of	O
microtubules	B
in	O
the	O
response	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
has	O
not	O
been	O
studied	O
in	O
viable	O
cells	O
.	O
Our	O
studies	O
examined	O
this	O
interaction	O
in	O
normal	O
human	O
monocytes	O
.	O
Monocytes	O
convert	O
25	O
(	O
OH	O
)	O
D3	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
and	O
to	O
24-hydroxylated	O
metabolites	O
more	O
polar	O
than	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O
Microtubule	O
disruption	O
totally	O
abolished	O
the	O
ability	O
of	O
exogenous	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
to	O
suppress	O
its	O
own	O
synthesis	O
and	O
to	O
induce	O
24-hydroxylase	O
mRNA	O
and	O
activity	O
,	O
without	O
affecting	O
either	O
total	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
uptake	O
or	O
maximal	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-VDR	B
binding	O
.	O
Thus	O
,	O
intact	O
microtubules	B
are	O
essential	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-dependent	O
modulation	O
of	O
gene	O
transcription	O
.	O
Interestingly	O
,	O
microtubule	B
disruption	O
also	O
decreased	O
monocyte	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
,	O
not	O
by	O
decreasing	O
the	O
Vmax	O
of	O
monocyte	B
mitochondrial	I
1	I
alpha	I
-	I
hydroxylase	I
but	O
through	O
an	O
increase	O
in	O
the	O
Km	O
for	O
25	O
(	O
OH	O
)	O
2D3	O
.	O
We	O
examined	O
25	O
(	O
OH	O
)	O
D3	O
transport	O
.	O
Microtubule	O
disruption	O
did	O
not	O
affect	O
total	O
cellular	O
25	O
(	O
OH	O
)	O
D3	O
uptake	O
but	O
reduced	O
its	O
intracellular	O
trafficking	O
to	O
the	O
mitochondria	O
.	O
Thus	O
,	O
microtubules	B
participate	O
in	O
intracellular	O
25	O
(	O
OH	O
)	O
D3	O
transport	O
,	O
and	O
their	O
integrity	O
determines	O
normal	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
.	O
Chromosomal	O
localization	O
of	O
two	O
KOX	O
zinc	O
finger	O
genes	O
on	O
chromosome	O
bands	O
7q21-q22	O
.	O
Human	O
cDNAs	O
encoding	O
Kruppel	B
-	I
type	I
zinc	I
finger	I
domains	I
,	O
designated	O
KOX	O
1	O
-	O
32	O
,	O
have	O
been	O
cloned	O
from	O
human	O
T	O
lymphocyte	O
cell	O
line	O
libraries	O
.	O
We	O
report	O
here	O
the	O
regional	O
localizations	O
by	O
in	O
situ	O
hybridization	O
of	O
KOX	O
18	O
and	O
KOX	O
25	O
on	O
chromosome	O
bands	O
7q21q22	O
.	O
Pulse	O
-	O
field	O
gel	O
electrophoresis	O
(	O
PFGE	O
)	O
analysis	O
showed	O
that	O
these	O
genes	O
are	O
physically	O
located	O
within	O
a	O
DNA	O
fragment	O
of	O
250	O
kb	O
.	O
The	O
genes	O
KOX	O
4	O
and	O
KOX	O
9	O
,	O
mapped	O
on	O
chromosome	O
8q24	O
,	O
were	O
found	O
to	O
be	O
located	O
within	O
a	O
DNA	O
fragment	O
of	O
450	O
kb	O
.	O
From	O
the	O
present	O
and	O
previous	O
data	O
,	O
eighteen	O
different	O
KOX	O
genes	O
have	O
been	O
located	O
at	O
least	O
two	O
by	O
two	O
within	O
nine	O
DNA	O
fragments	O
of	O
200	O
to	O
580	O
kb	O
.	O
Evidence	O
for	O
normal	O
vitamin	O
D	O
receptor	O
messenger	O
ribonucleic	O
acid	O
and	O
genotype	O
in	O
absorptive	O
hypercalciuria	O
.	O
Absorptive	O
hypercalciuria	O
(	O
a	O
stone	O
-	O
forming	O
condition	O
)	O
is	O
characterized	O
by	O
gut	O
hyperabsorption	O
of	O
calcium	O
,	O
hypercalciuria	O
,	O
and	O
reduced	O
bone	O
density	O
.	O
Inasmuch	O
as	O
these	O
features	O
implicate	O
enhanced	O
calcitriol	O
action	O
in	O
gut	O
and	O
bone	O
,	O
we	O
analyzed	O
the	O
vitamin	O
D	O
receptor	O
(	O
VDR	O
)	O
gene	O
to	O
ascertain	O
whether	O
an	O
abnormality	O
of	O
this	O
gene	O
marks	O
patients	O
with	O
intestinal	O
hyperabsorption	O
of	O
calcium	O
.	O
We	O
have	O
compared	O
the	O
frequency	O
of	O
a	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
Bsm	O
I	O
)	O
associated	O
with	O
different	O
alleles	O
of	O
the	O
VDR	O
gene	O
in	O
a	O
group	O
of	O
33	O
well	O
characterized	O
absorptive	O
hypercalciuric	O
patients	O
and	O
a	O
group	O
of	O
36	O
normal	O
race-	O
and	O
age	O
-	O
matched	O
control	O
subjects	O
.	O
There	O
was	O
no	O
difference	O
between	O
the	O
distribution	O
of	O
the	O
VDR	B
alleles	O
in	O
the	O
patient	O
population	O
when	O
compared	O
with	O
the	O
normal	O
population	O
.	O
The	O
coding	O
region	O
of	O
VDR	O
messenger	O
RNA	O
was	O
also	O
normal	O
,	O
as	O
determined	O
by	O
both	O
DNA	O
sequence	O
analysis	O
and	O
chemical	O
mismatch	O
cleavage	O
analysis	O
of	O
copy	O
DNA	O
from	O
11	O
index	O
absorptive	O
hypercalciuric	O
patients	O
.	O
On	O
the	O
basis	O
of	O
these	O
results	O
,	O
we	O
propose	O
that	O
the	O
enhanced	O
intestinal	O
calcium	O
absorption	O
invariably	O
seen	O
in	O
absorptive	O
hypercalciuria	O
and	O
attendant	O
symptoms	O
of	O
this	O
disorder	O
are	O
not	O
attributable	O
to	O
mutations	O
of	O
the	O
VDR	B
and	O
are	O
not	O
linked	O
to	O
a	O
common	O
VDR	O
genotype	O
.	O
Signalling	O
via	O
CD28	B
of	O
human	O
naive	O
neonatal	O
T	O
lymphocytes	O
.	O
Accessory	O
molecules	O
play	O
a	O
crucial	O
role	O
in	O
the	O
development	O
of	O
the	O
T	O
cell	O
response	O
to	O
antigenic	O
challenge	O
.	O
We	O
have	O
examined	O
the	O
role	O
of	O
CD28	B
in	O
modulating	O
the	O
'	O
naive	O
'	O
neonatal	O
T	O
cell	O
response	O
to	O
anti	B
-	I
CD2	I
-mediated	O
activation	O
.	O
To	O
compare	O
the	O
role	O
of	O
CD28	B
,	O
neonatal	O
and	O
adult	O
T	O
cells	O
were	O
stimulated	O
with	O
a	O
pair	O
of	O
mitogenic	B
anti	I
-	I
CD2	I
antibodies	I
in	O
the	O
presence	O
or	O
absence	O
of	O
anti	B
-	I
CD28	I
MoAb	I
.	O
With	O
anti	B
-	I
CD2	I
alone	O
,	O
neonatal	O
T	O
cells	O
proliferated	O
slightly	O
but	O
produced	O
no	O
detectable	O
IL-2	B
,	O
whereas	O
adult	O
T	O
cells	O
proliferated	O
vigorously	O
,	O
with	O
significant	O
IL-2	B
production	O
.	O
Costimulation	O
with	O
anti	B
-	I
CD28	I
MoAb	I
greatly	O
enhanced	O
the	O
proliferative	O
response	O
of	O
neonatal	O
T	O
cells	O
to	O
levels	O
equivalent	O
to	O
those	O
of	O
adult	O
T	O
cells	O
,	O
whereas	O
adult	O
T	O
cells	O
showed	O
only	O
slight	O
increases	O
.	O
Although	O
IL-2	B
secretion	O
was	O
increased	O
in	O
the	O
presence	O
of	O
anti	B
-	I
CD28	I
MoAb	I
,	O
neonatal	O
T	O
cell	O
IL-2	B
production	O
remained	O
lower	O
than	O
in	O
adults	O
.	O
In	O
contrast	O
,	O
enhancement	O
of	O
IL-2	O
mRNA	O
expression	O
in	O
neonates	O
was	O
similar	O
to	O
adult	O
levels	O
.	O
Anti-	O
CD28	B
MoAb	I
costimulation	O
increased	O
NF	B
kappa	I
B	I
levels	O
in	O
neonates	O
,	O
albeit	O
to	O
levels	O
lower	O
than	O
that	O
of	O
adults	O
.	O
The	O
cellular	O
mechanism	O
governing	O
the	O
diminished	O
proliferative	O
response	O
of	O
neonatal	O
T	O
lymphocytes	O
to	O
anti	B
-	I
CD2	I
may	O
therefore	O
be	O
due	O
to	O
decreased	O
NF	B
kappa	I
B	I
induction	O
,	O
reduced	O
IL-2	O
mRNA	O
expression	O
and	O
deficient	O
IL-2	B
production	O
.	O
Although	O
anti	B
-	I
CD28	I
MoAb	I
costimulation	O
enhances	O
all	O
of	O
the	O
above	O
signals	O
,	O
NF	O
kappa	O
B	O
and	O
IL-2	O
levels	O
remain	O
lower	O
than	O
in	O
adults	O
,	O
suggesting	O
the	O
need	O
for	O
further	O
activation	O
requirements	O
in	O
the	O
neonate	O
.	O
The	O
DNA	O
-	O
binding	O
properties	O
of	O
two	B
heat	I
shock	I
factors	I
,	O
HSF1	B
and	O
HSF3	B
,	O
are	O
induced	O
in	O
the	O
avian	O
erythroblast	O
cell	O
line	O
HD6	O
.	O
Avian	O
cells	O
express	O
three	O
heat	O
shock	O
transcription	O
factor	O
(	O
HSF	O
)	O
genes	O
corresponding	O
to	O
a	O
novel	B
factor	I
,	O
HSF3	B
,	O
and	O
homologs	O
of	O
mouse	O
and	O
human	O
HSF1	B
and	O
HSF2	B
.	O
Analysis	O
of	O
the	O
biochemical	O
and	O
cell	O
biological	O
properties	O
of	O
these	O
HSFs	B
reveals	O
that	O
HSF3	B
has	O
properties	O
in	O
common	O
with	O
both	O
HSF1	B
and	O
HSF2	B
and	O
yet	O
has	O
features	O
which	O
are	O
distinct	O
from	O
both	O
.	O
HSF3	B
is	O
constitutively	O
expressed	O
in	O
the	O
erythroblast	O
cell	O
line	O
HD6	O
,	O
the	O
lymphoblast	O
cell	O
line	O
MSB	O
,	O
and	O
embryo	O
fibroblasts	O
,	O
and	O
yet	O
its	O
DNA	O
-	O
binding	O
activity	O
is	O
induced	O
only	O
upon	O
exposure	O
of	O
HD6	O
cells	O
to	O
heat	O
shock	O
.	O
Acquisition	O
of	O
HSF3	B
DNA	O
-	O
binding	O
activity	O
in	O
HD6	O
cells	O
is	O
accompanied	O
by	O
oligomerization	O
from	O
a	O
non	B
-	I
DNA	I
-	I
binding	I
dimer	I
to	O
a	O
DNA	B
-	I
binding	I
trimer	I
,	O
whereas	O
the	O
effect	O
of	O
heat	O
shock	O
on	O
HSF1	B
is	O
oligomerization	O
of	O
an	O
inert	B
monomer	I
to	O
a	O
DNA	B
-	I
binding	I
trimer	I
.	O
Induction	O
of	O
HSF3	B
DNA	O
-	O
binding	O
activity	O
is	O
delayed	O
compared	O
with	O
that	O
of	O
HSF1	B
.	O
As	O
occurs	O
for	O
HSF1	B
,	O
heat	O
shock	O
leads	O
to	O
the	O
translocation	O
of	O
HSF3	B
to	O
the	O
nucleus	O
.	O
HSF	O
exhibits	O
the	O
properties	O
of	O
a	O
transcriptional	B
activator	I
,	O
as	O
judged	O
from	O
the	O
stimulatory	O
activity	O
of	O
transiently	B
overexpressed	I
HSF3	I
measured	O
by	O
using	O
a	O
heat	O
shock	O
element	O
-	O
containing	O
reporter	O
construct	O
and	O
as	O
independently	O
assayed	O
by	O
the	O
activity	O
of	O
a	O
chimeric	B
GAL4-HSF3	I
protein	I
on	O
a	O
GAL4	O
reporter	O
construct	O
.	O
These	O
results	O
reveal	O
that	O
HSF3	B
is	O
negatively	O
regulated	O
in	O
avian	O
cells	O
and	O
acquires	O
DNA	O
-	O
binding	O
activity	O
in	O
certain	O
cells	O
upon	O
heat	O
shock	O
.	O
A	O
central	O
role	O
for	O
a	O
single	O
c	O
-	O
Myb	O
binding	O
site	O
in	O
a	O
thymic	O
locus	O
control	O
region	O
.	O
Locus	O
control	O
regions	O
(	O
LCRs	O
)	O
are	O
powerful	O
assemblies	O
of	O
cis	O
elements	O
that	O
organize	O
the	O
actions	O
of	O
cell	B
-	I
type	I
-	I
specific	I
trans	I
-	I
acting	I
factors	I
.	O
A	O
2.3-kb	B
LCR	I
in	O
the	O
human	O
adenosine	O
deaminase	O
(	O
ADA	O
)	O
gene	O
first	O
intron	O
,	O
which	O
controls	O
expression	O
in	O
thymocytes	O
,	O
is	O
composed	O
of	O
a	O
200-bp	O
enhancer	O
domain	O
and	O
extended	O
flanking	O
sequences	O
that	O
facilitate	O
activation	O
from	O
within	O
chromatin	O
.	O
Prior	O
analyses	O
have	O
demonstrated	O
that	O
the	O
enhancer	O
contains	O
a	O
28-bp	O
core	O
region	O
and	O
local	O
adjacent	O
augmentative	O
cis	O
elements	O
.	O
We	O
now	O
show	O
that	O
the	O
core	O
contains	O
a	O
single	O
critical	O
c	O
-	O
Myb	O
binding	O
site	O
.	O
In	O
both	O
transiently	O
cotransfected	O
human	O
cells	O
and	O
stable	O
chromatin	O
-	O
integrated	O
yeast	O
cells	O
,	O
c	B
-	I
Myb	I
strongly	O
transactivated	O
reporter	O
constructs	O
that	O
contained	O
polymerized	O
core	O
sequences	O
.	O
c	B
-	I
Myb	I
protein	I
was	O
strongly	O
evident	O
in	O
T	O
lymphoblasts	O
in	O
which	O
the	O
enhancer	O
was	O
active	O
and	O
was	O
localized	O
within	O
discrete	O
nuclear	O
structures	O
.	O
Fetal	O
murine	O
thymus	O
exhibited	O
a	O
striking	O
concordance	O
of	O
endogenous	O
c	O
-	O
myb	O
expression	O
with	O
that	O
of	O
mouse	O
ADA	O
and	O
human	O
ADA	O
LCR	O
-directed	O
transgene	O
expression	O
.	O
Point	O
mutation	O
of	O
the	O
c	O
-	O
Myb	O
site	O
within	O
the	O
intact	O
2.3-kb	B
LCR	I
severely	O
attenuated	O
enhancer	O
activity	O
in	O
transfections	O
and	O
LCR	O
activity	O
in	O
transgenic	O
thymocytes	O
.	O
Within	O
the	O
context	O
of	O
a	O
complex	O
enhancer	O
and	O
LCR	O
,	O
c	B
-	I
Myb	I
can	O
act	O
as	O
an	O
organizer	O
of	O
thymocyte	O
-	O
specific	O
gene	O
expression	O
via	O
a	O
single	O
binding	O
site	O
.	O
Transcriptional	O
repression	O
of	O
the	O
interleukin-2	O
gene	O
by	O
vitamin	O
D3	O
:	O
direct	O
inhibition	O
of	O
NFATp	B
/	I
AP-1	I
complex	I
formation	O
by	O
a	O
nuclear	B
hormone	I
receptor	I
.	O
T	O
-	O
lymphocyte	O
proliferation	O
is	O
suppressed	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
the	O
active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
and	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
interleukin	O
2	O
(	O
IL-2	O
)	O
,	O
gamma	O
interferon	O
,	O
and	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
mRNA	O
levels	O
.	O
We	O
report	O
here	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
Jurkat	O
cells	O
is	O
cycloheximide	O
resistant	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
direct	O
transcriptional	O
repressive	O
effect	O
on	O
IL-2	B
expression	O
by	O
the	O
vitamin	B
D3	I
receptor	I
(	O
VDR	B
)	O
.	O
We	O
therefore	O
examined	O
vitamin	O
D3-mediated	O
repression	O
of	O
activated	O
IL-2	B
expression	O
by	O
cotransfecting	O
Jurkat	O
cells	O
with	O
IL-2	O
promoter	O
/	O
reporter	O
constructs	O
and	O
a	O
VDR	O
overexpression	O
vector	O
and	O
by	O
DNA	O
binding	O
.	O
We	O
delineated	O
an	O
element	O
conferring	O
both	O
DNA	O
binding	O
by	O
the	O
receptor	O
in	O
vitro	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
vivo	O
to	O
a	O
short	O
40-bp	O
region	O
encompassing	O
an	O
important	O
positive	O
regulatory	O
element	O
,	O
NF	O
-	O
AT-1	O
,	O
which	O
is	O
bound	O
by	O
a	O
T	B
-	I
cell	I
-	I
specific	I
transcription	I
factor	I
,	O
NFATp	B
,	O
as	O
well	O
as	O
by	O
AP-1	B
.	O
VDR	B
DNA	I
-	I
binding	I
mutants	I
were	O
unable	O
to	O
either	O
bind	O
to	O
this	O
element	O
in	O
vitro	O
or	O
repress	O
in	O
vivo	O
;	O
the	O
VDR	B
DNA	I
-	I
binding	I
domain	I
alone	O
,	O
however	O
,	O
bound	O
the	O
element	O
but	O
also	O
could	O
not	O
repress	O
IL-2	B
expression	O
.	O
These	O
results	O
indicate	O
that	O
DNA	O
binding	O
by	O
VDR	B
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
mediate	O
IL-2	B
repression	O
.	O
By	O
combining	O
partially	B
purified	I
proteins	I
in	O
vitro	O
,	O
we	O
observed	O
the	O
loss	O
of	O
the	O
bound	O
NFATp	B
/	I
AP-1-DNA	I
complex	I
upon	O
inclusion	O
of	O
VDR	B
or	O
VDR	B
-	I
retinoid	I
X	I
receptor	I
.	O
Order	O
of	O
addition	O
and	O
off	O
-	O
rate	O
experiments	O
indicate	O
that	O
the	O
VDR	B
-	I
retinoid	I
X	I
receptor	I
heterodimer	I
blocks	O
NFATp	B
/	I
AP-1	I
complex	I
formation	O
and	O
then	O
stably	O
associates	O
with	O
the	O
NF	O
-	O
AT-1	O
element	O
.	O
This	O
direct	O
inhibition	O
by	O
a	O
nuclear	O
hormone	O
receptor	O
of	O
transcriptional	B
activators	I
of	O
the	O
IL-2	O
gene	O
may	O
provide	O
a	O
mechanistic	O
explanation	O
of	O
how	O
vitamin	O
derivatives	O
can	O
act	O
as	O
potent	O
immunosuppressive	O
agents	O
.	O
PU.1	B
(	O
Spi-1	B
)	O
and	O
C	B
/	I
EBP	I
alpha	I
regulate	O
expression	O
of	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
receptor	O
alpha	O
gene	O
.	O
Growth	B
factor	I
receptors	I
play	O
an	O
important	O
role	O
in	O
hematopoiesis	O
.	O
In	O
order	O
to	O
further	O
understand	O
the	O
mechanisms	O
directing	O
the	O
expression	O
of	O
these	O
key	O
regulators	O
of	O
hematopoiesis	O
,	O
we	O
initiated	O
a	O
study	O
investigating	O
the	O
transcription	B
factors	I
activating	O
the	O
expression	O
of	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
receptor	O
alpha	O
gene	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
the	O
human	O
GM	O
-	O
CSF	O
receptor	O
alpha	O
promoter	O
directs	O
reporter	O
gene	O
activity	O
in	O
a	O
tissue	O
-	O
specific	O
fashion	O
in	O
myelomonocytic	O
cells	O
,	O
which	O
correlates	O
with	O
its	O
expression	O
pattern	O
as	O
analyzed	O
by	O
reverse	O
transcription	O
PCR	O
.	O
The	O
GM	O
-	O
CSF	O
receptor	O
alpha	O
promoter	O
contains	O
an	O
important	O
functional	O
site	O
between	O
positions	O
-53	O
and	O
-41	O
as	O
identified	O
by	O
deletion	O
analysis	O
of	O
reporter	O
constructs	O
.	O
We	O
show	O
that	O
the	O
myeloid	O
and	O
B	B
cell	I
transcription	I
factor	I
PU.1	B
binds	O
specifically	O
to	O
this	O
site	O
.	O
Furthermore	O
,	O
we	O
demonstrate	O
that	O
a	O
CCAAT	O
site	O
located	O
upstream	O
of	O
the	O
PU.1	O
site	O
between	O
positions	O
-70	O
and	O
-54	O
is	O
involved	O
in	O
positive	O
-	O
negative	O
regulation	O
of	O
the	O
GM	O
-	O
CSF	O
receptor	O
alpha	O
promoter	O
activity	O
.	O
C	B
/	I
EBP	I
alpha	I
is	O
the	O
major	O
CCAAT	B
/	I
enhancer	I
-	I
binding	I
protein	I
(	O
C	B
/	I
EBP	I
)	O
form	O
binding	O
to	O
this	O
site	O
in	O
nuclear	O
extracts	O
of	O
U937	O
cells	O
.	O
Point	O
mutations	O
of	O
either	O
the	O
PU.1	O
site	O
or	O
the	O
C	O
/	O
EBP	O
site	O
that	O
abolish	O
the	O
binding	O
of	O
the	O
respective	O
factors	O
result	O
in	O
a	O
significant	O
decrease	O
of	O
GM	O
-	O
CSF	O
receptor	O
alpha	O
promoter	O
activity	O
in	O
myelomonocytic	O
cells	O
only	O
.	O
Furthermore	O
,	O
we	O
demonstrate	O
that	O
in	O
myeloid	O
and	O
B	O
cell	O
extracts	O
,	O
PU.1	B
forms	O
a	O
novel	O
,	O
specific	O
,	O
more	O
slowly	O
migrating	O
complex	O
(	O
PU	B
-	I
SF	I
)	O
when	O
binding	O
the	O
GM	B
-	I
CSF	I
receptor	I
alpha	I
promoter	O
PU.1	O
site	O
.	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
specific	O
interaction	O
with	O
PU.1	B
on	O
a	O
myeloid	O
PU.1	O
binding	O
site	O
.	O
The	O
novel	O
complex	O
is	O
distinct	O
from	O
that	O
described	O
previously	O
as	O
binding	O
to	O
B	O
cell	O
enhancer	O
sites	O
and	O
can	O
be	O
formed	O
by	O
addition	O
of	O
PU.1	B
to	O
extracts	O
from	O
certain	O
nonmyeloid	O
cell	O
types	O
which	O
do	O
not	O
express	O
PU.1	B
,	O
including	O
T	O
cells	O
and	O
epithelial	O
cells	O
,	O
but	O
not	O
from	O
erythroid	O
cells	O
.	O
Furthermore	O
,	O
we	O
demonstrate	O
that	O
the	O
PU	B
-	I
SF	I
complex	I
binds	O
to	O
PU.1	B
sites	O
found	O
on	O
a	O
number	O
of	O
myeloid	O
promoters	O
,	O
and	O
its	O
formation	O
requires	O
an	O
intact	O
PU.1	O
site	O
adjacent	O
to	O
a	O
single	O
-	O
stranded	O
region	O
.	O
Expression	O
of	O
PU.1	B
in	O
nonmyeloid	O
cells	O
can	O
activate	O
the	O
GM	O
-	O
CSF	O
receptor	O
alpha	O
promoter	O
.	O
Deletion	O
of	O
the	O
amino	B
-	I
terminal	I
region	I
of	O
PU.1	B
results	O
in	O
a	O
failure	O
to	O
form	O
the	O
PU	B
-	I
SF	I
complex	O
and	O
in	O
a	O
concomitant	O
loss	O
of	O
transactivation	O
,	O
suggesting	O
that	O
formation	O
of	O
the	O
PU	B
-	I
SF	I
complex	I
is	O
of	O
functional	O
importance	O
for	O
the	O
activity	O
of	O
the	O
GM	O
-	O
CSF	O
receptor	O
alpha	O
promoter	O
.	O
Finally	O
,	O
we	O
demonstrate	O
that	O
C	B
/	I
EBP	I
alpha	I
can	O
also	O
active	O
the	O
GM	O
-	O
CSF	O
receptor	O
alpha	O
promoter	O
in	O
nonmyeloid	O
cells	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
Expression	O
of	O
the	O
chemokine	B
receptor	I
BLR2	B
/	I
EBI1	I
is	O
specifically	O
transactivated	O
by	O
Epstein	B
-	I
Barr	I
virus	I
nuclear	I
antigen	I
2	I
.	O
In	O
our	O
attempt	O
to	O
identify	O
chemokine	B
receptors	I
that	O
are	O
related	O
to	O
Burkitt	B
's	I
lymphoma	I
receptor	I
1	I
(	O
BLR1	B
)	O
and	O
are	O
expressed	O
in	O
activated	O
lymphocytes	O
we	O
used	O
RT	O
-	O
PCR	O
resulting	O
in	O
the	O
isolation	O
of	O
a	O
cDNA	O
encoding	O
a	O
seven	B
transmembrane	I
receptor	I
termed	O
BLR2	B
.	O
The	O
protein	O
shows	O
significant	O
sequence	O
similarities	O
to	O
the	O
family	O
of	O
G	B
-	I
protein	I
coupled	I
chemokine	I
receptors	I
and	O
turned	O
out	O
to	O
be	O
identical	O
to	O
the	O
recently	O
described	O
receptor	B
EBI1	I
.	O
Northern	O
blot	O
analysis	O
revealed	O
that	O
BLR2	O
mRNA	O
could	O
be	O
highly	O
stimulated	O
in	O
mitogen-	O
and	O
anti	O
-	O
CD3-treated	O
peripheral	O
blood	O
lymphocytes	O
.	O
BLR2-specific	O
mRNA	O
could	O
be	O
detected	O
in	O
all	O
Epstein	O
-	O
Barr	O
virus	O
positive	O
B	O
cell	O
lines	O
.	O
We	O
show	O
that	O
transcription	O
of	O
the	O
BLR2	O
gene	O
could	O
be	O
specifically	O
induced	O
in	O
Epstein	O
-	O
Barr	O
virus	O
negative	O
BL	O
41	O
cells	O
via	O
estrogen	O
-	O
mediated	O
activation	O
of	O
Epstein	B
-	I
Barr	I
virus	I
nuclear	I
antigen	I
2	I
,	O
a	O
key	O
regulator	O
of	O
viral	O
and	O
cellular	O
genes	O
in	O
immortalized	O
B	O
cells	O
.	O
Our	O
data	O
suggest	O
an	O
involvement	O
of	O
BLR2	B
in	O
the	O
regulation	O
of	O
migration	O
in	O
activated	O
lymphocytes	O
and	O
in	O
viral	O
pathogenesis	O
.	O
Pathogenesis	O
of	O
atherosclerosis	O
.	O
The	O
earliest	O
lesion	O
in	O
the	O
development	O
of	O
an	O
atherosclerotic	O
plaque	O
is	O
the	O
fatty	O
streak	O
.	O
This	O
chronic	O
inflammatory	O
reaction	O
results	O
from	O
a	O
sequence	O
of	O
events	O
that	O
begins	O
with	O
the	O
trapping	O
of	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
in	O
the	O
subendothelial	O
space	O
of	O
the	O
artery	O
wall	O
.	O
The	O
trapped	O
LDL	O
is	O
seeded	O
with	O
oxidative	O
species	O
released	O
by	O
the	O
overlying	O
endothelium	O
,	O
and	O
lipid	O
oxidation	O
is	O
initiated	O
within	O
the	O
LDL	O
particle	O
.	O
Some	O
of	O
the	O
lipids	O
that	O
result	O
lead	O
to	O
the	O
activation	O
of	O
NFkB	B
-	I
like	I
transcription	I
factors	I
that	O
cause	O
the	O
expression	O
of	O
genes	O
whose	O
protein	B
products	I
mediate	O
monocyte	O
binding	O
,	O
monocyte	O
chemotaxis	O
into	O
the	O
subendothelial	O
space	O
,	O
and	O
conversion	O
into	O
macrophages	O
.	O
At	O
least	O
1	O
major	O
gene	O
modulates	O
the	O
oxidation	O
of	O
LDL	O
lipids	O
and/or	O
the	O
biologic	O
response	O
to	O
these	O
lipids	O
.	O
The	O
inverse	O
relation	O
between	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
and	O
atherosclerotic	O
events	O
may	O
in	O
part	O
be	O
due	O
to	O
enzymes	B
associated	O
with	O
HDL	O
that	O
destroy	O
the	O
biologically	O
active	O
lipids	O
generated	O
in	O
LDL	O
.	O
HMG	B
-	I
I	I
binds	O
to	O
GATA	O
motifs	O
:	O
implications	O
for	O
an	O
HPFH	O
syndrome	O
.	O
We	O
have	O
examined	O
binding	O
of	O
the	O
nuclear	B
protein	I
HMG	B
-	I
I	I
to	O
the	O
human	O
gamma	O
-	O
globin	O
promoter	O
.	O
We	O
find	O
that	O
HMG	B
-	I
I	I
binds	O
preferentially	O
to	O
the	O
more	O
3	O
'	O
of	O
a	O
pair	O
of	O
GATA	O
motifs	O
in	O
the	O
gamma	O
-	O
globin	O
promoter	O
;	O
this	O
paired	O
motif	O
is	O
bound	O
by	O
the	O
erythroid	B
factor	I
GATA-1	I
.	O
A	O
naturally	O
occurring	O
mutation	O
(	O
-175	O
T	O
-	O
C	O
)	O
in	O
the	O
area	O
bound	O
by	O
HMG	B
-	I
I	I
results	O
in	O
overexpression	O
of	O
gamma	B
-	I
globin	I
in	O
adult	O
red	O
blood	O
cells	O
(	O
HPFH	O
)	O
and	O
up	O
-	O
regulation	O
of	O
the	O
gamma	O
-	O
globin	O
promoter	O
in	O
in	O
vitro	O
expression	O
assays	O
;	O
HMG	B
-	I
I	I
does	O
not	O
bind	O
to	O
this	O
mutant	O
sequence	O
.	O
A	O
survey	O
of	O
GATA	O
motifs	O
from	O
other	O
globin	O
cis	O
-	O
elements	O
demonstrates	O
HMG	B
-	I
I	I
binding	O
to	O
most	O
of	O
them	O
.	O
These	O
findings	O
implicate	O
HMG	B
-	I
I	I
in	O
the	O
HPFH	O
phenotype	O
;	O
we	O
speculate	O
that	O
it	O
may	O
participate	O
in	O
the	O
formation	O
of	O
multiprotein	B
complexes	I
that	O
regulate	O
globin	O
gene	O
expression	O
.	O
Multiple	O
proteins	O
interact	O
with	O
the	O
nuclear	O
inhibitory	O
protein	O
repressor	O
element	O
in	O
the	O
human	O
interleukin-3	O
promoter	O
.	O
T	O
cell	O
expression	O
of	O
interleukin	B
3	I
(	O
IL-3	B
)	O
is	O
directed	O
by	O
positive	O
and	O
negative	O
cis	O
-	O
acting	O
DNA	O
elements	O
clustered	O
within	O
300	O
base	O
pairs	O
of	O
the	O
transcriptional	O
start	O
site	O
.	O
A	O
strong	O
repressor	B
element	I
,	O
termed	O
nuclear	B
inhibitory	I
protein	I
(	O
NIP	B
)	O
,	O
was	O
previously	O
mapped	O
to	O
a	O
segment	O
of	O
the	O
IL-3	O
promoter	O
between	O
nucleotides	O
-271	O
and	O
-250	O
.	O
Functional	O
characterization	O
of	O
this	O
element	O
demonstrates	O
that	O
it	O
can	O
mediate	O
repression	O
when	O
linked	O
in	O
cis	O
to	O
a	O
heterologous	O
promoter	O
.	O
DNA	O
binding	O
experiments	O
were	O
carried	O
out	O
to	O
characterize	O
the	O
repressor	O
activity	O
.	O
Using	O
varying	O
conditions	O
,	O
three	O
distinct	O
complexes	O
were	O
shown	O
to	O
interact	O
specifically	O
with	O
the	O
NIP	O
region	O
,	O
although	O
only	O
one	O
correlates	O
with	O
repressor	O
activity	O
.	O
Complex	B
1	I
results	O
from	O
binding	O
of	O
a	O
ubiquitous	O
polypeptide	O
that	O
recognizes	O
the	O
3	O
'	O
portion	O
of	O
this	O
sequence	O
and	O
is	O
not	O
required	O
for	O
repression	O
.	O
Complex	B
2	I
corresponds	O
to	O
binding	O
of	O
transcription	B
factor	I
(	O
upstream	B
stimulatory	I
factor	I
)	O
to	O
an	O
E	O
-	O
box	O
motif	O
in	O
the	O
5	O
'	O
portion	O
of	O
the	O
NIP	O
region	O
.	O
DNA	O
binding	O
specificity	O
of	O
complex	O
3	O
overlaps	O
with	O
that	O
of	O
upstream	B
stimulatory	I
factor	I
but	O
is	O
clearly	O
distinct	O
.	O
To	O
determine	O
which	O
of	O
the	O
latter	O
two	O
complexes	O
represents	O
NIP	B
activity	O
,	O
we	O
incorporated	O
small	O
alterations	O
into	O
the	O
NIP	O
site	O
of	O
an	O
IL-3	O
promoter	O
-	O
linked	O
reporter	O
construct	O
and	O
examined	O
their	O
effects	O
on	O
NIP	B
-mediated	O
repression	O
.	O
Functional	O
specificity	O
for	O
repression	O
matches	O
the	O
DNA	O
binding	O
specificity	O
of	O
complex	B
3	I
;	O
both	O
repressor	O
activity	O
and	O
complex	B
3	I
binding	O
require	O
the	O
consensus	O
sequence	O
CTCACNTNC	O
.	O
Nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
by	O
macrophages	O
and	O
polymorphonuclear	O
leukocytes	O
requires	O
the	O
presence	O
of	O
the	O
bacterial	O
flagellum	O
.	O
Whereas	O
the	O
mechanism	O
of	O
nonopsonic	O
phagocytosis	O
of	O
Pseudomonas	O
aeruginosa	O
has	O
been	O
described	O
,	O
the	O
bacterial	O
ligands	O
required	O
are	O
poorly	O
understood	O
.	O
To	O
identify	O
the	O
requisite	O
bacterial	O
ligands	O
,	O
studies	O
with	O
isogenic	O
mutants	O
of	O
P.	O
aeruginosa	O
PAK	O
lacking	O
pili	O
,	O
flagella	O
,	O
and	O
the	O
RpoN	B
sigma	I
factor	I
were	O
undertaken	O
.	O
The	O
RpoN	O
mutant	O
,	O
lacking	O
pili	O
,	O
flagella	O
,	O
and	O
nonpilus	B
adhesins	I
,	O
bound	O
poorly	O
and	O
was	O
resistant	O
to	O
ingestion	O
by	O
both	O
macrophages	O
and	O
neutrophils	O
.	O
Pili	O
were	O
not	O
absolutely	O
required	O
for	O
binding	O
or	O
phagocytosis	O
of	O
P.	O
aeruginosa	O
.	O
The	O
presence	O
of	O
a	O
flagellum	O
was	O
not	O
required	O
for	O
binding	O
of	O
P.	O
aeruginosa	O
to	O
macrophages	O
but	O
was	O
critical	O
for	O
the	O
subsequent	O
internalization	O
of	O
the	O
bacterium	O
,	O
suggesting	O
that	O
this	O
factor	O
or	O
a	O
surface	O
ligand	O
associated	O
with	O
its	O
assembly	O
was	O
responsible	O
for	O
stimulation	O
of	O
nonopsonic	O
phagocytosis	O
.	O
Circumvention	O
of	O
tolerance	O
for	O
the	O
nuclear	B
T	I
cell	I
protein	I
TCF-1	B
by	O
immunization	O
of	O
TCF-1	B
knock	O
-	O
out	O
mice	O
.	O
Molecular	O
events	O
that	O
underlie	O
the	O
well	O
-	O
defined	O
phenotypic	O
changes	O
of	O
the	O
differentiating	O
thymocyte	O
are	O
poorly	O
understood	O
.	O
A	O
candidate	O
gene	O
to	O
control	O
thymocyte	O
differentiation	O
,	O
T	B
cell	I
factor-1	I
(	O
TCF-1	B
)	O
*	O
encodes	O
a	O
DNA	B
-	I
binding	I
protein	I
.	O
Its	O
mRNA	O
expression	O
pattern	O
is	O
complex	O
during	O
embryogenesis	O
,	O
yet	O
restricted	O
to	O
lymphocytes	O
postnatally	O
.	O
Expression	O
studies	O
on	O
TCF-1	B
protein	I
have	O
been	O
hampered	O
by	O
the	O
difficulty	O
to	O
raise	O
antibodies	B
due	O
to	O
extreme	O
evolutionary	O
conservation	O
.	O
TCF-1	B
knock	O
-	O
out	O
mice	O
,	O
generated	O
recently	O
in	O
our	O
laboratory	O
,	O
have	O
strongly	O
decreased	O
numbers	O
of	O
thymocytes	O
,	O
but	O
are	O
otherwise	O
normal	O
.	O
We	O
have	O
used	O
these	O
mice	O
to	O
generate	O
anti	B
-	I
TCF-1	I
antibodies	I
.	O
By	O
immunization	O
with	O
a	O
recombinant	B
fusion	I
protein	I
,	O
we	O
show	O
that	O
TCF-1	B
knock	O
-	O
out	O
mice	O
readily	O
yield	O
antiserum	O
titers	O
against	O
human	O
and	O
mouse	O
TCF-1	O
protein	O
.	O
Wild	O
-	O
type	O
littermates	O
remain	O
unresponsive	O
to	O
TCF-1	B
while	O
they	O
mount	O
a	O
high	O
-	O
titer	O
antibody	O
response	O
to	O
the	O
fusion	B
protein	I
,	O
Maltose	B
Binding	I
Protein	I
(	O
MBP	B
)	O
.	O
Subsequently	O
,	O
TCF-1-specific	O
hybridomas	O
could	O
be	O
prepared	O
from	O
the	O
spleens	O
of	O
immunized	O
knock	O
-	O
out	O
mice	O
.	O
This	O
study	O
illustrates	O
the	O
almost	O
complete	O
tolerance	O
of	O
mice	O
for	O
human	B
TCF-1	I
and	O
demonstrates	O
that	O
this	O
tolerance	O
is	O
readily	O
broken	O
by	O
gene	O
knock	O
-	O
out	O
.	O
Furthermore	O
,	O
the	O
usefulness	O
of	O
knock	O
-	O
out	O
mice	O
for	O
the	O
generation	O
of	O
monoclonal	B
antibodies	I
against	O
the	O
gene	O
product	O
of	O
interest	O
is	O
underscored	O
.	O
An	O
interferon	O
-	O
gamma	O
activation	O
sequence	O
mediates	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IgG	O
Fc	O
receptor	O
type	O
IC	O
gene	O
by	O
interferon	B
-	I
gamma	I
.	O
Expression	O
of	O
the	O
IgG	B
Fc	I
receptor	I
type	I
I	I
(	O
Fc	B
gamma	I
RI	I
)	O
on	O
myeloid	O
cells	O
is	O
dramatically	O
increased	O
by	O
treatment	O
with	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
.	O
We	O
observed	O
that	O
Fc	B
gamma	I
RI	I
transcript	O
levels	O
in	O
monoblast	O
-	O
like	O
U937	O
cells	O
were	O
elevated	O
within	O
3	O
hr	O
and	O
peaked	O
12	O
hr	O
after	O
exposure	O
to	O
IFN	B
-	I
gamma	I
.	O
Treatment	O
of	O
U937	O
with	O
IFN	B
-	I
gamma	I
for	O
9	O
hr	O
in	O
the	O
presence	O
of	O
cycloheximide	O
led	O
to	O
super	O
-	O
induction	O
of	O
Fc	B
gamma	I
RI	I
expression	O
.	O
Nuclear	O
run	O
-	O
on	O
analysis	O
revealed	O
that	O
the	O
rate	O
of	O
Fc	B
gamma	I
RI	I
transcription	O
was	O
increased	O
by	O
IFN	B
-	I
gamma	I
.	O
Genomic	O
sequence	O
upstream	O
of	O
the	O
Fc	O
gamma	O
RIC	O
gene	O
was	O
cloned	O
and	O
subjected	O
to	O
primer	O
extension	O
analysis	O
,	O
which	O
demonstrated	O
a	O
single	O
transcription	O
initiation	O
site	O
without	O
a	O
TATA	O
box	O
.	O
Transient	O
transfections	O
of	O
CAT	O
reporter	O
gene	O
constructs	O
containing	O
various	O
Fc	O
gamma	O
RIC	O
promoter	O
sequences	O
into	O
U937	O
cells	O
revealed	O
that	O
a	O
20-bp	O
region	O
surrounding	O
the	O
transcription	O
start	O
site	O
(	O
-7	O
to	O
+	O
13	O
)	O
was	O
capable	O
of	O
mediating	O
transcription	O
initiation	O
and	O
that	O
an	O
IFN	O
-	O
gamma	O
responsive	O
element	O
(	O
GIRE	O
)	O
was	O
present	O
within	O
74	O
bp	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
.	O
A	O
17-bp	O
sequence	O
between	O
positions	O
-51	O
and	O
-35	O
conferred	O
IFN	B
-	I
gamma	I
responsiveness	O
on	O
a	O
heterologous	O
promoter	O
.	O
Double	O
-	O
stranded	O
GIRE	O
sequence	O
,	O
but	O
not	O
a	O
scrambled	O
sequence	O
,	O
was	O
specifically	O
bound	O
by	O
nuclear	B
proteins	I
from	O
IFN	O
-	O
gamma	O
treated	O
U937	O
cells	O
.	O
Gel	O
shift	O
experiments	O
further	O
showed	O
that	O
the	O
STAT1	B
alpha	I
protein	I
bound	O
to	O
the	O
Fc	O
gamma	O
RIC	O
GIRE	O
in	O
response	O
to	O
IFN	B
-	I
gamma	I
treatment	O
of	O
U937	O
cells	O
.	O
The	O
Fc	O
gamma	O
RIC	O
GIRE	O
is	O
homologous	O
to	O
the	O
IFN	O
-	O
gamma	O
activation	O
sequence	O
(	O
GAS	O
)	O
of	O
the	O
guanylate	B
binding	I
protein	I
and	O
to	O
X	O
box	O
elements	O
of	O
class	O
II	O
MHC	O
genes	O
.	O
Our	O
results	O
demonstrate	O
that	O
transcriptional	O
regulation	O
of	O
the	O
Fc	O
gamma	O
RIC	O
gene	O
by	O
IFN	B
-	I
gamma	I
involves	O
the	O
binding	O
of	O
STAT1	B
alpha	I
to	O
a	O
17-bp	O
GAS	O
homology	O
in	O
the	O
proximal	O
promoter	O
.	O
Regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
cytokine	O
gene	O
expression	O
in	O
myeloid	O
cells	O
by	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
transcription	B
factors	I
.	O
CD4	O
+	O
macrophages	O
in	O
tissues	O
such	O
as	O
lung	O
,	O
skin	O
,	O
and	O
lymph	O
nodes	O
,	O
promyelocytic	O
cells	O
in	O
bone	O
marrow	O
,	O
and	O
peripheral	O
blood	O
monocytes	O
serve	O
as	O
important	O
targets	O
and	O
reservoirs	O
for	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
.	O
HIV-1-infected	O
myeloid	O
cells	O
are	O
often	O
diminished	O
in	O
their	O
ability	O
to	O
participate	O
in	O
chemotaxis	O
,	O
phagocytosis	O
,	O
and	O
intracellular	O
killing	O
.	O
HIV-1	O
infection	O
of	O
myeloid	O
cells	O
can	O
lead	O
to	O
the	O
expression	O
of	O
surface	B
receptors	I
associated	O
with	O
cellular	O
activation	O
and/or	O
differentiation	O
that	O
increase	O
the	O
responsiveness	O
of	O
these	O
cells	O
to	O
cytokines	B
secreted	O
by	O
neighboring	O
cells	O
as	O
well	O
as	O
to	O
bacteria	O
or	O
other	O
pathogens	O
.	O
Enhancement	O
of	O
HIV-1	O
replication	O
is	O
related	O
in	O
part	O
to	O
increased	O
DNA	O
-	O
binding	O
activity	O
of	O
cellular	B
transcription	I
factors	I
such	O
as	O
NF	B
-	I
kappa	I
B	I
.	O
NF	B
-	I
kappa	I
B	I
binds	O
to	O
the	O
HIV-1	O
enhancer	O
region	O
of	O
the	O
long	O
terminal	O
repeat	O
and	O
contributes	O
to	O
the	O
inducibility	O
of	O
HIV-1	O
gene	O
expression	O
in	O
response	O
to	O
multiple	O
activating	O
agents	O
.	O
Phosphorylation	O
and	O
degradation	O
of	O
the	O
cytoplasmic	B
inhibitor	I
I	B
kappa	I
B	I
alpha	O
are	O
crucial	O
regulatory	O
events	O
in	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
DNA	O
-	O
binding	O
activity	O
.	O
Both	O
N-	O
and	O
C	O
-	O
terminal	O
residues	O
of	O
I	B
kappa	I
B	I
alpha	O
are	O
required	O
for	O
inducer	O
-	O
mediated	O
degradation	O
.	O
Chronic	O
HIV-1	O
infection	O
of	O
myeloid	O
cells	O
leads	O
to	O
constitutive	O
NF	B
-	I
kappa	I
B	I
DNA	O
-	O
binding	O
activity	O
and	O
provides	O
an	O
intranuclear	O
environment	O
capable	O
of	O
perpetuating	O
HIV-1	O
replication	O
.	O
Increased	O
intracellular	O
stores	O
of	O
latent	B
NF	I
-	I
kappa	I
B	I
may	O
also	O
result	O
in	O
rapid	O
inducibility	O
of	O
NF	B
-	I
kappa	I
B	I
-dependent	O
cytokine	B
gene	O
expression	O
.	O
In	O
response	O
to	O
secondary	O
pathogenic	O
infections	O
or	O
antigenic	O
challenge	O
,	O
cytokine	B
gene	O
expression	O
is	O
rapidly	O
induced	O
,	O
enhanced	O
,	O
and	O
sustained	O
over	O
prolonged	O
periods	O
in	O
HIV-1-infected	O
myeloid	O
cells	O
compared	O
with	O
uninfected	O
cells	O
.	O
Elevated	O
levels	O
of	O
several	O
inflammatory	B
cytokines	I
have	O
been	O
detected	O
in	O
the	O
sera	O
of	O
HIV-1-infected	O
individuals	O
.	O
Secretion	O
of	O
myeloid	B
cell	I
-	I
derived	I
cytokines	I
may	O
both	O
increase	O
virus	O
production	O
and	O
contribute	O
to	O
AIDS	O
-	O
associated	O
disorders	O
.	O
Cloning	O
a	O
cDNA	O
from	O
human	O
NK	O
/	O
T	O
cells	O
which	O
codes	O
for	O
a	O
protein	O
with	O
high	O
proline	O
content	O
.	O
A	O
cDNA	O
clone	O
,	O
B4	O
-	O
2	O
,	O
was	O
isolated	O
from	O
a	O
natural	O
killer	O
(	O
NK	O
)	O
minus	O
T	O
cell	O
subtractive	O
library	O
.	O
The	O
B4	O
-	O
2	O
clone	O
coded	O
for	O
an	O
mRNA	O
of	O
2061	O
bp	O
in	O
length	O
.	O
It	O
encodes	O
a	O
deduced	O
327	B
aa	I
protein	I
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
35.2	O
kDa	O
.	O
Searching	O
of	O
B4	O
-	O
2	O
DNA	O
and	O
protein	O
sequences	O
against	O
various	O
databases	O
revealed	O
no	O
high	O
homology	O
to	O
other	O
sequences	O
.	O
However	O
,	O
B4	O
-	O
2	O
has	O
an	O
unusually	O
high	O
proline	O
content	O
(	O
13	O
%	O
)	O
,	O
contains	O
a	O
putative	O
nuclear	B
targeting	I
sequence	I
,	O
and	O
has	O
several	O
SPXX	B
motifs	I
which	O
are	O
frequently	O
found	O
in	O
gene	B
regulatory	I
proteins	I
.	O
One	O
of	O
the	O
stretches	O
of	O
prolines	O
in	O
B4	O
-	O
2	O
closely	O
resembles	O
the	O
ligand	O
for	O
proteins	O
with	O
SH3	B
domains	I
.	O
Northern	O
hybridization	O
data	O
showed	O
that	O
B4	O
-	O
2	O
is	O
not	O
a	O
lymphoid	O
specific	O
gene	O
and	O
is	O
expressed	O
in	O
a	O
hepatoma	O
cell	O
line	O
and	O
also	O
weakly	O
transcribed	O
or	O
absent	O
in	O
a	O
variety	O
of	O
other	O
cells	O
.	O
A	O
polyclonal	O
antiserum	O
raised	O
against	O
recombinant	B
B4	I
-	I
2	I
recognizes	O
a	O
32	B
-	I
34	I
kDa	I
protein	I
in	O
lymphocytes	O
.	O
The	O
normal	O
cell	O
cycle	O
activation	O
program	O
is	O
exploited	O
during	O
the	O
infection	O
of	O
quiescent	O
B	O
lymphocytes	O
by	O
Epstein	O
-	O
Barr	O
virus	O
.	O
B	O
lymphocytes	O
in	O
the	O
peripheral	O
circulation	O
are	O
maintained	O
in	O
a	O
non	O
-	O
proliferative	O
state	O
.	O
Antigen	O
recognition	O
stimulates	O
limited	O
proliferation	O
,	O
whereas	O
infection	O
with	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
results	O
in	O
continual	O
proliferation	O
and	O
the	O
outgrowth	O
of	O
immortal	O
cell	O
lines	O
.	O
Because	O
it	O
is	O
not	O
clear	O
at	O
which	O
point	O
in	O
cell	O
cycle	O
the	O
peripheral	O
B	O
lymphocytes	O
are	O
arrested	O
,	O
we	O
characterized	O
the	O
expression	O
of	O
several	O
cell	O
cycle	O
-	O
associated	O
genes	O
in	O
quiescent	O
and	O
stimulated	O
cells	O
.	O
We	O
show	O
that	O
the	O
expression	O
of	O
four	O
cell	O
genes	O
,	O
cdc-2	O
,	O
cyclin	O
E	O
,	O
CD23	O
,	O
and	O
cyclin	O
D2	O
,	O
are	O
up	O
-	O
regulated	O
approximately	O
100-fold	O
as	O
a	O
result	O
of	O
EBV	O
-	O
mediated	O
immortalization	O
.	O
Because	O
these	O
genes	O
play	O
a	O
positive	O
role	O
in	O
cell	O
proliferation	O
,	O
we	O
suggest	O
that	O
this	O
regulatory	O
switch	O
contributes	O
to	O
controlling	O
entry	O
into	O
the	O
cell	O
cycle	O
.	O
Transient	O
stimulation	O
of	O
quiescent	O
B	O
lymphocytes	O
with	O
either	O
a	O
cocktail	O
of	O
anti	B
-	I
CD40	I
,	O
anti	B
-	I
IgM	I
,	O
and	O
IL4	B
,	O
or	O
EBV	O
results	O
in	O
the	O
rapid	O
expression	O
of	O
the	O
same	O
four	O
genes	O
,	O
suggesting	O
that	O
,	O
after	O
infection	O
,	O
EBV	O
exploits	O
the	O
normal	O
program	O
of	O
B	O
-	O
lymphocyte	O
cell	O
cycle	O
activation	O
.	O
Costimulation	O
requirement	O
for	O
AP-1	B
and	O
NF	B
-	I
kappa	I
B	I
transcription	O
factor	O
activation	O
in	O
T	O
cells	O
.	O
The	O
transcriptional	O
activity	O
of	O
the	O
IL-2	O
promoter	O
requires	O
T	O
-	O
cell	O
costimulation	O
delivered	O
by	O
the	O
TCR	B
and	O
the	O
auxiliary	B
receptor	I
CD28	I
.	O
Several	O
transcription	B
factors	I
participate	O
in	O
IL-2	B
promoter	O
activation	O
,	O
among	O
which	O
are	O
AP-1-like	B
factors	I
and	O
NF	B
-	I
kappa	I
B	I
.	O
Protein	O
phosphorylation	O
has	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
these	O
two	O
factors	O
:	O
(	O
1	O
)	O
it	O
induces	O
the	O
transactivating	O
capacity	O
of	O
the	O
AP-1	B
protein	I
c	B
-	I
Jun	I
;	O
and	O
(	O
2	O
)	O
it	O
is	O
involved	O
in	O
the	O
release	O
of	O
the	O
cytoplasmic	B
inhibitor	I
,	O
I	B
kappa	I
B	I
,	O
from	O
NF	B
-	I
kappa	I
B	I
,	O
allowing	O
translocation	O
of	O
the	O
latter	O
into	O
the	O
nucleus	O
.	O
We	O
have	O
recently	O
shown	O
that	O
both	O
phosphorylation	O
processes	O
require	O
T	O
-	O
cell	O
costimulation	O
.	O
Furthermore	O
,	O
in	O
activated	O
T	O
cells	O
,	O
the	O
kinetics	O
of	O
the	O
two	O
phosphorylation	O
events	O
are	O
essentially	O
similar	O
.	O
According	O
to	O
our	O
results	O
,	O
however	O
,	O
the	O
kinases	O
responsible	O
for	O
the	O
two	O
processes	O
are	O
distinct	O
entities	O
.	O
Whereas	O
TPCK	B
inhibits	O
phosphorylation	O
of	O
I	B
kappa	I
B	I
and	O
,	O
consequently	O
,	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
it	O
markedly	O
enhances	O
the	O
activity	O
of	O
JNK	B
,	O
the	O
MAP	B
kinase	I
-	I
related	I
kinase	I
that	O
phosphorylates	O
the	O
transactivation	B
domain	I
of	O
c	B
-	I
Jun	I
.	O
We	O
,	O
therefore	O
,	O
propose	O
the	O
activation	O
scheme	O
presented	O
in	O
FIGURE	O
3	O
for	O
T	O
-	O
cell	O
costimulation	O
.	O
Costimulation	O
results	O
in	O
the	O
activation	O
of	O
a	O
signaling	O
pathway	O
that	O
leads	O
to	O
the	O
simultaneous	O
induction	O
of	O
the	O
two	O
transcription	B
factors	I
,	O
AP-1	B
and	O
NF	B
-	I
kappa	I
B	I
.	O
Integration	O
of	O
the	O
signals	O
generated	O
by	O
TCR	B
and	O
CD28	B
engagement	O
occurs	O
along	O
this	O
pathway	O
,	O
which	O
then	O
bifurcates	O
to	O
induce	O
I	B
kappa	I
B	I
phosphorylation	O
and	O
NF	B
-	I
kappa	I
B	I
activation	O
on	O
the	O
one	O
hand	O
,	O
and	O
JNK	B
activation	O
and	O
c	B
-	I
Jun	I
phosphorylation	O
on	O
the	O
other	O
.	O
We	O
are	O
currently	O
engaged	O
in	O
defining	O
where	O
the	O
two	O
signals	O
integrate	O
along	O
the	O
AP-1	B
/	O
NF	B
-	I
kappa	I
B	I
pathway	O
.	O
Mutation	O
of	O
Jak3	B
in	O
a	O
patient	O
with	O
SCID	O
:	O
essential	O
role	O
of	O
Jak3	B
in	O
lymphoid	O
development	O
.	O
Males	O
with	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
(	O
XSCID	O
)	O
have	O
defects	O
in	O
the	O
common	O
cytokine	O
receptor	O
gamma	O
chain	O
(	O
gamma	O
c	O
)	O
gene	O
that	O
encodes	O
a	O
shared	O
,	O
essential	O
component	O
of	O
the	O
receptors	O
of	O
interleukin-2	B
(	O
IL-2	B
)	O
,	O
IL-4	B
,	O
IL-7	B
,	O
IL-9	B
,	O
and	O
IL-15	B
.	O
The	O
Janus	B
family	I
tyrosine	I
kinase	I
Jak3	B
is	O
the	O
only	O
signaling	O
molecule	O
known	O
to	O
be	O
associated	O
with	O
gamma	B
c	I
,	O
so	O
it	O
was	O
hypothesized	O
that	O
defects	O
in	O
Jak3	B
might	O
cause	O
an	O
XSCID	O
-	O
like	O
phenotype	O
.	O
A	O
girl	O
with	O
immunological	O
features	O
indistinguishable	O
from	O
those	O
of	O
XSCID	O
was	O
therefore	O
selected	O
for	O
analysis	O
.	O
An	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-transformed	O
cell	O
line	O
derived	O
from	O
her	O
lymphocytes	O
had	O
normal	O
gamma	B
c	I
expression	O
but	O
lacked	O
Jak3	B
protein	I
and	O
had	O
greatly	O
diminished	O
Jak3	O
messenger	O
RNA	O
.	O
Sequencing	O
revealed	O
a	O
different	O
mutation	O
on	O
each	O
allele	O
:	O
a	O
single	O
nucleotide	O
insertion	O
resulting	O
in	O
a	O
frame	O
shift	O
and	O
premature	O
termination	O
in	O
the	O
Jak3	B
JH4	I
domain	I
and	O
a	O
nonsense	O
mutation	O
in	O
the	O
Jak3	B
JH2	O
domain	O
.	O
The	O
lack	O
of	O
Jak3	B
expression	O
correlated	O
with	O
impaired	O
B	O
cell	O
signaling	O
,	O
as	O
demonstrated	O
by	O
the	O
inability	O
of	O
IL-4	B
to	O
activate	O
Stat6	B
in	O
the	O
EBV	O
-	O
transformed	O
cell	O
line	O
from	O
the	O
patient	O
.	O
These	O
observations	O
indicate	O
that	O
the	O
functions	O
of	O
gamma	B
c	I
are	O
dependent	O
on	O
Jak3	B
and	O
that	O
Jak3	B
is	O
essential	O
for	O
lymphoid	O
development	O
and	O
signaling	O
.	O
The	O
effect	O
of	O
Toremifene	O
on	O
the	O
expression	O
of	O
some	O
genes	O
in	O
human	O
mononuclear	O
cells	O
.	O
Toremifene	O
exerts	O
multiple	O
and	O
varied	O
effects	O
on	O
the	O
gene	O
expression	O
of	O
human	O
peripheral	O
mononuclear	O
cells	O
.	O
After	O
short	O
-	O
term	O
,	O
in	O
vitro	O
exposure	O
to	O
therapeutical	O
levels	O
,	O
distinct	O
changes	O
in	O
P	O
-	O
glycoprotein	O
,	O
steroid	O
receptors	O
,	O
p53	O
and	O
Bcl-2	O
expression	O
take	O
place	O
.	O
In	O
view	O
of	O
the	O
increasing	O
use	O
of	O
antiestrogens	O
in	O
cancer	O
therapy	O
and	O
prevention	O
,	O
there	O
is	O
obvious	O
merit	O
in	O
long	O
-	O
term	O
in	O
vivo	O
studies	O
to	O
be	O
conducted	O
.	O
CD30	B
ligation	O
induces	O
nuclear	B
factor	I
-	I
kappa	I
B	I
activation	O
in	O
human	O
T	O
cell	O
lines	O
.	O
CD30	B
is	O
a	O
recently	O
described	O
member	O
of	O
the	O
tumor	B
necrosis	I
factor	I
/	I
nerve	I
growth	I
factor	I
receptor	I
superfamily	I
.	O
In	O
this	O
report	O
,	O
we	O
show	O
that	O
following	O
incubation	O
of	O
L540	O
cells	O
(	O
Hodgkin	O
's	O
disease	O
-	O
derived	O
,	O
T	O
cell	O
-	O
like	O
,	O
CD30	O
+	O
cells	O
)	O
with	O
the	O
agonistic	B
anti	I
-	I
CD30	I
monoclonal	I
antibodies	I
(	O
mAb	B
)	O
M44	B
and	O
M67	B
,	O
two	O
nuclear	B
factor	I
(	I
NF	I
)	I
-kappa	I
B	I
DNA	O
binding	O
activities	O
were	O
induced	O
in	O
nuclear	O
extracts	O
,	O
as	O
determined	O
in	O
gel	O
retardation	O
assays	O
.	O
The	O
effect	O
of	O
the	O
mAb	B
towards	O
NF	B
-	I
kappa	I
B	I
activation	O
was	O
rapid	O
,	O
as	O
it	O
occurred	O
within	O
20	O
min	O
,	O
and	O
was	O
sustained	O
for	O
up	O
to	O
6	O
h	O
.	O
By	O
comparison	O
,	O
an	O
isotype	B
-	I
matched	I
antibody	I
had	O
no	O
effect	O
on	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
Moreover	O
,	O
in	O
human	O
T	O
helper	O
(	O
Th	O
)	O
clones	O
functionally	O
characterized	O
as	O
being	O
of	O
the	O
type	O
0	O
,	O
type	O
1	O
and	O
type	O
2	O
(	O
28	O
%	O
,	O
<	O
1	O
%	O
und	O
93	O
%	O
CD30	O
+	O
,	O
respectively	O
)	O
,	O
the	O
extent	O
of	O
CD30	B
-mediated	O
NF	B
-	I
kappa	I
B	I
activation	O
correlated	O
with	O
the	O
proportion	O
of	O
CD30	O
+	O
cells	O
.	O
In	O
all	O
cell	O
lines	O
investigated	O
,	O
the	O
NF	B
-	I
kappa	I
B	I
complexes	I
induced	O
following	O
CD30	B
engagement	O
were	O
shown	O
to	O
contain	O
p50	B
NF	I
-	I
kappa	I
B1	I
,	O
p65	B
RelA	I
,	O
and	O
possibly	O
other	O
transcription	B
factors	I
.	O
Collectively	O
,	O
our	O
results	O
demonstrate	O
that	O
nuclear	O
translocation	O
and	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
rank	O
among	O
the	O
short	O
-	O
term	O
cellular	O
responses	O
elicited	O
following	O
CD30	B
ligation	O
.	O
Activation	O
of	O
the	O
signal	O
transducer	O
and	O
transcription	O
(	O
STAT	B
)	O
signaling	O
pathway	O
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O
Critical	O
role	O
for	O
IL-6	B
.	O
The	O
T	O
cell	O
activation	O
is	O
initiated	O
by	O
interaction	O
of	O
specific	O
Ags	B
with	O
TCR	B
,	O
followed	O
by	O
activation	O
of	O
intracellular	O
biochemical	O
events	O
leading	O
to	O
activation	O
of	O
several	O
genes	O
.	O
The	O
activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B
(	I
STAT	I
)	I
proteins	I
in	O
a	O
primary	O
TCR	B
-mediated	O
activation	O
of	O
T	O
cells	O
have	O
been	O
explored	O
.	O
In	O
purified	O
human	O
peripheral	O
blood	O
T	O
cells	O
,	O
nuclear	B
STAT	I
proteins	I
were	O
activated	O
approximately	O
3	O
h	O
after	O
activation	O
by	O
cross	O
-	O
linked	O
anti	B
-	I
CD3	I
Abs	I
.	O
These	O
STAT	B
proteins	I
were	O
detected	O
by	O
using	O
the	O
IFN	O
-	O
gamma	O
-	O
activated	O
sequence	O
(	O
GAS	O
)	O
and	O
related	O
oligonucleotides	O
as	O
probes	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
anti	B
-	I
STAT	I
Abs	I
indicated	O
that	O
they	O
contained	O
STAT-3	B
and	O
additional	O
proteins	O
crossreactive	O
with	O
the	O
STAT	B
family	I
.	O
The	O
induction	O
of	O
STAT	B
activity	O
was	O
inhibited	O
completely	O
by	O
pretreatment	O
with	O
either	O
cycloheximide	O
or	O
cyclosporin	O
A	O
,	O
thus	O
indicating	O
that	O
the	O
induction	O
was	O
due	O
to	O
a	O
secondary	B
factor	I
produced	O
by	O
the	O
activated	O
T	O
cells	O
.	O
As	O
neutralizing	B
anti	I
-	I
IL-6	I
Abs	I
effectively	O
down	O
-	O
regulated	O
the	O
early	O
induction	O
of	O
STAT	B
proteins	I
and	O
as	O
exogenously	O
added	O
IL-6	B
rapidly	O
activated	O
DNA	O
binding	O
similar	O
to	O
TCR	B
-mediated	O
bindings	O
,	O
it	O
can	O
be	O
concluded	O
that	O
IL-6	B
is	O
the	O
factor	O
responsible	O
for	O
the	O
activation	O
of	O
STAT	B
proteins	I
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O
The	O
DNA	O
and	O
steroid	B
binding	I
domains	I
of	O
the	O
glucocorticoid	B
receptor	I
are	O
not	O
altered	O
in	O
mononuclear	O
cells	O
of	O
treated	O
CLL	O
patients	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
mutations	O
in	O
the	O
glucocorticoid	B
receptor	I
could	O
account	O
for	O
the	O
increasing	O
unresponsiveness	O
of	O
patients	O
with	O
chronic	O
lymphatic	O
leukemia	O
(	O
CLL	O
)	O
to	O
combination	O
chemotherapy	O
.	O
The	O
receptor	O
was	O
tested	O
immunocytochemically	O
,	O
in	O
steroid	O
binding	O
assays	O
,	O
and	O
by	O
a	O
mutation	O
screening	O
(	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
)	O
of	O
the	O
receptor	B
-	I
cDNA	I
.	O
The	O
receptor	O
concentration	O
,	O
as	O
measured	O
by	O
staining	O
and	O
steroid	O
binding	O
test	O
,	O
varied	O
considerably	O
but	O
showed	O
no	O
clear	O
correlation	O
to	O
clinical	O
response	O
.	O
Using	O
a	O
highly	O
sensitive	O
mutation	O
screening	O
assay	O
of	O
the	O
DNA-	B
and	I
the	I
steroid	I
-	I
binding	I
region	I
,	O
none	O
of	O
the	O
treated	O
patients	O
revealed	O
any	O
mutation	O
,	O
suggesting	O
that	O
the	O
glucocorticoid	B
receptor	I
in	O
the	O
CLL	O
patients	O
tested	O
is	O
not	O
altered	O
in	O
these	O
domains	O
.	O
In	O
one	O
individual	O
who	O
had	O
not	O
been	O
treated	O
before	O
analysis	O
a	O
silent	O
mutation	O
was	O
found	O
in	O
one	O
receptor	O
allele	O
.	O
The	O
results	O
suggest	O
that	O
mechanisms	O
other	O
than	O
altered	O
ligand	O
or	O
DNA	O
binding	O
of	O
the	O
receptor	O
may	O
be	O
responsible	O
for	O
the	O
lack	O
of	O
response	O
to	O
chemotherapy	O
.	O
This	O
conclusion	O
is	O
discussed	O
in	O
relation	O
to	O
the	O
mechanism	O
of	O
corticoid	O
resistance	O
in	O
mouse	O
and	O
human	O
lymphoma	O
cells	O
in	O
culture	O
.	O
The	O
myeloid	O
zinc	O
finger	O
gene	O
,	O
MZF-1	O
,	O
regulates	O
the	O
CD34	O
promoter	O
in	O
vitro	O
.	O
MZF-1	O
is	O
a	O
C2H2	O
zinc	O
finger	O
gene	O
encoding	O
a	O
putative	B
transcriptional	I
regulator	I
of	O
myeloid	O
differentiation	O
.	O
The	O
MZF-1	O
protein	O
contains	O
13	O
C2H2	B
zinc	I
fingers	I
arranged	O
in	O
bipartite	O
DNA	B
binding	I
domains	I
containing	O
zinc	B
fingers	I
through	O
4	O
and	O
,	O
in	O
the	O
carboxy	B
-	I
terminus	I
,	O
5	O
through	O
13	O
.	O
We	O
previously	O
identified	O
the	O
DNA	O
consensus	O
binding	O
site	O
recognized	O
by	O
the	O
two	O
DNA	B
binding	I
domains	I
.	O
To	O
assess	O
the	O
transcription	O
regulatory	O
function	O
of	O
MZF-1	O
,	O
the	O
full	O
-	O
length	O
MZF-1	O
coding	O
region	O
was	O
fused	O
to	O
the	O
DNA	B
binding	I
domain	I
of	O
the	O
yeast	B
transactivator	I
GAL4	I
.	O
The	O
expression	O
vector	O
was	O
cotransfected	O
with	O
the	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
regulated	O
by	O
the	O
thymidine	O
kinase	O
promoter	O
containing	O
GAL4	O
DNA	O
binding	O
sites	O
into	O
NIH	O
3T3	O
,	O
293	O
,	O
K562	O
,	O
and	O
Jurkat	O
cell	O
lines	O
.	O
MZF-1	O
represses	O
CAT	O
reporter	O
gene	O
expression	O
via	O
GAL4	B
binding	O
sites	O
in	O
the	O
nonhematopoietic	O
cell	O
lines	O
NIH	O
3T3	O
and	O
293	O
.	O
In	O
contrast	O
,	O
MZF-1	O
activates	O
CAT	O
reporter	O
gene	O
expression	O
in	O
the	O
hematopoietic	O
cell	O
lines	O
K562	O
and	O
Jurkat	O
.	O
The	O
MZF-1	O
binding	O
sites	O
are	O
present	O
in	O
the	O
promoters	O
of	O
several	O
genes	O
expressed	O
during	O
myeloid	O
differentiation	O
,	O
including	O
the	O
CD34	O
promoter	O
.	O
MZF-1	O
transcriptional	O
regulation	O
of	O
this	O
physiologically	O
relevant	O
promoter	O
was	O
assessed	O
in	O
both	O
hematopoietic	O
and	O
nonhematopoietic	O
cell	O
lines	O
.	O
Recombinant	B
MZF-1	I
protein	I
specifically	O
binds	O
to	O
the	O
consensus	O
binding	O
sites	O
in	O
the	O
CD34	O
promoter	O
in	O
mobility	O
shift	O
assays	O
.	O
MZF-1	O
expression	O
vectors	O
were	O
cotransfected	O
with	O
the	O
luciferase	O
reporter	O
plasmids	O
regulated	O
by	O
the	O
CD34	O
promoter	O
into	O
both	O
nonhematopoietic	O
and	O
hematopoietic	O
cell	O
lines	O
.	O
As	O
with	O
the	O
heterologous	O
DNA	B
binding	I
domain	I
,	O
MZF-1	O
represses	O
reporter	O
gene	O
expression	O
in	O
nonhematopoietic	O
cell	O
lines	O
and	O
activates	O
expression	O
in	O
hematopoietic	O
cell	O
lines	O
.	O
Activation	O
of	O
CD34	B
expression	O
in	O
hematopoietic	O
cell	O
lines	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
intact	O
MZF-1	O
binding	O
sites	O
.	O
The	O
cell	O
type	O
-	O
specific	O
regulation	O
of	O
the	O
CD34	O
promoter	O
by	O
MZF-1	O
suggests	O
the	O
presence	O
of	O
tissue	O
-	O
specific	O
regulators	O
/	O
adapters	O
or	O
differential	O
MZF-1	O
modifications	O
that	O
determine	O
MZF-1	O
transcriptional	O
regulatory	O
function	O
.	O
Bik	B
,	O
a	O
novel	O
death	B
-	I
inducing	I
protein	I
shares	O
a	O
distinct	O
sequence	O
motif	O
with	O
Bcl-2	B
family	I
proteins	I
and	O
interacts	O
with	O
viral	O
and	O
cellular	B
survival	I
-	I
promoting	I
proteins	I
.	O
The	O
survival	O
-	O
promoting	O
activity	O
of	O
the	O
Bcl-2	B
family	I
of	O
proteins	O
appears	O
to	O
be	O
modulated	O
by	O
interactions	O
between	O
various	O
cellular	B
proteins	I
.	O
We	O
have	O
identified	O
a	O
novel	O
cellular	B
protein	I
,	O
Bik	B
,	O
that	O
interacts	O
with	O
the	O
cellular	B
survival	I
-	I
promoting	I
proteins	I
,	O
Bcl-2	B
and	O
Bcl	B
-	I
xL	I
,	O
as	O
well	O
as	O
the	O
viral	B
survival	I
-	I
promoting	I
proteins	I
,	O
Epstein	B
Barr	I
virus	I
-	I
BHRF1	I
and	O
adenovirus	B
E1B-19	I
kDa	I
.	O
In	O
transient	O
transfection	O
assays	O
,	O
Bik	B
promotes	O
cell	O
death	O
in	O
a	O
manner	O
similar	O
to	O
the	O
death	B
-	I
promoting	I
members	I
of	O
the	O
Bcl-2	B
family	I
,	O
Bax	B
and	O
Bak	B
.	O
This	O
death	O
-	O
promoting	O
activity	O
of	O
Bik	B
can	O
be	O
suppressed	O
by	O
coexpression	O
of	O
Bcl-2	B
,	O
Bcl	B
-	I
XL	I
,	O
EBV	B
-	I
BHRF1	I
and	O
E1B-19	B
kDa	I
proteins	O
suggesting	O
that	O
Bik	B
may	O
be	O
a	O
common	O
target	O
for	O
both	O
cellular	B
and	I
viral	I
anti	I
-	I
apoptotic	I
proteins	I
.	O
While	O
Bik	B
does	O
not	O
show	O
overt	O
homology	O
to	O
the	O
BH1	B
and	O
BH2	B
conserved	O
domains	O
characteristic	O
of	O
the	O
Bcl-2	B
family	I
,	O
it	O
does	O
share	O
a	O
9	O
amino	B
acid	I
domain	I
(	O
BH3	B
)	O
with	O
Bax	B
and	O
Bak	B
which	O
may	O
be	O
a	O
critical	O
determinant	O
for	O
the	O
death	O
-	O
promoting	O
activity	O
of	O
these	O
proteins	O
.	O
Identification	O
of	O
an	O
I	B
kappa	I
B	I
alpha	I
-	I
associated	I
protein	I
kinase	I
in	O
a	O
human	O
monocytic	O
cell	O
line	O
and	O
determination	O
of	O
its	O
phosphorylation	B
sites	I
on	O
I	B
kappa	I
B	I
alpha	I
.	O
Nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
is	O
stored	O
in	O
the	O
cytoplasm	O
as	O
an	O
inactive	O
form	O
through	O
interaction	O
with	O
I	B
kappa	I
B	I
.	O
Stimulation	O
of	O
cells	O
leads	O
to	O
a	O
rapid	O
phosphorylation	O
of	O
I	B
kappa	I
B	I
alpha	I
,	O
which	O
is	O
presumed	O
to	O
be	O
important	O
for	O
the	O
subsequent	O
degradation	O
.	O
We	O
have	O
recently	O
reported	O
the	O
establishment	O
of	O
a	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-dependent	O
cell	O
-	O
free	O
activation	O
system	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
association	O
with	O
the	O
induction	O
of	O
I	B
kappa	I
B	I
alpha	I
phosphorylation	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
identified	O
a	O
kinase	B
in	O
cell	O
extracts	O
from	O
the	O
LPS	O
-	O
stimulated	O
human	O
monocytic	O
cell	O
line	O
,	O
THP-1	O
,	O
that	O
specifically	O
binds	O
and	O
phosphorylates	O
I	B
kappa	I
B	I
alpha	I
.	O
LPS	O
stimulation	O
transiently	O
enhanced	O
the	O
I	B
kappa	I
B	I
alpha	I
-bound	B
kinase	I
activity	O
in	O
THP-1	O
cells	O
.	O
Mutational	O
analyses	O
of	O
I	B
kappa	I
B	I
alpha	O
and	O
competition	O
experiments	O
with	O
the	O
synthetic	O
peptides	O
identified	O
major	O
phosphorylation	B
sites	I
by	O
the	O
bound	O
kinase	B
as	O
Ser	O
and	O
Thr	O
residues	O
in	O
the	O
C	B
-	I
terminal	I
acidic	I
domain	I
of	O
I	B
kappa	I
B	I
alpha	I
.	O
Moreover	O
,	O
we	O
show	O
that	O
the	O
peptide	O
,	O
corresponding	O
to	O
the	O
C	B
-	I
terminal	I
acidic	I
domain	I
of	O
I	B
kappa	I
B	I
alpha	I
,	O
blocked	O
the	O
LPS	O
-	O
induced	O
NF	B
-	I
kappa	I
B	I
activation	O
as	O
well	O
as	O
inducible	O
phosphorylation	O
of	O
endogenous	O
I	B
kappa	I
B	I
alpha	I
in	O
a	O
cell	O
-	O
free	O
system	O
using	O
THP-1	O
cells	O
.	O
These	O
results	O
suggested	O
that	O
the	O
bound	B
kinase	I
is	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
LPS	O
by	O
inducing	O
the	O
phosphorylation	O
of	O
the	O
C	B
-	I
terminal	I
region	I
of	O
I	B
kappa	I
B	I
alpha	I
and	O
subsequent	O
dissociation	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
.	O
I	B
kappa	I
B	I
alpha	I
complex	I
.	O
Triggering	O
of	O
the	O
human	O
interleukin-6	O
gene	O
by	O
interferon	O
-	O
gamma	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
in	O
monocytic	O
cells	O
involves	O
cooperation	O
between	O
interferon	B
regulatory	I
factor-1	I
,	O
NF	B
kappa	I
B	I
,	O
and	O
Sp1	B
transcription	B
factors	I
.	O
We	O
investigated	O
the	O
molecular	O
basis	O
of	O
the	O
synergistic	O
induction	O
by	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
/	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
of	O
human	O
interleukin-6	O
(	O
IL-6	O
)	O
gene	O
in	O
THP-1	O
monocytic	O
cells	O
,	O
and	O
compared	O
it	O
with	O
the	O
basis	O
of	O
this	O
induction	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
Functional	O
studies	O
with	O
IL-6	O
promoter	O
demonstrated	O
that	O
three	O
regions	O
are	O
the	O
targets	O
of	O
the	O
IFN	B
-	I
gamma	I
and/or	O
TNF	B
-	I
alpha	I
action	O
,	O
whereas	O
only	O
one	O
of	O
these	O
regions	O
seemed	O
to	O
be	O
implicated	O
in	O
LPS	O
activation	O
.	O
The	O
three	O
regions	O
concerned	O
are	O
:	O
1	O
)	O
a	O
region	O
between	O
-73	O
and	O
-36	O
,	O
which	O
is	O
the	O
minimal	O
element	O
inducible	O
by	O
LPS	O
or	O
TNF	B
-	I
alpha	I
;	O
2	O
)	O
an	O
element	O
located	O
between	O
-181	O
and	O
-73	O
,	O
which	O
appeared	O
to	O
regulate	O
the	O
response	O
to	O
IFN	B
-	I
gamma	I
and	O
TNF	B
-	I
alpha	I
negatively	O
;	O
and	O
3	O
)	O
a	O
distal	O
element	O
upstream	O
of	O
-224	O
,	O
which	O
was	O
inducible	O
by	O
IFN	B
-	I
gamma	I
alone	O
.	O
LPS	O
signaling	O
was	O
found	O
to	O
involve	O
NF	B
kappa	I
B	I
activation	O
by	O
the	O
p50	B
/	I
p65	I
heterodimers	I
.	O
Synergistic	O
induction	O
of	O
the	O
IL-6	O
gene	O
by	O
IFN	B
-	I
gamma	I
and	O
TNF	B
-	I
alpha	I
,	O
in	O
monocytic	O
cells	O
,	O
involved	O
cooperation	O
between	O
the	O
IRF-1	B
and	O
NF	B
kappa	I
B	I
p65	I
homodimers	I
with	O
concomitant	O
removal	O
of	O
the	O
negative	O
effect	O
of	O
the	O
retinoblastoma	O
control	O
element	O
present	O
in	O
the	O
IL-6	O
promoter	O
.	O
This	O
removal	O
occurred	O
by	O
activation	O
of	O
the	O
constitutive	B
Sp1	I
factor	I
,	O
whose	O
increased	O
binding	O
activity	O
and	O
phosphorylation	O
were	O
mediated	O
by	O
IFN	B
-	I
gamma	I
.	O
Nuclear	B
factor	I
-	I
IL6	I
activates	O
the	O
human	O
IL-4	O
promoter	O
in	O
T	O
cells	O
.	O
Positive	O
regulatory	O
element	O
I	O
(	O
PRE	O
-	O
I	O
)	O
is	O
a	O
strong	O
enhancer	O
element	O
essential	O
for	O
expression	O
of	O
the	O
human	O
IL-4	O
gene	O
.	O
To	O
identify	O
transcription	B
factors	I
binding	O
to	O
PRE	O
-	O
I	O
,	O
we	O
screened	O
a	O
cDNA	O
expression	O
library	O
from	O
Jurkat	O
T	O
cells	O
and	O
isolated	O
a	O
cDNA	O
encoding	O
nuclear	B
factor	I
(	B
NF	I
)	I
-IL6	I
(	O
also	O
known	O
as	O
C	B
/	I
EBP	I
beta	I
)	O
.	O
NF	O
-	O
IL6	O
mRNA	O
was	O
found	O
in	O
human	O
Jurkat	O
T	O
cells	O
and	O
in	O
the	O
mouse	O
Th2	O
clone	O
D10	O
,	O
but	O
not	O
in	O
Th1	O
clone	O
29	O
.	O
rNF	B
-	I
IL6	I
expressed	O
in	O
bacteria	O
was	O
shown	O
to	O
specifically	O
bind	O
to	O
PRE	O
-	O
I	O
.	O
PRE	O
-	O
I	O
forms	O
multiple	B
DNA	I
-	I
protein	I
complexes	I
with	O
nuclear	O
extracts	O
from	O
Jurkat	O
cells	O
.	O
Some	O
of	O
these	O
complexes	O
were	O
demonstrated	O
to	O
contain	O
NF	B
-	I
IL6	I
by	O
using	O
anti	B
-	I
C	I
/	I
EBP	I
beta	I
Abs	I
.	O
Overexpression	O
of	O
NF	B
-	I
IL6	I
enhanced	O
expression	O
of	O
the	O
chloramphenicol	O
acetyl	O
transferase	O
reporter	O
gene	O
linked	O
to	O
the	O
PRE	B
-	I
I	I
-	I
thymidine	I
kinase	I
or	O
the	O
human	O
IL-4	O
promoter	O
more	O
than	O
10-fold	O
in	O
Jurkat	O
cells	O
.	O
Promoter	O
deletion	O
studies	O
revealed	O
two	O
additional	O
NF	O
-	O
IL6	O
binding	O
sites	O
located	O
at	O
positions	O
-44	O
to	O
-36	O
(	O
C	B
/	I
EBP	I
proximal	I
)	O
and	O
-87	O
to	O
-79	O
(	O
C	B
/	I
EBP	I
medial	I
)	O
,	O
respectively	O
.	O
Our	O
results	O
demonstrate	O
that	O
NF	B
-	I
IL6	I
is	O
involved	O
in	O
transcriptional	O
activation	O
of	O
the	O
human	O
IL-4	O
promoter	O
in	O
T	O
cells	O
.	O
Coexpression	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
and	O
Sp1	B
transcription	B
factors	I
in	O
human	O
immunodeficiency	O
virus	O
1-induced	O
,	O
dendritic	O
cell	O
-	O
T	O
-	O
cell	O
syncytia	O
.	O
Productive	O
infection	O
of	O
T	O
cells	O
with	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
typically	O
requires	O
that	O
the	O
T	O
cells	O
be	O
stimulated	O
with	O
antigens	O
or	O
mitogens	O
.	O
This	O
requirement	O
has	O
been	O
attributed	O
to	O
the	O
activation	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappa	I
B	I
,	O
which	O
synergizes	O
with	O
the	O
constitutive	B
transcription	I
factor	I
Sp1	B
to	O
drive	O
the	O
HIV-1	O
promoter	O
.	O
Recently	O
,	O
we	O
have	O
found	O
that	O
vigorous	O
replication	O
of	O
HIV-1	O
takes	O
place	O
in	O
nonactivated	O
memory	O
T	O
cells	O
after	O
syncytium	O
formation	O
with	O
dendritic	O
cells	O
(	O
DCs	O
)	O
.	O
These	O
syncytia	O
lack	O
activated	O
cells	O
as	O
determined	O
by	O
an	O
absence	O
of	O
staining	O
for	O
Ki-67	O
cell	O
cycle	O
antigen	O
.	O
The	O
expression	O
and	O
activity	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
Sp1	B
were	O
,	O
therefore	O
,	O
analyzed	O
in	O
isolated	O
T	O
cells	O
and	O
DCs	O
from	O
humans	O
and	O
mice	O
.	O
We	O
have	O
used	O
immunolabeling	O
,	O
Western	O
blot	O
analysis	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
.	O
T	O
cells	O
lack	O
active	O
NF	B
-	I
kappa	I
B	I
but	O
express	O
Sp1	B
as	O
expected	O
.	O
DCs	O
express	O
high	O
levels	O
of	O
all	O
known	O
NF	B
-	I
kappa	I
B	I
and	O
Rel	B
proteins	I
,	O
with	O
activity	O
residing	O
primarily	O
within	O
RelB	B
,	O
p50	B
,	O
and	O
p65	B
.	O
However	O
,	O
DCs	O
lack	O
Sp1	B
,	O
which	O
may	O
explain	O
the	O
failure	O
of	O
HIV-1	O
to	O
replicate	O
in	O
purified	O
DCs	O
.	O
Coexpression	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
Sp1	B
occurs	O
in	O
the	O
heterologous	O
DC	O
-	O
T	O
-	O
cell	O
syncytia	O
that	O
are	O
induced	O
by	O
HIV-1	O
.	O
Therefore	O
,	O
HIV-1-induced	O
cell	O
fusion	O
brings	O
together	O
factors	O
that	O
upregulate	O
virus	O
transcription	O
.	O
Since	O
DCs	O
and	O
memory	O
T	O
cells	O
frequently	O
traffic	O
together	O
in	O
situ	O
,	O
these	O
unusual	O
heterologous	O
syncytia	O
could	O
develop	O
in	O
infected	O
individuals	O
and	O
lead	O
to	O
chronic	O
HIV-1	O
replication	O
without	O
ostensible	O
immune	O
stimulation	O
.	O
Down	O
-	O
regulation	O
of	O
NF	B
-	I
kappa	I
B	I
protein	I
levels	O
in	O
activated	O
human	O
lymphocytes	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1996	O
Jan	O
9	O
;	O
93	O
(	O
1	O
)	O
:	O
524	O
]	O
The	O
effect	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2	O
)	O
D3	O
]	O
,	O
a	O
steroid	O
hormone	O
with	O
immunomodulating	O
properties	O
,	O
on	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
proteins	O
was	O
examined	O
in	O
in	O
vitro	O
activated	O
normal	O
human	O
lymphocytes	O
by	O
Western	O
blot	O
analysis	O
.	O
Over	O
a	O
72-hr	O
period	O
of	O
activation	O
,	O
the	O
expression	O
of	O
the	O
50-kDa	B
NF	I
-	I
kappa	I
B	I
,	O
p50	B
,	O
and	O
its	O
precursor	O
,	O
p105	B
,	O
was	O
increased	O
progressively	O
.	O
When	O
cells	O
were	O
activated	O
in	O
the	O
presence	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
the	O
levels	O
of	O
the	O
mature	O
protein	O
as	O
well	O
as	O
its	O
precursor	O
were	O
decreased	O
.	O
The	O
effect	O
of	O
the	O
hormone	O
on	O
the	O
levels	O
of	O
p50	B
was	O
demonstrable	O
in	O
the	O
cytosolic	O
and	O
nuclear	O
compartments	O
;	O
it	O
required	O
between	O
4	O
and	O
8	O
hr	O
and	O
was	O
specific	O
,	O
as	O
25-hydroxyvitamin	O
D3	O
and	O
24	O
,	O
25-dihydroxyvitamin	O
D3	O
were	O
ineffective	O
.	O
Besides	O
p50	B
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
decreased	O
the	O
levels	O
of	O
another	O
NF	B
-	I
kappa	I
B	I
protein	I
,	O
namely	O
c	B
-	I
rel	I
.	O
In	O
addition	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
decreased	O
the	O
abundance	O
of	O
a	O
specific	B
DNA	I
-	I
protein	I
complex	I
formed	O
upon	O
incubation	O
of	O
nuclear	O
extracts	O
from	O
activated	O
lymphocytes	O
with	O
a	O
labeled	O
NF	B
-	I
kappa	I
B	I
DNA	I
binding	I
motif	I
.	O
Further	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
inhibited	O
the	O
transcriptional	O
activity	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
Jurkat	O
cells	O
transiently	O
transfected	O
with	O
a	O
construct	O
containing	O
four	O
tandem	O
repeats	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
binding	O
sequence	O
of	O
the	O
immunoglobulin	O
kappa	O
light	O
chain	O
gene	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
reporter	O
gene	O
.	O
These	O
observations	O
demonstrate	O
directly	O
that	O
there	O
is	O
de	O
novo	O
synthesis	O
of	O
NF	B
-	I
kappa	I
B	I
during	O
human	O
lymphocyte	O
activation	O
and	O
suggest	O
that	O
this	O
process	O
is	O
hormonally	O
regulated	O
.	O
Oncogenicity	O
of	O
human	O
papillomavirus-	O
or	O
adenovirus	O
-	O
transformed	O
cells	O
correlates	O
with	O
resistance	O
to	O
lysis	O
by	O
natural	O
killer	O
cells	O
.	O
The	O
reasons	O
for	O
the	O
dissimilar	O
oncogenicities	O
of	O
human	O
adenoviruses	O
and	O
human	O
papillomaviruses	O
(	O
HPV	O
)	O
in	O
humans	O
are	O
unknown	O
but	O
may	O
relate	O
to	O
differences	O
in	O
the	O
capacities	O
of	O
the	O
E1A	B
and	O
E7	B
proteins	I
to	O
target	O
cells	O
for	O
rejection	O
by	O
the	O
host	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
response	O
.	O
As	O
one	O
test	O
of	O
this	O
hypothesis	O
,	O
we	O
compared	O
the	O
abilities	O
of	O
E1A	B
-and	O
E7	B
-expressing	O
human	O
fibroblastic	O
or	O
keratinocyte	O
-	O
derived	O
human	O
cells	O
to	O
be	O
selectively	O
killed	O
by	O
either	O
unstimulated	O
or	O
interferon	O
(	O
IFN	O
)	O
-activated	O
NK	O
cells	O
.	O
Cells	O
expressing	O
the	O
E1A	B
oncoprotein	I
were	O
selectively	O
killed	O
by	O
unstimulated	O
NK	O
cells	O
,	O
while	O
the	O
same	O
parental	O
cells	O
but	O
expressing	O
the	O
HPV	O
type	O
16	O
(	O
HPV-16	O
)	O
or	O
HPV-18	O
E7	B
oncoprotein	I
were	O
resistant	O
to	O
NK	O
cell	O
lysis	O
.	O
The	O
ability	O
of	O
IFN	O
-	O
activated	O
NK	O
cells	O
to	O
selectively	O
kill	O
virally	O
transformed	O
cells	O
depends	O
on	O
IFN	B
's	O
ability	O
to	O
induce	O
resistance	O
to	O
NK	O
cell	O
lysis	O
in	O
normal	O
(	O
i.e.	O
,	O
non	O
-	O
viral	O
oncogene	O
-	O
expressing	O
)	O
but	O
not	O
virally	O
transformed	O
cells	O
.	O
E1A	B
blocked	O
IFN	B
's	O
induction	O
of	O
cytolytic	O
resistance	O
,	O
resulting	O
in	O
the	O
selective	O
lysis	O
of	O
adenovirus	O
-	O
transformed	O
cells	O
by	O
IFN	O
-	O
activated	O
NK	O
cells	O
.	O
The	O
extent	O
of	O
IFN	B
-induced	O
NK	O
cell	O
killing	O
of	O
E1A	O
-	O
expressing	O
cells	O
was	O
proportional	O
to	O
the	O
level	O
of	O
E1A	B
expression	O
and	O
correlated	O
with	O
the	O
ability	O
of	O
E1A	B
to	O
block	O
IFN	B
-stimulated	O
gene	O
expression	O
in	O
target	O
cells	O
.	O
In	O
contrast	O
,	O
E7	B
blocked	O
neither	O
IFN	B
-stimulated	O
gene	O
expression	O
nor	O
IFN	B
's	O
induction	O
of	O
cytolytic	O
resistance	O
,	O
thereby	O
precluding	O
the	O
selective	O
lysis	O
of	O
HPV	O
-	O
transformed	O
cells	O
by	O
IFN	O
-	O
activated	O
NK	O
cells	O
.	O
In	O
conclusion	O
,	O
E1A	B
expression	O
marks	O
cells	O
for	O
destruction	O
by	O
the	O
host	O
NK	O
cell	O
response	O
,	O
whereas	O
the	O
E7	B
oncoprotein	I
lacks	O
this	O
activity	O
.	O
Expression	O
of	O
the	O
nucleoside	B
diphosphate	I
kinase	I
in	O
human	O
skin	O
cancers	O
:	O
an	O
immunohistochemical	O
study	O
.	O
Expression	O
of	O
nucleoside	B
diphosphate	I
(	I
NDP	I
)	I
kinase	I
,	O
which	O
is	O
homologous	O
to	O
the	O
nm23	B
gene	I
product	I
in	O
a	O
variety	O
of	O
species	O
,	O
has	O
been	O
found	O
to	O
be	O
inversely	O
associated	O
with	O
metastatic	O
potential	O
.	O
However	O
,	O
the	O
relationship	O
remains	O
controversial	O
according	O
to	O
the	O
tumor	O
cell	O
types	O
and	O
experimental	O
system	O
,	O
with	O
conflicting	O
results	O
from	O
different	O
research	O
groups	O
.	O
In	O
order	O
to	O
determine	O
whether	O
NDP	B
kinase	I
expression	O
serves	O
as	O
a	O
marker	O
for	O
metastatic	O
potential	O
in	O
human	O
skin	O
cancer	O
,	O
we	O
assessed	O
the	O
levels	O
of	O
NDP	B
kinase	I
expression	O
in	O
9	O
keratoacanthomas	O
(	O
KAs	O
)	O
,	O
26	O
squamous	O
cell	O
carcinomas	O
(	O
SCCs	O
)	O
,	O
and	O
25	O
basal	O
cell	O
carcinomas	O
(	O
BCCs	O
)	O
using	O
immunohistochemistry	O
.	O
The	O
expression	O
of	O
NDP	B
kinase	I
was	O
intense	O
in	O
KA	O
and	O
SCC	O
compared	O
with	O
BCC	O
.	O
However	O
,	O
the	O
difference	O
of	O
NDP	B
kinase	I
expression	O
between	O
KA	O
and	O
SCC	O
was	O
not	O
statistically	O
significant	O
.	O
And	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
NDP	B
kinase	I
expression	O
between	O
SCC	O
with	O
metastasis	O
and	O
SCC	O
without	O
metastasis	O
.	O
Our	O
results	O
contradict	O
the	O
hypothesis	O
concerning	O
the	O
possible	O
role	O
of	O
nm23	O
gene	O
as	O
a	O
metastatic	O
suppressor	O
gene	O
in	O
human	O
skin	O
cancer	O
.	O
The	O
mechanism	O
of	O
overexpression	O
in	O
various	O
tumor	O
cell	O
types	O
and	O
its	O
biological	O
significance	O
in	O
cutaneous	O
carcinogenesis	O
remain	O
to	O
be	O
determined	O
.	O
Interleukin-7	B
can	O
induce	O
the	O
activation	O
of	O
Jak	B
1	I
,	O
Jak	B
3	I
and	O
STAT	B
5	I
proteins	I
in	O
murine	O
T	O
cells	O
.	O
The	O
activation	O
of	O
Janus	B
protein	I
tyrosine	I
kinases	I
(	O
Jak	B
)	O
and	O
STAT	B
(	I
signal	I
transducer	I
and	I
activator	I
of	I
transcription	I
)	I
proteins	I
has	O
recently	O
been	O
linked	O
to	O
the	O
signal	O
transduction	O
mechanism	O
of	O
several	O
cytokines	B
.	O
IL-7	B
was	O
observed	O
to	O
induce	O
a	O
rapid	O
and	O
dose	O
-	O
dependent	O
tyrosine	O
phosphorylation	O
of	O
Jak	B
1	I
and	O
Jak	B
3	I
and	O
concomitantly	O
,	O
the	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
of	O
multiple	O
STAT	B
proteins	I
.	O
The	O
STAT	B
proteins	I
utilized	O
by	O
IL-7	B
were	O
identical	O
to	O
those	O
induced	O
by	O
IL-2	B
and	O
could	O
be	O
identified	O
as	O
various	O
STAT	B
5	I
isoforms	I
.	O
Moreover	O
,	O
the	O
induction	O
of	O
both	O
Jak	B
1	I
and	I
3	I
,	O
and	O
STAT	B
5	I
activity	O
strongly	O
correlated	O
with	O
the	O
growth	O
-	O
promoting	O
effects	O
of	O
IL-7	B
,	O
suggesting	O
that	O
this	O
signal	O
transduction	O
mechanism	O
may	O
play	O
a	O
key	O
role	O
in	O
IL-7	B
-induced	O
proliferation	O
.	O
Constitutive	O
NF	B
-	I
kappa	I
B	I
activation	O
,	O
enhanced	O
granulopoiesis	O
,	O
and	O
neonatal	O
lethality	O
in	O
I	B
kappa	I
B	I
alpha	I
-deficient	O
mice	O
.	O
Transcription	B
factors	I
belonging	O
to	O
the	O
NF	B
-	I
kappa	I
B	I
family	I
are	O
controlled	O
by	O
inhibitory	B
I	I
kappa	I
B	I
proteins	I
,	O
mainly	O
I	B
kappa	I
B	I
alpha	I
and	O
I	B
kappa	I
B	I
beta	I
.	O
Apparently	O
normal	O
at	O
birth	O
,	O
I	B
kappa	I
B	I
alpha	I
-	O
/	O
-	O
mice	O
exhibit	O
severe	O
runting	O
,	O
skin	O
defects	O
,	O
and	O
extensive	O
granulopoiesis	O
postnatally	O
,	O
typically	O
dying	O
by	O
8	O
days	O
.	O
Hematopoietic	O
tissues	O
from	O
these	O
mice	O
display	O
elevated	O
levels	O
of	O
both	O
nuclear	B
NF	I
-	I
kappa	I
B	I
and	O
mRNAs	O
of	O
some	O
,	O
but	O
not	O
all	O
,	O
genes	O
thought	O
to	O
be	O
regulated	O
by	O
NF	B
-	I
kappa	I
B	I
.	O
NF	B
-	I
kappa	I
B	I
elevation	O
results	O
in	O
these	O
phenotypic	O
abnormalities	O
because	O
mice	O
lacking	O
both	O
I	B
kappa	I
B	I
alpha	I
and	O
the	O
p50	B
subunit	I
of	O
NF	B
-	I
kappa	I
B	I
show	O
a	O
dramatically	O
delayed	O
onset	O
of	O
abnormalities	O
.	O
In	O
contrast	O
to	O
hematopoietic	O
cells	O
,	O
I	O
kappa	O
B	O
alpha-	O
/	O
-	O
embryonic	O
fibroblasts	O
show	O
minimal	O
constitutive	B
NF	I
-	I
kappa	I
B	I
,	O
as	O
well	O
as	O
normal	O
signal	O
-	O
dependent	O
NF	B
-	I
kappa	I
B	I
activation	O
that	O
is	O
concomitant	O
with	O
I	B
kappa	I
B	I
beta	I
degradation	O
.	O
Our	O
results	O
indicate	O
that	O
I	O
kappa	O
b	O
beta	O
,	O
but	O
not	O
I	B
kappa	I
B	I
alpha	I
,	O
is	O
required	O
for	O
the	O
signal	O
-	O
dependent	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
fibroblasts	O
.	O
However	O
,	O
I	B
kappa	I
B	I
alpha	I
is	O
required	O
for	O
the	O
postinduction	O
repression	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
fibroblasts	O
.	O
These	O
results	O
define	O
distinct	O
roles	O
for	O
the	O
two	O
forms	O
of	O
I	B
kappa	I
B	I
and	O
demonstrate	O
the	O
necessity	O
for	O
stringent	O
control	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
Hemoglobin	B
switching	O
in	O
humans	O
is	O
accompanied	O
by	O
changes	O
in	O
the	O
ratio	O
of	O
the	O
transcription	B
factors	I
,	O
GATA-1	B
and	O
SP1	B
.	O
BACKGROUND	O
:	O
Understanding	O
the	O
mechanism	O
of	O
developmental	O
regulation	O
of	O
hemoglobin	B
switching	O
has	O
scientific	O
as	O
well	O
as	O
clinical	O
relevance	O
because	O
of	O
the	O
influence	O
of	O
fetal	O
hemoglobin	B
(	O
HbF	B
)	O
production	O
in	O
adulthood	O
on	O
the	O
clinical	O
manifestation	O
of	O
thalassemia	O
and	O
sickle	O
cell	O
anemia	O
.	O
We	O
have	O
previously	O
found	O
that	O
the	O
normal	O
developmental	O
patterns	O
of	O
globin	O
gene	O
expression	O
are	O
recapitulated	O
in	O
an	O
experimental	O
system	O
of	O
primary	O
cultures	O
that	O
support	O
differentiation	O
of	O
erythroid	O
progenitors	O
.	O
We	O
further	O
found	O
that	O
high	O
activities	O
of	O
the	O
transcriptional	B
activators	I
,	O
GATA-1	B
and	O
SP1	B
,	O
are	O
associated	O
with	O
normal	O
adult	O
erythroid	O
differentiation	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
In	O
the	O
present	O
work	O
,	O
we	O
have	O
studied	O
,	O
the	O
activities	O
of	O
GATA-1	B
and	O
SP1	B
during	O
differentiation	O
of	O
cultured	O
erythroid	O
progenitors	O
derived	O
from	O
cord	O
blood	O
and	O
from	O
fetal	O
livers	O
,	O
as	O
well	O
as	O
from	O
beta	O
zero	O
-	O
thalassemia	O
patients	O
.	O
RESULTS	O
:	O
The	O
results	O
showed	O
high	O
GATA-1	B
binding	O
activity	O
and	O
very	O
low	O
SP1	B
activity	O
in	O
the	O
fetal	O
liver	O
cultures	O
.	O
This	O
pattern	O
was	O
in	O
contrast	O
to	O
cultures	O
derived	O
from	O
normal	O
adult	O
peripheral	O
blood	O
,	O
in	O
which	O
both	O
GATA-1	B
and	O
SP1	B
activities	O
were	O
high	O
.	O
Cord	O
blood	O
cultures	O
showed	O
an	O
additive	O
combination	O
of	O
`	O
`	O
adult	O
''	O
and	O
`	O
`	O
fetal	O
''	O
patterns	O
.	O
The	O
progenitors	O
derived	O
from	O
a	O
beta	O
zero	O
-	O
thalassemia	O
patient	O
with	O
high	O
HbF	B
production	O
showed	O
`	O
`	O
fetal	O
''	O
pattern	O
.	O
On	O
the	O
other	O
hand	O
,	O
in	O
cultures	O
of	O
2	O
beta	O
zero	O
-	O
thalassemia	O
patients	O
without	O
high	O
HbF	B
,	O
`	O
`	O
adult	O
''	O
pattern	O
was	O
observed	O
.	O
CONCLUSIONS	O
:	O
In	O
the	O
present	O
work	O
,	O
we	O
show	O
that	O
human	O
fetal	O
and	O
adult	O
erythroid	O
progenitors	O
are	O
distinct	O
in	O
their	O
transcription	B
factors	I
,	O
and	O
that	O
the	O
commitment	O
to	O
fetal	O
or	O
adult	O
program	O
occurs	O
at	O
a	O
very	O
early	O
differentiation	O
stage	O
.	O
Our	O
studies	O
also	O
demonstrate	O
that	O
under	O
anemic	O
stress	O
,	O
recruitment	O
of	O
fetal	O
progenitors	O
may	O
occur	O
in	O
adulthood	O
.	O
CIITA	B
activates	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
in	O
mouse	O
T	O
cells	O
.	O
It	O
has	O
long	O
been	O
a	O
puzzle	O
that	O
MHC	B
class	I
II	I
molecules	I
are	O
expressed	O
in	O
human	O
T	O
cells	O
after	O
activation	O
but	O
not	O
in	O
mouse	O
T	O
cells	O
;	O
this	O
expression	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
the	O
cell	O
mediated	O
immune	O
response	O
.	O
Recently	O
the	O
MHC	B
class	I
II	I
transactivator	I
(	O
CIITA	B
)	O
has	O
been	O
reported	O
to	O
be	O
a	O
major	B
regulatory	I
factor	I
for	O
both	O
the	O
constitutive	O
and	O
IFN	O
inducible	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O
Here	O
we	O
show	O
that	O
human	O
T	O
cells	O
expressing	O
MHC	O
class	O
II	O
have	O
CIITA	B
transcripts	O
while	O
MHC	O
class	O
II	O
-	O
negative	O
human	O
T	O
cells	O
and	O
mouse	O
T	O
cells	O
do	O
not	O
.	O
The	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
in	O
mouse	O
T	O
cells	O
can	O
be	O
reconstituted	O
upon	O
transfection	O
with	O
the	O
human	O
CIITA	O
cDNA	O
.	O
These	O
data	O
indicate	O
that	O
the	O
expression	O
of	O
CIITA	B
explains	O
the	O
expression	O
or	O
lack	O
of	O
expression	O
of	O
MHC	B
class	I
II	I
in	O
human	O
and	O
mouse	O
T	O
cells	O
respectively	O
.	O
Lymphocyte	B
glucocorticoid	I
receptor	I
:	O
predictor	O
of	O
sertraline	O
response	O
in	O
adolescent	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O
Major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
in	O
adolescents	O
demonstrates	O
resistance	O
to	O
tricyclic	O
antidepressants	O
and	O
absence	O
of	O
hypercortisolemia	O
.	O
The	O
efficacy	O
of	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SRIs	O
)	O
is	O
uncertain	O
,	O
and	O
response	O
predictors	O
are	O
unavailable	O
.	O
Abnormal	O
fast	O
feedback	O
and	O
negative	O
feedback	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
implicates	O
a	O
dampened	O
limbic	B
-	I
hippocampal	I
glucocorticoid	I
type	I
II	I
receptor	I
(	O
GCII	B
)	O
.	O
We	O
hypothesized	O
that	O
lymphocyte	B
GCII	I
is	O
altered	O
in	O
adolescent	O
MDD	O
and	O
could	O
serve	O
as	O
a	O
marker	O
for	O
response	O
to	O
SRIs	O
.	O
In	O
an	O
open	O
-	O
label	O
study	O
,	O
adolescents	O
(	O
n	O
=	O
20	O
)	O
meeting	O
DSM	O
-	O
III	O
-	O
R	O
criteria	O
for	O
MDD	O
showed	O
baseline	O
lymphocyte	B
GCII	I
sites	I
per	O
cell	O
(	O
sites	O
/	O
cell	O
)	O
values	O
of	O
793	O
+	O
/-	O
106	O
versus	O
2	O
,	O
563	O
+	O
/-	O
499	O
(	O
+	O
/-	O
SEM	O
)	O
for	O
matched	O
controls	O
(	O
n	O
=	O
18	O
)	O
(	O
t	O
=	O
3.5	O
;	O
df	O
=	O
36	O
;	O
p	O
<	O
.001	O
)	O
.	O
GCII	B
was	O
bimodally	O
distributed	O
,	O
with	O
SRI	O
responders	O
differing	O
from	O
nonresponders	O
(	O
t	O
=	O
3.9	O
;	O
df	O
=	O
14	O
;	O
p	O
<	O
.001	O
)	O
.	O
GCII	B
accurately	O
classified	O
90	O
percent	O
of	O
sertraline	O
responders	O
and	O
80	O
percent	O
of	O
nonresponders	O
.	O
Only	O
SRI	O
responders	O
showed	O
GCII	B
sites	O
/	O
cell	O
upregulated	O
after	O
6	O
weeks	O
of	O
treatment	O
(	O
t	O
=	O
2.1	O
,	O
df	O
=	O
10	O
;	O
p	O
<	O
.05	O
)	O
.	O
Transcriptional	O
activation	O
and	O
repression	O
,	O
two	O
properties	O
of	O
the	O
lymphoid	B
-	I
specific	I
transcription	I
factor	I
Oct-2a	B
.	O
The	O
lymphoid	B
-	I
specific	I
transcription	I
factor	I
Oct-2a	B
contains	O
two	O
transcriptional	B
activation	I
domains	I
which	O
are	O
located	O
within	O
the	O
N	B
-	I
terminal	I
and	O
C	B
-	I
terminal	I
regions	I
.	O
To	O
study	O
their	O
differential	O
activation	O
properties	O
,	O
we	O
linked	O
the	O
isolated	O
effector	B
domains	I
to	O
the	O
GAL4	B
DNA	I
-	I
binding	I
domain	I
.	O
We	O
have	O
shown	O
that	O
both	O
activating	O
regions	O
of	O
Oct-2a	B
,	O
isolated	O
from	O
their	O
natural	O
context	O
,	O
can	O
activate	O
transcription	O
as	O
promoter	B
factors	I
.	O
In	O
contrast	O
to	O
the	O
C	B
-	I
terminus	I
,	O
activation	O
by	O
the	O
N	B
-	I
terminal	I
domain	I
is	O
dependent	O
on	O
a	O
yet	O
unidentified	O
factor	O
(	O
s	O
)	O
binding	O
to	O
the	O
simian	O
virus	O
40	O
enhancer	O
.	O
The	O
results	O
obtained	O
by	O
duplication	O
of	O
activation	B
domains	I
or	O
their	O
mixed	O
combination	O
suggest	O
that	O
the	O
domains	O
are	O
functionally	O
independent	O
.	O
However	O
,	O
activation	O
from	O
a	O
remote	O
position	O
could	O
only	O
be	O
achieved	O
with	O
the	O
C	B
-	I
terminus	I
of	O
Oct-2a	B
in	O
B	O
cells	O
.	O
In	O
lymphoid	O
cells	O
,	O
higher	O
activation	O
levels	O
were	O
observed	O
,	O
suggesting	O
that	O
distinct	O
B	B
-	I
cell	I
-	I
specific	I
cofactors	I
in	O
concert	O
with	O
the	O
effector	B
domains	I
of	O
Oct-2a	B
might	O
be	O
involved	O
in	O
mediating	O
transcription	O
from	O
proximal	O
and	O
remote	O
positions	O
.	O
Furthermore	O
,	O
we	O
identified	O
a	O
repression	O
domain	O
at	O
the	O
N	O
-	O
terminus	O
of	O
Oct-2a	B
.	O
When	O
transferred	O
to	O
a	O
potent	O
activator	O
,	O
transcriptional	O
stimulation	O
was	O
inhibited	O
efficiently	O
.	O
These	O
results	O
underscore	O
the	O
modular	O
structure	O
of	O
Oct-2a	B
with	O
separable	O
domains	O
for	O
activation	O
and	O
repression	O
and	O
suggest	O
that	O
Oct-2a	B
might	O
have	O
complex	O
regulatory	O
functions	O
in	O
vivo	O
.	O
Protein	B
kinase	I
C	I
-	I
zeta	I
mediates	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
human	O
immunodeficiency	O
virus	O
-	O
infected	O
monocytes	O
.	O
The	O
molecular	O
mechanisms	O
regulating	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
persistence	O
in	O
a	O
major	O
cell	O
reservoir	O
such	O
as	O
the	O
macrophage	O
remain	O
unknown	O
.	O
NF	B
-	I
kappa	I
B	I
is	O
a	O
transcription	B
factor	I
involved	O
in	O
the	O
regulation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
and	O
is	O
selectively	O
activated	O
following	O
HIV	O
infection	O
of	O
human	O
macrophages	O
.	O
Although	O
little	O
information	O
as	O
to	O
what	O
signal	O
transduction	O
pathways	O
mediate	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
monocytes	O
-	O
macrophages	O
is	O
available	O
,	O
our	O
previous	O
work	O
indicated	O
that	O
classical	O
protein	B
kinase	I
C	I
(	I
PKC	I
)	I
isoenzymes	I
were	O
not	O
involved	O
in	O
the	O
HIV	O
-	O
mediated	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
focused	O
on	O
atypical	O
PKC	B
isoenzymes	I
.	O
PKC	B
-	I
zeta	I
belongs	O
to	O
this	O
family	O
and	O
is	O
known	O
to	O
be	O
an	O
important	O
step	O
in	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
other	O
cell	O
systems	O
.	O
Immunoblotting	O
experiments	O
with	O
U937	O
cells	O
demonstrate	O
that	O
PKC	B
-	I
zeta	I
is	O
present	O
in	O
these	O
cells	O
,	O
and	O
its	O
expression	O
can	O
be	O
downmodulated	O
by	O
antisense	O
oligonucleotides	O
(	O
AO	O
)	O
.	O
The	O
HIV	O
-	O
mediated	O
NF	B
-	I
kappa	I
B	I
activation	O
is	O
selectively	O
reduced	O
by	O
AO	O
to	O
PKC	B
-	I
zeta	I
.	O
In	O
addition	O
,	O
cotransfection	O
of	O
a	O
negative	O
dominant	O
molecule	O
of	O
PKC	B
-	I
zeta	I
(	O
PKC	B
-	I
zeta	I
mut	I
)	O
with	O
NF	B
-	I
kappa	I
B	I
-dependent	O
reporter	O
genes	O
selectively	O
inhibits	O
the	O
HIV	O
-but	O
not	O
phorbol	O
myristate	O
acetate-	O
or	O
lipopolysaccharide	O
-	O
mediated	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
That	O
PKC	B
-	I
zeta	I
is	O
specific	O
in	O
regulating	O
NF	B
-	I
kappa	I
B	I
is	O
concluded	O
from	O
the	O
inability	O
of	O
PKC	B
-	I
zeta	I
(	I
mut	I
)	I
to	O
interfere	O
with	O
the	O
basal	O
or	O
phorbol	O
myristate	O
acetate	O
-	O
inducible	O
CREB	B
-or	O
AP1	B
-dependent	O
transcriptional	O
activity	O
.	O
Lastly	O
,	O
we	O
demonstrate	O
a	O
selective	O
inhibition	O
of	O
p24	B
production	O
by	O
HIV	O
-	O
infected	O
human	O
macrophages	O
when	O
treated	O
with	O
AO	O
to	O
PKC	B
-	I
zeta	I
.	O
Altogether	O
,	O
these	O
results	O
suggest	O
that	O
atypical	B
PKC	I
isoenzymes	I
,	O
including	O
PKC	B
-	I
zeta	I
,	O
participate	O
in	O
the	O
signal	O
transduction	O
pathways	O
by	O
which	O
HIV	O
infection	O
results	O
in	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
human	O
monocytic	O
cells	O
and	O
macrophages	O
.	O
Functional	O
characterization	O
of	O
the	O
murine	B
homolog	I
of	O
the	O
B	B
cell	I
-	I
specific	I
coactivator	I
BOB.1	B
/	I
OBF.1	I
.	O
B	O
cell	O
-	O
specific	O
transcriptional	O
promoter	O
activity	O
mediated	O
by	O
the	O
octamer	O
motif	O
requires	O
the	O
Oct1	B
or	O
Oct2	B
protein	I
and	O
additional	O
B	B
cell	I
-	I
restricted	I
cofactors	I
.	O
One	O
such	O
cofactor	B
,	O
BOB.1	B
/	I
OBF.1	I
,	O
was	O
recently	O
isolated	O
from	O
human	O
B	O
cells	O
.	O
Here	O
,	O
we	O
describe	O
the	O
isolation	O
and	O
detailed	O
characterization	O
of	O
the	O
murine	B
homolog	I
.	O
Full	O
-	O
length	O
cDNAs	O
and	O
genomic	O
clones	O
were	O
isolated	O
,	O
and	O
the	O
gene	O
structure	O
was	O
determined	O
.	O
Comparison	O
of	O
the	O
deduced	O
amino	O
acids	O
shows	O
88	O
%	O
sequence	O
identity	O
between	O
mouse	B
and	I
human	I
BOB.1	I
/	I
OBF.1	I
.	O
The	O
NH2-terminal	B
126	I
amino	I
acids	I
of	O
BOB.1	B
/	I
OBF.1	I
are	O
both	O
essential	O
and	O
sufficient	O
for	O
interaction	O
with	O
the	O
POU	B
domains	I
of	O
either	O
Oct1	B
or	O
Oct2	B
.	O
This	O
protein	O
-	O
protein	O
interaction	O
does	O
not	O
require	O
the	O
simultaneous	O
binding	O
of	O
Oct	B
proteins	I
to	O
DNA	O
,	O
and	O
high	O
resolution	O
footprinting	O
of	O
the	O
Oct	O
-DNA	O
interaction	O
reveals	O
that	O
binding	O
of	O
BOB.1	B
/	I
OBF.1	I
to	O
Oct1	B
or	O
Oct2	B
does	O
not	O
alter	O
the	O
interaction	O
with	O
DNA	O
.	O
BOB.1	B
/	I
OBF.1	I
can	O
efficiently	O
activate	O
octamer	O
-	O
dependent	O
promoters	O
in	O
fibroblasts	O
;	O
however	O
,	O
it	O
fails	O
to	O
stimulate	O
octamer	O
-	O
dependent	O
enhancer	O
activity	O
.	O
Fusion	O
of	O
subdomains	O
of	O
BOB.1	B
/	I
OBF.1	I
with	O
the	O
GAL4	B
DNA	I
binding	I
domain	I
reveals	O
that	O
both	O
NH2-	B
and	I
COOH	I
-	I
terminal	I
domains	I
of	O
BOB.1	B
/	I
OBF.1	I
contribute	O
to	O
full	O
transactivation	O
function	O
,	O
the	O
COOH	B
-	I
terminal	I
domain	I
is	O
more	O
efficient	O
in	O
this	O
transactivation	O
assay	O
.	O
Consistent	O
with	O
the	O
failure	O
of	O
full	B
-	I
length	I
BOB.1	I
/	I
OBF.1	I
to	O
stimulate	O
octamer	O
-	O
dependent	O
enhancer	O
elements	O
in	O
non	O
B	O
cells	O
,	O
the	O
GAL4	B
fusions	I
likewise	O
only	O
stimulate	O
from	O
a	O
promoter	O
-	O
proximal	O
position	O
.	O
Inhibition	O
of	O
NF	B
-	I
AT	I
-dependent	O
transcription	O
by	O
NF	B
-	I
kappa	I
B	I
:	O
implications	O
for	O
differential	O
gene	O
expression	O
in	O
T	O
helper	O
cell	O
subsets	O
.	O
Activation	O
of	O
individual	O
CD4	O
+	O
T	O
cells	O
results	O
in	O
differential	O
lymphokine	B
expression	O
:	O
interleukin	B
2	I
(	O
IL-2	B
)	O
is	O
preferentially	O
produced	O
by	O
T	O
helper	O
type	O
1	O
(	O
TH1	O
)	O
cells	O
,	O
which	O
are	O
involved	O
in	O
cell	O
-	O
mediated	O
immune	O
responses	O
,	O
whereas	O
IL-4	B
is	O
synthesized	O
by	O
TH2	O
cells	O
,	O
which	O
are	O
essential	O
for	O
humoral	O
immunity	O
.	O
The	O
Ca	B
(	I
2	I
+	I
)	I
-dependent	I
factor	I
NF	B
-	I
ATp	I
plays	O
a	O
key	O
role	O
in	O
the	O
inducible	O
transcription	O
of	O
both	O
these	O
lymphokine	O
genes	O
.	O
However	O
,	O
while	O
IL2	B
expression	O
requires	O
the	O
contribution	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-	O
and	O
protein	B
kinase	I
C	I
-dependent	O
signals	O
,	O
we	O
report	O
that	O
activation	O
of	O
human	B
IL4	I
transcription	O
through	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
pathway	O
is	O
diminished	O
by	O
protein	B
kinase	I
C	I
stimulation	O
in	O
Jurkat	O
T	O
cells	O
.	O
This	O
phenomenon	O
is	O
due	O
to	O
mutually	O
exclusive	O
binding	O
of	O
NF	B
-	I
ATp	I
and	O
NF	B
-	I
kappa	I
B	I
to	O
the	O
P	O
sequence	O
,	O
an	O
element	O
located	O
69	O
bp	O
upstream	O
of	O
the	O
IL4	O
transcription	O
initiation	O
site	O
.	O
Human	O
IL4	O
promoter	O
-mediated	O
transcription	O
is	O
downregulated	O
in	O
Jurkat	O
cells	O
stimulated	O
with	O
the	O
NF	B
-	I
kappa	I
B	I
-	I
activating	I
cytokine	I
tumor	B
necrosis	I
factor	I
alpha	I
and	O
suppressed	O
in	O
RelA	O
-	O
overexpressing	O
cells	O
.	O
In	O
contrast	O
,	O
protein	B
kinase	I
C	I
stimulation	O
or	O
RelA	B
overexpression	O
does	O
not	O
affect	O
the	O
activity	O
of	O
a	O
human	O
IL4	O
promoter	O
containing	O
a	O
mouse	O
P	O
sequence	O
,	O
which	O
is	O
a	O
higher	O
-	O
affinity	O
site	O
for	O
NF	B
-	I
ATp	I
and	O
a	O
lower	O
-	O
affinity	O
site	O
for	O
RelA	B
.	O
Thus	O
,	O
competition	O
between	O
two	O
general	O
transcriptional	B
activators	I
,	O
RelA	B
and	O
NF	B
-	I
ATp	I
,	O
mediates	O
the	O
inhibitory	O
effect	O
of	O
protein	B
kinase	I
C	I
stimulation	O
on	O
IL4	B
expression	O
and	O
may	O
contribute	O
to	O
differential	O
gene	O
expression	O
in	O
TH	O
cells	O
.	O
Solution	O
structure	O
of	O
the	O
sequence	O
-	O
specific	O
HMG	O
box	O
of	O
the	O
lymphocyte	B
transcriptional	I
activator	I
Sox-4	B
.	O
Two	O
groups	O
of	O
HMG	B
box	I
proteins	I
are	O
distinguished	O
.	O
Proteins	O
in	O
the	O
first	O
group	O
contain	O
multiple	O
HMG	B
boxes	I
,	O
are	O
non	O
-	O
sequence	O
-	O
specific	O
,	O
and	O
recognize	O
structural	O
features	O
as	O
found	O
in	O
cruciform	O
DNA	O
and	O
cross	O
-	O
over	O
DNA	O
.	O
The	O
abundant	O
chromosomal	B
protein	I
HMG-1	B
belongs	O
to	O
this	O
subgroup	O
.	O
Proteins	O
in	O
the	O
second	O
group	O
carry	O
a	O
single	B
HMG	I
box	I
with	O
affinity	O
for	O
the	O
minor	O
groove	O
of	O
the	O
heptamer	O
motif	O
AACAAAG	O
or	O
variations	O
thereof	O
.	O
A	O
solution	O
structure	O
for	O
the	O
non	O
-	O
sequence	O
-	O
specific	O
C	B
-	I
terminal	I
HMG	I
box	I
of	O
HMG-1	B
has	O
recently	O
been	O
proposed	O
.	O
Now	O
,	O
we	O
report	O
the	O
solution	O
structure	O
of	O
the	O
sequence	B
-	I
specific	I
HMG	I
-	I
box	I
of	O
the	O
SRY	B
-	I
related	I
protein	I
Sox-4	B
.	O
NMR	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
three	O
alpha	B
-	I
helices	I
(	O
Val10-Gln22	B
,	O
Glu30-Leu41	B
and	O
Phe50-Tyr65	B
)	O
connected	O
by	O
loop	B
regions	I
(	O
Ser23-Ala49	B
and	O
Leu42-Pro49	B
)	O
.	O
Helices	B
I	I
and	I
II	I
are	O
positioned	O
in	O
an	O
antiparallel	B
mode	I
and	O
form	O
one	O
arm	O
of	O
the	O
HMG	B
box	I
.	O
Helix	B
III	I
is	O
less	O
rigid	O
,	O
makes	O
an	O
average	O
angle	O
of	O
about	O
90	O
degrees	O
with	O
helices	B
I	I
and	I
II	I
,	O
and	O
constitutes	O
the	O
other	O
arm	O
of	O
the	O
molecule	O
.	O
As	O
in	O
HMG1B	B
,	O
the	O
overall	O
structure	O
of	O
the	O
Sox-4	B
HMG	B
box	I
is	O
L	O
-	O
shaped	O
and	O
is	O
maintained	O
by	O
a	O
cluster	O
of	O
conserved	O
,	O
mainly	O
aromatic	O
residues	O
.	O
Dehydroepiandrosterone	O
modulation	O
of	O
lipopolysaccharide	O
-	O
stimulated	O
monocyte	O
cytotoxicity	O
.	O
Dehydroepiandrosterone	O
(	O
DHEA	O
)	O
,	O
the	O
predominant	O
androgen	O
secreted	O
by	O
the	O
adrenal	O
cortex	O
,	O
can	O
be	O
converted	O
to	O
both	O
potent	O
androgens	O
and	O
estrogens	O
.	O
In	O
addition	O
to	O
its	O
role	O
as	O
a	O
precursor	O
for	O
other	O
steroid	O
hormones	O
,	O
DHEA	O
has	O
been	O
proposed	O
to	O
play	O
an	O
important	O
role	O
in	O
immunity	O
.	O
This	O
study	O
has	O
investigated	O
DHEA	O
modulation	O
of	O
LPS	O
-	O
induced	O
monocyte	O
cytotoxicity	O
.	O
Cytotoxicity	B
markers	I
assessed	O
include	O
tumor	O
cell	O
killing	O
,	O
IL-1	B
secretion	O
,	O
reactive	O
oxygen	O
intermediate	O
release	O
,	O
nitric	B
oxide	I
synthetase	I
activity	O
as	O
measured	O
by	O
the	O
release	O
of	O
reactive	O
nitrogen	O
intermediates	O
,	O
complement	B
receptor-1	I
cell	I
surface	I
protein	I
,	O
and	O
TNF	B
-	I
alpha	I
protein	I
presence	O
.	O
Monocytes	O
stimulated	O
with	O
LPS	O
concentrations	O
of	O
1.0	O
micrograms	O
/	O
ml	O
displayed	O
the	O
above	O
cytotoxic	O
markers	O
,	O
whereas	O
monocytes	O
stimulated	O
with	O
DHEA	O
alone	O
or	O
with	O
LPS	O
at	O
a	O
lower	O
concentration	O
of	O
0.2	O
ng	O
/	O
ml	O
did	O
not	O
.	O
However	O
,	O
when	O
used	O
simultaneously	O
,	O
DHEA	O
and	O
LPS	O
0.2	O
ng	O
/	O
ml	O
displayed	O
a	O
synergistic	O
effect	O
on	O
monocyte	O
cytotoxicity	O
against	O
cancerous	O
cell	O
lines	O
,	O
IL-1	B
secretion	O
,	O
reactive	O
nitrogen	O
intermediate	O
release	O
,	O
complement	B
receptor-1	I
cell	I
-	I
surface	I
protein	I
,	O
and	O
TNF	B
-	I
alpha	I
protein	I
to	O
levels	O
comparable	O
with	O
levels	O
obtained	O
using	O
LPS	O
1.0	O
microgram	O
/	O
ml	O
.	O
Finally	O
,	O
Scatchard	O
plot	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
a	O
DHEA	O
receptor	O
in	O
monocytes	O
,	O
suggesting	O
that	O
DHEA	O
effects	O
on	O
LPS	O
-	O
stimulated	O
monocytes	O
are	O
mediated	O
through	O
a	O
receptor	O
-	O
dependent	O
process	O
.	O
BSAP	B
:	O
a	O
key	O
regulator	O
of	O
B	O
-	O
cell	O
development	O
and	O
differentiation	O
.	O
B	B
-	I
cell	I
-	I
specific	I
activator	I
protein	I
(	O
BSAP	B
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
Pax	O
-	O
gene	O
family	O
of	O
transcription	B
factors	I
;	O
in	O
the	O
lymphoid	O
system	O
,	O
BSAP	B
is	O
produced	O
only	O
in	O
B	O
cells	O
.	O
Here	O
,	O
Markus	O
Neurath	O
,	O
Eckhard	O
Stuber	O
and	O
Warren	O
Strober	O
describe	O
the	O
molecular	O
structure	O
of	O
BSAP	B
and	O
focus	O
on	O
the	O
ability	O
of	O
this	O
protein	O
to	O
regulate	O
the	O
expression	O
of	O
B	O
-	O
cell	O
-	O
specific	O
genes	O
.	O
They	O
propose	O
that	O
BSAP	B
is	O
a	O
key	B
protein	I
of	O
B	O
cells	O
and	O
that	O
it	O
not	O
only	O
influence	O
B	O
-	O
cell	O
development	O
but	O
also	O
influences	O
the	O
balance	O
between	O
B	O
-	O
cell	O
proliferation	O
and	O
immunoglobulin	B
secretion	O
at	O
later	O
stages	O
of	O
B	O
-	O
cell	O
differentiation	O
.	O
The	O
role	O
of	O
BSAP	B
(	O
Pax-5	B
)	O
in	O
B	O
-	O
cell	O
development	O
.	O
The	O
hierarchy	O
of	O
transcriptional	O
control	O
in	O
B	O
-	O
cell	O
development	O
has	O
recently	O
been	O
analyzed	O
by	O
targeted	O
gene	O
inactivation	O
in	O
the	O
mouse	O
.	O
In	O
this	O
manner	O
,	O
the	O
paired	O
box	O
containing	O
gene	O
Pax-5	O
,	O
encoding	O
the	O
B	B
cell	I
specific	I
transcription	I
factor	I
BSAP	B
,	O
has	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
early	O
B	O
lymphopoiesis	O
.	O
Other	O
experimental	O
strategies	O
have	O
implicated	O
BSAP	B
in	O
the	O
control	O
of	O
cell	O
proliferation	O
,	O
isotype	O
switching	O
and	O
transcription	O
of	O
the	O
immunoglobulin	B
heavy	I
-	I
chain	I
gene	O
at	O
late	O
stages	O
of	O
B	O
-	O
cell	O
differentiation	O
.	O
A	O
PEBP2	B
alpha	I
/	I
AML-1-related	I
factor	I
increases	O
osteocalcin	O
promoter	O
activity	O
through	O
its	O
binding	O
to	O
an	O
osteoblast	O
-	O
specific	O
cis	O
-	O
acting	O
element	O
.	O
To	O
identify	O
osteoblast	O
-	O
specific	O
cis	O
-	O
acting	O
elements	O
and	O
trans	B
-	I
acting	I
factors	I
,	O
we	O
initiated	O
an	O
analysis	O
of	O
the	O
promoter	O
of	O
a	O
mouse	O
osteocalcin	O
gene	O
,	O
an	O
osteoblast	O
-	O
specific	O
gene	O
.	O
In	O
this	O
promoter	O
,	O
we	O
identified	O
two	O
osteoblast	O
-	O
specific	O
cis	O
-	O
acting	O
elements	O
(	O
Ducy	O
,	O
P.and	O
Karsenty	O
,	O
G.	O
(	O
1995	O
)	O
Mol	O
.	O
Cell	O
.	O
Biol.15	O
,	O
1858	O
-	O
1869	O
)	O
.	O
The	O
sequence	O
of	O
one	O
of	O
these	O
elements	O
,	O
OSE2	O
,	O
is	O
identical	O
to	O
the	O
DNA	O
-	O
binding	O
site	O
of	O
the	O
PEBP2	B
alpha	I
/	I
AML-1	I
transcription	I
factors	I
,	O
the	O
mammalian	B
homologues	I
of	O
the	O
Drosophila	B
Runt	I
protein	I
.	O
Here	O
we	O
show	O
,	O
using	O
nuclear	O
extracts	O
,	O
recombinant	B
protein	I
,	O
and	O
a	O
specific	O
antiserum	O
against	O
AML-1	B
proteins	I
in	O
DNA	O
-	O
binding	O
assays	O
,	O
that	O
one	O
member	O
of	O
this	O
family	O
,	O
AML-1B	B
,	O
binds	O
specifically	O
to	O
OSE2	O
and	O
is	O
immunologically	O
related	O
to	O
OSF2	B
,	O
the	O
factor	O
present	O
in	O
osteoblast	O
nuclear	O
extracts	O
that	O
binds	O
to	O
OSE2	O
.	O
By	O
DNA	O
cotransfection	O
experiments	O
,	O
we	O
also	O
demonstrate	O
that	O
AML-1B	B
can	O
increase	O
the	O
activity	O
of	O
a	O
short	O
osteocalcin	O
promoter	O
through	O
its	O
binding	O
to	O
OSE2	O
.	O
Lastly	O
,	O
the	O
different	O
mobilities	O
of	O
osteoblast	B
nuclear	I
extract	I
-	I
DNA	I
complexes	I
compared	O
with	O
T	B
-	I
cell	I
nuclear	I
extract	I
-	I
DNA	I
complexes	I
,	O
along	O
with	O
the	O
inability	O
of	O
OSF2	B
to	O
be	O
upregulated	O
by	O
retinoic	O
acid	O
,	O
unlike	O
the	O
other	O
PEBP2	B
alpha	I
factors	I
,	O
suggest	O
that	O
OSF2	B
is	O
a	O
new	O
member	O
of	O
this	O
family	O
of	O
transcription	B
factors	I
.	O
Thus	O
,	O
this	O
study	O
demonstrates	O
that	O
AML-1B	B
can	O
increase	O
gene	O
expression	O
of	O
an	O
osteoblast	O
-	O
specific	O
gene	O
through	O
its	O
binding	O
to	O
an	O
osteoblast	O
-	O
specific	O
cis	O
-	O
acting	O
element	O
and	O
presents	O
evidence	O
that	O
OSF2	B
is	O
a	O
member	O
of	O
the	O
PEBP2	B
alpha	I
/	I
AML-1	I
family	I
of	O
transcription	B
factors	I
.	O
The	O
number	O
of	O
glucocorticoid	B
receptors	I
in	O
peripheral	O
human	O
lymphocytes	O
is	O
elevated	O
by	O
a	O
zinc	O
containing	O
trace	O
element	O
preparation	O
.	O
A	O
trace	O
element	O
preparation	O
(	O
Beres	O
Drops	O
Plus	O
,	O
BDP	O
)	O
elevates	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
(	O
gcR	B
)	O
in	O
peripheral	O
lymphocytes	O
isolated	O
both	O
from	O
healthy	O
blood	O
donors	O
and	O
rheumatoid	O
arthritis	O
patients	O
.	O
This	O
enhancement	O
by	O
BDP	O
was	O
found	O
either	O
for	O
constitutive	O
expression	O
of	O
gcRs	B
or	O
in	O
experiments	O
when	O
the	O
lymphocytes	O
were	O
stimulated	O
by	O
interleukin	B
(	I
IL	I
)	I
-6	I
.	O
There	O
was	O
no	O
significant	O
effect	O
of	O
BDP	O
on	O
IL-1	B
and	O
tumour	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
alpha	I
)	O
-induced	O
changes	O
of	O
gcRs	B
.	O
The	O
effect	O
of	O
BDP	O
was	O
greatly	O
dependent	O
on	O
the	O
presence	O
of	O
Zn++	O
ions	O
in	O
the	O
preparation	O
,	O
since	O
the	O
augmenting	O
effect	O
was	O
abolished	O
if	O
BDP	O
did	O
not	O
contain	O
zinc	O
.	O
Activation	O
of	O
JAK3	B
,	O
but	O
not	O
JAK1	B
,	O
is	O
critical	O
for	O
IL-2	B
-induced	O
proliferation	O
and	O
STAT5	B
recruitment	O
by	O
a	O
COOH	B
-	I
terminal	I
region	I
of	O
the	O
IL-2	B
receptor	I
beta	I
-	I
chain	I
.	O
A	O
number	O
of	O
cytokines	B
and	O
growth	B
factors	I
use	O
the	O
JAK	B
-STAT	B
pathway	O
to	O
signal	O
from	O
the	O
cell	O
membrane	O
to	O
the	O
nucleus	O
.	O
While	O
homodimerizing	B
cytokine	I
receptors	I
may	O
transmit	O
signal	O
via	O
a	O
single	O
form	O
of	O
JAK	B
(	O
i.e	O
.	O
growth	B
hormone	I
receptors	I
)	O
,	O
several	O
multicomponent	B
cytokine	I
receptors	I
have	O
been	O
shown	O
to	O
require	O
simultaneous	O
activation	O
of	O
pairs	O
of	O
different	O
JAK	B
kinases	I
(	O
i.e	O
.	O
interferon	B
receptors	I
)	O
.	O
Recent	O
evidence	O
for	O
a	O
preferential	O
coupling	O
of	O
JAK3	B
to	O
interleukin-2	B
receptor	I
-	I
gamma	I
(	O
IL-2R	B
gamma	I
)	O
and	O
JAK1	B
to	O
IL-2R	B
beta	I
supports	O
the	O
concept	O
of	O
heterotrans	O
-	O
activation	O
of	O
JAK1	B
and	O
JAK3	B
caused	O
by	O
IL-2	B
-induced	O
heterodimerization	O
of	O
their	O
receptor	O
partners	O
.	O
The	O
present	O
study	O
verified	O
the	O
ability	O
of	O
IL-2	B
to	O
cause	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
JAK1	B
and	O
JAK3	B
,	O
but	O
demonstrated	O
that	O
IL-2	B
stimulated	O
JAK3	B
to	O
a	O
significantly	O
larger	O
extent	O
than	O
JAK1	B
in	O
human	O
T	O
lymphocytes	O
and	O
the	O
YT	O
cell	O
line	O
.	O
This	O
conclusion	O
was	O
based	O
upon	O
several	O
independent	O
criteria	O
,	O
including	O
more	O
vigorous	O
tyrosine	O
phosphorylation	O
of	O
JAK3	B
,	O
more	O
marked	O
enzymatic	O
activation	O
of	O
JAK3	B
as	O
well	O
as	O
higher	O
abundance	O
of	O
JAK3	B
in	O
activated	O
IL-2	B
receptor	I
complexes	I
.	O
Furthermore	O
,	O
when	O
human	B
IL-2R	I
beta	I
was	O
stably	O
expressed	O
in	O
murine	O
BA	O
/	O
F3	O
cells	O
,	O
robust	O
IL-2	B
-induced	O
proliferation	O
and	O
JAK3	B
activation	O
occurred	O
without	O
detectable	O
involvement	O
of	O
either	O
JAK1	B
,	O
JAK2	B
or	O
TYK2	B
.	O
We	O
therefore	O
propose	O
that	O
IL-2	B
receptor	I
signal	O
transduction	O
does	O
not	O
depend	O
on	O
equimolar	O
heterodimerization	O
of	O
JAK1	B
and	O
JAK3	B
following	O
IL-2	B
-induced	O
heterodimerization	O
of	O
IL-2R	B
beta	I
and	O
IL-2R	B
gamma	I
.	O
Nonetheless	O
,	O
a	O
membrane	B
-	I
proximal	I
region	I
of	O
human	O
IL-2R	B
beta	I
(	O
Asn240-Leu335	B
)	O
was	O
critical	O
for	O
JAK3	B
activation	O
,	O
and	O
the	O
amount	O
of	O
JAK3	B
present	O
in	O
activated	O
IL-2	B
receptor	I
complexes	I
increased	O
with	O
time	O
,	O
suggesting	O
that	O
stabilization	O
of	O
JAK3	B
binding	O
to	O
the	O
receptor	B
complex	I
relies	O
on	O
both	O
IL-2R	B
beta	I
and	O
IL-2R	B
gamma	I
.	O
Moreover	O
,	O
STAT5	B
was	O
found	O
to	O
be	O
the	O
predominant	O
STAT	B
transcription	I
factor	I
used	O
by	O
IL-2	B
in	O
human	O
T	O
cells	O
,	O
and	O
specifically	O
required	O
a	O
COOH	B
-	I
terminal	I
region	I
of	O
IL-2R	B
beta	I
(	O
Ser386-Val525	B
)	O
,	O
while	O
STAT5	B
recruitment	O
was	O
not	O
correlated	O
to	O
activation	O
of	O
IL-2R	B
gamma	I
or	O
JAK3	B
.	O
Polymorphic	O
nucleotides	O
within	O
the	O
human	O
IL-4	O
promoter	O
that	O
mediate	O
overexpression	O
of	O
the	O
gene	O
.	O
Atopy	O
,	O
which	O
predisposes	O
individuals	O
to	O
develop	O
asthma	O
,	O
severe	O
systemic	O
anaphylaxis	O
,	O
and	O
atopic	O
dermatitis	O
,	O
is	O
usually	O
associated	O
with	O
dramatically	O
elevated	O
total	O
serum	O
IgE	B
levels	O
and	O
is	O
thought	O
to	O
be	O
controlled	O
by	O
a	O
major	O
susceptibility	O
gene	O
and	O
multiple	O
minor	O
susceptibility	O
genes	O
.	O
A	O
recent	O
sib	O
-	O
pair	O
analysis	O
revealed	O
a	O
tight	O
linkage	O
between	O
markers	O
on	O
5q31.1	O
and	O
a	O
major	O
susceptibility	O
gene	O
controlling	O
total	O
serum	O
IgE	B
levels	O
.	O
Due	O
to	O
its	O
location	O
within	O
this	O
cluster	O
and	O
its	O
biologic	O
role	O
in	O
Ig	O
class	O
switching	O
and	O
Th2	O
cell	O
differentiation	O
,	O
the	O
IL-4	O
gene	O
has	O
emerged	O
as	O
one	O
major	O
candidate	O
for	O
the	O
atopy	O
gene	O
.	O
In	O
one	O
model	O
,	O
polymorphisms	O
within	O
IL-4	O
regulatory	O
elements	O
might	O
result	O
in	O
overexpression	O
of	O
the	O
gene	O
,	O
amplifying	O
Th2	O
cell	O
differentiation	O
and	O
class	O
switching	O
to	O
IgE	B
.	O
In	O
support	O
of	O
this	O
model	O
,	O
we	O
report	O
that	O
the	O
human	O
IL-4	O
promoter	O
exists	O
in	O
multiple	O
allelic	O
forms	O
that	O
exhibit	O
distinct	O
transcriptional	O
activities	O
in	O
IL-4-positive	O
T	O
cells	O
.	O
A	O
particular	O
allele	O
has	O
an	O
unusually	O
high	O
transcriptional	O
activity	O
.	O
A	O
nucleotide	O
substitution	O
within	O
a	O
recently	O
described	O
OAP40	O
element	O
located	O
just	O
upstream	O
of	O
an	O
NF	O
-	O
AT	O
site	O
(	O
P	O
sequence	O
)	O
appears	O
to	O
be	O
largely	O
responsible	O
for	O
the	O
increased	O
promotor	O
strength	O
of	O
this	O
particular	O
allelic	O
form	O
of	O
the	O
IL-4	O
promoter	O
.	O
In	O
EMSAs	O
,	O
this	O
substitution	O
results	O
in	O
a	O
markedly	O
enhanced	O
affinity	O
for	O
sequence	O
-	O
specific	O
complexes	O
exhibiting	O
an	O
AP-1	B
specificity	O
.	O
The	O
identification	O
of	O
allelic	O
nucleotides	O
,	O
which	O
results	O
in	O
overexpression	O
of	O
the	O
IL-4	O
gene	O
,	O
provides	O
specific	O
targets	O
for	O
a	O
comprehensive	O
screening	O
of	O
atopic	O
and	O
nonatopic	O
individuals	O
and	O
may	O
provide	O
a	O
clue	O
for	O
genetic	O
predisposition	O
for	O
atopy	O
.	O
IL-10	B
cooperates	O
with	O
TNF	B
-	I
alpha	I
to	O
activate	O
HIV-1	O
from	O
latently	O
and	O
acutely	O
infected	O
cells	O
of	O
monocyte	O
/	O
macrophage	O
lineage	O
.	O
IL-10	B
is	O
elevated	O
in	O
HIV-1-infected	O
individuals	O
and	O
has	O
been	O
implicated	O
in	O
disease	O
progression	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
IL-10	B
on	O
the	O
activation	O
of	O
HIV-1	O
from	O
infected	O
monocytes	O
and	O
macrophages	O
.	O
Although	O
IL-10	B
alone	O
did	O
not	O
induce	O
HIV-1	O
replication	O
,	O
in	O
the	O
presence	O
of	O
TNF	B
-	I
alpha	I
,	O
IL-10	B
markedly	O
enhanced	O
virion	O
production	O
from	O
a	O
chronically	O
infected	O
promonocytic	O
cell	O
line	O
(	O
U1	O
)	O
and	O
in	O
acutely	O
infected	O
monocyte	O
-	O
derived	O
macrophages	O
.	O
Neutralizing	O
mAbs	B
to	O
IL-10	B
and	O
TNF	B
-	I
alpha	I
indicated	O
that	O
both	O
cytokines	B
were	O
essential	O
for	O
the	O
induction	O
and	O
were	O
required	O
to	O
generate	O
a	O
synergistic	O
increase	O
in	O
virus	O
expression	O
.	O
The	O
effects	O
of	O
the	O
two	O
cytokines	B
were	O
distinguishable	O
functionally	O
since	O
pretreatment	O
with	O
TNF	B
-	I
alpha	I
attenuated	O
the	O
cytokine	B
cooperativity	O
,	O
while	O
pretreatment	O
with	O
IL-10	B
potentiated	O
their	O
cooperativity	O
,	O
suggesting	O
that	O
IL-10	B
and	O
TNF	B
-	I
alpha	I
play	O
different	O
roles	O
in	O
the	O
activation	O
of	O
virus	O
.	O
Northern	O
blot	O
analysis	O
as	O
well	O
as	O
Ab	O
blocking	O
and	O
cytokine	B
secretion	O
studies	O
indicated	O
that	O
the	O
induction	O
of	O
either	O
endogenous	B
TNF	I
-	I
alpha	I
or	O
IL-10	B
was	O
not	O
involved	O
in	O
the	O
cooperativity	O
,	O
nor	O
was	O
an	O
up	O
-	O
regulation	O
of	O
TNF	B
-	I
alpha	I
receptors	I
.	O
In	O
combination	O
with	O
TNF	B
-	I
alpha	I
,	O
IL-10	B
stimulated	O
activating	B
protein-1	I
(	O
AP-1	B
)	O
and	O
nuclear	B
factor	I
(	I
NF	I
)	I
-kappa	I
B	I
binding	O
activities	O
and	O
cooperated	O
to	O
increase	O
HIV-1	O
steady	O
-	O
state	O
mRNA	O
levels	O
and	O
enhance	O
long	O
terminal	O
repeat	O
-directed	O
transcription	O
through	O
activation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
,	O
suggesting	O
the	O
IL-10	B
effect	O
occurs	O
at	O
least	O
in	O
part	O
at	O
the	O
transcriptional	O
level	O
.	O
These	O
results	O
indicate	O
that	O
IL-10	B
,	O
in	O
addition	O
to	O
down	O
-	O
regulating	O
the	O
cellular	O
immune	O
response	O
to	O
HIV-1	O
,	O
may	O
also	O
play	O
a	O
role	O
in	O
TNF	B
-	I
alpha	I
-mediated	O
activation	O
of	O
HIV-1	O
replication	O
in	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
.	O
NF	B
-	I
M	I
(	O
chicken	B
C	I
/	I
EBP	I
beta	I
)	O
induces	O
eosinophilic	O
differentiation	O
and	O
apoptosis	O
in	O
a	O
hematopoietic	O
progenitor	O
cell	O
line	O
.	O
CAAT	B
/	I
enhancer	I
binding	I
proteins	I
(	O
C	B
/	I
EBPs	I
)	O
are	O
transcriptional	O
activators	O
implicated	O
in	O
the	O
differentiation	O
processes	O
of	O
various	O
cell	O
lineages	O
.	O
We	O
have	O
shown	O
earlier	O
that	O
NF	B
-	I
M	I
,	O
the	O
chicken	B
homolog	I
of	O
C	B
/	I
EBP	I
beta	I
,	O
is	O
specifically	O
expressed	O
in	O
myelomonocytic	O
and	O
eosinophilic	O
cells	O
of	O
the	O
hematopoietic	O
system	O
.	O
To	O
investigate	O
the	O
role	O
of	O
NF	B
-	I
M	I
in	O
hematopoietic	O
cell	O
lineage	O
commitment	O
,	O
we	O
constructed	O
a	O
conditional	O
form	O
of	O
the	O
protein	O
by	O
fusing	O
it	O
to	O
the	O
hormone	B
binding	I
domain	I
of	O
the	O
human	B
estrogen	I
receptor	I
.	O
This	O
construct	O
was	O
stably	O
expressed	O
in	O
a	O
multipotent	O
progenitor	O
cell	O
line	O
transformed	O
by	O
the	O
Myb	B
-	I
Ets	I
oncoprotein	I
.	O
We	O
report	O
here	O
that	O
both	O
NF	O
-	O
M	O
-	O
dependent	O
promoter	O
constructs	O
and	O
resident	O
genes	O
could	O
be	O
activated	O
by	O
addition	O
of	O
beta	O
-	O
estradiol	O
to	O
the	O
NF	O
-	O
M	O
-	O
estrogen	O
receptor	O
expressing	O
progenitors	O
.	O
At	O
the	O
same	O
time	O
,	O
we	O
observed	O
a	O
down	O
-	O
regulation	O
of	O
progenitor	B
-	I
specific	I
surface	I
markers	I
and	O
the	O
up	O
-	O
regulation	O
of	O
differentiation	B
markers	I
restricted	O
to	O
the	O
eosinophil	O
and	O
myeloid	O
lineages	O
.	O
In	O
addition	O
to	O
the	O
onset	O
of	O
differentiation	O
,	O
cell	O
death	O
was	O
induced	O
with	O
typical	O
apoptotic	O
features	O
.	O
Our	O
results	O
suggest	O
that	O
NF	B
-	I
M	I
plays	O
an	O
important	O
role	O
in	O
commitment	O
along	O
the	O
eosinophil	O
lineage	O
and	O
in	O
the	O
induction	O
of	O
apoptosis	O
.	O
Immunophenotype	O
of	O
intraductal	O
carcinoma	O
.	O
OBJECTIVE	O
--	O
Mammography	O
and	O
breast	O
-	O
conserving	O
therapy	O
have	O
focused	O
attention	O
on	O
the	O
classification	O
of	O
intraductal	O
carcinoma	O
(	O
IDC	O
)	O
and	O
emphasized	O
the	O
prognostic	O
importance	O
of	O
comedo	O
versus	O
noncomedo	O
variants	O
.	O
We	O
used	O
histochemical	O
markers	O
to	O
define	O
the	O
immunophenotype	O
of	O
43	O
IDCs	O
with	O
respect	O
to	O
comedo	O
versus	O
noncomedo	O
status	O
and	O
patterns	O
of	O
angiogenesis	O
.	O
RESULTS	O
--	O
Reactions	O
in	O
comedo	O
carcinomas	O
were	O
significantly	O
negative	O
for	O
estrogen	B
receptor	I
and	O
progesterone	B
receptor	I
,	O
and	O
positive	O
for	O
p53	B
and	O
HER-2	B
/	I
neu	I
more	O
often	O
than	O
the	O
noncomedo	O
variant	O
.	O
All	O
seven	O
IDCs	O
associated	O
with	O
Paget	O
's	O
disease	O
showed	O
positive	O
reactions	O
for	O
HER-2	B
/	I
neu	I
.	O
Basement	O
membrane	O
immunoreactivity	O
for	O
type	B
IV	I
collagen	I
and	O
laminin	B
was	O
discontinuous	O
in	O
most	O
examples	O
of	O
IDC	O
regardless	O
of	O
type	O
,	O
with	O
a	O
trend	O
toward	O
more	O
intense	O
staining	O
in	O
comedo	O
than	O
in	O
noncomedo	O
carcinomas	O
.	O
Periductal	O
angiogenesis	O
was	O
not	O
significantly	O
related	O
to	O
the	O
type	O
of	O
IDC	O
but	O
was	O
more	O
pronounced	O
with	O
comedo	O
carcinomas	O
.	O
CONCLUSIONS	O
--	O
These	O
observations	O
indicate	O
that	O
there	O
are	O
immunophenotypic	O
correlates	O
to	O
the	O
current	O
structural	O
classification	O
of	O
IDC	O
.	O
The	O
immunophenotype	O
of	O
IDC	O
is	O
helpful	O
in	O
subclassifying	O
an	O
IDC	O
and	O
could	O
prove	O
useful	O
as	O
a	O
prognostic	O
indicator	O
for	O
local	O
control	O
in	O
patients	O
treated	O
by	O
breast	O
-	O
conserving	O
therapy	O
.	O
Inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
human	O
T	O
-	O
cell	O
lines	O
by	O
anetholdithiolthione	O
.	O
Nuclear	B
factor	I
(	I
NF	I
)	I
-kappa	I
B	I
is	O
a	O
redox	B
sensitive	I
cytosolic	I
transcription	I
factor	I
.	O
Redox	O
regulation	O
of	O
NF	B
-	I
kappa	I
B	I
has	O
been	O
implicated	O
in	O
the	O
activation	O
of	O
the	O
human	O
immuno	O
-	O
deficiency	O
virus	O
(	O
HIV	O
)	O
.	O
Therefore	O
,	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
may	O
be	O
an	O
effective	O
strategy	O
for	O
acquired	O
immunodeficiency	O
syndrome	O
therapy	O
.	O
Anetholdithiolthione	O
(	O
ADT	O
,	O
5-	O
[	O
p	O
-	O
methoxyphenyl	O
]	O
-3H-1	O
,	O
2-dithiol-3-thione	O
)	O
is	O
an	O
antioxidant	O
which	O
has	O
been	O
used	O
to	O
protect	O
against	O
acetaminophen-	O
and	O
CCl4-induced	O
hepatotoxicity	O
,	O
lipid	O
peroxidation	O
,	O
radiation	O
injury	O
,	O
and	O
also	O
has	O
been	O
used	O
clinically	O
as	O
an	O
anti	O
-	O
choleretic	O
agent	O
.	O
The	O
present	O
study	O
examined	O
the	O
effect	O
of	O
ADT	O
pretreatment	O
on	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
response	O
to	O
a	O
variety	O
of	O
stimuli	O
such	O
as	O
H2O2	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
or	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
alpha	I
)	O
.	O
PMA	O
and	O
TNF	B
alpha	I
induced	O
activation	O
of	O
(	B
NF	I
)	I
-kappa	I
B	I
in	O
human	O
Jurkat	O
T	O
-	O
cells	O
was	O
partially	O
inhibited	O
by	O
ADT	O
(	O
0.1	O
mM	O
)	O
pretreatment	O
.	O
ADT	O
(	O
0.1	O
mM	O
)	O
also	O
inhibited	O
H2O2	O
induced	O
activation	O
of	O
the	O
transcription	B
factor	I
in	O
the	O
peroxide	O
sensitive	O
human	O
Wurzburg	O
T	O
-	O
cells	O
.	O
Furthermore	O
,	O
ADT	O
treated	O
Wurzburg	O
cells	O
had	O
significantly	O
higher	O
glutathione	O
levels	O
as	O
compared	O
with	O
untreated	O
cells	O
.	O
H2O2	O
induced	O
lipid	O
peroxidation	O
in	O
Wurzburg	O
cells	O
was	O
remarkably	O
inhibited	O
by	O
ADT	O
pretreatment	O
.	O
ADT	O
,	O
a	O
pro	O
-	O
glutathione	O
antioxidant	O
,	O
was	O
observed	O
to	O
be	O
capable	O
of	O
modulating	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
Identification	O
of	O
a	O
physical	O
interaction	O
between	O
calcineurin	B
and	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFATp	B
)	O
.	O
In	O
T	O
lymphocytes	O
,	O
the	O
calcium	B
/	I
calmodulin	I
-	I
dependent	I
serine	I
/	I
threonine	I
phosphatase	I
,	O
calcineurin	B
,	O
plays	O
a	O
pivotal	O
role	O
in	O
transducing	O
membrane	O
-	O
associated	O
signals	O
to	O
the	O
nucleus	O
.	O
One	O
of	O
the	O
putative	O
targets	O
of	O
calcineurin	B
is	O
the	O
pre	O
-	O
existing	O
,	O
cytosolic	B
component	I
of	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFATp	B
;	O
also	O
referred	O
to	O
as	O
NFAT1	B
)	O
,	O
which	O
is	O
one	O
of	O
several	O
transcription	B
factors	I
required	O
for	O
the	O
expression	O
of	O
interleukin	B
2	I
.	O
Inhibition	O
of	O
calcineurin	B
by	O
the	O
immunosuppressive	O
drugs	O
cyclosporin	O
A	O
and	O
FK506	O
prevents	O
dephosphorylation	O
of	O
NFATp	B
and	O
its	O
translocation	O
to	O
the	O
nucleus	O
.	O
However	O
,	O
a	O
physical	O
interaction	O
between	O
calcineurin	B
and	O
NFATp	B
has	O
not	O
been	O
demonstrated	O
.	O
Here	O
we	O
demonstrate	O
the	O
binding	O
of	O
NFATp	B
from	O
lysates	O
of	O
T	O
cells	O
to	O
immobilized	O
calcineurin	B
.	O
Stimulation	O
of	O
T	O
cells	O
with	O
calcium	O
ionophore	O
induced	O
a	O
shift	O
in	O
the	O
molecular	O
weight	O
of	O
NFATp	B
that	O
is	O
due	O
to	O
its	O
dephosphorylation	O
.	O
This	O
dephosphorylation	O
was	O
inhibited	O
by	O
treatment	O
of	O
T	O
cells	O
with	O
cyclosporin	O
A	O
or	O
FK506	O
prior	O
to	O
stimulation	O
.	O
Of	O
note	O
,	O
both	O
the	O
phosphorylated	O
and	O
the	O
dephosphorylated	O
form	O
of	O
NFATp	B
bound	O
to	O
calcineurin	B
.	O
Furthermore	O
,	O
the	O
binding	O
of	O
both	O
forms	O
of	O
NFATp	B
to	O
calcineurin	B
was	O
inhibited	O
by	O
pretreatment	O
of	O
calcineurin	B
with	O
a	O
complex	O
of	O
FK506	O
and	O
its	O
ligand	O
FKBP12	O
.	O
Taken	O
together	O
these	O
data	O
strongly	O
suggest	O
a	O
direct	O
interaction	O
of	O
calcineurin	B
with	O
NFATp	B
and	O
that	O
this	O
interaction	O
does	O
not	O
depend	O
upon	O
the	O
phosphorylation	O
sites	O
of	O
NFATp	B
affected	O
by	O
activation	O
.	O
Distinctive	O
expression	O
pattern	O
of	O
the	O
BCL-6	B
protein	I
in	O
nodular	O
lymphocyte	O
predominance	O
Hodgkin	O
's	O
disease	O
.	O
The	O
BCL-6	O
gene	O
encoding	O
a	O
nuclear	B
-	I
located	I
Kruppel	I
-	I
type	I
zinc	I
finger	I
protein	I
is	O
rearranged	O
in	O
about	O
30	O
%	O
diffuse	O
large	O
B	O
-	O
cell	O
lymphomas	O
and	O
is	O
expressed	O
predominantly	O
in	O
normal	O
germinal	O
center	O
B	O
cells	O
and	O
related	O
lymphomas	O
.	O
These	O
findings	O
suggest	O
that	O
BCL-6	B
may	O
play	O
a	O
role	O
in	O
regulating	O
differentiation	O
of	O
normal	O
germinal	O
center	O
B	O
cells	O
and	O
that	O
its	O
deregulated	O
expression	O
caused	O
by	O
rearrangements	O
may	O
contribute	O
to	O
lymphomagenesis	O
.	O
This	O
prompted	O
us	O
to	O
investigate	O
the	O
expression	O
of	O
the	O
BCL-6	B
protein	I
in	O
Hodgkin	O
's	O
disease	O
(	O
HD	O
)	O
,	O
focusing	O
on	O
the	O
nodular	O
lymphocyte	O
predominance	O
subtype	O
(	O
NLPHD	O
)	O
,	O
which	O
differs	O
from	O
classical	O
HD	O
by	O
virtue	O
of	O
the	O
B	O
-	O
cell	O
nature	O
of	O
the	O
malignant	O
cell	O
population	O
(	O
so	O
-	O
called	O
L	O
&	O
H	O
cells	O
)	O
and	O
its	O
relationship	O
with	O
germinal	O
centers	O
.	O
Forty	O
-	O
one	O
HD	O
samples	O
(	O
19	O
NLPHD	O
,	O
12	O
nodular	O
sclerosis	O
,	O
and	O
10	O
mixed	O
cellularity	O
)	O
were	O
immunostained	O
with	O
the	O
monoclonal	B
antibodies	I
PG	B
-	I
B6	I
and	O
PG	B
-	I
B6p	I
that	O
react	O
with	O
a	O
fixative	O
-	O
sensitive	O
and	O
a	O
formalin	B
-	I
resistant	I
epitope	I
on	O
the	O
aminoterminal	B
region	I
of	O
the	O
BCL-6	B
gene	I
product	I
,	O
respectively	O
.	O
Strong	O
nuclear	O
positivity	O
for	O
the	O
BCL-6	B
protein	I
was	O
detected	O
in	O
tumor	O
(	O
L	O
&	O
H	O
)	O
cells	O
in	O
all	O
cases	O
of	O
NLPHD	O
.	O
In	O
contrast	O
,	O
BCL-6	B
was	O
expressed	O
only	O
in	O
a	O
small	O
percentage	O
of	O
Hodgkin	O
and	O
Reed	O
-	O
Sternberg	O
cells	O
in	O
about	O
30	O
%	O
of	O
classical	O
HD	O
cases	O
.	O
Notably	O
,	O
the	O
nuclei	O
of	O
reactive	O
CD3+	O
/	O
CD4	O
+	O
T	O
cells	O
nearby	O
to	O
and	O
rosetting	O
around	O
L	O
&	O
H	O
cells	O
in	O
NLPHD	O
were	O
also	O
strongly	O
BCL-6	B
+	O
,	O
but	O
lacked	O
CD40	B
ligand	I
(	O
CD40L	B
)	O
expression	O
.	O
This	O
staining	O
pattern	O
clearly	O
differed	O
from	O
that	O
of	O
classical	O
HD	O
,	O
whose	O
cellular	O
background	O
was	O
made	O
up	O
of	O
CD3+	O
/	O
CD4	O
+	O
T	O
cells	O
showing	O
the	O
BCL-6	B
-	O
/	O
CD40L	B
+	O
phenotype	O
.	O
These	O
results	O
further	O
support	O
the	O
concept	O
that	O
NLPHD	O
is	O
an	O
histogenetically	O
distinct	O
,	O
B	O
-	O
cell	O
-	O
derived	O
subtype	O
of	O
HD	O
and	O
suggest	O
a	O
role	O
for	O
BCL-6	B
in	O
its	O
development	O
.	O
The	O
promoter	O
and	O
5	O
'	O
flanking	O
sequences	O
controlling	O
human	O
B29	O
gene	O
expression	O
.	O
The	O
product	O
of	O
the	O
B	O
-	O
cell	O
-	O
specific	O
B29	O
gene	O
(	O
B29	B
,	O
Ig	B
beta	I
,	O
CD79b	B
)	O
is	O
essential	O
for	O
Ig	O
-	O
mediated	O
B	O
-	O
cell	O
activation	O
via	O
the	O
B	B
-	I
cell	I
antigen	I
receptor	I
complex	I
(	O
BCR	B
)	O
on	O
human	O
and	O
murine	O
B	O
lymphocytes	O
.	O
To	O
better	O
understand	O
the	O
regulation	O
of	O
this	O
pivotal	O
gene	O
,	O
we	O
have	O
analyzed	O
the	O
human	O
genomic	O
DNA	O
sequence	O
upstream	O
of	O
the	O
B29	B
ATG	O
start	O
codon	O
for	O
transcriptional	O
control	O
activity	O
.	O
The	O
human	O
B29	O
gene	O
lacks	O
either	O
a	O
TATA	O
or	O
a	O
CAAT	O
box	O
and	O
transcription	O
is	O
initiated	O
at	O
multiple	O
sites	O
.	O
The	O
minimal	O
promoter	O
of	O
the	O
human	O
B29	O
gene	O
is	O
contained	O
within	O
a	O
193-bp	O
region	O
5	O
'	O
of	O
these	O
multiple	O
start	O
sites	O
.	O
This	O
minimal	O
promoter	O
exhibits	O
B	O
-	O
cell	O
-	O
specific	O
activity	O
and	O
contains	O
SP1	O
,	O
ETS	O
,	O
OCT	O
,	O
and	O
IKAROS	O
/	O
LYF-1	O
transcription	O
factor	O
motifs	O
.	O
All	O
these	O
motifs	O
are	O
strikingly	O
conserved	O
in	O
sequence	O
and	O
placement	O
relative	O
to	O
the	O
previously	O
characterized	O
murine	O
B29	O
promoter	O
.	O
Additional	O
upstream	O
gene	O
segments	O
dramatically	O
affected	O
B29	B
minimal	O
promoter	O
activity	O
.	O
A	O
newly	O
identified	O
motif	O
called	O
the	O
B29	O
conserved	O
sequence	O
(	O
BCS	O
)	O
,	O
found	O
upstream	O
of	O
both	O
human	O
and	O
murine	O
B29	O
promoters	O
,	O
appears	O
to	O
stimulate	O
B29	B
transcription	O
through	O
a	O
novel	O
mechanism	O
.	O
A	O
single	O
BCS	O
had	O
little	O
effect	O
either	O
on	O
the	O
minimal	O
B29	O
promoter	O
or	O
on	O
a	O
heterologous	O
promoter	O
.	O
Instead	O
,	O
the	O
BCS	O
stimulated	O
transcription	O
by	O
counteracting	O
5	O
'	O
negative	O
regulatory	O
DNA	O
sequences	O
that	O
block	O
the	O
activity	O
of	O
the	O
B29	B
minimal	O
promoter	O
in	O
its	O
absence	O
.	O
These	O
findings	O
indicate	O
that	O
B29	O
gene	O
expression	O
is	O
controlled	O
by	O
the	O
complex	O
interplay	O
of	O
positive	O
and	O
negative	O
regulatory	O
elements	O
.	O
Selective	O
effects	O
of	O
DNA	O
damaging	O
agents	O
on	O
HIV	O
long	O
terminal	O
repeat	O
activation	O
and	O
virus	O
replication	O
in	O
vitro	O
.	O
Much	O
attention	O
has	O
recently	O
focused	O
on	O
the	O
observation	O
that	O
UV	O
light	O
can	O
activate	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O
Although	O
the	O
mechanism	O
of	O
LTR	O
activation	O
remains	O
obscure	O
,	O
several	O
lines	O
of	O
investigation	O
have	O
suggested	O
that	O
it	O
is	O
a	O
result	O
of	O
activation	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
transcription	B
factor	I
(	O
s	O
)	O
following	O
signaling	O
events	O
related	O
to	O
generalized	O
DNA	O
damage	O
.	O
In	O
this	O
report	O
,	O
we	O
present	O
data	O
demonstrating	O
that	O
HIV	O
LTR	O
activation	O
is	O
not	O
a	O
general	O
consequence	O
of	O
cellular	O
DNA	O
damage	O
,	O
but	O
rather	O
a	O
process	O
unique	O
to	O
specific	O
genotoxic	O
stimuli	O
,	O
and	O
that	O
it	O
does	O
not	O
necessarily	O
depend	O
on	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
Furthermore	O
,	O
we	O
demonstrate	O
that	O
several	O
of	O
these	O
agents	O
can	O
significantly	O
increase	O
HIV	O
replication	O
and	O
accelerate	O
CD4	B
-positive	O
lymphocyte	O
cytotoxicity	O
in	O
vitro	O
.	O
These	O
findings	O
,	O
therefore	O
,	O
could	O
have	O
clinical	O
significance	O
to	O
AIDS	O
patients	O
with	O
malignancies	O
who	O
are	O
undergoing	O
radiotherapy	O
and	O
chemotherapy	O
.	O
Fas	B
ligation	O
induces	O
apoptosis	O
and	O
Jun	B
kinase	I
activation	O
independently	O
of	O
CD45	B
and	O
Lck	B
in	O
human	O
T	O
cells	O
.	O
Stimulation	O
through	O
the	O
Fas	B
/	I
APO-1	I
receptor	I
results	O
in	O
apoptosis	O
through	O
an	O
incompletely	O
characterized	O
signaling	O
pathway	O
.	O
More	O
is	O
known	O
regarding	O
signal	O
transduction	O
events	O
that	O
occur	O
after	O
ligation	O
of	O
the	O
T	B
-	I
cell	I
antigen	I
receptor	I
(	O
TCR	B
)	O
.	O
It	O
has	O
been	O
shown	O
that	O
TCR	B
stimulation	O
requires	O
both	O
the	O
membrane	B
tyrosine	I
phosphatase	I
,	O
CD45	B
,	O
and	O
the	O
Src	B
-	I
family	I
kinase	I
,	O
Lck	B
,	O
to	O
result	O
in	O
cellular	O
activation	O
.	O
Although	O
prior	O
studies	O
suggest	O
a	O
role	O
for	O
protein	B
tyrosine	I
kinases	I
and	O
phosphatases	O
in	O
Fas	B
signaling	O
,	O
we	O
report	O
here	O
that	O
Fas	O
ligation	O
induces	O
apoptosis	O
in	O
T	O
cells	O
deficient	O
in	O
either	O
CD45	B
or	O
Lck	B
.	O
Further	O
,	O
in	O
normal	O
and	O
CD45-	O
or	O
Lck	O
-	O
deficient	O
cell	O
lines	O
,	O
Fas	O
stimulation	O
results	O
in	O
activation	O
of	O
Jun	B
kinase	I
(	O
JNK	B
)	O
,	O
a	O
proposed	O
mediator	O
of	O
stress	O
activation	O
pathways	O
.	O
Previous	O
studies	O
have	O
also	O
demonstrated	O
a	O
role	O
for	O
endogenous	O
ceramide	O
release	O
in	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O
We	O
show	O
that	O
stimulation	O
with	O
a	O
synthetic	O
ceramide	O
analog	O
results	O
in	O
JNK	B
activation	O
as	O
well	O
as	O
apoptosis	O
,	O
suggesting	O
ceramide	O
release	O
occurs	O
proximal	O
to	O
JNK	B
activation	O
in	O
Fas	B
signaling	O
.	O
Our	O
data	O
suggest	O
that	O
although	O
CD45	B
and	O
Lck	B
are	O
not	O
required	O
for	O
Fas	B
signaling	O
,	O
JNK	B
activation	O
may	O
play	O
an	O
important	O
role	O
transducing	O
distal	O
signals	O
that	O
lead	O
to	O
apoptosis	O
after	O
Fas	B
ligation	O
.	O
Expression	O
of	O
either	O
the	O
TCL1	O
oncogene	O
,	O
or	O
transcripts	O
from	O
its	O
homologue	O
MTCP1	O
/	O
c6.1B	O
,	O
in	O
leukaemic	O
and	O
non	O
-	O
leukaemic	O
T	O
cells	O
from	O
ataxia	O
telangiectasia	O
patients	O
.	O
Patients	O
with	O
the	O
recessively	O
inherited	O
disorder	O
ataxia	O
telangiectasia	O
(	O
A	O
-	O
T	O
)	O
have	O
a	O
high	O
level	O
of	O
specific	O
chromosome	O
translocations	O
which	O
can	O
be	O
easily	O
observed	O
in	O
peripheral	O
T	O
cells	O
and	O
show	O
a	O
greatly	O
increased	O
predisposition	O
to	O
leukaemia	O
/	O
lymphoma	O
,	O
mainly	O
of	O
T	O
cell	O
origin	O
.	O
Some	O
translocation	O
cells	O
proliferate	O
into	O
a	O
large	O
clone	O
and	O
may	O
develop	O
into	O
T	O
cell	O
prolymphocytic	O
leukaemia	O
(	O
T	O
-	O
PLL	O
)	O
.	O
By	O
the	O
time	O
of	O
diagnosis	O
of	O
T	O
-	O
PLL	O
,	O
the	O
clone	O
contains	O
many	O
more	O
genetic	O
changes	O
in	O
the	O
form	O
of	O
additional	O
translocations	O
.	O
T	O
-	O
PLL	O
is	O
also	O
seen	O
in	O
non	O
-	O
A	O
-	O
T	O
individuals	O
where	O
expression	O
of	O
either	O
TCL1	B
(	O
at	O
14q32	O
)	O
or	O
the	O
c6.1B	B
/	I
MTCP1	I
A1	I
transcript	I
(	O
at	O
-	O
Xq28	O
)	O
has	O
been	O
demonstrated	O
in	O
just	O
a	O
few	O
instances	O
.	O
We	O
show	O
here	O
,	O
that	O
expression	O
of	O
TCL1	B
occurs	O
in	O
leukaemic	O
T	O
cells	O
from	O
A	O
-	O
T	O
patients	O
with	O
chromosome	O
14	O
rearrangements	O
.	O
Expression	O
of	O
TCL1	B
also	O
occurs	O
in	O
the	O
preleukaemic	O
clone	O
cells	O
of	O
A	O
-	O
T	O
patients	O
containing	O
the	O
primary	O
translocation	O
alone	O
.	O
Some	O
expression	O
of	O
TCL1	B
could	O
also	O
be	O
detected	O
in	O
randomly	O
selected	O
A	O
-	O
T	O
patients	O
without	O
large	O
cytogenetic	O
clones	O
and	O
without	O
any	O
evidence	O
of	O
leukaemic	O
change	O
.	O
We	O
also	O
show	O
that	O
expression	O
of	O
the	O
B1	O
transcript	O
from	O
a	O
second	O
gene	O
,	O
MTCP1	O
,	O
occurred	O
at	O
a	O
relatively	O
high	O
level	O
only	O
in	O
two	O
T	O
-	O
PLL	O
tumours	O
from	O
A	O
-	O
T	O
patients	O
with	O
t	O
(	O
X	O
;	O
14	O
)	O
translocations	O
whereas	O
the	O
MTCP1	O
/	O
A1	O
transcript	O
is	O
much	O
more	O
widely	O
expressed	O
in	O
both	O
tumour	O
and	O
non	O
tumour	O
cells	O
of	O
A	O
-	O
T	O
and	O
non	O
-	O
A	O
-	O
T	O
individuals	O
.	O
Human	O
herpesvirus	O
6	O
variant	O
A	O
,	O
but	O
not	O
variant	O
B	O
,	O
infects	O
EBV	O
-	O
positive	O
B	O
lymphoid	O
cells	O
,	O
activating	O
the	O
latent	O
EBV	O
genome	O
through	O
a	O
BZLF-1	B
-dependent	O
mechanism	O
.	O
Human	O
herpesvirus	O
6	O
,	O
a	O
predominantly	O
T	O
lymphotropic	O
virus	O
,	O
has	O
been	O
recently	O
shown	O
to	O
infect	O
some	O
EBV	O
-	O
positive	O
B	O
cell	O
lines	O
,	O
and	O
to	O
induce	O
in	O
them	O
the	O
activation	O
of	O
the	O
EBV	O
lytic	O
cycle	O
.	O
Here	O
we	O
have	O
confirmed	O
and	O
extended	O
such	O
observations	O
,	O
showing	O
that	O
(	O
1	O
)	O
this	O
phenomenon	O
is	O
restricted	O
to	O
the	O
variant	O
A	O
of	O
HHV-6	O
:	O
in	O
fact	O
two	O
isolates	O
belonging	O
to	O
the	O
HHV-6	O
variant	O
B	O
(	O
BA92	O
and	O
Z29	O
)	O
were	O
neither	O
able	O
to	O
infect	O
any	O
B	O
cell	O
line	O
,	O
independently	O
of	O
the	O
EBV	O
status	O
,	O
nor	O
to	O
induce	O
the	O
EBV	O
genome	O
expression	O
.	O
The	O
only	O
exception	O
is	O
represented	O
by	O
the	O
P3HR1	O
cells	O
,	O
in	O
which	O
,	O
however	O
,	O
the	O
infection	O
by	O
the	O
variant	O
B	O
does	O
not	O
determine	O
induction	O
of	O
EBV	B
antigens	I
;	O
(	O
2	O
)	O
the	O
presence	O
of	O
the	O
EBV	O
genome	O
contributes	O
to	O
the	O
susceptibility	O
of	O
the	O
B	O
cell	O
lines	O
to	O
HHV-6	O
infection	O
,	O
increasing	O
the	O
binding	O
sites	O
and	O
the	O
percentage	O
of	O
infectable	O
cells	O
,	O
as	O
detected	O
by	O
immunoelectron	O
microscopy	O
;	O
and	O
(	O
3	O
)	O
HHV-6	O
infected	O
T	O
cells	O
,	O
transfected	O
with	O
plasmids	O
bearing	O
the	O
promoter	O
regions	O
of	O
the	O
EBV	O
early	O
genes	O
BZLF1	O
and	O
BMRF1	O
,	O
show	O
a	O
strong	O
transactivation	O
of	O
these	O
promoters	O
.	O
In	O
vivo	O
anergized	O
CD4	O
+	O
T	O
cells	O
express	O
perturbed	O
AP-1	O
and	O
NF	B
-	I
kappa	I
B	I
transcription	B
factors	I
.	O
Anergy	O
is	O
a	O
major	O
mechanism	O
to	O
ensure	O
antigen	O
-	O
specific	O
tolerance	O
in	O
T	O
lymphocytes	O
in	O
the	O
adult	O
.	O
In	O
vivo	O
,	O
anergy	O
has	O
mainly	O
been	O
studied	O
at	O
the	O
cellular	O
level	O
.	O
In	O
this	O
study	O
,	O
we	O
used	O
the	O
T	B
-	I
cell	I
-	I
activating	I
superantigen	I
staphylococcal	B
enterotoxin	I
A	I
(	O
SEA	B
)	O
to	O
investigate	O
molecular	O
mechanisms	O
of	O
T	O
-	O
lymphocyte	O
anergy	O
in	O
vivo	O
.	O
Injection	O
of	O
SEA	B
to	O
adult	O
mice	O
activates	O
CD4	O
+	O
T	O
cells	O
expressing	O
certain	O
T	B
-	I
cell	I
receptor	I
(	I
TCR	I
)	I
variable	I
region	I
beta	I
-	I
chain	I
families	I
and	O
induces	O
strong	O
and	O
rapid	O
production	O
of	O
interleukin	O
2	O
(	O
IL-2	B
)	O
.	O
In	O
contrast	O
,	O
repeated	O
injections	O
of	O
SEA	B
cause	O
CD4	O
+	O
T	O
-	O
cell	O
deletion	O
and	O
anergy	O
in	O
the	O
remaining	O
CD4	O
+	O
T	O
cells	O
,	O
characterized	O
by	O
reduced	O
expression	O
of	O
IL-2	B
at	O
mRNA	O
and	O
protein	O
levels	O
.	O
We	O
analyzed	O
expression	O
of	O
AP-1	B
,	O
NF	B
-	I
kappa	I
B	I
,	O
NF	B
-	I
AT	I
,	O
and	O
octamer	B
binding	I
transcription	I
factors	I
,	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
IL-2	B
gene	O
promoter	O
activity	O
.	O
Large	O
amounts	O
of	O
AP-1	B
and	O
NF	B
-	I
kappa	I
B	I
and	O
significant	O
quantities	O
of	O
NF	B
-	I
AT	I
were	O
induced	O
in	O
SEA	O
-	O
activated	O
CD4	O
+	O
spleen	O
T	O
cells	O
,	O
whereas	O
Oct-1	O
and	O
Oct-2	O
DNA	O
binding	O
activity	O
was	O
similar	O
in	O
both	O
resting	O
and	O
activated	O
T	O
cells	O
.	O
In	O
contrast	O
,	O
anergic	O
CD4	O
+	O
T	O
cells	O
contained	O
severely	O
reduced	O
levels	O
of	O
AP-1	B
and	O
Fos	B
/	I
Jun	I
-	I
containing	I
NF	I
-	I
AT	I
complexes	I
but	O
expressed	O
significant	O
amounts	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
Oct	B
binding	I
proteins	I
after	O
SEA	B
stimulation	O
.	O
Resolution	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
complex	I
demonstrated	O
predominant	O
expression	O
of	O
p50-p65	B
heterodimers	I
in	O
activated	O
CD4	O
+	O
T	O
cells	O
,	O
while	O
anergic	O
cells	O
mainly	O
expressed	O
the	O
transcriptionally	O
inactive	O
p50	B
homodimer	I
.	O
These	O
alterations	O
of	O
transcription	B
factors	I
are	O
likely	O
to	O
be	O
responsible	O
for	O
repression	O
of	O
IL-2	B
in	O
anergic	O
T	O
cells	O
.	O
Characterization	O
and	O
purification	O
of	O
a	O
protein	B
kinase	I
C	I
substrate	I
in	O
human	O
B	O
cells	O
.	O
Identification	O
as	O
lymphocyte	B
-	I
specific	I
protein	I
1	I
(	O
LSP1	B
)	O
.	O
Incubation	O
of	O
B	O
-	O
chronic	O
lymphocytic	O
leukemia	O
(	O
B	O
-	O
CLL	O
)	O
cells	O
with	O
phorbol	O
esters	O
resulted	O
in	O
the	O
phosphorylation	O
of	O
two	O
major	O
PKC	B
substrates	I
,	O
MARCKS	B
(	O
myristoylated	B
,	I
alanine	I
-	I
rich	I
C	I
kinase	I
substrate	I
)	O
and	O
MRP	B
(	O
MARCKS	B
-	I
related	I
protein	I
)	O
,	O
and	O
of	O
a	O
third	O
protein	O
,	O
with	O
an	O
apparent	O
m.w	O
.	O
of	O
60	O
,	O
000	O
that	O
was	O
the	O
most	O
prominent	O
protein	B
kinase	I
C	I
substrate	I
in	O
these	O
cells	O
.	O
p60	B
phosphorylation	O
was	O
time	O
and	O
PMA	O
dose	O
dependent	O
,	O
and	O
was	O
induced	O
by	O
cell	O
-	O
permeable	O
diacylglycerol	O
,	O
but	O
not	O
by	O
inactive	O
phorbol	O
esters	O
.	O
Two	O
-	O
dimensional	O
electrophoretic	O
analysis	O
of	O
the	O
protein	O
phosphorylation	O
pattern	O
from	O
the	O
B	O
cell	O
line	O
CESS	O
demonstrated	O
the	O
identity	O
between	O
the	O
p60	B
protein	I
expressed	O
in	O
this	O
cell	O
line	O
and	O
that	O
expressed	O
in	O
B	O
-	O
CLL	O
cells	O
.	O
p60	B
was	O
purified	O
from	O
CESS	O
cells	O
and	O
peptide	O
microsequencing	O
of	O
this	O
protein	O
revealed	O
that	O
it	O
was	O
lymphocyte	B
-	I
specific	I
protein	I
1	I
(	O
LSP1	B
)	O
,	O
that	O
is	O
here	O
characterized	O
as	O
the	O
most	O
prominent	O
protein	B
kinase	I
C	I
substrate	I
in	O
B	O
cells	O
.	O
Cross	O
-	O
linking	O
CD40	B
on	O
B	O
cells	O
preferentially	O
induces	O
stress	B
-	I
activated	I
protein	I
kinases	I
rather	O
than	O
mitogen	B
-	I
activated	I
protein	I
kinases	I
.	O
The	O
B	B
cell	I
-	I
associated	I
surface	I
molecule	I
CD40	B
plays	O
a	O
key	O
role	O
in	O
T	O
cell	O
-	O
dependent	O
B	O
cell	O
maturation	O
,	O
as	O
individuals	O
with	O
defects	O
in	O
either	O
CD40	B
or	O
its	O
ligand	O
are	O
impaired	O
in	O
immunoglobulin	B
isotype	O
class	O
switching	O
and	O
germinal	O
center	O
formation	O
.	O
CD40	B
signaling	O
activates	O
downstream	B
effectors	I
,	O
including	O
the	O
tyrosine	B
protein	I
kinase	I
,	O
Lyn	B
,	O
the	O
phosphatidylinositol-3-kinase	B
(	O
PI-3	B
kinase	I
)	O
,	O
and	O
the	O
transcription	O
factor	O
,	O
NF	B
-	I
kappa	I
B	I
.	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
stress	B
-	I
activated	I
protein	I
kinases	I
(	O
SAPK	B
)	O
are	O
activated	O
after	O
CD40	B
cross	O
-	O
linking	O
on	O
various	O
B	O
cell	O
lines	O
or	O
human	O
tonsillar	O
B	O
cells	O
.	O
The	O
activation	O
is	O
rapid	O
and	O
transient	O
and	O
is	O
mediated	O
through	O
a	O
cyclosporin	O
A	O
-	O
insensitive	O
pathway	O
.	O
Furthermore	O
,	O
this	O
signaling	O
pathway	O
appears	O
not	O
to	O
rely	O
on	O
protein	B
kinase	I
C	I
.	O
While	O
CD40	B
ligation	O
strongly	O
activates	O
the	O
SAPKs	B
(	O
up	O
to	O
25-fold	O
)	O
,	O
it	O
does	O
not	O
affect	O
members	O
of	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
family	I
(	O
MAPK	B
;	O
ERK1	B
and	O
ERK2	B
)	O
.	O
Consistent	O
with	O
these	O
data	O
,	O
CD40	B
signals	O
up	O
-	O
regulate	O
c	O
-	O
jun	O
but	O
not	O
c	O
-	O
fos	O
mRNA	O
and	O
alter	O
the	O
transcription	B
factor	I
ATF2	B
but	O
not	O
the	O
Raf-1	B
protein	I
.	O
In	O
summary	O
,	O
CD40	B
signaling	O
preferentially	O
induces	O
SAPK	B
but	O
not	O
MAPK	B
.	O
Autocrine	O
activation	O
by	O
interferon	B
-	I
gamma	I
of	O
STAT	B
factors	I
following	O
T	O
cell	O
activation	O
.	O
The	O
activation	O
of	O
T	O
cells	O
requires	O
engagement	O
of	O
the	O
T	B
cell	I
receptor	I
/	I
CD3	I
complex	I
and	O
co	B
-	I
stimulatory	I
molecules	I
,	O
and	O
results	O
in	O
the	O
triggering	O
of	O
several	O
signaling	O
pathways	O
which	O
lead	O
rapidly	O
to	O
the	O
nuclear	O
translocation	O
of	O
several	O
transcription	B
factors	I
,	O
such	O
as	O
nuclear	B
factor	I
(	I
NF	I
)	I
-kappa	I
B	I
and	O
NF	B
-	I
AT	I
.	O
A	O
result	O
of	O
this	O
activation	O
process	O
is	O
the	O
induction	O
of	O
a	O
number	O
of	O
genes	O
,	O
including	O
those	O
encoding	O
cytokines	B
such	O
as	O
interleukin-2	B
,	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
,	O
and	O
interferon	B
(	I
IFN	I
)	I
-gamma	I
which	O
have	O
important	O
immunoregulatory	B
effects	O
.	O
We	O
report	O
here	O
that	O
a	O
DNA	B
-	I
binding	I
factor	I
containing	O
STAT1	B
also	O
becomes	O
activated	O
in	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
or	O
Jurkat	O
cells	O
,	O
although	O
not	O
until	O
1	O
-	O
2	O
h	O
after	O
stimulation	O
.	O
Activation	O
is	O
delayed	O
a	O
further	O
1	O
-	O
2	O
hr	O
when	O
mononuclear	O
cell	O
cultures	O
are	O
stimulated	O
by	O
an	O
antigen	O
which	O
requires	O
processing	O
.	O
Appearance	O
of	O
the	O
STAT1	B
factor	O
is	O
significantly	O
reduced	O
in	O
the	O
presence	O
of	O
cyclosporin	O
A	O
,	O
and	O
blocked	O
by	O
cycloheximide	O
,	O
indicating	O
that	O
its	O
activation	O
is	O
dependent	O
upon	O
a	O
protein	O
(	O
s	O
)	O
synthesized	O
in	O
response	O
to	O
initial	O
signaling	O
events	O
.	O
Neutralizing	O
antiserum	O
against	O
IFN	B
-	I
gamma	I
,	O
but	O
not	O
other	O
cytokines	B
tested	O
,	O
blocked	O
activation	O
of	O
the	O
factor	O
almost	O
completely	O
,	O
and	O
IFN	B
-	I
gamma	I
was	O
found	O
in	O
the	O
culture	O
supernatants	O
of	O
stimulated	O
cells	O
at	O
levels	O
at	O
which	O
recombinant	O
IFN	B
-	I
gamma	I
could	O
activate	O
the	O
factor	O
in	O
naive	O
cells	O
.	O
Therefore	O
,	O
a	O
STAT1	B
transcription	B
factor	I
is	O
activated	O
by	O
IFN	B
-	I
gamma	I
synthesized	O
and	O
released	O
upon	O
stimulation	O
of	O
T	O
lymphocyte	O
populations	O
.	O
While	O
Jurkat	O
cells	O
both	O
secrete	O
and	O
respond	O
to	O
IFN	B
-	I
gamma	I
in	O
an	O
autocrine	O
loop	O
,	O
it	O
seems	O
likely	O
that	O
the	O
responding	O
cells	O
may	O
differ	O
from	O
those	O
synthesizing	O
this	O
cytokine	B
in	O
the	O
mononuclear	O
cell	O
cultures	O
in	O
the	O
light	O
of	O
the	O
recent	O
report	O
that	O
Th1	O
cells	O
lack	O
the	O
IFN	B
-	I
gamma	I
receptor	O
chain	O
necessary	O
for	O
activation	O
of	O
STAT1	B
(	O
Pernis	O
,	O
A.	O
,	O
Gupta	O
,	O
S.	O
,	O
Gollob	O
,	O
K.J.	O
,	O
Garfein	O
,	O
E.	O
,	O
Coffman	O
,	O
R.L.	O
,	O
Schindler	O
,	O
C.	O
,	O
and	O
Rothman	O
,	O
P.	O
,	O
Science	O
1995	O
.	O
269	O
:	O
245	O
)	O
.	O
A	O
model	O
of	O
latent	O
adenovirus	O
5	O
infection	O
in	O
the	O
guinea	O
pig	O
(	O
Cavia	O
porcellus	O
)	O
.	O
A	O
model	O
of	O
adenovirus	O
5	O
(	O
Ad5	O
)	O
infection	O
was	O
developed	O
in	O
guinea	O
pigs	O
to	O
begin	O
to	O
study	O
its	O
role	O
in	O
the	O
pathogenesis	O
of	O
peripheral	O
lung	O
inflammation	O
.	O
Forty	O
animals	O
were	O
inoculated	O
intranasally	O
with	O
10	O
(	O
7.0	O
)	O
pfu	O
of	O
Ad5	O
/	O
animal	O
,	O
and	O
15	O
animals	O
inoculated	O
with	O
sterile	O
culture	O
media	O
served	O
as	O
controls	O
.	O
Viral	O
titres	O
were	O
10	O
(	O
4.4	O
)	O
,	O
10	O
(	O
6.1	O
)	O
,	O
10	O
(	O
5.2	O
)	O
,	O
and	O
10	O
(	O
2.9	O
)	O
pfu	O
/	O
animal	O
,	O
on	O
days	O
1	O
,	O
3	O
,	O
4	O
,	O
and	O
7	O
after	O
infection	O
,	O
respectively	O
.	O
In	O
situ	O
hybridization	O
to	O
viral	O
DNA	O
and	O
immunocytochemistry	O
for	O
Ad5	O
E1A	B
protein	I
localized	O
the	O
virus	O
to	O
airway	O
and	O
alveolar	O
epithelial	O
cells	O
.	O
Histologic	O
examination	O
showed	O
an	O
extensive	O
inflammatory	O
cell	O
infiltration	O
around	O
the	O
airways	O
,	O
with	O
epithelial	O
necrosis	O
and	O
an	O
alveolar	O
exudate	O
that	O
caused	O
localized	O
alveolar	O
collapse	O
in	O
the	O
infected	O
areas	O
.	O
Immunocytochemistry	O
identified	O
the	O
cells	O
in	O
the	O
infiltrate	O
as	O
cytotoxic	O
T	O
cells	O
.	O
Although	O
all	O
animals	O
20	O
and	O
47	O
days	O
after	O
infection	O
had	O
seroconverted	O
to	O
Ad5	O
,	O
virus	O
was	O
not	O
detected	O
in	O
these	O
groups	O
either	O
by	O
viral	O
plaque	O
assay	O
or	O
in	O
situ	O
hybridization	O
.	O
Ad5	O
E1A	O
DNA	O
was	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
in	O
five	O
of	O
six	O
animals	O
20	O
days	O
after	O
infection	O
and	O
in	O
five	O
of	O
five	O
animals	O
47	O
days	O
after	O
infection	O
.	O
In	O
these	O
same	O
animals	O
,	O
E1A	B
protein	I
was	O
detected	O
20	O
days	O
after	O
infection	O
in	O
two	O
and	O
47	O
days	O
after	O
infection	O
in	O
one	O
while	O
persistent	O
bronchiolitis	O
was	O
observed	O
in	O
four	O
and	O
three	O
animals	O
20	O
and	O
47	O
days	O
after	O
infection	O
,	O
respectively	O
.	O
These	O
results	O
demonstrate	O
that	O
the	O
guinea	O
pig	O
provides	O
a	O
useful	O
model	O
to	O
study	O
the	O
role	O
of	O
Ad5	O
infection	O
in	O
chronic	O
airway	O
inflammation	O
.	O
Herpesvirus	O
saimiri	O
immortalized	O
gamma	O
delta	O
T	O
cell	O
line	O
activated	O
by	O
IL-12	B
.	O
IL-12	B
is	O
a	O
novel	O
heterodimeric	B
cytokine	I
important	O
for	O
the	O
regulation	O
and	O
differentiation	O
of	O
lymphocytes	O
and	O
NK	O
cells	O
.	O
Like	O
other	O
cytokines	O
,	O
IL-12	B
mediates	O
its	O
biologic	O
activity	O
through	O
high	O
-	O
affinity	O
receptors	O
expressed	O
on	O
responsive	O
cells	O
.	O
To	O
date	O
,	O
a	O
large	O
number	O
of	O
receptors	O
for	O
IL-12	B
have	O
been	O
found	O
only	O
on	O
PBMC	O
following	O
activation	O
with	O
PHA	B
or	O
IL-2	B
.	O
To	O
gain	O
further	O
knowledge	O
of	O
the	O
IL-12R	B
complex	I
and	O
the	O
IL-12	B
signal	O
transduction	O
pathway	O
in	O
cytotoxic	O
T	O
cells	O
,	O
we	O
studied	O
a	O
number	O
of	O
human	O
T	O
cell	O
lines	O
that	O
had	O
been	O
transformed	O
to	O
permanent	O
growth	O
with	O
Herpesvirus	O
saimiri	O
,	O
an	O
oncogenic	O
virus	O
of	O
nonhuman	O
primates	O
.	O
This	O
paper	O
reports	O
the	O
expression	O
of	O
IL-12R	B
on	O
a	O
human	O
gamma	O
delta	O
T	O
cell	O
line	O
that	O
responds	O
to	O
IL-12	B
with	O
enhanced	O
cytolytic	O
activity	O
and	O
increased	O
expression	O
of	O
cytolytic	B
effector	I
molecules	I
granzyme	B
B	I
and	O
perforin	B
.	O
Using	O
these	O
T	O
cells	O
as	O
a	O
model	O
of	O
IL-12	B
signal	O
transduction	O
,	O
we	O
confirmed	O
that	O
these	O
events	O
involve	O
members	O
of	O
the	O
Janus	B
kinase	I
family	I
of	O
nonreceptor	B
tyrosine	I
kinases	I
JAK2	B
,	O
TYK2	B
,	O
and	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
4	I
.	O
The	O
Epstein	B
-	I
Barr	I
virus	I
-	I
encoded	I
nuclear	I
antigen	I
EBNA-5	I
accumulates	O
in	O
PML	O
-	O
containing	O
bodies	O
.	O
EBNA-5	B
is	O
one	O
of	O
the	O
Epstein	B
-	I
Barr	I
virus	I
(	I
EBV	I
)	I
-encoded	I
nuclear	I
proteins	I
required	O
for	O
immortalization	O
of	O
human	O
B	O
lymphocytes	O
.	O
In	O
the	O
nuclei	O
of	O
EBV	O
-	O
transformed	O
lymphoblastoid	O
cell	O
lines	O
EBNA-5	B
is	O
preferentially	O
targetted	O
to	O
distinct	O
nuclear	O
foci	O
.	O
Previously	O
we	O
have	O
shown	O
(	O
W.Q.	O
Jiang	O
,	O
L.Szekely	O
,	O
V.Wendel	O
-	O
Hansen	O
,	O
N.Ringertz	O
,	O
G.Klein	O
,	O
and	O
A.	O
Rosen	O
,	O
Exp	O
.	O
Cell	O
Res	O
.	O
The	O
involvement	O
of	O
p23	B
,	O
hsp90	B
,	O
and	O
immunophilins	B
in	O
the	O
assembly	O
of	O
progesterone	B
receptor	I
complexes	I
.	O
To	O
better	O
understand	O
the	O
assembly	O
mechanism	O
for	O
the	O
progesterone	B
receptor	I
(	O
PR	B
)	O
,	O
we	O
have	O
developed	O
cell	O
-	O
free	O
systems	O
for	O
studying	O
interactions	O
of	O
PR	B
,	O
hsp90	B
,	O
and	O
other	O
associated	B
proteins	I
.	O
When	O
PR	B
is	O
incubated	O
in	O
rabbit	O
reticulocyte	O
lysate	O
,	O
its	O
association	O
with	O
hsp90	B
,	O
hsp70	B
,	O
the	O
three	O
immunophilins	B
FKBP54	B
,	O
FKBP52	B
and	O
CyP-40	B
,	O
and	O
with	O
p23	B
is	O
observed	O
.	O
These	O
interactions	O
require	O
ATP	O
/	O
Mg2	O
+	O
and	O
when	O
ATP	O
is	O
limiting	O
the	O
PR	B
complex	O
is	O
altered	O
to	O
one	O
containing	O
the	O
proteins	O
p60	B
and	O
p48	B
,	O
but	O
lacking	O
immunophilins	B
and	O
p23	B
.	O
We	O
have	O
studied	O
two	O
pre	B
-	I
formed	I
hsp90	I
complexes	I
that	O
may	O
participate	O
in	O
the	O
assembly	O
of	O
PR	B
complexes	I
.	O
One	O
contains	O
hsp90	B
bound	O
to	O
hsp70	B
and	O
p60	B
and	O
this	O
complex	O
forms	O
spontaneously	O
in	O
the	O
absence	O
of	O
ATP	O
.	O
A	O
second	O
complex	O
contains	O
hsp90	B
bound	O
to	O
p23	B
plus	O
the	O
three	O
immunophilins	B
and	O
some	O
hsp70	B
.	O
The	O
formation	O
of	O
this	O
complex	O
requires	O
ATP	O
.	O
In	O
further	O
studies	O
we	O
have	O
shown	O
that	O
purified	O
hsp90	B
can	O
bind	O
to	O
purified	O
p23	B
and	O
this	O
interaction	O
requires	O
both	O
ATP	O
and	O
molybdate	O
.	O
This	O
explains	O
,	O
in	O
part	O
,	O
the	O
known	O
effects	O
of	O
ATP	O
and	O
molybdate	O
on	O
assembly	O
of	O
PR	B
complexes	I
.	O
Expression	O
of	O
Retinoid	B
X	I
Receptor	I
alpha	I
is	O
increased	O
upon	O
monocytic	O
cell	O
differentiation	O
.	O
1	O
alpha	O
,	O
25-Dihydroxyvitamin	O
D3	O
(	O
VD	O
)	O
is	O
a	O
potent	O
inducer	O
of	O
monocytic	O
differentiation	O
of	O
both	O
normal	O
and	O
leukemic	O
cells	O
.	O
Its	O
effects	O
are	O
mediated	O
by	O
its	O
nuclear	B
receptor	I
(	O
VDR	B
)	O
.	O
Efficient	O
gene	O
activation	O
requires	O
the	O
heterodimerization	O
of	O
VDR	B
with	O
Retinoid	B
X	I
Receptors	I
(	O
RXR	B
)	O
.	O
In	O
the	O
present	O
study	O
using	O
specific	B
antibodies	I
,	O
we	O
analyzed	O
the	O
expression	O
of	O
the	O
RXR	B
alpha	I
protein	I
in	O
blood	O
mononuclear	O
cells	O
from	O
acute	O
myeloid	O
patients	O
(	O
AML	O
)	O
(	O
10	O
cases	O
)	O
and	O
from	O
myelomonocytic	O
cell	O
lines	O
arrested	O
at	O
different	O
stages	O
of	O
differentiation	O
.	O
We	O
observed	O
that	O
the	O
RXR	B
alpha	I
expression	O
increased	O
during	O
myelomonocytic	O
differentiation	O
,	O
since	O
the	O
highest	O
levels	O
were	O
found	O
in	O
AML	O
samples	O
and	O
in	O
myelomonocytic	O
cell	O
lines	O
having	O
the	O
highest	O
amounts	O
of	O
monocytic	O
precursors	O
.	O
We	O
also	O
demonstrated	O
that	O
fresh	O
leukemic	O
cells	O
,	O
whatever	O
their	O
stage	O
of	O
differentiation	O
,	O
as	O
well	O
as	O
myelomonocytic	O
cell	O
lines	O
,	O
respond	O
to	O
VD	O
by	O
an	O
increase	O
in	O
RXR	B
alpha	I
levels	O
.	O
Combinations	O
of	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
and	O
VD	O
,	O
in	O
some	O
cases	O
,	O
increased	O
this	O
effect	O
.	O
This	O
response	O
suggests	O
the	O
involvement	O
of	O
RXR	B
alpha	I
in	O
monocytic	O
differentiation	O
upon	O
VD	O
treatment	O
.	O
Coexpression	O
of	O
the	O
interleukin-13	O
and	O
interleukin-4	O
genes	O
correlates	O
with	O
their	O
physical	O
linkage	O
in	O
the	O
cytokine	O
gene	O
cluster	O
on	O
human	O
chromosome	O
5q23	O
-	O
31	O
.	O
Interleukin-13	B
(	O
IL-13	B
)	O
and	O
IL-4	B
are	O
cytokines	O
produced	O
by	O
T	O
cells	O
that	O
are	O
encoded	O
by	O
the	O
q23	O
-	O
31	O
region	O
of	O
human	O
chromosome	O
5	O
.	O
To	O
investigate	O
the	O
regulation	O
of	O
IL-13	O
gene	O
expression	O
by	O
T	O
cells	O
,	O
we	O
isolated	O
and	O
sequenced	O
the	O
human	O
IL-13	O
gene	O
,	O
analyzed	O
its	O
5'-flanking	O
region	O
for	O
potential	O
transcriptional	O
activation	O
elements	O
,	O
and	O
examined	O
its	O
expression	O
in	O
nontransformed	O
T	O
-	O
lineage	O
cell	O
populations	O
.	O
The	O
human	O
IL-13	O
gene	O
was	O
located	O
12.5-kb	O
upstream	O
of	O
the	O
IL-4	O
gene	O
and	O
2-kb	O
downstream	O
of	O
a	O
CpG	O
island	O
.	O
The	O
IL-13	O
gene	O
5	O
'	O
flank	O
region	O
included	O
a	O
segment	O
with	O
sequence	O
homology	O
to	O
P	O
elements	O
of	O
the	O
IL-4	O
promoter	O
involved	O
in	O
transcriptional	O
activation	O
in	O
T	O
cells	O
.	O
Mutation	O
of	O
the	O
IL-13	O
P	O
element	O
site	O
significantly	O
reduced	O
IL-13	B
promoter	O
activity	O
in	O
response	O
to	O
T	O
-	O
cell	O
activation	O
.	O
Oligonucleotides	O
containing	O
the	O
IL-13	B
or	O
IL-4	O
P	O
element	O
sites	O
specifically	O
bound	O
the	O
transcriptional	B
activator	I
protein	I
,	O
nuclear	B
factor	I
-	I
activated	I
T	I
cells	I
,	O
preformed	O
(	O
NF	B
-	I
ATp	I
)	O
,	O
when	O
incubated	O
with	O
nuclear	O
protein	O
extracts	O
from	O
activated	O
T	O
cells	O
.	O
Similar	O
to	O
IL-4	B
,	O
IL-13	O
mRNA	O
expression	O
was	O
highest	O
in	O
T	O
-	O
cell	O
populations	O
enriched	O
for	O
cells	O
that	O
had	O
previously	O
been	O
primed	O
in	O
vivo	O
or	O
in	O
vitro	O
,	O
indicating	O
that	O
priming	O
increases	O
the	O
expression	O
of	O
the	O
IL-13	O
and	O
IL-4	O
genes	O
in	O
a	O
coordinate	O
manner	O
.	O
Because	O
the	O
primed	O
T	O
cells	O
contain	O
higher	O
levels	O
of	O
nuclear	B
NF	I
-	I
ATp	I
,	O
capable	O
of	O
binding	O
to	O
P	O
elements	O
of	O
the	O
IL-4	O
and	O
IL-13	O
promoters	O
,	O
than	O
do	O
freshly	O
-	O
isolated	O
T	O
cells	O
,	O
the	O
NF	O
-	O
AT	O
-	O
binding	O
P	O
elements	O
are	O
attractive	O
candidates	O
to	O
mediate	O
the	O
coordinate	O
expression	O
of	O
these	O
two	O
cytokine	O
genes	O
.	O
Transactivation	O
of	O
the	O
interleukin-1alpha	O
promoter	O
by	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
I	I
and	I
type	I
II	I
Tax	I
proteins	I
.	O
Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
-infected	O
T	O
-	O
cell	O
lines	O
constitutively	O
produce	O
high	O
levels	O
of	O
interleukin-1alpha	B
(	O
IL-1alpha	B
)	O
.	O
To	O
analyze	O
the	O
mechanisms	O
that	O
lead	O
to	O
the	O
expression	O
of	O
IL-1alpha	B
in	O
HTLV	O
-	O
I	O
-	O
infected	O
cell	O
lines	O
,	O
we	O
studied	O
regulatory	O
regions	O
of	O
the	O
human	O
IL-1alpha	O
promoter	O
involved	O
in	O
activation	O
of	O
the	O
IL-1alpha	O
gene	O
.	O
IL-1alpha	O
promoter	O
constructs	O
drive	O
transcription	O
of	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
in	O
HTLV	O
-	O
I	O
-	O
positive	O
MT-2	O
cells	O
,	O
which	O
constitutively	O
produce	O
IL-1alpha	B
.	O
In	O
a	O
cotransfection	O
assay	O
,	O
the	O
Tax	B
protein	I
of	O
both	O
HTLV	O
-	O
I	O
and	O
HTLV	O
-	O
II	O
specifically	O
activated	O
transcription	O
from	O
the	O
IL-1alpha	O
promoter	O
in	O
an	O
uninfected	O
Jurkat	O
cell	O
line	O
.	O
A	O
mutant	O
Tax	B
protein	I
deficient	O
in	O
transactivation	O
of	O
genes	O
by	O
the	O
nuclear	B
factor	I
(	I
NF	I
)	I
-kappaB	I
pathway	O
was	O
unable	O
to	O
induce	O
transcriptional	O
activity	O
of	O
IL-1alpha	O
promoter	O
-	O
CAT	O
constructs	O
,	O
but	O
was	O
rescued	O
by	O
exogenous	O
provision	O
of	O
p65	B
/	I
p50	I
NF	B
-	I
kappaB	I
.	O
We	O
found	O
that	O
two	O
IL-1alpha	O
kappaB	O
-	O
like	O
sites	O
(	O
positions	O
-1	O
,	O
065	O
to	O
-1	O
,	O
056	O
and	O
+	O
646	O
to	O
+	O
655	O
)	O
specifically	O
formed	O
a	O
complex	O
with	O
NF	B
-	I
kappaB	I
-containing	O
nuclear	O
extract	O
from	O
MT-2	O
cells	O
and	O
that	O
NF	B
-	I
kappaB	I
bound	O
with	O
higher	O
affinity	O
to	O
the	O
3	O
'	O
NF	O
-	O
kappaB	O
binding	O
site	O
than	O
to	O
the	O
5	O
'	O
NF	O
-	O
kappaB	O
site	O
.	O
Moreover	O
,	O
deletion	O
of	O
either	O
5	O
'	O
or	O
3	O
'	O
NF	O
-	O
kappaB	O
sites	O
reduced	O
IL-1alpha	O
promoter	O
activity	O
in	O
MT-2	O
cells	O
and	O
transactivation	O
of	O
the	O
IL-1alpha	O
promoter	O
by	O
exogenous	O
NF	B
-	I
kappaB	I
and	O
Tax	B
in	O
Jurkat	O
cells	O
.	O
These	O
data	O
suggest	O
a	O
general	O
role	O
for	O
Tax	B
induction	O
of	O
IL-1alpha	O
gene	O
transcription	O
by	O
the	O
NF	B
-	I
kappaB	I
pathway	O
.	O
Expression	O
of	O
IL-1alpha	B
by	O
HTLV	O
-	O
I	O
productively	O
infected	O
cells	O
may	O
be	O
important	O
in	O
the	O
hypercalcemia	O
,	O
osteolytic	O
bone	O
lesions	O
,	O
neutrophilia	O
,	O
elevation	O
of	O
C	B
-	I
reactive	I
protein	I
,	O
and	O
fever	O
frequently	O
seen	O
in	O
patients	O
with	O
HTLV	O
-	O
I	O
-	O
induced	O
adult	O
T	O
-	O
cell	O
leukemia	O
/	O
lymphoma	O
.	O
A	O
mammalian	B
histone	I
deacetylase	I
related	O
to	O
the	O
yeast	B
transcriptional	I
regulator	I
Rpd3p	B
[	O
see	O
comments	O
]	O
Trapoxin	O
is	O
a	O
microbially	O
derived	O
cyclotetrapeptide	O
that	O
inhibits	O
histone	B
deacetylation	O
in	O
vivo	O
and	O
causes	O
mammalian	O
cells	O
to	O
arrest	O
in	O
the	O
cell	O
cycle	O
.	O
A	O
trapoxin	O
affinity	O
matrix	O
was	O
used	O
to	O
isolate	O
two	O
nuclear	O
proteins	O
that	O
copurified	O
with	O
histone	B
deacetylase	I
activity	O
.	O
Both	O
proteins	O
were	O
identified	O
by	O
peptide	O
microsequencing	O
,	O
and	O
a	O
complementary	O
DNA	O
encoding	O
the	O
histone	B
deacetylase	I
catalytic	I
subunit	I
(	O
HD1	B
)	O
was	O
cloned	O
from	O
a	O
human	O
Jurkat	O
T	O
cell	O
library	O
.	O
As	O
the	O
predicted	O
protein	O
is	O
very	O
similar	O
to	O
the	O
yeast	B
transcriptional	I
regulator	I
Rpd3p	B
,	O
these	O
results	O
support	O
a	O
role	O
for	O
histone	B
deacetylase	I
as	O
a	O
key	O
regulator	O
of	O
eukaryotic	O
transcription	O
.	O
Effects	O
of	O
interleukin-10	B
on	O
human	O
peripheral	O
blood	O
mononuclear	O
cell	O
responses	O
to	O
Cryptococcus	O
neoformans	O
,	O
Candida	O
albicans	O
,	O
and	O
lipopolysaccharide	O
.	O
Deactivation	O
of	O
mononuclear	O
phagocytes	O
is	O
critical	O
to	O
limit	O
the	O
inflammatory	O
response	O
but	O
can	O
be	O
detrimental	O
in	O
the	O
face	O
of	O
progressive	O
infection	O
.	O
We	O
compared	O
the	O
effects	O
of	O
the	O
deactivating	B
cytokine	I
interleukin	B
10	I
(	O
IL-10	B
)	O
on	O
human	O
peripheral	O
blood	O
mononuclear	O
cell	O
(	O
PBMC	O
)	O
responses	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
Cryptococcus	O
neoformans	O
,	O
and	O
Candida	O
albicans	O
.	O
IL-10	B
effected	O
dose	O
-	O
dependent	O
inhibition	O
of	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
release	O
in	O
PBMC	O
stimulated	O
by	O
LPS	O
and	O
C.	O
neoformans	O
,	O
with	O
significant	O
inhibition	O
seen	O
with	O
0.1	O
U	O
/	O
ml	O
and	O
greater	O
than	O
90	O
%	O
inhibition	O
noted	O
with	O
10	O
U	O
/	O
ml	O
.	O
In	O
contrast	O
,	O
even	O
at	O
doses	O
as	O
high	O
as	O
100	O
U	O
/	O
ml	O
,	O
IL-10	B
inhibited	O
TNF	B
-	I
alpha	I
release	O
in	O
response	O
to	O
C.	O
albicans	O
by	O
only	O
50	O
%	O
.	O
IL-10	B
profoundly	O
inhibited	O
release	O
of	O
IL-1beta	B
from	O
PBMC	O
stimulated	O
by	O
all	O
three	O
stimuli	O
.	O
TNF	O
-	O
alpha	O
mRNA	O
and	O
release	O
was	O
inhibited	O
even	O
if	O
IL-10	B
was	O
added	O
up	O
to	O
8	O
h	O
after	O
cryptococcal	O
stimulation	O
.	O
In	O
contrast	O
,	O
inhibition	O
of	O
IL-1	O
beta	O
mRNA	O
was	O
of	O
lesser	O
magnitude	O
and	O
occurred	O
only	O
when	O
IL-10	B
was	O
added	O
within	O
2	O
h	O
of	O
cryptococcal	O
stimulation	O
.	O
IL-10	B
inhibited	O
translocation	O
of	O
NF	B
-	I
kappaB	I
in	O
response	O
to	O
LPS	O
but	O
not	O
the	O
fungal	O
stimuli	O
.	O
All	O
three	O
stimuli	O
induced	O
IL-10	B
production	O
in	O
PBMC	O
,	O
although	O
over	O
10-fold	O
less	O
IL-10	B
was	O
released	O
in	O
response	O
to	O
C.	O
neoformans	O
compared	O
with	O
LPS	O
and	O
C.	O
albicans	O
.	O
Thus	O
,	O
while	O
IL-10	B
has	O
deactivating	O
effects	O
on	O
PBMC	O
responses	O
to	O
all	O
three	O
stimuli	O
,	O
disparate	O
stimulus-	O
and	O
response	O
-	O
specific	O
patterns	O
of	O
deactivation	O
are	O
seen	O
.	O
Inhibition	O
by	O
IL-10	B
of	O
proinflammatory	B
cytokine	I
release	O
appears	O
to	O
occur	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
for	O
TNF	B
-	I
alpha	I
and	O
both	O
transcriptionally	O
and	O
posttranscriptionally	O
for	O
IL-1beta	B
.	O
Permanent	O
occupancy	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
by	O
NF	B
-	I
kappa	I
B	I
is	O
needed	O
for	O
persistent	O
viral	O
replication	O
in	O
monocytes	O
.	O
This	O
work	O
aimed	O
to	O
ascertain	O
the	O
role	O
of	O
kappaB	O
-	O
responsive	O
elements	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
enhancer	O
not	O
only	O
in	O
early	O
initiation	O
but	O
also	O
in	O
long	O
-	O
term	O
maintenance	O
of	O
proviral	O
transcription	O
in	O
cells	O
of	O
the	O
monocytic	O
lineage	O
.	O
For	O
this	O
purpose	O
,	O
we	O
used	O
three	O
main	O
approaches	O
.	O
The	O
first	O
was	O
to	O
abruptly	O
terminate	O
tumor	O
necrosis	O
factor	O
-	O
induced	O
NF	B
-	I
kappaB	I
binding	O
to	O
the	O
enhancer	O
sequences	O
in	O
U1	O
monocytic	O
cells	O
,	O
using	O
a	O
short	O
pulse	O
of	O
exogenous	B
tumor	I
necrosis	I
factor	I
.	O
This	O
resulted	O
in	O
concomitant	O
decrease	O
in	O
nuclear	O
NF	B
-	I
kappaB	I
DNA	O
-	O
binding	O
activity	O
and	O
endogenous	O
long	O
terminal	O
repeat	O
transcriptional	O
activity	O
.	O
The	O
second	O
was	O
to	O
suppress	O
the	O
permanent	O
NF	B
-	I
kappaB	I
translocation	O
induced	O
by	O
HIV-1	O
replication	O
itself	O
in	O
chronically	O
infected	O
U937	O
cells	O
,	O
using	O
a	O
specific	O
proteasome	O
inhibitor	O
(	O
Z	O
-	O
LLL	O
-	O
H	O
)	O
.	O
As	O
early	O
as	O
2	O
h	O
after	O
addition	O
of	O
the	O
inhibitor	O
to	O
the	O
culture	O
medium	O
,	O
there	O
was	O
an	O
inhibition	O
of	O
both	O
constitutive	O
activation	O
of	O
NF	B
-	I
kappaB	I
and	O
HIV-1	O
genome	O
expression	O
.	O
The	O
third	O
approach	O
was	O
to	O
monitor	O
the	O
replication	O
competence	O
in	O
U937	O
cells	O
of	O
an	O
infectious	O
HIV-1	O
provirus	O
carrying	O
point	O
mutations	O
in	O
the	O
kappaB	O
-	O
responsive	O
elements	O
of	O
both	O
long	O
terminal	O
repeats	O
.	O
Compared	O
with	O
its	O
wild	O
-	O
type	O
counterpart	O
,	O
this	O
mutated	O
provirus	O
showed	O
a	O
profoundly	O
decreased	O
,	O
Z	O
-	O
LLL	O
-	O
H	O
-	O
insensitive	O
transcriptional	O
and	O
replicative	O
activity	O
in	O
U937	O
monocytes	O
.	O
Together	O
,	O
our	O
results	O
indicate	O
that	O
occupancy	O
of	O
the	O
viral	O
enhancer	O
by	O
NF	B
-	I
kappaB	I
(	I
p50	I
/	I
p65	I
)	I
heterodimers	I
is	O
required	O
for	O
ongoing	O
transcription	O
of	O
integrated	O
HIV	O
provirus	O
in	O
monocytes	O
,	O
even	O
in	O
cells	O
chronically	O
infected	O
and	O
permanently	O
producing	O
functional	O
HIV	B
Tat	I
protein	I
.	O
Thus	O
,	O
the	O
ability	O
of	O
HIV-1	O
replication	O
to	O
activate	O
NF	B
-	I
kappaB	I
is	O
crucial	O
to	O
the	O
intense	O
self	O
-	O
perpetuated	O
viral	O
transcription	O
observed	O
in	O
cells	O
of	O
the	O
monocytic	O
lineage	O
.	O
Surfactant	O
suppresses	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
human	O
monocytic	O
cells	O
.	O
In	O
addition	O
to	O
biophysical	O
properties	O
,	O
pulmonary	O
surfactant	O
has	O
immunomodulatory	O
activity	O
.	O
We	O
previously	O
demonstrated	O
that	O
both	O
synthetic	O
(	O
Exosurf	O
)	O
and	O
modified	O
natural	O
surfactant	O
(	O
Survanta	O
)	O
downregulated	O
endotoxin	O
-	O
stimulated	O
inflammatory	O
c	O
ytokine	O
mRNA	O
levels	O
and	O
protein	B
products	I
(	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
[	O
TNF	O
]	O
,	O
interleukin-1-beta	B
[	O
IL-1	B
]	O
,	O
interleukin-6	B
[	O
IL-6	B
]	O
)	O
in	O
human	O
alveolar	O
macrophages	O
.	O
In	O
this	O
study	O
,	O
we	O
report	O
that	O
both	O
Exosurf	O
and	O
Survanta	O
suppress	O
TNF	O
mRNA	O
and	O
secretion	O
(	O
85	O
+	O
/-	O
4	O
%	O
mean	O
percent	O
inhibition	O
+	O
/-	O
SEM	O
by	O
Exosurf	O
;	O
71	O
+	O
/-	O
6	O
%	O
by	O
Survanta	O
)	O
by	O
endotoxin	O
-	O
stimulated	O
THP-1	O
,	O
a	O
human	O
monocytic	O
cell	O
line	O
.	O
Because	O
surfactant	O
downregulated	O
inflammatory	B
cytokine	I
production	O
similarly	O
in	O
both	O
normal	O
human	O
alveolar	O
macrophages	O
and	O
the	O
THP-1	O
cell	O
line	O
,	O
we	O
used	O
this	O
cell	O
line	O
to	O
investigate	O
whether	O
surfactant	O
affected	O
transcriptional	O
mechanisms	O
.	O
Specifically	O
,	O
we	O
examined	O
nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
activation	O
because	O
it	O
is	O
crucial	O
in	O
transcriptional	O
regulation	O
of	O
many	O
inflammatory	O
cytokine	O
genes	O
including	O
TNF	O
,	O
IL-1	O
,	O
and	O
IL-6	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
both	O
surfactants	O
decreased	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
The	O
presence	O
of	O
both	O
p65	B
and	O
p50	B
NF	B
-	I
kappa	I
B	I
components	I
in	O
LPS	O
-	O
activated	O
THP-1	O
cells	O
was	O
confirmed	O
by	O
specific	O
antibody	O
induction	O
of	O
supershifts	O
in	O
mobility	O
assays	O
.	O
These	O
results	O
are	O
the	O
first	O
to	O
suggest	O
that	O
surfactant	O
's	O
suppressive	O
effects	O
on	O
inflammatory	B
cytokine	I
production	O
may	O
involve	O
transcriptional	O
regulation	O
through	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
Inactivation	O
of	O
IkappaBbeta	B
by	O
the	O
tax	B
protein	I
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
:	O
a	O
potential	O
mechanism	O
for	O
constitutive	O
induction	O
of	O
NF	B
-	I
kappaB	I
.	O
In	O
resting	O
T	O
lymphocytes	O
,	O
the	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
is	O
sequestered	O
in	O
the	O
cytoplasm	O
via	O
interactions	O
with	O
members	O
of	O
the	O
I	B
kappa	I
B	I
family	I
of	O
inhibitors	O
,	O
including	O
IkappaBalpha	B
and	O
IkappaBbeta	B
.	O
During	O
normal	O
T	O
-	O
cell	O
activation	O
,	O
IkappaBalpha	B
is	O
rapidly	O
phosphorylated	O
,	O
ubiquitinated	O
,	O
and	O
degraded	O
by	O
the	O
26S	B
proteasome	I
,	O
thus	O
permitting	O
the	O
release	O
of	O
functional	O
NF	B
-	I
kappaB	I
.	O
In	O
contrast	O
to	O
its	O
transient	O
pattern	O
of	O
nuclear	O
induction	O
during	O
an	O
immune	O
response	O
,	O
NF	B
-	I
kappaB	I
is	O
constitutively	O
activated	O
in	O
cells	O
expressing	O
the	O
Tax	B
transforming	I
protein	I
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-1	O
)	O
.	O
Recent	O
studies	O
indicate	O
that	O
HTLV-1	O
Tax	B
targets	O
IkappaBalpha	B
to	O
the	O
ubiquitin	O
-	O
proteasome	O
pathway	O
.	O
However	O
,	O
it	O
remains	O
unclear	O
how	O
this	O
viral	B
protein	I
induces	O
a	O
persistent	O
rather	O
than	O
transient	O
NF	B
-	I
kappaB	I
response	O
.	O
In	O
this	O
report	O
,	O
we	O
provide	O
evidence	O
that	O
in	O
addition	O
to	O
acting	O
on	O
IkappaBalpha	B
,	O
Tax	B
stimulates	O
the	O
turnover	O
Of	O
IkappaBbeta	B
via	O
a	O
related	O
targeting	O
mechanism	O
.	O
Like	O
IkappaBalpha	B
,	O
Tax	B
-mediated	O
breakdown	O
of	O
IkappaBbeta	B
in	O
transfected	O
T	O
lymphocytes	O
is	O
blocked	O
either	O
by	O
cell	O
-	O
permeable	O
proteasome	O
inhibitors	O
or	O
by	O
mutation	O
Of	O
IkappaBbeta	B
at	O
two	O
serine	O
residues	O
present	O
within	O
its	O
N	B
-	I
terminal	I
region	I
.	O
Despite	O
the	O
dual	O
specificity	O
of	O
HTLV-1	O
Tax	B
for	O
IkappaBalpha	B
and	O
IkappaBbeta	B
at	O
the	O
protein	O
level	O
,	O
Tax	B
selectively	O
stimulates	O
NF	B
-	I
kappaB	I
-directed	O
transcription	O
of	O
the	O
IkappaBalpha	O
gene	O
.	O
Consequently	O
,	O
IkappaBbeta	B
protein	O
expression	O
is	O
chronically	O
downregulated	O
in	O
HTLV-1-infected	O
T	O
lymphocytes	O
.	O
These	O
findings	O
with	O
IkappaBbeta	B
provide	O
a	O
potential	O
mechanism	O
for	O
the	O
constitutive	O
activation	O
of	O
NF	B
-	I
kappaB	I
in	O
Tax	O
-	O
expressing	O
cells	O
.	O
Genetic	O
characterization	O
of	O
transactivation	O
of	O
the	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
promoter	O
:	O
Binding	O
of	O
Tax	B
to	O
Tax	O
-	O
responsive	O
element	O
1	O
is	O
mediated	O
by	O
the	O
cyclic	B
AMP	I
-	I
responsive	I
members	I
of	O
the	O
CREB	B
/	I
ATF	I
family	I
of	O
transcription	O
factors	O
.	O
To	O
achieve	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
transactivation	O
by	O
Tax	B
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
Tax	O
-	O
responsive	O
element	O
1	O
(	O
TRE-1	O
)	O
,	O
we	O
developed	O
a	O
genetic	O
approach	O
with	O
Saccharomyces	O
cerevisiae	O
.	O
We	O
constructed	O
a	O
yeast	O
reporter	O
strain	O
containing	O
the	O
lacZ	O
gene	O
under	O
the	O
control	O
of	O
the	O
CYC1	O
promoter	O
associated	O
with	O
three	O
copies	O
of	O
TRE-1	O
.	O
Expression	O
of	O
either	O
the	O
cyclic	B
AMP	I
response	I
element	I
-	I
binding	I
protein	I
(	O
CREB	B
)	O
or	O
CREB	B
fused	O
to	O
the	O
GAL4	B
activation	I
domain	I
(	O
GAD	B
)	O
in	O
this	O
strain	O
did	O
not	O
modify	O
the	O
expression	O
of	O
the	O
reporter	O
gene	O
.	O
Tax	B
alone	O
was	O
also	O
inactive	O
.	O
However	O
,	O
expression	O
of	O
the	O
reporter	O
gene	O
was	O
induced	O
by	O
coexpression	O
of	O
Tax	B
and	O
CREB	B
.	O
This	O
effect	O
was	O
stronger	O
with	O
the	O
GAD	B
-	I
CREB	I
fusion	I
protein	I
.	O
Analysis	O
of	O
different	O
CREB	B
mutants	I
with	O
this	O
genetic	O
system	O
indicated	O
that	O
the	O
C	B
-	I
terminal	I
92	I
amino	I
acid	I
residues	I
,	O
which	O
include	O
the	O
basic	B
domain	I
and	O
the	O
leucine	B
zipper	I
,	O
are	O
necessary	O
and	O
sufficient	O
to	O
mediate	O
transactivation	O
by	O
Tax	B
.	O
To	O
identify	O
cellular	B
proteins	I
binding	O
to	O
TRE-1	O
in	O
a	O
Tax	B
-dependent	O
manner	O
,	O
this	O
strain	O
was	O
also	O
used	O
to	O
screen	O
a	O
library	O
of	O
human	O
cDNAs	O
fused	O
to	O
GAD	B
.	O
Of	O
five	O
positive	O
clones	O
isolated	O
from	O
0.75	O
x	O
10	O
(	O
6	O
)	O
yeast	O
colonies	O
,	O
four	O
were	O
members	O
of	O
the	O
CREB	B
/	I
activating	I
transcription	I
factor	I
(	I
ATF	I
)	I
family	I
:	O
CREB	B
,	O
two	B
isoforms	I
of	I
the	I
cyclic	I
AMP	I
-	I
responsive	I
element	I
modulator	I
(	O
CREM	B
)	O
,	O
and	O
ATF-1	B
.	O
Interestingly	O
,	O
these	O
three	O
proteins	O
can	O
be	O
phosphorylated	O
by	O
protein	B
kinase	I
A	I
and	O
thus	O
form	O
a	O
particular	O
subgroup	O
within	O
the	O
CREB	B
/	I
ATF	I
family	I
.	O
Expression	O
of	O
ATF-2	B
in	O
S.	O
cerevisiae	O
did	O
not	O
activate	O
TRE-1	O
in	O
the	O
presence	O
of	O
Tax	B
.	O
This	O
shows	O
that	O
in	O
a	O
eukaryotic	O
nucleus	O
,	O
Tax	B
specifically	O
interacts	O
with	O
the	O
basic	B
domain	I
-	I
leucine	I
zipper	I
region	I
of	O
ATF-1	B
,	O
CREB	B
,	O
and	O
CREM	B
.	O
The	O
fifth	O
clone	O
identified	O
in	O
this	O
screening	O
corresponded	O
to	O
the	O
Ku	B
autoantigen	I
p70	I
subunit	I
.	O
When	O
fused	O
to	O
GAD	B
,	O
the	O
C	B
-	I
terminal	I
region	I
of	O
Ku	B
was	O
able	O
to	O
activate	O
transcription	O
via	O
TRE-1	O
but	O
this	O
activation	O
was	O
not	O
dependent	O
on	O
Tax	B
.	O
Role	O
of	O
EGR1	B
in	O
regulation	O
of	O
stimulus	O
-	O
dependent	O
CD44	B
transcription	O
in	O
B	O
lymphocytes	O
.	O
The	O
immediate	O
-	O
early	O
gene	O
egr-1	O
encodes	O
a	O
transcription	B
factor	I
(	O
EGR1	B
)	O
that	O
links	O
B	B
-	I
cell	I
antigen	I
receptor	I
(	O
BCR	B
)	O
signals	O
to	O
downstream	O
activation	O
events	O
through	O
the	O
regulation	O
of	O
previously	O
unidentified	O
target	O
genes	O
.	O
Here	O
we	O
identify	O
the	O
gene	O
encoding	O
the	O
lymphocyte	B
homing	I
and	I
migration	I
protein	I
CD44	B
as	O
a	O
target	O
of	O
EGR1	B
regulation	O
in	O
B	O
cells	O
.	O
BCR	B
-induced	O
increases	O
in	O
CD44	O
mRNA	O
expression	O
and	O
transcription	O
levels	O
are	O
shown	O
to	O
occur	O
in	O
EGR1-expressing	O
but	O
not	O
in	O
nonexpressing	O
subclones	O
of	O
the	O
B	O
-	O
cell	O
line	O
WEHI-231	O
.	O
Kinetics	O
of	O
egr-1	O
transcription	O
and	O
the	O
appearance	O
of	O
nuclear	O
EGR1	B
protein	I
precede	O
CD44	B
induction	O
and	O
occur	O
within	O
30	O
min	O
after	O
stimulation	O
in	O
the	O
EGR1-expressing	O
subclone	O
.	O
A	O
single	O
EGR1	B
binding	O
motif	O
is	O
demonstrated	O
at	O
bp	O
-301	O
of	O
the	O
human	O
CD44	O
promoter	O
.	O
Cotransfection	O
of	O
a	O
CD44	O
promoter	O
-	O
chloramphenicol	O
acetyltransferase	O
reporter	O
construct	O
with	O
an	O
egr-1	O
expression	O
vector	O
resulted	O
in	O
a	O
6.5-	O
to	O
8.5-fold	O
induction	O
of	O
transcriptional	O
activity	O
relative	O
to	O
an	O
empty	O
expression	O
vector	O
.	O
The	O
EGR1	O
binding	O
motif	O
was	O
shown	O
to	O
be	O
necessary	O
for	O
stimulus	O
-	O
induced	O
expression	O
of	O
a	O
CD44	B
promoter	O
-	O
chloramphenicol	O
acetyltransferase	O
reporter	O
construct	O
in	O
nontransformed	O
B	O
lymphocytes	O
and	O
was	O
required	O
for	O
transactivation	O
by	O
an	O
EGR1	O
expression	O
vector	O
in	O
a	O
B	O
-	O
cell	O
line	O
.	O
These	O
studies	O
identify	O
EGR1	B
as	O
an	O
intermediary	O
linking	O
BCR	B
-derived	O
signals	O
to	O
the	O
induction	O
of	O
CD44	B
.	O
The	O
relevance	O
of	O
these	O
molecular	O
events	O
to	O
BCR	B
signal	O
transduction	O
and	O
antigen	O
-	O
stimulated	O
B	O
-	O
cell	O
-	O
mediated	O
immune	O
responses	O
is	O
discussed	O
.	O
Identification	O
of	O
an	O
inducible	B
regulator	I
of	O
c	O
-	O
myb	O
expression	O
during	O
T	O
-	O
cell	O
activation	O
.	O
Resting	O
T	O
cells	O
express	O
very	O
low	O
levels	O
of	O
c	B
-	I
Myb	I
protein	I
.	O
During	O
T	O
-	O
cell	O
activation	O
,	O
c	O
-	O
myb	O
expression	O
is	O
induced	O
and	O
much	O
of	O
the	O
increase	O
in	O
expression	O
occurs	O
at	O
the	O
transcriptional	O
level	O
.	O
We	O
identified	O
a	O
region	O
of	O
the	O
c	O
-	O
myb	O
5	O
'	O
flanking	O
sequence	O
that	O
increased	O
c	O
-	O
myb	O
expression	O
during	O
T	O
-	O
cell	O
activation	O
.	O
In	O
vivo	O
footprinting	O
by	O
ligation	O
-	O
mediated	O
PCR	O
was	O
performed	O
to	O
correlate	O
in	O
vivo	O
protein	O
binding	O
with	O
functional	O
activity	O
.	O
A	O
protein	O
footprint	O
was	O
visible	O
over	O
this	O
region	O
of	O
the	O
c	O
-	O
myb	O
5	O
'	O
flanking	O
sequence	O
in	O
activated	O
T	O
cells	O
but	O
not	O
in	O
unactivated	O
T	O
cells	O
.	O
An	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
with	O
nuclear	O
extract	O
from	O
activated	O
T	O
cells	O
and	O
an	O
oligonucleotide	O
of	O
this	O
binding	O
site	O
demonstrated	O
a	O
new	O
protein	B
-	I
DNA	I
complex	I
,	O
referred	O
to	O
as	O
CMAT	B
for	O
c	B
-	I
myb	I
in	I
activated	I
T	I
cells	I
;	O
this	O
complex	O
was	O
not	O
present	O
in	O
unactivated	O
T	O
cells	O
.	O
Because	O
the	O
binding	O
site	O
showed	O
some	O
sequence	O
similarity	O
with	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
binding	O
site	O
,	O
we	O
compared	O
the	O
kinetics	O
of	O
induction	O
of	O
the	O
two	O
binding	O
complexes	O
and	O
the	O
molecular	O
masses	O
of	O
the	O
two	O
proteins	O
.	O
Studies	O
of	O
the	O
kinetics	O
of	O
induction	O
showed	O
that	O
the	O
NFAT	B
EMSA	I
binding	I
complex	I
appeared	O
earlier	O
than	O
the	O
CMAT	B
complex	I
.	O
The	O
NFAT	B
protein	O
migrated	O
more	O
slowly	O
in	O
a	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
than	O
the	O
CMAT	B
protein	I
did	O
.	O
In	O
addition	O
,	O
an	O
antibody	O
against	O
NFAT	B
did	O
not	O
cross	O
-	O
react	O
with	O
the	O
CMAT	B
protein	I
.	O
The	O
appearance	O
of	O
the	O
CMAT	B
binding	I
complex	I
was	O
inhibited	O
by	O
both	O
cyclosporin	O
A	O
and	O
rapamycin	O
.	O
The	O
CMAT	B
protein	O
appears	O
to	O
be	O
a	O
novel	O
inducible	O
protein	O
involved	O
in	O
the	O
regulation	O
of	O
c	O
-	O
myb	O
expression	O
during	O
T	O
-	O
cell	O
activation	O
.	O
Identification	O
of	O
a	O
herpesvirus	O
Saimiri	O
cis	O
-	O
acting	O
DNA	O
fragment	O
that	O
permits	O
stable	O
replication	O
of	O
episomes	O
in	O
transformed	O
T	O
cells	O
.	O
Herpesvirus	O
saimiri	O
is	O
a	O
lymphotropic	O
herpesvirus	O
capable	O
of	O
immortalizing	O
and	O
transforming	O
T	O
cells	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Immortalized	O
and	O
transformed	O
T	O
cells	O
harbor	O
several	O
copies	O
of	O
the	O
viral	O
genome	O
as	O
a	O
persisting	O
genome	O
.	O
The	O
mapping	O
of	O
the	O
cis	O
-	O
acting	O
genetic	O
cis	O
-	O
acting	O
segment	O
(	O
oriP	O
)	O
required	O
for	O
viral	O
episomal	O
maintenance	O
is	O
reported	O
here	O
.	O
Viral	O
DNA	O
fragments	O
that	O
potentially	O
contain	O
oriP	O
were	O
cloned	O
into	O
a	O
plasmid	O
that	O
contains	O
the	O
hygromycin	O
resistance	O
gene	O
.	O
After	O
several	O
round	O
of	O
subcloning	O
followed	O
by	O
transfection	O
,	O
oriP	O
was	O
mapped	O
to	O
a	O
1.955-kb	O
viral	O
segment	O
.	O
This	O
viral	O
fragment	O
permits	O
stable	O
plasmid	O
replication	O
without	O
deletion	O
or	O
rearrangement	O
as	O
well	O
as	O
episomal	O
maintenance	O
without	O
integration	O
or	O
recombination	O
.	O
The	O
function	O
of	O
oriP	O
depends	O
on	O
a	O
trans	B
-	I
acting	I
factor	I
(	O
s	O
)	O
encoded	O
by	O
the	O
viral	O
genome	O
.	O
The	O
1.955-kb	O
viral	O
segment	O
includes	O
a	O
dyad	O
symmetry	O
region	O
located	O
between	O
two	O
small	O
nuclear	O
RNA	O
genes	O
and	O
is	O
located	O
upstream	O
of	O
the	O
dihydrofolate	O
reductase	O
gene	O
homolog	O
.	O
Therefore	O
,	O
this	O
oriP	O
contains	O
novel	O
elements	O
distinct	O
from	O
those	O
of	O
other	O
DNA	O
viruses	O
.	O
Regulation	O
of	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
in	O
stably	O
transfected	O
Jurkat	O
cell	O
clones	O
.	O
Two	O
Jurkat	O
cell	O
clones	O
have	O
been	O
stably	O
transfected	O
with	O
a	O
reporter	O
vector	O
for	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT	B
)	O
.	O
Upon	O
stimulation	O
,	O
they	O
express	O
high	O
levels	O
of	O
secreted	O
heat	O
stable	O
placental	B
alkaline	I
phosphatase	I
.	O
With	O
these	O
clones	O
,	O
we	O
demonstrated	O
that	O
NFAT	B
activation	O
induced	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
ionomycin	O
was	O
inhibited	O
by	O
both	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
(	O
IC50	O
=	O
8	O
nM	O
)	O
and	O
FK506	O
(	O
IC50	O
=	O
160	O
pM	O
)	O
,	O
presumably	O
by	O
inhibition	O
of	O
calcineurin	B
activity	O
.	O
Selective	O
phosphatase	O
inhibitors	O
for	O
protein	B
phosphatase	I
1	I
(	O
PP1	B
)	O
and	O
2A	B
(	O
PP2A	B
)	O
that	O
do	O
not	O
inhibit	O
calcineurin	B
,	O
such	O
as	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
,	O
also	O
inhibited	O
NFAT	B
activation	O
with	O
IC50s	O
of	O
87	O
nM	O
and	O
4	O
nM	O
,	O
respectively	O
,	O
suggesting	O
that	O
okadaic	O
acid	O
and	O
related	O
inhibitors	O
may	O
block	O
NFAT	B
activation	O
through	O
the	O
inhibition	O
of	O
PP1	B
,	O
instead	O
of	O
PP2A	B
.	O
NFAT	B
activation	O
was	O
also	O
inhibited	O
by	O
agents	O
that	O
increase	O
cAMP	O
concentrations	O
such	O
as	O
dibutyryl	O
cAMP	O
,	O
forskolin	O
and	O
prostaglandin	O
E2	O
.	O
These	O
stable	O
Jurkat	O
cell	O
clones	O
provide	O
a	O
convenient	O
and	O
sensitive	O
tool	O
to	O
study	O
NFAT	B
regulation	O
.	O
Menopause	O
is	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
blood	O
monocyte	O
number	O
and	O
a	O
relative	O
decrease	O
in	O
the	O
expression	O
of	O
estrogen	B
receptors	I
in	O
human	O
peripheral	O
monocytes	O
.	O
PROBLEM	O
:	O
The	O
clinical	O
significance	O
of	O
the	O
differential	O
expression	O
of	O
estrogen	B
receptor	I
(	O
ER	B
)	O
in	O
human	O
monocytes	O
was	O
evaluated	O
.	O
METHOD	O
:	O
Two	O
color	O
flow	O
cytometry	O
analysis	O
was	O
used	O
on	O
peripheral	O
blood	O
samples	O
of	O
young	O
and	O
postmenopausal	O
females	O
and	O
postmenopausal	O
females	O
treated	O
with	O
estrogen	O
replacement	O
therapy	O
.	O
In	O
addition	O
,	O
the	O
monocyte	O
and	O
lymphocyte	O
counts	O
and	O
the	O
blood	O
estrogen	O
levels	O
of	O
each	O
patient	O
were	O
determine	O
.	O
RESULTS	O
:	O
During	O
menopause	O
there	O
is	O
a	O
significant	O
decrease	O
in	O
the	O
percentage	O
of	O
ER	O
positive	O
monocytes	O
,	O
and	O
an	O
increase	O
in	O
blood	O
monocyte	O
number	O
,	O
which	O
declines	O
following	O
estrogen	O
replacement	O
therapy	O
to	O
values	O
of	O
the	O
young	O
.	O
CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
estrogen	O
modulates	O
the	O
monocyte	O
numbers	O
and	O
its	O
effects	O
may	O
be	O
mediated	O
through	O
the	O
ER	B
in	O
the	O
monocytes	O
.	O
Modulation	O
of	O
endogenous	O
IL-1	B
beta	I
and	O
IL-1	B
receptor	I
antagonist	O
results	O
in	O
opposing	O
effects	O
on	O
HIV	O
expression	O
in	O
chronically	O
infected	O
monocytic	O
cells	O
.	O
A	O
proportion	O
of	O
HIV	O
-	O
infected	O
individuals	O
experience	O
episodes	O
of	O
localized	O
or	O
systemic	O
bacterial	O
infections	O
caused	O
by	O
Gram	O
-	O
negative	O
bacteria	O
.	O
Many	O
of	O
the	O
clinical	O
side	O
effects	O
of	O
these	O
infections	O
are	O
associated	O
with	O
the	O
production	O
of	O
proinflammatory	B
cytokines	I
,	O
which	O
are	O
induced	O
primarily	O
by	O
LPS	O
,	O
a	O
constituent	O
of	O
the	O
bacterial	O
cell	O
wall	O
of	O
Gram	O
-	O
negative	O
bacteria	O
.	O
The	O
present	O
study	O
examines	O
the	O
mechanisms	O
involved	O
in	O
LPS	O
-	O
mediated	O
induction	O
of	O
HIV	O
expression	O
in	O
U1	O
cells	O
,	O
a	O
promonocytic	O
cell	O
line	O
chronically	O
infected	O
with	O
HIV	O
.	O
Stimulation	O
of	O
U1	O
cells	O
by	O
LPS	O
alone	O
induced	O
minimal	O
levels	O
of	O
HIV	O
expression	O
,	O
which	O
was	O
significantly	O
enhanced	O
by	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
.	O
Costimulation	O
of	O
U1	O
cells	O
with	O
LPS	O
plus	O
GM	B
-	I
CSF	I
resulted	O
in	O
the	O
accumulation	O
of	O
steady	O
-	O
state	O
levels	O
of	O
HIV	O
RNA	O
;	O
however	O
,	O
only	O
a	O
weak	O
induction	O
of	O
HIV	O
long	O
terminal	O
repeat	O
-driven	O
transcription	O
,	O
which	O
was	O
not	O
associated	O
with	O
the	O
activation	O
of	O
the	O
cellular	B
transcription	I
factor	I
nuclear	B
factor	I
-	I
kappa	I
B	I
,	O
was	O
noted	O
.	O
Costimulation	O
of	O
cells	O
with	O
LPS	O
plus	O
GM	B
-	I
CSF	I
induced	O
the	O
production	O
of	O
proinflammatory	B
cytokines	I
,	O
IL-8	B
,	O
IL-1	B
beta	I
and	O
IL-6	B
,	O
but	O
not	O
TNF	B
-	I
alpha	I
.	O
IL-1	B
receptor	I
antagonist	O
(	O
ra	O
)	O
inhibited	O
LPS	O
enhancement	O
of	O
HIV	O
expression	O
in	O
GM	O
-	O
CSF	O
-	O
stimulated	O
cells	O
,	O
suggesting	O
that	O
endogenous	B
IL-1	I
was	O
involved	O
in	O
LPS	O
-	O
mediated	O
viral	O
production	O
.	O
In	O
this	O
regard	O
,	O
anti	B
-	I
inflammatory	I
cytokines	I
inhibited	O
LPS	O
plus	O
GM	B
-	I
CSF	I
-stimulated	O
HIV	O
expression	O
,	O
and	O
this	O
effect	O
closely	O
correlated	O
with	O
inhibition	O
of	O
IL-1	B
beta	I
release	O
and	O
,	O
in	O
particular	O
,	O
with	O
up	O
-	O
regulation	O
of	O
endogenous	O
IL-1ra	O
production	O
.	O
Thus	O
,	O
the	O
balance	O
between	O
an	O
endogenously	B
produced	I
viral	I
inducer	I
(	O
IL-1	B
beta	I
)	O
and	O
an	O
inhibitor	O
(	O
IL-1ra	B
)	O
may	O
represent	O
an	O
important	O
pathway	O
leading	O
to	O
modulation	O
of	O
HIV	O
expression	O
from	O
monocytic	O
cells	O
.	O
Monocytic	O
cell	O
type	O
-	O
specific	O
transcriptional	O
induction	O
of	O
collagenase	B
.	O
Interstitial	O
collagenase	B
(	O
MMP-1	B
)	O
,	O
a	O
metalloproteinase	B
produced	O
by	O
resident	O
and	O
inflammatory	O
cells	O
during	O
connective	O
tissue	O
turnover	O
,	O
cleaves	O
type	B
I	I
collagen	I
fibrils	I
.	O
This	O
catalytic	O
event	O
is	O
rate	O
limiting	O
in	O
remodeling	O
of	O
tissues	O
rich	O
in	O
fibrillar	B
collagen	I
such	O
as	O
the	O
skin	O
and	O
lungs	O
.	O
The	O
regulation	O
of	O
collagenase	B
expression	O
is	O
cell	O
-	O
type	O
specific	O
;	O
bacterial	O
LPS	O
and	O
zymosan	O
,	O
a	O
yeast	O
cell	O
wall	O
derivative	O
,	O
are	O
potent	O
inducers	O
of	O
collagenase	B
expression	O
in	O
macrophages	O
,	O
but	O
do	O
not	O
alter	O
fibroblast	O
collagenase	B
expression	O
.	O
Since	O
promoter	O
elements	O
controlling	O
collagenase	B
transcription	O
in	O
monocytic	O
cells	O
have	O
not	O
been	O
previously	O
defined	O
,	O
we	O
sought	O
to	O
delineate	O
responsive	O
cis	O
-	O
acting	O
elements	O
of	O
the	O
collagenase	O
promoter	O
in	O
transiently	O
transfected	O
human	O
(	O
U937	O
)	O
and	O
murine	O
(	O
J774	O
)	O
monocytic	O
cell	O
lines	O
.	O
Deletion	O
constructs	O
containing	O
as	O
little	O
as	O
72	O
bp	O
of	O
5	O
'	O
-flanking	O
sequence	O
of	O
the	O
collagenase	O
promoter	O
were	O
sufficient	O
for	O
LPS-	O
or	O
zymosan	O
-	O
mediated	O
transcriptional	O
induction	O
,	O
whereas	O
phorbol	O
inducibility	O
exhibited	O
an	O
absolute	O
requirement	O
for	O
upstream	O
elements	O
including	O
the	O
polyoma	O
enhancer	O
A	O
-	O
binding	O
protein-3	O
site	O
(	O
-83	O
to	O
-91	O
)	O
and	O
TTCA	O
sequence	O
(	O
-102	O
to	O
-105	O
)	O
in	O
both	O
monocytic	O
cells	O
and	O
fibroblasts	O
.	O
Mutagenesis	O
of	O
the	O
activator	O
protein-1	O
[	O
AP-1	O
]	O
site	O
at	O
-72	O
abolished	O
basal	O
promoter	O
activity	O
and	O
LPS	O
/	O
zymosan	O
inducibility	O
,	O
while	O
mutagenesis	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
like	O
site	O
at	O
-20	O
to	O
-10	O
had	O
no	O
effect	O
.	O
Nuclear	O
extracts	O
from	O
LPS	O
-and	O
zymosan	O
-	O
treated	O
cells	O
showed	O
strong	O
AP-1	B
activity	O
by	O
gel	O
-	O
shift	O
analysis	O
,	O
and	O
supershift	O
analysis	O
showed	O
the	O
AP-1	B
complexes	I
contained	O
specific	O
members	O
of	O
both	O
the	O
jun	O
and	O
fos	O
gene	O
families	O
.	O
These	O
data	O
indicate	O
that	O
,	O
in	O
contrast	O
to	O
most	O
LPS	O
effects	O
,	O
AP-1	B
,	O
but	O
not	O
nuclear	B
factor	I
-	I
kappaB	I
,	O
mediates	O
LPS	O
induction	O
of	O
collagenase	B
transcription	O
in	O
macrophagelike	O
cells	O
.	O
Furthermore	O
,	O
as	O
compared	O
to	O
regulation	O
by	O
phorbol	O
ester	O
,	O
collagenase	B
induction	O
in	O
monocytic	O
cells	O
by	O
cell	O
wall	O
derivatives	O
of	O
bacteria	O
or	O
yeast	O
is	O
largely	O
independent	O
of	O
upstream	O
promoter	O
sequences	O
.	O
Rel	O
-	O
deficient	O
T	O
cells	O
exhibit	O
defects	O
in	O
production	O
of	O
interleukin	B
3	I
and	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
.	O
The	O
c	O
-	O
rel	O
protooncogene	O
encodes	O
a	O
subunit	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
-	I
like	I
family	I
of	I
transcription	I
factors	I
.	O
Mice	O
lacking	O
Rel	B
are	O
defective	O
in	O
mitogenic	O
activation	O
of	O
B	O
and	O
T	O
lymphocytes	O
and	O
display	O
impaired	O
humoral	O
immunity	O
.	O
In	O
an	O
attempt	O
to	O
identify	O
changes	O
in	O
gene	O
expression	O
that	O
accompany	O
the	O
T	O
-	O
cell	O
stimulation	O
defects	O
associated	O
with	O
the	O
loss	O
of	O
Rel	B
,	O
we	O
have	O
examined	O
the	O
expression	O
of	O
cell	B
surface	I
activation	I
markers	I
and	O
cytokine	O
production	O
in	O
mitogen	O
-	O
stimulated	O
Rel-	O
/	O
-	O
T	O
cells	O
.	O
The	O
expression	O
of	O
cell	O
surface	O
markers	O
including	O
the	O
interleukin	B
2	I
receptor	I
alpha	I
(	I
IL-2R	I
alpha	I
)	I
chain	I
(	O
CD25	B
)	O
,	O
CD69	B
and	O
L	B
-	I
selectin	I
(	O
CD62	B
)	O
is	O
normal	O
in	O
mitogen	O
-	O
activated	O
Rel-	O
/	O
-	O
T	O
cells	O
,	O
but	O
cytokine	B
production	O
is	O
impaired	O
.	O
In	O
Rel-	O
/	O
-	O
splenic	O
T	O
cell	O
cultures	O
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
ionomycin	O
,	O
the	O
levels	O
of	O
IL-3	O
,	O
IL-5	O
,	O
granulocyte-	B
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
,	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
,	O
and	O
gamma	B
interferon	I
(	O
IFN	B
-	I
gamma	I
)	O
were	O
only	O
2-	O
to	O
3-fold	O
lower	O
compared	O
with	O
normal	O
T	O
cells	O
.	O
In	O
contrast	O
,	O
anti	B
-	I
CD3	I
and	O
anti	B
-	I
CD28	I
stimulated	O
Rel-	O
/	O
-	O
T	O
cells	O
,	O
which	O
fail	O
to	O
proliferate	O
,	O
make	O
little	O
or	O
no	O
detectable	O
cytokines	B
.	O
Exogenous	O
IL-2	B
,	O
which	O
restitutes	O
the	O
proliferative	O
response	O
of	O
the	O
anti	O
-	O
CD3-	O
and	O
anti	O
-	O
CD28-treated	O
Rel-	O
/	O
-	O
T	O
cells	O
,	O
restores	O
production	O
of	O
IL-5	O
,	O
TNF	B
-	I
alpha	I
,	O
and	O
IFN	B
-	I
gamma	I
,	O
but	O
not	O
IL-3	B
and	O
GM	B
-	I
CSF	I
expression	O
to	O
approximately	O
normal	O
levels	O
.	O
In	O
contrast	O
to	O
mitogen	O
-	O
activated	O
Rel-	O
/	O
-	O
T	O
cells	O
,	O
lipopolysaccharide	O
-	O
stimulated	O
Rel-	O
/	O
-	O
macrophages	O
produce	O
higher	O
than	O
normal	O
levels	O
of	O
GM	B
-	I
CSF	I
.	O
These	O
findings	O
establish	O
that	O
Rel	B
can	O
function	O
as	O
an	O
activator	O
or	O
repressor	O
of	O
gene	O
expression	O
and	O
is	O
required	O
by	O
T	O
lymphocytes	O
for	O
production	O
of	O
IL-3	B
and	O
GM	B
-	I
CSF	I
.	O
Interferon	B
-	I
gamma	I
modulates	O
the	O
lipopolysaccharide	O
-	O
induced	O
expression	O
of	O
AP-1	B
and	O
NF	B
-	I
kappa	I
B	I
at	O
the	O
mRNA	O
and	O
protein	O
level	O
in	O
human	O
monocytes	O
.	O
Interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
modulates	O
the	O
expression	O
of	O
several	O
cytokines	B
by	O
human	O
monocytes	O
at	O
the	O
transcriptional	O
level	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
IFN	B
-	I
gamma	I
on	O
the	O
expression	O
of	O
different	O
transcription	B
factors	I
in	O
activated	O
human	O
monocytes	O
.	O
Priming	O
of	O
human	O
monocytes	O
with	O
IFN	B
-	I
gamma	I
resulted	O
in	O
the	O
down	O
regulation	O
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
in	O
response	O
to	O
stimulation	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
compared	O
to	O
the	O
effects	O
of	O
LPS	O
alone	O
.	O
Not	O
only	O
was	O
this	O
effect	O
observed	O
at	O
the	O
mRNA	O
level	O
,	O
but	O
activator	B
protein-1	I
(	O
AP-1	B
)	O
DNA	O
binding	O
capacity	O
was	O
affected	O
as	O
well	O
,	O
A	O
strong	O
reduction	O
was	O
observed	O
in	O
the	O
LPS	O
-	O
induced	O
DNA	O
-	O
binding	O
activity	O
of	O
AP-1	B
in	O
the	O
presence	O
of	O
IFN	B
-	I
gamma	I
.	O
LPS	O
-	O
stimulated	O
monocytes	O
showed	O
an	O
increased	O
expression	O
of	O
p105	O
mRNA	O
,	O
the	O
precursor	O
of	O
the	O
p50	B
subunit	I
of	O
the	O
transcription	B
factor	I
nuclear	I
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
,	O
while	O
no	O
effect	O
was	O
noticed	O
on	O
the	O
expression	O
of	O
p65	O
mRNA	O
.	O
In	O
contrast	O
,	O
IFN	B
-	I
gamma	I
priming	O
did	O
not	O
affect	O
the	O
expression	O
of	O
p105	O
transcripts	O
but	O
enhanced	O
the	O
expression	O
of	O
p65	O
mRNA	O
(	O
two	O
-	O
fold	O
)	O
.	O
Priming	O
with	O
IFN	B
-	I
gamma	I
followed	O
by	O
LPS	O
stimulation	O
resulted	O
in	O
a	O
further	O
increase	O
in	O
the	O
expression	O
of	O
p65	O
mRNA	O
.	O
This	O
was	O
due	O
to	O
an	O
increase	O
in	O
the	O
half	O
-	O
life	O
of	O
p65	O
mRNA	O
(	O
75	O
vs	O
150	O
minutes	O
)	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
demonstrated	O
that	O
unstimulated	O
monocytes	O
predominantly	O
expressed	O
p50	B
NF	B
-	I
kappa	I
B	I
.	O
Stimulation	O
with	O
LPS	O
or	O
IFN	B
-	I
gamma	I
resulted	O
in	O
the	O
expression	O
of	O
p50	B
and	O
p65	B
subunits	I
,	O
while	O
the	O
combination	O
of	O
IFN	B
-	I
gamma	I
plus	O
LPS	O
caused	O
a	O
further	O
increase	O
in	O
the	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
With	O
Western	O
blotting	O
,	O
it	O
was	O
shown	O
that	O
nuclear	O
extracts	O
from	O
monocytes	O
contained	O
p50	B
and	O
p65	B
protein	I
in	O
response	O
to	O
LPS	O
and	O
IFN	B
-	I
gamma	I
stimulation	O
.	O
However	O
,	O
the	O
combined	O
stimulation	O
did	O
not	O
result	O
in	O
enhanced	O
p50	B
and	O
p65	B
protein	I
expression	O
.	O
The	O
effects	O
of	O
IFN	B
-	I
gamma	I
on	O
the	O
transcription	B
factors	I
were	O
specific	O
,	O
since	O
no	O
change	O
was	O
observed	O
in	O
the	O
expression	O
of	O
NF	B
-	I
IL-6	I
or	O
I	B
kappa	I
B	I
alpha	I
,	O
the	O
inhibitor	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
We	O
conclude	O
that	O
the	O
effects	O
of	O
IFN	B
-	I
gamma	I
on	O
the	O
expression	O
of	O
the	O
transcription	B
factors	I
AP-1	B
and	O
NF	B
-	I
kappa	I
B	I
may	O
be	O
important	O
for	O
the	O
modulatory	O
effects	O
of	O
IFN	B
-	I
gamma	I
on	O
the	O
cytokine	B
expression	O
in	O
activated	O
human	O
monocytes	O
.	O
Transcriptional	O
basis	O
for	O
hyporesponsiveness	O
of	O
the	O
human	O
inducible	O
nitric	O
oxide	O
synthase	O
gene	O
to	O
lipopolysaccharide	O
/	O
interferon	O
-	O
gamma	O
.	O
The	O
work	O
reported	O
here	O
resolves	O
,	O
at	O
the	O
level	O
of	O
gene	O
regulation	O
,	O
the	O
controversy	O
as	O
to	O
whether	O
or	O
not	O
human	O
monocytes	O
/	O
macrophages	O
can	O
produce	O
nitric	O
oxide	O
(	O
NO	O
)	O
when	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
with	O
or	O
without	O
co	O
-	O
stimulation	O
by	O
interferon	O
-	O
gamma	O
(	O
IFN	B
-	I
gamma	I
)	O
.	O
Studies	O
included	O
structural	O
comparison	O
of	O
the	O
promoters	O
for	O
human	O
and	O
mouse	O
inducible	O
NO	O
synthase	O
(	O
iNOS	O
)	O
genes	O
,	O
transfection	O
and	O
assay	O
of	O
human	O
and	O
mouse	O
iNOS	O
promoter	O
regions	O
in	O
response	O
to	O
LPS	O
+	O
/-	O
IFN	B
-	I
gamma	I
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
of	O
kappa	O
B	O
response	O
elements	O
.	O
Two	O
explanations	O
for	O
hyporesponsiveness	O
of	O
the	O
human	O
iNOS	O
promoter	O
to	O
LPS	O
+	O
/-	O
IFN	B
-	I
gamma	I
were	O
found	O
:	O
(	O
1	O
)	O
multiple	O
inactivating	O
nucleotide	O
substitutions	O
in	O
the	O
human	O
counterpart	O
of	O
the	O
enhancer	O
element	O
that	O
has	O
been	O
shown	O
to	O
regulate	O
LPS	O
/	O
IFN	B
-	I
gamma	I
induced	O
expression	O
of	O
the	O
mouse	O
iNOS	O
gene	O
;	O
and	O
(	O
2	O
)	O
and	O
absence	O
of	O
one	O
or	O
more	O
nuclear	B
factors	I
in	O
human	O
macrophages	O
(	O
e.g.	O
,	O
an	O
LPS	B
-	I
inducible	I
nuclear	I
factor	I
-	I
kappa	I
B	I
/	I
Rel	I
complex	I
)	O
,	O
that	O
is	O
(	O
are	O
)	O
required	O
for	O
maximal	O
expression	O
of	O
the	O
gene	O
.	O
The	O
importance	O
of	O
resolution	O
of	O
this	O
controversy	O
is	O
that	O
future	O
research	O
in	O
this	O
area	O
should	O
be	O
directed	O
toward	O
the	O
understanding	O
of	O
alternative	O
mechanisms	O
that	O
can	O
result	O
in	O
the	O
successful	O
production	O
of	O
NO	O
.	O
STAT	O
-	O
related	O
transcription	B
factors	I
are	O
constitutively	O
activated	O
in	O
peripheral	O
blood	O
cells	O
from	O
acute	O
leukemia	O
patients	O
.	O
A	O
signal	O
transduction	O
pathway	O
activated	O
by	O
many	O
cytokines	B
has	O
recently	O
been	O
elaborated	O
.	O
The	O
JAK	B
kinases	I
and	O
the	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	I
STAT	I
)	I
factors	I
have	O
been	O
found	O
to	O
be	O
essential	O
components	O
.	O
In	O
this	O
report	O
,	O
we	O
describe	O
the	O
presence	O
of	O
constitutively	O
activated	O
STAT	B
factors	I
in	O
peripheral	O
blood	O
cells	O
from	O
patients	O
with	O
acute	O
leukemia	O
.	O
We	O
used	O
oligonucleotide	O
probes	O
from	O
the	O
beta	O
-	O
casein	O
and	O
IRF-1	O
gene	O
promoters	O
and	O
the	O
ISRE	O
probe	O
to	O
detect	O
STAT	B
proteins	I
in	O
nuclear	O
extracts	O
from	O
acute	O
leukemia	O
cells	O
in	O
bandshift	O
assays	O
.	O
Specific	O
DNA	O
protein	B
complex	I
formation	O
was	O
observed	O
with	O
the	O
probes	O
from	O
the	O
beta	O
-	O
casein	O
and	O
IRF-1	O
gene	O
promoters	O
,	O
but	O
not	O
with	O
the	O
ISRE	O
oligonucleotide	O
probe	O
,	O
when	O
cell	O
extracts	O
from	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
and	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
were	O
investigated	O
.	O
We	O
used	O
nonradioactive	O
oligonucleotides	O
as	O
competitors	O
to	O
show	O
the	O
specificity	O
of	O
the	O
complex	O
formation	O
.	O
Specific	O
antibodies	B
directed	O
against	O
the	O
individual	O
STAT	B
proteins	I
were	O
used	O
in	O
supershift	O
experiments	O
.	O
STAT5-	B
and	I
STAT1-related	I
factors	I
were	O
detected	O
in	O
ALL	O
and	O
STAT1-	B
,	I
STAT3-	I
,	I
and	I
STAT5-related	I
proteins	I
were	O
present	O
in	O
nuclear	O
cell	O
extracts	O
from	O
AML	O
.	O
Since	O
the	O
cells	O
were	O
not	O
treated	O
with	O
cytokines	B
before	O
the	O
nuclear	B
proteins	I
were	O
extracted	O
,	O
we	O
conclude	O
that	O
these	O
factors	O
are	O
constitutively	O
activated	O
in	O
vivo	O
.	O
It	O
is	O
likely	O
that	O
the	O
constitutive	O
activation	O
of	O
STAT	B
proteins	I
is	O
a	O
part	O
of	O
the	O
events	O
of	O
leukemogenesis	O
.	O
The	O
RAR	B
-	I
RXR	I
as	O
well	O
as	O
the	O
RXR	B
-	I
RXR	I
pathway	O
is	O
involved	O
in	O
signaling	O
growth	O
inhibition	O
of	O
human	O
CD34	O
+	O
erythroid	O
progenitor	O
cells	O
.	O
Previous	O
studies	O
have	O
shown	O
that	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
similar	O
to	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
,	O
can	O
act	O
as	O
a	O
bifunctional	O
regulator	O
of	O
the	O
growth	O
of	O
bone	O
marrow	O
progenitors	O
,	O
in	O
that	O
it	O
can	O
stimulate	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
-	O
or	O
interleukin-3	O
(	O
IL-3	O
)	O
-induced	O
GM	O
colony	O
formation	O
,	O
but	O
potently	O
inhibit	O
G	B
-	I
CSF	I
-induced	O
growth	O
.	O
The	O
present	O
study	O
,	O
using	O
highly	O
enriched	O
human	B
CD34	I
+	I
as	O
well	O
as	O
Lin-	O
murine	O
bone	O
marrow	O
progenitor	O
cells	O
,	O
demonstrates	O
a	O
potent	O
inhibitory	O
effect	O
of	O
9-cis	O
-	O
RA	O
on	O
burst	O
-	O
forming	O
unit	O
-	O
erythroid	O
(	O
BFU	O
-	O
E	O
)	O
colony	O
formation	O
regardless	O
of	O
the	O
cytokine	B
stimulating	O
growth	O
.	O
Specifically	O
,	O
9-cis	O
-	O
RA	O
potently	O
inhibited	O
the	O
growth	O
of	O
BFU	O
-	O
E	O
response	O
to	O
erythropoietin	B
(	O
Epo	B
)	O
(	O
100	O
%	O
)	O
,	O
stem	B
cell	I
factor	I
(	O
SCF	B
)	O
+	O
Epo	B
(	O
92	O
%	O
)	O
,	O
IL-3	B
+	O
Epo	B
(	O
97	O
%	O
)	O
,	O
IL-4	B
+	O
Epo	B
(	O
88	O
%	O
)	O
,	O
and	O
IL-9	B
+	O
Epo	B
(	O
100	O
%	O
)	O
.	O
Erythroid	O
colony	O
growth	O
was	O
also	O
inhibited	O
when	O
CD34	O
+	O
progenitors	O
were	O
seeded	O
at	O
one	O
cell	O
per	O
well	O
,	O
suggesting	O
a	O
direct	O
action	O
of	O
RA	O
.	O
Using	O
synthetic	O
ligands	O
to	O
retinoic	B
acid	I
receptors	I
(	O
RARs	B
)	O
and	O
retinoid	B
X	I
receptors	I
(	O
RXRs	B
)	O
that	O
selectively	O
bind	O
and	O
activate	O
RAR	B
-	I
RXR	I
or	O
RXR	B
-	I
RXR	I
dimers	O
,	O
respectively	O
,	O
we	O
dissected	O
the	O
involvement	O
of	O
the	O
two	O
retinoid	O
response	O
pathways	O
in	O
the	O
regulation	O
of	O
normal	O
myeloid	O
and	O
erythroid	O
progenitor	O
cell	O
growth	O
.	O
Transactivation	O
studies	O
showed	O
that	O
both	O
the	O
RAR	B
(	O
Ro	O
13	O
-	O
7410	O
)	O
and	O
RXR	B
(	O
Ro	O
25	O
-	O
6603	O
and	O
Ro	O
25	O
-	O
7386	O
)	O
ligands	O
were	O
highly	O
selective	O
at	O
100	O
nmol	O
/	O
L	O
.	O
At	O
this	O
concentration	O
,	O
Ro	O
13	O
-	O
7410	O
potently	O
inhibited	O
G	B
-	I
CSF	I
-stimulated	O
myeloid	O
as	O
well	O
as	O
SCF	B
+	O
Epo	B
-induced	O
erythroid	O
colony	O
growth	O
.	O
At	O
the	O
same	O
concentration	O
,	O
Ro	O
25	O
-	O
6603	O
and	O
Ro	O
25	O
-	O
7386	O
had	O
little	O
or	O
no	O
effect	O
on	O
G	B
-	I
CSF	I
-induced	O
colony	O
formation	O
,	O
whereas	O
they	O
inhibited	O
75	O
%	O
and	O
53	O
%	O
,	O
respectively	O
,	O
of	O
SCF	B
+	O
Epo	B
-stimulated	O
BFU	O
-	O
E	O
colony	O
growth	O
.	O
Thus	O
,	O
the	O
RAR	B
-	I
RXR	I
response	O
pathway	O
can	O
signal	O
growth	O
inhibition	O
of	O
normal	O
bone	O
marrow	O
myeloid	O
and	O
erythroid	O
progenitor	O
cells	O
.	O
In	O
addition	O
,	O
we	O
demonstrate	O
a	O
unique	O
involvement	O
of	O
the	O
RXR	B
-	I
RXR	I
pathway	O
in	O
mediating	O
growth	O
inhibition	O
of	O
erythroid	O
but	O
not	O
myeloid	O
progenitor	O
cells	O
.	O
Expression	O
of	O
p13MTCP1	B
is	O
restricted	O
to	O
mature	O
T	O
-	O
cell	O
proliferations	O
with	O
t	O
(	O
X	O
;	O
14	O
)	O
translocations	O
.	O
T	O
-	O
cell	O
prolymphocytic	O
leukemia	O
(	O
T	O
-	O
PLL	O
)	O
,	O
a	O
rare	O
form	O
of	O
mature	O
T	O
-	O
cell	O
leukemias	O
,	O
and	O
ataxia	O
telangiectasia	O
clonal	O
proliferation	O
,	O
a	O
related	O
condition	O
occurring	O
in	O
patients	O
suffering	O
from	O
ataxia	O
telangiectasia	O
,	O
have	O
been	O
associated	O
to	O
translocations	O
involving	O
the	O
14q32.1	O
or	O
Xq28	O
regions	O
,	O
where	O
are	O
located	O
the	O
TCL1	O
and	O
MTCP1	O
putative	O
oncogenes	O
,	O
respectively	O
.	O
The	O
MTCP1	O
gene	O
is	O
involved	O
in	O
the	O
t	O
(	O
X	O
;	O
14	O
)	O
(	O
q28	O
;	O
q11	O
)	O
translocation	O
associated	O
with	O
these	O
T	O
-	O
cell	O
proliferations	O
.	O
Alternative	O
splicing	O
generates	O
type	O
A	O
and	O
B	O
transcripts	O
that	O
potentially	O
encode	O
two	O
entirely	O
distinct	O
proteins	O
;	O
type	O
A	O
transcripts	O
code	O
for	O
a	O
small	O
mitochondrial	B
protein	I
,	O
p8MTCP1	B
,	O
and	O
type	O
B	O
transcripts	O
,	O
containing	O
an	O
additional	O
open	O
reading	O
frame	O
,	O
may	O
code	O
for	O
107	B
amino	I
-	I
acid	I
protein	I
,	O
p13MTCP1	B
.	O
The	O
recently	O
cloned	O
TCL1	O
gene	O
,	O
also	O
involved	O
in	O
translocations	O
and	O
inversions	O
associated	O
with	O
T	O
-	O
cell	O
proliferations	O
,	O
codes	O
for	O
a	O
14-kD	B
protein	I
that	O
displays	O
significant	O
homology	O
with	O
p13MTCP1	B
.	O
We	O
have	O
generated	O
rabbit	O
antisera	O
against	O
this	O
putative	O
p13MTCP1	B
protein	I
and	O
screened	O
for	O
expression	O
of	O
p13MTCP1	B
normal	O
lymphoid	O
tissues	O
and	O
33	O
cases	O
of	O
immature	O
and	O
mature	O
lymphoid	O
T	O
-	O
cell	O
proliferations	O
using	O
a	O
sensitive	O
Western	O
blot	O
assay	O
.	O
We	O
also	O
investigated	O
the	O
MTCP1	O
locus	O
configuration	O
by	O
Southern	O
blot	O
analysis	O
.	O
The	O
p13MTCP1	B
protein	I
was	O
detected	O
in	O
the	O
three	O
T	O
-	O
cell	O
proliferations	O
with	O
MTCP1	O
rearrangements	O
because	O
of	O
t	O
(	O
X	O
;	O
14	O
)	O
translocations	O
,	O
but	O
neither	O
in	O
normal	O
resting	O
and	O
activated	O
lymphocytes	O
nor	O
in	O
the	O
other	O
T	O
-	O
cell	O
leukemias	O
.	O
Our	O
data	O
support	O
the	O
hypothesis	O
that	O
p13MTCP1	B
and	O
p14TCL1	B
form	O
a	O
new	O
protein	B
family	I
that	O
plays	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	O
of	O
T	O
-	O
PLL	O
and	O
related	O
conditions	O
.	O
Activation	O
of	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
in	O
a	O
cyclosporin	O
A	O
-	O
resistant	O
pathway	O
.	O
The	O
mechanism	O
of	O
action	O
of	O
the	O
immunosuppressive	O
drug	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
is	O
the	O
inactivation	O
of	O
the	O
Ca2+	B
/	I
calmodulin	I
-	I
dependent	I
serine	I
-	I
threonine	I
phosphatase	I
calcineurin	B
by	O
the	O
drug	B
-	I
immunophilin	I
complex	I
.	O
Inactive	O
calcineurin	B
is	O
unable	O
to	O
activate	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT	B
)	O
,	O
a	O
transcription	B
factor	I
required	O
for	O
expression	O
of	O
the	O
interleukin	O
2	O
(	O
IL-2	O
)	O
gene	O
.	O
IL-2	B
production	O
by	O
CsA	O
-	O
treated	O
cells	O
is	O
therefore	O
dramatically	O
reduced	O
.	O
We	O
demonstrate	O
here	O
,	O
however	O
,	O
that	O
NFAT	B
can	O
be	O
activated	O
,	O
and	O
significant	O
levels	O
of	O
IL-2	B
can	O
be	O
produced	O
by	O
the	O
CsA	O
-	O
resistant	O
CD28	B
-signaling	O
pathway	O
.	O
In	O
transient	O
transfection	O
assays	O
,	O
both	O
multicopy	O
NFAT	B
-and	O
IL-2	O
promoter	O
-	O
beta	O
-	O
galactosidase	O
reporter	O
gene	O
constructs	O
could	O
be	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
/alpha-	O
CD28	B
stimulation	O
,	O
and	O
this	O
activation	O
was	O
resistant	O
to	O
CsA	O
.	O
Electrophoretic	O
mobility	O
shift	O
assay	O
showed	O
the	O
induction	O
of	O
a	O
CsA	B
-	I
resistant	I
NFAT	I
complex	I
in	O
the	O
nuclear	O
extracts	O
of	O
peripheral	O
blood	O
T	O
cells	O
stimulated	O
with	O
PMA	O
plus	O
alphaCD28	B
.	O
Peripheral	O
blood	O
T	O
cells	O
stimulated	O
with	O
PMA	O
/alphaCD28	B
produced	O
IL-2	B
in	O
the	O
presence	O
of	O
CsA	O
.	O
Collectively	O
,	O
these	O
data	O
suggest	O
that	O
NFAT	B
can	O
be	O
activated	O
and	O
IL-2	B
can	O
be	O
produced	O
in	O
a	O
calcineurin	B
independent	O
manner	O
.	O
Structural	O
and	O
functional	O
characterization	O
of	O
the	O
human	O
CD36	O
gene	O
promoter	O
:	O
identification	O
of	O
a	O
proximal	O
PEBP2	O
/	O
CBF	O
site	O
.	O
CD36	B
is	O
a	O
cell	O
surface	O
glycoprotein	B
composed	O
of	O
a	O
single	O
polypeptide	O
chain	O
,	O
which	O
interacts	O
with	O
thrombospondin	B
,	O
collagens	B
type	I
I	I
and	I
IV	I
,	O
oxidized	O
low	B
density	I
lipoprotein	I
,	O
fatty	O
acids	O
,	O
anionic	O
phospholipids	O
,	O
and	O
erythrocytes	O
parasitized	O
with	O
Plasmodium	O
falciparum	O
.	O
Its	O
expression	O
is	O
restricted	O
to	O
a	O
few	O
cell	O
types	O
,	O
including	O
monocyte	O
/	O
macrophages	O
.	O
In	O
these	O
cells	O
,	O
CD36	B
is	O
involved	O
in	O
phagocytosis	O
of	O
apoptotic	O
cells	O
,	O
and	O
foam	O
cell	O
formation	O
by	O
uptake	O
of	O
oxidized	B
low	I
density	I
lipoprotein	I
.	O
To	O
study	O
the	O
molecular	O
mechanisms	O
that	O
control	O
the	O
transcription	O
of	O
the	O
CD36	B
gene	O
in	O
monocytic	O
cells	O
we	O
have	O
isolated	O
and	O
analyzed	O
the	O
CD36	O
promoter	O
.	O
Transient	O
expression	O
experiments	O
of	O
5'-deletion	O
fragments	O
of	O
the	O
CD36	O
promoter	O
coupled	O
to	O
luciferase	B
demonstrated	O
that	O
as	O
few	O
as	O
158	O
base	O
pairs	O
upstream	O
from	O
the	O
transcription	O
initiation	O
site	O
were	O
sufficient	O
to	O
direct	O
the	O
monocyte	O
-	O
specific	O
transcription	O
of	O
the	O
reporter	O
gene	O
.	O
Within	O
the	O
above	O
region	O
,	O
the	O
fragment	O
spanning	O
nucleotides	O
-158	O
to	O
-90	O
was	O
required	O
for	O
optimal	O
transcription	O
in	O
monocytic	O
cells	O
.	O
Biochemical	O
analysis	O
of	O
the	O
region	O
-158	O
/	O
-90	O
revealed	O
a	O
binding	O
site	O
for	O
transcription	B
factors	I
of	O
the	O
polyomavirus	B
enhancer	I
-	I
binding	I
protein	I
2	I
/	I
core	I
-	I
binding	I
factor	I
(	I
PEBP2	I
/	I
CBF	I
)	I
family	I
at	O
position	O
-103	O
.	O
Disruption	O
of	O
the	O
PEBP2	O
/	O
CBF	O
site	O
markedly	O
diminished	O
the	O
role	O
of	O
the	O
PEBP2	B
/	I
CBF	I
factors	I
in	O
the	O
constitutive	O
transcription	O
of	O
the	O
CD36	O
gene	O
.	O
The	O
involvement	O
of	O
members	O
of	O
the	O
PEBP2	B
/	I
CBF	I
family	I
in	O
chromosome	O
translocations	O
associated	O
with	O
acute	O
myeloid	O
leukemia	O
,	O
and	O
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
myeloid	O
-	O
specific	O
genes	O
encoding	O
for	O
myeloperoxidase	B
,	O
elastase	B
,	O
and	O
the	O
colony	B
-	I
stimulating	I
factor	I
receptor	I
,	O
highlights	O
the	O
relevance	O
of	O
the	O
regulation	O
of	O
the	O
CD36	O
gene	O
promoter	O
in	O
monocytic	O
cells	O
by	O
members	O
of	O
the	O
PEBP2	B
/	I
CBF	I
family	I
.	O
Human	O
T	O
lymphotropic	O
virus	O
-	O
I	O
infection	O
of	O
human	O
T	O
lymphocytes	O
induces	O
expression	O
of	O
the	O
beta	B
-	I
galactoside	I
-	I
binding	I
lectin	I
,	O
galectin-3	B
.	O
Animal	O
lectins	B
play	O
important	O
roles	O
in	O
a	O
variety	O
of	O
biological	O
processes	O
via	O
their	O
recognition	O
of	O
glycoconjugates	O
.	O
Galectin-3	O
is	O
a	O
beta	B
-	I
galactoside	I
-	I
binding	I
lectin	I
previously	O
designated	O
as	O
epsilon	B
BP	I
(	O
IgE	B
-	I
binding	I
protein	I
)	O
,	O
CBP35	B
,	O
Mac-2	B
,	O
L-29	B
,	O
and	O
L-34	B
,	O
and	O
its	O
expression	O
has	O
been	O
associated	O
with	O
various	O
physiological	O
and	O
pathological	O
processes	O
,	O
including	O
cell	O
growth	O
,	O
tumor	O
transformation	O
,	O
and	O
metastasis	O
.	O
Galectin-3	B
is	O
widely	O
distributed	O
in	O
various	O
tissues	O
and	O
cell	O
types	O
and	O
is	O
expressed	O
in	O
many	O
leukocytes	O
,	O
with	O
the	O
notable	O
exception	O
of	O
B	O
and	O
T	O
lymphocytes	O
.	O
We	O
now	O
report	O
that	O
galectin-3	B
is	O
abundantly	O
expressed	O
in	O
a	O
number	O
of	O
human	O
T	O
lymphotropic	O
virus	O
(	O
HTLV	O
)	O
-I	O
-	O
infected	O
human	O
T	O
cell	O
lines	O
,	O
including	O
F6	O
T	O
,	O
HUT	O
102	O
,	O
K3	O
T	O
,	O
MT-2	O
,	O
and	O
SLB	O
-	O
I	O
,	O
but	O
is	O
not	O
expressed	O
in	O
non	O
-	O
HTLV	O
-	O
I	O
-	O
infected	O
T	O
cell	O
lines	O
such	O
as	O
Jurkat	O
,	O
CEM	O
,	O
and	O
MOLT-4	O
.	O
In	O
addition	O
,	O
the	O
galectin-3	B
level	O
was	O
markedly	O
increased	O
in	O
human	O
thymocytes	O
after	O
infection	O
with	O
HTLV	O
-	O
I	O
as	O
compared	O
with	O
uninfected	O
thymocytes	O
.	O
The	O
up	O
-	O
regulation	O
of	O
galectin-3	B
expression	O
appeared	O
to	O
correlate	O
well	O
with	O
HTLV	O
-	O
I	O
gene	O
expression	O
,	O
as	O
undetectable	O
or	O
very	O
low	O
levels	O
of	O
galectin-3	B
were	O
found	O
in	O
the	O
S1	O
T	O
and	O
ATL-1	O
K	O
cell	O
lines	O
,	O
which	O
are	O
nonproductively	O
infected	O
with	O
HTLV	O
-	O
I	O
.	O
In	O
co	O
-	O
transfection	O
experiments	O
,	O
the	O
galectin-3	O
promoter	O
was	O
significantly	O
up	O
-	O
regulated	O
by	O
expression	O
vectors	O
encoding	O
the	O
40-kd	B
Tax	I
protein	I
,	O
a	O
potent	O
transactivator	O
in	O
HTLV	O
-	O
I	O
.	O
Analysis	O
of	O
various	O
Tax	B
mutants	I
suggested	O
that	O
galectin-3	O
promoter	O
induction	O
is	O
dependent	O
on	O
activation	O
of	O
the	O
cyclic	B
-	I
AMP	I
-	I
responsive	I
element	I
binding	I
protein	I
/	I
activation	I
transcription	I
factor	I
family	I
of	O
transcription	B
factors	I
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
nuclear	B
factor	I
-	I
kappa	I
B	I
/	I
Rel	I
induction	O
.	O
Transfection	O
of	O
human	O
promonocytic	O
U-937	O
cells	O
with	O
an	O
HTLV	O
-	O
I	O
Tax	O
expression	O
vector	O
induced	O
galectin-3	B
expression	O
in	O
this	O
cell	O
line	O
.	O
Functionally	O
,	O
galectin-3	B
was	O
shown	O
to	O
activate	O
interleukin-2	B
production	O
in	O
Jurkat	O
T	O
cells	O
.	O
Together	O
,	O
these	O
findings	O
raise	O
the	O
possibility	O
that	O
HTLV	O
-	O
I	O
Tax	B
production	O
induces	O
the	O
transcription	O
and	O
subsequent	O
synthesis	O
and	O
secretion	O
of	O
galectin-3	B
,	O
which	O
in	O
turn	O
may	O
further	O
activate	O
these	O
T	O
cells	O
and	O
contribute	O
to	O
the	O
altered	O
properties	O
of	O
cell	O
growth	O
found	O
in	O
adult	O
T	O
cell	O
leukemia	O
induced	O
by	O
HTLV	O
-	O
I	O
.	O
Age	O
-	O
related	O
decreases	O
in	O
IL-2	B
production	O
by	O
human	O
T	O
cells	O
are	O
associated	O
with	O
impaired	O
activation	O
of	O
nuclear	B
transcriptional	I
factors	I
AP-1	B
and	O
NF	B
-	I
AT	I
.	O
Although	O
transcriptional	B
factors	I
AP-1	B
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	B
-	I
AT	I
)	O
are	O
important	O
for	O
the	O
normal	O
induction	O
of	O
IL-2	B
,	O
it	O
is	O
unknown	O
if	O
the	O
age	O
-	O
related	O
decline	O
in	O
IL-2	B
production	O
by	O
activated	O
human	O
T	O
cells	O
may	O
be	O
associated	O
with	O
aberrancies	O
in	O
transcriptional	B
regulatory	I
proteins	I
.	O
In	O
the	O
current	O
studies	O
,	O
IL-2	B
production	O
by	O
T	O
cells	O
from	O
elderly	O
(	O
mean	O
78	O
years	O
)	O
and	O
young	O
(	O
mean	O
37	O
years	O
)	O
humans	O
was	O
measured	O
in	O
cultures	O
stimulated	O
with	O
PHA	B
,	O
PHA	B
plus	O
PMA	O
,	O
crosslinked	O
anti	O
-	O
CD3	O
mAB	O
OKT3	O
plus	O
PMA	O
,	O
or	O
PMA	O
plus	O
ionomycin	O
.	O
Substantial	O
decreases	O
of	O
IL-2	B
production	O
were	O
observed	O
for	O
cell	O
cultures	O
from	O
7	O
of	O
12	O
elderly	O
individuals	O
in	O
response	O
to	O
the	O
different	O
stimuli	O
,	O
whereas	O
the	O
levels	O
of	O
IL-2	B
produced	O
by	O
stimulated	O
T	O
cells	O
from	O
other	O
elderly	O
individuals	O
were	O
equivalent	O
to	O
those	O
observed	O
for	O
stimulated	O
T	O
cells	O
of	O
young	O
subjects	O
.	O
Analyses	O
of	O
nuclear	O
extracts	O
by	O
electrophoretic	O
DNA	O
mobility	O
shift	O
assays	O
showed	O
that	O
decreased	O
IL-2	B
production	O
by	O
stimulated	O
T	O
cells	O
of	O
elderly	O
individuals	O
was	O
closely	O
associated	O
with	O
impairments	O
in	O
the	O
activation	O
of	O
both	O
AP-1	B
and	O
NF	B
-	I
AT	I
.	O
By	O
contrast	O
,	O
T	O
cells	O
from	O
elderly	O
subjects	O
with	O
normal	O
levels	O
of	O
IL-2	B
production	O
exhibited	O
normal	O
activation	O
of	O
AP-1	B
and	O
NF	B
-	I
AT	I
.	O
In	O
addition	O
,	O
the	O
results	O
of	O
competition	O
experiments	O
analyzing	O
the	O
normal	O
components	O
of	O
NF	B
-	I
AT	I
showed	O
that	O
the	O
age	O
-	O
related	O
reductions	O
in	O
stimulus	O
-	O
dependent	O
NF	B
-	I
AT	I
complexes	I
corresponded	O
to	O
the	O
slow	O
migrating	O
complexes	O
that	O
were	O
composed	O
of	O
c	B
-	I
Fos	I
/	I
c	I
-	I
Jun	I
AP-1	B
.	O
The	O
resting	O
and	O
stimulated	O
levels	O
of	O
NF	B
kappa	I
B	I
were	O
reduced	O
in	O
T	O
cells	O
from	O
certain	O
elderly	O
individuals	O
;	O
however	O
,	O
alterations	O
of	O
NF	B
kappa	I
B	I
did	O
not	O
correlate	O
with	O
changes	O
in	O
IL-2	B
expression	O
.	O
Thus	O
,	O
these	O
results	O
show	O
that	O
age	O
-	O
related	O
impairments	O
in	O
the	O
activation	O
of	O
AP-1	B
and	O
NF	B
-	I
AT	I
are	O
closely	O
associated	O
with	O
decreased	O
expression	O
of	O
IL-2	B
and	O
further	O
suggest	O
that	O
aberrancies	O
in	O
the	O
signaling	O
pathways	O
important	O
for	O
the	O
induction	O
of	O
transcriptionally	O
active	O
c	B
-	I
Fos	I
/	I
c	I
-	I
Jun	I
AP-1	B
may	O
contribute	O
to	O
the	O
impaired	O
activation	O
of	O
NF	B
-	I
AT	I
.	O
Inhibitory	O
effect	O
of	O
E3330	O
,	O
a	O
novel	O
quinone	O
derivative	O
able	O
to	O
suppress	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
generation	O
,	O
on	O
activation	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
.	O
(	O
2E	O
)	O
-3-	O
[	O
5-	O
(	O
2	O
,	O
3-Dimethoxy-6-methyl-1	O
,	O
4-benzoquinoyl	O
)	O
]	O
-2-nonyl-2-	O
propenoic	O
acid	O
(	O
E3330	O
)	O
,	O
is	O
a	O
novel	O
agent	O
with	O
hepatoprotective	O
activity	O
.	O
We	O
report	O
the	O
effect	O
of	O
E3330	O
on	O
transcriptional	O
activation	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-alpha	O
gene	O
and	O
on	O
nuclear	B
factor	I
(	I
NF	I
)	I
-kappa	I
B	I
activation	O
.	O
Nuclear	O
run	O
-	O
on	O
experiments	O
showed	O
that	O
E3330	O
decreases	O
transcriptional	O
activation	O
of	O
TNF	O
-	O
alpha	O
gene	O
induced	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
in	O
human	O
peripheral	O
monocytes	O
.	O
To	O
investigate	O
the	O
inhibitory	O
mechanisms	O
,	O
we	O
constructed	O
a	O
secreted	O
-	O
type	O
placental	O
alkaline	O
phosphatase	O
(	O
PLAP	O
)	O
reporter	O
gene	O
whose	O
transcription	O
is	O
controlled	O
by	O
a	O
1.4-kb	O
human	O
TNF	O
-	O
alpha	O
promoter	O
.	O
A	O
stable	O
transformant	O
of	O
the	O
PLAP	O
reporter	O
gene	O
derived	O
from	O
human	O
monocytic	O
cell	O
line	O
showed	O
very	O
little	O
activity	O
on	O
the	O
promoter	O
before	O
stimulation	O
,	O
whereas	O
LPS	O
stimulation	O
led	O
to	O
a	O
dramatic	O
increase	O
in	O
PLAP	B
activity	O
.	O
E3330	O
inhibited	O
this	O
induced	O
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
There	O
are	O
four	O
putative	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
(	O
kappa	O
B-1	O
,	O
kappa	O
B-2	O
,	O
kappa	O
B-3	O
,	O
kappa	O
B-4	O
)	O
in	O
human	O
TNF	O
-	O
alpha	O
promoter	O
.	O
By	O
using	O
mutated	O
promoter	O
-	O
PLAP	O
plasmids	O
,	O
we	O
established	O
that	O
these	O
NF	O
-	O
kappa	O
B	O
sites	O
were	O
necessary	O
for	O
induction	O
of	O
TNF	B
-	I
alpha	I
transcription	O
on	O
stimulation	O
with	O
LPS	O
.	O
A	O
gel	O
retardation	O
experiment	O
with	O
synthetic	O
double	O
-	O
stranded	O
oligonucleotides	O
showed	O
that	O
activated	O
NF	B
-	I
kappa	I
B	I
consisting	O
of	O
p50	B
/	I
p65	I
heterodimer	I
bound	O
to	O
all	O
four	O
putative	O
NF	O
-	O
kappa	O
B	O
DNA	O
probes	O
,	O
suggesting	O
that	O
all	O
four	O
putative	O
NF	O
-	O
kappa	O
B	O
recognition	O
sites	O
play	O
an	O
important	O
role	O
in	O
inducible	O
TNF	B
-	I
alpha	I
expression	O
.	O
E3330	O
decreased	O
activated	O
NF	B
-	I
kappa	I
B	I
in	O
nuclei	O
,	O
suggesting	O
that	O
E3330	O
inhibits	O
NF	B
-	I
kappa	I
B	I
activation	O
and/or	O
translocation	O
of	O
the	O
nuclei	O
.	O
Western	O
blotting	O
analysis	O
with	O
anti	B
-	I
I	I
kappa	I
B	I
-	I
alpha	I
antibody	I
indicated	O
that	O
E3330	O
inhibited	O
degradation	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
,	O
which	O
is	O
an	O
inhibitory	B
protein	I
of	O
NF	B
-	I
kappa	I
B	I
,	O
in	O
LPS	O
-	O
stimulated	O
monocytes	O
.	O
E3330	O
may	O
suppress	O
the	O
production	O
of	O
active	O
oxygen	O
species	O
serving	O
as	O
common	O
messengers	O
to	O
activate	O
NF	B
-	I
kappa	I
B	I
.	O
Ubiquitinylation	O
of	O
transcription	B
factors	I
c	B
-	I
Jun	I
and	O
c	B
-	I
Fos	I
using	O
reconstituted	B
ubiquitinylating	I
enzymes	I
.	O
Recombinant	O
c	B
-	I
Jun	I
and	O
c	B
-	I
Fos	I
were	O
ubiquitinylated	O
by	O
the	O
ubiquitin	B
carrier	I
enzymes	I
E214	B
K	I
,	O
E220	B
K	I
,	O
or	O
E232	B
K	I
in	O
the	O
presence	O
of	O
the	O
ubiquitin	B
-	I
activating	I
enzyme	I
,	O
E1	B
.	O
Addition	O
of	O
ubiquitin	B
protein	I
ligase	I
E3	I
substantially	O
enhanced	O
the	O
E214	B
K	I
-mediated	O
ubiquitinylation	O
of	O
c	B
-	I
Jun	I
and	O
c	B
-	I
Fos	I
.	O
Truncated	B
c	I
-	I
Jun	I
and	I
c	I
-	I
Fos	I
mutant	I
proteins	I
including	O
wbJun	B
and	O
wbFos	B
were	O
also	O
ubiquitinylated	O
under	O
the	O
same	O
conditions	O
,	O
suggesting	O
the	O
sites	O
of	O
ubiquitinylation	O
are	O
located	O
within	O
the	O
dimerization	B
and	I
DNA	I
binding	I
domains	I
of	O
c	B
-	I
Jun	I
and	O
c	B
-	I
Fos	I
.	O
The	O
E3-dependent	O
ubiquitinylation	O
of	O
c	B
-	I
Jun	I
was	O
inhibited	O
upon	O
the	O
heterodimerization	O
of	O
c	B
-	I
Jun	I
with	O
c	B
-	I
Fos	I
.	O
Further	O
addition	O
of	O
E220	B
K	I
significantly	O
enhanced	O
ubiquitinylation	O
of	O
c	B
-	I
Jun	I
in	O
the	O
heterodimer	O
suggesting	O
a	O
regulatory	O
role	O
of	O
E220	B
K	I
.	O
Polyubiquitinylated	O
c	B
-	I
Jun	I
,	O
wbFos	B
,	O
and	O
wbJun	B
,	O
but	O
not	O
E220K	B
-	I
ubiquitinylated	I
c	I
-	I
Jun	I
,	O
were	O
readily	O
degraded	O
by	O
the	O
ATP	B
-	I
dependent	I
26	I
S	I
multicatalytic	I
proteases	I
.	O
These	O
results	O
suggest	O
that	O
the	O
temporal	O
control	O
of	O
c	B
-	I
Jun	I
and	O
c	B
-	I
Fos	I
may	O
be	O
regulated	O
through	O
the	O
ubiquitinylation	O
pathways	O
,	O
and	O
the	O
ubiquitinylation	O
of	O
c	B
-	I
Jun	I
and	O
c	B
-	I
Fos	I
may	O
in	O
turn	O
be	O
regulated	O
in	O
response	O
to	O
the	O
heterodimerization	O
between	O
them	O
and	O
the	O
cooperation	O
between	O
E220	B
K	I
and	O
E3	O
mediated	O
polyubiquitinylation	O
.	O
Transcriptional	O
regulation	O
of	O
the	O
interleukin-2	O
gene	O
in	O
normal	O
human	O
peripheral	O
blood	O
T	O
cells	O
.	O
Convergence	O
of	O
costimulatory	O
signals	O
and	O
differences	O
from	O
transformed	O
T	O
cells	O
.	O
To	O
study	O
transcriptional	O
regulation	O
in	O
normal	O
human	O
T	O
cells	O
,	O
we	O
have	O
optimized	O
conditions	O
for	O
transient	O
transfection	O
.	O
Interleukin-2	O
(	O
IL-2	O
)	O
promoter	O
-reporter	O
gene	O
behavior	O
closely	O
parallels	O
the	O
endogenous	O
gene	O
in	O
response	O
to	O
T	B
cell	I
receptor	I
and	O
costimulatory	O
signals	O
.	O
As	O
assessed	O
with	O
mutagenized	O
promoters	O
,	O
the	O
most	O
important	O
IL-2	O
cis	O
-	O
regulatory	O
elements	O
in	O
normal	O
T	O
cells	O
are	O
the	O
proximal	O
AP-1	O
site	O
and	O
the	O
NF-	O
kappaB	O
site	O
.	O
Both	O
primary	O
activation	O
,	O
with	O
phytohemagglutinin	B
or	O
antibodies	B
to	I
CD3	I
,	O
and	O
costimulation	O
,	O
provided	O
by	O
pairs	O
of	O
CD2	B
antibodies	I
or	O
B7-positive	O
(	O
B	O
cells	O
)	O
or	O
B7-negative	O
(	O
endothelial	O
)	O
accessory	O
cells	O
,	O
are	O
mediated	O
through	O
the	O
same	O
cis	O
-	O
elements	O
.	O
Interestingly	O
,	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
sites	O
are	O
much	O
less	O
important	O
in	O
normal	O
T	O
cells	O
than	O
in	O
Jurkat	O
T	O
cells	O
.	O
We	O
conclude	O
that	O
IL-2	B
transcriptional	O
regulation	O
differs	O
in	O
tumor	O
cell	O
lines	O
compared	O
with	O
normal	O
T	O
cells	O
and	O
that	O
different	O
costimulatory	O
signals	O
converge	O
on	O
the	O
same	O
cis	O
-	O
elements	O
in	O
the	O
IL-2	O
promoter	O
.	O
Nuclear	O
appearance	O
of	O
a	O
factor	O
that	O
binds	O
the	O
CD28	O
response	O
element	O
within	O
the	O
interleukin-2	O
enhancer	O
correlates	O
with	O
interleukin-2	B
production	O
.	O
Activation	O
of	O
T	O
lymphocytes	O
requires	O
the	O
combined	O
signaling	O
of	O
the	O
T	B
cell	I
receptor	I
and	O
costimulatory	B
molecules	I
such	O
as	O
CD28	B
.	O
The	O
ability	O
of	O
T	O
cells	O
to	O
produce	O
interleukin-2	B
(	O
IL-2	B
)	O
is	O
a	O
critical	O
control	O
point	O
in	O
T	O
lymphocyte	O
activation	O
.	O
The	O
IL-2	B
enhancer	O
contains	O
a	O
functional	O
motif	O
named	O
CD28	O
response	O
element	O
(	O
CD28RE	O
)	O
that	O
serves	O
a	O
role	O
as	O
a	O
target	O
for	O
mitogenic	O
T	O
cell	O
activation	O
signals	O
.	O
The	O
CD28RE	O
sequence	O
reveals	O
similarity	O
to	O
the	O
consensus	O
kappaB	O
binding	O
motif	O
.	O
Here	O
we	O
demonstrate	O
that	O
CD28RE	O
binds	O
an	O
inducible	O
protein	O
with	O
a	O
molecular	O
mass	O
of	O
approximately	O
35	O
kDa	O
called	O
nuclear	B
factor	I
of	I
mitogenic	I
-	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
MATp35	I
)	O
that	O
is	O
clearly	O
different	O
from	O
the	O
known	O
NF-	B
kappaB	I
/	I
Rel	I
family	I
members	I
.	O
Induction	O
of	O
NF	B
-	I
MATp35	I
was	O
shown	O
to	O
depend	O
on	O
de	O
novo	O
protein	O
synthesis	O
and	O
was	O
restricted	O
to	O
T	O
cells	O
that	O
received	O
a	O
mitogenic	O
combination	O
of	O
T	O
cell	O
stimuli	O
,	O
not	O
necessarily	O
including	O
CD28	B
signaling	O
.	O
Nonmitogenic	O
T	O
cell	O
stimulation	O
did	O
not	O
result	O
in	O
appearance	O
of	O
NF	B
-	I
MATp35	I
.	O
These	O
results	O
indicate	O
that	O
mitogenic	O
combinations	O
of	O
T	O
cell	O
activation	O
signals	O
are	O
integrated	O
at	O
the	O
level	O
of	O
NF	B
-	I
MATp35	I
induction	O
.	O
Similar	O
to	O
its	O
effect	O
on	O
IL-2	B
production	O
,	O
cyclosporin	O
A	O
inhibited	O
the	O
induction	O
of	O
NF	B
-	I
MATp35	I
.	O
Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
nuclear	O
appearance	O
of	O
NF	B
-	I
MATp35	I
shows	O
excellent	O
correlation	O
with	O
IL-2	B
production	O
,	O
which	O
is	O
a	O
unique	O
characteristic	O
among	O
nuclear	O
factors	O
implicated	O
in	O
the	O
control	O
of	O
IL-2	B
gene	O
expression	O
.	O
Heat	O
shock	O
induces	O
HIV-1	O
replication	O
in	O
chronically	O
infected	O
promyelocyte	O
cell	O
line	O
OM10.1	O
.	O
A	O
long	O
period	O
of	O
clinical	O
latency	O
before	O
development	O
of	O
symptoms	O
is	O
characteristic	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
.	O
OM10.1	O
,	O
a	O
promyelocyte	O
cell	O
line	O
latently	O
infected	O
with	O
HIV-1	O
,	O
has	O
been	O
developed	O
as	O
a	O
model	O
for	O
studying	O
the	O
mechanism	O
of	O
viral	O
latency	O
and	O
the	O
activation	O
of	O
virus	O
expression	O
.	O
We	O
found	O
that	O
this	O
latently	O
infected	O
cell	O
line	O
with	O
heat	O
shock	O
at	O
42	O
degrees	O
C	O
for	O
2	O
h	O
resulted	O
in	O
a	O
high	O
level	O
of	O
HIV-1	O
production	O
without	O
addition	O
of	O
any	O
cytokines	B
.	O
The	O
mechanism	O
of	O
activation	O
was	O
analyzed	O
by	O
using	O
anti	B
-	I
TNF	I
-	I
alpha	I
antibody	I
and	O
various	O
inhibitors	O
.	O
Although	O
the	O
TNF	B
-	I
alpha	I
level	O
in	O
culture	O
supernatants	O
was	O
below	O
the	O
sensitivity	O
of	O
an	O
ELISA	O
assay	O
system	O
,	O
addition	O
of	O
anti-	O
TNF	B
-	I
alpha	I
antibody	O
in	O
culture	O
medium	O
could	O
partially	O
suppress	O
the	O
heat	O
shock	O
induced	O
HIV-1	O
production	O
.	O
Staurosporine	O
(	O
PKC	O
inhibitor	O
)	O
,	O
pentoxifylline	O
(	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
)	O
,	O
and	O
Ro5	O
-	O
3335	O
(	O
HIV-1	O
Tat	B
inhibitor	O
)	O
also	O
inhibited	O
significantly	O
the	O
heat	O
shock	O
induced	O
virus	O
activation	O
.	O
In	O
particular	O
,	O
staurosporine	O
achieved	O
approximately	O
90	O
%	O
inhibition	O
of	O
the	O
HIV-1	O
antigen	O
expression	O
in	O
heat	O
shock	O
-	O
treated	O
OM10.1	O
at	O
a	O
non	O
-	O
toxic	O
concentration	O
.	O
Although	O
the	O
mechanism	O
of	O
HIV-1	O
activation	O
with	O
heat	O
shock	O
has	O
not	O
been	O
fully	O
elucidated	O
yet	O
,	O
it	O
is	O
presumed	O
PKC	B
plays	O
an	O
important	O
role	O
in	O
HIV-1	O
activation	O
.	O
Thus	O
,	O
the	O
present	O
observations	O
will	O
provide	O
a	O
further	O
insight	O
into	O
the	O
pathogenesis	O
of	O
HIV-1	O
infections	O
.	O
Granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
stimulates	O
JAK2	B
signaling	O
pathway	O
and	O
rapidly	O
activates	O
p93fes	B
,	O
STAT1	B
p91	I
,	O
and	O
STAT3	B
p92	I
in	O
polymorphonuclear	O
leukocytes	O
.	O
Granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
,	O
supports	O
proliferation	O
,	O
differentiation	O
,	O
and	O
functional	O
activation	O
of	O
hemopoietic	O
cells	O
by	O
its	O
interaction	O
with	O
a	O
heterodimeric	O
receptor	O
.	O
Although	O
GM	B
-	I
CSF	I
receptor	O
is	O
devoid	O
of	O
tyrosine	B
kinase	I
enzymatic	O
activity	O
,	O
GM	O
-	O
CSF	O
-	O
induced	O
peripheral	O
blood	O
polymorphonuclear	O
leukocytes	O
(	O
PMN	O
)	O
functional	O
activation	O
is	O
mediated	O
by	O
the	O
phosphorylation	O
of	O
a	O
large	O
number	O
of	O
intracellular	B
signaling	I
molecules	I
.	O
We	O
have	O
previously	O
shown	O
that	O
JAK2	B
becomes	O
tyrosine	O
-	O
phosphorylated	O
in	O
response	O
to	O
GM	B
-	I
CSF	I
in	O
PMN	O
.	O
In	O
the	O
present	O
study	O
we	O
demonstrate	O
that	O
also	O
the	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	I
STAT	I
)	I
family	I
members	I
STAT1	B
p91	I
and	O
STAT3	B
p92	I
and	O
the	O
product	O
of	O
the	O
c	O
-	O
fps	O
/	O
fes	O
protooncogene	O
become	O
tyrosine	O
-	O
phosphorylated	O
upon	O
GM	B
-	I
CSF	I
stimulation	O
and	O
physically	O
associated	O
with	O
both	O
GM	B
-	I
CSF	I
receptor	O
beta	O
common	O
subunit	O
and	O
JAK2	B
.	O
Moreover	O
GM	B
-	I
CSF	I
was	O
able	O
to	O
induce	O
JAK2	B
and	O
p93fes	B
catalytic	O
activity	O
.	O
We	O
also	O
demonstrate	O
that	O
the	O
association	O
of	O
the	O
GM	B
-	I
CSF	I
receptor	I
beta	I
common	I
subunit	I
with	O
JAK2	B
is	O
ligand	O
-	O
dependent	O
.	O
Finally	O
we	O
demonstrate	O
that	O
GM	B
-	I
CSF	I
induces	O
a	O
DNA	B
-	I
binding	I
complex	I
that	O
contains	O
both	O
p91	B
and	O
p92	B
.	O
These	O
results	O
identify	O
a	O
new	O
signal	O
transduction	O
pathway	O
activated	O
by	O
GM	B
-	I
CSF	I
and	O
provide	O
a	O
mechanism	O
for	O
rapid	O
activation	O
of	O
gene	O
expression	O
in	O
GM	O
-	O
CSF	O
-	O
stimulated	O
PMN	O
.	O
Abundant	O
expression	O
of	O
erythroid	O
transcription	O
factor	O
P45	O
NF	O
-	O
E2	O
mRNA	O
in	O
human	O
peripheral	O
granurocytes	O
.	O
Transcription	B
factor	I
NF	I
-	I
E2	I
is	O
crucial	O
for	O
regulation	O
of	O
erythroid	O
-	O
specific	O
gene	O
expression	O
.	O
p45	B
subunit	I
of	O
NF	B
-	I
E2	I
contains	O
a	O
basic	B
-	I
leucine	I
zipper	I
domain	I
and	O
dimerizes	O
with	O
the	O
small	B
Maf	I
family	I
protein	I
to	O
form	O
functional	O
NF	B
-	I
E2	I
complex	I
.	O
While	O
p45	B
expression	O
was	O
shown	O
to	O
be	O
restricted	O
to	O
erythroid	O
cells	O
,	O
megakaryocytes	O
and	O
mast	O
cells	O
in	O
hematopoietic	O
lineage	O
,	O
we	O
found	O
in	O
this	O
study	O
that	O
p45	O
mRNA	O
is	O
abundantly	O
transcribed	O
in	O
the	O
granulocyte	O
fraction	O
of	O
human	O
peripheral	O
blood	O
cells	O
.	O
As	O
neutrophils	O
occupy	O
approximately	O
92	O
%	O
of	O
the	O
cells	O
in	O
granulocyte	O
fraction	O
of	O
human	O
peripheral	O
blood	O
cells	O
.	O
As	O
neutrophils	O
occupy	O
approximately	O
92	O
%	O
of	O
the	O
cells	O
in	O
this	O
fraction	O
,	O
the	O
cells	O
expressing	O
p45	B
is	O
most	O
likely	O
to	O
be	O
neutrophils	O
.	O
p45	O
mRNA	O
is	O
also	O
expressed	O
in	O
HL-60	O
promyelocytes	O
,	O
albeit	O
the	O
expression	O
level	O
is	O
much	O
lower	O
than	O
that	O
of	O
the	O
granulocyte	O
fraction	O
.	O
HL-60	O
cells	O
were	O
found	O
to	O
express	O
mafK	O
mRNA	O
,	O
indicating	O
the	O
presence	O
of	O
genuine	O
NF	B
-	I
E2	I
complex	I
in	O
the	O
cells	O
.	O
Although	O
p45	O
mRNA	O
is	O
transcribed	O
from	O
two	O
different	O
promoters	O
,	O
aNF	O
-	O
E2	O
promoter	O
and	O
fNF	O
-	O
E2	O
promoter	O
,	O
in	O
erythroid	O
and	O
megakaryocytic	O
lineage	O
cells	O
,	O
p45	O
mRNA	O
is	O
transcribed	O
only	O
from	O
aNF	O
-	O
E2	O
promoter	O
.	O
The	O
expression	O
of	O
p45	B
megakaryocytic	O
lineage	O
cells	O
,	O
p45	O
mRNA	O
is	O
transcribed	O
only	O
from	O
aNF	O
-	O
E2	O
promoter	O
.	O
The	O
expression	O
of	O
p45	O
mRNA	O
in	O
the	O
neutrophils	O
declined	O
rapidly	O
after	O
transfer	O
of	O
the	O
cells	O
to	O
in	O
vitro	O
culture	O
and	O
G	B
-	I
CSF	I
could	O
not	O
sustain	O
the	O
expression	O
from	O
the	O
down	O
-	O
regulation	O
,	O
suggesting	O
the	O
E2	B
may	O
also	O
participate	O
in	O
the	O
regulation	O
of	O
neutrophil	O
-	O
specific	O
gene	O
expression	O
.	O
Preassociation	O
of	O
STAT1	B
with	O
STAT2	B
and	O
STAT3	B
in	O
separate	O
signalling	B
complexes	I
prior	O
to	O
cytokine	B
stimulation	O
.	O
A	O
variety	O
of	O
cytokines	B
and	O
growth	B
factors	I
act	O
through	O
an	O
induction	O
of	O
gene	O
expression	O
mediated	O
by	O
a	O
family	O
of	O
latent	B
transcription	I
factors	I
called	O
STAT	B
(	I
signal	I
transducers	I
and	I
activators	I
of	I
transcription	I
)	I
proteins	I
.	O
Ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
STATs	B
promotes	O
their	O
homodimer	O
and	O
heterodimer	O
formation	O
and	O
subsequent	O
nuclear	O
translocation	O
.	O
We	O
demonstrate	O
here	O
that	O
STAT	B
protein	I
heterocomplexes	I
exist	O
prior	O
to	O
cytokine	B
treatment	O
.	O
When	O
unstimulated	O
HeLa	O
cells	O
are	O
ruptured	O
in	O
hypotonic	O
buffer	O
without	O
salt	O
or	O
detergent	O
,	O
immunoadsorption	O
of	O
either	O
STAT1	B
or	O
STAT2	B
from	O
the	O
resulting	O
cytosol	O
yields	O
coimmunoadsorption	O
of	O
the	O
other	O
STAT	B
protein	I
.	O
Similarly	O
,	O
STAT1	B
-STAT3	B
heterocomplexes	O
are	O
coimmunoadsorbed	O
from	O
hypotonic	O
cytosol	O
.	O
STAT1	B
and	O
STAT2	B
or	O
STAT1	B
and	O
STAT3	B
translated	O
in	O
reticulocyte	O
lysate	O
spontaneously	O
form	O
heterocomplexes	O
when	O
the	O
translation	O
lysates	O
are	O
mixed	O
at	O
0	O
degrees	O
C	O
.	O
Our	O
data	O
suggest	O
that	O
interferon	B
-	I
alpha	I
/beta	O
-	O
induced	O
tyrosine	O
phosphorylation	O
increases	O
the	O
stability	O
of	O
a	O
preexisting	O
,	O
latent	O
,	O
STAT1	B
-	O
STAT2	B
signaling	I
complex	I
.	O
Newly	O
translated	O
STAT1	B
binds	O
in	O
equilibrium	O
fashion	O
to	O
STAT2	B
and	O
STAT3	B
,	O
but	O
we	O
show	O
that	O
STAT2	B
and	O
STAT3	B
exist	O
in	O
separate	O
heterocomplexes	B
with	O
STAT1	B
,	O
consistent	O
with	O
a	O
model	O
in	O
which	O
STAT1	B
contains	O
a	O
common	O
binding	O
site	O
for	O
other	O
STAT	B
proteins	I
.	O
A	O
hydrophobic	O
domain	O
of	O
Ca2	B
+	I
-modulating	I
cyclophilin	I
ligand	I
modulates	O
calcium	O
influx	O
signaling	O
in	O
T	O
lymphocytes	O
.	O
Ca2	B
+	I
-modulating	I
cyclophilin	I
ligand	I
(	O
CAML	B
)	O
was	O
originally	O
described	O
as	O
a	O
cyclophilin	B
B	I
-	I
binding	I
protein	I
whose	O
overexpression	O
in	O
T	O
cells	O
causes	O
a	O
rise	O
in	O
intracellular	O
calcium	O
,	O
thus	O
activating	O
transcription	B
factors	I
responsible	O
for	O
the	O
early	O
immune	O
response	O
.	O
As	O
reported	O
here	O
,	O
structure	O
-	O
function	O
analysis	O
of	O
the	O
CAML	O
gene	O
in	O
Jurkat	O
T	O
cells	O
indicates	O
that	O
two	O
of	O
CAML	B
's	O
putative	B
membrane	I
-	I
spanning	I
domains	I
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
modulation	O
of	O
intracellular	O
calcium	O
.	O
We	O
propose	O
that	O
the	O
hydrophobic	B
C	I
-	I
terminal	I
tail	I
of	O
CAML	B
forms	O
its	O
effector	O
domain	O
,	O
thus	O
implicating	O
the	O
N	B
-	I
terminal	I
hydrophilic	I
domain	I
in	O
a	O
regulatory	O
role	O
.	O
These	O
findings	O
define	O
a	O
novel	B
protein	I
motif	I
that	O
functions	O
in	O
intracellular	O
calcium	O
signaling	O
.	O
Interactions	O
of	O
a	O
transcriptional	O
activator	O
in	O
the	O
env	O
gene	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
with	O
activation	B
-	I
dependent	I
,	I
T	I
cell	I
-	I
specific	I
transacting	I
factors	I
.	O
The	O
mouse	O
mammary	O
tumor	O
virus	O
env	O
gene	O
contains	O
a	O
transcriptional	O
activator	O
(	O
META	O
)	O
that	O
can	O
control	O
transcription	O
of	O
the	O
adjacent	O
long	O
terminal	O
repeat	O
region	O
.	O
Transcriptional	O
control	O
by	O
META	O
parallels	O
that	O
of	O
several	O
lymphokine	O
genes	O
,	O
being	O
specific	O
to	O
T	O
cells	O
,	O
dependent	O
on	O
their	O
activation	O
,	O
and	O
inhibited	O
by	O
the	O
immunosuppressive	O
drug	O
cyclosporine	O
(	O
CsA	O
)	O
.	O
DNase	B
I	I
footprinting	O
indicated	O
that	O
nuclear	B
factors	I
from	O
activated	O
T	O
lymphocytes	O
bound	O
a	O
promoter	O
-	O
proximal	O
site	O
,	O
META	O
(	O
P	O
)	O
,	O
and	O
a	O
promoter	O
-	O
distal	O
site	O
,	O
META	O
(	O
D+	O
)	O
,	O
within	O
the	O
400-base	O
pair	O
META	O
region	O
.	O
Nuclear	B
factors	I
from	O
unstimulated	O
,	O
but	O
not	O
from	O
activated	O
cells	O
,	O
bound	O
a	O
site	O
,	O
META	O
(	O
D-	O
)	O
,	O
adjacent	O
to	O
META	O
(	O
D+	O
)	O
.	O
META	O
(	O
D+	O
)	O
directed	O
transcription	O
of	O
a	O
linked	O
luciferase	O
gene	O
,	O
and	O
gel	O
shift	O
analysis	O
revealed	O
binding	O
of	O
inducible	O
,	O
CsA	B
-	I
sensitive	I
T	I
cell	I
factors	I
,	O
in	O
parallel	O
with	O
transfection	O
results	O
.	O
Authentic	O
NFAT	O
and	O
NF	O
-	O
kappaB	O
targets	O
did	O
not	O
compete	O
for	O
the	O
META	B
(	I
D+	I
)	I
binding	I
factor	I
(	O
s	O
)	O
.	O
The	O
SV40	O
core	O
sequence	O
competed	O
for	O
META	B
(	I
D+	I
)	I
binding	I
factors	I
,	O
but	O
META	O
(	O
D+	O
)	O
failed	O
to	O
compete	O
for	O
the	O
complexes	O
obtained	O
with	O
the	O
SV40	O
probe	O
.	O
Our	O
results	O
,	O
taken	O
together	O
,	O
indicate	O
that	O
META	O
(	O
D+	O
)	O
is	O
a	O
novel	O
transcriptional	O
enhancer	O
element	O
that	O
is	O
similar	O
in	O
its	O
cell	O
-	O
type	O
specificity	O
,	O
activation	O
dependence	O
,	O
and	O
CsA	O
sensitivity	O
to	O
the	O
NFAT	O
element	O
.	O
It	O
may	O
be	O
relevant	O
to	O
the	O
role	O
of	O
MMTV	O
in	O
expression	O
of	O
Mls	B
antigens	I
or	O
the	O
induction	O
of	O
T	O
cell	O
lymphomas	O
.	O
Expression	O
of	O
Id2	O
and	O
Id3	O
mRNA	O
in	O
human	O
lymphocytes	O
.	O
Helix	B
-	I
loop	I
-	I
helix	I
(	I
HLH	I
)	I
transcription	I
factors	I
are	O
involved	O
in	O
cellular	O
growth	O
and	O
differentiation	O
.	O
The	O
I	B
d	I
(	O
inhibitor	O
of	O
DNA	O
binding	O
and	O
differentiation	O
)	O
HLH	B
proteins	I
,	O
in	O
a	O
dominantly	O
negative	O
fashion	O
,	O
regulate	O
transcriptional	O
activities	O
of	O
basic	B
HLH	I
proteins	I
.	O
We	O
examined	O
by	O
northern	O
hybridization	O
the	O
expression	O
of	O
Id2	O
and	O
Id3	O
mRNA	O
in	O
human	O
leukemia	O
/	O
lymphoma	O
lines	O
and	O
patient	O
samples	O
,	O
as	O
well	O
as	O
resting	O
and	O
activated	O
normal	O
human	O
lymphocytes	O
from	O
peripheral	O
blood	O
(	O
PBL	O
)	O
.	O
The	O
Id2	O
mRNA	O
was	O
abundantly	O
expressed	O
in	O
5	O
/	O
12	O
T	O
-	O
cell	O
and	O
3	O
/	O
4	O
B	O
-	O
cell	O
lines	O
,	O
and	O
Id3	O
mRNA	O
was	O
detected	O
in	O
4	O
/	O
12	O
T	O
-	O
cell	O
and	O
3	O
/	O
4	O
B	O
-	O
cell	O
lines	O
.	O
Interestingly	O
,	O
Id2	O
,	O
but	O
not	O
Id3	O
,	O
mRNA	O
was	O
strongly	O
expressed	O
in	O
4	O
/	O
5	O
T	O
-	O
cell	O
lines	O
infected	O
with	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
(	O
ATL-1k	O
,	O
MT-2	O
,	O
S	O
-	O
LB1	O
)	O
and	O
type	O
II	O
(	O
Mo	O
)	O
.	O
Another	O
unexpected	O
finding	O
was	O
that	O
T	O
-	O
cell	O
leukemias	O
and	O
T	O
-	O
cell	O
lines	O
often	O
expressed	O
either	O
Id2	O
or	O
Id3	O
mRNA	O
.	O
In	O
addition	O
,	O
resting	O
PBL	O
constitutively	O
expressed	O
prominent	O
levels	O
of	O
Id2	O
mRNA	O
,	O
but	O
not	O
Id3	O
mRNA	O
.	O
Upon	O
PHA	B
-stimulation	O
,	O
Id2	B
expression	O
decreased	O
and	O
Id3	B
levels	O
increased	O
with	O
biphasic	O
kinetics	O
.	O
Taken	O
together	O
,	O
our	O
studies	O
revealed	O
three	O
unexpected	O
findings	O
which	O
require	O
further	O
analysis	O
:	O
(	O
1	O
)	O
expression	O
of	O
Id2	O
mRNA	O
is	O
often	O
associated	O
with	O
lymphocytic	O
transformation	O
by	O
HTLV	O
-	O
I	O
or	O
-II	O
;	O
(	O
2	O
)	O
T	O
-	O
cells	O
usually	O
express	O
either	O
Id2	B
or	O
Id3	O
mRNA	O
,	O
but	O
B	O
-	O
cells	O
often	O
express	O
both	O
simultaneously	O
;	O
(	O
3	O
)	O
non	O
-	O
dividing	O
,	O
normal	O
PBL	O
express	O
high	O
levels	O
of	O
Id2	B
and	O
no	O
Id3	O
mRNA	O
;	O
and	O
with	O
the	O
onset	O
of	O
cellular	O
proliferation	O
,	O
levels	O
of	O
Id2	O
mRNA	O
decrease	O
while	O
levels	O
of	O
Id3	O
mRNA	O
increase	O
,	O
suggesting	O
that	O
regulation	O
of	O
expression	O
of	O
these	O
closely	O
related	O
genes	O
is	O
disparate	O
.	O
Identification	O
of	O
a	O
human	O
LIM	O
-	O
Hox	O
gene	O
,	O
hLH-2	O
,	O
aberrantly	O
expressed	O
in	O
chronic	O
myelogenous	O
leukaemia	O
and	O
located	O
on	O
9q33	O
-	O
34.1	O
.	O
We	O
describe	O
the	O
isolation	O
of	O
human	B
LH-2	I
,	O
a	O
putative	B
transcription	I
factor	I
containing	O
two	O
cysteine	B
-	I
rich	I
regions	I
(	O
LIM	B
domains	I
)	O
and	O
a	O
homeobox	B
(	I
Hox	I
)	I
DNA	I
-	I
binding	I
domain	I
.	O
High	O
levels	O
of	O
hLH-2	O
expression	O
were	O
observed	O
in	O
all	O
cases	O
of	O
chronic	O
myelogenous	O
leukaemia	O
(	O
CML	O
)	O
tested	O
,	O
regardless	O
of	O
disease	O
status	O
.	O
hLH-2	O
was	O
mapped	O
to	O
chromosome	O
9Q33	O
-	O
34.1	O
,	O
in	O
the	O
same	O
region	O
as	O
the	O
reciprocal	O
translocation	O
that	O
creates	O
the	O
BCR	B
-	I
ABL	I
chimera	I
of	O
the	O
Philadelphia	O
chromosome	O
(	O
Ph	O
'	O
)	O
,	O
the	O
hallmark	O
of	O
CML	O
;	O
hLH-2	O
was	O
retained	O
on	O
the	O
derivative	O
9	O
chromosome	O
and	O
is	O
therefore	O
centromeric	O
of	O
c	O
-	O
ABL	O
.	O
The	O
proximity	O
of	O
hLH-2	O
to	O
the	O
breakpoint	O
on	O
chromosome	O
9	O
raises	O
the	O
possibility	O
of	O
cis	O
-	O
activation	O
by	O
the	O
t	O
(	O
9	O
;	O
22	O
)	O
(	O
q34	O
;	O
q11	O
)	O
translocation	O
.	O
In	O
addition	O
to	O
finding	O
hLH-2	O
expression	O
in	O
all	O
cases	O
of	O
CML	O
,	O
expression	O
was	O
observed	O
in	O
lymphoid	O
malignancies	O
and	O
myeloid	O
cell	O
lines	O
,	O
but	O
not	O
in	O
primary	O
cases	O
of	O
acute	O
myelogenous	O
leukaemia	O
.	O
The	O
role	O
of	O
hLH-2	O
in	O
the	O
development	O
or	O
progression	O
of	O
leukaemia	O
is	O
not	O
known	O
.	O
However	O
,	O
hLH-2	O
may	O
prove	O
useful	O
as	O
a	O
marker	O
of	O
CML	O
for	O
monitoring	O
residual	O
disease	O
.	O
A	O
cell	O
type	O
-	O
specific	O
enhancer	O
in	O
the	O
human	O
B7.1	O
gene	O
regulated	O
by	O
NF	B
-	I
kappaB	I
.	O
The	O
costimulatory	B
molecule	I
B7.1	I
provides	O
a	O
second	O
signal	O
critical	O
for	O
T	O
cell	O
activation	O
.	O
The	O
distribution	O
of	O
this	O
integral	B
membrane	I
protein	I
is	O
restricted	O
to	O
certain	O
tissues	O
where	O
its	O
level	O
of	O
expression	O
is	O
modulated	O
by	O
multiple	O
exogenous	O
stimuli	O
.	O
To	O
identify	O
the	O
molecular	O
basis	O
for	O
specificity	O
and	O
inducibility	O
,	O
the	O
chromatin	O
configuration	O
of	O
the	O
human	O
B7.1	O
gene	O
was	O
examined	O
in	O
intact	O
nuclei	O
from	O
various	O
cell	O
types	O
.	O
The	O
identification	O
of	O
a	O
tissue	O
-	O
specific	O
deoxyribonuclease	O
I	O
hypersensitive	O
site	O
approximately	O
3	O
kb	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
led	O
to	O
the	O
characterization	O
of	O
a	O
cell	O
type	O
-	O
specific	O
enhancer	O
region	O
.	O
This	O
183-bp	O
region	O
was	O
both	O
cell	O
type	O
specific	O
and	O
responsive	O
to	O
two	O
distinct	O
stimuli	O
,	O
lipopolysaccharide	O
and	O
dibutyryl	O
cAMP	O
,	O
known	O
to	O
regulate	O
B7.1	B
expression	O
.	O
Deletional	O
and	O
site	O
-	O
directed	O
mutagenesis	O
revealed	O
the	O
presence	O
of	O
multiple	O
functionally	O
critical	O
cis	O
elements	O
within	O
this	O
region	O
,	O
one	O
of	O
which	O
was	O
a	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappaB	O
consensus	O
sequence	O
.	O
In	O
B7.1-positive	O
B	O
cells	O
,	O
this	O
element	O
bound	O
several	O
members	O
of	O
the	O
NF	B
-	I
kappaB	I
family	I
,	O
transcription	B
factors	I
already	O
implicated	O
in	O
signal	O
transduction	O
pathways	O
relevant	O
to	O
B7.1	B
expression	O
.	O
This	O
is	O
the	O
first	O
description	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
regulatory	O
elements	O
that	O
control	O
expression	O
of	O
a	O
gene	O
encoding	O
a	O
B7	B
costimulatory	I
molecule	I
.	O
HLA	O
-	O
DQB1	O
codon	O
57	O
is	O
critical	O
for	O
peptide	O
binding	O
and	O
recognition	O
.	O
The	O
association	O
of	O
specific	O
HLA	O
-	O
DQ	O
alleles	O
with	O
autoimmunity	O
is	O
correlated	O
with	O
discrete	O
polymorphisms	O
in	O
the	O
HLA	O
-	O
DQ	O
sequence	O
that	O
are	O
localized	O
within	O
sites	O
suitable	O
for	O
peptide	O
recognition	O
.	O
The	O
polymorphism	O
at	O
residue	O
57	O
of	O
the	O
DQB1	O
polypeptide	O
is	O
of	O
particular	O
interest	O
since	O
it	O
may	O
play	O
a	O
major	O
structural	O
role	O
in	O
the	O
formation	O
of	O
a	O
salt	B
bridge	I
structure	I
at	O
one	O
end	O
of	O
the	O
peptide	B
-	I
binding	I
cleft	I
of	O
the	O
DQ	O
molecules	O
.	O
This	O
polymorphism	O
at	O
residue	O
57	O
is	O
a	O
recurrent	O
feature	O
of	O
HLA	O
-	O
DQ	O
evolution	O
,	O
occurring	O
in	O
multiple	O
distinct	O
allelic	O
families	O
,	O
which	O
implies	O
a	O
functional	O
selection	O
for	O
maintaining	O
variation	O
at	O
this	O
position	O
in	O
the	O
class	B
II	I
molecule	I
.	O
We	O
directly	O
tested	O
the	O
amino	O
acid	O
polymorphism	O
at	O
this	O
site	O
as	O
a	O
determinant	O
for	O
peptide	O
binding	O
and	O
for	O
antigen	O
-	O
specific	O
T	O
cell	O
stimulation	O
.	O
We	O
found	O
that	O
a	O
single	O
Ala	O
--	O
>	O
Asp	O
amino	O
acid	O
57	O
substitution	O
in	O
an	O
HLA	O
-	O
DQ3.2	O
molecule	O
regulated	O
binding	O
of	O
an	O
HSV-2	O
VP-16-derived	O
peptide	O
.	O
A	O
complementary	O
single	O
-	O
residue	O
substitution	O
in	O
the	O
peptide	O
abolished	O
its	O
binding	O
to	O
DQ3.2	O
and	O
converted	O
it	O
to	O
a	O
peptide	O
that	O
can	O
bind	O
to	O
DQ3.1	O
and	O
DQ3.3	B
Asp-57-positive	I
MHC	I
molecules	I
.	O
These	O
binding	O
studies	O
were	O
paralleled	O
by	O
specific	O
T	O
cell	O
recognition	O
of	O
the	O
class	B
II	I
-	I
peptide	I
complex	I
,	O
in	O
which	O
the	O
substituted	O
peptide	O
abolished	O
T	O
cell	O
reactivity	O
,	O
which	O
was	O
directed	O
to	O
the	O
DQ3.2-peptide	B
complex	I
,	O
whereas	O
the	O
same	O
T	O
cell	O
clone	O
recognized	O
the	O
substituted	O
peptide	O
presented	O
by	O
DQ3.3	O
,	O
a	O
class	O
II	O
restriction	O
element	O
differing	O
from	O
DQ3.2	O
only	O
at	O
residue	O
57	O
.	O
This	O
structural	O
and	O
functional	O
complementarity	O
for	O
residue	O
57	O
and	O
a	O
specific	O
peptide	O
residue	O
identifies	O
this	O
interaction	O
as	O
a	O
key	O
controlling	O
determinant	O
of	O
restricted	O
recognition	O
in	O
HLA	O
-	O
DQ	O
-	O
specific	O
immune	O
response	O
.	O
Transcription	B
factors	I
of	O
T	O
and	O
B	O
lymphocytes	O
--	O
basic	O
research	O
and	O
clinical	O
perspectives	O
for	O
gastroenterology	O
.	O
Tissue	O
specific	O
regulation	O
of	O
gene	O
expression	O
by	O
transcription	B
factors	I
is	O
a	O
fascinating	O
new	O
field	O
in	O
molecular	O
immunology	O
.	O
This	O
review	O
summarizes	O
data	O
on	O
specific	O
regulation	O
of	O
promoters	O
and	O
enhancers	O
by	O
nuclear	B
trans	I
-	I
acting	I
factors	I
in	O
lymphocytes	O
.	O
The	O
structural	O
classes	O
of	O
transcription	B
factors	I
are	O
described	O
and	O
basic	O
methods	O
for	O
detection	O
and	O
analysis	O
of	O
transcription	B
factors	I
are	O
detailed	O
.	O
Furthermore	O
,	O
the	O
most	O
important	O
trans	B
-	I
acting	I
factors	I
of	O
T	O
and	O
B	O
lymphocytes	O
(	O
e.g	O
.	O
NF	B
-	I
kB	I
,	O
NF	B
-	I
AT	I
and	O
STAT	B
families	I
)	O
and	O
their	O
functional	O
importance	O
are	O
described	O
.	O
Several	O
methods	O
for	O
specific	O
down	O
-	O
regulation	O
of	O
transcription	B
factors	I
are	O
shown	O
that	O
may	O
be	O
relevant	O
to	O
treatment	O
of	O
human	O
disease	O
.	O
The	O
data	O
are	O
discussed	O
with	O
regard	O
to	O
their	O
potential	O
clinical	O
relevance	O
for	O
gastroenterology	O
.	O
Inhibition	O
of	O
alpha	B
interferon	I
but	O
not	O
gamma	B
interferon	I
signal	O
transduction	O
by	O
phorbol	O
esters	O
is	O
mediated	O
by	O
a	O
tyrosine	B
phosphatase	I
.	O
Previous	O
studies	O
have	O
indicated	O
that	O
the	O
expression	O
of	O
viral	O
oncoproteins	O
,	O
cell	O
transformation	O
,	O
or	O
phorbol	O
ester	O
treatment	O
of	O
cells	O
can	O
inhibit	O
alpha	O
/	O
beta	O
interferon	O
(	O
IFN	O
-	O
alpha	O
/	O
beta	O
)	O
-induced	O
gene	O
expression	O
.	O
The	O
mechanisms	O
by	O
which	O
these	O
promoters	O
of	O
cell	O
growth	O
exert	O
their	O
inhibitory	O
effects	O
vary	O
,	O
but	O
in	O
most	O
instances	O
they	O
involve	O
a	O
disruption	O
of	O
the	O
IFN	O
-	O
alpha	O
/	O
beta	O
-	O
induced	O
transcription	O
complex	O
ISGF3	O
such	O
that	O
the	O
DNA	O
-	O
binding	O
component	O
of	O
this	O
complex	O
(	O
the	O
48-kDa	O
ISGF3gamma	O
protein	O
)	O
does	O
not	O
bind	O
to	O
the	O
interferon	O
-	O
stimulated	O
response	O
element	O
(	O
ISRE	O
)	O
.	O
In	O
this	O
report	O
,	O
we	O
demonstrated	O
that	O
phorbol	O
ester	O
treatment	O
of	O
human	O
peripheral	O
blood	O
monocytes	O
dramatically	O
inhibits	O
activation	O
of	O
IFN	O
-	O
alpha	O
/	O
B	O
-	O
stimulated	O
early	O
response	O
genes	O
but	O
by	O
a	O
mechanism	O
which	O
does	O
not	O
involve	O
abrogation	O
of	O
the	O
ISRE	O
binding	O
of	O
ISGF3gamma	O
.	O
Phorbol	O
ester	O
treatment	O
of	O
monocytes	O
inhibited	O
IFN	O
alpha	O
-	O
stimulated	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcription	B
factors	I
Stat1alpha	B
,	O
Stat2	B
,	O
and	O
Stat3	B
and	O
of	O
the	O
tyrosine	B
kinase	I
Tyk2	B
but	O
had	O
no	O
effect	O
on	O
IFN	B
-	I
gamma	I
activation	O
of	O
Stat1alpha	B
.	O
IFNalpha	O
-	O
stimulated	O
tyrosine	O
phosphorylation	O
of	O
Jak1	B
and	O
the	O
alpha	B
subunit	I
of	O
the	O
IFN	B
-	I
alpha	I
receptor	I
were	O
unaffected	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O
Moreover	O
,	O
PMA	O
caused	O
the	O
dephosphorylation	O
of	O
Tyk2	B
but	O
not	O
of	O
Jak1	B
,	O
which	O
was	O
activated	O
by	O
IFN	B
.	O
Pretreatment	O
of	O
cells	O
with	O
vanadate	O
prevented	O
the	O
effects	O
of	O
PMA	O
with	O
regard	O
to	O
PMA	O
-	O
induced	O
Tyk2	B
dephosphorylation	O
.	O
These	O
observations	O
suggest	O
that	O
PMA	O
exerts	O
its	O
inhibitory	O
effects	O
by	O
activation	O
of	O
a	O
tyrosine	B
phosphatase	I
which	O
selectively	O
regulates	O
Tyk2	B
but	O
not	O
Jak1	B
activity	O
.	O
Inhibition	O
of	O
p105	B
processing	O
by	O
NF	B
-	I
kappaB	I
proteins	I
in	O
transiently	O
transfected	O
cells	O
.	O
Regulation	O
of	O
the	O
transcription	O
factor	O
NF	B
-	I
kappaB	I
involves	O
proteasome	O
-	O
mediated	O
processing	O
of	O
the	O
NF	B
-	I
kappaB1	I
p105	I
precursor	I
protein	I
,	O
which	O
generates	O
the	O
p50	B
subunit	I
of	O
NF	B
-	I
kappaB	I
.	O
The	O
processing	O
of	O
p105	B
occurs	O
constitutively	O
in	O
vivo	O
but	O
can	O
be	O
markedly	O
enhanced	O
by	O
various	O
cellular	O
activation	O
agents	O
,	O
although	O
the	O
underlying	O
regulatory	O
mechanism	O
is	O
not	O
yet	O
clear	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
signal	O
-	O
mediated	O
induction	O
of	O
p105	B
processing	O
in	O
human	O
T	O
cells	O
is	O
associated	O
with	O
de	O
novo	O
synthesis	O
of	O
this	O
precursor	B
protein	I
.	O
Transient	O
transfection	O
studies	O
performed	O
in	O
COS7	O
cells	O
revealed	O
that	O
the	O
newly	O
synthesized	O
p105	B
protein	O
appears	O
to	O
be	O
more	O
rapidly	O
processed	O
compared	O
to	O
its	O
accumulated	O
form	O
that	O
is	O
already	O
associated	O
with	O
the	O
processed	O
product	O
p50	B
.	O
Interestingly	O
,	O
the	O
processing	O
rate	O
of	O
p105	B
is	O
markedly	O
inhibited	O
in	O
cells	O
co	O
-	O
transfected	O
with	O
p50	B
or	O
other	O
NF	B
-	I
kappaB	I
subunits	I
,	O
including	O
RelA	B
and	O
c	B
-	I
Rel	I
,	O
that	O
physically	O
interact	O
with	O
p105	B
.	O
These	O
findings	O
suggest	O
that	O
the	O
processing	O
of	O
p105	B
is	O
subject	O
to	O
negative	O
regulation	O
by	O
the	O
various	O
NF	B
-	I
kappaB	I
subunits	I
.	O
We	O
further	O
demonstrate	O
that	O
p105	B
undergoes	O
degradation	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
human	O
monocytic	O
cells	O
.	O
However	O
,	O
the	O
inducible	O
degradation	O
of	O
p105	B
is	O
not	O
coupled	O
with	O
the	O
generation	O
of	O
p50	B
.	O
Together	O
,	O
these	O
studies	O
demonstrate	O
that	O
the	O
processing	O
and	O
inducible	O
degradation	O
of	O
p105	B
are	O
differentially	O
regulated	O
.	O
BCL-6	B
expression	O
during	O
B	O
-	O
cell	O
activation	O
.	O
Translocations	O
involving	O
the	O
BCL-6	O
gene	O
are	O
common	O
in	O
the	O
diffuse	O
large	O
cell	O
subtype	O
of	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
.	O
Invariably	O
,	O
the	O
BCL-6	B
coding	O
region	O
is	O
intact	O
,	O
but	O
its	O
5	O
'	O
untranslated	O
region	O
is	O
replaced	O
with	O
sequences	O
from	O
the	O
translocation	O
partner	O
.	O
The	O
present	O
study	O
shows	O
that	O
BCL-6	B
expression	O
is	O
regulated	O
in	O
lymphocytes	O
during	O
mitogenic	O
stimulation	O
.	O
Resting	O
B	O
and	O
T	O
lymphocytes	O
contain	O
high	O
levels	O
of	O
BCL-6	O
mRNA	O
.	O
Stimulation	O
of	O
mouse	O
B	O
cells	O
with	O
anti	B
-	I
IgM	I
or	I
IgD	I
antibodies	I
,	O
bacterial	O
lipopolysaccharide	O
,	O
phorbol	O
12-myristate	O
13-acetate	O
plus	O
ionomycin	O
,	O
or	O
CD40	B
ligand	I
led	O
to	O
a	O
five	O
-	O
fold	O
to	O
35-fold	O
decrease	O
in	O
BCL-6	O
mRNA	O
levels	O
.	O
Similar	O
downregulation	O
of	O
BCL-6	O
mRNA	O
was	O
seen	O
in	O
human	O
B	O
cells	O
stimulated	O
with	O
Staphylococcus	O
aureus	O
plus	O
interleukin-2	B
or	O
anti	B
-	I
IgM	I
antibodies	I
and	O
in	O
human	O
T	O
lymphocytes	O
stimulated	O
with	O
phytohemagglutinin	B
.	O
BCL-6	O
mRNA	O
levels	O
began	O
to	O
decrease	O
8	O
to	O
16	O
hours	O
after	O
stimulation	O
,	O
before	O
cells	O
entered	O
S	O
phase	O
.	O
Although	O
polyclonal	O
activation	O
of	O
B	O
cells	O
in	O
vitro	O
invariably	O
decreased	O
BCL-6	B
MRNA	O
expression	O
,	O
activated	O
B	O
cells	O
from	O
human	O
germinal	O
centers	O
expressed	O
BCL-6	O
mRNA	O
at	O
levels	O
comparable	O
to	O
the	O
levels	O
in	O
resting	O
B	O
cells	O
.	O
Despite	O
these	O
similar	O
mRNA	O
levels	O
,	O
BCL-6	B
protein	O
expression	O
was	O
threefold	O
to	O
34-fold	O
higher	O
in	O
germinal	O
center	O
B	O
cells	O
than	O
in	O
resting	O
B	O
cells	O
,	O
suggesting	O
that	O
BCL-6	B
protein	O
levels	O
are	O
controlled	O
by	O
translational	O
or	O
posttranslational	O
mechanisms	O
.	O
These	O
observations	O
suggest	O
that	O
the	O
germinal	O
center	O
reaction	O
provides	O
unique	O
activation	O
signals	O
to	O
B	O
cells	O
that	O
allow	O
for	O
continued	O
,	O
high	O
-	O
level	O
BCL-6	B
expression	O
.	O
Modulation	O
of	O
the	O
expression	O
of	O
the	O
IFN	B
-	I
gamma	I
receptor	I
beta	I
-	I
chain	I
controls	O
responsiveness	O
to	O
IFN	B
-	I
gamma	I
in	O
human	O
peripheral	O
blood	O
T	O
cells	O
.	O
IFN	B
-	I
gamma	I
has	O
potent	O
antiproliferative	O
and	O
apoptotic	O
effects	O
in	O
T	O
cells	O
that	O
are	O
important	O
in	O
determining	O
T	O
cell	O
development	O
and	O
polarized	O
differentiation	O
.	O
Therefore	O
,	O
any	O
event	O
that	O
enables	O
T	O
cells	O
to	O
become	O
less	O
responsive	O
to	O
IFN-	B
gamma	I
may	O
potentially	O
alter	O
immune	O
responsiveness	O
to	O
Ag	B
.	O
In	O
this	O
work	O
,	O
we	O
show	O
that	O
human	O
peripheral	O
blood	O
T	O
cells	O
that	O
are	O
stimulated	O
through	O
the	O
TCR	B
and	O
expanded	O
with	O
IL-2	B
are	O
unresponsive	O
to	O
IFN	B
-	I
gamma	I
,	O
as	O
determined	O
by	O
a	O
lack	O
of	O
activation	O
of	O
jak	B
kinases	I
and	O
the	O
transcription	B
factor	I
,	O
STAT1	B
(	I
alpha	I
)	I
,	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
.	O
This	O
nonresponsiveness	O
occurs	O
because	O
of	O
a	O
lack	O
of	O
expression	O
of	O
the	O
beta-	B
chain	I
(	O
accessory	O
factor	O
)	O
of	O
the	O
IFN	B
-	I
gamma	I
receptor	I
,	O
while	O
at	O
the	O
same	O
time	O
maintaining	O
IFN	B
-	I
gamma	I
receptor	I
alpha	I
-	I
chain	I
expression	O
.	O
Expression	O
of	O
the	O
beta	B
-	I
chain	I
can	O
be	O
restored	O
by	O
secondary	O
TCR	B
ligation	O
or	O
PMA	O
treatment	O
.	O
T	O
cell	O
blasts	O
treated	O
with	O
PMA	O
are	O
now	O
responsive	O
to	O
IFN	B
-	I
gamma	I
.	O
When	O
freshly	O
isolated	O
,	O
highly	O
enriched	O
(	O
>	O
98	O
%	O
)	O
T	O
cells	O
are	O
examined	O
for	O
IFN	B
-	I
gamma	I
responsiveness	O
;	O
these	O
cells	O
can	O
respond	O
to	O
IFN	B
-	I
gamma	I
and	O
express	O
beta	B
-	I
chain	I
.	O
Therefore	O
,	O
as	O
T	O
cells	O
progress	O
from	O
primary	O
TCR	B
activation	O
through	O
IL-2	B
-dependent	O
proliferation	O
,	O
followed	O
by	O
secondary	O
TCR	B
stimulation	O
,	O
their	O
responsiveness	O
to	O
IFN	B
-	I
gamma	I
varies	O
,	O
and	O
this	O
may	O
affect	O
their	O
ability	O
to	O
participate	O
in	O
an	O
ongoing	O
immune	O
response	O
.	O
Antisense	O
inhibition	O
of	O
vitamin	B
D	I
receptor	I
expression	O
induces	O
apoptosis	O
in	O
monoblastoid	O
U937	O
cells	O
.	O
The	O
active	O
vitamin	O
D3	O
metabolite	O
1	O
,	O
25-dihydroxycholecalciferol	O
(	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
acts	O
as	O
an	O
antiproliferative	O
and	O
differentiating	O
agent	O
for	O
the	O
monoblastoid	O
cell	O
line	O
U937	O
and	O
as	O
an	O
important	O
immunologic	O
mediator	O
implicated	O
particularly	O
in	O
the	O
function	O
of	O
cells	O
belonging	O
to	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
.	O
These	O
effects	O
are	O
controlled	O
by	O
the	O
vitamin	B
D	I
receptor	I
(	O
VDR	B
)	O
,	O
a	O
member	O
of	O
the	O
steroid	B
hormone	I
receptor	I
family	I
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
develop	O
U937	O
transfectants	O
expressing	O
antisense	O
VDR	O
mRNA	O
,	O
and	O
to	O
use	O
these	O
to	O
examine	O
the	O
role	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-VDR	B
interaction	O
in	O
this	O
lineage	O
.	O
A	O
2-kb	O
VDR	O
cDNA	O
insert	O
(	O
including	O
the	O
complete	O
VDR	O
coding	O
region	O
)	O
was	O
cloned	O
in	O
an	O
antisense	O
orientation	O
into	O
the	O
EBV	O
episomal	O
vector	O
pMEP4	O
under	O
the	O
control	O
of	O
an	O
inducible	O
promoter	O
and	O
transfected	O
into	O
U937	O
.	O
The	O
resultant	O
cell	O
line	O
,	O
DH42	O
,	O
was	O
hygromycin	O
resistant	O
,	O
contained	O
VDR	O
cDNA	O
,	O
expressed	O
fewer	O
VDRs	B
than	O
controls	O
,	O
and	O
showed	O
a	O
substantial	O
decrease	O
in	O
antiproliferative	O
response	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O
However	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
increased	O
the	O
number	O
of	O
cells	O
expressing	O
macrophage	B
cell	I
surface	I
Ags	I
,	O
including	O
CD14	B
and	O
CD11b	B
.	O
A	O
subpopulation	O
of	O
smaller	O
cells	O
did	O
not	O
express	O
the	O
differentiation	O
markers	O
after	O
cadmium	O
stimulation	O
.	O
Cell	O
cycle	O
analysis	O
showed	O
shifts	O
in	O
the	O
distribution	O
of	O
cells	O
from	O
G1	O
to	O
S	O
phase	O
,	O
which	O
were	O
more	O
pronounced	O
after	O
cadmium	O
treatment	O
.	O
A	O
considerable	O
proportion	O
of	O
cells	O
were	O
outside	O
the	O
cycle	O
and	O
DNA	O
fragmentation	O
confirmed	O
apoptosis	O
.	O
Thus	O
,	O
the	O
functional	O
outcome	O
of	O
the	O
VDR	B
antisense	O
transfection	O
suggests	O
that	O
in	O
the	O
myelomonocytic	O
lineage	O
,	O
VDR	B
expression	O
may	O
act	O
as	O
a	O
protective	O
mechanism	O
against	O
programmed	O
cell	O
death	O
.	O
Opposing	O
effects	O
of	O
glucocorticoids	O
on	O
the	O
rate	O
of	O
apoptosis	O
in	O
neutrophilic	O
and	O
eosinophilic	O
granulocytes	O
.	O
Eosinophils	O
and	O
neutrophils	O
are	O
closely	O
related	O
,	O
terminally	O
differentiated	O
cells	O
that	O
in	O
vitro	O
undergo	O
constitutive	O
cell	O
death	O
by	O
apoptosis	O
.	O
The	O
onset	O
of	O
apoptosis	O
in	O
both	O
cell	O
types	O
can	O
be	O
delayed	O
by	O
hemopoietins	B
and	O
inflammatory	B
mediators	I
.	O
Although	O
there	O
have	O
been	O
a	O
number	O
of	O
reports	O
demonstrating	O
that	O
glucocorticoids	O
(	O
in	O
particular	O
dexamethasone	O
)	O
antagonize	O
the	O
eosinophil	O
life	O
-	O
prolonging	O
effects	O
of	O
hemopoietins	B
,	O
direct	O
effects	O
of	O
dexamethasone	O
on	O
eosinophil	O
apoptosis	O
have	O
not	O
been	O
documented	O
.	O
In	O
this	O
study	O
we	O
examined	O
the	O
direct	O
effects	O
of	O
glucocorticoids	O
on	O
eosinophil	O
and	O
neutrophil	O
apoptosis	O
in	O
light	O
of	O
their	O
common	O
therapeutic	O
use	O
as	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
allergic	O
/	O
hypereosinophilic	O
agents	O
.	O
We	O
found	O
that	O
treatment	O
with	O
dexamethasone	O
induced	O
eosinophil	O
apoptosis	O
.	O
In	O
contrast	O
,	O
dexamethasone	O
was	O
a	O
potent	O
inhibitor	O
of	O
neutrophil	O
apoptosis	O
.	O
The	O
effect	O
of	O
dexamethasone	O
on	O
both	O
cell	O
types	O
was	O
mediated	O
through	O
the	O
glucocorticoid	B
receptor	I
,	O
i.e.	O
,	O
it	O
was	O
abolished	O
by	O
the	O
glucocorticoid	B
receptor	I
antagonist	O
RU38486	O
.	O
This	O
is	O
the	O
first	O
description	O
of	O
an	O
agent	O
that	O
promotes	O
eosinophil	O
apoptosis	O
while	O
inhibiting	O
neutrophil	O
apoptosis	O
,	O
and	O
thus	O
presents	O
a	O
novel	O
approach	O
to	O
the	O
study	O
of	O
control	O
of	O
apoptosis	O
in	O
these	O
closely	O
related	O
cell	O
types	O
as	O
well	O
as	O
increases	O
our	O
understanding	O
of	O
the	O
clinical	O
action	O
of	O
glucocorticoids	O
in	O
inflammation	O
.	O
Recombinant	O
NFAT1	B
(	O
NFATp	O
)	O
is	O
regulated	O
by	O
calcineurin	O
in	O
T	O
cells	O
and	O
mediates	O
transcription	O
of	O
several	O
cytokine	O
genes	O
.	O
Transcription	B
factors	I
of	O
the	O
NFAT	B
family	I
play	O
a	O
key	O
role	O
in	O
the	O
transcription	O
of	O
cytokine	O
genes	O
and	O
other	O
genes	O
during	O
the	O
immune	O
response	O
.	O
We	O
have	O
identified	O
two	O
new	O
isoforms	O
of	O
the	O
transcription	B
factor	I
NFAT1	B
(	O
previously	O
termed	O
NFATp	B
)	O
that	O
are	O
the	O
predominant	O
isoforms	O
expressed	O
in	O
murine	O
and	O
human	O
T	O
cells	O
.	O
When	O
expressed	O
in	O
Jurkat	O
T	O
cells	O
,	O
recombinant	O
NFAT1	B
is	O
regulated	O
,	O
as	O
expected	O
,	O
by	O
the	O
calmodulin	B
-	I
dependent	I
phosphatase	I
calcineurin	B
,	O
and	O
its	O
function	O
is	O
inhibited	O
by	O
the	O
immunosuppressive	O
agent	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O
Transactivation	O
by	O
recombinant	O
NFAT1	B
in	O
Jurkat	O
T	O
cells	O
requires	O
dual	O
stimulation	O
with	O
ionomycin	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
;	O
this	O
activity	O
is	O
potentiated	O
by	O
coexpression	O
of	O
constitutively	O
active	O
calcineurin	B
and	O
is	O
inhibited	O
by	O
CsA	O
.	O
Immunocytochemical	O
analysis	O
indicates	O
that	O
recombinant	O
NFAT1	B
localizes	O
in	O
the	O
cytoplasm	O
of	O
transiently	O
transfected	O
T	O
cells	O
and	O
translocates	O
into	O
the	O
nucleus	O
in	O
a	O
CsA	O
-	O
sensitive	O
manner	O
following	O
ionomycin	O
stimulation	O
.	O
When	O
expressed	O
in	O
COS	O
cells	O
,	O
however	O
,	O
NFAT1	B
is	O
capable	O
of	O
transactivation	O
,	O
but	O
it	O
is	O
not	O
regulated	O
correctly	O
:	O
its	O
subcellular	O
localization	O
and	O
transcriptional	O
function	O
are	O
not	O
affected	O
by	O
stimulation	O
of	O
the	O
COS	O
cells	O
with	O
ionomycin	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
.	O
Recombinant	O
NFAT1	B
can	O
mediate	O
transcription	O
of	O
the	O
interleukin-2	B
,	O
interleukin-4	O
,	O
tumor	B
necrosis	I
factor	I
alpha	I
,	O
and	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
promoters	O
in	O
T	O
cells	O
,	O
suggesting	O
that	O
NFAT1	B
contributes	O
to	O
the	O
CsA	O
-	O
sensitive	O
transcription	O
of	O
these	O
genes	O
during	O
the	O
immune	O
response	O
.	O
Epstein	B
-	I
Barr	I
virus	I
nuclear	I
antigen	I
2	I
and	O
latent	B
membrane	I
protein	I
independently	O
transactivate	O
p53	B
through	O
induction	O
of	O
NF	B
-	I
kappaB	I
activity	O
.	O
B	O
-	O
cell	O
immortalization	O
by	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
dependent	O
on	O
permanent	O
control	O
of	O
the	O
cellular	O
processes	O
which	O
normally	O
regulate	O
cell	O
division	O
and	O
apoptosis	O
,	O
functions	O
possessed	O
by	O
p53	B
in	O
a	O
number	O
of	O
normal	O
cell	O
types	O
.	O
In	O
studies	O
initiated	O
to	O
evaluate	O
relationships	O
between	O
EBV	O
latent	O
genes	O
and	O
p53	B
,	O
p53	B
levels	O
were	O
found	O
to	O
increase	O
approximately	O
10-fold	O
4	O
to	O
5	O
days	O
after	O
EBV	O
infection	O
of	O
purified	O
resting	O
human	O
B	O
cells	O
;	O
the	O
induced	O
p53	B
was	O
transcriptionally	O
active	O
.	O
Latent	B
membrane	I
protein	I
1	I
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
EBV	B
nuclear	I
antigen	I
2	I
mediated	O
the	O
increase	O
in	O
p53	B
levels	O
via	O
activation	O
of	O
the	O
NF	B
-	I
kappaB	I
transcription	B
factor	I
.	O
Interleukin	B
10	I
induced	O
c	O
-	O
fos	O
expression	O
in	O
human	O
B	O
cells	O
by	O
activation	O
of	O
divergent	B
protein	I
kinases	I
.	O
IL-10	B
is	O
a	O
potent	O
mediator	O
of	O
human	O
B	O
cell	O
growth	O
and	O
plasma	O
cell	O
formation	O
.	O
However	O
,	O
signal	O
transduction	O
of	O
IL-10	B
in	O
B	O
cells	O
is	O
poorly	O
understood	O
.	O
In	O
this	O
study	O
the	O
effect	O
of	O
IL-10	B
on	O
the	O
expression	O
of	O
the	O
protooncogene	O
c	O
-	O
fos	O
was	O
investigated	O
,	O
because	O
Fos	O
plays	O
a	O
potential	O
role	O
in	O
the	O
regulation	O
of	O
B	O
cell	O
proliferation	O
and	O
differentiation	O
.	O
B	O
cells	O
were	O
purified	O
from	O
buffy	O
coat	O
preparations	O
of	O
healthy	O
blood	O
donors	O
by	O
positive	O
selection	O
using	O
an	O
anti	B
CD20	I
monoclonal	I
antibody	I
and	O
a	O
MiniMACS	O
separation	O
unit	O
.	O
B	O
cells	O
were	O
prestimulated	O
with	O
SAC	O
for	O
48	O
hrs	O
.	O
Then	O
,	O
cells	O
were	O
incubated	O
with	O
medium	O
or	O
IL-10	B
(	O
100	O
ng	O
/	O
ml	O
)	O
for	O
10	O
to	O
120	O
min	O
.	O
RNA	O
was	O
extracted	O
by	O
phenol	O
/	O
chloroform	O
and	O
c	O
-	O
fos	O
expression	O
was	O
analyzed	O
by	O
PCR	O
assisted	O
mRNA	O
assay	O
.	O
A	O
significant	O
2	O
-	O
4	O
fold	O
increase	O
of	O
c	O
-	O
fos	O
expression	O
was	O
observed	O
within	O
30	O
min	O
of	O
stimulation	O
with	O
IL-10	B
(	O
p	O
<	O
0.01	O
)	O
.	O
After	O
2	O
hrs	O
c	O
-	O
fos	O
expression	O
declined	O
to	O
basal	O
levels	O
.	O
The	O
effect	O
of	O
IL-10	B
was	O
dose	O
-	O
dependent	O
with	O
a	O
maximum	O
stimulation	O
using	O
100	O
ng	O
/	O
ml	O
of	O
IL-10	B
.	O
The	O
IL-10	B
effect	O
on	O
c	O
-	O
fos	O
expression	O
was	O
not	O
blocked	O
by	O
polymyxin	O
B	O
.	O
Using	O
the	O
tyrosine	O
kinase	O
inhibitor	O
genistein	O
(	O
10	O
microM	O
)	O
a	O
complete	O
inhibition	O
of	O
IL-10	B
induced	O
c	O
-	O
fos	O
expression	O
was	O
observed	O
.	O
In	O
addition	O
,	O
H-7	O
(	O
10	O
microM	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
serine	B
/	I
threonine	I
kinases	I
,	O
significantly	O
blocked	O
IL-10	B
mediated	O
c	O
-	O
fos	O
expression	O
(	O
p	O
<	O
0.05	O
)	O
.	O
In	O
conclusion	O
,	O
these	O
data	O
show	O
that	O
IL-10	B
induces	O
c	O
-	O
fos	O
expression	O
in	O
human	O
B	O
-	O
cells	O
by	O
activation	O
of	O
tyrosine	O
and	O
serine	B
/	I
threonine	I
kinases	I
.	O
Since	O
this	O
is	O
the	O
first	O
report	O
on	O
IL-10	B
induced	O
signal	O
transduction	O
,	O
these	O
data	O
may	O
help	O
to	O
identify	O
the	O
intracellular	O
mechanisms	O
by	O
which	O
IL-10	B
stimulates	O
human	O
B	O
-	O
cells	O
.	O
An	O
alternatively	O
spliced	O
isoform	O
of	O
the	O
Spi	B
-	I
B	I
transcription	B
factor	I
.	O
Spi	B
-	I
B	I
is	O
an	O
Ets	B
transcription	I
factor	I
related	O
to	O
the	O
oncoprotein	B
Spi-1	B
/	I
PU.1	I
and	O
highly	O
expressed	O
in	O
B	O
lymphoid	O
cells	O
.	O
The	O
Ets	B
proteins	I
share	O
a	O
conserved	O
Ets	B
domain	I
that	O
mediates	O
specific	O
DNA	O
binding	O
.	O
Spi	B
-	I
B	I
binds	O
DNA	O
sequences	O
containing	O
a	O
core	O
5'-GGAA-3	O
'	O
and	O
activates	O
transcription	O
through	O
this	O
motif	O
.	O
Up	O
to	O
date	O
,	O
the	O
biological	O
function	O
of	O
Spi	B
-	I
B	I
remains	O
unknown	O
.	O
Here	O
,	O
we	O
describe	O
the	O
characterization	O
of	O
an	O
alternatively	O
spliced	O
variant	O
of	O
Spi	B
-	I
B	I
,	O
named	O
deltaSpi	B
-	I
B	I
,	O
which	O
has	O
lost	O
the	O
Ets	B
domain	I
.	O
In	O
B	O
lymphoid	O
cells	O
,	O
deltaspi	O
-	O
B	O
and	O
spi	O
-	O
B	O
mRNAs	O
were	O
present	O
simultaneously	O
in	O
a	O
ratio	O
of	O
around	O
10	O
%	O
.	O
DeltaSpi	B
-	I
B	I
product	O
was	O
not	O
able	O
to	O
bind	O
DNA	O
and	O
was	O
recovered	O
in	O
cytoplasmic	O
cellular	O
extracts	O
.	O
We	O
raise	O
the	O
hypothesis	O
that	O
delta	B
Spi	I
-	I
B	I
might	O
affect	O
Spi	B
-	I
B	I
function	O
by	O
recruiting	O
factors	O
involved	O
in	O
Spi	B
-	I
B	I
activity	O
.	O
Differential	O
utilization	O
of	O
Janus	B
kinase	I
-signal	O
transducer	O
activator	O
of	O
transcription	O
signaling	O
pathways	O
in	O
the	O
stimulation	O
of	O
human	O
natural	O
killer	O
cells	O
by	O
IL-2	B
,	O
IL-12	B
,	O
and	O
IFN	B
-	I
alpha	I
.	O
IL-2-	O
,	O
IL-12-	O
,	O
and	O
IFN	O
-	O
alpha	O
-	O
mediated	O
signaling	O
pathways	O
were	O
analyzed	O
in	O
primary	O
NK	O
cells	O
and	O
in	O
the	O
NK3.3	O
cell	O
line	O
.	O
Gel	O
mobility	O
shift	O
and	O
immunoprecipitation	O
analyses	O
revealed	O
that	O
in	O
addition	O
to	O
activating	O
STAT3	B
(	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription-3	I
)	O
and	O
STAT5	B
,	O
IL-2	B
induced	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
STAT1	B
alpha	I
,	O
which	O
formed	O
IFN	B
-	I
gamma	I
-	I
activated	I
sequence	I
-	I
binding	I
complexes	I
by	O
itself	O
and	O
with	O
STAT3	B
.	O
Although	O
IL-2	B
and	O
IFN	B
-	I
alpha	I
activated	O
STAT1	B
alpha	I
and	O
STAT5	B
,	O
IL-2	B
predominantly	O
activated	O
STAT5	B
,	O
while	O
IFN	B
-	I
alpha	I
predominantly	O
activated	O
STAT1	B
alpha	I
.	O
IL-2	B
induced	O
less	O
STAT1	B
alpha	I
activation	O
and	O
IFN	B
-	I
alpha	I
induced	O
greater	O
STAT5	B
activation	O
in	O
NK3.3	O
cells	O
compared	O
with	O
preactivated	O
primary	O
NK	O
cells	O
.	O
In	O
NK3.3	O
cells	O
,	O
IL-2	B
induced	O
comparable	O
formation	O
of	O
c	B
-	I
fos	I
promoter	I
sis	I
-	I
inducible	I
element	I
IFN	I
-	I
gamma	I
-	I
activated	I
sequence	I
-	I
binding	I
complexes	I
containing	O
STAT3	B
alone	O
with	O
complexes	O
containing	O
STAT3	B
and	O
STAT1	B
alpha	I
,	O
while	O
in	O
preactivated	O
primary	O
NK	O
cells	O
,	O
it	O
preferentially	O
induced	O
complexes	O
containing	O
STAT3	B
and	O
STAT1	B
alpha	I
.	O
Thus	O
,	O
signaling	O
in	O
NK3.3	O
cells	O
is	O
not	O
always	O
identical	O
with	O
that	O
in	O
primary	O
NK	O
cells	O
.	O
In	O
contrast	O
to	O
IL-2	B
and	O
IFN	B
-	I
alpha	I
,	O
IL-12	B
induced	O
strong	O
tyrosine	O
phosphorylation	O
of	O
STAT4	B
and	O
variable	O
weak	O
phosphorylation	O
of	O
STAT3	B
.	O
However	O
,	O
supershift	O
analyses	O
using	O
the	O
c	O
-	O
fos	O
promoter	O
sis	O
-	O
inducible	O
element	O
probe	O
showed	O
that	O
IL-12	B
activated	O
STAT4	B
,	O
STAT1	B
alpha	I
,	O
and	O
STAT3	B
,	O
and	O
induced	O
complexes	O
containing	O
STAT4	B
only	O
,	O
STAT4	B
with	O
STAT1	B
alpha	I
,	O
STAT3	B
with	O
STAT1	B
alpha	I
,	O
or	O
STAT1	B
alpha	I
only	O
in	O
preactivated	O
primary	O
NK	O
cells	O
.	O
STAT1	B
alpha	I
activation	O
by	O
IL-12	B
correlated	O
with	O
increased	O
phosphorylation	O
of	O
serine	O
,	O
but	O
not	O
tyrosine	O
.	O
Finally	O
,	O
IL-2	B
induced	O
tyrosine	O
phosphorylation	O
of	O
JAK1	B
and	O
JAK3	B
,	O
while	O
IL-12	B
induced	O
phosphorylation	O
of	O
JAK2	B
and	O
TYK2	B
in	O
both	O
preactivated	O
primary	O
NK	O
and	O
NK3.3	O
cells	O
.	O
Differential	O
phosphorylation	O
and	O
consequent	O
differential	O
activation	O
of	O
both	O
separate	O
and	O
overlapping	O
STAT	B
proteins	I
by	O
IL-2	B
,	O
IL-12	B
,	O
and	O
IFN	B
-	I
alpha	I
may	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
similarities	O
and	O
differences	O
in	O
the	O
actions	O
of	O
these	O
cytokines	B
on	O
NK	O
cells	O
.	O
Glucocorticoids	O
and	O
interferon	B
-	I
alpha	I
in	O
the	O
acquired	O
immunodeficiency	O
syndrome	O
.	O
Some	O
patients	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
develop	O
glucocorticoid	O
resistance	O
characterized	O
by	O
low	O
receptor	O
affinity	O
(	O
Kd	O
)	O
for	O
glucocorticoids	O
in	O
mononuclear	O
,	O
cells	O
and	O
high	O
values	O
of	O
ACTH	O
and	O
cortisol	O
.	O
As	O
glucocorticoids	O
regulate	O
interferon	B
-	I
alpha	I
(	O
IFN	B
alpha	I
)	O
production	O
,	O
we	O
hypothesized	O
that	O
IFN	B
alpha	I
,	O
a	O
cytokine	B
produced	O
predominantly	O
by	O
monocytes	O
in	O
AIDS	O
,	O
should	O
be	O
increased	O
in	O
cortisol	O
-	O
resistant	O
AIDS	O
,	O
attributing	O
the	O
lack	O
of	O
cortisol	O
inhibition	O
to	O
IFN	B
alpha	I
production	O
.	O
Therefore	O
,	O
we	O
examined	O
glucocorticoid	B
receptor	I
characteristics	O
on	O
monocytes	O
by	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
measured	O
IFN	B
alpha	I
,	O
cortisol	O
,	O
and	O
ACTH	O
in	O
AIDS	O
patients	O
with	O
(	O
AIDS	O
-	O
GR	O
)	O
or	O
without	O
glucocorticoid	O
resistance	O
(	O
AIDS	O
-	O
C	O
)	O
and	O
controls	O
(	O
C	O
)	O
.	O
Monocytes	O
of	O
AIDS	O
-	O
GR	O
patients	O
had	O
a	O
receptor	O
Kd	O
of	O
10.5	O
+	O
/-	O
4.2	O
nmol	O
/	O
L	O
that	O
was	O
higher	O
than	O
that	O
in	O
the	O
AIDS	O
-	O
C	O
group	O
(	O
2.9	O
+	O
/-	O
0.8	O
nmol	O
/	O
L	O
)	O
and	O
normal	O
subjects	O
(	O
2.0	O
+	O
/-	O
0.8	O
nmol	O
/	O
L	O
;	O
P	O
<	O
0.01	O
)	O
.	O
IFN	B
alpha	I
levels	O
were	O
increased	O
in	O
the	O
AIDS	O
-	O
GR	O
group	O
(	O
17	O
+	O
/-	O
6	O
vs	O
.	O
4	O
+	O
/-	O
1	O
U	O
/	O
mL	O
in	O
the	O
AIDS	O
-	O
C	O
group	O
and	O
2	O
+	O
/-	O
0.5	O
U	O
/	O
mL	O
in	O
the	O
C	O
group	O
;	O
P	O
<	O
0.01	O
)	O
.	O
Correlations	O
were	O
found	O
between	O
plasma	B
IFN	I
alpha	I
and	O
receptor	O
Kd	O
on	O
monocytes	O
of	O
AIDS	O
-	O
GR	O
(	O
r	O
=	O
0.77	O
)	O
and	O
between	O
IFN	B
alpha	I
and	O
plasma	O
cortisol	O
in	O
the	O
same	O
group	O
(	O
r	O
=	O
0.74	O
)	O
.	O
The	O
poly	B
(	I
I	I
)	I
-poly	I
(	I
C	I
)	I
-induced	I
IFN	I
alpha	I
production	O
by	O
monocytes	O
was	O
inhibited	O
by	O
glucocorticoids	O
in	O
the	O
C	O
and	O
AIDS	O
-	O
C	O
groups	O
(	O
approximately	O
80	O
%	O
inhibition	O
in	O
both	O
groups	O
)	O
;	O
the	O
effect	O
was	O
reversed	O
by	O
the	O
receptor	O
antagonist	O
RU-38486	O
.	O
By	O
contrast	O
,	O
glucocorticoids	O
failed	O
to	O
inhibit	O
IFNalpha	B
production	O
from	O
AIDS	O
-	O
GR	O
monocytes	O
(	O
approximately	O
20	O
%	O
inhibition	O
)	O
.	O
In	O
conclusion	O
,	O
elevated	O
IFN	B
alpha	I
levels	O
in	O
AIDS	O
-	O
GR	O
may	O
be	O
due	O
to	O
the	O
lack	O
of	O
inhibitory	O
effect	O
of	O
cortisol	O
on	O
IFN	B
alpha	I
production	O
due	O
to	O
cortisol	O
resistance	O
in	O
monocytes	O
Receptors	O
for	O
interleukin	B
(	I
IL	I
)	I
-10	I
and	I
IL-6-type	I
cytokines	I
use	O
similar	O
signaling	O
mechanisms	O
for	O
inducing	O
transcription	O
through	O
IL-6	O
response	O
elements	O
.	O
The	O
cytoplasmic	B
domain	I
of	O
the	O
receptor	O
for	O
interleukin	B
10	I
(	O
IL-10R	B
)	O
contains	O
two	O
box	B
3	I
sequence	I
motifs	I
that	O
have	O
been	O
identified	O
in	O
the	O
signal	B
-	I
transducing	I
receptor	I
subunits	I
for	O
IL-6-type	B
cytokines	I
and	O
noted	O
to	O
be	O
required	O
for	O
activating	O
STAT3	B
and	O
inducing	O
transcription	O
through	O
IL-6-responsive	O
elements	O
.	O
To	O
determine	O
whether	O
the	O
IL-10R	B
has	O
signaling	O
functions	O
similar	O
to	O
IL-6R	B
in	O
cells	O
normally	O
expressing	O
these	O
receptors	O
,	O
leukocytes	O
of	O
the	O
B-	O
,	O
T-	O
,	O
and	O
NK	O
-	O
cell	O
lineages	O
were	O
treated	O
with	O
either	O
cytokine	O
.	O
Both	O
cytokines	B
activated	O
factors	O
that	O
bound	O
to	O
the	O
sis	O
-	O
inducible	O
element	O
and	O
included	O
STAT1	B
and	O
STAT3	B
.	O
The	O
cell	O
response	O
to	O
IL-10	B
characteristically	O
differed	O
from	O
that	O
to	O
IL-2	B
/	I
IL-15	I
,	O
IL-4	B
,	O
and	O
interferon	B
gamma	I
.	O
The	O
signaling	O
capabilities	O
of	O
the	O
IL-10R	B
for	O
activating	O
specific	O
STAT	B
proteins	I
and	O
inducing	O
gene	O
transcription	O
were	O
defined	O
by	O
reconstitution	O
of	O
receptor	O
functions	O
in	O
transfected	O
tissue	O
culture	O
cells	O
.	O
COS-1	O
cells	O
,	O
co	O
-	O
expressing	O
the	O
human	O
IL-10R	B
and	O
individual	O
STAT	B
proteins	I
,	O
confirmed	O
a	O
preference	O
of	O
the	O
IL-10R	B
for	O
STAT3	B
and	O
STAT1	B
.	O
Unlike	O
many	O
hematopoietin	B
receptors	I
,	O
the	O
IL-10R	B
did	O
not	O
detectably	O
activate	O
STAT5	B
.	O
The	O
IL-10R	B
,	O
together	O
with	O
reporter	O
gene	O
constructs	O
containing	O
different	O
IL-6-responsive	O
gene	O
elements	O
,	O
reconstituted	O
in	O
hepatoma	O
cells	O
an	O
induction	O
of	O
transcription	O
by	O
IL-10	B
that	O
was	O
comparable	O
to	O
that	O
by	O
IL-6	B
.	O
This	O
regulation	O
could	O
not	O
be	O
appreciably	O
modified	O
by	O
enhanced	O
expression	O
of	O
STAT	B
proteins	I
.	O
The	O
similar	O
actions	O
of	O
IL-10R	B
and	O
IL-6R	B
on	O
the	O
induction	O
of	O
endogenous	O
IL-6-responsive	O
genes	O
were	O
demonstrated	O
in	O
hepatoma	O
cells	O
stably	O
expressing	O
the	O
IL-10R	B
.	O
These	O
receptor	O
functions	O
required	O
the	O
presence	O
of	O
the	O
box	B
3	I
motifs	I
,	O
as	O
shown	O
by	O
the	O
analysis	O
of	O
the	O
mouse	O
IL-10R	B
constructs	O
containing	O
progressively	B
truncated	I
cytoplasmic	I
domains	I
.	O
The	O
data	O
demonstrate	O
that	O
the	O
IL-10R	B
,	O
unlike	O
other	O
members	O
of	O
the	O
interferon	O
receptor	O
family	O
,	O
is	O
highly	O
effective	O
in	O
recruiting	O
the	O
signaling	O
pathways	O
of	O
IL-6-type	B
cytokine	I
receptors	I
.	O
DNA	O
triplex	O
formation	O
selectively	O
inhibits	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
gene	O
expression	O
in	O
human	O
T	O
cells	O
.	O
Granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
is	O
a	O
hemopoietic	O
growth	O
factor	O
that	O
is	O
expressed	O
in	O
activated	O
T	O
cells	O
,	O
fibroblasts	O
,	O
macrophages	O
,	O
and	O
endothelial	O
cells	O
.	O
Although	O
GM	B
-	I
CSF	I
does	O
not	O
appear	O
to	O
be	O
essential	O
for	O
normal	O
hemopoiesis	O
,	O
overexpression	O
of	O
GM	O
-	O
CSF	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
some	O
diseases	O
such	O
as	O
myeloid	O
leukemia	O
and	O
chronic	O
inflammation	O
.	O
An	O
NF	B
-	I
kappaB	I
/Rel	O
binding	O
site	O
within	O
the	O
GM	O
-	O
CSF	O
promoter	O
,	O
termed	O
the	O
kappaB	O
element	O
appears	O
to	O
be	O
important	O
for	O
controlling	O
expression	O
in	O
reporter	O
gene	O
assays	O
in	O
response	O
to	O
a	O
number	O
of	O
stimuli	O
in	O
T	O
cells	O
.	O
We	O
investigated	O
oligonucleotide	O
-	O
directed	O
triple	O
helix	O
formation	O
across	O
this	O
regulatory	O
sequence	O
as	O
a	O
potential	O
tool	O
to	O
inhibit	O
GM	B
-	I
CSF	I
gene	O
transcription	O
.	O
A	O
15-base	O
oligonucleotide	O
,	O
GM3	O
,	O
was	O
targeted	O
to	O
a	O
purine	O
-	O
rich	O
region	O
in	O
the	O
GM	O
-	O
CSF	O
proximal	O
promoter	O
,	O
which	O
overlaps	O
the	O
kappaB	O
element	O
.	O
Gel	O
mobility	O
shift	O
assays	O
and	O
DNase	B
I	I
footprinting	O
demonstrated	O
that	O
GM3	O
formed	O
a	O
sequence	O
-	O
specific	O
collinear	O
triplex	O
with	O
its	O
double	O
-	O
stranded	O
DNA	O
target	O
.	O
Triplex	O
formation	O
by	O
GM3	O
blocked	O
recombinant	B
and	I
nuclear	I
NF	I
-	I
kappaB	I
proteins	I
binding	O
to	O
the	O
GM	O
-	O
CSF	O
element	O
.	O
GM3	O
also	O
caused	O
selective	O
inhibition	O
of	O
the	O
human	B
T	I
-	I
cell	I
lymphotrophic	I
virus-1	I
Tax	I
transactivator	O
-	O
induced	O
luciferase	B
activity	O
from	O
a	O
reporter	O
construct	O
driven	O
by	O
the	O
GM	O
-	O
CSF	O
promoter	O
in	O
Jurkat	O
T	O
cells	O
.	O
Finally	O
,	O
GM3	O
greatly	O
reduced	O
the	O
concentration	O
of	O
endogenous	O
GM	O
-	O
CSF	O
mRNA	O
induced	O
by	O
different	O
stimuli	O
in	O
Jurkat	O
T	O
cells	O
but	O
did	O
not	O
affect	O
interleukin	O
3	O
mRNA	O
levels	O
in	O
the	O
same	O
cells	O
.	O
We	O
conclude	O
that	O
the	O
kappaB	O
element	O
in	O
the	O
GM	O
-	O
CSF	O
promoter	O
plays	O
a	O
central	O
role	O
in	O
the	O
transcriptional	O
activation	O
of	O
the	O
endogenous	O
GM	O
-	O
CSF	O
gene	O
.	O
Colinear	O
triplex	O
formation	O
acts	O
as	O
a	O
selective	O
transcriptional	O
repressor	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
and	O
may	O
have	O
potential	O
therapeutic	O
application	O
in	O
cases	O
of	O
undesirable	O
overexpression	O
of	O
this	O
protein	O
.	O
Octamer	B
binding	I
factors	I
and	O
their	O
coactivator	B
can	O
activate	O
the	O
murine	O
PU.1	O
(	O
spi-1	O
)	O
promoter	O
.	O
PU.1	B
(	O
spi-1	B
)	O
,	O
a	O
member	O
of	O
the	O
Ets	B
transcription	I
factor	I
family	I
,	O
is	O
predominantly	O
expressed	O
in	O
myeloid	O
and	O
B	O
cells	O
,	O
activates	O
many	O
B	O
cell	O
and	O
myeloid	O
genes	O
,	O
and	O
is	O
critical	O
for	O
development	O
of	O
both	O
of	O
these	O
lineages	O
.	O
Our	O
previous	O
studies	O
(	O
Chen	O
,	O
H.M.	O
,	O
Ray	O
-	O
Gallet	O
,	O
D.	O
,	O
Zhang	O
,	O
P.	O
,	O
Hetherington	O
,	O
C.J.	O
,	O
Gonzalez	O
,	O
D.A.	O
,	O
Zhang	O
,	O
D	O
.-	O
E.	O
,	O
Moreau	O
-	O
Gachelin	O
,	O
F.	O
,	O
and	O
Tenen	O
,	O
D.G.	O
(	O
1995	O
)	O
Oncogene	O
11	O
,	O
1549	O
-	O
1560	O
)	O
demonstrate	O
that	O
the	O
PU.1	O
promoter	O
directs	O
cell	O
type	O
-	O
specific	O
reporter	O
gene	O
expression	O
in	O
myeloid	O
cell	O
lines	O
,	O
and	O
that	O
PU.1	B
activates	O
its	O
own	O
promoter	O
in	O
an	O
autoregulatory	O
loop	O
.	O
Here	O
we	O
show	O
that	O
the	O
murine	O
PU.1	O
promoter	O
is	O
also	O
specifically	O
and	O
highly	O
functional	O
in	O
B	O
cell	O
lines	O
as	O
well	O
.	O
Oct-1	B
and	O
Oct-2	B
can	O
bind	O
specifically	O
to	O
a	O
site	O
at	O
base	O
pair	O
-55	O
in	O
vitro	O
,	O
and	O
this	O
site	O
is	O
specifically	O
protected	O
in	O
B	O
cells	O
in	O
vivo	O
.	O
We	O
also	O
demonstrate	O
that	O
two	O
other	O
sites	O
contribute	O
to	O
promoter	O
activity	O
in	O
B	O
cells	O
;	O
an	O
Sp1	O
binding	O
site	O
adjacent	O
to	O
the	O
octamer	O
site	O
,	O
and	O
the	O
PU.1	O
autoregulatory	O
site	O
.	O
Finally	O
,	O
we	O
show	O
that	O
the	O
B	O
cell	O
coactivator	B
OBF-1	B
/	I
Bob1	I
/	I
OCA	I
-	I
B	I
is	O
only	O
expressed	O
in	O
B	O
cells	O
and	O
not	O
in	O
myeloid	O
cells	O
,	O
and	O
that	O
OBF-1	B
/	I
Bob1	I
/	I
OCA	I
-	I
B	I
can	O
transactivate	O
the	O
PU.1	O
promoter	O
in	O
HeLa	O
and	O
myeloid	O
cells	O
.	O
This	O
B	B
cell	I
restricted	I
coactivator	I
may	O
be	O
responsible	O
for	O
the	O
B	O
cell	O
specific	O
expression	O
of	O
PU.1	B
mediated	O
by	O
the	O
octamer	O
site	O
.	O
Multiple	O
transcription	B
factors	I
are	O
required	O
for	O
activation	O
of	O
human	O
interleukin	O
9	O
gene	O
in	O
T	O
cells	O
.	O
The	O
genetic	O
elements	O
and	O
regulatory	O
mechanisms	O
responsible	O
for	O
human	O
interleukin	O
9	O
(	O
IL-9	O
)	O
gene	O
expression	O
in	O
a	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
-	O
transformed	O
human	O
T	O
cell	O
line	O
,	O
C5MJ2	O
,	O
were	O
investigated	O
.	O
We	O
demonstrated	O
that	O
IL-9	O
gene	O
expression	O
is	O
controlled	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
transcriptional	O
activation	O
.	O
Transient	O
expression	O
of	O
the	O
luciferase	O
reporter	O
gene	O
linked	O
to	O
serially	O
deleted	O
sequences	O
of	O
the	O
5'-flanking	O
region	O
of	O
the	O
IL-9	O
gene	O
has	O
revealed	O
several	O
positive	O
and	O
negative	O
regulatory	O
elements	O
involved	O
in	O
the	O
basal	O
and	O
inducible	O
expression	O
of	O
the	O
IL-9	O
gene	O
in	O
C5MJ2	O
cells	O
.	O
An	O
AP-1	O
site	O
at	O
-146	O
to	O
-140	O
was	O
shown	O
to	O
be	O
involved	O
in	O
the	O
expression	O
of	O
the	O
IL-9	O
gene	O
.	O
A	O
proximal	O
region	O
between	O
-46	O
and	O
-80	O
was	O
identified	O
as	O
the	O
minimum	O
sequence	O
for	O
the	O
basal	O
and	O
inducible	O
expression	O
of	O
the	O
IL-9	O
gene	O
in	O
C5MJ2	O
cells	O
.	O
Within	O
this	O
region	O
,	O
an	O
NF	O
-	O
kappaB	O
site	O
at	O
-59	O
to	O
-50	O
and	O
its	O
adjacent	O
20-base	O
pair	O
upstream	O
sequence	O
were	O
demonstrated	O
to	O
play	O
a	O
critical	O
role	O
for	O
the	O
IL-9	O
promoter	O
activity	O
.	O
DNA	O
-	O
protein	O
binding	O
studies	O
indicated	O
that	O
NF	B
-	I
kappaB	I
,	O
c	B
-	I
Jun	I
,	O
and	O
potentially	O
novel	B
proteins	I
(	O
around	O
35	B
kDa	I
)	O
can	O
bind	O
to	O
this	O
important	O
sequence	O
.	O
Mutations	O
at	O
different	O
sites	O
within	O
this	O
proximal	O
promoter	O
region	O
abolished	O
the	O
promoter	O
activity	O
as	O
well	O
as	O
the	O
DNA	O
binding	O
.	O
Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
cooperation	O
of	O
different	O
transcription	B
factors	I
is	O
essential	O
for	O
IL-9	O
gene	O
expression	O
in	O
T	O
cells	O
.	O
A	O
3	O
'	O
--	O
>	O
5	O
'	O
XPB	B
helicase	I
defect	O
in	O
repair	B
/	I
transcription	I
factor	I
TFIIH	B
of	O
xeroderma	O
pigmentosum	O
group	O
B	O
affects	O
both	O
DNA	O
repair	O
and	O
transcription	O
.	O
XPB	B
is	O
a	O
subunit	O
of	O
the	O
basal	O
transcription	B
factor	I
TFIIH	B
,	O
which	O
is	O
also	O
involved	O
in	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
and	O
potentially	O
in	O
cell	O
cycle	O
regulation	O
.	O
A	O
frameshift	O
mutation	O
in	O
the	O
3'-end	O
of	O
the	O
XPB	O
gene	O
is	O
responsible	O
for	O
a	O
concurrence	O
of	O
two	O
disorders	O
:	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
and	O
Cockayne	O
's	O
syndrome	O
(	O
CS	O
)	O
.	O
We	O
have	O
isolated	O
TFIIH	B
from	O
cells	O
derived	O
from	O
a	O
patient	O
(	O
XP11BE	O
)	O
who	O
carries	O
this	O
frameshift	O
mutation	O
(	O
TFIIHmut	B
)	O
and	O
from	O
the	O
mother	O
of	O
this	O
patient	O
(	O
TFIIHwt	B
)	O
to	O
determine	O
the	O
biochemical	O
consequences	O
of	O
the	O
mutation	O
.	O
Although	O
identical	O
in	O
composition	O
and	O
stoichiometry	O
to	O
TFIIHwt	B
,	O
TFIIHmut	B
shows	O
a	O
reduced	O
3	O
'	O
--	O
>	O
5	O
'	O
XPB	B
helicase	O
activity	O
.	O
A	O
decrease	O
in	O
helicase	O
and	O
DNA	B
-	I
dependent	I
ATPase	I
activities	O
was	O
also	O
observed	O
with	O
the	O
mutated	O
recombinant	O
XPB	B
protein	I
.	O
The	O
XPB	B
mutation	O
causes	O
a	O
severe	O
NER	O
defect	O
.	O
In	O
addition	O
,	O
we	O
provide	O
evidence	O
for	O
a	O
decrease	O
in	O
basal	O
transcription	O
activity	O
in	O
vitro	O
.	O
The	O
latter	O
defect	O
may	O
provide	O
an	O
explanation	O
for	O
many	O
of	O
the	O
XP	O
and	O
CS	O
symptoms	O
that	O
are	O
difficult	O
to	O
rationalize	O
based	O
solely	O
on	O
an	O
NER	O
defect	O
.	O
Thus	O
,	O
this	O
work	O
presents	O
the	O
first	O
detailed	O
analysis	O
of	O
a	O
naturally	O
occurring	O
mutation	O
in	O
a	O
basal	B
transcription	I
factor	I
and	O
supports	O
the	O
concept	O
that	O
the	O
combined	O
XP	O
/	O
CS	O
clinical	O
entity	O
is	O
actually	O
the	O
result	O
of	O
a	O
combined	O
transcription	O
/	O
repair	O
deficiency	O
.	O
Cytokine	B
-modulating	O
activity	O
of	O
tepoxalin	O
,	O
a	O
new	O
potential	O
antirheumatic	O
.	O
Tepoxalin	O
is	O
a	O
new	O
dual	O
cyclooxygenase	O
/	O
5-lipoxygenase	O
anti	O
-	O
inflammatory	O
compound	O
currently	O
under	O
clinical	O
investigation	O
.	O
It	O
has	O
been	O
shown	O
to	O
possess	O
anti	O
-	O
inflammatory	O
activity	O
in	O
a	O
variety	O
of	O
animal	O
models	O
and	O
more	O
recently	O
to	O
inhibit	O
IL-2	B
induced	O
signal	O
transduction	O
.	O
The	O
current	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
cytokine	B
modulating	O
activity	O
of	O
tepoxalin	O
and	O
the	O
role	O
of	O
iron	O
in	O
these	O
effects	O
.	O
In	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
stimulated	O
with	O
OKT3	O
/	O
PMA	O
,	O
tepoxalin	O
inhibited	O
lymphocyte	O
proliferation	O
with	O
an	O
IC50	O
of	O
6	O
microM	O
.	O
Additionally	O
,	O
it	O
inhibited	O
the	O
production	O
of	O
LTB4	B
(	O
IC50	O
=	O
0.5	O
microM	O
)	O
and	O
the	O
cytokines	B
IL-2	B
,	O
IL-6	B
and	O
TNF	B
alpha	I
(	O
IC50	O
=	O
10	O
-	O
12	O
microM	O
)	O
.	O
Cytotoxicity	O
was	O
not	O
demonstrated	O
at	O
these	O
concentrations	O
.	O
Add	O
-	O
back	O
experiments	O
with	O
either	O
cytokines	B
(	O
IL-2	B
or	O
IL-6	B
)	O
,	O
LTB4	B
or	O
conditioned	O
media	O
failed	O
to	O
restore	O
the	O
proliferative	O
response	O
in	O
the	O
presence	O
of	O
tepoxalin	O
.	O
However	O
,	O
the	O
concurrent	O
addition	O
of	O
iron	O
(	O
in	O
the	O
form	O
of	O
ferrous	O
or	O
ferric	O
chloride	O
and	O
other	O
iron	O
salts	O
)	O
reversed	O
the	O
inhibition	O
of	O
proliferation	O
caused	O
by	O
tepoxalin	O
.	O
Tepoxalin	O
also	O
inhibits	O
the	O
activation	O
of	O
NF	B
kappa	I
B	I
,	O
a	O
transcription	B
factor	I
which	O
acts	O
on	O
several	O
cytokine	O
genes	O
.	O
Tepoxalin	O
's	O
effect	O
on	O
NF	B
kappa	I
B	I
is	O
also	O
reversed	O
by	O
the	O
addition	O
of	O
iron	O
salts	O
.	O
These	O
data	O
suggest	O
that	O
the	O
action	O
of	O
tepoxalin	O
to	O
inhibit	O
proliferation	O
in	O
PBMC	O
may	O
be	O
at	O
least	O
in	O
part	O
due	O
to	O
its	O
ability	O
to	O
reduce	O
the	O
amount	O
of	O
available	O
iron	O
resulting	O
in	O
decreased	O
activation	O
of	O
NF	B
kappa	I
B	I
and	O
subsequent	O
inhibition	O
of	O
cytokine	B
production	O
.	O
Characterization	O
of	O
Grb2-binding	B
proteins	I
in	O
human	O
platelets	O
activated	O
by	O
Fc	B
gamma	I
RIIA	I
cross	O
-	O
linking	O
.	O
Glutathione	B
-	I
S	I
-	I
transferase	I
(	I
GST	I
)	I
-Grb2	I
fusion	I
proteins	I
have	O
been	O
used	O
to	O
identify	O
the	O
potential	O
role	O
of	O
Grb2-binding	B
proteins	I
in	O
platelet	O
activation	O
by	O
the	O
platelet	B
low	I
-	I
affinity	I
IgG	I
receptor	I
,	O
Fc	B
gamma	I
RIIA	I
.	O
Two	O
tyrosine	B
phosphoproteins	I
of	O
38	O
and	O
63	O
kD	O
bind	O
to	O
the	O
SH2	B
domain	I
of	O
Grb2	B
following	O
Fc	B
gamma	I
RIIA	I
stimulation	O
of	O
platelets	O
.	O
Both	O
are	O
located	O
in	O
the	O
particulate	O
fraction	O
following	O
platelet	O
activation	O
and	O
are	O
also	O
able	O
to	O
bind	O
to	O
a	O
GST	B
-	I
construct	I
containing	O
the	O
SH2	B
and	I
SH3	I
domains	I
of	O
phospholipase	B
C	I
gamma	I
1	I
.	O
p38	O
also	O
forms	O
a	O
complex	O
with	O
the	O
tyrosine	B
kinase	I
csk	I
in	O
stimulated	O
cells	O
and	O
is	O
a	O
substrate	O
for	O
the	O
kinase	B
.	O
The	O
SH3	B
domains	I
of	O
Grb2	B
form	O
a	O
stable	O
complex	O
with	O
SOS1	B
and	O
two	O
proteins	O
of	O
75	B
kD	I
and	O
120	B
kD	I
,	O
which	O
undergo	O
tyrosine	O
phosphorylation	O
in	O
Fc	O
gamma	O
RIIA	O
stimulated	O
cells	O
.	O
The	O
75-kD	B
protein	I
is	O
recognized	O
by	O
antibodies	O
to	O
SLP-76	B
,	O
which	O
has	O
recently	O
been	O
isolated	O
from	O
T	O
cells	O
and	O
sequenced	O
.	O
Tyrosine	O
phosphorylation	O
of	O
p38	B
and	O
p63	B
is	O
also	O
observed	O
in	O
platelets	O
stimulated	O
by	O
the	O
tyrosine	B
kinase	I
-linked	O
receptor	O
agonist	O
collagen	B
and	O
by	O
the	O
G	B
protein	I
-coupled	O
receptor	O
agonist	O
thrombin	B
,	O
although	O
phosphorylation	O
of	O
SLP-76	B
is	O
only	O
observed	O
in	O
collagen	B
-stimulated	O
platelets	O
.	O
p38	B
and	O
p63	B
may	O
provide	O
a	O
docking	O
site	O
for	O
Grb2	B
,	O
thereby	O
linking	O
Grb2	B
SH3-binding	I
proteins	I
SOS1	B
,	O
SLP-76	B
,	O
and	O
p120	B
to	O
downstream	O
signalling	O
events	O
.	O
Retinoic	O
acid	O
activates	O
interferon	B
regulatory	I
factor-1	I
gene	O
expression	O
in	O
myeloid	O
cells	O
.	O
All	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
the	O
drug	O
of	O
choice	O
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O
ATRA	O
induces	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
differentiation	O
of	O
APL	O
cells	O
into	O
mature	O
granulocytes	O
.	O
However	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
ATRA	O
-	O
dependent	O
growth	O
inhibition	O
and	O
cellular	O
differentiation	O
are	O
not	O
presently	O
understood	O
.	O
The	O
NB4	O
cell	O
line	O
,	O
which	O
is	O
derived	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	O
with	O
APL	O
during	O
relapse	O
,	O
can	O
be	O
used	O
as	O
a	O
model	O
system	O
to	O
study	O
the	O
growth	O
and	O
differentiation	O
of	O
APL	O
cells	O
.	O
Because	O
interferon	B
(	I
IFN	I
)	I
regulatory	I
factors	I
(	O
IRF-1	B
and	O
IRF-2	B
)	O
and	O
other	O
IFN	B
-	I
inducible	I
gene	I
products	I
regulate	O
cell	O
growth	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
ATRA	O
on	O
the	O
expression	O
of	O
these	O
genes	O
.	O
We	O
show	O
that	O
ATRA	O
directly	O
activates	O
IRF-1	O
gene	O
expression	O
,	O
followed	O
by	O
activation	O
of	O
IRF-2	B
and	O
2'-5	B
'	I
oligoadenylate	I
synthetase	I
(	O
OAS	O
)	O
gene	O
expression	O
with	O
slower	O
kinetics	O
.	O
In	O
addition	O
to	O
NB4	O
cells	O
,	O
ATRA	O
also	O
activated	O
IRF-1	O
gene	O
expression	O
in	O
HL-60	O
,	O
U937	O
,	O
and	O
THP-1	O
cells	O
,	O
which	O
all	O
respond	O
to	O
ATRA	O
by	O
growth	O
inhibition	O
.	O
A	O
more	O
than	O
additive	O
increase	O
in	O
IRF-1	O
gene	O
expression	O
was	O
seen	O
with	O
ATRA	O
and	O
IFN	B
-	I
gamma	I
in	O
NB4	O
cells	O
.	O
ATRA	O
did	O
not	O
activate	O
nuclear	O
factor	O
kappa	O
B	O
or	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
activation	O
pathways	O
,	O
suggesting	O
that	O
an	O
alternate	O
mechanism	O
is	O
involved	O
in	O
IRF-1	O
gene	O
activation	O
.	O
The	O
ATRA	O
-	O
induced	O
expression	O
of	O
IRF-1	B
,	O
an	O
activator	O
of	O
transcription	O
and	O
repressor	O
of	O
transformation	O
,	O
may	O
be	O
one	O
of	O
the	O
molecular	O
mechanisms	O
of	O
ATRA	O
-	O
induced	O
growth	O
inhibition	O
,	O
and	O
the	O
basis	O
for	O
the	O
synergistic	O
actions	O
of	O
ATRA	O
and	O
IFNs	B
in	O
myeloid	O
leukemia	O
cells	O
.	O
The	O
c	B
-	I
Jun	I
delta	I
-	I
domain	I
inhibits	O
neuroendocrine	O
promoter	O
activity	O
in	O
a	O
DNA	O
sequence-	O
and	O
pituitary	O
-	O
specific	O
manner	O
.	O
The	O
transcription	O
and	O
transformation	O
activity	O
of	O
c	B
-	I
Jun	I
is	O
governed	O
by	O
a	O
27-amino	B
acid	I
regulatory	I
motif	I
,	O
labeled	O
the	O
delta	B
-	I
domain	I
,	O
which	O
is	O
deleted	O
in	O
v	B
-	I
Jun	I
.	O
We	O
have	O
previously	O
shown	O
that	O
c	B
-	I
Jun	I
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
rat	O
prolactin	O
(	O
rPRL	O
)	O
promoter	O
activity	O
induced	O
by	O
either	O
oncogenic	B
Ras	I
or	O
phorbol	O
esters	O
.	O
Here	O
,	O
we	O
have	O
characterized	O
the	O
structural	O
and	O
cell	O
-	O
specific	O
requirements	O
for	O
this	O
c	B
-	I
Jun	I
inhibitory	O
response	O
,	O
and	O
we	O
show	O
that	O
this	O
c	B
-	I
Jun	I
inhibitory	O
response	O
mapped	O
to	O
the	O
rPRL	O
footprint	O
II	O
repressor	O
site	O
,	O
was	O
pituitary	O
-	O
specific	O
and	O
required	O
the	O
c	B
-	I
Jun	I
delta	I
-	I
domain	I
.	O
Moreover	O
,	O
alteration	O
of	O
any	O
one	O
of	O
these	O
features	O
(	O
e.g.	O
,	O
cis	O
-	O
element	O
,	O
trans	O
-	O
factor	O
,	O
or	O
cell	O
-	O
specific	O
background	O
)	O
switched	O
c	B
-	I
Jun	I
to	O
a	O
transcriptional	B
activator	I
of	O
the	O
rPRL	O
promoter	O
.	O
In	O
HeLa	O
nonpituitary	O
cells	O
,	O
c	B
-	I
Jun	I
alone	O
activated	O
the	O
rPRL	O
promoter	O
via	O
the	O
most	O
proximal	O
GHF-1	O
/	O
Pit-1	O
binding	O
site	O
,	O
footprint	O
I	O
,	O
and	O
synergized	O
with	O
GHF-1	B
.	O
Finally	O
,	O
recombinant	O
GHF-1	B
interacted	O
directly	O
with	O
c	B
-	I
Jun	I
but	O
not	O
c	B
-	I
Fos	I
proteins	I
.	O
These	O
data	O
provide	O
important	O
fundamental	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
by	O
which	O
the	O
c	B
-	I
Jun	I
delta	I
-	I
domain	I
functions	O
as	O
a	O
modulatory	O
switch	O
and	O
further	O
imply	O
that	O
the	O
functional	O
role	O
of	O
c	B
-	I
Jun	I
is	O
dictated	O
by	O
cell	O
-	O
specific	O
influences	O
and	O
the	O
delta	B
-	I
domain	I
motif	I
.	O
BCL-6	B
,	O
a	O
POZ	B
/	I
zinc	I
-	I
finger	I
protein	I
,	O
is	O
a	O
sequence	B
-	I
specific	I
transcriptional	I
repressor	I
.	O
Approximately	O
40	O
%	O
of	O
diffuse	O
large	O
cell	O
lymphoma	O
are	O
associated	O
with	O
chromosomal	O
translocations	O
that	O
deregulate	O
the	O
expression	O
of	O
the	O
BCL6	O
gene	O
by	O
juxtaposing	O
heterologous	O
promoters	O
to	O
the	O
BCL-6	O
coding	O
domain	O
.	O
The	O
BCL6	O
gene	O
encodes	O
a	O
95-kDa	B
protein	I
containing	O
six	O
C	B
-	I
terminal	I
zinc	I
-	I
finger	I
motifs	I
and	O
an	O
N	B
-	I
terminal	I
POZ	I
domain	I
,	O
suggesting	O
that	O
it	O
may	O
function	O
as	O
a	O
transcription	B
factor	I
.	O
By	O
using	O
a	O
DNA	O
sequence	O
selected	O
for	O
its	O
ability	O
to	O
bind	O
recombinant	B
BCL-6	I
in	O
vitro	O
,	O
we	O
show	O
here	O
that	O
BCL-6	B
is	O
present	O
in	O
DNA	B
-	I
binding	I
complexes	I
in	O
nuclear	O
extracts	O
from	O
various	O
B	O
-	O
cell	O
lines	O
.	O
In	O
transient	O
transfectin	O
experiments	O
,	O
BCL6	B
can	O
repress	O
transcription	O
from	O
promoters	O
linked	O
to	O
its	O
DNA	O
target	O
sequence	O
and	O
this	O
activity	O
is	O
dependent	O
upon	O
specific	O
DNA	O
-	O
binding	O
and	O
the	O
presence	O
of	O
an	O
intact	O
N	B
-	I
terminal	I
half	I
of	O
the	O
protein	O
.	O
We	O
demonstrate	O
that	O
this	O
part	O
of	O
the	O
BCL6	B
molecule	I
contains	O
an	O
autonomous	B
transrepressor	I
domain	I
and	O
that	O
two	O
noncontiguous	B
regions	I
,	O
including	O
the	O
POZ	B
motif	I
,	O
mediate	O
maximum	O
transrepressive	O
activity	O
.	O
These	O
results	O
indicate	O
that	O
the	O
BCL-6	B
protein	I
can	O
function	O
as	O
a	O
sequence	B
-	I
specific	I
transcriptional	I
repressor	I
and	O
have	O
implications	O
for	O
the	O
role	O
of	O
BCL6	B
in	O
normal	O
lymphoid	O
development	O
and	O
lymphomagenesis	O
.	O
Mechanisms	O
of	O
transactivation	O
by	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells-1	I
.	O
Nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
-	I
family	I
proteins	I
(	O
NFAT1	B
/	I
NFATp	I
,	O
NFATc	B
,	O
NFAT3	B
,	O
and	O
NFAT4	B
/	I
NFATx	I
/	I
NFATc3	I
)	O
play	O
a	O
key	O
role	O
in	O
the	O
transcription	O
of	O
cytokine	O
genes	O
and	O
other	O
genes	O
during	O
the	O
immune	O
response	O
.	O
We	O
have	O
defined	O
the	O
mechanisms	O
of	O
transactivation	O
by	O
NFAT1	B
.	O
NFAT1	B
possesses	O
two	O
transactivation	O
domains	O
whose	O
sequences	O
are	O
not	O
conserved	O
in	O
the	O
other	O
NFAT	B
-	I
family	I
proteins	I
,	O
and	O
a	O
conserved	O
DNA	O
-	O
binding	O
domain	O
that	O
mediates	O
the	O
recruitment	O
of	O
cooperating	O
nuclear	B
transcription	I
factors	I
even	O
when	O
it	O
is	O
expressed	O
in	O
the	O
absence	O
of	O
other	O
regions	O
of	O
the	O
protein	O
.	O
The	O
activity	O
of	O
the	O
NH2-terminal	B
transactivation	I
domain	I
is	O
modulated	O
by	O
an	O
adjacent	O
regulatory	B
region	I
that	O
contains	O
several	O
conserved	O
sequence	O
motifs	O
represented	O
only	O
in	O
the	O
NFAT	B
family	I
.	O
Our	O
results	O
emphasize	O
the	O
multiple	O
levels	O
at	O
which	O
NFAT	O
-	O
dependent	O
transactivation	O
is	O
regulated	O
,	O
and	O
predict	O
significant	O
differences	O
in	O
the	O
architecture	O
of	O
cooperative	O
transcription	B
complexes	I
containing	O
different	O
NFAT	B
-	I
family	I
proteins	I
.	O
The	O
Ets	O
protein	O
Spi	B
-	I
B	I
is	O
expressed	O
exclusively	O
in	O
B	O
cells	O
and	O
T	O
cells	O
during	O
development	O
.	O
Spi	B
-	I
B	I
and	O
PU.1	B
are	O
hematopoietic	B
-	I
specific	I
transcription	I
factors	I
that	O
constitute	O
a	O
subfamily	O
of	O
the	O
Ets	B
family	I
of	O
DNA	B
-	I
binding	I
proteins	I
.	O
Here	O
we	O
show	O
that	O
contrary	O
to	O
previous	O
reports	O
,	O
PU.1	B
and	O
Spi	B
-	I
B	I
have	O
very	O
different	O
expression	O
patterns	O
.	O
PU.1	B
is	O
expressed	O
at	O
high	O
levels	O
in	O
B	O
cells	O
,	O
mast	O
cells	O
,	O
megakaryocytes	O
,	O
macrophages	O
,	O
neutrophils	O
,	O
and	O
immature	O
erythroid	O
cells	O
and	O
at	O
lower	O
levels	O
in	O
mature	O
erythrocytes	O
.	O
PU.1	B
is	O
completely	O
absent	O
from	O
peripheral	O
T	O
cells	O
and	O
most	O
T	O
cell	O
lines	O
based	O
on	O
sensitive	O
RT	O
-	O
PCR	O
assays	O
.	O
In	O
contrast	O
,	O
Spi	B
-	I
B	I
is	O
expressed	O
exclusively	O
in	O
lymphoid	O
cells	O
and	O
can	O
be	O
detected	O
in	O
early	O
fetal	O
thymus	O
and	O
spleen	O
.	O
In	O
situ	O
hybridizations	O
of	O
adult	O
murine	O
tissues	O
demonstrate	O
Spi	O
-	O
B	O
mRNA	O
in	O
the	O
medulla	O
of	O
the	O
thymus	O
,	O
the	O
white	O
pulp	O
of	O
the	O
spleen	O
,	O
and	O
the	O
germinal	O
centers	O
of	O
lymph	O
nodes	O
.	O
Spi	B
-	I
B	I
expression	O
is	O
very	O
abundant	O
in	O
B	O
cells	O
and	O
both	O
Spi	O
-	O
B	O
mRNA	O
and	O
protein	O
are	O
detected	O
in	O
some	O
T	O
cells	O
.	O
In	O
situ	O
hybridization	O
and	O
Northern	O
blot	O
analysis	O
suggest	O
that	O
Spi	B
-	I
B	I
gene	O
expression	O
increases	O
during	O
B	O
cell	O
maturation	O
and	O
decreases	O
during	O
T	O
cell	O
maturation	O
.	O
Gel	O
-	O
retardation	O
experiments	O
show	O
that	O
Spi	B
-	I
B	I
can	O
bind	O
to	O
all	O
putative	O
PU.1	O
binding	O
sites	O
,	O
but	O
do	O
not	O
reveal	O
any	O
preferred	O
Spi	O
-	O
B	O
binding	O
site	O
.	O
Finally	O
,	O
both	O
PU.1	B
and	O
Spi	B
-	I
B	I
function	O
as	O
transcriptional	O
activators	O
of	O
the	O
immunoglobulin	O
light	O
-	O
chain	O
enhancer	O
E	O
lambda	O
2.4	O
when	O
coexpressed	O
with	O
Pip	B
(	O
PU.1-interaction	B
partner	I
)	O
in	O
NIH-3T3	O
cells	O
.	O
Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
differences	O
in	O
patterns	O
of	O
expression	O
between	O
Spi	B
-	I
B	I
and	O
PU.1	B
distinguish	O
the	O
function	O
of	O
each	O
protein	O
during	O
development	O
of	O
the	O
immune	O
system	O
.	O
Precise	O
alignment	O
of	O
sites	O
required	O
for	O
mu	O
enhancer	O
activation	O
in	O
B	O
cells	O
.	O
The	O
lymphocyte	O
-	O
specific	O
immunoglobulin	O
mu	O
heavy	O
-	O
chain	O
gene	O
intronic	O
enhancer	O
is	O
regulated	O
by	O
multiple	O
nuclear	B
factors	I
.	O
The	O
previously	O
defined	O
minimal	O
enhancer	O
containing	O
the	O
muA	O
,	O
muE3	O
,	O
and	O
muB	O
sites	O
is	O
transactivated	O
by	O
a	O
combination	O
of	O
the	O
ETS	B
-	I
domain	I
proteins	I
PU.1	B
and	O
Ets-1	B
in	O
nonlymphoid	O
cells	O
.	O
The	O
core	O
GGAAs	O
of	O
the	O
muA	O
and	O
muB	O
sites	O
are	O
separated	O
by	O
30	O
nucleotides	O
,	O
suggesting	O
that	O
ETS	B
proteins	I
bind	O
to	O
these	O
sites	O
from	O
these	O
same	O
side	O
of	O
the	O
DNA	O
helix	O
.	O
We	O
tested	O
the	O
necessity	O
for	O
appropriate	O
spatial	O
alignment	O
of	O
these	O
elements	O
by	O
using	O
mutated	O
enhancers	O
with	O
altered	O
spacings	O
.	O
A	O
4-	O
or	O
10-bp	O
insertion	O
between	O
muE3	O
and	O
muB	O
inactivated	O
the	O
mu	O
enhancer	O
in	O
S194	O
plasma	O
cells	O
but	O
did	O
not	O
affect	O
in	O
vitro	O
binding	O
of	O
Ets-1	O
,	O
PU.1	B
,	O
or	O
the	O
muE3-binding	B
protein	I
TFE3	B
,	O
alone	O
or	O
in	O
pairwise	O
combinations	O
.	O
Circular	O
permutation	O
and	O
phasing	O
analyses	O
demonstrated	O
that	O
PU.1	B
binding	O
but	O
not	O
TFE3	B
or	O
Ets-1	B
bends	O
mu	O
enhancer	O
DNA	O
toward	O
the	O
major	O
groove	O
.	O
We	O
propose	O
that	O
the	O
requirement	O
for	O
precise	O
spacing	O
of	O
the	O
muA	O
and	O
muB	O
elements	O
is	O
due	O
in	O
part	O
to	O
a	O
directed	O
DNA	O
bend	O
induced	O
by	O
PU.1	B
.	O
Stimulation	O
of	O
the	O
T	B
-	I
cell	I
antigen	I
receptor	I
-	I
CD3	I
complex	I
signaling	O
pathway	O
by	O
the	O
tyrosine	B
phosphatase	I
inhibitor	O
pervanadate	O
is	O
mediated	O
by	O
inhibition	O
of	O
CD45	B
:	O
evidence	O
for	O
two	O
interconnected	O
Lck	O
/	O
Fyn-	O
or	O
zap-70-dependent	O
signaling	O
pathways	O
.	O
The	O
tyrosine	B
phosphatase	I
specific	O
inhibitor	O
pervanadate	O
is	O
a	O
potent	O
activator	O
of	O
T	O
lymphocytes	O
through	O
induction	O
of	O
tyrosine	B
phosphorylation	I
and	O
downstream	O
events	O
of	O
the	O
activation	O
cascade	O
.	O
Using	O
CD45-	O
or	O
CD3-negative	O
variants	O
of	O
the	O
Jurkat	O
leukemic	O
T	O
-	O
cell	O
line	O
we	O
show	O
that	O
the	O
different	O
biochemical	O
events	O
induced	O
by	O
pervanadate	O
appeared	O
to	O
be	O
dependent	O
on	O
the	O
presence	O
at	O
the	O
cell	O
surface	O
of	O
either	O
CD45	B
or	O
CD3	B
.	O
CD45	B
-dependent	O
events	O
such	O
as	O
tyrosine	B
phosphorylation	I
of	O
Shc	B
,	O
activation	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
,	O
activator	B
protein-1	I
(	O
AP-1	B
)	O
,	O
transcription	B
factors	I
,	O
and	O
stimulation	O
of	O
interleukin-2	O
(	O
IL-2	O
)	O
promoter	O
and	O
of	O
CD69	B
and	O
CD25	B
surface	O
expression	O
paralleled	O
activation	O
of	O
the	O
tyrosine	B
kinases	I
lck	B
and	O
fyn	B
.	O
By	O
contrast	O
,	O
stimulation	O
of	O
calcium	O
influx	O
,	O
a	O
CD3	B
-dependent	O
event	O
,	O
paralleled	O
zap-70	B
activation	O
.	O
The	O
data	O
demonstrate	O
that	O
the	O
T	O
-	O
cell	O
antigen	O
receptor	O
-CD3	B
(	I
TcR	I
-	I
CD3	I
)	I
complex	I
is	O
functionally	O
linked	O
to	O
two	O
different	O
protein	B
tyrosine	I
kinase	I
(	O
PTK	B
)	O
modules	O
with	O
separate	O
specific	O
functions	O
and	O
that	O
CD45	B
may	O
be	O
an	O
important	O
regulator	O
of	O
this	O
coupling	O
.	O
C	B
/	I
EBP	I
activators	I
are	O
required	O
for	O
HIV-1	O
replication	O
and	O
proviral	O
induction	O
in	O
monocytic	O
cell	O
lines	O
.	O
Previous	O
work	O
has	O
shown	O
that	O
C	O
/	O
EBP	O
sites	O
and	O
C	B
/	I
EBP	I
transcriptional	I
activators	I
are	O
necessary	O
for	O
HIV-1	O
LTR	O
activity	O
in	O
monocytes	O
/	O
macrophages	O
.	O
We	O
have	O
investigated	O
the	O
role	O
that	O
C	B
/	I
EBP	I
proteins	I
play	O
in	O
induction	O
and	O
replication	O
of	O
HIV-1	O
.	O
Ectopic	O
expression	O
of	O
the	O
dominant	O
negative	O
C	B
/	I
EBP	I
protein	I
LIP	I
inhibited	O
HIV-1	O
mRNA	O
and	O
virus	O
production	O
in	O
activated	O
U1	O
cells	O
,	O
demonstrating	O
that	O
C	B
/	I
EBP	I
proteins	I
are	O
required	O
for	O
provirus	O
induction	O
.	O
U1	O
lines	O
overexpressing	O
C	B
/	I
EBP	I
activator	I
NF	B
-	I
IL-6	I
produced	O
more	O
viral	O
mRNA	O
and	O
virus	O
particles	O
following	O
cellular	O
activation	O
than	O
control	O
lines	O
,	O
demonstrating	O
that	O
C	B
/	I
EBP	I
proteins	I
are	O
limiting	O
for	O
virus	O
transcription	O
.	O
HIV-1	O
harboring	O
mutations	O
within	O
two	O
C	O
/	O
EBP	O
sites	O
were	O
crippled	O
in	O
their	O
ability	O
to	O
replicate	O
in	O
U937	O
promonocytic	O
cells	O
,	O
indicating	O
that	O
these	O
sites	O
are	O
required	O
for	O
replication	O
.	O
These	O
data	O
identify	O
C	B
/	I
EBP	I
proteins	I
as	O
regulators	O
of	O
HIV-1	O
expression	O
in	O
monocytes	O
/	O
macrophages	O
.	O
Reversal	O
of	O
apoptosis	O
by	O
the	O
leukaemia	O
-	O
associated	O
E2A	B
-	I
HLF	I
chimaeric	I
transcription	I
factor	I
.	O
The	O
E2A	O
-	O
HLF	O
(	O
for	O
hepatic	O
leukaemia	O
factor	O
)	O
fusion	O
gene	O
,	O
formed	O
by	O
action	O
of	O
the	O
t	O
(	O
17	O
;	O
19	O
)	O
(	O
q22	O
;	O
p13	O
)	O
chromosomal	O
translocation	O
,	O
drives	O
the	O
leukaemic	O
transformation	O
of	O
early	O
B	O
-	O
cell	O
precursors	O
,	O
but	O
the	O
mechanism	O
of	O
this	O
activity	O
remains	O
unknown	O
.	O
Here	O
we	O
report	O
that	O
human	O
leukaemia	O
cells	O
carrying	O
the	O
translocation	O
t	O
(	O
17	O
;	O
19	O
)	O
rapidly	O
died	O
by	O
apoptosis	O
when	O
programmed	O
to	O
express	O
a	O
dominant	O
-	O
negative	O
suppressor	O
of	O
the	O
fusion	O
protein	O
E2A	B
-	I
HLF	I
,	O
indicating	O
that	O
the	O
chimaeric	B
oncoprotein	I
probably	O
affects	O
cell	O
survival	O
rather	O
than	O
cell	O
growth	O
.	O
Moreover	O
,	O
when	O
introduced	O
into	O
murine	O
pro	O
-	O
B	O
lymphocytes	O
,	O
the	O
oncogenic	B
E2A	I
-	I
HLF	I
fusion	I
protein	I
reversed	O
both	O
interleukin-3-dependent	O
and	O
p53-mediated	O
apoptosis	O
.	O
The	O
close	O
homology	O
of	O
the	O
basic	B
region	I
/	I
leucine	I
zipper	I
(	O
bZIP	B
)	O
DNA	O
-	O
binding	O
and	O
dimerization	B
domain	I
of	O
HLF	B
to	O
that	O
of	O
the	O
CES-2	B
cell	I
-	I
death	I
specification	I
protein	I
of	O
Caenorhabditis	O
elegans	O
suggests	O
a	O
model	O
of	O
leukaemogenesis	O
in	O
which	O
E2A	B
-	I
HLF	I
blocks	O
an	O
early	O
step	O
within	O
an	O
evolutionarily	O
conserved	O
cell	O
-	O
death	O
pathway	O
.	O
Interleukin-7	B
signaling	O
in	O
human	O
B	O
cell	O
precursor	O
acute	O
lymphoblastic	O
leukemia	O
cells	O
and	O
murine	O
BAF3	O
cells	O
involves	O
activation	O
of	O
STAT1	B
and	O
STAT5	B
mediated	O
via	O
the	O
interleukin-7	B
receptor	I
alpha	I
chain	I
.	O
Interleukin-7	B
(	O
IL-7	B
)	O
stimulates	O
the	O
proliferation	O
of	O
normal	O
and	O
leukemic	O
B	O
and	O
T	O
cell	O
precursors	O
and	O
T	O
lymphocytes	O
.	O
Activation	O
of	O
the	O
JAK	B
/STAT	B
pathway	O
has	O
been	O
implicated	O
in	O
IL-7R	B
signaling	O
.	O
We	O
investigated	O
which	O
STAT	B
complexes	I
are	O
formed	O
upon	O
stimulation	O
of	O
B	O
cell	O
precursor	O
acute	O
lymphoblastic	O
leukemia	O
(	O
BCP	O
-	O
ALL	O
)	O
cells	O
with	O
IL-7	B
.	O
Gel	O
retardation	O
assays	O
with	O
STAT	O
-	O
binding	O
oligonucleotides	O
showed	O
that	O
IL-7	B
induces	O
the	O
formation	O
of	O
two	O
major	O
STAT	B
complexes	I
in	O
BCP	O
-	O
ALL	O
cells	O
.	O
Supershifts	O
with	O
anti	O
-	O
STAT	O
antibodies	O
identified	O
these	O
as	O
STAT1	B
and	O
STAT5	B
complexes	I
.	O
This	O
pattern	O
of	O
STAT	B
activation	O
was	O
seen	O
in	O
all	O
BCP	O
-	O
ALL	O
cases	O
that	O
respond	O
to	O
IL-7	B
in	O
proliferation	O
assays	O
.	O
IL-7	B
also	O
induced	O
STAT	B
/DNA	O
binding	O
in	O
BCP	O
-	O
ALL	O
cases	O
that	O
failed	O
to	O
proliferate	O
in	O
response	O
to	O
IL-7	B
,	O
suggesting	O
that	O
the	O
ability	O
of	O
IL-7R	B
to	O
activate	O
the	O
JAK	B
/STAT	B
pathway	O
per	O
se	O
is	O
not	O
sufficient	O
for	O
proliferation	O
induction	O
.	O
To	O
determine	O
the	O
contribution	O
of	O
the	O
cytoplasmic	B
domain	I
of	O
the	O
IL-7	B
receptor	I
alpha	I
chain	I
(	O
IL-7R	B
alpha	I
)	O
to	O
activation	O
of	O
STAT	B
proteins	I
,	O
transfectants	O
of	O
the	O
murine	O
pro	O
-	O
B	O
cell	O
line	O
BAF3	O
were	O
made	O
that	O
express	O
chimeric	B
receptors	I
consisting	O
of	O
the	O
extracellular	B
domain	I
of	O
human	B
granulocyte	I
colony	I
-	I
stimulating	I
factor	I
receptor	I
(	O
G	B
-	I
CSF	I
-	I
R	I
)	O
and	O
the	O
transmembrane	B
and	I
intracellular	I
domains	I
of	O
human	B
IL-7R	I
alpha	I
.	O
Activation	O
of	O
the	O
chimeric	B
G	I
-	I
CSF	I
-	I
R	I
/	I
IL-7R	I
alpha	I
with	O
G	B
-	I
CSF	I
resulted	O
in	O
a	O
full	O
proliferative	O
response	O
and	O
induced	O
the	O
phosphorylation	O
of	O
JAK1	B
but	O
not	O
JAK2	B
.	O
Major	O
STAT	B
complexes	I
activated	O
by	O
G	B
-	I
CSF	I
-	I
R	I
/	I
IL-7R	I
alpha	I
contained	O
STAT1	B
or	O
STAT5	B
,	O
while	O
some	O
formation	O
of	O
STAT3-containing	B
complexes	I
was	O
also	O
seen	O
.	O
These	O
findings	O
establish	O
that	O
STAT1	B
and	O
STAT5	B
,	O
and	O
possibly	O
STAT3	B
,	O
are	O
activated	O
upon	O
stimulation	O
of	O
precursor	O
B	O
cells	O
with	O
IL-7	B
.	O
The	O
data	O
further	O
indicate	O
that	O
the	O
IL-7R	B
alpha	I
chains	I
are	O
directly	O
involved	O
in	O
the	O
activation	O
of	O
JAKs	B
and	O
STATs	B
and	O
have	O
a	O
major	O
role	O
in	O
proliferative	O
signaling	O
in	O
precursor	O
B	O
cells	O
.	O
Involvement	O
of	O
tyrosine	O
phosphorylation	O
in	O
endothelial	B
adhesion	I
molecule	I
induction	O
.	O
Induction	O
of	O
endothelial	B
adhesion	I
molecules	I
by	O
the	O
cytokine	B
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
)	O
can	O
occur	O
independently	O
of	O
protein	B
kinase	I
C	I
and	O
activation	O
of	O
a	O
protein	B
tyrosine	I
kinase	I
(	O
PTK	B
)	O
has	O
recently	O
been	O
implicated	O
in	O
the	O
upregulation	O
of	O
vascular	B
cell	I
adhesion	I
molecule	I
1	I
(	O
VCAM-1	B
)	O
by	O
interleukin-4	B
(	O
IL-4	B
)	O
on	O
endothelial	O
cells	O
.	O
We	O
demonstrate	O
that	O
the	O
PTK	B
inhibitors	O
herbimycin	O
A	O
or	O
genistein	O
suppress	O
induction	O
of	O
endothelial	O
VCAM-1	B
and	O
E	B
-	I
selectin	I
,	O
as	O
well	O
as	O
subsequent	O
monocytic	O
cell	O
adhesion	O
to	O
endothelial	O
cells	O
stimulated	O
by	O
TNF	B
.	O
Inhibition	O
studies	O
indicate	O
that	O
specific	O
tyrosine	O
phosphorylation	O
following	O
PTK	B
activation	O
is	O
involved	O
in	O
the	O
mobilization	O
of	O
the	O
transcription	B
factor	I
,	O
nuclear	B
factor	I
kappa	I
B	I
,	O
and	O
VCAM-1	O
mRNA	O
expression	O
.	O
This	O
may	O
have	O
implications	O
for	O
pathophysiological	O
conditions	O
that	O
involve	O
the	O
upregulation	O
of	O
these	O
molecules	O
(	O
e.g.	O
inflammation	O
and	O
atherosclerosis	O
)	O
.	O
Inhibition	O
of	O
transcription	B
factor	I
Stat1	B
activity	O
in	O
mononuclear	O
cell	O
cultures	O
and	O
T	O
cells	O
by	O
the	O
cyclic	O
AMP	O
signaling	O
pathway	O
.	O
Activation	O
of	O
T	O
cells	O
results	O
in	O
a	O
cascade	O
of	O
gene	O
activation	O
and	O
subsequent	O
proliferation	O
and	O
differentiation	O
into	O
effector	O
phenotypes	O
.	O
The	O
regulation	O
of	O
transcription	B
factors	I
belonging	O
to	O
the	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	I
STAT	I
)	I
family	I
was	O
analyzed	O
in	O
PHA	O
-	O
activated	O
mononuclear	O
cells	O
and	O
in	O
purified	O
T	O
cells	O
activated	O
by	O
cross	O
-	O
linking	O
cell	B
surface	I
CD3	I
.	O
Cell	O
activation	O
resulted	O
in	O
a	O
delayed	O
induction	O
of	O
STAT	B
DNA	O
-	O
binding	O
activity	O
,	O
which	O
was	O
sustained	O
for	O
several	O
days	O
,	O
was	O
composed	O
predominantly	O
of	O
Stat1	B
and	O
Stat3	B
,	O
and	O
was	O
blocked	O
by	O
cycloheximide	O
and	O
actinomycin	O
D	O
.	O
Increased	O
Stat1	O
and	O
Stat3	O
mRNA	O
and	O
protein	O
levels	O
were	O
detected	O
,	O
respectively	O
4	O
and	O
24	O
h	O
after	O
activation	O
.	O
Stimulation	O
of	O
the	O
cAMP	O
signal	O
transduction	O
pathway	O
,	O
which	O
skews	O
cytokine	B
production	O
toward	O
a	O
Th2	O
pattern	O
,	O
resulted	O
in	O
the	O
preferential	O
suppression	O
of	O
Stat1	B
activity	O
.	O
cAMP	O
inhibited	O
the	O
induction	O
of	O
expression	O
of	O
IL-2	B
receptor	I
components	I
,	O
but	O
did	O
not	O
inhibit	O
IL-4	B
receptor	I
alpha	I
-	I
chain	I
and	O
CD69	B
expression	O
or	O
the	O
induction	O
of	O
activator	B
protein	I
1	I
transcription	I
factors	I
.	O
cAMP	O
signaling	O
inhibited	O
Stat1	B
at	O
several	O
different	O
levels	O
,	O
including	O
suppression	O
of	O
DNA	O
binding	O
and	O
down	O
-	O
regulation	O
of	O
Stat1	O
protein	O
and	O
mRNA	O
levels	O
.	O
Our	O
results	O
demonstrate	O
the	O
regulation	O
of	O
STAT	B
activity	O
by	O
a	O
signaling	O
pathway	O
that	O
regulates	O
the	O
T	O
cell	O
functional	O
phenotype	O
and	O
is	O
distinct	O
from	O
the	O
cytokine	B
-activated	O
Janus	B
kinase	I
-STAT	B
signaling	O
pathway	O
.	O
Various	O
modes	O
of	O
basic	B
helix	I
-	I
loop	I
-	I
helix	I
protein	I
-mediated	O
regulation	O
of	O
murine	O
leukemia	O
virus	O
transcription	O
in	O
lymphoid	O
cell	O
lines	O
.	O
The	O
transcriptionally	O
regulatory	O
regions	O
of	O
the	O
lymphomagenic	O
Akv	O
and	O
SL3	O
-	O
3	O
murine	O
leukemia	O
retroviruses	O
(	O
MLVs	O
)	O
contain	O
two	O
types	O
of	O
E	O
-	O
box	O
consensus	O
motifs	O
,	O
CAGATG	O
.	O
One	O
type	O
,	O
EA	O
/	O
S	O
,	O
is	O
located	O
in	O
the	O
upstream	O
promoter	O
region	O
,	O
and	O
the	O
other	O
,	O
E	O
(	O
gre	O
)	O
,	O
is	O
located	O
in	O
a	O
tandem	O
repeat	O
with	O
enhancer	O
properties	O
.	O
We	O
have	O
examined	O
the	O
requirements	O
of	O
the	O
individual	O
E	O
-	O
boxes	O
in	O
MLV	O
transcriptional	O
regulation	O
.	O
In	O
lymphoid	O
cell	O
lines	O
only	O
,	O
the	O
E	B
(	I
gre	I
)	I
-binding	I
protein	I
complexes	I
included	O
ALF1	B
or	O
HEB	B
and	O
E2A	B
basic	I
helix	I
-	I
loop	I
-	I
helix	I
proteins	I
.	O
Ectopic	O
ALF1	B
and	O
E2A	B
proteins	I
required	O
intact	O
E	O
(	O
gre	O
)	O
motifs	O
for	O
mediating	O
transcriptional	O
activation	O
.	O
ALF1	B
transactivated	O
transcription	O
of	O
Akv	O
MLV	O
through	O
the	O
two	O
E	O
(	O
gre	O
)	O
motifs	O
equally	O
,	O
whereas	O
E2A	B
protein	I
required	O
the	O
promoter	O
-	O
proximal	O
E	O
(	O
gre	O
)	O
motif	O
.	O
In	O
T-	O
and	O
B	O
-	O
cell	O
lines	O
,	O
the	O
E	O
(	O
gre	O
)	O
motifs	O
were	O
of	O
major	O
importance	O
for	O
Akv	O
MLV	O
transcriptional	O
activity	O
,	O
while	O
the	O
EA	O
/	O
S	O
motif	O
had	O
some	O
effect	O
.	O
In	O
contrast	O
,	O
neither	O
E	O
(	O
gre	O
)	O
nor	O
EA	O
/	O
S	O
motifs	O
contributed	O
pronouncedly	O
to	O
Akv	O
MLV	O
transcription	O
in	O
NIH	O
3T3	O
cells	O
lacking	O
DNA	O
-	O
binding	O
ALF1	B
or	O
HEB	B
and	O
E2A	B
proteins	I
.	O
The	O
Id1	O
protein	O
was	O
found	O
to	O
repress	O
ALF1	B
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Moreover	O
,	O
ectopic	B
Id1	I
repressed	O
E	O
(	O
gre	O
)	O
-directed	O
but	O
not	O
EA	O
/	O
S	O
-directed	O
MLV	O
transcription	O
in	O
lymphoid	O
cell	O
lines	O
.	O
In	O
conclusion	O
,	O
E	O
(	O
gre	O
)	O
motifs	O
and	O
interacting	O
basic	B
helix	I
-	I
loop	I
-	I
helix	I
proteins	I
are	O
important	O
determinants	O
for	O
MLV	O
transcriptional	O
activity	O
in	O
lymphocytic	O
cell	O
lines	O
.	O
The	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
1	I
posttranscriptional	I
trans	I
-	I
activator	I
Rex	B
contains	O
a	O
nuclear	B
export	I
signal	I
.	O
The	O
Rex	B
protein	I
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
is	O
required	O
for	O
the	O
nuclear	O
export	O
of	O
unspliced	O
viral	O
mRNA	O
and	O
,	O
therefore	O
,	O
for	O
virus	O
replication	O
.	O
In	O
this	O
manuscript	O
,	O
we	O
demonstrate	O
that	O
Rex	B
shuttles	O
between	O
the	O
nucleus	O
and	O
the	O
cytoplasm	O
and	O
that	O
its	O
activation	B
domain	I
constitutes	O
a	O
nuclear	B
export	I
signal	I
that	O
specifies	O
efficient	O
transport	O
to	O
the	O
cytoplasm	O
.	O
These	O
findings	O
are	O
consistent	O
with	O
a	O
model	O
for	O
Rex	B
-mediated	O
trans	O
-	O
activation	O
in	O
which	O
Rex	B
-	I
viral	I
mRNA	I
complexes	I
are	O
targeted	O
for	O
nuclear	O
export	O
by	O
the	O
direct	O
action	O
of	O
the	O
activation	B
domain	I
.	O
Multiple	O
p21ras	B
effector	O
pathways	O
regulate	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
.	O
The	O
transcription	B
factor	I
,	O
Nuclear	B
Factor	I
of	I
Activated	I
T	I
cells	I
(	O
NFAT	B
)	O
is	O
a	O
major	O
target	O
for	O
p21ras	B
and	O
calcium	O
signalling	O
pathways	O
in	O
the	O
IL-2	O
gene	O
and	O
is	O
induced	O
by	O
p21ras	B
signals	O
acting	O
in	O
synergy	O
with	O
calcium	O
/calcineurin	B
signals	O
.	O
One	O
p21ras	B
effector	O
pathway	O
involves	O
the	O
MAP	B
kinase	I
ERK-2	B
,	O
and	O
we	O
have	O
examined	O
its	O
role	O
in	O
NFAT	B
regulation	O
.	O
Expression	O
of	O
dominant	B
negative	I
MAPKK-1	I
prevents	O
NFAT	B
induction	O
.	O
Constitutively	O
active	O
MAPKK-1	B
fully	O
activates	O
ERK-2	B
and	O
the	O
transcription	B
factor	I
Elk-1	B
,	O
but	O
does	O
not	O
substitute	O
for	O
activated	O
p21ras	B
and	O
synergize	O
with	O
calcium	O
/calcineurin	B
signals	O
to	O
induce	O
NFAT	B
.	O
Expression	O
of	O
dominant	B
negative	I
N17Rac	I
also	O
prevents	O
TCR	B
and	O
p21ras	B
activation	O
of	O
NFAT	B
,	O
but	O
without	O
interfering	O
with	O
the	O
ERK-2	B
pathway	O
.	O
The	O
transcriptional	O
activity	O
of	O
the	O
NFAT	O
binding	O
site	O
is	O
mediated	O
by	O
a	O
complex	O
comprising	O
a	O
member	O
of	O
the	O
NFAT	B
group	O
and	O
AP-1	B
family	I
proteins	I
.	O
The	O
induction	O
of	O
AP-1	B
by	O
p21ras	B
also	O
requires	O
Rac-1	B
function	O
.	O
Activated	B
Rac-1	I
could	O
mimic	O
activated	B
p21ras	I
to	O
induce	O
AP-1	B
but	O
not	O
to	O
induce	O
NFAT	B
.	O
Moreover	O
,	O
the	O
combination	O
of	O
activated	O
MAPKK-1	B
and	O
Rac-1	B
could	O
not	O
substitute	O
for	O
activated	O
p21ras	B
and	O
synergize	O
with	O
calcium	O
signals	O
to	O
induce	O
NFAT	B
.	O
Thus	O
,	O
p21ras	B
regulation	O
of	O
NFAT	B
in	O
T	O
cells	O
requires	O
the	O
activity	O
of	O
multiple	O
effector	O
pathways	O
including	O
those	O
regulated	O
by	O
MAPKK-1	B
/ERK-2	B
and	O
Rac-1	B
.	O
Granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
preferentially	O
activates	O
the	O
94-kD	B
STAT5A	I
and	O
an	O
80-kD	B
STAT5A	I
isoform	I
in	O
human	O
peripheral	O
blood	O
monocytes	O
.	O
Granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
induces	O
immediate	O
effects	O
in	O
monocytes	O
by	O
activation	O
of	O
the	O
Janus	B
kinase	I
(	O
JAK2	B
)	O
and	O
STAT	B
transcription	I
factor	I
(	O
STAT5	B
)	O
pathway	O
.	O
Recent	O
studies	O
have	O
identified	O
homologues	O
of	O
STAT5	B
,	O
STAT5A	B
,	O
and	O
STAT5B	B
,	O
as	O
well	O
as	O
lower	O
molecular	O
weight	O
variants	O
of	O
STAT5	B
.	O
To	O
define	O
the	O
activation	O
of	O
the	O
STAT5	B
homologues	I
and	O
lower	O
molecular	O
weight	O
variant	O
in	O
human	O
monocytes	O
and	O
monocytes	O
differentiated	O
into	O
macrophages	O
by	O
culture	O
in	O
macrophage	B
-	I
CSF	I
(	O
M	B
-	I
CSF	I
)	O
,	O
we	O
measured	O
the	O
GM	B
-	I
CSF	I
induced	O
tyrosine	O
phosphorylation	O
of	O
STAT5A	B
,	O
STAT5B	B
,	O
and	O
any	O
lower	O
molecular	O
weight	O
STAT5	B
isoforms	I
.	O
Freshly	O
isolated	O
monocytes	O
expressed	O
94-kD	B
STAT5A	I
,	O
92-kD	O
STAT5B	B
,	O
and	O
an	O
80-kD	B
STAT5A	I
molecule	I
.	O
Whereas	O
94-kD	B
STAT5A	I
was	O
clearly	O
tyrosine	O
phosphorylated	O
and	O
bound	O
to	O
the	O
enhancer	O
element	O
,	O
the	O
gamma	O
response	O
region	O
(	O
GRR	O
)	O
,	O
of	O
the	O
Fc	O
gamma	O
RI	O
gene	O
,	O
substantially	O
less	O
tyrosine	O
phosphorylated	O
STAT5B	B
bound	O
to	O
the	O
immobilized	O
GRR	O
element	O
.	O
Macrophages	O
lost	O
their	O
ability	O
to	O
express	O
the	O
80-kD	B
STAT5A	I
protein	I
,	O
but	O
retained	O
their	O
ability	O
to	O
activate	O
STAT5A	B
.	O
STAT5A	B
-	I
STAT5A	I
homodimers	I
and	O
STAT5A	B
-	I
STAT5B	I
heterodimers	I
formed	O
in	O
response	O
to	O
GM	B
-	I
CSF	I
.	O
Therefore	O
,	O
activation	O
of	O
STAT5A	B
predominates	O
compared	O
to	O
STAT5B	B
when	O
assayed	O
by	O
direct	O
immunoprecipitation	O
and	O
by	O
evaluation	O
of	O
bound	O
STATs	B
to	O
immobilized	O
GRR	O
.	O
Selective	O
activation	O
of	O
STAT5	B
homologues	I
in	O
addition	O
to	O
generation	O
of	O
lower	O
molecular	O
isoforms	O
may	O
provide	O
specificity	O
and	O
control	O
to	O
genes	O
expressed	O
in	O
response	O
to	O
cytokines	B
such	O
as	O
GM	B
-	I
CSF	I
.	O
Abnormalities	O
of	O
p16	O
,	O
p15	O
and	O
CDK4	O
genes	O
in	O
recurrent	O
malignant	O
astrocytomas	O
.	O
Abnormalities	O
in	O
the	O
p16	O
,	O
p15	O
and	O
CDK4	O
genes	O
that	O
regulate	O
transition	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
have	O
been	O
implicated	O
in	O
the	O
malignant	O
progression	O
of	O
astrocytomas	O
.	O
The	O
results	O
of	O
the	O
present	O
study	O
demonstrate	O
that	O
dysfunction	O
of	O
these	O
genes	O
also	O
occurs	O
during	O
recurrence	O
of	O
glial	O
tumors	O
that	O
were	O
highly	O
malignant	O
at	O
first	O
presentation	O
.	O
Analysis	O
of	O
10	O
matched	O
pairs	O
of	O
high	O
grade	O
malignant	O
astrocytomas	O
and	O
their	O
subsequent	O
recurrences	O
identified	O
three	O
distinct	O
groups	O
.	O
The	O
primary	O
and	O
recurrent	O
tumors	O
in	O
Group	O
A	O
did	O
not	O
show	O
structural	O
alterations	O
in	O
the	O
p16	O
,	O
p15	O
or	O
CDK4	O
genes	O
,	O
whereas	O
homozygous	O
codeletion	O
of	O
p16	O
and	O
p15	O
was	O
observed	O
in	O
both	O
primary	O
and	O
recurrent	O
tumors	O
in	O
Group	O
B	O
.	O
The	O
primary	O
tumors	O
in	O
Group	O
C	O
had	O
a	O
normal	O
profile	O
of	O
p16	B
,	O
p15	B
and	O
CDK4	B
at	O
presentation	O
.	O
Upon	O
recurrence	O
,	O
however	O
,	O
the	O
tumors	O
sustained	O
either	O
deletion	O
of	O
p16	B
alone	O
or	O
codeletion	O
of	O
both	O
p16	B
and	O
p15	B
or	O
amplification	O
of	O
CDK4	B
.	O
Analysis	O
of	O
the	O
molecular	O
differences	O
between	O
primary	O
anaplastic	O
astrocytomas	O
/	O
glioblastomas	O
and	O
their	O
subsequent	O
recurrences	O
,	O
which	O
are	O
clinically	O
indistinguishable	O
,	O
may	O
provide	O
better	O
therapeutic	O
options	O
for	O
treatment	O
.	O
CTL	O
recognition	O
of	O
an	O
altered	O
peptide	O
associated	O
with	O
asparagine	O
bond	O
rearrangement	O
.	O
Implications	O
for	O
immunity	O
and	O
vaccine	O
design	O
.	O
The	O
extent	O
to	O
which	O
peptides	O
containing	O
chemically	O
and	O
post	O
-	O
translationally	O
modified	O
amino	B
acid	I
side	I
chains	I
are	O
recognized	O
by	O
primed	O
CTL	O
has	O
not	O
been	O
clearly	O
defined	O
.	O
We	O
report	O
on	O
the	O
CTL	O
recognition	O
of	O
a	O
MHC	O
class	O
I	O
-	O
restricted	O
peptide	O
containing	O
a	O
cyclized	O
asparagine	O
(	O
succinimide	O
)	O
residue	O
.	O
This	O
modification	O
of	O
the	O
asparagine	O
side	O
chain	O
is	O
a	O
common	O
intermediate	O
structure	O
during	O
deamidation	O
,	O
isomerization	O
,	O
and	O
bond	O
rearrangements	O
of	O
amide	O
-	O
containing	O
amino	O
acids	O
and	O
also	O
occurs	O
as	O
a	O
side	O
reaction	O
in	O
peptide	O
synthesis	O
.	O
The	O
CTL	O
specifically	O
recognized	O
the	O
succinimide	O
-	O
containing	O
peptide	O
showing	O
only	O
weak	O
cross	O
-	O
reactivity	O
at	O
high	O
concentrations	O
of	O
the	O
parent	O
peptide	O
containing	O
unmodified	O
asparagine	O
.	O
Similarly	O
,	O
CTL	O
raised	O
against	O
the	O
parent	O
peptide	O
did	O
not	O
recognize	O
the	O
succinimide	O
derivative	O
of	O
this	O
peptide	O
.	O
Naturally	O
processed	O
forms	O
of	O
these	O
structures	O
are	O
likely	O
to	O
occur	O
given	O
the	O
importance	O
and	O
frequency	O
of	O
deamidation	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
Moreover	O
,	O
since	O
succinimide	O
intermediates	O
of	O
deamidated	O
peptides	O
can	O
occasionally	O
be	O
very	O
stable	O
,	O
these	O
peptides	O
have	O
the	O
potential	O
to	O
act	O
as	O
altered	O
self	O
-	O
Ags	O
with	O
significant	O
implications	O
for	O
autoimmunity	O
.	O
In	O
addition	O
,	O
unwanted	O
and	O
potentially	O
hazardous	O
specificities	O
may	O
be	O
elicited	O
when	O
using	O
synthetic	O
peptides	O
in	O
subunit	O
vaccines	O
in	O
which	O
succinimide	O
residues	O
may	O
form	O
spontaneously	O
during	O
storage	O
or	O
chemical	O
synthesis	O
.	O
Regulation	O
of	O
gene	O
expression	O
at	O
early	O
stages	O
of	O
B	O
-	O
cell	O
and	O
T	O
-	O
cell	O
differentiation	O
.	O
The	O
expression	O
of	O
distinct	O
sets	O
of	O
genes	O
at	O
different	O
stages	O
of	O
B	O
-	O
lymphocyte	O
and	O
T	O
-	O
lymphocyte	O
differentiation	O
is	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
.	O
A	O
number	O
of	O
recent	O
studies	O
have	O
described	O
interactions	O
between	O
transcription	B
factors	I
in	O
lymphocytes	O
that	O
provide	O
new	O
insights	O
into	O
mechanisms	O
regulating	O
gene	O
expression	O
.	O
These	O
mechanisms	O
include	O
the	O
assembly	O
of	O
higher	B
order	I
nucleoprotein	I
complexes	I
and	O
other	O
protein	O
-	O
protein	O
interactions	O
that	O
enhance	O
the	O
functional	O
specificity	O
of	O
transcriptional	B
regulators	I
in	O
lymphocytes	O
.	O
X	O
inactivation	O
analysis	O
in	O
a	O
female	O
with	O
hypomelanosis	O
of	O
Ito	O
associated	O
with	O
a	O
balanced	O
X	O
;	O
17	O
translocation	O
:	O
evidence	O
for	O
functional	O
disomy	O
of	O
Xp	O
.	O
X	O
inactivation	O
analysis	O
was	O
performed	O
on	O
normal	O
and	O
hypopigmented	O
skin	O
samples	O
obtained	O
from	O
a	O
female	O
with	O
hypomelanosis	O
of	O
Ito	O
associated	O
with	O
a	O
balanced	O
whole	O
arm	O
X	O
;	O
17	O
translocation	O
.	O
Severe	O
skewing	O
of	O
X	O
inactivation	O
resulting	O
in	O
inactivity	O
of	O
the	O
intact	O
X	O
was	O
found	O
in	O
blood	O
and	O
cultures	O
of	O
both	O
types	O
of	O
skin	O
,	O
but	O
analysis	O
of	O
DNA	O
prepared	O
directly	O
from	O
hypopigmented	O
skin	O
showed	O
significant	O
inactivation	O
of	O
the	O
translocated	O
X	O
,	O
inconsistent	O
with	O
the	O
usual	O
mechanism	O
of	O
phenotypic	O
expression	O
in	O
X	O
;	O
autosome	O
translocations	O
.	O
In	O
addition	O
,	O
dual	O
colour	O
FISH	O
analysis	O
using	O
centromere	O
specific	O
probes	O
for	O
chromosomes	O
X	O
and	O
17	O
showed	O
that	O
the	O
breakpoints	O
on	O
both	O
chromosomes	O
lie	O
within	O
the	O
alphoid	O
arrays	O
,	O
making	O
interruption	O
of	O
a	O
locus	O
on	O
either	O
chromosome	O
unlikely	O
.	O
While	O
partial	O
variable	O
monosomy	O
of	O
loci	O
on	O
chromosome	O
17p	O
can	O
not	O
be	O
excluded	O
as	O
contributing	O
to	O
the	O
phenotype	O
in	O
this	O
patient	O
,	O
it	O
is	O
argued	O
that	O
the	O
major	O
likely	O
factor	O
is	O
partial	O
functional	O
disomy	O
of	O
sequences	O
on	O
Xp	O
in	O
cell	O
lineages	O
that	O
have	O
failed	O
to	O
inactivate	O
the	O
intact	O
X	O
chromosome	O
.	O
Interaction	O
of	O
the	O
human	B
T	I
-	I
cell	I
lymphotropic	I
virus	I
type	I
1	I
tax	I
transactivator	I
with	O
transcription	B
factor	I
IIA	I
.	O
The	O
Tax	B
protein	I
of	O
human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
a	O
40-kDa	B
transcriptional	I
activator	I
which	O
is	O
critical	O
for	O
HTLV-1	O
gene	O
regulation	O
and	O
virus	O
-	O
induced	O
cellular	O
transformation	O
.	O
Tax	B
is	O
localized	O
to	O
the	O
DNA	O
through	O
its	O
interaction	O
with	O
the	O
site	B
-	I
specific	I
activators	I
cyclic	B
AMP	I
-	I
responsive	I
element	I
-	I
binding	I
protein	I
,	O
NF	B
-	I
kappaB	I
,	O
and	O
serum	B
response	I
factor	I
.	O
It	O
has	O
been	O
suggested	O
that	O
the	O
recruitment	O
of	O
Tax	B
to	O
the	O
DNA	O
positions	O
Tax	B
for	O
interaction	O
with	O
the	O
basal	O
transcriptional	O
machinery	O
.	O
On	O
the	O
basis	O
of	O
several	O
independent	O
assays	O
,	O
we	O
now	O
report	O
a	O
physical	O
and	O
functional	O
interaction	O
between	O
Tax	B
and	O
the	O
transcription	B
factor	I
,	O
TFIIA	B
.	O
First	O
,	O
Tax	B
was	O
found	O
to	O
interact	O
with	O
the	O
35-kDa	B
(	I
alpha	I
)	I
subunit	I
of	O
TFIIA	B
in	O
the	O
yeast	O
two	O
-	O
hybrid	O
interaction	O
system	O
.	O
Importantly	O
,	O
two	O
previously	O
characterized	O
mutants	B
with	O
point	O
mutations	O
in	O
Tax	B
,	O
M32	B
(	O
Y196A	O
,	O
K197S	O
)	O
and	O
M41	B
(	O
H287A	O
,	O
P288S	O
)	O
,	O
which	O
were	O
shown	O
to	O
be	O
defective	O
in	O
Tax	B
-activated	O
transcription	O
were	O
unable	O
to	O
interact	O
with	O
TFIIA	B
in	O
this	O
assay	O
.	O
Second	O
,	O
a	O
glutathione	O
-	O
S	O
-	O
transferase	O
(	O
GST	B
)	O
affinity	O
-	O
binding	O
assay	O
showed	O
that	O
the	O
interaction	O
of	O
holo-	O
TFIIA	B
with	O
GST	B
-	I
Tax	I
was	O
20-fold	O
higher	O
than	O
that	O
observed	O
with	O
either	O
the	O
GST	B
-	I
Tax	I
M32	I
activation	I
mutant	I
or	O
the	O
GST	O
control	O
.	O
Third	O
,	O
a	O
coimmunoprecipitation	O
assay	O
showed	O
that	O
in	O
HTLV-1-infected	O
human	O
T	O
lymphocytes	O
,	O
Tax	B
and	O
TFIIA	B
were	O
associated	O
.	O
Finally	O
,	O
TFIIA	B
facilitates	O
Tax	B
transactivation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
In	O
vitro	O
transcription	O
studies	O
showed	O
reduced	O
levels	O
of	O
Tax	B
-activated	O
transcription	O
in	O
cell	O
extracts	O
depleted	O
of	O
TFIIA	B
.	O
In	O
addition	O
,	O
transfection	O
of	O
human	O
T	O
lymphocytes	O
with	O
TFIIA	O
expression	O
vectors	O
enhanced	O
Tax	B
-activated	O
transcription	O
of	O
an	O
HTLV-1	O
long	O
terminal	O
repeat	O
-	O
chloramphenicol	O
acetyltransferase	O
reporter	O
construct	O
.	O
Our	O
study	O
suggests	O
that	O
the	O
interaction	O
of	O
Tax	B
with	O
the	O
transcription	B
factor	I
TFIIA	B
may	O
play	O
a	O
role	O
in	O
Tax	B
-mediated	O
transcriptional	O
activation	O
.	O
Transgenic	O
expression	O
of	O
PML	B
/	I
RARalpha	I
impairs	O
myelopoiesis	O
.	O
The	O
translocation	O
found	O
in	O
acute	O
promyelocytic	O
leukemia	O
rearranges	O
the	O
promyelocytic	O
leukemia	O
gene	O
(	O
PML	O
)	O
on	O
chromosome	O
15	O
with	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RARalpha	B
)	O
on	O
chromosome	O
17	O
.	O
This	O
yields	O
a	O
fusion	O
transcript	O
,	O
PML	B
/	I
RARalpha	I
,	O
a	O
transcription	B
factor	I
with	O
reported	O
dominant	O
negative	O
functions	O
in	O
the	O
absence	O
of	O
hormone	O
.	O
Clinical	O
remissions	O
induced	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
treatment	O
in	O
acute	O
promyelocytic	O
leukemia	O
are	O
linked	O
to	O
PML	B
/	I
RARalpha	I
expression	O
in	O
leukemic	O
cells	O
.	O
To	O
evaluate	O
the	O
PML	B
/	I
RARalpha	I
role	O
in	O
myelopoiesis	O
,	O
transgenic	O
mice	O
expressing	O
PML	B
/	I
RARalpha	I
were	O
engineered	O
.	O
A	O
full	O
-	O
length	O
PML	O
/	O
RARalpha	O
cDNA	O
driven	O
by	O
the	O
CD11b	O
promoter	O
was	O
expressed	O
in	O
transgenic	O
mice	O
.	O
Expression	O
was	O
confirmed	O
in	O
the	O
bone	O
marrow	O
with	O
a	O
reverse	O
transcription	O
PCR	O
assay	O
.	O
Basal	O
total	O
white	O
blood	O
cell	O
and	O
granulocyte	O
counts	O
did	O
not	O
appreciably	O
differ	O
between	O
PML	B
/	I
RARalpha	I
transgenic	O
and	O
control	O
mice	O
.	O
Cell	O
sorter	O
analysis	O
of	O
CD11b+	O
bone	O
marrow	O
cells	O
revealed	O
similar	O
CD11b+	O
populations	O
in	O
transgenic	O
and	O
control	O
mice	O
.	O
However	O
,	O
in	O
vitro	O
clonal	O
growth	O
assays	O
performed	O
on	O
peripheral	O
blood	O
from	O
transgenic	O
versus	O
control	O
mice	O
revealed	O
a	O
marked	O
reduction	O
of	O
myeloid	O
progenitors	O
,	O
especially	O
in	O
those	O
responding	O
to	O
granulocyte	B
/	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
.	O
Granulocyte	B
/	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
and	O
kit	O
ligand	O
cotreatment	O
did	O
not	O
overcome	O
this	O
inhibition	O
.	O
Impaired	O
myelopoiesis	O
in	O
vivo	O
was	O
shown	O
by	O
stressing	O
these	O
mice	O
with	O
sublethal	O
irradiation	O
.	O
Following	O
irradiation	O
,	O
PML	B
/	I
RARalpha	I
transgenic	O
mice	O
,	O
as	O
compared	O
with	O
controls	O
,	O
more	O
rapidly	O
depressed	O
peripheral	O
white	O
blood	O
cell	O
and	O
granulocyte	O
counts	O
.	O
As	O
expected	O
,	O
nearly	O
all	O
control	O
mice	O
(	O
94.4	O
%	O
)	O
survived	O
irradiation	O
,	O
yet	O
this	O
irradiation	O
was	O
lethal	O
to	O
45.8	O
%	O
of	O
PML	B
/	I
RARalpha	I
transgenic	O
mice	O
.	O
Lethality	O
was	O
associated	O
with	O
more	O
severe	O
leukopenia	O
in	O
transgenic	O
versus	O
control	O
mice	O
.	O
Retinoic	O
acid	O
treatment	O
of	O
irradiated	O
PML	B
/	I
RARalpha	I
mice	O
enhanced	O
granulocyte	O
recovery	O
.	O
These	O
data	O
suggest	O
that	O
abnormal	O
myelopoiesis	O
due	O
to	O
PML	B
/	I
RARalpha	I
expression	O
is	O
an	O
early	O
event	O
in	O
oncogenic	O
transformation	O
.	O
Alpha	B
4	I
beta	I
1	I
(	I
CD49d	I
/	I
CD29	I
)	I
integrin	I
costimulation	O
of	O
human	O
T	O
cells	O
enhances	O
transcription	B
factor	I
and	O
cytokine	O
induction	O
in	O
the	O
absence	O
of	O
altered	O
sensitivity	O
to	O
anti	B
-	I
CD3	I
stimulation	O
.	O
The	O
integrin	B
alpha	I
4	I
beta	I
1	I
can	O
provide	O
a	O
costimulus	O
to	O
induce	O
IL-2	B
secretion	O
and	O
IL-2R	B
expression	O
leading	O
to	O
enhanced	O
proliferation	O
of	O
purified	O
,	O
peripheral	O
blood	O
T	O
cells	O
.	O
Similar	O
to	O
expression	O
of	O
IL-2	B
,	O
we	O
demonstrated	O
that	O
recombinant	B
vascular	I
-	I
cell	I
adhesion	I
molecule-1	I
,	O
when	O
co	O
-	O
immobilized	O
with	O
anti	B
-	I
CD3	I
mAb	I
,	O
significantly	O
enhanced	O
the	O
induction	O
of	O
transcription	B
factors	I
NF	B
-	I
AT	I
,	O
AP-1	B
,	O
and	O
NF	B
-	I
kappa	I
B	I
as	O
determined	O
by	O
electromobility	O
shift	O
assays	O
.	O
alpha	B
4	I
beta	I
1	I
ligation	O
alone	O
had	O
no	O
effect	O
on	O
transcription	B
factor	I
binding	O
.	O
The	O
requirements	O
for	O
induction	O
of	O
transcription	B
factors	I
reflected	O
the	O
requirements	O
for	O
the	O
secretion	O
of	O
multiple	O
cytokines	B
,	O
including	O
IL-2	B
,	O
TNF	B
-	I
alpha	I
,	O
IFN	B
-	I
gamma	I
,	O
and	O
granulocyte	B
macrophage	I
-	I
CSF	I
.	O
In	O
contrast	O
to	O
freshly	O
isolated	O
T	O
cells	O
,	O
in	O
vitro	O
-	O
cultured	O
T	O
cells	O
did	O
not	O
require	O
costimulation	O
for	O
cytokine	B
secretion	O
in	O
response	O
to	O
anti	B
-	I
CD3	I
alone	O
.	O
Comparison	O
of	O
the	O
dose	O
response	O
to	O
anti	B
-	I
CD3	I
stimulation	O
demonstrated	O
that	O
half	O
-	O
maximal	O
induction	O
of	O
IL-2	B
was	O
achieved	O
using	O
the	O
same	O
dose	O
of	O
anti	B
-	I
CD3	I
for	O
both	O
freshly	O
isolated	O
and	O
cultured	O
T	O
cells	O
.	O
Furthermore	O
,	O
the	O
dose	O
of	O
OKT3	B
required	O
to	O
achieve	O
half	O
-	O
maximal	O
activation	O
was	O
the	O
same	O
using	O
PMA	O
or	O
different	O
concentrations	O
of	O
alpha	B
4	I
beta	I
1	I
ligands	O
.	O
Therefore	O
,	O
costimulation	O
by	O
alpha	B
4	I
beta	I
1	I
ligands	O
was	O
not	O
due	O
to	O
stabilization	O
of	O
the	O
interaction	O
of	O
the	O
cells	O
with	O
its	O
substrate	O
.	O
We	O
conclude	O
,	O
rather	O
,	O
that	O
alpha	B
4	I
beta	I
1	I
in	O
freshly	O
isolated	O
T	O
cells	O
delivers	O
a	O
distinct	O
signal	O
that	O
synergizes	O
early	O
with	O
signals	O
initiated	O
by	O
TCR	B
/	I
CD3	I
ligation	O
to	O
induce	O
DNA	O
binding	O
of	O
multiple	O
transcription	B
factors	I
required	O
for	O
cytokine	O
gene	O
induction	O
.	O
Elevated	O
cyclic	O
AMP	O
inhibits	O
NF	B
-	I
kappaB	I
-mediated	O
transcription	O
in	O
human	O
monocytic	O
cells	O
and	O
endothelial	O
cells	O
.	O
The	O
NF	B
-	I
kappaB	I
/	I
Rel	I
family	I
of	O
transcription	B
factors	I
regulates	O
the	O
inducible	O
expression	O
of	O
many	O
genes	O
in	O
activated	O
human	O
monocytes	O
and	O
endothelial	O
cells	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
molecular	O
mechanism	O
by	O
which	O
agents	O
that	O
elevate	O
intracellular	O
cAMP	O
inhibit	O
the	O
expression	O
of	O
the	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNFalpha	B
)	O
,	O
tissue	B
factor	I
,	O
endothelial	B
leukocyte	I
adhesion	I
molecule-1	I
,	O
and	O
vascular	O
cell	O
adhesion	O
molecule-1	O
genes	O
.	O
Both	O
forskolin	O
and	O
dibutyryl	O
cAMP	O
,	O
which	O
elevate	O
intracellular	O
cAMP	O
by	O
independent	O
mechanisms	O
,	O
inhibited	O
TNFalpha	B
and	O
tissue	B
factor	I
expression	O
at	O
the	O
level	O
of	O
transcription	O
.	O
Induction	O
of	O
NF	B
-	I
kappaB	I
-dependent	O
gene	O
expression	O
in	O
transiently	O
transfected	O
human	O
monocytic	O
THP-1	O
cells	O
and	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
was	O
inhibited	O
by	O
elevated	O
cAMP	O
and	O
by	O
overexpression	O
of	O
the	O
catalytic	B
subunit	I
of	O
protein	B
kinase	I
A	I
(	O
PKA	B
)	O
.	O
Elevated	O
cAMP	O
did	O
not	O
prevent	O
nuclear	O
translocation	O
of	O
p50	B
/	I
p65	I
and	O
c	B
-	I
Rel	I
/	I
p65	I
heterodimers	I
,	O
decrease	O
nuclear	O
translocation	O
of	O
p65	B
,	O
or	O
significantly	O
modify	O
TNFalpha	B
-induced	O
phosphorylation	O
of	O
p65	B
.	O
Functional	O
studies	O
demonstrated	O
that	O
transcriptional	O
activation	O
of	O
a	O
plasmid	O
containing	O
multimerized	O
kappaB	O
sites	O
by	O
p65	B
was	O
inhibited	O
by	O
agents	O
that	O
elevate	O
cAMP	O
and	O
by	O
overexpression	O
of	O
the	O
catalytic	B
subunit	I
of	O
PKA	B
.	O
This	O
study	O
indicates	O
that	O
activation	O
of	O
PKA	B
reduces	O
the	O
induction	O
of	O
a	O
distinct	O
set	O
of	O
genes	O
in	O
monocytes	O
and	O
endothelial	O
cells	O
by	O
inhibiting	O
NF	B
-	I
kappaB	I
-mediated	O
transcription	O
.	O
Activation	O
of	O
human	O
monocytic	O
cells	O
by	O
Treponema	B
pallidum	I
and	I
Borrelia	I
burgdorferi	I
lipoproteins	I
and	O
synthetic	O
lipopeptides	O
proceeds	O
via	O
a	O
pathway	O
distinct	O
from	O
that	O
of	O
lipopolysaccharide	O
but	O
involves	O
the	O
transcriptional	O
activator	O
NF	B
-	I
kappa	I
B	I
.	O
There	O
is	O
increasing	O
evidence	O
that	O
lipoproteins	B
of	O
Treponema	O
pallidum	O
and	O
Borrelia	O
burgdorferi	O
are	O
key	O
inflammatory	O
mediators	O
during	O
syphilis	O
and	O
Lyme	O
disease	O
.	O
A	O
principal	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
identify	O
more	O
precisely	O
similarities	O
and	O
divergences	O
among	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
and	O
lipoprotein	O
-	O
lipopeptide	O
-	O
induced	O
immune	O
cell	O
signaling	O
events	O
.	O
Like	O
LPS	O
,	O
purified	B
native	I
B.	I
burgdorferi	I
OspA	I
and	O
synthetic	O
analogs	O
of	O
OspA	B
,	O
OspB	B
,	O
and	O
two	O
T.	B
pallidum	I
lipoproteins	I
(	O
Tpp47	B
and	O
Tpp17	B
)	O
all	O
induced	O
NF	B
-	I
kappa	I
B	I
translocation	O
in	O
THP-1	O
human	O
monocytoid	O
cells	O
.	O
Acylation	O
of	O
OspA	B
and	O
the	O
synthetic	O
peptides	O
was	O
requisite	O
for	O
cell	O
activation	O
.	O
Polymyxin	O
B	O
abrogated	O
only	O
the	O
response	O
to	O
LPS	O
.	O
By	O
using	O
70Z	O
/	O
3-derived	O
pre	O
-	O
B	O
-	O
cell	O
lines	O
either	O
lacking	O
or	O
expressing	O
human	B
CD14	I
(	O
the	O
LPS	B
receptor	I
)	O
,	O
it	O
was	O
observed	O
that	O
expression	O
of	O
human	B
CD14	I
imparted	O
responsiveness	O
to	O
LPS	O
but	O
not	O
to	O
OspA	B
or	O
spirochetal	B
lipopeptides	I
(	O
assessed	O
by	O
induction	O
of	O
NF	B
-	I
kappa	I
B	I
and	O
expression	O
of	O
surface	B
immunoglobulin	I
M	I
)	O
.	O
Finally	O
,	O
the	O
biological	O
relevance	O
of	O
the	O
observation	O
that	O
T.	B
pallidum	I
lipoproteins	I
-lipopeptides	O
induce	O
both	O
NF	B
-	I
kappa	I
B	I
and	O
cytokine	B
production	O
in	O
monocytes	O
was	O
supported	O
by	O
the	O
ability	O
of	O
the	O
synthetic	O
analogs	O
to	O
promote	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
chronically	O
infected	O
U1	O
monocytoid	O
cells	O
;	O
these	O
observations	O
also	O
suggest	O
a	O
potential	O
mechanism	O
whereby	O
a	O
syphilitic	O
chancre	O
can	O
serve	O
as	O
a	O
cofactor	O
for	O
human	O
immunodeficiency	O
virus	O
transmission	O
.	O
The	O
combined	O
data	O
lend	O
additional	O
support	O
to	O
the	O
proposal	O
that	O
spirochetal	B
lipoproteins	I
and	O
LPS	O
initiate	O
monocyte	O
activation	O
via	O
different	O
cell	O
surface	O
events	O
but	O
that	O
the	O
signaling	O
pathways	O
ultimately	O
converge	O
to	O
produce	O
qualitatively	O
similar	O
cellular	O
responses	O
.	O
Transcription	O
specific	O
differences	O
visualized	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
pattern	O
on	O
interphase	O
nuclei	O
of	O
different	O
cell	O
types	O
.	O
Application	O
of	O
a	O
`	O
`	O
formamide	O
free	O
''	O
and	O
thus	O
`	O
`	O
material	O
preserving	O
''	O
in	O
situ	O
hybridization	O
technique	O
using	O
the	O
cDNA	O
of	O
the	O
myf3	O
gene	O
revealed	O
the	O
following	O
results	O
:	O
Human	O
rhabdomyosarcoma	O
cells	O
,	O
characterized	O
by	O
a	O
high	O
expression	O
of	O
myf3	O
show	O
intensive	O
hybridization	O
signals	O
in	O
their	O
interphase	O
.	O
RNase	B
treatment	O
prior	O
to	O
hybridization	O
considerably	O
reduces	O
the	O
size	O
of	O
this	O
signals	O
.	O
In	O
comparison	O
,	O
isolated	O
nuclei	O
of	O
human	O
lymphocytes	O
in	O
which	O
no	O
need	O
for	O
the	O
expression	O
of	O
this	O
gene	O
exists	O
,	O
show	O
barely	O
hybridization	O
signals	O
.	O
Correspondingly	O
,	O
RNase	B
treatment	O
had	O
no	O
effect	O
on	O
hybridization	O
pattern	O
at	O
all	O
.	O
In	O
conclusion	O
an	O
increased	O
transcription	O
efficiency	O
of	O
a	O
cell	O
type	O
specific	O
gene	O
is	O
accompanied	O
by	O
a	O
higher	O
hybridization	O
accessibility	O
in	O
the	O
corresponding	O
cell	O
nuclei	O
.	O
Chronic	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
infection	O
of	O
myeloid	O
cells	O
disrupts	O
the	O
autoregulatory	O
control	O
of	O
the	O
NF	B
-	I
kappaB	I
/	I
Rel	I
pathway	O
via	O
enhanced	O
IkappaBalpha	B
degradation	O
.	O
Productive	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
causes	O
sustained	O
NF	B
-	I
kappaB	I
DNA	O
-	O
binding	O
activity	O
in	O
chronically	O
infected	O
monocytic	O
cells	O
.	O
A	O
direct	O
temporal	O
correlation	O
exists	O
between	O
HIV	O
infection	O
and	O
the	O
appearance	O
of	O
NF	B
-	I
kappaB	I
DNA	O
-	O
binding	O
activity	O
in	O
myelomonoblastic	O
PLB-985	O
cells	O
.	O
To	O
examine	O
the	O
molecular	O
basis	O
of	O
constitutive	O
NF	B
-	I
kappaB	I
DNA	O
-	O
binding	O
activity	O
in	O
HIV1	O
-infected	O
cells	O
,	O
we	O
analyzed	O
the	O
phosphorylation	O
and	O
turnover	O
of	O
IkappaBalpha	B
protein	O
,	O
the	O
activity	O
of	O
the	O
double	B
-	I
stranded	I
RNA	I
-	I
dependent	I
protein	I
kinase	I
(	O
PKR	B
)	O
and	O
the	O
intracellular	O
levels	O
of	O
NF	B
-	I
kappaB	I
subunits	I
in	O
the	O
PLB-985	O
and	O
U937	O
myeloid	O
cell	O
models	O
.	O
HIV-1	O
infection	O
resulted	O
in	O
constitutive	O
,	O
low	O
-	O
level	O
expression	O
of	O
type	B
1	I
interferon	I
(	O
IFN	B
)	O
at	O
the	O
mRNA	O
level	O
.	O
Constitutive	O
PKR	B
activity	O
was	O
also	O
detected	O
in	O
HIV-1-infected	O
cells	O
as	O
a	O
result	O
of	O
low	O
-	O
level	O
IFN	B
production	O
,	O
since	O
the	O
addition	O
of	O
anti	B
-	I
IFN	I
-	I
alpha	I
/	I
beta	I
antibody	I
to	O
the	O
cells	O
decreased	O
PKR	B
expression	O
.	O
Furthermore	O
,	O
the	O
analysis	O
of	O
IkappaBalpha	B
turnover	O
demonstrated	O
an	O
increased	O
degradation	O
of	O
IkappaBalpha	B
in	O
HIV-1-infected	O
cells	O
that	O
may	O
account	O
for	O
the	O
constitutive	O
DNA	O
binding	O
activity	O
.	O
A	O
dramatic	O
increase	O
in	O
the	O
intracellular	O
levels	O
of	O
NF	B
-	I
kappaB	I
subunits	O
c	B
-	I
Rel	I
and	O
NF	B
-	I
kappaB2	I
p100	I
and	O
a	O
moderate	O
increase	O
in	O
NF	B
-	I
kappaB2	I
p52	I
and	O
RelA	B
(	I
p65	I
)	I
were	O
detected	O
in	O
HIV-1-infected	O
cells	O
,	O
whereas	O
NF	B
-	I
kappaB1	I
p105	I
/	I
p50	I
levels	O
were	O
not	O
altered	O
relative	O
to	O
the	O
levels	O
in	O
uninfected	O
cells	O
.	O
We	O
suggest	O
that	O
HIV-1	O
infection	O
of	O
myeloid	O
cells	O
induces	O
IFN	B
production	O
and	O
PKR	B
activity	O
,	O
which	O
in	O
turn	O
contribute	O
to	O
enhanced	O
IkappaBalpha	B
phosphorylation	O
and	O
subsequent	O
degradation	O
.	O
Nuclear	O
translocation	O
of	O
NF	B
-	I
kappaB	I
subunits	I
may	O
ultimately	O
increase	O
the	O
intracellular	O
pool	O
of	O
NF	B
-	I
kappaB	I
/	I
IkappaBalpha	I
by	O
an	O
autoregulatory	O
mechanism	O
.	O
Enhanced	O
turnover	O
of	O
IkappaBalpha	B
and	O
the	O
accumulation	O
of	O
NF	B
-	I
kappaB	I
/	I
Rel	I
proteins	I
may	O
contribute	O
to	O
the	O
chronically	O
activated	O
state	O
of	O
HIV-1-infected	O
cells	O
.	O
Sequence	O
-	O
specific	O
DNA	O
binding	O
of	O
the	O
B	B
-	I
cell	I
-	I
specific	I
coactivator	I
OCA	B
-	I
B	I
.	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
of	O
immunoglobulin	O
genes	O
is	O
mediated	O
by	O
the	O
interaction	O
of	O
a	O
POU	O
domain	O
containing	O
transcription	B
factor	I
Oct-1	B
or	O
Oct-2	B
,	O
with	O
the	O
B	B
-	I
cell	I
-	I
specific	I
coactivator	I
OCA	B
-	I
B	I
(	O
Bob-1	B
,	O
OBF-1	B
)	O
and	O
a	O
prototype	O
octamer	O
element	O
.	O
We	O
find	O
that	O
OCA	B
-	I
B	I
binds	O
DNA	O
directly	O
in	O
the	O
major	O
groove	O
between	O
the	O
two	O
subdomains	O
of	O
the	O
POU	O
domain	O
,	O
requiring	O
both	O
an	O
A	O
at	O
the	O
fifth	O
position	O
of	O
the	O
octamer	O
element	O
and	O
contact	O
with	O
the	O
POU	O
domain	O
.	O
An	O
amino	B
-	I
terminal	I
fragment	I
of	O
OCA	B
-	I
B	I
binds	O
the	O
octamer	O
site	O
in	O
the	O
absence	O
of	O
a	O
POU	O
domain	O
with	O
the	O
same	O
sequence	O
specificity	O
.	O
Coactivator	O
OCA	B
-	I
B	I
may	O
undergo	O
a	O
POU	O
-	O
dependent	O
conformational	O
change	O
that	O
exposes	O
its	O
amino	O
terminus	O
,	O
allowing	O
it	O
to	O
recognize	O
specific	O
DNA	O
sequences	O
in	O
the	O
major	O
groove	O
within	O
the	O
binding	O
site	O
for	O
Oct-1	B
or	O
Oct-2	B
.	O
The	O
recognition	O
of	O
both	O
the	O
POU	O
domain	O
and	O
the	O
octamer	O
sequence	O
by	O
OCA	B
-	I
B	I
provides	O
a	O
mechanism	O
for	O
differential	O
regulation	O
of	O
octamer	O
sites	O
containing	O
genes	O
by	O
the	O
ubiquitous	B
factor	I
Oct-1	B
.	O
Cross	O
talk	O
between	O
cell	O
death	O
and	O
cell	O
cycle	O
progression	O
:	O
BCL-2	B
regulates	O
NFAT	B
-mediated	O
activation	O
.	O
BCL-2-deficient	O
T	O
cells	O
demonstrate	O
accelerated	O
cell	O
cycle	O
progression	O
and	O
increased	O
apoptosis	O
following	O
activation	O
.	O
Increasing	O
the	O
levels	O
of	O
BCL-2	B
retarded	O
the	O
G0	O
--	O
>	O
S	O
transition	O
,	O
sustained	O
the	O
levels	O
of	O
cyclin	B
-	I
dependent	I
kinase	I
inhibitor	O
p27Kip1	O
,	O
and	O
repressed	O
postactivation	O
death	O
.	O
Proximal	O
signal	O
transduction	O
events	O
and	O
immediate	O
early	O
gene	O
transcription	O
were	O
unaffected	O
.	O
However	O
,	O
the	O
transcription	O
and	O
synthesis	O
of	O
interleukin	B
2	I
and	O
other	O
delayed	O
early	O
cytokines	B
were	O
markedly	O
attenuated	O
by	O
BCL-2	B
.	O
In	O
contrast	O
,	O
a	O
cysteine	O
protease	O
inhibitor	O
that	O
also	O
blocks	O
apoptosis	O
had	O
no	O
substantial	O
affect	O
upon	O
cytokine	B
production	O
.	O
InterleUkin	B
2	I
expression	O
requires	O
several	O
transcription	B
factors	I
of	O
which	O
nuclear	O
translocation	O
of	O
NFAT	B
(	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
)	O
and	O
NFAT	B
-mediated	O
transactivation	O
were	O
impaired	O
by	O
BCL-2	B
.	O
Thus	O
,	O
select	O
genetic	O
aberrations	O
in	O
the	O
apoptotic	O
pathway	O
reveal	O
a	O
cell	O
autonomous	O
coregulation	O
of	O
activation	O
.	O
Apoptosis	O
mediated	O
by	O
HIV	B
protease	I
is	O
preceded	O
by	O
cleavage	O
of	O
Bcl-2	B
.	O
Expression	O
of	O
the	O
human	B
immunodeficiency	I
virus	I
type	I
1	I
(	I
HIV	I
)	I
protease	I
in	O
cultured	O
cells	O
leads	O
to	O
apoptosis	O
,	O
preceded	O
by	O
cleavage	O
of	O
bcl-2	B
,	O
a	O
key	O
negative	O
regulator	O
of	O
cell	O
death	O
.	O
In	O
contrast	O
,	O
a	O
high	O
level	O
of	O
bcl-2	B
protects	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
from	O
the	O
viral	B
protease	I
and	O
prevents	O
cell	O
death	O
following	O
HIV	O
infection	O
of	O
human	O
lymphocytes	O
,	O
while	O
reducing	O
the	O
yields	O
of	O
viral	B
structural	I
proteins	I
,	O
infectivity	O
,	O
and	O
tumor	B
necrosis	I
factor	I
alpha	I
.	O
We	O
present	O
a	O
model	O
for	O
HIV	O
replication	O
in	O
which	O
the	O
viral	B
protease	I
depletes	O
the	O
infected	O
cells	O
of	O
bcl-2	B
,	O
leading	O
to	O
oxidative	O
stress	O
-	O
dependent	O
activation	O
of	O
NF	B
kappa	I
B	I
,	O
a	O
cellular	B
factor	I
required	O
for	O
HIV	O
transcription	O
,	O
and	O
ultimately	O
to	O
cell	O
death	O
.	O
Purified	O
bcl-2	B
is	O
cleaved	O
by	O
HIV	B
protease	I
between	O
phenylalanine	O
112	O
and	O
alanine	O
113	O
.	O
The	O
results	O
suggest	O
a	O
new	O
option	O
for	O
HIV	O
gene	O
therapy	O
;	O
bcl-2	B
muteins	I
that	O
have	O
noncleavable	B
alterations	I
surrounding	O
the	O
HIV	B
protease	I
cleavage	I
site	I
.	O
Activation	O
of	O
Stat	B
5b	I
in	O
erythroid	O
progenitors	O
correlates	O
with	O
the	O
ability	O
of	O
ErbB	B
to	O
induce	O
sustained	O
cell	O
proliferation	O
.	O
Self	O
renewal	O
of	O
normal	O
erythroid	O
progenitors	O
is	O
induced	O
by	O
the	O
receptor	B
tyrosine	I
kinase	I
c	B
-	I
ErbB	I
,	O
whereas	O
other	O
receptors	B
(	O
c	B
-	I
Kit	I
/	I
Epo	I
-	I
R	I
)	O
regulate	O
erythroid	O
differentiation	O
.	O
To	O
address	O
possible	O
mechanisms	O
that	O
could	O
explain	O
this	O
selective	O
activity	O
of	O
c	B
-	I
ErbB	I
,	O
we	O
analyzed	O
the	O
ability	O
of	O
these	O
receptors	O
to	O
activate	O
the	O
different	O
members	O
of	O
the	O
Stat	B
transcription	I
factor	I
family	I
.	O
Ligand	O
activation	O
of	O
c	B
-	I
ErbB	I
induced	O
the	O
tyrosine	O
phosphorylation	O
,	O
DNA	O
-	O
binding	O
,	O
and	O
reporter	O
gene	O
transcription	O
of	O
Stat	B
5b	I
in	O
erythroblasts	O
.	O
In	O
contrast	O
,	O
ligand	O
activation	O
of	O
c	B
-	I
Kit	I
was	O
unable	O
to	O
induce	O
any	O
of	O
these	O
effects	O
in	O
the	O
same	O
cells	O
.	O
Activation	O
of	O
the	O
erythropoietin	B
receptor	I
caused	O
specific	O
DNA	O
-	O
binding	O
of	O
Stat	B
5b	I
,	O
but	O
failed	O
to	O
induce	O
reporter	O
gene	O
transcription	O
.	O
These	O
biochemical	O
findings	O
correlate	O
perfectly	O
with	O
the	O
selective	O
ability	O
of	O
c	B
-	I
ErbB	I
to	O
cause	O
sustained	O
self	O
renewal	O
in	O
erythroid	O
progenitors	O
.	O
Retinoid	O
differentiation	O
therapy	O
in	O
promyelocytic	O
leukemia	O
.	O
Acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
a	O
specific	O
type	O
of	O
acute	O
myeloid	O
leukemia	O
characterized	O
by	O
the	O
morphology	O
of	O
the	O
blast	O
cells	O
,	O
a	O
specific	O
t	O
(	O
15	O
;	O
17	O
)	O
translocation	O
,	O
and	O
risks	O
of	O
definite	O
coagulopathy	O
.	O
Recently	O
this	O
leukemia	O
was	O
further	O
characterized	O
by	O
an	O
exquisite	O
sensitivity	O
to	O
all	O
-	O
trans	O
retinoic	O
acid	O
's	O
differentiation	O
effect	O
and	O
the	O
production	O
of	O
a	O
fusion	O
gene	O
altering	O
the	O
gene	O
of	O
RARalpha	B
and	O
a	O
novel	O
gene	O
PML	O
.	O
In	O
vivo	O
differentiation	O
therapy	O
with	O
retinoids	O
in	O
APL	O
patients	O
follows	O
strict	O
guidelines	O
related	O
both	O
to	O
the	O
APL	O
cell	O
and	O
the	O
biodisposal	O
of	O
all	O
-	O
trans	O
retinoic	O
acid	O
.	O
Evidence	O
for	O
lowered	O
induction	O
of	O
nuclear	B
factor	I
kappa	I
B	I
in	O
activated	O
human	O
T	O
lymphocytes	O
during	O
aging	O
.	O
Transcription	O
factor	O
NF	B
kappa	I
B	I
(	O
nuclear	B
factor	I
kappa	I
B	I
)	O
is	O
induced	O
in	O
T	O
lymphocytes	O
from	O
young	O
individuals	O
following	O
activation	O
with	O
a	O
variety	O
of	O
stimuli	O
including	O
anti	B
-	I
CD3	I
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
.	O
In	O
contrast	O
,	O
activated	O
T	O
lymphocytes	O
from	O
older	O
individuals	O
show	O
a	O
significant	O
reduction	O
in	O
the	O
induction	O
of	O
NF	B
kappa	I
B	I
in	O
response	O
to	O
the	O
same	O
stimuli	O
.	O
The	O
age	O
-	O
related	O
decline	O
in	O
induction	O
of	O
NF	B
kappa	I
B	I
could	O
not	O
be	O
attributed	O
to	O
alteration	O
in	O
the	O
composition	O
of	O
subunits	O
,	O
p50	B
and	O
p65	B
were	O
found	O
to	O
be	O
the	O
predominant	O
subunits	O
of	O
induced	O
NF	B
kappa	I
B	I
in	O
T	O
cells	O
from	O
young	O
as	O
well	O
as	O
elderly	O
donors	O
.	O
Furthermore	O
,	O
similar	O
levels	O
of	O
NF	B
kappa	I
B	I
were	O
found	O
in	O
the	O
cytosols	O
of	O
unactivated	O
T	O
cells	O
from	O
both	O
young	O
and	O
elderly	O
donors	O
suggesting	O
that	O
precursor	O
levels	O
of	O
NF	B
kappa	I
B	I
remain	O
unaltered	O
during	O
aging	O
.	O
These	O
results	O
suggest	O
that	O
an	O
age	O
-	O
associated	O
decline	O
in	O
the	O
induction	O
of	O
NF	B
kappa	I
B	I
in	O
activated	O
T	O
cells	O
from	O
elderly	O
individuals	O
may	O
be	O
attributable	O
to	O
altered	O
regulation	O
of	O
the	O
inhibitor	O
,	O
I	B
kappa	I
B	I
,	O
and	O
may	O
play	O
an	O
important	O
role	O
in	O
immune	O
dysregulation	O
accompanying	O
aging	O
.	O
Interaction	O
of	O
HTLV	B
-	I
I	I
Tax	I
with	O
the	O
human	B
proteasome	I
:	O
implications	O
for	O
NF	B
-	I
kappa	I
B	I
induction	O
.	O
The	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
has	O
been	O
etiologically	O
associated	O
with	O
the	O
development	O
of	O
the	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
as	O
well	O
as	O
degenerative	O
neurologic	O
syndrome	O
termed	O
tropical	O
spastic	O
paraparesis	O
(	O
TSP	O
)	O
.	O
HTLV	O
-	O
I	O
encodes	O
a	O
potent	O
transactivator	B
protein	O
termed	O
Tax	B
that	O
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
process	O
of	O
T	O
-	O
cell	O
immortalization	O
.	O
Even	O
though	O
the	O
mechanisms	O
by	O
which	O
Tax	B
induces	O
transformation	O
are	O
still	O
unknown	O
,	O
it	O
seems	O
likely	O
that	O
the	O
ability	O
of	O
Tax	B
to	O
alter	O
the	O
expression	O
of	O
many	O
cellular	O
genes	O
plays	O
an	O
important	O
part	O
in	O
this	O
process	O
.	O
Tax	B
does	O
not	O
bind	O
directly	O
to	O
DNA	O
but	O
rather	O
deregulates	O
the	O
activity	O
of	O
cellular	B
transcription	I
factors	I
.	O
One	O
family	O
of	O
host	B
transcription	I
factors	I
whose	O
activity	O
is	O
altered	O
by	O
Tax	B
includes	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
.	O
These	O
transcription	B
factors	I
are	O
post	O
-	O
transcriptionally	O
regulated	O
by	O
their	O
assembly	O
with	O
a	O
second	O
family	O
of	O
inhibitory	B
proteins	I
termed	O
I	B
kappa	I
B	I
that	O
serve	O
to	O
sequester	O
the	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
complexes	I
in	O
the	O
cytoplasm	O
.	O
Upon	O
cellular	O
activation	O
,	O
I	B
kappa	I
B	I
alpha	I
is	O
phosphorylated	O
,	O
polyubiquitinated	O
,	O
and	O
degraded	O
in	O
the	O
proteasome	B
.	O
This	O
proteolytic	O
event	O
liberates	O
NF	B
-	I
kappa	I
B	I
,	O
permitting	O
its	O
rapid	O
translocation	O
into	O
the	O
nucleus	O
where	O
it	O
binds	O
to	O
its	O
cognate	O
enhancer	O
elements	O
.	O
Similarly	O
,	O
the	O
p105	B
precursor	I
of	O
the	O
NF	B
-	I
kappa	I
B	I
p50	B
subunit	I
is	O
also	O
post	O
-	O
translationally	O
processed	O
in	O
the	O
proteasome	B
.	O
The	O
mechanisms	O
by	O
which	O
Tax	B
activates	O
NF	B
-	I
kappa	I
B	I
remain	O
unclear	O
,	O
and	O
findings	O
presented	O
in	O
the	O
literature	O
are	O
often	O
controversial	O
.	O
We	O
identified	O
a	O
physical	O
interaction	O
between	O
Tax	B
and	O
the	O
HsN3	B
subunit	I
of	O
the	O
human	B
proteasome	I
.	O
This	O
raises	O
the	O
intriguing	O
possibility	O
that	O
physical	O
association	O
of	O
the	O
HsN3	B
proteasome	I
subunit	I
with	O
HTLV	B
-	I
I	I
Tax	I
coupled	O
with	O
the	O
independent	O
interaction	O
of	O
Tax	B
with	O
either	O
p100	O
or	O
p65-	O
I	B
kappa	I
B	I
alpha	I
targets	O
these	O
cytoplasmic	B
NF	I
-	I
kappa	I
B	I
/	I
Rel	I
complexes	I
to	O
the	O
proteasome	B
for	O
processing	O
.	O
Epstein	O
-	O
Barr	O
viral	O
latency	O
is	O
disrupted	O
by	O
the	O
immediate	B
-	I
early	I
BRLF1	I
protein	I
through	O
a	O
cell	O
-	O
specific	O
mechanism	O
.	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
,	O
the	O
causative	O
agent	O
of	O
infectious	O
mononucleosis	O
,	O
is	O
a	O
human	O
herpesvirus	O
associated	O
with	O
epithelial	O
cell	O
malignancies	O
(	O
nasopharyngeal	O
carcinoma	O
)	O
as	O
well	O
as	O
B	O
-	O
cell	O
malignancies	O
.	O
Understanding	O
how	O
viral	O
latency	O
is	O
disrupted	O
is	O
a	O
central	O
issue	O
in	O
herpesvirus	O
biology	O
.	O
Epithelial	O
cells	O
are	O
the	O
major	O
site	O
of	O
lytic	O
EBV	O
replication	O
within	O
the	O
human	O
host	O
,	O
and	O
viral	O
reactivation	O
occurs	O
in	O
EBV	O
-	O
associated	O
nasopharyngeal	O
carcinomas	O
.	O
It	O
is	O
known	O
that	O
expression	O
of	O
a	O
single	O
viral	B
immediate	I
-	I
early	I
protein	I
,	O
BZLF1	B
,	O
is	O
sufficient	O
to	O
initiate	O
the	O
switch	O
from	O
latent	O
to	O
lytic	O
infection	O
in	O
B	O
cells	O
.	O
Cellular	O
regulation	O
of	O
BZLF1	B
transcription	O
is	O
therefore	O
thought	O
to	O
play	O
a	O
key	O
role	O
in	O
regulating	O
the	O
stringency	O
of	O
viral	O
latency	O
.	O
Here	O
we	O
show	O
that	O
,	O
unexpectedly	O
,	O
expression	O
of	O
another	O
viral	B
immediate	I
-	I
early	I
protein	I
,	O
BRLF1	B
,	O
can	O
disrupt	O
viral	O
latency	O
in	O
an	O
epithelial	O
cell	O
-	O
specific	O
fashion	O
.	O
Therefore	O
,	O
the	O
mechanisms	O
leading	O
to	O
disruption	O
of	O
EBV	O
latency	O
appear	O
to	O
be	O
cell	O
-	O
type	O
specific	O
.	O
IL4	B
and	I
IL13	I
receptors	I
share	O
the	O
gamma	B
c	I
chain	I
and	O
activate	O
STAT6	B
,	I
STAT3	I
and	I
STAT5	I
proteins	I
in	O
normal	O
human	O
B	O
cells	O
.	O
IL13	B
induces	O
the	O
same	O
biological	O
effects	O
as	O
IL4	B
in	O
normal	O
human	O
B	O
cells	O
.	O
We	O
show	O
that	O
as	O
in	O
the	O
IL4R	B
complex	I
,	O
both	O
IL4R	B
alpha	I
and	O
IL2R	B
gamma	I
c	I
are	O
components	O
of	O
the	O
IL13R	B
and	O
that	O
both	O
cytokines	B
induced	O
STAT6	B
,	O
STAT3	B
and	O
STAT5	B
activation	O
in	O
B	O
cells	O
.	O
In	O
spite	O
of	O
this	O
similar	O
downstream	O
signalling	O
,	O
IL4	B
and	O
IL13	B
used	O
a	O
different	O
set	O
of	O
Janus	B
kinases	I
:	O
IL13	B
is	O
unable	O
to	O
activate	O
JAK1	B
and	O
JAK3	B
.	O
Attenuated	O
function	O
of	O
a	O
variant	O
form	O
of	O
the	O
helix	B
-	I
loop	I
-	I
helix	I
protein	I
,	O
Id-3	B
,	O
generated	O
by	O
an	O
alternative	O
splicing	O
mechanism	O
.	O
The	O
I	O
d	O
family	O
of	O
helix	B
-	I
loop	I
-	I
helix	I
proteins	I
function	O
as	O
negative	O
regulators	O
of	O
DNA	O
binding	O
,	O
basic	O
helix	B
-	I
loop	I
-	I
helix	I
proteins	I
in	O
the	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O
We	O
report	O
here	O
on	O
the	O
identification	O
of	O
a	O
17	B
kDa	I
variant	I
of	O
the	O
14	B
kDa	I
Id-3	I
protein	O
termed	O
Id-3L	B
(	O
long	O
version	O
)	O
which	O
possesses	O
a	O
unique	O
60	B
amino	I
acid	I
carboxy	I
-	I
terminus	I
generated	O
by	O
read	O
through	O
of	O
a	O
'	O
coding	O
intron	O
'	O
and	O
alternative	O
splicing	O
.	O
Northern	O
analysis	O
revealed	O
expression	O
of	O
a	O
minor	O
1.1	O
kb	O
Id-3L	O
transcript	O
together	O
with	O
the	O
predominant	O
0.95	O
kb	O
Id-3	O
transcript	O
in	O
the	O
majority	O
of	O
adult	O
human	O
tissues	O
analysed	O
.	O
The	O
variant	O
Id-3L	B
protein	I
is	O
functionally	O
distinguishable	O
from	O
conventional	O
Id-3	B
since	O
in	O
in	O
vitro	O
DNA	O
mobility	O
shift	O
assays	O
,	O
it	O
was	O
greatly	O
impaired	O
in	O
its	O
ability	O
to	O
abrogate	O
binding	O
of	O
the	O
basic	O
helix	B
-	I
loop	I
-	I
helix	I
protein	I
,	O
E47	B
,	O
to	O
an	O
E	O
box	O
recognition	O
sequence	O
.	O
Multifactor	O
cis	O
-	O
dominant	O
negative	O
regulation	O
of	O
IL-2	O
gene	O
expression	O
in	O
anergized	O
T	O
cells	O
.	O
The	O
molecular	O
mechanism	O
underlying	O
IL-2	B
transcriptional	O
blockade	O
in	O
anergic	O
T	O
cell	O
clones	O
is	O
not	O
fully	O
understood	O
.	O
To	O
examine	O
whether	O
an	O
active	O
negative	O
regulatory	O
process	O
occurs	O
,	O
we	O
created	O
a	O
reporter	O
construct	O
containing	O
as	O
an	O
enhancer	O
four	O
copies	O
of	O
the	O
NF	O
-	O
AT	O
site	O
and	O
one	O
copy	O
of	O
the	O
octamer	O
site	O
(	O
4X	O
NF	O
-	O
AT	O
-	O
Oct	O
)	O
.	O
This	O
construct	O
was	O
only	O
slightly	O
reduced	O
(	O
1.3-fold	O
)	O
in	O
its	O
expression	O
when	O
stimulated	O
under	O
anergic	O
conditions	O
,	O
while	O
a	O
whole	O
mouse	O
IL-2	O
enhancer	O
construct	O
showed	O
a	O
reduction	O
of	O
4.3-fold	O
.	O
Addition	O
of	O
the	O
-176	O
to	O
-96	O
sequence	O
to	O
the	O
4X	O
NF	O
-	O
AT	O
-	O
Oct	O
construct	O
did	O
not	O
impart	O
the	O
ability	O
to	O
be	O
affected	O
by	O
anergy	O
,	O
but	O
addition	O
of	O
the	O
-236	O
to	O
-96	O
sequence	O
did	O
,	O
demonstrating	O
that	O
anergy	O
is	O
an	O
active	O
inhibitory	O
process	O
and	O
that	O
more	O
than	O
the	O
presence	O
of	O
the	O
-150	O
AP-1	O
binding	O
site	O
(	O
-152	O
to	O
-147	O
)	O
is	O
required	O
to	O
mediate	O
the	O
effect	O
.	O
Mutational	O
studies	O
of	O
the	O
-236	O
to	O
-96	O
sequence	O
indicated	O
that	O
the	O
presence	O
of	O
both	O
the	O
-130	O
AP-1-like	O
site	O
(	O
-187	O
to	O
-181	O
)	O
and	O
the	O
-150	O
proximal	O
AP-1	O
site	O
were	O
necessary	O
to	O
observe	O
anergy	O
.	O
Because	O
the	O
-180	O
site	O
is	O
not	O
required	O
for	O
trans	O
-	O
activation	O
,	O
it	O
was	O
possible	O
to	O
confirm	O
by	O
mutation	O
in	O
the	O
normal	O
mouse	O
IL-2	O
enhancer	O
that	O
this	O
site	O
is	O
absolutely	O
essential	O
for	O
anergy	O
induction	O
.	O
The	O
simplest	O
model	O
to	O
explain	O
these	O
results	O
is	O
that	O
anergy	O
is	O
mediated	O
by	O
a	O
complex	O
of	O
multiple	O
transcription	B
factors	I
that	O
exert	O
a	O
cis	O
-	O
acting	O
dominant	O
negative	O
regulatory	O
effect	O
on	O
the	O
trans	O
-	O
activation	O
of	O
the	O
IL-2	O
gene	O
.	O
Regulation	O
of	O
GM	O
-	O
CSF	O
gene	O
transcription	O
by	O
core	B
-	I
binding	I
factor	I
.	O
GM	O
-	O
CSF	O
gene	O
activation	O
in	O
T	O
cells	O
is	O
known	O
to	O
involve	O
the	O
transcription	B
factors	I
nuclear	B
factor	I
-	I
kappa	I
B	I
,	O
AP-1	B
,	O
NFAT	B
,	O
and	O
Sp1	O
.	O
Here	O
we	O
demonstrate	O
that	O
the	O
human	O
GM	O
-	O
CSF	O
promoter	O
and	O
enhancer	O
also	O
encompass	O
binding	O
sites	O
for	O
core	B
-	I
binding	I
factor	I
(	O
CBF	B
)	O
.	O
Significantly	O
,	O
the	O
CBF	O
sites	O
are	O
in	O
each	O
case	O
contained	O
within	O
the	O
minimum	O
essential	O
core	O
regions	O
required	O
for	O
inducible	O
activation	O
of	O
transcription	O
.	O
Furthermore	O
,	O
these	O
core	O
regions	O
of	O
the	O
enhancer	O
and	O
promoter	O
each	O
encompass	O
closely	O
linked	O
binding	O
sites	O
for	O
CBF	B
,	O
AP-1	B
,	O
and	O
NFATp	B
.	O
The	O
GM	O
-	O
CSF	O
promoter	O
CBF	O
site	O
TGTGGTCA	O
is	O
located	O
51	O
bp	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
and	O
also	O
overlaps	O
a	O
YY-1	O
binding	O
site	O
.	O
A	O
2-bp	O
mutation	O
within	O
the	O
CBF	B
site	O
resulted	O
in	O
a	O
2	O
-	O
3-fold	O
decrease	O
in	O
the	O
activities	O
of	O
both	O
a	O
69-bp	O
proximal	O
promoter	O
fragment	O
and	O
a	O
627-bp	O
full	O
-	O
length	O
promoter	O
fragment	O
.	O
Stepwise	O
deletions	O
into	O
the	O
proximal	O
promoter	O
also	O
revealed	O
that	O
the	O
CBF	B
site	O
,	O
but	O
not	O
the	O
YY-1	O
site	O
,	O
was	O
required	O
for	O
efficient	O
induction	O
of	O
transcriptional	O
activation	O
.	O
The	O
AML1	O
and	O
CBF	O
beta	O
genes	O
that	O
encode	O
CBF	B
each	O
have	O
the	O
ability	O
to	O
influence	O
cell	O
growth	O
and	O
differentiation	O
and	O
have	O
been	O
implicated	O
as	O
proto	O
-	O
oncogenes	O
in	O
acute	O
myeloid	O
leukemia	O
.	O
This	O
study	O
adds	O
GM	B
-	I
CSF	I
to	O
a	O
growing	O
list	O
of	O
cytokines	B
and	O
receptors	O
that	O
are	O
regulated	O
by	O
CBF	B
and	O
which	O
control	O
the	O
growth	O
,	O
differentiation	O
,	O
and	O
activation	O
of	O
hemopoietic	O
cells	O
.	O
The	O
GM	O
-	O
CSF	O
locus	O
may	O
represent	O
one	O
of	O
several	O
target	O
genes	B
that	O
are	O
dysregulated	O
in	O
acute	O
myeloid	O
leukemia	O
.	O
Mechanisms	O
that	O
contribute	O
to	O
the	O
development	O
of	O
lymphoid	O
malignancies	O
:	O
roles	O
for	O
genetic	O
alterations	O
and	O
cytokine	B
production	O
.	O
Recent	O
studies	O
have	O
defined	O
genetic	O
alterations	O
commonly	O
associated	O
with	O
transformed	O
lymphocytes	O
.	O
This	O
review	O
suggests	O
roles	O
for	O
these	O
alterations	O
in	O
the	O
development	O
of	O
lymphoid	O
neoplasms	O
.	O
Damage	O
to	O
the	O
genes	O
encoding	O
proteins	O
that	O
function	O
in	O
intracellular	O
signaling	O
,	O
transcription	O
,	O
or	O
regulation	O
of	O
the	O
cell	O
cycle	O
has	O
been	O
identified	O
and	O
linked	O
at	O
varying	O
degrees	O
to	O
the	O
progression	O
of	O
certain	O
lymphoid	O
malignancies	O
.	O
An	O
understanding	O
of	O
the	O
mechanistic	O
consequences	O
following	O
such	O
genetic	O
alterations	O
is	O
essential	O
to	O
an	O
understanding	O
of	O
the	O
development	O
of	O
these	O
lymphoid	O
neoplasms	O
.	O
In	O
contrast	O
,	O
it	O
is	O
also	O
becoming	O
clear	O
that	O
the	O
dysregulated	O
expression	O
of	O
proteins	O
that	O
are	O
not	O
genetically	O
altered	O
can	O
also	O
contribute	O
to	O
the	O
progression	O
of	O
lymphoid	O
malignancies	O
.	O
One	O
such	O
example	O
is	O
the	O
excessive	O
expression	O
of	O
`	B
`	I
normal	I
''	I
lymphokines	I
of	O
cytokines	B
which	O
accompanies	O
many	O
lymphoproliferative	O
diseases	O
.	O
The	O
dysregulated	O
expression	O
of	O
cytokines	B
during	O
malignancy	O
can	O
result	O
in	O
the	O
augmentation	O
of	O
growth	O
of	O
transformed	O
lymphocytes	O
,	O
as	O
well	O
as	O
an	O
alteration	O
of	O
the	O
anti	O
-	O
tumor	O
immune	O
response	O
.	O
The	O
latter	O
mechanism	O
is	O
especially	O
important	O
because	O
evasion	O
of	O
the	O
impending	O
immune	O
response	O
is	O
a	O
prerequisite	O
for	O
the	O
progression	O
of	O
lymphoproliferative	O
diseases	O
.	O
Taken	O
together	O
,	O
this	O
review	O
supports	O
the	O
notion	O
that	O
the	O
development	O
of	O
lymphoid	O
malignancies	O
is	O
multifactorial	O
,	O
involving	O
genetic	O
alterations	O
as	O
well	O
as	O
dysregulated	O
cytokine	B
expression	O
.	O
Tyloxapol	O
inhibits	O
NF	B
-	I
kappa	I
B	I
and	O
cytokine	B
release	O
,	O
scavenges	O
HOCI	B
,	O
and	O
reduces	O
viscosity	O
of	O
cystic	O
fibrosis	O
sputum	O
.	O
Cystic	O
fibrosis	O
(	O
CF	O
)	O
patients	O
develop	O
progressive	O
cytokine	B
-mediated	O
inflammatory	O
lung	O
disease	O
,	O
with	O
abundant	O
production	O
of	O
thick	O
,	O
tenacious	O
,	O
protease	B
-and	O
oxidant	O
-	O
rich	O
purulent	O
airway	O
secretions	O
that	O
are	O
difficult	O
to	O
clear	O
even	O
with	O
physiotherapy	O
.	O
In	O
the	O
search	O
for	O
a	O
potential	O
treatment	O
,	O
we	O
have	O
tested	O
tyloxapol	O
,	O
an	O
alkylaryl	O
polyether	O
alcohol	O
polymer	O
detergent	O
previously	O
used	O
as	O
a	O
mucolytic	O
agent	O
in	O
adult	O
chronic	O
bronchitis	O
.	O
Tyloxapol	O
inhibits	O
activation	O
of	O
the	O
transcription	B
factor	I
nuclear	I
factor	I
-	I
kappa	I
B	I
(	O
NK	B
-	I
kappa	I
B	I
)	O
,	O
reduces	O
resting	O
secretion	O
of	O
the	O
cytokine	B
interleukin-8	B
(	O
IL-8	B
)	O
in	O
cultured	O
human	O
monocytes	O
,	O
and	O
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-stimulated	O
release	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
,	O
IL-1	B
beta	I
,	O
IL-6	B
,	O
IL-8	B
,	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
,	O
and	O
the	O
eiconsanoids	O
thromboxane	O
A2	O
and	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
.	O
We	O
have	O
previously	O
shown	O
that	O
tyloxapol	O
is	O
a	O
potent	O
antioxidant	O
for	O
hydroxyl	O
radicals	O
(	O
OH	O
)	O
.	O
Tyloxapol	O
(	O
0.05	O
to	O
0.1	O
%	O
wt	O
/	O
vol	O
)	O
effectively	O
scavenges	O
the	O
oxidant	O
hypochlorous	O
acid	O
(	O
HOCl	O
;	O
1	O
to	O
7.5	O
mM	O
)	O
in	O
vitro	O
,	O
and	O
protects	O
from	O
HOCl	O
-	O
mediated	O
lung	O
injury	O
in	O
rats	O
.	O
Tyloxapol	O
also	O
reduces	O
the	O
viscosity	O
of	O
CF	O
sputum	O
(	O
from	O
463	O
+	O
/-	O
133	O
to	O
128	O
+	O
/-	O
52	O
centipoise	O
)	O
.	O
We	O
conclude	O
that	O
tyloxapol	O
is	O
potentially	O
useful	O
as	O
a	O
new	O
antiinflammatory	O
therapy	O
for	O
CF	O
lung	O
disease	O
,	O
and	O
could	O
possibly	O
promote	O
clearance	O
of	O
secretions	O
in	O
the	O
CF	O
airway	O
.	O
Requirements	O
for	O
induction	O
of	O
vitamin	O
D	O
-	O
mediated	O
gene	O
regulation	O
in	O
normal	O
human	O
B	O
lymphocytes	O
.	O
Mature	O
human	O
lymphocytes	O
are	O
unique	O
targets	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
)	O
in	O
that	O
vitamin	B
D	I
receptors	I
(	O
VDR	B
)	O
are	O
not	O
constitutively	O
expressed	O
,	O
and	O
specific	O
cellular	O
activation	O
signals	O
are	O
required	O
for	O
both	O
the	O
up	O
-	O
regulation	O
of	O
VDR	B
and	O
establishment	O
of	O
reactivity	O
to	O
the	O
lipophilic	O
ligand	O
.	O
Treatment	O
of	O
B	O
lymphocytes	O
with	O
the	O
cytokine	B
IL-4	B
(	O
IL-4	B
)	O
,	O
in	O
the	O
absence	O
of	O
prior	O
activation	O
,	O
induces	O
a	O
weak	O
up	O
-	O
regulation	O
of	O
VDR	B
expression	O
but	O
fails	O
to	O
generate	O
vitamin	B
D	I
-	I
responsive	I
element	I
(	I
VDRE	I
)	I
-reactive	I
nuclear	I
protein	I
complexes	I
or	O
to	O
initiate	O
the	O
genomic	O
transcription	O
of	O
25-hydroxyvitamin	B
D3	I
24-hydroxylase	I
.	O
Stimulation	O
of	O
B	O
lymphocytes	O
by	O
either	O
ligation	O
of	O
CD40	B
Ag	I
or	O
cross	O
-	O
linking	O
the	O
Ig	B
receptor	I
is	O
also	O
insufficient	O
to	O
render	O
B	O
lymphocytes	O
responsive	O
to	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O
However	O
,	O
this	O
apparent	O
lack	O
of	O
response	O
to	O
the	O
secosterol	O
can	O
be	O
overcome	O
by	O
stimulation	O
of	O
B	O
lymphocytes	O
with	O
a	O
combination	O
of	O
these	O
cellular	O
activation	O
signals	O
,	O
which	O
are	O
sufficient	O
to	O
lead	O
to	O
G1	O
cell	O
cycle	O
progression	O
.	O
In	O
the	O
presence	O
of	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
cellular	O
activation	O
associated	O
with	O
stimulation	O
of	O
such	O
a	O
progression	O
appears	O
to	O
be	O
sufficient	O
for	O
the	O
up	O
-	O
regulation	O
of	O
VDR	B
message	O
and	O
protein	O
and	O
necessary	O
for	O
the	O
establishment	O
of	O
VDRE	B
binding	I
complexes	I
and	O
the	O
induction	O
of	O
24-hydroxylase	B
message	O
.	O
Furthermore	O
,	O
biologic	O
functions	O
are	O
modulated	O
,	O
in	O
that	O
the	O
hormone	O
inhibits	O
proliferation	O
in	O
a	O
subset	O
of	O
the	O
activated	O
B	O
cells	O
.	O
These	O
observations	O
suggest	O
that	O
reactivity	O
to	O
1	O
alpha	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
tightly	O
regulated	O
in	O
B	O
lymphocytes	O
,	O
requiring	O
specific	O
signals	O
for	O
its	O
initiation	O
.	O
Analysis	O
of	O
the	O
ligand	B
-	I
binding	I
domain	I
of	O
human	B
retinoic	I
acid	I
receptor	I
alpha	I
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O
Three	O
subtypes	O
of	O
retinoic	B
acid	I
receptors	I
(	O
RAR	B
)	O
,	O
termed	O
RAR	B
alpha	I
,	O
RAR	B
beta	I
,	O
and	O
RAR	B
gamma	I
,	O
have	O
been	O
described	O
.	O
They	O
are	O
composed	O
of	O
different	O
structural	B
domains	I
,	O
including	O
distinct	O
domains	O
for	O
DNA	O
and	O
ligand	O
binding	O
.	O
RARs	B
specifically	O
bind	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
9-cis	O
-	O
RA	O
,	O
and	O
retinoid	O
analogs	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
functional	O
role	O
of	O
cysteine	O
and	O
arginine	O
residues	O
in	O
the	O
ligand	B
-	I
binding	I
domain	I
of	O
hRAR	B
alpha	I
(	O
hRAR	B
alpha	I
-	I
LBD	I
,	O
amino	B
acids	I
154	I
to	I
462	I
)	O
.	O
All	O
conserved	O
cysteine	O
and	O
arginine	O
residues	O
in	O
this	O
domain	O
were	O
mutated	O
by	O
site	O
-	O
directed	O
mutagenesis	O
,	O
and	O
the	O
mutant	B
proteins	I
were	O
characterized	O
by	O
blocking	O
reactions	O
,	O
ligand	O
-	O
binding	O
experiments	O
,	O
transactivation	O
assays	O
,	O
and	O
protease	B
mapping	O
.	O
Changes	O
of	O
any	O
cysteine	O
residue	O
of	O
the	O
hRAR	B
alpha	I
-	I
LBD	I
had	O
no	O
significant	O
influence	O
on	O
the	O
binding	O
of	O
all	O
-	O
trans	O
RA	O
or	O
9-cis	O
RA	O
.	O
Interestingly	O
,	O
residue	O
C-235	O
is	O
specifically	O
important	O
in	O
antagonist	O
binding	O
.	O
With	O
respect	O
to	O
arginine	O
residues	O
,	O
only	O
the	O
two	O
single	O
mutations	O
of	O
R-276	O
and	O
R-394	O
to	O
alanine	O
showed	O
a	O
dramatic	O
decrease	O
of	O
agonist	O
and	O
antagonist	O
binding	O
whereas	O
the	O
R272A	O
mutation	O
showed	O
only	O
a	O
slight	O
effect	O
.	O
For	O
all	O
other	O
arginine	O
mutations	O
,	O
no	O
differences	O
in	O
affinity	O
were	O
detectable	O
.	O
The	O
two	O
mutations	O
R217A	O
and	O
R294A	O
caused	O
an	O
increased	O
binding	O
efficiency	O
for	O
antagonists	O
but	O
no	O
change	O
in	O
agonist	O
binding	O
.	O
From	O
these	O
results	O
,	O
we	O
can	O
conclude	O
that	O
electrostatic	O
interactions	O
of	O
retinoids	O
with	O
the	O
RAR	B
alpha	I
-	I
LBD	I
play	O
a	O
significant	O
role	O
in	O
ligand	O
binding	O
.	O
In	O
addition	O
,	O
antagonists	O
show	O
distinctly	O
different	O
requirements	O
for	O
efficient	O
binding	O
,	O
which	O
may	O
contribute	O
to	O
their	O
interference	O
in	O
the	O
ligand	O
-	O
inducible	O
transactivation	O
function	O
of	O
RAR	B
alpha	I
.	O
Cloning	O
and	O
characterization	O
of	O
the	O
beta	B
subunit	I
of	O
human	B
proximal	I
sequence	I
element	I
-	I
binding	I
transcription	I
factor	I
and	O
its	O
involvement	O
in	O
transcription	O
of	O
small	O
nuclear	O
RNA	O
genes	O
by	O
RNA	B
polymerases	I
II	I
and	I
III	I
.	O
The	O
proximal	B
sequence	I
element	I
(	I
PSE	I
)	I
-binding	I
transcription	I
factor	I
(	O
PTF	B
)	O
,	O
which	O
binds	O
the	O
PSE	O
of	O
both	O
RNA	O
polymerase	O
II	O
-and	O
RNA	O
polymerase	O
III	O
-	O
transcribed	O
mammalian	O
small	O
nuclear	O
RNA	O
(	O
snRNA	O
)	O
genes	O
,	O
is	O
essential	O
for	O
their	O
transcription	O
.	O
We	O
previously	O
reported	O
the	O
purification	O
of	O
human	B
PTF	I
,	O
a	O
complex	O
of	O
four	B
subunits	I
,	O
and	O
the	O
molecular	O
cloning	O
and	O
characterization	O
of	O
PTF	B
gamma	I
and	I
delta	I
subunits	I
.	O
Here	O
we	O
describe	O
the	O
isolation	O
and	O
expression	O
of	O
a	O
cDNA	O
encoding	O
PTF	B
beta	I
,	O
as	O
well	O
as	O
functional	O
studies	O
using	O
anti	B
-	I
PTF	I
beta	I
antibodies	I
.	O
Native	O
PTF	B
beta	I
,	O
in	O
either	O
protein	O
fractions	O
or	O
a	O
PTF	B
-	I
Oct-1-DNA	I
complex	I
,	O
can	O
be	O
recognized	O
by	O
polyclonal	B
antibodies	I
raised	O
against	O
recombinant	B
PTF	I
beta	I
.	O
Immunodepletion	O
studies	O
show	O
that	O
PTF	B
beta	I
is	O
required	O
for	O
transcription	O
of	O
both	O
classes	O
of	O
snRNA	O
genes	O
in	O
vitro	O
.	O
In	O
addition	O
,	O
immunoprecipitation	O
analyses	O
demonstrate	O
that	O
substantial	O
and	O
similar	O
molar	O
amounts	O
of	O
TATA	B
-	I
binding	I
protein	I
(	O
TBP	B
)	O
and	O
TFIIIB90	B
can	O
weakly	O
associate	O
with	O
PTF	B
at	O
low	O
salt	O
conditions	O
,	O
but	O
this	O
association	O
is	O
dramatically	O
reduced	O
at	O
high	O
salt	O
concentrations	O
.	O
Along	O
with	O
our	O
previous	O
demonstration	O
of	O
both	O
physical	O
interactions	O
between	O
PTF	B
gamma	I
/	I
PTF	I
delta	I
and	O
TBP	B
and	O
the	O
involvement	O
of	O
TFIIIB90	B
in	O
the	O
transcription	O
of	O
class	O
III	O
snRNA	O
genes	O
,	O
these	O
results	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
a	O
TBP	B
-	I
containing	I
complex	I
related	O
to	O
TFIIIB	B
is	O
required	O
for	O
the	O
transcription	O
of	O
class	O
III	O
snRNA	O
genes	O
,	O
and	O
acts	O
through	O
weak	O
interaction	O
with	O
the	O
four	B
-	I
subunit	I
PTF	I
.	O
Cytomegalovirus	O
modulates	O
interleukin-6	O
gene	O
expression	O
.	O
Complications	O
after	O
lung	O
transplantation	O
include	O
the	O
development	O
of	O
rejection	O
and	O
an	O
increased	O
incidence	O
of	O
infection	O
,	O
particularly	O
with	O
cytomegalovirus	O
(	O
CMV	O
)	O
.	O
Several	O
recent	O
studies	O
have	O
suggested	O
that	O
interleukin	O
(	O
IL	O
)	O
-6	O
may	O
be	O
used	O
to	O
detect	O
both	O
infection	O
and	O
rejection	O
after	O
lung	O
transplantation	O
.	O
In	O
addition	O
,	O
IL-6	B
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
bronchiolitis	O
obliterans	O
after	O
transplantation	O
.	O
Because	O
CMV	O
is	O
also	O
associated	O
with	O
the	O
development	O
of	O
bronchiolitis	O
obliterans	O
after	O
transplantation	O
,	O
we	O
determined	O
whether	O
CMV	O
induces	O
IL-6	B
gene	O
expression	O
.	O
We	O
demonstrated	O
that	O
CMV	O
infection	O
increased	O
both	O
IL-6	B
protein	I
and	O
mRNA	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
We	O
also	O
demonstrated	O
that	O
the	O
CMV	B
immediate	I
early	I
1	I
gene	I
product	I
increased	O
expression	O
of	O
the	O
IL-6	O
promoter	O
.	O
This	O
effect	O
of	O
the	O
CMV	B
immediate	I
early	I
1	I
gene	I
product	I
was	O
dependent	O
upon	O
the	O
presence	O
of	O
specific	O
transcription	O
factor	O
binding	O
sites	O
in	O
the	O
IL-6	O
promoter	O
.	O
These	O
studies	O
demonstrate	O
that	O
CMV	O
may	O
be	O
an	O
important	O
cofactor	O
in	O
the	O
development	O
of	O
rejection	O
and	O
infection	O
after	O
transplantation	O
through	O
its	O
effects	O
on	O
IL-6	B
.	O
Suppression	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
by	O
CD8	O
+	O
T	O
cells	O
is	O
dependent	O
on	O
the	O
NFAT-1	O
element	O
.	O
CD8	O
+	O
T	O
lymphocytes	O
of	O
HIV-1	O
infected	O
individuals	O
produce	O
a	O
soluble	B
factor	I
that	O
efficiently	O
suppresses	O
HIV-1	O
replication	O
at	O
the	O
transcriptional	O
level	O
.	O
We	O
show	O
here	O
that	O
the	O
response	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
to	O
mitogenic	O
or	O
Tat	B
-mediated	O
activation	O
is	O
sensitive	O
to	O
the	O
suppressive	O
action	O
of	O
a	O
Herpesvirus	O
saimiri	O
(	O
HVS	O
)	O
-transformed	O
CD8	O
+	O
T	O
cell	O
clone	O
from	O
an	O
HIV	O
-	O
infected	O
individual	O
and	O
supernatants	O
from	O
CD8	O
+	O
T	O
cells	O
of	O
HIV-1-infected	O
asymptomatic	O
subjects	O
(	O
CD4	B
+	I
>	O
350	O
/	O
microliters	O
)	O
.	O
Mutagenesis	O
of	O
NF	O
kappa	O
B	O
or	O
Sp-1	O
elements	O
within	O
the	O
LTR	O
resulted	O
in	O
no	O
change	O
in	O
the	O
ability	O
of	O
CD8	O
+	O
T	O
cell	O
supernatants	O
to	O
inhibit	O
Tat-	O
or	O
mitogen	O
-	O
mediated	O
LTR	O
transcription	O
.	O
However	O
,	O
the	O
response	O
to	O
HIV-1	B
Tat	I
by	O
a	O
LTR	O
in	O
which	O
the	O
interleukin	O
(	O
IL	O
)	O
-2	O
homology	O
NFAT-1	O
region	O
was	O
mutated	O
resulted	O
in	O
almost	O
complete	O
elimination	O
of	O
suppression	O
by	O
CD8	O
+	O
T	O
cells	O
.	O
This	O
was	O
not	O
observed	O
when	O
the	O
NFAT-1	O
mutant	O
LTR	O
was	O
activated	O
by	O
mitogen	B
.	O
We	O
have	O
previously	O
shown	O
that	O
gene	O
expression	O
directed	O
by	O
the	O
HIV-1	O
NF	O
kappa	O
B	O
elements	O
is	O
inhibited	O
by	O
CD8	B
+	O
cell	O
-	O
derived	O
supernatants	O
(	O
Copeland	O
et	O
al.	O
,	O
AIDS	O
Res	O
Hum	O
Retroviruses	O
,	O
1995	O
;	O
11	O
:	O
1321	O
-	O
1326	O
)	O
.	O
Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
mitogenic	O
activation	O
,	O
mediated	O
primarily	O
through	O
the	O
NF	O
kappa	O
B	O
enhancer	O
,	O
is	O
susceptible	O
to	O
CD8	B
-mediated	O
inhibition	O
,	O
however	O
,	O
inhibition	O
of	O
Tat	B
-mediated	O
activation	O
may	O
rely	O
upon	O
a	O
different	O
pathway	O
that	O
is	O
NFAT-1	B
dependent	O
.	O
Interstitial	O
deletion	O
constitutes	O
the	O
major	O
mechanism	O
for	O
loss	O
of	O
heterozygosity	O
on	O
chromosome	O
20q	O
in	O
polycythemia	O
vera	O
.	O
An	O
acquired	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
20	O
is	O
a	O
recurrent	O
abnormality	O
in	O
myeloproliferative	O
disorders	O
,	O
particularly	O
polycythemia	O
vera	O
and	O
myelodysplastic	O
syndromes	O
.	O
The	O
association	O
of	O
20q	O
deletions	O
with	O
myeloid	O
`	O
`	O
stem	O
cell	O
''	O
disorders	O
suggests	O
that	O
the	O
deletions	O
mark	O
the	O
site	O
of	O
one	O
or	O
more	O
genes	O
,	O
loss	O
or	O
inactivation	O
of	O
which	O
plays	O
a	O
role	O
in	O
the	O
regulation	O
of	O
normal	O
hematopoietic	O
progenitors	O
.	O
We	O
have	O
recently	O
performed	O
a	O
detailed	O
molecular	O
analysis	O
of	O
20q	O
deletions	O
in	O
peripheral	O
blood	O
(	O
PB	O
)	O
granulocytes	O
and	O
defined	O
a	O
commonly	O
deleted	O
region	O
of	O
16	O
to	O
21	O
centimorgan	O
(	O
cM	O
)	O
.	O
To	O
further	O
reduce	O
the	O
size	O
of	O
the	O
common	O
deleted	O
region	O
we	O
have	O
searched	O
for	O
small	O
deletions	O
or	O
mitotic	O
recombination	O
events	O
,	O
neither	O
of	O
which	O
would	O
be	O
detected	O
by	O
conventional	O
cytogenetics	O
.	O
We	O
have	O
studied	O
48	O
patients	O
with	O
polycythemia	O
vera	O
and	O
four	O
patients	O
with	O
idiopathic	O
myelofibrosis	O
.	O
In	O
each	O
case	O
,	O
cytogenetic	O
analysis	O
had	O
either	O
failed	O
or	O
had	O
shown	O
no	O
abnormalities	O
of	O
chromosome	O
20	O
.	O
Seventeen	O
microsatellite	O
markers	O
that	O
span	O
the	O
common	O
deleted	O
region	O
were	O
used	O
to	O
search	O
for	O
loss	O
of	O
heterozygosity	O
in	O
granulocyte	O
DNA	O
.	O
No	O
instance	O
of	O
microsatellite	O
instability	O
was	O
observed	O
in	O
a	O
total	O
of	O
880	O
comparisons	O
of	O
granulocyte	O
and	O
T	O
-	O
cell	O
DNA	O
.	O
Granulocyte	O
DNA	O
from	O
four	O
patients	O
exhibited	O
allele	O
loss	O
on	O
20q	O
.	O
In	O
each	O
case	O
the	O
allele	O
loss	O
was	O
caused	O
by	O
an	O
interstitial	O
deletion	O
because	O
heterozygosity	O
at	O
distal	O
markers	O
was	O
retained	O
and	O
because	O
quantitative	O
Southern	O
blotting	O
demonstrated	O
hemizygosity	O
.	O
Loss	O
of	O
heterozygosity	O
in	O
PB	O
granulocytes	O
would	O
be	O
masked	O
by	O
the	O
presence	O
of	O
significant	O
numbers	O
of	O
normal	O
granulocytes	O
not	O
derived	O
from	O
the	O
malignant	O
clone	O
.	O
Therefore	O
,	O
the	O
human	B
androgen	I
receptor	I
assay	O
(	O
HUMARA	O
)	O
was	O
used	O
to	O
determine	O
granulocyte	O
clonality	O
.	O
In	O
21	O
of	O
27	O
informative	O
female	O
patients	O
the	O
majority	O
of	O
the	O
granulocytes	O
were	O
clonally	O
derived	O
.	O
In	O
5	O
patients	O
the	O
granulocytes	O
appeared	O
polyclonal	O
and	O
in	O
1	O
patient	O
unilateral	O
X	O
inactivation	O
was	O
observed	O
in	O
both	O
granulocytes	O
and	O
T	O
cells	O
.	O
These	O
results	O
show	O
that	O
,	O
in	O
the	O
vast	O
majority	O
of	O
patients	O
presented	O
here	O
,	O
the	O
failure	O
to	O
detect	O
loss	O
of	O
heterozygosity	O
can	O
not	O
be	O
attributed	O
to	O
the	O
presence	O
of	O
normal	O
polyclonal	O
granulocytes	O
.	O
Our	O
results	O
therefore	O
show	O
that	O
allele	O
loss	O
on	O
chromosome	O
20q	O
in	O
polycythemia	O
vera	O
does	O
not	O
commonly	O
involve	O
mitotic	O
recombination	O
or	O
chromosome	O
loss	O
and	O
that	O
microsatellite	O
instability	O
is	O
a	O
rare	O
event	O
in	O
this	O
disorder	O
.	O
Selenium	O
-	O
mediated	O
inhibition	O
of	O
transcription	B
factor	I
NF	I
-	I
kappa	I
B	I
and	O
HIV-1	O
LTR	O
promoter	O
activity	O
.	O
The	O
eukaryotic	B
transcription	I
factor	I
NF	I
-	I
kappa	I
B	I
is	O
involved	O
in	O
the	O
inducible	O
expression	O
of	O
various	O
inflammatory	O
genes	O
as	O
well	O
as	O
in	O
HIV-1	O
replication	O
.	O
Activation	O
of	O
NF	B
-	I
kappa	I
B	I
is	O
induced	O
by	O
prooxidants	O
and	O
several	O
stimuli	O
eliciting	O
oxidative	O
stress	O
,	O
such	O
as	O
cytokines	B
,	O
lipopolysaccharide	O
,	O
UV	O
irradiation	O
and	O
other	O
mediators	O
.	O
Various	O
antioxidants	O
inhibit	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
response	O
to	O
these	O
stimuli	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
selenium	O
,	O
an	O
integral	O
component	O
of	O
glutathione	B
peroxidase	I
(	O
GPX	B
)	O
,	O
on	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
In	O
selenium	O
-	O
deprived	O
Jurkat	O
and	O
ESb	O
-	O
L	O
T	O
lymphocytes	O
,	O
supplementation	O
of	O
selenium	O
led	O
to	O
a	O
substantial	O
increase	O
of	O
GPX	B
activity	O
.	O
Analysis	O
of	O
DNA	O
binding	O
revealed	O
that	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
response	O
to	O
TNF	B
was	O
significantly	O
inhibited	O
under	O
these	O
conditions	O
.	O
Likewise	O
,	O
reporter	O
gene	O
assays	O
using	O
luciferase	O
constructs	O
driven	O
by	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
showed	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
controlled	O
gene	O
expression	O
by	O
selenium	O
.	O
The	O
effects	O
of	O
selenium	O
were	O
specific	O
for	O
NF	B
-	I
kappa	I
B	I
,	O
since	O
the	O
activity	O
of	O
the	O
transcription	O
factor	O
AP-1	B
was	O
not	O
suppressed	O
.	O
These	O
data	O
suggest	O
that	O
selenium	O
supplementation	O
may	O
be	O
used	O
to	O
modulate	O
the	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
target	O
genes	O
and	O
HIV-1	O
.	O
Transcriptional	O
and	O
posttranscriptional	O
regulation	O
of	O
erythroid	O
gene	O
expression	O
in	O
anthracycline	O
-	O
induced	O
differentiation	O
of	O
human	O
erythroleukemic	O
cells	O
.	O
Aclacinomycin	O
(	O
ACLA	O
)	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
were	O
used	O
at	O
subtoxic	O
concentrations	O
to	O
induce	O
erythroid	O
differentiation	O
in	O
the	O
human	O
leukemic	O
cell	O
line	O
K562	O
.	O
Cell	O
hemoglobinization	O
was	O
accompanied	O
by	O
the	O
increased	O
expression	O
of	O
genes	O
encoding	O
gamma	B
-	I
globin	I
and	I
porphobilinogen	I
deaminase	I
(	O
PBGD	B
)	O
,	O
an	O
enzyme	O
of	O
heme	O
synthesis	O
.	O
By	O
using	O
run	O
-	O
on	O
assays	O
,	O
ACLA	O
was	O
shown	O
to	O
induce	O
an	O
enhancement	O
of	O
the	O
transcription	O
of	O
erythroid	O
genes	O
,	O
including	O
gamma	B
-	I
globin	I
,	O
PBGD	B
,	O
erythropoietin	B
receptor	I
,	O
and	O
GATA-1	B
transcription	B
factor	I
.	O
In	O
contrast	O
,	O
in	O
DOX	O
-	O
treated	O
cells	O
,	O
the	O
transcription	O
rate	O
of	O
these	O
genes	O
was	O
unchanged	O
in	O
comparison	O
with	O
control	O
cells	O
.	O
In	O
addition	O
,	O
inhibition	O
of	O
mRNA	O
synthesis	O
with	O
actinomycin	O
D	O
indicated	O
that	O
DOX	O
induced	O
an	O
increased	O
stability	O
of	O
PBGD	O
and	O
GATA-1	O
mRNAs	O
,	O
whereas	O
ACLA	O
did	O
not	O
affect	O
the	O
half	O
-	O
lives	O
of	O
these	O
mRNAs	O
.	O
Because	O
the	O
increase	O
in	O
erythroid	O
mRNA	O
steady	O
-	O
state	O
level	O
in	O
anthracycline	O
-	O
treated	O
cells	O
was	O
inhibited	O
by	O
cycloheximide	O
,	O
this	O
suggests	O
that	O
transcriptional	O
activation	O
in	O
ACLA	O
-	O
treated	O
cells	O
and	O
mRNA	O
stabilization	O
in	O
DOX	O
-	O
treated	O
cells	O
were	O
dependent	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O
Finally	O
,	O
GATA-1	B
protein	O
level	O
was	O
shown	O
to	O
be	O
increased	O
in	O
ACLA	O
-	O
treated	O
but	O
not	O
in	O
DOX	O
-	O
treated	O
cells	O
.	O
These	O
two	O
anthracyclines	O
,	O
although	O
closely	O
related	O
in	O
their	O
structures	O
,	O
appeared	O
to	O
act	O
as	O
differentiation	O
inducers	O
by	O
distinct	O
mechanisms	O
.	O
Indeed	O
,	O
erythroid	O
gene	O
expression	O
was	O
demonstrated	O
to	O
be	O
regulated	O
transcriptionally	O
by	O
ACLA	O
and	O
mainly	O
posttranscriptionally	O
by	O
DOX	O
.	O
Uneven	O
X	O
inactivation	O
in	O
a	O
female	O
monozygotic	O
twin	O
pair	O
with	O
Fabry	O
disease	O
and	O
discordant	O
expression	O
of	O
a	O
novel	O
mutation	O
in	O
the	O
alpha	O
-	O
galactosidase	O
A	O
gene	O
.	O
We	O
describe	O
two	O
female	O
monozygotic	O
(	O
MZ	O
)	O
twins	O
heterozygous	O
for	O
Fabry	O
disease	O
,	O
an	O
X	O
linked	O
disorder	O
resulting	O
from	O
the	O
deficient	O
activity	O
of	O
alpha	B
-	I
galactosidase	I
A	I
.	O
While	O
one	O
of	O
the	O
twins	O
was	O
clinically	O
affected	O
,	O
the	O
other	O
was	O
asymptomatic	O
.	O
Enzymatic	O
assay	O
of	O
alpha	B
-	I
galactosidase	I
in	O
blood	O
leucocytes	O
,	O
skin	O
fibroblasts	O
,	O
Epstein	O
-	O
Barr	O
virus	O
transformed	O
lymphoid	O
cell	O
lines	O
,	O
and	O
hair	O
follicles	O
of	O
the	O
twins	O
and	O
their	O
parents	O
confirmed	O
the	O
heterozygous	O
status	O
of	O
the	O
twins	O
and	O
indicated	O
that	O
Fabry	O
disease	O
had	O
occurred	O
as	O
a	O
result	O
of	O
a	O
de	O
novo	O
mutation	O
.	O
The	O
son	O
of	O
the	O
unaffected	O
twin	O
sister	O
was	O
shown	O
to	O
be	O
hemizygous	O
.	O
Molecular	O
analysis	O
of	O
the	O
alpha	O
-	O
galactosidase	O
A	O
gene	O
permitted	O
the	O
identification	O
of	O
an	O
as	O
yet	O
undescribed	O
point	O
mutation	O
at	O
position	O
10182	O
of	O
exon	O
5	O
which	O
causes	O
an	O
Asp	O
to	O
Asn	O
substitution	O
at	O
codon	O
231	O
.	O
Single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
again	O
showed	O
the	O
heterozygous	O
status	O
of	O
the	O
twins	O
and	O
a	O
normal	O
pattern	O
in	O
their	O
parents	O
.	O
The	O
basis	O
for	O
the	O
discordant	O
expression	O
of	O
this	O
d	O
novo	O
mutation	O
in	O
the	O
twins	O
was	O
investigated	O
by	O
studying	O
their	O
X	O
inactivation	O
status	O
.	O
Analysis	O
of	O
the	O
inactive	O
X	O
specific	O
methylation	O
at	O
the	O
androgen	O
receptor	O
gene	O
showed	O
unbalanced	O
inactivation	O
in	O
the	O
twins	O
'	O
fibroblasts	O
and	O
in	O
opposite	O
directions	O
.	O
While	O
the	O
maternally	O
derived	O
X	O
chromosome	O
was	O
preferentially	O
active	O
in	O
the	O
asymptomatic	O
twin	O
,	O
the	O
paternal	O
X	O
chromosome	O
was	O
active	O
in	O
the	O
other	O
,	O
affected	O
twin	O
and	O
was	O
found	O
in	O
her	O
hemizygotic	O
nephew	O
.	O
These	O
data	O
suggest	O
that	O
the	O
paternal	O
X	O
chromosome	O
carries	O
the	O
de	O
novo	O
alpha	B
-	I
galactosidase	I
A	I
mutation	O
and	O
that	O
uneven	O
X	O
inactivation	O
is	O
the	O
underlying	O
mechanism	O
for	O
disease	O
expression	O
in	O
this	O
novel	O
female	O
MZ	O
twin	O
pair	O
.	O
This	O
is	O
the	O
first	O
documented	O
case	O
of	O
female	O
twins	O
discordant	O
for	O
Fabry	O
disease	O
.	O
Signaling	O
by	O
IL-2	B
and	O
related	O
cytokines	B
:	O
JAKs	B
,	O
STATs	B
,	O
and	O
relationship	O
to	O
immunodeficiency	O
.	O
Cytokines	B
that	O
bind	O
to	O
the	O
interleukin-2	B
(	I
IL-2	I
)	I
receptor	I
common	I
gamma	I
chain	I
(	O
gamma	B
c	I
)	O
,	O
including	O
IL-2	B
,	O
IL-4	B
,	O
IL-7	B
,	O
IL-9	B
,	O
and	O
IL-15	B
,	O
are	O
important	O
for	O
the	O
growth	O
and	O
differentiation	O
of	O
T	O
and	O
B	O
lymphocytes	O
,	O
natural	O
killer	O
cells	O
,	O
macrophages	O
,	O
and	O
monoctyes	O
.	O
These	O
cytokines	B
have	O
overlapping	O
biological	O
effects	O
that	O
in	O
part	O
result	O
from	O
the	O
use	O
of	O
the	O
shared	B
receptor	I
subunit	I
gamma	I
c	I
.	O
Recently	O
it	O
has	O
become	O
clear	O
that	O
these	O
cytokines	B
activate	O
a	O
number	O
of	O
important	O
intracellular	B
signaling	I
molecules	I
,	O
including	O
the	O
Janus	B
kinases	I
JAK1	B
and	O
JAK3	B
and	O
members	O
of	O
the	O
transcription	B
factor	I
family	I
of	O
signal	B
transducers	I
and	O
activators	B
of	I
transcription	I
(	O
STATs	B
)	O
.	O
The	O
discovery	O
of	O
these	O
signaling	O
pathways	O
has	O
led	O
to	O
important	O
new	O
insights	O
into	O
their	O
role	O
in	O
lymphocyte	O
maturation	O
,	O
as	O
it	O
has	O
emerged	O
that	O
mutations	O
in	O
the	O
genes	O
encoding	O
both	O
gamma	B
c	I
and	O
JAK3	B
result	O
in	O
similar	O
forms	O
of	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
.	O
In	O
this	O
review	O
we	O
examine	O
the	O
structure	O
and	O
function	O
of	O
cytokine	B
receptors	I
and	O
the	O
signaling	O
pathways	O
involved	O
in	O
their	O
regulation	O
of	O
gene	O
expression	O
.	O
Furthermore	O
,	O
we	O
discuss	O
recent	O
advances	O
that	O
have	O
led	O
to	O
a	O
better	O
understanding	O
of	O
how	O
cytokines	B
elicit	O
intracellular	O
responses	O
,	O
as	O
well	O
as	O
their	O
role	O
in	O
normal	O
lymphoid	O
development	O
.	O
Eosinophil	O
priming	O
by	O
cytokines	B
:	O
from	O
cellular	O
signal	O
to	O
in	O
vivo	O
modulation	O
.	O
Eosinophils	O
play	O
an	O
important	O
role	O
in	O
the	O
effector	O
phase	O
of	O
allergic	O
inflammation	O
.	O
This	O
review	O
will	O
focus	O
on	O
the	O
conversion	O
of	O
the	O
unprimed	O
eosinophil	O
phenotype	O
in	O
the	O
peripheral	O
blood	O
of	O
normal	O
individuals	O
to	O
the	O
primed	O
phenotype	O
found	O
in	O
the	O
peripheral	O
blood	O
and	O
tissues	O
of	O
allergic	O
patients	O
,	O
a	O
phenomenon	O
called	O
priming	O
.	O
Recent	O
data	O
on	O
the	O
signals	O
initiated	O
after	O
cytokine	B
receptor	I
activation	O
on	O
eosinophils	O
will	O
be	O
reviewed	O
.	O
Molecular	O
mechanisms	O
of	O
steroid	O
action	O
:	O
a	O
novel	O
type	O
of	O
cross	O
-	O
talk	O
between	O
glucocorticoids	O
and	O
NF	B
-	I
kappa	I
B	I
transcription	B
factors	I
.	O
Despite	O
the	O
widespread	O
use	O
of	O
glucocorticoids	O
in	O
the	O
treatment	O
of	O
diseases	O
characterized	O
by	O
inflammation	O
,	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
hormones	O
exert	O
this	O
beneficial	O
effect	O
in	O
patients	O
with	O
asthma	O
remains	O
to	O
be	O
elucidated	O
.	O
Therefore	O
,	O
we	O
have	O
studied	O
the	O
transcriptional	O
regulation	O
of	O
intercellular	B
adhesion	I
molecule-1	I
(	O
ICAM-1	B
)	O
as	O
adhesion	B
molecules	I
are	O
likely	O
to	O
play	O
a	O
causal	O
role	O
in	O
inflammation	O
in	O
promoting	O
cell	O
-	O
cell	O
and	O
cell	O
-	O
matrix	O
interactions	O
.	O
We	O
observed	O
that	O
in	O
a	O
monocytic	O
(	O
U937	O
)	O
and	O
a	O
bronchial	O
epithelial	O
(	O
H292	O
)	O
cell	O
-	O
line	O
dexamethasone	O
strongly	O
suppressed	O
basal	O
and	O
induced	O
ICAM-1	B
expression	O
.	O
Subsequent	O
analysis	O
of	O
the	O
human	O
ICAM-1	O
promoter	O
has	O
revealed	O
that	O
both	O
12-O	O
-	O
tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
and	O
tumour	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
upregulate	O
ICAM-1	B
expression	O
through	O
the	O
presence	O
of	O
a	O
nuclear	O
factor	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
target	O
sequence	O
(	O
TGGAAATTCC	O
)	O
.	O
No	O
glucocorticoid	O
recognition	O
sequences	O
are	O
present	O
in	O
this	O
promoter	O
region	O
and	O
dexamethasone	O
is	O
still	O
able	O
to	O
repress	O
transcription	O
when	O
the	O
multimerized	O
NF	O
-	O
kappa	O
B	O
sequence	O
is	O
transactivated	O
by	O
TNF	B
-	I
alpha	I
upon	O
transfection	O
in	O
293	O
cells	O
.	O
We	O
propose	O
that	O
direct	O
interaction	O
between	O
the	O
glucocorticoid	B
receptor	I
and	O
nuclear	B
factor	I
-	I
kappa	I
B	I
factors	I
is	O
at	O
least	O
a	O
partial	O
explanation	O
for	O
the	O
effects	O
of	O
this	O
hormone	O
in	O
inflammatory	O
diseases	O
.	O
The	O
suppression	O
of	O
T	O
cell	O
function	O
and	O
NF	B
(	I
kappa	I
)	I
B	I
expression	O
by	O
serine	O
protease	O
inhibitors	O
is	O
blocked	O
by	O
N	O
-	O
acetylcysteine	O
.	O
Direct	O
evidence	O
that	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
)	O
enhances	O
the	O
immune	O
response	O
of	O
peripheral	O
blood	O
T	O
cells	O
at	O
the	O
level	O
of	O
NF	B
(	I
kappa	I
)	I
B	I
is	O
presented	O
.	O
In	O
addition	O
,	O
NAC	O
blocks	O
the	O
suppression	O
of	O
T	O
cell	O
mitogenesis	O
and	O
cytokine	B
production	O
by	O
protease	O
inhibitors	O
such	O
as	O
N	O
-	O
tosylphenylalanine	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
.	O
The	O
proliferative	O
responses	O
of	O
purified	O
CD4	O
+	O
or	O
CD8	O
+	O
T	O
cells	O
are	O
suppressed	O
more	O
strongly	O
by	O
TPCK	O
when	O
anti	B
-	I
CD28	I
rather	O
than	O
the	O
phorbol	O
ester	O
PMA	O
is	O
used	O
as	O
the	O
mitogenic	O
coactivator	B
.	O
Cytokine	B
(	O
IL-2	B
,	O
IL-6	B
,	O
INF	B
-	I
gamma	I
)	O
production	O
is	O
inhibited	O
95	O
-	O
100	O
%	O
by	O
concentrations	O
of	O
TPCK	O
that	O
totally	O
suppress	O
the	O
mitogenesis	O
of	O
CD4	O
+	O
or	O
CD8	O
+	O
cells	O
.	O
Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
find	O
that	O
TPCK	O
virtually	O
abolishes	O
(	O
to	O
less	O
than	O
1	O
%	O
)	O
the	O
levels	O
of	O
NF	B
(	I
kappa	I
)	I
B	I
(	O
but	O
not	O
Oct-1	B
)	O
found	O
in	O
nuclear	O
and	O
whole	O
cell	O
extracts	O
of	O
activated	O
T	O
cells	O
.	O
Strikingly	O
,	O
the	O
immunosuppressive	O
effects	O
of	O
TPCK	O
are	O
blocked	O
when	O
T	O
cells	O
are	O
pretreated	O
for	O
15	O
min	O
with	O
5	O
mM	O
NAC	O
.	O
NAC	O
not	O
only	O
blocks	O
the	O
effect	O
of	O
TPCK	O
but	O
enhances	O
mitogenesis	O
and	O
cytokine	B
production	O
(	O
>	O
2.5-fold	O
in	O
some	O
cases	O
)	O
upon	O
activation	O
of	O
unsuppressed	O
T	O
cells	O
.	O
Our	O
data	O
support	O
the	O
notion	O
that	O
NF	B
(	I
kappa	I
)	I
B	I
and	O
I	B
(	I
kappa	I
)	I
B	I
proteases	I
play	O
obligate	O
roles	O
in	O
T	O
cell	O
activation	O
and	O
mitogenesis	O
,	O
roles	O
that	O
are	O
enhanced	O
significantly	O
by	O
NAC	O
.	O
IL-12	B
-induced	O
activation	O
of	O
NK	O
and	O
T	O
cells	O
occurs	O
in	O
the	O
absence	O
of	O
immediate	O
-	O
early	O
activation	O
gene	O
expression	O
.	O
The	O
responses	O
of	O
lymphocytes	O
to	O
IL-2	B
and	O
IL-12	B
,	O
involving	O
proliferation	O
,	O
differentiation	O
,	O
and	O
cytokine	B
production	O
,	O
are	O
only	O
partially	O
overlapping	O
,	O
and	O
may	O
depend	O
on	O
induced	O
differential	O
expression	O
of	O
specific	O
sets	O
of	O
genes	B
.	O
Using	O
reverse	O
-	O
transcription	O
PCR	O
differential	O
display	O
,	O
we	O
isolated	O
an	O
mRNA	O
species	O
expressed	O
in	O
IL-2	O
-but	O
not	O
IL-12-stimulated	O
NK	O
cells	O
.	O
This	O
was	O
identified	O
as	O
the	O
mRNA	O
encoding	O
the	O
transcription	B
factor	I
egr-1	B
,	O
which	O
is	O
expressed	O
with	O
fast	O
kinetics	O
in	O
T	O
and	O
NK	O
cells	O
upon	O
IL-2	B
,	O
but	O
not	O
IL-12	B
,	O
stimulation	O
.	O
Analysis	O
of	O
the	O
accumulation	O
of	O
mRNA	B
-	I
encoding	I
members	I
of	O
the	O
AP-1	B
transcription	I
factor	I
family	I
demonstrated	O
that	O
c	O
-	O
fos	O
and	O
junB	O
are	O
also	O
expressed	O
upon	O
stimulation	O
of	O
NK	O
and	O
T	O
cells	O
with	O
IL-2	B
,	O
but	O
not	O
IL-12	B
,	O
whereas	O
expression	O
of	O
c	O
-	O
jun	O
and	O
junD	O
is	O
not	O
modified	O
by	O
either	O
cytokine	B
.	O
Accordingly	O
,	O
increased	O
AP-1	B
DNA	O
-	O
binding	O
activity	O
and	O
AP-1	B
-dependent	O
transcriptional	O
activity	O
were	O
detected	O
exclusively	O
in	O
IL-2-stimulated	O
cells	O
.	O
Analysis	O
of	O
the	O
expression	O
of	O
genes	B
reported	O
to	O
regulate	O
cytokine	B
-induced	O
proliferation	O
demonstrated	O
that	O
both	O
IL-2	B
and	O
IL-12	B
induce	O
c	O
-	O
myc	O
mRNA	O
accumulation	O
in	O
NK	O
and	O
T	O
cells	O
,	O
whereas	O
only	O
IL-2	B
induces	O
bcl-2	O
expression	O
.	O
Our	O
data	O
provide	O
the	O
first	O
demonstration	O
that	O
IL-12	B
-mediated	O
activation	O
of	O
T	O
and	O
NK	O
cells	O
does	O
not	O
involve	O
expression	O
of	O
members	O
of	O
the	O
immediate	O
-	O
early	O
activation	O
genes	O
family	O
(	O
egr-1	O
,	O
c	O
-	O
fos	O
,	O
and	O
junB	O
)	O
,	O
AP-1	B
transcriptional	O
activity	O
,	O
or	O
bcl-2	O
expression	O
.	O
This	O
indicates	O
that	O
functional	O
differences	O
observed	O
in	O
IL-2-	O
and	O
IL-12-stimulated	O
cells	O
may	O
depend	O
,	O
at	O
least	O
in	O
part	O
,	O
on	O
differential	O
gene	O
regulation	O
.	O
Induction	O
of	O
activator	B
protein	I
(	I
AP	I
)	I
-1	I
and	O
nuclear	B
factor	I
-	I
kappaB	I
by	O
CD28	B
stimulation	O
involves	O
both	O
phosphatidylinositol	B
3-kinase	I
and	O
acidic	B
sphingomyelinase	I
signals	O
.	O
A	O
major	O
obstacle	O
in	O
understanding	O
the	O
signaling	O
events	O
that	O
follow	O
CD28	B
receptor	O
ligation	O
arises	O
from	O
the	O
fact	O
that	O
CD28	B
acts	O
as	O
a	O
costimulus	O
to	O
TCR	B
engagement	O
,	O
making	O
it	O
difficult	O
to	O
assess	O
the	O
relative	O
contribution	O
of	O
CD28	B
signals	O
as	O
distinct	O
from	O
those	O
of	O
the	O
TCR	B
.	O
To	O
overcome	O
this	O
problem	O
,	O
we	O
have	O
exploited	O
the	O
observation	O
that	O
activated	O
human	O
T	O
cell	O
blasts	O
can	O
be	O
stimulated	O
via	O
the	O
CD28	B
surface	I
molecule	I
in	O
the	O
absence	O
of	O
antigenic	O
challenge	O
;	O
thus	O
,	O
we	O
have	O
been	O
able	O
to	O
observe	O
the	O
response	O
of	O
normal	O
T	O
cells	O
to	O
CD28	B
activation	O
in	O
isolation	O
.	O
Using	O
this	O
system	O
,	O
we	O
observed	O
that	O
CD28	B
stimulation	O
by	O
B7-transfected	O
CHO	O
cells	O
induced	O
a	O
proliferative	O
response	O
in	O
T	O
cells	O
that	O
was	O
not	O
accompanied	O
by	O
measurable	O
IL-2	B
production	O
.	O
However	O
,	O
subsequent	O
analysis	O
of	O
transcription	B
factor	I
generation	O
revealed	O
that	O
B7	O
stimulation	O
induced	O
both	O
activator	B
protein-1	I
(	O
AP-1	B
)	O
and	O
nuclear	B
factor	I
-	I
kappaB	I
(	I
NF	I
-	I
kappaB	I
)	I
complexes	I
,	O
but	O
not	O
NF	B
-	I
AT	I
.	O
In	O
contrast	O
,	O
engagement	O
of	O
the	O
TCR	B
by	O
class	B
II	I
MHC	I
/	I
superantigen	I
,	O
either	O
with	O
or	O
without	O
CD28	B
ligation	O
,	O
resulted	O
in	O
the	O
induction	O
of	O
NF	B
-	I
AT	I
,	O
AP-1	B
,	O
and	O
NF	B
-	I
kappaB	I
as	O
well	O
as	O
IL-2	B
production	O
.	O
Using	O
selective	O
inhibitors	O
,	O
we	O
investigated	O
the	O
signaling	O
pathways	O
involved	O
in	O
the	O
CD28	B
-mediated	O
induction	O
of	O
AP-1	B
and	O
NF	B
-	I
kappaB	I
.	O
This	O
revealed	O
that	O
NF	B
-	I
kappaB	I
generation	O
was	O
sensitive	O
to	O
chloroquine	O
,	O
an	O
inhibitor	O
of	O
acidic	B
sphingomyelinase	I
,	O
but	O
not	O
to	O
the	O
phosphatidylinositol	B
3-kinase	I
inhibitor	O
,	O
wortmannin	O
.	O
In	O
contrast	O
,	O
AP-1	B
generation	O
was	O
inhibited	O
by	O
wortmannin	O
and	O
was	O
also	O
variably	O
sensitive	O
to	O
chloroquine	O
.	O
These	O
data	O
suggest	O
that	O
in	O
activated	O
normal	O
T	O
cells	O
,	O
CD28	B
-derived	O
signals	O
can	O
stimulate	O
proliferation	O
at	O
least	O
in	O
part	O
via	O
NF	O
-	O
kappaB	O
and	O
AP-1	O
generation	O
,	O
and	O
that	O
this	O
response	O
uses	O
both	O
acidic	B
sphingomyelinase	I
and	O
phosphatidylinositol	B
3-kinase	I
-linked	O
pathways	O
.	O
A	O
critical	O
role	O
of	O
Sp1-	B
and	I
Ets	I
-	I
related	I
transcription	I
factors	I
in	O
maintaining	O
CTL	O
-	O
specific	O
expression	O
of	O
the	O
mouse	O
perforin	O
gene	O
.	O
This	O
study	O
was	O
designed	O
to	O
determine	O
the	O
potential	O
cis	O
-	O
elements	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
the	O
mouse	O
perforin	O
gene	O
.	O
DNase	O
I	O
hypersensitive	O
site	O
(	O
DHS	O
)	O
mapping	O
revealed	O
that	O
the	O
perforin	O
locus	O
contained	O
six	O
DHS	O
within	O
7.0	O
kb	O
of	O
the	O
5	O
'	O
upstream	O
sequence	O
(	O
-7.0	O
kb	O
)	O
and	O
two	O
DHS	O
in	O
intron	O
2	O
.	O
The	O
six	O
5	O
'	O
upstream	O
and	O
one	O
intronic	O
DHS	O
were	O
detected	O
in	O
only	O
perforin	O
-	O
expressing	O
lymphocytes	O
.	O
Chloramphenicol	B
acetyltransferase	I
(	O
CAT	B
)	O
activities	O
directed	O
by	O
5	O
'	O
upstream	O
promoter	O
were	O
detected	O
preferentially	O
in	O
perforin	O
-	O
expressing	O
cell	O
lines	O
.	O
A	O
construct	O
termed	O
PFP5a	O
containing	O
-795	O
bp	O
exhibited	O
the	O
highest	O
CAT	B
activity	O
,	O
and	O
PFP9a20	O
containing	O
only	O
-73	O
bp	O
also	O
produced	O
significantly	O
high	O
CAT	B
activity	O
in	O
CTLL	O
-	O
R8	O
cells	O
.	O
The	O
proximal	O
region	O
in	O
PFP9a20	O
contained	O
two	O
potential	O
Sp1	O
binding	O
sites	O
(	O
GC	O
box	O
and	O
GT	O
box	O
)	O
and	O
one	O
Ets	O
binding	O
site	O
(	O
EBS	O
)	O
.	O
Electrophoretic	O
mobility	O
shift	O
assay	O
showed	O
that	O
each	O
of	O
the	O
cis	O
-	O
elements	O
bound	O
specific	O
protein	B
factors	I
.	O
When	O
single	O
-	O
point	O
mutation	O
was	O
introduced	O
to	O
each	O
GC	O
box	O
,	O
EBS	O
,	O
and	O
GT	O
box	O
in	O
PFP9a20	O
,	O
at	O
least	O
3-fold	O
less	O
CAT	B
activity	O
was	O
observed	O
in	O
CTLL	O
-	O
R8	O
cells	O
.	O
To	O
confirm	O
the	O
importance	O
of	O
the	O
three	O
cis	O
-	O
acting	O
elements	O
in	O
the	O
perforin	O
gene	O
expression	O
,	O
point	O
mutation	O
was	O
introduced	O
again	O
to	O
each	O
proximal	O
GC	O
box	O
,	O
EBS	O
,	O
and	O
GT	O
box	O
of	O
PFP5a	O
.	O
The	O
point	O
mutations	O
resulted	O
in	O
a	O
2.5-	O
to	O
3-fold	O
reduction	O
of	O
CAT	B
activity	O
.	O
The	O
results	O
suggest	O
that	O
a	O
combination	O
of	O
the	O
three	O
proximal	O
cis	O
-	O
acting	O
elements	O
may	O
constitute	O
a	O
minimal	O
region	O
responsible	O
for	O
CTL	O
-	O
specific	O
expression	O
of	O
perforin	B
.	O
Stimulation	O
of	O
human	O
lymphocyte	O
proliferation	O
and	O
CD40	B
antigen	O
expression	O
by	O
phosphorothioate	O
oligonucleotides	O
complementary	O
to	O
hepatitis	O
B	O
virus	O
genome	O
.	O
We	O
have	O
studied	O
the	O
proliferation	O
and	O
CD40	B
antigen	O
expression	O
of	O
lymphocytes	O
,	O
and	O
the	O
cytotoxicity	O
to	O
monocytes	O
,	O
of	O
antisense	O
phosphorothioate	O
oligodeoxynucleotides	O
complementary	O
to	O
the	O
SP	O
II	O
promoter	O
of	O
HBV	O
mRNA	O
(	O
sequence	O
I	O
)	O
and	O
the	O
X	O
gene	O
(	O
sequence	O
II	O
)	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
.	O
The	O
oligo	O
sequence	O
I	O
stimulated	O
proliferation	O
of	O
both	O
T	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
B	O
cells	O
.	O
The	O
percentage	O
of	O
cells	O
expressing	O
CD40	B
in	O
T	O
and	O
B	O
cell	O
co	O
-	O
cultures	O
increased	O
from	O
4.2	O
%	O
to	O
13.8	O
%	O
after	O
oligo	O
stimulation	O
in	O
patients	O
,	O
while	O
it	O
increased	O
form	O
4.7	O
%	O
to	O
48.6	O
%	O
in	O
healthy	O
controls	O
.	O
The	O
sense	O
sequence	O
(	O
sequence	O
III	O
)	O
of	O
the	O
X	O
gene	O
also	O
enhanced	O
the	O
expression	O
of	O
CD40	B
antigen	I
in	O
patients	O
with	O
hepatitis	O
B	O
.	O
The	O
proportion	O
of	O
CD40	O
cells	O
(	O
26	O
%	O
)	O
in	O
a	O
resting	O
B	O
-	O
cell	O
preparation	O
from	O
hepatitis	O
B	O
patients	O
decreased	O
to	O
zero	O
after	O
a	O
5-day	O
culture	O
with	O
sequence	O
I	O
,	O
but	O
IgG	O
levels	O
in	O
the	O
culture	O
supernatant	O
increased	O
.	O
The	O
cytotoxic	O
properties	O
of	O
monocytes	O
were	O
not	O
influenced	O
by	O
the	O
oligos	O
.	O
These	O
findings	O
indicate	O
that	O
antisense	O
oligos	O
against	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
have	O
mitogenic	O
effects	O
on	O
the	O
proliferation	O
of	O
human	O
lymphocytes	O
in	O
a	O
non	O
-	O
specific	O
manner	O
and	O
may	O
activate	O
T	O
cells	O
to	O
express	O
CD40	B
antigen	I
.	O
Soluble	B
factors	I
secreted	O
by	O
activated	O
T	O
-	O
lymphocytes	O
modulate	O
the	O
transcription	O
of	O
the	O
immunosuppressive	B
cytokine	I
TGF	B
-	I
beta	I
2	I
in	O
glial	O
cells	O
.	O
Coordination	O
of	O
the	O
immune	O
response	O
to	O
injury	O
or	O
disease	O
in	O
the	O
brain	O
is	O
postulated	O
to	O
involve	O
bi	O
-	O
directional	O
discourse	O
between	O
the	O
immune	O
system	O
and	O
the	O
central	O
nervous	O
system	O
.	O
This	O
cross	O
communication	O
involves	O
soluble	O
mediators	O
,	O
including	O
various	O
growth	B
factors	I
,	O
cytokines	B
,	O
and	O
neuropeptides	O
.	O
In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
supernatant	O
from	O
activated	O
T	O
-	O
lymphocytes	O
is	O
able	O
to	O
induce	O
the	O
transcription	O
of	O
a	O
potent	O
cytokine	B
,	O
TGF	B
-	I
beta	I
2	I
in	O
glial	O
cells	O
.	O
The	O
activating	O
stimulus	O
invokes	O
signaling	O
mechanisms	O
distinct	O
from	O
known	O
kinase	O
or	O
protease	O
pathways	O
.	O
Activation	O
of	O
TGF	B
-	I
beta	I
2	I
transcription	O
correlates	O
with	O
the	O
loss	O
of	O
binding	O
activity	O
for	O
an	O
80	B
kDA	I
glial	I
labile	I
repressor	I
protein	I
,	O
GLRP	B
,	O
to	O
a	O
responsive	O
region	O
within	O
the	O
TFG	O
-	O
beta	O
2	O
promoter	O
.	O
Although	O
GLRP	B
shares	O
some	O
characteristics	O
with	O
the	O
inducible	O
transcription	B
factor	I
AP-1	B
,	O
it	O
appears	O
to	O
be	O
distinct	O
from	O
known	O
AP-1	B
family	I
members	I
.	O
These	O
data	O
along	O
with	O
previous	O
observations	O
demonstrating	O
the	O
potent	O
immunosuppressive	O
activity	O
of	O
TGF	B
-	I
beta	I
2	I
,	O
support	O
a	O
model	O
for	O
a	O
feedback	O
mechanism	O
between	O
the	O
activated	O
T	O
-	O
lymphocytes	O
and	O
astrocytes	O
via	O
TGF	B
-	I
beta	I
2	I
to	O
regulate	O
the	O
immune	O
response	O
.	O
Vitamin	O
D3-	O
and	O
retinoic	O
acid	O
-	O
induced	O
monocytic	O
differentiation	O
:	O
interactions	O
between	O
the	O
endogenous	B
vitamin	I
D3	I
receptor	I
,	O
retinoic	B
acid	I
receptors	I
,	O
and	O
retinoid	B
X	I
receptors	I
in	O
U-937	O
cells	O
.	O
Retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1	O
,	O
25	O
alpha	O
-	O
dihydroxycholecalciferol	O
(	O
VitD3	O
)	O
are	O
potent	O
regulators	O
of	O
hematopoletic	O
differentiation	O
.	O
Yet	O
,	O
little	O
is	O
known	O
as	O
to	O
how	O
the	O
RA	B
and	I
VitD3	I
receptor	I
network	I
operates	O
in	O
hematopoietic	O
cells	O
,	O
and	O
whether	O
receptor	O
interactions	O
can	O
explain	O
the	O
interplay	O
between	O
the	O
RA	O
-and	O
VitD3-signaling	O
pathways	O
during	O
differentiation	O
.	O
Therefore	O
,	O
we	O
analyzed	O
the	O
expression	O
,	O
DNA	O
binding	O
,	O
and	O
transcriptional	O
activity	O
of	O
the	O
endogenous	B
RA	I
and	I
VitD3	I
receptors	I
[	O
retinoic	B
acid	I
receptors	I
(	O
RARs	B
)	O
,	O
retinoid	B
X	I
receptors	I
(	O
RXRs	B
)	O
,	O
and	O
VitD3	B
receptor	I
(	O
VDR	B
)	O
]	O
in	O
the	O
U-937	O
cell	O
line	O
,	O
in	O
which	O
RA	O
and	O
VitD3	O
induce	O
distinct	O
monocytic	O
differentiation	O
pathways	O
.	O
VitD3	O
induction	O
resulted	O
in	O
the	O
formation	O
of	O
VDR	B
/	I
RXR	I
DNA	I
-	I
binding	I
complexes	I
on	O
both	O
VitD3	O
response	O
elements	O
and	O
RA	O
response	O
elements	O
(	O
RAREs	O
)	O
.	O
However	O
,	O
transcriptional	O
activation	O
was	O
only	O
observed	O
from	O
a	O
VitD3	O
response	O
element	O
-	O
driven	O
reporter	O
construct	O
.	O
Several	O
DNA	B
-	I
binding	I
complexes	I
were	O
detected	O
on	O
RAREs	O
in	O
undifferentiated	O
cells	O
.	O
Stimulation	O
by	O
RA	O
resulted	O
in	O
increased	O
RAR	B
beta	I
/RXR	B
DNA	O
binding	O
,	O
activated	O
RARE	O
-dependent	O
transcription	O
,	O
and	O
increased	O
expression	O
of	O
RAR	B
-	I
beta	I
.	O
Concomitant	O
stimulation	O
by	O
VitD3	O
inhibited	O
the	O
RA	O
-	O
stimulated	O
formation	O
of	O
RAR	B
beta	I
/	I
RXR	I
heterodimers	I
,	O
favoring	O
VDR	B
/RXR	B
binding	O
to	O
the	O
RARE	O
.	O
Also	O
,	O
VitD3	O
inhibited	O
the	O
expression	O
of	O
CD23	B
and	O
CD49f	B
,	O
characteristic	O
markers	O
of	O
retinoid	O
-	O
induced	O
U-937	O
cell	O
differentiation	O
.	O
In	O
contrast	O
,	O
neither	O
the	O
RA	O
-	O
stimulated	O
,	O
RARE	O
-mediated	O
transcription	O
nor	O
the	O
induced	O
RAR	B
-	I
beta	I
expression	O
was	O
suppressed	O
by	O
VitD3	O
,	O
suggesting	O
that	O
VitD3	O
selectively	O
inhibited	O
the	O
retinoid	O
-	O
induced	O
differentiation	O
program	O
but	O
not	O
the	O
RARE	O
-mediated	O
signal	O
.	O
These	O
results	O
demonstrate	O
a	O
complex	O
role	O
for	O
VitD3	O
in	O
modifying	O
the	O
retinoid	O
differentiation	O
pathway	O
and	O
may	O
have	O
implications	O
for	O
differentiation	O
-	O
inducing	O
therapy	O
of	O
hematopoietic	O
tumors	O
.	O
Calcium	O
-	O
dependent	O
immediate	O
-	O
early	O
gene	O
induction	O
in	O
lymphocytes	O
is	O
negatively	O
regulated	O
by	O
p21Ha	B
-	I
ras	I
.	O
The	O
induction	O
of	O
immediate	O
-	O
early	O
(	O
IE	O
)	O
response	O
genes	O
,	O
such	O
as	O
egr-1	O
,	O
c	O
-	O
fos	O
,	O
and	O
c	O
-	O
jun	O
,	O
occurs	O
rapidly	O
after	O
the	O
activation	O
of	O
T	O
lymphocytes	O
.	O
The	O
process	O
of	O
activation	O
involves	O
calcium	O
mobilization	O
,	O
activation	O
of	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
,	O
and	O
phosphorylation	O
of	O
tyrosine	B
kinases	I
.	O
p21	B
(	I
ras	I
)	I
,	O
a	O
guanine	B
nucleotide	I
binding	I
factor	I
,	O
mediates	O
T	O
-	O
cell	O
signal	O
transduction	O
through	O
PKC	B
-dependent	O
and	O
PKC	B
-independent	O
pathways	O
.	O
The	O
involvement	O
of	O
p21	B
(	I
ras	I
)	I
in	O
the	O
regulation	O
of	O
calcium	O
-	O
dependent	O
signals	O
has	O
been	O
suggested	O
through	O
analysis	O
of	O
its	O
role	O
in	O
the	O
activation	O
of	O
NF	B
-	I
AT	I
.	O
We	O
have	O
investigated	O
the	O
inductions	O
of	O
the	O
IE	O
genes	O
in	O
response	O
to	O
calcium	O
signals	O
in	O
Jurkat	O
cells	O
(	O
in	O
the	O
presence	O
of	O
activated	O
p21	B
(	I
ras	I
)	I
)	O
and	O
their	O
correlated	O
consequences	O
.	O
The	O
expression	O
of	O
activated	O
p21	B
(	I
ras	I
)	I
negatively	O
regulated	O
the	O
induction	O
of	O
IE	O
genes	O
by	O
calcium	O
ionophore	O
.	O
This	O
inhibition	O
of	O
calcium	O
-	O
activated	O
IE	O
gene	O
induction	O
was	O
reversed	O
by	O
treatment	O
with	O
cyclosporin	O
A	O
,	O
suggesting	O
the	O
involvement	O
of	O
calcineurin	B
in	O
this	O
regulation	O
.	O
A	O
later	O
result	O
of	O
inhibition	O
of	O
this	O
activation	O
pathway	O
by	O
p21	B
(	I
ras	I
)	I
was	O
down	O
-	O
regulation	O
of	O
the	O
activity	O
of	O
the	O
transcription	B
factor	I
AP-1	B
and	O
subsequent	O
coordinate	O
reductions	O
in	O
IL-2	O
gene	O
expression	O
and	O
protein	O
production	O
.	O
These	O
results	O
suggest	O
that	O
p2l	B
(	I
ras	I
)	I
is	O
an	O
essential	O
mediator	O
in	O
generating	O
not	O
only	O
positive	O
but	O
also	O
negative	O
modulatory	O
mechanisms	O
controlling	O
the	O
competence	O
of	O
T	O
cells	O
in	O
response	O
to	O
inductive	O
stimulations	O
.	O
CD14	B
-mediated	O
signal	O
pathway	O
of	O
Porphyromonas	O
gingivalis	O
lipopolysaccharide	O
in	O
human	O
gingival	O
fibroblasts	O
.	O
Lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
expression	O
of	O
inflammatory	B
cytokines	I
in	O
monocytes	O
/	O
macrophages	O
via	O
CD14	B
,	O
one	O
of	O
the	O
LPS	B
receptors	I
,	O
which	O
is	O
expressed	O
predominantly	O
in	O
these	O
cells	O
.	O
It	O
has	O
been	O
demonstrated	O
that	O
Porphyromonas	O
gingivalis	O
LPS	O
(	O
P	O
-	O
LPS	O
)	O
also	O
is	O
able	O
to	O
induce	O
inflammatory	B
cytokines	I
in	O
human	O
gingival	O
fibroblasts	O
.	O
Therefore	O
,	O
it	O
is	O
important	O
to	O
determine	O
whether	O
CD14	B
is	O
expressed	O
in	O
gingival	O
fibroblasts	O
and	O
to	O
define	O
the	O
P	O
-	O
LPS	O
-	O
mediated	O
signal	B
-	I
transducing	I
mechanism	O
in	O
the	O
cells	O
.	O
In	O
this	O
study	O
,	O
we	O
observed	O
unexpectedly	O
by	O
immunohistochemical	O
,	O
Western	O
blotting	O
(	O
immunoblotting	O
)	O
,	O
and	O
Northern	O
(	O
RNA	O
)	O
blotting	O
assays	O
that	O
CD14	B
is	O
expressed	O
at	O
high	O
density	O
in	O
human	O
gingival	O
fibroblasts	O
.	O
P	O
-	O
LPS	O
-	O
induced	O
expression	O
of	O
the	O
monocyte	O
chemoattractant	O
protein	O
1	O
(	O
MCP-1	O
)	O
gene	O
in	O
the	O
cells	O
was	O
inhibited	O
markedly	O
by	O
treatment	O
with	O
anti	O
-	O
human	O
CD14	B
antibody	O
and	O
was	O
completely	O
inhibited	O
by	O
herbimycin	O
A	O
,	O
a	O
potent	O
inhibitor	O
of	O
tyrosine	B
kinase	I
.	O
The	O
inhibitor	O
also	O
dramatically	O
inhibited	O
monocyte	O
chemotactic	O
activity	O
of	O
and	O
MCP-1	B
production	O
by	O
the	O
cells	O
.	O
Furthermore	O
,	O
P	O
-	O
LPS	O
-	O
induced	O
expression	O
of	O
the	O
MCP-1	O
gene	O
in	O
the	O
cells	O
also	O
was	O
blocked	O
by	O
inhibitors	O
of	O
two	O
transcription	B
factors	I
,	O
i.e.	O
,	O
curcumin	O
,	O
an	O
inhibitor	O
of	O
AP-1	B
,	O
and	O
pyrolidine	O
dithiocarbamate	O
,	O
an	O
inhibitor	O
of	O
NF	B
-	I
kappaB	I
.	O
Both	O
inhibitors	O
inhibited	O
monocyte	O
chemotactic	O
activity	O
in	O
the	O
culture	O
supernatant	O
of	O
P	O
-	O
LPS	O
-	O
treated	O
cells	O
.	O
Gel	O
shift	O
mobility	O
assay	O
showed	O
stimulation	O
of	O
the	O
AP-1	B
and	O
NF	B
-	I
kappaB	I
contents	O
in	O
P	O
-	O
LPS	O
-	O
treated	O
cells	O
.	O
This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
expression	O
of	O
CD14	B
in	O
human	O
gingival	O
fibroblasts	O
and	O
to	O
show	O
that	O
the	O
signal	O
-	O
transducing	O
pathway	O
of	O
P	O
-	O
LPS	O
in	O
the	O
cells	O
is	O
mediated	O
by	O
CD14	B
.	O
Tyrosines	O
113	O
,	O
128	O
,	O
and	O
145	O
of	O
SLP-76	B
are	O
required	O
for	O
optimal	O
augmentation	O
of	O
NFAT	O
promoter	O
activity	O
.	O
SLP-76	B
(	O
SH2	B
domain	I
leukocyte	I
protein	I
of	O
76	O
kDa	O
)	O
is	O
a	O
recently	O
identified	O
substrate	O
of	O
the	O
TCR	B
-	I
stimulated	I
protein	I
tyrosine	B
kinases	I
that	O
functions	O
in	O
the	O
signal	O
transduction	O
cascade	O
linking	O
the	O
TCR	B
with	O
IL-2	B
gene	O
expression	O
.	O
In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
engagement	O
of	O
the	O
TCR	B
results	O
in	O
tyrosine	O
phosphorylation	O
of	O
SLP-76	B
in	O
its	O
amino	B
-	I
terminal	I
acidic	I
region	I
.	O
Two	O
tyrosines	O
(	O
Y113	O
and	O
Y128	O
)	O
fall	O
within	O
an	O
identical	O
five	O
amino	O
-	O
acid	O
motif	O
and	O
are	O
shown	O
to	O
be	O
phosphorylated	O
upon	O
TCR	B
ligation	O
.	O
Although	O
mutation	O
of	O
either	O
Y113	O
and	O
Y128	O
has	O
a	O
minimal	O
effect	O
on	O
SLP-76	B
function	O
,	O
mutation	O
of	O
both	O
residues	O
decreases	O
significantly	O
the	O
ability	O
of	O
SLP-76	B
to	O
promote	O
T	O
cell	O
activation	O
.	O
A	O
third	O
tyrosine	O
within	O
the	O
amino	B
-	I
terminal	I
region	I
(	O
Y145	O
)	O
appears	O
to	O
be	O
the	O
most	O
important	O
for	O
optimal	O
SLP-76	B
function	O
,	O
as	O
altering	O
it	O
alone	O
to	O
phenylalanine	O
has	O
a	O
potent	O
impact	O
on	O
SLP-76	B
augmentation	O
of	O
NFAT	O
promoter	O
activity	O
.	O
Apoptosis	O
signaling	O
pathways	O
in	O
normal	O
T	O
cells	O
:	O
differential	O
activity	O
of	O
Bcl-2	B
and	O
IL-1beta	B
-	I
converting	I
enzyme	I
family	I
protease	O
inhibitors	O
on	O
glucocorticoid-	O
and	O
Fas	O
-	O
mediated	O
cytotoxicity	O
.	O
Fas	B
-mediated	O
apoptosis	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
the	O
immune	O
response	O
in	O
peripheral	O
T	O
cells	O
.	O
Restimulation	O
of	O
T	O
cell	O
blasts	O
up	O
-	O
regulates	O
Fas	B
and	O
Fas	B
ligand	O
expression	O
,	O
with	O
subsequent	O
interaction	O
leading	O
to	O
cell	O
death	O
.	O
Overexpression	O
of	O
Bcl-2	B
in	O
tumor	O
cells	O
blocks	O
apoptosis	O
induced	O
by	O
many	O
stimuli	O
,	O
but	O
inhibition	O
of	O
Fas	B
-mediated	O
killing	O
has	O
not	O
been	O
consistently	O
observed	O
.	O
To	O
examine	O
the	O
behavior	O
of	O
Bcl-2	B
in	O
normal	O
cells	O
,	O
T	O
cell	O
blasts	O
were	O
transiently	O
transfected	O
with	O
Bcl-2	B
and	O
related	O
gene	B
products	I
to	O
determine	O
the	O
effect	O
on	O
apoptotic	O
signaling	O
.	O
Transient	O
overexpression	O
of	O
Bcl-2	B
in	O
mouse	O
and	O
human	O
T	O
cell	O
blasts	O
did	O
not	O
block	O
Fas	B
-mediated	O
apoptosis	O
,	O
whereas	O
etoposide-	O
and	O
glucocorticoid	O
-	O
induced	O
cytotoxicity	O
was	O
potently	O
inhibited	O
.	O
Expression	O
of	O
Bcl	B
-	I
xL	I
and	O
adenovirus	B
E1B	I
19	I
K	I
did	O
not	O
interfere	O
with	O
anti-	O
Fas	B
killing	O
.	O
In	O
contrast	O
,	O
interleukin-1beta	O
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
Ac	O
-	O
DEVD	O
-	O
CHO	O
and	O
CrmA	O
blocked	O
Fas	B
-mediated	O
apoptosis	O
.	O
These	O
results	O
suggest	O
that	O
peripheral	O
T	O
cells	O
use	O
distinct	O
apoptosis	O
signaling	O
pathways	O
with	O
differential	O
sensitivity	O
to	O
Bcl-2	B
and	O
interleukin-1beta	O
-	O
converting	O
enzyme	O
family	O
protease	O
inhibitors	O
.	O
Since	O
T	O
cells	O
normally	O
express	O
Bcl-2	B
and	O
Bcl	B
-	I
xL	I
following	O
activation	O
,	O
their	O
inability	O
to	O
block	O
Fas	B
-mediated	O
apoptosis	O
may	O
allow	O
for	O
the	O
elimination	O
of	O
self	O
-	O
reactive	O
cells	O
and	O
the	O
appropriate	O
regulation	O
of	O
immune	O
responses	O
.	O
Rapid	O
shuttling	O
of	O
NF	B
-	I
AT	I
in	O
discrimination	O
of	O
Ca2	O
+	O
signals	O
and	O
immunosuppression	O
.	O
Cells	O
need	O
to	O
distinguish	O
between	O
transient	O
Ca2	O
+	O
signals	O
that	O
induce	O
events	O
such	O
as	O
muscle	O
contraction	O
,	O
secretion	O
,	O
adhesion	O
and	O
synaptic	O
transmission	O
,	O
and	O
sustained	O
Ca2	O
+	O
signals	O
that	O
are	O
involved	O
in	O
cell	O
proliferation	O
and	O
differentiation	O
.	O
The	O
latter	O
class	O
of	O
events	O
is	O
blocked	O
in	O
lymphocytes	O
by	O
the	O
immunosuppressive	O
drugs	O
cyclosporin	O
A	O
and	O
FK506	O
,	O
which	O
inhibit	O
calcineurin	B
,	O
a	O
Ca2	B
+	I
-activated	I
serine	I
/	I
threonine	I
phosphatase	I
necessary	O
for	O
the	O
nuclear	O
import	O
of	O
NF	B
-	I
AT	I
transcription	B
factors	I
.	O
Here	O
we	O
report	O
that	O
sustained	O
high	O
concentrations	O
of	O
Ca2	O
+	O
,	O
but	O
not	O
transient	O
pulses	O
,	O
are	O
required	O
to	O
maintain	O
NF	B
-	I
AT	I
transcription	B
factors	I
in	O
the	O
nucleus	O
,	O
where	O
they	O
participate	O
in	O
Ca2	O
+	O
-dependent	O
induction	O
of	O
genes	O
required	O
for	O
lymphocyte	O
activation	O
and	O
proliferation	O
.	O
Furthermore	O
,	O
overexpression	O
and	O
constitutive	O
nuclear	O
localization	O
of	O
NF	B
-	I
AT	I
,	O
but	O
not	O
Jun	B
,	I
Fos	I
,	I
NF	I
-	I
kappaB	I
,	I
Oct	I
or	I
Ets	I
family	I
members	I
,	O
renders	O
the	O
interleukin-2	O
enhancer	O
in	O
Jurkat	O
T	O
lymphocytes	O
resistant	O
to	O
FK506	O
and	O
cyclosporin	O
A	O
.	O
Thus	O
a	O
primary	O
effect	O
of	O
these	O
immunosuppressive	O
reagents	O
is	O
to	O
control	O
the	O
subcellular	O
localization	O
of	O
the	O
NF	B
-	I
AT	I
family	O
of	O
transcription	B
factors	I
.	O
Susceptibility	O
to	O
natural	O
killer	O
cells	O
and	O
down	O
regulation	O
of	O
MHC	B
class	O
I	O
expression	O
in	O
adenovirus	O
12	O
transformed	O
cells	O
are	O
regulated	O
by	O
different	O
E1A	O
domains	O
.	O
All	O
human	O
adenoviruses	O
transform	O
rodent	O
cells	O
in	O
vitro	O
,	O
but	O
only	O
cells	O
transformed	O
by	O
serotypes	O
belonging	O
to	O
subgroups	O
A	O
(	O
Ad12	O
)	O
and	O
B	O
(	O
Ad3	O
)	O
are	O
tumorigenic	O
for	O
immunocompetent	O
animals	O
.	O
In	O
these	O
cells	O
,	O
the	O
expression	O
of	O
MHC	B
-	I
class	I
I	I
antigens	I
is	O
repressed	O
and	O
might	O
allow	O
them	O
to	O
escape	O
from	O
recognition	O
by	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTL	O
)	O
and	O
to	O
develop	O
in	O
tumor	O
.	O
Furthermore	O
,	O
these	O
cell	O
lines	O
appear	O
resistant	O
to	O
lysis	O
by	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
.	O
To	O
determine	O
the	O
E1A	O
domain	O
(	O
s	O
)	O
responsible	O
for	O
these	O
properties	O
several	O
cell	O
lines	O
were	O
created	O
by	O
transforming	O
baby	O
rat	O
kidney	O
(	O
BRK	O
)	O
cells	O
with	O
a	O
set	O
of	O
plasmids	O
expressing	O
different	O
Ad2	B
/	I
Ad12	I
hybrid	I
E1A	I
gene	I
products	I
.	O
The	O
MHC	O
class	O
1	O
gene	O
expression	O
was	O
inhibited	O
in	O
cells	O
expressing	O
the	O
Ad12	B
13S	I
mRNA	I
product	I
and	O
in	O
cells	O
transformed	O
with	O
Ad2	B
/	I
Ad12	I
hybrid	I
E1A	I
gene	I
product	I
harboring	O
the	O
C	B
-	I
terminal	I
part	I
of	O
the	O
conserved	O
region	O
(	O
CR	O
)	O
3	O
of	O
Ad12	O
.	O
Susceptibility	O
of	O
these	O
transformed	O
cell	O
lines	O
to	O
NK	O
cells	O
was	O
determined	O
by	O
cytolytic	O
assays	O
.	O
The	O
results	O
obtained	O
suggest	O
that	O
two	O
Ad12	O
E1A	O
domains	O
are	O
required	O
to	O
induce	O
resistance	O
of	O
the	O
cell	O
lines	O
to	O
NK	O
cells	O
.	O
An	O
IL-2	O
response	O
element	O
in	O
the	O
human	O
IL-2	O
receptor	O
alpha	O
chain	O
promoter	O
is	O
a	O
composite	O
element	O
that	O
binds	O
Stat5	B
,	O
Elf-1	B
,	O
HMG	B
-	I
I	I
(	I
Y	I
)	I
and	O
a	O
GATA	B
family	I
protein	I
.	O
Expression	O
of	O
the	O
human	O
interleukin-2	O
(	O
IL-2	O
)	O
receptor	O
alpha	O
chain	O
gene	O
is	O
potently	O
upregulated	O
by	O
its	O
own	O
ligand	O
,	O
IL-2	B
.	O
In	O
this	O
study	O
,	O
we	O
characterize	O
an	O
essential	O
upstream	O
IL-2	O
response	O
element	O
that	O
contains	O
both	O
consensus	O
and	O
non	O
-	O
consensus	O
GAS	O
motifs	O
,	O
two	O
putative	O
Ets	O
binding	O
sites	O
(	O
EBS	O
)	O
,	O
one	O
of	O
which	O
overlaps	O
the	O
consensus	O
GAS	O
motif	O
,	O
and	O
a	O
GATA	O
motif	O
,	O
which	O
overlaps	O
the	O
non	O
-	O
consensus	O
GAS	O
motif	O
.	O
We	O
demonstrate	O
that	O
although	O
the	O
individual	O
components	O
of	O
this	O
element	O
do	O
not	O
respond	O
to	O
IL-2	B
,	O
together	O
they	O
form	O
a	O
composite	O
element	O
capable	O
of	O
conferring	O
IL-2	B
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
.	O
Multiple	O
factors	O
including	O
Stat5	B
,	O
Elf-1	B
,	O
HMG	B
-	I
I	I
(	I
Y	I
)	I
and	O
GATA	B
family	I
proteins	I
bind	O
to	O
the	O
IL-2	O
response	O
element	O
and	O
mutation	O
of	O
any	O
one	O
of	O
these	O
binding	O
sites	O
diminishes	O
the	O
activity	O
of	O
this	O
element	O
.	O
An	O
unidentified	O
Ets	B
family	I
protein	I
binds	O
to	O
the	O
EBS	O
overlapping	O
the	O
consensus	O
GAS	O
motif	O
and	O
appears	O
to	O
negatively	O
regulate	O
the	O
human	O
IL-2R	O
alpha	O
promoter	O
.	O
Thus	O
,	O
IL-2	B
-induced	O
IL-2R	O
alpha	O
promoter	O
activity	O
requires	O
a	O
complex	O
upstream	O
element	O
,	O
which	O
appears	O
to	O
contain	O
binding	O
sites	O
for	O
both	O
positive	B
and	I
negative	I
regulatory	I
factors	I
.	O
Tyrosine	B
kinase	I
and	O
cAMP	B
-	I
dependent	I
protein	I
kinase	I
activities	O
in	O
CD40-activated	O
human	O
B	O
lymphocytes	O
.	O
In	O
vitro	O
,	O
human	O
B	O
lymphocytes	O
undergo	O
long	O
-	O
term	O
proliferation	O
when	O
activated	O
through	O
CD40	B
,	O
a	O
protein	O
expressed	O
on	O
their	O
cell	O
surface	O
.	O
The	O
nature	O
of	O
CD40	B
-dependent	O
signals	O
in	O
proliferating	O
fresh	O
human	O
Epstein	O
-	O
Barr	O
virus	O
-	O
negative	O
B	O
lymphocytes	O
is	O
currently	O
unknown	O
.	O
In	O
this	O
study	O
,	O
a	O
CD40	B
-dependent	O
B	O
cell	O
culture	O
system	O
was	O
used	O
to	O
examine	O
the	O
role	O
of	O
different	O
signal	O
transduction	O
elements	O
.	O
Protein	O
kinase	O
C	O
(	O
PKC	B
)	O
depletion	O
generated	O
by	O
a	O
long	O
-	O
term	O
phorbol	O
12	O
myristate	O
13-acetate	O
treatment	O
had	O
weak	O
effects	O
on	O
proliferation	O
.	O
Rather	O
,	O
tyrosine	O
phosphorylation	O
was	O
shown	O
to	O
be	O
directly	O
involved	O
in	O
mediating	O
CD40	B
-dependent	O
signals	O
.	O
The	O
use	O
of	O
the	O
protein	B
tyrosine	I
kinase	I
(	O
PTK	B
)	O
-specific	O
inhibitor	O
herbimycin	O
A	O
dramatically	O
decreased	O
cellular	O
proliferation	O
without	O
altering	O
the	O
activity	O
of	O
the	O
human	O
immunodeficiency	O
virus-1	O
long	O
terminal	O
repeat	O
(	O
HIV-1	O
LTR	O
)	O
,	O
a	O
promoter	O
largely	O
dependent	O
on	O
the	O
binding	O
of	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF-	B
kappa	I
B	I
)	O
.	O
In	O
contrast	O
,	O
the	O
cAMP	B
-	I
dependent	I
protein	I
kinase	I
specific	O
inhibitor	O
H-89	O
totally	O
inhibited	O
HIV-1	O
LTR	O
activity	O
at	O
a	O
concentration	O
as	O
low	O
as	O
100	O
nM	O
without	O
affecting	O
cellular	O
proliferation	O
.	O
Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
supershift	O
assay	O
using	O
an	O
NF	O
-	O
kappa	O
B	O
binding	O
sequence	O
from	O
the	O
kappa	B
light	I
chain	I
as	O
a	O
probe	O
,	O
revealed	O
that	O
both	O
p65	B
(	O
RelA	B
)	O
and	O
c	B
-	I
Rel	I
were	O
present	O
in	O
CD40-stimulated	O
B	O
cells	O
.	O
While	O
PKC	B
depletion	O
did	O
not	O
alter	O
the	O
NF	B
-	I
kappa	I
B	I
level	O
,	O
treatment	O
of	O
B	O
lymphocytes	O
with	O
H-89	O
or	O
herbimycin	O
A	O
provoked	O
a	O
decrease	O
in	O
the	O
NF	B
-	I
kappa	I
B	I
level	O
.	O
These	O
observations	O
establish	O
the	O
importance	O
of	O
different	O
signal	O
transducing	O
pathways	O
leading	O
to	O
CD40	B
activation	O
of	O
B	O
lymphocytes	O
.	O
Active	O
suppression	O
of	O
the	O
class	O
II	O
transactivator	O
-	O
encoding	O
AIR-1	O
locus	O
is	O
responsible	O
for	O
the	O
lack	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
gene	O
expression	O
observed	O
during	O
differentiation	O
from	O
B	O
cells	O
to	O
plasma	O
cells	O
.	O
In	O
this	O
study	O
the	O
genetic	O
control	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
gene	O
expression	O
during	O
the	O
transition	O
from	O
B	O
cell	O
to	O
plasma	O
cell	O
has	O
been	O
analyzed	O
.	O
Class	B
II	I
molecules	I
are	O
not	O
expressed	O
in	O
plasma	O
cells	O
because	O
of	O
an	O
active	O
suppression	O
resulting	O
in	O
the	O
abrogation	O
of	O
class	O
II	O
gene	O
transcription	O
.	O
We	O
show	O
here	O
that	O
the	O
plasma	O
cell	O
-	O
specific	O
repressor	O
function	O
,	O
designated	O
SIR	O
(	O
suppressor	O
of	O
immune	O
response	O
genes	O
)	O
,	O
does	O
not	O
act	O
directly	O
on	O
the	O
transcription	O
of	O
class	O
II	O
genes	O
,	O
but	O
instead	O
on	O
the	O
transcription	O
of	O
the	O
AIR-1	O
gene	O
,	O
whose	O
product	O
,	O
the	O
class	B
II	I
transactivator	I
(	O
CIITA	B
)	O
,	O
is	O
fundamental	O
for	O
the	O
regulation	O
of	O
the	O
constitutive	O
and	O
inducible	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O
This	O
was	O
unambiguously	O
demonstrated	O
by	O
the	O
fact	O
that	O
plasmacytoma	O
x	O
B	O
cell	O
hybrids	O
carrying	O
an	O
AIR-1	O
locus	O
derived	O
from	O
CIITA	O
-	O
expressing	O
cells	O
do	O
not	O
express	O
CIITA	O
-	O
specific	O
transcripts	O
.	O
Transfection	O
of	O
a	O
cDNA	O
containing	O
the	O
human	O
CIITA	O
coding	O
sequence	O
under	O
the	O
control	O
of	O
an	O
heterologous	O
promoter	O
restores	O
expression	O
of	O
human	O
MHC	O
class	O
II	O
genes	O
in	O
the	O
hybrids	O
and	O
is	O
responsible	O
for	O
de	O
novo	O
expression	O
of	O
mouse	O
MHC	O
class	O
II	O
genes	O
in	O
both	O
the	O
mouse	O
plasmacytoma	O
cell	O
line	O
and	O
the	O
hybrids	O
.	O
These	O
results	O
confirm	O
and	O
extend	O
the	O
notion	O
of	O
the	O
functional	O
conservation	O
of	O
the	O
AIR-1	B
gene	I
product	I
across	O
species	O
barriers	O
.	O
Interestingly	O
,	O
in	O
CIITA	O
-	O
transfected	O
cell	O
hybrids	O
,	O
cell	O
surface	O
expression	O
of	O
the	O
human	B
HLA	I
-	I
DQ	I
heterodimer	I
was	O
not	O
observed	O
.	O
This	O
result	O
was	O
not	O
attributable	O
to	O
lack	O
of	O
HLA	O
-	O
DQ	O
alpha	O
or	O
-DQ	O
beta	O
transcription	O
,	O
because	O
both	O
transcripts	O
were	O
present	O
in	O
the	O
CIITA	O
-	O
transfected	O
hybrids	O
,	O
although	O
at	O
reduced	O
levels	O
.	O
These	O
findings	O
further	O
support	O
our	O
previous	O
observations	O
on	O
the	O
distinct	O
regulation	O
of	O
expression	O
of	O
the	O
human	O
HLA	O
-	O
DQ	O
class	O
II	O
subset	O
,	O
which	O
may	O
be	O
thus	O
controlled	O
at	O
the	O
posttranscriptional	O
level	O
by	O
a	O
CIITA	B
-independent	O
mechanism	O
.	O
Chromosome	O
1	O
aneusomy	O
with	O
1p36	O
under	O
-	O
representation	O
is	O
related	O
to	O
histologic	O
grade	O
,	O
DNA	O
aneuploidy	O
,	O
high	O
c	B
-	I
erb	I
B-2	I
and	O
loss	O
of	O
bcl-2	O
expression	O
in	O
ductal	O
breast	O
carcinoma	O
.	O
Chromosome	O
1	O
abnormalities	O
with	O
loss	O
of	O
1p36	O
have	O
been	O
investigated	O
in	O
95	O
breast	O
-	O
cancer	O
samples	O
by	O
means	O
of	O
a	O
dual	O
-	O
target	O
fluorescence	O
in	O
-	O
situ	O
hybridization	O
(	O
FISH	O
)	O
technique	O
using	O
the	O
pUC	O
1.77	O
and	O
p1	O
-	O
79	O
probes	O
,	O
specific	O
for	O
the	O
1q12	O
and	O
1p36	O
regions	O
,	O
respectively	O
.	O
Abnormalities	O
for	O
one	O
or	O
both	O
probes	O
were	O
detected	O
in	O
83	O
/	O
95	O
samples	O
.	O
Relative	O
1p36	O
under	O
-	O
representation	O
was	O
found	O
in	O
79	O
/	O
95	O
.	O
The	O
clinical	O
relevance	O
of	O
these	O
alterations	O
was	O
studied	O
by	O
comparing	O
the	O
FISH	O
results	O
with	O
several	O
parameters	O
currently	O
used	O
in	O
breast	O
-	O
cancer	O
pathology	O
.	O
Distinct	O
patterns	O
of	O
chromosome	O
1	O
abnormalities	O
were	O
found	O
among	O
the	O
histologic	O
types	O
of	O
breast	O
carcinoma	O
.	O
Lobular	O
or	O
mucinous	O
samples	O
showed	O
few	O
or	O
no	O
alterations	O
,	O
whereas	O
most	O
ductal	O
samples	O
had	O
high	O
chromosome	O
1	O
polysomy	O
with	O
under	O
-	O
representation	O
of	O
1p36	O
.	O
In	O
ductal	O
carcinomas	O
,	O
chromosome	O
1	O
alterations	O
increased	O
with	O
histologic	O
grade	O
,	O
DNA	O
aneuploidy	O
,	O
loss	O
of	O
bcl-2	O
and	O
high	O
c	B
-	I
erb	I
B-2	I
expression	O
.	O
These	O
associations	O
were	O
found	O
to	O
be	O
statistically	O
significant	O
.	O
No	O
correlation	O
between	O
chromosome	O
1	O
alterations	O
and	O
nuclear	O
grade	O
,	O
age	O
,	O
size	O
,	O
lymph	O
-	O
node	O
involvement	O
,	O
hormonal	O
receptor	O
presence	O
,	O
proliferation	O
activity	O
or	O
p53	B
protein	O
expression	O
was	O
detected	O
.	O
These	O
results	O
indicate	O
the	O
utility	O
of	O
this	O
FISH	O
technique	O
for	O
a	O
better	O
definition	O
of	O
the	O
biological	O
characteristics	O
of	O
ductal	O
carcinomas	O
.	O
Nasal	O
NK-	O
and	O
T	O
-	O
cell	O
lymphomas	O
share	O
the	O
same	O
type	O
of	O
Epstein	O
-	O
Barr	O
virus	O
latency	O
as	O
nasopharyngeal	O
carcinoma	O
and	O
Hodgkin	O
's	O
disease	O
.	O
Nasal	O
T	O
/	O
NK	O
-	O
cell	O
lymphomas	O
can	O
be	O
further	O
separated	O
into	O
those	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
lineage	O
or	O
of	O
T	O
-	O
cell	O
lineage	O
,	O
with	O
differences	O
in	O
cellular	O
phenotype	O
,	O
T	O
-	O
cell	O
receptor	O
(	O
TcR	O
)	O
gene	O
rearrangement	O
and	O
TcR	O
transcript	O
expression	O
.	O
Both	O
NK-	O
and	O
T	O
-	O
cell	O
subtypes	O
are	O
closely	O
associated	O
with	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O
In	O
this	O
study	O
,	O
EBV	O
gene	O
expression	O
was	O
determined	O
in	O
23	O
cases	O
of	O
nasal	O
lymphoma	O
(	O
NL	O
)	O
by	O
in	O
situ	O
hybridisation	O
(	O
ISH	O
)	O
,	O
reverse	B
transcriptase	I
-polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
immunohistochemistry	O
(	O
IH	O
)	O
.	O
Of	O
the	O
23	O
cases	O
,	O
19	O
were	O
classified	O
as	O
NK	O
-	O
cell	O
and	O
4	O
as	O
T	O
-	O
cell	O
tumours	O
.	O
ISH	O
for	O
EBV	O
-	O
encoded	O
small	O
non	O
-	O
polyadenylated	O
RNAs	O
showed	O
that	O
all	O
cases	O
,	O
whether	O
NK	O
or	O
T	O
,	O
harboured	O
EBV	O
in	O
virtually	O
all	O
tumour	O
cells	O
.	O
RT	O
-	O
PCR	O
demonstrated	O
that	O
NL	O
of	O
both	O
subtypes	O
expressed	O
EBNAI	B
of	O
the	O
QUK	O
splice	O
pattern	O
,	O
the	O
latent	B
membrane	I
proteins	I
,	O
LMP1	B
and	I
2	I
and	O
the	O
BamHI	O
A	O
rightward	O
transcripts	O
in	O
the	O
absence	O
of	O
EBNA2	O
mRNAs	O
,	O
compatible	O
with	O
the	O
latency	O
type	O
II	O
pattern	O
.	O
In	O
addition	O
,	O
analysis	O
of	O
EBV	O
protein	O
expression	O
by	O
IH	O
revealed	O
a	O
heterogeneous	O
pattern	O
of	O
EBV	O
gene	O
expression	O
at	O
the	O
single	O
-	O
cell	O
level	O
consisting	O
of	O
both	O
LMP1	O
+	O
and	O
LMP1-	O
tumour	O
cells	O
,	O
suggesting	O
a	O
mixture	O
of	O
latency	O
I	O
and	O
II	O
.	O
Although	O
2	O
early	B
lytic	I
transcripts	I
,	O
BZLF1	B
and	O
BHRF1	B
,	O
were	O
also	O
detected	O
in	O
13	O
and	O
10	O
cases	O
,	O
respectively	O
,	O
the	O
lack	O
of	O
ZEBRA	B
staining	O
in	O
any	O
case	O
indicates	O
that	O
these	O
lytic	O
transcripts	O
are	O
most	O
likely	O
expressed	O
by	O
rare	O
cells	O
in	O
the	O
biopsies	O
entering	O
lytic	O
cycle	O
.	O
The	O
viral	O
transcriptional	O
pattern	O
similar	O
to	O
that	O
of	O
nasopharyngeal	O
carcinoma	O
and	O
Hodgkin	O
's	O
disease	O
suggests	O
that	O
EBV	O
can	O
exploit	O
common	O
regulatory	O
mechanisms	O
for	O
gene	O
transcription	O
in	O
diverse	O
host	O
cell	O
types	O
.	O
Down	O
-	O
regulation	O
of	O
immunogenic	B
proteins	I
(	O
EBNA2-EBNA6	B
)	O
in	O
nasal	O
lymphoma	O
may	O
enable	O
tumour	O
cells	O
to	O
evade	O
host	O
cytotoxic	O
T	O
-	O
cell	O
surveillance	O
.	O
Presence	O
of	O
a	O
variant	O
form	O
of	O
the	O
estrogen	B
receptor	I
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
normal	O
individuals	O
and	O
lupus	O
patients	O
.	O
Estrogen	O
may	O
participate	O
in	O
the	O
pathogenesis	O
of	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
via	O
its	O
intracellular	B
receptor	I
.	O
To	O
investigate	O
the	O
presence	O
of	O
various	O
isoforms	O
of	O
the	O
estrogen	B
receptor	I
(	O
ER	B
)	O
in	O
SLE	O
we	O
isolated	O
RNA	O
from	O
mononuclear	O
cells	O
of	O
lupus	O
patients	O
and	O
normal	O
controls	O
.	O
Using	O
RT	O
-	O
PCR	O
we	O
were	O
able	O
to	O
identify	O
both	O
the	O
full	B
length	I
wild	I
-	I
type	I
form	I
and	O
an	O
isoform	O
of	O
the	O
ER	B
which	O
precisely	O
lacks	O
exon	O
V	O
in	O
both	O
patient	O
and	O
normal	O
individuals	O
.	O
Our	O
results	O
,	O
although	O
limited	O
,	O
suggest	O
that	O
normal	O
individuals	O
can	O
express	O
both	O
the	O
wild	O
-	O
type	O
and	O
truncated	O
version	O
at	O
the	O
same	O
time	O
,	O
whereas	O
lupus	O
patients	O
only	O
express	O
either	O
the	O
wild	B
-	I
type	I
or	I
the	I
truncated	I
ER	I
.	O
This	O
finding	O
may	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
reasons	O
for	O
the	O
prevalence	O
of	O
lupus	O
in	O
females	O
and	O
of	O
the	O
estrogenic	O
effects	O
on	O
SLE	O
disease	O
activity	O
.	O
Stat3	B
recruitment	O
by	O
two	O
distinct	O
ligand	B
-	I
induced	I
,	I
tyrosine	I
-	I
phosphorylated	I
docking	I
sites	I
in	O
the	O
interleukin-10	B
receptor	I
intracellular	I
domain	I
.	O
Recent	O
work	O
has	O
shown	O
that	O
IL-10	B
induces	O
activation	O
of	O
the	O
JAK	B
-STAT	B
signaling	O
pathway	O
.	O
To	O
define	O
the	O
mechanism	O
underlying	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	I
STAT	I
)	I
protein	I
recruitment	O
to	O
the	O
interleukin	B
10	I
(	I
IL-10	I
)	I
receptor	I
,	O
the	O
STAT	B
proteins	I
activated	O
by	O
IL-10	B
in	O
different	O
cell	O
populations	O
were	O
first	O
defined	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
In	O
all	O
cells	O
tested	O
,	O
IL-10	B
activated	O
Stat1	B
and	O
Stat3	B
and	O
induced	O
the	O
formation	O
of	O
three	O
distinct	O
DNA	B
binding	I
complexes	I
that	O
contained	O
different	O
combinations	O
of	O
these	O
two	O
transcription	B
factors	I
.	O
IL-10	B
also	O
activated	O
Stat5	B
in	O
Ba	O
/	O
F3	O
cells	O
that	O
stably	O
expressed	O
the	O
murine	O
IL-10	B
receptor	I
.	O
Using	O
a	O
structure	O
-	O
function	O
mutagenesis	O
approach	O
,	O
two	O
tyrosine	O
residues	O
(	O
Tyr427	O
and	O
Tyr477	O
)	O
in	O
the	O
intracellular	B
domain	I
of	O
the	O
murine	O
IL-10	B
receptor	O
were	O
found	O
to	O
be	O
redundantly	O
required	O
for	O
receptor	O
function	O
and	O
for	O
activation	O
of	O
Stat3	B
but	O
not	O
for	O
Stat1	B
or	O
Stat5	B
.	O
Twelve	O
amino	O
acid	O
peptides	O
encompassing	O
either	O
of	O
these	O
two	O
tyrosine	O
residues	O
in	O
phosphorylated	B
form	I
coprecipitated	O
Stat3	B
but	O
not	O
Stat1	B
and	O
blocked	O
IL-10	B
-induced	O
Stat3	B
phosphorylation	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O
In	O
contrast	O
,	O
tyrosine	O
-	O
phosphorylated	O
peptides	O
containing	O
Tyr374	O
or	O
Tyr396	O
did	O
not	O
interact	O
with	O
Stat3	B
or	O
block	O
Stat3	B
activation	O
.	O
These	O
data	O
demonstrate	O
that	O
Stat3	B
but	O
not	O
Stat1	B
or	O
Stat5	B
is	O
directly	O
recruited	O
to	O
the	O
ligand	B
-	I
activated	I
IL-10	I
receptor	I
by	O
binding	O
to	O
specific	O
but	O
redundant	O
receptor	B
intracellular	I
domain	I
sequences	I
containing	O
phosphotyrosine	O
.	O
This	O
study	O
thus	O
supports	O
the	O
concept	O
that	O
utilization	O
of	O
distinct	O
STAT	B
proteins	I
by	O
different	O
cytokine	B
receptors	I
is	O
dependent	O
on	O
the	O
expression	O
of	O
particular	O
ligand	O
-	O
activatable	O
,	O
tyrosine	B
-	I
containing	I
STAT	I
docking	I
sites	I
in	O
receptor	B
intracellular	I
domains	I
.	O
T	O
-	O
cell	O
-directed	O
TAL-1	B
expression	O
induces	O
T	O
-	O
cell	O
malignancies	O
in	O
transgenic	O
mice	O
.	O
The	O
TAL-1	O
gene	O
specifies	O
for	O
a	O
basic	O
domain	B
-	I
helix	I
-	I
loop	I
-	I
helix	I
protein	I
,	O
which	O
is	O
involved	O
in	O
the	O
control	O
of	O
normal	O
hematopoiesis	O
.	O
In	O
human	O
pathology	O
,	O
the	O
TAL-1	B
gene	I
product	I
is	O
expressed	O
in	O
a	O
high	O
percentage	O
of	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemias	O
in	O
the	O
pediatric	O
age	O
range	O
;	O
however	O
,	O
it	O
has	O
not	O
been	O
established	O
whether	O
the	O
expression	O
has	O
a	O
causal	O
role	O
in	O
oncogenesis	O
.	O
In	O
this	O
report	O
,	O
we	O
describe	O
the	O
phenotype	O
of	O
mouse	O
transgenic	O
lines	O
obtained	O
by	O
inducing	O
tal-1	B
protein	I
expression	O
in	O
lymphoid	O
tissues	O
using	O
the	O
LCK	O
promoter	O
.	O
The	O
survival	O
rate	O
of	O
tal-1	O
transgenic	O
animals	O
was	O
much	O
lower	O
as	O
compared	O
with	O
control	O
mice	O
.	O
Histopathological	O
analysis	O
revealed	O
lymphomas	O
of	O
T	O
-	O
cell	O
type	O
,	O
often	O
comprising	O
a	O
minor	O
B	O
-	O
cell	O
component	O
.	O
Some	O
mice	O
showed	O
marked	O
splenic	O
lymphocyte	O
depletion	O
.	O
Primary	O
lymphocyte	O
cultures	O
showed	O
partial	O
independence	O
from	O
exogenous	O
growth	O
stimuli	O
and	O
increased	O
resistance	O
to	O
low	O
-	O
serum	O
apoptosis	O
.	O
To	O
further	O
unravel	O
the	O
tal-1	O
oncogenic	O
potential	O
,	O
a	O
strain	O
of	O
tal-1	O
transgenic	O
mice	O
was	O
crossbred	O
with	O
p53-	O
/	O
-	O
mice	O
;	O
the	O
survival	O
rate	O
in	O
these	O
animals	O
was	O
reduced	O
by	O
more	O
than	O
one	O
-	O
half	O
when	O
compared	O
with	O
that	O
of	O
tal-1	O
mice	O
,	O
and	O
histopathological	O
analysis	O
revealed	O
exclusively	O
T	O
-	O
cell	O
lymphomas	O
.	O
These	O
data	O
indicate	O
that	O
TAL-1	B
,	O
expressed	O
in	O
T	O
cells	O
,	O
is	O
per	O
se	O
a	O
potent	O
oncogene	O
,	O
which	O
may	O
exert	O
a	O
key	O
leukemogenetic	O
role	O
in	O
the	O
majority	O
of	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemias	O
.	O
Naive	O
(	O
CD45RA+	O
)	O
T	O
lymphocytes	O
are	O
more	O
sensitive	O
to	O
oxidative	O
stress	O
-	O
induced	O
signals	O
than	O
memory	O
(	O
CD45RO+	O
)	O
cells	O
.	O
Formation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
after	O
oxidative	O
stress	O
has	O
been	O
shown	O
to	O
be	O
an	O
activation	O
signal	O
for	O
T	O
lymphocytes	O
,	O
e.g.	O
,	O
expression	O
of	O
IL-2	B
and	O
its	O
receptor	B
are	O
induced	O
.	O
These	O
ROI	O
-	O
induced	O
effects	O
can	O
,	O
to	O
a	O
large	O
extent	O
,	O
be	O
attributed	O
to	O
the	O
activation	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
.	O
Now	O
we	O
have	O
examined	O
whether	O
naive	O
and	O
memory	O
T	O
lymphocytes	O
differ	O
in	O
their	O
sensitivity	O
to	O
ROI	O
-	O
mediated	O
signals	O
.	O
When	O
CD45RA+	O
(	O
naive	O
)	O
and	O
CD45RO+	O
(	O
memory	O
)	O
T	O
lymphocytes	O
were	O
directly	O
stimulated	O
with	O
H2O2	O
,	O
NF	B
-	I
kappaB	I
nuclear	O
translocation	O
was	O
stronger	O
in	O
naive	O
cells	O
than	O
in	O
memory	O
cells	O
and	O
it	O
could	O
be	O
induced	O
with	O
lower	O
doses	O
.	O
The	O
composition	O
of	O
the	O
induced	O
nuclear	B
NF	I
-	I
kappaB	I
(	O
levels	O
of	O
p50	B
and	O
RelA	B
proteins	I
)	O
was	O
similar	O
in	O
these	O
cell	O
types	O
.	O
The	O
magnitude	O
and	O
kinetics	O
of	O
intracellular	O
ROI	O
were	O
similar	O
,	O
suggesting	O
that	O
there	O
were	O
no	O
differences	O
in	O
ROI	O
-	O
forming	O
mechanisms	O
or	O
antioxidative	O
capacities	O
.	O
The	O
probable	O
regulatory	O
point	O
was	O
the	O
cytoplasmic	O
IkappaB	B
inhibitor	O
:	O
in	O
CD45RA+	O
cells	O
,	O
H2O2	O
caused	O
a	O
more	O
profound	O
depression	O
in	O
the	O
levels	O
of	O
IkappaB	B
alpha	I
.	O
These	O
findings	O
indicate	O
that	O
T	O
cells	O
representing	O
different	O
activation	O
and/or	O
differentiation	O
stages	O
can	O
be	O
differentially	O
responsive	O
to	O
ROI	O
-	O
mediated	O
signals	O
.	O
Potent	O
gene	O
regulatory	O
and	O
antiproliferative	O
activities	O
of	O
20-methyl	O
analogues	O
of	O
1	O
,	O
25	O
dihydroxyvitamin	O
D3	O
.	O
The	O
biological	O
active	O
form	O
of	O
vitamin	O
D3	O
,	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD	O
)	O
,	O
regulates	O
cellular	O
growth	O
and	O
differentiation	O
.	O
This	O
provides	O
the	O
hormone	O
with	O
an	O
interesting	O
therapeutic	O
potential	O
.	O
However	O
,	O
hypercalcemia	O
is	O
a	O
side	O
effect	O
,	O
which	O
is	O
caused	O
by	O
VD	O
's	O
classical	O
action	O
,	O
the	O
regulation	O
of	O
calcium	O
homeostasis	O
.	O
This	O
made	O
the	O
need	O
for	O
VD	O
analogues	O
with	O
selectively	O
increased	O
cell	O
regulatory	O
properties	O
.	O
Studies	O
with	O
20-epi	O
analogues	O
pointed	O
out	O
the	O
importance	O
of	O
the	O
carbon-20	O
position	O
and	O
led	O
to	O
the	O
development	O
of	O
20-methyl	O
derivatives	O
of	O
VD	O
.	O
In	O
this	O
report	O
the	O
biological	O
properties	O
of	O
the	O
compounds	O
ZK161422	O
and	O
ZK157202	O
,	O
which	O
are	O
20-methyl-	O
and	O
20-methyl-23-eneanalogues	O
,	O
respectively	O
,	O
have	O
been	O
analyzed	O
in	O
comparison	O
with	O
VD	O
.	O
Both	O
compounds	O
show	O
about	O
2-fold	O
lower	O
affinity	O
to	O
the	O
VD	O
receptor	O
(	O
VDR	O
)	O
than	O
VD	O
.	O
However	O
,	O
compared	O
to	O
VD	O
,	O
their	O
antiproliferative	O
effect	O
is	O
up	O
to	O
30-fold	O
higher	O
on	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
even	O
up	O
to	O
300-fold	O
higher	O
on	O
human	O
breast	O
cancer	O
MCF-7	O
cells	O
.	O
Whereas	O
the	O
hypercalcemic	O
effect	O
for	O
ZK157202	O
is	O
also	O
increased	O
10-fold	O
,	O
ZK161422	O
has	O
the	O
same	O
calcium	O
-	O
mobilizing	O
potency	O
as	O
VD	O
.	O
Moreover	O
,	O
ZK161422	O
,	O
but	O
not	O
ZK157202	O
,	O
showed	O
preference	O
for	O
gene	O
activation	O
from	O
a	O
promoter	O
carrying	O
a	O
VD	O
response	O
element	O
with	O
a	O
palindromic	O
arrangement	O
of	O
two	O
hexameric	O
receptor	O
binding	O
sites	O
spaced	O
by	O
9	O
nucleotides	O
(	O
IP9	O
)	O
rather	O
than	O
for	O
activation	O
from	O
a	O
response	O
element	O
formed	O
by	O
a	O
direct	O
repeat	O
spaced	O
by	O
3	O
nucleotides	O
(	O
DR3	O
)	O
.	O
This	O
observation	O
supports	O
a	O
model	O
,	O
in	O
which	O
promoter	O
selectivity	O
reflects	O
the	O
selectively	O
increased	O
antiproliferative	O
effect	O
of	O
VD	O
analogues	O
.	O
Generation	O
of	O
CD1+RelB+	O
dendritic	O
cells	O
and	O
tartrate	O
-	O
resistant	O
acid	O
phosphatase	O
-	O
positive	O
osteoclast	O
-	O
like	O
multinucleated	O
giant	O
cells	O
from	O
human	O
monocytes	O
.	O
We	O
previously	O
showed	O
that	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
and	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
(	O
M	B
-	I
CSF	I
)	O
stimulate	O
the	O
differentiation	O
of	O
human	O
monocytes	O
into	O
two	O
phenotypically	O
distinct	O
types	O
of	O
macrophages	O
.	O
However	O
,	O
in	O
vivo	O
,	O
not	O
only	O
CSF	B
but	O
also	O
many	O
other	O
cytokines	B
are	O
produced	O
under	O
various	O
conditions	O
.	O
Those	O
cytokines	B
may	O
modulate	O
the	O
differentiation	O
of	O
monocytes	O
by	O
CSFs	B
.	O
In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
CD14	O
+	O
adherent	O
human	O
monocytes	O
can	O
differentiate	O
into	O
CD1+relB+	O
dendritic	O
cells	O
(	O
DC	O
)	O
by	O
the	O
combination	O
of	O
GM	B
-	I
CSF	I
plus	O
interleukin-4	B
(	O
IL-4	B
)	O
and	O
that	O
they	O
differentiate	O
into	O
tartrate	O
-	O
resistant	O
acid	O
phosphatase	O
(	O
TRAP	O
)	O
-positive	O
osteoclast	O
-	O
like	O
multinucleated	O
giant	O
cells	O
(	O
MGC	O
)	O
by	O
the	O
combination	O
of	O
M	B
-	I
CSF	I
plus	O
IL-4	B
.	O
However	O
,	O
the	O
monocyte	O
-	O
derived	O
DC	O
were	O
not	O
terminally	O
differentiated	O
cells	O
;	O
they	O
could	O
still	O
convert	O
to	O
macrophages	O
in	O
response	O
to	O
M	B
-	I
CSF	I
.	O
Tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
stimulated	O
the	O
terminal	O
differentiation	O
of	O
the	O
DC	O
by	O
downregulating	O
the	O
expression	O
of	O
the	O
M	B
-	I
CSF	I
receptor	I
,	O
cfms	O
mRNA	O
,	O
and	O
aborting	O
the	O
potential	O
to	O
convert	O
to	O
macrophages	O
.	O
In	O
contrast	O
to	O
IL-4	B
,	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
had	O
no	O
demonstrable	O
effect	O
on	O
the	O
differentiation	O
of	O
monocytes	O
.	O
Rather	O
,	O
IFN	B
-	I
gamma	I
antagonized	O
the	O
effect	O
of	O
IL-4	B
and	O
suppressed	O
the	O
DC	O
and	O
MGC	O
formation	O
induced	O
by	O
GM	B
-	I
CSF	I
+	O
IL-4	B
and	O
M	B
-	I
CSF	I
+	O
IL-4	B
,	O
respectively	O
.	O
Taken	O
together	O
,	O
these	O
results	O
provide	O
a	O
new	O
aspect	O
to	O
our	O
knowledge	O
of	O
monocyte	O
differentiation	O
and	O
provide	O
evidence	O
that	O
human	O
monocytes	O
are	O
flexible	O
in	O
their	O
differentiation	O
potential	O
and	O
are	O
precursors	O
not	O
only	O
of	O
macrophages	O
but	O
also	O
of	O
CD1+relB+DC	O
and	O
TRAP	O
-	O
positive	O
MGC	O
.	O
Such	O
a	O
diverse	O
pathway	O
of	O
monocyte	O
differentiation	O
may	O
constitute	O
one	O
of	O
the	O
basic	O
mechanisms	O
of	O
immune	O
regulation	O
.	O
Regulation	O
of	O
[	O
Ca2	O
+	O
]	O
i	O
rise	O
activated	O
by	O
doxepin	B
-	I
sensitive	I
H1-histamine	I
receptors	I
in	O
Jurkat	O
cells	O
,	O
cloned	O
human	O
T	O
lymphocytes	O
.	O
To	O
clarify	O
the	O
presence	O
of	O
histamine	B
receptor	I
and	O
its	O
transmembrane	O
mechanism	O
in	O
human	O
T	O
lymphocytes	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
agonists	O
or	O
antagonists	O
of	O
histamine	B
receptor	I
subtypes	O
and	O
bacterial	O
toxins	O
on	O
intracellular	O
concentration	O
of	O
Ca2	O
+	O
[	O
Ca2	O
+	O
]	O
i	O
)	O
,	O
[	O
3H	O
]	O
pyrilamine	O
binding	O
and	O
c	O
-	O
fos	O
mRNA	O
expression	O
in	O
Jurkat	O
cells	O
,	O
cloned	O
human	O
T	O
lymphocytes	O
.	O
H1-agonists	O
(	O
histamine	O
and	O
2-methylhistamine	O
)	O
caused	O
a	O
transient	O
rise	O
of	O
[	O
Ca2	O
+	O
]	O
,	O
and	O
H1-antagonists	O
(	O
pyrilamine	O
and	O
doxepin	O
)	O
inhibited	O
the	O
histamine	O
-	O
induced	O
[	O
Ca2	O
+	O
]	O
i	O
rise	O
more	O
potently	O
than	O
the	O
H2-antagonist	O
(	O
cimetidine	O
)	O
on	O
the	O
H3-antagonist	O
(	O
impromidine	O
)	O
.	O
Binding	O
parameters	O
of	O
[	O
3H	O
]	O
pyrilamine	O
binding	O
were	O
Kd	O
=	O
5.53	O
nM	O
and	O
Bmax	O
=	O
2	O
,	O
647	O
sites	O
/	O
cell	O
.	O
Pretreatment	O
with	O
B.pertussis	O
,	O
V.cholera	O
.	O
or	O
C.botulinum	O
toxin	O
did	O
not	O
influence	O
histamine	O
-	O
induced	O
[	O
Ca2	O
+	O
]	O
i	O
rise	O
.	O
Western	O
Blot	O
analysis	O
using	O
antibodies	O
against	O
subunits	O
of	O
GTP	B
-	I
binding	I
proteins	I
indicated	O
that	O
Gq	B
/	I
G11	I
richly	O
existed	O
in	O
Jurkat	O
cells	O
.	O
Histamine	O
induced	O
mRNA	O
expression	O
of	O
an	O
immediate	O
early	O
gene	O
c	O
-	O
fos	O
.	O
Pretreatment	O
with	O
a	O
protein	B
kinase	I
C	I
activator	O
,	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
caused	O
almost	O
complete	O
inhibition	O
of	O
histamine	O
-	O
induced	O
[	O
Ca2	O
+	O
]	O
i	O
rise	O
,	O
but	O
did	O
not	O
do	O
so	O
by	O
activators	O
of	O
cAMP-	B
and	I
cGMP	I
-	I
dependent	I
protein	I
kinases	I
.	O
Signal	O
transduction	O
by	O
DR3	B
,	O
a	O
death	B
domain	I
-	I
containing	I
receptor	I
related	O
to	O
TNFR-1	B
and	O
CD95	B
.	O
Tumor	B
necrosis	I
factor	I
receptor-1	I
(	O
TNFR-1	B
)	O
and	O
CD95	B
(	O
also	O
called	O
Fas	B
or	O
APO-1	B
)	O
are	O
cytokine	B
receptors	I
that	O
engage	O
the	O
apoptosis	O
pathway	O
through	O
a	O
region	O
of	O
intracellular	O
homology	O
,	O
designated	O
the	O
`	O
`	O
death	B
domain	I
.	O
''	O
Another	O
death	B
domain	I
-	I
containing	I
member	I
of	O
the	O
TNFR	B
family	I
,	O
death	B
receptor	I
3	I
(	O
DR3	B
)	O
,	O
was	O
identified	O
and	O
was	O
shown	O
to	O
induce	O
both	O
apoptosis	O
and	O
activation	O
of	O
nuclear	B
factor	I
kappaB	I
.	O
Expression	O
of	O
DR3	B
appears	O
to	O
be	O
restricted	O
to	O
tissues	O
enriched	O
in	O
lymphocytes	O
.	O
DR3	B
signal	O
transduction	O
is	O
mediated	O
by	O
a	O
complex	O
of	O
intracellular	B
signaling	I
molecules	I
including	O
TRADD	B
,	O
TRAF2	B
,	O
FADD	B
,	O
and	O
FLICE	B
.	O
Thus	O
,	O
DR3	B
likely	O
plays	O
a	O
role	O
in	O
regulating	O
lymphocyte	O
homeostasis	O
.	O
Regulation	O
of	O
cytokine	B
and	O
cytokine	B
receptor	I
expression	O
by	O
glucocorticoids	O
.	O
Glucocorticoids	O
(	O
GCS	O
)	O
profoundly	O
inhibit	O
several	O
aspects	O
of	O
T	O
cell	O
immunity	O
largely	O
through	O
inhibition	O
of	O
cytokine	B
expression	O
at	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O
GCS	O
were	O
also	O
reported	O
to	O
act	O
indirectly	O
by	O
inducing	O
transforming	O
growth	B
factor	I
-	I
beta	I
expression	O
,	O
which	O
in	O
turn	O
blocks	O
T	O
cell	O
immunity	O
.	O
In	O
exerting	O
their	O
antiproliferative	O
effects	O
,	O
GCS	O
diffuse	O
into	O
target	O
cells	O
where	O
they	O
bind	O
their	O
cytoplasmic	B
receptor	I
,	O
which	O
in	O
turn	O
translocates	O
to	O
the	O
nucleus	O
where	O
it	O
inhibits	O
transcription	O
of	O
cytokine	O
genes	O
through	O
direct	O
binding	O
to	O
the	O
glucocorticoid	O
response	O
elements	O
(	O
GRE	O
)	O
,	O
which	O
are	O
located	O
in	O
the	O
promoter	O
region	O
of	O
cytokine	O
genes	O
or	O
,	O
alternatively	O
,	O
through	O
antagonism	O
of	O
the	O
action	O
of	O
transcription	B
factors	I
required	O
for	O
optimal	O
transcriptional	O
activation	O
.	O
In	O
contrast	O
to	O
their	O
inhibitory	O
effects	O
on	O
cytokine	B
expression	O
,	O
GCS	O
up	O
-	O
regulate	O
cytokine	B
receptor	I
expression	O
that	O
correlates	O
with	O
enhanced	O
cytokine	B
effects	O
on	O
target	O
cells	O
.	O
In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
current	O
state	O
of	O
knowledge	O
of	O
the	O
mechanism	O
of	O
action	O
of	O
GCS	O
,	O
including	O
the	O
phenomenon	O
of	O
steroid	O
-	O
induced	O
rebound	O
,	O
which	O
ensues	O
upon	O
GCS	O
withdrawal	O
.	O
The	O
Oct-2	B
transcription	I
factor	I
.	O
The	O
Oct-2	B
transcription	I
factor	I
is	O
a	O
member	O
of	O
the	O
POU	B
(	I
Pit	I
-	I
Oct	I
-	I
Unc	I
)	I
family	I
of	O
transcription	B
factors	I
and	O
is	O
expressed	O
only	O
in	O
B	O
lymphocytes	O
and	O
in	O
neuronal	O
cells	O
but	O
not	O
in	O
other	O
cell	O
types	O
.	O
The	O
primary	O
RNA	O
transcript	O
of	O
the	O
gene	O
is	O
subject	O
to	O
alternative	O
splicing	O
to	O
yield	O
different	O
variants	O
which	O
can	O
either	O
activate	O
or	O
repress	O
gene	O
expression	O
.	O
The	O
forms	O
produced	O
in	O
B	O
lymphocytes	O
have	O
a	O
predominantly	O
activating	O
effect	O
on	O
gene	O
expression	O
whereas	O
those	O
produced	O
in	O
neuronal	O
cells	O
have	O
a	O
predominantly	O
inhibitory	O
effect	O
and	O
can	O
repress	O
the	O
expression	O
of	O
both	O
the	O
herpes	O
simplex	O
virus	O
immediate	O
-	O
early	O
genes	O
and	O
the	O
cellular	O
tyrosine	O
hydroxylase	O
gene	O
.	O
Thus	O
Oct-2	B
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cellular	O
gene	O
expression	O
in	O
both	O
B	O
cells	O
and	O
neuronal	O
cells	O
as	O
well	O
as	O
in	O
the	O
control	O
of	O
viral	O
latency	O
.	O
Cell	O
specific	O
expression	O
of	O
human	O
Bruton	O
's	O
agammaglobulinemia	O
tyrosine	O
kinase	O
gene	O
(	O
Btk	B
)	O
is	O
regulated	O
by	O
Sp1-	B
and	O
Spi-1	B
/	I
PU.1-family	I
members	I
.	O
Bruton	B
's	I
agammaglobulinemia	I
tyrosine	I
kinase	I
(	O
Btk	B
)	O
is	O
a	O
cytoplasmic	B
tyrosine	I
kinase	I
involved	O
in	O
the	O
human	O
disease	O
X	O
-	O
linked	O
agammaglobulinemia	O
(	O
XLA	O
)	O
.	O
The	O
gene	O
is	O
expressed	O
in	O
all	O
hematopoietic	O
cells	O
with	O
the	O
exception	O
of	O
T	O
-	O
cells	O
and	O
plasma	O
cells	O
.	O
For	O
this	O
expression	O
pattern	O
the	O
first	O
280	O
bp	O
upstream	O
of	O
the	O
major	O
transcriptional	O
start	O
site	O
seems	O
to	O
be	O
sufficient	O
.	O
In	O
vitro	O
footprinting	O
analysis	O
within	O
this	O
part	O
of	O
the	O
promoter	O
revealed	O
two	O
Sp1	O
binding	O
sites	O
as	O
well	O
as	O
a	O
PU	O
-	O
box	O
.	O
The	O
transcription	B
factor	I
Spi-1	B
/	I
PU.1	I
as	O
well	O
as	O
the	O
closely	O
related	O
factor	O
Spi	B
-	I
B	I
bound	O
to	O
the	O
PU	O
-	O
box	O
in	O
B	O
-	O
cells	O
.	O
In	O
the	O
erythroleukemia	O
cell	O
line	O
K562	O
,	O
due	O
to	O
the	O
absence	O
of	O
Spi	B
-	I
B	I
,	O
only	O
PU.1	B
bound	O
to	O
the	O
Btk	O
promoter	O
.	O
Mutation	O
of	O
either	O
site	O
reduced	O
the	O
expression	O
in	O
transient	O
transfection	O
experiments	O
.	O
However	O
,	O
mutation	O
of	O
the	O
PU	O
box	O
had	O
no	O
effect	O
in	O
the	O
T	O
-	O
cell	O
line	O
Jurkat	O
,	O
where	O
none	O
of	O
the	O
Spi-1	B
family	I
members	I
is	O
expressed	O
.	O
In	O
addition	O
Spi	B
-	I
B	I
as	O
well	O
as	O
PU.1	B
were	O
able	O
to	O
transactivate	O
Btk	B
expression	O
.	O
In	O
fetal	O
liver	O
of	O
PU.1-	O
/	O
-	O
mice	O
,	O
which	O
lack	O
lymphoid	O
and	O
myeloid	O
cells	O
,	O
expression	O
of	O
Btk	B
was	O
reduced	O
two-	O
to	O
threefold	O
but	O
not	O
abolished	O
.	O
Collectively	O
this	O
study	O
shows	O
that	O
expression	O
of	O
the	O
Btk	O
gene	O
is	O
regulated	O
by	O
the	O
combined	O
action	O
of	O
Sp1-	B
and	I
PU.1-family	I
members	I
.	O
Sterol	O
dependent	O
LDL	O
-	O
receptor	O
gene	O
transcription	O
in	O
lymphocytes	O
from	O
normal	O
and	O
CML	O
patients	O
.	O
Sterol	O
regulatory	O
element	O
(	O
SRE	O
)	O
has	O
been	O
recognized	O
to	O
regulate	O
various	O
key	O
genes	O
coding	O
for	O
especially	O
low	B
density	I
lipoprotein	I
(	I
LDL	I
)	I
-receptor	I
,	O
3-hydroxy-3-methylglutaryl	B
coenzyme	I
A	I
(	I
HMG	I
-	I
CoA	I
)	I
reductase	I
and	O
HMG	B
-	I
CoA	I
synthase	I
known	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
cholesterol	O
feedback	O
mechanism	O
.	O
The	O
deranged	O
cholesterol	O
feedback	O
mechanism	O
has	O
been	O
widely	O
recognised	O
in	O
initiation	O
as	O
well	O
as	O
progression	O
of	O
various	O
types	O
of	O
cancers	O
including	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
.	O
Consequently	O
,	O
the	O
present	O
study	O
was	O
addressed	O
to	O
understand	O
this	O
phenomenon	O
and	O
revealed	O
the	O
existence	O
of	O
a	O
unique	B
47	I
kDa	I
protein	I
factor	I
having	O
affinity	O
for	O
this	O
SRE	O
sequence	O
in	O
lymphocytes	O
from	O
normal	O
subjects	O
as	O
well	O
as	O
its	O
absence	O
in	O
lymphocytes	O
from	O
untreated	O
CML	O
patients	O
.	O
However	O
,	O
this	O
factor	O
appeared	O
when	O
the	O
CML	O
patients	O
achieved	O
complete	O
haematological	O
remission	O
(	O
CHR	O
)	O
through	O
alpha	B
-	I
interferon	I
therapy	O
.	O
Further	O
,	O
an	O
inverse	O
relationship	O
was	O
also	O
observed	O
between	O
sterol	O
modulated	O
LDL	O
-	O
receptor	O
gene	O
transcription	O
and	O
the	O
binding	O
affinity	O
of	O
this	O
47	B
kDa	I
factor	I
to	O
the	O
SRE	O
sequence	O
.	O
Based	O
upon	O
these	O
results	O
we	O
propose	O
that	O
alpha	B
-	I
interferon	I
through	O
its	O
receptor	O
initiates	O
phosphatidic	O
acid	O
dependent	O
signalling	O
which	O
in	O
turn	O
regulates	O
the	O
affinity	O
of	O
47	B
kDa	I
sterol	I
regulatory	I
element	I
binding	I
factor	I
as	O
well	O
as	O
LDL	O
-	O
receptor	O
gene	O
transcription	O
in	O
lymphocytes	O
from	O
CML	O
patients	O
.	O
Effects	O
of	O
Ara	O
-	O
C	O
on	O
neutral	B
sphingomyelinase	I
and	O
mitogen-	B
and	I
stress-	I
activated	I
protein	I
kinases	I
in	O
T	O
-	O
lymphocyte	O
cell	O
lines	O
.	O
Neutral	B
sphingomyelinase	I
(	O
SMase	B
)	O
can	O
be	O
activated	O
by	O
extracellular	O
signals	O
to	O
produce	O
ceramide	O
,	O
which	O
may	O
affect	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
activities	O
.	O
Neutral	O
SMase	B
activity	O
was	O
assessed	O
in	O
membranes	O
from	O
Jurkat	O
,	O
a	O
human	O
T	O
-	O
cell	O
line	O
,	O
and	O
EL4	O
,	O
a	O
murine	O
T	O
-	O
cell	O
line	O
.	O
Ara	O
-	O
C	O
activated	O
SMase	B
with	O
10	O
minutes	O
in	O
both	O
Jurkat	O
and	O
EL4	O
cells	O
,	O
while	O
phorbol	O
ester	O
(	O
PMA	O
)	O
had	O
no	O
effect	O
.	O
PMA	O
,	O
but	O
not	O
Ara	O
-	O
C	O
or	O
ceramides	O
,	O
activated	O
ERK	B
MAPKS	I
,	O
in	O
Jurkat	O
and	O
EL4	O
.	O
PMA	O
acted	O
synergistically	O
with	O
ionomycin	O
to	O
activate	O
JNK	B
MAPKs	I
in	O
Jurkat	O
and	O
EL4	O
within	O
10	O
minutes	O
.	O
Ara	O
-	O
C	O
activated	O
JNKs	B
only	O
after	O
prolonged	O
incubation	O
(	O
90	O
-	O
120	O
minutes	O
)	O
.	O
Thus	O
,	O
ceramide	O
is	O
not	O
a	O
positive	O
signal	O
for	O
ERK	B
activation	O
in	O
T	O
-	O
cell	O
lines	O
.	O
The	O
effects	O
of	O
Ara	O
-	O
C	O
on	O
JNK	B
activity	O
may	O
be	O
mediated	O
through	O
secondary	O
response	O
pathways	O
.	O
Expression	O
of	O
Egr-1	B
correlates	O
with	O
the	O
transformed	O
phenotype	O
and	O
the	O
type	O
of	O
viral	O
latency	O
in	O
EBV	O
genome	O
positive	O
lymphoid	O
cell	O
lines	O
.	O
In	O
this	O
paper	O
we	O
have	O
investigated	O
the	O
role	O
of	O
Egr-1	B
in	O
B	O
cell	O
growth	O
regulation	O
by	O
examining	O
the	O
gene	O
expression	O
in	O
a	O
panel	O
of	O
B	O
cell	O
lines	O
,	O
including	O
both	O
EBV	O
genome	O
negative	O
and	O
EBV	O
carrying	O
cell	O
lines	O
.	O
Egr-1	B
expression	O
correlates	O
with	O
the	O
cellular	O
phenotype	O
and	O
the	O
specific	O
pattern	O
of	O
viral	O
latency	O
established	O
within	O
the	O
individual	O
cell	O
lines	O
.	O
Thus	O
,	O
constitutive	O
activation	O
of	O
Egr-1	B
gene	O
is	O
invariably	O
associated	O
with	O
unrestricted	O
expression	O
of	O
viral	O
latent	O
genes	O
in	O
all	O
group	O
III	O
EBV	O
genome	O
carrying	O
cell	O
lines	O
.	O
In	O
contrast	O
,	O
Egr-1	B
expression	O
is	O
abrogated	O
in	O
group	O
I	O
Burkitt	O
tumor	O
cells	O
,	O
irrespective	O
of	O
the	O
EBV	O
genome	O
carrying	O
status	O
.	O
Activated	O
viral	O
gene	O
expression	O
associated	O
with	O
phenotypic	O
conversion	O
of	O
group	O
I	O
cell	O
lines	O
in	O
to	O
group	O
II	O
or	O
III	O
restores	O
the	O
Egr-1	O
gene	O
expression	O
.	O
Several	O
forms	O
of	O
EGR-1	B
protein	I
are	O
found	O
within	O
the	O
different	O
groups	O
of	O
cell	O
lines	O
,	O
and	O
the	O
binding	O
activity	O
to	O
DNA	O
consensus	O
sequences	O
was	O
investigated	O
.	O
Finally	O
,	O
time	O
course	O
analysis	O
of	O
Egr-1	B
expression	O
during	O
the	O
early	O
steps	O
of	O
EBV	O
infection	O
in	O
vitro	O
demonstrated	O
that	O
Egr-1	B
is	O
upregulated	O
within	O
minutes	O
from	O
the	O
initial	O
interaction	O
with	O
the	O
B	O
lymphocyte	O
.	O
Induction	O
of	O
the	O
CD11b	O
gene	O
during	O
activation	O
of	O
the	O
monocytic	O
cell	O
line	O
U937	O
requires	O
a	O
novel	O
nuclear	B
factor	I
MS-2	B
[	O
published	O
erratum	O
appears	O
in	O
J	O
Immunol	O
1999	O
Jul	O
15	O
;	O
163	O
(	O
2	O
)	O
:	O
1091	O
]	O
The	O
differentiation	O
of	O
myeloid	O
precursors	O
into	O
mature	O
myelomonocytic	O
cells	O
is	O
characterized	O
by	O
the	O
induction	O
of	O
the	O
gene	O
encoding	O
the	O
beta2	B
integrin	I
CD11b	B
.	O
The	O
transcription	B
factors	I
Sp1	B
and	O
PU.1	B
prime	I
the	O
CD11b	O
promoter	O
,	O
but	O
the	O
nature	O
of	O
the	O
factors	O
responsible	O
for	O
its	O
inducible	O
expression	O
are	O
unknown	O
.	O
In	O
addition	O
to	O
the	O
CD11b	O
gene	O
,	O
the	O
homologous	O
genes	O
encoding	O
CD11a	B
and	O
CD11c	B
also	O
exhibit	O
inducible	O
expression	O
during	O
myeloid	O
differentiation	O
.	O
Therefore	O
,	O
we	O
compared	O
the	O
nucleotide	O
sequences	O
of	O
the	O
CD11a	O
,	O
CD11b	O
,	O
and	O
CD11c	O
gene	O
promoters	O
to	O
identify	O
common	O
elements	O
that	O
might	O
contribute	O
to	O
inducible	O
expression	O
.	O
This	O
analysis	O
identified	O
one	O
such	O
element	O
repeated	O
four	O
times	O
within	O
the	O
CD11b	O
promoter	O
.	O
Mutation	O
of	O
these	O
elements	O
indicated	O
that	O
two	O
,	O
MS-2beta	B
and	O
MS-2gamma	B
,	O
are	O
critical	O
to	O
the	O
induction	O
of	O
the	O
CD11b	O
gene	O
during	O
differentiation	O
of	O
the	O
pro	O
-	O
monocytic	O
cell	O
line	O
U937	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
indicate	O
that	O
MS-2beta	B
and	O
MS-2gamma	B
interact	O
with	O
nuclear	B
factors	I
that	O
are	O
induced	O
during	O
U937	O
differentiation	O
.	O
These	O
factors	O
are	O
detected	O
at	O
the	O
time	O
the	O
CD11b	O
promoter	O
is	O
activated	O
.	O
The	O
molecular	O
mass	O
of	O
these	O
factors	O
is	O
approximately	O
28	O
kDa	O
,	O
and	O
their	O
DNA	O
binding	O
characteristics	O
are	O
indistinguishable	O
from	O
those	O
of	O
the	O
novel	O
nuclear	B
factor	I
MS-2	B
.	O
Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
MS-2	B
mediates	O
induction	O
of	O
the	O
CD11b	O
gene	O
as	O
cells	O
of	O
the	O
monocytic	O
lineage	O
mature	O
.	O
The	O
presence	O
of	O
multiple	O
potential	O
binding	O
sites	O
for	O
MS-2	B
in	O
the	O
promoter	O
regions	O
of	O
a	O
wide	O
range	O
of	O
genes	O
expressed	O
in	O
mature	O
myeloid	O
cells	O
suggests	O
this	O
factor	O
plays	O
a	O
general	O
role	O
in	O
myeloid	O
differentiation	O
.	O
Mutation	O
of	O
tyrosines	O
492	O
/	O
493	O
in	O
the	O
kinase	B
domain	I
of	O
ZAP-70	B
affects	O
multiple	O
T	B
-	I
cell	I
receptor	I
signaling	O
pathways	O
.	O
The	O
protein	B
-	I
tyrosine	I
kinase	I
ZAP-70	B
is	O
implicated	O
,	O
together	O
with	O
the	O
Src	B
kinase	I
p56	B
(	I
lck	I
)	I
,	O
in	O
controlling	O
the	O
early	O
steps	O
of	O
the	O
T	O
-	O
cell	O
antigen	O
receptor	O
(	O
TCR	B
)	O
signaling	O
cascade	O
.	O
To	O
help	O
elucidate	O
further	O
the	O
mechanism	O
by	O
which	O
ZAP-70	B
regulates	O
these	O
initial	O
events	O
,	O
we	O
used	O
a	O
dominant	O
-	O
negative	O
mutant	O
approach	O
.	O
We	O
overexpressed	O
in	O
the	O
Jurkat	O
T	O
-	O
cell	O
line	O
ZAP-70	B
mutated	O
on	O
Tyr-492	O
and	O
Tyr-493	O
in	O
the	O
putative	O
regulatory	O
loop	O
of	O
its	O
kinase	B
domain	I
.	O
This	O
mutant	O
inhibited	O
TCR	B
-induced	O
activation	O
of	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
by	O
interfering	O
with	O
both	O
intracellular	O
calcium	O
increase	O
and	O
Ras	B
-regulated	O
activation	O
of	O
extracellular	B
signal	I
-	I
regulated	I
kinases	I
.	O
Moreover	O
,	O
TCR	B
-induced	O
phosphorylation	O
of	O
pp36	B
-	I
38	I
,	O
thought	O
to	O
play	O
a	O
role	O
upstream	O
of	O
these	O
pathways	O
,	O
was	O
found	O
to	O
be	O
reduced	O
.	O
In	O
contrast	O
,	O
overexpression	O
of	O
wild	B
-	I
type	I
ZAP-70	I
induced	O
constitutive	O
activation	O
of	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
.	O
The	O
ZAP-70	B
mutant	O
studied	O
here	O
could	O
be	O
phosphorylated	O
on	O
tyrosine	O
when	O
associated	O
to	O
the	O
TCR	B
zeta	I
chain	I
and	O
was	O
able	O
to	O
bind	O
p56	B
(	I
lck	I
)	I
.	O
This	O
result	O
demonstrates	O
that	O
Tyr-492	O
and	O
Tyr-493	O
are	O
not	O
responsible	O
for	O
the	O
Src	O
homology	O
domain	O
2-mediated	O
association	O
of	O
p56	B
(	I
lck	I
)	I
with	O
ZAP-70	B
.	O
Our	O
data	O
are	O
most	O
consistent	O
with	O
a	O
model	O
in	O
which	O
recruitment	O
to	O
the	O
TCR	B
allows	O
ZAP-70	B
autophosphorylation	O
and	O
binding	O
to	O
p56	B
(	I
lck	I
)	I
,	O
which	O
in	O
turn	O
phosphorylates	O
Tyr-492	O
and/or	O
Tyr-493	O
with	O
consequent	O
up	O
-	O
regulation	O
of	O
the	O
ZAP-70	B
kinase	O
activity	O
.	O
ZAP-70	B
will	O
then	O
be	O
able	O
to	O
effectively	O
control	O
phosphorylation	O
of	O
its	O
substrates	O
and	O
lead	O
to	O
gene	O
activation	O
.	O
Dexamethasone	O
suppression	O
test	O
:	O
corticosteroid	B
receptors	I
regulation	O
in	O
mononuclear	O
leukocytes	O
of	O
young	O
and	O
aged	O
subjects	O
.	O
The	O
dexamethasone	O
suppression	O
test	O
(	O
DST	O
)	O
is	O
considered	O
an	O
indicator	O
of	O
the	O
function	O
of	O
the	O
adrenal	O
pituitary	O
axis	O
.	O
The	O
effect	O
of	O
the	O
steroid	O
is	O
mediated	O
by	O
its	O
binding	O
to	O
corticosteroid	B
receptors	I
.	O
We	O
previously	O
suggested	O
that	O
the	O
measurement	O
of	O
corticosteroid	B
receptors	I
in	O
lymphocytes	O
is	O
an	O
index	O
of	O
an	O
analogous	O
pattern	O
in	O
brain	O
.	O
In	O
the	O
present	O
study	O
,	O
corticosteroid	B
Type	I
I	I
and	I
Type	I
II	I
receptors	I
in	O
mononuclear	O
leukocytes	O
were	O
measured	O
in	O
10	O
elderly	O
subjects	O
and	O
in	O
9	O
young	O
adults	O
,	O
before	O
and	O
after	O
overnight	O
DST	O
(	O
1	O
mg	O
)	O
.	O
Receptors	O
were	O
measured	O
by	O
radioreceptor	O
assay	O
.	O
In	O
all	O
the	O
subjects	O
,	O
dexamethasone	O
was	O
able	O
to	O
suppress	O
plasma	O
cortisol	O
.	O
The	O
number	O
of	O
Type	B
I	I
and	I
Type	I
II	I
receptors	I
before	O
the	O
test	O
was	O
lower	O
in	O
elderly	O
subjects	O
than	O
in	O
adults	O
.	O
In	O
the	O
control	O
group	O
,	O
dexamethasone	O
produced	O
a	O
significant	O
depression	O
of	O
Type	B
I	I
receptors	I
(	O
from	O
267	O
+	O
/-	O
72	O
to	O
169	O
+	O
/-	O
71	O
receptors	O
per	O
cell	O
)	O
,	O
which	O
can	O
be	O
interpreted	O
as	O
a	O
primary	O
involvement	O
of	O
Type	B
I	I
receptors	I
in	O
the	O
response	O
to	O
dexamethasone	O
;	O
Type	B
II	I
receptors	I
decreased	O
in	O
half	O
the	O
subjects	O
(	O
from	O
2849	O
+	O
/-	O
703	O
to	O
2345	O
+	O
/-	O
569	O
receptors	O
per	O
cell	O
)	O
.	O
In	O
elderly	O
healthy	O
subjects	O
,	O
Type	B
II	I
receptors	I
were	O
also	O
significantly	O
decreased	O
(	O
from	O
1796	O
+	O
/-	O
671	O
to	O
720	O
+	O
/-	O
345	O
)	O
.	O
We	O
suggest	O
that	O
in	O
young	O
subjects	O
Type	B
II	I
receptors	I
are	O
initially	O
up	O
-	O
regulated	O
by	O
dexamethasone	O
,	O
and	O
then	O
down	O
-	O
regulated	O
,	O
while	O
in	O
aged	O
subjects	O
an	O
up	O
-	O
regulation	O
can	O
not	O
be	O
achieved	O
,	O
as	O
suggested	O
by	O
the	O
higher	O
values	O
of	O
plasma	O
cortisol	O
usually	O
found	O
in	O
aging	O
subjects	O
.	O
A	O
novel	O
immunosuppressive	B
factor	I
in	O
bovine	O
colostrum	O
blocks	O
activation	O
of	O
the	O
interleukin	O
2	O
gene	O
enhancer	O
at	O
the	O
NFAT	O
site	O
.	O
A	O
factor	O
in	O
bovine	O
colostrum	O
(	O
colostrum	B
inhibitory	I
factor	I
,	O
CIF	B
)	O
inhibits	O
interleukin	B
2	I
(	O
IL2	B
)	O
production	O
in	O
activated	O
T	O
helper	O
cells	O
by	O
blocking	O
the	O
accumulation	O
of	O
IL2	O
mRNA	O
.	O
To	O
determine	O
whether	O
CIF	B
blocks	O
at	O
the	O
level	O
of	O
IL2	B
transcription	O
,	O
we	O
introduced	O
reporter	O
plasmids	O
into	O
the	O
human	O
T	O
leukemia	O
cell	O
line	O
Jurkat	O
by	O
transient	O
transfection	O
.	O
These	O
contained	O
the	O
luciferase	O
gene	O
under	O
the	O
control	O
of	O
either	O
the	O
human	O
IL2	O
upstream	O
enhancer	O
region	O
(	O
segments	O
-326	O
to	O
+	O
45	O
)	O
or	O
three	O
repeats	O
of	O
the	O
NFAT	O
element	O
contained	O
within	O
it	O
(	O
segments	O
-255	O
to	O
-285	O
)	O
.	O
Expression	O
of	O
luciferase	B
in	O
these	O
cells	O
was	O
induced	O
by	O
phorbol	O
myristate	O
acetate	O
plus	O
a	O
calcium	O
ionophore	O
.	O
CIF	B
inhibited	O
induction	O
of	O
either	O
construct	O
as	O
did	O
cyclosporine	O
,	O
which	O
is	O
known	O
to	O
block	O
activation	O
of	O
the	O
NFAT	B
element	I
.	O
CIF	B
failed	O
to	O
inhibit	O
several	O
other	O
enhancer	O
elements	O
.	O
The	O
NFAT	O
-	O
controlled	O
luciferase	O
gene	O
system	O
distinguishes	O
CIF	B
from	O
other	O
T	O
cell	O
inhibitory	O
activities	O
present	O
in	O
colostrum	O
,	O
in	O
particular	O
,	O
TGF	B
beta	I
1	I
and	O
TGF	B
beta	I
2	I
and	O
the	O
glucocorticoids	O
.	O
Stably	O
transfected	O
Jurkat	O
cells	O
behaved	O
similarly	O
to	O
the	O
transiently	O
transfected	O
ones	O
with	O
respect	O
to	O
inhibition	O
by	O
CIF	B
and	O
cyclosporine	O
.	O
The	O
NFAT	B
-luc	O
assay	O
is	O
a	O
useful	O
technique	O
for	O
the	O
rapid	O
,	O
sensitive	O
measurement	O
of	O
CIF	B
or	O
other	O
immunosuppressants	O
with	O
a	O
similar	O
mode	O
of	O
action	O
.	O
Synergistic	O
interactions	O
between	O
overlapping	O
binding	O
sites	O
for	O
the	O
serum	B
response	I
factor	I
and	O
ELK-1	B
proteins	I
mediate	O
both	O
basal	O
enhancement	O
and	O
phorbol	O
ester	O
responsiveness	O
of	O
primate	O
cytomegalovirus	O
major	O
immediate	O
-	O
early	O
promoters	O
in	O
monocyte	O
and	O
T	O
-	O
lymphocyte	O
cell	O
types	O
.	O
Cytomegalovirus	O
(	O
CMV	O
)	O
infection	O
is	O
nonpermissive	O
or	O
persistent	O
in	O
many	O
lymphoid	O
and	O
myeloid	O
cell	O
types	O
but	O
can	O
be	O
activated	O
in	O
differentiated	O
macrophages	O
.	O
We	O
have	O
shown	O
elsewhere	O
that	O
both	O
the	O
major	O
immediate	O
-	O
early	O
gene	O
(	O
MIE	O
)	O
and	O
lytic	O
cycle	O
infectious	O
progeny	O
virus	O
expression	O
can	O
be	O
induced	O
in	O
otherwise	O
nonpermissive	O
monocyte	O
-	O
like	O
U-937	O
cell	O
cultures	O
infected	O
with	O
either	O
human	O
CMV	O
(	O
HCMV	O
)	O
or	O
simian	O
CMV	O
(	O
SCMV	O
)	O
by	O
treatment	O
with	O
the	O
phorbol	O
ester	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O
Two	O
multicopy	O
basal	O
enhancer	O
motifs	O
within	O
the	O
SCMV	O
MIE	O
enhancer	O
,	O
namely	O
,	O
11	O
copies	O
of	O
the	O
16-bp	O
cyclic	O
AMP	O
response	O
element	O
(	O
CRE	O
)	O
and	O
3	O
copies	O
of	O
novel	O
17-bp	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
binding	O
sites	O
referred	O
to	O
as	O
the	O
SNE	O
(	O
SRF	O
/	O
NFkappaB	O
-	O
like	O
element	O
)	O
,	O
as	O
well	O
as	O
four	O
classical	O
NFkappaB	O
sites	O
within	O
the	O
HCMV	O
version	O
,	O
contribute	O
to	O
TPA	O
responsiveness	O
in	O
transient	O
assays	O
in	O
monocyte	O
and	O
T	O
-	O
cell	O
types	O
.	O
The	O
SCMV	O
SNE	O
sites	O
contain	O
potential	O
overlapping	O
core	O
recognition	O
binding	O
motifs	O
for	O
SRF	B
,	O
Rel	B
/	I
NFkappaB	I
,	O
ETS	B
,	O
and	O
YY1	B
class	I
transcription	I
factors	I
but	O
fail	O
to	O
respond	O
to	O
either	O
serum	B
or	I
tumor	I
necrosis	I
factor	I
alpha	I
.	O
Therefore	O
,	O
to	O
evaluate	O
the	O
mechanism	O
of	O
TPA	O
responsiveness	O
of	O
the	O
SNE	O
motifs	O
and	O
of	O
a	O
related	O
16-bp	O
SEE	O
(	O
SRF	O
/	O
ETS	O
element	O
)	O
motif	O
found	O
in	O
the	O
HCMV	O
and	O
chimpanzee	O
CMV	O
MIE	O
enhancers	O
,	O
we	O
have	O
examined	O
the	O
functional	O
responses	O
and	O
protein	O
binding	O
properties	O
of	O
multimerized	O
wild	O
-	O
type	O
and	O
mutant	O
elements	O
added	O
upstream	O
to	O
the	O
SCMV	O
MIE	O
or	O
simian	O
virus	O
40	O
minimal	O
promoter	O
regions	O
in	O
the	O
U-937	O
,	O
K-562	O
,	O
HL-60	O
,	O
THP-1	O
,	O
and	O
Jurkat	O
cell	O
lines	O
.	O
Unlike	O
classical	O
NFkappaB	O
sites	O
,	O
neither	O
the	O
SNE	O
nor	O
the	O
SEE	O
motif	O
responded	O
to	O
phosphatase	O
inhibition	O
by	O
okadaic	O
acid	O
.	O
However	O
,	O
the	O
TPA	O
responsiveness	O
of	O
both	O
CMV	O
elements	O
proved	O
to	O
involve	O
synergistic	O
interactions	O
between	O
the	O
core	O
SRF	O
binding	O
site	O
(	O
CCATATATGG	O
)	O
and	O
the	O
adjacent	O
inverted	O
ETS	O
binding	O
motifs	O
(	O
TTCC	O
)	O
,	O
which	O
correlated	O
directly	O
with	O
formation	O
of	O
a	O
bound	O
tripartite	B
complex	I
containing	O
both	O
the	O
cellular	O
SRF	B
and	O
ELK-1	B
proteins	I
.	O
This	O
protein	B
complex	I
was	O
more	O
abundant	O
in	O
U-937	O
,	O
K-562	O
,	O
and	O
HeLa	O
cell	O
extracts	O
than	O
in	O
Raji	O
,	O
HF	O
,	O
BALB	O
/	O
c	O
3T3	O
,	O
or	O
HL-60	O
cells	O
,	O
but	O
the	O
binding	O
activity	O
was	O
altered	O
only	O
twofold	O
after	O
TPA	O
treatment	O
.	O
A	O
40-fold	O
stimulation	O
of	O
chloramphenicol	B
acetyltransferase	I
activity	O
mediated	O
by	O
four	O
tandem	O
repeats	O
of	O
the	O
SNE	O
could	O
be	O
induced	O
within	O
2	O
h	O
(	O
and	O
up	O
to	O
250-fold	O
within	O
6	O
h	O
)	O
after	O
addition	O
of	O
TPA	O
in	O
DNA	O
-	O
transfected	O
U-937	O
cells	O
,	O
indicating	O
that	O
the	O
stimulation	O
appeared	O
likely	O
to	O
be	O
a	O
true	O
protein	B
kinase	I
C	I
-mediated	O
signal	O
transduction	O
event	O
rather	O
than	O
a	O
differentiation	O
response	O
.	O
Slight	O
differences	O
in	O
the	O
sequence	O
of	O
the	O
core	O
SRF	O
binding	O
site	O
compared	O
with	O
that	O
of	O
the	O
classical	O
c	O
-	O
Fos	O
promoter	O
serum	O
response	O
element	O
,	O
together	O
with	O
differences	O
in	O
the	O
spacing	O
between	O
the	O
SRF	O
and	O
ETS	O
motifs	O
,	O
appear	O
to	O
account	O
for	O
the	O
inability	O
of	O
the	O
SCMV	O
SNEs	O
to	O
respond	O
to	O
serum	O
induction	O
.	O
Energy	O
substrates	O
,	O
hormone	O
responses	O
and	O
glucocorticoid	O
binding	O
in	O
lymphocytes	O
during	O
intense	O
physical	O
exercise	O
in	O
humans	O
following	O
phosphocreatine	O
administration	O
.	O
Eight	O
healthy	O
untrained	O
male	O
volunteers	O
pedalled	O
a	O
cycle	O
ergometer	O
according	O
to	O
two	O
exercise	O
protocols	O
:	O
the	O
first	O
involved	O
step	O
-	O
wise	O
increasing	O
physical	O
exercise	O
to	O
maximal	O
(	O
MPE	O
)	O
;	O
the	O
second	O
involved	O
prolonged	O
(	O
35	O
min	O
)	O
submaximal	O
physical	O
exercise	O
(	O
PPE	O
)	O
at	O
70	O
%	O
of	O
the	O
individual	O
's	O
maximal	O
oxygen	O
uptake	O
.	O
Each	O
volunteer	O
performed	O
these	O
exercise	O
twice	O
,	O
following	O
either	O
an	O
intravenous	O
injection	O
of	O
phosphocreatine	O
(	O
PCr	O
)	O
or	O
a	O
placebo	O
of	O
an	O
isotonic	O
NaCl	O
solution	O
.	O
Anaerobic	O
threshold	O
(	O
AT	O
)	O
was	O
determined	O
from	O
the	O
point	O
of	O
departure	O
of	O
the	O
ventilatory	O
response	O
from	O
linearity	O
and	O
from	O
the	O
sudden	O
increase	O
in	O
venous	O
blood	O
lactate	O
concentrations	O
during	O
MPE	O
.	O
After	O
exercise	O
following	O
placebo	O
administration	O
we	O
observed	O
increases	O
in	O
concentrations	O
of	O
blood	O
substrates	O
,	O
plasma	B
adrenocorticotropin	I
(	O
ACTH	B
)	O
,	O
growth	O
hormone	O
and	O
cortisol	O
and	O
in	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
in	O
lymphocytes	O
without	O
changes	O
in	O
the	O
dissociation	O
constant	O
.	O
Intravenous	O
administration	O
of	O
PCr	O
(	O
starting	O
1	O
day	O
before	O
exercise	O
)	O
led	O
to	O
an	O
increase	O
in	O
the	O
total	O
workload	O
(	O
on	O
average	O
by	O
5.8	O
%	O
)	O
and	O
in	O
AT	O
(	O
on	O
average	O
by	O
6.8	O
%	O
)	O
during	O
MPE	O
and	O
to	O
a	O
better	O
tolerance	O
of	O
exercise	O
during	O
PPE	O
.	O
Following	O
PCr	O
administration	O
we	O
observed	O
lower	O
blood	O
lactate	O
concentrations	O
and	O
different	O
patterns	O
of	O
some	O
enzyme	O
activities	O
,	O
less	O
pronounced	O
changes	O
in	O
plasma	B
ACTH	I
and	O
cortisol	O
concentrations	O
and	O
in	O
glucocorticoid	O
binding	O
in	O
lymphocytes	O
,	O
but	O
no	O
changes	O
in	O
plasma	O
growth	O
hormone	O
concentrations	O
compared	O
to	O
the	O
placebo	O
.	O
The	O
results	O
showed	O
that	O
intense	O
physical	O
exercise	O
led	O
not	O
only	O
to	O
increases	O
in	O
blood	O
hormone	O
concentrations	O
but	O
also	O
to	O
an	O
increase	O
in	O
the	O
density	O
of	O
glucocorticoid	B
receptors	I
in	O
lymphocytes	O
.	O
Intravenous	O
PCr	O
injection	O
led	O
to	O
smaller	O
changes	O
in	O
ACTH	B
and	O
cortisol	O
concentrations	O
as	O
well	O
as	O
to	O
a	O
lower	O
activation	O
of	O
glucocorticoid	O
binding	O
in	O
lymphocytes	O
.	O
Acetylsalicylic	O
acid	O
and	O
sodium	O
salicylate	O
inhibit	O
LPS	O
-	O
induced	O
NF	B
-	I
kappa	I
B	I
/	I
c	I
-	I
Rel	I
nuclear	O
translocation	O
,	O
and	O
synthesis	O
of	O
tissue	B
factor	I
(	O
TF	B
)	O
and	O
tumor	B
necrosis	I
factor	I
alfa	I
(	O
TNF	B
-	I
alpha	I
)	O
in	O
human	O
monocytes	O
.	O
We	O
have	O
investigated	O
the	O
effects	O
of	O
acetylsalicylic	O
acid	O
and	O
sodium	O
salicylate	O
on	O
the	O
LPS	O
-	O
induced	O
synthesis	O
of	O
the	O
pro	O
-	O
coagulant	O
protein	O
tissue	O
factor	O
(	O
TF	O
)	O
and	O
the	O
pro	O
-	O
inflammatory	O
protein	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	B
-	I
alpha	I
)	O
,	O
as	O
well	O
as	O
the	O
prostaglandin	B
PGE2	I
in	O
human	O
monocytes	O
.	O
Both	O
drugs	O
dose	O
-	O
dependently	O
inhibited	O
LPS	B
-	I
induced	I
TF	I
and	O
TNF	B
-	I
alpha	I
synthesis	O
at	O
the	O
mRNA	O
and	O
the	O
protein	O
level	O
,	O
and	O
reduced	O
PGE2	B
production	O
.	O
As	O
evidenced	O
by	O
electro	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
the	O
use	O
of	O
a	O
NF	O
-	O
kappa	O
B	O
prototypic	O
probe	O
,	O
these	O
drugs	O
probably	O
exert	O
their	O
inhibitory	O
effects	O
by	O
interference	O
with	O
the	O
nuclear	O
translocation	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
c	I
-	I
Rel	I
proteins	I
.	O
These	O
data	O
may	O
expand	O
the	O
understanding	O
of	O
the	O
anti	O
-	O
thrombotic	O
and	O
anti	O
-	O
inflammatory	O
effects	O
of	O
these	O
drugs	O
when	O
activation	O
of	O
monocytes	O
occurs	O
.	O
Octamer	O
independent	O
activation	O
of	O
transcription	O
from	O
the	O
kappa	O
immunoglobulin	O
germline	O
promoter	O
.	O
Previous	O
analyses	O
of	O
immunoglobulin	O
V	O
region	O
promoters	O
has	O
led	O
to	O
the	O
discovery	O
of	O
a	O
common	O
octamer	O
motif	O
which	O
is	O
functionally	O
important	O
in	O
the	O
tissue	O
-	O
specific	O
and	O
developmentally	O
regulated	O
transcriptional	O
activation	O
of	O
immunoglobulin	O
genes	O
.	O
The	O
germline	O
promoters	O
(	O
Ko	O
)	O
located	O
upstream	O
of	O
the	O
J	O
region	O
gene	O
segments	O
of	O
the	O
kappa	O
locus	O
also	O
contain	O
an	O
octamer	O
motif	O
(	O
containing	O
a	O
single	O
base	O
pair	O
mutation	O
and	O
referred	O
to	O
as	O
the	O
variant	O
octamer	O
)	O
which	O
has	O
been	O
shown	O
previously	O
to	O
bind	O
Oct-1	B
and	O
Oct-2	B
transcription	B
factors	I
in	O
vitro	O
.	O
To	O
further	O
elucidate	O
the	O
role	O
of	O
this	O
variant	O
octamer	O
motif	O
in	O
the	O
regulation	O
of	O
germline	O
transcription	O
from	O
the	O
unrearranged	O
kappa	O
locus	O
,	O
we	O
have	O
quantitated	O
the	O
relative	O
binding	O
affinity	O
of	O
Oct-1	B
and	O
Oct-2	B
for	O
the	O
variant	O
octamer	O
motif	O
and	O
determined	O
the	O
functional	O
role	O
of	O
this	O
octamer	O
motif	O
in	O
transcriptional	O
activation	O
.	O
We	O
find	O
that	O
,	O
although	O
the	O
variant	O
octamer	O
motif	O
binds	O
Oct-1	B
and	O
Oct-2	B
in	O
vitro	O
with	O
5-fold	O
lower	O
affinity	O
than	O
the	O
consensus	O
octamer	O
motif	O
,	O
mutation	O
of	O
the	O
variant	O
octamer	O
motif	O
to	O
either	O
a	O
consensus	O
octamer	O
or	O
non	O
-	O
octamer	O
motif	O
has	O
no	O
effect	O
on	O
transcriptional	O
activation	O
from	O
the	O
germline	O
promoter	O
.	O
We	O
also	O
find	O
significant	O
differences	O
in	O
activation	O
of	O
germline	O
and	O
V	O
region	O
promoters	O
by	O
kappa	O
enhancers	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
germline	O
promoters	O
and	O
V	O
region	O
promoters	O
differ	O
in	O
their	O
dependence	O
on	O
octamer	O
for	O
activation	O
and	O
respond	O
differently	O
to	O
enhancer	O
activation	O
.	O
These	O
findings	O
have	O
important	O
implications	O
in	O
regulation	O
of	O
germline	O
transcription	O
as	O
well	O
as	O
concomitant	O
activation	O
of	O
the	O
V	O
-	O
J	O
recombination	O
of	O
the	O
kappa	O
light	O
chain	O
locus	O
.	O
Characterization	O
of	O
the	O
murine	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
gene	O
p27Kip1	O
.	O
The	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p27Kip1	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
cell	O
-	O
cycle	O
progression	O
.	O
p27Kip1	O
directly	O
inhibits	O
the	O
catalytic	O
activity	O
of	O
cyclin	B
/	I
cdks	I
(	I
cyclin	I
-	I
dependent	I
kinase	I
)	I
complexes	I
and/or	O
interferes	O
physically	O
with	O
cyclin	B
/	I
cdks	I
activation	O
by	O
CAK	B
.	O
Interestingly	O
,	O
the	O
expression	O
level	O
of	O
p27Kip1	O
mRNA	O
was	O
maximal	O
in	O
resting	O
Go	O
T	O
-	O
cells	O
and	O
rapidly	O
declined	O
following	O
anti	B
-	I
CD3	I
activation	O
.	O
We	O
report	O
here	O
the	O
cloning	O
of	O
p27Kip1	O
gene	O
from	O
murine	O
genomic	O
DNA	O
and	O
the	O
functional	O
analysis	O
of	O
the	O
promoter	O
of	O
the	O
p27Kip1	O
gene	O
.	O
The	O
gene	O
consists	O
of	O
at	O
least	O
three	O
exons	O
and	O
spans	O
more	O
than	O
5.6	O
kb	O
of	O
DNA	O
.	O
Primer	O
extension	O
and	O
nuclease	O
S1	O
protection	O
analysis	O
revealed	O
two	O
major	O
transcription	O
initiation	O
sites	O
.	O
The	O
promoter	O
region	O
lacked	O
a	O
TATA	O
box	O
but	O
contained	O
potential	O
binding	O
sites	O
for	O
the	O
transcriptional	B
factors	I
including	O
two	O
Sp1	B
,	O
CRE	B
,	O
Myb	B
and	O
NFkB	B
located	O
at	O
positions	O
-153	O
,	O
-178	O
,	O
-286	O
,	O
-875	O
,	O
and	O
-1011	O
,	O
respectively	O
.	O
To	O
analyze	O
the	O
regulatory	O
mechanisms	O
controlling	O
p27Kip1	O
gene	O
expression	O
,	O
we	O
characterized	O
the	O
5'-flanking	O
region	O
from	O
nt	O
-1609	O
to	O
+	O
178	O
.	O
The	O
-326	O
to	O
-615	O
region	O
contained	O
positive	O
regulatory	O
elements	O
.	O
The	O
state	O
of	O
maturation	O
of	O
monocytes	O
into	O
macrophages	O
determines	O
the	O
effects	O
of	O
IL-4	B
and	O
IL-13	B
on	O
HIV	O
replication	O
.	O
The	O
molecular	O
mechanisms	O
of	O
the	O
effects	O
of	O
IL-4	B
and	O
IL-13	B
on	O
HIV	O
infection	O
in	O
human	O
monocytes	O
as	O
they	O
matured	O
into	O
monocyte	O
-	O
derived	O
macrophages	O
over	O
7	O
days	O
were	O
investigated	O
using	O
HIV-1	O
(	O
BaL	O
)	O
,	O
and	O
low	O
passage	O
clinical	O
strains	O
.	O
IL-4	B
and	O
IL-13	B
up	O
-	O
regulated	O
the	O
expression	O
of	O
both	O
genomic	O
and	O
spliced	O
HIV	O
mRNA	O
in	O
monocytes	O
cultured	O
on	O
Teflon	O
,	O
as	O
determined	O
by	O
Northern	O
analysis	O
and	O
p24	B
Ag	I
assay	O
.	O
Using	O
a	O
nuclear	O
run	O
-	O
on	O
assay	O
,	O
IL-4	B
stimulation	O
was	O
shown	O
to	O
enhance	O
transcription	O
by	O
two-	O
to	O
threefold	O
.	O
IL-4	B
stimulated	O
nuclear	B
factor	I
-	I
kappaB	I
nuclear	O
translocation	O
and	O
binding	O
before	O
enhancement	O
of	O
HIV	O
RNA	O
expression	O
.	O
Conversely	O
,	O
IL-4	B
and	O
IL-13	B
markedly	O
and	O
significantly	O
inhibited	O
HIV	O
replication	O
at	O
the	O
transcriptional	O
level	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
,	O
and	O
this	O
occurred	O
whether	O
these	O
cytokines	B
were	O
added	O
before	O
or	O
after	O
HIV	O
infection	O
.	O
The	O
reversal	O
from	O
stimulation	O
to	O
inhibition	O
occurred	O
after	O
3	O
to	O
5	O
days	O
of	O
adherence	O
to	O
plastic	O
.	O
IL-4	B
had	O
no	O
significant	O
effect	O
on	O
HIV	O
reverse	O
transcription	O
.	O
The	O
effect	O
of	O
both	O
cytokines	B
on	O
the	O
monocyte	O
maturation	O
/	O
differentiation	O
(	O
CD11b	B
,	O
CD13	B
,	O
and	O
CD26	B
)	O
and	O
other	O
macrophage	B
markers	I
(	O
CD14	B
and	O
CD68	B
)	O
was	O
examined	O
.	O
IL-4	B
enhanced	O
CD11b	B
,	O
but	O
inhibited	O
CD26	B
expression	O
and	O
delayed	O
CD13	B
loss	O
.	O
IL-13	B
had	O
similar	O
effects	O
on	O
CD11b	B
and	O
CD13	B
,	O
but	O
no	O
effect	O
on	O
CD26	B
.	O
Hence	O
,	O
these	O
cytokines	B
do	O
not	O
simply	O
enhance	O
monocyte	O
differentiation	O
,	O
but	O
have	O
complex	O
and	O
slightly	O
divergent	O
effects	O
that	O
impact	O
on	O
HIV	O
replication	O
probably	O
through	O
cell	O
signaling	O
pathways	O
and	O
nuclear	B
factor	I
-	I
kappaB	I
translocation	O
.	O
Effects	O
of	O
glucocorticoids	O
on	O
lymphocyte	O
activation	O
in	O
patients	O
with	O
steroid	O
-	O
sensitive	O
and	O
steroid	O
-	O
resistant	O
asthma	O
.	O
BACKGROUND	O
:	O
Glucocorticoids	O
are	O
important	O
medications	O
used	O
to	O
control	O
the	O
airway	O
inflammation	O
associated	O
with	O
asthma	O
.	O
Synthetic	O
glucocorticoids	O
vary	O
in	O
their	O
binding	O
affinity	O
for	O
the	O
glucocorticoid	O
receptor	O
(	O
GCR	O
)	O
.	O
METHODS	O
:	O
We	O
compared	O
hydrocortisone	O
,	O
beclomethasone	O
dipropionate	O
,	O
triamcinolone	O
acetonide	O
,	O
flunisolide	O
,	O
and	O
budesonide	O
with	O
regard	O
to	O
their	O
capacity	O
to	O
inhibit	O
phytohemagglutinin	B
-induced	O
peripheral	O
blood	O
mononuclear	O
cell	O
proliferation	O
from	O
six	O
patients	O
with	O
steroid	O
-	O
sensitive	O
asthma	O
and	O
seven	O
patients	O
with	O
steroid	O
-	O
resistant	O
asthma	O
.	O
Peripheral	O
blood	O
mononuclear	O
cell	O
GCR	B
binding	O
affinities	O
for	O
dexamethasone	O
and	O
budesonide	O
were	O
also	O
determined	O
for	O
both	O
patient	O
groups	O
by	O
using	O
a	O
radioligand	O
binding	O
assay	O
and	O
Scatchard	O
analysis	O
.	O
RESULTS	O
:	O
Dose	O
-	O
dependent	O
inhibition	O
was	O
demonstrated	O
for	O
all	O
glucocorticoids	O
in	O
both	O
patient	O
groups	O
,	O
with	O
the	O
steroid	O
-	O
resistant	O
group	O
requiring	O
approximately	O
2	O
log	O
-	O
fold	O
more	O
glucocorticoids	O
for	O
an	O
equivalent	O
degree	O
of	O
inhibition	O
.	O
The	O
mean	O
concentrations	O
necessary	O
to	O
cause	O
50	O
%	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
(	O
IC50s	O
)	O
for	O
the	O
steroid	O
-	O
sensitive	O
group	O
ranged	O
from	O
2	O
x	O
10	O
(	O
-10	O
)	O
mol	O
/	O
L	O
for	O
budesonide	O
to	O
7	O
x	O
10	O
(	O
-8	O
)	O
mol	O
/	O
L	O
for	O
hydrocortisone	O
,	O
whereas	O
the	O
mean	O
IC50s	O
for	O
the	O
steroid	O
-	O
resistant	O
group	O
ranged	O
from	O
approximately	O
2	O
x	O
10	O
(	O
-8	O
)	O
mol	O
/	O
L	O
for	O
budesonide	O
to	O
greater	O
than	O
10	O
(	O
-6	O
)	O
mol	O
/	O
L	O
for	O
hydrocortisone	O
.	O
In	O
addition	O
,	O
a	O
significant	O
correlation	O
was	O
noted	O
between	O
the	O
degree	O
of	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
(	O
IC50	O
)	O
and	O
the	O
binding	O
affinity	O
of	O
dexamethasone	O
to	O
the	O
GCR	B
.	O
Patients	O
with	O
steroid	O
-	O
resistant	O
asthma	O
have	O
been	O
shown	O
to	O
have	O
a	O
reduced	O
GCR	B
binding	O
affinity	O
.	O
The	O
GCR	B
binding	O
affinity	O
for	O
budesonide	O
was	O
significantly	O
higher	O
in	O
both	O
groups	O
(	O
i.e.	O
,	O
lower	O
dissociation	O
constant	O
)	O
than	O
that	O
obtained	O
for	O
dexamethasone	O
.	O
CONCLUSION	O
:	O
These	O
data	O
suggest	O
that	O
glucocorticoids	O
such	O
as	O
budesonide	O
,	O
by	O
virtue	O
of	O
their	O
high	O
GCR	B
binding	O
affinities	O
and	O
greater	O
ability	O
to	O
suppress	O
lymphocyte	O
proliferation	O
,	O
may	O
therefore	O
be	O
beneficial	O
in	O
the	O
management	O
of	O
difficult	O
-	O
to	O
-	O
control	O
asthma	O
.	O
Involvement	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
activation	O
in	O
IgE	B
synthesis	O
in	O
human	O
B	O
cells	O
.	O
Nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
is	O
a	O
transcription	O
factor	O
that	O
binds	O
to	O
the	O
consensus	O
DNA	O
sequence	O
in	O
the	O
cis	O
-	O
acting	O
elements	O
of	O
various	O
genes	O
.	O
Although	O
NF	B
-	I
kappa	I
B	I
activates	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
the	O
induction	O
of	O
IgE	O
synthesis	O
in	O
human	O
B	O
cells	O
.	O
Therefore	O
we	O
first	O
examined	O
the	O
participation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
germline	O
C	O
epsilon	O
transcription	O
in	O
a	O
human	O
Burkitt	O
lymphoma	O
B	O
cell	O
line	O
,	O
DND39	O
.	O
Stimulation	O
of	O
DND39	O
cells	O
with	O
IL-4	B
or	O
anti	B
-	I
CD40	I
monoclonal	I
antibody	I
(	O
mAb	B
)	O
activated	O
phosphatidylinositol	B
3-kinase	I
and	O
subsequently	O
induced	O
nuclear	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
which	O
was	O
identified	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
n	O
-	O
Acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
,	O
a	O
potent	O
antioxidant	O
,	O
blocked	O
NF	B
-	I
kappa	I
B	I
activation	O
caused	O
by	O
IL-4	B
and	O
by	O
anti	B
-	I
CD40	I
mAb	I
.	O
Although	O
inhibition	O
of	O
IL-4-driven	O
germline	O
C	O
epsilon	O
transcription	O
by	O
NAC	O
was	O
not	O
sufficient	O
,	O
the	O
agent	O
remarkably	O
diminished	O
anti	B
-	I
CD40	I
mAb	I
-mediated	O
up	O
-	O
regulation	O
of	O
germline	O
C	O
epsilon	O
transcription	O
.	O
Second	O
,	O
we	O
studied	O
the	O
effect	O
of	O
NAC	O
on	O
IgE	B
synthesis	O
in	O
human	O
normal	O
B	O
cells	O
costimulated	O
with	O
IL-4	B
and	O
anti	B
-	I
CD40	I
mAb	I
.	O
NAC	O
was	O
effective	O
in	O
inhibiting	O
mature	O
C	O
epsilon	O
transcription	O
and	O
IgE	B
synthesis	O
in	O
the	O
T	O
cell	O
-	O
independent	O
culture	O
system	O
.	O
However	O
,	O
NAC	O
did	O
not	O
significantly	O
affect	O
the	O
spontaneous	O
production	O
of	O
IgE	B
by	O
atopic	O
B	O
cells	O
.	O
These	O
results	O
indicate	O
that	O
NF	B
-	I
kappa	I
B	I
activity	O
is	O
commonly	O
inducible	O
in	O
DND39	O
cells	O
by	O
IL-4	B
and	O
anti	B
-	I
CD40	I
mAb	I
and	O
suggest	O
that	O
NF	B
-	I
kappa	I
B	I
sensitive	O
to	O
NAC	O
may	O
play	O
a	O
role	O
in	O
regulating	O
IgE	B
synthesis	O
in	O
B	O
cells	O
.	O
[	O
Molecular	O
mechanisms	O
of	O
age	O
-	O
related	O
lymphocyte	O
dysfunction	O
]	O
Aging	O
is	O
classically	O
accompanied	O
by	O
a	O
dysregulation	O
of	O
the	O
immunologic	O
machinery	O
.	O
As	O
a	O
consequence	O
,	O
the	O
immune	O
response	O
developed	O
in	O
senescent	O
organisms	O
is	O
usually	O
inappropriate	O
,	O
often	O
inefficient	O
,	O
sometimes	O
aberrant	O
,	O
and	O
potentially	O
detrimental	O
.	O
The	O
age	O
-	O
associated	O
immune	O
dysfunction	O
may	O
be	O
implicated	O
to	O
some	O
degree	O
in	O
the	O
extreme	O
susceptibility	O
of	O
the	O
elderly	O
to	O
infection	O
and	O
neoplasia	O
and	O
may	O
even	O
participate	O
in	O
various	O
aspects	O
of	O
senescence	O
.	O
The	O
current	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
underlying	O
immunosenescence	O
is	O
still	O
fragmentary	O
.	O
The	O
most	O
extensively	O
studied	O
phenomenon	O
is	O
the	O
progressive	O
decline	O
in	O
the	O
proliferative	O
capacities	O
of	O
T	O
lymphocytes	O
with	O
aging	O
.	O
The	O
loss	O
of	O
proliferative	O
potential	O
in	O
response	O
to	O
antigenic	O
challenge	O
is	O
a	O
characteristic	O
feature	O
of	O
immune	O
senescence	O
.	O
It	O
is	O
directly	O
implicated	O
in	O
the	O
emergence	O
of	O
the	O
age	O
-	O
related	O
immune	O
deficiency	O
.	O
The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
show	O
how	O
the	O
accumulation	O
of	O
various	O
biochemical	O
lesions	O
with	O
advancing	O
age	O
leads	O
to	O
the	O
failure	O
of	O
a	O
critical	O
cell	O
function	O
,	O
namely	O
the	O
activation	O
-	O
induced	O
lymphocyte	O
proliferation	O
.	O
The	O
biochemical	O
modifications	O
responsible	O
for	O
the	O
defect	O
in	O
transduction	O
and	O
execution	O
of	O
the	O
proliferative	O
signal	O
are	O
analyzed	O
as	O
a	O
function	O
of	O
age	O
.	O
The	O
multiple	O
alterations	O
observed	O
on	O
the	O
various	O
biochemical	O
pathways	O
may	O
appear	O
as	O
a	O
consequence	O
of	O
a	O
unique	O
deleterious	O
mechanism	O
more	O
fundamentally	O
related	O
to	O
the	O
process	O
of	O
senescence	O
such	O
as	O
the	O
inability	O
to	O
cope	O
with	O
oxidative	O
stress	O
.	O
Engagement	O
of	O
the	O
Lewis	O
X	O
antigen	O
(	O
CD15	O
)	O
results	O
in	O
monocyte	O
activation	O
.	O
We	O
previously	O
reported	O
that	O
monocyte	O
adhesion	O
to	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
-treated	O
endothelial	O
cells	O
increased	O
expression	O
of	O
tissue	O
factor	O
and	O
CD36	B
on	O
monocytes	O
.	O
Using	O
immunological	O
cross	O
-	O
linking	O
to	O
mimic	O
receptor	O
engagement	O
by	O
natural	O
ligands	O
,	O
we	O
now	O
show	O
that	O
CD15	O
(	O
Lewis	O
X	O
)	O
,	O
a	O
monocyte	B
counter	I
-	I
receptor	I
for	O
endothelial	B
selectins	I
may	O
participate	O
in	O
this	O
response	O
.	O
We	O
used	O
cytokine	O
production	O
as	O
a	O
readout	O
for	O
monocyte	O
activation	O
and	O
found	O
that	O
CD15	O
cross	O
-	O
linking	O
induced	O
TNF	B
-	I
alpha	I
release	O
from	O
peripheral	O
blood	O
monocytes	O
and	O
cells	O
from	O
the	O
monocytic	O
cell	O
line	O
MM6	O
.	O
Quantitative	O
reverse	B
transcriptase	I
-polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
showed	O
an	O
increase	O
in	O
steady	O
-	O
state	O
TNF	O
-	O
alpha	O
mRNA	O
after	O
3	O
to	O
4	O
hours	O
of	O
cross	O
-	O
linking	O
.	O
CD15	O
cross	O
-	O
linking	O
also	O
concomitantly	O
increased	O
interleukin-1	O
beta	O
(	O
IL-1	O
beta	O
)	O
mRNA	O
,	O
while	O
no	O
apparent	O
change	O
was	O
observed	O
in	O
the	O
levels	O
of	O
beta	O
-	O
actin	O
mRNA	O
,	O
indicating	O
specificity	O
.	O
To	O
examine	O
transcriptional	O
regulation	O
of	O
cytokine	O
genes	O
by	O
CD15	O
engagement	O
,	O
a	O
CAT	O
plasmid	O
reporter	O
construct	O
containing	O
IL-1	O
beta	O
promoter	O
/	O
enhancer	O
sequences	O
was	O
introduced	O
into	O
MM6	O
.	O
Subsequent	O
cross	O
-	O
linking	O
of	O
CD15	O
increased	O
CAT	B
activity	O
.	O
CD15	O
engagement	O
by	O
monoclonal	B
antibody	I
also	O
attenuated	O
IL-1	B
beta	I
transcript	O
degradation	O
,	O
demonstrating	O
that	O
signaling	O
via	O
CD15	O
also	O
had	O
posttranscriptional	O
effects	O
.	O
Nuclear	O
extracts	O
of	O
anti-	O
CD15	O
cross	O
-	O
linked	O
cells	O
demonstrated	O
enhanced	O
levels	O
of	O
the	O
transcriptional	B
factor	I
activator	I
protein-1	I
,	O
minimally	O
changed	O
nuclear	B
factor	I
-	I
kappa	I
B	I
,	O
and	O
did	O
not	O
affect	O
SV40	B
promoter	I
specific	I
protein-1	I
.	O
We	O
conclude	O
that	O
engagement	O
of	O
CD15	O
on	O
monocytes	O
results	O
in	O
monocyte	O
activation	O
.	O
In	O
addition	O
to	O
its	O
well	O
-	O
recognized	O
adhesive	O
role	O
,	O
CD15	O
may	O
function	O
as	O
an	O
important	O
signaling	O
molecule	O
capable	O
of	O
initiating	O
proinflammatory	O
events	O
in	O
monocytes	O
that	O
come	O
into	O
contact	O
with	O
activated	O
endothelium	O
.	O
Activation	O
of	O
signaling	O
pathways	O
and	O
prevention	O
of	O
apoptosis	O
by	O
cytokines	B
in	O
eosinophils	O
.	O
Inhibition	O
of	O
apoptosis	O
in	O
eosinophils	O
by	O
cytokines	B
such	O
as	O
IL-5	B
and	O
GM	B
-	I
CSF	I
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
and	O
parasitic	O
disorders	O
.	O
Recently	O
,	O
there	O
has	O
been	O
some	O
progress	O
in	O
the	O
understanding	O
of	O
the	O
signal	O
transduction	O
pathways	O
activated	O
by	O
these	O
cytokines	B
in	O
eosinophils	O
.	O
The	O
IL-3	B
,	O
IL-5	B
and	O
GM	B
-	I
CSF	I
receptors	I
share	O
a	O
common	B
signal	I
transducer	I
that	O
possesses	O
no	O
intrinsic	B
kinase	I
domain	I
.	O
It	O
has	O
been	O
shown	O
that	O
eosinophil	O
stimulation	O
by	O
these	O
cytokines	B
is	O
associated	O
with	O
increases	O
in	O
tyrosine	O
phosphorylation	O
of	O
several	O
cellular	O
substrates	O
.	O
In	O
the	O
past	O
few	O
years	O
,	O
there	O
has	O
been	O
some	O
progress	O
in	O
defining	O
the	O
tyrosine	O
kinases	O
that	O
are	O
activated	O
by	O
the	O
IL-3	B
/	I
IL-5	I
/	I
GM	I
-	I
CSF	I
receptor	I
beta	I
-	I
subunit	I
in	O
eosinophils	O
.	O
This	O
review	O
will	O
concentrate	O
on	O
this	O
topic	O
and	O
on	O
its	O
role	O
for	O
the	O
regulation	O
of	O
eosinophil	O
apoptosis	O
.	O
Stimulation	O
of	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
zinc	O
and	O
related	O
cations	O
.	O
Zinc	O
is	O
an	O
important	O
trace	O
element	O
for	O
immune	O
function	O
.	O
Here	O
,	O
we	O
show	O
that	O
zinc	O
addition	O
in	O
a	O
serum-	O
and	O
lipopolysaccharide	O
-	O
free	O
cell	O
culture	O
system	O
leads	O
to	O
significantly	O
enhanced	O
levels	O
of	O
interleukin	B
1	I
beta	I
(	O
IL-1	B
beta	I
)	O
and	O
tumour	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
and	O
to	O
expression	O
of	O
the	O
corresponding	O
mRNA	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O
Structurally	O
related	O
divalent	O
cations	O
like	O
cobalt	O
,	O
nickel	O
,	O
and	O
mercury	O
also	O
partially	O
increase	O
monokine	O
secretion	O
but	O
to	O
a	O
much	O
lower	O
and	O
thus	O
insignificant	O
extent	O
.	O
They	O
fail	O
to	O
induce	O
mRNA	O
of	O
TNF	B
-	I
alpha	I
after	O
3	O
h	O
of	O
culture	O
.	O
Therefore	O
,	O
monokine	O
induction	O
is	O
a	O
zinc	O
-	O
specific	O
effect	O
influenced	O
by	O
the	O
physicochemical	O
properties	O
of	O
the	O
ion	O
.	O
Confirmation	O
of	O
the	O
unique	O
significance	O
of	O
zinc	O
for	O
immune	O
function	O
provides	O
a	O
better	O
understanding	O
of	O
the	O
mechanisms	O
of	O
specific	O
zinc	O
-	O
mediated	O
immune	O
modulation	O
.	O
Sequence	O
analysis	O
and	O
expression	O
in	O
cultured	O
lymphocytes	O
of	O
the	O
human	O
FOSB	O
gene	O
(	O
G0S3	O
)	O
.	O
G0S3	O
is	O
a	O
member	O
of	O
a	O
set	O
of	O
putative	O
G0	O
/	O
G1	O
switch	O
regulatory	O
genes	O
(	O
G0S	O
genes	O
)	O
selected	O
by	O
screening	O
cDNA	O
libraries	O
prepared	O
from	O
human	O
blood	O
mononuclear	O
cells	O
cultured	O
for	O
2	O
hr	O
with	O
lectin	B
and	O
cycloheximide	O
.	O
The	O
sequence	O
shows	O
high	O
homology	O
with	O
the	O
murine	O
FOSB	O
gene	O
,	O
which	O
encodes	O
a	O
component	O
of	O
the	O
AP1	B
transcriptional	I
regulator	I
.	O
Comparison	O
of	O
cDNA	O
and	O
genomic	O
sequences	O
reveals	O
a	O
4-exon	O
structure	O
characteristic	O
of	O
the	O
FOS	O
family	O
of	O
genes	O
.	O
Freshly	O
isolated	O
cells	O
show	O
high	O
levels	O
of	O
FOSB	O
/	O
G0S3	O
and	O
FOS	O
/	O
G0S7	O
mRNAs	O
,	O
which	O
decline	O
rapidly	O
during	O
incubation	O
in	O
culture	O
medium	O
.	O
The	O
kinetics	O
of	O
expression	O
suggest	O
that	O
the	O
high	O
initial	O
levels	O
are	O
caused	O
by	O
the	O
isolation	O
procedure	O
,	O
and	O
do	O
not	O
reflect	O
constitutive	O
expression	O
.	O
In	O
cells	O
preincubated	O
for	O
a	O
day	O
,	O
levels	O
of	O
FOS	O
mRNA	O
reach	O
a	O
maximum	O
20	O
min	O
after	O
the	O
addition	O
of	O
lectin	B
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
3	O
hr	O
.	O
Levels	O
of	O
FOSB	O
mRNA	O
reach	O
a	O
maximum	O
40	O
min	O
after	O
the	O
addition	O
of	O
lectin	B
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
6	O
hr	O
.	O
In	O
freshly	O
isolated	O
cells	O
,	O
both	O
FOS	O
and	O
FOSB	O
mRNAs	O
increase	O
dramatically	O
in	O
response	O
to	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
.	O
In	O
preincubated	O
cells	O
,	O
the	O
cycloheximide	O
response	O
is	O
decreased	O
,	O
especially	O
in	O
the	O
case	O
of	O
FOSB	O
.	O
These	O
differences	O
in	O
expression	O
of	O
FOS	O
and	O
FOSB	O
suggest	O
different	O
roles	O
and	O
regulation	O
.	O
Regions	O
of	O
low	O
base	O
order	O
-	O
dependent	O
stem	O
-	O
loop	O
potential	O
in	O
the	O
region	O
of	O
the	O
gene	O
are	O
defined	O
.	O
These	O
indicate	O
where	O
base	O
order	O
has	O
been	O
adapted	O
for	O
purposes	O
other	O
than	O
stem	O
-	O
loop	O
stability	O
(	O
e.g.	O
,	O
encoding	O
proteins	O
or	O
gene	O
regulation	O
)	O
.	O
Regions	O
of	O
low	O
potential	O
in	O
a	O
68.5-kb	O
genomic	O
segment	O
containing	O
the	O
FOSB	O
gene	O
suggest	O
that	O
the	O
potential	O
may	O
help	O
locate	O
genes	O
in	O
uncharted	O
DNA	O
sequences	O
.	O
STAT1	B
pathway	O
is	O
involved	O
in	O
activation	O
of	O
caprine	O
arthritis	O
-	O
encephalitis	O
virus	O
long	O
terminal	O
repeat	O
in	O
monocytes	O
.	O
The	O
caprine	O
arthritis	O
-	O
encephalitis	O
virus	O
(	O
CAEV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
is	O
activated	O
by	O
gamma	B
interferon	I
(	O
IFN	B
-	I
gamma	I
)	O
in	O
promonocytic	O
cells	O
.	O
We	O
have	O
previously	O
shown	O
that	O
a	O
70-bp	O
element	O
is	O
necessary	O
and	O
sufficient	O
for	O
the	O
response	O
of	O
the	O
CAEV	O
LTR	O
to	O
this	O
cytokine	B
.	O
At	O
the	O
5	O
'	O
end	O
,	O
this	O
70-bp	O
IFN	O
-	O
gamma	O
response	O
element	O
contains	O
sequence	O
similarity	O
to	O
the	O
gamma	O
activated	O
site	O
(	O
GAS	O
)	O
.	O
Here	O
we	O
demonstrate	O
that	O
the	O
putative	O
GAS	O
element	O
in	O
the	O
CAEV	O
LTR	O
binds	O
specifically	O
to	O
a	O
cellular	B
factor	I
induced	O
by	O
IFN	B
-	I
gamma	I
in	O
promonocytic	O
cells	O
.	O
Substitution	O
mutations	O
in	O
this	O
consensus	O
sequence	O
eliminate	O
binding	O
of	O
the	O
inducible	B
factor	I
.	O
The	O
GAS	O
element	O
from	O
the	O
70-bp	O
motif	O
is	O
sufficient	O
to	O
confer	O
responsiveness	O
to	O
IFN	B
-	I
gamma	I
using	O
a	O
heterologous	O
minimal	O
promoter	O
.	O
Consistent	O
with	O
the	O
binding	O
data	O
,	O
the	O
same	O
mutations	O
in	O
the	O
GAS	O
element	O
eliminate	O
responsiveness	O
to	O
IFN	B
-	I
gamma	I
in	O
the	O
context	O
of	O
both	O
a	O
functional	O
CAEV	O
LTR	O
and	O
a	O
heterologous	O
promoter	O
.	O
The	O
cellular	O
factor	O
that	O
binds	O
to	O
the	O
GAS	O
element	O
is	O
present	O
from	O
5	O
min	O
to	O
14	O
h	O
after	O
stimulation	O
with	O
IFN	B
-	I
gamma	I
.	O
Binding	O
of	O
the	O
nuclear	O
factor	O
to	O
the	O
GAS	O
element	O
in	O
the	O
CAEV	O
LTR	O
is	O
inhibited	O
by	O
antibody	O
directed	O
against	O
STAT1	B
(	O
p91	B
/	I
84	I
)	O
.	O
Thus	O
,	O
the	O
GAS	O
sequence	O
in	O
the	O
CAEV	O
LTR	O
is	O
essential	O
for	O
the	O
response	O
to	O
IFN	B
-	I
gamma	I
and	O
a	O
STAT1-like	B
factor	I
binds	O
to	O
this	O
site	O
.	O
The	O
STAT-1	O
signaling	O
pathway	O
provides	O
at	O
least	O
one	O
mechanism	O
for	O
activation	O
of	O
the	O
CAEV	O
LTR	O
by	O
IFN	B
-	I
gamma	I
in	O
monocytes	O
.	O
These	O
data	O
are	O
the	O
first	O
demonstration	O
of	O
a	O
role	O
for	O
a	O
STAT	B
family	I
member	I
in	O
the	O
regulation	O
of	O
a	O
viral	O
promoter	O
.	O
Signaling	O
via	O
IL-2	B
and	O
IL-4	B
in	O
JAK3-deficient	O
severe	O
combined	O
immunodeficiency	O
lymphocytes	O
:	O
JAK3	B
-dependent	O
and	O
independent	O
pathways	O
.	O
Both	O
IL-2	B
and	O
IL-4	B
bind	O
to	O
receptors	O
containing	O
the	O
common	B
gamma	I
chain	I
and	O
JAK3	B
.	O
Although	O
JAK3	B
is	O
required	O
for	O
proper	O
lymphoid	O
development	O
,	O
the	O
precise	O
roles	O
of	O
this	O
kinase	O
in	O
IL-2	B
and	O
IL-4	B
signaling	O
in	O
lymphocytes	O
have	O
not	O
been	O
defined	O
.	O
Here	O
,	O
we	O
have	O
studied	O
IL-2	B
and	O
IL-4	B
signaling	O
in	O
B	O
cell	O
lines	O
lacking	O
JAK3	B
.	O
Although	O
IL-2	B
-induced	O
phosphorylation	O
of	O
IL-2R	B
beta	I
,	O
JAK1	B
,	O
and	O
STAT5	B
all	O
required	O
the	O
presence	O
of	O
JAK3	B
,	O
IL-4	B
-mediated	O
phosphorylation	O
of	O
JAK1	B
,	O
STAT6	B
,	O
and	O
insulin	B
receptor	I
substrates	O
1	O
and	O
2	O
did	O
not	O
.	O
However	O
,	O
IL-4	B
-induced	O
effects	O
were	O
clearly	O
improved	O
following	O
JAK3	B
expression	O
.	O
These	O
data	O
indicate	O
that	O
IL-4	B
signaling	O
occurs	O
in	O
the	O
absence	O
of	O
of	O
JAK3	B
,	O
but	O
is	O
comparatively	O
inefficient	O
.	O
These	O
findings	O
may	O
help	O
in	O
understanding	O
the	O
pathogenesis	O
of	O
the	O
immunodeficiency	O
that	O
occurs	O
with	O
mutations	O
of	O
JAK3	B
and	O
may	O
suggest	O
a	O
mechanism	O
for	O
the	O
pleiotropic	O
effects	O
of	O
IL-4	B
.	O
GATA-1	B
DNA	O
binding	O
activity	O
is	O
down	O
-	O
regulated	O
in	O
late	O
S	O
phase	O
in	O
erythroid	O
cells	O
.	O
We	O
have	O
set	O
out	O
to	O
test	O
a	O
model	O
for	O
tissue	O
-	O
specific	O
gene	O
expression	O
that	O
relies	O
on	O
the	O
early	O
replication	O
of	O
expressed	O
genes	O
to	O
sequester	O
limiting	O
activating	O
transcription	B
factors	I
.	O
Using	O
an	O
erythroid	O
cell	O
line	O
,	O
we	O
have	O
tested	O
the	O
changes	O
in	O
the	O
DNA	O
binding	O
activity	O
of	O
the	O
lineage	B
-	I
restricted	I
transcription	I
factor	I
GATA-1	B
through	O
the	O
cell	O
cycle	O
.	O
We	O
find	O
that	O
GATA-1	B
activity	O
is	O
low	O
in	O
G1	O
,	O
peaks	O
in	O
mid	O
-	O
S	O
phase	O
,	O
and	O
then	O
decreases	O
in	O
G2	O
/	O
M	O
.	O
In	O
contrast	O
,	O
the	O
binding	O
activities	O
of	O
two	O
ubiquitous	O
transcription	B
factors	I
,	O
Oct1	B
and	O
Sp1	B
,	O
remain	O
high	O
in	O
G2	O
/	O
M	O
.	O
GATA-1	B
protein	O
and	O
mRNA	O
vary	O
in	O
a	O
similar	O
manner	O
through	O
the	O
cell	O
cycle	O
,	O
suggesting	O
that	O
the	O
expression	O
of	O
the	O
gene	O
or	O
the	O
stability	O
of	O
its	O
message	O
is	O
regulated	O
.	O
Although	O
a	O
number	O
of	O
transcription	B
factors	I
involved	O
in	O
the	O
control	O
of	O
the	O
cell	O
cycle	O
or	O
DNA	O
replication	O
have	O
been	O
shown	O
to	O
peak	O
in	O
S	O
phase	O
,	O
this	O
is	O
the	O
first	O
example	O
of	O
a	O
lineage	B
-	I
restricted	I
transcription	I
factor	I
displaying	O
S	O
phase	O
-	O
specific	O
DNA	O
binding	O
activity	O
.	O
One	O
interpretation	O
of	O
these	O
data	O
leads	O
to	O
a	O
model	O
in	O
which	O
the	O
peak	O
in	O
GATA-1	B
DNA	O
binding	O
amplifies	O
the	O
effect	O
of	O
early	O
replication	O
on	O
the	O
activation	O
of	O
erythroid	O
-	O
specific	O
genes	O
at	O
the	O
same	O
time	O
as	O
preventing	O
activation	O
of	O
non	O
-	O
erythroid	O
genes	O
containing	O
GATA	O
-	O
responsive	O
elements	O
.	O
These	O
results	O
may	O
also	O
relate	O
to	O
recent	O
data	O
implicating	O
GATA-1	B
function	O
in	O
apoptosis	O
and	O
cell	O
cycle	O
progression	O
Constitutive	O
dephosphorylation	O
and	O
activation	O
of	O
a	O
member	O
of	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
,	O
NF	B
-	I
AT1	I
,	O
in	O
Tax	O
-	O
expressing	O
and	O
type	O
I	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
-	O
infected	O
human	O
T	O
cells	O
.	O
The	O
tax	O
gene	O
product	O
of	O
the	O
type	O
I	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
(	O
HTLV	O
-	O
I	O
)	O
transactivates	O
interleukin-2	O
(	O
IL-2	O
)	O
gene	O
through	O
activation	O
of	O
an	O
enhancer	O
termed	O
CD28	O
responsive	O
element	O
(	O
CD28RE	O
)	O
.	O
Tax	B
activation	O
of	O
the	O
CD28RE	O
is	O
partially	O
mediated	O
by	O
a	O
member	O
of	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
,	O
NF	B
-	I
AT1	I
.	O
We	O
have	O
previously	O
shown	O
that	O
NF	B
-	I
AT1	I
is	O
constitutively	O
active	O
in	O
Jurkat	O
T	O
cells	O
stably	O
transfected	O
with	O
the	O
Tax	O
cDNA	O
,	O
although	O
the	O
underlying	O
molecular	O
mechanism	O
and	O
physiological	O
relevance	O
of	O
this	O
finding	O
remain	O
unclear	O
.	O
In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
active	O
form	O
of	O
NF	B
-	I
AT1	I
is	O
also	O
present	O
in	O
the	O
nuclei	O
of	O
HTLV	O
-	O
I	O
-	O
transformed	O
T	O
cells	O
that	O
express	O
the	O
Tax	B
protein	I
.	O
Interestingly	O
,	O
the	O
constitutive	O
activation	O
of	O
NF	B
-	I
AT1	I
in	O
these	O
T	O
cells	O
is	O
associated	O
with	O
its	O
dephosphorylation	O
.	O
Furthermore	O
,	O
the	O
dephosphorylated	O
NF	B
-	I
AT1	I
can	O
be	O
rapidly	O
rephosphorylated	O
when	O
the	O
cells	O
are	O
incubated	O
with	O
cyclosporin	O
A	O
,	O
an	O
immunosuppressant	O
inhibiting	O
the	O
serine	B
/	I
threonine	I
phosphatase	I
calcineurin	B
.	O
These	O
results	O
suggest	O
that	O
activation	O
of	O
NF	B
-	I
AT1	I
in	O
Tax	O
-	O
expressing	O
and	O
HTLV	O
-	O
I	O
-	O
transformed	O
T	O
cells	O
results	O
from	O
its	O
dephosphorylation	O
,	O
which	O
in	O
turn	O
may	O
be	O
due	O
to	O
deregulation	O
of	O
calcineurin	B
Isolation	O
of	O
a	O
B	O
-	O
cell	O
-	O
specific	O
promoter	O
for	O
the	O
human	B
class	I
II	I
transactivator	I
.	O
The	O
class	B
II	I
transactivator	I
(	O
CIITA	B
)	O
is	O
essential	O
for	O
the	O
expression	O
of	O
major	B
histocompatibility	I
complex	I
(	I
MHC	I
)	I
class	I
II	I
antigens	I
.	O
The	O
tissular	O
patterns	O
of	O
CIITA	O
and	O
MHC	O
class	O
II	O
gene	O
expression	O
are	O
tightly	O
correlated	O
:	O
CIITA	O
mRNA	O
is	O
highly	O
expressed	O
in	O
B	O
cells	O
,	O
and	O
is	O
induced	O
by	O
interferon	B
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
in	O
macrophage	O
and	O
epithelial	O
cell	O
lines	O
.	O
We	O
first	O
isolated	O
two	O
overlapping	O
cosmids	O
encoding	O
human	B
CIITA	I
which	O
,	O
when	O
co	O
-	O
transfected	O
,	O
are	O
able	O
to	O
restore	O
MHC	B
class	I
II	I
expression	O
in	O
a	O
B	O
-	O
lymphoblastoid	O
cell	O
line	O
(	O
B	O
-	O
LCL	O
)	O
defective	O
for	O
CIITA	B
.	O
Subsequently	O
,	O
a	O
1.8	O
kilobase	O
(	O
kb	O
)	O
fragment	O
of	O
the	O
CIITA	O
promoter	O
was	O
isolated	O
and	O
sequenced	O
.	O
A	O
motif	O
presenting	O
a	O
strong	O
similarity	O
to	O
an	O
initiator	O
was	O
detected	O
,	O
as	O
well	O
as	O
putative	O
binding	O
sites	O
for	O
Sp1	B
,	O
GATA-2	B
,	O
LyF-1	B
,	O
ets-1	B
,	O
AP1	B
,	O
and	O
MZF1	B
transcription	B
factors	I
,	O
and	O
two	O
GAS	O
motifs	O
.	O
When	O
introduced	O
in	O
front	O
of	O
a	O
luciferase	O
reporter	O
gene	O
,	O
this	O
promoter	O
is	O
able	O
to	O
direct	O
a	O
high	O
luciferase	B
activity	O
in	O
a	O
human	O
B	O
-	O
LCL	O
.	O
In	O
contrast	O
,	O
luciferase	B
expression	O
was	O
not	O
stimulated	O
after	O
IFN	B
-	I
gamma	I
treatment	O
when	O
the	O
construct	O
was	O
transfected	O
in	O
macrophage	O
or	O
in	O
epithelial	O
cell	O
lines	O
.	O
However	O
,	O
an	O
induction	O
of	O
the	O
human	O
CIITA	O
gene	O
was	O
observed	O
in	O
mouse	O
macrophage	O
and	O
fibrosarcoma	O
cell	O
lines	O
,	O
when	O
the	O
cells	O
were	O
transfected	O
with	O
a	O
cosmid	O
containing	O
the	O
human	O
CIITA	O
gene	O
,	O
but	O
lacking	O
the	O
1.8	O
kb	O
promoter	O
described	O
above	O
.	O
Taken	O
together	O
,	O
these	O
data	O
suggest	O
the	O
existence	O
of	O
an	O
intragenic	O
promoter	O
driving	O
an	O
IFN	B
-	I
gamma	I
-inducible	O
expression	O
of	O
CIITA	B
.	O
Nuclear	B
factor	I
-	I
kappaB	I
activation	O
in	O
human	O
monocytes	O
stimulated	O
with	O
lipopolysaccharide	O
is	O
inhibited	O
by	O
fibroblast	O
conditioned	O
medium	O
and	O
exogenous	O
PGE2	O
.	O
The	O
nuclear	B
factor	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
is	O
thought	O
to	O
be	O
crucially	O
involved	O
in	O
the	O
gene	O
activation	O
of	O
several	O
cytokines	B
,	O
including	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
)	O
.	O
Previously	O
,	O
we	O
showed	O
that	O
fibroblast	O
conditioned	O
medium	O
(	O
FCM	O
)	O
is	O
able	O
to	O
inhibit	O
both	O
TNF	O
mRNA	O
accumulation	O
and	O
protein	O
release	O
in	O
peripheral	O
blood	O
-	O
derived	O
human	O
monocytes	O
(	O
PBM	O
)	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
In	O
this	O
study	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
FCM	O
on	O
the	O
LPS	O
-	O
induced	O
DNA	O
-	O
binding	O
activity	O
of	O
NF	B
-	I
kappaB	I
,	O
by	O
means	O
of	O
electrophoretic	O
shift	O
assay	O
(	O
EMSA	O
)	O
.	O
We	O
provide	O
evidence	O
that	O
FCM	O
strongly	O
inhibits	O
the	O
LPS	O
-	O
induced	O
NF	B
-	I
kappaB	I
activation	O
in	O
PBM	O
.	O
Furthermore	O
,	O
we	O
show	O
that	O
exogenous	O
PGE2	O
mimics	O
the	O
NF	B
-	I
kappaB	I
inhibitory	O
effect	O
of	O
FCM	O
.	O
On	O
the	O
other	O
hand	O
,	O
FCM	O
produced	O
in	O
the	O
presence	O
of	O
indomethacin	O
does	O
not	O
inhibit	O
NF	B
-	I
kappaB	I
activation	O
by	O
LPS	O
.	O
Our	O
results	O
lend	O
further	O
support	O
to	O
the	O
hypothesis	O
that	O
inflammatory	O
and	O
immune	O
responses	O
of	O
monocytes	O
/	O
macrophages	O
may	O
be	O
modulated	O
at	O
the	O
molecular	O
level	O
by	O
signals	O
originating	O
from	O
tissue	O
structural	O
cells	O
such	O
as	O
fibroblasts	O
.	O
Inhibitory	O
effect	O
of	O
growth	O
hormone	O
on	O
TNF	B
-	I
alpha	I
secretion	O
and	O
nuclear	B
factor	I
-	I
kappaB	I
translocation	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
human	O
monocytes	O
.	O
Several	O
studies	O
have	O
pointed	O
to	O
a	O
link	O
between	O
immune	O
and	O
endocrine	O
systems	O
,	O
including	O
a	O
regulatory	O
function	O
of	O
GH	O
on	O
monocyte	O
activation	O
.	O
The	O
present	O
study	O
demonstrates	O
that	O
human	O
THP-1	O
promonocytic	O
cells	O
,	O
engineered	O
by	O
gene	O
transfer	O
to	O
constitutively	O
produce	O
human	O
growth	O
hormone	O
(	O
hGH	O
)	O
,	O
secreted	O
depressed	O
amounts	O
of	O
TNF	B
-	I
alpha	I
in	O
response	O
to	O
challenge	O
by	O
LPS	O
.	O
The	O
effect	O
of	O
GH	O
appears	O
to	O
occur	O
in	O
an	O
autocrine	O
fashion	O
,	O
since	O
the	O
inhibitory	O
effect	O
on	O
TNF	B
-	I
alpha	I
secretion	O
by	O
constitutive	O
GH	O
production	O
could	O
be	O
abolished	O
in	O
the	O
presence	O
of	O
anti	B
-	I
hGH	I
mAb	I
.	O
The	O
GH	O
-	O
induced	O
inhibitory	O
effect	O
was	O
also	O
observed	O
using	O
normal	O
human	O
monocytes	O
and	O
monocyte	O
-	O
derived	O
macrophages	O
.	O
Inhibition	O
of	O
TNF	B
-	I
alpha	I
production	O
by	O
THP-1-hGH	O
-	O
transfected	O
cells	O
cultured	O
in	O
the	O
presence	O
of	O
LPS	O
is	O
dependent	O
on	O
a	O
selective	O
pathway	O
,	O
since	O
no	O
inhibition	O
of	O
TNF	B
-	I
alpha	I
production	O
was	O
observed	O
when	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
PMA	O
.	O
Inhibition	O
of	O
TNF	B
-	I
alpha	I
secretion	O
by	O
LPS	O
-	O
stimulated	O
THP-1-hGH	O
cells	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
nuclear	O
translocation	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
.	O
The	O
capacity	O
of	O
GH	O
to	O
inhibit	O
LPS	O
-	O
induced	O
TNF	B
-	I
alpha	I
production	O
by	O
monocytes	O
without	O
altering	O
other	O
pathways	O
leading	O
to	O
TNF	B
-	I
alpha	I
production	O
may	O
be	O
of	O
potential	O
relevance	O
in	O
septic	O
shock	O
,	O
since	O
GH	O
is	O
available	O
for	O
clinical	O
use	O
.	O
Impaired	O
induction	O
of	O
c	O
-	O
fos	O
/	O
c	O
-	O
jun	O
genes	O
and	O
of	O
transcriptional	B
regulatory	I
proteins	I
binding	O
distinct	O
c	O
-	O
fos	O
/	O
c	O
-	O
jun	O
promoter	O
elements	O
in	O
activated	O
human	O
T	O
cells	O
during	O
aging	O
.	O
The	O
activation	O
of	O
transcriptional	B
factor	I
c	O
-	O
Fos	O
/	O
c	O
-	O
Jun	O
AP-1	B
is	O
essential	O
for	O
normal	O
T	O
cell	O
responsiveness	O
and	O
is	O
often	O
impaired	O
in	O
T	O
cells	O
during	O
aging	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
aberrancies	O
in	O
the	O
regulation	O
of	O
c	O
-	O
fos	O
/	O
c	O
-	O
jun	O
at	O
the	O
mRNA	O
or	O
protein	O
level	O
might	O
underlie	O
the	O
age	O
-	O
associated	O
impairments	O
of	O
AP-1	B
in	O
human	O
T	O
cells	O
.	O
Whereas	O
T	O
cells	O
from	O
young	O
subjects	O
stimulated	O
with	O
cross	B
-	I
linked	I
anti	I
-	I
CD3epsilon	I
mAb	I
OKT3	B
plus	O
PMA	O
or	O
with	O
the	O
lectin	B
PHA	B
plus	O
PMA	O
demonstrated	O
considerable	O
increases	O
in	O
c	B
-	I
Fos	I
protein	O
expression	O
,	O
the	O
expression	O
of	O
c	B
-	I
Fos	I
but	O
not	O
c	B
-	I
Jun	I
was	O
markedly	O
reduced	O
in	O
stimulated	O
T	O
cells	O
from	O
certain	O
elderly	O
subjects	O
.	O
In	O
addition	O
,	O
RNase	B
protection	O
assays	O
revealed	O
that	O
anti	O
-	O
CD3	O
/	O
PMA	O
-	O
stimulated	O
T	O
cells	O
from	O
a	O
substantial	O
proportion	O
of	O
elderly	O
subjects	O
exhibited	O
decreased	O
levels	O
of	O
c	O
-	O
fos	O
and/or	O
c	O
-	O
jun	O
mRNA	O
compared	O
to	O
T	O
cells	O
from	O
young	O
subjects	O
.	O
Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
the	O
levels	O
of	O
nuclear	B
regulatory	I
proteins	I
recognizing	O
the	O
AP-1	O
consensus	O
TRE	O
motif	O
,	O
the	O
proximal	O
c	O
-	O
jun	O
TRE	O
-	O
like	O
promoter	O
element	O
,	O
and	O
the	O
c	O
-	O
fos	O
serum	O
response	O
element	O
(	O
SRE	O
)	O
were	O
determined	O
in	O
resting	O
and	O
stimulated	O
T	O
cells	O
.	O
Although	O
the	O
stimulation	O
of	O
T	O
cells	O
from	O
young	O
subjects	O
resulted	O
in	O
coordinated	O
increases	O
of	O
nuclear	B
protein	I
complexes	I
binding	O
the	O
AP-1	O
TRE	O
,	O
c	O
-	O
jun	O
TRE	O
,	O
and	O
c	O
-	O
fos	O
SRE	O
DNA	O
sequence	O
motifs	O
,	O
age	O
-	O
related	O
reductions	O
in	O
the	O
activation	O
of	O
AP-1	B
were	O
accompanied	O
by	O
decreased	O
levels	O
of	O
c	B
-	I
jun	I
TRE	I
and	I
c	I
-	I
fos	I
SRE	I
binding	I
complexes	I
.	O
Furthermore	O
,	O
the	O
nuclear	B
protein	I
complexes	I
binding	O
the	O
SRE	O
motif	O
induced	O
in	O
activated	O
T	O
cells	O
of	O
young	O
and	O
elderly	O
subjects	O
contained	O
serum	B
response	I
factor	I
and	O
Elk-1	B
pointing	O
toward	O
age	O
-	O
related	O
defects	O
in	O
the	O
activation	O
of	O
transcriptional	B
regulatory	I
proteins	I
distinct	O
from	O
c	B
-	I
jun	I
/	I
AP-1	I
.	O
These	O
results	O
suggest	O
that	O
underlying	O
aberrancies	O
in	O
the	O
induction	O
of	O
c	O
-	O
fos	O
/	O
c	O
-	O
jun	O
as	O
well	O
as	O
their	O
nuclear	B
regulatory	I
proteins	I
may	O
contribute	O
to	O
the	O
age	O
-	O
related	O
impairments	O
of	O
AP-1	B
activation	O
in	O
human	O
T	O
cells	O
.	O
Dissociation	O
of	O
the	O
Jak	B
kinase	I
pathway	O
from	O
G	B
-	I
CSF	I
receptor	I
signaling	O
in	O
neutrophils	O
.	O
Activation	O
of	O
the	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
receptor	I
(	O
G	B
-	I
CSFR	I
)	O
induces	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
multiple	O
intracellular	B
substrates	I
in	O
proliferating	O
cells	O
and	O
nonproliferating	O
,	O
terminally	O
differentiated	O
neutrophils	O
.	O
The	O
kinases	O
that	O
couple	O
ligand	O
binding	O
to	O
tyrosine	O
phosphorylation	O
of	O
cellular	B
substrates	I
by	O
the	O
G	O
-	O
CSFR	O
with	O
activation	O
of	O
specific	O
functional	O
programs	O
are	O
largely	O
unknown	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
early	O
signaling	O
events	O
in	O
proliferating	O
and	O
terminally	O
differentiated	O
cells	O
following	O
G	B
-	I
CSF	I
stimulation	O
to	O
determine	O
whether	O
identical	O
signaling	O
cascades	O
are	O
activated	O
.	O
In	O
murine	O
Ba	O
/	O
F3	O
cells	O
transfected	O
with	O
the	O
human	B
G	I
-	I
CSFR	I
and	O
NFS-60	O
cells	O
constitutively	O
expressing	O
the	O
murine	B
G	I
-	I
CSFR	I
,	O
G	B
-	I
CSF	I
induced	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
Jak1	B
,	O
Jak2	B
,	O
and	O
Tyk2	B
.	O
Tyrosine	O
phosphorylation	O
of	O
Stat3	B
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
Stat1	B
was	O
also	O
detected	O
following	O
G	B
-	I
CSF	I
stimulation	O
.	O
Using	O
a	O
mitogenically	B
incompetent	I
human	I
G	I
-	I
CSFR	I
mutant	I
in	O
which	O
Pro639	O
and	O
Pro641	O
were	O
substituted	O
by	O
alanine	O
,	O
the	O
box	B
1	I
PDP	I
motif	I
was	O
found	O
to	O
be	O
required	O
for	O
activation	O
of	O
Jak	B
kinases	I
,	O
tyrosine	O
phosphorylation	O
of	O
the	O
G	B
-	I
CSFR	I
,	O
and	O
recruitment	O
of	O
Stat	B
proteins	I
.	O
Notably	O
,	O
no	O
activation	O
of	O
Jak1	B
,	O
Jak2	B
,	O
Tyk2	B
,	O
Stat1	B
,	O
or	O
Stat3	B
was	O
observed	O
in	O
neutrophils	O
following	O
G	B
-	I
CSF	I
stimulation	O
.	O
In	O
addition	O
,	O
there	O
was	O
no	O
detectable	O
activation	O
in	O
neutrophils	O
of	O
the	O
recently	O
cloned	O
Jak3	B
kinase	I
,	O
which	O
has	O
been	O
reported	O
to	O
be	O
expressed	O
at	O
high	O
levels	O
as	O
myeloid	O
cells	O
undergo	O
terminal	O
neutrophilic	O
maturation	O
.	O
These	O
results	O
indicate	O
a	O
lack	O
of	O
involvement	O
of	O
Jak	B
kinases	I
in	O
signaling	O
by	O
the	O
G	B
-	I
CSFR	I
in	O
neutrophils	O
,	O
and	O
suggest	O
utilization	O
of	O
alternative	O
signal	O
transduction	O
pathways	O
distinct	O
from	O
those	O
in	O
proliferating	O
cells	O
.	O
Activation	O
of	O
the	O
Jak	B
-Stat	B
pathway	O
correlates	O
with	O
proliferative	O
signaling	O
by	O
the	O
G	B
-	I
CSFR	I
and	O
requires	O
the	O
membrane	B
-	I
proximal	I
box	I
1	I
PXP	I
motif	I
,	O
which	O
is	O
conserved	O
in	O
members	O
of	O
the	O
cytokine	B
receptor	I
superfamily	I
.	O
Adenovirus	B
E1B	I
19	I
K	I
protein	I
is	O
required	O
for	O
efficient	O
DNA	O
replication	O
in	O
U937	O
cells	O
.	O
The	O
adenovirus	O
E1B	O
19	O
K	O
gene	O
plays	O
an	O
essential	O
role	O
in	O
transformation	O
of	O
primary	O
rodent	O
cells	O
in	O
cooperation	O
with	O
E1A	B
and	O
in	O
the	O
inhibition	O
of	O
apoptosis	O
during	O
lytic	O
infection	O
.	O
It	O
has	O
been	O
shown	O
that	O
this	O
E1B	B
19	I
K	I
protein	I
is	O
not	O
necessary	O
for	O
viral	O
DNA	O
replication	O
in	O
human	O
cell	O
lines	O
,	O
such	O
as	O
HeLa	O
and	O
KB	O
.	O
We	O
reported	O
here	O
that	O
the	O
E1B	B
19	I
K	I
mutant	O
viruses	O
were	O
unable	O
to	O
replicate	O
efficiently	O
in	O
a	O
monocyte	O
cell	O
line	O
,	O
U937	O
.	O
Viral	O
DNA	O
synthesis	O
and	O
late	O
gene	O
expression	O
were	O
found	O
to	O
be	O
defective	O
in	O
U937	O
cells	O
infected	O
with	O
E1B	B
19	I
K	I
mutants	O
compared	O
with	O
wild	O
-	O
type	O
virus	O
.	O
Early	O
viral	O
RNA	O
splicing	O
patterns	O
also	O
differ	O
between	O
wild	O
-	O
type	O
and	O
dl337-infected	O
cells	O
.	O
Furthermore	O
,	O
the	O
defect	O
in	O
viral	O
replication	O
could	O
be	O
complemented	O
by	O
dl312	O
virus	O
defective	O
in	O
E1A	B
expression	O
4	O
days	O
after	O
infection	O
with	O
E1B	O
mutants	O
,	O
suggesting	O
persistence	O
of	O
the	O
E1B	O
mutant	O
genome	O
in	O
the	O
infected	O
cells	O
despite	O
defective	O
onset	O
of	O
the	O
late	O
phase	O
of	O
replication	O
.	O
These	O
results	O
imply	O
that	O
E1B	B
19	I
K	I
is	O
required	O
for	O
efficient	O
viral	O
DNA	O
replication	O
in	O
U937	O
cells	O
.	O
Inefficient	O
DNA	O
replication	O
is	O
also	O
found	O
in	O
another	O
monocyte	O
cell	O
line	O
,	O
THP-1	O
Interaction	O
of	O
transcription	B
factors	I
RFX1	B
and	O
MIBP1	B
with	O
the	O
gamma	O
motif	O
of	O
the	O
negative	O
regulatory	O
element	O
of	O
the	O
hepatitis	O
B	O
virus	O
core	O
promoter	O
.	O
The	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
of	O
the	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
core	O
promoter	O
contains	O
three	O
subregions	O
which	O
act	O
synergistically	O
to	O
suppress	O
core	O
promoter	O
activity	O
.	O
One	O
of	O
these	O
subregions	O
,	O
NRE	O
gamma	O
,	O
is	O
active	O
in	O
both	O
HeLa	O
cervical	O
carcinoma	O
cells	O
and	O
Huh7	O
hepatoma	O
cells	O
and	O
was	O
found	O
to	O
be	O
bound	O
by	O
a	O
protein	O
factor	O
present	O
in	O
both	O
cell	O
types	O
.	O
Here	O
we	O
show	O
that	O
the	O
transcription	B
factor	I
RFX1	B
can	O
bind	O
to	O
NRE	O
gamma	O
and	O
transactivate	O
the	O
core	O
promoter	O
through	O
this	O
site	O
.	O
Mutations	O
which	O
abrogated	O
the	O
gene	O
-	O
suppressive	O
activity	O
of	O
NRE	O
gamma	O
prevented	O
RFX1	B
from	O
binding	O
to	O
NRE	O
gamma	O
.	O
In	O
addition	O
,	O
RFX1	B
can	O
bind	O
simultaneously	O
,	O
most	O
likely	O
as	O
a	O
heterodimer	B
,	O
with	O
the	O
transcription	B
factor	I
MIBP1	B
to	O
NRE	O
gamma	O
.	O
In	O
the	O
absence	O
of	O
a	O
cloned	O
MIBP1	O
gene	O
for	O
further	O
studies	O
,	O
we	O
hypothesize	O
that	O
RFX1	B
acts	O
with	O
MIBP1	B
to	O
negatively	O
regulate	O
the	O
core	O
promoter	O
activity	O
through	O
the	O
NRE	O
gamma	O
site	O
.	O
The	O
ability	O
of	O
RFX1	B
to	O
transactivate	O
the	O
core	O
promoter	O
raises	O
the	O
possibility	O
that	O
RFX1	B
may	O
play	O
a	O
dual	O
role	O
in	O
regulating	O
HBV	O
gene	O
expression	O
Evaluation	O
of	O
monoclonal	O
anti	O
-	O
D	O
reagents	O
using	O
D	O
variant	O
cells	O
.	O
Monoclonal	B
anti	I
-	I
D	I
antibodies	I
submitted	O
to	O
the	O
Third	O
Monoclonal	O
International	O
Workshop	O
were	O
evaluated	O
against	O
a	O
number	O
of	O
D	O
variant	O
cells	O
using	O
standard	O
serological	O
techniques	O
.	O
The	O
monoclonal	B
antibodies	I
were	O
able	O
to	O
discriminate	O
between	O
the	O
cells	O
of	O
Categories	O
Va	O
,	O
VI	O
and	O
DFR	O
but	O
not	O
Category	O
III	O
cells	O
.	O
Cells	O
within	O
each	O
category	O
did	O
not	O
give	O
any	O
aberrant	O
results	O
.	O
The	O
Rh	O
:	O
33	O
cells	O
behaved	O
as	O
normal	O
Rh	O
(	O
D	O
)	O
positive	O
cells	O
.	O
Pancreatic	O
development	O
and	O
maturation	O
of	O
the	O
islet	O
B	O
cell	O
.	O
Studies	O
of	O
pluripotent	O
islet	O
cultures	O
.	O
Pancreas	O
organogenesis	O
is	O
a	O
highly	O
regulated	O
process	O
,	O
in	O
which	O
two	O
anlage	O
evaginate	O
from	O
the	O
primitive	O
gut	O
.	O
They	O
later	O
fuse	O
,	O
and	O
,	O
under	O
the	O
influence	O
of	O
the	O
surrounding	O
mesenchyme	O
,	O
the	O
mature	O
organ	O
develops	O
,	O
being	O
mainly	O
composed	O
of	O
ductal	O
,	O
exocrine	O
and	O
endocrine	O
compartments	O
.	O
Early	O
buds	O
are	O
characterized	O
by	O
a	O
branching	O
morphogenesis	O
of	O
the	O
ductal	O
epithelium	O
from	O
which	O
endocrine	O
and	O
exocrine	O
precursor	O
cells	O
bud	O
to	O
eventually	O
form	O
the	O
two	O
other	O
compartments	O
.	O
The	O
three	O
compartments	O
are	O
thought	O
to	O
be	O
of	O
common	O
endodermal	O
origin	O
;	O
in	O
contrast	O
to	O
earlier	O
hypotheses	O
,	O
which	O
suggested	O
that	O
the	O
endocrine	O
compartment	O
was	O
of	O
neuroectodermal	O
origin	O
.	O
It	O
is	O
thus	O
generally	O
believed	O
that	O
the	O
pancreatic	O
endocrine	O
-	O
lineage	O
possesses	O
the	O
ability	O
to	O
mature	O
along	O
a	O
differentiation	O
pathway	O
that	O
shares	O
many	O
characteristics	O
with	O
those	O
of	O
neuronal	O
differentiation	O
.	O
During	O
recent	O
years	O
,	O
studies	O
of	O
insulin	O
-	O
gene	O
regulation	O
and	O
,	O
in	O
particular	O
,	O
the	O
tissue	O
-	O
specific	O
transcriptional	O
control	O
of	O
insulin	O
-	O
gene	O
activity	O
have	O
provided	O
information	O
on	O
pancreas	O
development	O
in	O
general	O
.	O
The	O
present	O
review	O
summarizes	O
these	O
findings	O
,	O
with	O
a	O
special	O
focus	O
on	O
our	O
own	O
studies	O
on	O
pluripotent	O
endocrine	O
cultures	O
of	O
rat	O
pancreas	O
.	O
Cloning	O
and	O
expression	O
of	O
the	O
glucocorticoid	B
receptor	I
from	O
the	O
squirrel	O
monkey	O
(	O
Saimiri	O
boliviensis	O
boliviensis	O
)	O
,	O
a	O
glucocorticoid	O
-	O
resistant	O
primate	O
.	O
New	O
World	O
primates	O
such	O
as	O
the	O
squirrel	O
monkey	O
have	O
elevated	O
cortisol	O
levels	O
and	O
glucocorticoid	O
resistance	O
.	O
We	O
have	O
shown	O
that	O
the	O
apparent	O
binding	O
affinity	O
of	O
the	O
glucocorticoid	B
receptor	I
in	O
squirrel	O
monkey	O
lymphocytes	O
is	O
5-fold	O
lower	O
than	O
that	O
in	O
human	O
lymphocytes	O
(	O
apparent	O
Kd	O
,	O
20.9	O
+	O
/-	O
1.8	O
and	O
4.3	O
+	O
/-	O
0.2	O
nmol	O
/	O
L	O
,	O
respectively	O
;	O
n	O
=	O
3	O
)	O
,	O
consistent	O
with	O
previous	O
studies	O
in	O
mononuclear	O
leukocytes	O
isolated	O
from	O
the	O
two	O
species	O
.	O
As	O
a	O
first	O
step	O
in	O
understanding	O
the	O
mechanism	O
of	O
decreased	O
binding	O
affinity	O
in	O
New	O
World	O
primates	O
,	O
we	O
used	O
reverse	O
transcription	O
-	O
PCR	O
to	O
clone	O
the	O
glucocorticoid	B
receptor	I
from	O
squirrel	O
monkey	O
liver	O
and	O
have	O
compared	O
the	O
sequence	O
to	O
receptor	O
sequences	O
obtained	O
from	O
owl	O
monkey	O
liver	O
,	O
cotton	O
-	O
top	O
tamarin	O
B95	O
-	O
8	O
cells	O
,	O
and	O
human	O
lymphocytes	O
.	O
The	O
squirrel	O
monkey	O
glucocorticoid	B
receptor	I
is	O
approximately	O
97	O
%	O
identical	O
in	O
nucleotide	O
and	O
amino	O
acid	O
sequence	O
to	O
the	O
human	B
receptor	I
.	O
The	O
ligand	B
-	I
binding	I
domain	I
(	O
amino	B
acids	I
528	I
-	I
777	I
)	O
of	O
the	O
squirrel	O
monkey	O
glucocorticoid	B
receptor	I
contains	O
four	O
amino	O
acid	O
differences	O
(	O
Ser551	O
to	O
Thr	O
,	O
Ser616	O
to	O
Ala	O
,	O
Ala618	O
to	O
Ser	O
,	O
and	O
Ile761	O
to	O
Leu	O
)	O
,	O
all	O
of	O
which	O
are	O
present	O
in	O
owl	B
monkey	I
and	I
cotton	I
-	I
top	I
tamarin	I
receptors	I
.	O
The	O
DNA	B
-	I
binding	I
domain	I
(	O
amino	B
acids	I
421	I
-	I
486	I
)	O
is	O
completely	O
conserved	O
among	O
human	B
,	I
squirrel	I
monkey	I
,	I
owl	I
monkey	I
,	I
and	I
cotton	I
-	I
top	I
tamarin	I
receptors	I
.	O
Twenty	O
-	O
two	O
differences	O
from	O
the	O
human	O
sequence	O
were	O
found	O
in	O
the	O
N	B
-	I
terminal	I
region	I
(	O
amino	B
acids	I
1	I
-	I
421	I
)	O
of	O
the	O
squirrel	O
monkey	O
receptor	O
.	O
None	O
of	O
the	O
substitutions	O
in	O
the	O
ligand	B
-	I
binding	I
domain	I
matched	O
mutations	O
known	O
to	O
influence	O
binding	O
affinity	O
in	O
other	O
species	O
.	O
To	O
determine	O
whether	O
the	O
substitutions	O
per	O
se	O
were	O
responsible	O
for	O
decreased	O
affinity	O
,	O
squirrel	O
monkey	O
and	O
human	B
glucocorticoid	I
receptors	I
were	O
expressed	O
in	O
the	O
TNT	O
Coupled	O
Reticulocyte	O
Lysate	O
System	O
.	O
Expressions	O
of	O
human	O
and	O
squirrel	O
monkey	O
glucocorticoid	B
receptors	I
and	O
a	O
squirrel	B
monkey	I
receptor	I
in	O
which	O
Phe774	O
was	O
mutated	O
to	O
Leu	O
(	O
F774L	O
)	O
were	O
similar	O
.	O
When	O
expressed	O
in	O
the	O
TNT	O
System	O
,	O
squirrel	O
monkey	O
and	O
human	B
glucocorticoid	I
receptors	I
had	O
similar	O
,	O
high	O
affinity	O
binding	O
for	O
dexamethasone	O
(	O
apparent	O
Kd	O
,	O
5.9	O
+	O
/-	O
1.2	O
and	O
4.3	O
+	O
/-	O
0.5	O
nmol	O
/	O
L	O
,	O
respectively	O
;	O
n	O
=	O
3	O
)	O
,	O
whereas	O
the	O
squirrel	B
monkey	I
F774L	I
receptor	I
had	O
lower	O
affinity	O
binding	O
(	O
apparent	O
Kd	O
,	O
20.4	O
+	O
/-	O
2.0	O
nmol	O
/	O
L	O
;	O
n	O
=	O
3	O
)	O
.	O
Thus	O
,	O
substitutions	O
within	O
the	O
ligand	B
-	I
binding	I
domain	I
of	O
the	O
squirrel	O
monkey	O
glucocorticoid	B
receptor	I
can	O
not	O
account	O
for	O
the	O
decreased	O
binding	O
affinity	O
of	O
these	O
receptors	O
in	O
squirrel	O
monkey	O
cells	O
.	O
Rather	O
,	O
the	O
binding	O
affinity	O
is	O
probably	O
influenced	O
by	O
the	O
expression	O
of	O
cytosolic	B
factors	I
that	O
affect	O
glucocorticoid	B
receptor	I
function	O
.	O
Characterization	O
of	O
the	O
human	O
platelet	O
/	O
endothelial	O
cell	O
adhesion	O
molecule-1	O
promoter	O
:	O
identification	O
of	O
a	O
GATA-2	O
binding	O
element	O
required	O
for	O
optimal	O
transcriptional	O
activity	O
.	O
Platelet	B
/	I
endothelial	I
cell	I
adhesion	I
molecule-1	I
(	O
PECAM-1	B
)	O
is	O
a	O
130-kD	B
member	I
of	O
the	O
Ig	O
gene	O
superfamily	O
that	O
is	O
expressed	O
on	O
platelets	O
,	O
endothelial	O
cells	O
,	O
and	O
certain	O
leukocyte	O
subsets	O
.	O
To	O
examine	O
the	O
factors	O
controlling	O
vascular	O
-	O
specific	O
expression	O
of	O
PECAM-1	B
,	O
we	O
cloned	O
the	O
5'-flanking	O
region	O
of	O
the	O
PECAM-1	O
gene	O
and	O
analyzed	O
its	O
transcriptional	O
activity	O
.	O
5'-Rapid	O
amplification	O
of	O
cDNA	O
ends	O
(	O
5'-RACE	O
)	O
analysis	O
showed	O
that	O
transcription	O
initiation	O
occurred	O
at	O
several	O
closely	O
spaced	O
nearby	O
sites	O
originating	O
approximately	O
204	O
bp	O
upstream	O
from	O
the	O
translation	O
start	O
site	O
.	O
Analysis	O
of	O
the	O
sequence	O
immediately	O
upstream	O
from	O
the	O
transcription	O
initiation	O
site	O
(	O
TIS	O
)	O
showed	O
no	O
canonical	O
TATA	O
or	O
CAAT	O
elements	O
,	O
however	O
an	O
initiator	O
element	O
commonly	O
found	O
in	O
TATA	O
-	O
less	O
promoters	O
encompassed	O
the	O
TIS	O
.	O
5'-serially	O
truncated	O
PECAM-1	O
promoter	O
segments	O
cloned	O
in	O
front	O
of	O
a	O
luciferase	O
reporter	O
drove	O
transcription	O
in	O
both	O
a	O
lineage-	O
and	O
orientation	O
-	O
specific	O
manner	O
.	O
Putative	O
cis	O
-	O
acting	O
control	O
elements	O
present	O
within	O
a	O
300-bp	O
core	O
promoter	O
included	O
two	O
ets	O
sites	O
,	O
an	O
Sp1	O
site	O
,	O
tandem	O
E	O
-	O
box	O
domains	O
,	O
two	O
GATA	O
-	O
associated	O
sites	O
(	O
CACCC	O
)	O
,	O
an	O
AP-2	O
binding	O
site	O
,	O
and	O
a	O
GATA	O
element	O
at	O
-24	O
.	O
Mutational	O
analysis	O
showed	O
that	O
optimal	O
transcriptional	O
activity	O
required	O
the	O
GATA	O
sequence	O
at	O
position	O
-24	O
,	O
and	O
gel	O
-	O
shift	O
assays	O
further	O
showed	O
that	O
the	O
GATA-2	B
transcription	I
factor	I
,	O
but	O
not	O
GATA-1	B
,	O
bound	O
to	O
this	O
region	O
of	O
the	O
PECAM-1	O
promoter	O
.	O
Understanding	O
the	O
cis-	B
and	I
transacting	I
factors	I
that	O
regulate	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
PECAM-1	B
should	O
increase	O
our	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
vascular	O
-	O
specific	O
gene	O
expression	O
is	O
achieved	O
.	O
Expression	O
of	O
erythroid	O
-	O
specific	O
genes	O
in	O
megakaryoblastic	O
disorders	O
.	O
Currently	O
available	O
data	O
indicate	O
that	O
erythroid	O
and	O
megakaryocytic	O
differentiation	O
pathways	O
are	O
closely	O
related	O
to	O
each	O
other	O
,	O
and	O
there	O
may	O
exist	O
progenitor	O
cells	O
common	O
to	O
those	O
two	O
lineages	O
may	O
exist	O
.	O
Acute	O
megakaryoblastic	O
leukemia	O
(	O
AML	O
-	O
M7	O
)	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
's	O
syndrome	O
(	O
TMD	O
)	O
are	O
characterized	O
by	O
rapid	O
growth	O
of	O
abnormal	O
blast	O
cells	O
which	O
express	O
megakaryocytic	B
markers	I
.	O
These	O
blast	O
cells	O
express	O
lineage	B
-	I
specific	I
transcription	I
factors	I
such	O
as	O
GATA-1	B
common	O
to	O
these	O
lineages	O
and	O
frequently	O
express	O
erythroid	O
-	O
specific	O
mRNAs	O
such	O
as	O
gamma	B
-	I
globin	I
and	O
erythroid	B
delta	I
-	I
aminolevulinate	I
synthase	I
(	O
ALAS	B
-	I
E	I
)	O
,	O
indicating	O
that	O
most	O
of	O
the	O
blasts	O
in	O
M7	O
and	O
TMD	O
cases	O
have	O
erythroid	O
and	O
megakaryocytic	O
phenotypes	O
.	O
These	O
results	O
suggest	O
that	O
blasts	O
in	O
M7	O
and	O
TMD	O
may	O
correspond	O
to	O
progenitors	O
of	O
both	O
erythroid	O
and	O
megakaryocytic	O
lineages	O
.	O
Nuclear	B
NF	I
-	I
ATp	I
is	O
a	O
hallmark	O
of	O
unstimulated	O
B	O
cells	O
from	O
B	O
-	O
CLL	O
patients	O
.	O
B	O
lymphocytes	O
from	O
the	O
peripheral	O
blood	O
of	O
patients	O
with	O
chronic	O
lymphocytic	O
leukaemia	O
(	O
CLL	O
)	O
were	O
analysed	O
for	O
the	O
nuclear	O
presence	O
and	O
DNA	O
binding	O
of	O
a	O
panel	O
of	O
transcription	B
factors	I
which	O
are	O
involved	O
in	O
the	O
gene	O
control	O
of	O
lymphoid	O
cells	O
.	O
The	O
following	O
transcription	B
factors	I
were	O
studied	O
:	O
the	O
Octamer	B
factors	I
Oct-1	B
and	O
Oct-2	B
,	O
members	O
of	O
the	O
AP-1	B
factor	I
family	I
,	O
NF	B
-	I
AT	I
factors	I
,	O
in	O
particular	O
NF	B
-	I
ATp	I
,	O
and	O
members	O
of	O
the	O
Rel	B
/	I
NF	I
-	I
kB	I
family	I
.	O
We	O
show	O
that	O
the	O
constitutive	O
nuclear	O
translocation	O
of	O
NF	B
-	I
ATp	I
,	O
a	O
member	O
of	O
the	O
growing	O
family	O
of	O
NF	B
-	I
AT	I
factors	I
,	O
is	O
a	O
hallmark	O
of	O
nonstimulated	O
B	O
cells	O
from	O
CLL	O
patients	O
that	O
distinguishes	O
B	O
-	O
CLL	O
cells	O
from	O
'	O
normal	O
'	O
B	O
lymphocytes	O
.	O
Constitutive	O
nuclear	O
appearance	O
was	O
also	O
observed	O
for	O
NF	O
-	O
kB2	O
/	O
p52	O
.	O
Constitutive	O
binding	O
of	O
further	O
factor	B
proteins	I
to	O
DNA	O
,	O
such	O
as	O
JunD	B
,	O
c	B
-	I
Fos	I
and	O
FosB	B
,	O
was	O
detected	O
in	O
several	O
patients	O
whereas	O
the	O
localisation	O
and	O
DNA	O
binding	O
of	O
other	O
factors	O
such	O
as	O
c	B
-	I
Jun	I
,	O
RelA	B
/	I
p65	I
and	O
c	B
-	I
Rel	I
was	O
unaltered	O
.	O
It	O
is	O
remarkable	O
that	O
in	O
B	O
-	O
CLL	O
cells	O
the	O
nuclear	O
appearance	O
and	O
DNA	O
binding	O
of	O
specific	O
transcription	B
factors	I
is	O
dramatically	O
affected	O
whereas	O
other	O
members	O
of	O
the	O
same	O
factor	B
family	I
remained	O
unaltered	O
in	O
these	O
leukemic	O
cells	O
.	O
It	O
remains	O
to	O
be	O
shown	O
which	O
molecular	O
events	O
lead	O
to	O
the	O
specific	O
'	O
pre	O
-	O
activation	O
'	O
,	O
i.e	O
.	O
constitutive	O
nuclear	O
translocation	O
and	O
DNA	O
binding	O
,	O
of	O
these	O
members	O
of	O
NF	B
-	I
AT	I
,	O
NF	B
-	I
kB	I
and	O
AP-1	B
factor	I
families	I
.	O
Physical	O
and	O
functional	O
interaction	O
between	O
the	O
human	B
T	I
-	I
cell	I
lymphotropic	I
virus	I
type	I
1	I
Tax1	I
protein	I
and	O
the	O
CCAAT	B
binding	I
protein	I
NF	B
-	I
Y	I
.	O
Tax1	B
,	O
a	O
potent	O
activator	O
of	O
human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
transcription	O
,	O
has	O
been	O
shown	O
to	O
modulate	O
expression	O
of	O
many	O
cellular	O
genes	O
.	O
Tax1	B
does	O
not	O
bind	O
DNA	O
directly	O
but	O
regulates	O
transcription	O
through	O
protein	O
-	O
protein	O
interactions	O
with	O
sequence	B
-	I
specific	I
transcription	I
factors	I
.	O
Using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
to	O
screen	O
for	O
proteins	O
which	O
interact	O
with	O
Tax1	B
,	O
we	O
isolated	O
the	O
B	B
subunit	I
of	O
the	O
CCAAT	B
binding	I
protein	I
NF	B
-	I
Y	I
from	O
a	O
HeLa	O
cDNA	O
library	O
.	O
The	O
interaction	O
of	O
Tax1	B
with	O
NF	B
-	I
YB	I
was	O
specific	O
in	O
that	O
NF	B
-	I
YB	I
did	O
not	O
interact	O
with	O
a	O
variety	O
of	O
other	O
transcription	B
factors	I
,	O
including	O
human	B
immunodeficiency	I
virus	I
Tat	I
,	O
human	B
papillomavirus	I
E6	I
,	O
and	O
Bicoid	B
,	O
or	O
with	O
the	O
M7	B
(	I
amino	I
acids	I
29CP	I
-	I
AS	I
)	I
Tax1	I
mutant	I
.	O
However	O
,	O
NF	B
-	I
YB	I
did	O
interact	O
with	O
the	O
C	B
-	I
terminal	I
Tax1	I
mutants	I
M22	B
(	O
130TL	B
-	I
AS	I
)	O
and	O
M47	B
(	O
319LL	B
-	I
RS	I
)	O
.	O
We	O
also	O
show	O
that	O
in	O
vitro	O
-	O
translated	O
NF	B
-	I
YB	I
specifically	O
bound	O
to	O
a	O
glutathione	B
S	I
-	I
transferase	I
-	I
Tax1	I
fusion	I
protein	I
.	O
Further	O
,	O
Tax1	B
coimmunoprecipitated	O
with	O
NF	B
-	I
Y	I
from	O
nuclear	O
extracts	O
of	O
HTLV-1-transformed	O
cells	O
,	O
providing	O
evidence	O
for	O
in	O
vivo	O
interaction	O
of	O
Tax1	B
and	O
NF	B
-	I
YB	I
.	O
We	O
further	O
demonstrate	O
that	O
Tax1	B
specifically	O
activated	O
the	O
NF	O
-	O
Y	O
-	O
responsive	O
DQbeta	O
promoter	O
,	O
as	O
well	O
as	O
a	O
minimal	O
promoter	O
which	O
contains	O
only	O
the	O
Y	O
-	O
box	O
element	O
.	O
In	O
addition	O
,	O
mutation	O
of	O
the	O
Y	O
-	O
box	O
element	O
alone	O
abrogated	O
Tax1	B
-mediated	O
activation	O
.	O
Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
Tax1	B
interacts	O
with	O
NF	B
-	I
Y	I
through	O
the	O
B	B
subunit	I
and	O
that	O
this	O
interaction	O
results	O
in	O
activation	O
of	O
the	O
major	O
histocompatibility	O
complex	O
class	O
II	O
promoter	O
.	O
Through	O
activation	O
of	O
this	O
and	O
other	O
NF	B
-	I
Y	I
driven	O
promoters	O
,	O
the	O
Tax1	B
-NF	B
-	I
Y	I
interaction	O
may	O
play	O
a	O
critical	O
role	O
in	O
causing	O
cellular	O
transformation	O
and	O
HTLV-1	O
pathogenesis	O
.	O
Cloning	O
of	O
the	O
novel	B
human	I
myeloid	I
-	I
cell	I
-	I
specific	I
C	I
/	I
EBP	I
-	I
epsilon	I
transcription	I
factor	I
.	O
Chicken	B
NF	I
-	I
M	I
transcription	I
factor	I
,	O
in	O
cooperation	O
with	O
either	O
c	B
-	I
Myb	I
or	O
v	B
-	I
Myb	I
,	O
is	O
active	O
in	O
the	O
combinatorial	O
activation	O
of	O
myeloid	O
-	O
cell	O
-	O
specific	O
genes	O
in	O
heterologous	O
cell	O
types	O
,	O
such	O
as	O
embryonic	O
fibroblasts	O
.	O
In	O
humans	O
,	O
similar	O
effects	O
were	O
observed	O
with	O
homologous	O
members	O
of	O
the	O
CCAAT	B
/	I
enhancer	I
-	I
binding	I
protein	I
(	I
C	I
/	I
EBP	I
)	I
family	I
of	O
transcriptional	B
regulators	I
,	O
especially	O
the	O
human	O
homolog	O
of	O
chicken	B
NF	I
-	I
M	I
,	O
C	B
/	I
EBP	I
-	I
beta	I
(	O
NF	B
-	I
IL6	I
)	O
.	O
However	O
,	O
the	O
NF	O
-	O
IL6	O
gene	O
is	O
expressed	O
in	O
a	O
variety	O
of	O
nonmyeloid	O
cell	O
types	O
and	O
is	O
strongly	O
inducible	O
in	O
response	O
to	O
inflammatory	O
stimuli	O
,	O
making	O
it	O
an	O
unlikely	O
candidate	O
to	O
have	O
an	O
exclusive	O
role	O
as	O
a	O
combinatorial	O
differentiation	O
switch	O
during	O
myelopoiesis	O
in	O
human	O
cells	O
.	O
By	O
using	O
a	O
reverse	O
transcription	O
-	O
PCR	O
-	O
based	O
approach	O
and	O
a	O
set	O
of	O
primers	O
specific	O
for	O
the	O
DNA	O
-	O
binding	O
domains	O
of	O
highly	O
homologous	O
members	O
of	O
the	O
C	B
/	I
EBP	I
family	I
of	O
transcriptional	B
regulators	I
,	O
we	O
have	O
cloned	O
a	O
novel	O
human	O
gene	O
encoding	O
a	O
member	O
of	O
the	O
C	O
/	O
EBP	O
gene	O
family	O
,	O
identified	O
as	O
the	O
human	O
homolog	O
of	O
CRP1	B
,	O
C	B
/	I
EBP	I
-	I
epsilon	I
.	O
A	O
1.2-kb	O
cDNA	O
encoding	O
full	O
-	O
length	O
human	O
C	O
/	O
EBP	O
-	O
epsilon	O
was	O
cloned	O
from	O
a	O
promyelocyte	O
-	O
late	O
myeloblast	O
-	O
derived	O
lambda	O
gt11	O
library	O
.	O
Molecular	O
analysis	O
of	O
the	O
cDNA	O
and	O
genomic	O
clones	O
indicated	O
the	O
presence	O
of	O
two	O
exons	O
encoding	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
32	O
kDa	O
and	O
a	O
pI	O
of	O
9.5	O
.	O
Primer	O
extension	O
analysis	O
of	O
C	O
/	O
EBP	O
-	O
epsilon	O
mRNA	O
detected	O
a	O
single	O
major	O
transcription	O
start	O
site	O
approximately	O
200	O
bp	O
upstream	O
of	O
the	O
start	O
codon	O
.	O
The	O
putative	O
promoter	O
area	O
is	O
similar	O
to	O
those	O
of	O
several	O
other	O
myeloid	O
-	O
cell	O
-	O
specific	O
genes	O
in	O
that	O
it	O
contains	O
no	O
TATAAA	O
box	O
but	O
has	O
a	O
number	O
of	O
purine	O
-	O
rich	O
stretches	O
with	O
multiple	O
sites	O
for	O
the	O
factors	O
of	O
the	O
Ets	B
family	I
of	O
transcriptional	B
regulators	I
.	O
Northern	O
blot	O
analyses	O
indicated	O
a	O
highly	O
restricted	O
mRNA	O
expression	O
pattern	O
,	O
with	O
the	O
strongest	O
expression	O
occurring	O
in	O
promyelocyte	O
and	O
late	O
-	O
myeloblast	O
-	O
like	O
cell	O
lines	O
.	O
Western	O
blot	O
and	O
immunoprecipitation	O
studies	O
using	O
rabbit	B
anti	I
-	I
C	I
/	I
EBP	I
-	I
epsilon	I
antibodies	I
raised	O
against	O
the	O
N	B
-	I
terminal	I
portion	I
of	O
C	B
/	I
EBP	I
-	I
epsilon	I
(	O
amino	B
acids	I
1	I
to	I
115	I
)	O
showed	O
that	O
C	B
/	I
EBP	I
-	I
epsilon	I
is	O
a	O
32-kDa	B
nuclear	I
phosphoprotein	I
.	O
The	O
human	O
C	B
/	I
EBP	I
-	I
epsilon	I
protein	O
exhibited	O
strong	O
and	O
specific	O
binding	O
to	O
double	O
-	O
stranded	O
DNA	O
containing	O
consensus	O
C	O
/	O
EBP	O
sites	O
.	O
Cotransfection	O
of	O
the	O
C	B
/	I
EBP	I
-	I
epsilon	I
sense	O
and	O
antisense	O
expression	O
constructs	O
together	O
with	O
chloramphenicol	O
acetyltransferase	O
reporter	O
vectors	O
containing	O
myeloid	O
-	O
cell	O
-	O
specific	O
c	O
-	O
mim	O
and	O
human	O
myeloperoxidase	O
promoters	O
suggested	O
a	O
role	O
for	O
C	B
/	I
EBP	I
-	I
epsilon	I
transcription	B
factor	I
in	O
the	O
regulation	O
of	O
a	O
subset	O
of	O
myeloid	O
-	O
cell	O
-	O
specific	O
genes	O
.	O
Transient	O
tranfection	O
of	O
a	O
promyelocyte	O
cell	O
line	O
(	O
NB4	O
)	O
with	O
a	O
C	O
/	O
EBP	O
-	O
epsilon	O
expression	O
plasmid	O
increased	O
cell	O
growth	O
by	O
sevenfold	O
,	O
while	O
antisense	O
C	B
/	I
EBP	I
-	I
epsilon	I
caused	O
a	O
fivefold	O
decrease	O
in	O
clonal	O
growth	O
of	O
these	O
cells	O
.	O
Transcriptional	O
regulation	O
of	O
the	O
ferritin	O
heavy	O
-	O
chain	O
gene	O
:	O
the	O
activity	O
of	O
the	O
CCAAT	B
binding	I
factor	I
NF	I
-	I
Y	I
is	O
modulated	O
in	O
heme	O
-	O
treated	O
Friend	O
leukemia	O
cells	O
and	O
during	O
monocyte	O
-	O
to	O
-	O
macrophage	O
differentiation	O
.	O
The	O
ferritin	O
H	O
-	O
chain	O
gene	O
promoter	O
regulation	O
was	O
analyzed	O
in	O
heme	O
-	O
treated	O
Friend	O
leukemia	O
cells	O
(	O
FLCs	O
)	O
and	O
during	O
monocyte	O
-	O
to	O
-	O
macrophage	O
differentiation	O
.	O
In	O
the	O
majority	O
of	O
cell	O
lines	O
studied	O
,	O
the	O
regulation	O
of	O
ferritin	B
expression	O
was	O
exerted	O
mostly	O
at	O
the	O
translational	O
level	O
.	O
However	O
,	O
in	O
differentiating	O
erythroid	O
cells	O
,	O
which	O
must	O
incorporate	O
high	O
levels	O
of	O
iron	O
to	O
sustain	O
hemoglobin	B
synthesis	O
,	O
and	O
in	O
macrophages	O
,	O
which	O
are	O
involved	O
in	O
iron	O
storage	O
,	O
transcriptional	O
regulation	O
seemed	O
to	O
be	O
a	O
relevant	O
mechanism	O
.	O
We	O
show	O
here	O
that	O
the	O
minimum	O
region	O
of	O
the	O
ferritin	O
H	O
-	O
gene	O
promoter	O
that	O
is	O
able	O
to	O
confer	O
transcriptional	O
regulation	O
by	O
heme	O
in	O
FLCs	O
to	O
a	O
reporter	O
gene	O
is	O
77	O
nucleotides	O
upstream	O
of	O
the	O
TATA	O
box	O
.	O
This	O
cis	O
element	O
binds	O
a	O
protein	O
complex	O
referred	O
to	O
as	O
HRF	B
(	O
heme	B
-	I
responsive	I
factor	I
)	O
,	O
which	O
is	O
greatly	O
enhanced	O
both	O
in	O
heme	O
-	O
treated	O
FLCs	O
and	O
during	O
monocyte	O
-	O
to	O
-	O
macrophage	O
differentiation	O
.	O
The	O
CCAAT	O
element	O
present	O
in	O
reverse	O
orientation	O
in	O
this	O
promoter	O
region	O
of	O
the	O
ferritin	O
H	O
-	O
chain	O
gene	O
is	O
necessary	O
for	O
binding	O
and	O
for	O
gene	O
activity	O
,	O
since	O
a	O
single	O
point	O
mutation	O
is	O
able	O
to	O
abolish	O
the	O
binding	O
of	O
HRF	B
and	O
the	O
transcriptional	O
activity	O
in	O
transfected	O
cells	O
.	O
By	O
competition	O
experiments	O
and	O
supershift	O
assays	O
,	O
we	O
identified	O
the	O
induced	O
HRF	B
as	O
containing	O
at	O
least	O
the	O
ubiquitous	O
transcription	B
factor	I
NF	B
-	I
Y	I
.	O
NF	B
-	I
Y	I
is	O
formed	O
by	O
three	O
subunits	B
,	O
A	B
,	O
B	B
,	O
and	O
C	B
,	O
all	O
of	O
which	O
are	O
necessary	O
for	O
DNA	O
binding	O
.	O
Cotransfection	O
with	O
a	O
transdominant	B
negative	I
mutant	I
of	O
the	O
NF	B
-	I
YA	I
subunit	I
abolishes	O
the	O
transcriptional	O
activation	O
by	O
heme	B
,	O
indicating	O
that	O
NF	B
-	I
Y	I
plays	O
an	O
essential	O
role	O
in	O
this	O
activation	O
.	O
We	O
have	O
also	O
observed	O
a	O
differential	O
expression	O
of	O
the	O
NF	B
-	I
YA	I
subunit	I
in	O
heme	O
-	O
treated	O
and	O
control	O
FLCs	O
and	O
during	O
monocyte	O
-	O
to	O
-	O
macrophage	O
differentiation	O
.	O
Identification	O
of	O
nucleotide	O
sequences	O
that	O
regulate	O
transcription	O
of	O
the	O
MCF13	O
murine	O
leukemia	O
virus	O
long	O
terminal	O
repeat	O
in	O
activated	O
T	O
cells	O
.	O
The	O
region	O
downstream	O
of	O
the	O
enhancer	O
(	O
DEN	O
)	O
of	O
the	O
long	O
terminal	O
repeat	O
of	O
the	O
mink	O
cell	O
focus	O
-	O
forming	O
murine	O
leukemia	O
virus	O
is	O
important	O
for	O
viral	O
pathogenicity	O
.	O
Another	O
important	O
activity	O
of	O
DEN	O
is	O
its	O
control	O
of	O
transcription	O
in	O
activated	O
T	O
cells	O
,	O
and	O
we	O
have	O
determined	O
that	O
an	O
NF	B
-	I
kappaB	I
site	O
is	O
critical	O
for	O
this	O
activity	O
.	O
Activation	O
of	O
the	O
NF	B
-	I
kappaB	I
transcription	B
factor	I
in	O
a	O
T	O
-	O
lymphocytic	O
cell	O
line	O
by	O
hypochlorous	O
acid	O
.	O
Reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
such	O
as	O
hydrogen	O
peroxide	O
serve	O
as	O
second	O
messengers	O
in	O
the	O
induction	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
,	O
and	O
hence	O
in	O
the	O
activation	O
and	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
in	O
human	O
cells	O
.	O
During	O
inflammatory	O
reactions	O
,	O
many	O
oxidative	O
species	O
are	O
produced	O
,	O
one	O
of	O
which	O
is	O
hypochlorous	O
acid	O
(	O
HOCl	O
)	O
,	O
which	O
is	O
responsible	O
for	O
the	O
microbicidal	O
effects	O
of	O
activated	O
human	O
polymorphonuclear	O
leukocytes	O
.	O
Treatment	O
of	O
a	O
T	O
-	O
lymphocytic	O
cell	O
line	O
with	O
micromolar	O
concentrations	O
of	O
HOCl	O
promoted	O
the	O
appearance	O
of	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
(	O
the	O
heterodimer	B
p50	I
/	I
p65	I
)	O
in	O
the	O
nucleus	O
of	O
the	O
cells	O
,	O
even	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
.	O
Western	O
blot	O
analysis	O
of	O
the	O
NF	B
-	I
kappaB	I
inhibitory	I
subunits	I
(	O
IkappaB	B
)	O
demonstrated	O
that	O
both	O
IkappaB	B
-alpha	O
proteolysis	O
and	O
p105	B
processing	O
were	O
induced	O
by	O
the	O
treatment	O
.	O
NF	B
-	I
kappaB	I
activation	O
was	O
very	O
effective	O
when	O
cells	O
were	O
subjected	O
to	O
hyperthermia	O
before	O
being	O
treated	O
with	O
HOCl	O
.	O
Various	O
antioxidants	O
,	O
such	O
as	O
pyrrolidine	O
dithiocarbamate	O
,	O
p	O
-	O
bromophenacyl	O
-	O
bromide	O
and	O
nordihydroguaiaretic	O
acid	O
could	O
strongly	O
reduce	O
NF	B
-	I
kappaB	I
translocation	O
,	O
demonstrating	O
the	O
importance	O
of	O
oxidative	O
species	O
in	O
the	O
transduction	O
mechanism	O
.	O
Moreover	O
,	O
ACH-2	O
cells	O
treated	O
with	O
HOCl	O
or	O
H2O2	O
released	O
tumour	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
in	O
the	O
supernatants	O
.	O
The	O
importance	O
of	O
TNF	B
-	I
alpha	I
release	O
in	O
NF	B
-	I
kappaB	I
induction	O
by	O
HOCl	O
or	O
H2O2	O
was	O
demonstrated	O
by	O
the	O
fact	O
that	O
:	O
(	O
1	O
)	O
the	O
nuclear	O
appearance	O
of	O
NF	B
-	I
kappaB	I
was	O
promoted	O
in	O
untreated	O
cells	O
;	O
and	O
(	O
2	O
)	O
synergism	O
between	O
TNF	B
-	I
alpha	I
and	O
HOCl	O
was	O
detected	O
.	O
Collectively	O
,	O
these	O
results	O
suggest	O
that	O
HOCl	O
should	O
be	O
considered	O
as	O
an	O
oxidative	O
species	O
capable	O
of	O
inducing	O
NF	B
-	I
kappaB	I
in	O
a	O
T	O
-	O
lymphocytic	O
cell	O
line	O
through	O
a	O
transduction	O
mechanism	O
involving	O
ROS	O
,	O
and	O
having	O
a	O
long	O
-	O
distance	O
effect	O
through	O
subsequent	O
TNF	B
-	I
alpha	I
release	O
.	O
The	O
synthesis	O
and	O
immunogenicity	O
of	O
varicella	B
-	I
zoster	I
virus	I
glycoprotein	I
E	I
and	O
immediate	B
-	I
early	I
protein	I
(	O
IE62	B
)	O
expressed	O
in	O
recombinant	O
herpes	O
simplex	O
virus-1	O
.	O
In	O
order	O
to	O
evaluate	O
the	O
conditions	O
for	O
optimal	O
expression	O
and	O
immunogenicity	O
of	O
varicella	B
-	I
zoster	I
virus	I
(	I
VZV	I
)	I
proteins	I
in	O
a	O
herpes	O
simplex	O
virus-1	O
(	O
HSV-1	O
)	O
vector	O
,	O
we	O
selected	O
the	O
VZV	B
glycoprotein	I
E	I
(	O
gE	B
)	O
,	O
encoded	O
by	O
ORF	O
68	O
and	O
the	O
VZV	B
product	I
of	O
ORF	O
62	O
,	O
an	O
immediate	B
-	I
early	I
major	I
tegument	I
protein	I
(	O
IE62	B
)	O
.	O
Three	O
HSV	O
/	O
VZV	O
recombinants	O
were	O
generated	O
:	O
(	O
1	O
)	O
VZV	O
gE	O
protein	O
coding	O
sequences	O
along	O
with	O
the	O
promoter	B
region	I
were	O
inserted	O
into	O
the	O
thymidine	O
kinase	O
(	O
TK	O
)	O
gene	O
of	O
HSV-1	O
strain	O
KOS	O
;	O
(	O
2	O
)	O
VZV	B
gE	I
expressed	O
from	O
the	O
HSV-1	O
ICP4	O
promoter	O
was	O
inserted	O
into	O
the	O
glycoprotein	O
C	O
(	O
gC	O
)	O
gene	O
of	O
HSV-1	O
strain	O
F	O
;	O
and	O
(	O
3	O
)	O
VZV	O
IE62	O
protein	O
coding	O
sequences	O
under	O
the	O
control	O
of	O
the	O
HSV-1	O
ICP4	O
promoter	O
were	O
inserted	O
into	O
the	O
gC	O
gene	O
of	O
HSV-1	O
strain	O
F	O
.	O
Immunoblot	O
analysis	O
and	O
immunoperoxidase	O
staining	O
of	O
infected	O
cell	O
monolayers	O
demonstrated	O
vector	O
expression	O
of	O
VZV	B
proteins	I
.	O
Following	O
intracranial	O
inoculation	O
in	O
mice	O
,	O
both	O
VZV	B
gE	I
-	I
HSV	I
(	O
TK	B
)	O
and	O
VZV	B
IE62-HSV	I
(	O
gC	B
)	O
induced	O
an	O
IgG	B
response	O
against	O
VZV	B
gE	I
or	O
VZV	B
IE62	I
.	O
When	O
tested	O
in	O
cytotoxicity	O
assays	O
using	O
T	O
-	O
lymphocytes	O
from	O
VZV	O
immune	O
human	O
donors	O
,	O
the	O
range	O
of	O
precursor	O
frequencies	O
for	O
T	O
-	O
lymphocytes	O
that	O
recognized	O
VZV	B
gE	I
or	O
VZV	B
IE62	I
was	O
similar	O
whether	O
these	O
proteins	O
were	O
expressed	O
by	O
HSV-1	O
or	O
a	O
vaccinia	O
vector	O
.	O
These	O
experiments	O
demonstrate	O
that	O
HSV-1	O
is	O
a	O
competent	O
vector	O
for	O
expression	O
of	O
these	O
VZV	B
proteins	I
and	O
support	O
the	O
feasibility	O
of	O
engineering	O
a	O
combined	O
vaccine	O
for	O
these	O
closely	O
related	O
alpha	O
-	O
herpesviruses	O
.	O
[	O
Correlation	O
of	O
lymphocytic	O
infiltration	O
of	O
tumor	O
tissue	O
with	O
the	O
hormonal	O
and	O
metabolic	O
state	O
in	O
patients	O
with	O
breast	O
cancer	O
]	O
Lymphocyte	O
infiltration	O
of	O
tumor	O
was	O
studied	O
vis	O
-	O
a	O
-	O
vis	O
hormone	O
metabolic	O
status	O
,	O
tumor	O
tissue	O
hormone	O
sensitivity	O
and	O
tobacco	O
smoking	O
,	O
in	O
113	O
breast	O
cancer	O
patients	O
,	O
aged	O
25	O
-	O
77	O
.	O
On	O
the	O
average	O
,	O
no	O
correlation	O
was	O
established	O
between	O
degree	O
of	O
lymphocyte	O
infiltration	O
in	O
breast	O
tumor	O
and	O
age	O
and	O
menopause	O
onset	O
.	O
In	O
smoking	O
menopausal	O
patients	O
,	O
lymphocyte	O
infiltration	O
was	O
found	O
to	O
be	O
higher	O
than	O
in	O
non	O
-	O
smokers	O
(	O
p	O
<	O
0.05	O
)	O
.	O
There	O
was	O
a	O
direct	O
correlation	O
between	O
the	O
rate	O
of	O
lymphocyte	O
infiltration	O
and	O
the	O
level	O
of	O
progesterone	B
receptors	I
in	O
tumor	O
.	O
Some	O
subgroups	O
displayed	O
a	O
direct	O
correlation	O
between	O
infiltration	O
and	O
sex	B
-	I
binding	I
globulin	I
,	O
cholesterol	O
,	O
luteinizing	O
hormone	O
in	O
blood	O
,	O
and	O
lean	O
body	O
mass	O
.	O
It	O
was	O
matched	O
by	O
an	O
inverse	O
correlation	O
between	O
lymphocyte	O
infiltration	O
and	O
blood	O
-	O
thyroid	O
hormone	O
concentration	O
,	O
urine	O
catecholamines	O
and	O
free	O
cortisol	O
excretion	O
and	O
fat	O
/	O
lean	O
body	O
mass	O
ratio	O
.	O
Considering	O
the	O
abovesaid	O
as	O
well	O
as	O
the	O
lymphocyte	O
ability	O
to	O
perform	O
the	O
dual	O
function	O
of	O
immunocytes	O
and	O
hormonocytes	O
,	O
it	O
is	O
suggested	O
that	O
the	O
results	O
may	O
be	O
used	O
in	O
both	O
the	O
study	O
of	O
lymphocyte	O
infiltration	O
and	O
research	O
in	O
means	O
of	O
its	O
control	O
.	O
Thymocytes	O
control	O
the	O
CD4	O
gene	O
differently	O
from	O
mature	O
T	O
lymphocytes	O
.	O
We	O
analyzed	O
the	O
activity	O
of	O
the	O
enhancer	O
,	O
the	O
promoter	O
and	O
the	O
silencer	O
of	O
the	O
human	O
CD4	O
gene	O
during	O
T	O
cell	O
development	O
using	O
transgenic	O
mice	O
.	O
Immunofluorescence	O
studies	O
on	O
thymic	O
populations	O
of	O
mice	O
carrying	O
transgenes	O
in	O
various	O
combinations	O
of	O
these	O
regulatory	O
DNA	O
elements	O
revealed	O
that	O
thymocytes	O
control	O
the	O
CD4	O
gene	O
in	O
a	O
different	O
manner	O
than	O
mature	O
peripheral	O
T	O
lymphocytes	O
.	O
The	O
5'-positive	O
regulatory	O
unit	O
,	O
consisting	O
of	O
the	O
promoter	O
and	O
the	O
5	O
'	O
enhancer	O
,	O
is	O
already	O
active	O
at	O
the	O
CD4	B
-	O
CD8	B
-double	O
-	O
negative	O
(	O
DN	O
)	O
stage	O
of	O
development	O
.	O
However	O
,	O
its	O
activity	O
becomes	O
lower	O
in	O
the	O
double	O
-	O
positive	O
and	O
a	O
fraction	O
of	O
the	O
CD4	O
+	O
CD8int	O
/	O
-	O
cell	O
population	O
,	O
indicating	O
that	O
an	O
additional	O
enhancer	O
,	O
located	O
in	O
either	O
the	O
first	O
or	O
the	O
third	O
intron	O
of	O
the	O
CD4	O
gene	O
,	O
is	O
required	O
for	O
CD4	O
gene	O
expression	O
in	O
this	O
population	O
.	O
The	O
other	O
studied	O
regulatory	O
element	O
is	O
the	O
minimal	O
CD4	O
silencer	O
which	O
inhibits	O
CD4	O
gene	O
expression	O
in	O
peripheral	O
CD8	O
T	O
lymphocytes	O
.	O
This	O
silencer	O
is	O
inactive	O
in	O
the	O
most	O
immature	O
DN	O
thymocytes	O
,	O
which	O
probably	O
use	O
a	O
distinct	O
silencer	O
mechanism	O
to	O
down	O
-	O
regulate	O
CD4	O
gene	O
expression	O
.	O
Unexpectedly	O
,	O
the	O
CD4	O
silencer	O
is	O
also	O
active	O
in	O
CD4	O
+	O
CD8int	O
/	O
-	O
cells	O
of	O
the	O
thymus	O
,	O
implying	O
that	O
an	O
anti	O
-	O
silencer	O
may	O
be	O
required	O
to	O
resume	O
CD4	B
expression	O
in	O
this	O
cell	O
population	O
.	O
Altogether	O
,	O
the	O
CD4	O
gene	O
is	O
regulated	O
by	O
several	O
positive	O
and	O
negative	O
regulatory	O
mechanisms	O
which	O
come	O
into	O
play	O
in	O
a	O
developmentally	O
coordinated	O
manner	O
.	O
Heat	O
-	O
shock	O
and	O
cadmium	O
chloride	O
increase	O
the	O
vimentin	O
mRNA	O
and	O
protein	O
levels	O
in	O
U-937	O
human	O
promonocytic	O
cells	O
.	O
Heat	O
-	O
shock	O
for	O
2	O
hours	O
at	O
42	O
degrees	O
C	O
,	O
or	O
the	O
administration	O
for	O
3	O
hours	O
of	O
100	O
or	O
150	O
microM	O
cadmium	O
chloride	O
,	O
inhibited	O
the	O
subsequent	O
proliferation	O
activity	O
,	O
induced	O
the	O
expression	O
of	O
functional	O
differentiation	B
markers	I
,	O
and	O
caused	O
an	O
increase	O
in	O
the	O
amount	O
of	O
the	O
stress	B
-	I
responsive	I
HSP70	I
protein	I
in	O
U-937	O
human	O
promonocytic	O
cells	O
.	O
In	O
addition	O
,	O
both	O
heat	O
and	O
cadmium	O
produced	O
an	O
increase	O
in	O
the	O
amount	O
of	O
the	O
intermediate	B
filament	I
protein	I
vimentin	B
,	O
as	O
determined	O
by	O
immunoblot	O
and	O
immunofluorescence	O
assays	O
.	O
By	O
contrast	O
,	O
the	O
amounts	O
of	O
actin	B
and	O
beta	B
-	I
tubulin	I
were	O
not	O
significantly	O
altered	O
.	O
The	O
amount	O
of	O
vimentin	O
mRNA	O
was	O
also	O
increased	O
during	O
recovery	O
from	O
stress	O
,	O
indicating	O
that	O
vimentin	B
expression	O
was	O
not	O
exclusively	O
regulated	O
at	O
the	O
protein	O
level	O
.	O
Although	O
cadmium	O
caused	O
an	O
early	O
,	O
transient	O
stimulation	O
of	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
expression	O
and	O
AP-1	B
binding	O
activity	O
,	O
heat	O
-	O
shock	O
failed	O
to	O
alter	O
both	O
protooncogene	O
expression	O
and	O
transcription	O
factor	O
binding	O
,	O
indicating	O
that	O
the	O
stress	O
-	O
induced	O
vimentin	B
increase	O
was	O
not	O
the	O
result	O
of	O
AP-1	B
-mediated	O
transcriptional	O
activation	O
.	O
Finally	O
,	O
it	O
was	O
observed	O
that	O
the	O
rate	O
of	O
decay	O
of	O
vimentin	O
mRNA	O
upon	O
actinomycin	O
D	O
administration	O
was	O
decreased	O
in	O
heat-	O
and	O
cadmium	O
-	O
pretreated	O
cells	O
in	O
comparison	O
to	O
untreated	O
cells	O
.	O
These	O
results	O
indicate	O
that	O
stress	O
treatments	O
cause	O
an	O
increase	O
in	O
vimentin	B
levels	O
in	O
promonocytic	O
cells	O
,	O
which	O
may	O
be	O
explained	O
at	O
least	O
in	O
part	O
by	O
transcript	O
stabilization	O
.	O
Immune	O
hyperactivation	O
of	O
HIV-1-infected	O
T	O
cells	O
mediated	O
by	O
Tat	B
and	O
the	O
CD28	B
pathway	O
.	O
Human	O
immunodeficiency	O
virus	O
-	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
is	O
characterized	O
by	O
a	O
chronic	O
state	O
of	O
immune	O
hyperactivation	O
in	O
patients	O
.	O
Infection	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
with	O
HIV-1	O
in	O
vitro	O
resulted	O
in	O
increased	O
interleukin-2	O
(	O
IL-2	O
)	O
secretion	O
in	O
response	O
to	O
T	O
cell	O
activation	O
via	O
the	O
CD3	B
and	I
CD28	I
receptors	I
.	O
Expression	O
of	O
the	O
HIV-1	B
transactivator	I
Tat	B
recapitulated	O
this	O
phenotype	O
and	O
was	O
associated	O
with	O
increased	O
IL-2	B
secretion	O
in	O
response	O
to	O
costimulation	O
with	O
CD3	B
plus	O
CD28	B
.	O
IL-2	B
superinduction	O
by	O
Tat	B
occurred	O
at	O
the	O
transcriptional	O
level	O
,	O
was	O
mediated	O
by	O
the	O
CD28-responsive	O
element	O
in	O
the	O
IL-2	O
promoter	O
,	O
and	O
was	O
exclusively	O
dependent	O
on	O
the	O
29	B
amino	I
acids	I
encoded	O
by	O
the	O
second	O
exon	O
of	O
Tat	O
.	O
A	O
T	O
cell	O
-	O
specific	O
enhancer	O
in	O
the	O
interleukin-3	O
locus	O
is	O
activated	O
cooperatively	O
by	O
Oct	O
and	O
NFAT	O
elements	O
within	O
a	O
DNase	O
I	O
-	O
hypersensitive	O
site	O
.	O
Interleukin-3	B
(	O
IL-3	B
)	O
is	O
a	O
cytokine	B
that	O
is	O
expressed	O
primarily	O
in	O
activated	O
T	O
cells	O
.	O
Here	O
we	O
identified	O
an	O
inducible	O
T	O
cell	O
-	O
specific	O
enhancer	O
14	O
kb	O
upstream	O
of	O
the	O
IL-3	O
gene	O
that	O
responded	O
to	O
activation	O
of	O
T	B
cell	I
receptor	I
signaling	O
pathways	O
.	O
The	O
IL-3	B
enhancer	O
spanned	O
an	O
inducible	O
cyclosporin	O
A	O
-	O
sensitive	O
DNase	O
I	O
-	O
hypersensitive	O
site	O
found	O
only	O
in	O
T	O
cells	O
.	O
Four	O
NFAT	O
-	O
like	O
elements	O
exist	O
within	O
the	O
enhancer	O
.	O
The	O
two	O
most	O
active	O
NFAT	O
-	O
like	O
elements	O
were	O
located	O
at	O
the	O
center	O
of	O
the	O
DNase	O
I	O
-	O
hypersensitive	O
site	O
.	O
One	O
of	O
these	O
NFAT	O
-	O
like	O
elements	O
encompassed	O
overlapping	O
Oct-	O
and	O
NFATp	O
/	O
c	O
-	O
binding	O
sites	O
,	O
which	O
functioned	O
in	O
a	O
highly	O
synergistic	O
manner	O
.	O
We	O
suggest	O
that	O
the	O
T	O
cell	O
-	O
specific	O
expression	O
of	O
the	O
IL-3	O
gene	O
is	O
partly	O
controlled	O
through	O
the	O
enhancer	O
by	O
cooperation	O
between	O
Oct	B
and	I
NFAT	I
family	I
proteins	I
.	O
A	O
negative	O
regulatory	O
region	O
containing	O
a	O
glucocorticosteroid	O
response	O
element	O
(	O
nGRE	O
)	O
in	O
the	O
human	O
interleukin-1beta	O
gene	O
.	O
Interleukin-1	B
beta	I
(	O
IL-1beta	B
)	O
is	O
one	O
of	O
the	O
most	O
important	O
inflammatory	B
mediators	I
in	O
human	O
inflammatory	O
and	O
immunological	O
diseases	O
.	O
The	O
regulation	O
of	O
human	B
IL-1beta	I
gene	O
expression	O
has	O
been	O
studied	O
for	O
several	O
years	O
,	O
and	O
a	O
few	O
regulatory	O
elements	O
have	O
been	O
discovered	O
in	O
the	O
promoter	O
region	O
.	O
However	O
,	O
little	O
is	O
known	O
about	O
negative	O
regulation	O
of	O
IL-1beta	B
expression	O
at	O
the	O
transcriptional	O
level	O
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
anti	O
-	O
inflammatory	O
and	O
immunosuppressive	O
effects	O
.	O
We	O
have	O
identified	O
a	O
negative	O
regulatory	O
element	O
located	O
in	O
the	O
region	O
between	O
-685	O
and	O
-395	O
.	O
Within	O
this	O
region	O
,	O
a	O
19-bp	O
nuclear	O
factor	O
binding	O
site	O
(	O
-570	O
to	O
-552	O
)	O
was	O
characterized	O
by	O
DNase	B
I	I
footprinting	O
and	O
electromobility	O
shift	O
assay	O
.	O
A	O
consensus	O
sequence	O
for	O
a	O
negative	O
glucocorticoid	O
response	O
element	O
(	O
nGRE	O
)	O
and	O
a	O
transcription	O
activator	O
protein-2	O
binding	O
site	O
were	O
noted	O
within	O
this	O
footprint	O
.	O
Functional	O
studies	O
showed	O
a	O
2.5-fold	O
increase	O
in	O
promoter	O
activity	O
when	O
this	O
19-bp	O
binding	O
site	O
was	O
deleted	O
in	O
the	O
reporter	O
constructs	O
IL-1beta	B
/CAT	B
and	O
IL-1beta	B
/SV40	O
promoter	O
/CAT	B
.	O
Dexamethasone	O
(	O
10	O
(	O
-8	O
)	O
M	O
)	O
repressed	O
chloramphenicol	B
acetyltransferase	I
(	O
CAT	B
)	O
production	O
by	O
75	O
%	O
in	O
the	O
wild	O
-	O
type	O
fragment	O
but	O
not	O
in	O
a	O
deletion	O
mutant	O
lacking	O
the	O
19-bp	O
site	O
.	O
A	O
protein	O
of	O
about	O
150	B
kD	I
that	O
bound	O
to	O
this	O
negative	O
regulatory	O
sequence	O
was	O
identified	O
by	O
UV	O
cross	O
-	O
linking	O
.	O
This	O
is	O
the	O
first	O
description	O
of	O
a	O
negative	O
regulatory	O
region	O
responsive	O
to	O
glucocorticoids	O
in	O
a	O
cytokine	O
gene	O
.	O
TRAMP	B
,	O
a	O
novel	O
apoptosis	B
-	I
mediating	I
receptor	I
with	O
sequence	O
homology	O
to	O
tumor	B
necrosis	I
factor	I
receptor	I
1	I
and	O
Fas	B
(	O
Apo-1	B
/	I
CD95	I
)	O
.	O
A	O
novel	O
member	O
of	O
the	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
receptor	I
family	I
,	O
designated	O
TRAMP	B
,	O
has	O
been	O
identified	O
.	O
The	O
structural	O
organization	O
of	O
the	O
393	B
amino	I
acid	I
long	I
human	I
TRAMP	I
is	O
most	O
homologous	O
to	O
TNF	B
receptor	I
1	I
.	O
TRAMP	B
is	O
abundantly	O
expressed	O
on	O
thymocytes	O
and	O
lymphocytes	O
.	O
Its	O
extracellular	O
domain	O
is	O
composed	O
of	O
four	O
cysteine	B
-	I
rich	I
domains	I
,	O
and	O
the	O
cytoplasmic	B
region	I
contains	O
a	O
death	B
domain	I
known	O
to	O
signal	O
apoptosis	O
.	O
Overexpression	O
of	O
TRAMP	B
leads	O
to	O
two	O
major	O
responses	O
,	O
NF	B
-	I
kappaB	I
activation	O
and	O
apoptosis	O
.	O
TRAMP	B
-induced	O
cell	O
death	O
is	O
inhibited	O
by	O
an	O
inhibitor	O
of	O
ICE	B
-	I
like	I
proteases	I
,	O
but	O
not	O
by	O
Bcl-2	B
.	O
In	O
addition	O
,	O
TRAMP	B
does	O
not	O
appear	O
to	O
interact	O
with	O
any	O
of	O
the	O
known	O
apoptosis	B
-	I
inducing	I
ligands	I
of	O
the	O
TNF	B
family	I
.	O
AML1a	B
but	O
not	O
AML1b	B
inhibits	O
erythroid	O
differentiation	O
induced	O
by	O
sodium	O
butyrate	O
and	O
enhances	O
the	O
megakaryocytic	O
differentiation	O
of	O
K562	O
leukemia	O
cells	O
.	O
AML1	B
may	O
play	O
a	O
role	O
in	O
growth	O
and	O
differentiation	O
of	O
cells	O
along	O
erythroid	O
and/or	O
megakaryocytic	O
lineages	O
,	O
because	O
a	O
significant	O
level	O
of	O
the	O
AML1	B
gene	O
is	O
expressed	O
in	O
these	O
cells	O
.	O
We	O
overexpressed	O
AML1a	B
(	O
without	O
the	O
transcription	B
-	I
activating	I
domain	I
)	O
and	O
AML1b	B
(	O
with	O
the	O
domain	O
)	O
proteins	O
in	O
K562	O
leukemia	O
cells	O
,	O
which	O
can	O
be	O
induced	O
to	O
differentiate	O
into	O
hemoglobin	O
-	O
producing	O
cells	O
and	O
megakaryocytes	O
.	O
The	O
AML1a	O
-	O
transfected	O
K562	O
cells	O
had	O
a	O
reduced	O
capacity	O
to	O
differentiate	O
in	O
the	O
presence	O
of	O
sodium	O
n	O
-	O
butyrate	O
but	O
not	O
in	O
the	O
presence	O
of	O
other	O
inducers	O
,	O
such	O
as	O
hemin	O
,	O
1-beta	O
-	O
D	O
-	O
arabinofuranosylcytosine	O
,	O
and	O
herbimycin	O
A	O
.	O
The	O
AML1	B
antisense	O
oligodeoxynucleotide	O
but	O
not	O
the	O
sense	O
oligomer	O
recovered	O
its	O
differentiation	O
-	O
inducing	O
capacity	O
in	O
the	O
presence	O
of	O
butyrate	O
.	O
On	O
the	O
other	O
hand	O
,	O
AML1b	B
conferred	O
a	O
similar	O
differentiation	O
-	O
inducing	O
capacity	O
upon	O
K562	O
cells	O
transfected	O
with	O
vector	O
alone	O
.	O
AML1a	B
expression	O
was	O
associated	O
with	O
enhanced	O
sensitivity	O
to	O
megakaryocytic	O
differentiation	O
induced	O
by	O
phorbol	O
ester	O
.	O
These	O
results	O
provide	O
evidence	O
that	O
AML1	B
proteins	O
play	O
a	O
role	O
in	O
erythroid	O
and	O
megakaryocytic	O
differentiation	O
.	O
Upregulation	O
of	O
c	B
-	I
Fos	I
in	O
activated	O
T	O
lymphoid	O
and	O
monocytic	O
cells	O
by	O
human	B
immunodeficiency	I
virus-1	I
Tat	I
protein	I
.	O
The	O
regulatory	B
Tat	I
protein	I
of	O
the	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
is	O
essential	O
for	O
viral	O
replication	O
and	O
also	O
shows	O
pleiotropic	O
activities	O
on	O
various	O
cell	O
functions	O
.	O
To	O
get	O
further	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
biological	O
activity	O
of	O
Tat	B
,	O
we	O
investigated	O
the	O
effect	O
of	O
endogenous	O
and	O
exogenous	O
Tat	B
protein	I
on	O
c	O
-	O
fos	O
gene	O
expression	O
in	O
T	O
lymphoblastoid	O
(	O
Jurkat	O
)	O
and	O
monocytic	O
(	O
U937	O
)	O
cell	O
lines	O
,	O
as	O
well	O
as	O
in	O
primary	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O
Transient	O
cotransfection	O
of	O
tat	O
cDNA	O
in	O
sense	O
orientation	O
(	O
tat	O
/	O
S	O
)	O
,	O
together	O
with	O
a	O
plasmid	O
containing	O
the	O
c	O
-	O
fos	O
promoter	O
(	O
FC3	O
,	O
from-	O
711	O
to	O
+	O
42	O
)	O
in	O
front	O
of	O
the	O
bacterial	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
gene	O
significantly	O
enhanced	O
CAT	B
activity	O
in	O
Jurkat	O
cells	O
activated	O
by	O
the	O
addition	O
of	O
15	O
%	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
or	O
5	O
micrograms	O
/	O
mL	O
phytohemagglutinin	B
plus	O
10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
U937	O
cells	O
activated	O
by	O
15	O
%	O
FCS	O
or	O
10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
PMA	O
.	O
This	O
effect	O
was	O
specifically	O
due	O
to	O
Tat	B
,	O
since	O
Jurkat	O
and	O
U937	O
cells	O
cotransfected	O
either	O
with	O
tat	O
cDNA	O
in	O
antisense	O
orientation	O
(	O
tat	O
/	O
AS	O
)	O
,	O
tat	O
carrying	O
a	O
mutation	O
in	O
the	O
aminoacid	B
cys22-gly22	I
(	O
tat	O
22	O
/	O
S	O
)	O
or	O
with	O
the	O
backbone	O
vector	O
alone	O
(	O
pRPneo	O
-	O
SL3	O
)	O
did	O
not	O
show	O
any	O
significant	O
difference	O
in	O
c	O
-	O
fos	O
promoter	O
activity	O
as	O
compared	O
to	O
cells	O
transfected	O
with	O
FC3	O
plasmid	O
alone	O
.	O
By	O
using	O
deletion	O
mutants	O
of	O
the	O
c	O
-	O
fos	O
promoter	O
,	O
we	O
found	O
that	O
the	O
minimal	O
DNA	O
sequence	O
required	O
for	O
Tat	B
activity	O
was	O
located	O
between	O
nucleotides	O
-404	O
/	O
-220	O
and	O
that	O
the	O
serum	O
responsive	O
element	O
(	O
SRE	O
,	O
-317	O
/	O
-288	O
)	O
,	O
present	O
within	O
this	O
region	O
,	O
was	O
still	O
responsive	O
to	O
Tat	B
.	O
A	O
single	O
point	O
mutation	O
in	O
the	O
SRE	O
completely	O
abrogated	O
the	O
responsiveness	O
to	O
tat	O
/	O
S	O
.	O
Exogenous	O
recombinant	B
Tat	I
protein	I
was	O
also	O
able	O
to	O
upregulate	O
c	O
-	O
fos	O
promoter	O
activity	O
in	O
serum	O
-	O
activated	O
Jurkat	O
and	O
U937	O
cells	O
,	O
as	O
well	O
as	O
endogenous	O
c	O
-	O
fos	O
mRNA	O
expression	O
and	O
c	B
-	I
Fos	I
protein	O
synthesis	O
in	O
both	O
serum	O
-	O
activated	O
cell	O
lines	O
and	O
primary	O
PBMC	O
.	O
c	B
-	I
Fos	I
protein	O
was	O
shown	O
essential	O
for	O
an	O
optimal	O
transactivation	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
by	O
Tat	B
:	O
incubation	O
of	O
Jurkat	O
cells	O
with	O
antisense	O
,	O
but	O
not	O
sense	O
,	O
c	O
-	O
fos	O
oligonucleotides	O
significantly	O
reduced	O
either	O
the	O
Tat	B
-enhanced	O
expression	O
of	O
an	O
LTR	O
-	O
CAT	O
reporter	O
construct	O
or	O
the	O
levels	O
of	O
gag	B
p24	I
in	O
the	O
culture	O
supernatants	O
of	O
Jurkat	O
cells	O
and	O
PBMC	O
acutely	O
infected	O
with	O
HIV-1	O
.	O
Our	O
data	O
suggest	O
that	O
the	O
c	O
-	O
fos	O
upregulation	O
mediated	O
by	O
Tat	B
might	O
play	O
a	O
significant	O
role	O
in	O
the	O
control	O
of	O
viral	O
gene	O
transactivation	O
.	O
Alteration	O
of	O
a	O
single	O
serine	O
in	O
the	O
basic	B
domain	I
of	O
the	O
Epstein	B
-	I
Barr	I
virus	I
ZEBRA	I
protein	I
separates	O
its	O
functions	O
of	O
transcriptional	O
activation	O
and	O
disruption	O
of	O
latency	O
.	O
The	O
ZEBRA	B
protein	I
from	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
activates	O
a	O
switch	O
from	O
the	O
latent	O
to	O
the	O
lytic	O
expression	O
program	O
of	O
the	O
virus	O
.	O
ZEBRA	B
,	O
a	O
member	O
of	O
the	O
bZIP	B
family	I
of	O
DNA	B
-	I
binding	I
proteins	I
,	O
is	O
a	O
transcriptional	O
activator	O
capable	O
of	O
inducing	O
expression	O
from	O
viral	O
lytic	O
cycle	O
promoters	O
.	O
It	O
had	O
previously	O
been	O
thought	O
that	O
ZEBRA	B
's	O
capacity	O
to	O
disrupt	O
EBV	O
latency	O
resided	O
primarily	O
in	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
genes	O
that	O
encode	O
products	O
required	O
for	O
lytic	O
replication	O
.	O
We	O
generated	O
a	O
point	O
mutant	O
of	O
ZEBRA	B
,	O
Z	B
(	I
S186A	I
)	I
,	O
that	O
was	O
not	O
impaired	O
in	O
its	O
ability	O
to	O
activate	O
transcription	O
;	O
however	O
,	O
this	O
mutation	O
abolished	O
its	O
ability	O
to	O
initiate	O
the	O
viral	O
lytic	O
cascade	O
.	O
The	O
mutant	O
,	O
containing	O
a	O
serine	O
-	O
to	O
-	O
alanine	O
substitution	O
in	O
the	O
DNA	B
-	I
binding	I
domain	I
of	O
the	O
protein	O
,	O
bound	O
to	O
several	O
known	O
ZEBRA	O
-	O
binding	O
sites	O
and	O
activated	O
transcription	O
from	O
reporters	O
bearing	O
known	O
ZEBRA	O
-	O
responsive	O
promoters	O
but	O
did	O
not	O
disrupt	O
latency	O
in	O
EBV	O
-	O
infected	O
cell	O
lines	O
.	O
Therefore	O
,	O
initiation	O
of	O
the	O
EBV	O
lytic	O
cycle	O
by	O
the	O
ZEBRA	B
protein	I
requires	O
a	O
function	O
in	O
addition	O
to	O
transcriptional	O
activation	O
;	O
a	O
change	O
of	O
serine	O
186	O
to	O
alanine	O
in	O
the	O
DNA	B
-	I
binding	I
domain	I
of	O
ZEBRA	B
abolished	O
this	O
additional	O
function	O
and	O
uncovered	O
a	O
new	O
role	O
for	O
the	O
ZEBRA	B
protein	I
in	O
disruption	O
of	O
EBV	O
latency	O
.	O
The	O
additional	O
function	O
that	O
is	O
required	O
for	O
initiation	O
of	O
the	O
lytic	O
viral	O
life	O
cycle	O
is	O
likely	O
to	O
require	O
phosphorylation	O
of	O
serine	O
186	O
of	O
the	O
ZEBRA	B
protein	I
,	O
which	O
may	O
influence	O
either	O
DNA	O
recognition	O
or	O
transcriptional	O
activation	O
of	O
lytic	O
viral	O
promoters	O
in	O
a	O
chromatinized	O
viral	O
episome	O
.	O
Redox	O
regulation	O
of	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
pathway	O
during	O
lymphocyte	O
activation	O
.	O
We	O
have	O
previously	O
demonstrated	O
an	O
obligatory	O
requirement	O
for	O
intracellular	O
reactive	O
oxygen	O
species	O
generation	O
during	O
T	O
lymphocyte	O
activation	O
,	O
and	O
have	O
proposed	O
that	O
intracellular	O
reactive	O
oxygen	O
species	O
may	O
act	O
as	O
signalling	O
agents	O
in	O
the	O
regulation	O
of	O
certain	O
cellular	O
processes	O
,	O
for	O
example	O
,	O
during	O
cell	O
cycle	O
entry	O
.	O
To	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
been	O
interested	O
to	O
determine	O
which	O
,	O
if	O
any	O
,	O
cell	O
cycle	O
entry	O
events	O
are	O
affected	O
by	O
oxidative	O
signalling	O
.	O
In	O
earlier	O
studies	O
,	O
we	O
have	O
identified	O
the	O
transcription	B
factors	I
NF	B
-	I
kappa	I
B	I
and	O
AP-1	B
as	O
molecular	O
targets	O
for	O
oxidative	O
signalling	O
processes	O
during	O
cell	O
cycle	O
entry	O
,	O
and	O
have	O
shown	O
that	O
oxidative	O
signalling	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
early	O
changes	O
in	O
gene	O
expression	O
during	O
the	O
G0	O
to	O
G1	O
phase	O
transition	O
.	O
To	O
extend	O
these	O
initial	O
observations	O
,	O
we	O
have	O
examined	O
the	O
effect	O
of	O
antioxidant	O
treatment	O
on	O
the	O
activity	O
of	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinases	I
erk1	B
and	O
erk2	B
,	O
as	O
members	O
of	O
a	O
signal	O
transduction	O
pathway	O
known	O
to	O
directly	O
regulate	O
transcription	O
factor	O
function	O
.	O
Using	O
as	O
a	O
probe	O
cysteamine	O
,	O
an	O
aminothiol	O
compound	O
with	O
both	O
antioxidant	O
and	O
antiproliferative	O
activity	O
,	O
we	O
have	O
identified	O
erk2	B
,	O
a	O
key	O
element	O
of	O
the	O
MAP	O
kinase	O
pathway	O
,	O
as	O
being	O
responsive	O
to	O
oxidative	O
signalling	O
during	O
lymphocyte	O
activation	O
.	O
These	O
observations	O
provide	O
further	O
evidence	O
to	O
suggest	O
a	O
role	O
for	O
intracellular	O
oxidant	O
generation	O
as	O
a	O
regulatory	O
mechanism	O
during	O
cell	O
cycle	O
entry	O
,	O
and	O
establish	O
a	O
link	O
between	O
oxidative	O
signalling	O
and	O
other	O
aspects	O
of	O
the	O
intracellular	O
signalling	O
network	O
that	O
is	O
activated	O
in	O
response	O
to	O
mitogenic	O
stimulation	O
.	O
Identification	O
of	O
sequence	O
alterations	O
in	O
the	O
upstream	O
regulatory	O
region	O
of	O
the	O
estrogen	O
receptor	O
gene	O
in	O
an	O
ER	O
-	O
negative	O
breast	O
cancer	O
cell	O
line	O
.	O
Given	O
the	O
important	O
role	O
of	O
the	O
estrogen	B
receptor	I
(	O
ER	B
)	O
in	O
the	O
development	O
and	O
physiology	O
of	O
the	O
breast	O
,	O
it	O
is	O
essential	O
to	O
delineate	O
the	O
mechanisms	O
responsible	O
for	O
its	O
failed	O
expression	O
in	O
some	O
breast	O
tumors	O
.	O
We	O
have	O
cloned	O
and	O
sequenced	O
a	O
portion	O
of	O
the	O
ER	B
upstream	O
regulatory	O
region	O
from	O
the	O
ER	O
-	O
positive	O
MCF-7	O
and	O
the	O
ER	O
-	O
negative	O
MDA	O
-	O
MB-231	O
breast	O
cancer	O
cell	O
lines	O
to	O
determine	O
if	O
sequence	O
alterations	O
in	O
this	O
region	O
account	O
for	O
the	O
ER	B
-negative	O
phenotype	O
of	O
some	O
tumors	O
.	O
From	O
this	O
,	O
we	O
identified	O
a	O
number	O
of	O
variations	O
between	O
the	O
sequences	O
,	O
two	O
of	O
which	O
were	O
determined	O
to	O
be	O
associated	O
with	O
a	O
50	O
%	O
decrease	O
in	O
CAT	B
activity	O
.	O
Control	O
of	O
NFATx1	B
nuclear	O
translocation	O
by	O
a	O
calcineurin	B
-	I
regulated	I
inhibitory	I
domain	I
.	O
The	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT	B
)	O
regulates	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
through	O
cis	O
-	O
acting	O
elements	O
located	O
in	O
the	O
promoters	O
of	O
several	O
cytokine	O
genes	O
.	O
NFATx1	B
,	O
which	O
is	O
preferentially	O
expressed	O
in	O
the	O
thymus	O
and	O
peripheral	O
blood	O
leukocytes	O
,	O
is	O
one	O
of	O
four	O
members	O
of	O
the	O
NFAT	B
family	I
of	O
transcription	B
factors	I
.	O
We	O
have	O
performed	O
domain	O
analysis	O
of	O
NFATx1	B
by	O
examining	O
the	O
effects	O
of	O
deletion	O
mutations	O
.	O
We	O
found	O
that	O
NFATx1	B
DNA	O
binding	O
activity	O
and	O
interaction	O
with	O
AP-1	O
polypeptides	O
were	O
dependent	O
on	O
its	O
central	B
Rel	I
similarity	I
region	I
and	O
that	O
transcriptional	O
activation	O
was	O
reduced	O
by	O
deletions	O
of	O
either	O
its	O
N	B
-	I
terminal	I
domain	I
or	O
its	O
C	B
-	I
terminal	I
domain	I
,	O
suggesting	O
the	O
presence	O
of	O
intrinsic	B
transcriptional	I
activation	I
motifs	I
in	O
both	O
regions	O
.	O
We	O
also	O
identified	O
a	O
potent	O
inhibitory	B
sequence	I
within	O
its	O
N	B
-	I
terminal	I
domain	I
.	O
We	O
show	O
that	O
the	O
inactivation	O
of	O
the	O
inhibition	O
was	O
dependent	O
on	O
the	O
activity	O
of	O
calcineurin	B
,	O
a	O
calcium	B
-	I
calmodulin	I
-	I
dependent	I
phosphatase	I
.	O
We	O
also	O
show	O
that	O
calcineurin	B
associated	O
with	O
the	O
N	B
-	I
terminal	I
domain	I
of	O
NFATx1	B
at	O
multiple	B
docking	I
sites	I
and	O
caused	O
a	O
reduction	O
of	O
size	O
,	O
indicative	O
of	O
dephosphorylation	O
,	O
in	O
NFATx1	B
.	O
We	O
have	O
mapped	O
the	O
inhibitory	O
activity	O
to	O
less	O
than	O
60	B
residues	I
,	O
containing	O
motifs	O
that	O
are	O
conserved	O
in	O
all	O
NFAT	B
proteins	I
.	O
Finally	O
,	O
we	O
demonstrate	O
that	O
deletion	O
in	O
NFATx1	B
of	O
the	O
mapped	O
60	B
residues	I
leads	O
to	O
its	O
nuclear	O
translocation	O
independent	O
of	O
calcium	O
signaling	O
.	O
Our	O
results	O
support	O
the	O
model	O
proposing	O
that	O
the	O
N	B
-	I
terminal	I
domain	I
confers	O
calcium	O
-	O
signaling	O
dependence	O
on	O
NFATx1	B
transactivation	O
activity	O
by	O
regulating	O
its	O
intracellular	O
localization	O
through	O
a	O
protein	O
module	O
that	O
associates	O
with	O
calcineurin	B
and	O
is	O
a	O
target	O
of	O
its	O
phosphatase	B
activity	O
.	O
Possible	O
role	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
activity	O
in	O
germline	O
C	O
epsilon	O
transcription	O
in	O
a	O
human	O
Burkitt	O
lymphoma	O
B	O
cell	O
line	O
.	O
Nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
plays	O
a	O
broad	O
role	O
in	O
gene	O
regulation	O
,	O
but	O
it	O
is	O
not	O
evident	O
whether	O
NF	B
-	I
kappa	I
B	I
acts	O
as	O
a	O
messenger	O
system	O
for	O
germline	O
C	O
epsilon	O
transcription	O
.	O
We	O
report	O
here	O
that	O
the	O
signaling	O
cascade	O
triggered	O
by	O
interleukin-4	B
(	O
IL-4	B
)	O
or	O
anti	B
-	I
CD40	I
monoclonal	I
antibody	I
(	O
mAb	B
)	O
participates	O
in	O
NF	B
-	I
kappa	I
B	I
activation	O
responsible	O
for	O
germline	O
C	O
epsilon	O
transcription	O
in	O
a	O
human	O
Burkitt	O
lymphoma	O
B	O
cell	O
line	O
,	O
DND39	O
.	O
Both	O
IL-4	B
and	O
anti-	O
CD40	B
mAb	I
induced	O
activation	O
of	O
phosphatidylinositol	B
3-kinase	I
(	O
PI3-kinase	B
)	O
,	O
translocation	O
of	O
a	O
zeta	O
isoform	O
of	O
protein	B
kinase	I
C	I
,	O
and	O
nuclear	O
expression	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
All	O
such	O
events	O
were	O
abrogated	O
by	O
treatment	O
with	O
LY294002	O
,	O
a	O
specific	O
inhibitor	O
of	O
PI3-kinase	B
.	O
In	O
addition	O
,	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
,	O
a	O
potent	O
antioxidant	O
,	O
decreased	O
NF	B
-	I
kappa	I
B	I
activation	O
caused	O
by	O
IL-4	B
,	O
anti	B
-	I
CD40	I
mAb	I
,	O
or	O
their	O
combination	O
.	O
NAC	O
was	O
also	O
effective	O
in	O
diminishing	O
germline	O
C	O
epsilon	O
transcription	O
,	O
and	O
its	O
potency	O
was	O
higher	O
in	O
cultures	O
costimulated	O
with	O
IL-4	B
and	O
anti	B
-	I
CD40	I
mAb	I
than	O
in	O
those	O
stimulated	O
with	O
IL-4	B
alone	O
.	O
These	O
results	O
indicate	O
that	O
IL-4	B
and	O
ligation	O
of	O
CD40	B
induce	O
NF	B
-	I
kappa	I
B	I
expression	O
via	O
at	O
least	O
a	O
mechanism	O
dependent	O
on	O
the	O
PI3-kinase	B
pathway	O
and	O
suggest	O
that	O
NF	B
-	I
kappa	I
B	I
sensitive	O
to	O
NAC	O
may	O
play	O
a	O
role	O
in	O
regulating	O
germline	O
C	O
epsilon	O
transcription	O
.	O
A	O
PMLRARalpha	O
transgene	O
initiates	O
murine	O
acute	O
promyelocytic	O
leukemia	O
.	O
The	O
malignant	O
cells	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
contain	O
a	O
reciprocal	O
chromosomal	O
translocation	O
that	O
fuses	O
the	O
promyelocytic	O
leukemia	O
gene	O
(	O
PML	O
)	O
with	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
gene	O
(	O
RAR	B
alpha	I
)	O
.	O
To	O
test	O
the	O
hypothesis	O
that	O
the	O
chimera	B
PMLRAR	I
alpha	I
plays	O
a	O
role	O
in	O
leukemogenesis	O
,	O
we	O
expressed	O
a	O
PMLRAR	O
alpha	O
cDNA	O
in	O
myeloid	O
cells	O
of	O
transgenic	O
mice	O
.	O
PMLRAR	O
alpha	O
transgenic	O
mice	O
exhibited	O
impaired	O
neutrophil	O
maturation	O
early	O
in	O
life	O
,	O
which	O
progressed	O
at	O
a	O
low	O
frequency	O
over	O
the	O
course	O
of	O
several	O
months	O
to	O
overt	O
APL	O
.	O
Both	O
the	O
preleukemic	O
state	O
and	O
the	O
leukemia	O
could	O
be	O
transplanted	O
to	O
nontransgenic	O
mice	O
,	O
and	O
the	O
transplanted	O
preleukemia	O
could	O
progress	O
to	O
APL	O
.	O
The	O
APL	O
recapitulated	O
features	O
of	O
the	O
human	O
disease	O
,	O
including	O
a	O
response	O
to	O
retinoic	O
acid	O
.	O
Retinoic	O
acid	O
caused	O
the	O
leukemic	O
cells	O
to	O
differentiate	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
eliciting	O
remissions	O
of	O
both	O
the	O
preleukemic	O
state	O
and	O
APL	O
in	O
mice	O
.	O
Our	O
results	O
demonstrate	O
that	O
PMLRAR	B
alpha	I
impairs	O
neutrophil	O
differentiation	O
and	O
initiates	O
the	O
development	O
of	O
APL	O
.	O
The	O
transgenic	O
mice	O
described	O
here	O
provide	O
an	O
apparently	O
accurate	O
model	O
for	O
human	O
APL	O
that	O
includes	O
clear	O
evidence	O
of	O
tumor	O
progression	O
.	O
The	O
model	O
should	O
be	O
useful	O
for	O
exploring	O
the	O
molecular	O
pathogenesis	O
of	O
APL	O
and	O
the	O
mechanisms	O
of	O
the	O
therapeutic	O
response	O
to	O
retinoic	O
acid	O
,	O
as	O
well	O
as	O
for	O
preclinical	O
studies	O
of	O
therapeutic	O
regimens	O
.	O
Neuronal	B
(	I
type	I
I	I
)	I
nitric	I
oxide	I
synthase	I
regulates	O
nuclear	B
factor	I
kappaB	I
activity	O
and	O
immunologic	B
(	I
type	I
II	I
)	I
nitric	I
oxide	I
synthase	I
expression	O
.	O
Nitric	O
oxide	O
subserves	O
diverse	O
physiologic	O
roles	O
in	O
the	O
nervous	O
system	O
.	O
NO	O
is	O
produced	O
from	O
at	O
least	O
three	O
different	O
NO	B
synthase	I
(	I
NOS	I
)	I
isoforms	I
:	O
neuronal	B
NOS	I
(	O
nNOS	B
)	O
,	O
endothelial	B
NOS	I
,	O
and	O
immunologic	B
NOS	I
(	O
iNOS	B
)	O
.	O
We	O
show	O
that	O
nNOS	B
is	O
the	O
predominant	O
isoform	O
constitutively	O
expressed	O
in	O
glia	O
.	O
NO	O
derived	O
from	O
nNOS	B
in	O
glia	O
inhibits	O
the	O
transcription	B
factor	I
nuclear	B
factor	I
kappaB	I
(	O
NF	B
kappaB	I
)	O
as	O
NOS	O
inhibitors	O
enhance	O
basal	O
NF	B
kappaB	I
activation	O
.	O
Pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
is	O
an	O
inhibitor	O
of	O
NF	B
kappaB	I
in	O
most	O
cells	O
;	O
however	O
,	O
we	O
show	O
that	O
PDTC	O
is	O
also	O
a	O
potent	O
scavenger	O
of	O
NO	O
through	O
formation	O
of	O
mononitrosyl	O
iron	O
complexes	O
with	O
PDTC	O
.	O
In	O
Jurkat	O
cells	O
,	O
a	O
human	O
T	O
-	O
cell	O
lymphoma	O
cell	O
line	O
,	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
induces	O
NF	B
kappaB	I
activation	O
that	O
is	O
inhibited	O
by	O
PDTC	O
.	O
Contrary	O
to	O
the	O
results	O
in	O
Jurkat	O
cells	O
,	O
PDTC	O
did	O
not	O
inhibit	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
-induced	O
NF	B
kappaB	I
activation	O
in	O
astrocytes	O
;	O
instead	O
PDTC	O
itself	O
induces	O
NF	B
kappaB	I
activation	O
in	O
astrocytes	O
,	O
and	O
this	O
may	O
be	O
related	O
to	O
scavenging	O
of	O
endogenously	O
produced	O
NO	O
by	O
the	O
PDTC	O
iron	O
complex	O
.	O
In	O
astrocytes	O
PDTC	O
also	O
dramatically	O
induces	O
the	O
NF	B
kappaB	I
-	I
dependent	I
enzyme	I
,	O
iNOS	B
,	O
supporting	O
the	O
physiologic	O
relevance	O
of	O
endogenous	O
NO	O
regulation	O
of	O
NF	B
kappaB	I
.	O
NF	B
kappaB	I
activation	O
in	O
glia	O
from	O
mice	O
lacking	O
nNOS	B
responds	O
more	O
rapidly	O
to	O
PDTC	O
compared	O
with	O
astrocytes	O
from	O
wild	O
-	O
type	O
mice	O
.	O
Our	O
data	O
suggest	O
that	O
nNOS	B
in	O
astrocytes	O
regulates	O
NF	B
kappaB	I
activity	O
and	O
iNOS	B
expression	O
,	O
and	O
indicate	O
a	O
novel	O
regulatory	O
role	O
for	O
nNOS	B
in	O
tonically	O
suppressing	O
central	O
nervous	O
system	O
,	O
NF	O
kappaB	O
-	O
regulated	O
genes	O
.	O
The	O
predominant	O
E2F	B
complex	I
in	O
human	O
primary	O
haemopoietic	O
cells	O
and	O
in	O
AML	O
blasts	O
contains	O
E2F-4	B
,	O
DP-1	B
and	O
p130	B
.	O
The	O
E2F	B
family	I
of	O
transcription	B
factors	I
are	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
cell	O
cycle	O
progression	O
.	O
There	O
is	O
now	O
also	O
increasing	O
evidence	O
that	O
some	O
family	O
members	O
may	O
act	O
as	O
oncogenes	O
or	O
tumour	O
suppressor	O
genes	O
.	O
The	O
characterization	O
of	O
these	O
proteins	O
in	O
human	O
primary	O
haemopoietic	O
cells	O
and	O
acute	O
myeloid	O
leukaemia	O
(	O
AML	O
)	O
blasts	O
may	O
thus	O
give	O
an	O
insight	O
to	O
the	O
molecular	O
mechanisms	O
governing	O
proliferation	O
and	O
leukaemogenesis	O
in	O
these	O
cells	O
.	O
Therefore	O
we	O
analysed	O
the	O
expression	O
of	O
E2F	B
-DNA	O
binding	O
activity	O
and	O
the	O
constituent	O
proteins	O
found	O
in	O
the	O
complexes	O
in	O
human	O
primary	O
haemopoietic	O
cells	O
of	O
various	O
lineages	O
.	O
We	O
also	O
studied	O
blasts	O
from	O
18	O
patients	O
with	O
acute	O
myeloid	O
leukaemia	O
(	O
AML	O
)	O
.	O
On	O
electromobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
a	O
single	O
E2F	B
-	I
DNA	I
binding	I
complex	I
was	O
detected	O
in	O
T	O
cells	O
,	O
B	O
cells	O
and	O
monocytes	O
which	O
was	O
shown	O
to	O
contain	O
E2F-4	B
,	O
DP-1	B
and	O
p130	B
,	O
indicating	O
that	O
all	O
quiescent	O
haemopoietic	O
cells	O
have	O
the	O
same	O
complex	O
.	O
Examination	O
of	O
18	O
AML	O
samples	O
by	O
EMSA	O
revealed	O
the	O
presence	O
of	O
E2F	B
binding	O
and	O
no	O
gross	O
abnormalities	O
were	O
detected	O
.	O
An	O
E2F-4	B
/	I
p130	I
complex	I
was	O
detected	O
in	O
representative	O
samples	O
of	O
all	O
FAB	B
types	O
analysed	O
.	O
Thus	O
abnormalities	O
of	O
E2F	B
function	O
are	O
unlikely	O
to	O
play	O
a	O
primary	O
pathogenic	O
role	O
in	O
AML	O
.	O
Cell	O
-	O
to	O
-	O
cell	O
contact	O
activates	O
the	O
long	O
terminal	O
repeat	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
through	O
its	O
kappaB	O
motif	O
.	O
Cell	O
-	O
to	O
-	O
cell	O
contact	O
between	O
peripheral	O
blood	O
lymphocytes	O
and	O
transfected	O
human	O
colonic	O
carcinoma	O
cell	O
line	O
HT29	O
activates	O
transcription	O
of	O
the	O
long	O
terminal	O
repeats	O
(	O
LTR	O
)	O
of	O
human	O
immunodeficiency	O
virus	O
.	O
HIV-1	O
LTR	O
transcription	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virus	B
-	I
encoded	I
and	I
cellular	I
proteins	I
.	O
Using	O
various	O
constructs	O
expressing	O
a	O
lacZ	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
intact	O
or	O
three	O
deleted	O
forms	O
of	O
HIV-1	O
LTR	O
,	O
we	O
obtained	O
evidence	O
that	O
the	O
kappaB	O
regulatory	O
elements	O
located	O
in	O
the	O
U3	O
region	O
are	O
involved	O
in	O
cell	O
-	O
to	O
-	O
cell	O
activation	O
of	O
HIV-1	O
LTR	O
.	O
Cell	O
-	O
to	O
-	O
cell	O
contact	O
activates	O
in	O
vitro	O
binding	O
of	O
the	O
nuclear	B
factor	I
kappaB	I
(	I
NF	I
-	I
kappaB	I
)	I
p50	I
/	I
p65	I
heterodimer	I
to	O
an	O
HIV-1	O
kappaB	O
oligonucleotide	O
.	O
Cell	O
-	O
to	O
-	O
cell	O
contact	O
activation	O
of	O
NF	B
-	I
kappaB	I
was	O
only	O
partially	O
inhibited	O
by	O
100	O
microM	O
pyrrolidine	O
dithiocarbamate	O
and	O
was	O
not	O
correlated	O
with	O
a	O
significant	O
decrease	O
of	O
cellular	B
inhibitor	I
kappaB	I
alpha	I
.	O
NF	B
-	I
kappaB	I
nuclear	O
activation	O
was	O
not	O
detectable	O
before	O
1	O
h	O
after	O
cell	O
contact	O
and	O
was	O
dependent	O
on	O
protein	O
synthesis	O
.	O
Lineage-	O
and	O
stage	O
-	O
specific	O
expression	O
of	O
runt	B
box	I
polypeptides	I
in	O
primitive	O
and	O
definitive	O
hematopoiesis	O
.	O
Translocations	O
involving	O
the	O
human	O
CBFA2	O
locus	O
have	O
been	O
associated	O
with	O
leukemia	O
.	O
This	O
gene	O
,	O
originally	O
named	O
AML1	O
,	O
is	O
a	O
human	O
homologue	O
of	O
the	O
Drosophila	O
gene	O
runt	O
that	O
controls	O
early	O
events	O
in	O
fly	O
embryogenesis	O
.	O
To	O
clarify	O
the	O
role	O
of	O
mammalian	B
runt	I
products	I
in	O
normal	O
and	O
leukemic	O
hematopoiesis	O
,	O
we	O
have	O
studied	O
their	O
pattern	O
of	O
expression	O
in	O
mouse	O
hematopoietic	O
tissues	O
in	O
the	O
adult	O
and	O
during	O
ontogeny	O
using	O
an	O
anti	O
-	O
runt	O
box	O
antiserum	O
.	O
In	O
the	O
adult	O
bone	O
marrow	O
,	O
we	O
found	O
expression	O
of	O
runt	O
polypeptides	O
in	O
differentiating	O
myeloid	O
cells	O
and	O
in	O
B	O
lymphocytes	O
.	O
Within	O
the	O
erythroid	O
lineage	O
,	O
runt	O
expression	O
is	O
biphasic	O
,	O
clearly	O
present	O
in	O
the	O
erythroblasts	O
of	O
early	O
blood	O
islands	O
and	O
of	O
the	O
fetal	O
liver	O
,	O
but	O
absent	O
in	O
the	O
adult	O
.	O
Biochemical	O
analysis	O
by	O
Western	O
blotting	O
of	O
fetal	O
and	O
adult	O
hematopoietic	O
populations	O
shows	O
several	O
runt	B
isoforms	I
.	O
At	O
least	O
one	O
of	O
them	O
appears	O
to	O
be	O
myeloid	O
specific	O
.	O
T	O
-	O
lymphocytes	O
from	O
individuals	O
with	O
filarial	O
inflammatory	O
disease	O
have	O
increased	O
transendothelial	O
migration	O
in	O
vitro	O
.	O
The	O
in	O
vitro	O
transendothelial	O
migration	O
of	O
circulating	O
filarial	O
antigen	O
-	O
specific	O
T	O
-	O
cells	O
was	O
examined	O
in	O
Wuchereria	O
banerofti	O
infection	O
.	O
Circulating	O
T	O
-	O
cells	O
from	O
individuals	O
with	O
filaria	O
-	O
induced	O
lymphatic	O
pathology	O
(	O
LP	O
)	O
had	O
significantly	O
greater	O
migration	O
through	O
unstimulated	O
HUVEC	O
monolayers	O
than	O
did	O
T	O
-	O
cells	O
from	O
asymptomatic	O
infected	O
(	O
MF	O
)	O
individuals	O
(	O
P	O
=	O
0.04	O
)	O
.	O
In	O
contrast	O
to	O
the	O
MF	O
individuals	O
where	O
no	O
effect	O
was	O
seen	O
,	O
transendothelial	O
migration	O
of	O
48-hr	O
filarial	O
antigen	O
stimulated	O
T	O
-	O
cells	O
from	O
LP	O
individuals	O
was	O
significantly	O
(	O
P	O
=	O
0.01	O
)	O
greater	O
than	O
migration	O
of	O
48-hr	O
media	O
-	O
stimulated	O
T	O
-	O
cells	O
.	O
In	O
six	O
of	O
seven	O
patients	O
examined	O
,	O
inhibition	O
of	O
the	O
VLA-4	O
/	O
VCAM-1	B
pathway	O
resulted	O
in	O
greater	O
than	O
50	O
%	O
inhibition	O
of	O
transendothelial	O
migration	O
of	O
T	O
-	O
cells	O
.	O
Response	O
to	O
intranasal	O
fluticasone	O
propionate	O
in	O
perennial	O
allergic	O
rhinitis	O
not	O
associated	O
with	O
glucocorticoid	B
receptor	I
characteristics	O
.	O
BACKGROUND	O
:	O
The	O
reduction	O
of	O
symptoms	O
due	O
to	O
treatment	O
with	O
corticosteroids	O
varies	O
among	O
patients	O
with	O
perennial	O
rhinitis	O
.	O
Most	O
patients	O
will	O
respond	O
but	O
a	O
few	O
patients	O
respond	O
less	O
to	O
these	O
drugs	O
.	O
OBJECTIVE	O
:	O
To	O
investigate	O
the	O
association	O
in	O
reduction	O
of	O
symptoms	O
due	O
to	O
glucocorticoids	O
and	O
glucocorticoid	B
receptor	I
characteristics	O
in	O
patients	O
with	O
perennial	O
allergic	O
rhinitis	O
,	O
in	O
vitro	O
glucocorticoid	B
receptor	I
binding	O
studies	O
were	O
performed	O
with	O
peripheral	O
blood	O
mononuclear	O
cells	O
using	O
dexamethasone	O
and	O
in	O
vitro	O
production	O
of	O
mediators	B
were	O
measured	O
.	O
METHODS	O
:	O
During	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
crossover	O
study	O
,	O
200	O
micrograms	O
fluticasone	O
propionate	O
aqueous	O
nasal	O
spray	O
(	O
in	O
the	O
active	O
treatment	O
period	O
)	O
and	O
placebo	O
(	O
in	O
the	O
placebo	O
treatment	O
period	O
)	O
were	O
administered	O
twice	O
daily	O
for	O
2	O
weeks	O
to	O
22	O
patients	O
allergic	O
to	O
house	O
dust	O
mite	O
.	O
At	O
the	O
end	O
of	O
both	O
treatment	O
periods	O
symptoms	O
were	O
scored	O
after	O
allergen	O
provocation	O
(	O
100	O
,	O
1000	O
,	O
10000	O
BU	O
/	O
mL	O
)	O
and	O
during	O
the	O
9.5	O
hours	O
after	O
this	O
challenge	O
.	O
Receptor	O
binding	O
studies	O
with	O
dexamethasone	O
were	O
performed	O
with	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
Leukotriene	O
B4	O
produced	O
by	O
monocytes	O
in	O
vitro	O
and	O
soluble	O
interleukin-2	B
receptor	I
released	O
by	O
lymphocytes	O
in	O
vitro	O
and	O
cortisol	O
levels	O
in	O
plasma	O
were	O
determined	O
.	O
RESULTS	O
:	O
No	O
significant	O
partial	O
correlations	O
of	O
the	O
number	O
of	O
the	O
peripheral	B
blood	I
mononuclear	I
cell	I
glucocorticoid	I
receptors	I
(	O
6821	O
+	O
/-	O
5669	O
binding	O
sites	O
per	O
cell	O
)	O
and	O
the	O
affinity	O
(	O
Kd	O
:	O
16.5	O
+	O
/-	O
13.51	O
nmol	O
/	O
L	O
)	O
for	O
the	O
glucocorticoid	B
receptors	I
with	O
the	O
symptom	O
score	O
(	O
placebo	O
:	O
4.3	O
+	O
/-	O
2.45	O
pts	O
;	O
fluticasone	O
:	O
2.4	O
+	O
/-	O
1.55	O
pts	O
)	O
after	O
active	O
treatment	O
were	O
found	O
.	O
Also	O
no	O
significant	O
partial	O
correlations	O
of	O
the	O
levels	O
of	O
leukotriene	O
B4	O
(	O
45.6	O
+	O
/-	O
105.3	O
ng	O
/	O
10	O
(	O
6	O
)	O
cells	O
)	O
produced	O
by	O
monocytes	O
in	O
vitro	O
,	O
soluble	O
interleukin-2	B
receptor	I
(	O
734	O
+	O
/-	O
237	O
ng	O
/	O
10	O
(	O
6	O
)	O
cells	O
)	O
released	O
by	O
lymphocytes	O
in	O
vitro	O
and	O
cortisol	O
levels	O
(	O
571	O
+	O
/-	O
236	O
ng	O
/	O
mL	O
)	O
in	O
plasma	O
with	O
the	O
symptom	O
score	O
after	O
active	O
treatment	O
were	O
found	O
.	O
CONCLUSIONS	O
:	O
The	O
reduction	O
of	O
symptoms	O
due	O
to	O
topical	O
fluticasone	O
propionate	O
in	O
patients	O
with	O
rhinitis	O
and	O
allergy	O
to	O
house	O
dust	O
mite	O
is	O
not	O
correlated	O
with	O
the	O
characteristics	O
of	O
the	O
glucocorticoid	B
receptor	I
.	O
HIV	O
does	O
not	O
replicate	O
in	O
naive	O
CD4	O
T	O
cells	O
stimulated	O
with	O
CD3	B
/	I
CD28	I
.	O
In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
T	O
cell	O
tropic	O
strain	O
of	O
HIV	O
,	O
LAI	O
,	O
does	O
not	O
replicate	O
in	O
naive	O
CD4	O
T	O
cells	O
stimulated	O
by	O
cross	O
-	O
linking	O
CD3	B
and	O
CD28	B
.	O
In	O
contrast	O
,	O
LAI	O
replicates	O
well	O
in	O
memory	O
CD4	O
T	O
cells	O
stimulated	O
in	O
the	O
same	O
way	O
.	O
Unlike	O
this	O
physiologically	O
relevant	O
stimulation	O
,	O
PHA	B
stimulates	O
productive	O
LAI	O
replication	O
in	O
both	O
naive	O
and	O
memory	O
T	O
cells	O
.	O
These	O
studies	O
were	O
conducted	O
with	O
highly	O
purified	O
(	O
FACS	O
-	O
isolated	O
)	O
subsets	O
of	O
CD4	O
T	O
cells	O
identified	O
by	O
expression	O
of	O
both	O
CD45RA	B
and	O
CD62L	B
.	O
Remixing	O
of	O
purified	O
T	O
cells	O
showed	O
that	O
naive	O
T	O
cells	O
do	O
not	O
suppress	O
LAI	O
replication	O
in	O
memory	O
T	O
cells	O
and	O
that	O
memory	O
T	O
cells	O
do	O
not	O
restore	O
LAI	O
expression	O
in	O
naive	O
T	O
cells	O
.	O
The	O
suppression	O
of	O
productive	O
LAI	O
replication	O
in	O
naive	O
T	O
cells	O
is	O
not	O
due	O
to	O
differential	O
expression	O
of	O
viral	B
coreceptors	I
,	O
nor	O
is	O
it	O
due	O
to	O
inhibition	O
of	O
activation	O
of	O
the	O
important	O
HIV	O
transcription	B
factors	I
,	O
nuclear	B
factor	I
-	I
kappaB	I
and	O
activator	B
protein-1	I
.	O
The	O
inherent	O
resistance	O
of	O
naive	O
T	O
cells	O
to	O
productive	O
HIV	O
infection	O
,	O
coupled	O
with	O
their	O
proliferative	O
advantage	O
as	O
demonstrated	O
here	O
,	O
provides	O
a	O
sound	O
basis	O
for	O
proposed	O
clinical	O
therapies	O
using	O
ex	O
vivo	O
expansion	O
and	O
reinfusion	O
of	O
CD4	O
T	O
cells	O
from	O
HIV	O
-	O
infected	O
adults	O
.	O
Physical	O
interactions	O
between	O
Ets	B
and	I
NF	I
-	I
kappaB	I
/	I
NFAT	I
proteins	I
play	O
an	O
important	O
role	O
in	O
their	O
cooperative	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
enhancer	O
in	O
T	O
cells	O
.	O
The	O
transcriptional	O
regulatory	O
elements	O
of	O
many	O
inducible	O
T	O
-	O
cell	O
genes	O
contain	O
adjacent	O
or	O
overlapping	O
binding	O
sites	O
for	O
the	O
Ets	B
and	I
NF	I
-	I
kappaB	I
/	I
NFAT	I
families	I
of	O
transcription	B
factors	I
.	O
Similar	O
arrays	O
of	O
functionally	O
important	O
NF	O
-	O
kappaB	O
/	O
NFAT	O
and	O
Ets	O
binding	O
sites	O
are	O
present	O
in	O
the	O
transcriptional	O
enhancers	O
of	O
human	O
immunodeficiency	O
viruses	O
types	O
1	O
and	O
2	O
(	O
HIV-1	O
and	O
HIV-2	O
)	O
,	O
suggesting	O
that	O
this	O
pattern	O
of	O
nuclear	O
protein	O
binding	O
sites	O
reflects	O
an	O
evolutionarily	O
conserved	O
mechanism	O
for	O
regulating	O
inducible	O
T	O
-	O
cell	O
gene	O
expression	O
that	O
has	O
been	O
co	O
-	O
opted	O
during	O
HIV	O
evolution	O
.	O
Despite	O
these	O
findings	O
,	O
the	O
molecular	O
mechanisms	O
by	O
which	O
Ets	B
and	I
NF	I
-	I
kappaB	I
/	I
NFAT	I
proteins	I
cooperatively	O
regulate	O
inducible	O
T	O
-	O
cell	O
gene	O
expression	O
remained	O
unknown	O
.	O
In	O
the	O
studies	O
described	O
in	O
this	O
report	O
,	O
we	O
demonstrated	O
a	O
physical	O
interaction	O
between	O
multiple	O
Ets	B
and	I
NF	I
-	I
kappaB	I
/	I
NFAT	I
proteins	I
both	O
in	O
vitro	O
and	O
in	O
activated	O
normal	O
human	O
T	O
cells	O
.	O
This	O
interaction	O
is	O
mediated	O
by	O
the	O
Ets	O
domain	O
of	O
Ets	B
proteins	I
and	O
the	O
C	O
-	O
terminal	O
region	O
of	O
the	O
Rel	O
homology	O
domains	O
of	O
NF	B
-	I
kappaB	I
/	I
NFAT	I
proteins	I
.	O
In	O
addition	O
,	O
the	O
Ets	B
-	O
NF	B
-	I
kappaB	I
/	O
NFAT	B
interaction	O
requires	O
the	O
presence	O
of	O
DNA	O
binding	O
sites	O
for	O
both	O
proteins	O
,	O
as	O
it	O
is	O
abolished	O
by	O
the	O
DNA	O
intercalating	O
agents	O
propidium	O
iodide	O
and	O
ethidium	O
bromide	O
and	O
enhanced	O
by	O
the	O
presence	O
of	O
synthetic	O
oligonucleotides	O
containing	O
binding	O
sites	O
for	O
Ets	B
and	O
NF	B
-	I
kappaB	I
proteins	I
.	O
A	O
dominant	O
-	O
negative	O
mutant	O
of	O
NF	B
-	I
kappaB	I
p50	I
that	O
binds	O
DNA	O
but	O
fails	O
to	O
interact	O
with	O
Ets	B
proteins	I
inhibits	O
the	O
synergistic	O
activation	O
of	O
the	O
HIV-1	O
and	O
HIV-2	O
enhancers	O
by	O
NF	B
-	I
kappaB	I
(	O
p50	B
+	O
p65	B
)	O
and	O
Ets-1	B
,	O
suggesting	O
that	O
physical	O
interaction	O
between	O
Ets	B
and	O
NF	B
-	I
kappaB	I
proteins	I
is	O
required	O
for	O
the	O
transcriptional	O
activity	O
of	O
the	O
HIV-1	O
and	O
HIV-2	O
enhancers	O
.	O
Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
evolutionarily	O
conserved	O
physical	O
interactions	O
between	O
Ets	B
and	I
NF	I
-	I
kappaB	I
/	I
NFAT	I
proteins	I
are	O
important	O
in	O
regulating	O
the	O
inducible	O
expression	O
of	O
T	O
-	O
cell	O
genes	O
and	O
viruses	O
.	O
These	O
interactions	O
represent	O
a	O
potential	O
target	O
for	O
the	O
development	O
of	O
novel	O
immunosuppressive	O
and	O
antiviral	O
therapies	O
.	O
Oxidant	O
-	O
regulation	O
of	O
gene	O
expression	O
in	O
the	O
chronically	O
inflamed	O
intestine	O
.	O
It	O
is	O
becoming	O
increasingly	O
apparent	O
that	O
the	O
chronic	O
gut	O
inflammation	O
observed	O
in	O
the	O
idiopathic	O
inflammatory	O
bowel	O
diseases	O
(	O
e.g.	O
ulcerative	O
colitis	O
,	O
Crohn	O
's	O
disease	O
)	O
is	O
associated	O
with	O
enhanced	O
production	O
of	O
leukocyte	O
-	O
derived	O
oxidants	O
.	O
Oxidants	O
such	O
as	O
hydrogen	O
peroxide	O
are	O
known	O
to	O
activate	O
certain	O
transcription	B
factors	I
such	O
as	O
nuclear	B
transcription	I
factor	I
kappa	I
beta	I
.	O
Nuclear	B
transcription	I
factor	I
kB	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
is	O
a	O
ubiquitous	B
transcription	I
factor	I
and	O
pleiotropic	B
regulator	I
of	O
numerous	O
genes	O
involved	O
in	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O
This	O
transcription	B
factor	I
is	O
activated	O
via	O
the	O
selective	O
phosphorylation	O
,	O
ubiquination	O
and	O
degradation	O
of	O
its	O
inhibitor	B
protein	I
I	I
-	I
kB	I
thereby	O
allowing	O
translocation	O
of	O
NF	B
-	I
kappa	I
B	I
into	O
the	O
nucleus	O
where	O
it	O
upregulates	O
the	O
transcription	O
of	O
a	O
variety	O
of	O
adhesion	B
molecules	I
(	O
e.g	O
.	O
ICAM-1	B
,	O
VCAM-1	B
)	O
,	O
cytokines	B
(	O
TNF	B
,	O
IL-1	B
,	O
IL-6	B
)	O
and	O
enzymes	B
(	O
iNOS	B
)	O
.	O
The	O
proteolytic	O
degradation	O
of	O
the	O
post	O
-	O
translationally	O
modified	O
I	B
-	I
kappa	I
B	I
is	O
known	O
to	O
be	O
mediated	O
by	O
the	O
26S	B
proteasome	I
complex	I
.	O
Based	O
upon	O
work	O
from	O
our	O
laboratory	O
,	O
we	O
propose	O
that	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
produces	O
significant	O
anti	O
inflammatory	O
activity	O
which	O
may	O
be	O
mediated	O
by	O
the	O
inhibition	O
of	O
transcription	O
of	O
certain	O
pro	B
-	I
inflammatory	I
mediators	I
and	O
adhesion	B
molecules	I
.	O
Expression	O
of	O
LAZ3	B
/	I
BCL6	I
in	O
follicular	O
center	O
(	O
FC	O
)	O
B	O
cells	O
of	O
reactive	O
lymph	O
nodes	O
and	O
FC	O
-	O
derived	O
non	O
-	O
Hodgkin	O
lymphomas	O
.	O
Chromosomal	O
translocation	O
resulting	O
in	O
abnormal	O
expression	O
of	O
the	O
LAZ3	O
/	O
BCL6	O
gene	O
in	O
B	O
cells	O
has	O
been	O
implicated	O
in	O
the	O
tumorigenesis	O
of	O
non	O
-	O
Hodgkin	O
lymphoma	O
(	O
NHL	O
)	O
.	O
Therefore	O
we	O
studied	O
the	O
expression	O
pattern	O
of	O
LAZ3	B
/	I
BCL6	I
by	O
in	O
situ	O
hybridization	O
with	O
synthetic	O
oligonucleotide	O
probes	O
in	O
frozen	O
tissue	O
sections	O
from	O
five	O
reactive	O
lymph	O
nodes	O
and	O
38	O
B	O
cell	O
and	O
non	O
-	O
B	O
NHL	O
.	O
In	O
addition	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
LAZ3	B
/	I
BCL6	I
by	O
Northern	O
blot	O
analysis	O
on	O
multiple	O
human	O
tissues	O
.	O
The	O
LAZ3	O
/	O
BCL6	O
transcript	O
was	O
found	O
in	O
a	O
variety	O
of	O
tissues	O
,	O
including	O
skeletal	O
muscle	O
,	O
peripheral	O
blood	O
leukocytes	O
,	O
and	O
weakly	O
in	O
normal	O
lymph	O
nodes	O
.	O
In	O
the	O
tumor	O
samples	O
,	O
expression	O
of	O
LAZ3	B
/	I
BCL6	I
was	O
observed	O
in	O
68	O
%	O
of	O
all	O
B	O
cell	O
NHL	O
and	O
none	O
of	O
the	O
non	O
-	O
B	O
lymphomas	O
.	O
All	O
cases	O
of	O
follicular	O
,	O
mixed	O
small	O
and	O
large	O
cell	O
lymphomas	O
showed	O
LAZ3	B
/	I
BCL6	I
expression	O
confined	O
to	O
the	O
neoplastic	O
follicles	O
.	O
A	O
follicular	O
expression	O
pattern	O
was	O
also	O
found	O
in	O
all	O
non	O
-	O
malignant	O
reactive	O
lymph	O
nodes	O
.	O
Hence	O
,	O
the	O
expression	O
of	O
LAZ3	B
/	I
BCL6	I
does	O
not	O
correlate	O
to	O
malignancy	O
,	O
but	O
reflects	O
the	O
origin	O
of	O
B	O
cells	O
from	O
the	O
germinal	O
centers	O
.	O
Two	O
distinct	O
pathways	O
of	O
interleukin-5	B
synthesis	O
in	O
allergen	O
-	O
specific	O
human	O
T	O
-	O
cell	O
clones	O
are	O
suppressed	O
by	O
glucocorticoids	O
.	O
Glucocorticoids	O
(	O
GC	O
)	O
have	O
long	O
been	O
used	O
as	O
the	O
most	O
effective	O
agents	O
for	O
the	O
treatment	O
of	O
allergic	O
diseases	O
accompanied	O
by	O
eosinophilia	O
such	O
as	O
chronic	O
asthma	O
and	O
atopic	O
dermatitis	O
.	O
The	O
development	O
of	O
chronic	O
eosinophilic	O
inflammation	O
is	O
dependent	O
on	O
interleukin-5	B
(	O
IL-5	B
)	O
,	O
a	O
selective	B
eosinophil	I
-	I
activating	I
factor	I
,	O
produced	O
by	O
helper	O
T	O
cells	O
.	O
To	O
delineate	O
the	O
regulatory	O
mechanisms	O
of	O
human	O
IL-5	B
synthesis	O
,	O
we	O
established	O
allergen	O
-	O
specific	O
CD4	O
+	O
T	O
-	O
cell	O
clones	O
from	O
asthmatic	O
patients	O
.	O
GC	O
efficiently	O
suppressed	O
IL-5	B
synthesis	O
of	O
T	O
-	O
cell	O
clones	O
activated	O
via	O
either	O
T	B
-	I
cell	I
receptor	I
(	O
TCR	B
)	O
or	O
IL-2	B
receptor	I
(	O
IL-2R	B
)	O
.	O
Induction	O
of	O
IL-5	O
mRNA	O
upon	O
TCR	B
and	O
IL-2R	B
stimulation	O
was	O
totally	O
inhibited	O
by	O
dexamethasone	O
.	O
Human	O
IL-5	B
promoter	O
/	O
enhancer	O
-	O
luciferase	O
gene	O
construct	O
transfected	O
to	O
T	O
-	O
cell	O
clones	O
was	O
transcribed	O
on	O
either	O
TCR	B
or	O
IL-2R	B
stimulation	O
and	O
was	O
clearly	O
downregulated	O
by	O
dexamethasone	O
,	O
indicating	O
that	O
the	O
approximately	O
500-bp	O
human	O
IL-5	O
gene	O
segment	O
located	O
5	O
'	O
upstream	O
of	O
the	O
coding	O
region	O
contains	O
activation	O
-	O
inducible	O
enhancer	O
elements	O
responsible	O
for	O
the	O
regulation	O
by	O
GC	O
.	O
Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
suggested	O
that	O
AP-1	B
and	O
NF	B
-	I
kappaB	I
are	O
among	O
the	O
possible	O
targets	O
of	O
GC	O
actions	O
on	O
TCR	O
-	O
stimulated	O
T	O
cells	O
.	O
NF	B
-	I
AT	I
and	O
NF	B
-	I
kappaB	I
were	O
not	O
significantly	O
induced	O
by	O
IL-2	B
stimulation	O
.	O
Our	O
results	O
showing	O
that	O
GC	O
suppressed	O
IL-5	B
production	O
by	O
human	O
CD4	O
+	O
T	O
cells	O
activated	O
by	O
two	O
distinct	O
stimuli	O
,	O
TCR	B
and	O
IL-2R	B
stimulation	O
,	O
underscore	O
the	O
efficacy	O
of	O
GC	O
in	O
the	O
treatment	O
of	O
allergic	O
diseases	O
via	O
suppression	O
of	O
T	O
-	O
cell	O
IL-5	B
synthesis	O
.	O
Experimental	O
expression	O
in	O
mice	O
and	O
spontaneous	O
expression	O
in	O
human	O
SLE	O
of	O
polyomavirus	B
T	I
-	I
antigen	I
.	O
A	O
molecular	O
basis	O
for	O
induction	O
of	O
antibodies	B
to	O
DNA	O
and	O
eukaryotic	B
transcription	I
factors	I
.	O
We	O
have	O
previously	O
demonstrated	O
that	O
experimental	O
expression	O
of	O
the	O
polyomavirus	B
transcription	I
factor	I
T	I
-	I
antigen	I
has	O
the	O
potential	O
to	O
induce	O
anti	B
-	I
DNA	I
antibodies	I
in	O
mice	O
.	O
Two	O
sets	O
of	O
independent	O
evidences	O
are	O
presented	O
here	O
that	O
demonstrate	O
a	O
biological	O
relevance	O
for	O
this	O
model	O
.	O
First	O
,	O
we	O
describe	O
results	O
demonstrating	O
that	O
mice	O
inoculated	O
with	O
T	O
-	O
antigen	O
-	O
expressing	O
plasmids	O
produced	O
antibodies	B
,	O
not	O
only	O
to	O
T	B
-	I
antigen	I
and	O
DNA	O
,	O
but	O
also	O
to	O
the	O
DNA	B
-	I
binding	I
eukaryotic	I
transcription	I
factors	I
TATA	B
-	I
binding	I
protein	I
(	O
TBP	B
)	O
,	O
and	O
to	O
the	O
cAMP	B
-	I
response	I
-	I
element	I
-	I
binding	I
protein	I
(	O
CREB	B
)	O
.	O
Secondly	O
,	O
we	O
investigated	O
whether	O
polyomavirus	O
reactivation	O
occurs	O
in	O
SLE	O
patients	O
,	O
and	O
whether	O
antibodies	B
to	O
T	B
-	I
antigen	I
,	O
DNA	O
,	O
and	O
to	O
TBP	B
and	O
CREB	B
are	O
linked	O
to	O
such	O
events	O
.	O
Both	O
within	O
and	O
among	O
these	O
SLE	O
patients	O
,	O
frequent	O
polyomavirus	O
reactivations	O
were	O
observed	O
that	O
could	O
not	O
be	O
explained	O
by	O
certain	O
rearrangements	O
of	O
the	O
noncoding	O
control	O
regions	O
,	O
nor	O
by	O
corticosteroid	O
treatment	O
.	O
Linked	O
to	O
these	O
events	O
,	O
antibodies	B
to	O
T	B
-	I
antigen	I
,	O
DNA	O
,	O
TBP	B
,	O
and	O
CREB	B
were	O
detected	O
,	O
identical	O
to	O
what	O
we	O
observed	O
in	O
mice	O
.	O
Antibodies	O
recognizing	O
double	O
-	O
stranded	O
DNA	O
were	O
confined	O
to	O
patients	O
with	O
frequent	O
polyomavirus	O
reactivations	O
.	O
The	O
results	O
described	O
here	O
indicate	O
that	O
cognate	O
interaction	O
of	O
B	O
cells	O
recognizing	O
DNA	O
or	O
DNA	B
-	I
associated	I
proteins	I
and	O
T	O
cells	O
recognizing	O
T	B
antigen	I
had	O
taken	O
place	O
as	O
a	O
consequence	O
of	O
complex	O
formation	O
between	O
T	B
ag	I
and	O
DNA	O
in	O
vivo	O
in	O
the	O
context	O
of	O
polyomavirus	O
reactivations	O
.	O
Involvement	O
of	O
an	O
SAF	B
-	I
like	I
transcription	I
factor	I
in	O
the	O
activation	O
of	O
serum	O
amyloid	O
A	O
gene	O
in	O
monocyte	O
/	O
macrophage	O
cells	O
by	O
lipopolysaccharide	O
.	O
Serum	B
amyloid	I
A	I
(	O
SAA	B
)	O
has	O
been	O
linked	O
to	O
atherosclerosis	O
because	O
of	O
its	O
ability	O
to	O
remodel	O
high	O
-	O
density	O
lipoprotein	O
by	O
the	O
depletion	O
of	O
apolipoprotein	O
A1	O
,	O
its	O
ability	O
to	O
bind	O
cholesterol	O
,	O
and	O
its	O
presence	O
in	O
the	O
atherosclerotic	O
plaques	O
of	O
coronary	O
and	O
carotid	O
arteries	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
induction	O
mechanism	O
of	O
SAA	O
gene	O
in	O
THP-1	O
monocyte	O
/	O
macrophage	O
cells	O
which	O
play	O
a	O
critical	O
role	O
in	O
the	O
development	O
of	O
atherosclerotic	O
fatty	O
streak	O
and	O
plaque	O
formation	O
.	O
We	O
and	O
others	O
have	O
shown	O
that	O
SAA	B
gene	O
is	O
induced	O
in	O
monocyte	O
/	O
macrophage	O
cells	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
By	O
promoter	O
function	O
analysis	O
,	O
we	O
show	O
that	O
the	O
SAA	O
promoter	O
sequence	O
between	O
-280	O
and	O
-226	O
can	O
confer	O
LPS	O
responsiveness	O
.	O
Gel	O
electrophoretic	O
mobility	O
shift	O
assay	O
detected	O
an	O
induced	O
DNA	O
-	O
binding	O
activity	O
in	O
these	O
cells	O
in	O
response	O
to	O
LPS	O
.	O
Characterization	O
of	O
the	O
DNA	B
-	I
binding	I
protein	I
by	O
UV	O
cross	O
-	O
linking	O
,	O
Southwestern	O
blot	O
,	O
and	O
antibody	O
ablation	O
/	O
supershift	O
assays	O
revealed	O
that	O
it	O
is	O
similar	O
to	O
a	O
recently	O
reported	O
nuclear	B
factor	I
designated	O
SAF	B
.	O
These	O
results	O
demonstrated	O
that	O
LPS	O
-	O
mediated	O
SAA	B
gene	O
induction	O
in	O
monocyte	O
/	O
macrophage	O
cells	O
is	O
primarily	O
due	O
to	O
the	O
induction	O
of	O
SAF	B
activity	O
.	O
Expression	O
of	O
NFAT	B
-	I
family	I
proteins	I
in	O
normal	O
human	O
T	O
cells	O
.	O
NFAT	B
proteins	I
constitute	O
a	O
family	O
of	O
transcription	B
factors	I
involved	O
in	O
mediating	O
signal	O
transduction	O
.	O
Using	O
a	O
panel	O
of	O
specific	O
antisera	O
in	O
immunoprecipitation	O
assays	O
,	O
we	O
found	O
that	O
NFATp	B
(	O
135	B
kDa	I
)	O
is	O
constitutively	O
expressed	O
in	O
normal	O
human	O
T	O
cells	O
,	O
while	O
synthesis	O
of	O
NFATc	B
(	O
predominant	O
form	O
of	O
86	B
kDa	I
)	O
is	O
induced	O
by	O
ionomycin	O
treatment	O
.	O
NFAT4	B
/	I
x	I
was	O
very	O
weakly	O
expressed	O
in	O
unstimulated	O
cells	O
,	O
and	O
its	O
level	O
did	O
not	O
increase	O
upon	O
treatment	O
with	O
activating	O
agents	O
.	O
NFAT3	B
protein	I
was	O
not	O
observed	O
under	O
any	O
conditions	O
.	O
Higher	B
-	I
molecular	I
-	I
weight	I
species	I
of	O
NFATc	B
(	O
of	O
110	O
and	O
140	O
kDa	O
)	O
were	O
also	O
detected	O
.	O
In	O
addition	O
,	O
translation	O
of	O
NFATc	O
mRNA	O
apparently	O
initiates	O
at	O
two	O
different	O
AUG	O
codons	O
,	O
giving	O
rise	O
to	O
proteins	O
that	O
differ	O
in	O
size	O
by	O
36	O
amino	O
acids	O
.	O
Additional	O
size	O
heterogeneity	O
of	O
both	O
NFATc	B
and	O
NFATp	B
results	O
from	O
phosphorylation	O
.	O
In	O
contrast	O
to	O
ionomycin	O
treatment	O
,	O
exposure	O
of	O
cells	O
to	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
plus	O
anti	B
-	I
CD28	I
did	O
not	O
induce	O
NFATc	B
,	O
indicating	O
that	O
under	O
these	O
conditions	O
,	O
interleukin-2	B
synthesis	O
by	O
these	O
cells	O
is	O
apparently	O
independent	O
of	O
NFATc	B
.	O
In	O
DNA	O
binding	O
assays	O
,	O
both	O
PMA	O
plus	O
anti	B
-	I
CD28	I
and	O
PMA	O
plus	O
ionomycin	O
resulted	O
in	O
nuclear	B
NFAT	I
.	O
Surprisingly	O
,	O
the	O
PMA	O
-	O
ionomycin	O
-	O
induced	O
synthesis	O
of	O
NFATc	B
that	O
was	O
detected	O
by	O
immunoprecipitation	O
was	O
not	O
mirrored	O
in	O
the	O
DNA	O
binding	O
assays	O
:	O
nearly	O
all	O
of	O
the	O
activity	O
was	O
due	O
to	O
NFATp	B
.	O
This	O
is	O
the	O
first	O
study	O
of	O
expression	O
of	O
all	O
family	O
members	O
at	O
the	O
protein	O
level	O
in	O
normal	O
human	O
T	O
cells	O
.	O
Nucleolin	B
is	O
one	O
component	O
of	O
the	O
B	B
cell	I
-	I
specific	I
transcription	I
factor	I
and	O
switch	B
region	I
binding	I
protein	I
,	O
LR1	B
.	O
LR1	B
is	O
a	O
B	O
cell	O
-	O
specific	O
,	O
sequence	O
-	O
specific	O
DNA	O
binding	O
activity	O
that	O
regulates	O
transcription	O
in	O
activated	O
B	O
cells	O
.	O
LR1	B
also	O
binds	O
Ig	B
heavy	I
chain	I
switch	O
region	O
sequences	O
and	O
may	O
function	O
in	O
class	O
switch	O
recombination	O
.	O
LR1	B
contains	O
two	O
polypeptides	O
,	O
of	O
106	O
kDa	O
and	O
45	O
kDa	O
,	O
and	O
here	O
we	O
report	O
that	O
the	O
106-kDa	B
component	I
of	O
LR1	B
is	O
nucleolin	B
.	O
This	O
identification	O
,	O
initially	O
made	O
by	O
microsequence	O
analysis	O
,	O
was	O
verified	O
by	O
showing	O
that	O
(	O
i	O
)	O
LR1	B
-DNA	O
binding	O
activity	O
increased	O
in	O
B	O
cells	O
transfected	O
with	O
a	O
nucleolin	O
cDNA	O
expression	O
construct	O
;	O
(	O
ii	O
)	O
LR1	B
-DNA	O
binding	O
activity	O
was	O
recognized	O
by	O
antibodies	O
raised	O
against	O
recombinant	B
human	I
nucleolin	I
;	O
and	O
(	O
iii	O
)	O
in	O
B	O
cells	O
transfected	O
with	O
epitope	O
-	O
tagged	O
nucleolin	O
expression	O
constructs	O
,	O
the	O
LR1-DNA	B
complex	I
was	O
recognized	O
by	O
the	O
anti	B
-	I
tag	I
antibody	I
.	O
Nucleolin	B
is	O
an	O
abundant	B
nucleolar	I
protein	I
which	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
rDNA	O
transcription	O
or	O
organization	O
,	O
or	O
rRNA	O
processing	O
.	O
Homology	O
between	O
nucleolin	B
and	O
histone	B
H1	I
suggests	O
that	O
nucleolin	B
may	O
alter	O
DNA	O
organization	O
in	O
response	O
to	O
cell	O
cycle	O
controls	O
,	O
and	O
the	O
nucleolin	B
component	O
of	O
LR1	B
may	O
therefore	O
function	O
to	O
organize	O
switch	O
regions	O
before	O
,	O
during	O
,	O
or	O
after	O
switch	O
recombination	O
.	O
The	O
demonstration	O
that	O
nucleolin	B
is	O
a	O
component	O
of	O
a	O
B	B
cell	I
-	I
specific	I
complex	I
that	O
binds	O
switch	O
region	O
sequences	O
suggests	O
that	O
the	O
G	O
-	O
rich	O
switch	O
regions	O
may	O
have	O
evolved	O
from	O
rDNA	O
.	O
Human	B
neutrophil	I
elastase	I
proteolytically	O
activates	O
the	O
platelet	B
integrin	I
alphaIIbbeta3	B
through	O
cleavage	O
of	O
the	O
carboxyl	B
terminus	I
of	O
the	O
alphaIIb	B
subunit	I
heavy	I
chain	I
.	O
Involvement	O
in	O
the	O
potentiation	O
of	O
platelet	O
aggregation	O
.	O
Neutrophil	B
elastase	I
(	O
NE	B
)	O
and	O
cathepsin	B
G	I
are	O
two	O
serine	B
proteinases	I
released	O
concomitantly	O
by	O
stimulated	O
polymorphonuclear	O
neutrophils	O
.	O
We	O
previously	O
demonstrated	O
that	O
while	O
NE	B
by	O
itself	O
does	O
not	O
activate	O
human	O
platelets	O
,	O
it	O
strongly	O
enhances	O
the	O
weak	O
aggregation	O
induced	O
by	O
a	O
threshold	O
concentration	O
of	O
cathepsin	B
G	I
(	O
threshold	O
of	O
cathepsin	B
G	I
)	O
(	O
Renesto	O
,	O
P.	O
,	O
and	O
Chignard	O
,	O
M.	O
(	O
1993	O
)	O
Blood	O
82	O
,	O
139	O
-	O
144	O
)	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
delineate	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
this	O
potentiation	O
process	O
.	O
Two	O
main	O
pieces	O
of	O
data	O
prompted	O
us	O
to	O
focus	O
on	O
the	O
activation	O
of	O
the	O
platelet	B
fibrinogen	I
receptor	I
,	O
the	O
alphaIIbbeta3	B
integrin	I
.	O
First	O
,	O
previous	O
studies	O
have	O
shown	O
this	O
integrin	B
to	O
be	O
particularly	O
prone	O
to	O
proteolytic	O
regulation	O
of	O
its	O
function	O
.	O
Second	O
,	O
we	O
found	O
that	O
the	O
potentiating	O
activity	O
of	O
NE	B
on	O
the	O
threshold	O
of	O
cathepsin	B
G	I
-induced	O
platelet	O
aggregation	O
was	O
strictly	O
dependent	O
on	O
the	O
presence	O
of	O
exogenous	B
fibrinogen	I
.	O
Using	O
flow	O
cytometry	O
analysis	O
,	O
NE	B
was	O
shown	O
to	O
trigger	O
a	O
time	O
-	O
dependent	O
binding	O
of	O
PAC-1	B
and	O
AP-5	B
,	O
two	O
monoclonal	B
antibodies	I
specific	O
for	O
the	O
activated	O
and	O
ligand	O
-	O
occupied	O
conformers	O
of	O
alphaIIbbeta3	B
.	O
Furthermore	O
,	O
the	O
potentiated	O
aggregation	O
was	O
shown	O
to	O
result	O
from	O
an	O
increased	O
capacity	O
of	O
platelets	O
to	O
bind	O
fibrinogen	O
.	O
Indeed	O
,	O
the	O
combination	O
of	O
NE	B
and	O
threshold	O
of	O
cathepsin	B
G	I
increased	O
the	O
binding	O
of	O
PAC-1	B
approximately	O
5.5-fold	O
over	O
basal	O
values	O
measured	O
on	O
nontreated	O
platelets	O
,	O
whereas	O
this	O
binding	O
raised	O
only	O
by	O
approximately	O
3-fold	O
in	O
threshold	O
of	O
cathepsin	O
G	O
-	O
stimulated	O
platelets	O
(	O
p	O
<	O
0.05	O
)	O
.	O
By	O
contrast	O
,	O
phosphatidic	O
acid	O
accumulation	O
,	O
pleckstrin	O
phosphorylation	O
,	O
and	O
calcium	O
mobilization	O
produced	O
by	O
the	O
combination	O
of	O
NE	B
and	O
threshold	O
of	O
cathepsin	B
G	I
were	O
not	O
significantly	O
different	O
from	O
those	O
measured	O
with	O
threshold	O
of	O
cathepsin	B
G	I
alone	O
(	O
p	O
>	O
0.05	O
)	O
,	O
indicating	O
that	O
the	O
phospholipase	B
C	I
/protein	B
kinase	I
C	I
pathway	O
is	O
not	O
involved	O
in	O
the	O
potentiation	O
of	O
aggregation	O
.	O
The	O
foregoing	O
data	O
,	O
as	O
well	O
as	O
the	O
requirement	O
of	O
catalytically	O
active	O
NE	B
to	O
trigger	O
alphaIIbbeta3	B
activation	O
and	O
potentiate	O
threshold	O
of	O
cathepsin	B
G	I
-initiated	O
platelet	O
aggregation	O
,	O
led	O
us	O
to	O
examine	O
whether	O
the	O
structure	O
of	O
this	O
integrin	B
was	O
affected	O
by	O
NE	B
.	O
Immunoblot	O
and	O
flow	O
cytometry	O
analysis	O
revealed	O
a	O
limited	O
proteolysis	O
of	O
the	O
carboxyl	B
terminus	I
of	O
the	O
alphaIIb	B
subunit	I
heavy	I
chain	I
(	O
alphaIIbH	B
)	O
,	O
as	O
judged	O
by	O
the	O
disappearance	O
of	O
the	O
epitope	O
for	O
the	O
monoclonal	B
antibody	I
PMI-1	I
.	O
Mass	O
spectrometry	O
studies	O
performed	O
on	O
a	O
synthetic	O
peptide	O
mapping	O
over	O
the	O
cleavage	B
domain	I
of	O
alphaIIbH	B
predicted	O
the	O
site	O
of	O
proteolysis	O
as	O
located	O
between	O
Val837	O
and	O
Asp838	O
.	O
Treatment	O
by	O
NE	B
of	O
ATP	O
-	O
depleted	O
platelets	O
or	O
Chinese	O
hamster	O
ovary	O
cells	O
expressing	O
human	B
recombinant	I
alphaIIbbeta3	I
clearly	O
established	O
that	O
activation	O
of	O
the	O
integrin	B
was	O
independent	O
of	O
signal	O
transduction	O
events	O
and	O
was	O
concomitant	O
with	O
the	O
proteolysis	O
of	O
alphaIIbH	B
.	O
Activation	O
of	O
Ras	O
and	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
pathway	O
by	O
terminal	B
complement	I
complexes	I
is	O
G	B
protein	I
dependent	O
.	O
Assembly	O
of	O
terminal	B
complement	I
complexes	I
(	O
TCC	B
)	O
C5b-7	B
,	O
C5b-8	B
,	O
and	O
C5b-9	B
on	O
target	O
cells	O
during	O
acute	O
and	O
chronic	O
inflammation	O
induces	O
hydrolysis	O
of	O
plasma	O
membrane	O
phospholipids	O
and	O
heterotrimeric	O
G	B
protein	I
activation	O
.	O
TCC	B
also	O
stimulate	O
a	O
variety	O
of	O
cellular	O
activities	O
,	O
which	O
include	O
cytokine	B
synthesis	O
,	O
proto	O
-	O
oncogene	O
activation	O
,	O
and	O
mitotic	O
signaling	O
.	O
Now	O
we	O
report	O
that	O
sublytic	O
TCC	B
induced	O
Ras	B
,	O
Raf-1	B
,	O
and	O
extracellular	B
signal	I
-	I
regulated	I
kinase	I
(	I
ERK	I
)	I
1	I
activation	O
in	O
JY25	O
B	O
cell	O
line	O
.	O
When	O
cells	O
were	O
exposed	O
to	O
C5b-9	B
,	O
GTP	B
-	I
bound	I
Ras	I
in	O
anti	B
-	I
C5b-9	I
immunoprecipitates	I
was	O
increased	O
3.2-fold	O
at	O
2	O
min	O
,	O
while	O
GTP	B
-	I
bound	I
Ras	I
in	O
anti	B
-	I
Ras	I
immunoprecipitates	I
was	O
increased	O
2-fold	O
at	O
10	O
min	O
.	O
Both	O
C5b-9	B
and	O
C5b-7	B
,	O
but	O
not	O
C5b6	B
,	O
increased	O
Raf-1	B
kinase	O
activity	O
maximum	O
3.3-fold	O
at	O
2	O
min	O
and	O
2.8-fold	O
at	O
5	O
min	O
,	O
respectively	O
.	O
ERK1	B
activity	O
was	O
2-fold	O
increased	O
by	O
C5b-9	B
at	O
2	O
min	O
and	O
by	O
C5b-7	B
at	O
10	O
min	O
,	O
over	O
the	O
C5b6	B
level	O
.	O
The	O
role	O
of	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
pathway	O
on	O
TCC	B
-inducible	O
mitotic	O
signaling	O
was	O
evaluated	O
by	O
assessing	O
DNA	O
synthesis	O
and	O
activator	B
protein	I
1	I
(	O
AP-1	B
)	O
DNA	O
-	O
binding	O
activity	O
.	O
The	O
MAPK	O
/	O
ERK	O
-	O
specific	O
inhibitor	O
PD	O
098	O
,	O
059	O
abolished	O
the	O
C5b-9	B
-induced	O
DNA	O
synthesis	O
.	O
Involvement	O
of	O
G	B
protein	I
in	O
the	O
activation	O
of	O
MAPK	B
pathway	O
by	O
TCC	B
was	O
indicated	O
by	O
inhibition	O
of	O
Raf-1	B
and	O
ERK1	B
kinase	O
activity	O
,	O
as	O
well	O
as	O
the	O
DNA	O
synthesis	O
by	O
pretreatment	O
of	O
cells	O
with	O
pertussis	B
toxin	I
.	O
Overexpression	O
of	O
beta	O
-	O
adrenergic	O
receptor	O
kinase	O
1	O
carboxyl	O
-	O
terminal	O
peptide	O
in	O
JY25	O
cells	O
also	O
inhibited	O
Raf-1	B
and	O
ERK1	B
activity	O
,	O
indicating	O
a	O
direct	O
involvement	O
of	O
G	O
betagamma	O
subunits	O
in	O
the	O
signal	O
transduction	O
generated	O
through	O
activation	O
of	O
MAPK	B
pathway	O
by	O
TCC	B
assembly	O
in	O
the	O
plasma	O
membrane	O
.	O
Use	O
of	O
arsenic	O
trioxide	O
(	O
As2O3	O
)	O
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
:	O
II	O
.	O
Clinical	O
efficacy	O
and	O
pharmacokinetics	O
in	O
relapsed	O
patients	O
.	O
The	O
therapeutic	O
effect	O
of	O
arsenic	O
trioxide	O
(	O
As2O3	O
)	O
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
was	O
evaluated	O
among	O
15	O
APL	O
patients	O
at	O
relapse	O
after	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
induced	O
and	O
chemotherapy	O
maintained	O
complete	O
remission	O
(	O
CR	O
)	O
.	O
As2O3	O
was	O
administered	O
intravenously	O
at	O
the	O
dose	O
of	O
10	O
mg	O
/	O
d	O
.	O
Clinical	O
CR	O
was	O
achieved	O
in	O
nine	O
of	O
10	O
(	O
90	O
%	O
)	O
patients	O
treated	O
with	O
As2O3	O
alone	O
and	O
in	O
the	O
remaining	O
five	O
patients	O
treated	O
by	O
the	O
combination	O
of	O
As2O3	O
and	O
low	O
-	O
dose	O
chemotherapeutic	O
drugs	O
or	O
ATRA	O
.	O
During	O
the	O
treatment	O
with	O
As2O3	O
,	O
there	O
was	O
no	O
bone	O
marrow	O
depression	O
and	O
only	O
limited	O
side	O
effects	O
were	O
encountered	O
.	O
Pharmacokinetic	O
studies	O
,	O
which	O
were	O
performed	O
in	O
eight	O
patients	O
,	O
showed	O
that	O
after	O
a	O
peak	O
level	O
of	O
5.54	O
micromol	O
/	O
L	O
to	O
7.30	O
micromol	O
/	O
L	O
,	O
plasma	O
arsenic	O
was	O
rapidly	O
eliminated	O
,	O
and	O
the	O
continuous	O
administration	O
of	O
As2O3	O
did	O
not	O
alter	O
its	O
pharmacokinetic	O
behaviors	O
.	O
In	O
addition	O
,	O
increased	O
amounts	O
of	O
arsenic	O
appeared	O
in	O
the	O
urine	O
,	O
with	O
a	O
daily	O
excretion	O
accounting	O
for	O
approximately	O
1	O
%	O
to	O
8	O
%	O
of	O
the	O
total	O
daily	O
dose	O
administered	O
.	O
Arsenic	O
contents	O
in	O
hair	O
and	O
nail	O
were	O
increased	O
,	O
and	O
the	O
peak	O
content	O
of	O
arsenic	O
could	O
reach	O
2.5	O
to	O
2.7	O
microg	O
/	O
g	O
tissue	O
at	O
CR	O
.	O
On	O
the	O
other	O
hand	O
,	O
a	O
decline	O
of	O
the	O
arsenic	O
content	O
in	O
hair	O
and	O
nail	O
was	O
observed	O
after	O
withdrawal	O
of	O
the	O
drug	O
.	O
We	O
conclude	O
that	O
As2O3	O
treatment	O
is	O
an	O
effective	O
and	O
relatively	O
safe	O
drug	O
in	O
APL	O
patients	O
refractory	O
to	O
ATRA	O
and	O
conventional	O
chemotherapy	O
.	O
Activation	O
of	O
the	O
NF	B
-	I
kappaB	I
pathway	O
by	O
inflammatory	O
stimuli	O
in	O
human	O
neutrophils	O
.	O
Activated	O
neutrophils	O
have	O
the	O
ability	O
to	O
upregulate	O
the	O
expression	O
of	O
many	O
genes	O
,	O
in	O
particular	O
those	O
encoding	O
cytokines	B
and	O
chemokines	B
,	O
and	O
to	O
subsequently	O
release	O
the	O
corresponding	O
proteins	O
.	O
Although	O
little	O
is	O
known	O
to	O
date	O
concerning	O
the	O
regulation	O
of	O
gene	O
transcription	O
in	O
neutrophils	O
,	O
it	O
is	O
noteworthy	O
that	O
many	O
of	O
these	O
genes	O
depend	O
on	O
the	O
activation	O
of	O
transcription	B
factors	I
,	O
such	O
as	O
NF	B
-	I
kappaB	I
,	O
for	O
inducible	O
expression	O
.	O
We	O
therefore	O
investigated	O
whether	O
NF	B
-	I
kappaB	I
/	I
Rel	I
proteins	I
are	O
expressed	O
in	O
human	O
neutrophils	O
,	O
as	O
well	O
as	O
their	O
fate	O
on	O
cell	O
activation	O
.	O
We	O
now	O
report	O
that	O
dimers	O
consisting	O
of	O
p50	B
NFkappaB1	I
,	O
p65	B
RelA	I
,	O
and/or	O
c	B
-	I
Rel	I
are	O
present	O
in	O
neutrophils	O
and	O
that	O
the	O
greater	O
part	O
of	O
these	O
protein	B
complexes	I
is	O
physically	O
associated	O
with	O
cytoplasmic	B
IkappaB	I
-	I
alpha	I
in	O
resting	O
cells	O
.	O
Following	O
neutrophil	O
stimulation	O
with	O
proinflammatory	O
agonists	O
(	O
such	O
as	O
lipopolysaccharide	O
[	O
LPS	O
]	O
,	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
[	O
TNF	B
-	I
alpha	I
]	O
,	O
and	O
fMet	O
-	O
Leu	O
-	O
Phe	O
)	O
that	O
induce	O
the	O
production	O
of	O
cytokines	B
and	O
chemokines	B
in	O
these	O
cells	O
,	O
NF	B
-	I
kappaB	I
/	I
Rel	I
proteins	I
translocated	O
to	O
nuclear	O
fractions	O
,	O
resulting	O
in	O
a	O
transient	O
induction	O
of	O
NF	B
-	I
kappaB	I
DNA	O
binding	O
activity	O
,	O
as	O
determined	O
in	O
gel	O
mobility	O
shift	O
assays	O
.	O
The	O
onset	O
of	O
both	O
processes	O
was	O
found	O
to	O
be	O
closely	O
paralleled	O
by	O
,	O
and	O
dependent	O
on	O
,	O
IkappaB	B
-	I
alpha	I
degradation	O
.	O
Proinflammatory	O
neutrophil	O
stimuli	O
also	O
promoted	O
the	O
accumulation	O
of	O
IkappaB	O
-	O
alpha	O
mRNA	O
transcripts	O
,	O
resulting	O
in	O
the	O
reexpression	O
of	O
the	O
IkappaB	B
-	I
alpha	I
protein	I
.	O
To	O
our	O
knowledge	O
,	O
this	O
constitutes	O
the	O
first	O
indication	O
that	O
NF	B
-	I
kappaB	I
activation	O
may	O
underlie	O
the	O
action	O
of	O
proinflammatory	O
stimuli	O
towards	O
human	O
neutrophil	O
gene	O
expression	O
and	O
,	O
as	O
such	O
,	O
adds	O
a	O
new	O
facet	O
to	O
our	O
understanding	O
of	O
neutrophil	O
biology	O
.	O
Preferential	O
presentation	O
of	O
herpes	B
simplex	I
virus	I
T	I
-	I
cell	I
antigen	I
by	O
HLA	B
DQA1	I
*	I
0501	I
/	I
DQB1	I
*	I
0201	I
in	O
comparison	O
to	O
HLA	B
DQA1	I
*	I
0201	I
/	I
DQB1	I
*	I
0201	I
.	O
The	O
HLA	O
DQA1	O
locus	O
is	O
polymorphic	O
.	O
Haplotypes	O
containing	O
HLA	O
DQA1	O
*	O
0501	O
,	O
but	O
not	O
HLA	O
DQA1	O
*	O
0201	O
,	O
together	O
with	O
HLA	O
DQB1	O
*	O
0201	O
are	O
associated	O
with	O
Grave	O
's	O
disease	O
and	O
celiac	O
sprue	O
.	O
In	O
this	O
report	O
,	O
we	O
demonstrate	O
a	O
functional	O
correlate	O
of	O
DQA1	O
polymorphism	O
.	O
T	O
cells	O
infiltrating	O
a	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
lesion	O
from	O
a	O
HLA	O
DQ	O
2	O
,	O
7	O
individual	O
yielded	O
a	O
virus	O
-	O
specific	O
CD4	O
+	O
clone	O
restricted	O
by	O
DQ2	B
.	O
Presentation	O
of	O
viral	O
peptide	O
and	O
protein	O
segregated	O
with	O
DQA1	O
allele	O
,	O
because	O
cell	O
lines	O
bearing	O
DQA1	B
*	I
0501	I
/	I
DQB1	I
*	I
0201	I
heterodimers	I
presented	O
antigen	O
in	O
proliferation	O
and	O
cytotoxicity	O
assays	O
much	O
more	O
efficiently	O
than	O
cell	O
lines	O
bearing	O
DQA1	B
*	I
0201	I
/	I
DQB1	I
*	I
0201	I
.	O
Binding	O
of	O
viral	O
peptide	O
to	O
cell	O
lines	O
bearing	O
DQA1	B
*	I
0201	I
,	O
in	O
comparison	O
to	O
DQA1	B
*	I
0501	I
,	O
was	O
only	O
moderately	O
reduced	O
and	O
may	O
not	O
explain	O
this	O
effect	O
.	O
Truncation	O
and	O
substitution	O
analyses	O
of	O
peptide	O
binding	O
and	O
T	O
-	O
cell	O
activation	O
were	O
performed	O
to	O
determine	O
which	O
viral	O
peptide	O
residues	O
contacting	O
TCR	B
might	O
therefore	O
be	O
presented	O
in	O
an	O
altered	O
conformation	O
by	O
DQA1	B
*	I
0201	I
/	I
DQB1	I
*	I
0201	I
.	O
Residues	O
432	O
,	O
435	O
,	O
437	O
,	O
438	O
,	O
and	O
440	O
(	O
position	O
P1	O
,	O
P4	O
,	O
P6	O
,	O
P7	O
,	O
and	O
P9	O
)	O
contributed	O
to	O
DQ2	B
binding	O
,	O
whereas	O
residues	O
431	O
,	O
433	O
,	O
434	O
,	O
and	O
436	O
(	O
positions	O
P	O
1	O
,	O
P2	O
,	O
P3	O
,	O
and	O
P5	O
)	O
contributed	O
to	O
TCR	B
contact	O
.	O
Differential	O
presentation	O
of	O
peptide	O
by	O
HLA	B
DQ2	I
heterodimers	I
varying	O
at	O
the	O
DQA1	O
locus	O
may	O
have	O
relevance	O
to	O
host	O
defense	O
and	O
the	O
pathogenesis	O
of	O
HLA	O
DQ2	B
-associated	O
autoimmune	O
diseases	O
.	O
Significance	O
of	O
quantitative	O
analysis	O
of	O
AML1	O
/	O
ETO	O
transcripts	O
in	O
peripheral	O
blood	O
stem	O
cells	O
from	O
t	O
(	O
8	O
;	O
21	O
)	O
acute	O
myelogenous	O
leukemia	O
.	O
Autologous	O
peripheral	O
blood	O
stem	O
cell	O
transplantation	O
(	O
PBSCT	O
)	O
is	O
replacing	O
autologous	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
in	O
the	O
treatment	O
of	O
leukemia	O
.	O
One	O
of	O
the	O
potential	O
advantages	O
of	O
autologous	O
PBSCT	O
is	O
the	O
possibility	O
that	O
peripheral	O
blood	O
stem	O
cells	O
(	O
PBSC	O
)	O
are	O
less	O
likely	O
to	O
be	O
contaminated	O
by	O
leukemic	O
cells	O
than	O
bone	O
marrow	O
grafts	O
.	O
However	O
,	O
the	O
major	O
problem	O
still	O
remains	O
the	O
high	O
incidence	O
of	O
leukemic	O
relapse	O
following	O
autologous	O
PBSCT	O
,	O
which	O
may	O
be	O
caused	O
by	O
the	O
reinfusion	O
of	O
PBSC	O
contaminated	O
by	O
leukemic	O
cells	O
.	O
Recently	O
,	O
we	O
have	O
developed	O
a	O
quantitative	O
assay	O
using	O
competitive	O
reverse	B
transcriptase	I
polymerase	I
chain	O
reaction	O
that	O
estimates	O
the	O
number	O
of	O
AML1	O
/	O
ETO	O
transcripts	O
in	O
t	O
(	O
8	O
;	O
21	O
)	O
acute	O
myelogenous	O
leukemia	O
(	O
AML	O
)	O
,	O
in	O
order	O
to	O
determine	O
the	O
degree	O
of	O
leukemic	O
cell	O
contamination	O
in	O
PBSC	O
harvests	O
,	O
and	O
to	O
monitor	O
minimal	O
residual	O
disease	O
(	O
MRD	O
)	O
quantitatively	O
in	O
patients	O
with	O
t	O
(	O
8	O
;	O
21	O
)	O
AML	O
.	O
Our	O
data	O
indicate	O
that	O
although	O
PBSC	O
harvests	O
collected	O
after	O
consolidation	O
chemotherapy	O
are	O
contaminated	O
by	O
leukemic	O
cells	O
,	O
the	O
degree	O
of	O
leukemic	O
cell	O
contamination	O
decreases	O
with	O
repeated	O
cycles	O
of	O
chemotherapy	O
.	O
Furthermore	O
,	O
the	O
MRD	O
in	O
PBSC	O
harvests	O
is	O
less	O
than	O
in	O
the	O
corresponding	O
bone	O
marrow	O
obtained	O
on	O
the	O
day	O
of	O
the	O
PBSC	O
collection	O
.	O
There	O
appears	O
to	O
be	O
no	O
relationship	O
between	O
the	O
number	O
of	O
AML1	O
/	O
ETO	O
transcripts	O
found	O
in	O
the	O
infused	O
PBSC	O
harvests	O
and	O
the	O
incidence	O
of	O
leukemic	O
relapse	O
following	O
autologous	O
PBSCT	O
in	O
our	O
study	O
.	O
However	O
,	O
a	O
substantial	O
decrease	O
of	O
AML1	O
/	O
ETO	O
transcripts	O
was	O
seen	O
following	O
autologous	O
PBSCT	O
.	O
Thus	O
,	O
the	O
quantitative	O
analysis	O
of	O
AML1	O
/	O
ETO	O
transcripts	O
may	O
be	O
clinically	O
useful	O
in	O
patients	O
with	O
t	O
(	O
8	O
;	O
21	O
)	O
AML	O
.	O
Itk	B
,	O
a	O
T	B
cell	I
-	I
specific	I
tyrosine	I
kinase	I
,	O
is	O
required	O
for	O
CD2-mediated	O
interleukin-2	O
promoter	O
activation	O
in	O
the	O
human	O
T	O
cell	O
line	O
Jurkat	O
.	O
We	O
investigated	O
the	O
functional	O
role	O
of	O
Itk	B
,	O
a	O
member	O
of	O
the	O
cytoplasmic	B
tyrosine	I
kinase	I
Tec	I
family	I
,	O
in	O
T	O
cell	O
activation	O
.	O
Stimulation	O
of	O
either	O
CD2	B
or	O
T	O
cell	O
receptor	O
(	O
TCR	B
)	O
/CD3	O
on	O
Tcells	O
by	O
monoclonal	O
antibody	O
-	O
mediated	O
cross	O
-	O
linking	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Itk	B
,	O
which	O
was	O
maximal	O
as	O
early	O
as	O
1	O
min	O
after	O
stimulation	O
.	O
The	O
tyrosine	O
kinase	O
activity	O
in	O
the	O
anti-	O
Itk	B
immunoprecipitate	O
was	O
significantly	O
activated	O
upon	O
these	O
stimulations	O
.	O
Interleukin-2	O
(	O
IL-2	B
)	O
promoter	O
activity	O
stimulated	O
by	O
cross	O
-	O
linking	O
of	O
CD2	B
,	O
TCR	B
/CD3	O
,	O
and	O
CD28	B
with	O
antibodies	B
was	O
significantly	O
reduced	O
by	O
transient	O
expression	O
of	O
an	O
Itk	B
mutant	I
lacking	O
the	O
kinase	O
activity	O
.	O
The	O
reduction	O
paralleled	O
a	O
decrease	O
in	O
tyrosine	O
phosphorylation	O
of	O
endogenous	B
wild	I
-	I
type	I
Itk	I
.	O
Stimulation	O
of	O
CD2	B
or	O
TCR	B
/	I
CD3	I
induced	O
activation	O
of	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT	B
)	O
,	O
the	O
binding	O
site	O
of	O
which	O
is	O
included	O
in	O
the	O
IL-2	O
gene	O
promoter	O
.	O
The	O
activation	O
of	O
NFAT	B
was	O
also	O
impaired	O
by	O
expression	O
of	O
the	O
Itk	B
mutant	I
.	O
These	O
results	O
demonstrate	O
that	O
Itk	B
plays	O
a	O
role	O
in	O
IL-2	B
production	O
,	O
indicating	O
a	O
critical	O
involvement	O
of	O
Itk	B
in	O
the	O
initial	O
stage	O
of	O
T	O
cell	O
activation	O
by	O
mediating	O
signals	O
from	O
the	O
TCR	B
/	I
CD3	I
complex	I
,	O
CD2	B
,	O
and	O
CD28	B
.	O
DNA	O
methylation	O
changes	O
in	O
hematologic	O
malignancies	O
:	O
biologic	O
and	O
clinical	O
implications	O
.	O
DNA	O
methylation	O
changes	O
are	O
among	O
the	O
most	O
common	O
detectable	O
abnormalities	O
in	O
human	O
neoplasia	O
.	O
Hypermethylation	O
within	O
the	O
promoters	O
of	O
selected	O
genes	O
appears	O
to	O
be	O
especially	O
common	O
in	O
all	O
types	O
of	O
human	O
hematopoietic	O
neoplasms	O
,	O
and	O
is	O
usually	O
associated	O
with	O
inactivation	O
of	O
the	O
involved	O
gene	O
(	O
s	O
)	O
.	O
Such	O
hypermethylation	O
-	O
associated	O
silencing	O
of	O
gene	O
expression	O
has	O
been	O
shown	O
for	O
several	O
genes	O
regulating	O
the	O
growth	O
and	O
differentiation	O
of	O
hematopoietic	O
cells	O
,	O
including	O
the	O
estrogen	O
receptor	O
(	O
ER	O
)	O
gene	O
,	O
P15	O
,	O
P16	O
and	O
others	O
.	O
Hypermethylation	O
within	O
the	O
promoters	O
of	O
some	O
genes	O
appear	O
to	O
be	O
an	O
early	O
event	O
in	O
the	O
pathogenesis	O
of	O
neoplasia	O
(	O
ER	O
,	O
P15	O
)	O
,	O
while	O
other	O
genes	O
seem	O
to	O
become	O
methylated	O
during	O
the	O
progression	O
of	O
leukemias	O
(	O
HIC1	O
,	O
c	O
-	O
abl	O
)	O
.	O
The	O
high	O
prevalence	O
of	O
promoter	O
methylation	O
suggests	O
that	O
this	O
molecular	O
abnormality	O
can	O
be	O
used	O
to	O
monitor	O
disease	O
activity	O
during	O
therapy	O
.	O
In	O
addition	O
,	O
new	O
technology	O
allows	O
the	O
sensitive	O
identification	O
of	O
gene	O
hypermethylation	O
in	O
a	O
background	O
of	O
normal	O
cells	O
,	O
suggesting	O
possible	O
new	O
strategies	O
for	O
the	O
detection	O
of	O
minimal	O
residual	O
disease	O
.	O
Finally	O
,	O
reactivation	O
of	O
tumor	O
-	O
suppressor	O
gene	O
expression	O
through	O
pharmacologic	O
inhibition	O
of	O
DNA	B
methyltransferase	I
and	O
resultant	O
DNA	O
demethylation	O
appears	O
to	O
be	O
a	O
promising	O
new	O
avenue	O
of	O
therapy	O
in	O
acute	O
leukemia	O
.	O
A	O
novel	O
genetic	O
system	O
to	O
isolate	O
a	O
dominant	B
negative	I
effector	I
on	O
DNA	O
-	O
binding	O
activity	O
of	O
Oct-2	B
.	O
Recent	O
studies	O
have	O
revealed	O
that	O
interactions	O
between	O
transcription	B
factors	I
play	O
an	O
important	O
role	O
in	O
regulation	O
of	O
gene	O
expression	O
in	O
eukaryotic	O
cells	O
.	O
To	O
isolate	O
cDNA	O
clones	O
that	O
dominantly	O
inhibit	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
Oct-2	B
,	O
chosen	O
as	O
a	O
representative	O
factor	O
,	O
we	O
have	O
developed	O
a	O
novel	O
screening	O
system	O
.	O
This	O
employs	O
an	O
Escherichia	O
coli	O
tester	O
strain	O
carrying	O
a	O
modified	O
lac	O
operon	O
as	O
a	O
reporter	O
gene	O
,	O
with	O
the	O
lac	O
operator	O
sequence	O
replaced	O
by	O
an	O
octamer	O
sequence	O
.	O
Oct-2	B
expressed	O
in	O
this	O
tester	O
strain	O
represses	O
the	O
expression	O
of	O
the	O
reporter	O
gene	O
and	O
changes	O
the	O
phenotype	O
of	O
the	O
cell	O
from	O
Lac+to	O
Lac-	O
.	O
Introduction	O
of	O
a	O
cDNA	O
expression	O
library	O
prepared	O
from	O
a	O
human	O
T	O
-	O
cell	O
line	O
into	O
the	O
Oct-2	B
-harboring	O
tester	O
strain	O
allowed	O
selection	O
of	O
three	O
Lac+clones	O
out	O
of	O
1	O
x	O
10	O
(	O
5	O
)	O
transformants	O
.	O
One	O
of	O
them	O
,	O
hT86	O
,	O
encoding	O
a	O
putative	B
zinc	I
finger	I
protein	I
was	O
found	O
to	O
derepress	O
beta	B
-	I
galactosidase	I
activity	O
in	O
the	O
Oct-2	B
-harboring	O
tester	O
strain	O
at	O
the	O
transcriptional	O
level	O
.	O
In	O
gel	O
mobility	O
shift	O
assays	O
,	O
hT86	O
attenuated	O
the	O
intensity	O
of	O
the	O
retarded	O
band	O
composed	O
of	O
the	O
octamer	O
probe	O
and	O
Oct-2	B
,	O
suggesting	O
a	O
dominant	O
negative	O
effect	O
on	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
Oct-2	B
.	O
The	O
strategy	O
described	O
here	O
provides	O
a	O
new	O
approach	O
for	O
studying	O
protein	O
-	O
protein	O
interactions	O
that	O
govern	O
the	O
complex	O
regulation	O
of	O
gene	O
expression	O
.	O
A	O
negative	O
role	O
for	O
phosphoinositide	B
3-kinase	I
in	O
T	B
-	I
cell	I
antigen	I
receptor	I
function	O
.	O
BACKGROUND	O
:	O
A	O
delicate	O
balance	O
between	O
positive	O
and	O
negative	O
regulatory	O
mechanisms	O
during	O
T	O
-	O
cell	O
activation	O
determines	O
the	O
specificity	O
and	O
magnitude	O
of	O
an	O
immune	O
response	O
.	O
Phosphoinositide	B
3-kinase	I
(	O
PI	B
3-kinase	I
)	O
is	O
activated	O
by	O
a	O
diverse	O
set	O
of	O
receptors	O
that	O
determine	O
T	O
-	O
cell	O
function	O
,	O
including	O
the	O
T	B
-	I
cell	I
antigen	I
receptor	I
(	O
TCR	B
)	O
,	O
the	O
costimulatory	B
receptor	I
CD28	I
,	O
and	O
negative	B
regulators	I
of	O
T	O
-	O
cell	O
activation	O
such	O
as	O
CTLA-4	B
.	O
PI	B
3-kinase	I
is	O
also	O
regulated	O
by	O
the	O
haematopoietic	O
cytokines	O
that	O
determine	O
T	O
-	O
cell	O
differentiation	O
and	O
lymphocyte	O
proliferation	O
.	O
PI	B
3-kinase	I
can	O
thus	O
dynamically	O
influence	O
the	O
outcome	O
of	O
the	O
immune	O
reactions	O
at	O
various	O
stages	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
PI	B
3-kinase	I
in	O
TCR	B
-directed	O
T	O
-	O
cell	O
activation	O
using	O
activated	O
or	O
inhibitory	O
versions	O
of	O
PI	B
3-kinase	I
.	O
RESULTS	O
:	O
Certain	O
aspects	O
of	O
TCR	B
responses	O
such	O
as	O
the	O
induction	O
of	O
transcriptional	O
activity	O
of	O
AP1	B
and	O
serum	B
response	I
factor	I
were	O
not	O
affected	O
by	O
expression	O
of	O
the	O
mutant	O
forms	O
of	O
PI	B
3-kinase	I
.	O
We	O
found	O
,	O
however	O
,	O
that	O
PI	B
3-kinase	I
profoundly	O
influenced	O
the	O
transactivation	O
capacity	O
of	O
'	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
'	O
(	O
NF	B
-	I
AT	I
)	O
elicited	O
by	O
the	O
TCR	B
:	O
expression	O
of	O
an	O
activated	O
form	O
of	O
PI	B
3-kinase	I
inhibited	O
TCR	B
-mediated	O
NF	B
-	I
AT	I
responses	O
,	O
whereas	O
expression	O
of	O
a	O
dominant	O
negative	O
mutant	O
of	O
PI	B
3-kinase	I
potently	O
enhanced	O
TCR	B
-controlled	O
NF	B
-	I
AT	I
induction	O
.	O
These	O
effects	O
of	O
PI	B
3-kinase	I
were	O
not	O
mediated	O
by	O
previously	O
identified	O
PI	B
3-kinase	I
effectors	I
,	O
such	O
as	O
protein	B
kinase	I
B	I
,	O
a	O
positive	B
regulator	I
of	O
PI	B
3-kinase	I
,	O
or	O
the	O
GTPase	B
Rac	I
,	O
and	O
are	O
therefore	O
likely	O
to	O
involve	O
a	O
novel	O
,	O
as	O
yet	O
unknown	O
,	O
effector	B
molecule	I
.	O
CONCLUSIONS	O
:	O
Our	O
results	O
establish	O
that	O
PI	B
3-kinase	I
can	O
both	O
positively	O
and	O
negatively	O
regulate	O
T	O
-	O
cell	O
function	O
,	O
and	O
uncover	O
a	O
previously	O
unrecognized	O
function	O
for	O
PI	B
3-kinase	I
in	O
T	O
cells	O
as	O
a	O
selective	O
negative	O
regulator	O
of	O
TCR	B
-signalling	O
events	O
and	O
therefore	O
as	O
a	O
determinant	O
of	O
T	O
-	O
cell	O
homeostasis	O
.	O
Molecular	O
cloning	O
of	O
SLAP-130	B
,	O
an	O
SLP-76-associated	B
substrate	I
of	O
the	O
T	B
cell	I
antigen	I
receptor	I
-	I
stimulated	I
protein	I
tyrosine	I
kinases	I
.	O
Previous	O
work	O
has	O
demonstrated	O
that	O
SLP-76	B
,	O
a	O
Grb2-associated	B
tyrosine	I
-	I
phosphorylated	I
protein	I
,	O
augments	O
Interleukin-2	O
promoter	O
activity	O
when	O
overexpressed	O
in	O
the	O
Jurkat	O
T	O
cell	O
line	O
.	O
This	O
activity	O
requires	O
regions	O
of	O
SLP-76	B
that	O
mediate	O
protein	O
-	O
protein	O
interactions	O
with	O
other	O
molecules	O
in	O
T	O
cells	O
,	O
suggesting	O
that	O
SLP-76	B
-associated	O
proteins	O
also	O
function	O
to	O
regulate	O
signal	O
transduction	O
.	O
Here	O
we	O
describe	O
the	O
molecular	O
cloning	O
of	O
SLAP-130	B
,	O
a	O
SLP-76-associated	B
phosphoprotein	I
of	O
130	O
kDa	O
.	O
We	O
demonstrate	O
that	O
SLAP-130	B
is	O
hematopoietic	O
cell	O
-	O
specific	O
and	O
associates	O
with	O
the	O
SH2	B
domain	I
of	O
SLP-76	B
.	O
Additionally	O
,	O
we	O
show	O
that	O
SLAP-130	B
is	O
a	O
substrate	O
of	O
the	O
T	B
cell	I
antigen	I
receptor	I
-	I
induced	I
protein	I
tyrosine	B
kinases	I
.	O
Interestingly	O
,	O
we	O
find	O
that	O
in	O
contrast	O
to	O
SLP-76	B
,	O
overexpression	O
of	O
SLAP-130	B
diminishes	O
T	B
cell	I
antigen	I
receptor	I
-induced	O
activation	O
of	O
the	O
interleukin-2	O
promoter	O
in	O
Jurkat	O
T	O
cells	O
and	O
interferes	O
with	O
the	O
augmentation	O
of	O
interleukin-2	O
promoter	O
activity	O
seen	O
when	O
SLP-76	B
is	O
overexpressed	O
in	O
these	O
cells	O
.	O
These	O
data	O
suggest	O
that	O
SLP-76	B
recruits	O
a	O
negative	O
regulator	O
,	O
SLAP-130	B
,	O
as	O
well	O
as	O
positive	O
regulators	O
of	O
signal	O
transduction	O
in	O
T	O
cells	O
.	O
Transcriptional	O
induction	O
of	O
collagenase-1	B
in	O
differentiated	O
monocyte	O
-	O
like	O
(	O
U937	O
)	O
cells	O
is	O
regulated	O
by	O
AP-1	B
and	O
an	O
upstream	O
C	O
/	O
EBP	O
-	O
beta	O
site	O
.	O
In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
AP-1	B
site	O
and	O
a	O
distal	O
promoter	O
element	O
regulate	O
transcriptional	O
induction	O
of	O
collagenase-1	B
during	O
monocytic	O
differentiation	O
.	O
Chloramphenicol	O
acetyltransferase	O
expression	O
constructs	O
containing	O
regions	O
of	O
the	O
human	O
collagenase-1	O
promoter	O
were	O
stably	O
or	O
transiently	O
transfected	O
into	O
U937	O
cells	O
,	O
and	O
reporter	O
activity	O
was	O
assessed	O
at	O
various	O
times	O
after	O
the	O
onset	O
of	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-mediated	O
differentiation	O
.	O
Rapid	O
and	O
strong	O
induction	O
of	O
promoter	O
activity	O
was	O
lost	O
in	O
constructs	O
with	O
a	O
mutant	O
AP-1	O
element	O
;	O
however	O
,	O
at	O
16	O
-	O
96	O
h	O
post	O
-	O
PMA	O
,	O
the	O
mutant	O
collagenase-1	O
promoter	O
displayed	O
AP-1	B
independent	O
PMA	O
-	O
mediated	O
transactivation	O
.	O
The	O
AP-1	O
mutant	O
constructs	O
also	O
showed	O
delayed	O
transcriptional	O
activation	O
in	O
PMA	O
-	O
treated	O
fibroblasts	O
.	O
Western	O
and	O
supershift	O
analyses	O
indicated	O
that	O
functional	B
Jun	I
and	I
Fos	I
proteins	I
were	O
present	O
in	O
nuclear	O
extracts	O
of	O
PMA	O
-	O
differentiated	O
U937	O
cells	O
.	O
Promoter	O
deletion	O
constructs	O
demonstrated	O
the	O
potential	O
role	O
of	O
distal	O
promoter	O
sequences	O
in	O
regulating	O
collagenase-1	B
transcription	O
.	O
In	O
particular	O
,	O
Western	O
,	O
supershift	O
,	O
and	O
promoter	O
deletion	O
analyses	O
suggested	O
a	O
role	O
for	O
CCAAT	O
/	O
enhancer	O
-	O
binding	O
protein	O
-	O
beta	O
(	O
C	O
/	O
EBP	O
-	O
beta	O
)	O
binding	O
site	O
between	O
-2010	O
and	O
-1954	O
in	O
regulating	O
transcription	O
of	O
collagenase-1	B
in	O
monocytic	O
cells	O
.	O
Our	O
findings	O
suggest	O
that	O
distinct	O
regulatory	O
elements	O
,	O
acting	O
somewhat	O
independently	O
of	O
each	O
other	O
,	O
control	O
expression	O
of	O
collagenase-1	B
.	O
In	O
addition	O
,	O
our	O
data	O
suggests	O
that	O
the	O
rapid	O
PMA	O
-	O
mediated	O
induction	O
of	O
collagenase-1	B
transcription	O
is	O
controlled	O
by	O
a	O
mechanism	O
distinct	O
from	O
that	O
regulating	O
the	O
sustained	O
expression	O
of	O
this	O
proteinase	B
in	O
activated	O
macrophages	O
.	O
Jak3	B
is	O
associated	O
with	O
CD40	B
and	O
is	O
critical	O
for	O
CD40	B
induction	O
of	O
gene	O
expression	O
in	O
B	O
cells	O
.	O
CD40	B
is	O
a	O
receptor	O
that	O
is	O
critical	O
for	O
the	O
survival	O
,	O
growth	O
,	O
differentiation	O
,	O
and	O
isotype	O
switching	O
of	O
B	O
lymphocytes	O
.	O
Although	O
CD40	B
lacks	O
intrinsic	O
tyrosine	O
kinase	O
activity	O
,	O
its	O
ligation	O
induces	O
protein	O
tyrosine	O
phosphorylation	O
,	O
which	O
is	O
necessary	O
for	O
several	O
CD40	B
-mediated	O
events	O
.	O
We	O
show	O
that	O
engagement	O
of	O
CD40	B
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
Jak3	B
as	O
well	O
as	O
of	O
STAT3	B
.	O
Jak3	B
is	O
constitutively	O
associated	O
with	O
CD40	B
,	O
and	O
this	O
interaction	O
requires	O
a	O
proline	B
-	I
rich	I
sequence	I
in	O
the	O
membrane	B
-	I
proximal	I
region	I
of	O
CD40	B
.	O
Deletion	O
of	O
this	O
sequence	O
abolishes	O
the	O
capacity	O
of	O
CD40	B
to	O
induce	O
expression	O
of	O
CD23	B
,	O
ICAM-1	B
,	O
and	O
lymphotoxin	O
-	O
alpha	O
genes	O
in	O
B	O
cells	O
.	O
These	O
results	O
indicate	O
that	O
signaling	O
through	O
Jak3	B
is	O
activated	O
by	O
CD40	B
and	O
plays	O
an	O
important	O
role	O
in	O
CD40	B
-mediated	O
functions	O
.	O
Structure	O
and	O
function	O
analysis	O
of	O
the	O
human	O
myeloid	O
cell	O
nuclear	O
differentiation	O
antigen	O
promoter	O
:	O
evidence	O
for	O
the	O
role	O
of	O
Sp1	B
and	O
not	O
of	O
c	B
-	I
Myb	I
or	O
PU.1	B
in	O
myelomonocytic	O
lineage	O
-	O
specific	O
expression	O
.	O
The	O
human	B
myeloid	I
nuclear	I
differentiation	I
antigen	I
(	O
MNDA	B
)	O
is	O
expressed	O
specifically	O
in	O
maturing	O
cells	O
of	O
the	O
myelomonocytic	O
lineage	O
and	O
in	O
monocytes	O
and	O
granulocytes	O
.	O
Epitope	O
enhancement	O
was	O
used	O
to	O
confirm	O
the	O
strict	O
lineage-	O
and	O
stage	O
-	O
specific	O
expression	O
of	O
MNDA	B
in	O
bone	O
marrow	O
as	O
well	O
as	O
in	O
other	O
paraffin	O
-	O
embedded	O
fixed	O
tissues	O
.	O
A	O
1-kb	O
region	O
of	O
the	O
gene	O
that	O
includes	O
5	O
'	O
flanking	O
sequence	O
was	O
reported	O
earlier	O
to	O
contain	O
functional	O
promoter	O
activity	O
and	O
was	O
specifically	O
demethylated	O
in	O
expressing	O
cells	O
in	O
contrast	O
to	O
null	O
cells	O
.	O
Further	O
analysis	O
has	O
revealed	O
that	O
this	O
1-kb	O
fragment	O
promotes	O
higher	O
reporter	O
gene	O
activity	O
in	O
MNDA	B
-expressing	O
cells	O
than	O
non	O
-	O
expressing	O
cells	O
,	O
indicating	O
cell	O
-	O
specific	O
differences	O
in	O
transactivation	O
.	O
This	O
sequence	O
contains	O
consensus	O
elements	O
consistent	O
with	O
myeloid	O
-	O
specific	O
gene	O
expression	O
,	O
including	O
a	O
PU.1	O
consensus	O
site	O
near	O
the	O
major	O
transcription	O
start	O
site	O
and	O
a	O
cluster	O
of	O
c	O
-	O
Myb	O
sites	O
located	O
several	O
hundred	O
bases	O
upstream	O
of	O
this	O
region	O
.	O
However	O
,	O
analysis	O
of	O
deletion	O
mutants	O
localized	O
nearly	O
all	O
of	O
the	O
promoter	O
activity	O
to	O
a	O
short	O
region	O
(	O
-73	O
to	O
-16	O
)	O
that	O
did	O
not	O
include	O
the	O
cluster	O
of	O
c	O
-	O
Myb	O
sites	O
.	O
A	O
4-bp	O
mutation	O
of	O
the	O
core	O
Sp1	O
consensus	O
element	O
(	O
GC	O
box	O
)	O
(	O
-20	O
)	O
reduced	O
overall	O
promoter	O
activity	O
of	O
the	O
1-kb	O
fragment	O
.	O
Mutation	O
of	O
the	O
PU.1	O
site	O
did	O
not	O
significantly	O
affect	O
promoter	O
activity	O
.	O
Only	O
a	O
small	O
region	O
(	O
-35	O
to	O
+	O
22	O
)	O
including	O
the	O
Sp1	O
element	O
and	O
transcription	O
start	O
site	O
,	O
but	O
not	O
the	O
PU.1	O
site	O
was	O
footprinted	O
.	O
The	O
4-bp	O
mutation	O
of	O
the	O
core	O
Sp1	O
consensus	O
element	O
abolished	O
footprinting	O
at	O
the	O
site	O
and	O
an	O
antibody	O
super	O
-	O
shift	O
reaction	O
showed	O
that	O
Sp1	B
is	O
one	O
of	O
the	O
factors	O
binding	O
the	O
consensus	O
site	O
.	O
The	O
Sp1	O
site	O
also	O
co	O
-	O
localizes	O
with	O
a	O
DNase	O
I	O
hypersensitive	O
site	O
.	O
The	O
results	O
indicate	O
that	O
DNA	O
methylation	O
,	O
chromatin	O
structure	O
,	O
and	O
transactivation	O
at	O
an	O
Sp1	O
site	O
contribute	O
to	O
the	O
highly	O
restricted	O
expression	O
of	O
this	O
myelomonocytic	O
lineage	O
specific	O
gene	O
.	O
Effects	O
of	O
TPA	B
,	O
bryostatin	B
1	I
,	O
and	O
retinoic	O
acid	O
on	O
PO	B
-	I
B	I
,	O
AP-1	B
,	O
and	O
AP-2	B
DNA	O
binding	O
during	O
HL-60	O
differentiation	O
.	O
PO	B
-	I
B	I
was	O
originally	O
characterized	O
as	O
a	O
transcriptional	B
regulatory	I
factor	I
of	O
the	O
pro	O
-	O
opiomelanocortin	O
(	O
POMC	O
)	O
gene	O
;	O
however	O
,	O
it	O
has	O
become	O
increasingly	O
clear	O
that	O
this	O
protein	O
may	O
be	O
active	O
in	O
tissues	O
outside	O
the	O
pituitary	O
,	O
since	O
it	O
is	O
present	O
in	O
diverse	O
cell	O
types	O
,	O
including	O
differentiated	O
HL-60	O
promyelocytic	O
leukemia	O
cells	O
.	O
We	O
previously	O
showed	O
that	O
PO	B
-	I
B	I
DNA	O
-	O
binding	O
is	O
progressively	O
induced	O
during	O
differentiation	O
of	O
promyelomonocytic	O
leukemic	O
HL-60	O
cells	O
to	O
the	O
macrophage	O
-	O
like	O
lineage	O
(	O
with	O
phorbol	O
esters	O
)	O
.	O
We	O
now	O
report	O
that	O
PO	B
-	I
B	I
DNA	O
-	O
binding	O
in	O
HL-60	O
cells	O
is	O
similarly	O
induced	O
during	O
differentiation	O
to	O
the	O
granulocytic	O
lineage	O
(	O
with	O
either	O
retinoic	O
acid	O
or	O
dimethylsulfoxide	O
)	O
.	O
Either	O
a	O
genetic	O
or	O
pharmacologic	O
blockade	O
of	O
HL-60	O
differentiation	O
prohibited	O
these	O
inductive	O
effects	O
.	O
These	O
studies	O
have	O
prompted	O
our	O
interest	O
in	O
the	O
dynamics	O
of	O
other	O
transcription	B
factor	I
changes	O
during	O
HL-60	O
differentiation	O
.	O
Of	O
these	O
,	O
we	O
observed	O
that	O
another	O
transcription	B
factor	I
(	O
AP-1	B
)	O
is	O
also	O
robustly	O
induced	O
at	O
the	O
DNA	O
-	O
binding	O
level	O
during	O
macrophage	O
-	O
like	O
HL-60	O
differentiation	O
,	O
but	O
not	O
during	O
granulocytic	O
differentiation	O
.	O
Conversely	O
,	O
the	O
DNA	O
-	O
binding	O
of	O
the	O
transcription	B
factor	I
AP-2	B
was	O
slightly	O
reduced	O
by	O
TPA	B
-induced	O
HL-60	O
differentiation	O
but	O
unchanged	O
during	O
granulocyte	O
differentiation	O
.	O
From	O
these	O
data	O
,	O
we	O
conclude	O
that	O
the	O
induction	O
of	O
PO	B
-	I
B	I
DNA	O
binding	O
is	O
a	O
general	O
marker	O
of	O
HL-60	O
myelomonocytic	O
differentiation	O
,	O
but	O
that	O
qualitative	O
aspects	O
of	O
the	O
induction	O
of	O
additional	O
distinct	O
transcription	B
factors	I
,	O
such	O
as	O
AP-1	B
,	O
may	O
contribute	O
to	O
lineage	O
-	O
specific	O
determinants	O
of	O
cell	O
fate	O
.	O
Spontaneous	O
occurrence	O
of	O
early	O
region	O
1A	O
reiteration	O
mutants	O
of	O
type	O
5	O
adenovirus	O
in	O
persistently	O
infected	O
human	O
T	O
-	O
lymphocytes	O
.	O
Mutants	O
of	O
type	O
5	O
adenovirus	O
(	O
Ad5	O
)	O
with	O
reiterated	O
DNA	O
sequences	O
in	O
the	O
E1a	O
region	O
appeared	O
in	O
a	O
human	O
T	O
-	O
lymphocyte	O
cell	O
line	O
,	O
Molt-4	O
,	O
persistently	O
infected	O
with	O
H5sub304	O
,	O
a	O
deletion	O
/	O
substitution	O
mutant	O
that	O
has	O
a	O
wild	O
-	O
type	O
phenotype	O
in	O
viral	O
replication	O
.	O
Endonuclease	B
analyses	O
and	O
DNA	O
sequencing	O
revealed	O
DNA	O
reiteration	O
in	O
each	O
mutant	O
.	O
In	O
the	O
four	O
representative	O
mutants	O
investigated	O
,	O
the	O
DNA	O
reiterations	O
all	O
started	O
within	O
a	O
six	O
-	O
base	O
-	O
pair	O
consensus	O
sequence	O
,	O
G	O
(	O
or	O
C	O
)	O
CTGTG	O
,	O
located	O
in	O
the	O
second	O
exon	O
of	O
the	O
E1a	O
region	O
(	O
at	O
nt	O
1333	O
,	O
1367	O
,	O
or	O
1419	O
)	O
.	O
There	O
was	O
not	O
any	O
DNA	O
homology	O
between	O
the	O
breakpoints	O
in	O
the	O
second	O
exon	O
and	O
the	O
inserting	O
sequences	O
(	O
starting	O
at	O
nt	O
532	O
,	O
710	O
,	O
or	O
792	O
)	O
.	O
Northern	O
analyses	O
suggested	O
that	O
the	O
reiterated	O
splicing	O
sites	O
of	O
the	O
representative	O
mutants	O
were	O
all	O
used	O
in	O
RNA	O
splicing	O
,	O
and	O
the	O
closest	O
donor	O
and	O
recipient	O
joints	O
were	O
used	O
most	O
frequently	O
.	O
These	O
observations	O
imply	O
that	O
during	O
persistent	O
infection	O
Ad5	O
underwent	O
spontaneous	O
mutations	O
by	O
sequence	O
-	O
specific	O
breakage	O
and	O
nonhomologous	O
end	O
-	O
end	O
joining	O
recombination	O
events	O
.	O
These	O
E1a	O
reiteration	O
mutants	O
could	O
be	O
propagated	O
in	O
HeLa	O
,	O
A549	O
,	O
and	O
KB	O
cells	O
;	O
they	O
were	O
genetically	O
stable	O
;	O
and	O
they	O
killed	O
CREF	O
cells	O
at	O
a	O
strikingly	O
high	O
frequency	O
.	O
Preliminary	O
observations	O
tend	O
to	O
correlate	O
this	O
CREF	O
cell	O
killing	O
with	O
the	O
accumulation	O
of	O
the	O
early	B
viral	I
proteins	I
and/or	O
viral	O
DNA	O
in	O
the	O
infected	O
cells	O
.	O
This	O
degree	O
of	O
cell	O
damage	O
was	O
not	O
observed	O
in	O
Ad5wt	O
or	O
H5sub304	O
infection	O
of	O
CREF	O
cells	O
.	O
The	O
observed	O
E1a	O
reiterations	O
provide	O
a	O
model	O
to	O
gain	O
insight	O
into	O
understanding	O
the	O
evolutionary	O
events	O
of	O
some	O
,	O
if	O
not	O
all	O
,	O
adenovirus	O
types	O
during	O
many	O
years	O
of	O
symbiotic	O
,	O
persistent	O
relationship	O
in	O
human	O
tonsils	O
and	O
adenoids	O
and	O
possibly	O
other	O
lymphoid	O
organs	O
.	O
The	O
role	O
of	O
the	O
Ikaros	O
gene	O
in	O
lymphocyte	O
development	O
and	O
homeostasis	O
.	O
The	O
Ikaros	O
gene	O
,	O
which	O
encodes	O
a	O
family	O
of	O
hemopoietic	B
-	I
specific	I
zinc	I
finger	I
proteins	I
,	O
is	O
described	O
as	O
a	O
central	O
regulator	O
of	O
lymphocyte	O
differentiation	O
.	O
During	O
fetal	O
development	O
,	O
it	O
is	O
required	O
at	O
the	O
earliest	O
stage	O
of	O
T	O
cell	O
and	O
B	O
cell	O
specification	O
.	O
In	O
the	O
adult	O
,	O
however	O
,	O
lymphoid	O
lineages	O
rely	O
on	O
Ikaros	O
at	O
distinct	O
phases	O
of	O
their	O
development	O
.	O
Its	O
activity	O
is	O
essential	O
for	O
the	O
generation	O
of	O
B	O
cell	O
but	O
not	O
of	O
T	O
cell	O
precursors	O
,	O
although	O
the	O
differentiation	O
of	O
the	O
latter	O
is	O
not	O
normal	O
.	O
A	O
significant	O
increase	O
in	O
CD4	O
thymocytes	O
and	O
their	O
immediate	O
precursors	O
is	O
detected	O
,	O
and	O
because	O
these	O
cells	O
lack	O
markers	O
that	O
correlate	O
with	O
positive	O
selection	O
,	O
a	O
deregulation	O
in	O
their	O
maturation	O
process	O
is	O
suggested	O
.	O
Furthermore	O
,	O
Ikaros	O
-	O
null	O
thymocytes	O
hyperproliferate	O
in	O
response	O
to	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
signaling	O
;	O
within	O
days	O
after	O
their	O
appearance	O
in	O
the	O
thymus	O
,	O
clonally	O
expanding	O
populations	O
are	O
detected	O
.	O
Deregulated	O
TCR	B
-mediated	O
responses	O
and	O
the	O
fast	O
kinetics	O
of	O
tumor	O
development	O
in	O
these	O
mutant	O
thymocytes	O
implicate	O
Ikaros	O
as	O
a	O
central	O
tumor	O
suppressor	O
gene	O
for	O
the	O
T	O
cell	O
lineage	O
.	O
In	O
addition	O
,	O
lack	O
of	O
natural	O
killer	O
cells	O
and	O
selective	O
defects	O
in	O
gamma	O
delta	O
T	O
cells	O
and	O
dendritic	O
antigen	O
-	O
presenting	O
cells	O
point	O
to	O
Ikaros	B
as	O
an	O
essential	O
factor	O
for	O
the	O
establishment	O
of	O
early	O
branchpoints	O
of	O
the	O
T	O
cell	O
pathway	O
.	O
The	O
dominant	O
interference	O
activity	O
of	O
Ikaros	B
isoforms	I
unable	O
to	O
bind	O
DNA	O
and	O
their	O
effects	O
in	O
lymphocyte	O
development	O
suggest	O
that	O
Ikaros	B
works	O
in	O
concert	O
with	O
other	O
factors	O
.	O
The	O
role	O
of	O
Aiolos	O
,	O
a	O
lymphoid	O
-	O
restricted	O
and	O
structurally	O
related	O
gene	O
,	O
in	O
lymphoid	O
differentiation	O
is	O
discussed	O
.	O
A	O
model	O
is	O
proposed	O
that	O
defines	O
Ikaros	B
as	O
the	O
backbone	O
of	O
a	O
complex	B
regulatory	I
protein	I
network	I
that	O
controls	O
cell	O
fate	O
decisions	O
and	O
regulates	O
homeostasis	O
in	O
the	O
hemo	O
-	O
lymphoid	O
system	O
.	O
Changes	O
in	O
this	O
regulatory	O
network	O
may	O
reflect	O
differentiation	O
and	O
proliferation	O
adjustments	O
made	O
in	O
hemo	O
-	O
lymphoid	O
progenitors	O
and	O
precursors	O
as	O
they	O
give	O
rise	O
to	O
the	O
cells	O
of	O
our	O
immune	O
system	O
.	O
Quantification	O
of	O
vitamin	O
D	O
receptor	O
mRNA	O
by	O
competitive	O
polymerase	O
chain	O
reaction	O
in	O
PBMC	O
:	O
lack	O
of	O
correspondence	O
with	O
common	O
allelic	O
variants	O
.	O
It	O
has	O
been	O
recently	O
claimed	O
that	O
polymorphism	O
for	O
the	O
vitamin	B
D	I
receptor	I
(	O
VDR	B
)	O
influences	O
several	O
aspects	O
of	O
calcium	O
and	O
bone	O
metabolism	O
.	O
To	O
evaluate	O
the	O
physiologic	O
plausibility	O
of	O
these	O
claims	O
,	O
we	O
compared	O
the	O
abundance	O
of	O
the	O
VDR	O
mRNA	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
between	O
different	O
VDR	B
genotypes	I
using	O
a	O
quantitative	O
reverse	O
transcribed	O
polymerase	O
chain	O
reaction	O
-	O
based	O
method	O
.	O
The	O
method	O
is	O
based	O
on	O
the	O
coamplification	O
of	O
VDR	O
cDNA	O
and	O
an	O
internal	O
standard	O
consisting	O
of	O
known	O
concentrations	O
of	O
a	O
human	O
VDR	O
CDNA	O
mutated	O
at	O
a	O
BglII	O
restriction	O
site	O
;	O
the	O
interassay	O
coefficient	O
of	O
variation	O
is	O
11	O
%	O
.	O
To	O
validate	O
the	O
method	O
,	O
we	O
made	O
use	O
of	O
earlier	O
receptor	O
binding	O
studies	O
indicating	O
that	O
normal	O
human	O
monocytes	O
and	O
activated	O
,	O
but	O
not	O
resting	O
,	O
lymphocytes	O
expressed	O
the	O
VDR	B
.	O
The	O
concentration	O
of	O
the	O
VDR	O
mRNA	O
was	O
10	O
(	O
-8	O
)	O
to	O
10	O
(	O
-7	O
)	O
g	O
/	O
g	O
of	O
total	O
RNA	O
in	O
cell	O
-	O
sorted	O
monocytes	O
and	O
in	O
in	O
vitro	O
activated	O
lymphocytes	O
,	O
but	O
only	O
10	O
(	O
-12	O
)	O
g	O
/	O
g	O
of	O
total	O
mRNA	O
in	O
resting	O
lymphocytes	O
,	O
establishing	O
that	O
the	O
VDR	O
mRNA	O
determined	O
by	O
our	O
method	O
in	O
PBMCs	O
is	O
due	O
to	O
constitutive	O
expression	O
in	O
monocytes	O
.	O
Following	O
an	O
initial	O
genotype	O
screening	O
of	O
85	O
normal	O
volunteers	O
by	O
polymerase	O
chain	O
reaction	O
or	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
,	O
14	O
individuals	O
with	O
the	O
Bb	O
genotype	O
,	O
12	O
with	O
the	O
bb	O
genotype	O
,	O
and	O
12	O
with	O
the	O
BB	O
genotype	O
were	O
selected	O
.	O
The	O
concentration	O
of	O
the	O
VDR	O
mRNA	O
,	O
corrected	O
for	O
the	O
number	O
of	O
monocytes	O
,	O
was	O
similar	O
among	O
the	O
three	O
genotype	O
groups	O
,	O
as	O
were	O
the	O
other	O
variables	O
examined	O
:	O
serum	B
calcitriol	I
,	O
serum	B
osteocalcin	I
,	O
and	O
vertebral	O
and	O
hip	O
bone	O
density	O
.	O
We	O
conclude	O
that	O
VDR	B
polymorphism	O
does	O
not	O
affect	O
the	O
abundance	O
of	O
the	O
VDR	O
mRNA	O
.	O
Regulation	O
of	O
CD95	B
(	I
Fas	I
)	I
ligand	I
expression	O
by	O
TCR	B
-mediated	O
signaling	O
events	O
.	O
Stimulation	O
of	O
mature	O
peripheral	O
T	O
cells	O
by	O
TCR	B
engagement	O
results	O
in	O
activation	O
of	O
signals	O
that	O
drive	O
induction	O
of	O
cytokine	B
gene	O
expression	O
and	O
clonal	O
expansion	O
.	O
However	O
,	O
under	O
some	O
conditions	O
,	O
engagement	O
of	O
the	O
TCR	B
leads	O
instead	O
to	O
apoptosis	O
.	O
Recent	O
studies	O
demonstrate	O
that	O
TCR	B
-stimulated	O
apoptosis	O
requires	O
expression	O
of	O
CD95	B
ligand	I
on	O
activated	O
T	O
cells	O
followed	O
by	O
an	O
interaction	O
between	O
CD95	B
ligand	I
and	O
the	O
CD95	B
receptor	I
also	O
expressed	O
on	O
this	O
population	O
.	O
The	O
experiments	O
reported	O
in	O
this	O
study	O
were	O
designed	O
to	O
address	O
the	O
signaling	O
events	O
triggered	O
by	O
TCR	B
engagement	O
that	O
are	O
important	O
for	O
regulating	O
CD95	B
ligand	I
gene	O
expression	O
.	O
To	O
approach	O
this	O
,	O
we	O
generated	O
a	O
luciferase	O
reporter	O
construct	O
containing	O
elements	O
of	O
the	O
CD95	B
ligand	I
promoter	O
.	O
Using	O
a	O
previously	O
described	O
mutant	O
of	O
the	O
Jurkat	O
T	O
cell	O
line	O
,	O
we	O
show	O
that	O
proximal	O
signaling	O
events	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
CD45	B
tyrosine	I
phosphatase	I
are	O
required	O
for	O
TCR	B
-stimulated	O
CD95	B
ligand	I
expression	O
.	O
Transient	O
transfection	O
studies	O
demonstrate	O
further	O
that	O
TCR	B
-stimulated	O
activation	O
of	O
the	O
Ras	B
signaling	O
pathway	O
is	O
required	O
for	O
optimal	O
activation	O
of	O
CD95	B
ligand	I
.	O
Next	O
,	O
in	O
an	O
effort	O
to	O
determine	O
critical	O
transcription	B
factors	I
that	O
regulate	O
CD95	B
ligand	I
expression	O
,	O
we	O
demonstrate	O
a	O
cyclosporin	O
A	O
-	O
sensitive	O
nuclear	O
factor	O
-	O
AT	O
response	O
element	O
in	O
the	O
promoter	O
region	O
of	O
this	O
gene	O
that	O
is	O
critical	O
for	O
optimal	O
CD95	B
ligand	I
reporter	O
activity	O
in	O
stimulated	O
T	O
cells	O
.	O
Together	O
,	O
these	O
studies	O
begin	O
a	O
dissection	O
of	O
the	O
biochemical	O
events	O
that	O
lead	O
to	O
expression	O
of	O
CD95	B
ligand	I
,	O
a	O
required	O
step	O
for	O
TCR	B
-induced	O
apoptosis	O
.	O
Cytomegalovirus	O
immediate	O
early	O
genes	O
upregulate	O
interleukin-6	B
gene	O
expression	O
.	O
BACKGROUND	O
:	O
The	O
immediate	O
early	O
genes	O
(	O
IE	O
)	O
of	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
be	O
expressed	O
in	O
monocytic	O
cells	O
and	O
are	O
known	O
to	O
regulate	O
viral	O
and	O
cellular	O
genes	O
.	O
Interleukin-6	B
(	O
IL-6	B
)	O
plays	O
a	O
central	O
role	O
in	O
numerous	O
inflammatory	O
and	O
immune	O
processes	O
.	O
Interleukin-6	B
levels	O
are	O
increased	O
in	O
lung	O
transplant	O
patients	O
clinically	O
diagnosed	O
with	O
CMV	O
pneumonitis	O
.	O
The	O
regulation	O
of	O
IL-6	B
is	O
dependent	O
on	O
various	O
stimuli	O
that	O
include	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
viruses	O
,	O
and	O
other	O
cytokines	B
.	O
These	O
studies	O
examined	O
the	O
ability	O
of	O
CMV	O
IE	O
gene	O
products	O
to	O
modulate	O
IL-6	B
production	O
.	O
METHODS	O
:	O
THP-1	O
cells	O
,	O
a	O
monocytic	O
cell	O
line	O
,	O
were	O
transfected	O
with	O
the	O
CMV	O
IE	O
genes	O
.	O
Interleukin-6	B
protein	O
and	O
IL-6	O
mRNA	O
were	O
measured	O
in	O
control	O
and	O
CMV	O
immediate	O
early	O
transfected	O
cells	O
.	O
Cotransfection	O
of	O
CMV	O
IE	O
genes	O
and	O
IL-6	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
or	O
IL-6	O
luciferase	O
constructs	O
were	O
used	O
to	O
study	O
IL-6	B
promoter	O
activity	O
.	O
RESULTS	O
:	O
Interleukin-6	B
protein	I
and	O
mRNA	O
production	O
were	O
significantly	O
increased	O
in	O
cells	O
transfected	O
with	O
the	O
CMV	O
IE	O
genes	O
and	O
stimulated	O
with	O
LPS	O
compared	O
to	O
LPS	O
-	O
stimulated	O
control	O
cells	O
.	O
Cytomegalovirus	B
IE	I
gene	I
products	I
significantly	O
enhanced	O
LPS	O
stimulation	O
of	O
IL-6	O
promoter	O
activity	O
in	O
both	O
IL-6	B
CAT	O
and	O
IL-6	O
luciferase	O
assays	O
.	O
A	O
deletion	O
construct	O
that	O
contains	O
a	O
NF	O
-	O
kappa	O
B	O
site	O
but	O
is	O
missing	O
the	O
multiple	O
response	O
region	O
demonstrated	O
a	O
continued	O
increase	O
in	O
IL-6	B
luciferase	B
activity	O
in	O
LPS	O
-	O
stimulated	O
CMV	O
transfected	O
cells	O
.	O
CONCLUSION	O
:	O
Cytomegalovirus	B
immediate	I
early	I
gene	I
products	I
significantly	O
enhanced	O
expression	O
of	O
IL-6	B
in	O
LPS	O
-	O
stimulated	O
cells	O
.	O
The	O
increase	O
in	O
IL-6	B
luciferase	B
activity	O
occurs	O
in	O
the	O
absence	O
of	O
the	O
multiple	O
response	O
region	O
,	O
the	O
area	O
of	O
the	O
IL-6	O
promoter	O
responsive	O
to	O
IL-1	B
,	O
TNF	B
alpha	I
,	O
cyclic	O
amp	O
,	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
.	O
The	O
ability	O
of	O
CMV	B
IE	I
gene	I
products	I
to	O
enhance	O
IL-6	B
production	O
may	O
play	O
an	O
important	O
role	O
in	O
immune	O
inflammatory	O
states	O
associated	O
with	O
CMV	O
infection	O
.	O
Involvement	O
of	O
Stat3	B
in	O
interleukin-6	B
-induced	O
IgM	B
production	O
in	O
a	O
human	O
B	O
-	O
cell	O
line	O
.	O
Interleukin-6	B
(	O
IL-6	B
)	O
is	O
an	O
important	O
B	B
-	I
cell	I
growth	I
and	I
differentiation	I
factor	I
.	O
IL-6	B
treatment	O
of	O
the	O
human	O
lymphoblastoid	O
cell	O
line	O
,	O
SKW6.4	O
,	O
leads	O
to	O
increased	O
IgM	B
production	O
.	O
We	O
have	O
previously	O
shown	O
that	O
IL-6	B
induces	O
activation	O
of	O
JAK1	B
and	O
JAK2	B
in	O
human	O
B	O
cell	O
lines	O
.	O
A	O
chimeric	O
IL-6	B
receptor	I
,	O
comprised	O
of	O
the	O
intracellular	B
tail	I
of	O
the	O
IL-6	B
receptor	I
subunit	I
gp130	B
fused	O
to	O
the	O
extracellular	B
domain	I
of	O
the	O
epidermal	B
growth	I
factor	I
(	I
EGF	I
)	I
receptor	I
,	O
was	O
stably	O
transfected	O
into	O
SKW6.4	O
cells	O
.	O
EGF	O
treatment	O
induced	O
IgM	B
production	O
in	O
cells	O
transfected	O
with	O
an	O
intact	O
gp130	B
cytoplasmic	I
tail	I
,	O
but	O
not	O
in	O
untransfected	O
cells	O
or	O
cells	O
transfected	O
with	O
a	O
cytoplasmic	B
tail	I
lacking	O
all	O
four	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	I
Stat	I
)	I
binding	I
sites	I
.	O
Moreover	O
,	O
EGF	O
treatment	O
induced	O
Stat3	B
phosphorylation	O
in	O
cells	O
transfected	O
with	O
the	O
intact	O
chimeric	B
EGF	I
-	I
gp130	I
receptor	I
along	O
with	O
induction	O
of	O
DNA	O
-	O
mobility	O
shift	O
of	O
a	O
classical	O
interferon	O
-	O
gamma	O
-	O
activated	O
site	O
.	O
To	O
define	O
further	O
the	O
relation	O
between	O
Stat3	B
activation	O
and	O
enhanced	O
IgM	B
production	O
,	O
we	O
determined	O
the	O
effect	O
of	O
chimeric	O
gp130	O
on	O
the	O
transcriptional	O
activation	O
of	O
a	O
genetic	O
element	O
linked	O
to	O
immunoglobulin	B
production	O
,	O
namely	O
the	O
immunoglobulin	O
heavy	O
chain	O
enhancer	O
(	O
IgH	O
-	O
enhancer	O
)	O
.	O
Parental	O
as	O
well	O
as	O
transfected	O
SKW6.4	O
cells	O
were	O
transiently	O
transfected	O
with	O
an	O
IgH	O
-	O
enhancer	O
-	O
luciferase	O
construct	O
.	O
The	O
transcriptional	O
activity	O
of	O
the	O
IgH	O
-	O
luciferase	O
construct	O
was	O
induced	O
upon	O
ligation	O
of	O
the	O
full	B
-	I
length	I
chimeric	I
receptor	I
but	O
not	O
by	O
truncated	B
gp130	I
receptors	I
.	O
Moreover	O
,	O
the	O
gp130	B
-induced	O
activity	O
of	O
this	O
reporter	O
gene	O
was	O
abrogated	O
by	O
Stat3EE	B
,	O
a	O
mutant	O
Stat3	B
incapable	O
of	O
binding	O
DNA	O
.	O
These	O
results	O
indicate	O
that	O
IL-6	B
-induced	O
B	O
-	O
cell	O
differentiation	O
,	O
as	O
measured	O
by	O
IgM	B
production	O
,	O
may	O
be	O
controlled	O
by	O
Stat3	B
proteins	I
.	O
Characterization	O
of	O
peripheral	O
blood	O
T	O
-	O
lymphocytes	O
transduced	O
with	O
HTLV	B
-	I
I	I
Tax	I
mutants	I
with	O
different	O
trans	O
-	O
activating	O
phenotypes	O
.	O
Tax1	B
,	O
a	O
transcriptional	B
trans	I
-	I
activator	I
of	O
the	O
Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
,	O
induces	O
the	O
expression	O
of	O
many	O
cellular	O
genes	O
through	O
interaction	O
with	O
at	O
least	O
three	O
distinct	O
cellular	B
transcription	I
factors	I
;	O
CREB	B
/	I
ATF	I
,	O
NF	B
-	I
kappaB	I
,	O
and	O
SRF	B
.	O
This	O
Tax1	B
-induced	O
activation	O
of	O
cellular	O
genes	O
is	O
considered	O
to	O
be	O
a	O
critical	O
event	O
in	O
T	O
-	O
cell	O
transformation	O
by	O
HTLV	O
-	O
I	O
.	O
To	O
elucidate	O
the	O
role	O
of	O
each	O
Tax1	B
-inducible	O
transcriptional	O
pathway	O
in	O
T	O
-	O
cell	O
transformation	O
,	O
we	O
introduced	O
Tax1	B
mutants	I
with	O
different	O
trans	O
-	O
activating	O
phenotypes	O
into	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
by	O
retroviral	O
vectors	O
.	O
Analysis	O
of	O
these	O
PBLs	O
revealed	O
that	O
activation	O
of	O
the	O
NF	B
-	I
kappaB	I
pathway	O
is	O
sufficient	O
to	O
promote	O
the	O
growth	O
response	O
to	O
IL-2	B
.	O
However	O
,	O
for	O
the	O
clonal	O
expansion	O
of	O
CD4	O
+	O
T	O
-	O
cells	O
,	O
which	O
is	O
a	O
characteristic	O
result	O
of	O
HTLV	O
-	O
I	O
infection	O
,	O
activation	O
of	O
the	O
CREB	O
/	O
ATF	O
and	O
SRF	O
pathways	O
is	O
also	O
required	O
.	O
Involvement	O
of	O
phosphatidylinositol	B
3-kinase	I
in	O
NFAT	B
activation	O
in	O
T	O
cells	O
.	O
Phosphatidylinositol	B
3-kinase	I
(	O
PI3-K	B
)	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
in	O
many	O
cell	O
types	O
.	O
We	O
have	O
previously	O
shown	O
that	O
in	O
T	O
cells	O
the	O
PI3-K	B
inhibitor	O
,	O
wortmannin	O
,	O
interferes	O
with	O
activation	O
of	O
the	O
mitogen	B
-	I
activated	I
kinase	I
,	O
Erk2	B
,	O
after	O
T	B
cell	I
receptor	I
(	O
TcR	B
)	O
stimulation	O
.	O
To	O
further	O
explore	O
the	O
involvement	O
of	O
PI3-K	B
in	O
T	O
cell	O
activation	O
,	O
we	O
created	O
a	O
set	O
of	O
potentially	O
dominant	O
negative	O
PI3-K	O
constructs	O
comprising	O
individual	O
or	O
tandem	O
domains	O
of	O
the	O
regulatory	B
p85	I
subunit	I
and	O
tested	O
their	O
effect	O
on	O
downstream	O
signaling	O
events	O
like	O
Erk2	B
activation	O
and	O
transcription	O
from	O
an	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
element	O
taken	O
from	O
the	O
interleukin-2	O
promoter	O
.	O
Following	O
TcR	B
stimulation	O
,	O
activation	O
of	O
Erk2	B
was	O
only	O
inhibited	O
by	O
a	O
previously	O
described	O
truncated	B
form	I
of	I
p85	I
that	O
can	O
not	O
bind	O
the	O
catalytic	B
subunit	I
,	O
but	O
not	O
by	O
other	O
constructs	O
of	O
p85	B
.	O
In	O
contrast	O
,	O
several	O
mutant	O
p85	B
alleles	O
had	O
dramatic	O
effects	O
on	O
NFAT	B
activation	O
.	O
Most	O
interestingly	O
,	O
the	O
N	B
-	I
terminal	I
SH2	I
domain	I
had	O
an	O
inhibitory	O
effect	O
,	O
whereas	O
a	O
mutant	B
p85	I
containing	O
only	O
the	O
two	B
SH2	I
domains	I
enhanced	O
basal	O
NFAT	B
activity	O
in	O
a	O
Ras	B
-dependent	O
manner	O
.	O
Ionomycin	O
induced	O
synergistic	O
activation	O
of	O
NFAT	B
in	O
cells	O
expressing	O
p85	B
mutants	I
that	O
contained	O
the	O
C	B
-	I
terminal	I
SH2	I
domain	I
.	O
Analysis	O
of	O
phosphotyrosine	B
-	I
containing	I
proteins	I
bound	O
to	O
truncated	O
p85	B
constructs	I
revealed	O
cooperative	O
binding	O
of	O
the	O
two	B
SH2	I
domains	I
but	O
no	O
apparent	O
differences	O
between	O
the	O
N-	B
and	I
C-	I
terminal	I
SH2	I
domains	I
.	O
Wortmannin	O
did	O
not	O
interfere	O
with	O
NFAT	B
activation	O
,	O
although	O
it	O
inhibited	O
PI3-K	B
and	O
Erk2	B
activation	O
in	O
the	O
same	O
experiment	O
.	O
These	O
results	O
suggest	O
that	O
PI3-K	B
is	O
involved	O
in	O
NFAT	B
activation	O
through	O
a	O
complex	O
adaptor	O
function	O
of	O
its	O
regulatory	B
subunit	I
and	O
that	O
its	O
lipid	B
kinase	I
activity	O
is	O
dispensable	O
for	O
this	O
effect	O
.	O
An	O
isotype	O
-	O
specific	O
activator	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
genes	O
that	O
is	O
independent	O
of	O
class	B
II	I
transactivator	I
.	O
Patients	O
with	O
one	O
type	O
of	O
major	B
histocompatibility	I
complex	I
class	I
II	I
combined	O
immunodeficiency	O
have	O
mutations	O
in	O
a	O
gene	O
termed	O
class	B
II	I
transactivator	I
(	O
CIITA	B
)	O
,	O
which	O
coordinately	O
controls	O
the	O
transcription	O
of	O
the	O
three	O
major	O
human	O
class	O
II	O
genes	O
,	O
HLA	O
-	O
DR	O
,	O
-DQ	O
,	O
and	O
-DP	O
.	O
However	O
,	O
the	O
experimentally	O
derived	O
B	O
-	O
lymphoblastoid	O
cell	O
line	O
,	O
clone	O
13	O
,	O
expresses	O
high	O
levels	O
of	O
HLADQ	B
in	O
the	O
absence	O
of	O
HLA	O
-	O
DR	O
and	O
HLA	O
-	O
DP	O
,	O
despite	O
its	O
mapping	O
by	O
complementation	O
analysis	O
to	O
this	O
group	O
.	O
It	O
was	O
possible	O
that	O
one	O
of	O
the	O
clone	O
13	O
CIITA	O
alleles	O
bore	O
a	O
mutation	O
that	O
allowed	O
HLA	O
-	O
DQ	O
,	O
but	O
not	O
HLA	O
-	O
DR	O
or	O
-DP	O
transcription	O
.	O
Alternatively	O
,	O
another	O
factor	O
,	O
distinct	O
from	O
CIITA	B
,	O
might	O
control	O
HLA	O
-	O
DQ	O
expression	O
.	O
We	O
report	O
here	O
that	O
ectopic	O
expression	O
of	O
CIITA	O
cDNAs	O
derived	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
from	O
clone	O
13	O
do	O
not	O
restore	O
expression	O
of	O
HLA	O
-	O
DQ	O
in	O
another	O
CIITA	O
-	O
deficient	O
cell	O
line	O
,	O
RJ2.2.5	O
.	O
In	O
addition	O
,	O
no	O
CIITA	B
protein	O
is	O
detectable	O
in	O
clone	O
13	O
nuclear	O
extracts	O
.	O
In	O
contrast	O
,	O
somatic	O
cell	O
fusion	O
between	O
clone	O
13	O
and	O
RJ2.2.5	O
restored	O
expression	O
of	O
the	O
HLA	O
-	O
DQ	O
haplotype	O
encoded	O
by	O
the	O
RJ2.2.5	O
DQB	O
gene	O
.	O
Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
the	O
existence	O
of	O
an	O
HLA	B
-	I
DQ	I
isotype	I
-	I
specific	I
trans	I
-	I
acting	I
factor	I
,	O
which	O
functions	O
independently	O
of	O
CIITA	B
.	O
Uncoupling	O
of	O
cell	O
cycle	O
arrest	O
from	O
the	O
expression	O
of	O
monocytic	O
differentiation	O
markers	O
in	O
HL60	O
cell	O
variants	O
.	O
Differentiation	O
generally	O
leads	O
to	O
cell	O
cycle	O
arrest	O
.	O
Human	O
leukemia	O
HL60	O
cells	O
respond	O
to	O
the	O
presence	O
of	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25D3	O
)	O
by	O
expressing	O
a	O
number	O
of	O
markers	O
of	O
the	O
monocyte	O
/	O
macrophage	O
phenotype	O
and	O
become	O
arrested	O
predominantly	O
in	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O
We	O
have	O
recently	O
reported	O
a	O
series	O
(	O
A	O
)	O
of	O
1	O
,	O
25D3-resistant	O
variants	O
of	O
HL60	O
cells	O
which	O
proliferate	O
in	O
the	O
presence	O
of	O
1	O
,	O
25D3	O
and	O
do	O
not	O
express	O
differentiation	O
markers	O
(	O
Exp	O
.	O
Cell	O
Res	O
.	O
224	O
,	O
312	O
,	O
1996	O
)	O
.	O
We	O
now	O
describe	O
another	O
series	O
(	O
B	O
)	O
of	O
such	O
variants	O
,	O
which	O
differ	O
from	O
A	O
series	O
cells	O
grown	O
in	O
similar	O
concentrations	O
of	O
1	O
,	O
25D3	O
in	O
that	O
they	O
express	O
the	O
CD14	B
antigen	I
and	O
nonspecific	O
esterase	B
,	O
characteristic	O
of	O
the	O
monocyte	O
,	O
while	O
continuing	O
to	O
proliferate	O
and	O
they	O
develop	O
hypotetraploid	O
DNA	O
(	O
4C	O
)	O
content	O
at	O
higher	O
concentrations	O
of	O
ambient	O
1	O
,	O
25D3	O
than	O
the	O
A	O
series	O
cells	O
.	O
Cells	O
in	O
the	O
B	O
series	O
with	O
4C	O
DNA	O
content	O
(	O
100B	O
and	O
200B	O
)	O
also	O
differed	O
from	O
the	O
A	O
series	O
4C	O
cells	O
by	O
the	O
absence	O
of	O
DNA	O
binding	O
by	O
the	O
full	O
-	O
length	O
Sp1	B
transcription	B
factor	I
.	O
However	O
,	O
B	O
series	O
cells	O
resembled	O
the	O
A	O
series	O
cells	O
in	O
exhibiting	O
faster	O
growth	O
rates	O
than	O
the	O
parental	O
HL60	O
cells	O
and	O
showed	O
high	O
levels	O
of	O
vitamin	B
D	I
receptor	I
and	O
retinoid	B
receptor	I
X	I
proteins	I
.	O
These	O
results	O
show	O
that	O
the	O
initial	O
steps	O
in	O
the	O
1	O
,	O
25D3	O
signaling	O
pathway	O
are	O
intact	O
in	O
B	O
series	O
resistant	O
cells	O
and	O
lead	O
to	O
the	O
appearance	O
of	O
early	O
markers	O
of	O
monocytic	O
differentiation	O
.	O
However	O
,	O
the	O
progression	O
to	O
subsequent	O
events	O
which	O
comprise	O
terminal	O
differentiation	O
and	O
cell	O
cycle	O
arrest	O
is	O
halted	O
during	O
the	O
adaptation	O
to	O
the	O
presence	O
of	O
1	O
,	O
25D3	O
in	O
these	O
cells	O
.	O
Thus	O
,	O
the	O
availability	O
of	O
these	O
variant	O
cells	O
should	O
provide	O
a	O
system	O
for	O
studying	O
the	O
link	O
between	O
differentiation	O
and	O
cell	O
cycle	O
arrest	O
.	O
Induction	O
of	O
cytokine	B
expression	O
in	O
leukocytes	O
by	O
binding	O
of	O
thrombin	O
-	O
stimulated	O
platelets	O
.	O
BACKGROUND	O
:	O
Activated	O
platelets	O
tether	O
and	O
activate	O
myeloid	O
leukocytes	O
.	O
To	O
investigate	O
the	O
potential	O
relevance	O
of	O
this	O
mechanism	O
in	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
,	O
we	O
examined	O
cytokine	B
induction	O
by	O
leukocyte	O
-	O
platelet	O
adhesion	O
and	O
the	O
occurrence	O
of	O
leukocyte	O
-	O
platelet	O
conjugates	O
in	O
patients	O
with	O
AMI	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
We	O
obtained	O
peripheral	O
venous	O
blood	O
samples	O
in	O
20	O
patients	O
with	O
AMI	O
before	O
and	O
daily	O
for	O
5	O
days	O
after	O
direct	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
(	O
PTCA	O
)	O
and	O
in	O
20	O
patients	O
undergoing	O
elective	O
PTCA	O
.	O
Throughout	O
the	O
study	O
period	O
,	O
CD41	O
immunofluorescence	O
of	O
leukocytes	O
(	O
flow	O
cytometry	O
)	O
revealed	O
increased	O
leukocyte	O
-	O
platelet	O
adhesion	O
in	O
patients	O
with	O
AMI	O
compared	O
with	O
control	O
patients	O
(	O
mean	O
+	O
/-	O
SE	O
of	O
fluorescence	O
[	O
channels	O
]	O
before	O
PTCA	O
:	O
77	O
+	O
/-	O
16	O
versus	O
35	O
+	O
/-	O
9	O
;	O
P	O
=	O
.003	O
)	O
.	O
In	O
vitro	O
,	O
thrombin	O
-	O
stimulated	O
fixed	O
platelets	O
bound	O
to	O
neutrophils	O
and	O
monocytes	O
.	O
Within	O
2	O
hours	O
,	O
this	O
resulted	O
in	O
increased	O
mRNA	O
for	O
interleukin	B
(	I
IL	I
)	I
,	I
1	I
beta	I
,	O
IL-8	B
,	O
and	O
monocyte	B
chemoattractant	I
protein	I
(	I
MCP	I
)	I
-1	I
in	O
unfractionated	O
leukocytes	O
.	O
After	O
4	O
hours	O
,	O
IL-1	B
beta	I
and	O
IL-8	B
concentration	O
of	O
the	O
cell	O
-	O
free	O
supernatant	O
had	O
increased	O
by	O
268	O
+	O
/-	O
36	O
%	O
and	O
210	O
+	O
/-	O
7	O
%	O
,	O
respectively	O
,	O
and	O
cellular	O
MCP-1	B
content	O
had	O
increased	O
by	O
170	O
+	O
/-	O
8	O
%	O
.	O
Addition	O
of	O
activated	O
platelets	O
to	O
adherent	O
monocytes	O
had	O
a	O
similar	O
effect	O
and	O
was	O
associated	O
with	O
nuclear	B
factor	I
-	I
kappa	I
B	I
activation	O
.	O
Inhibition	O
of	O
binding	O
by	O
anti	B
-	I
P	I
selectin	I
antibodies	I
reduced	O
the	O
effect	O
of	O
activated	O
platelets	O
on	O
cytokine	B
production	O
.	O
CONCLUSIONS	O
:	O
In	O
patients	O
with	O
AMI	O
,	O
leukocyte	O
-	O
platelet	O
adhesion	O
is	O
increased	O
.	O
Binding	O
of	O
activated	O
platelets	O
induces	O
IL-1	B
beta	I
,	O
IL-8	B
,	O
and	O
MCP-1	B
in	O
leukocytes	O
.	O
Our	O
findings	O
suggest	O
that	O
leukocyte	O
-	O
platelet	O
adhesion	O
contributes	O
to	O
the	O
regulation	O
of	O
inflammatory	O
responses	O
in	O
AMI	O
.	O
Defective	O
survival	O
and	O
activation	O
of	O
thymocytes	O
in	O
transgenic	O
mice	O
expressing	O
a	O
catalytically	B
inactive	I
form	I
of	O
Ca2+	B
/	I
calmodulin	I
-	I
dependent	I
protein	I
kinase	I
IV	I
.	O
We	O
have	O
generated	O
transgenic	O
mice	O
that	O
express	O
a	O
catalytically	B
inactive	I
form	I
of	O
Ca2+	B
/	I
calmodulin	I
-	I
dependent	I
protein	I
kinase	I
IV	I
(	O
CaMKIV	B
)	O
specifically	O
in	O
thymic	O
T	O
cells	O
.	O
The	O
presence	O
of	O
this	O
protein	O
results	O
in	O
a	O
markedly	O
reduced	O
thymic	O
cellularity	O
,	O
although	O
the	O
distribution	O
of	O
the	O
remaining	O
cells	O
is	O
normal	O
based	O
on	O
evaluation	O
of	O
the	O
CD4	B
and	O
CD8	B
cell	B
surface	I
antigens	I
that	O
are	O
used	O
to	O
gauge	O
T	O
cell	O
development	O
.	O
Isolated	O
thymic	O
T	O
cells	O
from	O
the	O
transgenic	O
mice	O
also	O
show	O
a	O
dramatically	O
decreased	O
survival	O
rate	O
when	O
evaluated	O
in	O
culture	O
under	O
conditions	O
that	O
do	O
not	O
favor	O
activation	O
.	O
When	O
challenged	O
with	O
an	O
activating	O
stimulus	O
such	O
as	O
alpha	B
-	I
CD3	I
or	O
a	O
combination	O
of	O
phorbol	O
ester	O
plus	O
ionophore	O
,	O
the	O
cells	O
are	O
severely	O
compromised	O
in	O
their	O
ability	O
to	O
produce	O
the	O
cytokine	B
interleukin-2	B
(	O
IL-2	B
)	O
.	O
Reduction	O
of	O
IL-2	B
production	O
is	O
secondary	O
to	O
the	O
inability	O
to	O
phosphorylate	O
the	O
cAMP	B
response	I
element	I
binding	I
protein	I
,	O
CREB	B
,	O
and	O
induce	O
expression	O
of	O
the	O
immediate	O
early	O
genes	O
such	O
as	O
Fos	O
B	O
that	O
are	O
required	O
to	O
transactivate	O
the	O
IL-2	O
promoter	O
.	O
Because	O
transgene	O
expression	O
was	O
regulated	O
by	O
the	O
proximal	O
promoter	O
of	O
the	O
murine	O
lck	O
gene	O
and	O
this	O
promoter	O
is	O
inactivated	O
in	O
T	O
cells	O
that	O
exit	O
the	O
thymus	O
,	O
the	O
mutant	B
hCaMKIV	I
is	O
not	O
present	O
in	O
peripheral	O
T	O
cells	O
.	O
Consequently	O
,	O
T	O
lymphocytes	O
present	O
in	O
the	O
spleen	O
can	O
be	O
activated	O
normally	O
in	O
response	O
to	O
either	O
stimulus	O
mentioned	O
above	O
,	O
demonstrating	O
that	O
the	O
effects	O
of	O
the	O
inactive	B
CaMKIV	I
on	O
activation	O
are	O
reversible	O
.	O
Our	O
results	O
suggest	O
that	O
CaMKIV	B
may	O
represent	O
a	O
physiologically	O
relevant	O
CREB	B
kinase	I
in	O
T	O
cells	O
and	O
that	O
the	O
enzyme	O
is	O
also	O
required	O
to	O
ensure	O
normal	O
expansion	O
of	O
T	O
cells	O
in	O
the	O
thymus	O
.	O
Whereas	O
the	O
pathway	O
responsible	O
for	O
this	O
latter	O
role	O
is	O
yet	O
to	O
be	O
elucidated	O
,	O
it	O
is	O
unlikely	O
to	O
include	O
CREB	B
phosphorylation	O
.	O
The	O
class	B
II	I
trans	I
-	I
activator	I
CIITA	I
interacts	O
with	O
the	O
TBP	B
-	I
associated	I
factor	I
TAFII32	I
.	O
The	O
class	B
II	I
trans-	I
activator	I
(	O
CIITA	B
)	O
is	O
the	O
main	O
transcriptional	O
co	O
-	O
activator	O
for	O
the	O
expression	O
of	O
MHC	B
class	I
II	I
proteins	I
.	O
Its	O
N	B
-	I
terminal	I
125	I
amino	I
acids	I
function	O
as	O
an	O
independent	B
transcriptional	I
activation	I
domain	I
.	O
Analyses	O
of	O
the	O
primary	B
amino	I
acid	I
sequence	I
of	O
the	O
activation	B
domain	I
predict	O
the	O
presence	O
of	O
three	O
alpha	B
-	I
helices	I
,	O
each	O
with	O
a	O
high	O
proportion	O
of	O
acidic	O
residues	O
.	O
Using	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
found	O
that	O
two	O
of	O
these	O
predicted	O
alpha	B
-	I
helices	I
are	O
required	O
for	O
full	O
transcriptional	O
activation	O
by	O
CIITA	B
.	O
Moreover	O
,	O
a	O
CIITA	B
protein	I
in	O
which	O
both	O
functional	O
alpha	B
-	I
helices	I
have	O
been	O
deleted	O
displays	O
a	O
dominant	O
negative	O
phenotype	O
.	O
This	O
activation	B
domain	I
of	O
CIITA	B
interacts	O
with	O
the	O
32	B
kDa	I
subunit	I
of	O
the	O
general	B
transcription	I
complex	I
TFIID	B
,	O
TAFII32	B
.	O
Decreased	O
transcriptional	O
activation	O
by	O
N	B
-	I
terminal	I
deletions	I
of	O
CIITA	B
is	O
correlated	O
directly	O
with	O
their	O
reduced	O
binding	O
to	O
TAFII32	B
.	O
We	O
conclude	O
that	O
interactions	O
between	O
TAFII32	B
and	O
CIITA	B
are	O
responsible	O
for	O
activation	O
of	O
class	O
II	O
genes	O
.	O
Constitutive	O
and	O
inducible	O
protein	O
/	O
DNA	O
interactions	O
of	O
the	O
interferon	O
-	O
gamma	O
promoter	O
in	O
vivo	O
in	O
[	O
corrected	O
]	O
CD45RA	O
and	O
CD45R0	O
T	O
helper	O
subsets	O
[	O
published	O
erratum	O
appears	O
in	O
Eur	O
J	O
Immunol	O
1997	O
Jul	O
;	O
27	O
(	O
7	O
)	O
:	O
1830	O
]	O
Interferon	O
-	O
gamma	O
(	O
IFN	B
-	I
gamma	I
)	O
is	O
a	O
key	O
cytokine	O
of	O
T	O
lymphocytes	O
with	O
major	O
regulatory	O
functions	O
in	O
the	O
immune	O
system	O
.	O
To	O
determine	O
and	O
compare	O
protein	O
/	O
DNA	O
interactions	O
at	O
the	O
native	O
IFN	B
-	I
gamma	I
locus	O
in	O
T	O
cells	O
,	O
we	O
analyzed	O
the	O
human	O
IFN	O
-	O
gamma	O
promoter	O
by	O
ligation	O
-	O
mediated	O
polymerase	O
chain	O
reaction	O
(	O
LM	O
-	O
PCR	O
)	O
techniques	O
.	O
Accordingly	O
,	O
Jurkat	O
T	O
cells	O
and	O
primary	O
CD45RA	O
and	O
CD45R0	O
CD4	O
+	O
T	O
cell	O
subsets	O
isolated	O
from	O
peripheral	O
blood	O
using	O
immunomagnetic	O
beads	O
were	O
cultured	O
and	O
analyzed	O
by	O
LM	O
-	O
PCR	O
.	O
Constitutive	O
and	O
inducible	O
protein	O
/	O
DNA	O
interactions	O
of	O
the	O
IFN	O
-	O
gamma	O
promoter	O
in	O
vivo	O
were	O
detected	O
in	O
all	O
T	O
cells	O
tested	O
.	O
Interestingly	O
,	O
an	O
inducible	O
footprint	O
between	O
-183	O
and	O
-196	O
was	O
consistently	O
observed	O
in	O
Jurkat	O
T	O
cells	O
and	O
CD45RA	O
and	O
CD45R0	O
T	O
helper	O
subsets	O
upon	O
stimulation	O
with	O
phorbol	O
12-myristate	O
13-acetate+	O
phytohemagglutinin	B
(	O
PMA+	O
PHA	B
)	O
that	O
was	O
highly	O
sensitive	O
to	O
treatment	O
with	O
corticosteroids	O
.	O
This	O
novel	O
target	O
site	O
,	O
denoted	O
the	O
C	O
-	O
site	O
,	O
was	O
shown	O
by	O
several	O
criteria	O
,	O
including	O
cell	O
distribution	O
studies	O
,	O
stimulation	O
experiments	O
,	O
supershift	O
assays	O
,	O
and	O
cross	O
-	O
competition	O
electrophoretic	O
mobility	O
shift	O
assays	O
to	O
bind	O
the	O
transcription	B
factor	I
AP-1	I
.	O
Mutation	O
of	O
the	O
C	O
-	O
site	O
that	O
prevented	O
AP-1	B
binding	O
to	O
this	O
site	O
was	O
sufficient	O
strikingly	O
to	O
reduce	O
inducible	O
promoter	O
activity	O
in	O
primary	O
CD45R0	O
T	O
cells	O
.	O
In	O
summary	O
,	O
the	O
data	O
demonstrate	O
that	O
IFN	B
-	I
gamma	I
gene	O
transcription	O
in	O
primary	O
T	O
cells	O
is	O
regulated	O
in	O
vivo	O
at	O
the	O
level	O
of	O
constitutive	O
and	O
inducible	O
protein	O
/	O
DNA	O
interactions	O
.	O
We	O
propose	O
a	O
model	O
where	O
basal	O
transcription	O
is	O
maintained	O
by	O
binding	O
of	O
various	O
transcription	B
factors	I
to	O
the	O
IFN	O
-	O
gamma	O
promoter	O
,	O
whereas	O
PMA+	O
PHA	B
-inducible	O
IFN	B
-	I
gamma	I
transcription	O
in	O
CD45R0	O
T	O
cells	O
is	O
associated	O
with	O
binding	O
of	O
AP-1	B
to	O
the	O
C	O
-	O
site	O
.	O
Reactive	O
oxygen	O
species	O
and	O
antioxidants	O
in	O
inflammatory	O
diseases	O
.	O
This	O
paper	O
aims	O
to	O
review	O
the	O
role	O
of	O
free	O
radical	O
-	O
induced	O
tissue	O
damage	O
and	O
antioxidant	O
defence	O
mechanisms	O
in	O
inflammatory	O
diseases	O
that	O
involve	O
pathogenic	O
processes	O
similar	O
to	O
the	O
periodontal	O
diseases	O
.	O
There	O
is	O
a	O
clearly	O
defined	O
and	O
substantial	O
role	O
for	O
free	O
radicals	O
or	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
periodontitis	O
,	O
but	O
little	O
research	O
has	O
been	O
performed	O
in	O
this	O
area	O
.	O
This	O
paper	O
reviews	O
the	O
considerable	O
data	O
available	O
relating	O
ROS	O
activity	O
and	O
antioxidant	O
defence	O
to	O
inflammatory	O
diseases	O
and	O
attempts	O
to	O
draw	O
parallels	O
with	O
periodontitis	O
,	O
in	O
an	O
effort	O
to	O
stimulate	O
more	O
periodontal	O
research	O
in	O
this	O
important	O
area	O
.	O
The	O
recent	O
discovery	O
of	O
the	O
transcription	B
factor	I
nuclear	I
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
is	O
reviewed	O
and	O
several	O
potential	O
pathways	O
for	O
cytokine	B
-induced	O
periodontal	O
tissue	O
damage	O
,	O
mediated	O
by	O
NF	B
-	I
kappa	I
B1	I
are	O
discussed	O
.	O
Emphasis	O
is	O
placed	O
on	O
cytokines	B
that	O
have	O
been	O
studied	O
in	O
periodontitis	O
,	O
principally	O
TNF	B
-	I
alpha	I
,	O
IL-1	B
,	O
IL-6	B
,	O
IL-8	B
and	O
beta	B
-	I
interferon	I
.	O
The	O
link	O
between	O
cellular	O
production	O
of	O
such	O
important	O
mediators	O
of	O
inflammation	O
and	O
the	O
antioxidant	O
(	O
AO	O
)	O
thiols	O
,	O
cysteine	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
,	O
is	O
discussed	O
and	O
it	O
is	O
hypothesised	O
that	O
NF	B
-	I
kappa	I
B	I
antagonists	O
may	O
offer	O
important	O
therapeutic	O
benefits	O
.	O
Transactivation	O
by	O
CIITA	B
,	O
the	O
type	B
II	I
bare	I
lymphocyte	I
syndrome	I
-	I
associated	I
factor	I
,	O
requires	O
participation	O
of	O
multiple	O
regions	O
of	O
the	O
TATA	B
box	I
binding	I
protein	I
.	O
CIITA	B
is	O
a	O
positive	O
regulator	O
of	O
class	O
II	O
major	O
histocompatibility	O
complex	O
gene	O
transcription	O
that	O
has	O
been	O
found	O
to	O
be	O
defective	O
in	O
one	O
of	O
the	O
five	O
complementation	O
groups	O
of	O
class	O
II	O
major	O
histocompatibility	O
complex	O
-	O
negative	O
cell	O
lines	O
.	O
Its	O
N	B
-	I
terminal	I
region	I
is	O
capable	O
of	O
activating	O
transcription	O
from	O
a	O
reporter	O
gene	O
when	O
fused	O
to	O
a	O
DNA	B
binding	I
domain	I
.	O
We	O
have	O
investigated	O
the	O
mechanism	O
of	O
transactivation	O
mediated	O
by	O
the	O
CIITA	B
activation	I
domain	I
by	O
studying	O
its	O
role	O
in	O
the	O
process	O
of	O
transcription	O
initiation	O
and	O
elongation	O
.	O
Specifically	O
the	O
altered	O
specificity	O
TBP	O
(	O
TATA	B
box	I
binding	I
protein	I
)	O
assay	O
has	O
been	O
used	O
to	O
analyze	O
the	O
response	O
of	O
the	O
CIITA	B
activation	I
domain	I
to	O
mutations	O
in	O
TBP	B
known	O
to	O
disrupt	O
its	O
interaction	O
with	O
its	O
associated	B
general	I
factors	I
.	O
Transactivation	O
by	O
CIITA	B
was	O
extremely	O
sensitive	O
to	O
a	O
mutation	O
in	O
TBP	B
that	O
in	O
yeast	O
is	O
known	O
to	O
abolish	O
VP16	B
-mediated	O
transcription	O
but	O
leaves	O
basal	O
transcription	O
unaffected	O
.	O
A	O
TBP	O
mutant	O
defective	O
in	O
interaction	O
with	O
TBP	B
-	I
associated	I
factor	I
TAFII250	B
also	O
failed	O
to	O
mediate	O
transactivation	O
through	O
the	O
CIITA	B
activation	I
domain	I
.	O
Certain	O
interactions	O
between	O
TBP	B
and	O
general	B
factors	I
that	O
are	O
specifically	O
required	O
for	O
acidic	B
activation	I
domains	I
were	O
also	O
required	O
for	O
CIITA	B
-mediated	O
transactivation	O
to	O
reach	O
its	O
full	O
potential	O
.	O
Finally	O
,	O
like	O
VP16	O
,	O
CIITA	B
was	O
able	O
to	O
stimulate	O
elongation	O
of	O
transcription	O
.	O
Overall	O
the	O
mechanism	O
of	O
transactivation	O
by	O
the	O
human	B
B	I
-	I
cell	I
-	I
specific	I
CIITA	I
is	O
very	O
similar	O
to	O
that	O
mediated	O
by	O
the	O
herpes	B
virus	I
transactivator	I
VP16	B
in	O
the	O
ways	O
that	O
have	O
been	O
tested	O
.	O
Specific	O
complex	O
formation	O
between	O
the	O
type	B
II	I
bare	I
lymphocyte	I
syndrome	I
-	I
associated	I
transactivators	I
CIITA	B
and	O
RFX5	B
.	O
Two	O
of	O
the	O
genes	O
defective	O
in	O
the	O
five	O
complementation	O
groups	O
identified	O
in	O
the	O
class	O
II	O
-	O
negative	O
bare	O
lymphocyte	O
syndrome	O
or	O
corresponding	O
laboratory	O
mutants	O
have	O
been	O
cloned	O
.	O
One	O
gene	O
encodes	O
a	O
protein	O
,	O
RFX5	B
,	O
that	O
is	O
a	O
member	O
of	O
the	O
RFX	B
family	I
of	I
DNA	I
binding	I
proteins	I
.	O
The	O
other	O
,	O
CIITA	B
,	O
encodes	O
a	O
large	O
protein	O
with	O
a	O
defined	O
acidic	B
transcriptional	I
activation	I
domain	I
;	O
this	O
protein	O
does	O
not	O
interact	O
with	O
DNA	O
.	O
Expression	O
plasmids	O
encoding	O
regions	O
of	O
RFX5	B
fused	O
to	O
the	O
GAL4	B
DNA	I
binding	I
domain	I
activated	O
transcription	O
from	O
a	O
reporter	O
construct	O
containing	O
GAL4	O
sites	O
in	O
a	O
cotransfection	O
assay	O
in	O
the	O
Raji	O
human	O
B	O
cell	O
line	O
.	O
However	O
,	O
these	O
plasmids	O
produced	O
transcriptional	O
activity	O
in	O
HeLa	O
cells	O
only	O
in	O
conjunction	O
with	O
interferon	B
gamma	I
stimulation	O
,	O
a	O
condition	O
in	O
which	O
expression	O
of	O
both	O
CIITA	B
and	O
class	B
II	I
major	I
histocompatibility	I
complex	I
surface	I
proteins	I
are	O
induced	O
.	O
Furthermore	O
,	O
these	O
plasmids	O
were	O
not	O
active	O
in	O
RJ2.2.5	O
,	O
an	O
in	O
vitro	O
mutagenized	O
derivative	O
of	O
Raji	O
in	O
which	O
both	O
copies	O
of	O
CIITA	B
are	O
defective	O
.	O
Transcriptional	O
activation	O
by	O
the	O
RFX5	B
fusion	I
protein	I
could	O
be	O
restored	O
in	O
RJ2.2.5	O
by	O
cotransfection	O
with	O
a	O
CIITA	O
expression	O
plasmid	O
.	O
Finally	O
,	O
a	O
direct	O
interaction	O
between	O
RFX5	B
and	O
CIITA	B
was	O
detected	O
with	O
the	O
yeast	O
two	O
-	O
hybrid	O
and	O
far	O
-	O
Western	O
blot	O
assays	O
.	O
Thus	O
,	O
RFX5	B
can	O
activate	O
transcription	O
only	O
in	O
cooperation	O
with	O
CIITA	B
.	O
RFX5	B
and	O
CIITA	B
associate	O
to	O
form	O
a	O
complex	O
capable	O
of	O
activating	O
transcription	O
from	O
class	O
II	O
major	O
histocompatibility	O
complex	O
promoters	O
.	O
In	O
this	O
complex	O
,	O
promoter	O
specificity	O
is	O
determined	O
by	O
the	O
DNA	O
binding	O
domain	O
of	O
RFX5	B
and	O
the	O
general	O
transcription	O
apparatus	O
is	O
recruited	O
by	O
the	O
acidic	B
activation	I
domain	I
of	O
CIITA	B
.	O
Transcriptional	O
activity	O
and	O
constitutive	O
nuclear	O
localization	O
of	O
the	O
ETS	B
protein	I
Elf-1	B
.	O
Elf-1	B
is	O
a	O
lymphoid	B
-	I
specific	I
transcription	I
factor	I
that	O
belongs	O
to	O
the	O
ETS	B
protein	I
family	I
.	O
It	O
can	O
bind	O
to	O
DNA	O
target	O
sequences	O
within	O
a	O
variety	O
of	O
cytokine	O
genes	O
.	O
We	O
demonstrate	O
that	O
Elf-1	B
is	O
constitutively	O
localized	O
in	O
the	O
nucleus	O
which	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
amino	B
acids	I
86	I
-	I
265	I
.	O
Analysis	O
of	O
Gal4-Elf-1	B
fusion	I
proteins	I
revealed	O
that	O
the	O
N	O
-	O
terminal	O
86	O
amino	O
acids	O
of	O
Elf-1	B
contain	O
a	O
transcriptional	B
activation	I
domain	I
,	O
the	O
activity	O
of	O
which	O
is	O
attenuated	O
by	O
an	O
internal	B
repression	I
domain	I
.	O
Furthermore	O
,	O
Elf-1	B
interacts	O
specifically	O
with	O
the	O
E74	O
target	O
sequence	O
and	O
can	O
stimulate	O
transcription	O
driven	O
by	O
the	O
E74	O
site	O
independent	O
of	O
mitogenic	O
signaling	O
.	O
Thus	O
,	O
Elf-1	B
is	O
able	O
to	O
stimulate	O
gene	O
transcription	O
which	O
may	O
be	O
required	O
for	O
the	O
development	O
and	O
activity	O
of	O
lymphocytes	O
.	O
Histamine	O
modulates	O
the	O
expression	O
of	O
c	O
-	O
fos	O
through	O
cyclic	O
AMP	O
production	O
via	O
the	O
H2	B
receptor	I
in	O
the	O
human	O
promonocytic	O
cell	O
line	O
U937	O
.	O
We	O
examined	O
the	O
effects	O
of	O
histamine	O
and	O
its	O
agonists	O
on	O
the	O
expression	O
of	O
the	O
c	O
-	O
fos	O
and	O
c	O
-	O
myc	O
proto	O
-	O
oncogenes	O
at	O
the	O
transcriptional	O
and	O
translational	O
levels	O
in	O
the	O
human	O
promonocytic	O
U937	O
cell	O
line	O
.	O
Histamine	O
transiently	O
increased	O
cAMP	O
and	O
c	O
-	O
fos	O
expression	O
through	O
H2	B
receptors	I
.	O
Dibutyryl	O
cAMP	O
also	O
increased	O
c	O
-	O
fos	O
mRNA	O
and	O
protein	B
,	O
and	O
levels	O
remained	O
elevated	O
even	O
after	O
12	O
hr	O
of	O
treatment	O
.	O
Dose	O
-	O
dependence	O
studies	O
using	O
histamine	O
and	O
dimaprit	O
showed	O
that	O
the	O
EC50	O
values	O
for	O
cAMP	O
production	O
and	O
c	O
-	O
fos	O
increase	O
were	O
similar	O
,	O
suggesting	O
that	O
cAMP	O
might	O
be	O
involved	O
in	O
c	O
-	O
fos	O
induction	O
via	O
H2	B
receptors	I
.	O
Furthermore	O
,	O
studies	O
carried	O
out	O
using	O
H7	B
,	O
a	O
protein	B
kinase	I
A	I
/	I
protein	I
kinase	I
C	I
inhibitor	I
,	O
blocked	O
c	O
-	O
fos	O
induction	O
,	O
whereas	O
no	O
effect	O
was	O
observed	O
with	O
bisindolylmaleimide	O
,	O
a	O
specific	O
protein	B
kinase	I
C	I
inhibitor	O
.	O
No	O
modification	O
of	O
c	O
-	O
myc	O
expression	O
could	O
be	O
detected	O
on	O
treatment	O
with	O
histamine	O
or	O
its	O
analogues	O
.	O
Nevertheless	O
,	O
dibutyryl	O
cAMP	O
induced	O
a	O
down	O
-	O
regulation	O
of	O
the	O
levels	O
of	O
this	O
proto	O
-	O
oncogene	O
.	O
In	O
addition	O
,	O
dibutyryl	O
cAMP	O
inhibited	O
cell	O
growth	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
whereas	O
histamine	O
failed	O
to	O
affect	O
proliferation	O
and	O
differentiation	O
of	O
U937	O
cells	O
.	O
Cells	O
pretreated	O
with	O
dimaprit	O
showed	O
a	O
decrease	O
in	O
the	O
cAMP	O
response	O
to	O
subsequent	O
addition	O
of	O
H2	O
agonists	O
,	O
whereas	O
the	O
cAMP	O
response	O
to	O
prostaglandin	O
E2	O
remained	O
unaltered	O
.	O
This	O
homologous	O
mechanism	O
of	O
H2	B
receptor	I
desensitization	O
was	O
time	O
dependent	O
.	O
These	O
results	O
indicate	O
that	O
histamine	O
activates	O
several	O
mechanisms	O
involved	O
in	O
the	O
induction	O
of	O
differentiation	O
,	O
such	O
as	O
cAMP	O
and	O
c	O
-	O
fos	O
production	O
,	O
but	O
fails	O
to	O
promote	O
differentiation	O
of	O
U937	O
cells	O
,	O
apparently	O
due	O
to	O
the	O
rapid	O
desensitization	O
of	O
H2	B
receptors	I
.	O
Human	O
cytomegalovirus	O
induces	O
interleukin-8	B
production	O
by	O
a	O
human	O
monocytic	O
cell	O
line	O
,	O
THP-1	O
,	O
through	O
acting	O
concurrently	O
on	O
AP-1-	O
and	O
NF	O
-	O
kappaB	O
-	O
binding	O
sites	O
of	O
the	O
interleukin-8	O
gene	O
.	O
Cytomegalovirus	O
(	O
CMV	O
)	O
infection	O
induced	O
interleukin-8	B
(	O
IL-8	B
)	O
gene	O
transcription	O
in	O
a	O
human	O
monocytic	O
cell	O
line	O
,	O
THP-1	O
cells	O
,	O
leading	O
to	O
IL-8	B
secretion	O
.	O
The	O
functional	O
analysis	O
of	O
the	O
IL-8	O
gene	O
revealed	O
that	O
both	O
AP-1-	O
and	O
NF	O
-	O
kappaB	O
factor	O
-	O
binding	O
elements	O
were	O
involved	O
in	O
conferring	O
the	O
responsiveness	O
to	O
CMV	O
.	O
Moreover	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
CMV	O
induced	O
the	O
formation	O
of	O
NF	B
-	I
kappaB	I
and	O
AP-1	B
complexes	I
.	O
These	O
results	O
suggest	O
that	O
CMV	O
activates	O
these	O
transcriptional	B
factors	I
,	O
resulting	O
in	O
IL-8	B
gene	O
expression	O
.	O
Molecular	O
cloning	O
and	O
characterization	O
of	O
a	O
cDNA	O
,	O
CHEMR1	O
,	O
encoding	O
a	O
chemokine	B
receptor	I
with	O
a	O
homology	O
to	O
the	O
human	B
C	I
-	I
C	I
chemokine	I
receptor	I
,	O
CCR-4	B
.	O
Chemokines	B
refer	O
to	O
a	O
rapidly	O
expanding	O
family	O
of	O
small	O
cytokines	B
whose	O
primary	O
function	O
is	O
recruitment	O
of	O
leukocytes	O
to	O
inflammatory	O
sites	O
.	O
These	O
are	O
known	O
to	O
bind	O
to	O
seven	B
-	I
transmembrane	I
-	I
domain	I
containing	I
receptors	I
.	O
A	O
cDNA	O
clone	O
,	O
CHEMR1	O
,	O
resembling	O
the	O
typical	O
G	B
protein	I
-	I
coupled	I
receptor	I
,	O
was	O
isolated	O
from	O
a	O
mouse	O
cytotoxic	O
T	O
-	O
lymphocyte	O
(	O
CTL	O
)	O
library	O
.	O
Northern	O
blot	O
analysis	O
in	O
mouse	O
cell	O
lines	O
suggests	O
that	O
its	O
expression	O
is	O
found	O
in	O
a	O
variety	O
of	O
cells	O
,	O
including	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
macrophages	O
.	O
The	O
CHEMR1	O
gene	O
Scya3r2	O
is	O
a	O
single	O
-	O
copy	O
gene	O
whose	O
open	O
reading	O
frame	O
may	O
be	O
in	O
a	O
single	O
exon	O
and	O
maps	O
to	O
the	O
distal	O
region	O
of	O
mouse	O
Chr	O
9	O
where	O
the	O
mouse	O
macrophage	O
inflammatory	O
protein-1alpha	O
(	O
MIP-1alpha	O
)	O
receptor	O
gene	O
Scya3r	O
and	O
two	O
related	O
C	O
-	O
C	O
chemokine	O
receptor	O
-	O
like	O
genes	O
reside	O
.	O
Amino	O
acid	O
sequence	O
comparison	O
shows	O
that	O
CHEMR1	O
is	O
84	O
%	O
identical	O
to	O
human	B
CCR-4	I
,	O
indicating	O
that	O
CHEMR1	O
is	O
likely	O
to	O
be	O
a	O
mouse	B
CCR-4	I
.	O
Binding	O
assays	O
using	O
125I	B
-	I
labeled	I
C	I
-	I
C	I
chemokines	I
in	O
mammalian	O
cells	O
indicated	O
that	O
CHEMR1	O
did	O
not	O
bind	O
MIP-1alpha	O
,	O
RANTES	O
,	O
or	O
MIP-1beta	O
,	O
whereas	O
CCR-1	B
binds	O
MIP-1alpha	B
and	O
RANTES	B
.	O
Our	O
result	O
is	O
different	O
from	O
the	O
reported	O
properties	O
of	O
human	B
CCR-4	I
.	O
This	O
suggests	O
that	O
CHEMR1	O
may	O
be	O
a	O
receptor	O
for	O
unidentified	O
C	B
-	I
C	I
chemokine	I
or	O
a	O
low	O
-	O
affinity	O
receptor	O
for	O
MIP-1alpha	B
.	O
Biphasic	O
control	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
induced	O
by	O
the	O
triggering	O
of	O
HLA	B
-	I
DR	I
antigens	I
expressed	O
on	O
B	O
cells	O
.	O
The	O
regulation	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
following	O
the	O
triggering	O
of	O
HLA	B
-	I
DR	I
antigens	I
by	O
mAb	B
L243	I
has	O
been	O
studied	O
at	O
various	O
times	O
in	O
Raji	O
cells	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
a	O
strong	O
increase	O
of	O
NF	B
-	I
kappa	I
B	I
DNA	O
binding	O
after	O
triggering	O
of	O
HLA	B
-	I
DR	I
antigens	I
.	O
Using	O
TNF	B
-	I
alpha	I
-	I
activity	I
neutralizing	I
antibodies	I
,	O
the	O
authors	O
demonstrated	O
that	O
the	O
upregulation	O
of	O
NF	B
-	I
kappa	I
B	I
was	O
found	O
to	O
depend	O
,	O
at	O
later	O
time	O
point	O
,	O
on	O
an	O
autocrine	O
effect	O
of	O
TNF	B
-	I
alpha	I
secreted	O
following	O
triggering	O
of	O
HLA	B
-	I
DR	I
antigens	I
.	O
In	O
contrast	O
,	O
it	O
was	O
found	O
to	O
be	O
TNF	B
-	I
alpha	I
independent	O
in	O
the	O
early	O
time	O
point	O
.	O
Moreover	O
,	O
the	O
upregulation	O
of	O
NF	B
-	I
kappa	I
B	I
binding	O
activity	O
is	O
regulated	O
by	O
the	O
triggering	O
of	O
selected	O
epitopes	B
of	O
HLA	B
-	I
DR	I
antigens	I
.	O
In	O
fact	O
,	O
mAb	B
L243	I
but	O
not	O
the	O
staphylococcal	B
superantigens	I
,	O
staphylococcal	B
exotoxin	I
toxic	I
shock	I
syndrome	I
toxin	I
-	I
I	I
or	O
staphylococcal	B
enterotoxin	I
B	I
,	O
regulate	O
the	O
NF	B
-	I
kappa	I
B	I
binding	O
activity	O
.	O
The	O
immediate	O
-	O
early	O
gene	O
product	O
Egr-1	B
regulates	O
the	O
human	O
interleukin-2	O
receptor	O
beta	O
-	O
chain	O
promoter	O
through	O
noncanonical	O
Egr	O
and	O
Sp1	O
binding	O
sites	O
.	O
The	O
interleukin-2	B
IL-2	I
receptor	I
beta	I
-	I
chain	I
(	O
IL-2Rbeta	B
)	O
is	O
an	O
essential	O
component	O
of	O
the	O
receptors	O
for	O
IL-2	B
and	O
IL-15	B
.	O
Although	O
IL-2Rbeta	B
is	O
constitutively	O
expressed	O
by	O
lymphocytes	O
,	O
its	O
expression	O
can	O
be	O
further	O
induced	O
by	O
a	O
number	O
of	O
stimuli	O
,	O
including	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O
We	O
have	O
now	O
characterized	O
factors	O
that	O
bind	O
to	O
an	O
enhancer	O
region	O
located	O
between	O
nucleotides	O
-170	O
and	O
-139	O
of	O
the	O
human	O
IL-2Rbeta	O
promoter	O
.	O
Both	O
Sp1	B
and	O
Sp3	B
bound	O
to	O
the	O
5	O
'	O
portion	O
of	O
this	O
region	O
,	O
whereas	O
a	O
PMA	B
-	I
inducible	I
factor	I
(	O
PIF	B
)	O
mainly	O
bound	O
to	O
its	O
3	O
'	O
portion	O
and	O
bound	O
to	O
the	O
Sp	O
binding	O
motifs	O
as	O
well	O
.	O
In	O
Jurkat	O
T	O
cells	O
,	O
induction	O
of	O
PIF	B
DNA	O
binding	O
activity	O
was	O
rapidly	O
induced	O
,	O
required	O
de	O
novo	O
protein	O
synthesis	O
,	O
and	O
was	O
sustained	O
at	O
a	O
high	O
level	O
for	O
at	O
least	O
23	O
h	O
.	O
Interestingly	O
,	O
PIF	B
was	O
constitutively	O
activated	O
in	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1-transformed	O
MT-2	O
cells	O
.	O
In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
PIF	B
is	O
Egr-1	B
based	O
on	O
its	O
recognition	O
by	O
anti-	O
Egr-1	B
antisera	O
in	O
gel	O
mobility	O
shift	O
assays	O
,	O
even	O
though	O
the	O
IL-2Rbeta	O
DNA	O
binding	O
motif	O
differed	O
substantially	O
from	O
the	O
canonical	O
Egr-1	O
binding	O
site	O
.	O
In	O
addition	O
,	O
Egr-1	B
bound	O
to	O
the	O
Sp	O
binding	O
site	O
.	O
In	O
Jurkat	O
cells	O
,	O
both	O
sites	O
were	O
required	O
for	O
maximal	O
IL-2Rbeta	B
promoter	O
activity	O
,	O
and	O
in	O
HeLaS3	O
cells	O
,	O
transfection	O
of	O
Egr-1	B
could	O
drive	O
activity	O
of	O
a	O
reporter	O
construct	O
containing	O
both	O
sites	O
.	O
Moreover	O
,	O
Sp1	B
and	O
Egr-1	B
could	O
form	O
a	O
complex	O
with	O
kinetics	O
that	O
correlated	O
with	O
the	O
production	O
of	O
Egr-1	B
in	O
Jurkat	O
cells	O
upon	O
PMA	O
stimulation	O
.	O
Thus	O
,	O
Sp1	B
and	O
Egr-1	B
physically	O
and	O
functionally	O
cooperate	O
to	O
mediate	O
maximal	O
IL-2Rbeta	O
promoter	O
activity	O
.	O
Anti	B
-	I
Ehrlichia	I
chaffeensis	I
antibody	I
complexed	O
with	O
E.	O
chaffeensis	O
induces	O
potent	O
proinflammatory	O
cytokine	O
mRNA	O
expression	O
in	O
human	O
monocytes	O
through	O
sustained	O
reduction	O
of	O
IkappaB	B
-	I
alpha	I
and	O
activation	O
of	O
NF	B
-	I
kappaB	I
.	O
Ehrlichia	O
chaffeensis	O
is	O
an	O
obligatory	O
intracellular	O
bacterium	O
that	O
infects	O
monocytes	O
and	O
macrophages	O
and	O
is	O
the	O
etiologic	O
agent	O
of	O
human	O
ehrlichiosis	O
in	O
the	O
United	O
States	O
.	O
Our	O
previous	O
studies	O
showed	O
that	O
the	O
exposure	O
of	O
human	O
monocytes	O
to	O
E.	O
chaffeensis	O
induces	O
the	O
expression	O
of	O
interleukin-1beta	B
(	O
IL-1beta	B
)	O
,	O
IL-8	B
,	O
and	O
IL-10	O
genes	O
in	O
vitro	O
but	O
not	O
the	O
expression	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
IL-6	O
mRNAs	O
.	O
In	O
this	O
study	O
,	O
the	O
effect	O
of	O
anti	B
-	I
E.	I
chaffeensis	I
antibody	I
complexed	O
with	O
E.	O
chaffeensis	O
on	O
the	O
expression	O
of	O
major	B
proinflammatory	I
cytokines	I
in	O
human	O
monocytes	O
was	O
examined	O
.	O
Human	O
monocytic	O
cell	O
line	O
THP-1	O
was	O
treated	O
with	O
E.	O
chaffeensis	O
which	O
had	O
been	O
preincubated	O
with	O
human	O
anti	O
-	O
E.	O
chaffeensis	O
serum	O
for	O
2	O
h	O
,	O
and	O
the	O
levels	O
of	O
cytokine	O
mRNAs	O
were	O
evaluated	O
by	O
competitive	O
reverse	O
transcription	O
-	O
PCR	O
.	O
Anti	B
-	I
E.	I
chaffeensis	I
antibody	I
complexed	O
with	O
E.	O
chaffeensis	O
significantly	O
enhanced	O
mRNA	O
expression	O
of	O
IL-1beta	B
in	O
THP-1	O
cells	O
.	O
The	O
expression	O
of	O
TNF	O
-	O
alpha	O
and	O
IL-6	O
mRNAs	O
was	O
also	O
induced	O
.	O
The	O
levels	O
of	O
secreted	O
IL-1beta	B
,	O
TNF	B
-	I
alpha	I
,	O
and	O
IL-6	B
during	O
24	O
h	O
of	O
stimulation	O
were	O
comparable	O
to	O
those	O
induced	O
by	O
Escherichia	O
coli	O
lipopolysaccharide	O
at	O
1	O
microg	O
/	O
ml	O
.	O
Fab	O
fragment	O
of	O
anti	B
-	I
E.	I
chaffeensis	I
immunoglobulin	I
G	I
complexed	O
with	O
E.	O
chaffeensis	O
did	O
not	O
induce	O
any	O
of	O
these	O
three	O
cytokines	O
,	O
indicating	O
that	O
ehrlichial	O
binding	O
is	O
required	O
for	O
IL-1beta	O
mRNA	O
expression	O
and	O
that	O
binding	O
of	O
the	O
immune	B
complex	I
to	O
the	O
Fc	B
gamma	I
receptor	I
is	O
required	O
for	O
TNF	B
-	I
alpha	I
and	O
IL-6	O
mRNA	O
expression	O
and	O
enhanced	O
IL-1beta	O
mRNA	O
expression	O
.	O
Furthermore	O
,	O
prolonged	O
degradation	O
of	O
IkappaB	B
-	I
alpha	I
and	O
activation	O
of	O
NF	B
-	I
kappaB	I
were	O
demonstrated	O
in	O
THP-1	O
cells	O
exposed	O
to	O
anti	O
-	O
E.	O
chaffeensis	O
serum	O
and	O
E.	O
chaffeensis	O
.	O
This	O
result	O
implies	O
that	O
development	O
of	O
anti	B
-	I
E.	I
chaffeensis	I
antibody	I
in	O
patients	O
can	O
result	O
in	O
the	O
production	O
of	O
major	B
proinflammatory	I
cytokines	I
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
ehrlichiosis	O
and	O
immune	O
responses	O
to	O
it	O
.	O
S	O
-	O
allyl	O
cysteine	O
inhibits	O
activation	O
of	O
nuclear	B
factor	I
kappa	I
B	I
in	O
human	O
T	O
cells	O
.	O
Reactive	O
oxygen	O
species	O
are	O
involved	O
in	O
signal	O
transduction	O
pathways	O
leading	O
to	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
activation	O
which	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
gene	O
transcription	O
.	O
We	O
recently	O
reported	O
that	O
a	O
garlic	O
compound	O
,	O
S	O
-	O
allyl	O
cysteine	O
(	O
SAC	O
)	O
,	O
protects	O
bovine	O
pulmonary	O
artery	O
endothelial	O
cells	O
from	O
oxidant	O
injury	O
induced	O
by	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
.	O
In	O
this	O
study	O
we	O
determined	O
the	O
effects	O
of	O
SAC	O
on	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
human	O
T	O
lymphocytes	O
(	O
Jurkat	O
cells	O
)	O
induced	O
by	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF-	B
alpha	I
)	O
and	O
H2O2	O
.	O
Activated	O
NF	B
-	I
kappa	I
B	I
in	O
nuclear	O
extracts	O
was	O
measured	O
by	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
32P	O
-	O
labeled	O
probe	O
.	O
SAC	O
consistently	O
exhibited	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
induced	O
by	O
both	O
TNF	B
-	I
alpha	I
and	O
H2O2	O
.	O
Supershift	O
with	O
specific	O
antibodies	O
to	O
NF	B
-	I
kappa	I
B	I
subunits	I
confirmed	O
that	O
the	O
inducible	O
retarded	O
bands	O
observed	O
in	O
the	O
EMSA	O
and	O
p65-p50	B
heterodimer	I
of	O
the	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
protein	I
.	O
Our	O
data	O
suggest	O
that	O
SAC	O
may	O
act	O
via	O
antioxidant	O
mechanisms	O
to	O
block	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
Jurkat	O
cells	O
.	O
Role	O
of	O
ascorbate	O
in	O
the	O
activation	O
of	O
NF	B
-	I
kappaB	I
by	O
tumour	B
necrosis	I
factor	I
-	I
alpha	I
in	O
T	O
-	O
cells	O
.	O
The	O
first	O
product	O
of	O
ascorbate	O
oxidation	O
,	O
the	O
ascorbate	O
free	O
radical	O
(	O
AFR	O
)	O
,	O
acts	O
in	O
biological	O
systems	O
mainly	O
as	O
an	O
oxidant	O
,	O
and	O
through	O
its	O
role	O
in	O
the	O
plasma	O
membrane	O
redox	O
system	O
exerts	O
different	O
effects	O
on	O
the	O
cell	O
.	O
We	O
have	O
investigated	O
the	O
role	O
of	O
ascorbate	O
,	O
AFR	O
and	O
dehydroascorbate	O
(	O
DHA	O
)	O
in	O
the	O
activation	O
of	O
the	O
NF	B
-	I
kappaB	I
transcription	I
factor	I
in	O
Jurkat	O
T	O
-	O
cells	O
stimulated	O
by	O
tumour	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
.	O
Here	O
we	O
show	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
that	O
ascorbate	O
increases	O
the	O
binding	O
of	O
NF	B
-	I
kappaB	I
to	O
DNA	O
in	O
TNF	O
-	O
alpha	O
-	O
stimulated	O
Jurkat	O
cells	O
.	O
The	O
ability	O
of	O
ascorbate	O
to	O
enhance	O
cytoplasmic	O
inhibitory	O
IkBalpha	B
protein	I
degradation	O
correlates	O
completely	O
with	O
its	O
capacity	O
to	O
induce	O
NF	B
-	I
kappaB	I
binding	O
to	O
DNA	O
and	O
to	O
potentiate	O
NF	B
-	I
kappaB	I
-mediated	O
transactivation	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
promoter	O
in	O
TNF	O
-	O
alpha	O
-	O
stimulated	O
Jurkat	O
cells	O
but	O
not	O
in	O
cells	O
stimulated	O
with	O
PMA	O
plus	O
ionomycin	O
.	O
AFR	O
behaves	O
like	O
ascorbate	O
,	O
while	O
DHA	O
and	O
ascorbate	O
phosphate	O
do	O
not	O
affect	O
TNF	B
-	I
alpha	I
-mediated	O
NF	B
-	I
kappaB	I
activation	O
.	O
These	O
results	O
provide	O
new	O
evidence	O
for	O
a	O
possible	O
relationship	O
between	O
the	O
activation	O
of	O
the	O
electron	O
-	O
transport	O
system	O
at	O
the	O
plasma	O
membrane	O
by	O
ascorbate	O
or	O
its	O
free	O
radical	O
and	O
redox	O
-	O
dependent	O
gene	O
transcription	O
in	O
T	O
-	O
cells	O
.	O
Chimeric	B
oncoprotein	I
E2a	B
-	I
Pbx1	I
induces	O
apoptosis	O
of	O
hematopoietic	O
cells	O
by	O
a	O
p53	B
-independent	O
mechanism	O
that	O
is	O
suppressed	O
by	O
Bcl-2	B
.	O
The	O
chimeric	B
oncoprotein	I
E2a	B
-	I
Pbx1	I
results	O
from	O
fusion	O
of	O
the	O
E2A	O
and	O
PBX1	O
genes	O
following	O
t	O
(	O
1	O
;	O
19	O
)	O
chromosomal	O
translocations	O
in	O
B	O
cell	O
precursor	O
acute	O
leukemias	O
.	O
Experimentally	O
B	O
cell	O
progenitors	O
do	O
not	O
tolerate	O
constitutive	O
expression	O
of	O
E2a	B
-	I
Pbx1	I
which	O
contrasts	O
with	O
transformation	O
of	O
several	O
other	O
cell	O
types	O
following	O
its	O
stable	O
expression	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
To	O
further	O
investigate	O
the	O
effects	O
of	O
E2a	B
-	I
Pbx1	I
on	O
the	O
B	O
cell	O
progenitors	O
,	O
we	O
conditionally	O
expressed	O
E2a	B
-	I
Pbx1	I
under	O
control	O
of	O
a	O
metal	O
response	O
element	O
in	O
hematopoietic	O
precursor	O
cell	O
lines	O
in	O
vitro	O
.	O
Inducible	O
expression	O
of	O
E2a	B
-	I
Pbx1	I
resulted	O
in	O
cell	O
death	O
with	O
the	O
morphologic	O
and	O
molecular	O
features	O
of	O
apoptosis	O
.	O
A	O
structure	O
-	O
function	O
analysis	O
demonstrated	O
that	O
induction	O
of	O
apoptosis	O
was	O
not	O
a	O
dominant	O
-	O
negative	O
effect	O
of	O
the	O
E2a	B
moiety	I
but	O
,	O
rather	O
,	O
required	O
the	O
DNA	B
-	I
binding	I
homeodomain	I
of	O
Pbx1	B
.	O
E2a-	O
Pbx1	B
-induced	O
apoptosis	O
proceeded	O
through	O
a	O
BCL2	B
-responsive	O
checkpoint	O
eventuating	O
in	O
PARP	B
inactivation	O
but	O
did	O
require	O
p53	B
.	O
Constitutive	O
expression	O
of	O
E2a	B
-	I
Pbx1	I
did	O
not	O
induce	O
apoptosis	O
or	O
continued	O
cycling	O
of	O
Rat-1	O
fibroblasts	O
in	O
low	O
serum	O
conditions	O
.	O
These	O
studies	O
demonstrate	O
that	O
E2a	B
-	I
Pbx1	I
initiates	O
programmed	O
cell	O
death	O
of	O
hematopoietic	O
precursers	O
by	O
a	O
mechanism	O
that	O
requires	O
its	O
chimeric	O
transcriptional	O
properties	O
,	O
but	O
,	O
unlike	O
other	O
nuclear	B
oncoproteins	I
,	O
is	O
independent	O
of	O
p53	B
.	O
Sp	B
family	I
members	I
preferentially	O
interact	O
with	O
the	O
promoter	O
proximal	O
repeat	O
within	O
the	O
HTLV	O
-	O
I	O
enhancer	O
.	O
Human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
encodes	O
the	O
transactivator	B
protein	I
,	O
Tax	B
,	O
which	O
facilitates	O
viral	O
transcription	O
from	O
three	O
21	O
bp	O
repeated	O
elements	O
within	O
the	O
U3	O
region	O
of	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O
Examination	O
of	O
the	O
basal	B
factors	I
interacting	O
with	O
the	O
21	O
bp	O
repeat	O
elements	O
through	O
electrophoretic	O
mobility	O
shift	O
(	O
EMS	O
)	O
analyses	O
has	O
demonstrated	O
the	O
formation	O
of	O
DNA	B
-	I
protein	I
complexes	I
common	O
to	O
each	O
of	O
the	O
21	O
bp	O
repeats	O
(	O
C1-C3	O
)	O
as	O
well	O
as	O
three	O
DNA	B
-	I
protein	I
complexes	I
specific	O
to	O
the	O
promoter	O
proximal	O
(	O
pp	O
)	O
repeat	O
(	O
U1	O
(	O
U1A	O
/	O
U1B	O
)	O
and	O
U2	O
;	O
1	O
-	O
4	O
)	O
.	O
These	O
studies	O
have	O
indicated	O
that	O
the	O
individual	O
repeats	O
are	O
not	O
identical	O
with	O
respect	O
to	O
the	O
cellular	B
factors	I
with	O
which	O
they	O
interact	O
.	O
EMS	O
analyses	O
utilizing	O
a	O
series	O
of	O
mutated	O
pp	O
repeat	O
elements	O
demonstrate	O
that	O
the	O
nucleotide	O
sequence	O
requirements	O
for	O
U1	O
(	O
U1A	O
/	O
U1B	O
)	O
and	O
U2	O
formation	O
are	O
separable	O
from	O
those	O
required	O
for	O
C1-C3	O
formation	O
.	O
Competition	O
EMS	O
analyses	O
utilizing	O
Sp1	O
and	O
CREB	O
binding	O
site	O
oligonucleotides	O
demonstrate	O
that	O
Sp	B
family	I
members	I
are	O
critical	O
components	O
of	O
U1	O
(	O
U1A	O
/	O
U1B	O
)	O
and	O
U2	O
and	O
that	O
ATF	B
/	I
CREB	I
family	I
members	I
are	O
critical	O
components	O
of	O
C1-C3	O
.	O
EMS	O
supershift	O
analyses	O
have	O
demonstrated	O
that	O
Sp1	B
is	O
involved	O
in	O
U1A	O
formation	O
while	O
Sp3	B
is	O
involved	O
in	O
U1B	O
and	O
U2	O
formation	O
.	O
EMS	O
analyses	O
performed	O
with	O
nuclear	O
extracts	O
from	O
Tax	O
-	O
expressing	O
Jurkat	O
cells	O
and	O
HTLV	O
-	O
I	O
-	O
transformed	O
peripheral	O
blood	O
mononuclear	O
cells	O
demonstrate	O
that	O
Tax	B
prevents	O
the	O
formation	O
of	O
U1	O
(	O
U1A	O
/	O
U1B	O
)	O
and	O
U2	O
DNA	B
-	I
protein	I
complexes	I
.	O
Therefore	O
,	O
Tax	B
appears	O
to	O
inhibit	O
the	O
interaction	O
of	O
Sp	B
family	I
members	I
with	O
the	O
pp	O
repeat	O
.	O
Based	O
on	O
these	O
observations	O
,	O
it	O
is	O
possible	O
that	O
the	O
interaction	O
of	O
Sp	B
and	O
ATF	B
/	I
CREB	I
family	I
members	I
with	O
the	O
pp	O
repeat	O
during	O
basal	O
and	O
Tax	B
-mediated	O
transcription	O
may	O
play	O
a	O
critical	O
role	O
in	O
viral	O
gene	O
expression	O
during	O
the	O
initial	O
stages	O
of	O
virus	O
infection	O
or	O
during	O
activation	O
of	O
a	O
latent	O
infection	O
.	O
An	O
acute	O
myeloid	O
leukemia	O
gene	O
,	O
AML1	O
,	O
regulates	O
transcriptional	O
activation	O
and	O
hemopoietic	O
myeloid	O
cell	O
differentiation	O
antagonistically	O
by	O
two	O
alternative	O
spliced	O
forms	O
.	O
The	O
AML1	O
gene	O
on	O
chromosome	O
21	O
is	O
disrupted	O
in	O
the	O
(	O
8	O
;	O
21	O
)	O
(	O
q22	O
;	O
q22	O
)	O
and	O
(	O
3	O
;	O
21	O
)	O
(	O
q26	O
;	O
q22	O
)	O
translocations	O
associated	O
with	O
myelogenous	O
leukemias	O
and	O
encodes	O
a	O
DNA	B
-	I
binding	I
protein	I
.	O
From	O
AML1	O
gene	O
,	O
two	O
representative	O
forms	O
of	O
proteins	O
,	O
AML1a	B
and	O
AML1b	B
,	O
are	O
produced	O
by	O
an	O
alternative	O
splicing	O
.	O
Both	O
forms	O
have	O
DNA	B
-	I
binding	I
domain	I
,	O
but	O
AML1a	B
lacks	O
a	O
putative	O
transcriptional	O
activation	O
domain	O
which	O
AML1b	B
has	O
.	O
Here	O
we	O
demonstrate	O
that	O
AML1a	B
,	O
which	O
solely	O
has	O
no	O
effects	O
as	O
a	O
transcriptional	O
regulator	O
,	O
dominantly	O
suppresses	O
transcriptional	O
activation	O
by	O
AML1b	B
,	O
and	O
that	O
AML1a	B
exhibits	O
the	O
higher	O
affinity	O
for	O
DNA	O
-	O
binding	O
than	O
AML1b	B
.	O
Furthermore	O
a	O
dominant	B
negative	I
form	I
of	O
AML1	B
,	O
AML1a	B
,	O
totally	O
suppressed	O
granulocytic	O
differentiation	O
otherwise	O
induced	O
by	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
when	O
AML1a	B
was	O
overexpressed	O
in	O
32Dc13	O
murine	O
myeloid	O
cells	O
.	O
Such	O
differentiation	O
block	O
by	O
AML1a	B
was	O
canceled	O
by	O
the	O
concomitant	O
overexpression	O
of	O
AML1b	B
.	O
These	O
data	O
strongly	O
suggest	O
that	O
a	O
transcriptionally	O
active	O
form	O
of	O
AML1	B
is	O
essential	O
for	O
the	O
myeloid	O
cell	O
differentiation	O
.	O
In	O
addition	O
,	O
we	O
observed	O
an	O
altered	O
expression	O
level	O
of	O
AML1	B
along	O
with	O
the	O
myeloid	O
differentiation	O
in	O
several	O
hemopoietic	O
cell	O
lines	O
.	O
In	O
these	O
cases	O
,	O
at	O
least	O
,	O
the	O
AML1	B
expression	O
level	O
is	O
a	O
potential	O
regulator	O
for	O
myeloid	O
cell	O
differentiation	O
.	O
Of	O
the	O
GATA	B
-	I
binding	I
proteins	I
,	O
only	O
GATA-4	B
selectively	O
regulates	O
the	O
human	O
IL-5	O
gene	O
promoter	O
in	O
IL-5	O
producing	O
cells	O
which	O
express	O
multiple	B
GATA	I
-	I
binding	I
proteins	I
.	O
Interleukin-5	B
(	O
IL-5	B
)	O
is	O
produced	O
by	O
T	O
lymphocytes	O
and	O
known	O
to	O
support	O
B	O
cell	O
growth	O
and	O
eosinophilic	O
differentiation	O
of	O
the	O
progenitor	O
cells	O
.	O
Using	O
ATL-16	O
T	O
cells	O
which	O
express	O
IL-5	O
mRNA	O
,	O
we	O
have	O
identified	O
a	O
region	O
,	O
within	O
the	O
human	O
IL-5	O
gene	O
promoter	O
,	O
that	O
regulates	O
IL-5	O
gene	O
transcription	O
.	O
This	O
cis	O
-	O
acting	O
sequence	O
contains	O
the	O
core	O
binding	O
motif	O
,	O
(	O
A	O
/	O
T	O
)	O
GATA	O
(	O
A	O
/	O
G	O
)	O
,	O
for	O
GATA	B
-	I
binding	I
family	I
proteins	I
and	O
thus	O
suggests	O
the	O
involvement	O
of	O
these	O
family	O
members	O
.	O
In	O
this	O
report	O
,	O
we	O
describe	O
the	O
cloning	O
of	O
human	B
GATA-4	I
(	O
hGATA-4	B
)	O
and	O
show	O
that	O
hGATA-4	B
selectively	O
interacts	O
with	O
the	O
-70	O
GATA	O
site	O
within	O
the	O
IL-5	O
proximal	O
promoter	O
region	O
.	O
By	O
promoter	O
deletion	O
and	O
mutation	O
analyses	O
,	O
we	O
established	O
this	O
region	O
as	O
a	O
positive	O
regulatory	O
element	O
.	O
Cotransfection	O
experiments	O
revealed	O
that	O
both	O
hGATA-4	B
and	O
PMA	O
/	O
A23187	O
stimulation	O
are	O
necessary	O
for	O
the	O
IL-5	O
promoter	O
activation	O
.	O
The	O
requirement	O
of	O
another	O
regulatory	O
element	O
called	O
CLE0	O
,	O
which	O
lies	O
downstream	O
of	O
the	O
-70	O
GATA	O
site	O
,	O
was	O
also	O
demonstrated	O
.	O
ATL-16	O
T	O
cells	O
express	O
mRNA	O
of	O
three	O
GATA	B
-	I
binding	I
proteins	I
,	O
hGATA-2	B
,	O
hGATA-3	B
and	O
hGATA-4	B
,	O
and	O
each	O
of	O
them	O
has	O
a	O
potential	O
to	O
bind	O
to	O
the	O
consensus	O
(	O
A	O
/	O
T	O
)	O
GATA	O
(	O
G	O
/	O
A	O
)	O
motif	O
.	O
However	O
,	O
using	O
ATL-16	O
T	O
nuclear	O
extract	O
,	O
we	O
demonstrated	O
that	O
GATA-4	B
is	O
the	O
only	O
GATA	B
-	I
binding	I
protein	I
that	O
forms	O
specific	O
DNA	B
-	I
protein	I
complex	I
with	O
the	O
-70	O
GATA	O
site	O
.	O
The	O
electrophoretic	O
mobility	O
shift	O
assay	O
with	O
extracts	O
of	O
COS	O
cells	O
expressing	O
GATA	B
-	I
binding	I
proteins	I
showed	O
that	O
GATA-4	B
has	O
the	O
highest	O
binding	O
affinity	O
to	O
the	O
-70	O
GATA	O
site	O
among	O
the	O
three	O
GATA	B
-	I
binding	I
proteins	I
.	O
When	O
the	O
transactivation	O
ability	O
was	O
compared	O
among	O
the	O
three	O
,	O
GATA-4	B
showed	O
the	O
highest	O
activity	O
.	O
These	O
results	O
demonstrate	O
the	O
selective	O
role	O
of	O
GATA-4	B
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IL-5	O
gene	O
in	O
a	O
circumstance	O
where	O
multiple	O
members	O
of	O
the	O
GATA	B
-	I
binding	I
proteins	I
are	O
expressed	O
.	O
Increased	O
expression	O
of	O
Gs	B
(	I
alpha	I
)	I
enhances	O
activation	O
of	O
the	O
adenylyl	B
cyclase	I
signal	O
transduction	O
cascade	O
.	O
Expression	O
of	O
the	O
stimulatory	O
G	B
protein	I
,	O
G	B
(	I
S	I
)	I
alpha	I
,	O
can	O
vary	O
over	O
a	O
3-fold	O
range	O
in	O
human	O
tissues	O
and	O
in	O
rodent	O
central	O
nervous	O
system	O
.	O
In	O
fact	O
,	O
the	O
offspring	O
of	O
alcoholics	O
have	O
higher	O
levels	O
of	O
G	B
(	I
S	I
)	I
alpha	I
expression	O
in	O
certain	O
tissues	O
compared	O
with	O
the	O
offspring	O
of	O
nonalcoholics	O
.	O
The	O
aim	O
of	O
this	O
research	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
a	O
causal	O
relationship	O
exists	O
between	O
the	O
level	O
of	O
expression	O
of	O
G	B
(	I
S	I
)	I
alpha	I
and	O
induction	O
of	O
the	O
adenylyl	B
cyclase	I
(	O
AC	O
)	O
cascade	O
.	O
The	O
methodology	O
employed	O
transient	O
transfection	O
of	O
HEK	O
293	O
cells	O
with	O
a	O
cDNA	O
for	O
the	O
52-kDa	O
form	O
of	O
G	B
(	I
S	I
)	I
alpha	I
under	O
regulation	O
by	O
inducible	O
metallothionein	O
promoters	O
.	O
Transfectants	O
were	O
exposed	O
to	O
varying	O
concentrations	O
(	O
0	O
-	O
125	O
microM	O
)	O
of	O
zinc	O
sulfate	O
that	O
produced	O
a	O
3-fold	O
range	O
of	O
membrane	O
G	B
(	I
S	I
)	I
alpha	I
expression	O
.	O
The	O
range	O
of	O
G	B
(	I
S	I
)	I
alpha	I
expression	O
produced	O
was	O
found	O
to	O
mimic	O
a	O
physiologically	O
relevant	O
spectrum	O
of	O
G	B
(	I
S	I
)	I
alpha	I
expression	O
in	O
membranes	O
derived	O
from	O
human	O
tissues	O
and	O
rat	O
brain	O
.	O
It	O
was	O
observed	O
that	O
induction	O
of	O
G	B
(	I
S	I
)	I
alpha	I
expression	O
increased	O
constitutive	O
as	O
well	O
as	O
stimulated	O
cAMP	O
accumulation	O
.	O
Moreover	O
,	O
induction	O
of	O
G	B
(	I
S	I
)	I
alpha	I
expression	O
increased	O
events	O
distal	O
to	O
the	O
accumulation	O
of	O
cAMP	O
including	O
the	O
phosphorylation	O
of	O
the	O
transcription	O
factor	O
,	O
cAMP	B
response	I
element	I
binding	I
protein	I
and	O
transcriptional	O
activation	O
of	O
cAMP	O
-	O
dependent	O
reporter	O
genes	O
.	O
In	O
summary	O
,	O
these	O
studies	O
show	O
that	O
the	O
amount	O
of	O
G	B
(	I
S	I
)	I
alpha	I
expression	O
has	O
a	O
marked	O
impact	O
on	O
the	O
level	O
of	O
activity	O
of	O
the	O
AC	O
cascade	O
from	O
the	O
membrane	O
through	O
to	O
the	O
nucleus	O
.	O
It	O
is	O
hypothesized	O
that	O
individuals	O
who	O
differ	O
in	O
G	B
(	I
S	I
)	I
alpha	I
expression	O
may	O
also	O
differ	O
in	O
the	O
expression	O
of	O
certain	O
cAMP	O
-	O
dependent	O
genes	O
.	O
gamma	B
-	I
Interferon	I
-induced	O
resistance	O
to	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2	O
D3	O
in	O
human	O
monocytes	O
and	O
macrophages	O
:	O
a	O
mechanism	O
for	O
the	O
hypercalcemia	O
of	O
various	O
granulomatoses	O
.	O
The	O
hypercalcemia	O
of	O
various	O
granulomatoses	O
is	O
caused	O
by	O
endogenous	O
1	O
,	O
25-dihydroxyvitamin	O
D	O
[	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
]	O
overproduction	O
by	O
disease	O
-	O
activated	O
macrophages	O
.	O
The	O
inability	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
to	O
suppress	O
its	O
synthesis	O
in	O
macrophages	O
contrasts	O
with	O
the	O
tight	O
control	O
of	O
its	O
production	O
in	O
macrophage	O
precursors	O
,	O
peripheral	O
blood	O
monocytes	O
(	O
PBM	O
)	O
.	O
We	O
examined	O
whether	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
resistance	O
develops	O
as	O
PBM	O
differentiate	O
to	O
macrophages	O
or	O
with	O
macrophage	O
activation	O
.	O
Normal	O
human	O
pulmonary	O
alveolar	O
macrophages	O
(	O
PAM	O
)	O
are	O
less	O
sensitive	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
than	O
PBM	O
,	O
despite	O
similar	O
vitamin	B
D	I
receptor	I
content	O
;	O
however	O
,	O
both	O
PBM	O
and	O
PAM	O
respond	O
to	O
exogenous	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
by	O
inhibiting	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
and	O
inducing	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
degradation	O
through	O
enhancement	O
of	O
24-hydroxylase	B
mRNA	O
levels	O
and	O
activity	O
.	O
The	O
human	O
monocytic	O
cell	O
line	O
THP-1	O
mimics	O
PAM	O
in	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
and	O
sensitivity	O
to	O
exogenous	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O
We	O
utilized	O
THP-1	O
cells	O
to	O
examine	O
the	O
response	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
with	O
macrophage	O
activation	O
.	O
Activation	O
of	O
THP-1	O
cells	O
with	O
gamma	B
-	I
interferon	I
(	O
gamma	B
-	I
IFN	I
)	O
enhances	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
synthesis	O
30-fold	O
,	O
blocks	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
suppression	O
of	O
its	O
synthesis	O
,	O
and	O
reduces	O
by	O
42.2	O
%	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
induction	O
of	O
its	O
degradation	O
.	O
The	O
antagonistic	O
effects	O
of	O
gamma	B
-	I
IFN	I
are	O
not	O
merely	O
restricted	O
to	O
enzymatic	O
activities	O
.	O
In	O
THP-1	O
cells	O
and	O
in	O
normal	O
PBM	O
,	O
gamma	B
-	I
IFN	I
inhibits	O
1	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
induction	O
of	O
24-hydroxylase	B
mRNA	O
levels	O
without	O
reducing	O
mRNA	O
stability	O
,	O
suggesting	O
gamma	B
-	I
IFN	I
inhibition	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
transactivating	O
function	O
.	O
These	O
results	O
explain	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
overproduction	O
in	O
granulomatoses	O
and	O
demonstrate	O
potent	O
inhibition	O
by	O
gamma	B
-	I
IFN	I
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
action	O
in	O
immune	O
cells	O
.	O
Glucocorticoid	B
receptors	I
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
in	O
relation	O
to	O
age	O
and	O
to	O
sport	O
activity	O
.	O
Glucocorticoid	B
receptors	I
(	O
GR	B
)	O
are	O
ubiquitous	O
molecules	O
and	O
are	O
present	O
also	O
in	O
the	O
hippocampus	O
and	O
in	O
several	O
other	O
nervous	O
and	O
immune	O
tissues	O
.	O
Peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
are	O
a	O
good	O
model	O
for	O
studies	O
of	O
GR	B
in	O
humans	O
.	O
Glucocorticoids	O
are	O
important	O
for	O
maintaining	O
cellular	O
and	O
humoral	O
homeostasis	O
and	O
are	O
key	O
mediators	O
of	O
neuroendocrine	O
-	O
immune	O
regulatory	O
interactions	O
.	O
The	O
increase	O
of	O
cortisol	O
is	O
immunosuppressive	O
and	O
reduces	O
GR	B
concentration	O
both	O
in	O
nervous	O
and	O
immune	O
systems	O
.	O
Variation	O
of	O
glucocorticoids	O
in	O
healthy	O
aged	O
subjects	O
and	O
athletes	O
has	O
been	O
shown	O
.	O
Prompted	O
by	O
these	O
results	O
,	O
we	O
have	O
investigated	O
in	O
man	O
a	O
possible	O
relationship	O
between	O
GR	B
binding	O
capacity	O
in	O
the	O
PBMCs	O
and	O
age	O
,	O
in	O
relation	O
also	O
to	O
plasma	O
testosterone	O
and	O
cortisol	O
.	O
The	O
same	O
parameters	O
have	O
been	O
examined	O
in	O
a	O
group	O
of	O
soccer	O
players	O
for	O
comparison	O
with	O
the	O
sedentary	O
group	O
.	O
GR	B
binding	O
capacity	O
was	O
higher	O
in	O
younger	O
subjects	O
than	O
in	O
older	O
ones	O
,	O
and	O
lower	O
in	O
the	O
group	O
of	O
athletes	O
than	O
in	O
the	O
younger	O
and	O
older	O
sedentary	O
subjects	O
.	O
In	O
the	O
sedentary	O
group	O
a	O
negative	O
correlation	O
was	O
present	O
between	O
GR	B
binding	O
capacity	O
and	O
age	O
.	O
Plasma	O
cortisol	O
was	O
higher	O
and	O
testosterone	O
lower	O
in	O
the	O
athletes	O
;	O
they	O
were	O
negatively	O
correlated	O
in	O
athletes	O
and	O
positively	O
correlated	O
in	O
the	O
sedentary	O
subjects	O
.	O
The	O
results	O
for	O
athletes	O
agree	O
with	O
their	O
lower	O
anabolic	O
/	O
catabolic	O
balance	O
.	O
The	O
mechanism	O
of	O
reduced	O
GR	B
levels	O
in	O
relation	O
to	O
age	O
and	O
sport	O
activity	O
could	O
involve	O
a	O
loss	O
or	O
an	O
involution	O
of	O
receptor	O
synthesis	O
.	O
However	O
other	O
possibilities	O
,	O
such	O
as	O
altered	O
distribution	O
of	O
lymphocyte	O
subpopulations	O
with	O
different	O
receptor	O
concentrations	O
and	O
with	O
different	O
cytokine	B
production	O
,	O
can	O
not	O
be	O
excluded	O
.	O
Several	O
neuroendocrine	O
-	O
immune	O
interactions	O
could	O
be	O
responsible	O
for	O
reduced	O
GR	B
levels	O
with	O
age	O
and	O
sport	O
activity	O
in	O
man	O
.	O
Rescue	O
by	O
cytokines	B
of	O
apoptotic	O
cell	O
death	O
induced	O
by	O
IL-2	B
deprivation	O
of	O
human	O
antigen	O
-	O
specific	O
T	O
cell	O
clones	O
.	O
The	O
control	O
of	O
cell	O
survival	O
and	O
cell	O
death	O
is	O
of	O
central	O
importance	O
in	O
tissues	O
with	O
high	O
cell	O
turnover	O
such	O
as	O
the	O
lymphoid	O
system	O
.	O
We	O
have	O
examined	O
the	O
effect	O
of	O
cytokines	B
on	O
IL-2	B
deprivation	O
-	O
induced	O
apoptosis	O
of	O
human	O
antigen	O
-	O
specific	O
T	O
helper	O
clones	O
with	O
different	O
cytokine	B
production	O
profiles	O
.	O
We	O
found	O
that	O
IL-2	B
,	O
interferon	B
-	I
alpha	I
(	O
IFN	B
-	I
alpha	I
)	O
,	O
and	O
IFN	B
-	I
beta	I
inhibited	O
IL-2	B
deprivation	O
apoptosis	O
in	O
Th0	O
,	O
Th1	O
,	O
and	O
Th2	O
clones	O
.	O
We	O
also	O
found	O
that	O
IL-2	B
protects	O
T	O
cell	O
clones	O
from	O
IL-2	B
deprivation	O
apoptosis	O
accompanying	O
active	O
proliferation	O
and	O
enhanced	O
expression	O
of	O
P53	B
,	O
Rb	B
and	O
Bcl	B
-	I
xL	I
proteins	I
.	O
In	O
contrast	O
,	O
IFN	B
-	I
alpha	I
/	I
beta	I
rescued	O
T	O
cell	O
clones	O
from	O
apoptosis	O
without	O
active	O
proliferation	O
,	O
and	O
expression	O
of	O
apoptosis	B
-	I
associated	I
proteins	I
tested	O
so	O
far	O
was	O
unaffected	O
.	O
This	O
may	O
be	O
due	O
to	O
the	O
fact	O
that	O
T	O
cells	O
treated	O
with	O
IL-2	B
contained	O
those	O
located	O
in	O
S	O
+	O
G2	O
/	O
M	O
phases	O
of	O
the	O
cell	O
cycle	O
,	O
whereas	O
the	O
vast	O
majority	O
of	O
T	O
cells	O
treated	O
with	O
IFN	B
-	I
alpha	I
/	I
beta	I
were	O
located	O
in	O
G0	O
/	O
G1	O
phase	O
.	O
IFN	B
-	I
alpha	I
/	I
beta	I
specifically	O
induced	O
tyrosine	O
phosphorylation	O
and	O
translocation	O
into	O
nucleus	O
of	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	I
STAT	I
)	I
2	I
protein	I
in	O
the	O
T	O
cell	O
clones	O
.	O
In	O
addition	O
,	O
over	O
-	O
expression	O
of	O
STAT2	B
by	O
transfection	O
of	O
the	O
cDNA	O
prevented	O
apoptosis	O
of	O
the	O
T	O
cell	O
clones	O
.	O
Our	O
present	O
study	O
shows	O
that	O
IFN	B
-	I
alpha	I
and	I
-beta	I
mediate	O
anti	O
-	O
apoptotic	O
effect	O
through	O
other	O
pathways	O
than	O
that	O
of	O
IL-2	B
in	O
growth	O
factor	O
deprivation	O
apoptosis	O
.	O
The	O
cytoplasmic	B
domain	I
of	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	I
GM	I
-	I
CSF	I
)	I
receptor	I
alpha	I
subunit	I
is	O
essential	O
for	O
both	O
GM	B
-	I
CSF	I
-mediated	O
growth	O
and	O
differentiation	O
.	O
Granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
(	O
GM	B
-	I
CSF	I
)	O
regulates	O
differentiation	O
,	O
survival	O
,	O
and	O
proliferation	O
of	O
colony	O
-	O
forming	O
unit	O
-	O
granulocyte	O
-	O
macrophage	O
progenitor	O
cells	O
.	O
The	O
biologic	O
actions	O
of	O
GM	B
-	I
CSF	I
are	O
mediated	O
by	O
binding	O
to	O
a	O
specific	O
receptor	O
consisting	O
of	O
two	O
chains	O
designated	O
as	O
alpha	B
and	I
beta	I
subunits	I
.	O
We	O
have	O
demonstrated	O
that	O
the	O
murine	O
FDC	O
-	O
P1-derived	O
cell	O
line	O
WT-19	O
transfected	O
with	O
the	O
human	B
GM	I
-	I
CSF	I
receptor	I
alpha	I
and	I
beta	I
subunits	I
(	O
GM	B
-	I
CSFRalpha	I
and	I
beta	I
)	O
can	O
be	O
induced	O
to	O
differentiate	O
by	O
the	O
addition	O
of	O
human	B
GM	I
-	I
CSF	I
(	O
hGM	B
-	I
CSF	I
)	O
.	O
By	O
expressing	O
a	O
series	O
of	O
GM	B
-	I
CSFRalpha	I
mutants	I
in	O
WT19	O
cells	O
,	O
we	O
have	O
determined	O
the	O
amino	B
acid	I
domains	I
of	O
the	O
GM	B
-	I
CSFRalpha	I
cytoplasmic	B
domain	I
that	O
regulate	O
cell	O
differentiation	O
,	O
proliferation	O
,	O
and	O
survival	O
.	O
We	O
found	O
that	O
the	O
membrane	B
proximal	I
proline	I
-	I
rich	I
domain	I
and	O
adjacent	B
16	I
residues	I
are	O
essential	O
for	O
both	O
hGM	B
-	I
CSF	I
-dependent	O
cell	O
proliferation	O
and	O
differentiation	O
.	O
In	O
contrast	O
,	O
the	O
C	B
-	I
terminal	I
region	I
of	O
the	O
GM	B
-	I
CSFRalpha	I
cytoplasmic	I
domain	I
was	O
not	O
necessary	O
for	O
cell	O
differentiation	O
mediated	O
by	O
hGM	B
-	I
CSF	I
,	O
but	O
the	O
removal	O
of	O
this	O
region	O
severely	O
impaired	O
the	O
ability	O
of	O
hGM	B
-	I
CSF	I
to	O
support	O
cell	O
survival	O
.	O
While	O
the	O
activation	O
of	O
JAK2	B
,	O
Shc	B
,	O
Erk	B
,	O
and	O
STAT5	B
proteins	I
correlated	O
with	O
hGM	B
-	I
CSF	I
-mediated	O
cell	O
growth	O
,	O
cellular	O
differentiation	O
occurred	O
in	O
the	O
absence	O
of	O
activation	O
of	O
these	O
signal	O
transduction	O
pathways	O
.	O
Lipopolysaccharide	O
induction	O
of	O
the	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
promoter	O
in	O
human	O
monocytic	O
cells	O
.	O
Regulation	O
by	O
Egr-1	B
,	O
c	B
-	I
Jun	I
,	O
and	O
NF	B
-	I
kappaB	I
transcription	B
factors	I
.	O
Biosynthesis	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
is	O
predominantly	O
by	O
cells	O
of	O
the	O
monocytic	O
lineage	O
.	O
This	O
study	O
examined	O
the	O
role	O
of	O
various	O
cis	O
-	O
acting	O
regulatory	O
elements	O
in	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
the	O
human	O
TNF	O
-	O
alpha	O
promoter	O
in	O
cells	O
of	O
monocytic	O
lineage	O
.	O
Functional	O
analysis	O
of	O
monocytic	O
THP-1	O
cells	O
transfected	O
with	O
plasmids	O
containing	O
various	O
lengths	O
of	O
TNF	O
-	O
alpha	O
promoter	O
localized	O
enhancer	O
elements	O
in	O
a	O
region	O
(	O
-182	O
to	O
-37	O
base	O
pairs	O
(	O
bp	O
)	O
)	O
that	O
were	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
TNF	O
-	O
alpha	O
gene	O
in	O
response	O
to	O
LPS	O
.	O
Two	O
regions	O
were	O
identified	O
:	O
region	O
I	O
(	O
-182	O
to	O
-162	O
bp	O
)	O
contained	O
an	O
overlapping	O
Sp1	O
/	O
Egr-1	O
site	O
,	O
and	O
region	O
II	O
(	O
-119	O
to	O
-88	O
)	O
contained	O
CRE	O
and	O
NF	O
-	O
kappaB	O
(	O
designated	O
kappaB3	O
)	O
sites	O
.	O
In	O
unstimulated	O
THP-1	O
,	O
CRE	B
-	I
binding	I
protein	I
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
c	B
-	I
Jun	I
complexes	I
were	O
found	O
to	O
bind	O
to	O
the	O
CRE	O
site	O
.	O
LPS	O
stimulation	O
increased	O
the	O
binding	O
of	O
c	B
-	I
Jun	I
-	I
containing	I
complexes	I
.	O
In	O
addition	O
,	O
LPS	O
stimulation	O
induced	O
the	O
binding	O
of	O
cognate	O
nuclear	B
factors	I
to	O
the	O
Egr-1	O
and	O
kappaB3	O
sites	O
,	O
which	O
were	O
identified	O
as	O
Egr-1	B
and	O
p50	B
/	I
p65	I
,	O
respectively	O
.	O
The	O
CRE	O
and	O
kappaB3	O
sites	O
in	O
region	O
II	O
together	O
conferred	O
strong	O
LPS	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
,	O
whereas	O
individually	O
they	O
failed	O
to	O
provide	O
transcriptional	O
activation	O
.	O
Furthermore	O
,	O
increasing	O
the	O
spacing	O
between	O
the	O
CRE	O
and	O
the	O
kappaB3	O
sites	O
completely	O
abolished	O
LPS	O
induction	O
,	O
suggesting	O
a	O
cooperative	O
interaction	O
between	O
c	B
-	I
Jun	I
complexes	I
and	O
p50	B
/	I
p65	I
.	O
These	O
studies	O
indicate	O
that	O
maximal	O
LPS	O
induction	O
of	O
the	O
TNF	O
-	O
alpha	O
promoter	O
is	O
mediated	O
by	O
concerted	O
participation	O
of	O
at	O
least	O
two	O
separate	O
cis	O
-	O
acting	O
regulatory	O
elements	O
.	O
Inducible	O
expression	O
and	O
phosphorylation	O
of	O
coactivator	B
BOB.1	I
/	I
OBF.1	I
in	O
T	O
cells	O
[	O
see	O
comments	O
]	O
BOB.1	B
/	I
OBF.1	I
is	O
a	O
transcriptional	B
coactivator	I
that	O
is	O
constitutively	O
expressed	O
in	O
B	O
cells	O
and	O
interacts	O
with	O
the	O
Oct1	O
and	O
Oct2	O
transcription	B
factors	I
.	O
Upon	O
activation	O
of	O
Jurkat	O
T	O
cells	O
and	O
primary	O
murine	O
thymocytes	O
with	O
phorbol	O
esters	O
and	O
ionomycin	O
,	O
BOB.1	B
/	I
OBF.1	I
expression	O
and	O
transactivation	O
function	O
were	O
induced	O
.	O
BOB.1	B
/	I
OBF.1	I
was	O
phosphorylated	O
at	O
Ser184	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
and	O
this	O
modification	O
was	O
required	O
for	O
inducible	O
activation	O
.	O
Mutation	O
of	O
Ser184	O
also	O
diminished	O
transactivation	O
function	O
in	O
B	O
cells	O
,	O
suggesting	O
that	O
the	O
activating	O
phosphorylation	O
that	O
is	O
inducible	O
in	O
T	O
cells	O
is	O
constitutively	O
present	O
in	O
B	O
cells	O
.	O
Thus	O
,	O
BOB.1	B
/	I
OBF.1	I
is	O
a	O
transcriptional	B
coactivator	I
that	O
is	O
critically	O
regulated	O
by	O
posttranslational	O
modifications	O
to	O
mediate	O
cell	O
type	O
-	O
specific	O
gene	O
expression	O
.	O
Association	O
between	O
expression	O
of	O
intercellular	B
adhesion	I
molecule-1	I
and	O
integration	O
of	O
human	O
T	O
-	O
cell	O
-	O
leukemia	O
virus	O
type	O
1	O
in	O
adult	O
T	O
-	O
cell	O
leukemia	O
cells	O
.	O
It	O
is	O
known	O
that	O
the	O
expression	O
levels	O
of	O
intercellular	B
adhesion	I
molecule-1	I
(	O
ICAM-1	B
)	O
in	O
adult	O
T	O
cell	O
leukemia	O
(	O
ATL	O
)	O
cells	O
are	O
high	O
,	O
whereas	O
those	O
in	O
T	O
-	O
lymphoid	O
cells	O
are	O
not	O
.	O
In	O
order	O
to	O
investigate	O
the	O
factors	O
that	O
influence	O
the	O
induction	O
of	O
ICAM-1	B
molecules	O
,	O
Northern	O
blot	O
analysis	O
to	O
measure	O
the	O
expression	O
level	O
of	O
ICAM-1	O
mRNAs	O
and	O
Southern	O
blot	O
hybridization	O
to	O
analyze	O
the	O
integration	O
of	O
human	O
T	O
-	O
cell	O
-	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
provirus	O
were	O
done	O
.	O
The	O
levels	O
of	O
ICAM-1	O
mRNA	O
expression	O
of	O
ATL	O
cells	O
were	O
generally	O
higher	O
than	O
those	O
of	O
T	O
-	O
lymphoid	O
cells	O
.	O
However	O
,	O
ILT	O
-	O
mat	O
cells	O
and	O
ATL16	O
T	O
(	O
-	O
)	O
cells	O
,	O
although	O
they	O
were	O
ATL	O
cells	O
,	O
showed	O
rather	O
low	O
surface	O
ICAM-1	B
expression	O
and	O
ICAM-1	O
mRNA	O
expression	O
.	O
Southern	O
blot	O
hybridization	O
showed	O
that	O
only	O
two	O
and	O
four	O
bands	O
were	O
found	O
in	O
ILT	O
-	O
mat	O
and	O
ATL16	O
T	O
(	O
-	O
)	O
cells	O
,	O
respectively	O
,	O
whereas	O
>	O
10	O
bands	O
were	O
detected	O
in	O
other	O
ATL	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
monoclonal	O
integration	O
of	O
HTLV-1	O
provirus	O
to	O
the	O
genome	O
of	O
T	O
cell	O
,	O
especially	O
the	O
number	O
of	O
integration	O
sites	O
,	O
is	O
one	O
of	O
the	O
factors	O
for	O
induction	O
of	O
ICAM-1	B
molecules	I
.	O
Role	O
of	O
the	O
X2	O
box	O
in	O
activated	O
transcription	O
from	O
the	O
DRA	O
promoter	O
in	O
B	O
cells	O
.	O
We	O
investigated	O
the	O
function	O
of	O
the	O
evolutionary	O
conserved	O
X2	O
box	O
in	O
the	O
promoter	O
of	O
the	O
HLA	O
-	O
DRA	O
gene	O
from	O
the	O
human	B
major	I
histocompatibility	I
complex	I
(	O
MHC	B
)	O
in	O
resting	O
and	O
activated	O
B	O
cells	O
.	O
NF	O
-	O
X2	O
,	O
which	O
contains	O
members	O
of	O
the	O
AP-1	B
/	I
ATF	I
/	I
CREB	I
families	I
of	O
transcription	B
factors	I
,	O
interacts	O
with	O
the	O
X2	O
box	O
(	O
5'-TGCGTCA-3	O
'	O
)	O
from	O
positions	O
-97	O
to	O
-91	O
in	O
the	O
DRA	O
promoter	O
.	O
In	O
resting	O
Raji	O
cells	O
,	O
little	O
to	O
no	O
binding	O
to	O
the	O
X2	O
box	O
was	O
observed	O
.	O
In	O
sharp	O
contrast	O
,	O
in	O
B	O
cells	O
treated	O
with	O
the	O
phorbol	O
ester	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
,	O
strong	O
interactions	O
between	O
the	O
X2	O
box	O
and	O
NF	O
-	O
X2	O
containing	O
c	B
-	I
Fos	I
were	O
observed	O
.	O
As	O
determined	O
by	O
transient	O
expression	O
and	O
RNA	O
analyses	O
,	O
the	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
also	O
increased	O
rates	O
of	O
transcription	O
from	O
the	O
wild	O
-	O
type	O
DRA	O
promoter	O
but	O
not	O
from	O
a	O
DRA	O
promoter	O
bearing	O
clustered	O
point	O
mutations	O
in	O
the	O
X2	O
box	O
.	O
Since	O
the	O
co	O
-	O
expression	O
with	O
a	O
dominant	O
negative	O
c	B
-	I
Fos	I
abolished	O
the	O
responsiveness	O
to	O
TPA	O
,	O
we	O
conclude	O
that	O
activated	O
transcription	O
of	O
the	O
DRA	O
gene	O
depends	O
on	O
interactions	O
between	O
the	O
X2	O
box	O
and	O
NF	O
-	O
X2	O
,	O
which	O
contains	O
c	B
-	I
Fos	I
.	O
Transcription	B
factor	I
binding	O
sites	O
downstream	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
start	O
site	O
are	O
important	O
for	O
virus	O
infectivity	O
.	O
When	O
transcriptionally	O
active	O
,	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
promoter	O
contains	O
a	O
nucleosome	O
-	O
free	O
region	O
encompassing	O
both	O
the	O
promoter	O
/	O
enhancer	O
region	O
and	O
a	O
large	O
region	O
(	O
255	O
nucleotides	O
[	O
nt	O
]	O
)	O
downstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O
We	O
have	O
previously	O
identified	O
new	O
binding	O
sites	O
for	O
transcription	B
factors	I
downstream	O
of	O
the	O
transcription	O
start	O
site	O
(	O
nt	O
465	O
to	O
720	O
)	O
:	O
three	O
AP-1	O
sites	O
(	O
I	O
,	O
II	O
,	O
and	O
III	O
)	O
,	O
an	O
AP3-like	O
motif	O
(	O
AP3-L	O
)	O
,	O
a	O
downstream	O
binding	O
factor	O
(	O
DBF	O
)	O
site	O
,	O
and	O
juxtaposed	O
Sp1	O
sites	O
.	O
Here	O
,	O
we	O
show	O
that	O
the	O
DBF	O
site	O
is	O
an	O
interferon	O
-	O
responsive	O
factor	O
(	O
IRF	O
)	O
binding	O
site	O
and	O
that	O
the	O
AP3-L	O
motif	O
binds	O
the	O
T	B
-	I
cell	I
-	I
specific	I
factor	I
NF	B
-	I
AT	I
.	O
Mutations	O
that	O
abolish	O
the	O
binding	O
of	O
each	O
factor	O
to	O
its	O
cognate	O
site	O
are	O
introduced	O
in	O
an	O
infectious	O
HIV-1	O
molecular	O
clone	O
to	O
study	O
their	O
effect	O
on	O
HIV-1	O
transcription	O
and	O
replication	O
.	O
Individual	O
mutation	O
of	O
the	O
DBF	O
or	O
AP3-L	O
site	O
as	O
well	O
as	O
the	O
double	O
mutation	O
AP-1	O
(	O
III	O
)	O
/AP3-L	O
did	O
not	O
affect	O
HIV-1	O
replication	O
compared	O
to	O
that	O
of	O
the	O
wild	O
-	O
type	O
virus	O
.	O
In	O
contrast	O
,	O
proviruses	O
carrying	O
mutations	O
in	O
the	O
Sp1	O
sites	O
were	O
totally	O
defective	O
in	O
terms	O
of	O
replication	O
.	O
Virus	O
production	O
occurred	O
with	O
slightly	O
delayed	O
kinetics	O
for	O
viruses	O
containing	O
combined	O
mutations	O
in	O
the	O
AP-1	O
(	O
III	O
)	O
,	O
AP3-L	O
,	O
and	O
DBF	O
sites	O
and	O
in	O
the	O
AP3-L	O
and	O
DBF	O
-	O
sites	O
,	O
whereas	O
viruses	O
mutated	O
in	O
the	O
AP-1	O
(	O
I	O
,	O
II	O
,	O
III	O
)	O
and	O
AP3-L	O
sites	O
and	O
in	O
the	O
AP-1	O
(	O
I	O
,	O
II	O
,	O
III	O
)	O
,	O
AP3-L	O
,	O
and	O
DBF	O
sites	O
exhibited	O
a	O
severely	O
defective	O
replicative	O
phenotype	O
.	O
No	O
RNA	O
-	O
packaging	O
defect	O
could	O
be	O
measured	O
for	O
any	O
of	O
the	O
mutant	O
viruses	O
as	O
determined	O
by	O
quantification	O
of	O
their	O
HIV	O
genomic	O
RNA	O
.	O
Measurement	O
of	O
the	O
transcriptional	O
activity	O
of	O
the	O
HIV-1	O
promoter	O
after	O
transient	O
transfection	O
of	O
the	O
HIV-1	O
provirus	O
DNA	O
or	O
of	O
long	O
terminal	O
repeat	O
-	O
luciferase	O
constructs	O
showed	O
a	O
positive	O
correlation	O
between	O
the	O
transcriptional	O
and	O
the	O
replication	O
defects	O
for	O
most	O
mutants	O
.	O
The	O
role	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
in	O
cytokine	O
gene	O
regulation	O
.	O
Transcription	B
factors	I
are	O
DNA	B
-	I
binding	I
proteins	I
that	O
regulate	O
gene	O
expression	O
.	O
Nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
is	O
a	O
critical	O
transcription	B
factor	I
for	O
maximal	O
expression	O
of	O
many	O
cytokines	B
that	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
diseases	O
,	O
such	O
as	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
sepsis	O
syndrome	O
.	O
Activation	O
and	O
regulation	O
of	O
NF	B
-	I
kappa	I
B	I
are	O
tightly	O
controlled	O
by	O
a	O
group	O
of	O
inhibitory	B
proteins	I
(	O
I	B
kappa	I
B	I
)	O
that	O
sequester	O
NF	B
-	I
kappa	I
B	I
in	O
the	O
cytoplasm	O
of	O
immune	O
/	O
inflammatory	O
effector	O
cells	O
.	O
NF	B
-	I
kappa	I
B	I
activation	O
involves	O
signaled	O
phosphorylation	O
,	O
ubiquitination	O
,	O
and	O
proteolysis	O
of	O
I	B
kappa	I
B	I
.	O
Liberated	O
NF	B
-	I
kappa	I
B	I
migrates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
binds	O
to	O
specific	O
promoter	O
sites	O
and	O
activates	O
gene	O
transcription	O
.	O
The	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
initiates	O
both	O
extracellular	O
and	O
intracellular	O
regulatory	O
events	O
that	O
result	O
in	O
autoregulation	O
of	O
the	O
inflammatory	O
cascade	O
through	O
modulation	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
Recently	O
,	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
has	O
been	O
linked	O
to	O
ARDS	O
and	O
has	O
been	O
shown	O
to	O
be	O
a	O
critical	O
proximal	O
step	O
in	O
the	O
initiation	O
of	O
neutrophilic	O
inflammation	O
in	O
animal	O
models	O
.	O
Activation	O
of	O
NF	B
-	I
kappa	I
B	I
can	O
be	O
inhibited	O
in	O
vivo	O
by	O
treatment	O
with	O
antioxidants	O
,	O
corticosteroids	O
,	O
and	O
the	O
induction	O
of	O
endotoxin	B
tolerance	O
.	O
Identification	O
of	O
more	O
specific	O
and	O
efficacious	O
inhibitors	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
might	O
prove	O
beneficial	O
for	O
the	O
treatment	O
of	O
cytokine	O
-	O
mediated	O
inflammatory	O
diseases	O
.	O
Pancreatic	O
islet	O
expression	O
studies	O
and	O
polymorphic	O
DNA	O
markers	O
in	O
the	O
genes	O
encoding	O
hepatocyte	B
nuclear	I
factor-3alpha	I
,	I
-3beta	I
,	I
-3gamma	I
,	I
-4gamma	I
,	I
and	I
-6	I
.	O
The	O
genes	O
encoding	O
the	O
functionally	O
related	O
hepatocyte	B
nuclear	I
factors	I
HNF-1alpha	B
and	O
HNF-4alpha	B
play	O
a	O
critical	O
role	O
in	O
normal	O
pancreatic	O
beta	O
-	O
cell	O
function	O
.	O
Mutations	O
in	O
these	O
liver	B
-	I
enriched	I
transcription	I
factors	I
result	O
in	O
two	O
forms	O
of	O
early	O
-	O
onset	O
type	O
2	O
diabetes	O
(	O
maturity	O
-	O
onset	O
diabetes	O
of	O
the	O
young	O
[	O
MODY	O
]	O
)	O
,	O
MODY3	O
and	O
MODY1	O
,	O
which	O
are	O
characterized	O
by	O
impaired	O
glucose	O
-	O
stimulated	O
insulin	O
secretion	O
,	O
early	O
disease	O
onset	O
,	O
and	O
autosomal	O
dominant	O
inheritance	O
.	O
The	O
transcriptional	O
hierarchy	O
of	O
HNFs	O
suggests	O
that	O
other	O
proteins	O
of	O
the	O
regulatory	O
cascade	O
might	O
be	O
responsible	O
for	O
other	O
forms	O
of	O
MODY	O
and/or	O
late	O
-	O
onset	O
type	O
2	O
diabetes	O
.	O
In	O
this	O
study	O
,	O
we	O
show	O
that	O
HNF-3alpha	B
,	I
-3beta	I
,	I
-3gamma	I
,	I
-4gamma	I
,	I
and	I
-6	I
are	O
expressed	O
in	O
pancreatic	O
beta	O
-	O
cells	O
.	O
We	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
simple	O
tandem	O
repeat	O
DNA	O
polymorphisms	O
in	O
the	O
genes	O
encoding	O
HNF-3alpha	B
,	O
-3beta	B
,	O
-3gamma	B
,	O
-4gamma	B
,	O
and	O
-6	B
and	O
the	O
mapping	O
of	O
HNF-6	B
to	O
chromosome	O
bands	O
15q21.1	O
-	O
21.2	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O
These	O
markers	O
will	O
be	O
useful	O
to	O
study	O
the	O
role	O
of	O
genetic	O
variation	O
in	O
these	O
genes	O
in	O
the	O
pathogenesis	O
of	O
type	O
2	O
diabetes	O
.	O
RP1	O
,	O
a	O
new	O
member	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
-	O
binding	O
EB1-like	O
gene	O
family	O
,	O
is	O
differentially	O
expressed	O
in	O
activated	O
T	O
cells	O
.	O
Cross	O
-	O
linking	O
of	O
the	O
CD3	B
and	I
CD28	I
molecules	I
on	O
T	O
lymphocytes	O
represents	O
one	O
of	O
the	O
most	O
effective	O
signals	O
for	O
T	O
lymphocyte	O
activation	O
and	O
triggering	O
of	O
their	O
cytotoxic	O
effector	O
function	O
.	O
To	O
identify	O
genes	O
that	O
are	O
expressed	O
in	O
T	O
cells	O
after	O
stimulation	O
,	O
mRNA	O
from	O
T	O
lymphocytes	O
that	O
had	O
been	O
activated	O
by	O
the	O
simultaneous	O
stimulation	O
of	O
the	O
CD3	B
and	O
CD28	B
trigger	O
molecules	O
was	O
transcribed	O
for	O
a	O
differential	O
mRNA	O
display	O
analysis	O
into	O
cDNA	O
and	O
was	O
compared	O
with	O
cDNA	O
from	O
CD28	B
-or	O
CD3	B
-activated	O
or	O
resting	O
lymphocytes	O
.	O
Differential	O
expression	O
was	O
confirmed	O
subsequently	O
by	O
Northern	O
blot	O
analysis	O
.	O
One	O
of	O
the	O
cDNA	O
fragments	O
expressed	O
specifically	O
in	O
CD3	B
-and	O
CD28	B
-activated	O
T	O
cells	O
was	O
designated	O
RP1	O
.	O
The	O
predictive	O
protein	O
-	O
coding	O
region	O
of	O
RP1	O
had	O
a	O
significant	O
homology	O
to	O
members	O
of	O
the	O
recently	O
found	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
protein	O
-	O
binding	O
EB1	O
gene	O
family	O
,	O
which	O
codes	O
for	O
yet	O
unknown	O
protein	O
(	O
s	O
)	O
.	O
Bacterially	O
expressed	O
RP1	B
protein	I
revealed	O
specific	O
binding	O
to	O
wild	B
-	I
type	I
but	O
not	O
to	O
mutated	B
APC	I
protein	I
.	O
The	O
rapid	O
up	O
-	O
regulation	O
of	O
RP1	O
mRNA	O
in	O
properly	O
activated	O
T	O
cells	O
suggests	O
that	O
this	O
gene	O
might	O
belong	O
to	O
the	O
immediate	O
/	O
early	O
gene	O
family	O
,	O
which	O
controls	O
the	O
signal	O
transduction	O
cascade	O
downstream	O
of	O
the	O
TCR	B
.	O
As	O
the	O
expression	O
level	O
of	O
the	O
RP1	O
gene	O
in	O
activated	O
T	O
cells	O
and	O
a	O
spectrum	O
of	O
tumor	O
-	O
derived	O
cell	O
lines	O
correlates	O
with	O
the	O
proliferative	O
status	O
of	O
the	O
cells	O
,	O
members	O
of	O
the	O
EB1-like	O
gene	O
family	O
may	O
not	O
only	O
be	O
involved	O
in	O
the	O
tumorigenesis	O
of	O
colorectal	O
cancers	O
but	O
may	O
also	O
play	O
a	O
role	O
in	O
the	O
proliferative	O
control	O
of	O
normal	O
cells	O
.	O
Involvement	O
of	O
Rel	B
,	I
Fos	I
,	I
and	I
Jun	I
proteins	I
in	O
binding	O
activity	O
to	O
the	O
IL-2	O
promoter	O
CD28	O
response	O
element	O
/	O
AP-1	O
sequence	O
in	O
human	O
T	O
cells	O
.	O
CD28	B
is	O
an	O
important	O
costimulatory	B
molecule	I
in	O
the	O
activation	O
of	O
human	O
T	O
cells	O
.	O
Costimulation	O
of	O
T	O
cells	O
through	O
both	O
the	O
Ag	O
receptor	O
and	O
CD28	B
leads	O
to	O
high	O
level	O
IL-2	B
production	O
,	O
which	O
is	O
vital	O
to	O
the	O
development	O
of	O
an	O
immune	O
response	O
in	O
vivo	O
.	O
Previous	O
reports	O
have	O
suggested	O
the	O
CD28	B
stimulation	O
contributes	O
to	O
the	O
activation	O
of	O
the	O
IL-2	O
promoter	O
by	O
up	O
-	O
regulating	O
the	O
activity	O
of	O
several	O
transcription	B
factors	I
,	O
including	O
AP-1	B
and	O
nuclear	B
factor	I
-	I
kappaB	I
(	I
NF	I
-	I
kappaB	I
)	I
/Rel	I
family	I
members	I
as	O
well	O
as	O
an	O
uncharacterized	B
transcription	I
factor	I
called	O
CD28	B
response	O
complex	O
.	O
While	O
several	O
lines	O
of	O
investigation	O
have	O
suggested	O
that	O
NF	B
-	I
kappaB	I
/	I
Rel	I
family	I
members	I
make	O
up	O
the	O
CD28	B
response	O
complex	O
transcription	B
factor	I
,	O
other	O
work	O
has	O
not	O
supported	O
this	O
conclusion	O
.	O
Recent	O
studies	O
suggest	O
that	O
the	O
CD28	O
response	O
element	O
(	O
CD28RE	O
)	O
does	O
not	O
function	O
independently	O
but	O
works	O
instead	O
in	O
conjunction	O
with	O
the	O
adjacent	O
promoter	O
proximal	O
AP-1-binding	O
site	O
and	O
this	O
hypothesis	O
is	O
confirmed	O
here	O
.	O
Also	O
in	O
the	O
current	O
study	O
,	O
binding	O
activity	O
to	O
the	O
CD28RE	O
/	O
AP-1	O
sequence	O
of	O
the	O
IL-2	O
promoter	O
is	O
evaluated	O
.	O
Although	O
four	O
specific	O
complexes	O
can	O
be	O
detected	O
binding	O
to	O
this	O
sequence	O
,	O
only	O
one	O
of	O
these	O
complexes	O
is	O
specific	O
for	O
both	O
the	O
CD28RE	O
and	O
the	O
adjacent	O
AP-1	O
site	O
.	O
Of	O
the	O
NF	B
-	I
kappaB	I
/	I
Rel	I
family	I
members	I
tested	O
,	O
this	O
CD28RE	B
/	I
AP-1-specific	I
complex	I
contains	O
predominantly	O
c	B
-	I
Rel	I
,	O
despite	O
the	O
fact	O
that	O
both	O
p50	B
and	O
RelA	B
can	O
efficiently	O
bind	O
to	O
the	O
CD28RE	O
.	O
c	B
-	I
Fos	I
and	O
c	B
-	I
Jun	I
are	O
also	O
found	O
in	O
this	O
CD28RE	B
/	I
AP-1-specific	I
complex	I
.	O
These	O
data	O
indicate	O
that	O
functional	O
complexes	O
encompassing	O
both	O
the	O
CD28RE	O
and	O
the	O
AP-1-binding	O
sites	O
influence	O
IL-2	O
promoter	O
activity	O
in	O
CD28	B
-costimulated	O
T	O
cells	O
.	O
A	O
conserved	O
tissue	O
-	O
specific	O
structure	O
at	O
a	O
human	O
T	O
-	O
cell	O
receptor	O
beta	O
-	O
chain	O
core	O
promoter	O
.	O
The	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
beta	O
-	O
chain	O
promoters	O
have	O
been	O
characterized	O
as	O
nonstructured	O
basal	O
promoters	O
that	O
carry	O
a	O
single	O
conserved	O
ubiquitous	O
cyclic	O
AMP	O
-	O
responsive	O
element	O
.	O
Our	O
investigation	O
of	O
the	O
human	O
TCR	O
beta	O
gene	O
uncovers	O
a	O
surprisingly	O
complex	O
and	O
tissue	O
-	O
specific	O
structure	O
at	O
the	O
TCR	O
Vbeta	O
8.1	O
promoter	O
.	O
The	O
core	O
of	O
the	O
promoter	O
(	O
positions	O
-42	O
to	O
+	O
11	O
)	O
is	O
recognized	O
by	O
the	O
lymphoid	B
cell	I
-	I
specific	I
transcription	I
factors	I
Ets-1	B
,	O
LEF1	B
,	O
and	O
AML1	B
as	O
well	O
as	O
by	O
CREB	B
/	I
ATF-1	I
,	O
as	O
is	O
demonstrated	O
in	O
gel	O
shift	O
and	O
footprinting	O
experiments	O
.	O
With	O
the	O
exception	O
of	O
LEF1	B
,	O
these	O
factors	O
activate	O
transcription	O
in	O
T	O
cells	O
.	O
Binding	O
sites	O
at	O
the	O
core	O
region	O
show	O
little	O
conservation	O
with	O
consensus	O
sites	O
.	O
Nonetheless	O
,	O
CREB	B
,	O
Ets-1	B
,	O
and	O
AML1	B
bind	O
and	O
activate	O
cooperatively	O
and	O
very	O
efficiently	O
through	O
the	O
nonconsensus	O
binding	O
sites	O
at	O
the	O
core	O
promoter	O
region	O
.	O
Moderate	O
ubiquitous	O
activation	O
is	O
further	O
induced	O
by	O
CREB	B
/	I
ATF	I
and	I
Sp1	I
factors	I
through	O
proximal	O
upstream	O
elements	O
.	O
The	O
tissue	O
-	O
specific	O
core	O
promoter	O
structure	O
is	O
apparently	O
conserved	O
in	O
other	O
T	O
-	O
cell	O
-	O
specifically	O
expressed	O
genes	O
such	O
as	O
the	O
CD4	O
gene	O
.	O
Our	O
observations	O
suggest	O
that	O
both	O
the	O
enhancer	O
and	O
the	O
promoter	O
have	O
a	O
complex	O
tissue	O
-	O
specific	O
structure	O
whose	O
functional	O
interplay	O
potentiates	O
T	O
-	O
cell	O
-	O
specific	O
transcription	O
.	O
GABP	B
factors	I
bind	O
to	O
a	O
distal	O
interleukin	O
2	O
(	O
IL-2	O
)	O
enhancer	O
and	O
contribute	O
to	O
c	B
-	I
Raf	I
-mediated	O
increase	O
in	O
IL-2	B
induction	O
.	O
Triggering	O
of	O
the	O
T	B
-	I
cell	I
receptor	I
-	I
CD3	I
complex	I
activates	O
two	O
major	O
signal	O
cascades	O
in	O
T	O
lymphocytes	O
,	O
(	O
i	O
)	O
Ca2	O
+	O
-dependent	O
signal	O
cascades	O
and	O
(	O
ii	O
)	O
protein	B
kinase	I
cascades	O
.	O
Both	O
signal	O
cascades	O
contribute	O
to	O
the	O
induction	O
of	O
the	O
interleukin	O
2	O
(	O
IL-2	O
)	O
gene	O
during	O
T	O
-	O
cell	O
activation	O
.	O
Prominent	O
protein	B
kinase	I
cascades	O
are	O
those	O
that	O
activate	O
mitogen	B
-	I
activated	I
protein	I
(	I
MAP	I
)	I
kinases	I
.	O
We	O
show	O
here	O
that	O
c	B
-	I
Raf	I
,	O
which	O
is	O
at	O
the	O
helm	O
of	O
the	O
classic	O
MAP-	O
Erk	B
cascade	O
,	O
contributes	O
to	O
IL-2	B
induction	O
through	O
a	O
distal	O
enhancer	O
element	O
spanning	O
the	O
nucleotides	O
from	O
positions	O
-502	O
to	O
-413	O
in	O
front	O
of	O
the	O
transcriptional	O
start	O
site	O
of	O
the	O
IL-2	O
gene	O
.	O
Induction	O
of	O
this	O
distal	O
IL-2	O
enhancer	O
differs	O
from	O
induction	O
of	O
the	O
proximal	O
IL-2	O
promoter	O
-	O
enhancer	O
,	O
since	O
it	O
is	O
induced	O
by	O
phorbol	O
esters	O
alone	O
and	O
independent	O
from	O
Ca2	O
+	O
signals	O
.	O
In	O
DNA	O
-	O
protein	O
binding	O
studies	O
,	O
we	O
detected	O
the	O
binding	O
of	O
transcription	B
factors	I
GABP	B
alpha	I
and	I
-beta	I
to	O
a	O
dyad	O
symmetry	O
element	O
(	O
DSE	O
)	O
of	O
the	O
distal	O
enhancer	O
,	O
which	O
is	O
formed	O
by	O
palindromic	O
binding	O
sites	O
of	O
Ets	B
-	I
like	I
factors	I
.	O
Introduction	O
of	O
point	O
mutations	O
suppressing	O
GABP	O
binding	O
to	O
the	O
DSE	O
interfered	O
with	O
the	O
induction	O
of	O
the	O
distal	O
enhancer	O
and	O
the	O
entire	O
IL-2	O
promoter	O
-	O
enhancer	O
,	O
while	O
overexpression	O
of	O
both	O
GABP	B
factors	I
enhanced	O
the	O
IL-2	O
promoter	O
-	O
enhancer	O
induction	O
.	O
Overexpression	O
of	O
BXB	B
,	O
a	O
constitutive	O
active	O
version	O
of	O
c	B
-	I
Raf	I
,	O
and	O
of	O
further	O
members	O
of	O
the	O
Ras	B
-	O
Raf	B
-	O
Erk	B
signal	O
cascade	O
exerted	O
an	O
increase	O
of	O
GABP	B
-mediated	O
promoter	O
-	O
enhancer	O
induction	O
.	O
In	O
conjunction	O
with	O
previously	O
published	O
data	O
on	O
c	B
-	I
Raf	I
-induced	O
phosphorylation	O
of	O
GABP	B
factors	I
(	O
E.Flory	O
,	O
A.	O
Hoffmeyer	O
,	O
U.Smola	O
,	O
U.R.Rapp	O
,	O
and	O
J.T.Bruder	O
,	O
J.Virol.70	O
:	O
2260-	O
2268	O
,	O
1996	O
)	O
,	O
these	O
results	O
indicate	O
a	O
contribution	O
of	O
GABP	B
factors	I
to	O
the	O
Raf	B
-mediated	O
enhancement	O
of	O
IL-2	B
induction	O
during	O
T	O
-	O
cell	O
activation	O
.	O
The	O
product	O
of	O
the	O
murine	O
homolog	O
of	O
the	O
Drosophila	O
extra	O
sex	O
combs	O
gene	O
displays	O
transcriptional	B
repressor	I
activity	O
.	O
The	O
heterogeneous	B
nuclear	I
ribonucleoprotein	I
K	I
protein	I
represents	O
a	O
novel	O
class	O
of	O
proteins	O
that	O
may	O
act	O
as	O
docking	O
platforms	O
that	O
orchestrate	O
cross	O
-	O
talk	O
among	O
molecules	O
involved	O
in	O
signal	O
transduction	O
and	O
gene	O
expression	O
.	O
Using	O
a	O
fragment	O
of	O
K	B
protein	I
as	O
bait	O
in	O
the	O
yeast	O
two	O
-	O
hybrid	O
screen	O
,	O
we	O
isolated	O
a	O
cDNA	O
that	O
encodes	O
a	O
protein	O
whose	O
primary	O
structure	O
has	O
extensive	O
similarity	O
to	O
the	O
Drosophila	B
melanogaster	I
extra	I
sex	I
combs	I
(	I
esc	I
)	I
gene	I
product	I
,	O
Esc	B
,	O
a	O
putative	O
silencer	O
of	O
homeotic	O
genes	O
.	O
The	O
cDNA	O
that	O
we	O
isolated	O
is	O
identical	O
to	O
the	O
cDNA	O
of	O
the	O
recently	O
positionally	O
cloned	O
mouse	O
embryonic	O
ectoderm	O
development	O
gene	O
,	O
eed	O
.	O
Like	O
Esc	B
,	O
Eed	B
contains	O
six	O
WD-40	B
repeats	I
in	O
the	O
C	B
-	I
terminal	I
half	I
of	O
the	O
protein	O
and	O
is	O
thought	O
to	O
repress	O
homeotic	O
gene	O
expression	O
during	O
mouse	O
embryogenesis	O
.	O
Eed	B
binds	O
to	O
K	B
protein	I
through	O
a	O
domain	O
in	O
its	O
N	B
terminus	I
,	O
but	O
interestingly	O
,	O
this	O
domain	O
is	O
not	O
found	O
in	O
the	O
Drosophila	O
Esc	B
.	O
Gal4-Eed	B
fusion	I
protein	I
represses	O
transcription	O
of	O
a	O
reporter	O
gene	O
driven	O
by	O
a	O
promoter	O
that	O
contains	O
Gal4-binding	O
DNA	O
elements	O
.	O
Eed	B
also	O
represses	O
transcription	O
when	O
recruited	O
to	O
a	O
target	O
promoter	O
by	O
Gal4-K	B
protein	I
.	O
Point	O
mutations	O
within	O
the	O
eed	O
gene	O
that	O
are	O
responsible	O
for	O
severe	O
embryonic	O
development	O
abnormalities	O
abolished	O
the	O
transcriptional	B
repressor	I
activity	O
of	O
Eed	B
.	O
Results	O
of	O
this	O
study	O
suggest	O
that	O
Eed	B
-restricted	O
homeotic	O
gene	O
expression	O
during	O
embryogenesis	O
reflects	O
the	O
action	O
of	O
Eed	B
as	O
a	O
transcriptional	B
repressor	I
.	O
The	O
Eed	B
-mediated	O
transcriptional	O
effects	O
are	O
likely	O
to	O
reflect	O
the	O
interaction	O
of	O
Eed	B
with	O
multiple	O
molecular	O
partners	O
,	O
including	O
K	B
protein	I
.	O
Induction	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
in	O
monocytic	O
cells	O
by	O
Cryptococcus	O
neoformans	O
and	O
Candida	O
albicans	O
.	O
Because	O
candidiasis	O
and	O
cryptococcosis	O
are	O
common	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-infected	O
persons	O
,	O
the	O
effect	O
of	O
Cryptococcus	O
neoformans	O
and	O
Candida	O
albicans	O
on	O
HIV	O
expression	O
in	O
monocytic	O
cells	O
was	O
examined	O
.	O
Stimulation	O
of	O
the	O
latently	O
HIV	O
-	O
infected	O
myelomonocytic	O
cell	O
line	O
OM-10.1	O
with	O
C.	O
neoformans	O
and	O
C.	O
albicans	O
in	O
the	O
presence	O
of	O
pooled	O
human	O
serum	O
caused	O
a	O
ratio	O
-	O
dependent	O
increase	O
in	O
HIV	O
production	O
.	O
Induction	O
of	O
HIV	O
by	O
C.	O
neoformans	O
was	O
enhanced	O
by	O
anti	B
-	I
capsular	I
antibody	I
,	O
while	O
induction	O
by	O
both	O
organisms	O
was	O
inhibited	O
by	O
anti	B
-	I
TNF	I
-	I
alpha	I
antibody	I
.	O
In	O
THP-1	O
cells	O
transfected	O
with	O
HIV	O
plasmid	O
constructs	O
,	O
both	O
organisms	O
induced	O
transcription	O
from	O
the	O
HIV	O
long	O
terminal	O
repeat	O
that	O
was	O
dependent	O
on	O
intact	O
NF	O
-	O
kappaB	O
binding	O
sequences	O
.	O
Thus	O
,	O
C.	O
neoformans	O
and	O
C.	O
albicans	O
enhance	O
HIV	O
expression	O
in	O
monocytic	O
cells	O
through	O
a	O
TNF	O
-	O
alpha-	O
and	O
NF	O
-	O
kappaB	O
-	O
dependent	O
mechanism	O
.	O
In	O
HIV	O
-	O
infected	O
patients	O
,	O
such	O
enhancement	O
may	O
further	O
impair	O
host	O
immunity	O
and	O
could	O
accelerate	O
the	O
course	O
of	O
HIV	O
disease	O
.	O
Glucocorticoid	B
receptor	I
regulates	O
expression	O
of	O
L	B
-	I
selectin	I
and	O
CD11	B
/	I
CD18	I
on	O
human	O
neutrophils	O
[	O
see	O
comments	O
]	O
BACKGROUND	O
:	O
Recent	O
studies	O
have	O
raised	O
the	O
hypothesis	O
that	O
glucocorticoids	O
could	O
diminish	O
the	O
ability	O
of	O
endothelial	O
cells	O
to	O
direct	O
leukocyte	O
traffic	O
into	O
inflamed	O
tissues	O
by	O
inhibiting	O
expression	O
of	O
the	O
adhesion	B
molecules	I
endothelial	B
-	I
leukocyte	I
adhesion	I
molecule-1	I
and	O
intercellular	B
adhesion	I
molecule-1	I
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
glucocorticoids	O
also	O
regulate	O
the	O
expression	O
of	O
L	B
-	I
selectin	I
and	O
CD11	B
/	I
CD18	I
integrins	B
on	O
human	O
neutrophil	O
granulocytes	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
Incubation	O
of	O
human	O
whole	O
blood	O
with	O
platelet	B
-	I
activating	I
factor	I
(	O
PAF	B
,	O
1	O
mumol	O
/	O
L	O
)	O
evoked	O
downregulation	O
of	O
L	B
-	I
selectin	I
and	O
upregulation	O
of	O
CD11	B
/	I
CD18	I
adhesion	B
receptors	I
on	O
neutrophils	O
as	O
measured	O
by	O
flow	O
cytometry	O
.	O
While	O
dexamethasone	O
(	O
0.1	O
nmol	O
/	O
L	O
to	O
100	O
mumol	O
/	O
L	O
)	O
did	O
not	O
affect	O
expression	O
of	O
adhesion	B
molecules	I
on	O
resting	O
neutrophils	O
,	O
it	O
attenuated	O
the	O
PAF	B
-induced	O
changes	O
in	O
L	B
-	I
selectin	I
and	O
CD18	B
expression	O
in	O
a	O
time-	O
and	O
concentration	O
-	O
dependent	O
fashion	O
with	O
IC50	O
values	O
of	O
31	O
and	O
13	O
nmol	O
/	O
L	O
,	O
respectively	O
.	O
These	O
effects	O
of	O
dexamethasone	O
were	O
completely	O
aborted	O
by	O
RU-486	O
(	O
10	O
mumol	O
/	O
L	O
)	O
,	O
which	O
blocks	O
transcriptional	O
activation	O
of	O
the	O
glucocorticoid	B
receptor	I
,	O
and	O
by	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
(	O
35.5	O
mumol	O
/	O
L	O
)	O
.	O
Dexamethasone	O
,	O
up	O
to	O
a	O
concentration	O
of	O
1	O
mumol	O
/	O
L	O
,	O
neither	O
affected	O
significantly	O
the	O
release	O
of	O
granule	B
enzymes	I
nor	O
interfered	O
with	O
PAF	B
binding	O
to	O
its	O
membrane	B
receptors	I
.	O
CONCLUSIONS	O
:	O
Our	O
results	O
show	O
that	O
glucocorticoids	O
at	O
clinically	O
relevant	O
concentrations	O
exert	O
specific	O
actions	O
on	O
expression	O
of	O
adhesion	B
molecules	I
on	O
activated	O
neutrophils	O
,	O
which	O
are	O
mediated	O
through	O
ligation	O
of	O
glucocorticoid	B
receptors	I
and	O
induction	O
of	O
protein	O
synthesis	O
,	O
and	O
suggest	O
a	O
novel	O
mechanism	O
by	O
which	O
anti	O
-	O
inflammatory	O
corticosteroids	O
may	O
inhibit	O
leukocyte	O
accumulation	O
.	O
Induction	O
of	O
nuclear	B
factor	I
kappa	I
B	I
/	I
Rel	I
nuclear	O
activity	O
in	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
by	O
anti	B
-	I
HLA	I
class	I
I	I
monoclonal	I
antibodies	I
.	O
Monoclonal	O
antibodies	O
against	O
either	O
monomorphic	O
or	O
polymorphic	O
determinants	O
of	O
class	B
I	I
antigen	I
induced	O
in	O
PBMC	O
and	O
highly	O
purified	O
T	O
lymphocytes	O
the	O
nuclear	O
activity	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
complexes	I
.	O
These	O
included	O
both	O
p50	B
/	I
p50	I
and	O
p50	B
/	I
p65	I
dimers	I
,	O
recognized	O
by	O
specific	B
antibodies	I
in	O
EMSA	O
.	O
The	O
induced	O
complexes	B
were	O
detectable	O
in	O
extracts	O
of	O
cells	O
incubated	O
with	O
anti	B
-	I
class	I
I	I
monoclonal	I
antibody	I
(	O
mAb	B
)	O
for	O
1.5	O
h	O
;	O
the	O
induction	O
was	O
maximal	O
at	O
5	O
h	O
,	O
persistent	O
at	O
16	O
h	O
and	O
no	O
longer	O
observed	O
at	O
40	O
h	O
.	O
The	O
mAb	B
failed	O
to	O
induce	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
nuclear	O
activity	O
in	O
cells	O
incubated	O
in	O
the	O
presence	O
of	O
3	O
,	O
4-dichloroisocoumarin	O
,	O
an	O
inhibitor	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
degradation	O
.	O
Together	O
,	O
these	O
results	O
suggest	O
that	O
class	O
I	O
triggering	O
can	O
induce	O
the	O
activity	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
nuclear	O
activity	O
in	O
peripheral	O
blood	O
T	O
lymphocytes	O
,	O
thereby	O
modulating	O
the	O
expression	O
of	O
genes	O
regulated	O
by	O
these	O
transcription	B
factors	I
.	O
Cyclosporin	O
A	O
interferes	O
with	O
the	O
inducible	O
degradation	O
of	O
NF	B
-	I
kappa	I
B	I
inhibitors	O
,	O
but	O
not	O
with	O
the	O
processing	O
of	O
p105	O
/	O
NF	B
-	I
kappa	I
B1	I
in	O
T	O
cells	O
.	O
The	O
transcription	B
factor	I
NF	B
-	I
kappa	I
B	I
controls	O
the	O
induction	O
of	O
numerous	O
cytokine	O
promoters	O
during	O
the	O
activation	O
of	O
T	O
lymphocytes	O
.	O
Inhibition	O
of	O
T	O
cell	O
activation	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
exerts	O
a	O
suppressive	O
effect	O
on	O
the	O
induction	O
of	O
these	O
NF	O
-	O
kappa	O
B	O
-	O
controlled	O
cytokine	O
promoters	O
.	O
We	O
show	O
for	O
human	O
Jurkat	O
T	O
leukemia	O
cells	O
,	O
as	O
well	O
as	O
human	O
and	O
mouse	O
primary	O
T	O
lymphocytes	O
,	O
that	O
this	O
inhibitory	O
effect	O
is	O
accompanied	O
by	O
an	O
impaired	O
nuclear	O
translocation	O
of	O
the	O
Rel	B
proteins	I
c	B
-	I
Rel	I
,	O
RelA	B
/	I
p65	I
and	O
NF	B
-	I
kappa	I
B1	I
/	I
p50	I
,	O
whereas	O
the	O
nuclear	O
appearance	O
of	O
RelB	B
remains	O
unaffected	O
.	O
CsA	O
does	O
not	O
interfere	O
with	O
the	O
synthesis	O
of	O
Rel	B
proteins	I
,	O
but	O
prevents	O
the	O
inducible	O
degradation	O
of	O
cytosolic	B
NF	I
-	I
kappa	I
B	I
inhibitors	I
I	B
kappa	I
B	I
alpha	I
and	O
I	B
kappa	I
B	I
beta	I
upon	O
T	O
cell	O
activation	O
.	O
CsA	O
neither	O
inhibits	O
the	O
processing	O
of	O
the	O
NF	B
-	I
kappa	I
B1	I
precursor	I
p105	B
to	O
p50	B
,	O
nor	O
does	O
it	O
`	O
`	O
stabilize	O
''	O
the	O
C	O
-	O
terminal	O
portion	O
of	O
p105	B
,	O
I	B
kappa	I
B	I
gamma	I
,	O
which	O
is	O
degraded	O
during	O
p105	B
processing	O
to	O
mature	B
p50	I
.	O
These	O
results	O
indicate	O
that	O
CsA	O
interferes	O
with	O
a	O
specific	O
event	O
in	O
the	O
signal	O
-	O
induced	O
degradation	O
of	O
I	B
kappa	I
B	I
alpha	I
and	O
I	B
kappa	I
B	I
beta	I
,	O
but	O
does	O
not	O
affect	O
the	O
processing	O
of	O
NF	B
-	I
kappa	I
B1	I
/	I
p105	I
to	O
p50	B
.	O
EBF	B
and	O
E47	B
collaborate	O
to	O
induce	O
expression	O
of	O
the	O
endogenous	O
immunoglobulin	O
surrogate	O
light	O
chain	O
genes	O
.	O
Early	B
B	I
cell	I
factor	I
(	O
EBF	B
)	O
and	O
E47	B
participate	O
in	O
the	O
transcriptional	O
control	O
of	O
early	O
B	O
lymphocyte	O
differentiation	O
.	O
With	O
the	O
aim	O
of	O
identifying	O
genetic	O
targets	O
for	O
these	O
transcription	O
factors	O
,	O
we	O
stably	O
transfected	O
cDNAs	O
encoding	O
EBF	B
or	O
a	O
covalent	O
homodimer	O
of	O
E47	B
,	O
individually	O
or	O
together	O
,	O
into	O
immature	O
hematopoietic	O
Ba	O
/	O
F3	O
cells	O
,	O
which	O
lack	O
both	O
factors	O
.	O
In	O
combination	O
,	O
EBF	B
and	O
E47	B
induce	O
efficient	O
expression	O
of	O
the	O
endogenous	O
immunoglobulin	O
surrogate	O
light	O
chain	O
genes	O
,	O
lambda5	O
and	O
VpreB	O
,	O
whereas	O
other	O
pre	O
-	O
B	O
cell	O
-	O
specific	O
genes	O
remain	O
silent	O
.	O
Multiple	O
functionally	O
important	O
EBF	O
and	O
E47	O
binding	O
sites	O
were	O
identified	O
in	O
the	O
lambda5	O
promoter	O
/	O
enhancer	O
region	O
,	O
indicating	O
that	O
lambda5	O
is	O
a	O
direct	O
genetic	O
target	O
for	O
these	O
transcription	B
factors	I
.	O
Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
EBF	B
and	O
E47	B
synergize	O
to	O
activate	O
expression	O
of	O
a	O
subset	O
of	O
genes	O
that	O
define	O
an	O
early	O
stage	O
of	O
the	O
B	O
cell	O
lineage	O
.	O
Nuclear	O
levels	O
of	O
NF	B
-	I
kappaB	I
correlate	O
with	O
syncytium	O
-	O
forming	O
capacity	O
of	O
8e51	O
cells	O
,	O
expressing	O
a	O
defective	O
HIV	O
virus	O
.	O
The	O
double	O
NF	O
-	O
kappaB	O
site	O
identified	O
in	O
the	O
LTR	O
of	O
the	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
has	O
been	O
demonstrated	O
to	O
be	O
necessary	O
for	O
efficient	O
viral	O
transcription	O
.	O
In	O
this	O
report	O
we	O
present	O
the	O
characterisation	O
of	O
NF	B
-	I
kappaB	I
subunits	I
engaged	O
in	O
complexes	O
binding	O
to	O
the	O
HIV-1	O
NF	O
-	O
kappaB	O
site	O
in	O
human	O
8e51	O
T	O
-	O
cells	O
,	O
that	O
harbour	O
a	O
defective	O
HIV-1	O
.	O
At	O
least	O
four	O
different	O
specific	O
NF	B
-	I
kappaB	I
complexes	I
are	O
present	O
in	O
the	O
nucleus	O
of	O
these	O
cells	O
.	O
With	O
the	O
use	O
of	O
specific	B
antibodies	I
we	O
have	O
determined	O
the	O
composition	O
of	O
each	O
complex	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
The	O
results	O
show	O
the	O
presence	O
of	O
several	O
NF	B
-	I
kappaB	I
family	I
members	I
,	I
with	O
the	O
transactivating	O
RelA	B
being	O
engaged	O
in	O
multiple	O
complexes	O
.	O
The	O
importance	O
of	O
NF	B
-	I
kappaB	I
complexes	I
in	O
viral	O
functions	O
has	O
been	O
established	O
comparing	O
the	O
level	O
of	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
complexes	O
with	O
syncytia	O
-	O
forming	O
activity	O
of	O
8e51	O
cells	O
.	O
In	O
fact	O
,	O
8e51	O
cells	O
that	O
had	O
almost	O
lost	O
their	O
syncytia	O
-	O
forming	O
capacity	O
were	O
found	O
to	O
contain	O
at	O
least	O
10	O
times	O
less	O
active	O
NF	B
-	I
kappaB	I
DNA	I
-	I
binding	I
complex	I
than	O
the	O
actively	O
fusing	O
cells	O
.	O
The	O
correlation	O
is	O
specific	O
as	O
the	O
level	O
of	O
at	O
least	O
three	O
other	O
transcription	B
factors	I
did	O
not	O
change	O
.	O
Synthetic	O
glucocorticoids	O
that	O
dissociate	O
transactivation	O
and	O
AP-1	B
transrepression	O
exhibit	O
antiinflammatory	O
activity	O
in	O
vivo	O
.	O
Some	O
of	O
the	O
most	O
potent	O
antiinflammatory	O
and	O
immunosuppressive	O
agents	O
are	O
synthetic	O
glucocorticoids	O
.	O
However	O
,	O
major	O
side	O
effects	O
severely	O
limit	O
their	O
therapeutic	O
use	O
.	O
The	O
development	O
of	O
improved	O
glucocorticoid	O
-	O
based	O
drugs	O
will	O
require	O
the	O
separation	O
of	O
beneficial	O
from	O
deleterious	O
effects	O
.	O
One	O
possibility	O
toward	O
this	O
goal	O
is	O
to	O
try	O
to	O
dissociate	O
two	O
main	O
activities	O
of	O
glucocorticoids	O
,	O
i.e.	O
transactivation	O
and	O
transrepression	O
.	O
Screening	O
of	O
a	O
library	O
of	O
compounds	O
using	O
transactivation	O
and	O
AP-1	B
transrepression	O
models	O
in	O
transiently	O
transfected	O
cells	O
identified	O
dissociated	O
glucocorticoids	O
,	O
which	O
exert	O
strong	O
AP-1	B
inhibition	O
but	O
little	O
or	O
no	O
transactivation	O
.	O
Importantly	O
,	O
despite	O
high	O
ligand	O
binding	O
affinity	O
,	O
the	O
prototypic	O
dissociated	O
compound	O
,	O
RU24858	O
,	O
acted	O
as	O
a	O
weak	O
agonist	O
and	O
did	O
not	O
efficiently	O
antagonize	O
dexamethasone	O
-	O
induced	O
transcription	O
in	O
transfected	O
cells	O
.	O
Similar	O
results	O
were	O
obtained	O
in	O
hepatic	O
HTC	O
cells	O
for	O
the	O
transactivation	O
of	O
the	O
endogenous	O
tyrosine	O
amino	O
transferase	O
gene	O
(	O
TAT	O
)	O
,	O
which	O
encodes	O
one	O
of	O
the	O
enzymes	O
involved	O
in	O
the	O
glucocorticoid	O
-	O
dependent	O
stimulation	O
of	O
neoglucogenesis	O
.	O
To	O
investigate	O
whether	O
dissociated	O
glucocorticoids	O
retained	O
the	O
antiinflammatory	O
and	O
immunosuppressive	O
potential	O
of	O
classic	O
glucocorticoids	O
,	O
several	O
in	O
vitro	O
and	O
in	O
vivo	O
models	O
were	O
used	O
.	O
Indeed	O
,	O
secretion	O
of	O
the	O
proinflammatory	B
lymphokine	I
interleukin-1beta	I
was	O
severely	O
inhibited	O
by	O
dissociated	O
glucocorticoids	O
in	O
human	O
monocytic	O
THP	O
1	O
cells	O
.	O
Moreover	O
,	O
in	O
two	O
in	O
vivo	O
models	O
,	O
these	O
compounds	O
exerted	O
an	O
antiinflammatory	O
and	O
immunosuppressive	O
activity	O
as	O
potent	O
as	O
that	O
of	O
the	O
classic	O
glucocorticoid	O
prednisolone	O
.	O
These	O
results	O
may	O
lead	O
to	O
an	O
improvement	O
of	O
antiinflammatory	O
and	O
immunosuppressive	O
therapies	O
and	O
provide	O
a	O
novel	O
concept	O
for	O
drug	O
discovery	O
.	O
Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
in	O
vitro	O
by	O
a	O
novel	O
combination	O
of	O
anti	B
-	I
Tat	I
single	I
-	I
chain	I
intrabodies	I
and	O
NF	O
-	O
kappa	O
B	O
antagonists	O
.	O
Human	B
immunodeficiency	I
virus	I
type	I
1	I
(	I
HIV-1	I
)	I
Tat	I
,	O
an	O
early	O
regulatory	B
protein	I
that	O
is	O
critical	O
for	O
viral	O
gene	O
expression	O
and	O
replication	O
,	O
transactivates	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
via	O
its	O
binding	O
to	O
the	O
transactivation	O
response	O
element	O
(	O
TAR	O
)	O
and	O
,	O
along	O
with	O
other	O
cellular	O
factors	O
,	O
increases	O
viral	O
transcription	O
initiation	O
and	O
elongation	O
.	O
Tat	O
also	O
superactivates	O
the	O
HIV-1	O
promoter	O
through	O
a	O
TAR	O
-independent	O
mechanism	O
,	O
including	O
tumor	O
necrosis	O
factor	O
alpha	O
-	O
induced	O
and	O
protein	O
kinase	O
C	O
(	O
PKC	B
)	O
-dependent	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
and	O
inhibitors	O
of	O
Tat	B
and	O
NF	B
-	I
kappa	I
B	I
cooperatively	O
down	O
-	O
regulate	O
this	O
Tat	B
-mediated	O
LTR	O
superactivation	O
.	O
In	O
this	O
study	O
,	O
a	O
combined	O
pharmacologic	O
and	O
genetic	O
strategy	O
using	O
two	O
PKC	B
(	O
NF	B
-	I
kappa	I
B	I
)	O
inhibitors	O
,	O
pentoxifylline	O
(	O
PTX	O
)	O
and	O
Go-6976	O
,	O
and	O
a	O
stably	O
expressed	O
anti	B
-	I
Tat	I
single	I
-	I
chain	I
intracellular	I
antibody	I
(	O
sFv	B
intrabody	I
)	O
was	O
employed	O
to	O
obtain	O
cooperative	O
inhibition	O
of	O
both	O
HIV-1	O
LTR	O
-driven	O
gene	O
expression	O
and	O
HIV-1	O
replication	O
.	O
Treatment	O
of	O
cells	O
with	O
PTX	O
and	O
Go-6976	O
resulted	O
in	O
cooperative	O
inhibition	O
of	O
both	O
HIV-1	O
LTR	O
-driven	O
gene	O
expression	O
and	O
HIV-1	O
replication	O
.	O
In	O
addition	O
,	O
the	O
combined	O
use	O
of	O
anti	B
-	I
Tat	I
sFv	I
intrabodies	I
and	O
the	O
two	O
NF	B
-	I
kappa	I
B	I
inhibitors	O
retained	O
the	O
virus	O
in	O
the	O
latent	O
state	O
for	O
as	O
long	O
as	O
45	O
days	O
.	O
The	O
combined	O
treatment	O
resulted	O
in	O
more	O
durable	O
inhibition	O
of	O
HIV-1	O
replication	O
than	O
was	O
seen	O
with	O
the	O
NF	B
-	I
kappa	I
B	I
inhibitors	O
alone	O
or	O
the	O
anti-	O
Tat	B
sFv	I
intrabodies	I
alone	O
.	O
Together	O
,	O
these	O
results	O
suggest	O
that	O
in	O
future	O
clinical	O
gene	O
therapy	O
trials	O
,	O
a	O
combined	O
pharmacologic	O
and	O
genetic	O
strategy	O
like	O
the	O
one	O
reported	O
here	O
may	O
improve	O
the	O
survival	O
of	O
transduced	O
cells	O
and	O
prolong	O
clinical	O
benefit	O
.	O
Activation	O
domain	O
requirements	O
for	O
disruption	O
of	O
Epstein	O
-	O
Barr	O
virus	O
latency	O
by	O
ZEBRA	B
.	O
Latent	O
infection	O
of	O
B	O
lymphocytes	O
by	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
can	O
be	O
disrupted	O
by	O
expression	O
of	O
the	O
EBV	B
ZEBRA	I
protein	I
.	O
ZEBRA	B
,	O
a	O
transcriptional	O
activator	O
,	O
initiates	O
the	O
EBV	O
lytic	O
cascade	O
by	O
activating	O
viral	O
gene	O
expression	O
.	O
ZEBRA	B
is	O
also	O
indispensable	O
for	O
viral	O
replication	O
and	O
binds	O
directly	O
to	O
the	O
EBV	O
lytic	O
origin	O
of	O
replication	O
.	O
The	O
studies	O
described	O
herein	O
demonstrate	O
that	O
the	O
activation	O
domain	O
.	O
ZEBRA	B
activation	O
can	O
be	O
replaced	O
by	O
a	O
heterologous	B
acidic	I
,	I
proline	I
-	I
rich	I
,	I
or	I
glutamine	I
-	I
rich	I
activation	I
domain	I
.	O
ZEBRA	B
activation	O
domain	O
swap	O
constructs	O
retain	O
ZEBRA	B
's	O
native	O
abilities	O
to	O
activate	O
specific	O
EBV	O
promoters	O
,	O
to	O
disrupt	O
EBV	O
latency	O
,	O
and	O
to	O
stimulate	O
replication	O
at	O
the	O
EBV	O
lytic	O
origin	O
.	O
Additional	O
work	O
,	O
employing	O
sequential	O
and	O
internal	O
deletions	O
of	O
ZEBRA	B
's	O
N	B
-	I
terminal	I
activation	I
domain	I
,	O
indicates	O
that	O
its	O
separate	O
activities	O
are	O
not	O
attributable	O
to	O
specific	O
subdomains	B
but	O
are	O
spread	O
throughout	O
its	O
N	B
terminus	I
and	O
therefore	O
can	O
not	O
be	O
inactivated	O
by	O
deleting	O
localized	O
regions	O
.	O
Critical	O
cytoplasmic	B
domains	I
of	O
human	B
interleukin-9	I
receptor	I
alpha	I
chain	I
in	O
interleukin	B
-9-mediated	O
cell	O
proliferation	O
and	O
signal	O
transduction	O
.	O
Interleukin-9	B
receptor	I
(	I
IL-9R	I
)	I
complex	I
consists	O
of	O
a	O
ligand	B
-	I
specific	I
alpha	I
chain	I
and	O
IL-2R	B
gamma	I
chain	I
.	O
In	O
this	O
study	O
,	O
two	O
regions	O
in	O
the	O
cytoplasmic	B
domain	I
of	O
human	B
IL-9Ralpha	I
were	O
found	O
to	O
be	O
important	O
for	O
IL-9	B
-mediated	O
cell	O
growth	O
.	O
A	O
membrane	B
-	I
proximal	I
region	I
that	O
contains	O
the	O
BOX1	B
consensus	I
sequence	I
is	O
required	O
for	O
IL-9	B
-induced	O
cell	O
proliferation	O
and	O
tyrosine	O
phosphorylation	O
of	O
Janus	B
kinases	I
(	O
JAKs	B
)	O
.	O
Deletion	O
of	O
this	O
region	O
or	O
internal	O
deletion	O
of	O
the	O
BOX1	B
motif	I
abrogated	O
IL-9	B
-induced	O
cell	O
proliferation	O
and	O
signal	O
transduction	O
.	O
However	O
,	O
substitution	O
of	O
the	O
Pro	B
-	I
X	I
-	I
Pro	I
in	O
the	O
BOX1	B
motif	I
with	O
Ala	B
-	I
X	I
-	I
Ala	I
failed	O
to	O
abolish	O
IL-9	B
-induced	O
cell	O
proliferation	O
but	O
decreased	O
IL-9	B
-mediated	O
tyrosine	O
phosphorylation	O
of	O
JAK	B
kinases	I
,	O
insulin	B
receptor	I
substrate-2	I
,	O
and	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
3	I
(	O
STAT3	B
)	O
and	O
expression	O
of	O
c	O
-	O
myc	O
and	O
junB	O
.	O
Another	O
important	O
region	O
is	O
downstream	O
of	O
the	O
BOX1	B
motif	I
and	O
contains	O
a	O
STAT3	O
binding	O
motif	O
YLPQ	O
.	O
Deletion	O
of	O
this	O
region	O
significantly	O
impaired	O
IL-9	B
-induced	O
cell	O
growth	O
,	O
activation	O
of	O
JAK	B
kinases	I
,	O
insulin	B
receptor	I
substrate-2	I
,	O
and	O
STAT3	B
and	O
expression	O
of	O
early	O
response	O
genes	O
.	O
A	O
point	O
mutation	O
changing	O
YLPQ	O
into	O
YLPA	O
greatly	O
reduced	O
IL-9	B
-induced	O
activation	O
of	O
STAT3	B
and	O
expression	O
of	O
c	O
-	O
myc	O
but	O
did	O
not	O
affect	O
cell	O
proliferation	O
.	O
These	O
results	O
suggest	O
that	O
cooperation	O
or	O
cross	O
-	O
talk	O
of	O
signaling	O
molecules	O
associated	O
with	O
different	O
domains	O
of	O
IL-9Ralpha	B
other	O
than	O
STAT3	B
is	O
essential	O
for	O
IL-9	B
-mediated	O
cell	O
growth	O
.	O
Transcription	B
factors	I
in	O
immune	O
-	O
mediated	O
disease	O
.	O
A	O
large	O
amount	O
of	O
detailed	O
information	O
about	O
the	O
intracellular	B
proteins	I
regulating	O
NF	B
-	I
kappa	I
B	I
activation	O
and	O
the	O
cellular	O
response	O
to	O
NF	B
-	I
kappa	I
B	I
activation	O
has	O
emerged	O
recently	O
.	O
Several	O
small	O
molecules	O
,	O
an	O
antisense	O
oligonucleotide	O
,	O
and	O
gene	O
therapeutic	O
agents	O
that	O
inhibit	O
NF	B
-	I
kappa	I
b	I
activation	O
have	O
been	O
described	O
.	O
Despite	O
this	O
,	O
there	O
are	O
still	O
significant	O
gaps	O
in	O
our	O
understanding	O
of	O
this	O
process	O
and	O
its	O
consequences	O
.	O
In	O
contrast	O
,	O
the	O
characterization	O
of	O
transcription	B
factors	I
selectively	O
regulating	O
cytokine	O
production	O
by	O
CD4	O
+	O
T	O
cell	O
subsets	O
is	O
at	O
a	O
very	O
early	O
stage	O
.	O
Three	O
interacting	B
proteins	I
have	O
recently	O
been	O
shown	O
to	O
contribute	O
to	O
subset	O
-	O
restricted	O
expression	O
of	O
the	O
IL-4	O
gene	O
.	O
There	O
are	O
other	O
elements	O
regulating	O
IL-4	O
gene	O
expression	O
,	O
however	O
,	O
and	O
the	O
relative	O
importance	O
of	O
these	O
recently	O
identified	O
proteins	O
has	O
yet	O
to	O
be	O
determined	O
.	O
CholecystokininB	B
receptor	I
from	O
human	O
Jurkat	O
lymphoblastic	O
T	O
cells	O
is	O
involved	O
in	O
activator	B
protein-1	I
-responsive	O
gene	O
activation	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
role	O
of	O
cholecystokinin	B
(	I
CCK	I
(	I
B	I
)	I
)	I
receptor	I
in	O
human	O
lymphoblastic	O
Jurkat	O
T	O
cells	O
.	O
We	O
investigated	O
the	O
trophic	O
effect	O
resulting	O
from	O
activation	O
of	O
such	O
a	O
receptor	O
by	O
using	O
the	O
reporter	O
gene	O
strategy	O
.	O
For	O
this	O
purpose	O
,	O
we	O
transiently	O
transfected	O
Jurkat	O
T	O
cells	O
with	O
the	O
reporter	O
plasmid	O
p	O
[	O
(	O
TRE	O
)	O
3-tk	O
-	O
Luc	O
]	O
and	O
found	O
that	O
CCK-8	O
was	O
able	O
to	O
dose	O
-	O
dependently	O
induce	O
luciferase	B
expression	O
related	O
to	O
activator	B
protein-1	I
(	O
AP-1	B
)	O
activation	O
with	O
a	O
maximal	O
response	O
identical	O
to	O
that	O
obtained	O
with	O
compounds	O
known	O
to	O
activate	O
AP-1	B
complex	I
(	O
quantitatively	O
,	O
the	O
same	O
level	O
of	O
induction	O
was	O
obtained	O
with	O
1	O
nM	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
,	O
100	O
microM	O
diacylglycerol	O
,	O
or	O
4	O
nM	O
epidermal	O
growth	O
factor	O
)	O
.	O
The	O
involvement	O
of	O
the	O
CCK	B
(	I
B	I
)	I
receptor	I
in	O
such	O
a	O
stimulation	O
was	O
demonstrated	O
by	O
the	O
inhibiting	O
effect	O
of	O
the	O
selective	O
CCK	B
(	I
B	I
)	I
receptor	I
antagonist	O
PD-135	O
,	O
158	O
.	O
This	O
effect	O
was	O
confirmed	O
in	O
COS-7	O
cells	O
transfected	O
with	O
the	O
cDNA	O
of	O
CCK	B
(	I
B	I
)	I
receptor	I
cloned	O
from	O
Jurkat	O
T	O
cells	O
.	O
To	O
better	O
understand	O
the	O
AP-1	B
-dependent	O
luciferase	B
expression	O
in	O
Jurkat	O
T	O
cells	O
,	O
we	O
tested	O
two	O
specific	O
inhibitors	O
of	O
serine	B
/	I
threonine	I
phosphatases-1	I
and	I
-2A	I
:	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
.	O
These	O
compounds	O
strongly	O
increased	O
the	O
phorbol-12-myristate-13-acetate	O
response	O
,	O
whereas	O
we	O
have	O
not	O
observed	O
a	O
contribution	O
of	O
phosphatase	O
inhibitors	O
on	O
a	O
CCK-8-induced	O
luciferase	B
activity	O
.	O
To	O
confirm	O
that	O
CCK	B
(	I
B	I
)	I
receptors	I
are	O
involved	O
in	O
AP-1	B
response	O
,	O
we	O
investigated	O
the	O
CCK-8	O
effect	O
on	O
interleukin-2	B
expression	O
,	O
a	O
natural	O
endogenous	O
gene	O
regulated	O
by	O
several	O
factors	O
,	O
including	O
AP-1	B
.	O
In	O
Jurkat	O
T	O
cells	O
activated	O
by	O
phorbol-12-myristate-13-acetate	O
and	O
phytohemagglutinin	B
,	O
CCK-8	O
induced	O
IL-2	O
expression	O
.	O
This	O
induction	O
was	O
abolished	O
by	O
PD-135	O
,	O
158	O
.	O
Our	O
results	O
indicate	O
that	O
CCK-8	O
exerts	O
a	O
trophic	O
effect	O
in	O
Jurkat	O
T	O
cells	O
through	O
stimulation	O
of	O
CCK	B
(	I
B	I
)	I
receptors	I
by	O
modulation	O
of	O
expression	O
of	O
AP-1-regulated	O
genes	O
.	O
Epstein	O
-	O
Barr	O
virus	O
binding	O
to	O
CD21	B
activates	O
the	O
initial	O
viral	O
promoter	O
via	O
NF	B
-	I
kappaB	I
induction	O
.	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
,	O
an	O
oncogenic	O
human	O
herpesvirus	O
,	O
binds	O
to	O
and	O
infects	O
normal	O
human	O
B	O
lymphocytes	O
via	O
CD21	B
,	O
the	O
CR2	B
complement	I
receptor	I
.	O
Studies	O
of	O
the	O
mechanisms	O
that	O
enable	O
EBV	O
to	O
infect	O
nonactivated	O
,	O
noncycling	O
B	O
cells	O
provide	O
compelling	O
evidence	O
for	O
a	O
sequence	O
of	O
events	O
in	O
which	O
EBV	O
binding	O
to	O
CD21	B
on	O
purified	O
resting	O
human	O
B	O
cells	O
rapidly	O
activates	O
the	O
NF	B
-	I
kappaB	I
transcription	B
factor	I
,	O
which	O
,	O
in	O
turn	O
,	O
binds	O
to	O
and	O
mediates	O
transcriptional	O
activation	O
of	O
Wp	O
,	O
the	O
initial	O
viral	O
latent	O
gene	O
promoter	O
.	O
Thus	O
,	O
EBV	O
binding	O
to	O
its	O
cellular	O
receptor	O
on	O
resting	O
B	O
cells	O
triggers	O
an	O
NF	B
-	I
kappaB	I
-dependent	O
intracellular	O
signaling	O
pathway	O
which	O
is	O
required	O
for	O
infection	O
.	O
Human	O
monocyte	O
binding	O
to	O
fibronectin	B
enhances	O
IFN	B
-	I
gamma	I
-induced	O
early	O
signaling	O
events	O
.	O
Leukocyte	B
integrins	I
are	O
fundamentally	O
important	O
in	O
modulating	O
adhesion	O
to	O
extracellular	O
matrix	O
components	O
and	O
to	O
other	O
cells	O
.	O
This	O
integrin	O
-	O
mediated	O
adhesion	O
controls	O
leukocyte	O
arrest	O
and	O
extravasation	O
during	O
the	O
onset	O
of	O
inflammatory	O
responses	O
.	O
Moreover	O
,	O
integrin	B
-ligand	O
interactions	O
trigger	O
signaling	O
pathways	O
that	O
may	O
influence	O
leukocyte	O
phenotype	O
and	O
function	O
at	O
sites	O
of	O
inflammation	O
.	O
In	O
the	O
current	O
studies	O
,	O
we	O
evaluated	O
the	O
combinatorial	O
effects	O
of	O
monocyte	O
adhesion	O
and	O
IFN	B
-	I
gamma	I
on	O
intracellular	O
signaling	O
pathways	O
.	O
IFN	B
-	I
gamma	I
triggers	O
a	O
well	O
-	O
defined	O
signal	O
transduction	O
pathway	O
,	O
which	O
although	O
not	O
directly	O
stimulated	O
by	O
monocyte	O
adherence	O
to	O
fibronectin	B
or	O
arginine	B
-	I
glycine	I
-	I
aspartate	I
(	I
RGD	I
)	I
-coated	I
substrata	I
,	O
was	O
enhanced	O
significantly	O
in	O
these	O
matrix	O
-	O
adherent	O
cells	O
.	O
Compared	O
with	O
monocytes	O
in	O
suspension	O
or	O
adherent	O
on	O
plastic	O
surfaces	O
,	O
monocytes	O
adherent	O
to	O
fibronectin	B
or	O
RGD	O
exhibited	O
a	O
greater	O
than	O
threefold	O
increase	O
in	O
steady	O
state	O
levels	O
of	O
IFN	O
-	O
gamma	O
-	O
induced	O
mRNA	O
for	O
the	O
high	B
affinity	I
Fc	I
gammaRI	I
receptor	I
.	O
By	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
this	O
increase	O
in	O
mRNA	O
was	O
associated	O
with	O
a	O
5-	O
to	O
10-fold	O
increase	O
in	O
the	O
STAT1-containing	B
DNA	I
-	I
binding	I
complex	I
that	O
binds	O
to	O
Fc	O
gammaRI	O
promoter	O
elements	O
.	O
Furthermore	O
,	O
the	O
tyrosine	O
phosphorylation	O
of	O
STAT1	B
and	O
the	O
tyrosine	B
kinases	I
JAK1	B
and	O
JAK2	B
was	O
enhanced	O
significantly	O
in	O
RGD	O
-	O
adherent	O
monocytes	O
compared	O
with	O
control	O
cells	O
.	O
These	O
results	O
suggest	O
a	O
novel	O
mechanism	O
by	O
which	O
integrin	B
-mediated	O
cell	O
adhesion	O
can	O
modulate	O
the	O
magnitude	O
of	O
cytokine	B
-induced	O
signal	O
transduction	O
pathways	O
,	O
thereby	O
amplifying	O
cellular	O
events	O
leading	O
to	O
monocyte	O
activation	O
and	O
inflammation	O
.	O
Surfactant	B
protein	I
A	I
activates	O
NF	B
-	I
kappa	I
B	I
in	O
the	O
THP-1	O
monocytic	O
cell	O
line	O
.	O
The	O
expression	O
of	O
many	O
genes	O
for	O
which	O
products	O
are	O
involved	O
in	O
inflammation	O
is	O
controlled	O
by	O
the	O
transcriptional	B
regulator	I
nuclear	I
factor	I
(	I
NF	I
)	I
-kappa	I
B	I
.	O
Because	O
surfactant	B
protein	I
(	I
SP	I
)	I
A	I
is	O
involved	O
in	O
local	O
host	O
defense	O
in	O
the	O
lung	O
and	O
alters	O
immune	O
cell	O
function	O
by	O
modulating	O
the	O
expression	O
of	O
proinflammatory	B
cytokines	I
as	O
well	O
as	O
surface	B
proteins	I
involved	O
in	O
inflammation	O
,	O
we	O
hypothesized	O
that	O
SP	B
-	I
A	I
exerts	O
its	O
action	O
,	O
at	O
least	O
in	O
part	O
,	O
via	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
We	O
used	O
gel	O
shift	O
assays	O
to	O
determine	O
whether	O
SP	B
-	I
A	I
activated	O
NF	B
-	I
kappa	I
B	I
in	O
the	O
THP-1	O
cell	O
line	O
,	O
a	O
human	O
monocytic	O
cell	O
line	O
.	O
Activation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
THP-1	O
cells	O
by	O
SP	B
-	I
A	I
doses	O
as	O
low	O
as	O
1	O
microgram	O
/	O
ml	O
occurred	O
within	O
30	O
min	O
of	O
SP	B
-	I
A	I
treatment	O
,	O
peaked	O
at	O
60	O
min	O
,	O
and	O
then	O
declined	O
.	O
This	O
activation	O
is	O
inhibited	O
by	O
known	O
inhibitors	O
of	O
NF	B
-	I
kappa	I
B	I
or	O
by	O
simultaneous	O
treatment	O
of	O
the	O
cells	O
with	O
surfactant	O
lipids	O
.	O
Moreover	O
,	O
the	O
NF	B
-	I
kappa	I
B	I
inhibitors	I
blocked	O
SP	B
-	I
A	I
-dependent	O
increases	O
in	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
mRNA	O
levels	O
.	O
These	O
observations	O
suggest	O
a	O
mechanism	O
by	O
which	O
SP	B
-	I
A	I
plays	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
some	O
lung	O
conditions	O
and	O
point	O
to	O
potential	O
therapeutic	O
measures	O
that	O
could	O
be	O
used	O
to	O
prevent	O
SP	B
-	I
A	I
induced	O
inflammation	O
in	O
the	O
lung	O
.	O
Distinct	O
mechanisms	O
for	O
N	O
-	O
acetylcysteine	O
inhibition	O
of	O
cytokine	B
-	I
induced	I
E	I
-	I
selectin	I
and	O
VCAM-1	B
expression	O
.	O
We	O
have	O
examined	O
the	O
effects	O
of	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
,	O
a	O
well	O
-	O
characterized	O
,	O
thiol	O
-	O
containing	O
antioxidant	O
,	O
on	O
agonist	O
-	O
induced	O
monocytic	O
cell	O
adhesion	O
to	O
endothelial	O
cells	O
(	O
EC	O
)	O
.	O
NAC	O
inhibited	O
interleukin-1	B
(	O
IL-1	B
beta	I
)	O
-induced	O
,	O
but	O
not	O
basal	O
,	O
adhesion	O
with	O
50	O
%	O
inhibition	O
at	O
approximately	O
20	O
mM	O
.	O
Monocytic	O
cell	O
adhesion	O
to	O
EC	O
in	O
response	O
to	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
alpha	B
-	I
thrombin	I
,	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
was	O
similarly	O
inhibited	O
by	O
NAC	O
.	O
Unlike	O
published	O
studies	O
with	O
pyrrolidinedithiocarbamate	O
,	O
which	O
specifically	O
inhibited	O
vascular	B
cell	I
adhesion	I
molecule	I
1	I
(	O
VCAM-1	B
)	O
,	O
NAC	O
inhibited	O
IL-1	O
beta	O
-	O
induced	O
mRNA	O
and	O
cell	O
surface	O
expression	O
of	O
both	O
E	B
-	I
selectin	I
and	O
VCAM-1	B
.	O
NAC	O
had	O
no	O
effect	O
on	O
the	O
half	O
-	O
life	O
of	O
E	O
-	O
selectin	O
or	O
VCAM-1	O
mRNA	O
.	O
Although	O
NAC	O
reduced	O
nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
activation	O
in	O
EC	O
as	O
measured	O
by	O
gel	O
-	O
shift	O
assays	O
using	O
an	O
oligonucleotide	O
probe	O
corresponding	O
to	O
the	O
consensus	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
of	O
the	O
VCAM-1	O
gene	O
(	O
VCAM	B
-	I
NF	I
-	I
kappa	I
B	I
)	O
,	O
the	O
antioxidant	O
had	O
no	O
appreciable	O
effect	O
when	O
an	O
oligomer	O
corresponding	O
to	O
the	O
consensus	O
NF	O
-	O
kappa	O
B	O
binding	O
site	O
of	O
the	O
E	O
-	O
selectin	O
gene	O
(	O
E	B
-	I
selectin	I
-NF	B
-	I
kappa	I
B	I
)	O
was	O
used	O
.	O
Because	O
NF	B
-	I
kappa	I
B	I
has	O
been	O
reported	O
to	O
be	O
redox	O
sensitive	O
,	O
we	O
studied	O
the	O
effects	O
of	O
NAC	O
on	O
the	O
EC	O
redox	O
environment	O
.	O
NAC	O
caused	O
an	O
expected	O
dramatic	O
increase	O
in	O
the	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
levels	O
in	O
EC	O
.	O
In	O
vitro	O
studies	O
demonstrated	O
that	O
whereas	O
the	O
binding	O
affinity	O
of	O
NF	B
-	I
kappa	I
B	I
to	O
the	O
VCAM	O
-	O
NF	O
-	O
kappa	O
B	O
oligomer	O
peaked	O
at	O
a	O
GSH	O
-	O
to	O
-	O
oxidized	O
glutathione	O
(	O
GSSG	O
)	O
ratio	O
of	O
approximately	O
200	O
and	O
decreased	O
at	O
higher	O
ratios	O
,	O
the	O
binding	O
to	O
the	O
E	O
-	O
selectin	O
-	O
NF	O
-	O
kappa	O
B	O
oligomer	O
appeared	O
relatively	O
unaffected	O
even	O
at	O
ratios	O
>	O
400	O
,	O
i.e.	O
,	O
those	O
achieved	O
in	O
EC	O
treated	O
with	O
40	O
mM	O
NAC	O
.	O
These	O
results	O
suggest	O
that	O
NF	B
-	I
kappa	I
B	I
binding	O
to	O
its	O
consensus	O
sequences	O
in	O
the	O
VCAM-1	B
and	O
E	O
-	O
selectin	O
gene	O
exhibits	O
marked	O
differences	O
in	O
redox	O
sensitivity	O
,	O
allowing	O
for	O
differential	O
gene	O
expression	O
regulated	O
by	O
the	O
same	O
transcription	O
factor	O
.	O
Our	O
data	O
also	O
demonstrate	O
that	O
NAC	O
increases	O
the	O
GSH	O
-	O
to	O
-	O
GSSG	O
ratio	O
within	O
the	O
EC	O
suggesting	O
one	O
possible	O
mechanism	O
through	O
which	O
this	O
antioxidant	O
inhibits	O
agonist	O
-	O
induced	O
monocyte	O
adhesion	O
to	O
EC	O
.	O
Regulation	O
of	O
inosine-5'-monophosphate	B
dehydrogenase	I
type	I
II	I
gene	O
expression	O
in	O
human	O
T	O
cells	O
.	O
Role	O
for	O
a	O
novel	O
5	O
'	O
palindromic	O
octamer	O
sequence	O
.	O
Expression	O
of	O
the	O
gene	O
encoding	O
human	B
inosine-	I
5'-monophosphate	I
dehydrogenase	I
(	I
IMPDH	I
)	I
type	I
II	I
,	O
an	O
enzyme	B
catalyzing	O
the	O
rate	O
-	O
limiting	O
step	O
in	O
the	O
generation	O
of	O
guanine	O
nucleotides	O
,	O
is	O
increased	O
more	O
than	O
10-fold	O
in	O
activated	O
peripheral	O
blood	O
T	O
lymphocytes	O
and	O
is	O
required	O
for	O
T	O
cell	O
activation	O
.	O
We	O
have	O
examined	O
the	O
5'-regulatory	O
sequences	O
that	O
are	O
important	O
for	O
the	O
transcriptional	O
regulation	O
of	O
this	O
gene	O
in	O
T	O
cells	O
.	O
DNase	B
I	I
mapping	O
of	O
genomic	O
DNA	O
identified	O
a	O
hypersensitive	O
element	O
near	O
the	O
transcription	O
initiation	O
site	O
.	O
Fine	O
mapping	O
by	O
in	O
vivo	O
footprinting	O
demonstrated	O
five	O
transcription	O
factor	O
binding	O
sites	O
that	O
are	O
occupied	O
in	O
both	O
resting	O
and	O
activated	O
peripheral	O
blood	O
T	O
lymphocytes	O
;	O
these	O
are	O
tandem	O
CRE	O
motifs	O
,	O
a	O
Sp1	O
site	O
,	O
an	O
overlapping	O
Egr-1	O
/	O
Sp1	O
site	O
,	O
and	O
a	O
novel	O
palindromic	O
octamer	O
sequence	O
(	O
POS	O
)	O
.	O
The	O
tandem	O
CRE	O
and	O
POS	O
sites	O
are	O
of	O
major	O
functional	O
importance	O
as	O
judged	O
by	O
mutational	O
and	O
electrophoretic	O
mobility	O
shift	O
analyses	O
.	O
These	O
data	O
provide	O
evidence	O
that	O
expression	O
of	O
the	O
human	O
IMPDH	O
type	O
II	O
gene	O
is	O
predominantly	O
regulated	O
by	O
the	O
nuclear	B
factors	I
ATF-2	B
and	O
an	O
as	O
yet	O
unidentified	O
POS	B
-	I
binding	I
protein	I
.	O
Additional	O
major	O
protein	O
-	O
DNA	O
interactions	O
do	O
not	O
occur	O
within	O
the	O
promoter	O
region	O
after	O
T	O
lymphocyte	O
activation	O
,	O
indicating	O
a	O
requirement	O
for	O
additional	O
protein	O
-	O
protein	O
interactions	O
and/or	O
post	O
-	O
translational	O
modifications	O
of	O
pre	B
-	I
bound	I
transcription	I
factors	I
to	O
account	O
for	O
the	O
observed	O
increase	O
in	O
IMPDH	O
type	O
II	O
gene	O
expression	O
.	O
The	O
carboxyl	B
-	I
terminal	I
cytoplasmic	I
domain	I
of	O
CD36	B
is	O
required	O
for	O
oxidized	O
low	O
-	O
density	O
lipoprotein	O
modulation	O
of	O
NF	B
-	I
kappaB	I
activity	O
by	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
.	O
The	O
binding	O
of	O
oxidized	O
low	O
-	O
density	O
lipoprotein	O
(	O
Ox	O
LDL	O
)	O
by	O
monocyte	O
-macrophages	O
causes	O
pleiotropic	O
effects	O
,	O
including	O
changes	O
in	O
gene	O
expression	O
,	O
and	O
is	O
thought	O
to	O
represent	O
an	O
early	O
event	O
in	O
atherogenesis	O
.	O
The	O
integral	O
membrane	O
glycoprotein	B
CD36	I
appears	O
to	O
play	O
a	O
physiological	O
role	O
in	O
binding	O
and	O
uptake	O
of	O
Ox	O
LDL	O
by	O
monocyte	O
-	O
macrophages	O
,	O
although	O
the	O
molecular	O
events	O
associated	O
with	O
CD36	B
-Ox	O
LDL	O
interaction	O
are	O
unknown	O
.	O
To	O
approach	O
this	O
issue	O
,	O
we	O
used	O
CD36	B
transfected	O
Chinese	O
hampster	O
ovary	O
(	O
CHO	O
)	O
cells	O
,	O
exposed	O
them	O
to	O
Ox	O
LDL	O
,	O
and	O
determined	O
changes	O
in	O
the	O
activity	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
.	O
We	O
report	O
here	O
that	O
Ox	O
LDL	O
enhanced	O
DNA	O
binding	O
activity	O
of	O
nuclear	O
extracts	O
to	O
an	O
NF	O
-	O
kappaB	O
sequence	O
following	O
activation	O
of	O
CD36-producing	O
CHO	O
cells	O
with	O
the	O
proinflammatory	B
cytokine	I
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
.	O
This	O
enhanced	O
DNA	O
binding	O
activity	O
was	O
inhibited	O
by	O
coincubation	O
of	O
CD36	B
transfected	O
cells	O
with	O
the	O
human	B
CD36-specific	I
antibody	I
OKM5	B
.	O
We	O
also	O
determined	O
that	O
activation	O
of	O
NF	B
-	I
kappaB	I
DNA	O
binding	O
activity	O
required	O
an	O
intact	O
carboxyl	B
-	I
terminal	I
cytoplasmic	I
segment	I
on	O
CD36	B
.	O
Our	O
results	O
support	O
the	O
idea	O
that	O
human	B
CD36	I
mediates	O
signal	O
transduction	O
events	O
in	O
response	O
to	O
Ox	O
LDL	O
.	O
Transcriptional	O
regulation	O
during	O
myelopoiesis	O
.	O
The	O
coordinated	O
production	O
of	O
all	O
blood	O
cells	O
from	O
a	O
common	O
stem	O
cell	O
is	O
a	O
highly	O
regulated	O
process	O
involving	O
successive	O
stages	O
of	O
commitment	O
and	O
differentiation	O
.	O
From	O
analyses	O
of	O
mice	O
deficient	O
in	O
transcription	O
factor	O
genes	O
and	O
from	O
the	O
characterizations	O
of	O
chromosome	O
breakpoints	O
in	O
human	O
leukemias	O
,	O
it	O
has	O
become	O
evident	O
that	O
transcription	B
factors	I
are	O
important	O
regulators	O
of	O
hematopoiesis	O
.	O
During	O
myelopoiesis	O
,	O
which	O
includes	O
the	O
development	O
of	O
granulocytic	O
and	O
monocytic	O
lineages	O
,	O
transcription	B
factors	I
from	O
several	O
families	O
are	O
active	O
,	O
including	O
AML1	O
/	O
CBF	O
beta	O
,	O
C	O
/	O
EBP	O
,	O
Ets	O
,	O
c	O
-	O
Myb	O
,	O
HOX	O
,	O
and	O
MZF-1	O
.	O
Few	O
of	O
these	O
factors	O
are	O
expressed	O
exclusively	O
in	O
myeloid	O
cells	O
;	O
instead	O
it	O
appears	O
that	O
they	O
cooperatively	O
regulate	O
transcription	O
of	O
myeloid	O
-	O
specific	O
genes	O
.	O
Here	O
we	O
discuss	O
recent	O
advances	O
in	O
transcriptional	O
regulation	O
during	O
myelopoiesis	O
.	O
Transcription	O
factor	O
Egr-1	B
activity	O
down	O
-	O
regulates	O
Fas	O
and	O
CD23	O
expression	O
in	O
B	O
cells	O
.	O
Activation	O
of	O
mature	O
B	O
cells	O
via	O
Ag	B
receptor	I
cross	O
-	O
linking	O
induces	O
transient	O
expression	O
of	O
the	O
transcription	B
factor	I
Egr-1	B
.	O
Although	O
the	O
activating	O
signals	O
leading	O
to	O
Egr-1	B
induction	O
have	O
been	O
studied	O
extensively	O
,	O
little	O
is	O
known	O
about	O
the	O
genes	O
that	O
are	O
placed	O
further	O
downstream	O
within	O
this	O
activation	O
cascade	O
and	O
that	O
are	O
transcriptionally	O
regulated	O
by	O
Egr-1	B
.	O
To	O
identify	O
such	O
target	O
genes	O
,	O
we	O
established	O
Egr-1-overexpressing	O
transfectants	O
from	O
the	O
murine	O
B	O
cell	O
line	O
K46	O
and	O
from	O
human	O
Ramos	O
B	O
cells	O
.	O
All	O
clones	O
derived	O
from	O
K46	O
B	O
cells	O
showed	O
increased	O
expression	O
of	O
CD44	B
.	O
Most	O
interestingly	O
,	O
expression	O
of	O
CD95	B
(	O
Fas	B
/	I
Apo-1	I
)	O
and	O
of	O
CD23	B
was	O
down	O
-	O
regulated	O
in	O
all	O
K46	O
transfectants	O
.	O
As	O
a	O
consequence	O
,	O
they	O
became	O
resistant	O
to	O
apoptosis	O
induced	O
by	O
anti	B
-	I
CD95	I
Ab	I
treatment	O
.	O
Similarly	O
,	O
the	O
Egr-1-expressing	O
Ramos	O
cells	O
showed	O
reduced	O
levels	O
of	O
CD95	B
expression	O
.	O
Thus	O
,	O
Egr-1	B
seems	O
to	O
control	O
the	O
expression	O
of	O
downstream	O
target	O
genes	O
not	O
only	O
as	O
a	O
transcriptional	O
activator	O
,	O
but	O
also	O
as	O
a	O
repressor	B
molecule	I
.	O
In	O
B	O
cells	O
,	O
Egr-1	B
therefore	O
plays	O
a	O
critical	O
role	O
in	O
integrating	O
the	O
short	O
-	O
lived	O
signal	O
delivered	O
by	O
triggering	O
of	O
the	O
Ag	B
receptor	I
into	O
phenotypic	O
changes	O
,	O
including	O
repression	O
of	O
CD95	B
and	O
CD23	B
transcription	O
.	O
Genomic	O
organization	O
,	O
sequence	O
,	O
and	O
transcriptional	O
regulation	O
of	O
the	O
human	O
eotaxin	O
gene	O
.	O
Eotaxin	B
is	O
an	O
eosinophil	B
specific	I
beta	I
-	I
chemokine	I
assumed	O
to	O
be	O
involved	O
in	O
eosinophilic	O
inflammatory	O
diseases	O
such	O
as	O
atopic	O
dermatitis	O
,	O
allergic	O
rhinitis	O
,	O
asthma	O
and	O
parasitic	O
infections	O
.	O
Its	O
expression	O
is	O
stimulus-	O
and	O
cell	O
-	O
specific	O
.	O
We	O
here	O
describe	O
the	O
genomic	O
organisation	O
(	O
3	O
exons	O
of	O
132	O
,	O
112	O
and	O
542	O
bp	O
and	O
2	O
introns	O
of	O
1211	O
and	O
378	O
bp	O
)	O
and	O
sequence	O
including	O
3	O
kb	O
of	O
DNA	O
from	O
the	O
immediate	O
5	O
'	O
upstream	O
region	O
of	O
the	O
human	O
eotaxin	O
gene	O
.	O
Among	O
the	O
regulatory	O
promoter	O
elements	O
potentially	O
regulating	O
eotaxin	O
gene	O
expression	O
and/or	O
mediating	O
the	O
effects	O
of	O
anti	O
-	O
inflammatory	O
drugs	O
we	O
identified	O
consensus	O
sequences	O
known	O
to	O
interact	O
with	O
nuclear	B
factors	I
like	O
NF	B
-	I
IL6	I
,	O
AP-1	B
,	O
a	O
NF	O
-	O
kappa	O
-	O
B	O
like	O
consensus	O
sequence	O
and	O
gamma	O
-	O
interferon-	O
as	O
well	O
as	O
glucocorticoid	O
response	O
elements	O
.	O
STAT3	B
is	O
a	O
serine	B
kinase	I
target	I
in	O
T	O
lymphocytes	O
.	O
Interleukin	B
2	I
and	O
T	B
cell	I
antigen	I
receptor	I
signals	O
converge	O
upon	O
serine	O
727	O
.	O
Interleukin	B
2	I
(	O
IL-2	B
)	O
induces	O
tyrosine	O
phosphorylation	O
of	O
STATs	B
3	I
and	I
5	I
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
)	O
.	O
We	O
now	O
show	O
that	O
IL-2	B
regulation	O
of	O
STAT3	B
proteins	I
in	O
T	O
cells	O
is	O
a	O
complex	O
response	O
involving	O
activation	O
of	O
two	O
forms	O
of	O
STAT3	B
:	O
90-kDa	O
STAT3alpha	B
and	O
an	O
83-kDa	B
carboxyl	I
-	I
terminal	I
truncated	I
STAT3beta	I
.	O
The	O
phosphorylation	O
of	O
STAT	B
proteins	I
on	O
serine	O
residues	O
is	O
also	O
required	O
for	O
competent	O
STAT	B
transcription	O
.	O
A	O
critical	O
serine	B
phosphorylation	I
site	I
in	O
STAT3alpha	B
is	O
at	O
position	O
727	O
.	O
In	O
this	O
study	O
we	O
have	O
produced	O
an	O
antisera	O
specific	O
for	O
STAT3alpha	B
proteins	I
phosphorylated	O
on	O
serine	O
727	O
and	O
used	O
this	O
to	O
monitor	O
the	O
phosphorylation	O
of	O
this	O
residue	O
during	O
T	O
lymphocyte	O
activation	O
.	O
Our	O
results	O
show	O
that	O
phosphorylation	O
of	O
STAT3alpha	B
on	O
serine	O
727	O
is	O
not	O
constitutive	O
in	O
quiescent	O
T	O
cells	O
but	O
can	O
be	O
induced	O
by	O
the	O
cytokine	B
IL-2	I
.	O
Interestingly	O
,	O
triggering	O
of	O
the	O
T	B
cell	I
antigen	I
receptor	I
complex	I
or	O
activation	O
of	O
protein	B
kinase	I
C	I
with	O
phorbol	O
esters	O
also	O
induces	O
phosphorylation	O
of	O
serine	O
727	O
but	O
without	O
simultaneously	O
inducing	O
STAT3	B
tyrosine	O
phosphorylation	O
or	O
DNA	O
binding	O
.	O
Hence	O
,	O
the	O
present	O
results	O
show	O
that	O
STAT3	B
serine	O
phosphorylation	O
can	O
be	O
regulated	O
independently	O
of	O
the	O
tyrosine	O
phosphorylation	O
of	O
this	O
molecule	O
.	O
IL-2	B
and	O
T	B
cell	I
antigen	I
receptor	I
complex	I
induction	O
of	O
STAT3alpha	B
serine	O
727	O
phosphorylation	O
is	O
dependent	O
on	O
the	O
activity	O
of	O
the	O
MEK	B
/ERK	B
pathway	O
.	O
Previous	O
studies	O
have	O
identified	O
H-7-sensitive	O
kinase	O
pathways	O
that	O
regulate	O
STAT3	B
DNA	O
binding	O
.	O
We	O
show	O
that	O
H-7-sensitive	O
pathways	O
regulate	O
STAT3	B
DNA	O
binding	O
in	O
T	O
cells	O
.	O
Nevertheless	O
,	O
we	O
show	O
that	O
H-7-sensitive	B
kinases	I
do	O
not	O
regulate	O
STAT3	B
tyrosine	O
phosphorylation	O
or	O
phosphorylation	O
of	O
serine	O
727	O
.	O
These	O
results	O
thus	O
show	O
that	O
STAT3	B
proteins	I
are	O
targets	O
for	O
multiple	O
kinase	O
pathways	O
in	O
T	O
cells	O
and	O
can	O
integrate	O
signals	O
from	O
both	O
cytokine	B
receptors	I
and	O
antigen	B
receptors	I
.	O
Abnormal	O
apoptosis	O
and	O
cell	O
cycle	O
progression	O
in	O
humans	O
exposed	O
to	O
methyl	O
tertiary	O
-	O
butyl	O
ether	O
and	O
benzene	O
contaminating	O
water	O
.	O
1	O
.	O
In	O
this	O
study	O
we	O
hypothesized	O
that	O
in	O
individuals	O
with	O
certain	O
genetic	O
makeup	O
,	O
MTBE	O
,	O
benzene	O
or	O
their	O
metabolites	O
act	O
as	O
adducts	O
and	O
may	O
induce	O
programmed	O
cell	O
death	O
.	O
2	O
.	O
Our	O
study	O
involved	O
a	O
group	O
of	O
60	O
male	O
and	O
female	O
subjects	O
who	O
were	O
exposed	O
to	O
MTBE	O
and	O
benzene	O
-	O
contaminated	O
water	O
concentrations	O
up	O
to	O
76	O
PPB	O
for	O
MTBE	O
and	O
14	O
PPB	O
for	O
benzene	O
,	O
for	O
a	O
period	O
of	O
5	O
to	O
8	O
years	O
.	O
For	O
comparison	O
,	O
we	O
recruited	O
a	O
control	O
group	O
consisting	O
of	O
32	O
healthy	O
males	O
and	O
females	O
with	O
similar	O
age	O
distribution	O
and	O
without	O
a	O
history	O
of	O
exposure	O
to	O
MTBE	O
or	O
benzene	O
.	O
3	O
.	O
Peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
of	O
both	O
groups	O
were	O
tested	O
for	O
the	O
percentage	O
of	O
apoptotic	O
cells	O
and	O
cell	O
cycle	O
progression	O
using	O
flow	O
cytometry	O
.	O
4	O
.	O
When	O
apoptotic	O
lymphocytes	O
from	O
exposed	O
individuals	O
were	O
compared	O
to	O
apoptotic	O
lymphocytes	O
from	O
the	O
control	O
group	O
,	O
statistically	O
-	O
significant	O
differences	O
between	O
each	O
mean	O
group	O
were	O
detected	O
(	O
26.4	O
+	O
/-	O
1.8	O
and	O
12.1	O
+	O
/-	O
1.3	O
,	O
respectively	O
)	O
,	O
indicating	O
an	O
increased	O
rate	O
of	O
apoptosis	O
in	O
80.5	O
%	O
of	O
exposed	O
individuals	O
(	O
P	O
<	O
0.0001	O
,	O
Mann	O
-	O
Whitney	O
U	O
-	O
Test	O
)	O
.	O
MTBE	O
and	O
benzene	O
-	O
induced	O
apoptosis	O
is	O
attributed	O
to	O
a	O
discrete	O
block	O
within	O
the	O
cell	O
cycle	O
progression	O
.	O
Because	O
cell	O
cycle	O
analysis	O
showed	O
that	O
in	O
PBL	O
from	O
chemically	O
-	O
exposed	O
individuals	O
,	O
between	O
20	O
-	O
50	O
%	O
of	O
cells	O
were	O
accumulated	O
at	O
the	O
S	O
-	O
G2	O
/	O
M	O
boundaries	O
.	O
5	O
.	O
One	O
of	O
the	O
signaling	B
molecules	I
which	O
mediates	O
programmed	O
cell	O
death	O
is	O
nuclear	B
factor	I
Kappa	I
-	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
.	O
NF	B
-	I
kappa	I
B	I
was	O
examined	O
as	O
one	O
of	O
the	O
many	O
molecular	O
mechanisms	O
for	O
mediating	O
cell	O
death	O
by	O
MTBE	O
and	O
benzene	O
.	O
Indeed	O
,	O
addition	O
of	O
inhibitors	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
to	O
the	O
lymphocytes	O
of	O
the	O
chemically	O
-	O
exposed	O
group	O
was	O
capable	O
of	O
inhibiting	O
programmed	O
cell	O
death	O
by	O
40	O
%	O
.	O
This	O
reversal	O
of	O
apoptosis	O
almost	O
to	O
the	O
control	O
level	O
by	O
inhibitor	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
may	O
indicate	O
involvement	O
of	O
this	O
signaling	B
molecule	I
in	O
MTBE	O
and	O
benzene	O
induction	O
of	O
programmed	O
cell	O
death	O
.	O
Alcohol	O
-	O
induced	O
regulation	O
of	O
nuclear	B
regulatory	I
factor	I
-	I
kappa	I
beta	I
in	O
human	O
monocytes	O
.	O
Acute	O
ethanol	O
exposure	O
has	O
the	O
capacity	O
to	O
modulate	O
immune	O
functions	O
,	O
particularly	O
,	O
to	O
down	O
regulate	O
monocyte	O
production	O
of	O
inflammatory	B
cytokines	I
.	O
However	O
,	O
the	O
intracellular	O
mechanisms	O
for	O
these	O
effects	O
of	O
ethanol	O
are	O
yet	O
to	O
be	O
understood	O
.	O
Considering	O
that	O
nuclear	B
regulatory	I
factor	I
-	I
kappa	I
beta	I
(	B
NF	I
-	I
kappa	I
B	I
)	I
/Rel	I
is	O
a	O
common	O
regulatory	B
element	I
of	O
the	O
promoter	O
region	O
of	O
the	O
inflammatory	O
cytokine	O
genes	O
,	O
herein	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
acute	O
ethanol	O
affects	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
human	O
monocytes	O
.	O
Adherence	O
-	O
isolated	O
monocytes	O
showed	O
constitutive	O
DNA	O
binding	O
activity	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
A	O
clinically	O
relevant	O
dose	O
(	O
25	O
mM	O
)	O
of	O
acute	O
ethanol	O
treatment	O
in	O
vitro	O
increased	O
NF	B
-	I
kappa	I
B	I
binding	O
activity	O
in	O
monocytes	O
with	O
a	O
preferential	O
induction	O
of	O
the	O
inhibitory	O
,	O
p50	B
/	I
p50	I
,	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
homodimer	I
,	O
and	O
resulted	O
in	O
no	O
induction	O
of	O
the	O
p65	B
/	I
p50	I
heterodimer	I
.	O
In	O
contrast	O
,	O
lipopolysaccharide	O
stimulation	O
primarily	O
induced	O
the	O
p65	B
/	I
p50	I
heterodimer	I
that	O
has	O
been	O
shown	O
to	O
result	O
in	O
gene	O
activation	O
.	O
Thus	O
,	O
such	O
unique	O
activation	O
of	O
the	O
inhibitory	B
p50	I
/	I
p50	I
homodimer	I
by	O
acute	O
ethanol	O
treatment	O
may	O
result	O
in	O
inhibition	O
rather	O
than	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
regulated	O
inflammatory	O
cytokine	O
genes	O
.	O
Consequently	O
,	O
these	O
results	O
suggest	O
that	O
physiologically	O
relevant	O
concentrations	O
of	O
ethanol	O
may	O
affect	O
production	O
of	O
inflammatory	B
cytokines	I
,	O
such	O
as	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
,	O
interleukin-1	B
beta	I
,	O
and	O
interleukin-6	B
by	O
disrupting	O
NF	B
-	I
kappa	I
B	I
signaling	O
in	O
monocytes	O
.	O
NF	B
-	I
AT	I
activation	O
induced	O
by	O
a	O
CAML	B
-interacting	O
member	O
of	O
the	O
tumor	B
necrosis	I
factor	I
receptor	I
superfamily	I
.	O
Activation	O
of	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
transcription	B
factor	I
(	O
NF	B
-	I
AT	I
)	O
is	O
a	O
key	O
event	O
underlying	O
lymphocyte	O
action	O
.	O
The	O
CAML	B
(	I
calcium	I
-	I
modulator	I
and	I
cyclophilin	I
ligand	I
)	I
protein	I
is	O
a	O
coinducer	O
of	O
NF	B
-	I
AT	I
activation	O
when	O
overexpressed	O
in	O
Jurkat	O
T	O
cells	O
.	O
A	O
member	O
of	O
the	O
tumor	B
necrosis	I
factor	I
receptor	I
superfamily	I
was	O
isolated	O
by	O
virtue	O
of	O
its	O
affinity	O
for	O
CAML	B
.	O
Cross	O
-	O
linking	O
of	O
this	O
lymphocyte	B
-	I
specific	I
protein	I
,	O
designated	O
TACI	B
(	O
transmembrane	B
activator	I
and	I
CAML	I
-	I
interactor	I
)	O
,	O
on	O
the	O
surface	O
of	O
transfected	O
Jurkat	O
cells	O
with	O
TACI	B
-	I
specific	I
antibodies	I
led	O
to	O
activation	O
of	O
the	O
transcription	B
factors	I
NF	B
-	I
AT	I
,	O
AP-1	B
,	O
and	O
NFkappaB	B
.	O
TACI	B
-induced	O
activation	O
of	O
NF	B
-	I
AT	I
was	O
specifically	O
blocked	O
by	O
a	O
dominant	B
-	I
negative	I
CAML	I
mutant	I
,	O
thus	O
implicating	O
CAML	B
as	O
a	O
signaling	O
intermediate	O
.	O
Tissue	O
transglutaminase	O
-	O
dependent	O
posttranslational	O
modification	O
of	O
the	O
retinoblastoma	B
gene	I
product	I
in	O
promonocytic	O
cells	O
undergoing	O
apoptosis	O
.	O
The	O
retinoblastoma	B
gene	I
product	I
(	O
pRB	B
)	O
plays	O
an	O
important	O
role	O
in	O
controlling	O
both	O
cell	O
release	O
from	O
the	O
G1	O
phase	O
and	O
apoptosis	O
.	O
We	O
show	O
here	O
that	O
in	O
the	O
early	O
phases	O
of	O
apoptosis	O
,	O
pRB	B
is	O
posttranslationally	O
modified	O
by	O
a	O
tissue	O
transglutaminase	O
(	O
tTG	B
)	O
-catalyzed	O
reaction	O
.	O
In	O
fact	O
,	O
by	O
employing	O
a	O
novel	O
haptenized	O
lysis	O
synthetic	O
substrate	O
which	O
allows	O
the	O
isolation	O
of	O
glutaminyl	O
-	O
tTG	O
substrates	O
in	O
vivo	O
,	O
we	O
identified	O
pRB	B
as	O
a	O
potential	O
tTG	O
substrate	O
in	O
U937	O
cells	O
undergoing	O
apoptosis	O
.	O
In	O
keeping	O
with	O
this	O
finding	O
,	O
we	O
showed	O
that	O
apoptosis	O
of	O
U937	O
cells	O
is	O
characterized	O
by	O
the	O
rapid	O
disappearance	O
of	O
the	O
105	O
,	O
000-	O
to	O
110	O
,	O
000-molecular	O
-	O
weight	O
pRB	B
forms	O
concomitantly	O
with	O
the	O
appearance	O
of	O
a	O
smear	O
of	O
immunoreactive	O
products	O
with	O
a	O
molecular	O
weight	O
of	O
greater	O
than	O
250	O
,	O
000	O
.	O
The	O
shift	O
in	O
pRB	B
molecular	O
weight	O
was	O
reproduced	O
by	O
adding	O
exogenous	O
purified	O
tTG	O
to	O
extracts	O
obtained	O
from	O
viable	O
U937	O
cells	O
and	O
was	O
prevented	O
by	O
dansylcadaverine	O
,	O
a	O
potent	O
enzyme	O
inhibitor	O
.	O
The	O
effect	O
of	O
the	O
pRB	B
posttranslational	O
modification	O
during	O
apoptosis	O
was	O
investigated	O
by	O
determining	O
the	O
E2F-1	B
levels	O
and	O
by	O
isolating	O
and	O
characterizing	O
pRB	O
-	O
null	O
clones	O
from	O
U937	O
cells	O
.	O
Notably	O
,	O
the	O
lack	O
of	O
pRB	B
in	O
these	O
U937-derived	O
clones	O
renders	O
these	O
p53-null	O
cells	O
highly	O
resistant	O
to	O
apoptosis	O
induced	O
by	O
serum	O
withdrawal	O
,	O
calphostin	O
C	O
,	O
and	O
ceramide	O
.	O
Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
tTG	B
,	O
acting	O
on	O
the	O
pRB	B
protein	I
,	O
might	O
play	O
an	O
important	O
role	O
in	O
the	O
cell	O
progression	O
through	O
the	O
death	O
program	O
.	O
Cooperation	O
of	O
Spi-1	B
/	I
PU.1	I
with	O
an	O
activated	B
erythropoietin	I
receptor	I
inhibits	O
apoptosis	O
and	O
Epo	B
-dependent	O
differentiation	O
in	O
primary	O
erythroblasts	O
and	O
induces	O
their	O
Kit	O
ligand	O
-	O
dependent	O
proliferation	O
.	O
Spi-1	B
/	I
PU.1	I
is	O
a	O
myeloid-	B
and	I
B	I
-	I
cell	I
specific	I
transcription	I
factor	I
which	O
is	O
also	O
involved	O
in	O
Friend	O
virus	O
-	O
induced	O
murine	O
erythroleukemia	O
.	O
The	O
pre	O
-	O
leukemic	O
phase	O
of	O
Friend	O
erythroleukemia	O
results	O
from	O
activation	O
of	O
the	O
erythropoietin	B
receptor	I
(	O
EpoR	B
)	O
by	O
the	O
spleen	B
focus	I
forming	I
virus	I
(	I
SFFV	I
)	I
envelope	I
glycoprotein	I
,	O
followed	O
by	O
the	O
emergence	O
of	O
leukemic	O
clones	O
characterized	O
by	O
overexpression	O
of	O
Spi-1	B
and	O
mutation	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
.	O
We	O
developed	O
a	O
heterologous	O
system	O
to	O
analyze	O
the	O
contribution	O
of	O
these	O
alterations	O
to	O
the	O
induction	O
of	O
primary	O
erythroblast	O
transformation	O
.	O
Avian	O
erythroblasts	O
expressing	O
the	O
activated	B
mouse	I
EpoR	I
(	I
R129C	I
)	I
differentiated	O
into	O
erythrocytes	O
in	O
response	O
to	O
hEpo	B
.	O
Expression	O
of	O
Spi-1	B
in	O
these	O
cells	O
inhibited	O
this	O
ability	O
to	O
differentiate	O
and	O
rescued	O
the	O
cells	O
from	O
the	O
apoptotic	O
cell	O
death	O
program	O
normally	O
induced	O
upon	O
hEpo	B
withdrawal	O
.	O
Although	O
devoid	O
of	O
any	O
effect	O
by	O
itself	O
,	O
a	O
mutant	B
p53	I
cooperated	O
with	O
Spi-1	B
and	O
EpoR	B
(	I
R129C	I
)	I
to	O
reinforce	O
both	O
phenotypes	O
.	O
Analysis	O
of	O
erythroblasts	O
co	O
-	O
expressing	O
Spi-1	B
and	O
the	O
wild	B
-	I
type	I
mouse	I
EpoR	I
showed	O
that	O
differentiation	O
arrest	O
and	O
inhibition	O
of	O
apoptosis	O
depended	O
on	O
specific	O
cooperation	O
between	O
Spi-1	B
and	O
EpoR	B
(	I
R129C	I
)	I
.	O
This	O
cooperation	O
was	O
also	O
required	O
to	O
induce	O
the	O
sustained	O
proliferation	O
of	O
differentiation	O
-	O
blocked	O
erythroblasts	O
in	O
response	O
to	O
ligand	O
activation	O
of	O
the	O
endogenous	B
tyrosine	I
kinase	I
receptor	I
c	B
-	I
Kit	I
.	O
These	O
results	O
show	O
that	O
Spi-1	O
/	O
PU.1	B
requires	O
signals	O
emanating	O
from	O
specific	O
cytokine	O
and	O
growth	O
factor	O
receptors	O
to	O
affect	O
the	O
survival	O
,	O
proliferation	O
and	O
differentiation	O
control	O
of	O
primary	O
erythroblasts	O
.	O
They	O
also	O
suggest	O
that	O
the	O
function	O
of	O
Spi-1	B
/	I
PU.1	I
in	O
the	O
late	O
phase	O
of	O
Friend	O
leukemia	O
requires	O
specific	O
signaling	O
from	O
the	O
gp55-modified	B
EpoR	I
generated	O
during	O
the	O
early	O
phase	O
of	O
the	O
disease	O
.	O
Evidence	O
that	O
calcineurin	O
is	O
rate	O
-	O
limiting	O
for	O
primary	O
human	O
lymphocyte	O
activation	O
.	O
Cyclosporine	O
(	O
CsA	O
)	O
is	O
both	O
a	O
clinical	O
immunosuppressive	O
drug	O
and	O
a	O
probe	O
to	O
dissect	O
intracellular	O
signaling	O
pathways	O
.	O
In	O
vitro	O
,	O
CsA	O
inhibits	O
lymphocyte	O
gene	O
activation	O
by	O
inhibiting	O
the	O
phosphatase	B
activity	O
of	O
calcineurin	B
(	O
CN	B
)	O
.	O
In	O
clinical	O
use	O
,	O
CsA	O
treatment	O
inhibits	O
50	O
-	O
75	O
%	O
of	O
CN	B
activity	O
in	O
circulating	O
leukocytes	O
.	O
We	O
modeled	O
this	O
degree	O
of	O
CN	B
inhibition	O
in	O
primary	O
human	O
leukocytes	O
in	O
vitro	O
in	O
order	O
to	O
study	O
the	O
effect	O
of	O
partial	O
CN	B
inhibition	O
on	O
the	O
downstream	O
signaling	O
events	O
that	O
lead	O
to	O
gene	O
activation	O
.	O
In	O
CsA	O
-	O
treated	O
leukocytes	O
stimulated	O
by	O
calcium	O
ionophore	O
,	O
the	O
degree	O
of	O
reduction	O
in	O
CN	B
activity	O
was	O
accompanied	O
by	O
a	O
similar	O
degree	O
of	O
inhibition	O
of	O
each	O
event	O
tested	O
:	O
dephosphorylation	O
of	O
nuclear	B
factor	I
of	I
activated	I
T	I
cell	I
proteins	I
,	O
nuclear	O
DNA	O
binding	O
,	O
activation	O
of	O
a	O
transfected	O
reporter	O
gene	O
construct	O
,	O
IFN	O
-	O
gamma	O
and	O
IL-2	O
mRNA	O
accumulation	O
,	O
and	O
IFN	B
-	I
gamma	I
production	O
.	O
Furthermore	O
,	O
the	O
degree	O
of	O
CN	B
inhibition	O
was	O
reflected	O
by	O
a	O
similar	O
degree	O
of	O
reduction	O
in	O
lymphocyte	O
proliferation	O
and	O
IFN	B
-	I
gamma	I
production	O
in	O
the	O
allogeneic	O
mixed	O
lymphocyte	O
cultures	O
.	O
These	O
data	O
support	O
the	O
conclusion	O
that	O
CN	B
activity	O
is	O
rate	O
-	O
limiting	O
for	O
the	O
activation	O
of	O
primary	O
human	O
T	O
lymphocytes	O
.	O
Thus	O
,	O
the	O
reduction	O
of	O
CN	B
activity	O
observed	O
in	O
CsA	O
-	O
treated	O
patients	O
is	O
accompanied	O
by	O
a	O
similar	O
degree	O
of	O
reduction	O
in	O
lymphocyte	O
gene	O
activation	O
,	O
and	O
accounts	O
for	O
the	O
immunosuppression	O
observed	O
.	O
The	O
DNA	B
binding	I
domain	I
of	O
the	O
A	B
-	I
MYB	I
transcription	B
factor	I
is	O
responsible	O
for	O
its	O
B	O
cell	O
-	O
specific	O
activity	O
and	O
binds	O
to	O
a	O
B	B
cell	I
110-kDa	I
nuclear	I
protein	I
.	O
Expression	O
studies	O
as	O
well	O
as	O
the	O
use	O
of	O
transgenic	O
animals	O
have	O
demonstrated	O
that	O
the	O
A	B
-	I
MYB	I
transcription	B
factor	I
plays	O
central	O
and	O
specific	O
role	O
in	O
the	O
regulation	O
of	O
mature	O
B	O
cell	O
proliferation	O
and/or	O
differentiation	O
.	O
Furthermore	O
,	O
it	O
is	O
highly	O
expressed	O
in	O
Burkitt	O
's	O
lymphoma	O
cells	O
and	O
may	O
participate	O
in	O
the	O
pathogenesis	O
of	O
this	O
disease	O
.	O
We	O
have	O
therefore	O
investigated	O
the	O
transcriptional	O
activity	O
of	O
A	B
-	I
MYB	I
and	O
its	O
regulation	O
in	O
several	O
human	O
lymphoid	O
cell	O
lines	O
using	O
co	O
-	O
transfection	O
assays	O
and	O
show	O
that	O
A	B
-	I
MYB	I
is	O
transcriptionally	O
active	O
in	O
all	O
the	O
B	O
cell	O
lines	O
studied	O
,	O
but	O
not	O
in	O
T	O
cells	O
.	O
In	O
particular	O
the	O
best	O
responder	O
cell	O
line	O
was	O
the	O
Burkitt	O
's	O
cell	O
line	O
Namalwa	O
.	O
The	O
activity	O
of	O
A	B
-	I
MYB	I
in	O
B	O
and	O
not	O
T	O
cells	O
was	O
observed	O
when	O
either	O
an	O
artificial	O
construct	O
or	O
the	O
c	O
-	O
MYC	O
promoter	O
was	O
used	O
as	O
a	O
reporter	O
.	O
Furthermore	O
,	O
the	O
functional	B
domains	I
responsible	O
for	O
DNA	O
binding	O
,	O
transactivation	O
,	O
and	O
negative	O
regulation	O
,	O
previously	O
characterized	O
in	O
a	O
fibroblast	O
context	O
,	O
were	O
found	O
to	O
have	O
similar	O
activity	O
in	O
B	O
cells	O
.	O
The	O
region	O
of	O
A	B
-	I
MYB	I
responsible	O
for	O
the	O
B	O
cell	O
specific	O
activity	O
was	O
defined	O
to	O
be	O
the	O
N	B
-	I
terminal	I
218	I
amino	I
acids	I
containing	O
the	O
DNA	B
binding	I
domain	I
.	O
Finally	O
,	O
a	O
110-kDa	B
protein	I
has	O
been	O
identified	O
in	O
the	O
nuclei	O
of	O
all	O
the	O
B	O
,	O
but	O
not	O
T	O
,	O
cell	O
lines	O
that	O
specifically	O
binds	O
to	O
this	O
A	B
-	I
MYB	I
N	I
-	I
terminal	I
domain	I
.	O
We	O
hypothesize	O
that	O
this	O
110-kDa	B
protein	I
may	O
be	O
a	O
functionally	O
important	O
B	B
cell	I
-	I
specific	I
co	I
-	I
activator	I
of	O
A	B
-	I
MYB	I
.	O
Cooperation	O
of	O
binding	B
sites	I
for	O
STAT6	B
and	O
NF	B
kappa	I
B	I
/	I
rel	I
in	O
the	O
IL-4	B
-induced	O
up	O
-	O
regulation	O
of	O
the	O
human	O
IgE	O
germline	O
promoter	O
.	O
Ig	B
heavy	I
chain	I
class	O
switching	O
is	O
directed	O
by	O
cytokines	B
inducing	O
transcription	O
from	O
unrearranged	O
CH	O
genes	O
.	O
Subsequently	O
,	O
such	O
primed	O
cells	O
can	O
undergo	O
switch	O
recombination	O
to	O
express	O
the	O
selected	O
new	O
isotype	O
.	O
In	O
the	O
case	O
of	O
IgE	B
class	O
switching	O
,	O
IL-4	B
activates	O
the	O
IgE	O
germline	O
promoter	O
by	O
inducing	O
the	O
interaction	O
of	O
the	O
transcription	B
factor	I
STAT6	B
(	O
IL-4STAT	B
)	O
with	O
a	O
responsive	O
DNA	O
element	O
in	O
the	O
proximal	O
region	O
of	O
the	O
promoter	O
.	O
This	O
study	O
describes	O
the	O
characterization	O
of	O
two	O
additional	O
cis	O
-	O
acting	O
elements	O
that	O
interact	O
with	O
members	O
of	O
the	O
NF	B
kappa	I
B	I
/	I
rel	I
transcription	I
factor	I
family	I
in	O
an	O
IL-4	B
-independent	O
fashion	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
show	O
that	O
the	O
nucleoprotein	B
complex	I
formed	O
on	O
the	O
upstream	O
site	O
(	O
NF	B
kappa	I
B1	I
)	O
contains	O
the	O
classical	B
p50	I
/	I
p65	I
heterodimer	I
.	O
The	O
complex	O
on	O
the	O
proximal	O
site	O
(	O
NF	B
kappa	I
B2	I
)	O
appears	O
to	O
be	O
composed	O
of	O
p50	B
and	O
relB	B
.	O
IgE	O
germline	O
promoter	O
reporter	O
gene	O
constructs	O
carrying	O
point	O
mutations	O
in	O
the	O
NF	B
kappa	I
B2	I
site	O
were	O
largely	O
unresponsive	O
to	O
IL-4	B
stimulation	O
in	O
transient	O
transfection	O
experiments	O
,	O
while	O
plasmids	O
with	O
similar	O
mutations	O
in	O
the	O
NF	B
kappa	I
B1	I
site	O
responded	O
to	O
cytokine	B
stimulation	O
better	O
than	O
the	O
wild	O
-	O
type	O
promoter	O
.	O
The	O
NF	B
kappa	I
B2	I
effect	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
STAT6	O
binding	O
site	O
,	O
demonstrating	O
that	O
the	O
NF	B
kappa	I
B2	I
motif	I
is	O
necessary	O
but	O
not	O
sufficient	O
for	O
mediating	O
cytokine	B
up	O
-	O
regulation	O
.	O
In	O
addition	O
,	O
the	O
combination	O
of	O
a	O
NF	O
kappa	O
B	O
/	O
rel	O
binding	O
site	O
and	O
the	O
STAT6	O
response	O
element	O
conferred	O
IL-4	B
inducibility	O
to	O
a	O
heterologous	O
minimal	O
promoter	O
,	O
while	O
the	O
individual	O
sites	O
had	O
no	O
effect	O
.	O
The	O
available	O
data	O
suggest	O
that	O
the	O
NF	B
kappa	I
B2	I
nucleoprotein	I
complex	I
may	O
cooperate	O
with	O
DNA	B
-	I
bound	I
STAT6	I
to	O
achieve	O
IL-4	B
-dependent	O
activation	O
of	O
the	O
human	O
IgE	O
germline	O
gene	O
.	O
The	O
A	B
-	I
myb	I
transcription	I
factor	I
in	O
neoplastic	O
and	O
normal	O
B	O
cells	O
.	O
The	O
myb	B
family	I
of	O
transcription	B
factors	I
has	O
been	O
strongly	O
implicated	O
in	O
the	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
in	O
the	O
haematopoietic	O
system	O
.	O
The	O
v	O
-	O
myb	O
oncogene	O
,	O
carried	O
by	O
avian	O
defective	O
retroviruses	O
,	O
causes	O
leukaemias	O
in	O
the	O
chicken	O
and	O
transforms	O
haematopoietic	O
cells	O
in	O
vitro	O
.	O
Its	O
normal	O
cellular	O
equivalent	O
c	O
-	O
myb	O
,	O
has	O
been	O
shown	O
to	O
promote	O
the	O
proliferation	O
and	O
block	O
the	O
differentiation	O
of	O
haematopoietic	O
cells	O
in	O
several	O
experimental	O
models	O
and	O
is	O
required	O
for	O
fetal	O
haematopoiesis	O
.	O
Two	O
other	O
members	O
of	O
the	O
family	O
have	O
been	O
cloned	O
more	O
recently	O
,	O
A	B
-	I
myb	I
and	O
B	B
-	I
myb	I
,	O
which	O
show	O
sequence	O
homology	O
with	O
c	O
-	O
myb	O
in	O
several	O
domains	O
,	O
of	O
which	O
the	O
DNA	B
binding	I
domain	I
as	O
well	O
as	O
other	O
regulatory	B
domains	I
.	O
Both	O
have	O
been	O
shown	O
to	O
be	O
transcription	B
factors	I
.	O
B	B
-	I
myb	I
is	O
also	O
involved	O
in	O
the	O
control	O
of	O
proliferation	O
and	O
differentiation	O
,	O
but	O
,	O
unlike	O
c	O
-	O
myb	O
,	O
it	O
is	O
expressed	O
in	O
many	O
cell	O
types	O
.	O
The	O
third	O
member	O
of	O
the	O
family	B
,	O
A	B
-	I
myb	I
,	O
shows	O
the	O
most	O
restricted	O
pattern	O
of	O
expression	O
,	O
suggesting	O
a	O
very	O
specific	O
role	O
for	O
this	O
transcription	B
factor	I
.	O
A	B
-	I
myb	I
is	O
expressed	O
in	O
a	O
subpopulation	O
of	O
normal	O
B	O
lymphocytes	O
activated	O
in	O
vivo	O
and	O
localised	O
in	O
the	O
germinal	O
center	O
of	O
peripheral	O
lymphoid	O
organs	O
and	O
is	O
not	O
detected	O
at	O
significant	O
levels	O
in	O
all	O
other	O
mature	O
or	O
immature	O
haematopoietic	O
populations	O
studied	O
,	O
including	O
bone	O
marrow	O
cells	O
,	O
T	O
lymphocytes	O
,	O
granulocytes	O
,	O
monocytes	O
,	O
either	O
at	O
rest	O
or	O
after	O
in	O
vitro	O
activation	O
.	O
These	O
studies	O
indicate	O
that	O
A	B
-	I
myb	I
plays	O
a	O
role	O
during	O
a	O
narrow	O
window	O
of	O
normal	O
B	O
cell	O
differentiation	O
.	O
A	B
-	I
myb	I
expression	O
has	O
also	O
been	O
studied	O
in	O
a	O
wide	O
range	O
of	O
neoplastic	O
B	O
cells	O
,	O
representing	O
the	O
whole	O
spectrum	O
of	O
B	O
cell	O
differentiation	O
.	O
A	B
-	I
myb	I
is	O
strongly	O
expressed	O
in	O
Burkitt	O
's	O
lymphomas	O
(	O
BL	O
)	O
and	O
slg+	O
B	O
-	O
acute	O
lymphoblastic	O
leukaemias	O
(	O
B	O
-	O
ALL	O
)	O
and	O
not	O
in	O
all	O
other	O
leukaemias	O
/	O
lymphomas	O
tested	O
,	O
with	O
the	O
exception	O
of	O
a	O
subset	O
of	O
CLL	O
(	O
about	O
25	O
%	O
of	O
cases	O
)	O
.	O
It	O
is	O
intriguing	O
that	O
the	O
A	O
-	O
myb	O
genome	O
has	O
been	O
localised	O
relatively	O
close	O
to	O
the	O
c	O
-	O
myc	O
gene	O
on	O
chromosome	O
8	O
,	O
suggesting	O
that	O
the	O
c	O
-	O
myc	O
translocation	O
in	O
BL	O
and	O
B	O
-	O
ALL	O
may	O
affect	O
A	B
-	I
myb	I
transcription	O
.	O
Studies	O
are	O
in	O
progress	O
to	O
investigate	O
the	O
functional	O
relationship	O
between	O
A	B
-	I
myb	I
and	O
c	O
-	O
myc	O
,	O
particularly	O
in	O
the	O
context	O
of	O
BL	O
cells	O
and	O
to	O
determine	O
whether	O
A	B
-	I
myb	I
is	O
deregulated	O
in	O
these	O
cells	O
.	O
Interleukin-7	B
upregulates	O
the	O
interleukin-2-gene	O
expression	O
in	O
activated	O
human	O
T	O
lymphocytes	O
at	O
the	O
transcriptional	O
level	O
by	O
enhancing	O
the	O
DNA	O
binding	O
activities	O
of	O
both	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
and	O
activator	B
protein-1	I
.	O
In	O
the	O
present	O
report	O
,	O
we	O
studied	O
the	O
role	O
of	O
the	O
stromal	B
-	I
derived	I
cytokine	I
interleukin-7	I
(	O
IL-7	B
)	O
in	O
the	O
IL-2-gene	O
regulation	O
in	O
activated	O
T	O
lymphocytes	O
.	O
Production	O
of	O
IL-2	B
requires	O
the	O
formation	O
of	O
transcription	B
factors	I
involved	O
in	O
the	O
IL-2-gene	O
regulation	O
.	O
T	B
-	I
cell	I
receptor	I
(	B
TCR	I
)	I
/CD3	I
engagement	O
results	O
in	O
the	O
activation	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	B
)	O
,	O
activator	B
protein-1	I
(	O
AP-1	B
)	O
,	O
and	O
nuclear	B
factor	I
kappaB	I
(	O
NFkappaB	B
)	O
,	O
whereas	O
the	O
CD28	B
responsive	I
complex	I
(	O
CD28RC	B
)	O
is	O
activated	O
in	O
response	O
to	O
the	O
CD28	B
signal	O
.	O
Costimulation	O
of	O
phytohemagglutinin	O
/	O
anti	O
-	O
CD28	O
activated	O
T	O
lymphocytes	O
with	O
IL-7	B
induces	O
a	O
fivefold	O
enhanced	O
IL-2	B
-mRNA	O
accumulation	O
and	O
a	O
2.5-fold	O
enhanced	O
protein	O
secretion	O
.	O
The	O
IL-2-gene	O
transcription	O
rate	O
is	O
increased	O
3.4-fold	O
,	O
indicating	O
that	O
the	O
effect	O
of	O
IL-7	B
is	O
in	O
part	O
mediated	O
at	O
the	O
transcriptional	O
level	O
.	O
The	O
molecular	O
mechanisms	O
underlying	O
the	O
IL-7	B
effect	O
involve	O
the	O
upregulation	O
of	O
the	O
DNA	O
binding	O
activity	O
of	O
NFAT	B
(	O
60	O
%	O
)	O
and	O
AP-1	B
(	O
120	O
%	O
)	O
,	O
without	O
affecting	O
the	O
activities	O
of	O
NFkappaB	B
and	O
CD28RC	B
,	O
which	O
was	O
confirmed	O
by	O
transfection	O
assays	O
.	O
We	O
also	O
show	O
that	O
the	O
IL-7	B
-induced	O
enhancement	O
of	O
the	O
AP-1	B
-DNA	O
binding	O
activity	O
is	O
not	O
cyclosporin	O
A	O
-	O
sensitive	O
.	O
Since	O
AP-1	B
is	O
part	O
of	O
the	O
NFAT	B
complex	I
,	O
we	O
conclude	O
that	O
the	O
IL-7	B
-signaling	O
pathway	O
is	O
involved	O
in	O
the	O
activation	O
of	O
the	O
fos	B
and	I
jun	I
proteins	I
of	O
which	O
AP-1	B
consists	O
.	O
Phospholipase	B
C	I
gamma	I
1	I
overexpression	O
and	O
activation	O
induced	O
by	O
interferon	B
beta	I
in	O
human	O
T	O
lymphocytes	O
:	O
an	O
ISGF3	B
-independent	O
response	O
.	O
Interferons	B
exert	O
their	O
antiviral	O
,	O
antiproliferative	O
and	O
immunoregulatory	B
activities	O
by	O
stimulating	O
the	O
expression	O
of	O
several	O
genes	O
.	O
Such	O
genes	O
disclose	O
a	O
common	O
element	O
within	O
their	O
promoters	O
,	O
defined	O
Interferon	O
Stimulated	O
Response	O
Element	O
(	O
ISRE	O
)	O
,	O
which	O
binds	O
a	O
nuclear	B
factor	I
(	O
s	O
)	O
translocated	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
(	O
ISGF3	B
)	O
after	O
the	O
binding	O
of	O
interferon	B
(	O
IFN	B
)	O
to	O
the	O
specific	O
receptor	O
.	O
Here	O
we	O
report	O
the	O
induction	O
of	O
the	O
synthesis	O
and	O
of	O
the	O
hydrolytic	O
activity	O
of	O
phospholipase	B
C	I
gamma	I
1	I
(	O
PLC	B
gamma	I
1	I
)	O
in	O
human	O
T	O
lymphocytes	O
by	O
IFN	B
-	I
beta	I
.	O
The	O
increased	O
level	O
of	O
PLC	B
gamma	I
1	I
becomes	O
evident	O
after	O
90	O
min	O
of	O
IFN	B
-	I
beta	I
treatment	O
and	O
is	O
still	O
detectable	O
after	O
24	O
h	O
.	O
Neither	O
the	O
PLC	B
gamma	I
1	I
overexpression	O
induced	O
by	O
IFN	B
nor	O
the	O
increased	O
hydrolytic	O
activity	O
of	O
the	O
enzyme	B
appear	O
to	O
be	O
affected	O
by	O
pretreatment	O
of	O
the	O
cells	O
with	O
the	O
protein	O
tyrosine	B
kinase	I
inhibitor	O
genistein	O
,	O
which	O
is	O
known	O
to	O
prevent	O
the	O
association	O
of	O
ISGF3	B
components	O
.	O
These	O
results	O
suggest	O
that	O
in	O
human	O
T	O
lymphocytes	O
IFN	B
-	I
beta	I
can	O
activate	O
other	O
transcription	B
factor	I
(	O
s	O
)	O
distinct	O
from	O
ISGF3	B
to	O
regulate	O
PLC	B
gamma	I
1	I
expression	O
.	O
In	O
addition	O
,	O
the	O
ability	O
of	O
this	O
enzyme	B
to	O
hydrolyse	O
PIP2	O
,	O
also	O
in	O
the	O
presence	O
of	O
genistein	O
,	O
implies	O
the	O
possibility	O
that	O
this	O
enzyme	O
can	O
exert	O
its	O
hydrolytic	O
activity	O
independently	O
of	O
protein	B
tyrosine	I
kinase	I
activation	O
.	O
Glucocorticoids	O
and	O
the	O
immune	O
function	O
in	O
the	O
human	O
immunodeficiency	O
virus	O
infection	O
:	O
a	O
study	O
in	O
hypercortisolemic	O
and	O
cortisol	O
-	O
resistant	O
patients	O
.	O
Immunological	O
studies	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-positive	O
patients	O
suggest	O
that	O
the	O
disease	O
progression	O
is	O
accompanied	O
by	O
a	O
defective	O
production	O
of	O
type	O
1	B
cytokines	I
(	O
interleukin-2	B
(	O
IL-2	B
)	O
and	O
IL-12	B
]	O
,	O
an	O
increased	O
production	O
of	O
type	B
2	I
cytokines	I
(	O
IL-4	B
,	O
IL-6	B
,	O
and	O
IL-10	B
)	O
,	O
and	O
an	O
increased	O
production	O
of	O
IgE	B
.	O
HIV	O
infection	O
is	O
also	O
associated	O
with	O
activation	O
of	O
the	O
hypothalamo	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
function	O
and	O
increased	O
plasma	O
and	O
urinary	O
cortisol	O
concentrations	O
.	O
As	O
cortisol	O
is	O
involved	O
in	O
the	O
physiological	O
regulation	O
of	O
cytokines	B
,	O
a	O
study	O
was	O
conducted	O
to	O
examine	O
cytokine	B
patterns	O
in	O
two	O
groups	O
of	O
hypercortisolemic	O
patients	O
,	O
one	O
with	O
normal	O
sensitivity	O
to	O
glucocorticoids	O
and	O
the	O
other	O
with	O
glucocorticoid	O
resistance	O
.	O
Ten	O
HIV	O
-	O
infected	O
patients	O
with	O
normal	O
receptor	O
affinity	O
to	O
glucocorticoids	O
(	O
AIDS	O
-	O
C	O
)	O
,	O
10	O
HIV	O
-	O
infected	O
patients	O
with	O
low	O
receptor	O
affinity	O
to	O
glucocorticoids	O
(	O
AIDS	O
-	O
GR	O
)	O
,	O
and	O
20	O
healthy	O
subjects	O
were	O
studied	O
.	O
Receptor	O
characteristics	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
were	O
evaluated	O
by	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
.	O
Serum	O
cortisol	O
and	O
urinary	O
free	O
cortisol	O
were	O
measured	O
by	O
RIA	O
.	O
Serum	O
ACTH	O
and	O
IgE	B
were	O
measured	O
by	O
immunoradiometric	O
assay	O
,	O
and	O
IL-2	B
,	O
IL-4	B
,	O
and	O
IL-10	B
cytokines	B
and	O
interferon	B
-	I
gamma	I
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O
AIDS	O
-	O
C	O
patients	O
showed	O
low	O
IL-2	B
and	O
high	O
IL-4	B
,	O
IL-10	B
,	O
and	O
IgE	B
concentratios	O
;	O
conversely	O
,	O
AIDS	O
-	O
GR	O
patients	O
showed	O
high	O
IL-2	B
and	O
low	O
IL-4	B
and	O
IgE	B
concentrations	O
.	O
Thus	O
,	O
in	O
HIV	O
infection	O
,	O
elevated	O
cortisol	O
levels	O
suppress	O
cell	O
-	O
mediated	O
immunity	O
and	O
stimulate	O
humoral	O
immunity	O
,	O
whereas	O
this	O
response	O
is	O
not	O
detected	O
in	O
cortisol	O
-	O
resistant	O
patients	O
.	O
These	O
findings	O
indicate	O
that	O
cortisol	O
and	O
its	O
receptors	O
are	O
critically	O
involved	O
in	O
the	O
regulation	O
of	O
immune	O
function	O
in	O
HIV	O
infection	O
.	O
Molecular	O
characterization	O
and	O
pattern	O
of	O
tissue	O
expression	O
of	O
the	O
gene	O
for	O
neutrophil	B
gelatinase	I
-	I
associated	I
lipocalin	I
from	O
humans	O
.	O
Neutrophil	B
gelatinase	I
-	I
associated	I
lipocalin	I
(	O
NGAL	B
)	O
is	O
a	O
25-kDa	B
lipocalin	I
first	O
identified	O
as	O
a	O
protein	O
stored	O
in	O
specific	O
granules	O
of	O
the	O
human	O
neutrophil	O
.	O
The	O
protein	O
is	O
believed	O
to	O
bind	O
small	O
lipophilic	O
substances	O
such	O
as	O
bacterial	O
derived	O
formylpeptides	O
and	O
lipopolysaccharides	O
(	O
LPS	O
)	O
and	O
might	O
function	O
as	O
a	O
modulator	O
of	O
inflammation	O
.	O
To	O
characterize	O
the	O
regulation	O
of	O
NGAL	B
further	O
,	O
we	O
have	O
cloned	O
and	O
sequenced	O
a	O
5869-bp	O
region	O
of	O
the	O
NGAL	O
gene	O
including	O
1695	O
bp	O
of	O
the	O
5	O
'	O
nontranscribed	O
region	O
and	O
a	O
3696-bp	O
coding	O
region	O
encompassing	O
seven	O
exons	O
and	O
six	O
introns	O
.	O
The	O
transcriptional	O
start	O
sites	O
were	O
identified	O
by	O
an	O
RNase	B
protection	O
assay	O
.	O
The	O
NGAL	B
gene	O
is	O
highly	O
homologous	O
to	O
the	O
mouse	O
gene	O
24p3	O
.	O
NGAL	B
was	O
expressed	O
in	O
bone	O
marrow	O
and	O
in	O
tissues	O
that	O
are	O
prone	O
to	O
exposure	O
to	O
microorganisms	O
.	O
Potential	O
cis	O
-	O
acting	O
elements	O
were	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
NGAL	O
gene	O
by	O
computer	O
analysis	O
and	O
include	O
binding	O
sites	O
for	O
CTF	B
/	I
CBP	I
,	O
the	O
hematopoietic	B
transcription	I
factors	I
GATA-1	B
and	O
PU.1	B
,	O
and	O
the	O
LPS	B
-	I
inducible	I
factor	I
NF	I
-	I
kappa	I
B	I
.	O
Monocytic	O
differentiation	O
of	O
HL-60	O
promyelocytic	O
leukemia	O
cells	O
correlates	O
with	O
the	O
induction	O
of	O
Bcl	B
-	I
xL	I
.	O
Treatment	O
of	O
human	O
promyelocytic	O
leukemia	O
HL-60	O
cells	O
with	O
phorbol	O
esters	O
ultimately	O
induces	O
the	O
differentiation	O
of	O
these	O
cells	O
along	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
,	O
whereas	O
treatment	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
induces	O
granulocytic	O
/	O
neutrophillic	O
differentiation	O
.	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
the	O
disparate	O
fates	O
of	O
HL-60	O
cells	O
treated	O
with	O
the	O
phorbol	O
ester	O
12	O
,	O
13-phorbol	O
dibutyric	O
acid	O
(	O
PDBu	O
)	O
or	O
DMSO	O
.	O
After	O
DMSO	O
treatment	O
,	O
HL-60	O
cells	O
eventually	O
died	O
via	O
apoptosis	O
,	O
whereas	O
the	O
viability	O
of	O
PDBu	O
-	O
treated	O
cells	O
was	O
not	O
affected	O
during	O
the	O
same	O
interval	O
.	O
The	O
levels	O
of	O
the	O
apoptosis	O
effector	O
proteins	O
Bak	B
and	O
Bad	B
were	O
enhanced	O
,	O
whereas	O
there	O
was	O
a	O
slight	O
down	O
-	O
regulation	O
of	O
the	O
apoptosis	B
suppressor	I
protein	I
Bcl-2	B
after	O
treatment	O
of	O
the	O
cells	O
with	O
PDBu	O
and	O
DMSO	O
.	O
Treatment	O
with	O
DMSO	O
resulted	O
in	O
the	O
elevation	O
of	O
the	O
apoptosis	B
effector	I
Bax	B
,	O
whereas	O
treatment	O
with	O
PDBu	O
did	O
not	O
significantly	O
alter	O
the	O
levels	O
of	O
this	O
protein	O
.	O
However	O
,	O
treatment	O
of	O
HL-60	O
cells	O
with	O
PDBu	O
induced	O
the	O
rapid	O
expression	O
of	O
the	O
apoptosis	B
suppressor	I
protein	I
Bcl	B
-	I
xL	I
,	O
whereas	O
the	O
expression	O
of	O
this	O
protein	O
remained	O
unaltered	O
in	O
DMSO	O
-	O
treated	O
cells	O
.	O
The	O
generality	O
of	O
this	O
finding	O
was	O
confirmed	O
by	O
the	O
induction	O
of	O
Bcl	B
-	I
xL	I
in	O
human	O
myeloid	O
U-937	O
cells	O
,	O
human	O
peripheral	O
blood	O
monocytes	O
exposed	O
to	O
phorbol	O
ester	O
,	O
and	O
mouse	O
thioglycollate	O
-	O
activated	O
and	O
resident	O
peritoneal	O
macrophages	O
.	O
PDBu	O
-	O
treated	O
HL-60	O
cells	O
remained	O
viable	O
for	O
7	O
days	O
and	O
thereafter	O
began	O
to	O
die	O
via	O
apoptosis	O
,	O
with	O
a	O
concomitant	O
down	O
-	O
regulation	O
of	O
Bcl	B
-	I
xL	I
.	O
In	O
conclusion	O
,	O
we	O
propose	O
that	O
Bcl	B
-	I
xL	I
expression	O
is	O
associated	O
with	O
differentiation	O
and	O
survival	O
of	O
hematopoietic	O
cells	O
along	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
.	O
Induction	O
of	O
endothelial	B
cell	I
surface	I
adhesion	I
molecules	I
by	O
tumor	B
necrosis	I
factor	I
is	O
blocked	O
by	O
protein	O
tyrosine	O
phosphatase	O
inhibitors	O
:	O
role	O
of	O
the	O
nuclear	B
transcription	I
factor	I
NF	I
-	I
kappa	I
B	I
.	O
Recent	O
studies	O
from	O
our	O
laboratory	O
have	O
indicated	O
that	O
protein	B
tyrosine	I
phosphatase	I
(	O
PTPase	B
)	O
inhibitors	O
can	O
down	O
-	O
modulate	O
the	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
-mediated	O
activation	O
of	O
the	O
nuclear	B
transcription	I
factor	I
NF	I
-	I
kappa	I
B	I
in	O
ML-1a	O
,	O
a	O
monocytic	O
cell	O
line	O
(	O
Singh	O
and	O
Aggarwal	O
,	O
J.	O
Biol	O
.	O
Chem	O
.	O
1995	O
:	O
270	O
:	O
10631	O
)	O
.	O
Since	O
TNF	B
is	O
one	O
of	O
the	O
major	O
inducers	O
of	O
various	O
adhesion	B
molecules	I
in	O
human	O
endothelial	O
cells	O
and	O
their	O
expression	O
is	O
known	O
to	O
require	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
we	O
examined	O
the	O
effect	O
of	O
PTPase	B
inhibitors	O
on	O
the	O
TNF	B
-mediated	O
induction	O
of	O
intracellular	B
adhesion	I
molecule	I
(	I
ICAM	I
)	I
-1	I
,	O
vascular	B
cell	I
adhesion	I
molecule	I
(	I
VCAM	I
)	I
-1	I
and	O
endothelial	B
leukocyte	I
adhesion	I
molecule	I
(	I
ELAM	I
)	I
-1	I
.	O
Like	O
ML-1a	O
,	O
human	O
dermal	O
microvessel	O
endothelial	O
cells	O
(	O
MVEC	O
)	O
treated	O
with	O
TNF	B
rapidly	O
activated	O
(	O
within	O
30	O
min	O
)	O
NF	B
-	I
kappa	I
B	I
;	O
this	O
effect	O
was	O
completely	O
abolished	O
by	O
co	O
-	O
treatment	O
with	O
phenylarsine	O
oxide	O
(	O
PAO	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
PTPase	B
.	O
The	O
induction	O
of	O
ICAM-1	B
,	O
VCAM-1	B
,	O
and	O
ELAM-1	B
by	O
TNF	B
in	O
MVEC	O
occurred	O
within	O
6	O
h	O
and	O
was	O
also	O
completely	O
down	O
-	O
regulated	O
by	O
PAO	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
PAO	O
was	O
found	O
to	O
be	O
effective	O
even	O
when	O
added	O
3	O
h	O
after	O
TNF	B
,	O
suggesting	O
a	O
rapid	O
mode	O
of	O
action	O
of	O
this	O
inhibitor	O
.	O
Besides	O
PAO	O
,	O
other	O
inhibitors	O
of	O
PTPase	B
,	O
including	O
pervanadate	O
and	O
diamide	O
,	O
also	O
blocked	O
TNF	B
-dependent	O
NF	B
-	I
kappa	I
B	I
activation	O
and	O
induction	O
of	O
all	O
the	O
three	O
adhesion	B
proteins	I
.	O
Consistent	O
with	O
these	O
results	O
,	O
the	O
attachment	O
of	O
monocytes	O
to	O
MVEC	O
was	O
also	O
blocked	O
by	O
the	O
PTPase	B
inhibitors	O
.	O
Thus	O
,	O
overall	O
,	O
our	O
results	O
demonstrate	O
that	O
a	O
PTPase	B
is	O
involved	O
either	O
directly	O
or	O
indirectly	O
in	O
the	O
pathway	O
leading	O
to	O
the	O
induction	O
of	O
endothelial	B
cell	I
adhesion	I
molecules	I
by	O
TNF	B
.	O
Because	O
of	O
their	O
role	O
in	O
cell	O
adhesion	O
,	O
PTPase	B
may	O
provide	O
a	O
novel	O
target	O
of	O
drug	O
development	O
for	O
treatment	O
of	O
inflammation	O
,	O
atherogenesis	O
,	O
and	O
tumor	O
metastasis	O
.	O
The	O
spatial	O
distribution	O
of	O
human	O
immunoglobulin	O
genes	O
within	O
the	O
nucleus	O
:	O
evidence	O
for	O
gene	O
topography	O
independent	O
of	O
cell	O
type	O
and	O
transcriptional	O
activity	O
.	O
The	O
three	O
-	O
dimensional	O
positioning	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
genes	O
within	O
the	O
nucleus	O
of	O
human	O
cells	O
was	O
investigated	O
using	O
in	O
situ	O
hybridization	O
and	O
confocal	O
microscopy	O
.	O
The	O
visualization	O
of	O
heavy	O
and	O
light	O
chain	O
genes	O
in	O
B	O
-	O
lymphoid	O
cells	O
showed	O
that	O
the	O
three	O
Ig	O
genes	O
are	O
differentially	O
and	O
nonrandomly	O
distributed	O
in	O
different	O
nuclear	O
subvolumes	O
:	O
the	O
kappa	O
genes	O
were	O
found	O
to	O
be	O
preferentially	O
confined	O
to	O
an	O
outer	O
nuclear	O
volume	O
,	O
whereas	O
the	O
gamma	O
and	O
lambda	O
genes	O
consistently	O
occupied	O
more	O
central	O
positions	O
within	O
the	O
nucleus	O
,	O
the	O
lambda	O
genes	O
being	O
more	O
interior	O
when	O
compared	O
with	O
the	O
gamma	O
genes	O
.	O
The	O
data	O
further	O
show	O
that	O
these	O
overall	O
topographical	O
distributions	O
are	O
independent	O
of	O
gene	O
transcriptional	O
activity	O
and	O
are	O
conserved	O
in	O
different	O
cell	O
types	O
.	O
Although	O
subtle	O
gene	O
movements	O
within	O
those	O
defined	O
topographical	O
regions	O
can	O
not	O
be	O
excluded	O
by	O
this	O
study	O
,	O
the	O
results	O
indicate	O
that	O
tissue	O
specificity	O
of	O
gene	O
expression	O
is	O
not	O
accompanied	O
by	O
drastic	O
changes	O
in	O
gene	O
nuclear	O
topography	O
,	O
rather	O
suggesting	O
that	O
gene	O
organization	O
within	O
the	O
nucleus	O
may	O
be	O
primarily	O
dependent	O
on	O
structural	O
constraints	O
imposed	O
on	O
the	O
respective	O
chromosomes	O
.	O
Transcriptional	O
activation	O
of	O
the	O
vascular	O
cell	O
adhesion	O
molecule-1	O
gene	O
in	O
T	O
lymphocytes	O
expressing	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
1	I
Tax	I
protein	I
.	O
Recruitment	O
and	O
extravasation	O
of	O
T	O
cells	O
through	O
the	O
blood	O
-	O
brain	O
barrier	O
are	O
favored	O
by	O
adhesion	B
molecule	I
-mediated	O
interactions	O
of	O
circulating	O
T	O
cells	O
with	O
endothelial	O
cells	O
.	O
Since	O
a	O
common	O
pathological	O
finding	O
in	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
-associated	O
diseases	O
is	O
the	O
infiltration	O
of	O
HTLV-1-infected	O
T	O
lymphocytes	O
into	O
various	O
organs	O
,	O
we	O
have	O
looked	O
for	O
the	O
profile	O
of	O
adhesion	B
molecules	I
expressed	O
by	O
HTLV-1-transformed	O
T	O
cells	O
.	O
Flow	O
cytometry	O
analysis	O
indicated	O
that	O
these	O
cells	O
were	O
expressing	O
high	O
levels	O
of	O
vascular	B
cell	I
adhesion	I
molecule	I
1	I
(	O
VCAM-1	B
[	O
CD106	B
]	O
)	O
,	O
a	O
110-kDa	O
member	O
of	O
the	O
immunoglobulin	B
gene	I
superfamily	I
,	O
first	O
identified	O
on	O
endothelial	O
cells	O
stimulated	O
with	O
inflammatory	B
cytokines	I
.	O
This	O
adhesion	O
molecule	O
was	O
also	O
expressed	O
by	O
T	O
cells	O
obtained	O
from	O
one	O
patient	O
with	O
HTLV-1-associated	O
myelopathy	O
/	O
tropical	O
spastic	O
paraparesis	O
but	O
not	O
by	O
activated	O
T	O
cells	O
isolated	O
from	O
one	O
normal	O
blood	O
donor	O
.	O
The	O
role	O
of	O
the	O
viral	B
trans	I
-	I
activator	I
Tax	I
protein	I
in	O
the	O
induction	O
of	O
VCAM-1	B
was	O
first	O
indicated	O
by	O
the	O
detection	O
of	O
this	O
adhesion	B
molecule	I
on	O
Jurkat	O
T	O
-	O
cell	O
clones	O
stably	O
expressing	O
the	O
tax	O
gene	O
.	O
The	O
effect	O
of	O
Tax	B
on	O
VCAM-1	B
gene	O
transcription	O
was	O
next	O
confirmed	O
in	O
JPX-9	O
cells	O
,	O
a	O
subclone	O
of	O
Jurkat	O
cells	O
,	O
carrying	O
the	O
tax	O
sequences	O
under	O
the	O
control	O
of	O
an	O
inducible	O
promoter	O
.	O
Furthermore	O
,	O
deletion	O
and	O
mutation	O
analyses	O
of	O
the	O
VCAM-1	O
promoter	O
performed	O
with	O
chloramphenicol	O
acetyltransferase	O
constructs	O
revealed	O
that	O
Tax	B
was	O
trans	O
activating	O
the	O
VCAM-1	O
promoter	O
via	O
two	O
NF	O
-	O
kappaB	O
sites	O
present	O
at	O
bp	O
-72	O
and	O
-57	O
in	O
the	O
VCAM-1	O
gene	O
promoter	O
,	O
with	O
both	O
of	O
them	O
being	O
required	O
for	O
the	O
Tax	B
-induced	O
expression	O
of	O
this	O
adhesion	B
molecule	I
.	O
Finally	O
,	O
gel	O
mobility	O
shift	O
assays	O
demonstrated	O
the	O
nuclear	O
translocation	O
of	O
proteins	O
specifically	O
bound	O
to	O
these	O
two	O
NF	O
-	O
kappaB	O
motifs	O
,	O
confirming	O
that	O
VCAM-1	B
was	O
induced	O
on	O
Tax	O
-	O
expressing	O
cells	O
in	O
a	O
kappaB	B
-dependent	O
manner	O
.	O
Collectively	O
,	O
these	O
results	O
therefore	O
suggest	O
that	O
the	O
exclusive	O
Tax	B
-induced	O
expression	O
of	O
VCAM-1	B
on	O
T	O
cells	O
may	O
represent	O
a	O
pivotal	O
event	O
in	O
the	O
progression	O
of	O
HTLV-1-associated	O
diseases	O
.	O
Blockade	O
of	O
T	O
-	O
cell	O
activation	O
by	O
dithiocarbamates	O
involves	O
novel	O
mechanisms	O
of	O
inhibition	O
of	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
.	O
Dithiocarbamates	O
(	O
DTCs	O
)	O
have	O
recently	O
been	O
reported	O
as	O
powerful	O
inhibitors	O
of	O
NF	B
-	I
kappaB	I
activation	O
in	O
a	O
number	O
of	O
cell	O
types	O
.	O
Given	O
the	O
role	O
of	O
this	O
transcription	O
factor	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
in	O
the	O
inflammatory	O
response	O
,	O
NF	B
-	I
kappaB	I
inhibitors	O
have	O
been	O
suggested	O
as	O
potential	O
therapeutic	O
drugs	O
for	O
inflammatory	O
diseases	O
.	O
We	O
show	O
here	O
that	O
DTCs	O
inhibited	O
both	O
interleukin	B
2	I
(	O
IL-2	B
)	O
synthesis	O
and	O
membrane	O
expression	O
of	O
antigens	B
which	O
are	O
induced	O
during	O
T	O
-	O
cell	O
activation	O
.	O
This	O
inhibition	O
,	O
which	O
occurred	O
with	O
a	O
parallel	O
activation	O
of	O
c	B
-	I
Jun	I
transactivating	O
functions	O
and	O
expression	O
,	O
was	O
reflected	O
by	O
transfection	O
experiments	O
at	O
the	O
IL-2	O
promoter	O
level	O
,	O
and	O
involved	O
not	O
only	O
the	O
inhibition	O
of	O
NF	B
-	I
kappaB	I
-driven	O
reporter	O
activation	O
but	O
also	O
that	O
of	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT	B
)	O
.	O
Accordingly	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
indicated	O
that	O
pyrrolidine	O
DTC	O
(	O
PDTC	O
)	O
prevented	O
NF	B
-	I
kappaB	I
,	O
and	O
NFAT	B
DNA	O
-	O
binding	O
activity	O
in	O
T	O
cells	O
stimulated	O
with	O
either	O
phorbol	O
myristate	O
acetate	O
plus	O
ionophore	O
or	O
antibodies	O
against	O
the	O
CD3-T	B
-	I
cell	I
receptor	I
complex	I
and	O
simultaneously	O
activated	O
the	O
binding	O
of	O
AP-1	B
.	O
Furthermore	O
,	O
PDTC	O
differentially	O
targeted	O
both	O
NFATp	B
and	I
NFATc	I
family	I
members	I
,	O
inhibiting	O
the	O
transactivation	O
functions	O
of	O
NFATp	B
and	O
mRNA	O
induction	O
of	O
NFATc	B
.	O
Strikingly	O
,	O
Western	O
blotting	O
and	O
immunocytochemical	O
experiments	O
indicated	O
that	O
PDTC	O
promoted	O
a	O
transient	O
and	O
rapid	O
shuttling	O
of	O
NFATp	B
and	O
NFATc	B
,	O
leading	O
to	O
their	O
accelerated	O
export	O
from	O
the	O
nucleus	O
of	O
activated	O
T	O
cells	O
.	O
We	O
propose	O
that	O
the	O
activation	O
of	O
an	O
NFAT	O
kinase	O
by	O
PDTC	O
could	O
be	O
responsible	O
for	O
the	O
rapid	O
shuttling	O
of	O
the	O
NFAT	B
,	O
therefore	O
transiently	O
converting	O
the	O
sustained	O
transactivation	O
of	O
this	O
transcription	B
factor	I
that	O
occurs	O
during	O
lymphocyte	O
activation	O
,	O
and	O
show	O
that	O
c	B
-	I
Jun	I
NH2-terminal	I
kinase	I
(	O
JNK	B
)	O
can	O
act	O
by	O
directly	O
phosphorylating	O
NFATp	B
.	O
In	O
addition	O
,	O
the	O
combined	O
inhibitory	O
effects	O
on	O
NFAT	B
and	O
NF	B
-	I
KB	I
support	O
a	O
potential	O
use	O
of	O
DTCs	O
as	O
immunosuppressants	O
.	O
The	O
tax	B
protein	I
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
mediates	O
the	O
transactivation	O
of	O
the	O
c	O
-	O
sis	O
/	O
platelet	O
-	O
derived	O
growth	O
factor	O
-	O
B	O
promoter	O
through	O
interactions	O
with	O
the	O
zinc	B
finger	I
transcription	I
factors	I
Sp1	B
and	O
NGFI	B
-	I
A	I
/	I
Egr-1	I
.	O
Transcriptional	O
up	O
-	O
regulation	O
of	O
the	O
c	O
-	O
sis	O
/	O
platelet	O
-	O
derived	O
growth	O
factor	O
-	O
B	O
(	O
PDGF	O
-	O
B	O
)	O
proto	O
-	O
oncogene	O
by	O
the	O
Tax	B
protein	I
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
has	O
been	O
implicated	O
as	O
one	O
possible	O
mechanism	O
of	O
cellular	O
transformation	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
.	O
In	O
previous	O
work	O
,	O
we	O
identified	O
an	O
essential	O
site	O
in	O
the	O
c	O
-	O
sis	O
/	O
PDGF	O
-	O
B	O
promoter	O
,	O
Tax	O
-	O
responsive	O
element	O
1	O
(	O
TRE1	O
)	O
,	O
necessary	O
for	O
transactivation	O
by	O
Tax	B
.	O
We	O
also	O
identified	O
Sp1	B
,	O
Sp3	O
,	O
and	O
NGFI	B
-	I
A	I
/	I
Egr-1	I
as	O
the	O
primary	B
nuclear	I
transcription	I
factors	I
binding	O
to	O
TRE1	O
which	O
mediate	O
Tax	B
responsiveness	O
.	O
In	O
the	O
present	O
work	O
,	O
we	O
have	O
investigated	O
the	O
mechanism	O
(	O
s	O
)	O
whereby	O
Tax	B
transactivates	O
the	O
c	O
-	O
sis	O
/	O
PDGF	O
-	O
B	O
proto	O
-	O
oncogene	O
.	O
In	O
vitro	O
transcription	O
assays	O
showed	O
that	O
Tax	B
was	O
able	O
to	O
significantly	O
increase	O
the	O
transcriptional	O
activity	O
of	O
a	O
template	O
containing	O
the	O
-257	O
to	O
+	O
74	O
region	O
of	O
the	O
c	O
-	O
sis	O
/	O
PDGF	O
-	O
B	O
promoter	O
.	O
Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
showed	O
that	O
Tax	B
increased	O
the	O
DNA	O
binding	O
activity	O
of	O
both	O
Sp1	B
and	O
NGFI	B
-	I
A	I
/	I
Egr-1	I
using	O
a	O
TRE1	O
probe	O
.	O
Analysis	O
of	O
Tax	B
mutants	I
showed	O
that	O
two	O
mutants	O
,	O
IEXC29S	B
and	O
IEXL320	B
G	I
,	O
were	O
unable	O
to	O
significantly	O
transactivate	O
the	O
c	O
-	O
sis	O
/	O
PDGF	O
-	O
B	O
promoter	O
.	O
Finally	O
,	O
co	O
-	O
immunoprecipitation	O
analysis	O
revealed	O
that	O
Tax	B
is	O
able	O
to	O
stably	O
bind	O
to	O
both	O
Sp1	B
and	O
NGFI	B
-	I
A	I
/	I
Egr-1	I
.	O
Interestingly	O
,	O
co	O
-	O
immunoprecipitation	O
analysis	O
also	O
revealed	O
that	O
Tax	B
mutant	O
IEXC29S	B
is	O
unable	O
to	O
interact	O
with	O
NGFI	B
-	I
A	I
/	I
Egr-1	I
,	O
whereas	O
Tax	B
mutant	O
IEXL320	B
G	I
is	O
able	O
to	O
interact	O
with	O
NGFI	B
-	I
A	I
/	I
Egr-1	I
.	O
Suppression	O
of	O
nuclear	B
factor	I
kappa	I
B	I
and	O
CD18	B
-mediated	O
leukocyte	O
adhesion	O
to	O
the	O
corneal	O
endothelium	O
by	O
dexamethasone	O
.	O
PURPOSE	O
:	O
To	O
demonstrate	O
that	O
leukocyte	O
adhesion	O
to	O
cultured	O
corneal	O
endothelial	O
cells	O
is	O
mediated	O
by	O
the	O
CD18	B
antigen	I
,	O
and	O
to	O
determine	O
whether	O
dexamethasone	O
directly	O
suppresses	O
adhesion	O
by	O
inhibiting	O
activation	O
of	O
nuclear	B
factor	I
kappa	I
B	I
(	O
NFkappaB	B
)	O
.	O
METHODS	O
:	O
Cultured	O
bovine	O
corneal	O
endothelium	O
was	O
stimulated	O
for	O
6	O
hours	O
by	O
40	O
micron	O
/	O
ml	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNFalpha	B
)	O
.	O
Dexamethasone	O
was	O
added	O
1	O
hour	O
before	O
TNFalpha	B
stimulation	O
in	O
the	O
dexamethasone	O
group	O
.	O
After	O
stimulation	O
,	O
neutrophils	O
separated	O
from	O
a	O
healthy	O
human	O
volunteer	O
were	O
added	O
with	O
or	O
without	O
anti	B
-	I
CD18	I
antibody	I
.	O
The	O
culture	O
plate	O
was	O
settled	O
for	O
15	O
minutes	O
at	O
37	O
degrees	O
C	O
,	O
and	O
then	O
neutrophils	O
were	O
activated	O
by	O
N	O
-	O
formyl	O
-	O
methionyl	O
-	O
leucyl	O
-	O
phenylalanine	O
for	O
5	O
minutes	O
.	O
Nonadherent	O
neutrophils	O
were	O
removed	O
by	O
sealing	O
and	O
inverting	O
the	O
culture	O
well	O
.	O
The	O
intracellular	O
localization	O
of	O
NFkappaB	B
after	O
TNFalpha	B
simulation	O
was	O
determined	O
by	O
confocal	O
immunocytochemistry	O
using	O
an	O
anti	B
-	I
p65	I
antibody	I
.	O
RESULTS	O
:	O
Neutrophil	O
adhesion	O
to	O
cultured	O
corneal	O
endothelial	O
cells	O
increased	O
significantly	O
on	O
exposure	O
to	O
TNFalpha	B
(	O
451.4+	O
/	O
-45.4	O
cells	O
/	O
mm2	O
,	O
n	O
=	O
16	O
)	O
compared	O
to	O
control	O
(	O
156.7+	O
/	O
-27.3	O
cells	O
/	O
mm2	O
,	O
n	O
=	O
16	O
,	O
P	O
<	O
0.01	O
)	O
.	O
This	O
increased	O
adhesion	O
was	O
suppressed	O
by	O
the	O
addition	O
of	O
anti	B
-	I
CD18	I
antibody	I
(	O
157.6+	O
/	O
-25.1	O
cells	O
/	O
mm2	O
,	O
n	O
=	O
8	O
,	O
P	O
<	O
0.01	O
)	O
and	O
by	O
pretreatment	O
with	O
10	O
(	O
-7	O
)	O
M	O
dexamethasone	O
(	O
207.9+	O
/	O
-31.5	O
cells	O
/	O
mm2	O
,	O
n	O
=	O
10	O
,	O
P	O
<	O
0.01	O
)	O
.	O
Immunocytochemistry	O
60	O
minutes	O
after	O
stimulation	O
revealed	O
that	O
NFkappaB	B
was	O
located	O
in	O
the	O
cytoplasm	O
in	O
unstimulated	O
cells	O
;	O
however	O
,	O
the	O
addition	O
of	O
TNFalpha	B
caused	O
NFkappaB	B
to	O
translocate	O
into	O
the	O
nucleus	O
.	O
Pretreatment	O
with	O
dexamethasone	O
tapered	O
NFkappaB	B
translocation	O
into	O
the	O
nucleus	O
.	O
CONCLUSIONS	O
:	O
Leukocyte	O
adhesion	O
to	O
the	O
corneal	O
endothelium	O
was	O
shown	O
to	O
be	O
mediated	O
by	O
CD18	B
expressed	O
on	O
activated	O
leukocytes	O
.	O
Pretreatment	O
of	O
the	O
endothelium	O
with	O
dexamethasone	O
inhibited	O
leukocyte	O
adhesion	O
;	O
this	O
may	O
be	O
due	O
in	O
part	O
to	O
the	O
suppression	O
of	O
NFkappaB	B
entry	O
into	O
the	O
nucleus	O
.	O
Stable	O
transfection	O
of	O
U937	O
cells	O
with	O
sense	O
or	O
antisense	O
RXR	O
-	O
alpha	O
cDNA	O
suggests	O
a	O
role	O
for	O
RXR	B
-	I
alpha	I
in	O
the	O
control	O
of	O
monoblastic	O
differentiation	O
induced	O
by	O
retinoic	O
acid	O
and	O
vitamin	O
D	O
.	O
Although	O
retinoic	O
acid	O
(	O
RA	O
)	O
has	O
been	O
known	O
for	O
many	O
years	O
to	O
be	O
a	O
modulating	O
agent	O
that	O
plays	O
a	O
role	O
in	O
generating	O
both	O
granulocytes	O
and	O
monocytes	O
,	O
the	O
molecular	O
mechanism	O
underlying	O
this	O
role	O
has	O
not	O
been	O
defined	O
in	O
the	O
monoblast	O
lineage	O
.	O
In	O
particular	O
,	O
the	O
part	O
played	O
by	O
the	O
retinoid	B
X	I
receptors	I
(	O
RXRs	B
)	O
,	O
which	O
are	O
members	O
of	O
the	O
steroid	B
/	I
thyroid	I
hormone	I
nuclear	I
receptor	I
family	I
,	O
has	O
not	O
been	O
explored	O
.	O
In	O
this	O
study	O
,	O
therefore	O
,	O
the	O
human	O
monoblastic	O
leukemia	O
cell	O
line	O
U937	O
has	O
been	O
used	O
as	O
a	O
model	O
system	O
to	O
investigate	O
the	O
role	O
of	O
one	O
of	O
the	O
RXRs	B
,	O
RXR	B
-	I
alpha	I
,	O
in	O
monoblast	O
differentiation	O
.	O
RXR	O
-	O
alpha	O
mRNA	O
was	O
present	O
in	O
untreated	O
U937	O
cells	O
,	O
and	O
levels	O
increased	O
after	O
induction	O
of	O
differentiation	O
with	O
phorbol	O
ester	O
.	O
The	O
same	O
was	O
found	O
for	O
RXR	O
-	O
beta	O
mRNA	O
.	O
Using	O
plasmids	O
containing	O
sense	O
or	O
antisense	O
RXR	O
-	O
alpha	O
sequences	O
under	O
the	O
control	O
of	O
an	O
inducible	O
promoter	O
,	O
we	O
generated	O
stably	O
transfected	O
cell	O
lines	O
which	O
expressed	O
either	O
increased	O
or	O
decreased	O
levels	O
of	O
RXR	B
-	I
alpha	I
,	O
respectively	O
.	O
The	O
sense	O
cell	O
lines	O
(	O
U	O
alpha	O
S	O
and	O
its	O
clonal	O
derivative	O
alpha	O
G2S	O
)	O
showed	O
increased	O
sensitivity	O
to	O
RA	O
,	O
while	O
the	O
antisense	O
cell	O
lines	O
(	O
U	O
alpha	O
A	O
and	O
its	O
clonal	O
derivative	O
alpha	O
B5A	O
)	O
showed	O
decreased	O
sensitivity	O
to	O
RA	O
,	O
as	O
demonstrated	O
by	O
growth	O
inhibition	O
and	O
by	O
regulation	O
of	O
an	O
RA	O
-	O
responsive	O
reporter	O
gene	O
.	O
Both	O
U	O
alpha	O
A	O
and	O
alpha	O
B5A	O
also	O
failed	O
to	O
respond	O
to	O
another	O
modulating	O
agent	O
,	O
1	O
alpha	O
,	O
25-dihydroxycholecalciferol	O
(	O
DHCC	O
)	O
,	O
but	O
only	O
U	O
alpha	O
S	O
and	O
not	O
alpha	B
G2S	I
showed	O
an	O
enhanced	O
response	O
to	O
DHCC	O
.	O
The	O
combination	O
of	O
RA	O
and	O
DHCC	O
together	O
inhibited	O
growth	O
of	O
both	O
sense	O
and	O
antisense	O
cell	O
lines	O
.	O
In	O
addition	O
,	O
alpha	B
G2S	I
exhibited	O
increased	O
expression	O
of	O
CD11b	B
and	O
CD54	B
,	O
while	O
alpha	O
B5A	O
cells	O
showed	O
increased	O
expression	O
of	O
CD102	B
,	O
suggesting	O
that	O
RXR	B
-	I
alpha	I
has	O
a	O
role	O
in	O
regulating	O
expression	O
of	O
cell	B
adhesion	I
molecules	I
in	O
U937	O
cells	O
.	O
These	O
results	O
demonstrate	O
that	O
RXR	B
-	I
alpha	I
has	O
a	O
role	O
in	O
mediating	O
growth	O
inhibition	O
and	O
cell	O
adhesion	O
during	O
myelomonocytic	O
differentiation	O
,	O
and	O
suggest	O
that	O
different	O
species	O
of	O
heterodimers	B
involving	O
RXR	B
-	I
alpha	I
may	O
control	O
the	O
acquisition	O
of	O
different	O
features	O
of	O
mature	O
monocyte	O
/	O
macrophage	O
function	O
.	O
B	O
-	O
lymphoblastoid	O
cell	O
lines	O
from	O
multiple	O
sclerosis	O
patients	O
and	O
a	O
healthy	O
control	O
producing	O
a	O
putative	O
new	O
human	O
retrovirus	O
and	O
Epstein	O
-	O
Barr	O
virus	O
.	O
On	O
several	O
occasions	O
we	O
have	O
observed	O
retrovirus	O
-	O
like	O
particles	O
(	O
RVLPs	O
)	O
by	O
transmission	O
electron	O
microscopy	O
(	O
EM	O
)	O
of	O
cultured	O
T	O
cells	O
from	O
a	O
patient	O
with	O
MS	O
.	O
Later	O
we	O
established	O
spontaneously	O
formed	O
B	O
-	O
lymphoblastoid	O
cell	O
lines	O
(	O
LCLs	O
)	O
from	O
a	O
patient	O
with	O
an	O
MS	O
-	O
like	O
disease	O
and	O
from	O
another	O
patient	O
with	O
MS	O
who	O
had	O
a	O
reactivated	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
.	O
Both	O
LCLs	O
were	O
found	O
by	O
EM	O
to	O
produce	O
RVLP	O
and	O
EBV	O
particles	O
.	O
Reverse	O
transcriptase	O
(	O
RT	O
)	O
assays	O
were	O
positive	O
in	O
purified	O
viral	O
material	O
from	O
both	O
LCLs	O
.	O
To	O
substantiate	O
these	O
findings	O
we	O
initiated	O
an	O
intensified	O
culturing	O
procedure	O
and	O
were	O
able	O
to	O
establish	O
LCLs	O
from	O
5	O
out	O
of	O
21	O
consecutive	O
MS	O
patients	O
and	O
1	O
out	O
of	O
13	O
consecutive	O
healthy	O
controls	O
.	O
All	O
LCLs	O
were	O
found	O
to	O
produce	O
both	O
RVLP	O
and	O
EBV	O
particles	O
by	O
EM	O
.	O
Whether	O
the	O
putative	O
new	O
retrovirus	O
(	O
es	O
)	O
and	O
EBV	O
have	O
any	O
causal	O
relationship	O
to	O
MS	O
is	O
still	O
not	O
known	O
,	O
but	O
the	O
findings	O
support	O
this	O
possibility	O
.	O
Helenalin	O
,	O
an	O
anti	O
-	O
inflammatory	O
sesquiterpene	O
lactone	O
from	O
Arnica	O
,	O
selectively	O
inhibits	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
[	O
see	O
comments	O
]	O
Alcoholic	O
extracts	O
prepared	O
form	O
Arnicae	O
flos	O
,	O
the	O
collective	O
name	O
for	O
flowerheads	O
from	O
Arnica	O
montana	O
and	O
A.	O
chamissonis	O
ssp	O
.	O
foliosa	O
,	O
are	O
used	O
therapeutically	O
as	O
anti	O
-	O
inflammatory	O
remedies	O
.	O
The	O
active	O
ingredients	O
mediating	O
the	O
pharmacological	O
effect	O
are	O
mainly	O
sesquiterpene	O
lactones	O
,	O
such	O
as	O
helenalin	O
,	O
11alpha	O
,	O
13-dihydrohelenalin	O
,	O
chamissonolid	O
and	O
their	O
ester	O
derivatives	O
.	O
While	O
these	O
compounds	O
affect	O
various	O
cellular	O
processes	O
,	O
current	O
data	O
do	O
not	O
fully	O
explain	O
how	O
sesquiterpene	O
lactones	O
exert	O
their	O
anti	O
-	O
inflammatory	O
effect	O
.	O
We	O
show	O
here	O
that	O
helenalin	O
,	O
and	O
,	O
to	O
a	O
much	O
lesser	O
degree	O
,	O
11alpha	O
,	O
13-dihydrohelenalin	O
and	O
chamissonolid	O
,	O
inhibit	O
activation	O
of	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
.	O
This	O
difference	O
in	O
efficacy	O
,	O
which	O
correlates	O
with	O
the	O
compounds	O
'	O
anti	O
-	O
inflammatory	O
potency	O
in	O
vivo	O
,	O
may	O
be	O
explained	O
by	O
differences	O
in	O
structure	O
and	O
conformation	O
.	O
NF	B
-	I
kappaB	I
,	O
which	O
resides	O
in	O
an	O
inactive	O
,	O
cytoplasmic	B
complex	I
in	O
unstimulated	O
cells	O
,	O
is	O
activated	O
by	O
phosphorylation	O
and	O
degradation	O
of	O
its	O
inhibitory	B
subunit	I
,	O
IkappaB	B
.	O
Helenalin	O
inhibits	O
NF	B
-	I
kappaB	I
activation	O
in	O
response	O
to	O
four	O
different	O
stimuli	O
in	O
T	O
-	O
cells	O
,	O
B	O
-	O
cells	O
and	O
epithelial	O
cells	O
and	O
abrogates	O
kappaB	B
-driven	O
gene	O
expression	O
.	O
This	O
inhibition	O
is	O
selective	O
,	O
as	O
the	O
activity	O
of	O
four	O
other	O
transcription	B
factors	I
,	O
Oct-1	B
,	O
TBP	B
,	O
Sp1	B
and	O
STAT	B
5	I
was	O
not	O
affected	O
.	O
We	O
show	O
that	O
inhibition	O
is	O
not	O
due	O
to	O
a	O
direct	O
modification	O
of	O
the	O
active	O
NF	B
-	I
kappaB	I
heterodimer	I
.	O
Rather	O
,	O
helenalin	O
modifies	O
the	O
NF	B
-	I
kappaB	I
/	I
IkappaB	I
complex	I
,	O
preventing	O
the	O
release	O
of	O
IkappaB	B
.	O
These	O
data	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
sesquiterpene	O
lactones	O
,	O
which	O
differs	O
from	O
that	O
of	O
other	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
indomethacin	O
and	O
acetyl	O
salicylic	O
acid	O
.	O
Inhibition	O
of	O
T	O
cell	O
and	O
promotion	O
of	O
natural	O
killer	O
cell	O
development	O
by	O
the	O
dominant	B
negative	I
helix	I
loop	I
helix	I
factor	I
Id3	B
.	O
Bipotential	O
T	O
/	O
natural	O
killer	O
(	O
NK	O
)	O
progenitor	O
cells	O
are	O
present	O
in	O
the	O
human	O
thymus	O
.	O
Despite	O
their	O
bipotential	O
capacity	O
,	O
these	O
progenitors	O
develop	O
predominantly	O
to	O
T	O
cells	O
in	O
the	O
thymus	O
.	O
The	O
mechanisms	O
controlling	O
this	O
developmental	O
choice	O
are	O
unknown	O
.	O
Here	O
we	O
present	O
evidence	O
that	O
a	O
member	O
(	O
s	O
)	O
of	O
the	O
family	O
of	O
basic	B
helix	I
loop	I
helix	I
(	I
bHLH	I
)	I
transcription	I
factors	I
determines	O
lineage	O
specification	O
of	O
NK	O
/	O
T	O
cell	O
progenitors	O
.	O
The	O
natural	O
dominant	B
negative	I
HLH	I
factor	I
Id3	B
,	O
which	O
blocks	O
transcriptional	O
activity	O
of	O
a	O
number	O
of	O
known	O
bHLH	B
factors	I
,	O
was	O
expressed	O
in	O
CD34	O
+	O
progenitor	O
cells	O
by	O
retrovirus	O
-	O
mediated	O
gene	O
transfer	O
.	O
Constitutive	O
expression	O
of	O
Id3	B
completely	O
blocks	O
development	O
of	O
CD34	O
+	O
cells	O
into	O
T	O
cells	O
in	O
a	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O
In	O
contrast	O
,	O
development	O
into	O
NK	O
cells	O
in	O
an	O
FTOC	O
is	O
enhanced	O
.	O
Thus	O
,	O
the	O
activity	O
of	O
a	O
bHLH	B
transcription	I
factor	I
is	O
necessary	O
for	O
T	O
lineage	O
differentiation	O
of	O
bipotential	O
precursors	O
,	O
in	O
the	O
absence	O
of	O
which	O
a	O
default	O
pathway	O
leading	O
to	O
NK	O
cell	O
development	O
is	O
chosen	O
.	O
Our	O
results	O
identify	O
a	O
molecular	O
switch	O
for	O
lineage	O
specification	O
in	O
early	O
lymphoid	O
precursors	O
of	O
humans	O
.	O
Relationship	O
between	O
glucocorticoid	B
receptor	I
and	O
response	O
to	O
glucocorticoid	O
therapy	O
in	O
ulcerative	O
colitis	O
.	O
PURPOSE	O
:	O
To	O
clarify	O
the	O
relationship	O
between	O
the	O
glucocorticoid	B
receptor	I
and	O
the	O
effectiveness	O
of	O
glucocorticoid	O
therapy	O
in	O
patients	O
with	O
ulcerative	O
colitis	O
,	O
we	O
investigated	O
the	O
number	O
and	O
apparent	O
dissociation	O
constant	O
of	O
glucocorticoid	B
receptor	I
in	O
peripheral	O
blood	O
mononuclear	O
leukocytes	O
of	O
patients	O
with	O
ulcerative	O
colitis	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Eleven	O
patients	O
with	O
ulcerative	O
colitis	O
(	O
5	O
who	O
responded	O
to	O
intravenous	O
glucocorticoids	O
and	O
6	O
who	O
did	O
not	O
)	O
and	O
ten	O
control	O
subjects	O
were	O
studied	O
.	O
The	O
number	O
and	O
apparent	O
dissociation	O
constant	O
of	O
glucocorticoid	B
receptor	I
were	O
measured	O
using	O
a	O
whole	O
-	O
cell	O
binding	O
assay	O
.	O
Results	O
were	O
expressed	O
as	O
a	O
median	O
(	O
interquartile	O
range	O
)	O
.	O
RESULTS	O
:	O
The	O
number	O
of	O
glucocorticoid	B
receptors	I
from	O
the	O
six	O
nonresponders	O
,	O
five	O
responders	O
,	O
and	O
ten	O
healthy	O
controls	O
were	O
4922	O
(	O
range	O
,	O
4484	O
-	O
5643	O
)	O
,	O
3413	O
(	O
range	O
,	O
3183	O
-	O
4450	O
)	O
,	O
and	O
3610	O
(	O
range	O
,	O
2594	O
-	O
3979	O
)	O
binding	O
sites	O
/	O
cell	O
,	O
respectively	O
.	O
The	O
apparent	O
dissociation	O
constant	O
of	O
the	O
glucocorticoid	B
receptors	I
from	O
the	O
nonresponders	O
,	O
responders	O
,	O
and	O
healthy	O
controls	O
were	O
7.03	O
(	O
range	O
,	O
5.66	O
-	O
10	O
)	O
,	O
4.27	O
(	O
range	O
,	O
4	O
-	O
5.13	O
)	O
,	O
and	O
6.18	O
(	O
range	O
,	O
5.86	O
-	O
6.74	O
)	O
nM	O
,	O
respectively	O
.	O
Nonresponders	O
had	O
a	O
significant	O
increase	O
both	O
in	O
the	O
number	O
of	O
binding	B
sites	I
and	O
in	O
the	O
apparent	O
dissociation	O
constant	O
compared	O
with	O
responders	O
(	O
P	O
=	O
0.045	O
;	O
P	O
=	O
0.029	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
increased	O
number	O
and	O
apparent	O
dissociation	O
constant	O
of	O
glucocorticoid	B
receptor	I
are	O
closely	O
associated	O
with	O
the	O
effectiveness	O
of	O
glucocorticoid	O
therapy	O
.	O
The	O
measurement	O
of	O
the	O
number	O
and	O
apparent	O
dissociation	O
constant	O
of	O
glucocorticoid	B
receptor	I
may	O
be	O
useful	O
in	O
predicting	O
response	O
to	O
glucocorticoids	O
.	O
CD30	B
-dependent	O
degradation	O
of	O
TRAF2	B
:	O
implications	O
for	O
negative	O
regulation	O
of	O
TRAF	B
signaling	O
and	O
the	O
control	O
of	O
cell	O
survival	O
.	O
CD30	B
is	O
a	O
cell	B
-	I
surface	I
receptor	I
that	O
can	O
augment	O
lymphocyte	O
activation	O
and	O
survival	O
through	O
its	O
ability	O
to	O
induce	O
the	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
.	O
CD30	B
,	O
however	O
,	O
has	O
also	O
been	O
implicated	O
in	O
the	O
induction	O
of	O
apoptotic	O
cell	O
death	O
of	O
lymphocytes	O
.	O
Here	O
we	O
show	O
that	O
one	O
of	O
the	O
effects	O
of	O
CD30	B
signal	O
transduction	O
is	O
to	O
render	O
cells	O
sensitive	O
to	O
apoptosis	O
induced	O
by	O
the	O
type	B
1	I
tumor	I
necrosis	I
factor	I
receptor	I
(	O
TNFR1	B
)	O
.	O
This	O
sensitization	O
is	O
dependent	O
on	O
the	O
TRAF	B
-	I
binding	I
sites	I
within	O
the	O
CD30	B
cytoplasmic	B
domain	I
.	O
One	O
of	O
the	O
proteins	O
that	O
binds	O
to	O
these	O
sites	O
is	O
TRAF2	B
,	O
a	O
signal	B
transduction	I
molecule	I
that	O
is	O
also	O
utilized	O
by	O
TNFR1	B
to	O
mediate	O
the	O
activation	O
of	O
several	O
downstream	O
kinases	B
and	O
transcription	B
factors	I
.	O
During	O
CD30	B
signal	O
transduction	O
,	O
we	O
found	O
that	O
binding	O
of	O
TRAF2	B
to	O
the	O
cytoplasmic	B
domain	I
of	O
CD30	B
results	O
in	O
the	O
rapid	O
depletion	O
of	O
TRAF2	B
and	O
the	O
associated	O
protein	O
TRAF1	B
by	O
proteolysis	O
.	O
These	O
data	O
suggest	O
a	O
model	O
in	O
which	O
CD30	B
limits	O
its	O
own	O
ability	O
to	O
transduce	O
cell	O
survival	O
signals	O
through	O
signal	O
-	O
coupled	O
depletion	O
of	O
TRAF2	B
.	O
Depletion	O
of	O
intracellular	O
TRAF2	B
and	O
its	O
coassociated	B
proteins	I
also	O
increased	O
the	O
sensitivity	O
of	O
the	O
cell	O
to	O
undergoing	O
apoptosis	O
during	O
activation	O
of	O
death	B
-	I
inducing	I
receptors	I
such	O
as	O
TNFR1	B
.	O
Consistent	O
with	O
this	O
hypothesis	O
,	O
expression	O
of	O
a	O
dominant	B
-	I
negative	I
form	I
of	O
TRAF2	B
was	O
found	O
to	O
potentiate	O
TNFR1	B
-mediated	O
death	O
.	O
These	O
studies	O
provide	O
a	O
potential	O
mechanism	O
through	O
which	O
CD30	B
,	O
as	O
well	O
as	O
other	O
TRAF	B
-	I
binding	I
members	I
of	O
the	O
TNFR	B
superfamily	I
,	O
can	O
negatively	O
regulate	O
cell	O
survival	O
.	O
Switching	O
gears	O
during	O
T	O
-	O
cell	O
maturation	O
:	O
RANTES	B
and	O
late	O
transcription	O
.	O
Although	O
much	O
is	O
understood	O
about	O
the	O
induction	O
of	O
genes	O
expressed	O
early	O
(	O
within	O
24	O
h	O
)	O
after	O
T	O
-	O
cell	O
activation	O
,	O
little	O
is	O
known	O
about	O
the	O
regulation	O
of	O
expression	O
of	O
genes	O
expressed	O
'	O
late	O
'	O
(	O
three	O
or	O
more	O
days	O
)	O
post	O
-	O
stimulation	O
.	O
A	O
better	O
understanding	O
of	O
transcriptional	O
regulation	O
at	O
this	O
important	O
stage	O
of	O
T	O
-	O
cell	O
maturation	O
may	O
yield	O
new	O
insights	O
into	O
T	O
-	O
cell	O
development	O
and	O
new	O
immunotherapeutic	O
targets	O
.	O
PU.1	B
/	I
Pip	I
and	O
basic	B
helix	I
loop	I
helix	I
zipper	I
transcription	I
factors	I
interact	O
with	O
binding	O
sites	O
in	O
the	O
CD20	O
promoter	O
to	O
help	O
confer	O
lineage-	O
and	O
stage	O
-	O
specific	O
expression	O
of	O
CD20	B
in	O
B	O
lymphocytes	O
.	O
CD20	B
is	O
a	O
B	O
-	O
lineage	O
-	O
specific	O
gene	O
expressed	O
at	O
the	O
pre	O
-	O
B	O
-	O
cell	O
stage	O
of	O
B	O
-	O
cell	O
development	O
that	O
disappears	O
on	O
differentiation	O
to	O
plasma	O
cells	O
.	O
As	O
such	O
,	O
it	O
serves	O
as	O
an	O
excellent	O
paradigm	O
for	O
the	O
study	O
of	O
lineage	O
and	O
developmental	O
stage	O
-	O
specific	O
gene	O
expression	O
.	O
Using	O
in	O
vivo	O
footprinting	O
we	O
identified	O
two	O
sites	O
in	O
the	O
promoter	O
at	O
-45	O
and	O
-160	O
that	O
were	O
occupied	O
only	O
in	O
CD20	B
+	O
B	O
cells	O
.	O
The	O
-45	O
site	O
is	O
an	O
E	O
box	O
that	O
binds	O
basic	B
helix	I
-	I
loop	I
-	I
helix	I
-	I
zipper	I
proteins	I
whereas	O
the	O
-160	O
site	O
is	O
a	O
composite	O
PU.1	O
and	O
Pip	O
binding	O
site	O
.	O
Transfection	O
studies	O
with	O
reporter	O
constructs	O
and	O
various	O
expression	O
vectors	O
verified	O
the	O
importance	O
of	O
these	O
sites	O
.	O
The	O
composite	O
PU.1	O
and	O
Pip	O
site	O
likely	O
accounts	O
for	O
both	O
lineage	O
and	O
stage	O
-	O
specific	O
expression	O
of	O
CD20	B
whereas	O
the	O
CD20	B
E	I
box	I
binding	I
proteins	I
enhance	O
overall	O
promoter	O
activity	O
and	O
may	O
link	O
the	O
promoter	O
to	O
a	O
distant	O
enhancer	O
.	O
The	O
Epstein	B
-	I
Barr	I
virus	I
oncogene	I
product	I
latent	B
membrane	I
protein	I
1	I
engages	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
death	O
domain	O
protein	O
to	O
mediate	O
B	O
lymphocyte	O
growth	O
transformation	O
and	O
activate	O
NF	O
-	O
kappaB	O
.	O
The	O
Epstein	O
-	O
Barr	O
virus	O
latent	B
membrane	I
protein	I
1	I
(	O
LMP1	B
)	O
is	O
essential	O
for	O
the	O
transformation	O
of	O
B	O
lymphocytes	O
into	O
lymphoblastoid	O
cell	O
lines	O
.	O
Previous	O
data	O
are	O
consistent	O
with	O
a	O
model	O
that	O
LMP1	B
is	O
a	O
constitutively	B
activated	I
receptor	I
that	O
transduces	O
signals	O
for	O
transformation	O
through	O
its	O
carboxyl	B
-	I
terminal	I
cytoplasmic	I
tail	I
.	O
One	O
transformation	B
effector	I
site	I
(	O
TES1	B
)	O
,	O
located	O
within	O
the	O
membrane	B
proximal	I
45	I
residues	I
of	O
the	O
cytoplasmic	O
tail	O
,	O
constitutively	O
engages	O
tumor	B
necrosis	I
factor	I
receptor	I
-	I
associated	I
factors	I
.	O
Signals	O
from	O
TES1	B
are	O
sufficient	O
to	O
drive	O
initial	O
proliferation	O
of	O
infected	O
resting	O
B	O
lymphocytes	O
,	O
but	O
most	O
lymphoblastoid	O
cells	O
infected	O
with	O
a	O
virus	O
that	O
does	O
not	O
express	O
the	O
155	B
residues	I
beyond	O
TES1	B
fail	O
to	O
grow	O
as	O
long	O
-	O
term	O
cell	O
lines	O
.	O
We	O
now	O
find	O
that	O
mutating	O
two	O
tyrosines	O
to	O
an	O
isoleucine	O
at	O
the	O
carboxyl	B
end	I
of	O
the	O
cytoplasmic	B
tail	I
cripples	O
the	O
ability	O
of	O
EBV	O
to	O
cause	O
lymphoblastoid	O
cell	O
outgrowth	O
,	O
thereby	O
marking	O
a	O
second	O
transformation	B
effector	I
site	I
,	O
TES2	B
.	O
A	O
yeast	O
two	O
-	O
hybrid	O
screen	O
identified	O
TES2	B
interacting	I
proteins	I
,	O
including	O
the	O
tumor	B
necrosis	I
factor	I
receptor	I
-	I
associated	I
death	I
domain	I
protein	I
(	O
TRADD	B
)	O
.	O
TRADD	B
was	O
the	O
only	O
protein	O
that	O
interacted	O
with	O
wild	B
-	I
type	I
TES2	I
and	O
not	O
with	O
isoleucine	B
-	I
mutated	I
TES2	I
.	O
TRADD	B
associated	O
with	O
wild	B
-	I
type	I
LMP1	I
but	O
not	O
with	O
isoleucine	O
-	O
mutated	O
LMP1	B
in	O
mammalian	O
cells	O
,	O
and	O
TRADD	B
constitutively	O
associated	O
with	O
LMP1	B
in	O
EBV	O
-	O
transformed	O
cells	O
.	O
In	O
transfection	O
assays	O
,	O
TRADD	B
and	O
TES2	B
synergistically	O
mediated	O
high	O
-	O
level	O
NF	B
-	I
kappaB	I
activation	O
.	O
These	O
results	O
indicate	O
that	O
LMP1	B
appropriates	O
TRADD	B
to	O
enable	O
efficient	O
long	O
-	O
term	O
lymphoblastoid	O
cell	O
outgrowth	O
.	O
High	O
-	O
level	O
NF	B
-	I
kappaB	I
activation	O
also	O
appears	O
to	O
be	O
a	O
critical	O
component	O
of	O
long	O
-	O
term	O
outgrowth	O
.	O
The	O
activation	O
of	O
the	O
JAK2	B
/STAT5	B
pathway	O
is	O
commonly	O
involved	O
in	O
signaling	O
through	O
the	O
human	B
IL-5	I
receptor	I
.	O
The	O
JAK	B
(	I
Janus	I
kinase	I
)	I
family	I
of	O
protein	B
tyrosine	I
kinases	I
and	O
the	O
STATs	B
(	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
)	O
have	O
been	O
shown	O
to	O
be	O
activated	O
in	O
response	O
to	O
a	O
number	O
of	O
cytokines	B
and	O
growth	B
factors	I
.	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
activation	O
of	O
JAK	B
/STAT	B
pathway	O
upon	O
human	B
interleukin-5	I
(	O
hIL-5	B
)	O
stimulation	O
of	O
two	O
different	O
hIL-5-responsive	O
cell	O
lines	O
,	O
hIL-5	O
receptor	O
alpha	O
-	O
subunit	O
(	O
hIL-5R	O
alpha	O
)	O
cDNA	O
-	O
transfected	O
TF-1	O
(	O
TF	O
-	O
h5R	O
alpha	O
)	O
and	O
butyric	O
-	O
acid	O
-	O
treated	O
YY-1	O
(	O
YY	O
-	O
Bu	O
)	O
,	O
and	O
peripheral	O
eosinophils	O
.	O
Immunoprecipitation	O
and	O
electrophoretic	O
mobility	O
shift	O
analysis	O
revealed	O
that	O
tyrosine	O
phosphorylation	O
of	O
JAK2	B
and	O
activation	O
of	O
STAT5	B
were	O
induced	O
upon	O
stimulation	O
with	O
hIL-5	B
in	O
all	O
three	O
cell	O
types	O
,	O
while	O
STAT1	B
activation	O
was	O
only	O
observed	O
in	O
eosinophils	O
.	O
These	O
results	O
indicate	O
that	O
JAK2	B
/STAT5	B
activation	O
is	O
a	O
common	O
JAK	B
/STAT	B
pathway	O
for	O
hIL-5	B
-mediated	O
signal	O
in	O
these	O
cells	O
.	O
Transcription	B
factor	I
NF	B
-	I
kappaB	I
regulates	O
inducible	O
Oct-2	O
gene	O
expression	O
in	O
precursor	O
B	O
lymphocytes	O
.	O
The	O
POU	B
transcription	I
factors	I
Oct-1	B
and	O
Oct-2	B
regulate	O
the	O
activity	O
of	O
octamer	O
-	O
dependent	O
promoters	O
,	O
including	O
those	O
that	O
direct	O
transcription	O
from	O
rearranged	O
immunoglobulin	B
genes	I
.	O
Unlike	O
Oct-1	B
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
many	O
cell	O
types	O
,	O
Oct-2	B
expression	O
is	O
restricted	O
primarily	O
to	O
B	O
lymphocytes	O
and	O
can	O
be	O
induced	O
in	O
precursor	O
B	O
cells	O
by	O
stimulation	O
with	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
However	O
,	O
the	O
precise	O
factors	O
that	O
mediate	O
this	O
induction	O
mechanism	O
remain	O
unknown	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
monitored	O
Oct-2	B
expression	O
in	O
cells	O
arrested	O
for	O
the	O
activation	O
of	O
NF	B
-	I
kappaB	I
,	O
an	O
LPS	B
-	I
responsive	I
member	I
of	O
the	O
Rel	B
transcription	I
factor	I
family	I
.	O
Despite	O
stimulation	O
with	O
LPS	O
,	O
disruption	O
of	O
the	O
NF	B
-	I
kappaB	I
signaling	O
pathway	O
in	O
precursor	O
B	O
cells	O
led	O
to	O
the	O
loss	O
of	O
inducible	O
Oct-2	B
DNA	O
binding	O
activity	O
in	O
vitro	O
and	O
the	O
suppression	O
of	O
Oct-2	B
-directed	O
transcription	O
in	O
vivo	O
.	O
This	O
biochemical	O
defect	O
correlated	O
with	O
a	O
specific	O
block	O
to	O
Oct-2	O
gene	O
expression	O
at	O
the	O
level	O
of	O
transcription	O
,	O
whereas	O
the	O
expression	O
of	O
Oct-1	B
was	O
unaffected	O
.	O
The	O
finding	O
that	O
Oct-2	B
is	O
under	O
NF	B
-	I
kappaB	I
control	O
highlights	O
an	O
important	O
cross	O
-	O
talk	O
mechanism	O
involving	O
two	O
distinct	O
transcription	B
factor	I
families	I
that	O
regulate	O
B	O
lymphocyte	O
function	O
.	O
Is	O
celiac	O
disease	O
due	O
to	O
molecular	O
mimicry	O
between	O
gliadin	O
peptide	O
-HLA	B
class	I
II	I
molecule	I
-T	O
cell	O
interactions	O
and	O
those	O
of	O
some	O
unidentified	B
superantigen	I
?	O
This	O
paper	O
presents	O
a	O
new	O
hypothesis	O
for	O
the	O
etiology	O
and	O
pathogenesis	O
of	O
celiac	O
disease	O
(	O
CD	O
)	O
.	O
It	O
is	O
our	O
contention	O
that	O
CD	O
is	O
triggered	O
by	O
the	O
binding	O
of	O
one	O
or	O
more	O
gliadin	O
peptides	O
to	O
CD	B
-	I
associated	I
HLA	I
class	I
II	I
molecules	I
.	O
Furthermore	O
,	O
we	O
propose	O
that	O
these	O
putative	O
CD	O
peptides	O
bind	O
to	O
oligosaccharide	O
residues	O
on	O
HLA	B
class	I
II	I
molecules	I
distal	O
to	O
the	O
peptide	B
-	I
binding	I
groove	I
invoking	O
recognition	O
and	O
binding	O
by	O
specialized	O
subsets	O
of	O
gamma	O
delta	O
T	O
cell	O
receptor	O
-	O
bearing	O
lymphocytes	O
.	O
The	O
binding	O
of	O
these	O
gamma	O
delta	O
T	O
cells	O
serves	O
as	O
a	O
signal	O
for	O
abrogation	O
of	O
oral	O
tolerance	O
to	O
ingested	B
proteins	I
setting	O
in	O
motion	O
a	O
series	O
of	O
immune	O
responses	O
directed	O
against	O
the	O
small	O
intestinal	O
epithelium	O
of	O
CD	O
patients	O
.	O
CD	O
patients	O
are	O
victimized	O
by	O
this	O
self	O
-	O
distructed	O
immune	O
response	O
because	O
of	O
inheritance	O
of	O
certain	O
combinations	O
of	O
HLA	O
-	O
DQ	O
and	O
DR	O
haplotypes	O
.	O
Dimers	O
encoded	O
by	O
HLA	B
-	I
DR	I
haplotypes	O
may	O
be	O
the	O
primary	O
restriction	O
elements	O
for	O
lectin	O
-	O
like	O
,	O
gliadin	O
peptides	O
while	O
the	O
degree	O
of	O
immune	O
suppression	O
(	O
or	O
lack	O
thereof	O
)	O
to	O
ingested	O
gliadins	O
is	O
governed	O
by	O
inherited	O
HLA	O
-	O
DQ	O
haplotypes	O
.	O
Finally	O
,	O
we	O
speculate	O
that	O
molecular	O
mimicry	O
between	O
one	O
or	O
more	O
gliadin	O
peptides	O
and	O
some	O
,	O
as	O
yet	O
unidentified	O
,	O
bacterial	B
or	I
viral	I
superantigen	I
plays	O
a	O
role	O
in	O
disease	O
pathogenesis	O
.	O
Characterization	O
of	O
CD40	B
signaling	O
determinants	O
regulating	O
nuclear	B
factor	I
-	I
kappa	I
B	I
activation	O
in	O
B	O
lymphocytes	O
.	O
CD40	B
signaling	O
to	O
B	O
cells	O
is	O
important	O
for	O
generating	O
an	O
effective	O
humoral	O
immune	O
response	O
.	O
CD40	B
ligation	O
leads	O
to	O
B	O
cell	O
activation	O
events	O
such	O
as	O
proliferation	O
,	O
Ig	O
secretion	O
,	O
isotype	O
switching	O
,	O
and	O
up	O
-	O
regulation	O
of	O
cell	B
surface	I
molecules	I
,	O
as	O
well	O
as	O
the	O
generation	O
of	O
memory	O
B	O
cells	O
.	O
Many	O
of	O
these	O
events	O
are	O
dependent	O
upon	O
the	O
ability	O
of	O
CD40	B
to	O
activate	O
the	O
transcription	O
factor	O
NF	B
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
.	O
To	O
define	O
the	O
CD40	B
signaling	O
components	O
upstream	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
and	O
the	O
functional	O
consequences	O
downstream	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
,	O
we	O
examined	O
mouse	O
B	O
cell	O
transfectants	O
expressing	O
wild	B
-	I
type	I
or	I
mutant	I
human	I
CD40	I
.	O
Analysis	O
of	O
CD40	B
cytoplasmic	I
domain	I
truncation	O
and	O
point	O
mutants	O
defined	O
a	O
10-amino	B
acid	I
CD40	I
cytoplasmic	I
signaling	I
determinant	I
required	O
for	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
A	O
threonine	O
residue	O
at	O
position	B
234	I
,	O
previously	O
shown	O
to	O
be	O
important	O
for	O
CD40	B
association	O
with	O
TNF	B
receptor	I
-	I
associated	I
factor	I
2	I
(	O
TRAF2	B
)	O
,	O
TRAF3	B
,	O
and	O
TRAF5	B
,	O
was	O
not	O
required	O
for	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
This	O
suggests	O
that	O
in	O
B	O
cells	O
,	O
CD40	B
-induced	O
NF	B
-	I
kappa	I
B	I
activation	O
can	O
occur	O
independently	O
of	O
TRAF2	B
and	O
TRAF5	B
association	O
.	O
NF	B
-	I
kappa	I
B	I
activation	O
was	O
independent	O
of	O
the	O
transmembrane	B
domain	I
of	O
CD40	B
,	O
suggesting	O
that	O
it	O
is	O
independent	O
of	O
p23	B
,	O
a	O
molecule	O
that	O
associates	O
with	O
CD40	B
in	O
a	O
region	O
other	O
than	O
the	O
cytoplasmic	B
domain	I
.	O
Proteasome	O
-	O
dependent	O
inhibitory	O
kappa	O
B	O
alpha	O
(	O
I	B
kappa	I
B	I
alpha	I
)	O
and	O
I	B
kappa	I
B	I
beta	I
degradation	O
occurred	O
downstream	O
of	O
CD40	B
ligation	O
and	O
preceded	O
CD40	B
-mediated	O
NF	B
-	I
kappa	I
B	I
nuclear	O
translocation	O
.	O
CD40-	O
or	O
pervanadate	O
-	O
mediated	O
I	O
kappa	O
B	O
tyrosine	O
phosphorylation	O
was	O
not	O
detected	O
.	O
NF	B
-	I
kappa	I
B	I
activation	O
correlated	O
with	O
the	O
ability	O
of	O
CD40	B
to	O
induce	O
Ab	O
secretion	O
and	O
the	O
up	O
-	O
regulation	O
of	O
ICAM-1	B
and	O
LFA-1	B
.	O
However	O
,	O
NF	B
-	I
kappa	I
B	I
activation	O
was	O
insufficient	O
for	O
CD40	B
-mediated	O
up	O
-	O
regulation	O
of	O
B7	B
-	I
1	I
,	O
Fas	B
,	O
and	O
CD23	B
.	O
Impaired	O
cortisol	O
binding	O
to	O
glucocorticoid	B
receptors	I
in	O
hypertensive	O
patients	O
.	O
We	O
compared	O
glucocorticoid	O
receptor	O
binding	O
characteristics	O
and	O
glucocorticoid	O
responsiveness	O
of	O
human	O
mononuclear	O
leukocytes	O
(	O
HML	O
)	O
from	O
hypertensive	O
patients	O
and	O
matched	O
normotensive	O
volunteers	O
.	O
We	O
also	O
considered	O
associations	O
of	O
these	O
variables	O
with	O
plasma	O
renin	B
activity	O
,	O
aldosterone	O
,	O
cortisol	O
,	O
corticotropin	O
,	O
and	O
electrolyte	O
concentrations	O
.	O
We	O
calculated	O
binding	O
affinity	O
(	O
Kd	O
;	O
nmol	O
/	O
L	O
)	O
and	O
capacity	O
(	O
Bmax	O
;	O
sites	O
/	O
cell	O
)	O
for	O
dexamethasone	O
and	O
cortisol	O
from	O
homologous	O
and	O
heterologous	O
competition	O
curves	O
for	O
specific	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
sites	O
on	O
HML	O
isolated	O
from	O
the	O
blood	O
of	O
normotensive	O
volunteers	O
and	O
subjects	O
with	O
essential	O
hypertension	O
.	O
Glucocorticoid	O
responsiveness	O
of	O
HML	O
was	O
evaluated	O
as	O
IC50	O
values	O
(	O
nmol	O
/	O
L	O
)	O
for	O
dexamethasone	O
and	O
cortisol	O
for	O
the	O
inhibition	O
of	O
lysozyme	B
release	O
.	O
We	O
measured	O
plasma	O
hormones	O
by	O
radioimmunoassay	O
.	O
Kd	O
values	O
(	O
mean+	O
/	O
-SE	O
)	O
for	O
cortisol	O
in	O
HML	O
of	O
hypertensive	O
patients	O
were	O
higher	O
than	O
in	O
control	O
subjects	O
(	O
24.6+	O
/	O
-2.4	O
versus	O
17.5+	O
/	O
-1.7	O
nmol	O
/	O
L	O
,	O
P	O
<	O
.04	O
)	O
.	O
Binding	O
capacity	O
(	O
4978+	O
/	O
-391	O
versus	O
4131+	O
/	O
-321	O
sites	O
/	O
cell	O
)	O
,	O
Kd	O
values	O
for	O
dexamethasone	O
(	O
6.7+	O
/	O
-0.5	O
versus	O
5.7+	O
/	O
-0.3	O
nmol	O
/	O
L	O
)	O
,	O
and	O
IC50	O
values	O
for	O
dexamethasone	O
(	O
3.4+	O
/	O
-0.3	O
versus	O
3.1+	O
/	O
-0.2	O
nmol	O
/	O
L	O
)	O
and	O
cortisol	O
(	O
12.2+	O
/	O
-1.6	O
versus	O
9.5+	O
/	O
-0.3	O
nmol	O
/	O
L	O
)	O
were	O
not	O
significantly	O
different	O
.	O
Patients	O
with	O
renin	B
values	O
less	O
than	O
0.13	O
ng	O
angiotensin	O
I	O
/	O
L	O
per	O
second	O
were	O
markedly	O
less	O
sensitive	O
to	O
cortisol	O
than	O
those	O
with	O
higher	O
values	O
.	O
Both	O
Kd	O
(	O
30.3+	O
/	O
-2.5	O
versus	O
19.2+	O
/	O
-2.4	O
nmol	O
/	O
L	O
)	O
and	O
IC50	O
values	O
(	O
15.5+	O
/	O
-1.8	O
versus	O
8.9+	O
/	O
-1.2	O
nmol	O
/	O
L	O
)	O
for	O
cortisol	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
lower	O
renin	B
values	O
(	O
P	O
<	O
.03	O
)	O
.	O
Other	O
variables	O
,	O
including	O
plasma	O
hormone	O
and	O
electrolyte	O
values	O
and	O
binding	O
characteristics	O
for	O
dexamethasone	O
,	O
were	O
not	O
different	O
.	O
These	O
data	O
suggest	O
that	O
cortisol	O
binding	O
to	O
glucocorticoid	B
receptor	I
is	O
slightly	O
impaired	O
in	O
patients	O
with	O
essential	O
hypertension	O
.	O
In	O
vivo	O
,	O
this	O
could	O
lead	O
to	O
inappropriate	O
binding	O
of	O
cortisol	O
to	O
mineralocorticoid	O
receptors	O
.	O
Hence	O
,	O
decreased	O
sensitivity	O
to	O
cortisol	O
is	O
associated	O
with	O
renin	B
suppression	O
.	O
This	O
hypothesis	O
is	O
supported	O
by	O
evidence	O
of	O
hypertension	O
and	O
low	O
renin	B
activity	O
,	O
which	O
others	O
have	O
described	O
in	O
patients	O
with	O
primary	O
glucocorticoid	O
resistance	O
due	O
to	O
mutations	O
of	O
the	O
glucocorticoid	B
receptor	I
.	O
Regulation	O
of	O
Id3	B
cell	O
cycle	O
function	O
by	O
Cdk-2-dependent	O
phosphorylation	O
.	O
The	O
functions	O
of	O
basic	B
helix	I
-	I
loop	I
-	I
helix	I
(	I
bHLH	I
)	I
transcription	I
factors	I
in	O
activating	O
differentiation	O
-	O
linked	O
gene	O
expression	O
and	O
in	O
inducing	O
G1	O
cell	O
cycle	O
arrest	O
are	O
negatively	O
regulated	O
by	O
members	O
of	O
the	O
I	B
d	I
family	I
of	I
HLH	I
proteins	I
.	O
These	O
bHLH	B
antagonists	I
are	O
induced	O
during	O
a	O
mitogenic	O
signalling	O
response	O
,	O
and	O
they	O
function	O
by	O
sequestering	O
their	O
bHLH	B
targets	I
in	O
inactive	B
heterodimers	I
that	O
are	O
unable	O
to	O
bind	O
to	O
specific	O
gene	O
regulatory	O
(	O
E	O
box	O
)	O
sequences	O
.	O
Recently	O
,	O
cyclin	O
E	O
-	O
Cdk2-	O
and	O
cyclin	O
A	O
-	O
Cdk2-dependent	O
phosphorylation	O
of	O
a	O
single	O
conserved	O
serine	O
residue	O
(	O
Ser5	O
)	O
in	O
Id2	B
has	O
been	O
shown	O
to	O
occur	O
during	O
late	O
G1-to	O
-	O
S	O
phase	O
transition	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
this	O
neutralizes	O
the	O
function	O
of	O
Id2	B
in	O
abrogating	O
E	B
-	I
box	I
-	I
dependent	I
bHLH	I
homo	O
-or	O
heterodimer	O
complex	O
formation	O
in	O
vitro	O
(	O
E.Hara	O
,	O
M.Hall	O
,	O
and	O
G.Peters	O
,	O
EMBO	O
J.16	O
:	O
332	O
-	O
342	O
,	O
1997	O
)	O
.	O
We	O
now	O
show	O
that	O
an	O
analogous	O
cell	O
-	O
cycle	O
-	O
regulated	O
phosphorylation	O
of	O
Id3	B
alters	O
the	O
specificity	O
of	O
Id3	B
for	O
abrogating	O
both	O
E	B
-	I
box	I
-	I
dependent	I
bHLH	I
homo-	O
or	O
heterodimer	O
complex	O
formation	O
in	O
vitro	O
and	O
E	O
-	O
box	O
-	O
dependent	O
reporter	O
gene	O
function	O
in	O
vivo	O
.	O
Furthermore	O
,	O
compared	O
with	O
wild	B
-	I
type	I
Id3	I
,	O
an	O
Id3	B
Asp5	I
mutant	I
(	O
mimicking	O
phosphorylation	O
)	O
is	O
unable	O
to	O
promote	O
cell	O
cycle	O
S	O
phase	O
entry	O
in	O
transfected	O
fibroblasts	O
,	O
whereas	O
an	O
Id3	B
Ala5	I
mutant	I
(	O
ablating	O
phosphorylation	O
)	O
displays	O
an	O
activity	O
significantly	O
greater	O
than	O
that	O
of	O
wild	B
-	I
type	I
Id3	I
protein	I
.	O
Cdk2-dependent	O
phosphorylation	O
therefore	O
provides	O
a	O
switch	O
during	O
late	O
G1-to	O
-	O
S	O
phase	O
that	O
both	O
nullifies	O
an	O
early	O
G1	O
cell	O
cycle	O
regulatory	O
function	O
of	O
Id3	B
and	O
modulates	O
its	O
target	O
bHLH	B
specificity	O
.	O
These	O
data	O
also	O
demonstrate	O
that	O
the	O
ability	O
of	O
Id3	B
to	O
promote	O
cell	O
cycle	O
S	O
phase	O
entry	O
is	O
not	O
simply	O
a	O
function	O
of	O
its	O
ability	O
to	O
modulate	O
bHLH	B
heterodimer	O
-	O
dependent	O
gene	O
expression	O
and	O
establish	O
a	O
biologically	O
important	O
mechanism	O
through	O
which	O
Cdk2	O
and	O
Id	O
-	O
bHLH	O
functions	O
are	O
integrated	O
in	O
the	O
coordination	O
of	O
cell	O
proliferation	O
and	O
differentiation	O
.	O
Hypoxia	O
enhances	O
induction	O
of	O
endothelial	B
ICAM-1	I
:	O
role	O
for	O
metabolic	O
acidosis	O
and	O
proteasomes	B
.	O
Intercellular	B
adhesion	I
molecule	I
1	I
(	O
ICAM-1	B
)	O
is	O
an	O
important	O
molecule	O
in	O
promotion	O
of	O
polymorphonuclear	O
neutrophil	O
transendothelial	O
migration	O
during	O
inflammation	O
.	O
Coincident	O
with	O
many	O
inflammatory	O
diseases	O
is	O
tissue	O
hypoxia	O
.	O
Thus	O
we	O
hypothesized	O
that	O
combinations	O
of	O
hypoxia	O
and	O
inflammatory	O
stimuli	O
may	O
differentially	O
regulate	O
expression	O
of	O
endothelial	B
ICAM-1	I
.	O
Human	O
endothelial	O
cells	O
were	O
exposed	O
to	O
hypoxia	O
in	O
the	O
presence	O
or	O
absence	O
of	O
added	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
examined	O
for	O
expression	O
of	O
functional	O
ICAM-1	B
.	O
Although	O
hypoxia	O
alone	O
did	O
not	O
induce	O
ICAM-1	B
,	O
the	O
combination	O
of	O
LPS	O
and	O
hypoxia	O
enhanced	O
(	O
3	O
+	O
/-	O
0.4-fold	O
over	O
normoxia	O
)	O
ICAM-1	B
expression	O
.	O
Combinations	O
of	O
hypoxia	O
and	O
LPS	O
significantly	O
increased	O
lymphocyte	O
binding	O
,	O
and	O
such	O
increases	O
were	O
inhibited	O
by	O
addition	O
of	O
anti	B
-	I
ICAM-1	I
antibodies	I
or	O
antisense	O
oligonucleotides	O
.	O
Hypoxic	O
endothelia	O
showed	O
a	O
>	O
10-fold	O
increase	O
in	O
sensitivity	O
to	O
inhibitors	O
of	O
proteasome	B
activation	O
,	O
and	O
combinations	O
of	O
hypoxia	O
and	O
LPS	O
enhanced	O
proteasome	B
-dependent	O
cytoplasmic	O
-	O
to	O
-	O
nuclear	O
localization	O
of	O
the	O
nuclear	B
transcription	I
factor	I
-	I
kappa	I
B	I
p65	I
(	I
Rel	I
A	I
)	I
subunit	I
.	O
Such	O
proteasome	B
activation	O
correlated	O
with	O
hypoxia	O
-	O
evoked	O
decreases	O
in	O
both	O
extracellular	O
and	O
intracellular	O
pH	O
.	O
We	O
conclude	O
from	O
these	O
studies	O
that	O
endothelial	O
hypoxia	O
provides	O
a	O
novel	O
,	O
proteasome	B
-dependent	O
stimulus	O
for	O
ICAM-1	B
induction	O
.	O
[	O
The	O
value	O
of	O
the	O
clinical	O
test	O
of	O
glucocorticoid	B
receptors	I
of	O
peripheral	O
blood	O
leukocytes	O
in	O
patients	O
with	O
chronic	O
pulmonary	O
heart	O
disease	O
]	O
In	O
order	O
to	O
inquire	O
into	O
the	O
functional	O
state	O
of	O
adrenal	O
cortex	O
in	O
patients	O
with	O
pulmonary	O
heart	O
disease	O
,	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
(	O
GCR	B
)	O
of	O
peripheral	O
blood	O
leukocytes	O
in	O
patients	O
with	O
chronic	O
pulmonary	O
heart	O
disease	O
was	O
determined	O
with	O
radioligand	O
-	O
binding	O
assay	O
and	O
the	O
corresponding	O
plasma	O
cortisol	O
levels	O
were	O
assessed	O
with	O
radioimmune	O
assays	O
.	O
The	O
results	O
showed	O
that	O
the	O
number	O
of	O
GCR	B
in	O
the	O
patients	O
was	O
significantly	O
reduced	O
(	O
P	O
<	O
0.01	O
)	O
and	O
it	O
was	O
increased	O
when	O
their	O
health	O
state	O
was	O
improved	O
.	O
However	O
,	O
it	O
was	O
still	O
lower	O
than	O
that	O
in	O
healthy	O
subjects	O
(	O
P	O
<	O
0.01	O
)	O
.	O
The	O
number	O
of	O
GCR	B
in	O
the	O
patients	O
was	O
greatly	O
increased	O
when	O
these	O
patients	O
were	O
treated	O
with	O
oxygen	O
(	O
P	O
<	O
0.01	O
)	O
.	O
No	O
difference	O
in	O
plasma	O
cortisol	O
was	O
found	O
between	O
the	O
patients	O
and	O
the	O
healthy	O
subjects	O
(	O
P	O
>	O
0.05	O
)	O
.	O
These	O
results	O
indicate	O
that	O
the	O
function	O
of	O
adrenal	O
cortex	O
may	O
be	O
improved	O
by	O
the	O
compensation	O
mechanism	O
of	O
the	O
patients	O
,	O
but	O
the	O
lower	O
GCR	B
number	O
was	O
the	O
result	O
of	O
lacking	O
of	O
oxygen	O
in	O
the	O
patients	O
.	O
The	O
number	O
of	O
GCR	B
may	O
be	O
improved	O
by	O
inhalation	O
of	O
oxygen	O
.	O
Therefore	O
oxygen	O
therapy	O
is	O
helpful	O
in	O
raising	O
the	O
activity	O
of	O
glucocorticoid	B
receptors	I
and	O
controlling	O
the	O
development	O
of	O
the	O
disease	O
.	O
Molecular	O
cloning	O
and	O
functional	O
characterization	O
of	O
murine	B
cDNA	I
encoding	I
transcription	I
factor	I
NFATc	B
.	O
Transcription	B
factors	I
of	O
the	O
NFAT	B
(	I
nuclear	I
factor	I
of	I
activated	I
T	I
cells	I
)	I
family	I
play	O
important	O
roles	O
in	O
immune	O
and	O
inflammatory	O
responses	O
by	O
regulating	O
the	O
expression	O
of	O
genes	O
encoding	O
cytokines	B
and	O
immunoregulatory	B
proteins	I
.	O
Here	O
we	O
describe	O
cloning	O
and	O
characterization	O
of	O
full	O
-	O
length	O
cDNA	B
encoding	I
murine	I
(	I
m	I
)	I
NFATc	I
which	O
predicts	O
that	O
the	O
protein	O
has	O
all	O
the	O
conserved	B
structural	I
motifs	I
of	O
NFAT	B
family	I
members	I
,	O
including	O
the	O
rel	O
homology	O
domain	O
,	O
the	O
NFAT	B
homology	I
domain	I
and	O
the	O
nuclear	O
translocation	O
signals	O
.	O
mNFATc	B
complexed	O
with	O
AP-1	B
bound	O
specifically	O
to	O
the	O
murine	B
IL-2	I
NFAT	I
recognition	I
sequence	I
and	O
activated	O
transcription	O
from	O
the	O
co	O
-	O
transfected	O
IL-2	O
promoter	O
in	O
COS-7	O
cells	O
.	O
Northern	O
blot	O
analysis	O
showed	O
that	O
the	O
cDNA	O
probe	O
hybridized	O
with	O
a	O
4.5	O
kb	O
transcript	O
which	O
is	O
highly	O
inducible	O
in	O
murine	O
T	O
cells	O
.	O
By	O
Northern	O
and	O
in	O
situ	O
hybridization	O
,	O
mNFATc	O
transcript	O
was	O
detected	O
from	O
the	O
early	O
stage	O
of	O
development	O
.	O
In	O
the	O
mouse	O
embryo	O
,	O
mNFATc	O
transcript	O
was	O
strongly	O
expressed	O
in	O
thymus	O
,	O
lung	O
and	O
submandibular	O
gland	O
and	O
weakly	O
in	O
skeletal	O
muscle	O
and	O
heart	O
suggesting	O
that	O
mNFATc	B
may	O
have	O
a	O
role	O
both	O
in	O
embryogenesis	O
and	O
in	O
mature	O
T	O
cells	O
.	O
Thiol	O
modulation	O
inhibits	O
the	O
interleukin	B
(	I
IL	I
)	I
-1	I
-mediated	O
activation	O
of	O
an	O
IL-1	B
receptor	I
-	I
associated	I
protein	I
kinase	I
and	O
NF	B
-	I
kappa	I
B	I
.	O
The	O
interleukin-1	B
receptor	I
type	I
I	I
(	O
IL-1RI	B
)	O
is	O
associated	O
with	O
other	O
proteins	O
thus	O
forming	O
a	O
complex	B
system	I
by	O
which	O
IL-1	B
exerts	O
its	O
various	O
signals	O
.	O
The	O
initiating	O
event	O
is	O
still	O
uncertain	O
,	O
but	O
activation	O
of	O
a	O
recently	O
described	O
receptor	B
-	I
associated	I
protein	I
kinase	I
is	O
one	O
of	O
the	O
earliest	O
events	O
detectable	O
(	O
Martin	O
et	O
al.	O
,	O
Eur	O
.	O
J.Immunol.1994.24	O
:	O
1566	O
)	O
.	O
IL-1	B
signaling	O
is	O
commonly	O
accompanied	O
by	O
oxidative	O
processes	O
and	O
is	O
thought	O
to	O
be	O
subject	O
to	O
redox	O
regulation	O
.	O
We	O
therefore	O
investigated	O
whether	O
the	O
activation	O
of	O
the	O
IL-1RI	B
-	I
associated	I
protein	I
kinase	I
could	O
be	O
a	O
target	O
for	O
redox	O
regulation	O
and	O
whether	O
an	O
altered	O
activity	O
of	O
the	O
kinase	O
could	O
influence	O
IL-1	B
-mediated	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
A	O
murine	O
T	O
cell	O
line	O
,	O
EL4	O
,	O
was	O
stimulated	O
with	O
IL-1	B
with	O
and	O
without	O
pretreatment	O
with	O
different	O
compounds	O
known	O
to	O
influence	O
the	O
cellular	O
redox	O
status	O
.	O
Thiol	O
modifying	O
agents	O
like	O
diamide	O
,	O
menadione	O
,	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
diethyl	O
dithiocarbamate	O
or	O
phenylarsine	O
oxide	O
inhibited	O
the	O
IL-1	B
-induced	O
activation	O
of	O
the	O
IL-1RI	B
-	I
associated	I
protein	I
kinase	I
.	O
N	O
-	O
Acetylcysteine	O
,	O
alpha	O
,	O
alpha'-dipyridyl	O
,	O
aminotriazole	O
or	O
nitrofurantoin	O
did	O
not	O
show	O
any	O
effect	O
.	O
The	O
inhibition	O
by	O
PDTC	O
was	O
reversible	O
unless	O
glutathione	O
synthesis	O
was	O
blocked	O
by	O
buthionine	O
sulfoximine	O
.	O
The	O
described	O
conditions	O
which	O
inhibited	O
or	O
prevented	O
the	O
activation	O
of	O
the	O
IL-1RI	B
-	I
associated	I
kinase	I
similarly	O
impaired	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
EL4	O
cells	O
.	O
From	O
these	O
observations	O
we	O
conclude	O
that	O
free	O
thiols	O
in	O
the	O
IL-1RI	B
complex	I
are	O
essential	O
for	O
the	O
activation	O
of	O
the	O
IL-1RI	B
-	I
associated	I
protein	I
kinase	I
and	O
that	O
this	O
process	O
is	O
mandatory	O
for	O
IL-1	B
signaling	O
leading	O
to	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
Differanisole	O
A	O
,	O
a	O
novel	O
antitumor	O
antibiotic	O
,	O
enhances	O
growth	O
inhibition	O
and	O
differentiation	O
of	O
human	O
myeloid	O
leukemia	O
cells	O
induced	O
by	O
9-cis	O
retinoic	O
acid	O
.	O
Differanisole	O
A	O
,	O
3	O
,	O
5-dichloro-2-hydroxy-4-methoxy-6-n	O
-	O
propylbenzoic	O
acid	O
,	O
inhibited	O
growth	O
of	O
human	O
myeloid	O
leukemia	O
cells	O
.	O
The	O
compound	O
induced	O
G1	O
arrest	O
and	O
granulocytic	O
differentiation	O
of	O
HL-60	O
cells	O
,	O
although	O
the	O
differentiation	O
-	O
inducing	O
effect	O
was	O
modest	O
.	O
Differanisole	O
A	O
and	O
9-cis	O
retinoic	O
acid	O
(	O
9cisRA	O
)	O
synergistically	O
inhibited	O
the	O
growth	O
and	O
induced	O
functional	O
and	O
morphologic	O
differentiation	O
of	O
HL-60	O
and	O
NB4	O
cells	O
,	O
whereas	O
the	O
combined	O
treatment	O
with	O
differanisole	O
A	O
and	O
all	O
-	O
trans	O
retinoic	O
acid	O
or	O
1alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
was	O
less	O
effective	O
.	O
Similar	O
results	O
were	O
obtained	O
in	O
primary	O
culture	O
of	O
leukemia	O
cells	O
from	O
a	O
patient	O
with	O
acute	O
promyelocytic	O
leukemia	O
.	O
The	O
synergistic	O
effect	O
on	O
growth	O
inhibition	O
and	O
induction	O
of	O
differentiation	O
required	O
simultaneous	O
treatment	O
with	O
differanisole	O
A	O
and	O
9cisRA	O
.	O
Differanisole	O
A	O
and	O
an	O
RXR	O
-	O
specific	O
ligand	O
(	O
Ro47	O
-	O
5944	O
)	O
cooperatively	O
inhibited	O
the	O
cell	O
growth	O
,	O
while	O
the	O
combined	O
effect	O
of	O
differanisole	O
A	O
and	O
an	O
RAR	O
-	O
specific	O
ligand	O
Am80	O
was	O
just	O
additive	O
.	O
Differanisole	O
A	O
in	O
combination	O
with	O
9cisRA	O
may	O
have	O
implications	O
for	O
therapy	O
of	O
acute	O
promyelocytic	O
leukemia	O
patients	O
.	O
ATF1	B
and	O
CREB	B
trans	O
-	O
activate	O
a	O
cell	O
cycle	O
regulated	O
histone	O
H4	O
gene	O
at	O
a	O
distal	O
nuclear	O
matrix	O
associated	O
promoter	O
element	O
.	O
Proteins	O
of	O
the	O
ATF	O
/	O
CREB	B
class	O
of	O
transcription	B
factors	I
stimulate	O
gene	O
expression	O
of	O
several	O
cell	O
growth	O
-	O
related	O
genes	O
through	O
protein	O
kinase	O
A	O
-	O
related	O
cAMP	O
response	O
elements	O
.	O
The	O
promoter	O
activity	O
of	O
cell	O
cycle	O
regulated	O
histone	O
H4	O
genes	O
is	O
regulated	O
by	O
at	O
least	O
four	O
principal	O
cis	O
-	O
acting	O
elements	O
which	O
mediate	O
G1	O
/	O
S	O
phase	O
control	O
and/or	O
enhancement	O
of	O
transcription	O
during	O
the	O
cell	O
cycle	O
.	O
Using	O
protein	O
-	O
DNA	O
interaction	O
assays	O
we	O
show	O
that	O
the	O
H4	O
promoter	O
contains	O
two	O
ATF	O
/	O
CREB	B
recognition	O
motifs	O
which	O
interact	O
with	O
CREB	B
,	O
ATF1	B
,	O
and	O
ATF2	B
but	O
not	O
with	O
ATF4	B
/	I
CREB2	I
.	O
One	O
ATF	O
/	O
CRE	O
motif	O
is	O
located	O
in	O
the	O
distal	O
promoter	O
at	O
the	O
nuclear	O
matrix	O
-	O
associated	O
Site	O
IV	O
,	O
and	O
the	O
second	O
motif	O
is	O
present	O
in	O
the	O
proximal	O
promoter	O
at	O
Site	O
I	O
.	O
Both	O
ATF	O
/	O
CRE	O
motifs	O
overlap	O
binding	O
sequences	O
for	O
the	O
multifunctional	B
YY1	I
transcription	I
factor	I
,	O
which	O
has	O
previously	O
been	O
shown	O
to	O
be	O
nuclear	O
matrix	O
associated	O
.	O
Subnuclear	O
fractionation	O
reveals	O
that	O
there	O
are	O
two	O
ATF1	B
isoforms	I
which	O
appear	O
to	O
differ	O
with	O
respect	O
to	O
DNA	O
binding	O
activity	O
and	O
partition	O
selectively	O
between	O
nuclear	O
matrix	O
and	O
nonmatrix	O
compartments	O
,	O
consistent	O
with	O
the	O
role	O
of	O
the	O
nuclear	O
matrix	O
in	O
regulating	O
gene	O
expression	O
.	O
Site	O
-	O
directed	O
mutational	O
studies	O
demonstrate	O
that	O
Site	O
I	O
and	O
Site	O
IV	O
together	O
support	O
ATF1-	O
and	O
CREB	O
-	O
induced	O
trans	O
-	O
activation	O
of	O
the	O
H4	O
promoter	O
.	O
Thus	O
,	O
our	O
data	O
establish	O
that	O
ATF	B
/	I
CREB	I
factors	I
functionally	O
modulate	O
histone	O
H4	O
gene	O
transcription	O
at	O
distal	O
and	O
proximal	O
promoter	O
elements	O
.	O
IL-2	B
and	O
IL-7	B
induce	O
heterodimerization	O
of	O
STAT5	B
isoforms	I
in	O
human	O
peripheral	O
blood	O
T	O
lymphoblasts	O
.	O
Despite	O
differences	O
in	O
T	O
cell	O
responses	O
induced	O
by	O
interleukin	B
(	I
IL	I
)	I
-2	I
and	O
IL-7	B
,	O
both	O
cytokines	B
modulate	O
T	O
cell	O
functions	O
by	O
activation	O
of	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	I
STAT	I
)	I
proteins	I
.	O
We	O
examined	O
the	O
contribution	O
of	O
the	O
two	O
isoforms	O
of	O
STAT5	B
,	O
STAT5A	B
and	O
STAT5B	B
,	O
to	O
IL-2-	O
and	O
IL-7-induced	O
activation	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphoblasts	O
.	O
Both	O
cytokines	B
induced	O
assembly	O
of	O
STAT5A	B
and	O
STAT5B	B
containing	O
complexes	O
capable	O
of	O
binding	O
to	O
the	O
interferon	O
-	O
gamma	O
activation	O
sequence	O
(	O
GAS	O
)	O
,	O
and	O
these	O
complexes	O
rapidly	O
translocated	O
(	O
within	O
1	O
min	O
)	O
into	O
the	O
nucleus	O
of	O
IL-2-	O
or	O
IL-7-treated	O
cells	O
.	O
The	O
kinetics	O
of	O
this	O
translocation	O
were	O
delayed	O
in	O
IL-7-treated	O
as	O
compared	O
to	O
IL-2-treated	O
cells	O
.	O
IL-2	B
and	O
IL-7	B
were	O
equivalent	O
in	O
their	O
ability	O
to	O
induce	O
tyrosine	O
phosphorylation	O
of	O
STAT5A	B
and	O
STAT5B	B
and	O
to	O
facilitate	O
binding	O
of	O
these	O
STATs	B
to	O
an	O
immobilized	O
GAS	O
element	O
.	O
Both	O
IL-2	B
and	O
IL-7	B
induced	O
substantial	O
amounts	O
of	O
STAT5A	B
/STAT5B	B
heterodimerization	O
.	O
Moreover	O
,	O
we	O
observed	O
constitutive	O
association	O
of	O
STAT3	B
with	O
each	O
STAT5	B
isomer	I
.	O
These	O
data	O
suggest	O
that	O
IL-2	B
and	O
IL-7	B
induce	O
assembly	O
of	O
STAT	B
heterodimers	I
in	O
a	O
similar	O
manner	O
and	O
that	O
subsequent	O
cellular	O
responses	O
may	O
be	O
driven	O
by	O
induction	O
of	O
similar	O
sets	O
of	O
genes	O
.	O
B	O
lymphocytes	O
from	O
patients	O
with	O
chronic	O
lymphocytic	O
leukemia	O
contain	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	I
STAT	I
)	I
1	I
and	O
STAT3	B
constitutively	O
phosphorylated	O
on	O
serine	O
residues	O
.	O
To	O
explore	O
the	O
pathogenesis	O
of	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
,	O
we	O
examined	O
whether	O
phosphorylation	O
of	O
one	O
or	O
more	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	I
STAT	I
)	I
factors	I
was	O
abnormal	O
in	O
cells	O
from	O
CLL	O
patients	O
.	O
No	O
constitutive	O
tyrosine	O
phosphorylation	O
was	O
detected	O
on	O
any	O
STAT	B
in	O
CLL	O
cells	O
.	O
To	O
assess	O
the	O
phosphorylation	O
of	O
serine	O
residues	O
of	O
STAT1	B
and	O
STAT3	B
in	O
CLL	O
cells	O
,	O
we	O
raised	O
antibodies	O
that	O
specifically	O
recognize	O
the	O
form	O
of	O
STAT1	B
phosphorylated	O
on	O
ser-727	O
and	O
the	O
form	O
of	O
STAT3	B
phosphorylated	O
on	O
ser-727	O
.	O
We	O
found	O
that	O
in	O
100	O
%	O
of	O
patients	O
with	O
CLL	O
(	O
n	O
=	O
32	O
)	O
,	O
STAT1	B
and	O
STAT3	B
were	O
constitutively	O
phosphorylated	O
on	O
serine	O
.	O
This	O
was	O
in	O
contrast	O
to	O
normal	O
peripheral	O
blood	O
B	O
lymphocytes	O
or	O
CD5	O
+	O
)	O
B	O
cells	O
isolated	O
from	O
tonsils	O
,	O
in	O
which	O
this	O
phosphorylation	O
was	O
absent	O
.	O
Serine	O
phosphorylation	O
of	O
STAT1	B
and	O
STAT3	B
was	O
seen	O
occasionally	O
in	O
other	O
leukemias	O
,	O
but	O
it	O
was	O
a	O
universal	O
finding	O
only	O
in	O
CLL	O
.	O
The	O
serine	O
phosphorylation	O
of	O
these	O
STATs	B
was	O
a	O
continuous	O
process	O
,	O
as	O
incubation	O
of	O
CLL	O
cells	O
with	O
the	O
kinase	B
inhibitor	I
H7	I
led	O
to	O
the	O
dephosphorylation	O
of	O
these	O
serine	O
residues	O
.	O
The	O
STAT	O
serine	O
kinase	O
in	O
CLL	O
cells	O
has	O
not	O
been	O
identified	O
,	O
and	O
appears	O
to	O
be	O
neither	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
nor	O
pp70	B
(	I
s6k	I
)	I
.	O
In	O
summary	O
,	O
the	O
constitutive	O
serine	O
phosphorylation	O
of	O
STAT1	B
and	O
STAT3	B
is	O
present	O
in	O
all	O
CLL	O
samples	O
tested	O
to	O
date	O
,	O
although	O
the	O
physiologic	O
significance	O
of	O
this	O
modification	O
remains	O
to	O
be	O
determined	O
.	O
C	B
/	I
EBP	I
activates	O
the	O
human	O
corticotropin	O
-	O
releasing	O
hormone	O
gene	O
promoter	O
.	O
The	O
purpose	O
of	O
these	O
studies	O
was	O
to	O
identify	O
whether	O
transcription	O
factors	O
,	O
associated	O
with	O
cytokine	O
signalling	O
,	O
affected	O
promoter	O
activity	O
of	O
the	O
corticotropin	O
releasing	O
hormone	O
(	O
CRH	O
)	O
gene	O
.	O
Fragments	O
of	O
a	O
3.6	O
kb	O
sequence	O
of	O
the	O
human	O
CRH	O
gene	O
promoter	O
were	O
amplified	O
by	O
PCR	O
and	O
ligated	O
upstream	O
of	O
a	O
CAT	O
reporter	O
.	O
These	O
constructs	O
were	O
transfected	O
into	O
a	O
variety	O
of	O
cell	O
lines	O
,	O
either	O
alone	O
or	O
together	O
,	O
with	O
transcription	B
factor	I
expression	O
vectors	O
.	O
Basal	O
activity	O
of	O
a	O
3070	O
bp	O
CRH	O
promoter	O
fragment	O
was	O
only	O
seen	O
in	O
neuronal	O
and	O
lymphoblastoid	O
cell	O
lines	O
.	O
Promoter	O
activity	O
was	O
increased	O
by	O
the	O
transcription	B
factors	I
C	B
/	I
EBPbeta	I
(	O
NF	B
-	I
IL6	I
)	O
and	O
more	O
strongly	O
,	O
by	O
C	B
/	I
EBPdelta	I
(	O
NF	B
-	I
IL6beta	I
)	O
.	O
Increased	O
CRH	B
promoter	O
activity	O
following	O
phorbol	O
ester	O
treatment	O
was	O
inhibited	O
by	O
a	O
dominant	O
negative	O
NF	B
-	I
IL6	I
mutant	I
,	O
showing	O
that	O
the	O
effects	O
of	O
phorbol	O
ester	O
were	O
principally	O
mediated	O
by	O
C	B
/	I
EBP	I
.	O
Moreover	O
,	O
the	O
inverse	O
changes	O
in	O
the	O
expression	O
of	O
CRH	B
in	O
the	O
hypothalamus	O
and	O
spleens	O
of	O
arthritic	O
rats	O
were	O
paralleled	O
by	O
similar	O
inverse	O
changes	O
in	O
NF	B
-	I
IL6beta	I
expression	O
in	O
these	O
organs	O
.	O
These	O
data	O
show	O
that	O
some	O
transcription	B
factors	I
associated	O
with	O
cytokine	B
signalling	O
can	O
also	O
activate	O
the	O
CRH	O
promoter	O
.	O
[	O
Molecular	O
-	O
biologic	O
aspects	O
of	O
interaction	O
between	O
nervous	O
and	O
immune	O
systems	O
]	O
The	O
problem	O
of	O
the	O
neuro	O
-	O
immuno	O
interactions	O
on	O
the	O
level	O
of	O
the	O
protein	B
trans	I
-	I
factors	I
,	O
stimulating	O
interleukin-2	O
(	O
IL-2	O
)	O
gene	O
expression	O
was	O
discussed	O
.	O
The	O
physico	O
-	O
chemical	O
and	O
functional	O
parameters	O
of	O
the	O
low	B
molecular	I
nuclear	I
proteins	I
(	O
SP	B
and	O
BP-	B
14	I
,	I
18	I
,	I
19	I
kDs	I
)	O
isolated	O
from	O
splenic	O
and	O
brain	O
cells	O
of	O
immunized	O
rats	O
were	O
studied	O
.	O
The	O
binding	O
of	O
these	O
proteins	O
to	O
the	O
regulatory	O
region	O
of	O
IL-2	O
gene	O
in	O
vitro	O
and	O
stimulation	O
of	O
the	O
IL-2mRNA	O
synthesis	O
in	O
splenic	O
T	O
-	O
lymphocytes	O
culture	O
in	O
normal	O
conditions	O
were	O
shown	O
.	O
The	O
protective	O
effect	O
of	O
SP	B
and	O
BP	B
on	O
the	O
IL-2mRNA	O
synthesis	O
in	O
stressful	O
conditions	O
and	O
by	O
the	O
T	O
-	O
cells	O
treatment	O
with	O
the	O
CsA	O
was	O
demonstrated	O
.	O
A	O
novel	O
form	O
of	O
the	O
myeloid	B
-	I
specific	I
zinc	I
finger	I
protein	I
(	O
MZF-2	B
)	O
.	O
BACKGROUND	O
:	O
Myeloid	O
cell	O
development	O
is	O
controlled	O
by	O
tissue	O
-	O
specific	O
transcription	B
factors	I
.	O
Human	B
myeloid	I
zinc	I
finger	I
protein	I
(	O
MZF-1	B
)	O
is	O
a	O
putative	O
transcription	O
factor	O
containing	O
13	B
zinc	I
fingers	I
,	O
and	O
has	O
been	O
suggested	O
that	O
it	O
regulates	O
the	O
development	O
of	O
neutrophilic	O
granulocytes	O
.	O
RESULTS	O
:	O
Here	O
,	O
we	O
have	O
isolated	O
the	O
murine	O
and	O
human	O
cDNAs	O
which	O
encode	O
a	O
novel	O
form	O
of	O
MZF	B
protein	I
(	O
MZF-2	B
)	O
.	O
Murine	B
and	I
human	I
MZF-2	I
proteins	I
consisted	O
of	O
814	O
and	O
775	O
amino	O
acids	O
,	O
respectively	O
,	O
and	O
have	O
identity	O
of	O
75.3	O
%	O
between	O
them	O
.	O
The	O
C	B
-	I
terminal	I
half	I
of	O
human	B
MZF-2	I
,	O
carrying	O
the	O
zinc	B
finger	I
domains	I
,	O
was	O
completely	O
identical	O
with	O
that	O
of	O
human	B
MZF-1	I
,	O
whereas	O
the	O
N	B
-	I
terminal	I
half	I
of	O
MZF-2	B
was	O
different	O
from	O
the	O
corresponding	O
region	O
of	O
human	O
MZF-1	B
,	O
and	O
was	O
coded	O
by	O
distinct	O
exons	O
.	O
MZF-2	O
mRNA	O
was	O
expressed	O
in	O
myeloid	O
cells	O
,	O
particularly	O
in	O
the	O
cells	O
committed	O
to	O
the	O
neutrophilic	O
lineage	O
,	O
and	O
down	O
-	O
regulated	O
by	O
G	B
-	I
CSF	I
.	O
CONCLUSIONS	O
:	O
MZF-1	O
and	O
MZF-2	O
mRNAs	O
seem	O
to	O
be	O
produced	O
by	O
the	O
alternative	O
use	O
of	O
two	O
different	O
transcription	O
initiation	O
sites	O
.	O
The	O
distinct	O
N	B
-	I
terminal	I
half	I
of	O
MZF-2	B
carries	O
two	O
characteristic	O
domains	O
,	O
a	O
leucine	B
-	I
rich	I
domain	I
called	O
LeR	B
and	O
an	O
acidic	B
domain	I
,	O
which	O
suggests	O
a	O
unique	O
function	O
of	O
MZF-2	B
in	O
neutrophil	O
development	O
.	O
T	O
cell	O
reactivity	O
to	O
Sjogren	O
's	O
syndrome	O
related	O
antigen	O
La	B
(	I
SSB	I
)	I
.	O
OBJECTIVE	O
.	O
Many	O
patients	O
with	O
primary	O
Sjogren	O
's	O
syndrome	O
(	O
SS	O
)	O
make	O
high	O
titer	O
IgG	B
autoantibodies	I
to	O
the	O
La	B
(	I
SSB	I
)	I
antigen	O
,	O
suggesting	O
antigen	O
specific	O
T	O
cell	O
-	O
B	O
cell	O
interactions	O
.	O
T	O
cell	O
responses	O
to	O
some	O
nuclear	O
antigens	O
,	O
particularly	O
U1RNP	B
,	O
have	O
been	O
detected	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
and	O
in	O
healthy	O
subjects	O
.	O
We	O
investigated	O
T	O
cell	O
reactivity	O
to	O
the	O
autoantigen	B
SSB	I
in	O
patients	O
with	O
SS	O
and	O
healthy	O
controls	O
.	O
METHODS	O
.	O
Using	O
the	O
[	O
3H	O
]	O
thymidine	O
proliferation	O
assay	O
,	O
we	O
determined	O
reactivity	O
to	O
purified	B
recombinant	I
SSB	I
(	O
rSSB	B
)	O
in	O
20	O
patients	O
with	O
SS	O
and	O
19	O
controls	O
.	O
Specificity	O
was	O
determined	O
using	O
tetanus	O
toxoid	O
,	O
endotoxin	O
,	O
and	O
3	O
other	O
autoantigens	B
(	O
PBC.M2	B
,	O
Sc170	B
,	O
and	O
GAD	B
)	O
.	O
Precursor	O
frequency	O
was	O
calculated	O
by	O
limiting	O
dilution	O
analysis	O
.	O
HLA	O
Class	O
II	O
dependency	O
was	O
investigated	O
using	O
anti	B
-	I
Class	I
II	I
monoclonal	I
antibodies	I
.	O
HLA	O
-	O
DR	O
typing	O
was	O
by	O
polymerase	O
chain	O
reaction	O
and	O
sequence	O
specific	O
oligonucleotide	O
typing	O
.	O
RESULTS	O
.	O
Six	O
of	O
20	O
patients	O
with	O
SS	O
and	O
10	O
/	O
19	O
controls	O
proliferated	O
to	O
La	O
(	O
rSSB	B
)	O
.	O
Precursor	O
frequency	O
of	O
anti	O
-	O
SSB	O
T	O
cells	O
was	O
1	O
:	O
77	O
,	O
040	O
and	O
1	O
:	O
115	O
,	O
000	O
in	O
2	O
healthy	O
subjects	O
and	O
1	O
:	O
230	O
,	O
250	O
and	O
1	O
:	O
103	O
,	O
034	O
in	O
two	O
patients	O
with	O
SS	O
.	O
Anti-	O
HLA	B
-	I
DR	I
abrogated	O
proliferation	O
to	O
SSB	B
and	O
tetanus	O
toxoid	O
.	O
Thirteen	O
of	O
15	O
patients	O
with	O
SS	O
and	O
4	O
/	O
17	O
controls	O
were	O
HLA	B
-	I
DR3	I
positive	O
,	O
with	O
no	O
apparent	O
association	O
of	O
HLA	B
-	I
DR3	I
with	O
SSB	B
reactivity	O
in	O
controls	O
.	O
CONCLUSION	O
.	O
Anti	O
-	O
La	O
(	O
SSB	O
)	O
specific	O
T	O
cells	O
occur	O
in	O
a	O
significant	O
proportion	O
of	O
controls	O
and	O
in	O
some	O
patients	O
with	O
SS	O
.	O
The	O
function	O
of	O
SSB	O
T	O
cells	O
in	O
controls	O
remains	O
to	O
be	O
defined	O
.	O
They	O
may	O
represent	O
immunoregulatory	O
cells	O
,	O
and	O
further	O
analysis	O
of	O
these	O
cells	O
,	O
and	O
a	O
comparison	O
to	O
those	O
found	O
in	O
patients	O
with	O
SS	O
,	O
may	O
elucidate	O
normal	O
immunoregulation	O
and	O
the	O
derangements	O
that	O
lead	O
to	O
Sjogren	O
's	O
syndrome	O
.	O
Agonistic	O
activity	O
of	O
a	O
CD40-specific	B
single	I
-	I
chain	I
Fv	I
constructed	O
from	O
the	O
variable	B
regions	I
of	O
mAb	B
G28	I
-	I
5	I
.	O
A	O
single	B
-	I
chain	I
Fv	I
(	O
sFv	B
)	O
was	O
expressed	O
from	O
the	O
variable	B
regions	I
of	O
the	O
CD40-specific	O
mAb	B
G28	I
-	I
5	I
.	O
The	O
molecule	O
bound	O
CD40	B
with	O
a	O
high	O
affinity	O
(	O
2.2	O
nM	O
)	O
and	O
was	O
a	O
monomer	O
in	O
solution	O
.	O
Surprisingly	O
,	O
G28	B
-	I
5	I
sFv	I
was	O
a	O
potent	O
CD40	B
agonist	I
that	O
rapidly	O
crosslinked	O
CD40	B
on	O
the	O
cell	O
surface	O
but	O
did	O
not	O
crosslink	O
CD40-Ig	B
in	O
solution	O
.	O
G28	B
-	I
5	I
sFv	I
was	O
a	O
more	O
potent	O
agonist	O
than	O
G28	B
-	I
5	I
IgG	I
and	O
was	O
able	O
to	O
stimulate	O
CD40	B
responses	O
by	O
B	O
cells	O
and	O
monocytes	O
.	O
G28	B
-	I
5	I
IgG	I
partially	O
blocked	O
,	O
whereas	O
G28	B
-	I
5	I
sFv	I
augmented	O
CD40	B
responses	O
during	O
stimulation	O
with	O
natural	B
ligand	I
(	O
gp39-CD8	B
fusion	I
protein	I
)	O
.	O
These	O
results	O
indicate	O
that	O
the	O
functional	O
activity	O
of	O
ligands	O
built	O
from	O
the	O
binding	B
site	I
of	O
G28	B
-	I
5	I
is	O
highly	O
dependent	O
upon	O
the	O
size	O
and	O
physical	O
properties	O
of	O
the	O
molecule	O
both	O
in	O
solution	O
and	O
on	O
the	O
cell	O
surfaces	O
.	O
Cyclosporin	O
A	O
inhibits	O
early	O
mRNA	O
expression	O
of	O
G0	O
/	O
G1	O
switch	O
gene	O
2	O
(	O
G0S2	O
)	O
in	O
cultured	O
human	O
blood	O
mononuclear	O
cells	O
.	O
Cyclosporin	O
A	O
(	O
CsA	O
)	O
may	O
achieve	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	O
the	O
calcium-	B
and	I
calmodulin	I
-	I
dependent	I
phosphatase	I
calcineurin	B
which	O
is	O
required	O
for	O
activation	O
of	O
target	O
genes	O
by	O
members	O
of	O
the	O
NFAT	B
(	I
nuclear	I
factor	I
of	I
activated	I
T	I
cells	I
)	I
transcription	I
factor	I
family	I
.	O
Among	O
these	O
target	O
genes	O
is	O
the	O
gene	O
encoding	O
interleukin-2	B
(	O
IL2	B
)	O
,	O
a	O
cytokine	B
facilitating	O
progression	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O
However	O
,	O
IL2	B
does	O
not	O
reverse	O
CsA	O
inhibition	O
,	O
suggesting	O
that	O
at	O
least	O
one	O
other	O
NFAT	O
-	O
sensitive	O
gene	O
may	O
be	O
involved	O
.	O
The	O
human	O
G0	O
/	O
G1	O
switch	O
gene	O
,	O
G0S2	O
,	O
has	O
potential	O
NFAT	O
-	O
binding	O
sites	O
in	O
the	O
5	O
'	O
flank	O
and	O
encodes	O
a	O
small	B
basic	I
potential	I
phosphoprotein	I
of	O
unknown	O
function	O
.	O
Using	O
a	O
sensitive	O
,	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
,	O
G0S2	O
mRNA	O
levels	O
were	O
assayed	O
in	O
cultured	O
blood	O
mononuclear	O
cells	O
.	O
Freshly	O
isolated	O
cells	O
contain	O
high	O
levels	O
of	O
G0S2	O
mRNA	O
which	O
rapidly	O
decline	O
.	O
This	O
`	O
`	O
spontaneous	O
stimulation	O
''	O
is	O
also	O
noted	O
with	O
some	O
other	O
G0S	O
genes	O
and	O
has	O
been	O
attributed	O
to	O
some	O
aspect	O
of	O
the	O
isolation	O
procedure	O
.	O
In	O
cells	O
that	O
have	O
been	O
preincubated	O
to	O
lower	O
mRNA	O
levels	O
,	O
there	O
is	O
a	O
transient	O
increase	O
in	O
G0S2	O
mRNA	O
,	O
peaking	O
between	O
1	O
-	O
2	O
h	O
,	O
in	O
response	O
to	O
Concanavalin	O
-	O
A	O
(	O
ConA	O
)	O
,	O
or	O
to	O
the	O
combination	O
of	O
phorbol	O
ester	O
(	O
TPA	O
)	O
,	O
and	O
the	O
calcium	O
ionophore	O
,	O
ionomycin	O
.	O
Both	O
these	O
responses	O
are	O
inhibited	O
by	O
CsA	O
.	O
Our	O
results	O
suggest	O
that	O
G0S2	O
expression	O
is	O
required	O
to	O
commit	O
cells	O
to	O
enter	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
that	O
,	O
while	O
not	O
excluding	O
other	O
possible	O
targets	O
,	O
early	O
inhibition	O
of	O
G0S2	O
expression	O
by	O
CsA	O
may	O
be	O
important	O
in	O
achieving	O
immunosuppression	O
.	O
G0S2	O
may	O
be	O
of	O
value	O
as	O
a	O
reporter	O
gene	O
for	O
analyzing	O
the	O
mechanism	O
of	O
action	O
of	O
CsA	O
and	O
its	O
influence	O
on	O
the	O
positive	O
and	O
negative	O
selection	O
of	O
lymphocytes	O
in	O
response	O
to	O
self	O
and	O
not	O
-	O
self	O
antigens	O
.	O
Estrogen	B
receptor	I
diminishes	O
DNA	O
-	O
binding	O
activities	O
of	O
chicken	B
GATA-1	I
and	O
CACCC	B
-	I
binding	I
proteins	I
.	O
The	O
estrogen	B
receptor	I
(	O
ER	B
)	O
repressed	O
erythroid	O
differentiation	O
and	O
erythroid	O
-	O
specific	O
gene	O
expression	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
ER	B
alpha	I
(	O
referred	O
to	O
throughout	O
as	O
ER	B
)	O
on	O
DNA	O
-	O
binding	O
activities	O
of	O
transcription	B
factors	I
involved	O
in	O
regulating	O
the	O
expression	O
of	O
erythroid	O
-	O
specific	O
genes	O
,	O
and	O
,	O
in	O
particular	O
,	O
the	O
histone	O
H5	O
gene	O
.	O
Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
found	O
that	O
in	O
the	O
presence	O
of	O
rabbit	O
reticulocyte	O
lysate	O
,	O
human	B
ER	I
reduced	O
the	O
binding	O
activities	O
of	O
chicken	B
immature	I
erythrocyte	I
nuclear	I
extracted	I
proteins	I
to	O
GATA	O
and	O
CACCC	O
sites	O
in	O
the	O
H5	O
promoter	O
and	O
enhancer	O
.	O
In	O
contrast	O
,	O
the	O
binding	O
activities	O
of	O
NF1	B
and	O
Sp1	B
were	O
not	O
affected	O
by	O
ER	B
.	O
Binding	O
of	O
ER	B
to	O
an	O
estrogen	O
response	O
element	O
was	O
enhanced	O
by	O
addition	O
of	O
rabbit	O
reticulocyte	O
lysate	O
.	O
This	O
lysate	O
was	O
also	O
necessary	O
for	O
ER	B
to	O
diminish	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
GATA-1	B
.	O
These	O
results	O
suggest	O
that	O
additional	O
factor	O
(	O
s	O
)	O
are	O
necessary	O
for	O
full	O
ER	B
function	O
.	O
Both	O
GATA-1	B
and	O
CACCC	B
-	I
binding	I
proteins	I
are	O
critical	O
for	O
the	O
developmentally	O
regulated	O
expression	O
of	O
erythroid	O
-	O
specific	O
genes	O
.	O
We	O
hypothesize	O
that	O
interference	O
in	O
DNA	O
-	O
binding	O
activities	O
of	O
GATA-1	B
and	O
CACCC	B
-	I
binding	I
proteins	I
is	O
the	O
mechanism	O
by	O
which	O
the	O
ER	B
inhibits	O
regulation	O
of	O
these	O
genes	O
.	O
HLA	O
binding	O
characteristics	O
and	O
generation	O
of	O
cytotoxic	O
lymphocytes	O
against	O
peptides	O
derived	O
from	O
oncogenic	B
proteins	I
.	O
AIMS	O
AND	O
BACKGROUND	O
:	O
Structurally	O
altered	O
proteins	O
(	O
derived	O
from	O
chromosomal	O
translocations	O
or	O
gene	O
mutations	O
)	O
can	O
be	O
considered	O
tumor	O
specific	O
antigens	O
and	O
represent	O
an	O
attractive	O
target	O
for	O
a	O
T	O
-	O
cell	O
mediated	O
response	O
.	O
T	O
lymphocytes	O
recognize	O
antigens	O
in	O
the	O
form	O
of	O
peptides	O
bound	O
to	O
HLA	B
-	I
molecules	I
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Peptides	O
derived	O
from	O
oncogenic	B
proteins	I
were	O
screened	O
for	O
the	O
presence	O
of	O
HLA	B
binding	I
motifs	I
;	O
actual	O
binding	O
were	O
evaluated	O
by	O
HLA	O
stabilization	O
experiments	O
using	O
transfectants	O
and	O
specific	O
anti	B
-	I
HLA	I
antibodies	I
.	O
Specific	O
lymphocytes	O
were	O
induced	O
by	O
in	O
vitro	O
peptide	O
sensitization	O
and	O
screened	O
by	O
thymidine	O
uptake	O
or	O
cellular	O
cytotoxic	O
assays	O
.	O
RESULTS	O
:	O
We	O
identified	O
peptides	O
derived	O
from	O
EWS	B
/	I
FLI-1	I
fusion	I
protein	I
and	O
from	O
mutated	B
K	I
-	I
RAS	I
protein	I
(	O
encompassing	O
respectively	O
the	O
fusion	B
point	I
and	O
the	O
mutation	O
at	O
position	B
12	I
)	O
that	O
showed	O
binding	B
motif	I
for	O
HLA	B
-	I
Cw*0702	I
and	O
HLA	B
-	I
A3	I
respectively	O
.	O
The	O
actual	O
binding	O
of	O
these	O
peptides	O
was	O
analysed	O
in	O
a	O
stabilization	O
assay	O
.	O
We	O
detected	O
binding	O
for	O
the	O
EWS	O
/	O
FLI-1	O
peptide	O
and	O
for	O
5	O
RAS	O
peptides	O
(	O
1	O
wild	O
type	O
and	O
4	O
mutated	O
)	O
.	O
The	O
effect	O
of	O
temperature	O
,	O
beta	B
2-microglobulin	I
(	O
beta	B
2-m	I
)	O
and	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
on	O
the	O
binding	O
and	O
the	O
stability	O
of	O
the	O
HLA	B
/	I
peptide	I
complex	I
was	O
studied	O
.	O
A	O
low	O
temperature	O
(	O
26	O
degrees	O
C	O
)	O
increased	O
the	O
binding	O
both	O
in	O
HLA	B
-	I
A3	I
and	O
HLA	B
-	I
Cw*0702	I
,	O
while	O
FCS	O
reduced	O
it	O
.	O
beta	B
2-m	I
increased	O
the	O
binding	O
to	O
the	O
HLA	B
-	I
A3	I
molecule	I
but	O
did	O
not	O
influence	O
the	O
binding	O
to	O
the	O
HLA	B
-	I
Cw*0702	I
.	O
The	O
stability	O
of	O
already	O
formed	O
complexed	O
was	O
somewhat	O
different	O
in	O
the	O
HLA	B
-	I
A3	I
and	O
HLA	B
-	I
Cw*0702	I
system	O
:	O
both	O
were	O
more	O
stable	O
at	O
26	O
degrees	O
C	O
than	O
at	O
37	O
degrees	O
C	O
but	O
while	O
the	O
beta	B
2-m	I
and	O
FCS	O
did	O
not	O
influence	O
the	O
stability	O
of	O
the	O
HLA	B
-	I
A3	I
/	I
peptide	I
complex	I
,	O
they	O
seemed	O
to	O
cause	O
opposite	O
effects	O
in	O
the	O
HLA	B
-	I
Cw*0702	I
system	O
(	O
beta	B
2-m	I
stabilized	O
and	O
FCS	O
destabilized	O
the	O
complex	O
)	O
.	O
Finally	O
,	O
we	O
were	O
able	O
to	O
generate	O
a	O
specific	O
CD8	O
+	O
CTL	O
line	O
against	O
a	O
K	O
-	O
RAS	O
mutated	O
peptide	O
.	O
CONCLUSIONS	O
:	O
Although	O
binding	B
motifs	I
and	O
actual	O
HLA	O
binding	O
can	O
be	O
detected	O
in	O
several	O
cases	O
,	O
the	O
generation	O
of	O
a	O
cellular	O
response	O
is	O
infrequent	O
,	O
confirming	O
that	O
HLA	O
binding	O
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
obtain	O
an	O
in	O
vitro	O
response	O
.	O
Further	O
optimization	O
of	O
culture	O
conditions	O
,	O
type	O
of	O
Antigen	O
Presenting	O
Cells	O
(	O
APC	O
)	O
,	O
peptides	O
,	O
use	O
of	O
stabilizers	O
like	O
beta	B
2-m	I
are	O
still	O
needed	O
.	O
Replication	O
of	O
human	O
immunodeficiency	O
virus-1	O
in	O
primary	O
human	O
T	O
cells	O
is	O
dependent	O
on	O
the	O
autocrine	O
secretion	O
of	O
tumor	B
necrosis	I
factor	I
through	O
the	O
control	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
activation	O
.	O
Tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
-alpha	I
controls	O
T	O
-	O
cell	O
activation	O
and	O
is	O
a	O
major	O
inducer	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-1	O
replication	O
in	O
chronically	O
infected	O
cells	O
.	O
Therefore	O
,	O
we	O
have	O
investigated	O
its	O
role	O
in	O
primary	O
cultures	O
of	O
HIV	O
-	O
infected	O
human	O
T	O
lymphocytes	O
by	O
using	O
neutralizing	O
anti	B
-	I
TNF	I
-	I
alpha	I
antibodies	I
or	O
TNF	B
-	I
alpha	I
.	O
Primary	O
resting	O
T	O
lymphocytes	O
produced	O
TNF	B
-	I
alpha	I
and	O
supported	O
HIV	O
replication	O
after	O
T	O
-	O
cell	O
receptor	O
activation	O
.	O
Addition	O
of	O
neutralizing	O
anti	B
-	I
TNF	I
-	I
alpha	I
antibodies	I
drastically	O
reduced	O
p24	B
antigen	I
release	O
and	O
prevented	O
CD4	B
+	I
cell	O
depletion	O
associated	O
with	O
infection	O
.	O
Anti	B
-	I
TNF	I
-	I
alpha	I
also	O
prevented	O
nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
activation	O
,	O
and	O
a	O
good	O
correlation	O
between	O
this	O
inhibition	O
and	O
inhibition	O
of	O
HIV	O
replication	O
was	O
observed	O
.	O
Moreover	O
,	O
supplementing	O
the	O
cultures	O
with	O
high	O
doses	O
of	O
IL-2	O
reverted	O
anti-	O
TNF	B
-	I
alpha	I
inhibition	O
of	O
cell	O
proliferation	O
but	O
did	O
not	O
affect	O
the	O
inhibition	O
of	O
HIV	O
p24	B
antigen	I
release	O
or	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
the	O
same	O
cultures	O
.	O
Moreover	O
,	O
anti	B
-	I
TNF	I
-	I
alpha	I
inhibited	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-driven	O
transcription	O
of	O
a	O
reporter	O
gene	O
in	O
primary	O
T	O
cells	O
in	O
response	O
to	O
activation	O
,	O
either	O
in	O
the	O
presence	O
or	O
the	O
absence	O
of	O
HIV-1	B
Tat	I
.	O
Our	O
results	O
support	O
an	O
important	O
role	O
for	O
autocrine	O
TNF	B
-	I
alpha	I
secretion	O
in	O
controlling	O
HIV	O
replication	O
in	O
primary	O
T	O
cells	O
because	O
of	O
its	O
ability	O
to	O
maintain	O
NF	B
-	I
kappa	I
B	I
elevated	O
in	O
the	O
nucleus	O
of	O
T	O
cells	O
.	O
A	O
thiol	O
antioxidant	O
regulates	O
IgE	B
isotype	I
switching	O
by	O
inhibiting	O
activation	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
.	O
The	O
binding	O
site	O
for	O
nuclear	B
factor	I
-	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
is	O
present	O
at	O
the	O
promoter	O
region	O
of	O
the	O
germline	O
Cepsilon	O
gene	O
,	O
but	O
there	O
is	O
little	O
information	O
on	O
whether	O
this	O
factor	O
is	O
involved	O
in	O
regulating	O
IgE	B
synthesis	O
by	O
human	O
B	O
cells	O
.	O
Accordingly	O
,	O
we	O
studied	O
the	O
role	O
of	O
NF	B
-	I
kappaB	I
in	O
germline	O
Cepsilon	O
transcription	O
by	O
using	O
two	O
human	O
Burkitt	O
's	O
lymphoma	O
B	O
cell	O
lines	O
,	O
DND39	O
and	O
DG75	O
.	O
In	O
both	O
cell	O
lines	O
,	O
n	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
,	O
a	O
potent	O
thiol	O
antioxidant	O
,	O
inhibited	O
the	O
triggering	O
of	O
the	O
nuclear	O
expression	O
of	O
NF	B
-	I
kappaB	I
by	O
IL-4	B
and	O
by	O
anti	B
-	I
CD40	I
monoclonal	I
antibody	I
.	O
Although	O
IL-4	B
activated	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	I
STAT	I
)	I
6	I
in	O
addition	O
to	O
NF	B
-	I
kappaB	I
,	O
NAC	O
treatment	O
or	O
the	O
transfection	O
of	O
decoy	O
oligodeoxynucleotides	O
for	O
NF	B
-	I
kappaB	I
or	O
STAT6	B
only	O
partly	O
blocked	O
IL-4	B
-induced	O
germline	O
Cepsilon	O
transcription	O
.	O
However	O
,	O
these	O
two	O
decoy	O
oligodeoxynucleotides	O
together	O
almost	O
completely	O
abrogated	O
IL-4	B
-induced	O
germline	O
Cepsilon	O
transcription	O
.	O
Of	O
note	O
,	O
CD40	B
-mediated	O
enhancement	O
of	O
IL-4	B
-driven	O
germline	O
Cepsilon	O
transcription	O
was	O
markedly	O
decreased	O
by	O
NAC	O
or	O
by	O
a	O
decoy	O
oligodeoxynucleotide	O
for	O
NF	B
-	I
kappaB	I
.	O
The	O
effect	O
of	O
NAC	O
was	O
also	O
examined	O
on	O
deletional	O
switch	O
recombination	O
underlying	O
the	O
isotype	O
switch	O
to	O
IgE	B
.	O
NAC	O
inhibited	O
the	O
generation	O
of	O
Smu	B
/	I
Sepsilon	I
switch	I
fragments	I
in	O
normal	O
human	O
B	O
cells	O
costimulated	O
with	O
IL-4	B
and	O
anti	B
-	I
CD40	I
monoclonal	I
antibody	I
.	O
It	O
also	O
abolished	O
IL-4	B
-induced	O
upregulation	O
of	O
CD40	B
but	O
promoted	O
upregulation	O
of	O
CD23	O
.	O
These	O
results	O
suggest	O
that	O
coordination	O
of	O
NF	B
-	I
kappaB	I
and	O
STAT6	B
may	O
be	O
required	O
for	O
induction	O
of	O
germline	O
Cepsilon	O
transcription	O
by	O
IL-4	B
,	O
and	O
that	O
CD40	B
-mediated	O
NF	B
-	I
kappaB	I
activation	O
may	O
be	O
important	O
in	O
regulating	O
both	O
enhancement	O
of	O
germline	O
Cepsilon	O
transcription	O
and	O
class	O
switching	O
to	O
IgE	B
.	O
LPS	O
tolerance	O
in	O
monocytes	O
/	O
macrophages	O
:	O
three	O
3	O
'	O
cytosins	O
are	O
required	O
in	O
the	O
DNA	O
binding	O
motif	O
for	O
detection	O
of	O
upregulated	O
NF	B
-	I
kappa	I
B	I
p50	I
homodimers	I
.	O
When	O
monocytes	O
are	O
stimulated	O
with	O
LPS	O
(	O
lipopolysaccharide	O
)	O
repeatedly	O
then	O
the	O
initially	O
high	O
expression	O
of	O
the	O
TNF	O
(	O
tumor	O
necrosis	O
factor	O
)	O
gene	O
is	O
only	O
very	O
low	O
,	O
i.e.	O
the	O
cells	O
are	O
tolerant	O
to	O
LPS	O
.	O
Tolerant	O
cells	O
still	O
express	O
the	O
CD14	B
receptor	I
and	O
they	O
can	O
still	O
be	O
activated	O
to	O
mobilize	O
NF	B
-	I
kappa	I
B	I
into	O
nucleus	O
.	O
Analysis	O
of	O
the	O
binding	O
proteins	O
employing	O
the	O
-605	O
motif	O
of	O
the	O
human	O
TNF	O
promoter	O
(	O
GGGGCTGTCCC	O
)	O
revealed	O
that	O
in	O
tolerant	O
cells	O
of	O
the	O
human	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
there	O
is	O
a	O
predominance	O
of	O
p50p50	B
of	O
NF	B
-	I
kappa	I
B	I
.	O
We	O
now	O
show	O
that	O
a	O
mutant	O
motif	O
that	O
exchanges	O
the	O
terminal	O
3	O
'	O
C	O
for	O
a	O
G	O
fails	O
to	O
bind	O
the	O
p50	B
homodimer	I
that	O
is	O
upregulated	O
in	O
LPS	O
toler	O
ant	O
human	O
Mono	O
Mac	O
6	O
cells	O
.	O
The	O
same	O
is	O
true	O
for	O
nuclear	O
extracts	O
taken	O
from	O
the	O
murine	O
P388D1	O
macrophage	O
cell	O
line	O
when	O
tested	O
with	O
the	O
-516	O
motif	O
of	O
the	O
murine	O
TNF	O
promoter	O
(	O
GGGGGCTTTCCC	O
)	O
.	O
Here	O
the	O
wild	O
type	O
motif	O
gives	O
efficient	O
binding	O
of	O
p50p50	B
that	O
again	O
is	O
upregulated	O
in	O
tolerant	O
cells	O
whereas	O
a	O
mutant	O
with	O
a	O
3	O
'	O
G	O
shows	O
hardly	O
any	O
binding	O
of	O
p50p50	B
.	O
Conversely	O
,	O
the	O
murine	O
kappa	O
light	O
chain	O
enhancer	O
motif	O
(	O
GGGGACTTTCCG	O
)	O
does	O
not	O
efficiently	O
bind	O
the	O
nuclear	O
p50p50	B
from	O
tolerant	O
murine	O
P388	O
macrophages	O
.	O
Binding	O
is	O
,	O
however	O
,	O
readily	O
detected	O
when	O
the	O
3	O
'	O
G	O
is	O
replaced	O
by	O
a	O
C	O
.	O
These	O
data	O
show	O
that	O
the	O
detection	O
of	O
upregulated	O
p50	B
homodimers	I
in	O
LPS	O
tolerant	O
cells	O
is	O
dependent	O
on	O
subtle	O
differences	O
in	O
the	O
sequence	O
of	O
the	O
DNA	O
binding	O
motif	O
.	O
Inefficient	O
termination	O
of	O
antigen	O
responses	O
in	O
NF	B
-	I
ATp	I
-deficient	O
mice	O
.	O
In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
NF	B
-	I
ATp	I
,	O
one	O
of	O
the	O
most	O
prominent	O
members	O
of	O
family	O
of	O
NF	B
-	I
AT	I
transcription	I
factors	I
in	O
peripheral	O
T	O
lymphocytes	O
,	O
in	O
T	O
cell	O
activation	O
and	O
differentiation	O
we	O
created	O
NF	B
-	I
ATp	I
-deficient	O
mice	O
by	O
gene	O
targeting	O
.	O
Such	O
NF	B
-	I
ATp	I
-	O
/	O
-	O
mice	O
are	O
born	O
and	O
appear	O
to	O
develop	O
a	O
normal	O
immune	O
system	O
.	O
Apart	O
from	O
clear	O
-	O
cut	O
defects	O
in	O
the	O
synthesis	O
of	O
mRNAs	O
for	O
Th2-type	B
lymphokines	I
,	O
such	O
as	O
IL-4	B
,	O
IL-5	B
,	O
IL-10	B
and	O
IL-13	B
,	O
in	O
primary	O
and	O
secondary	O
stimulations	O
of	O
spleen	O
cells	O
in	O
vitro	O
,	O
of	O
a	O
distinct	O
impaired	O
deletion	O
of	O
V	O
beta	O
11+	O
/	O
CD4	O
+	O
T	O
lymphocytes	O
from	O
these	O
mice	O
was	O
detected	O
after	O
superantigen	O
injection	O
.	O
Moreover	O
,	O
NF	B
-	I
ATp	I
-	O
/	O
-	O
mice	O
older	O
than	O
6	O
weeks	O
show	O
an	O
2	O
-	O
5	O
fold	O
increase	O
in	O
number	O
of	O
lymphocytes	O
.	O
This	O
is	O
correlated	O
with	O
an	O
increased	O
expression	O
of	O
activation	B
markers	I
CD44	B
and	O
CD69	B
and	O
decreased	O
expression	O
of	O
CD62	B
.	O
Identification	O
of	O
target	O
genes	O
of	O
the	O
lymphoid	B
-	I
specific	I
transcription	I
factor	I
Oct2	I
.	O
The	O
Oct2	B
transcription	B
factor	I
is	O
expressed	O
predominantly	O
in	O
B	O
lymphocytes	O
and	O
plays	O
an	O
essential	O
role	O
during	O
the	O
terminal	O
phase	O
of	O
B	O
cell	O
differentiation	O
.	O
The	O
regulatory	O
regions	O
of	O
several	O
genes	O
specifically	O
expressed	O
in	O
B	O
cells	O
contain	O
functional	O
binding	O
sites	O
for	O
Oct2	B
.	O
Nevertheless	O
,	O
none	O
of	O
the	O
genes	O
originally	O
thought	O
to	O
be	O
regulated	O
by	O
Oct2	B
were	O
affected	O
in	O
their	O
expression	O
in	O
Oct2-deficient	O
B	O
cells	O
.	O
In	O
an	O
attempt	O
to	O
find	O
such	O
elusive	O
Oct2	B
target	O
genes	O
and	O
to	O
understand	O
the	O
molecular	O
function	O
of	O
Oct2	B
in	O
B	O
cell	O
development	O
,	O
we	O
isolated	O
cDNAs	O
for	O
Oct2	B
target	O
genes	O
.	O
So	O
far	O
,	O
we	O
have	O
identified	O
five	O
potential	O
targets	O
for	O
Oct2	B
:	O
the	O
membrane	B
glycoprotein	I
CD36	B
,	O
the	O
cysteine	B
-	I
rich	I
secreted	I
protein	I
3	I
(	O
CRISP-3	B
)	O
,	O
a	O
mouse	O
homolog	O
of	O
the	O
human	B
monocyte	I
/	I
neutrophil	I
elastase	I
inhibitor	I
(	O
mEI	B
)	O
and	O
two	O
unknown	O
cDNA	O
sequences	O
Nov1	O
and	O
Nov2	O
.	O
These	O
target	O
genes	O
show	O
quite	O
distinct	O
expression	O
patterns	O
demonstrating	O
that	O
transcription	B
factors	I
in	O
addition	O
to	O
Oct2	B
are	O
involved	O
in	O
their	O
regulation	O
.	O
Whereas	O
CD36	B
and	O
mEI	B
were	O
expressed	O
in	O
all	O
hematopoetic	O
cell	O
lines	O
containing	O
Oct2	B
,	O
.	O
CRISP-3	B
is	O
pre	O
-	O
B	O
cell	O
-	O
specific	O
,	O
Nov1	O
is	O
plasma	O
B	O
cell	O
-	O
specific	O
and	O
Nov2	O
is	O
B	O
cell	O
-	O
specifically	O
expressed	O
.	O
Induction	O
of	O
interleukin-12	B
p40	O
transcript	O
by	O
CD40	B
ligation	O
via	O
activation	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
.	O
Interleukin-12	B
is	O
produced	O
in	O
response	O
to	O
infection	O
with	O
bacteria	O
or	O
parasites	O
or	O
to	O
bacterial	O
constituents	O
such	O
as	O
LPS	O
in	O
monocytes	O
/	O
macrophages	O
and	O
dendritic	O
cells	O
,	O
and	O
also	O
generated	O
by	O
the	O
interaction	O
between	O
activated	O
T	O
cells	O
and	O
antigen	O
-	O
presenting	O
cells	O
via	O
CD40-CD40	B
ligand	I
(	O
CD40L	B
)	O
.	O
So	O
far	O
,	O
transcriptional	O
analyses	O
of	O
p40	B
have	O
been	O
carried	O
out	O
only	O
using	O
bacterial	O
constituents	O
such	O
as	O
LPS	O
as	O
stimuli	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
have	O
characterized	O
the	O
transcriptional	O
induction	O
of	O
p40	B
by	O
CD40	B
ligation	O
in	O
a	O
human	O
B	O
lymphoblastoid	O
cell	O
line	O
,	O
Daudi	O
,	O
and	O
a	O
human	O
acute	O
monocytic	O
leukemia	O
cell	O
line	O
,	O
THP-1	O
.	O
These	O
cells	O
,	O
stimulated	O
by	O
an	O
agonistic	O
monoclonal	O
antibody	O
against	O
CD40	B
or	O
by	O
transfection	O
with	O
a	O
CD40L	O
expression	O
vector	O
,	O
secreted	O
p40	B
and	O
showed	O
enhanced	O
p40	O
mRNA	O
expression	O
.	O
Sequence	O
analysis	O
of	O
the	O
p40	O
promoter	O
region	O
identified	O
two	O
potential	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappaB	O
binding	O
sites	O
conserved	O
between	O
mouse	O
and	O
human	O
.	O
Electrophoretic	O
mobility	O
shift	O
assay	O
revealed	O
that	O
the	O
potential	O
NF	O
-	O
kappaB	O
binding	O
sequence	O
which	O
is	O
located	O
around	O
120	O
bp	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
murine	O
and	O
human	O
p40	O
genes	O
formed	O
an	O
NF	B
-	I
kappaB	I
complex	I
with	O
nuclear	O
extract	O
from	O
Daudi	O
cells	O
stimulated	O
by	O
CD40	B
ligation	O
.	O
Moreover	O
,	O
transfection	O
of	O
Daudi	O
cells	O
with	O
the	O
polymerized	O
NF	O
-	O
kappaB	O
binding	O
sequence	O
ligated	O
to	O
a	O
thymidine	O
kinase	O
/	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
reporter	O
plasmid	O
greatly	O
induced	O
CAT	B
activity	O
,	O
but	O
transfection	O
with	O
the	O
polymerized	O
mutated	O
NF	O
-	O
kappaB	O
binding	O
sequence	O
did	O
not	O
.	O
These	O
results	O
suggest	O
that	O
the	O
NF	O
-	O
kappaB	O
binding	O
site	O
located	O
around	O
120	O
bp	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
murine	O
and	O
human	O
p40	O
promoter	O
regions	O
could	O
be	O
important	O
for	O
the	O
p40	B
induction	O
by	O
CD40	B
ligation	O
via	O
activation	O
of	O
NF	B
-	I
kappaB	I
.	O
Inhibition	O
of	O
nuclear	O
factor	O
kappa	O
B	O
subunit	O
p65	O
mRNA	O
accumulation	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
human	O
monocytic	O
cells	O
treated	O
with	O
sodium	O
salicylate	O
.	O
Lipopolysaccharide	O
is	O
one	O
of	O
the	O
most	O
potent	O
trigger	O
substances	O
for	O
monocytes	O
and	O
macrophages	O
causing	O
secretion	O
of	O
inflammatory	B
mediators	I
such	O
as	O
tumor	B
necrosis	I
factor	I
and	O
interleukin-1	B
.	O
The	O
nature	O
of	O
the	O
nuclear	O
factors	O
involved	O
in	O
regulation	O
of	O
these	O
cytokine	O
genes	O
is	O
still	O
unknown	O
.	O
Nuclear	B
factor	I
kappa	I
B	I
(	I
NF	I
-	I
kappa	I
B	I
;	I
heterodimer	I
of	I
p50	I
and	I
p65	I
)	I
proteins	I
have	O
been	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
gene	O
transcription	O
of	O
inflammatory	B
mediators	I
when	O
monocytes	O
are	O
stimulated	O
with	O
lipopolysaccharide	O
.	O
Nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
such	O
as	O
salicylates	O
have	O
been	O
used	O
to	O
treat	O
symptoms	O
of	O
inflammation	O
,	O
and	O
a	O
new	O
mechanism	O
of	O
drug	O
action	O
was	O
suggested	O
recently	O
.	O
Salicylates	O
have	O
been	O
shown	O
to	O
inhibit	O
lipopolysaccharide	O
-	O
induced	O
gene	O
transcription	O
via	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
by	O
preventing	O
the	O
degradation	O
of	O
NF	B
-	I
kappa	I
B	I
inhibitor	I
`	O
`	O
I	B
kappa	I
B	I
`	O
`	O
,	O
blocking	O
the	O
translocation	O
of	O
NF	B
-	I
kappa	I
B	I
into	O
the	O
nuclear	O
compartment	O
.	O
However	O
,	O
the	O
nature	O
of	O
the	O
subunit	O
involved	O
in	O
this	O
mechanism	O
has	O
not	O
been	O
defined	O
.	O
To	O
examine	O
the	O
mechanisms	O
by	O
which	O
salicylates	O
affect	O
cytokine	B
gene	O
transcription	O
,	O
the	O
amount	O
of	O
active	O
and	O
inactive	O
NF	B
-	I
kappa	I
B	I
and	O
NF	O
-	O
kappa	O
B	O
mRNA	O
,	O
in	O
Porphyromonas	O
gingivalis	O
lipopolysaccharide	O
-	O
stimulated	O
human	O
monocytic	O
cells	O
was	O
assessed	O
.	O
High	O
doses	O
of	O
sodium	O
salicylate	O
suppressed	O
NF	B
-	I
kappa	I
B	I
p65	O
mRNA	O
accumulation	O
,	O
resulting	O
in	O
suppression	O
of	O
total	O
NF	B
-	I
kappa	I
B	I
,	O
p50	B
on	O
tissue	O
oligonucleotide	O
had	O
no	O
effects	O
on	O
lipopolysaccharide	O
-	O
induced	O
NF	B
-	I
kappa	I
B	I
activation	O
.	O
The	O
data	O
demonstrate	O
that	O
the	O
p65	B
subunit	O
of	O
NF	B
-	I
kappa	I
B	I
is	O
inhibited	O
by	O
salicylate	O
treatment	O
and	O
highlight	O
the	O
role	O
of	O
salicylate	O
in	O
the	O
control	O
of	O
gene	O
expression	O
of	O
inflammatory	B
mediators	I
.	O
Glucocorticoid	B
receptors	I
in	O
cord	O
blood	O
lymphocytes	O
of	O
healthy	O
neonates	O
and	O
of	O
preterms	O
suffering	O
from	O
respiratory	O
distress	O
syndrome	O
.	O
We	O
measured	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
(	O
GR	B
)	O
in	O
cord	O
blood	O
lymphocytes	O
and	O
the	O
binding	O
affinity	O
(	O
Kd	O
)	O
in	O
15	O
term	O
and	O
in	O
20	O
preterm	O
babies	O
.	O
Thirteen	O
preterms	O
of	O
the	O
latter	O
group	O
received	O
prenatal	O
steroid	O
treatment	O
.	O
Seven	O
preterms	O
developed	O
neonatal	O
respiratory	O
distress	O
syndrome	O
(	O
NRDS	O
)	O
.	O
The	O
number	O
of	O
GR	B
and	O
the	O
Kd	O
were	O
similar	O
in	O
the	O
term	O
and	O
preterm	O
(	O
with	O
and	O
without	O
NRDS	O
)	O
babies	O
.	O
The	O
maximum	O
(	O
3H	O
)	O
-thymidine	O
incorporation	O
into	O
DNA	O
of	O
cord	O
blood	O
lymphocytes	O
from	O
all	O
preterms	O
,	O
with	O
or	O
without	O
NRDS	O
was	O
suppressed	O
when	O
compared	O
to	O
that	O
from	O
term	O
babies	O
or	O
adults	O
.	O
This	O
could	O
partly	O
be	O
explained	O
by	O
the	O
antenatal	O
steroid	O
treatment	O
.	O
Sensitivity	O
(	O
ID50	O
)	O
of	O
the	O
lymphocytes	O
for	O
the	O
inhibitory	O
effect	O
of	O
dexamethasone	O
was	O
the	O
same	O
in	O
all	O
groups	O
.	O
In	O
this	O
study	O
on	O
the	O
number	O
and	O
function	O
of	O
GR	B
in	O
lymphocytes	O
,	O
we	O
were	O
unable	O
to	O
find	O
a	O
relation	O
between	O
the	O
functionality	O
of	O
the	O
GR	B
and	O
the	O
development	O
of	O
NRDS	O
.	O
Oxidants	O
,	O
transcription	B
factors	I
,	O
and	O
intestinal	O
inflammation	O
.	O
It	O
is	O
now	O
well	O
appreciated	O
that	O
chronic	O
gut	O
inflammation	O
is	O
characterized	O
by	O
enhanced	O
production	O
of	O
reactive	O
metabolites	O
of	O
oxygen	O
and	O
nitrogen	O
.	O
Some	O
of	O
these	O
oxidants	O
are	O
known	O
to	O
modulate	O
the	O
expression	O
of	O
a	O
variety	O
of	O
genes	O
that	O
are	O
involved	O
in	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O
For	O
example	O
,	O
certain	O
oxidants	O
are	O
known	O
to	O
activate	O
the	O
nuclear	B
transcription	I
factor	I
kappa	I
B	I
,	O
which	O
regulates	O
the	O
expression	O
of	O
a	O
variety	O
of	O
different	O
adhesion	B
molecules	I
,	O
cytokines	B
,	O
and	O
enzymes	B
.	O
Oxidants	O
are	O
also	O
known	O
to	O
activate	O
another	O
transcription	B
factor	I
,	O
activator	B
protein-1	I
.	O
This	O
transcription	B
factor	I
is	O
composed	O
of	O
products	O
from	O
the	O
fos	B
and	I
jun	I
proto	I
-	I
oncogene	I
family	I
and	O
is	O
believed	O
to	O
be	O
important	O
in	O
regulating	O
cell	O
growth	O
and	O
proliferation	O
.	O
Finally	O
,	O
oxidants	O
are	O
believed	O
to	O
promote	O
intestinal	O
epithelial	O
cell	O
apoptosis	O
,	O
and	O
the	O
B	B
-	I
cell	I
lymphoma	I
/	I
leukemia-2	I
gene	I
product	I
is	O
believed	O
to	O
inhibit	O
this	O
phenomenon	O
in	O
an	O
antioxidant	O
-	O
dependent	O
manner	O
.	O
Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
nontoxic	O
concentrations	O
of	O
reactive	O
metabolites	O
of	O
oxygen	O
and	O
nitrogen	O
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
the	O
inflammatory	O
response	O
and	O
in	O
modulating	O
apoptosis	O
.	O
Transcription	B
factors	I
required	O
for	O
lymphoid	O
lineage	O
commitment	O
.	O
Intimate	O
interactions	O
between	O
multipotential	O
hemopoietic	O
stem	O
cells	O
and	O
their	O
microenvironment	O
work	O
towards	O
redefining	O
the	O
identity	O
and	O
the	O
differentiative	O
fate	O
of	O
these	O
primitive	O
cells	O
.	O
Molecular	O
cues	O
delivered	O
by	O
the	O
microenvironment	O
frequently	O
act	O
in	O
an	O
instructive	O
fashion	O
by	O
initiating	O
intracellular	O
signaling	O
pathways	O
that	O
ultimately	O
target	O
a	O
select	O
group	O
of	O
transcription	B
factors	I
.	O
These	O
transcriptional	O
regulators	O
in	O
turn	O
trigger	O
a	O
cascade	O
of	O
genetic	O
changes	O
that	O
ultimately	O
determine	O
the	O
course	O
of	O
the	O
cells	O
during	O
differentiation	O
.	O
Gene	O
inactivation	O
studies	O
on	O
the	O
PU.1	O
,	O
Ikaros	O
and	O
GATA-3	O
genes	O
have	O
revealed	O
that	O
their	O
encoded	O
factors	O
are	O
essential	O
for	O
the	O
earliest	O
commitment	O
step	O
into	O
the	O
B	O
and	O
T	O
lymphoid	O
lineages	O
.	O
Xenogeneic	O
human	O
serum	O
promotes	O
leukocyte	O
adhesion	O
to	O
porcine	O
endothelium	O
under	O
flow	O
conditions	O
,	O
possibly	O
through	O
the	O
activation	O
of	O
the	O
transcription	B
factor	I
NF	I
-	I
kappa	I
B	I
.	O
Endothelial	O
cell	O
activation	O
and	O
leukocyte	O
infiltration	O
are	O
a	O
consistent	O
feature	O
of	O
discordant	O
xenograft	O
rejection	O
.	O
Here	O
we	O
evaluated	O
whether	O
xenogeneic	O
serum	O
,	O
as	O
a	O
source	O
of	O
xenoreactive	B
natural	I
antibodies	I
and	O
complement	O
,	O
induced	O
endothelial	O
cell	O
activation	O
with	O
consequent	O
leukocyte	O
adhesion	O
under	O
flow	O
conditions	O
.	O
Porcine	O
aortic	O
endothelial	O
cells	O
(	O
PAEC	O
)	O
were	O
incubated	O
for	O
1	O
hr	O
30	O
min	O
or	O
5	O
hr	O
with	O
10	O
%	O
homologous	O
porcine	O
serum	O
(	O
control	O
)	O
or	O
10	O
%	O
xenogeneic	O
human	O
serum	O
and	O
then	O
perfused	O
with	O
total	O
human	O
leukocytes	O
in	O
a	O
parallel	O
plate	O
flow	O
chamber	O
under	O
laminar	O
flow	O
(	O
1.5	O
dynes	O
/	O
cm2	O
)	O
.	O
Adherent	O
cells	O
were	O
counted	O
by	O
digital	O
image	O
analysis	O
.	O
Xenogeneic	O
human	O
serum	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
increased	O
the	O
number	O
of	O
adherent	O
leukocytes	O
as	O
compared	O
with	O
porcine	O
serum	O
.	O
A	O
similar	O
adhesive	O
response	O
was	O
elicited	O
by	O
TNF	O
alpha	O
(	O
100	O
U	O
/	O
ml	O
)	O
,	O
one	O
of	O
the	O
most	O
potent	O
inducers	O
of	O
endothelial	O
cell	O
adhesive	O
properties	O
,	O
here	O
used	O
as	O
positive	O
control	O
.	O
In	O
order	O
to	O
elucidate	O
possible	O
mechanisms	O
underlying	O
endothelial	O
cell	O
activation	O
by	O
xenogeneic	O
serum	O
,	O
we	O
focussed	O
on	O
transcription	B
factor	I
NF	I
-	I
kappa	I
B	I
,	O
a	O
central	O
regulator	O
for	O
the	O
induction	O
of	O
different	O
genes	O
,	O
including	O
adhesive	B
molecules	I
and	O
chemoattractants	B
.	O
By	O
confocal	O
fluorescence	O
microscopy	O
,	O
we	O
observed	O
a	O
positive	O
staining	O
for	O
NF	B
-	I
kappa	I
B	I
(	O
p65	B
subunit	I
)	O
in	O
the	O
nuclei	O
of	O
PAEC	O
exposed	O
for	O
1	O
hr	O
30	O
min	O
to	O
human	O
serum	O
,	O
which	O
indicated	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
this	O
setting	O
.	O
At	O
variance	O
,	O
in	O
PAEC	O
incubated	O
with	O
the	O
homologous	O
serum	O
,	O
NF	B
-	I
kappa	I
B	I
was	O
strictly	O
localized	O
in	O
the	O
cell	O
cytoplasm	O
.	O
Treatment	O
of	O
PAEC	O
exposed	O
to	O
xenogeneic	O
serum	O
with	O
the	O
NF	B
-	I
kappa	I
B	I
inhibitors	O
pyrrolidinedithiocarbamate	O
(	O
PDTC	O
,	O
25	O
microM	O
)	O
and	O
tosyl	O
-	O
phechloromethylketone	O
(	O
TPCK	O
,	O
25	O
microM	O
)	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
reduced	O
leukocyte	O
adhesion	O
in	O
respect	O
to	O
PAEC	O
treated	O
with	O
human	O
serum	O
alone	O
.	O
Findings	O
that	O
xenogeneic	O
serum	O
promotes	O
leukocyte	O
-	O
endothelium	O
interaction	O
possibly	O
through	O
NF	B
-	I
kappa	I
B	I
activation	O
might	O
be	O
relevant	O
for	O
designing	O
future	O
therapeutic	O
strategies	O
aimed	O
at	O
prolonging	O
xenograft	O
survival	O
.	O
Delta	O
-	O
opioid	O
receptors	O
expressed	O
by	O
Jurkat	O
T	O
cells	O
enhance	O
IL-2	B
secretion	O
by	O
increasing	O
AP-1	B
complexes	I
and	O
activity	O
of	O
the	O
NF	O
-	O
AT	O
/	O
AP-1-binding	O
promoter	O
element	O
.	O
Recent	O
molecular	O
evidence	O
points	O
to	O
transient	O
and/or	O
stage	O
-	O
specific	O
expression	O
of	O
delta-	B
and	I
kappa	I
-	I
opioid	I
receptors	I
by	O
thymic	O
and	O
peripheral	O
T	O
lymphocytes	O
.	O
Since	O
medical	O
treatments	O
or	O
stress	O
commonly	O
increase	O
opioid	O
levels	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
by	O
which	O
opioids	O
affect	O
T	O
lymphocyte	O
functions	O
.	O
We	O
therefore	O
created	O
and	O
studied	O
a	O
T	O
cell	O
line	O
expressing	O
the	O
cloned	B
delta	I
-	I
opioid	I
receptor	I
(	O
DOR1	B
)	O
.	O
DOR1	B
ligation	O
by	O
a	O
specific	O
DOR1	B
agonist	O
,	O
deltorphin	O
,	O
augmented	O
IL-2	B
secretion	O
by	O
synergizing	O
with	O
signals	O
from	O
TCR	B
-	I
CD3	I
and	O
CD28	B
.	O
Reporter	O
gene	O
constructs	O
were	O
used	O
to	O
map	O
this	O
effect	O
of	O
deltorphin	O
to	O
the	O
AP-1-	O
and	O
NF	O
-	O
AT	O
/	O
AP-1-binding	O
sites	O
of	O
the	O
IL-2	O
promoter	O
.	O
Although	O
DOR1	B
signaling	O
increased	O
[	O
Ca2	O
+	O
]	O
i	O
,	O
deltorphin	O
enhanced	O
transcriptional	O
activity	O
of	O
the	O
NF	O
-	O
AT	O
/	O
AP-1-binding	O
site	O
via	O
a	O
mechanism	O
independent	O
of	O
calcineurin	B
and	O
distinct	O
from	O
the	O
effects	O
of	O
elevated	O
[	O
Ca2	O
+	O
]	O
i	O
.	O
Deltorphin	O
also	O
increased	O
accumulation	O
of	O
AP-1	B
transcription	I
factor	I
complexes	I
,	O
suggesting	O
that	O
DOR1	B
augments	O
IL-2	B
secretion	O
by	O
increasing	O
the	O
AP-1	B
component	I
of	O
the	O
NF	B
-	I
AT	I
/	I
AP-1	I
transcription	I
factor	I
.	O
These	O
results	O
advance	O
the	O
molecular	O
understanding	O
of	O
opioid	O
effects	O
on	O
lymphocytes	O
,	O
and	O
in	O
addition	O
,	O
demonstrate	O
regulation	O
of	O
IL-2	B
synthesis	O
and	O
secretion	O
by	O
the	O
novel	O
mechanism	O
of	O
receptor	O
-	O
mediated	O
AP-1	B
induction	O
.	O
Differential	O
induction	O
of	O
DNA	B
-	I
binding	I
activities	I
following	O
CD19	B
cross	O
-	O
linking	O
in	O
human	O
B	O
lineage	O
cells	O
.	O
The	O
B	B
cell	I
-	I
specific	I
cell	I
surface	I
molecule	I
CD19	B
is	O
expressed	O
at	O
all	O
stages	O
of	O
B	O
cell	O
development	O
,	O
including	O
normal	O
plasma	O
cells	O
,	O
and	O
mediates	O
signal	O
transduction	O
via	O
interaction	O
with	O
cytoplasmic	B
effector	I
proteins	I
.	O
Cross	O
-	O
linking	O
CD19	B
on	O
early	O
human	O
B	O
lineage	O
cells	O
induces	O
the	O
formation	O
of	O
a	O
CD19	B
/	I
Vav	I
/	I
phosphatidylinositol-3	I
kinase	I
complex	I
,	O
tyrosine	O
phosphorylation	O
of	O
CD19	B
and	O
Vav	B
,	O
and	O
activation	O
of	O
the	O
Ras	B
pathway	O
.	O
To	O
further	O
explore	O
the	O
ramifications	O
of	O
CD19	B
signaling	O
,	O
the	O
current	O
study	O
examined	O
whether	O
phosphorylation	O
of	O
Elk-1	B
,	O
activation	O
of	O
activator	B
protein-1	I
(	O
AP-1	B
)	O
,	O
or	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	B
-	I
kappaB	I
)	O
transcription	B
factors	I
occurred	O
following	O
CD19	B
cross	O
-	O
linking	O
.	O
The	O
cells	O
used	O
were	O
the	O
BLIN-1	O
pre	O
-	O
B	O
cell	O
line	O
expressing	O
low	O
levels	O
of	O
cell	B
surface	I
mu	I
heavy	I
chain	I
associated	O
with	O
surrogate	B
light	I
chain	I
and	O
the	O
1E8	O
immature	O
B	O
cell	O
line	O
expressing	O
cell	B
surface	I
mu	I
/	I
kappa	I
.	O
Lysates	O
from	O
CD19	B
cross	O
-	O
linked	O
1E8	O
cells	O
induced	O
robust	O
phosphorylation	O
of	O
an	O
Elk-1	B
fusion	I
protein	I
in	O
vitro	O
,	O
whereas	O
no	O
phosphorylation	O
of	O
Elk-1	B
fusion	I
protein	I
occurred	O
using	O
lysates	O
from	O
CD19	O
cross	O
-	O
linked	O
BLIN-1	O
cells	O
.	O
An	O
electrophoretic	O
mobility	O
shift	O
assay	O
employing	O
AP-1	B
and	O
NF	B
-	I
kappaB	I
consensus	O
oligonucleotides	O
was	O
used	O
to	O
demonstrate	O
that	O
AP-1	B
-binding	O
activity	O
increased	O
,	O
while	O
constitutive	O
NF	B
-	I
kappaB	I
-binding	O
activity	O
was	O
not	O
enhanced	O
,	O
following	O
2	O
h	O
of	O
CD19	B
cross	O
-	O
linking	O
in	O
1E8	O
cells	O
.	O
Supershift	O
experiments	O
revealed	O
that	O
JunD	B
and	O
c	B
-	I
Fos	I
proteins	I
mediated	O
anti-	O
CD19	B
induced	O
AP-1	B
-binding	O
activity	O
in	O
1E8	O
cells	O
.	O
In	O
contrast	O
,	O
CD19	B
cross	O
-	O
linking	O
in	O
BLIN-1	O
cells	O
resulted	O
in	O
the	O
induction	O
of	O
NF	B
-	I
kappaB	I
,	O
but	O
had	O
no	O
apparent	O
effect	O
on	O
AP-1	B
-binding	O
activity	O
.	O
These	O
data	O
suggest	O
that	O
CD19	B
-mediated	O
signal	O
transduction	O
activates	O
different	O
transcription	B
factors	I
at	O
juxtaposed	O
stages	O
of	O
B	O
cell	O
development	O
that	O
may	O
culminate	O
in	O
the	O
activation	O
or	O
suppression	O
of	O
distinct	O
sets	O
of	O
genes	O
.	O
Pharmacological	O
control	O
of	O
antigen	O
responsiveness	O
in	O
genetically	O
modified	O
T	O
lymphocytes	O
.	O
A	O
chimeric	O
TCR	O
gene	O
,	O
comprising	O
an	O
anti	B
-	I
hapten	I
single	I
-	I
chain	I
Ab	I
variable	I
fragment	I
fused	O
to	O
the	O
transmembrane	B
and	I
cytoplasmic	I
regions	I
of	O
the	O
human	B
TCR	I
zeta	I
-	I
chain	I
,	O
was	O
used	O
to	O
determine	O
whether	O
the	O
tetracycline	O
-	O
regulatable	O
system	O
could	O
be	O
used	O
to	O
regulate	O
gene	O
expression	O
in	O
T	O
cells	O
.	O
Jurkat	O
T	O
cells	O
were	O
stably	O
transfected	O
with	O
a	O
single	O
vector	O
encoding	O
the	O
tetracycline	B
trans	I
-	I
activator	I
protein	I
,	O
controlled	O
by	O
a	O
constitutive	O
promoter	O
,	O
and	O
the	O
chimeric	B
TCR	I
,	O
under	O
the	O
control	O
of	O
a	O
trans	O
-	O
activator	O
protein	O
-	O
responsive	O
promoter	O
.	O
In	O
the	O
absence	O
of	O
tetracyclines	O
,	O
the	O
transfected	O
T	O
cells	O
were	O
shown	O
to	O
express	O
the	O
chimeric	B
receptor	I
on	O
the	O
cell	O
surface	O
and	O
could	O
be	O
activated	O
by	O
its	O
cognate	B
Ag	I
,	O
leading	O
to	O
the	O
secretion	O
of	O
IL-2	B
.	O
When	O
the	O
cells	O
were	O
exposed	O
to	O
increasing	O
concentrations	O
of	O
tetracyclines	O
,	O
surface	O
expression	O
of	O
the	O
chimeric	B
receptor	I
was	O
suppressed	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
and	O
this	O
suppression	O
was	O
sufficient	O
to	O
result	O
in	O
complete	O
loss	O
of	O
responsiveness	O
to	O
the	O
targeted	B
Ag	I
.	O
Prolonged	O
suppression	O
of	O
trans	O
-	O
gene	O
expression	O
for	O
up	O
to	O
7	O
days	O
was	O
observed	O
after	O
doxycycline	O
was	O
removed	O
from	O
the	O
cultures	O
,	O
but	O
eventual	O
recovery	O
of	O
surface	O
expression	O
was	O
complete	O
,	O
and	O
the	O
absolute	O
time	O
to	O
recovery	O
was	O
directly	O
proportional	O
to	O
the	O
initial	O
concentration	O
of	O
the	O
drug	O
.	O
Pharmacologic	O
control	O
of	O
trans	O
-	O
gene	O
expression	O
in	O
gene	O
-	O
modified	O
T	O
cells	O
will	O
not	O
only	O
facilitate	O
new	O
approaches	O
to	O
the	O
study	O
of	O
different	O
aspects	O
of	O
T	O
cell	O
biology	O
,	O
but	O
will	O
also	O
provide	O
the	O
basis	O
for	O
new	O
gene	O
therapy	O
strategies	O
.	O
IFN	B
-	I
gamma	I
and	O
IL-10	B
inhibit	O
induction	O
of	O
IL-1	O
receptor	O
type	O
I	O
and	O
type	O
II	O
gene	O
expression	O
by	O
IL-4	B
and	O
IL-13	B
in	O
human	O
monocytes	O
.	O
The	O
Th2-type	B
cytokines	I
IL-4	B
and	O
IL-13	B
induce	O
expression	O
of	O
a	O
distinct	O
subset	O
of	O
genes	O
in	O
human	O
monocytes	O
.	O
These	O
include	O
Fc	B
epsilonRII	I
(	O
CD23	B
)	O
,	O
15-lipoxygenase	B
,	O
IL-1	B
receptor	I
antagonist	I
(	O
IL-1ra	B
)	O
,	O
and	O
type	B
I	I
and	I
type	I
II	I
IL-1	I
receptors	I
(	O
IL-1R	B
)	O
.	O
IFN	B
-	I
gamma	I
has	O
been	O
shown	O
to	O
inhibit	O
induction	O
of	O
CD23	B
and	O
15-lipoxygenase	B
in	O
monocytes	O
;	O
however	O
,	O
the	O
effects	O
of	O
IFN	B
-	I
gamma	I
on	O
type	O
I	O
and	O
type	O
II	O
IL-1R	O
gene	O
expression	O
have	O
not	O
been	O
defined	O
.	O
We	O
examined	O
the	O
effects	O
of	O
IFN	B
-	I
gamma	I
on	O
both	O
basal	O
and	O
IL-4	B
/	O
IL-13	B
-induced	O
IL-1R	O
gene	O
expression	O
in	O
primary	O
monocytes	O
.	O
IL-4	B
and	O
IL-13	B
induced	O
dose-	O
and	O
time	O
-	O
dependent	O
increases	O
in	O
IL-1RI	O
and	O
IL-1RII	O
mRNA	O
levels	O
.	O
IFN	B
-	I
gamma	I
decreased	O
basal	O
expression	O
as	O
well	O
as	O
the	O
induction	O
of	O
these	O
genes	O
by	O
IL-4	B
and	O
IL-13	B
.	O
Inhibition	O
of	O
IL-1RI	B
and	O
IL-1RII	O
mRNA	O
levels	O
by	O
IFN	B
-	I
gamma	I
was	O
transcriptionally	O
mediated	O
,	O
and	O
correlated	O
directly	O
with	O
decreased	O
production	O
of	O
soluble	O
IL-1RII	B
.	O
Furthermore	O
,	O
the	O
ability	O
to	O
suppress	O
IL-1RI	O
and	O
IL-1RII	B
mRNA	O
levels	O
was	O
not	O
unique	O
to	O
IFN	B
-	I
gamma	I
because	O
IL-10	B
also	O
inhibited	O
expression	O
of	O
these	O
genes	O
in	O
IL-4	O
/	O
IL-13-stimulated	O
monocytes	O
.	O
Inhibition	O
of	O
IL-1R	O
gene	O
expression	O
by	O
IFN	B
-	I
gamma	I
and	O
IL-10	B
was	O
not	O
due	O
to	O
down	O
-	O
regulation	O
of	O
surface	B
IL-4R	I
because	O
pretreatment	O
with	O
these	O
cytokines	O
did	O
not	O
decrease	O
the	O
number	O
of	O
IL-4	B
binding	O
sites	O
per	O
cell	O
.	O
However	O
,	O
suppression	O
of	O
IL-1R	O
gene	O
expression	O
by	O
IFN	B
-	I
gamma	I
and	O
IL-10	B
was	O
associated	O
with	O
decreased	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
the	O
IL-4	B
/	I
IL-13-inducible	I
transcription	I
factor	I
,	O
Stat6	B
,	O
suggesting	O
a	O
potential	O
mechanism	O
by	O
which	O
IFN	B
-	I
gamma	I
and	O
IL-10	B
may	O
mediate	O
their	O
suppressive	O
effects	O
.	O
These	O
findings	O
demonstrate	O
that	O
certain	O
cytokines	O
,	O
including	O
IFN	B
-	I
gamma	I
and	O
IL-10	B
,	O
antagonize	O
the	O
ability	O
of	O
IL-4	B
and	O
IL-13	B
to	O
induce	O
increased	O
expression	O
of	O
the	O
IL-1RI	O
and	O
IL-1RII	O
genes	O
in	O
monocytes	O
.	O
Human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
quasispecies	O
differ	O
in	O
basal	O
transcription	O
and	O
nuclear	O
factor	O
recruitment	O
in	O
human	O
glial	O
cells	O
and	O
lymphocytes	O
.	O
The	O
generation	O
of	O
genomic	O
diversity	O
during	O
the	O
course	O
of	O
infection	O
has	O
the	O
potential	O
to	O
affect	O
all	O
aspects	O
of	O
HIV-1	O
replication	O
,	O
including	O
expression	O
of	O
the	O
proviral	O
genome	O
.	O
To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
impact	O
of	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
sequence	O
diversity	O
on	O
LTR	O
-	O
directed	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
and	O
immune	O
system	O
,	O
we	O
amplified	O
and	O
cloned	O
LTRs	O
from	O
proviral	O
DNA	O
in	O
HIV-1-infected	O
peripheral	O
blood	O
.	O
Sequence	O
analysis	O
of	O
nineteen	O
LTRs	O
cloned	O
from	O
2	O
adult	O
and	O
3	O
pediatric	O
patients	O
revealed	O
an	O
average	O
of	O
33	O
nucleotide	O
changes	O
(	O
with	O
respect	O
to	O
the	O
sequence	O
of	O
the	O
LAI	O
LTR	O
)	O
within	O
the	O
455-bp	O
U3	O
region	O
.	O
Transient	O
expression	O
analyses	O
in	O
cells	O
of	O
neuroglial	O
and	O
lymphocytic	O
origin	O
demonstrated	O
that	O
some	O
of	O
these	O
LTRs	O
had	O
activities	O
which	O
varied	O
significantly	O
from	O
the	O
LAI	O
LTR	O
in	O
U-373	O
MG	O
cells	O
(	O
an	O
astrocytoma	O
cell	O
line	O
)	O
as	O
well	O
as	O
in	O
Jurkat	O
cells	O
(	O
a	O
CD4-positive	O
lymphocyte	O
cell	O
line	O
)	O
.	O
While	O
LTRs	O
which	O
demonstrated	O
the	O
highest	O
activities	O
in	O
U-373	O
MG	O
cells	O
also	O
yielded	O
high	O
activities	O
in	O
Jurkat	O
cells	O
,	O
the	O
LTRs	O
were	O
generally	O
more	O
active	O
in	O
Jurkat	O
cells	O
when	O
compared	O
to	O
the	O
LAI	O
LTR	O
.	O
Differences	O
in	O
LTR	O
sequence	O
also	O
resulted	O
in	O
differences	O
in	O
transcription	O
factor	O
recruitment	O
to	O
cis	O
-	O
acting	O
sites	O
within	O
the	O
U3	O
region	O
of	O
the	O
LTR	O
,	O
as	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
In	O
particular	O
,	O
naturally	O
occurring	O
sequence	O
variation	O
impacted	O
transcription	B
factor	I
binding	O
to	O
an	O
activating	B
transcription	I
factor	I
/	O
cAMP	B
response	I
element	I
binding	I
(	O
ATF	B
/	O
CREB	B
)	O
binding	O
site	O
(	O
located	O
between	O
the	O
LEF-1	O
and	O
distal	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
binding	O
sites	O
)	O
that	O
we	O
identified	O
in	O
previous	O
studies	O
of	O
the	O
HIV-1	O
LTR	O
.	O
These	O
findings	O
suggest	O
that	O
LTR	O
sequence	O
changes	O
can	O
significantly	O
affect	O
basal	O
LTR	O
function	O
and	O
transcription	O
factor	O
recruitment	O
,	O
which	O
may	O
,	O
in	O
turn	O
,	O
alter	O
the	O
course	O
of	O
viral	O
replication	O
in	O
cells	O
of	O
CNS	O
and	O
immune	O
system	O
origin	O
.	O
Activation	O
of	O
Stat-3	B
is	O
involved	O
in	O
the	O
induction	O
of	O
apoptosis	O
after	O
ligation	O
of	O
major	B
histocompatibility	I
complex	I
class	I
I	I
molecules	I
on	O
human	O
Jurkat	O
T	O
cells	O
.	O
Activation	O
of	O
Janus	B
tyrosine	I
kinases	I
(	O
Jak	B
)	O
and	O
Signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	O
Stat	B
)	O
after	O
ligation	O
of	O
major	B
histocompatibility	I
complex	I
class	I
I	I
(	O
MHC	B
-	I
I	I
)	O
was	O
explored	O
in	O
Jurkat	O
T	O
cells	O
.	O
Cross	O
-	O
linking	O
of	O
MHC	B
-	I
I	I
mediated	O
tyrosine	O
phosphorylation	O
of	O
Tyk2	B
,	O
but	O
not	O
Jak1	B
,	O
Jak2	B
,	O
and	O
Jak3	B
.	O
In	O
addition	O
,	O
the	O
transcription	B
factor	I
Stat-3	B
was	O
tyrosine	O
phosphorylated	O
in	O
the	O
cytoplasm	O
and	O
subsequently	O
translocated	O
to	O
the	O
cell	O
nucleus	O
.	O
Data	O
obtained	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
suggested	O
that	O
the	O
activated	B
Stat-3	I
protein	I
associates	O
with	O
the	O
human	O
serum	O
-	O
inducible	O
element	O
(	O
hSIE	O
)	O
DNA	O
-	O
probe	O
derived	O
from	O
the	O
interferon	O
-	O
gamma	O
activated	O
site	O
(	O
GAS	O
)	O
in	O
the	O
c	O
-	O
fos	O
promoter	O
,	O
a	O
common	O
DNA	O
sequence	O
for	O
Stat	B
protein	I
binding	O
.	O
An	O
association	O
between	O
hSIE	O
and	O
Stat-3	B
after	O
MHC	B
-	I
I	I
ligation	O
was	O
directly	O
demonstrated	O
by	O
precipitating	O
Stat-3	B
from	O
nuclear	O
extracts	O
with	O
biotinylated	O
hSIE	O
probe	O
and	O
avidin	B
-coupled	O
agarose	O
.	O
To	O
investigate	O
the	O
function	O
of	O
the	O
activated	O
Stat-3	B
,	O
Jurkat	O
T	O
cells	O
were	O
transiently	O
transfected	O
with	O
a	O
Stat-3	B
isoform	I
lacking	O
the	O
transactivating	B
domain	I
.	O
This	O
dominant	B
-	I
negative	I
acting	I
Stat-3	I
isoform	I
significantly	O
inhibited	O
apoptosis	O
induced	O
by	O
ligation	O
of	O
MHC	B
-	I
I	I
.	O
In	O
conclusion	O
,	O
our	O
data	O
suggest	O
the	O
involvement	O
of	O
the	O
Jak	B
/	I
Stat	I
signal	O
pathway	O
in	O
MHC	B
-	I
I	I
-induced	O
signal	O
transduction	O
in	O
T	O
cells	O
.	O
IL-2	B
-induced	O
growth	O
of	O
CD8	O
+	O
T	O
cell	O
prolymphocytic	O
leukemia	O
cells	O
mediated	O
by	O
NF	B
-	I
kappaB	I
induction	O
and	O
IL-2	B
receptor	I
alpha	I
expression	O
.	O
The	O
binding	O
of	O
interleukin-2	B
(	O
IL-2	B
)	O
to	O
its	O
receptor	O
on	O
normal	O
T	O
cells	O
induces	O
nuclear	O
expression	O
of	O
nuclear	B
factor	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
,	O
activation	O
of	O
the	O
IL-2	O
receptor	O
(	O
IL-2R	O
)	O
alpha	O
chain	O
gene	O
,	O
and	O
cell	O
proliferation	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
IL-2R	B
signaling	O
in	O
the	O
growth	O
of	O
CD8	O
+	O
T	O
cell	O
prolymphocytic	O
leukemia	O
(	O
T	O
-	O
PLL	O
)	O
cells	O
has	O
been	O
investigated	O
.	O
Flow	O
cytometry	O
revealed	O
that	O
primary	O
leukemia	O
cells	O
from	O
a	O
patient	O
with	O
CD8	O
+	O
T	O
-	O
PLL	O
expressed	O
IL-2Ralpha	B
and	I
beta	I
chains	I
,	O
and	O
the	O
cells	O
showed	O
a	O
proliferative	O
response	O
and	O
an	O
increase	O
in	O
IL-2Ralpha	B
expression	O
on	O
culture	O
with	O
exogeneous	O
IL-2	B
.	O
Northern	O
blot	O
analysis	O
failed	O
to	O
detect	O
IL-2	O
mRNA	O
,	O
suggesting	O
that	O
IL-2	B
may	O
act	O
in	O
a	O
paracrine	O
manner	O
in	O
vivo	O
.	O
Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
revealed	O
that	O
recombinant	O
IL-2	B
increased	O
NF	B
-	I
kappaB	I
binding	O
activity	O
in	O
nuclear	O
extracts	O
of	O
the	O
leukemia	O
cells	O
,	O
and	O
Northern	O
blot	O
analysis	O
showed	O
that	O
IL-2	B
increased	O
the	O
abundance	O
of	O
mRNAs	O
encoding	O
the	O
NF	B
-	I
kappaB	I
components	O
c	B
-	I
Rel	I
and	O
KBF1	B
in	O
these	O
cells	O
.	O
IL-2	B
binding	O
analysis	O
demonstrated	O
that	O
IL-2	B
markedly	O
increased	O
the	O
number	O
of	O
low	O
affinity	O
IL-2Rs	B
on	O
the	O
leukemia	O
cells	O
,	O
without	O
an	O
effect	O
on	O
the	O
number	O
of	O
high	B
-	I
affinity	I
IL-2Rs	I
.	O
These	O
results	O
show	O
that	O
IL-2	B
is	O
capable	O
of	O
inducing	O
the	O
nuclear	O
expression	O
of	O
NF	B
-	I
kappaB	I
in	O
primary	O
CD8	O
+	O
T	O
-	O
PLL	O
cells	O
,	O
and	O
that	O
this	O
effect	O
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
at	O
a	O
pretranslational	O
level	O
HMG	B
box	I
containing	I
transcription	I
factors	I
in	O
lymphocyte	O
differentiation	O
.	O
The	O
identification	O
of	O
the	O
mammalian	O
sex	O
-	O
determining	O
gene	O
Sry	O
has	O
led	O
to	O
the	O
discovery	O
of	O
a	O
large	O
family	O
of	O
related	O
(	O
'	O
HMG	B
box	I
'	O
)	O
transcription	B
factors	I
that	O
control	O
developmental	O
events	O
in	O
yeast	O
,	O
C.	O
elegans	O
,	O
Drosophila	O
and	O
vertebrates	O
.	O
In	O
lymphocyte	O
differentiation	O
,	O
several	O
HMG	B
box	I
proteins	I
play	O
a	O
decisive	O
role	O
.	O
Sox-4	B
is	O
important	O
for	O
very	O
early	O
B	O
-	O
cell	O
differentiation	O
,	O
while	O
TCF-1	B
/	O
LEF-1	B
play	O
a	O
crucial	O
role	O
in	O
early	O
thymocyte	O
development	O
.	O
TCF	B
/	I
LEF	I
proteins	I
have	O
recently	O
been	O
found	O
to	O
constitute	O
a	O
downstream	O
component	O
of	O
the	O
Wingless	O
/	O
Wnt	O
signal	O
transduction	O
pathway	O
.	O
In	O
flies	O
,	O
this	O
pathway	O
controls	O
segment	O
polarity	O
;	O
in	O
Xenopus	O
it	O
controls	O
the	O
definition	O
of	O
the	O
body	O
axis	O
.	O
Deregulation	O
of	O
the	O
pathway	O
occurs	O
in	O
several	O
human	O
tumors	O
.	O
These	O
insights	O
in	O
the	O
molecular	O
events	O
that	O
are	O
involved	O
in	O
TCF	B
/	I
LEF	I
function	O
in	O
these	O
organisms	O
may	O
eventually	O
lead	O
to	O
the	O
understanding	O
of	O
the	O
function	O
of	O
these	O
HMG	B
box	I
proteins	I
in	O
lymphoid	O
development	O
The	O
human	O
toll	O
signaling	O
pathway	O
:	O
divergence	O
of	O
nuclear	B
factor	I
kappaB	I
and	O
JNK	B
/SAPK	B
activation	O
upstream	O
of	O
tumor	B
necrosis	I
factor	I
receptor	I
-	I
associated	I
factor	I
6	I
(	O
TRAF6	B
)	O
.	O
The	O
human	O
homologue	O
of	O
Drosophila	B
Toll	I
(	O
hToll	B
)	O
is	O
a	O
recently	O
cloned	O
receptor	O
of	O
the	O
interleukin	B
1	I
receptor	I
(	I
IL-1R	I
)	I
superfamily	I
,	O
and	O
has	O
been	O
implicated	O
in	O
the	O
activation	O
of	O
adaptive	O
immunity	O
.	O
Signaling	O
by	O
hToll	B
is	O
shown	O
to	O
occur	O
through	O
sequential	O
recruitment	O
of	O
the	O
adapter	B
molecule	I
MyD88	B
and	O
the	O
IL-1R	B
-	I
associated	I
kinase	I
.	O
Tumor	B
necrosis	I
factor	I
receptor	I
-	I
activated	I
factor	I
6	I
(	O
TRAF6	B
)	O
and	O
the	O
nuclear	B
factor	I
kappaB	I
(	I
NF	I
-	I
kappaB	I
)	I
-inducing	I
kinase	I
(	O
NIK	B
)	O
are	O
both	O
involved	O
in	O
subsequent	O
steps	O
of	O
NF	B
-	I
kappaB	I
activation	O
.	O
Conversely	O
,	O
a	O
dominant	O
negative	O
version	O
of	O
TRAF6	B
failed	O
to	O
block	O
hToll	B
-induced	O
activation	O
of	O
stress	B
-	I
activated	I
protein	I
kinase	I
/	I
c	I
-	I
Jun	I
NH2-terminal	I
kinases	I
,	O
thus	O
suggesting	O
an	O
early	O
divergence	O
of	O
the	O
two	O
pathways	O
.	O
IL-4	B
-dependent	O
regulation	O
of	O
TGF	O
-	O
alpha	O
and	O
TGF	O
-	O
beta1	O
expression	O
in	O
human	O
eosinophils	O
.	O
TGFs	B
play	O
important	O
roles	O
in	O
wound	O
healing	O
and	O
carcinogenesis	O
.	O
We	O
have	O
previously	O
demonstrated	O
that	O
eosinophils	O
infiltrating	O
into	O
different	O
pathologic	O
processes	O
elaborate	O
TGF	B
-	I
alpha	I
and	O
TGF	B
-	I
beta1	I
.	O
Eosinophils	O
infiltrating	O
hamster	O
cutaneous	O
wounds	O
were	O
found	O
to	O
express	O
TGFs	B
sequentially	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
biologic	O
mediators	O
that	O
may	O
regulate	O
the	O
expression	O
of	O
TGF	B
-	I
alpha	I
and	I
-beta1	I
by	O
eosinophils	O
.	O
Eosinophils	O
were	O
isolated	O
from	O
the	O
peripheral	O
blood	O
of	O
healthy	O
donors	O
and	O
cultured	O
in	O
the	O
absence	O
or	O
presence	O
of	O
IL-3	B
,	O
IL-4	B
,	O
and	O
IL-5	B
.	O
Cells	O
were	O
analyzed	O
by	O
in	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
.	O
Supernatants	O
from	O
these	O
cultures	O
were	O
assayed	O
for	O
secreted	O
TGF	B
-	I
alpha	I
and	O
TGF	B
-	I
beta1	I
using	O
TGF	B
-specific	O
ELISAs	O
.	O
IL-3	B
,	O
IL-4	B
,	O
and	O
IL-5	B
independently	O
up	O
-	O
regulated	O
TGF	O
-	O
beta1	O
mRNA	O
and	O
product	O
expression	O
by	O
eosinophils	O
in	O
all	O
donors	O
.	O
Interestingly	O
,	O
TGF	B
-	I
alpha	I
production	O
by	O
eosinophils	O
was	O
up	O
-	O
regulated	O
by	O
IL-3	B
and	O
IL-5	B
but	O
was	O
down	O
-	O
regulated	O
by	O
IL-4	B
.	O
Consistent	O
with	O
the	O
ability	O
of	O
IL-4	B
to	O
regulate	O
eosinophil	O
responses	O
,	O
IL-4	B
signaling	I
molecules	I
are	O
present	O
in	O
human	O
eosinophils	O
.	O
The	O
observation	O
that	O
IL-4	B
can	O
differentially	O
regulate	O
the	O
expression	O
of	O
TGF	B
-	I
alpha	I
and	O
TGF	B
-	I
beta1	I
suggests	O
that	O
IL-4	B
may	O
serve	O
as	O
a	O
physiologic	O
molecular	O
switch	O
of	O
TGF	B
expression	O
by	O
the	O
infiltrating	O
eosinophils	O
in	O
wound	O
healing	O
and	O
carcinogenesis	O
.	O
Erythropoietin	B
induces	O
tyrosine	O
phosphorylation	O
of	O
Jak2	B
,	O
STAT5A	B
,	O
and	O
STAT5B	B
in	O
primary	O
cultured	O
human	O
erythroid	O
precursors	O
.	O
We	O
examined	O
signaling	O
by	O
erythropoietin	B
in	O
highly	O
purified	O
human	O
colony	O
forming	O
unit	O
-	O
erythroid	O
cells	O
,	O
generated	O
in	O
vitro	O
from	O
CD34	O
(	O
+	O
)	O
cells	O
.	O
We	O
found	O
that	O
erythropoietin	B
induces	O
tyrosine	O
phosphorylation	O
of	O
Jak2	B
,	O
STAT5A	B
,	O
and	O
STAT5B	B
.	O
Tyrosine	O
phosphorylation	O
of	O
Jak2	B
reaches	O
a	O
peak	O
around	O
10	O
minutes	O
after	O
stimulation	O
and	O
is	O
maximum	O
at	O
5	O
U	O
/	O
mL	O
of	O
erythropoietin	B
.	O
Tyrosine	O
phosphorylation	O
of	O
STAT5	B
is	O
accompanied	O
by	O
the	O
translocation	O
of	O
activated	O
STAT5	B
to	O
the	O
nucleus	O
as	O
shown	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
using	O
32Pi	O
-	O
labeled	O
STAT5	O
binding	O
site	O
in	O
the	O
beta	O
-	O
casein	O
promoter	O
.	O
Tyrosine	O
phosphorylation	O
STAT1	B
or	O
STAT3	B
was	O
not	O
detected	O
in	O
human	O
erythroid	O
precursors	O
after	O
stimulation	O
with	O
erythropoietin	B
.	O
Crkl	B
,	O
an	O
SH2	B
/	I
SH3	I
adapter	I
protein	I
,	O
becomes	O
coimmunoprecipitated	O
specifically	O
with	O
STAT5	B
from	O
erythropoietin	O
-	O
stimulated	O
erythroid	O
cells	O
;	O
although	O
it	O
was	O
shown	O
to	O
become	O
associated	O
with	O
c	B
-	I
Cbl	I
in	O
the	O
studies	O
using	O
cell	O
lines	O
.	O
Thus	O
,	O
human	O
erythroid	O
precursors	O
can	O
be	O
expanded	O
in	O
vitro	O
in	O
sufficient	O
numbers	O
and	O
purity	O
to	O
allow	O
its	O
usage	O
in	O
signal	O
transduction	O
studies	O
.	O
This	O
report	O
sets	O
a	O
basis	O
for	O
further	O
studies	O
on	O
signaling	O
in	O
primary	O
cultured	O
human	O
erythroid	O
precursors	O
,	O
which	O
in	O
turn	O
contribute	O
to	O
our	O
better	O
understanding	O
in	O
the	O
differentiation	O
processes	O
of	O
erythrocytes	O
and	O
their	O
precursors	O
.	O
A	O
small	O
,	O
nonpeptidyl	O
mimic	O
of	O
granulocyte	B
-	I
colony	I
-	I
stimulating	I
factor	I
[	O
see	O
commetns	O
]	O
A	O
nonpeptidyl	O
small	O
molecule	O
SB	O
247464	O
,	O
capable	O
of	O
activating	O
granulocyte	B
-	I
colony	I
-	I
stimulating	I
factor	I
(	O
G	B
-	I
CSF	I
)	O
signal	O
transduction	O
pathways	O
,	O
was	O
identified	O
in	O
a	O
high	O
-	O
throughput	O
assay	O
in	O
cultured	O
cells	O
.	O
Like	O
G	B
-	I
CSF	I
,	O
SB	O
247464	O
induced	O
tyrosine	O
phosphorylation	O
of	O
multiple	B
signaling	I
proteins	I
and	O
stimulated	O
primary	O
murine	O
bone	O
marrow	O
cells	O
to	O
form	O
granulocytic	O
colonies	O
in	O
vitro	O
.	O
It	O
also	O
elevated	O
peripheral	O
blood	O
neutrophil	O
counts	O
in	O
mice	O
.	O
The	O
extracellular	O
domain	O
of	O
the	O
murine	B
G	I
-	I
CSF	I
receptor	I
was	O
required	O
for	O
the	O
activity	O
of	O
SB	O
247464	O
,	O
suggesting	O
that	O
the	O
compound	O
acts	O
by	O
oligomerizing	B
receptor	I
chains	I
.	O
The	O
results	O
indicate	O
that	O
a	O
small	O
molecule	O
can	O
activate	O
a	O
receptor	O
that	O
normally	O
binds	O
a	O
relatively	O
large	O
protein	O
ligand	O
.	O
Thrombopoietin	B
supports	O
in	O
vitro	O
erythroid	O
differentiation	O
via	O
its	O
specific	O
receptor	O
c	B
-	I
Mpl	I
in	O
a	O
human	O
leukemia	O
cell	O
line	O
.	O
Thrombopoietin	B
(	O
TPO	B
)	O
acts	O
on	O
megakaryopoiesis	O
and	O
erythropoiesis	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
We	O
isolated	O
a	O
novel	O
subline	O
,	O
UT-7	O
/	O
GMT	O
,	O
from	O
the	O
human	O
leukemia	O
cell	O
line	O
UT-7	O
/	O
GM	O
(	O
N.	O
Komatsu	O
,	O
et	O
al.	O
,	O
Blood	O
,	O
89	O
:	O
4021	O
-	O
4033	O
,	O
1997	O
)	O
.	O
A	O
small	O
population	O
of	O
UT-7	O
/	O
GM	O
cells	O
positively	O
stained	O
for	O
hemoglobin	B
(	O
Hb	B
)	O
after	O
a	O
7-day	O
exposure	O
to	O
TPO	B
.	O
More	O
than	O
50	O
%	O
of	O
TPO	O
-	O
treated	O
UT-7	O
/	O
GMT	O
cells	O
positively	O
stained	O
for	O
Hb	B
.	O
Using	O
UT-7	O
/	O
GMT	O
cells	O
,	O
we	O
examined	O
how	O
TPO	B
promotes	O
hemoglobinization	O
.	O
TPO	B
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
TPO	B
receptor	O
but	O
not	O
the	O
erythropoietin	B
(	I
EPO	I
)	I
receptor	I
.	O
There	O
was	O
no	O
competition	O
between	O
TPO	B
and	O
EPO	B
for	O
binding	O
to	O
EPO	B
receptor	I
.	O
These	O
findings	O
suggest	O
that	O
TPO	B
has	O
a	O
direct	O
effect	O
on	O
hemoglobinization	O
via	O
a	O
specific	O
receptor	O
on	O
UT-7	O
/	O
GMT	O
cells	O
.	O
Isoelectric	O
focusing	O
demonstrated	O
that	O
TPO	B
induced	O
fetal	O
and	O
adult	O
Hb	O
synthesis	O
,	O
whereas	O
EPO	B
induced	O
embryonic	O
,	O
fetal	O
,	O
and	O
adult	O
Hb	O
synthesis	O
.	O
Thus	O
,	O
our	O
data	O
suggest	O
that	O
TPO	B
has	O
a	O
distinct	O
action	O
on	O
erythropoiesis	O
.	O
Peripheral	O
blood	O
T	O
cells	O
and	O
monocytes	O
and	O
B	O
cell	O
lines	O
derived	O
from	O
patients	O
with	O
lupus	O
express	O
estrogen	O
receptor	O
transcripts	O
similar	O
to	O
those	O
of	O
normal	O
cells	O
.	O
OBJECTIVE	O
:	O
To	O
identify	O
and	O
characterize	O
estrogen	O
receptor	O
(	O
ER	O
)	O
transcripts	O
expressed	O
in	O
immune	O
cells	O
of	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
and	O
healthy	O
donors	O
.	O
METHODS	O
:	O
Peripheral	O
blood	O
monocytes	O
and	O
T	O
cells	O
were	O
prepared	O
from	O
patients	O
with	O
SLE	O
(	O
n	O
=	O
6	O
)	O
and	O
healthy	O
donors	O
(	O
n	O
=	O
8	O
)	O
.	O
T	O
cells	O
were	O
separated	O
into	O
CD4	O
and	O
CD8	O
.	O
Some	O
monocytes	O
and	O
T	O
cells	O
were	O
stimulated	O
with	O
estradiol	O
,	O
PMA	O
,	O
and	O
ionomycin	O
.	O
Epstein	O
-	O
Barr	O
virus	O
-	O
transformed	O
B	O
cell	O
lines	O
(	O
n	O
=	O
7	O
)	O
and	O
B	O
cell	O
hybridomas	O
(	O
n	O
=	O
2	O
)	O
established	O
from	O
patients	O
with	O
SLE	O
and	O
a	O
healthy	O
individual	O
were	O
used	O
as	O
a	O
B	O
cell	O
source	O
.	O
These	O
cells	O
were	O
examined	O
for	O
ER	O
mRNA	O
by	O
reverse	O
transcription	O
nested	O
polymerase	O
chain	O
reaction	O
.	O
Amplified	O
cDNA	O
were	O
sequenced	O
by	O
standard	O
methods	O
.	O
RESULTS	O
:	O
In	O
all	O
cells	O
tested	O
,	O
ER	O
mRNA	O
was	O
expressed	O
without	O
prior	O
in	O
vitro	O
stimulation	O
.	O
Partial	O
sequences	O
from	O
exons	O
1	O
-	O
8	O
were	O
nearly	O
identical	O
to	O
the	O
published	O
sequence	O
of	O
the	O
human	O
ER	O
mRNA	O
.	O
There	O
were	O
no	O
notable	O
differences	O
in	O
the	O
ER	O
transcripts	O
between	O
patients	O
and	O
healthy	O
controls	O
.	O
Variant	O
receptor	O
transcripts	O
lacking	O
exon	O
5	O
or	O
exon	O
7	O
,	O
which	O
encodes	O
the	O
hormone	B
binding	I
domain	I
,	O
were	O
identified	O
in	O
the	O
majority	O
of	O
the	O
cells	O
.	O
Precise	O
deletion	O
of	O
the	O
exons	O
suggests	O
that	O
they	O
are	O
alternatively	O
spliced	O
transcripts	O
.	O
Whether	O
the	O
detected	O
transcripts	O
are	O
translated	O
into	O
functional	B
receptor	I
proteins	I
remains	O
to	O
be	O
determined	O
.	O
In	O
vitro	O
stimulation	O
did	O
not	O
affect	O
ER	O
mRNA	O
expression	O
.	O
The	O
presence	O
of	O
variants	O
did	O
not	O
correlate	O
with	O
disease	O
activity	O
or	O
medication	O
.	O
CONCLUSION	O
:	O
Monocytes	O
,	O
T	O
cells	O
,	O
and	O
B	O
cells	O
in	O
patients	O
express	O
transcripts	O
of	O
the	O
normal	O
wild	B
type	I
ER	I
and	O
the	O
hormone	B
binding	I
domain	I
variants	I
in	O
vivo	O
.	O
A	O
novel	O
retinoic	B
acid	I
receptor	I
(	O
RAR	B
)	O
-selective	O
antagonist	O
inhibits	O
differentiation	O
and	O
apoptosis	O
of	O
HL-60	O
cells	O
:	O
implications	O
of	O
RARalpha	B
-mediated	O
signals	O
in	O
myeloid	O
leukemic	O
cells	O
.	O
Retinoic	O
acid	O
(	O
RA	O
)	O
induces	O
HL-60	O
cells	O
to	O
differentiate	O
terminally	O
into	O
mature	O
granulocytes	O
,	O
which	O
subsequently	O
die	O
by	O
apoptosis	O
.	O
The	O
biological	O
effects	O
of	O
RA	O
are	O
mediated	O
by	O
two	O
distinct	O
families	O
of	O
transcription	B
factors	I
:	O
retinoic	B
acid	I
receptors	I
(	O
RARs	B
)	O
and	O
retinoid	B
X	I
receptors	I
(	O
RXRs	B
)	O
.	O
RARs	B
and	O
RXRs	B
form	O
heterodimers	B
and	O
regulate	O
retinoid	O
-	O
mediated	O
gene	O
expression	O
.	O
We	O
have	O
recently	O
developed	O
a	O
novel	O
RAR	B
-selective	O
antagonist	O
(	O
ER27191	O
)	O
which	O
prevents	O
RAR	B
activation	O
by	O
retinoids	O
.	O
Using	O
this	O
RAR	O
-	O
selective	O
antagonist	O
,	O
and	O
RXR	B
and	O
RAR	B
agonist	O
,	O
we	O
demonstrate	O
the	O
RAR	B
-mediated	O
signaling	O
pathway	O
is	O
important	O
for	O
differentiation	O
and	O
apoptosis	O
of	O
myeloid	O
leukemic	O
cells	O
.	O
Simple	O
activation	O
of	O
RXRs	B
is	O
not	O
sufficient	O
to	O
induce	O
apoptosis	O
of	O
the	O
cells	O
.	O
Interestingly	O
,	O
the	O
combination	O
of	O
the	O
RAR	O
-	O
selective	O
antagonist	O
and	O
9-cis	O
RA	O
resulted	O
in	O
partial	O
differentiation	O
and	O
apoptosis	O
of	O
HL-60	O
and	O
NB4	O
cells	O
,	O
whereas	O
the	O
RAR	B
antagonist	O
completely	O
blocked	O
all	O
-	O
trans	O
RA	O
-	O
induced	O
differentiation	O
and	O
apoptosis	O
of	O
the	O
cells	O
.	O
Additional	O
experiments	O
showed	O
that	O
levels	O
of	O
BCL-2	B
protein	I
decreased	O
during	O
differentiation	O
of	O
myeloid	O
leukemic	O
cells	O
.	O
Furthermore	O
,	O
HL-60	O
cells	O
transduced	O
with	O
a	O
bcl-2	O
expression	O
vector	O
showed	O
the	O
same	O
differentiation	O
response	O
to	O
retinoids	O
as	O
did	O
parental	O
HL-60	O
cells	O
even	O
though	O
apoptosis	O
was	O
inhibited	O
in	O
these	O
bcl-2-transduced	O
cells	O
,	O
suggesting	O
that	O
differentiation	O
and	O
apoptosis	O
are	O
regulated	O
independently	O
in	O
myeloid	O
leukemic	O
cells	O
.	O
Expression	O
of	O
gamma	O
-	O
IFN	O
responsive	O
genes	O
in	O
scavenger	O
receptor	O
over	O
-	O
expressing	O
monocytes	O
is	O
associated	O
with	O
xanthomatosis	O
.	O
We	O
have	O
recently	O
described	O
an	O
inherited	O
over	O
-	O
expression	O
of	O
the	O
macrophage	B
scavenger	I
receptor	I
(	O
SR	B
)	O
in	O
blood	O
monocytes	O
from	O
members	O
of	O
a	O
kindred	O
,	O
only	O
two	O
of	O
whom	O
displayed	O
extensive	O
xanthomatosis	O
.	O
Using	O
mRNA	O
differential	O
display	O
we	O
demonstrated	O
abnormally	O
high	O
expression	O
of	O
the	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	O
STAT1alpha	B
)	O
in	O
monocytes	O
from	O
the	O
proband	O
II-2	O
.	O
Expression	O
of	O
gamma	B
-	I
interferon	I
inducible	I
protein	I
10	I
(	O
IP-10	B
)	O
,	O
a	O
STAT1alpha	O
-	O
responsive	O
gene	O
and	O
mediator	O
of	O
inflammatory	O
response	O
,	O
was	O
also	O
abnormally	O
expressed	O
in	O
the	O
monocytes	O
from	O
II-2	O
.	O
Over	O
-	O
expression	O
of	O
both	O
genes	O
was	O
restricted	O
to	O
monocytes	O
from	O
II-2	O
and	O
was	O
not	O
observed	O
in	O
monocytes	O
from	O
the	O
clinically	O
unaffected	O
family	O
members	O
,	O
unlike	O
that	O
of	O
SR	B
.	O
Gel	O
retardation	O
assays	O
with	O
THP-1	O
cell	O
extracts	O
identified	O
gamma	B
-	I
IFN	I
inducible	O
DNA	O
binding	O
activity	O
to	O
three	O
potential	O
STATI	O
DNA	O
binding	O
elements	O
in	O
the	O
human	O
IP-10	O
promoter	O
region	O
from	O
nucleotides	O
-	O
245	O
to	O
-	O
188	O
.	O
Taken	O
together	O
these	O
results	O
suggest	O
that	O
gamma	O
-	O
interferon	O
mediated	O
cell	O
activation	O
is	O
responsible	O
for	O
STAT1alpha	B
-induced	O
transcription	O
of	O
the	O
IP-10	B
gene	O
in	O
THP-1	O
macrophages	O
as	O
well	O
as	O
in	O
monocytes	O
from	O
II-2	O
.	O
Analysis	O
of	O
monocytes	O
from	O
familial	O
hypercholesterolemic	O
(	O
FH	O
)	O
subjects	O
,	O
who	O
frequently	O
develop	O
xanthomatosis	O
,	O
revealed	O
a	O
significant	O
number	O
of	O
subjects	O
with	O
elevated	O
STAT1alpha	O
and	O
IP-10	O
expression	O
.	O
Our	O
data	O
suggest	O
that	O
the	O
inflammatory	O
effects	O
of	O
gamma	B
-	I
IFN	I
signaling	O
could	O
play	O
a	O
role	O
in	O
foam	O
cell	O
formation	O
and	O
xanthomatosis	O
.	O
Ciprofloxacin	O
induces	O
an	O
immunomodulatory	O
stress	O
response	O
in	O
human	O
T	O
lymphocytes	O
.	O
Exposure	O
of	O
cells	O
to	O
adverse	O
environmental	O
conditions	O
invokes	O
a	O
genetically	O
programmed	O
series	O
of	O
events	O
resulting	O
in	O
the	O
induction	O
of	O
specific	O
genes	O
.	O
The	O
fluoroquinolone	O
antibiotic	O
ciprofloxacin	O
has	O
recently	O
been	O
reported	O
to	O
upregulate	O
interleukin-2	B
(	O
IL-2	B
)	O
gene	O
induction	O
.	O
In	O
the	O
present	O
investigation	O
,	O
the	O
effect	O
of	O
ciprofloxacin	O
at	O
supratherapeutic	O
concentrations	O
on	O
immediate	O
-	O
early	O
(	O
<	O
2	O
h	O
)	O
gene	O
expression	O
in	O
primary	O
human	O
peripheral	O
blood	O
lymphocytes	O
was	O
studied	O
with	O
Northern	O
blots	O
.	O
In	O
addition	O
,	O
transcriptional	O
activity	O
of	O
IL-2	B
and	O
metallothionein	O
enhancer	O
and	O
promoter	O
regions	O
and	O
transcription	B
factors	I
AP-1	B
,	O
NF	B
-	I
kappaB	I
,	O
and	O
NF	B
-	I
AT	I
were	O
analyzed	O
by	O
chloramphenicol	B
acetyltransferase	I
(	O
CAT	B
)	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
respectively	O
.	O
The	O
concentration	O
of	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
,	O
c	O
-	O
myc	O
,	O
junB	O
,	O
and	O
fra-1	O
mRNAs	O
was	O
increased	O
in	O
activated	O
peripheral	O
blood	O
lymphocytes	O
incubated	O
with	O
ciprofloxacin	O
compared	O
to	O
that	O
in	O
untreated	O
controls	O
.	O
Ciprofloxacin	O
increased	O
CAT	B
activity	O
in	O
stimulated	O
lymphocytes	O
transfected	O
with	O
plasmids	O
containing	O
either	O
the	O
IL-2	B
or	O
metallothionein	O
enhancer	O
.	O
Furthermore	O
,	O
among	O
the	O
transcription	B
factors	I
tested	O
,	O
AP-1	B
activity	O
was	O
increased	O
in	O
stimulated	O
purified	O
T	O
helper	O
lymphocytes	O
incubated	O
with	O
ciprofloxacin	O
compared	O
to	O
drug	O
-	O
free	O
controls	O
.	O
Taken	O
together	O
,	O
ciprofloxacin	O
increased	O
the	O
levels	O
of	O
immediate	O
-	O
early	O
transcripts	O
,	O
enhanced	O
IL-2	B
and	O
metallothionein	B
promoter	O
induction	O
,	O
and	O
upregulated	O
AP-1	B
concentrations	O
in	O
primary	O
lymphocytes	O
,	O
reflecting	O
a	O
program	O
commonly	O
observed	O
in	O
mammalian	O
stress	O
responses	O
.	O
Human	O
15-lipoxygenase	O
gene	O
promoter	O
:	O
analysis	O
and	O
identification	O
of	O
DNA	O
binding	O
sites	O
for	O
IL-13-induced	B
regulatory	I
factors	I
in	O
monocytes	O
.	O
In	O
order	O
to	O
study	O
the	O
transcriptional	O
control	O
of	O
15-LO	B
expression	O
,	O
we	O
have	O
cloned	O
and	O
sequenced	O
the	O
human	O
15-LO	O
promoter	O
region	O
.	O
The	O
15-LO	B
promoter	O
is	O
associated	O
with	O
a	O
CpG	O
island	O
at	O
the	O
5'-end	O
of	O
the	O
gene	O
,	O
and	O
sequence	O
analysis	O
reveals	O
putative	O
Sp1	O
and	O
Ap2	O
binding	O
site	O
/	O
s	O
and	O
absence	O
of	O
TATA	O
or	O
CAAT	O
motifs	O
.	O
Transcription	O
is	O
initiated	O
at	O
one	O
major	O
site	O
.	O
Using	O
deletion	O
constructs	O
,	O
we	O
have	O
defined	O
an	O
active	O
promoter	O
region	O
of	O
1056	O
bp	O
.	O
Gel	O
-	O
shift	O
assays	O
revealed	O
that	O
transcriptional	B
factor	I
(	O
s	O
)	O
induced	O
only	O
in	O
response	O
to	O
IL-13	B
treatment	O
of	O
human	O
peripheral	O
blood	O
monocytes	O
bind	O
to	O
the	O
15-LO	O
promoter	O
DNA	O
.	O
Two	O
regions	O
,	O
DP1	O
(	O
-140	O
to	O
-92	O
bp	O
)	O
and	O
DP2	O
(	O
-353	O
to	O
-304	O
bp	O
)	O
of	O
the	O
promoter	O
were	O
essential	O
for	O
transcription	O
in	O
HeLa	O
cells	O
and	O
human	O
peripheral	O
monocytes	O
.	O
Hela	O
nuclear	O
extracts	O
contained	O
a	O
specific	B
nuclear	I
factor	I
(	I
s	I
)	I
binding	O
to	O
15-LO	O
promoter	O
DNA	O
which	O
are	O
distinct	O
from	O
those	O
derived	O
from	O
IL-13-treated	O
human	O
peripheral	O
monocyte	O
nuclear	O
extracts	O
.	O
In	O
addition	O
,	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
results	O
refined	O
the	O
previous	O
localization	O
of	O
15-LO	B
to	O
human	O
chromosome	O
17p13.3	O
.	O
Changes	O
in	O
PKC	B
isoforms	I
in	O
human	O
alveolar	O
macrophages	O
compared	O
with	O
blood	O
monocytes	O
.	O
Alveolar	O
macrophages	O
play	O
an	O
important	O
role	O
in	O
host	O
defense	O
and	O
in	O
other	O
types	O
of	O
inflammatory	O
processes	O
in	O
the	O
lung	O
.	O
These	O
cells	O
exhibit	O
many	O
alterations	O
in	O
function	O
compared	O
with	O
their	O
precursor	O
cells	O
,	O
blood	O
monocytes	O
.	O
To	O
evaluate	O
a	O
potential	O
mechanism	O
for	O
these	O
differences	O
in	O
function	O
,	O
we	O
evaluated	O
expression	O
of	O
protein	B
kinase	I
C	I
(	I
PKC	I
)	I
isoforms	I
.	O
We	O
found	O
an	O
increase	O
in	O
Ca2	B
+	I
-dependent	I
PKC	I
isoforms	I
in	O
monocytes	O
compared	O
with	O
alveolar	O
macrophages	O
.	O
We	O
also	O
found	O
differential	O
expression	O
of	O
the	O
Ca2	B
+	I
-independent	I
isoforms	I
in	O
alveolar	O
macrophages	O
compared	O
with	O
monocytes	O
.	O
One	O
consequence	O
of	O
the	O
activation	O
of	O
PKC	B
can	O
be	O
increased	O
expression	O
of	O
mitogen	B
-	I
activated	I
protein	I
(	I
MAP	I
)	I
kinase	I
pathways	O
.	O
Therefore	O
,	O
we	O
also	O
evaluated	O
activation	O
of	O
the	O
MAP	B
kinase	I
extracellular	I
signal	I
-	I
regulated	I
kinase	I
(	I
ERK	I
)	I
2	I
by	O
the	O
phorbol	O
ester	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O
PMA	O
activated	O
ERK2	B
kinase	I
in	O
both	O
alveolar	O
macrophages	O
and	O
monocytes	O
;	O
however	O
,	O
monocytes	O
consistently	O
showed	O
a	O
significantly	O
greater	O
activation	O
of	O
ERK2	B
kinase	I
by	O
PMA	O
compared	O
with	O
alveolar	O
macrophages	O
.	O
Another	O
known	O
consequence	O
of	O
the	O
activation	O
of	O
PKC	B
and	O
subsequent	O
activation	O
of	O
ERK	B
kinase	I
is	O
activation	O
of	O
the	O
transcription	B
factor	I
activator	I
protein-1	I
(	O
AP-1	B
)	O
.	O
We	O
evaluated	O
the	O
activation	O
of	O
AP-1	B
by	O
PMA	O
in	O
both	O
monocytes	O
and	O
macrophages	O
.	O
We	O
found	O
very	O
little	O
detectable	O
activation	O
of	O
AP-1	B
,	O
as	O
assessed	O
in	O
a	O
gel	O
shift	O
assay	O
,	O
in	O
alveolar	O
macrophages	O
,	O
whereas	O
monocytes	O
showed	O
a	O
substantial	O
activation	O
of	O
AP-1	B
by	O
PMA	O
.	O
These	O
studies	O
show	O
that	O
the	O
differential	O
expression	O
of	O
PKC	B
isoforms	I
in	O
alveolar	O
macrophages	O
and	O
blood	O
monocytes	O
is	O
associated	O
with	O
important	O
functional	O
alterations	O
in	O
the	O
cells	O
.	O
Dimethyldithiocarbamate	O
inhibits	O
in	O
vitro	O
activation	O
of	O
primary	O
human	O
CD4	O
+	O
T	O
lymphocytes	O
.	O
Dithiocarbamates	O
(	O
DTC	O
)	O
,	O
a	O
diverse	O
group	O
of	O
industrial	O
and	O
therapeutic	O
chemicals	O
,	O
have	O
been	O
reported	O
to	O
inhibit	O
,	O
enhance	O
or	O
have	O
no	O
effect	O
on	O
the	O
immune	O
system	O
.	O
These	O
apparent	O
inconsistencies	O
reflect	O
the	O
complexity	O
of	O
the	O
DTCs	O
biological	O
activities	O
and	O
are	O
probably	O
due	O
in	O
part	O
to	O
differences	O
in	O
dose	O
,	O
route	O
of	O
exposure	O
,	O
animal	O
species	O
used	O
and/or	O
specific	O
compound	O
tested	O
.	O
The	O
studies	O
described	O
herein	O
were	O
undertaken	O
to	O
investigate	O
the	O
immunotoxicity	O
of	O
one	O
member	O
of	O
this	O
family	O
,	O
dimethyldithiocarbamate	O
(	O
DMDTC	O
)	O
.	O
We	O
demonstrate	O
that	O
0.1	O
-	O
0.5	O
microM	O
DMDTC	O
inhibits	O
TNF	B
-	I
alpha	I
-induced	O
activation	O
of	O
NF	B
-	I
kappaB	I
in	O
primary	O
human	O
CD4	O
+	O
T	O
cells	O
.	O
This	O
inhibition	O
is	O
not	O
accompanied	O
by	O
a	O
loss	O
in	O
viability	O
,	O
and	O
DMDTC	O
-	O
treated	O
T	O
cells	O
retain	O
other	O
active	O
signaling	O
pathways	O
throughout	O
the	O
exposure	O
duration	O
.	O
The	O
inhibition	O
of	O
NF	B
-	I
kappaB	I
is	O
apparently	O
permanent	O
as	O
DMDTC	O
-	O
treated	O
T	O
cells	O
did	O
not	O
regain	O
normal	O
TNF	B
-	I
alpha	I
activation	O
,	O
even	O
after	O
72	O
h	O
in	O
culture	O
.	O
DMDTC	O
does	O
not	O
appear	O
to	O
alter	O
NF	B
-	I
kappaB	I
directly	O
as	O
pre	O
-	O
incubation	O
of	O
nuclear	O
extracts	O
with	O
DMDTC	O
does	O
not	O
diminish	O
binding	O
activity	O
of	O
this	O
protein	O
.	O
We	O
further	O
demonstrate	O
that	O
0.1	O
-	O
0.5	O
microM	O
DMDTC	O
inhibits	O
intracellular	O
IL-2	B
production	O
and	O
decreases	O
surface	O
expression	O
of	O
CD25	B
(	O
the	O
alpha	B
subunit	I
of	O
the	O
IL-2	B
receptor	I
)	O
in	O
T	O
cells	O
stimulated	O
with	O
phorbol	O
ester	O
.	O
These	O
data	O
demonstrate	O
that	O
DMDTC	O
is	O
a	O
potent	O
immunosuppressive	O
compound	O
in	O
vitro	O
.	O
A	O
regulatory	O
element	O
in	O
the	O
CD95	O
(	O
APO-1	O
/	O
Fas	O
)	O
ligand	O
promoter	O
is	O
essential	O
for	O
responsiveness	O
to	O
TCR	B
-mediated	O
activation	O
.	O
Expression	O
of	O
the	O
CD95	B
(	I
APO-1	I
/	I
Fas	I
)	I
ligand	I
(	O
CD95L	B
)	O
in	O
activated	O
T	O
cells	O
is	O
a	O
major	O
cause	O
of	O
T	O
cell	O
activation	O
-	O
induced	O
apoptosis	O
.	O
To	O
study	O
the	O
molecular	O
mechanisms	O
of	O
transcriptional	O
control	O
of	O
CD95L	B
expression	O
in	O
T	O
cells	O
,	O
we	O
investigated	O
the	O
human	O
CD95L	O
promoter	O
in	O
Jurkat	O
T	O
cells	O
.	O
Deletion	O
studies	O
revealed	O
that	O
the	O
CD95L	O
proximal	O
promoter	O
sequence	O
from	O
-220	O
to	O
the	O
transcription	O
start	O
site	O
is	O
essential	O
for	O
T	O
cell	O
stimulation	O
-	O
induced	O
expression	O
of	O
CD95L	B
.	O
In	O
this	O
study	O
,	O
we	O
discovered	O
a	O
novel	O
regulatory	O
element	O
located	O
at	O
-120	O
of	O
the	O
CD95L	O
promoter	O
which	O
contains	O
DNA	O
binding	O
sites	O
for	O
SP-1	B
and	O
a	O
yet	O
unknown	O
inducible	B
factor	I
.	O
Mutation	O
analysis	O
demonstrated	O
that	O
binding	O
of	O
the	O
inducible	O
factor	O
to	O
the	O
-120	O
region	O
is	O
crucial	O
for	O
the	O
biological	O
function	O
of	O
the	O
CD95L	O
promoter	O
upon	O
T	O
cell	O
stimulation	O
.	O
The	O
DNA	O
sequence	O
at	O
-120	O
also	O
contains	O
two	O
DNA	O
motifs	O
homologous	O
to	O
the	O
binding	O
site	O
for	O
NF	B
-	I
AT	I
.	O
NF	B
-	I
AT	I
does	O
not	O
directly	O
bind	O
to	O
this	O
element	O
.	O
However	O
,	O
cotransfection	O
studies	O
with	O
an	O
NF	O
-	O
AT	O
expression	O
vector	O
showed	O
that	O
NF	B
-	I
AT	I
may	O
confer	O
a	O
strong	O
inducible	O
activity	O
to	O
the	O
CD95L	O
promoter	O
at	O
this	O
regulatory	O
region	O
.	O
Our	O
data	O
also	O
show	O
that	O
the	O
immunosuppressive	O
agent	O
cyclosporin	O
A	O
down	O
-	O
regulates	O
CD95L	B
transcription	O
by	O
inhibiting	O
the	O
function	O
of	O
this	O
positive	O
regulatory	O
element	O
Acetylation	O
and	O
modulation	O
of	O
erythroid	B
Kruppel	I
-	I
like	I
factor	I
(	O
EKLF	B
)	O
activity	O
by	O
interaction	O
with	O
histone	B
acetyltransferases	I
.	O
Erythroid	B
Kruppel	I
-	I
like	I
factor	I
(	O
EKLF	B
)	O
is	O
a	O
red	B
cell	I
-	I
specific	I
transcriptional	I
activator	I
that	O
is	O
crucial	O
for	O
consolidating	O
the	O
switch	O
to	O
high	O
levels	O
of	O
adult	O
beta	O
-	O
globin	O
expression	O
during	O
erythroid	O
ontogeny	O
.	O
EKLF	B
is	O
required	O
for	O
integrity	O
of	O
the	O
chromatin	O
structure	O
at	O
the	O
beta	O
-	O
like	O
globin	O
locus	O
,	O
and	O
it	O
interacts	O
with	O
a	O
positive	B
-	I
acting	I
factor	I
in	O
vivo	O
.	O
We	O
find	O
that	O
EKLF	B
is	O
an	O
acetylated	B
transcription	I
factor	I
,	O
and	O
that	O
it	O
interacts	O
in	O
vivo	O
with	O
CBP	B
,	O
p300	B
,	O
and	O
P	B
/	I
CAF	I
.	O
However	O
,	O
its	O
interactions	O
with	O
these	O
histone	B
acetyltransferases	I
are	O
not	O
equivalent	O
,	O
as	O
CBP	B
and	O
p300	B
,	O
but	O
not	O
P	B
/	I
CAF	I
,	O
utilize	O
EKLF	B
as	O
a	O
substrate	O
for	O
in	O
vitro	O
acetylation	O
within	O
its	O
trans	O
-	O
activation	O
region	O
.	O
The	O
functional	O
effects	O
of	O
these	O
interactions	O
are	O
that	O
CBP	B
and	O
p300	B
,	O
but	O
not	O
P	B
/	I
CAF	I
,	O
enhance	O
EKLF	B
's	O
transcriptional	O
activation	O
of	O
the	O
beta	O
-	O
globin	O
promoter	O
in	O
erythroid	O
cells	O
.	O
These	O
results	O
establish	O
EKLF	B
as	O
a	O
tissue	B
-	I
specific	I
transcription	I
factor	I
that	O
undergoes	O
post	O
-	O
translational	O
acetylation	O
and	O
suggest	O
a	O
mechanism	O
by	O
which	O
EKLF	B
is	O
able	O
to	O
alter	O
chromatin	O
structure	O
and	O
induce	O
beta	O
-	O
globin	O
expression	O
within	O
the	O
beta	O
-	O
like	O
globin	O
cluster	O
.	O
Epstein	B
-	I
Barr	I
virus	I
-	I
transforming	I
protein	I
latent	B
infection	I
membrane	I
protein	I
1	I
activates	O
transcription	B
factor	I
NF	I
-	I
kappaB	I
through	O
a	O
pathway	O
that	O
includes	O
the	O
NF	B
-	I
kappaB	I
-	I
inducing	I
kinase	I
and	O
the	O
IkappaB	B
kinases	I
IKKalpha	B
and	O
IKKbeta	B
.	O
The	O
Epstein	B
-	I
Barr	I
virus	I
oncoprotein	I
latent	B
infection	I
membrane	I
protein	I
1	I
(	O
LMP1	B
)	O
is	O
a	O
constitutively	O
aggregated	O
pseudo	B
-	I
tumor	I
necrosis	I
factor	I
receptor	I
(	O
TNFR	B
)	O
that	O
activates	O
transcription	B
factor	I
NF	I
-	I
kappaB	I
through	O
two	O
sites	O
in	O
its	O
C	B
-	I
terminal	I
cytoplasmic	I
domain	I
.	O
One	O
site	O
is	O
similar	O
to	O
activated	O
TNFRII	B
in	O
associating	O
with	O
TNFR	B
-	I
associated	I
factors	I
TRAF1	B
and	O
TRAF2	B
,	O
and	O
the	O
second	O
site	O
is	O
similar	O
to	O
TNFRI	B
in	O
associating	O
with	O
the	O
TNFRI	B
death	I
domain	I
interacting	I
protein	I
TRADD	B
.	O
TNFRI	B
has	O
been	O
recently	O
shown	O
to	O
activate	O
NF	B
-	I
kappaB	I
through	O
association	O
with	O
TRADD	B
,	O
RIP	B
,	O
and	O
TRAF2	B
;	O
activation	O
of	O
the	O
NF	B
-	I
kappaB	I
-	I
inducing	I
kinase	I
(	O
NIK	B
)	O
;	O
activation	O
of	O
the	O
IkappaB	B
alpha	I
kinases	I
(	O
IKKalpha	B
and	O
IKKbeta	B
)	O
;	O
and	O
phosphorylation	O
of	O
IkappaB	B
alpha	I
.	O
IkappaB	B
alpha	I
phosphorylation	O
on	O
Ser-32	O
and	O
Ser-36	O
is	O
followed	O
by	O
its	O
degradation	O
and	O
NF	B
-	I
kappaB	I
activation	O
.	O
In	O
this	O
report	O
,	O
we	O
show	O
that	O
NF	B
-	I
kappaB	I
activation	O
by	O
LMP1	B
or	O
by	O
each	O
of	O
its	O
effector	B
sites	I
is	O
mediated	O
by	O
a	O
pathway	O
that	O
includes	O
NIK	B
,	O
IKKalpha	B
,	O
and	O
IKKbeta	B
.	O
Dominant	B
negative	I
mutants	I
of	O
NIK	B
,	O
IKKalpha	B
,	O
or	O
IKKbeta	B
substantially	O
inhibited	O
NF	B
-	I
kappaB	I
activation	O
by	O
LMP1	B
or	O
by	O
each	O
of	O
its	O
effector	B
sites	I
.	O
Class	O
II	O
transactivator	O
-	O
independent	O
endothelial	O
cell	O
MHC	B
class	I
II	I
gene	O
activation	O
induced	O
by	O
lymphocyte	O
adhesion	O
.	O
NK	O
cells	O
induce	O
MHC	B
class	I
II	I
molecules	O
on	O
the	O
surface	O
of	O
allogeneic	O
endothelial	O
cells	O
in	O
an	O
adhesion	O
-	O
dependent	O
,	O
IFN	B
-	I
gamma	I
-independent	O
manner	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
NK	O
cells	O
induce	O
HLA	B
-	I
DR	I
on	O
the	O
surface	O
of	O
a	O
mutant	O
cell	O
line	O
that	O
is	O
defective	O
in	O
IFN	B
-	I
gamma	I
-induced	O
MHC	B
class	I
II	I
expression	O
.	O
RNA	O
analysis	O
in	O
these	O
cells	O
and	O
in	O
a	O
cell	O
line	O
that	O
is	O
defective	O
in	O
class	B
II	I
transactivator	I
(	O
CIITA	B
)	O
demonstrates	O
that	O
NK	O
cell	O
-	O
induced	O
HLA	O
-	O
DR	O
alpha	O
mRNA	O
expression	O
is	O
also	O
CIITA	B
-independent	O
.	O
The	O
Janus	O
kinase-1-deficient	O
cell	O
line	O
U4A	O
expresses	O
HLA	O
-	O
DR	O
alpha	O
mRNA	O
in	O
response	O
to	O
NK	O
cell	O
activation	O
,	O
and	O
HLA	O
-	O
DR	O
alpha	O
promoter	O
constructs	O
transfected	O
into	O
these	O
cells	O
are	O
induced	O
by	O
NK	O
cells	O
but	O
not	O
IFN	B
-	I
gamma	I
.	O
These	O
data	O
indicate	O
that	O
the	O
IFN	B
-	I
gamma	I
-independent	O
component	O
of	O
the	O
target	O
cell	O
HLA	B
-	I
DR	I
expression	O
induced	O
by	O
lymphocyte	O
adhesion	O
uses	O
a	O
signaling	O
pathway	O
that	O
is	O
distinct	O
from	O
the	O
IFN	B
-	I
gamma	I
-dependent	O
mechanism	O
and	O
also	O
suggest	O
that	O
CIITA	B
is	O
not	O
required	O
.	O
Cyclosporin	O
A	O
-	O
resistant	O
transactivation	O
of	O
the	O
IL-2	O
promoter	O
requires	O
activity	O
of	O
okadaic	B
acid	I
-	I
sensitive	I
serine	I
/	I
threonine	I
phosphatases	I
.	O
Expression	O
of	O
the	O
IL-2	O
gene	O
requires	O
activation	O
of	O
T	O
cells	O
through	O
stimulation	O
of	O
the	O
TCR	B
and	O
costimulation	O
through	O
accessory	B
receptors	I
.	O
We	O
have	O
found	O
recently	O
that	O
okadaic	B
acid	I
-	I
sensitive	I
Ser	I
/	I
Thr	I
phosphatases	I
are	O
involved	O
in	O
a	O
cyclosporin	O
A	O
-	O
insensitive	O
pathway	O
that	O
selectively	O
transmits	O
costimulatory	O
signals	O
.	O
In	O
this	O
study	O
,	O
we	O
analyzed	O
whether	O
activities	O
of	O
these	O
phosphatases	O
are	O
necessary	O
for	O
the	O
expression	O
of	O
the	O
IL-2	O
gene	O
.	O
In	O
both	O
activated	O
peripheral	O
blood	O
T	O
lymphocytes	O
and	O
activated	O
tumorigenic	O
T	O
cell	O
lines	O
,	O
IL-2	B
gene	O
expression	O
was	O
blocked	O
at	O
the	O
transcriptional	O
level	O
by	O
okadaic	O
acid	O
.	O
The	O
transcription	B
factors	I
active	O
at	O
the	O
IL-2	O
promoter	O
were	O
differentially	O
influenced	O
:	O
upon	O
down	O
-	O
modulation	O
of	O
okadaic	B
acid	I
-	I
sensitive	I
phosphatases	I
,	O
transactivation	O
by	O
octamer	O
,	O
NF	B
-	I
kappa	I
B	I
,	O
and	O
NF	B
of	I
activated	I
T	I
cells	I
proteins	I
was	O
abrogated	O
,	O
while	O
transactivation	O
by	O
AP-1	B
proteins	I
was	I
even	I
enhanced	I
.	I
Inducible	O
nitric	O
oxide	O
:	O
an	O
autoregulatory	O
feedback	O
inhibitor	O
of	O
vascular	O
inflammation	O
.	O
Inducible	O
nitric	O
oxide	O
(	O
iNO	O
)	O
is	O
produced	O
at	O
sites	O
of	O
vascular	O
inflammation	O
by	O
resident	O
and	O
nonresident	O
vascular	O
wall	O
cells	O
,	O
but	O
its	O
role	O
in	O
the	O
inflammatory	O
process	O
is	O
not	O
known	O
.	O
In	O
this	O
study	O
,	O
we	O
show	O
that	O
a	O
novel	O
function	O
of	O
iNO	O
is	O
to	O
terminate	O
inflammatory	O
processes	O
.	O
We	O
find	O
that	O
iNO	O
produced	O
by	O
murine	O
macrophage	O
-	O
like	O
cells	O
,	O
RAW264.7	O
,	O
can	O
inhibit	O
cytokine	B
-induced	O
endothelial	O
cell	O
activation	O
in	O
a	O
separated	O
and	O
mixed	O
endothelial	O
-	O
RAW264.7	O
coculture	O
system	O
.	O
Both	O
iNO	O
production	O
and	O
endothelial	O
VCAM-1	B
expression	O
were	O
induced	O
simultaneously	O
with	O
bacterial	O
LPS	O
and	O
murine	B
-	I
specific	I
IFN	I
-	I
gamma	I
.	O
Inhibition	O
of	O
iNO	B
synthase	I
(	O
iNOS	B
)	O
activity	O
with	O
N	O
omega	O
-	O
monomethyl	O
-	O
L	O
-	O
arginine	O
in	O
endothelial	O
-	O
RAW264.7	O
cocultures	O
,	O
stimulated	O
with	O
murine	B
-	I
specific	I
IFN	I
-	I
gamma	I
and	O
LPS	O
,	O
decreased	O
iNO	O
production	O
by	O
86	O
%	O
,	O
augmented	O
VCAM-1	B
and	O
iNOS	B
expression	O
in	O
endothelial	O
and	O
RAW264.7	O
cells	O
,	O
respectively	O
,	O
and	O
increased	O
monocyte	O
adhesion	O
to	O
the	O
endothelial	O
cell	O
surface	O
.	O
Transient	O
transfection	O
studies	O
using	O
various	O
VCAM-1	O
promoter	O
constructs	O
demonstrated	O
that	O
inhibitory	O
effects	O
of	O
iNO	O
on	O
VCAM-1	B
gene	O
transcription	O
were	O
mediated	O
,	O
in	O
part	O
,	O
by	O
inhibitory	O
effects	O
of	O
iNO	O
on	O
kappa	O
B	O
cis	O
-	O
acting	O
elements	O
.	O
Immunofluorescence	O
studies	O
using	O
an	O
Ab	O
to	O
the	O
RelA	B
(	I
p65	I
)	I
subunit	I
of	O
nuclear	O
factor	B
-	I
kappa	I
B	I
revealed	O
that	O
iNO	O
inhibited	O
the	O
activation	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
.	O
These	O
studies	O
indicate	O
that	O
iNO	O
attenuates	O
iNOS	B
expression	O
in	O
macrophages	O
and	O
inhibits	O
monocyte	O
adhesion	O
to	O
endothelial	O
cells	O
,	O
and	O
suggest	O
that	O
endogenously	O
derived	O
iNO	O
may	O
be	O
an	O
important	O
autoregulatory	O
inhibitor	O
of	O
vascular	O
inflammation	O
Highly	O
polarized	O
HLA	B
class	I
II	I
antigen	I
processing	O
and	O
presentation	O
by	O
human	O
intestinal	O
epithelial	O
cells	O
.	O
The	O
high	O
concentration	O
of	O
foreign	B
antigen	I
in	O
the	O
lumen	O
of	O
the	O
gastrointestinal	O
tract	O
is	O
separated	O
from	O
the	O
underlying	O
lymphocytes	O
by	O
a	O
single	O
cell	O
layer	O
of	O
polarized	O
epithelium	O
.	O
Intestinal	O
epithelial	O
cells	O
can	O
express	O
HLA	B
class	I
II	I
antigens	I
and	O
may	O
function	O
as	O
antigen	O
-	O
presenting	O
cells	O
to	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
within	O
the	O
intestinal	O
mucosa	O
.	O
Using	O
tetanus	O
toxoid	O
specific	O
and	O
HLA	O
-	O
DR	O
-	O
restricted	O
T	O
lymphocytes	O
,	O
we	O
show	O
that	O
polarized	O
intestinal	O
epithelial	O
cells	O
directed	O
to	O
express	O
HLA	B
-	I
DR	I
molecules	I
are	O
able	O
to	O
initiate	O
class	O
II	O
processing	O
only	O
after	O
internalization	O
of	O
antigen	O
from	O
their	O
apical	O
surface	O
.	O
Coexpression	O
of	O
the	O
class	B
II	I
transactivator	I
CIITA	I
in	O
these	O
cells	O
,	O
which	O
stimulates	O
highly	O
efficient	O
class	O
II	O
processing	O
without	O
the	O
characteristic	O
decline	O
in	O
barrier	O
function	O
seen	O
in	O
polarized	O
monolayers	O
treated	O
with	O
the	O
proinflammatory	B
cytokine	I
gamma	I
-	I
IFN	I
,	O
facilitates	O
antigen	O
processing	O
from	O
the	O
basolateral	O
surface	O
.	O
In	O
both	O
cases	O
,	O
peptide	O
presentation	O
to	O
T	O
cells	O
via	O
class	B
II	I
molecules	I
was	O
restricted	O
to	O
the	O
basolateral	O
surface	O
.	O
These	O
data	O
indicate	O
a	O
highly	O
polarized	O
functional	O
architecture	O
for	O
antigen	O
processing	O
and	O
presentation	O
by	O
intestinal	O
epithelial	O
cells	O
,	O
and	O
suggest	O
that	O
the	O
functional	O
outcome	O
of	O
antigen	O
processing	O
by	O
the	O
intestinal	O
epithelium	O
is	O
both	O
dependent	O
on	O
the	O
cellular	O
surface	O
at	O
which	O
the	O
foreign	O
antigen	O
is	O
internalized	O
and	O
by	O
the	O
underlying	O
degree	O
of	O
mucosal	O
inflammation	O
The	O
small	B
GTP	I
-	I
binding	I
protein	I
Rho	I
potentiates	O
AP-1	B
transcription	O
in	O
T	O
cells	O
.	O
The	O
Rho	B
family	O
of	O
small	B
GTP	I
-	I
binding	I
proteins	I
is	O
involved	O
in	O
the	O
regulation	O
of	O
cytoskeletal	O
structure	O
,	O
gene	O
transcription	O
,	O
specific	O
cell	O
fate	O
development	O
,	O
and	O
transformation	O
.	O
We	O
demonstrate	O
in	O
this	O
report	O
that	O
overexpression	O
of	O
an	O
activated	O
form	O
of	O
Rho	B
enhances	O
AP-1	B
activity	O
in	O
Jurkat	O
T	O
cells	O
in	O
the	O
presence	O
of	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
but	O
activated	O
Rho	B
(	O
V14Rho	B
)	O
has	O
little	O
or	O
no	O
effect	O
on	O
NFAT	B
,	O
Oct-1	B
,	O
and	O
NF	O
-	O
kappaB	O
enhancer	O
element	O
activities	O
under	O
similar	O
conditions	O
.	O
Overexpression	O
of	O
a	O
V14Rho	O
construct	O
incapable	O
of	O
membrane	O
localization	O
(	O
CAAX	O
deleted	O
)	O
abolishes	O
PMA	O
-	O
induced	O
AP-1	B
transcriptional	O
activation	O
.	O
The	O
effect	O
of	O
Rho	B
on	O
AP-1	B
is	O
independent	O
of	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
pathway	O
,	O
as	O
a	O
dominant	B
-	I
negative	I
MEK	I
and	O
a	O
MEK	B
inhibitor	O
(	O
PD98059	O
)	O
did	O
not	O
affect	O
Rho	B
-induced	O
AP-1	B
activity	O
.	O
V14Rho	B
binds	O
strongly	O
to	O
protein	B
kinase	I
Calpha	I
(	O
PKCalpha	B
)	O
in	O
vivo	O
;	O
however	O
,	O
deletion	O
of	O
the	O
CAAX	O
site	O
on	O
V14Rho	B
severely	O
diminished	O
this	O
association	O
.	O
Evidence	O
for	O
a	O
role	O
for	O
PKCalpha	B
as	O
an	O
effector	O
of	O
Rho	B
was	O
obtained	O
by	O
the	O
observation	O
that	O
coexpression	O
of	O
the	O
N	B
-	I
terminal	I
domain	I
of	O
PKCalpha	B
blocked	O
the	O
effects	O
of	O
activated	O
Rho	B
plus	O
PMA	O
on	O
AP-1	B
transcriptional	O
activity	O
.	O
These	O
data	O
suggest	O
that	O
Rho	B
potentiates	O
AP-1	B
transcription	O
during	O
T	O
-	O
cell	O
activation	O
Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
Tax	B
induction	O
of	O
NF	B
-	I
kappaB	I
involves	O
activation	O
of	O
the	O
IkappaB	B
kinase	I
alpha	I
(	O
IKKalpha	B
)	O
and	O
IKKbeta	B
cellular	B
kinases	I
.	O
Tax	B
corresponds	O
to	O
a	O
40-kDa	B
transforming	I
protein	I
from	O
the	O
pathogenic	O
retrovirus	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
that	O
activates	O
nuclear	O
expression	O
of	O
the	O
NF	B
-	I
kappaB	I
/	I
Rel	I
family	I
of	O
transcription	B
factors	I
by	O
an	O
unknown	O
mechanism	O
.	O
Tax	B
expression	O
promotes	O
N	O
-	O
terminal	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaB	B
alpha	I
,	O
a	O
principal	O
cytoplasmic	O
inhibitor	O
of	O
NF	B
-	I
kappaB	I
.	O
Our	O
studies	O
now	O
demonstrate	O
that	O
HTLV-1	O
Tax	B
activates	O
the	O
recently	O
identified	O
cellular	B
kinases	I
IkappaB	B
kinase	I
alpha	I
(	O
IKKalpha	B
)	O
and	O
IKKbeta	B
,	O
which	O
normally	O
phosphorylate	O
IkappaB	B
alpha	I
on	O
both	O
of	O
its	O
N	O
-	O
terminal	O
regulatory	O
serines	O
in	O
response	O
to	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
and	O
interleukin-1	B
(	O
IL-1	B
)	O
stimulation	O
.	O
In	O
contrast	O
,	O
a	O
mutant	O
of	O
Tax	B
termed	O
M22	B
,	O
which	O
does	O
not	O
induce	O
NF	B
-	I
kappaB	I
,	O
fails	O
to	O
activate	O
either	O
IKKalpha	B
or	O
IKKbeta	B
.	O
Furthermore	O
,	O
endogenous	O
IKK	O
enzymatic	O
activity	O
was	O
significantly	O
elevated	O
in	O
HTLV-1-infected	O
and	O
Tax	O
-	O
expressing	O
T	O
-	O
cell	O
lines	O
.	O
Transfection	O
of	O
kinase	O
-	O
deficient	O
mutants	O
of	O
IKKalpha	B
and	O
IKKbeta	B
into	O
either	O
human	O
Jurkat	O
T	O
or	O
293	O
cells	O
also	O
inhibits	O
NF	B
-	I
kappaB	I
-dependent	O
reporter	O
gene	O
expression	O
induced	O
by	O
Tax	B
.	O
Similarly	O
,	O
a	O
kinase	B
-	I
deficient	I
mutant	I
of	O
NIK	B
(	O
NF	B
-	I
kappaB	I
-	I
inducing	I
kinase	I
)	O
,	O
which	O
represents	O
an	O
upstream	O
kinase	O
in	O
the	O
TNF	O
-	O
alpha	O
and	O
IL-1	O
signaling	O
pathways	O
leading	O
to	O
IKKalpha	B
and	O
IKKbeta	B
activation	O
,	O
blocks	O
Tax	B
induction	O
of	O
NF	B
-	I
kappaB	I
.	O
However	O
,	O
plasma	O
membrane	O
-	O
proximal	O
elements	O
in	O
these	O
proinflammatory	B
cytokine	I
pathways	O
are	O
apparently	O
not	O
involved	O
since	O
dominant	O
negative	O
mutants	O
of	O
the	O
TRAF2	B
and	I
TRAF6	I
adaptors	I
,	O
which	O
effectively	O
block	O
signaling	O
through	O
the	O
cytoplasmic	B
tails	I
of	O
the	O
TNF	B
-	I
alpha	I
and	O
IL-1	B
receptors	O
,	O
respectively	O
,	O
do	O
not	O
inhibit	O
Tax	B
induction	O
of	O
NF	B
-	I
kappaB	I
.	O
Together	O
,	O
these	O
studies	O
demonstrate	O
that	O
HTLV-1	O
Tax	B
exploits	O
a	O
distal	O
part	O
of	O
the	O
proinflammatory	B
cytokine	I
signaling	O
cascade	O
leading	O
to	O
induction	O
of	O
NF	B
-	I
kappaB	I
.	O
The	O
pathological	O
alteration	O
of	O
this	O
cytokine	O
pathway	O
leading	O
to	O
NF	B
-	I
kappaB	I
activation	O
by	O
Tax	B
may	O
play	O
a	O
central	O
role	O
in	O
HTLV-1-mediated	O
transformation	O
of	O
human	O
T	O
cells	O
,	O
clinically	O
manifested	O
as	O
the	O
adult	O
T	O
-	O
cell	O
leukemia	O
Inhibition	O
of	O
HIV-1	O
replication	O
by	O
combination	O
of	O
a	O
novel	O
inhibitor	O
of	O
TNF	B
-	I
alpha	I
with	O
AZT	O
.	O
The	O
small	O
molecule	O
S9a	O
was	O
derived	O
from	O
an	O
established	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
inhibitor	O
(	O
Canventol	O
)	O
by	O
replacement	O
of	O
the	O
isopropylidine	O
group	O
with	O
a	O
phenyl	O
ring	O
.	O
S9a	O
at	O
10	O
to	O
100	O
nM	O
inhibited	O
HIV	O
production	O
as	O
potently	O
as	O
3'-azido-3'-deoxythymidine	O
(	O
AZT	O
)	O
,	O
an	O
inhibitor	O
of	O
viral	B
reverse	I
transcriptase	I
.	O
Furthermore	O
,	O
S9a	O
and	O
AZT	O
in	O
combination	O
,	O
at	O
noncytoxic	O
concentrations	O
strongly	O
inhibited	O
HIV-1	O
replication	O
that	O
was	O
more	O
than	O
additive	O
and	O
substantially	O
prolonged	O
the	O
appearance	O
of	O
virus	O
both	O
in	O
acutely	O
infected	O
CD4	O
+	O
lymphocytes	O
(	O
SupT	O
)	O
in	O
culture	O
and	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
infected	O
with	O
a	O
primary	O
HIV-1	O
isolate	O
.	O
S9a	O
inhibited	O
TNF	B
-	I
alpha	I
promoter	O
-	O
driven	O
reporter	O
gene	O
activity	O
.	O
It	O
was	O
proposed	O
that	O
the	O
mechanism	O
of	O
antiviral	O
action	O
of	O
S9a	O
was	O
on	O
the	O
host	O
cell	O
,	O
by	O
blocking	O
TNF	B
-	I
alpha	I
transcription	O
via	O
a	O
Tat	B
-induced	O
tar	O
-	O
independent	O
loop	O
,	O
which	O
decreases	O
downstream	O
NF	B
-	I
kappaB	I
activation	O
of	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O
S9a	O
was	O
superior	O
to	O
the	O
first	O
generation	O
compound	O
Canventol	O
,	O
which	O
was	O
superior	O
to	O
the	O
natural	O
compound	O
sarcophytol	O
A	O
,	O
demonstrating	O
that	O
further	O
structure	O
-	O
based	O
enhancement	O
of	O
potency	O
of	O
these	O
compounds	O
is	O
feasible	O
.	O
This	O
study	O
suggests	O
a	O
therapeutic	O
approach	O
against	O
AIDS	O
by	O
application	O
of	O
two	O
drugs	O
,	O
one	O
against	O
a	O
cellular	O
and	O
the	O
other	O
a	O
viral	O
target	O
,	O
which	O
may	O
provide	O
an	O
approach	O
to	O
the	O
problem	O
of	O
frequent	O
emergence	O
of	O
resistant	O
variants	O
to	O
combinations	O
of	O
drugs	O
that	O
target	O
only	O
HIV	O
genes	O
.	O
Specific	O
glucocorticoid	O
binding	O
at	O
different	O
levels	O
of	O
human	O
motor	O
activity	O
.	O
We	O
studied	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
and	O
dissociation	O
constant	O
in	O
isolated	O
human	O
lymphocytes	O
as	O
well	O
as	O
blood	O
concentrations	O
of	O
hormones	O
produced	O
by	O
the	O
hypothalamic	O
-	O
hypophyseal	O
-	O
adrenocortical	O
system	O
in	O
three	O
experimental	O
series	O
:	O
at	O
normal	O
(	O
17	O
subjects	O
)	O
,	O
decreased	O
(	O
10	O
subjects	O
,	O
a	O
360-d	O
head	O
-	O
down	O
bed	O
rest	O
)	O
and	O
increased	O
(	O
8	O
subjects	O
,	O
physical	O
exercise	O
on	O
bicycle	O
ergometer	O
)	O
levels	O
of	O
motor	O
activity	O
.	O
In	O
the	O
first	O
series	O
we	O
found	O
that	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
and	O
dissociation	O
constant	O
did	O
not	O
depend	O
on	O
the	O
season	O
,	O
on	O
the	O
age	O
of	O
subjects	O
nor	O
on	O
cortisol	O
concentrations	O
in	O
blood	O
.	O
In	O
the	O
second	O
series	O
we	O
observed	O
the	O
following	O
:	O
at	O
the	O
end	O
of	O
the	O
first	O
month	O
of	O
bed	O
rest	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
and	O
receptor	O
affinity	O
significantly	O
increased	O
;	O
at	O
the	O
beginning	O
of	O
the	O
third	O
month	O
of	O
bed	O
rest	O
specific	O
glucocorticoid	O
binding	O
significantly	O
decreased	O
and	O
circadian	O
rhythms	O
of	O
adrenocorticotropin	O
and	O
cortisol	O
in	O
blood	O
varied	O
markedly	O
;	O
at	O
the	O
end	O
of	O
the	O
sixth	O
month	O
of	O
bed	O
rest	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
returned	O
to	O
prebed	O
rest	O
levels	O
and	O
dissociation	O
constant	O
decreased	O
.	O
In	O
the	O
third	O
series	O
physical	O
exercises	O
that	O
induced	O
an	O
activation	O
of	O
the	O
hypothalamic	O
-	O
hypophyseal	O
-	O
adrenocortical	O
system	O
(	O
maximal	O
physical	O
exercises	O
and	O
prolonged	O
submaximal	O
exercises	O
at	O
70	O
%	O
of	O
maximal	O
oxygen	O
uptake	O
)	O
led	O
to	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
glucocorticoid	B
receptors	I
without	O
changes	O
of	O
dissociation	O
constant	O
.	O
These	O
results	O
indicate	O
that	O
both	O
a	O
decrease	O
and	O
an	O
increase	O
of	O
human	O
motor	O
activity	O
resulted	O
in	O
significant	O
changes	O
of	O
specific	O
glucocorticoid	O
binding	O
which	O
were	O
not	O
influenced	O
by	O
changes	O
of	O
circulating	O
hormone	O
concentrations	O
in	O
blood	O
but	O
by	O
some	O
other	O
factors	O
affected	O
by	O
physical	O
activity	O
.	O
The	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
alpha	I
(	O
PPARalpha	B
)	O
ligand	O
WY	O
14	O
,	O
643	O
does	O
not	O
interfere	O
with	O
leukotriene	O
B4	O
induced	O
adhesion	O
of	O
neutrophils	O
to	O
endothelial	O
cells	O
.	O
Peroxisome	B
proliferator	I
-	I
activated	I
receptors	I
(	O
PPAR	B
)	O
control	O
discrete	O
genes	O
involved	O
in	O
fatty	O
acid	O
and	O
lipid	O
metabolism	O
.	O
Recently	O
,	O
it	O
was	O
suggested	O
that	O
activation	O
of	O
the	O
alpha	B
isoform	I
of	O
PPAR	B
by	O
the	O
potent	O
proinflammatory	O
mediator	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
enhanced	O
degradation	O
of	O
this	O
eicosanoid	O
,	O
offersuggesting	O
a	O
new	O
aspect	O
of	O
down	O
-	O
regulation	O
of	O
inflammation	O
.	O
Here	O
,	O
we	O
studied	O
whether	O
PPARalpha	B
activation	O
(	O
by	O
means	O
of	O
the	O
selective	O
agonist	O
WY	O
14	O
,	O
643	O
)	O
of	O
endothelial	O
cells	O
,	O
pivotal	O
in	O
the	O
regulation	O
of	O
inflammatory	O
responses	O
,	O
interfered	O
with	O
LTB4	O
induced	O
adhesion	O
of	O
PMN	O
neutrophil	O
granulocytes	O
in	O
vitro	O
.	O
When	O
endothelial	O
cells	O
were	O
treated	O
with	O
WY	O
14	O
,	O
643	O
prior	O
to	O
activation	O
with	O
LTB4	O
(	O
or	O
fMLP	B
,	O
IL-1beta	B
or	O
TNFalpha	B
,	O
as	O
controls	O
)	O
we	O
could	O
not	O
document	O
any	O
effect	O
on	O
the	O
number	O
of	O
adhering	O
PMN	O
or	O
duration	O
of	O
the	O
response	O
.	O
Thus	O
,	O
this	O
study	O
provides	O
no	O
evidence	O
indicating	O
a	O
regulatory	O
function	O
of	O
PPARalpha	B
in	O
LTB4	O
induced	O
adhesive	O
interactions	O
between	O
endothelial	O
cells	O
and	O
neutrophils	O
Stimulation	O
of	O
B	O
and	O
T	O
cells	O
activates	O
expression	O
of	O
transcription	B
and	I
differentiation	I
factors	I
.	O
During	O
B	O
and	O
T	O
cell	O
differentiation	O
and	O
proliferation	O
many	O
genes	O
are	O
induced	O
or	O
repressed	O
while	O
certain	O
genes	O
are	O
constitutively	O
expressed	O
.	O
To	O
investigate	O
processes	O
related	O
to	O
B	O
and	O
T	O
cell	O
activation	O
,	O
the	O
gene	O
expression	O
of	O
stimulated	O
and	O
nonstimulated	O
Ramos	O
and	O
Jurkat	O
cells	O
was	O
studied	O
using	O
cDNA	O
microarray	O
technology	O
.	O
Simultaneous	O
analysis	O
of	O
close	O
to	O
600	O
genes	O
indicated	O
highest	O
increase	O
in	O
the	O
expression	O
of	O
certain	O
transcription	B
,	I
differentiation	I
and	I
proliferation	I
factors	I
.	O
Many	O
of	O
these	O
genes	O
have	O
not	O
previously	O
been	O
shown	O
to	O
funcion	O
in	O
the	O
stimulated	O
lymphocytes	O
.	O
Also	O
genes	O
encoding	O
proteins	O
involved	O
in	O
DNA	O
replication	O
,	O
binding	O
,	O
transcription	O
and	O
translation	O
were	O
induced	O
.	O
Large	O
part	O
of	O
the	O
activated	O
genes	O
were	O
under	O
very	O
stringent	O
regulation	O
being	O
expressed	O
only	O
after	O
stimulation	O
.	O
The	O
mechanism	O
and	O
function	O
of	O
the	O
expressed	O
genes	O
during	O
lymphocyte	O
differentiation	O
and	O
in	O
disorders	O
is	O
discussed	O
.	O
The	O
transcription	B
factors	I
c	B
-	I
myb	I
and	O
C	B
/	I
EBP	I
alpha	I
regulate	O
the	O
monocytic	O
/	O
myeloic	O
gene	O
MRP14	O
.	O
The	O
entry	O
of	O
microorganisms	O
into	O
the	O
body	O
induces	O
inflammatory	O
processes	O
.	O
During	O
this	O
process	O
a	O
sequence	O
of	O
cellular	O
,	O
humoral	O
,	O
non	O
-	O
specific	O
and	O
specific	O
actions	O
are	O
evoked	O
to	O
combat	O
the	O
infection	O
.	O
Macrophages	O
and	O
granulocytes	O
,	O
which	O
are	O
developed	O
from	O
a	O
common	O
progenitor	O
cell	O
,	O
are	O
the	O
cellular	O
components	O
of	O
the	O
specific	O
and	O
non	O
-	O
specific	O
immunoreaction	O
.	O
MRP14	O
(	O
Macrophage	B
migration	I
inhibitory	I
related	I
protein	I
)	O
and	O
MRP8	B
,	O
two	O
S-100	B
proteins	I
contained	O
in	O
high	O
concentrations	O
in	O
these	O
cells	O
are	O
obviously	O
essential	O
for	O
adhesion	O
and	O
migration	O
of	O
monocytes	O
and	O
granulocytes	O
.	O
To	O
investigate	O
the	O
transcriptional	O
regulation	O
of	O
these	O
genes	O
we	O
cotransfected	O
constructs	O
expressing	O
CAT	B
under	O
control	O
of	O
the	O
MRP14	O
promoter	O
and	O
expression	O
constructs	O
of	O
C	B
/	I
EBP	I
alpha	I
and	O
v	B
-	I
myb	I
,	O
two	O
transcription	B
factors	I
involved	O
in	O
myeloid	O
/	O
monocytic	O
differentiation	O
.	O
Transfection	O
with	O
C	B
/	I
EBP	I
alpha	I
revealed	O
a	O
massive	O
enhancement	O
of	O
the	O
MRP14	O
promoter	O
in	O
both	O
,	O
HL	O
60	O
cells	O
(	O
granulocytic	O
differentiated	O
)	O
and	O
L132	O
fibroblasts	O
.	O
In	O
contrast	O
,	O
v	B
-	I
myb	I
reduces	O
MRP14	O
promoter	O
activity	O
.	O
Northern	O
blot	O
analysis	O
of	O
L132	O
cells	O
transfected	O
with	O
the	O
C	B
/	I
EBP	I
alpha	I
expression	O
vector	O
demonstrate	O
that	O
C	B
/	I
EBP	I
alpha	I
is	O
sufficient	O
to	O
enhance	O
MRP14	B
expression	O
in	O
the	O
context	O
of	O
the	O
whole	O
genome	O
.	O
Nuclear	B
factor	I
-	I
kappaB	I
induction	O
in	O
CD45RO+	O
and	O
CD45RA+	O
T	O
cell	O
subsets	O
during	O
aging	O
.	O
An	O
increase	O
in	O
the	O
ratio	O
of	O
memory	O
to	O
naive	O
T	O
cells	O
has	O
been	O
postulated	O
to	O
underlie	O
immune	O
hyporesponsiveness	O
accompanying	O
aging	O
.	O
Our	O
analyses	O
of	O
the	O
induction	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
(	O
NFkappaB	B
)	O
in	O
activated	O
memory	O
(	O
CD45RO+	O
)	O
and	O
naive	O
(	O
CD45RA+	O
)	O
T	O
cell	O
subsets	O
from	O
young	O
and	O
elderly	O
donors	O
has	O
demonstrated	O
that	O
,	O
regardless	O
of	O
donor	O
age	O
,	O
memory	O
T	O
cells	O
are	O
not	O
significantly	O
altered	O
in	O
their	O
responsiveness	O
to	O
TNF	B
-	I
alpha	I
-mediated	O
induction	O
of	O
NFkappaB	B
.	O
Although	O
treatment	O
with	O
TNF	B
-	I
alpha	I
induced	O
nuclear	O
localization	O
of	O
NFkappaB	B
in	O
both	O
memory	O
and	O
naive	O
T	O
cell	O
subsets	O
,	O
irrespective	O
of	O
the	O
age	O
of	O
the	O
donor	O
,	O
the	O
levels	O
of	O
induced	O
NFkappaB	B
were	O
significantly	O
lower	O
in	O
both	O
subsets	O
of	O
T	O
cells	O
obtained	O
from	O
the	O
elderly	O
,	O
when	O
compared	O
to	O
those	O
in	O
young	O
.	O
Examination	O
of	O
IkappaB	B
alpha	I
regulation	O
revealed	O
that	O
TNF	B
-	I
alpha	I
-mediated	O
degradation	O
of	O
IkappaB	B
alpha	I
in	O
both	O
memory	O
and	O
naive	O
T	O
cells	O
from	O
the	O
elderly	O
was	O
severely	O
impaired	O
,	O
thus	O
contributing	O
to	O
the	O
lowered	O
induction	O
of	O
the	O
observed	O
NFkappaB	B
.	O
In	O
addition	O
,	O
this	O
age	O
-	O
related	O
decrease	O
in	O
induction	O
of	O
nuclear	B
NFkappaB	I
correlated	O
with	O
decrease	O
in	O
intracellular	O
IL-2	B
receptor	O
expression	O
and	O
anti	B
-	I
CD3	I
-induced	O
proliferation	O
of	O
both	O
memory	O
and	O
naive	O
T	O
cells	O
subsets	O
.	O
Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
the	O
age	O
-	O
related	O
hyporesponsiveness	O
can	O
not	O
be	O
attributed	O
to	O
a	O
skewing	O
of	O
the	O
T	O
cell	O
population	O
towards	O
a	O
memory	O
phenotype	O
in	O
the	O
elderly	O
.	O
Glucocorticoid	O
-	O
induced	O
apoptosis	O
and	O
regulation	O
of	O
NF	B
-	I
kappaB	I
activity	O
in	O
human	O
leukemic	O
T	O
cells	O
.	O
Glucocorticoid	O
-	O
induced	O
apoptosis	O
was	O
investigated	O
in	O
glucocorticoid	O
-	O
sensitive	O
6TG1.1	O
and	O
resistant	O
ICR27TK.3	O
human	O
leukemic	O
T	O
cells	O
.	O
Following	O
glucocorticoid	O
treatment	O
of	O
6TG1.1	O
cells	O
,	O
chromatin	O
fragmentation	O
was	O
observed	O
after	O
a	O
delay	O
of	O
24	O
h	O
.	O
Fragmentation	O
was	O
not	O
observed	O
in	O
ICR27TK.3	O
cells	O
containing	O
mutant	B
glucocorticoid	I
receptors	I
(	O
L753F	O
)	O
that	O
are	O
activation	O
-	O
deficient	O
but	O
retain	O
the	O
ability	O
to	O
repress	O
AP-1	B
activity	O
.	O
Nor	O
was	O
fragmentation	O
observed	O
after	O
treatment	O
with	O
RU38486	O
,	O
indicating	O
that	O
repression	O
of	O
AP-1	B
activity	O
is	O
not	O
involved	O
.	O
As	O
described	O
in	O
other	O
systems	O
,	O
fragmentation	O
required	O
ongoing	O
protein	O
synthesis	O
.	O
However	O
,	O
inhibition	O
of	O
protein	O
synthesis	O
with	O
cycloheximide	O
anytime	O
during	O
the	O
first	O
18	O
h	O
of	O
steroid	O
treatment	O
was	O
as	O
effective	O
in	O
blocking	O
chromatin	O
fragmentation	O
as	O
inhibition	O
for	O
the	O
entire	O
period	O
,	O
suggesting	O
that	O
synthesis	O
of	O
a	O
component	O
with	O
a	O
rapid	O
turnover	O
rate	O
is	O
required	O
.	O
Dexamethasone	O
treatment	O
completely	O
blocked	O
12-O	O
-	O
tetradecanoylphorbol	O
13-acetate	O
induction	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
activity	O
and	O
elicited	O
an	O
increase	O
in	O
the	O
amount	O
of	O
immunoreactive	B
IkappaB	I
alpha	I
in	O
sensitive	O
6TG1.1	O
cells	O
but	O
not	O
in	O
resistant	O
ICR27TK.3	O
cells	O
.	O
In	O
addition	O
,	O
mild	O
detergent	O
treatment	O
of	O
cell	O
extracts	O
indicated	O
that	O
a	O
substantial	O
amount	O
of	O
cytoplasmic	B
NF	I
-	I
kappaB	I
is	O
complexed	O
with	O
IkappaB	B
alpha	I
or	O
some	O
other	O
inhibitory	O
factor	O
.	O
These	O
results	O
suggest	O
that	O
induction	O
of	O
a	O
labile	B
inhibitory	I
factor	I
such	O
as	O
IkappaB	B
alpha	I
may	O
contribute	O
to	O
glucocorticoid	O
-	O
induced	O
apoptosis	O
.	O
Protein	B
kinase	I
C	I
regulates	O
Fas	B
(	O
CD95	B
/	I
APO-1	I
)	O
expression	O
.	O
Fas	B
(	O
CD95	B
/	I
APO-1	I
)	O
is	O
a	O
transmembrane	B
protein	I
of	O
the	O
TNF	B
/	I
neuron	I
growth	I
factor	I
receptor	I
family	I
.	O
Ligation	O
of	O
Fas	B
by	O
specific	B
Abs	I
or	O
Fas	B
ligand	I
(	O
FasL	B
/	I
CD95	I
ligand	I
)	O
induces	O
rapid	O
apoptotic	O
cell	O
death	O
in	O
a	O
variety	O
of	O
cell	O
types	O
.	O
Despite	O
progress	O
in	O
understanding	O
the	O
death	O
signals	O
transduced	O
from	O
Fas	B
,	O
very	O
little	O
is	O
known	O
with	O
regard	O
to	O
the	O
mechanisms	O
by	O
which	O
Fas	B
expression	O
is	O
regulated	O
.	O
Using	O
our	O
previously	O
established	O
murine	O
T	O
cell	O
hybridoma	O
model	O
A1.1	O
,	O
we	O
show	O
that	O
specific	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
inhibitors	O
could	O
block	O
activation	O
-	O
induced	O
Fas	B
expression	O
and	O
apoptosis	O
.	O
The	O
activation	O
of	O
PKC	B
with	O
PMA	O
or	O
1-oleoyl-2-acetyl	O
-	O
sn	O
-	O
glycerol	O
could	O
mimic	O
the	O
TCR	B
signal	O
by	O
inducing	O
the	O
expression	O
of	O
Fas	B
but	O
not	O
FasL	O
.	O
PKC	B
-dependent	O
Fas	B
expression	O
was	O
also	O
observed	O
in	O
several	O
murine	O
and	O
human	O
tumor	O
cell	O
lines	O
.	O
Since	O
the	O
inhibition	O
of	O
Ca2	O
+	O
redistribution	O
by	O
an	O
inhibitor	O
of	O
intracellular	O
Ca2	O
+	O
mobilization	O
,	O
8-	O
(	O
diethylamino	O
)	O
-octyl-3	O
,	O
4	O
,	O
5-trimethoxybenzoate	O
hydrochloride	O
,	O
inhibited	O
TCR	B
-	I
induced	I
FasL	I
but	O
not	O
Fas	B
,	O
the	O
expression	O
of	O
Fas	B
appears	O
to	O
be	O
independent	O
of	O
Ca2	O
+	O
mobilization	O
.	O
Significantly	O
,	O
expression	O
of	O
the	O
newly	O
identified	O
Fas	O
-	O
regulatory	O
gene	O
,	O
TDAG51	O
,	O
was	O
found	O
to	O
be	O
dependent	O
upon	O
the	O
activity	O
of	O
PKC	B
.	O
PKC	B
activation	O
only	O
induced	O
Fas	B
expression	O
in	O
cells	O
expressing	O
wild	O
-	O
type	O
TDAG51	O
.	O
Thus	O
,	O
Fas	B
expression	O
is	O
likely	O
mediated	O
by	O
PKC	B
through	O
TDAG51	O
.	O
Transcription	O
of	O
a	O
minimal	O
promoter	O
from	O
the	O
NF	O
-	O
IL6	O
gene	O
is	O
regulated	O
by	O
CREB	B
/	I
ATF	I
and	O
SP1	B
proteins	I
in	O
U937	O
promonocytic	O
cells	O
.	O
NF	B
-	I
IL6	I
is	O
an	O
important	O
transcriptional	O
regulator	O
of	O
genes	O
induced	O
in	O
activated	O
monocytes	O
/	O
macrophages	O
,	O
and	O
NF	B
-	I
IL6	I
is	O
the	O
only	O
CCAAT	B
/	I
enhancer	I
-	I
binding	I
protein	I
(	I
C	I
/	I
EBP	I
)	I
family	I
member	O
whose	O
steady	O
-	O
state	O
mRNA	O
levels	O
increase	O
upon	O
activation	O
of	O
monocytes	O
(	O
1	O
)	O
.	O
We	O
show	O
that	O
increased	O
transcription	O
of	O
the	O
NF	O
-	O
IL6	O
gene	O
is	O
responsible	O
,	O
at	O
least	O
in	O
part	O
,	O
for	O
induction	O
of	O
NF	O
-	O
IL6	O
mRNA	O
following	O
activation	O
of	O
U937	O
promonocytic	O
cells	O
.	O
We	O
have	O
identified	O
a	O
104-bp	O
minimal	O
promoter	O
region	O
of	O
the	O
NF	O
-	O
IL6	O
gene	O
that	O
is	O
sufficient	O
for	O
basal	O
and	O
activation	O
-	O
dependent	O
induction	O
of	O
transcription	O
in	O
U937	O
cells	O
.	O
This	O
region	O
contains	O
binding	O
sites	O
for	O
the	O
cAMP	B
response	I
element	I
-	I
binding	I
protein	I
/	I
activation	I
transcription	I
factor	I
(	O
CREB	B
/	I
ATF	I
)	O
and	O
Sp1	B
families	O
of	O
transcription	B
factors	I
.	O
Each	O
site	O
is	O
functionally	O
important	O
and	O
contributes	O
independently	O
to	O
transcription	O
of	O
the	O
NF	O
-	O
IL6	O
gene	O
in	O
U937	O
cells	O
.	O
The	O
MHC	B
class	I
II	I
transactivator	I
(	O
CIITA	B
)	O
requires	O
conserved	O
leucine	B
charged	I
domains	I
for	O
interactions	O
with	O
the	O
conserved	O
W	O
box	O
promoter	O
element	O
.	O
The	O
class	B
II	I
transactivator	I
CIITA	B
is	O
required	O
for	O
transcriptional	O
activation	O
of	O
the	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
genes	O
.	O
Aside	O
from	O
an	O
N	O
-	O
terminal	O
acidic	O
transcriptional	O
activation	O
domain	O
,	O
little	O
is	O
known	O
about	O
how	O
this	O
factor	O
functions	O
.	O
Extensive	O
mutagenesis	O
of	O
CIITA	B
was	O
undertaken	O
to	O
identify	O
structural	O
motifs	O
required	O
for	O
function	O
.	O
The	O
ability	O
of	O
mutants	O
to	O
activate	O
a	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
MHC	B
class	I
II	I
conserved	O
W	O
-	O
X	O
-	O
Y	O
or	O
X	O
-	O
Y	O
regulatory	O
elements	O
was	O
determined	O
.	O
Two	O
mutants	O
displayed	O
differential	O
activity	O
between	O
the	O
two	O
promoters	O
,	O
activating	O
transcription	O
with	O
the	O
W	O
-	O
X	O
-	O
Y	O
but	O
not	O
the	O
X	O
-	O
Y	O
elements	O
.	O
All	O
mutants	O
were	O
tested	O
for	O
their	O
ability	O
to	O
interfere	O
with	O
wild	O
-	O
type	O
CIITA	B
activity	O
.	O
Five	O
CIITA	O
mutant	O
constructions	O
were	O
able	O
to	O
down	O
-	O
regulate	O
wild	O
-	O
type	O
CIITA	B
activity	O
.	O
Three	O
of	O
these	O
mutants	O
contained	O
targeted	O
disruptions	O
of	O
potential	O
functional	O
motifs	O
:	O
the	O
acidic	B
activation	I
domain	I
,	O
a	O
putative	O
GTP	B
-	I
binding	I
motif	I
and	O
two	O
leucine	B
charged	I
domains	I
(	O
LCD	B
motifs	I
)	O
.	O
The	O
other	O
two	O
contained	O
mutations	O
in	O
regions	O
that	O
do	O
not	O
have	O
homology	O
to	O
described	O
proteins	O
.	O
The	O
characterization	O
of	O
CIITA	B
mutants	I
that	O
are	O
able	O
to	O
discriminate	O
between	O
promoters	O
with	O
or	O
without	O
the	O
W	O
box	O
strongly	O
suggests	O
that	O
CIITA	B
requires	O
such	O
interactions	O
for	O
function	O
.	O
The	O
identification	O
of	O
LCD	B
motifs	I
required	O
for	O
CIITA	B
function	O
brings	O
to	O
light	O
a	O
previously	O
undefined	O
role	O
of	O
these	O
motifs	O
in	O
CIITA	B
function	O
.	O
Two	O
-	O
site	O
interaction	O
of	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
with	O
activated	O
calcineurin	B
.	O
Transcription	B
factors	I
belonging	O
to	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	I
NFAT	I
)	I
family	I
regulate	O
the	O
expression	O
of	O
cytokine	O
genes	O
and	O
other	O
inducible	O
genes	O
during	O
the	O
immune	O
response	O
.	O
The	O
functions	O
of	O
NFAT	B
proteins	I
are	O
directly	O
controlled	O
by	O
the	O
calcium-	B
and	I
calmodulin-	I
dependent	I
phosphatase	I
calcineurin	B
.	O
Here	O
we	O
show	O
that	O
the	O
binding	O
of	O
calcineurin	B
to	O
NFAT	B
is	O
substantially	O
increased	O
when	O
calcineurin	B
is	O
activated	O
with	O
calmodulin	B
and	O
calcium	O
.	O
FK506.FKBP12	O
drug	O
-	O
immunophilin	O
complexes	O
inhibited	O
the	O
interaction	O
of	O
NFAT	B
with	O
activated	O
calcineurin	B
much	O
more	O
effectively	O
than	O
they	O
inhibited	O
the	O
interaction	O
with	O
inactive	O
calcineurin	B
,	O
suggesting	O
that	O
part	O
of	O
the	O
interaction	O
with	O
activated	O
calcineurin	B
involved	O
the	O
enzyme	O
active	O
site	O
.	O
We	O
have	O
previously	O
shown	O
that	O
NFAT	B
is	O
targeted	O
to	O
inactive	O
calcineurin	B
at	O
a	O
region	O
distinct	O
from	O
the	O
calcineurin	O
active	O
site	O
(	O
Aramburu	O
,	O
J.	O
,	O
Garcia	O
-	O
Cozar	O
,	O
F.	O
J.	O
,	O
Raghavan	O
,	O
A.	O
,	O
Okamura	O
,	O
H.	O
,	O
Rao	O
,	O
A.	O
,	O
and	O
Hogan	O
,	O
P.	O
G.	O
(	O
1998	O
)	O
Mol	O
.	O
Cell	O
1	O
,	O
627	O
-	O
637	O
)	O
;	O
this	O
region	O
is	O
also	O
involved	O
in	O
NFAT	B
binding	O
to	O
activated	O
calcineurin	B
,	O
since	O
binding	O
is	O
inhibited	O
by	O
an	O
NFAT	O
peptide	O
spanning	O
the	O
calcineurin	B
docking	O
site	O
on	O
NFAT	B
.	O
The	O
interacting	O
surfaces	O
are	O
located	O
on	O
the	O
catalytic	B
domain	I
of	O
the	O
calcineurin	B
A	I
chain	I
and	O
on	O
an	O
86-amino	B
acid	I
fragment	I
of	O
the	O
NFAT	B
regulatory	I
domain	I
.	O
NFAT	B
binding	O
to	O
the	O
calcineurin	B
catalytic	I
domain	I
was	O
inhibited	O
by	O
the	O
calcineurin	B
autoinhibitory	I
domain	I
and	O
the	O
RII	O
substrate	O
peptide	O
,	O
which	O
bind	O
in	O
the	O
calcineurin	B
active	I
site	I
,	O
as	O
well	O
as	O
by	O
the	O
NFAT	B
docking	O
site	O
peptide	O
,	O
which	O
binds	O
to	O
a	O
region	O
of	O
calcineurin	B
distinct	O
from	O
the	O
active	B
site	I
.	O
We	O
propose	O
that	O
,	O
in	O
resting	O
cells	O
,	O
NFAT	B
is	O
targeted	O
to	O
a	O
region	O
of	O
the	O
calcineurin	B
catalytic	I
domain	I
that	O
does	O
not	O
overlap	O
the	O
calcineurin	B
active	I
site	I
.	O
Upon	O
cell	O
activation	O
,	O
displacement	O
of	O
the	O
autoinhibitory	B
domain	I
by	O
calmodulin	B
binding	O
allows	O
NFAT	B
to	O
bind	O
additionally	O
to	O
the	O
calcineurin	B
active	I
site	I
,	O
thus	O
positioning	O
NFAT	B
for	O
immediate	O
dephosphorylation	O
at	O
functional	O
phosphoserine	O
residues	O
.	O
CD30	B
is	O
a	O
CD40-inducible	B
molecule	I
that	O
negatively	O
regulates	O
CD40-mediated	B
immunoglobulin	I
class	O
switching	O
in	O
non	O
-	O
antigen	O
-	O
selected	O
human	O
B	O
cells	O
.	O
We	O
used	O
our	O
monoclonal	O
model	O
of	O
germinal	O
center	O
maturation	O
,	O
CL-01	O
B	O
cells	O
,	O
to	O
investigate	O
the	O
role	O
of	O
CD30	B
in	O
human	O
B	O
cell	O
differentiation	O
.	O
CL-01	O
cells	O
are	O
IgM	B
+	O
IgD	B
+	O
CD30	B
+	O
and	O
switch	O
to	O
IgG	B
,	O
IgA	B
,	O
and	O
IgE	B
when	O
exposed	O
to	O
CD40L	B
and	O
IL-4	B
.	O
Switching	O
is	O
hampered	O
by	O
CD30	B
coengagement	O
,	O
possibly	O
through	O
interference	O
with	O
the	O
CD40	B
-mediated	O
NF	B
-	I
kappaB	I
-dependent	O
transcriptional	O
activation	O
of	O
downstream	O
C	O
(	O
H	O
)	O
genes	O
.	O
The	O
physiological	O
relevance	O
of	O
this	O
phenomenon	O
is	O
emphasized	O
by	O
similar	O
CD30	B
-mediated	O
effects	O
in	O
naive	O
B	O
cells	O
.	O
Expression	O
of	O
CD30	B
by	O
these	O
cells	O
is	O
induced	O
by	O
CD40L	B
but	O
is	O
inhibited	O
by	O
B	O
cell	O
receptor	O
coengagement	O
and/or	O
exposure	O
to	O
IL-6	B
and	O
IL-12	B
.	O
Our	O
data	O
suggest	O
that	O
CD30	B
critically	O
regulates	O
the	O
CD40	B
-mediated	O
differentiation	O
of	O
non	O
-	O
antigen	O
-	O
selected	O
human	O
B	O
cells	O
.	O
Retinoid	B
X	I
receptor	I
and	O
c	B
-	I
cerbA	I
/	I
thyroid	I
hormone	I
receptor	I
regulate	O
erythroid	O
cell	O
growth	O
and	O
differentiation	O
.	O
Nuclear	B
receptors	I
are	O
important	O
regulators	O
of	O
erythroid	O
cell	O
development	O
.	O
Here	O
we	O
investigated	O
the	O
impact	O
of	O
retinoid	B
X	I
receptor	I
(	O
RXR	B
)	O
,	O
retinoic	B
acid	I
receptor	I
(	O
RAR	B
)	O
,	O
and	O
of	O
the	O
c	B
-	I
erbA	I
/	I
thyroid	I
hormone	I
(	I
T3	I
)	I
receptor	I
(	O
c	B
-	I
erbA	I
/	I
TR	I
)	O
on	O
growth	O
and	O
differentiation	O
of	O
erythroid	O
cells	O
using	O
an	O
in	O
vitro	O
culture	O
system	O
of	O
stem	O
cell	O
factor	O
-	O
dependent	O
erythroid	O
progenitors	O
.	O
RXR	B
,	O
RAR	B
,	O
and	O
c	B
-	I
erbA	I
/	I
TR	I
-specific	O
ligands	O
were	O
found	O
to	O
induce	O
erythroid	O
-	O
specific	O
gene	O
expression	O
and	O
to	O
accelerate	O
erythroid	O
differentiation	O
in	O
culture	O
,	O
with	O
T3	O
being	O
most	O
effective	O
.	O
Furthermore	O
,	O
while	O
ligand	O
-	O
activated	O
c	B
-	I
erbA	I
/	I
TR	I
accelerated	O
differentiation	O
,	O
unliganded	O
c	B
-	I
erbA	I
/	I
TR	I
effectively	O
blocked	O
differentiation	O
and	O
supported	O
sustained	O
progenitor	O
growth	O
in	O
culture	O
.	O
Thus	O
,	O
c	B
-	I
erbA	I
/	I
TR	I
appears	O
to	O
act	O
as	O
a	O
binary	O
switch	O
affecting	O
erythroid	O
cell	O
fate	O
:	O
unliganded	O
c	B
-	I
erbA	I
/	I
TR	I
supports	O
growth	O
while	O
ligand	O
-	O
activated	O
c	B
-	I
erbA	I
/	I
TR	I
induces	O
differentiation	O
.	O
Additionally	O
,	O
to	O
determine	O
the	O
impact	O
of	O
RXR	B
for	O
erythroid	O
cell	O
development	O
,	O
dominant	O
interfering	O
mutant	B
RXRs	I
,	O
lacking	O
the	O
transcriptional	O
activator	O
functions	O
AF-1	B
and	O
AF-2	B
,	O
or	O
AF-2	B
only	O
,	O
or	O
the	O
entire	O
DNA	O
-	O
binding	O
domain	O
,	O
were	O
introduced	O
into	O
erythroid	O
progenitor	O
cells	O
via	O
recombinant	O
retrovirus	O
vectors	O
and	O
analyzed	O
for	O
RXR	B
-specific	O
effects	O
.	O
It	O
was	O
found	O
that	O
expression	O
of	O
wild	B
-	I
type	I
RXR	I
and	O
of	O
the	O
RXR	B
mutants	I
devoid	O
of	O
AF-1	B
and/or	O
AF-2	B
supported	O
a	O
transient	O
outgrowth	O
of	O
erythroid	O
cells	O
.	O
In	O
marked	O
contrast	O
,	O
expression	O
of	O
the	O
dominant	B
interfering	I
deltaDNA	I
-	I
binding	I
domain	I
RXR	B
,	O
containing	O
a	O
deletion	O
of	O
the	O
entire	O
DNA	O
-	O
binding	O
domain	O
,	O
was	O
incompatible	O
with	O
erythroid	O
cell	O
growth	O
in	O
vitro	O
,	O
suggesting	O
a	O
pivotal	O
role	O
of	O
RXR	B
for	O
erythroid	O
cell	O
development	O
.	O
Induction	O
of	O
Mn	B
SOD	I
in	O
human	O
monocytes	O
without	O
inflammatory	B
cytokine	I
production	O
by	O
a	O
mutant	B
endotoxin	I
.	O
Endotoxin	B
selectively	O
induces	O
monocyte	B
Mn	I
superoxide	I
dismutase	I
(	O
SOD	B
)	O
without	O
affecting	O
levels	O
of	O
Cu	O
,	O
Zn	B
SOD	I
,	O
catalase	B
,	O
or	O
glutathione	B
peroxidase	I
.	O
However	O
,	O
little	O
is	O
known	O
about	O
the	O
structure	O
-	O
activity	O
relationship	O
and	O
the	O
mechanism	O
by	O
which	O
endotoxin	O
induces	O
Mn	B
SOD	I
.	O
In	O
this	O
study	O
we	O
demonstrated	O
that	O
a	O
mutant	O
Escherichia	O
coli	O
endotoxin	O
lacking	O
myristoyl	O
fatty	O
acid	O
at	O
the	O
3	O
'	O
R-3-hydroxymyristate	O
position	O
of	O
the	O
lipid	O
A	O
moiety	O
retained	O
its	O
full	O
capacity	O
to	O
coagulate	O
Limulus	O
amoebocyte	O
lysate	O
compared	O
with	O
the	O
wild	O
-	O
type	O
E.	O
coli	O
endotoxin	O
and	O
markedly	O
stimulated	O
the	O
activation	O
of	O
human	B
monocyte	I
nuclear	I
factor	I
-	I
kappaB	I
and	O
the	O
induction	O
of	O
Mn	O
SOD	O
mRNA	O
and	O
enzyme	O
activity	O
.	O
However	O
,	O
in	O
contrast	O
to	O
the	O
wild	O
-	O
type	O
endotoxin	O
,	O
it	O
failed	O
to	O
induce	O
significant	O
production	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
and	O
macrophage	B
inflammatory	I
protein-1alpha	I
by	O
monocytes	O
and	O
did	O
not	O
induce	O
the	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
.	O
These	O
results	O
suggest	O
that	O
1	O
)	O
lipid	O
A	O
myristoyl	O
fatty	O
acid	O
,	O
although	O
it	O
is	O
important	O
for	O
the	O
induction	O
of	O
inflammatory	B
cytokine	I
production	O
by	O
human	O
monocytes	O
,	O
is	O
not	O
necessary	O
for	O
the	O
induction	O
of	O
Mn	B
SOD	I
,	O
2	O
)	O
endotoxin	B
-mediated	O
induction	O
of	O
Mn	B
SOD	I
and	O
inflammatory	O
cytokines	B
are	O
regulated	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
different	O
signal	O
transduction	O
pathways	O
,	O
and	O
3	O
)	O
failure	O
of	O
the	O
mutant	B
endotoxin	I
to	O
induce	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
production	O
is	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
its	O
inability	O
to	O
activate	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
.	O
An	O
allosteric	O
drug	O
,	O
o	O
,	O
o'-bismyristoyl	O
thiamine	O
disulfide	O
,	O
suppresses	O
HIV-1	O
replication	O
through	O
prevention	O
of	O
nuclear	O
translocation	O
of	O
both	O
HIV-1	B
Tat	I
and	O
NF	B
-	I
kappa	I
B	I
.	O
The	O
efficacy	O
of	O
o	O
,	O
o'-bismyristoyl	O
thiamine	O
disulfide	O
(	O
BMT	O
)	O
was	O
examined	O
in	O
detail	O
against	O
HIV-1	O
laboratory	O
isolates	O
(	O
HTLV	O
-	O
IIIB	O
,	O
JRFL	O
,	O
and	O
MN	O
)	O
,	O
primary	O
isolates	O
(	O
KMT	O
and	O
KMO	O
)	O
,	O
and	O
simian	O
immunodeficiency	O
virus	O
(	O
SIVmac251	O
)	O
in	O
vitro	O
.	O
BMT	O
inhibited	O
the	O
replication	O
of	O
HIV-1	O
in	O
both	O
laboratory	O
and	O
primary	O
isolates	O
in	O
vitro	O
.	O
In	O
addition	O
,	O
BMT	O
exhibited	O
antiviral	O
activity	O
against	O
SIVmac251	O
.	O
Minimizing	O
energy	O
studies	O
of	O
BMT	O
structure	O
reveal	O
that	O
a	O
trans	O
-	O
disulfide	O
of	O
thiamine	O
(	O
holo	O
drug	O
)	O
disulfide	O
(	O
TDS	O
,	O
protodrug	O
)	O
is	O
allosterically	O
transited	O
to	O
the	O
reactive	O
twisted	O
disulfide	O
of	O
BMT	O
(	O
allo	O
drug	O
)	O
by	O
o	O
,	O
o'-bismyristoyl	O
esterification	O
of	O
TDS	O
.	O
BMT	O
inhibits	O
nuclear	O
translocation	O
of	O
both	O
HIV-1	B
transactivator	I
(	O
TAT	B
)	O
and	O
the	O
cellular	B
transcriptional	I
nuclear	I
factor	I
-	I
KB	I
(	O
NF	B
-	I
kappa	I
B	I
)	O
,	O
resulting	O
in	O
the	O
suppression	O
of	O
HIV-1	O
replication	O
.	O
Interferon	B
-	I
gamma	I
-	I
induced	I
factor	I
binding	O
to	O
the	O
interleukin-4-responsive	O
element	O
of	O
CD23b	O
promoter	O
in	O
human	O
tonsillar	O
mononuclear	O
cells	O
:	O
role	O
in	O
transient	O
up	O
-	O
regulation	O
of	O
the	O
interleukin-4-induced	O
CD23b	O
mRNA	O
.	O
Stimulation	O
of	O
human	O
tonsillar	O
mononuclear	O
cells	O
with	O
interleukin-4	B
(	O
IL-4	B
)	O
and	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
rapidly	O
induced	O
the	O
activation	O
of	O
distinct	O
nuclear	B
factors	I
with	O
different	O
mobilities	O
,	O
both	O
of	O
which	O
bind	O
the	O
IL-4	O
response	O
element	O
(	O
IL-4RE	O
)	O
of	O
CD23b	O
promoter	O
as	O
examined	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
.	O
Co	O
-	O
treatment	O
of	O
IL-4	B
and	O
IFN	B
-	I
gamma	I
induced	O
,	O
in	O
addition	O
to	O
the	O
two	O
distinct	O
complexes	O
,	O
a	O
new	O
complex	O
with	O
an	O
intermediate	O
mobility	O
.	O
The	O
IL-4-induced	B
complex	I
reacted	O
with	O
anti	B
-	I
STAT	I
(	I
signal	I
transducers	I
and	I
activators	I
of	I
transcription	I
)	I
6	I
,	O
resulting	O
in	O
a	O
supershift	O
whereas	O
the	O
formation	O
of	O
the	O
IFN	B
-	I
gamma	I
-	I
induced	I
complex	I
was	O
inhibited	O
by	O
anti	B
-	I
STAT	I
1	I
.	O
The	O
intermediate	O
complex	O
appeared	O
to	O
react	O
with	O
both	O
anti	B
-	I
STAT	I
6	I
and	O
anti	B
-	I
STAT	I
1	I
.	O
Although	O
IFN	B
-	I
gamma	I
alone	O
did	O
not	O
induce	O
CD23	O
mRNA	O
transcription	O
,	O
Northern	O
blot	O
analysis	O
revealed	O
a	O
transient	O
up	O
-	O
regulation	O
of	O
the	O
IL-4-induced	O
CD23	O
mRNA	O
by	O
IFN	B
-	I
gamma	I
within	O
2	O
h	O
of	O
IFN	B
-	I
gamma	I
treatment	O
in	O
these	O
tonsillar	O
cells	O
.	O
The	O
results	O
suggest	O
that	O
the	O
IL-4RE	O
of	O
the	O
IL-4-inducible	O
gene	O
can	O
accommodate	O
both	O
IL-4-	B
and	I
IFN	I
-	I
gamma	I
-	I
activated	I
factors	I
,	O
such	O
as	O
STAT	B
6	I
and	O
STAT	B
1	I
,	O
either	O
in	O
homodimeric	B
or	I
heterodimeric	I
forms	I
and	O
the	O
binding	O
of	O
these	O
different	O
proteins	O
to	O
the	O
respective	O
promoter	O
may	O
play	O
a	O
potential	O
regulatory	O
role	O
in	O
the	O
IL-4	B
-inducible	O
gene	O
expression	O
.	O
The	O
Epstein	B
-	I
Barr	I
virus	I
Rta	I
protein	I
activates	O
lytic	O
cycle	O
genes	O
and	O
can	O
disrupt	O
latency	O
in	O
B	O
lymphocytes	O
.	O
The	O
transition	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
from	O
latency	O
into	O
the	O
lytic	O
cycle	O
is	O
associated	O
with	O
the	O
expression	O
of	O
two	O
immediate	O
-	O
early	O
viral	O
genes	O
,	O
BZLF1	O
and	O
BRLF1	O
.	O
Overexpression	O
of	O
ZEBRA	O
,	O
the	O
product	O
of	O
BZLF1	O
,	O
is	O
sufficient	O
to	O
disrupt	O
latency	O
in	O
B	O
lymphocytes	O
and	O
epithelial	O
cells	O
by	O
stimulating	O
expression	O
of	O
lytic	O
cycle	O
genes	O
,	O
including	O
BRLF1	O
.	O
The	O
BRLF1	B
product	I
Rta	I
functions	O
as	O
a	O
transcriptional	O
activator	O
in	O
both	O
B	O
lymphocytes	O
and	O
epithelial	O
cells	O
.	O
However	O
,	O
Rta	B
has	O
recently	O
been	O
reported	O
to	O
disrupt	O
latency	O
in	O
an	O
epithelial	O
specific	O
manner	O
(	O
S.	O
Zalani	O
,	O
E.	O
Holley	O
-	O
Guthrie	O
,	O
and	O
S.	O
Kenney	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
93	O
:	O
9194	O
-	O
9199	O
,	O
1996	O
)	O
.	O
Here	O
we	O
demonstrate	O
that	O
expression	O
of	O
Rta	B
is	O
also	O
sufficient	O
for	O
disruption	O
of	O
latency	O
in	O
a	O
permissive	O
B	O
-	O
cell	O
line	O
.	O
In	O
HH514	O
-	O
16	O
cells	O
,	O
transfection	O
of	O
Rta	B
leads	O
to	O
synthesis	O
of	O
ZEBRA	B
,	O
viral	O
DNA	O
replication	O
,	O
and	O
late	O
gene	O
expression	O
.	O
However	O
,	O
Rta	B
by	O
itself	O
is	O
less	O
potent	O
than	O
ZEBRA	B
in	O
the	O
ability	O
to	O
activate	O
most	O
early	O
and	O
late	O
lytic	O
cycle	O
genes	O
.	O
In	O
light	O
of	O
previous	O
work	O
implicating	O
ZEBRA	B
in	O
the	O
activation	O
of	O
Rta	B
,	O
we	O
suggest	O
a	O
cooperative	O
model	O
for	O
EBV	O
entry	O
into	O
the	O
lytic	O
cycle	O
.	O
Expression	O
of	O
either	O
BZLF1	O
or	O
BRLF1	O
triggers	O
expression	O
of	O
the	O
other	O
immediate	B
-	I
early	I
factor	I
,	O
and	O
together	O
these	O
activators	O
act	O
individually	O
or	O
in	O
synergy	O
on	O
downstream	O
targets	O
to	O
activate	O
the	O
viral	O
lytic	O
cycle	O
.	O
Molecular	O
and	O
cellular	O
analysis	O
of	O
human	O
immunodeficiency	O
virus	O
-	O
induced	O
apoptosis	O
in	O
lymphoblastoid	B
T	I
-	I
cell	I
-	I
line	I
-	I
expressing	I
wild	I
-	I
type	I
and	I
mutated	I
CD4	I
receptors	I
.	O
We	O
have	O
previously	O
shown	O
that	O
the	O
presence	O
of	O
the	O
CD4	B
cytoplasmic	I
tail	I
is	O
critical	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-induced	O
apoptosis	O
(	O
J.Corbeil	O
,	O
M.Tremblay	O
,	O
and	O
D.D.Richman	O
,	O
J.Exp	O
.	O
Med.183	O
:	O
39	O
-	O
48	O
,	O
1996	O
)	O
.	O
We	O
have	O
pursued	O
our	O
investigation	O
of	O
the	O
role	O
of	O
the	O
CD4	B
transduction	O
pathway	O
in	O
HIV	O
-	O
induced	O
apoptosis	O
.	O
To	O
do	O
this	O
,	O
wild	O
-	O
type	O
and	O
mutant	O
forms	O
of	O
the	O
CD4	B
cytoplasmic	I
tail	I
were	O
stably	O
expressed	O
in	O
the	O
lymphoblastoid	O
T	O
-	O
cell	O
line	O
A2.01	O
.	O
Apoptosis	O
was	O
prevented	O
when	O
CD4	B
truncated	O
at	O
residue	O
402	O
was	O
expressed	O
;	O
however	O
,	O
cells	O
expressing	O
mutated	O
receptors	O
that	O
do	O
not	O
associate	O
with	O
p56	B
(	I
lck	I
)	I
(	O
mutated	O
at	O
the	O
dicysteine	B
motif	I
and	O
truncated	O
at	O
residue	O
418	O
)	O
but	O
which	O
conserved	O
proximal	O
domains	O
of	O
the	O
cytoplasmic	B
tail	I
underwent	O
apoptosis	O
like	O
wild-	B
type	I
CD4	I
.	O
The	O
differences	O
between	O
wild	B
-	I
type	I
and	I
mutated	I
receptors	I
in	O
the	O
induction	O
of	O
apoptosis	O
were	O
not	O
related	O
to	O
levels	O
of	O
p56	B
(	I
lck	I
)	I
or	O
NF-	B
kappaB	I
activation	O
.	O
Initial	O
signaling	O
through	O
the	O
CD4	B
receptor	I
played	O
a	O
major	O
role	O
in	O
the	O
sensitization	O
of	O
HIV	O
-	O
infected	O
T	O
cells	O
to	O
undergo	O
apoptosis	O
.	O
Incubation	O
of	O
HIV	O
-	O
infected	O
cells	O
with	O
monoclonal	B
antibody	I
(	I
MAb	I
)	I
13B8	I
-	I
2	I
,	O
which	O
binds	O
to	O
CD4	B
in	O
a	O
region	O
critical	O
for	O
dimerization	O
of	O
the	O
receptor	O
,	O
prevented	O
apoptosis	O
without	O
inhibiting	O
HIV	O
replication	O
.	O
Moreover	O
,	O
the	O
apoptotic	O
process	O
was	O
not	O
related	O
to	O
Fas	B
-Fas	B
ligand	I
interaction	O
;	O
however	O
,	O
an	O
antagonistic	O
anti	O
-	O
Fas	O
MAb	O
(	O
ZB-4	O
)	O
enhanced	O
apoptosis	O
in	O
HIV	O
-	O
infected	O
cells	O
without	O
inducing	O
apoptosis	O
in	O
uninfected	O
cells	O
.	O
These	O
observations	O
demonstrate	O
that	O
CD4	B
signaling	O
mediates	O
HIV	O
-	O
induced	O
apoptosis	O
by	O
a	O
mechanism	O
independent	O
of	O
Fas	B
-Fas	B
ligand	I
interaction	O
,	O
does	O
not	O
require	O
p56	B
(	I
lck	I
)	I
signaling	O
,	O
and	O
may	O
involve	O
a	O
critical	O
region	O
for	O
CD4	B
dimerization	O
.	O
Models	O
of	O
lineage	O
switching	O
in	O
hematopoietic	O
development	O
:	O
a	O
new	O
myeloid	O
-	O
committed	O
eosinophil	O
cell	O
line	O
(	O
YJ	O
)	O
demonstrates	O
trilineage	O
potential	O
.	O
A	O
new	O
human	O
leukemia	O
cell	O
line	O
with	O
an	O
eosinophilic	O
phenotype	O
,	O
designated	O
YJ	O
,	O
was	O
established	O
from	O
the	O
peripheral	O
blood	O
cells	O
of	O
a	O
patient	O
with	O
chronic	O
myelomonocytic	O
leukemia	O
(	O
CMMoL	O
)	O
with	O
eosinophilia	O
.	O
When	O
cultured	O
in	O
RPMI	O
1640	O
medium	O
containing	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
most	O
YJ	O
cells	O
were	O
myeloblastoid	O
with	O
a	O
small	O
number	O
of	O
the	O
cells	O
having	O
eosinophilic	O
granules	O
.	O
Cell	B
surface	I
markers	I
in	O
the	O
YJ	O
cells	O
were	O
positive	O
for	O
CD33	B
and	O
were	O
negative	O
for	O
CD34	B
,	O
CD16	B
and	O
CD23	B
.	O
The	O
eosinophilic	O
characteristics	O
of	O
YJ	O
cells	O
were	O
confirmed	O
by	O
histochemical	O
staining	O
with	O
Fast	O
-	O
Green	O
/	O
Neutral	O
-	O
Red	O
and	O
by	O
the	O
expression	O
of	O
mRNAs	O
for	O
eosinophil	B
-	I
associated	I
granule	I
proteins	I
,	O
eosinophil	B
cationic	I
protein	I
(	O
ECP	B
)	O
,	O
eosinophil	B
-	I
derived	I
neurotoxin	I
(	O
EDN	B
)	O
,	O
eosinophil	B
peroxidase	I
(	O
EPO	B
)	O
,	O
and	O
major	B
basic	I
protein	I
(	O
MBP	B
)	O
,	O
and	O
for	O
the	O
Charcot	B
-	I
Leyden	I
crystal	I
(	I
CLC	I
)	I
protein	I
.	O
The	O
YJ	O
cells	O
could	O
be	O
induced	O
towards	O
monocytic	O
differentiation	O
by	O
stimulation	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O
The	O
monocytic	O
characteristics	O
of	O
YJ	O
cells	O
treated	O
with	O
PMA	O
were	O
confirmed	O
by	O
morphological	O
analysis	O
with	O
alpha	O
-	O
naphthyl	O
butyrate	O
esterase	O
staining	O
,	O
by	O
CD14	B
expression	O
,	O
and	O
by	O
increased	O
expression	O
of	O
Egr-1	O
mRNA	O
.	O
Furthermore	O
,	O
YJ	O
cells	O
could	O
be	O
differentiated	O
towards	O
the	O
neutrophil	O
lineage	O
by	O
stimulation	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
.	O
YJ	O
cells	O
treated	O
in	O
vitro	O
with	O
2	O
microM	O
RA	O
differentiated	O
into	O
metamyelocytes	O
and	O
band	O
neutrophils	O
,	O
and	O
increased	O
the	O
number	O
of	O
nitroblue	O
tetrazolium	O
(	O
NBT	O
)	O
-positive	O
cells	O
and	O
increased	O
gp91phox	O
mRNA	O
expression	O
.	O
Thus	O
,	O
the	O
YJ	O
cell	O
line	O
exhibited	O
eosinophilic	O
characteristics	O
,	O
but	O
was	O
able	O
to	O
differentiate	O
to	O
the	O
monocytic	O
or	O
neutrophilic	O
lineages	O
in	O
response	O
to	O
PMA	O
or	O
RA	O
,	O
respectively	O
.	O
The	O
expression	O
of	O
genes	O
for	O
transcription	B
factors	I
involved	O
in	O
myeloid	O
differentiation	O
was	O
evaluated	O
by	O
Northern	O
blot	O
analysis	O
.	O
Increased	O
expression	O
of	O
Egr-1	B
was	O
observed	O
with	O
macrophage	O
differentiation	O
.	O
In	O
contrast	O
,	O
increased	O
expressions	O
of	O
C	B
/	I
EBPbeta	I
and	O
MZF-1	O
mRNA	O
occurred	O
with	O
neutrophilic	O
differentiation	O
.	O
The	O
YJ	O
cell	O
line	O
should	O
be	O
useful	O
for	O
elucidating	O
the	O
molecular	O
mechanisms	O
governing	O
lineage	O
switching	O
from	O
the	O
eosinophil	O
to	O
monocytic	O
or	O
neutrophil	O
lineages	O
.	O
Human	O
T	O
cell	O
leukemia	O
virus	O
-	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
Tax	B
-mediated	O
apoptosis	O
in	O
activated	O
T	O
cells	O
requires	O
an	O
enhanced	O
intracellular	O
prooxidant	O
state	O
.	O
We	O
have	O
shown	O
that	O
an	O
estradiol	O
-	O
dependent	O
activation	O
of	O
human	O
T	O
cell	O
leukemia	O
virus	O
-	O
I	O
Tax	B
leads	O
to	O
the	O
inhibition	O
of	O
cell	O
proliferation	O
and	O
to	O
the	O
induction	O
of	O
apoptosis	O
.	O
The	O
present	O
study	O
demonstrates	O
that	O
a	O
hormone	O
-	O
dependent	O
activation	O
of	O
Tax	B
promotes	O
an	O
enhanced	O
prooxidant	O
state	O
in	O
stably	O
transfected	O
Jurkat	O
cells	O
as	O
measured	O
by	O
changes	O
in	O
the	O
intracellular	O
levels	O
of	O
glutathione	O
and	O
H2O2	O
;	O
these	O
changes	O
are	O
followed	O
by	O
apoptotic	O
cell	O
death	O
.	O
Additional	O
stimulation	O
of	O
the	O
CD3	B
/TCR	B
pathway	O
enhances	O
the	O
oxidative	O
and	O
apoptotic	O
effects	O
.	O
Both	O
Tax	B
-mediated	O
apoptosis	O
and	O
oxidative	O
stress	O
can	O
be	O
potently	O
suppressed	O
by	O
antioxidants	O
,	O
as	O
is	O
seen	O
with	O
the	O
administration	O
of	O
recombinant	B
thioredoxin	I
(	O
adult	B
T	I
cell	I
leukemia	I
-	I
derived	I
factor	I
)	O
or	O
pyrrolidine	O
dithiocarbamate	O
.	O
Hormone	O
-	O
induced	O
Tax	B
activation	O
induces	O
a	O
long	O
-	O
lasting	O
activation	O
of	O
NF	B
-	I
kappaB	I
,	O
which	O
is	O
a	O
major	O
target	O
of	O
reactive	O
oxygen	O
intermediates	O
.	O
The	O
long	O
-	O
term	O
exposure	O
of	O
Jurkat	O
cells	O
to	O
hormone	O
eventually	O
results	O
in	O
a	O
selection	O
of	O
cell	O
clones	O
that	O
have	O
lost	O
Tax	B
activity	O
.	O
A	O
subsequent	O
transfection	O
of	O
these	O
apparently	O
`	O
`	O
nonresponsive	O
''	O
clones	O
allows	O
the	O
recovery	O
of	O
Tax	B
responses	O
in	O
these	O
cells	O
.	O
Our	O
observations	O
indicate	O
that	O
changes	O
in	O
the	O
intracellular	O
redox	O
status	O
may	O
be	O
a	O
determining	O
factor	O
in	O
Tax	B
-mediated	O
DNA	O
damage	O
,	O
apoptosis	O
,	O
and	O
selection	O
against	O
the	O
long	O
-	O
term	O
expression	O
of	O
Tax	B
function	O
.	O
Activated	O
platelets	O
induce	O
monocyte	B
chemotactic	I
protein-1	I
secretion	O
and	O
surface	O
expression	O
of	O
intercellular	O
adhesion	O
molecule-1	O
on	O
endothelial	O
cells	O
[	O
see	O
comments	O
]	O
BACKGROUND	O
:	O
Platelet	O
/	O
endothelium	O
interaction	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
inflammation	O
and	O
atherosclerosis	O
.	O
The	O
role	O
of	O
platelets	O
for	O
monocyte	B
chemotactic	I
protein-1	I
(	O
MCP-1	B
)	O
secretion	O
and	O
surface	O
expression	O
of	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	B
)	O
on	O
endothelial	O
cells	O
has	O
been	O
assessed	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
Monolayers	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
were	O
incubated	O
with	O
nonstimulated	O
or	O
ADP	O
-	O
activated	O
platelets	O
for	O
6	O
hours	O
,	O
and	O
secretion	O
of	O
MCP-1	B
and	O
surface	O
expression	O
of	O
ICAM-1	B
were	O
determined	O
by	O
ELISA	O
and	O
flow	O
cytometry	O
,	O
respectively	O
.	O
In	O
the	O
presence	O
of	O
ADP	O
-	O
activated	O
platelets	O
,	O
both	O
MCP-1	B
secretion	O
and	O
ICAM-1	B
surface	O
expression	O
were	O
significantly	O
increased	O
compared	O
with	O
nonstimulated	O
platelets	O
(	O
P	O
<	O
0.02	O
)	O
.	O
Activation	O
of	O
the	O
transcription	B
factor	I
nuclear	I
factor	I
-	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
kappaB	B
-dependent	O
transcriptional	O
activity	O
was	O
enhanced	O
in	O
the	O
presence	O
of	O
activated	O
platelets	O
.	O
In	O
addition	O
,	O
ADP	O
-	O
activated	O
platelets	O
induced	O
MCP-1	O
and	O
ICAM-1	O
promoter	O
-	O
dependent	O
transcription	O
.	O
Liposomal	O
transfection	O
of	O
a	O
double	O
-	O
stranded	O
kappaB	O
phosphorothioate	O
oligonucleotide	O
,	O
but	O
not	O
of	O
the	O
mutated	O
form	O
,	O
inhibited	O
MCP-1	B
secretion	O
and	O
surface	O
expression	O
of	O
ICAM-1	B
on	O
activated	O
endothelium	O
(	O
P	O
<	O
0.05	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
present	O
study	O
indicates	O
that	O
activated	O
platelets	O
modulate	O
chemotactic	O
(	O
MCP-1	B
)	O
and	O
adhesive	O
(	O
ICAM-1	B
)	O
properties	O
of	O
endothelial	O
cells	O
via	O
an	O
NF	B
-	I
kappaB	I
-dependent	O
mechanism	O
.	O
Platelet	O
-	O
induced	O
activation	O
of	O
the	O
NF	B
-	I
kappaB	I
system	O
might	O
contribute	O
to	O
early	O
inflammatory	O
events	O
in	O
atherogenesis	O
.	O
Upregulation	O
of	O
interleukin	B
6	I
and	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
receptors	I
by	O
transcription	B
factor	I
CCAAT	B
enhancer	I
binding	I
protein	I
alpha	I
(	O
C	B
/	I
EBP	I
alpha	I
)	O
is	O
critical	O
for	O
granulopoiesis	O
.	O
Cytokines	O
stimulate	O
granulopoiesis	O
through	O
signaling	O
via	O
receptors	O
whose	O
expression	O
is	O
controlled	O
by	O
lineage	O
-	O
specific	O
transcription	B
factors	I
.	O
Previously	O
,	O
we	O
demonstrated	O
that	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
receptor	O
mRNA	O
was	O
undetectable	O
and	O
granulocyte	O
maturation	O
blocked	O
in	O
CCAAT	B
enhancer	I
binding	I
protein	I
alpha	I
(	O
C	B
/	I
EBPalpha	I
)	O
-deficient	O
mice	O
.	O
This	O
phenotype	O
is	O
distinct	O
from	O
that	O
of	O
G	O
-	O
CSF	O
receptor-	O
/	O
-	O
mice	O
,	O
suggesting	O
that	O
other	O
genes	O
are	O
likely	O
to	O
be	O
adversely	O
affected	O
by	O
loss	O
of	O
C	B
/	I
EBPalpha	I
.	O
Here	O
we	O
demonstrate	O
loss	O
of	O
interleukin	B
6	I
(	I
IL-6	I
)	I
receptor	I
and	O
IL-6-responsive	B
colony	I
-	I
forming	I
units	I
(	O
CFU	B
-	I
IL6	I
)	O
in	O
C	B
/	I
EBPalpha	I
-	O
/	O
-	O
mice	O
.	O
The	O
observed	O
failure	O
of	O
granulopoiesis	O
could	O
be	O
rescued	O
by	O
the	O
addition	O
of	O
soluble	O
IL-6	B
receptor	I
and	O
IL-6	B
or	O
by	O
retroviral	O
transduction	O
of	O
G	B
-	I
CSF	I
receptors	I
,	O
demonstrating	O
that	O
loss	O
of	O
both	O
of	O
these	O
receptors	O
contributes	O
to	O
the	O
absolute	O
block	O
in	O
granulocyte	O
maturation	O
observed	O
in	O
C	O
/	O
EBPalpha	O
-	O
deficient	O
hematopoietic	O
cells	O
.	O
The	O
results	O
of	O
these	O
and	O
other	O
studies	O
suggest	O
that	O
additional	O
C	O
/	O
EBPalpha	O
target	O
genes	O
,	O
possibly	O
other	O
cytokine	O
receptors	O
,	O
are	O
also	O
important	O
for	O
the	O
block	O
in	O
granulocyte	O
differentiation	O
observed	O
in	O
vivo	O
in	O
C	B
/	I
EBPalpha	I
-deficient	O
mice	O
.	O
NF	B
-	I
kappaB	I
only	O
partially	O
mediates	O
Epstein	B
-	I
Barr	I
virus	I
latent	I
membrane	I
protein	I
1	I
activation	O
of	O
B	O
cells	O
.	O
The	O
latent	B
membrane	I
protein	I
1	I
(	O
LMP1	B
)	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
required	O
for	O
EBV	O
-	O
induced	O
immortalization	O
of	O
human	O
B	O
cells	O
and	O
causes	O
tumorigenic	O
transformation	O
of	O
cell	O
lines	O
.	O
LMP1	B
expression	O
induces	O
phenotypic	O
changes	O
resembling	O
B	O
cell	O
activation	O
,	O
such	O
as	O
cell	O
size	O
increase	O
and	O
up	O
-	O
regulation	O
of	O
cell	B
surface	I
activation	I
markers	I
.	O
LMP1	B
contains	O
two	O
domains	O
that	O
activate	O
the	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
,	O
one	O
through	O
interactions	O
with	O
TRAF	B
proteins	I
and	O
the	O
other	O
with	O
the	O
TRADD	B
protein	I
.	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
importance	O
of	O
NF	B
-	I
kappaB	I
induction	O
in	O
the	O
up	O
-	O
regulation	O
of	O
the	O
B	O
cell	O
activation	O
markers	O
ICAM-1	B
and	O
CD71	B
by	O
LMP1	B
.	O
This	O
study	O
shows	O
that	O
expression	O
of	O
LMP1	B
activates	O
transcription	O
from	O
p50	O
/	O
p65-	O
and	O
c	O
-	O
Rel-	O
responsive	O
promoters	O
,	O
and	O
that	O
this	O
activity	O
can	O
be	O
completely	O
inhibited	O
by	O
expression	O
of	O
a	O
dominant	O
inhibitory	B
IkappaB	I
mutant	I
.	O
ICAM-1	B
and	O
CD71	B
are	O
nevertheless	O
up	O
-	O
regulated	O
by	O
LMP1	B
in	O
primary	O
B	O
cells	O
and	O
cell	O
lines	O
expressing	O
the	O
dominant	B
IkappaB	I
.	O
Furthermore	O
,	O
LMP1	B
-induced	O
cell	O
size	O
increase	O
of	O
primary	O
B	O
cells	O
was	O
unaffected	O
by	O
IkappaB	B
expression	O
.	O
It	O
was	O
concluded	O
that	O
even	O
when	O
LMP1	B
is	O
unable	O
to	O
activate	O
NF	B
-	I
kappaB	I
,	O
it	O
is	O
still	O
capable	O
of	O
inducing	O
certain	O
characteristics	O
of	O
activated	O
B	O
cells	O
,	O
strongly	O
suggesting	O
that	O
LMP1	B
can	O
also	O
activate	O
cells	O
independently	O
of	O
NF	B
-	I
kappaB	I
.	O
Expression	O
status	O
of	O
BCL-6	B
and	O
syndecan-1	B
identifies	O
distinct	O
histogenetic	O
subtypes	O
of	O
Hodgkin	O
's	O
disease	O
.	O
The	O
tumor	O
cells	O
in	O
most	O
cases	O
of	O
Hodgkin	O
's	O
disease	O
(	O
HD	O
)	O
have	O
been	O
recently	O
recognized	O
to	O
originate	O
from	O
the	O
B	O
-	O
cell	O
lineage	O
,	O
but	O
their	O
precise	O
differentiation	O
stage	O
is	O
not	O
fully	O
clarified	O
.	O
Recently	O
,	O
we	O
have	O
reported	O
that	O
the	O
histogenesis	O
of	O
B	O
-	O
cell	O
lymphomas	O
may	O
be	O
assessed	O
by	O
monitoring	O
the	O
expression	O
pattern	O
of	O
BCL-6	B
,	O
a	O
transcription	B
factor	I
expressed	O
in	O
germinal	O
center	O
(	O
GC	O
)	O
B	O
cells	O
,	O
and	O
CD138	B
/	I
syndecan-1	I
(	O
syn-1	B
)	O
,	O
a	O
proteoglycan	O
associated	O
with	O
post	O
-	O
GC	O
,	O
terminal	O
B	O
-	O
cell	O
differentiation	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
applied	O
these	O
two	O
markers	O
to	O
the	O
study	O
of	O
HD	O
histogenesis	O
.	O
We	O
have	O
found	O
that	O
in	O
nodular	O
lymphocyte	O
predominance	O
HD	O
(	O
NLPHD	O
)	O
tumor	O
cells	O
consistently	O
display	O
the	O
BCL-6	B
(	O
+	O
)	O
/	O
syn-1	B
(	O
-	O
)	O
phenotype	O
,	O
indicating	O
their	O
derivation	O
from	O
GC	O
B	O
cells	O
.	O
Conversely	O
,	O
classic	O
HD	O
(	O
CHD	O
)	O
is	O
heterogeneous	O
because	O
the	O
tumor	O
cells	O
of	O
a	O
fraction	O
of	O
CHD	O
display	O
the	O
BCL-6	B
(	O
-	O
)	O
/	O
syn-1	B
(	O
+	O
)	O
phenotype	O
of	O
post	O
-	O
GC	O
B	O
-	O
cells	O
,	O
whereas	O
another	O
fraction	O
of	O
CHD	O
is	O
constituted	O
by	O
a	O
mixture	O
of	O
tumor	O
cells	O
reflecting	O
the	O
GC	O
(	O
BCL-6	B
(	O
+	O
)	O
/	O
syn-1	B
(	O
-	O
)	O
)	O
or	O
post	O
-	O
GC	O
(	O
BCL-6	B
(	O
-	O
)	O
/	O
syn-1	B
(	O
+	O
)	O
)	O
phenotypes	O
.	O
BCL-6	O
(	O
-	O
)	O
/syn-1	O
(	O
+	O
)	O
tumor	O
cells	O
of	O
CHD	O
are	O
mostly	O
found	O
surrounded	O
by	O
T	O
cells	O
expressing	O
CD40L	B
,	O
consistent	O
with	O
the	O
observation	O
that	O
CD40	B
signaling	O
downregulates	O
BCL-6	B
expression	O
.	O
These	O
data	O
indicate	O
that	O
tumor	O
cells	O
of	O
NLPHD	O
uniformly	O
display	O
a	O
GC	O
B	O
-	O
cell	O
phenotype	O
,	O
whereas	O
the	O
phenotype	O
of	O
tumor	O
cells	O
of	O
CHD	O
appears	O
to	O
be	O
modulated	O
by	O
the	O
surrounding	O
cellular	O
background	O
,	O
particularly	O
CD40L+	O
reactive	O
T	O
cells	O
.	O
Interleukin-4	B
and	I
-13	I
induce	O
upregulation	O
of	O
the	O
murine	O
macrophage	O
12	B
/	I
15-lipoxygenase	I
activity	I
:	O
evidence	O
for	O
the	O
involvement	O
of	O
transcription	B
factor	I
STAT6	B
.	O
When	O
human	O
monocytes	O
or	O
alveolar	O
macrophages	O
are	O
cultured	O
in	O
the	O
presence	O
of	O
interleukin	B
(	I
IL	I
)	I
-4	I
or	O
IL-13	B
,	O
the	O
expression	O
of	O
the	O
reticulocyte	B
-	I
type	I
15-lipoxygenase	I
is	O
induced	O
.	O
In	O
mice	O
a	O
15-lipoxygenase	B
is	O
not	O
expressed	O
,	O
but	O
a	O
leukocyte	B
-	I
type	I
12-lipoxygenase	I
is	O
present	O
in	O
peritoneal	O
macrophages	O
.	O
To	O
investigate	O
whether	O
both	O
lipoxygenase	B
isoforms	I
exhibit	O
a	O
similar	O
regulatory	O
response	O
toward	O
cytokine	B
stimulation	O
,	O
we	O
studied	O
the	O
regulation	O
of	O
the	O
leukocyte	B
-	I
type	I
12-lipoxygenase	I
of	O
murine	O
peritoneal	O
macrophages	O
by	O
interleukins	B
and	O
found	O
that	O
the	O
activity	O
of	O
this	O
enzyme	B
is	O
upregulated	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
when	O
the	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
the	O
IL-4	B
or	O
IL-13	B
but	O
not	O
by	O
IL-10	B
.	O
When	O
peripheral	O
murine	O
monocytes	O
that	O
do	O
not	O
express	O
the	O
lipoxygenase	B
were	O
treated	O
with	O
IL-4	B
expression	O
of	O
12	O
/	O
15-lipoxygenase	O
mRNA	O
was	O
induced	O
,	O
suggesting	O
pretranslational	O
control	O
mechanisms	O
.	O
In	O
contrast	O
,	O
no	O
upregulation	O
of	O
the	O
lipoxygenase	B
activity	O
was	O
observed	O
when	O
the	O
macrophages	O
were	O
prepared	O
from	O
homozygous	O
STAT6	B
-deficient	O
mice	O
.	O
Peritoneal	O
macrophages	O
of	O
transgenic	O
mice	O
that	O
systemically	O
overexpress	O
IL-4	B
exhibited	O
a	O
threefold	O
to	O
fourfold	O
higher	O
12-lipoxygenase	B
activity	O
than	O
cells	O
prepared	O
from	O
control	O
animals	O
.	O
A	O
similar	O
upregulation	O
of	O
12-lipoxygenase	B
activity	O
was	O
detected	O
in	O
heart	O
,	O
spleen	O
,	O
and	O
lung	O
of	O
the	O
transgenic	O
animals	O
.	O
Moreover	O
,	O
a	O
strong	O
induction	O
of	O
the	O
enzyme	O
was	O
observed	O
in	O
red	O
cells	O
during	O
experimental	O
anemia	O
in	O
mice	O
.	O
The	O
data	O
presented	O
here	O
indicate	O
that	O
(	O
1	O
)	O
the	O
12-lipoxygenase	B
activity	O
of	O
murine	O
macrophages	O
is	O
upregulated	O
in	O
vitro	O
and	O
in	O
vivo	O
by	O
IL-4	B
and/or	O
IL-13	B
,	O
(	O
2	O
)	O
this	O
upregulation	O
requires	O
expression	O
of	O
the	O
transcription	B
factor	I
STAT6	B
,	O
and	O
(	O
3	O
)	O
the	O
constitutive	O
expression	O
of	O
the	O
enzyme	O
appears	O
to	O
be	O
STAT6	B
independent	O
.	O
The	O
cytokine	B
-dependent	O
upregulation	O
of	O
the	O
murine	B
macrophage	I
12-lipoxygenase	I
and	O
its	O
induction	O
during	O
experimental	O
anemia	O
suggests	O
its	O
close	O
relatedness	O
with	O
the	O
human	B
reticulocyte	I
-	I
type	I
15-lipoxygenase	I
despite	O
their	O
differences	O
in	O
the	O
positional	O
specificity	O
of	O
arachidonic	O
acid	O
oxygenation	O
.	O
The	O
PEBP2betaMYH11	B
fusion	O
created	O
by	O
Inv	O
(	O
16	O
)	O
(	O
p13	O
;	O
q22	O
)	O
in	O
myeloid	O
leukemia	O
impairs	O
neutrophil	O
maturation	O
and	O
contributes	O
to	O
granulocytic	O
dysplasia	O
.	O
Chromosomal	O
translocations	O
involving	O
the	O
genes	O
encoding	O
the	O
alpha	B
and	I
beta	I
subunits	I
of	O
the	O
Pebp2	B
/	I
Cbf	I
transcription	I
factor	I
have	O
been	O
associated	O
with	O
human	O
acute	O
myeloid	O
leukemia	O
and	O
the	O
preleukemic	O
condition	O
,	O
myelodysplasia	O
.	O
Inv	O
(	O
16	O
)	O
(	O
p13	O
;	O
q22	O
)	O
fuses	O
the	O
gene	O
encoding	O
the	O
beta	B
subunit	I
of	O
Pebp2	B
to	O
the	O
MYH11	O
gene	O
encoding	O
a	O
smooth	B
muscle	I
myosin	I
heavy	I
chain	I
(	O
Smmhc	B
)	O
.	O
To	O
examine	O
the	O
effect	O
of	O
the	O
inv	O
(	O
16	O
)	O
(	O
p13	O
;	O
q22	O
)	O
on	O
myelopoiesis	O
,	O
we	O
used	O
the	O
hMRP8	O
promoter	O
element	O
to	O
generate	O
transgenic	O
mice	O
expressing	O
the	O
Pebp2beta	B
Smmhc	B
chimeric	I
fusion	I
protein	I
in	O
myeloid	O
cells	O
.	O
Neutrophil	O
maturation	O
was	O
impaired	O
in	O
PEBP2betaMYH11	B
transgenic	O
mice	O
.	O
Although	O
the	O
transgenic	O
mice	O
had	O
normal	O
numbers	O
of	O
circulating	O
neutrophils	O
,	O
their	O
bone	O
marrow	O
contained	O
increased	O
numbers	O
of	O
immature	O
neutrophilic	O
cells	O
,	O
which	O
exhibited	O
abnormal	O
characteristics	O
.	O
In	O
addition	O
,	O
PEBP2betaMYH11	B
inhibited	O
neutrophilic	O
differentiation	O
in	O
colonies	O
derived	O
from	O
hematopoietic	O
progenitors	O
.	O
Coexpression	O
of	O
both	O
PEBP2betaMYH11	B
and	O
activated	B
NRAS	I
induced	O
a	O
more	O
severe	O
phenotype	O
characterized	O
by	O
abnormal	O
nuclear	O
morphology	O
indicative	O
of	O
granulocytic	O
dysplasia	O
.	O
These	O
results	O
show	O
that	O
PEBP2betaMYH11	B
can	O
impair	O
neutrophil	O
development	O
and	O
provide	O
evidence	O
that	O
alterations	O
of	O
Pebp2	B
can	O
contribute	O
to	O
the	O
genesis	O
of	O
myelodysplasia	O
.	O
Carboxyl	B
-	I
terminal	I
15-amino	I
acid	I
sequence	I
of	O
NFATx1	B
is	O
possibly	O
created	O
by	O
tissue	O
-	O
specific	O
splicing	O
and	O
is	O
essential	O
for	O
transactivation	O
activity	O
in	O
T	O
cells	O
.	O
NFAT	B
regulates	O
transcription	O
of	O
a	O
number	O
of	O
cytokine	O
and	O
other	O
immunoregulatory	O
genes	O
.	O
We	O
have	O
isolated	O
NFATx	B
,	O
which	O
is	O
one	O
of	O
four	O
members	O
of	O
the	O
NFAT	B
family	I
of	O
transcription	B
factors	I
and	O
is	O
preferentially	O
expressed	O
in	O
the	O
thymus	O
and	O
peripheral	O
blood	O
leukocytes	O
,	O
and	O
an	O
isoform	O
of	O
NFATx	B
,	O
NFATx1	B
.	O
Here	O
we	O
provide	O
evidence	O
showing	O
that	O
15	O
amino	O
acids	O
in	O
the	O
carboxyl	B
-	I
terminal	I
end	I
of	O
NFATx1	B
are	O
required	O
for	O
its	O
maximum	O
transactivation	O
activity	O
in	O
Jurkat	O
T	O
cells	O
.	O
A	O
fusion	O
between	O
these	O
15	O
amino	O
acids	O
and	O
the	O
GAL4	B
DNA	I
binding	I
domain	I
was	O
capable	O
of	O
transactivating	O
reporters	O
driven	O
by	O
the	O
GAL4	O
DNA	O
binding	O
site	O
.	O
Interestingly	O
,	O
this	O
15-amino	B
acid	I
transactivation	I
sequence	I
is	O
well	O
conserved	O
in	O
NFAT	B
family	I
proteins	I
,	O
although	O
the	O
sequences	O
contiguous	O
to	O
the	O
carboxyl	B
-	I
terminal	I
regions	I
of	O
the	O
NFAT	B
family	I
are	O
much	O
less	O
conserved	O
.	O
We	O
also	O
report	O
three	O
additional	O
isoforms	O
of	O
NFATx	B
,	O
designated	O
NFATx2	B
,	O
NFATx3	B
,	O
and	O
NFATx4	B
.	O
This	O
transactivation	O
sequence	O
is	O
altered	O
by	O
tissue	O
-	O
specific	O
alternative	O
splicing	O
in	O
newly	O
isolated	O
NFATx	B
isoforms	I
,	O
resulting	O
in	O
lower	O
transactivation	O
activity	O
in	O
Jurkat	O
T	O
cells	O
.	O
NFATx1	B
is	O
expressed	O
predominantly	O
in	O
the	O
thymus	O
and	O
peripheral	O
blood	O
leukocyte	O
,	O
while	O
the	O
skeletal	O
muscle	O
expressed	O
primarily	O
NFATx2	B
.	O
In	O
Jurkat	O
cells	O
,	O
transcription	O
from	O
the	O
NFAT	O
site	O
of	O
the	O
IL-2	O
promoter	O
is	O
activated	O
strongly	O
by	O
NFATx1	B
but	O
only	O
weakly	O
by	O
NFATx2	B
.	O
These	O
data	O
demonstrate	O
that	O
the	O
15-amino	B
acid	I
sequence	I
of	O
NFATx1	B
is	O
a	O
major	B
transactivation	I
sequence	I
required	O
for	O
induction	O
of	O
genes	O
by	O
NFATx1	B
in	O
T	O
cells	O
and	O
possibly	O
regulates	O
NFAT	B
activity	O
through	O
tissue	O
-	O
specific	O
alternative	O
splicing	O
.	O
Potent	O
inhibition	O
of	O
HIV	O
type	O
1	O
replication	O
by	O
an	O
antiinflammatory	O
alkaloid	O
,	O
cepharanthine	O
,	O
in	O
chronically	O
infected	O
monocytic	O
cells	O
.	O
Cepharanthine	O
is	O
a	O
biscoclaurine	O
alkaloid	O
isolated	O
from	O
Stephania	O
cepharantha	O
Hayata	O
and	O
has	O
been	O
shown	O
to	O
have	O
antiinflammatory	O
,	O
antiallergic	O
,	O
and	O
immunomodulatory	O
activities	O
in	O
vivo	O
.	O
As	O
several	O
inflammatory	B
cytokines	I
and	O
oxidative	O
stresses	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
HIV-1	O
infection	O
,	O
we	O
investigated	O
the	O
inhibitory	O
effects	O
of	O
cepharanthine	O
on	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	B
-	I
alpha	I
)	O
-	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-induced	O
HIV-1	O
replication	O
in	O
chronically	O
infected	O
cell	O
lines	O
.	O
Two	O
chronically	O
HIV-1-infected	O
cell	O
lines	O
,	O
U1	O
(	O
monocytic	O
)	O
and	O
ACH-2	O
(	O
T	O
lymphocytic	O
)	O
,	O
were	O
stimulated	O
with	O
TNF	B
-	I
alpha	I
or	O
PMA	O
and	O
cultured	O
in	O
the	O
presence	O
of	O
various	O
concentrations	O
of	O
the	O
compound	O
.	O
HIV-1	O
replication	O
was	O
determined	O
by	O
p24	B
antigen	I
level	O
.	O
The	O
inhibitory	O
effects	O
of	O
cepharanthine	O
on	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-driven	O
gene	O
expression	O
and	O
nuclear	B
factor	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
activation	O
were	O
also	O
examined	O
.	O
Cepharanthine	O
dose	O
dependently	O
inhibited	O
HIV-1	O
replication	O
in	O
TNF	O
-	O
alpha-	O
and	O
PMA	O
-	O
stimulated	O
U1	O
cells	O
but	O
not	O
in	O
ACH-2	O
cells	O
.	O
Its	O
50	O
%	O
effective	O
and	O
cytotoxic	O
concentrations	O
were	O
0.016	O
and	O
2.2	O
microg	O
/	O
ml	O
in	O
PMA	O
-	O
stimulated	O
U1	O
cells	O
,	O
respectively	O
.	O
Cepharanthine	O
was	O
found	O
to	O
suppress	O
HIV-1	O
LTR	O
-driven	O
gene	O
expression	O
through	O
the	O
inhibition	O
of	O
NF	B
-	I
kappaB	I
activation	O
.	O
These	O
results	O
indicate	O
that	O
cepharanthine	O
is	O
a	O
highly	O
potent	O
inhibitor	O
of	O
HIV-1	O
replication	O
in	O
a	O
chronically	O
infected	O
monocytic	O
cell	O
line	O
.	O
Since	O
biscoclaurine	O
alkaloids	O
,	O
containing	O
cepharanthine	O
as	O
a	O
major	O
component	O
,	O
are	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
various	O
inflammatory	O
diseases	O
in	O
Japan	O
,	O
cepharanthine	O
should	O
be	O
further	O
pursued	O
for	O
its	O
chemotherapeutic	O
potential	O
in	O
HIV-1-infected	O
patients	O
.	O
Induction	O
of	O
T	O
cell	O
anergy	O
by	O
high	O
concentrations	O
of	O
immunodominant	O
native	O
peptide	O
is	O
accompanied	O
by	O
IL-10	B
production	O
and	O
a	O
block	O
in	O
JNK	B
activity	O
.	O
The	O
ability	O
to	O
induce	O
anergy	O
in	O
antigen	O
-	O
specific	O
T	O
cells	O
has	O
potential	O
therapeutic	O
value	O
for	O
altering	O
pathologic	O
immune	O
responses	O
.	O
This	O
study	O
was	O
undertaken	O
to	O
further	O
analyze	O
changes	O
in	O
cytokine	B
production	O
and	O
intracellular	O
signaling	O
during	O
anergy	O
induction	O
using	O
high	O
concentrations	O
of	O
native	O
peptide	O
ligand	O
of	O
tetanus	O
toxoid	O
(	O
TT	O
)	O
-	O
and	O
myelin	O
basic	O
protein	O
(	O
MBP	O
)	O
-specific	O
human	O
T	O
cell	O
lines	O
.	O
The	O
TT	O
-	O
selected	O
T	O
cell	O
line	O
could	O
be	O
rendered	O
unresponsive	O
to	O
its	O
dominant	O
epitope	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
IC50	O
=	O
0.03	O
microg	O
/	O
ml	O
)	O
.	O
The	O
TT	O
-	O
selected	O
line	O
,	O
as	O
well	O
as	O
three	O
T	O
cell	O
clones	O
established	O
from	O
this	O
line	O
,	O
continued	O
to	O
produce	O
IFN	B
-	I
gamma	I
and	O
significantly	O
increased	O
IL-4	B
and	O
IL-10	B
production	O
when	O
anergy	O
was	O
induced	O
with	O
high	O
concentrations	O
of	O
the	O
immunodominant	O
epitope	O
.	O
JNK	B
enzymatic	O
activity	O
was	O
blocked	O
in	O
anergized	O
T	O
cells	O
.	O
The	O
MBP	B
-selected	O
line	O
could	O
likewise	O
be	O
rendered	O
unresponsive	O
by	O
incubation	O
with	O
supraoptimal	O
concentrations	O
of	O
immunodominant	O
peptide	O
and	O
anergy	O
induction	O
was	O
accompanied	O
by	O
IL-10	B
release	O
.	O
Both	O
T	O
cell	O
lines	O
could	O
be	O
anergized	O
by	O
the	O
autopresentation	O
of	O
native	O
peptide	O
since	O
anergy	O
was	O
induced	O
in	O
cultures	O
lacking	O
fresh	O
antigen	O
-	O
presenting	O
cells	O
.	O
This	O
study	O
shows	O
that	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
cascade	O
is	O
blocked	O
when	O
anergy	O
is	O
induced	O
to	O
high	O
concentrations	O
of	O
soluble	O
peptide	O
.	O
Copyright	O
1998	O
Academic	O
Press	O
.	O
Tumor	B
suppressor	I
proteins	I
as	O
regulators	O
of	O
cell	O
differentiation	O
.	O
The	O
products	O
of	O
the	O
tumor	O
suppressor	O
genes	O
are	O
considered	O
to	O
function	O
as	O
specific	O
inhibitors	O
of	O
tumor	O
cell	O
growth	O
.	O
In	O
this	O
communication	O
,	O
we	O
present	O
evidence	O
to	O
show	O
that	O
these	O
proteins	O
inhibit	O
tumor	O
cell	O
proliferation	O
by	O
participating	O
in	O
the	O
activation	O
of	O
tumor	O
cell	O
differentiation	O
.	O
The	O
ML-1	O
human	O
myeloblastic	O
leukemia	O
cells	O
used	O
in	O
this	O
study	O
proliferate	O
when	O
treated	O
with	O
insulin	B
-	I
like	I
growth	I
factor	I
I	I
and	O
transferrin	B
but	O
differentiate	O
to	O
monocytes	O
when	O
exposed	O
to	O
tumor	B
necrosis	I
factor	I
alpha	I
or	O
transforming	B
growth	I
factor	I
beta1	I
,	O
or	O
to	O
macrophage	O
-	O
like	O
cells	O
when	O
treated	O
with	O
both	O
these	O
cytokines	B
.	O
Initiation	O
of	O
proliferation	O
but	O
not	O
of	O
differentiation	O
was	O
followed	O
by	O
a	O
20-	O
to	O
25-fold	O
increase	O
in	O
the	O
nuclear	O
level	O
of	O
the	O
DNA	B
polymerase	I
-	I
associated	I
processivity	I
factor	I
PCNA	I
and	O
of	O
the	O
proliferation	B
-	I
specific	I
transcription	I
factor	I
E2F1	I
.	O
In	O
contrast	O
,	O
induction	O
of	O
differentiation	O
but	O
not	O
of	O
proliferation	O
was	O
followed	O
by	O
a	O
25-	O
to	O
30-fold	O
increase	O
in	O
the	O
nuclear	O
level	O
of	O
the	O
tumor	B
suppressor	I
proteins	I
p53	I
(	O
wild	O
type	O
)	O
,	O
pRb	B
,	O
and	O
p130	B
/	I
Rb2	I
and	O
of	O
the	O
p53-dependent	B
cyclin	I
kinase	I
inhibitor	I
p21	B
/	I
Cip1	I
.	O
p53	B
and	O
p21	B
/	I
Cip1	I
,	O
respectively	O
,	O
inhibit	O
the	O
expression	O
and	O
activation	O
of	O
PCNA	B
,	O
whereas	O
p130	B
and	O
pRb	B
,	O
respectively	O
,	O
inhibit	O
the	O
expression	O
and	O
activation	O
of	O
E2F1	B
.	O
As	O
a	O
result	O
,	O
G1-S	O
-	O
associated	O
DNA	O
and	O
mRNA	O
synthesis	O
is	O
inhibited	O
,	O
growth	O
uncoupled	O
from	O
differentiation	O
,	O
and	O
maturation	O
enabled	O
to	O
proceed	O
.	O
Where	O
this	O
function	O
of	O
the	O
tumor	B
suppressor	I
proteins	I
is	O
impaired	O
,	O
the	O
capacity	O
for	O
differentiation	O
is	O
lost	O
,	O
which	O
leads	O
to	O
the	O
sustained	O
proliferation	O
that	O
is	O
characteristic	O
of	O
the	O
cancer	O
cell	O
.	O
Fcgamma	B
receptor	I
-mediated	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
activation	O
in	O
monocytes	O
is	O
independent	O
of	O
Ras	B
.	O
Receptors	O
for	O
the	O
Fc	B
portion	I
of	O
immunoglobulin	B
molecules	I
(	O
FcR	B
)	O
present	O
on	O
leukocyte	O
cell	O
membranes	O
mediate	O
a	O
large	O
number	O
of	O
cellular	O
responses	O
that	O
are	O
very	O
important	O
in	O
host	O
defense	O
,	O
including	O
phagocytosis	O
,	O
cell	O
cytotoxicity	O
,	O
production	O
and	O
secretion	O
of	O
inflammatory	B
mediators	I
,	O
and	O
modulation	O
of	O
the	O
immune	O
response	O
.	O
Cross	O
-	O
linking	O
of	O
FcR	B
with	O
immune	B
complexes	I
leads	O
,	O
first	O
to	O
activation	O
of	O
protein	B
-	I
tyrosine	I
kinases	I
.	O
The	O
molecular	O
events	O
that	O
follow	O
and	O
that	O
transduce	O
signals	O
from	O
these	O
receptors	O
to	O
the	O
nucleus	O
are	O
still	O
poorly	O
defined	O
.	O
We	O
have	O
investigated	O
the	O
signal	O
transduction	O
pathway	O
from	O
Fc	B
receptors	I
that	O
leads	O
to	O
gene	O
activation	O
and	O
production	O
of	O
cytokines	B
in	O
monocytes	O
.	O
Cross	O
-	O
linking	O
of	O
FcR	B
,	O
on	O
the	O
THP-1	O
monocytic	O
cell	O
line	O
,	O
by	O
immune	B
complexes	I
resulted	O
in	O
both	O
activation	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
and	O
interleukin	B
1	I
production	O
.	O
These	O
responses	O
were	O
completely	O
blocked	O
by	O
tyrosine	B
kinase	I
inhibitors	O
.	O
In	O
contrast	O
,	O
expression	O
of	O
dominant	B
negative	I
mutants	I
of	O
Ras	B
and	O
Raf-1	B
,	O
in	O
these	O
cells	O
,	O
did	O
not	O
have	O
any	O
effect	O
on	O
FcR	B
-mediated	O
nuclear	B
factor	I
activation	O
,	O
suggesting	O
that	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
signaling	O
pathway	O
was	O
not	O
used	O
by	O
these	O
receptors	O
.	O
However	O
,	O
MAPK	B
activation	O
was	O
easily	O
detected	O
by	O
in	O
vitro	O
kinase	O
assays	O
,	O
after	O
FcR	B
cross	O
-	O
linking	O
with	O
immune	B
complexes	I
.	O
Using	O
the	O
specific	O
MAPK	B
/extracellular	O
signal	O
-	O
regulated	O
kinase	O
kinase	O
(	O
MAPK	O
kinase	O
)	O
inhibitor	O
PD98059	O
,	O
we	O
found	O
that	O
MAPK	B
activation	O
is	O
necessary	O
for	O
FcR	B
-dependent	O
activation	O
of	O
the	O
nuclear	B
factor	I
NF	B
-	I
kappaB	I
.	O
These	O
results	O
strongly	O
suggest	O
that	O
the	O
signaling	O
pathway	O
from	O
Fc	B
receptors	I
leading	O
to	O
expression	O
of	O
different	O
genes	O
important	O
to	O
leukocyte	O
biology	O
,	O
initiates	O
with	O
tyrosine	B
kinases	I
and	O
requires	O
MAPK	B
activation	O
;	O
but	O
in	O
contrast	O
to	O
other	O
tyrosine	B
kinase	I
receptors	I
,	O
FcR	B
-mediated	O
MAPK	B
activation	O
does	O
not	O
involve	O
Ras	B
and	O
Raf	B
.	O
A	O
critical	O
role	O
of	O
the	O
p75	B
tumor	I
necrosis	I
factor	I
receptor	I
(	O
p75TNF	B
-	I
R	I
)	O
in	O
organ	O
inflammation	O
independent	O
of	O
TNF	B
,	O
lymphotoxin	B
alpha	I
,	O
or	O
the	O
p55TNF	B
-	I
R	I
.	I
Despite	O
overwhelming	O
evidence	O
that	O
enhanced	O
production	O
of	O
the	O
p75	B
tumor	I
necrosis	I
factor	I
receptor	I
(	O
p75TNF	B
-	I
R	I
)	O
accompanies	O
development	O
of	O
specific	O
human	O
inflammatory	O
pathologies	O
such	O
as	O
multi	O
-	O
organ	O
failure	O
during	O
sepsis	O
,	O
inflammatory	O
liver	O
disease	O
,	O
pancreatitis	O
,	O
respiratory	O
distress	O
syndrome	O
,	O
or	O
AIDS	O
,	O
the	O
function	O
of	O
this	O
receptor	O
remains	O
poorly	O
defined	O
in	O
vivo	O
.	O
We	O
show	O
here	O
that	O
at	O
levels	O
relevant	O
to	O
human	O
disease	O
,	O
production	O
of	O
the	O
human	B
p75TNF	I
-	I
R	I
in	O
transgenic	O
mice	O
results	O
in	O
a	O
severe	O
inflammatory	O
syndrome	O
involving	O
mainly	O
the	O
pancreas	O
,	O
liver	O
,	O
kidney	O
,	O
and	O
lung	O
,	O
and	O
characterized	O
by	O
constitutively	O
increased	O
NF	B
-	I
kappaB	I
activity	O
in	O
the	O
peripheral	O
blood	O
mononuclear	O
cell	O
compartment	O
.	O
This	O
process	O
is	O
shown	O
to	O
evolve	O
independently	O
of	O
the	O
presence	O
of	O
TNF	B
,	O
lymphotoxin	B
alpha	I
,	O
or	O
the	O
p55TNF	B
-	I
R	I
,	O
although	O
coexpression	O
of	O
a	O
human	O
TNF	O
transgene	O
accelerated	O
pathology	O
.	O
These	O
results	O
establish	O
an	O
independent	O
role	O
for	O
enhanced	O
p75TNF	B
-	I
R	I
production	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
disease	O
and	O
implicate	O
the	O
direct	O
involvement	O
of	O
this	O
receptor	O
in	O
a	O
wide	O
range	O
of	O
human	O
inflammatory	O
pathologies	O
.	O
musculin	O
:	O
a	O
murine	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
transcription	O
factor	O
gene	O
expressed	O
in	O
embryonic	O
skeletal	O
muscle	O
.	O
We	O
describe	O
the	O
embryonic	O
expression	O
of	O
musculin	B
,	O
a	O
new	O
murine	O
member	O
of	O
the	O
bHLH	B
family	I
of	O
transcription	B
factors	I
.	O
Musculin	O
protein	O
is	O
closely	O
related	O
to	O
human	B
ABF-1	I
,	O
which	O
is	O
expressed	O
in	O
activated	O
B	O
cells	O
,	O
and	O
to	O
epicardin	B
/	I
capsulin	I
/	I
Pod-1	I
,	O
which	O
is	O
expressed	O
in	O
branchial	O
myoblasts	O
,	O
visceral	O
and	O
urogenital	O
mesoderm	O
and	O
epicardium	O
.	O
In	O
situ	O
hybridisation	O
revealed	O
musculin	B
expression	O
in	O
embryos	O
was	O
largely	O
restricted	O
to	O
the	O
embryonic	O
skeletal	O
muscle	O
lineage	O
.	O
While	O
all	O
skeletal	O
muscles	O
expressed	O
the	O
gene	O
,	O
only	O
a	O
subset	O
of	O
myocytes	O
within	O
each	O
muscle	O
were	O
positive	O
,	O
indicating	O
molecular	O
heterogeneity	O
within	O
fetal	O
muscle	O
.	O
Copyright	O
1998	O
Elsevier	O
Science	O
Ireland	O
Ltd	O
.	O
All	O
Rights	O
Reserved	O
.	O
CD4	O
promoter	O
transactivation	O
by	O
human	O
herpesvirus	O
6	O
.	O
The	O
observation	O
that	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
can	O
induce	O
CD4	O
gene	O
transcription	O
and	O
expression	O
in	O
CD4	O
(	O
-	O
)	O
cells	O
was	O
reported	O
several	O
years	O
ago	O
(	O
P.Lusso	O
,	O
A.De	O
Maria	O
,	O
M.Malnati	O
,	O
F.Lori	O
,	O
S.E.DeRocco	O
,	O
M.	O
Baseler	O
,	O
and	O
R.C.Gallo	O
,	O
Nature	O
349	O
:	O
533	O
-	O
535	O
,	O
1991	O
)	O
and	O
subsequently	O
confirmed	O
(	O
P.Lusso	O
,	O
M.S.Malnati	O
,	O
A.Garzino	O
-	O
Demo	O
,	O
R.W.Crowley	O
,	O
E.	O
O.Long	O
,	O
and	O
R.C.Gallo	O
,	O
Nature	O
362	O
:	O
458	O
-	O
462	O
,	O
1993	O
;	O
G.Furlini	O
,	O
M.	O
Vignoli	O
,	O
E.Ramazzotti	O
,	O
M.C.Re	O
,	O
G.Visani	O
,	O
and	O
M.LaPlaca	O
,	O
Blood	O
87	O
:	O
4737	O
-	O
4745	O
,	O
1996	O
)	O
.	O
Our	O
objective	O
was	O
to	O
identify	O
the	O
mechanisms	O
underlying	O
such	O
phenomena	O
.	O
Using	O
reporter	O
gene	O
constructs	O
driven	O
by	O
the	O
CD4	O
promoter	O
,	O
we	O
report	O
that	O
HHV-6	O
can	O
efficiently	O
transactivate	O
such	O
genetic	O
elements	O
.	O
Activation	O
of	O
the	O
CD4	O
promoter	O
occurs	O
in	O
the	O
presence	O
of	O
the	O
viral	O
DNA	O
polymerase	O
inhibitor	O
phosphonoformic	O
acid	O
,	O
which	O
limits	O
expression	O
to	O
the	O
immediate	O
-	O
early	O
and	O
early	O
classes	O
of	O
viral	O
genes	O
.	O
Using	O
deletion	O
mutants	O
and	O
specific	O
CD4	O
promoter	O
mutants	O
,	O
we	O
identified	O
an	O
ATF	O
/	O
CRE	O
binding	O
site	O
located	O
at	O
nucleotides	O
-67	O
to	O
-60	O
upstream	O
of	O
the	O
CD4	O
gene	O
transcription	O
start	O
site	O
that	O
is	O
important	O
for	O
HHV-6	O
transactivation	O
.	O
The	O
ATF	O
/	O
CRE	O
site	O
is	O
also	O
essential	O
for	O
CD4	O
promoter	O
activation	O
by	O
forskolin	O
,	O
an	O
activator	O
of	O
adenylate	O
cyclase	O
.	O
Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
specific	O
antibodies	O
,	O
we	O
showed	O
that	O
CREB-1	B
binds	O
specifically	O
to	O
the	O
-79	O
to	O
-52	O
region	O
of	O
the	O
CD4	O
promoter	O
.	O
Last	O
,	O
we	O
have	O
identified	O
two	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
of	O
HHV-6	O
,	O
U86	O
and	O
U89	O
from	O
the	O
immediate	O
-	O
early	O
locus	O
A	O
,	O
that	O
can	O
transactivate	O
the	O
CD4	O
promoter	O
in	O
HeLa	O
cells	O
.	O
However	O
,	O
transactivation	O
of	O
the	O
CD4	O
promoter	O
by	O
ORFs	O
U86	O
and	O
U89	O
is	O
independent	O
of	O
the	O
CRE	O
element	O
,	O
suggesting	O
that	O
additional	O
HHV-6	O
ORFs	O
are	O
likely	O
to	O
contribute	O
to	O
CD4	O
gene	O
activation	O
.	O
Taken	O
together	O
,	O
our	O
results	O
will	O
help	O
to	O
understand	O
the	O
complex	O
interactions	O
occurring	O
between	O
HHV-6	O
and	O
the	O
CD4	O
promoter	O
and	O
provide	O
additional	O
information	O
regarding	O
the	O
class	O
of	O
transcription	B
factors	I
involved	O
in	O
the	O
control	O
of	O
CD4	O
gene	O
expression	O
.	O
Cross	O
-	O
priming	O
of	O
CTL	O
responses	O
in	O
vivo	O
does	O
not	O
require	O
antigenic	O
peptides	O
in	O
the	O
endoplasmic	O
reticulum	O
of	O
immunizing	O
cells	O
.	O
It	O
has	O
been	O
proposed	O
that	O
the	O
cross	O
-	O
priming	O
of	O
CTL	O
responses	O
in	O
vivo	O
involves	O
the	O
transfer	O
to	O
host	O
APCs	O
of	O
heat	B
shock	I
protein	I
glycoprotein	I
96	I
-chaperoned	O
antigenic	O
peptides	O
released	O
from	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
of	O
dying	O
or	O
infected	O
cells	O
.	O
We	O
have	O
tested	O
this	O
possibility	O
directly	O
using	O
TAP	O
-	O
deficient	O
cell	O
lines	O
lacking	O
antigenic	O
ER	O
peptides	O
derived	O
from	O
two	O
model	O
Ags	B
,	O
the	O
human	B
adenovirus	I
type	I
5	I
early	I
regions	I
E1A	I
and	I
E1B	I
.	O
Although	O
both	O
proteins	O
were	O
well	O
expressed	O
,	O
the	O
cells	O
were	O
not	O
recognized	O
by	O
E1A-	O
or	O
E1B	O
-	O
specific	O
CTLs	O
unless	O
the	O
relevant	O
epitope	O
was	O
either	O
provided	O
exogenously	O
as	O
a	O
synthetic	O
peptide	O
or	O
targeted	O
to	O
the	O
ER	O
in	O
a	O
TAP	O
-	O
independent	O
fashion	O
.	O
Despite	O
the	O
absence	O
of	O
these	O
ER	O
peptides	O
,	O
the	O
TAP1-	O
/	O
-	O
cells	O
were	O
able	O
to	O
efficiently	O
cross	O
-	O
prime	O
E1A-	O
and	O
E1B	O
-	O
specific	O
CTLs	O
following	O
immunization	O
of	O
syngeneic	O
mice	O
.	O
These	O
results	O
indicate	O
that	O
,	O
although	O
purified	O
peptide	B
/	I
glycoprotein	I
96	I
complexes	I
are	O
potent	O
immunogens	O
,	O
the	O
mechanism	O
of	O
CTL	O
cross	O
-	O
priming	O
in	O
vivo	O
does	O
not	O
depend	O
upon	O
antigenic	O
peptides	O
in	O
the	O
ER	O
of	O
immunizing	O
cells	O
.	O
Differential	O
responsiveness	O
of	O
the	O
IL-5	O
and	O
IL-4	O
genes	O
to	O
transcription	B
factor	I
GATA-3	I
.	O
The	O
cytokines	B
IL-4	B
and	O
IL-5	B
are	O
often	O
coordinately	O
produced	O
by	O
Th2	O
cells	O
as	O
in	O
asthma	O
.	O
However	O
,	O
it	O
is	O
unclear	O
whether	O
similar	O
molecular	O
mechanisms	O
underlie	O
transcription	O
of	O
the	O
two	O
genes	O
.	O
We	O
have	O
previously	O
shown	O
that	O
the	O
transcription	B
factor	I
GATA-3	I
is	O
expressed	O
in	O
Th2	O
but	O
not	O
Th1	O
cells	O
and	O
is	O
crucial	O
for	O
activation	O
of	O
the	O
IL-5	O
promoter	O
by	O
different	O
stimuli	O
.	O
In	O
a	O
different	O
study	O
,	O
GATA-3	B
was	O
shown	O
to	O
be	O
sufficient	O
for	O
the	O
expression	O
of	O
IL-4	B
and	O
other	O
Th2	O
cytokine	O
genes	O
.	O
Here	O
,	O
we	O
show	O
that	O
ectopic	O
expression	O
of	O
GATA-3	B
is	O
sufficient	O
to	O
drive	O
IL-5	B
but	O
not	O
IL-4	B
gene	O
expression	O
.	O
Also	O
,	O
in	O
Th2	O
cells	O
,	O
antisense	O
GATA-3	B
RNA	O
inhibits	O
IL-5	B
but	O
not	O
IL-4	B
promoter	O
activation	O
.	O
The	O
induction	O
of	O
IL-5	O
gene	O
expression	O
by	O
GATA-3	B
involves	O
high	O
affinity	O
binding	O
of	O
GATA-3	B
to	O
an	O
inverted	O
GATA	O
repeat	O
in	O
the	O
IL-5	O
promoter	O
.	O
Seminoma	O
in	O
a	O
postmenopausal	O
woman	O
with	O
a	O
Y	O
;	O
15	O
translocation	O
in	O
peripheral	O
blood	O
lymphocytes	O
and	O
a	O
t	O
(	O
Y	O
;	O
15	O
)	O
/45	O
,	O
X	O
Turner	O
mosaic	O
pattern	O
in	O
skin	O
fibroblasts	O
.	O
We	O
report	O
an	O
unusual	O
case	O
of	O
a	O
55	O
year	O
old	O
Japanese	O
woman	O
with	O
a	O
seminoma	O
but	O
relatively	O
normal	O
menses	O
.	O
The	O
patient	O
was	O
a	O
phenotypic	O
female	O
with	O
late	O
onset	O
menarche	O
(	O
18	O
years	O
of	O
age	O
)	O
,	O
who	O
was	O
amenorrhoeic	O
for	O
the	O
first	O
year	O
,	O
followed	O
by	O
menses	O
of	O
one	O
to	O
three	O
days	O
'	O
slight	O
flow	O
with	O
dysmenorrhoea	O
,	O
but	O
an	O
otherwise	O
normal	O
menstrual	O
history	O
.	O
A	O
typical	O
seminoma	O
was	O
removed	O
from	O
the	O
left	O
adnexal	O
region	O
and	O
an	O
immature	O
testis	O
was	O
identified	O
separately	O
as	O
an	O
associated	O
right	O
adnexal	O
mass	O
.	O
Repeated	O
karyotypic	O
studies	O
on	O
peripheral	O
blood	O
lymphocyte	O
cultures	O
showed	O
only	O
46	O
,	O
X	O
,	O
-Y	O
,	O
t	O
(	O
Y	O
;	O
15	O
)	O
(	O
q12	O
;	O
p13	O
)	O
.	O
Cytogenetic	O
examination	O
of	O
the	O
patient	O
's	O
younger	O
brother	O
,	O
who	O
had	O
fathered	O
three	O
healthy	O
children	O
,	O
showed	O
an	O
identical	O
karyotype	O
.	O
Mosaicism	O
of	O
46	O
,	O
X	O
,	O
-Y	O
,	O
t	O
(	O
Y	O
;	O
15	O
)	O
(	O
q12	O
;	O
p13	O
)	O
/45	O
,	O
X	O
cell	O
lines	O
was	O
found	O
in	O
skin	O
samples	O
from	O
the	O
patient	O
's	O
elbow	O
and	O
genital	O
regions	O
,	O
although	O
there	O
were	O
no	O
clinical	O
stigmata	O
of	O
Turner	O
syndrome	O
.	O
An	O
androgen	O
receptor	O
binding	O
assay	O
of	O
cultured	O
genital	O
skin	O
fibroblasts	O
was	O
negative	O
.	O
Molecular	O
analysis	O
using	O
Southern	O
blot	O
hybridisation	O
,	O
PCR	O
,	O
and	O
direct	O
DNA	O
sequencing	O
showed	O
that	O
neither	O
the	O
patient	O
nor	O
her	O
brother	O
had	O
a	O
detectable	O
deletion	O
or	O
other	O
abnormalities	O
of	O
Y	O
chromosome	O
sequences	O
,	O
including	O
the	O
SRY	O
(	O
sex	O
determining	O
region	O
of	O
the	O
Y	O
chromosome	O
)	O
gene	O
sequence	O
.	O
These	O
findings	O
suggest	O
that	O
Turner	O
mosaicism	O
of	O
the	O
45	O
,	O
X	O
cell	O
line	O
may	O
have	O
contributed	O
to	O
this	O
atypical	O
presentation	O
in	O
an	O
XY	O
female	O
,	O
although	O
we	O
can	O
not	O
exclude	O
abnormalities	O
of	O
other	O
genes	O
related	O
to	O
sex	O
differentiation	O
.	O
Differential	O
RNA	O
display	O
identifies	O
novel	O
genes	O
associated	O
with	O
decreased	O
vitamin	B
D	I
receptor	I
expression	O
.	O
To	O
characterize	O
further	O
the	O
function	O
of	O
the	O
intracellular	B
vitamin	I
D	I
receptor	I
(	O
VDR	B
)	O
,	O
we	O
have	O
developed	O
stable	O
transfectant	O
variants	O
of	O
a	O
vitamin	O
D	O
-	O
responsive	O
cell	O
line	O
(	O
U937	O
)	O
which	O
express	O
either	O
decreased	O
or	O
increased	O
numbers	O
of	O
VDR	B
.	O
In	O
this	O
study	O
we	O
have	O
analyzed	O
changes	O
in	O
gene	O
expression	O
associated	O
with	O
this	O
variable	O
VDR	B
expression	O
.	O
Initial	O
experiments	O
indicated	O
that	O
a	O
50	O
%	O
decrease	O
in	O
VDR	B
levels	O
was	O
associated	O
with	O
a	O
2-fold	O
increase	O
in	O
cell	O
proliferation	O
and	O
a	O
similar	O
rise	O
in	O
c	O
-	O
myc	O
mRNA	O
expression	O
.	O
Further	O
studies	O
were	O
carried	O
out	O
using	O
differential	O
RNA	O
display	O
(	O
DD	O
)	O
.	O
Sequence	O
analysis	O
of	O
DD	B
products	I
revealed	O
two	O
cDNAs	O
with	O
identity	O
to	O
known	B
gene	I
products	I
:	O
the	O
catalytic	B
sub	I
-	I
unit	I
of	I
DNA	I
-	I
protein	I
kinase	I
(	O
DNA	B
-	I
PK	I
(	I
CS	I
)	I
)	O
,	O
and	O
the	O
peroxisomal	B
enzyme	I
17beta	I
-	I
hydroxysteroid	I
dehydrogenase	I
type	I
IV	I
(	O
17beta	B
-	I
HSD	I
IV	I
)	O
.	O
Northern	O
analysis	O
confirmed	O
that	O
expression	O
of	O
both	O
mRNAs	O
was	O
reduced	O
in	O
cells	O
with	O
decreased	O
numbers	O
of	O
VDR	B
.	O
Down	O
-	O
regulation	O
of	O
17beta	B
-	I
HSD	I
IV	I
mRNA	O
expression	O
was	O
associated	O
with	O
enhanced	O
estradiol	O
inactivation	O
by	O
U937	O
cells	O
,	O
suggesting	O
a	O
link	O
between	O
estrogenic	O
pathways	O
and	O
cell	O
proliferation	O
.	O
Further	O
Northern	O
analyses	O
indicated	O
that	O
there	O
was	O
no	O
significant	O
change	O
in	O
17beta	B
-	I
HSD	I
IV	I
or	O
DNA	O
-	O
PK	O
(	O
CS	O
)	O
mRNA	O
levels	O
following	O
treatment	O
with	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
,	O
although	O
expression	O
of	O
both	O
genes	O
varied	O
with	O
changes	O
in	O
cell	O
proliferation	O
.	O
These	O
data	O
suggest	O
that	O
,	O
in	O
addition	O
to	O
its	O
established	O
role	O
as	O
a	O
hormone	B
-	I
dependent	I
trans	I
-	I
activator	I
,	O
VDR	B
may	O
influence	O
gene	O
expression	O
by	O
ligand	O
-	O
independent	O
mechanisms	O
.	O
The	O
role	O
of	O
caspases	O
in	O
T	O
cell	O
development	O
and	O
the	O
control	O
of	O
immune	O
responses	O
.	O
Apoptosis	O
is	O
responsible	O
for	O
the	O
removal	O
of	O
potentially	O
autoreactive	O
or	O
useless	O
T	O
cells	O
during	O
thymic	O
selection	O
and	O
activated	O
T	O
cells	O
in	O
the	O
periphery	O
.	O
Specific	O
families	O
of	O
receptors	B
,	O
kinases	B
,	O
transcription	B
factors	I
,	O
and	O
cysteine	B
proteases	I
,	O
termed	B
caspases	I
,	O
are	O
involved	O
in	O
the	O
apoptotic	O
cascade	O
leading	O
to	O
proteolysis	O
of	O
specific	O
substrates	O
and	O
to	O
morphological	O
changes	O
associated	O
with	O
programmed	O
cell	O
death	O
.	O
Although	O
common	O
members	O
of	O
the	O
apoptotic	O
cascade	O
are	O
shared	O
between	O
different	O
cell	O
types	O
,	O
it	O
appears	O
that	O
cell	B
-	I
specific	I
factors	I
can	O
influence	O
the	O
response	O
to	O
a	O
given	O
apoptotic	O
stimuli	O
.	O
Characterization	O
and	O
understanding	O
of	O
the	O
basic	O
mechanisms	O
involved	O
in	O
the	O
different	O
pathways	O
protecting	O
or	O
leading	O
to	O
cell	O
death	O
may	O
provide	O
novel	O
ways	O
to	O
control	O
inappropriate	O
apoptosis	O
involved	O
in	O
several	O
diseases	O
.	O
Relationship	O
between	O
IkappaBalpha	B
constitutive	O
expression	O
,	O
TNFalpha	B
synthesis	O
,	O
and	O
apoptosis	O
in	O
EBV	O
-	O
infected	O
lymphoblastoid	O
cells	O
.	O
In	O
order	O
to	O
understand	O
the	O
role	O
of	O
NF	B
-	I
kappaB	I
in	O
EBV	O
transformation	O
we	O
have	O
established	O
stably	O
transfected	O
IkappaBalpha	B
into	O
lymphoblastoid	O
cells	O
.	O
Two	O
clones	O
were	O
obtained	O
in	O
which	O
the	O
loss	O
of	O
NF	B
-	I
kappaB	I
binding	O
activity	O
correlated	O
with	O
the	O
constitutive	O
expression	O
of	O
the	O
transgenic	O
IkappaBalpha	B
.	O
Protein	O
latency	O
expression	O
was	O
determined	O
by	O
immunocytochemistry	O
.	O
Expression	O
of	O
surface	O
markers	O
,	O
intracytoplasmic	O
content	O
of	O
cytokines	B
cell	O
cycle	O
analysis	O
after	O
BrdU	B
incorporation	O
and	O
DNA	O
staining	O
with	O
propidium	O
iodide	O
were	O
studied	O
by	O
flow	O
cytometry	O
.	O
Percentage	O
of	O
apoptotic	O
cells	O
was	O
determined	O
by	O
in	O
-	O
situ	O
labelling	O
of	O
DNA	O
strand	O
breaks	O
.	O
No	O
significative	O
changes	O
in	O
EBV	O
latency	O
nor	O
in	O
cell	O
surface	O
marker	O
expression	O
was	O
found	O
.	O
In	O
contrast	O
,	O
intracytoplasmic	O
TNFalpha	B
levels	O
were	O
strongly	O
reduced	O
in	O
transfected	O
clones	O
.	O
Furthermore	O
,	O
30	O
%	O
of	O
IkappaBalpha	O
transfected	O
cells	O
were	O
apoptotic	O
after	O
8	O
h	O
of	O
TNFalpha	B
treatment	O
.	O
This	O
correlated	O
with	O
a	O
strong	O
reduction	O
of	O
BrdU	O
incorporation	O
after	O
24	O
h	O
of	O
TNFalpha	B
treatment	O
.	O
No	O
effect	O
was	O
seen	O
with	O
non	O
transfected	O
cells	O
or	O
with	O
cells	O
transfected	O
with	O
a	O
control	O
plasmid	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
TNFalpha	O
gene	O
could	O
be	O
one	O
of	O
the	O
targets	O
of	O
NF	B
-	I
kappaB	I
in	O
EBV	O
infected	O
cells	O
and	O
that	O
NF	O
-	O
kappaB	O
protects	O
EBV	O
-	O
infected	O
cells	O
from	O
apoptosis	O
induced	O
by	O
TNFalpha	B
,	O
which	O
may	O
favour	O
the	O
proliferative	O
effect	O
of	O
this	O
cytokine	B
.	O
Uncoupling	O
activation	O
-	O
dependent	O
HS1	B
phosphorylation	O
from	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
transcriptional	O
activation	O
in	O
Jurkat	O
T	O
cells	O
:	O
differential	O
signaling	O
through	O
CD3	B
and	O
the	O
costimulatory	O
receptors	O
CD2	B
and	O
CD28	B
.	O
CD3	B
,	O
CD2	B
,	O
and	O
CD28	B
are	O
functionally	O
distinct	O
receptors	O
on	O
T	O
lymphocytes	O
.	O
Engagement	O
of	O
any	O
of	O
these	O
receptors	O
induces	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
a	O
shared	O
group	O
of	O
intracellular	B
signaling	I
proteins	I
,	O
including	O
Vav	B
,	O
Cbl	B
,	O
p85	B
phosphoinositide	I
3-kinase	I
,	O
and	O
the	O
Src	B
family	I
kinases	I
Lck	B
and	O
Fyn	B
.	O
Ligation	O
of	O
CD3	B
also	O
induces	O
the	O
tyrosine	O
phosphorylation	O
of	O
HS1	B
,	O
a	O
75-kDa	B
hematopoietic	I
cell	I
-	I
specific	I
intracellular	I
signaling	I
protein	I
of	O
unknown	O
function	O
.	O
We	O
have	O
examined	O
changes	O
in	O
HS1	B
phosphorylation	O
after	O
differential	O
stimulation	O
of	O
CD3	B
,	O
CD2	B
,	O
and	O
CD28	B
to	O
elucidate	O
its	O
role	O
in	O
T	O
cells	O
and	O
to	O
further	O
delineate	O
the	O
signaling	O
pathways	O
recruited	O
by	O
these	O
receptors	O
.	O
Unlike	O
ligation	O
of	O
CD3	B
,	O
stimulation	O
with	O
anti	B
-	I
CD28	I
mAb	I
or	O
CHO	O
cells	O
expressing	O
the	O
CD28	B
ligands	I
CD80	B
or	O
CD86	B
did	O
not	O
lead	O
to	O
tyrosine	O
phosphorylation	O
of	O
HS1	B
in	O
Jurkat	O
T	O
cells	O
.	O
Additionally	O
,	O
no	O
tyrosine	O
phosphorylation	O
of	O
HS1	B
was	O
induced	O
by	O
mitogenic	O
pairs	O
of	O
anti	B
-	I
CD2	I
mAbs	I
capable	O
of	O
activating	O
the	O
transcription	B
factor	I
NFAT	I
(	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
)	O
.	O
Costimulation	O
through	O
CD28	B
and/or	O
CD2	B
did	O
not	O
modulate	O
the	O
CD3	B
-dependent	O
phosphorylation	O
of	O
HS1	B
.	O
In	O
vivo	O
studies	O
indicated	O
that	O
CD3	B
-induced	O
HSI	B
phosphorylation	O
was	O
dependent	O
upon	O
both	O
the	O
Src	B
family	I
tyrosine	I
kinase	I
Lck	B
and	O
the	O
tyrosine	B
phosphatase	I
CD45	B
,	O
did	O
not	O
require	O
MEK1	B
kinase	O
activity	O
,	O
and	O
was	O
regulated	O
by	O
protein	B
kinase	I
C	I
activation	O
.	O
Thus	O
,	O
although	O
CD3	B
,	O
CD28	B
,	O
and	O
CD2	O
activate	O
many	O
of	O
the	O
same	O
signaling	B
molecules	I
,	O
they	O
differed	O
in	O
their	O
capacity	O
to	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
HSI	B
.	O
Furthermore	O
,	O
activation	O
-	O
dependent	O
tyrosine	O
phosphorylation	O
of	O
HS1	B
was	O
not	O
required	O
for	O
NFAT	B
transcriptional	O
activation	O
.	O
A	O
mouse	O
carrying	O
genetic	O
defect	O
in	O
the	O
choice	O
between	O
T	O
and	O
B	O
lymphocytes	O
.	O
Transgenic	O
mice	O
with	O
human	O
CD3epsilon	O
gene	O
have	O
been	O
shown	O
to	O
exhibit	O
early	O
arrest	O
of	O
T	O
cell	O
development	O
in	O
the	O
thymus	O
.	O
The	O
present	O
study	O
shows	O
that	O
,	O
instead	O
of	O
T	O
cells	O
,	O
B	O
cells	O
are	O
generated	O
in	O
the	O
thymus	O
of	O
a	O
line	O
,	O
tg	O
epsilon26	O
,	O
of	O
the	O
human	O
CD3epsilon	O
transgenic	O
mice	O
.	O
The	O
accumulation	O
of	O
mature	O
B	O
cells	O
in	O
the	O
thymus	O
was	O
found	O
only	O
in	O
tg	O
epsilon26	O
mice	O
,	O
not	O
in	O
other	O
human	O
CD3epsilon	O
transgenic	O
mouse	O
lines	O
or	O
other	O
T	O
cell	O
-	O
deficient	O
mice	O
,	O
including	O
CD3-epsilon	O
knockout	O
mice	O
and	O
TCR	O
-	O
beta	O
/	O
TCR	O
-	O
delta	O
double	O
knockout	O
mice	O
.	O
Hanging	O
drop	O
-	O
mediated	O
transfer	O
into	O
2-deoxyguanosine	O
-	O
treated	O
thymus	O
lobes	O
showed	O
that	O
lymphoid	O
progenitor	O
cells	O
rather	O
than	O
thymus	O
stromal	O
cells	O
were	O
responsible	O
for	O
abnormal	O
B	O
cell	O
development	O
in	O
tg	B
epsilon26	I
thymus	O
,	O
and	O
that	O
tg	O
epsilon26	O
fetal	O
liver	O
cells	O
were	O
destined	O
to	O
become	O
B	O
cells	O
in	O
normal	O
thymus	O
even	O
in	O
the	O
presence	O
of	O
normal	O
progenitor	O
cells	O
undergoing	O
T	O
cell	O
development	O
.	O
These	O
results	O
indicate	O
that	O
lymphoid	O
progenitor	O
cells	O
in	O
tg	B
epsilon26	I
mice	O
are	O
genetically	O
defective	O
in	O
thymic	O
choice	O
between	O
T	O
cells	O
and	O
B	O
cells	O
,	O
generating	O
B	O
cells	O
even	O
in	O
normal	O
thymus	O
environment	O
.	O
Interestingly	O
,	O
tg	O
epsilon26	O
thymocytes	O
expressed	O
GATA-3	B
and	O
TCF-1	B
,	O
but	O
not	O
LEF-1	B
and	O
PEBP-2alpha	B
,	O
among	O
T	B
cell	I
-	I
specific	I
transcription	I
factors	I
that	O
are	O
involved	O
in	O
early	O
T	O
cell	O
development	O
,	O
indicating	O
that	O
GATA-3	B
and	O
TCF-1	B
expressed	O
during	O
thymocyte	O
development	O
do	O
not	O
necessarily	O
determine	O
the	O
cell	O
fate	O
into	O
T	O
cell	O
lineage	O
.	O
Thus	O
,	O
tg	B
epsilon26	I
mice	O
provide	O
a	O
novel	O
mouse	O
model	O
in	O
that	O
lineage	O
choice	O
between	O
T	O
and	O
B	O
lymphocytes	O
is	O
genetically	O
defective	O
.	O
The	O
role	O
of	O
protein	B
kinase	I
C	I
signaling	O
in	O
activated	O
DRA	O
transcription	O
.	O
Expression	O
of	O
human	O
MHC	O
HLA	O
-	O
DRA	O
class	O
II	O
gene	O
can	O
be	O
up	O
-	O
regulated	O
in	O
B	O
cells	O
by	O
Ig	O
cross	O
-	O
linking	O
as	O
well	O
as	O
by	O
phorbol	O
esters	O
such	O
as	O
12-O	O
-	O
tetradecanoyl	O
phorbol	O
13-acetate	O
(	O
TPA	O
)	O
.	O
Induced	O
DRA	O
expression	O
involves	O
activation	O
of	O
restricted	B
protein	I
kinase	I
C	I
(	I
PKC	I
)	I
isoforms	I
,	O
resulting	O
in	O
activated	O
activator	O
protein-1	B
-dependent	O
transcription	O
.	O
In	O
this	O
report	O
expression	O
profiles	O
and	O
activation	O
of	O
PKC	B
were	O
analyzed	O
in	O
human	O
Raji	O
B	O
lymphoblastoid	O
cells	O
.	O
Transient	O
transfection	O
analysis	O
with	O
target	O
plasmids	O
containing	O
either	O
DRA	O
promoter	O
(	O
wild	O
-	O
type	O
or	O
mutated	O
)	O
or	O
TPA	O
response	O
elements	O
demonstrated	O
that	O
pretreatment	O
with	O
the	O
selective	O
PKC	B
inhibitor	O
GF	O
109203X	O
repressed	O
TPA	O
-	O
mediated	O
activation	O
.	O
Western	O
analysis	O
performed	O
on	O
cellular	O
fractions	O
of	O
resting	O
cells	O
and	O
of	O
TPA	O
-	O
activated	O
cells	O
revealed	O
abundant	O
expression	O
of	O
classical	B
PKC	I
-	I
alpha	I
(	O
cPKC	B
-	I
alpha	I
)	O
,	O
cPKC	B
-	I
betaII	I
,	O
and	O
atypical	B
PKC	I
-	I
zeta	I
isoforms	I
and	O
identified	O
a	O
sustained	O
translocation	O
of	O
cPKC	B
-	I
alpha	I
and	O
cPKC	B
-	I
betaII	I
from	O
the	O
cytosolic	O
compartment	O
to	O
membranes	O
.	O
As	O
expected	O
,	O
the	O
distribution	O
of	O
atypical	B
PKC	I
-	I
zeta	I
was	O
unaffected	O
by	O
TPA	O
treatment	O
and	O
displayed	O
an	O
even	O
distribution	O
between	O
cytosol	O
and	O
membranes	O
.	O
This	O
finding	O
was	O
confirmed	O
by	O
immunofluorescence	O
microscopy	O
.	O
The	O
TPA	O
-	O
mediated	O
translocation	O
of	O
cPKC	B
-	I
alpha	I
and	O
cPKC	B
-	I
betaII	I
was	O
not	O
influenced	O
by	O
pretreatment	O
with	O
GF	O
109203X	O
.	O
Finally	O
,	O
functional	O
activation	O
and	O
translocation	O
of	O
PKC	B
were	O
investigated	O
with	O
a	O
selective	O
in	O
vitro	O
kinase	O
assay	O
.	O
Together	O
,	O
these	O
results	O
show	O
that	O
activated	O
HLA	B
-	I
DRA	I
expression	O
in	O
response	O
to	O
TPA	O
treatment	O
is	O
strictly	O
dependent	O
on	O
PKC	B
activation	O
acting	O
on	O
the	O
X2	O
box	O
of	O
the	O
DRA	O
promoter	O
and	O
that	O
selective	O
inhibition	O
of	O
PKC	B
enzymatic	O
activity	O
does	O
not	O
influence	O
subcellular	O
localization	O
of	O
expressed	O
PKC	B
isoenzymes	I
.	O
Thus	O
,	O
the	O
translocation	O
event	O
per	O
se	O
occurs	O
independently	O
of	O
PKC	B
activation	O
in	O
these	O
cells	O
.	O
Attenuation	O
of	O
HLA	B
-	I
DR	I
expression	O
by	O
mononuclear	O
phagocytes	O
infected	O
with	O
Mycobacterium	O
tuberculosis	O
is	O
related	O
to	O
intracellular	O
sequestration	O
of	O
immature	B
class	I
II	I
heterodimers	I
.	O
MHC	B
class	I
II	I
expression	O
was	O
examined	O
in	O
macrophages	O
infected	O
with	O
Mycobacterium	O
tuberculosis	O
.	O
IFN	B
-	I
gamma	I
increased	O
the	O
surface	O
expression	O
of	O
class	B
II	I
molecules	I
in	O
THP-1	O
cells	O
and	O
this	O
was	O
markedly	O
reduced	O
in	O
cells	O
infected	O
with	O
M.	O
tuberculosis	O
.	O
Despite	O
this	O
effect	O
,	O
steady	O
state	O
levels	O
of	O
HLA	B
-	I
DRalpha	I
,	O
HLA	B
-	I
DRbeta	I
,	O
and	O
invariant	B
(	I
Ii	I
)	I
chains	I
were	O
equivalent	O
in	O
control	O
and	O
infected	O
cells	O
.	O
Metabolic	O
labeling	O
combined	O
with	O
pulse	O
-	O
chase	O
experiments	O
and	O
biochemical	O
analysis	O
showed	O
that	O
the	O
majority	O
of	O
class	B
II	I
molecules	I
in	O
infected	O
cells	O
became	O
resistant	O
to	O
endoglycosidase	B
H	I
,	O
consistent	O
with	O
normal	O
Golgi	O
processing	O
.	O
However	O
,	O
results	O
of	O
intracellular	O
staining	O
and	O
dual	O
color	O
confocal	O
microscopy	O
revealed	O
a	O
significant	O
defect	O
in	O
transport	O
of	O
newly	O
synthesized	O
class	B
II	I
molecules	I
through	O
the	O
endocytic	O
compartment	O
.	O
Thus	O
,	O
compared	O
with	O
findings	O
in	O
control	O
cells	O
,	O
class	B
II	I
molecules	I
in	O
infected	O
cells	O
colocalized	O
to	O
a	O
minimal	O
extent	O
with	O
a	O
lysosomal	B
-	I
associated	I
membrane	I
protein-1	I
+	O
endosomal	O
compartment	O
.	O
In	O
addition	O
,	O
in	O
contrast	O
to	O
control	O
cells	O
,	O
class	B
II	I
molecules	I
in	O
infected	O
cells	O
failed	O
to	O
colocalize	O
with	O
endocytosed	B
BSA	I
under	O
conditions	O
where	O
this	O
marker	O
is	O
known	O
to	O
label	O
late	O
endosomes	O
,	O
lysosomes	O
,	O
and	O
the	O
MHC	B
class	I
II	I
compartment	O
.	O
Consistent	O
with	O
defective	O
transport	O
along	O
the	O
endocytic	O
pathway	O
,	O
the	O
maturation	O
of	O
SDS	B
-	I
stable	I
class	I
II	I
alphabeta	I
dimers	I
--	O
dependent	O
upon	O
removal	O
of	O
Ii	B
chain	I
and	O
peptide	O
loading	O
of	O
class	B
II	I
dimers	I
in	O
the	O
MHC	B
class	I
II	I
compartment	O
--	O
was	O
markedly	O
impaired	O
in	O
M.	O
tuberculosis	O
-infected	O
cells	O
.	O
These	O
findings	O
indicate	O
that	O
defective	O
transport	O
and	O
processing	O
of	O
class	B
II	I
molecules	I
through	O
the	O
endosomal	O
/	O
lysosomal	O
system	O
is	O
responsible	O
for	O
diminished	O
cell	O
surface	O
expression	O
of	O
MHC	B
class	I
II	I
molecules	I
in	O
cells	O
infected	O
with	O
M.	O
tuberculosis	O
.	O
Signal	O
transduction	O
abnormalities	O
in	O
T	O
lymphocytes	O
from	O
patients	O
with	O
advanced	O
renal	O
carcinoma	O
:	O
clinical	O
relevance	O
and	O
effects	O
of	O
cytokine	B
therapy	O
.	O
Studies	O
have	O
demonstrated	O
abnormalities	O
of	O
the	O
CD3	B
/	I
T	I
-	I
cell	I
antigen	I
receptor	I
(	O
TCR	B
)	O
and	O
pathways	O
of	O
signal	O
transduction	O
in	O
T	O
lymphocytes	O
from	O
animals	O
and	O
patients	O
with	O
advanced	O
malignancy	O
.	O
Diminished	O
expression	O
of	O
TCRzeta	B
and	O
p56	B
(	I
lck	I
)	I
that	O
are	O
associated	O
with	O
the	O
TCR	B
and	O
reduced	O
nuclear	O
localization	O
of	O
RelA	B
containing	I
nuclear	I
factor	I
kappaB	I
(	I
NFkappaB	I
)	I
complexes	I
have	O
been	O
noted	O
.	O
These	O
defects	O
have	O
been	O
described	O
in	O
T	O
cells	O
from	O
patients	O
with	O
malignant	O
melanoma	O
,	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
,	O
ovarian	O
cancer	O
,	O
and	O
colorectal	O
cancer	O
.	O
Preliminary	O
observations	O
also	O
indicate	O
possible	O
correlation	O
with	O
clinical	O
variables	O
such	O
as	O
stage	O
in	O
selected	O
instances	O
.	O
To	O
further	O
characterize	O
altered	O
expression	O
of	O
TCRzeta	B
,	O
p56	B
(	I
lck	I
)	I
,	O
and	O
impaired	O
activation	O
of	O
NFkappaB	B
,	O
T	O
lymphocytes	O
were	O
obtained	O
from	O
65	O
patients	O
with	O
RCC	O
,	O
the	O
majority	O
of	O
whom	O
were	O
receiving	O
combination	O
cytokine	B
therapy	O
[	O
interleukin	B
(	I
IL	I
)	I
-2	I
,	O
IFN	B
alpha	I
-containing	O
regimens	O
]	O
and	O
37	O
control	O
individuals	O
.	O
In	O
29	O
of	O
these	O
patients	O
,	O
levels	O
of	O
TCRzeta	B
and	O
p56	B
(	I
lck	I
)	I
were	O
determined	O
by	O
Western	O
blots	O
of	O
T	O
-	O
cell	O
lysates	O
and	O
semiquantitated	O
using	O
densitometry	O
.	O
Relative	O
levels	O
were	O
then	O
correlated	O
with	O
a	O
series	O
of	O
clinical	O
variables	O
including	O
response	O
to	O
therapy	O
,	O
performance	O
status	O
,	O
survival	O
,	O
disease	O
sites	O
,	O
age	O
,	O
and	O
others	O
.	O
In	O
another	O
group	O
of	O
28	O
patients	O
(	O
three	O
individuals	O
from	O
the	O
first	O
group	O
)	O
,	O
the	O
frequency	O
of	O
abnormal	O
NFkappaB	B
activation	O
was	O
studied	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
after	O
activation	O
of	O
T	O
cells	O
with	O
phorbol	O
myristate	O
acetate	O
/	O
ionomycin	O
or	O
anti	B
-	I
CD3	I
monoclonal	I
antibody	I
.	O
Changes	O
in	O
these	O
signaling	O
molecules	O
during	O
cytokine	B
treatment	O
were	O
also	O
investigated	O
.	O
TCRzeta	B
and	O
p56	B
(	I
lck	I
)	I
were	O
detected	O
in	O
the	O
peripheral	O
blood	O
T	O
cells	O
in	O
27	O
of	O
29	O
patients	O
,	O
and	O
overall	O
,	O
reduced	O
levels	O
were	O
noted	O
visually	O
in	O
12	O
of	O
29	O
(	O
41	O
%	O
)	O
and	O
13	O
of	O
29	O
(	O
45	O
%	O
)	O
individuals	O
,	O
respectively	O
.	O
When	O
levels	O
were	O
semiquantitated	O
using	O
densitometry	O
,	O
significant	O
decreases	O
of	O
TCRzeta	B
(	O
P	O
=	O
0.029	O
)	O
and	O
p56	B
(	I
lck	I
)	I
(	O
P	O
=	O
0.029	O
)	O
but	O
not	O
CD3epsilon	B
(	O
P	O
=	O
0.131	O
)	O
,	O
compared	O
with	O
control	O
levels	O
,	O
were	O
found	O
.	O
In	O
patients	O
treated	O
with	O
IL-2	O
/	O
IFN	B
alpha	I
-based	O
therapy	O
,	O
relative	O
levels	O
of	O
TCRzeta	B
increased	O
significantly	O
(	O
P	O
=	O
0.002	O
)	O
on	O
day	O
15	O
of	O
cycle	O
one	O
compared	O
with	O
the	O
baseline	O
.	O
Correlations	O
of	O
TCRzeta	B
or	O
p56	B
(	I
lck	I
)	I
levels	O
with	O
response	O
or	O
disease	O
variables	O
,	O
except	O
for	O
lower	O
TCRzeta	B
levels	O
(	O
P	O
<	O
0.001	O
)	O
in	O
the	O
presence	O
of	O
bone	O
metastases	O
,	O
were	O
not	O
found	O
.	O
Abnormal	O
NFkappaB	B
activation	O
after	O
stimulation	O
with	O
phorbol	O
myristate	O
acetate	O
/	O
ionomycin	O
and/or	O
anti	B
-	I
CD3	I
monoclonal	I
antibody	I
was	O
found	O
in	O
59	O
%	O
of	O
patients	O
(	O
17	O
of	O
28	O
)	O
and	O
was	O
not	O
accounted	O
for	O
by	O
the	O
advanced	O
age	O
of	O
the	O
study	O
cohort	O
.	O
Activation	O
of	O
NFkappaB	B
in	O
peripheral	O
blood	O
T	O
cells	O
was	O
inducible	O
during	O
cytokine	B
therapy	O
in	O
four	O
of	O
six	O
individuals	O
who	O
displayed	O
impaired	O
NFkappaB	B
activity	O
prior	O
to	O
therapy	O
.	O
Moreover	O
,	O
impaired	O
activation	O
of	O
NFkappaB	B
does	O
not	O
appear	O
linked	O
to	O
a	O
reduction	O
of	O
TCRzeta	B
expression	O
,	O
because	O
in	O
five	O
patients	O
,	O
normal	O
TCRzeta	B
levels	O
were	O
present	O
although	O
kappaB	B
binding	O
was	O
not	O
inducible	O
.	O
In	O
the	O
majority	O
of	O
patients	O
with	O
advanced	O
RCC	O
,	O
peripheral	O
blood	O
T	O
cells	O
express	O
TCRzeta	B
and	O
p56	B
(	I
lck	I
)	I
,	O
and	O
in	O
a	O
subset	O
,	O
reduced	O
levels	O
of	O
these	O
TCRzeta	B
associated	I
molecules	I
are	O
seen	O
that	O
may	O
increase	O
during	O
cytokine	B
-based	O
therapy	O
.	O
Abnormal	O
activation	O
of	O
NFkappaB	B
is	O
also	O
present	O
in	O
>	O
50	O
%	O
of	O
patients	O
and	O
may	O
also	O
revert	O
to	O
normal	O
during	O
IL-2	O
/	O
IFN	B
alpha	I
-based	O
treatment	O
.	O
This	O
alteration	O
in	O
NFkappaB	B
activation	O
occurred	O
in	O
the	O
presence	O
of	O
normal	O
expression	O
of	O
TCRzeta	O
-	O
associated	O
signaling	O
elements	O
.	O
The	O
clinical	O
significance	O
of	O
these	O
findings	O
remains	O
unclear	O
.	O
The	O
nuclear	B
receptor	I
PPARgamma	B
-	O
bigger	O
than	O
fat	O
.	O
Work	O
reported	O
over	O
the	O
past	O
year	O
has	O
provided	O
insights	O
into	O
the	O
mechanisms	O
whereby	O
ligand	O
activation	O
of	O
the	O
nuclear	B
receptor	I
peroxisome	I
proliferator	I
-	I
activated	I
receptor	I
gamma	I
(	O
PPARgamma	B
)	O
regulates	O
systemic	O
glucose	O
and	O
lipid	O
homeostasis	O
.	O
PPARgamma	B
has	O
also	O
been	O
implicated	O
recently	O
in	O
the	O
biology	O
of	O
monocytes	O
and	O
in	O
cell	O
-	O
cycle	O
regulation	O
and	O
cancer	O
.	O
Polyunsaturated	O
fatty	O
acids	O
and	O
eicosanoids	O
bind	O
and	O
activate	O
PPARgamma	B
,	O
suggesting	O
that	O
these	O
lipids	O
may	O
serve	O
as	O
hormonal	O
regulators	O
of	O
a	O
variety	O
of	O
biological	O
processes	O
.	O
GATA-3	B
represses	O
gp91phox	O
gene	O
expression	O
in	O
eosinophil	O
-	O
committed	O
HL-60-C15	O
cells	O
.	O
To	O
study	O
the	O
regulatory	O
mechanism	O
of	O
gp91phox	O
gene	O
expression	O
in	O
eosinophils	O
,	O
we	O
transiently	O
transfected	O
eosinophil	O
-	O
committed	O
HL-60-C15	O
cells	O
with	O
gp91phox	O
promoter	O
constructs	O
,	O
and	O
identified	O
a	O
negative	O
element	O
from	O
bp	O
-267	O
to	O
-246	O
of	O
the	O
gp91phox	O
gene	O
,	O
the	O
deletion	O
of	O
which	O
caused	O
an	O
83	O
%	O
increase	O
in	O
promoter	O
activity	O
.	O
Electrophoresis	O
mobility	O
shift	O
assays	O
demonstrated	O
GATA-3	B
binds	O
to	O
the	O
GATA	O
consensus	O
site	O
from	O
bp	O
-256	O
to	O
-250	O
.	O
An	O
81	O
%	O
increment	O
in	O
promoter	O
activity	O
was	O
obtained	O
when	O
a	O
mutation	O
was	O
introduced	O
in	O
the	O
GATA-3	O
binding	O
site	O
of	O
the	O
bp	O
-267	O
to	O
+	O
12	O
construct	O
,	O
which	O
is	O
comparable	O
to	O
that	O
of	O
the	O
bp	O
-245	O
to	O
+	O
12	O
construct	O
.	O
We	O
therefore	O
conclude	O
that	O
GATA-3	B
specifically	O
binding	O
to	O
the	O
GATA	O
site	O
negatively	O
regulates	O
the	O
expression	O
of	O
the	O
gene	O
in	O
HL-60-C15	O
cells	O
.	O
[	O
Molecular	O
mechanism	O
of	O
cytokine	O
gene	O
expression	O
in	O
Th1	O
and	O
Th2	O
]	O
Upon	O
activation	O
by	O
antigens	B
,	O
helper	O
T	O
cells	O
differentiate	O
into	O
one	O
of	O
several	O
subsets	O
,	O
characterized	O
by	O
their	O
distinct	O
cytokine	B
-production	O
patterns	O
.	O
Among	O
these	O
subsets	O
,	O
Th1	O
cells	O
are	O
known	O
to	O
activate	O
cellular	O
immunity	O
resulting	O
in	O
inflammatory	O
response	O
,	O
whereas	O
Th2	O
cells	O
induce	O
humoral	O
and	O
allergic	O
responses	O
and	O
suppress	O
inflammation	O
.	O
Th1	O
and	O
Th2	O
effector	O
functions	O
and	O
their	O
development	O
are	O
attributable	O
to	O
their	O
distinct	O
cytokine	B
expression	O
patterns	O
.	O
Recent	O
reports	O
have	O
demonstrated	O
that	O
differential	O
expression	O
of	O
cell	O
surface	O
molecules	O
,	O
such	O
as	O
adhesion	B
molecule	I
and	O
chemokine	B
receptor	I
,	O
is	O
involved	O
in	O
their	O
recruitment	O
into	O
target	O
tissues	O
.	O
It	O
is	O
,	O
therefore	O
,	O
suggested	O
that	O
clarification	O
of	O
the	O
mechanisms	O
of	O
differential	O
gene	O
expression	O
in	O
Th1	O
/	O
Th2	O
should	O
lead	O
to	O
rational	O
strategies	O
for	O
manipulating	O
pathological	O
immune	O
responses	O
.	O
Activation	O
of	O
helper	O
T	O
cells	O
mediated	O
by	O
the	O
T	O
cell	O
receptor	O
induces	O
a	O
series	O
of	O
biochemical	O
events	O
.	O
Among	O
them	O
,	O
both	O
the	O
activation	O
of	O
PKC	O
/	O
Ras-	O
and	O
CaM	O
/	O
CN	O
-	O
mediated	O
pathways	O
play	O
a	O
central	O
role	O
in	O
the	O
signal	O
transduction	O
of	O
cytokine	O
gene	O
expression	O
.	O
Closer	O
examination	O
using	O
non	O
-	O
transformed	O
murine	O
Th1	O
and	O
Th2	O
clones	O
suggested	O
that	O
a	O
balance	O
between	O
the	O
activities	O
of	O
the	O
two	O
signaling	O
pathways	O
contributes	O
to	O
cytokine	O
gene	O
expression	O
.	O
We	O
propose	O
that	O
one	O
of	O
the	O
targets	O
of	O
PGE2	O
,	O
whose	O
effect	O
distinguishes	O
Th1	O
from	O
Th2	O
,	O
resides	O
in	O
the	O
downstream	O
PKC	B
/	I
Ras	I
-mediated	O
pathway	O
.	O
Transcriptional	O
regulation	O
of	O
lysosomal	B
acid	I
lipase	I
in	O
differentiating	O
monocytes	O
is	O
mediated	O
by	O
transcription	B
factors	I
Sp1	B
and	O
AP-2	B
.	O
Human	O
lysosomal	B
acid	I
lipase	I
(	O
LAL	B
)	O
is	O
a	O
hydrolase	B
required	O
for	O
the	O
cleavage	O
of	O
cholesteryl	O
esters	O
and	O
triglycerides	O
derived	O
from	O
plasma	O
lipoproteins	O
.	O
It	O
is	O
shown	O
here	O
that	O
during	O
monocyte	O
to	O
macrophage	O
differentiation	O
,	O
the	O
expression	O
of	O
LAL	O
-	O
mRNA	O
is	O
induced	O
.	O
This	O
induction	O
is	O
dependent	O
on	O
protein	B
kinase	I
C	I
activity	O
and	O
protein	O
synthesis	O
.	O
The	O
cell	O
type	O
-	O
specific	O
increase	O
in	O
LAL	B
expression	O
is	O
further	O
investigated	O
in	O
the	O
THP-1	O
cell	O
line	O
with	O
respect	O
to	O
transcriptional	O
regulation	O
.	O
The	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
THP-1	O
differentiates	O
into	O
macrophage	O
-	O
like	O
cells	O
when	O
treated	O
with	O
phorbol	O
esters	O
.	O
In	O
order	O
to	O
determine	O
the	O
cis	O
-	O
acting	O
elements	O
necessary	O
for	O
both	O
basal	O
and	O
phorbol	O
12-myristate-13	O
acetate	O
(	O
PMA	O
)	O
-enhanced	O
promoter	O
activity	O
,	O
we	O
performed	O
deletion	O
analysis	O
and	O
reporter	O
gene	O
assays	O
.	O
A	O
PMA	O
responsive	O
element	O
has	O
been	O
identified	O
between	O
-182	O
bp	O
and	O
-107	O
bp	O
upstream	O
of	O
the	O
major	O
transcription	O
start	O
site	O
.	O
Gel	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
binding	O
of	O
Sp1	B
and	O
AP-2	B
to	O
the	O
LAL	O
promoter	O
is	O
increased	O
by	O
PMA	O
in	O
THP-1	O
cells	O
.	O
Co	O
-	O
transfections	O
with	O
expression	O
plasmids	O
for	O
Sp1	B
and	O
AP-2	B
further	O
emphasized	O
the	O
important	O
role	O
of	O
these	O
transcription	B
factors	I
in	O
both	O
basal	O
and	O
PMA	O
-	O
enhanced	O
LAL	B
expression	O
.	O
Our	O
data	O
suggest	O
that	O
differentiation	O
dependent	O
increase	O
of	O
lysosomal	B
acid	I
lipase	I
(	O
LAL	B
)	O
expression	O
in	O
THP-1	O
cells	O
is	O
mediated	O
by	O
a	O
concerted	O
action	O
of	O
Sp1	B
and	O
AP-2	B
.	O
A	O
nongenomic	O
mechanism	O
for	O
progesterone	O
-	O
mediated	O
immunosuppression	O
:	O
inhibition	O
of	O
K+	B
channels	I
,	O
Ca2	O
+	O
signaling	O
,	O
and	O
gene	O
expression	O
in	O
T	O
lymphocytes	O
.	O
The	O
mechanism	O
by	O
which	O
progesterone	O
causes	O
localized	O
suppression	O
of	O
the	O
immune	O
response	O
during	O
pregnancy	O
has	O
remained	O
elusive	O
.	O
Using	O
human	O
T	O
lymphocytes	O
and	O
T	O
cell	O
lines	O
,	O
we	O
show	O
that	O
progesterone	O
,	O
at	O
concentrations	O
found	O
in	O
the	O
placenta	O
,	O
rapidly	O
and	O
reversibly	O
blocks	O
voltage	B
-	I
gated	I
and	I
calcium	I
-	I
activated	I
K+	I
channels	I
(	O
KV	B
and	O
KCa	B
,	O
respectively	O
)	O
,	O
resulting	O
in	O
depolarization	O
of	O
the	O
membrane	O
potential	O
.	O
As	O
a	O
result	O
,	O
Ca2	O
+	O
signaling	O
and	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	O
NF	B
-	I
AT	I
)	O
-driven	O
gene	O
expression	O
are	O
inhibited	O
.	O
Progesterone	O
acts	O
distally	O
to	O
the	O
initial	O
steps	O
of	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
-mediated	O
signal	O
transduction	O
,	O
since	O
it	O
blocks	O
sustained	O
Ca2	O
+	O
signals	O
after	O
thapsigargin	O
stimulation	O
,	O
as	O
well	O
as	O
oscillatory	O
Ca2	O
+	O
signals	O
,	O
but	O
not	O
the	O
Ca2	O
+	O
transient	O
after	O
TCR	B
stimulation	O
.	O
K+	O
channel	O
blockade	O
by	O
progesterone	O
is	O
specific	O
;	O
other	O
steroid	O
hormones	O
had	O
little	O
or	O
no	O
effect	O
,	O
although	O
the	O
progesterone	O
antagonist	O
RU	O
486	O
also	O
blocked	O
KV	B
and	O
KCa	B
channels	O
.	O
Progesterone	O
effectively	O
blocked	O
a	O
broad	O
spectrum	O
of	O
K+	B
channels	I
,	O
reducing	O
both	O
Kv1.3	B
and	O
charybdotoxin	B
-	I
resistant	I
components	I
of	O
KV	B
current	O
and	O
KCa	B
current	O
in	O
T	O
cells	O
,	O
as	O
well	O
as	O
blocking	O
several	O
cloned	B
KV	I
channels	I
expressed	O
in	O
cell	O
lines	O
.	O
Progesterone	O
had	O
little	O
or	O
no	O
effect	O
on	O
a	O
cloned	B
voltage	I
-	I
gated	I
Na+	I
channel	I
,	O
an	O
inward	O
rectifier	O
K+	B
channel	I
,	O
or	O
on	O
lymphocyte	B
Ca2	I
+	I
and	I
Cl-	I
channels	I
.	O
We	O
propose	O
that	O
direct	O
inhibition	O
of	O
K+	B
channels	I
in	O
T	O
cells	O
by	O
progesterone	O
contributes	O
to	O
progesterone	O
-	O
induced	O
immunosuppression	O
.	O
Effects	O
of	O
overexpression	O
of	O
IL-1	B
receptor	I
-	I
associated	I
kinase	I
on	O
NFkappaB	B
activation	O
,	O
IL-2	B
production	O
and	O
stress	O
-	O
activated	O
protein	O
kinases	O
in	O
the	O
murine	O
T	O
cell	O
line	O
EL4	O
.	O
The	O
association	O
and	O
activation	O
of	O
the	O
IL-1	B
receptor	I
-	I
associated	I
protein	I
kinase	I
(	O
IRAK	B
)	O
to	O
the	O
IL-1	B
receptor	I
complex	I
is	O
one	O
of	O
the	O
earliest	O
events	O
detectable	O
in	O
IL-1	B
signal	O
transduction	O
.	O
We	O
generated	O
permanent	O
clones	O
of	O
the	O
murine	O
T	O
cell	O
line	O
EL4	O
6.1	O
overexpressing	O
human	B
(	I
h	I
)	I
IRAK	I
to	O
evaluate	O
the	O
role	O
of	O
this	O
kinase	O
in	O
IL-1	B
signaling	O
.	O
Overexpression	O
of	O
hIRAK	B
enhanced	O
IL-1	B
-stimulated	O
activation	O
of	O
the	O
transcription	B
factor	I
NFkappaB	I
,	O
whereas	O
a	O
truncated	O
form	O
(	O
N	B
-	I
IRAK	I
)	O
specifically	O
inhibited	O
IL-1	B
-dependent	O
NFkappaB	B
activity	O
.	O
In	O
clones	O
stably	O
overexpressing	O
hIRAK	B
a	O
weak	O
constitutive	O
activation	O
of	O
NFkappaB	B
correlated	O
with	O
a	O
low	O
basal	O
IL-2	B
production	O
which	O
was	O
enhanced	O
in	O
an	O
IL-1	B
-dependent	O
manner	O
.	O
Compared	O
to	O
the	O
parental	O
cell	O
line	O
the	O
dose	O
-	O
response	O
curve	O
of	O
IL-1	B
-induced	O
IL-2	B
production	O
was	O
shifted	O
in	O
both	O
potency	O
and	O
efficacy	O
.	O
These	O
results	O
demonstrate	O
that	O
IRAK	B
directly	O
triggers	O
NFkappaB	B
-mediated	O
gene	O
expression	O
in	O
EL4	O
cells	O
.	O
Qualitatively	O
different	O
effects	O
were	O
observed	O
for	O
the	O
IL-1	B
-induced	O
activation	O
of	O
stress	B
-	I
activated	I
protein	I
(	I
SAP	I
)	I
kinases	I
:	O
permanent	O
overexpression	O
of	O
IRAK	B
did	O
not	O
affect	O
the	O
dose	O
dependence	O
but	O
prolonged	O
the	O
kinetics	O
of	O
IL-1	B
-induced	O
activation	O
of	O
SAP	B
kinases	I
,	O
suggesting	O
that	O
this	O
signaling	O
branch	O
may	O
be	O
regulated	O
by	O
distinct	O
mechanisms	O
.	O
Decreased	O
IL-12	B
production	O
and	O
Th1	O
cell	O
development	O
by	O
acetyl	O
salicylic	O
acid	O
-	O
mediated	O
inhibition	O
of	O
NF	B
-	I
kappaB	I
.	O
IL-12	B
is	O
a	O
75-kDa	B
heterodimeric	I
cytokine	I
composed	O
of	O
two	O
covalently	O
linked	O
p35	B
and	I
p40	I
chains	I
.	O
This	O
pro	B
-	I
inflammatory	I
cytokine	I
plays	O
a	O
prominent	O
role	O
in	O
the	O
development	O
of	O
Th1	O
cell	O
-	O
mediated	O
immune	O
responses	O
.	O
Th1	O
cell	O
-	O
mediated	O
immune	O
responses	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
inflammatory	O
autoimmune	O
diseases	O
.	O
Thus	O
,	O
IL-12	B
appears	O
to	O
be	O
a	O
critical	O
factor	O
in	O
the	O
generation	O
and	O
maintenance	O
of	O
chronic	O
inflammatory	O
conditions	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
a	O
commonly	O
prescribed	O
anti	O
-	O
inflammatory	O
drug	O
,	O
acetyl	O
salicylic	O
acid	O
(	O
ASA	O
)	O
,	O
on	O
IL-12	B
production	O
and	O
Th1	O
cell	O
development	O
.	O
ASA	O
was	O
found	O
to	O
inhibit	O
secretion	O
of	O
the	O
IL-12	B
heterodimer	I
as	O
well	O
as	O
p40	B
monomer	I
by	O
human	O
monocytic	O
cells	O
.	O
This	O
was	O
associated	O
with	O
the	O
down	O
-	O
regulation	O
of	O
IL-12p40	O
mRNA	O
expression	O
.	O
Analysis	O
of	O
the	O
regulation	O
of	O
the	O
p40	O
gene	O
promoter	O
revealed	O
that	O
ASA	O
inhibited	O
NF	B
-	I
kappaB	I
activation	O
and	O
binding	O
to	O
the	O
p40-kappaB	O
site	O
in	O
the	O
p40	O
promoter	O
,	O
leading	O
to	O
transcriptional	O
repression	O
of	O
the	O
p40	O
gene	O
.	O
Addition	O
of	O
ASA	O
to	O
an	O
in	O
vitro	O
T	O
helper	O
cell	O
differentiation	O
system	O
,	O
at	O
concentrations	O
compatible	O
with	O
plasma	O
levels	O
reached	O
during	O
anti	O
-	O
inflammatory	O
therapy	O
,	O
resulted	O
in	O
reduced	O
development	O
of	O
Th1	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
the	O
inhibition	O
of	O
NF	B
-	I
kappaB	I
activation	O
by	O
ASA	O
leads	O
to	O
down	O
-	O
regulation	O
of	O
IL-12	B
production	O
and	O
inhibition	O
of	O
Th1	O
cell	O
development	O
.	O
YM268	O
increases	O
the	O
glucose	O
uptake	O
,	O
cell	O
differentiation	O
,	O
and	O
mRNA	O
expression	O
of	O
glucose	B
transporter	I
in	O
3T3-L1	O
adipocytes	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
bis	O
[	O
4-	O
[	O
2	O
,	O
4-dioxo-5-thiazolidinyl	O
)	O
methyl	O
]	O
phenyl	O
]	O
methane	O
(	O
YM-268	O
)	O
,	O
a	O
thiazolidinedione	O
derivative	O
,	O
on	O
glucose	O
uptake	O
,	O
adipocyte	O
differentiation	O
through	O
peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
gamma	I
(	O
PPARgamma	B
)	O
,	O
and	O
phosphatidylinositol	B
3-kinase	I
(	O
PI	B
3-kinase	I
)	O
activity	O
in	O
cultured	O
cells	O
.	O
YM268	O
and	O
pioglitazone	O
dose	O
-	O
dependently	O
increased	O
the	O
2-deoxyglucose	O
uptake	O
in	O
3T3-L1	O
cells	O
.	O
YM268	O
facilitated	O
the	O
insulin	O
-	O
stimulated	O
triglyceride	O
accumulation	O
in	O
3T3-L1	O
adipocytes	O
and	O
increased	O
the	O
mRNA	O
expression	O
of	O
fatty	B
acid	I
-	I
binding	I
protein	I
.	O
YM268	O
,	O
with	O
and	O
without	O
insulin	O
,	O
increased	O
the	O
mRNA	O
expression	O
of	O
glucose	B
transporter	I
isoforms	O
such	O
as	O
GLUT1	B
and	O
GLUT4	B
,	O
indicating	O
enhancement	O
of	O
adipocyte	O
differentiation	O
.	O
Additionally	O
,	O
YM268	O
and	O
pioglitazone	O
showed	O
activity	O
of	O
the	O
PPARgamma	B
ligand	I
,	O
a	O
member	O
of	O
the	O
nuclear	B
receptor	I
superfamily	I
responsible	O
for	O
adipogenesis	O
.	O
To	O
examine	O
the	O
possible	O
involvement	O
of	O
the	O
increased	O
activity	O
of	O
PI	B
3-kinase	I
in	O
YM268-stimulated	O
glucose	O
uptake	O
,	O
the	O
enzyme	O
activity	O
was	O
estimated	O
by	O
measuring	O
the	O
phosphatidylinositol-3	O
,	O
4	O
,	O
5-trisphosphate	O
(	O
PI-3	O
,	O
4	O
,	O
5-P3	O
)	O
concentration	O
in	O
human	O
monocytic	O
cells	O
.	O
Insulin	O
dose	O
-	O
dependently	O
increased	O
the	O
PI-3	O
,	O
4	O
,	O
5-P3	O
production	O
but	O
YM268	O
had	O
no	O
significant	O
effect	O
on	O
the	O
insulin	O
-	O
dependent	O
and	O
-independent	O
PI	O
3-kinase	O
activation	O
.	O
These	O
results	O
indicate	O
that	O
the	O
mechanism	O
by	O
which	O
YM268	O
increased	O
glucose	O
uptake	O
,	O
may	O
be	O
accounted	O
for	O
in	O
part	O
by	O
the	O
enhancement	O
of	O
GLUT1	B
and	O
GLUT4	B
expression	O
through	O
PPARgamma	B
activation	O
.	O
Role	O
of	O
IKK1	B
and	O
IKK2	B
in	O
lipopolysaccharide	O
signaling	O
in	O
human	O
monocytic	O
cells	O
.	O
Mononuclear	O
phagocytes	O
play	O
a	O
major	O
role	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O
Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
monocytes	O
to	O
express	O
a	O
variety	O
of	O
genes	O
by	O
activating	O
the	O
NF	B
-	I
kappaB	I
/	I
Rel	I
transcription	I
factor	I
family	I
.	O
Recently	O
,	O
we	O
have	O
reported	O
that	O
the	O
tumor	B
necrosis	I
factor	I
and	O
interleukin	B
1	I
signaling	O
pathways	O
activate	O
two	O
kinases	O
,	O
IKK1	B
and	O
IKK2	B
.	O
Phosphorylation	O
of	O
the	O
IkappaB	B
cytoplasmic	I
inhibitors	I
,	O
IkappaBalpha	B
,	O
IkappaBbeta	B
,	O
and	O
IkappaBepsilon	B
,	O
by	O
these	O
kinases	O
triggers	O
proteolytic	O
degradation	O
and	O
the	O
release	O
of	O
NF	B
-	I
kappaB	I
/	I
Rel	I
proteins	I
into	O
the	O
nucleus	O
.	O
At	O
present	O
,	O
the	O
role	O
of	O
the	O
IKKs	O
in	O
LPS	O
signaling	O
has	O
not	O
been	O
investigated	O
.	O
Here	O
,	O
we	O
report	O
that	O
LPS	O
induces	O
IKK	B
activity	O
in	O
human	O
monocytes	O
and	O
THP-1	O
monocytic	O
cells	O
.	O
The	O
kinetics	O
of	O
activation	O
of	O
kinase	O
activity	O
in	O
monocytic	O
cells	O
are	O
relatively	O
slow	O
with	O
maximal	O
activity	O
observed	O
at	O
60	O
min	O
,	O
which	O
coincides	O
with	O
the	O
degradation	O
of	O
IkappaBs	B
and	O
the	O
nuclear	O
translocation	O
of	O
NF	B
-	I
kappaB	I
.	O
In	O
transfection	O
experiments	O
,	O
overexpression	O
of	O
wild	O
type	O
IKK1	B
,	O
a	O
dominant	B
negative	I
mutant	I
IKK1	I
(	O
K44	B
M	I
)	O
,	O
or	O
wild	B
type	I
IKK2	I
did	O
not	O
affect	O
LPS	O
-	O
induced	O
kappaB	B
-dependent	O
transcription	O
in	O
monocytic	O
cells	O
.	O
In	O
contrast	O
,	O
a	O
dominant	O
negative	O
mutant	O
of	O
IKK2	B
inhibited	O
LPS	O
induction	O
of	O
kappaB	B
-dependent	O
transcription	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
These	O
results	O
indicate	O
that	O
LPS	O
induction	O
of	O
kappaB	O
-	O
dependent	O
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
requires	O
activation	O
of	O
IKK2	B
.	O
Interaction	O
of	O
sickle	O
erythrocytes	O
with	O
endothelial	O
cells	O
in	O
the	O
presence	O
of	O
endothelial	O
cell	O
conditioned	O
medium	O
induces	O
oxidant	O
stress	O
leading	O
to	O
transendothelial	O
migration	O
of	O
monocytes	O
.	O
The	O
abnormal	O
adherence	O
of	O
sickle	O
red	O
blood	O
cells	O
(	O
SS	O
RBC	O
)	O
to	O
endothelial	O
cells	O
has	O
been	O
thought	O
to	O
contribute	O
to	O
vascular	O
occlusion	O
,	O
a	O
major	O
cause	O
of	O
morbidity	O
in	O
sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
.	O
We	O
determined	O
whether	O
the	O
interaction	O
of	O
SS	O
RBC	O
with	O
cultured	O
endothelial	O
cells	O
induced	O
cellular	O
oxidant	O
stress	O
that	O
would	O
culminate	O
in	O
expression	O
of	O
cell	B
adhesion	I
molecules	I
(	O
CAMs	B
)	O
involved	O
in	O
the	O
adhesion	O
and	O
diapedesis	O
of	O
monocytes	O
and	O
the	O
adherence	O
of	O
SS	O
reticulocytes	O
.	O
We	O
showed	O
that	O
the	O
interaction	O
of	O
SS	O
RBC	O
at	O
2	O
%	O
concentration	O
in	O
the	O
presence	O
of	O
multimers	O
of	O
von	B
Willebrand	I
factor	I
(	O
vWf	B
)	O
,	O
derived	O
from	O
endothelial	O
cell	O
-	O
derived	O
conditioned	O
medium	O
(	O
E	O
-	O
CM	O
)	O
with	O
cultured	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
,	O
resulted	O
in	O
a	O
fivefold	O
increased	O
formation	O
of	O
thiobarbituric	O
acid	O
-	O
reactive	O
substances	O
(	O
TBARS	O
)	O
and	O
activation	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kB	I
,	O
both	O
indicators	O
of	O
cellular	O
oxidant	O
stress	O
.	O
Normal	O
RBC	O
show	O
none	O
of	O
these	O
phenomena	O
.	O
The	O
oxidant	O
stress	O
-	O
induced	O
signaling	O
resulted	O
in	O
an	O
increased	O
surface	O
expression	O
of	O
a	O
subset	O
of	O
CAMs	B
,	O
ICAM-1	B
,	O
E	B
-	I
selectin	I
,	O
and	O
VCAM-1	B
in	O
HUVEC	O
.	O
The	O
addition	O
of	O
oxygen	B
radical	I
scavenger	I
enzymes	I
(	O
catalase	B
,	O
superoxide	B
dismutase	I
)	O
and	O
antioxidant	O
(	O
probucol	O
)	O
inhibited	O
these	O
events	O
.	O
Additionally	O
,	O
preincubation	O
of	O
HUVEC	O
with	O
a	O
synthetic	O
peptide	O
Arg	O
-	O
Gly	O
-	O
Asp	O
(	O
RGD	O
)	O
that	O
prevents	O
vWf	B
-mediated	O
adhesion	O
of	O
SS	O
RBC	O
reduced	O
the	O
surface	O
expression	O
of	O
VCAM-1	B
and	O
NF	B
-	I
kB	I
activation	O
.	O
Furthermore	O
,	O
SS	O
RBC	O
-induced	O
oxidant	O
stress	O
resulted	O
in	O
a	O
twofold	O
increase	O
in	O
the	O
transendothelial	O
migration	O
of	O
both	O
monocyte	O
-	O
like	O
HL-60	O
cells	O
and	O
human	O
peripheral	O
blood	O
monocytes	O
,	O
and	O
approximately	O
a	O
sixfold	O
increase	O
in	O
platelet	B
-	I
endothelial	I
cell	I
adhesion	I
molecule-1	I
(	O
PECAM-1	B
)	O
phosphorylation	O
,	O
each	O
of	O
which	O
was	O
blocked	O
by	O
protein	B
kinase	I
C	I
inhibitor	O
and	O
antioxidants	O
.	O
These	O
results	O
suggest	O
that	O
the	O
adherence	O
/	O
contact	O
of	O
SS	O
RBC	O
to	O
endothelial	O
cells	O
in	O
large	O
vessel	O
can	O
generate	O
enhanced	O
oxidant	O
stress	O
leading	O
to	O
increased	O
adhesion	O
and	O
diapedesis	O
of	O
monocytes	O
,	O
as	O
well	O
as	O
heightened	O
adherence	O
of	O
SS	O
reticulocytes	O
,	O
indicating	O
that	O
injury	O
/	O
activation	O
of	O
endothelium	O
can	O
contribute	O
to	O
vaso	O
-	O
occlusion	O
in	O
SCD	O
.	O
Interleukin	B
2	I
and	I
15	I
activate	O
Stat3alpha	B
in	O
human	O
T	O
lymphocytes	O
.	O
Signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
3	I
(	O
Stat3	B
)	O
has	O
recently	O
been	O
shown	O
to	O
exist	O
in	O
two	O
alternatively	O
spliced	O
isoforms	O
,	O
a	O
short	O
form	O
,	O
Stat3beta	B
,	O
and	O
a	O
longer	O
form	O
,	O
Stat3alpha	B
,	O
displaying	O
differences	O
in	O
transcriptional	O
activity	O
.	O
It	O
is	O
unknown	O
which	O
Stat3	B
isoform	I
(	O
s	O
)	O
is	O
activated	O
in	O
response	O
to	O
interleukin	B
(	I
IL	I
)	I
-2	I
and	O
IL-15	B
.	O
Here	O
,	O
cytokine	B
-induced	O
activation	O
of	O
Stat3	B
in	O
previously	O
activated	O
CD4	O
(	O
+	O
)	O
human	O
T	O
cells	O
was	O
examined	O
using	O
Stat3	B
antibodies	O
directed	O
against	O
different	O
regions	O
of	O
Stat3	B
.	O
As	O
determined	O
by	O
tyrosine	O
phosphorylation	O
,	O
nuclear	O
translocation	O
and	O
binding	O
to	O
an	O
hSIE	O
-	O
oligonucleotide	O
probe	O
,	O
IL-2	B
and	O
IL-15	B
activated	O
the	O
slowly	O
migrating	O
isoform	O
,	O
Stat3alpha	B
.	O
In	O
contrast	O
,	O
minimal	O
or	O
no	O
activation	O
of	O
Stat3beta	B
was	O
observed	O
,	O
suggesting	O
that	O
IL-2	B
and	O
IL-15	B
predominantly	O
activate	O
Stat3alpha	B
in	O
human	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
.	O
In	O
this	O
way	O
,	O
diversity	O
in	O
the	O
expression	O
and	O
activation	O
of	O
Stat3	B
proteins	I
may	O
provide	O
additional	O
means	O
of	O
regulating	O
cytokine	B
-induced	O
T	O
cell	O
responses	O
.	O
Copyright	O
1998	O
Academic	O
Press	O
.	O
Promoter	O
sequence	O
,	O
exon	O
:	O
intron	O
structure	O
,	O
and	O
synteny	O
of	O
genetic	O
location	O
show	O
that	O
a	O
chicken	B
cytokine	I
with	O
T	O
-	O
cell	O
proliferative	O
activity	O
is	O
IL2	B
and	O
not	O
IL15	B
.	O
The	O
gene	O
encoding	O
a	O
chicken	B
cytokine	I
with	O
T	O
-	O
cell	O
proliferative	O
activity	O
was	O
cloned	O
,	O
sequenced	O
,	O
and	O
mapped	O
.	O
The	O
results	O
show	O
that	O
this	O
cytokine	B
is	O
chicken	O
IL2	B
and	O
not	O
IL15	B
.	O
The	O
exon	O
:	O
intron	O
structure	O
of	O
chicken	B
IL2	I
corresponds	O
almost	O
exactly	O
to	O
those	O
of	O
mammalian	O
IL2s	B
with	O
the	O
exceptions	O
of	O
exon	O
2	O
and	O
introns	O
2	O
and	O
3	O
which	O
are	O
shorter	O
.	O
Chicken	O
IL2	B
contains	O
five	O
repeats	O
of	O
the	O
`	O
`	O
instability	O
''	O
motif	O
ATTTA	O
in	O
the	O
3'untranslated	O
region	O
in	O
exon	O
4	O
.	O
It	O
is	O
a	O
single	O
-	O
copy	O
gene	O
,	O
with	O
neither	O
structural	O
(	O
amino	O
acid	O
)	O
nor	O
promoter	O
sequence	O
polymorphisms	O
identified	O
.	O
Analysis	O
of	O
the	O
predicted	O
amino	O
acid	O
sequence	O
suggests	O
that	O
overall	O
protein	B
structure	I
is	O
conserved	O
,	O
but	O
the	O
receptor	O
binding	O
sites	O
are	O
not	O
.	O
A	O
number	O
of	O
potential	O
regulatory	O
sequences	O
similar	O
to	O
those	O
found	O
in	O
mammals	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
.	O
These	O
include	O
(	O
5'-3	O
'	O
)	O
a	O
composite	O
NF	O
-	O
AT	O
/	O
`	O
`	O
AP-1	O
''	O
element	O
,	O
a	O
CD28	O
response	O
element	O
,	O
an	O
AP-1	O
element	O
,	O
an	O
NF	O
-	O
AT	O
element	O
,	O
and	O
the	O
AP-1	O
part	O
of	O
an	O
AP-1	O
/	O
octamer	O
composite	O
element	O
.	O
The	O
mammalian	B
NF	I
-	I
kappaB	I
and	O
octamer	O
binding	O
sites	O
seem	O
to	O
be	O
absent	O
,	O
although	O
there	O
are	O
alternative	O
potential	O
NF	B
-	I
kappaB	I
and	O
octamer	O
-	O
binding	O
elements	O
in	O
the	O
chicken	O
IL2	O
promoter	O
,	O
in	O
close	O
proximity	O
to	O
their	O
mammalian	O
homologues	O
.	O
Sequence	O
comparisons	O
also	O
predict	O
other	O
potential	O
transcription	O
factor	O
binding	O
sites	O
as	O
yet	O
undescribed	O
in	O
mammalian	O
IL2	O
promoters	O
.	O
A	O
Taq	O
I	O
polymorphism	O
was	O
identified	O
which	O
enabled	O
chicken	O
IL2	B
to	O
be	O
mapped	O
to	O
chromosome	O
4	O
,	O
linked	O
to	O
ANX5	O
,	O
with	O
synteny	O
with	O
mouse	O
chromosome	O
3	O
and	O
human	O
chromosome	O
4	O
.	O
This	O
is	O
the	O
first	O
non	O
-	O
mammalian	O
cytokine	O
gene	O
to	O
be	O
mapped	O
.	O
Transcriptional	O
regulation	O
of	O
the	O
beta	O
-	O
casein	O
gene	O
by	O
cytokines	B
:	O
cross	O
-	O
talk	O
between	O
STAT5	B
and	O
other	O
signaling	B
molecules	I
.	O
The	O
beta	O
-	O
casein	O
promoter	O
has	O
been	O
widely	O
used	O
to	O
monitor	O
the	O
activation	O
of	O
STAT	B
(	I
signal	I
transducer	I
and	I
activator	I
of	I
transcription	I
)	I
5	I
since	O
STAT5	B
was	O
originally	O
found	O
as	O
a	O
mediator	O
of	O
PRL	O
-	O
inducible	O
beta	B
-	I
casein	I
expression	O
.	O
However	O
,	O
not	O
only	O
is	O
expression	O
of	O
the	O
beta	O
-	O
casein	O
gene	O
regulated	O
by	O
STAT5	B
but	O
it	O
is	O
also	O
affected	O
by	O
other	O
molecules	O
such	O
as	O
glucocorticoid	O
and	O
Ras	B
.	O
In	O
this	O
report	O
,	O
we	O
describe	O
the	O
transcriptional	O
regulation	O
of	O
the	O
beta	O
-	O
casein	O
gene	O
by	O
cytokines	B
in	O
T	O
cells	O
.	O
We	O
have	O
found	O
that	O
the	O
beta	O
-	O
casein	O
gene	O
is	O
expressed	O
in	O
a	O
cytotoxic	O
T	O
cell	O
line	O
,	O
CTLL-2	O
,	O
in	O
response	O
to	O
interleukin-2	B
(	O
IL-2	B
)	O
,	O
which	O
activates	O
STAT5	B
.	O
While	O
IL-4	B
does	O
not	O
activate	O
STAT5	B
,	O
it	O
induces	O
expression	O
of	O
STAT5-regulated	O
genes	O
in	O
CTLL-2	O
,	O
i.e	O
.	O
beta	B
-	I
casein	I
,	O
a	O
cytokine	B
-	I
inducible	I
SH2-containing	I
protein	I
(	O
CIS	B
)	O
,	O
and	O
oncostatin	B
M	I
(	O
OSM	B
)	O
,	O
suggesting	O
that	O
STAT6	O
activated	O
by	O
IL-4	B
substitutes	O
for	O
the	O
function	O
of	O
STAT5	B
in	O
T	O
cells	O
.	O
IL-2	B
-induced	O
beta	B
-	I
casein	I
expression	O
was	O
enhanced	O
by	O
dexamethasone	O
,	O
and	O
this	O
synergistic	O
effect	O
of	O
Dexamethasone	O
requires	O
the	O
sequence	O
between	O
-155	O
and	O
-193	O
in	O
the	O
beta	O
-	O
casein	O
promoter	O
.	O
Coincidentally	O
,	O
a	O
deletion	O
of	O
this	O
region	O
enhanced	O
the	O
IL-2	B
-induced	O
expression	O
of	O
beta	B
-	I
casein	I
.	O
Expression	O
of	O
an	O
active	O
form	O
of	O
Ras	B
,	O
Ras	B
(	I
G12V	I
)	I
,	O
suppressed	O
the	O
IL-2	B
-induced	O
beta	B
-	I
casein	I
and	O
OSM	B
gene	O
expression	O
,	O
and	O
the	O
negative	O
effect	O
of	O
Ras	B
is	O
mediated	O
by	O
the	O
region	O
between	O
-105	O
and	O
-193	O
in	O
the	O
beta	O
-	O
casein	O
promoter	O
.	O
In	O
apparent	O
contradiction	O
,	O
expression	O
of	O
a	O
dominant	O
negative	O
form	O
of	O
Ras	B
,	O
RasN17	B
,	O
also	O
inhibited	O
IL-2	B
-induced	O
activation	O
of	O
the	O
promoter	O
containing	O
the	O
minimal	O
beta	O
-	O
casein	O
STAT5	O
element	O
as	O
well	O
as	O
the	O
promoters	O
of	O
CIS	B
and	O
OSM	B
.	O
In	O
addition	O
,	O
Ras	B
(	I
G12V	I
)	I
complemented	O
signaling	O
by	O
an	O
erythropoietin	B
receptor	I
mutant	I
defective	O
in	O
Ras	B
activation	O
and	O
augmented	O
the	O
activation	O
of	O
the	O
beta	O
-	O
casein	O
promoter	O
by	O
the	O
mutant	B
erythropoietin	I
receptor	I
signaling	O
,	O
suggesting	O
a	O
possible	O
role	O
of	O
Ras	B
in	O
Stat5	B
-mediated	O
gene	O
expression	O
.	O
These	O
results	O
collectively	O
reveal	O
a	O
complex	O
interaction	O
of	O
STAT5	B
with	O
other	O
signaling	O
pathways	O
and	O
illustrate	O
that	O
regulation	O
of	O
gene	O
expression	O
requires	O
integration	O
of	O
opposing	O
signals	O
Tobacco	O
smoke	O
induces	O
coordinate	O
activation	O
of	O
HSF	B
and	O
inhibition	O
of	O
NFkappaB	B
in	O
human	O
monocytes	O
:	O
effects	O
on	O
TNFalpha	B
release	O
.	O
Tobacco	O
smoke	O
(	O
TS	O
)	O
exposure	O
is	O
a	O
major	O
risk	O
factor	O
for	O
human	O
disease	O
,	O
and	O
macrophages	O
of	O
healthy	O
smokers	O
have	O
a	O
depressed	O
capacity	O
to	O
release	O
cytokines	B
,	O
including	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
alpha	I
.	O
TS	O
induces	O
the	O
synthesis	O
of	O
heat	B
shock	I
(	I
HS	I
)	I
/stress	I
proteins	I
(	O
HSP	B
)	O
,	O
and	O
,	O
in	O
particular	O
,	O
of	O
Hsp70	B
.	O
We	O
determined	O
whether	O
Hsp70	B
induction	O
by	O
TS	O
was	O
mediated	O
by	O
the	O
activation	O
of	O
the	O
HS	B
transcription	I
factor	I
,	O
HSF	B
.	O
HSF	B
activation	O
has	O
been	O
shown	O
to	O
inhibit	O
NFkappaB	B
.	O
Thus	O
,	O
we	O
also	O
determined	O
the	O
effects	O
of	O
TS	O
on	O
NFkappaB	B
.	O
U937	O
cells	O
and	O
human	O
peripheral	O
blood	O
monocytes	O
were	O
exposed	O
to	O
TS	O
,	O
binding	O
activities	O
of	O
the	O
respective	O
transcription	B
factors	I
were	O
analyzed	O
,	O
and	O
Hsp70	B
expression	O
and	O
TNFalpha	B
release	O
were	O
determined	O
in	O
parallel	O
.	O
TS	O
activated	O
HSF	B
,	O
which	O
was	O
associated	O
with	O
Hsp70	B
overexpression	O
and	O
inhibition	O
of	O
NFkappaB	B
binding	O
activity	O
and	O
TNFalpha	B
release	O
.	O
The	O
altered	O
cytokine	B
profile	I
observed	O
in	O
smokers	O
may	O
relate	O
to	O
an	O
HSF	B
/	O
Hsp70	B
-mediated	O
inhibition	O
of	O
NFkappaB	B
activity	O
.	O
Copyright	O
1998	O
Academic	O
Press	O
.	O
In	O
vivo	O
function	O
of	O
an	O
interleukin	B
2	I
receptor	I
beta	I
chain	I
(	B
IL-2Rbeta	I
)	I
/IL-4Ralpha	I
cytokine	I
receptor	I
chimera	I
potentiates	O
allergic	O
airway	O
disease	O
.	O
Strength	O
of	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
signaling	O
,	O
coreceptors	B
,	O
costimulation	O
,	O
antigen	O
-	O
presenting	O
cell	O
type	O
,	O
and	O
cytokines	O
all	O
play	O
crucial	O
roles	O
in	O
determining	O
the	O
efficiency	O
with	O
which	O
type	O
2	O
T	O
lymphocytes	O
(	O
Th2	O
,	O
Tc2	O
)	O
develop	O
from	O
uncommitted	B
precursors	I
.	O
To	O
investigate	O
in	O
vivo	O
regulatory	O
mechanisms	O
that	O
control	O
the	O
population	O
of	O
type	O
2	O
T	O
cells	O
and	O
disease	O
susceptibility	O
,	O
we	O
have	O
created	O
lines	O
of	O
transgenic	O
mice	O
in	O
which	O
expression	O
of	O
a	O
chimeric	B
cytokine	I
receptor	I
(	O
the	O
mouse	B
interleukin	I
2	I
receptor	I
beta	I
chain	I
[	I
IL-2Rbeta	I
]	I
extracellular	I
domain	I
fused	O
to	O
the	O
cytoplasmic	B
tail	I
of	O
IL-4Ralpha	B
)	O
is	O
targeted	O
to	O
the	O
T	O
lymphoid	O
lineage	O
using	O
the	O
proximal	O
lck	O
promoter	O
.	O
This	O
chimera	O
transduced	O
IL-4	B
-specific	O
signals	O
in	O
response	O
to	O
IL-2	B
binding	O
and	O
dramatically	O
enhanced	O
type	O
2	O
responses	O
(	O
IL-4	B
,	O
IL-5	B
,	O
and	O
immunoglobulin	B
E	I
production	O
)	O
upon	O
in	O
vitro	O
TCR	B
stimulation	O
or	O
in	O
vivo	O
antigen	O
challenge	O
.	O
Thus	O
,	O
type	O
2	O
effector	O
function	O
was	O
augmented	O
by	O
IL-4	B
signals	O
transduced	O
through	O
a	O
chimeric	B
receptor	I
expressed	O
in	O
a	O
T	O
cell	O
-	O
specific	O
manner	O
.	O
This	O
influence	O
was	O
sufficient	O
for	O
establishment	O
of	O
antigen	O
-	O
induced	O
allergic	O
airway	O
hyperresponsiveness	O
on	O
a	O
disease	O
-	O
resistant	O
background	O
The	O
T	B
-	I
cell	I
oncogenic	I
protein	I
HOX11	I
activates	O
Aldh1	B
expression	O
in	O
NIH	O
3T3	O
cells	O
but	O
represses	O
its	O
expression	O
in	O
mouse	O
spleen	O
development	O
.	O
Hox11	O
is	O
a	O
homeobox	O
gene	O
essential	O
for	O
spleen	O
formation	O
in	O
mice	O
,	O
since	O
atrophy	O
of	O
the	O
anlage	O
of	O
a	O
developing	O
spleen	O
occurs	O
in	O
early	O
embryonic	O
development	O
in	O
Hox11	O
null	O
mice	O
.	O
HOX11	B
is	O
also	O
expressed	O
in	O
a	O
subset	O
of	O
T	O
-	O
cell	O
acute	O
leukemias	O
after	O
specific	O
chromosomal	O
translocations	O
.	O
Since	O
the	O
protein	O
has	O
a	O
homeodomain	O
and	O
can	O
activate	O
transcription	O
,	O
it	O
probably	O
exerts	O
at	O
least	O
some	O
of	O
its	O
effects	O
in	O
vivo	O
by	O
regulation	O
of	O
target	O
genes	O
.	O
Representational	O
difference	O
analysis	O
has	O
been	O
used	O
to	O
isolate	O
cDNA	O
clones	O
corresponding	O
to	O
mRNA	O
species	O
activated	O
following	O
stable	O
expression	O
of	O
HOX11	B
in	O
NIH	O
3T3	O
cells	O
.	O
The	O
gene	O
encoding	O
the	O
retinoic	B
acid	I
-	I
synthesizing	I
enzyme	I
aldehyde	B
dehydrogenase	I
1	I
(	O
Aldh1	B
)	O
,	O
initially	O
called	O
Hdg-1	B
,	O
was	O
found	O
to	O
be	O
ectopically	O
activated	O
by	O
HOX11	B
in	O
this	O
system	O
.	O
Study	O
of	O
Aldh1	B
gene	O
expression	O
during	O
spleen	O
development	O
showed	O
that	O
the	O
presence	O
of	O
Aldh1	O
mRNA	O
inversely	O
correlated	O
with	O
Hox11	B
.	O
Hox11	B
null	O
mouse	O
embryos	O
have	O
elevated	O
Aldh1	O
mRNA	O
in	O
spleen	O
primordia	O
prior	O
to	O
atrophy	O
,	O
while	O
Aldh1	B
seems	O
to	O
be	O
repressed	O
by	O
Hox11	B
during	O
organogenesis	O
of	O
the	O
spleens	O
of	O
wild	O
-	O
type	O
mice	O
.	O
This	O
result	O
suggests	O
that	O
expression	O
of	O
Aldh1	B
protein	I
is	O
negatively	O
regulated	O
by	O
Hox11	B
and	O
that	O
abnormal	O
expression	O
of	O
Aldh1	B
in	O
Hox11	B
null	O
mice	O
may	O
cause	O
loss	O
of	O
splenic	O
precursor	O
cells	O
by	O
aberrant	O
retinoic	O
acid	O
metabolism	O
Granulocyte	B
colony	I
-	I
stimulating	I
factor	I
activates	O
a	O
72-kDa	B
isoform	I
of	O
STAT3	B
in	O
human	O
neutrophils	O
.	O
Granulocyte	B
colony	I
-	I
stimulating	I
factor	I
(	O
G	B
-	I
CSF	I
)	O
signaling	O
involves	O
activation	O
of	O
STATs	B
,	O
proteins	O
that	O
serve	O
the	O
dual	O
function	O
of	O
signal	O
transduction	O
and	O
activation	O
of	O
transcription	O
.	O
We	O
previously	O
demonstrated	O
that	O
G	B
-	I
CSF	I
activated	O
a	O
distinct	O
Stat3-like	B
protein	I
in	O
immature	O
and	O
mature	O
normal	O
myeloid	O
cells	O
,	O
StatG	B
.	O
StatG	B
in	O
normal	O
immature	O
human	O
myeloid	O
cells	O
,	O
i.e	O
.	O
adult	O
CD34	O
+	O
bone	O
marrow	O
cells	O
,	O
was	O
composed	O
of	O
Stat3beta	B
.	O
This	O
investigation	O
was	O
undertaken	O
to	O
determine	O
the	O
composition	O
of	O
StatG	B
in	O
mature	O
normal	O
human	O
myeloid	O
cells	O
,	O
i.e	O
.	O
polymorphonuclear	O
neutrophilic	O
granulocytes	O
(	O
PMN	O
)	O
.	O
These	O
studies	O
revealed	O
that	O
the	O
major	B
protein	I
in	O
extracts	O
of	O
PMN	O
activated	O
by	O
G	B
-	I
CSF	I
to	O
bind	O
the	O
high	O
-	O
affinity	O
serum	O
-	O
inducible	O
element	O
(	O
hSIE	O
)	O
is	O
a	O
72-kDa	B
protein	I
that	O
cross	O
-	O
reacts	O
with	O
Stat3	B
monoclonal	I
antibody	I
,	O
which	O
we	O
have	O
designated	O
Stat3gamma	B
.	O
Stat3gamma	B
is	O
derived	O
from	O
Stat3alpha	B
by	O
limited	O
proteolysis	O
and	O
lacks	O
the	O
carboxyl	B
-	I
terminal	I
portion	I
of	O
Stat3alpha	B
.	O
Because	O
this	O
region	O
of	O
Stat3alpha	B
is	O
involved	O
in	O
transcriptional	O
activation	O
,	O
our	O
findings	O
suggest	O
the	O
possibility	O
that	O
Stat3gamma	B
may	O
be	O
transcriptionally	O
inactive	O
and	O
may	O
compete	O
with	O
Stat3alpha	B
for	O
Stat3	O
binding	O
sites	O
in	O
these	O
terminally	O
differentiated	O
myeloid	O
cells	O
Membrane	B
-	I
associated	I
lymphotoxin	I
on	O
natural	O
killer	O
cells	O
activates	O
endothelial	O
cells	O
via	O
an	O
NF	B
-	I
kappaB	I
-dependent	O
pathway	O
.	O
BACKGROUND	O
:	O
Inhibition	O
of	O
complement	O
in	O
small	O
animal	O
models	O
of	O
xenotransplantation	O
has	O
demonstrated	O
graft	O
infiltration	O
with	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
and	O
monocytes	O
associated	O
with	O
endothelial	O
cell	O
(	O
EC	O
)	O
activation	O
.	O
We	O
have	O
previously	O
demonstrated	O
that	O
human	O
NK	O
cells	O
activate	O
porcine	O
EC	O
in	O
vitro	O
,	O
which	O
results	O
in	O
adhesion	B
molecule	I
expression	O
and	O
cytokine	B
secretion	O
.	O
In	O
this	O
study	O
,	O
we	O
used	O
the	O
NK	O
cell	O
line	O
NK92	O
to	O
define	O
the	O
molecular	O
and	O
cellular	O
basis	O
of	O
NK	O
cell	O
-	O
mediated	O
EC	O
activation	O
.	O
METHODS	O
:	O
EC	O
were	O
transfected	O
with	O
either	O
reporter	O
constructs	O
containing	O
the	O
luciferase	O
gene	O
driven	O
either	O
by	O
E	O
-	O
selectin	O
or	O
interleukin	O
(	O
IL	O
)	O
-8	O
promoters	O
or	O
a	O
synthetic	O
NF	O
-	O
kappaB	O
-	O
dependent	O
promoter	O
.	O
In	O
addition	O
,	O
a	O
dominant	O
-	O
negative	O
mutant	O
tumor	O
necrosis	O
factor	O
receptor	O
I	O
(	O
TNFRI	O
)	O
expression	O
vector	O
was	O
co	O
-	O
transfected	O
in	O
inhibition	O
studies	O
.	O
Forty	O
-	O
eight	O
hours	O
after	O
transfection	O
,	O
EC	O
were	O
stimulated	O
with	O
NK	O
cells	O
or	O
NK	O
cell	O
membrane	O
extracts	O
for	O
7	O
hr	O
and	O
activation	O
was	O
measured	O
by	O
a	O
luciferase	B
assay	O
.	O
RESULTS	O
:	O
Co	O
-	O
culture	O
of	O
NK	O
cells	O
with	O
transfected	O
EC	O
enhanced	O
E	B
-	I
selectin	I
,	O
IL-8	B
,	O
and	O
NF	B
-	I
kappaB	I
-dependent	O
promoter	O
activity	O
.	O
NK	O
cell	O
membrane	O
extracts	O
retained	O
the	O
capacity	O
to	O
activate	O
EC	O
and	O
induced	O
nuclear	O
translocation	O
of	O
NF	B
-	I
kappaB	I
(	O
p50	B
and	O
p65	B
)	O
.	O
Western	O
blotting	O
of	O
NK	O
cell	O
and	O
membrane	O
extracts	O
detected	O
the	O
presence	O
of	O
Lymphotoxin	B
-	I
alpha	I
(	O
LTalpha	B
)	O
but	O
not	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
.	O
Furthermore	O
,	O
LTalpha	B
was	O
secreted	O
in	O
NK	O
:	O
EC	O
co	O
-	O
cultures	O
.	O
Co	O
-	O
transfection	O
with	O
dominant	B
-	I
negative	I
mutant	I
TNFRI	I
inhibited	O
EC	O
activation	O
by	O
NK	O
cell	O
membrane	O
extracts	O
and	O
by	O
NK	O
cells	O
by	O
80	O
%	O
and	O
47	O
%	O
,	O
respectively	O
.	O
The	O
same	O
pattern	O
of	O
inhibition	O
was	O
observed	O
using	O
anti	O
-	O
human	O
LT	O
sera	O
.	O
CONCLUSIONS	O
:	O
Human	O
NK	O
cell	O
membrane	O
-	O
bound	O
LT	O
signals	O
across	O
species	O
via	O
TNFRI	B
,	O
leading	O
to	O
NF	B
-	I
kappaB	I
nuclear	O
translocation	O
and	O
transcription	O
of	O
E	B
-	I
selectin	I
and	O
IL-8	B
,	O
which	O
results	O
in	O
EC	O
activation	O
.	O
The	O
discrepancy	O
in	O
the	O
degree	O
of	O
inhibition	O
by	O
membrane	O
extracts	O
and	O
NK	O
cells	O
with	O
mutant	B
TNFRI	I
suggests	O
that	O
additional	O
pathways	O
are	O
utilized	O
by	O
NK	O
cells	O
to	O
activate	O
EC	O
Triptolide	O
induces	O
apoptotic	O
death	O
of	O
T	O
lymphocyte	O
.	O
Extract	O
of	O
Tripterygium	O
wilfordii	O
Hook	O
.	O
f	O
(	O
TWHf	O
)	O
has	O
immunosuppressive	O
activity	O
and	O
has	O
been	O
used	O
as	O
anti	O
-	O
inflammatory	O
agent	O
in	O
traditional	O
Chinese	O
medicine	O
for	O
centuries	O
.	O
Recent	O
studies	O
have	O
demonstrated	O
that	O
triptolide	O
is	O
the	O
major	O
active	O
component	O
in	O
the	O
extract	O
that	O
inhibits	O
antigen	O
or	O
mitogen	B
-induced	O
T	O
cell	O
proliferation	O
.	O
In	O
attempting	O
to	O
investigate	O
its	O
effect	O
on	O
activation	O
of	O
T	O
lymphocytes	O
,	O
we	O
found	O
triptolide	O
induces	O
apoptotic	O
death	O
of	O
T	O
cell	O
hybridomas	O
and	O
peripheral	O
T	O
cells	O
but	O
not	O
that	O
of	O
thymocytes	O
.	O
The	O
triptolide	O
-	O
induced	O
apoptosis	O
is	O
accompanied	O
by	O
increase	O
of	O
DEVD	O
-	O
cleavable	O
caspases	B
activity	O
and	O
degradation	O
of	O
caspase	B
substrate	I
poly	I
(	I
ADP	I
-	I
ribose	I
)	I
polymerase	I
(	O
PARP	B
)	O
.	O
A	O
specific	O
inhibitor	O
of	O
caspases	B
,	O
zVAD	O
-	O
FMK	O
,	O
prevents	O
triptolide	O
-	O
induced	O
PARP	B
degradation	O
and	O
DNA	O
fragmentation	O
but	O
not	O
growth	O
arrest	O
.	O
Furthermore	O
,	O
enforced	O
expression	O
of	O
Bcl-2	B
inhibited	O
triptolide	O
-	O
induced	O
degradation	O
of	O
PARP	B
and	O
apoptosis	O
.	O
These	O
results	O
indicate	O
that	O
triptolide	O
induces	O
T	O
cell	O
apoptosis	O
through	O
activating	O
caspases	B
,	O
and	O
suggest	O
the	O
growth	O
arrest	O
and	O
apoptotic	O
effect	O
of	O
triptolide	O
may	O
contribute	O
to	O
the	O
immunosuppressive	O
activity	O
of	O
TWHf	O
extract	O
Spi-1	O
/	O
PU.1	O
proto	O
-	O
oncogene	O
induces	O
opposite	O
effects	O
on	O
monocytic	O
and	O
erythroid	O
differentiation	O
of	O
K562	O
cells	O
.	O
Spi-1	B
/	I
PU.1	I
is	O
a	O
hematopoietic	B
transcription	I
factor	I
of	O
the	O
Ets	B
family	I
.	O
To	O
analyze	O
the	O
effects	O
of	O
ectopic	O
expression	O
of	O
spi-1	B
on	O
the	O
proliferation	O
/	O
differentiation	O
of	O
human	O
myeloid	O
leukemia	O
cells	O
,	O
K562	O
cells	O
were	O
stably	O
transfected	O
with	O
a	O
spi-1	O
expression	O
vector	O
.	O
The	O
transfected	O
cell	O
lines	O
expressed	O
elevated	O
levels	O
of	O
spi-1	O
mRNA	O
and	O
protein	O
and	O
high	O
Spi-1	B
-DNA	O
binding	O
activity	O
.	O
The	O
spi-1	O
transfected	O
cells	O
showed	O
reduced	O
growth	O
rates	O
and	O
reduced	O
clonogenic	O
cell	O
growth	O
.	O
When	O
the	O
erythroid	O
and	O
monocytic	O
differentiation	O
markers	O
were	O
analyzed	O
,	O
spi-1	B
overexpression	O
resulted	O
in	O
opposite	O
effects	O
:	O
erythroid	O
differentiation	O
was	O
significantly	O
inhibited	O
in	O
spi-1	O
transfectants	O
,	O
while	O
spi-1	B
overexpression	O
increased	O
the	O
monocytic	O
differentiation	O
of	O
cells	O
.	O
These	O
results	O
indicate	O
a	O
differential	O
role	O
of	O
Spi-1	O
on	O
the	O
differentiation	O
of	O
human	O
myeloid	O
leukemia	O
cells	O
.	O
Copyright	O
1998	O
Academic	O
Press	O
.	O
The	O
human	O
gene	O
encoding	O
the	O
lectin	B
-	I
type	I
oxidized	I
LDL	I
receptor	I
(	O
OLR1	B
)	O
is	O
a	O
novel	O
member	O
of	O
the	O
natural	B
killer	I
gene	I
complex	I
with	O
a	O
unique	O
expression	O
profile	O
.	O
LOX-1	B
is	O
an	O
endothelial	B
receptor	I
for	O
oxidized	B
low	I
-	I
density	I
lipoprotein	I
that	O
plays	O
essential	O
roles	O
in	O
atherogenesis	O
.	O
LOX-1	B
has	O
the	O
highest	O
homology	O
with	O
C	B
-	I
type	I
lectin	I
receptors	I
expressed	O
on	O
natural	O
killer	O
cells	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
cloned	O
and	O
characterized	O
the	O
human	O
LOX-1	O
gene	O
(	O
HGMW	B
-	I
approved	I
symbol	I
OLR1	I
)	O
.	O
The	O
gene	O
structure	O
of	O
LOX-1	B
resembles	O
that	O
of	O
the	O
natural	B
killer	I
cell	I
receptors	I
.	O
Fluorescence	O
in	O
situ	O
hybridization	O
and	O
analyses	O
of	O
a	O
yeast	O
artificial	O
chromosome	O
contig	O
revealed	O
that	O
the	O
human	O
LOX-1	O
gene	O
is	O
located	O
in	O
the	O
natural	B
killer	I
gene	I
complex	I
on	O
chromosome	O
12p12-p13	O
,	O
where	O
the	O
genes	O
of	O
the	O
natural	B
killer	I
cell	I
receptors	I
cluster	O
.	O
In	O
contrast	O
,	O
the	O
expression	O
pattern	O
of	O
LOX-1	B
is	O
different	O
from	O
that	O
of	O
the	O
natural	B
killer	I
cell	I
receptors	I
;	O
LOX-1	B
is	O
expressed	O
in	O
vascular	O
-	O
rich	O
organs	O
,	O
but	O
not	O
in	O
lymphocytes	O
.	O
A	O
1753-bp	O
fragment	O
of	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
LOX-1	O
gene	O
had	O
a	O
functional	O
promoter	O
activity	O
.	O
This	O
region	O
contains	O
binding	O
sites	O
for	O
several	O
transcription	B
factors	I
,	O
including	O
the	O
STAT	B
family	I
and	O
NF	B
-	I
IL6	I
,	O
and	O
the	O
expression	O
of	O
LOX-1	B
was	O
upregulated	O
by	O
several	O
cytokines	B
.	O
These	O
results	O
demonstrate	O
that	O
the	O
human	O
LOX-1	O
gene	O
is	O
a	O
new	O
member	O
of	O
the	O
natural	B
killer	I
gene	I
complex	I
with	O
a	O
unique	O
expression	O
profile	O
.	O
Copyright	O
1998	O
Academic	O
Press	O
.	O
Cloning	O
of	O
ARE	O
-	O
containing	O
genes	O
by	O
AU	O
-	O
motif	O
-	O
directed	O
display	O
.	O
A	O
procedure	O
suitable	O
for	O
cloning	O
labile	O
mRNAs	O
that	O
contain	O
AU	O
motifs	O
is	O
presented	O
(	O
AU	O
-	O
DD	O
)	O
.	O
These	O
motifs	O
are	O
regulatory	O
sequences	O
within	O
the	O
so	O
-	O
called	O
AU	O
-	O
rich	O
elements	O
(	O
AREs	O
)	O
often	O
found	O
in	O
3	O
'	O
untranslated	O
regions	O
of	O
genes	O
such	O
as	O
cytokines	B
,	O
proto	O
-	O
oncogenes	O
,	O
and	O
transcription	B
factors	I
.	O
AU	O
-	O
DD	O
is	O
an	O
AU	O
-	O
motif	O
-	O
directed	O
differential	O
display	O
that	O
permits	O
the	O
identification	O
of	O
ARE	O
-	O
containing	O
genes	O
differentially	O
expressed	O
after	O
cell	O
activation	O
.	O
It	O
has	O
been	O
applied	O
to	O
peripheral	O
blood	O
monocytes	O
and	O
a	O
T	O
cell	O
clone	O
to	O
isolate	O
59	O
cDNA	O
fragments	O
associated	O
to	O
activation	O
.	O
Fourteen	O
percent	O
of	O
isolated	O
fragments	O
belong	O
to	O
already	O
known	O
genes	O
that	O
certainly	O
are	O
cytokines	B
and	O
transduction	B
/	I
transcription	I
factors	I
.	O
The	O
remaining	O
86	O
%	O
correspond	O
to	O
unknown	O
genes	O
of	O
which	O
92	O
%	O
have	O
been	O
confirmed	O
to	O
be	O
differentially	O
expressed	O
.	O
These	O
data	O
demonstrate	O
the	O
efficiency	O
of	O
the	O
system	O
and	O
support	O
the	O
notion	O
that	O
numerous	O
genes	O
falling	O
into	O
those	O
categories	O
remain	O
unidentified	O
and	O
that	O
they	O
can	O
be	O
cloned	O
by	O
this	O
method	O
.	O
Copyright	O
1998	O
Academic	O
Press	O
.	O
BASH	B
,	O
a	O
novel	B
signaling	I
molecule	I
preferentially	O
expressed	O
in	O
B	O
cells	O
of	O
the	O
bursa	O
of	O
Fabricius	O
.	O
The	O
bursa	O
of	O
Fabricius	O
is	O
a	O
gut	O
-	O
associated	O
lymphoid	O
organ	O
that	O
is	O
essential	O
for	O
the	O
generation	O
of	O
a	O
diversified	O
B	O
cell	O
repertoire	O
in	O
the	O
chicken	O
.	O
We	O
describe	O
here	O
a	O
novel	O
gene	O
preferentially	O
expressed	O
in	O
bursal	O
B	O
cells	O
.	O
The	O
gene	O
encodes	O
an	O
85-kDa	B
protein	I
,	O
designated	O
BASH	B
(	O
B	B
cell	I
adaptor	I
containing	I
SH2	I
domain	I
)	O
,	O
that	O
contains	O
N	B
-	I
terminal	I
acidic	I
domains	I
with	O
SH2	B
domain	I
-	I
binding	I
phosphotyrosine	I
-	I
based	I
motifs	I
,	O
a	O
proline	B
-	I
rich	I
domain	I
,	O
and	O
a	O
C	B
-	I
terminal	I
SH2	I
domain	I
.	O
BASH	B
shows	O
a	O
substantial	O
sequence	O
similarity	O
to	O
SLP-76	B
,	O
an	O
adaptor	O
protein	O
functioning	O
in	O
TCR	B
-signal	O
transduction	O
.	O
BASH	B
becomes	O
tyrosine	O
-	O
phosphorylated	O
with	O
the	O
B	B
cell	I
Ag	I
receptor	I
(	O
BCR	B
)	O
cross	O
-	O
link	O
or	O
by	O
coexpression	O
with	O
Syk	B
and	O
Lyn	B
and	O
associates	O
with	O
signaling	B
molecules	I
including	O
Syk	B
and	O
a	O
putative	B
chicken	I
Shc	I
homologue	I
.	O
Overexpression	O
of	O
BASH	B
results	O
in	O
suppression	O
of	O
the	O
NF	B
-	I
AT	I
activation	O
induced	O
by	O
BCR	B
-cross	O
-	O
linking	O
.	O
These	O
findings	O
suggest	O
that	O
BASH	B
is	O
involved	O
in	O
BCR	B
-mediated	O
signal	O
transduction	O
and	O
could	O
play	O
a	O
critical	O
role	O
in	O
B	O
cell	O
development	O
in	O
the	O
bursa	O
.	O
Signaling	O
pathways	O
mediated	O
by	O
the	O
TNF-	B
and	I
cytokine	I
-	I
receptor	I
families	O
target	O
a	O
common	O
cis	O
-	O
element	O
of	O
the	O
IFN	O
regulatory	O
factor	O
1	O
promoter	O
.	O
CD40	B
activation	O
of	O
B	O
cells	O
is	O
strongly	O
influenced	O
by	O
the	O
presence	O
of	O
cytokines	B
.	O
However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
interplay	O
between	O
these	O
distinct	O
stimuli	O
is	O
not	O
clearly	O
delineated	O
.	O
IFN	B
regulatory	I
factor	I
1	I
(	O
IRF-1	B
)	O
is	O
a	O
transcription	B
factor	I
activated	O
by	O
either	O
CD40	B
or	O
cytokines	B
.	O
We	O
have	O
found	O
that	O
these	O
different	O
sets	O
of	O
signals	O
target	O
a	O
common	O
cis	O
-	O
acting	O
element	O
in	O
the	O
promoter	O
of	O
this	O
gene	O
,	O
the	O
IRF-1	O
gamma	O
-	O
activated	O
site	O
(	O
GAS	O
)	O
.	O
Targeting	O
of	O
the	O
IRF-1	O
GAS	O
is	O
not	O
confined	O
to	O
activation	O
via	O
CD40	B
but	O
extends	O
to	O
other	O
stimuli	O
that	O
mimic	O
the	O
CD40	B
signaling	O
cascade	O
,	O
like	O
TNF	B
-	I
alpha	I
and	O
EBV	O
.	O
In	O
contrast	O
to	O
induction	O
of	O
STATs	B
by	O
cytokines	B
,	O
the	O
IRF-1	O
GAS	O
-binding	O
complex	O
activated	O
by	O
CD40	B
,	O
TNF	B
-	I
alpha	I
,	O
or	O
EBV	O
contains	O
Rel	B
proteins	I
,	O
specifically	O
p50	B
and	O
p65	B
.	O
In	O
this	O
system	O
,	O
simultaneous	O
exposure	O
to	O
CD40L	B
together	O
with	O
either	O
IL-4	B
or	O
IFN	B
-	I
gamma	I
does	O
not	O
lead	O
to	O
the	O
activation	O
of	O
novel	O
Rel	B
/	I
STAT	I
complexes	I
.	O
Given	O
the	O
importance	O
of	O
IRF-1	B
in	O
a	O
variety	O
of	O
biologic	O
functions	O
from	O
proliferation	O
to	O
apoptosis	O
,	O
our	O
findings	O
support	O
the	O
notion	O
that	O
modulation	O
of	O
IRF-1	B
levels	O
may	O
be	O
a	O
critical	O
control	O
point	O
in	O
B	O
cell	O
activation	O
.	O
Regulation	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
AP-1	B
,	O
NFAT	B
,	O
and	O
STAT1	B
nuclear	O
import	O
in	O
T	O
lymphocytes	O
by	O
noninvasive	O
delivery	O
of	O
peptide	O
carrying	O
the	O
nuclear	B
localization	I
sequence	I
of	O
NF	B
-	I
kappa	I
B	I
p50	I
.	O
Activation	O
of	O
T	O
lymphocytes	O
by	O
Ags	B
or	O
cytokines	B
results	O
in	O
translocation	O
of	O
the	O
transcription	B
factors	I
NF	B
-	I
kappa	I
B	I
,	O
AP-1	B
,	O
NFAT	B
,	O
and	O
STAT	B
from	O
the	O
cytoplasm	O
into	O
the	O
nucleus	O
.	O
The	O
first	O
step	O
in	O
the	O
nuclear	O
import	O
process	O
is	O
recognition	O
of	O
a	O
nuclear	B
localization	I
sequence	I
(	O
NLS	B
)	O
within	O
the	O
karyophilic	B
protein	I
by	O
a	O
cytoplasmic	B
receptor	I
such	O
as	O
the	O
importin	B
(	I
karyopherin	I
)	I
-alpha	I
subunit	I
.	O
The	O
NLSs	B
of	O
NF	B
-	I
kappa	I
B	I
,	O
AP-1	B
,	O
and	O
NFAT	B
differ	O
and	O
the	O
NLS	B
of	O
STAT1	B
has	O
not	O
yet	O
been	O
identified	O
.	O
Herein	O
we	O
demonstrate	O
that	O
the	O
inducible	O
nuclear	O
import	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
AP-1	B
,	O
NFAT	B
,	O
and	O
STAT1	B
in	O
Jurkat	O
T	O
lymphocytes	O
is	O
significantly	O
inhibited	O
by	O
a	O
cell	O
-	O
permeable	O
peptide	O
carrying	O
the	O
NLS	B
of	O
the	O
NF	B
-	I
kappa	I
B	I
p50	I
subunit	I
.	O
NLS	B
peptide	O
-	O
mediated	O
disruption	O
of	O
the	O
nuclear	O
import	O
of	O
these	O
transcription	B
factors	I
results	O
in	O
inhibition	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
IL-2	O
gene	O
expression	O
,	O
processes	O
dependent	O
on	O
NF	B
-	I
kappa	I
B	I
or	O
the	O
combination	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
AP-1	B
,	O
and	O
NFAT	B
.	O
Further	O
,	O
we	O
show	O
that	O
inhibitory	O
NLS	B
peptide	O
interacts	O
in	O
vitro	O
with	O
a	O
cytoplasmic	B
NLS	I
receptor	I
complex	I
comprised	O
of	O
the	O
Rch1	B
/	I
importin	I
(	I
karyopherin	I
)	I
-beta	I
heterodimer	I
expressed	O
in	O
Jurkat	O
T	O
cells	O
.	O
Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
inducible	O
nuclear	O
import	O
of	O
NF	B
-	I
kappa	I
B	I
,	O
AP-1	B
,	O
NFAT	B
,	O
and	O
STAT1	B
in	O
Jurkat	O
T	O
cells	O
can	O
be	O
regulated	O
by	O
NLS	B
peptide	O
delivered	O
noninvasively	O
to	O
the	O
cytoplasm	O
of	O
Jurkat	O
T	O
cells	O
to	O
target	O
members	O
of	O
the	O
importin	B
(	I
karyopherin	I
)	I
-alpha	I
beta	I
NLS	B
receptor	I
complex	I
.	O
In	O
vitro	O
suppression	O
of	O
programmed	O
cell	O
death	O
of	O
B	O
cells	O
by	O
tissue	O
inhibitor	O
of	O
metalloproteinases-1	B
.	O
Cellular	O
pathways	O
for	O
induction	O
of	O
programmed	O
cell	O
death	O
(	O
PCD	O
)	O
have	O
been	O
identified	O
,	O
but	O
little	O
is	O
known	O
about	O
specific	O
extracellular	O
matrix	O
processes	O
that	O
may	O
affect	O
apoptosis	O
along	O
those	O
pathways	O
.	O
In	O
this	O
study	O
,	O
a	O
series	O
of	O
Burkitt	O
's	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines	O
were	O
assayed	O
for	O
their	O
expression	O
of	O
tissue	B
inhibitor	I
of	I
metalloproteinases	I
(	I
TIMP	I
)	I
-1	I
.	O
Results	O
indicate	O
that	O
TIMP-1-positive	O
BL	O
lines	O
show	O
resistance	O
to	O
cold	O
-	O
shock	O
-	O
induced	O
apoptosis	O
.	O
Furthermore	O
,	O
recombinant	O
TIMP-1	B
,	O
but	O
not	O
TIMP-2	B
or	O
a	O
synthetic	O
metalloproteinase	O
inhibitor	O
(	O
BB-94	O
)	O
,	O
confers	O
resistance	O
to	O
apoptosis	O
induced	O
by	O
both	O
CD95-dependent	O
and	O
-independent	O
(	O
cold	O
shock	O
,	O
serum	O
deprivation	O
,	O
and	O
gamma	O
-	O
radiation	O
)	O
pathways	O
in	O
TIMP-1-negative	O
BL	O
lines	O
.	O
TIMP-1	B
suppression	O
of	O
PCD	O
is	O
not	O
due	O
to	O
metalloproteinase	B
inhibition	O
,	O
as	O
reduction	O
and	O
alkylation	O
of	O
the	O
TIMP-1	B
did	O
not	O
abolish	O
this	O
activity	O
.	O
Retroviral	O
induction	O
of	O
TIMP-1	B
not	O
only	O
resulted	O
in	O
cell	O
survival	O
but	O
also	O
in	O
continued	O
DNA	O
synthesis	O
for	O
up	O
to	O
5	O
d	O
in	O
the	O
absence	O
of	O
serum	O
,	O
while	O
controls	O
underwent	O
apoptosis	O
.	O
This	O
resistance	O
to	O
apoptosis	O
is	O
reversed	O
by	O
anti	B
-	I
TIMP-1	I
antibodies	I
,	O
demonstrating	O
that	O
secreted	O
TIMP-1	B
is	O
active	O
in	O
blocking	O
apoptosis	O
.	O
Furthermore	O
,	O
TIMP-1	B
upregulation	O
induced	O
expression	O
of	O
Bcl	B
-	I
XL	I
but	O
not	O
Bcl-2	B
as	O
well	O
as	O
decreased	O
NF	B
-	I
kappaB	I
activity	O
as	O
compared	O
with	O
controls	O
.	O
These	O
results	O
demonstrate	O
that	O
TIMP-1	B
suppresses	O
apoptosis	O
in	O
B	O
cells	O
and	O
suggests	O
a	O
novel	O
activity	O
for	O
TIMP-1	B
in	O
tissue	O
homeostasis	O
.	O
Epithelial	O
cell	O
-	O
initiated	O
inflammation	O
plays	O
a	O
crucial	O
role	O
in	O
early	O
tissue	O
damage	O
in	O
amebic	O
infection	O
of	O
human	O
intestine	O
.	O
BACKGROUND	O
&	O
AIMS	O
:	O
Entamoeba	O
histolytica	O
infection	O
of	O
the	O
intestine	O
can	O
induce	O
severe	O
gut	O
inflammation	O
.	O
The	O
aims	O
of	O
this	O
study	O
were	O
to	O
assess	O
the	O
role	O
of	O
the	O
host	O
inflammatory	O
response	O
in	O
the	O
tissue	O
damage	O
observed	O
with	O
amebiasis	O
and	O
the	O
role	O
of	O
the	O
intestinal	O
epithelial	O
cell	O
in	O
initiating	O
that	O
response	O
.	O
METHODS	O
:	O
E.	O
histolytica	O
infection	O
was	O
established	O
in	O
human	O
intestinal	O
xenografts	O
in	O
severe	O
combined	O
immunodeficient	O
(	O
SCID	O
-	O
HU	O
-	O
INT	O
)	O
mice	O
.	O
Human	O
intestinal	O
epithelial	O
cell	O
inflammatory	O
responses	O
to	O
amebic	O
infection	O
were	O
inhibited	O
by	O
the	O
intraluminal	O
administration	O
of	O
an	O
antisense	O
oligonucleotide	O
to	O
the	O
human	B
p65	I
subunit	I
of	O
nuclear	B
factor	I
kappaB	I
,	O
and	O
the	O
role	O
of	O
neutrophils	O
in	O
tissue	O
damage	O
observed	O
with	O
amebiasis	O
was	O
studied	O
by	O
depleting	O
neutrophils	O
from	O
SCID	O
-	O
HU	O
-	O
INT	O
mice	O
.	O
RESULTS	O
:	O
Administration	O
of	O
the	O
antisense	O
oligonucleotide	O
blocked	O
the	O
production	O
of	O
human	B
interleukin	I
1beta	I
and	O
interleukin	B
8	I
by	O
intestinal	O
epithelial	O
cells	O
and	O
inhibited	O
neutrophil	O
influx	O
into	O
the	O
E.	O
histolytica	O
-	O
infected	O
intestinal	O
xenografts	O
.	O
Inhibition	O
of	O
the	O
gut	O
inflammatory	O
response	O
by	O
the	O
antisense	O
oligonucleotide	O
or	O
the	O
depletion	O
of	O
neutrophils	O
from	O
SCID	O
-	O
HU-	O
INT	O
mice	O
blocked	O
the	O
increase	O
in	O
intestinal	O
permeability	O
observed	O
with	O
amebic	O
infection	O
.	O
CONCLUSIONS	O
:	O
Intestinal	O
epithelial	O
cells	O
initiate	O
an	O
inflammatory	O
response	O
with	O
resulting	O
neutrophil	O
-	O
mediated	O
tissue	O
damage	O
in	O
response	O
to	O
E.	O
histolytica	O
infection	O
;	O
this	O
inflammatory	O
cascade	O
can	O
be	O
blocked	O
by	O
inhibiting	O
the	O
transcription	O
of	O
genes	O
regulated	O
by	O
nuclear	B
factor	I
kappaB	I
.	O
Heterogeneous	O
expression	O
of	O
the	O
lipocalin	B
NGAL	I
in	O
primary	O
breast	O
cancers	O
.	O
We	O
have	O
previously	O
shown	O
that	O
neu	O
oncogene	O
-	O
initiated	O
rat	O
mammary	O
carcinomas	O
uniquely	O
over	O
-	O
express	O
neu	B
-	I
related	I
lipocalin	I
(	O
NRL	B
)	O
,	O
a	O
member	O
of	O
the	O
calycin	B
protein	I
superfamily	I
.	O
Here	O
,	O
we	O
characterize	O
the	O
putative	B
human	I
homolog	I
of	O
NRL	B
,	O
neutrophil	B
gelatinase	I
-	I
associated	I
lipocalin	I
(	O
NGAL	B
)	O
.	O
ngal	O
gene	O
expression	O
was	O
found	O
at	O
moderate	O
levels	O
in	O
only	O
2	O
of	O
17	O
human	O
tissues	O
examined	O
,	O
breast	O
and	O
lung	O
.	O
When	O
breast	O
cancers	O
were	O
examined	O
for	O
NGAL	O
mRNA	O
and	O
protein	O
levels	O
,	O
they	O
were	O
found	O
to	O
exhibit	O
heterogeneous	O
expression	O
.	O
NGAL	B
levels	O
varied	O
in	O
these	O
tumors	O
from	O
undetectable	O
to	O
exceeding	O
those	O
in	O
normal	O
breast	O
parenchyma	O
.	O
Immuno	O
-	O
histochemical	O
analysis	O
confirmed	O
the	O
presence	O
of	O
NGAL	B
within	O
breast	O
carcinoma	O
cells	O
but	O
detected	O
only	O
low	O
levels	O
of	O
this	O
protein	O
in	O
normal	O
ductal	O
epithelium	O
.	O
In	O
contrast	O
,	O
large	O
amounts	O
of	O
the	O
protein	O
were	O
localized	O
to	O
the	O
lumen	O
of	O
normal	O
breast	O
ducts	O
in	O
the	O
vicinity	O
of	O
NGAL	B
-expressing	O
tumors	O
.	O
Interestingly	O
,	O
unlike	O
NRL	B
in	O
rat	O
mammary	O
carcinomas	O
,	O
no	O
significant	O
association	O
between	O
NGAL	B
expression	O
and	O
HER-2	B
/	I
neu	I
activation	O
was	O
found	O
in	O
human	O
breast	O
tumors	O
.	O
In	O
contrast	O
,	O
a	O
significant	O
correlation	O
between	O
NGAL	B
expression	O
in	O
breast	O
cancer	O
was	O
found	O
with	O
several	O
other	O
markers	O
of	O
poor	O
prognosis	O
,	O
including	O
estrogen	O
and	O
progesterone	B
receptor	I
-negative	O
status	O
and	O
high	O
proliferation	O
(	O
S	O
-	O
phase	O
fraction	O
)	O
.	O
NGAL	B
levels	O
were	O
stratified	O
as	O
high	O
or	O
low	O
in	O
breast	O
cancers	O
from	O
a	O
cohort	O
of	O
node	O
-	O
positive	O
patients	O
with	O
known	O
outcome	O
.	O
No	O
significant	O
association	O
between	O
NGAL	B
expression	O
and	O
disease	O
-	O
free	O
or	O
overall	O
survival	O
was	O
observed	O
.	O
Interleukin-12	B
expression	O
in	O
B	O
cells	O
by	O
transformation	O
with	O
Epstein	O
-	O
Barr	O
virus	O
.	O
Although	O
interleukin	B
(	I
IL	I
)	I
-12	I
was	O
originally	O
purified	O
from	O
an	O
Epstein	O
-	O
Barr	O
(	O
EBV	O
)	O
-transformed	O
B	O
cell	O
line	O
and	O
the	O
high	O
correlation	O
of	O
EBV	O
infection	O
and	O
IL-12	B
expression	O
has	O
been	O
suggested	O
,	O
no	O
study	O
has	O
reported	O
whether	O
EBV	O
infection	O
is	O
directly	O
linked	O
to	O
IL-12	B
expression	O
.	O
To	O
address	O
this	O
issue	O
,	O
we	O
have	O
investigated	O
IL-12	B
expression	O
in	O
B	O
cells	O
during	O
in	O
vitro	O
transformation	O
with	O
EBV	O
.	O
Human	O
peripheral	O
B	O
cells	O
became	O
capable	O
of	O
constitutively	O
producing	O
p40	O
by	O
in	O
vitro	O
transformation	O
with	O
EBV	O
,	O
coincident	O
with	O
the	O
expression	O
of	O
latent	B
membrane	I
protein	I
1	I
(	O
LMP1	B
)	O
of	O
EBV	O
.	O
These	O
B	O
cells	O
expressed	O
p40	O
and	O
p35	O
mRNA	O
,	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
stimulation	O
strongly	O
enhanced	O
p40	O
and	O
p70	O
production	O
.	O
Furthermore	O
,	O
transfection	O
with	O
LMP1	O
expression	O
vector	O
into	O
a	O
human	O
B	O
lymphoma	O
cell	O
line	O
,	O
Daudi	O
,	O
led	O
to	O
p40	B
production	O
with	O
nuclear	B
factor	I
(	I
NF	I
)	I
-kappaB	I
activation	O
.	O
These	O
results	O
suggest	O
that	O
transformation	O
of	O
primary	O
B	O
cells	O
with	O
EBV	O
induces	O
IL-12	B
expression	O
potentially	O
through	O
LMP1	B
expression	O
.	O
Copyright	O
1998	O
Academic	O
Press	O
.	O
Anaphylatoxins	B
C5a	B
and	O
C3a	B
induce	O
nuclear	B
factor	I
kappaB	I
activation	O
in	O
human	O
peripheral	O
blood	O
monocytes	O
.	O
The	O
anaphylatoxins	B
C5a	B
and	O
C3a	B
are	O
involved	O
in	O
the	O
regulation	O
of	O
cytokine	O
production	O
.	O
In	O
this	O
study	O
the	O
capability	O
of	O
C5a	B
and	O
C3a	B
to	O
induce	O
transcription	O
factor	O
activation	O
was	O
examined	O
.	O
C5a	B
and	O
C3a	B
stimulation	O
of	O
human	O
peripheral	O
blood	O
monocytes	O
resulted	O
in	O
nuclear	O
expression	O
of	O
a	O
DNA	O
binding	O
activity	O
with	O
specificity	O
to	O
the	O
kappaB	O
sequence	O
.	O
The	O
p50	B
and	I
p65	I
proteins	I
,	O
constituents	O
of	O
the	O
prototypic	O
nuclear	B
factor	I
kappaB	I
,	O
were	O
identified	O
as	O
components	O
of	O
the	O
DNA	O
-	O
protein	O
complexes	O
by	O
anti	B
-	I
peptide	I
antibodies	I
in	O
gel	O
supershift	O
assays	O
.	O
C5a	B
induced	O
kappaB	B
binding	O
activity	O
was	O
detected	O
15	O
min	O
after	O
agonist	O
stimulation	O
,	O
peaked	O
at	O
30	O
-	O
40	O
min	O
,	O
and	O
remained	O
detectable	O
at	O
2	O
h	O
.	O
Binding	O
to	O
kappaB	O
sequence	O
was	O
accompanied	O
by	O
an	O
initial	O
decrease	O
and	O
subsequent	O
increase	O
in	O
the	O
cytoplasmic	O
IkappaBalpha	B
levels	O
,	O
as	O
detected	O
by	O
Western	O
blotting	O
using	O
an	O
anti	B
-	I
IkappaBalpha	I
antibody	I
.	O
Pertussis	O
toxin	O
treatment	O
markedly	O
decreased	O
kappaB	B
binding	O
activities	O
induced	O
by	O
both	O
C5a	B
and	O
C3a	B
,	O
whereas	O
cholera	B
toxin	I
displayed	O
no	O
inhibitory	O
effect	O
.	O
Neither	O
of	O
the	O
two	O
toxins	O
affected	O
kappaB	B
binding	O
activity	O
induced	O
by	O
TNFalpha	B
in	O
the	O
same	O
cells	O
.	O
These	O
results	O
imply	O
a	O
potential	O
role	O
of	O
the	O
anaphylatoxins	B
C5a	B
and	O
C3a	B
in	O
regulating	O
leukocytes	O
gene	O
expression	O
through	O
G	O
protein	O
-	O
coupled	O
transcription	O
factor	O
activation	O
.	O
Host	O
control	O
of	O
HIV-1	O
parasitism	O
in	O
T	O
cells	O
by	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
.	O
Post	O
HIV-1	O
entry	O
,	O
productive	O
HIV-1	O
infection	O
of	O
primary	O
T	O
cells	O
requires	O
overcoming	O
several	O
cellular	O
blocks	O
to	O
provirus	O
establishment	O
and	O
replication	O
.	O
Activation	O
of	O
unknown	O
host	O
intracellular	O
events	O
overcomes	O
such	O
inhibitory	O
steps	O
and	O
is	O
concomitant	O
with	O
HIV-1	O
replication	O
.	O
We	O
show	O
that	O
the	O
transcription	B
factor	I
NFATc	B
was	O
sufficient	O
as	O
a	O
cellular	O
factor	O
to	O
induce	O
a	O
highly	O
permissive	O
state	O
for	O
HIV-1	O
replication	O
in	O
primary	O
CD4	O
+	O
T	O
cells	O
.	O
NFATc	B
overcame	O
a	O
blockade	O
at	O
reverse	O
transcription	O
and	O
permitted	O
active	O
HIV-1	O
replication	O
.	O
Pharmacologic	O
blockade	O
of	O
endogenous	B
NFAT	I
activity	O
by	O
FK506	O
or	O
CsA	O
inhibited	O
synthesis	O
of	O
reverse	O
transcription	O
and	O
also	O
potently	O
blocked	O
HIV-1	O
replication	O
.	O
T	O
cells	O
therefore	O
can	O
become	O
competent	O
for	O
HIV-1	O
replication	O
by	O
control	O
of	O
regulated	B
host	I
factors	I
such	O
as	O
the	O
NFATc	B
transcription	B
factor	I
.	O
The	O
host	O
mechanisms	O
regulated	O
by	O
such	O
permissivity	O
factors	O
are	O
potential	O
targets	O
for	O
anti	O
-	O
HIV-1	O
therapy	O
.	O
Regulation	O
of	O
PAK	O
activation	O
and	O
the	O
T	O
cell	O
cytoskeleton	O
by	O
the	O
linker	B
protein	I
SLP-76	B
.	O
Tyrosine	O
phosphorylation	O
of	O
linker	B
proteins	I
enables	O
the	O
T	B
cell	I
antigen	I
receptor	I
(	I
TCR	I
)	I
-associated	I
protein	I
tyrosine	I
kinases	I
to	O
phosphorylate	O
and	O
regulate	O
effector	B
molecules	I
that	O
generate	O
second	B
messengers	I
.	O
We	O
demonstrate	O
here	O
that	O
the	O
SLP-76	B
linker	O
protein	O
interacts	O
with	O
both	O
nck	B
,	O
an	O
adaptor	B
protein	I
,	O
and	O
Vav	B
,	O
a	O
guanine	B
nucleotide	I
exchange	I
factor	I
for	O
Rho	B
-	I
family	I
GTPases	I
.	O
The	O
assembly	O
of	O
this	O
tri	B
-	I
molecular	I
complex	I
permits	O
the	O
activated	O
Rho	B
-	I
family	I
GTPases	I
to	O
regulate	O
target	O
effectors	O
that	O
interact	O
through	O
nck	B
.	O
In	O
turn	O
,	O
assembly	O
of	O
this	O
complex	O
mediates	O
the	O
enzymatic	O
activation	O
of	O
the	O
p21-activated	B
protein	I
kinase	I
1	I
and	O
facilitates	O
actin	B
polymerization	O
.	O
Hence	O
,	O
phosphorylation	O
of	O
linker	B
proteins	I
not	O
only	O
bridges	O
the	O
TCR	B
-	I
associated	I
PTK	I
,	O
ZAP-70	B
,	O
with	O
downstream	O
effector	O
proteins	O
,	O
but	O
also	O
provides	O
a	O
scaffold	O
to	O
integrate	O
distinct	O
signaling	B
complexes	I
to	O
regulate	O
T	O
cell	O
function	O
.	O
Inhibition	O
of	O
Th1	O
development	O
mediated	O
by	O
GATA-3	B
through	O
an	O
IL-4-independent	O
mechanism	O
.	O
Recently	O
,	O
the	O
transcription	B
factor	I
GATA-3	B
was	O
shown	O
to	O
be	O
selectively	O
expressed	O
in	O
Th2	O
but	O
not	O
Th1	O
cells	O
and	O
to	O
augment	O
Th2-specific	B
cytokines	I
.	O
Here	O
,	O
we	O
show	O
that	O
loss	O
of	O
GATA-3	B
expression	O
by	O
developing	O
Th1	O
cells	O
requires	O
IL-12	B
signaling	O
through	O
Stat4	B
and	O
does	O
not	O
simply	O
result	O
from	O
an	O
absence	O
of	O
IL-4	B
.	O
Moreover	O
,	O
we	O
demonstrate	O
a	O
novel	O
role	O
for	O
GATA-3	B
in	O
directly	O
repressing	O
Th1	O
development	O
distinct	O
from	O
its	O
positive	O
actions	O
on	O
Th2-specific	B
cytokines	I
.	O
GATA-3	B
inhibits	O
Th1	B
cytokines	I
by	O
a	O
cell	O
-	O
intrinsic	O
mechanism	O
that	O
is	O
not	O
dependent	O
on	O
IL-4	B
and	O
that	O
may	O
involve	O
repression	O
of	O
IL-12	B
signaling	O
.	O
Thus	O
,	O
GATA-3	B
expression	O
and	O
IL-12	B
signaling	O
are	O
mutually	O
antagonistic	O
,	O
which	O
facilitates	O
rapid	O
dominance	O
of	O
one	O
pathway	O
during	O
early	O
Th	O
development	O
,	O
producing	O
a	O
stable	O
divergence	O
in	O
cytokine	B
profiles	O
.	O
Stat6	B
inhibits	O
human	O
interleukin-4	O
promoter	O
activity	O
in	O
T	O
cells	O
.	O
The	O
differentiation	O
of	O
naive	O
T	O
-	O
helper	O
(	O
Th	O
)	O
cells	O
into	O
cytokine	O
-	O
secreting	O
effector	O
Th	O
cells	O
requires	O
exposure	O
to	O
multiple	O
signals	O
,	O
including	O
exogenous	B
cytokines	I
.	O
Interleukin-4	B
(	O
IL-4	B
)	O
plays	O
a	O
major	O
role	O
in	O
this	O
process	O
by	O
promoting	O
the	O
differentiation	O
of	O
IL-4	B
-secreting	O
Th2	O
cells	O
.	O
In	O
Th2	O
cells	O
,	O
IL-4	B
gene	O
expression	O
is	O
tightly	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
by	O
the	O
coordinated	O
binding	O
of	O
multiple	O
transcription	B
factors	I
to	O
regulatory	O
elements	O
in	O
the	O
proximal	O
promoter	O
region	O
.	O
Nuclear	B
factor	I
of	I
activated	I
T	I
cell	I
(	I
NFAT	I
)	I
family	I
members	I
play	O
a	O
critical	O
role	O
in	O
regulating	O
IL-4	B
transcription	O
and	O
interact	O
with	O
up	O
to	O
five	O
sequences	O
(	O
termed	O
P0	O
through	O
P4	O
)	O
in	O
the	O
IL-4	O
promoter	O
.	O
The	O
molecular	O
mechanisms	O
by	O
which	O
IL-4	B
induces	O
expression	O
of	O
the	O
IL-4	O
gene	O
are	O
not	O
known	O
,	O
although	O
the	O
IL-4-activated	B
transcription	I
factor	I
signal	I
transducer	I
and	I
activator	I
of	I
transcription	I
6	I
(	O
Stat6	B
)	O
is	O
required	O
for	O
this	O
effect	O
.	O
We	O
report	O
here	O
that	O
Stat6	B
interacts	O
with	O
three	O
binding	O
sites	O
in	O
the	O
human	O
IL-4	O
promoter	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
These	O
sites	O
overlap	O
the	O
P1	O
,	O
P2	O
,	O
and	O
P4	O
NFAT	O
elements	O
.	O
To	O
investigate	O
the	O
role	O
of	O
Stat6	B
in	O
regulating	O
IL-4	B
transcription	O
,	O
we	O
used	O
Stat6	B
-deficient	O
Jurkat	O
T	O
cells	O
with	O
different	O
intact	O
IL-4	O
promoter	O
constructs	O
in	O
cotransfection	O
assays	O
.	O
We	O
show	O
that	O
,	O
whereas	O
a	O
multimerized	O
response	O
element	O
from	O
the	O
germline	O
IgE	O
promoter	O
was	O
highly	O
induced	O
by	O
IL-4	B
in	O
Stat6-expressing	O
Jurkat	O
cells	O
,	O
the	O
intact	O
human	O
IL-4	O
promoter	O
was	O
repressed	O
under	O
similar	O
conditions	O
.	O
We	O
conclude	O
that	O
the	O
function	O
of	O
Stat6	B
is	O
highly	O
dependent	O
on	O
promoter	O
context	O
and	O
that	O
this	O
factor	O
promotes	O
IL-4	B
gene	O
expression	O
in	O
an	O
indirect	O
manner	O
.	O
Glucocorticoid	B
receptors	I
on	O
mononuclear	O
leukocytes	O
in	O
polycystic	O
ovary	O
syndrome	O
.	O
OBJECTIVE	O
:	O
Many	O
studies	O
have	O
suggested	O
that	O
there	O
is	O
a	O
possible	O
hormonal	O
dysregulation	O
of	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
and	O
an	O
increased	O
cortisol	O
clearance	O
in	O
patients	O
with	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
.	O
Therefore	O
in	O
this	O
study	O
,	O
we	O
have	O
examined	O
the	O
role	O
of	O
glucocorticoid	B
receptor	I
/	I
s	I
(	O
GR	B
)	O
characteristics	O
in	O
the	O
developing	O
of	O
these	O
abnormalities	O
in	O
patients	O
with	O
PCOS	O
.	O
METHOD	O
:	O
For	O
this	O
purpose	O
,	O
the	O
number	O
and	O
affinity	O
of	O
GR	B
in	O
peripheral	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
of	O
10	O
patients	O
with	O
PCOS	O
and	O
10	O
healthy	O
women	O
(	O
controls	O
)	O
were	O
determined	O
.	O
RESULTS	O
:	O
There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
number	O
(	O
6500+	O
/	O
-1001	O
sites	O
/	O
cell	O
and	O
6352+	O
/	O
-1697	O
sites	O
/	O
cell	O
,	O
respectively	O
;	O
P	O
>	O
0.05	O
)	O
and	O
affinity	O
(	O
3.93+	O
/	O
-0.89	O
nM	O
and	O
4.49+	O
/	O
-0.71	O
nM	O
,	O
respectively	O
;	O
P	O
>	O
0.05	O
)	O
of	O
GR	B
between	O
the	O
PCOS	O
patients	O
and	O
the	O
controls	O
.	O
CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
the	O
alterations	O
in	O
the	O
HPA	O
axis	O
and	O
in	O
the	O
cortisol	O
metabolism	O
observed	O
in	O
PCOS	O
are	O
not	O
related	O
to	O
GR	B
deficiency	O
.	O
The	O
linkage	O
between	O
T	O
-	O
cell	O
and	O
dendritic	O
cell	O
development	O
in	O
the	O
mouse	O
thymus	O
.	O
Thymic	O
dendritic	O
cells	O
(	O
DC	O
)	O
mediate	O
negative	O
selection	O
at	O
a	O
relatively	O
late	O
stage	O
of	O
the	O
T	O
-	O
cell	O
developmental	O
pathway	O
.	O
We	O
present	O
evidence	O
that	O
the	O
development	O
of	O
thymic	O
DC	O
and	O
of	O
T	O
-	O
lineage	O
cells	O
is	O
linked	O
via	O
a	O
common	O
precursor	O
at	O
an	O
early	O
stage	O
of	O
thymocyte	O
development	O
.	O
T	O
-	O
lineage	O
precursor	O
populations	O
from	O
the	O
adult	O
mouse	O
thymus	O
,	O
prior	O
to	O
T	O
-	O
cell	O
receptor	O
gene	O
rearrangement	O
,	O
display	O
a	O
capacity	O
to	O
produce	O
DC	O
as	O
well	O
as	O
T	O
cells	O
in	O
the	O
thymus	O
,	O
and	O
are	O
very	O
efficient	O
precursors	O
of	O
DC	O
in	O
culture	O
.	O
These	O
lymphoid	O
/	O
DC	O
precursors	O
have	O
little	O
capacity	O
to	O
form	O
myeloid	O
cells	O
,	O
indicating	O
that	O
thymic	O
DC	O
are	O
a	O
lymphoid	O
-	O
related	O
rather	O
than	O
myeloid	O
-	O
related	O
lineage	O
.	O
In	O
contrast	O
to	O
myeloid	O
-	O
related	O
DC	O
,	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
is	O
not	O
required	O
for	O
the	O
development	O
of	O
these	O
lymphoid	O
-	O
related	O
DC	O
in	O
vivo	O
or	O
in	O
vitro	O
.	O
DC	O
can	O
develop	O
in	O
mutant	O
mice	O
lacking	O
mature	O
T	O
cells	O
,	O
provided	O
the	O
common	O
precursors	O
are	O
present	O
.	O
However	O
,	O
in	O
mutant	O
mice	O
lacking	O
functional	O
Ikaros	B
transcription	B
factors	I
,	O
there	O
are	O
deficiencies	O
in	O
lymphoid	O
precursor	O
cells	O
,	O
in	O
mature	O
lymphoid	O
cells	O
and	O
in	O
DC	O
.	O
The	O
involvement	O
of	O
multiple	O
tumor	B
necrosis	I
factor	I
receptor	I
(	I
TNFR	I
)	I
-associated	I
factors	I
in	O
the	O
signaling	O
mechanisms	O
of	O
receptor	B
activator	I
of	O
NF	B
-	I
kappaB	I
,	O
a	O
member	O
of	O
the	O
TNFR	B
superfamily	I
.	O
Receptor	B
activator	I
of	I
NF	I
-	I
kappaB	I
(	O
RANK	B
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
tumor	B
necrosis	I
factor	I
receptor	I
superfamily	I
and	O
is	O
expressed	O
on	O
activated	O
T	O
cells	O
and	O
dendritic	O
cells	O
.	O
Its	O
cognate	B
ligand	I
(	O
RANKL	B
)	O
plays	O
significant	O
roles	O
in	O
the	O
activation	O
of	O
dendritic	O
cell	O
function	O
and	O
osteoclast	O
differentiation	O
.	O
We	O
demonstrate	O
here	O
the	O
interaction	O
of	O
RANK	B
with	O
tumor	B
necrosis	I
factor	I
receptor	I
-	I
associated	I
factors	I
(	I
TRAFs	I
)	I
1	I
,	I
2	I
,	I
3	I
,	I
5	I
,	I
and	I
6	I
both	O
in	O
vitro	O
and	O
in	O
cells	O
.	O
Mapping	O
of	O
the	O
structural	O
requirements	O
for	O
TRAF	B
/RANK	B
interaction	O
revealed	O
multiple	O
TRAF	B
binding	I
sites	I
clustered	O
in	O
two	O
distinct	O
domains	O
in	O
the	O
RANK	B
cytoplasmic	I
tail	I
.	O
These	O
TRAF	B
binding	I
domains	I
were	O
shown	O
to	O
be	O
functionally	O
important	O
for	O
the	O
RANK	B
-dependent	O
induction	O
of	O
NF	B
-	I
kappaB	I
and	O
c	B
-	I
Jun	I
NH2-terminal	B
kinase	I
activities	O
.	O
Site	O
-	O
directed	O
mutagenesis	O
demonstrated	O
that	O
these	O
TRAF	B
binding	I
sites	I
exhibited	O
selective	O
binding	O
for	O
different	O
TRAF	B
proteins	I
.	O
In	O
particular	O
,	O
TRAF6	B
interacted	O
with	O
membrane	B
-	I
proximal	I
determinants	I
distinct	O
from	O
those	O
binding	O
TRAFs	B
1	I
,	I
2	I
,	I
3	I
,	I
and	I
5	I
.	O
When	O
this	O
membrane	B
-	I
proximal	I
TRAF6	I
interaction	I
domain	I
was	O
deleted	O
,	O
RANK	B
-mediated	O
NF	B
-	I
kappaB	I
signaling	O
was	O
completely	O
inhibited	O
while	O
c	B
-	I
Jun	I
NH2-terminal	I
kinase	I
activation	O
was	O
partially	O
inhibited	O
.	O
An	O
NH2-terminal	B
truncation	I
mutant	I
of	O
TRAF6	B
inhibited	O
RANKL	B
-mediated	O
NF	B
-	I
kappaB	I
activation	O
,	O
but	O
failed	O
to	O
affect	O
constitutive	O
signaling	O
induced	O
by	O
receptor	O
overexpression	O
,	O
revealing	O
a	O
selective	O
role	O
for	O
TRAF6	B
in	O
ligand	O
-	O
induced	O
activation	O
events	O
.	O
Molecular	O
cloning	O
of	O
FKHRL1P2	B
,	O
a	O
member	O
of	O
the	O
developmentally	O
regulated	O
fork	B
head	I
domain	I
transcription	I
factor	I
family	I
.	O
Here	O
we	O
report	O
the	O
expression	O
of	O
a	O
fork	B
head	I
domain	I
protein	I
in	O
human	O
T	O
helper	O
cells	O
.	O
We	O
cloned	O
and	O
characterized	O
a	O
fork	O
head	O
cDNA	O
from	O
human	O
T	O
helper	O
cell	O
mRNA	O
using	O
differential	O
display	O
RT	O
-	O
PCR	O
.	O
The	O
cDNA	O
contains	O
a	O
546-nucleotide	O
(	O
nt	O
)	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
that	O
codes	O
for	O
the	O
carboxyl	B
-	I
terminal	I
180	I
amino	I
acids	I
(	O
aa	O
)	O
of	O
the	O
recently	O
identified	O
fkhrl1	O
gene	O
.	O
This	O
ORF	O
does	O
not	O
contain	O
the	O
characteristic	O
DNA	O
-	O
binding	O
domain	O
found	O
in	O
members	O
of	O
the	O
forkhead	B
protein	I
family	I
.	O
In	O
-	O
vitro	O
transcription	O
/	O
translation	O
of	O
this	O
cDNA	O
expressed	O
a	O
protein	O
of	O
approximately	O
20	O
kDa	O
.	O
We	O
have	O
generated	O
antibodies	O
that	O
specifically	O
immunoprecipitated	O
the	O
in	B
-	I
vitro	I
-	I
translated	I
20-kDa	I
protein	I
.	O
This	O
antibody	O
also	O
recognizes	O
in	O
human	O
T	O
lymphocytes	O
a	O
70-kDa	O
protein	O
corresponding	O
in	O
size	O
to	O
that	O
predicted	O
for	O
the	O
fkhrl1	O
gene	O
product	O
.	O
The	O
mRNA	O
levels	O
for	O
fkhrl1	O
is	O
elevated	O
in	O
T	O
helper	O
-	O
induced	O
lymphocytes	O
in	O
comparison	O
to	O
PHA	O
-	O
stimulated	O
T	O
lymphocytes	O
.	O
Further	O
characterization	O
of	O
FKHRL1	O
and	O
its	O
related	O
family	O
members	O
should	O
shed	O
light	O
on	O
the	O
transcriptional	O
mechanisms	O
of	O
this	O
fork	O
head	O
gene	O
subfamily	O
and	O
their	O
role	O
in	O
T	O
helper	O
cell	O
differentiation	O
and	O
regulation	O
of	O
cell	O
growth	O
.	O
Activation	O
of	O
the	O
human	O
delta	O
-	O
globin	O
gene	O
promoter	O
in	O
primary	O
adult	O
erythroid	O
cells	O
.	O
Restoration	O
of	O
the	O
CCAAT	O
box	O
or	O
insertion	O
of	O
an	O
erythroid	O
Kruppel	O
-	O
like	O
factor	O
(	O
EKLF	O
)	O
binding	O
site	O
in	O
the	O
delta	O
promoter	O
activates	O
its	O
expression	O
in	O
several	O
erythroid	O
cell	O
lines	O
.	O
We	O
extended	O
these	O
studies	O
using	O
a	O
novel	O
primary	O
human	O
adult	O
erythroid	O
cell	O
(	O
hAEC	O
)	O
system	O
to	O
investigate	O
these	O
effects	O
at	O
the	O
late	O
erythroblast	O
stage	O
.	O
Restoration	O
of	O
the	O
CCAAT	O
box	O
at	O
-70	O
bp	O
,	O
or	O
insertion	O
of	O
an	O
EKLF	O
binding	O
site	O
at	O
-85	O
bp	O
or	O
-95	O
bp	O
in	O
the	O
promoter	O
significantly	O
increased	O
delta	O
globin	O
gene	O
expression	O
in	O
hAEC	O
.	O
Our	O
results	O
demonstrate	O
that	O
the	O
altered	O
CCAAT	O
box	O
(	O
CCAAC	O
)	O
and	O
the	O
lack	O
of	O
an	O
EKLF	O
binding	O
site	O
in	O
delta	B
-	I
globin	I
contribute	O
to	O
its	O
low	O
level	O
of	O
expression	O
in	O
the	O
hAEC	O
model	O
as	O
well	O
.	O
The	O
control	O
of	O
lytic	O
replication	O
of	O
Epstein	O
-	O
Barr	O
virus	O
in	O
B	O
lymphocytes	O
(	O
Review	O
)	O
.	O
Uncontrolled	O
replication	O
of	O
a	O
virus	O
,	O
which	O
is	O
harmful	O
to	O
the	O
host	O
is	O
also	O
disadvantageous	O
to	O
the	O
virus	O
.	O
Most	O
viruses	O
can	O
not	O
compete	O
with	O
the	O
various	O
immune	O
mechanisms	O
and	O
become	O
eliminated	O
in	O
the	O
course	O
of	O
infection	O
.	O
Therefore	O
,	O
only	O
the	O
time	O
between	O
infection	O
and	O
eradication	O
remains	O
for	O
these	O
viruses	O
to	O
proliferate	O
.	O
A	O
few	O
viruses	O
,	O
like	O
the	O
Herpesviruses	O
or	O
the	O
papillomaviruses	O
,	O
however	O
,	O
have	O
developed	O
a	O
sophisticated	O
strategy	O
for	O
persisting	O
lifelong	O
,	O
usually	O
asymptomatically	O
in	O
the	O
host	O
,	O
hiding	O
from	O
the	O
immune	O
system	O
and	O
producing	O
infectious	O
progeny	O
at	O
the	O
same	O
time	O
.	O
This	O
strategy	O
depends	O
on	O
a	O
separation	O
of	O
latency	O
and	O
the	O
lytic	O
replication	O
,	O
either	O
by	O
time	O
due	O
to	O
differentiation	O
-	O
dependent	O
mechanisms	O
or	O
by	O
spatial	O
separation	O
as	O
the	O
result	O
of	O
different	O
host	O
cell	O
types	O
.	O
Both	O
are	O
true	O
for	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O
B	O
cells	O
and	O
epithelial	O
cells	O
have	O
a	O
pivotal	O
role	O
in	O
the	O
life	O
cycle	O
of	O
the	O
virus	O
.	O
The	O
former	O
can	O
become	O
latently	O
infected	O
and	O
are	O
thought	O
to	O
be	O
the	O
virus	O
reservoir	O
in	O
vivo	O
,	O
whereas	O
the	O
latter	O
were	O
shown	O
to	O
be	O
permissive	O
for	O
lytic	O
replication	O
.	O
However	O
,	O
replication	O
of	O
EBV	O
in	O
vivo	O
is	O
controlled	O
primarily	O
by	O
host	O
immune	O
mechanisms	O
selecting	O
for	O
cells	O
that	O
are	O
not	O
permissive	O
for	O
viral	O
replication	O
as	O
the	O
result	O
of	O
a	O
particular	O
set	O
of	O
transcription	B
factors	I
.	O
These	O
factors	O
control	O
the	O
activity	O
of	O
the	O
regulatory	O
immediate	O
-	O
early	O
genes	O
and	O
,	O
in	O
addition	O
,	O
lytic	O
and	O
latent	O
cycle	O
regulatory	O
genes	O
negatively	O
interfere	O
with	O
each	O
other	O
and	O
thus	O
link	O
cellular	O
and	O
viral	O
gene	O
regulatory	O
mechanisms	O
.	O
Disturbance	O
of	O
both	O
the	O
immune	O
surveillance	O
as	O
well	O
as	O
viral	O
gene	O
regulation	O
may	O
result	O
in	O
EBV	O
-	O
associated	O
disease	O
.	O
Human	O
immunodeficiency	O
virus	O
type-1	O
transcription	O
:	O
role	O
of	O
the	O
5'-untranslated	O
leader	O
region	O
(	O
review	O
)	O
.	O
Human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
transcription	O
is	O
dependent	O
on	O
the	O
interaction	O
of	O
host	B
-	I
cell	I
transcription	I
factors	I
with	O
cis	O
-	O
regulatory	O
DNA	O
elements	O
within	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O
Much	O
attention	O
has	O
focused	O
on	O
the	O
series	O
of	O
sequence	O
elements	O
upstream	O
of	O
the	O
transcriptional	O
initiation	O
site	O
in	O
the	O
U3	O
region	O
of	O
the	O
LTR	O
including	O
the	O
Sp1	B
and	O
NF	B
-	I
kappaB	I
binding	O
sites	O
.	O
Recent	O
studies	O
,	O
however	O
,	O
demonstrate	O
that	O
the	O
transcribed	O
5'-untranslated	O
leader	O
region	O
(	O
5'-UTR	O
)	O
also	O
contains	O
important	O
transcriptional	O
elements	O
.	O
These	O
regulatory	O
elements	O
situated	O
downstream	O
of	O
transcription	O
interact	O
with	O
constitutive	O
and	O
inducible	O
transcription	B
factors	I
,	O
mediate	O
transmission	O
of	O
cellular	O
activation	O
signals	O
,	O
and	O
are	O
important	O
for	O
efficient	O
HIV-1	O
transcription	O
and	O
replication	O
.	O
The	O
5'-UTR	O
contains	O
binding	O
sites	O
for	O
the	O
transcription	B
factors	I
AP-1	O
,	O
NF	B
-	I
kappaB	I
,	O
NF	B
-	I
AT	I
,	O
IRF	B
,	O
and	O
Sp1	B
.	O
Mutations	O
in	O
these	O
binding	O
sites	O
can	O
interfere	O
with	O
the	O
viral	O
response	O
to	O
cell	O
activation	O
signals	O
,	O
decrease	O
LTR	O
transcription	O
,	O
and	O
inhibit	O
viral	O
replication	O
.	O
The	O
5'-UTR	O
also	O
interacts	O
with	O
a	O
specific	O
nucleosome	B
that	O
is	O
rapidly	O
displaced	O
during	O
transcriptional	O
activation	O
of	O
the	O
latent	O
provirus	O
.	O
We	O
propose	O
that	O
the	O
inducible	O
transcription	O
factor	O
binding	O
sites	O
in	O
the	O
5'-UTR	O
comprise	O
a	O
downstream	O
enhancer	O
domain	O
that	O
can	O
function	O
independent	O
of	O
,	O
or	O
in	O
concert	O
with	O
,	O
the	O
LTR	O
promoter	O
to	O
rapidly	O
increase	O
latent	O
proviral	O
transcription	O
in	O
response	O
to	O
cell	O
activation	O
signals	O
.	O
In	O
this	O
review	O
,	O
we	O
describe	O
the	O
host	B
-	I
cell	I
transcription	I
factors	I
that	O
interact	O
with	O
the	O
5'-UTR	O
and	O
discuss	O
their	O
role	O
in	O
the	O
transcriptional	O
regulation	O
of	O
HIV-1	O
gene	O
expression	O
.	O
Enhanced	O
differentiation	O
of	O
HL-60	O
leukemia	O
cells	O
to	O
macrophages	O
induced	O
by	O
ciprofibrate	O
.	O
Ciprofibrate	O
,	O
an	O
hypolipidaemic	O
peroxisome	O
proliferator	O
,	O
induced	O
differentiation	O
of	O
HL-60	O
cells	O
.	O
The	O
effect	O
was	O
greatly	O
potentiated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
at	O
a	O
concentration	O
where	O
neither	O
phorbol	O
ester	O
nor	O
ciprofibrate	O
alone	O
had	O
any	O
effect	O
on	O
these	O
cells	O
.	O
As	O
occurs	O
for	O
HL-60	O
cell	O
differentiation	O
induced	O
by	O
high	O
phorbol	O
ester	O
concentration	O
,	O
the	O
ciprofibrate	O
-	O
induced	O
phorbol	O
ester	O
-	O
dependent	O
differentiation	O
of	O
HL-60	O
cells	O
proceeded	O
through	O
the	O
monocytic	O
/	O
macrophage	O
pathway	O
and	O
induced	O
the	O
phosphorylation	O
of	O
proteins	O
with	O
similar	O
molecular	O
weights	O
suggesting	O
that	O
increased	O
protein	B
kinase	I
C	I
activity	O
may	O
be	O
involved	O
in	O
the	O
effect	O
.	O
The	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
(	O
PPARalpha	O
)	O
transcription	B
factor	I
is	O
expressed	O
in	O
HL-60	O
cells	O
,	O
but	O
no	O
changes	O
were	O
observed	O
in	O
its	O
expression	O
upon	O
HL-60	O
cell	O
differentiation	O
.	O
Nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
and	O
AP-1	B
are	O
insufficient	O
for	O
IL-2	O
promoter	O
activation	O
:	O
requirement	O
for	O
CD28	B
up	O
-	O
regulation	O
of	O
RE	B
/	I
AP	I
.	O
IL-2	B
gene	O
transcription	O
in	O
T	O
cells	O
requires	O
both	O
TCR	O
and	O
costimulatory	O
signals	O
.	O
IL-2	O
promoter	O
activation	O
in	O
Jurkat	O
T	O
cells	O
stimulated	O
with	O
superantigen	O
presented	O
by	O
Raji	O
B	O
cells	O
requires	O
CD28	B
activation	O
.	O
The	O
addition	O
of	O
rCTLA4Ig	O
,	O
which	O
blocks	O
CD28	B
binding	O
to	O
its	O
ligand	O
,	O
to	O
the	O
cultures	O
decreased	O
IL-2	O
promoter	O
activation	O
by	O
>	O
80	O
%	O
.	O
Interestingly	O
,	O
CTLA4Ig	O
did	O
not	O
significantly	O
inhibit	O
the	O
activation	O
of	O
either	O
NF	B
of	I
activated	I
T	I
cells	I
(	O
NFAT	B
)	O
or	O
AP-1	O
reporters	O
.	O
Therefore	O
,	O
activation	O
of	O
NFAT	B
and	O
AP-1	B
is	O
insufficient	O
for	O
IL-2	O
promoter	O
activation	O
.	O
In	O
contrast	O
,	O
an	O
RE	B
/	I
AP	I
reporter	O
was	O
blocked	O
by	O
CTLA4Ig	O
by	O
>	O
90	O
%	O
.	O
Thus	O
,	O
the	O
requirement	O
for	O
CD28	B
in	O
IL-2	O
promoter	O
activation	O
appears	O
to	O
be	O
due	O
to	O
RE	B
/	I
AP	I
and	O
not	O
the	O
NFAT	O
or	O
AP-1	O
sites	O
.	O
In	O
addition	O
,	O
these	O
data	O
suggest	O
that	O
transcriptional	O
activation	O
of	O
RE	B
/	I
AP	I
is	O
not	O
mediated	O
by	O
NFAT	B
,	O
because	O
activation	O
of	O
a	O
NFAT	B
reporter	O
is	O
not	O
affected	O
by	O
the	O
addition	O
of	O
CTLA4Ig	O
.	O
The	O
role	O
of	O
Stat4	B
in	O
species	O
-	O
specific	O
regulation	O
of	O
Th	O
cell	O
development	O
by	O
type	B
I	I
IFNs	I
.	O
Type	B
I	I
IFNs	I
(	O
IFN	B
-	I
alpha	I
/	I
beta	I
)	O
,	O
in	O
addition	O
to	O
IL-12	B
,	O
have	O
been	O
shown	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
differentiation	O
of	O
human	O
,	O
but	O
not	O
mouse	O
,	O
Th	O
cells	O
.	O
We	O
show	O
here	O
that	O
IFN	B
-	I
alpha	I
/	I
beta	I
act	O
directly	O
on	O
human	O
T	O
cells	O
to	O
drive	O
Th1	O
development	O
,	O
bypassing	O
the	O
need	O
for	O
IL-12	B
-induced	O
signaling	O
,	O
whereas	O
IFN	B
-	I
alpha	I
can	O
not	O
substitute	O
IL-12	B
for	O
mouse	O
Th1	O
development	O
.	O
The	O
molecular	O
basis	O
for	O
this	O
species	O
specificity	O
is	O
that	O
IFN	B
-	I
alpha	I
/	I
beta	I
activate	O
Stat4	B
in	O
differentiating	O
human	O
,	O
but	O
not	O
mouse	O
,	O
Th	O
cells	O
.	O
Unlike	O
IL-12	B
,	O
which	O
acts	O
only	O
on	O
Th1	O
cells	O
,	O
IFN	B
-	I
alpha	I
/	I
beta	I
can	O
activate	O
Stat4	B
not	O
only	O
in	O
human	O
Th1	O
,	O
but	O
also	O
in	O
Th2	O
cells	O
.	O
However	O
,	O
restimulation	O
of	O
human	O
Th2	O
lines	O
and	O
clones	O
in	O
the	O
presence	O
of	O
IFN	B
-	I
alpha	I
does	O
not	O
induce	O
the	O
production	O
of	O
IFN	B
-	I
gamma	I
.	O
These	O
results	O
suggest	O
that	O
activation	O
of	O
Stat4	B
,	O
which	O
is	O
necessary	O
for	O
the	O
differentiation	O
of	O
naive	O
T	O
cells	O
into	O
polarized	O
Th1	O
cells	O
,	O
is	O
not	O
sufficient	O
to	O
induce	O
phenotype	O
reversal	O
of	O
human	O
Th2	O
cells	O
.	O
Interactions	O
between	O
the	O
class	B
II	I
transactivator	I
and	O
CREB	B
binding	I
protein	I
increase	O
transcription	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
genes	O
.	O
Class	O
II	O
major	O
histocompatibility	O
(	O
class	O
II	O
)	O
genes	O
are	O
regulated	O
in	O
a	O
B	O
-	O
cell	O
-	O
specific	O
and	O
gamma	O
interferon	O
-	O
inducible	O
fashion	O
.	O
The	O
master	O
switch	O
for	O
the	O
expression	O
of	O
these	O
genes	O
is	O
the	O
class	B
II	I
transactivator	I
(	O
CIITA	B
)	O
.	O
In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
one	O
of	O
the	O
functions	O
of	O
CIITA	B
is	O
to	O
recruit	O
the	O
CREB	B
binding	I
protein	I
(	O
CBP	B
)	O
to	O
class	O
II	O
promoters	O
.	O
Not	O
only	O
functional	O
but	O
also	O
specific	O
binding	O
interactions	O
between	O
CIITA	B
and	O
CBP	B
were	O
demonstrated	O
.	O
Moreover	O
,	O
a	O
dominant	O
negative	O
form	O
of	O
CBP	B
decreased	O
the	O
activity	O
of	O
class	O
II	O
promoters	O
and	O
levels	O
of	O
class	B
II	I
determinants	I
on	O
the	O
surface	O
of	O
cells	O
.	O
Finally	O
,	O
the	O
inhibition	O
of	O
class	O
II	O
gene	O
expression	O
by	O
the	O
glucocorticoid	O
hormone	O
could	O
be	O
attributed	O
to	O
the	O
squelching	O
of	O
CBP	B
by	O
the	O
glucocorticoid	B
receptor	I
.	O
We	O
conclude	O
that	O
CBP	B
,	O
a	O
histone	B
acetyltransferase	I
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
transcription	O
of	O
class	O
II	O
genes	O
.	O
Interdomain	B
B	I
in	O
ZAP-70	B
regulates	O
but	O
is	O
not	O
required	O
for	O
ZAP-70	B
signaling	O
function	O
in	O
lymphocytes	O
.	O
The	O
protein	O
tyrosine	O
kinase	O
ZAP-70	B
plays	O
an	O
important	O
role	O
in	O
T	O
-	O
cell	O
activation	O
and	O
development	O
.	O
After	O
T	B
-	I
cell	I
receptor	I
stimulation	O
,	O
ZAP-70	B
associates	O
with	O
the	O
receptor	O
and	O
is	O
phosphorylated	O
on	O
many	O
tyrosines	O
,	O
including	O
Y292	O
,	O
Y315	O
,	O
and	O
Y319	O
within	O
interdomain	O
B	O
.	O
Previously	O
,	O
we	O
demonstrated	O
that	O
Y292	O
negatively	O
regulates	O
ZAP-70	B
function	O
and	O
that	O
Y315	O
positively	O
regulates	O
ZAP-70	B
function	O
by	O
interacting	O
with	O
Vav	B
.	O
Recent	O
studies	O
have	O
suggested	O
that	O
Y319	O
also	O
positively	O
regulate	O
ZAP-70	B
function	O
.	O
Paradoxically	O
,	O
removal	O
of	O
interdomain	B
B	I
(	O
to	O
create	O
the	O
construct	O
designated	O
Delta	B
)	O
,	O
containing	O
the	O
Y292	O
,	O
Y315	O
,	O
and	O
Y319	O
sites	O
,	O
did	O
not	O
eliminate	O
the	O
ability	O
of	O
ZAP-70	B
to	O
induce	O
multiple	O
gene	O
reporters	O
in	O
Syk	O
-	O
deficient	O
DT-40	O
B	O
cells	O
and	O
ZAP-70	O
/	O
Syk	O
-	O
deficient	O
Jurkat	O
cells	O
.	O
Here	O
we	O
show	O
that	O
Delta	B
still	O
utilizes	O
the	O
same	O
pathways	O
as	O
wild	O
-	O
type	O
ZAP-70	B
to	O
mediate	O
NF	B
-	I
AT	I
induction	O
.	O
This	O
is	O
manifested	O
by	O
the	O
ability	O
of	O
Delta	B
to	O
restore	O
induction	O
of	O
calcium	O
fluxes	O
and	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
activation	O
and	O
by	O
the	O
ability	O
of	O
dominant	O
negative	O
Ras	B
and	O
FK506	B
to	O
block	O
the	O
induction	O
of	O
NF	B
-	I
AT	I
activity	O
mediated	O
by	O
Delta	B
.	O
Biochemically	O
we	O
show	O
that	O
the	O
stimulated	O
tyrosine	O
phosphorylation	O
of	O
Vav	B
,	O
Shc	B
,	O
and	O
ZAP-70	B
itself	O
is	O
diminished	O
,	O
whereas	O
that	O
of	O
Slp-76	B
is	O
increased	O
in	O
cells	O
reconstituted	O
with	O
Delta	B
.	O
Deletion	O
of	O
interdomain	B
B	I
did	O
not	O
affect	O
the	O
ability	O
of	O
ZAP-70	B
to	O
bind	O
to	O
the	O
receptor	O
.	O
The	O
in	O
vitro	O
kinase	O
activity	O
of	O
ZAP-70	B
lacking	O
interdomain	B
B	I
was	O
markedly	O
reduced	O
,	O
but	O
the	O
kinase	O
activity	O
was	O
still	O
required	O
for	O
the	O
protein	O
's	O
in	O
vivo	O
activity	O
.	O
Based	O
on	O
these	O
data	O
,	O
we	O
concluded	O
that	O
interdomain	B
B	I
regulates	O
but	O
is	O
not	O
required	O
for	O
ZAP-70	B
signaling	O
function	O
leading	O
to	O
cellular	O
responses	O
.	O
Phenylarsine	O
oxide	O
inhibits	O
ex	O
vivo	O
HIV-1	O
expression	O
.	O
Phenylarsine	O
oxide	O
(	O
PAO	O
)	O
,	O
which	O
is	O
described	O
as	O
an	O
inhibitor	O
of	O
tyrosine	B
phosphatase	I
activity	O
,	O
inhibits	O
H2O2	O
release	O
from	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
as	O
measured	O
by	O
electrochemistry	O
.	O
Since	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
is	O
known	O
to	O
be	O
favored	O
under	O
oxidative	O
stress	O
conditions	O
,	O
ex	O
vivo	O
experiments	O
using	O
uninfected	O
PBMCs	O
,	O
primary	O
monocytes	O
or	O
a	O
latently	O
infected	O
promonocytic	O
U1	O
cell	O
line	O
show	O
that	O
HIV-1	O
replication	O
and	O
reactivation	O
,	O
monitored	O
by	O
p24	B
antigen	I
measurement	O
,	O
are	O
inhibited	O
by	O
PAO	O
in	O
a	O
time-	O
and	O
concentration	O
-	O
dependent	O
manner	O
.	O
These	O
observations	O
can	O
be	O
linked	O
with	O
the	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
when	O
uninfected	O
monocytes	O
are	O
induced	O
by	O
either	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
Mechanism	O
of	O
interleukin-10	B
inhibition	O
of	O
T	O
-	O
helper	O
cell	O
activation	O
by	O
superantigen	B
at	O
the	O
level	O
of	O
the	O
cell	O
cycle	O
.	O
We	O
have	O
analyzed	O
the	O
effects	O
of	O
interleukin-10	B
(	O
IL-10	B
)	O
on	O
the	O
entry	O
of	O
quiescent	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
into	O
the	O
cell	O
cycle	O
upon	O
stimulation	O
with	O
the	O
superantigen	B
staphylococcal	B
enterotoxin	I
B	I
(	O
SEB	B
)	O
.	O
IL-10	B
arrested	O
cells	O
at	O
G0	O
/	O
G1	O
.	O
IL-10	B
treatment	O
prevented	O
the	O
downregulation	O
of	O
p27	B
(	I
Kip1	I
)	O
,	O
an	O
inhibitory	B
protein	I
that	O
controls	O
progression	O
out	O
of	O
the	O
G0	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O
IL-10	B
also	O
prevented	O
the	O
upregulation	O
of	O
the	O
G1	B
cyclins	I
D2	B
and	O
D3	B
,	O
proteins	O
necessary	O
for	O
entry	O
and	O
progression	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O
Associated	O
with	O
the	O
inhibition	O
of	O
the	O
cell	O
cycle	O
,	O
IL-10	B
suppressed	O
SEB	B
induction	O
of	O
interleukin-2	B
(	O
IL-2	B
)	O
.	O
Addition	O
of	O
exogenous	O
IL-2	B
to	O
IL-10-treated	O
cells	O
significantly	O
reversed	O
the	O
antiproliferative	O
effects	O
of	O
IL-10	B
.	O
Moreover	O
,	O
IL-10	B
effects	O
on	O
the	O
early	B
G1	I
proteins	I
p27	B
(	I
Kip1	I
)	I
and	O
cyclin	B
D2	I
were	O
similarly	O
reversed	O
by	O
exogenous	O
IL-2	B
.	O
Although	O
this	O
reversal	O
by	O
IL-2	B
was	O
pronounced	O
,	O
it	O
was	O
not	O
complete	O
,	O
suggesting	O
that	O
IL-10	B
may	O
have	O
some	O
effects	O
not	O
directly	O
related	O
to	O
the	O
suppression	O
of	O
IL-2	B
production	O
.	O
Cell	O
separation	O
experiments	O
suggest	O
that	O
IL-10	B
can	O
effect	O
purified	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
directly	O
,	O
providing	O
functional	O
evidence	O
for	O
the	O
presence	O
of	O
IL-10	B
receptors	O
on	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
.	O
IL-10	B
also	O
inhibited	O
expression	O
of	O
IL-2	B
transcriptional	I
regulators	I
c	B
-	I
fos	I
and	O
c	B
-	I
jun	I
,	O
which	O
also	O
inhibit	O
other	O
cell	O
functions	O
.	O
Our	O
studies	O
show	O
that	O
the	O
mechanism	O
of	O
IL-10	B
regulation	O
of	O
quiescent	O
CD4	O
(	O
+	O
)	O
T	O
-	O
cell	O
activation	O
is	O
mainly	O
by	O
blocking	O
induction	O
of	O
IL-2	B
that	O
is	O
critical	O
to	O
downregulation	O
of	O
p27	B
(	I
Kip1	I
)	I
and	O
upregulation	O
of	O
D	B
cyclins	I
in	O
T	O
-	O
cell	O
activation	O
and	O
entry	O
into	O
the	O
cell	O
cycle	O
.	O
The	O
position	O
of	O
the	O
ZEBRA	B
activation	I
domain	I
does	O
not	O
influence	O
its	O
biological	O
activity	O
.	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
a	O
human	O
herpesvirus	O
which	O
latently	O
infects	O
B	O
lymphocytes	O
.	O
EBV	O
encodes	O
a	O
unique	O
transcriptional	O
activator	O
,	O
known	O
as	O
ZEBRA	B
,	O
which	O
can	O
disrupt	O
viral	O
latency	O
in	O
B	O
cells	O
and	O
induce	O
lytic	O
viral	O
replication	O
.	O
Furthermore	O
,	O
ZEBRA	B
has	O
been	O
shown	O
to	O
bind	O
at	O
the	O
EBV	O
origin	O
of	O
lytic	O
replication	O
,	O
and	O
is	O
necessary	O
for	O
viral	O
DNA	O
replication	O
to	O
occur	O
.	O
Previously	O
we	O
demonstrated	O
that	O
heterologous	B
activation	I
domains	I
can	O
fully	O
substitute	O
for	O
the	O
ZEBRA	B
activation	I
domain	I
.	O
Here	O
we	O
extend	O
those	O
results	O
by	O
showing	O
that	O
the	O
position	O
of	O
the	O
ZEBRA	B
activation	I
domain	I
or	O
a	O
heterologous	O
replacement	O
domain	O
does	O
not	O
influence	O
its	O
ability	O
to	O
function	O
in	O
the	O
disruption	O
of	O
EBV	O
latency	O
.	O
In	O
this	O
study	O
three	O
novel	O
clones	O
were	O
constructed	O
in	O
which	O
the	O
ZEBRA	B
activation	I
region	I
was	O
repositioned	O
to	O
the	O
carboxy	B
terminus	I
of	O
the	O
protein	O
.	O
These	O
mutants	O
were	O
used	O
to	O
demonstrate	O
that	O
the	O
ability	O
of	O
ZEBRA	B
's	I
wild	I
type	I
domain	I
to	O
function	O
in	O
the	O
complex	O
biological	O
process	O
of	O
virus	O
activation	O
is	O
not	O
compromised	O
by	O
altering	O
its	O
position	O
within	O
the	O
protein	O
.	O
Interleukin-10	B
stabilizes	O
inhibitory	O
kappaB	B
-	I
alpha	I
in	O
human	O
monocytes	O
.	O
Interleukin-10	B
(	O
IL-10	B
)	O
protects	O
animals	O
from	O
lethal	O
endotoxemia	O
.	O
This	O
beneficial	O
effect	O
is	O
mediated	O
,	O
in	O
part	O
,	O
by	O
inhibition	O
of	O
inflammatory	B
cytokine	I
production	O
,	O
including	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
.	O
Evidence	O
suggests	O
that	O
IL-10	B
may	O
inhibit	O
activation	O
of	O
the	O
transcription	B
factor	I
nuclear	B
factor	I
-	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
through	O
an	O
unknown	O
mechanism	O
.	O
NF	B
-	I
kappaB	I
activation	O
in	O
response	O
to	O
inflammatory	O
signals	O
is	O
dependent	O
upon	O
degradation	O
of	O
its	O
associated	O
inhibitory	O
peptide	O
,	O
inhibitory	B
kappaB	I
-	I
alpha	I
(	O
IkappaB	B
-	I
alpha	I
)	O
.	O
We	O
hypothesized	O
that	O
IL-10	B
prevents	O
human	O
monocyte	O
NF	B
-	I
kappaB	I
activation	O
and	O
resultant	O
TNF	B
-	I
alpha	I
production	O
by	O
stabilization	O
of	O
IkappaB	B
-	I
alpha	I
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
IL-10	B
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
human	O
monocyte	O
TNF	B
-	I
alpha	I
production	O
,	O
NF	B
-	I
kappaB	I
activation	O
,	O
and	O
IkappaB	B
-	I
alpha	I
degradation	O
.	O
Monocytes	O
were	O
isolated	O
from	O
human	O
donors	O
.	O
Cells	O
were	O
stimulated	O
with	O
endotoxin	B
(	O
LPS	O
,	O
100	O
ng	O
/	O
mL	O
)	O
with	O
and	O
without	O
human	O
IL-10	B
(	O
10	O
ng	O
/	O
mL	O
)	O
.	O
Following	O
stimulation	O
,	O
TNF	B
-	I
alpha	I
was	O
measured	O
in	O
cell	O
supernatants	O
by	O
ELISA	O
,	O
NF	B
-	I
kappaB	I
activity	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
and	O
IkappaB	B
-	I
alpha	I
levels	O
by	O
Western	O
blot	O
.	O
We	O
observed	O
that	O
after	O
LPS	O
stimulation	O
of	O
human	O
monocytes	O
,	O
TNF	B
-	I
alpha	I
increased	O
to	O
798+	O
/	O
-67	O
pg	O
/	O
mL	O
(	O
p	O
<	O
.001	O
versus	O
control	O
)	O
.	O
IL-10	B
attenuated	O
LPS	O
-	O
stimulated	O
TNF	B
-	I
alpha	I
production	O
(	O
297+	O
/	O
-54	O
;	O
p	O
<	O
.001	O
versus	O
LPS	O
alone	O
)	O
.	O
After	O
LPS	O
stimulation	O
in	O
human	O
monocytes	O
,	O
IkappaB	B
-	I
alpha	I
protein	O
levels	O
decreased	O
,	O
and	O
NF	B
-	I
kappaB	I
DNA	O
binding	O
increased	O
.	O
IL-10	B
pretreatment	O
prevented	O
LPS	O
-	O
induced	O
decreases	O
in	O
IkappaB	B
-	I
alpha	I
protein	O
levels	O
and	O
attenuated	O
NF	B
-	I
kappaB	I
DNA	O
binding	O
.	O
IL-10	B
appears	O
to	O
prevent	O
activation	O
of	O
NF	B
-	I
kappaB	I
by	O
preserving	O
IkappaB	B
-	I
alpha	I
protein	O
levels	O
,	O
leading	O
to	O
a	O
reduction	O
in	O
TNF	B
-	I
alpha	I
release	O
.	O
Functional	O
testosterone	B
receptors	I
in	O
plasma	O
membranes	O
of	O
T	O
cells	O
.	O
T	O
cells	O
are	O
considered	O
to	O
be	O
unresponsive	O
to	O
testosterone	O
due	O
to	O
the	O
absence	O
of	O
androgen	B
receptors	I
(	O
AR	B
)	O
.	O
Here	O
,	O
we	O
demonstrate	O
the	O
testosterone	O
responsiveness	O
of	O
murine	O
splenic	O
T	O
cells	O
in	O
vitro	O
as	O
well	O
as	O
the	O
presence	O
of	O
unconventional	B
cell	I
surface	I
receptors	I
for	O
testosterone	O
and	O
classical	B
intracellular	I
AR	I
.	O
Binding	O
sites	O
for	O
testosterone	O
on	O
the	O
surface	O
of	O
both	O
CD4	O
(	O
+	O
)	O
and	O
CD8	O
(	O
+	O
)	O
subsets	O
of	O
T	O
cells	O
are	O
directly	O
revealed	O
with	O
the	O
impeded	O
ligand	O
testosterone	O
-	O
BSA	O
-	O
FITC	O
by	O
confocal	O
laser	O
scanning	O
microscopy	O
(	O
CLSM	O
)	O
and	O
flow	O
cytometry	O
,	O
respectively	O
.	O
Binding	O
of	O
the	O
plasma	O
membrane	O
impermeable	O
testosterone	B
-	I
BSA	I
conjugate	I
induces	O
a	O
rapid	O
rise	O
(	O
<	O
5	O
s	O
)	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
of	O
Fura-2-loaded	O
T	O
cells	O
.	O
This	O
rise	O
reflects	O
influx	O
of	O
extracellular	O
Ca2	O
+	O
through	O
non	O
-	O
voltage	O
-	O
gated	O
and	O
Ni2	B
+	I
-blockable	I
Ca2	I
+	I
channels	I
of	O
the	O
plasma	O
membrane	O
.	O
The	O
testosterone	O
-	O
BSA	O
-	O
induced	O
Ca2	O
+	O
import	O
is	O
not	O
affected	O
by	O
cyproterone	O
,	O
a	O
blocker	O
of	O
the	O
AR	B
.	O
In	O
addition	O
,	O
AR	B
are	O
not	O
detectable	O
on	O
the	O
surface	O
of	O
intact	O
T	O
cells	O
when	O
using	O
anti	B
-	I
AR	I
antibodies	I
directed	O
against	O
the	O
amino	B
and	I
carboxy	I
terminus	I
of	O
the	O
AR	B
,	O
although	O
T	O
cells	O
contain	O
AR	B
,	O
as	O
revealed	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reactions	O
and	O
Western	O
blotting	O
.	O
AR	B
can	O
be	O
visualized	O
with	O
the	O
anti	B
-	I
AR	I
antibodies	I
in	O
the	O
cytoplasm	O
of	O
permeabilized	O
T	O
cells	O
by	O
using	O
CLSM	O
,	O
though	O
AR	B
are	O
not	O
detectable	O
in	O
cytosol	O
fractions	O
when	O
using	O
the	O
charcoal	O
binding	O
assay	O
with	O
3H	O
-	O
R1881	O
as	O
ligand	O
.	O
Cytoplasmic	B
AR	I
do	O
not	O
translocate	O
to	O
the	O
nucleus	O
of	O
T	O
cells	O
in	O
the	O
presence	O
of	O
testosterone	O
,	O
in	O
contrast	O
to	O
cytoplasmic	B
AR	I
in	O
human	O
cancer	O
LNCaP	O
cells	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
classical	B
AR	I
present	O
in	O
splenic	O
T	O
cells	O
are	O
not	O
active	O
in	O
the	O
genomic	O
pathway	O
.	O
By	O
contrast	O
,	O
the	O
cell	B
surface	I
receptors	I
for	O
testosterone	O
are	O
in	O
a	O
functionally	O
active	O
state	O
,	O
enabling	O
T	O
cells	O
a	O
nongenomic	O
response	O
to	O
testosterone	O
.	O
X	O
chromosome	O
inactivation	O
patterns	O
in	O
normal	O
females	O
.	O
Since	O
one	O
of	O
the	O
two	O
X	O
chromosomes	O
is	O
randomly	O
inactivated	O
at	O
an	O
early	O
stage	O
of	O
female	O
embryonic	O
development	O
,	O
X	B
-	I
linked	I
markers	I
have	O
been	O
used	O
to	O
study	O
the	O
origin	O
and	O
development	O
of	O
various	O
neoplastic	O
disorders	O
in	O
affected	O
heterozygous	O
women	O
;	O
clonality	O
assays	O
have	O
provided	O
a	O
useful	O
tool	O
to	O
the	O
understanding	O
of	O
the	O
mechanisms	O
underlying	O
the	O
development	O
of	O
neoplasia	O
.	O
Recently	O
,	O
a	O
technique	O
of	O
clonal	O
analysis	O
has	O
been	O
devised	O
that	O
takes	O
advantage	O
of	O
a	O
highly	O
polymorphic	O
short	O
tandem	O
repeat	O
within	O
the	O
X	O
-	O
linked	O
human	O
androgen	O
receptor	O
(	O
AR	O
)	O
gene	O
,	O
resulting	O
in	O
a	O
heterozygosity	O
rate	O
approaching	O
90	O
%	O
.	O
The	O
rapid	O
expansion	O
of	O
the	O
number	O
of	O
women	O
now	O
suitable	O
for	O
X	O
inactivation	O
analysis	O
has	O
however	O
given	O
rise	O
to	O
new	O
controversies	O
,	O
one	O
of	O
the	O
more	O
troublesome	O
being	O
the	O
possibility	O
of	O
a	O
modification	O
of	O
the	O
pattern	O
of	O
X-	O
chromosome	O
inactivation	O
pattern	O
in	O
blood	O
cells	O
of	O
elderly	O
women	O
.	O
In	O
the	O
present	O
study	O
we	O
analyze	O
with	O
the	O
AR	O
assay	O
a	O
group	O
of	O
166	O
healthy	O
females	O
aged	O
between	O
8	O
and	O
94	O
years	O
,	O
with	O
no	O
history	O
of	O
genetic	O
or	O
neoplastic	O
familial	O
disorders	O
.	O
We	O
failed	O
to	O
find	O
any	O
correlation	O
between	O
age	O
and	O
X-	O
chromosome	O
inactivation	O
pattern	O
(	O
r	O
=	O
0.17	O
)	O
,	O
even	O
subdividing	O
the	O
subjects	O
in	O
different	O
age	O
groups	O
according	O
to	O
the	O
criteria	O
used	O
by	O
other	O
researchers	O
,	O
and	O
therefore	O
reaffirm	O
that	O
,	O
when	O
tested	O
for	O
with	O
well	O
-	O
standardized	O
and	O
accurate	O
criteria	O
,	O
extremely	O
unbalanced	O
inactivation	O
of	O
the	O
X	O
chromosome	O
is	O
a	O
truly	O
uncommon	O
phenomenon	O
in	O
normal	O
women	O
.	O
Copyright	O
1998	O
Academic	O
Press	O
.	O
Reactivation	O
of	O
Kaposi	O
's	O
sarcoma	O
-	O
associated	O
herpesvirus	O
infection	O
from	O
latency	O
by	O
expression	O
of	O
the	O
ORF	B
50	I
transactivator	I
,	O
a	O
homolog	O
of	O
the	O
EBV	B
R	I
protein	I
.	O
Kaposi	O
's	O
sarcoma	O
(	O
KS	O
)	O
-associated	O
herpesvirus	O
(	O
KSHV	O
)	O
,	O
or	O
human	O
herpesvirus	O
8	O
,	O
is	O
a	O
lymphotropic	O
virus	O
strongly	O
linked	O
to	O
several	O
AIDS	O
-	O
related	O
neoplasms	O
.	O
The	O
primary	O
reservoir	O
of	O
infection	O
consists	O
of	O
latently	O
infected	O
B	O
lymphocytes	O
and	O
possibly	O
other	O
mononuclear	O
cells	O
.	O
Viral	O
reactivation	O
from	O
latency	O
and	O
spread	O
from	O
this	O
lymphoid	O
reservoir	O
is	O
presumably	O
required	O
for	O
development	O
of	O
nonlymphoid	O
tumors	O
like	O
KS	O
.	O
Here	O
we	O
show	O
that	O
deregulated	O
expression	O
of	O
a	O
single	O
viral	O
gene	O
,	O
ORF	O
50	O
,	O
which	O
encodes	O
a	O
transactivator	O
able	O
to	O
selectively	O
upregulate	O
delayed	O
-	O
early	O
viral	O
genes	O
,	O
suffices	O
to	O
disrupt	O
latency	O
and	O
induce	O
the	O
lytic	O
gene	O
cascade	O
in	O
latently	O
infected	O
B	O
cells	O
.	O
The	O
identification	O
of	O
this	O
gene	O
opens	O
the	O
way	O
to	O
studies	O
of	O
the	O
physiologic	O
mechanisms	O
controlling	O
reactvation	O
of	O
KSHV	O
from	O
latency	O
.	O
Copyright	O
1998	O
Academic	O
Press	O
.	O
Regulation	O
of	O
interleukin-1beta	B
transcription	O
by	O
Epstein	O
-	O
Barr	O
virus	O
involves	O
a	O
number	O
of	O
latent	B
proteins	I
via	O
their	O
interaction	O
with	O
RBP	B
.	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
infects	O
B	O
cells	O
,	O
resulting	O
in	O
the	O
outgrowth	O
of	O
immortalised	O
lymphoblastoid	O
cell	O
lines	O
(	O
LCLs	O
)	O
.	O
Here	O
,	O
we	O
demonstrate	O
through	O
the	O
use	O
of	O
intracellular	O
staining	O
that	O
interleukin-1beta	B
(	O
IL-1beta	B
)	O
is	O
expressed	O
in	O
LCLs	O
and	O
investigate	O
the	O
influence	O
of	O
the	O
individual	O
latent	B
proteins	I
on	O
the	O
expression	O
of	O
IL-1beta	B
.	O
Using	O
RT	O
-	O
PCR	O
,	O
IL-1beta	B
was	O
shown	O
to	O
be	O
up	O
-	O
regulated	O
in	O
EBV	O
-	O
transformed	O
LCLs	O
as	O
well	O
as	O
in	O
group	O
III	O
Burkitt	O
's	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines	O
,	O
compared	O
with	O
group	O
I	O
BL	O
cell	O
lines	O
.	O
The	O
up	O
-	O
regulation	O
of	O
IL-1beta	B
message	O
could	O
be	O
mediated	O
by	O
the	O
latent	B
membrane	I
protein-1	I
,	O
EBV	O
nuclear	O
proteins	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
6	O
genes	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
demonstrated	O
that	O
the	O
-300	O
region	O
of	O
the	O
IL-1beta	B
promoter	O
,	O
which	O
contains	O
a	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
binding	O
site	O
,	O
contained	O
a	O
functional	O
RBP	O
binding	O
site	O
.	O
Binding	O
of	O
RBP	O
to	O
this	O
site	O
could	O
be	O
inhibited	O
by	O
addition	O
of	O
EBV	B
nuclear	I
proteins	I
3	I
and	I
6	I
,	O
suggesting	O
that	O
these	O
proteins	O
displace	O
RBP	B
from	O
its	O
recognition	O
sequence	O
,	O
removing	O
transcriptional	O
repression	O
and	O
allowing	O
gene	O
transcription	O
to	O
occur	O
.	O
In	O
group	O
I	O
BL	O
cells	O
,	O
containing	O
low	O
levels	O
of	O
NF	B
-	I
kappaB	I
,	O
only	O
RBP	B
binding	O
was	O
observed	O
in	O
EMSAs	O
,	O
whereas	O
NF	B
-	I
kappaB	I
binding	O
could	O
be	O
demonstrated	O
in	O
EBV	O
-	O
transformed	O
B	O
cell	O
lines	O
containing	O
high	O
levels	O
of	O
activated	O
NF	B
-	I
kappaB	I
.	O
In	O
addition	O
,	O
the	O
expression	O
of	O
latent	B
membrane	I
protein-1	I
led	O
to	O
activation	O
of	O
NF	B
-	I
kappaB	I
that	O
was	O
capable	O
of	O
binding	O
the	O
IL-1beta	O
promoter	O
.	O
The	O
study	O
demonstrates	O
that	O
EBV	O
can	O
up	O
-	O
regulate	O
IL-1beta	B
expression	O
,	O
possibly	O
by	O
using	O
RBP	B
,	O
NF	B
-	I
kappaB	I
,	O
or	O
both	O
.	O
Copyright	O
1998	O
Academic	O
Press	O
.	O
Binding	O
of	O
HMG	B
-	I
I	I
(	I
Y	I
)	I
elicits	O
structural	O
changes	O
in	O
a	O
silencer	O
of	O
the	O
human	O
beta	O
-	O
globin	O
gene	O
.	O
Proteins	O
involved	O
in	O
repression	O
of	O
the	O
human	O
beta	O
-	O
globin	O
gene	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
sickle	O
cell	O
anemia	O
,	O
in	O
conjunction	O
with	O
therapy	O
to	O
reactivate	O
fetal	O
globin	O
genes	O
.	O
If	O
there	O
is	O
a	O
reciprocal	O
elevation	O
of	O
gamma	B
-	I
globin	I
expression	O
upon	O
repression	O
,	O
this	O
approach	O
could	O
be	O
useful	O
in	O
additional	O
hemoglobinopathies	O
.	O
We	O
previously	O
showed	O
that	O
repression	O
of	O
the	O
beta	O
-	O
globin	O
gene	O
appears	O
to	O
be	O
mediated	O
through	O
two	O
DNA	O
sequences	O
,	O
silencers	O
I	O
and	O
II	O
,	O
and	O
identified	O
a	O
protein	O
termed	O
BP1	B
which	O
binds	O
to	O
both	O
silencer	O
sequences	O
.	O
In	O
this	O
study	O
,	O
we	O
cloned	O
two	O
cDNAs	O
encoding	O
proteins	O
which	O
bind	O
to	O
an	O
oligonucleotide	O
in	O
silencer	O
I	O
containing	O
a	O
BP1	B
binding	O
site	O
.	O
These	O
cDNAs	O
correspond	O
to	O
HMG	B
-	I
I	I
and	O
HMG	B
-	I
Y	I
,	O
isoforms	O
regarded	O
as	O
architectural	B
proteins	I
.	O
We	O
demonstrate	O
that	O
binding	O
of	O
HMG	B
-	I
I	I
(	I
Y	I
)	I
to	O
this	O
oligonucleotide	O
causes	O
bending	O
/	O
flexure	O
of	O
the	O
DNA	O
.	O
HMG	B
-	I
I	I
(	I
Y	I
)	I
also	O
binds	O
to	O
a	O
second	O
oligonucleotide	O
containing	O
a	O
BP1	O
binding	O
site	O
located	O
in	O
a	O
negative	O
control	O
region	O
upstream	O
of	O
the	O
delta	O
-	O
globin	O
gene	O
,	O
suggesting	O
a	O
role	O
for	O
HMG	B
-	I
I	I
(	I
Y	I
)	I
in	O
repression	O
of	O
adult	O
globin	O
genes	O
.	O
Expression	O
studies	O
revealed	O
that	O
HMG	B
-	I
I	I
(	I
Y	I
)	I
is	O
ubiquitously	O
expressed	O
in	O
human	O
tissues	O
that	O
do	O
not	O
express	O
beta	B
-	I
globin	I
,	O
being	O
present	O
in	O
48	O
of	O
50	O
tissues	O
and	O
six	O
hematopoietic	O
cell	O
lines	O
examined	O
.	O
Furthermore	O
,	O
HMG	B
-	I
I	I
(	I
Y	I
)	I
expression	O
is	O
down	O
-	O
regulated	O
during	O
differentiation	O
of	O
primary	O
erythroid	O
cells	O
.	O
We	O
present	O
a	O
model	O
in	O
which	O
HMG	B
-	I
I	I
(	I
Y	I
)	I
alters	O
DNA	O
conformation	O
to	O
allow	O
binding	O
of	O
repressor	B
proteins	I
,	O
and	O
in	O
which	O
the	O
relative	O
amount	O
of	O
HMG	O
-	O
I	O
(	O
Y	O
)	O
helps	O
to	O
determine	O
the	O
repressive	O
state	O
of	O
the	O
beta	O
-	O
globin	O
gene	O
.	O
Induction	O
of	O
the	O
pro	O
-	O
myelocytic	O
leukaemia	O
gene	O
by	O
type	B
I	I
and	I
type	I
II	I
interferons	I
.	O
The	O
physiological	O
role	O
of	O
the	O
pro	B
-	I
myelocytic	I
leukaemia	I
(	I
PML	I
)	I
gene	I
product	I
is	O
poorly	O
defined	O
.	O
Among	O
other	O
functions	O
,	O
PML	O
is	O
involved	O
in	O
haematopoietic	O
differentiation	O
and	O
in	O
control	O
of	O
cell	O
growth	O
and	O
tumorigenesis	O
.	O
We	O
investigated	O
the	O
regulation	O
of	O
human	O
PML	O
expression	O
by	O
interferons	B
(	O
IFNs	B
)	O
and	O
IL-1	B
in	O
various	O
human	O
haematopoietic	O
lines	O
(	O
U937	O
,	O
THP1	O
,	O
HL60	O
,	O
NB4	O
)	O
,	O
in	O
human	O
diploid	O
fibroblasts	O
and	O
in	O
human	O
peripheral	O
blood	O
leukocytes	O
.	O
Cytokine	O
-	O
induced	O
modulation	O
of	O
PML	O
expression	O
was	O
assessed	O
by	O
Northern	O
blot	O
analyses	O
,	O
flow	O
cytometry	O
studies	O
and	O
in	O
situ	O
immunolabelling	O
.	O
Our	O
data	O
show	O
that	O
IFNs	B
and	O
IL-1	B
upregulate	O
PML	O
transcript	O
and	O
protein	O
expression	O
in	O
a	O
time	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O
In	O
situ	O
immunolabelling	O
revealed	O
that	O
upregulation	O
of	O
protein	O
expression	O
by	O
IFN	B
-	I
alpha	I
is	O
a	O
consequence	O
of	O
a	O
marked	O
increase	O
in	O
both	O
the	O
number	O
and	O
the	O
intensity	O
of	O
the	O
staining	O
of	O
so	O
-	O
called	O
PML	B
nuclear	I
bodies	I
.	O
Our	O
data	O
suggest	O
that	O
stimulation	O
of	O
PML	O
expression	O
by	O
interferons	B
and	O
IL-1	B
may	O
account	O
for	O
upregulation	O
of	O
PML	B
proteins	I
observed	O
in	O
inflammatory	O
tissues	O
and	O
in	O
proliferative	O
states	O
.	O
Characterization	O
of	O
the	O
human	O
elk-1	O
promoter	O
.	O
Potential	O
role	O
of	O
a	O
downstream	O
intronic	O
sequence	O
for	O
elk-1	O
gene	O
expression	O
in	O
monocytes	O
.	O
To	O
characterize	O
the	O
human	O
elk-1	O
promoter	O
,	O
we	O
mapped	O
the	O
transcriptional	O
start	O
site	O
and	O
isolated	O
elk-1-specific	O
genomic	O
phage	O
clones	O
that	O
contained	O
extensive	O
upstream	O
and	O
downstream	O
sequences	O
.	O
A	O
TATA	O
-	O
like	O
motif	O
was	O
identified	O
immediately	O
upstream	O
of	O
the	O
transcriptional	O
start	O
site	O
.	O
Functional	O
analyses	O
of	O
DNA	O
fragments	O
containing	O
the	O
TATA	O
element	O
and	O
the	O
identification	O
of	O
a	O
DNase	O
I	O
-	O
hypersensitive	O
chromatin	O
site	O
(	O
HS	O
1	O
)	O
in	O
close	O
proximity	O
to	O
the	O
TATA	O
box	O
suggest	O
that	O
the	O
identified	O
TATA	O
motif	O
is	O
important	O
for	O
elk-1	O
transcription	O
in	O
vivo	O
.	O
Sequences	O
upstream	O
and	O
downstream	O
from	O
the	O
TATA	O
box	O
were	O
found	O
to	O
contribute	O
to	O
elk-1	O
promoter	O
activity	O
.	O
A	O
second	O
hypersensitive	O
site	O
(	O
HS	O
2	O
)	O
was	O
identified	O
within	O
the	O
first	O
intron	O
in	O
pre	O
-	O
monocytic	O
cells	O
,	O
which	O
express	O
Elk-1	O
only	O
when	O
differentiating	O
to	O
monocytes	O
.	O
In	O
a	O
variety	O
of	O
other	O
cell	O
types	O
,	O
which	O
display	O
a	O
constitutive	O
Elk-1	B
expression	O
,	O
HS	O
2	O
did	O
not	O
exist	O
,	O
suggesting	O
that	O
inducibility	O
of	O
elk-1	O
expression	O
is	O
associated	O
with	O
the	O
presence	O
of	O
HS	O
2	O
.	O
Egr-1	O
and	O
the	O
serum	O
response	O
factor	O
were	O
found	O
to	O
interact	O
specifically	O
with	O
the	O
intronic	O
sequence	O
at	O
+	O
265	O
and	O
+	O
448	O
,	O
respectively	O
.	O
Because	O
Egr-1	O
mRNA	O
and	O
protein	O
levels	O
were	O
observed	O
to	O
increase	O
significantly	O
before	O
induction	O
of	O
elk-1	O
expression	O
,	O
we	O
propose	O
that	O
Egr-1	B
is	O
important	O
for	O
the	O
regulation	O
of	O
elk-1	O
transcription	O
in	O
differentiating	O
monocytes	O
.	O
Regulation	O
of	O
IL-6	B
synthesis	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
C3a	B
and	O
C3a	B
(	I
desArg	I
)	I
.	O
The	O
anaphylatoxin	B
C3a	B
has	O
been	O
reported	O
to	O
have	O
immunomodulatory	O
effects	O
on	O
a	O
number	O
of	O
different	O
cell	O
types	O
.	O
In	O
this	O
study	O
we	O
investigated	O
the	O
effects	O
of	O
C3a	B
and	O
C3a	B
(	I
desArg	I
)	I
on	O
gene	O
expression	O
and	O
protein	O
secretion	O
of	O
IL-6	B
in	O
human	O
PBMCs	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
LPS	O
or	O
IL-1beta	B
.	O
C3a	B
or	O
C3a	B
(	I
desArg	I
)	I
alone	O
exhibited	O
no	O
effect	O
on	O
the	O
expression	O
or	O
secretion	O
of	O
IL-6	B
.	O
However	O
,	O
when	O
PBMC	O
were	O
stimulated	O
with	O
LPS	O
or	O
IL-1beta	B
,	O
both	O
C3a	B
and	O
C3a	B
(	I
desArg	I
)	I
were	O
found	O
to	O
enhance	O
IL-6	B
release	O
by	O
PBMC	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
Since	O
C3a	B
has	O
been	O
shown	O
to	O
induce	O
PGE2	O
production	O
by	O
monocytes	O
,	O
and	O
PGE2	O
has	O
been	O
shown	O
to	O
influence	O
cytokine	O
production	O
,	O
we	O
investigated	O
the	O
potential	O
role	O
of	O
PGE2	O
in	O
C3a	B
-mediated	O
enhancement	O
of	O
LPS-	O
and	O
IL-1beta	O
-	O
induced	O
IL-6	O
production	O
.	O
Indomethacin	O
blocked	O
PGE2	O
release	O
,	O
but	O
had	O
no	O
influence	O
on	O
the	O
observed	O
effects	O
of	O
C3a	B
,	O
suggesting	O
that	O
the	O
effects	O
of	O
C3a	B
on	O
IL-6	B
production	O
are	O
independent	O
of	O
PGE2	O
formation	O
by	O
monocytes	O
.	O
Northern	O
blot	O
analysis	O
showed	O
that	O
C3a	B
as	O
well	O
as	O
C3a	B
(	I
desArg	I
)	I
enhanced	O
LPS	O
-induced	O
mRNA	O
levels	O
for	O
IL-6	B
.	O
Pretreatment	O
of	O
PBMCs	O
with	O
pertussis	B
toxin	I
blocked	O
the	O
functions	O
of	O
C3a	B
and	O
C3a	B
(	I
desArg	I
)	I
,	O
indicating	O
that	O
the	O
actions	O
of	O
these	O
two	O
molecules	O
are	O
mediated	O
by	O
a	O
G	B
protein	I
-coupled	O
pathway	O
.	O
Furthermore	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
C3a	B
and	O
C3a	B
(	I
desArg	I
)	I
on	O
induction	O
of	O
NF	B
-	I
kappaB	I
and	O
activating	B
protein-1	I
binding	O
.	O
Both	O
molecules	O
enhanced	O
LPS	O
-	O
induced	O
NF	B
-	I
kappaB	I
and	O
activating	B
protein-1	I
binding	O
activity	O
.	O
These	O
results	O
demonstrate	O
the	O
capacity	O
of	O
intact	O
C3a	B
and	O
its	O
circulating	O
des	B
-	I
Arg	I
form	I
to	O
exert	O
immunmodulatory	O
effects	O
in	O
vitro	O
.	O
Mildly	O
oxidized	O
low	B
-	I
density	I
lipoproteins	I
decrease	O
early	O
production	O
of	O
interleukin	B
2	I
and	O
nuclear	B
factor	I
kappaB	I
binding	O
to	O
DNA	O
in	O
activated	O
T	O
-	O
lymphocytes	O
.	O
Activated	O
T	O
-	O
lymphocytes	O
are	O
found	O
early	O
in	O
atherosclerosis	O
lesions	O
,	O
but	O
little	O
is	O
known	O
about	O
their	O
role	O
.	O
Oxidized	O
low	B
-	I
density	I
lipoproteins	I
(	O
oxLDLs	B
)	O
are	O
considered	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
the	O
lesions	O
,	O
and	O
we	O
have	O
previously	O
demonstrated	O
that	O
oxLDLs	B
inhibit	O
not	O
only	O
interleukin	B
(	I
IL	I
)	I
-2-receptor	I
expression	O
on	O
the	O
surface	O
of	O
in	O
vitro	O
-	O
activated	O
T	O
-	O
lymphocytes	O
but	O
also	O
their	O
proliferation	O
.	O
We	O
have	O
now	O
investigated	O
the	O
effect	O
of	O
oxLDLs	B
on	O
blast	O
differentiation	O
,	O
on	O
IL-2	B
synthesis	O
and	O
on	O
the	O
activation	O
of	O
the	O
nuclear	B
factor	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
system	O
in	O
activated	O
lymphocytes	O
.	O
Mildly	O
oxLDLs	B
(	O
50	O
and	O
100	O
microgram	O
/	O
ml	O
)	O
decreased	O
the	O
number	O
of	O
lymphoblasts	O
and	O
the	O
level	O
of	O
IL-2	O
concentration	O
in	O
the	O
culture	O
supernatants	O
after	O
activation	O
of	O
lymphocytes	O
by	O
phytohaemagglutinin	B
and	O
PMA+ionomycin	O
.	O
The	O
inhibition	O
of	O
IL-2	B
production	O
was	O
observed	O
in	O
the	O
CD3	B
(	O
+	O
)	O
T	O
-	O
lymphocyte	O
cytoplasm	O
as	O
early	O
as	O
4	O
h	O
after	O
activation	O
by	O
PMA+ionomycin	O
.	O
The	O
study	O
of	O
NF	B
-	I
kappaB	I
showed	O
that	O
oxLDLs	B
led	O
to	O
a	O
decrease	O
of	O
activation	B
-	I
induced	I
p65	I
/	I
p50	I
NF	B
-	I
kappaB	I
heterodimer	O
binding	O
to	O
DNA	O
,	O
whereas	O
the	O
presence	O
of	O
the	O
constitutive	O
nuclear	O
form	O
of	O
p50	B
dimer	I
was	O
unchanged	O
.	O
This	O
was	O
correlated	O
with	O
an	O
unchanged	O
level	O
of	O
the	O
active	O
form	O
of	O
the	O
cytosolic	B
inhibitor	I
protein	I
IkappaB	B
-	I
alpha	I
.	O
Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
the	O
immunosuppressive	O
effect	O
of	O
oxLDLs	B
might	O
operate	O
via	O
a	O
dysregulation	O
of	O
the	O
T	O
-	O
lymphocyte	O
activation	O
mechanisms	O
.	O
The	O
activity	O
of	O
the	O
CCAAT	B
-	I
box	I
binding	I
factor	I
NF	I
-	I
Y	I
is	O
modulated	O
through	O
the	O
regulated	O
expression	O
of	O
its	O
A	B
subunit	I
during	O
monocyte	O
to	O
macrophage	O
differentiation	O
:	O
regulation	O
of	O
tissue	O
-	O
specific	O
genes	O
through	O
a	O
ubiquitous	O
transcription	B
factor	I
.	O
In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
regulation	O
of	O
NF	B
-	I
Y	I
expression	O
during	O
human	O
monocyte	O
to	O
macrophage	O
maturation	O
.	O
NF	B
-	I
Y	I
is	O
a	O
ubiquitous	O
and	O
evolutionarily	O
conserved	O
transcription	B
factor	I
that	O
binds	O
specifically	O
to	O
the	O
CCAAT	O
motif	O
present	O
in	O
the	O
5	O
'	O
promoter	O
region	O
of	O
a	O
wide	O
variety	O
of	O
genes	O
.	O
We	O
show	O
here	O
that	O
in	O
circulating	O
monocytes	O
,	O
NF	B
-	I
Y	I
binding	O
activity	O
is	O
not	O
detected	O
on	O
the	O
CCAAT	O
motif	O
present	O
in	O
the	O
promoters	O
of	O
genes	O
such	O
as	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
,	O
gp91-phox	O
,	O
mig	O
,	O
and	O
fibronectin	O
,	O
whereas	O
during	O
macrophage	O
differentiation	O
,	O
a	O
progressive	O
increase	O
in	O
NF	B
-	I
Y	I
binding	O
activity	O
is	O
observed	O
on	O
these	O
promoters	O
.	O
Analysis	O
of	O
NF	B
-	I
Y	I
subunit	O
expression	O
indicates	O
that	O
the	O
absence	O
of	O
NF	B
-	I
Y	I
activity	O
in	O
circulating	O
monocytes	O
is	O
caused	O
by	O
a	O
lack	O
of	O
the	O
A	B
subunit	I
.	O
Furthermore	O
,	O
addition	O
of	O
the	O
recombinant	O
NF	B
-	I
Y	I
A	B
subunit	I
restores	O
NF	B
-	I
Y	I
binding	O
.	O
We	O
show	O
that	O
the	O
lack	O
of	O
NF	B
-	I
YA	I
protein	I
is	O
due	O
to	O
posttranscriptional	O
regulation	O
and	O
not	O
to	O
a	O
specific	O
proteolytic	O
activity	O
.	O
In	O
fact	O
,	O
NF	O
-	O
YA	O
mRNA	O
is	O
present	O
at	O
the	O
same	O
level	O
at	O
all	O
days	O
of	O
monocyte	O
cultivation	O
,	O
whereas	O
the	O
protein	O
is	O
absent	O
in	O
freshly	O
isolated	O
monocytes	O
but	O
is	O
progressively	O
synthesized	O
during	O
the	O
maturation	O
process	O
.	O
We	O
thus	O
conclude	O
that	O
the	O
NF	B
-	I
Y	I
A	B
subunit	I
plays	O
a	O
relevant	O
role	O
in	O
activating	O
transcription	O
of	O
genes	O
highly	O
expressed	O
in	O
mature	O
monocytes	O
.	O
In	O
line	O
with	O
this	O
conclusion	O
,	O
we	O
show	O
that	O
the	O
cut	B
/	I
CDP	I
protein	I
,	O
a	O
transcriptional	O
repressor	O
that	O
inhibits	O
gpc91-phox	O
gene	O
expression	O
by	O
preventing	O
NF	B
-	I
Y	I
binding	O
to	O
the	O
CAAT	O
box	O
,	O
is	O
absent	O
in	O
monocytes	O
.	O
Accessing	O
Epstein	O
-	O
Barr	O
virus	O
-	O
specific	O
T	O
-	O
cell	O
memory	O
with	O
peptide	O
-	O
loaded	O
dendritic	O
cells	O
.	O
The	O
conventional	O
means	O
of	O
studying	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-induced	O
cytotoxic	O
T	O
-	O
lymphocyte	O
(	O
CTL	O
)	O
memory	O
,	O
by	O
in	O
vitro	O
stimulation	O
with	O
the	O
latently	O
infected	O
autologous	O
lymphoblastoid	O
cell	O
line	O
(	O
LCL	O
)	O
,	O
has	O
important	O
limitations	O
.	O
First	O
,	O
it	O
gives	O
no	O
information	O
on	O
memory	O
to	O
lytic	B
cycle	I
antigens	I
;	O
second	O
,	O
it	O
preferentially	O
amplifies	O
the	O
dominant	O
components	O
of	O
latent	O
antigen	O
-	O
specific	O
memory	O
at	O
the	O
expense	O
of	O
key	O
subdominant	O
reactivities	O
.	O
Here	O
we	O
describe	O
an	O
alternative	O
approach	O
,	O
based	O
on	O
in	O
vitro	O
stimulation	O
with	O
epitope	O
peptide	O
-	O
loaded	O
dendritic	O
cells	O
(	O
DCs	O
)	O
,	O
which	O
allows	O
one	O
to	O
probe	O
the	O
CTL	O
repertoire	O
for	O
any	O
individual	O
reactivity	O
of	O
choice	O
;	O
this	O
method	O
proved	O
significantly	O
more	O
efficient	O
than	O
stimulation	O
with	O
peptide	O
alone	O
.	O
Using	O
this	O
approach	O
we	O
first	O
show	O
that	O
reactivities	O
to	O
the	O
immunodominant	O
and	O
subdominant	O
lytic	B
cycle	I
epitopes	I
identified	O
by	O
T	O
cells	O
during	O
primary	O
EBV	O
infection	O
are	O
regularly	O
detectable	O
in	O
the	O
CTL	O
memory	O
of	O
virus	O
carriers	O
;	O
this	O
implies	O
that	O
in	O
such	O
carriers	O
chronic	O
virus	O
replication	O
remains	O
under	O
direct	O
T	O
-	O
cell	O
control	O
.	O
We	O
further	O
show	O
that	O
subdominant	O
latent	O
cycle	O
reactivities	O
to	O
epitopes	O
in	O
the	O
latent	B
membrane	I
protein	I
LMP2	I
,	O
though	O
rarely	O
undetectable	O
in	O
LCL	O
-stimulated	O
populations	O
,	O
can	O
be	O
reactivated	O
by	O
DC	O
stimulation	O
and	O
selectively	O
expanded	O
as	O
polyclonal	O
CTL	O
lines	O
;	O
the	O
adoptive	O
transfer	O
of	O
such	O
preparations	O
may	O
be	O
of	O
value	O
in	O
targeting	O
certain	O
EBV	O
-	O
positive	O
malignancies	O
.	O
Regulation	O
of	O
IL-4	B
expression	O
by	O
the	O
transcription	B
factor	I
JunB	B
during	O
T	O
helper	O
cell	O
differentiation	O
.	O
The	O
molecular	O
basis	O
for	O
restricted	O
cytokine	B
expression	O
by	O
T	O
helper	O
1	O
(	O
Th1	O
)	O
and	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
cells	O
is	O
unclear	O
.	O
Previous	O
studies	O
found	O
that	O
P1	O
,	O
an	O
element	O
of	O
the	O
interleukin	O
4	O
(	O
IL-4	O
)	O
promoter	O
that	O
binds	O
AP-1	O
,	O
is	O
important	O
for	O
Th2-restricted	O
IL-4	B
expression	O
.	O
Here	O
we	O
show	O
that	O
JunB	B
,	O
but	O
not	O
the	O
other	O
Jun	B
family	I
members	I
,	O
was	O
selectively	O
induced	O
in	O
Th2	O
cells	O
and	O
not	O
in	O
Th1	O
cells	O
during	O
differentiation	O
.	O
JunB	B
has	O
previously	O
been	O
considered	O
to	O
be	O
a	O
negative	O
regulator	O
of	O
transcription	O
.	O
However	O
,	O
we	O
show	O
that	O
JunB	B
binds	O
directly	O
to	O
the	O
P1	O
site	O
and	O
synergizes	O
with	O
c	B
-	I
Maf	I
to	O
activate	O
an	O
IL-4	O
luciferase	O
reporter	O
gene	O
.	O
JunB	B
-control	O
of	O
IL-4	B
expression	O
is	O
mediated	O
by	O
the	O
phosphorylation	O
of	O
JunB	B
at	O
Thr102	O
and-	O
104	O
by	O
JNK	B
MAP	I
kinase	I
.	O
The	O
synergy	O
between	O
c	B
-	I
Maf	I
and	O
JunB	B
can	O
be	O
attributed	O
to	O
cooperative	O
DNA	O
binding	O
,	O
which	O
is	O
facilitated	O
by	O
JunB	B
phosphorylation	O
.	O
In	O
transgenic	O
mice	O
,	O
elevated	O
JunB	B
levels	O
caused	O
increased	O
expression	O
of	O
several	O
Th2	B
cytokines	I
in	O
developing	O
Th1	O
cells	O
.	O
JunB	B
also	O
upregulated	O
IL-4	B
expression	O
in	O
response	O
to	O
immunization	O
.	O
Thus	O
,	O
the	O
early	O
increase	O
of	O
JunB	B
protein	O
in	O
Th2	O
cells	O
can	O
provide	O
the	O
specificity	O
for	O
c	B
-	I
Maf	I
in	O
IL-4	B
expression	O
during	O
T	O
cell	O
development	O
and	O
directs	O
thereby	O
Th2	O
differentiation	O
.	O
Immunohistochemical	O
study	O
of	O
c	B
-	I
fos	I
-	I
positive	I
lymphocytes	I
infiltrated	O
into	O
human	O
squamous	O
cell	O
carcinomas	O
of	O
the	O
head	O
and	O
neck	O
during	O
radiation	O
therapy	O
and	O
its	O
clinical	O
significance	O
.	O
C	O
-	O
fos	O
has	O
been	O
reported	O
to	O
be	O
one	O
of	O
the	O
immediate	O
early	O
genes	O
in	O
signal	O
transduction	O
systems	O
after	O
many	O
kinds	O
of	O
stresses	O
,	O
including	O
ionizing	O
radiation	O
.	O
Changes	O
in	O
c	O
-	O
fos	O
expression	O
induced	O
by	O
radiation	O
therapy	O
in	O
tumor	O
tissues	O
have	O
not	O
yet	O
been	O
reported	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
attempted	O
to	O
determine	O
whether	O
c	O
-	O
fos	O
expression	O
is	O
induced	O
by	O
radiotherapy	O
in	O
human	O
squamous	O
cell	O
carcinomas	O
of	O
the	O
head	O
and	O
neck	O
and	O
to	O
establish	O
a	O
possible	O
correlation	O
between	O
c	O
-	O
fos	O
expression	O
and	O
the	O
therapeutic	O
effects	O
of	O
radiation	O
therapy	O
.	O
Twenty	O
-	O
seven	O
patients	O
with	O
tumors	O
of	O
the	O
oral	O
cavity	O
,	O
oropharynx	O
,	O
and	O
maxillary	O
sinus	O
were	O
examined	O
,	O
all	O
of	O
which	O
were	O
confirmed	O
as	O
squamous	O
cell	O
carcinomas	O
.	O
After	O
obtaining	O
the	O
patients	O
'	O
informed	O
consent	O
,	O
biopsies	O
were	O
performed	O
before	O
treatment	O
and	O
at	O
doses	O
of	O
4	O
,	O
10	O
,	O
and	O
20	O
Gy	O
of	O
radiotherapy	O
,	O
and	O
the	O
specimens	O
were	O
preserved	O
in	O
liquid	O
nitrogen	O
for	O
further	O
examination	O
.	O
Serial	O
sectioning	O
of	O
6	O
micrometer	O
was	O
performed	O
using	O
a	O
cryostat	O
,	O
and	O
samples	O
were	O
immunohistochemically	O
stained	O
using	O
the	O
streptoavidin	B
-biotin	B
peroxidase	I
method	O
and	O
a	O
monoclonal	O
antibody	O
against	O
c	O
-	O
fos	O
.	O
Three	O
of	O
the	O
27	O
patients	O
with	O
squamous	O
cell	O
carcinoma	O
showed	O
slight	O
expression	O
of	O
c	O
-	O
fos	O
in	O
their	O
tumor	O
cells	O
before	O
and/or	O
at	O
4	O
or	O
10	O
Gy	O
of	O
radiotherapy	O
.	O
The	O
tumors	O
showed	O
high	O
radiosensitivity	O
.	O
Concerning	O
tumor	O
-	O
infiltrating	O
lymphocytes	O
,	O
the	O
rate	O
of	O
moderate	O
or	O
remarkable	O
grades	O
of	O
c	B
-	I
fos	I
-	I
positive	I
lymphocytes	I
before	O
radiotherapy	O
and	O
at	O
radiation	O
doses	O
of	O
4	O
,	O
10	O
,	O
and	O
20	O
Gy	O
was	O
8.0	O
,	O
29.2	O
,	O
4.8	O
,	O
and	O
0	O
%	O
,	O
respectively	O
.	O
The	O
relationship	O
between	O
the	O
immunohistochemical	O
findings	O
and	O
the	O
antitumor	O
effect	O
at	O
a	O
radiation	O
dose	O
of	O
20	O
Gy	O
was	O
examined	O
on	O
the	O
corresponding	O
H	O
&	O
E	O
-	O
stained	O
sections	O
.	O
In	O
patients	O
whose	O
infiltration	O
of	O
c	B
-	I
fos	I
-	I
positive	I
lymphocytes	I
into	O
tumor	O
tissues	O
were	O
moderate	O
or	O
remarkable	O
at	O
4	O
Gy	O
of	O
radiotherapy	O
,	O
the	O
tumors	O
responded	O
significantly	O
well	O
to	O
radiation	O
therapy	O
(	O
P	O
<	O
0.025	O
,	O
chi2	O
test	O
)	O
,	O
and	O
the	O
patients	O
took	O
a	O
significantly	O
favorable	O
clinical	O
course	O
(	O
P	O
<	O
0.05	O
,	O
chi2	O
test	O
)	O
.	O
In	O
a	O
sample	O
from	O
one	O
of	O
the	O
patients	O
,	O
c	B
-	I
fos	I
-	I
positive	I
lymphocytes	I
were	O
identified	O
as	O
CD4	O
positive	O
and	O
CD8	O
negative	O
.	O
Therefore	O
,	O
the	O
high	O
radiosensitivity	O
of	O
squamous	O
cell	O
carcinomas	O
in	O
our	O
samples	O
could	O
be	O
explained	O
by	O
an	O
overexpression	O
of	O
c	B
-	I
fos	I
in	O
the	O
tumor	O
-	O
infiltrating	O
lymphocytes	O
induced	O
by	O
small	O
doses	O
of	O
radiation	O
therapy	O
,	O
and	O
these	O
activated	O
lymphocytes	O
exerted	O
a	O
cytotoxic	O
effect	O
against	O
the	O
cancer	O
cells	O
.	O
T	O
cell	O
priming	O
enhances	O
IL-4	O
gene	O
expression	O
by	O
increasing	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
.	O
The	O
repetitive	O
activation	O
of	O
T	O
cells	O
(	O
priming	O
)	O
enhances	O
the	O
expression	O
of	O
many	O
cytokines	B
,	O
such	O
as	O
IL-4	O
,	O
but	O
not	O
others	O
,	O
such	O
as	O
IL-2	B
.	O
Molecular	O
mechanisms	O
underlying	O
selective	O
expression	O
of	O
cytokines	B
by	O
T	O
cells	O
remain	O
poorly	O
understood	O
.	O
Here	O
we	O
show	O
that	O
priming	O
of	O
CD4	O
T	O
cells	O
selectively	O
enhances	O
IL-4	B
expression	O
relative	O
to	O
IL-2	B
expression	O
by	O
a	O
transcriptional	O
mechanism	O
involving	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	I
NFAT	I
)	I
proteins	I
.	O
As	O
detected	O
by	O
in	O
vivo	O
footprinting	O
,	O
priming	O
markedly	O
increases	O
the	O
activation	O
-	O
dependent	O
engagement	O
of	O
the	O
P0	O
and	O
P1	O
NFAT	O
-	O
binding	O
elements	O
of	O
the	O
IL-4	O
promoter	O
.	O
Moreover	O
,	O
each	O
proximal	O
P	O
element	O
is	O
essential	O
for	O
optimal	O
IL-4	O
promoter	O
activity	O
.	O
Activated	O
primed	O
CD4	O
T	O
cells	O
contain	O
more	O
NFAT1	B
and	O
support	O
greater	O
NFAT	B
-directed	O
transcription	O
than	O
unprimed	O
CD4	O
T	O
cells	O
,	O
while	O
activator	B
protein	I
1	I
binding	O
and	O
activator	B
protein	I
1	I
-mediated	O
transcription	O
by	O
both	O
cell	O
types	O
is	O
similar	O
.	O
Increased	O
expression	O
of	O
wild	O
-	O
type	O
NFAT1	B
substantially	O
increases	O
IL-4	O
promoter	O
activity	O
in	O
unprimed	O
CD4	O
T	O
cells	O
,	O
suggesting	O
NFAT1	B
may	O
be	O
limiting	O
for	O
IL-4	B
gene	O
expression	O
in	O
this	O
cell	O
type	O
.	O
Furthermore	O
,	O
a	O
truncated	O
form	O
of	O
NFAT1	B
acts	O
as	O
a	O
dominant	O
-	O
negative	O
,	O
reducing	O
IL-4	O
promoter	O
activity	O
in	O
primed	O
CD4	O
T	O
cells	O
and	O
confirming	O
the	O
importance	O
of	O
endogenous	B
NFAT	I
to	O
increased	O
IL-4	B
gene	O
expression	O
by	O
effector	O
T	O
cells	O
.	O
NFAT1	B
appears	O
to	O
be	O
the	O
major	O
NFAT	B
family	I
member	I
responsible	O
for	O
the	O
initial	O
increased	O
expression	O
of	O
IL-4	B
by	O
primed	O
CD4	O
T	O
cells	O
.	O
Anoxia	O
/	O
reoxygenation	O
-	O
induced	O
tolerance	O
with	O
respect	O
to	O
polymorphonuclear	O
leukocyte	O
adhesion	O
to	O
cultured	O
endothelial	O
cells	O
.	O
A	O
nuclear	B
factor	I
-	I
kappaB	I
-mediated	O
phenomenon	O
.	O
Exposing	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
to	O
anoxia	O
/	O
reoxygenation	O
(	O
A	O
/	O
R	O
)	O
results	O
in	O
an	O
increase	O
in	O
polymorphonuclear	O
leukocyte	O
(	O
PMN	O
)	O
adhesion	O
to	O
HUVECs	O
.	O
This	O
A	O
/	O
R	O
-	O
induced	O
hyperadhesion	O
is	O
completely	O
prevented	O
by	O
a	O
previous	O
(	O
24	O
hours	O
earlier	O
)	O
exposure	O
of	O
HUVECs	O
to	O
A	O
/	O
R	O
.	O
This	O
phenomenon	O
has	O
been	O
termed	O
`	O
`	O
A	O
/	O
R	O
tolerance	O
.	O
''	O
Exposing	O
HUVECs	O
to	O
A	O
/	O
R	O
induces	O
an	O
increase	O
in	O
nuclear	B
factor	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
in	O
HUVEC	O
nuclei	O
within	O
4	O
hours	O
.	O
Interfering	O
with	O
either	O
NF	B
-	I
kappaB	I
activation	O
(	O
proteasome	B
inhibitor	O
)	O
or	O
translocation	O
(	O
double	O
-	O
stranded	O
oligonucleotides	O
containing	O
NF	O
-	O
kappaB	O
binding	O
sequence	O
)	O
prevents	O
the	O
development	O
of	O
A	O
/	O
R	O
tolerance	O
(	O
ie	O
,	O
the	O
increase	O
in	O
A	O
/	O
R	O
-	O
induced	O
PMN	O
adhesion	O
to	O
HUVECs	O
is	O
the	O
same	O
after	O
the	O
first	O
and	O
second	O
A	O
/	O
R	O
challenges	O
)	O
.	O
NO	O
production	O
by	O
HUVECs	O
is	O
increased	O
after	O
the	O
second	O
A	O
/	O
R	O
challenge	O
,	O
but	O
not	O
after	O
the	O
first	O
A	O
/	O
R	O
challenge	O
.	O
Inhibition	O
of	O
NO	B
synthase	I
(	O
NOS	B
)	O
during	O
the	O
second	O
A	O
/	O
R	O
challenge	O
prevents	O
the	O
development	O
of	O
A	O
/	O
R	O
tolerance	O
with	O
respect	O
to	O
PMN	O
adhesion	O
.	O
However	O
,	O
while	O
HUVECs	O
contained	O
endothelial	O
NOS	B
protein	I
,	O
no	O
inducible	O
NOS	B
was	O
detected	O
in	O
either	O
tolerant	O
or	O
nontolerant	O
cells	O
.	O
Further	O
studies	O
indicated	O
that	O
inhibition	O
of	O
GTP	B
-	I
cyclohydrolase	I
I	I
(	O
an	O
enzyme	O
involved	O
in	O
de	O
novo	O
synthesis	O
of	O
an	O
important	O
cofactor	O
for	O
NOS	B
activity	O
,	O
tetrahydrobiopterin	O
)	O
prevented	O
the	O
generation	O
of	O
NO	O
in	O
A	O
/	O
R	O
-	O
tolerant	O
cells	O
.	O
Extracellular	O
generation	O
of	O
NO	O
(	O
NO	O
donor	O
)	O
did	O
not	O
effect	O
the	O
hyperadhesion	O
response	O
induced	O
by	O
the	O
initial	O
A	O
/	O
R	O
challenge	O
.	O
A	O
/	O
R	O
also	O
induced	O
an	O
oxidant	O
stress	O
in	O
naive	O
HUVECs	O
,	O
but	O
not	O
in	O
A	O
/	O
R	O
-	O
tolerant	O
HUVECs	O
.	O
Inhibition	O
of	O
NOS	B
during	O
the	O
second	O
A	O
/	O
R	O
insult	O
results	O
in	O
the	O
generation	O
of	O
an	O
oxidant	O
stress	O
similar	O
to	O
that	O
observed	O
after	O
the	O
first	O
A	O
/	O
R	O
challenge	O
.	O
Taken	O
together	O
,	O
the	O
findings	O
of	O
the	O
present	O
study	O
are	O
consistent	O
with	O
a	O
role	O
for	O
NF	B
-	I
kappaB	I
in	O
the	O
development	O
of	O
A	O
/	O
R	O
tolerance	O
(	O
with	O
respect	O
to	O
PMN	O
adhesion	O
)	O
,	O
perhaps	O
by	O
transcriptional	O
regulation	O
of	O
GTP	B
-	I
cyclohydrolase	I
.	O
The	O
increased	O
NO	O
production	O
during	O
the	O
second	O
A	O
/	O
R	O
insult	O
reduces	O
PMN	O
adhesion	O
most	O
likely	O
by	O
reducing	O
the	O
intracellular	O
oxidant	O
stress	O
induced	O
by	O
A	O
/	O
R	O
.	O
Involvement	O
of	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
pathways	O
in	O
interleukin-8	B
production	O
by	O
human	O
monocytes	O
and	O
polymorphonuclear	O
cells	O
stimulated	O
with	O
lipopolysaccharide	O
or	O
Mycoplasma	B
fermentans	I
membrane	I
lipoproteins	I
.	O
Interleukin-8	B
(	O
IL-8	B
)	O
is	O
a	O
chemokine	B
that	O
belongs	O
to	O
the	O
alpha	B
-	I
chemokine	I
or	O
CXC	B
subfamily	I
and	O
is	O
produced	O
by	O
a	O
wide	O
variety	O
of	O
human	O
cells	O
,	O
including	O
monocytes	O
and	O
polymorphonuclear	O
cells	O
(	O
PMN	O
)	O
.	O
IL-8	B
is	O
secreted	O
in	O
response	O
to	O
inflammatory	O
stimuli	O
,	O
notably	O
bacterial	O
products	O
such	O
as	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
mechanisms	O
by	O
which	O
these	O
agents	O
mediate	O
IL-8	B
induction	O
.	O
In	O
this	O
report	O
,	O
we	O
show	O
that	O
Mycoplasma	B
fermentans	I
lipid	I
-	I
associated	I
membrane	I
proteins	I
(	O
LAMPf	B
)	O
induce	O
the	O
production	O
of	O
high	O
levels	O
of	O
IL-8	B
by	O
THP-1	O
(	O
human	O
monocyte	O
)	O
cells	O
and	O
PMN	O
at	O
the	O
same	O
extent	O
as	O
LPS	O
.	O
It	O
was	O
previously	O
demonstrated	O
that	O
stimulation	O
of	O
monocytic	O
cells	O
with	O
either	O
LPS	O
or	O
LAMPf	B
led	O
to	O
a	O
series	O
of	O
common	O
downstream	O
signaling	O
events	O
,	O
including	O
the	O
activation	O
of	O
protein	B
tyrosine	I
kinase	I
and	O
of	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
cascades	O
.	O
By	O
using	O
PD-98059	O
and	O
SB203580	O
,	O
two	O
potent	O
and	O
selective	O
inhibitors	O
of	O
MEK1	B
(	O
a	O
kinase	B
upstream	O
of	O
ERK1	B
/	I
2	I
)	O
and	O
p38	B
,	O
respectively	O
,	O
we	O
have	O
demonstrated	O
that	O
both	O
ERK1	O
/	O
2	O
and	O
p38	O
cascades	O
play	O
a	O
key	O
role	O
in	O
the	O
production	O
of	O
IL-8	B
by	O
monocytes	O
and	O
PMN	O
stimulated	O
with	O
bacterial	O
fractions	O
.	O
CD80	B
and	O
CD86	B
are	O
not	O
equivalent	O
in	O
their	O
ability	O
to	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
CD28	B
.	O
Ligation	O
of	O
either	O
CD80	B
(	O
B7	B
-	I
1	I
)	O
or	O
CD86	B
(	O
B7	B
-	I
2	I
)	O
,	O
two	O
principal	O
ligands	O
for	O
CD28	B
,	O
is	O
thought	O
to	O
skew	O
the	O
immune	O
response	O
toward	O
Th1	O
or	O
Th2	O
differentiation	O
.	O
We	O
have	O
examined	O
early	O
signal	O
transduction	O
pathways	O
recruited	O
following	O
T	O
cell	O
stimulation	O
with	O
either	O
CD80	B
or	O
CD86	B
.	O
Purified	O
human	O
peripheral	O
T	O
cells	O
or	O
Jurkat	O
T	O
cells	O
were	O
stimulated	O
with	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
expressing	O
either	O
human	B
CD80	I
(	O
CHO	B
-	I
CD80	I
)	O
or	O
human	B
CD86	I
(	O
CHO	B
-	I
CD86	I
)	O
or	O
with	O
anti	B
-	I
CD28	I
monoclonal	I
antibody	I
(	O
mAb	O
)	O
.	O
In	O
the	O
presence	O
of	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
both	O
CHO	B
-	I
CD80	I
and	O
CHO	B
-	I
CD86	I
,	O
like	O
anti	B
-	I
CD28	I
mAb	I
,	O
were	O
capable	O
of	O
stimulating	O
cytokine	B
production	O
from	O
both	O
human	O
peripheral	O
T	O
cells	O
and	O
Jurkat	O
T	O
cells	O
.	O
Both	O
CHO	B
-	I
CD80	I
and	O
CHO	B
-	I
CD86	I
,	O
in	O
the	O
presence	O
of	O
anti	B
-	I
CD3	I
mAb	I
,	O
costimulated	O
NFAT	B
-dependent	O
transcriptional	O
activation	O
.	O
Several	O
intracellular	O
signaling	B
proteins	I
,	O
such	O
as	O
CBL	B
and	O
VAV	B
,	O
were	O
phosphorylated	O
on	O
tyrosine	O
in	O
response	O
to	O
CD80	B
,	O
CD86	B
,	O
and	O
anti	B
-	I
CD28	I
mAb	I
.	O
Surprisingly	O
,	O
although	O
stimulation	O
of	O
Jurkat	O
T	O
cells	O
with	O
either	O
CHO	B
-	I
CD80	I
or	O
anti	B
-	I
CD28	I
mAb	I
resulted	O
in	O
robust	O
tyrosine	O
phosphorylation	O
of	O
CD28	B
itself	O
,	O
ligation	O
with	O
CHO	B
-	I
CD86	I
was	O
unable	O
to	O
induce	O
detectable	O
CD28	B
tyrosyl	O
phosphorylation	O
over	O
a	O
range	O
of	O
stimulation	O
conditions	O
.	O
In	O
addition	O
,	O
the	O
association	O
of	O
phosphoinositide	B
3-kinase	I
with	O
CD28	B
and	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
phospholipase	O
Cgamma	O
were	O
seen	O
after	O
anti	O
-	O
CD28	O
mAb	O
and	O
CHO	O
-	O
CD80	O
stimulation	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
after	O
CHO	B
-	I
CD86	I
stimulation	O
.	O
Thus	O
,	O
ligation	O
of	O
CD28	B
with	O
either	O
CD80	B
or	O
CD86	B
leads	O
to	O
shared	O
early	O
signal	O
transduction	O
events	O
such	O
as	O
the	O
tyrosine	O
phosphorylation	O
of	O
CBL	B
and	O
VAV	B
,	O
to	O
NFAT	B
-mediated	O
transcriptional	O
activation	O
,	O
and	O
to	O
the	O
costimulation	O
of	O
interleukin-2	B
and	O
granulocyte	B
-	I
macrophage	I
colony	I
-	I
stimulating	I
factor	I
production	O
.	O
However	O
,	O
CD80	B
and	O
CD86	B
also	O
induce	O
distinct	O
signal	O
transduction	O
pathways	O
including	O
the	O
tyrosine	O
phosphorylation	O
of	O
CD28	B
and	O
phospholipase	B
Cgamma1	I
and	O
the	O
SH2	B
-dependent	O
association	O
of	O
phosphoinositide	B
3-kinase	I
with	O
CD28	B
.	O
These	O
quantitative	O
,	O
if	O
not	O
qualitative	O
,	O
differences	O
between	O
signaling	O
initiated	O
by	O
these	O
two	O
ligands	O
for	O
CD28	B
may	O
contribute	O
to	O
functional	O
differences	O
(	O
e.g.	O
Th1	O
or	O
Th2	O
differentiation	O
)	O
in	O
T	O
cell	O
responses	O
.	O
Role	O
of	O
Egr-2	B
in	O
up	O
-	O
regulation	O
of	O
Fas	B
ligand	I
in	O
normal	O
T	O
cells	O
and	O
aberrant	O
double	O
-	O
negative	O
lpr	O
and	O
gld	O
T	O
cells	O
.	O
We	O
previously	O
identified	O
a	O
Fas	O
ligand	O
regulatory	O
element	O
(	O
FLRE	O
)	O
in	O
the	O
Fas	O
ligand	O
(	O
fasL	O
)	O
promoter	O
that	O
binds	O
Egr	B
family	I
proteins	I
and	O
demonstrated	O
that	O
Egr-3	B
(	O
PILOT	B
)	O
but	O
not	O
Egr-1	B
(	O
NGFI	B
-	I
A	I
,	O
Krox-24	B
,	O
Tis-8	B
,	O
and	O
Zif-268	B
)	O
induces	O
transcription	O
of	O
fasL	B
.	O
The	O
aberrant	O
CD4	O
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
from	O
lpr	O
/	O
lpr	O
and	O
gld	O
/	O
gld	O
mice	O
,	O
which	O
have	O
mutations	O
in	O
the	O
genes	O
encoding	O
Fas	B
and	O
FasL	B
,	O
respectively	O
,	O
have	O
an	O
activated	O
phenotype	O
and	O
constitutively	O
express	O
high	O
levels	O
of	O
fasL	O
mRNA	O
,	O
prompting	O
us	O
to	O
ask	O
what	O
role	O
if	O
any	O
the	O
FLRE	O
and	O
Egr	B
family	I
proteins	I
have	O
in	O
this	O
aberrant	O
expression	O
of	O
fasL	B
.	O
Unstimulated	O
MRL	O
-	O
lpr	O
/	O
lpr	O
and	O
C3H	O
-	O
gld	O
/	O
gld	O
CD4	O
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
constitutively	O
contained	O
high	O
levels	O
of	O
two	O
proteins	O
that	O
bound	O
to	O
the	O
FLRE	O
.	O
Supershift	O
analysis	O
revealed	O
these	O
proteins	O
to	O
be	O
Egr-1	B
and	O
Egr-2	B
(	O
Krox-20	O
)	O
;	O
Egr-3	B
was	O
not	O
detected	O
.	O
Activation	O
of	O
normal	O
lymph	O
node	O
cells	O
resulted	O
in	O
increased	O
expression	O
of	O
Egr-1	B
,	I
-2	I
,	I
and	I
-3	I
.	O
As	O
with	O
egr-3	O
,	O
expression	O
of	O
egr-2	O
was	O
blocked	O
by	O
cyclosporin	O
A	O
.	O
Although	O
overexpressed	O
Egr-1	B
was	O
ineffective	O
,	O
overexpressed	O
Egr-2	B
was	O
as	O
potent	O
as	O
Egr-3	B
in	O
inducing	O
fasL	O
promoter	O
-	O
dependent	O
reporter	O
constructs	O
in	O
T	O
cell	O
hybridomas	O
and	O
HeLa	O
cells	O
,	O
and	O
both	O
up	O
-	O
regulated	O
endogenous	O
fasL	O
mRNA	O
in	O
HeLa	O
cells	O
.	O
FasL	O
-	O
dependent	O
reporter	O
constructs	O
in	O
MRL	O
-	O
lpr	O
/	O
lpr	O
and	O
C3H	O
-	O
gld	O
/	O
gld	O
CD4	O
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
were	O
constitutively	O
active	O
,	O
and	O
this	O
activity	O
was	O
largely	O
prevented	O
by	O
mutation	O
of	O
the	O
critical	O
Egr	O
family	O
binding	O
element	O
.	O
Thus	O
,	O
Egr-2	B
,	O
in	O
addition	O
to	O
Egr-3	B
,	O
regulates	O
FasL	B
expression	O
in	O
activated	O
normal	O
T	O
cells	O
,	O
and	O
Egr-2	B
is	O
likely	O
to	O
play	O
a	O
direct	O
role	O
in	O
aberrant	O
fasL	B
up	O
-	O
regulation	O
in	O
lpr	O
/	O
lpr	O
and	O
gld	O
/	O
gld	O
CD4	O
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
.	O
Inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
:	O
role	O
of	O
26S	B
proteasome	I
.	O
It	O
is	O
becoming	O
increasingly	O
apparent	O
that	O
NF	B
-	I
kappa	I
B	I
plays	O
a	O
critical	O
role	O
in	O
regulating	O
the	O
inflammatory	O
response	O
.	O
Data	O
obtained	O
from	O
studies	O
in	O
our	O
laboratories	O
demonstrate	O
that	O
the	O
proteasome	O
plays	O
an	O
important	O
role	O
in	O
the	O
inflammatory	O
cascade	O
by	O
regulating	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
.	O
Indeed	O
,	O
the	O
availability	O
of	O
selective	O
and	O
orally	O
active	O
proteasome	O
inhibitors	O
should	O
prove	O
useful	O
in	O
delineating	O
the	O
roles	O
of	O
the	O
proteasome	O
and	O
NF	B
-	I
kappa	I
B	I
in	O
other	O
pathophysiological	O
conditions	O
such	O
as	O
cancer	O
and	O
heart	O
disease	O
.	O
Imbalanced	O
expression	O
of	O
the	O
glucocorticoid	B
receptor	I
isoforms	I
in	O
cultured	O
lymphocytes	O
from	O
a	O
patient	O
with	O
systemic	O
glucocorticoid	O
resistance	O
and	O
chronic	O
lymphocytic	O
leukemia	O
.	O
The	O
human	B
glucocorticoid	I
receptor	I
(	O
GR	B
)	O
is	O
expressed	O
as	O
two	O
alternatively	O
spliced	O
isoforms	O
,	O
GRalpha	B
and	O
GRbeta	B
.	O
Whereas	O
GRalpha	B
is	O
a	O
hormone	O
-	O
activated	O
transcription	B
factor	I
,	O
GRbeta	B
does	O
not	O
bind	O
glucocorticoids	O
(	O
GCs	O
)	O
,	O
is	O
transcriptionally	O
inactive	O
,	O
and	O
is	O
a	O
potential	O
inhibitor	O
of	O
activated	O
GRalpha	B
.	O
Differential	O
expression	O
of	O
GR	B
isoforms	I
may	O
play	O
a	O
role	O
in	O
generalized	O
or	O
tissue	O
-	O
specific	O
GC	O
resistance	O
.	O
GCs	O
induce	O
apoptosis	O
in	O
neoplastic	O
lymphoid	O
cells	O
;	O
and	O
,	O
defective	O
apoptosis	O
is	O
implicated	O
in	O
the	O
genesis	O
of	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
.	O
We	O
studied	O
a	O
patient	O
with	O
generalized	O
GC	O
resistance	O
and	O
CLL	O
.	O
GR	O
number	O
in	O
the	O
patient	O
's	O
transformed	O
lymphocytes	O
was	O
approximately	O
one	O
half	O
that	O
of	O
control	O
cells	O
with	O
a	O
approximately	O
10-fold	O
reduction	O
in	O
binding	O
affinity	O
for	O
dexamethasone	O
.	O
In	O
vitro	O
apoptosis	O
induction	O
in	O
CLL	O
cells	O
was	O
delayed	O
in	O
response	O
to	O
GCs	O
,	O
but	O
not	O
to	O
other	O
apoptosis	O
inducers	O
.	O
Sequencing	O
of	O
the	O
GR	O
cDNA	O
and	O
gene	O
including	O
the	O
2.3-kb	O
coding	O
region	O
,	O
the	O
intron	O
/	O
exon	O
junctions	O
,	O
the	O
known	O
5'-regulatory	O
region	O
,	O
and	O
approximately	O
300	O
bp	O
of	O
the	O
3'-region	O
revealed	O
no	O
alterations	O
.	O
Western	O
blot	O
with	O
an	O
N	O
-	O
terminal	O
antibody	O
showed	O
normal	O
levels	O
of	O
immunoreactive	B
GR	I
,	O
but	O
quantitative	O
analysis	O
with	O
isoform	O
-	O
specific	O
C	B
-	I
terminal	I
antibodies	I
revealed	O
a	O
markedly	O
reduced	O
GRalpha	B
expression	O
,	O
and	O
high	O
GRbeta	B
expression	O
.	O
These	O
findings	O
indicate	O
that	O
imbalanced	O
expression	O
of	O
the	O
GR	B
isoforms	I
may	O
be	O
a	O
mechanism	O
of	O
GC	O
resistance	O
,	O
and	O
may	O
have	O
implications	O
for	O
tumorigenesis	O
by	O
enhancing	O
cell	O
survival	O
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
1	O
,	O
25-Dihydroxyvitamin	O
D3	O
receptors	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
patients	O
with	O
renal	O
insufficiency	O
.	O
A	O
reduced	O
expression	O
of	O
the	O
vitamin	B
D	I
receptor	I
(	O
VDR	O
)	O
in	O
parathyroid	O
glands	O
of	O
uremic	O
animals	O
and	O
humans	O
has	O
been	O
observed	O
.	O
Similar	O
results	O
have	O
been	O
obtained	O
by	O
our	O
own	O
group	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
from	O
patients	O
with	O
secondary	O
hyperparathyroidism	O
to	O
chronic	O
renal	O
failure	O
.	O
However	O
,	O
the	O
reasons	O
for	O
these	O
changes	O
are	O
not	O
clear	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
specific	O
uptake	O
of	O
[	O
3H	O
]	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
by	O
PBMC	O
of	O
11	O
women	O
with	O
advanced	O
chronic	O
renal	O
failure	O
(	O
A	O
-	O
CRF	O
)	O
,	O
6	O
women	O
with	O
mild	O
-	O
moderate	O
renal	O
insufficiency	O
(	O
M	O
-	O
CRF	O
)	O
,	O
and	O
23	O
healthy	O
women	O
.	O
The	O
mean	O
dissociation	O
constant	O
(	O
KD	O
)	O
was	O
similar	O
in	O
both	O
groups	O
of	O
patients	O
and	O
in	O
healthy	O
women	O
(	O
A	O
-	O
CRF	O
:	O
0.7	O
+	O
/-	O
0.5	O
x	O
10	O
(	O
-10	O
)	O
M	O
;	O
M	O
-	O
CRF	O
:	O
1.1	O
+	O
/-	O
0.9	O
x	O
10	O
(	O
-10	O
)	O
M	O
;	O
controls	O
:	O
1.0	O
+	O
/-	O
0.6	O
x	O
10	O
(	O
-10	O
)	O
M	O
)	O
.	O
However	O
,	O
VDR	B
concentration	O
was	O
significantly	O
decreased	O
in	O
A	O
-	O
CRF	O
(	O
0.8	O
+	O
/-	O
0.5	O
fmol	O
/	O
10	O
(	O
7	O
)	O
cells	O
vs.	O
2.3	O
+	O
/-	O
0.9	O
fmol	O
/	O
10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
,	O
p	O
<	O
0.001	O
)	O
,	O
whereas	O
no	O
changes	O
were	O
seen	O
in	O
M	O
-	O
CRF	O
(	O
1.7	O
+	O
/-	O
0.7	O
fmol	O
/	O
10	O
(	O
7	O
)	O
cells	O
vs.	O
2.3	O
+	O
/-	O
0.9	O
fmol	O
/	O
10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
)	O
.	O
No	O
correlation	O
was	O
seen	O
between	O
VDR	B
and	O
serum	O
calcitriol	O
or	O
PTH	O
levels	O
,	O
when	O
considering	O
both	O
groups	O
of	O
patients	O
together	O
or	O
separately	O
.	O
Conversely	O
,	O
a	O
significant	O
negative	O
correlation	O
was	O
found	O
between	O
VDR	B
and	O
serum	O
creatinine	O
values	O
when	O
A	O
-	O
CRF	O
and	O
M	O
-	O
CRF	O
were	O
considered	O
altogether	O
(	O
r	O
=	O
-0.63	O
;	O
p	O
<	O
0.01	O
)	O
.	O
Treatment	O
with	O
two	O
different	O
schedules	O
of	O
oral	O
calcitriol	O
(	O
five	O
patients	O
with	O
0.5	O
microgram	O
/	O
day	O
for	O
1	O
month	O
and	O
four	O
patients	O
with	O
2	O
micrograms	O
/	O
day	O
for	O
7	O
days	O
)	O
did	O
not	O
change	O
VDR	B
concentrations	O
.	O
We	O
conclude	O
that	O
the	O
low	O
levels	O
of	O
serum	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
of	O
uremia	O
are	O
not	O
responsible	O
for	O
the	O
decrease	O
in	O
VDR	B
concentration	O
found	O
in	O
these	O
patients	O
.	O
Transcription	B
factor	I
effects	O
on	O
chromosome	O
constitution	O
of	O
cell	O
hybrids	O
.	O
When	O
immunoglobulin	O
(	O
Ig	O
)	O
-secreting	O
plasmacytomas	O
are	O
fused	O
to	O
a	O
T	O
-	O
cell	O
lymphoma	O
,	O
Ig	O
gene	O
expression	O
ceases	O
in	O
greater	O
than	O
95	O
%	O
of	O
the	O
resulting	O
hybrids	O
.	O
In	O
the	O
rare	O
hybrids	O
that	O
continue	O
to	O
express	O
Ig	O
,	O
all	O
other	O
tested	O
B	O
lymphocyte	O
-	O
specific	O
genes	O
also	O
remain	O
active	O
.	O
The	O
low	O
frequency	O
with	O
which	O
these	O
Ig	O
-	O
expressing	O
hybrids	O
are	O
recovered	O
,	O
along	O
with	O
the	O
fact	O
that	O
cell	O
fusions	O
can	O
lead	O
to	O
chromosome	O
loss	O
,	O
led	O
us	O
to	O
propose	O
that	O
this	O
rare	O
phenotype	O
was	O
due	O
to	O
loss	O
of	O
a	O
T	B
-	I
cell	I
-	I
derived	I
chromosome	I
encoding	I
a	I
factor	I
or	O
factors	O
with	O
gene	O
silencing	O
activity	O
.	O
To	O
identify	O
the	O
relevant	O
chromosome	O
,	O
we	O
have	O
used	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-assisted	O
method	O
of	O
chromosome	O
mapping	O
to	O
analyze	O
both	O
Ig	O
-	O
silenced	O
(	O
common	O
)	O
and	O
Ig	O
-	O
expressing	O
(	O
rare	O
)	O
hybrids	O
.	O
Although	O
no	O
single	O
chromosome	O
was	O
found	O
to	O
correlate	O
with	O
Ig	O
gene	O
silencing	O
,	O
we	O
discovered	O
that	O
the	O
two	O
types	O
of	O
hybrids	O
had	O
undergone	O
distinct	O
patterns	O
of	O
chromosome	O
loss	O
.	O
Moreover	O
,	O
we	O
found	O
that	O
ectopic	O
expression	O
of	O
a	O
B	B
-	I
cell	I
-	I
specific	I
transcription	I
factor	I
(	O
Oct-2	B
)	O
dramatically	O
altered	O
both	O
the	O
phenotype	O
and	O
chromosome	O
constitution	O
of	O
hybrids	O
arising	O
in	O
these	O
cell	O
fusions	O
.	O
Both	O
Stat3	B
-activation	O
and	O
Stat3	B
-independent	O
BCL2	B
downregulation	O
are	O
important	O
for	O
interleukin-6	B
-induced	O
apoptosis	O
of	O
1A9-M	O
cells	O
.	O
A	O
unique	O
subclone	O
of	O
a	O
bone	O
marrow	O
-	O
derived	O
stromal	O
cell	O
line	O
,	O
BMS2.4	O
,	O
produces	O
soluble	B
factors	I
that	O
inhibit	O
proliferation	O
of	O
several	O
types	O
of	O
hematopoietic	O
cell	O
lines	O
.	O
An	O
understanding	O
of	O
these	O
molecules	O
may	O
be	O
informative	O
about	O
negative	O
regulatory	O
circuits	O
that	O
can	O
potentially	O
limit	O
blood	O
cell	O
formation	O
.	O
We	O
used	O
expression	O
cloning	O
to	O
identify	O
interleukin-6	B
(	O
IL-6	B
)	O
as	O
one	O
factor	O
that	O
suppressed	O
growth	O
of	O
a	O
pre	O
-	O
B	O
-	O
cell	O
variant	O
line	O
,	O
1A9-M	O
.	O
Moreover	O
,	O
IL-6	B
induced	O
macrophage	O
-	O
differentiation	O
and	O
apoptosis	O
of	O
1A9-M	O
cells	O
.	O
During	O
this	O
process	O
,	O
IL-6	B
downregulated	O
expression	O
of	O
BCL2	B
in	O
1A9-M	O
cells	O
and	O
stimulated	O
BCL	O
-	O
XL	O
expression	O
,	O
but	O
had	O
no	O
effect	O
on	O
p53	O
,	O
Bax	O
,	O
or	O
Bak	O
gene	O
expression	O
.	O
Mechanisms	O
for	O
transduction	O
of	O
IL-6	B
-induced	O
signals	O
were	O
then	O
evaluated	O
in	O
IL-6-stimulated	O
1A9-M	O
cells	O
.	O
Whereas	O
the	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
3	I
(	O
Stat3	B
)	O
was	O
phosphorylated	O
and	O
activated	O
,	O
there	O
was	O
no	O
effect	O
on	O
either	O
Stat1	B
or	O
Stat5	B
.	O
The	O
importance	O
of	O
BCL2	B
and	O
Stat3	B
on	O
IL-6	B
-induced	O
macrophage	O
-	O
differentiation	O
and	O
apoptosis	O
was	O
studied	O
with	O
1A9-M	O
cells	O
expressing	O
human	B
BCL2	I
or	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
Stat3	B
,	O
respectively	O
.	O
IL-6	B
-induced	O
apoptosis	O
,	O
but	O
not	O
macrophage	O
-	O
differentiation	O
,	O
was	O
blocked	O
by	O
continuously	O
expressed	O
BCL2	B
.	O
A	O
dominant	B
-	I
negative	I
form	I
of	I
Stat3	I
inhibited	O
both	O
macrophage	O
-	O
differentiation	O
and	O
apoptosis	O
induced	O
by	O
IL-6	B
.	O
However	O
,	O
diminished	O
Stat3	B
activity	O
did	O
not	O
prevent	O
IL-6	B
-induced	O
downregulation	O
of	O
the	O
BCL2	O
gene	O
.	O
Therefore	O
,	O
activation	O
of	O
Stat3	B
is	O
essential	O
for	O
IL-6	B
-induced	O
macrophage	O
-	O
differentiation	O
and	O
programmed	O
cell	O
death	O
in	O
this	O
model	O
.	O
Whereas	O
overexpression	O
of	O
BCL2	B
abrogates	O
the	O
apoptotic	O
response	O
,	O
Stat3	B
-independent	O
signals	O
appear	O
to	O
downregulate	O
expression	O
of	O
the	O
BCL2	O
gene	O
.	O
Granulosa	O
cell	O
tumor	O
of	O
the	O
ovary	O
.	O
Immunohistochemical	O
evidence	O
of	O
low	O
proliferative	O
activity	O
and	O
virtual	O
absence	O
of	O
mutation	O
of	O
the	O
p53	O
tumor	O
-	O
suppressor	O
gene	O
.	O
BACKGROUND	O
AND	O
METHODS	O
:	O
Because	O
the	O
use	O
of	O
immunohistochemistry	O
in	O
the	O
diagnosis	O
of	O
granulosa	O
cell	O
tumor	O
(	O
GCT	O
)	O
has	O
not	O
been	O
fully	O
explored	O
,	O
routinely	O
processed	O
(	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
)	O
tissue	O
from	O
11	O
GCT	O
,	O
adult	O
type	O
,	O
was	O
investigated	O
immunohistochemically	O
(	O
ABC	O
method	O
)	O
with	O
a	O
broad	O
spectrum	O
of	O
antibodies	O
against	O
various	O
markers	O
,	O
including	O
p53	B
and	O
Ki-67	B
.	O
All	O
of	O
the	O
tumors	O
exhibited	O
typical	O
morphology	O
,	O
were	O
limited	O
to	O
the	O
ovary	O
(	O
stage	O
I	O
)	O
,	O
and	O
7	O
cases	O
followed	O
a	O
benign	O
clinical	O
course	O
.	O
RESULTS	O
:	O
All	O
the	O
tumors	O
exhibited	O
strong	O
expression	O
of	O
vimentin	B
,	O
but	O
most	O
other	O
antigens	O
(	O
including	O
smooth	B
muscle	I
actin	I
)	O
were	O
expressed	O
infrequently	O
by	O
a	O
minority	O
of	O
tumor	O
cells	O
or	O
not	O
at	O
all	O
.	O
Tumor	O
cells	O
in	O
9	O
GCT	O
expressed	O
inhibin	O
A	O
.	O
All	O
the	O
tumors	O
exhibited	O
very	O
low	O
proliferative	O
activity	O
,	O
fewer	O
than	O
10	O
%	O
of	O
the	O
tumor	O
cell	O
nuclei	O
being	O
stained	O
by	O
the	O
antibody	B
MIB-1	I
(	O
Ki-67	B
antigen	I
)	O
.	O
The	O
antibody	B
D07	I
revealed	O
marked	O
overexpression	O
of	O
p53	B
protein	I
in	O
only	O
one	O
tumor	O
.	O
Clinical	O
outcome	O
was	O
not	O
found	O
to	O
be	O
related	O
to	O
immunophenotypic	O
differences	O
.	O
CONCLUSIONS	O
:	O
The	O
diagnosis	O
of	O
GCT	O
should	O
be	O
based	O
primarily	O
on	O
the	O
typical	O
morphology	O
revealed	O
by	O
conventional	O
stains	O
,	O
but	O
additional	O
immunohistochemical	O
staining	O
with	O
a	O
small	O
panel	O
of	O
selected	O
antibodies	O
(	O
for	O
example	O
,	O
against	O
keratin	B
,	O
vimentin	B
,	O
and	O
inhibin	B
A	I
)	O
may	O
be	O
helpful	O
in	O
a	O
few	O
cases	O
.	O
The	O
very	O
low	O
proliferative	O
activity	O
and	O
the	O
lack	O
of	O
overexpression	O
of	O
p53	B
protein	I
are	O
consistent	O
with	O
the	O
benign	O
clinical	O
behavior	O
of	O
the	O
majority	O
of	O
GCT	O
.	O
Lactobacilli	O
and	O
vaginal	O
host	O
defense	O
:	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
,	O
cytokine	B
production	O
,	O
and	O
NF	B
-	I
kappaB	I
.	O
Lactobacilli	O
,	O
a	O
component	O
of	O
the	O
normal	O
vaginal	O
flora	O
,	O
can	O
activate	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
in	O
the	O
Jurkat	O
T	O
lymphocyte	O
and	O
THP-1	O
macrophage	O
cell	O
lines	O
.	O
Activation	O
of	O
the	O
LTR	O
in	O
Jurkat	O
cells	O
was	O
strongly	O
enhanced	O
by	O
vanadate	O
and	O
inhibited	O
by	O
catalase	B
,	O
implicating	O
H2O2	O
.	O
In	O
contrast	O
,	O
activation	O
in	O
THP-1	B
cells	I
occurred	O
in	O
the	O
absence	O
of	O
vanadate	O
and	O
was	O
unaffected	O
by	O
catalase	B
.	O
The	O
active	O
material	O
partitioned	O
into	O
the	O
phenol	O
layer	O
on	O
hot	O
aqueous	O
phenol	O
extraction	O
.	O
Lactobacilli	O
also	O
increased	O
tumor	B
necrosis	I
factor	I
-alphaand	O
interleukin	B
-1betaproduction	O
and	O
activated	O
NF	B
-	I
kappaB	I
in	O
THP-1	B
cells	I
and	O
increased	O
tumor	B
necrosis	I
factor	I
-alphaproduction	O
by	O
human	O
monocytes	O
.	O
Human	O
vaginal	O
fluid	O
specimens	O
had	O
comparable	O
properties	O
,	O
which	O
correlated	O
with	O
their	O
bacterial	O
content	O
.	O
These	O
findings	O
suggest	O
the	O
presence	O
in	O
vaginal	O
fluid	O
of	O
agent	O
(	O
s	O
)	O
derived	O
from	O
indigenous	O
bacteria	O
that	O
can	O
activate	O
the	O
HIV-1	O
LTR	O
,	O
cytokine	B
production	O
,	O
and	O
NF	B
-	I
kappaB	I
in	O
cells	O
of	O
macrophage	O
lineage	O
,	O
with	O
possible	O
influence	O
on	O
vaginal	O
physiology	O
and	O
host	O
defense	O
.	O
Cross	O
-	O
linking	O
of	O
CD44	B
on	O
rheumatoid	O
synovial	O
cells	O
up	O
-	O
regulates	O
VCAM-1	B
.	O
CD44	O
is	O
a	O
ubiquitous	O
molecule	O
also	O
known	O
as	O
hyaluronic	O
acid	O
or	O
homing	O
receptor	O
.	O
However	O
,	O
the	O
cellular	O
functions	O
and	O
its	O
role	O
in	O
inflammation	O
,	O
for	O
example	O
,	O
rheumatoid	O
synovitis	O
,	O
are	O
currently	O
unknown	O
.	O
In	O
this	O
study	O
,	O
we	O
propose	O
a	O
novel	O
function	O
for	O
CD44	O
.	O
Using	O
synovial	O
cells	O
from	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
,	O
we	O
demonstrated	O
that	O
CD44	O
cross	O
-	O
linking	O
and	O
binding	O
to	O
hyaluronan	O
augmented	O
VCAM-1	B
expression	O
and	O
subsequently	O
VCAM-1	B
-mediated	O
cell	O
adhesion	O
.	O
Briefly	O
,	O
we	O
found	O
that	O
1	O
)	O
rheumatoid	O
synovial	O
cells	O
highly	O
expressed	O
CD44	B
;	O
2	O
)	O
cross	O
-	O
linking	O
of	O
CD44	B
markedly	O
but	O
transiently	O
augmented	O
VCAM-1	B
expression	O
and	O
its	O
mRNA	O
transcription	O
much	O
more	O
than	O
did	O
IL-1beta	B
and	O
TNF	O
-	O
alpha	O
;	O
3	O
)	O
hyaluronan	O
,	O
especially	O
when	O
fragmented	O
,	O
also	O
up	O
-	O
regulated	O
VCAM-1	B
;	O
4	O
)	O
CD44	B
activated	O
the	O
transcription	O
factor	O
AP-1	O
;	O
and	O
5	O
)	O
the	O
integrin	B
-dependent	O
adhesive	O
function	O
of	O
RA	O
synovial	O
cells	O
to	O
T	O
cells	O
was	O
also	O
amplified	O
by	O
CD44	B
cross	O
-	O
linking	O
.	O
These	O
results	O
indicate	O
that	O
the	O
adhesion	O
of	O
RA	O
synovial	O
cells	O
to	O
matrices	O
such	O
as	O
hyaluronic	O
acid	O
through	O
CD44	B
could	O
up	O
-	O
regulate	O
VCAM-1	B
expression	O
and	O
VCAM-1	B
-mediated	O
adhesion	O
to	O
T	O
cells	O
,	O
which	O
might	O
in	O
turn	O
cause	O
activation	O
of	O
T	O
cells	O
and	O
synovial	O
cells	O
in	O
RA	O
synovitis	O
.	O
We	O
therefore	O
propose	O
that	O
such	O
cross	O
-	O
talking	O
among	O
distinct	O
adhesion	O
molecules	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammation	O
,	O
including	O
RA	O
synovitis	O
.	O
High	O
-	O
level	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
in	O
thymocytes	O
requires	O
NF	B
-	I
kappaB	I
activation	O
through	O
interaction	O
with	O
thymic	O
epithelial	O
cells	O
.	O
We	O
have	O
previously	O
demonstrated	O
that	O
interaction	O
of	O
infected	O
thymocytes	O
with	O
autologous	O
thymic	O
epithelial	O
cells	O
(	O
TEC	O
)	O
is	O
a	O
prerequisite	O
for	O
a	O
high	O
level	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
in	O
thymocytes	O
(	O
M.Rothe	O
,	O
L.Chene	O
,	O
M.Nugeyre	O
,	O
F.Barre	O
-	O
Sinoussi	O
,	O
and	O
N.Israel	O
,	O
J.Virol.72	O
:	O
5852	O
-	O
5861	O
,	O
1998	O
)	O
.	O
We	O
report	O
here	O
that	O
this	O
activation	O
of	O
HIV	O
replication	O
takes	O
place	O
at	O
the	O
transcriptional	O
level	O
through	O
activation	O
of	O
the	O
Rel	B
/	I
NF	I
-	I
kappaB	I
transcription	B
factors	I
.	O
We	O
first	O
demonstrate	O
that	O
an	O
HIV-1	O
provirus	O
(	O
SF-2	O
strain	O
)	O
very	O
effectively	O
replicates	O
in	O
thymocytes	O
cocultured	O
with	O
TEC	O
whereas	O
this	O
provirus	O
,	O
with	O
kappaB	O
sites	O
deleted	O
,	O
fails	O
to	O
replicate	O
.	O
We	O
provide	O
evidence	O
that	O
several	O
NF	B
-	I
kappaB	I
complexes	I
are	O
constitutively	O
found	O
in	O
the	O
nuclei	O
of	O
thymocytes	O
either	O
freshly	O
isolated	O
from	O
the	O
thymus	O
or	O
maintained	O
in	O
coculture	O
with	O
autologous	O
or	O
heterologous	O
TEC	O
.	O
The	O
prevalent	O
complex	O
is	O
the	O
heterodimer	B
p50-p65	I
.	O
NF	B
-	I
kappaB	I
activity	O
is	O
tightly	O
correlated	O
with	O
the	O
transcriptional	O
activity	O
of	O
a	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV-1	O
transfected	O
in	O
thymocytes	O
.	O
The	O
cotransfection	O
of	O
this	O
LTR	O
with	O
a	O
mutated	O
IkappaBalpha	B
molecule	I
formally	O
demonstrates	O
that	O
LTR	O
transactivation	O
is	O
regulated	O
by	O
members	O
of	O
the	O
Rel	B
/	I
NF	I
-	I
kappaB	I
family	I
in	O
thymocytes	O
.	O
We	O
also	O
showed	O
that	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
and	O
to	O
a	O
lesser	O
extent	O
interleukin-1	B
(	O
IL-1	B
)	O
,	O
secreted	O
within	O
the	O
coculture	O
,	O
induce	O
NF	B
-	I
kappaB	I
activity	O
and	O
a	O
correlative	O
LTR	O
transactivation	O
.	O
However	O
IL-7	B
,	O
a	O
crucial	O
factor	O
for	O
thymopoiesis	O
that	O
is	O
secreted	O
mainly	O
by	O
TEC	O
,	O
is	O
a	O
necessary	O
cofactor	O
for	O
NF	B
-	I
kappaB	I
activation	O
elicited	O
by	O
TNF	B
or	O
IL-1	B
.	O
Together	O
,	O
these	O
data	O
indicate	O
that	O
NF	B
-	I
kappaB	I
activation	O
,	O
required	O
for	O
a	O
high	O
level	O
of	O
HIV	O
replication	O
in	O
thymocytes	O
,	O
is	O
regulated	O
in	O
a	O
specific	O
manner	O
in	O
the	O
thymic	O
microenvironment	O
which	O
provides	O
the	O
necessary	O
cytokines	O
:	O
TNF	B
,	O
IL-1	B
,	O
and	O
IL-7	B
.	O
Clonality	O
analysis	O
of	O
refractory	O
anemia	O
with	O
ring	O
sideroblasts	O
:	O
simultaneous	O
study	O
of	O
clonality	O
and	O
cytochemistry	O
of	O
bone	O
marrow	O
progenitors	O
.	O
X	O
chromosome	O
inactivation	O
and	O
polymorphism	O
of	O
the	O
human	O
androgen	O
receptor	O
(	O
HUMARA	O
)	O
gene	O
has	O
been	O
applied	O
for	O
analyzing	O
the	O
clonality	O
of	O
blood	O
cells	O
.	O
In	O
the	O
present	O
study	O
,	O
the	O
clonal	O
relationship	O
was	O
investigated	O
between	O
peripheral	O
blood	O
polymorphonuclear	O
cells	O
(	O
PMNCs	O
)	O
and	O
marrow	O
progenitor	O
cells	O
and	O
the	O
origin	O
of	O
ringed	O
sideroblasts	O
in	O
patients	O
with	O
refractory	O
anemia	O
with	O
ring	O
sideroblasts	O
(	O
RARS	O
)	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
of	O
HUMARA	O
gene	O
.	O
The	O
X	O
-	O
inactivation	O
patterns	O
of	O
circulating	O
PMNCs	O
and	O
T	O
lymphocytes	O
as	O
well	O
as	O
individual	O
granulocyte	O
colonies	O
grown	O
in	O
vitro	O
from	O
bone	O
marrow	O
cells	O
were	O
analyzed	O
.	O
The	O
development	O
of	O
ringed	O
sideroblasts	O
in	O
erythroid	O
colonies	O
by	O
iron	O
staining	O
and	O
their	O
X	O
-	O
inactivation	O
pattern	O
were	O
also	O
examined	O
.	O
All	O
three	O
RARS	O
patients	O
showed	O
monoclonal	O
PMNCs	O
.	O
In	O
granulocyte	O
colonies	O
,	O
however	O
,	O
two	O
different	O
X	O
-	O
inactivation	O
patterns	O
were	O
observed	O
in	O
all	O
patients	O
,	O
indicating	O
that	O
non	O
-	O
clonal	O
progenitor	O
cells	O
remained	O
in	O
the	O
bone	O
marrow	O
.	O
All	O
erythroid	O
colonies	O
consisted	O
of	O
ringed	O
sideroblasts	O
exclusively	O
showed	O
one	O
pattern	O
dominant	O
in	O
those	O
of	O
PMNCs	O
.	O
Our	O
findings	O
suggest	O
that	O
non	O
-	O
clonal	O
progenitor	O
cells	O
persist	O
in	O
some	O
RARS	O
cases	O
,	O
that	O
erythroid	O
progenitors	O
show	O
mosaicism	O
,	O
and	O
that	O
ringed	O
sideroblasts	O
may	O
be	O
derived	O
from	O
an	O
abnormal	O
clone	O
involved	O
in	O
the	O
pathogenesis	O
of	O
this	O
disease	O
.	O
Oleic	O
acid	O
inhibits	O
endothelial	O
activation	O
:	O
A	O
direct	O
vascular	O
antiatherogenic	O
mechanism	O
of	O
a	O
nutritional	O
component	O
in	O
the	O
mediterranean	O
diet	O
.	O
Because	O
oleic	O
acid	O
is	O
implicated	O
in	O
the	O
antiatherogenic	O
effects	O
attributed	O
to	O
the	O
Mediterranean	O
diet	O
,	O
we	O
investigated	O
whether	O
this	O
fatty	O
acid	O
can	O
modulate	O
endothelial	O
activation	O
,	O
ie	O
,	O
the	O
concerted	O
expression	O
of	O
gene	B
products	I
involved	O
in	O
leukocyte	O
recruitment	O
and	O
early	O
atherogenesis	O
.	O
We	O
incubated	O
sodium	O
oleate	O
with	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
for	O
0	O
to	O
72	O
hours	O
,	O
followed	O
by	O
coincubation	O
of	O
oleate	O
with	O
human	B
recombinant	I
tumor	I
necrosis	I
factor	I
,	O
interleukin	B
(	I
IL	I
)	I
-1alpha	I
,	O
IL-1beta	B
,	O
IL-4	B
,	O
Escherichia	O
coli	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
for	O
a	O
further	O
6	O
to	O
24	O
hours	O
.	O
The	O
endothelial	O
expression	O
of	O
vascular	B
cell	I
adhesion	I
molecule-1	I
(	O
VCAM-1	B
)	O
,	O
E	B
-	I
selectin	I
,	O
and	O
intercellular	B
adhesion	I
molecule-1	I
was	O
monitored	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
or	O
flow	O
cytometry	O
,	O
and	O
steady	O
-	O
state	O
levels	O
of	O
VCAM-1	O
mRNA	O
were	O
assessed	O
by	O
Northern	O
blot	O
analysis	O
.	O
At	O
10	O
to	O
100	O
micromol	O
/	O
L	O
for	O
>	O
24	O
hours	O
,	O
oleate	O
inhibited	O
the	O
expression	O
of	O
all	O
adhesion	B
molecules	I
tested	O
.	O
After	O
a	O
72-hour	O
incubation	O
with	O
oleate	O
and	O
a	O
further	O
16-hour	O
incubation	O
with	O
oleate	O
plus	O
1	O
microg	O
/	O
mL	O
LPS	O
,	O
VCAM-1	B
expression	O
was	O
reduced	O
by	O
>	O
40	O
%	O
compared	O
with	O
control	O
.	O
Adhesion	O
of	O
monocytoid	O
U937	O
cells	O
to	O
LPS	O
-	O
treated	O
endothelial	O
cells	O
was	O
reduced	O
concomitantly	O
.	O
Oleate	O
also	O
produced	O
a	O
quantitatively	O
similar	O
reduction	O
of	O
VCAM-1	O
mRNA	O
levels	O
on	O
Northern	O
blot	O
analysis	O
and	O
inhibited	O
nuclear	B
factor	I
-	I
kappaB	I
activation	O
on	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
Incubation	O
of	O
endothelial	O
cells	O
with	O
oleate	O
for	O
72	O
hours	O
decreased	O
the	O
relative	O
proportions	O
of	O
saturated	O
(	O
palmitic	O
and	O
stearic	O
)	O
acids	O
in	O
total	O
cell	O
lipids	O
and	O
increased	O
the	O
proportions	O
of	O
oleate	O
in	O
total	O
cell	O
lipids	O
without	O
significantly	O
changing	O
the	O
relative	O
proportions	O
of	O
polyunsaturated	O
fatty	O
acids	O
.	O
Although	O
less	O
potent	O
than	O
polyunsaturated	O
fatty	O
acids	O
in	O
inhibiting	O
endothelial	O
activation	O
,	O
oleic	O
acid	O
may	O
contribute	O
to	O
the	O
prevention	O
of	O
atherogenesis	O
through	O
selective	O
displacement	O
of	O
saturated	O
fatty	O
acids	O
in	O
cell	O
membrane	O
phospholipids	O
and	O
a	O
consequent	O
modulation	O
of	O
gene	O
expression	O
for	O
molecules	O
involved	O
in	O
monocyte	O
recruitment	O
.	O
Functional	O
association	O
of	O
Nmi	B
with	O
Stat5	B
and	O
Stat1	B
in	O
IL-2	B
-and	O
IFNgamma	B
-mediated	O
signaling	O
.	O
Using	O
the	O
coiled	O
-	O
coil	O
region	O
of	O
Stat5b	B
as	O
the	O
bait	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
,	O
we	O
identified	O
the	O
association	O
of	O
Nmi	B
,	O
a	O
protein	O
of	O
unknown	O
function	O
previously	O
reported	O
as	O
an	O
N	B
-	I
Myc	I
interactor	O
.	O
We	O
further	O
show	O
that	O
Nmi	B
interacts	O
with	O
all	O
STATs	B
except	O
Stat2	B
.	O
We	O
evaluated	O
two	O
cytokine	O
systems	O
,	O
IL-2	B
and	O
IFNgamma	B
,	O
and	O
demonstrate	O
that	O
Nmi	B
augments	O
STAT	B
-mediated	O
transcription	O
in	O
response	O
to	O
these	O
cytokines	B
.	O
Interestingly	O
,	O
Nmi	B
lacks	O
an	O
intrinsic	O
transcriptional	B
activation	I
domain	I
;	O
instead	O
,	O
Nmi	B
enhances	O
the	O
association	O
of	O
CBP	B
/	I
p300	I
coactivator	I
proteins	I
with	O
Stat1	B
and	O
Stat5	B
,	O
and	O
together	O
with	O
CBP	B
/	I
p300	I
can	O
augment	O
IL-2-	O
and	O
IFNgamma	O
-	O
dependent	O
transcription	O
.	O
Therefore	O
,	O
our	O
data	O
not	O
only	O
reveal	O
that	O
Nmi	B
can	O
potentiate	O
STAT	B
-dependent	O
transcription	O
,	O
but	O
also	O
suggest	O
that	O
it	O
can	O
augment	O
coactivator	O
protein	O
recruitment	O
to	O
at	O
least	O
some	O
members	O
of	O
a	O
group	O
of	O
sequence	B
-	I
specific	I
transcription	I
factors	I
.	O
GA	B
-	I
binding	I
protein	I
factors	I
,	O
in	O
concert	O
with	O
the	O
coactivator	B
CREB	I
binding	I
protein	I
/	I
p300	I
,	O
control	O
the	O
induction	O
of	O
the	O
interleukin	O
16	O
promoter	O
in	O
T	O
lymphocytes	O
.	O
Interleukin	B
16	I
(	O
IL-16	B
)	O
is	O
a	O
chemotactic	B
cytokine	I
that	O
binds	O
to	O
the	O
CD4	B
receptor	I
and	O
affects	O
the	O
activation	O
of	O
T	O
cells	O
and	O
replication	O
of	O
HIV	O
.	O
It	O
is	O
expressed	O
as	O
a	O
large	O
67-kDa	B
precursor	I
protein	I
(	O
pro	B
-	I
IL-16	I
)	O
in	O
lymphocytes	O
,	O
macrophages	O
,	O
and	O
mast	O
cells	O
,	O
as	O
well	O
as	O
in	O
airway	O
epithelial	O
cells	O
from	O
asthmatics	O
after	O
challenge	O
with	O
allergen	O
.	O
This	O
pro	B
-	I
IL-16	I
is	O
subsequently	O
processed	O
to	O
the	O
mature	O
cytokine	O
of	O
13	B
kDa	I
.	O
To	O
study	O
the	O
expression	O
of	O
IL-16	B
at	O
the	O
transcriptional	O
level	O
,	O
we	O
cloned	O
the	O
human	O
chromosomal	O
IL-16	O
gene	O
and	O
analyzed	O
its	O
promoter	O
.	O
The	O
human	O
IL-16	O
gene	O
consists	O
of	O
seven	O
exons	O
and	O
six	O
introns	O
.	O
The	O
5	O
'	O
sequences	O
up	O
to	O
nucleotide	O
-120	O
of	O
the	O
human	O
and	O
murine	O
IL-16	B
genes	O
share	O
>	O
84	O
%	O
sequence	O
homology	O
and	O
harbor	O
promoter	O
elements	O
for	O
constitutive	O
and	O
inducible	O
transcription	O
in	O
T	O
cells	O
.	O
Although	O
both	O
promoters	O
lack	O
any	O
TATA	O
box	O
,	O
they	O
contain	O
two	O
CAAT	O
box	O
-	O
like	O
motifs	O
and	O
three	O
binding	O
sites	O
of	O
GA	B
-	I
binding	I
protein	I
(	I
GABP	I
)	I
transcription	I
factors	I
.	O
Two	O
of	O
these	O
motifs	O
are	O
part	O
of	O
a	O
highly	O
conserved	O
and	O
inducible	O
dyad	O
symmetry	O
element	O
shown	O
previously	O
to	O
control	O
a	O
remote	O
IL-2	O
enhancer	O
and	O
the	O
CD18	O
promoter	O
.	O
In	O
concert	O
with	O
the	O
coactivator	B
CREB	I
binding	I
protein	I
/	I
p300	I
,	O
which	O
interacts	O
with	O
GABPalpha	B
,	O
the	O
binding	O
of	O
GABPalpha	B
and	O
-beta	B
to	O
the	O
dyad	O
symmetry	O
element	O
controls	O
the	O
induction	O
of	O
IL-16	O
promoter	O
in	O
T	O
cells	O
.	O
Supplementing	O
the	O
data	O
on	O
the	O
processing	O
of	O
pro	B
-	I
IL-16	I
,	O
our	O
results	O
indicate	O
the	O
complexity	O
of	O
IL-16	B
expression	O
,	O
which	O
is	O
tightly	O
controlled	O
at	O
the	O
transcriptional	O
and	O
posttranslational	O
levels	O
in	O
T	O
lymphocytes	O
.	O
RFLAT-1	B
:	O
a	O
new	O
zinc	B
finger	I
transcription	I
factor	I
that	O
activates	O
RANTES	O
gene	O
expression	O
in	O
T	O
lymphocytes	O
.	O
RANTES	B
(	O
Regulated	B
upon	I
Activation	I
,	I
Normal	I
T	I
cell	I
Expressed	I
and	I
Secreted	I
)	O
is	O
a	O
chemoattractant	B
cytokine	I
(	O
chemokine	B
)	O
important	O
in	O
the	O
generation	O
of	O
inflammatory	O
infiltrate	O
and	O
human	O
immunodeficiency	O
virus	O
entry	O
into	O
immune	O
cells	O
.	O
RANTES	B
is	O
expressed	O
late	O
(	O
3	O
-	O
5	O
days	O
)	O
after	O
activation	O
in	O
T	O
lymphocytes	O
.	O
Using	O
expression	O
cloning	O
,	O
we	O
identified	O
the	O
first	O
`	O
`	O
late	O
''	O
T	B
lymphocyte	I
associated	I
transcription	I
factor	I
and	O
named	O
it	O
`	O
`	O
RANTES	B
Factor	I
of	I
Late	I
Activated	I
T	I
Lymphocytes-1	I
`	O
`	O
(	O
RFLAT-1	B
)	O
.	O
RFLAT-1	B
is	O
a	O
novel	O
,	O
phosphorylated	O
,	O
zinc	B
finger	I
transcription	I
factor	I
that	O
is	O
expressed	O
in	O
T	O
cells	O
3	O
days	O
after	O
activation	O
,	O
coincident	O
with	O
RANTES	B
expression	O
.	O
While	O
Rel	B
proteins	I
play	O
the	O
dominant	O
role	O
in	O
RANTES	O
gene	O
expression	O
in	O
fibroblasts	O
,	O
RFLAT-1	B
is	O
a	O
strong	O
transactivator	O
for	O
RANTES	B
in	O
T	O
cells	O
.	O
Reactive	O
oxygen	O
intermediate	O
-	O
dependent	O
NF	B
-	I
kappaB	I
activation	O
by	O
interleukin-1beta	B
requires	O
5-lipoxygenase	B
or	O
NADPH	O
oxidase	O
activity	O
.	O
We	O
previously	O
reported	O
that	O
the	O
role	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
in	O
NF	B
-	I
kappaB	I
activation	O
by	O
proinflammatory	B
cytokines	I
was	O
cell	O
specific	O
.	O
However	O
,	O
the	O
sources	O
for	O
ROIs	O
in	O
various	O
cell	O
types	O
are	O
yet	O
to	O
be	O
determined	O
and	O
might	O
include	O
5-lipoxygenase	B
(	O
5-LOX	B
)	O
and	O
NADPH	O
oxidase	O
.	O
5-LOX	B
and	O
5-LOX	B
activating	I
protein	I
(	O
FLAP	B
)	O
are	O
coexpressed	O
in	O
lymphoid	O
cells	O
but	O
not	O
in	O
monocytic	O
or	O
epithelial	O
cells	O
.	O
Stimulation	O
of	O
lymphoid	O
cells	O
with	O
interleukin-1beta	B
(	O
IL-1beta	B
)	O
led	O
to	O
ROI	O
production	O
and	O
NF	B
-	I
kappaB	I
activation	O
,	O
which	O
could	O
both	O
be	O
blocked	O
by	O
antioxidants	O
or	O
FLAP	B
inhibitors	O
,	O
confirming	O
that	O
5-LOX	B
was	O
the	O
source	O
of	O
ROIs	O
and	O
was	O
required	O
for	O
NF	B
-	I
kappaB	I
activation	O
in	O
these	O
cells	O
.	O
IL-1beta	B
stimulation	O
of	O
epithelial	O
cells	O
did	O
not	O
generate	O
any	O
ROIs	O
and	O
NF	B
-	I
kappaB	I
induction	O
was	O
not	O
influenced	O
by	O
5-LOX	B
inhibitors	O
.	O
However	O
,	O
reintroduction	O
of	O
a	O
functional	O
5-LOX	B
system	O
in	O
these	O
cells	O
allowed	O
ROI	O
production	O
and	O
5-LOX	B
-dependent	O
NF	B
-	I
kappaB	I
activation	O
.	O
In	O
monocytic	O
cells	O
,	O
IL-1beta	B
treatment	O
led	O
to	O
a	O
production	O
of	O
ROIs	O
which	O
is	O
independent	O
of	O
the	O
5-LOX	B
enzyme	I
but	O
requires	O
the	O
NADPH	O
oxidase	O
activity	O
.	O
This	O
pathway	O
involves	O
the	O
Rac1	B
and	O
Cdc42	B
GTPases	B
,	O
two	O
enzymes	O
which	O
are	O
not	O
required	O
for	O
NF	B
-	I
kappaB	I
activation	O
by	O
IL-1beta	B
in	O
epithelial	O
cells	O
.	O
In	O
conclusion	O
,	O
three	O
different	O
cell	O
-	O
specific	O
pathways	O
lead	O
to	O
NF	B
-	I
kappaB	I
activation	O
by	O
IL-1beta	B
:	O
a	O
pathway	O
dependent	O
on	O
ROI	O
production	O
by	O
5-LOX	B
in	O
lymphoid	O
cells	O
,	O
an	O
ROI-	O
and	O
5-LOX	B
-independent	O
pathway	O
in	O
epithelial	O
cells	O
,	O
and	O
a	O
pathway	O
requiring	O
ROI	O
production	O
by	O
NADPH	B
oxidase	I
in	O
monocytic	O
cells	O
.	O
Activation	O
-	O
dependent	O
transcriptional	O
regulation	O
of	O
the	O
human	O
Fas	O
promoter	O
requires	O
NF	B
-	I
kappaB	I
p50-p65	I
recruitment	O
.	O
Fas	B
(	O
CD95	B
)	O
and	O
Fas	B
ligand	I
(	O
CD95L	B
)	O
are	O
an	O
interacting	O
receptor	O
-	O
ligand	O
pair	O
required	O
for	O
immune	O
homeostasis	O
.	O
Lymphocyte	O
activation	O
results	O
in	O
the	O
upregulation	O
of	O
Fas	B
expression	O
and	O
the	O
acquisition	O
of	O
sensitivity	O
to	O
FasL	B
-mediated	O
apoptosis	O
.	O
Although	O
Fas	O
upregulation	O
is	O
central	O
to	O
the	O
preservation	O
of	O
immunologic	O
tolerance	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
machinery	O
underlying	O
this	O
process	O
.	O
To	O
investigate	O
the	O
events	O
involved	O
in	O
activation	O
-	O
induced	O
Fas	B
upregulation	O
,	O
we	O
have	O
examined	O
mRNA	O
accumulation	O
,	O
fas	O
promoter	O
activity	O
,	O
and	O
protein	O
expression	O
in	O
the	O
Jurkat	O
T	O
-	O
cell	O
line	O
treated	O
with	O
phorbol	O
myristate	O
acetate	O
and	O
ionomycin	O
(	O
P	O
/	O
I	O
)	O
,	O
pharmacological	O
mimics	O
of	O
T	B
-	I
cell	I
receptor	I
activation	O
.	O
Although	O
resting	O
Jurkat	O
cells	O
express	O
Fas	B
,	O
Fas	O
mRNA	O
was	O
induced	O
approximately	O
10-fold	O
in	O
2	O
h	O
upon	O
P	O
/	O
I	O
stimulation	O
.	O
Using	O
sequential	O
deletion	O
mutants	O
of	O
the	O
human	O
fas	O
promoter	O
in	O
transient	O
transfection	O
assays	O
,	O
we	O
identified	O
a	O
47-bp	O
sequence	O
(	O
positions	O
-306	O
to	O
-260	O
relative	O
to	O
the	O
ATG	O
)	O
required	O
for	O
activation	O
-	O
driven	O
fas	O
upregulation	O
.	O
Sequence	O
analysis	O
revealed	O
the	O
presence	O
of	O
a	O
previously	O
unrecognized	O
composite	O
binding	O
site	O
for	O
both	O
the	O
Sp1	B
and	O
NF	B
-	I
kappaB	I
transcription	B
factors	I
at	O
positions	O
-295	O
to	O
-286	O
.	O
Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
supershift	O
analyses	O
of	O
this	O
region	O
documented	O
constitutive	O
binding	O
of	O
Sp1	B
in	O
unactivated	O
nuclear	O
extracts	O
and	O
inducible	O
binding	O
of	O
p50-p65	B
NF	I
-	I
kappaB	I
heterodimers	I
after	O
P	O
/	O
I	O
activation	O
.	O
Sp1	B
and	O
NF	B
-	I
kappaB	I
transcription	O
factor	O
binding	O
was	O
shown	O
to	O
be	O
mutually	O
exclusive	O
by	O
EMSA	O
displacement	O
studies	O
with	O
purified	O
recombinant	O
Sp1	B
and	O
recombinant	O
p50	B
.	O
The	O
functional	O
contribution	O
of	O
the	O
kappaB	O
-	O
Sp1	O
composite	O
site	O
in	O
P	O
/	O
I	O
-	O
inducible	O
fas	O
promoter	O
activation	O
was	O
verified	O
by	O
using	O
kappaB-	O
Sp1	B
concatamers	O
(	O
-295	O
to	O
-286	O
)	O
in	O
a	O
thymidine	O
kinase	O
promoter	O
-	O
driven	O
reporter	O
construct	O
and	O
native	O
promoter	O
constructs	O
in	O
Jurkat	O
cells	O
overexpressing	O
IkappaB	B
-	I
alpha	I
.	O
Site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
critical	O
guanine	O
nucleotides	O
in	O
the	O
kappaB	O
-	O
Sp1	O
element	O
documented	O
the	O
essential	O
role	O
of	O
this	O
site	O
in	O
activation	O
-	O
dependent	O
fas	O
promoter	O
induction	O
.	O
Daidzein	O
and	O
genistein	O
glucuronides	O
in	O
vitro	O
are	O
weakly	O
estrogenic	O
and	O
activate	O
human	O
natural	O
killer	O
cells	O
at	O
nutritionally	O
relevant	O
concentrations	O
.	O
Daidzein	O
and	O
genistein	O
glucuronides	O
(	O
DG	O
and	O
GG	O
)	O
,	O
major	O
isoflavone	O
metabolites	O
,	O
may	O
be	O
partly	O
responsible	O
for	O
biological	O
effects	O
of	O
isoflavones	O
,	O
such	O
as	O
estrogen	O
receptor	O
binding	O
and	O
natural	O
killer	O
cell	O
(	O
NK	O
)	O
activation	O
or	O
inhibition	O
.	O
DG	O
and	O
GG	O
were	O
synthesized	O
using	O
3-methylcholanthrene	O
-	O
induced	O
rat	O
liver	O
microsomes	O
.	O
The	O
Km	O
and	O
Vmax	O
for	O
daidzein	O
and	O
genistein	O
were	O
9.0	O
and	O
7.7	O
micromol	O
/	O
L	O
,	O
and	O
0.7	O
and	O
1.6	O
micromol	O
/	O
(	O
mg	O
protein	O
.	O
min	O
)	O
,	O
respectively	O
.	O
The	O
absence	O
of	O
ultraviolet	O
absorbance	O
maxima	O
shifts	O
in	O
the	O
presence	O
of	O
sodium	O
acetate	O
confirmed	O
that	O
the	O
synthesized	O
products	O
were	O
7-O	O
-	O
glucuronides	O
.	O
DG	O
and	O
GG	O
were	O
further	O
purified	O
by	O
a	O
Sephadex	O
LH-20	O
column	O
.	O
DG	O
and	O
GG	O
competed	O
with	O
the	O
binding	O
of	O
17beta-	O
(	O
3H	O
)	O
estradiol	O
to	O
estrogen	B
receptors	I
of	O
B6D2F1	O
mouse	O
uterine	O
cytosol	O
.	O
The	O
concentrations	O
required	O
for	O
50	O
%	O
displacement	O
of	O
17beta-	O
(	O
3H	O
)	O
estradiol	O
(	O
CB50	O
)	O
were	O
:	O
17beta	O
-	O
estradiol	O
,	O
1.34	O
nmol	O
/	O
L	O
;	O
diethylstilbestrol	O
,	O
1.46	O
nmol	O
/	O
L	O
;	O
daidzein	O
,	O
1.6	O
micromol	O
/	O
L	O
;	O
DG	O
,	O
14.7	O
micromol	O
/	O
L	O
;	O
genistein	O
,	O
0.154	O
micromol	O
/	O
L	O
;	O
GG	O
,	O
7.27	O
micromol	O
/	O
L	O
.	O
In	O
human	O
peripheral	O
blood	O
NK	O
cells	O
,	O
genistein	O
at	O
<	O
0.5	O
micromol	O
/	O
L	O
and	O
DG	O
and	O
GG	O
at	O
0.1	O
-	O
10	O
micromol	O
/	O
L	O
enhanced	O
NK	O
cell	O
-	O
mediated	O
K562	O
cancer	O
cell	O
killing	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
.	O
At	O
>	O
0.5	O
micromol	O
/	O
L	O
,	O
genistein	O
inhibited	O
NK	O
cytotoxicity	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
.	O
The	O
glucuronides	O
only	O
inhibited	O
NK	O
cytotoxicity	O
at	O
50	O
micromol	O
/	O
L	O
.	O
Isoflavones	O
,	O
and	O
especially	O
the	O
isoflavone	O
glucuronides	O
,	O
enhanced	O
activation	O
of	O
NK	O
cells	O
by	O
interleukin-2	B
(	O
IL-2	B
)	O
,	O
additively	O
.	O
At	O
physiological	O
concentrations	O
,	O
DG	O
and	O
GG	O
were	O
weakly	O
estrogenic	O
,	O
and	O
they	O
activated	O
human	O
NK	O
cells	O
in	O
nutritionally	O
relevant	O
concentrations	O
in	O
vitro	O
,	O
probably	O
at	O
a	O
site	O
different	O
from	O
IL-2	B
action	O
.	O
Differential	O
expression	O
and	O
phosphorylation	O
of	O
CTCF	B
,	O
a	O
c	O
-	O
myc	O
transcriptional	O
regulator	O
,	O
during	O
differentiation	O
of	O
human	O
myeloid	O
cells	O
.	O
CTCF	B
is	O
a	O
transcriptional	O
repressor	O
of	O
the	O
c	O
-	O
myc	O
gene	O
.	O
Although	O
CTCF	B
has	O
been	O
characterized	O
in	O
some	O
detail	O
,	O
there	O
is	O
very	O
little	O
information	O
about	O
the	O
regulation	O
of	O
CTCF	B
activity	O
.	O
Therefore	O
we	O
investigated	O
CTCF	B
expression	O
and	O
phosphorylation	O
during	O
induced	O
differentiation	O
of	O
human	O
myeloid	O
leukemia	O
cells	O
.	O
We	O
found	O
that	O
:	O
(	O
i	O
)	O
both	O
CTCF	O
mRNA	O
and	O
protein	O
are	O
down	O
-	O
regulated	O
during	O
terminal	O
differentiation	O
in	O
most	O
cell	O
lines	O
tested	O
;	O
(	O
ii	O
)	O
CTCF	B
down	O
-	O
regulation	O
is	O
retarded	O
and	O
less	O
pronounced	O
than	O
that	O
of	O
c	O
-	O
myc	O
;	O
(	O
iii	O
)	O
CTCF	B
protein	I
is	O
differentially	O
phosphorylated	O
and	O
the	O
phosphorylation	O
profiles	O
depend	O
on	O
the	O
differentiation	O
pathway	O
.	O
We	O
concluded	O
that	O
CTCF	B
expression	O
and	O
activity	O
is	O
controlled	O
at	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
levels	O
.	O
The	O
Megakaryocyte	O
/	O
Platelet	O
-	O
specific	O
enhancer	O
of	O
the	O
alpha2beta1	O
integrin	O
gene	O
:	O
two	O
tandem	O
AP1	O
sites	O
and	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
signaling	O
cascade	O
.	O
The	O
alpha2beta1	B
integrin	I
,	O
a	O
collagen	O
receptor	O
on	O
platelets	O
and	O
megakaryocytes	O
,	O
is	O
required	O
for	O
normal	O
platelet	O
function	O
.	O
Transcriptional	O
regulation	O
of	O
the	O
alpha2	O
integrin	O
gene	O
in	O
cells	O
undergoing	O
megakaryocytic	O
differentiation	O
requires	O
a	O
core	O
promoter	O
between	O
bp	O
-30	O
and	O
-92	O
,	O
a	O
silencer	O
between	O
bp	O
-92	O
and	O
-351	O
,	O
and	O
megakaryocytic	O
enhancers	O
in	O
the	O
distal	O
5	O
'	O
flank	O
.	O
We	O
have	O
now	O
identified	O
a	O
229-bp	O
region	O
of	O
the	O
distal	O
5	O
'	O
flank	O
of	O
the	O
alpha2	O
integrin	O
gene	O
required	O
for	O
high	O
-	O
level	O
enhancer	O
activity	O
in	O
cells	O
with	O
megakaryocytic	O
features	O
.	O
Two	O
tandem	O
AP1	O
binding	O
sites	O
with	O
dyad	O
symmetry	O
are	O
required	O
for	O
enhancer	O
activity	O
and	O
for	O
DNA	B
-	I
protein	I
complex	I
formation	O
with	O
members	O
of	O
the	O
c	B
-	I
fos	I
/	I
c	I
-	I
jun	I
family	I
.	O
The	O
requirement	O
for	O
AP1	B
activation	O
suggested	O
a	O
role	O
for	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
signaling	O
pathway	O
in	O
regulating	O
alpha2	O
integrin	O
gene	O
expression	O
.	O
Inhibition	O
of	O
the	O
MAP	B
kinase	I
cascade	O
with	O
PD98059	O
,	O
a	O
specific	O
inhibitor	O
of	O
MAPK	B
kinase	I
1	I
,	O
prevented	O
the	O
expression	O
of	O
the	O
alpha2	B
integrin	I
subunit	I
in	O
cells	O
induced	O
to	O
become	O
megakaryocytic	O
.	O
We	O
provide	O
a	O
model	O
of	O
megakaryocytic	O
differentiation	O
in	O
which	O
expression	O
of	O
the	O
alpha2	O
integrin	O
gene	O
requires	O
signaling	O
via	O
the	O
MAP	B
kinase	I
pathway	O
to	O
activate	O
two	O
tandem	O
AP1	O
binding	O
sites	O
in	O
the	O
alpha2	O
integrin	O
enhancer	O
.	O
Clonality	O
of	O
isolated	O
eosinophils	O
in	O
the	O
hypereosinophilic	O
syndrome	O
.	O
The	O
idiopathic	O
hypereosinophilic	O
syndrome	O
(	O
IHES	O
)	O
is	O
a	O
rare	O
disorder	O
characterized	O
by	O
unexplained	O
,	O
persistent	O
eosinophilia	O
associated	O
with	O
multiple	O
organ	O
dysfunction	O
due	O
to	O
eosinophilic	O
tissue	O
infiltration	O
.	O
In	O
the	O
absence	O
of	O
karyotypic	O
abnormalities	O
,	O
there	O
is	O
no	O
specific	O
test	O
to	O
detect	O
clonal	O
eosinophilia	O
in	O
IHES	O
.	O
Analysis	O
of	O
X	O
-	O
chromosome	O
inactivation	O
patterns	O
can	O
be	O
used	O
to	O
determine	O
whether	O
proliferative	O
disorders	O
are	O
clonal	O
in	O
origin	O
.	O
Methylation	O
of	O
HpaII	O
and	O
Hha	O
I	O
sites	O
near	O
the	O
polymorphic	O
trinucleotide	O
repeat	O
of	O
the	O
human	O
androgen	O
receptor	O
gene	O
(	O
HUMARA	O
)	O
has	O
been	O
shown	O
to	O
correlate	O
with	O
X	O
-	O
inactivation	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
used	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
with	O
nested	O
primers	O
to	O
analyze	O
X	O
-	O
inactivation	O
patterns	O
of	O
the	O
HUMARA	O
loci	O
in	O
purified	O
eosinophils	O
from	O
female	O
patients	O
with	O
eosinophilia	O
.	O
Peripheral	O
blood	O
eosinophils	O
were	O
isolated	O
by	O
their	O
autofluoresence	O
using	O
flow	O
cytometric	O
sorting	O
.	O
Eosinophils	O
purified	O
from	O
a	O
female	O
patient	O
presenting	O
with	O
IHES	O
were	O
found	O
to	O
show	O
a	O
clonal	O
pattern	O
of	O
X	O
-	O
inactivation	O
.	O
Eosinophil	O
-	O
depleted	O
leukocytes	O
from	O
this	O
patient	O
were	O
polyclonal	O
by	O
HUMARA	O
analysis	O
,	O
thus	O
excluding	O
skewedness	O
of	O
random	O
X	O
-	O
inactivation	O
.	O
After	O
corticosteroid	O
suppression	O
of	O
her	O
blood	O
eosinophilia	O
,	O
a	O
clonal	O
population	O
of	O
eosinophils	O
could	O
no	O
longer	O
be	O
detected	O
in	O
purified	O
eosinophils	O
.	O
In	O
contrast	O
,	O
eosinophils	O
purified	O
from	O
a	O
patient	O
with	O
Churg	O
-	O
Strauss	O
syndrome	O
and	O
from	O
six	O
patients	O
with	O
reactive	O
eosinophilias	O
attributed	O
to	O
allergy	O
,	O
parasitic	O
infection	O
,	O
or	O
drug	O
reaction	O
showed	O
a	O
polyclonal	O
pattern	O
of	O
X	O
-	O
inactivation	O
by	O
HUMARA	O
analysis	O
.	O
The	O
finding	O
of	O
clonal	O
eosinophilia	O
in	O
a	O
patient	O
presenting	O
with	O
IHES	O
indicates	O
that	O
such	O
patients	O
may	O
have	O
,	O
in	O
reality	O
,	O
a	O
low	O
-	O
grade	O
clonal	O
disorder	O
that	O
can	O
be	O
distinguished	O
from	O
reactive	O
eosinophilias	O
by	O
HUMARA	O
analysis	O
.	O
Further	O
,	O
the	O
method	O
described	O
can	O
be	O
used	O
to	O
monitor	O
disease	O
progression	O
.	O
Peripheral	O
blood	O
mononuclear	O
cells	O
isolated	O
from	O
patients	O
with	O
diabetic	O
nephropathy	O
show	O
increased	O
activation	O
of	O
the	O
oxidative	B
-	I
stress	I
sensitive	I
transcription	I
factor	I
NF	B
-	I
kappaB	I
.	O
Increased	O
oxidative	O
stress	O
and	O
subsequent	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	B
-	I
kappaB	I
has	O
been	O
linked	O
to	O
the	O
development	O
of	O
late	O
diabetic	O
complications	O
.	O
To	O
determine	O
whether	O
oxidative	O
stress	O
dependent	O
NF	B
-	I
kappaB	I
activation	O
is	O
evident	O
in	O
patients	O
with	O
diabetic	O
nephropathy	O
we	O
used	O
an	O
Electrophoretic	O
Mobility	O
Shift	O
Assay	O
based	O
semiquantitative	O
detection	O
system	O
which	O
enabled	O
us	O
to	O
determine	O
NF	B
-	I
kappaB	I
activation	O
in	O
ex	O
vivo	O
isolated	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
We	O
examined	O
33	O
patients	O
with	O
diabetes	O
mellitus	O
(	O
Type	O
I	O
and	O
Type	O
II	O
)	O
.	O
Patients	O
with	O
diabetic	O
nephropathy	O
showed	O
higher	O
NF	B
-	I
kappaB	I
binding	O
activity	O
in	O
Electrophoretic	O
Mobility	O
Shift	O
Assays	O
and	O
stronger	O
immunohistological	O
staining	O
for	O
activated	O
NF	B
-	I
kappaBp65	I
than	O
patients	O
without	O
renal	O
complications	O
.	O
NF	B
-	I
kappaB	I
binding	O
activity	O
correlated	O
with	O
the	O
degree	O
of	O
albuminuria	O
(	O
r	O
=	O
0.316	O
)	O
and	O
with	O
thrombomodulin	B
plasma	O
concentrations	O
(	O
r	O
=	O
0.33	O
)	O
,	O
indicative	O
for	O
albuminuria	O
associated	O
endothelial	O
dysfunction	O
.	O
In	O
a	O
3	O
day	O
intervention	O
study	O
in	O
which	O
600	O
mg	O
of	O
the	O
antioxidant	O
thioctic	O
acid	O
(	O
alpha	O
-	O
lipoic	O
acid	O
)	O
per	O
day	O
were	O
given	O
to	O
nine	O
patients	O
with	O
diabetic	O
nephropathy	O
oxidative	O
stress	O
in	O
plasma	O
samples	O
was	O
decreased	O
by	O
48	O
%	O
and	O
NF	B
-	I
kappaB	I
binding	O
activity	O
in	O
ex	O
vivo	O
isolated	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
38	O
%	O
.	O
In	O
conclusion	O
,	O
activation	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
in	O
ex	O
vivo	O
isolated	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
patients	O
with	O
diabetes	O
mellitus	O
correlates	O
with	O
the	O
degree	O
of	O
diabetic	O
nephropathy	O
.	O
NF	B
-	I
kappaB	I
activation	O
is	O
at	O
least	O
in	O
part	O
dependent	O
on	O
oxidative	O
stress	O
since	O
thioctic	O
acid	O
(	O
alpha	O
-	O
lipoic	O
acid	O
)	O
reduced	O
NF	B
-	I
kappaB	I
binding	O
activity	O
.	O
Crossreactive	O
recognition	O
of	O
viral	O
,	O
self	O
,	O
and	O
bacterial	O
peptide	O
ligands	O
by	O
human	O
class	O
I	O
-	O
restricted	O
cytotoxic	O
T	O
lymphocyte	O
clonotypes	O
:	O
implications	O
for	O
molecular	O
mimicry	O
in	O
autoimmune	O
disease	O
.	O
The	O
immunodominant	O
,	O
CD8	O
(	O
+	O
)	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
response	O
to	O
the	O
HLA	O
-	O
B8-restricted	O
peptide	O
,	O
RAKFKQLL	O
,	O
located	O
in	O
the	O
Epstein	B
-	I
Barr	I
virus	I
immediate	I
-	I
early	I
antigen	I
,	O
BZLF1	B
,	O
is	O
characterized	O
by	O
a	O
diverse	O
T	B
cell	I
receptor	I
(	I
TCR	I
)	I
repertoire	I
.	O
Here	O
,	O
we	O
show	O
that	O
this	O
diversity	O
can	O
be	O
partitioned	O
on	O
the	O
basis	O
of	O
crossreactive	O
cytotoxicity	O
patterns	O
involving	O
the	O
recognition	O
of	O
a	O
self	O
peptide	O
-	O
RSKFRQIV	O
-	O
located	O
in	O
a	O
serine	B
/	I
threonine	I
kinase	I
and	O
a	O
bacterial	O
peptide	O
-	O
RRKYKQII	O
-	O
located	O
in	O
Staphylococcus	B
aureus	I
replication	I
initiation	I
protein	I
.	O
Thus	O
CTL	O
clones	O
that	O
recognized	O
the	O
viral	O
,	O
self	O
,	O
and	O
bacterial	O
peptides	O
expressed	O
a	O
highly	O
restricted	O
alphabeta	O
TCR	B
phenotype	O
.	O
The	O
CTL	O
clones	O
that	O
recognized	O
viral	O
and	O
self	O
peptides	O
were	O
more	O
oligoclonal	O
,	O
whereas	O
clones	O
that	O
strictly	O
recognized	O
the	O
viral	O
peptide	O
displayed	O
a	O
diverse	O
TCR	B
profile	O
.	O
Interestingly	O
,	O
the	O
self	O
and	O
bacterial	O
peptides	O
equally	O
were	O
substantially	O
less	O
effective	O
than	O
the	O
cognate	O
viral	O
peptide	O
in	O
sensitizing	O
target	O
cell	O
lysis	O
,	O
and	O
also	O
resulted	O
only	O
in	O
a	O
weak	O
reactivation	O
of	O
memory	O
CTLs	O
in	O
limiting	O
dilution	O
assays	O
,	O
whereas	O
the	O
cognate	O
peptide	O
was	O
highly	O
immunogenic	O
.	O
The	O
described	O
crossreactions	O
show	O
that	O
human	O
antiviral	O
,	O
CD8	O
(	O
+	O
)	O
CTL	O
responses	O
can	O
be	O
shaped	O
by	O
peptide	O
ligands	O
derived	O
from	O
autoantigens	O
and	O
environmental	O
bacterial	O
antigens	O
,	O
thereby	O
providing	O
a	O
firm	O
structural	O
basis	O
for	O
molecular	O
mimicry	O
involving	O
class	O
I	O
-	O
restricted	O
CTLs	O
in	O
the	O
pathogenesis	O
of	O
autoimmune	O
disease	O
.	O
Anti	O
-	O
rheumatic	O
compound	O
aurothioglucose	O
inhibits	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
-induced	O
HIV-1	O
replication	O
in	O
latently	O
infected	O
OM10.1	O
and	O
Ach2	O
cells	O
.	O
NF	B
-	I
kappaB	I
is	O
a	O
potent	O
cellular	O
activator	O
of	O
HIV-1	O
gene	O
expression	O
.	O
Down	O
-	O
regulation	O
of	O
NF	B
-	I
kappaB	I
activation	O
is	O
known	O
to	O
inhibit	O
HIV	O
replication	O
from	O
the	O
latently	O
infected	O
cells	O
.	O
Gold	O
compounds	O
have	O
been	O
effectively	O
used	O
for	O
many	O
decades	O
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
.	O
We	O
previously	O
reported	O
that	O
gold	O
compounds	O
,	O
especially	O
aurothioglucose	O
(	O
AuTG	O
)	O
containing	O
monovalent	O
gold	O
ion	O
,	O
inhibited	O
the	O
DNA	O
-	O
binding	O
of	O
NF	B
-	I
kappaB	I
in	O
vitro	O
.	O
In	O
this	O
report	O
we	O
have	O
examined	O
the	O
efficacy	O
of	O
the	O
gold	O
compound	O
AuTG	O
as	O
an	O
inhibitor	O
of	O
HIV	O
replication	O
in	O
latently	O
infected	O
OM10.1	O
and	O
Ach2	O
cells	O
.	O
Tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
-alpha	I
-induced	O
HIV-1	O
replication	O
in	O
OM10.1	O
or	O
Ach2	O
cells	O
was	O
significantly	O
inhibited	O
by	O
non	O
-	O
cytotoxic	O
doses	O
of	O
AuTG	O
(	O
>	O
10	O
microM	O
in	O
OM10.1	O
cells	O
and	O
>	O
25	O
F.M	O
in	O
Ach2	O
cells	O
)	O
,	O
while	O
25	O
microM	O
of	O
the	O
counter	B
-	I
anion	I
thioglucose	I
(	O
TG	B
)	O
or	O
gold	O
compound	O
containing	O
divalent	O
gold	O
ion	O
,	O
HAuCl3	O
,	O
had	O
no	O
effect	O
.	O
The	O
effect	O
of	O
AuTG	O
on	O
NF	B
-	I
kappaB	I
-dependent	O
gene	O
expression	O
was	O
confirmed	O
by	O
a	O
transient	O
CAT	B
assay	O
.	O
Specific	O
staining	O
as	O
well	O
as	O
electron	O
microscopic	O
examinations	O
revealed	O
the	O
accumulation	O
of	O
metal	O
gold	O
in	O
the	O
cells	O
,	O
supporting	O
our	O
previous	O
hypothesis	O
that	O
gold	O
ions	O
could	O
block	O
NF	B
-	I
kappaB	I
-DNA	O
binding	O
by	O
a	O
redox	O
mechanism	O
.	O
These	O
observations	O
indicate	O
that	O
the	O
monovalent	O
gold	O
compound	O
AuTG	O
is	O
a	O
potentially	O
useful	O
drug	O
for	O
the	O
treatment	O
of	O
patients	O
infected	O
with	O
HIV	O
.	O
Evidence	O
for	O
suppressed	O
activity	O
of	O
the	O
transcription	B
factor	I
NFAT1	B
at	O
its	O
proximal	O
binding	O
element	O
P0	O
in	O
the	O
IL-4	O
promoter	O
associated	O
with	O
enhanced	O
IL-4	O
gene	O
transcription	O
in	O
T	O
cells	O
of	O
atopic	O
patients	O
.	O
Allergen	O
-	O
specific	O
T	O
cells	O
in	O
atopic	O
patients	O
are	O
polarized	O
IL-4-producing	O
Th2	O
cells	O
,	O
promoting	O
IgE	B
synthesis	O
by	O
B	O
cells	O
.	O
The	O
molecular	O
basis	O
for	O
increased	O
IL-4	O
gene	O
expression	O
in	O
atopy	O
is	O
not	O
fully	O
understood	O
.	O
IL-4	O
gene	O
regulation	O
in	O
general	O
involves	O
the	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
(	I
NFAT	I
)	I
family	I
of	O
transcription	B
factors	I
,	O
of	O
which	O
NFAT1	B
and	O
NFAT2	B
are	O
most	O
prominent	O
in	O
peripheral	O
T	O
cells	O
.	O
Recently	O
,	O
a	O
unique	O
inhibitory	O
role	O
of	O
NFAT1	B
in	O
IL-4	O
gene	O
control	O
was	O
shown	O
in	O
the	O
mouse	O
.	O
In	O
a	O
series	O
of	O
electrophoretic	O
mobility	O
shift	O
assays	O
with	O
protein	O
extracts	O
of	O
highly	O
polarized	O
Th2	O
clones	O
from	O
atopics	O
and	O
Th1	O
clones	O
from	O
controls	O
we	O
compared	O
DNA	O
-	O
binding	O
activities	O
at	O
the	O
two	O
NFAT	O
-	O
binding	O
elements	O
P0	O
and	O
P1	O
of	O
the	O
crucial	O
proximal	O
human	O
IL-4	O
promoter	O
.	O
At	O
the	O
most	O
proximal	O
P0	O
site	O
,	O
NFAT	O
-	O
containing	O
complexes	O
devoid	O
of	O
NFAT2	B
were	O
readily	O
inducible	O
in	O
the	O
Th1	O
clones	O
,	O
but	O
hardly	O
or	O
not	O
in	O
the	O
Th2	O
clones	O
.	O
In	O
contrast	O
,	O
both	O
in	O
Th1	O
and	O
Th2	O
clones	O
NFAT	O
-	O
containing	O
complexes	O
were	O
strongly	O
inducible	O
at	O
the	O
P1	O
site	O
,	O
consisting	O
of	O
NFAT2	B
and	O
a	O
P0	O
-compatible	O
NFAT	B
activity	O
,	O
without	O
apparent	O
differences	O
between	O
Th1	O
and	O
Th2	O
clones	O
.	O
Like	O
in	O
Th2	O
clones	O
,	O
suppressed	O
NFAT-	O
P0	O
complex	O
formation	O
was	O
observed	O
also	O
at	O
the	O
polyclonal	O
level	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
of	O
three	O
of	O
five	O
severe	O
atopic	O
dermatitis	O
patients	O
with	O
strongly	O
elevated	O
serum	O
IgE	B
levels	O
,	O
but	O
not	O
in	O
control	O
PBMC	O
.	O
These	O
findings	O
suggest	O
that	O
high	O
-	O
level	O
IL-4	B
production	O
in	O
atopic	O
Th2	O
cells	O
is	O
associated	O
with	O
selective	O
reduction	O
of	O
suppressive	O
NFAT1	B
activity	O
at	O
the	O
IL-4	O
P0	O
element	O
and	O
that	O
some	O
patients	O
with	O
this	O
multifactorial	O
disease	O
may	O
have	O
a	O
putative	O
systemic	O
disorder	O
at	O
this	O
level	O
.	O
Interferon	B
-	I
alpha	I
activates	O
multiple	O
STAT	B
proteins	I
and	O
upregulates	O
proliferation	O
-	O
associated	O
IL-2Ralpha	B
,	O
c	O
-	O
myc	O
,	O
and	O
pim-1	O
genes	O
in	O
human	O
T	O
cells	O
.	O
Interferon	B
-	I
alpha	I
(	O
IFN	B
-	I
alpha	I
)	O
is	O
a	O
pleiotropic	B
cytokine	I
that	O
has	O
antiviral	O
,	O
antiproliferative	O
,	O
and	O
immunoregulatory	B
functions	O
.	O
There	O
is	O
increasing	O
evidence	O
that	O
IFN	B
-	I
alpha	I
has	O
an	O
important	O
role	O
in	O
T	O
-	O
cell	O
biology	O
.	O
We	O
have	O
analyzed	O
the	O
expression	O
of	O
IL-2Ralpha	B
,	O
c	O
-	O
myc	O
,	O
and	O
pim-1	O
genes	O
in	O
anti	O
-	O
CD3-activated	O
human	O
T	O
lymphocytes	O
.	O
The	O
induction	O
of	O
these	O
genes	O
is	O
associated	O
with	O
interleukin-2	B
(	O
IL-2	B
)	O
-induced	O
T	O
-	O
cell	O
proliferation	O
.	O
Treatment	O
of	O
T	O
lymphocytes	O
with	O
IFN	B
-	I
alpha	I
,	O
IL-2	B
,	O
IL-12	B
,	O
and	O
IL-15	B
upregulated	O
IL-2Ralpha	B
,	O
c	O
-	O
myc	O
,	O
and	O
pim-1	O
gene	O
expression	O
.	O
IFN	B
-	I
alpha	I
also	O
sensitized	O
T	O
cells	O
to	O
IL-2	B
-induced	O
proliferation	O
,	O
further	O
suggesting	O
that	O
IFN	B
-	I
alpha	I
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
T	O
-	O
cell	O
mitogenesis	O
.	O
When	O
we	O
analyzed	O
the	O
nature	O
of	O
STAT	B
proteins	I
capable	O
of	O
binding	O
to	O
IL-2Ralpha	B
,	O
pim-1	O
,	O
and	O
IRF-1	O
GAS	O
elements	O
after	O
cytokine	B
stimulation	O
,	O
we	O
observed	O
IFN	B
-	I
alpha	I
-induced	O
binding	O
of	O
STAT1	B
,	O
STAT3	B
,	O
and	O
STAT4	B
,	O
but	O
not	O
STAT5	B
to	O
all	O
of	O
these	O
elements	O
.	O
Yet	O
,	O
IFN	B
-	I
alpha	I
was	O
able	O
to	O
activate	O
binding	O
of	O
STAT5	B
to	O
the	O
high	O
-	O
affinity	O
IFP53	O
GAS	O
site	O
.	O
IFN	B
-	I
alpha	I
enhanced	O
tyrosine	O
phosphorylation	O
of	O
STAT1	O
,	O
STAT3	B
,	O
STAT4	B
,	O
STAT5a	B
,	O
and	O
STAT5b	B
.	O
IL-12	B
induced	O
STAT4	B
and	O
IL-2	B
and	O
IL-15	B
induced	O
STAT5	B
binding	O
to	O
the	O
GAS	O
elements	O
.	O
Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
IFN	B
-	I
alpha	I
,	O
IL-2	B
,	O
IL-12	B
,	O
and	O
IL-15	B
have	O
overlapping	O
activities	O
on	O
human	O
T	O
cells	O
.	O
These	O
findings	O
thus	O
emphasize	O
the	O
importance	O
of	O
IFN	B
-	I
alpha	I
as	O
a	O
T	B
-	I
cell	I
regulatory	I
cytokine	I
.	O
Nuclear	B
factor	I
-	I
kappa	I
B	I
activity	O
in	O
T	O
cells	O
from	O
patients	O
with	O
rheumatic	O
diseases	O
:	O
a	O
preliminary	O
report	O
.	O
OBJECTIVE	O
:	O
The	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
family	I
of	O
transcription	B
factors	I
regulates	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
the	O
immune	O
or	O
inflammatory	O
response	O
at	O
the	O
transcriptional	O
level	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
distinctive	O
patterns	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
are	O
seen	O
in	O
different	O
forms	O
of	O
joint	O
disease	O
.	O
METHODS	O
:	O
The	O
DNA	O
binding	O
activity	O
of	O
these	O
nucleoproteins	B
was	O
examined	O
in	O
purified	O
synovial	O
and	O
peripheral	O
T	O
cells	O
from	O
patients	O
with	O
various	O
chronic	O
rheumatic	O
diseases	O
(	O
12	O
:	O
four	O
with	O
rheumatoid	O
arthritis	O
;	O
five	O
with	O
spondyloarthropathies	O
;	O
and	O
three	O
with	O
osteoarthritis	O
)	O
.	O
RESULTS	O
:	O
Electrophoretic	O
mobility	O
shift	O
assays	O
disclosed	O
two	O
specific	O
complexes	O
bound	O
to	O
a	O
NF	B
-	I
kappa	I
B	I
specific	O
32P	O
-	O
labelled	O
oligonucleotide	O
in	O
nucleoproteins	B
extracted	O
from	O
purified	O
T	O
cells	O
isolated	O
from	O
synovial	O
fluid	O
and	O
peripheral	O
blood	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
.	O
The	O
complexes	B
consisted	O
of	O
p50	B
/	I
p50	I
homodimers	I
and	O
p50	O
/	O
p65	O
heterodimers	O
.	O
Increased	O
NF	B
-	I
kappa	I
B	I
binding	O
to	O
DNA	O
in	O
synovial	O
T	O
cells	O
was	O
observed	O
relative	O
to	O
peripheral	O
T	O
cells	O
.	O
In	O
non	O
-	O
rheumatoid	O
arthritis	O
,	O
binding	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
synovial	O
T	O
cells	O
was	O
exclusively	O
mediated	O
by	O
p50	B
/	I
p50	I
homodimers	I
.	O
CONCLUSION	O
:	O
Overall	O
,	O
the	O
results	O
suggest	O
that	O
NF	B
-	I
kappa	I
B	I
may	O
play	O
a	O
central	O
part	O
in	O
the	O
activation	O
of	O
infiltrating	O
T	O
cells	O
in	O
chronic	O
rheumatoid	O
arthritis	O
.	O
The	O
activation	O
of	O
this	O
nuclear	O
factor	O
is	O
qualitatively	O
different	O
in	O
rheumatoid	O
synovial	O
T	O
cells	O
to	O
that	O
in	O
other	O
forms	O
of	O
non	O
-	O
rheumatoid	O
arthritis	O
(	O
for	O
example	O
,	O
osteoarthritis	O
,	O
spondyloarthropathies	O
)	O
.	O
RFX	O
-	O
B	O
is	O
the	O
gene	O
responsible	O
for	O
the	O
most	O
common	O
cause	O
of	O
the	O
bare	O
lymphocyte	O
syndrome	O
,	O
an	O
MHC	B
class	I
II	I
immunodeficiency	O
[	O
published	O
erratum	O
appears	O
in	O
Immunity	O
1999	O
Mar	O
;	O
10	O
(	O
3	O
)	O
:	O
399	O
]	O
The	O
bare	O
lymphocyte	O
syndrome	O
(	O
BLS	O
)	O
is	O
characterized	O
by	O
the	O
absence	O
of	O
MHC	B
class	I
II	I
transcription	O
and	O
humoral-	O
and	O
cellular	O
-	O
mediated	O
immune	O
responses	O
to	O
foreign	O
antigens	O
.	O
Three	O
of	O
the	O
four	O
BLS	O
genetic	O
complementation	O
groups	O
have	O
defects	O
in	O
the	O
activity	O
of	O
the	O
MHC	B
class	I
II	I
transcription	I
factor	I
RFX	B
.	O
We	O
have	O
purified	O
the	O
RFX	B
complex	I
and	O
sequenced	O
its	O
three	O
subunits	O
.	O
The	O
sequence	O
of	O
the	O
smallest	O
subunit	O
describes	O
a	O
novel	O
gene	O
,	O
termed	O
RFX	O
-	O
B	O
.	O
RFX	O
-	O
B	O
complements	O
the	O
predominant	O
BLS	B
complementation	I
group	I
(	O
group	B
B	I
)	O
and	O
was	O
found	O
to	O
be	O
mutant	O
in	O
cell	O
lines	O
from	O
this	O
BLS	O
group	O
.	O
The	O
protein	O
has	O
no	O
known	O
DNA	B
-	I
binding	I
domain	I
but	O
does	O
contain	O
three	O
ankyrin	O
repeats	O
that	O
are	O
likely	O
to	O
be	O
important	O
in	O
protein	O
-	O
protein	O
interactions	O
.	O
Glucocorticoid	O
hormone	O
suppression	O
of	O
human	O
neutrophil	O
-mediated	O
tumor	O
cell	O
cytostasis	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
glucocorticoid	O
hormones	O
on	O
neutrophil	O
-mediated	O
tumor	O
cell	O
cytostasis	O
and	O
found	O
that	O
hydrocortisone	O
and	O
a	O
synthetic	O
hormone	O
,	O
dexamethasone	O
(	O
Dex	O
)	O
,	O
inhibited	O
cytostasis	O
in	O
the	O
presence	O
or	O
absence	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
.	O
The	O
effect	O
of	O
Dex	O
was	O
completely	O
reversed	O
by	O
a	O
glucocorticoid	B
receptor	I
antagonist	O
,	O
RU38486	O
.	O
To	O
clarify	O
the	O
underlying	O
mechanisms	O
,	O
we	O
examined	O
effects	O
of	O
Dex	O
on	O
the	O
binding	O
avidity	O
of	O
beta2	B
integrin	I
on	O
the	O
neutrophil	O
surface	O
and	O
how	O
these	O
might	O
in	O
turn	O
affect	O
neutrophil	O
-to	O
-	O
tumor	O
cell	O
binding	O
.	O
Dex	O
was	O
found	O
to	O
inhibit	O
these	O
neutrophil	O
properties	O
,	O
and	O
RU38486	O
completely	O
suppressed	O
both	O
forms	O
of	O
Dex	O
inhibition	O
.	O
Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
glucocorticoid	O
hormone	O
inhibition	O
of	O
neutrophil	O
-mediated	O
tumor	O
cell	O
cytostasis	O
is	O
at	O
least	O
partially	O
due	O
to	O
a	O
lowering	O
of	O
the	O
ligand	O
binding	O
avidity	O
of	O
beta2	B
integrin	I
on	O
the	O
neutrophil	O
surface	O
.	O
Bacterial	O
lipopolysaccharide	O
activates	O
nuclear	B
factor	I
-	I
kappaB	I
through	O
interleukin-1	B
signaling	I
mediators	I
in	O
cultured	O
human	O
dermal	O
endothelial	O
cells	O
and	O
mononuclear	O
phagocytes	O
.	O
Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-mediated	O
immune	O
responses	O
,	O
including	O
activation	O
of	O
monocytes	O
,	O
macrophages	O
,	O
and	O
endothelial	O
cells	O
,	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
Gram	O
-	O
negative	O
bacteria	O
-	O
induced	O
sepsis	O
syndrome	O
.	O
Activation	O
of	O
NF	B
-	I
kappaB	I
is	O
thought	O
to	O
be	O
required	O
for	O
cytokine	O
release	O
from	O
LPS	O
-	O
responsive	O
cells	O
,	O
a	O
critical	O
step	O
for	O
endotoxic	O
effects	O
.	O
Here	O
we	O
investigated	O
the	O
role	O
and	O
involvement	O
of	O
interleukin-1	B
(	O
IL-1	B
)	O
and	O
tumor	B
necrosis	I
factor	I
(	O
TNF	B
-	I
alpha	I
)	O
signal	B
transducer	I
molecules	I
in	O
LPS	O
signaling	O
in	O
human	O
dermal	O
microvessel	O
endothelial	O
cells	O
(	O
HDMEC	O
)	O
and	O
THP-1	O
monocytic	O
cells	O
.	O
LPS	O
stimulation	O
of	O
HDMEC	O
and	O
THP-1	O
cells	O
initiated	O
an	O
IL-1	B
receptor	I
-like	O
NF	B
-	I
kappaB	I
signaling	O
cascade	O
.	O
In	O
transient	O
cotransfection	O
experiments	O
,	O
dominant	O
negative	O
mutants	O
of	O
the	O
IL-1	B
signaling	O
pathway	O
,	O
including	O
MyD88	B
,	O
IRAK	B
,	O
IRAK2	B
,	O
and	O
TRAF6	B
inhibited	O
both	O
IL-1	B
-and	O
LPS	O
-	O
induced	O
NF	B
-	I
kappaB	I
-luciferase	B
activity	O
.	O
LPS	O
-	O
induced	O
NF	B
-	I
kappaB	I
activation	O
was	O
not	O
inhibited	O
by	O
a	O
dominant	O
negative	O
mutant	O
of	O
TRAF2	B
that	O
is	O
involved	O
in	O
TNF	B
signaling	O
.	O
LPS	O
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
reporter	O
gene	O
was	O
not	O
inhibited	O
by	O
IL-1	B
receptor	O
antagonist	O
.	O
TLR2	B
and	O
TLR4	B
were	O
expressed	O
on	O
the	O
cell	O
surface	O
of	O
HDMEC	O
and	O
THP-1	O
cells	O
.	O
These	O
findings	O
suggest	O
that	O
a	O
signal	B
transduction	I
molecule	I
in	O
the	O
LPS	O
receptor	O
complex	O
may	O
belong	O
to	O
the	O
IL-1	B
receptor	O
/	O
toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
super	O
family	O
,	O
and	O
the	O
LPS	O
signaling	O
cascade	O
uses	O
an	O
analogous	O
molecular	O
framework	O
for	O
signaling	O
as	O
IL-1	B
in	O
mononuclear	O
phagocytes	O
and	O
endothelial	O
cells	O
.	O
A	O
direct	O
interaction	O
between	O
the	O
adaptor	B
protein	I
Cbl	B
-	I
b	I
and	O
the	O
kinase	B
zap-70	B
induces	O
a	O
positive	O
signal	O
in	O
T	O
cells	O
.	O
Engagement	O
of	O
the	O
T	B
-	I
cell	I
receptor	I
(	I
TCR	I
)	I
-CD3	I
complex	I
induces	O
a	O
rapid	O
increase	O
in	O
the	O
activities	O
of	O
Src	B
-	I
family	I
and	O
Syk	B
/	I
Zap-70-family	I
kinases	I
[	O
1	O
]	O
[	O
2	O
]	O
.	O
These	O
activated	B
kinases	I
then	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
multiple	B
intracellular	I
proteins	I
,	O
eventually	O
leading	O
to	O
T	O
-	O
cell	O
activation	O
.	O
One	O
of	O
the	O
prominent	O
substrates	O
for	O
these	O
kinases	B
is	O
the	O
adaptor	B
protein	I
Cbl	O
[	O
3	O
]	O
and	O
recent	O
studies	O
suggest	O
that	O
Cbl	B
negatively	O
regulates	O
upstream	B
kinases	I
such	O
as	O
Syk	B
and	O
Zap-70	B
[	O
4	O
]	O
[	O
5	O
]	O
.	O
Cbl	B
-	I
b	I
,	O
a	O
homologue	O
of	O
Cbl	B
,	O
is	O
widely	O
expressed	O
in	O
many	O
tissues	O
and	O
cells	O
including	O
hematopoietic	O
cells	O
[	O
6	O
]	O
[	O
7	O
]	O
.	O
Cbl	B
-	I
b	I
undergoes	O
rapid	O
tyrosine	O
phosphorylation	O
upon	O
stimulation	O
of	O
the	O
TCR	B
and	O
cytokine	O
receptors	O
[	O
8	O
]	O
[	O
9	O
]	O
.	O
The	O
role	O
of	O
Cbl	B
-	I
b	I
is	O
unclear	O
,	O
however	O
.	O
Here	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
Cbl	B
-	I
b	I
in	O
T	O
cells	O
induced	O
the	O
constitutive	O
activation	O
of	O
the	O
transcription	B
factor	I
nuclear	I
factor	I
of	I
activated	I
T	I
cells	I
(	O
NFAT	B
)	O
.	O
A	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
in	O
Cbl	B
-	I
b	I
disrupted	O
the	O
interaction	O
between	O
Cbl	B
-	I
b	I
and	O
Zap-70	B
and	O
nearly	O
completely	O
abrogated	O
the	O
Cbl	B
-	I
b	I
-mediated	O
activation	O
of	O
NFAT	B
.	O
Unlike	O
the	O
proposed	O
role	O
of	O
Cbl	B
as	O
a	O
negative	O
regulator	O
,	O
our	O
results	O
suggest	O
that	O
the	O
Cbl	B
homologue	O
Cbl	B
-	I
b	I
has	O
a	O
positive	O
role	O
in	O
T	O
-	O
cell	O
signaling	O
,	O
most	O
likely	O
via	O
a	O
direct	O
interaction	O
with	O
the	O
upstream	B
kinase	I
Zap-70	B
.	O
Abnormalities	O
of	O
cyclic	O
adenosine	O
monophosphate	O
signaling	O
in	O
platelets	O
from	O
untreated	O
patients	O
with	O
bipolar	O
disorder	O
.	O
BACKGROUND	O
:	O
Abnormalities	O
in	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
-dependent	O
phosphorylation	O
system	O
have	O
been	O
recently	O
reported	O
in	O
patients	O
with	O
bipolar	O
disorder	O
.	O
We	O
evaluated	O
the	O
immunoreactivity	O
of	O
the	O
regulatory	B
and	I
catalytic	I
subunits	I
of	O
cAMP	B
-	I
dependent	I
protein	I
kinase	I
(	O
protein	B
kinase	I
A	I
)	O
and	O
1	O
of	O
its	O
substrates	O
,	O
Rap1	B
,	O
in	O
platelets	O
from	O
untreated	O
euthymic	O
,	O
manic	O
,	O
and	O
depressed	O
patients	O
with	O
bipolar	O
disorder	O
and	O
healthy	O
subjects	O
.	O
METHODS	O
:	O
Platelets	O
were	O
collected	O
from	O
112	O
drug	O
-	O
free	O
patients	O
with	O
bipolar	O
disorder	O
(	O
52	O
euthymic	O
,	O
29	O
depressed	O
,	O
and	O
31	O
manic	O
)	O
and	O
62	O
healthy	O
subjects	O
.	O
The	O
levels	O
of	O
cAMP	B
-	I
dependent	I
protein	I
kinase	I
and	O
Rap1	B
were	O
assessed	O
by	O
Western	O
blot	O
analysis	O
,	O
immunostaining	O
,	O
and	O
computer	O
-	O
assisted	O
imaging	O
.	O
RESULTS	O
:	O
The	O
immunolabeling	O
of	O
the	O
catalytic	B
subunit	I
of	O
cAMP	B
-	I
dependent	I
protein	I
kinase	I
was	O
significantly	O
different	O
among	O
groups	O
(	O
P	O
<	O
.001	O
)	O
,	O
with	O
higher	O
values	O
in	O
untreated	O
depressed	O
and	O
manic	O
patients	O
with	O
bipolar	O
disorder	O
compared	O
with	O
untreated	O
euthymic	O
patients	O
with	O
bipolar	O
disorder	O
and	O
healthy	O
subjects	O
.	O
No	O
significant	O
differences	O
were	O
found	O
in	O
the	O
immunolabeling	O
of	O
the	O
regulatory	B
subunits	I
(	O
type	O
I	O
and	O
type	O
II	O
)	O
of	O
cAMP	B
-	I
dependent	I
protein	I
kinase	I
.	O
The	O
immunolabeling	O
of	O
Rap1	B
was	O
significantly	O
higher	O
(	O
P	O
<	O
.001	O
)	O
in	O
untreated	O
euthymic	O
,	O
depressed	O
,	O
and	O
manic	O
patients	O
than	O
in	O
healthy	O
persons	O
.	O
CONCLUSIONS	O
:	O
Levels	O
of	O
Rap1	B
and	O
the	O
catalytic	B
subunit	I
of	O
cAMP	B
-	I
dependent	I
protein	I
kinase	I
are	O
altered	O
in	O
the	O
platelets	O
of	O
bipolar	O
patients	O
.	O
These	O
findings	O
may	O
provide	O
clues	O
toward	O
understanding	O
the	O
involvement	O
of	O
cAMP	O
signaling	O
in	O
the	O
pathogenesis	O
of	O
bipolar	O
disorder	O
.	O
Inhibition	O
of	O
IL-4	B
-inducible	O
gene	O
expression	O
in	O
human	O
monocytes	O
by	O
type	B
I	I
and	I
type	I
II	I
interferons	I
.	O
The	O
Th2-type	B
cytokines	I
,	O
interleukin-4	B
(	O
IL-4	B
)	O
and	O
interleukin-13	B
(	O
IL-13	B
)	O
,	O
induce	O
expression	O
of	O
a	O
distinct	O
subset	O
of	O
genes	O
in	O
human	O
monocytes	O
,	O
including	O
FcepsilonRIIb	B
(	O
CD23	B
)	O
,	O
15-lipoxygenase	B
,	O
IL-1	B
receptor	I
antagonist	I
(	O
IL-1ra	B
)	O
,	O
and	O
type	B
I	I
and	I
type	I
II	I
IL-1	I
receptors	I
(	O
IL-1R	B
)	O
.	O
Type	B
I	I
interferons	I
(	O
IFN	B
-	I
alpha	I
and	O
IFN	B
-	I
beta	I
)	O
and	O
type	B
II	I
interferon	I
(	O
IFN	B
-	I
gamma	I
)	O
inhibit	O
induction	O
of	O
these	O
genes	O
by	O
IL-4	B
and	O
IL-13	B
.	O
However	O
,	O
the	O
mechanism	O
by	O
which	O
IFNs	B
mediate	O
this	O
inhibition	O
has	O
not	O
been	O
defined	O
.	O
In	O
this	O
overview	O
,	O
we	O
discuss	O
the	O
role	O
of	O
the	O
transcription	B
factor	I
,	O
STAT6	B
(	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription-6	I
)	O
in	O
mediating	O
IL-4-	O
and	O
IL-13-induced	O
gene	O
expression	O
in	O
monocytes	O
.	O
We	O
also	O
discuss	O
our	O
recent	O
findings	O
that	O
type	B
I	I
and	I
type	I
II	I
IFNs	I
suppress	O
IL-4	B
/	O
IL-13	B
-inducible	O
gene	O
expression	O
by	O
inhibiting	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
STAT6	B
.	O
The	O
ability	O
of	O
type	B
I	I
and	I
type	I
II	I
IFNs	I
to	O
inhibit	O
IL-4	B
/	O
IL-13	B
-induced	O
STAT6	B
activity	O
is	O
dose-	O
and	O
time	O
-	O
dependent	O
,	O
and	O
is	O
not	O
unique	O
to	O
monocytes	O
because	O
IFNs	B
induce	O
the	O
same	O
effects	O
in	O
fibroblasts	O
.	O
Inhibition	O
of	O
STAT6	B
activity	O
is	O
not	O
evident	O
unless	O
cells	O
are	O
preincubated	O
with	O
IFN	B
for	O
at	O
least	O
1	O
h	O
before	O
IL-4	B
stimulation	O
.	O
Furthermore	O
,	O
inhibition	O
can	O
be	O
blocked	O
by	O
actinomycin	O
D	O
,	O
indicating	O
a	O
requirement	O
for	O
de	O
novo	O
transcription	O
.	O
We	O
propose	O
a	O
model	O
in	O
which	O
stimulation	O
of	O
monocytes	O
by	O
IFN	B
activates	O
de	O
novo	O
synthesis	O
of	O
an	O
inhibitory	B
factor	I
,	O
possibly	O
one	O
or	O
more	O
members	O
of	O
the	O
SOCS	B
/	I
SSI	I
/	I
CIS	I
gene	I
family	I
,	O
capable	O
of	O
suppressing	O
activation	O
of	O
STAT6	B
by	O
IL-4	B
and	O
IL-13	B
.	O
Because	O
STAT6	B
activation	O
plays	O
an	O
essential	O
role	O
in	O
IL-4	B
/	O
IL-13	B
-induced	O
gene	O
expression	O
,	O
the	O
ability	O
of	O
IFN	B
-	I
beta	I
and	O
IFN	B
-	I
gamma	I
to	O
inhibit	O
STAT6	B
activity	O
provides	O
an	O
explanation	O
for	O
how	O
IFNs	B
can	O
suppress	O
IL-4	B
/	O
IL-13	B
-inducible	O
gene	O
expression	O
.	O
Selective	O
activation	O
and	O
functional	O
significance	O
of	O
p38alpha	B
mitogen	I
-	I
activated	I
protein	I
kinase	I
in	O
lipopolysaccharide	O
-	O
stimulated	O
neutrophils	O
.	O
Activation	O
of	O
leukocytes	O
by	O
proinflammatory	O
stimuli	O
selectively	O
initiates	O
intracellular	O
signal	O
transduction	O
via	O
sequential	O
phosphorylation	O
of	O
kinases	B
.	O
Lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
of	O
human	O
neutrophils	O
is	O
known	O
to	O
result	O
in	O
activation	O
of	O
p38	B
mitogen	I
-	I
activated	I
protein	I
kinase	I
(	O
MAPk	B
)	O
;	O
however	O
,	O
the	O
upstream	B
activator	I
(	O
s	O
)	O
of	O
p38	B
MAPk	I
is	O
unknown	O
,	O
and	O
consequences	O
of	O
p38	B
MAPk	I
activation	O
remain	O
largely	O
undefined	O
.	O
We	O
investigated	O
the	O
MAPk	B
kinase	I
(	O
MKK	B
)	O
that	O
activates	O
p38	B
MAPk	I
in	O
response	O
to	O
LPS	O
,	O
the	O
p38	B
MAPk	I
isoforms	I
that	O
are	O
activated	O
as	O
part	O
of	O
this	O
pathway	O
,	O
and	O
the	O
functional	O
responses	O
affected	O
by	O
p38	B
MAPk	I
activation	O
.	O
Although	O
MKK3	B
,	O
MKK4	B
,	O
and	O
MKK6	B
all	O
activated	O
p38	B
MAPk	I
in	O
experimental	O
models	O
,	O
only	O
MKK3	B
was	O
found	O
to	O
activate	O
recombinant	O
p38	B
MAPk	I
in	O
LPS	O
-	O
treated	O
neutrophils	O
.	O
Of	O
p38	B
MAPk	I
isoforms	I
studied	O
,	O
only	O
p38alpha	B
and	O
p38delta	B
were	O
detected	O
in	O
neutrophils	O
.	O
LPS	O
stimulation	O
selectively	O
activated	O
p38alpha	B
.	O
Specific	O
inhibitors	O
of	O
p38alpha	B
MAPk	I
blocked	O
LPS	O
-	O
induced	O
adhesion	O
,	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	B
-	I
kappaB	I
)	O
activation	O
,	O
and	O
synthesis	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
.	O
Inhibition	O
of	O
p38alpha	B
MAPk	I
resulted	O
in	O
a	O
transient	O
decrease	O
in	O
TNF	O
-	O
alpha	O
mRNA	O
accumulation	O
but	O
persistent	O
loss	O
of	O
TNF	B
-	I
alpha	I
synthesis	O
.	O
These	O
findings	O
support	O
a	O
pathway	O
by	O
which	O
LPS	O
stimulation	O
of	O
neutrophils	O
results	O
in	O
activation	O
of	O
MKK3	B
,	O
which	O
in	O
turn	O
activates	O
p38alpha	B
MAPk	I
,	O
ultimately	O
regulating	O
adhesion	O
,	O
NF	B
-	I
kappaB	I
activation	O
,	O
enhanced	O
gene	O
expression	O
of	O
TNF	B
-	I
alpha	I
,	O
and	O
regulation	O
of	O
TNF	B
-	I
alpha	I
synthesis	O
.	O
Cobalt	O
chloride	O
-	O
induced	O
signaling	O
in	O
endothelium	O
leading	O
to	O
the	O
augmented	O
adherence	O
of	O
sickle	O
red	O
blood	O
cells	O
and	O
transendothelial	O
migration	O
of	O
monocyte	O
-	O
like	O
HL-60	O
cells	O
is	O
blocked	O
by	O
PAF	O
-	O
receptor	O
antagonist	O
.	O
In	O
response	O
to	O
hypoxia	O
,	O
sickle	O
red	O
blood	O
cells	O
(	O
SS	O
RBC	O
)	O
and	O
leukocytes	O
exhibit	O
increased	O
adherence	O
to	O
the	O
vascular	O
endothelium	O
,	O
while	O
diapedesis	O
of	O
leukocytes	O
through	O
the	O
blood	O
vessel	O
increases	O
.	O
However	O
,	O
the	O
cellular	O
signaling	O
pathway	O
(	O
s	O
)	O
caused	O
by	O
hypoxia	O
is	O
poorly	O
understood	O
.	O
We	O
utilized	O
CoCl2	O
as	O
a	O
mimetic	O
molecule	O
for	O
hypoxia	O
to	O
study	O
cellular	O
signaling	O
pathways	O
.	O
We	O
found	O
that	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
,	O
CoCl2	O
at	O
2	O
mM	O
concentration	O
induced	O
the	O
surface	O
expression	O
of	O
a	O
subset	O
of	O
CAMs	B
(	O
VCAM-1	B
)	O
and	O
activation	O
of	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
in	O
the	O
nuclear	O
extracts	O
of	O
HUVEC	O
.	O
Furthermore	O
,	O
CoCl2	O
also	O
caused	O
time	O
-	O
dependent	O
tyrosine	O
phosphorylation	O
of	O
mitogen	B
-	I
activated	I
protein	I
(	I
MAP	I
)	I
kinase	I
isoform	O
ERK2	B
without	O
significantly	O
affecting	O
ERK1	B
,	O
indicating	O
ERK2	B
is	O
the	O
preferred	O
substrate	O
for	O
upstream	B
kinase	I
of	O
the	O
MAPK	B
pathway	O
.	O
Inhibitors	O
of	O
MAP	B
kinase	I
(	O
PD98059	O
)	O
or	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
-	O
receptor	O
antagonist	O
(	O
CV3988	O
)	O
inhibited	O
the	O
CoCl2-induced	O
NF	B
-	I
kappaB	I
activation	O
and	O
VCAM-1	B
expression	O
.	O
Augmented	O
expression	O
of	O
VCAM-1	B
led	O
to	O
increased	O
SS	O
RBC	O
adhesion	O
,	O
inhibitable	O
by	O
a	O
VCAM-1	B
antibody	I
.	O
Additionally	O
,	O
CoCl2	O
caused	O
a	O
two-	O
to	O
threefold	O
increase	O
in	O
the	O
rate	O
of	O
transendothelial	O
migration	O
of	O
monocyte	O
-	O
like	O
HL-60	O
cells	O
and	O
a	O
twentyfold	O
increase	O
in	O
phosphorylation	O
of	O
platelet	B
endothelial	I
cell	I
adhesion	I
molecules	I
(	O
PECAM-1	B
)	O
.	O
The	O
transendothelial	O
migration	O
of	O
monocytes	O
was	O
inhibited	O
by	O
an	O
antibody	O
to	O
PECAM-1	B
.	O
Both	O
phosphorylation	O
of	O
PECAM-1	B
and	O
transendothelial	O
migration	O
of	O
monocytes	O
in	O
response	O
to	O
CoCl2	O
were	O
inhibited	O
by	O
protein	O
kinase	O
inhibitor	O
(	O
GF109203X	O
)	O
and	O
augmented	O
by	O
protein	O
phosphatase	O
inhibitor	O
(	O
Calyculin	O
A	O
)	O
.	O
Our	O
data	O
suggests	O
that	O
CoCl2-induced	O
cellular	O
signals	O
directing	O
increased	O
expression	O
of	O
VCAM-1	B
in	O
HUVEC	O
involve	O
downstream	O
activation	O
of	O
MAP	B
kinase	I
and	O
NF	B
-	I
kappaB	I
,	O
while	O
the	O
phosphorylation	O
of	O
PECAM-1	B
occurs	O
as	O
a	O
result	O
of	O
activation	O
of	O
PKC	B
.	O
We	O
conclude	O
that	O
PAF	O
-	O
receptor	O
antagonist	O
inhibits	O
the	O
CoCl2	O
-or	O
hypoxia	O
-	O
induced	O
increase	O
in	O
the	O
adhesion	O
of	O
SS	O
RBC	O
,	O
PECAM-1	B
phosphorylation	O
,	O
and	O
the	O
concomitant	O
transendothelial	O
migration	O
of	O
monocytes	O
.	O
Impaired	O
binding	O
of	O
a	O
DQ2	B
and	O
DQ8	B
-binding	O
HSV	O
VP16	O
peptide	O
to	O
a	O
DQA1	B
*	I
0501	I
/	I
DQB1	I
*	I
0302	I
trans	I
class	I
II	I
heterodimer	I
.	O
DQalpha	B
and	I
DQbeta	I
trans	I
heterodimeric	I
HLA	I
-	I
DQ	I
molecules	I
form	O
in	O
individuals	O
heterozygous	O
for	O
the	O
DQ2	B
and	O
DQ8	B
specificities	O
.	O
Unique	O
functions	O
and	O
disease	O
associations	O
have	O
been	O
postulated	O
for	O
such	O
trans	B
-	I
dimers	I
,	O
which	O
may	O
be	O
different	O
from	O
cis	B
-	I
encoded	I
DQ	I
molecules	I
encoded	O
by	O
the	O
corresponding	O
haplotypes	O
.	O
We	O
analyzed	O
the	O
ability	O
of	O
the	O
trans	O
-	O
dimer	O
encoded	O
by	O
HLA	B
-	I
DQA1	I
*	I
0501	I
/	I
DQB1	I
*	I
0302	I
to	O
bind	O
a	O
peptide	O
antigen	O
which	O
interacts	O
with	O
DQ	B
molecules	I
encoded	O
by	O
both	O
parental	O
haplotypes	O
.	O
Markedly	O
impaired	O
binding	O
was	O
observed	O
,	O
consistent	O
with	O
both	O
the	O
use	O
of	O
different	O
anchor	O
residues	O
and	O
with	O
changes	O
in	O
levels	O
of	O
DQ	O
cis-	O
dimer	B
availability	O
for	O
peptide	O
binding	O
interactions	O
.	O
Phosphorylation	O
of	O
TRAF2	B
inhibits	O
binding	O
to	O
the	O
CD40	B
cytoplasmic	I
domain	I
.	O
TRAF2	B
is	O
a	O
signal	B
transducing	I
adaptor	I
molecule	I
which	O
binds	O
to	O
the	O
CD40	B
cytoplasmic	I
domain	I
.	O
We	O
have	O
found	O
that	O
it	O
is	O
phosphorylated	O
,	O
predominantly	O
on	O
serine	O
residues	O
,	O
when	O
transiently	O
overexpressed	O
in	O
293	O
cells	O
.	O
The	O
phosphorylation	O
appears	O
to	O
be	O
related	O
to	O
the	O
signaling	O
events	O
that	O
are	O
activated	O
by	O
TRAF2	B
under	O
these	O
circumstances	O
,	O
since	O
two	O
nonfunctional	O
mutants	O
were	O
found	O
to	O
be	O
phosphorylated	O
significantly	O
less	O
than	O
the	O
wild	B
-	I
type	I
protein	I
.	O
Furthermore	O
,	O
the	O
phosphorylation	O
status	O
of	O
TRAF2	B
had	O
significant	O
effects	O
on	O
the	O
ability	O
of	O
the	O
protein	O
to	O
bind	O
to	O
CD40	B
,	O
as	O
evidenced	O
by	O
our	O
observations	O
that	O
the	O
CD40	B
cytoplasmic	I
domain	I
interacted	O
preferentially	O
with	O
underphosphorylated	O
TRAF2	B
and	O
that	O
phosphatase	B
treatment	O
significantly	O
enhanced	O
the	O
binding	O
of	O
TRAF2	B
to	O
CD40	B
.	O
We	O
conclude	O
from	O
these	O
studies	O
that	O
the	O
phosphorylation	O
of	O
TRAF2	B
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
regulating	O
signaling	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
influence	O
the	O
CD40	B
-TRAF2	B
interaction	O
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
Analysis	O
of	O
the	O
modulation	O
of	O
transcriptional	O
activity	O
in	O
myelopoiesis	O
and	O
leukemogenesis	O
.	O
Acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
is	O
still	O
associated	O
with	O
a	O
mortality	O
of	O
60	O
to	O
80	O
%	O
.	O
AML	O
is	O
characterized	O
by	O
a	O
block	O
in	O
myeloid	O
differentiation	O
.	O
The	O
transcription	B
factors	I
PU.1	B
and	O
C	B
/	I
EBPalpha	I
are	O
responsible	O
for	O
normal	O
myeloid	O
differentiation	O
from	O
stem	O
cells	O
to	O
monocytes	O
or	O
granulocytes	O
.	O
In	O
particular	O
,	O
PU.1	B
induces	O
expression	O
of	O
the	O
macrophage	B
colony	I
-	I
stimulating	I
factor	I
(	I
M	I
-	I
CSF	I
)	I
receptor	I
and	O
the	O
development	O
of	O
monocytes	O
,	O
whereas	O
C	B
/	I
EBPalpha	I
increases	O
the	O
expression	O
of	O
the	O
granulocyte	B
colony	I
-	I
stimulating	I
factor	I
(	I
G	I
-	I
CSF	I
)	I
receptor	I
and	O
leads	O
to	O
mature	O
granulocytes	O
.	O
In	O
AML	O
,	O
chromosomal	O
aberrations	O
result	O
in	O
oncoproteins	B
such	O
as	O
AML1	B
/	I
ETO	I
,	O
PML	B
/	I
RARalpha	I
,	O
or	O
activated	B
Ras	I
,	O
which	O
can	O
deregulate	O
genes	O
important	O
for	O
normal	O
myelopoiesis	O
.	O
Thus	O
,	O
AML1	B
/	I
ETO	I
can	O
bind	O
to	O
the	O
transcription	B
factor	I
C	B
/	I
EBPalpha	I
,	O
inhibit	O
C	B
/	I
EBPalpha	I
-dependent	O
transcription	O
,	O
and	O
block	O
granulocytic	O
differentiation	O
.	O
However	O
,	O
AML1	B
/	I
ETO	I
can	O
also	O
synergize	O
with	O
the	O
transcription	B
factor	I
AML1	B
to	O
enhance	O
the	O
activity	O
of	O
the	O
M	O
-	O
CSF	O
receptor	O
promoter	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
PML	B
/	I
RARalpha	I
fusion	I
protein	I
causes	O
transcriptional	O
repression	O
by	O
recruiting	O
the	O
nuclear	B
corepressor	I
(	I
N	I
-	I
CoR	I
)	I
histone	I
deacetylase	I
complex	I
to	O
the	O
DNA	O
,	O
which	O
results	O
in	O
decreased	O
histone	B
acetylation	O
and	O
a	O
repressive	O
chromatin	O
organization	O
.	O
Here	O
we	O
describe	O
methods	O
to	O
investigate	O
whether	O
and	O
how	O
signaling	O
agonists	O
induce	O
myeloid	O
differentiation	O
and	O
how	O
oncoproteins	B
might	O
cause	O
AML	O
by	O
modulating	O
the	O
activity	O
of	O
transcription	B
factors	I
that	O
are	O
pivotal	O
for	O
normal	O
myeloid	O
development	O
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
Involvement	O
of	O
NF	B
-	I
kappaB	I
p50	I
/	I
p65	I
heterodimer	I
in	O
activation	O
of	O
the	O
human	O
pro	O
-	O
interleukin-1beta	O
gene	O
at	O
two	O
subregions	O
of	O
the	O
upstream	O
enhancer	O
element	O
.	O
A	O
region	O
between-3134	O
and	O
-2729	O
bp	O
upstream	O
from	O
the	O
transcription	O
site	O
of	O
the	O
human	O
pro	O
-	O
interleukin	O
1beta	O
(	O
proIL-1beta	O
)	O
gene	O
was	O
identified	O
as	O
an	O
LPS	O
-	O
responsive	O
enhancer	O
element	O
.	O
In	O
this	O
study	O
,	O
the	O
influence	O
of	O
the	O
sequences	O
located	O
between	O
-3134	O
and	O
-2987	O
on	O
the	O
transcriptional	O
activity	O
of	O
the	O
proIL-1beta	O
gene	O
in	O
LPS	O
-	O
stimulated	O
Raw	O
264.7	O
cells	O
was	O
examined	O
in	O
detail	O
.	O
The	O
results	O
obtained	O
by	O
transient	O
transfection	O
of	O
fos	O
-CAT	O
constructs	O
that	O
contained	O
serial	O
5'-deletion	O
mutations	O
showed	O
that	O
the	O
region	O
between	O
-3134	O
and	O
-3059	O
appears	O
to	O
be	O
required	O
for	O
the	O
induction	O
of	O
transcription	O
by	O
LPS	O
.	O
Gel	O
shift	O
assay	O
studies	O
with	O
synthetic	O
oligonucleotides	O
corresponding	O
to	O
partial	O
sequences	O
of	O
the	O
latter	O
region	O
and	O
nuclear	O
extracts	O
from	O
stimulated	O
cells	O
revealed	O
specific	O
protein	O
binding	O
sites	O
between	O
-3110	O
and	O
-3090	O
and	O
between	O
-3079	O
and	O
-3059	O
.	O
These	O
specific	O
bindings	O
were	O
time	O
and	O
LPS	O
dose	O
dependent	O
.	O
The	O
results	O
of	O
supershift	O
analysis	O
using	O
specific	O
antibodies	O
against	O
transcription	B
factors	I
suggested	O
that	O
both	O
binding	O
complexes	O
contained	O
the	O
NF	B
-	I
kappaB	I
components	I
p50	B
and	O
p65	B
,	O
and	O
did	O
not	O
contain	O
other	O
NF	B
-	I
kappaB	I
proteins	I
(	O
p52	B
,	O
c	B
-	I
Rel	I
,	O
Rel	B
B	I
)	O
,	O
AP-1	B
proteins	I
(	O
c	B
-	I
Fos	I
,	O
C	B
-	I
Jun	I
)	O
,	O
CREB	B
or	O
C	B
/	I
EBPbeta	I
(	O
NF	B
-	I
IL6	I
)	O
.	O
Mutation	O
of	O
either	O
of	O
the	O
putative	O
NF	O
-	O
kappaB	O
-	O
binding	O
sites	O
in	O
the	O
enhancer	O
element	O
decreased	O
the	O
LPS	O
-	O
stimulated	O
transcriptional	O
activity	O
.	O
These	O
data	O
indicated	O
that	O
two	O
NF	O
-	O
kappaB	O
-	O
binding	O
sites	O
,	O
which	O
are	O
located	O
between	O
-3134	O
and	O
-3059	O
,	O
are	O
critical	O
for	O
the	O
activation	O
of	O
proIL-1beta	O
gene	O
transcription	O
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
MDS1	O
/	O
EVI1	O
enhances	O
TGF	B
-	I
beta1	I
signaling	O
and	O
strengthens	O
its	O
growth	O
-	O
inhibitory	O
effect	O
but	O
the	O
leukemia	B
-	I
associated	I
fusion	I
protein	I
AML1	B
/	I
MDS1	I
/	I
EVI1	I
,	O
product	O
of	O
the	O
t	O
(	O
3	O
;	O
21	O
)	O
,	O
abrogates	O
growth	O
-	O
inhibition	O
in	O
response	O
to	O
TGF	B
-	I
beta1	I
.	O
MDS1	O
/	O
EVI1	O
,	O
located	O
on	O
chromosome	O
3	O
band	O
q26	O
,	O
encodes	O
a	O
zinc	B
-	I
finger	I
DNA	I
-	I
binding	I
transcription	I
activator	I
not	O
detected	O
in	O
normal	O
hematopoietic	O
cells	O
but	O
expressed	O
in	O
several	O
normal	O
tissues	O
.	O
MDS1	O
/	O
EVI1	O
is	O
inappropriately	O
activated	O
in	O
myeloid	O
leukemias	O
following	O
chromosomal	O
rearrangements	O
involving	O
band	B
3q26	I
.	O
The	O
rearrangements	O
lead	O
either	O
to	O
gene	O
truncation	O
,	O
and	O
to	O
expression	O
of	O
the	O
transcription	B
repressor	I
EVI1	I
,	O
as	O
seen	O
in	O
the	O
t	O
(	O
3	O
;	O
3	O
)	O
(	O
q21	O
;	O
q26	O
)	O
and	O
inv	O
(	O
3	O
)	O
(	O
q21q26	O
)	O
,	O
or	O
to	O
gene	O
fusion	O
,	O
as	O
seen	O
in	O
the	O
t	O
(	O
3	O
;	O
21	O
)	O
(	O
q26	O
;	O
q22	O
)	O
which	O
results	O
in	O
the	O
fusion	O
protein	O
AML1	B
/	I
MDS1	I
/	I
EVI1	I
.	O
This	O
fusion	O
protein	O
contains	O
the	O
DNA	B
-	I
binding	I
domain	I
of	O
the	O
transcription	B
factor	I
AML1	B
fused	O
in	O
-	O
frame	O
to	O
the	O
entire	O
MDS1	O
/	O
EVI1	O
with	O
the	O
exclusion	O
of	O
its	O
first	O
12	O
amino	O
acids	O
.	O
In	O
this	O
report	O
,	O
we	O
have	O
analyzed	O
the	O
response	O
of	O
the	O
hematopoietic	O
precursor	O
cell	O
line	O
32Dcl3	O
,	O
expressing	O
either	O
the	O
normal	B
protein	I
MDS1	I
/	I
EVI1	I
or	O
the	O
fusion	B
protein	I
AML1	I
/	I
MDS1	I
/	I
EVI1	I
,	O
to	O
factors	O
that	O
control	O
cell	O
differentiation	O
or	O
cell	O
replication	O
.	O
The	O
32Dcl3	O
cells	O
are	O
IL-3	B
-dependent	O
for	O
growth	O
and	O
they	O
differentiate	O
into	O
granulocytes	O
when	O
exposed	O
to	O
G	B
-	I
CSF	I
.	O
They	O
are	O
growth	O
-	O
inhibited	O
by	O
TGF	B
-	I
beta1	I
.	O
We	O
show	O
that	O
whereas	O
the	O
expression	O
of	O
MDS1	O
/	O
EVI1	O
has	O
no	O
effect	O
on	O
granulocytic	O
differentiation	O
induced	O
by	O
G	B
-	I
CSF	I
,	O
expression	O
of	O
AML1	B
/	I
MDS1	I
/	I
EVI1	I
blocks	O
differentiation	O
resulting	O
in	O
cell	O
death	O
.	O
This	O
effect	O
is	O
similar	O
to	O
that	O
previously	O
described	O
by	O
others	O
for	O
32Dcl3	O
cells	O
that	O
express	O
transgenic	B
Evil	I
.	O
Furthermore	O
,	O
we	O
show	O
that	O
whereas	O
the	O
expression	O
of	O
the	O
fusion	O
protein	O
AML1	B
/	I
MDS1	I
/	I
EVI1	I
completely	O
abrogates	O
the	O
growth	O
-	O
inhibitory	O
effect	O
of	O
TGF	B
-	I
beta1	I
and	O
allows	O
32Dcl3	O
cells	O
to	O
proliferate	O
,	O
expression	O
of	O
the	O
normal	O
protein	O
MDS1	O
/	O
EVI1	O
has	O
the	O
opposite	O
effect	O
,	O
and	O
it	O
strengthens	O
the	O
response	O
of	O
cells	O
to	O
the	O
growth	O
-	O
inhibitory	O
effect	O
of	O
TGF	B
-	I
beta1	I
.	O
By	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
,	O
we	O
also	O
show	O
that	O
EVI1	B
(	O
contained	O
in	O
its	O
entirety	O
in	O
MDS1	O
/	O
EVI1	O
and	O
AML1	B
/	I
MDS1	I
/	I
EVI1	I
)	O
physically	O
interacts	O
with	O
SMAD3	B
,	O
which	O
is	O
an	O
intracellular	O
mediator	O
of	O
TGF	B
-	I
beta1	I
signaling	O
.	O
Finally	O
,	O
we	O
have	O
correlated	O
the	O
response	O
of	O
the	O
cells	O
to	O
G	B
-	I
CSF	I
or	O
TGF	B
-	I
beta1	I
with	O
the	O
ability	O
of	O
the	O
normal	O
and	O
fusion	B
proteins	I
to	O
activate	O
or	O
repress	O
promoters	O
which	O
they	O
can	O
directly	O
regulate	O
by	O
binding	O
to	O
the	O
promoter	O
site	O
.	O
We	O
propose	O
that	O
mutations	O
of	O
MDS1	O
/	O
EVI1	O
either	O
by	O
gene	O
truncation	O
resulting	O
in	O
the	O
transcription	B
repressor	I
EVI1	I
or	O
by	O
gene	O
fusion	O
to	O
AML1	B
lead	O
to	O
an	O
altered	O
cellular	O
response	O
to	O
growth	O
and	O
differentiation	B
factors	I
that	O
could	O
result	O
in	O
leukemic	O
transformation	O
.	O
The	O
different	O
response	O
of	O
myeloid	O
cells	O
ectopically	O
expressing	O
the	O
normal	O
or	O
the	O
fusion	B
protein	I
to	O
G	B
-	I
CSF	I
and	O
TGF	B
-	I
beta1	I
could	O
depend	O
on	O
the	O
different	O
transactivation	O
properties	O
of	O
these	O
proteins	O
resulting	O
in	O
divergent	O
expression	O
of	O
downstream	O
genes	O
regulated	O
by	O
the	O
two	O
proteins	O
.	O
Identification	O
of	O
upstream	O
regulatory	O
elements	O
that	O
repress	O
expression	O
of	O
adult	O
beta	O
-	O
like	O
globin	O
genes	O
in	O
a	O
primitive	O
erythroid	O
environment	O
.	O
Our	O
investigations	O
have	O
focused	O
on	O
localizing	O
cis	O
-	O
elements	O
responsible	O
for	O
the	O
down	O
regulation	O
of	O
the	O
adult	O
beta	O
-	O
like	O
globin	O
genes	O
(	O
delta	O
and	O
beta	O
)	O
in	O
immature	O
,	O
or	O
primitive	O
erythroid	O
tissues	O
.	O
We	O
studied	O
their	O
activity	O
after	O
transfection	O
into	O
K562	O
cells	O
,	O
an	O
erythroleukemia	O
cell	O
line	O
with	O
an	O
embryonic	O
-	O
fetal	O
phenotype	O
.	O
Analyzed	O
DNA	O
sequences	O
included	O
delta	O
and	O
beta	O
5	O
'	O
flanking	O
regions	O
extending	O
from	O
approximately	O
-500	O
to	O
+	O
50bp	O
(	O
promoter	O
regions	O
)	O
,	O
truncated	O
delta	O
and	O
beta	O
5	O
'	O
flanking	O
regions	O
extending	O
from	O
approximately	O
-250	O
to	O
+	O
50	O
bp	O
,	O
and	O
chimeric	O
promoter	O
constructions	O
,	O
which	O
consisted	O
of	O
a	O
distal	O
delta	O
or	O
beta	O
fragment	O
fused	O
to	O
a	O
proximal	O
beta	O
or	O
delta	O
sequence	O
.	O
In	O
CAT	O
reporter	O
constructions	O
no	O
appreciable	O
level	O
of	O
CAT	B
activity	O
was	O
supported	O
by	O
the	O
beta	O
globin	O
promoter	O
,	O
and	O
only	O
low	O
level	O
activity	O
by	O
the	O
delta	O
promoter	O
.	O
Truncation	O
of	O
the	O
beta	O
globin	O
promoter	O
led	O
to	O
a	O
2	O
-	O
3	O
fold	O
increase	O
in	O
promoter	O
activity	O
.	O
In	O
contrast	O
,	O
deletion	O
of	O
the	O
upstream	O
portion	O
of	O
the	O
delta	O
promoter	O
led	O
to	O
a	O
10	O
fold	O
decrease	O
in	O
expression	O
.	O
Coupling	O
of	O
the	O
upstream	O
beta	O
globin	O
sequence	O
from	O
approximately	O
-500	O
to	O
-250	O
bp	O
to	O
the	O
truncated	O
delta	O
promoter	O
fragment	O
led	O
to	O
complete	O
extinction	O
of	O
transcription	O
activity	O
,	O
consistent	O
with	O
a	O
negative	O
regulatory	O
effect	O
of	O
the	O
beta	O
globin	O
gene	O
upstream	O
element	O
(	O
s	O
)	O
.	O
Fusion	O
of	O
the	O
upstream	O
portion	O
of	O
the	O
delta	O
promoter	O
to	O
the	O
truncated	O
beta	O
globin	O
promoter	O
yielded	O
a	O
modest	O
increase	O
in	O
promoter	O
strength	O
relative	O
to	O
the	O
truncated	O
beta	O
gene	O
promoter	O
,	O
indicating	O
the	O
presence	O
of	O
a	O
positive	O
transcriptional	O
element	O
(	O
s	O
)	O
in	O
the	O
upstream	O
delta	O
globin	O
regulatory	O
region	O
.	O
Site	O
-	O
directed	O
mutagenesis	O
of	O
binding	O
sites	O
for	O
the	O
repressor	B
proteins	I
BP1	I
and	I
BP2	I
in	O
the	O
upstream	O
portion	O
of	O
the	O
beta	O
globin	O
gene	O
flanking	O
region	O
led	O
to	O
a	O
4	O
-	O
6	O
fold	O
increase	O
in	O
promoter	O
activity	O
.	O
DNase	B
I	I
footprinting	O
of	O
the	O
upstream	O
delta	O
-	O
globin	O
region	O
revealed	O
protected	O
sequences	O
corresponding	O
to	O
consensus	O
binding	O
sites	O
for	O
GATA-1	B
and	O
BP2	B
.	O
These	O
results	O
confirm	O
that	O
sequences	O
in	O
the	O
upstream	O
promoter	O
region	O
of	O
the	O
adult	O
beta	O
globin	O
gene	O
contribute	O
to	O
its	O
factor	O
-	O
mediated	O
suppression	O
early	O
in	O
development	O
and	O
then	O
may	O
modulate	O
its	O
expression	O
at	O
a	O
later	O
stage	O
.	O
Interferon	B
-	I
alpha	I
induction	O
of	O
STATs1	B
,	I
-3	I
DNA	O
binding	O
and	O
growth	O
arrest	O
is	O
independent	O
of	O
Lck	B
and	O
active	O
mitogen	B
-	I
activated	I
kinase	I
in	O
T	O
cells	O
.	O
Type	O
I	O
interferons	B
(	O
IFNs	B
)	O
are	O
a	O
family	O
of	O
cytokines	B
that	O
have	O
antiviral	O
and	O
antiproliferative	O
effects	O
.	O
Data	O
regarding	O
the	O
processes	O
by	O
which	O
these	O
cytokines	B
transduce	O
signals	O
from	O
the	O
cell	O
membrane	O
to	O
the	O
nucleus	O
are	O
becoming	O
increasingly	O
complex	O
.	O
The	O
most	O
characterized	O
pathway	O
is	O
via	O
JAK	B
-STAT	B
signaling	O
.	O
Previous	O
studies	O
established	O
a	O
potential	O
role	O
for	O
the	O
Src	B
-	I
family	I
kinase	I
Lck	B
in	O
JAK	B
-STAT	B
signaling	O
.	O
Therefore	O
,	O
this	O
study	O
was	O
designed	O
to	O
analyze	O
the	O
role	O
of	O
Lck	B
in	O
IFN	B
-	I
alpha	I
signaling	O
by	O
using	O
the	O
Jurkat	O
,	O
JCam	O
(	O
an	O
Lck	O
-	O
defective	O
cell	O
line	O
derived	O
from	O
Jurkat	O
)	O
,	O
and	O
JCam	O
/	O
Lck	O
(	O
JCam	O
cells	O
with	O
Lck	B
restored	O
)	O
.	O
The	O
results	O
show	O
that	O
IFN	B
-	I
alpha	I
can	O
induce	O
MAPK	B
activity	O
,	O
but	O
only	O
in	O
cells	O
containing	O
Lck	B
.	O
Furthermore	O
,	O
STATs1	B
and	I
-3	I
are	O
effectively	O
phosphorylated	O
and	O
activated	O
to	O
bind	O
DNA	O
in	O
the	O
absence	O
of	O
Lck	B
expression	O
in	O
IFN	O
-	O
alpha	O
-	O
treated	O
cells	O
.	O
Finally	O
,	O
the	O
results	O
demonstrate	O
that	O
IFN	B
-	I
alpha	I
exerts	O
an	O
antiproliferative	O
effect	O
in	O
all	O
three	O
cell	O
lines	O
.	O
These	O
data	O
indicate	O
that	O
Lck	B
and	O
active	O
MAPK	B
do	O
not	O
affect	O
IFN	B
-	I
alpha	I
-induced	O
growth	O
arrest	O
or	O
induction	O
of	O
STAT1s1	O
and	O
-3	O
DNA	O
binding	O
ability	O
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
Decreased	O
proteasome	B
-mediated	O
degradation	O
in	O
T	O
cells	O
from	O
the	O
elderly	O
:	O
A	O
role	O
in	O
immune	O
senescence	O
.	O
Induction	O
of	O
NFkappaB	B
is	O
a	O
highly	O
regulated	O
process	O
requiring	O
phosphorylation	O
,	O
ubiquitination	O
,	O
and	O
proteasome	B
-mediated	O
degradation	O
of	O
the	O
cytosolic	B
inhibitor	I
IkappaBalpha	B
.	O
Analyses	O
of	O
the	O
regulation	O
of	O
IkappaBalpha	B
in	O
TNF	O
-	O
alpha	O
-	O
treated	O
T	O
lymphocytes	O
from	O
young	O
and	O
elderly	O
donors	O
revealed	O
severely	O
compromised	O
degradation	O
of	O
IkappaBalpha	B
in	O
T	O
cells	O
from	O
the	O
elderly	O
.	O
Examination	O
of	O
activation	O
-	O
induced	O
phosphorylation	O
and	O
ubiquitination	O
of	O
IkappaBalpha	B
did	O
not	O
demonstrate	O
any	O
significant	O
age	O
-	O
related	O
alterations	O
.	O
However	O
,	O
examination	O
of	O
proteasome	B
activity	O
in	O
these	O
T	O
cells	O
using	O
fluorogenic	O
peptide	O
assays	O
revealed	O
a	O
significant	O
age	O
-	O
related	O
decline	O
in	O
chymotryptic	O
activity	O
.	O
These	O
results	O
suggest	O
that	O
a	O
decline	O
in	O
proteasome	B
activity	O
results	O
in	O
a	O
failure	O
to	O
fully	O
degrade	O
IkappaBalpha	B
in	O
the	O
elderly	O
.	O
This	O
failure	O
to	O
degrade	O
IkappaBalpha	B
may	O
underlie	O
both	O
the	O
observed	O
decrease	O
in	O
NFkappaB	B
induction	O
and	O
the	O
IL-2	B
receptor	O
expression	O
in	O
TNF	O
-	O
treated	O
T	O
cells	O
during	O
aging	O
.	O
Thus	O
,	O
decreased	O
proteasome	B
-mediated	O
degradation	O
may	O
be	O
central	O
to	O
immune	O
dysfunction	O
that	O
accompanies	O
aging	O
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
Estrone	O
potentiates	O
myeloid	O
cell	O
differentiation	O
:	O
a	O
role	O
for	O
17	B
beta	I
-	I
hydroxysteroid	I
dehydrogenase	I
in	O
modulating	O
hemopoiesis	O
.	O
Hormones	O
such	O
as	O
1	O
alpha	O
,	O
25-dihydroxy	O
vitamin	O
D3	O
(	O
D3	O
)	O
,	O
all	O
-	O
trans	O
retinoic	O
acid	O
,	O
and	O
9-cis	O
retinoic	O
acid	O
stimulate	O
differentiation	O
of	O
myeloid	O
progenitor	O
cells	O
via	O
their	O
interaction	O
with	O
specific	O
hormone	B
receptors	I
.	O
However	O
,	O
the	O
sensitivity	O
of	O
cells	O
to	O
these	O
agents	O
is	O
not	O
merely	O
governed	O
by	O
the	O
expression	O
of	O
their	O
receptors	O
and	O
the	O
availability	O
of	O
ligand	O
to	O
bind	O
them	O
.	O
Recent	O
studies	O
from	O
our	O
group	O
suggested	O
that	O
the	O
actions	O
of	O
D3	O
and	O
retinoids	O
on	O
myelopoiesis	O
also	O
are	O
influenced	O
by	O
endogenous	O
mechanisms	O
involving	O
other	O
steroid	O
hormones	O
.	O
In	O
this	O
study	O
we	O
examined	O
the	O
influence	O
of	O
local	O
estrogen	O
metabolism	O
on	O
the	O
differentiation	O
of	O
HL60	O
cells	O
and	O
normal	O
primitive	O
myeloid	O
progenitor	O
cells	O
.	O
Quantitative	O
thin	O
-	O
layer	O
chromatography	O
(	O
TLC	O
)	O
analyses	O
showed	O
that	O
HL60	O
and	O
normal	O
cells	O
are	O
able	O
to	O
generate	O
estrone	O
(	O
E1	O
)	O
from	O
estradiol	O
(	O
E2	O
)	O
.	O
Neither	O
cell	O
population	O
generated	O
significant	O
amounts	O
of	O
E2	O
from	O
E1	O
.	O
Reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
and	O
Northern	O
analyses	O
confirmed	O
that	O
normal	O
and	O
leukemic	O
myeloid	O
progenitor	O
cells	O
expressed	O
mRNA	O
for	O
the	O
type	O
I	O
and	O
IV	O
isoforms	O
of	O
17	B
beta	I
-	I
hydroxysteroid	I
dehydrogenase	I
.	O
Conversion	O
of	O
E2	O
to	O
E1	O
was	O
upregulated	O
within	O
24	O
hours	O
when	O
HL60	O
cells	O
were	O
treated	O
with	O
either	O
all	O
-	O
trans	O
retinoic	O
acid	O
or	O
D3	O
at	O
doses	O
that	O
induce	O
their	O
differentiation	O
toward	O
neutrophils	O
or	O
monocytes	O
,	O
respectively	O
.	O
Similarly	O
,	O
D3-induced	O
monocyte	O
differentiation	O
of	O
normal	O
myeloid	O
progenitor	O
cells	O
was	O
associated	O
with	O
increased	O
capacity	O
to	O
generate	O
E1	O
from	O
E2	O
.	O
When	O
HL60	O
cells	O
or	O
normal	O
myeloid	O
progenitor	O
cells	O
were	O
exposed	O
to	O
exogenous	O
E1	O
they	O
became	O
more	O
sensitive	O
to	O
the	O
differentiation	O
-	O
inducing	O
effects	O
of	O
D3	O
.	O
Data	O
presented	O
provide	O
further	O
evidence	O
for	O
the	O
local	O
modulation	O
of	O
myelopoiesis	O
by	O
intracrine	O
mechanisms	O
.	O
In	O
particular	O
,	O
our	O
findings	O
suggest	O
that	O
local	O
metabolism	O
of	O
steroids	O
by	O
normal	O
as	O
well	O
as	O
leukemic	O
myeloid	O
cells	O
influences	O
their	O
responsiveness	O
to	O
D3	O
and	O
retinoids	O
.	O
Interferon	B
-	I
beta	I
mediates	O
stromal	O
cell	O
rescue	O
of	O
T	O
cells	O
from	O
apoptosis	O
.	O
The	O
resolution	O
of	O
immune	O
responses	O
is	O
characterized	O
by	O
extensive	O
apoptosis	O
of	O
activated	O
T	O
cells	O
.	O
However	O
,	O
to	O
generate	O
and	O
maintain	O
immunological	O
memory	O
,	O
some	O
antigen	O
-	O
specific	O
T	O
cells	O
must	O
survive	O
and	O
revert	O
to	O
a	O
resting	O
G0	O
/	O
G1	O
state	O
.	O
Cytokines	B
that	O
bind	O
to	O
the	O
common	O
gamma	B
chain	I
of	O
the	O
IL-2	B
receptor	O
promote	O
the	O
survival	O
of	O
T	O
cell	O
blasts	O
,	O
but	O
also	O
induce	O
proliferation	O
.	O
In	O
contrast	O
,	O
soluble	B
factors	I
secreted	O
by	O
stromal	O
cells	O
induce	O
Tcell	O
survival	O
in	O
a	O
resting	O
G0	O
/	O
G1	O
state	O
.	O
We	O
now	O
report	O
that	O
interferon	O
-	O
beta	O
is	O
the	O
principal	O
mediator	O
of	O
stromal	O
cell	O
-	O
mediated	O
Tcell	O
rescue	O
from	O
apoptosis	O
.	O
Interferon	B
-	I
alpha	I
and	I
-beta	I
promote	O
the	O
reversion	O
of	O
blast	O
Tcells	O
to	O
a	O
resting	O
G0	O
/	O
G1	O
configuration	O
with	O
all	O
the	O
characteristic	O
features	O
of	O
stromal	O
cell	O
rescue	O
;	O
such	O
as	O
high	O
Bcl	B
-	I
XL	I
expression	O
and	O
low	O
Bcl-2	B
.	O
Type	B
I	I
interferons	I
and	O
stromal	O
cells	O
stimulate	O
apparently	O
identical	O
signaling	O
pathways	O
,	O
leading	O
to	O
STAT-1	B
activation	O
.	O
We	O
also	O
show	O
that	O
this	O
mechanism	O
may	O
play	O
a	O
fundamental	O
role	O
in	O
the	O
persistence	O
of	O
T	O
cells	O
at	O
sites	O
of	O
chronic	O
inflammation	O
;	O
suggesting	O
that	O
chronic	O
inflammation	O
is	O
an	O
aberrant	O
consequence	O
of	O
immunological	O
memory	O
.	O
Reduction	O
of	O
tumour	B
necrosis	I
factor	I
alpha	I
expression	O
and	O
signalling	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
patients	O
with	O
thalassaemia	O
or	O
sickle	O
cell	O
anaemia	O
upon	O
treatment	O
with	O
desferrioxamine	O
.	O
Recent	O
evidence	O
indicates	O
that	O
the	O
rate	O
of	O
progression	O
of	O
the	O
HIV-1	O
disease	O
is	O
significantly	O
reduced	O
in	O
thalassaemia	O
major	O
patients	O
upon	O
treatment	O
with	O
high	O
doses	O
of	O
desferrioxamine	O
(	O
DFX	O
)	O
.	O
The	O
authors	O
have	O
previously	O
demonstrated	O
that	O
in	O
vitro	O
exposure	O
of	O
mononuclear	O
cells	O
to	O
DFX	O
decreases	O
the	O
bioavailability	O
of	O
tumour	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
which	O
has	O
a	O
stimulatory	O
effect	O
on	O
HIV-1	O
replication	O
.	O
In	O
this	O
study	O
,	O
therefore	O
,	O
TNF	B
-	I
alpha	I
bioavailability	O
from	O
mononuclear	O
cells	O
isolated	O
from	O
10	O
patients	O
with	O
thalassaemia	O
or	O
sickle	O
cell	O
anaemia	O
given	O
DFX	O
as	O
compared	O
to	O
10	O
untreated	O
subjects	O
has	O
been	O
evaluated	O
.	O
Evidence	O
is	O
presented	O
showing	O
that	O
DFX	O
treatment	O
reduces	O
TNF	B
-	I
alpha	I
bioavailability	O
(	O
P	O
<	O
0.05	O
)	O
by	O
inhibiting	O
its	O
steady	O
state	O
(	O
P	O
<	O
0.05	O
)	O
and	O
by	O
enhancing	O
its	O
inactivation	O
through	O
binding	O
to	O
soluble	O
TNF	B
-	I
alpha	I
receptor	O
type	O
II	O
(	O
P	O
<	O
0.05	O
)	O
.	O
We	O
also	O
show	O
that	O
DFX	O
treatment	O
limits	O
the	O
in	O
vivo	O
activation	O
of	O
NF	B
-	I
kappaB	I
,	O
a	O
transcription	B
factor	I
involved	O
in	O
both	O
TNF	B
-	I
alpha	I
gene	O
transcription	O
and	O
TNF	B
-	I
alpha	I
signalling	O
(	O
P	O
<	O
0.005	O
)	O
.	O
We	O
conclude	O
that	O
TNF	B
-	I
alpha	I
bioavailability	O
and	O
signalling	O
are	O
impaired	O
in	O
patients	O
upon	O
DFX	O
treatment	O
.	O
This	O
mechanism	O
may	O
contribute	O
to	O
delayed	O
progression	O
of	O
the	O
HIV-1	O
infection	O
in	O
vivo	O
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
Involvement	O
of	O
adenylate	B
cyclase	I
and	O
p70	B
(	I
S6	I
)	I
-kinase	I
activation	O
in	O
IL-10	B
up	O
-	O
regulation	O
in	O
human	O
monocytes	O
by	O
gp41	B
envelope	I
protein	I
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O
Our	O
previous	O
results	O
show	O
that	O
recombinant	B
gp41	I
(	O
aa565	B
-	I
647	I
)	O
,	O
the	O
extracellular	B
domain	I
of	O
HIV-1	B
transmembrane	I
glycoprotein	I
,	O
stimulates	O
interleukin-10	B
(	O
IL-10	B
)	O
production	O
in	O
human	O
monocytes	O
.	O
The	O
signal	O
cascade	O
transducing	O
this	O
effect	O
is	O
not	O
yet	O
clear	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
gp41	B
-induced	O
IL-10	B
up	O
-	O
regulation	O
is	O
mediated	O
by	O
the	O
previously	O
described	O
synergistic	O
activation	O
of	O
cAMP	O
and	O
NF	B
-	I
kappaB	I
pathways	O
.	O
gp41	B
induced	O
cAMP	O
accumulation	O
in	O
monocytes	O
in	O
a	O
time-	O
and	O
concentration	O
-	O
dependent	O
manner	O
and	O
the	O
adenylate	B
cyclase	I
inhibitor	O
SQ	O
22536	O
suppressed	O
gp41	B
-induced	O
IL-10	B
production	O
in	O
monocytes	O
.	O
In	O
contrast	O
,	O
gp41	B
failed	O
to	O
stimulate	O
NF	B
-	I
kappaB	I
binding	O
activity	O
in	O
as	O
much	O
as	O
no	O
NF	B
-	I
kappaB	I
bound	O
to	O
the	O
main	O
NF	O
-	O
kappaB	O
-	O
binding	O
site	O
2	O
of	O
the	O
IL-10	O
promoter	O
after	O
addition	O
of	O
gp41	B
.	O
We	O
also	O
examined	O
the	O
involvement	O
of	O
other	O
signal	O
transduction	O
pathways	O
.	O
Specific	O
inhibitors	O
of	O
p70	B
(	I
S6	I
)	I
-kinase	I
(	O
rapamycin	O
)	O
,	O
and	O
Gi	B
protein	I
(	O
pertussis	B
toxin	I
)	O
,	O
prevented	O
induction	O
of	O
IL-10	B
production	O
by	O
gp41	B
in	O
monocytes	O
,	O
while	O
inhibitors	O
of	O
the	O
phosphatidylinositol	B
3-kinase	I
(	O
PI	B
3-kinase	I
)	O
(	O
wortmannin	O
)	O
and	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	B
)	O
pathway	O
(	O
PD	O
98059	O
)	O
did	O
not	O
.	O
Thus	O
HIV-1	O
gp41	B
-induced	O
IL-10	B
up	O
-	O
regulation	O
in	O
monocytes	O
may	O
not	O
involve	O
NF	B
-	I
kappaB	I
,	O
MAPK	B
,	O
or	O
PI	B
3-kinase	I
activation	O
,	O
but	O
rather	O
may	O
operate	O
through	O
activation	O
of	O
adenylate	B
cyclase	I
and	O
pertussis	B
-	I
toxin	I
-	I
sensitive	I
Gi	I
/	I
Go	I
protein	I
to	O
effect	O
p70	B
(	I
S6	I
)	I
-kinase	I
activation	O
.	O
Nonimmunoglobulin	O
gene	O
hypermutation	O
in	O
germinal	O
center	O
B	O
cells	O
.	O
Somatic	O
hypermutation	O
is	O
the	O
most	O
critical	O
mechanism	O
underlying	O
the	O
diversification	O
of	O
Ig	O
genes	O
.	O
Although	O
mutation	O
occurs	O
specifically	O
in	O
B	O
cells	O
during	O
the	O
germinal	O
center	O
reaction	O
,	O
it	O
remains	O
a	O
matter	O
of	O
debate	O
whether	O
the	O
mutation	O
machinery	O
also	O
targets	O
non	O
-	O
Ig	O
genes	O
.	O
We	O
have	O
studied	O
mutations	O
in	O
the	O
5	O
'	O
noncoding	O
region	O
of	O
the	O
Bcl6	O
gene	O
in	O
different	O
subtypes	O
of	O
lymphomas	O
.	O
We	O
found	O
frequent	O
hypermutation	O
in	O
follicular	O
lymphoma	O
(	O
25	O
of	O
59	O
=	O
42	O
%	O
)	O
(	O
germinal	O
center	O
cell	O
origin	O
)	O
and	O
mucosa	O
-	O
associated	O
lymphoid	O
tissue	O
(	O
MALT	O
)	O
lymphoma	O
(	O
19	O
of	O
45	O
=	O
42	O
%	O
)	O
(	O
postgerminal	O
center	O
)	O
,	O
but	O
only	O
occasionally	O
in	O
mantle	O
cell	O
lymphoma	O
(	O
1	O
of	O
21	O
=	O
4.8	O
%	O
)	O
(	O
pregerminal	O
center	O
)	O
.	O
Most	O
mutations	O
were	O
outside	O
the	O
motifs	O
potentially	O
important	O
for	O
transcription	O
,	O
suggesting	O
they	O
were	O
not	O
important	O
in	O
lymphomagenesis	O
but	O
may	O
,	O
like	O
Ig	O
mutation	O
,	O
represent	O
an	O
inherent	O
feature	O
of	O
the	O
lymphoma	O
precursor	O
cells	O
.	O
Therefore	O
,	O
we	O
investigated	O
their	O
normal	O
cell	O
counterparts	O
microdissected	O
from	O
a	O
reactive	O
tonsil	O
.	O
Bcl6	O
mutation	O
was	O
found	O
in	O
13	O
of	O
24	O
(	O
54	O
%	O
)	O
clones	O
from	O
the	O
germinal	O
centre	O
but	O
only	O
in	O
1	O
of	O
24	O
(	O
4	O
%	O
)	O
clones	O
from	O
the	O
naive	O
B	O
cells	O
of	O
the	O
mantle	O
zone	O
.	O
The	O
frequency	O
,	O
distribution	O
,	O
and	O
nature	O
of	O
these	O
mutations	O
were	O
similar	O
to	O
those	O
resulting	O
from	O
the	O
Ig	O
hypermutation	O
process	O
.	O
The	O
results	O
show	O
unequivocal	O
evidence	O
of	O
non-	O
Ig	O
gene	O
hypermutation	O
in	O
germinal	O
center	O
B	O
cells	O
and	O
provide	O
fresh	O
insights	O
into	O
the	O
process	O
of	O
hypermutation	O
and	O
lymphomagenesis	O
.	O
Human	O
immunodeficiency	O
virus	O
-	O
associated	O
Hodgkin	O
's	O
disease	O
derives	O
from	O
post	O
-	O
germinal	O
center	O
B	O
cells	O
.	O
Human	O
immunodeficiency	O
virus	O
-	O
associated	O
Hodgkin	O
's	O
disease	O
(	O
HIV	O
-	O
HD	O
)	O
displays	O
several	O
peculiarities	O
when	O
compared	O
with	O
HD	O
of	O
the	O
general	O
population	O
.	O
These	O
include	O
overrepresentation	O
of	O
clinically	O
aggressive	O
histologic	O
types	O
and	O
frequent	O
infection	O
of	O
Reed	O
-	O
Sternberg	O
(	O
RS	O
)	O
cells	O
by	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O
Recently	O
,	O
we	O
have	O
reported	O
that	O
the	O
histogenesis	O
of	O
HD	O
of	O
the	O
general	O
population	O
may	O
be	O
assessed	O
by	O
monitoring	O
the	O
expression	O
pattern	O
of	O
BCL-6	B
,	O
a	O
transcription	B
factor	I
expressed	O
in	O
germinal	O
center	O
(	O
GC	O
)	O
B	O
cells	O
,	O
and	O
of	O
CD138	B
/	I
syndecan-1	I
(	O
syn-1	B
)	O
,	O
a	O
proteoglycan	O
associated	O
with	O
post	O
-	O
GC	O
,	O
terminal	O
B	O
-	O
cell	O
differentiation	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
applied	O
these	O
two	O
markers	O
to	O
the	O
study	O
of	O
HIV	O
-	O
HD	O
histogenesis	O
and	O
correlated	O
their	O
expression	O
status	O
to	O
the	O
virologic	O
features	O
of	O
this	O
disease	O
.	O
We	O
have	O
found	O
that	O
RS	O
cells	O
of	O
all	O
histologic	O
categories	O
of	O
HIV	O
-	O
HD	O
consistently	O
display	O
the	O
BCL-6	B
(	O
-	O
)	O
/syn-1	O
(	O
+	O
)	O
phenotype	O
and	O
thus	O
reflect	O
post	O
-	O
GC	O
B	O
cells	O
.	O
Although	O
BCL-6	B
(	O
-	O
)	O
/syn-1	O
(	O
+	O
)	O
RS	O
cells	O
of	O
HIV	O
-	O
HD	O
express	O
CD40	B
,	O
they	O
are	O
not	O
surrounded	O
by	O
CD40	O
ligand	O
-	O
positive	O
(	O
CD40L+	O
)	O
reactive	O
T	O
lymphocytes	O
,	O
which	O
,	O
in	O
HD	O
of	O
the	O
general	O
population	O
,	O
are	O
thought	O
to	O
regulate	O
the	O
disease	O
phenotype	O
through	O
CD40	B
/CD40L	B
interactions	O
.	O
Conversely	O
,	O
RS	O
cells	O
of	O
virtually	O
all	O
HIV	O
-	O
HD	O
express	O
the	O
EBV	B
-	I
encoded	I
latent	I
membrane	I
protein	I
1	I
(	O
LMP1	B
)	O
,	O
which	O
,	O
being	O
functionally	O
homologous	O
to	O
CD40	B
,	O
may	O
contribute	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
modulation	O
of	O
the	O
HIV	O
-	O
HD	O
phenotype	O
.	O
Evidence	O
for	O
distinct	O
intracellular	O
signaling	O
pathways	O
in	O
CD34	O
+	O
progenitor	O
to	O
dendritic	O
cell	O
differentiation	O
from	O
a	O
human	O
cell	O
line	O
model	O
.	O
Intracellular	O
signals	O
that	O
mediate	O
differentiation	O
of	O
pluripotent	O
hemopoietic	O
progenitors	O
to	O
dendritic	O
cells	O
(	O
DC	O
)	O
are	O
largely	O
undefined	O
.	O
We	O
have	O
previously	O
shown	O
that	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
activation	O
(	O
with	O
phorbol	O
ester	O
(	O
PMA	O
)	O
alone	O
)	O
specifically	O
induces	O
differentiation	O
of	O
primary	O
human	O
CD34	O
+	O
hemopoietic	O
progenitor	O
cells	O
(	O
HPC	O
)	O
to	O
mature	O
DC	O
.	O
We	O
now	O
find	O
that	O
cytokine	O
-	O
driven	O
(	O
granulocyte	O
-	O
macrophage	O
CSF	O
and	O
TNF	O
-	O
alpha	O
)	O
CD34	O
+	O
HPC	O
--	O
>	O
DC	O
differentiation	O
is	O
preferentially	O
blocked	O
by	O
inhibitors	O
of	O
PKC	B
activation	O
.	O
To	O
further	O
identify	O
intracellular	O
signals	O
and	O
downstream	O
events	O
important	O
in	O
CD34	O
+	O
HPC	O
--	O
>	O
DC	O
differentiation	O
we	O
have	O
characterized	O
a	O
human	O
leukemic	O
cell	O
line	O
model	O
of	O
this	O
process	O
.	O
The	O
CD34	O
+	O
myelomonocytic	O
cell	O
line	O
KG1	O
differentiates	O
into	O
dendritic	O
-	O
like	O
cells	O
in	O
response	O
to	O
granulocyte	B
-	I
macrophage	I
CSF	I
plus	O
TNF	B
-	I
alpha	I
,	O
or	O
PMA	O
(	O
with	O
or	O
without	O
the	O
calcium	O
ionophore	O
ionomycin	O
,	O
or	O
TNF	B
-	I
alpha	I
)	O
,	O
with	O
different	O
stimuli	O
mediating	O
different	O
aspects	O
of	O
the	O
process	O
.	O
Phenotypic	O
DC	O
characteristics	O
of	O
KG1	O
dendritic	O
-	O
like	O
cells	O
include	O
morphology	O
(	O
loosely	O
adherent	O
cells	O
with	O
long	O
neurite	O
processes	O
)	O
,	O
MHC	B
I+	O
/	O
MHC	B
IIbright	O
/	O
CD83+	O
/	O
CD86+	O
/	O
CD14	B
-	O
surface	O
Ag	O
expression	O
,	O
and	O
RelB	B
and	O
DC	O
-CK1	O
gene	O
expression	O
.	O
Functional	O
DC	O
characteristics	O
include	O
fluid	O
phase	O
macromolecule	O
uptake	O
(	O
FITC	O
-	O
dextran	O
)	O
and	O
activation	O
of	O
resting	O
T	O
cells	O
.	O
Comparison	O
of	O
KG1	O
to	O
the	O
PMA	O
-	O
unresponsive	O
subline	O
KG1a	O
reveals	O
differences	O
in	O
expression	O
of	O
TNF	B
receptors	I
1	I
and	I
2	I
;	O
PKC	B
isoforms	I
alpha	I
,	I
beta	I
I	I
,	I
beta	I
II	I
,	I
and	I
mu	I
;	O
and	O
RelB	B
,	O
suggesting	O
that	O
these	O
components	O
/	O
pathways	O
are	O
important	O
for	O
DC	O
differentiation	O
.	O
Together	O
,	O
these	O
findings	O
demonstrate	O
that	O
cytokine	O
or	O
phorbol	O
ester	O
stimulation	O
of	O
KG1	O
is	O
a	O
model	O
of	O
human	O
CD34	O
+	O
HPC	O
to	O
DC	O
differentiation	O
and	O
suggest	O
that	O
specific	O
intracellular	O
signaling	O
pathways	O
mediate	O
specific	O
events	O
in	O
DC	O
lineage	O
commitment	O
.	O
Glucocorticoids	O
promote	O
nonphlogistic	O
phagocytosis	O
of	O
apoptotic	O
leukocytes	O
.	O
Phagocyte	O
recognition	O
,	O
uptake	O
,	O
and	O
nonphlogistic	O
degradation	O
of	O
neutrophils	O
and	O
other	O
leukocytes	O
undergoing	O
apoptosis	O
promote	O
the	O
resolution	O
of	O
inflammation	O
.	O
This	O
study	O
assessed	O
the	O
effects	O
of	O
anti	O
-	O
inflammatory	O
glucocorticoids	O
on	O
this	O
leukocyte	O
clearance	O
mechanism	O
.	O
Pretreatment	O
of	O
`	O
`	O
semimature	O
''	O
5-day	O
human	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
M	O
phi	O
)	O
for	O
24	O
h	O
with	O
methylprednisolone	O
,	O
dexamethasone	O
,	O
and	O
hydrocortisone	O
,	O
but	O
not	O
the	O
nonglucocorticoid	O
steroids	O
aldosterone	O
,	O
estradiol	O
,	O
and	O
progesterone	O
,	O
potentiated	O
phagocytosis	O
of	O
apoptotic	O
neutrophils	O
.	O
These	O
effects	O
were	O
specific	O
in	O
that	O
the	O
potentiated	O
phagocytosis	O
of	O
apoptotic	O
neutrophils	O
was	O
completely	O
blocked	O
by	O
the	O
glucocorticoid	B
receptor	I
antagonist	O
RU38486	O
,	O
and	O
glucocorticoids	O
did	O
not	O
promote	O
5-day	O
M	O
phi	O
ingestion	O
of	O
opsonized	O
erythrocytes	O
.	O
Similar	O
glucocorticoid	O
-	O
mediated	O
potentiation	O
was	O
observed	O
with	O
5-day	O
M	O
phi	O
uptake	O
of	O
alternative	O
apoptotic	O
`	O
`	O
targets	O
''	O
(	O
eosinophils	O
and	O
Jurkat	O
T	O
cells	O
)	O
and	O
in	O
uptake	O
of	O
apoptotic	O
neutrophils	O
by	O
alternative	O
phagocytes	O
(	O
human	O
glomerular	O
mesangial	O
cells	O
and	O
murine	O
M	O
phi	O
elicited	O
into	O
the	O
peritoneum	O
or	O
derived	O
from	O
bone	O
marrow	O
)	O
.	O
Importantly	O
,	O
methylprednisolone	O
-	O
mediated	O
enhancement	O
of	O
the	O
uptake	O
of	O
apoptotic	O
neutrophils	O
did	O
not	O
trigger	O
the	O
release	O
of	O
the	O
chemokines	B
IL-8	B
and	O
monocyte	B
chemoattractant	I
protein-1	I
.	O
Furthermore	O
,	O
longer	O
-	O
term	O
potentiation	O
by	O
methylprednisolone	O
was	O
observed	O
in	O
maturing	O
human	O
monocyte	O
-	O
derived	O
M	O
phi	O
,	O
with	O
greater	O
increases	O
in	O
5-day	O
M	O
phi	O
uptake	O
of	O
apoptotic	O
cells	O
being	O
observed	O
the	O
earlier	O
glucocorticoids	O
were	O
added	O
during	O
monocyte	O
maturation	O
into	O
M	O
phi	O
.	O
We	O
conclude	O
that	O
potentiation	O
of	O
nonphlogistic	O
clearance	O
of	O
apoptotic	O
leukocytes	O
by	O
phagocytes	O
is	O
a	O
hitherto	O
unrecognized	O
property	O
of	O
glucocorticoids	O
that	O
has	O
potential	O
implications	O
for	O
therapies	O
aimed	O
at	O
promoting	O
the	O
resolution	O
of	O
inflammatory	O
diseases	O
.	O
Stimulation	O
of	O
CD40	B
on	O
immunogenic	O
human	O
malignant	O
melanomas	O
augments	O
their	O
cytotoxic	O
T	O
lymphocyte	O
-mediated	O
lysis	O
and	O
induces	O
apoptosis	O
.	O
Here	O
,	O
we	O
report	O
the	O
functional	O
expression	O
of	O
CD40	B
on	O
human	O
malignant	O
melanomas	O
(	O
MMs	O
)	O
.	O
Comparison	O
of	O
tumor	O
specimen	O
from	O
MM	O
precursor	O
lesions	O
,	O
primary	O
tumors	O
,	O
and	O
metastases	O
revealed	O
that	O
CD40	B
surface	O
expression	O
is	O
down	O
-	O
regulated	O
during	O
tumor	O
progression	O
.	O
CD40	B
expression	O
was	O
confirmed	O
in	O
7	O
human	O
MM	O
cell	O
lines	O
established	O
from	O
immunogenic	O
primary	O
tumors	O
or	O
metastases	O
,	O
whereas	O
11	O
cell	O
lines	O
established	O
from	O
advanced	O
stages	O
were	O
CD40	B
negative	O
.	O
CD40	B
expression	O
could	O
be	O
enhanced	O
in	O
CD40	B
-positive	O
MM	O
by	O
stimulation	O
with	O
IFN	B
-	I
gamma	I
and	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
but	O
not	O
by	O
interleukin	B
(	I
IL	I
)	I
-1beta	I
or	O
CD40	B
triggering	O
.	O
CD40	B
ligation	O
on	O
MM	O
by	O
CD40L	O
-	O
transfected	O
murine	O
L	O
-	O
cells	O
or	O
by	O
a	O
soluble	O
CD40L	B
fusion	I
protein	I
up	O
-	O
regulated	O
their	O
expression	O
of	O
intercellular	B
adhesion	I
molecule-1	I
and	O
MHC	B
class	I
I	I
and	I
class	I
II	I
molecules	I
and	O
their	O
secretion	O
of	O
IL-6	B
,	O
IL-8	B
,	O
tumor	B
necrosis	I
factor	I
-	I
a	I
,	O
and	O
granulocyte	B
macrophage	I
colony	I
-	I
stimulating	I
factor	I
and	O
also	O
induced	O
a	O
rapid	O
activation	O
of	O
the	O
transcription	B
factor	I
nuclear	B
factor	I
kappaB	I
.	O
Furthermore	O
,	O
CD40	B
ligation	O
of	O
a	O
HLA	O
-	O
A2	O
+	O
,	O
MelanA	O
/	O
MART1	O
+	O
MM	O
cell	O
line	O
enhanced	O
its	O
susceptibility	O
to	O
specific	O
lysis	O
by	O
a	O
HLA	O
-	O
A2-restricted	O
,	O
MelanA	O
/	O
MART-1-specific	O
CTL	O
clone	O
.	O
Finally	O
,	O
CD40	B
ligation	O
induced	O
growth	O
inhibition	O
and	O
apoptosis	O
in	O
MM	O
.	O
These	O
results	O
indicate	O
that	O
CD40	B
-CD40L	B
interactions	O
may	O
play	O
an	O
important	O
role	O
in	O
augmenting	O
antitumor	O
immunity	O
and	O
inducing	O
apoptosis	O
in	O
some	O
CD40	B
-positive	O
immunogenic	O
human	O
MMs	O
.	O
Glucocorticoid	O
-	O
induced	O
cell	O
death	O
requires	O
autoinduction	O
of	O
glucocorticoid	B
receptor	I
expression	O
in	O
human	O
leukemic	O
T	O
cells	O
.	O
In	O
contrast	O
to	O
the	O
negative	O
autoregulation	O
of	O
glucocorticoid	B
receptor	I
(	O
GR	B
)	O
expression	O
seen	O
in	O
most	O
cells	O
and	O
tissues	O
,	O
GR	B
expression	O
is	O
positively	O
autoregulated	O
in	O
human	O
leukemic	O
T	O
cells	O
and	O
in	O
other	O
cells	O
sensitive	O
to	O
glucocorticoid	O
-	O
induced	O
cell	O
death	O
.	O
To	O
determine	O
whether	O
positive	O
autoregulation	O
is	O
a	O
necessary	O
component	O
of	O
glucocorticoid	O
-	O
induced	O
cell	O
death	O
,	O
a	O
wild	O
-	O
type	O
GR	O
gene	O
under	O
the	O
control	O
of	O
a	O
tetracycline	O
-	O
regulated	O
promoter	O
was	O
stably	O
transfected	O
into	O
glucocorticoid	O
-	O
resistant	O
cells	O
lacking	O
endogenous	O
functional	O
receptor	O
.	O
Transfectants	O
grown	O
in	O
the	O
presence	O
of	O
tetracycline	O
contained	O
about	O
15	O
,	O
000	O
receptors	O
/	O
cell	O
,	O
a	O
value	O
approximately	O
equal	O
to	O
basal	O
level	O
GR	B
expression	O
in	O
glucocorticoid	O
-	O
sensitive	O
6TG1.1	O
cells	O
before	O
steroid	O
treatment	O
.	O
Under	O
these	O
conditions	O
,	O
dexamethasone	O
had	O
a	O
minimal	O
effect	O
on	O
cell	O
growth	O
,	O
elicited	O
little	O
internucleosomal	O
DNA	O
fragmentation	O
,	O
and	O
induced	O
no	O
cell	O
cycle	O
perturbation	O
.	O
In	O
the	O
absence	O
of	O
tetracycline	O
,	O
GR	O
mRNA	O
and	O
protein	O
expression	O
increased	O
2	O
-	O
3-fold	O
,	O
and	O
cells	O
expressed	O
48	O
,	O
000	O
receptors	O
,	O
a	O
level	O
nearly	O
equivalent	O
to	O
that	O
present	O
in	O
6TG1.1	O
cells	O
after	O
18	O
h	O
of	O
autoinduction	O
.	O
Under	O
these	O
conditions	O
,	O
dexamethasone	O
markedly	O
inhibited	O
cell	O
growth	O
,	O
caused	O
G1	O
arrest	O
,	O
and	O
induced	O
significant	O
internucleosomal	O
DNA	O
fragmentation	O
.	O
These	O
studies	O
therefore	O
suggest	O
that	O
basal	O
level	O
GR	B
expression	O
is	O
inadequate	O
to	O
mediate	O
glucocorticoid	O
-	O
induced	O
apoptosis	O
in	O
glucocorticoid	O
-	O
sensitive	O
T	O
cells	O
and	O
that	O
positive	O
autoregulation	O
is	O
a	O
necessary	O
component	O
of	O
this	O
process	O
.	O
Expression	O
of	O
IkappaBalpha	B
in	O
the	O
nucleus	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
.	O
According	O
to	O
current	O
models	O
the	O
inhibitory	O
capacity	O
of	O
I	B
(	I
kappa	I
)	I
B	I
(	I
alpha	I
)	I
would	O
be	O
mediated	O
through	O
the	O
retention	O
of	O
Rel	B
/	I
NF	I
-	I
kappaB	I
proteins	I
in	O
the	O
cytosol	O
.	O
However	O
,	O
I	B
(	I
kappa	I
)	I
B	I
(	I
alpha	I
)	I
has	O
also	O
been	O
detected	O
in	O
the	O
nucleus	O
of	O
cell	O
lines	O
and	O
when	O
overexpressed	O
by	O
transient	O
transfection	O
.	O
To	O
gain	O
better	O
insight	O
into	O
the	O
potential	O
role	O
of	O
nuclear	B
I	I
(	I
kappa	I
)	I
B	I
(	I
alpha	I
)	I
in	O
a	O
physiological	O
context	O
we	O
have	O
analysed	O
its	O
presence	O
in	O
the	O
nucleus	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
(	O
PBL	O
)	O
.	O
We	O
demonstrate	O
the	O
nuclear	O
localization	O
of	O
I	B
(	I
kappa	I
)	I
B	I
(	I
alpha	I
)	I
in	O
PBL	O
by	O
different	O
techniques	O
:	O
Western	O
blot	O
,	O
indirect	O
immunofluorescence	O
and	O
electron	O
microscopy	O
.	O
Low	O
levels	O
of	O
nuclear	O
I	B
(	I
kappa	I
)	I
B	I
(	I
alpha	I
)	I
were	O
detected	O
in	O
resting	O
cells	O
whereas	O
a	O
superinduction	O
was	O
obtained	O
after	O
PMA	O
activation	O
.	O
The	O
nuclear	O
pool	O
of	O
I	B
(	I
kappa	I
)	I
B	I
(	I
alpha	I
)	I
showed	O
a	O
higher	O
stability	O
than	O
cytosolic	O
I	B
(	I
kappa	I
)	I
B	I
(	I
alpha	I
)	I
and	O
was	O
partially	O
independent	O
of	O
the	O
resynthesis	O
of	O
the	O
protein	O
.	O
Unexpectedly	O
,	O
the	O
presence	O
of	O
nuclear	B
I	I
(	I
kappa	I
)	I
B	I
(	I
alpha	I
)	I
did	O
not	O
inhibit	O
NF	B
-	I
kappaB	I
binding	O
to	O
DNA	O
and	O
this	O
phenomenon	O
was	O
not	O
due	O
to	O
the	O
presence	O
of	O
IkappaBbeta	B
at	O
the	O
nuclear	O
level	O
.	O
Immunoprecipitation	O
experiments	O
failed	O
to	O
demonstrate	O
an	O
association	O
between	O
nuclear	O
I	B
(	I
kappa	I
)	I
B	I
(	I
alpha	I
)	I
and	O
NF	B
-	I
kappaB	I
proteins	O
.	O
Our	O
results	O
demonstrate	O
that	O
in	O
resting	O
and	O
PMA	O
-	O
activated	O
human	O
PBL	O
,	O
I	B
(	I
kappa	I
)	I
B	I
(	I
alpha	I
)	I
is	O
present	O
in	O
the	O
nucleus	O
in	O
an	O
apparently	O
inactive	O
form	O
unable	O
to	O
disrupt	O
NF	B
-	I
kappaB	I
binding	O
from	O
DNA	O
.	O
Modulation	O
of	O
the	O
immune	O
response	O
by	O
progesterone	B
-	I
induced	I
lymphocyte	I
factors	I
.	O
Rat	O
spleen	O
and	O
peripheral	O
blood	O
lymphocytes	O
express	O
progesterone	B
receptors	I
whose	O
concentration	O
is	O
increased	O
greatly	O
during	O
the	O
early	O
phase	O
of	O
pregnancy	O
.	O
After	O
stimulation	O
of	O
progesterone	O
the	O
expression	O
of	O
receptors	O
was	O
augmented	O
2	O
-	O
3	O
times	O
.	O
When	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
progesterone	O
they	O
released	O
a	O
soluble	B
factor	I
that	O
inhibited	O
cellular	O
immunoreactions	O
(	O
MLR	O
,	O
CRC	O
)	O
and	O
cellular	O
proliferation	O
as	O
measured	O
by	O
thymidine	O
incorporation	O
by	O
spleen	O
-	O
cell	O
culture	O
.	O
This	O
factor	O
also	O
inhibited	O
the	O
synthesis	O
of	O
anti	B
-	I
DNP	I
antibodies	I
by	O
a	O
mouse	O
hybridoma	O
and	O
diminished	O
the	O
proportion	O
of	O
cells	O
in	O
phase	O
S	O
.	O
However	O
,	O
the	O
percentage	O
of	O
asymmetric	B
molecules	I
produced	O
by	O
the	O
hybridoma	O
remained	O
unaltered	O
.	O
These	O
results	O
support	O
the	O
hypothesis	O
that	O
soluble	B
factors	I
released	O
by	O
rat	O
lymphocytes	O
modulate	O
the	O
immune	O
response	O
of	O
the	O
mother	O
and	O
participate	O
in	O
the	O
mechanism	O
that	O
protects	O
the	O
fetus	O
against	O
antipaternal	B
antibodies	I
.	O
PGG	O
-	O
glucan	O
,	O
a	O
soluble	O
beta-	O
(	O
1	O
,	O
3	O
)	O
-glucan	O
,	O
enhances	O
the	O
oxidative	O
burst	O
response	O
,	O
microbicidal	O
activity	O
,	O
and	O
activates	O
an	O
NF	B
-	I
kappa	I
B	I
-	I
like	I
factor	I
in	O
human	O
PMN	O
:	O
evidence	O
for	O
a	O
glycosphingolipid	B
beta-	I
(	I
1	I
,	I
3	I
)	I
-glucan	I
receptor	I
.	O
PGG	O
-	O
Glucan	O
,	O
a	O
soluble	O
beta-	O
(	O
1	O
,	O
6	O
)	O
-branched	O
beta-	O
(	O
1	O
,	O
3	O
)	O
-linked	O
glucose	O
homopolymer	O
derived	O
from	O
the	O
cell	O
wall	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
is	O
an	O
immunomodulator	O
which	O
enhances	O
leukocyte	O
anti	O
-	O
infective	O
activity	O
and	O
enhances	O
myeloid	O
and	O
megakaryocyte	O
progenitor	O
proliferation	O
.	O
Incubation	O
of	O
human	O
whole	O
blood	O
with	O
PGG	O
-	O
Glucan	O
significantly	O
enhanced	O
the	O
oxidative	O
burst	O
response	O
of	O
subsequently	O
isolated	O
blood	O
leukocytes	O
to	O
both	O
soluble	O
and	O
particulate	O
activators	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
and	O
increased	O
leukocyte	O
microbicidal	O
activity	O
.	O
No	O
evidence	O
for	O
inflammatory	O
cytokine	B
production	O
was	O
obtained	O
under	O
these	O
conditions	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
PGG	O
-	O
Glucan	O
induced	O
the	O
activation	O
of	O
an	O
NF	B
-	I
kappaB	I
-	I
like	I
nuclear	I
transcription	I
factor	I
in	O
purified	O
human	O
neutrophils	O
.	O
The	O
binding	O
of	O
3H	O
-	O
PGG	O
-	O
Glucan	O
to	O
human	O
leukocyte	O
membranes	O
was	O
specific	O
,	O
concentration	O
-	O
dependent	O
,	O
saturable	O
,	O
and	O
high	O
affinity	O
(	O
Kd	O
approximately	O
6	O
nM	O
)	O
.	O
A	O
monoclonal	B
antibody	I
specific	O
to	O
the	O
glycosphingolipid	O
lactosylceramide	O
was	O
able	O
to	O
inhibit	O
activation	O
of	O
the	O
NF	B
-	I
kappaB	I
-	I
like	I
factor	I
by	O
PGG	O
-	O
Glucan	O
,	O
and	O
ligand	O
binding	O
data	O
,	O
including	O
polysaccharide	O
specificity	O
,	O
suggested	O
that	O
the	O
PGG	O
-	O
Glucan	O
binding	O
moiety	O
was	O
lactosylceramide	O
.	O
These	O
results	O
indicate	O
that	O
PGG	O
-	O
Glucan	O
enhances	O
neutrophil	O
anti	O
-	O
microbial	O
functions	O
and	O
that	O
interaction	O
between	O
this	O
beta	O
-	O
glucan	O
and	O
human	O
neutrophils	O
is	O
mediated	O
by	O
the	O
glycosphingolipid	O
lactosylceramide	O
present	O
at	O
the	O
cell	O
surface	O
.	O
Essential	O
role	O
of	O
alveolar	O
macrophages	O
in	O
intrapulmonary	O
activation	O
of	O
NF	B
-	I
kappaB	I
.	O
Acute	O
inflammatory	O
injury	O
in	O
rat	O
lung	O
induced	O
by	O
deposition	O
of	O
immunoglobulin	B
G	I
immune	I
complexes	I
requires	O
expression	O
of	O
cytokines	B
and	O
chemokines	B
as	O
well	O
as	O
activation	O
of	O
the	O
transcription	B
factor	I
nuclear	B
factor	I
(	I
NF	I
)	I
-kappaB	I
.	O
There	O
is	O
little	O
direct	O
evidence	O
regarding	O
the	O
role	O
of	O
alveolar	O
macrophages	O
in	O
these	O
activation	O
events	O
.	O
In	O
the	O
present	O
studies	O
,	O
rat	O
lungs	O
were	O
depleted	O
of	O
alveolar	O
macrophages	O
by	O
airway	O
instillation	O
of	O
liposome	O
-	O
encapsulated	O
dichloromethylene	O
diphosphonate	O
.	O
These	O
procedures	O
,	O
which	O
greatly	O
reduced	O
the	O
number	O
of	O
retrievable	O
alveolar	O
macrophages	O
,	O
suppressed	O
activation	O
of	O
lung	B
NF	I
-	I
kappaB	I
in	O
the	O
inflammatory	O
model	O
.	O
In	O
addition	O
,	O
bronchoalveolar	O
lavage	O
levels	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
and	O
the	O
CXC	B
chemokine	I
,	O
macrophage	B
inflammatory	I
protein-2	I
,	O
were	O
substantially	O
reduced	O
.	O
In	O
parallel	O
,	O
upregulation	O
of	O
the	O
lung	B
vascular	I
adhesion	I
molecule	I
,	O
intercellular	B
adhesion	I
molecule-1	I
,	O
was	O
greatly	O
reduced	O
by	O
intrapulmonary	O
instillation	O
of	O
phosphonate	O
-	O
containing	O
liposomes	O
.	O
Neutrophil	O
accumulation	O
and	O
development	O
of	O
lung	O
injury	O
were	O
also	O
substantially	O
diminished	O
.	O
Lung	O
instillation	O
of	O
TNF	B
-	I
alpha	I
in	O
alveolar	O
macrophage	O
-	O
depleted	O
rats	O
restored	O
the	O
NF	B
-	I
kappaB	I
activation	O
response	O
in	O
whole	O
lung	O
.	O
These	O
data	O
suggest	O
that	O
,	O
in	O
this	O
inflammatory	O
model	O
,	O
initial	O
activation	O
of	O
NF	B
-	I
kappaB	I
occurs	O
in	O
alveolar	O
macrophages	O
and	O
the	O
ensuing	O
production	O
of	O
TNF	B
-	I
alpha	I
may	O
propagate	O
NF	B
-	I
kappaB	I
activation	O
to	O
other	O
cell	O
types	O
in	O
the	O
lung	O
.	O
Inhibition	O
of	O
cyclooxygenase-2	B
expression	O
by	O
4-trifluoromethyl	O
derivatives	O
of	O
salicylate	O
,	O
triflusal	O
,	O
and	O
its	O
deacetylated	O
metabolite	O
,	O
2-hydroxy-4-trifluoromethylbenzoic	O
acid	O
.	O
The	O
therapeutic	O
potential	O
of	O
drugs	O
that	O
block	O
the	O
induction	O
of	O
cyclooxygenase-2	B
has	O
been	O
emphasized	O
.	O
When	O
two	O
4-trifluoromethyl	O
salicylate	O
derivatives	O
[	O
2-acetoxy-4-trifluoromethyl	O
-	O
benzoic	O
acid	O
(	O
triflusal	O
)	O
and	O
its	O
deacetylated	O
metabolite	O
2-hydroxy-4-trifluoromethylbenzoic	O
acid	O
(	O
HTB	O
)	O
]	O
were	O
compared	O
with	O
aspirin	O
and	O
sodium	O
salicylate	O
as	O
cyclooxygenase-2	B
(	O
COX-2	O
)	O
inhibitors	O
,	O
we	O
observed	O
that	O
in	O
bacterial	O
lipopolysaccharide	O
-	O
activated	O
human	O
blood	O
,	O
triflusal	O
,	O
aspirin	O
,	O
and	O
HTB	O
,	O
but	O
not	O
sodium	O
salicylate	O
,	O
inhibited	O
COX-2-mediated	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
production	O
(	O
IC50	O
=	O
0.16	O
,	O
0.18	O
,	O
0.39	O
,	O
and	O
>	O
10	O
mM	O
,	O
respectively	O
)	O
.	O
However	O
,	O
only	O
triflusal	O
and	O
aspirin	O
inhibited	O
purified	B
COX-2	I
enzyme	I
.	O
To	O
test	O
this	O
apparent	O
discrepancy	O
,	O
we	O
realized	O
that	O
HTB	O
and	O
triflusal	O
(	O
but	O
neither	O
aspirin	O
nor	O
salicylate	O
)	O
produced	O
a	O
concentration	O
-	O
dependent	O
inhibition	O
of	O
COX-2	B
protein	O
expression	O
in	O
peripheral	O
human	O
mononuclear	O
cells	O
.	O
This	O
observation	O
was	O
further	O
confirmed	O
in	O
a	O
rat	O
air	O
pouch	O
model	O
in	O
vivo	O
,	O
in	O
which	O
both	O
aspirin	O
and	O
triflusal	O
inhibited	O
PGE2	O
production	O
(	O
ID50	O
=	O
18.9	O
and	O
11.4	O
mg	O
/	O
kg	O
p.o	O
.	O
,	O
respectively	O
)	O
but	O
only	O
triflusal	O
-	O
treated	O
animals	O
showed	O
a	O
decrease	O
in	O
COX-2	B
expression	O
.	O
This	O
different	O
behavior	O
may	O
be	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
the	O
ability	O
of	O
HTB	O
and	O
triflusal	O
to	O
block	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	B
factor	I
-	I
kappaB	I
to	O
a	O
higher	O
extent	O
than	O
aspirin	O
and	O
sodium	O
salicylate	O
.	O
Thus	O
,	O
in	O
addition	O
to	O
inhibiting	O
the	O
COX-2	O
activity	O
at	O
therapeutic	O
concentrations	O
,	O
triflusal	O
is	O
able	O
to	O
block	O
through	O
its	O
metabolite	O
HTB	O
the	O
expression	O
of	O
new	O
enzyme	O
,	O
and	O
hence	O
the	O
resumption	O
of	O
PGE2	O
synthesis	O
.	O
Triflusal	O
and	O
HTB	O
may	O
exert	O
beneficial	O
effects	O
in	O
processes	O
in	O
which	O
de	O
novo	O
COX-2	B
expression	O
is	O
involved	O
and	O
,	O
in	O
a	O
broader	O
sense	O
,	O
in	O
pathological	O
situations	O
in	O
which	O
genes	O
under	O
nuclear	B
factor	I
-	I
kappaB	I
control	O
are	O
up	O
-	O
regulated	O
.	O
Vitamin	B
D	I
receptor	I
3'-untranslated	O
region	O
polymorphisms	O
:	O
lack	O
of	O
effect	O
on	O
mRNA	O
stability	O
.	O
Allelic	O
variation	O
at	O
the	O
3'-end	O
of	O
the	O
vitamin	O
D	O
receptor	O
(	O
VDR	O
)	O
gene	O
has	O
been	O
associated	O
with	O
a	O
3	O
-	O
5-fold	O
increased	O
risk	O
of	O
developing	O
prostate	O
cancer	O
and	O
with	O
differences	O
in	O
bone	O
mineralization	O
.	O
This	O
genetic	O
diversity	O
does	O
not	O
alter	O
the	O
VDR	B
protein	I
structurally	O
,	O
but	O
instead	O
may	O
be	O
a	O
marker	O
(	O
s	O
)	O
of	O
other	O
,	O
nearby	O
polymorphisms	O
that	O
influence	O
message	O
stability	O
or	O
translation	O
.	O
The	O
work	O
reported	O
here	O
was	O
instigated	O
to	O
identify	O
additional	O
VDR	B
3'-UTR	O
polymorphisms	O
that	O
may	O
have	O
functional	O
significance	O
and	O
to	O
then	O
test	O
whether	O
these	O
genetic	O
variants	O
alter	O
message	O
stability	O
.	O
Initially	O
,	O
four	O
novel	O
,	O
frequently	O
occurring	O
sequence	O
variants	O
were	O
identified	O
that	O
associated	O
with	O
two	O
common	O
haplotypes	O
that	O
were	O
described	O
previously	O
.	O
These	O
common	O
sequence	O
variants	O
were	O
not	O
found	O
within	O
three	O
message	O
-	O
destabilizing	O
elements	O
that	O
we	O
mapped	O
within	O
the	O
3'-UTR	O
of	O
the	O
vitamin	O
D	O
receptor	O
mRNA	O
.	O
Furthermore	O
,	O
the	O
two	O
VDR	O
3'-UTR	O
haplotypes	O
conferred	O
an	O
identical	O
half	O
-	O
life	O
on	O
a	O
heterologous	O
beta	O
-	O
globin	O
reporter	O
gene	O
,	O
in	O
an	O
in	O
vitro	O
assay	O
.	O
We	O
therefore	O
conclude	O
that	O
common	O
polymorphisms	O
within	O
the	O
VDR	O
3'-UTR	O
do	O
not	O
influence	O
message	O
stability	O
.	O
Cleavage	O
of	O
transcription	B
factor	I
SP1	B
by	O
caspases	B
during	O
anti	O
-	O
IgM	O
-	O
induced	O
B	O
-	O
cell	O
apoptosis	O
.	O
Apoptosis	O
is	O
instrumental	O
in	O
the	O
processes	O
generating	O
the	O
diversity	O
of	O
the	O
B	O
-	O
cell	O
repertoire	O
.	O
Autoreactive	O
B	O
-	O
cells	O
are	O
eliminated	O
by	O
anti	B
-	I
IgM	I
crosslinking	O
after	O
encountering	O
self	B
-	I
antigens	I
,	O
but	O
precise	O
mechanisms	O
leading	O
to	O
B	O
-	O
cell	O
apoptosis	O
are	O
still	O
not	O
well	O
understood	O
.	O
We	O
report	O
here	O
the	O
cleavage	O
of	O
the	O
transcription	B
factor	I
SP1	B
in	O
the	O
human	O
Burkitt	O
lymphoma	O
cell	O
line	O
BL60	O
during	O
anti	B
-	I
IgM	I
-induced	O
apoptosis	O
.	O
Western	O
blot	O
analysis	O
revealed	O
two	O
cleavage	O
products	O
of	O
approximately	O
68	B
kDa	I
and	O
45	B
kDa	I
after	O
induction	O
of	O
apoptosis	O
.	O
Cleavage	O
could	O
be	O
completely	O
inhibited	O
by	O
zDEVD	O
-	O
fmk	O
,	O
an	O
inhibitor	O
specific	O
for	O
caspase	B
3-like	I
proteases	I
.	O
In	O
-	O
vitro	O
cleavage	O
of	O
recombinant	B
SP1	I
by	O
recombinant	B
caspase	I
3	I
(	O
CPP32	B
)	O
or	O
caspase	B
7	I
(	O
Mch	B
3	I
)	O
results	O
in	O
similar	O
cleavage	O
products	O
as	O
those	O
observed	O
in	O
vivo	O
.	O
Recombinant	B
caspase	I
6	I
(	O
Mch	B
2	I
)	O
primarily	O
generates	O
a	O
68-kDa	O
cleavage	O
product	O
,	O
as	O
observed	O
after	O
calcium	O
ionophore	O
(	O
CaI	O
)	O
induced	O
B	O
-	O
cell	O
apoptosis	O
.	O
In	O
contrast	O
,	O
caspase	O
1	O
(	O
ICE	O
)	O
did	O
not	O
cleave	O
SP1	B
in	O
vitro	O
.	O
The	O
time	O
course	O
of	O
SP1	B
cleavage	O
during	O
anti	O
-	O
IgM	O
-	O
induced	O
apoptosis	O
is	O
paralleled	O
by	O
an	O
increase	O
of	O
caspase	O
activity	O
measured	O
by	O
DEVD	O
-	O
p	O
-	O
nitroanilide	O
(	O
DEVD	O
-	O
pNA	O
)	O
cleavage	O
.	O
DNA	O
band	O
-	O
shift	O
assays	O
revealed	O
a	O
decrease	O
in	O
the	O
intensity	O
of	O
the	O
full	O
length	O
SP1	B
/DNA	O
complex	O
and	O
an	O
increase	O
in	O
the	O
intensity	O
of	O
a	O
smaller	O
complex	O
due	O
to	O
the	O
binding	O
of	O
one	O
SP1	B
cleavage	O
product	O
.	O
By	O
Edman	O
sequencing	O
we	O
could	O
identify	O
a	O
caspase	O
3	O
cleavage	O
site	O
after	O
Asp584	O
(	O
D584AQPQAGR	O
)	O
,	O
generating	O
a	O
22-kDa	O
C	O
-	O
terminal	O
SP1	B
protein	O
fragment	O
which	O
still	O
contains	O
the	O
DNA	O
binding	O
site	O
.	O
Our	O
results	O
show	O
the	O
cleavage	O
of	O
the	O
human	O
transcription	B
factor	I
SP1	B
in	O
vivo	O
and	O
in	O
vitro	O
,	O
underlining	O
the	O
central	O
role	O
of	O
caspase	B
3-like	I
proteases	I
during	O
the	O
process	O
of	O
anti	O
-	O
IgM	O
-	O
induced	O
apoptosis	O
.	O
[	O
Corticoids	O
and	O
allergy	O
]	O
Inflammation	O
is	O
constantly	O
observed	O
in	O
allergic	O
reactions	O
.	O
Corticosteroids	O
are	O
most	O
effective	O
in	O
preventing	O
the	O
late	O
phase	O
of	O
allergic	O
reaction	O
.	O
The	O
action	O
of	O
glucocorticosteroids	O
is	O
mediated	O
through	O
glucocorticoid	B
receptors	I
present	O
in	O
the	O
cellular	O
cytoplasm	O
.	O
When	O
activated	O
,	O
glucocorticoid	B
receptors	I
form	O
a	O
dimer	B
and	O
bind	O
to	O
DNA	O
after	O
migration	O
into	O
the	O
nucleus	O
.	O
Interaction	O
to	O
DNA	O
induces	O
changes	O
in	O
the	O
transcription	O
rate	O
,	O
leading	O
to	O
either	O
gene	O
induction	O
or	O
gene	O
repression	O
.	O
Glucocorticoid	O
receptors	O
are	O
also	O
able	O
to	O
interact	O
with	O
transcriptional	O
factors	O
such	O
as	O
AP-1	B
(	O
activator	B
protein-1	I
)	O
of	O
NF	B
-	I
kappa	I
B	I
(	O
nuclear	B
factor	I
-	I
kappa	I
B	I
)	O
.	O
Through	O
these	O
actions	O
glucocorticosteroids	O
are	O
susceptible	O
to	O
modify	O
functions	O
of	O
cells	O
involved	O
in	O
the	O
allergic	O
inflammatory	O
response	O
.	O
They	O
are	O
in	O
particular	O
able	O
to	O
inhibit	O
most	O
of	O
the	O
pro	O
-	O
inflammatory	O
functions	O
of	O
the	O
eosinophils	O
.	O
Evidence	O
for	O
a	O
polyclonal	O
etiology	O
of	O
palmar	O
fibromatosis	O
.	O
X	O
chromosome	O
inactivation	O
patterns	O
at	O
the	O
androgen	O
receptor	O
locus	O
were	O
evaluated	O
to	O
determine	O
clonality	O
in	O
microdissected	O
lesional	O
tissue	O
and	O
in	O
leukocytes	O
from	O
2	O
women	O
with	O
Dupuytren	O
's	O
disease	O
.	O
The	O
tissue	O
from	O
both	O
patients	O
generated	O
a	O
polyclonal	O
pattern	O
of	O
X	O
chromosome	O
inactivation	O
of	O
the	O
human	O
androgen	O
receptor	O
gene	O
.	O
This	O
finding	O
supports	O
a	O
polyclonal	O
reactive	O
process	O
as	O
the	O
underlying	O
etiology	O
for	O
palmar	O
fibromatosis	O
.	O
The	O
Epstein	B
-	I
Barr	I
virus	I
nuclear	I
antigen	I
2	I
(	O
EBNA2	B
)	O
,	O
a	O
protein	O
required	O
for	O
B	O
lymphocyte	O
immortalization	O
,	O
induces	O
the	O
synthesis	O
of	O
type	B
I	I
interferon	I
in	O
Burkitt	O
's	O
lymphoma	O
cell	O
lines	O
.	O
Epstein	B
-	I
Barr	I
virus	I
nuclear	I
antigen	I
2	I
(	O
EBNA2	B
)	O
,	O
a	O
protein	O
involved	O
in	O
cell	O
transformation	O
,	O
interferes	O
with	O
the	O
cellular	O
response	O
to	O
type	B
I	I
interferons	I
(	O
IFN	B
-	I
alpha	I
/	I
beta	I
)	O
.	O
We	O
investigated	O
the	O
function	O
of	O
conditionally	O
expressed	O
EBNA2	B
in	O
the	O
context	O
of	O
the	O
IFN	B
response	O
in	O
Burkitt	O
's	O
lymphoma	O
cell	O
lines	O
.	O
Expression	O
of	O
EBNA2	B
led	O
to	O
the	O
transcriptional	O
activation	O
of	O
both	O
endogenous	O
or	O
transfected	O
IFN	O
-	O
stimulated	O
genes	O
(	O
ISGs	O
)	O
,	O
genes	O
which	O
contain	O
within	O
their	O
promoters	O
either	O
the	O
interferon	O
-	O
stimulated	O
response	O
element	O
(	O
ISRE	O
)	O
or	O
the	O
gamma	O
interferon	O
activation	O
site	O
(	O
GAS	O
)	O
.	O
In	O
search	O
of	O
a	O
molecular	O
mechanism	O
for	O
the	O
transcriptional	O
induction	O
of	O
ISGs	O
,	O
we	O
observed	O
an	O
EBNA2	B
-dependent	O
synthesis	O
of	O
IFN	O
-	O
beta	O
mRNA	O
at	O
low	O
levels	O
and	O
the	O
secretion	O
of	O
low	O
amounts	O
of	O
IFN	O
.	O
A	O
transfected	O
IFN	O
-	O
beta	O
promoter	O
responded	O
to	O
EBNA2	B
activation	O
,	O
and	O
a	O
sequence	O
closely	O
resembling	O
a	O
RBP	O
-	O
Jkappa	O
binding	O
site	O
was	O
pinpointed	O
as	O
a	O
potential	O
target	O
of	O
EBNA2	B
activity	O
.	O
EBNA2	B
-dependent	O
transcriptional	O
induction	O
of	O
the	O
IFN	O
-	O
beta	O
promoter	O
occurred	O
in	O
EBV	O
-	O
negative	O
Burkitt	O
's	O
lymphoma	O
cells	O
,	O
indicating	O
that	O
other	O
EBV	O
genes	O
were	O
not	O
required	O
for	O
the	O
induction	O
of	O
IFN	B
-	I
beta	I
synthesis	O
.	O
Activation	O
of	O
NF	B
-	I
kappaB	I
in	O
Mycobacterium	O
tuberculosis	O
-induced	O
interleukin-2	B
receptor	I
expression	O
in	O
mononuclear	O
phagocytes	O
.	O
Soluble	O
interleukin-2	B
receptor	I
-	I
alpha	I
(	O
IL-2Ralpha	B
)	O
has	O
been	O
reported	O
to	O
be	O
increased	O
in	O
the	O
sera	O
of	O
patients	O
with	O
advanced	O
tuberculosis	O
,	O
and	O
levels	O
decline	O
after	O
therapy	O
in	O
accordance	O
with	O
improvement	O
of	O
radiologic	O
findings	O
.	O
We	O
investigated	O
expression	O
of	O
the	O
IL-2Ralpha	B
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
cells	O
in	O
active	O
pulmonary	O
tuberculosis	O
,	O
and	O
evaluated	O
the	O
mechanism	O
Mycobacterium	O
tuberculosis	O
induces	O
in	O
the	O
IL-2Ralpha	B
using	O
the	O
THP-1	O
mononuclear	O
phagocyte	O
cell	O
line	O
.	O
We	O
found	O
IL-2Ralpha	B
expression	O
to	O
be	O
increased	O
in	O
BAL	O
cells	O
from	O
involved	O
sites	O
of	O
active	O
pulmonary	O
tuberculosis	O
.	O
Expression	O
of	O
the	O
alpha	B
-	I
chain	I
of	O
IL-2Ralpha	B
on	O
peripheral	O
blood	O
monocytes	O
(	O
PBM	O
)	O
was	O
induced	O
by	O
M.	O
tuberculosis	O
by	O
flow	O
cytometry	O
evaluation	O
.	O
Northern	O
analysis	O
demonstrated	O
increased	O
IL-2Ralpha	B
gene	O
expression	O
after	O
stimulation	O
with	O
M.	O
tuberculosis	O
which	O
was	O
further	O
induced	O
by	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
.	O
The	O
IL-2Ralpha	O
promoter	O
containing	O
the	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
site	O
was	O
transcriptionally	O
induced	O
by	O
M.	O
tuberculosis	O
and	O
this	O
NF	B
-	I
kappaB	I
site	O
could	O
confer	O
inducibility	O
to	O
a	O
heterologous	O
herpes	O
thymidine	O
kinase	O
(	O
TK	O
)	O
promoter	O
by	O
M.	O
tuberculosis	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
revealed	O
specific	O
binding	O
of	O
nuclear	O
protein	O
to	O
the	O
NF	O
-	O
kappaB	O
site	O
upon	O
induction	O
with	O
M.	O
tuberculosis	O
.	O
Using	O
antibodies	O
against	O
the	O
p50	B
and	O
p65	B
subunits	I
of	O
NF	B
-	I
kappaB	I
in	O
EMSAs	O
,	O
the	O
involvement	O
of	O
both	O
p50	B
and	O
p65	B
proteins	I
was	O
further	O
demonstrated	O
.	O
Functional	O
expression	O
of	O
the	O
IL-2Ralpha	B
on	O
mononuclear	O
phagocytes	O
in	O
M.	O
tuberculosis	O
infection	O
may	O
play	O
an	O
important	O
immunomodulatory	O
role	O
in	O
the	O
host	O
response	O
.	O
Regulation	O
of	O
the	O
megakaryocytic	O
glycoprotein	O
IX	O
promoter	O
by	O
the	O
oncogenic	B
Ets	I
transcription	I
factor	I
Fli-1	B
.	O
Glycoprotein	B
(	I
GP	I
)	I
IX	I
is	O
a	O
subunit	O
of	O
the	O
von	B
Willebrand	I
receptor	I
,	O
GPIb	B
-	I
V	I
-	I
IX	I
,	O
which	O
mediates	O
adhesion	O
of	O
platelets	O
to	O
the	O
subendothelium	O
of	O
damaged	O
blood	O
vessels	O
.	O
Previous	O
characterization	O
of	O
the	O
GPIX	O
promoter	O
identified	O
a	O
functional	O
Ets	O
site	O
that	O
,	O
when	O
disrupted	O
,	O
reduced	O
promoter	O
activity	O
.	O
However	O
,	O
the	O
Ets	B
protein	I
(	O
s	O
)	O
that	O
regulated	O
GPIX	O
promoter	O
expression	O
was	O
unknown	O
.	O
In	O
this	O
study	O
,	O
transient	O
cotransfection	O
of	O
several	O
GPIX	O
promoter	O
/	O
reporter	O
constructs	O
into	O
293	O
T	O
kidney	O
fibroblasts	O
with	O
a	O
Fli-1	O
expression	O
vector	O
shows	O
that	O
the	O
oncogenic	O
protein	O
Fli-1	B
can	O
transactivate	O
the	O
GPIX	O
promoter	O
when	O
an	O
intact	O
GPIX	O
Ets	O
site	O
is	O
present	O
.	O
In	O
addition	O
,	O
Fli-1	B
binding	O
of	O
the	O
GPIX	O
Ets	O
site	O
was	O
identified	O
in	O
antibody	O
supershift	O
experiments	O
in	O
nuclear	O
extracts	O
derived	O
from	O
hematopoietic	O
human	O
erythroleukemia	O
cells	O
.	O
Comparative	O
studies	O
showed	O
that	O
Fli-1	B
was	O
also	O
able	O
to	O
transactivate	O
the	O
GPIbalpha	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
the	O
GPIIb	O
promoter	O
.	O
Immunoblot	O
analysis	O
identified	O
Fli-1	B
protein	I
in	O
lysates	O
derived	O
from	O
platelets	O
.	O
In	O
addition	O
,	O
expression	O
of	O
Fli-1	B
was	O
identified	O
immunohistochemically	O
in	O
megakaryocytes	O
derived	O
from	O
CD34	O
(	O
+	O
)	O
cells	O
treated	O
with	O
the	O
megakaryocyte	B
differentiation	I
and	I
proliferation	I
factor	I
,	O
thrombopoietin	B
.	O
These	O
results	O
suggest	O
that	O
Fli-1	B
is	O
likely	O
to	O
regulate	O
lineage	O
-	O
specific	O
genes	O
during	O
megakaryocytopoiesis	O
.	O
Spi	B
-	I
C	I
,	O
a	O
novel	O
Ets	B
protein	I
that	O
is	O
temporally	O
regulated	O
during	O
B	O
lymphocyte	O
development	O
.	O
A	O
novel	O
Ets	B
protein	I
was	O
isolated	O
by	O
yeast	O
one	O
-	O
hybrid	O
screening	O
of	O
a	O
cDNA	O
library	O
made	O
from	O
lipopolysaccharide	O
-	O
stimulated	O
mouse	O
splenic	O
B	O
cells	O
,	O
using	O
the	O
SP6	O
kappa	O
promoter	O
kappaY	O
element	O
as	O
a	O
bait	O
.	O
The	O
novel	O
Ets	B
protein	I
was	O
most	O
closely	O
related	O
to	O
PU.1	B
and	O
Spi	B
-	I
B	I
within	O
the	O
DNA	O
binding	O
Ets	O
domain	O
and	O
was	O
therefore	O
named	O
Spi	B
-	I
C	I
.	O
However	O
,	O
Spi	B
-	I
C	I
may	O
represent	O
a	O
novel	O
subgroup	O
within	O
the	O
Ets	B
protein	I
family	I
,	O
as	O
it	O
differed	O
significantly	O
from	O
Spi	B
-	I
B	I
and	O
PU.1	B
within	O
helix	B
1	I
of	O
the	O
Ets	B
domain	I
.	O
Spi	B
-	I
C	I
was	O
encoded	O
by	O
a	O
single	O
-	O
copy	O
gene	O
that	O
was	O
mapped	O
to	O
chromosome	O
10	O
,	O
region	O
C	O
.	O
Spi	B
-	I
C	I
interacted	O
with	O
DNA	O
similarly	O
to	O
PU.1	B
as	O
judged	O
by	O
methylation	O
interference	O
,	O
band	O
-	O
shift	O
and	O
site	O
selection	O
analysis	O
,	O
and	O
activated	O
transcription	O
of	O
a	O
kappaY	O
element	O
reporter	O
gene	O
upon	O
co	O
-	O
transfection	O
of	O
HeLa	O
cells	O
.	O
Spi	O
-	O
C	O
RNA	O
was	O
expressed	O
in	O
mature	O
B	O
lymphocytes	O
and	O
at	O
lower	O
levels	O
in	O
macrophages	O
.	O
Furthermore	O
,	O
pre	O
-	O
B	O
cell	O
and	O
plasma	O
cell	O
lines	O
were	O
Spi	B
-	I
C	I
-negative	O
,	O
suggesting	O
that	O
Spi	B
-	I
C	I
might	O
be	O
a	O
regulatory	B
molecule	I
during	O
a	O
specific	O
phase	O
of	O
B	O
lymphoid	O
development	O
.	O
In	O
vivo	O
modulation	O
of	O
glucocorticoid	O
receptor	O
mRNA	O
by	O
inhaled	O
fluticasone	O
propionate	O
in	O
bronchial	O
mucosa	O
and	O
blood	O
lymphocytes	O
in	O
subjects	O
with	O
mild	O
asthma	O
.	O
BACKGROUND	O
:	O
In	O
vivo	O
regulation	O
of	O
the	O
glucocorticoid	B
receptor	I
(	O
GR	B
)	O
by	O
glucocorticoids	O
provides	O
a	O
means	O
of	O
modulating	O
sensitivity	O
of	O
targeted	O
cells	O
.	O
OBJECTIVE	O
:	O
We	O
sought	O
to	O
determine	O
the	O
in	O
vivo	O
modulation	O
of	O
GR	O
mRNA	O
expression	O
by	O
fluticasone	O
propionate	O
(	O
FP	O
)	O
in	O
subjects	O
with	O
mild	O
asthma	O
.	O
METHODS	O
:	O
Ten	O
atopic	O
asthmatic	O
subjects	O
were	O
treated	O
with	O
FP	O
250	O
microg	O
twice	O
daily	O
for	O
4	O
weeks	O
.	O
Before	O
and	O
after	O
treatment	O
,	O
the	O
patients	O
underwent	O
fiberoptic	O
bronchoscopy	O
with	O
endobronchial	O
biopsy	O
and	O
sampling	O
of	O
venous	O
blood	O
for	O
measurements	O
of	O
GR	O
mRNA	O
levels	O
.	O
A	O
solution	O
hybridization	O
assay	O
was	O
used	O
for	O
quantitative	O
analysis	O
of	O
GR	O
mRNA	O
.	O
In	O
addition	O
,	O
a	O
24-hour	O
urinary	O
cortisol	O
excretion	O
and	O
an	O
adrenocorticotropic	O
hormone	O
test	O
before	O
and	O
after	O
treatment	O
with	O
FP	O
were	O
performed	O
.	O
RESULTS	O
:	O
A	O
high	O
interindividual	O
variation	O
in	O
GR	O
mRNA	O
expression	O
was	O
seen	O
.	O
However	O
,	O
we	O
detected	O
a	O
significant	O
reduction	O
of	O
the	O
GR	O
mRNA	O
levels	O
in	O
the	O
endobronchial	O
biopsy	O
specimens	O
after	O
FP	O
treatment	O
(	O
36.6	O
+	O
/-	O
23.1	O
and	O
25.0	O
+	O
/-	O
10.9	O
amol	O
GR	O
mRNA	O
/microg	O
RNA	O
,	O
respectively	O
;	O
P	O
<	O
.01	O
)	O
.	O
In	O
the	O
peripheral	O
blood	O
lymphocytes	O
an	O
even	O
more	O
striking	O
downregulation	O
of	O
the	O
GR	O
by	O
its	O
cognate	O
ligand	O
was	O
documented	O
(	O
30.3	O
+	O
/-	O
26.5	O
and	O
8.8	O
+	O
/-	O
5	O
amol	O
GR	O
mRNA	O
/microg	O
RNA	O
,	O
respectively	O
;	O
P	O
<	O
.001	O
)	O
,	O
possibly	O
reflecting	O
differences	O
in	O
glucocorticoid	O
sensitivity	O
between	O
tissues	O
.	O
A	O
small	O
but	O
significant	O
reduction	O
of	O
the	O
24-hour	O
urinary	O
cortisol	O
excretion	O
was	O
observed	O
(	O
233	O
+	O
/-	O
109	O
and	O
157	O
+	O
/-	O
66	O
nmol	O
/	O
L	O
,	O
respectively	O
;	O
P	O
<	O
.01	O
)	O
,	O
whereas	O
the	O
feedback	O
regulation	O
of	O
glucocorticoid	O
synthesis	O
by	O
means	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
as	O
assessed	O
by	O
the	O
adrenocorticotropic	O
hormone	O
test	O
remained	O
normal	O
after	O
treatment	O
with	O
FP	O
.	O
CONCLUSION	O
:	O
The	O
results	O
in	O
this	O
study	O
confirm	O
the	O
potency	O
of	O
the	O
inhaled	O
corticosteroid	O
FP	O
and	O
provide	O
evidence	O
for	O
a	O
considerable	O
tissue	O
-	O
specific	O
interindividual	O
variation	O
in	O
the	O
expression	O
of	O
the	O
GR	B
.	O
Fludarabine	O
-	O
induced	O
immunosuppression	O
is	O
associated	O
with	O
inhibition	O
of	O
STAT1	B
signaling	O
.	O
Fludarabine	O
is	O
a	O
nucleoside	O
analog	O
used	O
in	O
the	O
treatment	O
of	O
hematologic	O
malignancies	O
that	O
can	O
induce	O
severe	O
and	O
prolonged	O
immunosuppression	O
.	O
Although	O
it	O
can	O
be	O
incorporated	O
into	O
the	O
DNA	O
of	O
dividing	O
cells	O
,	O
fludarabine	O
is	O
also	O
a	O
potent	O
inhibitor	O
of	O
cells	O
with	O
a	O
low	O
growth	O
fraction	O
,	O
thus	O
it	O
must	O
have	O
other	O
mechanisms	O
of	O
action	O
.	O
STAT1	B
,	O
which	O
is	O
activated	O
in	O
response	O
to	O
many	O
lymphocyte	B
-	I
activating	I
cytokines	I
including	O
the	O
interferons	B
,	O
is	O
essential	O
for	O
cell	O
-	O
mediated	O
immunity	O
,	O
as	O
the	O
absence	O
of	O
this	O
protein	O
is	O
associated	O
with	O
prominent	O
defects	O
in	O
the	O
ability	O
to	O
control	O
viral	O
infections	O
.	O
Here	O
we	O
show	O
that	O
fludarabine	O
,	O
but	O
not	O
the	O
immunosuppressant	O
cyclosporine	O
A	O
,	O
inhibits	O
the	O
cytokine	B
-induced	O
activation	O
of	O
STAT1	B
and	O
STAT1	B
-dependent	O
gene	O
transcription	O
in	O
normal	O
resting	O
or	O
activated	O
lymphocytes	O
.	O
Fludarabine	O
caused	O
a	O
specific	O
depletion	O
of	O
STAT1	B
protein	I
(	O
and	O
mRNA	O
)	O
but	O
not	O
of	O
other	O
STATs	B
.	O
This	O
loss	O
of	O
STAT1	B
was	O
also	O
seen	O
in	O
cells	O
from	O
patients	O
treated	O
with	O
fludarabine	O
in	O
vivo	O
.	O
Brief	O
exposure	O
to	O
fludarabine	O
led	O
to	O
a	O
sustained	O
loss	O
of	O
STAT1	B
,	O
analogous	O
to	O
the	O
prolonged	O
period	O
of	O
immunosuppression	O
induced	O
by	O
exposure	O
to	O
the	O
drug	O
in	O
vivo	O
.	O
Thus	O
,	O
STAT1	B
may	O
be	O
a	O
useful	O
target	O
in	O
the	O
development	O
of	O
new	O
immunosuppressive	O
and	O
antineoplastic	O
agents	O
.	O
A	O
novel	O
lipopolysaccharide	B
-	I
induced	I
transcription	I
factor	I
regulating	O
tumor	B
necrosis	I
factor	I
alpha	I
gene	O
expression	O
:	O
molecular	O
cloning	O
,	O
sequencing	O
,	O
characterization	O
,	O
and	O
chromosomal	O
assignment	O
.	O
Lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
a	O
potent	O
stimulator	O
of	O
monocytes	O
and	O
macrophages	O
,	O
causing	O
secretion	O
of	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
and	O
other	O
inflammatory	O
mediators	O
.	O
Given	O
the	O
deleterious	O
effects	O
to	O
the	O
host	O
of	O
TNF	B
-	I
alpha	I
,	O
it	O
has	O
been	O
postulated	O
that	O
TNF	B
-	I
alpha	I
gene	O
expression	O
must	O
be	O
tightly	O
regulated	O
.	O
The	O
nature	O
of	O
the	O
nuclear	B
factor	I
(	O
s	O
)	O
that	O
control	O
TNF	B
-	I
alpha	I
gene	O
transcription	O
in	O
humans	O
remains	O
obscure	O
,	O
although	O
NF	B
-	I
kappaB	I
has	O
been	O
suggested	O
.	O
Our	O
previous	O
studies	O
pertaining	O
to	O
macrophage	O
response	O
to	O
LPS	O
identified	O
a	O
novel	O
DNA	B
-	I
binding	I
domain	I
located	O
from	O
-550	O
to	O
-487	O
in	O
the	O
human	O
TNF	O
-	O
alpha	O
promoter	O
that	O
contains	O
transcriptional	O
activity	O
,	O
but	O
lacks	O
any	O
known	O
NF	B
-	I
kappaB	I
-binding	O
sites	O
.	O
We	O
have	O
used	O
this	O
DNA	O
fragment	O
to	O
isolate	O
and	O
purify	O
a	O
60-kDa	B
protein	I
binding	O
to	O
this	O
fragment	O
and	O
obtained	O
its	O
amino	B
-	I
terminal	I
sequence	I
,	O
which	O
was	O
used	O
to	O
design	O
degenerate	O
probes	O
to	O
screen	O
a	O
cDNA	O
library	O
from	O
THP-1	O
cells	O
.	O
A	O
novel	O
cDNA	O
clone	O
(	O
1.8	O
kb	O
)	O
was	O
isolated	O
and	O
fully	O
sequenced	O
.	O
Characterization	O
of	O
this	O
cDNA	O
clone	O
revealed	O
that	O
its	O
induction	O
was	O
dependent	O
on	O
LPS	O
activation	O
of	O
THP-1	O
cells	O
;	O
hence	O
,	O
the	O
name	O
LPS	B
-	I
induced	I
TNF	I
-	I
alpha	I
factor	I
(	O
LITAF	B
)	O
.	O
Inhibition	O
of	O
LITAF	O
mRNA	O
expression	O
in	O
THP-1	O
cells	O
resulted	O
in	O
a	O
reduction	O
of	O
TNF	B
-	I
alpha	I
transcripts	O
.	O
In	O
addition	O
,	O
high	O
level	O
of	O
expression	O
of	O
LITAF	O
mRNA	O
was	O
observed	O
predominantly	O
in	O
the	O
placenta	O
,	O
peripheral	O
blood	O
leukocytes	O
,	O
lymph	O
nodes	O
,	O
and	O
the	O
spleen	O
.	O
Finally	O
,	O
chromosomal	O
localization	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
revealed	O
that	O
LITAF	B
mapped	O
to	O
chromosome	O
16p12	O
-	O
16p13.3	O
.	O
Together	O
,	O
these	O
findings	O
suggest	O
that	O
LITAF	B
plays	O
an	O
important	O
role	O
in	O
the	O
activation	O
of	O
the	O
human	O
TNF	O
-	O
alpha	O
gene	O
and	O
proposes	O
a	O
new	O
mechanism	O
to	O
control	O
TNF	B
-	I
alpha	I
gene	O
expression	O
.	O
p38	B
mitogen	I
-	I
activated	I
protein	I
kinase	I
mediates	O
signal	O
integration	O
of	O
TCR	B
/CD28	B
costimulation	O
in	O
primary	O
murine	O
T	O
cells	O
.	O
Optimal	O
T	O
cell	O
activation	O
requires	O
two	O
signals	O
,	O
one	O
generated	O
by	O
TCR	B
and	O
another	O
by	O
the	O
CD28	B
costimulatory	I
receptor	I
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
regulation	O
of	O
costimulation	O
-	O
induced	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
activation	O
in	O
primary	O
mouse	O
T	O
cells	O
.	O
In	O
contrast	O
to	O
that	O
reported	O
for	O
human	O
Jurkat	O
T	O
cells	O
,	O
we	O
found	O
that	O
p38	B
MAPK	I
,	O
but	O
not	O
Jun	B
NH2-terminal	I
kinase	I
(	O
JNK	B
)	O
,	O
is	O
weakly	O
activated	O
upon	O
stimulation	O
with	O
either	O
anti	B
-	I
CD3	I
or	O
anti	B
-	I
CD28	I
in	O
murine	O
thymocytes	O
and	O
splenic	O
T	O
cells	O
.	O
However	O
,	O
p38	B
MAPK	I
is	O
activated	O
strongly	O
and	O
synergistically	O
by	O
either	O
CD3	B
/	I
CD28	I
coligation	O
or	O
PMA	O
/	O
Ca2	O
+	O
ionophore	O
stimulation	O
,	O
which	O
mimics	O
TCR	B
-	O
CD3	B
/	I
CD28	I
-mediated	O
signaling	O
.	O
Activation	O
of	O
p38	B
MAPK	I
correlates	O
closely	O
with	O
the	O
stimulation	O
of	O
T	O
cell	O
proliferation	O
.	O
In	O
contrast	O
,	O
PMA	O
-	O
induced	O
JNK	B
activation	O
is	O
inhibited	O
by	O
Ca2	O
+	O
ionophore	O
.	O
T	O
cell	O
proliferation	O
and	O
production	O
of	O
IL-2	B
,	O
IL-4	B
,	O
and	O
IFN	B
-	I
gamma	I
induced	O
by	O
both	O
CD3	B
and	O
CD3	B
/CD28	B
ligation	O
and	O
the	O
nuclear	O
expression	O
of	O
the	O
c	B
-	I
Jun	I
and	I
ATF-2	I
proteins	I
are	O
each	O
blocked	O
by	O
the	O
p38	B
MAPK	I
inhibitor	O
SB203580	O
.	O
Our	O
findings	O
demonstrate	O
that	O
p38	B
MAPK	I
1	O
)	O
plays	O
an	O
important	O
role	O
in	O
signal	O
integration	O
during	O
costimulation	O
of	O
primary	O
mouse	O
T	O
cells	O
,	O
2	O
)	O
may	O
be	O
involved	O
in	O
the	O
induction	O
of	O
c	B
-	I
Jun	I
activation	O
and	O
augmentation	O
of	O
AP-1	B
transcriptional	O
activity	O
,	O
and	O
3	O
)	O
regulates	O
whether	O
T	O
cells	O
enter	O
a	O
state	O
of	O
functional	O
unresponsiveness	O
.	O
The	O
functional	O
synergy	O
between	O
IL-12	B
and	O
IL-2	B
involves	O
p38	B
mitogen	I
-	I
activated	I
protein	I
kinase	I
and	O
is	O
associated	O
with	O
the	O
augmentation	O
of	O
STAT	O
serine	O
phosphorylation	O
.	O
IL-12	B
and	O
IL-2	B
can	O
stimulate	O
mitogen-	O
or	O
CD3-activated	O
T	O
cells	O
to	O
proliferate	O
,	O
produce	O
IFN	B
-	I
gamma	I
,	O
and	O
kill	O
tumor	O
cells	O
.	O
The	O
magnitude	O
of	O
these	O
functional	O
responses	O
is	O
greatly	O
augmented	O
when	O
T	O
cells	O
are	O
activated	O
by	O
the	O
combination	O
of	O
IL-12	B
and	O
IL-2	B
.	O
Although	O
peripheral	O
blood	O
T	O
cells	O
are	O
largely	O
unresponsive	O
to	O
these	O
cytokines	B
without	O
prior	O
activation	O
,	O
a	O
small	O
subset	O
of	O
CD8	O
+	O
T	O
cells	O
(	O
CD8+CD18bright	O
)	O
is	O
strongly	O
activated	O
by	O
the	O
combination	O
of	O
IL-12	B
and	O
IL-2	B
.	O
In	O
this	O
report	O
we	O
show	O
that	O
the	O
functional	O
synergy	O
between	O
IL-12	B
and	O
IL-2	B
in	O
CD8+CD18bright	O
T	O
cells	O
correlates	O
with	O
the	O
activation	O
of	O
the	O
stress	B
kinases	I
,	O
p38	B
mitogen	I
-	I
activated	I
protein	I
(	I
MAP	I
)	I
kinase	I
and	O
stress	B
-	I
activated	I
protein	I
kinase	I
(	I
SAPK	I
)	I
/Jun	I
N	I
-	I
terminal	I
kinase	I
,	O
but	O
not	O
with	O
the	O
activation	O
of	O
the	O
extracellular	B
signal	I
-	I
regulated	I
kinases	I
.	O
The	O
functional	O
synergy	O
between	O
IL-2	B
and	O
IL-12	B
is	O
also	O
associated	O
with	O
a	O
prominent	O
increase	O
in	O
STAT1	B
and	O
STAT3	B
serine	O
phosphorylation	O
over	O
that	O
observed	O
with	O
IL-12	B
or	O
IL-2	B
alone	O
.	O
By	O
contrast	O
,	O
STAT	B
tyrosine	O
phosphorylation	O
is	O
not	O
augmented	O
over	O
that	O
seen	O
with	O
either	O
cytokine	O
alone	O
.	O
A	O
specific	O
inhibitor	O
of	O
p38	O
MAP	O
kinase	O
completely	O
inhibits	O
the	O
serine	O
phosphorylation	O
of	O
STAT1	B
and	O
STAT3	B
induced	O
by	O
IL-12	B
and	O
IL-2	B
and	O
abrogates	O
the	O
functional	O
synergy	O
between	O
IL-12	B
and	O
IL-2	B
without	O
affecting	O
STAT	O
tyrosine	O
phosphorylation	O
.	O
This	O
suggests	O
that	O
p38	O
MAP	O
kinase	O
may	O
play	O
an	O
important	O
role	O
in	O
regulating	O
STAT	O
serine	O
phosphorylation	O
in	O
response	O
to	O
the	O
combination	O
of	O
IL-12	B
and	O
IL-2	B
.	O
Furthermore	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
optimal	O
activation	O
of	O
T	O
cells	O
by	O
IL-12	B
and	O
IL-2	B
may	O
depend	O
on	O
an	O
interaction	O
between	O
the	O
p38	B
MAP	I
kinase	I
and	O
Janus	B
kinase	I
/	I
STAT	I
signaling	O
pathways	O
.	O
Signal	O
transduction	O
pathways	O
activated	O
in	O
endothelial	O
cells	O
following	O
infection	O
with	O
Chlamydia	O
pneumoniae	O
.	O
Chlamydia	O
pneumoniae	O
is	O
an	O
important	O
respiratory	O
pathogen	O
.	O
Recently	O
,	O
its	O
presence	O
has	O
been	O
demonstrated	O
in	O
atherosclerotic	O
lesions	O
.	O
In	O
this	O
study	O
,	O
we	O
characterized	O
C.	O
pneumoniae	O
-	O
mediated	O
activation	O
of	O
endothelial	O
cells	O
and	O
demonstrated	O
an	O
enhanced	O
expression	O
of	O
endothelial	B
adhesion	I
molecules	I
followed	O
by	O
subsequent	O
rolling	O
,	O
adhesion	O
,	O
and	O
transmigration	O
of	O
leukocytes	O
(	O
monocytes	O
,	O
granulocytes	O
)	O
.	O
These	O
effects	O
were	O
blocked	O
by	O
mAbs	B
against	O
endothelial	B
and/or	I
leukocyte	I
adhesion	I
molecules	I
(	O
beta1	B
and	I
beta2	I
integrins	I
)	O
.	O
Additionally	O
,	O
activation	O
of	O
different	O
signal	O
transduction	O
pathways	O
in	O
C.	O
pneumoniae	O
-	O
infected	O
endothelial	O
cells	O
was	O
shown	O
:	O
protein	O
tyrosine	O
phosphorylation	O
,	O
up	O
-	O
regulation	O
of	O
phosphorylated	O
p42	B
/	I
p44	I
mitogen	I
-	I
activated	I
protein	I
kinase	I
,	O
and	O
NF	B
-	I
kappaB	I
activation	O
/	O
translocation	O
occurred	O
within	O
10	O
-	O
15	O
min	O
.	O
Increased	O
mRNA	O
and	O
surface	O
expression	O
of	O
E	B
-	I
selectin	I
,	O
ICAM-1	B
,	O
and	O
VCAM-1	B
were	O
noted	O
within	O
hours	O
.	O
Thus	O
,	O
C.	O
pneumoniae	O
triggers	O
a	O
cascade	O
of	O
events	O
that	O
could	O
lead	O
to	O
endothelial	O
activation	O
,	O
inflammation	O
,	O
and	O
thrombosis	O
,	O
which	O
in	O
turn	O
may	O
result	O
in	O
or	O
may	O
promote	O
atherosclerosis	O
.	O
Differential	O
induction	O
of	O
interferon	B
(	I
IFN	I
)	I
-inducible	I
protein	I
10	I
following	O
differentiation	O
of	O
a	O
monocyte	O
,	O
macrophage	O
cell	O
lineage	O
is	O
related	O
to	O
the	O
changes	O
of	O
nuclear	B
proteins	I
bound	O
to	O
IFN	O
stimulus	O
response	O
element	O
and	O
kappaB	O
sites	O
.	O
We	O
examined	O
chemokine	B
gene	O
expression	O
following	O
the	O
differentiation	O
of	O
a	O
monocyte	O
,	O
macrophage	O
cell	O
lineage	O
.	O
The	O
human	O
monoblastic	O
cell	O
line	O
,	O
U937	O
was	O
differentiated	O
to	O
macrophages	O
by	O
the	O
treatment	O
with	O
either	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
or	O
vitamin	O
D3	O
(	O
VitD3	O
)	O
.	O
The	O
gene	O
expression	O
of	O
interferon	B
(	I
IFN	I
)	I
-inducible	I
protein	I
10	I
(	O
IP-10	B
)	O
(	O
a	O
CXC	B
chemokine	I
)	O
was	O
markedly	O
augmented	O
by	O
the	O
IFNgamma	B
treatment	O
in	O
PMA	O
-or	O
RA	O
-	O
differentiated	O
U937	O
cells	O
,	O
but	O
only	O
marginally	O
in	O
undifferentiated	O
or	O
VitD3-treated	O
cells	O
.	O
In	O
contrast	O
,	O
another	O
inducible	O
gene	O
expression	O
of	O
monocyte	B
chemotactic	I
protein-1	I
(	O
a	O
CC	B
chemokine	I
)	O
and	O
the	O
activation	O
of	O
the	O
transcriptional	B
factor	I
(	O
FcRFgamma	B
)	O
bound	O
to	O
the	O
gamma	O
response	O
region	O
were	O
similarly	O
or	O
less	O
abundantly	O
induced	O
by	O
IFNgamma	B
treatment	O
in	O
PMA	O
-or	O
RA	O
-	O
differentiated	O
U937	O
cells	O
,	O
indicating	O
that	O
increased	O
IP-10	O
mRNA	O
induction	O
was	O
not	O
due	O
to	O
the	O
augmented	O
ability	O
of	O
the	O
cells	O
to	O
respond	O
to	O
the	O
presence	O
of	O
IFNgamma	B
.	O
Increased	O
expression	O
of	O
IFNgamma	B
-induced	O
IP-10	O
mRNA	O
following	O
the	O
differentiation	O
of	O
U937	O
cells	O
was	O
mediated	O
largely	O
by	O
augmented	O
transcriptional	O
activity	O
of	O
the	O
gene	O
and	O
was	O
related	O
to	O
differentiation	O
-	O
dependent	O
changes	O
of	O
the	O
proteins	O
bound	O
to	O
IFN	O
stimulus	O
response	O
element	O
(	O
ISRE	O
)	O
and	O
kB	O
sites	O
,	O
suggesting	O
that	O
these	O
nuclear	B
proteins	I
may	O
determine	O
the	O
IP-10	O
mRNA	O
inducibility	O
by	O
IFNgamma	B
.	O
Amelioration	O
of	O
rat	O
cerulein	O
pancreatitis	O
by	O
guamerin	O
-	O
derived	O
peptide	O
,	O
a	O
novel	O
elastase	B
inhibitor	O
.	O
Increased	O
activity	O
of	O
various	O
proteases	B
is	O
observed	O
in	O
both	O
human	O
and	O
experimental	O
pancreatitis	O
;	O
however	O
,	O
the	O
information	O
on	O
the	O
effects	O
of	O
specific	O
protease	O
inhibitors	O
on	O
the	O
disease	O
is	O
limited	O
.	O
In	O
this	O
study	O
we	O
show	O
that	O
a	O
novel	O
elastase	O
inhibitor	O
,	O
guamerin	O
-	O
derived	O
synthetic	O
peptide	O
(	O
GDSP	O
)	O
,	O
improves	O
the	O
parameters	O
of	O
cerulein	O
-	O
induced	O
acute	O
pancreatitis	O
in	O
the	O
rat	O
.	O
The	O
effects	O
of	O
GDSP	O
on	O
pancreatic	O
weight	O
,	O
serum	B
amylase	I
and	I
lipase	I
,	O
morphologic	O
changes	O
in	O
the	O
pancreas	O
,	O
neutrophil	O
infiltration	O
,	O
and	O
nuclear	B
factor	I
KB	I
(	O
NF	B
-	I
KB	I
)	O
activation	O
were	O
measured	O
in	O
rats	O
infused	O
with	O
supramaximal	O
dose	O
of	O
cerulein	O
(	O
5	O
(	O
g	O
/	O
kg	O
/	O
h	O
)	O
for	O
6	O
h	O
.	O
The	O
effects	O
of	O
GDSP	O
were	O
also	O
measured	O
on	O
superoxide	O
formation	O
by	O
activated	O
human	O
neutrophils	O
.	O
The	O
effects	O
of	O
GDSP	O
were	O
compared	O
with	O
those	O
of	O
another	O
elastase	O
inhibitor	O
,	O
elastatinal	O
.	O
GDSP	O
significantly	O
inhibited	O
edema	O
formation	O
,	O
neutrophil	O
infiltration	O
,	O
acinar	O
cell	O
damage	O
,	O
and	O
plasma	B
lipase	I
and	O
amylase	B
increases	O
caused	O
by	O
cerulein	O
.	O
GDSP	O
also	O
completely	O
inhibited	O
superoxide	O
formation	O
in	O
the	O
human	O
neutrophils	O
stimulated	O
by	O
N	O
-	O
formyl	O
-	O
methionine	O
-	O
leucine	O
-	O
phenyl	O
-	O
alanine	O
(	O
fMLP	O
)	O
or	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O
Elastatinal	O
had	O
some	O
of	O
the	O
same	O
effects	O
as	O
GDSP	O
but	O
was	O
less	O
potent	O
and	O
effective	O
.	O
These	O
results	O
demonstrate	O
a	O
beneficial	O
effect	O
of	O
GDSP	O
,	O
a	O
novel	O
specific	O
elastase	O
inhibitor	O
,	O
on	O
the	O
development	O
of	O
rat	O
cerulein	O
pancreatitis	O
.	O
Bcl-6	B
expression	O
in	O
reactive	O
follicular	O
hyperplasia	O
,	O
follicular	O
lymphoma	O
,	O
and	O
angioimmunoblastic	O
T	O
-	O
cell	O
lymphoma	O
with	O
hyperplastic	O
germinal	O
centers	O
:	O
heterogeneity	O
of	O
intrafollicular	O
T	O
-	O
cells	O
and	O
their	O
altered	O
distribution	O
in	O
the	O
pathogenesis	O
of	O
angioimmunoblastic	O
T	O
-	O
cell	O
lymphoma	O
.	O
BACKGROUND	O
:	O
The	O
Bcl-6	B
gene	I
product	I
,	O
a	O
nuclear	B
phosphoprotein	I
,	O
is	O
expressed	O
independently	O
of	O
Bcl-6	B
gene	O
rearrangement	O
.	O
In	O
lymph	O
nodes	O
,	O
expression	O
of	O
Bcl-6	B
protein	O
is	O
restricted	O
to	O
germinal	O
center	O
(	O
GC	O
)	O
B	O
-	O
cells	O
and	O
10	O
%	O
to	O
15	O
%	O
of	O
CD3	O
/	O
CD4	O
+	O
intrafollicular	O
T	O
cells	O
.	O
Interfollicular	O
cells	O
are	O
negative	O
for	O
Bcl-6	B
protein	I
,	O
except	O
for	O
rare	O
CD3+	O
/	O
CD4	O
+	O
T	O
cells	O
.	O
Recently	O
,	O
we	O
reported	O
cases	O
of	O
angioimmunoblastic	O
T	O
-	O
cell	O
lymphoma	O
(	O
AITL	O
)	O
with	O
hyperplastic	O
GCs	O
(	O
AITL	O
/	O
GC	O
)	O
,	O
and	O
observed	O
that	O
borders	O
of	O
enlarged	O
GCs	O
were	O
ill	O
defined	O
,	O
with	O
features	O
suggestive	O
of	O
an	O
outward	O
migration	O
of	O
GC	O
cells	O
to	O
surrounding	O
interfollicular	O
zones	O
.	O
This	O
prompted	O
a	O
study	O
of	O
follicular	O
borders	O
with	O
Bcl-6	B
staining	O
in	O
reactive	O
follicular	O
hyperplasias	O
and	O
follicular	O
lymphomas	O
to	O
compare	O
with	O
AITL	O
/	O
GC	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Formalin	O
-	O
fixed	O
paraffin	O
sections	O
were	O
used	O
for	O
immunostaining	O
of	O
Bcl-6	B
.	O
Six	O
cases	O
of	O
AITL	O
/	O
GC	O
,	O
12	O
nonspecific	O
reactive	O
follicular	O
hyperplasia	O
(	O
FH	O
)	O
,	O
7	O
HIV	O
adenopathy	O
,	O
10	O
follicular	O
lymphoma	O
(	O
FL	O
)	O
,	O
and	O
8	O
typical	O
AITL	O
(	O
ie	O
,	O
AITL	O
without	O
GC	O
)	O
were	O
studied	O
.	O
Double	O
staining	O
for	O
Bcl-6	B
/	I
CD20	I
,	O
Bcl-6	B
/	I
CD3	I
,	O
and	O
Bcl-6	B
/	I
CD57	I
was	O
performed	O
in	O
selected	O
cases	O
.	O
RESULTS	O
:	O
In	O
FH	O
and	O
HIV	O
adenopathy	O
,	O
staining	O
for	O
Bcl-6	B
revealed	O
densely	O
populated	O
GCs	O
with	O
well	O
-	O
defined	O
and	O
regular	O
GC	O
borders	O
,	O
whereas	O
Bcl-6	O
+	O
cells	O
were	O
rare	O
in	O
the	O
interfollicular	O
areas	O
.	O
An	O
occasional	O
GC	O
with	O
an	O
ill	O
-	O
defined	O
border	O
was	O
invariably	O
surrounded	O
by	O
a	O
broad	O
mantle	O
zone	O
;	O
those	O
with	O
indistinct	O
mantle	O
zones	O
had	O
well	O
-	O
defined	O
,	O
regular	O
borders	O
.	O
In	O
FL	O
,	O
follicles	O
were	O
densely	O
populated	O
,	O
and	O
their	O
borders	O
were	O
irregular	O
,	O
with	O
some	O
Bcl-6	O
+	O
cells	O
in	O
the	O
interfollicular	O
zones	O
.	O
In	O
AITL	O
/	O
GC	O
,	O
GCs	O
were	O
less	O
dense	O
,	O
GC	O
borders	O
were	O
ill	O
defined	O
and	O
irregular	O
,	O
and	O
the	O
number	O
of	O
interfollicular	O
Bcl-6	O
+	O
cells	O
was	O
markedly	O
increased	O
.	O
Double	O
staining	O
revealed	O
that	O
these	O
interfollicular	O
Bcl-6	O
+	O
cells	O
in	O
AITL	O
/	O
GC	O
were	O
Bcl6+	O
/	O
CD3+	O
/	O
CD20-	O
/	O
CD57-	O
T	O
cells	O
.	O
Moreover	O
,	O
CD3	O
+	O
intrafollicular	O
T	O
cells	O
were	O
depleted	O
in	O
AITL	O
/	O
GC	O
,	O
whereas	O
they	O
were	O
abundant	O
in	O
FH	O
.	O
Intrafollicular	O
CD57	O
+	O
cells	O
did	O
not	O
stain	O
for	O
Bcl-6	B
,	O
and	O
were	O
also	O
depleted	O
in	O
AITL	O
/	O
GC	O
.	O
In	O
typical	O
AITL	O
,	O
some	O
neoplastic	O
cells	O
were	O
positive	O
for	O
Bcl-6	B
,	O
showing	O
variable	O
degrees	O
of	O
staining	O
.	O
CONCLUSIONS	O
:	O
(	O
1	O
)	O
GCs	O
of	O
AITL	O
/	O
GC	O
differed	O
from	O
those	O
of	O
other	O
reactive	O
follicular	O
hyperplasias	O
and	O
follicular	O
lymphomas	O
,	O
and	O
staining	O
for	O
Bcl-6	B
was	O
useful	O
to	O
discern	O
them	O
.	O
(	O
2	O
)	O
Intrafollicular	O
CD3	O
+	O
T	O
cells	O
,	O
many	O
of	O
which	O
were	O
also	O
positive	O
for	O
Bcl-6	B
,	O
were	O
markedly	O
depleted	O
in	O
AITL	O
/	O
GC	O
,	O
with	O
increased	O
interfollicular	O
Bcl-6+	O
/	O
CD3	O
+	O
cells	O
,	O
suggesting	O
an	O
outward	O
migration	O
of	O
intrafollicular	O
T	O
cells	O
in	O
this	O
condition	O
.	O
(	O
3	O
)	O
Interfollicular	O
Bcl-6+	O
/	O
CD3	O
+	O
cells	O
in	O
AITL	O
/	O
GC	O
were	O
too	O
numerous	O
to	O
be	O
accounted	O
for	O
by	O
migration	O
alone	O
,	O
suggesting	O
local	O
proliferation	O
.	O
(	O
4	O
)	O
Intrafollicular	O
CD57	O
+	O
cells	O
were	O
negative	O
for	O
Bcl-6	B
,	O
indicating	O
heterogeneity	O
of	O
the	O
intrafollicular	O
T	O
-	O
cell	O
population	O
.	O
(	O
5	O
)	O
Some	O
neoplastic	O
cells	O
in	O
AITL	O
stained	O
for	O
Bcl-6	B
,	O
suggesting	O
up	O
-	O
regulation	O
of	O
Bcl-6	B
expression	O
in	O
this	O
tumor	O
.	O
Inhibition	O
of	O
T	O
cell	O
signaling	O
by	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
-	I
targeted	I
hematopoietic	I
tyrosine	I
phosphatase	I
(	O
HePTP	B
)	O
.	O
Activation	O
of	O
T	O
lymphocytes	O
to	O
produce	O
cytokines	B
is	O
regulated	O
by	O
the	O
counterbalance	O
of	O
protein	B
-	I
tyrosine	I
kinases	I
and	O
protein	O
-	O
tyrosine	O
phosphatases	O
,	O
many	O
of	O
which	O
have	O
a	O
high	O
degree	O
of	O
substrate	O
specificity	O
because	O
of	O
physical	O
association	O
with	O
their	O
targets	O
.	O
Overexpression	O
of	O
hematopoietic	B
protein	I
-	I
tyrosine	I
phosphatase	I
(	O
HePTP	B
)	O
results	O
in	O
suppression	O
of	O
T	O
lymphocyte	O
activation	O
as	O
measured	O
by	O
T	B
cell	I
antigen	I
receptor	I
-induced	O
activation	O
of	O
transcription	B
factors	I
binding	O
to	O
the	O
5	O
'	O
promoter	O
of	O
the	O
interleukin-2	O
gene	O
.	O
Efforts	O
to	O
pinpoint	O
the	O
exact	O
site	O
of	O
action	O
and	O
specificity	O
of	O
HePTP	B
in	O
the	O
signaling	O
cascade	O
revealed	O
that	O
HePTP	B
acts	O
directly	O
on	O
the	O
mitogen	B
-	I
activated	I
protein	I
(	I
MAP	I
)	I
kinases	I
Erk1	B
and	I
2	I
and	O
consequently	O
reduces	O
the	O
magnitude	O
and	O
duration	O
of	O
their	O
catalytic	O
activation	O
in	O
intact	O
T	O
cells	O
.	O
In	O
contrast	O
,	O
HePTP	B
had	O
no	O
effects	O
on	O
N	B
-	I
terminal	I
c	I
-	I
Jun	I
kinase	I
or	O
on	O
events	O
upstream	O
of	O
the	O
MAP	O
kinases	O
.	O
The	O
specificity	O
of	O
HePTP	B
correlated	O
with	O
its	O
physical	O
association	O
through	O
its	O
noncatalytic	O
N	B
terminus	I
with	O
Erk	B
and	O
another	O
MAP	B
kinase	I
,	O
p38	B
,	O
but	O
not	O
Jnk	B
or	O
other	O
proteins	O
.	O
We	O
propose	O
that	O
HePTP	B
plays	O
a	O
negative	O
role	O
in	O
antigen	O
receptor	O
signaling	O
by	O
specifically	O
regulating	O
MAP	B
kinases	I
in	O
the	O
cytosol	O
and	O
at	O
early	O
time	O
points	O
of	O
T	O
cell	O
activation	O
before	O
the	O
activation	O
-	O
induced	O
expression	O
of	O
nuclear	B
dual	I
-	I
specific	I
MAP	I
kinase	I
phosphatases	I
.	O
Modulation	O
of	O
E2F	B
complexes	I
during	O
G0	O
to	O
S	O
phase	O
transition	O
in	O
human	O
primary	O
B	O
-	O
lymphocytes	O
.	O
The	O
pocket	B
protein	I
-	I
E2F	I
complexes	I
are	O
convergence	O
points	O
for	O
cell	O
cycle	O
signaling	O
.	O
In	O
the	O
present	O
report	O
,	O
we	O
identified	O
and	O
monitored	O
the	O
pocket	B
protein	I
-	I
E2F	I
complexes	I
in	O
human	O
primary	O
B	O
-	O
lymphocytes	O
after	O
activation	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
.	O
Consistent	O
with	O
previous	O
data	O
from	O
human	O
and	O
mouse	O
fibroblasts	O
and	O
T	O
-	O
lymphocytes	O
,	O
E2F4	B
and	O
DP1	B
form	O
the	O
predominant	O
E2F	B
heterodimers	I
both	O
in	O
G0	O
and	O
G1	O
phases	O
of	O
the	O
human	O
B	O
-	O
lymphocyte	O
cell	O
cycle	O
,	O
whereas	O
E2F1	B
and	I
-3	I
are	O
first	O
detected	O
in	O
late	O
G1	O
,	O
and	O
their	O
expression	O
levels	O
increase	O
towards	O
S	O
phase	O
.	O
Intriguingly	O
,	O
the	O
major	B
E2F	I
complex	I
that	O
we	O
detected	O
in	O
quiescent	O
human	O
B	O
-	O
lymphocytes	O
is	O
consisted	O
of	O
pRB	B
,	O
E2F4	B
,	O
and	O
DP1	B
.	O
Though	O
the	O
levels	O
of	O
DP1	B
and	I
-2	I
increase	O
when	O
cells	O
progress	O
from	O
G0	O
to	O
S	O
,	O
the	O
proportion	O
of	O
DP1	B
to	O
DP2	B
remains	O
relatively	O
constant	O
during	O
the	O
cell	O
cycle	O
.	O
We	O
also	O
observed	O
an	O
increase	O
in	O
electrophoretic	O
mobility	O
of	O
the	O
predominant	O
E2F	B
components	I
,	O
DP1	B
and	O
E2F4	B
,	O
as	O
B	O
-	O
lymphocytes	O
progressed	O
from	O
G0	O
into	O
early	O
G1	O
.	O
This	O
increase	O
in	O
mobility	O
was	O
attributable	O
to	O
dephosphorylation	O
,	O
as	O
lambda	O
phosphatase	O
treatment	O
could	O
convert	O
the	O
slower	B
migrating	I
forms	I
into	O
the	O
corresponding	B
faster	I
mobility	I
forms	I
.	O
We	O
further	O
demonstrated	O
that	O
this	O
change	O
in	O
phosphorylation	O
status	O
correlates	O
with	O
a	O
decrease	O
in	O
DNA	O
binding	O
activity	O
.	O
This	O
modulation	O
of	O
DNA	O
binding	O
activity	O
mediated	O
through	O
the	O
dephosphorylation	O
of	O
DP1	B
and	O
E2F4	B
could	O
help	O
to	O
explain	O
the	O
lack	O
of	O
in	O
vivo	O
DNA	O
footprinting	O
in	O
late	O
G1	O
and	O
S	O
phases	O
of	O
gene	O
promoters	O
negatively	O
regulated	O
through	O
E2F	O
sites	O
and	O
suggests	O
a	O
novel	O
mechanism	O
for	O
controlling	O
E2F	B
transcriptional	O
activity	O
during	O
the	O
transition	O
from	O
quiescence	O
to	O
proliferation	O
.	O
Unexpected	O
and	O
coordinated	O
expression	O
of	O
Spi-1	B
,	O
Fli-1	B
,	O
and	O
megakaryocytic	O
genes	O
in	O
four	O
Epo	O
-	O
dependent	O
cell	O
lines	O
established	O
from	O
transgenic	O
mice	O
displaying	O
erythroid	O
-	O
specific	O
expression	O
of	O
a	O
thermosensitive	B
SV40	I
T	I
antigen	I
.	O
Most	O
erythroleukemic	O
cell	O
lines	O
established	O
in	O
vitro	O
coexpress	O
erythrocytic	B
and	I
megakaryocytic	I
markers	I
that	O
often	O
are	O
associated	O
with	O
expression	O
of	O
Spi-1	B
and/or	O
Fli-1	B
transcription	I
factors	I
known	O
as	O
transactivators	B
of	I
megakaryocyte	I
-	I
specific	I
promoters	I
.	O
In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
possibility	O
of	O
establishing	O
new	O
cell	O
lines	O
keeping	O
strictly	O
erythroid	O
-	O
specific	O
properties	O
in	O
vitro	O
through	O
the	O
targeted	O
and	O
conditional	O
immortalization	O
of	O
erythrocytic	O
progenitors	O
.	O
For	O
that	O
purpose	O
,	O
we	O
established	O
several	O
lines	O
of	O
transgenic	O
mice	O
displaying	O
erythroid	O
-	O
specific	O
expression	O
of	O
a	O
thermosensitive	B
SV40	I
T	I
antigen	I
.	O
As	O
expected	O
,	O
these	O
transgenic	O
mice	O
developed	O
splenomegaly	O
due	O
to	O
the	O
massive	O
amplification	O
of	O
Ter	O
119	O
positive	O
erythroid	O
nucleated	O
cells	O
expressing	O
T	B
antigen	I
.	O
Despite	O
this	O
drastic	O
effect	O
in	O
vivo	O
,	O
the	O
in	O
vitro	O
immortalization	O
of	O
erythropoietin	O
-	O
dependent	O
erythroid	O
progenitors	O
unexpectedly	O
occurred	O
at	O
low	O
frequency	O
,	O
and	O
all	O
four	O
cell	O
lines	O
established	O
expressed	O
both	O
erythrocytic	B
(	I
globins	I
)	I
and	I
megakaryocytic	I
markers	I
(	O
glycoprotein	B
IIb	I
,	O
platelet	B
factor	I
4	I
)	O
as	O
well	O
as	O
Spi-1	B
and	O
Fli-1	B
transcripts	I
at	O
permissive	O
temperature	O
.	O
Switching	O
the	O
cells	O
to	O
the	O
nonpermissive	O
temperature	O
led	O
to	O
a	O
marked	O
increase	O
in	O
globin	O
gene	O
expression	O
and	O
concomitant	O
decrease	O
in	O
expression	O
of	O
Spi-1	B
,	O
Fli-1	B
,	O
and	O
megakaryocytic	O
genes	O
in	O
an	O
erythropoietin	B
-dependent	O
manner	O
.	O
Interestingly	O
,	O
enhanced	O
expression	O
of	O
Spi-1	O
and	O
Fli-1	O
genes	O
already	O
was	O
detected	O
in	O
the	O
Ter	O
119	O
positive	O
cell	O
population	O
of	O
transgenic	O
mice	O
spleen	O
in	O
vivo	O
.	O
However	O
,	O
like	O
normal	O
Ter	O
119	O
erythroid	O
cells	O
,	O
these	O
Ter	O
119	O
positive	O
cells	O
from	O
transgenic	O
mice	O
still	O
expressed	O
high	O
levels	O
of	O
beta	B
-	I
globin	I
and	O
very	O
low	O
or	O
undetectable	O
glycoprotein	B
IIb	I
and	O
platelet	B
factor	I
4	I
megakaryocytic	I
transcripts	I
.	O
Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
unexpected	O
expression	O
of	O
megakaryocytic	O
genes	O
is	O
a	O
specific	O
property	O
of	O
immortalized	O
cells	O
that	O
can	O
not	O
be	O
explained	O
only	O
by	O
enhanced	O
expression	O
of	O
Spi-1	O
and/or	O
Fli-1	O
genes	O
.	O
Angiotensin	B
II	I
activates	O
the	O
proinflammatory	B
transcription	I
factor	I
nuclear	B
factor	I
-	I
kappaB	I
in	O
human	O
monocytes	O
.	O
The	O
renin	B
-angiotensin	O
system	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
.	O
A	O
common	O
feature	O
of	O
all	O
stages	O
of	O
atherosclerosis	O
is	O
inflammation	O
of	O
the	O
vessel	O
wall	O
.	O
The	O
transcription	O
factor	O
nuclear	B
factor	I
-	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
participates	O
in	O
most	O
signaling	O
pathways	O
involved	O
in	O
inflammation	O
.	O
This	O
study	O
therefore	O
examined	O
the	O
effect	O
of	O
angiotensin	B
(	I
ANG	I
)	I
II	I
on	O
NF	B
-	I
kappaB	I
activation	O
in	O
monocytic	O
cells	O
,	O
a	O
major	O
cellular	O
component	O
of	O
human	O
atheroma	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
ANG	B
II	I
,	O
like	O
TNFalpha	B
,	O
caused	O
rapid	O
activation	O
of	O
NF	B
-	I
kappaB	I
in	O
human	O
mononuclear	O
cells	O
isolated	O
from	O
peripheral	O
blood	O
by	O
Ficoll	O
density	O
gradient	O
.	O
This	O
ANG	B
II	I
effect	O
was	O
blocked	O
by	O
the	O
angiotensin	O
AT1	O
receptor	O
antagonist	O
losartan	O
.	O
Specificity	O
of	O
ANG	B
II	I
-induced	O
NF	B
-	I
kappaB	I
activation	O
was	O
ascertained	O
by	O
supershift	O
and	O
competition	O
experiments	O
.	O
Moreover	O
,	O
ANG	B
II	I
stimulated	O
NF	B
-	I
kappaB	I
activation	O
in	O
human	O
monocytes	O
,	O
but	O
not	O
in	O
lymphocytes	O
from	O
the	O
same	O
preparation	O
.	O
Together	O
,	O
the	O
data	O
demonstrate	O
the	O
ability	O
of	O
the	O
vasoactive	O
peptide	O
ANG	B
II	I
to	O
activate	O
inflammatory	O
pathways	O
in	O
human	O
monocytes	O
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
LPS	O
-	O
Induced	O
NF	B
-	I
kappaB	I
activation	O
and	O
TNF	B
-	I
alpha	I
release	O
in	O
human	O
monocytes	O
are	O
protein	B
tyrosine	I
kinase	I
dependent	O
and	O
protein	B
kinase	I
C	I
independent	O
.	O
BACKGROUND	O
:	O
Tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
is	O
an	O
important	O
mediator	O
of	O
septic	O
shock	O
.	O
Endotoxin	O
(	O
LPS	O
)	O
signal	O
transduction	O
in	O
human	O
monocytes	O
leads	O
to	O
activation	O
of	O
nuclear	B
factor	I
-	I
kappa	I
B	I
(	O
NF	B
-	I
kappaB	I
)	O
and	O
TNF	B
-	I
alpha	I
release	O
.	O
Previous	O
studies	O
have	O
implicated	O
activation	O
of	O
both	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
and	O
protein	B
tyrosine	I
kinases	I
(	O
PTK	B
)	O
in	O
LPS	O
-	O
induced	O
NF	B
-	I
kappaB	I
activation	O
and	O
TNF	B
-	I
alpha	I
production	O
.	O
We	O
hypothesized	O
that	O
inhibition	O
of	O
either	O
PKC	B
or	O
PTK	B
would	O
decrease	O
LPS	O
-	O
induced	O
NF	B
-	I
kappaB	I
DNA	O
binding	O
and	O
TNF	B
-	I
alpha	I
release	O
in	O
human	O
monocytes	O
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Human	O
monocytes	O
were	O
stimulated	O
with	O
PMA	O
(	O
50	O
ng	O
/	O
ml	O
)	O
alone	O
or	O
LPS	O
(	O
100	O
ng	O
/	O
ml	O
)	O
with	O
and	O
without	O
a	O
nonspecific	O
serine	B
/	I
threonine	I
protein	I
kinase	I
inhibitor	O
staurosporine	O
(	O
Stauro	O
)	O
,	O
a	O
specific	O
pan-	O
PKC	B
inhibitor	O
bisindolylmaleimide	O
(	O
Bis	O
)	O
,	O
or	O
an	O
inhibitor	O
of	O
PTK	B
genistein	O
(	O
Gen	O
)	O
.	O
TNF	B
-	I
alpha	I
release	O
in	O
culture	O
supernatants	O
was	O
measured	O
by	O
an	O
ELISA	O
.	O
NF	B
-	I
kappaB	I
DNA	O
binding	O
was	O
evaluated	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
RESULTS	O
:	O
LPS	O
increased	O
NF	B
-	I
kappaB	I
DNA	O
binding	O
and	O
TNF	B
-	I
alpha	I
release	O
in	O
human	O
monocytes	O
.	O
Nonspecific	O
protein	B
kinase	I
inhibition	O
inhibited	O
NF	B
-	I
kappaB	I
activation	O
and	O
TNF	B
-	I
alpha	I
release	O
,	O
while	O
specific	O
PKC	B
inhibition	O
with	O
Bis	O
had	O
no	O
effect	O
on	O
LPS	O
-	O
induced	O
NF	B
-	I
kappaB	I
DNA	O
binding	O
or	O
TNF	B
-	I
alpha	I
release	O
.	O
PTK	B
inhibition	O
with	O
Gen	O
attenuated	O
both	O
LPS	O
-	O
induced	O
NF	B
-	I
kappaB	I
DNA	O
binding	O
and	O
TNF	B
-	I
alpha	I
production	O
in	O
human	O
monocytes	O
.	O
Direct	O
activation	O
of	O
PKC	B
with	O
PMA	O
induced	O
both	O
NF	B
-	I
kappaB	I
activation	O
and	O
TNF	B
-	I
alpha	I
production	O
by	O
human	O
monocytes	O
.	O
CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
LPS	O
-	O
induced	O
NF	B
-	I
kappaB	I
activation	O
and	O
TNF	B
-	I
alpha	I
release	O
in	O
human	O
monocytes	O
are	O
independent	O
of	O
PKC	B
activity	O
.	O
Furthermore	O
,	O
our	O
results	O
provide	O
evidence	O
that	O
PTK	B
plays	O
a	O
role	O
in	O
LPS	O
-	O
induced	O
NF	B
-	I
kappaB	I
activation	O
and	O
TNF	B
-	I
alpha	I
release	O
in	O
human	O
monocytes	O
and	O
thus	O
could	O
be	O
a	O
potential	O
therapeutic	O
target	O
in	O
inflammatory	O
states	O
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
Modulation	O
of	O
the	O
immune	O
response	O
and	O
tumor	O
growth	O
by	O
activated	O
Ras	B
.	O
As	O
a	O
result	O
of	O
its	O
transforming	O
abilities	O
,	O
activated	B
Ras	I
is	O
expressed	O
in	O
a	O
great	O
number	O
of	O
cancers	O
.	O
The	O
ras	O
mutation	O
frequency	O
varies	O
between	O
95	O
%	O
in	O
pancreatic	O
cancer	O
and	O
5	O
%	O
in	O
breast	O
cancer	O
.	O
In	O
leukemia	O
,	O
the	O
highest	O
frequency	O
(	O
30	O
%	O
)	O
is	O
found	O
in	O
acute	O
myeloid	O
leukemia	O
.	O
The	O
presence	O
of	O
ras	O
mutations	O
has	O
been	O
correlated	O
with	O
a	O
poor	O
prognosis	O
and	O
negative	O
clinical	O
outcome	O
.	O
This	O
suggests	O
that	O
mutated	B
Ras	I
activates	O
mechanisms	O
,	O
which	O
favor	O
tumor	O
growth	O
,	O
enhance	O
the	O
metastatic	O
capacity	O
of	O
tumors	O
or	O
modulate	O
tumor	O
-	O
specific	O
immune	O
responses	O
.	O
Several	O
new	O
functions	O
of	O
Ras	B
,	O
such	O
as	O
downregulation	O
of	O
major	B
histocompatibility	I
complex	I
molecules	I
,	O
upregulation	O
of	O
certain	O
cytokines	B
,	O
growth	B
factors	I
and	O
degradative	B
enzymes	I
have	O
been	O
uncovered	O
in	O
the	O
last	O
decade	O
.	O
Additionally	O
,	O
mutated	B
Ras	I
can	O
also	O
serve	O
as	O
a	O
primary	O
target	O
for	O
the	O
development	O
of	O
immunotherapy	O
or	O
drug	O
therapy	O
.	O
This	O
review	O
will	O
discuss	O
the	O
mechanisms	O
by	O
which	O
Ras	B
expressing	O
tumors	O
are	O
able	O
to	O
evade	O
destruction	O
by	O
the	O
immune	O
system	O
and	O
enhance	O
their	O
growth	O
and	O
metastatic	O
potential	O
.	O
It	O
will	O
further	O
elaborate	O
on	O
the	O
attempts	O
to	O
develop	O
successful	O
immunotherapy	O
and	O
drug	O
therapy	O
targeting	O
Ras	B
expressing	O
tumors	O
.	O
Cellular	O
disposition	O
of	O
sulphamethoxazole	O
and	O
its	O
metabolites	O
:	O
implications	O
for	O
hypersensitivity	O
.	O
1	O
.	O
Bioactivation	O
of	O
sulphamethoxazole	O
(	O
SMX	O
)	O
to	O
chemically	O
-	O
reactive	O
metabolites	O
and	O
subsequent	O
protein	O
conjugation	O
is	O
thought	O
to	O
be	O
involved	O
in	O
SMX	O
hypersensitivity	O
.	O
We	O
have	O
therefore	O
examined	O
the	O
cellular	O
metabolism	O
,	O
disposition	O
and	O
conjugation	O
of	O
SMX	O
and	O
its	O
metabolites	O
in	O
vitro	O
.	O
2	O
.	O
Flow	O
cytometry	O
revealed	O
binding	O
of	O
N	O
-	O
hydroxy	O
(	O
SMX	O
-	O
NHOH	O
)	O
and	O
nitroso	O
(	O
SMX	O
-	O
NO	O
)	O
metabolites	O
of	O
SMX	O
,	O
but	O
not	O
of	O
SMX	O
itself	O
,	O
to	O
the	O
surface	O
of	O
viable	O
white	O
blood	O
cells	O
.	O
Cellular	O
haptenation	O
by	O
SMX	O
-	O
NO	O
was	O
reduced	O
by	O
exogenous	O
glutathione	O
(	O
GSH	O
)	O
.	O
3	O
.	O
SMX	O
-	O
NHOH	O
and	O
SMX	O
-	O
NO	O
were	O
rapidly	O
reduced	O
back	O
to	O
the	O
parent	O
compound	O
by	O
cysteine	O
(	O
CYS	O
)	O
,	O
GSH	O
,	O
human	O
peripheral	O
blood	O
cells	O
and	O
plasma	O
,	O
suggesting	O
that	O
this	O
is	O
an	O
important	O
and	O
ubiquitous	B
bioinactivation	O
mechanism	O
.	O
4	O
.	O
Fluorescence	O
HPLC	O
showed	O
that	O
SMX	O
-	O
NHOH	O
and	O
SMX	O
-	O
NO	O
depleted	O
CYS	O
and	O
GSH	O
in	O
buffer	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
in	O
cells	O
and	O
plasma	O
.	O
5	O
.	O
Neutrophil	O
apoptosis	O
and	O
inhibition	O
of	O
neutrophil	O
function	O
were	O
induced	O
at	O
lower	O
concentrations	O
of	O
SMX	O
-	O
NHOH	O
and	O
SMX	O
-	O
NO	O
than	O
those	O
inducing	O
loss	O
of	O
membrane	O
viability	O
,	O
with	O
SMX	O
having	O
no	O
effect	O
.	O
Lymphocytes	O
were	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
more	O
sensitive	O
to	O
the	O
direct	O
cytotoxic	O
effects	O
of	O
SMX	O
-	O
NO	O
than	O
neutrophils	O
.	O
6	O
.	O
Partitioning	O
of	O
SMX	O
-	O
NHOH	O
into	O
red	O
blood	O
cells	O
was	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
lower	O
than	O
with	O
the	O
hydroxylamine	O
of	O
dapsone	O
.	O
7	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
balance	O
between	O
oxidation	O
of	O
SMX	O
to	O
its	O
toxic	O
metabolites	O
and	O
their	O
reduction	O
is	O
an	O
important	O
protective	O
cellular	O
mechanism	O
.	O
If	O
an	O
imbalance	O
exists	O
,	O
haptenation	O
of	O
the	O
toxic	O
metabolites	O
to	O
bodily	O
proteins	O
including	O
the	O
surface	O
of	O
viable	O
cells	O
can	O
occur	O
,	O
and	O
may	O
result	O
in	O
drug	O
hypersensitivity	O
.	O
Tcf-1	B
-mediated	O
transcription	O
in	O
T	O
lymphocytes	O
:	O
differential	O
role	O
for	O
glycogen	B
synthase	I
kinase-3	I
in	O
fibroblasts	O
and	O
T	O
cells	O
.	O
Beta	O
-	O
catenin	O
is	O
the	O
vertebrate	O
homolog	O
of	O
the	O
Drosophila	O
segment	O
polarity	O
gene	O
Armadillo	O
and	O
plays	O
roles	O
in	O
both	O
cell	O
-	O
cell	O
adhesion	O
and	O
transduction	O
of	O
the	O
Wnt	O
signaling	O
cascade	O
.	O
Recently	O
,	O
members	O
of	O
the	O
Lef	B
/	I
Tcf	I
transcription	I
factor	I
family	I
have	O
been	O
identified	O
as	O
protein	O
partners	O
of	O
beta	B
-	I
catenin	I
,	O
explaining	O
how	O
beta	B
-	I
catenin	I
alters	O
gene	O
expression	O
.	O
Here	O
we	O
report	O
that	O
in	O
T	O
cells	O
,	O
Tcf-1	B
also	O
becomes	O
transcriptionally	O
active	O
through	O
interaction	O
with	O
beta	B
-	I
catenin	I
,	O
suggesting	O
that	O
the	O
Wnt	O
signal	O
transduction	O
pathway	O
is	O
operational	O
in	O
T	O
lymphocytes	O
as	O
well	O
.	O
However	O
,	O
although	O
Wnt	O
signals	O
are	O
known	O
to	O
inhibit	O
the	O
activity	O
of	O
the	O
negative	B
regulatory	I
protein	I
kinase	I
glycogen	B
synthase	I
kinase-3beta	I
(	O
GSK-3beta	B
)	O
,	O
resulting	O
in	O
increased	O
levels	O
of	O
beta	B
-	I
catenin	I
,	O
we	O
find	O
no	O
evidence	O
for	O
involvement	O
of	O
GSK-3beta	B
in	O
Tcf	O
-	O
mediated	O
transcription	O
in	O
T	O
cells	O
.	O
That	O
is	O
,	O
a	O
dominant	B
negative	I
GSK-3beta	I
does	O
not	O
specifically	O
activate	O
Tcf	O
transcription	O
and	O
stimuli	O
(	O
lithium	O
or	O
phytohemagglutinin	B
)	O
that	O
inhibit	O
GSK-3beta	B
activity	O
also	O
do	O
not	O
activate	O
Tcf	O
reporter	O
genes	O
.	O
Thus	O
,	O
inhibition	O
of	O
GSK-3beta	B
is	O
insufficient	O
to	O
activate	O
Tcf	O
-	O
dependent	O
transcription	O
in	O
T	O
lymphocytes	O
.	O
In	O
contrast	O
,	O
in	O
C57MG	O
fibroblast	O
cells	O
,	O
lithium	O
inactivates	O
GSK-3beta	B
and	O
induces	O
Tcf	O
-	O
controlled	O
transcription	O
.	O
This	O
is	O
the	O
first	O
demonstration	O
that	O
lithium	O
can	O
alter	O
gene	O
expression	O
of	O
Tcf	O
-	O
responsive	O
genes	O
,	O
and	O
points	O
to	O
a	O
difference	O
in	O
regulation	O
of	O
Wnt	O
signaling	O
between	O
fibroblasts	O
and	O
lymphocytes	O
.	O
CIITA	B
-induced	O
occupation	O
of	O
MHC	O
class	O
II	O
promoters	O
is	O
independent	O
of	O
the	O
cooperative	O
stabilization	O
of	O
the	O
promoter	B
-	I
bound	I
multi	I
-	I
protein	I
complexes	I
.	O
Precise	O
regulation	O
of	O
MHC	O
class	O
II	O
expression	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
control	O
of	O
the	O
immune	O
response	O
.	O
The	O
transactivator	B
CIITA	B
behaves	O
as	O
a	O
master	O
controller	O
of	O
constitutive	O
and	O
inducible	O
MHC	O
class	O
II	O
gene	O
activation	O
,	O
but	O
its	O
exact	O
mechanism	O
of	O
action	O
is	O
not	O
known	O
.	O
Activation	O
of	O
MHC	O
class	O
II	O
promoters	O
requires	O
binding	O
of	O
at	O
least	O
three	O
distinct	O
multi	B
-	I
protein	I
complexes	I
(	O
RFX	B
,	O
X2BP	B
and	O
NF	B
-	I
Y	I
)	O
.	O
It	O
is	O
known	O
that	O
the	O
stability	O
of	O
this	O
binding	O
results	O
from	O
cooperative	O
interactions	O
between	O
these	O
proteins	O
.	O
We	O
show	O
here	O
that	O
expression	O
of	O
CIITA	B
in	O
MHC	O
class	O
II	O
-cells	O
triggers	O
occupation	O
of	O
the	O
promoters	O
by	O
these	O
complexes	O
.	O
This	O
observation	O
raised	O
the	O
possibility	O
that	O
the	O
effect	O
of	O
CIITA	B
on	O
promoter	O
occupation	O
is	O
mediated	O
by	O
an	O
effect	O
on	O
the	O
cooperative	O
stabilization	O
of	O
the	O
DNA	B
-	I
bound	I
multi	I
-	I
protein	I
complexes	I
.	O
We	O
show	O
,	O
however	O
,	O
that	O
the	O
presence	O
of	O
CIITA	B
does	O
not	O
affect	O
the	O
stability	O
of	O
the	O
higher	O
-	O
order	O
protein	O
complex	O
formed	O
on	O
DNA	O
by	O
RFX	B
,	O
X2BP	B
and	O
NF	B
-	I
Y	I
.	O
This	O
suggests	O
other	O
mechanisms	O
for	O
CIITA	B
-induced	O
promoter	O
occupancy	O
,	O
such	O
as	O
an	O
effect	O
on	O
chromatin	O
structure	O
leading	O
to	O
increased	O
accessibility	O
of	O
MHC	O
class	O
II	O
promoters	O
.	O
This	O
ability	O
of	O
CIITA	B
to	O
facilitate	O
promoter	O
occupation	O
is	O
undissociable	O
from	O
its	O
transactivation	O
potential	O
.	O
Finally	O
,	O
we	O
conclude	O
that	O
this	O
effect	O
of	O
CIITA	B
is	O
cell	O
-	O
type	O
specific	O
,	O
since	O
expression	O
of	O
CIITA	B
is	O
not	O
required	O
for	O
normal	O
occupation	O
of	O
MHC	O
class	O
II	O
promoters	O
in	O
B	O
lymphocytes	O
.	O
Activation	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
by	O
lipopolysaccharide	O
in	O
mononuclear	O
leukocytes	O
is	O
prevented	O
by	O
inhibitors	O
of	O
cytosolic	B
phospholipase	I
A2	I
.	O
In	O
monocytes	O
,	O
lipopolysaccharide	O
induces	O
synthesis	O
and	O
activity	O
of	O
the	O
85-kDa	O
cytosolic	B
phospholipase	I
A2	I
.	O
This	O
enzyme	O
releases	O
arachidonic	O
acid	O
and	O
lyso	O
-	O
phospholipids	O
from	O
membranes	O
which	O
are	O
metabolized	O
to	O
eicosanoids	O
and	O
platelet	O
-	O
activating	O
-	O
factor	O
.	O
These	O
lipid	O
mediators	O
increase	O
activity	O
of	O
transcription	B
factors	I
and	O
expression	O
of	O
cytokine	O
genes	O
indicating	O
a	O
function	O
for	O
cytosolic	B
phospholipase	I
A2	I
in	O
signal	O
transduction	O
and	O
inflammation	O
.	O
We	O
have	O
shown	O
previously	O
that	O
trifluoromethylketone	O
inhibitors	O
of	O
cytosolic	B
phospholipase	I
A2	I
suppressed	O
interleukin-1beta	O
protein	O
and	O
steady	O
-	O
state	O
mRNA	O
levels	O
in	O
human	O
lipopolysaccharide	O
-	O
stimulated	O
peripheral	O
blood	O
mononuclear	O
leukocytes	O
.	O
In	O
this	O
study	O
,	O
the	O
subcellular	O
mechanisms	O
were	O
analyzed	O
by	O
which	O
trifluoromethylketones	O
interfere	O
with	O
gene	O
expression	O
.	O
We	O
found	O
that	O
they	O
reduced	O
the	O
initial	O
interleukin-1beta	O
mRNA	O
transcription	O
rate	O
through	O
prevention	O
of	O
degradation	O
of	O
inhibitor	B
-	I
kappaB	I
alpha	I
.	O
Consequently	O
,	O
cytosolic	O
activation	O
,	O
nuclear	O
translocation	O
and	O
DNA	O
-	O
binding	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
were	O
decreased	O
.	O
Trifluoromethylketones	O
ameliorate	O
chronic	O
inflammation	O
in	O
vivo	O
.	O
Thus	O
,	O
this	O
therapeutic	O
potency	O
may	O
reside	O
in	O
retention	O
of	O
inactive	O
nuclear	B
factor	I
-	I
kappaB	I
in	O
the	O
cytosol	O
thereby	O
abrogating	O
interleukin-1beta	B
gene	O
transcription	O
.	O
Immunosuppressant	O
PG490	O
(	O
triptolide	O
)	O
inhibits	O
T	B
-	I
cell	I
interleukin-2	I
expression	O
at	O
the	O
level	O
of	O
purine	B
-	I
box	I
/	I
nuclear	I
factor	I
of	O
activated	O
T	O
-	O
cells	O
and	O
NF	B
-	I
kappaB	I
transcriptional	O
activation	O
.	O
PG490	O
(	O
triptolide	O
)	O
is	O
a	O
diterpene	O
triepoxide	O
with	O
potent	O
immunosuppressive	O
and	O
antiinflammatory	O
properties	O
.	O
PG490	O
inhibits	O
interleukin	B
(	I
IL	I
)	I
-2	I
expression	O
by	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
antibody	O
to	O
CD3	B
(	O
IC50	O
of	O
10	O
ng	O
/	O
ml	O
)	O
,	O
and	O
with	O
PMA	O
and	O
ionomycin	O
(	O
Iono	O
,	O
IC50	O
of	O
40	O
ng	O
/	O
ml	O
)	O
.	O
In	O
Jurkat	O
T	O
-	O
cells	O
,	O
PG490	O
inhibits	O
PMA	O
/	O
Iono	O
-	O
stimulated	O
IL-2	B
transcription	O
.	O
PG490	O
inhibits	O
the	O
induction	O
of	O
DNA	O
binding	O
activity	O
at	O
the	O
purine	O
-	O
box	O
/	O
antigen	O
receptor	O
response	O
element	O
(	O
ARRE	O
)	O
/nuclear	O
factor	O
of	O
activated	O
T	O
-	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
target	O
sequence	O
but	O
not	O
at	O
the	O
NF	O
-	O
kappaB	O
site	O
.	O
PG490	O
can	O
completely	O
inhibit	O
transcriptional	O
activation	O
at	O
the	O
purine	O
-	O
box	O
/	O
ARRE	O
/	O
NF	O
-	O
AT	O
and	O
NF	O
-	O
kappaB	O
target	O
DNA	O
sequences	O
triggered	O
by	O
all	O
stimuli	O
examined	O
(	O
PMA	O
,	O
PMA	O
/	O
Iono	O
,	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
)	O
.	O
PG490	O
also	O
inhibits	O
PMA	O
-	O
stimulated	O
activation	O
of	O
a	O
chimeric	B
transcription	I
factor	I
in	O
which	O
the	O
C	B
-	I
terminal	I
TA1	I
transactivation	I
domain	I
of	O
NF	B
-	I
kappaB	I
p65	I
is	O
fused	O
to	O
the	O
DNA	B
binding	I
domain	I
of	O
GAL4	B
.	O
In	O
16HBE	O
human	O
bronchial	O
epithelial	O
cells	O
,	O
IL-8	B
expression	O
is	O
regulated	O
predominantly	O
by	O
NF	B
-	I
kappaB	I
,	O
and	O
PG490	O
but	O
not	O
cyclosporin	O
A	O
can	O
completely	O
inhibit	O
expression	O
of	O
IL-8	B
.	O
The	O
mechanism	O
of	O
PG490	O
inhibition	O
of	O
cytokine	O
gene	O
expression	O
differs	O
from	O
cyclosporin	O
A	O
and	O
involves	O
nuclear	O
inhibition	O
of	O
transcriptional	O
activation	O
of	O
NF	B
-	I
kappaB	I
and	O
the	O
purine	O
-	O
box	O
regulator	O
operating	O
at	O
the	O
ARRE	O
/	O
NF	O
-	O
AT	O
site	O
at	O
a	O
step	O
after	O
specific	O
DNA	O
binding	O
.	O
Signal	O
transduction	O
through	O
interferon	B
-	I
gamma	I
receptor	I
on	O
human	O
eosinophils	O
.	O
BACKGROUND	O
:	O
We	O
reported	O
on	O
the	O
constitutive	O
interferon	B
-	I
gamma	I
receptor	I
(	O
IFN	B
-	I
gammaR	I
)	O
expression	O
on	O
eosinophils	O
.	O
But	O
signal	O
transduction	O
through	O
IFN	B
-	I
gammaR	I
on	O
eosinophils	O
remains	O
to	O
be	O
elucidated	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
involvement	O
of	O
the	O
Jak	B
/	I
Stat	I
pathway	O
in	O
the	O
signaling	O
of	O
eosinophils	O
after	O
IFN	B
-	I
gammaR	I
conjugation	O
by	O
the	O
ligand	O
binding	O
.	O
METHODS	O
:	O
Purified	O
peripheral	O
eosinophils	O
were	O
stimulated	O
with	O
IFN	B
-	I
gamma	I
at	O
37	O
degrees	O
C	O
for	O
1	O
-	O
60	O
min	O
.	O
Tyrosine	O
phosphorylation	O
of	O
IFN	B
-	I
gammaR	I
,	O
Jak1	B
,	O
Jak2	B
,	O
and	O
Stat1alpha	B
was	O
examined	O
by	O
immunoblotting	O
.	O
Gel	O
-	O
shift	O
assay	O
was	O
also	O
examined	O
to	O
show	O
the	O
formation	O
of	O
Stat1alpha	B
-	I
DNA	I
complexes	I
.	O
RESULTS	O
:	O
We	O
show	O
that	O
binding	O
of	O
IFN	B
-	I
gamma	I
to	O
human	O
eosinophils	O
initiated	O
a	O
series	O
of	O
events	O
that	O
resulted	O
in	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
not	O
only	O
the	O
IFN	B
-	I
gammaRalpha	I
chain	I
but	O
also	O
Jak1	B
,	O
Jak2	B
,	O
and	O
Stat1alpha	B
.	O
In	O
addition	O
,	O
IFN	B
-	I
gamma	I
enhanced	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
Stat1alpha	B
.	O
CONCLUSION	O
:	O
These	O
data	O
indicate	O
that	O
IFN	B
-	I
gamma	I
affects	O
eosinophils	O
through	O
its	O
specific	O
receptor	O
and	O
utilizes	O
the	O
Jak	B
/	I
Stat	I
pathway	O
as	O
its	O
mode	O
of	O
signaling	O
.	O
Estrogen	O
and	O
progesterone	O
induction	O
of	O
survival	O
of	O
monoblastoid	O
cells	O
undergoing	O
TNF	B
-	I
alpha	I
-induced	O
apoptosis	O
.	O
Induction	O
of	O
apoptosis	O
of	O
mononucleated	O
cells	O
is	O
a	O
physiological	O
process	O
for	O
regulating	O
the	O
intensity	O
of	O
the	O
immune	O
response	O
.	O
The	O
female	O
steroid	O
hormones	O
estrogen	O
(	O
E2	O
)	O
and	O
progesterone	O
(	O
Prog	O
)	O
are	O
known	O
to	O
modulate	O
the	O
reactivity	O
of	O
the	O
immune	O
system	O
;	O
recently	O
it	O
has	O
been	O
demonstrated	O
that	O
they	O
can	O
regulate	O
induction	O
of	O
apoptosis	O
of	O
endothelial	O
cells	O
and	O
osteoblasts	O
.	O
TNF	B
-	I
alpha	I
-mediated	O
induction	O
of	O
apoptosis	O
has	O
been	O
well	O
characterized	O
in	O
myeloid	O
cells	O
.	O
We	O
investigated	O
whether	O
E2	O
and	O
Prog	O
could	O
interfere	O
with	O
TNF	B
-	I
alpha	I
-induced	O
apoptosis	O
of	O
the	O
monoblastoid	O
U937	O
cell	O
line	O
.	O
Treatment	O
with	O
E2	O
or	O
Prog	O
increased	O
survival	O
and	O
prevented	O
apoptosis	O
induced	O
by	O
TNF	B
-	I
alpha	I
in	O
both	O
undifferentiated	O
and	O
macrophage	O
-	O
like	O
PMA	O
-	O
differentiated	O
U937	O
cells	O
,	O
as	O
assessed	O
by	O
trypan	O
blue	O
exclusion	O
cell	O
counting	O
,	O
thymidine	O
incorporation	O
,	O
AnnexinV	O
labeling	O
,	O
followed	O
by	O
flow	O
cytometry	O
and	O
DNA	O
fragmentation	O
studies	O
.	O
This	O
effect	O
can	O
be	O
associated	O
with	O
the	O
activation	O
of	O
specific	O
hormone	O
receptors	O
,	O
since	O
we	O
observed	O
the	O
expression	O
of	O
the	O
estrogen	O
receptor	O
alpha	O
(	O
ER	O
-	O
alpha	O
)	O
,	O
ER	O
-	O
beta	O
,	O
and	O
progesterone	O
receptor	O
(	O
PR	O
)	O
mRNAs	O
;	O
the	O
ER	B
-	I
alpha	I
protein	O
expression	O
was	O
confirmed	O
by	O
immunocytochemical	O
analysis	O
.	O
In	O
addition	O
,	O
hormone	O
-	O
mediated	O
survival	O
against	O
apoptosis	O
was	O
concentration	O
dependent	O
,	O
reaching	O
the	O
half	O
-	O
maximal	O
effect	O
at	O
10	O
nM	O
and	O
blocked	O
by	O
the	O
ER	O
antagonist	O
ICI	O
182	O
,	O
780	O
in	O
undifferentiated	O
cells	O
,	O
further	O
supporting	O
a	O
receptor	O
-	O
mediated	O
mechanism	O
of	O
cell	O
survival	O
.	O
Other	O
steroid	O
receptor	O
drugs	O
such	O
as	O
Raloxifene	O
,	O
RU486	O
,	O
or	O
the	O
ICI	O
182	O
,	O
780	O
in	O
PMA	O
-	O
differentiated	O
cells	O
displayed	O
agonist	O
activity	O
by	O
preventing	O
TNF	B
-	I
alpha	I
-induced	O
apoptosis	O
as	O
efficiently	O
as	O
the	O
hormones	O
alone	O
,	O
providing	O
further	O
evidence	O
to	O
the	O
notion	O
that	O
steroid	O
receptor	O
drugs	O
may	O
manifest	O
agonist	O
or	O
antagonist	O
activities	O
depending	O
on	O
the	O
cellular	O
context	O
in	O
which	O
they	O
are	O
studied	O
.	O
Treatment	O
with	O
E2	O
was	O
also	O
associated	O
with	O
a	O
time	O
-	O
dependent	O
decrease	O
in	O
the	O
mRNA	O
level	O
of	O
the	O
proapoptotic	B
Nip-2	I
protein	I
,	O
supporting	O
the	O
hypothesis	O
that	O
hormone	O
responsiveness	O
of	O
U937	O
cells	O
is	O
mediated	O
by	O
target	O
gene	O
transcription	O
.	O
Together	O
,	O
these	O
results	O
demonstrate	O
that	O
ER	B
and	O
PR	B
can	O
be	O
activated	O
by	O
endogenous	O
or	O
exogenous	O
ligands	O
to	O
induce	O
a	O
genetic	O
response	O
that	O
impairs	O
TNF	B
-	I
alpha	I
-induced	O
apoptosis	O
in	O
U937	O
cells	O
.	O
The	O
data	O
presented	O
here	O
suggest	O
that	O
the	O
female	B
steroid	I
receptors	I
play	O
a	O
role	O
in	O
regulation	O
of	O
the	O
immune	O
response	O
by	O
preventing	O
apoptosis	O
of	O
monoblastoid	O
cells	O
;	O
this	O
effect	O
might	O
have	O
important	O
consequences	O
in	O
the	O
clinical	O
use	O
of	O
steroid	O
receptor	O
drugs	O
.	O
--	O
Vegeto	O
,	O
E.	O
,	O
Pollio	O
,	O
G.	O
,	O
Pellicciari	O
,	O
C.	O
,	O
Maggi	O
,	O
A	O
.	O
Estrogen	O
and	O
progesterone	O
induction	O
of	O
survival	O
of	O
monoblastoid	O
cells	O
undergoing	O
TNF	B
-	I
alpha	I
-inuced	O
apoptosis	O
.	O
Constitutive	O
activation	O
of	O
an	O
epithelial	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	B
)	O
pathway	O
in	O
asthma	O
.	O
Cytokine	B
effects	O
on	O
immunity	O
and	O
inflammation	O
often	O
depend	O
on	O
the	O
transcription	B
factors	I
termed	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	O
STATs	B
)	O
,	O
so	O
STAT	B
signaling	O
pathways	O
are	O
candidates	O
for	O
influencing	O
inflammatory	O
disease	O
.	O
We	O
reasoned	O
that	O
selective	O
IFN	B
responsiveness	O
of	O
the	O
first	O
STAT	B
family	I
member	I
(	O
Stat1	B
)	O
and	O
Stat1-dependent	O
immune	O
-	O
response	O
genes	O
such	O
as	O
intercellular	B
adhesion	I
molecule-1	I
(	O
ICAM-1	B
)	O
,	O
IFN	B
regulatory	I
factor-1	I
(	O
IRF-1	B
)	O
,	O
and	O
Stat1	B
itself	O
in	O
airway	O
epithelial	O
cells	O
provides	O
a	O
basis	O
for	O
detecting	O
cytokine	B
signaling	O
abnormalities	O
in	O
inflammatory	O
airway	O
disease	O
.	O
On	O
the	O
basis	O
of	O
nuclear	O
localization	O
and	O
phosphorylation	O
,	O
we	O
found	O
that	O
epithelial	B
Stat1	I
(	O
but	O
not	O
other	O
control	O
transcription	B
factors	I
)	O
was	O
invariably	O
activated	O
in	O
asthmatic	O
compared	O
with	O
normal	O
control	O
or	O
chronic	O
bronchitis	O
subjects	O
.	O
Furthermore	O
,	O
epithelial	O
levels	O
of	O
activated	O
Stat1	B
correlated	O
with	O
levels	O
of	O
expression	O
for	O
epithelial	B
ICAM-1	I
,	O
IRF-1	B
,	O
and	O
Stat1	B
,	O
and	O
in	O
turn	O
,	O
ICAM-1	B
levels	O
correlated	O
with	O
T	O
-	O
cell	O
accumulation	O
in	O
tissue	O
.	O
However	O
,	O
only	O
low	O
levels	O
of	O
IFN	B
-	I
gamma	I
or	O
IFN	O
-	O
gamma	O
-	O
producing	O
cells	O
were	O
detected	O
in	O
airway	O
tissue	O
in	O
all	O
subjects	O
.	O
The	O
results	O
therefore	O
provide	O
initial	O
evidence	O
linking	O
abnormal	O
behavior	O
of	O
STAT	B
pathways	O
for	O
cytokine	B
signaling	O
to	O
the	O
development	O
of	O
an	O
inflammatory	O
disease	O
.	O
In	O
that	O
context	O
,	O
the	O
results	O
also	O
change	O
the	O
current	O
scheme	O
for	O
asthma	O
pathogenesis	O
to	O
one	O
that	O
must	O
include	O
a	O
localized	O
gain	O
in	O
transcriptional	O
signal	O
ordinarily	O
used	O
for	O
a	O
T	B
helper	I
1-type	I
cytokine	I
(	O
IFN	B
-	I
gamma	I
)	O
in	O
combination	O
with	O
allergy	O
-	O
driven	O
overproduction	O
of	O
T	B
helper	I
2-type	I
cytokines	I
.	O
Molecular	O
regulation	O
of	O
cytokine	O
gene	O
expression	O
during	O
the	O
immune	O
response	O
.	O
Cytokine	B
expression	O
by	O
immune	O
system	O
cells	O
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
the	O
immune	O
response	O
.	O
On	O
first	O
encounter	O
with	O
antigen	O
,	O
naive	O
CD4	O
+	O
T	O
helper	O
(	O
Th	O
)	O
cells	O
differentiate	O
into	O
cytokine	O
-	O
producing	O
effector	O
cells	O
.	O
Two	O
types	O
of	O
effector	O
cells	O
characterized	O
by	O
their	O
distinct	O
expression	O
of	O
cytokine	B
profiles	O
have	O
been	O
described	O
.	O
Th1	O
cells	O
produce	O
IL-2	B
and	O
IFN	B
-	I
gamma	I
,	O
whereas	O
Th2	O
cells	O
produce	O
IL-4	B
,	O
IL-5	B
,	O
IL-6	B
,	O
IL-10	B
,	O
and	O
IL-13	B
.	O
In	O
many	O
pathological	O
situations	O
,	O
the	O
balance	O
between	O
Th1	O
and	O
Th2	O
immune	O
responses	O
determines	O
the	O
outcome	O
of	O
diverse	O
immunologically	O
mediated	O
clinical	O
syndromes	O
including	O
infectious	O
,	O
autoimmune	O
,	O
and	O
allergic	O
diseases	O
.	O
However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
Th1	B
/	I
Th2-like	I
cytokines	I
has	O
remained	O
elusive	O
.	O
In	O
this	O
review	O
we	O
evaluate	O
the	O
possible	O
in	O
vivo	O
role	O
of	O
different	O
transcription	O
factors	O
and	O
transcriptional	O
mechanisms	O
in	O
T	O
cell	O
differentiation	O
and	O
the	O
immune	O
response	O
.	O
Differences	O
in	O
phosphorylation	O
of	O
the	O
IL-2R	B
associated	I
JAK	I
/	I
STAT	I
proteins	I
between	O
HTLV	O
-	O
I	O
(	O
+	O
)	O
,	O
IL-2-independent	O
and	O
IL-2-dependent	O
cell	O
lines	O
and	O
uncultured	O
leukemic	O
cells	O
from	O
patients	O
with	O
adult	O
T	O
-	O
cell	O
lymphoma	O
/	O
leukemia	O
.	O
To	O
determine	O
activation	O
status	O
of	O
the	O
IL-2R	B
-associated	O
(	O
Jak	B
/	I
STAT	I
)	O
pathway	O
in	O
the	O
HTLV	O
-	O
I	O
infected	O
cells	O
,	O
we	O
examined	O
tyrosine	O
phosphorylation	O
of	O
Jak3	B
,	O
STAT3	B
,	O
and	O
STAT5	B
in	O
several	O
HTLV	O
-	O
I	O
(	O
+	O
)	O
T	O
-	O
cell	O
lines	O
and	O
in	O
uncultured	O
leukemic	O
T	O
cells	O
isolated	O
from	O
patients	O
with	O
adult	O
T	O
-	O
cell	O
lymphoma	O
/	O
leukemia	O
(	O
ATLL	O
)	O
.	O
Constitutive	O
basal	O
phosphorylation	O
of	O
Jak3	B
and	O
,	O
usually	O
,	O
STAT3	B
and	O
STAT5	B
was	O
detected	O
in	O
all	O
four	O
IL-2-independent	O
cell	O
lines	O
tested	O
,	O
but	O
in	O
none	O
of	O
the	O
three	O
IL-2-dependent	O
cell	O
lines	O
.	O
Similarly	O
,	O
there	O
was	O
no	O
detectable	O
basal	O
phosphorylation	O
of	O
Jak3	B
and	O
STAT5	B
in	O
the	O
leukemic	O
cells	O
from	O
ATLL	O
patients	O
(	O
0	O
/	O
8	O
and	O
0	O
/	O
3	O
,	O
respectively	O
)	O
.	O
However	O
,	O
stimulation	O
with	O
IL-2	B
resulted	O
in	O
Jak3	B
and	O
STAT5	B
phosphorylation	O
in	O
both	O
leukemic	O
ATLL	O
cells	O
and	O
IL-2-dependent	O
lines	O
.	O
Furthermore	O
,	O
expression	O
of	O
SHP-1	B
phosphatase	I
which	O
is	O
a	O
negative	O
regulator	O
of	O
cytokine	B
receptor	I
signaling	O
,	O
was	O
lost	O
in	O
most	O
IL-2	O
independent	O
cell	O
lines	O
(	O
3	O
/	O
4	O
)	O
but	O
not	O
in	O
the	O
leukemic	O
ATLL	O
cells	O
(	O
0	O
/	O
3	O
)	O
.	O
Finally	O
,	O
the	O
HTLV	O
-	O
I	O
(	O
+	O
)	O
T	O
-	O
cell	O
lines	O
(	O
313	O
)	O
but	O
not	O
the	O
control	O
,	O
HTLV	O
-	O
I	O
(	O
-	O
)	O
T	O
-	O
cell	O
lines	O
were	O
resistant	O
to	O
rapamycin	O
and	O
its	O
novel	O
analog	O
RAD	O
.	O
We	O
conclude	O
that	O
(	O
1	O
)	O
HTLV	O
-	O
I	O
infection	O
per	O
se	O
does	O
not	O
result	O
in	O
a	O
constitutive	O
phosphorylation	O
of	O
the	O
Jak3	B
,	O
STAT3	B
,	O
and	O
STAT5	B
proteins	O
;	O
(	O
2	O
)	O
malignant	O
transformation	O
in	O
at	O
least	O
some	O
cases	O
of	O
ATLL	O
does	O
not	O
require	O
the	O
constitutive	O
,	O
but	O
may	O
require	O
IL-2	B
-induced	O
,	O
activation	O
of	O
the	O
IL-2R	B
Jak	B
/	I
STAT	I
pathway	O
;	O
and	O
(	O
3	O
)	O
there	O
are	O
major	O
differences	O
in	O
T	O
-	O
cell	O
immortalization	O
mechanism	O
(	O
s	O
)	O
which	O
appear	O
to	O
involve	O
SHP-1	B
and	O
target	O
molecules	O
for	O
rapamycin	O
and	O
RAD	O
.	O
The	O
evolutionarily	O
conserved	O
sequence	O
upstream	O
of	O
the	O
human	B
Ig	I
heavy	I
chain	I
S	I
gamma	I
3	I
region	I
is	O
an	O
inducible	O
promoter	O
:	O
synergistic	O
activation	O
by	O
CD40	B
ligand	I
and	O
IL-4	B
via	O
cooperative	O
NF	O
-	O
kappa	O
B	O
and	O
STAT-6	O
binding	O
sites	O
.	O
Germline	O
C	O
gamma	O
gene	O
transcription	O
is	O
a	O
crucial	O
event	O
in	O
the	O
process	O
that	O
leads	O
to	O
switch	O
DNA	O
recombination	O
to	O
IgG	B
,	O
but	O
its	O
regulation	O
in	O
the	O
human	O
is	O
poorly	O
understood	O
.	O
We	O
took	O
advantage	O
of	O
our	O
monoclonal	O
model	O
of	O
germinal	O
center	O
B	O
cell	O
differentiation	O
,	O
IgM+	O
IgD+	O
CL-01	O
cells	O
,	O
to	O
define	O
the	O
role	O
of	O
the	O
I	B
gamma	I
3	I
evolutionarily	O
conserved	O
sequence	O
(	O
ECS	O
)	O
in	O
the	O
germline	O
transcriptional	O
activation	O
of	O
the	O
human	O
C	O
gamma	O
3	O
gene	O
.	O
The	O
I	B
gamma	I
3	I
ECS	O
lies	O
upstream	O
of	O
the	O
major	O
I	O
gamma	O
3	O
transcription	O
initiation	O
site	O
and	O
displays	O
more	O
than	O
90	O
%	O
identity	O
with	O
the	O
corresponding	O
human	O
I	O
gamma	O
1	O
,	O
I	O
gamma	O
2	O
,	O
and	O
I	O
gamma	O
4	O
regions	O
.	O
Reporter	O
luciferase	O
gene	O
vectors	O
containing	O
the	O
human	O
gamma	O
3	O
ECS	O
were	O
used	O
to	O
transfect	O
CL-01	O
cells	O
,	O
which	O
have	O
been	O
shown	O
to	O
undergo	O
Smu	O
--	O
>	O
S	O
gamma	O
3	O
DNA	O
recombination	O
,	O
upon	O
engagement	O
of	O
CD40	B
by	O
CD40	B
ligand	I
(	O
CD40L	B
)	O
and	O
exposure	O
to	O
IL-4	B
.	O
In	O
these	O
transfected	O
CL-01	O
cells	O
,	O
CD40	O
:	O
CD40L	B
engagement	O
and	O
exposure	O
to	O
IL-4	B
synergistically	O
induced	O
gamma	O
3	O
ECS	O
-	O
dependent	O
luciferase	O
reporter	O
gene	O
activation	O
.	O
Targeted	O
mutational	O
analysis	O
demonstrated	O
that	O
a	O
tandem	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
binding	O
motif	O
is	O
critical	O
for	O
the	O
gamma	O
3	O
ECS	O
responsiveness	O
to	O
both	O
CD40L	B
and	O
IL-4	B
,	O
while	O
a	O
STAT-6-binding	O
site	O
is	O
additionally	O
required	O
for	O
IL-4	B
inducibility	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
p50	B
/	I
p65	I
/	I
c	I
-	I
Rel	I
and	O
STAT-6	B
are	O
effectively	O
induced	O
by	O
CD40L	B
and	O
IL-4	B
,	O
respectively	O
,	O
and	O
bind	O
to	O
specific	O
DNA	O
motifs	O
within	O
the	O
ECS	O
.	O
These	O
partially	O
overlapping	O
CD40L	O
and	O
IL-4	O
responsive	O
elements	O
are	O
functionally	O
cooperative	O
as	O
the	O
disruption	O
of	O
one	O
of	O
them	O
prevents	O
synergistic	O
promoter	O
activation	O
.	O
Thus	O
,	O
the	O
gamma	O
3	O
ECS	O
is	O
an	O
inducible	O
promoter	O
containing	O
cis	O
elements	O
that	O
critically	O
mediate	O
CD40L	B
and	O
IL-4	B
-triggered	O
transcriptional	O
activation	O
of	O
the	O
human	O
C	O
gamma	O
3	O
gene	O
.	O
Thrombin	B
-	I
induced	I
p65	I
homodimer	I
binding	O
to	O
downstream	O
NF	O
-	O
kappa	O
B	O
site	O
of	O
the	O
promoter	O
mediates	O
endothelial	O
ICAM-1	B
expression	O
and	O
neutrophil	O
adhesion	O
.	O
We	O
investigated	O
the	O
mechanisms	O
by	O
which	O
proinflammatory	B
mediator	I
,	O
thrombin	B
,	O
released	O
during	O
intravascular	O
coagulation	O
and	O
tissue	O
injury	O
,	O
induces	O
ICAM-1	B
(	O
CD54	B
)	O
expression	O
in	O
endothelial	O
cells	O
.	O
Stimulation	O
of	O
HUVEC	O
with	O
thrombin	B
resulted	O
in	O
dose-	O
and	O
time	O
-	O
dependent	O
increases	O
in	O
ICAM-1	O
mRNA	O
and	O
cell	O
surface	O
expression	O
and	O
in	O
ICAM-1	B
-dependent	O
endothelial	O
adhesivity	O
toward	O
polymorphonuclear	O
leukocytes	O
.	O
Transient	O
transfection	O
of	O
endothelial	O
cells	O
with	O
ICAM-1	O
promoter	O
luciferase	O
reporter	O
gene	O
(	O
ICAM-1LUC	O
)	O
constructs	O
indicated	O
that	O
deletion	O
of	O
upstream	O
NF	O
-	O
kappa	O
B	O
site	O
(	O
-533	O
bases	O
from	O
translation	O
start	O
site	O
)	O
had	O
no	O
effect	O
on	O
thrombin	B
responsiveness	O
,	O
whereas	O
mutation	O
/	O
deletion	O
of	O
downstream	O
NF	O
-	O
kappa	O
B	O
site	O
(	O
-223	O
bases	O
from	O
the	O
translation	O
start	O
site	O
)	O
prevented	O
the	O
activation	O
of	O
ICAM-1	O
promoter	O
,	O
indicating	O
that	O
the	O
downstream	O
NF	O
-	O
kappa	O
B	O
site	O
is	O
critical	O
for	O
thrombin	B
inducibility	O
.	O
NF	B
-	I
kappa	I
B	I
-directed	O
luciferase	B
activity	O
increased	O
approximately	O
3-fold	O
when	O
cells	O
transfected	O
with	O
the	O
plasmid	O
pNF	O
-	O
kappa	O
BLUC	O
containing	O
five	O
copies	O
of	O
consensus	O
NF	O
-	O
kappa	O
B	O
site	O
linked	O
to	O
a	O
minimal	O
adenovirus	O
E1B	O
promoter	O
-	O
luciferase	O
gene	O
were	O
exposed	O
to	O
thrombin	B
,	O
indicating	O
that	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
was	O
essential	O
for	O
thrombin	B
response	O
.	O
Gel	O
supershift	O
assays	O
demonstrated	O
that	O
thrombin	B
induced	O
binding	O
of	O
NF	B
-	I
kappa	I
Bp65	I
(	O
Rel	B
A	I
)	O
to	O
downstream	O
NF	O
-	O
kappa	O
B	O
site	O
of	O
the	O
ICAM-1	O
promoter	O
.	O
Thrombin	B
receptor	O
activation	O
peptide	O
,	O
a	O
14-amino	O
-	O
acid	O
peptide	O
representing	O
the	O
new	O
NH2	B
terminus	I
of	O
proteolytically	O
activated	O
receptor-1	B
,	O
mimicked	O
thrombin	B
's	O
action	O
in	O
inducing	O
ICAM-1	B
expression	O
.	O
These	O
data	O
indicate	O
that	O
thrombin	B
activates	O
endothelial	O
ICAM-1	B
expression	O
and	O
polymorphonuclear	O
leukocyte	O
adhesion	O
by	O
NF	B
-	I
kappa	I
Bp65	I
binding	O
to	O
the	O
downstream	O
NF	O
-	O
kappa	O
B	O
site	O
of	O
ICAM-1	O
promoter	O
after	O
proteolytically	O
activated	O
receptor-1	O
activation	O
.	O
Increased	O
glucocorticoid	B
receptor	I
beta	I
in	O
airway	O
cells	O
of	O
glucocorticoid	O
-	O
insensitive	O
asthma	O
.	O
Glucocorticoid	O
(	O
GC	O
)	O
-insensitive	O
asthma	O
is	O
a	O
challenging	O
clinical	O
problem	O
that	O
can	O
be	O
associated	O
with	O
life	O
-	O
threatening	O
disease	O
progression	O
.	O
The	O
molecular	O
basis	O
of	O
GC	O
insensitivity	O
is	O
unknown	O
.	O
Alternative	O
splicing	O
of	O
the	O
GC	O
receptor	O
(	O
GCR	O
)	O
pre	O
-	O
mRNA	O
generates	O
a	O
second	O
GCR	B
,	O
termed	O
GCRbeta	B
,	O
which	O
does	O
not	O
bind	O
GC	O
but	O
antagonizes	O
the	O
transactivating	O
activity	O
of	O
the	O
classic	O
GCR	B
.	O
Thus	O
increased	O
expression	O
of	O
GCRbeta	B
could	O
account	O
for	O
glucocorticoid	O
insensitivity	O
.	O
Bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
cells	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
were	O
examined	O
for	O
GCRbeta	B
immunoreactivity	O
using	O
a	O
GCRbeta	B
-	I
specific	I
antibody	I
by	O
immunohistochemical	O
staining	O
.	O
Cell	O
localization	O
of	O
GCRbeta	B
expression	O
was	O
performed	O
using	O
a	O
double	O
immunostaining	O
technique	O
.	O
Patients	O
with	O
GC	O
-	O
insensitive	O
asthma	O
expressed	O
a	O
significantly	O
higher	O
number	O
of	O
GCRbeta	O
-	O
immunoreactive	O
cells	O
in	O
their	O
BAL	O
and	O
peripheral	O
blood	O
than	O
GC	O
-	O
sensitive	O
asthmatics	O
or	O
normal	O
control	O
subjects	O
.	O
Furthermore	O
,	O
GCRbeta	B
expression	O
in	O
GC	O
-	O
insensitive	O
asthma	O
was	O
particularly	O
high	O
in	O
airway	O
T	O
cells	O
,	O
which	O
are	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
pathogenesis	O
of	O
asthma	O
.	O
We	O
also	O
examined	O
the	O
expression	O
of	O
GCRbeta	B
in	O
specimens	O
from	O
the	O
airways	O
of	O
patients	O
with	O
chronic	O
bronchitis	O
.	O
In	O
chronic	O
bronchitis	O
,	O
few	O
cells	O
were	O
GCRbeta	O
-	O
positive	O
and	O
their	O
numbers	O
did	O
not	O
differ	O
significantly	O
from	O
normal	O
control	O
subjects	O
.	O
We	O
conclude	O
that	O
GC	O
-	O
insensitive	O
asthma	O
is	O
associated	O
with	O
increased	O
expression	O
of	O
GCRbeta	B
in	O
airway	O
T	O
cells	O
.	O
Resistance	O
to	O
tumor	B
necrosis	I
factor	I
induced	O
apoptosis	O
in	O
vitro	O
correlates	O
with	O
high	O
metastatic	O
capacity	O
of	O
cells	O
in	O
vivo	O
.	O
TNF	B
is	O
one	O
of	O
the	O
cytokines	B
secreted	O
by	O
the	O
cells	O
of	O
the	O
immune	O
system	O
.	O
Our	O
data	O
demonstrate	O
that	O
those	O
cell	O
lines	O
lacking	O
capability	O
to	O
form	O
metastatic	O
tumors	O
in	O
vivo	O
are	O
susceptible	O
to	O
TNF	B
induced	O
apoptosis	O
in	O
vitro	O
.	O
However	O
,	O
cell	O
lines	O
with	O
high	O
metastatic	O
potential	O
are	O
resistant	O
to	O
TNF	B
in	O
vitro	O
.	O
Furthermore	O
,	O
the	O
same	O
cell	O
lines	O
were	O
resistant	O
to	O
cytolytic	O
action	O
of	O
other	O
cytotoxic	B
proteins	I
secreted	O
by	O
LAK	O
cells	O
.	O
Our	O
data	O
showed	O
that	O
TNF	B
resistance	O
in	O
vitro	O
correlates	O
with	O
the	O
increased	O
level	O
of	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
.	O
This	O
finding	O
may	O
provide	O
a	O
tool	O
to	O
improve	O
current	O
protocols	O
of	O
immunotherapy	O
and	O
insights	O
to	O
how	O
tumor	O
cells	O
are	O
or	O
are	O
not	O
killed	O
by	O
LAK	O
cells	O
.	O
CTLA-4	B
-Mediated	O
inhibition	O
of	O
early	O
events	O
of	O
T	O
cell	O
proliferation	O
.	O
CTLA-4	B
engagement	O
by	O
mAbs	B
inhibits	O
,	O
while	O
CD28	B
enhances	O
,	O
IL-2	B
production	O
and	O
proliferation	O
upon	O
T	O
cell	O
activation	O
.	O
Here	O
,	O
we	O
have	O
analyzed	O
the	O
mechanisms	O
involved	O
in	O
CTLA-4	B
-mediated	O
inhibition	O
of	O
T	O
cell	O
activation	O
of	O
naive	O
CD4	O
+	O
T	O
cells	O
using	O
Ab	O
cross	O
-	O
linking	O
.	O
CTLA-4	B
ligation	O
inhibited	O
CD3	O
/	O
CD28	B
-induced	O
IL-2	O
mRNA	O
accumulation	O
by	O
inhibiting	O
IL-2	B
transcription	O
,	O
which	O
appears	O
to	O
be	O
mediated	O
in	O
part	O
through	O
decreasing	O
NF	B
-	I
AT	I
accumulation	O
in	O
the	O
nuclei	O
.	O
However	O
,	O
CTLA-4	B
ligation	O
did	O
not	O
appear	O
to	O
affect	O
the	O
CD28	B
-mediated	O
stabilization	O
of	O
IL-2	O
mRNA	O
.	O
Further	O
,	O
CTLA-4	B
engagement	O
inhibited	O
progression	O
through	O
the	O
cell	O
cycle	O
by	O
inhibiting	O
the	O
production	O
of	O
cyclin	B
D3	I
,	O
cyclin	B
-	I
dependent	I
kinase	I
(	B
cdk	I
)	I
4	I
,	O
and	O
cdk6	B
when	O
the	O
T	O
cells	O
were	O
stimulated	O
with	O
anti	B
-	I
CD3	I
/	I
CD28	I
and	O
with	O
anti	B
-	I
CD3	I
alone	O
.	O
These	O
results	O
indicate	O
that	O
CTLA-4	B
signaling	O
inhibits	O
events	O
early	O
in	O
T	O
cell	O
activation	O
both	O
at	O
IL-2	B
transcription	O
and	O
at	O
the	O
level	O
of	O
IL-2	B
-independent	O
events	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
does	O
not	O
simply	O
oppose	O
CD28	B
-mediated	O
costimulation	O
.	O
Fibroblast	B
growth	I
factor-1	I
(	O
FGF-1	B
)	O
enhances	O
IL-2	B
production	O
and	O
nuclear	O
translocation	O
of	O
NF	B
-	I
kappaB	I
in	O
FGF	O
receptor	O
-	O
bearing	O
Jurkat	O
T	O
cells	O
.	O
Fibroblast	B
growth	I
factors	I
(	O
FGFs	B
)	O
are	O
heparin	B
-	I
binding	I
proteins	I
crucial	O
to	O
embryogenesis	O
,	O
angiogenesis	O
,	O
and	O
wound	O
healing	O
.	O
FGF-1	B
is	O
abundantly	O
expressed	O
in	O
the	O
synovium	O
in	O
rheumatoid	O
arthritis	O
and	O
in	O
rejecting	O
allografts	O
,	O
sites	O
of	O
chronic	O
immune	O
-	O
mediated	O
inflammation	O
.	O
The	O
frequency	O
of	O
FGF-1	B
-responsive	O
T	O
cells	O
is	O
increased	O
in	O
the	O
peripheral	O
blood	O
of	O
these	O
disorders	O
,	O
and	O
a	O
high	O
percentage	O
of	O
infiltrating	O
T	O
cells	O
in	O
rheumatoid	O
arthritis	O
synovium	O
express	O
receptors	O
for	O
FGF-1	B
.	O
To	O
understand	O
the	O
action	O
of	O
FGF-1	B
in	O
T	O
cells	O
,	O
studies	O
were	O
initiated	O
in	O
Jurkat	O
T	O
cells	O
that	O
express	O
the	O
signaling	O
isoform	O
of	O
FGF	B
receptor-1	I
.	O
These	O
experiments	O
show	O
that	O
FGF-1	B
stimulation	O
of	O
Jurkat	O
T	O
cells	O
provides	O
a	O
second	O
signal	O
that	O
augments	O
TCR	O
-	O
mediated	O
IL-2	B
production	O
.	O
Analogous	O
to	O
costimulation	O
via	O
CD28	B
,	O
this	O
activity	O
is	O
mediated	O
through	O
activation	O
of	O
Rel	B
/	I
kappaB	I
,	O
a	O
family	O
of	O
transcription	B
factors	I
known	O
to	O
regulate	O
IL-2	B
and	O
other	O
activation	B
-	I
inducible	I
proteins	I
.	O
FGF-1	B
alone	O
induces	O
modest	O
nuclear	O
translocation	O
of	O
kappaB	B
-	I
binding	I
proteins	I
,	O
and	O
this	O
translocation	O
is	O
enhanced	O
by	O
the	O
combination	O
of	O
anti	B
-	I
CD3	I
and	O
FGF-1	B
.	O
This	O
NF	B
-	I
kappaB	I
binding	I
complex	I
is	O
composed	O
of	O
transcriptionally	B
active	I
p65	I
(	I
RelA	I
)	I
/p50	I
heterodimers	I
and	O
results	O
primarily	O
from	O
the	O
targeted	O
degradation	O
of	O
IkappaB	B
-	I
alpha	I
,	O
an	O
inhibitor	O
that	O
sequesters	O
Rel	B
/	I
kappaB	I
in	O
the	O
cytoplasm	O
.	O
These	O
data	O
are	O
the	O
first	O
to	O
show	O
a	O
connection	O
between	O
FGF-1	B
signaling	O
and	O
NF	B
-	I
kappaB	I
activation	O
outside	O
of	O
embryonic	O
development	O
.	O
The	O
signaling	O
events	O
that	O
link	O
FGF	B
receptor-1	I
engagement	O
and	O
NF	B
-	I
kappaB	I
activation	O
in	O
Jurkat	O
are	O
probably	O
distinct	O
from	O
the	O
CD28	B
costimulation	O
pathway	O
,	O
since	O
FGF-1	B
-induced	O
Rel	B
/	I
kappaB	I
binding	I
proteins	I
do	O
not	O
contain	O
significant	O
levels	O
of	O
c	B
-	I
Rel	I
and	O
are	O
not	O
identical	O
with	O
the	O
CD28	B
response	I
complex	I
.	O
USF	B
/	I
c	I
-	I
Myc	I
enhances	O
,	O
while	O
Yin	B
-	I
Yang	I
1	I
suppresses	O
,	O
the	O
promoter	O
activity	O
of	O
CXCR4	B
,	O
a	O
coreceptor	B
for	O
HIV-1	O
entry	O
.	O
Transcription	B
factors	I
USF1	B
and	O
USF2	B
up	O
-	O
regulate	O
gene	O
expression	O
(	O
i.e.	O
,	O
HIV-1	O
long	O
terminal	O
repeats	O
)	O
via	O
interaction	O
with	O
an	O
E	O
box	O
on	O
their	O
target	O
promoters	O
,	O
which	O
is	O
also	O
a	O
binding	O
site	O
for	O
c	B
-	I
Myc	I
.	O
The	O
c	B
-	I
Myc	I
oncoprotein	I
is	O
important	O
in	O
control	O
of	O
cellular	O
proliferation	O
and	O
differentiation	O
,	O
while	O
Yin	B
-	I
Yang	I
1	I
(	O
YY1	B
)	O
has	O
been	O
shown	O
to	O
control	O
the	O
expression	O
of	O
a	O
number	O
of	O
cellular	O
and	O
viral	O
genes	O
.	O
These	O
two	O
proteins	O
physically	O
interact	O
with	O
each	O
other	O
and	O
mutually	O
inhibit	O
their	O
respective	O
biological	O
functions	O
.	O
In	O
this	O
study	O
,	O
we	O
show	O
that	O
USF	B
/	I
c	I
-	I
Myc	I
up	O
-	O
regulates	O
,	O
while	O
YY1	B
down	O
-	O
regulates	O
the	O
promoter	O
activity	O
of	O
CXCR4	B
,	O
a	O
coreceptor	O
for	O
T	O
cell	O
-	O
tropic	O
HIV-1	O
entry	O
.	O
We	O
have	O
identified	O
an	O
E	O
box	O
around	O
-260	O
and	O
a	O
YY1	O
binding	O
site	O
around	O
-300	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
.	O
Mutation	O
of	O
the	O
E	O
box	O
abolished	O
USF	B
/	I
c	I
-	I
Myc	I
-mediated	O
up	O
-	O
regulation	O
of	O
CXCR4	B
promoter	O
activity	O
,	O
and	O
mutation	O
of	O
the	O
YY1	O
binding	O
site	O
was	O
associated	O
with	O
unresponsiveness	O
to	O
YY1	B
-mediated	O
inhibition	O
.	O
These	O
data	O
suggest	O
that	O
USF	B
/	I
c	I
-	I
Myc	I
and	O
YY1	B
may	O
play	O
an	O
important	O
role	O
in	O
the	O
HIV-1-replicative	O
cycle	O
,	O
by	O
modulating	O
both	O
the	O
viral	O
fusion	O
/	O
entry	O
process	O
and	O
viral	O
expression	O
.	O
Signaling	O
through	O
the	O
lymphotoxin	B
-	I
beta	I
receptor	I
stimulates	O
HIV-1	O
replication	O
alone	O
and	O
in	O
cooperation	O
with	O
soluble	O
or	O
membrane	B
-	I
bound	I
TNF	I
-	I
alpha	I
.	O
The	O
level	O
of	O
ongoing	O
HIV-1	O
replication	O
within	O
an	O
individual	O
is	O
critical	O
to	O
HIV-1	O
pathogenesis	O
.	O
Among	O
host	O
immune	O
factors	O
,	O
the	O
cytokine	B
TNF	B
-	I
alpha	I
has	O
previously	O
been	O
shown	O
to	O
increase	O
HIV-1	O
replication	O
in	O
various	O
monocyte	O
and	O
T	O
cell	O
model	O
systems	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
signaling	O
through	O
the	O
TNF	B
receptor	O
family	O
member	O
,	O
the	O
lymphotoxin	B
-	I
beta	I
(	I
LT	I
-	I
beta	I
)	I
receptor	I
(	O
LT	B
-	I
betaR	I
)	O
,	O
also	O
regulates	O
HIV-1	O
replication	O
.	O
Furthermore	O
,	O
HIV-1	O
replication	O
is	O
cooperatively	O
stimulated	O
when	O
the	O
distinct	O
LT	B
-	I
betaR	I
and	O
TNF	B
receptor	I
systems	I
are	O
simultaneously	O
engaged	O
by	O
their	O
specific	O
ligands	O
.	O
Moreover	O
,	O
in	O
a	O
physiological	O
coculture	O
cellular	O
assay	O
system	O
,	O
we	O
show	O
that	O
membrane	B
-	I
bound	I
TNF	I
-	I
alpha	I
and	O
LT	B
-	I
alpha1beta2	I
act	O
virtually	O
identically	O
to	O
their	O
soluble	O
forms	O
in	O
the	O
regulation	O
of	O
HIV-1	O
replication	O
.	O
Thus	O
,	O
cosignaling	O
via	O
the	O
LT	B
-	I
beta	I
and	I
TNF	I
-	I
alpha	I
receptors	I
is	O
probably	O
involved	O
in	O
the	O
modulation	O
of	O
HIV-1	O
replication	O
and	O
the	O
subsequent	O
determination	O
of	O
HIV-1	O
viral	O
burden	O
in	O
monocytes	O
.	O
Intriguingly	O
,	O
surface	O
expression	O
of	O
LT	B
-	I
alpha1beta2	I
is	O
up	O
-	O
regulated	O
on	O
a	O
T	O
cell	O
line	O
acutely	O
infected	O
with	O
HIV-1	O
,	O
suggesting	O
a	O
positive	O
feedback	O
loop	O
between	O
HIV-1	O
infection	O
,	O
LT	B
-	I
alpha1beta2	I
expression	O
,	O
and	O
HIV-1	O
replication	O
.	O
Given	O
the	O
critical	O
role	O
that	O
LT	B
-	I
alpha1beta2	I
plays	O
in	O
lymphoid	O
architecture	O
,	O
we	O
speculate	O
that	O
LT	B
-	I
alpha1beta2	I
may	O
be	O
involved	O
in	O
HIV	O
-	O
associated	O
abnormalities	O
of	O
the	O
lymphoid	O
organs	O
.	O
Glucocorticoid	B
receptors	I
are	O
down	O
-	O
regulated	O
in	O
inflamed	O
colonic	O
mucosa	O
but	O
not	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
[	O
see	O
comments	O
]	O
BACKGROUND	O
:	O
Growing	O
evidence	O
indicates	O
that	O
the	O
immune	O
system	O
and	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
system	O
are	O
linked	O
by	O
several	O
mechanisms	O
,	O
for	O
example	O
intracellular	O
glucocorticoid	B
receptors	I
(	O
hGR	B
)	O
.	O
Glucocorticoids	O
are	O
the	O
standard	O
treatment	O
of	O
acute	O
attacks	O
of	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O
Binding	O
of	O
glucocorticoids	O
to	O
hGR	B
down	O
-	O
regulates	O
the	O
transcription	O
of	O
inflammatory	O
genes	O
that	O
can	O
propagate	O
IBD	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
IBD	O
patients	O
were	O
either	O
treated	O
with	O
5	O
-	O
60	O
mg	O
of	O
prednisolone	O
for	O
more	O
than	O
1	O
week	O
or	O
were	O
without	O
glucocorticoid	O
treatment	O
for	O
more	O
than	O
4	O
weeks	O
.	O
hGR	B
levels	O
were	O
determined	O
from	O
isolated	O
cytosol	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
or	O
mucosal	O
biopsies	O
using	O
a	O
radioassay	O
with	O
[	O
3H	O
]	O
-dexamethasone	O
.	O
Interleukin	O
(	O
IL	O
)	O
6	O
levels	O
were	O
determined	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O
RESULTS	O
:	O
The	O
systemic	O
(	O
PBMC	O
)	O
hGR	B
levels	O
of	O
corticosteroid	O
-	O
treated	O
IBD	O
patients	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
control	O
subjects	O
(	O
59.6	O
+	O
/-	O
57.1	O
dpm	O
mg-1	O
cytosol	B
protein	I
vs	O
.	O
227.0	O
+	O
/-	O
90.8	O
dpm	O
mg-1	O
cytosol	B
protein	I
,	O
P	O
=	O
0.007	O
)	O
and	O
IBD	O
patients	O
not	O
receiving	O
glucocorticoid	O
treatment	O
(	O
179.7	O
+	O
/-	O
171.3	O
dpm	O
mg-1	O
cytosol	B
protein	I
,	O
P	O
=	O
0.002	O
)	O
.	O
Systemic	O
hGR	B
levels	O
in	O
untreated	O
IBD	O
patients	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
in	O
control	O
subjects	O
.	O
In	O
patients	O
with	O
connective	O
tissue	O
diseases	O
,	O
systemic	O
hGR	B
levels	O
were	O
also	O
found	O
to	O
be	O
decreased	O
in	O
the	O
absence	O
of	O
glucocorticoid	O
treatment	O
.	O
Systemic	O
hGR	B
levels	O
in	O
patients	O
with	O
Crohn	O
's	O
disease	O
(	O
CD	O
)	O
treated	O
with	O
steroids	O
(	O
66.6	O
+	O
/-	O
61.0	O
dpm	O
mg-1	O
cytosol	B
protein	I
)	O
were	O
not	O
different	O
from	O
those	O
in	O
patients	O
with	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
(	O
56.1	O
+	O
/-	O
51.6	O
dpm	O
mg-1	O
cytosol	B
protein	I
)	O
.	O
In	O
contrast	O
to	O
these	O
findings	O
,	O
mucosal	O
hGR	B
levels	O
were	O
significantly	O
decreased	O
in	O
both	O
steroid	O
-	O
treated	O
(	O
18.0	O
+	O
/-	O
15.5	O
)	O
and	O
not	O
steroid	O
-	O
treated	O
(	O
37.8	O
+	O
/-	O
30.5	O
)	O
patients	O
compared	O
with	O
control	O
subjects	O
(	O
125.6	O
+	O
/-	O
97.1	O
;	O
P	O
=	O
0.00009	O
and	O
P	O
=	O
0.0008	O
respectively	O
)	O
.	O
IL-6	O
levels	O
in	O
all	O
IBD	O
groups	O
with	O
and	O
without	O
steroids	O
were	O
significantly	O
different	O
from	O
those	O
in	O
control	O
subjects	O
.	O
CONCLUSION	O
:	O
In	O
IBD	O
there	O
is	O
no	O
difference	O
in	O
systemic	O
hGR	B
levels	O
between	O
not	O
steroid	O
-	O
treated	O
patients	O
and	O
control	O
subjects	O
,	O
in	O
spite	O
of	O
inflammatory	O
activity	O
(	O
IL-6	B
)	O
.	O
Mucosal	O
hGR	B
levels	O
were	O
decreased	O
independently	O
of	O
treatment	O
,	O
probably	O
leading	O
to	O
a	O
decreased	O
protection	O
against	O
NF	B
-	I
kappaB	I
action	O
in	O
the	O
intestinal	O
mucosa	O
.	O
The	O
oestrogen	B
receptor	I
codon	O
10	O
polymorphism	O
detected	O
in	O
breast	O
cancer	O
is	O
also	O
present	O
in	O
non	O
-	O
malignant	O
cells	O
.	O
The	O
effect	O
of	O
oestrogens	O
on	O
oestrogen	O
-	O
receptive	O
organs	O
and	O
cells	O
is	O
mediated	O
via	O
intracellular	B
receptors	I
(	O
ERalpha	B
and	O
ERbeta	B
)	O
.	O
Oestrogen	B
receptor	I
gene	O
polymorphisms	O
in	O
the	O
region	O
encoding	O
the	O
N	B
-	I
terminal	I
portion	I
of	O
the	O
protein	O
are	O
reportedly	O
associated	O
with	O
pathological	O
conditions	O
including	O
breast	O
cancer	O
,	O
hypertension	O
,	O
spontaneous	O
abortion	O
and	O
coronary	O
heart	O
disease	O
.	O
A	O
silent	O
mutation	O
in	O
codon	O
10	O
of	O
exon	O
1	O
,	O
detected	O
in	O
ER	O
-	O
negative	O
and	O
ER	O
-	O
positive	O
human	O
breast	O
cancer	O
cell	O
lines	O
,	O
in	O
breast	O
tumors	O
and	O
blood	O
DNA	O
from	O
breast	O
cancer	O
patients	O
,	O
has	O
been	O
recognized	O
as	O
a	O
polymorphic	O
site	O
.	O
In	O
this	O
study	O
we	O
examined	O
,	O
by	O
denaturing	O
gradient	O
-	O
gel	O
electrophoresis	O
and	O
DNA	O
sequence	O
analysis	O
,	O
the	O
possible	O
presence	O
of	O
a	O
codon	O
10	O
polymorphic	O
site	O
in	O
normal	O
oestrogen	O
target	O
organs	O
and	O
cells	O
such	O
as	O
the	O
uterus	O
(	O
myometrium	O
and	O
endometrium	O
)	O
,	O
in	O
the	O
placenta	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
in	O
a	O
benign	O
uterus	O
tumour	O
(	O
leiomyoma	O
)	O
.	O
We	O
have	O
detected	O
ER	O
codon	O
10	O
polymorphism	O
in	O
these	O
samples	O
and	O
have	O
compared	O
them	O
to	O
those	O
observed	O
in	O
breast	O
cancer	O
samples	O
.	O
All	O
tissues	O
and	O
cells	O
studied	O
were	O
homozygous	O
for	O
the	O
wild	O
-	O
type	O
gene	O
,	O
and	O
were	O
heterozygous	O
as	O
well	O
as	O
homozygous	O
for	O
the	O
codon-10-variant	O
type	O
.	O
These	O
results	O
indicate	O
that	O
the	O
presence	O
of	O
the	O
codon-10-variant	O
type	O
is	O
not	O
a	O
characteristic	O
of	O
breast	O
cancer	O
.	O
Out	O
current	O
findings	O
suggest	O
that	O
further	O
investigations	O
are	O
warranted	O
to	O
elucidate	O
the	O
possible	O
linkage	O
of	O
ER	O
codon	O
10	O
polymorphism	O
to	O
physiological	O
and	O
pathological	O
conditions	O
.	O
HIV-1	O
reactivation	O
in	O
resting	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
infected	O
adults	O
upon	O
in	O
vitro	O
CD4	B
cross	O
-	O
linking	O
by	O
ligands	O
of	O
the	O
CDR2-loop	B
in	O
extracellular	B
domain	I
1	I
.	O
HIV-1	O
infects	O
resting	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
but	O
remains	O
inactive	O
state	O
until	O
subsequent	O
cell	O
activation	O
.	O
We	O
have	O
demonstrated	O
that	O
the	O
cross	O
-	O
linking	O
of	O
cell	B
surface	I
CD4	I
by	O
gp120-anti	B
-	I
gp120	I
immune	I
complexes	I
or	O
heat	O
-	O
inactivated	O
HIV-1	O
(	O
iHIV-1	O
)	O
is	O
sufficient	O
to	O
trigger	O
activation	O
signals	O
leading	O
to	O
virus	O
reactivation	O
(	O
9	O
)	O
.	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
NF	B
-	I
kappaB	I
nuclear	O
translocation	O
and	O
stimulation	O
of	O
virus	O
production	O
by	O
iHIV-1	O
were	O
strictly	O
linked	O
to	O
the	O
concentrations	O
of	O
viral	B
proteins	I
used	O
as	O
exogenous	O
stimuli	O
.	O
Moreover	O
,	O
we	O
further	O
investigated	O
the	O
physiologic	O
relevance	O
of	O
these	O
observations	O
.	O
When	O
submitted	O
to	O
an	O
in	O
vitro	O
CD4	B
cross	O
-	O
linking	O
by	O
iHIV-1	O
,	O
PBMCs	O
from	O
HIV-1-infected	O
patients	O
were	O
found	O
to	O
produce	O
virus	O
.	O
This	O
viral	O
reactivation	O
was	O
associated	O
with	O
increased	O
NF	B
-	I
kappaB	I
nuclear	O
translocation	O
in	O
patients	O
'	O
PBMCs	O
.	O
Additionally	O
,	O
virus	O
reactivation	O
in	O
resting	O
PBMCs	O
infected	O
in	O
vitro	O
with	O
HIV-1	O
was	O
found	O
to	O
be	O
specifically	O
induced	O
by	O
ligands	O
of	O
the	O
CDR2-loop	B
in	O
domain	B
1	I
(	O
D1	B
)	O
of	O
CD4	B
(	O
virus	B
envelope	I
and	I
anti	I
-	I
CD4	I
monoclonal	I
antibodies	I
)	O
.	O
In	O
contrast	O
,	O
virus	O
reactivation	O
was	O
not	O
observed	O
following	O
CD4	B
oligomerization	O
by	O
antibodies	B
that	O
bind	O
other	O
epitopes	O
in	O
D1	B
,	O
including	O
the	O
D1	B
/	I
CDR3-loop	I
.	O
Finally	O
,	O
soluble	B
CD4	I
(	O
sCD4	B
)	O
prevented	O
virus	O
reactivation	O
by	O
D1	B
/	I
CDR2-loop	I
ligands	I
.	O
Our	O
results	O
indicate	O
that	O
the	O
signaling	O
events	O
initiated	O
in	O
PBMCs	O
by	O
oligomerization	O
of	O
CD4	B
at	O
the	O
D1	B
/	I
CDR2-loop	I
can	O
trigger	O
HIV-1	O
upregulation	O
in	O
infected	O
individuals	O
.	O
NF	B
-	I
kappaB	I
activation	O
is	O
required	O
for	O
C5a	O
-	O
induced	O
interleukin-8	O
gene	O
expression	O
in	O
mononuclear	O
cells	O
.	O
C5a	O
,	O
a	O
potent	O
peptide	O
chemoattractant	O
,	O
stimulates	O
interleukin-8	B
(	O
IL-8	B
)	O
secretion	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O
Experiments	O
were	O
conducted	O
to	O
understand	O
the	O
mechanisms	O
for	O
C5a	O
-	O
induced	O
IL-8	B
production	O
,	O
which	O
was	O
14-fold	O
greater	O
than	O
that	O
in	O
unstimulated	O
cells	O
by	O
2	O
hours	O
.	O
IL-8	B
secretion	O
was	O
accompanied	O
by	O
accumulation	O
of	O
IL-8	O
mRNA	O
in	O
the	O
cytosol	O
and	O
by	O
nuclear	O
expression	O
of	O
a	O
kappaB	B
DNA	O
binding	O
activity	O
within	O
30	O
minutes	O
.	O
AP-1	B
but	O
not	O
NF	B
-	I
IL-6	I
DNA	O
binding	O
activity	O
was	O
also	O
detected	O
in	O
C5a	O
-	O
stimulated	O
PBMC	O
;	O
however	O
,	O
its	O
delayed	O
expression	O
(	O
maximal	O
at	O
4	O
hours	O
)	O
suggested	O
a	O
less	O
important	O
role	O
in	O
the	O
rapid	O
production	O
of	O
IL-8	B
.	O
The	O
correlation	O
between	O
C5a	O
-	O
induced	O
kappaB	B
binding	O
activity	O
and	O
IL-8	B
gene	O
expression	O
was	O
examined	O
in	O
the	O
RAW264.7	O
macrophage	O
cells	O
using	O
reporter	O
genes	O
directed	O
by	O
the	O
kappaB	O
sequence	O
from	O
IkappaBalpha	B
and	O
IL-8	O
promoter	O
regions	O
.	O
C5a	O
-	O
induced	O
reporter	O
gene	O
expression	O
was	O
abolished	O
by	O
introducing	O
mutations	O
into	O
the	O
kappaB	O
sites	O
and	O
by	O
coexpression	O
of	O
a	O
dominant	O
negative	O
IkappaBalpha	O
construct	O
resistant	O
to	O
agonist	O
-	O
induced	O
phosphorylation	O
.	O
Pertussis	O
toxin	O
,	O
which	O
ADP	O
-	O
ribosylates	O
the	O
Gi	B
proteins	I
known	O
to	O
couple	O
to	O
the	O
C5a	B
receptor	I
,	O
produced	O
minimal	O
inhibition	O
of	O
C5a	O
-	O
induced	O
IL-8	B
expression	O
and	O
had	O
little	O
effect	O
on	O
C5a	O
-	O
induced	O
calcium	O
mobilization	O
in	O
RAW264.7	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
NF	B
-	I
kappaB	I
activation	O
is	O
required	O
for	O
C5a	O
-	O
induced	O
IL-8	B
gene	O
expression	O
and	O
that	O
this	O
response	O
is	O
mediated	O
primarily	O
through	O
a	O
pertussis	O
toxin	O
-	O
insensitive	O
pathway	O
.	O
Control	O
of	O
cell	O
cycle	O
entry	O
and	O
apoptosis	O
in	O
B	O
lymphocytes	O
infected	O
by	O
Epstein	O
-	O
Barr	O
virus	O
.	O
Infection	O
of	O
human	O
B	O
cells	O
with	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
results	O
in	O
activation	O
of	O
the	O
cell	O
cycle	O
and	O
cell	O
growth	O
.	O
To	O
interpret	O
the	O
mechanisms	O
by	O
which	O
EBV	O
activates	O
the	O
cell	O
,	O
we	O
have	O
assayed	O
many	O
proteins	O
involved	O
in	O
control	O
of	O
the	O
G0	O
and	O
G1	O
phases	O
of	O
the	O
cell	O
cycle	O
and	O
regulation	O
of	O
apoptosis	O
.	O
In	O
EBV	O
infection	O
most	O
of	O
the	O
changes	O
,	O
including	O
the	O
early	O
induction	O
of	O
cyclin	B
D2	I
,	O
are	O
dependent	O
on	O
expression	O
of	O
EBV	O
genes	O
,	O
but	O
an	O
alteration	O
in	O
the	O
E2F-4	B
profile	O
was	O
partly	O
independent	O
of	O
viral	O
gene	O
expression	O
,	O
presumably	O
occurring	O
in	O
response	O
to	O
signal	O
transduction	O
activated	O
when	O
the	O
virus	O
binds	O
to	O
its	O
receptor	O
,	O
CD21	B
.	O
By	O
comparing	O
the	O
expression	O
of	O
genes	O
controlling	O
apoptosis	O
,	O
including	O
those	O
encoding	O
several	O
members	O
of	O
the	O
BCL-2	B
family	I
of	O
proteins	O
,	O
the	O
known	O
relative	O
resistance	O
of	O
EBV	O
-	O
immortalized	O
B	O
-	O
cell	O
lines	O
to	O
apoptosis	O
induced	O
by	O
low	O
serum	O
was	O
found	O
to	O
correlate	O
with	O
expression	O
of	O
both	O
BCL-2	B
and	O
A20	B
.	O
A20	O
can	O
be	O
regulated	O
by	O
the	O
NF	B
-	I
kappaB	I
transcription	B
factor	I
,	O
which	O
is	O
known	O
to	O
be	O
activated	O
by	O
the	O
EBV	B
LMP-1	I
protein	I
.	O
Quantitative	O
assays	O
demonstrated	O
a	O
direct	O
temporal	O
relationship	O
between	O
LMP-1	B
protein	I
levels	O
and	O
active	O
NF	B
-	I
kappaB	I
during	O
the	O
time	O
course	O
of	O
infection	O
.	O
Immortalization	O
of	O
CD4	O
(	O
+	O
)	O
and	O
CD8	O
(	O
+	O
)	O
T	O
lymphocytes	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
Tax	B
mutants	I
expressed	O
in	O
a	O
functional	O
molecular	O
clone	O
.	O
The	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
1	I
(	I
HTLV-1	I
)	I
transcriptional	I
trans	I
-	I
activator	I
Tax	B
has	O
been	O
demonstrated	O
to	O
have	O
transforming	O
activity	O
in	O
multiple	O
cell	O
culture	O
and	O
transgenic	O
-	O
mouse	O
models	O
.	O
In	O
addition	O
to	O
activating	O
transcription	O
from	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
through	O
the	O
cyclic	B
AMP	I
response	I
element	I
binding	I
protein	I
/	I
activating	I
transcription	I
factor	I
(	I
CREB	I
/	I
ATF	I
)	I
family	I
of	O
transcription	B
factors	I
,	O
Tax	B
activates	O
the	O
expression	O
of	O
multiple	O
cellular	O
promoters	O
through	O
the	O
NF	B
-	I
kappaB	I
pathway	O
of	O
transcriptional	O
activation	O
.	O
The	O
Tax	B
mutants	I
M22	B
and	O
M47	B
have	O
previously	O
been	O
demonstrated	O
to	O
selectively	O
abrogate	O
the	O
ability	O
of	O
Tax	B
to	O
activate	O
transcription	O
through	O
the	O
NF	O
-	O
kappaB	O
or	O
CREB	O
/	O
ATF	O
pathway	O
,	O
respectively	O
.	O
These	O
mutations	O
were	O
introduced	O
in	O
the	O
tax	O
gene	O
of	O
the	O
ACH	O
functional	O
molecular	O
clone	O
of	O
HTLV-1	O
,	O
and	O
virus	O
produced	O
from	O
the	O
mutant	O
ACH	O
clones	O
was	O
examined	O
for	O
the	O
ability	O
to	O
replicate	O
and	O
immortalize	O
primary	O
human	O
lymphocytes	O
.	O
While	O
virus	O
derived	O
from	O
the	O
clone	O
containing	O
the	O
M47	B
mutation	O
retained	O
the	O
ability	O
to	O
immortalize	O
T	O
lymphocytes	O
,	O
the	O
M22	B
mutant	O
lost	O
the	O
ability	O
to	O
immortalize	O
infected	O
cells	O
.	O
These	O
results	O
indicate	O
that	O
activation	O
of	O
the	O
CREB	B
/	I
ATF	I
pathway	O
by	O
Tax	B
is	O
dispensable	O
for	O
the	O
immortalization	O
of	O
T	O
cells	O
by	O
HTLV-1	O
,	O
whereas	O
activation	O
of	O
the	O
NF	B
-	I
kappaB	I
pathway	O
may	O
be	O
critical	O
.	O
Defining	O
therapeutic	O
targets	O
by	O
using	O
adenovirus	O
:	O
blocking	O
NF	B
-	I
kappaB	I
inhibits	O
both	O
inflammatory	O
and	O
destructive	O
mechanisms	O
in	O
rheumatoid	O
synovium	O
but	O
spares	O
anti	B
-	I
inflammatory	I
mediators	I
.	O
The	O
role	O
of	O
the	O
transcription	B
factor	I
NF	B
-	I
kappaB	I
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
has	O
long	O
been	O
a	O
subject	O
of	O
controversy	O
.	O
We	O
used	O
an	O
adenoviral	O
technique	O
of	O
blocking	O
NF	B
-	I
kappaB	I
through	O
overexpression	O
of	O
the	O
inhibitory	B
subunit	I
IkappaBalpha	B
,	O
which	O
has	O
the	O
advantage	O
that	O
it	O
can	O
be	O
used	O
in	O
the	O
diseased	O
tissue	O
itself	O
,	O
with	O
>	O
90	O
%	O
of	O
the	O
synovial	O
macrophages	O
,	O
fibroblasts	O
,	O
and	O
T	O
cells	O
infected	O
.	O
We	O
found	O
that	O
the	O
spontaneous	O
production	O
of	O
tumor	B
necrosis	I
factor	I
alpha	I
and	O
other	O
pro	B
-	I
inflammatory	I
cytokines	I
is	O
NF	B
-	I
kappaB	I
-dependent	O
in	O
rheumatoid	O
synovial	O
tissue	O
,	O
in	O
contrast	O
to	O
the	O
main	O
anti	B
-	I
inflammatory	I
mediators	I
,	O
like	O
IL-10	B
and	I
-11	I
,	O
and	O
the	O
IL-1	B
receptor	I
antagonist	I
.	O
Of	O
even	O
more	O
interest	O
,	O
IkappaBalpha	B
overexpression	O
inhibited	O
the	O
production	O
of	O
matrix	B
metalloproteinases	I
1	I
and	I
3	I
while	O
not	O
affecting	O
their	O
tissue	O
inhibitor	O
.	O
Blocking	O
NF	B
-	I
kappaB	I
in	O
the	O
rheumatoid	O
joint	O
thus	O
has	O
a	O
very	O
beneficial	O
profile	O
,	O
reducing	O
both	O
the	O
inflammatory	O
response	O
and	O
the	O
tissue	O
destruction	O
.	O
The	O
adenoviral	O
technique	O
described	O
here	O
has	O
widespread	O
applicability	O
,	O
allowing	O
rapid	O
testing	O
of	O
the	O
effects	O
of	O
blocking	O
a	O
potential	O
therapeutic	O
target	O
in	O
either	O
cultures	O
of	O
normal	O
cells	O
or	O
in	O
the	O
diseased	O
tissue	O
itself	O
.	O
Nuclear	B
factor-90	I
of	O
activated	O
T	O
-	O
cells	O
:	O
A	O
double	O
-	O
stranded	O
RNA	O
-binding	O
protein	O
and	O
substrate	O
for	O
the	O
double	B
-	I
stranded	I
RNA	I
-	I
dependent	I
protein	I
kinase	I
,	O
PKR	B
.	O
NFAT	O
transcription	O
factors	O
play	O
a	O
central	O
role	O
in	O
initiating	O
T	O
-	O
cell	O
activation	O
through	O
the	O
induction	O
of	O
immediate	O
-	O
early	O
T	O
-	O
cell	O
specific	O
genes	O
including	O
interleukin-2	O
(	O
IL-2	B
)	O
.	O
NFAT	O
transcription	O
factors	O
bind	O
to	O
a	O
sequence	O
in	O
the	O
IL-2	O
enhancer	O
known	O
as	O
the	O
antigen	O
receptor	O
response	O
element	O
2	O
(	O
ARRE-2	O
)	O
.	O
Multiple	O
proteins	O
exhibiting	O
ARRE-2	O
binding	O
activity	O
have	O
been	O
isolated	O
,	O
including	O
a	O
heterodimer	B
from	O
stimulated	O
T	O
-	O
cell	O
nuclear	O
extracts	O
consisting	O
of	O
Mr	O
=	O
90	O
000	O
(	O
NF90	B
)	O
and	O
Mr	O
=	O
45	O
000	O
(	O
NF45	B
)	O
subunits	O
.	O
The	O
subunits	O
of	O
this	O
heterodimer	B
have	O
been	O
cloned	O
,	O
and	O
NF90	B
was	O
found	O
to	O
encode	O
a	O
protein	O
containing	O
two	O
domains	O
that	O
are	O
predicted	O
to	O
form	O
motifs	O
capable	O
of	O
binding	O
to	O
double	O
-	O
stranded	O
RNA	O
.	O
Using	O
in	O
vitro	O
translated	O
polypeptides	O
,	O
we	O
have	O
demonstrated	O
that	O
NF90	B
specifically	O
binds	O
to	O
double	O
-	O
stranded	O
RNA	O
.	O
Furthermore	O
,	O
NF90	B
was	O
phosphorylated	O
in	O
a	O
double	O
-	O
stranded	O
RNA	O
-dependent	O
manner	O
likely	O
by	O
the	O
interferon	O
-	O
induced	O
,	O
double	B
-	I
stranded	I
RNA	I
-	I
dependent	I
protein	I
kinase	I
,	O
PKR	B
.	O
The	O
NF90	B
protein	O
was	O
found	O
to	O
be	O
expressed	O
not	O
only	O
in	O
T	O
-	O
cells	O
,	O
but	O
also	O
in	O
nonimmune	O
HeLa	O
cells	O
.	O
In	O
HeLa	O
cells	O
,	O
the	O
protein	O
was	O
almost	O
exclusively	O
localized	O
to	O
the	O
ribosome	O
salt	O
wash	O
fraction	O
of	O
cell	O
lysates	O
.	O
Cell	O
growth	O
-	O
regulated	O
expression	O
of	O
mammalian	O
MCM5	O
and	O
MCM6	O
genes	O
mediated	O
by	O
the	O
transcription	B
factor	I
E2F	B
.	O
Initiation	O
of	O
DNA	O
replication	O
requires	O
the	O
function	O
of	O
MCM	B
gene	I
products	I
,	O
which	O
participate	O
in	O
ensuring	O
that	O
DNA	O
replication	O
occurs	O
only	O
once	O
in	O
the	O
cell	O
cycle	O
.	O
Expression	O
of	O
all	O
mammalian	O
genes	O
of	O
the	O
MCM	O
family	O
is	O
induced	O
by	O
growth	O
stimulation	O
,	O
unlike	O
yeast	O
,	O
and	O
the	O
mRNA	O
levels	O
peak	O
at	O
G1	O
/	O
S	O
boundary	O
.	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
transcriptional	O
activities	O
of	O
isolated	O
human	O
MCM	O
gene	O
promoters	O
.	O
Human	O
MCM5	O
and	O
MCM6	O
promoters	O
with	O
mutation	O
in	O
the	O
E2F	O
sites	O
failed	O
in	O
promoter	O
regulation	O
following	O
serum	O
stimulation	O
and	O
exogenous	O
E2F	B
expression	O
.	O
In	O
addition	O
,	O
we	O
identified	O
a	O
novel	O
E2F	O
-	O
like	O
sequence	O
in	O
human	O
MCM6	O
promoter	O
which	O
cooperates	O
with	O
the	O
authentic	O
E2F	O
sites	O
in	O
E2F	B
-dependent	O
regulation	O
.	O
Forced	O
expression	O
of	O
E2F1	B
could	O
induce	O
expression	O
of	O
all	O
members	O
of	O
the	O
endogenous	O
MCM	O
genes	O
in	O
rat	O
embryonal	O
fibroblast	O
REF52	O
cells	O
.	O
Our	O
results	O
demonstrated	O
that	O
the	O
growth	O
-	O
regulated	O
expression	O
of	O
mammalian	O
MCM5	O
and	O
MCM6	O
genes	O
,	O
and	O
presumably	O
other	O
MCM	O
members	O
,	O
is	O
primarily	O
regulated	O
by	O
E2F	B
through	O
binding	O
to	O
multiple	O
E2F	O
sites	O
in	O
the	O
promoters	O
.	O
Control	O
of	O
lymphocyte	O
development	O
by	O
the	O
Ikaros	O
gene	O
family	O
.	O
Lymphoid	O
cell	O
differentiation	O
relies	O
on	O
precisely	O
orchestrated	O
gene	O
activation	O
and	O
repression	O
events	O
.	O
Gene	O
targeting	O
studies	O
have	O
demonstrated	O
crucial	O
roles	O
for	O
the	O
transcription	B
factors	I
Ikaros	B
and	O
Aiolos	B
in	O
regulating	O
multiple	O
stages	O
of	O
B	O
and	O
T	O
cell	O
development	O
.	O
Recent	O
experiments	O
suggest	O
that	O
Ikaros	B
and	O
Aiolos	B
set	O
B	O
cell	O
antigen	O
-	O
receptor	O
(	O
BCR	O
)	O
-	O
and	O
TCR	O
-	O
mediated	O
signaling	O
thresholds	O
and	O
that	O
the	O
molecules	O
exist	O
within	O
T	O
cells	O
in	O
nuclear	B
complexes	I
that	O
contain	O
nucleosome	O
remodeling	O
and	O
histone	B
deacetylase	I
activities	O
.	O
Apoptosis	O
and	O
growth	O
inhibition	O
in	O
malignant	O
lymphocytes	O
after	O
treatment	O
with	O
arsenic	O
trioxide	O
at	O
clinically	O
achievable	O
concentrations	O
[	O
see	O
comments	O
]	O
BACKGROUND	O
:	O
Arsenic	O
trioxide	O
(	O
As2O3	O
)	O
can	O
induce	O
clinical	O
remission	O
in	O
patients	O
with	O
acute	O
promyelocytic	O
leukemia	O
via	O
induction	O
of	O
differentiation	O
and	O
programmed	O
cell	O
death	O
(	O
apoptosis	O
)	O
.	O
We	O
investigated	O
the	O
effects	O
of	O
As2O3	O
on	O
a	O
panel	O
of	O
malignant	O
lymphocytes	O
to	O
determine	O
whether	O
growth	O
-	O
inhibitory	O
and	O
apoptotic	O
effects	O
of	O
As2O3	O
can	O
be	O
observed	O
in	O
these	O
cells	O
at	O
clinically	O
achievable	O
concentrations	O
.	O
METHODS	O
:	O
Eight	O
malignant	O
lymphocytic	O
cell	O
lines	O
and	O
primary	O
cultures	O
of	O
lymphocytic	O
leukemia	O
and	O
lymphoma	O
cells	O
were	O
treated	O
with	O
As2O3	O
,	O
with	O
or	O
without	O
dithiothreitol	O
(	O
DTT	O
)	O
or	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
(	O
an	O
inhibitor	O
of	O
glutathione	O
synthesis	O
)	O
.	O
Apoptosis	O
was	O
assessed	O
by	O
cell	O
morphology	O
,	O
flow	O
cytometry	O
,	O
annexin	O
V	O
protein	O
level	O
,	O
and	O
terminal	B
deoxynucleotidyl	I
transferase	I
labeling	O
of	O
DNA	O
fragments	O
.	O
Cellular	O
proliferation	O
was	O
determined	O
by	O
5-bromo-2'-deoxyuridine	O
incorporation	O
into	O
DNA	O
and	O
flow	O
cytometry	O
and	O
by	O
use	O
of	O
a	O
mitotic	O
arrest	O
assay	O
.	O
Mitochondrial	O
transmembrane	O
potential	O
(	O
delta	O
psi	O
(	O
m	O
)	O
)	O
was	O
measured	O
by	O
means	O
of	O
rhodamine	O
123	O
staining	O
and	O
flow	O
cytometry	O
.	O
Protein	O
expression	O
was	O
assessed	O
by	O
western	O
blot	O
analysis	O
or	O
immunofluorescence	O
.	O
RESULTS	O
:	O
Therapeutic	O
concentrations	O
of	O
As2O3	O
(	O
1	O
-	O
2	O
microM	O
)	O
had	O
dual	O
effects	O
on	O
malignant	O
lymphocytes	O
:	O
1	O
)	O
inhibition	O
of	O
growth	O
through	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
depletion	O
and	O
prolongation	O
of	O
cell	O
cycle	O
time	O
and	O
2	O
)	O
induction	O
of	O
apoptosis	O
.	O
As2O3-induced	O
apoptosis	O
was	O
preceded	O
by	O
delta	O
psi	O
(	O
m	O
)	O
collapse	O
.	O
DTT	O
antagonized	O
and	O
BSO	O
enhanced	O
As2O3-induced	O
ATP	O
depletion	O
,	O
delta	O
psi	O
(	O
m	O
)	O
collapse	O
,	O
and	O
apoptosis	O
.	O
Caspase-3	B
activation	O
,	O
usually	O
resulting	O
from	O
delta	O
psi	O
(	O
m	O
)	O
collapse	O
,	O
was	O
not	O
always	O
associated	O
with	O
As2O3-induced	O
apoptosis	O
.	O
As2O3	O
induced	O
PML	O
(	O
promyelocytic	O
leukemia	O
)	O
protein	O
degradation	O
but	O
did	O
not	O
modulate	O
expression	O
of	O
cell	B
cycle	I
-	I
related	I
proteins	I
,	O
including	O
c	B
-	I
myc	I
,	O
retinoblastoma	B
protein	I
,	O
cyclin	B
-	I
dependent	I
kinase	I
4	I
,	O
cyclin	B
D1	I
,	O
and	O
p53	B
,	O
or	O
expression	O
of	O
differentiation	B
-	I
related	I
antigens	I
.	O
CONCLUSIONS	O
:	O
Substantial	O
growth	O
inhibition	O
and	O
apoptosis	O
without	O
evidence	O
of	O
differentiation	O
were	O
induced	O
in	O
most	O
malignant	O
lymphocytic	O
cells	O
treated	O
with	O
1	O
-	O
2	O
microM	O
As2O3	O
.	O
As2O3	O
may	O
prove	O
useful	O
in	O
the	O
treatment	O
of	O
malignant	O
lymphoproliferative	O
disorders	O
.	O
Expression	O
of	O
Th1	B
and	I
Th2	I
type	I
cytokines	I
responding	O
to	O
HBsAg	B
and	O
HBxAg	B
in	O
chronic	O
hepatitis	O
B	O
patients	O
.	O
The	O
cytokine	B
pattern	I
on	O
viral	O
antigen	O
recognition	O
is	O
believed	O
to	O
exert	O
a	O
profound	O
influence	O
on	O
the	O
resolution	O
of	O
viral	O
infections	O
and	O
viral	O
clearance	O
.	O
This	O
study	O
was	O
initiated	O
to	O
investigate	O
whether	O
a	O
cytokine	B
imbalance	O
oriented	O
toward	O
Th2	O
type	O
response	O
plays	O
a	O
role	O
in	O
chronic	O
hepatitis	O
B	O
.	O
Cytokine	B
profiles	I
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
associated	O
with	O
chronic	O
hepatitis	O
B	O
were	O
analysed	O
by	O
RT	O
-	O
PCR	O
.	O
Upon	O
HBsAg	B
stimulation	O
,	O
expression	O
of	O
IFN	B
-	I
gamma	I
,	O
IL-2	B
,	O
IL-4	B
,	O
and	O
IL-10	B
was	O
detected	O
in	O
41	O
%	O
,	O
8	O
%	O
,	O
41	O
%	O
,	O
and	O
50	O
%	O
of	O
the	O
patients	O
,	O
respectively	O
.	O
Among	O
these	O
cytokines	B
,	O
the	O
expression	O
of	O
IFN	B
-	I
gamma	I
was	O
associated	O
with	O
high	O
levels	O
of	O
serum	B
AST	I
/	I
ALT	I
.	O
However	O
,	O
we	O
could	O
not	O
prove	O
that	O
Th2	B
type	I
cytokines	I
had	O
a	O
protective	O
effect	O
on	O
hepatocytes	O
.	O
Upon	O
HBxAg	B
stimulation	O
,	O
there	O
was	O
no	O
recognizable	O
association	O
of	O
cytokine	B
patterns	I
with	O
AST	O
/	O
ALT	O
levels	O
.	O
In	O
conclusion	O
,	O
production	O
of	O
a	O
Th1	B
cytokine	I
,	O
IFN	B
-	I
gamma	I
,	O
by	O
HBsAg	B
-reactive	O
cells	O
was	O
associated	O
with	O
hepatocyte	O
damage	O
in	O
chronic	O
hepatitis	O
B	O
,	O
while	O
no	O
counteracting	O
effect	O
of	O
Th2	B
cytokines	I
produced	O
by	O
those	O
cells	O
was	O
observed	O
.	O
Regulation	O
of	O
low	O
shear	O
flow	O
-	O
induced	O
HAEC	O
VCAM-1	B
expression	O
and	O
monocyte	O
adhesion	O
.	O
We	O
recently	O
reported	O
that	O
prolonged	O
exposure	O
of	O
human	O
aortic	O
endothelial	O
cells	O
(	O
HAEC	O
)	O
to	O
low	O
shear	O
stress	O
flow	O
patterns	O
is	O
associated	O
with	O
a	O
sustained	O
increase	O
in	O
the	O
activated	O
form	O
of	O
the	O
transcriptional	O
regulator	O
nuclear	B
factor	I
-	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
.	O
Here	O
we	O
investigate	O
the	O
hypothesis	O
that	O
low	O
shear	O
-	O
induced	O
activation	O
of	O
NF	B
-	I
kappaB	I
is	O
responsible	O
for	O
enhanced	O
expression	O
of	O
vascular	B
cell	I
adhesion	I
molecule	I
(	O
VCAM-1	B
)	O
resulting	O
in	O
augmented	O
endothelial	O
cell	O
-	O
monocyte	O
(	O
EC	O
-	O
Mn	O
)	O
adhesion	O
and	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
intracellular	O
oxidant	O
activity	O
.	O
Before	O
exposure	O
to	O
low	O
shear	O
(	O
2	O
dyn	O
/	O
cm2	O
)	O
for	O
6	O
h	O
,	O
HAEC	O
were	O
preincubated	O
with	O
or	O
without	O
the	O
antioxidants	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
or	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
.	O
PDTC	O
strongly	O
inhibited	O
low	O
shear	O
-	O
induced	O
activation	O
of	O
NF	B
-	I
kappaB	I
,	O
expression	O
of	O
VCAM-1	B
,	O
and	O
EC	O
-	O
Mn	O
adhesion	O
.	O
Paradoxically	O
,	O
NAC	O
exerted	O
a	O
positive	O
effect	O
on	O
low	O
shear	O
-	O
induced	O
VCAM-1	B
expression	O
and	O
EC	O
-	O
Mn	O
adhesion	O
and	O
only	O
slightly	O
downregulated	O
NF	B
-	I
kappaB	I
activation	O
.	O
However	O
,	O
cytokine	O
-	O
induced	O
NF	B
-	I
kappaB	I
activation	O
and	O
VCAM-1	B
expression	O
are	O
blocked	O
by	O
both	O
PDTC	O
and	O
NAC	O
.	O
These	O
data	O
suggest	O
that	O
NF	B
-	I
kappaB	I
plays	O
a	O
key	O
role	O
in	O
low	O
shear	O
-	O
induced	O
VCAM-1	B
expression	O
and	O
that	O
pathways	O
mediating	O
low	O
shear-	O
and	O
cytokine	O
-	O
induced	O
EC	O
-	O
Mn	O
adhesion	O
may	O
be	O
differentially	O
regulated	O
.	O
Non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
inhibit	O
the	O
expression	O
of	O
cytokines	B
and	O
induce	O
HSP70	B
in	O
human	O
monocytes	O
.	O
Recent	O
studies	O
have	O
shown	O
that	O
the	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
activate	O
heat	B
shock	I
transcription	I
factor	I
(	O
HSF1	B
)	O
from	O
a	O
latent	B
cytoplasmic	I
form	I
to	O
a	O
nuclear	B
,	I
DNA	I
binding	I
state	I
.	O
As	O
HSF1	B
can	O
function	O
as	O
both	O
an	O
activator	O
of	O
heat	O
shock	O
genes	O
and	O
a	O
repressor	O
of	O
non	O
-	O
heat	O
shock	O
genes	O
such	O
as	O
IL1B	O
and	O
c-	O
fos	O
,	O
we	O
have	O
examined	O
the	O
potential	O
role	O
of	O
HSF1	B
in	O
the	O
effects	O
of	O
NSAIDs	O
on	O
gene	O
expression	O
in	O
a	O
human	O
monocytic	O
cell	O
line	O
THP-1	O
.	O
We	O
found	O
that	O
two	O
members	O
of	O
the	O
NSAIDs	O
,	O
sodium	O
salicylate	O
and	O
sulindac	O
repress	O
the	O
IL1B	O
promoter	O
to	O
similar	O
degree	O
to	O
heat	O
shock	O
or	O
HSF1	B
overexpression	O
.	O
In	O
addition	O
,	O
sodium	O
salicylate	O
and	O
additional	O
NSAIDs	O
used	O
at	O
concentrations	O
that	O
activate	O
HSF1	B
also	O
inhibited	O
the	O
expression	O
of	O
other	O
monocytic	O
genes	O
(	O
TNF	O
-	O
alpha	O
,	O
IL-1beta	O
,	O
IL-6	O
,	O
IL-8	O
,	O
IL-10	O
,	O
ICAM-1	O
)	O
activated	O
by	O
exposure	O
to	O
a	O
pro	O
-	O
inflammatory	O
stimulus	O
(	O
lipopolysaccharide	O
,	O
LPS	O
)	O
.	O
At	O
least	O
in	O
the	O
case	O
of	O
the	O
IL1B	O
promoter	O
,	O
repression	O
did	O
not	O
seem	O
to	O
involve	O
another	O
factor	O
whose	O
activity	O
is	O
affected	O
by	O
the	O
NSAIDs	O
,	O
NFkappaB	B
as	O
the	O
IL1B	O
promoter	O
fragment	O
used	O
in	O
our	O
studies	O
is	O
not	O
NFkappaB	B
responsive	O
and	O
binds	O
specifically	O
to	O
HSF1	B
.	O
Exposure	O
to	O
NSAIDs	O
had	O
a	O
complex	O
effect	O
on	O
HSP	O
gene	O
expression	O
and	O
while	O
sulindac	O
activated	O
the	O
stress	O
responsive	O
HSP70B	O
promoter	O
,	O
sodium	O
salicylate	O
did	O
not	O
.	O
In	O
addition	O
,	O
only	O
a	O
subset	O
of	O
the	O
NSAIDs	O
induced	O
HSP70	O
mRNA	O
species	O
.	O
These	O
findings	O
reflect	O
the	O
properties	O
of	O
HSF1	B
which	O
can	O
be	O
activated	O
to	O
at	O
least	O
two	O
DNA	B
binding	I
forms	I
only	O
one	O
of	O
which	O
activates	O
heat	O
shock	O
promoters	O
and	O
suggest	O
that	O
individual	O
NSAID	O
family	O
members	O
may	O
differentially	O
induce	O
one	O
or	O
other	O
of	O
these	O
forms	O
.	O
Overall	O
therefore	O
,	O
exposure	O
to	O
NSAIDs	O
leads	O
to	O
a	O
profound	O
switch	O
in	O
gene	O
expression	O
in	O
monocytic	O
cells	O
,	O
with	O
suppression	O
of	O
genes	O
involved	O
in	O
macrophage	O
activation	O
and	O
induction	O
of	O
stress	O
genes	O
and	O
HSF1	B
appears	O
to	O
play	O
a	O
regulatory	O
role	O
in	O
these	O
effects	O
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
Disruption	O
of	O
alpha	O
beta	O
but	O
not	O
of	O
gamma	O
delta	O
T	O
cell	O
development	O
by	O
overexpression	O
of	O
the	O
helix	B
-	I
loop	I
-	I
helix	I
protein	I
Id3	B
in	O
committed	O
T	O
cell	O
progenitors	O
.	O
Enforced	O
expression	O
of	O
Id3	B
,	O
which	O
has	O
the	O
capacity	O
to	O
inhibit	O
many	O
basic	B
helix	I
-	I
loop	I
-	I
helix	I
(	I
bHLH	I
)	I
transcription	I
factors	I
,	O
in	O
human	O
CD34	O
(	O
+	O
)	O
hematopoietic	O
progenitor	O
cells	O
that	O
have	O
not	O
undergone	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
gene	O
rearrangements	O
inhibits	O
development	O
of	O
the	O
transduced	O
cells	O
into	O
TCRalpha	O
beta	O
and	O
gamma	O
delta	O
cells	O
in	O
a	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O
Here	O
we	O
document	O
that	O
overexpression	O
of	O
Id3	B
,	O
in	O
progenitors	O
that	O
have	O
initiated	O
TCR	O
gene	O
rearrangements	O
(	O
pre	O
-	O
T	O
cells	O
)	O
,	O
inhibits	O
development	O
into	O
TCRalpha	O
beta	O
but	O
not	O
into	O
TCRgamma	O
delta	O
T	O
cells	O
.	O
Furthermore	O
,	O
Id3	B
impedes	O
expression	O
of	O
recombination	O
activating	O
genes	O
and	O
downregulates	O
pre	O
-	O
Talpha	O
mRNA	O
.	O
These	O
observations	O
suggest	O
possible	O
mechanisms	O
by	O
which	O
Id3	B
overexpression	O
can	O
differentially	O
affect	O
development	O
of	O
pre	O
-	O
T	O
cells	O
into	O
TCRalpha	O
beta	O
and	O
gamma	O
delta	O
cells	O
.	O
We	O
also	O
observed	O
that	O
cell	O
surface	O
CD4	O
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
-	O
)	O
cells	O
with	O
rearranged	O
TCR	O
genes	O
developed	O
from	O
Id3-transduced	O
but	O
not	O
from	O
control	O
-	O
transduced	O
pre	O
-	O
T	O
cells	O
in	O
an	O
FTOC	O
.	O
These	O
cells	O
had	O
properties	O
of	O
both	O
natural	O
killer	O
(	O
NK	O
)	O
and	O
pre	O
-	O
T	O
cells	O
.	O
These	O
findings	O
suggest	O
that	O
bHLH	B
factors	I
are	O
required	O
to	O
control	O
T	O
cell	O
development	O
after	O
the	O
T	O
/	O
NK	O
developmental	O
checkpoint	O
.	O
Rel	B
/	I
NF	I
-	I
kappaB	I
can	O
trigger	O
the	O
Notch	O
signaling	O
pathway	O
by	O
inducing	O
the	O
expression	O
of	O
Jagged1	B
,	O
a	O
ligand	O
for	O
Notch	B
receptors	I
.	O
Jagged1	B
belongs	O
to	O
the	O
DSL	B
family	I
of	I
ligands	I
for	O
Notch	B
receptors	I
that	O
control	O
the	O
proliferation	O
and	O
differentiation	O
of	O
various	O
cell	O
lineages	O
.	O
However	O
,	O
little	O
is	O
known	O
about	O
the	O
transcription	B
factors	I
that	O
regulate	O
its	O
expression	O
.	O
Here	O
,	O
we	O
show	O
that	O
Jagged1	B
is	O
a	O
Rel	O
/	O
NF	O
-	O
kappaB	O
-	O
responsive	O
gene	O
.	O
Both	O
c	B
-	I
Rel	I
and	O
RelA	B
induced	O
jagged1	O
gene	O
expression	O
,	O
whereas	O
a	O
mutant	O
defective	O
for	O
transactivation	O
did	O
not	O
.	O
Importantly	O
,	O
jagged1	B
transcripts	I
were	O
also	O
upregulated	O
by	O
endogenous	O
NF	B
-	I
kappaB	I
activation	O
and	O
this	O
effect	O
was	O
inhibited	O
by	O
a	O
dominant	O
mutant	O
of	O
IkappaBalpha	B
,	O
a	O
physiological	O
inhibitor	O
of	O
NF	B
-	I
kappaB	I
.	O
Cell	O
surface	O
expression	O
of	O
Jagged1	B
in	O
c	O
-	O
Rel	O
-	O
expressing	O
cell	O
monolayers	O
led	O
to	O
a	O
functional	O
interaction	O
with	O
lymphocytes	O
expressing	O
the	O
Notch1	B
/	I
TAN-1	I
receptor	I
.	O
This	O
correlated	O
with	O
the	O
initiation	O
of	O
signaling	O
downstream	O
of	O
Notch	O
,	O
as	O
evidenced	O
by	O
increased	O
levels	O
of	O
HES-1	O
transcripts	O
in	O
co	O
-	O
cultivated	O
T	O
cells	O
and	O
of	O
CD23	O
transcripts	O
in	O
co	O
-	O
cultivated	O
B	O
cells	O
.	O
Consistent	O
with	O
its	O
Rel	B
/	I
NF	I
-	I
kappaB	I
-dependent	O
induction	O
,	O
Jagged1	B
was	O
found	O
to	O
be	O
highly	O
expressed	O
in	O
splenic	O
B	O
cells	O
where	O
c	B
-	I
Rel	I
is	O
expressed	O
constitutively	O
.	O
These	O
results	O
demonstrate	O
that	O
c	B
-	I
Rel	I
can	O
trigger	O
the	O
Notch	O
signaling	O
pathway	O
in	O
neighboring	O
cells	O
by	O
inducing	O
jagged1	O
gene	O
expression	O
,	O
and	O
suggest	O
a	O
role	O
for	O
Jagged1	B
in	O
B	O
-	O
cell	O
activation	O
,	O
differentiation	O
or	O
function	O
.	O
These	O
findings	O
also	O
highlight	O
the	O
potential	O
for	O
an	O
interplay	O
between	O
the	O
Notch	O
and	O
NF	O
-	O
kappaB	O
signaling	O
pathways	O
in	O
the	O
immune	O
system	O
.	O
Transcriptional	O
control	O
of	O
the	O
IL-5	B
gene	O
by	O
human	O
helper	O
T	O
cells	O
:	O
IL-5	B
synthesis	O
is	O
regulated	O
independently	O
from	O
IL-2	B
or	O
IL-4	B
synthesis	O
.	O
BACKGROUND	O
:	O
IL-5	B
is	O
fundamentally	O
involved	O
in	O
eosinophilic	O
inflammation	O
.	O
Control	O
of	O
IL-5	B
production	O
may	O
be	O
effective	O
for	O
the	O
management	O
of	O
allergic	O
diseases	O
.	O
OBJECTIVE	O
:	O
We	O
aimed	O
to	O
find	O
the	O
transcriptional	O
mechanisms	O
that	O
regulate	O
the	O
IL-5	B
gene	O
to	O
selectively	O
control	O
IL-5	B
synthesis	O
.	O
METHODS	O
:	O
Allergen	O
-	O
specific	O
T	O
-	O
cell	O
clones	O
and	O
T	O
-	O
cell	O
hybridomas	O
were	O
established	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
asthma	O
,	O
and	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IL-5	O
gene	O
was	O
investigated	O
with	O
transient	O
transfection	O
and	O
electrophoretic	O
mobility	O
shift	O
analysis	O
.	O
RESULTS	O
:	O
A	O
human	O
IL-5	O
promoter	O
/	O
enhancer	O
-	O
luciferase	O
gene	O
construct	O
,	O
pIL-5	O
(	O
-511	O
)	O
Luc	O
,	O
was	O
transcribed	O
on	O
activation	O
of	O
IL-5-producing	O
T	O
-	O
cell	O
clones	O
,	O
but	O
not	O
IL-5-nonproducing	O
clones	O
.	O
pIL-5	O
(	O
-511	O
)	O
Luc	O
was	O
transcribed	O
by	O
T	O
-	O
cell	O
hybridomas	O
derived	O
from	O
fusion	O
between	O
IL-5-producing	O
T	O
-	O
cell	O
clones	O
and	O
an	O
IL-5	O
gene	O
-	O
nonexpressing	O
T	O
-	O
cell	O
line	O
,	O
but	O
not	O
by	O
hybridomas	O
derived	O
from	O
IL-5-nonproducing	O
T	O
-	O
cell	O
clones	O
.	O
IL-5	B
synthesis	O
was	O
not	O
only	O
induced	O
by	O
T	O
-	O
cell	O
receptor	O
stimulation	O
but	O
also	O
by	O
IL-2	B
receptor	O
stimulation	O
.	O
Binding	O
of	O
NF	B
-	I
AT	I
,	O
NF	B
-	I
kappaB	I
,	O
and	O
AP-1	B
was	O
induced	O
by	O
T	B
-	I
cell	I
receptor	I
(	O
TcR	B
)	O
stimulation	O
,	O
although	O
there	O
was	O
no	O
significant	O
upregulation	O
of	O
binding	O
by	O
IL-2	B
stimulation	O
.	O
CONCLUSION	O
:	O
IL-5	B
synthesis	O
by	O
human	O
helper	O
T	O
cells	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O
A	O
unique	O
transcriptional	O
mechanism	O
distinct	O
from	O
those	O
regulating	O
the	O
IL-2	O
or	O
IL-4	O
genes	O
seems	O
to	O
control	O
the	O
IL-5	O
gene	O
.	O
Selective	O
regulation	O
of	O
IL-5	B
gene	O
transcription	O
may	O
be	O
useful	O
for	O
treating	O
eosinophlic	O
inflammation	O
.	O
Recognition	O
of	O
NFATp	O
/	O
AP-1	O
composite	O
elements	O
within	O
genes	O
induced	O
upon	O
the	O
activation	O
of	O
immune	O
cells	O
.	O
Composite	O
elements	O
are	O
regulatory	O
modules	O
of	O
promoters	O
or	O
enhancers	O
that	O
consist	O
of	O
binding	O
sites	O
of	O
two	O
different	O
but	O
synergizing	O
transcription	B
factors	I
.	O
A	O
well	O
-	O
studied	O
example	O
is	O
nuclear	O
factors	O
of	O
activated	O
T	O
-	O
cell	O
(	O
NFAT	O
)	O
sites	O
which	O
are	O
composite	O
elements	O
of	O
a	O
NFATp	O
/	O
c	O
and	O
an	O
activating	O
protein	O
1	O
(	O
AP-1	O
)	O
binding	O
site	O
.	O
We	O
have	O
developed	O
a	O
computational	O
approach	O
to	O
identify	O
potential	O
NFAT	O
target	O
genes	O
which	O
(	O
a	O
)	O
comprises	O
an	O
improved	O
method	O
to	O
scan	O
for	O
individual	O
NFAT	O
composite	O
elements	O
;	O
(	O
b	O
)	O
considers	O
positional	O
effects	O
relative	O
to	O
transcription	O
start	O
sites	O
;	O
and	O
(	O
c	O
)	O
involves	O
cluster	O
analysis	O
of	O
potential	O
NFAT	O
composite	O
elements	O
.	O
All	O
three	O
steps	O
progressively	O
helpX	O
?	O
ed	O
to	O
discriminate	O
T	O
-	O
cell	O
-	O
specific	O
promoter	O
sequences	O
against	O
other	O
functional	O
regions	O
(	O
coding	O
and	O
intronic	O
sequences	O
)	O
of	O
the	O
same	O
genes	O
,	O
against	O
promoters	O
of	O
muscle	O
-	O
specific	O
genes	O
or	O
against	O
random	O
sequences	O
.	O
Using	O
this	O
approach	O
,	O
we	O
identified	O
potential	O
NFAT	O
composite	O
elements	O
in	O
promoters	O
of	O
cytokine	O
genes	O
and	O
their	O
receptors	O
as	O
well	O
as	O
in	O
promoters	O
of	O
genes	O
for	O
AP-1	B
family	I
members	I
,	O
Ca2	B
+	I
-binding	I
proteins	I
and	O
some	O
other	O
components	O
of	O
the	O
regulatory	O
network	O
operating	O
in	O
activated	O
T	O
-	O
cells	O
and	O
other	O
immune	O
cells	O
.	O
The	O
method	O
developed	O
can	O
be	O
adapted	O
to	O
characterize	O
and	O
identify	O
other	O
composite	O
elements	O
as	O
well	O
.	O
The	O
program	O
for	O
recognition	O
NFAT	O
composite	O
elements	O
is	O
available	O
through	O
the	O
World	O
Wide	O
Web	O
(	O
http	O
:	O
/	O
/	O
compel.bionet.nsc.ru	O
/	O
FunSite	O
/	O
CompelScan.html	O
and	O
http	O
:	O
/	O
/	O
transfac.gbf.de	O
/	O
dbsearch	O
/	O
funsitep	O
/	O
s_comp.html	O
)	O
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
Nuclear	O
localization	O
and	O
formation	O
of	O
beta	B
-	I
catenin	I
-	I
lymphoid	I
enhancer	I
factor	I
1	I
complexes	I
are	O
not	O
sufficient	O
for	O
activation	O
of	O
gene	O
expression	O
.	O
In	O
response	O
to	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
,	O
beta	B
-	I
catenin	I
accumulates	O
in	O
the	O
nucleus	O
,	O
where	O
it	O
cooperates	O
with	O
LEF	B
/	I
TCF	I
(	O
for	O
lymphoid	B
enhancer	I
factor	I
and	I
T	I
-	I
cell	I
factor	I
)	O
transcription	B
factors	I
to	O
activate	O
gene	O
expression	O
.	O
The	O
mechanisms	O
by	O
which	O
beta	B
-	I
catenin	I
undergoes	O
this	O
shift	O
in	O
location	O
and	O
participates	O
in	O
activation	O
of	O
gene	O
transcription	O
are	O
unknown	O
.	O
We	O
demonstrate	O
here	O
that	O
beta	B
-	I
catenin	I
can	O
be	O
imported	O
into	O
the	O
nucleus	O
independently	O
of	O
LEF	B
/	I
TCF	I
binding	O
,	O
and	O
it	O
may	O
also	O
be	O
exported	O
from	O
nuclei	O
.	O
We	O
have	O
introduced	O
a	O
small	O
deletion	O
within	O
beta	B
-	I
catenin	I
(	O
Delta19	O
)	O
that	O
disrupts	O
binding	O
to	O
LEF-1	B
,	O
E	B
-	I
cadherin	I
,	O
and	O
APC	B
but	O
not	O
axin	B
.	O
This	O
Delta19	B
beta	I
-	I
catenin	I
mutant	I
localizes	O
to	O
the	O
nucleus	O
because	O
it	O
may	O
not	O
be	O
efficiently	O
sequestered	O
in	O
the	O
cytoplasm	O
.	O
The	O
nuclear	O
localization	O
of	O
Delta19	O
definitively	O
demonstrates	O
that	O
the	O
mechanisms	O
by	O
which	O
beta	B
-	I
catenin	I
localizes	O
in	O
the	O
nucleus	O
are	O
completely	O
independent	O
of	O
LEF	B
/	I
TCF	I
factors	I
.	O
beta	B
-	I
Catenin	I
and	O
LEF-1	B
complexes	I
can	O
activate	O
reporter	O
gene	O
expression	O
in	O
a	O
transformed	O
T	O
-	O
lymphocyte	O
cell	O
line	O
(	O
Jurkat	O
)	O
but	O
not	O
in	O
normal	O
T	O
lymphocytes	O
,	O
even	O
though	O
both	O
factors	O
are	O
nuclear	O
.	O
Thus	O
,	O
localization	O
of	O
both	O
factors	O
to	O
the	O
nucleus	O
is	O
not	O
sufficient	O
for	O
activation	O
of	O
gene	O
expression	O
.	O
Excess	O
beta	B
-	I
catenin	I
can	O
squelch	O
reporter	O
gene	O
activation	O
by	O
LEF-1-beta	B
-	I
catenin	I
complexes	I
but	O
not	O
activation	O
by	O
the	O
transcription	B
factor	I
VP16	B
.	O
Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
a	O
third	O
component	O
is	O
necessary	O
for	O
gene	O
activation	O
and	O
that	O
this	O
third	O
component	O
may	O
vary	O
with	O
cell	O
type	O
.	O
A	O
role	O
for	O
RanBP1	B
in	O
the	O
release	O
of	O
CRM1	B
from	O
the	O
nuclear	B
pore	I
complex	I
in	O
a	O
terminal	O
step	O
of	O
nuclear	O
export	O
.	O
We	O
recently	O
developed	O
an	O
assay	O
in	O
which	O
nuclear	O
export	O
of	O
the	O
shuttling	O
transcription	B
factor	I
NFAT	I
(	O
nuclear	B
factor	I
of	I
activated	I
T	I
cells	I
)	O
can	O
be	O
reconstituted	O
in	O
permeabilized	O
cells	O
with	O
the	O
GTPase	B
Ran	B
and	O
the	O
nuclear	O
export	O
receptor	O
CRM1	B
.	O
We	O
have	O
now	O
used	O
this	O
assay	O
to	O
identify	O
another	O
export	O
factor	O
.	O
After	O
preincubation	O
of	O
permeabilized	O
cells	O
with	O
a	O
Ran	B
mutant	I
that	O
can	O
not	O
hydrolyze	O
GTP	O
(	O
RanQ69L	B
)	O
,	O
cytosol	O
supports	O
NFAT	B
export	O
,	O
but	O
CRM1	B
and	O
Ran	B
alone	O
do	O
not	O
.	O
The	O
RanQ69L	B
preincubation	O
leads	O
to	O
accumulation	O
of	O
CRM1	B
at	O
the	O
cytoplasmic	O
periphery	O
of	O
the	O
nuclear	B
pore	I
complex	I
(	O
NPC	B
)	O
in	O
association	O
with	O
the	O
p62	B
complex	I
and	O
Can	O
/	O
Nup214	O
.	O
Ran	B
GTP	O
-	O
dependent	O
association	O
of	O
CRM1	B
with	O
these	O
nucleoporins	B
was	O
reconstituted	O
in	O
vitro	O
.	O
By	O
biochemical	O
fractionation	O
and	O
reconstitution	O
,	O
we	O
showed	O
that	O
RanBP1	B
restores	O
nuclear	O
export	O
after	O
the	O
RanQ69L	B
preincubation	O
.	O
It	O
also	O
stimulates	O
nuclear	O
export	O
in	O
cells	O
that	O
have	O
not	O
been	O
preincubated	O
with	O
RanQ69L	B
.	O
RanBP1	B
as	O
well	O
as	O
Ran	B
-	I
binding	I
domains	I
of	O
the	O
cytoplasmic	B
nucleoporin	I
RanBP2	B
promote	O
the	O
release	O
of	O
CRM1	B
from	O
the	O
NPC	B
.	O
Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
Ran	B
GTP	O
is	O
important	O
for	O
the	O
targeting	O
of	O
export	O
complexes	O
to	O
the	O
cytoplasmic	O
side	O
of	O
the	O
NPC	B
and	O
that	O
RanBP1	B
and	O
probably	O
RanBP2	B
are	O
involved	O
in	O
the	O
dissociation	O
of	O
nuclear	B
export	I
complexes	I
from	O
the	O
NPC	B
in	O
a	O
terminal	O
step	O
of	O
transport	O
.	O
Monocyte	O
arrest	O
and	O
transmigration	O
on	O
inflamed	O
endothelium	O
in	O
shear	O
flow	O
is	O
inhibited	O
by	O
adenovirus	O
-	O
mediated	O
gene	O
transfer	O
of	O
IkappaB	B
-	I
alpha	I
.	O
Mobilization	O
of	O
nuclear	B
factor	I
-	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
activates	O
transcription	O
of	O
genes	O
encoding	O
endothelial	B
adhesion	I
molecules	I
and	O
chemokines	O
that	O
contribute	O
to	O
monocyte	O
infiltration	O
critical	O
in	O
atherogenesis	O
.	O
Inhibition	O
of	O
NF	B
-	I
kappaB	I
has	O
been	O
achieved	O
by	O
pharmacological	O
and	O
genetic	O
approaches	O
;	O
however	O
,	O
monocyte	O
interactions	O
with	O
activated	O
endothelium	O
in	O
shear	O
flow	O
following	O
gene	O
transfer	O
of	O
the	O
NF	B
-	I
kappaB	I
inhibitor	O
IkappaB	B
-	I
alpha	I
have	O
not	O
been	O
studied	O
.	O
We	O
found	O
that	O
overexpression	O
of	O
IkappaB	B
-	I
alpha	I
in	O
endothelial	O
cells	O
using	O
a	O
recombinant	O
adenovirus	O
prevented	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
-induced	O
degradation	O
of	O
IkappaB	B
-	I
alpha	I
and	O
suppressed	O
the	O
upregulation	O
of	O
vascular	B
cell	I
adhesion	I
molecule-1	I
(	O
VCAM-1	B
)	O
,	O
intercellular	B
adhesion	I
molecule-1	I
(	O
ICAM-1	B
)	O
,	O
and	O
E	O
-	O
selectin	O
mRNA	O
and	O
surface	O
protein	O
expression	O
and	O
the	O
upregulation	O
of	O
transcripts	O
for	O
the	O
chemokines	B
monocyte	B
chemoattractant	I
protein	I
1	I
(	O
MCP-1	B
)	O
and	O
growth	B
-	I
related	I
activity	I
-	I
alpha	I
(	O
GRO	B
-	I
alpha	I
)	O
by	O
TNF	B
-	I
alpha	I
.	O
This	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
endothelial	O
MCP-1	B
secretion	O
and	O
GRO	B
-	I
alpha	I
immobilization	O
.	O
Adhesion	O
assays	O
under	O
physiological	O
shear	O
flow	O
conditions	O
showed	O
that	O
firm	O
arrest	O
,	O
spreading	O
,	O
and	O
transmigration	O
of	O
monocytes	O
on	O
TNF	B
-	I
alpha	I
-activated	O
endothelium	O
was	O
markedly	O
inhibited	O
by	O
IkappaB	B
-	I
alpha	I
overexpression	O
.	O
Inhibition	O
with	O
monoclonal	B
antibodies	I
and	O
peptide	O
antagonists	O
inferred	O
that	O
this	O
was	O
due	O
to	O
reduced	O
expression	O
of	O
Ig	O
integrin	O
ligand	O
as	O
well	O
as	O
of	O
chemokines	B
specifically	O
involved	O
in	O
these	O
events	O
.	O
In	O
contrast	O
,	O
rolling	O
of	O
monocytes	O
was	O
increased	O
by	O
IkappaB	B
-	I
alpha	I
transfer	O
and	O
was	O
partly	O
mediated	O
by	O
P	B
-	I
selectin	I
;	O
however	O
,	O
it	O
appeared	O
to	O
be	O
unaffected	O
by	O
the	O
inhibition	O
of	O
E	B
-	I
selectin	I
induction	O
.	O
Thus	O
,	O
our	O
data	O
provide	O
novel	O
evidence	O
that	O
selective	O
modulation	O
of	O
NF	B
-	I
kappaB	I
by	O
adenoviral	O
transfer	O
of	O
IkappaB	B
-	I
alpha	I
impairs	O
the	O
expression	O
of	O
multiple	O
endothelial	B
gene	I
products	I
required	O
for	O
subsequent	O
monocyte	O
arrest	O
and	O
emigration	O
in	O
shear	O
flow	O
and	O
thus	O
for	O
monocyte	O
infiltration	O
in	O
atherosclerotic	O
plaques	O
.	O
Human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
1	I
Tax	I
protein	I
induces	O
the	O
expression	O
of	O
STAT1	O
and	O
STAT5	O
genes	O
in	O
T	O
-	O
cells	O
.	O
Human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
1	I
(	I
HTLV-1	I
)	I
Tax	I
transforms	O
normal	O
T	O
-	O
cells	O
in	O
the	O
presence	O
of	O
interleukin	B
(	I
IL	I
)	I
-2	I
in	O
vitro	O
.	O
STAT	B
is	O
a	O
family	O
of	O
transcription	B
factors	I
that	O
play	O
a	O
pivotal	O
role	O
in	O
cytokine	O
-	O
induced	O
functions	O
of	O
a	O
various	O
type	O
of	O
cells	O
.	O
We	O
investigated	O
the	O
involvement	O
of	O
STATs	B
in	O
the	O
transformation	O
of	O
T	O
-	O
cells	O
by	O
HTLV-1	O
.	O
HTLV-1-transformed	O
T	O
-	O
cell	O
lines	O
expressed	O
higher	O
amounts	O
of	O
STAT1	O
,	O
STAT3	O
and	O
STAT5	O
RNA	O
and	O
proteins	O
than	O
virus	O
-	O
negative	O
T	O
cells	O
.	O
The	O
expression	O
of	O
STAT1	B
and	O
STAT5	B
in	O
a	O
human	O
T	O
-	O
cell	O
line	O
was	O
induced	O
by	O
Tax	B
.	O
IL-2	B
induced	O
the	O
DNA	O
binding	O
activity	O
of	O
STAT3	B
and	O
STAT5	B
of	O
a	O
HTLV-1-transformed	O
cell	O
line	O
and	O
then	O
stimulated	O
its	O
proliferation	O
.	O
In	O
contrast	O
,	O
IL-2	B
did	O
neither	O
in	O
a	O
cell	O
line	O
lacking	O
STAT3	B
and	O
STAT5	B
.	O
The	O
expression	O
of	O
STAT1	O
,	O
STAT3	O
and	O
STAT5	O
mRNAs	O
were	O
also	O
induced	O
by	O
a	O
T	B
-	I
cell	I
mitogen	I
in	O
normal	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
STAT1	B
and	O
STAT5	B
by	O
Tax	B
enhances	O
cytokine	B
-induced	O
functions	O
of	O
virus	O
-	O
infected	O
T	O
-	O
cells	O
,	O
hence	O
the	O
induction	O
may	O
play	O
a	O
role	O
in	O
IL-2	B
-dependent	O
transformation	O
steps	O
of	O
T	O
-	O
cells	O
by	O
HTLV-1	O
.	O
Selection	O
and	O
long	O
-	O
term	O
persistence	O
of	O
reactive	O
CTL	O
clones	O
during	O
an	O
EBV	O
chronic	O
response	O
are	O
determined	O
by	O
avidity	O
,	O
CD8	B
variable	O
contribution	O
compensating	O
for	O
differences	O
in	O
TCR	B
affinities	O
.	O
Recent	O
studies	O
have	O
suggested	O
that	O
the	O
diversity	O
of	O
TCR	B
repertoire	O
after	O
primary	O
immunization	O
is	O
conserved	O
in	O
memory	O
T	O
cells	O
and	O
that	O
a	O
progressive	O
narrowing	O
of	O
this	O
repertoire	O
may	O
take	O
place	O
during	O
recall	O
infections	O
.	O
It	O
now	O
remains	O
to	O
be	O
investigated	O
which	O
parameters	O
determine	O
the	O
repertoire	O
of	O
the	O
memory	O
response	O
and	O
possibly	O
restrict	O
its	O
diversity	O
after	O
subsequent	O
antigenic	O
challenges	O
.	O
To	O
address	O
this	O
question	O
,	O
we	O
took	O
advantage	O
of	O
a	O
panel	O
of	O
CD8	O
+	O
T	O
cell	O
clones	O
from	O
the	O
joint	O
of	O
a	O
rheumatoid	O
arthritis	O
patient	O
and	O
selected	O
for	O
their	O
reactivity	O
against	O
a	O
single	B
MHC	I
/	I
peptide	I
complex	I
.	O
Characterization	O
of	O
both	O
TCR	B
chains	I
documented	O
a	O
great	O
diversity	O
among	O
those	O
clones	O
and	O
the	O
persistence	O
of	O
clonotypes	O
over	O
a	O
2-yr	O
period	O
.	O
Strikingly	O
,	O
despite	O
the	O
observed	O
repertoire	O
heterogeneity	O
,	O
all	O
clones	O
displayed	O
a	O
narrow	O
range	O
of	O
MHC	B
/peptide	O
density	O
requirements	O
in	O
cytotoxicity	O
assays	O
(	O
ED50	O
between	O
9	O
and	O
36	O
nM	O
)	O
.	O
TCR	B
affinities	O
were	O
then	O
indirectly	O
estimated	O
by	O
blocking	O
CD8	B
interaction	O
with	O
an	O
anti	B
-	I
CD8	I
mAb	I
.	O
We	O
found	O
a	O
wide	O
range	O
of	O
TCR	B
affinities	O
among	O
the	O
different	O
clonotypes	O
that	O
segregated	O
with	O
Vbeta	O
usage	O
.	O
We	O
thus	O
propose	O
that	O
during	O
an	O
in	O
vivo	O
chronic	O
response	O
,	O
a	O
narrow	O
range	O
of	O
avidity	O
of	O
the	O
TCR	B
-	I
CD8	I
complex	I
conditions	O
long	O
-	O
term	O
clonotype	O
persistence	O
,	O
and	O
that	O
the	O
level	O
of	O
CD8	B
contribution	O
is	O
adjusted	O
to	O
keep	O
clonotypes	O
with	O
variable	O
TCR	B
affinities	O
within	O
this	O
avidity	O
window	O
.	O
In	O
vivo	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
in	O
T	O
-	O
lineage	O
cells	O
leads	O
to	O
a	O
dramatic	O
decrease	O
in	O
cell	O
proliferation	O
and	O
cytokine	B
production	O
and	O
to	O
increased	O
cell	O
apoptosis	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
,	O
but	O
not	O
to	O
abnormal	O
thymopoiesis	O
.	O
To	O
understand	O
the	O
role	O
of	O
NF	B
-	I
kappa	I
B	I
complexes	O
in	O
T	O
cell	O
development	O
and	O
activation	O
,	O
we	O
have	O
generated	O
transgenic	O
mice	O
in	O
which	O
RelA	B
and	O
c	B
-	I
Rel	I
complexes	I
were	O
selectively	O
inhibited	O
in	O
the	O
T	O
-	O
lineage	O
cells	O
by	O
specific	O
expression	O
of	O
a	O
trans	O
-	O
dominant	O
form	O
of	O
I	B
kappa	I
B	I
alpha	I
.	O
Transgene	O
expression	O
did	O
not	O
affect	O
the	O
thymic	O
development	O
,	O
but	O
led	O
to	O
lowered	O
numbers	O
of	O
splenic	O
T	O
cells	O
and	O
to	O
a	O
dramatic	O
decrease	O
in	O
the	O
ex	O
vivo	O
proliferative	O
response	O
of	O
splenic	O
T	O
lymphocytes	O
.	O
Analysis	O
of	O
IL-2	B
and	O
IL-2R	B
alpha	I
expression	O
demonstrated	O
that	O
the	O
perturbation	O
of	O
the	O
proliferation	O
response	O
was	O
not	O
attributable	O
to	O
an	O
abnormal	O
expression	O
of	O
these	O
genes	O
.	O
In	O
contrast	O
,	O
expression	O
of	O
IL-4	B
,	O
IL-10	B
,	O
and	O
IFN	B
-	I
gamma	I
was	O
strongly	O
inhibited	O
in	O
the	O
transgenic	O
T	O
cells	O
.	O
The	O
proliferative	O
deficiency	O
of	O
the	O
transgenic	O
T	O
cells	O
was	O
associated	O
with	O
an	O
increased	O
apoptosis	O
.	O
These	O
results	O
point	O
out	O
the	O
involvement	O
of	O
NF	B
-	I
kappa	I
B	I
/	I
Rel	I
family	I
proteins	I
in	O
growth	O
signaling	O
pathways	O
by	O
either	O
regulating	B
proteins	I
involved	O
in	O
the	O
IL-2	B
signaling	O
or	O
by	O
functionally	O
interfering	O
with	O
the	O
cell	O
cycle	O
progression	O
.	O
Glucocorticoid	B
receptors	I
in	O
anorexia	O
nervosa	O
and	O
Cushing	O
's	O
disease	O
.	O
BACKGROUND	O
:	O
Patients	O
with	O
anorexia	O
nervosa	O
do	O
not	O
display	O
cushingoid	O
features	O
in	O
spite	O
of	O
elevated	O
cortisol	O
plasma	O
levels	O
.	O
Whether	O
a	O
cortisol	O
resistance	O
or	O
a	O
reduced	O
availability	O
of	O
the	O
metabolic	O
substrates	O
necessary	O
to	O
develop	O
the	O
effect	O
of	O
glucocorticoids	O
is	O
responsible	O
for	O
this	O
has	O
not	O
been	O
established	O
.	O
METHODS	O
:	O
Twenty	O
-	O
two	O
patients	O
with	O
severe	O
restrictive	O
anorexia	O
nervosa	O
,	O
10	O
patients	O
with	O
active	O
Cushing	O
's	O
disease	O
,	O
and	O
24	O
healthy	O
volunteers	O
without	O
psychiatric	O
disorders	O
or	O
mood	O
alterations	O
were	O
investigated	O
.	O
Glucocorticoid	O
receptor	O
characteristics	O
were	O
examined	O
on	O
mononuclear	O
leukocytes	O
by	O
measuring	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
the	O
effect	O
of	O
dexamethasone	O
on	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
which	O
represents	O
an	O
index	O
of	O
DNA	O
synthesis	O
.	O
RESULTS	O
:	O
The	O
number	O
of	O
glucocorticoid	B
receptors	I
on	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
was	O
comparable	O
in	O
patients	O
with	O
anorexia	O
nervosa	O
,	O
patients	O
with	O
active	O
Cushing	O
's	O
disease	O
,	O
and	O
normal	O
subjects	O
(	O
binding	O
capacity	O
3.3	O
+	O
/-	O
0.23	O
vs.	O
3.7	O
+	O
/-	O
0.30	O
and	O
3.5	O
+	O
/-	O
0.20	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cells	O
)	O
.	O
Conversely	O
,	O
glucocorticoid	B
receptor	I
affinity	O
was	O
significantly	O
decreased	O
in	O
anorexia	O
nervosa	O
as	O
well	O
as	O
in	O
Cushing	O
's	O
patients	O
compared	O
to	O
control	O
subjects	O
(	O
dissociation	O
constant	O
4.0	O
+	O
/-	O
0.31	O
and	O
4.1	O
+	O
/-	O
0.34	O
vs.	O
2.9	O
+	O
/-	O
0.29	O
nmol	O
/	O
L	O
,	O
p	O
<	O
.001	O
)	O
and	O
inversely	O
correlated	O
with	O
the	O
levels	O
of	O
urinary	O
free	O
cortisol	O
in	O
both	O
groups	O
of	O
patients	O
.	O
Basal	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
in	O
MNL	O
was	O
significantly	O
reduced	O
in	O
anorexia	O
nervosa	O
as	O
well	O
as	O
in	O
Cushing	O
's	O
patients	O
compared	O
to	O
control	O
subjects	O
(	O
p	O
<	O
.001	O
)	O
and	O
was	O
diminished	O
by	O
dexamethasone	O
to	O
an	O
extent	O
similar	O
to	O
control	O
subjects	O
in	O
patients	O
with	O
anorexia	O
nervosa	O
,	O
but	O
significantly	O
(	O
p	O
<	O
.001	O
)	O
less	O
in	O
those	O
with	O
Cushing	O
's	O
disease	O
.	O
In	O
patients	O
with	O
anorexia	O
nervosa	O
,	O
the	O
incorporation	O
of	O
[	O
3H	O
]	O
thymidine	O
into	O
the	O
MNL	O
was	O
inversely	O
correlated	O
with	O
urinary	O
free	O
cortisol	O
levels	O
.	O
CONCLUSIONS	O
:	O
These	O
data	O
indicate	O
that	O
the	O
lack	O
of	O
cushingoid	O
features	O
in	O
patients	O
with	O
anorexia	O
nervosa	O
is	O
not	O
ascribable	O
to	O
a	O
reduced	O
sensitivity	O
to	O
glucocorticoids	O
but	O
is	O
more	O
likely	O
due	O
to	O
the	O
paucity	O
of	O
metabolic	O
substrates	O
.	O
Phorbol	O
ester	O
-	O
induced	O
mononuclear	O
cell	O
differentiation	O
is	O
blocked	O
by	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
kinase	I
(	O
MEK	B
)	O
inhibitor	O
PD98059	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
whether	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
(	O
MAPK	B
)	O
signaling	O
pathway	O
contributes	O
to	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
-induced	O
mononuclear	O
differentiation	O
in	O
the	O
human	O
myeloblastic	O
leukemia	O
ML-1	O
cells	O
.	O
Upon	O
TPA	O
treatment	O
,	O
the	O
activity	O
of	O
ERK1	B
and	O
ERK2	B
rapidly	O
increased	O
,	O
with	O
maximal	O
induction	O
between	O
1	O
and	O
3	O
h	O
,	O
while	O
ERK2	B
protein	O
levels	O
remained	O
constant	O
.	O
The	O
activity	O
of	O
JNK1	B
was	O
also	O
significantly	O
induced	O
,	O
with	O
JNK1	B
protein	O
levels	O
increasing	O
moderately	O
during	O
exposure	O
to	O
TPA	O
.	O
Treatment	O
of	O
cells	O
with	O
PD98059	O
,	O
a	O
specific	O
inhibitor	O
of	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
kinase	I
(	O
MEK	B
)	O
,	O
inhibited	O
TPA	O
-	O
induced	O
ERK2	B
activity	O
.	O
Furthermore	O
,	O
PD98059	O
completely	O
blocked	O
the	O
TPA	O
-	O
induced	O
differentiation	O
of	O
ML-1	O
cells	O
,	O
as	O
assessed	O
by	O
a	O
number	O
of	O
features	O
associated	O
with	O
mononuclear	O
differentiation	O
including	O
changes	O
in	O
morphology	O
,	O
nonspecific	O
esterase	B
activity	O
,	O
phagocytic	O
ability	O
,	O
NADPH	B
oxidase	I
activity	O
,	O
mitochondrial	O
respiration	O
,	O
and	O
c	O
-	O
jun	O
mRNA	O
inducibility	O
.	O
We	O
conclude	O
that	O
activation	O
of	O
the	O
MEK	B
/ERK	O
signaling	O
pathway	O
is	O
necessary	O
for	O
TPA	O
-	O
induced	O
mononuclear	O
cell	O
differentiation	O
.	O
Immune	O
functions	O
,	O
clinical	O
parameters	O
and	O
hormone	O
receptor	O
status	O
in	O
breast	O
cancer	O
patients	O
.	O
We	O
have	O
carried	O
out	O
a	O
detailed	O
analysis	O
of	O
the	O
cellular	O
immune	O
functions	O
of	O
breast	O
cancer	O
patients	O
in	O
comparison	O
with	O
healthy	O
controls	O
.	O
A	O
possible	O
correlation	O
between	O
immune	O
and	O
clinical	O
parameters	O
was	O
analysed	O
in	O
50	O
breast	O
cancer	O
patients	O
.	O
Immune	O
parameters	O
,	O
natural	O
killer	O
cell	O
and	O
T	O
lymphocyte	O
functions	O
and	O
the	O
numbers	O
of	O
circulating	O
T	O
lymphocytes	O
were	O
analysed	O
against	O
the	O
clinical	O
parameters	O
comprising	O
the	O
tumour	O
burden	O
,	O
the	O
stage	O
of	O
the	O
disease	O
and	O
the	O
expression	O
of	O
hormone	B
receptors	I
on	O
the	O
tumour	O
.	O
In	O
order	O
to	O
analyse	O
the	O
immune	O
function	O
data	O
effectively	O
,	O
low	O
responders	O
were	O
identified	O
with	O
stringent	O
cut	O
-	O
off	O
values	O
.	O
Considerably	O
higher	O
proportions	O
of	O
low	O
responders	O
were	O
found	O
among	O
the	O
patient	O
population	O
.	O
Elevated	O
numbers	O
of	O
circulating	O
T	O
lymphocytes	O
and	O
CD3	B
-directed	O
cytolysis	O
correlated	O
with	O
the	O
expression	O
of	O
oestrogen	B
receptors	I
independently	O
of	O
the	O
clinical	O
/	O
histological	O
parameters	O
.	O
Latent	B
membrane	I
protein	I
1	I
of	O
Epstein	O
-	O
Barr	O
virus	O
interacts	O
with	O
JAK3	B
and	O
activates	O
STAT	B
proteins	I
.	O
Latent	B
membrane	I
protein	I
1	I
(	O
LMP1	B
)	O
acts	O
like	O
a	O
permanently	B
activated	I
receptor	I
of	O
the	O
tumor	B
necrosis	I
factor	I
(	I
TNF	I
)	I
-receptor	I
superfamily	I
and	O
is	O
absolutely	O
required	O
for	O
B	O
cell	O
immortalization	O
by	O
Epstein	O
-	O
Barr	O
virus	O
.	O
Molecular	O
and	O
biochemical	O
approaches	O
demonstrated	O
that	O
LMP1	B
usurps	O
cellular	O
signaling	O
pathways	O
resulting	O
in	O
the	O
induction	O
of	O
NF	B
-	I
kappaB	I
and	O
AP-1	B
via	O
two	O
C	B
-	I
terminal	I
activating	I
regions	I
.	O
We	O
demonstrate	O
here	O
that	O
a	O
third	O
region	O
encompassing	O
a	O
proline	B
rich	I
sequence	I
within	O
the	O
33	O
bp	O
repetitive	O
stretch	O
of	O
LMP1	B
's	O
C	B
-	I
terminus	I
is	O
required	O
for	O
the	O
activation	O
of	O
Janus	B
kinase	I
3	I
(	O
JAK3	B
)	O
.	O
The	O
interaction	O
of	O
LMP1	B
and	O
JAK3	B
leads	O
to	O
the	O
enhanced	O
tyrosine	O
auto	O
/	O
transphosphorylation	O
of	O
JAK3	B
within	O
minutes	O
after	O
crosslinking	O
of	O
a	O
conditional	O
NGF	B
-	I
R	I
:	I
LMP1	I
chimera	I
and	O
is	O
a	O
prerequisite	O
for	O
the	O
activation	O
of	O
STAT	B
transcription	I
factors	I
.	O
These	O
results	O
reveal	O
a	O
novel	O
activating	O
region	O
in	O
the	O
LMP1	B
C	B
-	I
terminus	I
and	O
identify	O
the	O
JAK	B
/STAT	B
pathway	O
as	O
a	O
target	O
of	O
this	O
viral	B
integral	I
membrane	I
protein	I
in	O
B	O
cells	O
.	O
New	O
immunosuppressive	O
drug	O
PNU156804	O
blocks	O
IL-2	B
-dependent	O
proliferation	O
and	O
NF	O
-	O
kappa	O
B	O
and	O
AP-1	O
activation	O
.	O
We	O
had	O
previously	O
shown	O
that	O
the	O
drug	O
undecylprodigiosin	O
(	O
UP	O
)	O
blocks	O
human	O
lymphocyte	O
proliferation	O
in	O
vitro	O
.	O
We	O
have	O
now	O
investigated	O
the	O
mechanism	O
of	O
action	O
of	O
a	O
new	O
analogue	O
of	O
UP	O
,	O
PNU156804	O
,	O
which	O
shows	O
a	O
more	O
favorable	O
activity	O
profile	O
than	O
UP	O
in	O
mice	O
.	O
We	O
demonstrate	O
here	O
that	O
the	O
biological	O
effect	O
of	O
PNU156804	O
in	O
vitro	O
is	O
indistinguishable	O
from	O
UP	O
:	O
PNU156804	O
blocks	O
human	O
T	O
cell	O
proliferation	O
in	O
mid	O
-	O
late	O
G1	O
,	O
as	O
determined	O
by	O
cell	O
cycle	O
analysis	O
,	O
expression	O
of	O
cyclins	B
,	O
and	O
cyclin	B
-	I
dependent	I
kinases	I
and	O
retinoblastoma	O
phosphorylation	O
.	O
In	O
addition	O
,	O
we	O
show	O
that	O
PNU156804	O
does	O
not	O
block	O
significantly	O
the	O
induction	O
of	O
either	O
IL-2	B
or	O
IL-2R	B
alpha-	I
and	I
gamma	I
-	I
chains	I
but	O
inhibits	O
IL-2	B
-dependent	O
T	O
cell	O
proliferation	O
.	O
We	O
have	O
investigated	O
several	O
molecular	O
pathways	O
that	O
are	O
known	O
to	O
be	O
activated	O
by	O
IL-2	B
in	O
T	O
cells	O
.	O
We	O
show	O
that	O
PNU156804	O
does	O
not	O
inhibit	O
c	O
-	O
myc	O
and	O
bcl-2	O
mRNA	O
induction	O
.	O
On	O
the	O
other	O
hand	O
,	O
PNU156804	O
efficiently	O
inhibits	O
the	O
activation	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
and	O
AP-1	B
transcription	O
factors	O
.	O
PNU156804	O
inhibition	O
of	O
NF	B
-	I
kappa	I
B	I
activation	O
is	O
due	O
to	O
the	O
inhibition	O
of	O
the	O
degradation	O
of	O
I	B
kappa	I
B	I
-	I
alpha	I
and	O
I	B
kappa	I
B	I
-	I
beta	I
.	O
PNU156804	O
action	O
is	O
restricted	O
to	O
some	O
signaling	O
pathways	O
;	O
it	O
does	O
not	O
affect	O
NF	B
-	I
kappa	I
B	I
activation	O
by	O
PMA	O
in	O
T	O
cells	O
but	O
blocks	O
that	O
induced	O
by	O
CD40	B
cross	O
-	O
linking	O
in	O
B	O
lymphocytes	O
.	O
We	O
conclude	O
that	O
the	O
prodigiosin	O
family	O
of	O
immunosuppressants	O
is	O
a	O
new	O
family	O
of	O
molecules	O
that	O
show	O
a	O
novel	O
target	O
specificity	O
clearly	O
distinct	O
from	O
that	O
of	O
other	O
immunosuppressive	O
drugs	O
such	O
as	O
cyclosporin	O
A	O
,	O
FK506	O
,	O
and	O
rapamycin	O
.	O
IL-12	B
induces	O
IFN	B
regulating	I
factor-1	I
(	I
IRF-1	I
)	I
gene	O
expression	O
in	O
human	O
NK	O
and	O
T	O
cells	O
.	O
IL-12	B
is	O
a	O
critical	B
immunoregulatory	I
cytokine	I
that	O
promotes	O
cell	O
-	O
mediated	O
immune	O
responses	O
and	O
the	O
differentiation	O
of	O
naive	O
CD4	O
+	O
cells	O
to	O
Th1	O
cells	O
;	O
however	O
,	O
relatively	O
few	O
IL-12	B
target	O
genes	O
have	O
been	O
identified	O
.	O
To	O
better	O
clarify	O
the	O
molecular	O
basis	O
of	O
IL-12	B
action	O
,	O
we	O
set	O
out	O
to	O
characterize	O
genes	O
up	O
-	O
regulated	O
by	O
IL-12	B
,	O
first	O
by	O
contrasting	O
IL-12	O
-and	O
IFN	O
-	O
alpha	O
-	O
inducible	O
genes	O
.	O
We	O
identified	O
several	O
genes	O
up	O
-	O
regulated	O
by	O
IL-12	B
,	O
namely	O
,	O
MIP-1alpha	B
,	O
MIP-1beta	B
,	O
IL-1RA	B
,	O
and	O
IFN	B
regulatory	I
factor-1	I
(	I
IRF-1	I
)	I
.	O
IRF-1	B
is	O
a	O
transcription	B
factor	I
regulated	O
by	O
IFNs	B
that	O
is	O
also	O
essential	O
for	O
Th1	O
responses	O
.	O
We	O
demonstrated	O
that	O
IL-12	B
directly	O
up	O
-	O
regulates	O
IRF-1	B
to	O
the	O
same	O
extent	O
as	O
IFN	B
-	I
alpha	I
in	O
normal	O
human	O
T	O
cells	O
and	O
in	O
NK	O
cells	O
.	O
We	O
showed	O
that	O
IL-12	B
had	O
a	O
direct	O
effect	O
on	O
IRF-1	B
,	O
an	O
effect	O
not	O
mediated	O
indirectly	O
by	O
the	O
induction	O
of	O
IFN	B
-	I
gamma	I
production	O
.	O
Furthermore	O
,	O
IL-2	B
and	O
IL-12	B
synergistically	O
induced	O
IRF-1	B
,	O
whereas	O
IFN	B
-	I
alpha	I
and	O
IL-12	B
did	O
not	O
.	O
The	O
participation	O
of	O
STAT4	B
in	O
the	O
regulation	O
of	O
IRF-1	B
was	O
demonstrated	O
in	O
two	O
ways	O
.	O
First	O
,	O
STAT4	B
was	O
required	O
for	O
the	O
IL-12	B
-dependent	O
transactivation	O
of	O
an	O
IRF-1	O
reporter	O
construct	O
,	O
and	O
second	O
,	O
STAT4	B
binding	O
to	O
the	O
IRF-1	O
promoter	O
was	O
shown	O
using	O
EMSA	O
.	O
In	O
contrast	O
to	O
IL-12	B
,	O
no	O
up	O
-	O
regulation	O
of	O
IRF-1	B
was	O
found	O
in	O
IL-4-stimulated	O
cells	O
,	O
and	O
IL-4	B
did	O
not	O
block	O
IL-12	B
-dependent	O
up	O
-	O
regulation	O
of	O
IRF-1	B
.	O
Therefore	O
,	O
IRF-1	B
may	O
be	O
an	O
important	O
contributor	O
to	O
IL-12	B
signaling	O
,	O
and	O
we	O
speculate	O
that	O
the	O
defective	O
IL-12	B
responses	O
seen	O
in	O
IRF	B
-1-	O
/	O
-	O
mice	O
might	O
be	O
attributable	O
,	O
in	O
part	O
,	O
to	O
the	O
absence	O
of	O
this	O
transcription	B
factor	I
.	O
Direct	O
interaction	O
of	O
hematopoietic	B
transcription	I
factors	I
PU.1	I
and	I
GATA-1	I
:	O
functional	O
antagonism	O
in	O
erythroid	O
cells	O
.	O
Malignant	O
transformation	O
usually	O
inhibits	O
terminal	O
cell	O
differentiation	O
but	O
the	O
precise	O
mechanisms	O
involved	O
are	O
not	O
understood	O
.	O
PU.1	B
is	O
a	O
hematopoietic	B
-	I
specific	I
Ets	I
family	I
transcription	I
factor	I
that	O
is	O
required	O
for	O
development	O
of	O
some	O
lymphoid	O
and	O
myeloid	O
lineages	O
.	O
PU.1	B
can	O
also	O
act	O
as	O
an	O
oncoprotein	B
as	O
activation	O
of	O
its	O
expression	O
in	O
erythroid	O
precursors	O
by	O
proviral	O
insertion	O
or	O
transgenesis	O
causes	O
erythroleukemias	O
in	O
mice	O
.	O
Restoration	O
of	O
terminal	O
differentiation	O
in	O
the	O
mouse	O
erythroleukemia	O
(	O
MEL	O
)	O
cells	O
requires	O
a	O
decline	O
in	O
the	O
level	O
of	O
PU.1	B
,	O
indicating	O
that	O
PU.1	B
can	O
block	O
erythroid	O
differentiation	O
.	O
Here	O
we	O
investigate	O
the	O
mechanism	O
by	O
which	O
PU.1	B
interferes	O
with	O
erythroid	O
differentiation	O
.	O
We	O
find	O
that	O
PU.1	B
interacts	O
directly	O
with	O
GATA-1	B
,	O
a	O
zinc	B
finger	I
transcription	I
factor	I
required	O
for	O
erythroid	O
differentiation	O
.	O
Interaction	O
between	O
PU.1	B
and	O
GATA-1	B
requires	O
intact	O
DNA	B
-	I
binding	I
domains	I
in	O
both	O
proteins	O
.	O
PU.1	B
represses	O
GATA-1	B
-mediated	O
transcriptional	O
activation	O
.	O
Both	O
the	O
DNA	B
binding	I
and	O
transactivation	B
domains	I
of	O
PU.1	B
are	O
required	O
for	O
repression	O
and	O
both	O
domains	O
are	O
also	O
needed	O
to	O
block	O
terminal	O
differentiation	O
in	O
MEL	O
cells	O
.	O
We	O
also	O
show	O
that	O
ectopic	O
expression	O
of	O
PU.1	B
in	O
Xenopus	O
embryos	O
is	O
sufficient	O
to	O
block	O
erythropoiesis	O
during	O
normal	O
development	O
.	O
Furthermore	O
,	O
introduction	O
of	O
exogenous	O
GATA-1	B
in	O
both	O
MEL	O
cells	O
and	O
Xenopus	O
embryos	O
and	O
explants	O
relieves	O
the	O
block	O
to	O
erythroid	O
differentiation	O
imposed	O
by	O
PU.1	B
.	O
Our	O
results	O
indicate	O
that	O
the	O
stoichiometry	O
of	O
directly	O
interacting	O
but	O
opposing	O
transcription	B
factors	I
may	O
be	O
a	O
crucial	O
determinant	O
governing	O
processes	O
of	O
normal	O
differentiation	O
and	O
malignant	O
transformation	O
.	O
Oxidative	O
stress	O
triggers	O
STAT3	B
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
in	O
human	O
lymphocytes	O
.	O
Oxidizing	O
agents	O
are	O
powerful	O
activators	O
of	O
factors	O
responsible	O
for	O
the	O
transcriptional	O
activation	O
of	O
cytokine	O
-	O
encoding	O
genes	O
involved	O
in	O
tissue	O
injury	O
.	O
In	O
this	O
study	O
we	O
show	O
evidence	O
that	O
STAT3	B
is	O
a	O
transcription	B
factor	I
whose	O
activity	O
is	O
modulated	O
by	O
H2O2	O
in	O
human	O
lymphocytes	O
,	O
in	O
which	O
endogenous	O
catalase	B
had	O
previously	O
been	O
inhibited	O
.	O
H2O2-induced	O
nuclear	O
translocation	O
of	O
STAT3	B
to	O
form	O
sequence	B
-	I
specific	I
DNA	I
-	I
bound	I
complexes	I
was	O
evidenced	O
by	O
immunoblotting	O
of	O
nuclear	O
fractions	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
and	O
vanadate	O
was	O
found	O
to	O
strongly	O
synergize	O
with	O
H2O2	O
.	O
Moreover	O
,	O
anti-	O
STAT3	B
antibodies	I
specifically	O
precipitated	O
a	O
protein	O
of	O
92	B
kDa	I
that	O
becomes	O
phosphorylated	O
on	O
tyrosine	O
upon	O
lymphocyte	O
treatment	O
with	O
H2O2	O
.	O
Phenylarsine	O
oxide	O
,	O
a	O
tyrosine	O
phosphatase	O
inhibitor	O
,	O
and	O
genistein	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
cooperated	O
and	O
cancelled	O
,	O
respectively	O
,	O
the	O
H2O2-promoted	O
STAT3	B
nuclear	O
translocation	O
.	O
Evidence	O
is	O
also	O
presented	O
,	O
using	O
Fe2+	O
/	O
Cu2	O
+	O
ions	O
,	O
that	O
.	O
OH	O
generated	O
from	O
H2O2	O
through	O
Fenton	O
reactions	O
could	O
be	O
a	O
candidate	O
oxygen	O
reactive	O
species	O
to	O
directly	O
activate	O
STAT3	B
.	O
Present	O
data	O
suggest	O
that	O
H2O2	O
and	O
vanadate	O
are	O
likely	O
to	O
inhibit	O
the	O
activity	O
of	O
intracellular	B
tyrosine	I
phosphatase	I
(	O
s	O
)	O
,	O
leading	O
to	O
enhanced	O
STAT3	B
tyrosine	O
phosphorylation	O
and	O
hence	O
its	O
translocation	O
to	O
the	O
nucleus	O
.	O
These	O
results	O
demonstrate	O
that	O
the	O
DNA	O
binding	O
activity	O
of	O
STAT3	B
can	O
be	O
modulated	O
by	O
oxidizing	O
agents	O
and	O
provide	O
a	O
framework	O
to	O
understand	O
the	O
effects	O
of	O
oxidative	O
stress	O
on	O
the	O
JAK	B
-STAT	B
signaling	O
pathway	O
.	O
Human	O
alveolar	O
macrophages	O
are	O
markedly	O
deficient	O
in	O
REF-1	B
and	O
AP-1	B
DNA	O
binding	O
activity	O
.	O
Although	O
many	O
functions	O
of	O
human	O
alveolar	O
macrophages	O
are	O
altered	O
compared	O
with	O
their	O
precursor	O
cell	O
,	O
the	O
blood	O
monocyte	O
(	O
monocyte	O
)	O
,	O
the	O
reason	O
(	O
s	O
)	O
for	O
these	O
functional	O
changes	O
have	O
not	O
been	O
determined	O
.	O
We	O
recently	O
reported	O
that	O
human	O
alveolar	O
macrophages	O
do	O
not	O
express	O
AP-1	B
DNA	O
binding	O
activity	O
(	O
Monick	O
,	O
M.	O
M.	O
,	O
Carter	O
,	O
A.	O
B.	O
,	O
Gudmundsson	O
,	O
G.	O
,	O
Geist	O
,	O
L.	O
J.	O
,	O
and	O
Hunninghake	O
,	O
G.	O
W.	O
(	O
1998	O
)	O
Am	O
.	O
J.	O
Physiol	O
.	O
275	O
,	O
L389-L397	O
)	O
.	O
To	O
determine	O
why	O
alveolar	O
macrophages	O
do	O
not	O
express	O
AP-1	B
DNA	O
binding	O
activity	O
,	O
we	O
first	O
showed	O
that	O
there	O
was	O
not	O
a	O
decrease	O
in	O
expression	O
of	O
the	O
FOS	B
and	I
JUN	I
proteins	I
that	O
make	O
up	O
the	O
AP-1	B
complex	O
.	O
There	O
was	O
,	O
however	O
,	O
a	O
significant	O
difference	O
in	O
the	O
amounts	O
of	O
the	O
nuclear	B
protein	I
,	O
REF-1	B
(	O
which	O
regulates	O
AP-1	B
DNA	O
binding	O
by	O
altering	O
the	O
redox	O
status	O
of	O
FOS	B
and	O
JUN	B
proteins	I
)	O
,	O
in	O
alveolar	O
macrophages	O
compared	O
with	O
monocytes	O
.	O
In	O
addition	O
,	O
in	O
vitro	O
differentiation	O
of	O
monocytes	O
to	O
a	O
macrophage	O
-	O
like	O
cell	O
resulted	O
in	O
decreased	O
amounts	O
of	O
REF-1	B
.	O
Finally	O
,	O
addition	O
of	O
REF-1	B
from	O
activated	O
monocytes	O
to	O
alveolar	O
macrophage	O
nuclear	O
proteins	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
AP-1	B
DNA	O
binding	O
.	O
These	O
studies	O
strongly	O
suggest	O
that	O
the	O
process	O
of	O
differentiation	O
of	O
monocytes	O
into	O
alveolar	O
macrophages	O
is	O
associated	O
with	O
a	O
loss	O
of	O
REF-1	B
and	O
AP-1	B
activity	O
.	O
This	O
observation	O
may	O
explain	O
,	O
in	O
part	O
,	O
some	O
of	O
the	O
functional	O
differences	O
observed	O
for	O
alveolar	O
macrophages	O
compared	O
with	O
monocytes	O
.	O
Binding	O
characteristics	O
of	O
the	O
glucocorticoid	B
receptor	I
in	O
peripheral	O
blood	O
lymphocytes	O
in	O
multiple	O
sclerosis	O
.	O
Although	O
the	O
exact	O
etiology	O
of	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
remains	O
unresolved	O
,	O
immune	O
reactions	O
are	O
believed	O
to	O
be	O
the	O
central	O
pathogenic	O
mechanisms	O
.	O
Endogenous	O
and	O
therapeutic	O
steroid	O
hormones	O
affect	O
the	O
immune	O
system	O
,	O
and	O
inflammatory	O
diseases	O
are	O
associated	O
with	O
activation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
,	O
providing	O
evidence	O
of	O
an	O
immune	O
-	O
endocrine	O
interplay	O
.	O
Function	O
tests	O
in	O
MS	O
have	O
revealed	O
dysregulation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
system	O
in	O
a	O
substantial	O
proportion	O
of	O
patients	O
.	O
We	O
characterized	O
glucocorticoid	B
receptor	I
(	O
GR	B
)	O
binding	O
in	O
peripheral	O
blood	O
lymphocytes	O
from	O
39	O
MS	O
patients	O
and	O
14	O
age-	O
and	O
sex	O
-	O
matched	O
controls	O
with	O
respect	O
to	O
dissociation	O
constant	O
and	O
binding	O
capacity	O
,	O
using	O
a	O
whole	O
-	O
cell	O
binding	O
assay	O
with	O
[	O
3H	O
]	O
dexamethasone	O
as	O
the	O
ligand	O
.	O
GR	B
binding	O
parameters	O
did	O
not	O
differ	O
significantly	O
between	O
patients	O
(	O
Kd	O
8.98	O
+	O
/-	O
1.07	O
nM	O
,	O
Bmax	O
183	O
+	O
/-	O
29.8	O
fmol	O
/	O
mg	O
)	O
and	O
controls	O
(	O
Kd	O
9.36	O
+	O
/-	O
1.17	O
nM	O
,	O
Bmax	O
158	O
+	O
/-	O
16	O
fmol	O
/	O
mg	O
)	O
.	O
No	O
effect	O
of	O
age	O
,	O
sex	O
,	O
course	O
,	O
duration	O
or	O
severity	O
of	O
disease	O
,	O
or	O
prior	O
steroid	O
treatments	O
was	O
detected	O
.	O
GR	B
binding	O
parameters	O
were	O
analyzed	O
in	O
relation	O
to	O
the	O
results	O
of	O
the	O
combined	O
dexamethasone	O
-CRH	B
test	O
,	O
which	O
reflects	O
corticosteroid	O
receptor	O
function	O
at	O
the	O
hypothalamus	O
,	O
in	O
30	O
patients	O
and	O
9	O
controls	O
.	O
While	O
controls	O
showed	O
a	O
moderate	O
correlation	O
between	O
binding	O
affinity	O
of	O
the	O
GR	B
in	O
lymphocytes	O
and	O
regulatory	O
function	O
at	O
the	O
hypothalamic	O
level	O
,	O
the	O
patients	O
did	O
not	O
.	O
These	O
data	O
suggest	O
that	O
the	O
physiological	O
relationship	O
between	O
binding	O
and	O
function	O
of	O
the	O
glucocorticoid	B
receptor	I
is	O
disturbed	O
in	O
MS	O
.	O
Association	O
of	O
the	O
interleukin-4	B
receptor	I
alpha	I
chain	I
with	O
p47phox	O
,	O
an	O
activator	O
of	O
the	O
phagocyte	B
NADPH	I
oxidase	I
in	O
B	O
cells	O
.	O
Interleukin	B
(	I
IL	I
)	I
-4	I
plays	O
an	O
important	O
role	O
in	O
IgE	B
synthesis	O
in	O
B	O
cells	O
and	O
in	O
Th2	O
differentiation	O
in	O
T	O
cells	O
.	O
IL-4	B
conducts	O
its	O
biological	O
activities	O
through	O
binding	O
to	O
the	O
IL-4	B
receptor	I
(	O
IL-4R	B
)	O
on	O
the	O
surface	O
of	O
target	O
cells	O
.	O
IL-4R	B
are	O
thought	O
to	O
be	O
composed	O
of	O
the	O
IL-4R	B
alpha	I
chain	I
(	O
IL-4R	B
alpha	I
)	O
and	O
either	O
the	O
IL-2R	B
gamma	I
chain	I
or	O
the	O
IL-13R	B
alpha	I
chain	I
.	O
We	O
have	O
previously	O
shown	O
that	O
the	O
membrane	B
-	I
proximal	I
portion	I
in	O
the	O
cytoplasmic	B
domain	I
of	O
the	O
human	B
IL-4R	I
alpha	I
(	O
hIL-4R	B
alpha	I
)	O
is	O
critical	O
for	O
proliferation	O
,	O
generation	O
of	O
germline	O
epsilon	O
transcript	O
,	O
and	O
activation	O
of	O
STAT6	B
,	O
based	O
on	O
analyses	O
of	O
truncated	B
hIL-4R	I
alphas	I
.	O
In	O
this	O
study	O
,	O
we	O
found	O
that	O
p47phox	O
,	O
an	O
activator	O
of	O
the	O
phagocyte	B
NADPH	I
oxidase	I
,	O
binds	O
to	O
this	O
portion	O
by	O
the	O
two	O
-	O
hybrid	O
system	O
.	O
Furthermore	O
,	O
we	O
observed	O
the	O
association	O
of	O
p47phox	O
with	O
the	O
hIL-4R	B
alpha	I
in	O
B	O
cells	O
derived	O
from	O
a	O
normal	O
donor	O
.	O
These	O
results	O
suggest	O
that	O
p47phox	O
is	O
involved	O
in	O
the	O
signal	O
transduction	O
of	O
IL-4	B
in	O
B	O
cells	O
.	O
However	O
,	O
activation	O
of	O
STAT6	B
,	O
CD23	B
expression	O
,	O
and	O
IgE	B
synthesis	O
induced	O
by	O
IL-4	B
were	O
not	O
affected	O
in	O
p47phox	O
-	O
deficient	O
patients	O
,	O
which	O
raises	O
the	O
possibility	O
that	O
p47phox	O
may	O
be	O
important	O
in	O
other	O
signaling	O
activities	O
as	O
well	O
in	O
B	O
cells	O
.	O
Monocyte	O
adhesion	O
and	O
spreading	O
on	O
human	O
endothelial	O
cells	O
is	O
dependent	O
on	O
Rho	B
-regulated	O
receptor	O
clustering	O
.	O
The	O
GTPase	B
Rho	B
is	O
known	O
to	O
mediate	O
the	O
assembly	O
of	O
integrin	O
-	O
containing	O
focal	O
adhesions	O
and	O
actin	O
stress	O
fibers	O
.	O
Here	O
,	O
we	O
investigate	O
the	O
role	O
of	O
Rho	B
in	O
regulating	O
the	O
distribution	O
of	O
the	O
monocyte	B
-	I
binding	I
receptors	I
E	B
-	I
selectin	I
,	O
ICAM-1	B
,	O
and	O
VCAM-1	B
in	O
human	O
endothelial	O
cells	O
.	O
Inhibition	O
of	O
Rho	B
activity	O
with	O
C3	B
transferase	I
or	O
N19RhoA	B
,	O
a	O
dominant	O
negative	O
RhoA	B
mutant	I
,	O
reduced	O
the	O
adhesion	O
of	O
monocytes	O
to	O
activated	O
endothelial	O
cells	O
and	O
inhibited	O
their	O
spreading	O
.	O
Similar	O
effects	O
were	O
observed	O
after	O
pretreatment	O
of	O
endothelial	O
cells	O
with	O
cytochalasin	O
D	O
.	O
In	O
contrast	O
,	O
dominant	B
negative	I
Rac	I
and	I
Cdc42	I
proteins	I
did	O
not	O
affect	O
monocyte	O
adhesion	O
or	O
spreading	O
.	O
C3	O
transferase	O
and	O
cytochalasin	O
D	O
did	O
not	O
alter	O
the	O
expression	O
levels	O
of	O
monocyte	B
-	I
binding	I
receptors	I
on	O
endothelial	O
cells	O
,	O
but	O
did	O
inhibit	O
clustering	O
of	O
E	B
-	I
selectin	I
,	O
ICAM-1	B
,	O
and	O
VCAM-1	B
on	O
the	O
cell	O
surface	O
induced	O
by	O
monocyte	O
adhesion	O
or	O
cross	B
-	I
linking	I
antibodies	I
.	O
Similarly	O
,	O
N19RhoA	B
inhibited	O
receptor	O
clustering	O
.	O
Monocyte	O
adhesion	O
and	O
receptor	O
cross	O
-	O
linking	O
induced	O
stress	O
fiber	O
assembly	O
,	O
and	O
inhibitors	O
of	O
myosin	B
light	I
chain	I
kinase	I
prevented	O
this	O
response	O
but	O
did	O
not	O
affect	O
receptor	O
clustering	O
.	O
Finally	O
,	O
receptor	O
clusters	O
colocalized	O
with	O
ezrin	B
/	I
moesin	I
/	I
radixin	I
proteins	I
.	O
These	O
results	O
suggest	O
that	O
Rho	B
is	O
required	O
in	O
endothelial	O
cells	O
for	O
the	O
assembly	O
of	O
stable	O
adhesions	O
with	O
monocytes	O
via	O
the	O
clustering	O
of	O
monocyte	B
-	I
binding	I
receptors	I
and	O
their	O
association	O
with	O
the	O
actin	O
cytoskeleton	O
,	O
independent	O
of	O
stress	O
fiber	O
formation	O
.	O
Aiolos	B
transcription	B
factor	I
controls	O
cell	O
death	O
in	O
T	O
cells	O
by	O
regulating	O
Bcl-2	B
expression	O
and	O
its	O
cellular	O
localization	O
.	O
We	O
searched	O
for	O
proteins	O
that	O
interact	O
with	O
Ras	B
in	O
interleukin	O
(	O
IL	O
)	O
-2-stimulated	O
or	O
IL-2-deprived	O
cells	O
,	O
and	O
found	O
that	O
the	O
transcription	B
factor	I
Aiolos	B
interacts	O
with	O
Ras	B
.	O
The	O
Ras	B
-Aiolos	B
interaction	O
was	O
confirmed	O
in	O
vitro	O
and	O
in	O
vivo	O
by	O
co	O
-	O
immunoprecipitation	O
.	O
Indirect	O
immunofluorescence	O
shows	O
that	O
IL-2	B
controls	O
the	O
cellular	O
distribution	O
of	O
Aiolos	B
and	O
induces	O
its	O
tyrosine	O
phosphorylation	O
,	O
required	O
for	O
dissociation	O
from	O
Ras	B
.	O
We	O
also	O
identified	O
functional	O
Aiolos	O
-	O
binding	O
sites	O
in	O
the	O
Bcl-2	O
promoter	O
,	O
which	O
are	O
able	O
to	O
activate	O
the	O
luciferase	O
reporter	O
gene	O
.	O
Mutation	O
of	O
Aiolos	O
-	O
binding	O
sites	O
within	O
the	O
Bcl-2	O
promoter	O
inhibits	O
transactivation	O
of	O
the	O
reporter	O
gene	O
luciferase	O
,	O
suggesting	O
direct	O
control	O
of	O
Bcl-2	B
expression	O
by	O
Aiolos	B
.	O
Co	O
-	O
transfection	O
experiments	O
confirm	O
that	O
Aiolos	B
induces	O
Bcl-2	B
expression	O
and	O
prevents	O
apoptosis	O
in	O
IL-2-deprived	O
cells	O
.	O
We	O
propose	O
a	O
model	O
for	O
the	O
regulation	O
of	O
Bcl-2	B
expression	O
via	O
Aiolos	B
.	O
C	B
/	I
EBP	I
beta	I
in	O
rheumatoid	O
arthritis	O
:	O
correlation	O
with	O
inflammation	O
,	O
not	O
disease	O
specificity	O
.	O
Rheumatoid	O
arthritis	O
synovial	O
tissue	O
was	O
examined	O
and	O
compared	O
with	O
osteoarthritis	O
tissue	O
for	O
the	O
presence	O
of	O
the	O
nuclear	B
transcription	I
factor	I
C	I
/	I
EBP	I
beta	I
(	I
NF	I
-	I
IL-6	I
)	I
.	O
The	O
region	O
(	O
lining	O
or	O
sublining	O
)	O
,	O
cell	O
type	O
,	O
and	O
subcellular	O
distribution	O
(	O
cytoplasmic	O
or	O
nuclear	O
)	O
of	O
the	O
expression	O
of	O
C	B
/	I
EBP	I
beta	I
was	O
characterized	O
.	O
Rheumatoid	O
arthritis	O
synovial	O
fluid	O
and	O
blood	O
and	O
normal	O
peripheral	O
blood	O
were	O
also	O
examined	O
.	O
C	B
/	I
EBP	I
beta	I
was	O
detected	O
in	O
the	O
synovial	O
lining	O
and	O
in	O
sublining	O
cells	O
of	O
synovial	O
tissue	O
from	O
patients	O
with	O
both	O
rheumatoid	O
and	O
osteoarthritis	O
.	O
A	O
significant	O
(	O
P	O
<	O
0.001	O
and	O
<	O
0.05	O
,	O
respectively	O
)	O
increase	O
in	O
the	O
percentage	O
of	O
cells	O
with	O
nuclear	O
staining	O
was	O
seen	O
in	O
the	O
lining	O
layer	O
,	O
compared	O
to	O
cells	O
in	O
the	O
sublining	O
region	O
,	O
in	O
rheumatoid	O
and	O
osteoarthritis	O
.	O
In	O
both	O
diseases	O
a	O
strong	O
correlation	O
(	O
r	O
=	O
0.79	O
,	O
P	O
<	O
0.001	O
)	O
was	O
observed	O
between	O
the	O
percentage	O
of	O
cells	O
in	O
the	O
synovial	O
lining	O
that	O
were	O
positive	O
for	O
nuclear	B
C	I
/	I
EBP	I
beta	I
and	O
lining	O
cell	O
depth	O
.	O
Two	O
-	O
color	O
immunohistochemistry	O
demonstrated	O
that	O
both	O
macrophages	O
and	O
fibroblast	O
-	O
like	O
synoviocytes	O
were	O
positive	O
for	O
nuclear	O
C	B
/	I
EBP	I
beta	I
.	O
The	O
presence	O
of	O
C	B
/	I
EBP	I
beta	I
was	O
confirmed	O
by	O
immunohistochemistry	O
and	O
Western	O
blot	O
analysis	O
with	O
isolated	O
synovial	O
fibroblasts	O
.	O
Nuclear	O
C	B
/	I
EBP	I
beta	I
was	O
also	O
detected	O
in	O
rheumatoid	O
synovial	O
fluid	O
monocytes	O
/	O
macrophages	O
,	O
but	O
not	O
in	O
lymphocytes	O
or	O
neutrophils	O
.	O
Western	O
blot	O
analysis	O
confirmed	O
the	O
presence	O
of	O
C	B
/	I
EBP	I
beta	I
in	O
these	O
cells	O
.	O
The	O
intensity	O
of	O
C	B
/	I
EBP	I
beta	I
staining	O
was	O
greater	O
(	O
P	O
<	O
0.001	O
)	O
in	O
synovial	O
fluid	O
monocytes	O
than	O
in	O
those	O
from	O
normal	O
or	O
rheumatoid	O
peripheral	O
blood	O
.	O
In	O
conclusion	O
,	O
the	O
enhanced	O
nuclear	O
staining	O
for	O
C	B
/	I
EBP	I
beta	I
in	O
the	O
synovial	O
lining	O
,	O
compared	O
to	O
the	O
sublining	O
,	O
suggesting	O
activation	O
in	O
the	O
lining	O
,	O
and	O
the	O
positive	O
correlation	O
of	O
lining	O
layer	O
depth	O
with	O
the	O
percentage	O
of	O
cells	O
in	O
the	O
lining	O
positive	O
for	O
nuclear	O
C	B
/	I
EBP	I
beta	I
,	O
suggest	O
a	O
potential	O
role	O
for	O
C	B
/	I
EBP	I
beta	I
in	O
chronic	O
inflammation	O
.	O
The	O
regulation	O
of	O
the	O
production	O
or	O
activity	O
of	O
C	B
/	I
EBP	I
beta	I
,	O
to	O
inhibit	O
inflammatory	O
mediator	O
expression	O
by	O
synovial	O
macrophages	O
and	O
fibroblasts	O
,	O
offers	O
a	O
novel	O
approach	O
to	O
therapeutic	O
intervention	O
.	O
The	O
role	O
of	O
gamma	O
/	O
delta	O
T	O
cell	O
receptor	O
positive	O
cells	O
in	O
pregnancy	O
.	O
PROBLEM	O
:	O
Due	O
to	O
the	O
lack	O
of	O
classical	B
HLA	I
antigens	I
on	O
the	O
trophoblast	O
,	O
fetal	B
antigens	I
are	O
possibly	O
presented	O
in	O
a	O
non	O
major	B
histocompatibility	I
complex	I
(	O
MHC	B
)	O
restricted	O
way	O
.	O
Decidual	O
gammadelta	O
T	O
cells	O
,	O
which	O
significantly	O
increase	O
in	O
number	O
during	O
pregnancy	O
,	O
might	O
play	O
a	O
role	O
in	O
recognition	O
of	O
fetal	B
antigens	I
and	O
also	O
in	O
determining	O
the	O
quality	O
of	O
the	O
response	O
to	O
these	O
antigens	B
.	O
Our	O
study	O
was	O
aimed	O
at	O
investigating	O
the	O
role	O
of	O
this	O
cell	O
population	O
in	O
progesterone	O
-	O
dependent	O
immunomodulation	O
.	O
METHOD	O
OF	O
STUDY	O
:	O
Peripheral	O
lymphocytes	O
from	O
healthy	O
pregnant	O
women	O
and	O
from	O
habitual	O
aborters	O
were	O
tested	O
by	O
immunocytochemistry	O
for	O
the	O
presence	O
of	O
gamma	O
/	O
delta	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
and	O
progesterone	O
receptor	O
.	O
To	O
investigate	O
the	O
effect	O
of	O
treatment	O
with	O
a	O
pan	O
anti	B
gamma	I
/	I
delta	I
antibody	I
,	O
lymphocytes	O
were	O
incubated	O
for	O
3	O
hr	O
with	O
the	O
antibody	O
,	O
and	O
then	O
interleukin	B
(	I
IL	I
)	I
-10	I
,	O
IL-12	B
and	O
progesterone	B
-	I
induced	I
blocking	I
factor	I
(	O
PIBF	B
)	O
expression	O
(	O
by	O
immuno	O
-	O
cytochemistry	O
)	O
as	O
well	O
as	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
activity	O
were	O
determined	O
.	O
RESULTS	O
:	O
In	O
peripheral	O
blood	O
of	O
healthy	O
pregnant	O
women	O
the	O
percentage	O
of	O
gamma	O
/	O
delta	O
TCR+	O
cells	O
was	O
significantly	O
higher	O
(	O
P	O
<	O
0.001	O
)	O
than	O
in	O
that	O
of	O
recurrent	O
aborters	O
or	O
of	O
non	O
-	O
pregnant	O
individuals	O
.	O
Ninety	O
-	O
seven	O
percent	O
of	O
gamma	O
/	O
delta	O
TCR+	O
pregnancy	O
lymphocytes	O
expressed	O
progesterone	B
receptor	I
.	O
Binding	O
of	O
a	O
specific	O
antibody	O
to	O
the	O
gamma	O
/	O
delta	O
TCR	O
inhibited	O
PIBF	O
-as	O
well	O
as	O
IL-10	O
production	O
,	O
whereas	O
it	O
increased	O
NK	O
activity	O
and	O
IL-12	B
expression	O
.	O
CONCLUSIONS	O
:	O
These	O
data	O
suggest	O
the	O
role	O
of	O
gamma	O
/	O
delta	O
TCR	O
-	O
bearing	O
lymphocytes	O
in	O
progesterone	O
-	O
dependent	O
immunomodulation	O
.	O
SOCS-3	B
is	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
interleukin-2	B
and	O
suppresses	O
STAT5	B
phosphorylation	O
and	O
lymphocyte	O
proliferation	O
.	O
Members	O
of	O
the	O
recently	O
discovered	O
SOCS	B
/	I
CIS	I
/	I
SSI	I
family	I
have	O
been	O
proposed	O
as	O
regulators	O
of	O
cytokine	B
signaling	O
,	O
and	O
while	O
targets	O
and	O
mechanisms	O
have	O
been	O
suggested	O
for	O
some	O
family	O
members	O
,	O
the	O
precise	O
role	O
of	O
these	O
proteins	O
remains	O
to	O
be	O
defined	O
.	O
To	O
date	O
no	O
SOCS	B
proteins	I
have	O
been	O
specifically	O
implicated	O
in	O
interleukin-2	B
(	O
IL-2	B
)	O
signaling	O
in	O
T	O
cells	O
.	O
Here	O
we	O
report	O
SOCS-3	B
expression	O
in	O
response	O
to	O
IL-2	B
in	O
both	O
T	O
-	O
cell	O
lines	O
and	O
human	O
peripheral	O
blood	O
lymphocytes	O
.	O
SOCS-3	B
protein	O
was	O
detectable	O
as	O
early	O
as	O
30	O
min	O
following	O
IL-2	B
stimulation	O
,	O
while	O
CIS	B
was	O
seen	O
only	O
at	O
low	O
levels	O
after	O
2	O
h	O
.	O
Unlike	O
CIS	B
,	O
SOCS-3	B
was	O
rapidly	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
IL-2	B
.	O
Tyrosine	O
phosphorylation	O
of	O
SOCS-3	B
was	O
observed	O
upon	O
coexpression	O
with	O
Jak1	B
and	O
Jak2	B
but	O
only	O
weakly	O
with	O
Jak3	B
.	O
In	O
these	O
experiments	O
,	O
SOCS-3	B
associated	O
with	O
Jak1	B
and	O
inhibited	O
Jak1	B
phosphorylation	O
,	O
and	O
this	O
inhibition	O
was	O
markedly	O
enhanced	O
by	O
the	O
presence	O
of	O
IL-2	B
receptor	I
beta	I
chain	I
(	O
IL-2Rbeta	B
)	O
.	O
Moreover	O
,	O
following	O
IL-2	B
stimulation	O
of	O
T	O
cells	O
,	O
SOCS-3	B
was	O
able	O
to	O
interact	O
with	O
the	O
IL-2	B
receptor	I
complex	I
,	O
and	O
in	O
particular	O
tyrosine	B
phosphorylated	I
Jak1	I
and	O
IL-2Rbeta	B
.	O
Additionally	O
,	O
in	O
lymphocytes	O
expressing	O
SOCS-3	B
but	O
not	O
CIS	B
,	O
IL-2	B
-induced	O
tyrosine	O
phosphorylation	O
of	O
STAT5b	B
was	O
markedly	O
reduced	O
,	O
while	O
there	O
was	O
only	O
a	O
weak	O
effect	O
on	O
IL-3-mediated	B
STAT5b	I
tyrosine	O
phosphorylation	O
.	O
Finally	O
,	O
proliferation	O
induced	O
by	O
both	O
IL-2	B
-and	O
IL-3	B
was	O
significantly	O
inhibited	O
in	O
the	O
presence	O
of	O
SOCS-3	B
.	O
The	O
findings	O
suggest	O
that	O
when	O
SOCS-3	B
is	O
rapidly	O
induced	O
by	O
IL-2	B
in	O
T	O
cells	O
,	O
it	O
acts	O
to	O
inhibit	O
IL-2	B
responses	O
in	O
a	O
classical	O
negative	O
feedback	O
loop	O
.	O
Downregulation	O
of	O
Wilms	O
'	O
tumor	O
gene	O
(	O
WT1	O
)	O
is	O
not	O
a	O
prerequisite	O
for	O
erythroid	O
or	O
megakaryocytic	O
differentiation	O
of	O
the	O
leukemic	O
cell	O
line	O
K562	O
.	O
The	O
Wilms	O
'	O
tumor	O
gene	O
(	O
WT1	O
)	O
encodes	O
a	O
transcription	B
factor	I
of	O
the	O
zinc	B
finger	I
type	I
.	O
A	O
high	O
expression	O
of	O
WT1	O
has	O
been	O
detected	O
in	O
a	O
range	O
of	O
acute	O
leukemias	O
,	O
and	O
WT1	O
is	O
downregulated	O
during	O
induced	O
differentiation	O
of	O
some	O
leukemic	O
cell	O
lines	O
.	O
Overexpression	O
of	O
WT1	O
in	O
some	O
myeloid	O
cell	O
lines	O
confers	O
resistance	O
to	O
differentiation	O
induction	O
.	O
These	O
observations	O
suggest	O
that	O
a	O
high	O
WT1	O
expression	O
in	O
hematopoietic	O
cells	O
is	O
incompatible	O
with	O
differentiation	O
.	O
In	O
this	O
study	O
,	O
each	O
of	O
the	O
four	O
different	O
isoforms	O
of	O
WT1	O
was	O
constitutively	O
overexpressed	O
in	O
the	O
leukemic	O
cell	O
line	O
K562	O
.	O
K562	O
cells	O
express	O
endogenous	O
WT1	O
,	O
which	O
is	O
downregulated	O
as	O
a	O
response	O
to	O
induced	O
differentiation	O
along	O
the	O
erythroid	O
and	O
megakaryocytic	O
pathways	O
.	O
We	O
now	O
demonstrate	O
that	O
a	O
forced	O
exogenous	O
expression	O
of	O
the	O
four	O
different	O
isoforms	O
of	O
WT1	O
in	O
K562	O
does	O
not	O
affect	O
the	O
differentiation	O
response	O
,	O
as	O
judged	O
by	O
accumulation	O
of	O
hemoglobin	B
in	O
response	O
to	O
hemin	B
or	O
the	O
expression	O
of	O
megakaryocytic	B
cell	I
surface	I
markers	I
in	O
response	O
to	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O
We	O
conclude	O
that	O
downregulation	O
of	O
WT1	O
during	O
induced	O
differentiation	O
of	O
K562	O
cells	O
is	O
not	O
a	O
prerequisite	O
for	O
erythroid	O
or	O
megakaryocytic	O
differentiation	O
of	O
these	O
cells	O
.	O
Tyrphostin	O
AG-490	O
inhibits	O
cytokine	O
-	O
mediated	O
JAK3	B
/STAT5a	B
/	I
b	I
signal	O
transduction	O
and	O
cellular	O
proliferation	O
of	O
antigen	O
-	O
activated	O
human	O
T	O
cells	O
.	O
Janus	B
kinase	I
3	I
(	I
JAK3	I
)	I
is	O
a	O
cytoplasmic	B
tyrosine	I
kinase	I
required	O
for	O
T	O
cell	O
development	O
and	O
activated	O
by	O
cytokines	B
that	O
utilize	O
the	O
interleukin-2	B
(	I
IL-2	I
)	I
receptor	I
common	I
gamma	I
chain	I
(	I
gamma	I
(	I
c	I
)	I
)	I
.	O
Genetic	O
inactivation	O
of	O
JAK3	B
is	O
manifested	O
as	O
severe	O
combined	O
immunodeficiency	O
disease	O
(	O
SCID	O
)	O
in	O
humans	O
and	O
mice	O
.	O
These	O
findings	O
have	O
suggested	O
that	O
JAK3	B
represents	O
a	O
pharmacological	O
target	O
to	O
control	O
certain	O
lymphoid	O
-	O
derived	O
diseases	O
.	O
Here	O
we	O
provide	O
novel	O
evidence	O
that	O
AG-490	O
potently	O
inhibits	O
the	O
autokinase	O
activity	O
of	O
JAK3	B
and	O
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
of	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
5a	I
and	I
5b	I
(	I
STAT5a	I
/	I
b	I
)	I
.	O
Similar	O
inhibitory	O
effects	O
were	O
observed	O
with	O
other	O
cytokines	B
that	O
use	O
gamma	B
(	I
c	I
)	I
.	O
AG-490	O
also	O
inhibited	O
IL-2	B
-mediated	O
proliferative	O
growth	O
in	O
human	O
T	O
cells	O
with	O
an	O
IC50	O
)	O
=	O
25	O
microM	O
that	O
was	O
partially	O
recoverable	O
.	O
Moreover	O
,	O
we	O
demonstrate	O
that	O
this	O
inhibitor	O
prevented	O
tetanus	O
toxoid	O
antigen	O
-	O
specific	O
T	O
cell	O
proliferation	O
and	O
expansion	O
but	O
failed	O
to	O
block	O
activation	O
of	O
Zap70	B
or	O
p56Lck	B
after	O
anti	B
-	I
CD3	I
stimulation	O
of	O
human	O
T	O
cells	O
.	O
Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
AG-490	O
inhibits	O
the	O
JAK3	B
-mediated	O
Type	O
II	O
signaling	O
pathway	O
but	O
not	O
the	O
T	O
cell	O
receptor	O
-	O
derived	O
Type	O
I	O
pathway	O
and	O
possesses	O
therapeutic	O
potential	O
for	O
T	O
cell	O
-derived	O
pathologies	O
such	O
as	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
,	O
allergy	O
,	O
and	O
autoimmune	O
disorders	O
.	O
GATA-1	B
and	O
erythropoietin	B
cooperate	O
to	O
promote	O
erythroid	O
cell	O
survival	O
by	O
regulating	O
bcl	B
-	I
xL	I
expression	O
.	O
The	O
transcription	B
factor	I
GATA-1	B
is	O
essential	O
for	O
normal	O
erythropoiesis	O
.	O
By	O
examining	O
in	O
vitro	O
-	O
differentiated	O
embryonic	O
stem	O
cells	O
,	O
we	O
showed	O
previously	O
that	O
in	O
the	O
absence	O
of	O
GATA-1	B
,	O
committed	O
erythroid	O
precursors	O
fail	O
to	O
complete	O
maturation	O
and	O
instead	O
undergo	O
apoptosis	O
.	O
The	O
mechanisms	O
by	O
which	O
GATA-1	B
controls	O
cell	O
survival	O
are	O
unknown	O
.	O
Here	O
we	O
report	O
that	O
in	O
erythroid	O
cells	O
,	O
GATA-1	B
strongly	O
induces	O
the	O
expression	O
of	O
the	O
anti	B
-	I
apoptotic	I
protein	I
bcl	B
-	I
xL	I
,	O
but	O
not	O
the	O
related	O
proteins	O
bcl-2	B
and	O
mcl-1	B
.	O
Consistent	O
with	O
a	O
role	O
for	O
bcl	B
-	I
xL	I
in	O
mediating	O
GATA-1	B
-induced	O
erythroid	O
cell	O
survival	O
,	O
in	O
vitro	O
-	O
differentiated	O
bcl	O
-	O
xL-	O
/	O
-	O
embryonic	O
stem	O
cells	O
fail	O
to	O
generate	O
viable	O
mature	O
definitive	O
erythroid	O
cells	O
,	O
a	O
phenotype	O
resembling	O
that	O
of	O
GATA-1	O
gene	O
disruption	O
.	O
In	O
addition	O
,	O
we	O
show	O
that	O
erythropoietin	B
,	O
which	O
is	O
also	O
required	O
for	O
erythroid	O
cell	O
survival	O
,	O
cooperates	O
with	O
GATA-1	B
to	O
stimulate	O
bcl	B
-	I
xL	I
gene	O
expression	O
and	O
to	O
maintain	O
erythroid	O
cell	O
viability	O
during	O
terminal	O
maturation	O
.	O
Together	O
,	O
our	O
data	O
show	O
that	O
bcl	B
-	I
xL	I
is	O
essential	O
for	O
normal	O
erythroid	O
development	O
and	O
suggest	O
a	O
regulatory	O
hierarchy	O
in	O
which	O
bcl	B
-	I
xL	I
is	O
a	O
critical	O
downstream	O
effector	O
of	O
GATA-1	B
and	O
erythropoietin	B
-mediated	O
signals	O
.	O
STAT1	B
activation	O
during	O
monocyte	O
to	O
macrophage	O
maturation	O
:	O
role	O
of	O
adhesion	B
molecules	I
.	O
Human	O
monocytes	O
isolated	O
from	O
peripheral	O
blood	O
of	O
healthy	O
donors	O
show	O
a	O
time	O
-	O
dependent	O
differentiation	O
into	O
macrophages	O
upon	O
in	O
vitro	O
cultivation	O
,	O
closely	O
mimicking	O
their	O
in	O
vivo	O
migration	O
and	O
maturation	O
into	O
extravascular	O
tissues	O
.	O
The	O
mediator	O
(	O
s	O
)	O
of	O
this	O
maturation	O
process	O
has	O
not	O
been	O
yet	O
defined	O
.	O
We	O
investigated	O
the	O
involvement	O
of	O
signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	I
STAT	I
)	I
factors	I
in	O
this	O
phenomenon	O
and	O
reported	O
the	O
specific	O
,	O
time	O
-	O
dependent	O
,	O
activation	O
of	O
STAT1	B
protein	O
starting	O
at	O
day	O
0	O
/	O
1	O
of	O
cultivation	O
and	O
maximally	O
expressed	O
at	O
day	O
5	O
.	O
STAT1	B
activity	O
was	O
evident	O
on	O
the	O
STAT	O
binding	O
sequences	O
(	O
SBE	O
)	O
present	O
in	O
the	O
promoters	O
of	O
genes	O
which	O
are	O
up	O
-	O
regulated	O
during	O
monocyte	O
to	O
macrophage	O
maturation	O
such	O
as	O
FcgammaRI	O
and	O
ICAM-1	O
,	O
and	O
in	O
the	O
promoter	O
of	O
the	O
transcription	O
factor	O
IFN	O
regulatory	O
factor-1	O
.	O
Moreover	O
,	O
the	O
effect	O
of	O
cell	O
adhesion	O
to	O
fibronectin	O
or	O
laminin	O
was	O
studied	O
to	O
investigate	O
mechanisms	O
involved	O
in	O
STAT1	B
activation	O
.	O
Compared	O
with	O
monocytes	O
adherent	O
on	O
plastic	O
surfaces	O
,	O
freshly	O
isolated	O
cells	O
allowed	O
to	O
adhere	O
either	O
to	O
fibronectin-	O
or	O
laminin	O
-	O
coated	O
flasks	O
exhibited	O
an	O
increased	O
STAT1	B
binding	O
activity	O
both	O
in	O
control	O
and	O
in	O
IFN	O
-	O
gamma	O
-	O
treated	O
cells	O
.	O
The	O
molecular	O
events	O
leading	O
to	O
enhanced	O
STAT1	B
activation	O
and	O
cytokine	B
responsiveness	O
concerned	O
both	O
Y701	B
and	O
S727	B
STAT1	I
phosphorylation	O
.	O
Exogenous	O
addition	O
of	O
transforming	B
growth	I
factor	I
-	I
beta	I
,	O
which	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
some	O
monocytic	B
differentiation	I
markers	I
,	O
inhibited	O
macrophage	O
maturation	O
,	O
integrin	O
expression	O
and	O
STAT1	B
binding	O
activity	O
.	O
Taken	O
together	O
these	O
results	O
indicate	O
that	O
STAT1	B
plays	O
a	O
pivotal	O
role	O
in	O
the	O
differentiation	O
/	O
maturation	O
process	O
of	O
monocytes	O
as	O
an	O
early	O
transcription	B
factor	I
initially	O
activated	O
by	O
adherence	O
and	O
then	O
able	O
to	O
modulate	O
the	O
expression	O
of	O
functional	O
genes	O
,	O
such	O
as	O
ICAM-1	B
and	O
FcgammaRI	B
.	O
3-deazaadenosine	O
,	O
a	O
S	B
-	I
adenosylhomocysteine	I
hydrolase	I
inhibitor	O
,	O
has	O
dual	O
effects	O
on	O
NF	B
-	I
kappaB	I
regulation	O
.	O
Inhibition	O
of	O
NF	B
-	I
kappaB	I
transcriptional	O
activity	O
and	O
promotion	O
of	O
IkappaBalpha	B
degradation	O
.	O
Previously	O
we	O
reported	O
that	O
3-deazaadenosine	O
(	O
DZA	O
)	O
,	O
a	O
potent	O
inhibitor	O
and	O
substrate	O
for	O
S	B
-	I
adenosylhomocysteine	I
hydrolase	I
inhibits	O
bacterial	O
lipopolysaccharide	O
-	O
induced	O
transcription	O
of	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
and	O
interleukin-1beta	B
in	O
mouse	O
macrophage	O
RAW	O
264.7	O
cells	O
.	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
the	O
effects	O
of	O
DZA	O
on	O
nuclear	B
factor	I
-	I
kappaB	I
(	O
NF	B
-	I
kappaB	I
)	O
regulation	O
.	O
DZA	O
inhibits	O
the	O
transcriptional	O
activity	O
of	O
NF	B
-	I
kappaB	I
through	O
the	O
hindrance	O
of	O
p65	B
(	O
Rel	B
-	I
A	I
)	O
phosphorylation	O
without	O
reduction	O
of	O
its	O
nuclear	O
translocation	O
and	O
DNA	O
binding	O
activity	O
.	O
The	O
inhibitory	O
effect	O
of	O
DZA	O
on	O
NF	B
-	I
kappaB	I
transcriptional	O
activity	O
is	O
potentiated	O
by	O
the	O
addition	O
of	O
homocysteine	O
.	O
Taken	O
together	O
,	O
DZA	O
promotes	O
the	O
proteolytic	O
degradation	O
of	O
IkappaBalpha	B
,	O
but	O
not	O
IkappaBbeta	B
,	O
resulting	O
in	O
an	O
increase	O
of	O
DNA	O
binding	O
activity	O
of	O
NF	B
-	I
kappaB	I
in	O
the	O
nucleus	O
in	O
the	O
absence	O
of	O
its	O
transcriptional	O
activity	O
in	O
RAW	O
264.7	O
cells	O
.	O
The	O
reduction	O
of	O
IkappaBalpha	B
by	O
DZA	O
is	O
neither	O
involved	O
in	O
IkappaB	B
kinase	I
complex	I
activation	O
nor	O
modulated	O
by	O
the	O
addition	O
of	O
homocysteine	O
.	O
This	O
study	O
strongly	O
suggests	O
that	O
DZA	O
may	O
be	O
a	O
potent	O
drug	O
for	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
NF	B
-	I
kappaB	I
plays	O
a	O
central	O
pathogenic	O
role	O
,	O
as	O
well	O
as	O
a	O
useful	O
tool	O
for	O
studying	O
the	O
regulation	O
and	O
physiological	O
functions	O
of	O
NF	B
-	I
kappaB	I
.	O
Altered	O
memory	O
T	O
cell	O
differentiation	O
in	O
patients	O
with	O
early	O
rheumatoid	O
arthritis	O
.	O
The	O
chronic	O
immune	O
response	O
in	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
might	O
be	O
driven	O
by	O
activated	O
Th1	O
cells	O
without	O
sufficient	O
Th2	O
cell	O
differentiation	O
to	O
down	O
-	O
modulate	O
inflammation	O
.	O
To	O
test	O
whether	O
disordered	O
memory	O
T	O
cell	O
differentiation	O
contributes	O
to	O
the	O
typical	O
Th1-dominated	O
chronic	O
inflammation	O
in	O
RA	O
we	O
investigated	O
differentiation	O
of	O
resting	O
CD4	O
+	O
memory	O
T	O
cells	O
in	O
patients	O
with	O
early	O
(	O
6	O
wk	O
to	O
12	O
mo	O
)	O
untreated	O
RA	O
and	O
in	O
age-	O
and	O
sex	O
-	O
matched	O
healthy	O
controls	O
in	O
vitro	O
.	O
No	O
difference	O
in	O
cytokine	B
secretion	O
profiles	O
of	O
freshly	O
isolated	O
memory	O
T	O
cells	O
was	O
detected	O
between	O
patients	O
and	O
controls	O
.	O
A	O
cell	O
culture	O
system	O
was	O
then	O
employed	O
that	O
permitted	O
the	O
differentiation	O
of	O
Th	B
effectors	I
from	O
resting	O
memory	O
T	O
cells	O
by	O
short	O
term	O
priming	O
.	O
Marked	O
differences	O
were	O
found	O
in	O
response	O
to	O
priming	O
.	O
Th2	O
cells	O
could	O
be	O
induced	O
in	O
all	O
healthy	O
controls	O
by	O
priming	O
with	O
anti	B
-	I
CD28	I
in	O
the	O
absence	O
of	O
TCR	B
ligation	O
.	O
By	O
contrast	O
,	O
priming	O
under	O
those	O
conditions	O
resulted	O
in	O
Th2	O
differentiation	O
in	O
only	O
9	O
of	O
24	O
RA	O
patients	O
.	O
Exogenous	O
IL-4	B
could	O
overcome	O
the	O
apparent	O
Th2	O
differentiation	O
defect	O
in	O
seven	O
patients	O
but	O
was	O
without	O
effect	O
in	O
the	O
remaining	O
eight	O
patients	O
.	O
In	O
all	O
patients	O
a	O
marked	O
decrease	O
in	O
IL-2-producing	O
cells	O
and	O
a	O
significant	O
increase	O
in	O
well	O
-	O
differentiated	O
Th1	O
cells	O
that	O
produced	O
IFN	B
-	I
gamma	I
but	O
not	O
IL-2	B
were	O
evident	O
after	O
priming	O
with	O
anti	B
-	I
CD3	I
and	O
anti	B
-	I
CD28	I
.	O
The	O
data	O
suggest	O
that	O
CD4	O
+	O
memory	O
T	O
cells	O
from	O
patients	O
with	O
early	O
untreated	O
RA	O
manifest	O
an	O
intrinsic	O
abnormality	O
in	O
their	O
ability	O
to	O
differentiate	O
into	O
specific	O
cytokine	O
-	O
producing	O
effector	O
cells	O
that	O
might	O
contribute	O
to	O
the	O
characteristic	O
Th1-dominated	O
chronic	O
(	O
auto	O
)	O
immune	O
inflammation	O
in	O
RA	O
.	O
Ovarian	O
and	O
breast	O
cytotoxic	O
T	O
lymphocytes	O
can	O
recognize	O
peptides	O
from	O
the	O
amino	O
enhancer	O
of	O
split	O
protein	O
of	O
the	O
Notch	B
complex	I
.	O
In	O
this	O
study	O
we	O
investigated	O
recognition	O
by	O
ovarian	O
tumor	O
associated	O
lymphocyte	O
(	O
OVTAL	O
)	O
,	O
and	O
breast	O
tumor	O
associated	O
lymphocytes	O
(	O
BRTAL	O
)	O
,	O
of	O
peptides	O
corresponding	O
to	O
the	O
sequence	O
125	B
-	I
135	I
of	I
the	I
Aminoenhancer	I
of	I
split	I
(	I
AES	I
)	I
protein	I
.	O
Three	O
of	O
these	O
peptides	O
designated	O
as	O
G75	O
:	O
AES1	O
/	O
2	O
(	O
128	B
-	I
135	I
)	O
,	O
G60	O
:	O
AES1	O
/	O
2	O
(	O
127	B
-	I
137	I
)	O
and	O
G61	O
:	O
AES1	O
/	O
2	O
(	O
125	B
-	I
133	I
)	O
correspond	O
to	O
the	O
wildtype	O
AES	O
sequence	O
,	O
while	O
the	O
fourth	O
G76	O
:	O
GPLTPLPV	O
,	O
AES1	B
/	I
2	I
(	I
128	I
-	I
135	I
)	I
corresponds	O
to	O
a	O
variant	O
sequence	O
of	O
the	O
peptide	O
G75	O
with	O
the	O
N	O
-	O
terminal	O
Leu	O
substituted	O
to	O
glycine	O
.	O
These	O
sequences	O
were	O
chosen	O
for	O
study	O
because	O
mass	O
-	O
spectrometric	O
analysis	O
(	O
MS	O
)	O
of	O
a	O
CTL	O
active	O
HPLC	O
peptide	O
fraction	O
eluted	O
from	O
immunoaffinity	B
precipitated	I
HLA	I
-	I
A2	I
molecule	I
,	O
revealed	O
:	O
(	O
a	O
)	O
the	O
presence	O
of	O
an	O
ion	O
with	O
a	O
mass	O
-	O
to	O
-	O
charge	O
ratio	O
(	O
m	O
/	O
z	O
)	O
of	O
793	O
which	O
was	O
more	O
abundant	O
than	O
other	O
ions	O
of	O
similar	O
masses	O
;	O
(	O
b	O
)	O
the	O
tentatively	O
reconstituted	O
sequence	O
of	O
the	O
ion	O
793	O
matched	O
the	O
sequence	O
of	O
peptide	O
G76	O
.	O
We	O
found	O
that	O
AES	O
peptides	O
G75	O
(	O
128	B
-	I
135	I
)	O
and	O
G76	O
(	O
128	B
-	I
135	I
)	O
(	O
L128	O
G	O
)	O
reconstituted	O
CTL	O
recognition	O
at	O
concentrations	O
ranging	O
between	O
200	O
-	O
500	O
nM	O
.	O
These	O
concentrations	O
are	O
lower	O
than	O
concentrations	O
reported	O
to	O
activate	O
effector	O
function	O
of	O
CTL	O
recognizing	O
other	O
epithelial	B
tumor	I
Ag	I
.	O
Furthermore	O
,	O
analysis	O
with	O
cloned	O
CD8	O
+	O
T	O
cells	O
indicated	O
that	O
G75	O
and	O
G76	O
were	O
not	O
cross	O
-	O
reactive	O
specificities	O
,	O
suggesting	O
a	O
key	O
role	O
for	O
the	O
N	B
-	I
terminal	I
residues	I
of	O
the	O
variant	O
peptide	O
in	O
dictating	O
specificities	O
.	O
Since	O
the	O
AES	B
proteins	I
are	O
part	O
of	O
a	O
set	O
of	O
transcriptional	O
repressors	O
encoded	O
by	O
the	O
Enhancer	O
of	O
split	O
[	O
E	O
(	O
spl	O
)	O
]	O
genes	O
,	O
and	O
since	O
these	O
repressors	O
are	O
activated	O
to	O
suppress	O
cell	O
differentiation	O
in	O
response	O
to	O
Notch	B
receptors	I
signalling	O
,	O
the	O
AES	O
peptides	O
may	O
represent	O
a	O
novel	O
class	O
of	O
self	B
-	I
antigens	I
that	O
deserve	O
further	O
consideration	O
as	O
tumor	B
Ag	I
in	O
epithelial	O
cancers	O
.	O
Activation	O
of	O
the	O
Janus	B
kinase	I
3	I
-STAT5a	B
pathway	O
after	O
CD40	B
triggering	O
of	O
human	O
monocytes	O
but	O
not	O
of	O
resting	O
B	O
cells	O
.	O
CD40	B
/CD40	B
ligand	O
interactions	O
play	O
a	O
key	O
role	O
in	O
the	O
immune	O
responses	O
of	O
B	O
lymphocytes	O
,	O
monocytes	O
,	O
and	O
dendritic	O
cells	O
.	O
The	O
signal	O
transduction	O
events	O
triggered	O
by	O
cross	O
-	O
linking	O
of	O
the	O
CD40	B
receptor	I
have	O
been	O
widely	O
studied	O
in	O
B	O
cell	O
lines	O
,	O
but	O
little	O
is	O
known	O
about	O
signaling	O
following	O
CD40	B
stimulation	O
of	O
monocytes	O
and	O
resting	O
tonsillar	O
B	O
cells	O
.	O
Therefore	O
,	O
we	O
studied	O
the	O
CD40	B
pathway	O
in	O
highly	O
purified	O
human	O
monocytes	O
and	O
resting	O
B	O
cells	O
.	O
After	O
CD40	B
triggering	O
,	O
a	O
similar	O
activation	O
of	O
the	O
NF	B
-	I
kappaB	I
(	O
but	O
not	O
of	O
the	O
AP-1	B
)	O
transcription	B
factor	I
complex	I
occurred	O
in	O
both	O
cell	O
preparations	O
.	O
However	O
,	O
the	O
components	O
of	O
the	O
NF	B
-	I
kappaB	I
complexes	I
were	O
different	O
in	O
monocytes	O
and	O
B	O
cells	O
,	O
because	O
p50	B
is	O
part	O
of	O
the	O
NF	B
-	I
kappaB	I
complex	I
induced	O
by	O
CD40	B
triggering	O
in	O
both	O
monocytes	O
and	O
B	O
cells	O
,	O
whereas	O
p65	B
was	O
only	O
induced	O
in	O
B	O
cells	O
.	O
In	O
contrast	O
,	O
although	O
the	O
Janus	B
kinase	I
3	I
tyrosine	I
kinase	I
was	O
associated	O
with	O
CD40	B
molecules	O
in	O
both	O
monocytes	O
and	O
resting	O
B	O
cells	O
,	O
Janus	B
kinase	I
3	I
phosphorylation	O
induction	O
was	O
observed	O
only	O
in	O
CD40-activated	O
monocytes	O
,	O
with	O
subsequent	O
induction	O
of	O
STAT5a	B
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O
These	O
results	O
suggest	O
that	O
the	O
activation	O
signals	O
in	O
human	O
B	O
cells	O
and	O
monocytes	O
differ	O
following	O
CD40	B
stimulation	O
.	O
This	O
observation	O
is	O
consistent	O
with	O
the	O
detection	O
of	O
normal	O
CD40	B
-induced	O
monocyte	O
activation	O
in	O
patients	O
with	O
CD40	B
ligand+	O
hyper	O
IgM	B
syndrome	O
in	O
whom	O
a	O
defect	O
in	O
CD40	B
-induced	O
B	O
cell	O
activation	O
has	O
been	O
reported	O
.	O
Suppression	O
of	O
NF	B
-	I
kappaB	I
activation	O
in	O
normal	O
T	O
cells	O
by	O
supernatant	O
fluid	O
from	O
human	O
renal	O
cell	O
carcinomas	O
.	O
T	O
lymphocytes	O
from	O
patients	O
with	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
show	O
reduced	O
immune	O
function	O
and	O
impaired	O
activation	O
of	O
the	O
transcription	B
factor	I
,	O
NF	B
-	I
kappaB	I
.	O
We	O
determined	O
the	O
mechanism	O
of	O
NF	B
-	I
kappaB	I
suppression	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
and	O
determined	O
whether	O
supernatant	O
fluid	O
from	O
RCC	O
explants	O
(	O
RCC	O
-	O
S	O
)	O
induced	O
the	O
same	O
phenotype	O
of	O
NF	B
-	I
kappaB	I
suppression	O
in	O
normal	O
T	O
cells	O
that	O
is	O
observed	O
in	O
patient	O
T	O
cells	O
.	O
The	O
pattern	O
of	O
kappaB	B
-binding	O
activity	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
was	O
altered	O
as	O
compared	O
to	O
that	O
seen	O
in	O
T	O
cells	O
obtained	O
from	O
normal	O
volunteers	O
.	O
In	O
some	O
patients	O
,	O
no	O
activation	O
of	O
RelA	B
/	I
NFkappaB1	I
-binding	O
activity	O
was	O
detectable	O
,	O
while	O
in	O
others	O
kappaB	B
-binding	O
activity	O
was	O
modestly	O
induced	O
but	O
the	O
duration	O
was	O
reduced	O
.	O
IkappaBalpha	B
was	O
degraded	O
normally	O
following	O
stimulation	O
in	O
both	O
normal	O
controls	O
and	O
T	O
cells	O
from	O
RCC	O
patients	O
.	O
RCC	O
-	O
S	O
did	O
not	O
alter	O
the	O
cytoplasmic	O
levels	O
of	O
RelA	B
and	O
NF	B
-	I
kappaB1	I
but	O
did	O
suppress	O
their	O
nuclear	O
localization	O
and	O
inhibited	O
the	O
activation	O
of	O
RelA	B
/	I
NF	I
-	I
kappaB1	I
binding	I
complexes	I
.	O
These	O
results	O
show	O
that	O
RCC	O
-	O
S	O
can	O
induce	O
in	O
normal	O
T	O
cells	O
the	O
same	O
phenotype	O
of	O
impaired	O
NF	B
-	I
kappaB	I
activation	O
that	O
is	O
detected	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
.	O
It	O
also	O
appears	O
that	O
NF	B
-	I
kappaB	I
suppression	O
by	O
RCC	O
-	O
S	O
may	O
contribute	O
to	O
the	O
immunosuppression	O
of	O
host	O
immunity	O
.	O
ICSAT	B
overexpression	O
is	O
not	O
sufficient	O
to	O
cause	O
adult	O
T	O
-	O
cell	O
leukemia	O
or	O
multiple	O
myeloma	O
.	O
ICSAT	B
(	O
Interferon	B
Consensus	I
Sequence	I
binding	I
protein	I
for	I
Activated	I
T	I
cells	I
)	O
is	O
a	O
lymphocyte	O
-	O
specific	O
member	O
of	O
the	O
interferon	B
regulatory	I
factor	I
(	I
IRF	I
)	I
family	I
of	O
transcription	O
factors	O
,	O
originally	O
identified	O
through	O
Southwestern	O
screening	O
of	O
the	O
ATL	O
(	O
Adult	O
T	O
-	O
cell	O
leukemia	O
)	O
-16	O
T	O
expression	O
library	O
.	O
In	O
this	O
study	O
,	O
we	O
created	O
transgenic	O
mice	O
overexpressing	O
ICSAT	B
in	O
lymphocytes	O
.	O
Although	O
spontaneous	O
tumorigenesis	O
was	O
not	O
observed	O
,	O
IL-2	B
production	O
with	O
Concanavalin	O
A	O
stimulation	O
was	O
significantly	O
increased	O
in	O
transgenic	O
mice	O
overexpressing	O
ICSAT	B
.	O
ICSAT	B
overexpression	O
in	O
lymphocytes	O
seems	O
insufficient	O
for	O
the	O
leukemogenesis	O
of	O
ATL	O
or	O
multiple	O
myeloma	O
(	O
MM	O
)	O
,	O
however	O
,	O
it	O
may	O
regulate	O
T	O
cell	O
activation	O
and	O
its	O
overexpression	O
may	O
lead	O
to	O
leukemogenesis	O
via	O
controlling	O
IL-2	B
production	O
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
ETS	B
transcription	I
factors	I
regulate	O
an	O
enhancer	O
activity	O
in	O
the	O
third	O
intron	O
of	O
TNF	B
-	I
alpha	I
.	O
We	O
describe	O
an	O
enhancer	O
site	O
in	O
the	O
third	O
intron	O
of	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
.	O
A	O
reporter	O
construct	O
containing	O
the	O
5'-flanking	O
region	O
of	O
the	O
mouse	O
TNF	O
-	O
alpha	O
gene	O
displayed	O
weak	O
activity	O
when	O
transfected	O
into	O
RAW264.7	O
macrophage	O
-	O
like	O
cells	O
.	O
The	O
addition	O
of	O
the	O
third	O
intron	O
of	O
TNF	B
-	I
alpha	I
to	O
this	O
construct	O
resulted	O
in	O
an	O
enhancement	O
of	O
CAT	B
protein	I
.	O
This	O
enhancement	O
was	O
eliminated	O
if	O
a	O
conserved	O
20-bp	O
sequence	O
was	O
removed	O
from	O
the	O
intron	O
or	O
if	O
a	O
dominant	B
-	I
negative	I
ets	I
-	I
binding	I
factor	I
was	O
co	O
-	O
transfected	O
with	O
the	O
reporter	O
gene	O
.	O
Mutations	O
of	O
this	O
site	O
that	O
destroyed	O
potential	O
ets	O
transcription	O
factor	O
binding	O
sites	O
had	O
reduced	O
transcriptional	O
activity	O
.	O
The	O
major	O
transcription	O
factor	O
that	O
bound	O
to	O
the	O
oligonucleotide	O
was	O
confirmed	O
to	O
be	O
GABP	B
by	O
supershift	O
and	O
competition	O
analysis	O
.	O
In	O
RAW264.7	O
cells	O
,	O
the	O
binding	O
was	O
constitutive	O
,	O
however	O
,	O
in	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
binding	O
activity	O
was	O
shown	O
to	O
be	O
interferon	B
-	I
gamma	I
inducible	O
.	O
This	O
may	O
imply	O
a	O
role	O
for	O
ets	B
transcription	I
factors	I
in	O
the	O
production	O
of	O
TNF	B
-	I
alpha	I
.	O
The	O
p53	B
paradox	O
in	O
the	O
pathogenesis	O
of	O
tumor	O
progression	O
.	O
Recent	O
evidence	O
suggests	O
that	O
the	O
p53	B
molecule	I
appears	O
in	O
two	O
different	O
forms	O
:	O
the	O
mutant	B
p53	I
that	O
stimulates	O
tumor	O
progression	O
,	O
and	O
wild	B
type	I
p53	I
that	O
inhibits	O
tumor	O
progression	O
.	O
In	O
addition	O
,	O
it	O
has	O
been	O
established	O
that	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
can	O
activate	O
the	O
expression	O
of	O
wild	B
type	I
p53	I
in	O
concert	O
with	O
the	O
nuclear	B
transcription	I
factor	I
,	O
NF	B
-	I
kappa	I
B	I
.	O
Both	O
TNF	B
-	I
alpha	I
and	O
NF	B
-	I
kappa	I
B	I
are	O
also	O
involved	O
in	O
the	O
stimulation	O
of	O
the	O
pathway	O
that	O
leads	O
to	O
the	O
expression	O
of	O
major	B
histocompatibility	I
complex	I
(	I
MHC	I
)	I
class	I
I	I
molecules	I
and	O
,	O
hence	O
,	O
antigen	O
presentation	O
to	O
the	O
T	O
cells	O
.	O
In	O
this	O
paper	O
we	O
shall	O
advance	O
the	O
hypothesis	O
that	O
:	O
(	O
i	O
)	O
TNF	B
-	I
alpha	I
indirectly	O
controls	O
immune	O
surveillance	O
;	O
and	O
(	O
ii	O
)	O
TNF	B
-	I
alpha	I
controls	O
DNA	O
repair	O
and	O
tumor	O
suppression	O
through	O
the	O
regulation	O
of	O
wild	B
type	I
p53	I
.	O
Thus	O
,	O
it	O
is	O
hypothesized	O
that	O
elevated	O
TNF	B
-	I
alpha	I
is	O
primarily	O
responsible	O
for	O
promoting	O
tumor	O
progression	O
.	O
Abnormal	O
NF	B
-	I
kappa	I
B	I
activity	O
in	O
T	O
lymphocytes	O
from	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
is	O
associated	O
with	O
decreased	O
p65-RelA	B
protein	O
expression	O
.	O
Numerous	O
cellular	O
and	O
biochemical	O
abnormalities	O
in	O
immune	O
regulation	O
have	O
been	O
described	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
including	O
surface	O
Ag	B
receptor	I
-initiated	O
signaling	O
events	O
and	O
lymphokine	B
production	O
.	O
Because	O
NF	B
-	I
kappa	I
B	I
contributes	O
to	O
the	O
transcription	O
of	O
numerous	O
inflammatory	O
genes	O
and	O
has	O
been	O
shown	O
to	O
be	O
a	O
molecular	O
target	O
of	O
antiinflammatory	O
drugs	O
,	O
we	O
sought	O
to	O
characterize	O
the	O
functional	O
role	O
of	O
the	O
NF	B
-	I
kappa	I
B	I
protein	I
complex	I
in	O
lupus	O
T	O
cells	O
.	O
Freshly	O
isolated	O
T	O
cells	O
from	O
lupus	O
patients	O
,	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
,	O
and	O
normal	O
individuals	O
were	O
activated	O
physiologically	O
via	O
the	O
TCR	B
with	O
anti	B
-	I
CD3	I
and	O
anti	B
-	I
CD28	I
Abs	I
to	O
assess	O
proximal	O
membrane	O
signaling	O
,	O
and	O
with	O
PMA	O
and	O
a	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
to	O
bypass	O
membrane	O
-	O
mediated	O
signaling	O
events	O
.	O
We	O
measured	O
the	O
NF	B
-	I
kappa	I
B	I
binding	O
activity	O
in	O
nuclear	O
extracts	O
by	O
gel	O
shift	O
analysis	O
.	O
When	O
compared	O
with	O
normal	O
cells	O
,	O
the	O
activation	O
of	O
NF	B
-	I
kappa	I
B	I
activity	O
in	O
SLE	O
patients	O
was	O
significantly	O
decreased	O
in	O
SLE	O
,	O
but	O
not	O
in	O
RA	O
,	O
patients	O
.	O
NF	B
-	I
kappa	I
B	I
binding	O
activity	O
was	O
absent	O
in	O
several	O
SLE	O
patients	O
who	O
were	O
not	O
receiving	O
any	O
medication	O
,	O
including	O
corticosteroids	O
.	O
Also	O
,	O
NF	B
-	I
kappa	I
B	I
activity	O
remained	O
absent	O
in	O
follow	O
-	O
up	O
studies	O
.	O
In	O
supershift	O
experiments	O
using	O
specific	O
Abs	B
,	O
we	O
showed	O
that	O
,	O
in	O
the	O
group	O
of	O
SLE	O
patients	O
who	O
displayed	O
undetectable	O
NF	B
-	I
kappa	I
B	I
activity	O
,	O
p65	B
complexes	I
were	O
not	O
formed	O
.	O
Finally	O
,	O
immunoblot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
decreased	O
or	O
absent	O
p65	B
protein	I
levels	O
.	O
As	O
p65	B
complexes	I
are	O
transcriptionally	O
active	O
in	O
comparison	O
to	O
the	O
p50	O
homodimer	O
,	O
this	O
novel	O
finding	O
may	O
provide	O
insight	O
on	O
the	O
origin	O
of	O
abnormal	B
cytokine	I
or	O
other	O
gene	O
transcription	O
in	O
SLE	O
patients	O
.	O
Peptide	O
binding	O
affinity	O
and	O
pH	O
variation	O
establish	O
functional	O
thresholds	O
for	O
activation	O
of	O
HLA	O
-	O
DQ	O
-restricted	O
T	O
cell	O
recognition	O
.	O
Peptides	O
derived	O
from	O
the	O
HSV-2	B
VP16	I
protein	I
were	O
utilized	O
for	O
studies	O
of	O
peptide	O
binding	O
to	O
DQ0302	O
molecules	O
and	O
T	O
cell	O
activation	O
at	O
both	O
neutral	O
and	O
acidic	O
pH	O
.	O
The	O
native	O
peptide	O
VP16	O
430	O
-	O
444	O
contains	O
an	O
Asp	O
at	O
position	B
442	I
,	O
binds	O
to	O
DQ0302	O
strongly	O
,	O
with	O
a	O
Kd	O
value	O
of	O
50nM	O
at	O
acidic	O
pH	O
and	O
very	O
weakly	O
,	O
with	O
a	O
Kd	O
value	O
of	O
greater	O
than	O
10	O
microM	O
at	O
neutral	O
pH	O
.	O
A	O
truncated	O
version	O
of	O
430	O
-	O
444	O
,	O
i.e.	O
,	O
VP16	O
433	O
-	O
442	O
,	O
binds	O
with	O
an	O
affinity	O
10-fold	O
lower	O
compared	O
to	O
430	O
-	O
444	O
at	O
acidic	O
pH	O
,	O
and	O
binding	O
at	O
neutral	O
pH	O
was	O
barely	O
detectable	O
.	O
The	O
homologous	O
peptide	O
430	O
-	O
444	O
,	O
442A	O
has	O
an	O
Asp	O
to	O
Ala	O
substitution	O
at	O
position	O
442	O
and	O
binds	O
to	O
DQ0302	O
with	O
a	O
Kd	O
similar	O
to	O
433	O
-	O
442	O
.	O
The	O
short	O
truncated	O
analog	O
433	O
-	O
442A	O
binds	O
very	O
poorly	O
at	O
both	O
acidic	O
and	O
neutral	O
pH	O
.	O
Both	O
the	O
wild	O
type	O
430	O
-	O
444	O
and	O
433	O
-	O
442	O
peptides	O
stimulated	O
a	O
HSV	O
-	O
specific	O
T	O
cell	O
clone	O
after	O
a	O
brief	O
incubation	O
with	O
antigen	O
presenting	O
cells	O
(	O
APC	O
)	O
expressing	O
DQ0302	O
at	O
acidic	O
pH	O
.	O
Much	O
higher	O
concentrations	O
of	O
wild	O
type	O
peptides	O
were	O
needed	O
to	O
activate	O
T	O
cells	O
at	O
neutral	O
pH	O
.	O
In	O
contrast	O
,	O
APC	O
pulsed	O
with	O
Ala	O
-	O
substituted	O
peptides	O
430	O
-	O
444	O
,	O
442A	O
or	O
433	O
-	O
442A	O
at	O
neutral	O
pH	O
failed	O
to	O
stimulate	O
the	O
T	O
cell	O
clone	O
,	O
while	O
APC	O
pulsed	O
at	O
acidic	O
pH	O
and	O
subsequently	O
washed	O
led	O
to	O
successful	O
T	O
cell	O
activation	O
.	O
The	O
Ala	O
-	O
substituted	O
peptide	O
was	O
recognized	O
by	O
the	O
T	O
cell	O
clone	O
at	O
neutral	O
pH	O
only	O
when	O
it	O
was	O
present	O
in	O
the	O
APC	O
culture	O
throughout	O
the	O
stimulation	O
process	O
.	O
While	O
the	O
MHC	B
-	I
peptide	I
complexes	I
formed	O
with	O
the	O
native	O
peptide	O
are	O
stable	O
,	O
complexes	O
formed	O
with	O
the	O
Ala	O
-	O
substituted	O
peptide	O
had	O
a	O
functional	O
t1	O
/	O
2	O
of	O
less	O
than	O
4	O
hr	O
at	O
neutral	O
pH	O
.	O
Stimulation	O
of	O
neutrophil	O
interleukin-8	B
production	O
by	O
eosinophil	B
granule	I
major	I
basic	I
protein	I
.	O
We	O
evaluated	O
the	O
ability	O
of	O
eosinophil	B
granule	I
major	I
basic	I
protein	I
(	O
MBP	B
)	O
to	O
stimulate	O
interleukin	B
(	I
IL	I
)	I
-8	I
production	O
by	O
neutrophils	O
.	O
MBP	B
over	O
the	O
concentration	O
range	O
of	O
0.1	O
to	O
10	O
microM	O
stimulated	O
the	O
release	O
of	O
up	O
to	O
approximately	O
8	O
ng	O
/	O
ml	O
IL-8	B
.	O
Incubation	O
with	O
2	O
microM	O
MBP	B
showed	O
that	O
,	O
after	O
a	O
1	O
h	O
lag	O
,	O
the	O
level	O
of	O
IL-8	B
release	O
increased	O
with	O
time	O
for	O
approximately	O
10	O
h	O
.	O
At	O
the	O
2	O
microM	O
concentration	O
,	O
eosinophil	B
cationic	I
protein	I
,	O
eosinophil	O
-	O
derived	O
neurotoxin	O
,	O
and	O
eosinophil	B
peroxidase	I
did	O
not	O
stimulate	O
significant	O
levels	O
of	O
IL-8	B
production	O
.	O
MBP	B
stimulated	O
2-fold	O
increases	O
in	O
IL-8	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
after	O
1	O
and	O
3	O
h	O
of	O
incubation	O
,	O
which	O
were	O
blocked	O
by	O
pretreatment	O
with	O
actinomycin	O
D	O
.	O
However	O
,	O
stimulation	O
with	O
MBP	B
did	O
not	O
produce	O
an	O
increase	O
in	O
the	O
binding	O
activity	O
of	O
nuclear	B
factor	I
(	I
NF	I
)	I
-kappaB	I
or	O
activator	B
protein-1	I
.	O
No	O
NF	B
-	I
IL-6	I
binding	O
activity	O
was	O
detected	O
in	O
the	O
same	O
nuclear	O
extracts	O
.	O
In	O
addition	O
,	O
stimulation	O
with	O
MBP	B
prolonged	O
the	O
stability	O
of	O
IL-8	O
mRNA	O
.	O
MBP	B
also	O
induced	O
transient	O
increases	O
in	O
mRNA	O
for	O
macrophage	B
inflammatory	I
protein	I
(	I
MIP	I
)	I
-1alpha	I
and	O
MIP-1beta	B
,	O
but	O
did	O
not	O
stimulate	O
the	O
release	O
of	O
either	O
chemokine	B
.	O
These	O
findings	O
indicate	O
that	O
MBP	B
is	O
selective	O
among	O
the	O
eosinophil	B
granule	I
proteins	I
as	O
a	O
stimulus	O
for	O
neutrophil	O
IL-8	B
release	O
and	O
,	O
further	O
,	O
that	O
stimulation	O
of	O
neutrophil	O
IL-8	B
release	O
by	O
MBP	B
involves	O
both	O
transcriptional	O
and	O
posttranscriptional	O
regulation	O
.	O
We	O
postulate	O
that	O
MBP	B
-induced	O
release	O
of	O
IL-8	B
by	O
neutrophils	O
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
acute	O
asthma	O
and	O
other	O
inflammatory	O
lung	O
diseases	O
.	O
Diminished	O
responses	O
to	O
IL-13	B
by	O
human	O
monocytes	O
differentiated	O
in	O
vitro	O
:	O
role	O
of	O
the	O
IL-13Ralpha1	B
chain	I
and	O
STAT6	B
.	O
The	O
primary	O
IL-13	B
receptor	I
complex	I
on	O
human	O
monocytes	O
is	O
believed	O
to	O
be	O
a	O
heterodimer	O
comprised	O
of	O
the	O
IL-4R	B
alpha	I
chain	I
and	O
the	O
IL-2R	B
gamma	I
chain	I
(	B
gamma	I
(	I
c	I
)	I
)	I
-like	I
molecule	I
,	O
IL-13R	B
alpha1	I
.	O
mRNA	O
levels	O
for	O
IL-13R	B
alpha1	I
,	O
but	O
not	O
IL-4R	B
alpha	I
,	O
were	O
markedly	O
decreased	O
in	O
in	O
vitro	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMac	O
)	O
,	O
and	O
with	O
increasing	O
time	O
of	O
monocytes	O
in	O
culture	O
correlated	O
with	O
the	O
loss	O
of	O
IL-13	B
regulation	O
of	O
lipopolysaccharide	O
-	O
induced	O
TNF	B
-	I
alpha	I
production	O
.	O
Analysis	O
of	O
cell	O
lines	O
Daudi	O
and	O
THP-1	O
that	O
differentially	O
express	O
gamma	B
(	I
c	I
)	I
and	O
IL-13R	B
alpha1	I
showed	O
that	O
IL-13	B
can	O
activate	O
STAT6	B
in	O
IL-13R	O
alpha1-positive	O
THP-1	O
cells	O
but	O
not	O
in	O
gamma	O
(	O
c	O
)	O
-positive	O
,	O
IL-13R	O
alpha1-negative	O
Daudi	O
cells	O
.	O
IL-13	B
activation	O
of	O
STAT6	B
was	O
reduced	O
in	O
MDMac	O
which	O
was	O
associated	O
with	O
diminished	O
IL-13	B
-induced	O
expression	O
of	O
CD23	B
and	O
MHC	B
class	I
II	I
.	O
However	O
,	O
with	O
reduced	O
IL-13R	B
alpha1	I
expression	O
and	O
low	O
nuclear	O
STAT6	B
activity	O
,	O
some	O
IL-13	B
-induced	O
responses	O
were	O
unaltered	O
in	O
magnitude	O
in	O
MDMac	O
.	O
In	O
the	O
absence	O
of	O
functional	O
IL-13R	B
alpha1	I
and	O
gamma	B
(	I
c	I
)	I
,	O
IL-13	B
must	O
signal	O
through	O
an	O
alternative	O
receptor	B
complex	I
on	O
MDMac	O
.	O
Experiments	O
with	O
a	O
blocking	O
antibody	O
to	O
IL-4R	B
alpha	I
showed	O
that	O
this	O
chain	O
remains	O
an	O
essential	O
component	O
of	O
the	O
IL-13	B
receptor	I
complex	I
on	O
MDMac	O
.	O
Reactive	O
oxygen	O
intermediate	O
-	O
release	O
of	O
fibre	O
-	O
exposed	O
monocytes	O
increases	O
inflammatory	O
cytokine	O
-	O
mRNA	O
level	O
,	O
protein	B
tyrosine	I
kinase	I
and	O
NF	B
-	I
kappaB	I
activity	O
in	O
co	O
-	O
cultured	O
bronchial	O
epithelial	O
cells	O
(	O
BEAS-2B	O
)	O
.	O
Some	O
pulmonary	O
diseases	O
like	O
bronchitis	O
or	O
asthma	O
bronchiale	O
are	O
mediated	O
by	O
inflammatory	O
mechanisms	O
in	O
bronchial	O
epithelial	O
cells	O
.	O
Alveolar	O
macrophages	O
are	O
located	O
directly	O
in	O
the	O
surrounding	O
of	O
these	O
cells	O
,	O
so	O
that	O
we	O
suppose	O
an	O
interaction	O
between	O
epithelial	O
cells	O
and	O
macrophages	O
regarding	O
to	O
the	O
release	O
of	O
inflammatory	B
mediators	I
.	O
For	O
measuring	O
the	O
contribution	O
of	O
macrophages	O
to	O
the	O
release	O
of	O
inflammatory	B
mediators	I
by	O
bronchial	O
epithelial	O
cells	O
,	O
we	O
established	O
an	O
in	O
vitro	O
model	O
of	O
co	O
-	O
cultured	O
blood	O
monocytes	O
(	O
BM	O
)	O
and	O
BEAS-2B	O
cells	O
in	O
a	O
transwell	O
system	O
(	O
Costar	O
)	O
.	O
BM	O
were	O
exposed	O
to	O
Chrysotile	O
B	O
and	O
soot	O
particle	O
FR	O
101	O
in	O
a	O
concentration	O
of	O
100	O
microg	O
/	O
10	O
(	O
6	O
)	O
cells	O
.	O
After	O
up	O
to	O
90	O
min	O
exposure	O
time	O
ELISA	O
,	O
EMSA	O
(	O
electromobility	O
shift	O
assay	O
)	O
and	O
RT	O
-	O
PCR	O
were	O
used	O
to	O
measure	O
protein	B
tyrosine	I
kinase	I
activity	O
,	O
protein	O
activity	O
of	O
NF	B
-	I
kappaB	I
and	O
cytokine	B
(	O
IL-1beta	B
,	O
IL-6	B
,	O
TNF	B
-	I
alpha	I
)	O
specific	O
mRNA	O
levels	O
in	O
BEAS-2B	O
cells	O
.	O
We	O
observed	O
an	O
increase	O
in	O
protein	B
tyrosine	I
kinase	I
activity	O
(	O
up	O
to	O
1.8	O
+	O
/-	O
0.5-fold	O
)	O
and	O
NF	B
-	I
kappaB	I
protein	O
activity	O
in	O
BEAS-2B	O
cells	O
after	O
particle	O
or	O
fibre	O
exposure	O
of	O
co	O
-	O
cultured	O
BM	O
.	O
Consecutive	O
IL-1beta-	O
,	O
IL-6-	O
and	O
TNF	O
-	O
alpha	O
-	O
mRNA	O
were	O
elevated	O
(	O
up	O
to	O
1.9	O
+	O
/-	O
0.58-fold	O
)	O
.	O
Protein	B
tyrosine	I
kinase	I
activity	O
,	O
NF	B
-	I
kappaB	I
activity	O
,	O
and	O
the	O
synthesis	O
of	O
cytokine	O
-	O
specific	O
mRNA	O
were	O
inhibited	O
by	O
antioxidants	O
.	O
These	O
data	O
suggest	O
a	O
ROI	O
-	O
dependent	O
NF	B
-	I
kappaB	I
mediated	O
transcription	O
of	O
inflammatory	B
cytokines	I
in	O
bronchial	O
epithelial	O
cells	O
.	O
Monoallelic	O
expression	O
of	O
Pax5	B
:	O
a	O
paradigm	O
for	O
the	O
haploinsufficiency	O
of	O
mammalian	O
Pax	O
genes	O
?	O
It	O
is	O
generally	O
assumed	O
that	O
most	O
mammalian	O
genes	O
are	O
transcribed	O
from	O
both	O
alleles	O
.	O
Hence	O
,	O
the	O
diploid	O
state	O
of	O
the	O
genome	O
offers	O
the	O
advantage	O
that	O
a	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
in	O
one	O
allele	O
can	O
be	O
compensated	O
for	O
by	O
the	O
remaining	O
wild	O
-	O
type	O
allele	O
of	O
the	O
same	O
gene	O
.	O
Indeed	O
,	O
the	O
vast	O
majority	O
of	O
human	O
disease	O
syndromes	O
and	O
engineered	O
mutations	O
in	O
the	O
mouse	O
genome	O
are	O
recessive	O
,	O
indicating	O
that	O
recessiveness	O
is	O
the	O
'	O
default	O
'	O
state	O
.	O
However	O
,	O
a	O
minority	O
of	O
genes	O
are	O
semi	O
-	O
dominant	O
,	O
as	O
heterozygous	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
in	O
these	O
genes	O
leads	O
to	O
phenotypic	O
abnormalities	O
.	O
This	O
condition	O
,	O
known	O
as	O
haploinsufficiency	O
,	O
has	O
been	O
described	O
for	O
five	O
of	O
the	O
nine	O
mammalian	O
Pax	O
genes	O
,	O
which	O
are	O
associated	O
with	O
mouse	O
developmental	O
mutants	O
and	O
human	O
disease	O
syndromes	O
.	O
Recently	O
we	O
have	O
reported	O
that	O
the	O
Pax5	O
gene	O
is	O
subject	O
to	O
allele	O
-specific	O
regulation	O
during	O
B	O
cell	O
development	O
.	O
Pax5	B
is	O
predominantly	O
transcribed	O
from	O
only	O
one	O
of	O
its	O
two	O
alleles	O
in	O
early	O
B	O
-	O
lymphoid	O
progenitors	O
and	O
mature	O
B	O
cells	O
,	O
while	O
it	O
transiently	O
switches	O
to	O
a	O
biallelic	O
mode	O
of	O
transcription	O
in	O
pre	O
-	O
B	O
and	O
immature	O
B	O
cells	O
.	O
As	O
a	O
consequence	O
,	O
B	O
-	O
lymphoid	O
tissues	O
are	O
mosaic	O
with	O
regard	O
to	O
the	O
transcribed	O
allele	O
,	O
and	O
heterozygous	O
mutation	O
of	O
Pax5	B
therefore	O
results	O
in	O
deletion	O
of	O
B	O
lymphocytes	O
expressing	O
only	O
the	O
mutant	O
allele	O
.	O
The	O
allele	O
-specific	O
regulation	O
of	O
Pax5	B
raises	O
the	O
intriguing	O
possibility	O
that	O
monoallelic	O
expression	O
may	O
also	O
be	O
the	O
mechanism	O
causing	O
the	O
haploinsufficiency	O
of	O
other	O
Pax	O
genes	O
.	O
In	O
this	O
review	O
,	O
we	O
discuss	O
different	O
models	O
accounting	O
for	O
the	O
haploinsufficiency	O
of	O
mammalian	O
Pax	O
genes	O
,	O
provide	O
further	O
evidence	O
in	O
support	O
of	O
the	O
allele	O
-specific	O
regulation	O
of	O
Pax5	B
and	O
discuss	O
the	O
implication	O
of	O
these	O
findings	O
in	O
the	O
context	O
of	O
the	O
recent	O
literature	O
describing	O
the	O
stochastic	O
and	O
monoallelic	O
activation	O
of	O
other	O
hematopoietic	O
genes	O
.	O
Tissue	O
-	O
specific	O
regulation	O
of	O
the	O
ecto-5'-nucleotidase	O
promoter	O
.	O
Role	O
of	O
the	O
camp	O
response	O
element	O
site	O
in	O
mediating	O
repression	O
by	O
the	O
upstream	O
regulatory	O
region	O
.	O
We	O
have	O
isolated	O
the	O
5	O
'	O
region	O
of	O
the	O
ecto-5'-nucleotidase	O
(	O
low	O
K	O
(	O
m	O
)	O
5'-NT	O
)	O
gene	O
and	O
established	O
that	O
a	O
969-base	O
pair	O
(	O
bp	O
)	O
fragment	O
confers	O
cell	O
-	O
specific	O
expression	O
of	O
a	O
CAT	O
reporter	O
gene	O
that	O
correlates	O
with	O
the	O
expression	O
of	O
endogenous	O
ecto-5'-NT	O
mRNA	O
and	O
enzymatic	O
activity	O
.	O
A	O
768-bp	O
upstream	O
negative	O
regulatory	O
region	O
has	O
been	O
identified	O
that	O
conferred	O
lymphocyte	O
-	O
specific	O
negative	O
regulation	O
in	O
a	O
heterologous	O
system	O
with	O
a	O
244-bp	O
deoxycytidine	O
kinase	O
core	O
promoter	O
.	O
DNase	B
I	I
footprinting	O
identified	O
several	O
protected	O
areas	O
including	O
Sp1	O
,	O
Sp1	O
/	O
AP-2	O
,	O
and	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
binding	O
sites	O
within	O
the	O
201-bp	O
core	O
promoter	O
region	O
and	O
Sp1	O
,	O
NRE-2a	O
,	O
TCF-1	O
/	O
LEF-1	O
,	O
and	O
Sp1	O
/	O
NF	O
-	O
AT	O
binding	O
sites	O
in	O
the	O
upstream	O
regulatory	O
region	O
.	O
Whereas	O
the	O
CRE	O
site	O
was	O
essential	O
in	O
mediating	O
the	O
negative	O
activity	O
of	O
the	O
upstream	O
regulatory	O
region	O
in	O
Jurkat	O
but	O
not	O
in	O
HeLa	O
cells	O
,	O
mutation	O
of	O
the	O
Sp1	O
/	O
AP-2	O
site	O
decreased	O
promoter	O
activity	O
in	O
both	O
cell	O
lines	O
.	O
Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
of	O
proteins	O
binding	O
to	O
the	O
CRE	O
site	O
identified	O
both	O
ATF-1	B
and	O
ATF-2	B
in	O
Jurkat	O
cells	O
.	O
Finally	O
,	O
phorbol	O
12-myristate	O
13-acetate	O
increased	O
the	O
activity	O
of	O
both	O
the	O
core	O
and	O
the	O
969-bp	O
promoter	O
fragments	O
,	O
and	O
this	O
increase	O
was	O
abrogated	O
by	O
mutations	O
at	O
the	O
CRE	O
site	O
.	O
In	O
summary	O
,	O
we	O
have	O
identified	O
a	O
tissue	O
-	O
specific	O
regulatory	O
region	O
5	O
'	O
of	O
the	O
ecto-5'-NT	O
core	O
promoter	O
that	O
requires	O
the	O
presence	O
of	O
a	O
functional	O
CRE	O
site	O
within	O
the	O
basal	O
promoter	O
for	O
its	O
suppressive	O
activity	O
.	O
Cell	O
activation	O
and	O
apoptosis	O
by	O
bacterial	B
lipoproteins	I
through	O
toll	B
-	I
like	I
receptor-2	I
.	O
Apoptosis	O
is	O
implicated	O
in	O
the	O
generation	O
and	O
resolution	O
of	O
inflammation	O
in	O
response	O
to	O
bacterial	O
pathogens	O
.	O
All	O
bacterial	O
pathogens	O
produce	O
lipoproteins	B
(	I
BLPs	I
)	I
,	O
which	O
trigger	O
the	O
innate	O
immune	O
response	O
.	O
BLPs	B
were	O
found	O
to	O
induce	O
apoptosis	O
in	O
THP-1	O
monocytic	O
cells	O
through	O
human	B
Toll	I
-	I
like	I
receptor-2	I
(	I
hTLR2	I
)	I
.	O
BLPs	B
also	O
initiated	O
apoptosis	O
in	O
an	O
epithelial	O
cell	O
line	O
transfected	O
with	O
hTLR2	B
.	O
In	O
addition	O
,	O
BLPs	B
stimulated	O
nuclear	B
factor	I
-	I
kappaB	I
,	O
a	O
transcriptional	B
activator	I
of	O
multiple	O
host	O
defense	O
genes	O
,	O
and	O
activated	O
the	O
respiratory	O
burst	O
through	O
hTLR2	B
.	O
Thus	O
,	O
hTLR2	B
is	O
a	O
molecular	O
link	O
between	O
microbial	O
products	O
,	O
apoptosis	O
,	O
and	O
host	O
defense	O
mechanisms	O
.	O
Selective	O
DNA	O
-	O
binding	O
activity	O
of	O
interleukin-10-stimulated	B
STAT	I
molecules	I
in	O
human	O
monocytes	O
.	O
It	O
has	O
been	O
demonstrated	O
that	O
interferon	B
-	I
gamma	I
(	O
IFN	B
-	I
gamma	I
)	O
and	O
interleukin-10	B
(	O
IL-10	B
)	O
have	O
various	O
reverse	O
effects	O
on	O
macrophages	O
;	O
however	O
,	O
the	O
molecular	O
mechanism	O
of	O
this	O
difference	O
has	O
not	O
been	O
fully	O
understood	O
.	O
In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
binding	O
activity	O
of	O
IL-10-	B
and	I
IFN	I
-	I
gamma	I
-	I
activated	I
STAT	I
molecules	I
to	O
two	O
kinds	O
of	O
GAS	O
-motif	O
sequences	O
.	O
IL-10-activated	B
STAT1	I
could	O
bind	O
to	O
the	O
GAS	O
-	O
motif	O
sequence	O
in	O
the	O
promoter	O
region	O
of	O
the	O
Fcgamma	B
receptor	I
,	O
but	O
not	O
to	O
that	O
in	O
the	O
promoter	O
region	O
of	O
the	O
COX-2	O
gene	O
,	O
whereas	O
IFN	B
-	I
gamma	I
-	I
activated	I
STAT1	I
and	O
STAT5	B
could	O
bind	O
to	O
both	O
sequences	O
.	O
IL-10	B
inhibited	O
IFN	B
-	I
gamma	I
-induced	O
STAT	B
activation	O
without	O
newly	B
synthesized	I
protein	I
.	O
We	O
further	O
demonstrated	O
that	O
aspirin	O
,	O
but	O
not	O
dexamethasone	O
,	O
suppressed	O
IFN	B
-	I
gamma	I
-induced	O
STAT	B
activation	O
.	O
Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
IL-10-activated	B
STAT1	I
has	O
a	O
specificity	O
in	O
binding	O
to	O
the	O
GAS	O
-	O
motif	O
sequences	O
,	O
whereas	O
IFN	B
-	I
gamma	I
-	I
activated	I
STAT1	I
and	O
STAT5	B
have	O
a	O
broader	O
spectrum	O
in	O
binding	O
to	O
the	O
GAS	O
-	O
motif	O
sequences	O
.	O
This	O
may	O
explain	O
the	O
difference	O
between	O
IL-10	B
and	O
IFN	B
-	I
gamma	I
in	O
biological	O
activity	O
,	O
and	O
the	O
inhibitory	O
effect	O
of	O
IL-10	B
on	O
IFN	B
-	I
gamma	I
activities	O
.	O
Block	O
of	O
granulocytic	O
differentiation	O
of	O
32Dcl3	O
cells	O
by	O
AML1	O
/	O
ETO	O
(	O
MTG8	O
)	O
but	O
not	O
by	O
highly	O
expressed	O
Bcl-2	B
.	O
The	O
chimeric	O
gene	O
,	O
AML1	O
/	O
ETO	O
(	O
MTG8	O
)	O
,	O
generated	O
in	O
t	O
(	O
8	O
;	O
21	O
)	O
acute	O
myeloid	O
leukemia	O
enhances	O
the	O
expression	O
of	O
Bcl-2	B
.	O
To	O
evaluate	O
whether	O
this	O
enhancement	O
is	O
the	O
primary	O
role	O
of	O
AML1	O
/	O
ETO	O
in	O
leukemogenesis	O
,	O
effects	O
of	O
over	O
-	O
expression	O
of	O
Bcl-2	B
in	O
the	O
murine	O
myeloid	O
precursor	O
cell	O
line	O
,	O
32Dcl3	O
,	O
were	O
examined	O
.	O
When	O
32Dcl3	O
cells	O
expressing	O
exogenous	O
Bcl-2	B
were	O
induced	O
to	O
differentiate	O
,	O
the	O
onset	O
of	O
morphological	O
differentiation	O
was	O
delayed	O
.	O
However	O
,	O
even	O
the	O
cells	O
expressing	O
very	O
high	O
levels	O
of	O
exogenous	O
Bcl-2	B
eventually	O
underwent	O
differentiation	O
without	O
a	O
significant	O
decrease	O
in	O
the	O
synthesis	O
of	O
Bcl-2	B
.	O
On	O
the	O
contrary	O
,	O
32Dcl3	O
cells	O
stably	O
expressing	O
AML1	O
/	O
ETO	O
were	O
completely	O
resistant	O
to	O
differentiation	O
and	O
continued	O
to	O
grow	O
in	O
the	O
presence	O
of	O
G	B
-	I
CSF	I
.	O
These	O
results	O
are	O
consistent	O
with	O
the	O
interpretation	O
that	O
stimulation	O
of	O
Bcl-2	B
expression	O
is	O
not	O
the	O
primary	O
target	O
of	O
AML1	O
/	O
ETO	O
.	O
NF	O
-	O
kappaB	O
-	O
mediated	O
up	O
-	O
regulation	O
of	O
Bcl	B
-	I
x	I
and	O
Bfl-1	B
/	I
A1	I
is	O
required	O
for	O
CD40	B
survival	O
signaling	O
in	O
B	O
lymphocytes	O
.	O
Activation	O
of	O
CD40	B
is	O
essential	O
for	O
thymus	O
-	O
dependent	O
humoral	O
immune	O
responses	O
and	O
rescuing	O
B	O
cells	O
from	O
apoptosis	O
.	O
Many	O
of	O
the	O
effects	O
of	O
CD40	B
are	O
believed	O
to	O
be	O
achieved	O
through	O
altered	O
gene	O
expression	O
.	O
In	O
addition	O
to	O
Bcl	B
-	I
x	I
,	O
a	O
known	O
CD40-regulated	B
antiapoptotic	I
molecule	I
,	O
we	O
identified	O
a	O
related	O
antiapoptotic	B
molecule	I
,	O
A1	B
/	I
Bfl-1	I
,	O
as	O
a	O
CD40-inducible	O
gene	O
.	O
Inhibition	O
of	O
the	O
NF	B
-	I
kappaB	I
pathway	O
by	O
overexpression	O
of	O
a	O
dominant	O
-	O
active	O
inhibitor	O
of	O
NF	B
-	I
kappaB	I
abolished	O
CD40	B
-induced	O
up	O
-	O
regulation	O
of	O
both	O
the	O
Bfl-1	B
and	O
Bcl	B
-	I
x	I
genes	O
and	O
also	O
eliminated	O
the	O
ability	O
of	O
CD40	B
to	O
rescue	O
Fas	B
-induced	O
cell	O
death	O
.	O
Within	O
the	O
upstream	O
promoter	O
region	O
of	O
Bcl	B
-	I
x	I
,	O
a	O
potential	O
NF	O
-	O
kappaB	O
-	O
binding	O
sequence	O
was	O
found	O
to	O
support	O
NF	B
-	I
kappaB	I
-dependent	O
transcriptional	O
activation	O
.	O
Furthermore	O
,	O
expression	O
of	O
physiological	O
levels	O
of	O
Bcl	O
-	O
x	O
protected	O
B	O
cells	O
from	O
Fas	O
-	O
mediated	O
apoptosis	O
in	O
the	O
absence	O
of	O
NF	B
-	I
kappaB	I
signaling	O
.	O
Thus	O
,	O
our	O
results	O
suggest	O
that	O
CD40	B
-mediated	O
cell	O
survival	O
proceeds	O
through	O
NF	B
-	I
kappaB	I
-dependent	O
up	O
-	O
regulation	O
of	O
Bcl-2	B
family	I
members	I
.	O
The	O
Epstein	O
-	O
Barr	O
virus	O
latency	O
BamHI	O
-	O
Q	O
promoter	O
is	O
positively	O
regulated	O
by	O
STATs	B
and	O
Zta	B
interference	O
with	O
JAK	B
/STAT	B
activation	O
leads	O
to	O
loss	O
of	O
BamHI	O
-	O
Q	O
promoter	O
activity	O
.	O
In	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-associated	O
tumors	O
in	O
nonimmunocompromised	O
patients	O
,	O
EBV	O
gene	O
expression	O
is	O
highly	O
restricted	O
.	O
EBV	B
-	I
encoded	I
nuclear	I
antigen	I
(	I
EBNA	I
)	I
-1	I
is	O
expressed	O
,	O
whereas	O
the	O
immunogenic	O
and	O
proliferative	O
EBNAs	B
are	O
not	O
.	O
This	O
pattern	O
of	O
EBNA	B
expression	O
is	O
generated	O
by	O
usage	O
of	O
the	O
BamHI	O
-	O
Q	O
promoter	O
(	O
Qp	O
)	O
.	O
We	O
have	O
determined	O
that	O
the	O
JAK	B
/STAT	B
pathway	O
positively	O
regulates	O
Qp	O
activity	O
.	O
In	O
transient	O
-	O
transfection	O
assays	O
,	O
a	O
Qp	O
-	O
CAT	O
reporter	O
was	O
activated	O
by	O
cotransfected	O
JAK-1	B
and	O
by	O
treatment	O
of	O
cells	O
with	O
the	O
cytokine	B
IL-6	B
.	O
The	O
ability	O
of	O
Qp	O
to	O
bind	O
signal	B
transducer	I
and	I
activator	I
of	I
transcription	I
(	I
STAT	I
)	I
proteins	I
was	O
directly	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
-	O
shift	O
assay	O
,	O
and	O
mutation	O
of	O
potential	O
STAT	O
-	O
binding	O
sites	O
reduced	O
Qp	O
responsiveness	O
to	O
Janus	B
kinase	I
(	I
JAK	I
)	I
-1	I
.	O
Consistent	O
with	O
a	O
role	O
for	O
STATs	B
in	O
Qp	O
function	O
,	O
Qp	O
using	O
Burkitt	O
's	O
lymphoma	O
Rael	O
cells	O
and	O
cultured	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
cells	O
contained	O
nuclear	O
STAT	B
protein	I
.	O
We	O
investigated	O
whether	O
the	O
inability	O
to	O
maintain	O
EBV	O
-	O
positive	O
NPC	O
cell	O
lines	O
in	O
culture	O
was	O
related	O
to	O
Qp	O
activity	O
.	O
Passaging	O
of	O
the	O
NPC	O
cell	O
line	O
HK666	O
led	O
to	O
activation	O
of	O
expression	O
of	O
BZLF1	O
,	O
which	O
encodes	O
Zta	B
and	O
loss	O
of	O
Qp	O
function	O
.	O
Transient	O
expression	O
assays	O
linked	O
Zta	B
expression	O
to	O
the	O
down	O
-	O
regulation	O
of	O
Qp	O
.	O
Cotransfection	O
of	O
Zta	B
reduced	O
Qp	O
activity	O
in	O
reporter	O
assays	O
.	O
This	O
negative	O
regulation	O
required	O
Zta	B
DNA	O
-	O
binding	O
activity	O
.	O
We	O
provide	O
evidence	O
that	O
Zta	B
up	O
-	O
regulation	O
of	O
p53	B
leads	O
to	O
p53	B
-mediated	O
interference	O
with	O
JAK	B
/STAT	B
activation	O
of	O
Qp	O
.	O
The	O
data	O
imply	O
that	O
JAK	B
/STAT	B
signaling	O
has	O
a	O
role	O
in	O
EBV	O
-	O
associated	O
malignancies	O
.	O
Retinoblastoma	O
protein	O
expression	O
leads	O
to	O
reduced	O
Oct-1	B
DNA	O
binding	O
activity	O
and	O
enhances	O
interleukin-8	B
expression	O
.	O
Tumor	O
cell	O
lines	O
with	O
a	O
defective	O
retinoblastoma	O
gene	O
are	O
unable	O
to	O
transcribe	O
the	O
HLA	O
class	O
II	O
genes	O
in	O
response	O
to	O
IFN	B
-	I
gamma	I
treatment	O
,	O
and	O
reconstitution	O
of	O
functional	O
Rb	B
rescues	O
IFN	O
-	O
gamma	O
-	O
induced	O
class	O
II	O
gene	O
expression	O
.	O
However	O
,	O
the	O
molecular	O
mechanism	O
of	O
Rb	B
rescue	O
of	O
the	O
class	O
II	O
genes	O
is	O
unknown	O
.	O
We	O
have	O
examined	O
the	O
effect	O
of	O
Rb	B
expression	O
on	O
the	O
activation	O
of	O
the	O
promoter	O
for	O
HLA	O
-	O
DRA	O
,	O
the	O
prototype	O
class	O
II	O
gene	O
.	O
Oct-1	B
,	O
a	O
POU	B
domain	I
transcription	I
factor	I
,	O
was	O
identified	O
as	O
a	O
repressor	O
of	O
HLA	O
-	O
DRA	O
promoter	O
activity	O
in	O
the	O
Rb	O
-	O
defective	O
cells	O
.	O
Rb	B
expression	O
led	O
to	O
phosphorylation	O
of	O
Oct-1	B
,	O
thus	O
relieving	O
its	O
repressive	O
effect	O
.	O
Oct-1	B
has	O
also	O
been	O
shown	O
to	O
repress	O
interleukin	B
8	I
promoter	O
activity	O
.	O
Consistent	O
with	O
reduced	O
levels	O
of	O
Oct-1	B
DNA	O
binding	O
activity	O
in	O
the	O
Rb	O
-	O
transformed	O
cell	O
lines	O
,	O
interleukin	B
8	I
expression	O
is	O
higher	O
in	O
these	O
cell	O
lines	O
.	O
Protein	B
kinase	I
C	I
and	O
calcineurin	B
synergize	O
to	O
activate	O
IkappaB	B
kinase	I
and	O
NF	B
-	I
kappaB	I
in	O
T	O
lymphocytes	O
.	O
The	O
nuclear	O
factor	O
of	O
kappaB	O
(	O
NF	B
-	I
kappaB	I
)	O
is	O
a	O
ubiquitous	B
transcription	I
factor	I
that	O
is	O
key	O
in	O
the	O
regulation	O
of	O
the	O
immune	O
response	O
and	O
inflammation	O
.	O
T	B
cell	I
receptor	I
(	O
TCR	B
)	O
cross	O
-	O
linking	O
is	O
in	O
part	O
required	O
for	O
activation	O
of	O
NF	B
-	I
kappaB	I
,	O
which	O
is	O
dependent	O
on	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaBalpha	B
.	O
By	O
using	O
Jurkat	O
and	O
primary	O
human	O
T	O
lymphocytes	O
,	O
we	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
two	O
second	O
messengers	O
of	O
the	O
TCR	B
-initiated	O
signal	O
transduction	O
,	O
protein	B
kinase	I
C	I
(	O
PKC	B
)	O
and	O
calcineurin	B
,	O
results	O
in	O
the	O
synergistic	O
activation	O
of	O
the	O
IkappaBalpha	B
kinase	I
(	I
IKK	I
)	I
complex	I
but	O
not	O
of	O
another	O
putative	B
IkappaBalpha	I
kinase	I
,	O
p90	B
(	I
rsk	I
)	I
.	O
We	O
also	O
demonstrate	O
that	O
the	O
IKK	B
complex	I
,	O
but	O
not	O
p90	B
(	I
rsk	I
)	I
,	O
is	O
responsible	O
for	O
the	O
in	O
vivo	O
phosphorylation	O
of	O
IkappaBalpha	B
mediated	O
by	O
the	O
co	O
-	O
activation	O
of	O
PKC	B
and	O
calcineurin	B
.	O
Each	O
second	O
messenger	O
is	O
necessary	O
,	O
as	O
inhibition	O
of	O
either	O
one	O
reverses	O
the	O
activation	O
of	O
the	O
IKK	B
complex	I
and	O
IkappaBalpha	B
phosphorylation	O
in	O
vivo	O
.	O
Overexpression	O
of	O
dominant	O
negative	O
forms	O
of	O
IKKalpha	B
and	I
-beta	I
demonstrates	O
that	O
only	O
IKKbeta	B
is	O
the	O
target	O
for	O
PKC	B
and	O
calcineurin	B
.	O
These	O
results	O
indicate	O
that	O
within	O
the	O
TCR	B
/CD3	B
signal	O
transduction	O
pathway	O
both	O
PKC	B
and	O
calcineurin	B
are	O
required	O
for	O
the	O
effective	O
activation	O
of	O
the	O
IKK	B
complex	I
and	O
NF	B
-	I
kappaB	I
in	O
T	O
lymphocytes	O
.	O
C	B
/	I
EBPbeta	I
and	O
GATA-1	B
synergistically	O
regulate	O
activity	O
of	O
the	O
eosinophil	O
granule	O
major	O
basic	O
protein	O
promoter	O
:	O
implication	O
for	O
C	B
/	I
EBPbeta	I
activity	O
in	O
eosinophil	O
gene	O
expression	O
.	O
Eosinophil	B
granule	I
major	I
basic	I
protein	I
(	O
MBP	B
)	O
is	O
expressed	O
exclusively	O
in	O
eosinophils	O
and	O
basophils	O
in	O
hematopoietic	O
cells	O
.	O
In	O
our	O
previous	O
study	O
,	O
we	O
demonstrated	O
a	O
major	O
positive	O
regulatory	O
role	O
for	O
GATA-1	B
and	O
a	O
negative	O
regulatory	O
role	O
for	O
GATA-2	B
in	O
MBP	B
gene	O
transcription	O
.	O
Further	O
analysis	O
of	O
the	O
MBP	O
promoter	O
region	O
identified	O
a	O
C	O
/	O
EBP	O
(	O
CCAAT	O
/	O
enhancer	O
-	O
binding	O
protein	O
)	O
consensus	O
binding	O
site	O
6	O
bp	O
upstream	O
of	O
the	O
functional	O
GATA	O
-	O
binding	O
site	O
in	O
the	O
MBP	O
gene	O
.	O
In	O
the	O
cell	O
line	O
HT93A	O
,	O
which	O
is	O
capable	O
of	O
differentiating	O
towards	O
both	O
the	O
eosinophil	O
and	O
neutrophil	O
lineages	O
in	O
response	O
to	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
C	O
/	O
EBPalpha	O
mRNA	O
expression	O
decreased	O
significantly	O
concomitant	O
with	O
eosinophilic	O
and	O
neutrophilic	O
differentiation	O
,	O
whereas	O
C	B
/	I
EBPbeta	I
expression	O
was	O
markedly	O
increased	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
showed	O
that	O
recombinant	O
C	B
/	I
EBPbeta	I
protein	O
could	O
bind	O
to	O
the	O
potential	O
C	O
/	O
EBP	O
-	O
binding	O
site	O
(	O
bp	O
-90	O
to	O
-82	O
)	O
in	O
the	O
MBP	B
promoter	O
.	O
Furthermore	O
,	O
we	O
have	O
demonstrated	O
that	O
both	O
C	B
/	I
EBPbeta	I
and	O
GATA-1	B
can	O
bind	O
simultaneously	O
to	O
the	O
C	O
/	O
EBP-	O
and	O
GATA	O
-	O
binding	O
sites	O
in	O
the	O
MBP	O
promoter	O
.	O
To	O
determine	O
the	O
functionality	O
of	O
both	O
the	O
C	O
/	O
EBP-	O
and	O
GATA-	O
binding	O
sites	O
,	O
we	O
analyzed	O
whether	O
C	B
/	I
EBPbeta	I
and	O
GATA-1	B
can	O
stimulate	O
the	O
MBP	O
promoter	O
in	O
the	O
C	O
/	O
EBPbeta	O
and	O
GATA-1	O
negative	O
Jurkat	O
T	O
-	O
cell	O
line	O
.	O
Cotransfection	O
with	O
C	O
/	O
EBPbeta	O
and	O
GATA-1	O
expression	O
vectors	O
produced	O
a	O
5-fold	O
increase	O
compared	O
with	O
cotransfection	O
with	O
the	O
C	B
/	I
EBPbeta	I
or	O
GATA-1	O
expression	O
vectors	O
individually	O
.	O
In	O
addition	O
,	O
GST	B
pull	O
-	O
down	O
experiments	O
demonstrated	O
a	O
physical	O
interaction	O
between	O
human	O
GATA-1	B
and	O
C	B
/	I
EBPbeta	I
.	O
Expression	O
of	O
FOG	B
(	O
riend	B
ATA	I
)	O
,	O
which	O
binds	O
to	O
GATA-1	B
and	O
acts	O
as	O
a	O
cofactor	O
for	O
GATA	B
-	I
binding	I
proteins	I
,	O
decreased	O
transactivation	O
activity	O
of	O
GATA-1	B
for	O
the	O
MBP	O
promoter	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
Our	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
both	O
GATA-1	B
and	O
C	B
/	I
EBPbeta	I
synergistically	O
transactivate	O
the	O
promoter	O
of	O
an	O
eosinophil	O
-	O
specific	O
granule	O
protein	O
gene	O
and	O
that	O
FOG	B
may	O
act	O
as	O
a	O
negative	O
cofactor	O
for	O
the	O
eosinophil	O
lineage	O
,	O
unlike	O
its	O
positively	O
regulatory	O
function	O
for	O
the	O
erythroid	O
and	O
megakaryocyte	O
lineages	O
.	O
The	O
Legionella	O
pneumophila	O
rpoS	O
gene	O
is	O
required	O
for	O
growth	O
within	O
Acanthamoeba	O
castellanii	O
.	O
To	O
investigate	O
regulatory	O
networks	O
in	O
Legionella	O
pneumophila	O
,	O
the	O
gene	O
encoding	O
the	O
homolog	O
of	O
the	O
Escherichia	B
coli	I
stress	I
and	I
stationary	I
-	I
phase	I
sigma	I
factor	I
RpoS	B
was	O
identified	O
by	O
complementation	O
of	O
an	O
E.	O
coli	O
rpoS	O
mutation	O
.	O
An	O
open	O
reading	O
frame	O
that	O
is	O
approximately	O
60	O
%	O
identical	O
to	O
the	O
E.	O
coli	O
rpoS	O
gene	O
was	O
identified	O
.	O
Western	O
blot	O
analysis	O
showed	O
that	O
the	O
level	O
of	O
L.	O
pneumophila	O
RpoS	B
increased	O
in	O
stationary	O
phase	O
.	O
An	O
insertion	O
mutation	O
was	O
constructed	O
in	O
the	O
rpoS	O
gene	O
on	O
the	O
chromosome	O
of	O
L.	O
pneumophila	O
,	O
and	O
the	O
ability	O
of	O
this	O
mutant	O
strain	O
to	O
survive	O
various	O
stress	O
conditions	O
was	O
assayed	O
and	O
compared	O
with	O
results	O
for	O
the	O
wild	O
-	O
type	O
strain	O
.	O
Both	O
the	O
mutant	O
and	O
wild	O
-	O
type	O
strains	O
were	O
more	O
resistant	O
to	O
stress	O
when	O
in	O
stationary	O
phase	O
than	O
when	O
in	O
the	O
logarithmic	O
phase	O
of	O
growth	O
.	O
This	O
finding	O
indicates	O
that	O
L.	O
pneumophila	O
RpoS	B
is	O
not	O
required	O
for	O
a	O
stationary	O
-	O
phase	O
-	O
dependent	O
resistance	O
to	O
stress	O
.	O
Although	O
the	O
mutant	O
strain	O
was	O
able	O
to	O
kill	O
HL-60-	O
and	O
THP-1-derived	O
macrophages	O
,	O
it	O
could	O
not	O
replicate	O
within	O
a	O
protozoan	O
host	O
,	O
Acanthamoeba	O
castellanii	O
.	O
These	O
data	O
suggest	O
that	O
L.	O
pneumophila	O
possesses	O
a	O
growth	O
phase	O
-	O
dependent	O
resistance	O
to	O
stress	O
that	O
is	O
independent	O
of	O
RpoS	B
control	O
and	O
that	O
RpoS	B
likely	O
regulates	O
genes	O
that	O
enable	O
it	O
to	O
survive	O
in	O
the	O
environment	O
within	O
protozoa	O
.	O
Our	O
data	O
indicate	O
that	O
the	O
role	O
of	O
rpoS	O
in	O
L.	O
pneumophila	O
is	O
very	O
different	O
from	O
what	O
has	O
previously	O
been	O
reported	O
for	O
E.	O
coli	O
rpoS	O
.	O
Suppression	O
of	O
TNFalpha	B
-mediated	O
NFkappaB	B
activity	O
by	O
myricetin	O
and	O
other	O
flavonoids	O
through	O
downregulating	O
the	O
activity	O
of	O
IKK	B
in	O
ECV304	O
cells	O
.	O
Flavonoids	O
are	O
a	O
group	O
of	O
naturally	O
-	O
occurring	O
phenolic	O
compounds	O
in	O
the	O
plant	O
kingdom	O
,	O
and	O
many	O
flavonoids	O
are	O
found	O
with	O
vascular	O
protective	O
properties	O
.	O
Nevertheless	O
how	O
the	O
protective	O
response	O
is	O
exerted	O
by	O
flavonoids	O
is	O
not	O
well	O
characterized	O
.	O
In	O
view	O
of	O
the	O
nuclear	B
factor	I
-	I
kappaB	I
(	O
NFkappaB	B
)	O
may	O
play	O
a	O
central	O
role	O
in	O
the	O
initiation	O
of	O
atherosclerosis	O
,	O
prevention	O
of	O
the	O
activation	O
of	O
NFkappaB	B
represents	O
an	O
important	O
role	O
in	O
protecting	O
vascular	O
injury	O
.	O
In	O
this	O
study	O
,	O
the	O
effects	O
of	O
flavonoids	O
on	O
NFkappaB	B
/inhibitor	O
-	O
kappaB	O
(	O
IkappaB	B
)	O
system	O
in	O
ECV304	O
cells	O
activated	O
with	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNFalpha	B
)	O
were	O
examined	O
.	O
We	O
investigated	O
the	O
inhibitory	O
action	O
of	O
six	O
flavonoids	O
on	O
IkappaB	B
kinase	I
(	O
IKK	B
)	O
activity	O
,	O
an	O
enzyme	O
recently	O
found	O
to	O
phosphorylate	O
critical	O
serine	O
residues	O
of	O
IkappaB	O
for	O
degradation	O
.	O
Of	O
six	O
flavonoids	O
tested	O
,	O
myricetin	O
was	O
found	O
to	O
strongly	O
inhibit	O
IKK	B
kinase	O
activity	O
,	O
and	O
prevent	O
the	O
degradation	O
of	O
IkappaBalpha	B
and	O
IkappaBbeta	B
in	O
activated	O
endothelial	O
cells	O
.	O
Furthermore	O
,	O
myricetin	O
was	O
also	O
found	O
to	O
inhibit	O
NFkappaB	B
activity	O
correlated	O
with	O
suppression	O
of	O
monocyte	O
adhesion	O
to	O
ECV304	O
cells	O
.	O
Therefore	O
we	O
conclude	O
that	O
flavonoids	O
may	O
be	O
of	O
therapeutic	O
value	O
for	O
vascular	O
disease	O
through	O
down	O
regulation	O
of	O
NFkappaB	B
/IkappaB	B
system	O
.	O
Copyright	O
1999	O
Wiley	O
-	O
Liss	O
,	O
Inc	O
.	O
IL-2	B
-independent	O
activation	O
and	O
proliferation	O
in	O
human	O
T	O
cells	O
induced	O
by	O
CD28	B
.	O
Although	O
the	O
role	O
of	O
CD28	B
in	O
T	O
cell	O
costimulation	O
is	O
firmly	O
established	O
,	O
the	O
mechanisms	O
by	O
which	O
it	O
exerts	O
its	O
costimulatory	O
actions	O
are	O
less	O
clear	O
.	O
In	O
many	O
circumstances	O
it	O
is	O
difficult	O
to	O
distinguish	O
the	O
effects	O
of	O
CD28	B
from	O
subsequent	O
actions	O
of	O
cytokines	B
,	O
such	O
as	O
IL-2	B
,	O
on	O
T	O
cell	O
proliferation	O
.	O
Here	O
,	O
we	O
report	O
a	O
model	O
of	O
CD28	B
costimulation	O
using	O
PMA	O
plus	O
the	O
natural	B
ligand	I
CD80	I
that	O
resulted	O
in	O
very	O
limited	O
stimulation	O
of	O
IL-2	B
,	O
as	O
evidenced	O
by	O
both	O
cytokine	B
production	O
and	O
IL-2	O
promoter	O
stimulation	O
.	O
Promoter	O
assays	O
revealed	O
CD28	B
-dependent	O
effects	O
on	O
both	O
NF	B
-	I
kappaB	I
and	O
AP-1	B
,	O
but	O
not	O
on	O
NF	B
-	I
AT	I
or	O
the	O
intact	O
IL-2	O
promoter	O
.	O
In	O
addition	O
,	O
T	O
cell	O
proliferation	O
was	O
completely	O
resistant	O
to	O
the	O
actions	O
of	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O
Moreover	O
T	O
cell	O
proliferation	O
was	O
unaffected	O
by	O
the	O
addition	O
of	O
blocking	O
Abs	B
to	O
both	O
IL-2	B
and	O
the	O
IL-2	B
receptor	I
,	O
demonstrating	O
that	O
this	O
form	O
of	O
costimulation	O
by	O
CD28	B
was	O
independent	O
of	O
IL-2	B
.	O
We	O
also	O
investigated	O
the	O
effects	O
of	O
stimulating	O
T	O
cell	O
blasts	O
with	O
CD80	B
alone	O
and	O
found	O
that	O
there	O
was	O
a	O
limited	O
requirement	O
for	O
IL-2	B
in	O
this	O
system	O
.	O
We	O
conclude	O
that	O
CD28	B
costimulation	O
can	O
cause	O
substantial	O
T	O
cell	O
proliferation	O
in	O
the	O
absence	O
of	O
IL-2	B
,	O
which	O
is	O
driven	O
by	O
a	O
soluble	B
factor	I
independent	O
of	O
NF	B
-	I
AT	I
transactivation	O
.	O
Thymocyte	O
-	O
thymic	O
epithelial	O
cell	O
interaction	O
leads	O
to	O
high	O
-	O
level	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
exclusively	O
in	O
mature	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
+	O
)	O
thymocytes	O
:	O
a	O
critical	O
role	O
for	O
tumor	B
necrosis	I
factor	I
and	O
interleukin-7	B
.	O
This	O
work	O
aims	O
at	O
identifying	O
the	O
thymocyte	O
subpopulation	O
able	O
to	O
support	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
replication	O
under	O
the	O
biological	O
stimuli	O
of	O
the	O
thymic	O
microenvironment	O
.	O
In	O
this	O
report	O
we	O
demonstrate	O
that	O
interaction	O
with	O
thymic	O
epithelial	O
cells	O
(	O
TEC	O
)	O
induces	O
a	O
high	O
-	O
level	O
replication	O
of	O
the	O
T	B
-	I
tropic	I
primary	I
isolate	I
HIV-1	I
(	O
B	B
-	I
LAIp	I
)	O
exclusively	O
in	O
the	O
mature	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
+	O
)	O
thymocytes	O
.	O
Tumor	B
necrosis	I
factor	I
(	O
TNF	B
)	O
and	O
interleukin-7	B
(	O
IL-7	B
)	O
,	O
secreted	O
during	O
this	O
interaction	O
,	O
are	O
critical	O
cytokines	O
for	O
HIV	O
long	O
terminal	O
repeat	O
transactivation	O
through	O
NF	B
-	I
kappaB	I
-dependent	O
activation	O
.	O
TNF	B
is	O
the	O
major	O
inducer	O
of	O
NF	B
-	I
kappaB	I
and	O
particularly	O
of	O
the	O
p50-p65	B
complex	I
,	O
whereas	O
IL-7	B
acts	O
as	O
a	O
cofactor	O
by	O
sustaining	O
the	O
expression	O
of	O
the	O
p75	B
TNF	I
receptor	I
.	O
The	O
requirement	O
for	O
TNF	B
is	O
further	O
confirmed	O
by	O
the	O
observation	O
that	O
the	O
inability	O
of	O
the	O
intermediate	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
-	O
)	O
thymocytes	O
to	O
replicate	O
the	O
virus	O
is	O
associated	O
with	O
a	O
defect	O
in	O
TNF	B
production	O
during	O
their	O
interaction	O
with	O
TEC	O
and	O
correlates	O
with	O
the	O
absence	O
of	O
nuclear	O
NF	B
-	I
kappaB	I
activity	O
in	O
these	O
freshly	O
isolated	O
thymocytes	O
.	O
Addition	O
of	O
exogenous	O
TNF	B
to	O
the	O
intermediate	O
thymocyte	O
cultures	O
induces	O
NF	B
-	I
kappaB	I
activity	O
and	O
is	O
sufficient	O
to	O
promote	O
HIV	O
replication	O
in	O
the	O
cocultures	O
with	O
TEC	O
.	O
The	O
other	O
major	O
subpopulation	O
expressing	O
the	O
CD4	B
receptor	I
,	O
namely	O
,	O
the	O
double	O
-	O
positive	O
(	O
DP	O
)	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
CD3	O
(	O
+	O
/-	O
)	O
thymocytes	O
,	O
despite	O
the	O
entry	O
of	O
the	O
virus	O
,	O
do	O
not	O
produce	O
a	O
significant	O
level	O
of	O
virus	O
,	O
presumably	O
because	O
they	O
are	O
unresponsive	O
to	O
TNF	B
and	O
IL-7	B
.	O
Together	O
,	O
these	O
data	O
suggest	O
that	O
in	O
vivo	O
,	O
despite	O
an	O
efficient	O
entry	O
of	O
the	O
virus	O
in	O
all	O
the	O
CD4	O
(	O
+	O
)	O
subpopulations	O
,	O
a	O
high	O
viral	O
load	O
may	O
be	O
generated	O
exclusively	O
within	O
the	O
mature	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
+	O
)	O
subset	O
of	O
thymocytes	O
.	O
However	O
,	O
under	O
conditions	O
of	O
inflammatory	O
response	O
after	O
infection	O
,	O
TNF	B
might	O
also	O
be	O
present	O
in	O
the	O
intermediate	O
thymocyte	O
compartment	O
,	O
leading	O
to	O
efficient	O
HIV	O
replication	O
in	O
these	O
cells	O
.	O
Tumor	B
necrosis	I
factor	I
alpha	I
decreases	O
,	O
and	O
interleukin-10	B
increases	O
,	O
the	O
sensitivity	O
of	O
human	O
monocytes	O
to	O
dexamethasone	O
:	O
potential	O
regulation	O
of	O
the	O
glucocorticoid	B
receptor	I
.	O
Resistance	O
to	O
glucocorticoid	O
therapy	O
has	O
been	O
observed	O
in	O
patients	O
with	O
autoimmune	O
/	O
inflammatory	O
diseases	O
and	O
may	O
be	O
related	O
to	O
the	O
inflammatory	O
process	O
itself	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
ability	O
of	O
tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNFalpha	B
,	O
a	O
proinflammatory	B
cytokine	I
)	O
and	O
interleukin	B
(	I
IL	I
)	I
-10	I
(	O
an	O
anti	B
-	I
inflammatory	I
cytokine	I
)	O
to	O
differentially	O
regulate	O
the	O
sensitivity	O
of	O
human	O
monocytes	O
/macrophages	O
to	O
glucocorticoids	O
.	O
To	O
accomplish	O
this	O
,	O
we	O
first	O
analyzed	O
the	O
pattern	O
of	O
TNFalpha	B
and	O
IL-10	O
inhibition	O
by	O
dexamethasone	O
in	O
LPS	O
-	O
stimulated	O
whole	O
-	O
blood	O
cell	O
cultures	O
.	O
Second	O
,	O
we	O
studied	O
the	O
modulation	O
of	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
dexamethasone	O
by	O
preincubation	O
with	O
TNFalpha	B
or	O
IL-10	B
and	O
measurement	O
of	O
LPS	O
-	O
stimulated	O
IL-6	B
secretion	O
.	O
In	O
addition	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
dexamethasone	O
on	O
phorbolmyristate	O
-	O
acetate	O
-	O
stimulated	O
IL-1	B
receptor	I
antagonist	O
secretion	O
by	O
the	O
human	O
monocytic	O
cell	O
line	O
U937	O
.	O
Finally	O
,	O
we	O
investigated	O
whether	O
the	O
modulation	O
of	O
corticosensitivity	O
in	O
TNFalpha-	O
and	O
IL-10-pretreated	O
U937	O
cells	O
was	O
related	O
to	O
a	O
change	O
of	O
the	O
glucocorticoid	B
receptor	I
concentration	O
and	O
affinity	O
.	O
Dexamethasone	O
had	O
different	O
effects	O
on	O
LPS	O
-	O
induced	O
TNFalpha	B
and	O
IL-10	B
secretion	O
;	O
whereas	O
it	O
suppressed	O
TNFalpha	B
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
,	O
its	O
effect	O
on	O
IL-10	B
secretion	O
was	O
biphasic	O
,	O
producing	O
stimulation	O
at	O
lower	O
,	O
and	O
inhibition	O
at	O
higher	O
doses	O
.	O
The	O
concentration	O
of	O
LPS	O
employed	O
influenced	O
the	O
effect	O
of	O
dexamethasone	O
on	O
IL-10	B
secretion	O
(	O
P	O
<	O
0.001	O
)	O
.	O
Pretreatment	O
with	O
TNFalpha	B
diminished	O
,	O
and	O
with	O
IL-10	B
improved	O
,	O
the	O
ability	O
of	O
dexamethasone	O
to	O
suppress	O
IL-6	B
secretion	O
in	O
whole	O
-	O
blood	O
cell	O
cultures	O
(	O
P	O
<	O
0.01	O
for	O
both	O
)	O
and	O
to	O
enhance	O
IL-1	B
receptor	O
antagonist	O
secretion	O
by	O
U937	O
cells	O
(	O
P	O
<	O
0.05	O
for	O
both	O
)	O
.	O
TNFalpha	B
decreased	O
(	O
P	O
<	O
0.001	O
)	O
,	O
while	O
IL-10	B
increased	O
(	O
P	O
<	O
0.001	O
)	O
,	O
the	O
concentration	O
of	O
dexamethasone	O
binding	O
sites	O
in	O
these	O
cells	O
,	O
with	O
no	O
discernible	O
effect	O
on	O
their	O
binding	O
affinity	O
.	O
We	O
conclude	O
that	O
glucocorticoids	O
differentially	O
modulate	O
TNFalpha	B
and	O
IL-10	B
secretion	O
by	O
human	O
monocytes	O
in	O
a	O
LPS	O
dose	O
-	O
dependent	O
fashion	O
and	O
that	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
glucocorticoids	O
is	O
altered	O
by	O
TNFalpha	B
or	O
IL-10	B
pretreatment	O
;	O
TNFalpha	B
blocks	O
their	O
effects	O
,	O
whereas	O
IL-10	B
acts	O
synergistically	O
with	O
glucocorticoids	O
.	O
This	O
is	O
accompanied	O
by	O
opposite	O
glucocorticoid	B
receptor	I
changes	O
,	O
respectively	O
opposing	O
and	O
favoring	O
glucocorticoid	O
actions	O
.	O
This	O
study	O
suggests	O
that	O
the	O
pattern	O
of	O
pro-	O
/	O
antiinflammatory	O
cytokine	B
secretion	O
may	O
alter	O
the	O
response	O
of	O
patients	O
to	O
glucocorticoid	O
therapy	O
.	O
Induction	O
of	O
a	O
functional	O
vitamin	B
D	I
receptor	I
in	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
-	O
induced	O
monocytic	O
differentiation	O
of	O
M2-type	O
leukemic	O
blast	O
cells	O
.	O
Different	O
types	O
of	O
acute	O
myeloid	O
leukemia	O
blast	O
cells	O
were	O
induced	O
to	O
differentiate	O
in	O
vitro	O
with	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
vitamin	O
D3	O
(	O
VD	O
)	O
.	O
M0	O
/	O
M1	O
leukemic	O
cells	O
are	O
not	O
sensitive	O
to	O
differentiating	O
agents	O
,	O
whereas	O
M3	O
leukemic	O
cells	O
are	O
induced	O
to	O
undergo	O
granulocytic	O
differentiation	O
after	O
ATRA	O
treatment	O
but	O
are	O
not	O
sensitive	O
to	O
VD	O
.	O
M2	O
leukemic	O
blast	O
cells	O
behave	O
differently	O
because	O
they	O
undergo	O
monocytic	O
differentiation	O
with	O
both	O
the	O
differentiation	O
inducers	O
.	O
To	O
gain	O
some	O
insight	O
into	O
the	O
maturation	O
of	O
M2-type	O
leukemic	O
cells	O
,	O
we	O
studied	O
the	O
molecular	O
mechanisms	O
underlying	O
monocytic	O
differentiation	O
induced	O
by	O
ATRA	O
and	O
VD	O
in	O
spontaneous	O
M2	O
blast	O
cells	O
as	O
well	O
as	O
in	O
Kasumi-1	O
cells	O
(	O
an	O
acute	O
myeloid	O
leukemia	O
M2-type	O
cell	O
line	O
)	O
.	O
Our	O
results	O
indicate	O
that	O
ATRA	O
as	O
well	O
as	O
VD	O
efficiently	O
increases	O
the	O
nuclear	O
abundance	O
of	O
VD	B
receptor	I
(	O
VDR	B
)	O
and	O
promotes	O
monocytic	O
differentiation	O
.	O
VDR	B
is	O
functionally	O
active	O
in	O
ATRA	O
-	O
treated	O
Kasumi-1	O
cells	O
because	O
it	O
efficiently	O
heterodimerizes	O
with	O
retinoid	B
X	I
receptor	I
,	O
binds	O
to	O
a	O
DR3-type	O
vitamin	O
D	O
-	O
responsive	O
element	O
,	O
and	O
activates	O
the	O
transcription	O
of	O
a	O
vitamin	O
D	O
-	O
responsive	O
element	O
-	O
regulated	O
reporter	O
gene	O
.	O
Consistent	O
with	O
these	O
findings	O
,	O
VD	O
-	O
responsive	O
genes	O
are	O
induced	O
by	O
ATRA	O
treatment	O
of	O
Kasumi-1	O
cells	O
,	O
suggesting	O
that	O
the	O
genetic	O
program	O
underlying	O
monocytic	O
differentiation	O
is	O
activated	O
.	O
The	O
molecular	O
mechanism	O
by	O
which	O
ATRA	O
increases	O
the	O
nuclear	O
abundance	O
of	O
a	O
functional	O
VDR	B
is	O
still	O
unknown	O
,	O
but	O
our	O
data	O
clearly	O
indicate	O
that	O
the	O
M2	O
leukemic	O
cell	O
context	O
is	O
only	O
permissive	O
of	O
monocytic	O
differentiation	O
.	O
Dendritic	O
cells	O
and	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
.	O
Rheumatoid	O
arthritis	O
(	O
RA	O
)	O
is	O
a	O
chronic	O
autoimmune	O
inflammatory	O
disease	O
in	O
which	O
unknown	O
arthrogenic	B
autoantigen	I
is	O
presented	O
to	O
CD4	O
+	O
T	O
cells	O
.	O
The	O
strong	O
association	O
of	O
the	O
disease	O
with	O
an	O
epitope	B
within	O
the	O
HLA	B
-	I
DR	I
chain	I
shared	O
between	O
various	O
alleles	O
of	O
HLA	B
-	I
DR4	I
and	O
DR1	B
emphasizes	O
the	O
importance	O
of	O
antigen	O
presentation	O
.	O
This	O
immune	O
response	O
predominantly	O
occurs	O
in	O
the	O
synovial	O
tissue	O
and	O
fluid	O
of	O
the	O
joints	O
and	O
autoreactive	O
T	O
cells	O
are	O
readily	O
demonstrable	O
in	O
both	O
the	O
synovial	O
compartment	O
and	O
blood	O
.	O
Circulating	O
dendritic	O
cells	O
(	O
DC	O
)	O
are	O
phenotypically	O
and	O
functionally	O
identical	O
with	O
normal	O
peripheral	O
blood	O
(	O
PB	O
)	O
DC	O
.	O
In	O
the	O
synovial	O
tissue	O
,	O
fully	O
differentiated	O
perivascular	O
DC	O
are	O
found	O
in	O
close	O
association	O
with	O
T	O
cells	O
and	O
with	O
B	O
cell	O
follicles	O
,	O
sometimes	O
containing	O
follicular	O
DC	O
.	O
These	O
perivascular	O
DC	O
migrate	O
across	O
the	O
activated	O
endothelium	O
from	O
blood	O
and	O
receive	O
differentiative	O
signals	O
within	O
the	O
joint	O
from	O
monocyte	B
-	I
derived	I
cytokines	I
and	O
CD40-ligand+	O
T	O
cells	O
.	O
In	O
the	O
SF	O
,	O
DC	O
manifest	O
an	O
intermediate	O
phenotype	O
,	O
similar	O
to	O
that	O
of	O
monocyte	O
-	O
derived	O
DC	O
in	O
vitro	O
.	O
Like	O
a	O
delayed	O
-	O
type	O
hypersensitivity	O
response	O
,	O
the	O
rheumatoid	O
synovium	O
represents	O
an	O
effector	O
site	O
.	O
DC	O
at	O
many	O
effector	O
sites	O
have	O
a	O
characteristic	O
pattern	O
of	O
infiltration	O
and	O
differentiation	O
.	O
It	O
is	O
important	O
to	O
note	O
that	O
the	O
effector	O
response	O
is	O
not	O
self	O
-	O
limiting	O
in	O
RA	O
autoimmune	O
inflammation	O
.	O
In	O
this	O
article	O
,	O
we	O
argue	O
that	O
the	O
presentation	O
of	O
self	B
-	I
antigen	I
by	O
DC	O
and	O
by	O
autoantibody	O
-	O
producing	O
B	O
cells	O
is	O
critical	O
for	O
the	O
perpetuation	O
of	O
the	O
autoimmune	O
response	O
.	O
Permanently	O
arresting	O
this	O
ongoing	O
immune	O
response	O
with	O
either	O
pharmaceutical	O
agents	O
or	O
immunotherapy	O
is	O
a	O
major	O
challenge	O
for	O
immunology	O
.	O
Transcriptional	O
inhibition	O
by	O
interleukin-6	B
of	O
the	O
class	B
A	I
macrophage	I
scavenger	I
receptor	I
in	O
macrophages	O
derived	O
from	O
human	O
peripheral	O
monocytes	O
and	O
the	O
THP-1	O
monocytic	O
cell	O
line	O
.	O
Expression	O
of	O
the	O
class	B
A	I
macrophage	I
scavenger	I
receptor	I
(	I
MSR	I
)	I
contributes	O
to	O
the	O
uptake	O
of	O
modified	B
low	I
density	I
lipoproteins	I
(	I
LDL	I
)	I
by	O
macrophages	O
and	O
transformation	O
of	O
these	O
cells	O
into	O
lipid	O
-	O
laden	O
foam	O
cells	O
,	O
which	O
characterize	O
atherosclerosis	O
.	O
Many	O
environmental	O
factors	O
,	O
in	O
particular	O
,	O
proinflammatory	B
cytokines	I
and	O
growth	B
factors	I
,	O
can	O
exert	O
regulatory	O
effects	O
on	O
MSR	B
expression	O
,	O
whereas	O
intracellular	O
accumulation	O
of	O
cholesterol	O
itself	O
does	O
not	O
influence	O
MSR	B
levels	O
to	O
any	O
considerable	O
extent	O
.	O
In	O
the	O
present	O
study	O
,	O
by	O
using	O
an	O
in	O
vitro	O
model	O
,	O
we	O
examined	O
whether	O
stimulation	O
with	O
interleukin-6	B
(	I
IL-6	I
)	I
,	O
an	O
immunoregulatory	B
,	O
multipotential	B
cytokine	I
,	O
modulates	O
the	O
expression	O
and	O
activities	O
of	O
the	O
MSR	B
in	O
macrophages	O
.	O
When	O
treated	O
with	O
IL-6	B
,	O
macrophages	O
derived	O
from	O
peripheral	O
monocytes	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-differentiated	O
THP-1	O
monocytic	O
cells	O
showed	O
significantly	O
reduced	O
uptake	O
and/or	O
binding	O
of	O
the	O
MSR	B
ligand	O
,	O
acetylated	B
LDL	I
.	O
This	O
effect	O
was	O
paralleled	O
by	O
a	O
reduction	O
in	O
the	O
expression	O
of	O
MSR	B
protein	O
and	O
mRNA	O
.	O
Analysis	O
of	O
MSR	O
promoter	O
activity	O
in	O
THP-1	O
cells	O
transfected	O
with	O
an	O
MSR	O
promoter	O
-	O
reporter	O
gene	O
construct	O
demonstrated	O
decreased	O
activity	O
of	O
the	O
MSR	O
promoter	O
in	O
IL-6	B
-treated	O
THP-1	O
macrophages	O
.	O
Electrophoretic	O
mobility	O
gel	O
shift	O
assay	O
also	O
showed	O
a	O
reduction	O
in	O
the	O
binding	O
of	O
a	O
transcription	B
factor	I
to	O
the	O
MSR	O
promoter	O
AP-1	O
/	O
ets	O
elements	O
in	O
IL-6	B
-treated	O
cells	O
.	O
Thus	O
,	O
exposure	O
to	O
IL-6	B
may	O
inhibit	O
expression	O
of	O
the	O
class	B
A	I
MSR	I
in	O
differentiated	O
macrophages	O
at	O
transcriptional	O
levels	O
.	O
This	O
result	O
suggests	O
that	O
this	O
cytokine	B
may	O
modulate	O
foam	O
cell	O
formation	O
during	O
atherogenesis	O
.	O
Immune	O
responses	O
to	O
adenoviruses	O
:	O
viral	O
evasion	O
mechanisms	O
and	O
their	O
implications	O
for	O
the	O
clinic	O
.	O
Adenoviruses	O
encode	O
proteins	O
that	O
block	O
responses	O
to	O
interferons	B
,	O
intrinsic	O
cellular	O
apoptosis	O
,	O
killing	O
by	O
CD8	O
(	O
+	O
)	O
cytotoxic	O
T	O
lymphocytes	O
and	O
killing	O
by	O
the	O
death	B
ligands	I
TNF	B
,	O
Fas	B
ligand	I
and	O
TRAIL	B
.	O
The	O
viral	B
proteins	I
are	O
believed	O
to	O
prolong	O
acute	O
and	O
persistent	O
adenovirus	O
infections	O
.	O
The	O
proteins	O
may	O
prove	O
useful	O
in	O
protecting	O
adenovirus	O
gene	O
therapy	O
vectors	O
and	O
transplanted	O
cells	O
from	O
the	O
immune	O
system	O
.	O
Estrogen	O
decreases	O
TNF	B
gene	O
expression	O
by	O
blocking	O
JNK	B
activity	O
and	O
the	O
resulting	O
production	O
of	O
c	B
-	I
Jun	I
and	O
JunD	B
.	O
Central	O
to	O
the	O
bone	O
-	O
sparing	O
effect	O
of	O
estrogen	O
(	O
E	O
(	O
2	O
)	O
)	O
is	O
its	O
ability	O
to	O
block	O
the	O
monocytic	O
production	O
of	O
the	O
osteoclastogenic	B
cytokine	I
TNF	I
-	I
alpha	I
(	O
TNF	B
)	O
.	O
However	O
,	O
the	O
mechanism	O
by	O
which	O
E	O
(	O
2	O
)	O
downregulates	O
TNF	B
production	O
is	O
presently	O
unknown	O
.	O
Transient	O
transfection	O
studies	O
in	O
HeLa	O
cells	O
,	O
an	O
E	O
(	O
2	O
)	O
receptor	O
-	O
negative	O
line	O
,	O
suggest	O
that	O
E	O
(	O
2	O
)	O
inhibits	O
TNF	B
gene	O
expression	O
through	O
an	O
effect	O
mediated	O
by	O
estrogen	B
receptor	I
beta	I
(	O
ERbeta	B
)	O
.	O
We	O
also	O
report	O
that	O
in	O
RAW	O
264.7	O
cells	O
,	O
an	O
E	O
(	O
2	O
)	O
receptor	O
-	O
positive	O
murine	O
monocytic	O
line	O
,	O
E	O
(	O
2	O
)	O
downregulates	O
cytokine	O
-	O
induced	O
TNF	B
gene	O
expression	O
by	O
decreasing	O
the	O
activity	O
of	O
the	O
Jun	B
NH	I
(	I
2	I
)	I
-terminal	I
kinase	I
(	O
JNK	B
)	O
.	O
The	O
resulting	O
diminished	O
phosphorylation	O
of	O
c	B
-	I
Jun	I
and	O
JunD	B
at	O
their	O
NH	B
(	I
2	I
)	I
-termini	I
decreases	O
the	O
ability	O
of	O
these	O
nuclear	O
proteins	O
to	O
autostimulate	O
the	O
expression	O
of	O
the	O
c	O
-	O
Jun	O
and	O
JunD	O
genes	O
,	O
thus	O
leading	O
to	O
lower	O
production	O
of	O
c	B
-	I
Jun	I
and	O
JunD	B
.	O
The	O
consequent	O
decrease	O
in	O
the	O
nuclear	O
levels	O
of	O
c	B
-	I
Jun	I
and	O
JunD	B
leads	O
to	O
diminished	O
binding	O
of	O
c	B
-	I
Jun	I
/	I
c	I
-	I
Fos	I
and	O
JunD	B
/	I
c	I
-	I
Fos	I
heterodimers	I
to	O
the	O
AP-1	O
consensus	O
sequence	O
in	O
the	O
TNF	O
promoter	O
and	O
,	O
thus	O
,	O
to	O
decreased	O
transactivation	O
of	O
the	O
TNF	O
gene	O
.	O
Signal	O
transduction	O
pathways	O
triggered	O
by	O
the	O
FcepsilonRIIb	B
receptor	I
(	O
CD23	B
)	O
in	O
human	O
monocytes	O
lead	O
to	O
nuclear	B
factor	I
-	I
kappaB	I
activation	O
.	O
BACKGROUND	O
:	O
Alveolar	O
macrophages	O
play	O
a	O
key	O
role	O
in	O
the	O
initiation	O
of	O
the	O
inflammatory	O
reaction	O
of	O
allergic	O
asthma	O
.	O
Alveolar	O
macrophages	O
and	O
peripheral	O
blood	O
monocytes	O
are	O
activated	O
when	O
IgE	B
/	I
allergen	I
immune	I
complexes	I
bind	O
to	O
the	O
CD23	B
receptor	I
,	O
which	O
leads	O
to	O
the	O
production	O
of	O
inflammatory	B
cytokines	I
.	O
OBJECTIVE	O
:	O
We	O
sought	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
regulating	O
this	O
early	O
inflammatory	O
response	O
.	O
We	O
have	O
focused	O
on	O
the	O
study	O
of	O
the	O
signal	O
transduction	O
pathways	O
triggered	O
by	O
CD23	B
in	O
human	O
monocytes	O
and	O
the	O
promonocytic	O
cell	O
line	O
U937	O
.	O
METHODS	O
:	O
CD23	B
was	O
cross	O
-	O
linked	O
in	O
human	O
monocytes	O
and	O
U937	O
cells	O
with	O
IgE	B
immune	I
complexes	I
.	O
Surface	O
expression	O
of	O
CD23	B
was	O
determined	O
by	O
FACS	O
analysis	O
.	O
Transcription	B
factor	I
activation	O
and	O
gene	O
transcription	O
were	O
studied	O
by	O
gel	O
-	O
shift	O
assays	O
and	O
Northern	O
blot	O
analysis	O
,	O
respectively	O
.	O
IkappaBalpha	B
phosphorylation	O
and	O
degradation	O
was	O
analyzed	O
by	O
Western	O
blot	O
.	O
RESULTS	O
:	O
Nuclear	B
factor	I
(	I
NF	I
)	I
-kappaB	I
is	O
the	O
main	O
transcription	O
factor	O
involved	O
in	O
the	O
gene	O
activation	O
that	O
follows	O
CD23	B
cross	O
-	O
linking	O
in	O
monocytes	O
.	O
CD23-induced	B
NF	I
-	I
kappaB	I
is	O
a	O
heterodimer	O
composed	O
of	O
p65	B
/	I
p50	I
subunits	I
.	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
is	O
secondary	O
to	O
the	O
phosphorylation	O
and	O
subsequent	O
degradation	O
of	O
the	O
NF	B
-	I
kappaB	I
inhibitory	I
molecule	I
IkappaBalpha	B
.	O
Tyrosine	B
kinase	I
-dependent	O
,	O
and	O
not	O
protein	B
kinase	I
C	I
-dependent	O
,	O
pathways	O
mediate	O
CD23	B
-triggered	O
NF	B
-	I
kappaB	I
activation	O
but	O
do	O
not	O
participate	O
in	O
the	O
direct	O
phosphorylation	O
of	O
IkappaBalpha	B
.	O
IkappaBalpha	B
degradation	O
and	O
NF	B
-	I
kappaB	I
nuclear	O
translocation	O
correlate	O
with	O
transcriptional	O
activation	O
of	O
the	O
inflammatory	B
cytokines	I
TNF	B
-	I
alpha	I
and	O
IL-1beta	O
.	O
CONCLUSIONS	O
:	O
NF	B
-	I
kappaB	I
is	O
the	O
main	O
transcription	O
factor	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
of	O
CD23	B
in	O
monocytes	O
.	O
Dopamine	O
stimulates	O
expression	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
via	O
NF	B
-	I
kappaB	I
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O
Recent	O
studies	O
have	O
reported	O
that	O
lymphocytes	O
produce	O
,	O
transport	O
and	O
bind	O
dopamine	O
present	O
in	O
plasma	O
.	O
However	O
,	O
the	O
action	O
of	O
dopamine	O
on	O
HIV-1	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
immune	O
system	O
has	O
not	O
yet	O
been	O
examined	O
.	O
Here	O
,	O
we	O
have	O
investigated	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
by	O
dopamine	O
in	O
Jurkat	O
T	O
cells	O
and	O
in	O
primary	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O
HIV-1	O
replication	O
was	O
increased	O
by	O
dopamine	O
,	O
which	O
correlated	O
with	O
the	O
increased	O
levels	O
of	O
HIV-1	O
transactivation	O
.	O
Our	O
transient	O
expression	O
data	O
revealed	O
that	O
dopamine	O
stimulated	O
transcription	O
through	O
the	O
NF	O
-	O
kappaB	O
element	O
present	O
in	O
the	O
long	O
terminal	O
repeat	O
.	O
The	O
importance	O
of	O
NF	O
-	O
kappaB	O
sites	O
was	O
confirmed	O
by	O
using	O
vectors	O
containing	O
wild	O
-	O
type	O
or	O
mutant	O
kappaB	O
sites	O
in	O
a	O
heterologous	O
promoter	O
.	O
Consistent	O
with	O
the	O
role	O
of	O
NF	B
-	I
kappaB	I
in	O
mediating	O
dopamine	O
responsiveness	O
,	O
the	O
proteasome	O
inhibitor	O
MG132	O
abolished	O
dopamine	O
-	O
induced	O
transcriptional	O
activation	O
.	O
We	O
further	O
explored	O
the	O
effect	O
of	O
dopamine	O
in	O
the	O
presence	O
of	O
phorbol	O
esters	O
or	O
tumor	B
necrosis	I
factor	I
-	I
alpha	I
(	O
TNF	B
-	I
alpha	I
)	O
known	O
to	O
activate	O
NF	B
-	I
kappaB	I
.	O
The	O
combination	O
of	O
dopamine	O
and	O
TNF	B
-	I
alpha	I
led	O
to	O
a	O
stimulation	O
of	O
HIV-1	O
transcription	O
and	O
replication	O
.	O
However	O
,	O
in	O
contrast	O
with	O
TNF	B
-	I
alpha	I
,	O
dopamine	O
treatment	O
did	O
not	O
affect	O
NF	B
-	I
kappaB	I
DNA	O
binding	O
activity	O
nor	O
the	O
concentrations	O
of	O
p50	B
,	O
p65	B
and	O
IkappaB	B
-	I
alpha	I
proteins	I
,	O
which	O
suggests	O
a	O
distinct	O
NF	B
-	I
kappaB	I
activation	O
mechanism	O
.	O
These	O
results	O
reveal	O
a	O
new	O
link	O
between	O
the	O
dopamine	O
system	O
,	O
cytokine	B
signaling	O
pathway	O
and	O
regulation	O
of	O
gene	O
expression	O
via	O
the	O
involvement	O
of	O
NF	B
-	I
kappaB	I
in	O
T	O
cells	O
and	O
PBMC	O
.	O
AML1	B
(	I
CBFalpha2	I
)	I
cooperates	O
with	O
B	B
cell	I
-	I
specific	I
activating	I
protein	I
(	I
BSAP	I
/	I
PAX5	I
)	I
in	O
activation	O
of	O
the	O
B	O
cell	O
-	O
specific	O
BLK	O
gene	O
promoter	O
.	O
AML1	B
plays	O
a	O
critical	O
role	O
during	O
hematopoiesis	O
and	O
chromosomal	O
translocations	O
involving	O
AML1	B
are	O
commonly	O
associated	O
with	O
different	O
forms	O
of	O
leukemia	O
,	O
including	O
pre	O
-	O
B	O
acute	O
lymphoblastic	O
leukemia	O
.	O
To	O
understand	O
the	O
function	O
of	O
AML1	B
during	O
B	O
cell	O
differentiation	O
,	O
we	O
analyzed	O
regulatory	O
regions	O
of	O
B	O
cell	O
-	O
specific	O
genes	O
for	O
potential	O
AML1-binding	O
sites	O
and	O
have	O
identified	O
a	O
putative	O
AML1-binding	O
site	O
in	O
the	O
promoter	O
of	O
the	O
B	O
cell	O
-	O
specific	O
tyrosine	O
kinase	O
gene	O
,	O
blk	O
.	O
Gel	O
mobility	O
shift	O
assays	O
and	O
transient	O
transfection	O
assays	O
demonstrate	O
that	O
AML1	B
binds	O
specifically	O
to	O
this	O
site	O
in	O
the	O
blk	O
promoter	O
and	O
this	O
binding	O
site	O
is	O
important	O
for	O
blk	O
promoter	O
activity	O
.	O
Furthermore	O
,	O
in	O
vitro	O
binding	O
analysis	O
revealed	O
that	O
the	O
AML1	O
runt	O
DNA	O
-	O
binding	O
domain	O
physically	O
interacts	O
with	O
the	O
paired	O
DNA	O
-	O
binding	O
domain	O
of	O
BSAP	B
,	O
a	O
B	B
cell	I
-	I
specific	I
transcription	I
factor	I
.	O
BSAP	B
has	O
been	O
shown	O
previously	O
to	O
be	O
important	O
for	O
B	O
cell	O
-	O
specific	O
regulation	O
of	O
the	O
blk	O
gene	O
.	O
Physical	O
interaction	O
of	O
AML1	B
with	O
BSAP	B
correlates	O
with	O
functional	O
cooperativity	O
in	O
transfection	O
studies	O
where	O
AML1	B
and	O
BSAP	B
synergistically	O
activate	O
blk	O
promoter	O
transcription	O
by	O
more	O
than	O
50-fold	O
.	O
These	O
results	O
demonstrate	O
physical	O
and	O
functional	O
interactions	O
between	O
AML1	B
and	O
BSAP	B
and	O
suggest	O
that	O
AML1	B
is	O
an	O
important	O
factor	O
for	O
regulating	O
a	O
critical	O
B	O
cell	O
-	O
specific	O
gene	O
,	O
blk	O
.	O
Dephosphorylation	O
of	O
ZAP-70	B
and	O
inhibition	O
of	O
T	O
cell	O
activation	O
by	O
activated	B
SHP1	I
.	O
Studies	O
with	O
motheaten	O
mice	O
,	O
which	O
lack	O
the	O
SHP1	B
protein	I
tyrosine	B
phosphatase	I
,	O
indicate	O
that	O
this	O
enzyme	O
plays	O
an	O
important	O
negative	O
role	O
in	O
T	B
cell	I
antigen	I
receptor	I
(	O
TCR	B
)	O
signaling	O
.	O
The	O
physiological	O
substrates	O
for	O
SHP1	B
in	O
T	O
lymphocytes	O
,	O
however	O
,	O
have	O
remained	O
unclear	O
or	O
controversial	O
.	O
To	O
define	O
these	O
targets	O
for	O
SHP1	B
we	O
have	O
compared	O
the	O
effects	O
of	O
constitutively	O
active	O
and	O
inactive	O
mutants	O
of	O
SHP1	B
on	O
TCR	B
signaling	O
.	O
Expression	O
of	O
wild	B
-	I
type	I
SHP1	I
had	O
a	O
very	O
small	O
effect	O
on	O
the	O
TCR	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
ZAP-70	B
and	O
Syk	B
,	O
even	O
when	O
SHP1	B
was	O
overexpressed	O
20	O
-	O
100-fold	O
over	O
endogenous	B
SHP1	I
.	O
Inactive	B
SHP1-D421A	I
and	O
wild	B
-	I
type	I
SHP2	I
were	O
without	O
effects	O
.	O
Constitutively	B
active	I
SHP1-DeltaSH2	I
had	O
a	O
more	O
pronounced	O
effect	O
on	O
ZAP-70	B
and	O
Syk	B
,	O
even	O
when	O
expressed	O
at	O
near	O
physiological	O
levels	O
.	O
SHP1-DeltaSH2	B
also	O
inhibited	O
events	O
downstream	O
of	O
ZAP-70	B
and	O
Syk	B
,	O
such	O
as	O
activation	O
of	O
the	O
mitogen	B
-	I
activated	I
protein	I
kinase	I
Erk2	B
and	O
the	O
transcriptional	O
activation	O
of	O
the	O
interleukin-2	O
gene	O
.	O
In	O
contrast	O
,	O
a	O
constitutively	O
active	O
SHP2-DeltaSH2	B
had	O
no	O
statistically	O
significant	O
effect	O
(	O
although	O
it	O
caused	O
a	O
slight	O
augmentation	O
in	O
some	O
individual	O
experiments	O
)	O
.	O
None	O
of	O
the	O
constructs	O
influenced	O
the	O
anti	O
-	O
CD3-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
TCR	B
zeta	I
-	I
chain	I
or	O
phospholipase	B
Cgamma1	I
,	O
indicating	O
that	O
Src	B
family	I
kinase	I
function	O
was	O
intact	O
.	O
Taken	O
together	O
,	O
our	O
findings	O
support	O
the	O
notion	O
that	O
ZAP-70	B
and	O
Syk	B
can	O
be	O
direct	O
substrates	O
for	O
SHP1	B
in	O
intact	O
cells	O
.	O
However	O
,	O
the	O
two	O
SH2	B
domains	I
of	O
SHP1	B
did	O
not	O
facilitate	O
its	O
recognition	O
of	O
ZAP-70	B
and	O
Syk	B
as	O
substrates	O
in	O
intact	O
cells	O
.	O
Therefore	O
,	O
we	O
suggest	O
that	O
SHP1	B
is	O
not	O
actively	O
recruited	O
to	O
inhibit	O
TCR	B
signaling	O
induced	O
by	O
ligation	O
of	O
this	O
receptor	O
alone	O
.	O
Instead	O
,	O
we	O
propose	O
that	O
ligation	O
of	O
a	O
distinct	O
inhibitory	B
receptor	I
leads	O
to	O
the	O
recruitment	O
of	O
SHP1	B
via	O
its	O
SH2	B
domains	I
,	O
activation	O
of	O
SHP1	B
and	O
subsequently	O
inhibition	O
of	O
TCR	B
signals	O
if	O
the	O
inhibitory	B
receptor	I
is	O
juxtaposed	O
to	O
the	O
TCR	B
.	O
Human	O
T	O
-	O
cell	O
lymphotrophic	O
virus	O
type	O
-	O
I	O
tax	O
gene	O
induces	O
secretion	O
of	O
human	B
macrophage	I
inflammatory	I
protein-1alpha	I
.	O
Human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
encodes	O
for	O
a	O
40-kDa	B
protein	I
,	O
Tax	B
,	O
which	O
is	O
important	O
for	O
the	O
immortalization	O
of	O
T	O
cells	O
.	O
Tax	B
has	O
been	O
shown	O
to	O
transactivate	O
several	O
cellular	O
genes	O
.	O
In	O
this	O
study	O
,	O
we	O
show	O
that	O
MIP-1alpha	B
is	O
selectively	O
expressed	O
and	O
secreted	O
in	O
the	O
tax	O
transfected	O
Jurkat	O
cell	O
line	O
upon	O
mitogen	B
stimulation	O
.	O
Expression	O
of	O
MIP-1alpha	O
-	O
R	O
mRNA	O
in	O
these	O
cells	O
suggests	O
an	O
autocrine	O
role	O
for	O
this	O
chemokine	B
in	O
HTLV	O
-	O
I	O
infected	O
T	O
-	O
cells	O
.	O
Induced	O
MIP-1alpha	B
expression	O
and	O
secretion	O
in	O
PMA	O
/	O
PHA	O
stimulated	O
tax	O
transfected	O
cells	O
correlate	O
with	O
the	O
noninduction	O
of	O
MNP-1	B
transcription	B
factor	I
,	O
which	O
is	O
intimately	O
involved	O
in	O
downmodulating	O
the	O
MIP-1alpha	O
gene	O
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
Gender	O
and	O
vascular	O
reactivity	O
.	O
Estrogen	B
receptors	I
are	O
found	O
on	O
vascular	O
endothelial	O
and	O
smooth	O
muscle	O
cells	O
;	O
their	O
expression	O
is	O
influenced	O
by	O
exposure	O
to	O
the	O
hormone	O
.	O
Estrogen	B
receptors	I
influence	O
non	O
-	O
genomic	O
events	O
,	O
which	O
are	O
rapid	O
in	O
onset	O
and	O
genomic	O
events	O
,	O
which	O
are	O
longer	O
acting	O
responses	O
.	O
Estrogens	O
affect	O
vascular	O
tone	O
indirectly	O
by	O
modulating	O
release	O
of	O
endothelium	B
-	I
derived	I
vasoactive	I
factors	I
and	O
directly	O
by	O
modulating	O
intracellular	O
calcium	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
.	O
Estrogens	O
indirectly	O
affect	O
thrombotic	O
events	O
and	O
inflammation	O
by	O
altering	O
platelet	O
aggregation	O
and	O
leukocyte	O
adherence	O
and	O
migration	O
,	O
respectively	O
.	O
Estrogens	O
also	O
influence	O
production	O
of	O
mitogens	O
which	O
,	O
when	O
released	O
at	O
sites	O
of	O
vascular	O
injury	O
,	O
affect	O
vascular	O
remodeling	O
.	O
Although	O
estrogens	O
initiate	O
vascular	O
responses	O
,	O
genomic	O
sex	O
may	O
influence	O
and/or	O
limit	O
expression	O
of	O
estrogen	O
receptors	O
and	O
therefore	O
actions	O
of	O
sex	O
steroid	O
hormones	O
throughout	O
the	O
vasculature	O
.	O
E1A	O
oncogene	O
induction	O
of	O
cellular	O
susceptibility	O
to	O
killing	O
by	O
cytolytic	O
lymphocytes	O
through	O
target	O
cell	O
sensitization	O
to	O
apoptotic	O
injury	O
.	O
E1A	O
oncogene	O
expression	O
increases	O
mammalian	O
cell	O
susceptibility	O
to	O
lysis	O
by	O
cytolytic	O
lymphocytes	O
(	O
CLs	O
)	O
at	O
a	O
stage	O
in	O
this	O
intercellular	O
interaction	O
that	O
is	O
independent	O
of	O
cell	O
surface	O
recognition	O
events	O
.	O
Since	O
CLs	O
can	O
induce	O
either	O
apoptotic	O
or	O
necrotic	O
cell	O
death	O
,	O
we	O
asked	O
whether	O
E1A	B
sensitization	O
to	O
injury	O
-	O
induced	O
apoptosis	O
is	O
sufficient	O
to	O
explain	O
E1A	B
-induced	O
cytolytic	O
susceptibility	O
.	O
Mouse	O
,	O
rat	O
,	O
hamster	O
,	O
and	O
human	O
cells	O
that	O
were	O
rendered	O
cytolytic	O
susceptible	O
by	O
E1A	B
were	O
also	O
sensitized	O
to	O
CL	O
-	O
induced	O
and	O
chemically	O
induced	O
apoptosis	O
.	O
In	O
contrast	O
,	O
E1A	O
-	O
positive	O
cells	O
were	O
no	O
more	O
susceptible	O
to	O
injury	O
-	O
induced	O
necrosis	O
than	O
E1A	O
-	O
negative	O
cells	O
.	O
Similar	O
to	O
induction	O
of	O
cytolytic	O
susceptibility	O
and	O
in	O
contrast	O
to	O
other	O
E1A	B
activities	O
,	O
cellular	O
sensitization	O
to	O
chemically	O
induced	O
apoptosis	O
depended	O
on	O
high	O
-	O
level	O
E1A	B
oncoprotein	B
expression	O
.	O
Loss	O
of	O
both	O
cytolytic	O
susceptibility	O
and	O
sensitization	O
to	O
chemically	O
induced	O
apoptosis	O
was	O
coselected	O
during	O
in	O
vivo	O
selection	O
of	O
E1A	O
-	O
positive	O
sarcoma	O
cells	O
for	O
increased	O
tumorigenicity	O
.	O
Furthermore	O
,	O
E1A	B
mutant	B
proteins	I
that	O
can	O
not	O
bind	O
the	O
cellular	B
transcriptional	I
coactivator	I
,	O
p300	B
,	O
and	O
that	O
fail	O
to	O
induce	O
cytolytic	O
susceptibility	O
also	O
failed	O
to	O
sensitize	O
cells	O
to	O
injury	O
-	O
induced	O
apoptosis	O
.	O
These	O
data	O
indicate	O
that	O
E1A	B
induces	O
susceptibility	O
to	O
killer	O
cell	O
-	O
induced	O
lysis	O
through	O
sensitization	O
of	O
cells	O
to	O
injury	O
-	O
induced	O
apoptosis	O
.	O
Copyright	O
1999	O
Academic	O
Press	O
.	O
Polyamines	O
in	O
human	O
breast	O
cancer	O
and	O
its	O
relations	O
to	O
classical	O
prognostic	O
features	O
:	O
clinical	O
implications	O
.	O
Experimental	O
evidence	O
suggest	O
an	O
important	O
role	O
of	O
polyamines	O
in	O
breast	O
cancer	O
development	O
.	O
Polyamines	O
have	O
been	O
determined	O
in	O
tissue	O
and	O
erythrocyte	O
samples	O
from	O
100	O
patients	O
with	O
primary	O
invasive	O
breast	O
cancer	O
and	O
30	O
patients	O
with	O
fibroadenomas	O
.	O
Statistical	O
analysis	O
was	O
performed	O
in	O
order	O
to	O
determine	O
the	O
prognostic	O
value	O
of	O
the	O
polyamine	O
patterns	O
of	O
tumor	O
tissues	O
and	O
erythrocytes	O
in	O
comparison	O
with	O
clinical	O
and	O
histological	O
prognostic	O
factors	O
.	O
In	O
malignant	O
tissues	O
,	O
polyamine	O
levels	O
were	O
significantly	O
higher	O
than	O
in	O
benign	O
tissues	O
.	O
They	O
correlated	O
with	O
markers	O
of	O
tumor	O
aggressivity	O
(	O
axillary	O
node	O
involvement	O
and	O
especially	O
with	O
markers	O
of	O
high	O
mitotic	O
rate	O
as	O
Ki-67	O
staining	O
,	O
histological	O
grade	O
)	O
.	O
No	O
correlation	O
was	O
found	O
between	O
estrogen	O
and	O
progesterone	O
status	O
,	O
tumor	O
size	O
and	O
polyamine	O
concentrations	O
.	O
Erythrocyte	O
polyamines	O
levels	O
were	O
identical	O
between	O
cancer	O
patients	O
and	O
controls	O
.	O
The	O
knowledge	O
of	O
the	O
polyamine	O
pattern	O
in	O
breast	O
cancer	O
could	O
become	O
useful	O
in	O
clinical	O
practice	O
particularly	O
if	O
polyamine	O
metabolism	O
is	O
targeted	O
as	O
a	O
therapeutic	O
approach	O
.	O
An	O
activation	O
-	O
responsive	O
element	O
in	O
single	O
C	O
motif-1	O
/	O
lymphotactin	O
promoter	O
is	O
a	O
site	O
of	O
constitutive	O
and	O
inducible	O
DNA	O
-	O
protein	O
interactions	O
involving	O
nuclear	B
factor	I
of	I
activated	I
T	I
cell	I
.	O
Single	B
C	I
motif-1	I
(	I
SCM-1	I
)	I
/lymphotactin	I
is	O
a	O
C	B
-	I
type	I
chemokine	I
whose	O
expression	O
is	O
activation	O
dependent	O
,	O
cyclosporin	O
A	O
sensitive	O
and	O
restricted	O
to	O
CD8	O
+	O
T	O
cells	O
,	O
double	O
-	O
negative	O
thymocytes	O
,	O
gammadelta	O
-	O
type	O
T	O
cells	O
,	O
and	O
NK	O
cells	O
.	O
In	O
humans	O
,	O
there	O
are	O
two	O
highly	O
homologous	O
genes	O
encoding	O
SCM-1alpha	B
and	O
SCM-1beta	B
.	O
Here	O
we	O
examined	O
the	O
regulatory	O
mechanism	O
of	O
the	O
SCM-1	O
genes	O
.	O
The	O
luciferase	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
5	O
'	O
flanking	O
region	O
of	O
0.7	O
kb	O
was	O
strongly	O
induced	O
upon	O
activation	O
with	O
anti	B
-	I
CD3	I
or	O
PHA	B
plus	O
PMA	O
only	O
in	O
SCM-1-producer	O
T	O
cell	O
lines	O
through	O
a	O
cyclosporin	O
A	O
-	O
sensitive	O
mechanism	O
.	O
An	O
element	O
termed	O
E1	O
located	O
at	O
-108	O
to	O
-95	O
nt	O
relative	O
to	O
the	O
major	O
transcription	O
start	O
site	O
was	O
found	O
to	O
be	O
critical	O
for	O
the	O
promoter	O
activity	O
.	O
In	O
electrophoretic	O
mobility	O
shift	O
assays	O
using	O
the	O
E1	O
oligonucleotide	O
as	O
probe	O
,	O
nuclear	O
extracts	O
from	O
unstimulated	O
T	O
and	O
B	O
cell	O
lines	O
formed	O
a	O
constitutive	B
complex	I
termed	O
complex	B
I	I
,	O
while	O
nuclear	O
extracts	O
from	O
stimulated	O
SCM-1-producer	O
T	O
cell	O
lines	O
formed	O
a	O
higher	B
mobility	I
complex	I
termed	O
complex	B
II	I
with	O
a	O
concomitant	O
decrease	O
in	O
complex	B
I	I
.	O
The	O
shift	O
from	O
complex	B
I	I
to	O
complex	B
II	I
seen	O
only	O
in	O
SCM-1-producer	O
T	O
cell	O
lines	O
upon	O
activation	O
was	O
completely	O
suppressed	O
by	O
cyclosporin	O
A	O
.	O
Both	O
complexes	O
were	O
critically	O
dependent	O
on	O
the	O
NF	O
-	O
AT	O
core	O
sequence	O
TTTCC	O
in	O
the	O
E1	O
element	O
and	O
were	O
partially	O
supershifted	O
by	O
anti	B
-	I
NF	I
-	I
ATp	I
.	O
One	O
-	O
hybrid	O
assays	O
in	O
yeast	B
isolated	I
NF	I
-	I
ATp	I
as	O
an	O
E1	B
binding	I
protein	I
,	O
and	O
transfection	O
of	O
NF	B
-	I
ATp	I
into	O
T	O
and	O
B	O
cell	O
lines	O
strongly	O
enhanced	O
the	O
activation	B
-	I
dependent	I
SCM-1	I
promoter	O
activity	O
.	O
Collectively	O
,	O
a	O
unique	O
mechanism	O
involving	O
NF	B
-	I
ATp	I
appears	O
to	O
regulate	O
the	O
cell	O
type	O
-	O
specific	O
and	O
activation	O
-	O
dependent	O
expression	O
of	O
the	O
SCM-1	O
genes	O
.	O
Glucocorticoids	O
induce	O
apoptosis	O
in	O
human	O
monocytes	O
:	O
potential	O
role	O
of	O
IL-1	B
beta	I
.	O
Glucocorticoids	O
(	O
GC	O
)	O
are	O
potent	O
anti	O
-	O
inflammatory	O
and	O
immunosuppressive	O
agents	O
that	O
act	O
on	O
a	O
variety	O
of	O
immune	O
cells	O
,	O
including	O
monocytes	O
and	O
macrophages	O
.	O
However	O
,	O
the	O
exact	O
cellular	O
mechanisms	O
underlying	O
this	O
anti	O
-	O
inflammatory	O
capacity	O
are	O
still	O
unknown	O
.	O
In	O
our	O
study	O
,	O
we	O
determined	O
the	O
induction	O
of	O
apoptosis	O
by	O
GC	O
in	O
human	O
monocytes	O
.	O
Peripheral	O
blood	O
monocytes	O
were	O
isolated	O
by	O
density	O
centrifugation	O
methods	O
with	O
a	O
purity	O
of	O
>	O
90	O
%	O
and	O
were	O
cultured	O
in	O
RPMI	O
1640	O
medium	O
.	O
Monocyte	O
apoptosis	O
was	O
determined	O
by	O
four	O
independent	O
methods	O
,	O
including	O
annexin	O
-	O
V	O
staining	O
,	O
TUNEL	O
,	O
DNA	O
-	O
laddering	O
,	O
and	O
typical	O
morphology	O
by	O
means	O
of	O
transmission	O
electron	O
microscopy	O
.	O
TNF	B
-	I
alpha	I
and	O
IL-1beta	B
were	O
measured	O
by	O
ELISA	O
.	O
GC	B
receptor	I
was	O
blocked	O
with	O
mifepristone	O
.	O
Caspase	O
3	O
was	O
inhibited	O
with	O
caspase-3	O
inhibitor	O
(	O
DEVD	O
-	O
CHO	O
)	O
.	O
Stimulation	O
with	O
different	O
GC	O
at	O
therapeutic	O
concentrations	O
resulted	O
in	O
monocyte	O
apoptosis	O
in	O
a	O
time-	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O
Necrosis	O
was	O
excluded	O
by	O
propidium	O
iodide	O
staining	O
.	O
Proinflammatory	B
cytokines	I
such	O
as	O
IL-1beta	B
and	O
TNF	B
-	I
alpha	I
were	O
down	O
-	O
regulated	O
by	O
GC	O
treatment	O
.	O
Continuous	O
treatment	O
of	O
monocytes	O
with	O
IL-1beta	B
,	O
but	O
not	O
with	O
TNF	B
-	I
alpha	I
,	O
could	O
almost	O
completely	O
prevent	O
GC	O
-	O
induced	O
cell	O
death	O
.	O
The	O
addition	O
of	O
mifepristone	O
or	O
caspase-3	O
inhibitor	O
could	O
partially	O
abrogate	O
GC	O
-	O
induced	O
apoptosis	O
as	O
well	O
as	O
GC	O
-	O
induced	O
inhibition	O
of	O
IL-1beta	B
.	O
This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
induction	O
of	O
apoptosis	O
by	O
GC	O
in	O
human	O
monocytes	O
.	O
GC	O
-	O
induced	O
monocyte	O
apoptosis	O
may	O
be	O
partially	O
mediated	O
through	O
effects	O
on	O
IL-1beta	B
production	O
.	O
It	O
is	O
conceivable	O
that	O
GC	O
exert	O
their	O
anti	O
-	O
inflammatory	O
capacity	O
in	O
various	O
diseases	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
induction	O
of	O
apoptosis	O
in	O
monocytes	O
.	O
Neutrophil	O
maturation	O
and	O
the	O
role	O
of	O
retinoic	O
acid	O
.	O
Neutrophil	O
maturation	O
occurs	O
in	O
well	O
defined	O
morphological	O
stages	O
that	O
correlate	O
with	O
the	O
acquisition	O
of	O
molecular	B
markers	I
associated	O
with	O
neutrophil	O
function	O
.	O
A	O
variety	O
of	O
factors	O
are	O
known	O
to	O
play	O
a	O
role	O
in	O
terminal	O
neutrophil	O
maturation	O
,	O
including	O
the	O
vitamin	O
A	O
derivative	O
,	O
retinoic	O
acid	O
.	O
Retinoic	O
acid	O
can	O
directly	O
modulate	O
gene	O
expression	O
via	O
binding	O
to	O
its	O
nuclear	B
receptors	I
,	O
which	O
can	O
,	O
in	O
turn	O
,	O
activate	O
transcription	O
of	O
target	O
genes	O
.	O
A	O
role	O
for	O
retinoic	O
acid	O
during	O
neutrophil	O
maturation	O
has	O
been	O
suggested	O
from	O
a	O
variety	O
of	O
sources	O
.	O
Here	O
we	O
present	O
a	O
review	O
of	O
the	O
mechanism	O
of	O
retinoic	B
acid	I
receptor	I
action	O
and	O
the	O
major	O
evidence	O
showing	O
that	O
normal	O
retinoid	O
signaling	O
is	O
required	O
for	O
neutrophil	O
maturation	O
.	O
Nuclear	B
factor	I
-	I
kappaB	I
-dependent	O
induction	O
of	O
interleukin-8	B
gene	O
expression	O
by	O
tumor	B
necrosis	I
factor	I
alpha	I
:	O
evidence	O
for	O
an	O
antioxidant	O
sensitive	O
activating	O
pathway	O
distinct	O
from	O
nuclear	O
translocation	O
.	O
Tumor	B
necrosis	I
factor	I
alpha	I
(	O
TNFalpha	B
)	O
is	O
a	O
pluripotent	O
activator	O
of	O
inflammation	O
by	O
inducing	O
a	O
proinflammatory	B
cytokine	I
cascade	O
.	O
This	O
phenomenon	O
is	O
mediated	O
,	O
in	O
part	O
,	O
through	O
inducible	O
expression	O
of	O
the	O
CXC	B
chemokine	I
,	O
interleukin-8	B
(	O
IL-8	O
)	O
.	O
In	O
this	O
study	O
,	O
we	O
investigate	O
the	O
role	O
of	O
TNFalpha	B
-inducible	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
IL-8	B
expression	O
by	O
`	O
`	O
monocyte	O
-	O
like	O
''	O
U937	O
histiocytic	O
lymphoma	O
cells	O
.	O
TNFalpha	B
is	O
a	O
rapid	O
activator	O
of	O
IL-8	O
gene	O
expression	O
by	O
U937	O
,	O
producing	O
a	O
50-fold	O
induction	O
of	O
mRNA	O
within	O
1	O
hour	O
of	O
treatment	O
.	O
In	O
gene	O
transfection	O
assays	O
,	O
the	O
effect	O
of	O
TNFalpha	B
requires	O
the	O
presence	O
of	O
an	O
inducible	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
(	O
Rel	O
A	O
)	O
binding	O
site	O
in	O
the	O
IL-8	O
promoter	O
.	O
TNFalpha	B
treatment	O
induces	O
a	O
rapid	O
translocation	O
of	O
the	O
65	B
kD	I
transcriptional	I
activator	I
NF	B
-	I
kappaB	I
subunit	I
,	O
Rel	B
A	I
,	O
whose	O
binding	O
in	O
the	O
nucleus	O
occurs	O
before	O
changes	O
in	O
intracellular	O
ROS	O
.	O
Pretreatment	O
(	O
or	O
up	O
to	O
15	O
minutes	O
posttreatment	O
)	O
relative	O
to	O
TNFalpha	B
with	O
the	O
antioxidant	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
(	O
2	O
%	O
[	O
vol	O
/	O
vol	O
]	O
)	O
blocks	O
80	O
%	O
of	O
NF	B
-	I
kappaB	I
-dependent	O
transcription	O
.	O
Surprisingly	O
,	O
however	O
,	O
DMSO	O
has	O
no	O
effect	O
on	O
inducible	O
Rel	B
A	I
binding	O
.	O
Similar	O
selective	O
effects	O
on	O
NF	B
-	I
kappaB	I
transcription	O
are	O
seen	O
with	O
the	O
unrelated	O
antioxidants	O
,	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
)	O
and	O
vitamin	O
C	O
.	O
These	O
data	O
indicate	O
that	O
TNFalpha	B
induces	O
a	O
delayed	O
ROS	O
-	O
dependent	O
signalling	O
pathway	O
that	O
is	O
required	O
for	O
NF	B
-	I
kappaB	I
transcriptional	O
activation	O
and	O
is	O
separable	O
from	O
that	O
required	O
for	O
its	O
nuclear	O
translocation	O
.	O
Further	O
definition	O
of	O
this	O
pathway	O
will	O
yield	O
new	O
insights	O
into	O
inflammation	O
initiated	O
by	O
TNFalpha	B
signalling	O
.	O
c	B
-	I
Maf	I
induces	O
monocytic	O
differentiation	O
and	O
apoptosis	O
in	O
bipotent	O
myeloid	O
progenitors	O
.	O
The	O
transcriptional	O
mechanisms	O
that	O
drive	O
colony	O
-	O
forming	O
unit	O
granulocyte	O
-	O
macrophage	O
(	O
CFU	O
-	O
GM	O
)	O
myeloid	O
progenitors	O
to	O
differentiate	O
into	O
cells	O
of	O
either	O
the	O
granulocytic	O
or	O
monocytic	O
lineage	O
are	O
not	O
fully	O
understood	O
.	O
We	O
have	O
shown	O
that	O
the	O
c	B
-	I
Maf	I
and	O
c	B
-	I
Myb	I
transcription	I
factors	I
physically	O
interact	O
in	O
myeloid	O
cells	O
to	O
form	O
inhibitory	O
complexes	O
that	O
hinder	O
transactivation	O
of	O
c	O
-	O
Myb	O
target	O
genes	O
through	O
direct	O
binding	O
to	O
Myb	O
consensus	O
sites	O
.	O
These	O
complexes	O
arise	O
in	O
a	O
developmentally	O
regulated	O
pattern	O
,	O
peaking	O
at	O
the	O
promyelocyte	O
stage	O
,	O
or	O
in	O
cell	O
model	O
systems	O
,	O
appearing	O
soon	O
after	O
the	O
induction	O
of	O
monocytic	O
differentiation	O
.	O
We	O
wished	O
to	O
determine	O
if	O
this	O
developmentally	O
related	O
interaction	O
is	O
a	O
consequence	O
of	O
myeloid	O
differentiation	O
or	O
an	O
intrinsic	O
differentiating	O
stimulus	O
.	O
Because	O
the	O
elevated	O
Myb	B
:	I
Maf	I
status	O
seen	O
in	O
differentiating	O
cells	O
can	O
be	O
recapitulated	O
by	O
overexpression	O
of	O
c	B
-	I
Maf	I
in	O
myeloid	O
cell	O
lines	O
,	O
we	O
inducibly	O
expressed	O
the	O
c	O
-	O
Maf	O
cDNA	O
in	O
2	O
bipotent	O
human	O
myeloid	O
progenitor	O
cells	O
.	O
Elevated	O
levels	O
of	O
c	B
-	I
Maf	I
protein	I
led	O
to	O
marked	O
increases	O
in	O
Myb	B
:	I
Maf	I
complexes	I
and	O
the	O
accumulation	O
of	O
monocyte	O
/	O
macrophage	O
cells	O
,	O
followed	O
by	O
eventual	O
programmed	O
cell	O
death	O
.	O
Analysis	O
of	O
targets	O
that	O
could	O
mediate	O
these	O
phenotypic	O
changes	O
indicated	O
that	O
c	B
-	I
Maf	I
likely	O
plays	O
a	O
key	O
role	O
in	O
myeloid	O
cell	O
development	O
through	O
dual	O
mechanisms	O
;	O
inhibition	O
of	O
a	O
select	O
set	O
of	O
c	B
-	I
Myb	I
regulated	O
targets	O
,	O
such	O
as	O
Bcl-2	B
and	O
CD13	B
/	I
APN	I
,	O
coupled	O
with	O
the	O
activation	O
of	O
as	O
yet	O
undefined	O
differentiation	O
-	O
promoting	O
genes	O
.	O
Peroxisome	B
proliferator	I
-	I
activated	I
receptor	I
activators	I
target	O
human	O
endothelial	O
cells	O
to	O
inhibit	O
leukocyte	O
-endothelial	O
cell	O
interaction	O
.	O
An	O
early	O
event	O
in	O
acute	O
and	O
chronic	O
inflammation	O
and	O
associated	O
diseases	O
such	O
as	O
atherosclerosis	O
and	O
rheumatoid	O
arthritis	O
is	O
the	O
induced	O
expression	O
of	O
specific	O
adhesion	B
molecules	I
on	O
the	O
surface	O
of	O
endothelial	O
cells	O
(	O
ECs	O
)	O
,	O
which	O
subsequently	O
bind	O
leukocytes	O
.	O
Peroxisome	B
proliferator	I
-	I
activated	I
receptors	I
(	O
PPARs	B
)	O
,	O
members	O
of	O
the	O
nuclear	B
receptor	I
superfamily	I
of	O
transcription	B
factors	I
,	O
are	O
activated	O
by	O
fatty	O
acid	O
metabolites	O
,	O
peroxisome	O
proliferators	O
,	O
and	O
thiazolidinediones	O
and	O
are	O
now	O
recognized	O
as	O
important	O
mediators	O
in	O
the	O
inflammatory	O
response	O
.	O
Whether	O
PPAR	O
activators	O
influence	O
the	O
inflammatory	O
responses	O
of	O
ECs	O
is	O
unknown	O
.	O
We	O
show	O
that	O
the	O
PPAR	O
activators	O
15-deoxy	O
-	O
Delta	O
(	O
12	O
,	O
14	O
)	O
-prostaglandin	O
J	O
(	O
2	O
)	O
(	O
15d	O
-	O
PGJ	O
(	O
2	O
)	O
)	O
,	O
Wyeth	O
14643	O
,	O
ciglitazone	O
,	O
and	O
troglitazone	O
,	O
but	O
not	O
BRL	O
49653	O
,	O
partially	O
inhibit	O
the	O
induced	O
expression	O
of	O
vascular	B
cell	I
adhesion	I
molecule-1	I
(	O
VCAM-1	B
)	O
,	O
as	O
measured	O
by	O
ELISA	O
,	O
and	O
monocyte	O
binding	O
to	O
human	O
aortic	O
endothelial	O
cells	O
(	O
HAECs	O
)	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
or	O
lipopolysaccharide	O
.	O
The	O
`	O
`	O
natural	O
''	O
PPAR	O
activator	O
15d	O
-	O
PGJ	O
(	O
2	O
)	O
had	O
the	O
greatest	O
potency	O
and	O
was	O
the	O
only	O
tested	O
molecule	O
capable	O
of	O
partially	O
inhibiting	O
the	O
induced	O
expression	O
of	O
E	B
-	I
selectin	I
and	O
neutrophil	O
-	O
like	O
HL60	O
cell	O
binding	O
to	O
PMA	O
-	O
activated	O
HAECs	O
.	O
Intracellular	O
adhesion	O
molecule-1	O
induction	O
by	O
PMA	O
was	O
unaffected	O
by	O
any	O
of	O
the	O
molecules	O
tested	O
.	O
Both	O
PPAR	O
-	O
alpha	O
and	O
PPAR	O
-	O
gamma	O
mRNAs	O
were	O
detected	O
in	O
HAECs	O
by	O
using	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
a	O
ribonuclease	B
protection	O
assay	O
;	O
however	O
,	O
we	O
have	O
yet	O
to	O
determine	O
which	O
,	O
if	O
any	O
,	O
of	O
the	O
PPARs	B
are	O
mediating	O
this	O
process	O
.	O
These	O
results	O
suggest	O
that	O
certain	O
PPAR	O
activators	O
may	O
help	O
limit	O
chronic	O
inflammation	O
mediated	O
by	O
VCAM-1	B
and	O
monocytes	O
without	O
affecting	O
acute	O
inflammation	O
mediated	O
by	O
E	B
-	I
selectin	I
and	O
neutrophil	O
binding	O
.	O
9-cis	O
retinoic	O
acid	O
induces	O
monocyte	B
chemoattractant	I
protein-1	I
secretion	O
in	O
human	O
monocytic	O
THP-1	O
cells	O
.	O
Monocyte	O
migration	O
and	O
activation	O
are	O
regulated	O
by	O
monocyte	B
chemoattractant	I
protein-1	I
(	O
MCP-1	B
)	O
.	O
Prior	O
studies	O
have	O
shown	O
MCP-1	B
expression	O
is	O
modulated	O
by	O
a	O
variety	O
of	O
ligands	O
that	O
act	O
through	O
extracellular	B
receptors	I
.	O
In	O
the	O
current	O
study	O
,	O
we	O
show	O
9-cis	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
a	O
ligand	O
for	O
the	O
nuclear	B
hormone	I
receptor	I
retinoid	I
X	I
receptor	I
(	O
RXR	B
)	O
and	O
retinoic	B
acid	I
receptor	I
(	O
RAR	B
)	O
,	O
markedly	O
induces	O
the	O
expression	O
of	O
MCP-1	B
.	O
In	O
human	O
THP-1	O
monocytic	O
leukemia	O
cells	O
cultured	O
with	O
RA	O
(	O
0.05	O
to	O
500	O
nmol	O
/	O
L	O
)	O
,	O
MCP-1	B
expression	O
was	O
induced	O
rapidly	O
,	O
significantly	O
,	O
and	O
dose	O
-	O
dependently	O
by	O
as	O
much	O
as	O
165-fold	O
.	O
MCP-1	O
RNA	O
level	O
was	O
also	O
increased	O
in	O
RA	O
-	O
treated	O
cells	O
.	O
Expression	O
of	O
PPARgamma	B
,	O
a	O
heterodimer	O
partner	O
of	O
RXR	B
,	O
is	O
also	O
markedly	O
induced	O
by	O
RA	O
in	O
THP-1	O
cells	O
.	O
However	O
,	O
BRL49653	O
,	O
a	O
PPARgamma	B
ligand	O
,	O
failed	O
to	O
induce	O
MCP-1	B
secretion	O
either	O
alone	O
or	O
to	O
modify	O
the	O
expression	O
level	O
induced	O
by	O
RA	O
.	O
In	O
contrast	O
,	O
BRL49653	O
significantly	O
increased	O
MCP-1	B
(	O
biotinylated	B
MCP-1	I
)	O
binding	O
to	O
THP-1	O
cells	O
,	O
whereas	O
RA	O
had	O
no	O
effect	O
.	O
Other	O
peroxisome	B
proliferator	I
activated	I
receptor	I
(	O
PPAR	B
)	O
ligands	O
,	O
15d	O
-	O
PGJ	O
(	O
2	O
)	O
and	O
troglitazone	O
(	O
PPARgamma	B
)	O
,	O
Wy14	O
,	O
643	O
(	O
PPARalpha	B
)	O
,	O
and	O
PD195599	O
(	O
PPARbeta	B
)	O
inhibited	O
the	O
induction	O
of	O
MCP-1	B
by	O
RA	O
.	O
RA	O
's	O
effect	O
on	O
MCP-1	B
expression	O
in	O
human	O
elutriated	O
monocytes	O
were	O
similar	O
to	O
that	O
observed	O
in	O
the	O
THP-1	O
cells	O
.	O
These	O
studies	O
identify	O
RA	O
as	O
a	O
nuclear	O
signal	O
for	O
MCP-1	B
induction	O
in	O
undifferentiated	O
human	O
monocytic	O
cells	O
.	O
These	O
studies	O
also	O
suggest	O
monocyte	O
MCP-1	B
expression	O
induced	O
through	O
RA	O
may	O
modulate	O
cell	O
migration	O
.	O
Target	O
structures	O
of	O
the	O
CD8	O
(	O
+	O
)	O
-T	O
-	O
cell	O
response	O
to	O
human	O
cytomegalovirus	O
:	O
the	O
72-kilodalton	B
major	I
immediate	I
-	I
early	I
protein	I
revisited	O
.	O
Cell	O
-	O
mediated	O
immunity	O
plays	O
an	O
essential	O
role	O
in	O
the	O
control	O
of	O
infection	O
with	O
the	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
.	O
However	O
,	O
only	O
a	O
few	O
CD8	B
(	I
+	I
)	I
-T	I
-	I
cell	I
epitopes	I
are	O
known	O
,	O
with	O
the	O
majority	O
being	O
contained	O
in	O
the	O
pp65	B
phosphoprotein	I
,	O
which	O
is	O
believed	O
to	O
dominate	O
the	O
CD8	O
(	O
+	O
)	O
-T	O
-	O
cell	O
response	O
to	O
HCMV	O
.	O
Here	O
,	O
we	O
have	O
readdressed	O
the	O
issue	O
of	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
specific	O
for	O
the	O
72-kDa	B
major	I
immediate	I
-	I
early	I
protein	I
(	O
IE-1	B
)	O
,	O
which	O
is	O
nonstructural	O
but	O
is	O
found	O
very	O
early	O
and	O
throughout	O
the	O
replicative	O
cycle	O
.	O
Using	O
a	O
novel	O
flow	O
-	O
cytometric	O
assay	O
,	O
we	O
were	O
able	O
to	O
identify	O
CD8	B
(	I
+	I
)	I
-T	I
-	I
cell	I
epitopes	I
(	O
by	O
IE-1	B
peptide	O
-	O
specific	O
induction	O
of	O
cytokine	B
synthesis	O
)	O
and	O
simultaneously	O
measure	O
the	O
frequency	O
of	O
cells	O
directed	O
against	O
them	O
.	O
For	O
this	O
purpose	O
,	O
81	O
pentadecamer	O
peptides	O
covering	O
the	O
complete	O
491-amino	B
-	I
acid	I
sequence	I
of	O
IE-1	B
were	O
tested	O
on	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
anti	O
-	O
HCMV	O
immunoglobulin	O
G	O
-	O
seropositive	O
donors	O
.	O
At	O
least	O
10	O
new	O
epitopes	B
were	O
identified	O
,	O
and	O
the	O
fine	O
specificity	O
and	O
presenting	O
HLA	B
molecule	I
of	O
the	O
first	O
of	O
them	O
was	O
determined	O
.	O
The	O
frequencies	O
of	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
directed	O
against	O
IE-1	B
were	O
similar	O
to	O
those	O
directed	O
against	O
pp65	B
in	O
donors	O
tested	O
with	O
known	O
pp65	B
-derived	O
peptides	O
.	O
Importantly	O
,	O
additional	O
testing	O
of	O
a	O
corresponding	O
set	O
of	O
peptides	O
covering	O
the	O
complete	O
sequence	O
of	O
pp65	B
on	O
10	O
of	O
these	O
donors	O
identified	O
individuals	O
whose	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
recognized	O
IE-1	B
but	O
not	O
pp65	B
and	O
vice	O
versa	O
,	O
clearly	O
illustrating	O
that	O
either	O
protein	O
may	O
be	O
a	O
major	O
target	O
.	O
In	O
summary	O
,	O
our	O
results	O
suggest	O
that	O
IE-1	B
is	O
far	O
more	O
important	O
as	O
a	O
CD8	O
(	O
+	O
)	O
-T	O
-	O
cell	O
target	O
than	O
current	O
opinion	O
suggests	O
.	O
Increased	O
IkappaB	B
expression	O
and	O
diminished	O
nuclear	B
NF	I
-	I
kappaB	I
in	O
human	O
mononuclear	O
cells	O
following	O
hydrocortisone	O
injection	O
.	O
We	O
have	O
recently	O
demonstrated	O
that	O
hydrocortisone	O
and	O
other	O
glucocorticoids	O
inhibit	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
generation	O
by	O
mononuclear	O
(	O
MNC	O
)	O
and	O
polymorphonuclear	O
leucocytes	O
(	O
PMNL	O
)	O
.	O
Since	O
NF	O
-	O
kappaB	O
/	O
IkappaB	B
system	O
regulates	O
the	O
transcription	O
of	O
proinflammatory	B
genes	I
,	O
including	O
those	O
responsible	O
for	O
ROS	O
generation	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
hydrocortisone	O
may	O
stimulate	O
IkappaB	B
production	O
thus	O
inhibiting	O
NF	B
-	I
kappaB	I
translocation	O
from	O
the	O
cytosol	O
into	O
the	O
nucleus	O
in	O
MNC	O
,	O
in	O
vivo	O
.	O
One	O
hundred	O
milligram	O
of	O
hydrocortisone	O
was	O
injected	O
intravenously	O
into	O
4	O
normal	O
subjects	O
.	O
Blood	O
samples	O
were	O
obtained	O
prior	O
to	O
the	O
injection	O
and	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
8	O
and	O
24	O
hr	O
after	O
the	O
injection	O
.	O
Nuclear	O
extracts	O
and	O
total	O
cell	O
lysates	O
were	O
prepared	O
from	O
MNC	O
by	O
standard	O
techniques	O
.	O
IkappaB	B
levels	O
in	O
MNC	O
homogenates	O
increased	O
at	O
1	O
hr	O
,	O
peaked	O
at	O
2	O
-	O
4	O
hr	O
,	O
started	O
to	O
decrease	O
at	O
8	O
hr	O
,	O
and	O
returned	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O
NF	B
-	I
kappaB	I
in	O
MNC	O
nuclear	O
extracts	O
decreased	O
at	O
1	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
4	O
hr	O
,	O
gradually	O
increased	O
at	O
8	O
hr	O
and	O
returned	O
back	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O
The	O
total	O
protein	O
content	O
of	O
NF	B
-	I
kappaB	I
subunit	I
(	O
P65	B
)	O
in	O
MNC	O
lysates	O
also	O
showed	O
a	O
decrease	O
following	O
hydrocortisone	O
injection	O
.	O
This	O
decrease	O
was	O
observed	O
at	O
2	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
4	O
hr	O
,	O
and	O
returned	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O
ROS	O
generation	O
inhibition	O
paralleled	O
NF	B
-	I
kappaB	I
levels	O
in	O
the	O
nucleus	O
.	O
It	O
was	O
inhibited	O
at	O
1	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
2	O
-	O
4	O
hr	O
,	O
started	O
to	O
increase	O
at	O
8	O
hr	O
,	O
and	O
returned	O
to	O
basal	O
levels	O
at	O
24	O
hr	O
.	O
Our	O
data	O
demonstrate	O
that	O
hydrocortisone	O
induces	O
IkappaB	B
and	O
suppresses	O
NF	B
-	I
kappaB	I
expression	O
in	O
MNC	O
in	O
parallel	O
.	O
IkappaB	B
further	O
reduces	O
the	O
translocation	O
of	O
NF	B
-	I
kappaB	I
into	O
the	O
nucleus	O
thus	O
preventing	O
the	O
expression	O
of	O
proinflammatory	O
genes	O
.	O
Inhibition	O
of	O
protein	B
phosphatase	I
2A	I
induces	O
serine	O
/	O
threonine	O
phosphorylation	O
,	O
subcellular	O
redistribution	O
,	O
and	O
functional	O
inhibition	O
of	O
STAT3	B
.	O
Signal	B
transducers	I
and	I
activators	I
of	I
transcription	I
(	O
STATs	B
)	O
are	O
rapidly	O
phosphorylated	O
on	O
tyrosine	O
residues	O
in	O
response	O
to	O
cytokine	B
and	O
growth	B
factor	I
stimulation	O
of	O
cell	B
surface	I
receptors	I
.	O
STATs	B
hereafter	O
are	O
translocated	O
to	O
the	O
nucleus	O
where	O
they	O
act	O
as	O
transcription	B
factors	I
.	O
Recent	O
reports	O
suggest	O
that	O
serine	O
phosphorylation	O
of	O
STATs	B
also	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
STAT	B
-mediated	O
gene	O
transcription	O
.	O
Here	O
,	O
we	O
studied	O
the	O
role	O
of	O
serine	B
/	I
threonine	I
phosphatases	I
in	O
STAT3	B
signaling	O
in	O
human	O
antigen	O
-	O
specific	O
CD4	O
(	O
+	O
)	O
T	O
cell	O
lines	O
and	O
cutaneous	O
T	O
cell	O
lymphoma	O
lines	O
,	O
expressing	O
a	O
constitutively	O
activated	O
STAT3	B
.	O
We	O
show	O
that	O
an	O
inhibitor	O
of	O
protein	B
phosphatases	I
(	O
PPs	B
)	O
PP1	B
/	I
PP2A	I
,	O
calyculin	B
A	I
,	O
induces	O
(	O
i	O
)	O
phosphorylation	O
of	O
STAT3	B
on	O
serine	O
and	O
threonine	O
residues	O
,	O
(	O
ii	O
)	O
inhibition	O
of	O
STAT3	B
tyrosine	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
,	O
and	O
(	O
iii	O
)	O
relocation	O
of	O
STAT3	B
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O
Similar	O
results	O
were	O
obtained	O
with	O
other	O
PP2A	O
inhibitors	O
(	O
okadaic	O
acid	O
,	O
endothall	O
thioanhydride	O
)	O
but	O
not	O
with	O
inhibitors	O
of	O
PP1	B
(	O
tautomycin	O
)	O
or	O
PP2B	B
(	O
cyclosporine	O
A	O
)	O
.	O
Pretreatment	O
with	O
the	O
broad	O
serine	O
/	O
threonine	O
kinase	O
inhibitor	O
staurosporine	O
partly	O
blocked	O
the	O
calyculin	B
A	I
-induced	O
STAT3	B
phosphorylation	O
,	O
whereas	O
inhibitors	O
of	O
serine	B
/	I
threonine	I
kinases	I
,	O
such	O
as	O
mitogen	B
-	I
activated	I
protein	I
kinase-1	I
extracellular	I
-	I
regulated	I
kinase	I
-	I
kinase	I
,	O
mitogen	B
-	I
activated	I
protein	I
p38	I
kinase	I
,	O
and	O
phosphatidylinositol	B
3-kinase	I
,	O
did	O
not	O
.	O
In	O
conclusion	O
,	O
we	O
provide	O
evidence	O
that	O
PP2A	B
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
STAT3	B
phosphorylation	O
and	O
subcellular	O
distribution	O
in	O
T	O
cells	O
.	O
Moreover	O
,	O
our	O
findings	O
suggest	O
that	O
the	O
level	O
of	O
STAT3	B
phosphorylation	O
is	O
balanced	O
between	O
a	O
staurosporine	B
-	I
sensitive	I
kinase	I
(	O
s	O
)	O
and	O
PP2A	B
.	O
Immunocytochemical	O
analysis	O
of	O
MNDA	B
in	O
tissue	O
sections	O
and	O
sorted	O
normal	O
bone	O
marrow	O
cells	O
documents	O
expression	O
only	O
in	O
maturing	O
normal	O
and	O
neoplastic	O
myelomonocytic	O
cells	O
and	O
a	O
subset	O
of	O
normal	O
and	O
neoplastic	O
B	O
lymphocytes	O
.	O
The	O
human	O
myeloid	O
cell	O
nuclear	O
differentiation	O
antigen	O
(	O
MNDA	B
)	O
is	O
a	O
nuclear	O
antigen	O
known	O
to	O
be	O
expressed	O
in	O
mature	O
myelomonocytic	O
cell	O
lines	O
.	O
An	O
extensive	O
immunocytochemical	O
evaluation	O
of	O
fixed	O
tissues	O
confirmed	O
MNDA	B
expression	O
in	O
normal	O
maturing	O
granulocytes	O
and	O
monocytes	O
and	O
in	O
acute	O
nonlymphocytic	O
leukemias	O
and	O
chronic	O
myelogenous	O
leukemia	O
.	O
MNDA	B
was	O
not	O
detected	O
in	O
normal	O
tissue	O
histiocytes	O
but	O
was	O
found	O
in	O
activated	O
macrophages	O
and	O
foreign	O
body	O
giant	O
cells	O
associated	O
with	O
inflammation	O
.	O
Flow	O
cytometric	O
cell	O
sorting	O
of	O
normal	O
bone	O
marrow	O
established	O
that	O
MNDA	B
is	O
initially	O
expressed	O
in	O
myeloid	O
blast	O
cells	O
.	O
Examination	O
of	O
lymphoid	O
tissues	O
showed	O
a	O
low	O
level	O
of	O
expression	O
in	O
a	O
population	O
of	O
normal	O
mande	O
B	O
lymphocytes	O
but	O
not	O
in	O
germinal	O
center	O
cells	O
or	O
plasma	O
cells	O
.	O
A	O
subset	O
of	O
B	O
cell	O
neoplasms	O
expressing	O
MNDA	B
included	O
hairy	O
cell	O
leukemia	O
,	O
parafollicular	O
(	O
monocytoid	O
)	O
B	O
cell	O
lymphoma	O
,	O
mantle	O
cell	O
lymphoma	O
,	O
and	O
small	O
lymphocytic	O
lymphoma	O
.	O
Cell	O
sorting	O
of	O
normal	O
bone	O
marrow	O
showed	O
MNDA	B
expression	O
in	O
CD20	B
+	O
/CD10-	O
/	O
CD5-	O
B	O
cells	O
.	O
MNDA	B
was	O
not	O
detected	O
in	O
other	O
normal	O
bone	O
marrow	O
or	O
all	O
other	O
nonhematopoietic	O
cells	O
.	O
The	O
hematopoietic	O
cell	O
-	O
specific	O
pattern	O
of	O
MNDA	B
expression	O
was	O
elucidated	O
through	O
a	O
comprehensive	O
analysis	O
of	O
normal	O
and	O
neoplastic	O
tissues	O
,	O
and	O
the	O
results	O
provide	O
further	O
evidence	O
of	O
the	O
coexpression	O
of	O
B-	B
and	I
myeloid	I
cell	I
markers	I
in	O
neoplastic	O
B	O
cells	O
and	O
identify	O
a	O
normal	O
B	O
cell	O
population	O
that	O
might	O
be	O
related	O
to	O
the	O
cell	O
of	O
origin	O
of	O
a	O
subset	O
of	O
B	O
cell	O
neoplasms	O
.	O
Activation	O
of	O
the	O
CDC42	B
effector	I
N	B
-	I
WASP	I
by	O
the	O
Shigella	B
flexneri	I
IcsA	I
protein	I
promotes	O
actin	B
nucleation	O
by	O
Arp2	B
/	I
3	I
complex	I
and	O
bacterial	O
actin	B
-based	O
motility	O
.	O
To	O
propel	O
itself	O
in	O
infected	O
cells	O
,	O
the	O
pathogen	O
Shigella	O
flexneri	O
subverts	O
the	O
Cdc42	B
-controlled	O
machinery	O
responsible	O
for	O
actin	B
assembly	O
during	O
filopodia	O
formation	O
.	O
Using	O
a	O
combination	O
of	O
bacterial	O
motility	O
assays	O
in	O
platelet	O
extracts	O
with	O
Escherichia	O
coli	O
expressing	O
the	O
Shigella	B
IcsA	I
protein	I
and	O
in	O
vitro	O
analysis	O
of	O
reconstituted	O
systems	O
from	O
purified	B
proteins	I
,	O
we	O
show	O
here	O
that	O
the	O
bacterial	B
protein	I
IcsA	I
binds	O
N	B
-	I
WASP	I
and	O
activates	O
it	O
in	O
a	O
Cdc42	B
-like	O
fashion	O
.	O
Dramatic	O
stimulation	O
of	O
actin	B
assembly	O
is	O
linked	O
to	O
the	O
formation	O
of	O
a	O
ternary	O
IcsA	B
-	I
N	I
-	I
WASP	I
-	I
Arp2	I
/	I
3	I
complex	I
,	O
which	O
nucleates	O
actin	B
polymerization	O
.	O
The	O
Arp2	B
/	I
3	I
complex	I
is	O
essential	O
in	O
initiation	O
of	O
actin	B
assembly	O
and	O
Shigella	O
movement	O
,	O
as	O
previously	O
observed	O
for	O
Listeria	O
monocytogenes	O
.	O
Activation	O
of	O
N	B
-	I
WASP	I
by	O
IcsA	B
unmasks	O
two	O
domains	O
acting	O
together	O
in	O
insertional	O
actin	B
polymerization	O
.	O
The	O
isolated	O
COOH	B
-	I
terminal	I
domain	I
of	O
N	B
-	I
WASP	I
containing	O
a	O
verprolin	B
-	I
homology	I
region	I
,	O
a	O
cofilin	O
-	O
homology	O
sequence	O
,	O
and	O
an	O
acidic	B
terminal	I
segment	I
(	O
VCA	B
)	O
interacts	O
with	O
G	B
-	I
actin	I
in	O
a	O
unique	O
profilin	O
-	O
like	O
functional	O
fashion	O
.	O
Hence	O
,	O
when	O
N	B
-	I
WASP	I
is	O
activated	O
,	O
its	O
COOH	B
-	I
terminal	I
domain	I
feeds	O
barbed	O
end	O
growth	O
of	O
filaments	O
and	O
lowers	O
the	O
critical	O
concentration	O
at	O
the	O
bacterial	O
surface	O
.	O
On	O
the	O
other	O
hand	O
,	O
the	O
NH	B
(	I
2	I
)	I
-terminal	I
domain	I
of	O
N	B
-	I
WASP	I
interacts	O
with	O
F	B
-	I
actin	I
,	O
mediating	O
the	O
attachment	O
of	O
the	O
actin	B
tail	I
to	O
the	O
bacterium	O
surface	O
.	O
VASP	O
is	O
not	O
involved	O
in	O
Shigella	O
movement	O
,	O
and	O
the	O
function	O
of	O
profilin	B
does	O
not	O
require	O
its	O
binding	O
to	O
proline	B
-	I
rich	I
regions	I
.	O
Affinity	O
-	O
driven	O
peptide	O
selection	O
of	O
an	O
NFAT	O
inhibitor	O
more	O
selective	O
than	O
cyclosporin	O
A	O
[	O
see	O
comments	O
]	O
The	O
flow	O
of	O
information	O
from	O
calcium	B
-	I
mobilizing	I
receptors	I
to	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
-dependent	O
genes	O
is	O
critically	O
dependent	O
on	O
interaction	O
between	O
the	O
phosphatase	B
calcineurin	B
and	O
the	O
transcription	B
factor	I
NFAT	B
.	O
A	O
high	O
-	O
affinity	O
calcineurin	B
-binding	O
peptide	O
was	O
selected	O
from	O
combinatorial	O
peptide	O
libraries	O
based	O
on	O
the	O
calcineurin	B
docking	I
motif	I
of	O
NFAT	B
.	O
This	O
peptide	O
potently	O
inhibited	O
NFAT	B
activation	O
and	O
NFAT	B
-dependent	O
expression	O
of	O
endogenous	O
cytokine	O
genes	O
in	O
T	O
cells	O
,	O
without	O
affecting	O
the	O
expression	O
of	O
other	O
cytokines	B
that	O
require	O
calcineurin	B
but	O
not	O
NFAT	B
.	O
Substitution	O
of	O
the	O
optimized	O
peptide	O
sequence	O
into	O
the	O
natural	O
calcineurin	B
docking	I
site	I
increased	O
the	O
calcineurin	B
responsiveness	O
of	O
NFAT	B
.	O
Compounds	O
that	O
interfere	O
selectively	O
with	O
the	O
calcineurin	B
-NFAT	B
interaction	O
without	O
affecting	O
calcineurin	B
phosphatase	B
activity	O
may	O
be	O
useful	O
as	O
therapeutic	O
agents	O
that	O
are	O
less	O
toxic	O
than	O
current	O
drugs	O
.	O
